{"id": 1082663, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 738, "source_info": {"seq_id": "0877d67f-15ae-49e9-b227-5638fa6d8dec", "title": null, "text": "【0】页码:33\n This publication includes text taken from the Royal College of Anaesthetists (RCoA) leaflet \"Sedation explained\" 2 nd Edition June 2021 and then adapted for use in endoscopy departments.\n\n【1】 We try very hard to keep the information in this leaflet accurate and up-to-date, but we cannot guarantee this. We don't expect this general information to cover all the questions you might have or to deal with everything that might be important to you. You should discuss your choices and any worries you have with your medical team, using this leaflet as a guide. This leaflet on its own should not be treated as advice. It cannot be used for any commercial or business purpose.\n\n【2】 Please consider the visual impairments of patients when printing or photocopying this leaflet.\n\n【3】Photocopies of photocopies are discouraged as these tend to be low quality prints and can be very difficult for patients to read.", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "This publication includes text taken from the Royal College of Anaesthetists (RCoA) leaflet \"Sedation", "bbox": [119.0, 172.0, 660.0, 188.0]}, {"text": "explained\" 2 nd Edition June 2021 and then adapted for use in endoscopy departments.", "bbox": [119.0, 188.0, 586.0, 205.0]}], "type": "Text", "position": 2}, {"raw_context": [{"text": "We try very hard to keep the information in this leaflet accurate and up-to-date, but we cannot", "bbox": [118.0, 218.0, 634.0, 234.0]}, {"text": "guarantee this. We don't expect this general information to cover all the questions you might have or to", "bbox": [118.0, 235.0, 682.0, 249.0]}, {"text": "deal with everything that might be important to you. You should discuss your choices and any worries", "bbox": [119.0, 250.0, 669.0, 266.0]}, {"text": "you have with your medical team, using this leaflet as a guide. This leaflet on its own should not be", "bbox": [119.0, 267.0, 654.0, 282.0]}, {"text": "treated as advice. It cannot be used for any commercial or business purpose.", "bbox": [119.0, 283.0, 534.0, 299.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "Please consider the visual impairments of patients when printing or photocopying this leaflet.", "bbox": [119.0, 313.0, 624.0, 329.0]}, {"text": "Photocopies of photocopies are discouraged as these tend to be low quality prints and can be very", "bbox": [119.0, 330.0, 652.0, 344.0]}, {"text": "difficult for patients to read.", "bbox": [119.0, 345.0, 275.0, 361.0]}], "type": "Text", "position": 4}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/消化科/_2023 BSG指南：胃肠内窥镜检查中的镇静.pdf", "page_num": 33}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": null, "type3": null, "type4": null, "type5": null, "type6": null}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:42", "update_time": "2024-05-08 01:31:23"}
{"id": 1082662, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 738, "source_info": {"seq_id": "1e65de8d-6834-441f-b44e-71c18d405bdf", "title": null, "text": "【0】页码:3\n\n【1】## 18\n\n【2】\n 肝胆外科会志 2023 年 2 月 第 31 基 第 1 期   Journal of Hepatobiliary Surgery,Vol.31,No.1,Feb. 2023\n\n【3】 采用 PD-1 抗体联合仑伐替尼对伴有大血管癌栓的 晚期肝癌行转化治疗的前瞻性临床研究初步结果。 在已完成评估的 33 例患者中,联合治疗后 ORR 为 45. 5% , 影像学评估转化成功率为 42. 4% ( 14/33 ) ,  实际手术率为 30. 3% ( 10/33 ) ; 术后 2 例证实为病 理 性 完 全 缓 解（pathological complete response, pCR),术后 6 个月无复发率为 60% [26]。Zhu 等回 顾性分析了 63 例 TKIs 联合 PD-1 抗体治疗初始不 可切除肝癌患者资料,结果共 10 例患者经靶免联合 治疗后转化成功并行 R0 切除, 其中 6 例证实为 pCR;10 位转化成功患者在中位随访期(11.2 月) 内,8 例实现无瘤生存,1 例死于免疫相关副反应,1 例肿瘤复发 [7]。该中心继续观察了 101 例一线靶免 联合治疗初始不可切除肝癌患者情况,最终转化成 功手术率为 23.8% (24/101), 其中 10 例证实为 pCR,术后1年的无复发生存率和总体生存率分别 为 75% 和 95. 8% ; 在中位随访期( 21. 5 月 ) 内 , 转化  成功切除患者取得了生存获益 [27] .\n\n【4】 ICIs 联合 AATDs 可获得更好的 ORR,为肝癌转 化治疗带来了希望和方向。对于潜在可切除肝癌应 积极尝试靶免联合治疗方案,以争取提高肝癌转化 治疗成功率。\n 2.2  非手术局部治疗\n\n【5】 疗栓 塞 ( transhepatic  arterial  chemoembolization , TA- CE) , 肝动脉灌注化疗 ( hepatic arterial infusion chem¬ otherapy,HAIC)、经导管动脉内放疗栓塞术(transcatheter arterial redioembolization,TARE) 和放疗等, 是不可切除肝癌重要的转化治疗方式。随着系统性 药物治疗方案的进步,部分研究探索表明,局部治疗 联合系统治疗能取得更好的抗肿瘤活性和更高的转 [4] [8,11-14]\n\n【6】 –项纳人 120 例不可切除肝癌患者的回顾性研 2 究结果表明,TACE 联合仑伐替尼组的 OS,PFS 和 ORR 均优于单纯行 TACE 组 81 。 另一项多中心随 机对照研究比较了基于 FOLFOX 方案( 奥沙利铂 + 亚叶酸钙 + 5-氟尿喀啶) 的 HAIC 联合索拉非尼与 3 索拉非尼单药对合并门静脉癌栓的晚期肝癌疗效和 安全性, 结果提示联合治疗组的中位 OS,PFS 和 ORR 均优于索拉非尼单药组;虽然两组间总体的治 4 疗相关不良反应发生率无统计学差异,但联合治疗 组的 3 ~4 级不良事件出现更加频繁[28] 为了更好地发挥多模式治疗的协同增效作用, 5 进一步提升肿瘤 ORR 和肝癌转化治疗成功率,有学\n\n【7】 者尝试了局部治疗联合靶免抗肿瘤治疗的“三联方 案”。一项纳人 170 例 PD-L1 阳性不可切除肝癌患 者的多中心回顾性研究结果表明,基于 FOLFOX 方 案的 HAIC 联合帕博利珠单抗与仑伐替尼(三联方 案)组的中位 OS 和 PFS 均优于帕博利珠单抗联合 仑伐替尼组,但三联方案组的不良反应发生率更 高 29 。另一项多中心回顾性研究比较了仓伐替尼 + TACE + 帕博利珠单抗(三联方案)与仑伐替尼 + TACE(两联序贯方案)对 PD-L1 阳性初始不可切除 肝癌患者的疗效和安全性,结果说明三联方案组的 转化成功率、中位 OS 和 PFS 均优于两联序贯方案 组,但三联方案组的高血压、恶心和皮疹不良反应发 生率更高[30] 上述研究结果提示,非手术局部治疗联合系统治 疗可提高抗肿瘤活性,继而获得更高的转化治疗成 功切除率。但多维治疗联合会导致不良反应的交 叉,如何平衡治疗的有效性和安全性仍需大量研究 探索。\n\n【8】## 3\n\n【9】\n 肝癌转化治疗方兴未艾,为中晚期不可切除肝 癌的治疗指明了方向。但是,目前肝癌转化治疗尚 处于探索阶段,缺乏高级别循证医学证据所支持的 优化方案,仍面临诸多问题和挑战亟待解决。例如 如何提高转化成功率?  如何确保多模式治疗后手术 的安全性？如何判断肿瘤长期缓解后是否仍需手术 切除? 如何选择最佳的手术时机? 为回答上述问题 需要进行大量多中心前瞻性对照研究。现阶段为保 障肝癌转化治疗的安全性和有效性,建议在多学科 会诊的框架内进行,以患者的生存获益作为最重要 的考量因素。\n\n【10】## 参考文献 :\n\n【11】 1 Chen WQ, Zheng RS, Baade PD, etal. Cancer statistics in China, 2015.  CA Cancer J Clin , 2016 , 66 ( 2 ) : 115 – 132.\n Feng RM, Zong YN, Cao SM, et al. Current cancer situation in Chi¬ na : good or bad news from the 2018 Global Cancer Statistics? Cancer\n\n【12】 Commun ( Lond ) , 2019 , 39 ( 1 ) : 22. doi : 10. 1186/s40880 – 019\n – 0368 – 6\n Sung H, Ferlay J, Siegel RL, et al.  Global Cancer Statistics 2020 ; GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36\n\n【13】 249.\n Xiang X, Zhong JH, Wang YY, et al. Distribution of tumor stage and initial treatment modality in patients with primary hepatocellular\n\n【14】 carcinoma.  Clin Transl Oncol, 2017, 19(7): 891 – 897.\n\n【15】Zhong JH, Ke Y, Gong WF, et al. Hepatic resection associated with good survival for selected patients with intermediate and advanced¬", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "18", "bbox": [201.0, 203.0, 263.0, 236.0]}], "type": "Section-header", "position": 0}, {"raw_context": [{"text": "肝胆外科会志 2023 年 2 月 第 31 基 第 1 期   Journal of Hepatobiliary Surgery,Vol.31,No.1,Feb. 2023", "bbox": [397.0, 199.0, 1992.0, 235.0]}], "type": "Text", "position": 1}, {"raw_context": [{"text": "采用 PD-1 抗体联合仑伐替尼对伴有大血管癌栓的", "bbox": [177.0, 310.0, 1169.0, 357.0]}, {"text": "晚期肝癌行转化治疗的前瞻性临床研究初步结果。", "bbox": [173.0, 378.0, 1164.0, 419.0]}, {"text": "在已完成评估的 33 例患者中,联合治疗后 ORR 为", "bbox": [175.0, 441.0, 1173.0, 488.0]}, {"text": "45. 5% , 影像学评估转化成功率为 42. 4% ( 14/33 ) , ", "bbox": [173.0, 507.0, 1173.0, 551.0]}, {"text": "实际手术率为 30. 3% ( 10/33 ) ; 术后 2 例证实为病", "bbox": [176.0, 567.0, 1173.0, 617.0]}, {"text": "理 性 完 全 缓 解（pathological complete response,", "bbox": [175.0, 637.0, 1171.0, 680.0]}, {"text": "pCR),术后 6 个月无复发率为 60% [26]。Zhu 等回", "bbox": [172.0, 704.0, 1172.0, 742.0]}, {"text": "顾性分析了 63 例 TKIs 联合 PD-1 抗体治疗初始不", "bbox": [173.0, 767.0, 1173.0, 811.0]}, {"text": "可切除肝癌患者资料,结果共 10 例患者经靶免联合", "bbox": [175.0, 835.0, 1174.0, 875.0]}, {"text": "治疗后转化成功并行 R0 切除, 其中 6 例证实为", "bbox": [175.0, 899.0, 1172.0, 942.0]}, {"text": "pCR;10 位转化成功患者在中位随访期(11.2 月)", "bbox": [173.0, 965.0, 1167.0, 1009.0]}, {"text": "内,8 例实现无瘤生存,1 例死于免疫相关副反应,1", "bbox": [175.0, 1031.0, 1172.0, 1073.0]}, {"text": "例肿瘤复发 [7]。该中心继续观察了 101 例一线靶免", "bbox": [175.0, 1094.0, 1173.0, 1141.0]}, {"text": "联合治疗初始不可切除肝癌患者情况,最终转化成", "bbox": [175.0, 1161.0, 1173.0, 1205.0]}, {"text": "功手术率为 23.8% (24/101), 其中 10 例证实为", "bbox": [175.0, 1227.0, 1169.0, 1268.0]}, {"text": "pCR,术后1年的无复发生存率和总体生存率分别", "bbox": [173.0, 1294.0, 1167.0, 1336.0]}, {"text": "为 75% 和 95. 8% ; 在中位随访期( 21. 5 月 ) 内 , 转化 ", "bbox": [181.0, 1360.0, 1173.0, 1401.0]}, {"text": "成功切除患者取得了生存获益 [27] .", "bbox": [176.0, 1429.0, 846.0, 1464.0]}], "type": "Text", "position": 2}, {"raw_context": [{"text": "ICIs 联合 AATDs 可获得更好的 ORR,为肝癌转", "bbox": [261.0, 1491.0, 1168.0, 1529.0]}, {"text": "化治疗带来了希望和方向。对于潜在可切除肝癌应", "bbox": [177.0, 1556.0, 1167.0, 1597.0]}, {"text": "积极尝试靶免联合治疗方案,以争取提高肝癌转化", "bbox": [177.0, 1622.0, 1175.0, 1663.0]}, {"text": "治疗成功率。", "bbox": [176.0, 1687.0, 433.0, 1727.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "2.2  非手术局部治疗", "bbox": [171.0, 1752.0, 609.0, 1792.0]}], "type": "List-item", "position": 4}, {"raw_context": [{"text": "疗栓 塞 ( transhepatic  arterial  chemoembolization , TA-", "bbox": [173.0, 1885.0, 1166.0, 1920.0]}, {"text": "CE) , 肝动脉灌注化疗 ( hepatic arterial infusion chem¬", "bbox": [172.0, 1951.0, 1162.0, 1985.0]}, {"text": "otherapy,HAIC)、经导管动脉内放疗栓塞术(tran-", "bbox": [175.0, 2013.0, 1163.0, 2056.0]}, {"text": "scatheter arterial redioembolization,TARE) 和放疗等,", "bbox": [176.0, 2077.0, 1163.0, 2120.0]}, {"text": "是不可切除肝癌重要的转化治疗方式。随着系统性", "bbox": [177.0, 2145.0, 1170.0, 2185.0]}, {"text": "药物治疗方案的进步,部分研究探索表明,局部治疗", "bbox": [175.0, 2210.0, 1167.0, 2251.0]}, {"text": "联合系统治疗能取得更好的抗肿瘤活性和更高的转", "bbox": [175.0, 2276.0, 1169.0, 2317.0]}, {"text": "[4] [8,11-14]", "bbox": [173.0, 2344.0, 501.0, 2372.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "–项纳人 120 例不可切除肝癌患者的回顾性研", "bbox": [295.0, 2403.0, 1165.0, 2451.0]}, {"text": "2", "bbox": [1232.0, 2465.0, 1278.0, 2494.0]}, {"text": "究结果表明,TACE 联合仑伐替尼组的 OS,PFS 和", "bbox": [177.0, 2471.0, 1165.0, 2517.0]}, {"text": "ORR 均优于单纯行 TACE 组 81 。 另一项多中心随", "bbox": [175.0, 2533.0, 1165.0, 2582.0]}, {"text": "机对照研究比较了基于 FOLFOX 方案( 奥沙利铂 +", "bbox": [177.0, 2602.0, 1158.0, 2646.0]}, {"text": "亚叶酸钙 + 5-氟尿喀啶) 的 HAIC 联合索拉非尼与", "bbox": [181.0, 2667.0, 1167.0, 2713.0]}, {"text": "3", "bbox": [1232.0, 2688.0, 1268.0, 2717.0]}, {"text": "索拉非尼单药对合并门静脉癌栓的晚期肝癌疗效和", "bbox": [179.0, 2733.0, 1167.0, 2781.0]}, {"text": "安全性, 结果提示联合治疗组的中位 OS,PFS 和", "bbox": [178.0, 2797.0, 1169.0, 2848.0]}, {"text": "ORR 均优于索拉非尼单药组;虽然两组间总体的治", "bbox": [175.0, 2864.0, 1167.0, 2912.0]}, {"text": "4", "bbox": [1232.0, 2917.0, 1268.0, 2944.0]}, {"text": "疗相关不良反应发生率无统计学差异,但联合治疗", "bbox": [175.0, 2929.0, 1167.0, 2978.0]}, {"text": "组的 3 ~4 级不良事件出现更加频繁[28]", "bbox": [175.0, 2998.0, 935.0, 3042.0]}, {"text": "为了更好地发挥多模式治疗的协同增效作用,", "bbox": [271.0, 3064.0, 1161.0, 3110.0]}, {"text": "5", "bbox": [1232.0, 3082.0, 1270.0, 3111.0]}, {"text": "进一步提升肿瘤 ORR 和肝癌转化治疗成功率,有学", "bbox": [175.0, 3129.0, 1165.0, 3176.0]}], "type": "Text", "position": 6}, {"raw_context": [{"text": "者尝试了局部治疗联合靶免抗肿瘤治疗的“三联方", "bbox": [1230.0, 307.0, 2220.0, 355.0]}, {"text": "案”。一项纳人 170 例 PD-L1 阳性不可切除肝癌患", "bbox": [1230.0, 375.0, 2216.0, 418.0]}, {"text": "者的多中心回顾性研究结果表明,基于 FOLFOX 方", "bbox": [1232.0, 439.0, 2222.0, 485.0]}, {"text": "案的 HAIC 联合帕博利珠单抗与仑伐替尼(三联方", "bbox": [1230.0, 505.0, 2220.0, 551.0]}, {"text": "案)组的中位 OS 和 PFS 均优于帕博利珠单抗联合", "bbox": [1231.0, 567.0, 2218.0, 618.0]}, {"text": "仑伐替尼组,但三联方案组的不良反应发生率更", "bbox": [1232.0, 636.0, 2218.0, 682.0]}, {"text": "高 29 。另一项多中心回顾性研究比较了仓伐替尼", "bbox": [1231.0, 700.0, 2220.0, 750.0]}, {"text": "+ TACE + 帕博利珠单抗(三联方案)与仑伐替尼 +", "bbox": [1238.0, 768.0, 2210.0, 813.0]}, {"text": "TACE(两联序贯方案)对 PD-L1 阳性初始不可切除", "bbox": [1226.0, 835.0, 2220.0, 877.0]}, {"text": "肝癌患者的疗效和安全性,结果说明三联方案组的", "bbox": [1228.0, 899.0, 2222.0, 945.0]}, {"text": "转化成功率、中位 OS 和 PFS 均优于两联序贯方案", "bbox": [1228.0, 966.0, 2222.0, 1010.0]}, {"text": "组,但三联方案组的高血压、恶心和皮疹不良反应发", "bbox": [1228.0, 1032.0, 2220.0, 1077.0]}, {"text": "生率更高[30]", "bbox": [1225.0, 1099.0, 1487.0, 1139.0]}, {"text": "上述研究结果提示,非手术局部治疗联合系统治", "bbox": [1254.0, 1163.0, 2220.0, 1211.0]}, {"text": "疗可提高抗肿瘤活性,继而获得更高的转化治疗成", "bbox": [1228.0, 1232.0, 2222.0, 1273.0]}, {"text": "功切除率。但多维治疗联合会导致不良反应的交", "bbox": [1230.0, 1298.0, 2224.0, 1339.0]}, {"text": "叉,如何平衡治疗的有效性和安全性仍需大量研究", "bbox": [1234.0, 1363.0, 2222.0, 1403.0]}, {"text": "探索。", "bbox": [1230.0, 1428.0, 1360.0, 1472.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "3 ", "bbox": [1224.0, 1496.0, 1402.0, 1535.0]}], "type": "Section-header", "position": 8}, {"raw_context": [{"text": "肝癌转化治疗方兴未艾,为中晚期不可切除肝", "bbox": [1316.0, 1560.0, 2220.0, 1603.0]}, {"text": "癌的治疗指明了方向。但是,目前肝癌转化治疗尚", "bbox": [1232.0, 1627.0, 2218.0, 1669.0]}, {"text": "处于探索阶段,缺乏高级别循证医学证据所支持的", "bbox": [1232.0, 1691.0, 2222.0, 1734.0]}, {"text": "优化方案,仍面临诸多问题和挑战亟待解决。例如", "bbox": [1230.0, 1757.0, 2222.0, 1800.0]}, {"text": "如何提高转化成功率?  如何确保多模式治疗后手术", "bbox": [1234.0, 1823.0, 2224.0, 1865.0]}, {"text": "的安全性？如何判断肿瘤长期缓解后是否仍需手术", "bbox": [1230.0, 1889.0, 2222.0, 1931.0]}, {"text": "切除? 如何选择最佳的手术时机? 为回答上述问题", "bbox": [1232.0, 1954.0, 2220.0, 1995.0]}, {"text": "需要进行大量多中心前瞻性对照研究。现阶段为保", "bbox": [1230.0, 2020.0, 2220.0, 2062.0]}, {"text": "障肝癌转化治疗的安全性和有效性,建议在多学科", "bbox": [1230.0, 2086.0, 2218.0, 2128.0]}, {"text": "会诊的框架内进行,以患者的生存获益作为最重要", "bbox": [1232.0, 2153.0, 2218.0, 2195.0]}, {"text": "的考量因素。", "bbox": [1230.0, 2218.0, 1488.0, 2261.0]}], "type": "Text", "position": 9}, {"raw_context": [{"text": "参考文献 :", "bbox": [1232.0, 2285.0, 1446.0, 2326.0]}], "type": "Section-header", "position": 10}, {"raw_context": [{"text": "1 Chen WQ, Zheng RS, Baade PD, etal. Cancer statistics in China,", "bbox": [1232.0, 2351.0, 2210.0, 2380.0]}, {"text": "2015.  CA Cancer J Clin , 2016 , 66 ( 2 ) : 115 – 132.", "bbox": [1287.0, 2395.0, 1993.0, 2443.0]}], "type": "List-item", "position": 11}, {"raw_context": [{"text": "Feng RM, Zong YN, Cao SM, et al. Current cancer situation in Chi¬", "bbox": [1286.0, 2459.0, 2214.0, 2495.0]}, {"text": "na : good or bad news from the 2018 Global Cancer Statistics? Cancer", "bbox": [1288.0, 2517.0, 2218.0, 2550.0]}], "type": "List-item", "position": 12}, {"raw_context": [{"text": "Commun ( Lond ) , 2019 , 39 ( 1 ) : 22. doi : 10. 1186/s40880 – 019", "bbox": [1288.0, 2573.0, 2218.0, 2608.0]}], "type": "Text", "position": 13}, {"raw_context": [{"text": "– 0368 – 6", "bbox": [1300.0, 2630.0, 1458.0, 2663.0]}], "type": "List-item", "position": 14}, {"raw_context": [{"text": "Sung H, Ferlay J, Siegel RL, et al.  Global Cancer Statistics 2020 ;", "bbox": [1286.0, 2688.0, 2215.0, 2717.0]}, {"text": "GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36", "bbox": [1288.0, 2742.0, 2218.0, 2776.0]}], "type": "List-item", "position": 15}, {"raw_context": [{"text": "249.", "bbox": [1288.0, 2857.0, 1362.0, 2889.0]}], "type": "Text", "position": 16}, {"raw_context": [{"text": "Xiang X, Zhong JH, Wang YY, et al. Distribution of tumor stage", "bbox": [1286.0, 2912.0, 2216.0, 2947.0]}, {"text": "and initial treatment modality in patients with primary hepatocellular", "bbox": [1290.0, 2970.0, 2218.0, 3004.0]}], "type": "List-item", "position": 17}, {"raw_context": [{"text": "carcinoma.  Clin Transl Oncol, 2017, 19(7): 891 – 897.", "bbox": [1288.0, 3024.0, 2072.0, 3058.0]}, {"text": "Zhong JH, Ke Y, Gong WF, et al. Hepatic resection associated with", "bbox": [1284.0, 3082.0, 2218.0, 3117.0]}, {"text": "good survival for selected patients with intermediate and advanced¬", "bbox": [1288.0, 3138.0, 2214.0, 3172.0]}], "type": "Text", "position": 18}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/肿瘤科/解读/肝细胞癌转化治疗临床策略与指南解读.pdf", "page_num": 3}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": "错别字#6#6#–应是一", "type2": "缺少换行#6#6#为了更好地发挥多模式治疗另起一行\n多余换行#6#7#成功率,有学和者尝试了局部治疗是一句话\n缺少换行#7#7#上述研究结果提示,非手另起一行\n", "type3": "无关文本#0#15#例肿瘤复发 [7]部分段落末尾，以及句末的数字问题无关噪声应用全文", "type4": "语义不完整#5#5#句首不完整（非手术局部治疗......)句末不完整（转化成功率）\n语义不完整#8#8#3结语", "type5": null, "type6": "有用性#2#2#肝胆外科会志 2023 年 2 月 第 31 基 第 1 期   Journal of Hepatobiliary Surgery,Vol.31,No.1,Feb. 2023为页眉内容\n有用性#10#15#参考文献内容\n"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:42", "update_time": "2024-05-07 23:36:57"}
{"id": 1082661, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 738, "source_info": {"seq_id": "184ad42b-36e3-4295-9db7-daa6cc34951f", "title": null, "text": "【0】页码:2\n • 791 •\n\n【1】 2. 2 o .\n\n【2】\"  , , 100 , , . \n\n【3】(   ,   , Chapter 1 __    -  GB/T1.1–2020  《 , , 100 . \n\n【4】10.\n\n【5】Chapter Portage , [2] , 2012 Chapter 3 o __ » [3], 2017  >  [4] , 2018 Spine 3. 1 10.1.1 4.\n\n【6】. \n\n【7】[5] , 2019 .\n\n【8】, __ . . . .\n\n【9】[6] , Chapter 1 Chapter 1 __ Chapter 1 , __ Chapter Portage    1990, 1990.\n\n【10】, T/ .\n\n【11】, , 100 , CAIM018–2021  .\n\n【12】, ,  1   3. 2 3. 2. 1 , 100–110, 110–111, 111, , , . \n\n【13】, Chapter 9 .\n\n【14】the complete of the complete complete and the complete of the complete complete and the complete complete and the complete complete and the complete complete complete and the \"  , Chapter 3 Chapter 1 ,  , Chapter 1 ..\n\n【15】2 , 2. 1 [8,11]  , 3. 2. 2 Hoffmann Chapter 1  Hoffmann .\n\n【16】, , o  [12] .\n\n【17】Chapter 1 ,  ., Chapter 1 Chapter 1 3.3  , 3. 3. 1  Construction , , , , , [7] .\n\n【18】,  . \n\n【19】, Chapter 1 , Chapter 1 [  Chapter Portage )<0.75)], __ , 100 [8] .\n\n【20】(  ,", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "• 791 •", "bbox": [676.0, 66.0, 717.0, 83.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "2. 2", "bbox": [411.0, 106.0, 441.0, 124.0]}, {"text": "o", "bbox": [192.0, 111.0, 205.0, 124.0]}, {"text": ".", "bbox": [236.0, 132.0, 248.0, 144.0]}, {"text": "\" ", "bbox": [426.0, 149.0, 628.0, 181.0]}, {"text": ",", "bbox": [660.0, 152.0, 673.0, 165.0]}, {"text": ", 100", "bbox": [182.0, 170.0, 252.0, 184.0]}, {"text": ",", "bbox": [591.0, 189.0, 624.0, 203.0]}, {"text": ",", "bbox": [496.0, 190.0, 530.0, 205.0]}, {"text": ". ", "bbox": [469.0, 199.0, 632.0, 223.0]}, {"text": "( ", "bbox": [157.0, 203.0, 309.0, 222.0]}, {"text": "", "bbox": [426.0, 213.0, 691.0, 275.0]}, {"text": ", ", "bbox": [95.0, 223.0, 149.0, 249.0]}, {"text": "", "bbox": [178.0, 225.0, 203.0, 239.0]}, {"text": ",", "bbox": [238.0, 229.0, 298.0, 253.0]}, {"text": "", "bbox": [164.0, 237.0, 286.0, 271.0]}, {"text": "Chapter 1", "bbox": [96.0, 250.0, 156.0, 266.0]}, {"text": "__", "bbox": [241.0, 261.0, 366.0, 288.0]}, {"text": "  ", "bbox": [236.0, 283.0, 396.0, 345.0]}, {"text": "- ", "bbox": [581.0, 288.0, 647.0, 305.0]}, {"text": "GB/T1.1–2020  《", "bbox": [109.0, 303.0, 218.0, 322.0]}, {"text": ",", "bbox": [556.0, 306.0, 640.0, 326.0]}, {"text": ", 100", "bbox": [418.0, 307.0, 537.0, 328.0]}, {"text": ". ", "bbox": [638.0, 311.0, 698.0, 324.0]}, {"text": "10.", "bbox": [154.0, 327.0, 215.0, 342.0]}, {"text": "Chapter Portage", "bbox": [563.0, 327.0, 704.0, 350.0]}, {"text": ",", "bbox": [428.0, 330.0, 532.0, 346.0]}, {"text": "[2] , 2012", "bbox": [238.0, 344.0, 398.0, 361.0]}, {"text": "Chapter 3", "bbox": [407.0, 345.0, 442.0, 365.0]}, {"text": "o", "bbox": [489.0, 348.0, 504.0, 364.0]}, {"text": "__", "bbox": [445.0, 349.0, 490.0, 366.0]}, {"text": "» [3], 2017 ", "bbox": [288.0, 362.0, 475.0, 382.0]}, {"text": ">", "bbox": [82.0, 366.0, 123.0, 383.0]}, {"text": "", "bbox": [250.0, 366.0, 289.0, 382.0]}, {"text": "[4] , 2018", "bbox": [277.0, 383.0, 381.0, 402.0]}, {"text": "Spine", "bbox": [78.0, 384.0, 117.0, 404.0]}, {"text": "3. 1", "bbox": [410.0, 385.0, 440.0, 403.0]}, {"text": "10.1.1", "bbox": [172.0, 404.0, 234.0, 422.0]}, {"text": "4.", "bbox": [79.0, 406.0, 121.0, 424.0]}, {"text": ". ", "bbox": [651.0, 409.0, 693.0, 427.0]}, {"text": "[5] , 2019", "bbox": [175.0, 423.0, 234.0, 442.0]}, {"text": ".", "bbox": [468.0, 422.0, 528.0, 449.0]}, {"text": ",", "bbox": [545.0, 428.0, 608.0, 447.0]}, {"text": "__", "bbox": [621.0, 430.0, 684.0, 444.0]}, {"text": ". . . .", "bbox": [616.0, 447.0, 705.0, 464.0]}, {"text": "[6] ,", "bbox": [172.0, 462.0, 253.0, 480.0]}, {"text": "Chapter 1", "bbox": [384.0, 468.0, 398.0, 484.0]}, {"text": "Chapter 1", "bbox": [585.0, 467.0, 705.0, 485.0]}, {"text": "__", "bbox": [408.0, 481.0, 704.0, 506.0]}, {"text": "Chapter 1", "bbox": [161.0, 487.0, 257.0, 506.0]}, {"text": ",", "bbox": [109.0, 490.0, 134.0, 505.0]}, {"text": "__", "bbox": [414.0, 506.0, 703.0, 525.0]}, {"text": "Chapter Portage", "bbox": [136.0, 507.0, 271.0, 521.0]}, {"text": "  ", "bbox": [122.0, 523.0, 240.0, 545.0]}, {"text": "1990, 1990.", "bbox": [425.0, 527.0, 473.0, 543.0]}, {"text": ",", "bbox": [504.0, 531.0, 548.0, 543.0]}, {"text": "T/", "bbox": [373.0, 543.0, 395.0, 561.0]}, {"text": ".", "bbox": [512.0, 545.0, 622.0, 570.0]}, {"text": ",", "bbox": [398.0, 546.0, 486.0, 564.0]}, {"text": ", 100", "bbox": [180.0, 548.0, 199.0, 563.0]}, {"text": ",", "bbox": [334.0, 549.0, 353.0, 564.0]}, {"text": "CAIM018–2021  .", "bbox": [79.0, 563.0, 189.0, 582.0]}, {"text": ",", "bbox": [425.0, 567.0, 459.0, 587.0]}, {"text": ", ", "bbox": [537.0, 567.0, 694.0, 606.0]}, {"text": "1 ", "bbox": [80.0, 585.0, 95.0, 601.0]}, {"text": "", "bbox": [416.0, 585.0, 448.0, 598.0]}, {"text": "3. 2", "bbox": [411.0, 603.0, 457.0, 621.0]}, {"text": "3. 2. 1", "bbox": [412.0, 624.0, 455.0, 642.0]}, {"text": ", 100–110, 110–111, 111,", "bbox": [122.0, 625.0, 260.0, 646.0]}, {"text": ",", "bbox": [339.0, 629.0, 375.0, 643.0]}, {"text": ",", "bbox": [664.0, 629.0, 702.0, 644.0]}, {"text": ". ", "bbox": [260.0, 630.0, 306.0, 646.0]}, {"text": ",", "bbox": [340.0, 649.0, 371.0, 663.0]}, {"text": "Chapter 9", "bbox": [177.0, 651.0, 220.0, 662.0]}, {"text": ".", "bbox": [622.0, 651.0, 666.0, 662.0]}, {"text": "the complete of the complete complete and the complete of the complete complete and the complete complete and the complete complete and the complete complete complete and the", "bbox": [105.0, 666.0, 384.0, 686.0]}, {"text": "\" ", "bbox": [512.0, 668.0, 600.0, 699.0]}, {"text": ", ", "bbox": [598.0, 667.0, 709.0, 704.0]}, {"text": "Chapter 3", "bbox": [303.0, 685.0, 370.0, 706.0]}, {"text": "Chapter 1", "bbox": [109.0, 689.0, 229.0, 704.0]}, {"text": ",", "bbox": [368.0, 689.0, 381.0, 703.0]}, {"text": "", "bbox": [540.0, 699.0, 689.0, 771.0]}, {"text": ",", "bbox": [169.0, 709.0, 254.0, 724.0]}, {"text": "Chapter 1", "bbox": [296.0, 709.0, 364.0, 733.0]}, {"text": "..", "bbox": [426.0, 709.0, 461.0, 724.0]}, {"text": "2", "bbox": [80.0, 724.0, 122.0, 741.0]}, {"text": ",", "bbox": [426.0, 727.0, 459.0, 759.0]}, {"text": "2. 1", "bbox": [79.0, 744.0, 108.0, 763.0]}, {"text": "[8,11]", "bbox": [425.0, 761.0, 459.0, 779.0]}, {"text": "", "bbox": [408.0, 764.0, 428.0, 777.0]}, {"text": ",", "bbox": [318.0, 769.0, 364.0, 784.0]}, {"text": "3. 2. 2", "bbox": [411.0, 783.0, 457.0, 802.0]}, {"text": "Hoffmann", "bbox": [536.0, 783.0, 684.0, 802.0]}, {"text": "Chapter 1", "bbox": [305.0, 784.0, 364.0, 805.0]}, {"text": "", "bbox": [686.0, 787.0, 707.0, 798.0]}, {"text": "Hoffmann", "bbox": [551.0, 805.0, 711.0, 821.0]}, {"text": ".", "bbox": [136.0, 809.0, 209.0, 823.0]}, {"text": ",", "bbox": [317.0, 828.0, 361.0, 842.0]}, {"text": ",", "bbox": [611.0, 828.0, 658.0, 842.0]}, {"text": "o ", "bbox": [135.0, 829.0, 250.0, 843.0]}, {"text": "[12] .", "bbox": [534.0, 841.0, 564.0, 858.0]}, {"text": "Chapter 1", "bbox": [122.0, 844.0, 262.0, 864.0]}, {"text": ", ", "bbox": [369.0, 844.0, 489.0, 867.0]}, {"text": ".,", "bbox": [303.0, 845.0, 364.0, 863.0]}, {"text": "Chapter 1", "bbox": [302.0, 862.0, 367.0, 887.0]}, {"text": "Chapter 1", "bbox": [399.0, 866.0, 458.0, 883.0]}, {"text": "3.3 ", "bbox": [410.0, 883.0, 477.0, 900.0]}, {"text": ",", "bbox": [290.0, 884.0, 350.0, 905.0]}, {"text": "3. 3. 1 ", "bbox": [411.0, 903.0, 584.0, 922.0]}, {"text": "Construction ,", "bbox": [585.0, 902.0, 703.0, 927.0]}, {"text": ", , ,", "bbox": [289.0, 906.0, 361.0, 923.0]}, {"text": ",", "bbox": [151.0, 908.0, 213.0, 923.0]}, {"text": "[7] .", "bbox": [106.0, 922.0, 192.0, 939.0]}, {"text": ",", "bbox": [637.0, 924.0, 704.0, 947.0]}, {"text": "", "bbox": [436.0, 926.0, 471.0, 940.0]}, {"text": ". ", "bbox": [493.0, 928.0, 639.0, 952.0]}, {"text": ",", "bbox": [702.0, 929.0, 715.0, 943.0]}, {"text": "Chapter 1", "bbox": [576.0, 944.0, 661.0, 964.0]}, {"text": ",", "bbox": [312.0, 947.0, 351.0, 963.0]}, {"text": "Chapter 1", "bbox": [161.0, 949.0, 257.0, 962.0]}, {"text": "[ ", "bbox": [430.0, 961.0, 711.0, 984.0]}, {"text": "Chapter Portage", "bbox": [135.0, 965.0, 242.0, 982.0]}, {"text": ")<0.75)],", "bbox": [428.0, 983.0, 554.0, 1001.0]}, {"text": "__", "bbox": [133.0, 986.0, 211.0, 1005.0]}, {"text": ", 100", "bbox": [645.0, 990.0, 664.0, 1001.0]}, {"text": "[8] .", "bbox": [271.0, 1001.0, 297.0, 1021.0]}, {"text": "( ", "bbox": [467.0, 1001.0, 706.0, 1020.0]}, {"text": ",", "bbox": [122.0, 1007.0, 228.0, 1022.0]}], "type": "Text", "position": 4}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/骨科/共识/脊髓型颈椎病中西医结合诊疗专家共识.pdf", "page_num": 2}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "格式杂乱#0#20#全篇格式杂乱", "type3": null, "type4": null, "type5": null, "type6": null}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:42", "update_time": "2024-05-08 01:34:31"}
{"id": 1082660, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 738, "source_info": {"seq_id": "a2c1c270-3977-42ac-b2cf-0a80a5fd5e64", "title": null, "text": "【0】页码:1\n DOI: 10.1111/bjh.18781.\n# British Society For Haematology Guideline For Anticoagulant\n\n【1】\n management of pregnant individuals with mechanical heart valves\n\n Will Lester 1 ©  Joanna Trinder 6 | Julia Anderson 7 | Kenneth Hodson 8 | Lorna Swan 2 Charlotte Bradbury 9,10 \n\n【3】 1 Centre for Clinical Haematology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK 2 Department of Cardiology, Golden Jubilee National Hospital West of Scotland Regional Heart and Lung Centre, Clydebank, UK 3Department of Anaesthetics, Manchester University NHS Foundation Trust, Manchester, UK 4 Department of Obstetrics & Gynaecology, Leeds Teaching Hospitals NHS Trust, Leeds, UK 5 Department of Obstetric Medicine, Women's Services, Guy's and St Thomas' Hospitals NHS Foundation Trust, London, England 6Department of Obstetrics, University Hospitals Bristol NHS Foundation Trust, Bristol, UK 7 Department of Haematology, NHS Lothian, Edinburgh, UK 8 Department of Maternity, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK °Cellular and Molecular Medicine, University of Bristol, Bristol, UK 10 Bristol Haematology and Oncology Centre, Bristol, UK 11 Department of Maternity, Birmingham Women's and Children's NHS Foundation Trust, Birmingham, UK 12 Department of Obstetric and Maternal and Fetal Medicine, Manchester University NHS Foundation Trust, Manchester, UK\n\n【4】 Correspondence Will Lester, Centre for Clinical Haematology, University Hospitals Birmingham NHS Foundation Trust, Edgbaston, Birmingham B152TH, UK.\n\n【5】Email: will.lester@uhb.nhs.uk .\n\n【6】 Keywords: anticoagulation, embryopathy, mechanical heart valve, pregnancy\n\n【7】## Introduction\n\n【8】\n Evidence is limited regarding the prevalence and optimal management of pregnancy in individuals with mechanical heart valves (MHVs). Studies are scarce, often with small numbers of patients included. Mechanical valve thrombosis (MVT) occurs more frequently in pregnancy and there is a high risk of postpartum haemorrhage (PPH). There are a number of options for anticoagulation with differing risks to the pregnant individual and foetus. In the absence of high-quality data, this guideline aims to give recommendations using observational data, evidence from outside of pregnancy and expert opinion to address the key risks at different stages during pregnancy, at delivery and postpartum.\n\n【9】Although no single strategy for anticoagulation can be recommended, key risks are identified with recommendations to optimise current management options.\n\n【10】## Recommendations\n\n【11】\n • Individuals with a MHV of childbearing age should be offered pre-pregnancy counselling as soon as appropriate (Grade 1D).\n\n【12】• Prior to cardiac surgery, all individuals of childbearing age should be counselled about the impact of valve replacement choice on future pregnancy risk (Grade 1D).\n\n【13】• Individuals with MHV who are pregnant should be managed in a designated specialist centre with an experienced multidisciplinary team (MDT) including obstetrics, cardiology, cardiac surgery, anaesthetics, neonatology and haematology (Grade 2C).\n\n【14】• Anticoagulation options, including risks and benefits to the mother and the foetus, should be discussed, and a written management plan incorporating patient preference should be agreed (Grade 1D).\n\n【15】 [Correction added on 13 April 2023, after first online publication: The affiliation of the fifth author was corrected in this version.] ..\n\n【16】© 2023 British Society for Haematology and John Wiley & Sons Ltd.", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "DOI: 10.1111/bjh.18781.", "bbox": [59.0, 55.0, 150.0, 70.0]}], "type": "Text", "position": 1}, {"raw_context": [{"text": "British Society for Haematology guideline for anticoagulant", "bbox": [58.0, 145.0, 659.0, 172.0]}], "type": "Title", "position": 4}, {"raw_context": [{"text": "management of pregnant individuals with mechanical", "bbox": [58.0, 176.0, 601.0, 199.0]}, {"text": "heart valves", "bbox": [57.0, 207.0, 181.0, 231.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "Will Lester 1 © ", "bbox": [58.0, 260.0, 700.0, 283.0]}, {"text": "Joanna Trinder 6 | Julia Anderson 7 | Kenneth Hodson 8 | Lorna Swan 2", "bbox": [58.0, 287.0, 579.0, 308.0]}, {"text": "Charlotte Bradbury 9,10 ", "bbox": [58.0, 309.0, 485.0, 332.0]}], "type": "Text", "position": 6}, {"raw_context": [{"text": "1 Centre for Clinical Haematology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK", "bbox": [58.0, 345.0, 490.0, 359.0]}, {"text": "2 Department of Cardiology, Golden Jubilee National Hospital West of Scotland Regional Heart and Lung Centre, Clydebank, UK", "bbox": [58.0, 361.0, 559.0, 374.0]}, {"text": "3Department of Anaesthetics, Manchester University NHS Foundation Trust, Manchester, UK", "bbox": [58.0, 376.0, 424.0, 391.0]}, {"text": "4 Department of Obstetrics & Gynaecology, Leeds Teaching Hospitals NHS Trust, Leeds, UK", "bbox": [58.0, 393.0, 417.0, 406.0]}, {"text": "5 Department of Obstetric Medicine, Women's Services, Guy's and St Thomas' Hospitals NHS Foundation Trust, London, England", "bbox": [58.0, 408.0, 562.0, 422.0]}, {"text": "6Department of Obstetrics, University Hospitals Bristol NHS Foundation Trust, Bristol, UK", "bbox": [58.0, 425.0, 415.0, 438.0]}, {"text": "7 Department of Haematology, NHS Lothian, Edinburgh, UK", "bbox": [58.0, 441.0, 296.0, 455.0]}, {"text": "8 Department of Maternity, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK", "bbox": [58.0, 456.0, 488.0, 471.0]}, {"text": "°Cellular and Molecular Medicine, University of Bristol, Bristol, UK", "bbox": [58.0, 473.0, 323.0, 486.0]}, {"text": "10 Bristol Haematology and Oncology Centre, Bristol, UK", "bbox": [58.0, 488.0, 280.0, 502.0]}, {"text": "11 Department of Maternity, Birmingham Women's and Children's NHS Foundation Trust, Birmingham, UK", "bbox": [58.0, 504.0, 480.0, 518.0]}, {"text": "12 Department of Obstetric and Maternal and Fetal Medicine, Manchester University NHS Foundation Trust, Manchester, UK", "bbox": [59.0, 521.0, 545.0, 535.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "Correspondence", "bbox": [59.0, 548.0, 129.0, 559.0]}, {"text": "Will Lester, Centre for Clinical Haematology, University Hospitals Birmingham NHS Foundation Trust, Edgbaston, Birmingham B152TH, UK.", "bbox": [58.0, 557.0, 614.0, 572.0]}, {"text": "Email: will.lester@uhb.nhs.uk .", "bbox": [59.0, 572.0, 177.0, 583.0]}], "type": "Text", "position": 8}, {"raw_context": [{"text": "Keywords: anticoagulation, embryopathy, mechanical heart valve, pregnancy", "bbox": [58.0, 594.0, 360.0, 608.0]}], "type": "Text", "position": 9}, {"raw_context": [{"text": "INTRODUCTION", "bbox": [58.0, 637.0, 205.0, 657.0]}], "type": "Section-header", "position": 10}, {"raw_context": [{"text": "Evidence is limited regarding the prevalence and optimal", "bbox": [58.0, 674.0, 386.0, 688.0]}, {"text": "management of pregnancy in individuals with mechanical", "bbox": [58.0, 690.0, 385.0, 704.0]}, {"text": "heart valves (MHVs). Studies are scarce, often with small", "bbox": [58.0, 706.0, 385.0, 721.0]}, {"text": "numbers of patients included. Mechanical valve thrombo-", "bbox": [58.0, 722.0, 384.0, 736.0]}, {"text": "sis (MVT) occurs more frequently in pregnancy and there", "bbox": [58.0, 738.0, 386.0, 753.0]}, {"text": "is a high risk of postpartum haemorrhage (PPH). There", "bbox": [58.0, 755.0, 386.0, 768.0]}, {"text": "are a number of options for anticoagulation with differing", "bbox": [58.0, 770.0, 385.0, 784.0]}, {"text": "risks to the pregnant individual and foetus. In the absence", "bbox": [58.0, 786.0, 386.0, 801.0]}, {"text": "of high-quality data, this guideline aims to give recommen-", "bbox": [58.0, 803.0, 385.0, 816.0]}, {"text": "dations using observational data, evidence from outside of", "bbox": [58.0, 818.0, 386.0, 833.0]}, {"text": "pregnancy and expert opinion to address the key risks at dif-", "bbox": [58.0, 835.0, 384.0, 848.0]}, {"text": "ferent stages during pregnancy, at delivery and postpartum.", "bbox": [58.0, 849.0, 385.0, 864.0]}, {"text": "Although no single strategy for anticoagulation can be rec-", "bbox": [58.0, 866.0, 384.0, 881.0]}, {"text": "ommended, key risks are identified with recommendations", "bbox": [58.0, 883.0, 385.0, 896.0]}, {"text": "to optimise current management options.", "bbox": [58.0, 898.0, 285.0, 913.0]}], "type": "Text", "position": 11}, {"raw_context": [{"text": "RECOMMENDATIONS", "bbox": [406.0, 637.0, 597.0, 657.0]}], "type": "Section-header", "position": 12}, {"raw_context": [{"text": "• Individuals with a MHV of childbearing age should be", "bbox": [406.0, 673.0, 735.0, 689.0]}, {"text": "offered pre-pregnancy counselling as soon as appropriate", "bbox": [418.0, 689.0, 734.0, 704.0]}, {"text": "(Grade 1D).", "bbox": [418.0, 707.0, 485.0, 720.0]}, {"text": "• Prior to cardiac surgery, all individuals of childbearing", "bbox": [406.0, 722.0, 735.0, 736.0]}, {"text": "age should be counselled about the impact of valve re-", "bbox": [419.0, 738.0, 733.0, 753.0]}, {"text": "placement choice on future pregnancy risk (Grade 1D).", "bbox": [419.0, 754.0, 719.0, 768.0]}, {"text": "• Individuals with MHV who are pregnant should be man-", "bbox": [406.0, 770.0, 733.0, 784.0]}, {"text": "aged in a designated specialist centre with an experienced", "bbox": [418.0, 786.0, 735.0, 801.0]}, {"text": "multidisciplinary team (MDT) including obstetrics, car-", "bbox": [419.0, 803.0, 733.0, 816.0]}, {"text": "diology, cardiac surgery, anaesthetics, neonatology and", "bbox": [418.0, 818.0, 735.0, 833.0]}, {"text": "haematology (Grade 2C).", "bbox": [418.0, 835.0, 557.0, 848.0]}, {"text": "• Anticoagulation options, including risks and benefits to", "bbox": [406.0, 849.0, 735.0, 864.0]}, {"text": "the mother and the foetus, should be discussed, and a", "bbox": [418.0, 866.0, 735.0, 880.0]}, {"text": "written management plan incorporating patient prefer-", "bbox": [418.0, 883.0, 733.0, 896.0]}, {"text": "ence should be agreed (Grade 1D).", "bbox": [418.0, 898.0, 606.0, 913.0]}], "type": "Text", "position": 13}, {"raw_context": [{"text": "[Correction added on 13 April 2023, after first online publication: The affiliation of the fifth author was corrected in this version.]", "bbox": [59.0, 942.0, 564.0, 953.0]}, {"text": "..", "bbox": [60.0, 955.0, 733.0, 966.0]}, {"text": "© 2023 British Society for Haematology and John Wiley & Sons Ltd.", "bbox": [59.0, 964.0, 324.0, 977.0]}], "type": "Text", "position": 14}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/心血管/指南/2023 BSH 指南：机械心脏瓣膜妊娠个体抗凝管理(1).pdf", "page_num": 1}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": null, "type3": "无关文本#0#6#非正文\n无关文本#15#16#非正文", "type4": null, "type5": null, "type6": null}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:42", "update_time": "2024-05-07 22:07:25"}
{"id": 1082659, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 738, "source_info": {"seq_id": "bde2d95b-7a5d-4aaa-93a8-c1a4fe8c3523", "title": null, "text": "【0】页码:3\n\n【1】 Table 1 – Histological penile carcinoma subtypes according to the 2020 WHO classification [13,14] with frequency and outcomes (modified from [15]) Mortality Other features Subtype Frequency (% of cases) (%) HPV-independent SCC 45–75 20–38 Diagnosis of exclusion. Various degrees of differentiation.\n\n【2】Usual Well differentiated, superficially spreading, simulating pseudoepitheliomatous hyperplasia.\n\n【3】Pseudohyperplastic 8 <1> Pseudoglandular 1 <1 30 Poorly differentiated carcinoma with acantholytic pseudolumina-simulating glands.\n\n【4】Verrucous 3–8 Extremely well-differentiated, broad-based, and pushing tumour front. No metastasis reported.\n\n【5】Chapter 9 Cuniculatum <1 0 Endophytic labyrinthine growth pattern with broad-based pushing margins.\n\n【6】Papillae covered by well- to moderately differentiated cells without koilocytes.\n\n【7】Papillary 2-15 0–6 Sarcomatoid 1-7 45–90 Biphasic epithelial and spindle cell neoplasia. Most aggressive and worse prognosis.\n\n【8】Two or more subtypes in the same specimen. Prognosis is related to the subtypes involved.\n\n【9】Mixed 10–19 3–7 HPV-associated carcinoma Basaloid 4–10 21–67 Uniform basaloid cells in nests or sheets, with comedonecrosis or abrupt keratinisation.\n\n【10】Warty 5–10 0-10 Condylomatous papillae with central fibrovascular cores and koilocytes.\n\n【11】Nests or sheets of cells with ample, clear cytoplasm with central or geographical necrosis.\n\n【12】Clear cell 20–30 <1 Lymphoepithelioma- <1 Unknown Poorly differentiated cells intermixed with dense lymphoplasmacytic and eosinophilic infiltrates.\n\n【13】like Mixed 30–50 Mainly warty-basaloid carcinoma according to the WHO 2022 classification.\n\n【14】4–10 Others SCC NOS Unknown Unknown Keratinising carcinoma. This must be used only when evaluation of p16 is not available.\n\n【15】Squamous tumour nests intermixed with a minor mucinous glandular component Adenosquamous 1–2 0–14 Mucoepidermoid Unknown Unknown Clear separation between adenosquamous and mucoepidermoid is not provided in the WHO classification. Salivary gland criteria can be applied but there is no consensus HPV = human papillomavirus; NOS = not otherwise specified; SCC = squamous cell carcinoma; WHO = World Health Organization.\n\n【16】* The WHO 2022 classification consider these subtypes as part of usual-type SCC.\n\n【17】b This is considered a variant of cuniculatum carcinoma.\n\n【18】\n disease are discouraged). Following the 2022 World Health Organization (WHO) classification, PeINs are now classified as HPV-independent or HPV-associated carcinomas [ 8 ].\n\n【19】HPV infection is the main risk factor for penile cancer. Up to 50% of cases are HPV-related, with HPV 16 the most frequent HPV genotype [ 9 ]. The new pathology classification more clearly separates HPV-related and non–HPV-related tumours ( Table 1 ). In analogy to other HPV-associated cancers, HPV-positive penile cancer may be associated with better survival than HPV-negative disease, but more data are needed, underlining the importance of routine assessment of HPV status in all patients with penile cancer [10,11] . Several other risk factors for penile cancer have been identified, including phimosis, chronic penile inflammation, lichen sclerosus, smoking, ultraviolet A phototherapy, and low socioeconomic status [12] .\n\n【20】## Survival\n\n【21】\n Survival 3.1.3.\n\n【22】Patient outcomes are influenced by clinical and histological features ( Table 1 ) [ 13 – 15 ]. The most important prognostic factor for survival is the presence and extent of nodal metastases, with 5- yr cancer-specific survival (CSS) of approximately 95%, 80%, 65%, and 35% for N0, N1, N2, and N3 disease, respectively [ 16 ]. Patients with distant metastases have the worst outcomes, with 5-yr survival of only 16% [ 17 ].\n\n【23】 Pathology reporting 3.1.4.\n\n【24】The data set template from the International Collaboration on Cancer Reporting (ICCR) should be used for pathology reporting, which includes fields for information on the anatomic site of the primary tumour, histological type, grade, depth of invasion, perineural invasion, vascular invasion (venous and/or lymphatic), invasion of the corpus spongio-\n\n【25】 sum and/or cavernosum, surgical margins, and p16 immunohistochemistry results [18] .\n\n【26】## Classification 3.2.\n\n【27】\n The eighth edition of the Union for International Cancer Control/American Joint Committee on Cancer TNM classification is the system currently used for penile cancer and was last updated in 2017 (Table 2) [19,20] .\n\n【28】## 3.3.\n\n【29】\n## Diagnostic Evaluation And Staging\n\n【30】\n Primary tumour staging 3.3.1.\n\n【31】Penile cancers are usually clinically evident lesions, often presenting as raised or ulcerated lesions [ 21 ]. However, the appearance of penile tumours can be heterogeneous and can sometimes be hidden under the foreskin in the case of phimosis. Physical examination is a reliable method for estimating penile tumour size and clinical T stage. The dimensions, anatomic location, and extent of local invasion should be noted. In distinguishing T1 from T2 disease, magnetic resonance imaging (MRI) does not outperform physical examination. However, when there is uncertainty as to whether the tumour is invading the cavernosal bodies (cT3) and/or if organ-sparing treatment options are being considered, MRI can be helpful [22,23] . Ultrasound (US) can be considered if MRI is not available [ 24 ].\n\n【32】## Penile Biopsy\n\n【33】\n Penile biopsy 3.3.2.\n\n【34】A biopsy of the primary tumour should be obtained when there is doubt about the exact nature of the lesion. Histological confirmation is necessary to guide management when treatment is planned with topical agents, radiotherapy, or laser surgery [ 21 ].\n\n【35】 3\n\n【36】 Please cite this article as: O.R. Brouwer, M. Albersen, A. Parnham et al., European Association of Urology-American Society of Clinical Oncology Col-", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "Table 1 – Histological penile carcinoma subtypes according to the 2020 WHO classification [13,14] with frequency and outcomes (modified from [15])", "bbox": [75.0, 88.0, 731.0, 100.0]}, {"text": "Mortality", "bbox": [248.0, 108.0, 296.0, 120.0]}, {"text": "Other features", "bbox": [303.0, 108.0, 372.0, 120.0]}, {"text": "Subtype", "bbox": [78.0, 109.0, 118.0, 121.0]}, {"text": "Frequency (%", "bbox": [174.0, 109.0, 236.0, 120.0]}, {"text": "of cases)", "bbox": [175.0, 121.0, 215.0, 133.0]}, {"text": "(%)", "bbox": [251.0, 122.0, 265.0, 132.0]}, {"text": "HPV-independent SCC", "bbox": [78.0, 138.0, 175.0, 149.0]}, {"text": "45–75", "bbox": [175.0, 149.0, 203.0, 160.0]}, {"text": "20–38", "bbox": [249.0, 149.0, 277.0, 160.0]}, {"text": "Diagnosis of exclusion. Various degrees of differentiation.", "bbox": [305.0, 149.0, 541.0, 160.0]}, {"text": "Usual", "bbox": [78.0, 150.0, 105.0, 160.0]}, {"text": "Well differentiated, superficially spreading, simulating pseudoepitheliomatous hyperplasia.", "bbox": [305.0, 159.0, 676.0, 172.0]}, {"text": "Pseudohyperplastic 8", "bbox": [78.0, 160.0, 162.0, 172.0]}, {"text": "<1>", "bbox": [176.0, 160.0, 187.0, 171.0]}, {"text": "Pseudoglandular 1", "bbox": [78.0, 172.0, 150.0, 183.0]}, {"text": "<1", "bbox": [175.0, 173.0, 186.0, 181.0]}, {"text": "30", "bbox": [249.0, 172.0, 262.0, 181.0]}, {"text": "Poorly differentiated carcinoma with acantholytic pseudolumina-simulating glands.", "bbox": [305.0, 172.0, 647.0, 183.0]}, {"text": "Verrucous", "bbox": [78.0, 184.0, 121.0, 193.0]}, {"text": "3–8", "bbox": [175.0, 184.0, 191.0, 192.0]}, {"text": "Extremely well-differentiated, broad-based, and pushing tumour front. No metastasis reported.", "bbox": [305.0, 184.0, 694.0, 194.0]}, {"text": "Chapter 9", "bbox": [249.0, 186.0, 257.0, 192.0]}, {"text": "Cuniculatum", "bbox": [78.0, 195.0, 132.0, 206.0]}, {"text": "<1", "bbox": [175.0, 195.0, 187.0, 204.0]}, {"text": "0", "bbox": [248.0, 195.0, 258.0, 203.0]}, {"text": "Endophytic labyrinthine growth pattern with broad-based pushing margins.", "bbox": [305.0, 195.0, 616.0, 206.0]}, {"text": "Papillae covered by well- to moderately differentiated cells without koilocytes.", "bbox": [305.0, 205.0, 627.0, 217.0]}, {"text": "Papillary", "bbox": [78.0, 206.0, 117.0, 217.0]}, {"text": "2-15", "bbox": [176.0, 206.0, 197.0, 217.0]}, {"text": "0–6", "bbox": [248.0, 206.0, 267.0, 217.0]}, {"text": "Sarcomatoid", "bbox": [78.0, 217.0, 132.0, 228.0]}, {"text": "1-7", "bbox": [176.0, 217.0, 193.0, 226.0]}, {"text": "45–90", "bbox": [249.0, 217.0, 277.0, 228.0]}, {"text": "Biphasic epithelial and spindle cell neoplasia. Most aggressive and worse prognosis.", "bbox": [305.0, 217.0, 647.0, 228.0]}, {"text": "Two or more subtypes in the same specimen. Prognosis is related to the subtypes involved.", "bbox": [305.0, 229.0, 679.0, 241.0]}, {"text": "Mixed", "bbox": [78.0, 230.0, 107.0, 238.0]}, {"text": "10–19", "bbox": [176.0, 230.0, 201.0, 238.0]}, {"text": "3–7", "bbox": [250.0, 230.0, 267.0, 239.0]}, {"text": "HPV-associated carcinoma", "bbox": [78.0, 240.0, 195.0, 252.0]}, {"text": "Basaloid", "bbox": [78.0, 252.0, 114.0, 262.0]}, {"text": "4–10", "bbox": [176.0, 252.0, 197.0, 262.0]}, {"text": "21–67", "bbox": [250.0, 252.0, 276.0, 262.0]}, {"text": "Uniform basaloid cells in nests or sheets, with comedonecrosis or abrupt keratinisation.", "bbox": [305.0, 252.0, 664.0, 263.0]}, {"text": "Warty", "bbox": [78.0, 263.0, 107.0, 274.0]}, {"text": "5–10", "bbox": [174.0, 262.0, 197.0, 274.0]}, {"text": "0-10", "bbox": [249.0, 263.0, 273.0, 274.0]}, {"text": "Condylomatous papillae with central fibrovascular cores and koilocytes.", "bbox": [305.0, 262.0, 600.0, 274.0]}, {"text": "Nests or sheets of cells with ample, clear cytoplasm with central or geographical necrosis.", "bbox": [305.0, 274.0, 672.0, 285.0]}, {"text": "Clear cell", "bbox": [78.0, 275.0, 117.0, 284.0]}, {"text": "20–30", "bbox": [250.0, 275.0, 277.0, 284.0]}, {"text": "<1", "bbox": [176.0, 276.0, 187.0, 283.0]}, {"text": "Lymphoepithelioma-", "bbox": [78.0, 286.0, 165.0, 298.0]}, {"text": "<1", "bbox": [174.0, 286.0, 186.0, 296.0]}, {"text": "Unknown", "bbox": [248.0, 286.0, 291.0, 298.0]}, {"text": "Poorly differentiated cells intermixed with dense lymphoplasmacytic and eosinophilic infiltrates.", "bbox": [305.0, 286.0, 701.0, 298.0]}, {"text": "like", "bbox": [90.0, 298.0, 107.0, 308.0]}, {"text": "Mixed", "bbox": [78.0, 308.0, 107.0, 320.0]}, {"text": "30–50", "bbox": [250.0, 308.0, 278.0, 320.0]}, {"text": "Mainly warty-basaloid carcinoma according to the WHO 2022 classification.", "bbox": [305.0, 308.0, 616.0, 320.0]}, {"text": "4–10", "bbox": [175.0, 309.0, 197.0, 320.0]}, {"text": "Others", "bbox": [78.0, 320.0, 110.0, 330.0]}, {"text": "SCC NOS", "bbox": [78.0, 332.0, 117.0, 343.0]}, {"text": "Unknown", "bbox": [174.0, 333.0, 216.0, 344.0]}, {"text": "Unknown", "bbox": [248.0, 333.0, 291.0, 344.0]}, {"text": "Keratinising carcinoma. This must be used only when evaluation of p16 is not available.", "bbox": [305.0, 332.0, 665.0, 344.0]}, {"text": "Squamous tumour nests intermixed with a minor mucinous glandular component", "bbox": [305.0, 343.0, 640.0, 354.0]}, {"text": "Adenosquamous", "bbox": [78.0, 344.0, 148.0, 354.0]}, {"text": "1–2", "bbox": [176.0, 344.0, 191.0, 354.0]}, {"text": "0–14", "bbox": [248.0, 344.0, 272.0, 354.0]}, {"text": "Mucoepidermoid", "bbox": [79.0, 354.0, 150.0, 366.0]}, {"text": "Unknown", "bbox": [174.0, 354.0, 216.0, 365.0]}, {"text": "Unknown", "bbox": [249.0, 354.0, 291.0, 365.0]}, {"text": "Clear separation between adenosquamous and mucoepidermoid is not provided in the WHO", "bbox": [305.0, 354.0, 686.0, 366.0]}, {"text": "classification. Salivary gland criteria can be applied but there is no consensus", "bbox": [306.0, 366.0, 621.0, 378.0]}, {"text": "HPV = human papillomavirus; NOS = not otherwise specified; SCC = squamous cell carcinoma; WHO = World Health Organization.", "bbox": [78.0, 382.0, 612.0, 394.0]}, {"text": "* The WHO 2022 classification consider these subtypes as part of usual-type SCC.", "bbox": [78.0, 392.0, 411.0, 405.0]}, {"text": "b This is considered a variant of cuniculatum carcinoma.", "bbox": [78.0, 404.0, 311.0, 417.0]}], "type": "Table", "position": 2}, {"raw_context": [{"text": "disease are discouraged). Following the 2022 World Health", "bbox": [66.0, 465.0, 390.0, 479.0]}, {"text": "Organization (WHO) classification, PeINs are now classified", "bbox": [66.0, 480.0, 390.0, 495.0]}, {"text": "as HPV-independent or HPV-associated carcinomas [ 8 ].", "bbox": [66.0, 495.0, 368.0, 510.0]}, {"text": "HPV infection is the main risk factor for penile cancer. Up", "bbox": [82.0, 511.0, 390.0, 525.0]}, {"text": "to 50% of cases are HPV-related, with HPV 16 the most fre-", "bbox": [66.0, 526.0, 387.0, 540.0]}, {"text": "quent HPV genotype [ 9 ]. The new pathology classification", "bbox": [66.0, 541.0, 389.0, 555.0]}, {"text": "more clearly separates HPV-related and non–HPV-related", "bbox": [66.0, 557.0, 389.0, 570.0]}, {"text": "tumours ( Table 1 ). In analogy to other HPV-associated can-", "bbox": [66.0, 572.0, 388.0, 586.0]}, {"text": "cers, HPV-positive penile cancer may be associated with", "bbox": [66.0, 588.0, 390.0, 601.0]}, {"text": "better survival than HPV-negative disease, but more data", "bbox": [66.0, 603.0, 390.0, 616.0]}, {"text": "are needed, underlining the importance of routine assess-", "bbox": [66.0, 618.0, 387.0, 632.0]}, {"text": "ment of HPV status in all patients with penile cancer", "bbox": [66.0, 633.0, 389.0, 647.0]}, {"text": "[10,11] . Several other risk factors for penile cancer have", "bbox": [66.0, 649.0, 389.0, 662.0]}, {"text": "been identified, including phimosis, chronic penile inflam-", "bbox": [66.0, 664.0, 388.0, 679.0]}, {"text": "mation, lichen sclerosus, smoking, ultraviolet A photother-", "bbox": [66.0, 680.0, 388.0, 693.0]}, {"text": "apy, and low socioeconomic status [12] .", "bbox": [66.0, 695.0, 285.0, 708.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "Survival", "bbox": [115.0, 738.0, 159.0, 751.0]}], "type": "Section-header", "position": 4}, {"raw_context": [{"text": "Survival", "bbox": [115.0, 738.0, 159.0, 751.0]}, {"text": "3.1.3.", "bbox": [67.0, 739.0, 96.0, 751.0]}, {"text": "Patient outcomes are influenced by clinical and histological", "bbox": [66.0, 751.0, 389.0, 766.0]}, {"text": "features ( Table 1 ) [ 13 – 15 ]. The most important prognostic", "bbox": [66.0, 767.0, 389.0, 781.0]}, {"text": "factor for survival is the presence and extent of nodal", "bbox": [66.0, 783.0, 389.0, 797.0]}, {"text": "metastases, with 5- yr cancer-specific survival (CSS) of", "bbox": [66.0, 798.0, 389.0, 812.0]}, {"text": "approximately 95%, 80%, 65%, and 35% for N0, N1, N2, and", "bbox": [66.0, 813.0, 389.0, 827.0]}, {"text": "N3 disease, respectively [ 16 ]. Patients with distant metas-", "bbox": [66.0, 829.0, 388.0, 842.0]}, {"text": "tases have the worst outcomes, with 5-yr survival of only", "bbox": [66.0, 844.0, 389.0, 859.0]}, {"text": "16% [ 17 ].", "bbox": [67.0, 859.0, 119.0, 874.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "Pathology reporting", "bbox": [115.0, 902.0, 214.0, 916.0]}, {"text": "3.1.4.", "bbox": [68.0, 904.0, 95.0, 916.0]}, {"text": "The data set template from the International Collaboration", "bbox": [67.0, 917.0, 390.0, 931.0]}, {"text": "on Cancer Reporting (ICCR) should be used for pathology", "bbox": [66.0, 932.0, 389.0, 947.0]}, {"text": "reporting, which includes fields for information on the ana-", "bbox": [66.0, 948.0, 387.0, 962.0]}, {"text": "tomic site of the primary tumour, histological type, grade,", "bbox": [66.0, 963.0, 389.0, 977.0]}, {"text": "depth of invasion, perineural invasion, vascular invasion", "bbox": [66.0, 978.0, 390.0, 993.0]}, {"text": "(venous and/or lymphatic), invasion of the corpus spongio-", "bbox": [66.0, 995.0, 387.0, 1008.0]}], "type": "Text", "position": 6}, {"raw_context": [{"text": "sum and/or cavernosum, surgical margins, and p16", "bbox": [411.0, 466.0, 732.0, 479.0]}, {"text": "immunohistochemistry results [18] .", "bbox": [410.0, 480.0, 607.0, 495.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "Classification", "bbox": [450.0, 524.0, 518.0, 538.0]}, {"text": "3.2.", "bbox": [411.0, 525.0, 430.0, 538.0]}], "type": "Section-header", "position": 8}, {"raw_context": [{"text": "The eighth edition of the Union for International Cancer", "bbox": [410.0, 548.0, 732.0, 563.0]}, {"text": "Control/American Joint Committee on Cancer TNM classifi-", "bbox": [410.0, 564.0, 731.0, 578.0]}, {"text": "cation is the system currently used for penile cancer and", "bbox": [410.0, 578.0, 732.0, 592.0]}, {"text": "was last updated in 2017 (Table 2) [19,20] .", "bbox": [410.0, 593.0, 645.0, 608.0]}], "type": "Text", "position": 9}, {"raw_context": [{"text": "3.3.", "bbox": [410.0, 638.0, 430.0, 651.0]}], "type": "Section-header", "position": 10}, {"raw_context": [{"text": "Diagnostic evaluation and staging", "bbox": [450.0, 636.0, 620.0, 651.0]}], "type": "Section-header", "position": 11}, {"raw_context": [{"text": "Primary tumour staging", "bbox": [458.0, 660.0, 577.0, 674.0]}, {"text": "3.3.1.", "bbox": [411.0, 661.0, 438.0, 674.0]}, {"text": "Penile cancers are usually clinically evident lesions, often", "bbox": [410.0, 675.0, 733.0, 690.0]}, {"text": "presenting as raised or ulcerated lesions [ 21 ]. However,", "bbox": [410.0, 690.0, 732.0, 705.0]}, {"text": "the appearance of penile tumours can be heterogeneous", "bbox": [410.0, 706.0, 733.0, 720.0]}, {"text": "and can sometimes be hidden under the foreskin in the case", "bbox": [410.0, 721.0, 732.0, 736.0]}, {"text": "of phimosis. Physical examination is a reliable method for", "bbox": [410.0, 736.0, 731.0, 751.0]}, {"text": "estimating penile tumour size and clinical T stage. The", "bbox": [410.0, 751.0, 732.0, 766.0]}, {"text": "dimensions, anatomic location, and extent of local invasion", "bbox": [410.0, 766.0, 732.0, 781.0]}, {"text": "should be noted. In distinguishing T1 from T2 disease, mag-", "bbox": [410.0, 783.0, 731.0, 796.0]}, {"text": "netic resonance imaging (MRI) does not outperform physi-", "bbox": [410.0, 797.0, 731.0, 811.0]}, {"text": "cal examination. However, when there is uncertainty as to", "bbox": [410.0, 813.0, 733.0, 827.0]}, {"text": "whether the tumour is invading the cavernosal bodies", "bbox": [410.0, 829.0, 732.0, 842.0]}, {"text": "(cT3) and/or if organ-sparing treatment options are being", "bbox": [410.0, 844.0, 732.0, 857.0]}, {"text": "considered, MRI can be helpful [22,23] . Ultrasound (US)", "bbox": [410.0, 858.0, 733.0, 873.0]}, {"text": "can be considered if MRI is not available [ 24 ].", "bbox": [410.0, 874.0, 661.0, 888.0]}], "type": "Text", "position": 12}, {"raw_context": [{"text": "Penile biopsy", "bbox": [459.0, 919.0, 525.0, 932.0]}], "type": "Section-header", "position": 13}, {"raw_context": [{"text": "Penile biopsy", "bbox": [459.0, 919.0, 525.0, 932.0]}, {"text": "3.3.2.", "bbox": [411.0, 920.0, 438.0, 931.0]}, {"text": "A biopsy of the primary tumour should be obtained when", "bbox": [410.0, 933.0, 733.0, 947.0]}, {"text": "there is doubt about the exact nature of the lesion. Histolog-", "bbox": [410.0, 949.0, 731.0, 962.0]}, {"text": "ical confirmation is necessary to guide management when", "bbox": [410.0, 965.0, 733.0, 977.0]}, {"text": "treatment is planned with topical agents, radiotherapy, or", "bbox": [410.0, 978.0, 732.0, 993.0]}, {"text": "laser surgery [ 21 ].", "bbox": [410.0, 995.0, 510.0, 1008.0]}], "type": "Text", "position": 14}, {"raw_context": [{"text": "3", "bbox": [723.0, 43.0, 732.0, 54.0]}], "type": "Text", "position": 15}, {"raw_context": [{"text": "Please cite this article as: O.R. Brouwer, M. Albersen, A. Parnham et al., European Association of Urology-American Society of Clinical Oncology Col-", "bbox": [70.0, 1028.0, 729.0, 1040.0]}], "type": "Text", "position": 16}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/泌尿外科/2023 EAU／ASCO指南：阴茎癌（更新版）.pdf", "page_num": 3}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type2": "缺少换行#1#1#Mortality Other features Subtype另起一行\n序号格式不一致#21#21#3.1.3.应该在句首\n序号格式不一致#23#23#3.1.4.应该在句首\n多余换行#24#25#the corpus spongio-和sum and/or cavernosum是一句话\n序号格式不一致#26#26#3.2.应该在句首\n序号格式不一致#30#30#3.3.1.应该在句首\n序号格式不一致#33#33#3.3.2.应该在句首", "type3": "无关文本#0#36#classification [13,14] 部分段落末尾，以及句末的数字问题无关噪声应用全文\n无关文本#22#22# ( Table 1 ) \n无关文本#27#27# (Table 2)\n无关文本#32#32#  Penile Biopsy\n无关文本#35#35#3", "type4": "语意重复#20#20# Survival", "type6": "准确性#1#17#表格内容内容杂乱\n有用性#36#36#Please cite this article as: ....为页脚内容\n"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:42", "update_time": "2024-05-08 23:01:21"}
{"id": 1082658, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 738, "source_info": {"seq_id": "cff69166-6acb-4eff-96e6-b45f4d50cf3d", "title": null, "text": "【0】页码:5\n\n【1】## // Apem\n\n【2】\n other day rather than every day, while maintaining calcium and vitamin D concentrations in the normal range. As short-term administration or inhaled formulations of corticosteroid can also affect bone density, 13 it is difficult to recommend safe doses and durations. 15\n\n【3】## Evaluation In Patient With Low Bmd Or Increased Risk Of Fracture\n\n【4】\n In pediatric patients with primary bone disease or those at risk of secondary bone disease, DXA should be performed when the patient might benefit from interventions to decrease the risk of clinically significant fracture. If follow-up DXA is indicated, the minimum interval between scans should be 6–12 months. 91 The evaluation processes according to risk of osteoporosis are shown in Fig. 1.\n\n【5】## Conservative Management For Optimizing Bone Health\n\n【6】\n Modifiable determinants of bone mass include nutrition, exercise, lifestyle, body weight, lean body mass, and hormonal status. These conditions should be adequately maintained to optimize bone health. 83\n\n【7】 12. In 11. Nutrition\n\n【8】 Many studies have reported that calcium and vitamin D supplementation is helpful in increasing bone mass and BMD in children. These nutritional elements should be supplemented\n\n【9】 Table 4. Dietary reference intake of calcium and vitamin D\n\n【10】 according to age Vitamin D (IU/day) Calcium (mg/day) Age RDA RDA UL UL 0–6 Months 1,000 1,000 6–12 Months 1,500 1,500 1–2 Years 500 2,500 2,500 3–5 Years 2,500 600 3,000 400–600 6–8 Years 700 2,500 3,000 9–11 Years 800 3,000 4,000 12-14 Years M, 1,000; F, 900 3,000 4,000 15–18 Years M, 900; F, 800 3,000 4,000 RDA, recommended daily allowance; UL, upper limit; M, male; F, female.\n\n【11】\n Adapted from The Korean Nutrition Society. 2020 Dietary Reference Intakes for Koreans. 31\n\n【12】 using food rather than medicine in healthy children. 34 - 371 Many types of foods are good dietary sources of calcium and vitamin D. Human milk or infant formula is the primary source of calcium for healthy infants in the first year, and milk and other ,dairy products are the major sources of calcium after the first year of life. Other dietary sources include green leafy vegetables, legumes, nuts, cereal, and fruit juices. The bioavailability of calcium from vegetables is generally high but is reduced by binding with oxalate in spinach, collard greens, and beans and with phytate in whole bran cereals. Natural dietary sources of vitamin D include cod liver oil, salmon, sardines, tuna, and fortified foods. Exposure to ultraviolet B radiation from sunlight is the major source of vitamin D production. 83 The recommended daily allowance and upper limit of calcium and vitamin D are shown in Table 4. 8,36-39 If calcium or vitamin D deficiency causes low BMD, it should be administered at a therapeutic dosage (Table 5). 8,40 Several types of vitamin D prescriptions are available including ergocalciferol (vitamin D2), /cholecalciferol (vitamin D3), alphacalcidol (1 a -hydroxyvitamin D3), and calcitriol (1,25-dihydroxyvitamin D3). Vitamin D3, an active form of vitamin D, is frequently used in children with vitamin D deficiencies. Alphacalcidol or calcitriol is used in children with renal diseases. 90 Ingestion of adequate amounts of calories, proteins, and vegetables or fruits containing high vitamin C, vitamin K, potassium, magnesium, copper, and manganese contents is also needed to maintain bone health in children. 417 The prescription forms of calcium are calcium carbonate (40% elemental calcium), calcium citrate (21% elemental calcium), calcium lactate (13% elemental calcium), and calcium glutamate (9% elemental calcium). Calcium carbonate should be taken with meals to promote absorption, but calcium citrate can be taken on an empty stomach. The adverse effects of consuming excessive calcium are dyspepsia, constipation, urinary stones, and hypercalcemia, especially when taken with vitamin D. 89\n\n【13】## 2. Exercise\n\n【14】\n Mechanical forces applied to the skeleton increase bone formation, and weight-bearing exercises improve bone mineral , deposition. 42-45 High-impact and low-frequency exercises such as jumping, skipping, and hopping for 10 minutes 3 times per week increases the BMD of the femoral neck in healthy children. 46) Weight-bearing exercises such as walking, jogging, jumping, and dancing are better than non-weight-bearing exercises such as swimming or bicycle riding. 45, 46 ) However, excessive high-impact and prolonged exercises can increase\n\n【15】 Table 5. Treatment of Vitamin D deficiency according to Guidelines Pediatric Endocrine Society American Academy of Pediatrics Age 1,000 IU daily, for 2–4 weeks 50,000 IU weekly, for 6 weeks or 2,000 IU daily for 6 weeks followed by a maintenance dose 0–1 Month of 400–1,000 IU daily 1–12 Months 1,000–5,000 IU daily, for 2–4 weeks 50,000 IU weekly, for 6–8 weeks or 2,000 IU daily for 6–8 weeks followed by a maintenance 1–18 Years More than 5,000 IU daily, For 2–4 weeks dose of 600–1,000 IU daily Adapted from Holick et al. J Clin Endocrinol Metab 2011;96:1911-30. 1\n", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "// apem", "bbox": [36.0, 31.0, 134.0, 63.0]}], "type": "Section-header", "position": 1}, {"raw_context": [{"text": "other day rather than every day, while maintaining calcium and", "bbox": [65.0, 93.0, 383.0, 108.0]}, {"text": "vitamin D concentrations in the normal range. As short-term", "bbox": [65.0, 109.0, 383.0, 124.0]}, {"text": "administration or inhaled formulations of corticosteroid can", "bbox": [66.0, 125.0, 383.0, 140.0]}, {"text": "also affect bone density, 13 it is difficult to recommend safe doses", "bbox": [66.0, 141.0, 384.0, 156.0]}, {"text": "and durations. 15", "bbox": [66.0, 157.0, 144.0, 172.0]}], "type": "Text", "position": 2}, {"raw_context": [{"text": "Evaluation in patient with low BMD or", "bbox": [66.0, 189.0, 324.0, 203.0]}, {"text": "increased risk of fracture", "bbox": [66.0, 205.0, 234.0, 220.0]}], "type": "Section-header", "position": 3}, {"raw_context": [{"text": "In pediatric patients with primary bone disease or those at", "bbox": [77.0, 239.0, 383.0, 254.0]}, {"text": "risk of secondary bone disease, DXA should be performed when", "bbox": [66.0, 255.0, 383.0, 270.0]}, {"text": "the patient might benefit from interventions to decrease the risk", "bbox": [64.0, 270.0, 383.0, 285.0]}, {"text": "of clinically significant fracture. If follow-up DXA is indicated,", "bbox": [65.0, 286.0, 383.0, 301.0]}, {"text": "the minimum interval between scans should be 6–12 months. 91", "bbox": [65.0, 302.0, 381.0, 316.0]}, {"text": "The evaluation processes according to risk of osteoporosis are", "bbox": [66.0, 317.0, 383.0, 333.0]}, {"text": "shown in Fig. 1.", "bbox": [66.0, 333.0, 144.0, 348.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": "Conservative management for optimizing", "bbox": [65.0, 367.0, 350.0, 382.0]}, {"text": "bone health", "bbox": [66.0, 382.0, 151.0, 398.0]}], "type": "Section-header", "position": 5}, {"raw_context": [{"text": "Modifiable determinants of bone mass include nutrition,", "bbox": [77.0, 416.0, 383.0, 430.0]}, {"text": "exercise, lifestyle, body weight, lean body mass, and hormonal", "bbox": [65.0, 431.0, 383.0, 446.0]}, {"text": "status. These conditions should be adequately maintained to", "bbox": [66.0, 448.0, 383.0, 462.0]}, {"text": "optimize bone health. 83", "bbox": [66.0, 463.0, 181.0, 478.0]}], "type": "Text", "position": 6}, {"raw_context": [{"text": "12. In 11. Nutrition", "bbox": [20.0, 476.0, 128.0, 520.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "Many studies have reported that calcium and vitamin D", "bbox": [77.0, 529.0, 383.0, 545.0]}, {"text": "supplementation is helpful in increasing bone mass and BMD", "bbox": [66.0, 546.0, 383.0, 560.0]}, {"text": "in children. These nutritional elements should be supplemented", "bbox": [66.0, 561.0, 383.0, 576.0]}], "type": "Text", "position": 8}, {"raw_context": [{"text": "Table 4. Dietary reference intake of calcium and vitamin D", "bbox": [67.0, 600.0, 381.0, 615.0]}], "type": "Text", "position": 9}, {"raw_context": [{"text": "according to age", "bbox": [66.0, 616.0, 150.0, 630.0]}, {"text": "Vitamin D (IU/day)", "bbox": [275.0, 631.0, 359.0, 645.0]}, {"text": "Calcium (mg/day)", "bbox": [154.0, 633.0, 234.0, 645.0]}, {"text": "Age", "bbox": [68.0, 640.0, 88.0, 653.0]}, {"text": "RDA", "bbox": [160.0, 647.0, 181.0, 661.0]}, {"text": "RDA", "bbox": [274.0, 647.0, 296.0, 661.0]}, {"text": "UL", "bbox": [224.0, 649.0, 239.0, 661.0]}, {"text": "UL", "bbox": [342.0, 649.0, 355.0, 661.0]}, {"text": "0–6 Months", "bbox": [67.0, 664.0, 123.0, 676.0]}, {"text": "1,000", "bbox": [220.0, 665.0, 246.0, 676.0]}, {"text": "1,000", "bbox": [337.0, 665.0, 363.0, 676.0]}, {"text": "6–12 Months", "bbox": [66.0, 679.0, 128.0, 693.0]}, {"text": "1,500", "bbox": [220.0, 679.0, 247.0, 693.0]}, {"text": "1,500", "bbox": [336.0, 679.0, 363.0, 693.0]}, {"text": "1–2 Years", "bbox": [67.0, 695.0, 112.0, 708.0]}, {"text": "500", "bbox": [162.0, 696.0, 181.0, 707.0]}, {"text": "2,500", "bbox": [220.0, 696.0, 246.0, 708.0]}, {"text": "2,500", "bbox": [337.0, 696.0, 363.0, 708.0]}, {"text": "3–5 Years", "bbox": [66.0, 710.0, 112.0, 724.0]}, {"text": "2,500", "bbox": [219.0, 710.0, 247.0, 724.0]}, {"text": "600", "bbox": [162.0, 711.0, 181.0, 724.0]}, {"text": "3,000", "bbox": [337.0, 711.0, 363.0, 724.0]}, {"text": "400–600", "bbox": [266.0, 720.0, 307.0, 732.0]}, {"text": "6–8 Years", "bbox": [68.0, 728.0, 112.0, 740.0]}, {"text": "700", "bbox": [162.0, 728.0, 182.0, 740.0]}, {"text": "2,500", "bbox": [219.0, 727.0, 246.0, 740.0]}, {"text": "3,000", "bbox": [337.0, 728.0, 363.0, 740.0]}, {"text": "9–11 Years", "bbox": [67.0, 742.0, 117.0, 756.0]}, {"text": "800", "bbox": [162.0, 743.0, 182.0, 754.0]}, {"text": "3,000", "bbox": [220.0, 743.0, 247.0, 755.0]}, {"text": "4,000", "bbox": [336.0, 743.0, 363.0, 756.0]}, {"text": "12-14 Years", "bbox": [68.0, 758.0, 123.0, 771.0]}, {"text": "M, 1,000; F, 900", "bbox": [136.0, 758.0, 207.0, 771.0]}, {"text": "3,000", "bbox": [219.0, 758.0, 246.0, 771.0]}, {"text": "4,000", "bbox": [336.0, 758.0, 363.0, 771.0]}, {"text": "15–18 Years", "bbox": [67.0, 773.0, 122.0, 787.0]}, {"text": "M, 900; F, 800", "bbox": [140.0, 773.0, 203.0, 787.0]}, {"text": "3,000", "bbox": [220.0, 774.0, 246.0, 786.0]}, {"text": "4,000", "bbox": [337.0, 774.0, 363.0, 786.0]}, {"text": "RDA, recommended daily allowance; UL, upper limit; M, male; F,", "bbox": [66.0, 790.0, 381.0, 803.0]}, {"text": "female.", "bbox": [67.0, 805.0, 104.0, 817.0]}], "type": "Table", "position": 10}, {"raw_context": [{"text": "Adapted from The Korean Nutrition Society. 2020 Dietary", "bbox": [67.0, 819.0, 379.0, 833.0]}, {"text": "Reference Intakes for Koreans. 31", "bbox": [66.0, 833.0, 215.0, 847.0]}], "type": "Text", "position": 11}, {"raw_context": [{"text": "using food rather than medicine in healthy children. 34 - 371 Many", "bbox": [410.0, 94.0, 725.0, 107.0]}, {"text": "types of foods are good dietary sources of calcium and vitamin", "bbox": [409.0, 109.0, 727.0, 124.0]}, {"text": "D. Human milk or infant formula is the primary source of", "bbox": [410.0, 125.0, 727.0, 140.0]}, {"text": "calcium for healthy infants in the first year, and milk and other", "bbox": [409.0, 141.0, 727.0, 156.0]}, {"text": ",dairy products are the major sources of calcium after the first", "bbox": [408.0, 157.0, 727.0, 172.0]}, {"text": "year of life. Other dietary sources include green leafy vegetables,", "bbox": [410.0, 172.0, 727.0, 187.0]}, {"text": "legumes, nuts, cereal, and fruit juices. The bioavailability of", "bbox": [410.0, 187.0, 727.0, 202.0]}, {"text": "calcium from vegetables is generally high but is reduced by", "bbox": [409.0, 204.0, 726.0, 218.0]}, {"text": "binding with oxalate in spinach, collard greens, and beans and", "bbox": [409.0, 219.0, 727.0, 234.0]}, {"text": "with phytate in whole bran cereals. Natural dietary sources", "bbox": [410.0, 235.0, 727.0, 249.0]}, {"text": "of vitamin D include cod liver oil, salmon, sardines, tuna,", "bbox": [409.0, 251.0, 727.0, 266.0]}, {"text": "and fortified foods. Exposure to ultraviolet B radiation from", "bbox": [410.0, 267.0, 732.0, 281.0]}, {"text": "sunlight is the major source of vitamin D production. 83 The", "bbox": [410.0, 282.0, 727.0, 297.0]}, {"text": "recommended daily allowance and upper limit of calcium and", "bbox": [410.0, 298.0, 727.0, 313.0]}, {"text": "vitamin D are shown in Table 4. 8,36-39 If calcium or vitamin", "bbox": [410.0, 313.0, 727.0, 328.0]}, {"text": "D deficiency causes low BMD, it should be administered at", "bbox": [410.0, 329.0, 727.0, 345.0]}, {"text": "a therapeutic dosage (Table 5). 8,40 Several types of vitamin D", "bbox": [409.0, 343.0, 727.0, 361.0]}, {"text": "prescriptions are available including ergocalciferol (vitamin D2),", "bbox": [410.0, 360.0, 727.0, 376.0]}, {"text": "/cholecalciferol (vitamin D3), alphacalcidol (1 a -hydroxyvitamin", "bbox": [408.0, 377.0, 727.0, 391.0]}, {"text": "D3), and calcitriol (1,25-dihydroxyvitamin D3). Vitamin D3,", "bbox": [409.0, 392.0, 727.0, 407.0]}, {"text": "an active form of vitamin D, is frequently used in children with", "bbox": [410.0, 408.0, 727.0, 422.0]}, {"text": "vitamin D deficiencies. Alphacalcidol or calcitriol is used in", "bbox": [410.0, 424.0, 728.0, 439.0]}, {"text": "children with renal diseases. 90", "bbox": [410.0, 440.0, 559.0, 454.0]}, {"text": "Ingestion of adequate amounts of calories, proteins, and", "bbox": [420.0, 456.0, 727.0, 471.0]}, {"text": "vegetables or fruits containing high vitamin C, vitamin K,", "bbox": [410.0, 472.0, 727.0, 486.0]}, {"text": "potassium, magnesium, copper, and manganese contents", "bbox": [410.0, 487.0, 727.0, 503.0]}, {"text": "is also needed to maintain bone health in children. 417 The", "bbox": [410.0, 504.0, 727.0, 517.0]}, {"text": "prescription forms of calcium are calcium carbonate (40%", "bbox": [410.0, 518.0, 727.0, 533.0]}, {"text": "elemental calcium), calcium citrate (21% elemental calcium),", "bbox": [408.0, 534.0, 727.0, 549.0]}, {"text": "calcium lactate (13% elemental calcium), and calcium glutamate", "bbox": [409.0, 550.0, 727.0, 565.0]}, {"text": "(9% elemental calcium). Calcium carbonate should be taken", "bbox": [409.0, 566.0, 727.0, 580.0]}, {"text": "with meals to promote absorption, but calcium citrate can be", "bbox": [410.0, 582.0, 727.0, 596.0]}, {"text": "taken on an empty stomach. The adverse effects of consuming", "bbox": [408.0, 597.0, 727.0, 612.0]}, {"text": "excessive calcium are dyspepsia, constipation, urinary stones,", "bbox": [408.0, 613.0, 728.0, 627.0]}, {"text": "and hypercalcemia, especially when taken with vitamin D. 89", "bbox": [410.0, 629.0, 702.0, 644.0]}], "type": "Text", "position": 12}, {"raw_context": [{"text": "2. Exercise", "bbox": [410.0, 659.0, 472.0, 675.0]}], "type": "Section-header", "position": 13}, {"raw_context": [{"text": "Mechanical forces applied to the skeleton increase bone", "bbox": [421.0, 695.0, 727.0, 711.0]}, {"text": "formation, and weight-bearing exercises improve bone mineral ,", "bbox": [410.0, 711.0, 732.0, 726.0]}, {"text": "deposition. 42-45 High-impact and low-frequency exercises", "bbox": [408.0, 724.0, 730.0, 744.0]}, {"text": "such as jumping, skipping, and hopping for 10 minutes 3 times", "bbox": [410.0, 743.0, 727.0, 758.0]}, {"text": "per week increases the BMD of the femoral neck in healthy", "bbox": [410.0, 758.0, 727.0, 773.0]}, {"text": "children. 46) Weight-bearing exercises such as walking, jogging,", "bbox": [408.0, 773.0, 727.0, 790.0]}, {"text": "jumping, and dancing are better than non-weight-bearing", "bbox": [409.0, 790.0, 728.0, 804.0]}, {"text": "exercises such as swimming or bicycle riding. 45, 46 ) However,", "bbox": [408.0, 805.0, 727.0, 820.0]}, {"text": "excessive high-impact and prolonged exercises can increase", "bbox": [410.0, 822.0, 727.0, 836.0]}], "type": "Text", "position": 14}, {"raw_context": [{"text": "Table 5. Treatment of Vitamin D deficiency according to Guidelines", "bbox": [67.0, 868.0, 387.0, 882.0]}, {"text": "Pediatric Endocrine Society", "bbox": [170.0, 883.0, 292.0, 898.0]}, {"text": "American Academy of Pediatrics", "bbox": [454.0, 883.0, 597.0, 898.0]}, {"text": "Age", "bbox": [67.0, 886.0, 88.0, 898.0]}, {"text": "1,000 IU daily, for 2–4 weeks", "bbox": [138.0, 900.0, 264.0, 914.0]}, {"text": "50,000 IU weekly, for 6 weeks or 2,000 IU daily for 6 weeks followed by a maintenance dose", "bbox": [328.0, 900.0, 725.0, 913.0]}, {"text": "0–1 Month", "bbox": [67.0, 901.0, 121.0, 913.0]}, {"text": "of 400–1,000 IU daily", "bbox": [334.0, 914.0, 428.0, 927.0]}, {"text": "1–12 Months", "bbox": [67.0, 915.0, 131.0, 929.0]}, {"text": "1,000–5,000 IU daily, for 2–4 weeks", "bbox": [137.0, 915.0, 293.0, 930.0]}, {"text": "50,000 IU weekly, for 6–8 weeks or 2,000 IU daily for 6–8 weeks followed by a maintenance", "bbox": [326.0, 930.0, 724.0, 946.0]}, {"text": "1–18 Years", "bbox": [66.0, 931.0, 118.0, 945.0]}, {"text": "More than 5,000 IU daily, For 2–4 weeks", "bbox": [136.0, 931.0, 314.0, 945.0]}, {"text": "dose of 600–1,000 IU daily", "bbox": [334.0, 946.0, 453.0, 958.0]}, {"text": "Adapted from Holick et al. J Clin Endocrinol Metab 2011;96:1911-30. 1", "bbox": [66.0, 961.0, 393.0, 975.0]}], "type": "Table", "position": 15}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2022】全科室最全临床指南+专家共识（最全版）/2022全科室临床指南/内分泌科/KSPE：优化儿童和青少年骨健康的临床实践指南（2022）.pdf", "page_num": 5}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "多余换行#8#12#8和12为同段\n表格格式错误#10#11#非表格格式\n缺少换行#12#12#Ingestion of adequate amounts of这里开始应换行\n表格格式错误#15#15#非表格格式", "type3": "无关文本#0#14#存在多处无关数字", "type4": null, "type5": null, "type6": null}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:42", "update_time": "2024-05-07 19:57:34"}
{"id": 1082657, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 738, "source_info": {"seq_id": "96c937cf-9b8a-4f0a-b590-025b0d3b3869", "title": null, "text": "【0】页码:10\n 10 H\n# 小狗 Sapem\n\n【1】\n E, Giuca MR. Pamidronate treatment stimulates the onset of recovery phase reducing fracture rate and skeletal deformities in patients with idiopathic juvenile osteoporosis: comparison with untreated patients. J Bone Miner Metab 2013;31:533-43.\n\n【2】53.\n\n【3】Bachrach LK, Ward LM. Clinical review 1: bisphosphonate use in childhood osteoporosis. J Clin Endocrinol Metab 2009;94:400-9.\n\n【4】54. Simm PJ, Biggin A, Zacharin MR, Rodda CP, Tham E, Siafarikas A, et al. Consensus guidelines on the use of bisphosphonate therapy in children and adolescents. J /Paediatr Child Health 2018;54:223-33.\n\n【5】55. Ozel S, Switzer L, Macintosh A, Fehlings D. Informing evidence based clinical practice guidelines for children with cerebral palsy at risk of osteoporosis: an update. Dev Med Child Neurol 2016;58:918-23.\n\n【6】Iwasaki T, Takei K, Nakamura S, Hosoda N, Yokota Y, Ishii M.\n\n【7】56.\n\n【8】Secondary osteoporosis in long-term bedridden patients with cerebral palsy. Pediatr Int 2008;50:269-75.\n\n【9】57.\n\n【10】Thornton J, Ashcroft DM, Mughal MZ, Elliott RA, O'Neill TW, Symmons D. Systematic review of effectiveness of bisphosphonates in treatment of low bone mineral density and fragility fractures in juvenile idiopathic arthritis. Arch Dis Child 2006;91:753-61.\n\n【11】Acott PD, Wong JA, Lang BA, Crocker JF. Pamidronate 58.\n\n【12】treatment of pediatric fracture patients on chronic steroid therapy. Pediatr Nephrol 2005;20:368-73.\n\n【13】59. El-Husseini AA, El-Agroudy AE, El-Sayed MF, Sobh MA, Ghoneim MA. Treatment of osteopenia and osteoporosis in renal transplant children and adolescents. Pediatr nate serv\n\n【14】 2/1.\n\n【15】 Transplant 2004;8:357-61.\n\n【16】60. Sbrocchi AM, Forget S, Laforte D, Azouz EM, Rodd C.\n\n【17】Zoledronic acid for the treatment of osteopenia in pediatric Crohn's disease. Pediatr Int 2010;52:754-61.\n\n【18】261 / Gordon KE, Dooley JM, Sheppard KM, MacSween J, Esser MJ Impact of bisphosphonates on survival for patients with Duchenne muscular dystrophy. Pediatrics 2011;127:e353-8.\n\n【19】Sbrocchi AM, Rauch F, Jacob P, McCormick A, McMillan 100.\n\n【20】HJ, Matzinger MA, et al. The use of intravenous bisphosphonate therapy to treat vertebral fractures due to osteoporosis among boys with Duchenne muscular 1941 dystrophy. Osteoporos Int 2012;23:2703-11.\n\n【21】63. Lee JM, Kim JE, Bae SH, Hah JO. Efficacy of pamidronate in children with low bone mineral density during and after chemotherapy for acute lymphoblastic leukemia and non- Hodgkin lymphoma. Blood Res 2013;48:99-106.\n\n【22】64. Carpenter PA, Hoffmeister P, Chesnut CH 3rd, Storer B, Charuhas PM, Woolfrey AE, et al. Bisphosphonate therapy for reduced bone mineral density in children with chronic graft-yersus-host disease. Biol Blood Marrow Transplant 2007;13:683-90.\n\n【23】65. Suresh E, Pazianas M, Abrahamsen B. Safety issues with bisphosphonate therapy for osteoporosis. Rheumatology (Oxford) 2014;53:19-31.\n\n【24】Khosla S, Bilezikian JP, Dempster DW, Lewiecki EM, Miller 66.\n\n【25】PD, Neer RM, et al. Benefits and risks of bisphosphonate /15 therapy for osteoporosis. J Clin Endocrinol Metab 2012;97:2272-82.\n\n【26】Makitie O. Causes, mechanisms and management of 67.\n\n【27】paediatric osteoporosis. Nat Rev Rheumatol 2013;9:465-75.\n\n【28】 小狗科研公开课\n\n【29】 4B 2 sig\n\n【30】 小狗科研公开jg", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "10 H", "bbox": [101.0, 57.0, 132.0, 75.0]}], "type": "Text", "position": 1}, {"raw_context": [{"text": "小狗 sapem", "bbox": [589.0, 23.0, 727.0, 73.0]}], "type": "Title", "position": 2}, {"raw_context": [{"text": "E, Giuca MR. Pamidronate treatment stimulates the", "bbox": [88.0, 93.0, 383.0, 108.0]}, {"text": "onset of recovery phase reducing fracture rate and", "bbox": [88.0, 109.0, 383.0, 124.0]}, {"text": "skeletal deformities in patients with idiopathic juvenile", "bbox": [88.0, 125.0, 383.0, 140.0]}, {"text": "osteoporosis: comparison with untreated patients. J Bone", "bbox": [88.0, 141.0, 385.0, 156.0]}, {"text": "Miner Metab 2013;31:533-43.", "bbox": [88.0, 157.0, 238.0, 171.0]}, {"text": "53.", "bbox": [66.0, 173.0, 87.0, 185.0]}, {"text": "Bachrach LK, Ward LM. Clinical review 1: bisphosphonate", "bbox": [84.0, 172.0, 383.0, 187.0]}, {"text": "use in childhood osteoporosis. J Clin Endocrinol Metab", "bbox": [88.0, 187.0, 383.0, 202.0]}, {"text": "2009;94:400-9.", "bbox": [89.0, 204.0, 164.0, 217.0]}, {"text": "54. Simm PJ, Biggin A, Zacharin MR, Rodda CP, Tham E,", "bbox": [66.0, 219.0, 383.0, 233.0]}, {"text": "Siafarikas A, et al. Consensus guidelines on the use of", "bbox": [88.0, 235.0, 383.0, 249.0]}, {"text": "bisphosphonate therapy in children and adolescents. J", "bbox": [88.0, 250.0, 383.0, 265.0]}, {"text": "/Paediatr Child Health 2018;54:223-33.", "bbox": [86.0, 266.0, 279.0, 281.0]}, {"text": "55. Ozel S, Switzer L, Macintosh A, Fehlings D. Informing", "bbox": [66.0, 282.0, 383.0, 297.0]}, {"text": "evidence based clinical practice guidelines for children", "bbox": [88.0, 298.0, 383.0, 313.0]}, {"text": "with cerebral palsy at risk of osteoporosis: an update. Dev", "bbox": [88.0, 314.0, 383.0, 328.0]}, {"text": "Med Child Neurol 2016;58:918-23.", "bbox": [88.0, 330.0, 263.0, 344.0]}, {"text": "Iwasaki T, Takei K, Nakamura S, Hosoda N, Yokota Y, Ishii M.", "bbox": [87.0, 345.0, 382.0, 360.0]}, {"text": "56.", "bbox": [66.0, 346.0, 86.0, 359.0]}, {"text": "Secondary osteoporosis in long-term bedridden patients", "bbox": [88.0, 360.0, 382.0, 375.0]}, {"text": "with cerebral palsy. Pediatr Int 2008;50:269-75.", "bbox": [88.0, 377.0, 320.0, 391.0]}, {"text": "57.", "bbox": [66.0, 393.0, 86.0, 407.0]}, {"text": "Thornton J, Ashcroft DM, Mughal MZ, Elliott RA, O'Neill", "bbox": [87.0, 392.0, 383.0, 407.0]}, {"text": "TW, Symmons D. Systematic review of effectiveness of", "bbox": [88.0, 409.0, 383.0, 422.0]}, {"text": "bisphosphonates in treatment of low bone mineral density", "bbox": [88.0, 424.0, 382.0, 439.0]}, {"text": "and fragility fractures in juvenile idiopathic arthritis. Arch", "bbox": [88.0, 440.0, 383.0, 454.0]}, {"text": "Dis Child 2006;91:753-61.", "bbox": [88.0, 456.0, 220.0, 470.0]}, {"text": "Acott PD, Wong JA, Lang BA, Crocker JF. Pamidronate", "bbox": [87.0, 471.0, 383.0, 486.0]}, {"text": "58.", "bbox": [67.0, 472.0, 86.0, 485.0]}, {"text": "treatment of pediatric fracture patients on chronic steroid", "bbox": [88.0, 487.0, 383.0, 502.0]}, {"text": "therapy. Pediatr Nephrol 2005;20:368-73.", "bbox": [88.0, 503.0, 293.0, 518.0]}, {"text": "59. El-Husseini AA, El-Agroudy AE, El-Sayed MF, Sobh MA,", "bbox": [66.0, 518.0, 383.0, 533.0]}, {"text": "Ghoneim MA. Treatment of osteopenia and osteoporosis", "bbox": [88.0, 534.0, 383.0, 549.0]}, {"text": "in renal transplant children and adolescents. Pediatr", "bbox": [88.0, 550.0, 383.0, 564.0]}, {"text": "nate serv", "bbox": [267.0, 560.0, 409.0, 623.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "2/1.", "bbox": [396.0, 381.0, 421.0, 401.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": "Transplant 2004;8:357-61.", "bbox": [432.0, 93.0, 561.0, 108.0]}, {"text": "60. Sbrocchi AM, Forget S, Laforte D, Azouz EM, Rodd C.", "bbox": [409.0, 109.0, 726.0, 123.0]}, {"text": "Zoledronic acid for the treatment of osteopenia in pediatric", "bbox": [432.0, 125.0, 726.0, 140.0]}, {"text": "Crohn's disease. Pediatr Int 2010;52:754-61.", "bbox": [432.0, 141.0, 649.0, 155.0]}, {"text": "261 / Gordon KE, Dooley JM, Sheppard KM, MacSween J, Esser", "bbox": [407.0, 155.0, 727.0, 173.0]}, {"text": "MJ Impact of bisphosphonates on survival for patients with", "bbox": [431.0, 172.0, 727.0, 187.0]}, {"text": "Duchenne muscular dystrophy. Pediatrics 2011;127:e353-8.", "bbox": [432.0, 187.0, 727.0, 202.0]}, {"text": "Sbrocchi AM, Rauch F, Jacob P, McCormick A, McMillan", "bbox": [430.0, 204.0, 727.0, 218.0]}, {"text": "100.", "bbox": [410.0, 205.0, 430.0, 217.0]}, {"text": "HJ, Matzinger MA, et al. The use of intravenous", "bbox": [432.0, 219.0, 727.0, 234.0]}, {"text": "bisphosphonate therapy to treat vertebral fractures due", "bbox": [432.0, 235.0, 727.0, 249.0]}, {"text": "to osteoporosis among boys with Duchenne muscular", "bbox": [432.0, 250.0, 727.0, 266.0]}, {"text": "1941", "bbox": [737.0, 258.0, 784.0, 300.0]}, {"text": "dystrophy. Osteoporos Int 2012;23:2703-11.", "bbox": [432.0, 266.0, 650.0, 281.0]}, {"text": "63. Lee JM, Kim JE, Bae SH, Hah JO. Efficacy of pamidronate", "bbox": [409.0, 282.0, 727.0, 297.0]}, {"text": "in children with low bone mineral density during and after", "bbox": [432.0, 298.0, 726.0, 313.0]}, {"text": "chemotherapy for acute lymphoblastic leukemia and non-", "bbox": [432.0, 314.0, 725.0, 329.0]}, {"text": "Hodgkin lymphoma. Blood Res 2013;48:99-106.", "bbox": [432.0, 330.0, 672.0, 345.0]}, {"text": "64. Carpenter PA, Hoffmeister P, Chesnut CH 3rd, Storer B,", "bbox": [408.0, 345.0, 727.0, 360.0]}, {"text": "Charuhas PM, Woolfrey AE, et al. Bisphosphonate therapy", "bbox": [432.0, 360.0, 726.0, 375.0]}, {"text": "for reduced bone mineral density in children with chronic", "bbox": [432.0, 377.0, 727.0, 391.0]}, {"text": "graft-yersus-host disease. Biol Blood Marrow Transplant", "bbox": [431.0, 392.0, 727.0, 407.0]}, {"text": "2007;13:683-90.", "bbox": [432.0, 408.0, 516.0, 422.0]}, {"text": "65. Suresh E, Pazianas M, Abrahamsen B. Safety issues with", "bbox": [409.0, 423.0, 727.0, 439.0]}, {"text": "bisphosphonate therapy for osteoporosis. Rheumatology", "bbox": [432.0, 440.0, 727.0, 454.0]}, {"text": "(Oxford) 2014;53:19-31.", "bbox": [432.0, 455.0, 554.0, 470.0]}, {"text": "Khosla S, Bilezikian JP, Dempster DW, Lewiecki EM, Miller", "bbox": [431.0, 471.0, 727.0, 486.0]}, {"text": "66.", "bbox": [410.0, 473.0, 429.0, 485.0]}, {"text": "PD, Neer RM, et al. Benefits and risks of bisphosphonate", "bbox": [432.0, 487.0, 727.0, 502.0]}, {"text": "/15", "bbox": [737.0, 493.0, 782.0, 521.0]}, {"text": "therapy for osteoporosis. J Clin Endocrinol Metab", "bbox": [432.0, 503.0, 727.0, 518.0]}, {"text": "2012;97:2272-82.", "bbox": [432.0, 517.0, 520.0, 534.0]}, {"text": "Makitie O. Causes, mechanisms and management of", "bbox": [430.0, 533.0, 727.0, 548.0]}, {"text": "67.", "bbox": [409.0, 535.0, 430.0, 548.0]}, {"text": "paediatric osteoporosis. Nat Rev Rheumatol 2013;9:465-75.", "bbox": [432.0, 550.0, 725.0, 564.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "小狗科研公开课", "bbox": [579.0, 654.0, 755.0, 742.0]}], "type": "Text", "position": 6}, {"raw_context": [{"text": "4B 2 sig", "bbox": [11.0, 712.0, 132.0, 780.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "小狗科研公开jg", "bbox": [278.0, 804.0, 454.0, 888.0]}], "type": "Text", "position": 8}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2022】全科室最全临床指南+专家共识（最全版）/2022全科室临床指南/内分泌科/KSPE：优化儿童和青少年骨健康的临床实践指南（2022）.pdf", "page_num": 10}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": null, "type3": null, "type4": null, "type5": null, "type6": "信息有用性#0#30#参考文献"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:42", "update_time": "2024-05-07 19:31:50"}
{"id": 1082656, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 738, "source_info": {"seq_id": "6f563865-3706-4100-900e-13e3419e4492", "title": null, "text": "【0】页码:11\n 11\n\n【1】 dynamic sentinel lymph node biopsy in men with impalpable and palpable inguinal lymph nodes. BJU Int 2022;130:331–6.\n\n【2】[34] Wever L, de Vries HM, Dell'Oglio P, et al. Incidence and risk factor analysis of complications after sentinel node biopsy for penile cancer. BJU Int 2022;130:486–95 .\n\n【3】[35] Dell'Oglio P, de Vries HM, Mazzone E, et al. Hybrid indocyanine green-( 39 m)Tc-nanocolloid for single-photon emission computed tomography and combined radio- and fluorescence-guided sentinel node biopsy in penile cancer: results of 740 inguinal basins assessed at a single institution. Eur Urol 2020;78:865–72 .\n\n【4】[36] Zou ZJ, Liu ZH, Tang LY, et al. Radiocolloid-based dynamic sentinel lymph node biopsy in penile cancer with clinically negative inguinal lymph node: an updated systematic review and metaanalysis. Int Urol Nephrol 2016;48:2001–13 .\n\n【5】[37] de Vries HM, Lee HJ, Lam W, et al. Clinicopathological predictors of finding additional inguinal lymph node metastases in penile cancer patients after positive dynamic sentinel node biopsy: a European multicentre evaluation. BJU Int 2022;130:126–32 .\n\n【6】[38] Hughes B, Leijte J, Shabbir M, Watkin N, Horenblas S. Non-invasive and minimally invasive staging of regional lymph nodes in penile cancer. World J Urol 2009;27:197–203 .\n\n【7】[39] Hövels AM, Heesakkers RA, Adang EM, et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol 2008;63:387–95 .\n\n【8】[40] Graafland NM, Leijte JA, Valdes Olmos RA, Hoefnagel CA, Teertstra HJ, Horenblas S. Scanning with 18 F-FDG-PET/CT for detection of pelvic nodal involvement in inguinal node-positive penile carcinoma. Eur Urol 2009;56:339–45 .\n\n【9】[41] Ashley S, Shanks JH, Oliveira P, et al. Human papilloma virus (HPV) status may impact treatment outcomes in patients with precancerous penile lesions (an eUROGEN Study). Int J Impot Res 2021;33:620–6 .\n\n【10】[42] Hoekstra RJ, Trip EJ, Ten Kate FJ, Horenblas S, Lock MT. Penile intraepithelial neoplasia: Nomenclature, incidence and progression to malignancy in the Netherlands. Int J Urol 2019;26:353–7 .\n\n【11】[43] Kravvas G, Ge L, Ng J, et al. The management of penile intraepithelial neoplasia (PeIN): clinical and histological features and treatment of 345 patients and a review of the literature. J Dermatol Treat 2022;33:1047–62 .\n\n【12】[44] Shabbir M, Muneer A, Kalsi J, et al. Glans resurfacing for the treatment of carcinoma in situ of the penis: surgical technique and outcomes. Eur Urol 2011;59:142–7 .\n\n【13】[45] Caldamone AA, Edstrom LE, Koyle MA, Rabinowitz R, Hulbert WC.\n\n【14】Buccal mucosal grafts for urethral reconstruction. Urology 1998;51:15–9 .\n\n【15】[46] Håkansson U, Kirrander P, Uvelius B, Baseckas G, Torbrand C, Organ-sparing reconstructive surgery in penile cancer: initial experiences at two Swedish referral centres. Scand J Urol 2015;49:149–54 .\n\n【16】[47] Pang KH, Alnajjar HM, Muneer A. Advances in penile-sparing surgical approaches. Asian J Urol 2022;9:359–73 .\n\n【17】[48] Kristiansen S, Torbrand C, Svensson A, Forslund O, Bjartling C.\n\n【18】Incidence of penile intraepithelial neoplasia and treatment strategies in Sweden 2000–2019. BJU Int 2022;129:752–9 .\n\n【19】[49] Alnajjar HM, Lam W, Bolgeri M, Rees RW, Perry MJ, Watkin NA.\n\n【20】Treatment of carcinoma in situ of the glans penis with topical chemotherapy agents. Eur Urol 2012;62:923–8 .\n\n【21】[50] Deen K, Burdon-Jones D. Imiquimod in the treatment of penile intraepithelial neoplasia: An update. Australas J Dermatol 2017;58:86–92 .\n\n【22】[51] Issa A, Sebro K, Kwok A, et al. Treatment options and outcomes for men with penile intraepithelial neoplasia: a systematic review.\n\n【23】Eur Urol Focus 2022;8:829–32 .\n\n【24】[52] Leone A, Inman B, Spiess PE. Need for evidence and consensus on laser treatment for management of select primary penile tumors.\n\n【25】Eur Urol 2017;72:4–6 .\n\n【26】[53] Roussel E, Peeters E, Vanthoor J, et al. Predictors of local recurrence and its impact on survival after glansectomy for penile cancer: time to challenge the dogma? BJU Int 2021;127:606–13 .\n\n【27】[54] Sri D, Sujenthiran A, Lam W, et al. A study into the association between local recurrence rates and surgical resection margins in organ-sparing surgery for penile squamous cell cancer. BJU Int 2018; 122:576–82 .\n\n【28】 [55] Gunia S, Koch S, Jain A, May M. Does the width of the surgical margin of safety or premalignant dermatoses at the negative surgical margin affect outcome in surgically treated penile cancer?\n\n【29】J Clin Pathol 2014;67:268–71 .\n\n【30】[56] Ellul T, Grice P, Mainwaring A, et al. Frozen section analysis for organ-conserving surgery in penile cancer: assessing oncological outcomes and trends of local recurrence. J Clin Urol 2020;13:419–24 .\n\n【31】[57] Kamel MH, Bissada N, Warford R, Farias J, Davis R. Organ sparing surgery for penile cancer: a systematic review. J Urol 2017; 198:770–9 .\n\n【32】[58] Tang DH, Yan S, Ottenhof SR, et al. Laser ablation as monotherapy for penile squamous cell carcinoma: a multi-center cohort analysis. Urol Oncol 2018;36:147–52 .\n\n【33】[59] Ottenhof SR, Leone A, Djajadiningrat RS, et al. Surgical and oncological outcomes in patients after vascularised flap reconstruction for locoregionally advanced penile cancer. Eur Urol Focus 2019;5:867–74 .\n\n【34】[60] Yi XY, Cao DH, You PH, et al. Neoadjuvant chemotherapy for patients with locally advanced penile cancer: an updated evidence. Asian J Androl 2022;24:180–5 .\n\n【35】[61] Yao K, Zou ZJ, Li ZS, et al. Fascia lata preservation during inguinal lymphadenectomy for penile cancer: rationale and outcome.\n\n【36】Urology 2013;82:642-7 .\n\n【37】[62] Gopman JM, Djajadiningrat RS, Baumgarten AS, et al. Predicting postoperative complications of inguinal lymph node dissection for penile cancer in an international multicentre cohort. BJU Int 2015; 116 : 196–201 .\n\n【38】[63] Hegarty PK, Dinney CP, Pettaway CA. Controversies in ilioinguinal lymphadenectomy. Urol Clin North Am 2010;37:421–34 .\n\n【39】[64] Koifman L, Hampl D, Koifman N, Vides AJ, Ornellas AA. Radical open inguinal lymphadenectomy for penile carcinoma: surgical technique, early complications and late outcomes. J Urol 2013; 190:2086–92 .\n\n【40】[65] Stuiver MM, Djajadiningrat RS, Graafland NM, Vincent AD, Lucas C, Horenblas S. Early wound complications after inguinal lymphadenectomy in penile cancer: a historical cohort study and risk-factor analysis. Eur Urol 2013;64:486–92 .\n\n【41】[66] Leewansangtong      S, Srinualnad        S, Chaiyaprasithi Taweemonkongsap T, Soontrapa S. The risks of lymph node metastasis and the prognostic factors in carcinoma of the penis: analysis of 50 patients treated with bilateral ilioinguinal lymphadenectomy. J Med Assoc Thai 2001;84:204–11 .\n\n【42】[67] Gulia AK, Mandhani A, Muruganandham K, Kapoor R, Ansari MS, Srivastava A. Impact of delay in inguinal lymph node dissection in patients with carcinoma of penis. Indian J Cancer 2009;46:214–8 .\n\n【43】[68] Sharma P, Zargar-Shoshtari K, Caracciolo JT, et al. Sarcopenia as a predictor of complications in penile cancer patients undergoing inguinal lymph node dissection. World J Urol 2015;33:1585–92 .\n\n【44】[69] Bevan-Thomas R, Slaton JW, Pettaway CA. Contemporary morbidity from lymphadenectomy for penile squamous cell carcinoma: the M.D. Anderson Cancer Center experience. J Urol 2002;167:1638–42 .\n\n【45】[70] Bouchot O, Rigaud J, Maillet F, Hetet JF, Karam G. Morbidity of inguinal lymphadenectomy for invasive penile carcinoma. Eur Urol 2004;45:761–5 .\n\n【46】[71] Mistretta FA, Mazzone E, Palumbo C, et al. Adherence to guideline recommendations for lymph node dissection in squamous cell carcinoma of the penis: effect on survival and complication rates.\n\n【47】Urol Oncol 2019;37:578.e11–e19 .\n\n【48】[72] Nelson BA, Cookson MS, Smith Jr JA, Chang SS. Complications of inguinal and pelvic lymphadenectomy for squamous cell carcinoma of the penis: a contemporary series. J Urol 2004; 172:494–7 .\n\n【49】[73] Ray MD, Jakhetiya A, Kumar S, Mishra A, Singh S, Shukla NK.\n\n【50】Minimizing post-operative complications of groin dissection using modified skin bridge technique: a single- centre descriptive study showing post-operative and early oncological outcomes. World J Surg 2018;42:3196–201 .\n\n【51】[74] Schwentner C, Todenhöfer T, Seibold J, et al. Endoscopic inguinofemoral lymphadenectomy—extended follow-up.\n\n【52】J Endourol 2013;27:497–503 .\n\n【53】[75] Singh A, Jaipuria J, Goel A, et al. Comparing outcomes of robotic and open inguinal lymph node dissection in patients with carcinoma of the penis. J Urol 2018;199:1518–25 .", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "11", "bbox": [715.0, 42.0, 732.0, 55.0]}], "type": "Text", "position": 2}, {"raw_context": [{"text": "dynamic sentinel lymph node biopsy in men with impalpable and", "bbox": [94.0, 89.0, 390.0, 100.0]}, {"text": "palpable inguinal lymph nodes. BJU Int 2022;130:331–6.", "bbox": [94.0, 99.0, 349.0, 112.0]}, {"text": "[34] Wever L, de Vries HM, Dell'Oglio P, et al. Incidence and risk factor", "bbox": [71.0, 111.0, 390.0, 122.0]}, {"text": "analysis of complications after sentinel node biopsy for penile", "bbox": [94.0, 124.0, 390.0, 135.0]}, {"text": "cancer. BJU Int 2022;130:486–95 .", "bbox": [94.0, 135.0, 248.0, 147.0]}, {"text": "[35] Dell'Oglio P, de Vries HM, Mazzone E, et al. Hybrid indocyanine", "bbox": [71.0, 147.0, 389.0, 160.0]}, {"text": "green-( 39 m)Tc-nanocolloid for single-photon emission computed", "bbox": [93.0, 159.0, 389.0, 172.0]}, {"text": "tomography and combined radio- and fluorescence-guided", "bbox": [93.0, 170.0, 389.0, 184.0]}, {"text": "sentinel node biopsy in penile cancer: results of 740 inguinal", "bbox": [93.0, 183.0, 389.0, 195.0]}, {"text": "basins assessed at a single institution. Eur Urol 2020;78:865–72 .", "bbox": [93.0, 195.0, 387.0, 207.0]}, {"text": "[36] Zou ZJ, Liu ZH, Tang LY, et al. Radiocolloid-based dynamic sentinel", "bbox": [71.0, 208.0, 390.0, 220.0]}, {"text": "lymph node biopsy in penile cancer with clinically negative", "bbox": [93.0, 219.0, 389.0, 232.0]}, {"text": "inguinal lymph node: an updated systematic review and meta-", "bbox": [93.0, 231.0, 388.0, 243.0]}, {"text": "analysis. Int Urol Nephrol 2016;48:2001–13 .", "bbox": [94.0, 244.0, 295.0, 255.0]}, {"text": "[37] de Vries HM, Lee HJ, Lam W, et al. Clinicopathological predictors of", "bbox": [71.0, 255.0, 389.0, 268.0]}, {"text": "finding additional inguinal lymph node metastases in penile", "bbox": [94.0, 268.0, 390.0, 280.0]}, {"text": "cancer patients after positive dynamic sentinel node biopsy: a", "bbox": [94.0, 279.0, 390.0, 292.0]}, {"text": "European multicentre evaluation. BJU Int 2022;130:126–32 .", "bbox": [94.0, 291.0, 366.0, 303.0]}, {"text": "[38] Hughes B, Leijte J, Shabbir M, Watkin N, Horenblas S. Non-invasive", "bbox": [72.0, 304.0, 389.0, 315.0]}, {"text": "and minimally invasive staging of regional lymph nodes in penile", "bbox": [93.0, 315.0, 390.0, 327.0]}, {"text": "cancer. World J Urol 2009;27:197–203 .", "bbox": [94.0, 327.0, 271.0, 339.0]}, {"text": "[39] Hövels AM, Heesakkers RA, Adang EM, et al. The diagnostic", "bbox": [71.0, 339.0, 389.0, 352.0]}, {"text": "accuracy of CT and MRI in the staging of pelvic lymph nodes in", "bbox": [94.0, 350.0, 390.0, 365.0]}, {"text": "patients with prostate cancer: a meta-analysis. Clin Radiol", "bbox": [94.0, 364.0, 390.0, 375.0]}, {"text": "2008;63:387–95 .", "bbox": [95.0, 375.0, 172.0, 387.0]}, {"text": "[40] Graafland NM, Leijte JA, Valdes Olmos RA, Hoefnagel CA, Teertstra", "bbox": [72.0, 387.0, 389.0, 399.0]}, {"text": "HJ, Horenblas S. Scanning with 18 F-FDG-PET/CT for detection of", "bbox": [93.0, 399.0, 389.0, 412.0]}, {"text": "pelvic nodal involvement in inguinal node-positive penile", "bbox": [93.0, 410.0, 389.0, 422.0]}, {"text": "carcinoma. Eur Urol 2009;56:339–45 .", "bbox": [94.0, 421.0, 264.0, 434.0]}, {"text": "[41] Ashley S, Shanks JH, Oliveira P, et al. Human papilloma virus (HPV)", "bbox": [71.0, 435.0, 390.0, 447.0]}, {"text": "status may impact treatment outcomes in patients with pre-", "bbox": [93.0, 446.0, 389.0, 458.0]}, {"text": "cancerous penile lesions (an eUROGEN Study). Int J Impot Res", "bbox": [93.0, 458.0, 390.0, 471.0]}, {"text": "2021;33:620–6 .", "bbox": [94.0, 470.0, 168.0, 482.0]}, {"text": "[42] Hoekstra RJ, Trip EJ, Ten Kate FJ, Horenblas S, Lock MT. Penile", "bbox": [71.0, 482.0, 389.0, 495.0]}, {"text": "intraepithelial", "bbox": [94.0, 495.0, 166.0, 506.0]}, {"text": "neoplasia:", "bbox": [170.0, 495.0, 225.0, 506.0]}, {"text": "Nomenclature,", "bbox": [228.0, 495.0, 303.0, 506.0]}, {"text": "incidence", "bbox": [310.0, 495.0, 360.0, 506.0]}, {"text": "and", "bbox": [369.0, 495.0, 390.0, 505.0]}, {"text": "progression to malignancy in the Netherlands. Int J Urol", "bbox": [93.0, 506.0, 390.0, 518.0]}, {"text": "2019;26:353–7 .", "bbox": [94.0, 519.0, 168.0, 531.0]}, {"text": "[43] Kravvas G, Ge L, Ng J, et al. The management of penile", "bbox": [71.0, 531.0, 389.0, 542.0]}, {"text": "intraepithelial neoplasia (PeIN): clinical and histological features", "bbox": [94.0, 543.0, 390.0, 553.0]}, {"text": "and treatment of 345 patients and a review of the literature. J", "bbox": [94.0, 555.0, 390.0, 567.0]}, {"text": "Dermatol Treat 2022;33:1047–62 .", "bbox": [94.0, 566.0, 249.0, 578.0]}, {"text": "[44] Shabbir M, Muneer A, Kalsi J, et al. Glans resurfacing for the", "bbox": [71.0, 578.0, 389.0, 591.0]}, {"text": "treatment of carcinoma in situ of the penis: surgical technique and", "bbox": [93.0, 590.0, 389.0, 602.0]}, {"text": "outcomes. Eur Urol 2011;59:142–7 .", "bbox": [93.0, 602.0, 256.0, 614.0]}, {"text": "[45] Caldamone AA, Edstrom LE, Koyle MA, Rabinowitz R, Hulbert WC.", "bbox": [71.0, 614.0, 387.0, 626.0]}, {"text": "Buccal mucosal grafts for urethral reconstruction. Urology", "bbox": [93.0, 626.0, 389.0, 638.0]}, {"text": "1998;51:15–9 .", "bbox": [95.0, 638.0, 162.0, 650.0]}, {"text": "[46] Håkansson U, Kirrander P, Uvelius B, Baseckas G, Torbrand C,", "bbox": [71.0, 650.0, 387.0, 662.0]}, {"text": "Organ-sparing reconstructive surgery in penile cancer: initial", "bbox": [93.0, 662.0, 390.0, 675.0]}, {"text": "experiences at two Swedish referral centres. Scand J Urol", "bbox": [94.0, 675.0, 389.0, 687.0]}, {"text": "2015;49:149–54 .", "bbox": [94.0, 686.0, 174.0, 698.0]}, {"text": "[47] Pang KH, Alnajjar HM, Muneer A. Advances in penile-sparing", "bbox": [72.0, 698.0, 389.0, 711.0]}, {"text": "surgical approaches. Asian J Urol 2022;9:359–73 .", "bbox": [94.0, 710.0, 318.0, 722.0]}, {"text": "[48] Kristiansen S, Torbrand C, Svensson A, Forslund O, Bjartling C.", "bbox": [71.0, 722.0, 388.0, 736.0]}, {"text": "Incidence of penile intraepithelial neoplasia and treatment", "bbox": [94.0, 735.0, 390.0, 746.0]}, {"text": "strategies in Sweden 2000–2019. BJU Int 2022;129:752–9 .", "bbox": [94.0, 745.0, 358.0, 758.0]}, {"text": "[49] Alnajjar HM, Lam W, Bolgeri M, Rees RW, Perry MJ, Watkin NA.", "bbox": [71.0, 757.0, 389.0, 769.0]}, {"text": "Treatment of carcinoma in situ of the glans penis with topical", "bbox": [95.0, 770.0, 390.0, 781.0]}, {"text": "chemotherapy agents. Eur Urol 2012;62:923–8 .", "bbox": [93.0, 781.0, 310.0, 793.0]}, {"text": "[50] Deen K, Burdon-Jones D. Imiquimod in the treatment of penile", "bbox": [71.0, 793.0, 389.0, 807.0]}, {"text": "intraepithelial neoplasia: An update. Australas J Dermatol", "bbox": [94.0, 805.0, 389.0, 818.0]}, {"text": "2017;58:86–92 .", "bbox": [94.0, 818.0, 167.0, 828.0]}, {"text": "[51] Issa A, Sebro K, Kwok A, et al. Treatment options and outcomes for", "bbox": [71.0, 830.0, 390.0, 841.0]}, {"text": "men with penile intraepithelial neoplasia: a systematic review.", "bbox": [94.0, 841.0, 389.0, 853.0]}, {"text": "Eur Urol Focus 2022;8:829–32 .", "bbox": [93.0, 853.0, 236.0, 865.0]}, {"text": "[52] Leone A, Inman B, Spiess PE. Need for evidence and consensus on", "bbox": [71.0, 865.0, 389.0, 878.0]}, {"text": "laser treatment for management of select primary penile tumors.", "bbox": [93.0, 877.0, 389.0, 890.0]}, {"text": "Eur Urol 2017;72:4–6 .", "bbox": [94.0, 890.0, 195.0, 901.0]}, {"text": "[53] Roussel E, Peeters E, Vanthoor J, et al. Predictors of local recurrence", "bbox": [71.0, 901.0, 390.0, 914.0]}, {"text": "and its impact on survival after glansectomy for penile cancer:", "bbox": [94.0, 914.0, 389.0, 925.0]}, {"text": "time to challenge the dogma? BJU Int 2021;127:606–13 .", "bbox": [94.0, 925.0, 350.0, 938.0]}, {"text": "[54] Sri D, Sujenthiran A, Lam W, et al. A study into the association", "bbox": [71.0, 937.0, 390.0, 949.0]}, {"text": "between local recurrence rates and surgical resection margins in", "bbox": [93.0, 950.0, 391.0, 961.0]}, {"text": "organ-sparing surgery for penile squamous cell cancer. BJU Int", "bbox": [93.0, 961.0, 390.0, 974.0]}, {"text": "2018; 122:576–82 .", "bbox": [94.0, 974.0, 179.0, 986.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "[55] Gunia S, Koch S, Jain A, May M. Does the width of the surgical", "bbox": [414.0, 88.0, 732.0, 100.0]}, {"text": "margin of safety or premalignant dermatoses at the negative", "bbox": [438.0, 99.0, 731.0, 112.0]}, {"text": "surgical margin affect outcome in surgically treated penile cancer?", "bbox": [438.0, 111.0, 732.0, 123.0]}, {"text": "J Clin Pathol 2014;67:268–71 .", "bbox": [438.0, 124.0, 573.0, 135.0]}, {"text": "[56] Ellul T, Grice P, Mainwaring A, et al. Frozen section analysis for", "bbox": [414.0, 135.0, 731.0, 147.0]}, {"text": "organ-conserving surgery in penile cancer: assessing oncological", "bbox": [437.0, 149.0, 732.0, 159.0]}, {"text": "outcomes and trends of local recurrence. J Clin Urol", "bbox": [438.0, 159.0, 732.0, 172.0]}, {"text": "2020;13:419–24 .", "bbox": [438.0, 171.0, 516.0, 182.0]}, {"text": "[57] Kamel MH, Bissada N, Warford R, Farias J, Davis R. Organ sparing", "bbox": [414.0, 183.0, 731.0, 195.0]}, {"text": "surgery for penile cancer: a systematic review. J Urol", "bbox": [438.0, 195.0, 732.0, 207.0]}, {"text": "2017; 198:770–9 .", "bbox": [437.0, 207.0, 516.0, 218.0]}, {"text": "[58] Tang DH, Yan S, Ottenhof SR, et al. Laser ablation as monotherapy", "bbox": [414.0, 219.0, 731.0, 232.0]}, {"text": "for penile squamous cell carcinoma: a multi-center cohort", "bbox": [438.0, 231.0, 732.0, 243.0]}, {"text": "analysis. Urol Oncol 2018;36:147–52 .", "bbox": [438.0, 244.0, 606.0, 255.0]}, {"text": "[59] Ottenhof SR, Leone A, Djajadiningrat RS, et al. Surgical and", "bbox": [414.0, 255.0, 732.0, 268.0]}, {"text": "oncological outcomes in patients after vascularised flap", "bbox": [438.0, 268.0, 732.0, 279.0]}, {"text": "reconstruction for locoregionally advanced penile cancer. Eur", "bbox": [438.0, 279.0, 731.0, 292.0]}, {"text": "Urol Focus 2019;5:867–74 .", "bbox": [437.0, 291.0, 562.0, 302.0]}, {"text": "[60] Yi XY, Cao DH, You PH, et al. Neoadjuvant chemotherapy for", "bbox": [414.0, 303.0, 731.0, 315.0]}, {"text": "patients with locally advanced penile cancer: an updated", "bbox": [437.0, 315.0, 732.0, 327.0]}, {"text": "evidence. Asian J Androl 2022;24:180–5 .", "bbox": [438.0, 328.0, 620.0, 339.0]}, {"text": "[61] Yao K, Zou ZJ, Li ZS, et al. Fascia lata preservation during inguinal", "bbox": [414.0, 339.0, 732.0, 352.0]}, {"text": "lymphadenectomy for penile cancer: rationale and outcome.", "bbox": [438.0, 351.0, 731.0, 364.0]}, {"text": "Urology 2013;82:642-7 .", "bbox": [438.0, 364.0, 549.0, 375.0]}, {"text": "[62] Gopman JM, Djajadiningrat RS, Baumgarten AS, et al. Predicting", "bbox": [414.0, 375.0, 732.0, 387.0]}, {"text": "postoperative complications of inguinal lymph node dissection for", "bbox": [438.0, 388.0, 732.0, 399.0]}, {"text": "penile cancer in an international multicentre cohort. BJU Int", "bbox": [438.0, 399.0, 732.0, 412.0]}, {"text": "2015; 116 : 196–201 .", "bbox": [438.0, 411.0, 528.0, 422.0]}, {"text": "[63] Hegarty PK, Dinney CP, Pettaway CA. Controversies in ilioinguinal", "bbox": [414.0, 421.0, 733.0, 435.0]}, {"text": "lymphadenectomy. Urol Clin North Am 2010;37:421–34 .", "bbox": [438.0, 435.0, 694.0, 447.0]}, {"text": "[64] Koifman L, Hampl D, Koifman N, Vides AJ, Ornellas AA. Radical", "bbox": [414.0, 446.0, 732.0, 457.0]}, {"text": "open inguinal lymphadenectomy for penile carcinoma: surgical", "bbox": [438.0, 459.0, 732.0, 471.0]}, {"text": "technique, early complications and late outcomes. J Urol", "bbox": [438.0, 471.0, 732.0, 482.0]}, {"text": "2013; 190:2086–92 .", "bbox": [437.0, 482.0, 527.0, 493.0]}, {"text": "[65] Stuiver MM, Djajadiningrat RS, Graafland NM, Vincent AD, Lucas C,", "bbox": [414.0, 495.0, 731.0, 506.0]}, {"text": "Horenblas S. Early wound complications after inguinal", "bbox": [438.0, 506.0, 732.0, 518.0]}, {"text": "lymphadenectomy in penile cancer: a historical cohort study and", "bbox": [438.0, 519.0, 732.0, 531.0]}, {"text": "risk-factor analysis. Eur Urol 2013;64:486–92 .", "bbox": [438.0, 531.0, 647.0, 542.0]}, {"text": "[66] Leewansangtong      S,", "bbox": [414.0, 542.0, 543.0, 555.0]}, {"text": "Srinualnad        S,", "bbox": [545.0, 543.0, 631.0, 553.0]}, {"text": "Chaiyaprasithi", "bbox": [635.0, 543.0, 711.0, 555.0]}, {"text": "Taweemonkongsap T, Soontrapa S. The risks of lymph node", "bbox": [438.0, 554.0, 731.0, 566.0]}, {"text": "metastasis and the prognostic factors in carcinoma of the penis:", "bbox": [438.0, 566.0, 731.0, 578.0]}, {"text": "analysis of 50 patients treated with bilateral ilioinguinal", "bbox": [438.0, 578.0, 733.0, 592.0]}, {"text": "lymphadenectomy. J Med Assoc Thai 2001;84:204–11 .", "bbox": [438.0, 590.0, 683.0, 602.0]}, {"text": "[67] Gulia AK, Mandhani A, Muruganandham K, Kapoor R, Ansari MS,", "bbox": [414.0, 602.0, 732.0, 615.0]}, {"text": "Srivastava A. Impact of delay in inguinal lymph node dissection in", "bbox": [438.0, 615.0, 732.0, 627.0]}, {"text": "patients with carcinoma of penis. Indian J Cancer 2009;46:214–8 .", "bbox": [438.0, 626.0, 732.0, 638.0]}, {"text": "[68] Sharma P, Zargar-Shoshtari K, Caracciolo JT, et al. Sarcopenia as a", "bbox": [414.0, 638.0, 732.0, 652.0]}, {"text": "predictor of complications in penile cancer patients undergoing", "bbox": [438.0, 650.0, 732.0, 662.0]}, {"text": "inguinal lymph node dissection. World J Urol 2015;33:1585–92 .", "bbox": [438.0, 662.0, 728.0, 675.0]}, {"text": "[69] Bevan-Thomas R, Slaton JW, Pettaway CA. Contemporary", "bbox": [414.0, 675.0, 731.0, 687.0]}, {"text": "morbidity from lymphadenectomy for penile squamous cell", "bbox": [438.0, 686.0, 732.0, 698.0]}, {"text": "carcinoma: the M.D. Anderson Cancer Center experience. J Urol", "bbox": [438.0, 698.0, 732.0, 712.0]}, {"text": "2002;167:1638–42 .", "bbox": [437.0, 711.0, 527.0, 721.0]}, {"text": "[70] Bouchot O, Rigaud J, Maillet F, Hetet JF, Karam G. Morbidity of", "bbox": [414.0, 721.0, 733.0, 735.0]}, {"text": "inguinal lymphadenectomy for invasive penile carcinoma. Eur", "bbox": [438.0, 735.0, 733.0, 746.0]}, {"text": "Urol 2004;45:761–5 .", "bbox": [438.0, 745.0, 533.0, 757.0]}, {"text": "[71] Mistretta FA, Mazzone E, Palumbo C, et al. Adherence to guideline", "bbox": [414.0, 757.0, 731.0, 770.0]}, {"text": "recommendations for lymph node dissection in squamous cell", "bbox": [438.0, 770.0, 732.0, 781.0]}, {"text": "carcinoma of the penis: effect on survival and complication rates.", "bbox": [438.0, 781.0, 731.0, 793.0]}, {"text": "Urol Oncol 2019;37:578.e11–e19 .", "bbox": [437.0, 793.0, 590.0, 805.0]}, {"text": "[72] Nelson BA, Cookson MS, Smith Jr JA, Chang SS. Complications of", "bbox": [414.0, 805.0, 732.0, 818.0]}, {"text": "inguinal and pelvic lymphadenectomy for squamous cell", "bbox": [438.0, 817.0, 733.0, 829.0]}, {"text": "carcinoma of the penis: a contemporary series. J Urol", "bbox": [438.0, 830.0, 732.0, 841.0]}, {"text": "2004; 172:494–7 .", "bbox": [438.0, 841.0, 517.0, 853.0]}, {"text": "[73] Ray MD, Jakhetiya A, Kumar S, Mishra A, Singh S, Shukla NK.", "bbox": [414.0, 853.0, 731.0, 866.0]}, {"text": "Minimizing post-operative complications of groin dissection using", "bbox": [438.0, 865.0, 731.0, 878.0]}, {"text": "modified skin bridge technique: a single- centre descriptive study", "bbox": [438.0, 877.0, 731.0, 889.0]}, {"text": "showing post-operative and early oncological outcomes. World J", "bbox": [438.0, 890.0, 732.0, 901.0]}, {"text": "Surg 2018;42:3196–201 .", "bbox": [438.0, 901.0, 551.0, 913.0]}, {"text": "[74] Schwentner C, Todenhöfer T, Seibold J, et al. Endoscopic", "bbox": [414.0, 913.0, 732.0, 926.0]}, {"text": "inguinofemoral", "bbox": [438.0, 925.0, 512.0, 937.0]}, {"text": "lymphadenectomy—extended", "bbox": [516.0, 925.0, 658.0, 938.0]}, {"text": "follow-up.", "bbox": [663.0, 926.0, 718.0, 938.0]}, {"text": "J", "bbox": [723.0, 927.0, 732.0, 937.0]}, {"text": "Endourol 2013;27:497–503 .", "bbox": [437.0, 937.0, 566.0, 948.0]}, {"text": "[75] Singh A, Jaipuria J, Goel A, et al. Comparing outcomes of robotic", "bbox": [414.0, 949.0, 731.0, 961.0]}, {"text": "and open inguinal lymph node dissection in patients with", "bbox": [438.0, 961.0, 733.0, 973.0]}, {"text": "carcinoma of the penis. J Urol 2018;199:1518–25 .", "bbox": [438.0, 974.0, 662.0, 986.0]}], "type": "Text", "position": 4}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/泌尿外科/2023 EAU／ASCO指南：阴茎癌（更新版）.pdf", "page_num": 11}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": null, "type3": null, "type4": null, "type5": null, "type6": "信息有用性#0#53#参考文献"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:42", "update_time": "2024-05-07 18:15:50"}
{"id": 1082655, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 738, "source_info": {"seq_id": "fe4abc2a-cbd2-4153-b6dc-a951dbb7d451", "title": null, "text": "【0】页码:1\n Guideline\n\n【1】 American Society for Transplantation and Cellular Therapy Series, #6: Management of Invasive Candidiasis in Hematopoietic Cell Transplantation Recipients\n\n【2】 Dionysios Neofytos 1.4 , William J. Steinbach 2 , Kimberly Hanson 3 , Paul A. Carpenter 4 , Genovefa A. Papanicolaou 5 , Monica A. Slavin 6\n\n【3】 1 Division of Infectious Diseases, Transplant Infectious Disease Service, University Hospital of Geneva, Geneva, Switzerland ² Department of Pediatrics, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas 3 Transplant Infectious Diseases and Immunocompromised Host Service, Clinical Microbiology, University of Utah, Salt Lake City, Utah 4 Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 5 Infectious Diseases Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 6 Department of Infectious Disease Peter MacCallum Cancer Centre, Melbourne, Australia\n\n【4】 Article history: Received 7 January 2023.\n\n【5】Accepted 9 January 2023 Key Words : Candida Invasive candidiasis Guidelines Epidemiology Diagnosis Treatment Prophylaxis Hematopoietic cell transplantation\n\n【6】\n A B S T R A C T The Practice Guidelines Committee of the American Society of Transplantation and Cellular Therapy (ASTCT) partnered with its Transplant Infectious Disease Special Interest Group (TID-SIG) to update its 2009 compendiumstyle infectious disease guidelines for hematopoietic cell transplantation (HCT). A completely new approach was taken with the goal of better serving clinical providers by publishing each standalone topic in the infectious disease series as a concise format of frequently asked questions (FAQ), tables, and figures. Adult and pediatric infectious disease and HCT content experts developed and then answered FAQs and finalized topics with harmonized recommendations made by assigning an A through E strength of recommendation paired with a level of supporting evidence graded I through III. This sixth guideline in the series focuses on invasive candidiasis (IC) with FAQs to address epidemiology, clinical diagnosis, prophylaxis, and treatment of IC, plus special considerations for pediatric, cord blood, haploidentical, and T cell-depleted HCT recipients and chimeric antigen receptor T cell recipients, as well as future research directions.\n\n【7】© 2023 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ )\n\n【8】## Introduction\n\n【9】\n Conditioning chemotherapy-induced mucositis and gastrointestinal graft-versus-host disease (GVHD) represent the major risk factors for invasive candidiasis (IC) in hematopoietic cell transplantation (HCT) recipients due to gastrointestinal flora translocation. Routine primary antifungal prophylaxis beginning in the 1990s led to a significant decline in posttransplantation IC to an incidence of 1% to 2% and a significant shift in the epidemiology of Candida species [ 1 ]. Current challenges include the changing Candida epidemiology, suboptimal diagnostic tools, and poor clinical outcomes, despite the availability of effective and safe treatment options. The principles discussed for allogeneic HCT recipients prior to engraftment are applicable to autologous HCT recipients and patients\n\n【10】 Financial disclosure: See Acknowledgments on page 226.\n\n【11】*Correspondence and reprint requests: Dionysios Neofytos, Division of Infectious Diseases, University Hospital of Geneva, Rue Gabrielle-Perret-Gentil 4, 1211 Geneva, Switzerland\n E-mail address : dionysios.neofytos@hcuge.ch (D. Neofytos).\n\n【12】 receiving cellular therapies, such as chimeric antigen receptor (CAR) T cells, at least until neutrophil recovery and in the absence of prolonged glucocorticoid therapy.\n\n【13】In this update to the 2009 compendium-style infectious disease guidelines for HCT, a completely new approach was taken with the goal of better serving clinical providers by publishing each standalone topic in the infectious disease series as a concise format of frequently asked questions (FAQ), tables, and figures [2] . For grading of strength of recommendation (A to E) and quality of supporting evidence (level I to III), see Supplementary Data. The key recommendations provided below are accompanied by grading in parentheses.\n\n【14】## Epidemiology Faq1: What Is The Epidemiology Of Candida Infections In Hct Recipients?\n\n【15】\n Collectively, non- albicans Candida species are more frequently encountered in HCT recipients with IC [ 3 , 4 ]. Infections due to Candida glabrata ( Nakaseomyces glabrata ) are up to 25% to 50% fluconazole-resistant, and Candida krusei (Pichia", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "Guideline", "bbox": [83.0, 177.0, 143.0, 192.0]}], "type": "Text", "position": 1}, {"raw_context": [{"text": "American Society for Transplantation and Cellular Therapy Series, #6:", "bbox": [83.0, 202.0, 653.0, 223.0]}, {"text": "Management of Invasive Candidiasis in Hematopoietic Cell", "bbox": [83.0, 226.0, 565.0, 247.0]}, {"text": "Transplantation Recipients", "bbox": [83.0, 249.0, 307.0, 270.0]}], "type": "Text", "position": 6}, {"raw_context": [{"text": "Dionysios Neofytos 1.4 , William J. Steinbach 2 , Kimberly Hanson 3 , Paul A. Carpenter 4 ,", "bbox": [83.0, 280.0, 617.0, 301.0]}, {"text": "Genovefa A. Papanicolaou 5 , Monica A. Slavin 6", "bbox": [83.0, 300.0, 375.0, 318.0]}], "type": "Text", "position": 8}, {"raw_context": [{"text": "1 Division of Infectious Diseases, Transplant Infectious Disease Service, University Hospital of Geneva, Geneva, Switzerland", "bbox": [85.0, 324.0, 535.0, 337.0]}, {"text": "² Department of Pediatrics, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas", "bbox": [83.0, 336.0, 502.0, 350.0]}, {"text": "3 Transplant Infectious Diseases and Immunocompromised Host Service, Clinical Microbiology, University of Utah, Salt Lake City, Utah", "bbox": [83.0, 347.0, 579.0, 361.0]}, {"text": "4 Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington", "bbox": [83.0, 359.0, 419.0, 372.0]}, {"text": "5 Infectious Diseases Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York", "bbox": [83.0, 370.0, 515.0, 383.0]}, {"text": "6 Department of Infectious Disease Peter MacCallum Cancer Centre, Melbourne, Australia", "bbox": [84.0, 382.0, 415.0, 395.0]}], "type": "Text", "position": 9}, {"raw_context": [{"text": "Article history:", "bbox": [84.0, 427.0, 141.0, 439.0]}, {"text": "Received 7 January 2023.", "bbox": [84.0, 439.0, 180.0, 449.0]}, {"text": "Accepted 9 January 2023", "bbox": [84.0, 450.0, 182.0, 462.0]}, {"text": "Key Words :", "bbox": [84.0, 476.0, 128.0, 487.0]}, {"text": "Candida", "bbox": [84.0, 487.0, 118.0, 498.0]}, {"text": "Invasive candidiasis", "bbox": [84.0, 498.0, 163.0, 509.0]}, {"text": "Guidelines", "bbox": [83.0, 510.0, 128.0, 520.0]}, {"text": "Epidemiology", "bbox": [83.0, 521.0, 139.0, 533.0]}, {"text": "Diagnosis", "bbox": [85.0, 533.0, 125.0, 544.0]}, {"text": "Treatment", "bbox": [84.0, 544.0, 128.0, 555.0]}, {"text": "Prophylaxis", "bbox": [84.0, 557.0, 133.0, 567.0]}, {"text": "Hematopoietic cell", "bbox": [83.0, 567.0, 160.0, 579.0]}, {"text": "transplantation", "bbox": [83.0, 579.0, 147.0, 589.0]}], "type": "Table", "position": 10}, {"raw_context": [{"text": "A B S T R A C T", "bbox": [227.0, 425.0, 317.0, 439.0]}, {"text": "The Practice Guidelines Committee of the American Society of Transplantation and Cellular Therapy (ASTCT) part-", "bbox": [227.0, 439.0, 725.0, 453.0]}, {"text": "nered with its Transplant Infectious Disease Special Interest Group (TID-SIG) to update its 2009 compendium-", "bbox": [228.0, 452.0, 724.0, 465.0]}, {"text": "style infectious disease guidelines for hematopoietic cell transplantation (HCT). A completely new approach was", "bbox": [228.0, 465.0, 725.0, 477.0]}, {"text": "taken with the goal of better serving clinical providers by publishing each standalone topic in the infectious dis-", "bbox": [228.0, 478.0, 724.0, 491.0]}, {"text": "ease series as a concise format of frequently asked questions (FAQ), tables, and figures. Adult and pediatric infec-", "bbox": [228.0, 491.0, 724.0, 503.0]}, {"text": "tious disease and HCT content experts developed and then answered FAQs and finalized topics with harmonized", "bbox": [227.0, 503.0, 726.0, 516.0]}, {"text": "recommendations made by assigning an A through E strength of recommendation paired with a level of support-", "bbox": [228.0, 517.0, 724.0, 528.0]}, {"text": "ing evidence graded I through III. This sixth guideline in the series focuses on invasive candidiasis (IC) with FAQs", "bbox": [228.0, 529.0, 725.0, 541.0]}, {"text": "to address epidemiology, clinical diagnosis, prophylaxis, and treatment of IC, plus special considerations for pedi-", "bbox": [228.0, 542.0, 724.0, 555.0]}, {"text": "atric, cord blood, haploidentical, and T cell-depleted HCT recipients and chimeric antigen receptor T cell recipients,", "bbox": [228.0, 555.0, 725.0, 567.0]}, {"text": "as well as future research directions.", "bbox": [229.0, 568.0, 388.0, 579.0]}, {"text": "© 2023 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. This is an open", "bbox": [233.0, 578.0, 726.0, 593.0]}, {"text": "access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ )", "bbox": [295.0, 593.0, 726.0, 605.0]}], "type": "Text", "position": 11}, {"raw_context": [{"text": "INTRODUCTION", "bbox": [83.0, 644.0, 166.0, 659.0]}], "type": "Section-header", "position": 12}, {"raw_context": [{"text": "Conditioning chemotherapy-induced mucositis and gastro-", "bbox": [99.0, 659.0, 390.0, 674.0]}, {"text": "intestinal graft-versus-host disease (GVHD) represent the", "bbox": [83.0, 674.0, 390.0, 687.0]}, {"text": "major risk factors for invasive candidiasis (IC) in hematopoietic", "bbox": [83.0, 687.0, 390.0, 701.0]}, {"text": "cell transplantation (HCT) recipients due to gastrointestinal", "bbox": [83.0, 701.0, 390.0, 715.0]}, {"text": "flora translocation. Routine primary antifungal prophylaxis", "bbox": [83.0, 716.0, 391.0, 729.0]}, {"text": "beginning in the 1990s led to a significant decline in post-", "bbox": [83.0, 729.0, 389.0, 743.0]}, {"text": "transplantation IC to an incidence of 1% to 2% and a significant", "bbox": [83.0, 743.0, 390.0, 757.0]}, {"text": "shift in the epidemiology of Candida species [ 1 ]. Current chal-", "bbox": [83.0, 757.0, 389.0, 770.0]}, {"text": "lenges include the changing Candida epidemiology, suboptimal", "bbox": [83.0, 772.0, 391.0, 784.0]}, {"text": "diagnostic tools, and poor clinical outcomes, despite the avail-", "bbox": [83.0, 786.0, 389.0, 798.0]}, {"text": "ability of effective and safe treatment options. The principles", "bbox": [84.0, 799.0, 390.0, 812.0]}, {"text": "discussed for allogeneic HCT recipients prior to engraftment", "bbox": [83.0, 813.0, 390.0, 826.0]}, {"text": "are applicable to autologous HCT recipients and patients", "bbox": [84.0, 827.0, 390.0, 840.0]}], "type": "Text", "position": 13}, {"raw_context": [{"text": "Financial disclosure: See Acknowledgments on page 226.", "bbox": [91.0, 870.0, 309.0, 882.0]}, {"text": "*Correspondence and reprint requests: Dionysios Neofytos, Division of Infec-", "bbox": [92.0, 883.0, 389.0, 893.0]}, {"text": "tious Diseases, University Hospital of Geneva, Rue Gabrielle-Perret-Gentil 4,", "bbox": [85.0, 894.0, 390.0, 906.0]}, {"text": "1211 Geneva, Switzerland", "bbox": [85.0, 906.0, 188.0, 916.0]}], "type": "Text", "position": 14}, {"raw_context": [{"text": "E-mail address : dionysios.neofytos@hcuge.ch (D. Neofytos).", "bbox": [99.0, 916.0, 328.0, 928.0]}], "type": "Footnote", "position": 15}, {"raw_context": [{"text": "receiving cellular therapies, such as chimeric antigen receptor", "bbox": [418.0, 645.0, 725.0, 660.0]}, {"text": "(CAR) T cells, at least until neutrophil recovery and in the", "bbox": [417.0, 659.0, 725.0, 673.0]}, {"text": "absence of prolonged glucocorticoid therapy.", "bbox": [419.0, 674.0, 637.0, 688.0]}, {"text": "In this update to the 2009 compendium-style infectious", "bbox": [434.0, 687.0, 725.0, 701.0]}, {"text": "disease guidelines for HCT, a completely new approach was", "bbox": [417.0, 701.0, 726.0, 715.0]}, {"text": "taken with the goal of better serving clinical providers by pub-", "bbox": [418.0, 715.0, 724.0, 729.0]}, {"text": "lishing each standalone topic in the infectious disease series as", "bbox": [418.0, 730.0, 725.0, 743.0]}, {"text": "a concise format of frequently asked questions (FAQ), tables,", "bbox": [418.0, 743.0, 724.0, 756.0]}, {"text": "and figures [2] . For grading of strength of recommendation (A", "bbox": [419.0, 758.0, 726.0, 770.0]}, {"text": "to E) and quality of supporting evidence (level I to III), see Sup-", "bbox": [418.0, 772.0, 724.0, 784.0]}, {"text": "plementary Data. The key recommendations provided below", "bbox": [419.0, 785.0, 725.0, 798.0]}, {"text": "are accompanied by grading in parentheses.", "bbox": [418.0, 799.0, 632.0, 812.0]}], "type": "Text", "position": 16}, {"raw_context": [{"text": "EPIDEMIOLOGY", "bbox": [418.0, 829.0, 500.0, 843.0]}, {"text": "FAQ1: What is the epidemiology of Candida infections in HCT", "bbox": [417.0, 843.0, 722.0, 858.0]}, {"text": "recipients?", "bbox": [419.0, 859.0, 475.0, 872.0]}], "type": "Section-header", "position": 17}, {"raw_context": [{"text": "Collectively, non- albicans Candida species are more fre-", "bbox": [434.0, 872.0, 724.0, 886.0]}, {"text": "quently encountered in HCT recipients with IC [ 3 , 4 ]. Infections", "bbox": [419.0, 887.0, 725.0, 900.0]}, {"text": "due to Candida glabrata ( Nakaseomyces glabrata ) are up to 25%", "bbox": [419.0, 902.0, 725.0, 914.0]}, {"text": "to 50% fluconazole-resistant, and Candida krusei (Pichia", "bbox": [419.0, 916.0, 726.0, 928.0]}], "type": "Text", "position": 18}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/血液科/2023 ASTCT指南：造血细胞移植受者侵袭性念珠菌病的管理.pdf", "page_num": 1}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type2": "缺少换行#3#3# ² Department of Pediatrics另起一行\n 3 Transplant Infectious 另起一行\n4 Clinical Research Division另起一行\n5 Infectious Diseases Service另起一行\n6 Department of Infectious另起一行\n缺少换行#14#14#Faq1: What Is The Epidemiology另起一行\n", "type3": "无关文本#0#15#Dionysios Neofytos 1.4部分段落末尾，以及句末的数字问题无关噪声应用全文", "type6": "有用性#4#5#为侧边栏目内容，非正文内容\n有用性#7#7#© 2023 The American Society....出版信息，非正文内容\n有用性#10#11#Financial disclosure: See Acknowledgments on page 226.....其他披露信息，非正文内容"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:42", "update_time": "2024-05-08 22:52:32"}
{"id": 1082654, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 738, "source_info": {"seq_id": "6d18c244-12b3-41c2-ad97-a7df48dcdb50", "title": null, "text": "【0】页码:9\n\n【1】 GUIDELINE BJHaem Observational cohort data on the risk of peripartum and postpartum haemorrhage in individuals with MHVs.\n\n【2】T A B L E  3 Reference N (MHV) Comments Results UKOSS Prospective Primary PPH 2 (2%) 17 (29%) patients needed return Vause 2017 5 58 to theatre. (10 had delivered Secondary PPH 6 (10%) by CS and 7 delivered Wound haematoma 6 (10%) vaginally) Anticoagulation Intraabdominal bleed 4 (7%) around delivery likely variable and not reported Vaginal haematoma 1 (2%) International registry, Van Hagan 2015 49 (23%) haemorrhagic complication.\n\n【3】Postpartum anticoagulation 212 (ROPAC) 6 (15.1% major haemorrhagic event, regimen not specified prospective 10.4% PPH) Khader 2016 55 5 (12.5%) PPH UFH commenced 4–6h after Prospective, Egypt 10.40 delivery Abildgaard 2009 56 2 (16.6%) Primary PPH after CS LMWH commenced within 24 h Retrospective, Norway N = 12 Quinn 2009 25 3 (25%) PPH LMWH commenced within 24 h Retrospective UK N = 12 Wound haematoma 1 (8.3%) needing following delivery re-exploration Irani 2018 57 14 pregnancies 6 (42%) deliveries – PPH Anticoagulation re-started Single unit, retrospective USA median 6h, predominantly Primary PPH UFH IV. 2 intra-abdominal 3 (21%), secondary PPH 3 (21%). Wound bleeds and one wound haematoma haematoma in those who restarted <6h, no intra- 2 (14%) intra-abdominal bleed and 2 abdominal bleeds in the (14%) wound haematomas.\n\n【4】<6h group and 1 wound haematoma Kariv 2018 58 Single-centre 29 pregnancies 5 (17%) returns to theatre (including 2 UFH initiated at 6 h if stable, prospective cohort, wound haematoma) warfarin on day after delivery South Africa 6 (21%) major haemorrhage. 1 (3.4%) Primary, 5 (17.2%) Secondary PPH 15 (32%) PPH McLintock 2009 21 Restart UFH at 6 h post-VD 6–12 Retrospective audit, 47 pregnancies New Zealand CS, warfarin on day 1 (VD) 6 (12.8%) primary PPH (3 abruptions) or day 2–3 (CS) 9 (19%) secondary PPH 2 (11%) – Primary PPH Median time to restart Cousin 2018 59 Retrospective, single 18 cases anticoagulation 7h centre, France 5 (30%) – Secondary PPH needing post-delivery re-operation Dos Santos 2021 41 All with PPH/haematoma Retrospective 17% Primary PPH 44 pregnancies received prophylactic dose of 4 (31%) Secondary PPH Two centres, the UK and LMWH 4–6h after delivery the Netherlands 4 (31%) Wound haematoma 2 (10%) Intra-abdominal Abbreviations: CS, caesarean section; LMVH, low molecular weight heparin; MHVs, mechanical heart valves; PPH, postpartum haemorrhage; UFH, unfractionated heparin;\n\n【5】\n VD, vaginal delivery.\n\n【6】 Protamine is a reversal agent for UFH and has been used occasionally in pregnant individuals with MHVs on IV UFH who present with life-threatening haemorrhage. Its role in reversing LMWH however is limited and is not recommended routinely. Potential risks of protamine include anaphylaxis, pulmonary oedema, bronchoconstriction, bradycardia and increased bleeding and thrombosis risk.\n\n【7】In pregnant individuals, who are at least partially anticoagulated at the time of delivery (<24h), we recommend a low threshold for use of tranexamic acid 1 g IV post¬ delivery. Otherwise, it can be used as for normal PPH criteria. Evidence is lacking regarding any increased risk of\n\n【8】 MVT with the use of tranexamic acid 46 but a single dose is unlikely to be associated with a significant risk when considering the known very high risk of bleeding ( Table 3 ) which could lead to prolonged period of pausing anticoagulation. However, the use of repeated doses of tranexamic beyond the two doses used in the WOMAN trial 47 is probably best avoided.\n\n【9】If using aspirin, it is not mandated to stop however, in view of the high risk of PPH in this group of individuals, we recommend consideration of stopping for at least 3 days prior to scheduled delivery with anticipated correction of any associated bleeding risk. 48 , 49\n\n【10】 Prolife, perdict pieroviru M&V secot, - p ns Aq 1828 [ 49/1111 01/19/110], uso\n\n【11】 smot on 008 [520540/81] no vand", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "GUIDELINE", "bbox": [58.0, 26.0, 113.0, 40.0]}, {"text": "BJHaem", "bbox": [637.0, 32.0, 705.0, 53.0]}, {"text": "Observational cohort data on the risk of peripartum and postpartum haemorrhage in individuals with MHVs.", "bbox": [121.0, 58.0, 606.0, 72.0]}, {"text": "T A B L E  3", "bbox": [59.0, 60.0, 113.0, 71.0]}, {"text": "Reference", "bbox": [66.0, 83.0, 114.0, 96.0]}, {"text": "N (MHV)", "bbox": [292.0, 83.0, 340.0, 96.0]}, {"text": "Comments", "bbox": [574.0, 83.0, 627.0, 96.0]}, {"text": "Results", "bbox": [379.0, 84.0, 416.0, 96.0]}, {"text": "UKOSS Prospective", "bbox": [167.0, 104.0, 258.0, 117.0]}, {"text": "Primary PPH 2 (2%)", "bbox": [379.0, 104.0, 472.0, 117.0]}, {"text": "17 (29%) patients needed return", "bbox": [574.0, 104.0, 717.0, 117.0]}, {"text": "Vause 2017 5", "bbox": [67.0, 105.0, 119.0, 117.0]}, {"text": "58", "bbox": [293.0, 106.0, 306.0, 116.0]}, {"text": "to theatre. (10 had delivered", "bbox": [591.0, 119.0, 715.0, 130.0]}, {"text": "Secondary PPH 6 (10%)", "bbox": [379.0, 121.0, 486.0, 135.0]}, {"text": "by CS and 7 delivered", "bbox": [591.0, 130.0, 688.0, 145.0]}, {"text": "Wound haematoma 6 (10%)", "bbox": [379.0, 140.0, 504.0, 154.0]}, {"text": "vaginally) Anticoagulation", "bbox": [591.0, 145.0, 712.0, 157.0]}, {"text": "Intraabdominal bleed 4 (7%)", "bbox": [379.0, 158.0, 508.0, 173.0]}, {"text": "around delivery likely", "bbox": [591.0, 158.0, 690.0, 170.0]}, {"text": "variable and not reported", "bbox": [590.0, 170.0, 705.0, 183.0]}, {"text": "Vaginal haematoma 1 (2%)", "bbox": [379.0, 178.0, 500.0, 192.0]}, {"text": "International registry,", "bbox": [168.0, 194.0, 268.0, 211.0]}, {"text": "Van Hagan 2015", "bbox": [66.0, 195.0, 142.0, 210.0]}, {"text": "49 (23%) haemorrhagic complication.", "bbox": [380.0, 196.0, 546.0, 211.0]}, {"text": "Postpartum anticoagulation", "bbox": [575.0, 196.0, 702.0, 210.0]}, {"text": "212", "bbox": [292.0, 197.0, 311.0, 210.0]}, {"text": "(ROPAC) 6", "bbox": [82.0, 209.0, 128.0, 222.0]}, {"text": "(15.1% major haemorrhagic event,", "bbox": [395.0, 209.0, 547.0, 224.0]}, {"text": "regimen not specified", "bbox": [590.0, 209.0, 689.0, 223.0]}, {"text": "prospective", "bbox": [184.0, 210.0, 237.0, 223.0]}, {"text": "10.4% PPH)", "bbox": [397.0, 223.0, 451.0, 236.0]}, {"text": "Khader 2016 55", "bbox": [66.0, 240.0, 131.0, 254.0]}, {"text": "5 (12.5%) PPH", "bbox": [379.0, 240.0, 445.0, 254.0]}, {"text": "UFH commenced 4–6h after", "bbox": [574.0, 240.0, 705.0, 254.0]}, {"text": "Prospective, Egypt", "bbox": [168.0, 241.0, 254.0, 255.0]}, {"text": "10.40", "bbox": [294.0, 242.0, 307.0, 254.0]}, {"text": "delivery", "bbox": [591.0, 255.0, 629.0, 267.0]}, {"text": "Abildgaard 2009 56", "bbox": [66.0, 272.0, 148.0, 287.0]}, {"text": "2 (16.6%) Primary PPH after CS", "bbox": [379.0, 272.0, 522.0, 287.0]}, {"text": "LMWH commenced within 24 h", "bbox": [574.0, 273.0, 723.0, 287.0]}, {"text": "Retrospective, Norway", "bbox": [168.0, 274.0, 271.0, 287.0]}, {"text": "N = 12", "bbox": [293.0, 274.0, 322.0, 287.0]}, {"text": "Quinn 2009 25", "bbox": [66.0, 290.0, 126.0, 304.0]}, {"text": "3 (25%) PPH", "bbox": [379.0, 290.0, 438.0, 304.0]}, {"text": "LMWH commenced within 24 h", "bbox": [574.0, 290.0, 721.0, 304.0]}, {"text": "Retrospective UK", "bbox": [168.0, 291.0, 249.0, 304.0]}, {"text": "N = 12", "bbox": [293.0, 292.0, 322.0, 304.0]}, {"text": "Wound haematoma 1 (8.3%) needing", "bbox": [379.0, 308.0, 545.0, 323.0]}, {"text": "following delivery", "bbox": [591.0, 307.0, 672.0, 319.0]}, {"text": "re-exploration", "bbox": [396.0, 325.0, 461.0, 336.0]}, {"text": "Irani 2018 57", "bbox": [66.0, 341.0, 120.0, 354.0]}, {"text": "14 pregnancies", "bbox": [293.0, 341.0, 361.0, 355.0]}, {"text": "6 (42%) deliveries – PPH", "bbox": [379.0, 341.0, 490.0, 354.0]}, {"text": "Anticoagulation re-started", "bbox": [574.0, 341.0, 696.0, 354.0]}, {"text": "Single unit,", "bbox": [168.0, 342.0, 221.0, 354.0]}, {"text": "retrospective USA", "bbox": [183.0, 355.0, 267.0, 368.0]}, {"text": "median 6h, predominantly", "bbox": [591.0, 355.0, 712.0, 369.0]}, {"text": "Primary PPH", "bbox": [379.0, 359.0, 441.0, 374.0]}, {"text": "UFH IV. 2 intra-abdominal", "bbox": [591.0, 369.0, 714.0, 381.0]}, {"text": "3 (21%), secondary PPH 3 (21%). Wound", "bbox": [379.0, 377.0, 559.0, 391.0]}, {"text": "bleeds and one wound", "bbox": [591.0, 383.0, 692.0, 395.0]}, {"text": "haematoma", "bbox": [396.0, 394.0, 448.0, 405.0]}, {"text": "haematoma in those who", "bbox": [591.0, 397.0, 702.0, 408.0]}, {"text": "restarted <6h, no intra-", "bbox": [591.0, 409.0, 697.0, 421.0]}, {"text": "2 (14%) intra-abdominal bleed and 2", "bbox": [380.0, 411.0, 542.0, 423.0]}, {"text": "abdominal bleeds in the", "bbox": [591.0, 422.0, 700.0, 435.0]}, {"text": "(14%) wound haematomas.", "bbox": [395.0, 425.0, 512.0, 436.0]}, {"text": "<6h group and 1 wound", "bbox": [591.0, 436.0, 700.0, 448.0]}, {"text": "haematoma", "bbox": [591.0, 449.0, 643.0, 461.0]}, {"text": "Kariv 2018 58", "bbox": [67.0, 468.0, 123.0, 480.0]}, {"text": "Single-centre", "bbox": [168.0, 468.0, 230.0, 480.0]}, {"text": "29 pregnancies", "bbox": [293.0, 468.0, 361.0, 481.0]}, {"text": "5 (17%) returns to theatre (including 2", "bbox": [379.0, 467.0, 550.0, 481.0]}, {"text": "UFH initiated at 6 h if stable,", "bbox": [575.0, 468.0, 702.0, 480.0]}, {"text": "prospective cohort,", "bbox": [184.0, 481.0, 272.0, 493.0]}, {"text": "wound haematoma)", "bbox": [398.0, 481.0, 485.0, 493.0]}, {"text": "warfarin on day after delivery", "bbox": [591.0, 481.0, 724.0, 494.0]}, {"text": "South Africa", "bbox": [185.0, 495.0, 244.0, 507.0]}, {"text": "6 (21%) major haemorrhage. 1 (3.4%)", "bbox": [379.0, 498.0, 543.0, 511.0]}, {"text": "Primary, 5 (17.2%) Secondary PPH", "bbox": [395.0, 512.0, 551.0, 526.0]}, {"text": "15 (32%) PPH", "bbox": [379.0, 528.0, 443.0, 543.0]}, {"text": "McLintock 2009 21", "bbox": [66.0, 529.0, 147.0, 543.0]}, {"text": "Restart UFH at 6 h post-VD 6–12", "bbox": [574.0, 529.0, 723.0, 544.0]}, {"text": "Retrospective audit,", "bbox": [168.0, 531.0, 258.0, 543.0]}, {"text": "47 pregnancies", "bbox": [293.0, 532.0, 361.0, 544.0]}, {"text": "New Zealand", "bbox": [183.0, 544.0, 246.0, 558.0]}, {"text": "CS, warfarin on day 1 (VD)", "bbox": [590.0, 544.0, 715.0, 558.0]}, {"text": "6 (12.8%) primary PPH (3 abruptions)", "bbox": [379.0, 548.0, 549.0, 562.0]}, {"text": "or day 2–3 (CS)", "bbox": [590.0, 557.0, 660.0, 571.0]}, {"text": "9 (19%) secondary PPH", "bbox": [379.0, 567.0, 485.0, 580.0]}, {"text": "2 (11%) – Primary PPH", "bbox": [379.0, 584.0, 484.0, 601.0]}, {"text": "Median time to restart", "bbox": [574.0, 586.0, 677.0, 600.0]}, {"text": "Cousin 2018 59", "bbox": [67.0, 587.0, 129.0, 599.0]}, {"text": "Retrospective, single", "bbox": [168.0, 587.0, 262.0, 600.0]}, {"text": "18 cases", "bbox": [293.0, 588.0, 331.0, 600.0]}, {"text": "anticoagulation 7h", "bbox": [591.0, 600.0, 678.0, 612.0]}, {"text": "centre, France", "bbox": [183.0, 601.0, 249.0, 613.0]}, {"text": "5 (30%) – Secondary PPH needing", "bbox": [379.0, 603.0, 532.0, 617.0]}, {"text": "post-delivery", "bbox": [591.0, 614.0, 651.0, 625.0]}, {"text": "re-operation", "bbox": [396.0, 619.0, 453.0, 631.0]}, {"text": "Dos Santos 2021 41", "bbox": [66.0, 635.0, 148.0, 649.0]}, {"text": "All with PPH/haematoma", "bbox": [575.0, 635.0, 692.0, 650.0]}, {"text": "Retrospective", "bbox": [168.0, 636.0, 231.0, 649.0]}, {"text": "17% Primary PPH", "bbox": [379.0, 636.0, 462.0, 649.0]}, {"text": "44 pregnancies", "bbox": [293.0, 637.0, 361.0, 649.0]}, {"text": "received prophylactic dose of", "bbox": [592.0, 651.0, 721.0, 662.0]}, {"text": "4 (31%) Secondary PPH", "bbox": [379.0, 654.0, 485.0, 667.0]}, {"text": "Two centres, the UK and", "bbox": [169.0, 655.0, 279.0, 667.0]}, {"text": "LMWH 4–6h after delivery", "bbox": [591.0, 663.0, 715.0, 677.0]}, {"text": "the Netherlands", "bbox": [183.0, 669.0, 258.0, 682.0]}, {"text": "4 (31%) Wound haematoma", "bbox": [379.0, 672.0, 502.0, 687.0]}, {"text": "2 (10%) Intra-abdominal", "bbox": [379.0, 690.0, 491.0, 704.0]}, {"text": "Abbreviations: CS, caesarean section; LMVH, low molecular weight heparin; MHVs, mechanical heart valves; PPH, postpartum haemorrhage; UFH, unfractionated heparin;", "bbox": [59.0, 713.0, 732.0, 726.0]}], "type": "Table", "position": 0}, {"raw_context": [{"text": "VD, vaginal delivery.", "bbox": [59.0, 728.0, 141.0, 739.0]}], "type": "Text", "position": 1}, {"raw_context": [{"text": "Protamine is a reversal agent for UFH and has been used", "bbox": [74.0, 769.0, 387.0, 784.0]}, {"text": "occasionally in pregnant individuals with MHVs on IV UFH", "bbox": [58.0, 786.0, 386.0, 801.0]}, {"text": "who present with life-threatening haemorrhage. Its role in re-", "bbox": [58.0, 802.0, 385.0, 816.0]}, {"text": "versing LMWH however is limited and is not recommended", "bbox": [58.0, 817.0, 386.0, 833.0]}, {"text": "routinely. Potential risks of protamine include anaphylaxis,", "bbox": [58.0, 834.0, 385.0, 848.0]}, {"text": "pulmonary oedema, bronchoconstriction, bradycardia and", "bbox": [58.0, 849.0, 386.0, 864.0]}, {"text": "increased bleeding and thrombosis risk.", "bbox": [58.0, 866.0, 276.0, 880.0]}, {"text": "In pregnant individuals, who are at least partially anti-", "bbox": [74.0, 882.0, 385.0, 896.0]}, {"text": "coagulated at the time of delivery (<24h), we recommend", "bbox": [58.0, 897.0, 385.0, 913.0]}, {"text": "a low threshold for use of tranexamic acid 1 g IV post¬", "bbox": [58.0, 913.0, 385.0, 929.0]}, {"text": "delivery. Otherwise, it can be used as for normal PPH cri-", "bbox": [58.0, 930.0, 385.0, 944.0]}, {"text": "teria. Evidence is lacking regarding any increased risk of", "bbox": [58.0, 946.0, 386.0, 961.0]}], "type": "Text", "position": 2}, {"raw_context": [{"text": "MVT with the use of tranexamic acid 46 but a single dose", "bbox": [406.0, 768.0, 735.0, 784.0]}, {"text": "is unlikely to be associated with a significant risk when", "bbox": [406.0, 786.0, 735.0, 801.0]}, {"text": "considering the known very high risk of bleeding ( Table 3 )", "bbox": [406.0, 802.0, 735.0, 816.0]}, {"text": "which could lead to prolonged period of pausing anticoag-", "bbox": [406.0, 817.0, 733.0, 833.0]}, {"text": "ulation. However, the use of repeated doses of tranexamic", "bbox": [406.0, 834.0, 734.0, 848.0]}, {"text": "beyond the two doses used in the WOMAN trial 47 is prob-", "bbox": [406.0, 849.0, 733.0, 864.0]}, {"text": "ably best avoided.", "bbox": [406.0, 866.0, 506.0, 880.0]}, {"text": "If using aspirin, it is not mandated to stop however, in", "bbox": [422.0, 881.0, 735.0, 896.0]}, {"text": "view of the high risk of PPH in this group of individuals,", "bbox": [406.0, 897.0, 734.0, 913.0]}, {"text": "we recommend consideration of stopping for at least 3 days", "bbox": [406.0, 914.0, 735.0, 928.0]}, {"text": "prior to scheduled delivery with anticipated correction of", "bbox": [406.0, 930.0, 735.0, 944.0]}, {"text": "any associated bleeding risk. 48 , 49", "bbox": [406.0, 946.0, 583.0, 959.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "Prolife, perdict pieroviru M&V secot, - p ns Aq 1828 [ 49/1111 01/19/110], uso", "bbox": [769.0, 182.0, 780.0, 396.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": "smot on 008 [520540/81] no vand", "bbox": [771.0, 422.0, 780.0, 523.0]}], "type": "Text", "position": 5}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/心血管/指南/2023 BSH 指南：机械心脏瓣膜妊娠个体抗凝管理(1).pdf", "page_num": 9}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type2": "标点错误#7#7#  post¬  应该是-\n多余换行#8#8# MVT with the use of tranexamic 与上面7段联接", "type3": "无关文本#1#11#...tranexamic acid 46 but a single...类似的数字引用过多\n无关文本#10#11#侧面信息栏的内容", "type6": "准确性#1#5#表格的内容，内容混乱"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:42", "update_time": "2024-05-08 23:16:00"}
{"id": 1082653, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 738, "source_info": {"seq_id": "4009273d-d948-46bd-9cda-c0864e364cc5", "title": null, "text": "【0】页码:29\n What are the benefits if sedation is an option for your treatment?\n 1.\n\n【1】1.2.\n\n【2】 Sedation works quickly and the dose can be adjusted so you get just the right amount.\n\n【3】It allows you to be relaxed during your treatment. You may not remember much about your treatment afterwards.\n\n【4】 1.3.\n\n【5】 For most endoscopies, it is possible to give sedation instead of a general anaesthetic, which may be helpful for patients with some medical problems.\n\n【6】It usually has fewer side effects than a general anaesthetic.\n\n【7】Recovery is quicker than after a general anaesthetic, so you can usually go home within an hour\n 4.\n\n【8】5.\n It usually has fewer side effects than a general anaesthetic.\n\n【9】or two of your treatment if you feel well.\n\n【10】 There are three different levels of intravenous sedation. They are called 'minimal', 'moderate' (sometimes also called conscious sedation) and 'deep' sedation. However, the levels are not precise and depend on how sensitive a patient is to the medication used.\n\n【11】 What are the alternatives to sedation?\n\n【12】 Local anaesthetic without any sedation: you will be fully awake during your treatment but will be comfortable. Many endoscopies are performed without the need for sedation. Your team will explain the test and you will be able to decide which option would be best for you.\n\n【13】 Inhaled pain relief: To further support endoscopy especially if no other sedation is used, you may be offered an inhaled gas to help relieve pain and anxiety. This is usually the drug \"Entonox\" sometimes referred to as \"Gas and Air\".  This a drug that you breath in and out as you need it. The endoscopy team will show you how to use the equipment and support you. It has the benefit of rapidly wearing off so there are fewer precautions required after use.\n\n【14】 A general anaesthetic: you will be fully unconscious throughout and will have no memory of the procedure. This is not usually necessary for most endoscopy tests.", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "What are the benefits if sedation is an option for your treatment?", "bbox": [120.0, 141.0, 474.0, 156.0]}], "type": "Text", "position": 2}, {"raw_context": [{"text": "1.", "bbox": [142.0, 175.0, 159.0, 187.0]}, {"text": "1.2.", "bbox": [142.0, 191.0, 158.0, 203.0]}], "type": "List-item", "position": 3}, {"raw_context": [{"text": "Sedation works quickly and the dose can be adjusted so you get just the right amount.", "bbox": [160.0, 173.0, 628.0, 188.0]}, {"text": "It allows you to be relaxed during your treatment. You may not remember much about your", "bbox": [161.0, 190.0, 659.0, 204.0]}, {"text": "treatment afterwards.", "bbox": [161.0, 205.0, 286.0, 220.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": "1.3.", "bbox": [141.0, 223.0, 158.0, 234.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "For most endoscopies, it is possible to give sedation instead of a general anaesthetic, which may", "bbox": [161.0, 221.0, 683.0, 235.0]}, {"text": "be helpful for patients with some medical problems.", "bbox": [161.0, 237.0, 446.0, 251.0]}, {"text": "It usually has fewer side effects than a general anaesthetic.", "bbox": [161.0, 253.0, 482.0, 267.0]}, {"text": "Recovery is quicker than after a general anaesthetic, so you can usually go home within an hour", "bbox": [161.0, 269.0, 680.0, 284.0]}], "type": "Text", "position": 6}, {"raw_context": [{"text": "4.", "bbox": [140.0, 255.0, 160.0, 266.0]}, {"text": "5.", "bbox": [141.0, 271.0, 159.0, 283.0]}], "type": "List-item", "position": 7}, {"raw_context": [{"text": "It usually has fewer side effects than a general anaesthetic.", "bbox": [161.0, 253.0, 482.0, 267.0]}, {"text": "or two of your treatment if you feel well.", "bbox": [161.0, 285.0, 385.0, 299.0]}], "type": "List-item", "position": 8}, {"raw_context": [{"text": "There are three different levels of intravenous sedation. They are called 'minimal', 'moderate'", "bbox": [120.0, 315.0, 626.0, 330.0]}, {"text": "(sometimes also called conscious sedation) and 'deep' sedation. However, the levels are not precise and", "bbox": [120.0, 332.0, 682.0, 346.0]}, {"text": "depend on how sensitive a patient is to the medication used.", "bbox": [119.0, 348.0, 449.0, 362.0]}], "type": "Text", "position": 9}, {"raw_context": [{"text": "What are the alternatives to sedation?", "bbox": [120.0, 380.0, 331.0, 395.0]}], "type": "Text", "position": 10}, {"raw_context": [{"text": "Local anaesthetic without any sedation: you will be fully awake during your treatment but will be", "bbox": [119.0, 410.0, 649.0, 426.0]}, {"text": "comfortable. Many endoscopies are performed without the need for sedation. Your team will explain", "bbox": [119.0, 426.0, 667.0, 441.0]}, {"text": "the test and you will be able to decide which option would be best for you.", "bbox": [119.0, 443.0, 524.0, 457.0]}], "type": "Text", "position": 11}, {"raw_context": [{"text": "Inhaled pain relief: To further support endoscopy especially if no other sedation is used, you may be", "bbox": [119.0, 474.0, 663.0, 488.0]}, {"text": "offered an inhaled gas to help relieve pain and anxiety. This is usually the drug \"Entonox\" sometimes", "bbox": [119.0, 490.0, 663.0, 505.0]}, {"text": "referred to as \"Gas and Air\".  This a drug that you breath in and out as you need it. The endoscopy team", "bbox": [119.0, 506.0, 680.0, 520.0]}, {"text": "will show you how to use the equipment and support you. It has the benefit of rapidly wearing off so", "bbox": [119.0, 521.0, 664.0, 536.0]}, {"text": "there are fewer precautions required after use.", "bbox": [119.0, 538.0, 376.0, 552.0]}], "type": "Text", "position": 12}, {"raw_context": [{"text": "A general anaesthetic: you will be fully unconscious throughout and will have no memory of the", "bbox": [119.0, 569.0, 640.0, 583.0]}, {"text": "procedure. This is not usually necessary for most endoscopy tests.", "bbox": [120.0, 585.0, 478.0, 600.0]}], "type": "Text", "position": 13}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/消化科/_2023 BSG指南：胃肠内窥镜检查中的镇静.pdf", "page_num": 29}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "多余换行#0#8#序号和正文分离1.和Sedation works quickly and相连，以此类推\n多余换行#7#9#Recovery is quicker than 和treatment if you feel well.是一句话\n", "type3": "无关文本#1#1#1.\n无关文本#4#4#1.", "type4": null, "type5": null, "type6": null}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:42", "update_time": "2024-05-07 23:30:54"}
{"id": 1082652, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 738, "source_info": {"seq_id": "b7c56429-3e54-42a7-b4aa-ae5ee181eb08", "title": null, "text": "【0】页码:2\n\n【1】 • 22 • 2023 100, 121 : INT-0116 2.\n\n【2】D2 OS ( ORR ) 42% 9% 11 ; D2 33%  35 ..\n\n【3】10 . .\n\n【4】OS ORR 39% .\n\n【5】\n\n【6】D2 r . \n\n【7】, FDA     2021     8 dMMR l 1.\n\n【8】: ( perform– : CT 1.\n\n【9】\n ance status PS)\n\n【10】 o 2.\n\n【11】: l 135 ~ 200 mg/m 2                75 mg/m 2 (2) (nivolumab) ..\n\n【12】pd-1 ( food and drug administration FDA)\n\n【13】 : CT 1.\n\n【14】3D ( intensity–modulated radiation therapy IM–  \"IMRT RT)  ( ) Construction of the Construction 3D  3D IMRT  1346\n\n【15】 7\n\n【16】 III\n\n【17】 CheckMate-649  《Lancet 》 11 'HER2 ,\n\n【18】 45 ~ 50. 4 Gy 2.\n\n【19】1. 8 Gy 25 ~ 28 . (1) ..\n\n【20】 ( XELOX FOLFOX        ) PD-L1_CPS  ≥ 5  0.000 1)     PFS(7.7     vs.6      HR:0.68  P <0.000 1) PD-L1 CPS ≥ 1  HR: 0. 77; 13. 8             vs. 11. 6            HR: 0. 80) PFS(7.5           vs. 6. 9             HR: 0. 74; 7. 7           vs. 6. 9 3 ~ 4 HR: 0. 77) 59% 44% 2.0% 0.5% .\n\n【21】PD-L1 CPS ≥ 5  HER2\n\n【22】 30 Gy 15% 40% 10 Gy (2) :\n\n【23】\n 40 Gy 10% 20 Gy 20% 5 Gy 50%\n\n【24】\n PD-L1 CPS ≥ 5 > 26. 1 Gy  / HER2 :         > 30 Gy 50% PD-L1_CPS < 5 > 30 Gy / 17 (2B ) .\n\n【25】3.\n\n【26】30 Gy ( 26 Gy ) . (3) :  . 13% ( dostarlimb-gxly) MSI-H/dMMR 2 2 PD-1 o l GARNET 30% 18 .\n\n【27】I I 209 PD-1 CTLA4  54 Gy dMMR 103 106 99 MMR CNGS\n\n【28】\n : 54 Gy\n\n【29】 7\n\n【30】 o\n\n【31】 MSI", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "• 22 •", "bbox": [68.0, 53.0, 107.0, 70.0]}, {"text": "2023", "bbox": [441.0, 57.0, 734.0, 73.0]}, {"text": "100, 121", "bbox": [499.0, 89.0, 514.0, 102.0]}, {"text": ": INT-0116", "bbox": [168.0, 90.0, 237.0, 107.0]}, {"text": "2.", "bbox": [84.0, 91.0, 103.0, 108.0]}, {"text": "D2", "bbox": [363.0, 91.0, 385.0, 107.0]}, {"text": "OS", "bbox": [330.0, 113.0, 353.0, 129.0]}, {"text": "( ORR ) 42%", "bbox": [406.0, 112.0, 503.0, 129.0]}, {"text": "9%", "bbox": [606.0, 112.0, 630.0, 129.0]}, {"text": "11 ; D2", "bbox": [97.0, 133.0, 129.0, 150.0]}, {"text": "33%", "bbox": [407.0, 133.0, 438.0, 149.0]}, {"text": "", "bbox": [449.0, 133.0, 502.0, 148.0]}, {"text": "35", "bbox": [545.0, 132.0, 567.0, 149.0]}, {"text": "..", "bbox": [590.0, 136.0, 604.0, 149.0]}, {"text": "10 . .", "bbox": [109.0, 152.0, 136.0, 170.0]}, {"text": "OS", "bbox": [58.0, 154.0, 80.0, 170.0]}, {"text": "ORR 39% .", "bbox": [406.0, 154.0, 498.0, 171.0]}, {"text": "", "bbox": [83.0, 155.0, 110.0, 167.0]}, {"text": "D2", "bbox": [58.0, 175.0, 79.0, 192.0]}, {"text": "r", "bbox": [437.0, 179.0, 447.0, 192.0]}, {"text": ". ", "bbox": [452.0, 201.0, 489.0, 212.0]}, {"text": ",", "bbox": [490.0, 201.0, 509.0, 213.0]}, {"text": "FDA     2021     8", "bbox": [407.0, 218.0, 517.0, 233.0]}, {"text": "dMMR", "bbox": [690.0, 217.0, 734.0, 233.0]}, {"text": "l", "bbox": [117.0, 219.0, 129.0, 233.0]}, {"text": "1.", "bbox": [85.0, 261.0, 105.0, 277.0]}, {"text": ":", "bbox": [155.0, 262.0, 165.0, 276.0]}, {"text": "( perform–", "bbox": [324.0, 303.0, 386.0, 317.0]}, {"text": ": CT", "bbox": [574.0, 302.0, 604.0, 317.0]}, {"text": "1.", "bbox": [434.0, 304.0, 484.0, 319.0]}], "type": "Table", "position": 0}, {"raw_context": [{"text": "ance status PS)", "bbox": [58.0, 322.0, 151.0, 339.0]}], "type": "Text", "position": 1}, {"raw_context": [{"text": "o", "bbox": [84.0, 347.0, 112.0, 361.0]}, {"text": "2.", "bbox": [72.0, 364.0, 189.0, 381.0]}, {"text": ":", "bbox": [214.0, 367.0, 224.0, 380.0]}, {"text": "l", "bbox": [297.0, 387.0, 308.0, 401.0]}, {"text": "135 ~ 200 mg/m 2                75 mg/m 2", "bbox": [75.0, 403.0, 311.0, 424.0]}, {"text": "(2)", "bbox": [58.0, 428.0, 135.0, 444.0]}, {"text": "(nivolumab)", "bbox": [150.0, 427.0, 308.0, 444.0]}, {"text": "..", "bbox": [136.0, 430.0, 151.0, 444.0]}, {"text": "pd-1", "bbox": [74.0, 447.0, 212.0, 466.0]}, {"text": "( food and drug administration FDA)", "bbox": [58.0, 469.0, 269.0, 486.0]}], "type": "Text", "position": 2}, {"raw_context": [{"text": ": CT", "bbox": [574.0, 302.0, 604.0, 317.0]}, {"text": "1.", "bbox": [434.0, 304.0, 484.0, 319.0]}, {"text": "3D", "bbox": [437.0, 322.0, 731.0, 339.0]}, {"text": "( intensity–modulated radiation therapy IM–", "bbox": [479.0, 343.0, 735.0, 360.0]}, {"text": "", "bbox": [422.0, 345.0, 481.0, 358.0]}, {"text": "\"IMRT", "bbox": [574.0, 364.0, 619.0, 379.0]}, {"text": "RT) ", "bbox": [408.0, 365.0, 521.0, 384.0]}, {"text": "(", "bbox": [475.0, 386.0, 530.0, 403.0]}, {"text": ")", "bbox": [675.0, 386.0, 688.0, 402.0]}, {"text": "Construction of the Construction", "bbox": [532.0, 387.0, 676.0, 403.0]}, {"text": "3D", "bbox": [569.0, 407.0, 629.0, 422.0]}, {"text": "", "bbox": [633.0, 409.0, 651.0, 422.0]}, {"text": "3D", "bbox": [584.0, 427.0, 610.0, 443.0]}, {"text": "IMRT", "bbox": [696.0, 427.0, 734.0, 443.0]}, {"text": "", "bbox": [677.0, 430.0, 696.0, 443.0]}, {"text": "1346", "bbox": [639.0, 443.0, 674.0, 458.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "7", "bbox": [152.0, 512.0, 163.0, 525.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": "III", "bbox": [324.0, 512.0, 340.0, 526.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "CheckMate-649 ", "bbox": [58.0, 532.0, 209.0, 548.0]}, {"text": "《Lancet 》 11", "bbox": [251.0, 532.0, 333.0, 548.0]}, {"text": "'HER2", "bbox": [105.0, 553.0, 189.0, 569.0]}, {"text": ",", "bbox": [303.0, 558.0, 312.0, 570.0]}], "type": "Text", "position": 6}, {"raw_context": [{"text": "45 ~ 50. 4 Gy", "bbox": [492.0, 510.0, 671.0, 527.0]}, {"text": "2.", "bbox": [434.0, 512.0, 473.0, 528.0]}, {"text": "1. 8 Gy", "bbox": [521.0, 532.0, 618.0, 549.0]}, {"text": "25 ~ 28", "bbox": [616.0, 532.0, 667.0, 549.0]}, {"text": ". (1)", "bbox": [522.0, 554.0, 565.0, 570.0]}, {"text": "..", "bbox": [569.0, 554.0, 600.0, 569.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "( XELOX", "bbox": [312.0, 572.0, 383.0, 589.0]}, {"text": "FOLFOX        )", "bbox": [74.0, 594.0, 169.0, 611.0]}, {"text": "PD-L1_CPS", "bbox": [313.0, 595.0, 385.0, 611.0]}, {"text": "", "bbox": [286.0, 596.0, 314.0, 609.0]}, {"text": "≥ 5 ", "bbox": [59.0, 615.0, 383.0, 632.0]}, {"text": "0.000 1)     PFS(7.7     vs.6      HR:0.68  P <0.000 1)", "bbox": [56.0, 636.0, 363.0, 654.0]}, {"text": "PD-L1 CPS ≥ 1 ", "bbox": [74.0, 655.0, 383.0, 676.0]}, {"text": "HR: 0. 77; 13. 8             vs. 11. 6            HR: 0. 80)", "bbox": [77.0, 677.0, 388.0, 696.0]}, {"text": "PFS(7.5           vs. 6. 9             HR: 0. 74; 7. 7           vs. 6. 9", "bbox": [58.0, 699.0, 387.0, 716.0]}, {"text": "3 ~ 4", "bbox": [160.0, 717.0, 297.0, 736.0]}, {"text": "HR: 0. 77)", "bbox": [69.0, 720.0, 160.0, 737.0]}, {"text": "59% 44%", "bbox": [158.0, 741.0, 265.0, 758.0]}, {"text": "2.0% 0.5% .", "bbox": [115.0, 762.0, 217.0, 779.0]}, {"text": "PD-L1 CPS ≥ 5", "bbox": [265.0, 783.0, 366.0, 800.0]}, {"text": "", "bbox": [217.0, 784.0, 265.0, 797.0]}, {"text": "HER2", "bbox": [58.0, 804.0, 97.0, 821.0]}], "type": "Text", "position": 8}, {"raw_context": [{"text": "30 Gy", "bbox": [406.0, 658.0, 446.0, 674.0]}, {"text": "15%", "bbox": [503.0, 657.0, 535.0, 673.0]}, {"text": "40%", "bbox": [502.0, 678.0, 535.0, 694.0]}, {"text": "10 Gy", "bbox": [406.0, 679.0, 447.0, 695.0]}, {"text": "(2)", "bbox": [405.0, 700.0, 436.0, 716.0]}, {"text": ":", "bbox": [458.0, 701.0, 469.0, 715.0]}], "type": "Table", "position": 9}, {"raw_context": [{"text": "40 Gy", "bbox": [565.0, 636.0, 606.0, 653.0]}, {"text": "10%", "bbox": [665.0, 636.0, 696.0, 653.0]}, {"text": "20 Gy", "bbox": [566.0, 657.0, 605.0, 675.0]}, {"text": "20%", "bbox": [664.0, 657.0, 695.0, 673.0]}, {"text": "5 Gy", "bbox": [569.0, 679.0, 604.0, 695.0]}, {"text": "50%", "bbox": [664.0, 679.0, 694.0, 694.0]}], "type": "Table", "position": 10}, {"raw_context": [{"text": "PD-L1 CPS ≥ 5", "bbox": [265.0, 783.0, 366.0, 800.0]}, {"text": "> 26. 1 Gy", "bbox": [482.0, 783.0, 548.0, 800.0]}, {"text": "", "bbox": [217.0, 784.0, 265.0, 797.0]}, {"text": "/", "bbox": [606.0, 785.0, 617.0, 799.0]}, {"text": "HER2", "bbox": [58.0, 804.0, 97.0, 821.0]}, {"text": ":         > 30 Gy", "bbox": [448.0, 804.0, 541.0, 821.0]}, {"text": "50%", "bbox": [559.0, 804.0, 592.0, 820.0]}, {"text": "PD-L1_CPS < 5", "bbox": [165.0, 825.0, 255.0, 842.0]}, {"text": "> 30 Gy", "bbox": [468.0, 825.0, 519.0, 842.0]}, {"text": "/", "bbox": [636.0, 828.0, 647.0, 841.0]}, {"text": "17", "bbox": [476.0, 845.0, 510.0, 863.0]}, {"text": "(2B", "bbox": [98.0, 846.0, 131.0, 863.0]}, {"text": ") .", "bbox": [168.0, 848.0, 204.0, 864.0]}, {"text": "3.", "bbox": [84.0, 868.0, 103.0, 884.0]}, {"text": "30 Gy", "bbox": [406.0, 868.0, 447.0, 884.0]}, {"text": "( 26 Gy", "bbox": [448.0, 868.0, 520.0, 885.0]}, {"text": ") . (3)", "bbox": [553.0, 868.0, 624.0, 885.0]}, {"text": ":", "bbox": [198.0, 869.0, 208.0, 884.0]}, {"text": "", "bbox": [627.0, 872.0, 649.0, 885.0]}, {"text": ". 13%", "bbox": [563.0, 889.0, 608.0, 905.0]}, {"text": "( dostarlimb-gxly)", "bbox": [161.0, 909.0, 296.0, 927.0]}, {"text": "MSI-H/dMMR", "bbox": [297.0, 909.0, 384.0, 926.0]}, {"text": "2 2", "bbox": [556.0, 929.0, 586.0, 947.0]}, {"text": "PD-1", "bbox": [332.0, 931.0, 365.0, 947.0]}, {"text": "o", "bbox": [185.0, 933.0, 197.0, 947.0]}, {"text": "l ", "bbox": [545.0, 932.0, 557.0, 946.0]}, {"text": "GARNET", "bbox": [157.0, 950.0, 244.0, 968.0]}, {"text": "30% 18 .", "bbox": [508.0, 950.0, 566.0, 967.0]}, {"text": "I I", "bbox": [125.0, 953.0, 140.0, 967.0]}, {"text": "209", "bbox": [58.0, 971.0, 87.0, 988.0]}, {"text": "PD-1", "bbox": [170.0, 972.0, 250.0, 989.0]}, {"text": "CTLA4", "bbox": [250.0, 973.0, 308.0, 989.0]}, {"text": "", "bbox": [336.0, 972.0, 373.0, 986.0]}, {"text": "54 Gy", "bbox": [452.0, 973.0, 490.0, 990.0]}, {"text": "dMMR", "bbox": [58.0, 992.0, 101.0, 1009.0]}, {"text": "103", "bbox": [341.0, 992.0, 367.0, 1009.0]}, {"text": "106", "bbox": [207.0, 1014.0, 234.0, 1031.0]}, {"text": "99", "bbox": [346.0, 1014.0, 367.0, 1030.0]}, {"text": "MMR", "bbox": [407.0, 1014.0, 446.0, 1031.0]}, {"text": "CNGS", "bbox": [445.0, 1015.0, 513.0, 1031.0]}], "type": "Table", "position": 11}, {"raw_context": [{"text": ":", "bbox": [648.0, 870.0, 659.0, 885.0]}, {"text": "54 Gy", "bbox": [695.0, 888.0, 733.0, 904.0]}], "type": "Text", "position": 12}, {"raw_context": [{"text": "7", "bbox": [701.0, 910.0, 716.0, 926.0]}], "type": "Text", "position": 13}, {"raw_context": [{"text": "o", "bbox": [665.0, 977.0, 675.0, 990.0]}], "type": "Text", "position": 14}, {"raw_context": [{"text": "MSI", "bbox": [686.0, 992.0, 714.0, 1009.0]}], "type": "Text", "position": 15}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/肿瘤科/解读/美国国立综合癌症网络临床实践指南：胃癌(2022.V2)更新解读(1).pdf", "page_num": 2}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "格式杂乱#0#31#内容无法理解", "type3": null, "type4": null, "type5": null, "type6": null}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:42", "update_time": "2024-05-07 23:30:28"}
{"id": 1082651, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 738, "source_info": {"seq_id": "2b015ae8-92c1-4ccb-9b0c-3f467e1e9807", "title": null, "text": "【0】页码:13\n the management of cardiovascular diseases during pregnancy. Eur Heart J. 2018;39:3165–241.\n\n【1】8. Steinberg ZL, Dominguez-Islas CP, Otto CM, Stout KK, Krieger EV.\n\n【2】Maternal and fetal outcomes of anticoagulation in pregnant women withmechanicalheartvalves.J AmCollCardiol.2017;69:2681–91.\n\n【3】D'Souza R, Ostro J, Shah PS, Silversides CK, Malinowski A, Murphy KE, et al. Anticoagulation for pregnant women with mechanical heart valves: a systematic review and meta-analysis. Eur Heart J.\n\n【4】2017;38:1509–16.\n\n【5】10. Xu Z, Fan J, Luo X, Zhang WB, Ma J, Lin YB, et al. Anticoagulation regimens during pregnancy in patients with mechanical heart valves: a systematic review and meta-analysis. Can J Cardiol. 2016;32:1248.e1–9.\n\n【6】11. Batra J, Itagaki S, Egorova NN, Chikwe J. Outcomes and long-term effects of pregnancy in women with biologic and mechanical valve prostheses. Am J Cardiol. 2018;122:1738–44.\n\n【7】12. Lameijer H, van Slooten YJ, Jongbloed MRM, Oudijk MA, Kampman MAM, van Dijk AP, et al. Biological versus mechanical heart valve prosthesis during pregnancy in women with congenital heart disease.\n\n【8】Int J Cardiol. 2018;268:106–12.\n\n【9】13. Güner A, Kalçık M, Gürsoy MO, Gündüz S, Astarcıoğlu MA, Bayam E, et al. Comparison of different anticoagulation regimens regarding maternal and fetal outcomes in pregnant patients with mechanical prosthetic heart valves (from the multicenter ANATOLIA-PREG registry). Am J Cardiol. 2020;127:113–9.\n\n【10】14. Ayad SW, Hassanein MM, Mohamed EA, Gohar AM. Maternal and fetal outcomes in pregnant women with a prosthetic mechanical heart valve. Clin Med Insights Cardiol. 2016;10:11–7.\n\n【11】15. McLintock C. The obstetric haematology manual. 2nd ed. Cambridge, UK: Cambridge University Press; 2018.\n\n【12】16. Ikonen E, Merikallio E, Osterlund K, Seppälä M. Mitral-valve prosthesis, warfarin anticoagulation, and pregnancy. Lancet. 1970;2:1252.\n\n【13】17. Pauli RM, Hall JG, Wilson KM. Risks of anticoagulation during pregnancy. Am Heart J. 1980;100:761–2.\n\n【14】18. van Driel D, Wesseling J, Sauer PJ, Touwen BC, van der Veer E, Heymans HS. Teratogen update: fetal effects after in utero exposure to coumarins overview of cases, follow-up findings, and pathogenesis. Teratology. 2002;66:127–40.\n\n【15】19. Wesseling J, Van Driel D, Heymans HS, Rosendaal FR, Geven-Boere LM, Smrkovsky M, et al. Coumarins during pregnancy: long-term effects on growth and development of school-age children. Thromb Haemost. 2001;85:609–13.\n\n【16】20. McLintock C. Anticoagulant therapy in pregnant women with mechanical prosthetic heart valves: no easy option. Thromb Res.\n\n【17】2011;127(Suppl 3):S56–60.\n\n【18】21. McLintock C, McCowan LM, North RA. Maternal complications and pregnancy outcome in women with mechanical prosthetic heart valves treated with enoxaparin. BJOG. 2009;116:1585–92.\n\n【19】22. Kjaergaard AB, Fuglsang J, Hvas A-M. Anti-Xa monitoring of lowmolecular-weight heparin during pregnancy: a systematic review.\n\n【20】Semin Thromb Hemost. 2021;47:824–42.\n\n【21】23. Oran B, Lee- Parritz A, Ansell J. Low molecular weight heparin for the prophylaxis of thromboembolism in women with prosthetic mechanical heart valves during pregnancy. Thromb Haemost. 2004;92:747–51.\n\n【22】24. James AH, Brancazio LR, Gehrig TR, Wang A, Ortel TL. Low-molecularweight heparin for thromboprophylaxis in pregnant women with mechanical heart valves. J Matern Fetal Neonatal Med. 2006;19:543–9.\n\n【23】25. Quinn J, Von Klemperer K, Brooks R, Peebles D, Walker F, Cohen H. Use of high intensity adjusted dose low molecular weight heparin in women with mechanical heart valves during pregnancy: a singlecenter experience. Haematologica. 2009;94:1608–12.\n\n【24】26. Berresheim M, Wilkie J, Nerenberg KA, Ibrahim Q, Bungard TJ. A case series of LMWH use in pregnancy: should trough anti-Xa levels guide dosing? Thromb Res. 2014;134:1234–40.\n\n【25】27. Gray E, Mulloy B, Barrowcliffe TW. Heparin and low- molecularweight heparin. Thromb Haemost. 2008;99:807–18.\n\n【26】28. McLintock C. Thromboembolism in pregnancy: challenges and controversies in the prevention of pregnancy-associated venous thromboembolism and management of anticoagulation in women\n\n【27】## Bjhaem\n\n【28】\n online/capable and her class annot whose [ EDS40/81 no gended online] you'll , yourdely plens with Make assot - is no collect 140/111 01/84/080 collec candionline//\n\n【29】 tears absolute oth ed bomardg on solving AC case to solvi an yeardel onlin0 yoli/W  no (amitibuto-bus-anna/moo.colive.gendlor\n\n【30】 with mechanical prosthetic heart valves. Best Pract Res Clin Obstet Gynaecol. 2014;28:519–36.\n\n【31】29. Elkayam U, Goland S. The search for a safe and effective anticoagulation regimen in pregnant women with mechanical prosthetic heart valves. J Am Coll Cardiol. 2012;59:1116–8.\n\n【32】Wu T, Xia X, Chen W, Fu J, Zhang J. The effect of anti-Xa monitoring 30.\n\n【33】on the safety and efficacy of low-molecular-weight heparin anticoagulation therapy: a systematic review and meta-analysis. J Clin Pharm Ther. 2020;45:602–8.\n\n【34】31. Droege ME, Mueller EW, Besl KM, Lemmink JA, Kramer EA, Athota KP, et al. Effect of a dalteparin prophylaxis protocol using anti-factor Xa concentrations on venous thromboembolism in high-risk trauma patients. J Trauma Acute Care Surg. 2014;76:450–6.\n\n【35】32.\n\n【36】Goland S, Schwartzenberg S, Fan J, Kozak N, Khatri N, Elkayam U.\n\n【37】Monitoring of anti-Xa in pregnant patients with mechanical prosthetic valves receiving low-molecular-weight heparin: peak or trough levels? J Cardiovasc Pharmacol Ther. 2014;19:451–6.\n\n【38】Malhamé I, Othman M, Casais P, D'Souza R, Wald RM, Silversides CK, et  al. Communication from the ISTH SSC subcommittee on Women's health issues in thrombosis and Haemostasis: a survey on anticoagulation for mechanical heart valves in pregnancy. J Thromb Haemost. 2021;19:859–64.\n\n【39】34. Massel DR, Little SH. Antiplatelet and anticoagulation for patients with prosthetic heart valves. Cochrane Database Syst Rev.\n\n【40】2013;2013:Cd003464.\n\n【41】35. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Guyton RA, et al. 2014 AHA/ACC guideline for the Management of Patients with Valvular Heart Disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:2440–92.\n\n【42】36. Elkayam U. Anticoagulation therapy for pregnantwomen with mechanicalprosthetic heartvalves: how to improve safety? J Am Coll Cardiol. 2017;69:2692–5.\n\n【43】37. Van Doorn R, Mukhtarova N, Flyke IP, Lasarev M, Kim K, Hennekens CH, et al. Dose of aspirin to prevent preterm preeclampsia in women with moderate or high-risk factors: a systematic review and metaanalysis. PloS One. 2021;16:e0247782.\n\n【44】38. Chu J, Hardy P, Beeson L, Coomarasamy A. What is the best method for managing early miscarriage? BMJ. 2020;368:l6438.\n\n【45】39. Özkan M, Çakal B, Karakoyun S, Gürsoy OM, Çevik C, Kalçık M, et al. Thrombolytic therapy for the treatment of prosthetic heart valve thrombosis in pregnancy with low-dose, slow infusion of tissue-type plasminogen activator. Circulation. 2013;128:532–40.\n\n【46】40.\n\n【47】Jha N, Jha AK, Chand Chauhan R, Chauhan NS. Maternal and fetal outcome after cardiac operations during pregnancy: a meta-analysis.\n\n【48】Ann Thorac Surg. 2018;106:618–26.\n\n【49】41. Dos Santos F, Baris L, Varley A, Cornette J, Allam J, Steer P, et al.\n\n【50】Mechanical heart valves and pregnancy: issues surrounding anticoagulation. Experience from two obstetric cardiac centres. Obstet Med. 2021;14:95–101.\n\n【51】42. Bates SM, Rajasekhar A, Middeldorp S, McLintock C, Rodger MA, James AH, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy. Blood Adv. 2018;2:3317–59.\n\n【52】43. Knol HM, Schultinge L, Veeger NJ, Kluin-Nelemans HC, Erwich JJ, Meijer K. The risk of postpartum hemorrhage in women using high dose of low-molecular-weight heparins during pregnancy. Thromb Res. 2012;130:334–8.\n\n【53】44. Keeling D, Baglin T, Tait C, Watson H, Perry D, Baglin C, et  al.\n\n【54】Guidelines on oral anticoagulation with warfarin—fourth edition. Br J Haematol. 2011;154:311–24.\n\n【55】45. Vandiver JW, Vondracek TG. Antifactor Xa levels versus activated partial thromboplastin time for monitoring unfractionated heparin.\n\n【56】Pharmacotherapy. 2012;32:546–58.\n\n【57】Taeuber I, Weibel S, Herrmann E, Neef V, Schlesinger T, Kranke P, 46.\n\n【58】et al. Association of intravenous tranexamic acid with thromboembolic events and mortality: a systematic review, meta-analysis, and meta-regression. JAMA Surg. 2021;156:e210884.", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "the management of cardiovascular diseases during pregnancy. Eur", "bbox": [80.0, 58.0, 386.0, 72.0]}, {"text": "Heart J. 2018;39:3165–241.", "bbox": [80.0, 73.0, 198.0, 84.0]}, {"text": "8. Steinberg ZL, Dominguez-Islas CP, Otto CM, Stout KK, Krieger EV.", "bbox": [64.0, 85.0, 386.0, 99.0]}, {"text": "Maternal and fetal outcomes of anticoagulation in pregnant women", "bbox": [80.0, 99.0, 387.0, 112.0]}, {"text": "withmechanicalheartvalves.J AmCollCardiol.2017;69:2681–91.", "bbox": [80.0, 113.0, 373.0, 125.0]}, {"text": "D'Souza R, Ostro J, Shah PS, Silversides CK, Malinowski A, Murphy", "bbox": [77.0, 126.0, 385.0, 138.0]}, {"text": "KE, et al. Anticoagulation for pregnant women with mechanical", "bbox": [80.0, 139.0, 387.0, 152.0]}, {"text": "heart valves: a systematic review and meta-analysis. Eur Heart J.", "bbox": [80.0, 153.0, 386.0, 166.0]}, {"text": "2017;38:1509–16.", "bbox": [81.0, 166.0, 156.0, 179.0]}, {"text": "10. Xu Z, Fan J, Luo X, Zhang WB, Ma J, Lin YB, et al. Anticoagulation", "bbox": [61.0, 178.0, 387.0, 192.0]}, {"text": "regimens during pregnancy in patients with mechanical heart valves: a", "bbox": [80.0, 193.0, 387.0, 205.0]}, {"text": "systematic review and meta-analysis. Can J Cardiol. 2016;32:1248.e1–9.", "bbox": [80.0, 206.0, 385.0, 218.0]}, {"text": "11. Batra J, Itagaki S, Egorova NN, Chikwe J. Outcomes and long-term", "bbox": [61.0, 219.0, 386.0, 232.0]}, {"text": "effects of pregnancy in women with biologic and mechanical valve", "bbox": [80.0, 234.0, 387.0, 246.0]}, {"text": "prostheses. Am J Cardiol. 2018;122:1738–44.", "bbox": [81.0, 247.0, 277.0, 259.0]}, {"text": "12. Lameijer H, van Slooten YJ, Jongbloed MRM, Oudijk MA, Kampman", "bbox": [60.0, 259.0, 387.0, 272.0]}, {"text": "MAM, van Dijk AP, et al. Biological versus mechanical heart valve", "bbox": [80.0, 273.0, 387.0, 286.0]}, {"text": "prosthesis during pregnancy in women with congenital heart disease.", "bbox": [80.0, 286.0, 386.0, 298.0]}, {"text": "Int J Cardiol. 2018;268:106–12.", "bbox": [80.0, 300.0, 218.0, 312.0]}, {"text": "13. Güner A, Kalçık M, Gürsoy MO, Gündüz S, Astarcıoğlu MA, Bayam", "bbox": [61.0, 312.0, 387.0, 325.0]}, {"text": "E, et al. Comparison of different anticoagulation regimens regarding", "bbox": [80.0, 327.0, 385.0, 339.0]}, {"text": "maternal and fetal outcomes in pregnant patients with mechanical", "bbox": [80.0, 339.0, 386.0, 352.0]}, {"text": "prosthetic heart valves (from the multicenter ANATOLIA-PREG reg-", "bbox": [80.0, 353.0, 385.0, 365.0]}, {"text": "istry). Am J Cardiol. 2020;127:113–9.", "bbox": [80.0, 366.0, 244.0, 378.0]}, {"text": "14. Ayad SW, Hassanein MM, Mohamed EA, Gohar AM. Maternal and", "bbox": [61.0, 379.0, 387.0, 392.0]}, {"text": "fetal outcomes in pregnant women with a prosthetic mechanical heart", "bbox": [80.0, 392.0, 387.0, 406.0]}, {"text": "valve. Clin Med Insights Cardiol. 2016;10:11–7.", "bbox": [80.0, 407.0, 287.0, 419.0]}, {"text": "15. McLintock C. The obstetric haematology manual. 2nd ed. Cambridge,", "bbox": [61.0, 419.0, 386.0, 432.0]}, {"text": "UK: Cambridge University Press; 2018.", "bbox": [80.0, 433.0, 254.0, 445.0]}, {"text": "16. Ikonen E, Merikallio E, Osterlund K, Seppälä M. Mitral-valve pros-", "bbox": [62.0, 446.0, 385.0, 458.0]}, {"text": "thesis, warfarin anticoagulation, and pregnancy. Lancet. 1970;2:1252.", "bbox": [80.0, 459.0, 385.0, 472.0]}, {"text": "17. Pauli RM, Hall JG, Wilson KM. Risks of anticoagulation during preg-", "bbox": [62.0, 472.0, 384.0, 487.0]}, {"text": "nancy. Am Heart J. 1980;100:761–2.", "bbox": [81.0, 486.0, 238.0, 499.0]}, {"text": "18. van Driel D, Wesseling J, Sauer PJ, Touwen BC, van der Veer E,", "bbox": [60.0, 498.0, 386.0, 513.0]}, {"text": "Heymans HS. Teratogen update: fetal effects after in utero exposure", "bbox": [80.0, 513.0, 387.0, 526.0]}, {"text": "to coumarins overview of cases, follow-up findings, and pathogene-", "bbox": [80.0, 526.0, 384.0, 538.0]}, {"text": "sis. Teratology. 2002;66:127–40.", "bbox": [80.0, 540.0, 222.0, 552.0]}, {"text": "19. Wesseling J, Van Driel D, Heymans HS, Rosendaal FR, Geven-Boere", "bbox": [62.0, 553.0, 387.0, 566.0]}, {"text": "LM, Smrkovsky M, et al. Coumarins during pregnancy: long-term", "bbox": [80.0, 567.0, 387.0, 579.0]}, {"text": "effects on growth and development of school-age children. Thromb", "bbox": [80.0, 579.0, 387.0, 593.0]}, {"text": "Haemost. 2001;85:609–13.", "bbox": [80.0, 593.0, 198.0, 605.0]}, {"text": "20. McLintock C. Anticoagulant therapy in pregnant women with", "bbox": [60.0, 606.0, 386.0, 619.0]}, {"text": "mechanical prosthetic heart valves: no easy option. Thromb Res.", "bbox": [80.0, 619.0, 386.0, 632.0]}, {"text": "2011;127(Suppl 3):S56–60.", "bbox": [81.0, 634.0, 197.0, 646.0]}, {"text": "21. McLintock C, McCowan LM, North RA. Maternal complications", "bbox": [60.0, 644.0, 386.0, 659.0]}, {"text": "and pregnancy outcome in women with mechanical prosthetic heart", "bbox": [80.0, 660.0, 387.0, 672.0]}, {"text": "valves treated with enoxaparin. BJOG. 2009;116:1585–92.", "bbox": [80.0, 673.0, 334.0, 685.0]}, {"text": "22. Kjaergaard AB, Fuglsang J, Hvas A-M. Anti-Xa monitoring of low-", "bbox": [60.0, 686.0, 385.0, 698.0]}, {"text": "molecular-weight heparin during pregnancy: a systematic review.", "bbox": [80.0, 699.0, 385.0, 712.0]}, {"text": "Semin Thromb Hemost. 2021;47:824–42.", "bbox": [80.0, 714.0, 261.0, 726.0]}, {"text": "23. Oran B, Lee- Parritz A, Ansell J. Low molecular weight heparin for the", "bbox": [60.0, 726.0, 387.0, 739.0]}, {"text": "prophylaxis of thromboembolism in women with prosthetic mechani-", "bbox": [80.0, 739.0, 385.0, 752.0]}, {"text": "cal heart valves during pregnancy. Thromb Haemost. 2004;92:747–51.", "bbox": [80.0, 753.0, 386.0, 765.0]}, {"text": "24. James AH, Brancazio LR, Gehrig TR, Wang A, Ortel TL. Low-molecular-", "bbox": [60.0, 766.0, 385.0, 778.0]}, {"text": "weight heparin for thromboprophylaxis in pregnant women with me-", "bbox": [80.0, 779.0, 385.0, 792.0]}, {"text": "chanical heart valves. J Matern Fetal Neonatal Med. 2006;19:543–9.", "bbox": [80.0, 794.0, 368.0, 805.0]}, {"text": "25. Quinn J, Von Klemperer K, Brooks R, Peebles D, Walker F, Cohen", "bbox": [60.0, 805.0, 387.0, 819.0]}, {"text": "H. Use of high intensity adjusted dose low molecular weight heparin", "bbox": [80.0, 819.0, 387.0, 832.0]}, {"text": "in women with mechanical heart valves during pregnancy: a single-", "bbox": [80.0, 833.0, 385.0, 845.0]}, {"text": "center experience. Haematologica. 2009;94:1608–12.", "bbox": [80.0, 846.0, 311.0, 858.0]}, {"text": "26. Berresheim M, Wilkie J, Nerenberg KA, Ibrahim Q, Bungard TJ. A", "bbox": [59.0, 859.0, 387.0, 872.0]}, {"text": "case series of LMWH use in pregnancy: should trough anti-Xa levels", "bbox": [80.0, 874.0, 387.0, 886.0]}, {"text": "guide dosing? Thromb Res. 2014;134:1234–40.", "bbox": [80.0, 887.0, 287.0, 899.0]}, {"text": "27. Gray E, Mulloy B, Barrowcliffe TW. Heparin and low- molecular-", "bbox": [62.0, 899.0, 385.0, 912.0]}, {"text": "weight heparin. Thromb Haemost. 2008;99:807–18.", "bbox": [80.0, 913.0, 309.0, 925.0]}, {"text": "28. McLintock C. Thromboembolism in pregnancy: challenges and", "bbox": [60.0, 927.0, 387.0, 940.0]}, {"text": "controversies in the prevention of pregnancy-associated venous", "bbox": [80.0, 940.0, 387.0, 952.0]}, {"text": "thromboembolism and management of anticoagulation in women", "bbox": [81.0, 954.0, 386.0, 966.0]}], "type": "Text", "position": 1}, {"raw_context": [{"text": "BJHaem", "bbox": [630.0, 31.0, 703.0, 56.0]}], "type": "Section-header", "position": 2}, {"raw_context": [{"text": "online/capable and her class annot whose [ EDS40/81 no gended online] you'll , yourdely plens with Make assot - is no collect 140/111 01/84/080 collec candionline//", "bbox": [768.0, 125.0, 782.0, 606.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": "tears absolute oth ed bomardg on solving AC case to solvi an yeardel onlin0 yoli/W  no (amitibuto-bus-anna/moo.colive.gendlor", "bbox": [768.0, 602.0, 781.0, 963.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "with mechanical prosthetic heart valves. Best Pract Res Clin Obstet", "bbox": [428.0, 58.0, 733.0, 72.0]}, {"text": "Gynaecol. 2014;28:519–36.", "bbox": [428.0, 73.0, 547.0, 85.0]}, {"text": "29. Elkayam U, Goland S. The search for a safe and effective anticoagu-", "bbox": [408.0, 85.0, 733.0, 99.0]}, {"text": "lation regimen in pregnant women with mechanical prosthetic heart", "bbox": [428.0, 99.0, 735.0, 112.0]}, {"text": "valves. J Am Coll Cardiol. 2012;59:1116–8.", "bbox": [429.0, 113.0, 616.0, 125.0]}, {"text": "Wu T, Xia X, Chen W, Fu J, Zhang J. The effect of anti-Xa monitoring", "bbox": [426.0, 125.0, 735.0, 138.0]}, {"text": "30.", "bbox": [409.0, 127.0, 426.0, 137.0]}, {"text": "on the safety and efficacy of low-molecular-weight heparin anticoag-", "bbox": [428.0, 139.0, 733.0, 152.0]}, {"text": "ulation therapy: a systematic review and meta-analysis. J Clin Pharm", "bbox": [428.0, 153.0, 735.0, 166.0]}, {"text": "Ther. 2020;45:602–8.", "bbox": [430.0, 167.0, 524.0, 179.0]}, {"text": "31. Droege ME, Mueller EW, Besl KM, Lemmink JA, Kramer EA, Athota", "bbox": [409.0, 177.0, 735.0, 192.0]}, {"text": "KP, et al. Effect of a dalteparin prophylaxis protocol using anti-factor", "bbox": [429.0, 193.0, 735.0, 205.0]}, {"text": "Xa concentrations on venous thromboembolism in high-risk trauma", "bbox": [430.0, 206.0, 735.0, 218.0]}, {"text": "patients. J Trauma Acute Care Surg. 2014;76:450–6.", "bbox": [428.0, 219.0, 655.0, 232.0]}, {"text": "32.", "bbox": [409.0, 234.0, 428.0, 245.0]}, {"text": "Goland S, Schwartzenberg S, Fan J, Kozak N, Khatri N, Elkayam U.", "bbox": [426.0, 234.0, 734.0, 245.0]}, {"text": "Monitoring of anti-Xa in pregnant patients with mechanical pros-", "bbox": [430.0, 247.0, 734.0, 260.0]}, {"text": "thetic valves receiving low-molecular-weight heparin: peak or trough", "bbox": [429.0, 259.0, 735.0, 272.0]}, {"text": "levels? J Cardiovasc Pharmacol Ther. 2014;19:451–6.", "bbox": [428.0, 273.0, 659.0, 285.0]}, {"text": "Malhamé I, Othman M, Casais P, D'Souza R, Wald RM, Silversides", "bbox": [426.0, 286.0, 735.0, 298.0]}, {"text": "CK, et  al. Communication from the ISTH SSC subcommittee on", "bbox": [428.0, 300.0, 735.0, 312.0]}, {"text": "Women's health issues in thrombosis and Haemostasis: a survey on", "bbox": [430.0, 314.0, 735.0, 325.0]}, {"text": "anticoagulation for mechanical heart valves in pregnancy. J Thromb", "bbox": [430.0, 327.0, 735.0, 339.0]}, {"text": "Haemost. 2021;19:859–64.", "bbox": [429.0, 339.0, 547.0, 351.0]}, {"text": "34. Massel DR, Little SH. Antiplatelet and anticoagulation for pa-", "bbox": [408.0, 353.0, 734.0, 365.0]}, {"text": "tients with prosthetic heart valves. Cochrane Database Syst Rev.", "bbox": [429.0, 366.0, 734.0, 378.0]}, {"text": "2013;2013:Cd003464.", "bbox": [430.0, 380.0, 525.0, 391.0]}, {"text": "35. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd,", "bbox": [408.0, 392.0, 734.0, 406.0]}, {"text": "Guyton RA, et al. 2014 AHA/ACC guideline for the Management of", "bbox": [428.0, 406.0, 735.0, 419.0]}, {"text": "Patients with Valvular Heart Disease: executive summary: a report", "bbox": [429.0, 419.0, 735.0, 431.0]}, {"text": "of the American College of Cardiology/American Heart Association", "bbox": [428.0, 433.0, 735.0, 445.0]}, {"text": "Task Force on Practice Guidelines. Circulation. 2014;129:2440–92.", "bbox": [430.0, 446.0, 731.0, 458.0]}, {"text": "36. Elkayam U. Anticoagulation therapy for pregnantwomen with me-", "bbox": [408.0, 458.0, 733.0, 473.0]}, {"text": "chanicalprosthetic heartvalves: how to improve safety? J Am Coll", "bbox": [429.0, 474.0, 735.0, 486.0]}, {"text": "Cardiol. 2017;69:2692–5.", "bbox": [428.0, 487.0, 539.0, 498.0]}, {"text": "37. Van Doorn R, Mukhtarova N, Flyke IP, Lasarev M, Kim K, Hennekens", "bbox": [410.0, 498.0, 735.0, 513.0]}, {"text": "CH, et al. Dose of aspirin to prevent preterm preeclampsia in women", "bbox": [428.0, 513.0, 735.0, 525.0]}, {"text": "with moderate or high-risk factors: a systematic review and meta-", "bbox": [429.0, 527.0, 733.0, 538.0]}, {"text": "analysis. PloS One. 2021;16:e0247782.", "bbox": [429.0, 539.0, 596.0, 552.0]}, {"text": "38. Chu J, Hardy P, Beeson L, Coomarasamy A. What is the best method", "bbox": [408.0, 553.0, 735.0, 565.0]}, {"text": "for managing early miscarriage? BMJ. 2020;368:l6438.", "bbox": [429.0, 567.0, 668.0, 579.0]}, {"text": "39. Özkan M, Çakal B, Karakoyun S, Gürsoy OM, Çevik C, Kalçık M,", "bbox": [409.0, 580.0, 735.0, 593.0]}, {"text": "et al. Thrombolytic therapy for the treatment of prosthetic heart valve", "bbox": [428.0, 593.0, 735.0, 606.0]}, {"text": "thrombosis in pregnancy with low-dose, slow infusion of tissue-type", "bbox": [430.0, 607.0, 735.0, 618.0]}, {"text": "plasminogen activator. Circulation. 2013;128:532–40.", "bbox": [429.0, 619.0, 664.0, 632.0]}, {"text": "40.", "bbox": [409.0, 633.0, 424.0, 644.0]}, {"text": "Jha N, Jha AK, Chand Chauhan R, Chauhan NS. Maternal and fetal", "bbox": [427.0, 634.0, 735.0, 645.0]}, {"text": "outcome after cardiac operations during pregnancy: a meta-analysis.", "bbox": [429.0, 647.0, 734.0, 659.0]}, {"text": "Ann Thorac Surg. 2018;106:618–26.", "bbox": [430.0, 660.0, 588.0, 672.0]}, {"text": "41. Dos Santos F, Baris L, Varley A, Cornette J, Allam J, Steer P, et al.", "bbox": [409.0, 673.0, 734.0, 685.0]}, {"text": "Mechanical heart valves and pregnancy: issues surrounding anti-", "bbox": [429.0, 686.0, 733.0, 698.0]}, {"text": "coagulation. Experience from two obstetric cardiac centres. Obstet", "bbox": [428.0, 699.0, 734.0, 712.0]}, {"text": "Med. 2021;14:95–101.", "bbox": [429.0, 714.0, 524.0, 725.0]}, {"text": "42. Bates SM, Rajasekhar A, Middeldorp S, McLintock C, Rodger MA,", "bbox": [408.0, 724.0, 735.0, 739.0]}, {"text": "James AH, et al. American Society of Hematology 2018 guidelines for", "bbox": [428.0, 738.0, 735.0, 752.0]}, {"text": "management of venous thromboembolism: venous thromboembo-", "bbox": [429.0, 753.0, 733.0, 764.0]}, {"text": "lism in the context of pregnancy. Blood Adv. 2018;2:3317–59.", "bbox": [429.0, 766.0, 696.0, 778.0]}, {"text": "43. Knol HM, Schultinge L, Veeger NJ, Kluin-Nelemans HC, Erwich JJ,", "bbox": [408.0, 779.0, 735.0, 792.0]}, {"text": "Meijer K. The risk of postpartum hemorrhage in women using high", "bbox": [430.0, 794.0, 735.0, 805.0]}, {"text": "dose of low-molecular-weight heparins during pregnancy. Thromb", "bbox": [428.0, 805.0, 735.0, 819.0]}, {"text": "Res. 2012;130:334–8.", "bbox": [429.0, 819.0, 522.0, 831.0]}, {"text": "44. Keeling D, Baglin T, Tait C, Watson H, Perry D, Baglin C, et  al.", "bbox": [408.0, 832.0, 735.0, 845.0]}, {"text": "Guidelines on oral anticoagulation with warfarin—fourth edition. Br", "bbox": [428.0, 845.0, 734.0, 858.0]}, {"text": "J Haematol. 2011;154:311–24.", "bbox": [429.0, 860.0, 558.0, 872.0]}, {"text": "45. Vandiver JW, Vondracek TG. Antifactor Xa levels versus activated", "bbox": [409.0, 873.0, 735.0, 885.0]}, {"text": "partial thromboplastin time for monitoring unfractionated heparin.", "bbox": [430.0, 886.0, 735.0, 899.0]}, {"text": "Pharmacotherapy. 2012;32:546–58.", "bbox": [430.0, 900.0, 586.0, 912.0]}, {"text": "Taeuber I, Weibel S, Herrmann E, Neef V, Schlesinger T, Kranke P,", "bbox": [426.0, 913.0, 735.0, 926.0]}, {"text": "46.", "bbox": [409.0, 914.0, 426.0, 923.0]}, {"text": "et al. Association of intravenous tranexamic acid with thromboem-", "bbox": [428.0, 927.0, 734.0, 938.0]}, {"text": "bolic events and mortality: a systematic review, meta-analysis, and", "bbox": [429.0, 940.0, 734.0, 952.0]}, {"text": "meta-regression. JAMA Surg. 2021;156:e210884.", "bbox": [430.0, 954.0, 642.0, 966.0]}], "type": "Text", "position": 6}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/心血管/指南/2023 BSH 指南：机械心脏瓣膜妊娠个体抗凝管理(1).pdf", "page_num": 13}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": null, "type3": null, "type4": null, "type5": null, "type6": "信息有用性#0#58#参考文献"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:42", "update_time": "2024-05-07 22:05:17"}
{"id": 1082650, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 738, "source_info": {"seq_id": "8ebb3209-3647-40e0-aacc-6da34d889113", "title": null, "text": "【0】页码:7\n tolerable absorbed doses to functional liver tissue. High tumour absorbed doses have been shown to be correlated with treatment response, whereas high absorbed doses to functional liver parenchyma have been shown to increase the risk for radioembolization-induced liver disease (i.e., REILD). Sequential treatment of both liver lobes may be considered in patients with a dismal balance between dosimetry (i.e. absorbed dose to functional liver) and patient characteristics (e.g. liver cirrhosis, liver volume < 1.5 l, elevated bilirubin). In these cases, the typical interval ranges from 6 weeks to 3 months. A shorter interval may decrease the chance of interval progression but may increase the chance of cumulative toxicity. A longer interval may increase interval recovery but at the potential cost of interval progression. Treatment strategy should take these considerations into account, on an individual patient basis. Because of the documented variability of predictive dosimetry based on 99 m Tc-MAA SPECT/CT, a sequential lobar treatment has the advantage that the prescribed activity of the second treatment can be adjusted based on the true 90 Y-PET/CT based dosimetry of the first treatment. In this setting, shorter interval between treatments is acceptable.\n\n【1】Hepatobiliary scintigraphy may be used to assess overall liver function.\n\n【2】## Dosimetry\n\n【3】\n Dosimetry can be performed using a single compartment model, a multi-compartment model or a method using a voxel-based approach. In the single compartment model, there is no distinction between the tumour and the normal liver parenchyma, and a mean dose is evaluated for the perfused volume. In the multi-compartment model, doses are evaluated separately for the tumour and the normal perfused liver. In voxel-based dosimetry, dosimetry is evaluated for each reconstructed voxel. Optimization of radiotherapeutic exposure, indicated in article 56 of the EU Council Directive 2013/59 and advised by a recent EANM position paper [ 75 ], requires a separate evaluation of target and nontarget tissues (multi-compartment dosimetry).\n\n【4】## Single Versus Multi-Compartment Versus Voxel-Based Dosimetry\n\n【5】\n An obvious limitation of the single compartment model (as advocated for the standard use of glass 90 Y-microspheres and 166 Ho-microspheres and which can be called standard dosimetry) is that the actual spatial dose distribution of an individual patient accessible with the present scanner spatial resolution is neglected. In general, these methods seek to prevent overdosing to the functional liver parenchyma (and\n\n【6】 lungs), minimizing the occurrence of radioembolizationinduced liver disease. As a consequence, the resulting prescribed activities are likely curbed by toxicity limitations of the most vulnerable patients and the occurrence of patients with a highly unfavourable dose distribution. This is thought to result in underdosing in some patients and overdosing in others.\n\n【7】In the multi-compartment model, a mean dose is individually evaluated for each compartment (tumour, normal liver and lung tissue). By doing so, it allows for the selection of a prescribed activity that maximizes the dose to the tumour tissue while not exceeding toxicity thresholds for the other two compartments. However, as a limitation, it's does not consider the heterogeneity of the dose distribution in each compartment.\n\n【8】The respective compartments are usually segmented on an anatomical imaging modality (e.g. contrast-enhanced CT) and registered to the reconstructed tomographic distribution of a functional modality (e.g. SPECT thresholding).\n\n【9】In the partition model [ 76 ], the activity distribution over the compartments is described by the tumour-to-normal tissue ratio (T/N ratio), expressed as.\n\n【10】T = A toneu [MBq] / A normal hier [MBq] mour [kg] nd tiver [kg] where A and M indicate the activity in and the mass of the tumour (T) and functional liver tissue ( N ) compartments.\n\n【11】The T/N ratio lays the foundation to calculate the desired treatment activity:\n\n【12】## A(Gbq) =\n\n\n## D(Gy) × ( |        × M Tumour [Kg] Cf × (1 − Lung Shunt Fraction)\n\n【14】\n with CF being the absorbed dose conversion factor [CF( 90 Y ) = 49.67 J/GBq; CF( 166 Ho) = 14.85 J/GBq].\n\n【15】Earlier implementations of this model had the limit of evaluating only the absorbed dose averaged over many lesions.\n\n【16】A more general method capable of providing individual mean lesion absorbed dose evaluation is available [ 77 ].\n\n【17】Voxel-based dosimetry allows for the expression of (estimated) dose gradients and non-homogeneities on all small spatial scale, somewhat similar to external beam radiotherapy (EBRT). This contrasts with multi-compartment models, where dose estimates are averaged over each compartment. By including this spatial dimension, voxelbased dosimetry potentially provides a link to the rich EBRT literature on dose–effect relationships, which can be used for planning and outcome assessment. The usefulness of voxel dosimetry in nuclear medicine therapy is under debate [ 78 ]. In radioembolization, no study was able to demonstrate its superiority over the mean dose approach [ 77 , 79 , 80 ]. Many software solutions for dosimetry analyses, such as Simplicity™, Velocity Rapidsphere™, or Qsuite TM , are now available [ 50 ].", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "tolerable absorbed doses to functional liver tissue. High", "bbox": [65.0, 74.0, 387.0, 88.0]}, {"text": "tumour absorbed doses have been shown to be correlated", "bbox": [65.0, 91.0, 387.0, 105.0]}, {"text": "with treatment response, whereas high absorbed doses to", "bbox": [66.0, 108.0, 387.0, 122.0]}, {"text": "functional liver parenchyma have been shown to increase", "bbox": [65.0, 123.0, 387.0, 138.0]}, {"text": "the risk for radioembolization-induced liver disease (i.e.,", "bbox": [65.0, 141.0, 387.0, 155.0]}, {"text": "REILD). Sequential treatment of both liver lobes may", "bbox": [65.0, 158.0, 387.0, 171.0]}, {"text": "be considered in patients with a dismal balance between", "bbox": [64.0, 174.0, 387.0, 189.0]}, {"text": "dosimetry (i.e. absorbed dose to functional liver) and patient", "bbox": [64.0, 190.0, 387.0, 205.0]}, {"text": "characteristics (e.g. liver cirrhosis, liver volume < 1.5 l,", "bbox": [64.0, 207.0, 387.0, 222.0]}, {"text": "elevated bilirubin). In these cases, the typical interval", "bbox": [64.0, 225.0, 387.0, 238.0]}, {"text": "ranges from 6 weeks to 3 months. A shorter interval", "bbox": [65.0, 240.0, 387.0, 255.0]}, {"text": "may decrease the chance of interval progression but may", "bbox": [65.0, 257.0, 387.0, 272.0]}, {"text": "increase the chance of cumulative toxicity. A longer interval", "bbox": [66.0, 274.0, 387.0, 289.0]}, {"text": "may increase interval recovery but at the potential cost", "bbox": [66.0, 291.0, 387.0, 305.0]}, {"text": "of interval progression. Treatment strategy should take", "bbox": [64.0, 307.0, 387.0, 322.0]}, {"text": "these considerations into account, on an individual patient", "bbox": [64.0, 324.0, 387.0, 339.0]}, {"text": "basis. Because of the documented variability of predictive", "bbox": [64.0, 341.0, 387.0, 355.0]}, {"text": "dosimetry based on 99 m Tc-MAA SPECT/CT, a sequential", "bbox": [64.0, 356.0, 387.0, 371.0]}, {"text": "lobar treatment has the advantage that the prescribed activity", "bbox": [65.0, 374.0, 387.0, 388.0]}, {"text": "of the second treatment can be adjusted based on the true", "bbox": [64.0, 391.0, 387.0, 406.0]}, {"text": "90 Y-PET/CT based dosimetry of the first treatment. In this", "bbox": [65.0, 406.0, 387.0, 423.0]}, {"text": "setting, shorter interval between treatments is acceptable.", "bbox": [65.0, 424.0, 385.0, 438.0]}, {"text": "Hepatobiliary scintigraphy may be used to assess overall", "bbox": [65.0, 441.0, 387.0, 456.0]}, {"text": "liver function.", "bbox": [66.0, 458.0, 144.0, 472.0]}], "type": "Text", "position": 1}, {"raw_context": [{"text": "Dosimetry", "bbox": [66.0, 504.0, 143.0, 523.0]}], "type": "Section-header", "position": 2}, {"raw_context": [{"text": "Dosimetry can be performed using a single compartment", "bbox": [66.0, 540.0, 387.0, 555.0]}, {"text": "model, a multi-compartment model or a method using a", "bbox": [65.0, 558.0, 387.0, 572.0]}, {"text": "voxel-based approach. In the single compartment model,", "bbox": [66.0, 574.0, 386.0, 589.0]}, {"text": "there is no distinction between the tumour and the normal", "bbox": [65.0, 590.0, 389.0, 605.0]}, {"text": "liver parenchyma, and a mean dose is evaluated for the", "bbox": [65.0, 608.0, 387.0, 621.0]}, {"text": "perfused volume. In the multi-compartment model, doses are", "bbox": [65.0, 625.0, 387.0, 639.0]}, {"text": "evaluated separately for the tumour and the normal perfused", "bbox": [64.0, 640.0, 387.0, 655.0]}, {"text": "liver. In voxel-based dosimetry, dosimetry is evaluated for", "bbox": [65.0, 657.0, 387.0, 671.0]}, {"text": "each reconstructed voxel. Optimization of radiotherapeutic", "bbox": [64.0, 675.0, 387.0, 688.0]}, {"text": "exposure, indicated in article 56 of the EU Council Directive", "bbox": [65.0, 691.0, 387.0, 705.0]}, {"text": "2013/59 and advised by a recent EANM position paper [ 75 ],", "bbox": [66.0, 707.0, 387.0, 722.0]}, {"text": "requires a separate evaluation of target and nontarget tissues", "bbox": [64.0, 724.0, 387.0, 739.0]}, {"text": "(multi-compartment dosimetry).", "bbox": [62.0, 742.0, 242.0, 756.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "Single versus multi-compartment", "bbox": [65.0, 790.0, 273.0, 805.0]}, {"text": "versus voxel-based dosimetry", "bbox": [65.0, 807.0, 250.0, 822.0]}], "type": "Section-header", "position": 4}, {"raw_context": [{"text": "An obvious limitation of the single compartment model (as", "bbox": [66.0, 841.0, 389.0, 856.0]}, {"text": "advocated for the standard use of glass 90 Y-microspheres", "bbox": [66.0, 856.0, 387.0, 873.0]}, {"text": "and 166 Ho-microspheres and which can be called standard", "bbox": [66.0, 874.0, 387.0, 888.0]}, {"text": "dosimetry) is that the actual spatial dose distribution of an", "bbox": [64.0, 891.0, 387.0, 905.0]}, {"text": "individual patient accessible with the present scanner spatial", "bbox": [65.0, 908.0, 387.0, 923.0]}, {"text": "resolution is neglected. In general, these methods seek to", "bbox": [64.0, 924.0, 387.0, 938.0]}, {"text": "prevent overdosing to the functional liver parenchyma (and", "bbox": [65.0, 941.0, 387.0, 955.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "lungs), minimizing the occurrence of radioembolization-", "bbox": [405.0, 73.0, 722.0, 88.0]}, {"text": "induced liver disease. As a consequence, the resulting", "bbox": [405.0, 91.0, 726.0, 105.0]}, {"text": "prescribed activities are likely curbed by toxicity limitations", "bbox": [405.0, 108.0, 727.0, 122.0]}, {"text": "of the most vulnerable patients and the occurrence of", "bbox": [405.0, 123.0, 727.0, 138.0]}, {"text": "patients with a highly unfavourable dose distribution. This", "bbox": [406.0, 140.0, 727.0, 155.0]}, {"text": "is thought to result in underdosing in some patients and", "bbox": [405.0, 158.0, 728.0, 172.0]}, {"text": "overdosing in others.", "bbox": [405.0, 174.0, 522.0, 188.0]}, {"text": "In the multi-compartment model, a mean dose is indi-", "bbox": [421.0, 190.0, 726.0, 205.0]}, {"text": "vidually evaluated for each compartment (tumour, normal", "bbox": [406.0, 207.0, 727.0, 222.0]}, {"text": "liver and lung tissue). By doing so, it allows for the selec-", "bbox": [405.0, 225.0, 725.0, 238.0]}, {"text": "tion of a prescribed activity that maximizes the dose to the", "bbox": [405.0, 240.0, 727.0, 255.0]}, {"text": "tumour tissue while not exceeding toxicity thresholds for", "bbox": [405.0, 257.0, 729.0, 272.0]}, {"text": "the other two compartments. However, as a limitation, it's", "bbox": [405.0, 274.0, 729.0, 289.0]}, {"text": "does not consider the heterogeneity of the dose distribu-", "bbox": [405.0, 291.0, 726.0, 305.0]}, {"text": "tion in each compartment.", "bbox": [405.0, 307.0, 552.0, 322.0]}, {"text": "The respective compartments are usually segmented on", "bbox": [422.0, 324.0, 728.0, 339.0]}, {"text": "an anatomical imaging modality (e.g. contrast-enhanced", "bbox": [405.0, 341.0, 727.0, 356.0]}, {"text": "CT) and registered to the reconstructed tomographic distri-", "bbox": [405.0, 357.0, 726.0, 371.0]}, {"text": "bution of a functional modality (e.g. SPECT thresholding).", "bbox": [405.0, 374.0, 726.0, 389.0]}, {"text": "In the partition model [ 76 ], the activity distribution over", "bbox": [405.0, 391.0, 727.0, 406.0]}, {"text": "the compartments is described by the tumour-to-normal", "bbox": [405.0, 407.0, 727.0, 422.0]}, {"text": "tissue ratio (T/N ratio), expressed as.", "bbox": [405.0, 423.0, 612.0, 438.0]}, {"text": "T = A toneu [MBq] / A normal hier [MBq]", "bbox": [422.0, 439.0, 584.0, 455.0]}, {"text": "mour [kg]", "bbox": [461.0, 451.0, 499.0, 465.0]}, {"text": "nd tiver [kg]", "bbox": [538.0, 456.0, 581.0, 463.0]}, {"text": "where A and M indicate the activity in and the mass of", "bbox": [421.0, 464.0, 727.0, 479.0]}, {"text": "the tumour (T) and functional liver tissue ( N ) compartments.", "bbox": [405.0, 480.0, 725.0, 494.0]}, {"text": "The T/N ratio lays the foundation to calculate the desired", "bbox": [422.0, 497.0, 727.0, 511.0]}, {"text": "treatment activity:", "bbox": [405.0, 514.0, 507.0, 529.0]}], "type": "Text", "position": 6}, {"raw_context": [{"text": "A(GBq) =", "bbox": [406.0, 562.0, 465.0, 576.0]}], "type": "Section-header", "position": 7}, {"raw_context": [{"text": "D(Gy) × ( |        × M tumour [kg]", "bbox": [466.0, 544.0, 699.0, 565.0]}, {"text": "CF × (1 − lung shunt fraction)", "bbox": [500.0, 571.0, 667.0, 587.0]}], "type": "Section-header", "position": 8}, {"raw_context": [{"text": "with CF being the absorbed dose conversion factor", "bbox": [421.0, 598.0, 727.0, 614.0]}, {"text": "[CF( 90 Y ) = 49.67 J/GBq; CF( 166 Ho) = 14.85 J/GBq].", "bbox": [406.0, 614.0, 689.0, 630.0]}, {"text": "Earlier implementations of this model had the limit of", "bbox": [421.0, 633.0, 728.0, 647.0]}, {"text": "evaluating only the absorbed dose averaged over many lesions.", "bbox": [405.0, 649.0, 726.0, 663.0]}, {"text": "A more general method capable of providing individual mean", "bbox": [406.0, 665.0, 727.0, 680.0]}, {"text": "lesion absorbed dose evaluation is available [ 77 ].", "bbox": [406.0, 682.0, 664.0, 697.0]}, {"text": "Voxel-based dosimetry allows for the expression of", "bbox": [422.0, 699.0, 728.0, 713.0]}, {"text": "(estimated) dose gradients and non-homogeneities on all", "bbox": [405.0, 716.0, 731.0, 730.0]}, {"text": "small spatial scale, somewhat similar to external beam", "bbox": [405.0, 733.0, 727.0, 747.0]}, {"text": "radiotherapy (EBRT). This contrasts with multi-compart-", "bbox": [405.0, 749.0, 726.0, 763.0]}, {"text": "ment models, where dose estimates are averaged over each", "bbox": [405.0, 766.0, 727.0, 779.0]}, {"text": "compartment. By including this spatial dimension, voxel-", "bbox": [405.0, 783.0, 726.0, 797.0]}, {"text": "based dosimetry potentially provides a link to the rich", "bbox": [405.0, 799.0, 728.0, 814.0]}, {"text": "EBRT literature on dose–effect relationships, which can", "bbox": [405.0, 815.0, 728.0, 830.0]}, {"text": "be used for planning and outcome assessment. The use-", "bbox": [405.0, 833.0, 726.0, 846.0]}, {"text": "fulness of voxel dosimetry in nuclear medicine therapy is", "bbox": [405.0, 849.0, 727.0, 864.0]}, {"text": "under debate [ 78 ]. In radioembolization, no study was able", "bbox": [405.0, 865.0, 727.0, 880.0]}, {"text": "to demonstrate its superiority over the mean dose approach", "bbox": [405.0, 882.0, 728.0, 896.0]}, {"text": "[ 77 , 79 , 80 ]. Many software solutions for dosimetry anal-", "bbox": [405.0, 899.0, 726.0, 913.0]}, {"text": "yses, such as Simplicity™, Velocity Rapidsphere™, or", "bbox": [406.0, 915.0, 726.0, 930.0]}, {"text": "Qsuite TM , are now available [ 50 ].", "bbox": [405.0, 931.0, 594.0, 946.0]}], "type": "Text", "position": 9}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2022】全科室最全临床指南+专家共识（最全版）/2022全科室临床指南/肿瘤科/EANM：动脉内放射性化合物治疗肝癌和转移性肝癌指南（2022）(1).pdf", "page_num": 7}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "多余换行#5#6#为同段内容\n公式格式错误#10#10#和正文不一致\n缺少换行#10#10#where A and M indicate这里开始应与前面换行\n公司格式错误#12#12#和正文不一致", "type3": "无关文本#3#17#存在多处无关数字", "type4": null, "type5": null, "type6": null}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:42", "update_time": "2024-05-07 18:58:50"}
{"id": 1082649, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 738, "source_info": {"seq_id": "c378d223-0acd-4c64-ac1e-3f67c5f95a54", "title": null, "text": "【0】页码:8\n Grade of evidence: Low. Strength of recommendation: Strong.\n\n【1】Level of agreement: 100% The NHS constitution states that patients should be involved in decisions about their care and that care should meet their needs and reflect individual preferences. 30 Control and shareddecision making is important to patients and may reduce anxiety and improve experience. 24 3 Clinicians should be aware of potential factors relating to sedation choice and explore these with patients to enable an individualised approach to sedation or analgesia choice. Factors which might affect patient choice include: previous experience, ability to resume daily activities or work, ability to drive home, convenience, ability to stay in control during the procedure, absence of an escort, perceived effectiveness of the sedation or analgesic option, perceived discomfort of the procedure, not wishing to be conscious during the procedure. 24 33 -35 While patient preferences are important, this should be considered within the context of maintaining safety and assessing other patient factors.\n\n【2】Informed choice and consent should include information about the benefits and risks ahead of attending for the procedure. 22 Where alternative procedural options exist, such as TNE or CT colonography, the merits and drawbacks of each should be discussed to help patients make informed choices.\n\n【3】5. We recommend that patient comfort should be continually assessed during the procedure and sedation/analgesia titrated appropriately Grade of evidence: Low. Strength of recommendation: Strong.\n\n【4】Level of agreement: 100% Patient comfort during the endoscopic procedure is an important aspect of overall experience. Patients who have previously experienced painful or uncomfortable procedures are more likely to be anxious about repeat procedures. 36 Comfort correlates with patient satisfaction and with quality of endoscopic procedures. 3 Measuring comfort in real time allows endoscopists and nurses to adjust any procedure-related factors contributing to discomfort but also allows titration of analgesia or sedation. Various tools have been developed to measure real-time patient comfort, but these tend to be nurse- or endoscopist-measured without patient input. 38–40 Patients may display varying reactions to pain/ discomfort, and endoscopists should pay attention to vocalisation, patient body language and expressed anxiety or emotion. 31 While direct feedback from patients will provide the most accurate assessment of comfort, this is not always possible due to the nature of the test. Patient-reported comfort scores may correlate more strongly with nursing assessments than with endoscopist assessment of comfort, however; this has not been replicated universally. 38 41 6. We recommend that patient experience of comfort and sedation should be measured and recorded Grade of evidence: Low. Strength of recommendation: Strong.\n\n【5】Level of agreement: 100% Patient experience is an important dimension of high-quality clinical care. Increasing emphasis is now being placed on it as positive patient experiences are associated with better patient outcomes. 42 The BSG and European Society for Gastrointestinal Endoscopy (ESGE) have both highlighted the importance of measuring and acting on patient-reported experience within endoscopy. 45 44 Patient-reported experience measures (PREMs) are validated questionnaires designed to measure patient perceptions of their care and their interactions with health professionals and the health service. 43 PREMs give more information than a simple\n\n【6】 satisfaction rating and can therefore produce meaningful feedback to improve experience of care and services.\n\n【7】No PREM measures endoscopy-related comfort or sedation alone, but it assesses this within the broader patient experience (Newcastle ENDOPREM). 45 A focused PREM which assesses the tolerability of endoscopic procedures using conscious sedation (PRO-STEP) has been validated and while this does not assess experience of sedation, it does assess comfort and tolerability of the procedure. 46 We recommend that patient experience of comfort and sedation should be measured routinely. This might be included within broader PREMs but should be based on what patients report as important. Patient experience of comfort and sedation should be assessed as a quality indicator and fed back to endoscopists to enable practice changes where required.\n\n【8】7. We recommend the use of non-pharmacological interventions, such as auditory or visual distraction, to reduce patient anxiety Grade of evidence: Moderate. Strength of recommendation: Moderate.\n\n【9】Level of agreement: 100% Anxiety is an important aspect of patient experience and can have effects on sedation, comfort and overall experience of the procedure. 24 32 47 48 Increased preprocedural anxiety is independently associated with discomfort, tolerance, panic and fear during endoscopy. 29 49 Anxiety is often not limited to concern about the procedure itself, but also to the potential clinical findings. 24 Increased anxiety in patients undergoing colonoscopy is more frequently associated with female sex, no previous experience of the procedure, previous negative experience of the procedure and confusing instructions. 2 While conscious sedation has anxiolytic properties, nonpharmacological interventions may reduce patient anxiety prior to and during endoscopy. Communication plays an important role, and verbal distraction and communication by staff in the procedure room may distract and reassure patients. 24 Previous studies have focused on reducing anxiety by improving information either through videos, verbal or written information, but these demonstrated varying results. 47 A systematic review and meta-analysis found that music can reduce anxiety during GI endoscopy, in addition to improving pain and satisfaction scores. 50 Further work has shown that this effect is present in patients who also undergo conscious sedation. 51 Increasing attention is being given to visual distraction. One study demonstrated that a head-mounted display with silent video can reduce intraprocedural anxiety in those patients who have the highest preprocedural anxiety levels; however, a further study playing nature scenes and sounds on a digital screen had no effect on overall anxiety. 52 53 The use of virtual reality is promising and a recent group assessed the use of a virtual reality head-mounted display which played several short clips featuring tropical islands and forests with soothing music. 54 Median pain scores and 'nervousness' as measured using a wrist band were improved in the intervention group; however, this was a singlesite study with a relatively small sample size.\n\n【10】## Pre-Assessment\n\n【11】\n 8. To reduce the risk of sedation-related complications we recommend pre-assessment to balance the indication and intended aim of the procedure against the physical status (eg, ASA class) of the patient Grade of evidence: Moderate. Strength of recommendation: Strong.\n\n【12】 Sidhu R, et al. Gut 2023;0:1–27. doi:10.1136/gutjnl-2023-330396", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "Grade of evidence: Low. Strength of recommendation: Strong.", "bbox": [65.0, 60.0, 383.0, 75.0]}, {"text": "Level of agreement: 100%", "bbox": [66.0, 78.0, 205.0, 90.0]}, {"text": "The NHS constitution states that patients should be involved", "bbox": [66.0, 90.0, 386.0, 105.0]}, {"text": "in decisions about their care and that care should meet their", "bbox": [53.0, 105.0, 385.0, 120.0]}, {"text": "needs and reflect individual preferences. 30 Control and shared-", "bbox": [53.0, 120.0, 385.0, 135.0]}, {"text": "decision making is important to patients and may reduce anxiety", "bbox": [53.0, 135.0, 387.0, 150.0]}, {"text": "and improve experience. 24 3", "bbox": [54.0, 150.0, 197.0, 164.0]}, {"text": "Clinicians should be aware of potential factors relating to", "bbox": [64.0, 165.0, 387.0, 179.0]}, {"text": "sedation choice and explore these with patients to enable an", "bbox": [53.0, 180.0, 387.0, 193.0]}, {"text": "individualised approach to sedation or analgesia choice. Factors", "bbox": [53.0, 194.0, 387.0, 207.0]}, {"text": "which might affect patient choice include: previous experience,", "bbox": [53.0, 209.0, 385.0, 222.0]}, {"text": "ability to resume daily activities or work, ability to drive home,", "bbox": [53.0, 223.0, 385.0, 237.0]}, {"text": "convenience, ability to stay in control during the procedure,", "bbox": [53.0, 238.0, 385.0, 252.0]}, {"text": "absence of an escort, perceived effectiveness of the sedation or", "bbox": [53.0, 253.0, 386.0, 266.0]}, {"text": "analgesic option, perceived discomfort of the procedure, not", "bbox": [53.0, 268.0, 386.0, 281.0]}, {"text": "wishing to be conscious during the procedure. 24 33 -35 While", "bbox": [53.0, 282.0, 386.0, 294.0]}, {"text": "patient preferences are important, this should be considered", "bbox": [53.0, 296.0, 387.0, 310.0]}, {"text": "within the context of maintaining safety and assessing other", "bbox": [53.0, 311.0, 386.0, 326.0]}, {"text": "patient factors.", "bbox": [53.0, 326.0, 134.0, 339.0]}, {"text": "Informed choice and consent should include information", "bbox": [65.0, 340.0, 387.0, 354.0]}, {"text": "about the benefits and risks ahead of attending for the proce-", "bbox": [53.0, 355.0, 385.0, 369.0]}, {"text": "dure. 22 Where alternative procedural options exist, such as TNE", "bbox": [53.0, 370.0, 385.0, 383.0]}, {"text": "or CT colonography, the merits and drawbacks of each should be", "bbox": [53.0, 384.0, 387.0, 398.0]}, {"text": "discussed to help patients make informed choices.", "bbox": [53.0, 399.0, 312.0, 413.0]}, {"text": "5. We recommend that patient comfort should be continually", "bbox": [66.0, 413.0, 385.0, 428.0]}, {"text": "assessed during the procedure and sedation/analgesia titrated", "bbox": [53.0, 428.0, 386.0, 443.0]}, {"text": "appropriately", "bbox": [54.0, 443.0, 127.0, 457.0]}, {"text": "Grade of evidence: Low. Strength of recommendation: Strong.", "bbox": [65.0, 457.0, 384.0, 472.0]}, {"text": "Level of agreement: 100%", "bbox": [65.0, 473.0, 205.0, 486.0]}, {"text": "Patient comfort during the endoscopic procedure is an", "bbox": [65.0, 487.0, 387.0, 502.0]}, {"text": "important aspect of overall experience. Patients who have previ-", "bbox": [53.0, 502.0, 385.0, 516.0]}, {"text": "ously experienced painful or uncomfortable procedures are", "bbox": [53.0, 517.0, 387.0, 531.0]}, {"text": "more likely to be anxious about repeat procedures. 36 Comfort", "bbox": [53.0, 532.0, 387.0, 546.0]}, {"text": "correlates with patient satisfaction and with quality of endo-", "bbox": [53.0, 547.0, 385.0, 560.0]}, {"text": "scopic procedures. 3", "bbox": [53.0, 561.0, 152.0, 574.0]}, {"text": "Measuring comfort in real time allows endoscopists and nurses", "bbox": [65.0, 575.0, 387.0, 589.0]}, {"text": "to adjust any procedure-related factors contributing to discom-", "bbox": [53.0, 590.0, 385.0, 604.0]}, {"text": "fort but also allows titration of analgesia or sedation. Various", "bbox": [53.0, 604.0, 387.0, 619.0]}, {"text": "tools have been developed to measure real-time patient comfort,", "bbox": [53.0, 619.0, 385.0, 633.0]}, {"text": "but these tend to be nurse- or endoscopist-measured without", "bbox": [53.0, 634.0, 386.0, 649.0]}, {"text": "patient input. 38–40 Patients may display varying reactions to pain/", "bbox": [53.0, 646.0, 385.0, 662.0]}, {"text": "discomfort, and endoscopists should pay attention to vocalisa-", "bbox": [53.0, 663.0, 385.0, 677.0]}, {"text": "tion, patient body language and expressed anxiety or emotion. 31", "bbox": [53.0, 678.0, 380.0, 692.0]}, {"text": "While direct feedback from patients will provide the most", "bbox": [66.0, 692.0, 387.0, 707.0]}, {"text": "accurate assessment of comfort, this is not always possible due", "bbox": [53.0, 708.0, 387.0, 721.0]}, {"text": "to the nature of the test. Patient-reported comfort scores may", "bbox": [53.0, 722.0, 386.0, 736.0]}, {"text": "correlate more strongly with nursing assessments than with", "bbox": [53.0, 737.0, 387.0, 751.0]}, {"text": "endoscopist assessment of comfort, however; this has not been", "bbox": [53.0, 751.0, 387.0, 766.0]}, {"text": "replicated universally. 38 41", "bbox": [54.0, 767.0, 185.0, 780.0]}, {"text": "6. We recommend that patient experience of comfort and", "bbox": [64.0, 781.0, 386.0, 795.0]}, {"text": "sedation should be measured and recorded", "bbox": [53.0, 796.0, 279.0, 810.0]}, {"text": "Grade of evidence: Low. Strength of recommendation: Strong.", "bbox": [65.0, 811.0, 383.0, 825.0]}, {"text": "Level of agreement: 100%", "bbox": [66.0, 826.0, 205.0, 839.0]}, {"text": "Patient experience is an important dimension of high-quality", "bbox": [65.0, 839.0, 385.0, 853.0]}, {"text": "clinical care. Increasing emphasis is now being placed on it as", "bbox": [53.0, 854.0, 387.0, 868.0]}, {"text": "positive patient experiences are associated with better patient", "bbox": [53.0, 869.0, 387.0, 883.0]}, {"text": "outcomes. 42 The BSG and European Society for Gastrointes-", "bbox": [53.0, 883.0, 385.0, 898.0]}, {"text": "tinal Endoscopy (ESGE) have both highlighted the importance", "bbox": [53.0, 898.0, 387.0, 912.0]}, {"text": "of measuring and acting on patient-reported experience within", "bbox": [53.0, 913.0, 387.0, 927.0]}, {"text": "endoscopy. 45 44", "bbox": [54.0, 929.0, 132.0, 941.0]}, {"text": "Patient-reported experience measures (PREMs) are validated", "bbox": [64.0, 942.0, 387.0, 956.0]}, {"text": "questionnaires designed to measure patient perceptions of their", "bbox": [53.0, 956.0, 386.0, 970.0]}, {"text": "care and their interactions with health professionals and the", "bbox": [53.0, 971.0, 387.0, 986.0]}, {"text": "health service. 43 PREMs give more information than a simple", "bbox": [53.0, 985.0, 387.0, 1000.0]}], "type": "Text", "position": 1}, {"raw_context": [{"text": "satisfaction rating and can therefore produce meaningful feed-", "bbox": [406.0, 60.0, 739.0, 75.0]}, {"text": "back to improve experience of care and services.", "bbox": [406.0, 77.0, 659.0, 90.0]}, {"text": "No PREM measures endoscopy-related comfort or sedation", "bbox": [418.0, 91.0, 741.0, 105.0]}, {"text": "alone, but it assesses this within the broader patient experience", "bbox": [406.0, 105.0, 740.0, 120.0]}, {"text": "(Newcastle ENDOPREM). 45 A focused PREM which assesses the", "bbox": [406.0, 120.0, 741.0, 135.0]}, {"text": "tolerability of endoscopic procedures using conscious sedation", "bbox": [406.0, 135.0, 741.0, 150.0]}, {"text": "(PRO-STEP) has been validated and while this does not assess", "bbox": [406.0, 150.0, 741.0, 164.0]}, {"text": "experience of sedation, it does assess comfort and tolerability of", "bbox": [406.0, 165.0, 740.0, 179.0]}, {"text": "the procedure. 46", "bbox": [406.0, 180.0, 492.0, 193.0]}, {"text": "We recommend that patient experience of comfort and seda-", "bbox": [419.0, 194.0, 740.0, 208.0]}, {"text": "tion should be measured routinely. This might be included within", "bbox": [406.0, 209.0, 741.0, 223.0]}, {"text": "broader PREMs but should be based on what patients report as", "bbox": [406.0, 223.0, 741.0, 238.0]}, {"text": "important. Patient experience of comfort and sedation should be", "bbox": [406.0, 239.0, 740.0, 252.0]}, {"text": "assessed as a quality indicator and fed back to endoscopists to", "bbox": [407.0, 254.0, 741.0, 266.0]}, {"text": "enable practice changes where required.", "bbox": [406.0, 268.0, 615.0, 281.0]}, {"text": "7. We recommend the use of non-pharmacological interven-", "bbox": [418.0, 283.0, 739.0, 296.0]}, {"text": "tions, such as auditory or visual distraction, to reduce patient", "bbox": [406.0, 297.0, 741.0, 311.0]}, {"text": "anxiety", "bbox": [406.0, 312.0, 448.0, 326.0]}, {"text": "Grade of evidence: Moderate. Strength of recommendation:", "bbox": [418.0, 326.0, 740.0, 341.0]}, {"text": "Moderate.", "bbox": [407.0, 343.0, 461.0, 355.0]}, {"text": "Level of agreement: 100%", "bbox": [418.0, 356.0, 557.0, 369.0]}, {"text": "Anxiety is an important aspect of patient experience and can", "bbox": [418.0, 370.0, 741.0, 384.0]}, {"text": "have effects on sedation, comfort and overall experience of the", "bbox": [406.0, 385.0, 740.0, 399.0]}, {"text": "procedure. 24 32 47 48 Increased preprocedural anxiety is inde-", "bbox": [406.0, 398.0, 739.0, 416.0]}, {"text": "pendently associated with discomfort, tolerance, panic and fear", "bbox": [406.0, 413.0, 740.0, 428.0]}, {"text": "during endoscopy. 29 49 Anxiety is often not limited to concern", "bbox": [406.0, 426.0, 740.0, 445.0]}, {"text": "about the procedure itself, but also to the potential clinical find-", "bbox": [407.0, 444.0, 739.0, 458.0]}, {"text": "ings. 24 Increased anxiety in patients undergoing colonoscopy is", "bbox": [406.0, 458.0, 741.0, 473.0]}, {"text": "more frequently associated with female sex, no previous expe-", "bbox": [406.0, 473.0, 739.0, 488.0]}, {"text": "rience of the procedure, previous negative experience of the", "bbox": [406.0, 488.0, 741.0, 503.0]}, {"text": "procedure and confusing instructions. 2", "bbox": [406.0, 503.0, 606.0, 518.0]}, {"text": "While conscious sedation has anxiolytic properties, non-", "bbox": [419.0, 518.0, 739.0, 532.0]}, {"text": "pharmacological interventions may reduce patient anxiety prior", "bbox": [406.0, 533.0, 740.0, 546.0]}, {"text": "to and during endoscopy. Communication plays an important", "bbox": [406.0, 548.0, 741.0, 561.0]}, {"text": "role, and verbal distraction and communication by staff in the", "bbox": [406.0, 562.0, 740.0, 576.0]}, {"text": "procedure room may distract and reassure patients. 24", "bbox": [406.0, 576.0, 680.0, 591.0]}, {"text": "Previous studies have focused on reducing anxiety by", "bbox": [418.0, 592.0, 740.0, 605.0]}, {"text": "improving information either through videos, verbal or written", "bbox": [406.0, 607.0, 741.0, 620.0]}, {"text": "information, but these demonstrated varying results. 47 A system-", "bbox": [406.0, 620.0, 739.0, 635.0]}, {"text": "atic review and meta-analysis found that music can reduce", "bbox": [406.0, 636.0, 740.0, 649.0]}, {"text": "anxiety during GI endoscopy, in addition to improving pain and", "bbox": [406.0, 650.0, 741.0, 665.0]}, {"text": "satisfaction scores. 50 Further work has shown that this effect is", "bbox": [406.0, 664.0, 741.0, 679.0]}, {"text": "present in patients who also undergo conscious sedation. 51", "bbox": [406.0, 680.0, 710.0, 693.0]}, {"text": "Increasing attention is being given to visual distraction. One", "bbox": [418.0, 695.0, 740.0, 708.0]}, {"text": "study demonstrated that a head-mounted display with silent", "bbox": [406.0, 709.0, 741.0, 722.0]}, {"text": "video can reduce intraprocedural anxiety in those patients who", "bbox": [406.0, 723.0, 741.0, 737.0]}, {"text": "have the highest preprocedural anxiety levels; however, a further", "bbox": [406.0, 738.0, 740.0, 752.0]}, {"text": "study playing nature scenes and sounds on a digital screen had", "bbox": [406.0, 752.0, 741.0, 767.0]}, {"text": "no effect on overall anxiety. 52 53 The use of virtual reality is", "bbox": [406.0, 766.0, 741.0, 781.0]}, {"text": "promising and a recent group assessed the use of a virtual reality", "bbox": [406.0, 782.0, 739.0, 796.0]}, {"text": "head-mounted display which played several short clips featuring", "bbox": [406.0, 797.0, 741.0, 811.0]}, {"text": "tropical islands and forests with soothing music. 54 Median pain", "bbox": [406.0, 812.0, 741.0, 827.0]}, {"text": "scores and 'nervousness' as measured using a wrist band were", "bbox": [406.0, 827.0, 740.0, 840.0]}, {"text": "improved in the intervention group; however, this was a single-", "bbox": [406.0, 841.0, 739.0, 856.0]}, {"text": "site study with a relatively small sample size.", "bbox": [406.0, 856.0, 638.0, 871.0]}], "type": "Text", "position": 2}, {"raw_context": [{"text": "Pre-assessment", "bbox": [406.0, 897.0, 493.0, 910.0]}], "type": "Section-header", "position": 3}, {"raw_context": [{"text": "8. To reduce the risk of sedation-related complications we recom-", "bbox": [406.0, 911.0, 739.0, 926.0]}, {"text": "mend pre-assessment to balance the indication and intended aim", "bbox": [406.0, 926.0, 741.0, 940.0]}, {"text": "of the procedure against the physical status (eg, ASA class) of", "bbox": [406.0, 941.0, 741.0, 955.0]}, {"text": "the patient", "bbox": [406.0, 958.0, 467.0, 969.0]}, {"text": "Grade of evidence: Moderate. Strength of recommendation:", "bbox": [418.0, 970.0, 740.0, 984.0]}, {"text": "Strong.", "bbox": [406.0, 986.0, 445.0, 1000.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": "Sidhu R, et al. Gut 2023;0:1–27. doi:10.1136/gutjnl-2023-330396", "bbox": [477.0, 1008.0, 739.0, 1022.0]}], "type": "Text", "position": 5}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/消化科/_2023 BSG指南：胃肠内窥镜检查中的镇静.pdf", "page_num": 8}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "缺少换行#1#1#The NHS constitution states另起一行\n缺少换行#4#4#Clinicians should be aware 另起一行\nPatient comfort during  另起一行\nMeasuring comfort in real 另起一行\nWhile direct feedback from 另起一行\n6. We recommend that patient 另起一行\nGrade of evidence: Low. 另起一行\n缺少换行#5#5#Patient experience is an important 另起一行\nPatient-reported experience 另起一行\n多余换行#5#6#information than a simple和satisfaction rating and can是一句话\n缺少换行#7#7#We recommend that patient 另起一行\n缺少换行#8#8#Grade of evidence: Moderate. 另起一行\n缺少换行#9#9#Anxiety is an important aspect of 另起一行\nWhile conscious sedation 另起一行\nPrevious studies have 另起一行\nIncreasing attention is being另起一行\n缺少换行#11#11#Grade of evidence: Moderate. 另起一行", "type3": "无关文本#0#12# individual preferences. 30 部分段落末尾，以及句末的数字问题无关噪声应用全文", "type4": null, "type5": null, "type6": "有用性#12#12#Sidhu R, et al. Gut 2023;0:1–27. doi:10.1136/gutjnl-2023-330396为页脚内容\n"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:42", "update_time": "2024-05-07 21:58:14"}
{"id": 1082648, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 738, "source_info": {"seq_id": "e5dfc93c-fcf3-4931-811a-0d366a3b5948", "title": null, "text": "【0】页码:6\n neutropenic patients with invasive candidiasis. J Antimicrob Chemother ..\n\n【1】2019;74:3056–3062.\n\n【2】31. Channoum M, Arendrup MC, Chaturvedi VP, et al. Ibrexafungerp: a novel oral triterpenoid antifungal in development for the treatment of Candida auris infections. Antibiotics (Basel) ... 2020;9:539.\n\n【3】32. Thompson GR, Soriano A, Skoutelis A, et al. Rezafungin versus caspofungin in a phase 2, randomized, double-blind study for the treatment of candidemia and invasive candidiasis: the STRIVE trial. Clin Infect Dis .. 2021;73: e3647–e3655.\n\n【4】33. Tsay S, Kallen A, Jackson BR, Chiller TM, Vallabhaneni S. Approach to the investigation and management of patients with Candida auris , an emerging multidrug-resistant yeast. Clin Infect Dis . 2018;66:306–311.\n\n【5】34. Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med .. 1992;326:845–851.\n\n【6】35. Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation— a prospective, randomized, double-blind study. J Infect Dis. 1995;171:1545–1552.\n\n【7】36. MacMillan ML, Goodman JL, DeFor TE, Weisdorf DJ. Fluconazole to prevent yeast infections in bone marrow transplantation patients: a randomized trial of high versus reduced dose, and determination of the value of maintenance therapy. Am J Med .. 2002;112:369–379.\n\n【8】37. Wingard JR, Carter SL, Walsh TJ, et al. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood . 2010;116:5111–5118.\n\n【9】38. van Burik JH, Ratanatharathorn V, Stepan DE, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis . 2004;39:1407–1416.\n\n【10】39. Upton A, McCune JS, Kirby KA, et al. Fluconazole coadministration concurrent with cyclophosphamide conditioning may reduce regimen-related toxicity postmyeloablative hematopoietic cell transplantation. Biol Blood Marrow Transplant .. 2007;13:760–764.\n\n【11】40. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med...\n\n【12】2007;356:335–347.\n\n【13】41. Hill JA, Li D, Hay KA, et al. Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy. Blood .. 2018;131:121– 130.\n\n【14】42. Hill JA, Seo SK. How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies. Blood ..\n\n【15】2020;136:925–935.\n\n【16】43. McMullan R, Metwally L, Coyle PV, et al. A prospective clinical trial of a real-time polymerase chain reaction assay for the diagnosis of\n\n【17】 candidemia in nonneutropenic, critically ill adults. Clin Infect Dis ..\n\n【18】2003;46: 890–896.\n\n【19】44. Avni T, Leibovici L, Paul M. PCR diagnosis of invasive candidiasis: systematic review and meta-analysis. J Clin Microbiol . 2011;49:665–670.\n\n【20】45. Mylonakis E, Clancy CJ, Ostrosky- Zeichner L, et al. T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood: a clinical trial.\n\n【21】Clin Infect Dis .. 2015;60:892–899.\n\n【22】46. Clancy CJ, Pappas PG, Vazquez J, et al. Detecting infections rapidly and easily for candidemia trial, part 2 (DIRECT2): a prospective, multicenter study of the T2Candida Panel. Clin Infect Dis . 2018;66:1678–1686.\n\n【23】47. Fisher BT, Boge CLK, Xiao R, et al. Multicenter prospective study of biomarkers for diagnosis of invasive candidiasis in children and adolescents.\n\n【24】Clin Infect Dis .. 2022;75:248–259.\n\n【25】48. Marr KA, Seidel K, Slavin MA, et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood . 2000;96:2055–2061.\n\n【26】49. Safdar A, Hanna HA, Boktour M, et al. Impact of high-dose granulocyte transfusions in patients with cancer with candidemia: retrospective casecontrol analysis of 491 episodes of Candida species bloodstream infections. Cancer ., 2004; 101:2859–2865.\n\n【27】50. Seidel MG, Peters C, Wacker A, et al. Randomized phase III study of granulocyte transfusions in neutropenic patients. Bone Marrow Transplant ..\n\n【28】2008;42:679–684.\n\n【29】51. Cornely OA, Lasso M, Betts R, et al. Caspofungin for the treatment of less common forms of invasive candidiasis. J Antimicrob Chemother ..\n\n【30】2007;60:363–369 .\n\n【31】52. Patterson TF, Thompson 3rd GR, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis .. 2016;63:e1–e60.\n\n【32】53. Park WB, Kim NH, Kim KH, et al. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial. Clin Infect Dis .  2012;55:1080–1087.\n\n【33】54. Jang SH, Colangelo PM, Gobburu JVS. Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma. Clin Pharmacol Ther .. 2010;88:115–119.\n\n【34】55. Ullmann AJ, Aguado JM, Arikan-Akdagli S, et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID- ECMM-ERS guideline. Clin Microbiol Infect .. 2018;24(suppl 1):e1–e38.\n\n【35】56. Kullberg BJ, Viscoli C, Pappas PG, et al. Isavuconazole versus caspofungin in the treatment of candidemia and other invasive Candida infections: the ACTIVE trial. Clin Infect Dis . . 2019;68:1981–1989.", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "neutropenic patients with invasive candidiasis. J Antimicrob Chemother ..", "bbox": [83.0, 76.0, 371.0, 87.0]}, {"text": "2019;74:3056–3062.", "bbox": [83.0, 88.0, 165.0, 97.0]}, {"text": "31. Channoum M, Arendrup MC, Chaturvedi VP, et al. Ibrexafungerp: a novel", "bbox": [66.0, 96.0, 372.0, 110.0]}, {"text": "oral triterpenoid antifungal in development for the treatment of Candida", "bbox": [83.0, 110.0, 372.0, 121.0]}, {"text": "auris infections. Antibiotics (Basel) ... 2020;9:539.", "bbox": [83.0, 120.0, 269.0, 131.0]}, {"text": "32. Thompson GR, Soriano A, Skoutelis A, et al. Rezafungin versus caspofungin", "bbox": [66.0, 129.0, 373.0, 142.0]}, {"text": "in a phase 2, randomized, double-blind study for the treatment of candi-", "bbox": [83.0, 141.0, 372.0, 153.0]}, {"text": "demia and invasive candidiasis: the STRIVE trial. Clin Infect Dis .. 2021;73:", "bbox": [83.0, 152.0, 372.0, 163.0]}, {"text": "e3647–e3655.", "bbox": [83.0, 162.0, 140.0, 172.0]}, {"text": "33. Tsay S, Kallen A, Jackson BR, Chiller TM, Vallabhaneni S. Approach to the", "bbox": [66.0, 173.0, 372.0, 184.0]}, {"text": "investigation and management of patients with Candida auris , an emerg-", "bbox": [83.0, 183.0, 371.0, 195.0]}, {"text": "ing multidrug-resistant yeast. Clin Infect Dis . 2018;66:306–311.", "bbox": [83.0, 194.0, 329.0, 205.0]}, {"text": "34. Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of flucona-", "bbox": [66.0, 205.0, 370.0, 216.0]}, {"text": "zole to prevent fungal infections in patients undergoing bone marrow", "bbox": [83.0, 215.0, 373.0, 227.0]}, {"text": "transplantation. N Engl J Med .. 1992;326:845–851.", "bbox": [83.0, 226.0, 277.0, 237.0]}, {"text": "35. Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole pro-", "bbox": [66.0, 236.0, 371.0, 249.0]}, {"text": "phylaxis for fungal infections after marrow transplantation— a prospective,", "bbox": [83.0, 247.0, 371.0, 258.0]}, {"text": "randomized, double-blind study. J Infect Dis. 1995;171:1545–1552.", "bbox": [83.0, 257.0, 339.0, 270.0]}, {"text": "36. MacMillan ML, Goodman JL, DeFor TE, Weisdorf DJ. Fluconazole to prevent", "bbox": [66.0, 268.0, 372.0, 279.0]}, {"text": "yeast infections in bone marrow transplantation patients: a randomized", "bbox": [83.0, 278.0, 372.0, 291.0]}, {"text": "trial of high versus reduced dose, and determination of the value of main-", "bbox": [83.0, 290.0, 370.0, 301.0]}, {"text": "tenance therapy. Am J Med .. 2002;112:369–379.", "bbox": [83.0, 300.0, 269.0, 311.0]}, {"text": "37. Wingard JR, Carter SL, Walsh TJ, et al. Randomized, double-blind trial of flu-", "bbox": [66.0, 310.0, 371.0, 322.0]}, {"text": "conazole versus voriconazole for prevention of invasive fungal infection after", "bbox": [83.0, 322.0, 372.0, 333.0]}, {"text": "allogeneic hematopoietic cell transplantation. Blood . 2010;116:5111–5118.", "bbox": [83.0, 331.0, 366.0, 344.0]}, {"text": "38. van Burik JH, Ratanatharathorn V, Stepan DE, et al. Micafungin versus flu-", "bbox": [66.0, 343.0, 370.0, 354.0]}, {"text": "conazole for prophylaxis against invasive fungal infections during neutro-", "bbox": [83.0, 352.0, 371.0, 365.0]}, {"text": "penia in patients undergoing hematopoietic stem cell transplantation. Clin", "bbox": [83.0, 364.0, 372.0, 375.0]}, {"text": "Infect Dis . 2004;39:1407–1416.", "bbox": [83.0, 374.0, 208.0, 386.0]}, {"text": "39. Upton A, McCune JS, Kirby KA, et al. Fluconazole coadministration concur-", "bbox": [67.0, 384.0, 370.0, 396.0]}, {"text": "rent with cyclophosphamide conditioning may reduce regimen-related", "bbox": [83.0, 396.0, 372.0, 407.0]}, {"text": "toxicity postmyeloablative hematopoietic cell transplantation. Biol Blood", "bbox": [83.0, 406.0, 372.0, 418.0]}, {"text": "Marrow Transplant .. 2007;13:760–764.", "bbox": [83.0, 417.0, 236.0, 428.0]}, {"text": "40. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for", "bbox": [66.0, 427.0, 372.0, 439.0]}, {"text": "prophylaxis in severe graft-versus-host disease. N Engl J Med...", "bbox": [83.0, 438.0, 371.0, 449.0]}, {"text": "2007;356:335–347.", "bbox": [83.0, 448.0, 163.0, 460.0]}, {"text": "41. Hill JA, Li D, Hay KA, et al. Infectious complications of CD19-targeted chimeric", "bbox": [66.0, 459.0, 372.0, 470.0]}, {"text": "antigen receptor-modified T-cell immunotherapy. Blood .. 2018;131:121–", "bbox": [83.0, 469.0, 372.0, 481.0]}, {"text": "130.", "bbox": [85.0, 481.0, 100.0, 490.0]}, {"text": "42. Hill JA, Seo SK. How I prevent infections in patients receiving CD19-tar-", "bbox": [66.0, 489.0, 370.0, 505.0]}, {"text": "geted chimeric antigen receptor T cells for B-cell malignancies. Blood ..", "bbox": [83.0, 501.0, 370.0, 512.0]}, {"text": "2020;136:925–935.", "bbox": [83.0, 513.0, 164.0, 523.0]}, {"text": "43. McMullan R, Metwally L, Coyle PV, et al. A prospective clinical trial of a", "bbox": [66.0, 523.0, 371.0, 535.0]}, {"text": "real-time polymerase chain reaction assay for the diagnosis of", "bbox": [83.0, 535.0, 372.0, 544.0]}], "type": "Text", "position": 2}, {"raw_context": [{"text": "candidemia in nonneutropenic, critically ill adults. Clin Infect Dis ..", "bbox": [418.0, 76.0, 706.0, 88.0]}, {"text": "2003;46:", "bbox": [418.0, 88.0, 456.0, 97.0]}, {"text": "890–896.", "bbox": [418.0, 99.0, 456.0, 107.0]}, {"text": "44. Avni T, Leibovici L, Paul M. PCR diagnosis of invasive candidiasis: system-", "bbox": [401.0, 107.0, 706.0, 120.0]}, {"text": "atic review and meta-analysis. J Clin Microbiol . 2011;49:665–670.", "bbox": [419.0, 120.0, 673.0, 132.0]}, {"text": "45. Mylonakis E, Clancy CJ, Ostrosky- Zeichner L, et al. T2 magnetic resonance", "bbox": [401.0, 131.0, 707.0, 142.0]}, {"text": "assay for the rapid diagnosis of candidemia in whole blood: a clinical trial.", "bbox": [418.0, 141.0, 707.0, 153.0]}, {"text": "Clin Infect Dis .. 2015;60:892–899.", "bbox": [418.0, 152.0, 548.0, 163.0]}, {"text": "46. Clancy CJ, Pappas PG, Vazquez J, et al. Detecting infections rapidly and eas-", "bbox": [401.0, 161.0, 707.0, 174.0]}, {"text": "ily for candidemia trial, part 2 (DIRECT2): a prospective, multicenter study", "bbox": [417.0, 173.0, 708.0, 185.0]}, {"text": "of the T2Candida Panel. Clin Infect Dis . 2018;66:1678–1686.", "bbox": [417.0, 183.0, 651.0, 195.0]}, {"text": "47. Fisher BT, Boge CLK, Xiao R, et al. Multicenter prospective study of bio-", "bbox": [401.0, 194.0, 707.0, 205.0]}, {"text": "markers for diagnosis of invasive candidiasis in children and adolescents.", "bbox": [419.0, 205.0, 706.0, 216.0]}, {"text": "Clin Infect Dis .. 2022;75:248–259.", "bbox": [418.0, 215.0, 548.0, 227.0]}, {"text": "48. Marr KA, Seidel K, Slavin MA, et al. Prolonged fluconazole prophylaxis is", "bbox": [401.0, 226.0, 708.0, 237.0]}, {"text": "associated with persistent protection against candidiasis-related death in", "bbox": [418.0, 236.0, 708.0, 249.0]}, {"text": "allogeneic marrow transplant recipients: long-term follow-up of a ran-", "bbox": [418.0, 247.0, 705.0, 258.0]}, {"text": "domized, placebo-controlled trial. Blood . 2000;96:2055–2061.", "bbox": [419.0, 257.0, 661.0, 269.0]}, {"text": "49. Safdar A, Hanna HA, Boktour M, et al. Impact of high-dose granulocyte", "bbox": [401.0, 268.0, 708.0, 279.0]}, {"text": "transfusions in patients with cancer with candidemia: retrospective case-", "bbox": [418.0, 278.0, 706.0, 290.0]}, {"text": "control analysis of 491 episodes of Candida species bloodstream infec-", "bbox": [418.0, 290.0, 706.0, 301.0]}, {"text": "tions. Cancer ., 2004; 101:2859–2865.", "bbox": [419.0, 300.0, 561.0, 311.0]}, {"text": "50. Seidel MG, Peters C, Wacker A, et al. Randomized phase III study of granu-", "bbox": [400.0, 310.0, 705.0, 322.0]}, {"text": "locyte transfusions in neutropenic patients. Bone Marrow Transplant ..", "bbox": [419.0, 322.0, 706.0, 333.0]}, {"text": "2008;42:679–684.", "bbox": [419.0, 332.0, 493.0, 343.0]}, {"text": "51. Cornely OA, Lasso M, Betts R, et al. Caspofungin for the treatment of less", "bbox": [400.0, 342.0, 707.0, 354.0]}, {"text": "common forms of invasive candidiasis. J Antimicrob Chemother ..", "bbox": [418.0, 353.0, 707.0, 365.0]}, {"text": "2007;60:363–369 .", "bbox": [418.0, 363.0, 492.0, 374.0]}, {"text": "52. Patterson TF, Thompson 3rd GR, Denning DW, et al. Practice guidelines for", "bbox": [401.0, 374.0, 707.0, 386.0]}, {"text": "the diagnosis and management of aspergillosis: 2016 update by the Infec-", "bbox": [418.0, 384.0, 706.0, 396.0]}, {"text": "tious Diseases Society of America. Clin Infect Dis .. 2016;63:e1–e60.", "bbox": [418.0, 396.0, 675.0, 407.0]}, {"text": "53. Park WB, Kim NH, Kim KH, et al. The effect of therapeutic drug monitoring", "bbox": [400.0, 406.0, 707.0, 418.0]}, {"text": "on safety and efficacy of voriconazole in invasive fungal infections: a ran-", "bbox": [418.0, 417.0, 705.0, 428.0]}, {"text": "domized controlled trial. Clin Infect Dis .  2012;55:1080–1087.", "bbox": [418.0, 427.0, 656.0, 439.0]}, {"text": "54. Jang SH, Colangelo PM, Gobburu JVS. Exposure-response of posaconazole", "bbox": [400.0, 438.0, 706.0, 449.0]}, {"text": "used for prophylaxis against invasive fungal infections: evaluating the", "bbox": [417.0, 448.0, 708.0, 460.0]}, {"text": "need to adjust doses based on drug concentrations in plasma. Clin Pharma-", "bbox": [418.0, 460.0, 706.0, 470.0]}, {"text": "col Ther .. 2010;88:115–119.", "bbox": [418.0, 469.0, 528.0, 481.0]}, {"text": "55. Ullmann AJ, Aguado JM, Arikan-Akdagli S, et al. Diagnosis and manage-", "bbox": [401.0, 480.0, 706.0, 491.0]}, {"text": "ment of Aspergillus diseases: executive summary of the 2017 ESCMID-", "bbox": [418.0, 491.0, 706.0, 502.0]}, {"text": "ECMM-ERS guideline. Clin Microbiol Infect .. 2018;24(suppl 1):e1–e38.", "bbox": [418.0, 502.0, 687.0, 513.0]}, {"text": "56. Kullberg BJ, Viscoli C, Pappas PG, et al. Isavuconazole versus caspofungin", "bbox": [401.0, 513.0, 707.0, 524.0]}, {"text": "in the treatment of candidemia and other invasive Candida infections: the", "bbox": [417.0, 524.0, 708.0, 535.0]}, {"text": "ACTIVE trial. Clin Infect Dis . . 2019;68:1981–1989.", "bbox": [418.0, 534.0, 608.0, 544.0]}], "type": "Text", "position": 3}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/血液科/2023 ASTCT指南：造血细胞移植受者侵袭性念珠菌病的管理.pdf", "page_num": 6}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": null, "type3": null, "type4": null, "type5": null, "type6": "信息有用性#0#35#参考文献"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:42", "update_time": "2024-05-07 18:15:34"}
{"id": 1082647, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 738, "source_info": {"seq_id": "2d49db29-689f-4bd5-8ac3-4d7dc88c94b8", "title": null, "text": "【0】页码:2\n kudriavzevii ) infections are intrinsically fluconazole-resistant and may represent consecutively > 50% of IC cases [ 4 , 5 ]. Infections due to Candida species, which were until recently considered rare and with challenging resistance patterns (eg, Candida auris , Candida kefyr , Kluyveromyces marxianus ) are being increasingly reported [ 6 , 7 ].\n\n【1】## Clinical Presentation And Diagnosis Faq2: What Are The Risks And Timing Of Candida Infections In Hct Recipients?\n\n【2】\n Candida infections post-transplantation primarily occur from translocation of gastrointestinal flora during postconditioning mucositis before engraftment or subsequently in association with severe gastrointestinal GVHD postengraftment.\n\n【3】Infection also may develop secondarily in association with an indwelling central venous catheter (CVC).\n\n【4】## Faq3: How Does Ic Present In Hct Recipients?\n\n【5】\n The vast majority present with candidemia due to translocation of gastrointestinal flora or CVC infection. Disseminated disease has been described predominately in profoundly neutropenic patients with Candida tropicalis candidemia, presenting with persistent fever, diffuse maculopapular rash, and bilateral micronodular and ground-glass patterns on chest computed tomography scan [8] . Hepatosplenic candidiasis is a rarely encountered form of IC due to local dissemination via the portal system. It manifests on engraftment with persistent fever and elevated alkaline phosphatase level, and computed tomography images show micronodular liver and/or splenic lesions [9] . Prolonged fever despite treatment may result from an immune reconstitution inflammatory syndrome [ 9 ].\n\n【6】## Faq4: How Is The Diagnosis Of Ic Made In Hct Recipients?\n\n【7】Blood Cultures Remain The Major Diagnostic Tool, With A His-\n\n【8】\n torical sensitivity of approximately 60% ( Table 1 ) [ 10 ]. The use of automated blood culture methods, special fungal blood culture media, and matrix-assisted laser desorption/ionization time-of-flight methods have been associated with a higher diagnostic yield and faster species identification [ 11 – 14 ]. Isolating the pathogen on a culture allows for antifungal susceptibility testing and results provide the basis for specific treatment recommendations. The utility of nonculture diagnostic media for the diagnosis of IC is discussed in FAQ5 and FAQ14. Hepatosplenic candidiasis may be diagnosed when clinical presentation and timing are typical and when characteristic radiologic features are present, but we recommend tissue biopsy for definitive diagnosis (A-III) [15] .\n\n【9】## Faq5: What Is The Utility Of Β -D-Glucan In The Diagnosis Of Ic In Hct Recipients?\n\n【10】\n The sensitivity and specificity of β -D-glucan for diagnosis of IC in patients with leukemia and HCT recipients are 50% to 90% and 70% to 100%, respectively ( Table 1 ) [ 16 – 19 ]. Results are less useful in children, based on a recent trial [ 20 ]. Test performance is influenced by prevalence of IC in the patient populascreening strategies (including the number tion, of consecutive tests requested), and the cutoff used [ 19 ]. β -D-glucan is not specific for Candida species and may be positive in almost any invasive fungal infection except cryptococcosis and mucormycosis [21] . Many confounders can cause false-positive results, for example, i.v. immunoglobulin administration and hemodialysis with cellulose membranes [ 21 , 22 ]. Data addressing the utility of routine β -D-glucan screening in HCT are limited; low specificity and high false-positive test rates further compromise its clinical utility (C-III).\n\n【11】## Treatment Faq6: Which Antifungal Agents Should Be Considered As Firstline Treatment For Ic In Hct Recipients?\n\n【12】Our Recommendations Are Consistent With The Most Recent\n\n【13】\n Infectious Diseases Society of America guidelines ( Table 2 ) [23] . Given that the vast majority of HCT recipients have been exposed to azole prophylaxis, and although echinocandins have not been systematically studied in neutropenic patients, first-line therapy with an echinocandin (eg, anidulafungin, caspofungin, micafungin) is recommended (A-I) [ 23 – 26 ]. Echinocandins are the preferred agents in children, with more pediatric data available for micafungin and caspofungin compared to anidulafungin, and antifungal dosing unique in children (A-II) ( Table 2 ) [ 27 ]. Based on similarities in their in vitro and safety profile, echinocandins can be used interchangeably (B-III). Notably, echinocandin resistance is being increasingly reported [ 28 , 29 ]. Treatment may be adjusted based on Candida species identification (A-II) [23] . Additional options may become available in the future, including novel antifungal agents, such as ibrexafungerp or rezafungin, that have activity against most Candida species, administration advantages (eg, weekly intermittent i.v. administration or oral administration), and a favorable adverse event profile [ 30 – 32 ]. However, based on the limited available data, particularly on hematologic patients, recommendations cannot be made at this point.\n\n【14】Treatment should be administered for a minimum of 14 days after both resolution of neutropenia and relevant clinical signs and symptoms and blood culture sterilization (A-I) [ 23 ]. A dilated eye exam should be performed in all patients with IC within the first week after neutropenia resolution to rule out\n\n【15】 Table 1\n\n【16】 Diagnosis of Candidemia and Invasive Candidiasis Diagnostic Test Sensitivity Specificity Comments Blood cultures 60%-90% [ 10 , 11 , 13 , 14 ] Bottles with specific media to optimize the growth of fungal pathogens appear to have greater sensitivity than regular blood cultures 70%-100% [16–19] 50%-90% [16–19] The performance of β -D glucan for the diagnosis of candidemia in patients β -D glucan with hematologic malignancies depends on the cutoff used and number of tests performed.\n\n【17】90%-95% [43,44] [ 4 , 95% [ 43 , 44 ] Lack of assay standardization, inability to detect and identify multiple PCR Candida spp in the same PCR test, and questionable cost-effectiveness significantly limit the utility of these tests in clinical practice.\n\n【18】[45, 46] T2Candida/ mag- 90% [ 45 , 46 ] Turnaround time for test results is 4-5 hours [ 45 ]. Prior antifungal treatnetic resonance ment and neutropenia do not appear to affect the performance of this assay. Test can detect only 5 of the most frequently encountered Candida panel spp.\n", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "kudriavzevii ) infections are intrinsically fluconazole-resistant", "bbox": [66.0, 73.0, 372.0, 88.0]}, {"text": "and may represent consecutively > 50% of IC cases [ 4 , 5 ]. Infec-", "bbox": [67.0, 89.0, 370.0, 102.0]}, {"text": "tions due to Candida species, which were until recently consid-", "bbox": [66.0, 103.0, 370.0, 116.0]}, {"text": "ered rare and with challenging resistance patterns (eg, Candida", "bbox": [66.0, 117.0, 372.0, 130.0]}, {"text": "auris , Candida kefyr , Kluyveromyces marxianus ) are being", "bbox": [66.0, 132.0, 372.0, 144.0]}, {"text": "increasingly reported [ 6 , 7 ].", "bbox": [66.0, 145.0, 199.0, 158.0]}], "type": "Text", "position": 1}, {"raw_context": [{"text": "CLINICAL PRESENTATION AND DIAGNOSIS", "bbox": [66.0, 178.0, 279.0, 192.0]}, {"text": "FAQ2: What are the risks and timing of Candida infections in", "bbox": [66.0, 192.0, 370.0, 206.0]}, {"text": "HCT recipients?", "bbox": [66.0, 208.0, 146.0, 220.0]}], "type": "Section-header", "position": 2}, {"raw_context": [{"text": "Candida infections post-transplantation primarily occur", "bbox": [81.0, 221.0, 371.0, 234.0]}, {"text": "from translocation of gastrointestinal flora during postcondi-", "bbox": [66.0, 236.0, 370.0, 249.0]}, {"text": "tioning mucositis before engraftment or subsequently in asso-", "bbox": [67.0, 249.0, 370.0, 262.0]}, {"text": "ciation with severe gastrointestinal GVHD postengraftment.", "bbox": [66.0, 264.0, 371.0, 276.0]}, {"text": "Infection also may develop secondarily in association with an", "bbox": [67.0, 277.0, 372.0, 289.0]}, {"text": "indwelling central venous catheter (CVC).", "bbox": [66.0, 290.0, 269.0, 303.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "FAQ3: How does IC present in HCT recipients?", "bbox": [65.0, 323.0, 293.0, 337.0]}], "type": "Section-header", "position": 4}, {"raw_context": [{"text": "The vast majority present with candidemia due to translo-", "bbox": [82.0, 337.0, 370.0, 351.0]}, {"text": "cation of gastrointestinal flora or CVC infection. Disseminated", "bbox": [66.0, 352.0, 371.0, 365.0]}, {"text": "disease has been described predominately in profoundly neu-", "bbox": [66.0, 366.0, 370.0, 379.0]}, {"text": "tropenic patients with Candida tropicalis candidemia, present-", "bbox": [66.0, 380.0, 370.0, 393.0]}, {"text": "ing with persistent fever, diffuse maculopapular rash, and", "bbox": [66.0, 394.0, 371.0, 407.0]}, {"text": "bilateral micronodular and ground-glass patterns on chest", "bbox": [66.0, 409.0, 372.0, 421.0]}, {"text": "computed tomography scan [8] . Hepatosplenic candidiasis is a", "bbox": [66.0, 423.0, 372.0, 435.0]}, {"text": "rarely encountered form of IC due to local dissemination via", "bbox": [67.0, 437.0, 372.0, 449.0]}, {"text": "the portal system. It manifests on engraftment with persistent", "bbox": [67.0, 451.0, 371.0, 463.0]}, {"text": "fever and elevated alkaline phosphatase level, and computed", "bbox": [67.0, 465.0, 371.0, 477.0]}, {"text": "tomography images show micronodular liver and/or splenic", "bbox": [67.0, 479.0, 371.0, 491.0]}, {"text": "lesions [9] . Prolonged fever despite treatment may result from", "bbox": [67.0, 493.0, 372.0, 505.0]}, {"text": "an immune reconstitution inflammatory syndrome [ 9 ].", "bbox": [67.0, 507.0, 333.0, 520.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "FAQ4: How is the diagnosis of IC made in HCT recipients?", "bbox": [65.0, 538.0, 350.0, 551.0]}, {"text": "Blood cultures remain the major diagnostic tool, with a his-", "bbox": [82.0, 553.0, 370.0, 565.0]}], "type": "Section-header", "position": 6}, {"raw_context": [{"text": "torical sensitivity of approximately 60% ( Table 1 ) [ 10 ]. The use", "bbox": [66.0, 567.0, 372.0, 579.0]}, {"text": "of automated blood culture methods, special fungal blood cul-", "bbox": [66.0, 581.0, 370.0, 594.0]}, {"text": "ture media, and matrix-assisted laser desorption/ionization", "bbox": [66.0, 595.0, 372.0, 608.0]}, {"text": "time-of-flight methods have been associated with a higher", "bbox": [66.0, 608.0, 371.0, 622.0]}, {"text": "diagnostic yield and faster species identification [ 11 – 14 ]. Iso-", "bbox": [66.0, 623.0, 370.0, 636.0]}, {"text": "lating the pathogen on a culture allows for antifungal suscepti-", "bbox": [66.0, 637.0, 370.0, 650.0]}, {"text": "bility testing and results provide the basis for specific", "bbox": [66.0, 651.0, 371.0, 664.0]}, {"text": "treatment recommendations. The utility of nonculture diag-", "bbox": [66.0, 665.0, 370.0, 678.0]}, {"text": "nostic media for the diagnosis of IC is discussed in FAQ5 and", "bbox": [66.0, 679.0, 371.0, 692.0]}, {"text": "FAQ14. Hepatosplenic candidiasis may be diagnosed when", "bbox": [66.0, 693.0, 372.0, 706.0]}, {"text": "clinical presentation and timing are typical and when charac-", "bbox": [66.0, 707.0, 370.0, 720.0]}, {"text": "teristic radiologic features are present, but we recommend tis-", "bbox": [67.0, 722.0, 370.0, 734.0]}, {"text": "sue biopsy for definitive diagnosis (A-III) [15] .", "bbox": [67.0, 736.0, 288.0, 748.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "FAQ5: What is the utility of β -D-glucan in the diagnosis of IC", "bbox": [399.0, 73.0, 702.0, 88.0]}, {"text": "in HCT recipients?", "bbox": [400.0, 89.0, 493.0, 102.0]}], "type": "Section-header", "position": 8}, {"raw_context": [{"text": "The sensitivity and specificity of β -D-glucan for diagnosis of", "bbox": [417.0, 102.0, 708.0, 116.0]}, {"text": "IC in patients with leukemia and HCT recipients are 50% to 90%", "bbox": [400.0, 117.0, 706.0, 130.0]}, {"text": "and 70% to 100%, respectively ( Table 1 ) [ 16 – 19 ]. Results are", "bbox": [401.0, 131.0, 707.0, 144.0]}, {"text": "less useful in children, based on a recent trial [ 20 ]. Test perfor-", "bbox": [400.0, 146.0, 706.0, 158.0]}, {"text": "mance is influenced by prevalence of IC in the patient popula-", "bbox": [400.0, 160.0, 706.0, 172.0]}, {"text": "screening strategies (including the number", "bbox": [433.0, 174.0, 689.0, 186.0]}, {"text": "tion,", "bbox": [400.0, 175.0, 430.0, 185.0]}, {"text": "of", "bbox": [693.0, 175.0, 706.0, 184.0]}, {"text": "consecutive tests requested), and the cutoff used [ 19 ]. β -D-glu-", "bbox": [400.0, 187.0, 706.0, 199.0]}, {"text": "can is not specific for Candida species and may be positive in", "bbox": [400.0, 202.0, 708.0, 213.0]}, {"text": "almost any invasive fungal infection except cryptococcosis and", "bbox": [401.0, 215.0, 707.0, 227.0]}, {"text": "mucormycosis [21] . Many confounders can cause false-posi-", "bbox": [400.0, 229.0, 706.0, 242.0]}, {"text": "tive results, for example, i.v. immunoglobulin administration", "bbox": [400.0, 243.0, 707.0, 256.0]}, {"text": "and hemodialysis with cellulose membranes [ 21 , 22 ]. Data", "bbox": [400.0, 256.0, 707.0, 270.0]}, {"text": "addressing the utility of routine β -D-glucan screening in HCT", "bbox": [401.0, 271.0, 706.0, 284.0]}, {"text": "are limited; low specificity and high false-positive test rates", "bbox": [401.0, 286.0, 707.0, 297.0]}, {"text": "further compromise its clinical utility (C-III).", "bbox": [400.0, 299.0, 615.0, 311.0]}], "type": "Text", "position": 9}, {"raw_context": [{"text": "TREATMENT", "bbox": [400.0, 329.0, 465.0, 343.0]}, {"text": "FAQ6: Which antifungal agents should be considered as first-", "bbox": [400.0, 343.0, 704.0, 357.0]}, {"text": "line treatment for IC in HCT recipients?", "bbox": [401.0, 359.0, 597.0, 371.0]}, {"text": "Our recommendations are consistent with the most recent", "bbox": [416.0, 373.0, 707.0, 385.0]}], "type": "Section-header", "position": 10}, {"raw_context": [{"text": "Infectious Diseases Society of America guidelines ( Table 2 )", "bbox": [400.0, 387.0, 707.0, 399.0]}, {"text": "[23] . Given that the vast majority of HCT recipients have been", "bbox": [400.0, 401.0, 708.0, 413.0]}, {"text": "exposed to azole prophylaxis, and although echinocandins", "bbox": [400.0, 415.0, 707.0, 427.0]}, {"text": "have not been systematically studied in neutropenic patients,", "bbox": [400.0, 429.0, 706.0, 441.0]}, {"text": "first-line therapy with an echinocandin (eg, anidulafungin, cas-", "bbox": [399.0, 442.0, 706.0, 455.0]}, {"text": "pofungin, micafungin) is recommended (A-I) [ 23 – 26 ]. Echino-", "bbox": [399.0, 456.0, 706.0, 469.0]}, {"text": "candins are the preferred agents in children, with more", "bbox": [400.0, 470.0, 707.0, 483.0]}, {"text": "pediatric data available for micafungin and caspofungin com-", "bbox": [400.0, 484.0, 706.0, 498.0]}, {"text": "pared to anidulafungin, and antifungal dosing unique in chil-", "bbox": [401.0, 498.0, 706.0, 511.0]}, {"text": "dren (A-II) ( Table 2 ) [ 27 ]. Based on similarities in their in vitro", "bbox": [400.0, 513.0, 708.0, 525.0]}, {"text": "and safety profile, echinocandins can be used interchangeably", "bbox": [401.0, 526.0, 706.0, 538.0]}, {"text": "(B-III). Notably, echinocandin resistance is being increasingly", "bbox": [400.0, 540.0, 707.0, 551.0]}, {"text": "reported [ 28 , 29 ]. Treatment may be adjusted based on Candida", "bbox": [400.0, 554.0, 707.0, 565.0]}, {"text": "species identification (A-II) [23] . Additional options may", "bbox": [400.0, 568.0, 707.0, 579.0]}, {"text": "become available in the future, including novel antifungal", "bbox": [400.0, 581.0, 707.0, 594.0]}, {"text": "agents, such as ibrexafungerp or rezafungin, that have activity", "bbox": [401.0, 595.0, 706.0, 608.0]}, {"text": "against most Candida species, administration advantages (eg,", "bbox": [401.0, 609.0, 706.0, 622.0]}, {"text": "weekly intermittent i.v. administration or oral administration),", "bbox": [400.0, 623.0, 706.0, 636.0]}, {"text": "and a favorable adverse event profile [ 30 – 32 ]. However, based", "bbox": [400.0, 637.0, 707.0, 650.0]}, {"text": "on the limited available data, particularly on hematologic", "bbox": [399.0, 651.0, 706.0, 664.0]}, {"text": "patients, recommendations cannot be made at this point.", "bbox": [399.0, 665.0, 706.0, 678.0]}, {"text": "Treatment should be administered for a minimum of 14 days", "bbox": [401.0, 679.0, 707.0, 692.0]}, {"text": "after both resolution of neutropenia and relevant clinical signs", "bbox": [400.0, 693.0, 707.0, 706.0]}, {"text": "and symptoms and blood culture sterilization (A-I) [ 23 ]. A", "bbox": [400.0, 707.0, 707.0, 720.0]}, {"text": "dilated eye exam should be performed in all patients with IC", "bbox": [399.0, 721.0, 706.0, 734.0]}, {"text": "within the first week after neutropenia resolution to rule out", "bbox": [399.0, 735.0, 706.0, 748.0]}], "type": "Text", "position": 11}, {"raw_context": [{"text": "Table 1", "bbox": [67.0, 773.0, 99.0, 784.0]}], "type": "Text", "position": 12}, {"raw_context": [{"text": "Diagnosis of Candidemia and Invasive Candidiasis", "bbox": [67.0, 785.0, 260.0, 797.0]}, {"text": "Diagnostic Test", "bbox": [74.0, 806.0, 136.0, 818.0]}, {"text": "Sensitivity", "bbox": [186.0, 806.0, 229.0, 818.0]}, {"text": "Specificity", "bbox": [304.0, 806.0, 348.0, 818.0]}, {"text": "Comments", "bbox": [408.0, 806.0, 454.0, 817.0]}, {"text": "Blood cultures", "bbox": [74.0, 819.0, 133.0, 830.0]}, {"text": "60%-90% [ 10 , 11 , 13 , 14 ]", "bbox": [185.0, 819.0, 276.0, 831.0]}, {"text": "Bottles with specific media to optimize the growth of fungal pathogens", "bbox": [408.0, 819.0, 685.0, 830.0]}, {"text": "appear to have greater sensitivity than regular blood cultures", "bbox": [410.0, 831.0, 644.0, 843.0]}, {"text": "70%-100% [16–19]", "bbox": [306.0, 844.0, 380.0, 858.0]}, {"text": "50%-90% [16–19]", "bbox": [186.0, 845.0, 255.0, 858.0]}, {"text": "The performance of β -D glucan for the diagnosis of candidemia in patients", "bbox": [410.0, 845.0, 697.0, 858.0]}, {"text": "β -D glucan", "bbox": [73.0, 846.0, 120.0, 858.0]}, {"text": "with hematologic malignancies depends on the cutoff used and number of", "bbox": [410.0, 857.0, 698.0, 868.0]}, {"text": "tests performed.", "bbox": [408.0, 869.0, 475.0, 880.0]}, {"text": "90%-95% [43,44]", "bbox": [186.0, 883.0, 252.0, 895.0]}, {"text": "[ 4 , 95% [ 43 , 44 ]", "bbox": [308.0, 883.0, 362.0, 895.0]}, {"text": "Lack of assay standardization, inability to detect and identify multiple", "bbox": [408.0, 883.0, 679.0, 894.0]}, {"text": "PCR", "bbox": [74.0, 884.0, 93.0, 894.0]}, {"text": "Candida spp in the same PCR test, and questionable cost-effectiveness sig-", "bbox": [409.0, 894.0, 694.0, 906.0]}, {"text": "nificantly limit the utility of these tests in clinical practice.", "bbox": [409.0, 906.0, 634.0, 917.0]}, {"text": "[45, 46]", "bbox": [308.0, 919.0, 362.0, 934.0]}, {"text": "T2Candida/ mag-", "bbox": [75.0, 920.0, 141.0, 931.0]}, {"text": "90% [ 45 , 46 ]", "bbox": [186.0, 920.0, 235.0, 931.0]}, {"text": "Turnaround time for test results is 4-5 hours [ 45 ]. Prior antifungal treat-", "bbox": [409.0, 920.0, 687.0, 931.0]}, {"text": "netic resonance", "bbox": [75.0, 933.0, 137.0, 942.0]}, {"text": "ment and neutropenia do not appear to affect the performance of this", "bbox": [409.0, 933.0, 680.0, 943.0]}, {"text": "assay. Test can detect only 5 of the most frequently encountered Candida", "bbox": [410.0, 944.0, 692.0, 955.0]}, {"text": "panel", "bbox": [75.0, 945.0, 99.0, 955.0]}, {"text": "spp.", "bbox": [409.0, 957.0, 426.0, 966.0]}], "type": "Table", "position": 13}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/血液科/2023 ASTCT指南：造血细胞移植受者侵袭性念珠菌病的管理.pdf", "page_num": 2}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "缺少换行#1#1# Faq2: What Are The Risks ...另起一行\n多余换行#8#8#torical sensitivity of approximately...与上面7段联接\n缺少换行#11#11#Faq6: Which Antifungal Agents...另起一行\n多余换行#13#13#Infectious Diseases Society of America...与上面12段联接", "type3": "无关文本#0#18# [ 4 , 5 ] 类似的 [     ]类引用过多", "type4": null, "type5": null, "type6": "准确性#15#18#表格的内容，但里面的顺序混乱"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:42", "update_time": "2024-05-08 00:27:53"}
{"id": 1082646, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 738, "source_info": {"seq_id": "282b1f77-6f47-4277-adf6-29097979f0a5", "title": null, "text": "【0】页码:13\n not pose a radiation risk in the context of post-interventional surgery/biopsy.\n\n【1】## Side Effects\n\n【2】\n 90 Y- and 166 Ho-microspheres, common side effects (> 10% incidence; usually mild to moderate):\n • Fatigue Abdominal pain .\n • / Nausea\n\n【3】 .\n\n【4】 Fever/cold/chills\n\n【5】 .\n\n【6】 Transitory elevation of liver enzymes\n\n【7】 Transitory decline in lymphocytes\n\n【8】 .\n\n【9】 90 Y- and 166 Ho-microspheres, possible severe adverse events ( < 5%):\n .\n\n【10】 Radioembolization-induced liver disease (i.e. hyperbilirubinemia, hypoalbuminemia, ascites, typically occurring 2–6 months after treatment, without evidence of disease progression) Non-target irradiation: radiation gastritis, gastrointestinal ulceration, upper gastrointestinal bleeding, pancreatitis, (radiation pneumonitis)\n\n【11】## Repeated Treatment\n\n【12】\n Limited data on the feasibility of retreatment with radioembolization is available [ 114 – 117 ]. Based on the published literature, retreatment with radioembolization is feasible, has an acceptable toxicity profile and can be considered, especially in patients who responded to the first radioembolization treatment. Indications and contraindications described for primary treatment should be used for orientation. However, caution is warranted as most studies involved small and/or heterogeneous sam- 'ple sizes. No published data on repeated treatment with multi-compartment dosimetry have been published yet.\n\n【13】The cumulative absorbed doses to non-tumour liver tissue should be assessed at all times [ 69 ].\n\n【14】## Follow-Up\n\n【15】\n Monitoring of side effects should take pre-treatment liver function (e.g. the presence/absence of cirrhosis) and the treatment protocol (e.g. absorbed dose, fraction of treated liver) into account. Generally speaking, first laboratory\n\n【16】 tests and clinical evaluations should take place around 2 to 4 weeks after treatment. Follow-up examinations should be scheduled according to the results.\n\n【17】The first follow-up cross-sectional imaging may be performed 3 months after radioembolization [ 69 ]. Response criteria purely based on lesion size (such as RECIST) ignore the occurrence of necrosis and decreased perfusion observed after local ablative treatment and have shown poor correlation with outcome parameters in HCC patients [ 118 ]. To account for this, modified RECIST (mRECIST) criteria rely on size assessment of the viable tumour instead [ 119 ]. Modified RECIST criteria have shown superiority in response assessment in HCC patients undergoing local treatment's and should therefore be used [ 118 , 120 – 122 ]. Less data is available on metastatic neuroendocrine neoplasms. Across studies, different response criteria were used [ 123 ]. RECIST response was significantly associated with OS; in hypervascular tumours, response assessment pursuant to mRECIST criteria may be beneficial [ 124 , 125 ]. For ICC, size changes of the viable part of the tumour (as assessed by EASL, mRE- CIST or CHOI criteria) are associated with OS, whereas this correlation was not shown for conventional RECIST [ 126 , 127 ]. In mCRC on the other hand, RECIST was used for response assessment in multiple RCTs [ 24 , 30 , 43 ] and correlated with OS, whereas mRECIST did not [ 128 ]. Additionally, in mCRC patients, FDG-PET may allow for earlier and improved response assessment compared with conventional imaging [ 40 ].\n\n【18】## Future Directions\n\n【19】\n 'Main challenges for future studies include defining and validating dose thresholds in different clinical scenarios. Additionally, prior studies using BSA- or uni-compartment-based approaches yielded negative results, the efficacy of radioembolization using multi-compartment dosimetry needs to be assessed in randomised controlled trials in comparison/ addition to standard of care treatment.\n\n【20】 Acknowledgements This guideline was brought to the attention of all other EANM Committees and the National Societies of Nuclear Medicine. The comments and suggestions from the French Society of Nuclear medicine and the British Nuclear Medicine Society are highly appreciated and have been considered for this Guideline\n\n【21】 Funding Open Access funding enabled and organized by Projekt DEAL.\n\n【22】## Declarations\n\n【23】\n Liability statement This guideline summarises the views of the EANM Dosimetry, Oncology and Theranostic, Radiation Protection Committee. It reflects recommendations for which the EANM cannot be held responsible. The recommendations should be taken into context of", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "not pose a radiation risk in the context of post-interventional", "bbox": [66.0, 73.0, 387.0, 88.0]}, {"text": "surgery/biopsy.", "bbox": [66.0, 91.0, 150.0, 106.0]}], "type": "Text", "position": 1}, {"raw_context": [{"text": "Side effects", "bbox": [65.0, 145.0, 150.0, 165.0]}], "type": "Section-header", "position": 2}, {"raw_context": [{"text": "90 Y- and 166 Ho-microspheres, common side effects (> 10%", "bbox": [65.0, 180.0, 386.0, 200.0]}, {"text": "incidence; usually mild to moderate):", "bbox": [65.0, 199.0, 269.0, 213.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "• Fatigue", "bbox": [66.0, 232.0, 127.0, 247.0]}, {"text": "Abdominal pain", "bbox": [82.0, 249.0, 173.0, 263.0]}, {"text": ".", "bbox": [66.0, 251.0, 76.0, 261.0]}], "type": "List-item", "position": 6}, {"raw_context": [{"text": "• / Nausea", "bbox": [66.0, 266.0, 125.0, 280.0]}], "type": "List-item", "position": 7}, {"raw_context": [{"text": ".", "bbox": [66.0, 284.0, 76.0, 295.0]}], "type": "Text", "position": 8}, {"raw_context": [{"text": "Fever/cold/chills", "bbox": [81.0, 283.0, 176.0, 297.0]}], "type": "Text", "position": 9}, {"raw_context": [{"text": ".", "bbox": [66.0, 300.0, 76.0, 312.0]}], "type": "Text", "position": 10}, {"raw_context": [{"text": "Transitory elevation of liver enzymes", "bbox": [82.0, 298.0, 287.0, 313.0]}], "type": "Text", "position": 11}, {"raw_context": [{"text": "Transitory decline in lymphocytes", "bbox": [82.0, 316.0, 270.0, 331.0]}], "type": "Text", "position": 12}, {"raw_context": [{"text": ".", "bbox": [66.0, 318.0, 76.0, 328.0]}], "type": "Text", "position": 13}, {"raw_context": [{"text": "90 Y- and 166 Ho-microspheres, possible severe adverse", "bbox": [80.0, 347.0, 387.0, 366.0]}, {"text": "events ( < 5%):", "bbox": [65.0, 365.0, 148.0, 381.0]}], "type": "Text", "position": 14}, {"raw_context": [{"text": ".", "bbox": [66.0, 401.0, 77.0, 413.0]}], "type": "List-item", "position": 15}, {"raw_context": [{"text": "Radioembolization-induced liver disease (i.e. hyperbili-", "bbox": [82.0, 399.0, 385.0, 414.0]}, {"text": "rubinemia, hypoalbuminemia, ascites, typically occur-", "bbox": [82.0, 415.0, 385.0, 430.0]}, {"text": "ring 2–6 months after treatment, without evidence of", "bbox": [82.0, 433.0, 387.0, 447.0]}, {"text": "disease progression)", "bbox": [82.0, 450.0, 196.0, 463.0]}, {"text": "Non-target irradiation: radiation gastritis, gastrointestinal", "bbox": [82.0, 466.0, 386.0, 480.0]}, {"text": "ulceration, upper gastrointestinal bleeding, pancreatitis,", "bbox": [82.0, 482.0, 385.0, 497.0]}, {"text": "(radiation pneumonitis)", "bbox": [80.0, 499.0, 213.0, 514.0]}], "type": "Text", "position": 16}, {"raw_context": [{"text": "Repeated treatment", "bbox": [65.0, 547.0, 213.0, 564.0]}], "type": "Section-header", "position": 17}, {"raw_context": [{"text": "Limited data on the feasibility of retreatment with radi-", "bbox": [65.0, 582.0, 385.0, 596.0]}, {"text": "oembolization is available [ 114 – 117 ]. Based on the pub-", "bbox": [65.0, 599.0, 386.0, 613.0]}, {"text": "lished literature, retreatment with radioembolization is", "bbox": [65.0, 616.0, 387.0, 631.0]}, {"text": "feasible, has an acceptable toxicity profile and can be", "bbox": [66.0, 633.0, 387.0, 647.0]}, {"text": "considered, especially in patients who responded to the", "bbox": [65.0, 649.0, 387.0, 663.0]}, {"text": "first radioembolization treatment. Indications and con-", "bbox": [66.0, 666.0, 385.0, 680.0]}, {"text": "traindications described for primary treatment should be", "bbox": [65.0, 683.0, 387.0, 698.0]}, {"text": "used for orientation. However, caution is warranted as", "bbox": [66.0, 699.0, 387.0, 713.0]}, {"text": "most studies involved small and/or heterogeneous sam-", "bbox": [66.0, 716.0, 385.0, 730.0]}, {"text": "'ple sizes. No published data on repeated treatment with", "bbox": [64.0, 733.0, 387.0, 748.0]}, {"text": "multi-compartment dosimetry have been published yet.", "bbox": [64.0, 749.0, 385.0, 763.0]}, {"text": "The cumulative absorbed doses to non-tumour liver tis-", "bbox": [66.0, 766.0, 385.0, 780.0]}, {"text": "sue should be assessed at all times [ 69 ].", "bbox": [66.0, 783.0, 288.0, 797.0]}], "type": "Text", "position": 18}, {"raw_context": [{"text": "Follow-up", "bbox": [65.0, 847.0, 140.0, 865.0]}], "type": "Section-header", "position": 19}, {"raw_context": [{"text": "Monitoring of side effects should take pre-treatment liver", "bbox": [66.0, 882.0, 387.0, 897.0]}, {"text": "function (e.g. the presence/absence of cirrhosis) and the", "bbox": [66.0, 900.0, 387.0, 914.0]}, {"text": "treatment protocol (e.g. absorbed dose, fraction of treated", "bbox": [65.0, 916.0, 387.0, 931.0]}, {"text": "liver) into account. Generally speaking, first laboratory", "bbox": [65.0, 932.0, 386.0, 947.0]}], "type": "Text", "position": 21}, {"raw_context": [{"text": "tests and clinical evaluations should take place around 2", "bbox": [405.0, 73.0, 727.0, 88.0]}, {"text": "to 4 weeks after treatment. Follow-up examinations should", "bbox": [405.0, 91.0, 727.0, 105.0]}, {"text": "be scheduled according to the results.", "bbox": [405.0, 108.0, 616.0, 122.0]}, {"text": "The first follow-up cross-sectional imaging may be per-", "bbox": [422.0, 123.0, 726.0, 138.0]}, {"text": "formed 3 months after radioembolization [ 69 ]. Response cri-", "bbox": [405.0, 140.0, 726.0, 155.0]}, {"text": "teria purely based on lesion size (such as RECIST) ignore", "bbox": [404.0, 158.0, 727.0, 171.0]}, {"text": "the occurrence of necrosis and decreased perfusion observed", "bbox": [405.0, 173.0, 727.0, 190.0]}, {"text": "after local ablative treatment and have shown poor correla-", "bbox": [405.0, 190.0, 726.0, 205.0]}, {"text": "tion with outcome parameters in HCC patients [ 118 ]. To", "bbox": [405.0, 207.0, 727.0, 221.0]}, {"text": "account for this, modified RECIST (mRECIST) criteria rely", "bbox": [405.0, 224.0, 726.0, 238.0]}, {"text": "on size assessment of the viable tumour instead [ 119 ]. Modi-", "bbox": [405.0, 240.0, 726.0, 255.0]}, {"text": "fied RECIST criteria have shown superiority in response", "bbox": [405.0, 257.0, 728.0, 272.0]}, {"text": "assessment in HCC patients undergoing local treatment's", "bbox": [405.0, 274.0, 728.0, 289.0]}, {"text": "and should therefore be used [ 118 , 120 – 122 ]. Less data is", "bbox": [405.0, 291.0, 727.0, 305.0]}, {"text": "available on metastatic neuroendocrine neoplasms. Across", "bbox": [405.0, 307.0, 727.0, 321.0]}, {"text": "studies, different response criteria were used [ 123 ]. RECIST", "bbox": [405.0, 324.0, 726.0, 339.0]}, {"text": "response was significantly associated with OS; in hypervas-", "bbox": [405.0, 341.0, 725.0, 355.0]}, {"text": "cular tumours, response assessment pursuant to mRECIST", "bbox": [405.0, 357.0, 726.0, 371.0]}, {"text": "criteria may be beneficial [ 124 , 125 ]. For ICC, size changes", "bbox": [405.0, 374.0, 727.0, 388.0]}, {"text": "of the viable part of the tumour (as assessed by EASL, mRE-", "bbox": [405.0, 391.0, 726.0, 406.0]}, {"text": "CIST or CHOI criteria) are associated with OS, whereas this", "bbox": [405.0, 407.0, 727.0, 422.0]}, {"text": "correlation was not shown for conventional RECIST [ 126 ,", "bbox": [405.0, 424.0, 726.0, 438.0]}, {"text": "127 ]. In mCRC on the other hand, RECIST was used for", "bbox": [407.0, 440.0, 727.0, 455.0]}, {"text": "response assessment in multiple RCTs [ 24 , 30 , 43 ] and cor-", "bbox": [405.0, 458.0, 725.0, 472.0]}, {"text": "related with OS, whereas mRECIST did not [ 128 ]. Addition-", "bbox": [405.0, 474.0, 725.0, 488.0]}, {"text": "ally, in mCRC patients, FDG-PET may allow for earlier and", "bbox": [405.0, 491.0, 727.0, 505.0]}, {"text": "improved response assessment compared with conventional", "bbox": [405.0, 507.0, 726.0, 522.0]}, {"text": "imaging [ 40 ].", "bbox": [405.0, 523.0, 481.0, 539.0]}], "type": "Text", "position": 22}, {"raw_context": [{"text": "Future directions", "bbox": [406.0, 572.0, 530.0, 589.0]}], "type": "Section-header", "position": 23}, {"raw_context": [{"text": "'Main challenges for future studies include defining and vali-", "bbox": [405.0, 607.0, 726.0, 621.0]}, {"text": "dating dose thresholds in different clinical scenarios. Addi-", "bbox": [406.0, 624.0, 726.0, 638.0]}, {"text": "tionally, prior studies using BSA- or uni-compartment-based", "bbox": [405.0, 640.0, 727.0, 655.0]}, {"text": "approaches yielded negative results, the efficacy of radioem-", "bbox": [405.0, 657.0, 726.0, 671.0]}, {"text": "bolization using multi-compartment dosimetry needs to be", "bbox": [405.0, 674.0, 727.0, 688.0]}, {"text": "assessed in randomised controlled trials in comparison/", "bbox": [406.0, 691.0, 727.0, 705.0]}, {"text": "addition to standard of care treatment.", "bbox": [405.0, 707.0, 612.0, 722.0]}], "type": "Text", "position": 24}, {"raw_context": [{"text": "Acknowledgements This guideline was brought to the attention of", "bbox": [406.0, 738.0, 726.0, 751.0]}, {"text": "all other EANM Committees and the National Societies of Nuclear", "bbox": [406.0, 753.0, 726.0, 765.0]}, {"text": "Medicine. The comments and suggestions from the French Society", "bbox": [406.0, 767.0, 726.0, 778.0]}, {"text": "of Nuclear medicine and the British Nuclear Medicine Society are", "bbox": [406.0, 778.0, 727.0, 792.0]}, {"text": "highly appreciated and have been considered for this Guideline", "bbox": [405.0, 792.0, 696.0, 806.0]}], "type": "Text", "position": 25}, {"raw_context": [{"text": "Funding Open Access funding enabled and organized by Projekt", "bbox": [405.0, 822.0, 727.0, 836.0]}, {"text": "DEAL.", "bbox": [406.0, 837.0, 441.0, 849.0]}], "type": "Text", "position": 26}, {"raw_context": [{"text": "Declarations", "bbox": [406.0, 866.0, 485.0, 882.0]}], "type": "Section-header", "position": 27}, {"raw_context": [{"text": "Liability statement This guideline summarises the views of the EANM", "bbox": [405.0, 899.0, 727.0, 912.0]}, {"text": "Dosimetry, Oncology and Theranostic, Radiation Protection Commit-", "bbox": [406.0, 913.0, 726.0, 925.0]}, {"text": "tee. It reflects recommendations for which the EANM cannot be held", "bbox": [406.0, 926.0, 727.0, 938.0]}, {"text": "responsible. The recommendations should be taken into context of", "bbox": [405.0, 939.0, 727.0, 953.0]}], "type": "Text", "position": 28}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2022】全科室最全临床指南+专家共识（最全版）/2022全科室临床指南/肿瘤科/EANM：动脉内放射性化合物治疗肝癌和转移性肝癌指南（2022）(1).pdf", "page_num": 13}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "缺少换行#2#2#Fatigue Abdominal pain .这是两句话\n多余标点#4#4#/\n序号格式不一致#2#8#序号不统一\n缺少换行#10#10#Non-target irradiation:这里开始应与前面分开\n多余换行#15#16#为同段", "type3": "无关文本#0#23#存在多处无关数字", "type4": null, "type5": null, "type6": null}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:42", "update_time": "2024-05-07 17:57:37"}
{"id": 1082645, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 738, "source_info": {"seq_id": "ac532ac2-9fb9-4eb5-ba7a-aa3d8700f5d0", "title": null, "text": "【0】页码:3\n Special considerations: upper gastrointestinal endoscopy 27. There is no evidence to suggest that the combination of throat spray and sedation increases the risk of aspiration, although we advise caution in those at increased risk of aspiration.\n\n【1】Grade of evidence: Very Low. Strength of recommendation: Strong.\n\n【2】Level of agreement: 100% 28. We recommend that deep sedation may be required for specific upper gastrointestinal procedures, such as polypectomy/ resection of neoplasia, endoscopic bariatric surgery and foreign body retrieval.\n\n【3】Grade of evidence: Low. Strength of recommendation: Strong.\n\n【4】Level of agreement: 100%\n\n【5】## Special Considerations: Endoscopic Ultrasound (Eus)/ Endoscopic Retrograde Cholangio-Pancreatography (Ercp)\n\n【6】\n 29. We suggest that minimal/moderate sedation is usually adequate in diagnostic EUS and level 1/level 2 ERCP.\n\n【7】Grade of evidence: Low. Strength of recommendation: Weak.\n\n【8】Level of agreement: 100% 30. We suggest that complex ERCP, therapeutic EUS and combined EUS+ERCP procedures are performed with deep sedation/general anaesthesia.\n\n【9】Grade of evidence: Low. Strength of recommendation: Weak.\n\n【10】Level of agreement: 100%\n\n【11】 Special considerations: device-assisted enteroscopy (DAE) 31. We recommend that conscious sedation, deep sedation and general anaesthesia (GA) are all options for DAE. The choice of sedation should be dependent on patient and procedural factors and local resources.\n\n【12】Grade of evidence: Low. Strength of recommendation: Strong.\n\n【13】Level of agreement: 100%\n\n【14】 Special considerations: transnasal endoscopy (TNE) 32. We recommend unsedated TNE as an acceptable alternative to conventional oral endoscopy for routine diagnostic upper endoscopy.\n\n【15】Grade of evidence: Moderate. Strength of recommendation: Strong.\n\n【16】Level of agreement: 100%\n\n【17】 Special considerations: lower gastrointestinal endoscopy 33. We recommend for colonoscopy that alternatives to sedation, including no sedation, inhalational agents and other adjuncts, are considered.\n\n【18】Grade of evidence: Moderate. Strength of recommendation: Strong.\n\n【19】Level of agreement: 100% 34. We suggest that lower gastrointestinal endoscopy with deep sedation (propofol) or general anaesthesia should be available for selected patients undergoing planned prolonged procedures or complex endotherapy.\n\n【20】Grade of evidence: Low. Strength of recommendation: Weak.\n\n【21】Level of agreement: 100%\n\n【22】## Special Considerations: High-Risk Groups\n\n【23】\n 35. We recommend that clinicians fully discuss with patients at an increased risk from sedation for endoscopy (eg, due to age, frailty or comorbidity), the benefits and potential risks of sedation and alternatives to sedation, including no sedation.\n\n【24】Grade of evidence: Low. Strength of recommendation: Strong.\n\n【25】Level of agreement: 92.3% Sidhu R, et al. Gut 2023;0:1–27. doi:10.1136/gutjnl-2023-330396\n\n【26】 36. We recommend that frail, elderly or comorbid (American Society of Anesthesiologists (ASA) grade 3 or greater) patients are given half or less of the dose required for younger healthy patients and smaller incremental doses, if required.\n\n【27】Grade of evidence: Low. Strength of recommendation: Strong.\n\n【28】Level of agreement: 92.3% 37. We suggest that patients with established cardiovascular disease at high risk of cardiac dysrhythmias undergo ECG monitoring and be given supplemental oxygen during endoscopy with sedation.\n\n【29】Grade of evidence: Low. Strength of recommendation: Weak.\n\n【30】Level of agreement: 84.6% 38. We recommend that patients at risk of myocardial ischaemia during endoscopy with sedation should continue their normal anti-anginal therapy and receive supplemental oxygen before, during and after endoscopy.\n\n【31】Grade of evidence: Low. Strength of recommendation: Strong.\n\n【32】Level of agreement: 100% 39. We recommend that patients with decompensated chronic liver disease undergoing endoscopy with sedation should be assessed for hepatic encephalopathy prior to endoscopy.\n\n【33】Grade of evidence: Low. Strength of recommendation: Strong.\n\n【34】Level of agreement: 92.3% 40. We recommend that patients undergoing endoscopy, with hepatic encephalopathy or chronic liver disease with ASA grade 4 or higher, should have this undertaken with anaesthetic support.\n\n【35】Grade of evidence: Low. Strength of recommendation: Strong.\n\n【36】Level of agreement: 100% 41. We recommend adjunctive non-invasive ventilation and the use of high-flow oxygen in patients with chronic progressive neuromyopathic disorders and severely impaired respiratory function (forced vital capacity < 50% ) undergoing endoscopy with conscious sedation.\n\n【37】Grade of evidence: Moderate. Strength of recommendation: Strong.\n\n【38】Level of agreement: 100%\n\n【39】 42. We recommend that patients with renal impairment (estimated glomerular filtration rate < 30 mL/min/1.73 m 2 ) undergoing endoscopy with sedation should have their doses of opioids or benzodiazepines reduced.\n\n【40】Grade of evidence: Low. Strength of recommendation: Strong.\n\n【41】Level of agreement: 100% 43. We recommend the use of adjunctive non-invasive ventilation (NIV) and high-flow oxygen in patients with respiratory failure undergoing endoscopy.\n\n【42】Grade of evidence: Low. Strength of recommendation: Strong.\n\n【43】Level of agreement: 100%\n\n【44】## Special Considerations: Pregnancy And Breast Feeding\n\n【45】\n 44. We recommend that sedation providers should be aware of the actions and interactions of sedative agents in pregnant women, including the increased risk of aspiration.\n\n【46】Grade of evidence: Low. Strength of recommendation: Strong.\n\n【47】Level of agreement: 100% 45. The use of diazepam in the first trimester has been associated with congenital malformations, whereas no associations have been reported for midazolam. We recommend single doses of midazolam for endoscopic procedures during pregnancy if clinically necessary.\n\n【48】Grade of evidence: Low. Strength of recommendation: Strong.\n\n【49】Level of agreement: 92.3% 46. We recommend that fentanyl, propofol and nitrous oxide (Entonox) can safely be used in pregnancy Grade of evidence: Low. Strength of recommendation: Strong.", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "Special considerations: upper gastrointestinal endoscopy", "bbox": [54.0, 61.0, 359.0, 76.0]}, {"text": "27. There is no evidence to suggest that the combination of throat", "bbox": [53.0, 77.0, 387.0, 90.0]}, {"text": "spray and sedation increases the risk of aspiration, although we", "bbox": [53.0, 91.0, 387.0, 105.0]}, {"text": "advise caution in those at increased risk of aspiration.", "bbox": [53.0, 106.0, 332.0, 120.0]}, {"text": "Grade of evidence: Very Low. Strength of recommendation:", "bbox": [64.0, 120.0, 386.0, 135.0]}, {"text": "Strong.", "bbox": [53.0, 135.0, 93.0, 150.0]}, {"text": "Level of agreement: 100%", "bbox": [65.0, 150.0, 204.0, 165.0]}, {"text": "28. We recommend that deep sedation may be required for", "bbox": [66.0, 165.0, 386.0, 179.0]}, {"text": "specific upper gastrointestinal procedures, such as polypectomy/", "bbox": [53.0, 180.0, 386.0, 193.0]}, {"text": "resection of neoplasia, endoscopic bariatric surgery and foreign", "bbox": [53.0, 195.0, 387.0, 208.0]}, {"text": "body retrieval.", "bbox": [53.0, 209.0, 131.0, 223.0]}, {"text": "Grade of evidence: Low. Strength of recommendation: Strong.", "bbox": [64.0, 223.0, 384.0, 238.0]}, {"text": "Level of agreement: 100%", "bbox": [65.0, 239.0, 204.0, 253.0]}], "type": "Text", "position": 0}, {"raw_context": [{"text": "Special considerations: endoscopic ultrasound (EUS)/", "bbox": [53.0, 270.0, 337.0, 285.0]}, {"text": "endoscopic retrograde cholangio-pancreatography (ERCP)", "bbox": [53.0, 285.0, 365.0, 299.0]}], "type": "Section-header", "position": 1}, {"raw_context": [{"text": "29. We suggest that minimal/moderate sedation is usually", "bbox": [53.0, 300.0, 386.0, 314.0]}, {"text": "adequate in diagnostic EUS and level 1/level 2 ERCP.", "bbox": [53.0, 315.0, 329.0, 329.0]}, {"text": "Grade of evidence: Low. Strength of recommendation: Weak.", "bbox": [64.0, 329.0, 378.0, 344.0]}, {"text": "Level of agreement: 100%", "bbox": [66.0, 345.0, 205.0, 358.0]}, {"text": "30. We suggest that complex ERCP, therapeutic EUS and", "bbox": [66.0, 358.0, 387.0, 373.0]}, {"text": "combined EUS+ERCP procedures are performed with deep", "bbox": [53.0, 374.0, 386.0, 388.0]}, {"text": "sedation/general anaesthesia.", "bbox": [54.0, 390.0, 205.0, 401.0]}, {"text": "Grade of evidence: Low. Strength of recommendation: Weak.", "bbox": [64.0, 402.0, 378.0, 417.0]}, {"text": "Level of agreement: 100%", "bbox": [65.0, 417.0, 205.0, 432.0]}], "type": "Text", "position": 2}, {"raw_context": [{"text": "Special considerations: device-assisted enteroscopy (DAE)", "bbox": [53.0, 449.0, 364.0, 464.0]}, {"text": "31. We recommend that conscious sedation, deep sedation and", "bbox": [53.0, 465.0, 386.0, 478.0]}, {"text": "general anaesthesia (GA) are all options for DAE. The choice of", "bbox": [53.0, 480.0, 386.0, 493.0]}, {"text": "sedation should be dependent on patient and procedural factors", "bbox": [53.0, 494.0, 386.0, 507.0]}, {"text": "and local resources.", "bbox": [53.0, 509.0, 158.0, 522.0]}, {"text": "Grade of evidence: Low. Strength of recommendation: Strong.", "bbox": [64.0, 523.0, 383.0, 538.0]}, {"text": "Level of agreement: 100%", "bbox": [65.0, 538.0, 204.0, 552.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "Special considerations: transnasal endoscopy (TNE)", "bbox": [53.0, 569.0, 328.0, 584.0]}, {"text": "32. We recommend unsedated TNE as an acceptable alternative", "bbox": [53.0, 585.0, 387.0, 599.0]}, {"text": "to conventional oral endoscopy for routine diagnostic upper", "bbox": [53.0, 600.0, 386.0, 613.0]}, {"text": "endoscopy.", "bbox": [53.0, 614.0, 113.0, 627.0]}, {"text": "Grade of evidence: Moderate. Strength of recommendation:", "bbox": [64.0, 628.0, 386.0, 643.0]}, {"text": "Strong.", "bbox": [53.0, 644.0, 92.0, 657.0]}, {"text": "Level of agreement: 100%", "bbox": [64.0, 657.0, 203.0, 672.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": "Special considerations: lower gastrointestinal endoscopy", "bbox": [53.0, 689.0, 359.0, 704.0]}, {"text": "33. We recommend for colonoscopy that alternatives to sedation,", "bbox": [53.0, 705.0, 386.0, 719.0]}, {"text": "including no sedation, inhalational agents and other adjuncts,", "bbox": [53.0, 720.0, 387.0, 733.0]}, {"text": "are considered.", "bbox": [54.0, 736.0, 134.0, 747.0]}, {"text": "Grade of evidence: Moderate. Strength of recommendation:", "bbox": [64.0, 748.0, 386.0, 763.0]}, {"text": "Strong.", "bbox": [53.0, 762.0, 92.0, 778.0]}, {"text": "Level of agreement: 100%", "bbox": [66.0, 779.0, 203.0, 792.0]}, {"text": "34. We suggest that lower gastrointestinal endoscopy with", "bbox": [66.0, 793.0, 387.0, 807.0]}, {"text": "deep sedation (propofol) or general anaesthesia should be avail-", "bbox": [53.0, 808.0, 385.0, 821.0]}, {"text": "able for selected patients undergoing planned prolonged proce-", "bbox": [53.0, 822.0, 384.0, 836.0]}, {"text": "dures or complex endotherapy.", "bbox": [53.0, 837.0, 218.0, 850.0]}, {"text": "Grade of evidence: Low. Strength of recommendation: Weak.", "bbox": [64.0, 851.0, 377.0, 865.0]}, {"text": "Level of agreement: 100%", "bbox": [65.0, 866.0, 205.0, 880.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "Special considerations: high-risk groups", "bbox": [53.0, 898.0, 268.0, 912.0]}], "type": "Section-header", "position": 6}, {"raw_context": [{"text": "35. We recommend that clinicians fully discuss with patients at", "bbox": [53.0, 913.0, 387.0, 926.0]}, {"text": "an increased risk from sedation for endoscopy (eg, due to age,", "bbox": [53.0, 928.0, 386.0, 941.0]}, {"text": "frailty or comorbidity), the benefits and potential risks of seda-", "bbox": [53.0, 942.0, 385.0, 955.0]}, {"text": "tion and alternatives to sedation, including no sedation.", "bbox": [53.0, 957.0, 342.0, 970.0]}, {"text": "Grade of evidence: Low. Strength of recommendation: Strong.", "bbox": [64.0, 971.0, 384.0, 986.0]}, {"text": "Level of agreement: 92.3%", "bbox": [65.0, 986.0, 207.0, 1000.0]}, {"text": "Sidhu R, et al. Gut 2023;0:1–27. doi:10.1136/gutjnl-2023-330396", "bbox": [54.0, 1009.0, 317.0, 1022.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "36. We recommend that frail, elderly or comorbid (American", "bbox": [418.0, 60.0, 740.0, 75.0]}, {"text": "Society of Anesthesiologists (ASA) grade 3 or greater) patients", "bbox": [406.0, 76.0, 740.0, 90.0]}, {"text": "are given half or less of the dose required for younger healthy", "bbox": [406.0, 91.0, 739.0, 105.0]}, {"text": "patients and smaller incremental doses, if required.", "bbox": [406.0, 105.0, 672.0, 120.0]}, {"text": "Grade of evidence: Low. Strength of recommendation: Strong.", "bbox": [418.0, 120.0, 737.0, 135.0]}, {"text": "Level of agreement: 92.3%", "bbox": [418.0, 136.0, 561.0, 149.0]}, {"text": "37. We suggest that patients with established cardiovascular", "bbox": [418.0, 149.0, 740.0, 164.0]}, {"text": "disease at high risk of cardiac dysrhythmias undergo ECG moni-", "bbox": [406.0, 165.0, 739.0, 179.0]}, {"text": "toring and be given supplemental oxygen during endoscopy with", "bbox": [406.0, 180.0, 741.0, 193.0]}, {"text": "sedation.", "bbox": [407.0, 195.0, 455.0, 207.0]}, {"text": "Grade of evidence: Low. Strength of recommendation: Weak.", "bbox": [418.0, 208.0, 732.0, 223.0]}, {"text": "Level of agreement: 84.6%", "bbox": [418.0, 223.0, 560.0, 237.0]}, {"text": "38. We recommend that patients at risk of myocardial isch-", "bbox": [418.0, 237.0, 739.0, 252.0]}, {"text": "aemia during endoscopy with sedation should continue their", "bbox": [406.0, 253.0, 739.0, 266.0]}, {"text": "normal anti-anginal therapy and receive supplemental oxygen", "bbox": [406.0, 268.0, 740.0, 281.0]}, {"text": "before, during and after endoscopy.", "bbox": [406.0, 282.0, 591.0, 295.0]}, {"text": "Grade of evidence: Low. Strength of recommendation: Strong.", "bbox": [418.0, 296.0, 737.0, 311.0]}, {"text": "Level of agreement: 100%", "bbox": [418.0, 311.0, 557.0, 325.0]}, {"text": "39. We recommend that patients with decompensated chronic", "bbox": [418.0, 325.0, 740.0, 340.0]}, {"text": "liver disease undergoing endoscopy with sedation should be", "bbox": [406.0, 340.0, 740.0, 354.0]}, {"text": "assessed for hepatic encephalopathy prior to endoscopy.", "bbox": [407.0, 355.0, 697.0, 369.0]}, {"text": "Grade of evidence: Low. Strength of recommendation: Strong.", "bbox": [418.0, 370.0, 737.0, 383.0]}, {"text": "Level of agreement: 92.3%", "bbox": [419.0, 386.0, 560.0, 398.0]}, {"text": "40. We recommend that patients undergoing endoscopy, with", "bbox": [418.0, 399.0, 741.0, 413.0]}, {"text": "hepatic encephalopathy or chronic liver disease with ASA grade 4", "bbox": [406.0, 413.0, 739.0, 428.0]}, {"text": "or higher, should have this undertaken with anaesthetic support.", "bbox": [406.0, 428.0, 739.0, 443.0]}, {"text": "Grade of evidence: Low. Strength of recommendation: Strong.", "bbox": [418.0, 443.0, 737.0, 458.0]}, {"text": "Level of agreement: 100%", "bbox": [418.0, 458.0, 557.0, 472.0]}, {"text": "41. We recommend adjunctive non-invasive ventilation and", "bbox": [418.0, 473.0, 740.0, 486.0]}, {"text": "the use of high-flow oxygen in patients with chronic progres-", "bbox": [406.0, 488.0, 739.0, 501.0]}, {"text": "sive neuromyopathic disorders and severely impaired respiratory", "bbox": [406.0, 502.0, 740.0, 516.0]}, {"text": "function (forced vital capacity < 50% ) undergoing endoscopy", "bbox": [406.0, 516.0, 740.0, 531.0]}, {"text": "with conscious sedation.", "bbox": [406.0, 532.0, 534.0, 545.0]}, {"text": "Grade of evidence: Moderate. Strength of recommendation:", "bbox": [418.0, 546.0, 739.0, 560.0]}, {"text": "Strong.", "bbox": [406.0, 562.0, 445.0, 574.0]}, {"text": "Level of agreement: 100%", "bbox": [419.0, 577.0, 557.0, 588.0]}], "type": "Text", "position": 9}, {"raw_context": [{"text": "42. We recommend that patients with renal impairment (esti-", "bbox": [418.0, 589.0, 739.0, 603.0]}, {"text": "mated glomerular filtration rate < 30 mL/min/1.73 m 2 ) under-", "bbox": [406.0, 604.0, 739.0, 619.0]}, {"text": "going endoscopy with sedation should have their doses of", "bbox": [406.0, 619.0, 740.0, 633.0]}, {"text": "opioids or benzodiazepines reduced.", "bbox": [406.0, 634.0, 596.0, 648.0]}, {"text": "Grade of evidence: Low. Strength of recommendation: Strong.", "bbox": [418.0, 648.0, 737.0, 662.0]}, {"text": "Level of agreement: 100%", "bbox": [419.0, 665.0, 556.0, 676.0]}, {"text": "43. We recommend the use of adjunctive non-invasive venti-", "bbox": [418.0, 678.0, 739.0, 692.0]}, {"text": "lation (NIV) and high-flow oxygen in patients with respiratory", "bbox": [406.0, 692.0, 739.0, 707.0]}, {"text": "failure undergoing endoscopy.", "bbox": [406.0, 707.0, 564.0, 721.0]}, {"text": "Grade of evidence: Low. Strength of recommendation: Strong.", "bbox": [418.0, 722.0, 737.0, 736.0]}, {"text": "Level of agreement: 100%", "bbox": [418.0, 737.0, 557.0, 751.0]}], "type": "Text", "position": 10}, {"raw_context": [{"text": "Special considerations: pregnancy and breast feeding", "bbox": [406.0, 766.0, 694.0, 781.0]}], "type": "Section-header", "position": 11}, {"raw_context": [{"text": "44. We recommend that sedation providers should be aware", "bbox": [406.0, 781.0, 740.0, 795.0]}, {"text": "of the actions and interactions of sedative agents in pregnant", "bbox": [406.0, 796.0, 741.0, 810.0]}, {"text": "women, including the increased risk of aspiration.", "bbox": [406.0, 811.0, 667.0, 824.0]}, {"text": "Grade of evidence: Low. Strength of recommendation: Strong.", "bbox": [418.0, 825.0, 737.0, 839.0]}, {"text": "Level of agreement: 100%", "bbox": [418.0, 840.0, 557.0, 853.0]}, {"text": "45. The use of diazepam in the first trimester has been asso-", "bbox": [418.0, 854.0, 739.0, 868.0]}, {"text": "ciated with congenital malformations, whereas no associations", "bbox": [405.0, 869.0, 741.0, 883.0]}, {"text": "have been reported for midazolam. We recommend single doses", "bbox": [406.0, 883.0, 741.0, 898.0]}, {"text": "of midazolam for endoscopic procedures during pregnancy if", "bbox": [406.0, 898.0, 740.0, 912.0]}, {"text": "clinically necessary.", "bbox": [406.0, 913.0, 509.0, 926.0]}, {"text": "Grade of evidence: Low. Strength of recommendation: Strong.", "bbox": [418.0, 927.0, 737.0, 941.0]}, {"text": "Level of agreement: 92.3%", "bbox": [419.0, 943.0, 560.0, 955.0]}, {"text": "46. We recommend that fentanyl, propofol and nitrous oxide", "bbox": [418.0, 956.0, 740.0, 970.0]}, {"text": "(Entonox) can safely be used in pregnancy", "bbox": [407.0, 971.0, 626.0, 985.0]}, {"text": "Grade of evidence: Low. Strength of recommendation: Strong.", "bbox": [418.0, 987.0, 737.0, 1001.0]}], "type": "Text", "position": 12}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/消化科/_2023 BSG指南：胃肠内窥镜检查中的镇静.pdf", "page_num": 3}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "缺少换行#2#2#28. We recommend that deep另起一行\n缺少换行#8#8#30. We suggest that complex 另起一行\n缺少换行#11#11#31. We recommend that 另起一行\n缺少换行#14#14#32. We recommend unsedated另起一行\n缺少换行#17#17#33. We recommend for colonoscopy另起一行\n缺少换行#19#19#34. We suggest that lower另起一行\n缺少换行#19#19#34. We suggest that lower另起一行\n缺少换行#28#28#37. We suggest that patients 另起一行\n缺少换行#30#30#38. We recommend that 另起一行\n缺少换行#32#32#39. We recommend that patients 另起一行\n缺少换行#34#34#40. We recommend that patients 另起一行\n缺少换行#36#36#41. We recommend adjunctive另起一行\n缺少换行#41#41#43. We recommend the use of另起一行\n缺少换行#47#47# 45. The use of diazepam in 另起一行\n缺少换行#49#49# 46. We recommend that fentanyl, 另起一行", "type3": null, "type4": null, "type5": null, "type6": "有用性#25#25#Sidhu R, et al. Gut 2023;0:1–27. doi:10.1136/gutjnl-2023-330396为页脚内容\n"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:42", "update_time": "2024-05-07 23:08:20"}
{"id": 1082644, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 738, "source_info": {"seq_id": "8c3bd409-0747-49c5-8f8c-487516338f43", "title": null, "text": "【0】页码:5\n Chapter 1 Chapter 1 .\n\n【1】, o .\n\n【2】x CT >3 Chapter 1 .\n\n【3】, , 1990, 1990, .\n\n【4】MRI ( visual analogue ; ., , , 100 scale,VAS), (neck disability in- Chapter 1 , dex,NDI), JOA ; , o , 100  [27–28]  65 (4)  , , Chapter 1 , , . \n\n【5】o , o , , Chapter 3 [32] .\n\n【6】\n\n【7】, .\n\n【8】, .\n\n【9】2 , .\n\n【10】, , o         , , o , , .\n\n【11】Chapter 1 o Chapter 1 , 5 , Chapter 1 [27-28] , 100 , , 4. 9. 4 Chapter 1 .\n\n【12】, C 5 Chapter 1 , 100 o [29] , , , .\n\n【13】. \n\n【14】Chapter 1 , [30] [30] [33] , 3 (1) , o .\n\n【15】, ,     , , 10. See also   , 1. See also   1990   5. 1 , , , . \n\n【16】K–line 1  10. See also   , , [31] .\n\n【17】o .\n\n【18】(anterior cervical discectomy and fusion , , , __ ACDF), (anterior cervical o corpectomy decompression and fusion , ACCF) , : ADR , 100 (artificial disc redlacement , ADR ) 。 11, 112 l , (2) 1,2 . ACDF o , 1~2 , , >3 2~3 1,3~4 o , 3~4 1,6 ; , 4 ,6~8 . ACCF .\n\n【19】4 ,4~6 , , ,6~8 o , , 12 ( ), 3 + Chapter 1 : o , (3) 2 2 ,2~3 ,3~4 o , o 1. See also\n\n【20】 • 794 •", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "Chapter 1", "bbox": [80.0, 111.0, 119.0, 127.0]}, {"text": "Chapter 1", "bbox": [175.0, 112.0, 187.0, 125.0]}, {"text": ".", "bbox": [254.0, 113.0, 267.0, 126.0]}, {"text": ",", "bbox": [610.0, 112.0, 621.0, 124.0]}, {"text": "o", "bbox": [106.0, 131.0, 121.0, 145.0]}, {"text": ".", "bbox": [353.0, 131.0, 367.0, 145.0]}, {"text": "x", "bbox": [152.0, 146.0, 168.0, 163.0]}, {"text": "CT", "bbox": [254.0, 146.0, 277.0, 162.0]}, {"text": ">3", "bbox": [580.0, 147.0, 607.0, 163.0]}, {"text": "Chapter 1", "bbox": [209.0, 149.0, 223.0, 165.0]}, {"text": ".", "bbox": [454.0, 149.0, 469.0, 164.0]}, {"text": ",", "bbox": [547.0, 150.0, 574.0, 165.0]}, {"text": ", 1990, 1990,", "bbox": [606.0, 150.0, 629.0, 163.0]}, {"text": ".", "bbox": [334.0, 151.0, 346.0, 163.0]}, {"text": "MRI", "bbox": [64.0, 166.0, 97.0, 182.0]}, {"text": "( visual analogue", "bbox": [281.0, 166.0, 381.0, 184.0]}, {"text": ";", "bbox": [119.0, 167.0, 133.0, 183.0]}, {"text": ".,", "bbox": [483.0, 169.0, 498.0, 184.0]}, {"text": ",", "bbox": [578.0, 171.0, 591.0, 185.0]}, {"text": ", 100", "bbox": [657.0, 172.0, 670.0, 184.0]}, {"text": "scale,VAS),", "bbox": [64.0, 185.0, 144.0, 203.0]}, {"text": "(neck disability in-", "bbox": [265.0, 185.0, 378.0, 203.0]}, {"text": "Chapter 1", "bbox": [539.0, 191.0, 552.0, 203.0]}, {"text": ",", "bbox": [631.0, 191.0, 642.0, 203.0]}, {"text": "dex,NDI),", "bbox": [64.0, 205.0, 135.0, 224.0]}, {"text": "JOA", "bbox": [190.0, 205.0, 222.0, 222.0]}, {"text": ";", "bbox": [249.0, 208.0, 262.0, 224.0]}, {"text": ",", "bbox": [541.0, 210.0, 558.0, 225.0]}, {"text": "o", "bbox": [650.0, 211.0, 665.0, 225.0]}, {"text": ", 100", "bbox": [455.0, 212.0, 466.0, 223.0]}, {"text": "", "bbox": [295.0, 223.0, 338.0, 234.0]}, {"text": "[27–28] ", "bbox": [340.0, 222.0, 379.0, 240.0]}, {"text": "65", "bbox": [63.0, 225.0, 86.0, 242.0]}, {"text": "(4)", "bbox": [426.0, 225.0, 454.0, 243.0]}, {"text": "", "bbox": [134.0, 231.0, 152.0, 243.0]}, {"text": ",", "bbox": [154.0, 231.0, 164.0, 244.0]}, {"text": ",", "bbox": [239.0, 251.0, 250.0, 264.0]}, {"text": "Chapter 1", "bbox": [353.0, 251.0, 367.0, 266.0]}, {"text": ",", "bbox": [512.0, 251.0, 522.0, 264.0]}, {"text": ",", "bbox": [590.0, 251.0, 601.0, 264.0]}, {"text": ". ", "bbox": [80.0, 270.0, 129.0, 287.0]}, {"text": "o", "bbox": [453.0, 271.0, 467.0, 284.0]}, {"text": ",", "bbox": [248.0, 289.0, 310.0, 305.0]}, {"text": "o", "bbox": [162.0, 290.0, 177.0, 304.0]}, {"text": ",", "bbox": [617.0, 290.0, 631.0, 305.0]}, {"text": ",", "bbox": [354.0, 291.0, 367.0, 306.0]}, {"text": "Chapter 3", "bbox": [539.0, 291.0, 615.0, 304.0]}, {"text": "[32] .", "bbox": [425.0, 302.0, 456.0, 320.0]}, {"text": "", "bbox": [248.0, 308.0, 289.0, 323.0]}, {"text": ",", "bbox": [291.0, 312.0, 303.0, 325.0]}, {"text": ".", "bbox": [93.0, 330.0, 127.0, 344.0]}, {"text": ",", "bbox": [207.0, 330.0, 218.0, 344.0]}, {"text": ".", "bbox": [440.0, 330.0, 455.0, 345.0]}, {"text": "2", "bbox": [540.0, 344.0, 555.0, 362.0]}, {"text": ",", "bbox": [80.0, 351.0, 91.0, 364.0]}, {"text": ".", "bbox": [227.0, 351.0, 240.0, 364.0]}, {"text": ",", "bbox": [164.0, 371.0, 179.0, 385.0]}, {"text": ",", "bbox": [624.0, 372.0, 638.0, 385.0]}, {"text": "o         ,", "bbox": [588.0, 390.0, 643.0, 405.0]}, {"text": ",", "bbox": [177.0, 392.0, 191.0, 404.0]}, {"text": "o", "bbox": [368.0, 392.0, 380.0, 404.0]}, {"text": ",", "bbox": [496.0, 392.0, 510.0, 404.0]}, {"text": ",", "bbox": [234.0, 411.0, 264.0, 424.0]}, {"text": ".", "bbox": [327.0, 413.0, 338.0, 424.0]}, {"text": "Chapter 1", "bbox": [325.0, 431.0, 339.0, 447.0]}, {"text": "o", "bbox": [684.0, 431.0, 698.0, 445.0]}, {"text": "Chapter 1", "bbox": [193.0, 432.0, 205.0, 445.0]}, {"text": ",", "bbox": [440.0, 432.0, 452.0, 445.0]}, {"text": "5", "bbox": [397.0, 445.0, 411.0, 462.0]}, {"text": ",", "bbox": [228.0, 450.0, 264.0, 464.0]}, {"text": "Chapter 1", "bbox": [123.0, 451.0, 134.0, 464.0]}, {"text": "[27-28]", "bbox": [315.0, 460.0, 350.0, 478.0]}, {"text": ", 100", "bbox": [79.0, 468.0, 94.0, 482.0]}, {"text": ",", "bbox": [624.0, 470.0, 636.0, 483.0]}, {"text": ",", "bbox": [171.0, 471.0, 181.0, 483.0]}, {"text": "4. 9. 4", "bbox": [63.0, 485.0, 107.0, 503.0]}, {"text": "Chapter 1", "bbox": [554.0, 491.0, 565.0, 503.0]}, {"text": ".", "bbox": [674.0, 491.0, 687.0, 504.0]}, {"text": ",", "bbox": [526.0, 511.0, 535.0, 523.0]}, {"text": "C 5", "bbox": [455.0, 525.0, 480.0, 543.0]}, {"text": "Chapter 1", "bbox": [310.0, 530.0, 322.0, 543.0]}, {"text": ", 100", "bbox": [93.0, 531.0, 106.0, 543.0]}, {"text": "o", "bbox": [603.0, 531.0, 616.0, 543.0]}, {"text": "[29] ,", "bbox": [280.0, 542.0, 305.0, 560.0]}, {"text": ",", "bbox": [95.0, 550.0, 130.0, 564.0]}, {"text": ",", "bbox": [132.0, 551.0, 142.0, 563.0]}, {"text": ".", "bbox": [586.0, 551.0, 627.0, 563.0]}, {"text": ". ", "bbox": [514.0, 552.0, 565.0, 564.0]}, {"text": "Chapter 1", "bbox": [107.0, 569.0, 121.0, 585.0]}, {"text": ",", "bbox": [455.0, 571.0, 467.0, 582.0]}, {"text": "[30] [30]", "bbox": [161.0, 581.0, 183.0, 597.0]}, {"text": "[33]", "bbox": [425.0, 581.0, 447.0, 599.0]}, {"text": ",", "bbox": [645.0, 591.0, 658.0, 604.0]}, {"text": "3", "bbox": [415.0, 604.0, 429.0, 620.0]}, {"text": "(1)", "bbox": [92.0, 605.0, 120.0, 621.0]}, {"text": ",", "bbox": [291.0, 609.0, 339.0, 624.0]}, {"text": "o", "bbox": [156.0, 610.0, 169.0, 623.0]}, {"text": ".", "bbox": [342.0, 611.0, 361.0, 622.0]}, {"text": ",", "bbox": [93.0, 629.0, 107.0, 643.0]}, {"text": ",     ,", "bbox": [157.0, 630.0, 206.0, 644.0]}, {"text": ",", "bbox": [355.0, 630.0, 365.0, 644.0]}, {"text": "10. See also   ,", "bbox": [455.0, 630.0, 467.0, 642.0]}, {"text": "1. See also   1990  ", "bbox": [546.0, 630.0, 557.0, 642.0]}, {"text": "5. 1", "bbox": [397.0, 644.0, 425.0, 661.0]}, {"text": ",", "bbox": [205.0, 649.0, 219.0, 664.0]}, {"text": ",", "bbox": [106.0, 669.0, 120.0, 685.0]}, {"text": ",", "bbox": [285.0, 670.0, 295.0, 684.0]}, {"text": ". ", "bbox": [512.0, 670.0, 588.0, 685.0]}, {"text": "K–line", "bbox": [299.0, 683.0, 350.0, 702.0]}, {"text": "1 ", "bbox": [172.0, 684.0, 206.0, 702.0]}, {"text": "10. See also   ,", "bbox": [469.0, 690.0, 481.0, 702.0]}, {"text": ",", "bbox": [81.0, 692.0, 91.0, 704.0]}, {"text": "[31] .", "bbox": [105.0, 702.0, 129.0, 719.0]}, {"text": "o", "bbox": [510.0, 710.0, 524.0, 724.0]}, {"text": ".", "bbox": [619.0, 712.0, 630.0, 723.0]}, {"text": "(anterior cervical discectomy and fusion ,", "bbox": [143.0, 723.0, 381.0, 743.0]}, {"text": ",", "bbox": [659.0, 728.0, 672.0, 744.0]}, {"text": ",", "bbox": [567.0, 730.0, 581.0, 744.0]}, {"text": "__", "bbox": [620.0, 731.0, 658.0, 741.0]}, {"text": "ACDF),", "bbox": [64.0, 745.0, 119.0, 762.0]}, {"text": "(anterior cervical", "bbox": [275.0, 745.0, 382.0, 763.0]}, {"text": "o", "bbox": [469.0, 749.0, 481.0, 765.0]}, {"text": "corpectomy decompression and fusion , ACCF) ,", "bbox": [64.0, 763.0, 335.0, 782.0]}, {"text": ": ADR", "bbox": [511.0, 764.0, 552.0, 781.0]}, {"text": ", 100", "bbox": [665.0, 769.0, 679.0, 783.0]}, {"text": "(artificial disc redlacement , ADR ) 。", "bbox": [148.0, 784.0, 357.0, 802.0]}, {"text": "11, 112", "bbox": [468.0, 784.0, 504.0, 802.0]}, {"text": "l", "bbox": [444.0, 785.0, 457.0, 801.0]}, {"text": ",", "bbox": [645.0, 789.0, 657.0, 802.0]}, {"text": "(2)", "bbox": [92.0, 803.0, 121.0, 822.0]}, {"text": "1,2", "bbox": [526.0, 804.0, 546.0, 822.0]}, {"text": ". ACDF", "bbox": [659.0, 804.0, 713.0, 822.0]}, {"text": "o", "bbox": [155.0, 807.0, 168.0, 822.0]}, {"text": ",", "bbox": [339.0, 808.0, 352.0, 823.0]}, {"text": "1~2", "bbox": [555.0, 823.0, 584.0, 842.0]}, {"text": ",", "bbox": [510.0, 826.0, 523.0, 842.0]}, {"text": ",", "bbox": [106.0, 827.0, 134.0, 842.0]}, {"text": ">3", "bbox": [276.0, 844.0, 301.0, 862.0]}, {"text": "2~3", "bbox": [442.0, 844.0, 472.0, 862.0]}, {"text": "1,3~4", "bbox": [479.0, 844.0, 518.0, 861.0]}, {"text": "o", "bbox": [105.0, 846.0, 121.0, 862.0]}, {"text": ",", "bbox": [303.0, 847.0, 325.0, 862.0]}, {"text": "3~4", "bbox": [553.0, 862.0, 583.0, 880.0]}, {"text": "1,6", "bbox": [412.0, 864.0, 432.0, 882.0]}, {"text": ";", "bbox": [515.0, 864.0, 528.0, 881.0]}, {"text": ",", "bbox": [93.0, 869.0, 111.0, 883.0]}, {"text": "4", "bbox": [455.0, 883.0, 471.0, 900.0]}, {"text": ",6~8", "bbox": [477.0, 883.0, 518.0, 901.0]}, {"text": ". ACCF", "bbox": [585.0, 883.0, 640.0, 901.0]}, {"text": ".", "bbox": [94.0, 889.0, 134.0, 903.0]}, {"text": "4 ,4~6", "bbox": [592.0, 904.0, 654.0, 920.0]}, {"text": ",", "bbox": [456.0, 909.0, 467.0, 923.0]}, {"text": ",", "bbox": [250.0, 911.0, 260.0, 921.0]}, {"text": ",6~8", "bbox": [555.0, 924.0, 588.0, 940.0]}, {"text": "o", "bbox": [107.0, 928.0, 121.0, 942.0]}, {"text": ",", "bbox": [256.0, 929.0, 269.0, 943.0]}, {"text": ",", "bbox": [455.0, 929.0, 467.0, 942.0]}, {"text": "12", "bbox": [611.0, 942.0, 655.0, 962.0]}, {"text": "(", "bbox": [107.0, 944.0, 121.0, 964.0]}, {"text": "),", "bbox": [207.0, 944.0, 228.0, 962.0]}, {"text": "3", "bbox": [441.0, 944.0, 457.0, 960.0]}, {"text": "+", "bbox": [280.0, 945.0, 294.0, 960.0]}, {"text": "Chapter 1", "bbox": [160.0, 950.0, 172.0, 963.0]}, {"text": ":", "bbox": [510.0, 968.0, 522.0, 982.0]}, {"text": "o", "bbox": [191.0, 969.0, 203.0, 982.0]}, {"text": ",", "bbox": [603.0, 969.0, 615.0, 983.0]}, {"text": "(3)", "bbox": [92.0, 983.0, 120.0, 1001.0]}, {"text": "2", "bbox": [307.0, 982.0, 322.0, 1001.0]}, {"text": "2", "bbox": [397.0, 983.0, 411.0, 1001.0]}, {"text": ",2~3", "bbox": [421.0, 983.0, 457.0, 1001.0]}, {"text": ",3~4", "bbox": [661.0, 983.0, 696.0, 1001.0]}, {"text": "o", "bbox": [197.0, 987.0, 212.0, 1002.0]}, {"text": ",", "bbox": [555.0, 990.0, 567.0, 1002.0]}, {"text": "o", "bbox": [136.0, 1010.0, 146.0, 1022.0]}, {"text": "1. See also", "bbox": [469.0, 1010.0, 479.0, 1022.0]}], "type": "Text", "position": 1}, {"raw_context": [{"text": "• 794 •", "bbox": [76.0, 65.0, 115.0, 83.0]}], "type": "Text", "position": 2}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/骨科/共识/脊髓型颈椎病中西医结合诊疗专家共识.pdf", "page_num": 5}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type2": "格式杂乱#0#20#全篇格式杂乱"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:42", "update_time": "2024-05-07 22:18:02"}
{"id": 1082643, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 738, "source_info": {"seq_id": "dc8fed87-8c98-4ac8-a476-a37b3a547d40", "title": null, "text": "【0】页码:11\n\n【1】## Neonatal Considerations\n\n【2】\n## Breast Feeding\n\n【3】\n## Anaesthesia For Caesarean Birth (Or Any Operative Intervention)\n\n【4】\n## Postpartum Cardiology Care Of Individuals With Mhv\n\n【5】\n## Postoperative Analgesia\n\n【6】\n## Contraception\n\n【7】\n## Uterotonic Agents\n\n【8】\n The AOA have published guidelines on acceptable time intervals for neuraxial blockade in patients taking anticoagulants. 54 For individuals receiving VKAs, an INR ≤ 1.4 is necessary, whilst those receiving therapeutic LMWH, a 24-h interval between the last dose of LMWH and neuraxial blockade is recommended. If a prophylactic dose of LMWH has been administered to the patient after interrupting therapeutic anticoagulation for 24h, then the recommended time interval for placement of neuraxial labour analgesia is 12h.\n\n【9】For patients receiving UFH, a minimum of 4 h should elapse without UFH, ideally confirmed with a normal APTTR and platelet count before a neuraxial blockade is attempted.\n\n【10】The guidance and the recommended time intervals for administering a prophylactic dose of LMWH following an epidural catheter insertion for labour analgesia varies internationally (AOA 54 4–6h and American Society of Regional Anesthesia 61 12h). The MDT needs to evaluate the risks and benefits of administration of any anticoagulant whilst an epidural is in situ very carefully and discuss the same with the patient. If a prophylactic dose of LMWH is administered with an epidural catheter in situ, the epidural catheter should be removed 12 h after the last prophylactic dose of LMWH following delivery in line with AOA guidance. Alternatively, non-neuraxial labour analgesia techniques could be considered in patients needing anticoagulants whilst in labour.\n\n【11】 prostaglandin F2 α (in the absence of asthma, right heart dysfunction or pulmonary hypertension) or ergotamine (in the absence of vasculitis or hypertensive disorders of pregnancy, concurrent aortopathy, known coronary disease or ventricular dysfunction) are the alternative agents that can be used in this cohort.\n\n【12】 If presenting in labour and on VKA within previous 2 weeks, a caesarean birth should be considered to decrease foetal complications from labour. Instrumentation and invasive foetal monitoring should be avoided. However, in very advanced labour, if indicated, an outlet forceps delivery may be less traumatic to the foetus than a second stage CS. Ventouse should not be used. Close liaison with the neonatology team is required and a coagulation screen should be performed on the newborn. An INR above the age-appropriate reference range should be managed with IV vitamin K (30 µ g/ kg by slow IV infusion) rather than the standard neonatal prophylactic dose and FFP or 20–30 IU/kg PCC should be considered. 64 , 65\n\n【13】 Breast feeding can be safely undertaken on UFH, LMWH or VKAs.\n\n【14】 The above-mentioned time intervals need to be adhered to for patients having a caesarean birth under a neuraxial anaesthetic technique. When above recommended intervals have not been met, a general anaesthetic (GA) is usually administered. The reported GA rates in patients with MHV having a caesarean birth vary from 36%, 5 52%, 41 55% 57 to 100%. 59 Sedation or a GA can be considered in a pregnant patient having a surgical termination if neuraxial anaesthesia cannot be performed.\n\n【15】 The maternal physiology changes rapidly during the postpartum period, and the cardiac output peaking between 24 and 48 h following birth, making this a time when heart failure symptoms may manifest if there is left ventricular systolic dysfunction. Women with MHV need a tailored plan for postnatal care and monitoring, including plan for postnatal echocardiography as required (e.g. if there is concern about valve function or cardiac function). The expected duration of inpatient monitoring should be discussed in the antenatal period acknowledging the need to re-establish anticoagulation. Pre-discharge arrangements for INR testing should be put in place together with a plan for postnatal follow-up for clinical review, discussion about pregnancy-related concerns or events and future pregnancy plans.\n\n【16】 Multi-modal analgesia using paracetamol, opioids and a short course of non-steroidal anti-inflammatory agents (NSAIDS) may be utilised following the operative intervention. Outside of pregnancy, an increased bleeding risk has been shown in individuals on therapeutic anticoagulation for VTE when taking NSAIDS and appropriate alternatives (oral or IV opioids) may be necessary. 62 Opioid PCA is often necessary following a GA for a caesarean birth. 63\n\n【17】 All postpartum individuals must leave hospital with a plan for contraception, agreed with the individual and the MDT. This should include consideration of the risks of future pregnancy, need for reversibility, drug interactions, compliance and cardiovascular risk from insertion.\n\n【18】 Oxytocin is commonly utilised to improve and maintain uterine tone in this cohort. Sublingual or rectal misoprostol,\n\n【19】 capat) and in 5 has annot at so 8 [120540/81] no cardid online colivity, conduct glory and MaxV asso] · 15 ha 4 [1828140/111101/89/unco-cardid]\n\n【20】 II mi solation VO case to solet and caradici online volitar no (anotabuse\n\n【21】 obtrainings out will be", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "Neonatal considerations", "bbox": [406.0, 193.0, 572.0, 208.0]}], "type": "Section-header", "position": 3}, {"raw_context": [{"text": "Breast feeding", "bbox": [407.0, 465.0, 506.0, 481.0]}], "type": "Section-header", "position": 4}, {"raw_context": [{"text": "Anaesthesia for caesarean birth (or any", "bbox": [58.0, 497.0, 322.0, 512.0]}, {"text": "operative intervention)", "bbox": [58.0, 514.0, 215.0, 528.0]}], "type": "Section-header", "position": 5}, {"raw_context": [{"text": "Postpartum cardiology Care of Individuals", "bbox": [406.0, 560.0, 700.0, 578.0]}, {"text": "with MHV", "bbox": [406.0, 577.0, 481.0, 593.0]}], "type": "Section-header", "position": 6}, {"raw_context": [{"text": "Postoperative analgesia", "bbox": [58.0, 721.0, 218.0, 736.0]}], "type": "Section-header", "position": 7}, {"raw_context": [{"text": "Contraception", "bbox": [406.0, 865.0, 507.0, 881.0]}], "type": "Section-header", "position": 8}, {"raw_context": [{"text": "Uterotonic agents", "bbox": [58.0, 913.0, 179.0, 929.0]}], "type": "Section-header", "position": 9}, {"raw_context": [{"text": "The AOA have published guidelines on acceptable time", "bbox": [74.0, 64.0, 387.0, 79.0]}, {"text": "intervals for neuraxial blockade in patients taking antico-", "bbox": [58.0, 80.0, 385.0, 95.0]}, {"text": "agulants. 54 For individuals receiving VKAs, an INR ≤ 1.4", "bbox": [58.0, 96.0, 387.0, 112.0]}, {"text": "is necessary, whilst those receiving therapeutic LMWH, a", "bbox": [58.0, 113.0, 387.0, 127.0]}, {"text": "24-h interval between the last dose of LMWH and neuraxial", "bbox": [58.0, 129.0, 387.0, 144.0]}, {"text": "blockade is recommended. If a prophylactic dose of LMWH", "bbox": [58.0, 145.0, 387.0, 159.0]}, {"text": "has been administered to the patient after interrupting ther-", "bbox": [58.0, 160.0, 385.0, 176.0]}, {"text": "apeutic anticoagulation for 24h, then the recommended time", "bbox": [58.0, 177.0, 387.0, 192.0]}, {"text": "interval for placement of neuraxial labour analgesia is 12h.", "bbox": [58.0, 194.0, 386.0, 207.0]}, {"text": "For patients receiving UFH, a minimum of 4 h should elapse", "bbox": [58.0, 209.0, 386.0, 224.0]}, {"text": "without UFH, ideally confirmed with a normal APTTR and", "bbox": [58.0, 226.0, 387.0, 240.0]}, {"text": "platelet count before a neuraxial blockade is attempted.", "bbox": [58.0, 242.0, 358.0, 256.0]}, {"text": "The guidance and the recommended time intervals for", "bbox": [74.0, 258.0, 386.0, 273.0]}, {"text": "administering a prophylactic dose of LMWH following an", "bbox": [58.0, 274.0, 387.0, 288.0]}, {"text": "epidural catheter insertion for labour analgesia varies inter-", "bbox": [58.0, 289.0, 385.0, 304.0]}, {"text": "nationally (AOA 54 4–6h and American Society of Regional", "bbox": [58.0, 305.0, 387.0, 321.0]}, {"text": "Anesthesia 61 12h). The MDT needs to evaluate the risks and", "bbox": [58.0, 321.0, 387.0, 336.0]}, {"text": "benefits of administration of any anticoagulant whilst an", "bbox": [58.0, 338.0, 387.0, 353.0]}, {"text": "epidural is in situ very carefully and discuss the same with", "bbox": [58.0, 354.0, 387.0, 368.0]}, {"text": "the patient. If a prophylactic dose of LMWH is administered", "bbox": [58.0, 369.0, 386.0, 386.0]}, {"text": "with an epidural catheter in situ, the epidural catheter should", "bbox": [58.0, 386.0, 387.0, 401.0]}, {"text": "be removed 12 h after the last prophylactic dose of LMWH", "bbox": [58.0, 402.0, 387.0, 416.0]}, {"text": "following delivery in line with AOA guidance. Alternatively,", "bbox": [58.0, 418.0, 386.0, 433.0]}, {"text": "non-neuraxial labour analgesia techniques could be consid-", "bbox": [58.0, 435.0, 384.0, 448.0]}, {"text": "ered in patients needing anticoagulants whilst in labour.", "bbox": [58.0, 449.0, 365.0, 465.0]}], "type": "Text", "position": 10}, {"raw_context": [{"text": "prostaglandin F2 α (in the absence of asthma, right heart", "bbox": [406.0, 65.0, 733.0, 79.0]}, {"text": "dysfunction or pulmonary hypertension) or ergotamine (in", "bbox": [406.0, 80.0, 735.0, 95.0]}, {"text": "the absence of vasculitis or hypertensive disorders of preg-", "bbox": [406.0, 97.0, 733.0, 112.0]}, {"text": "nancy, concurrent aortopathy, known coronary disease or", "bbox": [406.0, 113.0, 735.0, 127.0]}, {"text": "ventricular dysfunction) are the alternative agents that can", "bbox": [406.0, 129.0, 735.0, 144.0]}, {"text": "be used in this cohort.", "bbox": [406.0, 145.0, 530.0, 160.0]}], "type": "Text", "position": 11}, {"raw_context": [{"text": "If presenting in labour and on VKA within previous 2 weeks,", "bbox": [406.0, 226.0, 734.0, 240.0]}, {"text": "a caesarean birth should be considered to decrease foetal", "bbox": [406.0, 241.0, 735.0, 256.0]}, {"text": "complications from labour. Instrumentation and invasive", "bbox": [406.0, 258.0, 735.0, 273.0]}, {"text": "foetal monitoring should be avoided. However, in very ad-", "bbox": [406.0, 274.0, 733.0, 288.0]}, {"text": "vanced labour, if indicated, an outlet forceps delivery may be", "bbox": [406.0, 290.0, 735.0, 305.0]}, {"text": "less traumatic to the foetus than a second stage CS. Ventouse", "bbox": [406.0, 306.0, 735.0, 321.0]}, {"text": "should not be used. Close liaison with the neonatology team", "bbox": [406.0, 322.0, 735.0, 336.0]}, {"text": "is required and a coagulation screen should be performed", "bbox": [406.0, 338.0, 735.0, 353.0]}, {"text": "on the newborn. An INR above the age-appropriate refer-", "bbox": [406.0, 354.0, 733.0, 368.0]}, {"text": "ence range should be managed with IV vitamin K (30 µ g/", "bbox": [406.0, 370.0, 734.0, 384.0]}, {"text": "kg by slow IV infusion) rather than the standard neonatal", "bbox": [406.0, 386.0, 735.0, 401.0]}, {"text": "prophylactic dose and FFP or 20–30 IU/kg PCC should be", "bbox": [406.0, 401.0, 734.0, 416.0]}, {"text": "considered. 64 , 65", "bbox": [406.0, 418.0, 488.0, 433.0]}], "type": "Text", "position": 12}, {"raw_context": [{"text": "Breast feeding can be safely undertaken on UFH, LMWH", "bbox": [406.0, 497.0, 734.0, 513.0]}, {"text": "or VKAs.", "bbox": [406.0, 514.0, 461.0, 528.0]}], "type": "Text", "position": 13}, {"raw_context": [{"text": "The above-mentioned time intervals need to be adhered to", "bbox": [58.0, 546.0, 387.0, 561.0]}, {"text": "for patients having a caesarean birth under a neuraxial an-", "bbox": [58.0, 562.0, 385.0, 576.0]}, {"text": "aesthetic technique. When above recommended intervals", "bbox": [58.0, 578.0, 387.0, 593.0]}, {"text": "have not been met, a general anaesthetic (GA) is usually ad-", "bbox": [58.0, 595.0, 385.0, 609.0]}, {"text": "ministered. The reported GA rates in patients with MHV", "bbox": [58.0, 609.0, 385.0, 624.0]}, {"text": "having a caesarean birth vary from 36%, 5 52%, 41 55% 57 to", "bbox": [58.0, 625.0, 386.0, 641.0]}, {"text": "100%. 59 Sedation or a GA can be considered in a pregnant", "bbox": [58.0, 642.0, 387.0, 656.0]}, {"text": "patient having a surgical termination if neuraxial anaesthe-", "bbox": [58.0, 658.0, 384.0, 673.0]}, {"text": "sia cannot be performed.", "bbox": [58.0, 674.0, 196.0, 689.0]}], "type": "Text", "position": 14}, {"raw_context": [{"text": "The maternal physiology changes rapidly during the post-", "bbox": [407.0, 609.0, 734.0, 624.0]}, {"text": "partum period, and the cardiac output peaking between 24", "bbox": [406.0, 626.0, 735.0, 641.0]}, {"text": "and 48 h following birth, making this a time when heart fail-", "bbox": [406.0, 642.0, 734.0, 656.0]}, {"text": "ure symptoms may manifest if there is left ventricular sys-", "bbox": [406.0, 658.0, 734.0, 673.0]}, {"text": "tolic dysfunction. Women with MHV need a tailored plan for", "bbox": [406.0, 673.0, 735.0, 689.0]}, {"text": "postnatal care and monitoring, including plan for postnatal", "bbox": [406.0, 689.0, 735.0, 705.0]}, {"text": "echocardiography as required (e.g. if there is concern about", "bbox": [406.0, 706.0, 735.0, 720.0]}, {"text": "valve function or cardiac function). The expected duration", "bbox": [406.0, 722.0, 735.0, 736.0]}, {"text": "of inpatient monitoring should be discussed in the antenatal", "bbox": [406.0, 738.0, 735.0, 753.0]}, {"text": "period acknowledging the need to re-establish anticoagula-", "bbox": [406.0, 755.0, 733.0, 769.0]}, {"text": "tion. Pre-discharge arrangements for INR testing should be", "bbox": [406.0, 769.0, 735.0, 784.0]}, {"text": "put in place together with a plan for postnatal follow-up for", "bbox": [406.0, 786.0, 734.0, 801.0]}, {"text": "clinical review, discussion about pregnancy-related concerns", "bbox": [406.0, 803.0, 735.0, 816.0]}, {"text": "or events and future pregnancy plans.", "bbox": [406.0, 818.0, 612.0, 833.0]}], "type": "Text", "position": 15}, {"raw_context": [{"text": "Multi-modal analgesia using paracetamol, opioids and a", "bbox": [58.0, 754.0, 387.0, 768.0]}, {"text": "short course of non-steroidal anti-inflammatory agents", "bbox": [58.0, 769.0, 387.0, 784.0]}, {"text": "(NSAIDS) may be utilised following the operative interven-", "bbox": [58.0, 786.0, 385.0, 801.0]}, {"text": "tion. Outside of pregnancy, an increased bleeding risk has", "bbox": [58.0, 802.0, 387.0, 816.0]}, {"text": "been shown in individuals on therapeutic anticoagulation", "bbox": [58.0, 818.0, 387.0, 833.0]}, {"text": "for VTE when taking NSAIDS and appropriate alternatives", "bbox": [58.0, 834.0, 386.0, 849.0]}, {"text": "(oral or IV opioids) may be necessary. 62 Opioid PCA is often", "bbox": [58.0, 849.0, 386.0, 864.0]}, {"text": "necessary following a GA for a caesarean birth. 63", "bbox": [58.0, 866.0, 326.0, 881.0]}], "type": "Text", "position": 16}, {"raw_context": [{"text": "All postpartum individuals must leave hospital with a", "bbox": [407.0, 897.0, 735.0, 913.0]}, {"text": "plan for contraception, agreed with the individual and", "bbox": [406.0, 915.0, 735.0, 928.0]}, {"text": "the MDT. This should include consideration of the risks", "bbox": [406.0, 930.0, 735.0, 944.0]}, {"text": "of future pregnancy, need for reversibility, drug interac-", "bbox": [406.0, 946.0, 733.0, 961.0]}, {"text": "tions, compliance and cardiovascular risk from insertion.", "bbox": [406.0, 963.0, 733.0, 977.0]}], "type": "Text", "position": 17}, {"raw_context": [{"text": "Oxytocin is commonly utilised to improve and maintain", "bbox": [58.0, 946.0, 387.0, 961.0]}, {"text": "uterine tone in this cohort. Sublingual or rectal misoprostol,", "bbox": [58.0, 962.0, 385.0, 977.0]}], "type": "Text", "position": 18}, {"raw_context": [{"text": "capat) and in 5 has annot at so 8 [120540/81] no cardid online colivity, conduct glory and MaxV asso] · 15 ha 4 [1828140/111101/89/unco-cardid]", "bbox": [768.0, 146.0, 782.0, 586.0]}], "type": "Text", "position": 19}, {"raw_context": [{"text": "II mi solation VO case to solet and caradici online volitar no (anotabuse", "bbox": [768.0, 687.0, 781.0, 876.0]}], "type": "Text", "position": 20}, {"raw_context": [{"text": "obtrainings out will be", "bbox": [770.0, 896.0, 780.0, 947.0]}], "type": "Text", "position": 21}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/心血管/指南/2023 BSH 指南：机械心脏瓣膜妊娠个体抗凝管理(1).pdf", "page_num": 11}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": null, "type3": "无关文本#8#18#...Regional Anesthesia 61 12h)\n...delayed with shock.67像这样在.号或，号的开头或结尾和句子中间穿插出现的数字都是无关引用\n无关文本#19#21#可能是侧目栏的内容", "type4": "栏目混乱#1#18#标题和内容分离，内容互相穿插", "type5": null, "type6": null}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:42", "update_time": "2024-05-07 21:46:42"}
{"id": 1082642, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 738, "source_info": {"seq_id": "805e8711-3b5f-4fea-ae4c-a062a1622886", "title": null, "text": "【0】页码:9\n Level of agreement: 84.6% Patient assessment is key prior to consideration of any endoscopic intervention and the principles of 'first, do no harm' ( primum non nocere ) should be adhered to. This involves full evaluation of the indication and intended aim of the endoscopic procedure balanced with the physical status and cardiopulmonary reserve of the patient. Risk stratification is an essential component of a thorough preprocedure evaluation and to determine selected patients that should undergo formal pre-assessment. A systematic approach, including patient history and comorbidities and physical examination, should be balanced with the expectation of the patient. The pre-assesment also allows the identification of other higk-risk problems to alert the team that additional tests— for for example, pulmonary function test or echocardiogram, may be required prior to interventional endoscopy.\n\n【1】The requirement for anaesthetic assessment should be highlighted at the time of consideration of the endoscopic procedure.\n\n【2】Patient and procedural factors help to determine which patients should be considered for formal anaesthetic assessment. Procedures where deep sedation should be considered include those of longer duration and where complex therapeutic intervention is likely to be required.\n\n【3】Patients attending the pre-assessment should have prior knowledge and understanding of the indication and risks of the procedure, including that of sedation and types of sedation that can be reasonably offered safely. The discussion should be balanced, detailing sedated and unsedated endoscopy. Patients referred via the open access route would have received information via their general practitioner at time of referral, endoscopy information leaflets that are subsequently posted out and usually via a telephone nurse triage.\n\n【4】It is well documented that patients with a higher ASA class (online supplemental appendix 2) are at increased risk of complications during endoscopy. 35 A recent study of patients undergoing ERCP demonstrated a significantly higher risk of adverse events (particularly cardiopulmonary) in those with performance status 4 compared with performance 0-3. 565 Physiologic changes that occur with older age also have the ability to affect drug metabolism and pharmacokinetics. A recent nationwide population based study in South Korea identified that both sedation and older age were independent risk factors for cardiac and cerebrovascular events. Approximately 2.23% of study subjects who underwent diagnostic GI endoscopy (222.5/10 000 people) had cardiac and cerebrovascular adverse events within 14 days after endoscopy. 51 Similarly, another small study of 250 inpatients showed that the risk of lower respiratory infections and pneumonia was increased in older patients (>65 years) undergoing sedated endoscopy compared with age, gender-matched patients without endoscopic intervention. 59 During pre-assessment, the fasting instructions preprocedure (eg, 6 hours before upper GI endoscopy) should be highlighted. In certain cases, this fasting may need to be extended depending on patient characteristics (eg, for patients with gastroparesis).\n\n【5】9. In patients with obstructive sleep apnoea (OSA) and/or a high body mass index (BMI ≥ 35 kg/m 2 ) we recommend preassessment and enhanced periprocedural monitoring as these patients may be at an increased risk of periprocedural apnoea.\n\n【6】Grade of evidence: Low. Strength of recommendation: Strong.\n\n【7】Level of agreement: 100% Morbidly obese patients are at higher risk of respiratory complications for several reasons, including increased upper airway resistance with propensity for OSA and the potential for obesity–hypoventilation syndrome.\n\n【8】Sidhu R, et al. Gut 2023;0:1–27. doi:10.1136/gutjnl-2023-330396\n\n【9】 Hypoxia is the the most common sedation-related adverse event no matter which sedative agent is used. Hypoxaemia can occur in, and results from, the combination of airway obstruction by the endoscope, anaesthesia-induced upper airway collapse, and respiratory depression and lung compression because of intestinal gas insufflation which may be more problematic for upper GI and small bowel procedures.\n\n【10】Although meta analyses have not demonstrated an increased cardiopulmonary risk related to conscious sedation for patients with OSA, clinicians need to be aware of the potential risk of apnoea. 60 – 62 Patients at risk of OSA can be identified during pre-assessment\n\n【11】 by validated instrument tools such as the Berlin or STOP-BANG questionnaires as some cases may be undiagnosed. Parameters within the tool include male sex, age >50 years, hypertension, regular snoring, daytime somnolence, episodes of apnoea/ gasping, BMI ≥ 35 kg/m 2 and increased neck circumference. 63 – 66 Management of patients with OSA undergoing sedation requires understanding of different pharmacological options available, where minimal doses of hypnotics should be used and opioids carefully titrated. The questionnaire should be used as a tool to highlight to the endoscopy team those at higher risk. 67 This would enable the endoscopist to discuss the risk of sedation, during the process of consent. The information would also be useful in deciding whether a procedure could be done unsedated or if the dose of sedation requires titration or a referral for anaesthetic assessment, particularly for therapeutic or anticipated prolonged procedures. These patients require enhanced periprocedural monitoring. A suggested monitoring schedule includes observations (non-invasive blood pressure, oxygen saturations using pulse oximetry, respiratory rate and pulse every 10 min during the procedure) and monitoring continued for a minimum of 90–120 min after the procedure.\n\n【12】Pulse oximetry is the most commonly used technique to evaluate oxygenation levels owing to its simplicity and non-invasive design. Nonetheless, it does not provide additional information about the adequacy of ventilation or precise arterial oxygenation, particularly when arterial oxygen levels are extremely high or low.\n\n【13】The measurement of end-tidal carbon dioxide with capnography, is another non-invasive method for estimating PaCO,.\n\n【14】Bedside capnography can easily measure end-tidal carbon dioxide and detect apnoea. 68 Capnography has been shown to reduce the incidence of hypoxaemia and oxygen desaturations compared with pulse oximetry alone, in the emergency setting 69 70 and with procedural sedation for dental procedures. 71 In this highrisk group, we would strongly advise the use of capnography as an additional monitoring tool to reduce the risk of such adverse events.\n\n【15】The delivery of sedation is affected by a number of both procedural and patient-related factors, which include systemic comorbidities and airway-specific considerations, as detailed in table 2 .\n\n【16】Patients who have oropharyngeal abnormalities or who take large amount of pain medications are at risk. The Mallampati Classification is recognised as an important tool to help anaesthetists measure and categorise the amount of space in a patient's oral cavity. It helps to predict difficulty with any proposed endotracheal intubation. This classification is based on the structures visualised with maximal mouth opening and tongue protrusion in the sitting position. Patients with a higher Mallampati class (III–IV) have more difficult airway management and this should be assessed prior to consideration of complex endoscopic procedures requiring deeper levels of sedation.", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "Level of agreement: 84.6%", "bbox": [66.0, 61.0, 207.0, 75.0]}, {"text": "Patient assessment is key prior to consideration of any endo-", "bbox": [65.0, 75.0, 385.0, 90.0]}, {"text": "scopic intervention and the principles of 'first, do no harm'", "bbox": [53.0, 91.0, 385.0, 105.0]}, {"text": "( primum non nocere ) should be adhered to. This involves full", "bbox": [53.0, 105.0, 386.0, 120.0]}, {"text": "evaluation of the indication and intended aim of the endoscopic", "bbox": [53.0, 120.0, 387.0, 135.0]}, {"text": "procedure balanced with the physical status and cardiopulmonary", "bbox": [53.0, 135.0, 387.0, 150.0]}, {"text": "reserve of the patient. Risk stratification is an essential compo-", "bbox": [53.0, 150.0, 385.0, 164.0]}, {"text": "nent of a thorough preprocedure evaluation and to determine", "bbox": [53.0, 165.0, 387.0, 179.0]}, {"text": "selected patients that should undergo formal pre-assessment. A", "bbox": [53.0, 180.0, 387.0, 193.0]}, {"text": "systematic approach, including patient history and comorbidities", "bbox": [53.0, 194.0, 387.0, 207.0]}, {"text": "and physical examination, should be balanced with the expecta-", "bbox": [53.0, 208.0, 385.0, 222.0]}, {"text": "tion of the patient. The pre-assesment also allows the identifica-", "bbox": [53.0, 223.0, 385.0, 237.0]}, {"text": "tion of other higk-risk problems to alert the team that additional", "bbox": [53.0, 237.0, 387.0, 252.0]}, {"text": "tests— for for example, pulmonary function test or echocardio-", "bbox": [53.0, 253.0, 385.0, 266.0]}, {"text": "gram, may be required prior to interventional endoscopy.", "bbox": [53.0, 268.0, 351.0, 281.0]}, {"text": "The requirement for anaesthetic assessment should be high-", "bbox": [66.0, 282.0, 385.0, 295.0]}, {"text": "lighted at the time of consideration of the endoscopic procedure.", "bbox": [54.0, 297.0, 386.0, 310.0]}, {"text": "Patient and procedural factors help to determine which patients", "bbox": [53.0, 311.0, 387.0, 325.0]}, {"text": "should be considered for formal anaesthetic assessment. Proce-", "bbox": [53.0, 325.0, 385.0, 340.0]}, {"text": "dures where deep sedation should be considered include those", "bbox": [53.0, 341.0, 387.0, 354.0]}, {"text": "of longer duration and where complex therapeutic intervention", "bbox": [53.0, 355.0, 387.0, 369.0]}, {"text": "is likely to be required.", "bbox": [53.0, 370.0, 175.0, 383.0]}, {"text": "Patients attending the pre-assessment should have prior", "bbox": [64.0, 384.0, 386.0, 398.0]}, {"text": "knowledge and understanding of the indication and risks of", "bbox": [53.0, 399.0, 387.0, 413.0]}, {"text": "the procedure, including that of sedation and types of sedation", "bbox": [53.0, 413.0, 387.0, 428.0]}, {"text": "that can be reasonably offered safely. The discussion should be", "bbox": [53.0, 428.0, 387.0, 443.0]}, {"text": "balanced, detailing sedated and unsedated endoscopy. Patients", "bbox": [53.0, 443.0, 387.0, 458.0]}, {"text": "referred via the open access route would have received informa-", "bbox": [53.0, 458.0, 385.0, 472.0]}, {"text": "tion via their general practitioner at time of referral, endoscopy", "bbox": [53.0, 473.0, 386.0, 486.0]}, {"text": "information leaflets that are subsequently posted out and usually", "bbox": [53.0, 488.0, 386.0, 502.0]}, {"text": "via a telephone nurse triage.", "bbox": [53.0, 502.0, 202.0, 516.0]}, {"text": "It is well documented that patients with a higher ASA class", "bbox": [64.0, 516.0, 387.0, 531.0]}, {"text": "(online supplemental appendix 2) are at increased risk of compli-", "bbox": [53.0, 532.0, 386.0, 546.0]}, {"text": "cations during endoscopy. 35 A recent study of patients under-", "bbox": [53.0, 547.0, 386.0, 560.0]}, {"text": "going ERCP demonstrated a significantly higher risk of adverse", "bbox": [53.0, 561.0, 387.0, 574.0]}, {"text": "events (particularly cardiopulmonary) in those with performance", "bbox": [53.0, 575.0, 387.0, 589.0]}, {"text": "status 4 compared with performance 0-3. 565", "bbox": [53.0, 590.0, 283.0, 604.0]}, {"text": "Physiologic changes that occur with older age also have the", "bbox": [64.0, 604.0, 387.0, 619.0]}, {"text": "ability to affect drug metabolism and pharmacokinetics. A recent", "bbox": [53.0, 619.0, 387.0, 633.0]}, {"text": "nationwide population based study in South Korea identified", "bbox": [53.0, 635.0, 386.0, 648.0]}, {"text": "that both sedation and older age were independent risk factors", "bbox": [53.0, 649.0, 387.0, 662.0]}, {"text": "for cardiac and cerebrovascular events. Approximately 2.23%", "bbox": [53.0, 663.0, 387.0, 677.0]}, {"text": "of study subjects who underwent diagnostic GI endoscopy", "bbox": [53.0, 678.0, 387.0, 692.0]}, {"text": "(222.5/10 000 people) had cardiac and cerebrovascular adverse", "bbox": [53.0, 692.0, 387.0, 707.0]}, {"text": "events within 14 days after endoscopy. 51", "bbox": [53.0, 707.0, 258.0, 721.0]}, {"text": "Similarly, another small study of 250 inpatients showed that", "bbox": [64.0, 722.0, 387.0, 736.0]}, {"text": "the risk of lower respiratory infections and pneumonia was", "bbox": [53.0, 737.0, 387.0, 751.0]}, {"text": "increased in older patients (>65 years) undergoing sedated", "bbox": [53.0, 751.0, 387.0, 765.0]}, {"text": "endoscopy compared with age, gender-matched patients without", "bbox": [53.0, 766.0, 387.0, 781.0]}, {"text": "endoscopic intervention. 59 During pre-assessment, the fasting", "bbox": [53.0, 780.0, 386.0, 795.0]}, {"text": "instructions preprocedure (eg, 6 hours before upper GI endos-", "bbox": [53.0, 795.0, 385.0, 810.0]}, {"text": "copy) should be highlighted. In certain cases, this fasting may", "bbox": [53.0, 811.0, 386.0, 825.0]}, {"text": "need to be extended depending on patient characteristics (eg, for", "bbox": [53.0, 826.0, 385.0, 839.0]}, {"text": "patients with gastroparesis).", "bbox": [53.0, 840.0, 201.0, 853.0]}, {"text": "9. In patients with obstructive sleep apnoea (OSA) and/or a", "bbox": [64.0, 854.0, 387.0, 869.0]}, {"text": "high body mass index (BMI ≥ 35 kg/m 2 ) we recommend pre-", "bbox": [53.0, 869.0, 385.0, 884.0]}, {"text": "assessment and enhanced periprocedural monitoring as these", "bbox": [53.0, 883.0, 387.0, 898.0]}, {"text": "patients may be at an increased risk of periprocedural apnoea.", "bbox": [53.0, 898.0, 379.0, 912.0]}, {"text": "Grade of evidence: Low. Strength of recommendation: Strong.", "bbox": [64.0, 913.0, 384.0, 927.0]}, {"text": "Level of agreement: 100%", "bbox": [64.0, 928.0, 205.0, 941.0]}, {"text": "Morbidly obese patients are at higher risk of respiratory", "bbox": [65.0, 942.0, 386.0, 956.0]}, {"text": "complications for several reasons, including increased upper", "bbox": [53.0, 957.0, 386.0, 970.0]}, {"text": "airway resistance with propensity for OSA and the potential for", "bbox": [53.0, 971.0, 386.0, 986.0]}, {"text": "obesity–hypoventilation syndrome.", "bbox": [53.0, 986.0, 236.0, 1000.0]}, {"text": "Sidhu R, et al. Gut 2023;0:1–27. doi:10.1136/gutjnl-2023-330396", "bbox": [54.0, 1009.0, 317.0, 1022.0]}], "type": "Text", "position": 0}, {"raw_context": [{"text": "Hypoxia is the the most common sedation-related adverse", "bbox": [418.0, 60.0, 739.0, 75.0]}, {"text": "event no matter which sedative agent is used. Hypoxaemia can", "bbox": [406.0, 76.0, 740.0, 90.0]}, {"text": "occur in, and results from, the combination of airway obstruction", "bbox": [406.0, 91.0, 740.0, 105.0]}, {"text": "by the endoscope, anaesthesia-induced upper airway collapse,", "bbox": [406.0, 105.0, 740.0, 120.0]}, {"text": "and respiratory depression and lung compression because of", "bbox": [406.0, 120.0, 740.0, 135.0]}, {"text": "intestinal gas insufflation which may be more problematic for", "bbox": [406.0, 135.0, 740.0, 150.0]}, {"text": "upper GI and small bowel procedures.", "bbox": [406.0, 150.0, 607.0, 164.0]}, {"text": "Although meta analyses have not demonstrated an increased", "bbox": [418.0, 165.0, 741.0, 179.0]}, {"text": "cardiopulmonary risk related to conscious sedation for patients", "bbox": [406.0, 180.0, 740.0, 193.0]}, {"text": "with OSA, clinicians need to be aware of the potential risk of", "bbox": [406.0, 194.0, 740.0, 208.0]}, {"text": "apnoea. 60 – 62", "bbox": [408.0, 210.0, 471.0, 221.0]}, {"text": "Patients at risk of OSA can be identified during pre-assessment", "bbox": [418.0, 223.0, 741.0, 238.0]}], "type": "Text", "position": 2}, {"raw_context": [{"text": "by validated instrument tools such as the Berlin or STOP-BANG", "bbox": [406.0, 238.0, 740.0, 252.0]}, {"text": "questionnaires as some cases may be undiagnosed. Parameters", "bbox": [406.0, 253.0, 741.0, 266.0]}, {"text": "within the tool include male sex, age >50 years, hyperten-", "bbox": [406.0, 267.0, 739.0, 281.0]}, {"text": "sion, regular snoring, daytime somnolence, episodes of apnoea/", "bbox": [406.0, 282.0, 739.0, 295.0]}, {"text": "gasping, BMI ≥ 35 kg/m 2 and increased neck circumference. 63 – 66", "bbox": [406.0, 297.0, 739.0, 310.0]}, {"text": "Management of patients with OSA undergoing sedation", "bbox": [418.0, 311.0, 741.0, 326.0]}, {"text": "requires understanding of different pharmacological options", "bbox": [406.0, 325.0, 741.0, 340.0]}, {"text": "available, where minimal doses of hypnotics should be used and", "bbox": [406.0, 341.0, 741.0, 354.0]}, {"text": "opioids carefully titrated. The questionnaire should be used as", "bbox": [406.0, 355.0, 741.0, 369.0]}, {"text": "a tool to highlight to the endoscopy team those at higher risk. 67", "bbox": [406.0, 370.0, 735.0, 383.0]}, {"text": "This would enable the endoscopist to discuss the risk of seda-", "bbox": [418.0, 384.0, 739.0, 398.0]}, {"text": "tion, during the process of consent. The information would also", "bbox": [406.0, 399.0, 741.0, 413.0]}, {"text": "be useful in deciding whether a procedure could be done unse-", "bbox": [406.0, 413.0, 739.0, 428.0]}, {"text": "dated or if the dose of sedation requires titration or a referral", "bbox": [406.0, 428.0, 740.0, 443.0]}, {"text": "for anaesthetic assessment, particularly for therapeutic or antic-", "bbox": [406.0, 443.0, 739.0, 458.0]}, {"text": "ipated prolonged procedures. These patients require enhanced", "bbox": [406.0, 458.0, 740.0, 472.0]}, {"text": "periprocedural monitoring. A suggested monitoring schedule", "bbox": [406.0, 473.0, 740.0, 486.0]}, {"text": "includes observations (non-invasive blood pressure, oxygen", "bbox": [406.0, 488.0, 741.0, 502.0]}, {"text": "saturations using pulse oximetry, respiratory rate and pulse every", "bbox": [406.0, 502.0, 740.0, 517.0]}, {"text": "10 min during the procedure) and monitoring continued for a", "bbox": [408.0, 516.0, 741.0, 531.0]}, {"text": "minimum of 90–120 min after the procedure.", "bbox": [406.0, 531.0, 644.0, 545.0]}, {"text": "Pulse oximetry is the most commonly used technique to eval-", "bbox": [418.0, 547.0, 740.0, 560.0]}, {"text": "uate oxygenation levels owing to its simplicity and non-invasive", "bbox": [406.0, 561.0, 740.0, 574.0]}, {"text": "design. Nonetheless, it does not provide additional information", "bbox": [406.0, 574.0, 741.0, 590.0]}, {"text": "about the adequacy of ventilation or precise arterial oxygen-", "bbox": [406.0, 590.0, 739.0, 603.0]}, {"text": "ation, particularly when arterial oxygen levels are extremely", "bbox": [406.0, 604.0, 739.0, 619.0]}, {"text": "high or low.", "bbox": [406.0, 619.0, 471.0, 633.0]}, {"text": "The measurement of end-tidal carbon dioxide with capnog-", "bbox": [420.0, 634.0, 739.0, 648.0]}, {"text": "raphy, is another non-invasive method for estimating PaCO,.", "bbox": [406.0, 649.0, 739.0, 662.0]}, {"text": "Bedside capnography can easily measure end-tidal carbon dioxide", "bbox": [406.0, 663.0, 740.0, 677.0]}, {"text": "and detect apnoea. 68 Capnography has been shown to reduce the", "bbox": [406.0, 678.0, 740.0, 693.0]}, {"text": "incidence of hypoxaemia and oxygen desaturations compared", "bbox": [406.0, 692.0, 741.0, 707.0]}, {"text": "with pulse oximetry alone, in the emergency setting 69 70", "bbox": [406.0, 707.0, 716.0, 721.0]}, {"text": "and", "bbox": [714.0, 709.0, 741.0, 721.0]}, {"text": "with procedural sedation for dental procedures. 71 In this high-", "bbox": [406.0, 722.0, 739.0, 736.0]}, {"text": "risk group, we would strongly advise the use of capnography as", "bbox": [406.0, 737.0, 741.0, 751.0]}, {"text": "an additional monitoring tool to reduce the risk of such adverse", "bbox": [406.0, 751.0, 740.0, 766.0]}, {"text": "events.", "bbox": [406.0, 766.0, 445.0, 781.0]}, {"text": "The delivery of sedation is affected by a number of both proce-", "bbox": [418.0, 780.0, 739.0, 795.0]}, {"text": "dural and patient-related factors, which include systemic comor-", "bbox": [406.0, 795.0, 739.0, 810.0]}, {"text": "bidities and airway-specific considerations, as detailed in table 2 .", "bbox": [406.0, 811.0, 739.0, 825.0]}, {"text": "Patients who have oropharyngeal abnormalities or who take", "bbox": [418.0, 826.0, 740.0, 839.0]}, {"text": "large amount of pain medications are at risk. The Mallam-", "bbox": [406.0, 840.0, 739.0, 853.0]}, {"text": "pati Classification is recognised as an important tool to help", "bbox": [406.0, 854.0, 741.0, 868.0]}, {"text": "anaesthetists measure and categorise the amount of space in", "bbox": [406.0, 869.0, 741.0, 883.0]}, {"text": "a patient's oral cavity. It helps to predict difficulty with any", "bbox": [406.0, 883.0, 740.0, 898.0]}, {"text": "proposed endotracheal intubation. This classification is based", "bbox": [406.0, 898.0, 741.0, 913.0]}, {"text": "on the structures visualised with maximal mouth opening", "bbox": [406.0, 913.0, 741.0, 927.0]}, {"text": "and tongue protrusion in the sitting position. Patients with a", "bbox": [407.0, 928.0, 741.0, 941.0]}, {"text": "higher Mallampati class (III–IV) have more difficult airway", "bbox": [406.0, 942.0, 739.0, 956.0]}, {"text": "management and this should be assessed prior to consideration", "bbox": [406.0, 956.0, 741.0, 970.0]}, {"text": "of complex endoscopic procedures requiring deeper levels of", "bbox": [406.0, 971.0, 740.0, 986.0]}, {"text": "sedation.", "bbox": [407.0, 987.0, 457.0, 1000.0]}], "type": "Text", "position": 3}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/消化科/_2023 BSG指南：胃肠内窥镜检查中的镇静.pdf", "page_num": 9}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "缺少换行#0#0#Patient assessment is key另起一行\n缺少换行#4#4#Physiologic changes that另起一行\nSimilarly, another smal另起一行\n缺少换行#7#7#Morbidly obese patients另起一行\n缺少换行#10#10#Patients at risk of OSA另起一行\n多余换行#10#11#during pre-assessment和by validated instrument是一句话\n缺少换行#11#11#Patients at risk of OSA另起一行\nManagement of patients另起一行\nThis would enable the 另起一行", "type3": "无关文本#0#16# during endoscopy.55部分段落末尾，以及句末的数字问题无关噪声应用全文", "type4": null, "type5": null, "type6": "有用性#8#8#Sidhu R, et al. Gut 2023;0:1–27. doi:10.1136/gutjnl-2023-330396为页脚内容"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:42", "update_time": "2024-05-08 00:35:09"}
{"id": 1082641, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 738, "source_info": {"seq_id": "6f2178ab-4d32-4fda-8ea6-1cbb376eb68a", "title": null, "text": "【0】页码:12\n managers, administrators and finally, users. The governance of a sedation service should be a collaborative approach involving all those stakeholders with an investment in service delivery. 9 The objective of governance of the sedation service should be supporting continuous improvement through training, auditing and risk management including clinical incidents. 95 The structure of the governance and its delivery will be locally led by the sedation committee, with broad objectives determined, in part, by national organisations. While the evidence is low for the introduction of a sedation committee to oversee clinical governance, this approach is recommended by both European and North American Societies. 9 The sedation committee should also oversee local training in sedation. The standards for training in sedation can be determined by national organisations, with local committees providing individual accreditation and documentation for sedation practitioners. Training is discussed in more detail in the subsequent section.\n\n【1】The governance structure should provide clear lines of accountability from national organisations, local committees to individuals. The performance of sedation practitioners can be regularly assessed and compared with local and national standards with regards to outcomes and number of procedures performed. Within governance, mild and moderate sedation should be considered separately from deep sedation. The role of governance of sedation services is one element in a chain linking national organisations setting standards, and local provision of services. The role is an oversight of the safety of the service and to promote improvements in professional and clinical standards. 9 The training in sedation including deep sedation can consider six elements 97 Levels of sedation provided and procedural and patient risks.\n\n【2】.\n\n【3】Perioperative planning including pre-assessment and .\n\n【4】follow-up.\n\n【5】Drugs and therapeutics used in sedation.\n\n【6】.\n\n【7】Basic and intermediate and cardiopulmonary resuscitation, .\n\n【8】with an emphasis on airway rescue.\n\n【9】Monitoring and oxygen therapy.\n\n【10】.\n\n【11】.\n\n【12】Patient safety and safeguarding The gastroenterology team should provide regular data to assist the process of auditing outcomes within the broader aspect of delivery of endoscopy services, and this should feed into the regular endoscopy user group meetings: Named clinicians responsible for delivering sedation.\n\n【13】.\n\n【14】Training certificates in sedation and resuscitation certificates .\n\n【15】that are up to date.\n\n【16】Clinical activity, number of procedures, average doses of .\n\n【17】sedation and complication data.\n\n【18】Record of clinical incidents and discussion through morbidity .\n\n【19】and mortality meetings.\n\n【20】## Recovery And Discharge\n\n【21】\n 16. We recommend that monitoring of sedation should extend into the recovery period until the patient's conscious state has consistently returned to baseline. This requires sufficient staff trained in sedation, monitoring and the recognition of complications Grade of evidence: Very Low. Strength of recommendation: Strong.\n\n【22】Level of agreement: 100% Recovery from endoscopy and any required sedation is an important part of an endoscopy service and should be efficient, reliable and safe. 1 Safe recovery from sedation requires the same\n\n【23】 1212\n\n【24】 level of training and competency in monitoring and the recognition of complications as required in the endoscopy room itself.\n\n【25】Recovery from endoscopy can be divided into several stages 19 First stage: the return to baseline consciousness levels and function—that is, the patient is awake and protective reflexes have returned.\n\n【26】Second stage: covers the patient being made ready to leave the endoscopy unit. This will include information exchange, follow-up planning and discharge advice for both patient and carers. At this stage, the patient will be able to resume normal activities such as eating and drinking.\n\n【27】Late stage: occurs after the patient has left the department.\n\n【28】Monitoring of the effects of sedative drugs is most crucial within the first stage; however, complications arising from sedation or the procedure itself may only become apparent in the second or final stage. Protocols and practices need to ensure safety of the patient throughout all three stages.\n\n【29】The degree of monitoring established for the patient should be continued until baseline levels are reached. In first-stage recovery, the emphasis is on normalisation of physiology. 99 is possible that complications that arise from either sedation or the procedure itself become apparent only within this first-stage recovery period or subsequent second or late recovery.\n\n【30】Appropriate staffing for endoscopy recovery needs to be considered carefully for each individual endoscopy service. 1 Patients who receive moderate or deep sedation (or undergo high-risk procedures) may require one to one nursing during this period. Additionally, for an anaesthetic-led deep sedation list, two recovery nurses trained in resuscitation have been previously proposed. 3 This recommendation can be extended to cases where the sedationist, other than anaesthetic personnel, uses moderate or deep sedation. Staffing needs within a recovery area are determined by the case mix and degree of sedation but also by additional factors, including number of patients, gender mix, layout of the recovery area and availability of automatic or remote monitoring equipment. Decisions on the correct level of staffing within recovery and the endoscopy service overall are supported by the non-medical staffing BSG document. 7 17. We recommend that the endoscopist–sedationist should be responsible for ensuring the safe and complete recovery of the patient after endoscopy Grade of evidence: Very Low. Strength of recommendation: Strong.\n\n【31】Level of agreement: 100% The sedationist–endoscopist remains responsible for the patient beyond the endoscopy room and throughout the complete recovery period. 1 Clinical duties often mean that an endoscopist will leave the unit before the discharge of all the list's patients. Therefore, after the list is complete, endoscopists should ensure they are contactable and that the recovery staff are aware of their location. This responsibility can be transferred to a suitable deputy who is capable of the recognition and management of complications from either the procedure or sedation.\n\n【32】It is good practice on completion of an endoscopy list for the responsible endoscopist to visit the recovery area, to review progress, discuss any issues with recovery staff and therefore facilitate safe discharge of patients 100 (see below).\n\n【33】18. We recommend that patients should be formally assessed for suitability for discharge. This should be documented to demonstrate recovery from sedation and the absence of complications Grade of evidence: Very Low. Strength of recommendation: Strong.", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "managers, administrators and finally, users. The governance of", "bbox": [53.0, 60.0, 387.0, 75.0]}, {"text": "a sedation service should be a collaborative approach involving", "bbox": [53.0, 76.0, 385.0, 90.0]}, {"text": "all those stakeholders with an investment in service delivery. 9", "bbox": [53.0, 91.0, 380.0, 105.0]}, {"text": "The objective of governance of the sedation service should be", "bbox": [54.0, 106.0, 387.0, 120.0]}, {"text": "supporting continuous improvement through training, auditing", "bbox": [53.0, 120.0, 387.0, 135.0]}, {"text": "and risk management including clinical incidents. 95 The struc-", "bbox": [53.0, 136.0, 385.0, 150.0]}, {"text": "ture of the governance and its delivery will be locally led by the", "bbox": [53.0, 151.0, 387.0, 165.0]}, {"text": "sedation committee, with broad objectives determined, in part,", "bbox": [53.0, 165.0, 386.0, 180.0]}, {"text": "by national organisations. While the evidence is low for the", "bbox": [53.0, 180.0, 387.0, 195.0]}, {"text": "introduction of a sedation committee to oversee clinical gover-", "bbox": [53.0, 195.0, 385.0, 210.0]}, {"text": "nance, this approach is recommended by both European and", "bbox": [53.0, 210.0, 386.0, 225.0]}, {"text": "North American Societies. 9", "bbox": [53.0, 225.0, 192.0, 239.0]}, {"text": "The sedation committee should also oversee local training", "bbox": [66.0, 240.0, 386.0, 255.0]}, {"text": "in sedation. The standards for training in sedation can be", "bbox": [53.0, 255.0, 387.0, 270.0]}, {"text": "determined by national organisations, with local committees", "bbox": [53.0, 270.0, 387.0, 284.0]}, {"text": "providing individual accreditation and documentation for seda-", "bbox": [53.0, 285.0, 385.0, 299.0]}, {"text": "tion practitioners. Training is discussed in more detail in the", "bbox": [53.0, 300.0, 387.0, 313.0]}, {"text": "subsequent section.", "bbox": [53.0, 315.0, 156.0, 328.0]}, {"text": "The governance structure should provide clear lines of", "bbox": [66.0, 329.0, 387.0, 344.0]}, {"text": "accountability from national organisations, local committees", "bbox": [53.0, 344.0, 387.0, 359.0]}, {"text": "to individuals. The performance of sedation practitioners can", "bbox": [53.0, 360.0, 387.0, 373.0]}, {"text": "be regularly assessed and compared with local and national", "bbox": [53.0, 374.0, 387.0, 388.0]}, {"text": "standards with regards to outcomes and number of procedures", "bbox": [53.0, 389.0, 387.0, 403.0]}, {"text": "performed. Within governance, mild and moderate sedation", "bbox": [53.0, 404.0, 387.0, 418.0]}, {"text": "should be considered separately from deep sedation. The role of", "bbox": [53.0, 419.0, 387.0, 433.0]}, {"text": "governance of sedation services is one element in a chain linking", "bbox": [53.0, 434.0, 387.0, 447.0]}, {"text": "national organisations setting standards, and local provision of", "bbox": [53.0, 449.0, 387.0, 462.0]}, {"text": "services. The role is an oversight of the safety of the service and to", "bbox": [53.0, 463.0, 387.0, 478.0]}, {"text": "promote improvements in professional and clinical standards. 9", "bbox": [53.0, 479.0, 376.0, 493.0]}, {"text": "The training in sedation including deep sedation can consider", "bbox": [66.0, 494.0, 386.0, 507.0]}, {"text": "six elements 97", "bbox": [53.0, 508.0, 123.0, 521.0]}, {"text": "Levels of sedation provided and procedural and patient risks.", "bbox": [71.0, 522.0, 385.0, 537.0]}, {"text": ".", "bbox": [54.0, 524.0, 70.0, 534.0]}, {"text": "Perioperative planning including pre-assessment and", "bbox": [72.0, 537.0, 387.0, 552.0]}, {"text": ".", "bbox": [54.0, 539.0, 67.0, 549.0]}, {"text": "follow-up.", "bbox": [74.0, 553.0, 130.0, 566.0]}, {"text": "Drugs and therapeutics used in sedation.", "bbox": [73.0, 568.0, 286.0, 581.0]}, {"text": ".", "bbox": [54.0, 570.0, 66.0, 580.0]}, {"text": "Basic and intermediate and cardiopulmonary resuscitation,", "bbox": [73.0, 583.0, 386.0, 596.0]}, {"text": ".", "bbox": [54.0, 584.0, 66.0, 595.0]}, {"text": "with an emphasis on airway rescue.", "bbox": [74.0, 597.0, 259.0, 611.0]}, {"text": "Monitoring and oxygen therapy.", "bbox": [74.0, 612.0, 243.0, 626.0]}, {"text": ".", "bbox": [54.0, 614.0, 66.0, 625.0]}, {"text": ".", "bbox": [54.0, 628.0, 68.0, 638.0]}, {"text": "Patient safety and safeguarding", "bbox": [72.0, 627.0, 236.0, 641.0]}, {"text": "The gastroenterology team should provide regular data to", "bbox": [66.0, 640.0, 387.0, 655.0]}, {"text": "assist the process of auditing outcomes within the broader aspect", "bbox": [53.0, 656.0, 387.0, 670.0]}, {"text": "of delivery of endoscopy services, and this should feed into the", "bbox": [53.0, 671.0, 387.0, 686.0]}, {"text": "regular endoscopy user group meetings:", "bbox": [53.0, 686.0, 262.0, 701.0]}, {"text": "Named clinicians responsible for delivering sedation.", "bbox": [72.0, 701.0, 350.0, 715.0]}, {"text": ".", "bbox": [54.0, 703.0, 67.0, 714.0]}, {"text": "Training certificates in sedation and resuscitation certificates", "bbox": [74.0, 716.0, 387.0, 730.0]}, {"text": ".", "bbox": [54.0, 718.0, 66.0, 729.0]}, {"text": "that are up to date.", "bbox": [74.0, 731.0, 175.0, 745.0]}, {"text": "Clinical activity, number of procedures, average doses of", "bbox": [72.0, 744.0, 387.0, 762.0]}, {"text": ".", "bbox": [54.0, 748.0, 66.0, 759.0]}, {"text": "sedation and complication data.", "bbox": [74.0, 761.0, 240.0, 774.0]}, {"text": "Record of clinical incidents and discussion through morbidity", "bbox": [73.0, 775.0, 386.0, 789.0]}, {"text": ".", "bbox": [54.0, 777.0, 66.0, 788.0]}, {"text": "and mortality meetings.", "bbox": [74.0, 790.0, 199.0, 804.0]}], "type": "Text", "position": 1}, {"raw_context": [{"text": "Recovery and discharge", "bbox": [53.0, 822.0, 184.0, 835.0]}], "type": "Section-header", "position": 2}, {"raw_context": [{"text": "16. We recommend that monitoring of sedation should extend", "bbox": [54.0, 837.0, 387.0, 851.0]}, {"text": "into the recovery period until the patient's conscious state", "bbox": [53.0, 851.0, 386.0, 866.0]}, {"text": "has consistently returned to baseline. This requires sufficient", "bbox": [53.0, 866.0, 386.0, 880.0]}, {"text": "staff trained in sedation, monitoring and the recognition of", "bbox": [53.0, 881.0, 387.0, 895.0]}, {"text": "complications", "bbox": [54.0, 898.0, 130.0, 910.0]}, {"text": "Grade of evidence: Very Low. Strength of recommendation:", "bbox": [64.0, 911.0, 386.0, 926.0]}, {"text": "Strong.", "bbox": [54.0, 928.0, 92.0, 940.0]}, {"text": "Level of agreement: 100%", "bbox": [65.0, 942.0, 204.0, 955.0]}, {"text": "Recovery from endoscopy and any required sedation is an", "bbox": [65.0, 956.0, 387.0, 969.0]}, {"text": "important part of an endoscopy service and should be efficient,", "bbox": [53.0, 970.0, 386.0, 984.0]}, {"text": "reliable and safe. 1 Safe recovery from sedation requires the same", "bbox": [53.0, 985.0, 386.0, 1000.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "1212", "bbox": [54.0, 1010.0, 68.0, 1022.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": "level of training and competency in monitoring and the recogni-", "bbox": [406.0, 60.0, 739.0, 75.0]}, {"text": "tion of complications as required in the endoscopy room itself.", "bbox": [406.0, 76.0, 739.0, 90.0]}, {"text": "Recovery from endoscopy can be divided into several stages 19", "bbox": [407.0, 91.0, 724.0, 105.0]}, {"text": "First stage: the return to baseline consciousness levels and", "bbox": [418.0, 105.0, 740.0, 120.0]}, {"text": "function—that is, the patient is awake and protective reflexes", "bbox": [406.0, 120.0, 741.0, 135.0]}, {"text": "have returned.", "bbox": [406.0, 136.0, 485.0, 150.0]}, {"text": "Second stage: covers the patient being made ready to leave", "bbox": [418.0, 150.0, 740.0, 165.0]}, {"text": "the endoscopy unit. This will include information exchange,", "bbox": [406.0, 165.0, 739.0, 179.0]}, {"text": "follow-up planning and discharge advice for both patient and", "bbox": [406.0, 180.0, 741.0, 195.0]}, {"text": "carers. At this stage, the patient will be able to resume normal", "bbox": [406.0, 195.0, 741.0, 210.0]}, {"text": "activities such as eating and drinking.", "bbox": [407.0, 210.0, 599.0, 225.0]}, {"text": "Late stage: occurs after the patient has left the department.", "bbox": [418.0, 225.0, 725.0, 239.0]}, {"text": "Monitoring of the effects of sedative drugs is most crucial", "bbox": [418.0, 240.0, 740.0, 254.0]}, {"text": "within the first stage; however, complications arising from seda-", "bbox": [406.0, 255.0, 739.0, 269.0]}, {"text": "tion or the procedure itself may only become apparent in the", "bbox": [406.0, 270.0, 740.0, 284.0]}, {"text": "second or final stage. Protocols and practices need to ensure", "bbox": [406.0, 285.0, 740.0, 299.0]}, {"text": "safety of the patient throughout all three stages.", "bbox": [406.0, 300.0, 655.0, 313.0]}, {"text": "The degree of monitoring established for the patient should", "bbox": [419.0, 315.0, 741.0, 328.0]}, {"text": "be continued until baseline levels are reached. In first-stage", "bbox": [406.0, 329.0, 739.0, 344.0]}, {"text": "recovery, the emphasis is on normalisation of physiology. 99", "bbox": [406.0, 344.0, 740.0, 358.0]}, {"text": "is possible that complications that arise from either sedation or", "bbox": [406.0, 359.0, 740.0, 373.0]}, {"text": "the procedure itself become apparent only within this first-stage", "bbox": [406.0, 374.0, 739.0, 387.0]}, {"text": "recovery period or subsequent second or late recovery.", "bbox": [406.0, 390.0, 691.0, 402.0]}, {"text": "Appropriate staffing for endoscopy recovery needs to be", "bbox": [418.0, 403.0, 740.0, 418.0]}, {"text": "considered carefully for each individual endoscopy service. 1", "bbox": [406.0, 418.0, 738.0, 432.0]}, {"text": "Patients who receive moderate or deep sedation (or undergo", "bbox": [406.0, 433.0, 741.0, 446.0]}, {"text": "high-risk procedures) may require one to one nursing during", "bbox": [406.0, 448.0, 741.0, 461.0]}, {"text": "this period. Additionally, for an anaesthetic-led deep sedation", "bbox": [406.0, 462.0, 741.0, 475.0]}, {"text": "list, two recovery nurses trained in resuscitation have been", "bbox": [406.0, 476.0, 741.0, 490.0]}, {"text": "previously proposed. 3 This recommendation can be extended to", "bbox": [406.0, 491.0, 741.0, 505.0]}, {"text": "cases where the sedationist, other than anaesthetic personnel,", "bbox": [406.0, 505.0, 740.0, 520.0]}, {"text": "uses moderate or deep sedation. Staffing needs within a recovery", "bbox": [406.0, 520.0, 739.0, 534.0]}, {"text": "area are determined by the case mix and degree of sedation but", "bbox": [406.0, 535.0, 740.0, 549.0]}, {"text": "also by additional factors, including number of patients, gender", "bbox": [406.0, 550.0, 739.0, 563.0]}, {"text": "mix, layout of the recovery area and availability of automatic or", "bbox": [406.0, 564.0, 739.0, 578.0]}, {"text": "remote monitoring equipment. Decisions on the correct level of", "bbox": [406.0, 579.0, 741.0, 593.0]}, {"text": "staffing within recovery and the endoscopy service overall are", "bbox": [406.0, 593.0, 740.0, 608.0]}, {"text": "supported by the non-medical staffing BSG document. 7", "bbox": [406.0, 609.0, 692.0, 623.0]}, {"text": "17. We recommend that the endoscopist–sedationist should be", "bbox": [419.0, 623.0, 740.0, 638.0]}, {"text": "responsible for ensuring the safe and complete recovery of the", "bbox": [406.0, 638.0, 740.0, 652.0]}, {"text": "patient after endoscopy", "bbox": [406.0, 653.0, 531.0, 666.0]}, {"text": "Grade of evidence: Very Low. Strength of recommendation:", "bbox": [418.0, 667.0, 740.0, 682.0]}, {"text": "Strong.", "bbox": [407.0, 683.0, 445.0, 697.0]}, {"text": "Level of agreement: 100%", "bbox": [418.0, 696.0, 557.0, 711.0]}, {"text": "The sedationist–endoscopist remains responsible for the", "bbox": [419.0, 711.0, 740.0, 726.0]}, {"text": "patient beyond the endoscopy room and throughout the", "bbox": [406.0, 727.0, 740.0, 740.0]}, {"text": "complete recovery period. 1 Clinical duties often mean that an", "bbox": [406.0, 741.0, 741.0, 755.0]}, {"text": "endoscopist will leave the unit before the discharge of all the", "bbox": [406.0, 755.0, 741.0, 769.0]}, {"text": "list's patients. Therefore, after the list is complete, endoscopists", "bbox": [406.0, 770.0, 741.0, 785.0]}, {"text": "should ensure they are contactable and that the recovery staff are", "bbox": [406.0, 785.0, 741.0, 799.0]}, {"text": "aware of their location. This responsibility can be transferred to", "bbox": [406.0, 799.0, 741.0, 813.0]}, {"text": "a suitable deputy who is capable of the recognition and manage-", "bbox": [406.0, 814.0, 739.0, 828.0]}, {"text": "ment of complications from either the procedure or sedation.", "bbox": [406.0, 829.0, 739.0, 842.0]}, {"text": "It is good practice on completion of an endoscopy list for the", "bbox": [406.0, 842.0, 740.0, 858.0]}, {"text": "responsible endoscopist to visit the recovery area, to review", "bbox": [406.0, 858.0, 740.0, 872.0]}, {"text": "progress, discuss any issues with recovery staff and therefore", "bbox": [406.0, 872.0, 740.0, 887.0]}, {"text": "facilitate safe discharge of patients 100 (see below).", "bbox": [406.0, 886.0, 663.0, 901.0]}, {"text": "18. We recommend that patients should be formally assessed", "bbox": [420.0, 901.0, 740.0, 916.0]}, {"text": "for suitability for discharge. This should be documented", "bbox": [406.0, 917.0, 740.0, 931.0]}, {"text": "to demonstrate recovery from sedation and the absence of", "bbox": [406.0, 931.0, 740.0, 946.0]}, {"text": "complications", "bbox": [406.0, 946.0, 483.0, 960.0]}, {"text": "Grade of evidence: Very Low. Strength of recommendation:", "bbox": [418.0, 960.0, 739.0, 975.0]}, {"text": "Strong.", "bbox": [407.0, 977.0, 445.0, 990.0]}], "type": "Text", "position": 5}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/消化科/_2023 BSG指南：胃肠内窥镜检查中的镇静.pdf", "page_num": 12}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "缺少换行#0#0#The sedation committee另起一行\n缺少换行#1#1#The training in sedation另起一行\nLevels of sedation provided 另起一行\n多余换行#3#4#pre-assessment and 和follow-up.是一句话\n多余换行#7#8#diopulmonary resuscitation,和with an emphasis on airway rescue.是一句话\n缺少换行#12#12#The gastroenterology team另起一行\nNamed clinicians 另起一行\n序号格式不一致#2#19#.应该是►在句首\n多余换行#14#15#resuscitation certificates和that are up to date.是一句话\n多余换行#16#17# average doses of和sedation and complication data.是一句话\n多余换行#18#19#through morbidity和and mortality meetings.是一句话\n缺少换行#21#21#Grade of evidence: Very Low. 另起一行\n缺少换行#22#22#Recovery from endoscopy另起一行\n多余换行#22#23#requires the same和level of training and 是一句话\n缺少换行#25#25#First stage: the return另起一行\n缺少换行#30#30#17. We recommend that the另起一行\n Grade of evidence: Very Low另起一行\n缺少换行#31#31#The sedationist–endoscopist 另起一行\n缺少换行#33#33#Grade of evidence: Very Low另起一行", "type3": "无关文本#0#33#service delivery. 9 部分段落末尾，以及句末的数字问题无关噪声应用全文\n无关文本#23#23#1212", "type4": null, "type5": null, "type6": null}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:42", "update_time": "2024-05-08 01:01:55"}
{"id": 1082640, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 738, "source_info": {"seq_id": "b7345686-26fd-40bf-820b-aa78dabf6bcd", "title": null, "text": "【0】页码:13\n 70. Parikh NS, Salehi Omran S, Kamel H, Elkind MSV, Willey JZ. Smoking-cessation pharmacotherapy for patients with stroke and TIA: systematic review.\n\n【1】J Clin Neurosci. 2020;78:236-241. doi: 10.1016/j.jocn.2020.04.026 71. Wilcock AD, Zachrison KS, Schwamm LH, Uscher-Pines L, Zubizarreta JR, Mehrotra A. Trends among rural and urban Medicare beneficiaries in care delivery and outcomes for acute stroke and transient ischemic attacks, 2008– 2017. JAMA Neurol. 2020;77:863-871. doi: 10.1001/jamaneurol.2020.0770 172.\n\n【2】Duncan PW, Abbott RM, Rushing S, Johnson AM, Condon CN, Lycan SL, Lutz BJ, Cummings DM, Pastva AM, D'Agostino RB Jr, et al; COMPASS Investigative Team. COMPASS-CP: an electronic application to capture patient-reported outcomes to develop actionable stroke and transient ischemic attack care plans. Circ Cardiovasc Qual Outcomes . 2018;11:e004444.\n\n【3】doi: 10.1 161/CIRCOUTCOMES.117.004444 73. Faiz KW, Sundseth A, Thommessen B, Rønning OM. Patient knowledge on stroke risk factors, symptoms and treatment options. Vasc Health Risk Manag. 2018;14:37–40. doi: 10.2147/VHRM.S152173 74. Rothwell PM, Giles MF, Chandratheva A, Marquardt L, Geraghty O, Redgrave JN, Lovelock CE, Binney LE, Bull LM, Cuthbertson FC, et\n\n【4】 al; Early use of Existing Preventive Strategies for Stroke (EXPRESS) study. Effect of urgent treatment of transient ischaemic attack and minor stroke on early recurrent stroke (EXPRESS study): a prospective population-based sequential comparison. Lancet. 2007;370:1432-1442. doi: 10.1016/S0140-6736(07)61448-2 75. Edwards JD, Kapral MK, Fang J, Swartz RH. Long-term morbidity and mortality in patients without early complications after stroke or transient ischemic attack. CMAJ. 2017;189:E954-E961. doi: 10.1503/cmaj.\n\n【5】161142 76. Yan LL, Gong E, Gu W, Turner EL, Gallis JA, Zhou Y, Li Z, McCormack KE, Xu LQ, Bettger JP, et al. Effectiveness of a primary care-based integrated mobile health intervention for stroke management in rural China (SINEMA): a cluster-randomized controlled trial. PLoS Med. 2021;18:e1003582. doi: 10.1371/journal.pmed.1003582 77. Ögren J, Irewall AL, Söderström L, Mooe T. Long-term, telephone-based follow-up after stroke and TIA improves risk factors: 36-month results from the randomized controlled NAILED stroke risk factor trial. BMC Neurol.\n\n【6】2018;18:153. doi: 10.1186/s12883-018-1158-5\n\n【7】 STN3M3TATS JAOINIT\n      S3N113O1U9 ONA\n\n【8】 '9 cremeds-1 no cd gro slemnoleds/\\ qud mort bebeome", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "70. Parikh NS, Salehi Omran S, Kamel H, Elkind MSV, Willey JZ. Smoking-ces-", "bbox": [66.0, 76.0, 378.0, 89.0]}, {"text": "sation pharmacotherapy for patients with stroke and TIA: systematic review.", "bbox": [85.0, 89.0, 378.0, 101.0]}, {"text": "J Clin Neurosci. 2020;78:236-241. doi: 10.1016/j.jocn.2020.04.026", "bbox": [85.0, 101.0, 358.0, 113.0]}, {"text": "71. Wilcock AD, Zachrison KS, Schwamm LH, Uscher-Pines L, Zubizarreta JR,", "bbox": [66.0, 113.0, 380.0, 126.0]}, {"text": "Mehrotra A. Trends among rural and urban Medicare beneficiaries in care", "bbox": [85.0, 126.0, 379.0, 138.0]}, {"text": "delivery and outcomes for acute stroke and transient ischemic attacks, 2008–", "bbox": [86.0, 137.0, 378.0, 148.0]}, {"text": "2017. JAMA Neurol. 2020;77:863-871. doi: 10.1001/jamaneurol.2020.0770", "bbox": [85.0, 150.0, 375.0, 161.0]}, {"text": "172.", "bbox": [66.0, 161.0, 84.0, 173.0]}, {"text": "Duncan PW, Abbott RM, Rushing S, Johnson AM, Condon CN, Lycan SL,", "bbox": [83.0, 161.0, 378.0, 173.0]}, {"text": "Lutz BJ, Cummings DM, Pastva AM, D'Agostino RB Jr, et al; COMPASS", "bbox": [84.0, 174.0, 380.0, 186.0]}, {"text": "Investigative Team. COMPASS-CP: an electronic application to capture", "bbox": [85.0, 185.0, 380.0, 197.0]}, {"text": "patient-reported outcomes to develop actionable stroke and transient isch-", "bbox": [85.0, 198.0, 378.0, 210.0]}, {"text": "emic attack care plans. Circ Cardiovasc Qual Outcomes . 2018;11:e004444.", "bbox": [85.0, 209.0, 379.0, 221.0]}, {"text": "doi: 10.1 161/CIRCOUTCOMES.117.004444", "bbox": [85.0, 221.0, 267.0, 233.0]}, {"text": "73. Faiz KW, Sundseth A, Thommessen B, Rønning OM. Patient knowledge", "bbox": [66.0, 234.0, 379.0, 246.0]}, {"text": "on stroke risk factors, symptoms and treatment options. Vasc Health Risk", "bbox": [85.0, 246.0, 380.0, 257.0]}, {"text": "Manag. 2018;14:37–40. doi: 10.2147/VHRM.S152173", "bbox": [85.0, 258.0, 308.0, 269.0]}, {"text": "74. Rothwell PM, Giles MF, Chandratheva A, Marquardt L, Geraghty O,", "bbox": [68.0, 269.0, 379.0, 281.0]}, {"text": "Redgrave JN, Lovelock CE, Binney LE, Bull LM, Cuthbertson FC, et", "bbox": [85.0, 282.0, 380.0, 294.0]}], "type": "Text", "position": 2}, {"raw_context": [{"text": "al; Early use of Existing Preventive Strategies for Stroke (EXPRESS)", "bbox": [421.0, 76.0, 716.0, 89.0]}, {"text": "study. Effect of urgent treatment of transient ischaemic attack and minor", "bbox": [421.0, 90.0, 716.0, 100.0]}, {"text": "stroke on early recurrent stroke (EXPRESS study): a prospective popu-", "bbox": [421.0, 101.0, 716.0, 113.0]}, {"text": "lation-based sequential comparison. Lancet. 2007;370:1432-1442. doi:", "bbox": [421.0, 113.0, 716.0, 126.0]}, {"text": "10.1016/S0140-6736(07)61448-2", "bbox": [422.0, 126.0, 568.0, 137.0]}, {"text": "75. Edwards JD, Kapral MK, Fang J, Swartz RH. Long-term morbidity and", "bbox": [403.0, 137.0, 716.0, 149.0]}, {"text": "mortality in patients without early complications after stroke or transient", "bbox": [421.0, 150.0, 716.0, 162.0]}, {"text": "ischemic attack. CMAJ. 2017;189:E954-E961. doi: 10.1503/cmaj.", "bbox": [421.0, 161.0, 716.0, 173.0]}, {"text": "161142", "bbox": [422.0, 174.0, 459.0, 185.0]}, {"text": "76. Yan LL, Gong E, Gu W, Turner EL, Gallis JA, Zhou Y, Li Z, McCormack KE,", "bbox": [404.0, 185.0, 714.0, 197.0]}, {"text": "Xu LQ, Bettger JP, et al. Effectiveness of a primary care-based integrated", "bbox": [421.0, 198.0, 716.0, 210.0]}, {"text": "mobile health intervention for stroke management in rural China (SINEMA):", "bbox": [421.0, 209.0, 716.0, 221.0]}, {"text": "a cluster-randomized controlled trial. PLoS Med. 2021;18:e1003582. doi:", "bbox": [421.0, 221.0, 716.0, 234.0]}, {"text": "10.1371/journal.pmed.1003582", "bbox": [422.0, 234.0, 552.0, 246.0]}, {"text": "77. Ögren J, Irewall AL, Söderström L, Mooe T. Long-term, telephone-based", "bbox": [404.0, 245.0, 716.0, 258.0]}, {"text": "follow-up after stroke and TIA improves risk factors: 36-month results from", "bbox": [421.0, 258.0, 716.0, 269.0]}, {"text": "the randomized controlled NAILED stroke risk factor trial. BMC Neurol.", "bbox": [421.0, 269.0, 715.0, 281.0]}, {"text": "2018;18:153. doi: 10.1186/s12883-018-1158-5", "bbox": [421.0, 282.0, 622.0, 294.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "STN3M3TATS JAOINIT\n      S3N113O1U9 ONA", "bbox": [739.0, 101.0, 771.0, 205.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": "'9 cremeds-1 no cd gro slemnoleds/\\ qud mort bebeome", "bbox": [16.0, 549.0, 36.0, 778.0]}], "type": "Text", "position": 6}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/神经科/共识/2023 AHA科学声明：急诊科短暂性脑缺血发作的诊断、检查和风险降低(1).pdf", "page_num": 13}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": null, "type3": null, "type4": null, "type5": null, "type6": "信息有用性#0#8#参考文献"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:42", "update_time": "2024-05-07 17:50:43"}
{"id": 1082639, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 738, "source_info": {"seq_id": "cd4b7bc0-95c0-4c8e-9e7c-5e47471e4d83", "title": null, "text": "【0】页码:13\n [117] Wan X, Zheng D, Liu C, et al. A comparative study of two types of organ-sparing surgeries for early stage penile cancer: wide local excision vs partial penectomy. Eur J Surg Oncol 2018;44:1425–31 .\n\n【1】[118] Skeppner E, Windahl T, Andersson SO, Fugl-Meyer KS. Treatmentseeking, aspects of sexual activity and life satisfaction in men with laser-treated penile carcinoma. Eur Urol 2008;54:631–9.\n\n【2】[119] Croghan SM, Compton N, Daniels AE, Fitzgibbon L, Daly PJ, Cullen IM. Phallus preservation in penile cancer surgery: patient-reported aesthetic & functional outcomes. Urology 2021;152:60–6 .\n\n【3】[120] Opjordsmoen S, Fosså SD. Quality of life in patients treated for penile cancer. A follow-up study. Br J Urol 1994;74:652–7.\n\n【4】[121] Gulino G, Sasso F, Palermo G, et al. Sexual outcomes after organ potency-sparing surgery and glans reconstruction in patients with penile carcinoma. Indian J Urol 2013;29:119–23 .\n\n【5】 [122] Jakobsen JK, Jensen JB. DaPeCa-2: implementation of fast-track clinical pathways for penile cancer shortens waiting time and accelerates the diagnostic process—a comparative before-andafter study in a tertiary referral centre in Denmark. Scand J Urol 2016;50:80–7 .\n\n【6】[123] Jakobsen JK, Pettaway CA, Ayres B. Centralization and equitable care in rare urogenital malignancies: the case for penile cancer.\n\n【7】Eur Urol Focus 2021;7:924-8 .\n\n【8】[124] Ayres BE, Hounsome L, Alnajjar H, Sharma D, Verne J, Watkin NA.\n\n【9】Has centralisation of penile cancer services in the United Kingdom improved survival? Eur Urol Suppl 2014;13:e50 .", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "[117] Wan X, Zheng D, Liu C, et al. A comparative study of two types of", "bbox": [66.0, 87.0, 391.0, 101.0]}, {"text": "organ-sparing surgeries for early stage penile cancer: wide local", "bbox": [95.0, 99.0, 390.0, 112.0]}, {"text": "excision vs partial penectomy. Eur J Surg Oncol 2018;44:1425–31 .", "bbox": [95.0, 111.0, 391.0, 124.0]}, {"text": "[118] Skeppner E, Windahl T, Andersson SO, Fugl-Meyer KS. Treatment-", "bbox": [66.0, 123.0, 389.0, 137.0]}, {"text": "seeking, aspects of sexual activity and life satisfaction in men with", "bbox": [95.0, 135.0, 391.0, 147.0]}, {"text": "laser-treated penile carcinoma. Eur Urol 2008;54:631–9.", "bbox": [95.0, 148.0, 351.0, 159.0]}, {"text": "[119] Croghan SM, Compton N, Daniels AE, Fitzgibbon L, Daly PJ, Cullen", "bbox": [66.0, 158.0, 390.0, 172.0]}, {"text": "IM. Phallus preservation in penile cancer surgery: patient-reported", "bbox": [95.0, 170.0, 391.0, 184.0]}, {"text": "aesthetic & functional outcomes. Urology 2021;152:60–6 .", "bbox": [96.0, 184.0, 350.0, 195.0]}, {"text": "[120] Opjordsmoen S, Fosså SD. Quality of life in patients treated for", "bbox": [66.0, 194.0, 391.0, 207.0]}, {"text": "penile cancer. A follow-up study. Br J Urol 1994;74:652–7.", "bbox": [97.0, 208.0, 361.0, 220.0]}, {"text": "[121] Gulino G, Sasso F, Palermo G, et al. Sexual outcomes after organ", "bbox": [66.0, 218.0, 390.0, 232.0]}, {"text": "potency-sparing surgery and glans reconstruction in patients with", "bbox": [95.0, 231.0, 391.0, 243.0]}, {"text": "penile carcinoma. Indian J Urol 2013;29:119–23 .", "bbox": [95.0, 244.0, 316.0, 256.0]}], "type": "Text", "position": 2}, {"raw_context": [{"text": "[122] Jakobsen JK, Jensen JB. DaPeCa-2: implementation of fast-track", "bbox": [408.0, 87.0, 732.0, 101.0]}, {"text": "clinical pathways for penile cancer shortens waiting time and", "bbox": [438.0, 99.0, 732.0, 112.0]}, {"text": "accelerates the diagnostic process—a comparative before-and-", "bbox": [438.0, 111.0, 731.0, 123.0]}, {"text": "after study in a tertiary referral centre in Denmark. Scand J Urol", "bbox": [438.0, 124.0, 733.0, 136.0]}, {"text": "2016;50:80–7 .", "bbox": [439.0, 135.0, 506.0, 147.0]}, {"text": "[123] Jakobsen JK, Pettaway CA, Ayres B. Centralization and equitable", "bbox": [408.0, 145.0, 732.0, 160.0]}, {"text": "care in rare urogenital malignancies: the case for penile cancer.", "bbox": [437.0, 158.0, 732.0, 172.0]}, {"text": "Eur Urol Focus 2021;7:924-8 .", "bbox": [438.0, 171.0, 574.0, 183.0]}, {"text": "[124] Ayres BE, Hounsome L, Alnajjar H, Sharma D, Verne J, Watkin NA.", "bbox": [408.0, 182.0, 731.0, 195.0]}, {"text": "Has centralisation of penile cancer services in the United Kingdom", "bbox": [438.0, 195.0, 733.0, 207.0]}, {"text": "improved survival? Eur Urol Suppl 2014;13:e50 .", "bbox": [438.0, 208.0, 657.0, 220.0]}], "type": "Text", "position": 3}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/泌尿外科/2023 EAU／ASCO指南：阴茎癌（更新版）.pdf", "page_num": 13}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": null, "type3": null, "type4": null, "type5": null, "type6": "信息有用性#0#9#参考文献"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:42", "update_time": "2024-05-07 19:16:16"}
{"id": 1082638, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 738, "source_info": {"seq_id": "684bae55-d0b4-4b0e-acd5-0d7b6bd71a93", "title": null, "text": "【0】页码:14\n good practice of nuclear medicine and do not substitute for national and international legal or regulatory provisions\n\n【1】 Ethics approval This article does not contain any studies with human participants performed by any of the authors.\n\n【2】 Conflict of interest M. Weber holds/held consulting roles for Boston Scientific, Terumo, and Lilly. M. Lam is a consultant and received research support from Terumo and Boston Scientific. UMC Utrecht receives royalty payments from Terumo. C. Chiesa has been a consultant for Boston Scientific and TERUMO for guideline development and congress symposia. He received a research grant in 2018 from Boston Scientific.\n\n【3】P. Flamen reports advisory board and consultancy fees for SIRTEX.\n\n【4】L. Bodei reports non-remunerated consultant/speaker roles for AAA- Novartis, ITG, Iba, Clovis Oncology, and MTTI and research grants by AAA-Novartis. J E. Garin is a consultant for Boston, Scientific (1 grant for DOSI- SPHERE trial, personal fees). K. Herrmann reports personal fees from Bayer, personal fees and other from Sofie Biosciences, personal fees from SIRTEX, non-financial support from ABX, personal fees from Adacap, personal fees from Curium, personal fees from Endocyte, grants and personal fees from BTG, personal fees from IPSEN, personal fees from Siemens Healthineers, personal fees from GE Healthcare, personal fees from Amgen, personal fees from Novartis, personal fees from ymabs, personal fees from Aktis Oncology, personal fees from Theragnostics, and personal fees from Pharma15, outside the submitted work.\n\n【5】M. Konijnenberg, M. Lustre, M. Cremonesi, S. Gnesin, and T. Kracmerova have nothing to disclose.\n\n【6】 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not a permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ .\n\n【7】## References\n\n【8】\n 2.\n\n【9】 1.3.\n\n【10】 4.\n\n【11】 Cremonesi M, et al. Dosimetry in peptide radionuclide receptor therapy: a review. J Nucl Med. 2006;47(9):1467–75.\n\n【12】Salem R, Thurston KG. Radioembolization with (90)yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies part 1: technical and methodologic considerations. J Vasc Interv Radiol.\n\n【13】2006;17(8):1251–78.\n\n【14】Smits MLJ, et al., Holmium-166 radioembolization for the treatment of patients with liver metastases: design of the phase I HEPAR trial. Journal of Experimental & Clinical Cancer Research, 2010. 29.\n\n【15】Westcott MA, et al. The development, commercialization, and clinical context of yttrium-90 radiolabeled resin and glass microspheres. Adv Radiat Oncol. 2016;1(4):351–64.\n\n【16】 Pasciak AS, et al. Radioembolization and the dynamic role of 1. 5.\n\n【17】(90)Y PET/CT. Front Oncol. 2014;4:38.\n\n【18】Lau WY, Li AK. Therapeutic aspects of radioisotopes in hepa- 1.16.\n\n【19】tobiliary malignancy. Br J Surg. 1992;79(7):711.\n\n【20】Okuda K, et al. Natural history of hepatocellular carcinoma 7.\n\n【21】and prognosis in relation to treatment. Study of 850 patients.\n\n【22】Cancer. 1985;56(4):918–28.\n\n【23】Schafer DF, Sorrell MF. Hepatocellular carcinoma. Lancet.\n\n【24】1999;353(9160):1253–7.\n\n【25】Lambert B, et al. 99mTc-labelled macroaggregated albumin 19.\n\n【26】(MAA) scintigraphy for planning treatment with 90Y microspheres. Eur J Nucl Med Mol Imaging. 2010;37(12):2328–33.\n\n【27】10.\n\n【28】Leung WT, et al. Measuring lung shunting in hepatocellular carcinoma with intrahepatic-arterial technetium-99m macroaggregated albumin. J Nucl Med. 1994;35(1):70–3.\n\n【29】11.\n\n【30】Braat A, et al. Safety analysis of holmium-166 microsphere scout dose imaging during radioembolisation work-up: a cohort study.\n\n【31】Eur Radiol. 2018;28(3):920–8.\n\n【32】12.\n\n【33】Elschot M, et al. ((9)(9)m)Tc-MAA overestimates the absorbed dose to the lungs in radioembolization: a quantitative evaluation in patients treated with (1)(6)(6)Ho-microspheres. Eur J Nucl Med Mol Imaging. 2014;41(10):1965–75.\n\n【34】13.\n\n【35】Dancey JE, et al. Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres. J Nucl Med.\n\n【36】2000;41(10):1673–81.\n\n【37】14.\n\n【38】Geschwind JF, et al. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology. 2004;127(5 Suppl 1):S194–205.\n\n【39】15.\n\n【40】Goin JE, et al. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: a risk-stratification analysis. J Vasc Interv Radiol. 2005;16(2 Pt 1):195–203.\n\n【41】16.\n\n【42】Kennedy AS, et al. Pathologic response and microdosimetry of (90)Y microspheres in man: review of four explanted whole livers. Int J Radiat Oncol Biol Phys. 2004;60(5):1552–63.\n\n【43】17.\n\n【44】Lau WY, et al. Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres. Int J Radiat Oncol Biol Phys.\n\n【45】1998;40(3):583–92.\n\n【46】Sharma RA, et al. Radioembolization of liver metastases from 18.\n\n【47】colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol. 2007;25(9):1099–106.\n\n【48】Stubbs RS, Cannan RJ, Mitchell AW. Selective internal radia- 19.\n\n【49】tion therapy with 90yttrium microspheres for extensive colorectal liver metastases. J Gastrointest Surg. 2001;5(3):294–302.\n\n【50】20.\n\n【51】Hogberg J, et al. Increased absorbed liver dose in selective internal radiation therapy (SIRT) correlates with increased spherecluster frequency and absorbed dose inhomogeneity. EJNMMI Phys. 2015;2(1):10.\n\n【52】21.\n\n【53】Carr BI. Hepatic arterial 90Yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients. Liver Transpl. 2004;10(2 Suppl 1):S107–10.\n\n【54】22.\n\n【55】Garin E, et al. First experience of hepatic radioembolization using microspheres labelled with yttrium-90 (TheraSphere): practical aspects concerning its implementation. Eur J Nucl Med Mol Imaging. 2010;37(3):453–61.\n\n【56】23.\n\n【57】Sangro B, et al. Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2006;66(3):792–800.\n\n【58】24.\n\n【59】Van Hazel G, et al. Randomised phase 2 trial of SIR-spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/ leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol. 2004;88(2):78–85.", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "good practice of nuclear medicine and do not substitute for national", "bbox": [66.0, 73.0, 387.0, 87.0]}, {"text": "and international legal or regulatory provisions", "bbox": [66.0, 88.0, 284.0, 101.0]}], "type": "Text", "position": 0}, {"raw_context": [{"text": "Ethics approval This article does not contain any studies with human", "bbox": [64.0, 116.0, 387.0, 130.0]}, {"text": "participants performed by any of the authors.", "bbox": [66.0, 131.0, 274.0, 143.0]}], "type": "Text", "position": 1}, {"raw_context": [{"text": "Conflict of interest M. Weber holds/held consulting roles for Boston", "bbox": [65.0, 163.0, 386.0, 177.0]}, {"text": "Scientific, Terumo, and Lilly. M. Lam is a consultant and received", "bbox": [66.0, 178.0, 387.0, 191.0]}, {"text": "research support from Terumo and Boston Scientific. UMC Utrecht", "bbox": [66.0, 191.0, 387.0, 203.0]}, {"text": "receives royalty payments from Terumo. C. Chiesa has been a consult-", "bbox": [66.0, 204.0, 386.0, 217.0]}, {"text": "ant for Boston Scientific and TERUMO for guideline development and", "bbox": [66.0, 218.0, 387.0, 231.0]}, {"text": "congress symposia. He received a research grant in 2018 from Boston", "bbox": [66.0, 232.0, 387.0, 244.0]}, {"text": "Scientific.", "bbox": [66.0, 246.0, 114.0, 256.0]}, {"text": "P. Flamen reports advisory board and consultancy fees for SIRTEX.", "bbox": [66.0, 258.0, 386.0, 269.0]}, {"text": "L. Bodei reports non-remunerated consultant/speaker roles for AAA-", "bbox": [64.0, 270.0, 385.0, 283.0]}, {"text": "Novartis, ITG, Iba, Clovis Oncology, and MTTI and research grants", "bbox": [66.0, 285.0, 387.0, 298.0]}, {"text": "by AAA-Novartis. J", "bbox": [66.0, 299.0, 158.0, 311.0]}, {"text": "E. Garin is a consultant for Boston, Scientific (1 grant for DOSI-", "bbox": [65.0, 308.0, 386.0, 325.0]}, {"text": "SPHERE trial, personal fees). K. Herrmann reports personal fees from", "bbox": [66.0, 325.0, 387.0, 337.0]}, {"text": "Bayer, personal fees and other from Sofie Biosciences, personal fees", "bbox": [67.0, 338.0, 387.0, 350.0]}, {"text": "from SIRTEX, non-financial support from ABX, personal fees from", "bbox": [66.0, 352.0, 387.0, 363.0]}, {"text": "Adacap, personal fees from Curium, personal fees from Endocyte,", "bbox": [67.0, 365.0, 385.0, 378.0]}, {"text": "grants and personal fees from BTG, personal fees from IPSEN, per-", "bbox": [67.0, 378.0, 385.0, 390.0]}, {"text": "sonal fees from Siemens Healthineers, personal fees from GE Health-", "bbox": [66.0, 391.0, 386.0, 403.0]}, {"text": "care, personal fees from Amgen, personal fees from Novartis, personal", "bbox": [66.0, 404.0, 387.0, 417.0]}, {"text": "fees from ymabs, personal fees from Aktis Oncology, personal fees", "bbox": [66.0, 419.0, 387.0, 430.0]}, {"text": "from Theragnostics, and personal fees from Pharma15, outside the", "bbox": [66.0, 432.0, 387.0, 443.0]}, {"text": "submitted work.", "bbox": [66.0, 444.0, 142.0, 457.0]}, {"text": "M. Konijnenberg, M. Lustre, M. Cremonesi, S. Gnesin, and T. Krac-", "bbox": [66.0, 457.0, 386.0, 471.0]}, {"text": "merova have nothing to disclose.", "bbox": [67.0, 472.0, 217.0, 484.0]}], "type": "Text", "position": 2}, {"raw_context": [{"text": "Open Access This article is licensed under a Creative Commons Attri-", "bbox": [64.0, 500.0, 386.0, 513.0]}, {"text": "bution 4.0 International License, which permits use, sharing, adapta-", "bbox": [66.0, 515.0, 386.0, 527.0]}, {"text": "tion, distribution and reproduction in any medium or format, as long", "bbox": [66.0, 528.0, 387.0, 540.0]}, {"text": "as you give appropriate credit to the original author(s) and the source,", "bbox": [66.0, 542.0, 387.0, 553.0]}, {"text": "provide a link to the Creative Commons licence, and indicate if changes", "bbox": [66.0, 555.0, 387.0, 567.0]}, {"text": "were made. The images or other third party material in this article are", "bbox": [67.0, 568.0, 387.0, 581.0]}, {"text": "included in the article's Creative Commons licence, unless indicated", "bbox": [66.0, 582.0, 387.0, 593.0]}, {"text": "otherwise in a credit line to the material. If material is not included in", "bbox": [66.0, 594.0, 389.0, 607.0]}, {"text": "the article's Creative Commons licence and your intended use is not a", "bbox": [66.0, 609.0, 389.0, 620.0]}, {"text": "permitted by statutory regulation or exceeds the permitted use, you will", "bbox": [66.0, 622.0, 387.0, 634.0]}, {"text": "need to obtain permission directly from the copyright holder. To view a", "bbox": [66.0, 634.0, 387.0, 647.0]}, {"text": "copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ .", "bbox": [66.0, 648.0, 386.0, 660.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "References", "bbox": [66.0, 712.0, 146.0, 727.0]}], "type": "Section-header", "position": 4}, {"raw_context": [{"text": "2.", "bbox": [77.0, 771.0, 90.0, 783.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "1.3.", "bbox": [78.0, 837.0, 90.0, 850.0]}], "type": "Text", "position": 6}, {"raw_context": [{"text": "4.", "bbox": [77.0, 891.0, 89.0, 902.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "Cremonesi M, et al. Dosimetry in peptide radionuclide receptor", "bbox": [90.0, 743.0, 387.0, 757.0]}, {"text": "therapy: a review. J Nucl Med. 2006;47(9):1467–75.", "bbox": [91.0, 757.0, 342.0, 771.0]}, {"text": "Salem R, Thurston KG. Radioembolization with (90)yttrium", "bbox": [90.0, 771.0, 387.0, 783.0]}, {"text": "microspheres: a state-of-the-art brachytherapy treatment for", "bbox": [93.0, 784.0, 387.0, 797.0]}, {"text": "primary and secondary liver malignancies part 1: techni-", "bbox": [93.0, 799.0, 386.0, 811.0]}, {"text": "cal and methodologic considerations. J Vasc Interv Radiol.", "bbox": [93.0, 812.0, 387.0, 824.0]}, {"text": "2006;17(8):1251–78.", "bbox": [93.0, 825.0, 195.0, 836.0]}, {"text": "Smits MLJ, et al., Holmium-166 radioembolization for the", "bbox": [91.0, 837.0, 389.0, 850.0]}, {"text": "treatment of patients with liver metastases: design of the phase", "bbox": [93.0, 851.0, 389.0, 864.0]}, {"text": "I HEPAR trial. Journal of Experimental & Clinical Cancer", "bbox": [93.0, 865.0, 387.0, 877.0]}, {"text": "Research, 2010. 29.", "bbox": [93.0, 878.0, 188.0, 890.0]}, {"text": "Westcott MA, et al. The development, commercialization,", "bbox": [92.0, 891.0, 387.0, 903.0]}, {"text": "and clinical context of yttrium-90 radiolabeled resin and glass", "bbox": [93.0, 904.0, 387.0, 916.0]}, {"text": "microspheres. Adv Radiat Oncol. 2016;1(4):351–64.", "bbox": [93.0, 917.0, 343.0, 931.0]}], "type": "Text", "position": 8}, {"raw_context": [{"text": "Pasciak AS, et al. Radioembolization and the dynamic role of", "bbox": [431.0, 73.0, 727.0, 87.0]}, {"text": "1. 5.", "bbox": [416.0, 74.0, 430.0, 86.0]}, {"text": "(90)Y PET/CT. Front Oncol. 2014;4:38.", "bbox": [434.0, 88.0, 624.0, 100.0]}, {"text": "Lau WY, Li AK. Therapeutic aspects of radioisotopes in hepa-", "bbox": [432.0, 101.0, 725.0, 114.0]}, {"text": "1.16.", "bbox": [416.0, 102.0, 430.0, 113.0]}, {"text": "tobiliary malignancy. Br J Surg. 1992;79(7):711.", "bbox": [434.0, 114.0, 666.0, 127.0]}, {"text": "Okuda K, et al. Natural history of hepatocellular carcinoma", "bbox": [432.0, 128.0, 727.0, 139.0]}, {"text": "7.", "bbox": [418.0, 129.0, 430.0, 139.0]}, {"text": "and prognosis in relation to treatment. Study of 850 patients.", "bbox": [435.0, 141.0, 726.0, 153.0]}, {"text": "Cancer. 1985;56(4):918–28.", "bbox": [432.0, 154.0, 568.0, 167.0]}, {"text": "Schafer DF, Sorrell MF. Hepatocellular carcinoma. Lancet.", "bbox": [432.0, 165.0, 727.0, 182.0]}, {"text": "1999;353(9160):1253–7.", "bbox": [435.0, 181.0, 552.0, 193.0]}, {"text": "Lambert B, et al. 99mTc-labelled macroaggregated albumin", "bbox": [432.0, 193.0, 727.0, 206.0]}, {"text": "19.", "bbox": [416.0, 195.0, 429.0, 205.0]}, {"text": "(MAA) scintigraphy for planning treatment with 90Y micro-", "bbox": [432.0, 207.0, 726.0, 220.0]}, {"text": "spheres. Eur J Nucl Med Mol Imaging. 2010;37(12):2328–33.", "bbox": [434.0, 222.0, 726.0, 234.0]}, {"text": "10.", "bbox": [413.0, 234.0, 430.0, 246.0]}, {"text": "Leung WT, et al. Measuring lung shunting in hepatocellular", "bbox": [432.0, 234.0, 727.0, 247.0]}, {"text": "carcinoma with intrahepatic-arterial technetium-99m macroag-", "bbox": [433.0, 247.0, 725.0, 260.0]}, {"text": "gregated albumin. J Nucl Med. 1994;35(1):70–3.", "bbox": [434.0, 261.0, 659.0, 273.0]}, {"text": "11.", "bbox": [412.0, 274.0, 428.0, 286.0]}, {"text": "Braat A, et al. Safety analysis of holmium-166 microsphere scout", "bbox": [433.0, 275.0, 726.0, 286.0]}, {"text": "dose imaging during radioembolisation work-up: a cohort study.", "bbox": [434.0, 289.0, 726.0, 300.0]}, {"text": "Eur Radiol. 2018;28(3):920–8.", "bbox": [434.0, 301.0, 576.0, 313.0]}, {"text": "12.", "bbox": [413.0, 314.0, 429.0, 326.0]}, {"text": "Elschot M, et al. ((9)(9)m)Tc-MAA overestimates the absorbed", "bbox": [432.0, 314.0, 727.0, 326.0]}, {"text": "dose to the lungs in radioembolization: a quantitative evaluation", "bbox": [433.0, 327.0, 727.0, 340.0]}, {"text": "in patients treated with (1)(6)(6)Ho-microspheres. Eur J Nucl", "bbox": [434.0, 341.0, 727.0, 354.0]}, {"text": "Med Mol Imaging. 2014;41(10):1965–75.", "bbox": [434.0, 356.0, 626.0, 367.0]}, {"text": "13.", "bbox": [413.0, 368.0, 430.0, 380.0]}, {"text": "Dancey JE, et al. Treatment of nonresectable hepatocellular", "bbox": [432.0, 368.0, 727.0, 380.0]}, {"text": "carcinoma with intrahepatic 90Y-microspheres. J Nucl Med.", "bbox": [432.0, 381.0, 727.0, 393.0]}, {"text": "2000;41(10):1673–81.", "bbox": [433.0, 395.0, 536.0, 407.0]}, {"text": "14.", "bbox": [413.0, 408.0, 430.0, 420.0]}, {"text": "Geschwind JF, et al. Yttrium-90 microspheres for the treatment", "bbox": [432.0, 407.0, 727.0, 421.0]}, {"text": "of hepatocellular carcinoma. Gastroenterology. 2004;127(5", "bbox": [433.0, 421.0, 727.0, 434.0]}, {"text": "Suppl 1):S194–205.", "bbox": [433.0, 435.0, 529.0, 446.0]}, {"text": "15.", "bbox": [412.0, 448.0, 430.0, 459.0]}, {"text": "Goin JE, et al. Treatment of unresectable hepatocellular carci-", "bbox": [431.0, 448.0, 726.0, 459.0]}, {"text": "noma with intrahepatic yttrium 90 microspheres: a risk-stratifi-", "bbox": [433.0, 461.0, 726.0, 473.0]}, {"text": "cation analysis. J Vasc Interv Radiol. 2005;16(2 Pt 1):195–203.", "bbox": [433.0, 475.0, 725.0, 487.0]}, {"text": "16.", "bbox": [412.0, 488.0, 429.0, 500.0]}, {"text": "Kennedy AS, et al. Pathologic response and microdosimetry of", "bbox": [433.0, 488.0, 727.0, 501.0]}, {"text": "(90)Y microspheres in man: review of four explanted whole liv-", "bbox": [433.0, 501.0, 726.0, 513.0]}, {"text": "ers. Int J Radiat Oncol Biol Phys. 2004;60(5):1552–63.", "bbox": [433.0, 515.0, 688.0, 526.0]}, {"text": "17.", "bbox": [412.0, 528.0, 428.0, 539.0]}, {"text": "Lau WY, et al. Selective internal radiation therapy for non-", "bbox": [432.0, 528.0, 725.0, 540.0]}, {"text": "resectable hepatocellular carcinoma with intraarterial infu-", "bbox": [433.0, 542.0, 726.0, 553.0]}, {"text": "sion of 90yttrium microspheres. Int J Radiat Oncol Biol Phys.", "bbox": [434.0, 555.0, 726.0, 567.0]}, {"text": "1998;40(3):583–92.", "bbox": [435.0, 567.0, 527.0, 580.0]}, {"text": "Sharma RA, et al. Radioembolization of liver metastases from", "bbox": [432.0, 580.0, 727.0, 593.0]}, {"text": "18.", "bbox": [413.0, 582.0, 429.0, 592.0]}, {"text": "colorectal cancer using yttrium-90 microspheres with concomi-", "bbox": [432.0, 594.0, 725.0, 607.0]}, {"text": "tant systemic oxaliplatin, fluorouracil, and leucovorin chemo-", "bbox": [433.0, 609.0, 726.0, 620.0]}, {"text": "therapy. J Clin Oncol. 2007;25(9):1099–106.", "bbox": [433.0, 623.0, 640.0, 633.0]}, {"text": "Stubbs RS, Cannan RJ, Mitchell AW. Selective internal radia-", "bbox": [432.0, 634.0, 726.0, 647.0]}, {"text": "19.", "bbox": [413.0, 635.0, 430.0, 647.0]}, {"text": "tion therapy with 90yttrium microspheres for extensive colorectal", "bbox": [433.0, 648.0, 727.0, 660.0]}, {"text": "liver metastases. J Gastrointest Surg. 2001;5(3):294–302.", "bbox": [434.0, 662.0, 696.0, 674.0]}, {"text": "20.", "bbox": [412.0, 675.0, 430.0, 687.0]}, {"text": "Hogberg J, et al. Increased absorbed liver dose in selective inter-", "bbox": [432.0, 675.0, 727.0, 687.0]}, {"text": "nal radiation therapy (SIRT) correlates with increased sphere-", "bbox": [433.0, 688.0, 726.0, 700.0]}, {"text": "cluster frequency and absorbed dose inhomogeneity. EJNMMI", "bbox": [433.0, 701.0, 727.0, 713.0]}, {"text": "Phys. 2015;2(1):10.", "bbox": [433.0, 715.0, 526.0, 727.0]}, {"text": "21.", "bbox": [411.0, 728.0, 430.0, 740.0]}, {"text": "Carr BI. Hepatic arterial 90Yttrium glass microspheres (Theras-", "bbox": [431.0, 727.0, 725.0, 741.0]}, {"text": "phere) for unresectable hepatocellular carcinoma: interim safety", "bbox": [433.0, 742.0, 727.0, 754.0]}, {"text": "and survival data on 65 patients. Liver Transpl. 2004;10(2 Suppl", "bbox": [434.0, 755.0, 727.0, 768.0]}, {"text": "1):S107–10.", "bbox": [435.0, 768.0, 492.0, 779.0]}, {"text": "22.", "bbox": [412.0, 780.0, 428.0, 793.0]}, {"text": "Garin E, et al. First experience of hepatic radioembolization", "bbox": [432.0, 780.0, 727.0, 793.0]}, {"text": "using microspheres labelled with yttrium-90 (TheraSphere):", "bbox": [433.0, 795.0, 726.0, 807.0]}, {"text": "practical aspects concerning its implementation. Eur J Nucl Med", "bbox": [435.0, 809.0, 727.0, 821.0]}, {"text": "Mol Imaging. 2010;37(3):453–61.", "bbox": [434.0, 821.0, 593.0, 833.0]}, {"text": "23.", "bbox": [412.0, 835.0, 428.0, 846.0]}, {"text": "Sangro B, et al. Radioembolization using 90Y-resin microspheres", "bbox": [433.0, 835.0, 727.0, 846.0]}, {"text": "for patients with advanced hepatocellular carcinoma. Int J Radiat", "bbox": [434.0, 848.0, 727.0, 860.0]}, {"text": "Oncol Biol Phys. 2006;66(3):792–800.", "bbox": [433.0, 862.0, 613.0, 873.0]}, {"text": "24.", "bbox": [412.0, 875.0, 428.0, 887.0]}, {"text": "Van Hazel G, et al. Randomised phase 2 trial of SIR-spheres", "bbox": [433.0, 875.0, 727.0, 887.0]}, {"text": "plus fluorouracil/leucovorin chemotherapy versus fluorouracil/", "bbox": [434.0, 887.0, 727.0, 901.0]}, {"text": "leucovorin chemotherapy alone in advanced colorectal cancer. J", "bbox": [434.0, 902.0, 727.0, 913.0]}, {"text": "Surg Oncol. 2004;88(2):78–85.", "bbox": [434.0, 915.0, 578.0, 927.0]}], "type": "Text", "position": 11}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2022】全科室最全临床指南+专家共识（最全版）/2022全科室临床指南/肿瘤科/EANM：动脉内放射性化合物治疗肝癌和转移性肝癌指南（2022）(1).pdf", "page_num": 14}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "缺少换行#4#4#E. Garin is a consultant for...另起一行", "type3": "无关文本#4#4#by AAA-Novartis. J 后面的 J ", "type4": null, "type5": null, "type6": "有用性#0#6#资金披露和下载地址等内容\n有用性#7#59#参考文献的内容"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:42", "update_time": "2024-05-08 00:18:08"}
{"id": 1082637, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 738, "source_info": {"seq_id": "44418045-fc52-455f-ac81-475dbf352de2", "title": null, "text": "【0】页码:13\n Level of agreement: 100% Standards and guidance for sedation from the AoMRC recommend discharge criteria as follows 1 :- 1. The patient has returned to their baseline level of consciousness.\n\n【1】Vital signs are within normal limits for that patient.\n\n【2】19. 2.\n\n【3】3. Respiratory status is not compromised.\n\n【4】4. Pain and discomfort have been addressed.\n\n【5】Patients meeting discharge criteria following sedation should be discharged into the care of a suitable adult (18 years and above). This carer needs to be available to support the patient for 24 hours after the procedure. 99 Verbal and written instructions should be provided that are appropriate for both the sedation received, and procedure performed. This evaluation of recovery and readiness for discharge should be recorded in endoscopy documentation and retained in the patient record. 1 19. We recommend that patients receiving sedation and/ or analgesia for endoscopy should not drive a vehicle or ride a bicycle, operate machinery, sign legal documents or make important decisions, or drink alcohol for 24 hours after the procedure Grade of evidence: Very Low. Strength of recommendation: Strong.\n\n【6】Level of agreement: 92.3% Many endoscopy procedures occur with minimal or moderate sedation where the patient remains conscious and communicative both during the test and after the procedure. However, owing to the ongoing effects of the sedative drugs, cognition and therefore critical decision-making can be altered and unpredictable.\n\n【7】This may not be appreciated by patients, carers and family. The British National Formulary (BNF) 101 clearly states that patients who have received intravenous benzodiazepines should not drive a car, operate machinery, sign legal documents or drink alcohol for 24 hours. This list can extend to anything which requires critical decision-making and can have an adverse impact on the patient or others in their care, such as children. While there is no evidence to make recommendations against flying, patients need to be aware of being in a position where there is no immediate prospect of medical support being available.\n\n【8】This should include all forms of intravenous sedation/analgesia (eg, opiates) which establishes these restrictions as precautionary, therefore straightforward and easy to follow for carers and relatives. It is in line with the RCoA advice for caring for someone recovering from a general anaesthetic or sedation. 95 Treating all forms of intravenous sedation equally with respect to restrictions during recovery prevents trade-offs in discussions with patients about the nature and choice of sedative in order to prioritise patient comfort and safety.\n\n【9】20. We recommend that all patients and any carers providing support after the procedure should receive clear instructions and advice for late recovery, in verbal and written form that includes contact information Grade of evidence: Very Low. Strength of recommendation: Strong.\n\n【10】Level of agreement: 100% Owing to the alteration of critical decision-making secondary to sedation and or the physiological effects of endoscopy itself, patients may require additional support following discharge— that is, late recovery. Clear advice in an appropriate form must be given to responsible third parties, carers and families about how to look after patients in the late recovery period. 1 102 This includes both verbal discussion and written information that must be supported by including patient information leaflets and\n\n【11】 discharge advice sheets. An example document is provided in the online supplemental appendix. 102 103 This should include information on where to seek advice on postprocedure complications, when and how to contact the endoscopy department, or alternate forms of support both in and out of working hours.\n\n【12】One common alternative to intravenous sedation is to use nitrous oxide to provide anxiolysis and analgesia to the patient during the procedure. 104 The advantages of nitrous oxide over traditional conscious sedation are that patients are deemed fit to drive 30 min after their procedure and do not require a responsible adult to accompany them home. The recovery time is also reduced, having a positive impact on the endoscopy recovery for safe and efficient discharge.\n\n【13】Entonox is a 50:50 mix of oxygen and nitrous oxide, 105 and the latter is now recognised as an important potent greenhouse gas. Therefore, its clinical efficacy must be balanced against its environmental impact. This balance should be understood by both staff and patients to support informed choice of this agent when used as an alternative to traditional sedation. This is discussed further in the BGS/JAG position statement on green endoscopy. 106\n\n【14】## Complications Related To Sedation And Reversal Agents\n\n【15】\n Sedation-related complications during GI endoscopy are mostly cardiopulmonary in nature: hypoxaemia, hypotension, aspiration pneumonia, arrhythmia and vasovagal syncope. 107 – 111 Comparing the rates of sedation-related complications can be challenging owing to differing definitions of 'adverse event' across studies, varying inclusion criteria for patients and procedures, and different sedation regimens. Based on findings from studies looking at sedation-related complication rates from more than 100 000 endoscopic examinations, the complication rate is estimated as between 0.01% and 0.9%, with a sedation-related mortality rate of 0.0006% to 0.00896. 107 109 111 The ProSed2 study, a multicentre German prospective observational study included more than 350 000 endoscopies performed under sedation (81% propofol-based sedation and 6.5% midazolam alone). The major sedation-related complication rate (defined as need for intensive care support, resuscitation or death) was 0.01% and the minor (defined as increased restlessness, oxygen saturation < 90% for > 10 s, drop in blood pressure by more than 20%, drop in heart rate > 20%, tachycardia > 100/min) sedation-related complication rate was 0.3%. 1 Independent risk factors associated with complications included, but were not limited to, ASA score >2, prolonged procedure time and therapeutic endoscopy. 107 A previous metaanalysis showed no difference in complication rates between in propofol-based and benzodiazepine-based sedation with opiate. 108 The complication rate for midazolam-based sedation during GI endoscopy is estimated to be 0.38%, most commonly due to hypoxaemia (40.7% of all complications). 112 Different reported thresholds have been used for defining respiratory depression and other associated abnormal physiological parameters (eg, oxygen desaturation, changes in heart rate, arterial CO2 partial pressure). 113 – 117 For these guidelines, we define respiratory depression secondary to opiates or benzodiazepines as a reduced respiratory rate < 10 breaths/min, which may or may not lead to an oxygen desaturation to < 90% , elevated arterial CO, partial pressure > 6.66 kPa or reduced levels of consciousness. 118 In instances of respiratory depression or hypoxaemia during or shortly after administration of conscious sedation, supportive 1313", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "Level of agreement: 100%", "bbox": [66.0, 60.0, 205.0, 75.0]}, {"text": "Standards and guidance for sedation from the AoMRC recom-", "bbox": [65.0, 75.0, 385.0, 90.0]}, {"text": "mend discharge criteria as follows 1 :-", "bbox": [53.0, 91.0, 244.0, 105.0]}, {"text": "1. The patient has returned to their baseline level of", "bbox": [54.0, 106.0, 387.0, 119.0]}, {"text": "consciousness.", "bbox": [72.0, 121.0, 150.0, 135.0]}, {"text": "Vital signs are within normal limits for that patient.", "bbox": [71.0, 135.0, 340.0, 150.0]}, {"text": "19. 2.", "bbox": [54.0, 136.0, 69.0, 149.0]}, {"text": "3. Respiratory status is not compromised.", "bbox": [53.0, 150.0, 276.0, 164.0]}, {"text": "4. Pain and discomfort have been addressed.", "bbox": [53.0, 164.0, 290.0, 179.0]}, {"text": "Patients meeting discharge criteria following sedation should", "bbox": [65.0, 180.0, 386.0, 193.0]}, {"text": "be discharged into the care of a suitable adult (18 years and", "bbox": [53.0, 194.0, 386.0, 207.0]}, {"text": "above). This carer needs to be available to support the patient for", "bbox": [53.0, 209.0, 386.0, 223.0]}, {"text": "24 hours after the procedure. 99 Verbal and written instructions", "bbox": [53.0, 222.0, 387.0, 238.0]}, {"text": "should be provided that are appropriate for both the sedation", "bbox": [53.0, 237.0, 387.0, 252.0]}, {"text": "received, and procedure performed. This evaluation of recovery", "bbox": [53.0, 253.0, 386.0, 267.0]}, {"text": "and readiness for discharge should be recorded in endoscopy", "bbox": [53.0, 268.0, 385.0, 281.0]}, {"text": "documentation and retained in the patient record. 1", "bbox": [53.0, 282.0, 316.0, 295.0]}, {"text": "19. We recommend that patients receiving sedation and/", "bbox": [66.0, 297.0, 385.0, 311.0]}, {"text": "or analgesia for endoscopy should not drive a vehicle or ride", "bbox": [53.0, 311.0, 387.0, 325.0]}, {"text": "a bicycle, operate machinery, sign legal documents or make", "bbox": [53.0, 325.0, 387.0, 340.0]}, {"text": "important decisions, or drink alcohol for 24 hours after the", "bbox": [53.0, 340.0, 387.0, 354.0]}, {"text": "procedure", "bbox": [54.0, 357.0, 109.0, 369.0]}, {"text": "Grade of evidence: Very Low. Strength of recommendation:", "bbox": [64.0, 369.0, 385.0, 383.0]}, {"text": "Strong.", "bbox": [54.0, 384.0, 92.0, 399.0]}, {"text": "Level of agreement: 92.3%", "bbox": [66.0, 399.0, 207.0, 413.0]}, {"text": "Many endoscopy procedures occur with minimal or moderate", "bbox": [65.0, 413.0, 387.0, 428.0]}, {"text": "sedation where the patient remains conscious and communicative", "bbox": [53.0, 428.0, 386.0, 443.0]}, {"text": "both during the test and after the procedure. However, owing to", "bbox": [53.0, 443.0, 387.0, 458.0]}, {"text": "the ongoing effects of the sedative drugs, cognition and there-", "bbox": [53.0, 458.0, 385.0, 472.0]}, {"text": "fore critical decision-making can be altered and unpredictable.", "bbox": [53.0, 473.0, 385.0, 486.0]}, {"text": "This may not be appreciated by patients, carers and family. The", "bbox": [54.0, 486.0, 387.0, 503.0]}, {"text": "British National Formulary (BNF) 101 clearly states that patients", "bbox": [53.0, 502.0, 387.0, 517.0]}, {"text": "who have received intravenous benzodiazepines should not drive", "bbox": [53.0, 516.0, 387.0, 531.0]}, {"text": "a car, operate machinery, sign legal documents or drink alcohol", "bbox": [53.0, 532.0, 387.0, 546.0]}, {"text": "for 24 hours. This list can extend to anything which requires", "bbox": [53.0, 547.0, 387.0, 560.0]}, {"text": "critical decision-making and can have an adverse impact on the", "bbox": [53.0, 561.0, 387.0, 574.0]}, {"text": "patient or others in their care, such as children. While there is no", "bbox": [53.0, 576.0, 387.0, 589.0]}, {"text": "evidence to make recommendations against flying, patients need", "bbox": [53.0, 590.0, 387.0, 604.0]}, {"text": "to be aware of being in a position where there is no immediate", "bbox": [53.0, 605.0, 387.0, 619.0]}, {"text": "prospect of medical support being available.", "bbox": [53.0, 619.0, 282.0, 633.0]}, {"text": "This should include all forms of intravenous sedation/anal-", "bbox": [66.0, 635.0, 385.0, 648.0]}, {"text": "gesia (eg, opiates) which establishes these restrictions as precau-", "bbox": [53.0, 649.0, 385.0, 662.0]}, {"text": "tionary, therefore straightforward and easy to follow for carers", "bbox": [53.0, 663.0, 387.0, 677.0]}, {"text": "and relatives. It is in line with the RCoA advice for caring for", "bbox": [53.0, 678.0, 386.0, 692.0]}, {"text": "someone recovering from a general anaesthetic or sedation. 95", "bbox": [53.0, 693.0, 381.0, 707.0]}, {"text": "Treating all forms of intravenous sedation equally with respect", "bbox": [54.0, 707.0, 387.0, 721.0]}, {"text": "to restrictions during recovery prevents trade-offs in discussions", "bbox": [53.0, 723.0, 387.0, 736.0]}, {"text": "with patients about the nature and choice of sedative in order to", "bbox": [53.0, 737.0, 387.0, 751.0]}, {"text": "prioritise patient comfort and safety.", "bbox": [54.0, 753.0, 245.0, 766.0]}, {"text": "20. We recommend that all patients and any carers providing", "bbox": [66.0, 766.0, 385.0, 781.0]}, {"text": "support after the procedure should receive clear instructions and", "bbox": [53.0, 781.0, 386.0, 795.0]}, {"text": "advice for late recovery, in verbal and written form that includes", "bbox": [53.0, 796.0, 385.0, 810.0]}, {"text": "contact information", "bbox": [53.0, 811.0, 162.0, 824.0]}, {"text": "Grade of evidence: Very Low. Strength of recommendation:", "bbox": [64.0, 824.0, 385.0, 839.0]}, {"text": "Strong.", "bbox": [54.0, 841.0, 93.0, 853.0]}, {"text": "Level of agreement: 100%", "bbox": [65.0, 856.0, 204.0, 868.0]}, {"text": "Owing to the alteration of critical decision-making secondary", "bbox": [64.0, 869.0, 385.0, 882.0]}, {"text": "to sedation and or the physiological effects of endoscopy itself,", "bbox": [53.0, 883.0, 386.0, 898.0]}, {"text": "patients may require additional support following discharge—", "bbox": [53.0, 898.0, 384.0, 912.0]}, {"text": "that is, late recovery. Clear advice in an appropriate form must", "bbox": [53.0, 913.0, 386.0, 927.0]}, {"text": "be given to responsible third parties, carers and families about", "bbox": [53.0, 928.0, 386.0, 941.0]}, {"text": "how to look after patients in the late recovery period. 1 102 This", "bbox": [54.0, 942.0, 387.0, 955.0]}, {"text": "includes both verbal discussion and written information that", "bbox": [53.0, 957.0, 386.0, 970.0]}, {"text": "must be supported by including patient information leaflets and", "bbox": [53.0, 971.0, 387.0, 986.0]}], "type": "Text", "position": 0}, {"raw_context": [{"text": "discharge advice sheets. An example document is provided in the", "bbox": [406.0, 60.0, 739.0, 75.0]}, {"text": "online supplemental appendix. 102 103", "bbox": [406.0, 78.0, 595.0, 89.0]}, {"text": "This should include information on where to seek advice on", "bbox": [419.0, 91.0, 741.0, 105.0]}, {"text": "postprocedure complications, when and how to contact the", "bbox": [406.0, 105.0, 740.0, 120.0]}, {"text": "endoscopy department, or alternate forms of support both in", "bbox": [406.0, 120.0, 741.0, 135.0]}, {"text": "and out of working hours.", "bbox": [406.0, 135.0, 546.0, 150.0]}, {"text": "One common alternative to intravenous sedation is to use", "bbox": [418.0, 150.0, 740.0, 164.0]}, {"text": "nitrous oxide to provide anxiolysis and analgesia to the patient", "bbox": [406.0, 165.0, 741.0, 179.0]}, {"text": "during the procedure. 104 The advantages of nitrous oxide over", "bbox": [406.0, 178.0, 740.0, 193.0]}, {"text": "traditional conscious sedation are that patients are deemed fit to", "bbox": [406.0, 193.0, 740.0, 207.0]}, {"text": "drive 30 min after their procedure and do not require a respon-", "bbox": [406.0, 209.0, 739.0, 223.0]}, {"text": "sible adult to accompany them home. The recovery time is also", "bbox": [406.0, 223.0, 741.0, 238.0]}, {"text": "reduced, having a positive impact on the endoscopy recovery for", "bbox": [406.0, 239.0, 739.0, 253.0]}, {"text": "safe and efficient discharge.", "bbox": [406.0, 254.0, 551.0, 267.0]}, {"text": "Entonox is a 50:50 mix of oxygen and nitrous oxide, 105 and", "bbox": [418.0, 268.0, 740.0, 280.0]}, {"text": "the latter is now recognised as an important potent greenhouse", "bbox": [406.0, 282.0, 740.0, 296.0]}, {"text": "gas. Therefore, its clinical efficacy must be balanced against", "bbox": [406.0, 297.0, 740.0, 311.0]}, {"text": "its environmental impact. This balance should be understood", "bbox": [406.0, 311.0, 741.0, 326.0]}, {"text": "by both staff and patients to support informed choice of this", "bbox": [406.0, 327.0, 741.0, 340.0]}, {"text": "agent when used as an alternative to traditional sedation. This", "bbox": [407.0, 341.0, 740.0, 355.0]}, {"text": "is discussed further in the BGS/JAG position statement on green", "bbox": [406.0, 356.0, 740.0, 369.0]}, {"text": "endoscopy. 106", "bbox": [406.0, 371.0, 479.0, 384.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "Complications related to sedation and reversal agents", "bbox": [406.0, 412.0, 698.0, 426.0]}], "type": "Section-header", "position": 4}, {"raw_context": [{"text": "Sedation-related complications during GI endoscopy are mostly", "bbox": [406.0, 427.0, 740.0, 440.0]}, {"text": "cardiopulmonary in nature: hypoxaemia, hypotension, aspira-", "bbox": [406.0, 441.0, 739.0, 454.0]}, {"text": "tion pneumonia, arrhythmia and vasovagal syncope. 107 – 111", "bbox": [406.0, 456.0, 707.0, 469.0]}, {"text": "Comparing the rates of sedation-related complications can", "bbox": [418.0, 470.0, 740.0, 484.0]}, {"text": "be challenging owing to differing definitions of 'adverse event'", "bbox": [406.0, 485.0, 739.0, 499.0]}, {"text": "across studies, varying inclusion criteria for patients and proce-", "bbox": [407.0, 500.0, 739.0, 514.0]}, {"text": "dures, and different sedation regimens. Based on findings from", "bbox": [406.0, 515.0, 740.0, 528.0]}, {"text": "studies looking at sedation-related complication rates from more", "bbox": [406.0, 529.0, 740.0, 542.0]}, {"text": "than 100 000 endoscopic examinations, the complication rate is", "bbox": [406.0, 544.0, 741.0, 557.0]}, {"text": "estimated as between 0.01% and 0.9%, with a sedation-related", "bbox": [406.0, 558.0, 741.0, 572.0]}, {"text": "mortality rate of 0.0006% to 0.00896. 107 109 111 The ProSed2", "bbox": [406.0, 573.0, 739.0, 586.0]}, {"text": "study, a multicentre German prospective observational study", "bbox": [406.0, 588.0, 740.0, 602.0]}, {"text": "included more than 350 000 endoscopies performed under", "bbox": [406.0, 603.0, 740.0, 616.0]}, {"text": "sedation (81% propofol-based sedation and 6.5% midazolam", "bbox": [406.0, 617.0, 741.0, 631.0]}, {"text": "alone). The major sedation-related complication rate (defined", "bbox": [406.0, 632.0, 741.0, 646.0]}, {"text": "as need for intensive care support, resuscitation or death) was", "bbox": [407.0, 647.0, 741.0, 661.0]}, {"text": "0.01% and the minor (defined as increased restlessness, oxygen", "bbox": [406.0, 662.0, 741.0, 675.0]}, {"text": "saturation < 90% for > 10 s, drop in blood pressure by more", "bbox": [406.0, 676.0, 739.0, 690.0]}, {"text": "than 20%, drop in heart rate > 20%, tachycardia > 100/min)", "bbox": [406.0, 691.0, 740.0, 705.0]}, {"text": "sedation-related complication rate was 0.3%. 1", "bbox": [406.0, 706.0, 643.0, 720.0]}, {"text": "Independent risk factors associated with complications", "bbox": [418.0, 721.0, 741.0, 736.0]}, {"text": "included, but were not limited to, ASA score >2, prolonged", "bbox": [406.0, 735.0, 741.0, 750.0]}, {"text": "procedure time and therapeutic endoscopy. 107 A previous meta-", "bbox": [406.0, 749.0, 739.0, 764.0]}, {"text": "analysis showed no difference in complication rates between", "bbox": [407.0, 765.0, 740.0, 779.0]}, {"text": "in propofol-based and benzodiazepine-based sedation", "bbox": [406.0, 780.0, 709.0, 793.0]}, {"text": "with", "bbox": [708.0, 781.0, 741.0, 792.0]}, {"text": "opiate. 108 The complication rate for midazolam-based sedation", "bbox": [406.0, 794.0, 740.0, 809.0]}, {"text": "during GI endoscopy is estimated to be 0.38%, most commonly", "bbox": [406.0, 809.0, 739.0, 823.0]}, {"text": "due to hypoxaemia (40.7% of all complications). 112", "bbox": [406.0, 823.0, 673.0, 838.0]}, {"text": "Different reported thresholds have been used for defining", "bbox": [418.0, 838.0, 740.0, 852.0]}, {"text": "respiratory depression and other associated abnormal physiolog-", "bbox": [406.0, 854.0, 739.0, 867.0]}, {"text": "ical parameters (eg, oxygen desaturation, changes in heart rate,", "bbox": [406.0, 868.0, 741.0, 881.0]}, {"text": "arterial CO2 partial pressure). 113 – 117 For these guidelines, we", "bbox": [406.0, 880.0, 740.0, 896.0]}, {"text": "define respiratory depression secondary to opiates or benzodiaz-", "bbox": [406.0, 897.0, 739.0, 912.0]}, {"text": "epines as a reduced respiratory rate < 10 breaths/min, which may", "bbox": [406.0, 911.0, 739.0, 926.0]}, {"text": "or may not lead to an oxygen desaturation to < 90% , elevated", "bbox": [406.0, 927.0, 740.0, 940.0]}, {"text": "arterial CO, partial pressure > 6.66 kPa or reduced levels of", "bbox": [406.0, 942.0, 740.0, 955.0]}, {"text": "consciousness. 118", "bbox": [406.0, 957.0, 494.0, 969.0]}, {"text": "In instances of respiratory depression or hypoxaemia during", "bbox": [418.0, 970.0, 741.0, 984.0]}, {"text": "or shortly after administration of conscious sedation, supportive", "bbox": [406.0, 985.0, 740.0, 999.0]}, {"text": "1313", "bbox": [727.0, 1011.0, 739.0, 1022.0]}], "type": "Text", "position": 5}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/消化科/_2023 BSG指南：胃肠内窥镜检查中的镇静.pdf", "page_num": 13}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "缺少换行#0#0#Standards and guidance for...\n1. The patient has returned...都另起一行\n多余换行#2#2#序号2.与上面1段内容联接\n缺少换行#5#5#19. We recommend that patients...\n Grade of evidence: Very ...都另起一行\n缺少换行#6#6#Many endoscopy procedures...另起一行\n缺少换行#9#9#Grade of evidence: Very Low....另起一行\n缺少换行#10#10#Owing to the alteration of critical ...另起一行\n多余换行#11#11# discharge advice sheets. 与上面10段联接\n缺少换行#11#11# This should include information ...另起一行\n缺少换行#15#15#Comparing the rates of sedation-related ...\n Independent risk factors associated ...\nDifferent reported thresholds have...\nIn instances of respiratory...都另起一行", "type3": "无关文本#0#15# ...after the procedure. 99 \n...discharge criteria as follows 1像这样在.号或，号的开头或结尾出现的数字都是无关引用\n无关文本#2#2# 19. \n", "type4": null, "type5": null, "type6": null}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:42", "update_time": "2024-05-07 20:00:48"}
{"id": 1082636, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 738, "source_info": {"seq_id": "353ae780-a895-4f2e-b6d1-db7f05445a5b", "title": null, "text": "【0】页码:4\n Main portal vein thrombosis (PVT) with poor targeting .\n\n【1】evidenced by scintigraphy. These patients will have a very poor outcome with little benefit from treatment.\n\n【2】Poor targeting of portal vein thrombosis in the main trunk.\n\n【3】.\n\n【4】Acute or severe chronic renal failure (i.e. creatinine clear- .\n\n【5】ance <30 ml/min).\n\n【6】Contraindications to hepatic artery catheterization (e.g.\n\n【7】.\n\n【8】unmanageable coagulation disorder, renal failure, severe allergy to contrast media, vascular abnormalities).\n\n【9】Lung shunting that would lead to a lung dose >30 Gy .\n\n【10】per session or> 50 Gy cumulatively (determined by pretreatment planar 99 m Tc-MAA scintigraphy). Not an absolute contraindication, because lung shunting by planar 99m Tc-MAA is overestimated and a reliable safety limit has not been established yet.\n\n【11】## Special Warnings\n\n【12】\n Inadvertent delivery of microspheres to the gastrointes- .\n\n【13】tinal tract or pancreas may cause acute abdominal pain, acute pancreatitis or peptic ulceration.\n\n【14】Prior external beam radiation therapy (EBRT) of the liver.\n\n【15】.\n\n【16】Radioembolization appears to be safe for the treatment of hepatic malignancies only in patients who have had limited hepatic exposure to prior EBRT, with the strongest predictor for hepatotoxicity being the liver fraction exposed to ≥ 30 Gy [ 25 ]. While liver regeneration might allow combined treatments, little is known about the cumulative thresholds.\n\n【17】Absorbed dose values cannot be, simply summed, since a reliable method to combine such values is still lacking.\n\n【18】Repeated radioembolization treatments seem less criti- .\n\n【19】cal than radioembolization after EBRT. Young et al.\n\n【20】[ 26 ] repeated lobar radioembolization an average of 2.6 [ times in HCC patients with 17% toxicity incidence. No data is available to strictly demonstrate whether the dose tolerance in a second treatment can be considered the same as for the first treatment. However, liver regeneration might allow this strategy, provided that a sufficient interval between treatments is kept (3 months or longer).\n\n【21】Radioembolization after peptide radioreceptor therapy (PRRT) of neuroendocrine tumours was reported as safe and effective, with a low incidence (5%) of REILD [ 27 , 28 ].\n\n【22】Markedly abnormal liver function tests (e.g. aspartate .\n\n【23】aminotransferase or alanine aminotransferase > 5 times upper limit of normal or elevated bilirubin). Caution is advised when bilirubin exceeds normal levels, especially in bilobar metastatic disease, in case whole liver treatment is warranted.\n\n【24】Excessive radiation to the normal liver parenchyma may .\n\n【25】result in radiation hepatitis or radioembolization-induced liver disease [ 29 ], characterized by the combination of increased bilirubin, low albumin and ascites. The usual onset is 2–6 months after radioembolization [ 79 ]. It\n\n【26】 may co-exist with progressive disease (complicating the clinical presentation), but the diagnosis is definite in the absence of progressive disease.\n\n【27】The risk of cholangitis or abscess may be elevated in .\n\n【28】patients with a history of biliary intervention. Although a direct relation has not been established (in contrast to TACE), caution is advised, and prophylactic antibiotics may be considered.\n\n【29】Excessive hepatotoxic systemic therapy prior to radi- .\n\n【30】oembolization may increase the risk of post-treatment liver failure. However, in mCRC, it was evidenced in randomized controlled trials that the combination of firstand second-line systemic therapy with radioembolization is safe [ 30 – 32 ]. In HCC, the combination of first-line sorafenib and radioembolization proved to be safe [ 33 ], but an unacceptable risk of liver failure was identified for ICC patients with underlying cirrhosis treated as firstline with concomitant radioembolization and standard chemotherapy in a multicentre phase II study [ 34 ].\n\n【31】Non-dosimetric activity calculation methods (single com- .\n\n【32】partment modelling; BSA-method) may lead to under- or overtreatment. Please note that under- and overtreatment may be equally harmful to the patient.\n\n【33】## Diagnostic Work-Up\n\n【34】\n## Clinical And Laboratory Evaluation\n\n【35】\n Patients should be accurately staged according to international standards. Clinical history, physical examination, laboratory values and performance status are evaluated. Parameters to assess the indication for radioembolization include determination of tumour load, volume and serum tumour markers (e.g. alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA)). Serum liver enzymes, bilirubin, albumin, cholinesterase, blood cell count, coagulation and creatinine should be monitored and known before the procedure: Selection of patients with adequate hepatic reserve and good functional status will maximize the beneficial therapeutic effect with minimal risk to normal liver parenchyma.\n\n【36】## Pre-Treatment Imaging\n\n【37】\n Pre-treatment imaging is important to establish feasibility and objectives of treatment, which can extend from palliative treatments to radiation segmentectomy for very limited disease. Imaging techniques include contrast-enhanced CT or MRI performed within 30 days of the procedure for the calculation of the tumour volume and for staging purposes. In addition, (early) arterial phase CT is done to identify hepatic arterial anatomy (e.g. origin of right gastric artery, origin of segment 4 artery). Also, for FDG-avid hepatic malignancies,", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "Main portal vein thrombosis (PVT) with poor targeting", "bbox": [82.0, 72.0, 387.0, 88.0]}, {"text": ".", "bbox": [66.0, 76.0, 76.0, 86.0]}, {"text": "evidenced by scintigraphy. These patients will have a", "bbox": [82.0, 90.0, 388.0, 105.0]}, {"text": "very poor outcome with little benefit from treatment.", "bbox": [82.0, 107.0, 370.0, 122.0]}, {"text": "Poor targeting of portal vein thrombosis in the main trunk.", "bbox": [82.0, 123.0, 386.0, 138.0]}, {"text": ".", "bbox": [66.0, 124.0, 78.0, 137.0]}, {"text": "Acute or severe chronic renal failure (i.e. creatinine clear-", "bbox": [82.0, 140.0, 387.0, 155.0]}, {"text": ".", "bbox": [66.0, 142.0, 76.0, 153.0]}, {"text": "ance <30 ml/min).", "bbox": [82.0, 158.0, 186.0, 171.0]}, {"text": "Contraindications to hepatic artery catheterization (e.g.", "bbox": [82.0, 174.0, 386.0, 189.0]}, {"text": ".", "bbox": [66.0, 175.0, 76.0, 186.0]}, {"text": "unmanageable coagulation disorder, renal failure, severe", "bbox": [82.0, 190.0, 387.0, 205.0]}, {"text": "allergy to contrast media, vascular abnormalities).", "bbox": [82.0, 207.0, 355.0, 222.0]}, {"text": "Lung shunting that would lead to a lung dose >30 Gy", "bbox": [82.0, 224.0, 387.0, 238.0]}, {"text": ".", "bbox": [66.0, 225.0, 76.0, 237.0]}, {"text": "per session or> 50 Gy cumulatively (determined by pre-", "bbox": [82.0, 240.0, 385.0, 255.0]}, {"text": "treatment planar 99 m Tc-MAA scintigraphy). Not an abso-", "bbox": [82.0, 256.0, 385.0, 273.0]}, {"text": "lute contraindication, because lung shunting by planar", "bbox": [82.0, 274.0, 387.0, 289.0]}, {"text": "99m Tc-MAA is overestimated and a reliable safety limit", "bbox": [83.0, 290.0, 387.0, 306.0]}, {"text": "has not been established yet.", "bbox": [82.0, 306.0, 238.0, 322.0]}], "type": "Text", "position": 0}, {"raw_context": [{"text": "Special warnings", "bbox": [80.0, 341.0, 177.0, 356.0]}], "type": "Section-header", "position": 1}, {"raw_context": [{"text": "Inadvertent delivery of microspheres to the gastrointes-", "bbox": [82.0, 373.0, 384.0, 388.0]}, {"text": ".", "bbox": [66.0, 376.0, 76.0, 386.0]}, {"text": "tinal tract or pancreas may cause acute abdominal pain,", "bbox": [82.0, 391.0, 385.0, 406.0]}, {"text": "acute pancreatitis or peptic ulceration.", "bbox": [82.0, 407.0, 290.0, 422.0]}, {"text": "Prior external beam radiation therapy (EBRT) of the liver.", "bbox": [82.0, 424.0, 387.0, 438.0]}, {"text": ".", "bbox": [67.0, 426.0, 76.0, 436.0]}, {"text": "Radioembolization appears to be safe for the treatment of", "bbox": [82.0, 440.0, 387.0, 455.0]}, {"text": "hepatic malignancies only in patients who have had limited", "bbox": [82.0, 458.0, 387.0, 472.0]}, {"text": "hepatic exposure to prior EBRT, with the strongest predictor", "bbox": [82.0, 474.0, 387.0, 488.0]}, {"text": "for hepatotoxicity being the liver fraction exposed to ≥ 30 Gy", "bbox": [82.0, 491.0, 387.0, 505.0]}, {"text": "[ 25 ]. While liver regeneration might allow combined", "bbox": [82.0, 507.0, 387.0, 522.0]}, {"text": "treatments, little is known about the cumulative thresholds.", "bbox": [82.0, 523.0, 386.0, 538.0]}, {"text": "Absorbed dose values cannot be, simply summed, since a", "bbox": [83.0, 541.0, 387.0, 554.0]}, {"text": "reliable method to combine such values is still lacking.", "bbox": [82.0, 557.0, 361.0, 572.0]}, {"text": "Repeated radioembolization treatments seem less criti-", "bbox": [82.0, 574.0, 386.0, 589.0]}, {"text": ".", "bbox": [66.0, 575.0, 76.0, 587.0]}, {"text": "cal than radioembolization after EBRT. Young et al.", "bbox": [82.0, 590.0, 387.0, 605.0]}, {"text": "[ 26 ] repeated lobar radioembolization an average of 2.6 [", "bbox": [82.0, 608.0, 389.0, 621.0]}, {"text": "times in HCC patients with 17% toxicity incidence. No", "bbox": [82.0, 624.0, 387.0, 639.0]}, {"text": "data is available to strictly demonstrate whether the dose", "bbox": [82.0, 640.0, 387.0, 655.0]}, {"text": "tolerance in a second treatment can be considered the", "bbox": [82.0, 657.0, 387.0, 672.0]}, {"text": "same as for the first treatment. However, liver regenera-", "bbox": [82.0, 675.0, 385.0, 688.0]}, {"text": "tion might allow this strategy, provided that a sufficient", "bbox": [82.0, 691.0, 387.0, 705.0]}, {"text": "interval between treatments is kept (3 months or longer).", "bbox": [82.0, 707.0, 387.0, 722.0]}, {"text": "Radioembolization after peptide radioreceptor therapy", "bbox": [95.0, 724.0, 387.0, 739.0]}, {"text": "(PRRT) of neuroendocrine tumours was reported as safe", "bbox": [82.0, 741.0, 387.0, 755.0]}, {"text": "and effective, with a low incidence (5%) of REILD [ 27 , 28 ].", "bbox": [82.0, 757.0, 385.0, 772.0]}, {"text": "Markedly abnormal liver function tests (e.g. aspartate", "bbox": [82.0, 774.0, 387.0, 789.0]}, {"text": ".", "bbox": [67.0, 776.0, 76.0, 786.0]}, {"text": "aminotransferase or alanine aminotransferase > 5 times", "bbox": [82.0, 791.0, 387.0, 805.0]}, {"text": "upper limit of normal or elevated bilirubin). Caution is", "bbox": [82.0, 807.0, 387.0, 822.0]}, {"text": "advised when bilirubin exceeds normal levels, especially", "bbox": [82.0, 824.0, 387.0, 839.0]}, {"text": "in bilobar metastatic disease, in case whole liver treat-", "bbox": [82.0, 841.0, 390.0, 856.0]}, {"text": "ment is warranted.", "bbox": [82.0, 858.0, 185.0, 872.0]}, {"text": "Excessive radiation to the normal liver parenchyma may", "bbox": [82.0, 874.0, 387.0, 888.0]}, {"text": ".", "bbox": [67.0, 876.0, 75.0, 886.0]}, {"text": "result in radiation hepatitis or radioembolization-induced", "bbox": [82.0, 891.0, 388.0, 905.0]}, {"text": "liver disease [ 29 ], characterized by the combination of", "bbox": [82.0, 908.0, 387.0, 923.0]}, {"text": "increased bilirubin, low albumin and ascites. The usual", "bbox": [82.0, 924.0, 387.0, 938.0]}, {"text": "onset is 2–6 months after radioembolization [ 79 ]. It", "bbox": [82.0, 941.0, 387.0, 955.0]}], "type": "Text", "position": 2}, {"raw_context": [{"text": "may co-exist with progressive disease (complicating the", "bbox": [424.0, 73.0, 727.0, 88.0]}, {"text": "clinical presentation), but the diagnosis is definite in the", "bbox": [423.0, 91.0, 727.0, 105.0]}, {"text": "absence of progressive disease.", "bbox": [424.0, 108.0, 593.0, 122.0]}, {"text": "The risk of cholangitis or abscess may be elevated in", "bbox": [422.0, 123.0, 728.0, 138.0]}, {"text": ".", "bbox": [406.0, 125.0, 415.0, 135.0]}, {"text": "patients with a history of biliary intervention. Although", "bbox": [424.0, 140.0, 728.0, 155.0]}, {"text": "a direct relation has not been established (in contrast to", "bbox": [422.0, 158.0, 727.0, 171.0]}, {"text": "TACE), caution is advised, and prophylactic antibiotics", "bbox": [423.0, 174.0, 727.0, 189.0]}, {"text": "may be considered.", "bbox": [423.0, 190.0, 529.0, 205.0]}, {"text": "Excessive hepatotoxic systemic therapy prior to radi-", "bbox": [422.0, 207.0, 727.0, 222.0]}, {"text": ".", "bbox": [406.0, 209.0, 416.0, 219.0]}, {"text": "oembolization may increase the risk of post-treatment", "bbox": [423.0, 224.0, 727.0, 238.0]}, {"text": "liver failure. However, in mCRC, it was evidenced in", "bbox": [423.0, 240.0, 728.0, 255.0]}, {"text": "randomized controlled trials that the combination of first-", "bbox": [423.0, 257.0, 729.0, 272.0]}, {"text": "and second-line systemic therapy with radioembolization", "bbox": [424.0, 274.0, 729.0, 289.0]}, {"text": "is safe [ 30 – 32 ]. In HCC, the combination of first-line", "bbox": [424.0, 291.0, 727.0, 305.0]}, {"text": "sorafenib and radioembolization proved to be safe [ 33 ],", "bbox": [423.0, 307.0, 727.0, 322.0]}, {"text": "but an unacceptable risk of liver failure was identified for", "bbox": [423.0, 324.0, 727.0, 339.0]}, {"text": "ICC patients with underlying cirrhosis treated as first-", "bbox": [424.0, 341.0, 726.0, 355.0]}, {"text": "line with concomitant radioembolization and standard", "bbox": [423.0, 357.0, 728.0, 371.0]}, {"text": "chemotherapy in a multicentre phase II study [ 34 ].", "bbox": [422.0, 374.0, 698.0, 388.0]}, {"text": "Non-dosimetric activity calculation methods (single com-", "bbox": [420.0, 391.0, 727.0, 406.0]}, {"text": ".", "bbox": [403.0, 392.0, 417.0, 404.0]}, {"text": "partment modelling; BSA-method) may lead to under- or", "bbox": [423.0, 407.0, 727.0, 422.0]}, {"text": "overtreatment. Please note that under- and overtreatment", "bbox": [422.0, 424.0, 728.0, 438.0]}, {"text": "may be equally harmful to the patient.", "bbox": [423.0, 440.0, 630.0, 455.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "Diagnostic work-up", "bbox": [406.0, 488.0, 549.0, 506.0]}], "type": "Section-header", "position": 6}, {"raw_context": [{"text": "Clinical and laboratory evaluation", "bbox": [405.0, 523.0, 616.0, 538.0]}], "type": "Section-header", "position": 7}, {"raw_context": [{"text": "Patients should be accurately staged according to interna-", "bbox": [405.0, 557.0, 726.0, 572.0]}, {"text": "tional standards. Clinical history, physical examination, lab-", "bbox": [405.0, 574.0, 726.0, 589.0]}, {"text": "oratory values and performance status are evaluated. Param-", "bbox": [406.0, 590.0, 726.0, 605.0]}, {"text": "eters to assess the indication for radioembolization include", "bbox": [405.0, 608.0, 727.0, 621.0]}, {"text": "determination of tumour load, volume and serum tumour", "bbox": [405.0, 624.0, 727.0, 639.0]}, {"text": "markers (e.g. alpha-fetoprotein (AFP), carcinoembryonic", "bbox": [405.0, 640.0, 727.0, 655.0]}, {"text": "antigen (CEA)). Serum liver enzymes, bilirubin, albumin,", "bbox": [406.0, 657.0, 727.0, 672.0]}, {"text": "cholinesterase, blood cell count, coagulation and creatinine", "bbox": [405.0, 674.0, 727.0, 688.0]}, {"text": "should be monitored and known before the procedure: Selec-", "bbox": [405.0, 691.0, 726.0, 705.0]}, {"text": "tion of patients with adequate hepatic reserve and good func-", "bbox": [405.0, 707.0, 727.0, 722.0]}, {"text": "tional status will maximize the beneficial therapeutic effect", "bbox": [405.0, 724.0, 731.0, 739.0]}, {"text": "with minimal risk to normal liver parenchyma.", "bbox": [406.0, 742.0, 659.0, 756.0]}], "type": "Text", "position": 8}, {"raw_context": [{"text": "Pre-treatment imaging", "bbox": [405.0, 773.0, 549.0, 788.0]}], "type": "Section-header", "position": 9}, {"raw_context": [{"text": "Pre-treatment imaging is important to establish feasibility", "bbox": [405.0, 807.0, 727.0, 822.0]}, {"text": "and objectives of treatment, which can extend from pallia-", "bbox": [406.0, 824.0, 726.0, 839.0]}, {"text": "tive treatments to radiation segmentectomy for very limited", "bbox": [405.0, 841.0, 729.0, 856.0]}, {"text": "disease. Imaging techniques include contrast-enhanced CT", "bbox": [404.0, 858.0, 727.0, 873.0]}, {"text": "or MRI performed within 30 days of the procedure for the", "bbox": [406.0, 874.0, 727.0, 888.0]}, {"text": "calculation of the tumour volume and for staging purposes. In", "bbox": [405.0, 890.0, 728.0, 905.0]}, {"text": "addition, (early) arterial phase CT is done to identify hepatic", "bbox": [406.0, 908.0, 727.0, 923.0]}, {"text": "arterial anatomy (e.g. origin of right gastric artery, origin of", "bbox": [406.0, 924.0, 727.0, 938.0]}, {"text": "segment 4 artery). Also, for FDG-avid hepatic malignancies,", "bbox": [405.0, 941.0, 725.0, 956.0]}], "type": "Text", "position": 10}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2022】全科室最全临床指南+专家共识（最全版）/2022全科室临床指南/肿瘤科/EANM：动脉内放射性化合物治疗肝癌和转移性肝癌指南（2022）(1).pdf", "page_num": 4}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "多余换行#1#1#evidenced by scintigraphy.连接上面0段\n多余换行#5#5#ance <30 ml/min).连接上面4段\n多余换行#8#8#unmanageable coagulation disorder, 与上面6段联接\n多余换行#10#10#per session or> 50 Gy cumulatively 与上面9段联接\n多余换行#13#13#tinal tract or pancreas may...与上面12段联接\n多余换行#19#19#cal than radioembolization 与上面18段联接\n多余换行#23#23#aminotransferase or alanine 与上面22段联接\n多余换行#25#25#result in radiation hepatitis与上面24段联接\n多余换行#26#26#may co-exist with progressive 与上面25段联接\n多余换行#28#28#patients with a history of与上面27段联接\n多余换行#30#30#oembolization may increase与上面29段联接\n多余换行#32#32#partment modelling; BSA-method)与上面31段联接", "type3": "无关文本#3#3#  .\n无关文本#7#7#  .\n无关文本#15#15#  .\n无关文本#16#37# [ 25 ]类似的 [   ]类无关引用过多", "type4": null, "type5": null, "type6": null}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:42", "update_time": "2024-05-07 22:49:57"}
{"id": 1082635, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 738, "source_info": {"seq_id": "e0ac4988-76c8-4147-b957-763228071a6b", "title": null, "text": "【0】页码:2\n 1.1\n\n【1】 [8]. D PIPOST 2015; (population,P) (intervention , I) 1 , 3\n\n【2】 (professional,P) 4 ; (outcome,0) ; 5) (setting,S) ; @ (type of evidence,T) , Meta\n\n【3】 1.2\n\n【4】 1.2.1\n\n【5】 \"6S\" [9] [9] \" / / / \"knee osteoarthritis/osteoarthritis\" \"selfmanagement/exercise/nutrition\" BMJ Best Prac-\n\n【6】 tice UpToDate ,\n\n【7】 1.2.2\n\n【8】 2012 —2022 10 1\n\n【9】 / / / / / / / / / / / /Meta / / / / \"osteoarthritis of knee/osteoarthritis , knee/osteoarthritis of the knee/age-related arthritis/ KOA\" \"self-management/management/exercise/education/ nutrition/aerobic/strengthening/resistance/training\"\"guid*/ consensus/recommendation*/evidence*/systematic review/Meta-analysis/randomized controlled trial\"\n\n【10】 , Cochrane Library , PubMed , Web of Science , Embase ,\n\n【11】 /\n\n【12】 /\n\n【13】 /\n\n【14】 /\n\n【15】 AND (\n\n【16】 /\n\n【17】 /\n\n【18】 / / / / / / / PubMed\n /\n , ) AND (\n\n【19】 (\n / / / /Meta / /\n )\n\n【20】 3\n\n【21】 58\n\n【22】 6\n\n【23】 (\"osteoarthritis of knee\"[Mesh] OR \"osteoarthritis, knee\"[Title/Abstract] OR\"osteoarthritis of the knee\" [Title/Abstract] OR \"age-related arthritis\" [Title/Abstract]OR\"KOA\"[Title/Abstract])AND(\"self-management\" [Mesh]OR \"management\" [Title/Abstract]OR \"exercise\" [Title/Abstract]OR \"education\" [Title/Abstract]OR\"nutrition\"[Title/Abstract]OR\"aerobic\"[Title/Abstract ] OR \"strengthening\" [Title/Abstract ]OR \"resistance\" [Title/Abstract] OR \"training\" [Title/Abstract])AND \"guid*\" [Title/Abstract]OR \"consensus\" [Title/Abstract] OR \"recommendation*\" [Title/Abstract] OR\"evidence*\"[Title/Abstract] OR\"systematic review\" [Title/Abstract]OR \"Meta-analysis\" [Title/ Abstract] OR \"randomized controlled trial\"[Title/Abstract]) .\n\n【24】1.3\n\n【25】 1. D\n\n【26】 KOA\n\n【27】 1.4\n\n【28】 ;  3\n\n【29】 2018;\n\n【30】 KOA\n\n【31】 1. D 1999, pp. 1111\n\n【32】 2 (appraisal of guidelines for research and evaluation,AGREE ) [10] (intraclass correlation coefficient,ICC)\n\n【33】 , ICC<0.40 11 ; ICC 0.60~0.74 [11] , 2 2016\n\n【34】 [12]\n\n【35】 1, 2\n\n【36】 3\n\n【37】 :\n\n【38】 [4]\n\n【39】 [13]\n\n【40】 ; ICC 0.40~0.59 ;ICC ≥ 0.75\n\n【41】 Chin J Nurs, March 2023, Vol. 58, No. 6\n\n【42】 1.5\n\n【43】 (1).", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "1.1", "bbox": [61.0, 93.0, 82.0, 109.0]}], "type": "Text", "position": 0}, {"raw_context": [{"text": "[8]. D", "bbox": [274.0, 112.0, 318.0, 131.0]}, {"text": "PIPOST", "bbox": [117.0, 114.0, 164.0, 130.0]}, {"text": "2015;", "bbox": [267.0, 136.0, 291.0, 152.0]}, {"text": "(population,P)", "bbox": [62.0, 137.0, 151.0, 152.0]}, {"text": "(in-", "bbox": [347.0, 137.0, 371.0, 152.0]}, {"text": "tervention , I)", "bbox": [61.0, 159.0, 138.0, 174.0]}, {"text": "1 , 3", "bbox": [335.0, 159.0, 359.0, 175.0]}], "type": "Text", "position": 1}, {"raw_context": [{"text": "(professional,P)", "bbox": [135.0, 180.0, 232.0, 195.0]}, {"text": "4 ;", "bbox": [76.0, 202.0, 101.0, 217.0]}, {"text": "(outcome,0)", "bbox": [153.0, 202.0, 232.0, 217.0]}, {"text": "; 5)", "bbox": [91.0, 223.0, 117.0, 239.0]}, {"text": "(setting,S)", "bbox": [201.0, 224.0, 268.0, 239.0]}, {"text": "; @", "bbox": [130.0, 246.0, 155.0, 260.0]}, {"text": "(type of evidence,T)", "bbox": [212.0, 246.0, 342.0, 261.0]}, {"text": ",", "bbox": [93.0, 251.0, 102.0, 263.0]}, {"text": "Meta", "bbox": [93.0, 288.0, 127.0, 303.0]}], "type": "Text", "position": 2}, {"raw_context": [{"text": "1.2", "bbox": [61.0, 309.0, 83.0, 325.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "1.2.1", "bbox": [61.0, 331.0, 91.0, 346.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": "\"6S\"", "bbox": [117.0, 351.0, 148.0, 365.0]}, {"text": "[9] [9]", "bbox": [316.0, 352.0, 331.0, 364.0]}, {"text": "\"", "bbox": [320.0, 373.0, 330.0, 385.0]}, {"text": "/", "bbox": [117.0, 376.0, 127.0, 388.0]}, {"text": "/", "bbox": [252.0, 376.0, 261.0, 388.0]}, {"text": "/", "bbox": [285.0, 376.0, 294.0, 388.0]}, {"text": "\"knee osteoarthritis/osteoarthritis\" \"self-", "bbox": [135.0, 397.0, 372.0, 411.0]}, {"text": "management/exercise/nutrition\"", "bbox": [61.0, 417.0, 238.0, 432.0]}, {"text": "BMJ Best Prac-", "bbox": [275.0, 439.0, 371.0, 455.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "tice UpToDate ,", "bbox": [61.0, 460.0, 152.0, 477.0]}], "type": "Text", "position": 6}, {"raw_context": [{"text": "1.2.2", "bbox": [61.0, 589.0, 93.0, 605.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "2012", "bbox": [167.0, 568.0, 200.0, 583.0]}, {"text": "—2022", "bbox": [229.0, 567.0, 277.0, 583.0]}, {"text": "10", "bbox": [287.0, 568.0, 307.0, 583.0]}, {"text": "1", "bbox": [210.0, 570.0, 220.0, 583.0]}], "type": "Text", "position": 8}, {"raw_context": [{"text": "/", "bbox": [104.0, 634.0, 113.0, 646.0]}, {"text": "/", "bbox": [166.0, 634.0, 176.0, 646.0]}, {"text": "/", "bbox": [228.0, 634.0, 237.0, 646.0]}, {"text": "/", "bbox": [365.0, 634.0, 373.0, 646.0]}, {"text": "/", "bbox": [89.0, 655.0, 99.0, 669.0]}, {"text": "/", "bbox": [156.0, 655.0, 166.0, 669.0]}, {"text": "/", "bbox": [189.0, 655.0, 199.0, 669.0]}, {"text": "/", "bbox": [256.0, 655.0, 265.0, 669.0]}, {"text": "/", "bbox": [365.0, 655.0, 374.0, 668.0]}, {"text": "/", "bbox": [123.0, 656.0, 131.0, 669.0]}, {"text": "/", "bbox": [223.0, 656.0, 231.0, 668.0]}, {"text": "/Meta", "bbox": [190.0, 676.0, 226.0, 691.0]}, {"text": "/", "bbox": [89.0, 677.0, 99.0, 691.0]}, {"text": "/", "bbox": [123.0, 678.0, 132.0, 690.0]}, {"text": "/", "bbox": [157.0, 678.0, 165.0, 691.0]}, {"text": "/", "bbox": [252.0, 678.0, 260.0, 690.0]}, {"text": "\"osteoarthritis of knee/osteoarthritis ,", "bbox": [158.0, 698.0, 371.0, 713.0]}, {"text": "knee/osteoarthritis of the knee/age-related arthritis/", "bbox": [61.0, 719.0, 373.0, 734.0]}, {"text": "KOA\" \"self-management/management/exercise/education/", "bbox": [61.0, 741.0, 373.0, 756.0]}, {"text": "nutrition/aerobic/strengthening/resistance/training\"\"guid*/", "bbox": [61.0, 762.0, 371.0, 778.0]}, {"text": "consensus/recommendation*/evidence*/systematic re-", "bbox": [61.0, 784.0, 372.0, 800.0]}, {"text": "view/Meta-analysis/randomized controlled trial\"", "bbox": [61.0, 805.0, 340.0, 821.0]}], "type": "Text", "position": 10}, {"raw_context": [{"text": ", Cochrane Library , PubMed , Web of", "bbox": [160.0, 849.0, 373.0, 864.0]}, {"text": "Science , Embase ,", "bbox": [61.0, 871.0, 164.0, 886.0]}], "type": "Text", "position": 11}, {"raw_context": [{"text": "/", "bbox": [89.0, 914.0, 99.0, 927.0]}], "type": "Text", "position": 12}, {"raw_context": [{"text": "/", "bbox": [74.0, 936.0, 84.0, 949.0]}], "type": "Text", "position": 13}, {"raw_context": [{"text": "/", "bbox": [110.0, 936.0, 121.0, 949.0]}], "type": "Text", "position": 14}, {"raw_context": [{"text": "/", "bbox": [153.0, 915.0, 162.0, 927.0]}], "type": "Text", "position": 15}, {"raw_context": [{"text": "AND (", "bbox": [61.0, 956.0, 99.0, 971.0]}], "type": "Text", "position": 16}, {"raw_context": [{"text": "/", "bbox": [127.0, 959.0, 136.0, 971.0]}], "type": "Text", "position": 17}, {"raw_context": [{"text": "/", "bbox": [183.0, 936.0, 191.0, 949.0]}], "type": "Text", "position": 18}, {"raw_context": [{"text": "/", "bbox": [183.0, 936.0, 191.0, 949.0]}, {"text": "/", "bbox": [218.0, 936.0, 227.0, 949.0]}, {"text": "/", "bbox": [254.0, 936.0, 264.0, 949.0]}, {"text": "/", "bbox": [147.0, 937.0, 155.0, 949.0]}, {"text": "/", "bbox": [160.0, 958.0, 170.0, 971.0]}, {"text": "/", "bbox": [193.0, 958.0, 202.0, 971.0]}, {"text": "/", "bbox": [226.0, 958.0, 236.0, 971.0]}, {"text": "PubMed", "bbox": [218.0, 978.0, 269.0, 993.0]}], "type": "Text", "position": 19}, {"raw_context": [{"text": "/", "bbox": [217.0, 915.0, 226.0, 927.0]}], "type": "Formula", "position": 20}, {"raw_context": [{"text": ",", "bbox": [259.0, 899.0, 267.0, 909.0]}, {"text": ") AND (", "bbox": [283.0, 913.0, 326.0, 928.0]}], "type": "Formula", "position": 21}, {"raw_context": [{"text": "(", "bbox": [321.0, 894.0, 328.0, 905.0]}], "type": "Text", "position": 22}, {"raw_context": [{"text": "/", "bbox": [218.0, 936.0, 227.0, 949.0]}, {"text": "/", "bbox": [254.0, 936.0, 264.0, 949.0]}, {"text": "/", "bbox": [324.0, 936.0, 332.0, 949.0]}, {"text": "/Meta", "bbox": [259.0, 956.0, 296.0, 971.0]}, {"text": "/", "bbox": [226.0, 958.0, 236.0, 971.0]}, {"text": "/", "bbox": [321.0, 957.0, 330.0, 971.0]}], "type": "Formula", "position": 23}, {"raw_context": [{"text": ")", "bbox": [363.0, 936.0, 373.0, 949.0]}], "type": "Formula", "position": 24}, {"raw_context": [{"text": "3", "bbox": [606.0, 49.0, 617.0, 58.0]}], "type": "Text", "position": 26}, {"raw_context": [{"text": "58", "bbox": [643.0, 48.0, 658.0, 60.0]}], "type": "Text", "position": 27}, {"raw_context": [{"text": "6", "bbox": [684.0, 49.0, 694.0, 59.0]}], "type": "Text", "position": 28}, {"raw_context": [{"text": "(\"osteoarthritis of knee\"[Mesh] OR \"osteoarthritis,", "bbox": [397.0, 92.0, 707.0, 109.0]}, {"text": "knee\"[Title/Abstract] OR\"osteoarthritis of the knee\"", "bbox": [395.0, 114.0, 706.0, 131.0]}, {"text": "[Title/Abstract] OR \"age-related arthritis\" [Title/Ab-", "bbox": [396.0, 136.0, 703.0, 152.0]}, {"text": "stract]OR\"KOA\"[Title/Abstract])AND(\"self-manage-", "bbox": [395.0, 158.0, 706.0, 174.0]}, {"text": "ment\" [Mesh]OR \"management\" [Title/Abstract]OR", "bbox": [395.0, 179.0, 708.0, 195.0]}, {"text": "\"exercise\" [Title/Abstract]OR \"education\" [Title/Ab-", "bbox": [396.0, 201.0, 702.0, 217.0]}, {"text": "stract]OR\"nutrition\"[Title/Abstract]OR\"aerobic\"[Ti-", "bbox": [395.0, 222.0, 703.0, 238.0]}, {"text": "tle/Abstract ] OR \"strengthening\" [Title/Abstract ]OR", "bbox": [395.0, 244.0, 708.0, 260.0]}, {"text": "\"resistance\" [Title/Abstract] OR \"training\" [Title/Ab-", "bbox": [397.0, 265.0, 703.0, 282.0]}, {"text": "stract])AND \"guid*\" [Title/Abstract]OR \"consensus\"", "bbox": [395.0, 287.0, 706.0, 303.0]}, {"text": "[Title/Abstract] OR \"recommendation*\" [Title/Ab-", "bbox": [396.0, 309.0, 702.0, 325.0]}, {"text": "stract] OR\"evidence*\"[Title/Abstract] OR\"systemat-", "bbox": [395.0, 330.0, 707.0, 346.0]}, {"text": "ic review\" [Title/Abstract]OR \"Meta-analysis\" [Title/", "bbox": [395.0, 352.0, 707.0, 368.0]}, {"text": "Abstract] OR \"randomized controlled trial\"[Title/Ab-", "bbox": [397.0, 374.0, 707.0, 389.0]}, {"text": "stract]) .", "bbox": [395.0, 396.0, 449.0, 412.0]}, {"text": "1.3", "bbox": [397.0, 417.0, 418.0, 432.0]}], "type": "Text", "position": 29}, {"raw_context": [{"text": "1. D", "bbox": [481.0, 439.0, 505.0, 455.0]}], "type": "Text", "position": 30}, {"raw_context": [{"text": "KOA", "bbox": [410.0, 460.0, 441.0, 476.0]}], "type": "Text", "position": 31}, {"raw_context": [{"text": "1.4", "bbox": [396.0, 546.0, 418.0, 562.0]}], "type": "Text", "position": 32}, {"raw_context": [{"text": ";  3", "bbox": [524.0, 461.0, 557.0, 475.0]}], "type": "Text", "position": 33}, {"raw_context": [{"text": "2018;", "bbox": [627.0, 439.0, 651.0, 455.0]}], "type": "Text", "position": 35}, {"raw_context": [{"text": "KOA", "bbox": [570.0, 439.0, 602.0, 454.0]}], "type": "Text", "position": 36}, {"raw_context": [{"text": "1. D", "bbox": [580.0, 503.0, 604.0, 520.0]}, {"text": "1999, pp. 1111", "bbox": [453.0, 525.0, 477.0, 541.0]}], "type": "Text", "position": 38}, {"raw_context": [{"text": "2", "bbox": [438.0, 569.0, 449.0, 583.0]}, {"text": "(appraisal of guidelines", "bbox": [567.0, 591.0, 708.0, 606.0]}, {"text": "for research and evaluation,AGREE", "bbox": [395.0, 611.0, 615.0, 627.0]}, {"text": ")", "bbox": [624.0, 614.0, 635.0, 626.0]}, {"text": "[10]", "bbox": [469.0, 632.0, 488.0, 645.0]}, {"text": "(intraclass cor-", "bbox": [614.0, 634.0, 705.0, 649.0]}, {"text": "relation coefficient,ICC)", "bbox": [395.0, 654.0, 541.0, 670.0]}], "type": "Text", "position": 40}, {"raw_context": [{"text": ", ICC<0.40", "bbox": [411.0, 676.0, 475.0, 691.0]}, {"text": "11 ; ICC", "bbox": [440.0, 698.0, 478.0, 713.0]}, {"text": "0.60~0.74", "bbox": [478.0, 697.0, 542.0, 711.0]}, {"text": "[11]", "bbox": [473.0, 719.0, 492.0, 732.0]}, {"text": ",", "bbox": [411.0, 726.0, 420.0, 737.0]}, {"text": "2", "bbox": [411.0, 742.0, 421.0, 757.0]}, {"text": "2016", "bbox": [504.0, 742.0, 535.0, 756.0]}], "type": "Text", "position": 41}, {"raw_context": [{"text": "[12]", "bbox": [410.0, 782.0, 428.0, 795.0]}], "type": "Text", "position": 42}, {"raw_context": [{"text": "1, 2", "bbox": [559.0, 785.0, 575.0, 800.0]}], "type": "Text", "position": 43}, {"raw_context": [{"text": "3", "bbox": [655.0, 806.0, 666.0, 820.0]}], "type": "Text", "position": 44}, {"raw_context": [{"text": ":", "bbox": [580.0, 876.0, 587.0, 885.0]}], "type": "Text", "position": 45}, {"raw_context": [{"text": "[4]", "bbox": [665.0, 891.0, 680.0, 902.0]}], "type": "Text", "position": 46}, {"raw_context": [{"text": "[13]", "bbox": [539.0, 933.0, 558.0, 945.0]}], "type": "Text", "position": 47}, {"raw_context": [{"text": "; ICC 0.40~0.59", "bbox": [559.0, 676.0, 661.0, 691.0]}, {"text": ";ICC ≥ 0.75", "bbox": [638.0, 698.0, 707.0, 713.0]}], "type": "Text", "position": 48}, {"raw_context": [{"text": "Chin J Nurs, March 2023, Vol. 58, No. 6", "bbox": [76.0, 1016.0, 288.0, 1032.0]}], "type": "Text", "position": 50}, {"raw_context": [{"text": "1.5", "bbox": [397.0, 848.0, 417.0, 864.0]}], "type": "Text", "position": 52}, {"raw_context": [{"text": "(1).", "bbox": [108.0, 981.0, 123.0, 995.0]}], "type": "Text", "position": 53}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/骨科/解读/膝骨关节炎患者自我管理的最佳证据总结.pdf", "page_num": 2}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "格式杂乱#0#42#内容无法理解", "type3": null, "type4": null, "type5": null, "type6": null}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:42", "update_time": "2024-05-07 19:22:29"}
{"id": 1082634, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 738, "source_info": {"seq_id": "99c85ad6-515c-4cb6-8932-2ef335a778bf", "title": null, "text": "【0】页码:12\n supicy specially approach and a signal volume of the content structure of the conten\n\n【1】## \" Bjhaem\n\n【2】\n In some individuals, insertion of an intrauterine contraceptive device or implant may be appropriate at the time of delivery or on the postnatal ward. The faculty of Sexual Health and Reproductive Healthcare has provided guidance for the contraceptive choices for individuals with cardiac disease. 66 This includes UK Medical Eligibility Criteria for Contraceptive use. There is no specific advice on contraceptive choice in individuals with MHV but it recommends against oestrogen containing contraception in individuals with complex valvular and congenital heart disease and the guidance also states that the presence of a MHV increases the risk of thrombus formation. We consider long-acting reversible contraceptives to be preferable in the postpartum period.\n\n【3】## Review Process\n\n【4】\n Members of the writing group will inform the writing group Chair if any new evidence becomes available that would alter the strength of the recommendations made in this document or render it obsolete. The document will be reviewed regularly by the relevant Task Force and the literature search will be re-run every 3years to search systematically for any new evidence that may have been missed. The document will be archived and removed from the BSH current guidelines website if it becomes obsolete.\n\n【5】If new recommendations are made, an addendum will be published on the BSH guidelines website ( www.b-s-h.org.\n\n【6】uk/guidelines).\n\n【7】## Disclaimer\n\n【8】\n While the advice and information in this guidance is believed to be true and accurate at the time of going to press, neither the authors, the BSH nor the publishers accept any legal responsibility for the content of this guidance.\n\n【9】## Author Contributions\n\n【10】\n All authors contributed to writing, editing and reviewing the manuscript.\n\n【11】## Acknowledgements\n\n【12】\n WL chaired the writing group. All authors contributed to writing, editing and reviewing the manuscript. Additional members of the BSH Haemostasis and Thrombosis Task Force at the time of writing this guideline were as follows: Keith Gomez, Raza Alikhan, Deepa Arachchillage, Julia Anderson, Tina Biss, Elaine Grey, Stella Williams, Khalid Saja, Renu Riat, Karen Breen, Peter Baker, Sean Platton and Ian Jennings.\n\n【13】## Conflict Of Interest Statement\n\n【14】\n The BSH paid the expenses incurred during the writing of this guidance. All authors have made a full declaration of interests to the BSH and Task Force Chairs which may be viewed on request. WL has received speaker fees from Sanofi Aventis and Leo Pharma and speaker fees and attendance of\n\n【15】 advisory boards for Pfizer. CB has received speaker fees and financial support to attend scientific meetings from Sanofi Aventis and speaker fees and attendance of advisory boards for Pfizer.\n\n【16】## Methodology\n\n【17】\n This guideline was compiled according to the BSH process at [https://b-s-h.org.uk/media/16732/bsh-guidance-developmen t-process-dec-5-18.pdf ]. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) nomenclature was used to evaluate levels of evidence and to assess the strength of recommendations. The GRADE criteria can be found at http://www.gradeworkinggroup.org . In the manuscript, the term 'should' indicates a strong recommendation and the term 'recommends' suggests a recommendation that is conditional. A literature search was performed using the terms given in Appendix S1 until April 2022.\n\n【18】## Review Of Manuscript\n\n【19】\n Review of the manuscript was performed by the British Society for Haematology (BSH) Guidelines Haemostasis and Thrombosis Task Force, BSH Guidelines Executive Committee and by the Haemostasis and Thrombosis sounding board of the BSH. It has also been sent to the following organisations for review: UK Maternal Cardiology Society, MacDonald Obstetric Medicine Society, Obstetric Anaesthesia Association and the UK teratology information service. These organisations do not necessarily approve or endorse the contents.\n\n【20】## Orcid\n\n【21】\n Will Lester © https://orcid.org/0000-0001-8790-7112\n REFERENCES 1. Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP 3rd, Gentile F, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation.\n\n【22】2021;143:e35–71.\n\n【23】2. Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur J Cardiothorac Surg. 2021;60:727–800.\n\n【24】3. Caldeira D, David C, Santos AT, Costa J, Pinto FJ, Ferreira JJ. Efficacy and safety of low molecular weight heparin in patients with mechanical heart valves: systematic review and meta-analysis. J Thromb Haemost. 2014;12:650–9.\n\n【25】4. Douketis JD, Spyropoulos AC, Kaatz S, Becker RC, Caprini JA, Dunn AS, et al. Perioperative bridging anticoagulation in patients with atrial fibrillation. N Engl J Med. 2015;373:823–33.\n\n【26】5. Vause S, Clarke B, Tower CL, Hay C, Knight M. Pregnancy outcomes in women with mechanical prosthetic heart valves: a prospective descriptive population based study using the United Kingdom obstetric surveillance system (UKOSS) data collection system. BJOG.\n\n【27】2017;124:1411–9.\n\n【28】6. van Hagen IM, Roos-Hesselink JW, Ruys TP, Merz WM, Goland S, Gabriel H, et al. Pregnancy in women with a mechanical heart valve: data of the European Society of Cardiology Registry of Pregnancy and Cardiac Disease (ROPAC). Circulation. 2015;132:132–42.\n\n【29】7. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomström- Lundqvist C, Cífková R, De Bonis M, et al. 2018 ESC guidelines for", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "supicy specially approach and a signal volume of the content structure of the conten", "bbox": [768.0, 26.0, 782.0, 970.0]}], "type": "Text", "position": 0}, {"raw_context": [{"text": "\" BJHaem", "bbox": [58.0, 23.0, 163.0, 63.0]}], "type": "Section-header", "position": 1}, {"raw_context": [{"text": "In some individuals, insertion of an intrauterine contra-", "bbox": [58.0, 65.0, 385.0, 79.0]}, {"text": "ceptive device or implant may be appropriate at the time", "bbox": [58.0, 80.0, 387.0, 95.0]}, {"text": "of delivery or on the postnatal ward. The faculty of Sexual", "bbox": [58.0, 97.0, 387.0, 112.0]}, {"text": "Health and Reproductive Healthcare has provided guid-", "bbox": [58.0, 113.0, 385.0, 127.0]}, {"text": "ance for the contraceptive choices for individuals with", "bbox": [58.0, 129.0, 387.0, 144.0]}, {"text": "cardiac disease. 66 This includes UK Medical Eligibility", "bbox": [58.0, 144.0, 386.0, 160.0]}, {"text": "Criteria for Contraceptive use. There is no specific advice", "bbox": [58.0, 161.0, 387.0, 175.0]}, {"text": "on contraceptive choice in individuals with MHV but it", "bbox": [58.0, 177.0, 387.0, 192.0]}, {"text": "recommends against oestrogen containing contraception", "bbox": [58.0, 194.0, 387.0, 208.0]}, {"text": "in individuals with complex valvular and congenital heart", "bbox": [58.0, 210.0, 387.0, 225.0]}, {"text": "disease and the guidance also states that the presence of a", "bbox": [58.0, 226.0, 387.0, 240.0]}, {"text": "MHV increases the risk of thrombus formation. We con-", "bbox": [58.0, 242.0, 385.0, 256.0]}, {"text": "sider long-acting reversible contraceptives to be preferable", "bbox": [58.0, 258.0, 387.0, 273.0]}, {"text": "in the postpartum period.", "bbox": [58.0, 274.0, 207.0, 289.0]}], "type": "Text", "position": 2}, {"raw_context": [{"text": "REVIEW PROCESS", "bbox": [58.0, 319.0, 219.0, 337.0]}], "type": "Section-header", "position": 3}, {"raw_context": [{"text": "Members of the writing group will inform the writing", "bbox": [58.0, 354.0, 387.0, 369.0]}, {"text": "group Chair if any new evidence becomes available that", "bbox": [58.0, 370.0, 387.0, 385.0]}, {"text": "would alter the strength of the recommendations made in", "bbox": [58.0, 386.0, 387.0, 401.0]}, {"text": "this document or render it obsolete. The document will", "bbox": [58.0, 402.0, 387.0, 416.0]}, {"text": "be reviewed regularly by the relevant Task Force and the", "bbox": [58.0, 418.0, 387.0, 433.0]}, {"text": "literature search will be re-run every 3years to search", "bbox": [58.0, 435.0, 387.0, 448.0]}, {"text": "systematically for any new evidence that may have been", "bbox": [58.0, 448.0, 387.0, 466.0]}, {"text": "missed. The document will be archived and removed from", "bbox": [58.0, 466.0, 387.0, 481.0]}, {"text": "the BSH current guidelines website if it becomes obsolete.", "bbox": [58.0, 482.0, 386.0, 496.0]}, {"text": "If new recommendations are made, an addendum will be", "bbox": [58.0, 498.0, 387.0, 513.0]}, {"text": "published on the BSH guidelines website ( www.b-s-h.org.", "bbox": [58.0, 515.0, 386.0, 528.0]}, {"text": "uk/guidelines).", "bbox": [58.0, 529.0, 146.0, 545.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": "DISCLAIMER", "bbox": [58.0, 561.0, 158.0, 576.0]}], "type": "Section-header", "position": 5}, {"raw_context": [{"text": "While the advice and information in this guidance is be-", "bbox": [58.0, 577.0, 385.0, 593.0]}, {"text": "lieved to be true and accurate at the time of going to press,", "bbox": [58.0, 595.0, 387.0, 609.0]}, {"text": "neither the authors, the BSH nor the publishers accept any", "bbox": [58.0, 609.0, 386.0, 624.0]}, {"text": "legal responsibility for the content of this guidance.", "bbox": [58.0, 626.0, 339.0, 641.0]}], "type": "Text", "position": 6}, {"raw_context": [{"text": "AUTHOR CONTRIBUTIONS", "bbox": [58.0, 657.0, 261.0, 672.0]}], "type": "Section-header", "position": 7}, {"raw_context": [{"text": "All authors contributed to writing, editing and reviewing", "bbox": [58.0, 674.0, 387.0, 689.0]}, {"text": "the manuscript.", "bbox": [58.0, 689.0, 147.0, 705.0]}], "type": "Text", "position": 8}, {"raw_context": [{"text": "ACKNOWLEDGEMENTS", "bbox": [58.0, 721.0, 234.0, 736.0]}], "type": "Section-header", "position": 9}, {"raw_context": [{"text": "WL chaired the writing group. All authors contributed to", "bbox": [58.0, 737.0, 387.0, 753.0]}, {"text": "writing, editing and reviewing the manuscript. Additional", "bbox": [58.0, 755.0, 387.0, 769.0]}, {"text": "members of the BSH Haemostasis and Thrombosis Task", "bbox": [58.0, 769.0, 386.0, 784.0]}, {"text": "Force at the time of writing this guideline were as follows:", "bbox": [58.0, 786.0, 386.0, 801.0]}, {"text": "Keith Gomez, Raza Alikhan, Deepa Arachchillage, Julia", "bbox": [58.0, 802.0, 387.0, 816.0]}, {"text": "Anderson, Tina Biss, Elaine Grey, Stella Williams, Khalid", "bbox": [58.0, 818.0, 387.0, 833.0]}, {"text": "Saja, Renu Riat, Karen Breen, Peter Baker, Sean Platton and", "bbox": [58.0, 834.0, 386.0, 849.0]}, {"text": "Ian Jennings.", "bbox": [58.0, 849.0, 132.0, 865.0]}], "type": "Text", "position": 10}, {"raw_context": [{"text": "CONFLICT OF INTEREST STATEMENT", "bbox": [58.0, 881.0, 342.0, 896.0]}], "type": "Section-header", "position": 11}, {"raw_context": [{"text": "The BSH paid the expenses incurred during the writing of", "bbox": [58.0, 898.0, 387.0, 913.0]}, {"text": "this guidance. All authors have made a full declaration of", "bbox": [58.0, 915.0, 387.0, 928.0]}, {"text": "interests to the BSH and Task Force Chairs which may be", "bbox": [58.0, 930.0, 387.0, 944.0]}, {"text": "viewed on request. WL has received speaker fees from Sanofi", "bbox": [58.0, 946.0, 387.0, 961.0]}, {"text": "Aventis and Leo Pharma and speaker fees and attendance of", "bbox": [59.0, 963.0, 387.0, 977.0]}], "type": "Text", "position": 12}, {"raw_context": [{"text": "advisory boards for Pfizer. CB has received speaker fees and", "bbox": [406.0, 65.0, 735.0, 79.0]}, {"text": "financial support to attend scientific meetings from Sanofi", "bbox": [406.0, 80.0, 735.0, 95.0]}, {"text": "Aventis and speaker fees and attendance of advisory boards", "bbox": [407.0, 97.0, 735.0, 111.0]}, {"text": "for Pfizer.", "bbox": [406.0, 113.0, 464.0, 127.0]}], "type": "Text", "position": 14}, {"raw_context": [{"text": "METHODOLOGY", "bbox": [406.0, 144.0, 530.0, 159.0]}], "type": "Section-header", "position": 15}, {"raw_context": [{"text": "This guideline was compiled according to the BSH process at", "bbox": [406.0, 160.0, 735.0, 175.0]}, {"text": "[https://b-s-h.org.uk/media/16732/bsh-guidance-developmen", "bbox": [406.0, 177.0, 735.0, 192.0]}, {"text": "t-process-dec-5-18.pdf ]. The Grading of Recommendations", "bbox": [406.0, 194.0, 735.0, 208.0]}, {"text": "Assessment, Development and Evaluation (GRADE) nomen-", "bbox": [407.0, 210.0, 734.0, 224.0]}, {"text": "clature was used to evaluate levels of evidence and to assess", "bbox": [406.0, 226.0, 735.0, 240.0]}, {"text": "the strength of recommendations. The GRADE criteria can", "bbox": [406.0, 242.0, 735.0, 256.0]}, {"text": "be found at http://www.gradeworkinggroup.org . In the manu-", "bbox": [406.0, 258.0, 734.0, 273.0]}, {"text": "script, the term 'should' indicates a strong recommendation", "bbox": [406.0, 274.0, 735.0, 288.0]}, {"text": "and the term 'recommends' suggests a recommendation that", "bbox": [406.0, 290.0, 735.0, 305.0]}, {"text": "is conditional. A literature search was performed using the", "bbox": [406.0, 306.0, 735.0, 321.0]}, {"text": "terms given in Appendix S1 until April 2022.", "bbox": [406.0, 322.0, 645.0, 336.0]}], "type": "Text", "position": 16}, {"raw_context": [{"text": "REVIEW OF MANUSCRIPT", "bbox": [406.0, 353.0, 604.0, 368.0]}], "type": "Section-header", "position": 17}, {"raw_context": [{"text": "Review of the manuscript was performed by the British", "bbox": [406.0, 369.0, 735.0, 384.0]}, {"text": "Society for Haematology (BSH) Guidelines Haemostasis", "bbox": [406.0, 386.0, 735.0, 401.0]}, {"text": "and Thrombosis Task Force, BSH Guidelines Executive", "bbox": [406.0, 401.0, 735.0, 416.0]}, {"text": "Committee and by the Haemostasis and Thrombosis sound-", "bbox": [406.0, 418.0, 734.0, 433.0]}, {"text": "ing board of the BSH. It has also been sent to the follow-", "bbox": [406.0, 435.0, 733.0, 448.0]}, {"text": "ing organisations for review: UK Maternal Cardiology", "bbox": [406.0, 449.0, 734.0, 464.0]}, {"text": "Society, MacDonald Obstetric Medicine Society, Obstetric", "bbox": [406.0, 466.0, 735.0, 481.0]}, {"text": "Anaesthesia Association and the UK teratology information", "bbox": [407.0, 482.0, 735.0, 496.0]}, {"text": "service. These organisations do not necessarily approve or", "bbox": [406.0, 498.0, 734.0, 513.0]}, {"text": "endorse the contents.", "bbox": [406.0, 515.0, 524.0, 528.0]}], "type": "Text", "position": 18}, {"raw_context": [{"text": "ORCID", "bbox": [406.0, 545.0, 459.0, 560.0]}], "type": "Section-header", "position": 19}, {"raw_context": [{"text": "Will Lester © https://orcid.org/0000-0001-8790-7112", "bbox": [408.0, 561.0, 695.0, 576.0]}], "type": "Text", "position": 20}, {"raw_context": [{"text": "REFERENCES", "bbox": [407.0, 593.0, 509.0, 608.0]}, {"text": "1. Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP 3rd,", "bbox": [413.0, 609.0, 734.0, 624.0]}, {"text": "Gentile F, et al. 2020 ACC/AHA guideline for the management of", "bbox": [428.0, 624.0, 735.0, 638.0]}, {"text": "patients with valvular heart disease: executive summary: a report of", "bbox": [430.0, 639.0, 735.0, 651.0]}, {"text": "the American College of Cardiology/American Heart Association", "bbox": [430.0, 652.0, 735.0, 664.0]}, {"text": "Joint Committee on Clinical Practice Guidelines. Circulation.", "bbox": [429.0, 664.0, 733.0, 677.0]}, {"text": "2021;143:e35–71.", "bbox": [430.0, 679.0, 506.0, 691.0]}, {"text": "2. Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs", "bbox": [413.0, 690.0, 735.0, 704.0]}, {"text": "J, et al. 2021 ESC/EACTS Guidelines for the management of valvular", "bbox": [429.0, 705.0, 734.0, 718.0]}, {"text": "heart disease. Eur J Cardiothorac Surg. 2021;60:727–800.", "bbox": [429.0, 719.0, 680.0, 732.0]}, {"text": "3. Caldeira D, David C, Santos AT, Costa J, Pinto FJ, Ferreira JJ. Efficacy", "bbox": [414.0, 732.0, 734.0, 744.0]}, {"text": "and safety of low molecular weight heparin in patients with mechan-", "bbox": [429.0, 746.0, 733.0, 757.0]}, {"text": "ical heart valves: systematic review and meta-analysis. J Thromb", "bbox": [429.0, 759.0, 734.0, 771.0]}, {"text": "Haemost. 2014;12:650–9.", "bbox": [430.0, 773.0, 541.0, 784.0]}, {"text": "4. Douketis JD, Spyropoulos AC, Kaatz S, Becker RC, Caprini JA, Dunn", "bbox": [413.0, 783.0, 735.0, 798.0]}, {"text": "AS, et al. Perioperative bridging anticoagulation in patients with", "bbox": [430.0, 799.0, 735.0, 811.0]}, {"text": "atrial fibrillation. N Engl J Med. 2015;373:823–33.", "bbox": [429.0, 812.0, 649.0, 824.0]}, {"text": "5. Vause S, Clarke B, Tower CL, Hay C, Knight M. Pregnancy outcomes", "bbox": [414.0, 825.0, 734.0, 837.0]}, {"text": "in women with mechanical prosthetic heart valves: a prospective", "bbox": [428.0, 838.0, 734.0, 851.0]}, {"text": "descriptive population based study using the United Kingdom ob-", "bbox": [429.0, 853.0, 733.0, 865.0]}, {"text": "stetric surveillance system (UKOSS) data collection system. BJOG.", "bbox": [429.0, 865.0, 734.0, 878.0]}, {"text": "2017;124:1411–9.", "bbox": [430.0, 879.0, 504.0, 891.0]}, {"text": "6. van Hagen IM, Roos-Hesselink JW, Ruys TP, Merz WM, Goland S,", "bbox": [414.0, 891.0, 735.0, 904.0]}, {"text": "Gabriel H, et al. Pregnancy in women with a mechanical heart valve:", "bbox": [429.0, 905.0, 735.0, 917.0]}, {"text": "data of the European Society of Cardiology Registry of Pregnancy", "bbox": [429.0, 918.0, 734.0, 931.0]}, {"text": "and Cardiac Disease (ROPAC). Circulation. 2015;132:132–42.", "bbox": [430.0, 932.0, 698.0, 944.0]}, {"text": "7. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomström-", "bbox": [414.0, 944.0, 734.0, 958.0]}, {"text": "Lundqvist C, Cífková R, De Bonis M, et al. 2018 ESC guidelines for", "bbox": [428.0, 958.0, 734.0, 972.0]}], "type": "List-item", "position": 21}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/心血管/指南/2023 BSH 指南：机械心脏瓣膜妊娠个体抗凝管理(1).pdf", "page_num": 12}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type2": "多余换行#5#6#( www.b-s-h.org.和uk/guidelines).是一句话\n多余换行#14#15#attendance of和advisory boards for Pfizer是一句话\n缺少换行#21#21#1. Otto CM, Nishimura RA, 另起一行\n多余换行#21#22# Guidelines. Circulation.和2021;143:e35–71.是一句话\n多余换行#26#27#collection system. BJOG.和2017;124:1411–9.是一句话", "type3": "无关文本#0#0#supicy specially approach and a signal volume of the content structure of the conten\n无关文本#1#1#\" Bjhaem\n无关文本#0#29#cardiac disease. 66 部分段落末尾，以及句末的数字问题无关噪声应用全文", "type6": null}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:42", "update_time": "2024-05-08 00:04:03"}
{"id": 1082633, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 738, "source_info": {"seq_id": "8f281568-c846-48c8-81dc-c727f7249d3d", "title": null, "text": "【0】页码:6\n in large HCC has been provided in a multicentre randomized study comparing standard administration versus 99mTc-MAA-based personalized dosimetry. Statistically significant increases of the response rate and the median OS (26.7 months versus 10.7 months, p =0.012) were observed.\n\n【1】in the personalized dosimetry arm [ 67 ].\n\n【2】Despite the above-mentioned limitations, 99 n Tc-MAA is currently the only method available for treatment planning for 90 Y-microspheres.\n\n【3】Because the isotope 166 Ho also emits gamma rays, the administration of a scout dose (250 MBq divided among injection positions; ±3 million particles) of 166 Ho-microspheres is a viable alternative to 99 m Tc-MAA. It has been shown to be safe [ 11 ],and to give a more accurate assessment of the lung shunt fraction [ 12 ], Moreover, a scout dose of 166Ho-microspheres has also been shown to have a superior predictive value in comparison with 99 m Tc-MAA for the prediction of intrahepatic of 166 Ho-microsphere activity distribution [ 68 ]. Using the same microspheres for simulation and therapy, at least, the intrinsic problem of particle difference is overcome. Nevertheless, even the 166 Ho-microspheres scout dose gives uncertain tumour absorbed dose prediction (95% C.I. of about ±100 Gy), indicating that, with the present available devices, the discrepancy between prediction and treatment is an intrinsic feature of radioembolization.\n\n【4】At is important to emphasize that in order to use 99mTc- MAA or 166 Ho-microsphere scout dose for intrahepatic dosimetry, the surrogate used ( 99 m Tc-MAA or 166 Ho-microspheres) and 90 Y/ 166 Ho microspheres should be injected in the same angiographic position, minimizing arterial spasm and the influence of vessel bifurcations, and injected slowly (20–30 s), in order to mimic microsphere infusion [ 67 , 69 ].\n\n【5】Minimizing arterial spasm includes avoiding (whenever technically possible) coil embolization and favouring (whenever technically possible) the use of floppy catheters [ 67 ].\n\n【6】When 99m Tc-MAA (or 166 Ho-microspheres scout dose) is used to plan the treatment with personalized dosimetry, a minimal pretherapy visual quality control is required evaluating the concordance between the 99 m Tc-MAA tumour coverage and the CT or MRI tumour vascularity. Large dis- 'crepancies mean that the simulation was not accurate (e.g.\n\n【7】influence of a bifurcation, spasm) and may be reconsidered.\n\n【8】To optimise the prediction of microsphere distribution, treatment should be performed timely after the diagnostic work up, ideally within 15 days.\n\n【9】## Treatment Planning\n\n【10】\n A subset of different clinical scenarios has been described, depending on the tumour burden [ 69 ]. The following sections provide definitions of clinical scenarios and general dosimetry recommendations for the respective cohorts.\n\n【11】## Radiation Segmentectomy\n\n【12】\n In patients with liver malignancy limited to < 2 liver segments, higher absorbed doses to the perfused target volume can be administered. This leads to high response rates and long PFS [ 70 – 72 ], potentially superior to chemoembolization [ 73 ]. The risk is mitigated by the small volume of the irradiated liver. Therefore, it may also entail a viable treatment strategy for patients with a worse liver function. Limited data is available on patients with liver tumours other than HCC. Yet, the available literature suggests that the same principles can be applied [ 71 ], but further research is warranted.\n\n【13】## Radiation Lobectomy\n\n【14】\n In some patients with unilobar disease, future liver remnants are insufficient to allow for resection. Unilobar treatment allows for higher absorbed doses, since part of the liver remains untreated, aiming for tumour control. Additionally, contralateral/lobar/hypertrophy can be induced, with the potential of bridging previously ineligible patients to resection with curative intent. Radiation lobectomy is also a feasible strategy in downstaging/bridge-to-transplant settings and includes a biologic test of time which may help identify patients most likely to benefit from resection. Hepatobiliary scintigraphy may be considered to assess future liver remnant function at baseline and during follow-up.\n\n【15】## Lobar Disease With/Without Pvt\n\n【16】\n Patients with unilobar disease, who are not amenable for curative surgery because of portal hypertension, cirrhosis, PVT, extrahepatic disease or clinical performance, may be treated with a palliative intent. It is advised to use dosimetry for activity planning, aiming for a sufficient tumour absorbed dose, while keeping the absorbed dose to functional liver tissue below safety limits. Since only part of the liver is treated, higher absorbed doses to functional liver tissue may be acceptable to optimize the tumour absorbed dose. Hepatobiliary scintigraphy may be used to assess the differential function of the treated and non-treated parts of the liver. Targeting of existing PVT is fundamental for treatment success and should be evaluated prior to treatment [ 74 ].\n\n【17】## Bilobar Disease\n\n【18】\n Patients in whom extensive disease precludes radiation segmentectomy or lobectomy, activity has to be planned with the aim to achieve high tumour absorbed doses with", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "in large HCC has been provided in a multicentre rand-", "bbox": [65.0, 72.0, 386.0, 88.0]}, {"text": "omized study comparing standard administration versus", "bbox": [64.0, 90.0, 387.0, 105.0]}, {"text": "99mTc-MAA-based personalized dosimetry. Statistically", "bbox": [66.0, 106.0, 387.0, 123.0]}, {"text": "significant increases of the response rate and the median OS", "bbox": [65.0, 123.0, 387.0, 138.0]}, {"text": "(26.7 months versus 10.7 months, p =0.012) were observed.", "bbox": [64.0, 140.0, 389.0, 155.0]}, {"text": "in the personalized dosimetry arm [ 67 ].", "bbox": [65.0, 157.0, 281.0, 171.0]}, {"text": "Despite the above-mentioned limitations, 99 n Tc-MAA is", "bbox": [80.0, 174.0, 387.0, 188.0]}, {"text": "currently the only method available for treatment planning", "bbox": [64.0, 190.0, 387.0, 205.0]}, {"text": "for 90 Y-microspheres.", "bbox": [65.0, 207.0, 183.0, 221.0]}, {"text": "Because the isotope 166 Ho also emits gamma rays, the", "bbox": [80.0, 222.0, 387.0, 238.0]}, {"text": "administration of a scout dose (250 MBq divided among", "bbox": [66.0, 240.0, 387.0, 255.0]}, {"text": "injection positions; ±3 million particles) of 166 Ho-micro-", "bbox": [65.0, 256.0, 385.0, 272.0]}, {"text": "spheres is a viable alternative to 99 m Tc-MAA. It has been", "bbox": [66.0, 273.0, 387.0, 289.0]}, {"text": "shown to be safe [ 11 ],and to give a more accurate assessment", "bbox": [66.0, 291.0, 387.0, 305.0]}, {"text": "of the lung shunt fraction [ 12 ], Moreover, a scout dose of", "bbox": [65.0, 306.0, 387.0, 321.0]}, {"text": "166Ho-microspheres has also been shown to have a superior", "bbox": [66.0, 322.0, 387.0, 340.0]}, {"text": "predictive value in comparison with 99 m Tc-MAA for the pre-", "bbox": [65.0, 339.0, 385.0, 355.0]}, {"text": "diction of intrahepatic of 166 Ho-microsphere activity distri-", "bbox": [64.0, 356.0, 385.0, 371.0]}, {"text": "bution [ 68 ]. Using the same microspheres for simulation and", "bbox": [64.0, 373.0, 387.0, 388.0]}, {"text": "therapy, at least, the intrinsic problem of particle difference", "bbox": [65.0, 391.0, 387.0, 405.0]}, {"text": "is overcome. Nevertheless, even the 166 Ho-microspheres", "bbox": [65.0, 406.0, 387.0, 422.0]}, {"text": "scout dose gives uncertain tumour absorbed dose prediction", "bbox": [66.0, 424.0, 387.0, 438.0]}, {"text": "(95% C.I. of about ±100 Gy), indicating that, with the pre-", "bbox": [65.0, 440.0, 386.0, 455.0]}, {"text": "sent available devices, the discrepancy between prediction", "bbox": [66.0, 457.0, 387.0, 472.0]}, {"text": "and treatment is an intrinsic feature of radioembolization.", "bbox": [66.0, 474.0, 379.0, 488.0]}, {"text": "At is important to emphasize that in order to use 99mTc-", "bbox": [79.0, 491.0, 385.0, 504.0]}, {"text": "MAA or 166 Ho-microsphere scout dose for intrahepatic", "bbox": [66.0, 507.0, 387.0, 522.0]}, {"text": "dosimetry, the surrogate used ( 99 m Tc-MAA or 166 Ho-micro-", "bbox": [64.0, 523.0, 385.0, 538.0]}, {"text": "spheres) and 90 Y/ 166 Ho microspheres should be injected in", "bbox": [66.0, 538.0, 387.0, 556.0]}, {"text": "the same angiographic position, minimizing arterial spasm", "bbox": [65.0, 557.0, 387.0, 572.0]}, {"text": "and the influence of vessel bifurcations, and injected slowly", "bbox": [66.0, 574.0, 387.0, 589.0]}, {"text": "(20–30 s), in order to mimic microsphere infusion [ 67 , 69 ].", "bbox": [65.0, 590.0, 387.0, 605.0]}, {"text": "Minimizing arterial spasm includes avoiding (whenever", "bbox": [66.0, 607.0, 389.0, 621.0]}, {"text": "technically possible) coil embolization and favouring (when-", "bbox": [65.0, 624.0, 386.0, 639.0]}, {"text": "ever technically possible) the use of floppy catheters [ 67 ].", "bbox": [64.0, 640.0, 381.0, 655.0]}, {"text": "When 99m Tc-MAA (or 166 Ho-microspheres scout dose)", "bbox": [81.0, 657.0, 387.0, 671.0]}, {"text": "is used to plan the treatment with personalized dosimetry, a", "bbox": [64.0, 674.0, 388.0, 688.0]}, {"text": "minimal pretherapy visual quality control is required evalu-", "bbox": [65.0, 691.0, 387.0, 705.0]}, {"text": "ating the concordance between the 99 m Tc-MAA tumour", "bbox": [66.0, 706.0, 387.0, 722.0]}, {"text": "coverage and the CT or MRI tumour vascularity. Large dis-", "bbox": [64.0, 724.0, 385.0, 739.0]}, {"text": "'crepancies mean that the simulation was not accurate (e.g.", "bbox": [64.0, 742.0, 386.0, 755.0]}, {"text": "influence of a bifurcation, spasm) and may be reconsidered.", "bbox": [64.0, 757.0, 387.0, 772.0]}, {"text": "To optimise the prediction of microsphere distribution,", "bbox": [82.0, 774.0, 387.0, 789.0]}, {"text": "treatment should be performed timely after the diagnostic", "bbox": [65.0, 791.0, 387.0, 806.0]}, {"text": "work up, ideally within 15 days.", "bbox": [66.0, 807.0, 246.0, 822.0]}], "type": "Text", "position": 0}, {"raw_context": [{"text": "Treatment planning", "bbox": [66.0, 856.0, 210.0, 873.0]}], "type": "Section-header", "position": 1}, {"raw_context": [{"text": "A subset of different clinical scenarios has been described,", "bbox": [66.0, 890.0, 387.0, 905.0]}, {"text": "depending on the tumour burden [ 69 ]. The following sec-", "bbox": [64.0, 908.0, 385.0, 923.0]}, {"text": "tions provide definitions of clinical scenarios and general", "bbox": [64.0, 924.0, 387.0, 938.0]}, {"text": "dosimetry recommendations for the respective cohorts.", "bbox": [64.0, 941.0, 364.0, 955.0]}], "type": "Text", "position": 2}, {"raw_context": [{"text": "Radiation segmentectomy", "bbox": [405.0, 73.0, 570.0, 89.0]}], "type": "Section-header", "position": 4}, {"raw_context": [{"text": "In patients with liver malignancy limited to < 2 liver", "bbox": [406.0, 108.0, 727.0, 122.0]}, {"text": "segments, higher absorbed doses to the perfused target", "bbox": [405.0, 124.0, 727.0, 139.0]}, {"text": "volume can be administered. This leads to high response", "bbox": [406.0, 141.0, 727.0, 156.0]}, {"text": "rates and long PFS [ 70 – 72 ], potentially superior to", "bbox": [405.0, 158.0, 728.0, 173.0]}, {"text": "chemoembolization [ 73 ]. The risk is mitigated by the", "bbox": [405.0, 174.0, 728.0, 189.0]}, {"text": "small volume of the irradiated liver. Therefore, it may also", "bbox": [406.0, 191.0, 728.0, 206.0]}, {"text": "entail a viable treatment strategy for patients with a worse", "bbox": [405.0, 208.0, 727.0, 223.0]}, {"text": "liver function. Limited data is available on patients with", "bbox": [405.0, 225.0, 728.0, 240.0]}, {"text": "liver tumours other than HCC. Yet, the available literature", "bbox": [405.0, 241.0, 727.0, 255.0]}, {"text": "suggests that the same principles can be applied [ 71 ], but", "bbox": [405.0, 258.0, 729.0, 273.0]}, {"text": "further research is warranted.", "bbox": [406.0, 275.0, 565.0, 290.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "Radiation lobectomy", "bbox": [405.0, 306.0, 535.0, 322.0]}], "type": "Section-header", "position": 6}, {"raw_context": [{"text": "In some patients with unilobar disease, future liver remnants", "bbox": [405.0, 341.0, 727.0, 356.0]}, {"text": "are insufficient to allow for resection. Unilobar treatment", "bbox": [406.0, 358.0, 727.0, 372.0]}, {"text": "allows for higher absorbed doses, since part of the liver", "bbox": [405.0, 375.0, 727.0, 389.0]}, {"text": "remains untreated, aiming for tumour control. Additionally,", "bbox": [405.0, 392.0, 727.0, 406.0]}, {"text": "contralateral/lobar/hypertrophy can be induced, with the", "bbox": [405.0, 408.0, 728.0, 423.0]}, {"text": "potential of bridging previously ineligible patients to", "bbox": [405.0, 425.0, 728.0, 439.0]}, {"text": "resection with curative intent. Radiation lobectomy is also a", "bbox": [405.0, 442.0, 727.0, 456.0]}, {"text": "feasible strategy in downstaging/bridge-to-transplant settings", "bbox": [406.0, 458.0, 727.0, 473.0]}, {"text": "and includes a biologic test of time which may help identify", "bbox": [406.0, 475.0, 726.0, 489.0]}, {"text": "patients most likely to benefit from resection. Hepatobiliary", "bbox": [406.0, 492.0, 727.0, 506.0]}, {"text": "scintigraphy may be considered to assess future liver", "bbox": [405.0, 509.0, 727.0, 523.0]}, {"text": "remnant function at baseline and during follow-up.", "bbox": [405.0, 524.0, 681.0, 539.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "Lobar disease with/without PVT", "bbox": [405.0, 574.0, 602.0, 589.0]}], "type": "Section-header", "position": 8}, {"raw_context": [{"text": "Patients with unilobar disease, who are not amenable for", "bbox": [405.0, 608.0, 727.0, 624.0]}, {"text": "curative surgery because of portal hypertension, cirrhosis,", "bbox": [405.0, 625.0, 727.0, 640.0]}, {"text": "PVT, extrahepatic disease or clinical performance, may", "bbox": [405.0, 642.0, 727.0, 656.0]}, {"text": "be treated with a palliative intent. It is advised to use", "bbox": [405.0, 658.0, 727.0, 673.0]}, {"text": "dosimetry for activity planning, aiming for a sufficient", "bbox": [405.0, 675.0, 727.0, 691.0]}, {"text": "tumour absorbed dose, while keeping the absorbed dose", "bbox": [405.0, 692.0, 727.0, 706.0]}, {"text": "to functional liver tissue below safety limits. Since only", "bbox": [405.0, 708.0, 729.0, 723.0]}, {"text": "part of the liver is treated, higher absorbed doses to", "bbox": [405.0, 725.0, 729.0, 740.0]}, {"text": "functional liver tissue may be acceptable to optimize the", "bbox": [405.0, 742.0, 727.0, 756.0]}, {"text": "tumour absorbed dose. Hepatobiliary scintigraphy may be", "bbox": [405.0, 758.0, 727.0, 772.0]}, {"text": "used to assess the differential function of the treated and", "bbox": [405.0, 775.0, 728.0, 790.0]}, {"text": "non-treated parts of the liver. Targeting of existing PVT is", "bbox": [405.0, 792.0, 728.0, 807.0]}, {"text": "fundamental for treatment success and should be evaluated", "bbox": [405.0, 808.0, 727.0, 823.0]}, {"text": "prior to treatment [ 74 ].", "bbox": [405.0, 825.0, 535.0, 839.0]}], "type": "Text", "position": 9}, {"raw_context": [{"text": "Bilobar disease", "bbox": [405.0, 874.0, 501.0, 889.0]}], "type": "Section-header", "position": 10}, {"raw_context": [{"text": "Patients in whom extensive disease precludes radiation", "bbox": [405.0, 909.0, 727.0, 923.0]}, {"text": "segmentectomy or lobectomy, activity has to be planned", "bbox": [405.0, 925.0, 728.0, 940.0]}, {"text": "with the aim to achieve high tumour absorbed doses with", "bbox": [406.0, 942.0, 727.0, 956.0]}], "type": "Text", "position": 11}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2022】全科室最全临床指南+专家共识（最全版）/2022全科室临床指南/肿瘤科/EANM：动脉内放射性化合物治疗肝癌和转移性肝癌指南（2022）(1).pdf", "page_num": 6}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": "错别字#4#4#At is important应该是It is important", "type2": "多余换行#1#1#in the personalized...与上面0段联接\n多余换行#7#7#influence of a bifurcation, 与上面6段联接", "type3": "无关文本#0#18#...administration versus 99mTc-MAA-based...\n...isotope 166 Ho also...类似里面的99m和数字和 [    ]类的无关引用过多", "type4": null, "type5": null, "type6": null}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:42", "update_time": "2024-05-08 00:56:48"}
{"id": 1082632, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 738, "source_info": {"seq_id": "7c156ef4-919d-418b-a1dd-8edde695810a", "title": null, "text": "【0】页码:1\n Contents lists available at ScienceDirect\n\n【1】 journal homepage: www.elsevier.com/locate/lungcan\n\n【2】 Use of radiation therapy among patients with Extensive-stage Small-cell lung cancer receiving Immunotherapy: Canadian consensus recommendations\n\n【3】 Alexander Sun a ,* , Bassam Abdulkarim b , Normand Blais c , Jonathan Greenland d , Alexander V. Louie 6 , Barbara Melosky f , Devin Schellenberg 8 , Stephanie Snow h , Geoffrey Liu 1\n\n【4】 a Princess Margaret Cancer Centre, 700 University Avenue, Toronto, ON MSG 1Z5, Canada b McGill University Health Centre, McGill University, 1001 Decarie Boulevard, Montréal, QC H4A 3J1, Canada 6 Centre Hospitalier de l'Université de Montréal, University of Montréal, 1051 Rue Sanguanet, Montréal, QC H2X 3E4, Canada a Eastern Health, 300 Prince Philip Drive, St. John's, NL A1B 3V6, Canada \" Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, ON M4N 3M5, Canada 2 BC Cancer—Vancouver Centre, 600 W 10th Avenue, Vancouver, BC V5Z 4E6, Canada 8 BC Cancer— Surrey Centre, 13750 96 Avenue Surrey, BC V3V 1Z2, Canada b QEII Health Sciences Centre, Dathousie University, 5788 University Avenue, Halifax, NS B3H 1V8, Canada 1 Princess Margaret Cancer Centre, University Health Network, 610 University Avenue, Toronto, ON MSG 2M9, Canada\n\n【5】 A R T I C L E  I N F O Keywords: Extensive-stage small-cell lung cancer Thoracic radiation therapy Prophylactic cranial irradiation Immunotherapy Consensus recommendations Guidelines\n\n【6】\n A B S T R A C T\n\n【7】\n Objectives: Thoracic radiation therapy (TRT) and prophylactic cranial irradiation (PCI) are commonly used in the management of extensive-stage small-cell lung cancer (ES-SCLC); however, Phase III trials of first-line immunotherapy often excluded these options. Guidance is needed regarding appropriate use of TRT, PCI, and magnetic resonance imaging (MRI) surveillance while new data are awaited.\n\n【8】Materials and methods: In two web-based meetings, a pan-Canadian expert working group of five radiation oncologists and four medical oncologists addressed eight clinical questions regarding use of radiation therapy (RT) and MRI surveillance among patients with ES-SCLC receiving immunotherapy. A targeted literature review was conducted using PubMed and conference proceedings to identify recent (January 2019–April 2022) publications in this setting. Fifteen recommendations were developed; online voting was conducted to gauge agreement with each recommendation, Results: After considering recently available evidence across lung cancer populations and clinical experience, the experts recommended that all patients with a response to chemo-immunotherapy, good performance status (PS), and limited metastases be considered for consolidation TRT (e.g., 30 Gy in 10 fractions). When considered appropriate after multidisciplinary team discussion, TRT can be initiated during maintenance immunotherapy.\n\n【9】All patients who respond to concurrent chemo-immunotherapy should undergo restaging with brain MRI to guide decision-making regarding PCI versus MRI surveillance alone. MRI surveillance should be conducted for two years after response to initial therapy. PCI (e.g., 25 Gy in 10 fractions or 20 Gy in 5 fractions) can be considered for patients without central nervous system involvement who have a response to chemoimmunotherapy and good PS.  Concurrent treatment with PCI and immunotherapy or with TRT, PCI, and immunotherapy is appropriate after completion of initial therapy. All recommendations were agreed upon unanimously.\n\n【10】Conclusions : These consensus recommendations provide practical guidance regarding appropriate use of RT and immunotherapy in ES-SCLC while awaiting new clinical trial data.\n\n【11】 Corresponding author.\n\n【12】E-mail addresses: alex.sun@rmp.uhn.ca (A. Sun), bassam.abdulkarim@mcgill.ca (B. Abdulkarim), normand.blais.med@ssss.gouv.qc.ca (N. Blais), jonathan.\n\n【13】greenland@easternhealth.ca (J. Greenland), alexander.louie@sunnybrook.ca (A.V. Louie), bmelosky@bccancer.bc.ca (B. Melosky), dschellenberg@bccancer.bc.ca (D. Schellenberg), stephanie.snow@nshealth.ca (S. Snow), geoffrey.liu@uhn.ca (G. Liu).\n\n【14】 https://doi.org/10.1016/j.lungcan.2023.03.002 Received 21 December 2022; Received in revised form 23 February 2023; Accepted 6 March 2023 Available online 9 March 2023 0169-5002/© 2023 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/bync-nd/4.0/ ).", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "Contents lists available at ScienceDirect", "bbox": [303.0, 82.0, 492.0, 94.0]}], "type": "Text", "position": 1}, {"raw_context": [{"text": "journal homepage: www.elsevier.com/locate/lungcan", "bbox": [262.0, 156.0, 533.0, 168.0]}], "type": "Text", "position": 8}, {"raw_context": [{"text": "Use of radiation therapy among patients with Extensive-stage Small-cell", "bbox": [48.0, 219.0, 629.0, 240.0]}, {"text": "lung cancer receiving Immunotherapy: Canadian", "bbox": [48.0, 243.0, 445.0, 263.0]}, {"text": "consensus recommendations", "bbox": [48.0, 267.0, 279.0, 285.0]}], "type": "Text", "position": 9}, {"raw_context": [{"text": "Alexander Sun a ,* , Bassam Abdulkarim b , Normand Blais c , Jonathan Greenland d ,", "bbox": [48.0, 300.0, 557.0, 321.0]}, {"text": "Alexander V. Louie 6 , Barbara Melosky f , Devin Schellenberg 8 , Stephanie Snow h , Geoffrey Liu 1", "bbox": [48.0, 319.0, 645.0, 337.0]}], "type": "Text", "position": 10}, {"raw_context": [{"text": "a Princess Margaret Cancer Centre, 700 University Avenue, Toronto, ON MSG 1Z5, Canada", "bbox": [48.0, 345.0, 382.0, 358.0]}, {"text": "b McGill University Health Centre, McGill University, 1001 Decarie Boulevard, Montréal, QC H4A 3J1, Canada", "bbox": [47.0, 355.0, 453.0, 370.0]}, {"text": "6 Centre Hospitalier de l'Université de Montréal, University of Montréal, 1051 Rue Sanguanet, Montréal, QC H2X 3E4, Canada", "bbox": [47.0, 368.0, 508.0, 380.0]}, {"text": "a Eastern Health, 300 Prince Philip Drive, St. John's, NL A1B 3V6, Canada", "bbox": [47.0, 378.0, 324.0, 393.0]}, {"text": "\" Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, ON M4N 3M5, Canada", "bbox": [48.0, 391.0, 393.0, 404.0]}, {"text": "2 BC Cancer—Vancouver Centre, 600 W 10th Avenue, Vancouver, BC V5Z 4E6, Canada", "bbox": [48.0, 403.0, 368.0, 414.0]}, {"text": "8 BC Cancer— Surrey Centre, 13750 96 Avenue Surrey, BC V3V 1Z2, Canada", "bbox": [47.0, 413.0, 333.0, 426.0]}, {"text": "b QEII Health Sciences Centre, Dathousie University, 5788 University Avenue, Halifax, NS B3H 1V8, Canada", "bbox": [48.0, 425.0, 445.0, 436.0]}, {"text": "1 Princess Margaret Cancer Centre, University Health Network, 610 University Avenue, Toronto, ON MSG 2M9, Canada", "bbox": [48.0, 436.0, 485.0, 449.0]}], "type": "Text", "position": 11}, {"raw_context": [{"text": "A R T I C L E  I N F O", "bbox": [48.0, 480.0, 156.0, 492.0]}, {"text": "Keywords:", "bbox": [48.0, 506.0, 89.0, 518.0]}, {"text": "Extensive-stage small-cell lung cancer", "bbox": [48.0, 517.0, 194.0, 528.0]}, {"text": "Thoracic radiation therapy", "bbox": [48.0, 529.0, 151.0, 539.0]}, {"text": "Prophylactic cranial irradiation", "bbox": [48.0, 540.0, 170.0, 552.0]}, {"text": "Immunotherapy", "bbox": [48.0, 552.0, 111.0, 563.0]}, {"text": "Consensus recommendations", "bbox": [48.0, 564.0, 160.0, 573.0]}, {"text": "Guidelines", "bbox": [48.0, 576.0, 91.0, 586.0]}], "type": "Table", "position": 12}, {"raw_context": [{"text": "A B S T R A C T", "bbox": [267.0, 480.0, 346.0, 492.0]}], "type": "Table", "position": 13}, {"raw_context": [{"text": "Objectives: Thoracic radiation therapy (TRT) and prophylactic cranial irradiation (PCI) are commonly used in the", "bbox": [267.0, 506.0, 745.0, 518.0]}, {"text": "management of extensive-stage small-cell lung cancer (ES-SCLC); however, Phase III trials of first-line immu-", "bbox": [267.0, 519.0, 745.0, 532.0]}, {"text": "notherapy often excluded these options. Guidance is needed regarding appropriate use of TRT, PCI, and magnetic", "bbox": [267.0, 533.0, 745.0, 545.0]}, {"text": "resonance imaging (MRI) surveillance while new data are awaited.", "bbox": [267.0, 545.0, 557.0, 556.0]}, {"text": "Materials and methods: In two web-based meetings, a pan-Canadian expert working group of five radiation on-", "bbox": [268.0, 557.0, 744.0, 570.0]}, {"text": "cologists and four medical oncologists addressed eight clinical questions regarding use of radiation therapy (RT)", "bbox": [267.0, 570.0, 746.0, 582.0]}, {"text": "and MRI surveillance among patients with ES-SCLC receiving immunotherapy. A targeted literature review was", "bbox": [267.0, 583.0, 745.0, 595.0]}, {"text": "conducted using PubMed and conference proceedings to identify recent (January 2019–April 2022) publications", "bbox": [267.0, 596.0, 746.0, 608.0]}, {"text": "in this setting. Fifteen recommendations were developed; online voting was conducted to gauge agreement with", "bbox": [267.0, 608.0, 745.0, 620.0]}, {"text": "each recommendation,", "bbox": [268.0, 622.0, 364.0, 633.0]}, {"text": "Results: After considering recently available evidence across lung cancer populations and clinical experience, the", "bbox": [267.0, 632.0, 745.0, 648.0]}, {"text": "experts recommended that all patients with a response to chemo-immunotherapy, good performance status (PS),", "bbox": [267.0, 647.0, 745.0, 659.0]}, {"text": "and limited metastases be considered for consolidation TRT (e.g., 30 Gy in 10 fractions). When considered", "bbox": [267.0, 660.0, 746.0, 672.0]}, {"text": "appropriate after multidisciplinary team discussion, TRT can be initiated during maintenance immunotherapy.", "bbox": [267.0, 672.0, 745.0, 683.0]}, {"text": "All patients who respond to concurrent chemo-immunotherapy should undergo restaging with brain MRI to", "bbox": [268.0, 685.0, 745.0, 698.0]}, {"text": "guide decision-making regarding PCI versus MRI surveillance alone. MRI surveillance should be conducted for", "bbox": [268.0, 699.0, 745.0, 710.0]}, {"text": "two years after response to initial therapy. PCI (e.g., 25 Gy in 10 fractions or 20 Gy in 5 fractions) can be", "bbox": [267.0, 711.0, 745.0, 722.0]}, {"text": "considered for patients without central nervous system involvement who have a response to chemo-", "bbox": [267.0, 724.0, 745.0, 736.0]}, {"text": "immunotherapy and good PS.  Concurrent treatment with PCI and immunotherapy or with TRT, PCI, and", "bbox": [267.0, 736.0, 746.0, 748.0]}, {"text": "immunotherapy is appropriate after completion of initial therapy. All recommendations were agreed upon", "bbox": [268.0, 749.0, 745.0, 761.0]}, {"text": "unanimously.", "bbox": [268.0, 763.0, 325.0, 772.0]}, {"text": "Conclusions : These consensus recommendations provide practical guidance regarding appropriate use of RT and", "bbox": [267.0, 774.0, 746.0, 786.0]}, {"text": "immunotherapy in ES-SCLC while awaiting new clinical trial data.", "bbox": [267.0, 788.0, 554.0, 799.0]}], "type": "Text", "position": 14}, {"raw_context": [{"text": "Corresponding author.", "bbox": [61.0, 870.0, 162.0, 881.0]}, {"text": "E-mail addresses: alex.sun@rmp.uhn.ca (A. Sun), bassam.abdulkarim@mcgill.ca (B. Abdulkarim), normand.blais.med@ssss.gouv.qc.ca (N. Blais), jonathan.", "bbox": [64.0, 880.0, 744.0, 894.0]}, {"text": "greenland@easternhealth.ca (J. Greenland), alexander.louie@sunnybrook.ca (A.V. Louie), bmelosky@bccancer.bc.ca (B. Melosky), dschellenberg@bccancer.bc.ca", "bbox": [48.0, 893.0, 745.0, 906.0]}, {"text": "(D. Schellenberg), stephanie.snow@nshealth.ca (S. Snow), geoffrey.liu@uhn.ca (G. Liu).", "bbox": [48.0, 908.0, 427.0, 919.0]}], "type": "Text", "position": 15}, {"raw_context": [{"text": "https://doi.org/10.1016/j.lungcan.2023.03.002", "bbox": [48.0, 930.0, 255.0, 941.0]}, {"text": "Received 21 December 2022; Received in revised form 23 February 2023; Accepted 6 March 2023", "bbox": [48.0, 940.0, 475.0, 954.0]}, {"text": "Available online 9 March 2023", "bbox": [48.0, 955.0, 185.0, 966.0]}, {"text": "0169-5002/© 2023 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-", "bbox": [48.0, 965.0, 743.0, 979.0]}, {"text": "nc-nd/4.0/ ).", "bbox": [48.0, 979.0, 103.0, 991.0]}], "type": "Text", "position": 16}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/肿瘤科/共识/加拿大共识建议：在接受免疫治疗的广泛期小细胞肺癌患者中使用放射治疗.pdf", "page_num": 1}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "缺少换行#8#8#Results: After considering recently...另起一行", "type3": null, "type4": null, "type5": null, "type6": "有用性#0#4#期刊信息\n有用性#11#14#作者信息和邮件"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:42", "update_time": "2024-05-07 22:18:19"}
{"id": 1082631, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 738, "source_info": {"seq_id": "2422d88e-5f10-4fec-8c9d-67614994a442", "title": null, "text": "【0】页码:7\n 7\n\n【1】 DSS than those without pelvic involvement (17%, 95% CI 6– 47 vs 62%, 95% CI 50–76%; p < 0.001). A retrospective multicentre study compared the outcomes of bilateral pPLND for N2 or N3 disease versus no surgery and reported better 5- yr overall survival (OS) in the pPLND group (35% vs 25%) without reaching statistical significance [84] . Among patients with N2 disease, 3-yr OS was significantly better in the PLND group than in the no-surgery group (83.3% vs 50.2%, p = 0.03) [84].\n\n【2】Jaipuria et al [85] reported longer OS with adjuvant radiation therapy (54 Gy for extranodal extension [ENE] and 57–60 Gy for residual disease) in comparison to adjuvant chemotherapy for patients with more than two positive LNs but negative pelvic nodes (n = 32; 48 mo vs 14 mo; p < 0.0001). Ager et al [86] reported their experience with pN3 disease (either ENE or pelvic LN+) in two tertiary referral centres, where 121 of 146 patients received adjuvant radiotherapy. The 5- yr recurrence- free survival rate was 51%. The risk of in-field failure was twice as high for lower doses ( ≤ 50 Gy).\n\n【3】Although pelvic LND is recommended for patients with high-risk inguinal pathology (N2–N3), Maibom et al [87] reported on the use of inguinopelvic chemoradiotherapy in 21 patients with median follow-up of 74 mo. All patients had ENE and two-thirds had bilateral inguinal disease. The median OS was 84 mo and the 5-yr survival rate was 57%.\n\n【4】The use of adjuvant chemotherapy was examined in a recent meta-analysis [88] . There was no difference in survival between patients receiving adjuvant chemotherapy and those undergoing observation (hazard ratio 0.95, 95% CI 0.48–1.80).\n\n【5】There are no strong data supporting the use of adjuvant chemotherapy to improve OS following surgical resection.\n\n【6】## 3.5.2.\n\n【7】\n## Cn3 Disease\n\n【8】\n Surgery alone will rarely cure patients with cN3 disease.\n\n【9】While often technically feasible, a surgery-first approach often results in complications (65–77%) and failure to receive adjuvant therapy [89,90] .\n\n【10】Neoadjuvant chemotherapy can be considered in patients with cN3 disease. A recent systematic review reported a radiological response rate of approximately 53% and a pathological complete response in approximately 12.8% of patients [2,91] . The complete response rate in the intention-to-treat population was 10% (paclitaxel, ifosfamide, and cisplatin [TIP]) in comparison to 4% (docetaxel, cisplatin, and fluorouracil [TPF]) in prospective trials [92,93] . In responding patients and those with no evidence of disease progression, surgical resection to remove all residual disease using rILND and pelvic LND techniques is the preferred strategy, with mean 5-yr survival of 56.9% [ 2 ].\n\n【11】Table 5 lists recommendations for management of regional LNs.\n\n【12】## Systemic And Palliative Therapies For Advanced Disease 3.6.\n\n【13】\n The most common regimens currently used for advanced disease are similar to those routinely used in the perioperative setting, consisting of platinum-based regimens.\n\n【14】 Table 5 – Recommendations for management of regional lymph nodes\n\n【15】 Recommendation\n\n【16】\n Strength rating\n\n【17】\n Surgery\n\n【18】\n possible.\n\n【19】 examination.\n\n【20】 Radiotherapy\n\n【21】 Chemotherapy 3.6.1.\n\n【22】Data support the recommendation of platinum-based chemotherapy as the preferred approach for first-line palliative systemic therapy. Choices include triplet regimens (TPF, TIP), with response rates of 38.5–50% and median OS of 7–14 mo [93–95] , and doublets (paclitaxel + 5-FU, paclitaxel + car boplatin), with a response rate of 32% and median OS of 8 mo [96] , with lower toxicity. While data for paclitaxelcarboplatin in advanced penile cancer are limited, it is reasonable to extrapolate from its use as palliative treatment for squamous-cell cancers in other sites [97–99] .\n\n【23】 Immunotherapy and targeted therapies 3.6.2.\n\n【24】Immune-based therapies have emerged as potential treatment options for advanced penile cancer [100] . Trials presented at conferences reported response rates of 14–17% [101,102] . Evidence of sporadic activity of several EGFR inhibitors has been reported [103–105] . Dacomitinib, an orally-available pan-HER inhibitor, was tested in a phase 2 study of 28 patients with locally advanced or distant metastatic penile SCC; the objective response rate was 32.1%, with one patient experiencing a complete response [106] .", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "7", "bbox": [723.0, 42.0, 731.0, 54.0]}], "type": "Text", "position": 2}, {"raw_context": [{"text": "DSS than those without pelvic involvement (17%, 95% CI 6–", "bbox": [66.0, 87.0, 387.0, 101.0]}, {"text": "47 vs 62%, 95% CI 50–76%; p < 0.001). A retrospective mul-", "bbox": [66.0, 102.0, 389.0, 116.0]}, {"text": "ticentre study compared the outcomes of bilateral pPLND", "bbox": [66.0, 117.0, 390.0, 132.0]}, {"text": "for N2 or N3 disease versus no surgery and reported better", "bbox": [66.0, 134.0, 389.0, 147.0]}, {"text": "5- yr overall survival (OS) in the pPLND group (35% vs 25%)", "bbox": [66.0, 149.0, 390.0, 163.0]}, {"text": "without reaching statistical significance [84] . Among", "bbox": [66.0, 164.0, 390.0, 178.0]}, {"text": "patients with N2 disease, 3-yr OS was significantly better", "bbox": [66.0, 180.0, 389.0, 193.0]}, {"text": "in the PLND group than in the no-surgery group (83.3% vs", "bbox": [66.0, 195.0, 389.0, 209.0]}, {"text": "50.2%, p = 0.03) [84].", "bbox": [66.0, 210.0, 181.0, 224.0]}, {"text": "Jaipuria et al [85] reported longer OS with adjuvant radi-", "bbox": [82.0, 225.0, 389.0, 239.0]}, {"text": "ation therapy (54 Gy for extranodal extension [ENE] and", "bbox": [66.0, 240.0, 390.0, 255.0]}, {"text": "57–60 Gy for residual disease) in comparison to adjuvant", "bbox": [66.0, 255.0, 389.0, 270.0]}, {"text": "chemotherapy for patients with more than two positive", "bbox": [66.0, 271.0, 389.0, 285.0]}, {"text": "LNs but negative pelvic nodes (n = 32; 48 mo vs 14 mo;", "bbox": [66.0, 286.0, 389.0, 300.0]}, {"text": "p < 0.0001). Ager et al [86] reported their experience with", "bbox": [66.0, 300.0, 390.0, 315.0]}, {"text": "pN3 disease (either ENE or pelvic LN+) in two tertiary refer-", "bbox": [66.0, 317.0, 388.0, 330.0]}, {"text": "ral centres, where 121 of 146 patients received adjuvant", "bbox": [66.0, 332.0, 390.0, 346.0]}, {"text": "radiotherapy. The 5- yr recurrence- free survival rate was", "bbox": [66.0, 347.0, 389.0, 361.0]}, {"text": "51%. The risk of in-field failure was twice as high for lower", "bbox": [66.0, 363.0, 389.0, 376.0]}, {"text": "doses ( ≤ 50 Gy).", "bbox": [66.0, 378.0, 155.0, 391.0]}, {"text": "Although pelvic LND is recommended for patients with", "bbox": [82.0, 392.0, 390.0, 407.0]}, {"text": "high-risk inguinal pathology (N2–N3), Maibom et al [87]", "bbox": [66.0, 408.0, 389.0, 422.0]}, {"text": "reported on the use of inguinopelvic chemoradiotherapy", "bbox": [66.0, 424.0, 389.0, 437.0]}, {"text": "in 21 patients with median follow-up of 74 mo. All patients", "bbox": [66.0, 439.0, 389.0, 453.0]}, {"text": "had ENE and two-thirds had bilateral inguinal disease. The", "bbox": [66.0, 455.0, 389.0, 468.0]}, {"text": "median OS was 84 mo and the 5-yr survival rate was 57%.", "bbox": [66.0, 469.0, 386.0, 483.0]}, {"text": "The use of adjuvant chemotherapy was examined in a", "bbox": [83.0, 484.0, 389.0, 499.0]}, {"text": "recent meta-analysis [88] . There was no difference in survival", "bbox": [66.0, 501.0, 389.0, 514.0]}, {"text": "between patients receiving adjuvant chemotherapy and those", "bbox": [66.0, 516.0, 389.0, 529.0]}, {"text": "undergoing observation (hazard ratio 0.95, 95% CI 0.48–1.80).", "bbox": [66.0, 530.0, 389.0, 545.0]}, {"text": "There are no strong data supporting the use of adjuvant", "bbox": [66.0, 547.0, 389.0, 560.0]}, {"text": "chemotherapy to improve OS following surgical resection.", "bbox": [66.0, 562.0, 375.0, 576.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "3.5.2.", "bbox": [68.0, 615.0, 96.0, 627.0]}], "type": "Section-header", "position": 4}, {"raw_context": [{"text": "cN3 disease", "bbox": [115.0, 615.0, 175.0, 627.0]}], "type": "Section-header", "position": 5}, {"raw_context": [{"text": "Surgery alone will rarely cure patients with cN3 disease.", "bbox": [66.0, 628.0, 389.0, 642.0]}, {"text": "While often technically feasible, a surgery-first approach", "bbox": [66.0, 643.0, 390.0, 658.0]}, {"text": "often results in complications (65–77%) and failure to", "bbox": [66.0, 659.0, 390.0, 673.0]}, {"text": "receive adjuvant therapy [89,90] .", "bbox": [67.0, 675.0, 248.0, 688.0]}, {"text": "Neoadjuvant chemotherapy can be considered in", "bbox": [82.0, 689.0, 390.0, 704.0]}, {"text": "patients with cN3 disease. A recent systematic review", "bbox": [66.0, 705.0, 389.0, 719.0]}, {"text": "reported a radiological response rate of approximately 53%", "bbox": [66.0, 720.0, 390.0, 733.0]}, {"text": "and a pathological complete response in approximately", "bbox": [66.0, 735.0, 390.0, 750.0]}, {"text": "12.8% of patients [2,91] . The complete response rate in the", "bbox": [67.0, 751.0, 390.0, 765.0]}, {"text": "intention-to-treat population was 10% (paclitaxel, ifos-", "bbox": [66.0, 766.0, 388.0, 780.0]}, {"text": "famide, and cisplatin [TIP]) in comparison to 4% (docetaxel,", "bbox": [66.0, 781.0, 389.0, 796.0]}, {"text": "cisplatin, and fluorouracil [TPF]) in prospective trials", "bbox": [66.0, 796.0, 389.0, 811.0]}, {"text": "[92,93] . In responding patients and those with no evidence", "bbox": [67.0, 812.0, 389.0, 826.0]}, {"text": "of disease progression, surgical resection to remove all", "bbox": [66.0, 826.0, 390.0, 841.0]}, {"text": "residual disease using rILND and pelvic LND techniques is", "bbox": [66.0, 842.0, 389.0, 856.0]}, {"text": "the preferred strategy, with mean 5-yr survival of 56.9% [ 2 ].", "bbox": [66.0, 857.0, 389.0, 871.0]}, {"text": "Table 5 lists recommendations for management of regio-", "bbox": [83.0, 872.0, 388.0, 886.0]}, {"text": "nal LNs.", "bbox": [66.0, 888.0, 113.0, 902.0]}], "type": "Text", "position": 6}, {"raw_context": [{"text": "Systemic and palliative therapies for advanced disease", "bbox": [107.0, 939.0, 377.0, 953.0]}, {"text": "3.6.", "bbox": [67.0, 941.0, 87.0, 953.0]}], "type": "Section-header", "position": 7}, {"raw_context": [{"text": "The most common regimens currently used for advanced", "bbox": [67.0, 963.0, 389.0, 977.0]}, {"text": "disease are similar to those routinely used in the perioper-", "bbox": [66.0, 978.0, 387.0, 993.0]}, {"text": "ative setting, consisting of platinum-based regimens.", "bbox": [66.0, 994.0, 355.0, 1008.0]}], "type": "Text", "position": 8}, {"raw_context": [{"text": "Table 5 – Recommendations for management of regional lymph nodes", "bbox": [418.0, 89.0, 729.0, 100.0]}], "type": "Text", "position": 9}, {"raw_context": [{"text": "Recommendation", "bbox": [422.0, 109.0, 502.0, 120.0]}], "type": "Table", "position": 10}, {"raw_context": [{"text": "Strength", "bbox": [668.0, 109.0, 710.0, 120.0]}, {"text": "rating", "bbox": [668.0, 121.0, 697.0, 133.0]}], "type": "Table", "position": 11}, {"raw_context": [{"text": "Surgery", "bbox": [422.0, 139.0, 455.0, 149.0]}], "type": "Table", "position": 12}, {"raw_context": [{"text": "possible.", "bbox": [436.0, 192.0, 473.0, 202.0]}], "type": "Text", "position": 13}, {"raw_context": [{"text": "examination.", "bbox": [435.0, 339.0, 490.0, 347.0]}], "type": "Text", "position": 14}, {"raw_context": [{"text": "Radiotherapy", "bbox": [422.0, 555.0, 482.0, 566.0]}], "type": "Text", "position": 15}, {"raw_context": [{"text": "Chemotherapy", "bbox": [458.0, 660.0, 531.0, 673.0]}, {"text": "3.6.1.", "bbox": [411.0, 661.0, 439.0, 673.0]}, {"text": "Data support the recommendation of platinum-based", "bbox": [410.0, 674.0, 733.0, 688.0]}, {"text": "chemotherapy as the preferred approach for first-line pallia-", "bbox": [410.0, 689.0, 731.0, 704.0]}, {"text": "tive systemic therapy. Choices include triplet regimens (TPF,", "bbox": [410.0, 706.0, 731.0, 719.0]}, {"text": "TIP), with response rates of 38.5–50% and median OS of 7–14", "bbox": [410.0, 720.0, 733.0, 734.0]}, {"text": "mo [93–95] , and doublets (paclitaxel + 5-FU, paclitaxel + car", "bbox": [410.0, 735.0, 732.0, 750.0]}, {"text": "boplatin), with a response rate of 32% and median OS of 8 mo", "bbox": [410.0, 751.0, 733.0, 765.0]}, {"text": "[96] , with lower toxicity. While data for paclitaxel-", "bbox": [410.0, 766.0, 731.0, 780.0]}, {"text": "carboplatin in advanced penile cancer are limited, it is rea-", "bbox": [410.0, 781.0, 731.0, 796.0]}, {"text": "sonable to extrapolate from its use as palliative treatment", "bbox": [410.0, 797.0, 731.0, 811.0]}, {"text": "for squamous-cell cancers in other sites [97–99] .", "bbox": [410.0, 811.0, 674.0, 826.0]}], "type": "Text", "position": 17}, {"raw_context": [{"text": "Immunotherapy and targeted therapies", "bbox": [458.0, 856.0, 652.0, 871.0]}, {"text": "3.6.2.", "bbox": [411.0, 858.0, 438.0, 870.0]}, {"text": "Immune-based therapies have emerged as potential treat-", "bbox": [410.0, 871.0, 731.0, 886.0]}, {"text": "ment options for advanced penile cancer [100] . Trials pre-", "bbox": [410.0, 886.0, 731.0, 901.0]}, {"text": "sented at conferences reported response rates of 14–17%", "bbox": [410.0, 903.0, 732.0, 916.0]}, {"text": "[101,102] . Evidence of sporadic activity of several EGFR", "bbox": [410.0, 917.0, 732.0, 931.0]}, {"text": "inhibitors has been reported [103–105] . Dacomitinib, an", "bbox": [410.0, 932.0, 733.0, 947.0]}, {"text": "orally-available pan-HER inhibitor, was tested in a phase 2", "bbox": [410.0, 948.0, 731.0, 962.0]}, {"text": "study of 28 patients with locally advanced or distant meta-", "bbox": [410.0, 963.0, 731.0, 977.0]}, {"text": "static penile SCC; the objective response rate was 32.1%,", "bbox": [410.0, 978.0, 731.0, 993.0]}, {"text": "with one patient experiencing a complete response [106] .", "bbox": [410.0, 995.0, 725.0, 1008.0]}], "type": "Text", "position": 18}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/泌尿外科/2023 EAU／ASCO指南：阴茎癌（更新版）.pdf", "page_num": 7}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "多余换行#7#7#Cn3 Disease联接6段\n序号格式不一致#12#12#...Therapies For Advanced Disease 3.6.  序号3.6.  应该在前面\n序号格式不一致#21#21#Chemotherapy 3.6.1.序号3.6.1.应该在前面\n序号格式不一致#23#23#targeted therapies 3.6.2.序号 3.6.2.应该在前面", "type3": "无关文本#0#0# 7\n无关文本#1#24# [84]  类似的 [   ]类无关引用过多", "type4": null, "type5": null, "type6": "准确性#14#20#表格的内容，但是不完整，缺少大部分内容"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:42", "update_time": "2024-05-07 18:54:59"}
{"id": 1082630, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 738, "source_info": {"seq_id": "4f7063c8-c5d9-44d5-83e3-01087d5b1151", "title": null, "text": "【0】页码:2\n\n【1】## 1. Introduction\n\n【2】\n With more than 2.2 million cases diagnosed globally in 2020, lung cancer is one of the most common malignancies in both Canada and worldwide [1,2] . Small-cell lung cancer (SCLC) is an aggressive disease subtype that represents approximately 12% to 15% of all lung cancer cases [2,3] . At diagnosis, about two-thirds of patients with SCLC present with metastatic disease (defined as stage IV using TNM staging from the American Joint Committee on Cancer [AJCC]; previously defined as extensive stage [ES]), which is not amenable to curative local therapy [4,5] .\n\n【3】For over three decades, standard treatment of ES-SCLC included platinum chemotherapy with etoposide (EP), with or without addition of prophylactic cranial irradiation (PCI) [6–8] . Despite high initial objective response rates, median overall survival (mOS) was only about 10 months with this regimen [9–12] . Several randomized clinical trials and a meta-analysis subsequently reported reduced disease progression and improved survival with the addition of thoracic radiation therapy (TRT) to first-line EP [13–16] . Most notably, the Chest Radiotherapy Extensive-Stage Trial (CREST) showed statistically significant improvement of OS with TRT versus no TRT at two years among patients who had responded to EP (13% [n = 14] vs. 3% [n = 5], respectively; p = 0.004), although significance was not met at one year, the primary endpoint [13] . Collectively, the clinical findings for TRT led to its consideration as part of the standard of care for patients with ES-SCLC who respond to chemotherapy, though practices vary globally [17–21] . In contrast, the benefits of PCI have remained more ambiguous, with conflicting OS data reported across studies and concerns arising regarding potential declines in neurocognition and healthrelated quality of life (HRQoL) [6,22,23] . Still, PCI remains commonly used and is recommended in recent guidelines under certain circumstances [17,18,24,25] .\n\n【4】Given the high tumor mutational burden associated with SCLC, as well as the presence of autoimmune paraneoplastic syndromes in some patients, it was hypothesized that immunotherapy may also be beneficial in the first-line setting of ES-SCLC [26,27] . Indeed, the Phase III IMpower133 trial showed that the addition of concurrent and maintenance atezolizumab to chemotherapy resulted in significantly longer OS and progression-free survival (PFS) than chemotherapy alone [28] .\n\n【5】Similarly, the Phase III CASPIAN trial found that concurrent and maintenance durvalumab used in combination with chemotherapy led to significantly longer OS than chemotherapy alone [29] . Both atezolizumab and durvalumab have received approval worldwide and are now included as part of the standard of care in recent treatment guidelines for ES-SCLC [17,18] . In contrast, the Phase III KEYNOTE–604 trial failed to show a statistically significant OS benefit with pembrolizumab and therefore has not received regulatory approval in this setting [30] .\n\n【6】Notably, these trials did not include upfront stratification based on the presence of brain metastases and specified variable requirements for brain scanning and treatment that may have impacted patient selection and treatment outcomes.\n\n【7】The availability of immunotherapy has resulted in a paradigm shift in the treatment of ES-SCLC. Given the limited use of radiation therapy (RT) in the IMpower133 and CASPIAN trials, however, questions remain regarding optimal administration of TRT, PCI, as well as magnetic resonance imaging (MRI) surveillance among patients receiving immunotherapy. In the maintenance phase of IMpower133, PCI was permitted in both treatment arms, but was only administered to approximately 11% of patients; TRT was not allowed [28] . In CASPIAN, PCI was only permitted in the chemotherapy group at the investigator's discretion [29] . Use of TRT was not allowed in CASPIAN, although some patients did receive such therapy either concurrently or subsequent to study treatment [31] . Considering the results of IMpower133, CASPIAN, CREST, and earlier investigations, the American Society for Radiation Oncology (ASTRO) published clinical practice guidelines in 2020 for the recommended use of RT in SCLC [24] . These recommendations were\n\n【8】 subsequently endorsed by the American Society of Clinical Oncology (ASCO) in 2021 [25] . Both guidelines provide statements regarding which patients should receive RT and surveillance and preferred dosefractionation schedules; however, given the limited available evidence at the time of publication, the guidelines do not fully address the timing of RT, MRI surveillance, and immunotherapy administration. The paucity of robust clinical evidence and limited formal guidance for use of RT and immunotherapy have prompted discussions at multidisciplinary team (MDT) meetings regarding the safety, efficacy, and appropriate timing of combining these treatments. This uncertainty has resulted in variations in practice patterns and initiation of several clinical trials (MAVERICK, TRIPLEX, TREASURE, RAPTOR, LUMINANCE), which are expected to read out over the next several years [32–36] .\n\n【9】While awaiting these findings, healthcare providers require clearer guidance on how to appropriately use RT during immunotherapy in ES- SCLC.\n\n【10】Over the last two years, a number of early-phase clinical trials and real- world studies have investigated outcomes among patients with ES- SCLC receiving immunotherapy and concurrent use of TRT and/or PCI [37–43] . The efficacy and tolerability of these combinations have also been preliminarily explored in limited-stage (LS) SCLC [44–46] and demonstrated in non-small cell lung cancer (NSCLC) [47,48] . Given these recent findings and the need for guidance beyond recommendations from ASTRO and ASCO, a Canadian expert working group was convened to define key clinical questions, review the latest evidence, discuss practice recommendations, and reach consensus on practical use of RT among patients with ES-SCLC receiving immunotherapy while additional randomized trial data are awaited.\n\n【11】## 2. Material And Methods\n\n【12】\n## 2.1. Expert Working Group Meeting 1\n\n【13】\n In early 2022, a pan-Canadian multidisciplinary expert working group was convened that included nine clinicians: five radiation oncologists (BA, JG, AVL, AS, DS) and four medical oncologists (NB, BM, GL, SS). The clinicians were selected based on their representative geographic locations across Canada and their expertise related to radiation or medical oncology in the treatment of ES-SCLC. The number of working group members was considered appropriate to achieve consensus based on published literature [49] .\n\n【14】The first of two expert working group meetings occurred virtually via videoconference in January 2022. The experts reviewed clinical data from the IMpower133 and CASPIAN trials and the most recent clinical practice guidelines for RT in SCLC from ASTRO and ASCO [24,25] . The group then discussed eight preliminary key clinical questions related to use of TRT, PCI, and MRI surveillance among patients with ES-SCLC undergoing treatment with immunotherapy. The wording of each question was considered and clinical experiences, key considerations, and information gaps were discussed.\n\n【15】## 2.2. Targeted Literature Search Strategy\n\n【16】\n Following Meeting 1, a series of targeted literature searches were conducted to inform the key clinical questions and data gaps regarding the safety, efficacy, and timing of combining immunotherapy, TRT, and/ or PCI in ES-SCLC. In PubMed, searches were conducted using varying combinations of the following terms: ES-SCLC, TRT, PCI, immunotherapy, durvalumab, and atezolizumab. The conference libraries of ASCO, the European Society for Medical Oncology (ESMO), and the World Conference on Lung Cancer (WCLC) were also searched using a similar set of terms and a time horizon of 2019 onwards. Hand- searching of publication bibliographies was additionally undertaken, as well as Google Scholar searches using the aforementioned terms to identify publications not captured in other searches. Studies of immunotherapy and RT among patients with LS-SCLC were also reviewed, as well as two", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "1. Introduction", "bbox": [48.0, 70.0, 131.0, 83.0]}], "type": "Section-header", "position": 1}, {"raw_context": [{"text": "With more than 2.2 million cases diagnosed globally in 2020, lung", "bbox": [64.0, 97.0, 386.0, 112.0]}, {"text": "cancer is one of the most common malignancies in both Canada and", "bbox": [48.0, 112.0, 387.0, 125.0]}, {"text": "worldwide [1,2] . Small-cell lung cancer (SCLC) is an aggressive disease", "bbox": [48.0, 127.0, 387.0, 139.0]}, {"text": "subtype that represents approximately 12% to 15% of all lung cancer", "bbox": [47.0, 139.0, 387.0, 153.0]}, {"text": "cases [2,3] . At diagnosis, about two-thirds of patients with SCLC present", "bbox": [47.0, 154.0, 387.0, 167.0]}, {"text": "with metastatic disease (defined as stage IV using TNM staging from the", "bbox": [48.0, 167.0, 387.0, 181.0]}, {"text": "American Joint Committee on Cancer [AJCC]; previously defined as", "bbox": [48.0, 181.0, 387.0, 195.0]}, {"text": "extensive stage [ES]), which is not amenable to curative local therapy", "bbox": [47.0, 195.0, 386.0, 210.0]}, {"text": "[4,5] .", "bbox": [48.0, 211.0, 78.0, 224.0]}, {"text": "For over three decades, standard treatment of ES-SCLC included", "bbox": [63.0, 223.0, 387.0, 238.0]}, {"text": "platinum chemotherapy with etoposide (EP), with or without addition of", "bbox": [47.0, 237.0, 387.0, 251.0]}, {"text": "prophylactic cranial irradiation (PCI) [6–8] . Despite high initial objec-", "bbox": [47.0, 251.0, 385.0, 265.0]}, {"text": "tive response rates, median overall survival (mOS) was only about 10", "bbox": [47.0, 265.0, 387.0, 279.0]}, {"text": "months with this regimen [9–12] . Several randomized clinical trials and", "bbox": [48.0, 280.0, 387.0, 292.0]}, {"text": "a meta-analysis subsequently reported reduced disease progression and", "bbox": [48.0, 293.0, 387.0, 306.0]}, {"text": "improved survival with the addition of thoracic radiation therapy (TRT)", "bbox": [47.0, 307.0, 387.0, 320.0]}, {"text": "to first-line EP [13–16] . Most notably, the Chest Radiotherapy", "bbox": [47.0, 321.0, 387.0, 334.0]}, {"text": "Extensive-Stage Trial (CREST) showed statistically significant", "bbox": [47.0, 335.0, 387.0, 348.0]}, {"text": "improvement of OS with TRT versus no TRT at two years among patients", "bbox": [47.0, 349.0, 387.0, 362.0]}, {"text": "who had responded to EP (13% [n = 14] vs. 3% [n = 5], respectively; p", "bbox": [47.0, 363.0, 387.0, 376.0]}, {"text": "= 0.004), although significance was not met at one year, the primary", "bbox": [48.0, 377.0, 387.0, 390.0]}, {"text": "endpoint [13] . Collectively, the clinical findings for TRT led to its", "bbox": [47.0, 391.0, 387.0, 405.0]}, {"text": "consideration as part of the standard of care for patients with ES-SCLC", "bbox": [47.0, 405.0, 387.0, 419.0]}, {"text": "who respond to chemotherapy, though practices vary globally", "bbox": [48.0, 420.0, 387.0, 433.0]}, {"text": "[17–21] . In contrast, the benefits of PCI have remained more ambig-", "bbox": [48.0, 434.0, 386.0, 447.0]}, {"text": "uous, with conflicting OS data reported across studies and concerns", "bbox": [48.0, 448.0, 387.0, 460.0]}, {"text": "arising regarding potential declines in neurocognition and health-", "bbox": [47.0, 461.0, 386.0, 474.0]}, {"text": "related quality of life (HRQoL) [6,22,23] . Still, PCI remains commonly", "bbox": [47.0, 474.0, 387.0, 488.0]}, {"text": "used and is recommended in recent guidelines under certain circum-", "bbox": [47.0, 488.0, 385.0, 503.0]}, {"text": "stances [17,18,24,25] .", "bbox": [48.0, 503.0, 158.0, 517.0]}, {"text": "Given the high tumor mutational burden associated with SCLC, as", "bbox": [62.0, 517.0, 387.0, 531.0]}, {"text": "well as the presence of autoimmune paraneoplastic syndromes in some", "bbox": [47.0, 531.0, 387.0, 545.0]}, {"text": "patients, it was hypothesized that immunotherapy may also be benefi-", "bbox": [47.0, 544.0, 386.0, 558.0]}, {"text": "cial in the first-line setting of ES-SCLC [26,27] . Indeed, the Phase III", "bbox": [46.0, 558.0, 387.0, 573.0]}, {"text": "IMpower133 trial showed that the addition of concurrent and mainte-", "bbox": [47.0, 572.0, 385.0, 586.0]}, {"text": "nance atezolizumab to chemotherapy resulted in significantly longer OS", "bbox": [48.0, 587.0, 387.0, 600.0]}, {"text": "and progression-free survival (PFS) than chemotherapy alone [28] .", "bbox": [48.0, 601.0, 386.0, 614.0]}, {"text": "Similarly, the Phase III CASPIAN trial found that concurrent and", "bbox": [48.0, 615.0, 387.0, 627.0]}, {"text": "maintenance durvalumab used in combination with chemotherapy led", "bbox": [47.0, 628.0, 387.0, 641.0]}, {"text": "to significantly longer OS than chemotherapy alone [29] . Both atezoli-", "bbox": [47.0, 642.0, 385.0, 655.0]}, {"text": "zumab and durvalumab have received approval worldwide and are now", "bbox": [48.0, 656.0, 386.0, 669.0]}, {"text": "included as part of the standard of care in recent treatment guidelines for", "bbox": [47.0, 670.0, 386.0, 683.0]}, {"text": "ES-SCLC [17,18] . In contrast, the Phase III KEYNOTE–604 trial failed to", "bbox": [48.0, 685.0, 387.0, 698.0]}, {"text": "show a statistically significant OS benefit with pembrolizumab and", "bbox": [48.0, 698.0, 387.0, 712.0]}, {"text": "therefore has not received regulatory approval in this setting [30] .", "bbox": [48.0, 713.0, 386.0, 726.0]}, {"text": "Notably, these trials did not include upfront stratification based on the", "bbox": [48.0, 726.0, 387.0, 739.0]}, {"text": "presence of brain metastases and specified variable requirements for", "bbox": [48.0, 740.0, 387.0, 753.0]}, {"text": "brain scanning and treatment that may have impacted patient selection", "bbox": [48.0, 754.0, 387.0, 767.0]}, {"text": "and treatment outcomes.", "bbox": [48.0, 769.0, 168.0, 781.0]}, {"text": "The availability of immunotherapy has resulted in a paradigm shift", "bbox": [64.0, 781.0, 387.0, 796.0]}, {"text": "in the treatment of ES-SCLC. Given the limited use of radiation therapy", "bbox": [47.0, 796.0, 386.0, 810.0]}, {"text": "(RT) in the IMpower133 and CASPIAN trials, however, questions remain", "bbox": [47.0, 810.0, 387.0, 824.0]}, {"text": "regarding optimal administration of TRT, PCI, as well as magnetic", "bbox": [47.0, 824.0, 387.0, 838.0]}, {"text": "resonance imaging (MRI) surveillance among patients receiving immu-", "bbox": [47.0, 838.0, 385.0, 852.0]}, {"text": "notherapy. In the maintenance phase of IMpower133, PCI was permitted", "bbox": [47.0, 851.0, 387.0, 865.0]}, {"text": "in both treatment arms, but was only administered to approximately", "bbox": [47.0, 865.0, 387.0, 879.0]}, {"text": "11% of patients; TRT was not allowed [28] . In CASPIAN, PCI was only", "bbox": [48.0, 879.0, 386.0, 893.0]}, {"text": "permitted in the chemotherapy group at the investigator's discretion", "bbox": [48.0, 893.0, 387.0, 908.0]}, {"text": "[29] . Use of TRT was not allowed in CASPIAN, although some patients", "bbox": [48.0, 908.0, 387.0, 922.0]}, {"text": "did receive such therapy either concurrently or subsequent to study", "bbox": [47.0, 922.0, 386.0, 935.0]}, {"text": "treatment [31] . Considering the results of IMpower133, CASPIAN,", "bbox": [48.0, 937.0, 386.0, 949.0]}, {"text": "CREST, and earlier investigations, the American Society for Radiation", "bbox": [48.0, 951.0, 387.0, 962.0]}, {"text": "Oncology (ASTRO) published clinical practice guidelines in 2020 for the", "bbox": [47.0, 963.0, 387.0, 976.0]}, {"text": "recommended use of RT in SCLC [24] . These recommendations were", "bbox": [48.0, 977.0, 387.0, 991.0]}], "type": "Text", "position": 2}, {"raw_context": [{"text": "subsequently endorsed by the American Society of Clinical Oncology", "bbox": [406.0, 68.0, 745.0, 83.0]}, {"text": "(ASCO) in 2021 [25] . Both guidelines provide statements regarding", "bbox": [406.0, 84.0, 745.0, 98.0]}, {"text": "which patients should receive RT and surveillance and preferred dose-", "bbox": [406.0, 99.0, 744.0, 112.0]}, {"text": "fractionation schedules; however, given the limited available evidence", "bbox": [406.0, 113.0, 745.0, 125.0]}, {"text": "at the time of publication, the guidelines do not fully address the timing", "bbox": [406.0, 126.0, 745.0, 141.0]}, {"text": "of RT, MRI surveillance, and immunotherapy administration. The", "bbox": [405.0, 140.0, 745.0, 153.0]}, {"text": "paucity of robust clinical evidence and limited formal guidance for use", "bbox": [406.0, 154.0, 745.0, 167.0]}, {"text": "of RT and immunotherapy have prompted discussions at multidisci-", "bbox": [405.0, 168.0, 745.0, 181.0]}, {"text": "plinary team (MDT) meetings regarding the safety, efficacy, and", "bbox": [405.0, 181.0, 747.0, 195.0]}, {"text": "appropriate timing of combining these treatments. This uncertainty has", "bbox": [405.0, 195.0, 746.0, 210.0]}, {"text": "resulted in variations in practice patterns and initiation of several clin-", "bbox": [406.0, 210.0, 745.0, 224.0]}, {"text": "ical trials (MAVERICK, TRIPLEX, TREASURE, RAPTOR, LUMINANCE),", "bbox": [405.0, 223.0, 745.0, 238.0]}, {"text": "which are expected to read out over the next several years [32–36] .", "bbox": [405.0, 238.0, 745.0, 251.0]}, {"text": "While awaiting these findings, healthcare providers require clearer", "bbox": [405.0, 251.0, 745.0, 265.0]}, {"text": "guidance on how to appropriately use RT during immunotherapy in ES-", "bbox": [406.0, 265.0, 745.0, 280.0]}, {"text": "SCLC.", "bbox": [406.0, 280.0, 438.0, 292.0]}, {"text": "Over the last two years, a number of early-phase clinical trials and", "bbox": [421.0, 292.0, 747.0, 306.0]}, {"text": "real- world studies have investigated outcomes among patients with ES-", "bbox": [405.0, 307.0, 745.0, 320.0]}, {"text": "SCLC receiving immunotherapy and concurrent use of TRT and/or PCI", "bbox": [405.0, 321.0, 747.0, 334.0]}, {"text": "[37–43] . The efficacy and tolerability of these combinations have also", "bbox": [406.0, 335.0, 746.0, 348.0]}, {"text": "been preliminarily explored in limited-stage (LS) SCLC [44–46] and", "bbox": [405.0, 349.0, 746.0, 362.0]}, {"text": "demonstrated in non-small cell lung cancer (NSCLC) [47,48] . Given", "bbox": [406.0, 363.0, 746.0, 376.0]}, {"text": "these recent findings and the need for guidance beyond recommenda-", "bbox": [405.0, 377.0, 745.0, 390.0]}, {"text": "tions from ASTRO and ASCO, a Canadian expert working group was", "bbox": [405.0, 391.0, 746.0, 405.0]}, {"text": "convened to define key clinical questions, review the latest evidence,", "bbox": [405.0, 405.0, 745.0, 419.0]}, {"text": "discuss practice recommendations, and reach consensus on practical use", "bbox": [406.0, 420.0, 745.0, 433.0]}, {"text": "of RT among patients with ES-SCLC receiving immunotherapy while", "bbox": [405.0, 433.0, 745.0, 446.0]}, {"text": "additional randomized trial data are awaited.", "bbox": [405.0, 447.0, 623.0, 460.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": "2. Material and Methods", "bbox": [405.0, 474.0, 539.0, 488.0]}], "type": "Section-header", "position": 5}, {"raw_context": [{"text": "2.1. Expert working group Meeting 1", "bbox": [405.0, 503.0, 577.0, 517.0]}], "type": "Section-header", "position": 6}, {"raw_context": [{"text": "In early 2022, a pan-Canadian multidisciplinary expert working", "bbox": [421.0, 531.0, 746.0, 545.0]}, {"text": "group was convened that included nine clinicians: five radiation on-", "bbox": [405.0, 544.0, 745.0, 558.0]}, {"text": "cologists (BA, JG, AVL, AS, DS) and four medical oncologists (NB, BM,", "bbox": [405.0, 559.0, 745.0, 572.0]}, {"text": "GL, SS). The clinicians were selected based on their representative", "bbox": [405.0, 572.0, 745.0, 586.0]}, {"text": "geographic locations across Canada and their expertise related to radi-", "bbox": [406.0, 587.0, 745.0, 599.0]}, {"text": "ation or medical oncology in the treatment of ES-SCLC. The number of", "bbox": [406.0, 601.0, 747.0, 614.0]}, {"text": "working group members was considered appropriate to achieve", "bbox": [406.0, 615.0, 746.0, 629.0]}, {"text": "consensus based on published literature [49] .", "bbox": [406.0, 630.0, 625.0, 641.0]}, {"text": "The first of two expert working group meetings occurred virtually via", "bbox": [423.0, 644.0, 747.0, 656.0]}, {"text": "videoconference in January 2022. The experts reviewed clinical data", "bbox": [406.0, 657.0, 746.0, 669.0]}, {"text": "from the IMpower133 and CASPIAN trials and the most recent clinical", "bbox": [406.0, 671.0, 746.0, 683.0]}, {"text": "practice guidelines for RT in SCLC from ASTRO and ASCO [24,25] . The", "bbox": [406.0, 684.0, 745.0, 698.0]}, {"text": "group then discussed eight preliminary key clinical questions related to", "bbox": [406.0, 698.0, 746.0, 712.0]}, {"text": "use of TRT, PCI, and MRI surveillance among patients with ES-SCLC", "bbox": [406.0, 712.0, 745.0, 726.0]}, {"text": "undergoing treatment with immunotherapy. The wording of each", "bbox": [406.0, 727.0, 746.0, 739.0]}, {"text": "question was considered and clinical experiences, key considerations,", "bbox": [406.0, 740.0, 745.0, 753.0]}, {"text": "and information gaps were discussed.", "bbox": [406.0, 755.0, 586.0, 767.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "2.2. Targeted literature search strategy", "bbox": [406.0, 782.0, 586.0, 796.0]}], "type": "Section-header", "position": 8}, {"raw_context": [{"text": "Following Meeting 1, a series of targeted literature searches were", "bbox": [422.0, 811.0, 745.0, 825.0]}, {"text": "conducted to inform the key clinical questions and data gaps regarding", "bbox": [406.0, 826.0, 745.0, 838.0]}, {"text": "the safety, efficacy, and timing of combining immunotherapy, TRT, and/", "bbox": [406.0, 840.0, 744.0, 852.0]}, {"text": "or PCI in ES-SCLC. In PubMed, searches were conducted using varying", "bbox": [406.0, 853.0, 745.0, 866.0]}, {"text": "combinations of the following terms: ES-SCLC, TRT, PCI, immuno-", "bbox": [406.0, 866.0, 745.0, 880.0]}, {"text": "therapy, durvalumab, and atezolizumab. The conference libraries of", "bbox": [406.0, 880.0, 746.0, 894.0]}, {"text": "ASCO, the European Society for Medical Oncology (ESMO), and the", "bbox": [406.0, 893.0, 746.0, 908.0]}, {"text": "World Conference on Lung Cancer (WCLC) were also searched using a", "bbox": [406.0, 908.0, 747.0, 922.0]}, {"text": "similar set of terms and a time horizon of 2019 onwards. Hand- searching", "bbox": [405.0, 922.0, 745.0, 935.0]}, {"text": "of publication bibliographies was additionally undertaken, as well as", "bbox": [405.0, 936.0, 745.0, 949.0]}, {"text": "Google Scholar searches using the aforementioned terms to identify", "bbox": [406.0, 951.0, 745.0, 963.0]}, {"text": "publications not captured in other searches. Studies of immunotherapy", "bbox": [406.0, 965.0, 745.0, 976.0]}, {"text": "and RT among patients with LS-SCLC were also reviewed, as well as two", "bbox": [406.0, 978.0, 745.0, 991.0]}], "type": "Text", "position": 9}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/肿瘤科/共识/加拿大共识建议：在接受免疫治疗的广泛期小细胞肺癌患者中使用放射治疗.pdf", "page_num": 2}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "多余换行#7#8#为同段", "type3": "无关文本#0#16#存在多处无关数字", "type4": null, "type5": null, "type6": null}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:42", "update_time": "2024-05-07 19:22:54"}
{"id": 1082629, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 738, "source_info": {"seq_id": "c1a47dbc-9b71-481f-a3c2-8188b48f25a3", "title": null, "text": "【0】页码:6\n fracture risk; therefore, children who want to participate in these sports should cross-train with low-impact activities. 40\n\n【1】## 3. Lifestyle\n\n【2】\n Ingestion of fast food, alcohol, caffeine, and smoking can promote bone loss and should be avoided. 413 Sedentary activities, such as prolonged TV watching, internet gaming, and cellular phone use, also have negative effects on bone mass. 80\n\n【3】## 4. Body Weight And Composition\n\n【4】\n Body mass index and lean body mass are directly correlated with BMD in most healthy adolescents; conversely, increased adiposity can be related with increased fracture risk. This implies the importance of maintaining healthy body composition during childhood and adolescence.\n\n【5】## 5. Hormonal Status\n\n【6】\n Estrogen, testosterone, GH, and IGF-I can promote bone formation, but excess glucocorticoid increases bone resorption. 8,10,11) Therefore, bone mineral depositions in children with endocrine disorders, such as hypogonadism, Turner syndrome, GH deficiency, and Cushing syndrome, should be carefully investigated and adequately maintained.\n\n【7】## Pharmacological Treatment For Bmd Enhancement\n\n【8】\n## 1. Bisphosphonate\n\n【9】\n 1) Action mechanism and forms of bisphosphonate Bisphosphonates inhibit osteoclast-mediated bone resorption and prevent osteoblast or osteocyte apoptosis. These medications have been used in children with osteogenesis imperfecta, diseases treated with corticosteroids, cerebral palsy, and connective tissue diseases. Bisphosphonates have been reported to increase BMD and decrease pain and fracture in children with these diseases. However, their use in children remains controversial because of long half-lives and potential adverse effects. 49 The various prescription forms of bisphosphonates are shown in Table 6.\n\n【10】 2) Indication for bisphosphonate treatment (1) Primary osteoporosis Bisphosphonates are commonly prescribed for individuals with osteogenesis imperfecta. Many reports have demonstrated that oral or intravenous bisphosphonates increase BMD in children and adults with this condition. 30,51 ) Most patients with idiopathic juvenile osteoporosis tend to remit spontaneously, but if there is a possibility of permanent deformity after vertebral or long bone fracture, bisphosphonate treatment should be considered. 52)\n\n【11】 (2) Secondary osteoporosis Bisphosphonates should be used in children with recurrent extremity fractures, symptomatic vertebral collapse, and severe bone pain caused by other clinical conditions but should not be used to treat asymptomatic reduction in bone mass in children. 539 In addition, sufficient nutrition including calcium/ vitamin D, adequate body weight, physical activity within the /possible range, and supplementation in cases of hormone deficiencies should be prioritized over bisphosphonate treatment. 51 ' Bisphosphonates have been reported to be effective for pediatric patients presenting with secondary osteoporosis with cerebral palsy, juvenile idiopathic arthritis, renal transplantation, renal disease with chronic steroid therapy, Crohn disease, Duchenne muscular dystrophy, leukemia or lymphoma with chemotherapy, or chronic graft-versus-host disease. 55\n\n【12】 3) Practical bisphosphonate therapy Although guideline consensus for bisphosphonate forms, dosage, treatment duration, and interval of administration is needed in children, pamidronate is often used in young children, followed by switching to zoledronate in older patients with moderate-to-severe disease. 540 Pamidronate doses vary from 9 to 12 mg/kg/yr in 4 to 6 divided doses, and zoledronate is initiated at 0.1 mg/kg/yr in 2 divided doses. The starting doses for pamidronate and zoledronate are usually recommended to be reduced to 0.5 mg/kg and 0.0125 or 0.025 mg/kg respectively, to minimize acute-phase reactions and hypocalcemia.\n\n【13】Maintenance therapy at reduced doses is determined by a combination of fracture history, bone pain, BMD, and growth.\n\n【14】The maintenance dosages for pamidronate and zoledronate are 3.0 and 0.025 mg/kg/yr, respectively, administered in 2 divided doses. 543 The typical treatment approaches for children with primary and secondary osteoporosis are shown in Fig. 2.\n\n【15】Contraindications for bisphosphonate therapy include\n\n【16】 Table 6. Name, route of administration, dose, and relative potency of bisphosphonates Name Route dose Potency Etidronate PO 5–40 mg/kg/day for 2 weeks, every 3 months Pamidronate 0.5–1.5 mg/kg/day for 3 days, every 2–6 months (mixed with 200–250 mL of normal saline, infusion for 3 hr) IV 100 1–2 mg/kg/wk or 5 mg/day (<20 kg) 10 mg/day (>20 kg) Alendronate PO 100–1,000 0.015–0.05 mg/kg, every 3–6 months (mixed with 50 mL of normal saline, infusion for 30–45 minut Zoledronate IV PO, per os; IV, intravenous.\n\n【17】Adapted from Baroncelli and Bertelloni. Horm Res Paediatr 2014;82:290-302. 497\n", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "fracture risk; therefore, children who want to participate in these", "bbox": [66.0, 93.0, 383.0, 108.0]}, {"text": "sports should cross-train with low-impact activities. 40", "bbox": [66.0, 109.0, 326.0, 124.0]}], "type": "Text", "position": 2}, {"raw_context": [{"text": "3. Lifestyle", "bbox": [65.0, 140.0, 126.0, 156.0]}], "type": "Section-header", "position": 3}, {"raw_context": [{"text": "Ingestion of fast food, alcohol, caffeine, and smoking can", "bbox": [77.0, 175.0, 383.0, 191.0]}, {"text": "promote bone loss and should be avoided. 413 Sedentary activities,", "bbox": [66.0, 191.0, 383.0, 206.0]}, {"text": "such as prolonged TV watching, internet gaming, and cellular", "bbox": [66.0, 208.0, 382.0, 221.0]}, {"text": "phone use, also have negative effects on bone mass. 80", "bbox": [66.0, 223.0, 321.0, 238.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "4. Body weight and composition", "bbox": [66.0, 254.0, 243.0, 270.0]}], "type": "Section-header", "position": 8}, {"raw_context": [{"text": "Body mass index and lean body mass are directly correlated", "bbox": [76.0, 289.0, 383.0, 305.0]}, {"text": "with BMD in most healthy adolescents; conversely, increased", "bbox": [66.0, 306.0, 383.0, 320.0]}, {"text": "adiposity can be related with increased fracture risk. This implies", "bbox": [66.0, 321.0, 383.0, 337.0]}, {"text": "the importance of maintaining healthy body composition", "bbox": [65.0, 337.0, 383.0, 352.0]}, {"text": "during childhood and adolescence.", "bbox": [64.0, 353.0, 240.0, 368.0]}], "type": "Text", "position": 9}, {"raw_context": [{"text": "5. Hormonal status", "bbox": [65.0, 383.0, 170.0, 398.0]}], "type": "Section-header", "position": 10}, {"raw_context": [{"text": "Estrogen, testosterone, GH, and IGF-I can promote", "bbox": [77.0, 419.0, 383.0, 434.0]}, {"text": "bone formation, but excess glucocorticoid increases bone", "bbox": [64.0, 435.0, 383.0, 450.0]}, {"text": "resorption. 8,10,11) Therefore, bone mineral depositions in children", "bbox": [66.0, 449.0, 383.0, 465.0]}, {"text": "with endocrine disorders, such as hypogonadism, Turner", "bbox": [66.0, 466.0, 383.0, 481.0]}, {"text": "syndrome, GH deficiency, and Cushing syndrome, should be", "bbox": [65.0, 482.0, 383.0, 496.0]}, {"text": "carefully investigated and adequately maintained.", "bbox": [64.0, 497.0, 310.0, 512.0]}], "type": "Text", "position": 11}, {"raw_context": [{"text": "Pharmacological treatment for", "bbox": [66.0, 531.0, 275.0, 546.0]}, {"text": "BMD enhancement", "bbox": [66.0, 548.0, 203.0, 563.0]}], "type": "Section-header", "position": 12}, {"raw_context": [{"text": "1. Bisphosphonate", "bbox": [66.0, 580.0, 170.0, 595.0]}], "type": "Section-header", "position": 13}, {"raw_context": [{"text": "1) Action mechanism and forms of bisphosphonate", "bbox": [77.0, 615.0, 332.0, 630.0]}, {"text": "Bisphosphonates inhibit osteoclast-mediated bone", "bbox": [77.0, 631.0, 383.0, 645.0]}, {"text": "resorption and prevent osteoblast or osteocyte apoptosis. These", "bbox": [66.0, 646.0, 383.0, 661.0]}, {"text": "medications have been used in children with osteogenesis", "bbox": [66.0, 663.0, 383.0, 676.0]}, {"text": "imperfecta, diseases treated with corticosteroids, cerebral", "bbox": [65.0, 678.0, 383.0, 693.0]}, {"text": "palsy, and connective tissue diseases. Bisphosphonates have", "bbox": [66.0, 694.0, 383.0, 708.0]}, {"text": "been reported to increase BMD and decrease pain and", "bbox": [65.0, 710.0, 383.0, 725.0]}, {"text": "fracture in children with these diseases. However, their use in", "bbox": [66.0, 726.0, 383.0, 740.0]}, {"text": "children remains controversial because of long half-lives and", "bbox": [64.0, 741.0, 383.0, 757.0]}, {"text": "potential adverse effects. 49 The various prescription forms of", "bbox": [66.0, 757.0, 383.0, 772.0]}, {"text": "bisphosphonates are shown in Table 6.", "bbox": [66.0, 773.0, 255.0, 788.0]}], "type": "Text", "position": 15}, {"raw_context": [{"text": "2) Indication for bisphosphonate treatment", "bbox": [421.0, 93.0, 636.0, 108.0]}, {"text": "(1) Primary osteoporosis", "bbox": [420.0, 109.0, 546.0, 124.0]}, {"text": "Bisphosphonates are commonly prescribed for individuals", "bbox": [421.0, 125.0, 727.0, 140.0]}, {"text": "with osteogenesis imperfecta. Many reports have demonstrated", "bbox": [410.0, 141.0, 727.0, 155.0]}, {"text": "that oral or intravenous bisphosphonates increase BMD in", "bbox": [408.0, 157.0, 728.0, 172.0]}, {"text": "children and adults with this condition. 30,51 ) Most patients with", "bbox": [409.0, 172.0, 727.0, 186.0]}, {"text": "idiopathic juvenile osteoporosis tend to remit spontaneously,", "bbox": [410.0, 187.0, 727.0, 202.0]}, {"text": "but if there is a possibility of permanent deformity after", "bbox": [409.0, 203.0, 727.0, 218.0]}, {"text": "vertebral or long bone fracture, bisphosphonate treatment", "bbox": [410.0, 219.0, 727.0, 234.0]}, {"text": "should be considered. 52)", "bbox": [410.0, 235.0, 529.0, 249.0]}], "type": "Text", "position": 16}, {"raw_context": [{"text": "(2) Secondary osteoporosis", "bbox": [421.0, 267.0, 557.0, 281.0]}, {"text": "Bisphosphonates should be used in children with recurrent", "bbox": [421.0, 282.0, 726.0, 297.0]}, {"text": "extremity fractures, symptomatic vertebral collapse, and severe", "bbox": [410.0, 298.0, 726.0, 313.0]}, {"text": "bone pain caused by other clinical conditions but should not", "bbox": [409.0, 314.0, 727.0, 329.0]}, {"text": "be used to treat asymptomatic reduction in bone mass in", "bbox": [409.0, 330.0, 727.0, 345.0]}, {"text": "children. 539 In addition, sufficient nutrition including calcium/", "bbox": [409.0, 345.0, 726.0, 360.0]}, {"text": "vitamin D, adequate body weight, physical activity within the", "bbox": [410.0, 361.0, 727.0, 376.0]}, {"text": "/possible range, and supplementation in cases of hormone", "bbox": [408.0, 377.0, 727.0, 391.0]}, {"text": "deficiencies should be prioritized over bisphosphonate", "bbox": [409.0, 392.0, 727.0, 407.0]}, {"text": "treatment. 51 ' Bisphosphonates have been reported to be", "bbox": [410.0, 407.0, 727.0, 424.0]}, {"text": "effective for pediatric patients presenting with secondary", "bbox": [408.0, 424.0, 727.0, 439.0]}, {"text": "osteoporosis with cerebral palsy, juvenile idiopathic arthritis,", "bbox": [409.0, 440.0, 727.0, 454.0]}, {"text": "renal transplantation, renal disease with chronic steroid therapy,", "bbox": [410.0, 456.0, 727.0, 471.0]}, {"text": "Crohn disease, Duchenne muscular dystrophy, leukemia or", "bbox": [408.0, 472.0, 727.0, 486.0]}, {"text": "lymphoma with chemotherapy, or chronic graft-versus-host", "bbox": [410.0, 487.0, 726.0, 503.0]}, {"text": "disease. 55", "bbox": [410.0, 503.0, 455.0, 518.0]}], "type": "Text", "position": 17}, {"raw_context": [{"text": "3) Practical bisphosphonate therapy", "bbox": [421.0, 533.0, 600.0, 548.0]}, {"text": "Although guideline consensus for bisphosphonate forms,", "bbox": [422.0, 549.0, 727.0, 564.0]}, {"text": "dosage, treatment duration, and interval of administration", "bbox": [410.0, 565.0, 728.0, 580.0]}, {"text": "is needed in children, pamidronate is often used in young", "bbox": [410.0, 582.0, 727.0, 596.0]}, {"text": "children, followed by switching to zoledronate in older patients", "bbox": [408.0, 597.0, 727.0, 612.0]}, {"text": "with moderate-to-severe disease. 540 Pamidronate doses vary", "bbox": [409.0, 612.0, 727.0, 629.0]}, {"text": "from 9 to 12 mg/kg/yr in 4 to 6 divided doses, and zoledronate", "bbox": [410.0, 629.0, 727.0, 644.0]}, {"text": "is initiated at 0.1 mg/kg/yr in 2 divided doses. The starting doses", "bbox": [410.0, 645.0, 727.0, 659.0]}, {"text": "for pamidronate and zoledronate are usually recommended to", "bbox": [410.0, 660.0, 728.0, 675.0]}, {"text": "be reduced to 0.5 mg/kg and 0.0125 or 0.025 mg/kg respectively,", "bbox": [409.0, 675.0, 727.0, 690.0]}, {"text": "to minimize acute-phase reactions and hypocalcemia.", "bbox": [410.0, 691.0, 727.0, 706.0]}, {"text": "Maintenance therapy at reduced doses is determined by a", "bbox": [410.0, 708.0, 730.0, 722.0]}, {"text": "combination of fracture history, bone pain, BMD, and growth.", "bbox": [410.0, 723.0, 729.0, 738.0]}, {"text": "The maintenance dosages for pamidronate and zoledronate are", "bbox": [410.0, 739.0, 727.0, 754.0]}, {"text": "3.0 and 0.025 mg/kg/yr, respectively, administered in 2 divided", "bbox": [410.0, 755.0, 727.0, 770.0]}, {"text": "doses. 543 The typical treatment approaches for children with", "bbox": [409.0, 771.0, 728.0, 786.0]}, {"text": "primary and secondary osteoporosis are shown in Fig. 2.", "bbox": [410.0, 787.0, 688.0, 801.0]}, {"text": "Contraindications for bisphosphonate therapy include", "bbox": [420.0, 802.0, 727.0, 817.0]}], "type": "Text", "position": 18}, {"raw_context": [{"text": "Table 6. Name, route of administration, dose, and relative potency of bisphosphonates", "bbox": [67.0, 850.0, 483.0, 865.0]}, {"text": "Name", "bbox": [68.0, 869.0, 95.0, 881.0]}, {"text": "Route", "bbox": [142.0, 870.0, 164.0, 880.0]}, {"text": "dose", "bbox": [404.0, 870.0, 430.0, 880.0]}, {"text": "Potency", "bbox": [676.0, 870.0, 710.0, 881.0]}, {"text": "Etidronate", "bbox": [67.0, 884.0, 115.0, 896.0]}, {"text": "PO", "bbox": [144.0, 884.0, 162.0, 895.0]}, {"text": "5–40 mg/kg/day for 2 weeks, every 3 months", "bbox": [171.0, 884.0, 370.0, 897.0]}, {"text": "Pamidronate", "bbox": [66.0, 898.0, 126.0, 912.0]}, {"text": "0.5–1.5 mg/kg/day for 3 days, every 2–6 months (mixed with 200–250 mL of normal saline, infusion for 3 hr)", "bbox": [169.0, 898.0, 643.0, 912.0]}, {"text": "IV", "bbox": [146.0, 900.0, 160.0, 911.0]}, {"text": "100", "bbox": [684.0, 900.0, 704.0, 911.0]}, {"text": "1–2 mg/kg/wk or 5 mg/day (<20 kg) 10 mg/day (>20 kg)", "bbox": [170.0, 914.0, 424.0, 929.0]}, {"text": "Alendronate", "bbox": [68.0, 915.0, 125.0, 927.0]}, {"text": "PO", "bbox": [145.0, 916.0, 163.0, 927.0]}, {"text": "100–1,000", "bbox": [672.0, 916.0, 717.0, 927.0]}, {"text": "0.015–0.05 mg/kg, every 3–6 months (mixed with 50 mL of normal saline, infusion for 30–45 minut", "bbox": [168.0, 929.0, 602.0, 946.0]}, {"text": "Zoledronate", "bbox": [68.0, 931.0, 123.0, 944.0]}, {"text": "IV", "bbox": [147.0, 931.0, 160.0, 942.0]}, {"text": "PO, per os; IV, intravenous.", "bbox": [67.0, 947.0, 194.0, 960.0]}, {"text": "Adapted from Baroncelli and Bertelloni. Horm Res Paediatr 2014;82:290-302. 497", "bbox": [66.0, 960.0, 437.0, 974.0]}], "type": "Table", "position": 19}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2022】全科室最全临床指南+专家共识（最全版）/2022全科室临床指南/内分泌科/KSPE：优化儿童和青少年骨健康的临床实践指南（2022）.pdf", "page_num": 6}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "缺少换行#10#10#2) Indication for bisphosphonate treatment\n (1) Primary osteoporosis这两处应和前面换行\n缺少换行#11#11#Bisphosphonates should这里开始应与前面换行\n缺少换行#12#12#Although guideline这里开始应与前面换行\n表格格式错误#16#16#不是表格格式呈现的", "type3": "无关文本#0#17#存在多处无关数字", "type4": null, "type5": null, "type6": "信息有用性#17#17#无用内容"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:42", "update_time": "2024-05-07 18:02:48"}
{"id": 1082628, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 738, "source_info": {"seq_id": "3927120f-c31d-44d7-9ff0-b579a1c8b33d", "title": null, "text": "【0】页码:17\n reported with TNE, at the expense of more pain on insertion and a risk of mild epistaxis of up to 4%. 191 Patients are also more tional oral endoscopy in the future. 186 187 191 192 The lack of standardised definitions of discomfort, tolerance and acceptability, the use of subjective and non-validated tools for measurement and lack of blinding in often small studies limits the strength of these findings.\n\n【1】TNE is also an attractive option in patients with comorbidity and at risk of sedation-related complications. Studies have shown that TNE causes fewer effects on cardiovascular function than sedated transoral endoscopy, with less tachycardia and less hypotension in some, but not all, studies. 186 187 190 193 Studies using objective markers of cardiovascular stress, such as pulse rate, systolic blood pressure (SBP) and double product (DP = SBP × heart rate (HR)), rate–pressure product (RPP = HR × SBP/100) or sympathetic stimulation (power spectral analysis), have found less impact on these parameters than with oral endoscopy. 187 190 194 Mori et al found that sympathetic stimulation occurred only with oral endoscopy, but not with TNE. 193 As TNE is performed unsedated, there are no specific sedationrelated complications. Other complications and adverse effects are infrequent and limited to minor epistaxis in up to 3–4% and inability to pass the endoscope transnasally due to narrow nasal passages or altered anatomy in 3–8% of patients. 196\n\n【2】## Special Considerations: Lower Gi Endoscopy\n\n【3】\n 33. We recommend for colonoscopy that alternatives to sedation, including no sedation, inhalational agents and other adjuncts, are considered Grade of evidence: Moderate. Strength of recommendation: Strong.\n\n【4】Level of agreement: 100% In a case series of 22 725 colonoscopies in the Polish bowel cancer screening programme, the majority of colonoscopies were undertaken without any sedation (64%), and 73% of these patients subsequently reported no discomfort during or after the procedure. 197 In an older case series of colonoscopies, when given the choice, patients were more likely to choose unsedated rather than sedated colonoscopy if they were male or not anxious before the procedure. There was no difference in caecal intubation rate or time to reach the caecum between the two groups. Although unsedated colonoscopy was statistically more uncomfortable, there was no reported difference in the willingness to repeat the procedure if needed in future. 1 In a randomised controlled trial, Entonox (50% nitrous oxide and 50% oxygen) has been shown to provide better control of pain than sedation, better patient satisfaction and more rapid recovery during colonoscopy. 20 A systematic review concluded that nitrous oxide is as good at controlling pain or discomfort as sedation and safer. 19 Another randomised trial showed that either water exchange during intubation and carbon dioxide (rather than air) insufflation on extubation or carbon dioxide throughout the procedure reduced discomfort and interference with activities on the day of colonoscopy. 20 A number of factors can predict pain during endoscopy and guide clinician advice on sedation and alternatives. Female sex, age <40 years, previous abdominal surgery, abdominal pain as an indication for colonoscopy, expectation of pain, a previous painful colonoscopy, previous sexual abuse 201 and a history of diverticulitis were independently associated with pain during colonoscopy. 202\n\n【5】 34. We suggest that lower GI endoscopy with deep sedation (propofol) or general anaesthesia should be available for selected patients undergoing planned prolonged procedures or complex endotherapy Grade of evidence: Low. Strength of recommendation: Weak.\n\n【6】Level of agreement: 100% In a systematic review of 20 studies of propofol for colonoscopy, recovery and discharge times were shorter and there was higher patient satisfaction. There was no difference in procedure time, caecal intubation rate or complications. 203 In a more recent case series of 22.725 colonoscopies, in the Polish bowel cancer screening programme, undertaken with no sedation, benzodiazepine/opiate or propofol, independent modifiable factors associated with less pain during the procedure included propofol sedation, adequate bowel preparation, newer endoscopes and high colonoscopy volume endoscopists. 1 In the UK, the use of propofol has been limited owing to concerns about its narrow therapeutic index, the lack of an antidote, the need for anaesthetic support and the risk of cardiorespiratory complications, especially in the elderly. 3 It has been recommended that propofol (or general anaesthesia) is considered for patients undergoing planned prolonged procedures (>60 min) or complex endotherapy in the colon. 3 Deep sedation can also be considered for selected patients who are unable to tolerate colonoscopy with standard sedation and where alternative procedures are deemed not suitable.\n\n【7】Concerns have been raised about an increased rate of perforation during colonoscopy and an increased rate of aspiration pneumonia and other anaesthetic complications following deep sedation with propofol. In a single-centre retrospective study of 118 000 colonoscopies, deep sedation with propofol was associated with a threefold increased risk of perforation during therapeutic colonoscopy. 204 The results of subsequent large population-based studies of deep sedation and colonoscopy are conflicting, with three having not revealed an increased perfoand one revealing an increased risk in patients ration risk 205 – 207 undergoing colonoscopy and polypectomy. 208 All these studies were unable to control for the complexity of polypectomy, and it is possible that the increased risk in two of the studies relates to the underlying polyp and polypectomy rather than the use of deep sedation. However, all of the population-based studies reported an increased risk of aspiration pneumonia or anaesthetic complications with anaesthetic support to provide deep sedation with propofol. 205 207 208\n\n【8】## Special Considerations: High-Risk Groups\n\n【9】\n 35. We recommend that clinicians fully discuss with patients at an increased risk from sedation for endoscopy (eg, due to age, frailty or comorbidity), the benefits and potential risks of sedation and alternatives to sedation, including no sedation Grade of evidence: Low. Strength of recommendation: Strong.\n\n【10】Level of agreement: 92.3% The 2004 National Confidential Enquiry into Patient Outcome and Death 'Scoping our practice' reviewed 30-day mortality associated with gastrointestinal endoscopy. 209 Of patients who died, 79% had received some form of sedation.\n\n【11】Sedation was considered inappropriate in 14% of cases, with excessive drug doses and drug combinations, particularly in the elderly, being identified as issues. Reversal of sedation was needed in 14% of cases, often owing to poor recognition by endoscopists of how sensitive those with comorbidity can be to the effects of sedation and the use of a 'standard' dose of sedation, most commonly 5 mg IV midazolam, which was clearly too 17", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "reported with TNE, at the expense of more pain on insertion", "bbox": [53.0, 60.0, 387.0, 75.0]}, {"text": "and a risk of mild epistaxis of up to 4%. 191 Patients are also more", "bbox": [53.0, 74.0, 387.0, 90.0]}, {"text": "tional oral endoscopy in the future. 186 187 191 192 The lack of stan-", "bbox": [52.0, 90.0, 386.0, 120.0]}, {"text": "dardised definitions of discomfort, tolerance and acceptability,", "bbox": [53.0, 120.0, 387.0, 135.0]}, {"text": "the use of subjective and non-validated tools for measurement", "bbox": [53.0, 135.0, 387.0, 150.0]}, {"text": "and lack of blinding in often small studies limits the strength of", "bbox": [53.0, 150.0, 387.0, 164.0]}, {"text": "these findings.", "bbox": [54.0, 166.0, 131.0, 179.0]}, {"text": "TNE is also an attractive option in patients with comorbidity", "bbox": [66.0, 180.0, 385.0, 193.0]}, {"text": "and at risk of sedation-related complications. Studies have", "bbox": [54.0, 195.0, 387.0, 208.0]}, {"text": "shown that TNE causes fewer effects on cardiovascular function", "bbox": [53.0, 209.0, 387.0, 223.0]}, {"text": "than sedated transoral endoscopy, with less tachycardia and less", "bbox": [53.0, 223.0, 387.0, 238.0]}, {"text": "hypotension in some, but not all, studies. 186 187 190 193 Studies", "bbox": [54.0, 237.0, 387.0, 252.0]}, {"text": "using objective markers of cardiovascular stress, such as pulse", "bbox": [53.0, 254.0, 387.0, 266.0]}, {"text": "rate, systolic blood pressure (SBP) and double product (DP =", "bbox": [53.0, 268.0, 385.0, 281.0]}, {"text": "SBP × heart rate (HR)), rate–pressure product (RPP = HR ×", "bbox": [53.0, 282.0, 385.0, 296.0]}, {"text": "SBP/100) or sympathetic stimulation (power spectral analysis),", "bbox": [53.0, 297.0, 385.0, 312.0]}, {"text": "have found less impact on these parameters than with oral", "bbox": [53.0, 311.0, 387.0, 326.0]}, {"text": "endoscopy. 187 190 194 Mori et al found that sympathetic stimula-", "bbox": [53.0, 324.0, 385.0, 340.0]}, {"text": "tion occurred only with oral endoscopy, but not with TNE. 193", "bbox": [53.0, 342.0, 371.0, 355.0]}, {"text": "As TNE is performed unsedated, there are no specific sedation-", "bbox": [66.0, 356.0, 385.0, 369.0]}, {"text": "related complications. Other complications and adverse effects", "bbox": [54.0, 372.0, 387.0, 384.0]}, {"text": "are infrequent and limited to minor epistaxis in up to 3–4% and", "bbox": [53.0, 385.0, 387.0, 399.0]}, {"text": "inability to pass the endoscope transnasally due to narrow nasal", "bbox": [53.0, 400.0, 386.0, 414.0]}, {"text": "passages or altered anatomy in 3–8% of patients. 196", "bbox": [53.0, 414.0, 317.0, 428.0]}], "type": "Text", "position": 0}, {"raw_context": [{"text": "Special considerations: lower GI endoscopy", "bbox": [53.0, 455.0, 287.0, 469.0]}], "type": "Section-header", "position": 1}, {"raw_context": [{"text": "33. We recommend for colonoscopy that alternatives to seda-", "bbox": [53.0, 470.0, 385.0, 485.0]}, {"text": "tion, including no sedation, inhalational agents and other", "bbox": [53.0, 485.0, 385.0, 499.0]}, {"text": "adjuncts, are considered", "bbox": [54.0, 502.0, 183.0, 513.0]}, {"text": "Grade of evidence: Moderate. Strength of recommendation:", "bbox": [64.0, 513.0, 385.0, 528.0]}, {"text": "Strong.", "bbox": [54.0, 531.0, 93.0, 543.0]}, {"text": "Level of agreement: 100%", "bbox": [64.0, 545.0, 203.0, 558.0]}, {"text": "In a case series of 22 725 colonoscopies in the Polish bowel", "bbox": [65.0, 558.0, 387.0, 573.0]}, {"text": "cancer screening programme, the majority of colonoscopies", "bbox": [53.0, 573.0, 387.0, 587.0]}, {"text": "were undertaken without any sedation (64%), and 73% of", "bbox": [53.0, 588.0, 387.0, 602.0]}, {"text": "these patients subsequently reported no discomfort during or", "bbox": [53.0, 603.0, 386.0, 616.0]}, {"text": "after the procedure. 197 In an older case series of colonoscopies,", "bbox": [53.0, 617.0, 386.0, 631.0]}, {"text": "when given the choice, patients were more likely to choose unse-", "bbox": [53.0, 632.0, 385.0, 646.0]}, {"text": "dated rather than sedated colonoscopy if they were male or not", "bbox": [53.0, 647.0, 386.0, 661.0]}, {"text": "anxious before the procedure. There was no difference in caecal", "bbox": [53.0, 661.0, 386.0, 675.0]}, {"text": "intubation rate or time to reach the caecum between the two", "bbox": [53.0, 677.0, 387.0, 690.0]}, {"text": "groups. Although unsedated colonoscopy was statistically more", "bbox": [53.0, 692.0, 387.0, 705.0]}, {"text": "uncomfortable, there was no reported difference in the willing-", "bbox": [53.0, 706.0, 385.0, 720.0]}, {"text": "ness to repeat the procedure if needed in future. 1", "bbox": [53.0, 721.0, 306.0, 735.0]}, {"text": "In a randomised controlled trial, Entonox (50% nitrous oxide", "bbox": [65.0, 736.0, 386.0, 750.0]}, {"text": "and 50% oxygen) has been shown to provide better control of", "bbox": [53.0, 751.0, 387.0, 764.0]}, {"text": "pain than sedation, better patient satisfaction and more rapid", "bbox": [53.0, 765.0, 387.0, 779.0]}, {"text": "recovery during colonoscopy. 20 A systematic review concluded", "bbox": [53.0, 780.0, 387.0, 793.0]}, {"text": "that nitrous oxide is as good at controlling pain or discomfort as", "bbox": [53.0, 794.0, 387.0, 809.0]}, {"text": "sedation and safer. 19", "bbox": [53.0, 809.0, 158.0, 823.0]}, {"text": "Another randomised trial showed that either water exchange", "bbox": [66.0, 823.0, 386.0, 838.0]}, {"text": "during intubation and carbon dioxide (rather than air) insuffla-", "bbox": [53.0, 839.0, 385.0, 852.0]}, {"text": "tion on extubation or carbon dioxide throughout the procedure", "bbox": [53.0, 854.0, 386.0, 867.0]}, {"text": "reduced discomfort and interference with activities on the day", "bbox": [53.0, 868.0, 385.0, 881.0]}, {"text": "of colonoscopy. 20", "bbox": [54.0, 884.0, 144.0, 896.0]}, {"text": "A number of factors can predict pain during endoscopy and", "bbox": [65.0, 897.0, 387.0, 912.0]}, {"text": "guide clinician advice on sedation and alternatives. Female sex,", "bbox": [53.0, 912.0, 386.0, 926.0]}, {"text": "age <40 years, previous abdominal surgery, abdominal pain as", "bbox": [53.0, 927.0, 387.0, 941.0]}, {"text": "an indication for colonoscopy, expectation of pain, a previous", "bbox": [53.0, 942.0, 387.0, 955.0]}, {"text": "painful colonoscopy, previous sexual abuse 201 and a history of", "bbox": [53.0, 954.0, 387.0, 971.0]}, {"text": "diverticulitis were independently associated with pain during", "bbox": [53.0, 970.0, 387.0, 985.0]}, {"text": "colonoscopy. 202", "bbox": [53.0, 985.0, 133.0, 1000.0]}], "type": "Text", "position": 2}, {"raw_context": [{"text": "34. We suggest that lower GI endoscopy with deep sedation", "bbox": [418.0, 60.0, 740.0, 75.0]}, {"text": "(propofol) or general anaesthesia should be available for selected", "bbox": [406.0, 76.0, 740.0, 90.0]}, {"text": "patients undergoing planned prolonged procedures or complex", "bbox": [406.0, 91.0, 740.0, 105.0]}, {"text": "endotherapy", "bbox": [407.0, 107.0, 475.0, 119.0]}, {"text": "Grade of evidence: Low. Strength of recommendation: Weak.", "bbox": [418.0, 120.0, 732.0, 135.0]}, {"text": "Level of agreement: 100%", "bbox": [418.0, 135.0, 557.0, 150.0]}, {"text": "In a systematic review of 20 studies of propofol for colonos-", "bbox": [418.0, 150.0, 739.0, 164.0]}, {"text": "copy, recovery and discharge times were shorter and there was", "bbox": [406.0, 165.0, 741.0, 179.0]}, {"text": "higher patient satisfaction. There was no difference in procedure", "bbox": [406.0, 180.0, 740.0, 193.0]}, {"text": "time, caecal intubation rate or complications. 203 In a more recent", "bbox": [406.0, 195.0, 741.0, 208.0]}, {"text": "case series of 22.725 colonoscopies, in the Polish bowel cancer", "bbox": [406.0, 209.0, 739.0, 222.0]}, {"text": "screening programme, undertaken with no sedation, benzodiaz-", "bbox": [406.0, 223.0, 739.0, 238.0]}, {"text": "epine/opiate or propofol, independent modifiable factors asso-", "bbox": [406.0, 238.0, 739.0, 252.0]}, {"text": "ciated with less pain during the procedure included propofol", "bbox": [406.0, 253.0, 740.0, 267.0]}, {"text": "sedation, adequate bowel preparation, newer endoscopes and", "bbox": [406.0, 268.0, 740.0, 281.0]}, {"text": "high colonoscopy volume endoscopists. 1", "bbox": [406.0, 283.0, 613.0, 296.0]}, {"text": "In the UK, the use of propofol has been limited owing to", "bbox": [418.0, 297.0, 741.0, 312.0]}, {"text": "concerns about its narrow therapeutic index, the lack of an anti-", "bbox": [406.0, 311.0, 739.0, 326.0]}, {"text": "dote, the need for anaesthetic support and the risk of cardio-", "bbox": [406.0, 327.0, 739.0, 341.0]}, {"text": "respiratory complications, especially in the elderly. 3 It has been", "bbox": [406.0, 342.0, 740.0, 355.0]}, {"text": "recommended that propofol (or general anaesthesia) is consid-", "bbox": [406.0, 356.0, 739.0, 369.0]}, {"text": "ered for patients undergoing planned prolonged procedures", "bbox": [406.0, 370.0, 740.0, 384.0]}, {"text": "(>60 min) or complex endotherapy in the colon. 3 Deep sedation", "bbox": [406.0, 385.0, 741.0, 399.0]}, {"text": "can also be considered for selected patients who are unable to", "bbox": [406.0, 399.0, 741.0, 414.0]}, {"text": "tolerate colonoscopy with standard sedation and where alterna-", "bbox": [406.0, 415.0, 739.0, 428.0]}, {"text": "tive procedures are deemed not suitable.", "bbox": [406.0, 430.0, 617.0, 443.0]}, {"text": "Concerns have been raised about an increased rate of perfo-", "bbox": [418.0, 444.0, 739.0, 458.0]}, {"text": "ration during colonoscopy and an increased rate of aspiration", "bbox": [406.0, 459.0, 741.0, 473.0]}, {"text": "pneumonia and other anaesthetic complications following deep", "bbox": [406.0, 473.0, 740.0, 488.0]}, {"text": "sedation with propofol. In a single-centre retrospective study", "bbox": [406.0, 488.0, 740.0, 503.0]}, {"text": "of 118 000 colonoscopies, deep sedation with propofol was", "bbox": [406.0, 503.0, 741.0, 518.0]}, {"text": "associated with a threefold increased risk of perforation during", "bbox": [406.0, 518.0, 741.0, 532.0]}, {"text": "therapeutic colonoscopy. 204 The results of subsequent large", "bbox": [406.0, 532.0, 740.0, 546.0]}, {"text": "population-based studies of deep sedation and colonoscopy are", "bbox": [406.0, 547.0, 740.0, 562.0]}, {"text": "conflicting, with three having not revealed an increased perfo-", "bbox": [406.0, 562.0, 739.0, 577.0]}, {"text": "and one revealing an increased risk in patients", "bbox": [492.0, 577.0, 741.0, 591.0]}, {"text": "ration risk 205 – 207", "bbox": [406.0, 579.0, 493.0, 589.0]}, {"text": "undergoing colonoscopy and polypectomy. 208 All these studies", "bbox": [406.0, 591.0, 741.0, 605.0]}, {"text": "were unable to control for the complexity of polypectomy, and", "bbox": [406.0, 606.0, 740.0, 620.0]}, {"text": "it is possible that the increased risk in two of the studies relates", "bbox": [406.0, 621.0, 741.0, 635.0]}, {"text": "to the underlying polyp and polypectomy rather than the use", "bbox": [406.0, 636.0, 740.0, 650.0]}, {"text": "of deep sedation. However, all of the population-based studies", "bbox": [406.0, 650.0, 741.0, 665.0]}, {"text": "reported an increased risk of aspiration pneumonia or anaes-", "bbox": [406.0, 665.0, 739.0, 679.0]}, {"text": "thetic complications with anaesthetic support to provide deep", "bbox": [406.0, 678.0, 740.0, 695.0]}, {"text": "sedation with propofol. 205 207 208", "bbox": [407.0, 696.0, 573.0, 707.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "Special considerations: high-risk groups", "bbox": [406.0, 735.0, 621.0, 750.0]}], "type": "Section-header", "position": 6}, {"raw_context": [{"text": "35. We recommend that clinicians fully discuss with patients at", "bbox": [408.0, 751.0, 740.0, 765.0]}, {"text": "an increased risk from sedation for endoscopy (eg, due to age,", "bbox": [406.0, 766.0, 740.0, 779.0]}, {"text": "frailty or comorbidity), the benefits and potential risks of seda-", "bbox": [406.0, 780.0, 739.0, 793.0]}, {"text": "tion and alternatives to sedation, including no sedation", "bbox": [406.0, 795.0, 695.0, 808.0]}, {"text": "Grade of evidence: Low. Strength of recommendation: Strong.", "bbox": [418.0, 809.0, 737.0, 824.0]}, {"text": "Level of agreement: 92.3%", "bbox": [418.0, 824.0, 561.0, 838.0]}, {"text": "The 2004 National Confidential Enquiry into Patient", "bbox": [419.0, 838.0, 739.0, 852.0]}, {"text": "Outcome and Death 'Scoping our practice' reviewed 30-day", "bbox": [406.0, 853.0, 739.0, 867.0]}, {"text": "mortality associated with gastrointestinal endoscopy. 209 Of", "bbox": [406.0, 868.0, 739.0, 881.0]}, {"text": "patients who died, 79% had received some form of sedation.", "bbox": [407.0, 882.0, 739.0, 897.0]}, {"text": "Sedation was considered inappropriate in 14% of cases, with", "bbox": [406.0, 897.0, 741.0, 912.0]}, {"text": "excessive drug doses and drug combinations, particularly in", "bbox": [406.0, 912.0, 741.0, 926.0]}, {"text": "the elderly, being identified as issues. Reversal of sedation was", "bbox": [406.0, 927.0, 741.0, 941.0]}, {"text": "needed in 14% of cases, often owing to poor recognition by", "bbox": [406.0, 942.0, 740.0, 955.0]}, {"text": "endoscopists of how sensitive those with comorbidity can be to", "bbox": [406.0, 956.0, 741.0, 969.0]}, {"text": "the effects of sedation and the use of a 'standard' dose of seda-", "bbox": [406.0, 970.0, 739.0, 984.0]}, {"text": "tion, most commonly 5 mg IV midazolam, which was clearly too", "bbox": [406.0, 985.0, 740.0, 1000.0]}, {"text": "17", "bbox": [727.0, 1011.0, 738.0, 1021.0]}], "type": "Text", "position": 7}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/消化科/_2023 BSG指南：胃肠内窥镜检查中的镇静.pdf", "page_num": 17}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "缺少换行#1#1#As TNE is performed unsedated, 这里开始应换行\n缺少换行#3#3#Grade of evidence:这里开始应换行\n缺少换行#4#4#In a randomised controlled tria               Another randomised trial              A number of factors can predict pai这三处开始应换行\n缺少换行#5#5#Grade of evidence: L这里开始应换行\n缺少换行#6#6#In the UK, the use of propofol这里开始应换行\n缺少换行#9#9Grade of evidence: Low.这里开始应换行\n缺少换行#10#10#The 2004 National Confidential这里开始应换行", "type3": "无关文本#0#11#存在多处无关数字", "type4": null, "type5": null, "type6": null}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:42", "update_time": "2024-05-07 19:08:31"}
{"id": 1082627, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 738, "source_info": {"seq_id": "5b78d920-0a63-425c-a99d-aa2aaf0ec274", "title": null, "text": "【0】页码:4\n\n【1】 Lung Cancer 179 (2023) 107166 A. Sun et al.\n\n【2】Table 1 Summary of recommendations regarding use of RT among patients with ES-SCLC receiving immunotherapy.\n\n【3】Target Population Patients with ES-SCLC undergoing first-line treatment with chemo-immunotherapy.\n\n【4】Medical oncologists; radiation oncologists; oncology nurses and physician assistants; pulmonologists, radiologists; community care Target Audience practitioners; and patients.\n\n【5】Clinical Question Recommendation(s) Level of Key Considerations Agreement Thoracic Radiation Therapy 1. Which patients with ES-SCLC should be 1.1 All patients with a response to concurrent chemo- Unanimous . All patients should be referred to a radiation oncologist referred to a radiation oncologist for immunotherapy, good PS, and limited metastases barring major contraindications for TRT (e.g., consideration of consolidation TRT?\n\n【6】should be considered for consolidation TRT.\n\n【7】comorbidities, poor PS).\n\n【8】1.2 Patients with expected or existing lung cancer symptoms should also be considered for palliative TRT, regardless of response to concurrent chemoimmunotherapy.\n\n【9】2. What is the appropriate dose- 2.1 TRT to a dose of 30 Gy in 10 fractions is Unanimous • Schedule has shown acceptable disease control and fractionation schedule for recommended; a modified schedule may be appropriate toxicity in several clinical studies.\n\n【10】consolidation TRT?\n\n【11】based on patient characteristics and preferences.\n\n【12】• An alternative schedule may be appropriate depending on the response to concurrent chemo-immunotherapy, the need for palliation/symptom control, and/or patient willingness to receive TRT.\n\n【13】3. What is the optimal timing of 3.1 Although current randomized Phase III trials do not Unanimous • As the IMpower133 and CASPIAN trials did not permit consolidation TRT during include TRT, concurrent treatment with TRT and planned administration of TRT, robust evidence for immunotherapy?\n\n【14】maintenance immunotherapy can be initiated if concurrent use with immunotherapy is limited; however, considered appropriate based on discussions between other studies conducted in ES-SCLC, LS-SCLC, and the medical and radiation oncologists.\n\n【15】NSCLC suggest that toxicity is acceptable, and survival 3.2 Consolidation TRT should be provided after may be improved with concurrent administration of completion of concurrent chemo-immunotherapy.\n\n【16】immunotherapy and TRT.\n\n【17】• Given the relatively long half-lives of immunotherapies, holding treatment during TRT may not be beneficial.\n\n【18】. Clinical trials are ongoing to address this question (e.g., TRIPLEX, TREASURE, RAPTOR).\n\n【19】Prophylactic Cranial Irradiation & MRI Surveillance 4. Which patients with ES-SCLC should be 4.1 All patients who respond to concurrent chemo- Unanimous • Patients with brain metastases are not candidates for PCI referred to a radiation oncologist for immunotherapy should undergo restaging with brain or MRI surveillance.\n\n【20】• If MRI surveillance and PCI are not options, CT consideration of PCI or MRI MRI to guide decision-making regarding PCI or MRI surveillance?\n\n【21】surveillance alone.\n\n【22】surveillance can be offered however does not have 4.2 Consultation with a radiation oncologist is clinical equipoise recommended to enhance shared decision-making on • Good communication is required across the MDT to PCI versus MRI surveillance alone.\n\n【23】confirm who is responsible for PCI/MRI surveillance.\n\n【24】4.3 Patients with a response to concurrent chemo- • Clinical trials are ongoing to address this question in the immunotherapy, without brain metastases and with context of immunotherapy (e.g., MAVERICK).\n\n【25】good PS, should be considered for PCI.\n\n【26】5. What is the recommended timing of 5.1 MRI surveillance should be conducted for 2 years Unanimous • MRI frequency recommendation is generally aligned after response to concurrent chemo-immunotherapy: MRI surveillance?\n\n【27】with that in Takahashi 2017. [22] every 3 months in Year 1 and every 6 months in Year 2.\n\n【28】CT is inferior to MRI for detection of brain metastases; 5.2 MRI surveillance may be conducted by the medical however, patients with medical devices or other oncologist or the radiation oncologist.\n\n【29】contraindications may not be eligible for MRI.\n\n【30】5.3 Computed tomography should only be used when MRI is not an option.\n\n【31】6. What is the appropriate dose- 6.1 PCI to a dose of 25 Gy in 10 fractions is Unanimous • Schedule has shown acceptable disease control and fractionation schedule for PCI?\n\n【32】recommended; 20 Gy in 5 fractions is an alternative.\n\n【33】toxicity in several clinical studies.\n\n【34】. Hippocampal sparing and use of memantine may be considered to prevent cognitive decline.\n\n【35】7. What is the optimal timing of PCI 7.1 Concurrent treatment with PCI and immunotherapy . PCI was permitted in the immunotherapy arms of Unanimous during immunotherapy?\n\n【36】IMpower133 and KEYNOTE-604 and has been used in is appropriate.\n\n【37】7.2 PCI should be provided after completion of other recent immunotherapy studies; no safety signals concurrent chemo- immunotherapy.\n\n【38】were identified.\n\n【39】• The MDT should discuss appropriate timing on a case-bycase basis.\n\n【40】. Clinical trials are ongoing to address this question (e.g., MAVERICK, LUMINANCE).\n\n【41】Thoracic Radiation Therapy & Prophylactic Cranial Irradiation 8.1 Concurrent treatment with TRT, PCI, and • See Key Considerations for Questions 3 and 7.\n\n【42】8. What is the optimal timing of TRT + Unanimous PCI among patients receiving immunotherapy is appropriate.\n\n【43】• As the toxicities associated with PCI and TRT differ, immunotherapy?\n\n【44】8.2 Consolidation TRT and PCI should be provided after concurrent treatment with PCI, TRT, and completion of concurrent chemo-immunotherapy.\n\n【45】immunotherapy is appropriate for suitable patients.\n\n【46】. Clinical trials are ongoing to address this question (e.g., MAVERICK).\n\n【47】Abbreviations: ASTRO = American Society for Radiation Oncology; ATZ = atezolizumab; chemo-immunotherapy = chemotherapy and immunotherapy; CT = computed tomography; DUR = durvalumab; ES = extensive stage; Gy = gray; LS = limited stage; MDT = multidisciplinary team; MRI = magnetic resonance imaging; NSCIC = non-small cell lung cancer; PCI = prophylactic cranial irradiation; PS = performance status; RT = radiation therapy; SCIC = small-cell lung cancer; TRT = thoracic radiation therapy.\n", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "Lung Cancer 179 (2023) 107166", "bbox": [621.0, 45.0, 747.0, 58.0]}, {"text": "A. Sun et al.", "bbox": [48.0, 46.0, 95.0, 58.0]}, {"text": "Table 1", "bbox": [48.0, 72.0, 84.0, 83.0]}, {"text": "Summary of recommendations regarding use of RT among patients with ES-SCLC receiving immunotherapy.", "bbox": [48.0, 82.0, 510.0, 97.0]}, {"text": "Target Population", "bbox": [56.0, 103.0, 127.0, 114.0]}, {"text": "Patients with ES-SCLC undergoing first-line treatment with chemo-immunotherapy.", "bbox": [225.0, 103.0, 543.0, 114.0]}, {"text": "Medical oncologists; radiation oncologists; oncology nurses and physician assistants; pulmonologists, radiologists; community care", "bbox": [226.0, 113.0, 721.0, 126.0]}, {"text": "Target Audience", "bbox": [56.0, 114.0, 120.0, 126.0]}, {"text": "practitioners; and patients.", "bbox": [226.0, 126.0, 329.0, 136.0]}, {"text": "Clinical Question", "bbox": [56.0, 136.0, 124.0, 148.0]}, {"text": "Recommendation(s)", "bbox": [226.0, 138.0, 305.0, 146.0]}, {"text": "Level of", "bbox": [448.0, 138.0, 483.0, 147.0]}, {"text": "Key Considerations", "bbox": [514.0, 137.0, 590.0, 149.0]}, {"text": "Agreement", "bbox": [449.0, 150.0, 493.0, 161.0]}, {"text": "Thoracic Radiation Therapy", "bbox": [56.0, 166.0, 168.0, 178.0]}, {"text": "1. Which patients with ES-SCLC should be", "bbox": [56.0, 177.0, 213.0, 189.0]}, {"text": "1.1 All patients with a response to concurrent chemo-", "bbox": [226.0, 178.0, 430.0, 189.0]}, {"text": "Unanimous", "bbox": [448.0, 178.0, 496.0, 189.0]}, {"text": ". All patients should be referred to a radiation oncologist", "bbox": [514.0, 177.0, 737.0, 189.0]}, {"text": "referred to a radiation oncologist for", "bbox": [63.0, 188.0, 205.0, 200.0]}, {"text": "immunotherapy, good PS, and limited metastases", "bbox": [226.0, 188.0, 415.0, 200.0]}, {"text": "barring major contraindications for TRT (e.g.,", "bbox": [522.0, 188.0, 699.0, 200.0]}, {"text": "consideration of consolidation TRT?", "bbox": [64.0, 202.0, 203.0, 212.0]}, {"text": "should be considered for consolidation TRT.", "bbox": [226.0, 202.0, 394.0, 212.0]}, {"text": "comorbidities, poor PS).", "bbox": [523.0, 202.0, 617.0, 213.0]}, {"text": "1.2 Patients with expected or existing lung cancer", "bbox": [226.0, 212.0, 416.0, 224.0]}, {"text": "symptoms should also be considered for palliative TRT,", "bbox": [226.0, 223.0, 436.0, 234.0]}, {"text": "regardless of response to concurrent chemo-", "bbox": [226.0, 234.0, 394.0, 246.0]}, {"text": "immunotherapy.", "bbox": [226.0, 246.0, 291.0, 257.0]}, {"text": "2. What is the appropriate dose-", "bbox": [56.0, 258.0, 179.0, 270.0]}, {"text": "2.1 TRT to a dose of 30 Gy in 10 fractions is", "bbox": [226.0, 258.0, 397.0, 270.0]}, {"text": "Unanimous", "bbox": [448.0, 258.0, 496.0, 270.0]}, {"text": "• Schedule has shown acceptable disease control and", "bbox": [514.0, 258.0, 721.0, 270.0]}, {"text": "fractionation schedule for", "bbox": [64.0, 269.0, 164.0, 280.0]}, {"text": "recommended; a modified schedule may be appropriate", "bbox": [226.0, 269.0, 437.0, 280.0]}, {"text": "toxicity in several clinical studies.", "bbox": [523.0, 269.0, 653.0, 280.0]}, {"text": "consolidation TRT?", "bbox": [64.0, 280.0, 140.0, 292.0]}, {"text": "based on patient characteristics and preferences.", "bbox": [226.0, 280.0, 410.0, 292.0]}, {"text": "• An alternative schedule may be appropriate depending", "bbox": [514.0, 280.0, 734.0, 292.0]}, {"text": "on the response to concurrent chemo-immunotherapy,", "bbox": [522.0, 292.0, 732.0, 302.0]}, {"text": "the need for palliation/symptom control, and/or patient", "bbox": [523.0, 304.0, 736.0, 314.0]}, {"text": "willingness to receive TRT.", "bbox": [523.0, 315.0, 626.0, 326.0]}, {"text": "3. What is the optimal timing of", "bbox": [56.0, 325.0, 181.0, 337.0]}, {"text": "3.1 Although current randomized Phase III trials do not", "bbox": [226.0, 325.0, 438.0, 337.0]}, {"text": "Unanimous", "bbox": [448.0, 326.0, 496.0, 337.0]}, {"text": "• As the IMpower133 and CASPIAN trials did not permit", "bbox": [515.0, 326.0, 733.0, 337.0]}, {"text": "consolidation TRT during", "bbox": [64.0, 337.0, 164.0, 349.0]}, {"text": "include TRT, concurrent treatment with TRT and", "bbox": [226.0, 337.0, 414.0, 348.0]}, {"text": "planned administration of TRT, robust evidence for", "bbox": [522.0, 337.0, 721.0, 349.0]}, {"text": "immunotherapy?", "bbox": [64.0, 350.0, 131.0, 360.0]}, {"text": "maintenance immunotherapy can be initiated if", "bbox": [226.0, 350.0, 410.0, 361.0]}, {"text": "concurrent use with immunotherapy is limited; however,", "bbox": [523.0, 350.0, 736.0, 360.0]}, {"text": "considered appropriate based on discussions between", "bbox": [226.0, 360.0, 430.0, 373.0]}, {"text": "other studies conducted in ES-SCLC, LS-SCLC, and", "bbox": [523.0, 360.0, 716.0, 372.0]}, {"text": "the medical and radiation oncologists.", "bbox": [226.0, 372.0, 373.0, 383.0]}, {"text": "NSCLC suggest that toxicity is acceptable, and survival", "bbox": [523.0, 372.0, 733.0, 383.0]}, {"text": "3.2 Consolidation TRT should be provided after", "bbox": [226.0, 383.0, 408.0, 394.0]}, {"text": "may be improved with concurrent administration of", "bbox": [522.0, 383.0, 723.0, 394.0]}, {"text": "completion of concurrent chemo-immunotherapy.", "bbox": [226.0, 394.0, 415.0, 406.0]}, {"text": "immunotherapy and TRT.", "bbox": [522.0, 396.0, 623.0, 406.0]}, {"text": "• Given the relatively long half-lives of immunotherapies,", "bbox": [514.0, 405.0, 736.0, 418.0]}, {"text": "holding treatment during TRT may not be beneficial.", "bbox": [522.0, 417.0, 726.0, 429.0]}, {"text": ". Clinical trials are ongoing to address this question (e.g.,", "bbox": [514.0, 429.0, 735.0, 440.0]}, {"text": "TRIPLEX, TREASURE, RAPTOR).", "bbox": [523.0, 441.0, 649.0, 452.0]}, {"text": "Prophylactic Cranial Irradiation & MRI Surveillance", "bbox": [56.0, 451.0, 263.0, 464.0]}, {"text": "4. Which patients with ES-SCLC should be", "bbox": [56.0, 463.0, 213.0, 474.0]}, {"text": "4.1 All patients who respond to concurrent chemo-", "bbox": [226.0, 463.0, 420.0, 474.0]}, {"text": "Unanimous", "bbox": [449.0, 463.0, 496.0, 474.0]}, {"text": "• Patients with brain metastases are not candidates for PCI", "bbox": [514.0, 463.0, 738.0, 474.0]}, {"text": "referred to a radiation oncologist for", "bbox": [63.0, 474.0, 205.0, 486.0]}, {"text": "immunotherapy should undergo restaging with brain", "bbox": [226.0, 474.0, 429.0, 486.0]}, {"text": "or MRI surveillance.", "bbox": [522.0, 474.0, 602.0, 486.0]}, {"text": "• If MRI surveillance and PCI are not options, CT", "bbox": [514.0, 485.0, 705.0, 496.0]}, {"text": "consideration of PCI or MRI", "bbox": [64.0, 486.0, 174.0, 496.0]}, {"text": "MRI to guide decision-making regarding PCI or MRI", "bbox": [226.0, 487.0, 425.0, 496.0]}, {"text": "surveillance?", "bbox": [64.0, 498.0, 116.0, 510.0]}, {"text": "surveillance alone.", "bbox": [226.0, 498.0, 297.0, 509.0]}, {"text": "surveillance can be offered however does not have", "bbox": [523.0, 498.0, 718.0, 510.0]}, {"text": "4.2 Consultation with a radiation oncologist is", "bbox": [226.0, 509.0, 403.0, 520.0]}, {"text": "clinical equipoise", "bbox": [523.0, 510.0, 590.0, 520.0]}, {"text": "recommended to enhance shared decision-making on", "bbox": [226.0, 520.0, 430.0, 532.0]}, {"text": "• Good communication is required across the MDT to", "bbox": [514.0, 520.0, 723.0, 532.0]}, {"text": "PCI versus MRI surveillance alone.", "bbox": [226.0, 533.0, 357.0, 541.0]}, {"text": "confirm who is responsible for PCI/MRI surveillance.", "bbox": [522.0, 533.0, 725.0, 541.0]}, {"text": "4.3 Patients with a response to concurrent chemo-", "bbox": [226.0, 544.0, 416.0, 553.0]}, {"text": "• Clinical trials are ongoing to address this question in the", "bbox": [515.0, 544.0, 736.0, 554.0]}, {"text": "immunotherapy, without brain metastases and with", "bbox": [226.0, 555.0, 424.0, 566.0]}, {"text": "context of immunotherapy (e.g., MAVERICK).", "bbox": [523.0, 555.0, 698.0, 567.0]}, {"text": "good PS, should be considered for PCI.", "bbox": [226.0, 566.0, 373.0, 578.0]}, {"text": "5. What is the recommended timing of", "bbox": [56.0, 578.0, 207.0, 588.0]}, {"text": "5.1 MRI surveillance should be conducted for 2 years", "bbox": [226.0, 578.0, 430.0, 588.0]}, {"text": "Unanimous", "bbox": [449.0, 578.0, 496.0, 588.0]}, {"text": "• MRI frequency recommendation is generally aligned", "bbox": [514.0, 578.0, 725.0, 590.0]}, {"text": "after response to concurrent chemo-immunotherapy:", "bbox": [226.0, 589.0, 428.0, 601.0]}, {"text": "MRI surveillance?", "bbox": [64.0, 590.0, 133.0, 599.0]}, {"text": "with that in Takahashi 2017. [22]", "bbox": [522.0, 590.0, 652.0, 599.0]}, {"text": "every 3 months in Year 1 and every 6 months in Year 2.", "bbox": [226.0, 600.0, 435.0, 612.0]}, {"text": "CT is inferior to MRI for detection of brain metastases;", "bbox": [521.0, 600.0, 731.0, 612.0]}, {"text": "5.2 MRI surveillance may be conducted by the medical", "bbox": [226.0, 612.0, 436.0, 623.0]}, {"text": "however, patients with medical devices or other", "bbox": [522.0, 612.0, 707.0, 623.0]}, {"text": "oncologist or the radiation oncologist.", "bbox": [226.0, 623.0, 371.0, 634.0]}, {"text": "contraindications may not be eligible for MRI.", "bbox": [523.0, 623.0, 700.0, 634.0]}, {"text": "5.3 Computed tomography should only be used when", "bbox": [226.0, 636.0, 431.0, 646.0]}, {"text": "MRI is not an option.", "bbox": [226.0, 646.0, 307.0, 658.0]}, {"text": "6. What is the appropriate dose-", "bbox": [56.0, 658.0, 178.0, 669.0]}, {"text": "6.1 PCI to a dose of 25 Gy in 10 fractions is", "bbox": [225.0, 658.0, 393.0, 669.0]}, {"text": "Unanimous", "bbox": [449.0, 658.0, 496.0, 668.0]}, {"text": "• Schedule has shown acceptable disease control and", "bbox": [514.0, 657.0, 720.0, 669.0]}, {"text": "fractionation schedule for PCI?", "bbox": [64.0, 668.0, 183.0, 680.0]}, {"text": "recommended; 20 Gy in 5 fractions is an alternative.", "bbox": [226.0, 668.0, 427.0, 680.0]}, {"text": "toxicity in several clinical studies.", "bbox": [522.0, 668.0, 655.0, 680.0]}, {"text": ". Hippocampal sparing and use of memantine may be", "bbox": [514.0, 682.0, 723.0, 693.0]}, {"text": "considered to prevent cognitive decline.", "bbox": [523.0, 692.0, 675.0, 704.0]}, {"text": "7. What is the optimal timing of PCI", "bbox": [56.0, 703.0, 197.0, 714.0]}, {"text": "7.1 Concurrent treatment with PCI and immunotherapy", "bbox": [226.0, 703.0, 438.0, 714.0]}, {"text": ". PCI was permitted in the immunotherapy arms of", "bbox": [514.0, 703.0, 715.0, 714.0]}, {"text": "Unanimous", "bbox": [448.0, 704.0, 496.0, 714.0]}, {"text": "during immunotherapy?", "bbox": [64.0, 714.0, 158.0, 726.0]}, {"text": "IMpower133 and KEYNOTE-604 and has been used in", "bbox": [522.0, 714.0, 731.0, 726.0]}, {"text": "is appropriate.", "bbox": [226.0, 715.0, 281.0, 726.0]}, {"text": "7.2 PCI should be provided after completion of", "bbox": [226.0, 726.0, 406.0, 737.0]}, {"text": "other recent immunotherapy studies; no safety signals", "bbox": [522.0, 727.0, 731.0, 736.0]}, {"text": "concurrent chemo- immunotherapy.", "bbox": [226.0, 738.0, 363.0, 750.0]}, {"text": "were identified.", "bbox": [523.0, 738.0, 584.0, 749.0]}, {"text": "• The MDT should discuss appropriate timing on a case-by-", "bbox": [514.0, 749.0, 735.0, 761.0]}, {"text": "case basis.", "bbox": [522.0, 761.0, 565.0, 772.0]}, {"text": ". Clinical trials are ongoing to address this question (e.g.,", "bbox": [514.0, 771.0, 737.0, 783.0]}, {"text": "MAVERICK, LUMINANCE).", "bbox": [522.0, 784.0, 628.0, 796.0]}, {"text": "Thoracic Radiation Therapy & Prophylactic Cranial Irradiation", "bbox": [56.0, 795.0, 305.0, 807.0]}, {"text": "8.1 Concurrent treatment with TRT, PCI, and", "bbox": [225.0, 805.0, 400.0, 818.0]}, {"text": "• See Key Considerations for Questions 3 and 7.", "bbox": [514.0, 805.0, 699.0, 818.0]}, {"text": "8. What is the optimal timing of TRT +", "bbox": [56.0, 806.0, 207.0, 818.0]}, {"text": "Unanimous", "bbox": [449.0, 806.0, 496.0, 817.0]}, {"text": "PCI among patients receiving", "bbox": [63.0, 818.0, 178.0, 829.0]}, {"text": "immunotherapy is appropriate.", "bbox": [226.0, 818.0, 345.0, 829.0]}, {"text": "• As the toxicities associated with PCI and TRT differ,", "bbox": [514.0, 818.0, 723.0, 828.0]}, {"text": "immunotherapy?", "bbox": [64.0, 830.0, 130.0, 840.0]}, {"text": "8.2 Consolidation TRT and PCI should be provided after", "bbox": [225.0, 830.0, 438.0, 839.0]}, {"text": "concurrent treatment with PCI, TRT, and", "bbox": [522.0, 830.0, 682.0, 840.0]}, {"text": "completion of concurrent chemo-immunotherapy.", "bbox": [226.0, 841.0, 415.0, 852.0]}, {"text": "immunotherapy is appropriate for suitable patients.", "bbox": [523.0, 841.0, 719.0, 853.0]}, {"text": ". Clinical trials are ongoing to address this question (e.g.,", "bbox": [514.0, 852.0, 737.0, 863.0]}, {"text": "MAVERICK).", "bbox": [522.0, 863.0, 573.0, 874.0]}, {"text": "Abbreviations: ASTRO = American Society for Radiation Oncology; ATZ = atezolizumab; chemo-immunotherapy = chemotherapy and immunotherapy; CT =", "bbox": [48.0, 881.0, 745.0, 894.0]}, {"text": "computed tomography; DUR = durvalumab; ES = extensive stage; Gy = gray; LS = limited stage; MDT = multidisciplinary team; MRI = magnetic resonance imaging;", "bbox": [48.0, 893.0, 745.0, 906.0]}, {"text": "NSCIC = non-small cell lung cancer; PCI = prophylactic cranial irradiation; PS = performance status; RT = radiation therapy; SCIC = small-cell lung cancer; TRT =", "bbox": [48.0, 908.0, 744.0, 919.0]}, {"text": "thoracic radiation therapy.", "bbox": [48.0, 920.0, 164.0, 932.0]}], "type": "Table", "position": 1}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/肿瘤科/共识/加拿大共识建议：在接受免疫治疗的广泛期小细胞肺癌患者中使用放射治疗.pdf", "page_num": 4}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": null, "type3": null, "type4": null, "type5": null, "type6": "有用性#1#1#页眉的内容\n准确性#2#46#表格的内容，但里面的内容杂乱"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:42", "update_time": "2024-05-08 00:02:53"}
{"id": 1082626, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 738, "source_info": {"seq_id": "5c6a2d75-f3d2-494f-93a6-9b9836eb6596", "title": null, "text": "【0】页码:4\n 19\n\n【1】 stage hepatocellular carcinoma.  Ann Surg, 2014, 260(2): 329 – 340.\n\n【2】 6\n\n【3】 7\n\n【4】 8\n\n【5】 9\n\n【6】 Yen YH, Cheng YF, Wang JH, et al. Real world clinical practice in treating advanced hepatocellular carcinoma: When East meets West.\n\n【7】PLoS One, 2020, 15(3): e230005.\n\n【8】 Zhu XD, Huang C, Shen YH, et al. Downstaging and Resection of Initially Unresectable Hepatocellular Carcinoma with Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody Combinations. Liver Cancer, 2021, 10(4): 320-329.\n\n【9】 transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma ( uHCC) : a retrospective controlled study. Hepa¬ tol Int, 2021, 15(3): 663 – 675.\n\n【10】platin plus fluorouracil/leucovorin vs. sorafenib for advanced hepato¬ cellular carcinoma. J Hepatol, 2018 , 69 (1): 60 – 69.\n\n【11】 10 Salem R, Lewandowski RJ, Mulcahy MF, et al. Radioembolization \n for hepatocellular carcinoma using Yttrium-90 microspheres: a com¬ prehensive report of long-term outcomes. Gastroenterology, 2010, 138(1): 52–64.\n\n【12】 11 中国抗癌协会肝癌专业委员会转化治疗协作组. 肝癌转化治疗\n\n【13】 中国专家共识(2021 版). 中华消化外科杂志 , 2021 , 20(6):\n\n【14】 600 – 616.\n\n【15】 12   中华人民共和国国家卫生健康委员会医政医管局.  原发性肝癌\n\n【16】 诊疗规范(2019 年版). 中华消化外科杂志, 2020, 19(1): 1 –\n\n【17】 20.\n\n【18】 13   中华人民共和国国家卫生健康委员会医政医管局.  原发性肝癌 诊疗指南(2022 年版). 中华消化外科杂志 , 2022 , 21 ( 2 ) : 143\n\n【19】 = 168.\n 14 Sun HC, Zhou J, Wang Z, et al. Chinese expert consensus on con¬ version therapy for hepatocellular carcinoma (2021 edition). Hepa¬ tobiliary Surg Nutr, 2022 , 11 (2): 227 – 252.\n 15 Lim C, Compagnon P, Sebagh M, et al. Hepatectomy for hepatocellular carcinoma larger than 10 cm: preoperative risk stratification to prevent futile surgery.  HPB ( Oxford) , 2015 , 17(7): 611 – 623.\n\n【20】16 Zhang W, Liu C, Tan YF, et al. Role of liver resection in treating intermediate and advanced stage adolescent and young adult hepato¬ cellular carcinoma patients: A propensity-matching cohort study. Int J Surg, 2018 , 54(Pt A): 259 -264.\n\n【21】17 中华预防医学会肝胆胰疾病预防与控制专业委员会,中国抗癌 协会肝癌专业委员会,北京医学会外科学分会肝脏学组,等. 基 于免疫联合靶向方案的晚期肝细胞癌转化治疗中国专家共识 (2021 版). 中华肝胆外科杂志 , 2021 , 27(4) ; 241 – 251.\n\n【22】18 Kim HY, Park JW, Joo J, et al. Worse outcome of sorafenib therapy associated with ascites and Child-Pugh score in advanced hepatocel¬ lular carcinoma.  J Gastroenterol Hepatol, 2013 , 28 ( 11 ) :  1756 – 1761.\n 19 Yoshimoto T , Imura S, Morine Y, et al. The Outcome of Sorafenib\n\n【23】 Therapy on Unresectable Hepatocellular Carcinoma; Experience of Conversion and Salvage Hepatectomy. Anticancer Res, 2018, 38 (1) : 501 – 507.\n\n【24】 20 Kudo M, Finn RS, Qin SK, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carci¬ noma :  a randomised phase 3 non-inferiority trial.  Lancet, 2018, 391 (10126) : 1163 – 1173.\n\n【25】 21 Tomonari T, Sato Y, Tanaka H, et al. Conversion therapy for unre¬ sectable hepatocellular carcinoma after lenvatinib : Three case re¬ ports.  Medicine ( Baltimore ) , 2020 , 99 ( 42 ) : e22782.\n\n【26】 22 Qin SK, Bi F, Gu SZ, et al. Donafenib Versus Sorafenib in First¬ Line Treatment of Unresectable or Metastatic Hepatocellular Carcino¬ ma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial. J Clin Oncol, 2021, 39(27): 3002 – 3011.\n\n【27】23 国际肝胆胰协会中国分会,中华医学会外科学分会肝脏外科学 组,肝癌专家委员会中国临床肿瘤学会 CSCO.  基于免疫节点抑 制剂的肝细胞癌免疫联合治疗多学科中国专家共识(2021 版).\n\n【28】中华消化外科杂志 , 2021 , 20(7): 740 – 753.\n\n【29】 24 Finn RS, Qin SK, Ikeda M, et al. Atezolizumab plus Bevacizumab\n in Unresectable Hepatocellular Carcinoma. N Engl J Med, 2020, 382(20): 1894 – 1905.\n\n【30】 25 Chen X , Zhang YZ , Zhang N , et al. Lenvatinib combined nivolum¬ ab injection followed by extended right hepatectomy is a feasible treatment for patients with massive hepatocellular carcinoma: a case report. 'OncoTargets and Therapy', 2019', 12: 7355 -7359.\n\n【31】26 张雯雯, 胡丙洋, 韩骏, 等. PD-1 抑制剂与多靶点酪氨酸激酶 抑制剂联合方案用于进展期肝癌转化治疗研究的初步报告. 中 华肝胆外科杂志 , 2020 , 26 ( 12 ) : 947 – 948 .\n\n【32】 27 Zhu XD, Huang C, Shen YH, et al. Hepatectomy After Conversion Therapy Using Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibody Therapy for Patients with Unresectable Hepatocellular Carcinoma.\n Ann Surg Oncol, 2022. doi: 10.1245/s10434 - 022 - 12530 - z 28 He MK, Li QJ, Zou RH, et al. Sorafenib Plus Hepatic Arterial Infu¬ sion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Random¬ ized Clinical Trial.  JAMA Oncol, 2019 , 5 (7): 953 – 960.\n\n【33】29 Chen S, Xu B, Wu ZQ, et al. Pembrolizumab plus lenvatinib with or without hepatic arterial infusion chemotherapy in selected popula¬ tions of patients with treatment-naive unresectable hepatocellular car¬ cinoma exhibiting PD-L1 staining: a multicenter retrospective study.\n\n【34】BMC Cancer, 2021, 21(1): 1126.\n 30 Chen S, Wu ZQ, Shi F, et al. Lenvatinib plus TACE with or without pembrolizumab for the treatment of initially unresectable hepatocellu¬ lar carcinoma harbouring PD-L1 expression: a retrospective study. J Cancer Res Clin Oncol, 2022, 148(8): 2115-2125.\n 取小千) ( 本文编辑", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "19", "bbox": [2137.0, 196.0, 2197.0, 231.0]}], "type": "Text", "position": 1}, {"raw_context": [{"text": "stage hepatocellular carcinoma.  Ann Surg, 2014, 260(2): 329 –", "bbox": [243.0, 309.0, 1158.0, 341.0]}, {"text": "340.", "bbox": [243.0, 365.0, 315.0, 397.0]}], "type": "Text", "position": 2}, {"raw_context": [{"text": "6", "bbox": [183.0, 423.0, 221.0, 449.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "7", "bbox": [187.0, 586.0, 215.0, 613.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": "8", "bbox": [185.0, 806.0, 223.0, 833.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "9", "bbox": [187.0, 1026.0, 219.0, 1053.0]}], "type": "Text", "position": 6}, {"raw_context": [{"text": "Yen YH, Cheng YF, Wang JH, et al. Real world clinical practice in", "bbox": [239.0, 419.0, 1168.0, 452.0]}, {"text": "treating advanced hepatocellular carcinoma: When East meets West.", "bbox": [243.0, 474.0, 1160.0, 507.0]}, {"text": "PLoS One, 2020, 15(3): e230005.", "bbox": [243.0, 528.0, 745.0, 561.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "Zhu XD, Huang C, Shen YH, et al. Downstaging and Resection of", "bbox": [239.0, 584.0, 1168.0, 617.0]}, {"text": "Initially Unresectable Hepatocellular Carcinoma with Tyrosine Kinase", "bbox": [247.0, 639.0, 1166.0, 671.0]}, {"text": "Inhibitor and Anti-PD-1 Antibody Combinations. Liver Cancer,", "bbox": [247.0, 695.0, 1164.0, 727.0]}, {"text": "2021, 10(4): 320-329.", "bbox": [243.0, 749.0, 602.0, 783.0]}], "type": "Text", "position": 8}, {"raw_context": [{"text": "transarterial chemoembolization for treatment of unresectable hepato-", "bbox": [245.0, 860.0, 1164.0, 892.0]}, {"text": "cellular carcinoma ( uHCC) : a retrospective controlled study. Hepa¬", "bbox": [243.0, 915.0, 1162.0, 948.0]}, {"text": "tol Int, 2021, 15(3): 663 – 675.", "bbox": [243.0, 969.0, 715.0, 1002.0]}, {"text": "platin plus fluorouracil/leucovorin vs. sorafenib for advanced hepato¬", "bbox": [247.0, 1079.0, 1164.0, 1111.0]}, {"text": "cellular carcinoma. J Hepatol, 2018 , 69 (1): 60 – 69.", "bbox": [243.0, 1134.0, 989.0, 1166.0]}], "type": "Text", "position": 9}, {"raw_context": [{"text": "10 Salem R, Lewandowski RJ, Mulcahy MF, et al. Radioembolization ", "bbox": [183.0, 1184.0, 1176.0, 1221.0]}], "type": "Text", "position": 10}, {"raw_context": [{"text": "for hepatocellular carcinoma using Yttrium-90 microspheres: a com¬", "bbox": [243.0, 1244.0, 1162.0, 1275.0]}, {"text": "prehensive report of long-term outcomes. Gastroenterology, 2010,", "bbox": [247.0, 1298.0, 1164.0, 1330.0]}, {"text": "138(1): 52–64.", "bbox": [245.0, 1353.0, 500.0, 1386.0]}], "type": "List-item", "position": 11}, {"raw_context": [{"text": "11 中国抗癌协会肝癌专业委员会转化治疗协作组. 肝癌转化治疗", "bbox": [185.0, 1405.0, 1164.0, 1442.0]}], "type": "Text", "position": 12}, {"raw_context": [{"text": "中国专家共识(2021 版). 中华消化外科杂志 , 2021 , 20(6):", "bbox": [247.0, 1462.0, 1168.0, 1498.0]}], "type": "Text", "position": 13}, {"raw_context": [{"text": "600 – 616.", "bbox": [241.0, 1516.0, 400.0, 1549.0]}], "type": "Text", "position": 14}, {"raw_context": [{"text": "12   中华人民共和国国家卫生健康委员会医政医管局.  原发性肝癌", "bbox": [185.0, 1571.0, 1170.0, 1607.0]}], "type": "Text", "position": 15}, {"raw_context": [{"text": "诊疗规范(2019 年版). 中华消化外科杂志, 2020, 19(1): 1 –", "bbox": [247.0, 1626.0, 1158.0, 1663.0]}], "type": "Text", "position": 16}, {"raw_context": [{"text": "20.", "bbox": [243.0, 1683.0, 301.0, 1712.0]}], "type": "Text", "position": 17}, {"raw_context": [{"text": "13   中华人民共和国国家卫生健康委员会医政医管局.  原发性肝癌", "bbox": [185.0, 1735.0, 1170.0, 1771.0]}, {"text": "诊疗指南(2022 年版). 中华消化外科杂志 , 2022 , 21 ( 2 ) : 143", "bbox": [247.0, 1789.0, 1166.0, 1826.0]}], "type": "Text", "position": 18}, {"raw_context": [{"text": "= 168.", "bbox": [253.0, 1846.0, 352.0, 1877.0]}], "type": "Text", "position": 19}, {"raw_context": [{"text": "14 Sun HC, Zhou J, Wang Z, et al. Chinese expert consensus on con¬", "bbox": [187.0, 1902.0, 1164.0, 1931.0]}, {"text": "version therapy for hepatocellular carcinoma (2021 edition). Hepa¬", "bbox": [247.0, 1955.0, 1164.0, 1988.0]}, {"text": "tobiliary Surg Nutr, 2022 , 11 (2): 227 – 252.", "bbox": [247.0, 2010.0, 883.0, 2043.0]}], "type": "List-item", "position": 20}, {"raw_context": [{"text": "15 Lim C, Compagnon P, Sebagh M, et al. Hepatectomy for hepatocel-", "bbox": [187.0, 2065.0, 1168.0, 2098.0]}, {"text": "lular carcinoma larger than 10 cm: preoperative risk stratification to", "bbox": [247.0, 2121.0, 1170.0, 2153.0]}, {"text": "prevent futile surgery.  HPB ( Oxford) , 2015 , 17(7): 611 – 623.", "bbox": [247.0, 2175.0, 1140.0, 2208.0]}, {"text": "16 Zhang W, Liu C, Tan YF, et al. Role of liver resection in treating", "bbox": [189.0, 2231.0, 1168.0, 2261.0]}, {"text": "intermediate and advanced stage adolescent and young adult hepato¬", "bbox": [247.0, 2285.0, 1166.0, 2318.0]}, {"text": "cellular carcinoma patients: A propensity-matching cohort study. Int", "bbox": [247.0, 2341.0, 1172.0, 2373.0]}, {"text": "J Surg, 2018 , 54(Pt A): 259 -264.", "bbox": [258.0, 2395.0, 765.0, 2425.0]}, {"text": "17 中华预防医学会肝胆胰疾病预防与控制专业委员会,中国抗癌", "bbox": [185.0, 2445.0, 1166.0, 2484.0]}, {"text": "协会肝癌专业委员会,北京医学会外科学分会肝脏学组,等. 基", "bbox": [244.0, 2502.0, 1168.0, 2538.0]}, {"text": "于免疫联合靶向方案的晚期肝细胞癌转化治疗中国专家共识", "bbox": [246.0, 2557.0, 1170.0, 2594.0]}, {"text": "(2021 版). 中华肝胆外科杂志 , 2021 , 27(4) ; 241 – 251.", "bbox": [247.0, 2613.0, 1072.0, 2650.0]}, {"text": "18 Kim HY, Park JW, Joo J, et al. Worse outcome of sorafenib therapy", "bbox": [186.0, 2671.0, 1164.0, 2699.0]}, {"text": "associated with ascites and Child-Pugh score in advanced hepatocel¬", "bbox": [247.0, 2723.0, 1162.0, 2756.0]}, {"text": "lular carcinoma.  J Gastroenterol Hepatol, 2013 , 28 ( 11 ) :  1756 –", "bbox": [246.0, 2780.0, 1156.0, 2808.0]}, {"text": "1761.", "bbox": [245.0, 2835.0, 337.0, 2866.0]}], "type": "List-item", "position": 21}, {"raw_context": [{"text": "19 Yoshimoto T , Imura S, Morine Y, et al. The Outcome of Sorafenib", "bbox": [188.0, 2890.0, 1164.0, 2918.0]}], "type": "List-item", "position": 22}, {"raw_context": [{"text": "Therapy on Unresectable Hepatocellular Carcinoma; Experience of", "bbox": [1294.0, 310.0, 2223.0, 343.0]}, {"text": "Conversion and Salvage Hepatectomy. Anticancer Res, 2018, 38", "bbox": [1293.0, 367.0, 2223.0, 396.0]}, {"text": "(1) : 501 – 507.", "bbox": [1291.0, 422.0, 1529.0, 450.0]}], "type": "Text", "position": 23}, {"raw_context": [{"text": "20 Kudo M, Finn RS, Qin SK, et al. Lenvatinib versus sorafenib in", "bbox": [1234.0, 476.0, 2223.0, 506.0]}, {"text": "first-line treatment of patients with unresectable hepatocellular carci¬", "bbox": [1293.0, 532.0, 2219.0, 560.0]}, {"text": "noma :  a randomised phase 3 non-inferiority trial.  Lancet, 2018, 391", "bbox": [1293.0, 588.0, 2217.0, 614.0]}, {"text": "(10126) : 1163 – 1173.", "bbox": [1296.0, 640.0, 1627.0, 673.0]}], "type": "Text", "position": 24}, {"raw_context": [{"text": "21 Tomonari T, Sato Y, Tanaka H, et al. Conversion therapy for unre¬", "bbox": [1234.0, 694.0, 2217.0, 727.0]}, {"text": "sectable hepatocellular carcinoma after lenvatinib : Three case re¬", "bbox": [1294.0, 750.0, 2217.0, 782.0]}, {"text": "ports.  Medicine ( Baltimore ) , 2020 , 99 ( 42 ) : e22782.", "bbox": [1294.0, 803.0, 2051.0, 837.0]}], "type": "Text", "position": 25}, {"raw_context": [{"text": "22 Qin SK, Bi F, Gu SZ, et al. Donafenib Versus Sorafenib in First¬", "bbox": [1234.0, 860.0, 2219.0, 893.0]}, {"text": "Line Treatment of Unresectable or Metastatic Hepatocellular Carcino¬", "bbox": [1294.0, 915.0, 2215.0, 947.0]}, {"text": "ma: A Randomized, Open-Label, Parallel-Controlled Phase II-III", "bbox": [1294.0, 969.0, 2221.0, 1002.0]}, {"text": "Trial. J Clin Oncol, 2021, 39(27): 3002 – 3011.", "bbox": [1294.0, 1023.0, 1986.0, 1057.0]}, {"text": "23 国际肝胆胰协会中国分会,中华医学会外科学分会肝脏外科学", "bbox": [1234.0, 1076.0, 2221.0, 1113.0]}, {"text": "组,肝癌专家委员会中国临床肿瘤学会 CSCO.  基于免疫节点抑", "bbox": [1294.0, 1131.0, 2221.0, 1168.0]}, {"text": "制剂的肝细胞癌免疫联合治疗多学科中国专家共识(2021 版).", "bbox": [1290.0, 1180.0, 2219.0, 1223.0]}, {"text": "中华消化外科杂志 , 2021 , 20(7): 740 – 753.", "bbox": [1297.0, 1244.0, 1953.0, 1274.0]}], "type": "Text", "position": 26}, {"raw_context": [{"text": "24 Finn RS, Qin SK, Ikeda M, et al. Atezolizumab plus Bevacizumab", "bbox": [1236.0, 1298.0, 2223.0, 1331.0]}], "type": "Text", "position": 27}, {"raw_context": [{"text": "in Unresectable Hepatocellular Carcinoma. N Engl J Med, 2020,", "bbox": [1293.0, 1354.0, 2219.0, 1385.0]}, {"text": "382(20): 1894 – 1905.", "bbox": [1294.0, 1406.0, 1629.0, 1441.0]}], "type": "List-item", "position": 28}, {"raw_context": [{"text": "25 Chen X , Zhang YZ , Zhang N , et al. Lenvatinib combined nivolum¬", "bbox": [1234.0, 1462.0, 2217.0, 1495.0]}, {"text": "ab injection followed by extended right hepatectomy is a feasible", "bbox": [1296.0, 1517.0, 2223.0, 1550.0]}, {"text": "treatment for patients with massive hepatocellular carcinoma: a case", "bbox": [1293.0, 1573.0, 2221.0, 1603.0]}, {"text": "report. 'OncoTargets and Therapy', 2019', 12: 7355 -7359.", "bbox": [1293.0, 1630.0, 2111.0, 1658.0]}, {"text": "26 张雯雯, 胡丙洋, 韩骏, 等. PD-1 抑制剂与多靶点酪氨酸激酶", "bbox": [1236.0, 1681.0, 2223.0, 1716.0]}, {"text": "抑制剂联合方案用于进展期肝癌转化治疗研究的初步报告. 中", "bbox": [1296.0, 1734.0, 2223.0, 1772.0]}, {"text": "华肝胆外科杂志 , 2020 , 26 ( 12 ) : 947 – 948 .", "bbox": [1297.0, 1792.0, 1936.0, 1822.0]}], "type": "Text", "position": 29}, {"raw_context": [{"text": "27 Zhu XD, Huang C, Shen YH, et al. Hepatectomy After Conversion", "bbox": [1236.0, 1846.0, 2223.0, 1878.0]}, {"text": "Therapy Using Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibody", "bbox": [1296.0, 1900.0, 2221.0, 1933.0]}, {"text": "Therapy for Patients with Unresectable Hepatocellular Carcinoma.", "bbox": [1296.0, 1955.0, 2211.0, 1988.0]}], "type": "Text", "position": 30}, {"raw_context": [{"text": "Ann Surg Oncol, 2022. doi: 10.1245/s10434 - 022 - 12530 - z", "bbox": [1300.0, 2009.0, 2177.0, 2042.0]}, {"text": "28 He MK, Li QJ, Zou RH, et al. Sorafenib Plus Hepatic Arterial Infu¬", "bbox": [1236.0, 2066.0, 2219.0, 2096.0]}, {"text": "sion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone", "bbox": [1296.0, 2121.0, 2225.0, 2153.0]}, {"text": "for Hepatocellular Carcinoma With Portal Vein Invasion: A Random¬", "bbox": [1294.0, 2175.0, 2219.0, 2208.0]}, {"text": "ized Clinical Trial.  JAMA Oncol, 2019 , 5 (7): 953 – 960.", "bbox": [1296.0, 2230.0, 2105.0, 2263.0]}, {"text": "29 Chen S, Xu B, Wu ZQ, et al. Pembrolizumab plus lenvatinib with", "bbox": [1236.0, 2283.0, 2225.0, 2320.0]}, {"text": "or without hepatic arterial infusion chemotherapy in selected popula¬", "bbox": [1294.0, 2339.0, 2219.0, 2374.0]}, {"text": "tions of patients with treatment-naive unresectable hepatocellular car¬", "bbox": [1298.0, 2396.0, 2217.0, 2427.0]}, {"text": "cinoma exhibiting PD-L1 staining: a multicenter retrospective study.", "bbox": [1296.0, 2448.0, 2211.0, 2485.0]}, {"text": "BMC Cancer, 2021, 21(1): 1126.", "bbox": [1296.0, 2502.0, 1784.0, 2537.0]}], "type": "List-item", "position": 31}, {"raw_context": [{"text": "30 Chen S, Wu ZQ, Shi F, et al. Lenvatinib plus TACE with or without", "bbox": [1236.0, 2559.0, 2223.0, 2593.0]}, {"text": "pembrolizumab for the treatment of initially unresectable hepatocellu¬", "bbox": [1296.0, 2615.0, 2219.0, 2648.0]}, {"text": "lar carcinoma harbouring PD-L1 expression: a retrospective study. J", "bbox": [1296.0, 2668.0, 2225.0, 2704.0]}, {"text": "Cancer Res Clin Oncol, 2022, 148(8): 2115-2125.", "bbox": [1294.0, 2721.0, 2040.0, 2757.0]}], "type": "List-item", "position": 32}, {"raw_context": [{"text": "取小千)", "bbox": [2061.0, 2778.0, 2217.0, 2815.0]}, {"text": "( 本文编辑", "bbox": [1858.0, 2780.0, 2069.0, 2817.0]}], "type": "Formula", "position": 33}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/肿瘤科/解读/肝细胞癌转化治疗临床策略与指南解读.pdf", "page_num": 4}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": null, "type3": null, "type4": null, "type5": null, "type6": "有用性#0#34#参考文献的内容"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:42", "update_time": "2024-05-07 18:15:10"}
{"id": 1082625, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 738, "source_info": {"seq_id": "5f68d3ac-9766-4862-b6f4-85fc206c6f61", "title": null, "text": "【0】页码:6\n 治内分泌专家共识[J]. 中华内分泌代谢杂志, 2018, 34 (1) : 1-7.\n\n【1】[2] LEGRO R S ,  ARSLANIAN S A ,  EHRMANN D A ,  et al.\n\n【2】Diagnosis and treatment of polycystic ovary syndrome: an endocrine society clinical practice guideline[J]. J Clin Endocrinol Metab, 2013, 98 (12) : 4565-4592.\n\n【3】[3] CONWAY G, DEWAILLY D, DIAMANTI-KANDARAKIS E , et al. The polycystic ovary syndrome : a position statement from the European Society of Endocrinology[J]. Eur J Endocrinol, 2014, 171 (4) : P1-P29.\n\n【4】WITCHEL S F ,  OBERFIELD S ,  ROSENFIELD R L , [4] et al. The diagnosis of polycystic ovary syndrome during adolescence[J]. Horm Res Paediatr, 2015.\n\n【5】中华医学会妇产科学分会内分泌学组及指南专家组. 多囊 [5] 卵巢综合征中国诊疗指南[J]. 中华妇产科杂志, 2018, 53 (1) : 2-6.\n\n【6】LIZNEVA D , GAVRILOVA-JORDAN L , WALKER W , [6] et al. Androgen excess: investigations and management[J].\n\n【7】Best Pract Res Clin Obstet Gynaecol, 2016, 37: 98-118.\n\n【8】赵丽，蔡昭炜，李雪玲，等. 抗爆勒氏管激素联合性激素 [7] 检查在诊断多義明巢综合征的价值[J]. 現代诊断与治疗 , 2020, 31 (2): 269-270.\n\n【9】ESCOBAR-MORREALE H F. Polycystic ovary syndrome : [8] definition, aetiology, diagnosis and treatment[J]. Nat Rev Endocrinol, 2018, 14 ( 5 ) : 270-284.\n\n【10】KEEVIL B G, ADAWAY J. Assessment of free testosterone [9] concentration[J]. J Steroid Biochem Mol Biol, 2019, 190: 207-211.\n\n【11】VERMEULEN A , VERDONCK L , KAUFMAN J M . A [10] critical evaluation of simple methods for the estimation of free testosterone in serum[J]. J Clin Endocrinol Metab, 1999, 84 (10): 3666-3672.\n\n【12】叶雅萍，李萍. 性激素结合球蛋白在生殖医学中的应用研 [11] 究进展[J]. 生殖医学杂志 , 2022, 31 ( 2 ) : 273-277.\n\n【13】[12] KEEVIL B G, ADAWAY J, FIERS T, et al. The free androgen index is inaccurate in women when the SHBG concentration is low[J]. Clin Endocrinol ( Oxf )  ,  2018 ,  88 (5): 706-710.\n\n【14】[13] O'REILLY M W, TAYLOR A E, CRABTREE N J, et al. Hyperandrogenemia predicts metabolic phenotype in polycystic ovary syndrome: the utility of serum androstenedione[J]. J Clin Endocrinol Metab, 2014, 99 (3) : 1027-1036.\n\n【15】CHEN F, CHEN M, ZHANG W, et al. Comparison of [14] the efficacy of different androgens measured by LC-MS/ MS in representing hyperandrogenemia and an evaluation of adrenal-origin androgens with a dexamethasone suppression test in patients with PCOS[J]. J Ovarian Res, 2021, 14 (1): 32.\n\n【16】牛静云，侯丽辉，寇丽辉，等. 不同高堆激素血症表型多 [15] 藥卵巢综合征患者临床特征分析[J]. 实用妇产科杂志 , 2018, 34 (4): 286-290.\n\n【17】GOODMAN N F , COBIN R H , FUTTERWEIT W , [16] et al. American Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and PCOS Society disease state clinical review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome-part 1[J]. Endocr Pract, 2015, 21 ( 11 ) : 1291-1300.\n\n【18】[17] [17] GOODARZI M O ,  CARMINA E ,  AZZIZ R ,  DHEA , DHEAS and PCOS[J]. J Steroid Biochem Mol Biol, 2015, 145 : 213-225.\n\n【19】夏曦，邓玉颖，顾俊婕，等. 趙高压液相色谱- 质谱联用 [18] 技术联合分析血清率酮和硫酸脱氢装雄酮提高多褰卵 巢综合征的诊断率[J]. 中华内分泌代谢杂志, 2018, 34\n\n【20】 [19] [19]\n\n【21】 [20]\n\n【22】 [21]\n\n【23】 [22]\n\n【24】 [23]\n\n【25】 [24]\n\n【26】 [25]\n\n【27】 [26]\n\n【28】 [27]\n\n【29】 [28]\n\n【30】 [29]\n\n【31】 [30]\n\n【32】 [31]\n\n【33】 [32]\n\n【34】 [33]\n\n【35】 [34]\n\n【36】 ( 2 ) : 136-140.\n\n【37】CAO Z , LU Y , CONG Y , et al. Simultaneous quantitation of four androgens and 17-hydroxyprogesterone in polycystic ovarian syndrome patients by LC-MS/MS[J]. J Clin Lab Anal, 2020, 34 (12): c23539.\n\n【38】TOSI F , FIERS T , KAUFMAN J M , et al. Implications of androgen assay accuracy in the phenotyping of women with polycystic ovary syndrome[J]. J Clin Endocrinol Metab, 2016, 101 (2): 610-618.\n\n【39】KEEVIL B. Steroid mass spectrometry for the diagnosis of PCOS[J]. Med Sci ( Basel ) , 2019, 7 ( 7 ) : 78.\n\n【40】AMBROZIAK U, KĘPCZYŃSKA-NYK A, KURYŁOWICZ A, et al. LC-MS/MS improves screening towards 21-hydroxylase deficiency[J]. Gynecol Endocrinol , 2015, 31 (4): 296-300.\n\n【41】HANDELSMAN D J ,  WARTOFSKY L. Requirement for mass spectrometry sex steroid assays in the Journal of Clinical Endocrinology and Metabolism [J]. J Clin Endocrinol Metab, 2013, 98 ( 10 ) : 3971-3973.\n\n【42】WIERMAN M E ,  AUCHUS R J ,  HAISENLEDER D J, et al. Editorial: the new instructions to authors for the reporting of steroid hormone measurements[J]. Mol Endocrinol, 2014, 28 ( 12 ) : 1917.\n\n【43】TEEDE H J ,  MISSO M L ,  COSTELLO M F ,  et al.\n\n【44】Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome[J]. Hum Reprod, 2018, 33 ( 9 ) : 1602- 1618.\n\n【45】ZHAO M, BAKER S D, YAN X, et al. Simultaneous determination of steroid composition of human testicular fluid using liquid chromatography tandem mass spectrometry[J].\n\n【46】Steroids, 2004, 69 (11-12) : 721-726.\n\n【47】OLIVEIRA L R ,  LONGUI C A ,  GUARAGNA-FILHO G , et al. Androgens by immunoassay and mass spectrometry in children with 46, XY disorder of sex development[J].\n\n【48】Endocr Connect, 2020, 9 ( 11 ) : 1085-1094.\n\n【49】SHIRAISHI S, LEE P W, LEUNG A, et al. Simultaneous measurement of serum testosterone and dihydrotestosterone by liquid chromatography-tandem mass spectrometry[J]. Clin Chem, 2008, 54 ( 11 ) : 1855-1863.\n\n【50】YARROW J F , BECK D T , CONOVER C F , et al. Invalidation of a commercially available human 5 α -dihydrotestosterone immunoassay[J]. Steroids, 2013, 78 ( 12-13 ) : 1220-1225.\n\n【51】KEEFE C C, GOLDMAN M M, ZHANG K, et al.\n\n【52】Simultaneous measurement of thirteen steroid hormones in women with polycystic ovary syndrome and control women using liquid chromatography-tandem mass spectrometry[J].\n\n【53】PLoS One, 2014, 9 (4) : e93805.\n\n【54】FANELLI F, BELLUOMO I, DI LALLO V D, et al. Serum steroid profiling by isotopic dilution-liquid chromatography-mass spectrometry: comparison with current immunoassays and reference intervals in healthy adults[J].Steroids, 2011, 76 (3): 244-253.\n\n【55】医疗器械监督管理条例[EB/OL]. ( 2021-03-19 ) [2021-04-01]. https: //www.nmpa.gov.cn/xxgk/fgwj/ flxzhfg/20210319202057136.html.\n\n【56】Clinical and Laboratory Standards Institute. Liquid chromatography-mass spectrometry methods[S]. C62-A, CLSI, 2014.\n\n【57】Clinical and Laboratory Standards Institute. Defining, establishing, and verifying reference intervals in the clinical laboratory[S]. EP28-A3c, CLSI, 2010.\n\n【58】( 收稿日期: 2022-12-01; 修回日期: 2023-01-10 ) ( 本文编辑：李　欣 )", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "治内分泌专家共识[J]. 中华内分泌代谢杂志, 2018, 34", "bbox": [122.0, 123.0, 389.0, 137.0]}, {"text": "(1) : 1-7.", "bbox": [125.0, 138.0, 179.0, 151.0]}, {"text": "[2]", "bbox": [90.0, 151.0, 110.0, 165.0]}, {"text": "LEGRO R S ,  ARSLANIAN S A ,  EHRMANN D A ,  et al.", "bbox": [121.0, 151.0, 388.0, 165.0]}, {"text": "Diagnosis and treatment of polycystic ovary syndrome:", "bbox": [123.0, 165.0, 383.0, 178.0]}, {"text": "an endocrine society clinical practice guideline[J]. J Clin", "bbox": [123.0, 179.0, 388.0, 193.0]}, {"text": "Endocrinol Metab, 2013, 98 (12) : 4565-4592.", "bbox": [123.0, 194.0, 346.0, 207.0]}, {"text": "[3]", "bbox": [90.0, 207.0, 110.0, 221.0]}, {"text": "CONWAY G, DEWAILLY D, DIAMANTI-KANDARAKIS", "bbox": [121.0, 207.0, 389.0, 220.0]}, {"text": "E , et al. The polycystic ovary syndrome : a position statement", "bbox": [123.0, 221.0, 389.0, 234.0]}, {"text": "from the European Society of Endocrinology[J]. Eur J", "bbox": [123.0, 235.0, 388.0, 248.0]}, {"text": "Endocrinol, 2014, 171 (4) : P1-P29.", "bbox": [123.0, 250.0, 296.0, 262.0]}, {"text": "WITCHEL S F ,  OBERFIELD S ,  ROSENFIELD R L ,", "bbox": [123.0, 263.0, 383.0, 277.0]}, {"text": "[4]", "bbox": [91.0, 264.0, 109.0, 277.0]}, {"text": "et al. The diagnosis of polycystic ovary syndrome during", "bbox": [122.0, 278.0, 388.0, 291.0]}, {"text": "adolescence[J]. Horm Res Paediatr, 2015.", "bbox": [123.0, 292.0, 308.0, 305.0]}, {"text": "中华医学会妇产科学分会内分泌学组及指南专家组. 多囊", "bbox": [122.0, 305.0, 388.0, 319.0]}, {"text": "[5]", "bbox": [91.0, 307.0, 110.0, 320.0]}, {"text": "卵巢综合征中国诊疗指南[J]. 中华妇产科杂志, 2018, 53", "bbox": [123.0, 321.0, 388.0, 334.0]}, {"text": "(1) : 2-6.", "bbox": [125.0, 335.0, 179.0, 347.0]}, {"text": "LIZNEVA D , GAVRILOVA-JORDAN L , WALKER W ,", "bbox": [121.0, 348.0, 381.0, 360.0]}, {"text": "[6]", "bbox": [91.0, 349.0, 110.0, 362.0]}, {"text": "et al. Androgen excess: investigations and management[J].", "bbox": [123.0, 362.0, 386.0, 375.0]}, {"text": "Best Pract Res Clin Obstet Gynaecol, 2016, 37: 98-118.", "bbox": [123.0, 377.0, 379.0, 389.0]}, {"text": "赵丽，蔡昭炜，李雪玲，等. 抗爆勒氏管激素联合性激素", "bbox": [123.0, 388.0, 387.0, 406.0]}, {"text": "[7]", "bbox": [91.0, 391.0, 109.0, 404.0]}, {"text": "检查在诊断多義明巢综合征的价值[J]. 現代诊断与治疗 ,", "bbox": [123.0, 404.0, 383.0, 418.0]}, {"text": "2020, 31 (2): 269-270.", "bbox": [123.0, 418.0, 242.0, 431.0]}, {"text": "ESCOBAR-MORREALE H F. Polycystic ovary syndrome :", "bbox": [122.0, 431.0, 382.0, 447.0]}, {"text": "[8]", "bbox": [91.0, 433.0, 110.0, 446.0]}, {"text": "definition, aetiology, diagnosis and treatment[J]. Nat Rev", "bbox": [123.0, 447.0, 388.0, 459.0]}, {"text": "Endocrinol, 2018, 14 ( 5 ) : 270-284.", "bbox": [123.0, 460.0, 300.0, 472.0]}, {"text": "KEEVIL B G, ADAWAY J. Assessment of free testosterone", "bbox": [122.0, 474.0, 388.0, 487.0]}, {"text": "[9]", "bbox": [91.0, 475.0, 110.0, 488.0]}, {"text": "concentration[J]. J Steroid Biochem Mol Biol, 2019,", "bbox": [123.0, 489.0, 381.0, 501.0]}, {"text": "190: 207-211.", "bbox": [123.0, 504.0, 189.0, 515.0]}, {"text": "VERMEULEN A , VERDONCK L , KAUFMAN J M . A", "bbox": [122.0, 516.0, 390.0, 530.0]}, {"text": "[10]", "bbox": [91.0, 517.0, 115.0, 530.0]}, {"text": "critical evaluation of simple methods for the estimation of", "bbox": [123.0, 531.0, 388.0, 543.0]}, {"text": "free testosterone in serum[J]. J Clin Endocrinol Metab,", "bbox": [123.0, 545.0, 383.0, 558.0]}, {"text": "1999, 84 (10): 3666-3672.", "bbox": [123.0, 560.0, 257.0, 572.0]}, {"text": "叶雅萍，李萍. 性激素结合球蛋白在生殖医学中的应用研", "bbox": [121.0, 571.0, 388.0, 587.0]}, {"text": "[11]", "bbox": [91.0, 574.0, 115.0, 587.0]}, {"text": "究进展[J]. 生殖医学杂志 , 2022, 31 ( 2 ) : 273-277.", "bbox": [123.0, 587.0, 369.0, 600.0]}, {"text": "[12]", "bbox": [91.0, 602.0, 115.0, 615.0]}, {"text": "KEEVIL B G, ADAWAY J, FIERS T, et al. The free", "bbox": [122.0, 602.0, 388.0, 614.0]}, {"text": "androgen index is inaccurate in women when the SHBG", "bbox": [123.0, 616.0, 388.0, 629.0]}, {"text": "concentration is low[J]. Clin Endocrinol ( Oxf )  ,  2018 ,  88", "bbox": [123.0, 630.0, 388.0, 643.0]}, {"text": "(5): 706-710.", "bbox": [125.0, 644.0, 200.0, 655.0]}, {"text": "[13]", "bbox": [91.0, 658.0, 116.0, 671.0]}, {"text": "O'REILLY M W, TAYLOR A E, CRABTREE N J,", "bbox": [120.0, 657.0, 383.0, 670.0]}, {"text": "et al. Hyperandrogenemia predicts metabolic phenotype", "bbox": [123.0, 672.0, 388.0, 685.0]}, {"text": "in polycystic ovary syndrome: the utility of serum", "bbox": [123.0, 687.0, 389.0, 699.0]}, {"text": "androstenedione[J]. J Clin Endocrinol Metab, 2014, 99", "bbox": [123.0, 700.0, 389.0, 713.0]}, {"text": "(3) : 1027-1036.", "bbox": [125.0, 714.0, 211.0, 726.0]}, {"text": "CHEN F, CHEN M, ZHANG W, et al. Comparison of", "bbox": [121.0, 728.0, 390.0, 741.0]}, {"text": "[14]", "bbox": [91.0, 729.0, 115.0, 741.0]}, {"text": "the efficacy of different androgens measured by LC-MS/", "bbox": [123.0, 742.0, 388.0, 755.0]}, {"text": "MS in representing hyperandrogenemia and an evaluation of", "bbox": [123.0, 756.0, 390.0, 769.0]}, {"text": "adrenal-origin androgens with a dexamethasone suppression", "bbox": [123.0, 770.0, 388.0, 782.0]}, {"text": "test in patients with PCOS[J]. J Ovarian Res, 2021, 14", "bbox": [123.0, 784.0, 388.0, 797.0]}, {"text": "(1): 32.", "bbox": [125.0, 799.0, 175.0, 812.0]}, {"text": "牛静云，侯丽辉，寇丽辉，等. 不同高堆激素血症表型多", "bbox": [121.0, 810.0, 388.0, 826.0]}, {"text": "[15]", "bbox": [91.0, 813.0, 116.0, 826.0]}, {"text": "藥卵巢综合征患者临床特征分析[J]. 实用妇产科杂志 ,", "bbox": [123.0, 825.0, 382.0, 841.0]}, {"text": "2018, 34 (4): 286-290.", "bbox": [123.0, 841.0, 243.0, 853.0]}, {"text": "GOODMAN N F , COBIN R H , FUTTERWEIT W ,", "bbox": [121.0, 855.0, 381.0, 868.0]}, {"text": "[16]", "bbox": [91.0, 856.0, 115.0, 868.0]}, {"text": "et al. American Association of Clinical Endocrinologists,", "bbox": [123.0, 870.0, 382.0, 882.0]}, {"text": "American College of Endocrinology, and Androgen", "bbox": [123.0, 883.0, 389.0, 896.0]}, {"text": "Excess and PCOS Society disease state clinical review:", "bbox": [123.0, 897.0, 383.0, 909.0]}, {"text": "guide to the best practices in the evaluation and treatment of", "bbox": [123.0, 911.0, 388.0, 924.0]}, {"text": "polycystic ovary syndrome-part 1[J]. Endocr Pract, 2015,", "bbox": [123.0, 925.0, 382.0, 938.0]}, {"text": "21 ( 11 ) : 1291-1300.", "bbox": [123.0, 939.0, 227.0, 951.0]}, {"text": "[17] [17]", "bbox": [91.0, 953.0, 115.0, 967.0]}, {"text": "GOODARZI M O ,  CARMINA E ,  AZZIZ R ,  DHEA ,", "bbox": [121.0, 952.0, 382.0, 965.0]}, {"text": "DHEAS and PCOS[J]. J Steroid Biochem Mol Biol, 2015,", "bbox": [123.0, 967.0, 382.0, 980.0]}, {"text": "145 : 213-225.", "bbox": [123.0, 981.0, 189.0, 994.0]}, {"text": "夏曦，邓玉颖，顾俊婕，等. 趙高压液相色谱- 质谱联用", "bbox": [123.0, 994.0, 388.0, 1008.0]}, {"text": "[18]", "bbox": [91.0, 995.0, 115.0, 1008.0]}, {"text": "技术联合分析血清率酮和硫酸脱氢装雄酮提高多褰卵", "bbox": [123.0, 1008.0, 388.0, 1022.0]}, {"text": "巢综合征的诊断率[J]. 中华内分泌代谢杂志, 2018, 34", "bbox": [123.0, 1022.0, 388.0, 1036.0]}], "type": "Text", "position": 2}, {"raw_context": [{"text": "[19] [19]", "bbox": [426.0, 138.0, 452.0, 151.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "[20]", "bbox": [426.0, 194.0, 450.0, 207.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": "[21]", "bbox": [426.0, 250.0, 449.0, 262.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "[22]", "bbox": [426.0, 278.0, 449.0, 291.0]}], "type": "Text", "position": 6}, {"raw_context": [{"text": "[23]", "bbox": [426.0, 335.0, 450.0, 348.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "[24]", "bbox": [426.0, 391.0, 450.0, 404.0]}], "type": "Text", "position": 8}, {"raw_context": [{"text": "[25]", "bbox": [426.0, 447.0, 450.0, 460.0]}], "type": "Text", "position": 9}, {"raw_context": [{"text": "[26]", "bbox": [426.0, 517.0, 450.0, 530.0]}], "type": "Text", "position": 10}, {"raw_context": [{"text": "[27]", "bbox": [426.0, 574.0, 450.0, 587.0]}], "type": "Text", "position": 11}, {"raw_context": [{"text": "[28]", "bbox": [426.0, 631.0, 450.0, 643.0]}], "type": "Text", "position": 12}, {"raw_context": [{"text": "[29]", "bbox": [426.0, 687.0, 450.0, 699.0]}], "type": "Text", "position": 13}, {"raw_context": [{"text": "[30]", "bbox": [426.0, 743.0, 450.0, 755.0]}], "type": "Text", "position": 14}, {"raw_context": [{"text": "[31]", "bbox": [426.0, 814.0, 450.0, 826.0]}], "type": "Text", "position": 15}, {"raw_context": [{"text": "[32]", "bbox": [426.0, 884.0, 450.0, 897.0]}], "type": "Text", "position": 16}, {"raw_context": [{"text": "[33]", "bbox": [426.0, 925.0, 450.0, 938.0]}], "type": "Text", "position": 17}, {"raw_context": [{"text": "[34]", "bbox": [426.0, 967.0, 450.0, 980.0]}], "type": "Text", "position": 18}, {"raw_context": [{"text": "( 2 ) : 136-140.", "bbox": [460.0, 124.0, 534.0, 137.0]}, {"text": "CAO Z , LU Y , CONG Y , et al. Simultaneous quantitation", "bbox": [455.0, 138.0, 724.0, 151.0]}, {"text": "of four androgens and 17-hydroxyprogesterone in polycystic", "bbox": [456.0, 151.0, 724.0, 165.0]}, {"text": "ovarian syndrome patients by LC-MS/MS[J]. J Clin Lab", "bbox": [456.0, 165.0, 724.0, 178.0]}, {"text": "Anal, 2020, 34 (12): c23539.", "bbox": [458.0, 179.0, 609.0, 193.0]}, {"text": "TOSI F , FIERS T , KAUFMAN J M , et al. Implications of", "bbox": [456.0, 194.0, 725.0, 207.0]}, {"text": "androgen assay accuracy in the phenotyping of women with", "bbox": [457.0, 207.0, 724.0, 221.0]}, {"text": "polycystic ovary syndrome[J]. J Clin Endocrinol Metab,", "bbox": [456.0, 221.0, 717.0, 234.0]}, {"text": "2016, 101 (2): 610-618.", "bbox": [458.0, 236.0, 583.0, 248.0]}, {"text": "KEEVIL B. Steroid mass spectrometry for the diagnosis of", "bbox": [456.0, 250.0, 725.0, 262.0]}, {"text": "PCOS[J]. Med Sci ( Basel ) , 2019, 7 ( 7 ) : 78.", "bbox": [457.0, 263.0, 682.0, 277.0]}, {"text": "AMBROZIAK U, KĘPCZYŃSKA-NYK A,", "bbox": [456.0, 277.0, 718.0, 290.0]}, {"text": "KURYŁOWICZ A, et al. LC-MS/MS improves screening", "bbox": [457.0, 292.0, 723.0, 304.0]}, {"text": "towards 21-hydroxylase deficiency[J]. Gynecol Endocrinol ,", "bbox": [457.0, 306.0, 718.0, 319.0]}, {"text": "2015, 31 (4): 296-300.", "bbox": [458.0, 321.0, 578.0, 333.0]}, {"text": "HANDELSMAN D J ,  WARTOFSKY L. Requirement", "bbox": [456.0, 333.0, 724.0, 347.0]}, {"text": "for mass spectrometry sex steroid assays in the Journal of", "bbox": [458.0, 348.0, 725.0, 360.0]}, {"text": "Clinical Endocrinology and Metabolism [J]. J Clin Endocrinol", "bbox": [457.0, 362.0, 723.0, 375.0]}, {"text": "Metab, 2013, 98 ( 10 ) : 3971-3973.", "bbox": [457.0, 377.0, 631.0, 389.0]}, {"text": "WIERMAN M E ,  AUCHUS R J ,  HAISENLEDER D", "bbox": [456.0, 390.0, 725.0, 404.0]}, {"text": "J, et al. Editorial: the new instructions to authors for", "bbox": [457.0, 404.0, 723.0, 417.0]}, {"text": "the reporting of steroid hormone measurements[J]. Mol", "bbox": [456.0, 418.0, 723.0, 431.0]}, {"text": "Endocrinol, 2014, 28 ( 12 ) : 1917.", "bbox": [458.0, 433.0, 625.0, 445.0]}, {"text": "TEEDE H J ,  MISSO M L ,  COSTELLO M F ,  et al.", "bbox": [456.0, 446.0, 723.0, 460.0]}, {"text": "Recommendations from the international evidence-based", "bbox": [457.0, 460.0, 724.0, 472.0]}, {"text": "guideline for the assessment and management of polycystic", "bbox": [457.0, 475.0, 723.0, 487.0]}, {"text": "ovary syndrome[J]. Hum Reprod, 2018, 33 ( 9 ) : 1602-", "bbox": [457.0, 489.0, 722.0, 501.0]}, {"text": "1618.", "bbox": [458.0, 504.0, 484.0, 515.0]}, {"text": "ZHAO M, BAKER S D, YAN X, et al. Simultaneous", "bbox": [456.0, 516.0, 724.0, 530.0]}, {"text": "determination of steroid composition of human testicular fluid", "bbox": [456.0, 531.0, 724.0, 544.0]}, {"text": "using liquid chromatography tandem mass spectrometry[J].", "bbox": [456.0, 546.0, 723.0, 558.0]}, {"text": "Steroids, 2004, 69 (11-12) : 721-726.", "bbox": [457.0, 560.0, 642.0, 572.0]}, {"text": "OLIVEIRA L R ,  LONGUI C A ,  GUARAGNA-FILHO", "bbox": [456.0, 575.0, 725.0, 586.0]}, {"text": "G , et al. Androgens by immunoassay and mass spectrometry", "bbox": [456.0, 588.0, 722.0, 600.0]}, {"text": "in children with 46, XY disorder of sex development[J].", "bbox": [457.0, 602.0, 722.0, 614.0]}, {"text": "Endocr Connect, 2020, 9 ( 11 ) : 1085-1094.", "bbox": [457.0, 616.0, 667.0, 628.0]}, {"text": "SHIRAISHI S, LEE P W, LEUNG A, et al. Simultaneous", "bbox": [456.0, 630.0, 723.0, 643.0]}, {"text": "measurement of serum testosterone and dihydrotestosterone", "bbox": [456.0, 644.0, 723.0, 656.0]}, {"text": "by liquid chromatography-tandem mass spectrometry[J]. Clin", "bbox": [456.0, 658.0, 723.0, 670.0]}, {"text": "Chem, 2008, 54 ( 11 ) : 1855-1863.", "bbox": [456.0, 672.0, 628.0, 685.0]}, {"text": "YARROW J F , BECK D T , CONOVER C F ,", "bbox": [456.0, 686.0, 717.0, 699.0]}, {"text": "et al. Invalidation of a commercially available human", "bbox": [456.0, 700.0, 724.0, 712.0]}, {"text": "5 α -dihydrotestosterone immunoassay[J]. Steroids, 2013,", "bbox": [458.0, 714.0, 717.0, 726.0]}, {"text": "78 ( 12-13 ) : 1220-1225.", "bbox": [458.0, 728.0, 575.0, 740.0]}, {"text": "KEEFE C C, GOLDMAN M M, ZHANG K, et al.", "bbox": [456.0, 742.0, 723.0, 755.0]}, {"text": "Simultaneous measurement of thirteen steroid hormones in", "bbox": [457.0, 756.0, 725.0, 768.0]}, {"text": "women with polycystic ovary syndrome and control women", "bbox": [457.0, 770.0, 723.0, 782.0]}, {"text": "using liquid chromatography-tandem mass spectrometry[J].", "bbox": [456.0, 784.0, 723.0, 797.0]}, {"text": "PLoS One, 2014, 9 (4) : e93805.", "bbox": [456.0, 799.0, 622.0, 811.0]}, {"text": "FANELLI F, BELLUOMO I, DI LALLO V D,", "bbox": [456.0, 813.0, 717.0, 826.0]}, {"text": "et al. Serum steroid profiling by isotopic dilution-liquid", "bbox": [456.0, 827.0, 724.0, 840.0]}, {"text": "chromatography-mass spectrometry: comparison with", "bbox": [456.0, 841.0, 724.0, 853.0]}, {"text": "current immunoassays and reference intervals in healthy", "bbox": [456.0, 855.0, 723.0, 868.0]}, {"text": "adults[J].Steroids, 2011, 76 (3): 244-253.", "bbox": [457.0, 870.0, 664.0, 882.0]}, {"text": "医疗器械监督管理条例[EB/OL]. ( 2021-03-19 )", "bbox": [456.0, 883.0, 721.0, 897.0]}, {"text": "[2021-04-01]. https: //www.nmpa.gov.cn/xxgk/fgwj/", "bbox": [457.0, 897.0, 723.0, 910.0]}, {"text": "flxzhfg/20210319202057136.html.", "bbox": [458.0, 911.0, 607.0, 924.0]}, {"text": "Clinical and Laboratory Standards Institute. Liquid", "bbox": [456.0, 925.0, 724.0, 938.0]}, {"text": "chromatography-mass spectrometry methods[S]. C62-A,", "bbox": [456.0, 939.0, 718.0, 952.0]}, {"text": "CLSI, 2014.", "bbox": [456.0, 953.0, 518.0, 965.0]}, {"text": "Clinical and Laboratory Standards Institute. Defining,", "bbox": [456.0, 967.0, 718.0, 980.0]}, {"text": "establishing, and verifying reference intervals in the clinical", "bbox": [457.0, 981.0, 723.0, 994.0]}, {"text": "laboratory[S]. EP28-A3c, CLSI, 2010.", "bbox": [457.0, 995.0, 635.0, 1008.0]}, {"text": "( 收稿日期: 2022-12-01; 修回日期: 2023-01-10 )", "bbox": [485.0, 1010.0, 720.0, 1024.0]}, {"text": "( 本文编辑：李　欣 )", "bbox": [616.0, 1027.0, 720.0, 1040.0]}], "type": "Text", "position": 19}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/妇产科/多囊卵巢综合征雄激素质谱检测专家共识.pdf", "page_num": 6}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": null, "type3": null, "type4": null, "type5": null, "type6": "信息有用性#0#55#参考文献"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:42", "update_time": "2024-05-07 18:52:17"}
{"id": 1082624, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 738, "source_info": {"seq_id": "08683915-32d0-496f-8cc0-64bf4432b50d", "title": null, "text": "【0】页码:113\n of t\n\n【1】 11\n# 小狗科研究究\n\n【2】\n  ( 接姓氏笔画排斥)\n\n【3】 e  小狗霸组长  马飞、王翔\n 张 清媛、张瑾、陈佳艺、逐渐亦 ኃ久春、魏文强\n。 e the first International 47 is\n\n【4】 小猪\n\n【5】 on t\n 小狗科研公开课\n  l 19 Dis \n 4 H 2 2 2 2 2\n\n【6】 \n\n【7】 \n\n【8】 e t", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "of t", "bbox": [524.0, 16.0, 592.0, 62.0]}], "type": "Text", "position": 0}, {"raw_context": [{"text": "11", "bbox": [597.0, 31.0, 778.0, 120.0]}], "type": "Text", "position": 1}, {"raw_context": [{"text": "小狗科研究究\n ", "bbox": [20.0, 37.0, 614.0, 238.0]}], "type": "Title", "position": 2}, {"raw_context": [{"text": "", "bbox": [540.0, 225.0, 794.0, 336.0]}, {"text": "( 接姓氏笔画排斥)", "bbox": [334.0, 227.0, 531.0, 248.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "e  小狗霸组长  马飞、王翔\n", "bbox": [0.0, 265.0, 649.0, 414.0]}, {"text": "张 清媛、张瑾、陈佳艺、逐渐亦 ኃ久春、魏文强\n。", "bbox": [185.0, 395.0, 658.0, 486.0]}, {"text": "e the first", "bbox": [94.0, 422.0, 344.0, 559.0]}, {"text": "International", "bbox": [73.0, 456.0, 111.0, 484.0]}, {"text": "47 is", "bbox": [0.0, 499.0, 77.0, 548.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": "小猪", "bbox": [745.0, 514.0, 794.0, 554.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "on t", "bbox": [159.0, 560.0, 224.0, 606.0]}], "type": "Text", "position": 9}, {"raw_context": [{"text": "小狗科研公开课", "bbox": [231.0, 575.0, 411.0, 664.0]}], "type": "Formula", "position": 10}, {"raw_context": [{"text": "", "bbox": [469.0, 558.0, 536.0, 612.0]}, {"text": "l 19 Dis", "bbox": [541.0, 584.0, 718.0, 683.0]}, {"text": "", "bbox": [516.0, 671.0, 768.0, 781.0]}], "type": "Formula", "position": 11}, {"raw_context": [{"text": "4 H 2 2 2 2 2", "bbox": [0.0, 757.0, 125.0, 814.0]}], "type": "Formula", "position": 12}, {"raw_context": [{"text": "", "bbox": [136.0, 785.0, 506.0, 954.0]}], "type": "Text", "position": 13}, {"raw_context": [{"text": "", "bbox": [513.0, 913.0, 794.0, 1053.0]}], "type": "Text", "position": 15}, {"raw_context": [{"text": "e t", "bbox": [26.0, 1009.0, 92.0, 1057.0]}], "type": "Text", "position": 16}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2022】全科室最全临床指南+专家共识（最全版）/2022全科室临床指南/肿瘤科/乳腺癌诊疗指南（2022年版）.pdf", "page_num": 113}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": null, "type3": null, "type4": null, "type5": null, "type6": "有用性#0#8#是编写专家的名字，但是提取的杂乱，都是错误信息"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:42", "update_time": "2024-05-07 18:14:13"}
{"id": 1082623, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 738, "source_info": {"seq_id": "976bddcd-7069-4a82-bb85-8c1b17b17023", "title": null, "text": "【0】页码:14\n measures include verbal or physical stimulation of patients to encourage deeper breathing; administration of supplemental oxygen87 to target an oxygen saturation level of 94% and above, or between 88% and 92% in those at risk of hypercapnic respiratory failure, fluid resuscitation if hypotensive and consideration for use of reversal agents as outlined below, alongside further anaesthetic support if spontaneous ventilation does not maintain adequate ventilatory status. 87 Th In the UK, data extrapolated by the National Endoscopy Database showed that reversal agents were used in 0.02% of colonoscopies, 0.05% of gastroscopies and 0.08% of ERCPs, where opiates or sedatives were used for the procedure. 120\n\n【1】## Opiate-Related Toxicity And Naloxone\n\n【2】\n Opiate toxicity can lead to respiratory depression, reduced consciousness, pin-point pupils, arrhythmia, hypotension, desaturation, seizures, apnoea and respiratory arrest. The hallmark feature of opiate-related toxicity requiring reversal is respiratory depression.\n\n【3】Naloxone is a rapid-acting opioid receptor antagonist, with an onset of action of 1–2 min, and a half-life of 30–120 min, dependent on the route of administration. When administered intravenously, it rapidly reverses sedation, the analgesic effect and respiratory depression related to opiates. Careful consideration needs to be given to patients receiving long-term opiates due to the risk of acute withdrawal symptoms after naloxone administration. Common potential side effects include dizziness, headache, hypertension, hypotension, vomiting and arrhythmias. 121 Observational studies and case reports show the successful reversal of respiratory depression and oxygen desaturation after naloxone administration in non-anaesthetic supported units. 122–124 The recommended regimen according to the BNF is an initial dose of 400 µ g IV, followed by 800 µ g for up to two doses at 1 min intervals if no response, then increased to 2 mg for one dose if there is still no response. If repeated administration of naloxone is needed, an infusion of naloxone and transfer to an appropriately monitored environment, such as a highdependency unit, may be considered.\n\n【4】Due to the potential for further sedation following initial administration of naloxone, extended monitoring may be recommended. The American multisociety curriculum on sedation in GI endoscopy suggests a period of observation of up to 2 hours. 12\n\n【5】## Benzodiazepine-Related Toxicity And Flumazenil\n\n【6】\n Symptoms of benzodiazepine-related overdose include reduced consciousness, hypotension, respiratory depression and apnoea.\n\n【7】Management is largely supportive, although flumazenil, a benzodiazepine antagonist, which acts by competitively binding at a benzodiazepine-binding site on the γ -aminobutyric acid receptor, 126 can be used to reverse the effects of benzodiazepine toxicity. It has more efficacy at reversing central nervous system depression than respiratory depression. Thus, in patients administered both benzodiazepine and opiate as part of their sedation regimen, it would make sense to give naloxone first before flumazenil. 12 Flumazenil is given intravenously and has a rapid onset of action of 1–2 min, with the maximal effect reached within 10 min after administration. The BNF recommends a dosage of 200 μ g , administered over 15 s, followed by 100 μ g every minute, if required, up to a maximum of 2 mg. 1\n\n【8】 Potential side effects related to flumazenil are nausea, vomiting, headaches and dizziness. 129 There are also reported cases of benzodiazepine reversal-related seizures, in particular in patients receiving long-term benzodiazepines 130 or high-dose tricyclic antidepressants. 13 The reversal of the effects of midazolam with flumazenil may occur within 2 min. Since midazolam has a longer duration of action than flumazenil, re-sedation may occur following administration of flumazenil. It is prudent to observe patients receiving flumazenil for an extended duration period in recovery (eg, 2 hours longer than usual). 7 21. In patients with opiate or benzodiazepine-induced respiratory depression during or following endoscopy, we recommend the use of a relevant reversal agent Grade of evidence: Low. Strength of recommendation: Strong.\n\n【9】Level of agreement: 92.3% 22. We recommend that only low-strength midazolam (1 mg/ mL) be stocked and used instead of high-strength midazolam to reduce the risk of adverse events related to oversedation Grade of evidence: Very Low. Strength of recommendation: Strong.\n\n【10】Level of agreement: 92.3%\n\n【11】 23. We recommend that endoscopy rooms (or units) should stock flumazenil and naloxone; and all endoscopy clinical staff should be aware of where they are stored and how to access them in case of sedation-related emergencies Grade of evidence: Very Low. Strength of recommendation: Strong.\n\n【12】Level of agreement: 100%\n\n【13】 24. We recommend that all cases of benzodiazepine or opiate toxicity, requiring the use of reversal, should be reported through local incident reporting systems, and any lessons learnt disseminated Grade of evidence: Very Low. Strength of recommendation: Strong.\n\n【14】Level of agreement: 100%\n\n【15】## Routine Use Of Flumazenil After Gi Endoscopy\n\n【16】\n 25. We do not recommend routine benzodiazepine reversal after gastrointestinal endoscopy of patients receiving conscious sedation with a benzodiazepine Grade of evidence: Moderate. Strength of recommendation: Strong.\n\n【17】Level of agreement: 100% Some studies have looked at the routine use of flumazenil after benzodiazepine-based sedation for GI endoscopy. Routine use of flumazenil has been associated with resolution of baseline  psychomotor  skills  within  30  min, 132  improvements  in stay in recovery rooms, 134 135 without significant differences in patient satisfaction, psychological status or procedure-related discomforts. 13 Although some of these studies may suggest an overall decrease in length of stay in the recovery room, clinical benefit from routine use of flumazenil has not been shown. Additionally, flumazenil carries risks of adverse events. 137\n\n【18】## Risk Management Considerations To Reduce Sedation-Related Complications\n\n【19】\n Between 2004 and 2008, the UK's former National Patient Safety Agency (NPSA) received reports of 498 midazolamrelated patients safety incidents (not exclusive to endoscopy units), including three deaths. Concerns were raised from a\n\n【20】 Sidhu R, et al. Gut 2023;0:1–27. doi:10.1136/gutjnl-2023-330396", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "measures include verbal or physical stimulation of patients to", "bbox": [53.0, 60.0, 387.0, 75.0]}, {"text": "encourage deeper breathing; administration of supplemental", "bbox": [53.0, 76.0, 386.0, 90.0]}, {"text": "oxygen87 to target an oxygen saturation level of 94% and above,", "bbox": [53.0, 91.0, 387.0, 105.0]}, {"text": "or between 88% and 92% in those at risk of hypercapnic respira-", "bbox": [53.0, 105.0, 385.0, 120.0]}, {"text": "tory failure, fluid resuscitation if hypotensive and consideration", "bbox": [53.0, 120.0, 387.0, 135.0]}, {"text": "for use of reversal agents as outlined below, alongside further", "bbox": [53.0, 135.0, 386.0, 150.0]}, {"text": "anaesthetic support if spontaneous ventilation does not maintain", "bbox": [53.0, 149.0, 387.0, 165.0]}, {"text": "adequate ventilatory status. 87 Th", "bbox": [54.0, 166.0, 216.0, 179.0]}, {"text": "In the UK, data extrapolated by the National Endoscopy Data-", "bbox": [65.0, 180.0, 385.0, 193.0]}, {"text": "base showed that reversal agents were used in 0.02% of colo-", "bbox": [53.0, 194.0, 385.0, 208.0]}, {"text": "noscopies, 0.05% of gastroscopies and 0.08% of ERCPs, where", "bbox": [53.0, 209.0, 387.0, 223.0]}, {"text": "opiates or sedatives were used for the procedure. 120", "bbox": [53.0, 224.0, 318.0, 238.0]}], "type": "Text", "position": 1}, {"raw_context": [{"text": "Opiate-related toxicity and naloxone", "bbox": [53.0, 264.0, 252.0, 278.0]}], "type": "Section-header", "position": 2}, {"raw_context": [{"text": "Opiate toxicity can lead to respiratory depression, reduced", "bbox": [53.0, 279.0, 387.0, 293.0]}, {"text": "consciousness, pin-point pupils, arrhythmia, hypotension, desat-", "bbox": [53.0, 294.0, 385.0, 308.0]}, {"text": "uration, seizures, apnoea and respiratory arrest. The hallmark", "bbox": [53.0, 310.0, 386.0, 323.0]}, {"text": "feature of opiate-related toxicity requiring reversal is respiratory", "bbox": [53.0, 324.0, 385.0, 338.0]}, {"text": "depression.", "bbox": [53.0, 338.0, 114.0, 352.0]}, {"text": "Naloxone is a rapid-acting opioid receptor antagonist, with", "bbox": [64.0, 353.0, 387.0, 368.0]}, {"text": "an onset of action of 1–2 min, and a half-life of 30–120 min,", "bbox": [53.0, 368.0, 385.0, 383.0]}, {"text": "dependent on the route of administration. When administered", "bbox": [53.0, 383.0, 386.0, 398.0]}, {"text": "intravenously, it rapidly reverses sedation, the analgesic effect", "bbox": [53.0, 398.0, 386.0, 412.0]}, {"text": "and respiratory depression related to opiates. Careful consider-", "bbox": [53.0, 413.0, 385.0, 426.0]}, {"text": "ation needs to be given to patients receiving long-term opiates", "bbox": [53.0, 428.0, 387.0, 441.0]}, {"text": "due to the risk of acute withdrawal symptoms after naloxone", "bbox": [53.0, 442.0, 386.0, 456.0]}, {"text": "administration. Common potential side effects include dizzi-", "bbox": [53.0, 457.0, 385.0, 471.0]}, {"text": "ness, headache, hypertension, hypotension, vomiting and", "bbox": [53.0, 472.0, 386.0, 486.0]}, {"text": "arrhythmias. 121", "bbox": [54.0, 488.0, 135.0, 499.0]}, {"text": "Observational studies and case reports show the successful", "bbox": [64.0, 501.0, 387.0, 516.0]}, {"text": "reversal of respiratory depression and oxygen desaturation", "bbox": [53.0, 516.0, 387.0, 531.0]}, {"text": "after naloxone administration in non-anaesthetic supported", "bbox": [53.0, 531.0, 387.0, 545.0]}, {"text": "units. 122–124 The recommended regimen according to the BNF", "bbox": [53.0, 544.0, 386.0, 561.0]}, {"text": "is an initial dose of 400 µ g IV, followed by 800 µ g for up to two", "bbox": [53.0, 561.0, 387.0, 574.0]}, {"text": "doses at 1 min intervals if no response, then increased to 2 mg", "bbox": [53.0, 575.0, 387.0, 588.0]}, {"text": "for one dose if there is still no response. If repeated administra-", "bbox": [53.0, 589.0, 385.0, 603.0]}, {"text": "tion of naloxone is needed, an infusion of naloxone and transfer", "bbox": [53.0, 604.0, 386.0, 618.0]}, {"text": "to an appropriately monitored environment, such as a high-", "bbox": [53.0, 619.0, 385.0, 633.0]}, {"text": "dependency unit, may be considered.", "bbox": [54.0, 635.0, 246.0, 648.0]}, {"text": "Due to the potential for further sedation following initial", "bbox": [65.0, 648.0, 387.0, 662.0]}, {"text": "administration of naloxone, extended monitoring may be", "bbox": [53.0, 663.0, 387.0, 677.0]}, {"text": "recommended. The American multisociety curriculum on seda-", "bbox": [53.0, 678.0, 385.0, 692.0]}, {"text": "tion in GI endoscopy suggests a period of observation of up to", "bbox": [53.0, 693.0, 387.0, 707.0]}, {"text": "2 hours. 12", "bbox": [54.0, 709.0, 107.0, 722.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "Benzodiazepine-related toxicity and flumazenil", "bbox": [53.0, 748.0, 306.0, 763.0]}], "type": "Section-header", "position": 4}, {"raw_context": [{"text": "Symptoms of benzodiazepine-related overdose include reduced", "bbox": [53.0, 763.0, 387.0, 778.0]}, {"text": "consciousness, hypotension, respiratory depression and apnoea.", "bbox": [53.0, 778.0, 385.0, 793.0]}, {"text": "Management is largely supportive, although flumazenil, a", "bbox": [53.0, 794.0, 387.0, 807.0]}, {"text": "benzodiazepine antagonist, which acts by competitively binding", "bbox": [53.0, 808.0, 387.0, 821.0]}, {"text": "at a benzodiazepine-binding site on the γ -aminobutyric acid", "bbox": [53.0, 823.0, 386.0, 836.0]}, {"text": "receptor, 126 can be used to reverse the effects of benzodiazepine", "bbox": [53.0, 837.0, 387.0, 852.0]}, {"text": "toxicity. It has more efficacy at reversing central nervous system", "bbox": [53.0, 852.0, 387.0, 866.0]}, {"text": "depression than respiratory depression. Thus, in patients admin-", "bbox": [53.0, 867.0, 385.0, 881.0]}, {"text": "istered both benzodiazepine and opiate as part of their seda-", "bbox": [53.0, 882.0, 385.0, 895.0]}, {"text": "tion regimen, it would make sense to give naloxone first before", "bbox": [53.0, 896.0, 387.0, 910.0]}, {"text": "flumazenil. 12", "bbox": [53.0, 911.0, 121.0, 925.0]}, {"text": "Flumazenil is given intravenously and has a rapid onset of", "bbox": [64.0, 926.0, 387.0, 940.0]}, {"text": "action of 1–2 min, with the maximal effect reached within 10", "bbox": [53.0, 941.0, 387.0, 955.0]}, {"text": "min after administration. The BNF recommends a dosage of 200", "bbox": [53.0, 956.0, 387.0, 969.0]}, {"text": "μ g , administered over 15 s, followed by 100 μ g every minute, if", "bbox": [52.0, 970.0, 387.0, 984.0]}, {"text": "required, up to a maximum of 2 mg. 1", "bbox": [53.0, 985.0, 246.0, 999.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "Potential side effects related to flumazenil are nausea,", "bbox": [418.0, 60.0, 739.0, 75.0]}, {"text": "vomiting, headaches and dizziness. 129 There are also reported", "bbox": [406.0, 75.0, 740.0, 89.0]}, {"text": "cases of benzodiazepine reversal-related seizures, in particular", "bbox": [406.0, 90.0, 740.0, 105.0]}, {"text": "in patients receiving long-term benzodiazepines 130", "bbox": [406.0, 105.0, 665.0, 120.0]}, {"text": "or high-dose", "bbox": [667.0, 107.0, 740.0, 119.0]}, {"text": "tricyclic antidepressants. 13", "bbox": [406.0, 120.0, 542.0, 135.0]}, {"text": "The reversal of the effects of midazolam with flumazenil may", "bbox": [419.0, 135.0, 740.0, 150.0]}, {"text": "occur within 2 min. Since midazolam has a longer duration of", "bbox": [406.0, 150.0, 740.0, 164.0]}, {"text": "action than flumazenil, re-sedation may occur following admin-", "bbox": [407.0, 165.0, 739.0, 179.0]}, {"text": "istration of flumazenil. It is prudent to observe patients receiving", "bbox": [406.0, 180.0, 741.0, 193.0]}, {"text": "flumazenil for an extended duration period in recovery (eg, 2", "bbox": [406.0, 194.0, 740.0, 208.0]}, {"text": "hours longer than usual). 7", "bbox": [406.0, 209.0, 540.0, 223.0]}, {"text": "21. In patients with opiate or benzodiazepine-induced respira-", "bbox": [418.0, 223.0, 740.0, 238.0]}, {"text": "tory depression during or following endoscopy, we recommend", "bbox": [406.0, 238.0, 741.0, 252.0]}, {"text": "the use of a relevant reversal agent", "bbox": [406.0, 254.0, 588.0, 267.0]}, {"text": "Grade of evidence: Low. Strength of recommendation: Strong.", "bbox": [418.0, 267.0, 737.0, 281.0]}, {"text": "Level of agreement: 92.3%", "bbox": [418.0, 282.0, 559.0, 296.0]}, {"text": "22. We recommend that only low-strength midazolam (1 mg/", "bbox": [418.0, 297.0, 739.0, 312.0]}, {"text": "mL) be stocked and used instead of high-strength midazolam to", "bbox": [406.0, 311.0, 741.0, 326.0]}, {"text": "reduce the risk of adverse events related to oversedation", "bbox": [406.0, 326.0, 699.0, 340.0]}, {"text": "Grade of evidence: Very Low. Strength of recommendation:", "bbox": [418.0, 341.0, 740.0, 355.0]}, {"text": "Strong.", "bbox": [407.0, 357.0, 445.0, 369.0]}, {"text": "Level of agreement: 92.3%", "bbox": [418.0, 371.0, 560.0, 383.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "23. We recommend that endoscopy rooms (or units) should", "bbox": [418.0, 384.0, 741.0, 399.0]}, {"text": "stock flumazenil and naloxone; and all endoscopy clinical staff", "bbox": [406.0, 399.0, 741.0, 413.0]}, {"text": "should be aware of where they are stored and how to access", "bbox": [406.0, 414.0, 740.0, 428.0]}, {"text": "them in case of sedation-related emergencies", "bbox": [406.0, 428.0, 640.0, 444.0]}, {"text": "Grade of evidence: Very Low. Strength of recommendation:", "bbox": [418.0, 443.0, 739.0, 458.0]}, {"text": "Strong.", "bbox": [407.0, 459.0, 445.0, 472.0]}, {"text": "Level of agreement: 100%", "bbox": [418.0, 473.0, 557.0, 488.0]}], "type": "Text", "position": 8}, {"raw_context": [{"text": "24. We recommend that all cases of benzodiazepine or opiate", "bbox": [418.0, 487.0, 741.0, 502.0]}, {"text": "toxicity, requiring the use of reversal, should be reported", "bbox": [406.0, 502.0, 741.0, 517.0]}, {"text": "through local incident reporting systems, and any lessons learnt", "bbox": [406.0, 518.0, 741.0, 532.0]}, {"text": "disseminated", "bbox": [406.0, 533.0, 478.0, 546.0]}, {"text": "Grade of evidence: Very Low. Strength of recommendation:", "bbox": [418.0, 547.0, 740.0, 560.0]}, {"text": "Strong.", "bbox": [406.0, 562.0, 445.0, 575.0]}, {"text": "Level of agreement: 100%", "bbox": [418.0, 576.0, 557.0, 591.0]}], "type": "Text", "position": 9}, {"raw_context": [{"text": "Routine use of flumazenil after GI endoscopy", "bbox": [406.0, 607.0, 649.0, 621.0]}], "type": "Section-header", "position": 10}, {"raw_context": [{"text": "25. We do not recommend routine benzodiazepine reversal after", "bbox": [406.0, 622.0, 741.0, 636.0]}, {"text": "gastrointestinal endoscopy of patients receiving conscious seda-", "bbox": [406.0, 637.0, 739.0, 651.0]}, {"text": "tion with a benzodiazepine", "bbox": [406.0, 652.0, 549.0, 665.0]}, {"text": "Grade of evidence: Moderate. Strength of recommendation:", "bbox": [418.0, 667.0, 740.0, 680.0]}, {"text": "Strong.", "bbox": [407.0, 682.0, 445.0, 694.0]}, {"text": "Level of agreement: 100%", "bbox": [419.0, 696.0, 557.0, 709.0]}, {"text": "Some studies have looked at the routine use of flumazenil", "bbox": [418.0, 710.0, 741.0, 724.0]}, {"text": "after benzodiazepine-based sedation for GI endoscopy. Routine", "bbox": [406.0, 724.0, 740.0, 739.0]}, {"text": "use of flumazenil has been associated with resolution of base-", "bbox": [406.0, 738.0, 739.0, 753.0]}, {"text": "line  psychomotor  skills  within  30  min, 132  improvements  in", "bbox": [405.0, 751.0, 741.0, 783.0]}, {"text": "stay in recovery rooms, 134 135 without significant differences in", "bbox": [406.0, 781.0, 741.0, 796.0]}, {"text": "patient satisfaction, psychological status or procedure-related", "bbox": [407.0, 798.0, 741.0, 812.0]}, {"text": "discomforts. 13", "bbox": [406.0, 812.0, 478.0, 826.0]}, {"text": "Although some of these studies may suggest an overall", "bbox": [418.0, 827.0, 741.0, 841.0]}, {"text": "decrease in length of stay in the recovery room, clinical benefit", "bbox": [406.0, 842.0, 741.0, 856.0]}, {"text": "from routine use of flumazenil has not been shown. Additionally,", "bbox": [406.0, 857.0, 741.0, 871.0]}, {"text": "flumazenil carries risks of adverse events. 137", "bbox": [406.0, 871.0, 632.0, 886.0]}], "type": "Text", "position": 11}, {"raw_context": [{"text": "Risk management considerations to reduce sedation-related", "bbox": [406.0, 910.0, 731.0, 925.0]}, {"text": "complications", "bbox": [406.0, 926.0, 484.0, 940.0]}], "type": "Section-header", "position": 12}, {"raw_context": [{"text": "Between 2004 and 2008, the UK's former National Patient", "bbox": [406.0, 941.0, 741.0, 955.0]}, {"text": "Safety Agency (NPSA) received reports of 498 midazolam-", "bbox": [406.0, 956.0, 739.0, 969.0]}, {"text": "related patients safety incidents (not exclusive to endoscopy", "bbox": [406.0, 971.0, 739.0, 985.0]}, {"text": "units), including three deaths. Concerns were raised from a", "bbox": [406.0, 985.0, 741.0, 1000.0]}], "type": "Text", "position": 13}, {"raw_context": [{"text": "Sidhu R, et al. Gut 2023;0:1–27. doi:10.1136/gutjnl-2023-330396", "bbox": [477.0, 1009.0, 739.0, 1022.0]}], "type": "Text", "position": 14}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/消化科/_2023 BSG指南：胃肠内窥镜检查中的镇静.pdf", "page_num": 14}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "缺少换行#3#3#Observational studies另起一行\n缺少换行#7#7#Flumazenil is given 另起一行\n缺少换行#8#8#The reversal of the effects 另起一行\n21. In patients with opiate另起一行\nGrade of evidence: Low. Strength另起一行\n缺少换行#9#9# 22. We recommend that only另起一行\nGrade of evidence: Very Low.另起一行\n缺少换行#11#11#Grade of evidence: Very Low.另起一行\n缺少换行#13#13#Grade of evidence: Very Low.另起一行\n缺少换行#16#16#Grade of evidence: Moderate.另起一行\n缺少换行#17#17#Some studies have looked at另起一行\n Although some of these studies 另起一行", "type3": "无关文本#0#20#ventilatory status. 87部分段落末尾，以及句末的数字问题无关噪声应用全文\n", "type4": null, "type5": null, "type6": "有用性#20#20#Sidhu R, et al. Gut 2023;0:1–27. doi:10.1136/gutjnl-2023-330396为页脚内容"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:42", "update_time": "2024-05-07 19:04:01"}
{"id": 1082622, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 738, "source_info": {"seq_id": "b98ac62c-c2f7-4f46-af3d-9956efecc690", "title": null, "text": "【0】页码:16\n the upper GI tract), certain foreign body retrieval procedures and prolonged bariatric endoscopy, deep sedation and especially, general anaesthesia may be safer and decrease procedure times.\n\n【1】## Special Considerations: Eus/Ercp\n\n【2】\n Endoscopic ultrasound uses larger echoendoscopes, which are wider and bigger than standard endoscopes and the therapeutic range of EUS is widening significantly.\n\n【3】Endoscopic retrograde cholangiopancreatography is a highly complex procedure used to treat biliary and pancreatic pathologies. The therapeutic range of ERCP has also broadened with the use of cholangioscopy in managing difficult stones and strictures.\n\n【4】EUS and ERCP are also increasingly performed as a double procedure at the same time (eg, diagnostic EUS±biopsy followed by ERCP; and therapeutic EUS following failed ERCP).\n\n【5】29. We suggest that minimal/moderate sedation is usually adequate in diagnostic EUS and level 1/level 2 ERCP Grade of evidence: Low. Strength of recommendation: Weak.\n\n【6】Level of agreement: 100% There is no specific evidence to support the level of sedation required for EUS and ERCP. Common practice for performing either ERCP or EUS in UK is with conscious sedation. 168 The availability of a deep sedation/GA service to support these procedures in the UK is currently limited. Diagnostic EUS and noncomplex ERCP (grade 1–2) are quicker to perform and usually better tolerated than therapeutic EUS and complex ERCP (grade 3–4). Titrated doses of conscious sedation may be adequate in the majority of these procedures. 169 It is important to note that even grade 1 and grade 2 ERCP and diagnostic EUS can at times be challenging and prolonged.\n\n【7】Apart from the expected procedural complexity, the patient's anxiety level, BMI, ASA class, cardiopulmonary comorbidity, medication history and tolerance of previous procedures under sedation need to be considered when deciding whether mild/ moderate sedation is adequate in these patients.\n\n【8】30. We suggest that complex ERCP, therapeutic EUS and combined EUS+ERCP procedures are performed with deep sedation/general anaesthesia Grade of evidence: Low. Strength of recommendation: Weak Level of agreement: 100% Complex ERCP, therapeutic EUS and combined EUS and ERCP procedures take longer even in skilled hands. The range of therapeutic EUS has widened. EUS-guided pseudocyst and gallbladder drainage, EUS-guided bile duct access, vascular therapy and cyst ablation are being performed. Combined EUS and ERCP is a feasible approach to establish a tissue diagnosis, complete local staging and relieve the biliary obstruction in a single session.\n\n【9】Ensuring patient comfort and safety and achieving successful completion of these procedures may require significantly higher doses of sedative agents, risking unintended adverse effects.\n\n【10】In a meta-analysis, 170 overall sedation-related side effects were similar between groups of patients receiving propofol or general anaesthesia. Propofol could be a safer alternative to general anaesthesia. It remains unclear whether propofol/GA is safer than conscious sedation, but patients sedated with propofol recover more quickly than patients who receive conscious sedation. 171 -175\n\n【11】## Special Considerations: Device-Assisted Enteroscopy (Dae) 31. We Recommend That Conscious Sedation, Deep Sedation And\n\n【12】\n GA are all options for DAE. The choice of sedation should be dependent on patient and procedural factors and local resources Grade of evidence: Low. Strength of recommendation: Strong.\n\n【13】 1616\n\n【14】 Level of agreement: 100% Device-assisted enteroscopy allows deep intubation into the small bowel for histological sampling and therapeutic intervention. This includes double balloon, single balloon or spiral enteroscopy. The insertion route depends on prior findings of capsule endoscopy or radiology. The average procedure is 75 min or longer for the retrograde route. The technique involves repeated advancement and withdrawal of enteroscope and overtube which results in stretching of the mesentery and might result in pain. Conscious sedation, propofol and general anaesthetic have all been used for DAE. A large German registry highlighted that 0.5% of complications during DAE were related to sedation. 176 While DAE can safely be done on an outpatient basis, in patients with significant comorbidity an inpatient procedure is recommended with prolonged monitoring after the procedure.\n\n【15】Insufficient data currently exist that relate to different DAE techniques or to different insertion routes according to the sedation regimen. Similarly, specific data about patient satisfaction according to sedation or different devices are lacking.\n\n【16】Some studies have highlighted that DAE is poorly tolerated under conscious sedation, particularly by the antegrade route. 177 However, there are no prospective randomised trials comparing different sedation techniques in DAE. Evidence to date is mainly from retrospective studies, which suggest no difference in outcomes even when including elderly groups. 178 – 186 As for other advanced endoscopic procedures, the choice of sedation regimen depends on patient-related, clinical factors, technical issues (eg, expected procedure duration, planned therapy, etc) and also on local organisational protocols.\n\n【17】Other endoscopic adjuncts should also be considered for DAE.\n\n【18】A meta-analysis of four randomised controlled trials (two on double-balloon enteroscopy and two on single-balloon enteroscopy; 461 patients overall, 235 randomised to undergo enteroscopy with air and 226 with CO, insufflation) demonstrated that, compared with air, use of CO2 significantly increased the insertion depth for antegrade enteroscopy, but not for the retrograde approach. The use of CO 2 significantly reduced postprocedure abdominal pain in both retrograde and antegrade DAF. 181 Use of high-flow supportive nasal oxygen therapy has shown reduction in hypoxaemic events (oxygen desaturation <90% for 60 s or more) in patients undergoing gastroscopy using propofol.\n\n【19】These data could be extrapolated for DAE. 1\n\n【20】## Special Considerations: Transnasal Endoscopy (Tne) 32. We Recommend Unsedated Transnasal Endoscopy As An\n\n【21】\n acceptable alternative to conventional oral endoscopy for routine diagnostic upper endoscopy.\n\n【22】Grade of evidence: Moderate. Strength of recommendation: Strong.\n\n【23】Level of agreement: 100% In patients who require sedation for an upper GI examination but who are unable to have analgesia or sedation, TNE can be considered. TNE is performed without sedation using an ultrathin endoscope (approximate diameter 5–6 mm) inserted via the nasal passages. Despite the smaller diameter, the latest instruments have most of the functionality of standard endoscopes, and numerous studies have shown TNE to have similar effectiveness in routine practice for diagnostic upper GI endoscopy. 18 Studies comparing tolerance for unsedated TNE and conventional transoral oesophagogastroduodenoscopy (with or without sedation) report better patient tolerance, satisfaction and acceptability for TNE, using a variety of patient, nurse or endoscopistreported questionnaires. 186 -190 Less gagging and discomfort are Sidhu R, et al. Gut 2023;0:1–27. doi:10.1136/gutjnl-2023-330396", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "the upper GI tract), certain foreign body retrieval procedures", "bbox": [53.0, 60.0, 387.0, 75.0]}, {"text": "and prolonged bariatric endoscopy, deep sedation and espe-", "bbox": [53.0, 76.0, 385.0, 90.0]}, {"text": "cially, general anaesthesia may be safer and decrease proce-", "bbox": [53.0, 91.0, 385.0, 105.0]}, {"text": "dure times.", "bbox": [53.0, 106.0, 118.0, 120.0]}], "type": "Text", "position": 1}, {"raw_context": [{"text": "Special considerations: EUS/ERCP", "bbox": [53.0, 137.0, 232.0, 150.0]}], "type": "Section-header", "position": 2}, {"raw_context": [{"text": "Endoscopic ultrasound uses larger echoendoscopes, which are", "bbox": [53.0, 151.0, 387.0, 166.0]}, {"text": "wider and bigger than standard endoscopes and the therapeutic", "bbox": [53.0, 166.0, 387.0, 181.0]}, {"text": "range of EUS is widening significantly.", "bbox": [53.0, 181.0, 252.0, 195.0]}, {"text": "Endoscopic retrograde cholangiopancreatography is a highly", "bbox": [65.0, 196.0, 386.0, 210.0]}, {"text": "complex procedure used to treat biliary and pancreatic patholo-", "bbox": [53.0, 211.0, 385.0, 225.0]}, {"text": "gies. The therapeutic range of ERCP has also broadened with the", "bbox": [53.0, 225.0, 387.0, 240.0]}, {"text": "use of cholangioscopy in managing difficult stones and strictures.", "bbox": [53.0, 240.0, 386.0, 255.0]}, {"text": "EUS and ERCP are also increasingly performed as a double", "bbox": [64.0, 255.0, 387.0, 270.0]}, {"text": "procedure at the same time (eg, diagnostic EUS±biopsy followed", "bbox": [53.0, 270.0, 387.0, 285.0]}, {"text": "by ERCP; and therapeutic EUS following failed ERCP).", "bbox": [53.0, 285.0, 341.0, 299.0]}, {"text": "29. We suggest that minimal/moderate sedation is usually", "bbox": [65.0, 300.0, 386.0, 313.0]}, {"text": "adequate in diagnostic EUS and level 1/level 2 ERCP", "bbox": [54.0, 314.0, 330.0, 328.0]}, {"text": "Grade of evidence: Low. Strength of recommendation: Weak.", "bbox": [64.0, 329.0, 379.0, 343.0]}, {"text": "Level of agreement: 100%", "bbox": [65.0, 344.0, 205.0, 357.0]}, {"text": "There is no specific evidence to support the level of sedation", "bbox": [66.0, 358.0, 387.0, 373.0]}, {"text": "required for EUS and ERCP. Common practice for performing", "bbox": [53.0, 373.0, 386.0, 387.0]}, {"text": "either ERCP or EUS in UK is with conscious sedation. 168 The", "bbox": [53.0, 388.0, 387.0, 401.0]}, {"text": "availability of a deep sedation/GA service to support these proce-", "bbox": [53.0, 402.0, 385.0, 416.0]}, {"text": "dures in the UK is currently limited. Diagnostic EUS and non-", "bbox": [53.0, 417.0, 385.0, 431.0]}, {"text": "complex ERCP (grade 1–2) are quicker to perform and usually", "bbox": [53.0, 431.0, 386.0, 446.0]}, {"text": "better tolerated than therapeutic EUS and complex ERCP (grade", "bbox": [53.0, 446.0, 387.0, 460.0]}, {"text": "3–4). Titrated doses of conscious sedation may be adequate in", "bbox": [53.0, 461.0, 387.0, 475.0]}, {"text": "the majority of these procedures. 169", "bbox": [53.0, 476.0, 237.0, 489.0]}, {"text": "It is important to note that even grade 1 and grade 2 ERCP", "bbox": [64.0, 490.0, 386.0, 505.0]}, {"text": "and diagnostic EUS can at times be challenging and prolonged.", "bbox": [53.0, 505.0, 386.0, 519.0]}, {"text": "Apart from the expected procedural complexity, the patient's", "bbox": [53.0, 519.0, 387.0, 534.0]}, {"text": "anxiety level, BMI, ASA class, cardiopulmonary comorbidity,", "bbox": [53.0, 534.0, 387.0, 550.0]}, {"text": "medication history and tolerance of previous procedures under", "bbox": [53.0, 550.0, 386.0, 563.0]}, {"text": "sedation need to be considered when deciding whether mild/", "bbox": [53.0, 564.0, 385.0, 578.0]}, {"text": "moderate sedation is adequate in these patients.", "bbox": [53.0, 579.0, 301.0, 593.0]}, {"text": "30. We suggest that complex ERCP, therapeutic EUS and", "bbox": [66.0, 593.0, 387.0, 608.0]}, {"text": "combined EUS+ERCP procedures are performed with deep", "bbox": [53.0, 608.0, 387.0, 623.0]}, {"text": "sedation/general anaesthesia", "bbox": [53.0, 623.0, 203.0, 638.0]}, {"text": "Grade of evidence: Low. Strength of recommendation: Weak", "bbox": [65.0, 637.0, 376.0, 652.0]}, {"text": "Level of agreement: 100%", "bbox": [64.0, 653.0, 204.0, 666.0]}, {"text": "Complex ERCP, therapeutic EUS and combined EUS and ERCP", "bbox": [64.0, 667.0, 386.0, 681.0]}, {"text": "procedures take longer even in skilled hands. The range of thera-", "bbox": [53.0, 682.0, 385.0, 696.0]}, {"text": "peutic EUS has widened. EUS-guided pseudocyst and gallbladder", "bbox": [53.0, 696.0, 386.0, 711.0]}, {"text": "drainage, EUS-guided bile duct access, vascular therapy and cyst", "bbox": [53.0, 712.0, 386.0, 726.0]}, {"text": "ablation are being performed. Combined EUS and ERCP is a", "bbox": [53.0, 727.0, 387.0, 740.0]}, {"text": "feasible approach to establish a tissue diagnosis, complete local", "bbox": [53.0, 741.0, 387.0, 755.0]}, {"text": "staging and relieve the biliary obstruction in a single session.", "bbox": [53.0, 756.0, 386.0, 770.0]}, {"text": "Ensuring patient comfort and safety and achieving successful", "bbox": [53.0, 770.0, 387.0, 785.0]}, {"text": "completion of these procedures may require significantly higher", "bbox": [53.0, 785.0, 386.0, 799.0]}, {"text": "doses of sedative agents, risking unintended adverse effects.", "bbox": [53.0, 800.0, 363.0, 814.0]}, {"text": "In a meta-analysis, 170 overall sedation-related side effects were", "bbox": [64.0, 814.0, 387.0, 828.0]}, {"text": "similar between groups of patients receiving propofol or general", "bbox": [53.0, 829.0, 386.0, 842.0]}, {"text": "anaesthesia. Propofol could be a safer alternative to general", "bbox": [53.0, 843.0, 387.0, 857.0]}, {"text": "anaesthesia. It remains unclear whether propofol/GA is safer than", "bbox": [53.0, 858.0, 387.0, 872.0]}, {"text": "conscious sedation, but patients sedated with propofol recover", "bbox": [53.0, 873.0, 385.0, 887.0]}, {"text": "more quickly than patients who receive conscious sedation. 171 -175", "bbox": [53.0, 889.0, 383.0, 902.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "Special considerations: device-assisted enteroscopy (DAE)", "bbox": [53.0, 925.0, 364.0, 940.0]}, {"text": "31. We recommend that conscious sedation, deep sedation and", "bbox": [53.0, 941.0, 386.0, 954.0]}], "type": "Section-header", "position": 4}, {"raw_context": [{"text": "GA are all options for DAE. The choice of sedation should be", "bbox": [53.0, 956.0, 387.0, 969.0]}, {"text": "dependent on patient and procedural factors and local resources", "bbox": [53.0, 970.0, 386.0, 983.0]}, {"text": "Grade of evidence: Low. Strength of recommendation: Strong.", "bbox": [65.0, 985.0, 384.0, 999.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "1616", "bbox": [54.0, 1010.0, 68.0, 1022.0]}], "type": "Text", "position": 6}, {"raw_context": [{"text": "Level of agreement: 100%", "bbox": [418.0, 61.0, 557.0, 75.0]}, {"text": "Device-assisted enteroscopy allows deep intubation into the", "bbox": [418.0, 75.0, 740.0, 90.0]}, {"text": "small bowel for histological sampling and therapeutic inter-", "bbox": [406.0, 91.0, 739.0, 105.0]}, {"text": "vention. This includes double balloon, single balloon or spiral", "bbox": [406.0, 105.0, 740.0, 120.0]}, {"text": "enteroscopy. The insertion route depends on prior findings of", "bbox": [406.0, 120.0, 740.0, 135.0]}, {"text": "capsule endoscopy or radiology. The average procedure is 75", "bbox": [406.0, 135.0, 740.0, 150.0]}, {"text": "min or longer for the retrograde route. The technique involves", "bbox": [406.0, 150.0, 741.0, 164.0]}, {"text": "repeated advancement and withdrawal of enteroscope and over-", "bbox": [406.0, 165.0, 739.0, 179.0]}, {"text": "tube which results in stretching of the mesentery and might result", "bbox": [406.0, 180.0, 741.0, 193.0]}, {"text": "in pain. Conscious sedation, propofol and general anaesthetic", "bbox": [406.0, 195.0, 740.0, 208.0]}, {"text": "have all been used for DAE. A large German registry highlighted", "bbox": [406.0, 209.0, 741.0, 223.0]}, {"text": "that 0.5% of complications during DAE were related to seda-", "bbox": [406.0, 223.0, 739.0, 238.0]}, {"text": "tion. 176 While DAE can safely be done on an outpatient basis, in", "bbox": [406.0, 237.0, 741.0, 253.0]}, {"text": "patients with significant comorbidity an inpatient procedure is", "bbox": [406.0, 253.0, 741.0, 267.0]}, {"text": "recommended with prolonged monitoring after the procedure.", "bbox": [406.0, 268.0, 734.0, 281.0]}, {"text": "Insufficient data currently exist that relate to different DAE", "bbox": [418.0, 282.0, 740.0, 296.0]}, {"text": "techniques or to different insertion routes according to the", "bbox": [406.0, 297.0, 741.0, 312.0]}, {"text": "sedation regimen. Similarly, specific data about patient satis-", "bbox": [406.0, 312.0, 739.0, 326.0]}, {"text": "faction according to sedation or different devices are lacking.", "bbox": [406.0, 327.0, 739.0, 341.0]}, {"text": "Some studies have highlighted that DAE is poorly tolerated", "bbox": [406.0, 342.0, 739.0, 355.0]}, {"text": "under conscious sedation, particularly by the antegrade route. 177", "bbox": [406.0, 356.0, 735.0, 370.0]}, {"text": "However, there are no prospective randomised trials comparing", "bbox": [406.0, 371.0, 740.0, 384.0]}, {"text": "different sedation techniques in DAE. Evidence to date is mainly", "bbox": [406.0, 385.0, 740.0, 399.0]}, {"text": "from retrospective studies, which suggest no difference in", "bbox": [406.0, 399.0, 741.0, 414.0]}, {"text": "outcomes even when including elderly groups. 178 – 186", "bbox": [406.0, 415.0, 674.0, 428.0]}, {"text": "As for other advanced endoscopic procedures, the choice of", "bbox": [418.0, 429.0, 740.0, 443.0]}, {"text": "sedation regimen depends on patient-related, clinical factors,", "bbox": [406.0, 444.0, 739.0, 458.0]}, {"text": "technical issues (eg, expected procedure duration, planned", "bbox": [406.0, 457.0, 740.0, 474.0]}, {"text": "therapy, etc) and also on local organisational protocols.", "bbox": [406.0, 473.0, 694.0, 488.0]}, {"text": "Other endoscopic adjuncts should also be considered for DAE.", "bbox": [418.0, 488.0, 739.0, 503.0]}, {"text": "A meta-analysis of four randomised controlled trials (two on", "bbox": [406.0, 503.0, 741.0, 518.0]}, {"text": "double-balloon enteroscopy and two on single-balloon enteros-", "bbox": [406.0, 518.0, 739.0, 532.0]}, {"text": "copy; 461 patients overall, 235 randomised to undergo enteros-", "bbox": [406.0, 533.0, 739.0, 546.0]}, {"text": "copy with air and 226 with CO, insufflation) demonstrated that,", "bbox": [406.0, 547.0, 740.0, 561.0]}, {"text": "compared with air, use of CO2 significantly increased the inser-", "bbox": [406.0, 562.0, 739.0, 577.0]}, {"text": "tion depth for antegrade enteroscopy, but not for the retrograde", "bbox": [406.0, 577.0, 741.0, 591.0]}, {"text": "approach. The use of CO 2 significantly reduced postprocedure", "bbox": [406.0, 591.0, 740.0, 606.0]}, {"text": "abdominal pain in both retrograde and antegrade DAF. 181", "bbox": [406.0, 607.0, 704.0, 620.0]}, {"text": "Use of high-flow supportive nasal oxygen therapy has shown", "bbox": [418.0, 621.0, 741.0, 634.0]}, {"text": "reduction in hypoxaemic events (oxygen desaturation <90% for", "bbox": [406.0, 636.0, 740.0, 650.0]}, {"text": "60 s or more) in patients undergoing gastroscopy using propofol.", "bbox": [406.0, 650.0, 739.0, 665.0]}, {"text": "These data could be extrapolated for DAE. 1", "bbox": [407.0, 665.0, 633.0, 679.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "Special considerations: transnasal endoscopy (TNE)", "bbox": [406.0, 706.0, 681.0, 719.0]}, {"text": "32. We recommend unsedated transnasal endoscopy as an", "bbox": [407.0, 721.0, 741.0, 735.0]}], "type": "Section-header", "position": 8}, {"raw_context": [{"text": "acceptable alternative to conventional oral endoscopy for", "bbox": [406.0, 735.0, 740.0, 750.0]}, {"text": "routine diagnostic upper endoscopy.", "bbox": [406.0, 751.0, 596.0, 764.0]}, {"text": "Grade of evidence: Moderate. Strength of recommendation:", "bbox": [418.0, 765.0, 740.0, 778.0]}, {"text": "Strong.", "bbox": [407.0, 781.0, 445.0, 793.0]}, {"text": "Level of agreement: 100%", "bbox": [418.0, 795.0, 557.0, 809.0]}, {"text": "In patients who require sedation for an upper GI examination", "bbox": [418.0, 809.0, 741.0, 824.0]}, {"text": "but who are unable to have analgesia or sedation, TNE can be", "bbox": [406.0, 823.0, 740.0, 838.0]}, {"text": "considered. TNE is performed without sedation using an ultra-", "bbox": [406.0, 839.0, 739.0, 852.0]}, {"text": "thin endoscope (approximate diameter 5–6 mm) inserted via the", "bbox": [406.0, 854.0, 740.0, 867.0]}, {"text": "nasal passages. Despite the smaller diameter, the latest instru-", "bbox": [406.0, 868.0, 739.0, 881.0]}, {"text": "ments have most of the functionality of standard endoscopes,", "bbox": [406.0, 882.0, 741.0, 896.0]}, {"text": "and numerous studies have shown TNE to have similar effective-", "bbox": [406.0, 897.0, 739.0, 911.0]}, {"text": "ness in routine practice for diagnostic upper GI endoscopy. 18", "bbox": [406.0, 912.0, 713.0, 926.0]}, {"text": "Studies comparing tolerance for unsedated TNE and conven-", "bbox": [418.0, 927.0, 739.0, 941.0]}, {"text": "tional transoral oesophagogastroduodenoscopy (with or without", "bbox": [406.0, 942.0, 741.0, 955.0]}, {"text": "sedation) report better patient tolerance, satisfaction and accept-", "bbox": [406.0, 956.0, 739.0, 969.0]}, {"text": "ability for TNE, using a variety of patient, nurse or endoscopist-", "bbox": [406.0, 969.0, 739.0, 986.0]}, {"text": "reported questionnaires. 186 -190 Less gagging and discomfort are", "bbox": [406.0, 984.0, 740.0, 1000.0]}, {"text": "Sidhu R, et al. Gut 2023;0:1–27. doi:10.1136/gutjnl-2023-330396", "bbox": [477.0, 1009.0, 739.0, 1022.0]}], "type": "Text", "position": 9}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/消化科/_2023 BSG指南：胃肠内窥镜检查中的镇静.pdf", "page_num": 16}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "缺少换行#6#6#There is no specific evidence这里开始应换行\n缺少换行#11#11# 31. We Recommend That这里开始应换行\n多余换行#11#12#为同段\n缺少换行#14#14# Device-assisted enteroscopy这里开始应换行\n缺少换行#20#20# 32. We Recommend这里开始应换行\n多余换行#20#21#为同段\n缺少换行#23#23# In patients who require这里开始应换行", "type3": "无关文本#0#23#存在多处多余数字\n页脚#23#23#Sidhu R, et al. Gut 2023;0:1–27. doi:10.1136/gutjnl-2023-330396非正文", "type4": null, "type5": null, "type6": null}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:42", "update_time": "2024-05-07 21:52:17"}
{"id": 1082621, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 738, "source_info": {"seq_id": "24098148-7cbc-4875-81fe-939b21351a44", "title": null, "text": "【0】页码:10\n A. Sun et al.\n\n【1】 Lung Cancer 179 (2023) 107166\n\n【2】 [81] NIH, Whole-brain radiation therapy with or without hippocampal avoidance in treating patients with limited stage or extensive stage small cell lung cancer (NRG- CC003). Available at: https://clinicaltrials.gov/ct2/show/NCT02635009?\n\n【3】term=nrg-cc003&draw=2&rank=1. Accessed: 14 April 2022, 2022.\n\n【4】[82] P.D. Brown, M.W. Parsons, C.G. Rusthoven, V. Gondi, Hippocampal avoidance prophylactic cranial irradiation: a new standard of care? J Clin Oncol. 39 (28) (2021) 3093–3096, https://doi.org/10.1200/jco.21.01632 .\n\n【5】[83] N.R. de Dios, F. Couñago, M. Murcia-Mejía, M. Rico-Oses, P. Calvo-Crespo, P. Samper, C. Vallejo, J. Luna, I. Trueba, A. Sotoca, C. Cigarral, N. Farré, R.\n\n【6】M. Manero, X. Durán, J.D. Gispert, G. Sánchez-Benavides, T. Rognoni, M. Torrente, J. Capellades, M. Jīménez, T. Cabada, M. Blanco, A. Alonso, J.-M.-S. Millán, J. Escribano, B. Gonzalez, J.L. Lopez-Guerra, Randomized phase III trial of prophylactic cranial irradiation with or without hippocampal avoidance for smallcell lung cancer (PREMER): A GICOR-GOECP-SEOR study, J Clin Oncol. 39 (28) (2021) 3118–3127, https://doi.org/10.1200/jco.21.00639 .\n\n【7】 [84] J.S.A. Belderbos, D.K.M. De Ruysscher, K. De Jaeger, F. Koppe, M.L.F. Lambrecht, Y.N. Lievens, E.M.T. Dieleman, J.P.M. Jaspers, J.P. Van Meerbeeck, F. Ubbels, M.\n\n【8】H. Kwint, M.A. Kuenen, S. Deprez, M.B. De Ruiter, W. Boogerd, K. Sikorska, H. Van Tinteren, S.B. Schagen, Phase 3 randomized trial of prophylactic cranial Irradiation with or without hippocampus avoidance in SCLC (NCT01780675), J Thorac Oncol.\n\n【9】16 (5) (2021) 840–849, https://doi.org/10.1016/j.jtho.2020.12.024 .\n\n【10】[85] Y. Chen, L. Paz-Ares, M. Dvorkin, D. Trukhin, N. Reinmuth, M.C. Garassino, G. Statsenko, et al., 9068 : First-line durvalumab plus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN) : impact of brain metastasis on treatment patterns and outcomes , ASCO 2020 (2020) .\n\n【11】[86] L. Horn, A.S. Mansfield, A. Szczesna, L. Havel, M. Krzakowski, M.J. Hochmair, F.\n\n【12】Huemer, G. Losonczy, M.L. Johnson, M. Nishio, M. Reck, T. Mok, S. Lam, D.S.\n\n【13】Shames, J. Liu, B. Ding, A. Lopez-Chavez, F. Kabbinavar, W. Lin, A. Sandler, S.V.\n\n【14】Liu, I.M.S. Group, Protocol: First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer, N Engl J Med. 23 (2018) 2220–2229, https://doi.org/10.1056/NEJMoa1809064 .", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "A. Sun et al.", "bbox": [47.0, 46.0, 96.0, 58.0]}], "type": "Text", "position": 0}, {"raw_context": [{"text": "Lung Cancer 179 (2023) 107166", "bbox": [621.0, 45.0, 747.0, 58.0]}], "type": "Text", "position": 1}, {"raw_context": [{"text": "[81] NIH, Whole-brain radiation therapy with or without hippocampal avoidance in", "bbox": [48.0, 70.0, 377.0, 83.0]}, {"text": "treating patients with limited stage or extensive stage small cell lung cancer (NRG-", "bbox": [70.0, 82.0, 384.0, 93.0]}, {"text": "CC003). Available at: https://clinicaltrials.gov/ct2/show/NCT02635009?", "bbox": [70.0, 92.0, 353.0, 105.0]}, {"text": "term=nrg-cc003&draw=2&rank=1. Accessed: 14 April 2022, 2022.", "bbox": [70.0, 103.0, 330.0, 115.0]}, {"text": "[82] P.D. Brown, M.W. Parsons, C.G. Rusthoven, V. Gondi, Hippocampal avoidance", "bbox": [48.0, 112.0, 373.0, 125.0]}, {"text": "prophylactic cranial irradiation: a new standard of care? J Clin Oncol. 39 (28)", "bbox": [70.0, 124.0, 374.0, 136.0]}, {"text": "(2021) 3093–3096, https://doi.org/10.1200/jco.21.01632 .", "bbox": [70.0, 135.0, 295.0, 147.0]}, {"text": "[83] N.R. de Dios, F. Couñago, M. Murcia-Mejía, M. Rico-Oses, P. Calvo-Crespo,", "bbox": [48.0, 144.0, 357.0, 158.0]}, {"text": "P. Samper, C. Vallejo, J. Luna, I. Trueba, A. Sotoca, C. Cigarral, N. Farré, R.", "bbox": [70.0, 156.0, 362.0, 168.0]}, {"text": "M. Manero, X. Durán, J.D. Gispert, G. Sánchez-Benavides, T. Rognoni, M. Torrente,", "bbox": [70.0, 166.0, 383.0, 178.0]}, {"text": "J. Capellades, M. Jīménez, T. Cabada, M. Blanco, A. Alonso, J.-M.-S. Millán,", "bbox": [70.0, 177.0, 363.0, 189.0]}, {"text": "J. Escribano, B. Gonzalez, J.L. Lopez-Guerra, Randomized phase III trial of", "bbox": [69.0, 187.0, 359.0, 200.0]}, {"text": "prophylactic cranial irradiation with or without hippocampal avoidance for small-", "bbox": [70.0, 198.0, 384.0, 210.0]}, {"text": "cell lung cancer (PREMER): A GICOR-GOECP-SEOR study, J Clin Oncol. 39 (28)", "bbox": [70.0, 209.0, 380.0, 221.0]}, {"text": "(2021) 3118–3127, https://doi.org/10.1200/jco.21.00639 .", "bbox": [70.0, 219.0, 297.0, 232.0]}], "type": "Text", "position": 2}, {"raw_context": [{"text": "[84] J.S.A. Belderbos, D.K.M. De Ruysscher, K. De Jaeger, F. Koppe, M.L.F. Lambrecht,", "bbox": [405.0, 69.0, 742.0, 83.0]}, {"text": "Y.N. Lievens, E.M.T. Dieleman, J.P.M. Jaspers, J.P. Van Meerbeeck, F. Ubbels, M.", "bbox": [430.0, 82.0, 743.0, 94.0]}, {"text": "H. Kwint, M.A. Kuenen, S. Deprez, M.B. De Ruiter, W. Boogerd, K. Sikorska, H. Van", "bbox": [428.0, 92.0, 744.0, 105.0]}, {"text": "Tinteren, S.B. Schagen, Phase 3 randomized trial of prophylactic cranial Irradiation", "bbox": [429.0, 103.0, 743.0, 115.0]}, {"text": "with or without hippocampus avoidance in SCLC (NCT01780675), J Thorac Oncol.", "bbox": [429.0, 113.0, 743.0, 126.0]}, {"text": "16 (5) (2021) 840–849, https://doi.org/10.1016/j.jtho.2020.12.024 .", "bbox": [429.0, 124.0, 692.0, 136.0]}, {"text": "[85] Y. Chen, L. Paz-Ares, M. Dvorkin, D. Trukhin, N. Reinmuth, M.C. Garassino,", "bbox": [406.0, 135.0, 721.0, 147.0]}, {"text": "G. Statsenko, et al., 9068 : First-line durvalumab plus platinum-etoposide in", "bbox": [429.0, 145.0, 720.0, 157.0]}, {"text": "extensive-stage small-cell lung cancer (CASPIAN) : impact of brain metastasis on", "bbox": [429.0, 156.0, 737.0, 168.0]}, {"text": "treatment patterns and outcomes , ASCO 2020 (2020) .", "bbox": [429.0, 166.0, 636.0, 178.0]}, {"text": "[86] L. Horn, A.S. Mansfield, A. Szczesna, L. Havel, M. Krzakowski, M.J. Hochmair, F.", "bbox": [406.0, 177.0, 742.0, 189.0]}, {"text": "Huemer, G. Losonczy, M.L. Johnson, M. Nishio, M. Reck, T. Mok, S. Lam, D.S.", "bbox": [429.0, 187.0, 729.0, 200.0]}, {"text": "Shames, J. Liu, B. Ding, A. Lopez-Chavez, F. Kabbinavar, W. Lin, A. Sandler, S.V.", "bbox": [428.0, 198.0, 742.0, 210.0]}, {"text": "Liu, I.M.S. Group, Protocol: First-line atezolizumab plus chemotherapy in", "bbox": [428.0, 209.0, 711.0, 221.0]}, {"text": "extensive-stage small-cell lung cancer, N Engl J Med. 23 (2018) 2220–2229,", "bbox": [428.0, 218.0, 723.0, 232.0]}, {"text": "https://doi.org/10.1056/NEJMoa1809064 .", "bbox": [429.0, 231.0, 592.0, 241.0]}], "type": "Text", "position": 3}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/肿瘤科/共识/加拿大共识建议：在接受免疫治疗的广泛期小细胞肺癌患者中使用放射治疗.pdf", "page_num": 10}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": null, "type3": null, "type4": null, "type5": null, "type6": "有用性#0#14#参考文献的内容"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:42", "update_time": "2024-05-07 19:21:24"}
{"id": 1082620, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 738, "source_info": {"seq_id": "e63af7dc-d89d-45e8-80fe-df2b2d042837", "title": null, "text": "【0】页码:1\n Expert consensus for diagnosis and treatment of cervical spondylotic myelopathy with the integrated traditional Chinese and western medicine Orthopaedics and Traumatology Branch of Chinese Society of Integrative Medicine , MO Wen' , and YUAN Wen'. I. Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine , Shanghai  200032, China ; 2. The Second Affiliated Hospital of the Naval Military Medical University , Shanghai 200003, China ABSTRACT Cervical spondylotic myelopathy (CSM) is the most serious subtype, which is characterized by severe clinical symptoms , a high disability rate , and poor prognosis. Traditional Chinese medicine and Western medicine have their own advantages in the diagnosis and treatment of CSM at different stages. In order to further standardize the clinical diagnosis and treatment of CSM and improve the clinical efficacy , based on previous experience and evidence-based medicine , after repeated discussions by the national expert group,the expert consensus on the diagnosis and treatment of integrated traditional Chinese and Western medicine was compiled. This consensus comprehensively introduces the definition , etiology , pathogenesis , diagnosis treatment principles, integrated traditional Chinese and Western medicine treatment, postoperative rehabilitation and nursing care of cervical spondylotic myelopathy , so as to provide reference for clinicians.\n\n【1】KEYWORDS Cervical spondylotic myelopathy ; Integrated traditional Chinese and western medicine ; Expert consensus\n\n【2】 (cervical spondylotic myelopathy,CSM)\n\n【3】 : 2021LPTD–008 ) ( Fund program : National Clinical Pilot Project of Traditional Chinese and Western Medicine for Major and Difficult Diseases (No. 2018–3) E-mail ; mw2218@126.com ; E-mail , yuanwen- : spine@smmu.edu.cn\n\n【4】 Corresponding author ; MO Wen E-mail ; mw2218@126.com ; YUAN Wen E-mail ; yuanwenspine@smmu.edu.cn\n\n【5】 .\n\n【6】 (1) (1.\n\n【7】 10%~15% [1] .\n\n【8】 [1]\n\n【9】 2018–\n\n【10】 ;2020–6);\n\n【11】 3);\n\n【12】 (", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "Expert consensus for diagnosis and treatment of cervical spondylotic myelopathy with the integrated traditional Chi-", "bbox": [64.0, 526.0, 661.0, 541.0]}, {"text": "nese and western medicine Orthopaedics and Traumatology Branch of Chinese Society of Integrative Medicine , MO Wen' ,", "bbox": [64.0, 544.0, 661.0, 558.0]}, {"text": "and YUAN Wen'. I. Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine , Shanghai  200032,", "bbox": [64.0, 562.0, 662.0, 576.0]}, {"text": "China ; 2. The Second Affiliated Hospital of the Naval Military Medical University , Shanghai 200003, China", "bbox": [64.0, 579.0, 573.0, 594.0]}, {"text": "ABSTRACT Cervical spondylotic myelopathy (CSM) is the most serious subtype, which is characterized by severe clinical", "bbox": [64.0, 596.0, 664.0, 612.0]}, {"text": "symptoms , a high disability rate , and poor prognosis. Traditional Chinese medicine and Western medicine have their own ad-", "bbox": [64.0, 615.0, 661.0, 630.0]}, {"text": "vantages in the diagnosis and treatment of CSM at different stages. In order to further standardize the clinical diagnosis and", "bbox": [64.0, 633.0, 663.0, 648.0]}, {"text": "treatment of CSM and improve the clinical efficacy , based on previous experience and evidence-based medicine , after repeated", "bbox": [64.0, 651.0, 665.0, 666.0]}, {"text": "discussions by the national expert group,the expert consensus on the diagnosis and treatment of integrated traditional Chinese", "bbox": [64.0, 669.0, 662.0, 683.0]}, {"text": "and Western medicine was compiled. This consensus comprehensively introduces the definition , etiology , pathogenesis , diag-", "bbox": [64.0, 686.0, 661.0, 702.0]}, {"text": "nosis treatment principles, integrated traditional Chinese and Western medicine treatment, postoperative rehabilitation and", "bbox": [64.0, 705.0, 664.0, 719.0]}, {"text": "nursing care of cervical spondylotic myelopathy , so as to provide reference for clinicians.", "bbox": [64.0, 723.0, 481.0, 737.0]}, {"text": "KEYWORDS Cervical spondylotic myelopathy ; Integrated traditional Chinese and western medicine ; Expert consensus", "bbox": [64.0, 740.0, 657.0, 755.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "(cervical spondylotic myelopathy,CSM)", "bbox": [66.0, 838.0, 294.0, 853.0]}], "type": "Text", "position": 6}, {"raw_context": [{"text": ": 2021LPTD–008 )", "bbox": [91.0, 918.0, 173.0, 931.0]}, {"text": "(", "bbox": [65.0, 920.0, 74.0, 930.0]}, {"text": "Fund program : National Clinical Pilot Project of Traditional Chinese and", "bbox": [64.0, 934.0, 378.0, 948.0]}, {"text": "Western Medicine for Major and Difficult Diseases (No. 2018–3)", "bbox": [65.0, 952.0, 339.0, 965.0]}, {"text": "E-mail ; mw2218@126.com ;", "bbox": [146.0, 968.0, 269.0, 981.0]}, {"text": "E-mail , yuanwen-", "bbox": [299.0, 969.0, 375.0, 981.0]}, {"text": ":", "bbox": [109.0, 971.0, 117.0, 980.0]}, {"text": "spine@smmu.edu.cn", "bbox": [65.0, 986.0, 155.0, 999.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "Corresponding author ; MO Wen E-mail ; mw2218@126.com ;", "bbox": [64.0, 1001.0, 329.0, 1014.0]}, {"text": "YUAN Wen E-mail ; yuanwenspine@smmu.edu.cn", "bbox": [66.0, 1019.0, 283.0, 1033.0]}], "type": "Text", "position": 8}, {"raw_context": [{"text": ".", "bbox": [573.0, 117.0, 580.0, 125.0]}], "type": "Text", "position": 9}, {"raw_context": [{"text": "(1) (1.", "bbox": [65.0, 330.0, 83.0, 344.0]}], "type": "Text", "position": 10}, {"raw_context": [{"text": "10%~15% [1] .", "bbox": [399.0, 777.0, 473.0, 792.0]}], "type": "Text", "position": 11}, {"raw_context": [{"text": "[1]", "bbox": [671.0, 798.0, 685.0, 807.0]}], "type": "Text", "position": 12}, {"raw_context": [{"text": "2018–", "bbox": [343.0, 870.0, 375.0, 883.0]}], "type": "Text", "position": 13}, {"raw_context": [{"text": ";2020–6);", "bbox": [316.0, 885.0, 367.0, 898.0]}], "type": "Text", "position": 14}, {"raw_context": [{"text": "3);", "bbox": [64.0, 886.0, 85.0, 899.0]}], "type": "Text", "position": 15}, {"raw_context": [{"text": "(", "bbox": [289.0, 888.0, 297.0, 897.0]}], "type": "Text", "position": 16}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/骨科/共识/脊髓型颈椎病中西医结合诊疗专家共识.pdf", "page_num": 1}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": null, "type3": null, "type4": null, "type5": null, "type6": "有用性#3#12#补充类的参考"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:42", "update_time": "2024-05-07 18:33:43"}
{"id": 1082619, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 738, "source_info": {"seq_id": "9e251d6c-69b7-4446-be35-dcbe71693d26", "title": null, "text": "【0】页码:1\n 文章编号 : 1673-8640 ( 2023 ) 03-0203-06\n\n【1】 中图分类号 : R446.1\n\n【2】 文献标志码 : A\n# 多囊卵巢综合征雄激素质谱检测专家共识\n\n【3】\n 多 \n\n【4】 中国人体健康科技促进会生育力保护与保育专业委员会\n\n【5】 摘要: 多葉卵巢综合征 ( PCOS ) 是常见的育龄期女性内分泌疾病，也是导致女性不孕的主要因素。 PCOS病理生理的主要问题是高峰激素血症。高峰激素血症可以通过生化检验或临床表现进行评估。目前, 大多临床实验室常规开展的基于免疫学的雄激素检测方法存在诸多缺陷，如交又反应、检测低浓度样本时准 确性差、不同品牌试剂检测结果缺乏可比性，导致高雄激素血症评估时出现假阳性结果。液相色谱串联质谱 (LC-MS/MS)具有灵敏度高、特异性强、线性范围宽、可多目标物同时检测等优势，是更高效的雌激素检测 方法。基于临床和实验室循证医学证据，首都医科大学附属北京妇产医院和中国人体健康科技促进会生育力 保护与保存专业委员会联合临床检验、妇科内分泌、质谱应用领域学者共同制定该专家共识，旨在为医疗机 构开展PCOS蜂激素检测提供建议指导。该专家共识的声明包括PCOS蜂激素实验室检测项目和检测方法的建 议，以及采用LC-MS/MS检测堆激素的挑战与应对。 关键词: 多義卵巢综合征; 高雄激素血症; 液相色谱串联质谱\n\n【6】 Consensus on androgen testing in polycystic ovary syndrome Expert Group on the Consensus on Androgen Testing in Polycystic Ovary Syndrome,  China Association for Promotion of Health Science and Technology-Fertility Protection and Preservation Committee.\n\n【7】Abstract: Polycystic ovary syndrome ( PCOS ) is one of the most common endocrine disorders in reproductiveage females, frequently leading to female infertility. Hyperandrogenemia plays a role in the pathogenesis of PCOS.\n\n【8】Hyperandrogenemia can be evaluated by biochemical tests or clinical signs. At present,  there are some limitations of immunology-based testing methods for androgen, such as cross-reaction, poor accuracy in low-concentration samples and lack of comparability among different reagent manufacturers,  leading to false positivity. With the advantages of high sensitivity, high specificity, wide linear range and the capability of simultaneous determination of multiple molecules,  liquid chromatography-tandem mass spectrometry ( LC-MS/MS )  becomes a good choice for androgen testing. On the basis of published clinical and laboratory evidence,  Beijing Obstetrics and Gynecology Hospital of Capital Medical University,  China Association for Promotion of Health Science and Technology-Fertility Protection and Preservation Committee, along with the experts in the clinical laboratory, gynecological endocrinology and mass spectrometry application relevant field made this consensus,  in order to provide professional guidance in PCOS androgen testing in clinical laboratories. The consensus includes recommendations on types and methods of androgen testing for PCOS and challenges of androgen testing with LC-MS/MS.\n\n【9】Key words :  Polycystic ovary syndrome;  Hyperandrogenemia;  Liquid chromatography-tandem mass spectrometry\n\n【10】## 1\n\n【11】\n## 多囊卵巢综合征概述\n\n【12】\n 多 囊 卵 巢 综 合 征 ( p o l y c y s t i c  o v a r y syndrome, PCOS ) 即Stein-Leventhal 综合征, 于1935年被Stein和Leventhal首次报道，是由遗\n\n【13】 传和环境因素共同导致的一种常见的内分泌代谢 性疾病，其主要的临床表现为月经不调、不孕、 高雄激素血症、卵巢多囊，可伴有肥胖、胰岛素 抵抗、血脂紊乱等代谢异常，并可导致2型糖尿\n\n【14】 基金项目: 北京市医院管理中心 \"登峰\" 计划专项 ( DFL20181401 )\n 通信作者: 营  正, E-mail; zhengcao2011@ccmu.edu.cn; 阮祥燕, E-mail; ruanxiangyan@ccmu.edu.cn.\n\n【15】引用本文: 多義卵巢综合征雄激素质谱检测共识专家组，中国人体健康科技促进会生育力保护与保存专业委员会. 多義卵巢综合征雄激 素质谱检测专家共识[J].检验医学, 2023, 38 (3) : 203-208.", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "文章编号 : 1673-8640 ( 2023 ) 03-0203-06", "bbox": [93.0, 124.0, 293.0, 137.0]}], "type": "Text", "position": 2}, {"raw_context": [{"text": "中图分类号 : R446.1", "bbox": [305.0, 123.0, 407.0, 137.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "文献标志码 : A", "bbox": [420.0, 123.0, 502.0, 137.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": "多囊卵巢综合征雄激素质谱检测专家共识", "bbox": [191.0, 164.0, 625.0, 195.0]}], "type": "Title", "position": 6}, {"raw_context": [{"text": "多 ", "bbox": [275.0, 227.0, 542.0, 244.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "中国人体健康科技促进会生育力保护与保育专业委员会", "bbox": [240.0, 252.0, 575.0, 269.0]}], "type": "Text", "position": 8}, {"raw_context": [{"text": "摘要: 多葉卵巢综合征 ( PCOS ) 是常见的育龄期女性内分泌疾病，也是导致女性不孕的主要因素。", "bbox": [142.0, 298.0, 689.0, 314.0]}, {"text": "PCOS病理生理的主要问题是高峰激素血症。高峰激素血症可以通过生化检验或临床表现进行评估。目前,", "bbox": [118.0, 317.0, 690.0, 333.0]}, {"text": "大多临床实验室常规开展的基于免疫学的雄激素检测方法存在诸多缺陷，如交又反应、检测低浓度样本时准", "bbox": [119.0, 338.0, 696.0, 353.0]}, {"text": "确性差、不同品牌试剂检测结果缺乏可比性，导致高雄激素血症评估时出现假阳性结果。液相色谱串联质谱", "bbox": [118.0, 357.0, 697.0, 372.0]}, {"text": "(LC-MS/MS)具有灵敏度高、特异性强、线性范围宽、可多目标物同时检测等优势，是更高效的雌激素检测", "bbox": [122.0, 376.0, 697.0, 392.0]}, {"text": "方法。基于临床和实验室循证医学证据，首都医科大学附属北京妇产医院和中国人体健康科技促进会生育力", "bbox": [119.0, 396.0, 697.0, 412.0]}, {"text": "保护与保存专业委员会联合临床检验、妇科内分泌、质谱应用领域学者共同制定该专家共识，旨在为医疗机", "bbox": [118.0, 414.0, 696.0, 430.0]}, {"text": "构开展PCOS蜂激素检测提供建议指导。该专家共识的声明包括PCOS蜂激素实验室检测项目和检测方法的建", "bbox": [118.0, 433.0, 697.0, 451.0]}, {"text": "议，以及采用LC-MS/MS检测堆激素的挑战与应对。", "bbox": [118.0, 455.0, 388.0, 469.0]}, {"text": "关键词: 多義卵巢综合征; 高雄激素血症; 液相色谱串联质谱", "bbox": [142.0, 473.0, 469.0, 488.0]}], "type": "Text", "position": 9}, {"raw_context": [{"text": "Consensus on androgen testing in polycystic ovary syndrome Expert Group on the Consensus on Androgen", "bbox": [142.0, 511.0, 697.0, 527.0]}, {"text": "Testing in Polycystic Ovary Syndrome,  China Association for Promotion of Health Science and Technology-Fertility", "bbox": [119.0, 531.0, 697.0, 546.0]}, {"text": "Protection and Preservation Committee.", "bbox": [119.0, 552.0, 313.0, 565.0]}, {"text": "Abstract: Polycystic ovary syndrome ( PCOS ) is one of the most common endocrine disorders in reproductive-", "bbox": [142.0, 570.0, 696.0, 584.0]}, {"text": "age females, frequently leading to female infertility. Hyperandrogenemia plays a role in the pathogenesis of PCOS.", "bbox": [117.0, 589.0, 695.0, 604.0]}, {"text": "Hyperandrogenemia can be evaluated by biochemical tests or clinical signs. At present,  there are some limitations of", "bbox": [117.0, 608.0, 698.0, 623.0]}, {"text": "immunology-based testing methods for androgen, such as cross-reaction, poor accuracy in low-concentration samples", "bbox": [118.0, 628.0, 698.0, 643.0]}, {"text": "and lack of comparability among different reagent manufacturers,  leading to false positivity. With the advantages", "bbox": [118.0, 647.0, 697.0, 662.0]}, {"text": "of high sensitivity, high specificity, wide linear range and the capability of simultaneous determination of multiple", "bbox": [117.0, 667.0, 697.0, 681.0]}, {"text": "molecules,  liquid chromatography-tandem mass spectrometry ( LC-MS/MS )  becomes a good choice for androgen", "bbox": [118.0, 686.0, 697.0, 701.0]}, {"text": "testing. On the basis of published clinical and laboratory evidence,  Beijing Obstetrics and Gynecology Hospital of", "bbox": [117.0, 705.0, 698.0, 720.0]}, {"text": "Capital Medical University,  China Association for Promotion of Health Science and Technology-Fertility Protection", "bbox": [117.0, 724.0, 697.0, 740.0]}, {"text": "and Preservation Committee, along with the experts in the clinical laboratory, gynecological endocrinology and", "bbox": [118.0, 744.0, 697.0, 759.0]}, {"text": "mass spectrometry application relevant field made this consensus,  in order to provide professional guidance in PCOS", "bbox": [118.0, 763.0, 697.0, 778.0]}, {"text": "androgen testing in clinical laboratories. The consensus includes recommendations on types and methods of androgen", "bbox": [118.0, 783.0, 697.0, 798.0]}, {"text": "testing for PCOS and challenges of androgen testing with LC-MS/MS.", "bbox": [117.0, 802.0, 459.0, 816.0]}, {"text": "Key words :  Polycystic ovary syndrome;  Hyperandrogenemia;  Liquid chromatography-tandem mass", "bbox": [142.0, 821.0, 697.0, 836.0]}, {"text": "spectrometry", "bbox": [118.0, 841.0, 185.0, 856.0]}], "type": "Text", "position": 10}, {"raw_context": [{"text": "1", "bbox": [92.0, 870.0, 104.0, 886.0]}], "type": "Section-header", "position": 11}, {"raw_context": [{"text": "多囊卵巢综合征概述", "bbox": [113.0, 869.0, 242.0, 888.0]}], "type": "Section-header", "position": 12}, {"raw_context": [{"text": "多 囊 卵 巢 综 合 征 ( p o l y c y s t i c  o v a r y", "bbox": [121.0, 893.0, 388.0, 909.0]}, {"text": "syndrome, PCOS ) 即Stein-Leventhal 综合征,", "bbox": [91.0, 914.0, 381.0, 930.0]}, {"text": "于1935年被Stein和Leventhal首次报道，是由遗", "bbox": [93.0, 937.0, 388.0, 953.0]}], "type": "Text", "position": 13}, {"raw_context": [{"text": "传和环境因素共同导致的一种常见的内分泌代谢", "bbox": [426.0, 870.0, 724.0, 886.0]}, {"text": "性疾病，其主要的临床表现为月经不调、不孕、", "bbox": [426.0, 892.0, 716.0, 909.0]}, {"text": "高雄激素血症、卵巢多囊，可伴有肥胖、胰岛素", "bbox": [426.0, 914.0, 723.0, 931.0]}, {"text": "抵抗、血脂紊乱等代谢异常，并可导致2型糖尿", "bbox": [426.0, 937.0, 723.0, 953.0]}], "type": "Text", "position": 14}, {"raw_context": [{"text": "基金项目: 北京市医院管理中心 \"登峰\" 计划专项 ( DFL20181401 )", "bbox": [92.0, 973.0, 411.0, 988.0]}], "type": "Text", "position": 15}, {"raw_context": [{"text": "通信作者: 营  正, E-mail; zhengcao2011@ccmu.edu.cn; 阮祥燕, E-mail; ruanxiangyan@ccmu.edu.cn.", "bbox": [93.0, 993.0, 573.0, 1006.0]}, {"text": "引用本文: 多義卵巢综合征雄激素质谱检测共识专家组，中国人体健康科技促进会生育力保护与保存专业委员会. 多義卵巢综合征雄激", "bbox": [92.0, 1009.0, 723.0, 1024.0]}, {"text": "素质谱检测专家共识[J].检验医学, 2023, 38 (3) : 203-208.", "bbox": [145.0, 1027.0, 430.0, 1042.0]}], "type": "Footnote", "position": 16}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/妇产科/多囊卵巢综合征雄激素质谱检测专家共识.pdf", "page_num": 1}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": "错别字#4#4#与保育专业应该是与保存专业\n错别字#5#5#多葉卵巢应该是多囊卵巢\n多義卵巢应该是多囊卵巢", "type2": "缺少换行#5#5#关键词: 多義卵巢综合征; 高雄激素血症; 液相色谱串联质谱   另起一行\n多余换行#11#11#多囊卵巢综合征概述  与上面10段序号联接\n多余换行#13#13#传和环境因素共同导致……与上面12段联接", "type3": null, "type4": "语义不完整#3#3#多 后面缺少内容", "type5": null, "type6": "有用性#0#1#文章编号\n有用性#2#2# 文献标志码 : A\n有用性#14#15#引用的补充信息"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:42", "update_time": "2024-05-08 00:43:17"}
{"id": 1082618, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 738, "source_info": {"seq_id": "e3a27049-8507-4cc7-9836-83c8f3c12aa9", "title": null, "text": "【0】页码:10\n\n【1】 European Journal of Nuclear Medicine and Molecular Imaging Table 4 Absorbed dose One-compartment Multi-compartment recommendations for LOE Whole normal liver dose microspheres and the respective Clinical scenario Perfused vol- Tumour dose LOE level of evidence (LOE) ume dose HCC Not applicable Segmentectomy 1060 Lobectomy 60 Not available 4 Unilobar 60 Not available 4 Bilobar 60 < 40 a Not available 4 ICC Not applicable Segmentectomy 60 3 > 150* Lobectomy 60 3 < 60 Unilobar 60 3 < 60 > 150* Bilobar 60 3 < 40*** [96] > 150* [96] mCRC Segmentectomy 60 3 Not applicable Lobectomy > 90** [97] 60 3 37 < 60 Unilobar 1060 3 < 60 > 90** [97] 37 Bilobar > 90** [97] 60 < 40*** 37 LOE , level of evidence *Based on median tumour absorbed dose for stable disease in a mixed population **Based on 100% sensitivity for response\n\n【2】\n **Based on 100% sensitivity for response ***Up to 60 Gy in patients with more favourable liver function\n\n【3】 The compartment mass may be determined using either CT, MRI, PET or 99 m Tc-MAA SPECT, Lung dose is calculated, assuming a lung mass of 1 kg, using the following MIRD formula: DLung [Gy] = injected Activity [GBq] × LSF × 50\n\n【4】 The maximal tolerated dose is 30 Gy for one treatment and 50 Gy for repeated treatments.\n\n【5】The activity calculation is based on the desired mean absorbed dose to the target mass (tumour, perfused liver, normal liver), following\n\n【6】## A [ Gbq ]\n\n【7】\n It has to be underlined that reported values for multi-compartment dosimetry (personalized dosimetry) were obtained for the use of glass microspheres on week 1 post-calibration, usually between 2- or 4-day post-calibration. No dosimetric data are available for a use on week 2 post-calibration.\n\n【8】## 166 Ho-Microspheres\n\n【9】\n Currently, activity calculation for 166 Ho-microspheres is based on a method comparable to the Medical Internal Radiation\n\n【10】 Dose (MIRD) method used for glass 90 Y-microspheres, as described above. The absorbed dose in Gy delivered by beta rays by 1 GBq in 1 kg tissue is 15.87 Gy for 166 Ho, under the assumption of homogenous distribution in the target volume and absorption of all energy within that volume. The absorbed dose from gamma rays is relatively negligible. The formula for the prescribed activity is based on a 60 Gy average absorbed dose to the whole liver, following\n\n【11】## A [ Gbq ] =\n\n【12】\n## Desired Dose [Gy] × Mtarget [Kg] 15.87 [J/Gbq]\n\n【13】\n According to current instructions for use, the average absorbed dose to the perfused volume may exceed 60 Gy, as long as the average absorbed to the whole liver does not exceed 60 Gy. Multi-compartment modelling is advised to optimize tumour absorbed doses while keeping absorbed doses to functional liver tissue within safety limits.\n\n【14】## Administration\n\n【15】\n For resin 90 Y-microspheres, a typical treatment consists of injecting about 40–80 million 90 Y-microspheres. Given the higher embolic load, no blind infusions should be performed.", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "European Journal of Nuclear Medicine and Molecular Imaging", "bbox": [456.0, 42.0, 725.0, 54.0]}, {"text": "Table 4 Absorbed dose", "bbox": [67.0, 75.0, 175.0, 89.0]}, {"text": "One-compartment", "bbox": [342.0, 81.0, 427.0, 94.0]}, {"text": "Multi-compartment", "bbox": [470.0, 81.0, 562.0, 94.0]}, {"text": "recommendations for", "bbox": [66.0, 89.0, 166.0, 101.0]}, {"text": "LOE", "bbox": [420.0, 101.0, 445.0, 114.0]}, {"text": "Whole normal liver dose", "bbox": [471.0, 101.0, 584.0, 114.0]}, {"text": "microspheres and the respective", "bbox": [67.0, 102.0, 212.0, 114.0]}, {"text": "Clinical scenario", "bbox": [236.0, 102.0, 314.0, 114.0]}, {"text": "Perfused vol-", "bbox": [342.0, 102.0, 404.0, 114.0]}, {"text": "Tumour dose", "bbox": [613.0, 102.0, 672.0, 114.0]}, {"text": "LOE", "bbox": [702.0, 102.0, 725.0, 114.0]}, {"text": "level of evidence (LOE)", "bbox": [67.0, 116.0, 177.0, 129.0]}, {"text": "ume dose", "bbox": [341.0, 116.0, 387.0, 128.0]}, {"text": "HCC", "bbox": [236.0, 140.0, 262.0, 152.0]}, {"text": "Not applicable", "bbox": [559.0, 156.0, 629.0, 170.0]}, {"text": "Segmentectomy", "bbox": [236.0, 157.0, 310.0, 169.0]}, {"text": "1060", "bbox": [342.0, 158.0, 355.0, 168.0]}, {"text": "Lobectomy", "bbox": [236.0, 173.0, 289.0, 185.0]}, {"text": "60", "bbox": [342.0, 173.0, 355.0, 185.0]}, {"text": "Not available", "bbox": [612.0, 173.0, 674.0, 185.0]}, {"text": "4", "bbox": [702.0, 174.0, 710.0, 184.0]}, {"text": "Unilobar", "bbox": [236.0, 189.0, 277.0, 202.0]}, {"text": "60", "bbox": [342.0, 190.0, 355.0, 202.0]}, {"text": "Not available", "bbox": [612.0, 190.0, 674.0, 202.0]}, {"text": "4", "bbox": [702.0, 190.0, 710.0, 202.0]}, {"text": "Bilobar", "bbox": [236.0, 206.0, 273.0, 219.0]}, {"text": "60", "bbox": [342.0, 207.0, 355.0, 219.0]}, {"text": "< 40 a", "bbox": [472.0, 208.0, 497.0, 217.0]}, {"text": "Not available", "bbox": [612.0, 207.0, 674.0, 219.0]}, {"text": "4", "bbox": [702.0, 208.0, 710.0, 219.0]}, {"text": "ICC", "bbox": [236.0, 223.0, 258.0, 235.0]}, {"text": "Not applicable", "bbox": [559.0, 239.0, 631.0, 253.0]}, {"text": "Segmentectomy", "bbox": [236.0, 240.0, 310.0, 252.0]}, {"text": "60", "bbox": [342.0, 240.0, 355.0, 252.0]}, {"text": "3", "bbox": [420.0, 240.0, 428.0, 252.0]}, {"text": "> 150*", "bbox": [612.0, 256.0, 647.0, 269.0]}, {"text": "Lobectomy", "bbox": [236.0, 257.0, 289.0, 269.0]}, {"text": "60", "bbox": [342.0, 257.0, 355.0, 269.0]}, {"text": "3", "bbox": [420.0, 257.0, 427.0, 268.0]}, {"text": "< 60", "bbox": [471.0, 257.0, 495.0, 269.0]}, {"text": "Unilobar", "bbox": [236.0, 271.0, 277.0, 285.0]}, {"text": "60", "bbox": [342.0, 273.0, 355.0, 285.0]}, {"text": "3", "bbox": [420.0, 273.0, 428.0, 285.0]}, {"text": "< 60", "bbox": [471.0, 273.0, 496.0, 285.0]}, {"text": "> 150*", "bbox": [612.0, 273.0, 646.0, 285.0]}, {"text": "Bilobar", "bbox": [236.0, 290.0, 272.0, 302.0]}, {"text": "60", "bbox": [342.0, 290.0, 355.0, 302.0]}, {"text": "3", "bbox": [420.0, 290.0, 428.0, 301.0]}, {"text": "< 40*** [96]", "bbox": [471.0, 290.0, 533.0, 301.0]}, {"text": "> 150* [96]", "bbox": [612.0, 290.0, 670.0, 302.0]}, {"text": "mCRC", "bbox": [236.0, 305.0, 269.0, 319.0]}, {"text": "Segmentectomy", "bbox": [236.0, 323.0, 310.0, 335.0]}, {"text": "60", "bbox": [342.0, 323.0, 355.0, 335.0]}, {"text": "3", "bbox": [420.0, 323.0, 429.0, 334.0]}, {"text": "Not applicable", "bbox": [559.0, 322.0, 629.0, 335.0]}, {"text": "Lobectomy", "bbox": [236.0, 339.0, 289.0, 354.0]}, {"text": "> 90** [97]", "bbox": [612.0, 339.0, 669.0, 351.0]}, {"text": "60", "bbox": [342.0, 340.0, 355.0, 351.0]}, {"text": "3", "bbox": [420.0, 340.0, 428.0, 350.0]}, {"text": "37", "bbox": [702.0, 340.0, 710.0, 352.0]}, {"text": "< 60", "bbox": [471.0, 341.0, 496.0, 352.0]}, {"text": "Unilobar", "bbox": [236.0, 355.0, 277.0, 368.0]}, {"text": "1060", "bbox": [342.0, 356.0, 355.0, 368.0]}, {"text": "3", "bbox": [420.0, 356.0, 427.0, 366.0]}, {"text": "< 60", "bbox": [471.0, 356.0, 496.0, 368.0]}, {"text": "> 90** [97]", "bbox": [612.0, 356.0, 669.0, 368.0]}, {"text": "37", "bbox": [702.0, 356.0, 710.0, 368.0]}, {"text": "Bilobar", "bbox": [236.0, 371.0, 273.0, 385.0]}, {"text": "> 90** [97]", "bbox": [612.0, 371.0, 668.0, 385.0]}, {"text": "60", "bbox": [342.0, 373.0, 357.0, 385.0]}, {"text": "< 40***", "bbox": [472.0, 372.0, 508.0, 385.0]}, {"text": "37", "bbox": [702.0, 373.0, 710.0, 385.0]}, {"text": "LOE , level of evidence", "bbox": [236.0, 397.0, 343.0, 410.0]}, {"text": "*Based on median tumour absorbed dose for stable disease in a mixed population", "bbox": [236.0, 414.0, 607.0, 428.0]}, {"text": "**Based on 100% sensitivity for response", "bbox": [236.0, 429.0, 428.0, 446.0]}], "type": "Table", "position": 0}, {"raw_context": [{"text": "**Based on 100% sensitivity for response", "bbox": [236.0, 429.0, 428.0, 446.0]}, {"text": "***Up to 60 Gy in patients with more favourable liver function", "bbox": [236.0, 446.0, 525.0, 462.0]}], "type": "Text", "position": 1}, {"raw_context": [{"text": "The compartment mass may be determined using either", "bbox": [80.0, 532.0, 387.0, 547.0]}, {"text": "CT, MRI, PET or 99 m Tc-MAA SPECT,", "bbox": [64.0, 548.0, 277.0, 564.0]}, {"text": "Lung dose is calculated, assuming a lung mass of 1 kg,", "bbox": [80.0, 565.0, 386.0, 583.0]}, {"text": "using the following MIRD formula:", "bbox": [65.0, 583.0, 262.0, 597.0]}, {"text": "DLung [Gy] = injected Activity [GBq] × LSF × 50", "bbox": [66.0, 610.0, 342.0, 627.0]}], "type": "Text", "position": 2}, {"raw_context": [{"text": "The maximal tolerated dose is 30 Gy for one treatment", "bbox": [80.0, 641.0, 386.0, 656.0]}, {"text": "and 50 Gy for repeated treatments.", "bbox": [66.0, 658.0, 254.0, 673.0]}, {"text": "The activity calculation is based on the desired mean", "bbox": [82.0, 675.0, 387.0, 690.0]}, {"text": "absorbed dose to the target mass (tumour, perfused liver,", "bbox": [66.0, 691.0, 386.0, 706.0]}, {"text": "normal liver), following", "bbox": [66.0, 707.0, 198.0, 722.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "A [ GBq ] ", "bbox": [64.0, 735.0, 306.0, 775.0]}], "type": "Section-header", "position": 4}, {"raw_context": [{"text": "It has to be underlined that reported values for multi-com-", "bbox": [80.0, 788.0, 385.0, 803.0]}, {"text": "partment dosimetry (personalized dosimetry) were obtained", "bbox": [66.0, 806.0, 387.0, 821.0]}, {"text": "for the use of glass microspheres on week 1 post-calibration,", "bbox": [66.0, 822.0, 387.0, 836.0]}, {"text": "usually between 2- or 4-day post-calibration. No dosimetric", "bbox": [66.0, 839.0, 390.0, 853.0]}, {"text": "data are available for a use on week 2 post-calibration.", "bbox": [65.0, 856.0, 361.0, 871.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "166 Ho-microspheres", "bbox": [66.0, 885.0, 188.0, 906.0]}], "type": "Section-header", "position": 6}, {"raw_context": [{"text": "Currently, activity calculation for 166 Ho-microspheres is based", "bbox": [64.0, 921.0, 387.0, 937.0]}, {"text": "on a method comparable to the Medical Internal Radiation", "bbox": [64.0, 938.0, 387.0, 953.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "Dose (MIRD) method used for glass 90 Y-microspheres, as", "bbox": [405.0, 532.0, 727.0, 546.0]}, {"text": "described above. The absorbed dose in Gy delivered by beta", "bbox": [405.0, 549.0, 727.0, 564.0]}, {"text": "rays by 1 GBq in 1 kg tissue is 15.87 Gy for 166 Ho, under the", "bbox": [405.0, 567.0, 727.0, 581.0]}, {"text": "assumption of homogenous distribution in the target volume", "bbox": [406.0, 583.0, 726.0, 597.0]}, {"text": "and absorption of all energy within that volume. The absorbed", "bbox": [405.0, 600.0, 727.0, 614.0]}, {"text": "dose from gamma rays is relatively negligible. The formula for", "bbox": [405.0, 616.0, 727.0, 631.0]}, {"text": "the prescribed activity is based on a 60 Gy average absorbed", "bbox": [405.0, 633.0, 727.0, 647.0]}, {"text": "dose to the whole liver, following", "bbox": [405.0, 649.0, 583.0, 664.0]}], "type": "Text", "position": 8}, {"raw_context": [{"text": "A [ GBq ] =", "bbox": [406.0, 688.0, 465.0, 705.0]}], "type": "Section-header", "position": 9}, {"raw_context": [{"text": "Desired dose [Gy] × Mtarget [kg]", "bbox": [467.0, 669.0, 649.0, 696.0]}, {"text": "15.87 [J/GBq]", "bbox": [516.0, 699.0, 600.0, 717.0]}], "type": "Section-header", "position": 10}, {"raw_context": [{"text": "According to current instructions for use, the average", "bbox": [422.0, 731.0, 725.0, 745.0]}, {"text": "absorbed dose to the perfused volume may exceed 60 Gy, as", "bbox": [406.0, 747.0, 726.0, 762.0]}, {"text": "long as the average absorbed to the whole liver does not exceed", "bbox": [405.0, 763.0, 727.0, 778.0]}, {"text": "60 Gy. Multi-compartment modelling is advised to optimize", "bbox": [405.0, 780.0, 727.0, 795.0]}, {"text": "tumour absorbed doses while keeping absorbed doses to func-", "bbox": [405.0, 797.0, 725.0, 811.0]}, {"text": "tional liver tissue within safety limits.", "bbox": [405.0, 814.0, 603.0, 829.0]}], "type": "Text", "position": 11}, {"raw_context": [{"text": "Administration", "bbox": [405.0, 856.0, 518.0, 883.0]}], "type": "Section-header", "position": 12}, {"raw_context": [{"text": "For resin 90 Y-microspheres, a typical treatment consists of", "bbox": [405.0, 896.0, 728.0, 914.0]}, {"text": "injecting about 40–80 million 90 Y-microspheres. Given the", "bbox": [405.0, 913.0, 727.0, 930.0]}, {"text": "higher embolic load, no blind infusions should be performed.", "bbox": [405.0, 931.0, 725.0, 945.0]}], "type": "Text", "position": 13}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2022】全科室最全临床指南+专家共识（最全版）/2022全科室临床指南/肿瘤科/EANM：动脉内放射性化合物治疗肝癌和转移性肝癌指南（2022）(1).pdf", "page_num": 10}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "缺少换行#2#2#***Up to 60 Gy in patients另起一行\n缺少换行#3#3# Lung dose is calculated, assuming ...另起一行\n多余换行#12#12#Desired Dose [Gy] × Mtarget [Kg] 15.87 [J/Gbq] 与11段同为公式内容，但是12段的内容错误", "type3": "无关文本#3#3#99 m \n无关文本#8#15#166 Ho-Microspheres 类似的数字是无关引用，应用全文", "type4": "语义不完整#6#6#A [ Gbq ] 公式内容不完整", "type5": null, "type6": "准确性#1#2#表格的内容，但是顺序杂乱"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:42", "update_time": "2024-05-08 23:00:16"}
{"id": 1082617, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 738, "source_info": {"seq_id": "19d0559d-fa25-46d4-9c6e-3963d2773124", "title": null, "text": "【0】页码:40\n .\n\n【1】 Identify the need for simple and advanced airway management during the intra- and postinterventional phase (e.g., chin lift, Wendel or Guedel tube) and to initiate relevant treatment\n\n【2】 Support, perform and/or organize techniques of life support according to professional skills and\n\n【3】 .\n\n【4】 responsibilities (e.g., BLS, ACSL)\n\n【5】 .\n\n【6】 Identify intra- and post-interventional risk situations that require the presence of an\n\n【7】 anesthesiologist.\n\n【8】 Post-interventional monitoring and care\n\n【9】 After completing the course, the participant should be able to:\n\n【10】 .\n\n【11】 Assess patient status with regard to cardiorespiratory activity, pain, and sedation level, by using standardized methods and scores\n\n【12】 .\n\n【13】 Identify adverse events and complications requiring additional monitoring and treatment and initiate relevant precautionary manoeuvres and treatment\n\n【14】 .\n\n【15】 Use standardized medical and nursing protocols for documenting:\n\n【16】 vital signs o\n\n【17】 o\n\n【18】 sedation level\n\n【19】 o\n\n【20】 pain level (e.g., visual analogue scale from 0 to 10 with 0 equivalent to no pain)\n\n【21】 o\n\n【22】 changes in patient health status\n\n【23】 adverse events and complications\n\n【24】 o\n\n【25】 o\n\n【26】 related adequate patient care and medical action\n\n【27】 o\n\n【28】 home discharge\n\n【29】 Legal issues\n\n【30】 After completing the course the participant should be able to demonstrate understanding of", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": ".", "bbox": [141.0, 143.0, 153.0, 156.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "Identify the need for simple and advanced airway management during the intra- and post-", "bbox": [161.0, 141.0, 652.0, 157.0]}, {"text": "interventional phase (e.g., chin lift, Wendel or Guedel tube) and to initiate relevant treatment", "bbox": [161.0, 165.0, 671.0, 181.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": "Support, perform and/or organize techniques of life support according to professional skills and", "bbox": [161.0, 201.0, 680.0, 217.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": ".", "bbox": [140.0, 204.0, 153.0, 216.0]}], "type": "Text", "position": 6}, {"raw_context": [{"text": "responsibilities (e.g., BLS, ACSL)", "bbox": [161.0, 227.0, 337.0, 242.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": ".", "bbox": [141.0, 264.0, 153.0, 277.0]}], "type": "Text", "position": 8}, {"raw_context": [{"text": "Identify intra- and post-interventional risk situations that require the presence of an", "bbox": [161.0, 263.0, 618.0, 278.0]}], "type": "Text", "position": 9}, {"raw_context": [{"text": "anesthesiologist.", "bbox": [162.0, 287.0, 256.0, 301.0]}], "type": "Text", "position": 10}, {"raw_context": [{"text": "Post-interventional monitoring and care", "bbox": [119.0, 371.0, 337.0, 386.0]}], "type": "Text", "position": 11}, {"raw_context": [{"text": "After completing the course, the participant should be able to:", "bbox": [119.0, 396.0, 458.0, 410.0]}], "type": "Text", "position": 12}, {"raw_context": [{"text": ".", "bbox": [141.0, 422.0, 154.0, 434.0]}], "type": "Text", "position": 13}, {"raw_context": [{"text": "Assess patient status with regard to cardiorespiratory activity, pain, and sedation level, by using", "bbox": [161.0, 419.0, 680.0, 435.0]}, {"text": "standardized methods and scores", "bbox": [161.0, 443.0, 348.0, 459.0]}], "type": "Text", "position": 14}, {"raw_context": [{"text": ".", "bbox": [140.0, 482.0, 153.0, 494.0]}], "type": "Text", "position": 15}, {"raw_context": [{"text": "Identify adverse events and complications requiring additional monitoring and treatment and", "bbox": [161.0, 479.0, 669.0, 495.0]}, {"text": "initiate relevant precautionary manoeuvres and treatment", "bbox": [161.0, 504.0, 481.0, 519.0]}], "type": "Text", "position": 16}, {"raw_context": [{"text": ".", "bbox": [141.0, 543.0, 153.0, 555.0]}], "type": "Text", "position": 17}, {"raw_context": [{"text": "Use standardized medical and nursing protocols for documenting:", "bbox": [161.0, 541.0, 520.0, 556.0]}], "type": "Text", "position": 18}, {"raw_context": [{"text": "vital signs", "bbox": [204.0, 577.0, 263.0, 593.0]}, {"text": "o", "bbox": [184.0, 579.0, 204.0, 592.0]}], "type": "Text", "position": 19}, {"raw_context": [{"text": "o", "bbox": [183.0, 616.0, 198.0, 628.0]}], "type": "Text", "position": 20}, {"raw_context": [{"text": "sedation level", "bbox": [204.0, 613.0, 284.0, 628.0]}], "type": "Text", "position": 21}, {"raw_context": [{"text": "o", "bbox": [183.0, 652.0, 198.0, 664.0]}], "type": "Text", "position": 22}, {"raw_context": [{"text": "pain level (e.g., visual analogue scale from 0 to 10 with 0 equivalent to no pain)", "bbox": [204.0, 648.0, 636.0, 664.0]}], "type": "Text", "position": 23}, {"raw_context": [{"text": "o", "bbox": [183.0, 688.0, 197.0, 699.0]}], "type": "Text", "position": 24}, {"raw_context": [{"text": "changes in patient health status", "bbox": [204.0, 685.0, 382.0, 700.0]}], "type": "Text", "position": 25}, {"raw_context": [{"text": "adverse events and complications", "bbox": [204.0, 721.0, 392.0, 736.0]}], "type": "Text", "position": 26}, {"raw_context": [{"text": "o", "bbox": [184.0, 724.0, 198.0, 735.0]}], "type": "Text", "position": 27}, {"raw_context": [{"text": "o", "bbox": [184.0, 761.0, 197.0, 772.0]}], "type": "Text", "position": 28}, {"raw_context": [{"text": "related adequate patient care and medical action", "bbox": [204.0, 758.0, 475.0, 773.0]}], "type": "Text", "position": 29}, {"raw_context": [{"text": "o", "bbox": [184.0, 797.0, 197.0, 808.0]}], "type": "Text", "position": 30}, {"raw_context": [{"text": "home discharge", "bbox": [204.0, 794.0, 295.0, 808.0]}], "type": "Text", "position": 31}, {"raw_context": [{"text": "Legal issues", "bbox": [119.0, 878.0, 187.0, 893.0]}], "type": "Text", "position": 32}, {"raw_context": [{"text": "After completing the course the participant should be able to demonstrate understanding of", "bbox": [119.0, 901.0, 620.0, 917.0]}], "type": "Text", "position": 33}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/消化科/_2023 BSG指南：胃肠内窥镜检查中的镇静.pdf", "page_num": 40}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "多余换行#0#28#序号和正文分离\n多余换行#2#4#为同段\n多余换行#6#7#为同段", "type3": null, "type4": null, "type5": null, "type6": null}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:42", "update_time": "2024-05-07 21:42:28"}
{"id": 1082616, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 738, "source_info": {"seq_id": "a6f29c89-eebc-4671-96b9-059a4ce78d87", "title": null, "text": "【0】页码:15\n rapid response report of the lack of awareness of the short half-life of the benzodiazepine reversal agent, flumazenil (in comparison with midazolam), leading to residual sedation.\n\n【1】Numerous actions were proposed by the NPSA 138 to reduce the risk of midazolam-related adverse events, including some relevant to endoscopy units. In England and Wales, misselection of high-strength midazolam (5 mg/mL or 2 mg/mL instead of 1 mg/mL) during conscious sedation is listed as a 'never event' requiring reporting to NHS England via local incident reporting arrangements. 13 Key risk management considerations at unit level include preferable stocking and use of only low-strength midazolam (1 mg/mL in 2 mL or 5 mL ampoules) rather than highstrength midazolam (5 mg/mL in 2 mL and 10 mL ampoules or 2 mg/mL in 5 mL ampoules) for conscious sedation in non-anaesthetic settings, ensuring the availability of reversal agents, the development of hospital or departmental policies relating to sedation, with overall responsibility assigned to a senior clinician. 1 Evaluation of changes in practice arising over 15 months after the release of the rapid response report from the NPSA showed that there were no incidents resulting in severe harm or death from midazolam-related safety incidents. 141 However, drug-related harm in endoscopy remains a burden to patient safety. The 2019 JAG census of UK endoscopy services showed that drug-related incidents were the most likely patient safety incidents to be reported by endoscopy users, 142 about threequarters of services had an endoscopy-specific sedation policy, although fewer than half had a named sedation or anaesthetic lead for endoscopy. 142 Similarly, other serious adverse events such as cardiac arrests, significant hypotension or hypoxia requiring intervention should also be reported via local incident reporting systems.\n\n【2】## Special Considerations: Emergency Endoscopy In The Sick Patient\n\n【3】\n 26. In the critically ill patient requiring emergency endoscopy, we recommend discussion with the anaesthetic team about the choice of sedation technique and the appropriateness of escalation to critical care Grade of evidence: Low. Strength of recommendation: Strong.\n\n【4】Level of agreement: 100% There are a limited number of well-established indications for emergency endoscopy, of which acute upper GI bleeding is the most common. Current guidelines recommend performing endoscopy within 24 hours of patient presentation, while emphasising haemodynamic stabilisation before the procedure. 143 144 Emergency ERCP may be required in patients with severe cholangitis who rapidly deteriorate in spite of antibiotic treatment. 145 Emergency upper GI endoscopy is associated with a higher risk of serious cardiopulmonary complications, including aspiration pneumonia, pulmonary oedema and acute lung injury.\n\n【5】Up to 20% of patients in the intensive care unit undergoing upper GI endoscopy for GI bleeding develop new radiographic pulmonary infiltrates, most of which are accompanied by fever, leucocytosis and hypoxaemia. 146 Cardiac arrest is the most feared complication in critically ill patients undergoing emergency endoscopy. 147 In critically ill patients, decision-making on the choice of sedation, the need for prophylactic intubation prior to endoscopy 148 and the need for intensive care treatment after endoscopy is complex. Factors that favour prophylactic endotracheal Sidhu R, et al. Gut 2023;0:1–27. doi:10.1136/gutjnl-2023-330396\n\n【6】 intubation and general anaesthesia include ongoing haematemesis, cardiopulmonary status, altered mental status, targeted level of sedation or a need for protection of the airway. 143 It is also important to note that intubation itself is associated with adverse events, including hypoxaemia and pulmonary aspiration. 150 In one study, 151 prophylactic endotracheal intubation before upper GI endoscopy for brisk upper GI bleeding in critically ill patients was associated with an increased risk of patients developing pneumonia.\n\n【7】There is no universally agreed approach to the level of monitoring and anaesthetic support required for emergency endoscopy in critically ill patients. This needs detailed discussion with the anaesthetic team.\n\n【8】## Special Considerations: Upper Gi Endoscopy\n\n【9】\n 27. There is no evidence to suggest the combination of throat spray and sedation increases the risk of aspiration, although we advise caution in those at increased risk of aspiration.\n\n【10】Grade of evidence: Very Low. Strength of recommendation: Strong.\n\n【11】 Level of agreement: 100% Good evidence shows that combining sedation with oropharyngeal anaesthesia improves tolerance and comfort of gastroscopy. 152–155 Topical pharyngeal anaesthesia reduces the gag reflex in patients sedated with propofol. 156 However, concerns have been raised as to whether the combination of throat spray and sedation increases the risk of aspiration pneumonia 152 157 – 159 ; no published evidence is available to substantiate these concerns.\n\n【12】The combination of an opiate and benzodiazepine, however, may lead to a better quality examination due to improved patient tolerance. 16 The risk of aspiration is higher in patients with serious underlying illness, active gastrointestinal bleeding, or those having therapeutic procedures. 8 It is advisable to exercise caution in patients with increased risk of aspiration and, in selected patients, general anaesthesia with airway protection needs to be considered.\n\n【13】28. We recommend that deep sedation may be required for specific upper GI procedures, such as polypectomy/resection of neoplasia, endoscopic bariatric surgery and foreign body retrieval Grade of evidence: Low. Strength of recommendation: Strong.\n\n【14】 Level of agreement: 100% Therapeutically complex upper GI procedures, such as endoscopic submucosal dissection, bariatric endoscopy and foreign body retrieval, might require prolonged procedure times. This might be further increased by patient movement and safety concerns (gag reflex, cough, oropharyngeal suctioning). Any patient movements might impede the chances of successful completion of a procedure and/or increase the risk of complications—for example, bleeding, perforation or aspiration pneumonia. There is no consensus on the optimal technique of sedation or anaesthesia for these complex procedures.\n\n【15】Studies have described both general anaesthesia and endoscopist-controlled, anaesthetist-maintained sedation protocols for endoscopic submucosal dissection and emergency foreign body retrieval. 161 - 166 In a study of sedation for upper GI endoscopy in obese patients with gastric bypass, 167 procedure length and not absolute BMI was the predictor of sedation requirement. Thus, in selected patients where procedures are prolonged or therapeutically complex, for example, endoscopic submucosal dissection (particularly in 15", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "rapid response report of the lack of awareness of the short", "bbox": [53.0, 60.0, 387.0, 75.0]}, {"text": "half-life of the benzodiazepine reversal agent, flumazenil (in", "bbox": [53.0, 76.0, 387.0, 90.0]}, {"text": "comparison with midazolam), leading to residual sedation.", "bbox": [53.0, 91.0, 386.0, 105.0]}, {"text": "Numerous actions were proposed by the NPSA 138 to reduce", "bbox": [53.0, 105.0, 387.0, 120.0]}, {"text": "the risk of midazolam-related adverse events, including some", "bbox": [53.0, 120.0, 387.0, 135.0]}, {"text": "relevant to endoscopy units. In England and Wales, mis-", "bbox": [53.0, 135.0, 385.0, 150.0]}, {"text": "selection of high-strength midazolam (5 mg/mL or 2 mg/mL", "bbox": [53.0, 150.0, 387.0, 164.0]}, {"text": "instead of 1 mg/mL) during conscious sedation is listed as a", "bbox": [53.0, 165.0, 387.0, 179.0]}, {"text": "'never event' requiring reporting to NHS England via local", "bbox": [53.0, 180.0, 387.0, 193.0]}, {"text": "incident reporting arrangements. 13", "bbox": [54.0, 195.0, 237.0, 208.0]}, {"text": "Key risk management considerations at unit level include", "bbox": [65.0, 209.0, 387.0, 222.0]}, {"text": "preferable stocking and use of only low-strength midazolam", "bbox": [53.0, 223.0, 387.0, 237.0]}, {"text": "(1 mg/mL in 2 mL or 5 mL ampoules) rather than high-", "bbox": [53.0, 237.0, 385.0, 252.0]}, {"text": "strength midazolam (5 mg/mL in 2 mL and 10 mL ampoules", "bbox": [53.0, 252.0, 387.0, 267.0]}, {"text": "or 2 mg/mL in 5 mL ampoules) for conscious sedation in", "bbox": [53.0, 268.0, 387.0, 281.0]}, {"text": "non-anaesthetic settings, ensuring the availability of reversal", "bbox": [53.0, 282.0, 386.0, 295.0]}, {"text": "agents, the development of hospital or departmental policies", "bbox": [53.0, 296.0, 387.0, 310.0]}, {"text": "relating to sedation, with overall responsibility assigned to a", "bbox": [53.0, 311.0, 387.0, 326.0]}, {"text": "senior clinician. 1", "bbox": [53.0, 326.0, 146.0, 339.0]}, {"text": "Evaluation of changes in practice arising over 15 months", "bbox": [65.0, 340.0, 387.0, 355.0]}, {"text": "after the release of the rapid response report from the NPSA", "bbox": [53.0, 355.0, 386.0, 369.0]}, {"text": "showed that there were no incidents resulting in severe harm", "bbox": [53.0, 370.0, 386.0, 383.0]}, {"text": "or death from midazolam-related safety incidents. 141 However,", "bbox": [53.0, 384.0, 386.0, 398.0]}, {"text": "drug-related harm in endoscopy remains a burden to patient", "bbox": [53.0, 398.0, 386.0, 413.0]}, {"text": "safety. The 2019 JAG census of UK endoscopy services showed", "bbox": [53.0, 413.0, 386.0, 428.0]}, {"text": "that drug-related incidents were the most likely patient safety", "bbox": [53.0, 428.0, 386.0, 443.0]}, {"text": "incidents to be reported by endoscopy users, 142 about three-", "bbox": [53.0, 443.0, 385.0, 457.0]}, {"text": "quarters of services had an endoscopy-specific sedation policy,", "bbox": [53.0, 458.0, 386.0, 472.0]}, {"text": "although fewer than half had a named sedation or anaesthetic", "bbox": [53.0, 473.0, 387.0, 486.0]}, {"text": "lead for endoscopy. 142 Similarly, other serious adverse events", "bbox": [53.0, 485.0, 387.0, 503.0]}, {"text": "such as cardiac arrests, significant hypotension or hypoxia", "bbox": [53.0, 502.0, 387.0, 517.0]}, {"text": "requiring intervention should also be reported via local inci-", "bbox": [53.0, 516.0, 385.0, 531.0]}, {"text": "dent reporting systems.", "bbox": [53.0, 532.0, 180.0, 546.0]}], "type": "Text", "position": 0}, {"raw_context": [{"text": "Special considerations: emergency endoscopy in the sick", "bbox": [53.0, 574.0, 357.0, 588.0]}, {"text": "patient", "bbox": [53.0, 590.0, 96.0, 604.0]}], "type": "Section-header", "position": 1}, {"raw_context": [{"text": "26. In the critically ill patient requiring emergency endoscopy,", "bbox": [53.0, 604.0, 386.0, 619.0]}, {"text": "we recommend discussion with the anaesthetic team about the", "bbox": [53.0, 619.0, 387.0, 633.0]}, {"text": "choice of sedation technique and the appropriateness of escala-", "bbox": [53.0, 635.0, 385.0, 648.0]}, {"text": "tion to critical care", "bbox": [53.0, 649.0, 154.0, 662.0]}, {"text": "Grade of evidence: Low. Strength of recommendation: Strong.", "bbox": [64.0, 663.0, 383.0, 678.0]}, {"text": "Level of agreement: 100%", "bbox": [65.0, 678.0, 204.0, 692.0]}, {"text": "There are a limited number of well-established indications", "bbox": [66.0, 692.0, 387.0, 707.0]}, {"text": "for emergency endoscopy, of which acute upper GI bleeding is", "bbox": [53.0, 707.0, 387.0, 721.0]}, {"text": "the most common. Current guidelines recommend performing", "bbox": [53.0, 722.0, 386.0, 736.0]}, {"text": "endoscopy within 24 hours of patient presentation, while", "bbox": [53.0, 737.0, 386.0, 751.0]}, {"text": "emphasising haemodynamic stabilisation before the proce-", "bbox": [53.0, 751.0, 385.0, 765.0]}, {"text": "dure. 143 144 Emergency ERCP may be required in patients with", "bbox": [53.0, 765.0, 387.0, 780.0]}, {"text": "severe cholangitis who rapidly deteriorate in spite of antibiotic", "bbox": [53.0, 779.0, 386.0, 795.0]}, {"text": "treatment. 145", "bbox": [54.0, 797.0, 121.0, 809.0]}, {"text": "Emergency upper GI endoscopy is associated with a higher", "bbox": [65.0, 810.0, 385.0, 825.0]}, {"text": "risk of serious cardiopulmonary complications, including aspi-", "bbox": [53.0, 826.0, 385.0, 839.0]}, {"text": "ration pneumonia, pulmonary oedema and acute lung injury.", "bbox": [53.0, 840.0, 386.0, 853.0]}, {"text": "Up to 20% of patients in the intensive care unit undergoing", "bbox": [53.0, 854.0, 387.0, 868.0]}, {"text": "upper GI endoscopy for GI bleeding develop new radiographic", "bbox": [53.0, 869.0, 387.0, 883.0]}, {"text": "pulmonary infiltrates, most of which are accompanied by", "bbox": [53.0, 883.0, 387.0, 898.0]}, {"text": "fever, leucocytosis and hypoxaemia. 146 Cardiac arrest is the", "bbox": [53.0, 897.0, 387.0, 912.0]}, {"text": "most feared complication in critically ill patients undergoing", "bbox": [53.0, 911.0, 387.0, 927.0]}, {"text": "emergency endoscopy. 147", "bbox": [53.0, 928.0, 185.0, 941.0]}, {"text": "In critically ill patients, decision-making on the choice of", "bbox": [65.0, 942.0, 387.0, 956.0]}, {"text": "sedation, the need for prophylactic intubation prior to endos-", "bbox": [53.0, 957.0, 385.0, 971.0]}, {"text": "copy 148 and the need for intensive care treatment after endos-", "bbox": [53.0, 971.0, 385.0, 986.0]}, {"text": "copy is complex. Factors that favour prophylactic endotracheal", "bbox": [53.0, 987.0, 387.0, 1001.0]}, {"text": "Sidhu R, et al. Gut 2023;0:1–27. doi:10.1136/gutjnl-2023-330396", "bbox": [54.0, 1009.0, 316.0, 1022.0]}], "type": "Text", "position": 2}, {"raw_context": [{"text": "intubation and general anaesthesia include ongoing haematem-", "bbox": [406.0, 60.0, 739.0, 75.0]}, {"text": "esis, cardiopulmonary status, altered mental status, targeted level", "bbox": [406.0, 76.0, 740.0, 90.0]}, {"text": "of sedation or a need for protection of the airway. 143", "bbox": [406.0, 92.0, 686.0, 104.0]}, {"text": "It is also", "bbox": [688.0, 93.0, 741.0, 104.0]}, {"text": "important to note that intubation itself is associated with adverse", "bbox": [406.0, 105.0, 740.0, 120.0]}, {"text": "events, including hypoxaemia and pulmonary aspiration. 150 In", "bbox": [406.0, 120.0, 741.0, 135.0]}, {"text": "one study, 151 prophylactic endotracheal intubation before upper", "bbox": [406.0, 135.0, 740.0, 150.0]}, {"text": "GI endoscopy for brisk upper GI bleeding in critically ill patients", "bbox": [406.0, 150.0, 741.0, 165.0]}, {"text": "was associated with an increased risk of patients developing", "bbox": [406.0, 165.0, 741.0, 180.0]}, {"text": "pneumonia.", "bbox": [406.0, 181.0, 471.0, 193.0]}, {"text": "There is no universally agreed approach to the level of moni-", "bbox": [419.0, 194.0, 739.0, 209.0]}, {"text": "toring and anaesthetic support required for emergency endos-", "bbox": [406.0, 209.0, 739.0, 224.0]}, {"text": "copy in critically ill patients. This needs detailed discussion with", "bbox": [406.0, 224.0, 741.0, 238.0]}, {"text": "the anaesthetic team.", "bbox": [406.0, 239.0, 518.0, 253.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": "Special considerations: upper GI endoscopy", "bbox": [406.0, 286.0, 641.0, 301.0]}], "type": "Section-header", "position": 5}, {"raw_context": [{"text": "27. There is no evidence to suggest the combination of throat", "bbox": [406.0, 301.0, 740.0, 316.0]}, {"text": "spray and sedation increases the risk of aspiration, although we", "bbox": [406.0, 317.0, 740.0, 330.0]}, {"text": "advise caution in those at increased risk of aspiration.", "bbox": [406.0, 332.0, 688.0, 345.0]}, {"text": "Grade of evidence: Very Low. Strength of recommendation:", "bbox": [418.0, 346.0, 740.0, 361.0]}, {"text": "Strong.", "bbox": [407.0, 362.0, 445.0, 375.0]}], "type": "Text", "position": 6}, {"raw_context": [{"text": "Level of agreement: 100%", "bbox": [418.0, 376.0, 557.0, 390.0]}, {"text": "Good evidence shows that combining sedation with oropha-", "bbox": [418.0, 391.0, 739.0, 405.0]}, {"text": "ryngeal anaesthesia improves tolerance and comfort of gastros-", "bbox": [406.0, 406.0, 739.0, 420.0]}, {"text": "copy. 152–155 Topical pharyngeal anaesthesia reduces the gag reflex", "bbox": [406.0, 419.0, 740.0, 437.0]}, {"text": "in patients sedated with propofol. 156 However, concerns have", "bbox": [406.0, 434.0, 740.0, 450.0]}, {"text": "been raised as to whether the combination of throat spray and", "bbox": [406.0, 450.0, 740.0, 465.0]}, {"text": "sedation increases the risk of aspiration pneumonia 152 157 – 159 ; no", "bbox": [406.0, 466.0, 740.0, 478.0]}, {"text": "published evidence is available to substantiate these concerns.", "bbox": [407.0, 480.0, 739.0, 495.0]}, {"text": "The combination of an opiate and benzodiazepine, however,", "bbox": [408.0, 495.0, 740.0, 510.0]}, {"text": "may lead to a better quality examination due to improved patient", "bbox": [406.0, 510.0, 740.0, 525.0]}, {"text": "tolerance. 16", "bbox": [406.0, 526.0, 464.0, 539.0]}, {"text": "The risk of aspiration is higher in patients with serious under-", "bbox": [419.0, 540.0, 739.0, 553.0]}, {"text": "lying illness, active gastrointestinal bleeding, or those having", "bbox": [406.0, 555.0, 740.0, 569.0]}, {"text": "therapeutic procedures. 8 It is advisable to exercise caution", "bbox": [406.0, 569.0, 740.0, 584.0]}, {"text": "in patients with increased risk of aspiration and, in selected", "bbox": [406.0, 584.0, 740.0, 599.0]}, {"text": "patients, general anaesthesia with airway protection needs to be", "bbox": [406.0, 600.0, 740.0, 613.0]}, {"text": "considered.", "bbox": [406.0, 615.0, 469.0, 627.0]}, {"text": "28. We recommend that deep sedation may be required for", "bbox": [418.0, 628.0, 740.0, 643.0]}, {"text": "specific upper GI procedures, such as polypectomy/resection", "bbox": [406.0, 643.0, 741.0, 658.0]}, {"text": "of neoplasia, endoscopic bariatric surgery and foreign body", "bbox": [406.0, 658.0, 740.0, 673.0]}, {"text": "retrieval", "bbox": [406.0, 674.0, 454.0, 687.0]}, {"text": "Grade of evidence: Low. Strength of recommendation: Strong.", "bbox": [418.0, 688.0, 737.0, 702.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "Level of agreement: 100%", "bbox": [418.0, 703.0, 557.0, 717.0]}, {"text": "Therapeutically complex upper GI procedures, such as endo-", "bbox": [419.0, 717.0, 739.0, 732.0]}, {"text": "scopic submucosal dissection, bariatric endoscopy and foreign", "bbox": [406.0, 733.0, 741.0, 747.0]}, {"text": "body retrieval, might require prolonged procedure times. This", "bbox": [406.0, 748.0, 741.0, 761.0]}, {"text": "might be further increased by patient movement and safety", "bbox": [406.0, 762.0, 739.0, 777.0]}, {"text": "concerns (gag reflex, cough, oropharyngeal suctioning). Any", "bbox": [406.0, 777.0, 740.0, 792.0]}, {"text": "patient movements might impede the chances of successful", "bbox": [406.0, 792.0, 740.0, 807.0]}, {"text": "completion of a procedure and/or increase the risk of compli-", "bbox": [406.0, 807.0, 739.0, 821.0]}, {"text": "cations—for example, bleeding, perforation or aspiration", "bbox": [406.0, 822.0, 740.0, 835.0]}, {"text": "pneumonia. There is no consensus on the optimal technique", "bbox": [406.0, 836.0, 740.0, 850.0]}, {"text": "of sedation or anaesthesia for these complex procedures.", "bbox": [406.0, 851.0, 711.0, 865.0]}, {"text": "Studies have described both general anaesthesia and", "bbox": [418.0, 866.0, 741.0, 880.0]}, {"text": "endoscopist-controlled, anaesthetist-maintained sedation", "bbox": [406.0, 881.0, 740.0, 895.0]}, {"text": "protocols for endoscopic submucosal dissection and emer-", "bbox": [406.0, 895.0, 739.0, 909.0]}, {"text": "gency foreign body retrieval. 161 - 166 In a study of sedation for", "bbox": [406.0, 909.0, 739.0, 923.0]}, {"text": "upper GI endoscopy in obese patients with gastric bypass, 167", "bbox": [406.0, 925.0, 736.0, 940.0]}, {"text": "procedure length and not absolute BMI was the predictor", "bbox": [406.0, 940.0, 740.0, 954.0]}, {"text": "of sedation requirement. Thus, in selected patients where", "bbox": [406.0, 955.0, 740.0, 969.0]}, {"text": "procedures are prolonged or therapeutically complex, for", "bbox": [406.0, 970.0, 740.0, 983.0]}, {"text": "example, endoscopic submucosal dissection (particularly in", "bbox": [406.0, 984.0, 741.0, 998.0]}, {"text": "15", "bbox": [727.0, 1011.0, 739.0, 1022.0]}], "type": "Text", "position": 8}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/消化科/_2023 BSG指南：胃肠内窥镜检查中的镇静.pdf", "page_num": 15}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "缺少换行#1#1#Key risk management considerations...\n Evaluation of changes in practice...都另起一行\n缺少换行#3#3#Grade of evidence: Low.另起一行\n缺少换行#4#4# There are a limited number ...\n Emergency upper GI endoscopy...都另起一行\n缺少换行#5#5# In critically ill patients,另起一行\n多余换行#6#6# intubation and general anaesthesia...与上面5段联接\n缺少换行#11#11# Good evidence shows that ...另起一行\n缺少换行#12#12#The risk of aspiration is ...另起一行\n缺少换行#13#13#Grade of evidence: Low. 另起一行\n缺少换行#14#14#Therapeutically complex upper...另起一行", "type3": "无关文本#1#15#... reporting arrangements. 13\n...related safety incidents. 141类似的数字引用过多", "type4": null, "type5": null, "type6": "有用性#5#5#Sidhu R, et al. Gut 2023;0:1–27. doi:10.1136/gutjnl-2023-330396页脚的内容"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:42", "update_time": "2024-05-08 01:44:14"}
{"id": 1082615, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 738, "source_info": {"seq_id": "e9744f2b-8e47-4594-af27-f7270992a93c", "title": null, "text": "【0】页码:1\n 16\n\n【1】## 肝胆外科杂志 2023 年 2 月 第 31 卷 第 1 期   Journal Of Hepatobiliary Surgery,Vol ,31 , No. 1 , Feb. 2023\n\n【2】\n 18 Giannis D, Sideris G, Kakos CD, et al. The role of liver transplan¬ tation for colorectal liver metastases: A systematic review and pooled analysis. Transplant Rev (Orlando), 2020, 34: 100570.\n\n【3】 19 Smedman TM, Line PD, Hagness M, et al. Liver transplantation for unresectable colorectal liver metastases in patients and donors with ex¬ tended criteria ( SECA-II arm D study). BJS Open, 2020 , 4 : 467 – .477.\n\n【4】 20 Line PD, Hagness M, Berstad AE, et al. A novel concept for partial liver transplantation in nonresectable colorectal liver metastases: the RAPID concept.  Ann Surg, 2015,262 : e5 – e.\n\n【5】 21 Tran, Lillian, Humar, Abhinav. Current status of adult liver trans¬ plantation : utilization of living donor versus deceased donor graft.\n\n【6】Current Opinion in Organ Transplantation, 2021,26 (2),133 – 138.\n\n【7】22 Organ Procurement and Transplantation Network. National Data: Transplant by Donor Type. Annual Report of the U. S. Organ Pro- Transplant Recipients. Department of Health and Human Serves, Health Resources and Services Administration, Healthcare Systems\n\n【8】 Bureau, Division of Transplantation, Rockville, MD; United Net¬ work for Organ Sharing , Richmond , VA. http://optn. transplant. hrsa. gov/data/view – data – reports/national – data.\n\n【9】 23 Cameron AM. Just How Low a Model for End-stage Liver Disease Score Benefits From Living-Donor Liver Transplant? JAMA Surg, 2022 , 157 ( 10 ) :933 .\n\n【10】 24 Sparrelid E, Johansson H, Gilg S, et al. Serial assessment of growth factors associated with liver regeneration in patients operated with as¬ sociating liver partition and portal vein ligation for staged hepatectomy.  Eur Surg Res, 2018, 59 : 72 – 82.\n\n【11】 25 Hernandez-Alejandro R, Ruffolo LI, Sasaki K, et al. Recipient and Donor Outcomes After Living-Donor Liver Transplant for Unresectable Colorectal Liver Metastases. JAMA Surg,2022,157(6):524 – 530.\n\n【12】26 S. Nadalina, U. Settmacherb, F. Rauchfub, et al. RAPID procedure for colorectal cancer liver metastasis. Int J Surg, ( 2020 ).\n\n【13】 ( 本文编辑\n\n【14】 程　远,徐子今,英卫东\n\n【15】 【 关键词 】  肝癌 ; 转化治疗 .\n\n【16】【 中图分类号】 R 735.7  【 文献标识码】 C     【 文章编号】\n\n【17】 1006-4761 ( 2023 ) 01-0016-04\n\n【18】 在我国恶性肿瘤的发病率及致死率排行中,原 发性肝癌均位居前列 ( 发病率第 4 位和致死率第 2  位),严重危害人民生命健康『,²』。肝细胞癌(hepatocellular carcinoma, HCC, 以下简称肝癌) 是原发性 肝癌中最常见的病理类型, 约占 75% ~85% [3]。由 于肝癌起病隐匿且在早期缺乏特异性临床表现, 导 致半数以上肝癌患者确诊时已为中晚期,丧失根治 性手术切除的机会,造成患者较差的生命质量和远 期生存预后( 中位生存时间通常低于 1 年 ) [4-6] 。 随着系统性药物治疗和非手术局部治疗在肝癌 领域的应用与发展,部分中晚期或不可切除肝癌可 实现较好的客观缓解率 ( objective  response  rate , ORR)或肿瘤降期,继而获得根治性切除机会并提\n\n【19】 【 基金项目】2021 年安徽省重点研究与开发计划项目(202104j07) 【作者单位】 中国科学技术大学附属第 — 医院肝脏外科,合肥 230001 【通讯作者】英卫东。\n\n【20】 高手术切除后的疗效[7-10]。肝癌转化治疗的内涵 即为通过减少肿瘤负荷或使肿瘤降期,以提高 R0 切除成功率、增加患者术后的生存获益(n)、 手术为主的综合治疗是中晚期肝癌患者可能行 根治性切除和改善预后的主要策略,国家卫生健康 委员会《原发性肝癌诊疗规范(2019 版)》和《原发 性肝癌诊疗指南(2022 版)》均推荐转化治疗作为中 晚期肝癌综合治疗新策略的重要起始环节[12,13].\n\n【21】为进一步推动肝癌转化治疗的临床实践与研究,我 国相关领域专家制订了《肝癌转化治疗中国专家共 识(2021 版) 》[11.14] 。本文将围绕上述指南与共识, 侧重于系统治疗和非手术局部治疗等手段在肝癌转 化治疗中的作用,并结合最新研究进展,就肝癌转化 治疗的人群和原则、策略选择进行阐述与解读。\n\n【22】## 1  肝癌转化治疗的人群和原则\n\n【23】\n 肝癌转化治疗的定义是将“不可切除肝癌”转 化为“可切除肝癌”,阶段性目标为切除肿瘤,最终", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "16", "bbox": [217.0, 211.0, 282.0, 247.0]}], "type": "Text", "position": 0}, {"raw_context": [{"text": "肝胆外科杂志 2023 年 2 月 第 31 卷 第 1 期   Journal of Hepatobiliary Surgery,Vol ,31 , No. 1 , Feb. 2023", "bbox": [417.0, 209.0, 2012.0, 248.0]}], "type": "Section-header", "position": 1}, {"raw_context": [{"text": "18 Giannis D, Sideris G, Kakos CD, et al. The role of liver transplan¬", "bbox": [197.0, 321.0, 1181.0, 351.0]}, {"text": "tation for colorectal liver metastases: A systematic review and pooled", "bbox": [249.0, 377.0, 1185.0, 404.0]}, {"text": "analysis. Transplant Rev (Orlando), 2020, 34: 100570.", "bbox": [250.0, 429.0, 1036.0, 463.0]}], "type": "Text", "position": 2}, {"raw_context": [{"text": "19 Smedman TM, Line PD, Hagness M, et al. Liver transplantation for", "bbox": [197.0, 484.0, 1189.0, 518.0]}, {"text": "unresectable colorectal liver metastases in patients and donors with ex¬", "bbox": [250.0, 539.0, 1179.0, 572.0]}, {"text": "tended criteria ( SECA-II arm D study). BJS Open, 2020 , 4 : 467 –", "bbox": [250.0, 594.0, 1175.0, 627.0]}, {"text": ".477.", "bbox": [246.0, 649.0, 324.0, 681.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "20 Line PD, Hagness M, Berstad AE, et al. A novel concept for partial", "bbox": [193.0, 703.0, 1183.0, 736.0]}, {"text": "liver transplantation in nonresectable colorectal liver metastases: the", "bbox": [250.0, 758.0, 1185.0, 790.0]}, {"text": "RAPID concept.  Ann Surg, 2015,262 : e5 – e.", "bbox": [250.0, 814.0, 885.0, 848.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": "21 Tran, Lillian, Humar, Abhinav. Current status of adult liver trans¬", "bbox": [193.0, 869.0, 1181.0, 902.0]}, {"text": "plantation : utilization of living donor versus deceased donor graft.", "bbox": [250.0, 924.0, 1175.0, 957.0]}, {"text": "Current Opinion in Organ Transplantation, 2021,26 (2),133 – 138.", "bbox": [250.0, 979.0, 1175.0, 1012.0]}, {"text": "22 Organ Procurement and Transplantation Network. National Data:", "bbox": [193.0, 1033.0, 1183.0, 1066.0]}, {"text": "Transplant by Donor Type. Annual Report of the U. S. Organ Pro-", "bbox": [250.0, 1088.0, 1179.0, 1121.0]}, {"text": "Transplant Recipients. Department of Health and Human Serves,", "bbox": [254.0, 1196.0, 1165.0, 1230.0]}, {"text": "Health Resources and Services Administration, Healthcare Systems", "bbox": [250.0, 1252.0, 1177.0, 1285.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "Bureau, Division of Transplantation, Rockville, MD; United Net¬", "bbox": [1302.0, 317.0, 2232.0, 353.0]}, {"text": "work for Organ Sharing , Richmond , VA. http://optn. transplant. hr-", "bbox": [1302.0, 371.0, 2232.0, 409.0]}, {"text": "sa. gov/data/view – data – reports/national – data.", "bbox": [1302.0, 429.0, 1976.0, 461.0]}], "type": "Text", "position": 6}, {"raw_context": [{"text": "23 Cameron AM. Just How Low a Model for End-stage Liver Disease", "bbox": [1248.0, 484.0, 2234.0, 517.0]}, {"text": "Score Benefits From Living-Donor Liver Transplant? JAMA Surg,", "bbox": [1300.0, 539.0, 2232.0, 572.0]}, {"text": "2022 , 157 ( 10 ) :933 .", "bbox": [1300.0, 590.0, 1593.0, 625.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "24 Sparrelid E, Johansson H, Gilg S, et al. Serial assessment of growth", "bbox": [1250.0, 648.0, 2234.0, 682.0]}, {"text": "factors associated with liver regeneration in patients operated with as¬", "bbox": [1300.0, 701.0, 2230.0, 739.0]}, {"text": "sociating liver partition and portal vein ligation for staged hepatecto-", "bbox": [1300.0, 759.0, 2232.0, 791.0]}, {"text": "my.  Eur Surg Res, 2018, 59 : 72 – 82.", "bbox": [1300.0, 813.0, 1845.0, 846.0]}], "type": "Text", "position": 8}, {"raw_context": [{"text": "25 Hernandez-Alejandro R, Ruffolo LI, Sasaki K, et al. Recipient and", "bbox": [1248.0, 868.0, 2234.0, 902.0]}, {"text": "Donor Outcomes After Living-Donor Liver Transplant for Unresectable", "bbox": [1300.0, 921.0, 2234.0, 958.0]}, {"text": "Colorectal Liver Metastases. JAMA Surg,2022,157(6):524 – 530.", "bbox": [1300.0, 979.0, 2202.0, 1012.0]}, {"text": "26 S. Nadalina, U. Settmacherb, F. Rauchfub, et al. RAPID procedure", "bbox": [1248.0, 1034.0, 2232.0, 1067.0]}, {"text": "for colorectal cancer liver metastasis. Int J Surg, ( 2020 ).", "bbox": [1300.0, 1087.0, 2079.0, 1122.0]}], "type": "Text", "position": 9}, {"raw_context": [{"text": "( 本文编辑", "bbox": [1869.0, 1144.0, 2227.0, 1182.0]}], "type": "Text", "position": 10}, {"raw_context": [{"text": "程　远,徐子今,英卫东", "bbox": [984.0, 1667.0, 1443.0, 1713.0]}], "type": "Text", "position": 12}, {"raw_context": [{"text": "【 关键词 】  肝癌 ; 转化治疗 .", "bbox": [272.0, 1830.0, 732.0, 1871.0]}, {"text": "【 中图分类号】 R 735.7  【 文献标识码】 C     【 文章编号】", "bbox": [268.0, 1889.0, 1314.0, 1929.0]}], "type": "Text", "position": 13}, {"raw_context": [{"text": "1006-4761 ( 2023 ) 01-0016-04", "bbox": [1306.0, 1891.0, 1776.0, 1927.0]}], "type": "Text", "position": 14}, {"raw_context": [{"text": "在我国恶性肿瘤的发病率及致死率排行中,原", "bbox": [282.0, 2009.0, 1189.0, 2056.0]}, {"text": "发性肝癌均位居前列 ( 发病率第 4 位和致死率第 2 ", "bbox": [197.0, 2075.0, 1189.0, 2121.0]}, {"text": "位),严重危害人民生命健康『,²』。肝细胞癌(hepa-", "bbox": [193.0, 2137.0, 1181.0, 2187.0]}, {"text": "tocellular carcinoma, HCC, 以下简称肝癌) 是原发性", "bbox": [193.0, 2208.0, 1185.0, 2251.0]}, {"text": "肝癌中最常见的病理类型, 约占 75% ~85% [3]。由", "bbox": [191.0, 2272.0, 1179.0, 2314.0]}, {"text": "于肝癌起病隐匿且在早期缺乏特异性临床表现, 导", "bbox": [195.0, 2338.0, 1185.0, 2383.0]}, {"text": "致半数以上肝癌患者确诊时已为中晚期,丧失根治", "bbox": [193.0, 2398.0, 1182.0, 2447.0]}, {"text": "性手术切除的机会,造成患者较差的生命质量和远", "bbox": [193.0, 2469.0, 1183.0, 2512.0]}, {"text": "期生存预后( 中位生存时间通常低于 1 年 ) [4-6] 。", "bbox": [193.0, 2532.0, 1131.0, 2578.0]}, {"text": "随着系统性药物治疗和非手术局部治疗在肝癌", "bbox": [278.0, 2600.0, 1181.0, 2644.0]}, {"text": "领域的应用与发展,部分中晚期或不可切除肝癌可", "bbox": [193.0, 2666.0, 1175.0, 2709.0]}, {"text": "实现较好的客观缓解率 ( objective  response  rate ,", "bbox": [193.0, 2731.0, 1175.0, 2774.0]}, {"text": "ORR)或肿瘤降期,继而获得根治性切除机会并提", "bbox": [191.0, 2797.0, 1179.0, 2841.0]}], "type": "Text", "position": 15}, {"raw_context": [{"text": "【 基金项目】2021 年安徽省重点研究与开发计划项目(202104j07)", "bbox": [191.0, 2959.0, 1137.0, 2994.0]}, {"text": "【作者单位】 中国科学技术大学附属第 — 医院肝脏外科,合肥", "bbox": [191.0, 3014.0, 1145.0, 3049.0]}, {"text": "230001", "bbox": [373.0, 3072.0, 486.0, 3101.0]}, {"text": "【通讯作者】英卫东。", "bbox": [189.0, 3125.0, 498.0, 3162.0]}], "type": "Text", "position": 16}, {"raw_context": [{"text": "高手术切除后的疗效[7-10]。肝癌转化治疗的内涵", "bbox": [1244.0, 2005.0, 2234.0, 2057.0]}, {"text": "即为通过减少肿瘤负荷或使肿瘤降期,以提高 R0", "bbox": [1246.0, 2075.0, 2232.0, 2124.0]}, {"text": "切除成功率、增加患者术后的生存获益(n)、", "bbox": [1245.0, 2146.0, 2048.0, 2187.0]}, {"text": "手术为主的综合治疗是中晚期肝癌患者可能行", "bbox": [1331.0, 2210.0, 2234.0, 2256.0]}, {"text": "根治性切除和改善预后的主要策略,国家卫生健康", "bbox": [1246.0, 2276.0, 2234.0, 2321.0]}, {"text": "委员会《原发性肝癌诊疗规范(2019 版)》和《原发", "bbox": [1243.0, 2344.0, 2230.0, 2386.0]}, {"text": "性肝癌诊疗指南(2022 版)》均推荐转化治疗作为中", "bbox": [1244.0, 2407.0, 2232.0, 2453.0]}, {"text": "晚期肝癌综合治疗新策略的重要起始环节[12,13].", "bbox": [1245.0, 2477.0, 2214.0, 2514.0]}, {"text": "为进一步推动肝癌转化治疗的临床实践与研究,我", "bbox": [1250.0, 2542.0, 2230.0, 2585.0]}, {"text": "国相关领域专家制订了《肝癌转化治疗中国专家共", "bbox": [1246.0, 2609.0, 2232.0, 2651.0]}, {"text": "识(2021 版) 》[11.14] 。本文将围绕上述指南与共识,", "bbox": [1246.0, 2669.0, 2226.0, 2720.0]}, {"text": "侧重于系统治疗和非手术局部治疗等手段在肝癌转", "bbox": [1246.0, 2741.0, 2232.0, 2786.0]}, {"text": "化治疗中的作用,并结合最新研究进展,就肝癌转化", "bbox": [1246.0, 2808.0, 2232.0, 2853.0]}, {"text": "治疗的人群和原则、策略选择进行阐述与解读。", "bbox": [1246.0, 2872.0, 2140.0, 2920.0]}], "type": "Text", "position": 17}, {"raw_context": [{"text": "1  肝癌转化治疗的人群和原则", "bbox": [1240.0, 3006.0, 1853.0, 3048.0]}], "type": "Section-header", "position": 18}, {"raw_context": [{"text": "肝癌转化治疗的定义是将“不可切除肝癌”转", "bbox": [1328.0, 3073.0, 2228.0, 3113.0]}, {"text": "化为“可切除肝癌”,阶段性目标为切除肿瘤,最终", "bbox": [1246.0, 3138.0, 2228.0, 3181.0]}], "type": "Text", "position": 19}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/肿瘤科/解读/肝细胞癌转化治疗临床策略与指南解读.pdf", "page_num": 1}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "缺少换行#18#18#随着系统性药物治疗和非手术....另起一行\n多余换行#20#20#高手术切除后的疗效[7-10]。连接上面18段后面\n缺少换行#20#20#手术为主的综合治疗是......另起一行\n标点错误#20#20#生存获益(n)、 应该是。\n多余空格#18#23#原 发性肝癌、由 于肝癌类似的多余空格很多，应用全文", "type3": "无关文本#18#21#『,²』  [3]类似的无关引用过多\n无关文本#20#20#(n)", "type4": null, "type5": null, "type6": "有用性#0#17#是参考文献和文章版号等内容\n有用性#19#19#文章补充信息"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:42", "update_time": "2024-05-07 23:51:40"}
{"id": 1082614, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 738, "source_info": {"seq_id": "7983706d-062a-4bd2-8dd7-9ec6eadf282c", "title": null, "text": "【0】页码:1\n GUIDELINES\n# Eanm Procedure Guideline For The Treatment Of Liver Cancer And Liver Metastases With Intra-Arterial Radioactive Compounds\n\n【1】\n M. Weber 1 · M. Lam 2 · C. Chiesa 3 · M. Konijnenberg 4 · M. Cremonesi 5 · P. Flamen 6 · S. Gnesin 7 · L. Bodei 8 · T. Kracmerova 9 · M. Luster¹ ⁰ · E. Garin¹¹ · K. Herrmann¹\n\n【2】 Received: 9 September 2021 / Accepted: 19 October 2021 © The Author(s) 2022\n\n【3】## Abstract\n\n【4】\n Primary liver tumours (i.e. hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICC)) are among the most frequent cancers worldwide. However, only 10–20% of patients are amenable to curative treatment, such as resection or transplant. Liver metastases are most frequently caused by colorectal cancer, which accounts for the second most cancerrelated deaths in Europe. In both primary and secondary tumours, radioembolization has been shown to be a safe and effective treatment option. The vast potential of personalized dosimetry has also been shown, resulting in markedly increased response rates and overall survival. In a rapidly evolving therapeutic landscape, the role of radioembolization will be subject to changes.\n\n【5】Therefore, the decision for radioembolization should be taken by a multidisciplinary tumour board in accordance with the current clinical guidelines. The purpose of this procedure guideline is to assist the nuclear medicine physician in treating and managing patients undergoing radioembolization treatment.\n\n【6】## Preamble\n\n【7】\n The European Association of Nuclear Medicine (EANM) is a professional non-profit medical association that facilitates communication worldwide among individuals pursuing clinical and research excellence in nuclear medicine. The EANM was founded in 1985. These guidelines are intended to assist practitioners in providing appropriate nuclear medicine care for patients. They are notinflexible rules or requirements of practice and are not intended, nor should they be used, to establish a legal standard of care. The ultimate judgment regarding the propriety of any specific procedure or course of action must be made by medical professionals taking into account the unique circumstances of each case. Thus, there is no implication that an approach differing from the guidelines, standing alone, is below the standard of care. To the contrary, a conscientious practitioner may responsibly adopt a course of action different from that set out in the guidelines when, in the reasonable judgment of the practitioner, such course of action is indicated by the condition of the patient, limitations of available resources or advances in knowledge or technology subsequent to publication of the guidelines. The practice of médicing involves not only the science but also the art of dealing with the prevention, diagnosis, alleviation and treatment of disease. The variety and complexity of human conditions make it impossible to always reach the most appropriate diagnosis or topredict with a 'cèriäinty,a particular response to treatment. Therefore, it should be recognised that adherence to these guidelines will not ensure an accurate diagnosis or a successful outcome. All that should be expected is that the practitioner will follow a reasonable course of action based on current knowledge, available resources and the needs of the patient to deliver effective and safe medical care. The sole purpose of these guidelines is to assist practitioners in achieving this objective.\n\n【8】 The Therapy, Oncology and Dosimetry Committees collaborated\n\n【9】 with the aim to revise the European Association of Nuclear\n\n【10】 Medicine (EANM) guidelines on radioembolization.\n This article is part of the Topical Collection on Oncology - Digestive tract\n Extended author information available on the last page of the article\n\n【11】 Keywords Guidelines · Nuclear medicine · Liver cancer · 90Y-microspheres · SIR-spheres® · TheraSphere® · Resin microspheres · Glass microspheres · 166 Ho-microspheres · QuiremSpheres® · Dosimetry\n Published online: 11 February 2022.", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "GUIDELINES", "bbox": [72.0, 85.0, 151.0, 101.0]}], "type": "Text", "position": 1}, {"raw_context": [{"text": "EANM procedure guideline for the treatment of liver cancer and liver", "bbox": [65.0, 138.0, 653.0, 161.0]}, {"text": "metastases with intra-arterial radioactive compounds", "bbox": [65.0, 164.0, 528.0, 186.0]}], "type": "Title", "position": 5}, {"raw_context": [{"text": "M. Weber 1 · M. Lam 2 · C. Chiesa 3 · M. Konijnenberg 4 · M. Cremonesi 5 · P. Flamen 6 · S. Gnesin 7 · L. Bodei 8 ·", "bbox": [66.0, 208.0, 649.0, 224.0]}, {"text": "T. Kracmerova 9 · M. Luster¹ ⁰ · E. Garin¹¹ · K. Herrmann¹", "bbox": [66.0, 225.0, 373.0, 240.0]}], "type": "Text", "position": 6}, {"raw_context": [{"text": "Received: 9 September 2021 / Accepted: 19 October 2021", "bbox": [66.0, 263.0, 316.0, 278.0]}, {"text": "© The Author(s) 2022", "bbox": [66.0, 278.0, 160.0, 293.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "Abstract", "bbox": [66.0, 317.0, 120.0, 331.0]}], "type": "Section-header", "position": 8}, {"raw_context": [{"text": "Primary liver tumours (i.e. hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICC)) are among the most", "bbox": [66.0, 333.0, 727.0, 348.0]}, {"text": "frequent cancers worldwide. However, only 10–20% of patients are amenable to curative treatment, such as resection or", "bbox": [66.0, 349.0, 727.0, 364.0]}, {"text": "transplant. Liver metastases are most frequently caused by colorectal cancer, which accounts for the second most cancer-", "bbox": [65.0, 366.0, 726.0, 381.0]}, {"text": "related deaths in Europe. In both primary and secondary tumours, radioembolization has been shown to be a safe and effective", "bbox": [66.0, 383.0, 727.0, 399.0]}, {"text": "treatment option. The vast potential of personalized dosimetry has also been shown, resulting in markedly increased response", "bbox": [66.0, 400.0, 727.0, 414.0]}, {"text": "rates and overall survival. In a rapidly evolving therapeutic landscape, the role of radioembolization will be subject to changes.", "bbox": [66.0, 417.0, 725.0, 431.0]}, {"text": "Therefore, the decision for radioembolization should be taken by a multidisciplinary tumour board in accordance with the", "bbox": [66.0, 433.0, 727.0, 449.0]}, {"text": "current clinical guidelines. The purpose of this procedure guideline is to assist the nuclear medicine physician in treating", "bbox": [65.0, 450.0, 727.0, 465.0]}, {"text": "and managing patients undergoing radioembolization treatment.", "bbox": [66.0, 467.0, 412.0, 481.0]}], "type": "Text", "position": 9}, {"raw_context": [{"text": "Preamble", "bbox": [65.0, 525.0, 127.0, 539.0]}], "type": "Section-header", "position": 10}, {"raw_context": [{"text": "The European Association of Nuclear Medicine (EANM) is a professional non-profit medical association that facilitates", "bbox": [66.0, 541.0, 727.0, 557.0]}, {"text": "communication worldwide among individuals pursuing clinical and research excellence in nuclear medicine. The EANM", "bbox": [65.0, 559.0, 727.0, 574.0]}, {"text": "was founded in 1985. These guidelines are intended to assist practitioners in providing appropriate nuclear medicine care for", "bbox": [66.0, 575.0, 727.0, 590.0]}, {"text": "patients. They are notinflexible rules or requirements of practice and are not intended, nor should they be used, to establish", "bbox": [66.0, 592.0, 728.0, 606.0]}, {"text": "a legal standard of care. The ultimate judgment regarding the propriety of any specific procedure or course of action must", "bbox": [65.0, 608.0, 727.0, 624.0]}, {"text": "be made by medical professionals taking into account the unique circumstances of each case. Thus, there is no implication", "bbox": [65.0, 625.0, 727.0, 640.0]}, {"text": "that an approach differing from the guidelines, standing alone, is below the standard of care. To the contrary, a conscientious", "bbox": [65.0, 642.0, 728.0, 656.0]}, {"text": "practitioner may responsibly adopt a course of action different from that set out in the guidelines when, in the reasonable judg-", "bbox": [65.0, 658.0, 726.0, 673.0]}, {"text": "ment of the practitioner, such course of action is indicated by the condition of the patient, limitations of available resources", "bbox": [66.0, 675.0, 727.0, 691.0]}, {"text": "or advances in knowledge or technology subsequent to publication of the guidelines. The practice of médicing involves not", "bbox": [65.0, 692.0, 727.0, 706.0]}, {"text": "only the science but also the art of dealing with the prevention, diagnosis, alleviation and treatment of disease. The variety", "bbox": [65.0, 708.0, 729.0, 723.0]}, {"text": "and complexity of human conditions make it impossible to always reach the most appropriate diagnosis or topredict with a", "bbox": [66.0, 725.0, 729.0, 740.0]}, {"text": "'cèriäinty,a particular response to treatment. Therefore, it should be recognised that adherence to these guidelines will not", "bbox": [64.0, 742.0, 727.0, 756.0]}, {"text": "ensure an accurate diagnosis or a successful outcome. All that should be expected is that the practitioner will follow a reason-", "bbox": [66.0, 758.0, 725.0, 773.0]}, {"text": "able course of action based on current knowledge, available resources and the needs of the patient to deliver effective and", "bbox": [66.0, 775.0, 727.0, 790.0]}, {"text": "safe medical care. The sole purpose of these guidelines is to assist practitioners in achieving this objective.", "bbox": [66.0, 792.0, 640.0, 807.0]}], "type": "Text", "position": 11}, {"raw_context": [{"text": "The Therapy, Oncology and Dosimetry Committees collaborated", "bbox": [67.0, 849.0, 370.0, 862.0]}], "type": "Text", "position": 12}, {"raw_context": [{"text": "with the aim to revise the European Association of Nuclear", "bbox": [67.0, 863.0, 338.0, 875.0]}], "type": "Text", "position": 13}, {"raw_context": [{"text": "Medicine (EANM) guidelines on radioembolization.", "bbox": [66.0, 876.0, 307.0, 888.0]}], "type": "Text", "position": 14}, {"raw_context": [{"text": "This article is part of the Topical Collection on Oncology -", "bbox": [67.0, 903.0, 336.0, 916.0]}, {"text": "Digestive tract", "bbox": [66.0, 918.0, 135.0, 930.0]}], "type": "Footnote", "position": 15}, {"raw_context": [{"text": "Extended author information available on the last page of the article", "bbox": [66.0, 944.0, 377.0, 958.0]}], "type": "Footnote", "position": 16}, {"raw_context": [{"text": "Keywords Guidelines · Nuclear medicine · Liver cancer ·", "bbox": [405.0, 841.0, 713.0, 856.0]}, {"text": "90Y-microspheres · SIR-spheres® · TheraSphere® · Resin", "bbox": [405.0, 857.0, 717.0, 873.0]}, {"text": "microspheres · Glass microspheres · 166 Ho-microspheres ·", "bbox": [405.0, 873.0, 715.0, 888.0]}, {"text": "QuiremSpheres® · Dosimetry", "bbox": [405.0, 891.0, 567.0, 906.0]}], "type": "Text", "position": 17}, {"raw_context": [{"text": "Published online: 11 February 2022.", "bbox": [65.0, 983.0, 230.0, 996.0]}], "type": "Footnote", "position": 18}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2022】全科室最全临床指南+专家共识（最全版）/2022全科室临床指南/肿瘤科/EANM：动脉内放射性化合物治疗肝癌和转移性肝癌指南（2022）(1).pdf", "page_num": 1}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": null, "type3": null, "type4": null, "type5": null, "type6": "有用性#8#11#页脚内容，与正文无关"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:42", "update_time": "2024-05-07 18:25:07"}
{"id": 1082613, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 738, "source_info": {"seq_id": "16f5e8fd-11e1-4fa6-bf24-9404ad9a2eb3", "title": null, "text": "【0】页码:3\n\n【1】 Table 2 Treatment of Candidemia and Invasive Candidiasis [23] Dose, Maintenance Side Effects/Toxicities Agent Dose, Induction Route Echinocandins ' Rare infusion reactions Anidulafungin Adult (A-l) 200 mg × 1 dose 100 mg once daily i.v.\n\n【2】Child 1 3 mg/kg × 1 dose 1.5 mg/kg once daily i.v.\n\n【3】Caspofungin Adult (A-I) 70 mg × 1 dose 50 mg once daily 1. I. I.V.\n\n【4】Child <3 mo 25 mg/m2 once daily None i.v.\n\n【5】Child ≥ 3 mo to < 18 yr 70 mg/m2 × 1 dose 50 mg/m2 once daily i.v.\n\n【6】(increase to 70 mg/m2 daily, depending on clinical response; maximum dose, 70 mg daily) Micafungin Adult (A-I) None 100 mg once daily i.v.\n\n【7】Infant < 4 mo None 2 mg/kg/day once daily i.v.\n\n【8】(increase to 4-10 mg/kg daily, depending on clinical response) Child ≥ 4 mo to < 18 yr None 2 mg/kg/day once daily i.v.\n\n【9】(maximum dose, 100 mg daily) Azoles' Fluconazole (A-I) 8 Hepatotoxicity Adult 800 mg × 1 dose 400 mg once daily i.v./oral Child 12 mg/kg once daily (maxi- None i.v./oral mum dose, 800 mg/day) Voriconazole (A-I) 1 Hepatotoxicity, visual hallucinations, neurologic toxicity, QTc prolongation, rash, photosensitivity reactions, periostitis Adult 6 mg/kg twice daily × 2 doses 4 mg/kg twice daily i.v. 5 /oral Child 5 2 to < 12 yr 9 mg/kg twice daily × 2 doses 8 mg/kg twice daily (maxii.v.\"/oral mum oral dose, 350 mg once daily) Child ≥ 12 to ≤ 14 yr, < 50 kg 9 mg/kg twice daily × 2 doses 8 mg/kg twice daily (maxii.v. 5 /oral mum oral dose, 350 mg once daily) Child > 12 to < 14 yr, > 50 kg 6 mg/kg twice daily × 2 doses 4 mg/kg twice daily i.v. 5 /oral Child > 15 yr 6 mg/kg twice daily × 2 doses 4 mg/kg twice daily i.v. 5 /oral Polyenes Amphotericin B lipid formulation a Nephrotoxicity, electrolyte abnormalities Adult None 3-5 mg/kg once daily i.v.\n\n【10】Child None 3-5 mg/kg once daily i.v.\n\n【11】Echinocandins are considered interchangeable for the treatment of IC. Notably, only a limited number of patients with neutropenia have been included in the major echinocandin clinical trials [ 24 – 26 ]. In adult patients with critical illness or obesity, higher doses of echinocandins may be used; doses as high as 150 mg/day.\n\n【12】\n 200 mg/day, and 150 mg/day for caspofungin, anidulafungin, and micafungin, respectively, have been well tolerated [23,26,51] (A-I/II). Echinocandins should not be used in patients with endophthalmitis (particularly with involvement of the vitreous fluid) or central nervous system involvement because of poor penetration.\n\n【13】Anidulafungin is not approved for use in children.\n\n【14】Based on lack of relevant data, posaconazole is not included among the recommended options for the treatment of invasive candidiasis [ 23 ]. Isavuconazole is not approved for the treatment of candidemia based on failure to demonstrate noninferiority compared to caspofungin for primary treatment of invasive candidiasis [56].\n\n【15】Fluconazole can be used in patients with fluconazole-susceptible Candida spp as step-down therapy.\n\n【16】1 Voriconazole can be used in patients with candidemia due to C. glabrata ( Nakaseomyces glabrata ) and/or C. krusei ( Pichia kudriavzevii ) as step-down oral treatment. Cross-resistance between voriconazole and fluconazole for C. glabrata ( Nakaseomyces glabrata ) may be encountered.\n\n【17】Weight-based dosing of voriconazole is preferred for both Lv. and oral administration. Voriconazole trough therapeutic drug monitoring should be performed, particularly in children [ 52 , 53 ]. Administration of i.v. voriconazole is not recommended if creatinine clearance < 50 mL/min.\n\n【18】Amphotericin B lipid formulations may be used to treat IC based on available data and fungicidal profile, but are not favored as first-line therapy because of associated potential toxicities.", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "Table 2", "bbox": [84.0, 75.0, 117.0, 87.0]}, {"text": "Treatment of Candidemia and Invasive Candidiasis [23]", "bbox": [84.0, 88.0, 299.0, 99.0]}, {"text": "Dose, Maintenance", "bbox": [403.0, 106.0, 479.0, 118.0]}, {"text": "Side Effects/Toxicities", "bbox": [602.0, 106.0, 689.0, 118.0]}, {"text": "Agent", "bbox": [92.0, 108.0, 118.0, 118.0]}, {"text": "Dose, Induction", "bbox": [260.0, 107.0, 325.0, 118.0]}, {"text": "Route", "bbox": [541.0, 107.0, 567.0, 118.0]}, {"text": "Echinocandins '", "bbox": [92.0, 121.0, 153.0, 133.0]}, {"text": "Rare infusion reactions", "bbox": [602.0, 121.0, 694.0, 133.0]}, {"text": "Anidulafungin", "bbox": [101.0, 137.0, 159.0, 149.0]}, {"text": "Adult (A-l)", "bbox": [109.0, 152.0, 155.0, 163.0]}, {"text": "200 mg × 1 dose", "bbox": [262.0, 152.0, 328.0, 163.0]}, {"text": "100 mg once daily", "bbox": [404.0, 152.0, 477.0, 163.0]}, {"text": "i.v.", "bbox": [541.0, 152.0, 555.0, 163.0]}, {"text": "Child 1", "bbox": [109.0, 166.0, 133.0, 177.0]}, {"text": "3 mg/kg × 1 dose", "bbox": [262.0, 166.0, 328.0, 177.0]}, {"text": "1.5 mg/kg once daily", "bbox": [404.0, 166.0, 485.0, 177.0]}, {"text": "i.v.", "bbox": [541.0, 167.0, 554.0, 177.0]}, {"text": "Caspofungin", "bbox": [102.0, 181.0, 152.0, 192.0]}, {"text": "Adult (A-I)", "bbox": [110.0, 196.0, 154.0, 208.0]}, {"text": "70 mg × 1 dose", "bbox": [262.0, 197.0, 322.0, 209.0]}, {"text": "50 mg once daily", "bbox": [403.0, 197.0, 472.0, 209.0]}, {"text": "1. I. I.V.", "bbox": [541.0, 198.0, 555.0, 209.0]}, {"text": "Child <3 mo", "bbox": [109.0, 211.0, 160.0, 223.0]}, {"text": "25 mg/m2 once daily", "bbox": [403.0, 211.0, 487.0, 223.0]}, {"text": "None", "bbox": [261.0, 212.0, 283.0, 223.0]}, {"text": "i.v.", "bbox": [541.0, 212.0, 556.0, 223.0]}, {"text": "Child ≥ 3 mo to < 18 yr", "bbox": [109.0, 226.0, 199.0, 236.0]}, {"text": "70 mg/m2 × 1 dose", "bbox": [262.0, 226.0, 339.0, 237.0]}, {"text": "50 mg/m2 once daily", "bbox": [403.0, 226.0, 487.0, 236.0]}, {"text": "i.v.", "bbox": [542.0, 226.0, 555.0, 236.0]}, {"text": "(increase to 70 mg/m2 daily,", "bbox": [404.0, 235.0, 516.0, 249.0]}, {"text": "depending on clinical", "bbox": [403.0, 248.0, 489.0, 259.0]}, {"text": "response; maximum dose,", "bbox": [403.0, 259.0, 507.0, 270.0]}, {"text": "70 mg daily)", "bbox": [404.0, 271.0, 455.0, 283.0]}, {"text": "Micafungin", "bbox": [102.0, 286.0, 149.0, 298.0]}, {"text": "Adult (A-I)", "bbox": [110.0, 300.0, 154.0, 312.0]}, {"text": "None", "bbox": [262.0, 300.0, 283.0, 311.0]}, {"text": "100 mg once daily", "bbox": [404.0, 300.0, 476.0, 312.0]}, {"text": "i.v.", "bbox": [541.0, 300.0, 554.0, 311.0]}, {"text": "Infant < 4 mo", "bbox": [109.0, 315.0, 163.0, 326.0]}, {"text": "None", "bbox": [262.0, 315.0, 283.0, 326.0]}, {"text": "2 mg/kg/day once daily", "bbox": [404.0, 315.0, 496.0, 326.0]}, {"text": "i.v.", "bbox": [542.0, 315.0, 555.0, 325.0]}, {"text": "(increase to 4-10 mg/kg", "bbox": [403.0, 327.0, 497.0, 337.0]}, {"text": "daily, depending on clinical", "bbox": [404.0, 338.0, 513.0, 350.0]}, {"text": "response)", "bbox": [404.0, 350.0, 444.0, 360.0]}, {"text": "Child ≥ 4 mo to < 18 yr", "bbox": [110.0, 364.0, 199.0, 375.0]}, {"text": "None", "bbox": [262.0, 364.0, 284.0, 374.0]}, {"text": "2 mg/kg/day once daily", "bbox": [404.0, 364.0, 496.0, 375.0]}, {"text": "i.v.", "bbox": [541.0, 365.0, 555.0, 374.0]}, {"text": "(maximum dose, 100 mg", "bbox": [403.0, 374.0, 503.0, 388.0]}, {"text": "daily)", "bbox": [405.0, 388.0, 429.0, 397.0]}, {"text": "Azoles'", "bbox": [93.0, 402.0, 120.0, 414.0]}, {"text": "Fluconazole (A-I) 8", "bbox": [101.0, 416.0, 170.0, 427.0]}, {"text": "Hepatotoxicity", "bbox": [602.0, 416.0, 661.0, 427.0]}, {"text": "Adult", "bbox": [110.0, 430.0, 135.0, 442.0]}, {"text": "800 mg × 1 dose", "bbox": [261.0, 431.0, 328.0, 443.0]}, {"text": "400 mg once daily", "bbox": [403.0, 431.0, 476.0, 442.0]}, {"text": "i.v./oral", "bbox": [541.0, 431.0, 574.0, 443.0]}, {"text": "Child", "bbox": [109.0, 445.0, 133.0, 456.0]}, {"text": "12 mg/kg once daily (maxi-", "bbox": [403.0, 445.0, 510.0, 456.0]}, {"text": "None", "bbox": [262.0, 446.0, 285.0, 456.0]}, {"text": "i.v./oral", "bbox": [541.0, 447.0, 574.0, 457.0]}, {"text": "mum dose, 800 mg/day)", "bbox": [405.0, 457.0, 502.0, 467.0]}, {"text": "Voriconazole (A-I) 1", "bbox": [102.0, 471.0, 177.0, 483.0]}, {"text": "Hepatotoxicity, visual hallu-", "bbox": [602.0, 472.0, 712.0, 484.0]}, {"text": "cinations, neurologic toxic-", "bbox": [603.0, 484.0, 708.0, 495.0]}, {"text": "ity, QTc prolongation, rash,", "bbox": [603.0, 495.0, 708.0, 506.0]}, {"text": "photosensitivity reactions,", "bbox": [603.0, 506.0, 707.0, 516.0]}, {"text": "periostitis", "bbox": [603.0, 518.0, 645.0, 529.0]}, {"text": "Adult", "bbox": [111.0, 533.0, 133.0, 544.0]}, {"text": "6 mg/kg twice daily × 2 doses", "bbox": [260.0, 533.0, 378.0, 544.0]}, {"text": "4 mg/kg twice daily", "bbox": [403.0, 533.0, 481.0, 544.0]}, {"text": "i.v. 5 /oral", "bbox": [541.0, 533.0, 576.0, 544.0]}, {"text": "Child 5 2 to < 12 yr", "bbox": [110.0, 545.0, 182.0, 559.0]}, {"text": "9 mg/kg twice daily × 2 doses", "bbox": [261.0, 547.0, 378.0, 557.0]}, {"text": "8 mg/kg twice daily (maxi-", "bbox": [403.0, 547.0, 509.0, 558.0]}, {"text": "i.v.\"/oral", "bbox": [542.0, 547.0, 577.0, 558.0]}, {"text": "mum oral dose, 350 mg once", "bbox": [403.0, 559.0, 517.0, 569.0]}, {"text": "daily)", "bbox": [404.0, 571.0, 429.0, 581.0]}, {"text": "Child ≥ 12 to ≤ 14 yr, < 50 kg", "bbox": [110.0, 585.0, 222.0, 596.0]}, {"text": "9 mg/kg twice daily × 2 doses", "bbox": [262.0, 585.0, 378.0, 596.0]}, {"text": "8 mg/kg twice daily (maxi-", "bbox": [403.0, 585.0, 509.0, 596.0]}, {"text": "i.v. 5 /oral", "bbox": [542.0, 585.0, 577.0, 597.0]}, {"text": "mum oral dose, 350 mg once", "bbox": [405.0, 596.0, 516.0, 607.0]}, {"text": "daily)", "bbox": [403.0, 609.0, 429.0, 620.0]}, {"text": "Child > 12 to < 14 yr, > 50 kg", "bbox": [109.0, 623.0, 221.0, 635.0]}, {"text": "6 mg/kg twice daily × 2 doses", "bbox": [260.0, 623.0, 379.0, 635.0]}, {"text": "4 mg/kg twice daily", "bbox": [403.0, 623.0, 483.0, 635.0]}, {"text": "i.v. 5 /oral", "bbox": [541.0, 623.0, 578.0, 635.0]}, {"text": "Child > 15 yr", "bbox": [109.0, 638.0, 161.0, 649.0]}, {"text": "6 mg/kg twice daily × 2 doses", "bbox": [261.0, 638.0, 378.0, 649.0]}, {"text": "4 mg/kg twice daily", "bbox": [403.0, 638.0, 482.0, 649.0]}, {"text": "i.v. 5 /oral", "bbox": [542.0, 638.0, 578.0, 649.0]}, {"text": "Polyenes", "bbox": [93.0, 652.0, 129.0, 663.0]}, {"text": "Amphotericin B lipid formulation a", "bbox": [102.0, 667.0, 233.0, 678.0]}, {"text": "Nephrotoxicity, electrolyte", "bbox": [603.0, 667.0, 708.0, 678.0]}, {"text": "abnormalities", "bbox": [603.0, 677.0, 660.0, 689.0]}, {"text": "Adult", "bbox": [109.0, 694.0, 134.0, 704.0]}, {"text": "None", "bbox": [260.0, 694.0, 285.0, 703.0]}, {"text": "3-5 mg/kg once daily", "bbox": [403.0, 694.0, 488.0, 705.0]}, {"text": "i.v.", "bbox": [541.0, 694.0, 555.0, 705.0]}, {"text": "Child", "bbox": [109.0, 708.0, 133.0, 719.0]}, {"text": "None", "bbox": [260.0, 708.0, 283.0, 719.0]}, {"text": "3-5 mg/kg once daily", "bbox": [403.0, 708.0, 487.0, 720.0]}, {"text": "i.v.", "bbox": [540.0, 709.0, 555.0, 719.0]}, {"text": "Echinocandins are considered interchangeable for the treatment of IC. Notably, only a limited number of patients with neutropenia have been included in the", "bbox": [100.0, 722.0, 724.0, 734.0]}, {"text": "major echinocandin clinical trials [ 24 – 26 ]. In adult patients with critical illness or obesity, higher doses of echinocandins may be used; doses as high as 150 mg/day.", "bbox": [83.0, 734.0, 725.0, 747.0]}], "type": "Table", "position": 1}, {"raw_context": [{"text": "200 mg/day, and 150 mg/day for caspofungin, anidulafungin, and micafungin, respectively, have been well tolerated [23,26,51] (A-I/II). Echinocandins should not be", "bbox": [85.0, 747.0, 725.0, 757.0]}, {"text": "used in patients with endophthalmitis (particularly with involvement of the vitreous fluid) or central nervous system involvement because of poor penetration.", "bbox": [84.0, 757.0, 700.0, 769.0]}, {"text": "Anidulafungin is not approved for use in children.", "bbox": [101.0, 769.0, 295.0, 780.0]}, {"text": "Based on lack of relevant data, posaconazole is not included among the recommended options for the treatment of invasive candidiasis [ 23 ]. Isavuconazole is not", "bbox": [100.0, 779.0, 725.0, 791.0]}, {"text": "approved for the treatment of candidemia based on failure to demonstrate noninferiority compared to caspofungin for primary treatment of invasive candidiasis [56].", "bbox": [85.0, 792.0, 724.0, 804.0]}, {"text": "Fluconazole can be used in patients with fluconazole-susceptible Candida spp as step-down therapy.", "bbox": [100.0, 803.0, 489.0, 814.0]}, {"text": "1 Voriconazole can be used in patients with candidemia due to C. glabrata ( Nakaseomyces glabrata ) and/or C. krusei ( Pichia kudriavzevii ) as step-down oral treat-", "bbox": [91.0, 814.0, 724.0, 826.0]}, {"text": "ment. Cross-resistance between voriconazole and fluconazole for C. glabrata ( Nakaseomyces glabrata ) may be encountered.", "bbox": [84.0, 825.0, 559.0, 837.0]}, {"text": "Weight-based dosing of voriconazole is preferred for both Lv. and oral administration. Voriconazole trough therapeutic drug monitoring should be performed,", "bbox": [98.0, 836.0, 724.0, 849.0]}, {"text": "particularly in children [ 52 , 53 ]. Administration of i.v. voriconazole is not recommended if creatinine clearance < 50 mL/min.", "bbox": [84.0, 849.0, 562.0, 860.0]}, {"text": "Amphotericin B lipid formulations may be used to treat IC based on available data and fungicidal profile, but are not favored as first-line therapy because of asso-", "bbox": [102.0, 859.0, 724.0, 872.0]}, {"text": "ciated potential toxicities.", "bbox": [84.0, 871.0, 186.0, 882.0]}], "type": "Text", "position": 2}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/血液科/2023 ASTCT指南：造血细胞移植受者侵袭性念珠菌病的管理.pdf", "page_num": 3}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": null, "type3": "无关文本#16#16#1 \n无关文本#0#18#Candidiasis [23]部分段落末尾，以及句末的数字问题无关噪声应用全文", "type4": null, "type5": null, "type6": "准确性#1#10#表格内容杂乱"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:42", "update_time": "2024-05-08 00:22:47"}
{"id": 1082612, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 738, "source_info": {"seq_id": "4fabb94b-be75-4790-8bc6-2081de0e5712", "title": null, "text": "【0】页码:6\n\n【1】## 疗效评价 7\n\n【2】\n## 评定内容\n\n【3】\n 评定内容 7.1 按照 “4.2 临床评估 ” 有关查体 、 量表评估及影像 学检查方法评定临床疗效。 评定方法 7.2\n\n【4】## 评定方法\n\n【5】\n 根据数据类型选择评定方法,临床观察根据实 际情况选择描述性评定;等级资料按等级数据分析 方法进行疗效评定 [41 。 计量资料按照尼莫地平法 进行评定 , 计算方式如下 .\n\n【6】减分率 =  治疗前积分 -  治疗后积分 × 100% 治疗前积分 对于临床观察到的额外获益,进行描述性效疗 评定。对于临床观察、等级量表与数据量表,进行 描述性效疗的组合评定。 疗效评定及周期 7.3 可按减分率评价临床疗效,每2周评定1次 [47] .\n\n【7】具体见表4。\n\n【8】## 表4  临床疗效评价表\n\n【9】\n## Table 4 Clinical Efficacy Evaluation Table\n\n【10】\n 病情变化 减分率 评价结果 症状 ∩ 体征消失或基本消失 ≥ 95% 临床痊愈 症状 . 体征明显改善 ≥ 75% 且 < 95% 显效 症状 . 体征改善 ≥ 30% 且 < 75% 有效 症状 . 体征无明显改善 < 30% 无效\n\n【11】\n## 参考文献\n\n【12】\n 国家市场监督管理总局,国家标准化管理委员会.经穴名称与 [1] 定位 : GB/T 12346—2021[S] . 北京 : 中国标准出版社 , 2021.\n\n【13】State Administration for Market Regulation, Standardization Administration of the People's Republic of China. Nomenclature and location of meridian points; GB/T 12346—2021 [S]. Beijing; Standards Press of China ,  2021 .\n\n【14】[2] JIN C, WANG S R, YANG G D, et al. A review of the methods on Cobb angle measurements for spinal curvature [J]. Sensors (Basel),2022,22(9):3258.\n\n【15】中华医学会骨科学分会脊柱外科学组. 中国青少年脊柱侧 [3] 凸筛查临床实践指南及路径指引 [J]. 中华骨科杂志 , 2020, 40(23): 1574–1582.\n\n【16】Spinal Surgery Group of Osteology Branch of Chinese Medical As-\n\n【17】 sociation. Adolescent scoliosis screening in China; clinical practice guideline and pathway [J]. Chin J Orthop, 2020, 40 (23) : 1574–1582.\n\n【18】 余升华,尹得龙,杨辰翔.青少年脊柱侧弯的研究进展[J]. 岭 [4] 南现代临床外科,2014,14(6):708–711.\n\n【19】YU S H , YIN D L , YANG Z X. Research progress in scoliosis for adolescent [J]. Lingnan Mod Clin Surg, 2014, 14(6):708–711.\n\n【20】[5] 国家质量监督检验检疫总局,中国国家标准化管理委员会. 儿 童青少年脊柱弯曲异常的筛查 : GB/T 16133—2014[S]. 北京 : 中国标准出版社 , 2015.\n\n【21】 General Administration of Quality Supervision, Inspection and Quarantine of the People's Republic of China , Standardization Administration of the People's Republic of China. Screening of spinal curvature abnormality of children and adolescents; GB/T 16133—2014 [S]. Beijing : Standards Press of China ,  2015 .\n\n【22】[6] 袁望新 , 陈丽渡 , 沈建堆 , 等 . 不同年龄 , 性别和类型的特发性 脊柱侧凸患者轴向躯干旋转角度与Cobb角度的相关性[J]. 中 国组织工程研究, 2021, 25( 27):4386–4389.\n\n【23】YUAN W S, CHEN L X, SHEN J X, et al. Correlation between axial trunk rotation angle and Cobb angle in different ages, genders, and types of idiopathic scoliosis patients [J]. Chin J Tissue Eng Res , 2021 , 25( 27) : 4386–4389.\n\n【24】吕中凡. 运动 \"弱链接\" 及其训练学应对路径分析[J]. 南京体 [7] 育学院学报(社会科学版),2010,24(3):112–115.\n\n【25】LYU Z F. \"weak link\" in sports and its response to the approaches of athletic training [J]. J Nanjing Inst Phys Educ Soc Sci, 2010, 24(3): 112–115.\n\n【26】李新怡 , 刘海燕 . 不同康复方法对青少年脊柱侧弯影响进展研 [8] $[J]. 当代体育科技,2021,11(30):19–21.\n\n【27】LI X Y , LIU H Y. Study on the influence of different rehabilitation methods on adolescent scoliosis [J]. Contemp Sports Technol, 2021, 11(30): 19–21.\n\n【28】李丽 , 王元红 . 督灸改善强宜性脊柱炎病人脊柱活动度的 Meta [9] 分析[J]. 全科护理,2023,21(5):581–586.\n\n【29】LI L, WANG Y H. Meta–analysis of supervised moxibustion to improve spinal mobility in patients with ankylosing spondylitis [J].\n\n【30】General Practice Nursing ,  2023 ,  21( 5):581–586 .\n\n【31】[10] 罗丹妮,庞亚铮,鲁士友 . 督灸疗法起源及应用探析[J] . 山东 中医杂志 ,2018,37(5):360–363.\n\n【32】LUO D N , PANG Y Z , LU S Y. Discussion on the origin and application of governor vessel moxibustion therapy [J]. China Ind Econ, 2018, 37( 5 ): 360–363.\n\n【33】[11] LAU R W , CHEUK K Y , NG B K , et al. Effects of a home–based exercise intervention (E–fit) on bone density, muscle function, and quality of life in girls with adolescent idiopathic scoliosis (AIS) : a pilot randomized controlled trial [J]. Int J Environ Res Public Health, 2021, 18(20): 10899.\n\n【34】[12] 白玉树, 翟骁, 陈自强, 等. 退变性脊柱侧凸手术加速康复外科 固手术期管理策略专家共识[J]. 第二军医大学学报, 2020, 41(3):233–242.\n\n【35】BAI Y S, ZHAI X, CHEN Z Q, et al. Enhanced recovery after surgery for degenerative scoliosis; consensus on perioperative management strategy [J]. Acad J Second Mil Med Univ, 2020, 41(3): 233–242.\n\n【36】[13] KNOTT P, PAPPO E, CAMERON M, et al. SOSORT 2012 consensus paper: reducing X–ray exposure in pediatric patients with\n scoliosis [J]. Scoliosis, 2014, 9:4.\n\n【37】[14] 世界中医药学会联合会 . 世界中医药学会联合会 国际中医临 床实践指南青少年特发性脊柱侧凸症 SCM0059-2021[ M ]. : [ L ] .\n\n【38】京 : 中国中医药出版社 , 2021 : 11.\n\n【39】World Federation of Chinese Medicine Societies. World Federa-\n\n【40】 tion of Chinese Medicine Societies International Clinical Practice Guidelines for Chinese Medicine in Adolescents with Idiopathic Scoliosis SCM0059–2021 [M]. Beijing: China Traditional Chinese Medicine Press ,  2021 ; 11 , [15] UGHWANOGHO E, PATEL N M, BALDWIN K D, et al. Computed", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "疗效评价", "bbox": [90.0, 106.0, 157.0, 124.0]}, {"text": "7", "bbox": [65.0, 108.0, 78.0, 123.0]}], "type": "Section-header", "position": 1}, {"raw_context": [{"text": "评定内容", "bbox": [91.0, 135.0, 157.0, 151.0]}], "type": "Section-header", "position": 2}, {"raw_context": [{"text": "评定内容", "bbox": [91.0, 135.0, 157.0, 151.0]}, {"text": "7.1", "bbox": [65.0, 136.0, 90.0, 151.0]}, {"text": "按照 “4.2 临床评估 ” 有关查体 、 量表评估及影像", "bbox": [94.0, 154.0, 375.0, 170.0]}, {"text": "学检查方法评定临床疗效。", "bbox": [66.0, 174.0, 229.0, 190.0]}, {"text": "评定方法", "bbox": [96.0, 194.0, 157.0, 210.0]}, {"text": "7.2", "bbox": [65.0, 195.0, 92.0, 209.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "评定方法", "bbox": [96.0, 194.0, 157.0, 210.0]}], "type": "Section-header", "position": 4}, {"raw_context": [{"text": "根据数据类型选择评定方法,临床观察根据实", "bbox": [94.0, 214.0, 375.0, 231.0]}, {"text": "际情况选择描述性评定;等级资料按等级数据分析", "bbox": [65.0, 234.0, 375.0, 250.0]}, {"text": "方法进行疗效评定 [41 。 计量资料按照尼莫地平法", "bbox": [66.0, 253.0, 375.0, 270.0]}, {"text": "进行评定 , 计算方式如下 .", "bbox": [65.0, 274.0, 222.0, 289.0]}, {"text": "减分率 =  治疗前积分 -  治疗后积分 × 100%", "bbox": [104.0, 293.0, 337.0, 313.0]}, {"text": "治疗前积分", "bbox": [192.0, 310.0, 256.0, 325.0]}, {"text": "对于临床观察到的额外获益,进行描述性效疗", "bbox": [94.0, 328.0, 375.0, 345.0]}, {"text": "评定。对于临床观察、等级量表与数据量表,进行", "bbox": [65.0, 349.0, 375.0, 364.0]}, {"text": "描述性效疗的组合评定。", "bbox": [66.0, 369.0, 214.0, 385.0]}, {"text": "疗效评定及周期", "bbox": [92.0, 388.0, 199.0, 404.0]}, {"text": "7.3", "bbox": [65.0, 389.0, 90.0, 403.0]}, {"text": "可按减分率评价临床疗效,每2周评定1次 [47] .", "bbox": [94.0, 407.0, 372.0, 424.0]}, {"text": "具体见表4。", "bbox": [66.0, 427.0, 139.0, 444.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "表4  临床疗效评价表", "bbox": [162.0, 453.0, 279.0, 467.0]}], "type": "Section-header", "position": 6}, {"raw_context": [{"text": "Table 4", "bbox": [111.0, 473.0, 156.0, 487.0]}, {"text": "Clinical efficacy evaluation table", "bbox": [159.0, 472.0, 331.0, 487.0]}], "type": "Section-header", "position": 7}, {"raw_context": [{"text": "病情变化", "bbox": [115.0, 493.0, 168.0, 509.0]}, {"text": "减分率", "bbox": [246.0, 493.0, 287.0, 508.0]}, {"text": "评价结果", "bbox": [319.0, 494.0, 371.0, 509.0]}, {"text": "症状 ∩ 体征消失或基本消失", "bbox": [70.0, 512.0, 213.0, 527.0]}, {"text": "≥ 95%", "bbox": [222.0, 513.0, 261.0, 526.0]}, {"text": "临床痊愈", "bbox": [320.0, 512.0, 370.0, 527.0]}, {"text": "症状 . 体征明显改善", "bbox": [89.0, 530.0, 194.0, 544.0]}, {"text": "≥ 75% 且 < 95%", "bbox": [222.0, 530.0, 310.0, 544.0]}, {"text": "显效", "bbox": [331.0, 531.0, 358.0, 544.0]}, {"text": "症状 . 体征改善", "bbox": [101.0, 547.0, 183.0, 561.0]}, {"text": "≥ 30% 且 < 75%", "bbox": [222.0, 547.0, 310.0, 561.0]}, {"text": "有效", "bbox": [331.0, 549.0, 358.0, 562.0]}, {"text": "症状 . 体征无明显改善", "bbox": [83.0, 564.0, 201.0, 579.0]}, {"text": "< 30%", "bbox": [222.0, 565.0, 260.0, 579.0]}, {"text": "无效", "bbox": [333.0, 566.0, 358.0, 580.0]}], "type": "Table", "position": 8}, {"raw_context": [{"text": "参考文献", "bbox": [66.0, 592.0, 125.0, 610.0]}], "type": "Section-header", "position": 9}, {"raw_context": [{"text": "国家市场监督管理总局,国家标准化管理委员会.经穴名称与", "bbox": [90.0, 616.0, 376.0, 630.0]}, {"text": "[1]", "bbox": [66.0, 618.0, 90.0, 630.0]}, {"text": "定位 : GB/T 12346—2021[S] . 北京 : 中国标准出版社 , 2021.", "bbox": [92.0, 633.0, 362.0, 646.0]}, {"text": "State Administration for Market Regulation, Standardization Ad-", "bbox": [92.0, 649.0, 377.0, 661.0]}, {"text": "ministration of the People's Republic of China. Nomenclature and", "bbox": [92.0, 663.0, 377.0, 678.0]}, {"text": "location of meridian points; GB/T 12346—2021 [S]. Beijing; Stan-", "bbox": [92.0, 680.0, 376.0, 692.0]}, {"text": "dards Press of China ,  2021 .", "bbox": [93.0, 696.0, 211.0, 707.0]}, {"text": "[2]", "bbox": [66.0, 711.0, 87.0, 724.0]}, {"text": "JIN C, WANG S R, YANG G D, et al. A review of the methods on", "bbox": [92.0, 711.0, 377.0, 723.0]}, {"text": "Cobb angle measurements for spinal curvature [J]. Sensors (Ba-", "bbox": [92.0, 727.0, 377.0, 739.0]}, {"text": "sel),2022,22(9):3258.", "bbox": [93.0, 741.0, 201.0, 753.0]}, {"text": "中华医学会骨科学分会脊柱外科学组. 中国青少年脊柱侧", "bbox": [91.0, 755.0, 377.0, 769.0]}, {"text": "[3]", "bbox": [66.0, 757.0, 86.0, 769.0]}, {"text": "凸筛查临床实践指南及路径指引 [J]. 中华骨科杂志 , 2020,", "bbox": [92.0, 772.0, 375.0, 785.0]}, {"text": "40(23): 1574–1582.", "bbox": [93.0, 788.0, 186.0, 799.0]}, {"text": "Spinal Surgery Group of Osteology Branch of Chinese Medical As-", "bbox": [92.0, 800.0, 377.0, 817.0]}], "type": "Text", "position": 10}, {"raw_context": [{"text": "sociation. Adolescent scoliosis screening in China; clinical prac-", "bbox": [92.0, 819.0, 376.0, 831.0]}, {"text": "tice guideline and pathway [J]. Chin J Orthop, 2020, 40 (23) :", "bbox": [92.0, 834.0, 376.0, 846.0]}, {"text": "1574–1582.", "bbox": [94.0, 849.0, 147.0, 861.0]}], "type": "Text", "position": 11}, {"raw_context": [{"text": "余升华,尹得龙,杨辰翔.青少年脊柱侧弯的研究进展[J]. 岭", "bbox": [92.0, 863.0, 375.0, 877.0]}, {"text": "[4]", "bbox": [65.0, 864.0, 87.0, 877.0]}, {"text": "南现代临床外科,2014,14(6):708–711.", "bbox": [93.0, 880.0, 276.0, 892.0]}, {"text": "YU S H , YIN D L , YANG Z X. Research progress in scoliosis for", "bbox": [94.0, 894.0, 377.0, 909.0]}, {"text": "adolescent [J]. Lingnan Mod Clin Surg, 2014, 14(6):708–711.", "bbox": [94.0, 911.0, 366.0, 923.0]}, {"text": "[5]", "bbox": [66.0, 926.0, 86.0, 938.0]}, {"text": "国家质量监督检验检疫总局,中国国家标准化管理委员会. 儿", "bbox": [92.0, 926.0, 376.0, 938.0]}, {"text": "童青少年脊柱弯曲异常的筛查 : GB/T 16133—2014[S]. 北京 :", "bbox": [94.0, 941.0, 375.0, 954.0]}, {"text": "中国标准出版社 , 2015.", "bbox": [94.0, 956.0, 200.0, 969.0]}], "type": "Text", "position": 12}, {"raw_context": [{"text": "General Administration of Quality Supervision, Inspection and", "bbox": [429.0, 107.0, 712.0, 119.0]}, {"text": "Quarantine of the People's Republic of China , Standardization Ad-", "bbox": [429.0, 122.0, 712.0, 134.0]}, {"text": "ministration of the People's Republic of China. Screening of spi-", "bbox": [429.0, 138.0, 712.0, 150.0]}, {"text": "nal curvature abnormality of children and adolescents; GB/T", "bbox": [429.0, 153.0, 712.0, 165.0]}, {"text": "16133—2014 [S]. Beijing : Standards Press of China ,  2015 .", "bbox": [429.0, 169.0, 683.0, 181.0]}, {"text": "[6]", "bbox": [401.0, 184.0, 422.0, 196.0]}, {"text": "袁望新 , 陈丽渡 , 沈建堆 , 等 . 不同年龄 , 性别和类型的特发性", "bbox": [429.0, 185.0, 712.0, 196.0]}, {"text": "脊柱侧凸患者轴向躯干旋转角度与Cobb角度的相关性[J]. 中", "bbox": [429.0, 200.0, 712.0, 212.0]}, {"text": "国组织工程研究, 2021, 25( 27):4386–4389.", "bbox": [429.0, 216.0, 626.0, 227.0]}, {"text": "YUAN W S, CHEN L X, SHEN J X, et al. Correlation between axi-", "bbox": [429.0, 231.0, 712.0, 242.0]}, {"text": "al trunk rotation angle and Cobb angle in different ages, genders,", "bbox": [429.0, 246.0, 711.0, 258.0]}, {"text": "and types of idiopathic scoliosis patients [J]. Chin J Tissue Eng", "bbox": [429.0, 261.0, 712.0, 274.0]}, {"text": "Res , 2021 , 25( 27) : 4386–4389.", "bbox": [429.0, 277.0, 568.0, 289.0]}, {"text": "吕中凡. 运动 \"弱链接\" 及其训练学应对路径分析[J]. 南京体", "bbox": [427.0, 290.0, 712.0, 304.0]}, {"text": "[7]", "bbox": [401.0, 292.0, 421.0, 304.0]}, {"text": "育学院学报(社会科学版),2010,24(3):112–115.", "bbox": [429.0, 307.0, 654.0, 320.0]}, {"text": "LYU Z F. \"weak link\" in sports and its response to the approach-", "bbox": [429.0, 324.0, 712.0, 335.0]}, {"text": "es of athletic training [J]. J Nanjing Inst Phys Educ Soc Sci,", "bbox": [428.0, 338.0, 711.0, 352.0]}, {"text": "2010, 24(3): 112–115.", "bbox": [429.0, 355.0, 530.0, 366.0]}, {"text": "李新怡 , 刘海燕 . 不同康复方法对青少年脊柱侧弯影响进展研", "bbox": [427.0, 367.0, 712.0, 382.0]}, {"text": "[8]", "bbox": [401.0, 370.0, 422.0, 382.0]}, {"text": "$[J]. 当代体育科技,2021,11(30):19–21.", "bbox": [429.0, 385.0, 625.0, 397.0]}, {"text": "LI X Y , LIU H Y. Study on the influence of different rehabilitation", "bbox": [429.0, 401.0, 712.0, 412.0]}, {"text": "methods on adolescent scoliosis [J]. Contemp Sports Technol,", "bbox": [429.0, 416.0, 711.0, 428.0]}, {"text": "2021, 11(30): 19–21.", "bbox": [429.0, 431.0, 526.0, 443.0]}, {"text": "李丽 , 王元红 . 督灸改善强宜性脊柱炎病人脊柱活动度的 Meta", "bbox": [428.0, 446.0, 712.0, 459.0]}, {"text": "[9]", "bbox": [401.0, 447.0, 421.0, 458.0]}, {"text": "分析[J]. 全科护理,2023,21(5):581–586.", "bbox": [429.0, 462.0, 620.0, 474.0]}, {"text": "LI L, WANG Y H. Meta–analysis of supervised moxibustion to im-", "bbox": [429.0, 478.0, 712.0, 490.0]}, {"text": "prove spinal mobility in patients with ankylosing spondylitis [J].", "bbox": [429.0, 493.0, 712.0, 505.0]}, {"text": "General Practice Nursing ,  2023 ,  21( 5):581–586 .", "bbox": [428.0, 508.0, 641.0, 520.0]}, {"text": "[10] 罗丹妮,庞亚铮,鲁士友 . 督灸疗法起源及应用探析[J] . 山东", "bbox": [401.0, 523.0, 712.0, 536.0]}, {"text": "中医杂志 ,2018,37(5):360–363.", "bbox": [429.0, 539.0, 577.0, 551.0]}, {"text": "LUO D N , PANG Y Z , LU S Y. Discussion on the origin and appli-", "bbox": [429.0, 554.0, 712.0, 567.0]}, {"text": "cation of governor vessel moxibustion therapy [J]. China Ind", "bbox": [429.0, 571.0, 713.0, 582.0]}, {"text": "Econ, 2018, 37( 5 ): 360–363.", "bbox": [429.0, 585.0, 556.0, 597.0]}, {"text": "[11] LAU R W , CHEUK K Y , NG B K , et al. Effects of a home–based", "bbox": [400.0, 600.0, 712.0, 614.0]}, {"text": "exercise intervention (E–fit) on bone density, muscle function,", "bbox": [429.0, 617.0, 711.0, 628.0]}, {"text": "and quality of life in girls with adolescent idiopathic scoliosis", "bbox": [429.0, 632.0, 712.0, 644.0]}, {"text": "(AIS) : a pilot randomized controlled trial [J]. Int J Environ Res", "bbox": [429.0, 647.0, 713.0, 660.0]}, {"text": "Public Health, 2021, 18(20): 10899.", "bbox": [429.0, 663.0, 588.0, 675.0]}, {"text": "[12] 白玉树, 翟骁, 陈自强, 等. 退变性脊柱侧凸手术加速康复外科", "bbox": [400.0, 676.0, 712.0, 690.0]}, {"text": "固手术期管理策略专家共识[J]. 第二军医大学学报, 2020,", "bbox": [428.0, 692.0, 711.0, 706.0]}, {"text": "41(3):233–242.", "bbox": [429.0, 709.0, 504.0, 721.0]}, {"text": "BAI Y S, ZHAI X, CHEN Z Q, et al. Enhanced recovery after sur-", "bbox": [429.0, 723.0, 712.0, 739.0]}, {"text": "gery for degenerative scoliosis; consensus on perioperative man-", "bbox": [429.0, 741.0, 712.0, 752.0]}, {"text": "agement strategy [J]. Acad J Second Mil Med Univ, 2020, 41(3):", "bbox": [429.0, 756.0, 712.0, 767.0]}, {"text": "233–242.", "bbox": [429.0, 770.0, 473.0, 782.0]}, {"text": "[13] KNOTT P, PAPPO E, CAMERON M, et al. SOSORT 2012 con-", "bbox": [401.0, 784.0, 712.0, 799.0]}, {"text": "sensus paper: reducing X–ray exposure in pediatric patients with", "bbox": [429.0, 801.0, 713.0, 814.0]}], "type": "Text", "position": 14}, {"raw_context": [{"text": "scoliosis [J]. Scoliosis, 2014, 9:4.", "bbox": [429.0, 817.0, 579.0, 830.0]}, {"text": "[14] 世界中医药学会联合会 . 世界中医药学会联合会 国际中医临", "bbox": [400.0, 831.0, 712.0, 845.0]}, {"text": "床实践指南青少年特发性脊柱侧凸症 SCM0059-2021[ M ]. : [ L ] .", "bbox": [429.0, 848.0, 712.0, 861.0]}, {"text": "京 : 中国中医药出版社 , 2021 : 11.", "bbox": [429.0, 864.0, 578.0, 876.0]}, {"text": "World Federation of Chinese Medicine Societies. World Federa-", "bbox": [429.0, 879.0, 712.0, 892.0]}], "type": "List-item", "position": 15}, {"raw_context": [{"text": "tion of Chinese Medicine Societies International Clinical Practice", "bbox": [428.0, 893.0, 712.0, 908.0]}, {"text": "Guidelines for Chinese Medicine in Adolescents with Idiopathic", "bbox": [429.0, 911.0, 712.0, 923.0]}, {"text": "Scoliosis SCM0059–2021 [M]. Beijing: China Traditional Chinese", "bbox": [429.0, 925.0, 712.0, 938.0]}, {"text": "Medicine Press ,  2021 ; 11 ,", "bbox": [429.0, 941.0, 542.0, 954.0]}, {"text": "[15] UGHWANOGHO E, PATEL N M, BALDWIN K D, et al. Computed", "bbox": [401.0, 956.0, 712.0, 969.0]}], "type": "Text", "position": 16}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/骨科/指南/中医康复临床实践指南·儿童青少年特发性脊柱侧弯.pdf", "page_num": 6}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "序号格式不一致#1#1#疗效评价 7  序号在前\n序号格式不一致#2#2#评定内容  前面缺少7.1 \n缺少换行#3#3#评定方法 7.2\n缺少换行#6#6#疗效评定及周期 7.3...另起一行，并且序号应在前\n标点错误#10#10#症状 ∩ 体征应该是症状、体征\n症状 . 体征  应该是症状、体征", "type3": "无关文本#3#3#评定内容 7.1 \n无关文本#4#4#评定方法\n无关文本#5#5# [41 \n无关文本#6#6# [47]", "type4": null, "type5": null, "type6": "准确性#6#6#减分率 =  治疗前积分 -  治疗后积分 × 100% 治疗前积分  公式错误\n有用性#11#40#参考文献的内容"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:42", "update_time": "2024-05-07 22:01:35"}
{"id": 1082611, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 738, "source_info": {"seq_id": "fe271c71-f1c5-4eaf-8e4a-a61106a457e1", "title": null, "text": "【0】页码:8\n [38] 翰林东 , 李明 . 青少年特发性脊柱侧弯非手术治疗研究进 展[J]. 医学信息,2018,31(8):28-30.\n\n【1】 HAN L D, LI M. Progress in non–operative treatment of adolescent idiopathic scoliosis [J]. Med Inf, 2018, 31(8): 28–30.\n\n【2】[39] 朱泽章 , 邱男 , 王斌 , 等 . 青少年特发性脊柱側凸的支具治 $[J]. 中华骨科杂志,2004,24(5):276-280.\n\n【3】ZHU Z Z, QIU Y, WANG B, et al. Clinical outcomes of bracing in adolescent idiopathic scoliosis [J]. Chin J Orthop, 2004, 24(5): 276–280.\n\n【4】[40] BRIGHAM E M, ARMSTRONG D G. Motivations for compliance with bracing in adolescent idiopathic scoliosis [J]. Spine Deform, 2017,5(1):46–51.\n\n【5】[41] 陈小芹 . 全程健康教育在三维矫形术治疗脊柱侧凸患者中的 应用[J] . 护理学杂志 , 2007 , 22(2):66-67.\n\n【6】CHEN X Q. Perioperative health education of the scoliosis patients treated by three–dimensional correction [J]. J Nurs Sci, 2007,22(2):66–67.\n\n【7】[42] R H , R R R I .\n\n【8】卫生, 2008, 29(12): 1163–1165.\n\n【9】DONG B, HUO Z P. Prevention and treatment of abnormal spinal curvature in children and adolescents [J]. Chin J Sch Health, 2008, 29(12):1163–1165.\n\n【10】[43] 陈玉娟 , 李立 , 杨惠玲 , 等 . 石家庄儿童脊柱側弯现状及影响因\n 素分析[J]. 中国学校卫生 ,2021 ,42(11) ; 1674–1678.\n\n【11】CHEN Y J , LI L , YANG H L , et al. Current status and influencing factors of scoliosis of children in Shijiazhuang [J]. Chin J Sch\n Health , 2021 , 42( 11 ) : 1674–1678.\n\n【12】[44] 胡妤,周劲松,王卓慧,等. 成都市青羊区小学儿童特发性脊柱 側夸現状及其相关因素分析[J]. 中国儿童保健杂志 , 2022, 30(6):617–621.\n\n【13】HU T,ZHOU J S, WANG Z H, et al. Current situation and related\n\n【14】 factors of idiopathic scoliosis in primary school children from Qingyang district Chengdu [ J ]. Chin J Child Health Care , 2022 , 30(6):617–621.\n\n【15】[45] 张翠娴 , 项明强 , 侯晓晖 , 等 . 脊柱侧夸青少年社会支持自我 效能与健康行为的关系[J]. 中国学校卫生, 2016, 37(10) : 1523–1525.\n\n【16】ZHANG C X, XIANG M Q, HOU X H, et al. Relationships of social support with general self–efficacy and health–promoting lifestyle among adolescents with scoliosis [J]. Chin J Sch Health, 2016, 37( 10): 1523–1525.\n\n【17】[46] 筹被英 . 中药新药临床研究指导原则(试行)[$]. 北京 : 中国医 药科技出版社 ,2002 : 383.\n\n【18】ZHENG X Y. Guiding principles for clinical research of new traditional Chinese medicine (trial) [S]. Beijing; China Health Media Group, 2002 : 383.\n\n【19】[47] 孙传兴 : 临床疾病诊断依据治愈好转标准[M]. 北京 : 人民军 医出版社 , 2006 : 411.\n\n【20】SUN C X. Cure and improvement criteria of Clinical disease diagnosis [M]. Beijing: People's Military Medical Publishing House,\n 2006;411.\n\n【21】## Clinical Practice Guidelines For Idiopathic Scoliosis In Children And Adolescents Of Traditional Chinese Medicine\n\n【22】\n LI Li ', YU Shaohong\", ZHOU Xia 1 , WANG Mingyue 1 , YU Juan 3 , WANG Shengchun 4 , LI Nianhu 3 , LIU Yuanfeng 3 , CHANG Yulin 1 1 The Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250001, China ; 2 School of Medicine, Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250355, China: ² Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250014, China: 4 Provincial Hospital of Shandong First Medical University , Jinan, Shandong 250021, China *Correspondence: YU Shaohong, E-mail: sutcm2006@163.com\n\n【23】 ABSTRACT Idiopathic scoliosis in children and adolescents refers to the development of unexplained scoliosis during childhood and adolescence. Chinese medicine rehabilitation is one of the effective methods to prevent its occurrence and improve clinical symptoms. In order to standardize the diagnosis and treatment of scoliosis in children and adolescents in China, to increase the importance of scoliosis in children and adolescents in society, and to ensure the standardization of Chinese medicine rehabilitation treatment, the expert group wrote this guideline based on the concept and method of evidence-based medicine and combined with expert evidence and clinical evaluation, in accordance with the rules for reporting clinical treatment guidelines. This guideline covers the technical scope, normative references, terms and definitions (Cobb angle,idiopathic scoliosis,functional scoliosis, trunk rotation angle, weak linkage, core muscle training,and Du-moxibustion), clinical diagnosis (clinical symptoms, clinical assessment,and imaging), TCM identification and typing, rehabilitation treatment [TCM rehabilitation treatment (internal Chinese medicine, Tui-na therapy, moxibustion,acupuncture therapy needle knife therapy, and Chinese medicine rehabilitation treatment (Chinese medicine internal medicine, Tui-na therapy, moxibustion,acupuncture therapy, acupuncture, traditional Chinese gongfu), modern rehabilitation therapy (physical factor therapy, exercise therapy, brace therapy and psychotherapy), prevention and management of functional scoliosis], and efficacy evaluation are standardized. This guideline can provide standardized consultation and treatment procedures for Chinese medicine rehabilitation treatment of idiopathic scoliosis in children and adolescents in various rehabilitation institutions at all levels in China,other Chinese medicine hospitals or general hospitals in the departments of rehabilitation and pediatrics, and rehabilitation therapists, and provide a reliable evidence reference for clinical decision-making practice, with good clinical applicability, safety and effectiveness.\n\n【24】KEY WORDS idiopathic scoliosis; Chinese medicine rehabilitation; children and adolescents; clinical practice; guideline DOI:10.3724/SP.J.1329.2023.04002", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "[38] 翰林东 , 李明 . 青少年特发性脊柱侧弯非手术治疗研究进", "bbox": [65.0, 105.0, 375.0, 120.0]}, {"text": "展[J]. 医学信息,2018,31(8):28-30.", "bbox": [92.0, 121.0, 264.0, 133.0]}], "type": "List-item", "position": 1}, {"raw_context": [{"text": "HAN L D, LI M. Progress in non–operative treatment of adoles-", "bbox": [92.0, 135.0, 377.0, 151.0]}, {"text": "cent idiopathic scoliosis [J]. Med Inf, 2018, 31(8): 28–30.", "bbox": [92.0, 151.0, 347.0, 165.0]}, {"text": "[39] 朱泽章 , 邱男 , 王斌 , 等 . 青少年特发性脊柱側凸的支具治", "bbox": [65.0, 166.0, 377.0, 180.0]}, {"text": "$[J]. 中华骨科杂志,2004,24(5):276-280.", "bbox": [92.0, 181.0, 295.0, 195.0]}, {"text": "ZHU Z Z, QIU Y, WANG B, et al. Clinical outcomes of bracing in", "bbox": [92.0, 197.0, 377.0, 210.0]}, {"text": "adolescent idiopathic scoliosis [J]. Chin J Orthop, 2004, 24(5):", "bbox": [93.0, 213.0, 376.0, 225.0]}, {"text": "276–280.", "bbox": [94.0, 228.0, 136.0, 240.0]}, {"text": "[40] BRIGHAM E M, ARMSTRONG D G. Motivations for compliance", "bbox": [65.0, 242.0, 377.0, 256.0]}, {"text": "with bracing in adolescent idiopathic scoliosis [J]. Spine Deform,", "bbox": [94.0, 258.0, 375.0, 271.0]}, {"text": "2017,5(1):46–51.", "bbox": [93.0, 273.0, 179.0, 286.0]}, {"text": "[41] 陈小芹 . 全程健康教育在三维矫形术治疗脊柱侧凸患者中的", "bbox": [65.0, 287.0, 377.0, 302.0]}, {"text": "应用[J] . 护理学杂志 , 2007 , 22(2):66-67.", "bbox": [92.0, 303.0, 284.0, 318.0]}, {"text": "CHEN X Q. Perioperative health education of the scoliosis pa-", "bbox": [92.0, 318.0, 377.0, 332.0]}, {"text": "tients treated by three–dimensional correction [J]. J Nurs Sci,", "bbox": [92.0, 333.0, 377.0, 348.0]}, {"text": "2007,22(2):66–67.", "bbox": [93.0, 349.0, 185.0, 363.0]}, {"text": "[42] R H , R R R I .", "bbox": [65.0, 364.0, 376.0, 379.0]}, {"text": "卫生, 2008, 29(12): 1163–1165.", "bbox": [94.0, 380.0, 237.0, 393.0]}, {"text": "DONG B, HUO Z P. Prevention and treatment of abnormal spinal", "bbox": [92.0, 395.0, 377.0, 409.0]}, {"text": "curvature in children and adolescents [J]. Chin J Sch Health,", "bbox": [93.0, 410.0, 375.0, 424.0]}, {"text": "2008, 29(12):1163–1165.", "bbox": [93.0, 425.0, 210.0, 438.0]}, {"text": "[43] 陈玉娟 , 李立 , 杨惠玲 , 等 . 石家庄儿童脊柱側弯现状及影响因", "bbox": [65.0, 440.0, 377.0, 455.0]}], "type": "Text", "position": 2}, {"raw_context": [{"text": "素分析[J]. 中国学校卫生 ,2021 ,42(11) ; 1674–1678.", "bbox": [94.0, 456.0, 333.0, 470.0]}, {"text": "CHEN Y J , LI L , YANG H L , et al. Current status and influencing", "bbox": [92.0, 471.0, 377.0, 484.0]}, {"text": "factors of scoliosis of children in Shijiazhuang [J]. Chin J Sch", "bbox": [92.0, 486.0, 377.0, 499.0]}], "type": "List-item", "position": 3}, {"raw_context": [{"text": "Health , 2021 , 42( 11 ) : 1674–1678.", "bbox": [429.0, 105.0, 579.0, 119.0]}, {"text": "[44] 胡妤,周劲松,王卓慧,等. 成都市青羊区小学儿童特发性脊柱", "bbox": [401.0, 120.0, 712.0, 134.0]}, {"text": "側夸現状及其相关因素分析[J]. 中国儿童保健杂志 , 2022,", "bbox": [429.0, 135.0, 712.0, 150.0]}, {"text": "30(6):617–621.", "bbox": [429.0, 152.0, 504.0, 164.0]}, {"text": "HU T,ZHOU J S, WANG Z H, et al. Current situation and related", "bbox": [428.0, 166.0, 713.0, 180.0]}], "type": "List-item", "position": 4}, {"raw_context": [{"text": "factors of idiopathic scoliosis in primary school children from Qin-", "bbox": [428.0, 181.0, 712.0, 195.0]}, {"text": "gyang district Chengdu [ J ]. Chin J Child Health Care , 2022 ,", "bbox": [429.0, 196.0, 712.0, 210.0]}, {"text": "30(6):617–621.", "bbox": [429.0, 212.0, 505.0, 225.0]}, {"text": "[45] 张翠娴 , 项明强 , 侯晓晖 , 等 . 脊柱侧夸青少年社会支持自我", "bbox": [400.0, 227.0, 712.0, 242.0]}, {"text": "效能与健康行为的关系[J]. 中国学校卫生, 2016, 37(10) :", "bbox": [429.0, 242.0, 712.0, 257.0]}, {"text": "1523–1525.", "bbox": [429.0, 259.0, 482.0, 271.0]}, {"text": "ZHANG C X, XIANG M Q, HOU X H, et al. Relationships of so-", "bbox": [428.0, 272.0, 712.0, 287.0]}, {"text": "cial support with general self–efficacy and health–promoting life-", "bbox": [427.0, 287.0, 712.0, 302.0]}, {"text": "style among adolescents with scoliosis [J]. Chin J Sch Health,", "bbox": [429.0, 303.0, 711.0, 317.0]}, {"text": "2016, 37( 10): 1523–1525.", "bbox": [429.0, 318.0, 547.0, 332.0]}, {"text": "[46] 筹被英 . 中药新药临床研究指导原则(试行)[$]. 北京 : 中国医", "bbox": [401.0, 333.0, 712.0, 348.0]}, {"text": "药科技出版社 ,2002 : 383.", "bbox": [429.0, 349.0, 546.0, 363.0]}, {"text": "ZHENG X Y. Guiding principles for clinical research of new tradi-", "bbox": [428.0, 364.0, 712.0, 378.0]}, {"text": "tional Chinese medicine (trial) [S]. Beijing; China Health Media", "bbox": [428.0, 380.0, 713.0, 394.0]}, {"text": "Group, 2002 : 383.", "bbox": [427.0, 395.0, 507.0, 409.0]}, {"text": "[47] 孙传兴 : 临床疾病诊断依据治愈好转标准[M]. 北京 : 人民军", "bbox": [400.0, 410.0, 712.0, 424.0]}, {"text": "医出版社 , 2006 : 411.", "bbox": [428.0, 425.0, 525.0, 438.0]}, {"text": "SUN C X. Cure and improvement criteria of Clinical disease diag-", "bbox": [428.0, 441.0, 712.0, 455.0]}, {"text": "nosis [M]. Beijing: People's Military Medical Publishing House,", "bbox": [428.0, 456.0, 710.0, 469.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "2006;411.", "bbox": [429.0, 471.0, 477.0, 484.0]}], "type": "List-item", "position": 6}, {"raw_context": [{"text": "Clinical Practice Guidelines for Idiopathic Scoliosis in Children", "bbox": [65.0, 525.0, 503.0, 543.0]}, {"text": "and Adolescents of Traditional Chinese Medicine", "bbox": [65.0, 544.0, 404.0, 561.0]}], "type": "Section-header", "position": 7}, {"raw_context": [{"text": "LI Li ', YU Shaohong\", ZHOU Xia 1 , WANG Mingyue 1 , YU Juan 3 , WANG Shengchun 4 , LI Nianhu 3 , LIU Yuanfeng 3 , CHANG Yulin 1", "bbox": [65.0, 581.0, 702.0, 597.0]}, {"text": "1 The Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250001, China ;", "bbox": [65.0, 597.0, 643.0, 612.0]}, {"text": "2 School of Medicine, Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250355, China:", "bbox": [65.0, 611.0, 581.0, 627.0]}, {"text": "² Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250014, China:", "bbox": [65.0, 626.0, 587.0, 641.0]}, {"text": "4 Provincial Hospital of Shandong First Medical University , Jinan, Shandong 250021, China", "bbox": [65.0, 640.0, 502.0, 657.0]}, {"text": "*Correspondence: YU Shaohong, E-mail: sutcm2006@163.com", "bbox": [66.0, 656.0, 379.0, 670.0]}], "type": "Text", "position": 8}, {"raw_context": [{"text": "ABSTRACT Idiopathic scoliosis in children and adolescents refers to the development of unexplained scoliosis during childhood", "bbox": [65.0, 684.0, 713.0, 698.0]}, {"text": "and adolescence. Chinese medicine rehabilitation is one of the effective methods to prevent its occurrence and improve clinical", "bbox": [65.0, 699.0, 713.0, 713.0]}, {"text": "symptoms. In order to standardize the diagnosis and treatment of scoliosis in children and adolescents in China, to increase the im-", "bbox": [65.0, 714.0, 712.0, 729.0]}, {"text": "portance of scoliosis in children and adolescents in society, and to ensure the standardization of Chinese medicine rehabilitation treat-", "bbox": [65.0, 729.0, 712.0, 743.0]}, {"text": "ment, the expert group wrote this guideline based on the concept and method of evidence-based medicine and combined with expert", "bbox": [65.0, 744.0, 713.0, 757.0]}, {"text": "evidence and clinical evaluation, in accordance with the rules for reporting clinical treatment guidelines. This guideline covers the", "bbox": [65.0, 758.0, 713.0, 771.0]}, {"text": "technical scope, normative references, terms and definitions (Cobb angle,idiopathic scoliosis,functional scoliosis, trunk rotation an-", "bbox": [65.0, 773.0, 712.0, 786.0]}, {"text": "gle, weak linkage, core muscle training,and Du-moxibustion), clinical diagnosis (clinical symptoms, clinical assessment,and imag-", "bbox": [65.0, 787.0, 712.0, 801.0]}, {"text": "ing), TCM identification and typing, rehabilitation treatment [TCM rehabilitation treatment (internal Chinese medicine, Tui-na thera-", "bbox": [65.0, 802.0, 712.0, 816.0]}, {"text": "py, moxibustion,acupuncture therapy needle knife therapy, and Chinese medicine rehabilitation treatment (Chinese medicine internal", "bbox": [65.0, 817.0, 712.0, 831.0]}, {"text": "medicine, Tui-na therapy, moxibustion,acupuncture therapy, acupuncture, traditional Chinese gongfu), modern rehabilitation therapy", "bbox": [65.0, 832.0, 712.0, 845.0]}, {"text": "(physical factor therapy, exercise therapy, brace therapy and psychotherapy), prevention and management of functional scoliosis],", "bbox": [65.0, 846.0, 712.0, 860.0]}, {"text": "and efficacy evaluation are standardized. This guideline can provide standardized consultation and treatment procedures for Chinese", "bbox": [65.0, 861.0, 712.0, 875.0]}, {"text": "medicine rehabilitation treatment of idiopathic scoliosis in children and adolescents in various rehabilitation institutions at all levels", "bbox": [65.0, 876.0, 712.0, 890.0]}, {"text": "in China,other Chinese medicine hospitals or general hospitals in the departments of rehabilitation and pediatrics, and rehabilitation", "bbox": [65.0, 890.0, 712.0, 904.0]}, {"text": "therapists, and provide a reliable evidence reference for clinical decision-making practice, with good clinical applicability, safety and", "bbox": [65.0, 904.0, 713.0, 919.0]}, {"text": "effectiveness.", "bbox": [66.0, 921.0, 131.0, 933.0]}, {"text": "KEY WORDS idiopathic scoliosis; Chinese medicine rehabilitation; children and adolescents; clinical practice; guideline", "bbox": [65.0, 933.0, 666.0, 947.0]}, {"text": "DOI:10.3724/SP.J.1329.2023.04002", "bbox": [65.0, 948.0, 245.0, 962.0]}], "type": "Text", "position": 9}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/骨科/指南/中医康复临床实践指南·儿童青少年特发性脊柱侧弯.pdf", "page_num": 8}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": null, "type3": null, "type4": null, "type5": null, "type6": "信息有用性#0#24#参考文献"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:42", "update_time": "2024-05-07 21:33:56"}
{"id": 1082610, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 738, "source_info": {"seq_id": "d5ddba86-3a46-4ed7-a4b5-871a5572604c", "title": null, "text": "【0】页码:4\n of iodinated contrast is a concern, expedited MRI with MRA is an alternative. Time-of-flight MRA is of lesser quality and may overestimate the degree of cervical carotid stenosis compared with gadolinium-enhanced MRA. 27 Although time-of-flight is suitable for screening purposes, gadolinium-enhanced MRA neck is preferred in patients who can safely receive gadolinium contrast.\n\n【1】Duplex carotid ultrasound and transcranial Doppler are noncontrast options to evaluate cervical and intracranial vessels, respectively, but may not be available in the ED. Admission to a 24-hour observation or an inpatient unit are typically required to obtain these studies. Digital subtraction angiography, although considered the gold standard to assess cerebral vasculature, is invasive and should not be used to screen for carotid stenosis.\n\n【2】## Laboratory And Cardiac Testing, Neurology Consultation\n\n【3】\n Point-of-care blood glucose testing should be performed for all patients with suspected TIA to rule out hypoglycemia, a known stroke mimic. A complete blood count, chemistry panel, hemoglobin A1c, and lipid profile can help identify potential risk factors. A nonfasting lipid profile is acceptable to identify hyperlipidemia as a risk factor. 28 In addition, patients >50 years of age with visual, complaints may benefit from screening with erythrocyte sedimentation rate and C-reactive protein to assess for temporal arteritis. Other workups, including for infectious or toxic/metabolic processes, could be performed if such diagnoses are suspected.\n\n【4】Telemetry, troponin assays, and electrocardiography are warranted on all patients with TIA given the shared risk factors for myocardial infarction and ischemic stroke, and to screen for AF. Initial electrocardiography detects AF in up to 7% of patients with ischemic stroke and TIA, but longer cardiac monitoring results in higher detection rates, especially among patients with palpitations or structural heart disease. 29 Focal neuro¬ logical symptoms in the absence of vasculopathy may suggest a cardioembolic process. Detection of AF is important to guide medical management and prevent future events. 30 In patients with TIA/stroke in whom a cardioembolic source is suspected, the American Heart Association/American Stroke Association recommends prolonged rhythm monitoring (30 days) within 6 months of the event. 17 This can be coordinated through cardiology, vascular neurology, primary care, or, if possible, the ED. The role of routine transthoracic echocardiogram for patients with TIA has not been well established but is often performed to identify a source of cardiac embolism and structural abnormalities associated with arrhythmia (eg, left atrial dilation). 16 If suspicion for a cardioembolic process is low and the patient is otherwise safe for discharge, a transthoracic echocardiogram could be\n\n【5】 arranged as an expedited outpatient study (ideally within 1 week).\n\n【6】When available, a neurology (preferably vascular neurology) consultation, either in person or through telemedicine, is a central part of the evaluation of patients with suspected TIA. The involvement of early neurology consultation has been associated with lower 90-day and 1-year mortality rates. 31 Multiple studies have demon¬ strated noninferiority of telemedicine neurology evalua¬ tions compared with traditional in-person evaluations in terms of patient and caregiver satisfaction. 32 If early neurology consultation is not possible, consider establishing a mechanism by which an appointment with a neurolo¬ gist, ideally within 48 hours but no later than a week after TIA, can be scheduled given the high risk of stroke in the days after TIA. 33\n\n【7】## Considerations For Clinical Practice\n\n【8】 • NCCT is insensitive to rule out small acute ischemic strokes but can help rule out TIA mimics.\n\n【9】MRI with DWI is the preferred imaging modality to rule out acute infarct. If MRI with DWI can be obtained without delay for patients with TIA, NCCT can be safely avoided. 34 NCCT and CTA can be performed together to eval¬ uate for hemorrhage and symptomatic stenosis.\n\n【10】CTA is safe in patients with chronic kidney disease, .\n\n【11】and the risk of acute kidney injury related to con¬ trast administration is low.\n\n【12】Extended cardiac monitoring in selected patients is helpful to evaluate for potential sources of car¬ diac embolism.\n\n【13】Patients benefit from early neurology consultation; preferably in the ED or rapid follow-up within 1-week after the TIA.\n\n【14】## Risk Stratification\n\n【15】\n The use of validated risk scores as risk stratification tools for suspected TIA have gained wider acceptance. 45 An ideal scale for stroke risk prediction after TIA is one that is easy to calculate, has high predictive value, can categorize patients into clinically distinct risk groups, has been validated, and has broad generalizability. Several TIA risk stratification instruments are available to help predict the short-term stroke risk for individual patients and to guide disposition (Table 3). It is critical, however, for physicians to be aware of the limitations of the vari¬ ous TIA risk-scoring systems, including accuracy (ie, not incorporating high-risk features such as carotid stenosis, recurrent TIA, or AF) and external validity.\n\n【16】The most widely used risk stratification tool is Age, Blood Pressure, Clinical Features, Duration, and Diabetes (ABCD 2 ) score. It can be used to stratify patients into low-, moderate-, or high-risk groups on the basis of\n\n【17】 : '9 AmnidaH uo Aq aro slemnolede//dnd mort bebeohrwoO", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "of iodinated contrast is a concern, expedited MRI with", "bbox": [63.0, 77.0, 380.0, 93.0]}, {"text": "MRA is an alternative. Time-of-flight MRA is of lesser", "bbox": [63.0, 93.0, 380.0, 108.0]}, {"text": "quality and may overestimate the degree of cervical", "bbox": [63.0, 110.0, 380.0, 124.0]}, {"text": "carotid stenosis compared with gadolinium-enhanced", "bbox": [63.0, 126.0, 380.0, 140.0]}, {"text": "MRA. 27 Although time-of-flight is suitable for screen-", "bbox": [63.0, 142.0, 378.0, 156.0]}, {"text": "ing purposes, gadolinium-enhanced MRA neck is pre-", "bbox": [63.0, 158.0, 378.0, 173.0]}, {"text": "ferred in patients who can safely receive gadolinium", "bbox": [63.0, 174.0, 380.0, 188.0]}, {"text": "contrast.", "bbox": [63.0, 191.0, 117.0, 204.0]}, {"text": "Duplex carotid ultrasound and transcranial Doppler", "bbox": [79.0, 205.0, 380.0, 220.0]}, {"text": "are noncontrast options to evaluate cervical and intracra-", "bbox": [63.0, 222.0, 378.0, 236.0]}, {"text": "nial vessels, respectively, but may not be available in the", "bbox": [63.0, 238.0, 380.0, 252.0]}, {"text": "ED. Admission to a 24-hour observation or an inpatient", "bbox": [63.0, 254.0, 380.0, 268.0]}, {"text": "unit are typically required to obtain these studies. Digital", "bbox": [63.0, 270.0, 380.0, 284.0]}, {"text": "subtraction angiography, although considered the gold", "bbox": [63.0, 286.0, 380.0, 301.0]}, {"text": "standard to assess cerebral vasculature, is invasive and", "bbox": [63.0, 302.0, 380.0, 316.0]}, {"text": "should not be used to screen for carotid stenosis.", "bbox": [63.0, 318.0, 342.0, 333.0]}], "type": "Text", "position": 2}, {"raw_context": [{"text": "Laboratory and Cardiac Testing, Neurology", "bbox": [63.0, 357.0, 344.0, 374.0]}, {"text": "Consultation", "bbox": [63.0, 376.0, 151.0, 392.0]}], "type": "Section-header", "position": 3}, {"raw_context": [{"text": "Point-of-care blood glucose testing should be performed", "bbox": [63.0, 399.0, 380.0, 413.0]}, {"text": "for all patients with suspected TIA to rule out hypogly-", "bbox": [63.0, 414.0, 378.0, 429.0]}, {"text": "cemia, a known stroke mimic. A complete blood count,", "bbox": [63.0, 431.0, 380.0, 445.0]}, {"text": "chemistry panel, hemoglobin A1c, and lipid profile can", "bbox": [63.0, 447.0, 380.0, 461.0]}, {"text": "help identify potential risk factors. A nonfasting lipid pro-", "bbox": [63.0, 462.0, 378.0, 477.0]}, {"text": "file is acceptable to identify hyperlipidemia as a risk fac-", "bbox": [63.0, 479.0, 378.0, 493.0]}, {"text": "tor. 28 In addition, patients >50 years of age with visual,", "bbox": [63.0, 495.0, 380.0, 509.0]}, {"text": "complaints may benefit from screening with erythrocyte", "bbox": [63.0, 511.0, 380.0, 525.0]}, {"text": "sedimentation rate and C-reactive protein to assess for", "bbox": [63.0, 527.0, 378.0, 542.0]}, {"text": "temporal arteritis. Other workups, including for infectious", "bbox": [63.0, 542.0, 378.0, 558.0]}, {"text": "or toxic/metabolic processes, could be performed if such", "bbox": [63.0, 559.0, 380.0, 574.0]}, {"text": "diagnoses are suspected.", "bbox": [63.0, 575.0, 211.0, 589.0]}, {"text": "Telemetry, troponin assays, and electrocardiography", "bbox": [80.0, 591.0, 380.0, 605.0]}, {"text": "are warranted on all patients with TIA given the shared", "bbox": [63.0, 607.0, 380.0, 622.0]}, {"text": "risk factors for myocardial infarction and ischemic", "bbox": [63.0, 622.0, 380.0, 637.0]}, {"text": "stroke, and to screen for AF. Initial electrocardiogra-", "bbox": [63.0, 639.0, 378.0, 653.0]}, {"text": "phy detects AF in up to 7% of patients with ischemic", "bbox": [63.0, 655.0, 380.0, 669.0]}, {"text": "stroke and TIA, but longer cardiac monitoring results in", "bbox": [63.0, 671.0, 380.0, 685.0]}, {"text": "higher detection rates, especially among patients with", "bbox": [63.0, 687.0, 380.0, 702.0]}, {"text": "palpitations or structural heart disease. 29 Focal neuro¬", "bbox": [63.0, 702.0, 378.0, 717.0]}, {"text": "logical symptoms in the absence of vasculopathy may", "bbox": [63.0, 719.0, 380.0, 733.0]}, {"text": "suggest a cardioembolic process. Detection of AF is", "bbox": [63.0, 735.0, 380.0, 749.0]}, {"text": "important to guide medical management and prevent", "bbox": [63.0, 751.0, 380.0, 765.0]}, {"text": "future events. 30 In patients with TIA/stroke in whom a", "bbox": [63.0, 767.0, 380.0, 782.0]}, {"text": "cardioembolic source is suspected, the American Heart", "bbox": [63.0, 783.0, 380.0, 797.0]}, {"text": "Association/American Stroke Association recommends", "bbox": [63.0, 799.0, 380.0, 813.0]}, {"text": "prolonged rhythm monitoring (30 days) within 6 months", "bbox": [63.0, 815.0, 380.0, 829.0]}, {"text": "of the event. 17 This can be coordinated through cardiol-", "bbox": [63.0, 831.0, 378.0, 845.0]}, {"text": "ogy, vascular neurology, primary care, or, if possible, the", "bbox": [63.0, 847.0, 380.0, 862.0]}, {"text": "ED. The role of routine transthoracic echocardiogram for", "bbox": [63.0, 863.0, 380.0, 877.0]}, {"text": "patients with TIA has not been well established but is", "bbox": [63.0, 879.0, 380.0, 893.0]}, {"text": "often performed to identify a source of cardiac embolism", "bbox": [63.0, 895.0, 380.0, 910.0]}, {"text": "and structural abnormalities associated with arrhythmia", "bbox": [63.0, 911.0, 380.0, 925.0]}, {"text": "(eg, left atrial dilation). 16 If suspicion for a cardioem-", "bbox": [63.0, 926.0, 378.0, 942.0]}, {"text": "bolic process is low and the patient is otherwise safe", "bbox": [63.0, 943.0, 380.0, 957.0]}, {"text": "for discharge, a transthoracic echocardiogram could be", "bbox": [63.0, 958.0, 380.0, 975.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": "arranged as an expedited outpatient study (ideally within", "bbox": [399.0, 77.0, 716.0, 93.0]}, {"text": "1 week).", "bbox": [401.0, 94.0, 451.0, 108.0]}, {"text": "When available, a neurology (preferably vascular neu-", "bbox": [414.0, 109.0, 715.0, 124.0]}, {"text": "rology) consultation, either in person or through tele-", "bbox": [399.0, 126.0, 714.0, 140.0]}, {"text": "medicine, is a central part of the evaluation of patients", "bbox": [399.0, 142.0, 716.0, 156.0]}, {"text": "with suspected TIA. The involvement of early neurology", "bbox": [399.0, 158.0, 716.0, 173.0]}, {"text": "consultation has been associated with lower 90-day and", "bbox": [399.0, 174.0, 716.0, 188.0]}, {"text": "1-year mortality rates. 31 Multiple studies have demon¬", "bbox": [401.0, 189.0, 715.0, 204.0]}, {"text": "strated noninferiority of telemedicine neurology evalua¬", "bbox": [399.0, 205.0, 715.0, 220.0]}, {"text": "tions compared with traditional in-person evaluations in", "bbox": [399.0, 222.0, 716.0, 236.0]}, {"text": "terms of patient and caregiver satisfaction. 32 If early neu-", "bbox": [399.0, 238.0, 715.0, 253.0]}, {"text": "rology consultation is not possible, consider establishing", "bbox": [399.0, 254.0, 716.0, 268.0]}, {"text": "a mechanism by which an appointment with a neurolo¬", "bbox": [399.0, 270.0, 715.0, 284.0]}, {"text": "gist, ideally within 48 hours but no later than a week after", "bbox": [399.0, 286.0, 716.0, 301.0]}, {"text": "TIA, can be scheduled given the high risk of stroke in the", "bbox": [400.0, 302.0, 716.0, 316.0]}, {"text": "days after TIA. 33", "bbox": [399.0, 318.0, 492.0, 332.0]}], "type": "Text", "position": 6}, {"raw_context": [{"text": "Considerations for Clinical Practice", "bbox": [399.0, 357.0, 632.0, 374.0]}], "type": "Section-header", "position": 7}, {"raw_context": [{"text": "• NCCT is insensitive to rule out small acute ischemic", "bbox": [414.0, 381.0, 716.0, 395.0]}, {"text": "strokes but can help rule out TIA mimics.", "bbox": [428.0, 397.0, 658.0, 411.0]}, {"text": "MRI with DWI is the preferred imaging modality", "bbox": [426.0, 413.0, 716.0, 427.0]}, {"text": "to rule out acute infarct. If MRI with DWI can be", "bbox": [428.0, 428.0, 716.0, 443.0]}, {"text": "obtained without delay for patients with TIA, NCCT", "bbox": [427.0, 445.0, 715.0, 459.0]}, {"text": "can be safely avoided. 34", "bbox": [427.0, 461.0, 563.0, 475.0]}, {"text": "NCCT and CTA can be performed together to eval¬", "bbox": [425.0, 476.0, 715.0, 492.0]}, {"text": "uate for hemorrhage and symptomatic stenosis.", "bbox": [428.0, 494.0, 697.0, 507.0]}, {"text": "CTA is safe in patients with chronic kidney disease,", "bbox": [426.0, 508.0, 716.0, 523.0]}, {"text": ".", "bbox": [414.0, 511.0, 424.0, 520.0]}, {"text": "and the risk of acute kidney injury related to con¬", "bbox": [428.0, 525.0, 715.0, 539.0]}, {"text": "trast administration is low.", "bbox": [427.0, 542.0, 574.0, 555.0]}, {"text": "Extended cardiac monitoring in selected patients", "bbox": [426.0, 556.0, 716.0, 571.0]}, {"text": "is helpful to evaluate for potential sources of car¬", "bbox": [427.0, 573.0, 715.0, 588.0]}, {"text": "diac embolism.", "bbox": [427.0, 588.0, 517.0, 603.0]}, {"text": "Patients benefit from early neurology consulta-", "bbox": [427.0, 603.0, 715.0, 621.0]}, {"text": "tion; preferably in the ED or rapid follow-up within", "bbox": [428.0, 621.0, 716.0, 635.0]}, {"text": "1-week after the TIA.", "bbox": [429.0, 637.0, 549.0, 651.0]}], "type": "List-item", "position": 8}, {"raw_context": [{"text": "RISK STRATIFICATION", "bbox": [400.0, 678.0, 566.0, 697.0]}], "type": "Section-header", "position": 9}, {"raw_context": [{"text": "The use of validated risk scores as risk stratification tools", "bbox": [401.0, 702.0, 716.0, 717.0]}, {"text": "for suspected TIA have gained wider acceptance. 45 An", "bbox": [399.0, 719.0, 716.0, 733.0]}, {"text": "ideal scale for stroke risk prediction after TIA is one that", "bbox": [398.0, 735.0, 716.0, 749.0]}, {"text": "is easy to calculate, has high predictive value, can cat-", "bbox": [398.0, 751.0, 715.0, 765.0]}, {"text": "egorize patients into clinically distinct risk groups, has", "bbox": [399.0, 767.0, 716.0, 782.0]}, {"text": "been validated, and has broad generalizability. Several", "bbox": [398.0, 783.0, 716.0, 797.0]}, {"text": "TIA risk stratification instruments are available to help", "bbox": [400.0, 799.0, 716.0, 813.0]}, {"text": "predict the short-term stroke risk for individual patients", "bbox": [399.0, 815.0, 716.0, 829.0]}, {"text": "and to guide disposition (Table 3). It is critical, however,", "bbox": [399.0, 831.0, 716.0, 845.0]}, {"text": "for physicians to be aware of the limitations of the vari¬", "bbox": [399.0, 847.0, 715.0, 862.0]}, {"text": "ous TIA risk-scoring systems, including accuracy (ie, not", "bbox": [399.0, 863.0, 716.0, 877.0]}, {"text": "incorporating high-risk features such as carotid stenosis,", "bbox": [398.0, 879.0, 716.0, 893.0]}, {"text": "recurrent TIA, or AF) and external validity.", "bbox": [399.0, 895.0, 631.0, 910.0]}, {"text": "The most widely used risk stratification tool is Age,", "bbox": [416.0, 911.0, 716.0, 925.0]}, {"text": "Blood Pressure, Clinical Features, Duration, and Diabe-", "bbox": [399.0, 927.0, 715.0, 942.0]}, {"text": "tes (ABCD 2 ) score. It can be used to stratify patients", "bbox": [399.0, 943.0, 716.0, 957.0]}, {"text": "into low-, moderate-, or high-risk groups on the basis of", "bbox": [399.0, 959.0, 716.0, 973.0]}], "type": "Text", "position": 10}, {"raw_context": [{"text": ": '9 AmnidaH uo Aq aro slemnolede//dnd mort bebeohrwoO", "bbox": [18.0, 526.0, 38.0, 781.0]}], "type": "Text", "position": 11}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/神经科/共识/2023 AHA科学声明：急诊科短暂性脑缺血发作的诊断、检查和风险降低(1).pdf", "page_num": 4}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type2": "多余换行#4#5#echocardiogram could be和arranged as an expedited 是一句话\n缺少换行#9#9#NCCT and CTA can be performed另起一行\n多余换行#10#12#CTA is safe in patients和of car¬ diac embolism是一句话\n多余标点#4#4#neuro¬ logical为换行连接字符，可以不需要\n多余标点#6#6#demon¬ strated和evalua¬ tions和neurolo¬ gist为换行连接字符，可以不需要\n多余标点#9#9#eval¬ uate为换行连接字符，可以不需要\n多余标点#11#11#con¬ trast为换行连接字符，可以不需要\n多余标点#12#12#car¬ diac为换行连接字符，可以不需要\n多余标点#15#15#vari¬ ous为换行连接字符，可以不需要\n", "type3": "无关文本#0#17#enhanced MRA. 27 部分段落末尾，以及句末的数字问题无关噪声应用全文", "type6": "有用性#17#17# : '9 AmnidaH uo Aq aro slemnolede//dnd mort bebeohrwoO为页脚内容"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:42", "update_time": "2024-05-07 22:43:39"}
{"id": 1082609, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 738, "source_info": {"seq_id": "e3498ad9-aa65-4926-bcc2-29067d23b5e6", "title": null, "text": "【0】页码:25\n 84 Shimizu H, Homma Y, Norii T, et al . Incidence of adverse events among elderly vs non-elderly patients during procedural sedation and analgesia with propofol. Am J Emerg Med 2021;44:411–4.\n\n【1】1000 1000 Tao Y, Sun M, Miao M, et al. High flow nasal cannula for patients undergoing bronchoscopy and gastrointestinal endoscopy: a systematic review and metaanalysis. Front Surg 2022;9:949614.\n\n【2】Turnbull D. High-flow nasal oxygen, procedural sedation, and clinical governance.\n\n【3】1086 Minerva Anestesiol 2022;88:407–10.\n\n【4】87 Practice guidelines for moderate procedural sedation and analgesia 2018: a report by the American Society of Anesthesiologists task force on moderate procedural sedation and analgesia, the American Association of Oral and Maxillofacial Surgeons, American College of Radiology, American Dental Association, American Society of Dentist Anesthesiologists, and Society of Interventional Radiology.\n\n【5】Anesthesiology 2018;128:437–79.\n\n【6】88 Herzog M, Rudzki M, Plößl S, et al. Depth of sedation during drug induced sedation endoscopy monitored by bispectral index® and cerebral state index®. Sleep Breath 2021;25:1029–35.\n\n【7】89 Lin Y-J, Wang Y-C, Huang H-H, et al . Target-controlled propofol infusion with or without bispectral index monitoring of sedation during advanced gastrointestinal endoscopy. J Gastroenterol Hepatol 2020;35:1189–95.\n\n【8】90 Conway A, Ersotelos S, Sutherland J, et al. Forced air warming during sedation in the cardiac catheterisation laboratory: a randomised controlled trial. Heart 2018;104:685-90.\n\n【9】91 GMC. Good medical practice. n.d. Available: https://www.gmc-uk.org/ethicalguidance/ethical-guidance-for-doctors/good-medical-practicehttps://www.gmc-uk.\n\n【10】org/ethical-guidance/ethical-guidance-for-doctors/good-medical-practice 19292 RCSEng. Good surgical practice. n.d. Available: https://www.rcseng.ac.uk/ standards-and-research/gsp/https://www.rcseng.ac.uk/standards-and-research/ gsp/ 1939 ) World Health Organization. Global patient safety action plan 2021–2030:towards eliminating avoidable harm E ahealth care. 2021. Available: https://www.who.int/ teams/integrated-health-services/patient-safety/policy/global-patient-safety-actionplan 94 Pickard S, Marshall M, Rogers A, et al. User involvement in clinical governance.\n\n【11】Health Expect 2002;5:187–98.\n\n【12】95 Veenstra GL, Ahaus K, Welker GA, et al . Rethinking clinical governance: healthcare professionals' views: a Delphi study. BMJ Open 2017;7:e012591.\n\n【13】19696 Thomas M. The evidence base for clinical governance. J Eval Clin Pract 2002;8:251-4.\n\n【14】Long DM. Competency based residency training: the next advance in graduate medical education. Acta Neurochir Suppl 2001;78:153–8.\n\n【15】98 Crespo J, Terán Á. Endoscopy and sedation: an inseparable binomial for the gastroenterologist. Rev Esp Enferm Dig 2018;110:250–2.\n\n【16】99 Bailey CR, Ahuja M, Bartholomew K, et al. Guidelines for day-case surgery 2019: guidelines from the Association of Anaesthetists and the British Association of Day Surgery. Anaesthesia 2019;74:778–92.\n\n【17】100 GMC-UK. Domain 3: communication partnership and teamwork - ethical guidance - GMC. 2012. Available: https://www.gmc-uk.org/ethical-guidance/ethical-guidancefor-doctors/good-medical-practice/domain-3---communication-partnership-andteamwork#paragraph-39 101 NICE. British national formulary (BNF). n.d. Available: https://bnf.nice.org.uk/ 102 RCoA. Caring for someone recovering from a general anaesthetic or sedation.\n\n【18】2021: 1–3. Available: https://www.rcoa.ac.uk/sites/default/files/documents/2021- 11/12-SedationCarer2021web.pdf 103 Royal College of Anaesthetists. Sedation explained . 2021: 6–7. Available: https:// www.rcoa.ac.uk/sites/default/files/documents/2019-10/12-SedationExplainedweb.\n\n【19】104 Latto IP, Molloy MJ, Rosen M. Arterial concentrations of nitrous oxide during intermittent patient-controlled inhalation of 50 percent nitrous oxide in oxygen (Entonox) during the first stage of labour. Br J Anaesth 1973;45:1029–34.\n\n【20】105 The essential guide © BOC: living healthcare. n.d. Available: https://www.boconline.\n\n【21】co.uk/wcsstore/UK_BOC_Industrial_Ntl_Store/pdf/downloads/Entonox-essentialguide.pdf 106 Sebastian S, Dhar A, Baddeley R, et al . Green endoscopy: British Society of Gastroenterology (BSG), Joint Accreditation Group (JAG) and Centre for Sustainable Health (CSH) joint consensus on practical measures for environmental sustainability in endoscopy. Gut 2023;72:12–26.\n\n【22】107 Behrens A, Kreuzmayr A, Manner H, et al . Acute sedation-associated complications in GI endoscopy (ProSed 2 study): results from the prospective multicentre electronic registry of sedation-associated complications. Gut 2019;68:445–52.\n\n【23】108 Qadeer MA, Vargo JJ, Khandwala F, et al. Propofol versus traditional sedative agents for gastrointestinal endoscopy: a meta-analysis. Clin Gastroenterol Hepatol 2005;3:1049–56.\n\n【24】109 Sharma VK, Nguyen CC, Crowell MD, et al. A national study of cardiopulmonary unplanned events after GI endoscopy. Gastrointest Endosc 2007;66:27–34.\n\n【25】110 Rex DK, Deenadayalu VP, Eid E, et al. Endoscopist-directed administration of propofol: a worldwide safety experience. Gastroenterology 2009;137:1229–37.\n\n【26】Sidhu R, et al. Gut 2023;0:1–27. doi:10.1136/gutjnl-2023-330396\n\n【27】 111 Behrens A, Labenz J, Schuler A, et al . How safe is sedation in gastrointestinal endoscopy? A multicentre analysis of 388,404 endoscopies and analysis of data from prospective registries of complications managed by members of the working group of leading hospital gastroenterologists (ALGK). Z Gastroenterol 2013;51:432–6.\n\n【28】112 Jun J, Han JI, Choi AL, et al. Adverse events of conscious sedation using midazolam for gastrointestinal endoscopy. Anesth Pain Med 2019;14:401–6.\n\n【29】113 Cashman JN, Dolin SJ. Respiratory and haemodynamic effects of acute postoperative pain management: evidence from published data. Br J Anaesth 2004;93:212–23.\n\n【30】114 Khanna AK, Overdyk FJ, Greening C, et al. Respiratory depression in low acuity hospital settings-seeking answers from the PRODIGY trial. J Crit Care 2018;47:80–7.\n\n【31】115 Ayad S, Khanna AK, Iqbal SU, et al. Characterisation and monitoring of postoperative respiratory depression: current approaches and future considerations. Br J Anaesth 2019;123:378–91.\n\n【32】116   Overdyk FJ, Carter R, Maddox RR, et al. Continuous oximetry/capnometry monitoring reveals frequent desaturation and bradypnea during patient-controlled analgesia.\n\n【33】Anesth Analg 2007;105:412–8.\n\n【34】117 Overdyk F, Dahan A, Roozekrans M, et al. Opioid-induced respiratory depression in the acute care setting: a compendium of case reports. Pain Manag 2014;4:317–25.\n\n【35】118 Practice guidelines for the prevention, detection, and management of respiratory depression associated with neuraxial opioid administration: an updated report by the American Society of Anesthesiologists task force on neuraxial opioids and the American Society of Regional Anesthesia and Pain Medicine. Anesthesiology 2016;124:535–52.\n\n【36】119   Morse J, Bamias G. Ability to reverse deeper levels of unintended sedation. Digestion 2010;82:94–6.\n\n【37】120 National endoscopy database. n.d. Available: https://nedpilot.thejag.org.uk/ 121 Naloxone hydrochloride _ drugs _ BNF _ NICE. n.d. Available: https://bnf.nice.org.\n\n【38】uk/drug/naloxone-hydrochloride.html#sideEffects 122 Balsells F, Wyllie R, Kay M, et al. Use of conscious sedation for lower and upper gastrointestinal endoscopic examinations in children, adolescents, and young adults: a twelve-year review. Gastrointest Endosc 1997;45:375–80.\n\n【39】123 Greenwald B. Narcan use in the endoscopy lab: an important component of patient safety. Gastroenterol Nurs 2004;27:20–1.\n\n【40】124 Miller DL, Wall RT. Fentanyl and diazepam for analgesia and sedation during radiologic special procedures. Radiology 1987;162:195–8.\n\n【41】125 American Association for Study of Liver Diseases, American College of Gastroenterology, American Gastroenterological Association Institute, et al.\n\n【42】Multisociety sedation curriculum for gastrointestinal endoscopy. Gastrointest Endosc 2012;76:e1–25.\n\n【43】126 Mora CT, Torjman M, White PF. Sedative and ventilatory effects of midazolam infusion: effect of flumazenil reversal. Can J Anaesth 1995;42:677–84.\n\n【44】127 Waring JP, Baron TH, Hirota WK, et al. Guidelines for conscious sedation and monitoring during gastrointestinal endoscopy. Gastrointest Endosc 2003;58:317–22.\n\n【45】128 Flumazenil _ drugs _ BNF _ NICE. n.d. Available: https://bnf.nice.org.uk/drugs/ flumazenil/ 129 Fassoulaki A, Theodoraki K, Melemeni A. Pharmacology of sedation agents and reversal agents. Digestion 2010;82:80–3.\n\n【46】130 Spivey WH. Flumazenil and seizures: analysis of 43 cases. Clin Ther 1992;14:292-305.\n\n【47】Mordel A, Winkler E, Almog S, et al. Seizures after flumazenil administration in a 131 case of combined benzodiazepine and tricyclic antidepressant overdose. Crit Care Med 1992;20:1733–4.\n\n【48】132 Kankaria A, Lewis JH, Ginsberg G, et al. Flumazenil reversal of psychomotor impairment due to midazolam or diazepam for conscious sedation for upper endoscopy. Gastrointest Endosc 1996;44:416–21.\n\n【49】133 Spinelli P, Pacilli P, Sicignano A. Clinical use of flumazenil (Ro 15-1788) after endoscopic procedures. Endoscopy 1988;20:86.\n\n【50】134 Mathus-Vliegen EMH, de Jong L, Kos-Foekema HA. Significant and safe shortening of the recovery time after flumazenil-reversed midazolam sedation. Dig Dis Sci 2014;59:1717–25.\n\n【51】135 Alarcón Fernández O, Baudet Arteaga JS, Sánchez del Río A, et al. Utility of routine use of reversion after sedation in outpatient colonoscopy. Gastroenterol Hepatol 2005;28:10–4.\n\n【52】136 Lee SP, Sung I-K, Kim JH, et al. Efficacy and safety of flumazenil injection for the reversal of midazolam sedation after elective outpatient endoscopy. J Dig Dis 2018;19:93–101.\n\n【53】137 Penninga El, Graudal N, Ladekarl MB, et al. Adverse events associated with flumazenil treatment for the management of suspected benzodiazepine intoxication- -a systematic review with meta-analyses of randomised trials. Basic Clin Pharmacol Toxicol 2016;118:37–44.\n\n【54】138 Lamont T, Matthew L, Cousins D, et al. Avoiding midazolam overdose: summary of a safety report from the National Patient Safety Agency. BMJ 2009;339:b4459.\n\n【55】139 NHS Improvement. Never events list 2018 ( revised in 2021 ). 2021: 1–22. Available: https://improvement.nhs.uk/documents/2266/Never_Events_list_2018_FINAL_v5.\n\n【56】pdf", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "84 Shimizu H, Homma Y, Norii T, et al . Incidence of adverse events among elderly vs", "bbox": [58.0, 61.0, 370.0, 74.0]}, {"text": "non-elderly patients during procedural sedation and analgesia with propofol. Am J", "bbox": [76.0, 75.0, 377.0, 87.0]}, {"text": "Emerg Med 2021;44:411–4.", "bbox": [76.0, 86.0, 181.0, 97.0]}, {"text": "1000 1000", "bbox": [58.0, 97.0, 73.0, 109.0]}, {"text": "Tao Y, Sun M, Miao M, et al. High flow nasal cannula for patients undergoing", "bbox": [74.0, 97.0, 358.0, 111.0]}, {"text": "bronchoscopy and gastrointestinal endoscopy: a systematic review and meta-", "bbox": [76.0, 110.0, 358.0, 122.0]}, {"text": "analysis. Front Surg 2022;9:949614.", "bbox": [76.0, 123.0, 213.0, 134.0]}, {"text": "Turnbull D. High-flow nasal oxygen, procedural sedation, and clinical governance.", "bbox": [75.0, 134.0, 371.0, 146.0]}, {"text": "1086", "bbox": [59.0, 135.0, 72.0, 145.0]}, {"text": "Minerva Anestesiol 2022;88:407–10.", "bbox": [75.0, 146.0, 215.0, 157.0]}, {"text": "87 Practice guidelines for moderate procedural sedation and analgesia 2018: a report", "bbox": [58.0, 157.0, 377.0, 171.0]}, {"text": "by the American Society of Anesthesiologists task force on moderate procedural", "bbox": [75.0, 170.0, 368.0, 182.0]}, {"text": "sedation and analgesia, the American Association of Oral and Maxillofacial", "bbox": [75.0, 181.0, 351.0, 193.0]}, {"text": "Surgeons, American College of Radiology, American Dental Association, American", "bbox": [75.0, 195.0, 374.0, 206.0]}, {"text": "Society of Dentist Anesthesiologists, and Society of Interventional Radiology.", "bbox": [76.0, 206.0, 355.0, 217.0]}, {"text": "Anesthesiology 2018;128:437–79.", "bbox": [76.0, 219.0, 206.0, 229.0]}, {"text": "88 Herzog M, Rudzki M, Plößl S, et al. Depth of sedation during drug induced sedation", "bbox": [59.0, 230.0, 381.0, 242.0]}, {"text": "endoscopy monitored by bispectral index® and cerebral state index®. Sleep Breath", "bbox": [76.0, 242.0, 382.0, 254.0]}, {"text": "2021;25:1029–35.", "bbox": [76.0, 255.0, 146.0, 266.0]}, {"text": "89 Lin Y-J, Wang Y-C, Huang H-H, et al . Target-controlled propofol infusion with or", "bbox": [59.0, 266.0, 363.0, 277.0]}, {"text": "without bispectral index monitoring of sedation during advanced gastrointestinal", "bbox": [75.0, 278.0, 373.0, 291.0]}, {"text": "endoscopy. J Gastroenterol Hepatol 2020;35:1189–95.", "bbox": [76.0, 290.0, 279.0, 302.0]}, {"text": "90 Conway A, Ersotelos S, Sutherland J, et al. Forced air warming during sedation", "bbox": [59.0, 301.0, 361.0, 314.0]}, {"text": "in the cardiac catheterisation laboratory: a randomised controlled trial. Heart", "bbox": [75.0, 315.0, 355.0, 326.0]}, {"text": "2018;104:685-90.", "bbox": [76.0, 326.0, 147.0, 337.0]}, {"text": "91 GMC. Good medical practice. n.d. Available: https://www.gmc-uk.org/ethical-", "bbox": [58.0, 336.0, 358.0, 352.0]}, {"text": "guidance/ethical-guidance-for-doctors/good-medical-practicehttps://www.gmc-uk.", "bbox": [76.0, 350.0, 376.0, 362.0]}, {"text": "org/ethical-guidance/ethical-guidance-for-doctors/good-medical-practice", "bbox": [75.0, 362.0, 342.0, 374.0]}, {"text": "19292", "bbox": [58.0, 374.0, 73.0, 385.0]}, {"text": "RCSEng. Good surgical practice. n.d. Available: https://www.rcseng.ac.uk/", "bbox": [73.0, 375.0, 352.0, 386.0]}, {"text": "standards-and-research/gsp/https://www.rcseng.ac.uk/standards-and-research/", "bbox": [75.0, 386.0, 374.0, 398.0]}, {"text": "gsp/", "bbox": [76.0, 400.0, 93.0, 409.0]}, {"text": "1939 )", "bbox": [59.0, 410.0, 74.0, 421.0]}, {"text": "World Health Organization. Global patient safety action plan 2021–2030:towards", "bbox": [72.0, 410.0, 375.0, 422.0]}, {"text": "eliminating avoidable harm E ahealth care. 2021. Available: https://www.who.int/", "bbox": [75.0, 421.0, 375.0, 434.0]}, {"text": "teams/integrated-health-services/patient-safety/policy/global-patient-safety-action-", "bbox": [75.0, 435.0, 377.0, 446.0]}, {"text": "plan", "bbox": [76.0, 448.0, 94.0, 456.0]}, {"text": "94 Pickard S, Marshall M, Rogers A, et al. User involvement in clinical governance.", "bbox": [58.0, 458.0, 363.0, 471.0]}, {"text": "Health Expect 2002;5:187–98.", "bbox": [76.0, 470.0, 190.0, 482.0]}, {"text": "95 Veenstra GL, Ahaus K, Welker GA, et al . Rethinking clinical governance: healthcare", "bbox": [59.0, 481.0, 377.0, 494.0]}, {"text": "professionals' views: a Delphi study. BMJ Open 2017;7:e012591.", "bbox": [78.0, 495.0, 314.0, 506.0]}, {"text": "19696", "bbox": [59.0, 506.0, 74.0, 517.0]}, {"text": "Thomas M. The evidence base for clinical governance. J Eval Clin Pract", "bbox": [74.0, 506.0, 332.0, 518.0]}, {"text": "2002;8:251-4.", "bbox": [76.0, 518.0, 134.0, 530.0]}, {"text": "Long DM. Competency based residency training: the next advance in graduate", "bbox": [74.0, 530.0, 361.0, 542.0]}, {"text": "medical education. Acta Neurochir Suppl 2001;78:153–8.", "bbox": [76.0, 542.0, 289.0, 554.0]}, {"text": "98 Crespo J, Terán Á. Endoscopy and sedation: an inseparable binomial for the", "bbox": [59.0, 555.0, 350.0, 566.0]}, {"text": "gastroenterologist. Rev Esp Enferm Dig 2018;110:250–2.", "bbox": [76.0, 566.0, 287.0, 578.0]}, {"text": "99 Bailey CR, Ahuja M, Bartholomew K, et al. Guidelines for day-case surgery 2019:", "bbox": [59.0, 578.0, 371.0, 591.0]}, {"text": "guidelines from the Association of Anaesthetists and the British Association of Day", "bbox": [76.0, 590.0, 377.0, 602.0]}, {"text": "Surgery. Anaesthesia 2019;74:778–92.", "bbox": [76.0, 601.0, 222.0, 613.0]}, {"text": "100 GMC-UK. Domain 3: communication partnership and teamwork - ethical guidance", "bbox": [54.0, 614.0, 377.0, 626.0]}, {"text": "- GMC. 2012. Available: https://www.gmc-uk.org/ethical-guidance/ethical-guidance-", "bbox": [76.0, 626.0, 382.0, 638.0]}, {"text": "for-doctors/good-medical-practice/domain-3---communication-partnership-and-", "bbox": [75.0, 638.0, 367.0, 651.0]}, {"text": "teamwork#paragraph-39", "bbox": [76.0, 649.0, 170.0, 663.0]}, {"text": "101 NICE. British national formulary (BNF). n.d. Available: https://bnf.nice.org.uk/", "bbox": [54.0, 661.0, 356.0, 675.0]}, {"text": "102", "bbox": [54.0, 675.0, 74.0, 686.0]}, {"text": "RCoA. Caring for someone recovering from a general anaesthetic or sedation.", "bbox": [72.0, 675.0, 358.0, 686.0]}, {"text": "2021: 1–3. Available: https://www.rcoa.ac.uk/sites/default/files/documents/2021-", "bbox": [76.0, 686.0, 374.0, 698.0]}, {"text": "11/12-SedationCarer2021web.pdf", "bbox": [76.0, 699.0, 205.0, 711.0]}, {"text": "103 Royal College of Anaesthetists. Sedation explained . 2021: 6–7. Available: https://", "bbox": [54.0, 711.0, 372.0, 722.0]}, {"text": "www.rcoa.ac.uk/sites/default/files/documents/2019-10/12-SedationExplainedweb.", "bbox": [76.0, 723.0, 377.0, 736.0]}, {"text": "104 Latto IP, Molloy MJ, Rosen M. Arterial concentrations of nitrous oxide during", "bbox": [54.0, 746.0, 355.0, 758.0]}, {"text": "intermittent patient-controlled inhalation of 50 percent nitrous oxide in oxygen", "bbox": [76.0, 759.0, 365.0, 771.0]}, {"text": "(Entonox) during the first stage of labour. Br J Anaesth 1973;45:1029–34.", "bbox": [75.0, 771.0, 348.0, 782.0]}, {"text": "105", "bbox": [54.0, 782.0, 72.0, 794.0]}, {"text": "The essential guide © BOC: living healthcare. n.d. Available: https://www.boconline.", "bbox": [74.0, 783.0, 382.0, 796.0]}, {"text": "co.uk/wcsstore/UK_BOC_Industrial_Ntl_Store/pdf/downloads/Entonox-essential-", "bbox": [75.0, 795.0, 371.0, 807.0]}, {"text": "guide.pdf", "bbox": [76.0, 808.0, 113.0, 818.0]}, {"text": "106", "bbox": [54.0, 819.0, 73.0, 830.0]}, {"text": "Sebastian S, Dhar A, Baddeley R, et al . Green endoscopy: British Society of", "bbox": [74.0, 819.0, 347.0, 832.0]}, {"text": "Gastroenterology (BSG), Joint Accreditation Group (JAG) and Centre for Sustainable", "bbox": [75.0, 831.0, 382.0, 842.0]}, {"text": "Health (CSH) joint consensus on practical measures for environmental sustainability", "bbox": [75.0, 844.0, 381.0, 856.0]}, {"text": "in endoscopy. Gut 2023;72:12–26.", "bbox": [75.0, 856.0, 205.0, 867.0]}, {"text": "107 Behrens A, Kreuzmayr A, Manner H, et al . Acute sedation-associated", "bbox": [54.0, 866.0, 336.0, 878.0]}, {"text": "complications in GI endoscopy (ProSed 2 study): results from the prospective", "bbox": [75.0, 879.0, 367.0, 892.0]}, {"text": "multicentre electronic registry of sedation-associated complications. Gut", "bbox": [76.0, 891.0, 351.0, 904.0]}, {"text": "2019;68:445–52.", "bbox": [76.0, 903.0, 144.0, 915.0]}, {"text": "108 Qadeer MA, Vargo JJ, Khandwala F, et al. Propofol versus traditional sedative", "bbox": [54.0, 915.0, 357.0, 927.0]}, {"text": "agents for gastrointestinal endoscopy: a meta-analysis. Clin Gastroenterol Hepatol", "bbox": [76.0, 927.0, 377.0, 940.0]}, {"text": "2005;3:1049–56.", "bbox": [76.0, 939.0, 142.0, 951.0]}, {"text": "109 Sharma VK, Nguyen CC, Crowell MD, et al. A national study of cardiopulmonary", "bbox": [54.0, 951.0, 367.0, 962.0]}, {"text": "unplanned events after GI endoscopy. Gastrointest Endosc 2007;66:27–34.", "bbox": [76.0, 964.0, 353.0, 976.0]}, {"text": "110 Rex DK, Deenadayalu VP, Eid E, et al. Endoscopist-directed administration of", "bbox": [54.0, 975.0, 353.0, 987.0]}, {"text": "propofol: a worldwide safety experience. Gastroenterology 2009;137:1229–37.", "bbox": [76.0, 987.0, 367.0, 1000.0]}, {"text": "Sidhu R, et al. Gut 2023;0:1–27. doi:10.1136/gutjnl-2023-330396", "bbox": [54.0, 1011.0, 317.0, 1022.0]}], "type": "Text", "position": 0}, {"raw_context": [{"text": "111 Behrens A, Labenz J, Schuler A, et al . How safe is sedation in gastrointestinal", "bbox": [408.0, 60.0, 709.0, 73.0]}, {"text": "endoscopy? A multicentre analysis of 388,404 endoscopies and analysis of", "bbox": [428.0, 74.0, 703.0, 84.0]}, {"text": "data from prospective registries of complications managed by members of the", "bbox": [428.0, 85.0, 713.0, 97.0]}, {"text": "working group of leading hospital gastroenterologists (ALGK). Z Gastroenterol", "bbox": [429.0, 97.0, 715.0, 109.0]}, {"text": "2013;51:432–6.", "bbox": [430.0, 110.0, 491.0, 121.0]}, {"text": "112", "bbox": [408.0, 121.0, 426.0, 132.0]}, {"text": "Jun J, Han JI, Choi AL, et al. Adverse events of conscious sedation using midazolam", "bbox": [427.0, 121.0, 733.0, 133.0]}, {"text": "for gastrointestinal endoscopy. Anesth Pain Med 2019;14:401–6.", "bbox": [430.0, 134.0, 669.0, 144.0]}, {"text": "113 Cashman JN, Dolin SJ. Respiratory and haemodynamic effects of acute postoperative", "bbox": [408.0, 145.0, 737.0, 157.0]}, {"text": "pain management: evidence from published data. Br J Anaesth 2004;93:212–23.", "bbox": [430.0, 157.0, 727.0, 169.0]}, {"text": "114", "bbox": [408.0, 169.0, 428.0, 180.0]}, {"text": "Khanna AK, Overdyk FJ, Greening C, et al. Respiratory depression in low acuity", "bbox": [426.0, 170.0, 712.0, 181.0]}, {"text": "hospital settings-seeking answers from the PRODIGY trial. J Crit Care 2018;47:80–7.", "bbox": [429.0, 181.0, 739.0, 193.0]}, {"text": "115 Ayad S, Khanna AK, Iqbal SU, et al. Characterisation and monitoring of postoperative", "bbox": [408.0, 194.0, 739.0, 205.0]}, {"text": "respiratory depression: current approaches and future considerations. Br J Anaesth", "bbox": [428.0, 206.0, 730.0, 217.0]}, {"text": "2019;123:378–91.", "bbox": [430.0, 218.0, 501.0, 230.0]}, {"text": "116   Overdyk FJ, Carter R, Maddox RR, et al. Continuous oximetry/capnometry monitoring", "bbox": [408.0, 230.0, 738.0, 242.0]}, {"text": "reveals frequent desaturation and bradypnea during patient-controlled analgesia.", "bbox": [428.0, 241.0, 727.0, 255.0]}, {"text": "Anesth Analg 2007;105:412–8.", "bbox": [430.0, 255.0, 546.0, 266.0]}, {"text": "117 Overdyk F, Dahan A, Roozekrans M, et al. Opioid-induced respiratory depression", "bbox": [408.0, 266.0, 729.0, 277.0]}, {"text": "in the acute care setting: a compendium of case reports. Pain Manag", "bbox": [428.0, 279.0, 686.0, 290.0]}, {"text": "2014;4:317–25.", "bbox": [430.0, 291.0, 492.0, 301.0]}, {"text": "118 Practice guidelines for the prevention, detection, and management of respiratory", "bbox": [408.0, 301.0, 724.0, 315.0]}, {"text": "depression associated with neuraxial opioid administration: an updated report", "bbox": [428.0, 315.0, 716.0, 326.0]}, {"text": "by the American Society of Anesthesiologists task force on neuraxial opioids and", "bbox": [428.0, 326.0, 723.0, 337.0]}, {"text": "the American Society of Regional Anesthesia and Pain Medicine. Anesthesiology", "bbox": [429.0, 338.0, 721.0, 351.0]}, {"text": "2016;124:535–52.", "bbox": [430.0, 350.0, 500.0, 361.0]}, {"text": "119   Morse J, Bamias G. Ability to reverse deeper levels of unintended sedation. Digestion", "bbox": [408.0, 361.0, 739.0, 376.0]}, {"text": "2010;82:94–6.", "bbox": [430.0, 375.0, 487.0, 386.0]}, {"text": "120 National endoscopy database. n.d. Available: https://nedpilot.thejag.org.uk/", "bbox": [408.0, 386.0, 705.0, 398.0]}, {"text": "121 Naloxone hydrochloride _ drugs _ BNF _ NICE. n.d. Available: https://bnf.nice.org.", "bbox": [408.0, 399.0, 728.0, 410.0]}, {"text": "uk/drug/naloxone-hydrochloride.html#sideEffects", "bbox": [430.0, 410.0, 609.0, 422.0]}, {"text": "122 Balsells F, Wyllie R, Kay M, et al. Use of conscious sedation for lower and upper", "bbox": [408.0, 421.0, 719.0, 434.0]}, {"text": "gastrointestinal endoscopic examinations in children, adolescents, and young adults:", "bbox": [430.0, 435.0, 737.0, 446.0]}, {"text": "a twelve-year review. Gastrointest Endosc 1997;45:375–80.", "bbox": [429.0, 446.0, 651.0, 458.0]}, {"text": "123", "bbox": [408.0, 458.0, 428.0, 470.0]}, {"text": "Greenwald B. Narcan use in the endoscopy lab: an important component of patient", "bbox": [426.0, 458.0, 735.0, 471.0]}, {"text": "safety. Gastroenterol Nurs 2004;27:20–1.", "bbox": [429.0, 470.0, 583.0, 482.0]}, {"text": "124 Miller DL, Wall RT. Fentanyl and diazepam for analgesia and sedation during", "bbox": [408.0, 481.0, 707.0, 494.0]}, {"text": "radiologic special procedures. Radiology 1987;162:195–8.", "bbox": [430.0, 495.0, 642.0, 506.0]}, {"text": "125 American Association for Study of Liver Diseases, American College of", "bbox": [408.0, 506.0, 684.0, 518.0]}, {"text": "Gastroenterology, American Gastroenterological Association Institute, et al.", "bbox": [428.0, 519.0, 704.0, 530.0]}, {"text": "Multisociety sedation curriculum for gastrointestinal endoscopy. Gastrointest Endosc", "bbox": [429.0, 530.0, 737.0, 542.0]}, {"text": "2012;76:e1–25.", "bbox": [430.0, 542.0, 492.0, 553.0]}, {"text": "126 Mora CT, Torjman M, White PF. Sedative and ventilatory effects of midazolam", "bbox": [408.0, 554.0, 710.0, 566.0]}, {"text": "infusion: effect of flumazenil reversal. Can J Anaesth 1995;42:677–84.", "bbox": [429.0, 566.0, 688.0, 578.0]}, {"text": "127", "bbox": [408.0, 578.0, 428.0, 590.0]}, {"text": "Waring JP, Baron TH, Hirota WK, et al. Guidelines for conscious sedation", "bbox": [426.0, 578.0, 692.0, 590.0]}, {"text": "and monitoring during gastrointestinal endoscopy. Gastrointest Endosc", "bbox": [430.0, 590.0, 688.0, 602.0]}, {"text": "2003;58:317–22.", "bbox": [430.0, 601.0, 497.0, 613.0]}, {"text": "128", "bbox": [408.0, 614.0, 427.0, 626.0]}, {"text": "Flumazenil _ drugs _ BNF _ NICE. n.d. Available: https://bnf.nice.org.uk/drugs/", "bbox": [426.0, 614.0, 716.0, 626.0]}, {"text": "flumazenil/", "bbox": [429.0, 626.0, 472.0, 638.0]}, {"text": "129 Fassoulaki A, Theodoraki K, Melemeni A. Pharmacology of sedation agents and", "bbox": [408.0, 637.0, 718.0, 651.0]}, {"text": "reversal agents. Digestion 2010;82:80–3.", "bbox": [430.0, 650.0, 580.0, 662.0]}, {"text": "130 Spivey WH. Flumazenil and seizures: analysis of 43 cases. Clin Ther", "bbox": [408.0, 662.0, 672.0, 674.0]}, {"text": "1992;14:292-305.", "bbox": [430.0, 675.0, 500.0, 686.0]}, {"text": "Mordel A, Winkler E, Almog S, et al. Seizures after flumazenil administration in a", "bbox": [426.0, 686.0, 723.0, 698.0]}, {"text": "131", "bbox": [408.0, 687.0, 426.0, 697.0]}, {"text": "case of combined benzodiazepine and tricyclic antidepressant overdose. Crit Care", "bbox": [429.0, 698.0, 727.0, 711.0]}, {"text": "Med 1992;20:1733–4.", "bbox": [429.0, 710.0, 514.0, 721.0]}, {"text": "132 Kankaria A, Lewis JH, Ginsberg G, et al. Flumazenil reversal of psychomotor", "bbox": [408.0, 721.0, 704.0, 735.0]}, {"text": "impairment due to midazolam or diazepam for conscious sedation for upper", "bbox": [430.0, 735.0, 707.0, 746.0]}, {"text": "endoscopy. Gastrointest Endosc 1996;44:416–21.", "bbox": [429.0, 746.0, 615.0, 758.0]}, {"text": "133", "bbox": [408.0, 758.0, 428.0, 770.0]}, {"text": "Spinelli P, Pacilli P, Sicignano A. Clinical use of flumazenil (Ro 15-1788) after", "bbox": [426.0, 758.0, 707.0, 770.0]}, {"text": "endoscopic procedures. Endoscopy 1988;20:86.", "bbox": [430.0, 770.0, 604.0, 782.0]}, {"text": "134 Mathus-Vliegen EMH, de Jong L, Kos-Foekema HA. Significant and safe shortening", "bbox": [408.0, 781.0, 731.0, 794.0]}, {"text": "of the recovery time after flumazenil-reversed midazolam sedation. Dig Dis Sci", "bbox": [429.0, 795.0, 715.0, 806.0]}, {"text": "2014;59:1717–25.", "bbox": [430.0, 806.0, 500.0, 818.0]}, {"text": "135 Alarcón Fernández O, Baudet Arteaga JS, Sánchez del Río A, et al. Utility of routine", "bbox": [408.0, 816.0, 731.0, 832.0]}, {"text": "use of reversion after sedation in outpatient colonoscopy. Gastroenterol Hepatol", "bbox": [430.0, 830.0, 722.0, 842.0]}, {"text": "2005;28:10–4.", "bbox": [430.0, 842.0, 486.0, 853.0]}, {"text": "136", "bbox": [408.0, 854.0, 427.0, 866.0]}, {"text": "Lee SP, Sung I-K, Kim JH, et al. Efficacy and safety of flumazenil injection for the", "bbox": [426.0, 854.0, 720.0, 866.0]}, {"text": "reversal of midazolam sedation after elective outpatient endoscopy. J Dig Dis", "bbox": [428.0, 865.0, 711.0, 880.0]}, {"text": "2018;19:93–101.", "bbox": [430.0, 879.0, 495.0, 891.0]}, {"text": "137", "bbox": [408.0, 891.0, 426.0, 902.0]}, {"text": "Penninga El, Graudal N, Ladekarl MB, et al. Adverse events associated with", "bbox": [427.0, 891.0, 704.0, 902.0]}, {"text": "flumazenil treatment for the management of suspected benzodiazepine intoxication-", "bbox": [430.0, 904.0, 738.0, 914.0]}, {"text": "-a systematic review with meta-analyses of randomised trials. Basic Clin Pharmacol", "bbox": [430.0, 915.0, 733.0, 927.0]}, {"text": "Toxicol 2016;118:37–44.", "bbox": [430.0, 927.0, 524.0, 938.0]}, {"text": "138", "bbox": [408.0, 939.0, 428.0, 951.0]}, {"text": "Lamont T, Matthew L, Cousins D, et al. Avoiding midazolam overdose: summary of a", "bbox": [426.0, 939.0, 736.0, 951.0]}, {"text": "safety report from the National Patient Safety Agency. BMJ 2009;339:b4459.", "bbox": [428.0, 951.0, 712.0, 963.0]}, {"text": "139 NHS Improvement. Never events list 2018 ( revised in 2021 ). 2021: 1–22. Available:", "bbox": [408.0, 962.0, 734.0, 976.0]}, {"text": "https://improvement.nhs.uk/documents/2266/Never_Events_list_2018_FINAL_v5.", "bbox": [428.0, 975.0, 731.0, 987.0]}, {"text": "pdf", "bbox": [428.0, 988.0, 444.0, 999.0]}], "type": "Text", "position": 2}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/消化科/_2023 BSG指南：胃肠内窥镜检查中的镇静.pdf", "page_num": 25}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": null, "type3": null, "type4": null, "type5": null, "type6": "有用性#0#56#参考文献的内容"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:42", "update_time": "2024-05-07 22:53:02"}
{"id": 1082608, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 738, "source_info": {"seq_id": "51feef6e-76b3-45ce-8d69-e20a0686498c", "title": null, "text": "【0】页码:43\n whose sole responsibility is to administer sedation, monitor the patient and address any sedationrelated issues and that if a dedicated sedationist is not used the operator-sedationist must be prepared to justify the decision ", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "whose sole responsibility is to administer sedation, monitor the patient and address any sedation-", "bbox": [146.0, 140.0, 679.0, 159.0]}, {"text": "related issues and that if a dedicated sedationist is not used the operator-sedationist must be", "bbox": [146.0, 165.0, 655.0, 183.0]}, {"text": "prepared to justify the decision ", "bbox": [146.0, 189.0, 323.0, 207.0]}], "type": "Text", "position": 3}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/消化科/_2023 BSG指南：胃肠内窥镜检查中的镇静.pdf", "page_num": 43}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": null, "type3": null, "type4": null, "type5": null, "type6": null}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:42", "update_time": "2024-05-07 17:55:34"}
{"id": 1082607, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 738, "source_info": {"seq_id": "cdbe620e-9cc0-4e8c-809e-48bffab902d3", "title": null, "text": "【0】页码:6\n Flowchart illustrating the patient journey. ASA, American Figure 1 Society of Anesthesiologists; BMI, body mass index.\n\n【1】 and Ireland. Based on stakeholder feedback, revised domains were constructed prior to starting the guideline.\n\n【2】These guidelines are based on a comprehensive literature search for key evidence over the last 10 years. Individual members of each section provided key search/MESH terms and references from Medline/PubMed/Embase were retrieved into a reference manager.\n\n【3】Section members developed PICO statements (where P stands for population/patient; I for intervention/indicator; C for comparator/control; and O for outcome) to inform searches for available evidence to support the statements. Assessment of the literature by the section members and the development of recommendations have been made according to the 'Grading of Recommendations, Assessment, Development and Evaluation (GRADE)' system. which was subsequently reviewed via a Delphi voting process. The clinical statements were adapted and/ or excluded during the iterative rounds during the Delphi voting process. The agreement that is given for the different statements refers to the last voting round in the Delphi process. A statement\n\n【4】## Levels Of Sedation Table 1\n\n【5】\n Moderate sedation/analgesia Minimal sedation anxiolysis ('conscious sedation') Deep sedation/analgesia General anaesthesia Purposeful response following Unrousable even with painful Normal response to verbal Purposeful response to verbal or tactile Responsiveness stimulation stimulation repeated or painful stimulation stimulus Airway Unaffected No intervention required Intervention may be required Intervention often required Spontaneous ventilation Unaffected Adequate May be inadequate Frequently inadequate While most sedatives in large doses can provide deeper levels of sedation, for many this would not be practical in routine use. The drugs used frequently that can provide a defined level of sedation are indicated.\n\n【6】fentanyl, 57 midazolam 57 propofol, 579 nitrous oxide 5\n\n【7】\n was accepted if at least 80% agreement was reached. If such agreement was not achieved, the GDG members discussed the statements during teleconferences and two face-to-face meetings and rephrased the statements to reflect the comments of the voting group. The guidelines were reviewed by AUGIS, ACPGBI, United Kingdom and Ireland EUS Society (UKIEUS), BSGNA, JAG and the RCoA with several revisions prior to endorsement.\n\n【8】These guidelines are intended to inform practising clinicians and all staff who are involved in the delivery of endoscopy and sedation. Figure 1 depicts the patient journey in relation to sedation. It is expected that these guidelines will be revised in 5-years' time.\n\n【9】## Type Of Sedation\n\n【10】\n 1. We recommend that sedation providers should tailor the doses dependent on patient factors, procedure type and duration, and complexity Grade of evidence: Moderate. Strength of recommendation: Strong.\n\n【11】Level of agreement: 92.3% 2.We recommend the provision of inhalational agents to provide the patient with an alternative to sedation Grade of evidence: Moderate. Strength of recommendation: Strong.\n\n【12】Level of agreement: 100% A number of drugs are routinely used within UK endoscopy services either on their own or in combination to provide differing levels of sedation (defined in table 1 ). The most frequently used are midazolam, fentanyl, pethidine, and propofol and each will be summarised briefly.\n\n【13】## Drug Selection\n\n【14】\n In the UK the vast majority of endoscopic procedures are performed either with oropharyngeal local anaesthetic sprays (upper GI) or intravenous sedation using mainly fentanyl and midazolam. 2 However, advanced and prolonged therapeutic procedures may be more successful and better tolerated if performed under propofol. High-quality evidence on selecting patients for deep sedation or general anaesthesia are lacking. 3 However, education delivered to staff concerning sedation may translate into reduced adverse events. 4\n\n【15】## Midazolam\n\n【16】\n Midazolam is a short-acting benzodiazepine with a short elimination half-life (1.5–2.5 h) and better retrograde amnesic effect than similar drugs such as diazepam. 5 Given intravenously, midazolam has onset at around 2 to 3 min and is metabolised into an active metabolite called α 1-hydroxymidazolam. Several factors may affect the metabolism of midazolam, including age (the elderly and young children), renal function, liver function", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "Flowchart illustrating the patient journey. ASA, American", "bbox": [104.0, 479.0, 368.0, 493.0]}, {"text": "Figure 1", "bbox": [54.0, 480.0, 101.0, 493.0]}, {"text": "Society of Anesthesiologists; BMI, body mass index.", "bbox": [53.0, 494.0, 290.0, 508.0]}], "type": "Caption", "position": 1}, {"raw_context": [{"text": "and Ireland. Based on stakeholder feedback, revised domains", "bbox": [53.0, 533.0, 387.0, 548.0]}, {"text": "were constructed prior to starting the guideline.", "bbox": [53.0, 548.0, 302.0, 563.0]}, {"text": "These guidelines are based on a comprehensive litera-", "bbox": [66.0, 563.0, 385.0, 577.0]}, {"text": "ture search for key evidence over the last 10 years. Individual", "bbox": [53.0, 578.0, 385.0, 592.0]}, {"text": "members of each section provided key search/MESH terms and", "bbox": [53.0, 593.0, 386.0, 606.0]}, {"text": "references from Medline/PubMed/Embase were retrieved into a", "bbox": [53.0, 607.0, 386.0, 620.0]}, {"text": "reference manager.", "bbox": [53.0, 622.0, 154.0, 635.0]}, {"text": "Section members developed PICO statements (where P", "bbox": [65.0, 636.0, 386.0, 651.0]}, {"text": "stands for population/patient; I for intervention/indicator; C", "bbox": [53.0, 651.0, 386.0, 666.0]}, {"text": "for comparator/control; and O for outcome) to inform searches", "bbox": [53.0, 667.0, 387.0, 680.0]}, {"text": "for available evidence to support the statements. Assessment of", "bbox": [53.0, 681.0, 386.0, 694.0]}, {"text": "the literature by the section members and the development of", "bbox": [54.0, 696.0, 387.0, 709.0]}, {"text": "recommendations have been made according to the 'Grading", "bbox": [53.0, 710.0, 387.0, 723.0]}, {"text": "of Recommendations, Assessment, Development and Evalua-", "bbox": [53.0, 724.0, 385.0, 738.0]}, {"text": "tion (GRADE)' system. which was subsequently reviewed via a", "bbox": [53.0, 739.0, 386.0, 753.0]}, {"text": "Delphi voting process. The clinical statements were adapted and/", "bbox": [53.0, 753.0, 385.0, 767.0]}, {"text": "or excluded during the iterative rounds during the Delphi voting", "bbox": [53.0, 769.0, 386.0, 782.0]}, {"text": "process. The agreement that is given for the different statements", "bbox": [53.0, 783.0, 387.0, 796.0]}, {"text": "refers to the last voting round in the Delphi process. A statement", "bbox": [53.0, 797.0, 386.0, 811.0]}], "type": "Text", "position": 2}, {"raw_context": [{"text": "Levels of sedation", "bbox": [106.0, 844.0, 191.0, 858.0]}, {"text": "Table 1", "bbox": [59.0, 845.0, 97.0, 857.0]}], "type": "Section-header", "position": 3}, {"raw_context": [{"text": "Moderate sedation/analgesia", "bbox": [303.0, 863.0, 428.0, 876.0]}, {"text": "Minimal sedation anxiolysis", "bbox": [176.0, 877.0, 295.0, 889.0]}, {"text": "('conscious sedation')", "bbox": [302.0, 878.0, 397.0, 889.0]}, {"text": "Deep sedation/analgesia", "bbox": [459.0, 877.0, 565.0, 889.0]}, {"text": "General anaesthesia", "bbox": [604.0, 877.0, 692.0, 889.0]}, {"text": "Purposeful response following", "bbox": [457.0, 894.0, 576.0, 906.0]}, {"text": "Unrousable even with painful", "bbox": [604.0, 894.0, 719.0, 906.0]}, {"text": "Normal response to verbal", "bbox": [176.0, 895.0, 279.0, 906.0]}, {"text": "Purposeful response to verbal or tactile", "bbox": [303.0, 895.0, 456.0, 907.0]}, {"text": "Responsiveness", "bbox": [59.0, 897.0, 120.0, 906.0]}, {"text": "stimulation", "bbox": [176.0, 908.0, 220.0, 920.0]}, {"text": "stimulation", "bbox": [303.0, 908.0, 348.0, 919.0]}, {"text": "repeated or painful stimulation", "bbox": [459.0, 908.0, 580.0, 920.0]}, {"text": "stimulus", "bbox": [604.0, 908.0, 638.0, 919.0]}, {"text": "Airway", "bbox": [59.0, 923.0, 87.0, 936.0]}, {"text": "Unaffected", "bbox": [176.0, 923.0, 220.0, 934.0]}, {"text": "No intervention required", "bbox": [303.0, 923.0, 399.0, 935.0]}, {"text": "Intervention may be required", "bbox": [459.0, 923.0, 573.0, 935.0]}, {"text": "Intervention often required", "bbox": [604.0, 923.0, 710.0, 935.0]}, {"text": "Spontaneous ventilation", "bbox": [59.0, 939.0, 154.0, 951.0]}, {"text": "Unaffected", "bbox": [176.0, 939.0, 220.0, 951.0]}, {"text": "Adequate", "bbox": [304.0, 939.0, 343.0, 951.0]}, {"text": "May be inadequate", "bbox": [459.0, 939.0, 535.0, 951.0]}, {"text": "Frequently inadequate", "bbox": [604.0, 939.0, 692.0, 951.0]}, {"text": "While most sedatives in large doses can provide deeper levels of sedation, for many this would not be practical in routine use. The drugs used frequently that can provide a", "bbox": [59.0, 957.0, 709.0, 969.0]}, {"text": "defined level of sedation are indicated.", "bbox": [59.0, 970.0, 208.0, 983.0]}, {"text": "fentanyl, 57 midazolam 57 propofol, 579 nitrous oxide 5", "bbox": [59.0, 983.0, 256.0, 994.0]}], "type": "Table", "position": 4}, {"raw_context": [{"text": "was accepted if at least 80% agreement was reached. If such", "bbox": [406.0, 60.0, 739.0, 75.0]}, {"text": "agreement was not achieved, the GDG members discussed the", "bbox": [406.0, 75.0, 740.0, 90.0]}, {"text": "statements during teleconferences and two face-to-face meetings", "bbox": [406.0, 91.0, 740.0, 105.0]}, {"text": "and rephrased the statements to reflect the comments of the", "bbox": [406.0, 105.0, 740.0, 119.0]}, {"text": "voting group. The guidelines were reviewed by AUGIS, ACPGBI,", "bbox": [406.0, 120.0, 740.0, 134.0]}, {"text": "United Kingdom and Ireland EUS Society (UKIEUS), BSGNA,", "bbox": [406.0, 135.0, 740.0, 149.0]}, {"text": "JAG and the RCoA with several revisions prior to endorsement.", "bbox": [406.0, 149.0, 738.0, 164.0]}, {"text": "These guidelines are intended to inform practising clinicians", "bbox": [419.0, 165.0, 740.0, 178.0]}, {"text": "and all staff who are involved in the delivery of endoscopy and", "bbox": [406.0, 180.0, 740.0, 193.0]}, {"text": "sedation. Figure 1 depicts the patient journey in relation to", "bbox": [406.0, 194.0, 741.0, 207.0]}, {"text": "sedation. It is expected that these guidelines will be revised in", "bbox": [406.0, 209.0, 741.0, 223.0]}, {"text": "5-years' time.", "bbox": [406.0, 224.0, 479.0, 238.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "Type of sedation", "bbox": [406.0, 256.0, 499.0, 273.0]}], "type": "Section-header", "position": 6}, {"raw_context": [{"text": "1. We recommend that sedation providers should tailor the doses", "bbox": [408.0, 272.0, 740.0, 286.0]}, {"text": "dependent on patient factors, procedure type and duration, and", "bbox": [406.0, 287.0, 740.0, 301.0]}, {"text": "complexity", "bbox": [406.0, 303.0, 467.0, 315.0]}, {"text": "Grade of evidence: Moderate. Strength of recommendation:", "bbox": [417.0, 315.0, 739.0, 330.0]}, {"text": "Strong.", "bbox": [406.0, 333.0, 445.0, 345.0]}, {"text": "Level of agreement: 92.3%", "bbox": [418.0, 346.0, 560.0, 360.0]}, {"text": "2.We recommend the provision of inhalational agents to", "bbox": [418.0, 360.0, 741.0, 375.0]}, {"text": "provide the patient with an alternative to sedation", "bbox": [406.0, 375.0, 670.0, 390.0]}, {"text": "Grade of evidence: Moderate. Strength of recommendation:", "bbox": [418.0, 390.0, 739.0, 405.0]}, {"text": "Strong.", "bbox": [406.0, 406.0, 445.0, 418.0]}, {"text": "Level of agreement: 100%", "bbox": [418.0, 420.0, 557.0, 433.0]}, {"text": "A number of drugs are routinely used within UK endoscopy", "bbox": [418.0, 434.0, 739.0, 448.0]}, {"text": "services either on their own or in combination to provide differing", "bbox": [406.0, 449.0, 740.0, 463.0]}, {"text": "levels of sedation (defined in table 1 ). The most frequently used", "bbox": [406.0, 463.0, 740.0, 478.0]}, {"text": "are midazolam, fentanyl, pethidine, and propofol and each will", "bbox": [406.0, 478.0, 740.0, 492.0]}, {"text": "be summarised briefly.", "bbox": [406.0, 493.0, 524.0, 506.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "Drug selection", "bbox": [406.0, 527.0, 479.0, 541.0]}], "type": "Section-header", "position": 8}, {"raw_context": [{"text": "In the UK the vast majority of endoscopic procedures are", "bbox": [406.0, 541.0, 740.0, 556.0]}, {"text": "performed either with oropharyngeal local anaesthetic sprays", "bbox": [406.0, 557.0, 740.0, 570.0]}, {"text": "(upper GI) or intravenous sedation using mainly fentanyl and", "bbox": [407.0, 573.0, 740.0, 585.0]}, {"text": "midazolam. 2 However, advanced and prolonged therapeutic", "bbox": [406.0, 586.0, 740.0, 601.0]}, {"text": "procedures may be more successful and better tolerated if", "bbox": [406.0, 601.0, 740.0, 615.0]}, {"text": "performed under propofol. High-quality evidence on selecting", "bbox": [406.0, 616.0, 740.0, 630.0]}, {"text": "patients for deep sedation or general anaesthesia are lacking. 3", "bbox": [406.0, 631.0, 735.0, 645.0]}, {"text": "However, education delivered to staff concerning sedation may", "bbox": [406.0, 645.0, 739.0, 660.0]}, {"text": "translate into reduced adverse events. 4", "bbox": [406.0, 660.0, 604.0, 675.0]}], "type": "Text", "position": 9}, {"raw_context": [{"text": "Midazolam", "bbox": [406.0, 695.0, 465.0, 708.0]}], "type": "Section-header", "position": 10}, {"raw_context": [{"text": "Midazolam is a short-acting benzodiazepine with a short elimi-", "bbox": [406.0, 709.0, 739.0, 723.0]}, {"text": "nation half-life (1.5–2.5 h) and better retrograde amnesic effect", "bbox": [406.0, 724.0, 740.0, 739.0]}, {"text": "than similar drugs such as diazepam. 5 Given intravenously,", "bbox": [406.0, 738.0, 738.0, 753.0]}, {"text": "midazolam has onset at around 2 to 3 min and is metabolised", "bbox": [406.0, 754.0, 739.0, 768.0]}, {"text": "into an active metabolite called α 1-hydroxymidazolam. Several", "bbox": [406.0, 769.0, 739.0, 782.0]}, {"text": "factors may affect the metabolism of midazolam, including age", "bbox": [406.0, 783.0, 740.0, 796.0]}, {"text": "(the elderly and young children), renal function, liver function", "bbox": [406.0, 798.0, 740.0, 811.0]}], "type": "Text", "position": 11}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/消化科/_2023 BSG指南：胃肠内窥镜检查中的镇静.pdf", "page_num": 6}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "缺少换行#11#11# 2.We recommend the provision另起一行\n缺少换行#12#12# A number of drugs are routinely另起一行\n", "type3": "无关文本#0#16#adverse events. 6部分段落末尾，以及句末的数字问题无关噪声应用全文", "type4": null, "type5": null, "type6": "准确性#4#6#表格内容杂乱"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:42", "update_time": "2024-05-08 01:27:13"}
{"id": 1082606, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 738, "source_info": {"seq_id": "f91c2a68-5505-4767-a157-abe678aea8af", "title": null, "text": "【0】页码:83\n\n【1】 e of the s 管状腺瘤 [ 兒 ]   inte 4  哺乳期腺瘤 导管腺瘤 ch [0]\n\n【2】\n e 小狗科研公开课\n e\n\n【3】 小狗科研公开课\n e l 15 D 15 \n\n【4】 公开课\n e d by\n\n【5】 小狗科研公开课\n s.\n\n【6】d 19 D is\n\n【7】 on 小狗科研公开课\n \n\n【8】   小狗科研公开课 83\n e", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "e of the s", "bbox": [114.0, 95.0, 249.0, 139.0]}, {"text": "管状腺瘤 [ 兒 ]   inte", "bbox": [160.0, 137.0, 346.0, 177.0]}, {"text": "4 ", "bbox": [358.0, 147.0, 536.0, 246.0]}, {"text": "哺乳期腺瘤", "bbox": [160.0, 188.0, 269.0, 217.0]}, {"text": "导管腺瘤", "bbox": [162.0, 229.0, 248.0, 259.0]}, {"text": "ch", "bbox": [545.0, 236.0, 582.0, 262.0]}, {"text": "[0]", "bbox": [578.0, 259.0, 629.0, 286.0]}], "type": "Table", "position": 1}, {"raw_context": [{"text": "e", "bbox": [4.0, 274.0, 50.0, 312.0]}, {"text": "小狗科研公开课", "bbox": [60.0, 278.0, 241.0, 375.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": "e", "bbox": [324.0, 380.0, 387.0, 423.0]}], "type": "Formula", "position": 5}, {"raw_context": [{"text": "小狗科研公开课", "bbox": [395.0, 393.0, 577.0, 487.0]}], "type": "Text", "position": 6}, {"raw_context": [{"text": "e ", "bbox": [109.0, 421.0, 159.0, 492.0]}, {"text": "l 15 D 15", "bbox": [168.0, 455.0, 343.0, 559.0]}, {"text": "", "bbox": [160.0, 559.0, 223.0, 608.0]}], "type": "Formula", "position": 7}, {"raw_context": [{"text": "公开课", "bbox": [0.0, 497.0, 77.0, 555.0]}], "type": "Text", "position": 9}, {"raw_context": [{"text": "e", "bbox": [676.0, 499.0, 742.0, 539.0]}, {"text": "d by", "bbox": [749.0, 514.0, 794.0, 558.0]}], "type": "Formula", "position": 10}, {"raw_context": [{"text": "小狗科研公开课", "bbox": [232.0, 573.0, 412.0, 669.0]}], "type": "Text", "position": 11}, {"raw_context": [{"text": "s.", "bbox": [479.0, 556.0, 535.0, 611.0]}, {"text": "d 19 D is", "bbox": [545.0, 582.0, 719.0, 687.0]}], "type": "Formula", "position": 12}, {"raw_context": [{"text": "on", "bbox": [515.0, 677.0, 579.0, 726.0]}, {"text": "小狗科研公开课", "bbox": [586.0, 691.0, 768.0, 787.0]}], "type": "Text", "position": 14}, {"raw_context": [{"text": "", "bbox": [0.0, 758.0, 122.0, 817.0]}], "type": "Formula", "position": 15}, {"raw_context": [{"text": "", "bbox": [137.0, 784.0, 507.0, 957.0]}, {"text": "", "bbox": [515.0, 913.0, 794.0, 1059.0]}, {"text": "小狗科研公开课", "bbox": [100.0, 1023.0, 280.0, 1118.0]}, {"text": "83", "bbox": [399.0, 1093.0, 416.0, 1108.0]}], "type": "Text", "position": 17}, {"raw_context": [{"text": "e", "bbox": [27.0, 1011.0, 89.0, 1054.0]}], "type": "Formula", "position": 18}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2022】全科室最全临床指南+专家共识（最全版）/2022全科室临床指南/肿瘤科/乳腺癌诊疗指南（2022年版）.pdf", "page_num": 83}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": null, "type3": "无关文本#0#8#全篇内容为水印内容，正文内容太少", "type4": null, "type5": null, "type6": null}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:41", "update_time": "2024-05-07 20:04:14"}
{"id": 1082605, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 738, "source_info": {"seq_id": "f4759f87-3e79-49de-976d-eaf5b309802b", "title": null, "text": "【0】页码:4\n\n【1】## Guideline\n\n【2】\n Level of agreement: 100% 47. We recommend that breast feeding does not need to be suspended after a single intravenous dose of midazolam, fentanyl or pethidine or when used in combination, or after administration of propofol.\n\n【3】Grade of evidence: Low. Strength of recommendation: Strong.\n\n【4】Level of agreement: 100%\n\n【5】## Other Special Considerations: Including Transition Group And Learning Difficulties\n\n【6】\n 48. We recommend that young patients undergoing endoscopy should participate in a structured transition programme, including education around the choice of sedative agents.\n\n【7】Grade of evidence: Very Low. Strength of recommendation: Strong.\n\n【8】Level of agreement: 92.3% 49.We recommend that information about the risks and benefits of endoscopy with sedation should be tailored to the individual young person.\n\n【9】Grade of evidence: Very Low. Strength of recommendation: Strong.\n\n【10】Level of agreement: 100%\n\n【11】 50. We recommend that in patients with cognitive impairment and or learning disability, an assessment of capacity is carried out to inform the discussion around choice of sedation.\n\n【12】Grade of evidence: Very Low. Strength of recommendation: Strong.\n\n【13】Level of agreement: 100% 51. We recommend that if during a sedated endoscopy, the patient appears to be tolerating the procedure poorly, the endoscopist should stop the procedure (if safe to do so) in order to assess the patient's wishes and decide if the procedure should be abandoned and alternatives arranged.\n\n【14】Grade of evidence: Very Low. Strength of recommendation: Strong.\n\n【15】Level of agreement: 92.3%\n\n【16】## Special Considerations: Lone Working\n\n【17】\n 52. We recommend that a minimum of two appropriately trained endoscopy assistants are required for endoscopic procedures in which sedation has been administered.\n\n【18】Grade of evidence: Very Low. Strength of recommendation: Strong.\n\n【19】 Level of agreement: 100% 53. We recommend that sedation should be administered only if there is immediate access to the resources (staff and facilities) required to manage complications of sedation Grade of evidence: Very Low. Strength of recommendation: Strong.\n\n【20】Level of agreement: 100%\n\n【21】## Training\n\n【22】\n 54. We recommend that all endoscopy staff responsible for assessment of risk, administering sedation and monitoring of patients, undergo formal training in the recognition and management of related complications, and this should be a continuing process Grade of evidence: Low. Strength of recommendation: Strong.\n\n【23】Level of agreement: 100%\n\n【24】## Patient/Lay Summary Introduction\n\n【25】\n Gastrointestinal endoscopy procedures are those where flexible cameras are inserted into the gut, to investigate patient symptoms or monitor diseases. The type of camera used and length of\n\n【26】 the examination can be varied. Some cameras also have an ultrasound probe attached to obtain extra images, and small samples can be taken to make or confirm a diagnosis or assess severity of a disease. Procedures can either be done unsedated with a local anaesthetic ('throat spray') alone or in combination with a sedative drug and/or painkiller. Sedation can help to make some examinations more comfortable or tolerable. The type of sedation administered is dependent on the nature and complexity of the procedure and also patient and local factors.\n\n【27】## Methodology\n\n【28】\n These guidelines have been produced by the BSG Endoscopy Committee with other stakeholders. Two patient representatives formed part of the guideline development group (GDG).\n\n【29】A comprehensive literature search was conducted followed by several meetings of the GDG. The final recommendations after four rounds of voting by the experts/GDG members form the basis of this guideline.\n\n【30】## Patient Information\n\n【31】\n A significant number of patients are anxious prior to an endoscopy. Patients should receive comprehensive information about what to expect from the sensation of the procedure and effects of any sedative drug, to provide better understanding. Patients should be involved in shared decision-making when choosing which sedative medication (if any) to proceed with during an endoscopic procedure.\n\n【32】## Provision Of Sedation\n\n【33】\n Sedation can sometimes be associated with unwanted complications. Clinicians need to weigh the benefits and risks of sedation to ensure that the patient has good or acceptable tolerance of the procedure while achieving the aim of the procedure and minimising unwanted side effects. This process starts from the pre-assessment when patients' medical history is carefully scrutinised. Certain medical conditions, such as kidney, liver, chest or heart problems, or older age, may make the patient more susceptible to the effects of sedative drugs or increase the risk of aspiration (stomach contents inadvertently going into the lungs), and these are taken into account when sedation is considered. Some patients may require the involvement of anaesthetic doctors to provide them with a deeper level of sedation or even a general anaesthetic. The critical care team should be involved when a very unwell patient requires a sedated endoscopy, if deemed appropriate. All such patients should have a clear plan of the 'ceiling of care' outlined in their records.\n\n【34】## Patient Monitoring\n\n【35】\n This guideline provides recommendations for the monitoring equipment the patient needs before, during and after the procedure, depending on the type of sedation and for when the patient can be safely discharged. Where the clinician administers sedation and also performs the procedure, there must be at least an appropriately trained second member of the team present to monitor the patient. Patient comfort should be assessed routinely during the procedure and sedation/pain medication adjusted accordingly with additional medication given as required and recorded, in a safe fashion. Additional interventions, such as music, can also help to alleviate anxiety for some patients.\n\n【36】In cases where deeper levels of sedation are used, greater monitoring is required with a heart rhythm trace (ECG) in addition to blood pressure, pulse, oxygen levels and body temperature.\n\n【37】Sidhu R, et al. Gut 2023;0:1–27. doi:10.1136/gutjnl-2023-330396", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "Guideline", "bbox": [55.0, 29.0, 129.0, 47.0]}], "type": "Section-header", "position": 0}, {"raw_context": [{"text": "Level of agreement: 100%", "bbox": [66.0, 60.0, 204.0, 75.0]}, {"text": "47. We recommend that breast feeding does not need to be", "bbox": [66.0, 75.0, 386.0, 90.0]}, {"text": "suspended after a single intravenous dose of midazolam, fentanyl", "bbox": [53.0, 91.0, 387.0, 105.0]}, {"text": "or pethidine or when used in combination, or after administra-", "bbox": [53.0, 105.0, 385.0, 120.0]}, {"text": "tion of propofol.", "bbox": [53.0, 120.0, 145.0, 135.0]}, {"text": "Grade of evidence: Low. Strength of recommendation: Strong.", "bbox": [64.0, 135.0, 384.0, 150.0]}, {"text": "Level of agreement: 100%", "bbox": [65.0, 150.0, 205.0, 164.0]}], "type": "Text", "position": 1}, {"raw_context": [{"text": "Other special considerations: including transition group and", "bbox": [53.0, 183.0, 376.0, 199.0]}, {"text": "learning difficulties", "bbox": [53.0, 199.0, 160.0, 213.0]}], "type": "Section-header", "position": 2}, {"raw_context": [{"text": "48. We recommend that young patients undergoing endos-", "bbox": [53.0, 214.0, 385.0, 228.0]}, {"text": "copy should participate in a structured transition programme,", "bbox": [53.0, 229.0, 385.0, 242.0]}, {"text": "including education around the choice of sedative agents.", "bbox": [54.0, 244.0, 352.0, 257.0]}, {"text": "Grade of evidence: Very Low. Strength of recommendation: Strong.", "bbox": [65.0, 258.0, 385.0, 272.0]}, {"text": "Level of agreement: 92.3%", "bbox": [66.0, 272.0, 208.0, 286.0]}, {"text": "49.We recommend that information about the risks and bene-", "bbox": [66.0, 286.0, 384.0, 301.0]}, {"text": "fits of endoscopy with sedation should be tailored to the indi-", "bbox": [53.0, 302.0, 385.0, 316.0]}, {"text": "vidual young person.", "bbox": [53.0, 317.0, 165.0, 330.0]}, {"text": "Grade of evidence: Very Low. Strength of recommendation:", "bbox": [64.0, 331.0, 386.0, 346.0]}, {"text": "Strong.", "bbox": [54.0, 347.0, 92.0, 360.0]}, {"text": "Level of agreement: 100%", "bbox": [65.0, 360.0, 204.0, 375.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "50. We recommend that in patients with cognitive impairment", "bbox": [66.0, 375.0, 386.0, 390.0]}, {"text": "and or learning disability, an assessment of capacity is carried out", "bbox": [53.0, 390.0, 386.0, 405.0]}, {"text": "to inform the discussion around choice of sedation.", "bbox": [53.0, 405.0, 321.0, 419.0]}, {"text": "Grade of evidence: Very Low. Strength of recommendation:", "bbox": [64.0, 420.0, 385.0, 433.0]}, {"text": "Strong.", "bbox": [53.0, 435.0, 91.0, 449.0]}, {"text": "Level of agreement: 100%", "bbox": [65.0, 449.0, 204.0, 463.0]}, {"text": "51. We recommend that if during a sedated endoscopy, the", "bbox": [66.0, 463.0, 386.0, 478.0]}, {"text": "patient appears to be tolerating the procedure poorly, the endos-", "bbox": [53.0, 479.0, 385.0, 492.0]}, {"text": "copist should stop the procedure (if safe to do so) in order to", "bbox": [53.0, 493.0, 387.0, 507.0]}, {"text": "assess the patient's wishes and decide if the procedure should be", "bbox": [53.0, 508.0, 386.0, 521.0]}, {"text": "abandoned and alternatives arranged.", "bbox": [54.0, 523.0, 250.0, 535.0]}, {"text": "Grade of evidence: Very Low. Strength of recommendation:", "bbox": [64.0, 537.0, 386.0, 550.0]}, {"text": "Strong.", "bbox": [53.0, 550.0, 92.0, 567.0]}, {"text": "Level of agreement: 92.3%", "bbox": [65.0, 566.0, 207.0, 581.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": "Special considerations: lone working", "bbox": [53.0, 600.0, 252.0, 615.0]}], "type": "Section-header", "position": 5}, {"raw_context": [{"text": "52. We recommend that a minimum of two appropriately trained", "bbox": [53.0, 615.0, 386.0, 630.0]}, {"text": "endoscopy assistants are required for endoscopic procedures in", "bbox": [53.0, 629.0, 387.0, 645.0]}, {"text": "which sedation has been administered.", "bbox": [53.0, 645.0, 255.0, 659.0]}, {"text": "Grade of evidence: Very Low. Strength of recommendation:", "bbox": [64.0, 660.0, 386.0, 674.0]}, {"text": "Strong.", "bbox": [53.0, 675.0, 91.0, 689.0]}], "type": "Text", "position": 6}, {"raw_context": [{"text": "Level of agreement: 100%", "bbox": [66.0, 689.0, 204.0, 703.0]}, {"text": "53. We recommend that sedation should be administered only", "bbox": [66.0, 703.0, 386.0, 718.0]}, {"text": "if there is immediate access to the resources (staff and facilities)", "bbox": [53.0, 719.0, 386.0, 732.0]}, {"text": "required to manage complications of sedation", "bbox": [54.0, 735.0, 292.0, 747.0]}, {"text": "Grade of evidence: Very Low. Strength of recommendation:", "bbox": [64.0, 748.0, 386.0, 761.0]}, {"text": "Strong.", "bbox": [54.0, 764.0, 91.0, 775.0]}, {"text": "Level of agreement: 100%", "bbox": [64.0, 777.0, 203.0, 790.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "Training", "bbox": [54.0, 811.0, 99.0, 825.0]}], "type": "Section-header", "position": 8}, {"raw_context": [{"text": "54. We recommend that all endoscopy staff responsible for assess-", "bbox": [53.0, 826.0, 385.0, 840.0]}, {"text": "ment of risk, administering sedation and monitoring of patients,", "bbox": [53.0, 841.0, 386.0, 854.0]}, {"text": "undergo formal training in the recognition and management of", "bbox": [53.0, 855.0, 386.0, 870.0]}, {"text": "related complications, and this should be a continuing process", "bbox": [53.0, 870.0, 379.0, 884.0]}, {"text": "Grade of evidence: Low. Strength of recommendation: Strong.", "bbox": [64.0, 885.0, 383.0, 899.0]}, {"text": "Level of agreement: 100%", "bbox": [66.0, 900.0, 204.0, 913.0]}], "type": "Text", "position": 9}, {"raw_context": [{"text": "PATIENT/LAY SUMMARY", "bbox": [53.0, 925.0, 187.0, 940.0]}, {"text": "Introduction", "bbox": [53.0, 942.0, 123.0, 955.0]}], "type": "Section-header", "position": 10}, {"raw_context": [{"text": "Gastrointestinal endoscopy procedures are those where flexible", "bbox": [53.0, 956.0, 387.0, 971.0]}, {"text": "cameras are inserted into the gut, to investigate patient symp-", "bbox": [53.0, 971.0, 385.0, 986.0]}, {"text": "toms or monitor diseases. The type of camera used and length of", "bbox": [53.0, 987.0, 386.0, 1001.0]}], "type": "Text", "position": 11}, {"raw_context": [{"text": "the examination can be varied. Some cameras also have an ultra-", "bbox": [406.0, 60.0, 739.0, 75.0]}, {"text": "sound probe attached to obtain extra images, and small samples", "bbox": [406.0, 77.0, 740.0, 90.0]}, {"text": "can be taken to make or confirm a diagnosis or assess severity", "bbox": [406.0, 91.0, 739.0, 105.0]}, {"text": "of a disease. Procedures can either be done unsedated with a", "bbox": [406.0, 106.0, 741.0, 120.0]}, {"text": "local anaesthetic ('throat spray') alone or in combination with a", "bbox": [406.0, 120.0, 741.0, 135.0]}, {"text": "sedative drug and/or painkiller. Sedation can help to make some", "bbox": [406.0, 135.0, 740.0, 150.0]}, {"text": "examinations more comfortable or tolerable. The type of seda-", "bbox": [406.0, 150.0, 739.0, 164.0]}, {"text": "tion administered is dependent on the nature and complexity of", "bbox": [406.0, 165.0, 740.0, 179.0]}, {"text": "the procedure and also patient and local factors.", "bbox": [406.0, 180.0, 657.0, 193.0]}], "type": "Text", "position": 12}, {"raw_context": [{"text": "Methodology", "bbox": [406.0, 215.0, 482.0, 229.0]}], "type": "Section-header", "position": 13}, {"raw_context": [{"text": "These guidelines have been produced by the BSG Endoscopy", "bbox": [407.0, 230.0, 739.0, 245.0]}, {"text": "Committee with other stakeholders. Two patient representa-", "bbox": [406.0, 245.0, 739.0, 259.0]}, {"text": "tives formed part of the guideline development group (GDG).", "bbox": [406.0, 260.0, 739.0, 274.0]}, {"text": "A comprehensive literature search was conducted followed by", "bbox": [406.0, 275.0, 739.0, 288.0]}, {"text": "several meetings of the GDG. The final recommendations after", "bbox": [406.0, 289.0, 740.0, 303.0]}, {"text": "four rounds of voting by the experts/GDG members form the", "bbox": [406.0, 304.0, 740.0, 318.0]}, {"text": "basis of this guideline.", "bbox": [406.0, 318.0, 523.0, 333.0]}], "type": "Text", "position": 14}, {"raw_context": [{"text": "Patient information", "bbox": [406.0, 355.0, 514.0, 369.0]}], "type": "Section-header", "position": 15}, {"raw_context": [{"text": "A significant number of patients are anxious prior to an endos-", "bbox": [406.0, 370.0, 739.0, 383.0]}, {"text": "copy. Patients should receive comprehensive information about", "bbox": [406.0, 384.0, 741.0, 398.0]}, {"text": "what to expect from the sensation of the procedure and effects", "bbox": [406.0, 399.0, 741.0, 413.0]}, {"text": "of any sedative drug, to provide better understanding. Patients", "bbox": [406.0, 413.0, 740.0, 428.0]}, {"text": "should be involved in shared decision-making when choosing", "bbox": [406.0, 428.0, 740.0, 443.0]}, {"text": "which sedative medication (if any) to proceed with during an", "bbox": [406.0, 443.0, 740.0, 458.0]}, {"text": "endoscopic procedure.", "bbox": [406.0, 458.0, 526.0, 472.0]}], "type": "Text", "position": 16}, {"raw_context": [{"text": "Provision of sedation", "bbox": [406.0, 494.0, 523.0, 508.0]}], "type": "Section-header", "position": 17}, {"raw_context": [{"text": "Sedation can sometimes be associated with unwanted compli-", "bbox": [406.0, 509.0, 739.0, 524.0]}, {"text": "cations. Clinicians need to weigh the benefits and risks of seda-", "bbox": [406.0, 524.0, 739.0, 538.0]}, {"text": "tion to ensure that the patient has good or acceptable tolerance", "bbox": [406.0, 539.0, 740.0, 553.0]}, {"text": "of the procedure while achieving the aim of the procedure and", "bbox": [406.0, 554.0, 740.0, 567.0]}, {"text": "minimising unwanted side effects. This process starts from the", "bbox": [406.0, 568.0, 740.0, 581.0]}, {"text": "pre-assessment when patients' medical history is carefully scru-", "bbox": [406.0, 582.0, 739.0, 596.0]}, {"text": "tinised. Certain medical conditions, such as kidney, liver, chest", "bbox": [406.0, 597.0, 740.0, 611.0]}, {"text": "or heart problems, or older age, may make the patient more", "bbox": [406.0, 612.0, 739.0, 626.0]}, {"text": "susceptible to the effects of sedative drugs or increase the risk", "bbox": [406.0, 627.0, 739.0, 640.0]}, {"text": "of aspiration (stomach contents inadvertently going into the", "bbox": [406.0, 642.0, 739.0, 655.0]}, {"text": "lungs), and these are taken into account when sedation is consid-", "bbox": [406.0, 656.0, 739.0, 669.0]}, {"text": "ered. Some patients may require the involvement of anaesthetic", "bbox": [406.0, 671.0, 740.0, 684.0]}, {"text": "doctors to provide them with a deeper level of sedation or even", "bbox": [406.0, 685.0, 741.0, 700.0]}, {"text": "a general anaesthetic. The critical care team should be involved", "bbox": [406.0, 700.0, 740.0, 714.0]}, {"text": "when a very unwell patient requires a sedated endoscopy, if", "bbox": [406.0, 715.0, 740.0, 729.0]}, {"text": "deemed appropriate. All such patients should have a clear plan", "bbox": [406.0, 730.0, 740.0, 743.0]}, {"text": "of the 'ceiling of care' outlined in their records.", "bbox": [406.0, 744.0, 653.0, 758.0]}], "type": "Text", "position": 18}, {"raw_context": [{"text": "Patient monitoring", "bbox": [406.0, 780.0, 510.0, 794.0]}], "type": "Section-header", "position": 19}, {"raw_context": [{"text": "This guideline provides recommendations for the monitoring", "bbox": [407.0, 795.0, 741.0, 810.0]}, {"text": "equipment the patient needs before, during and after the proce-", "bbox": [406.0, 811.0, 739.0, 825.0]}, {"text": "dure, depending on the type of sedation and for when the", "bbox": [406.0, 826.0, 740.0, 839.0]}, {"text": "patient can be safely discharged. Where the clinician administers", "bbox": [406.0, 840.0, 741.0, 853.0]}, {"text": "sedation and also performs the procedure, there must be at least", "bbox": [406.0, 855.0, 741.0, 868.0]}, {"text": "an appropriately trained second member of the team present to", "bbox": [406.0, 869.0, 741.0, 883.0]}, {"text": "monitor the patient. Patient comfort should be assessed routinely", "bbox": [406.0, 883.0, 740.0, 897.0]}, {"text": "during the procedure and sedation/pain medication adjusted", "bbox": [406.0, 898.0, 740.0, 912.0]}, {"text": "accordingly with additional medication given as required and", "bbox": [406.0, 913.0, 740.0, 927.0]}, {"text": "recorded, in a safe fashion. Additional interventions, such as", "bbox": [406.0, 928.0, 740.0, 941.0]}, {"text": "music, can also help to alleviate anxiety for some patients.", "bbox": [406.0, 942.0, 709.0, 955.0]}, {"text": "In cases where deeper levels of sedation are used, greater moni-", "bbox": [418.0, 957.0, 739.0, 971.0]}, {"text": "toring is required with a heart rhythm trace (ECG) in addition", "bbox": [406.0, 971.0, 740.0, 986.0]}, {"text": "to blood pressure, pulse, oxygen levels and body temperature.", "bbox": [406.0, 987.0, 729.0, 1001.0]}, {"text": "Sidhu R, et al. Gut 2023;0:1–27. doi:10.1136/gutjnl-2023-330396", "bbox": [477.0, 1009.0, 739.0, 1022.0]}], "type": "Text", "position": 20}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/消化科/_2023 BSG指南：胃肠内窥镜检查中的镇静.pdf", "page_num": 4}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "缺少换行#2#2# 47. We recommend that这里开始应换行\n缺少换行#8#8#49.We recommend that 这里开始应换行\n缺少换行#13#13#51. We recommend that这里开始应换行\n缺少换行#19#19#53. We recommend that sedation这里开始应换行\n多余换行#25#26#为同段", "type3": "页脚#37#37#非正文", "type4": null, "type5": null, "type6": null}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:41", "update_time": "2024-05-07 22:02:00"}
{"id": 1082604, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 738, "source_info": {"seq_id": "f61a173c-ec59-47ec-bb4c-f89667b60350", "title": null, "text": "【0】页码:5\n 2023\n\n【1】 3\n\n【2】 58\n\n【3】 6\n\n【4】 ( n =11) 2 Table 2 Quality evaluation results of included guidelines ( n =11) (%) ≥ 60% 1 30% ( ) ( ) EULAR [17] 48.95 50.00 100 100 100 100 4 o B NICE [21] 100 91.66 89.58 100 72.91 100 o 6 A RACGP (201 100 97.91 94.44 77.08 100 86.11 6 A o EULAR [14] 100 100 65.63 100 81.25 100 o A 6 3.3 OARSI [ 71 100 97.22 88.54 100 62.50 100 6 o A [13] [13] 97.22 100 65.63 25.00 70.83 5 100 B I [18] [18] 97.22 66.66 54.16 100 41.66 100 4 B o [16] [16] 100 61.90 95.83 100 91.66 75.00 6 o A [19] [19] Mitchell 100 86.11 84.37 100 89.58 100 6 o A 141 100 91.66 63.54 70.83 100 6 o 100 A AAOS [15] 94.44 91.66 79.10 95.83 95.83 97.91 o 6 A ; EULAR ; NICE ; RACGP ; OARSI ; AAOS o [20] , , (40%~60% >60%) , , [43] ×(220– = - :\n\n【5】\n 10.\n\n【6】 ,\n\n【7】 [42]\n\n【8】 Chapter 3\n\n【9】 21~23\n\n【10】 KOA\n\n【11】 , 141 100 91.66 63.54 70.83 100 6 o 100 A AAOS [15] 94.44 91.66 79.10 95.83 95.83 97.91 o 6 A ; EULAR ; NICE ; RACGP [14,16,18,20,25] ; OARSI ; AAOS o 1 o KOA [20] , , (40%~60% >60%) , , [43] ×(220– = - : , [40] [40] (1)+ ( KOA 5.0%~7.5%), , , Chapter 1 [14] [14] , , , , [39] , ,  , o [26] [26] Borg 12~17 ( , , ) KOA ; Chapter 3 [16] [16] , , 1 , , o 50%~60% >60%~80% .\n\n【12】3.4 , 3 .\n\n【13】8~15 24~30 KOA 30 min, 10.\n\n【14】, , [41] [41] , , , 9 KOA , [4,20] KOA Chapter 1 , , , , [7] [30] [44] Meta 10. See also  , , Chapter 1 , , , , ,\n\n【15】 .\n\n【16】 ,\n\n【17】 Chapter 3\n\n【18】 ,\n\n【19】 ,\n\n【20】 ,\n\n【21】 o KOA\n\n【22】 739", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "2023", "bbox": [158.0, 45.0, 187.0, 61.0]}], "type": "Text", "position": 0}, {"raw_context": [{"text": "3", "bbox": [199.0, 47.0, 211.0, 61.0]}], "type": "Text", "position": 1}, {"raw_context": [{"text": "58", "bbox": [235.0, 46.0, 252.0, 61.0]}], "type": "Text", "position": 2}, {"raw_context": [{"text": "6", "bbox": [276.0, 48.0, 287.0, 61.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "( n =11)", "bbox": [395.0, 93.0, 436.0, 108.0]}, {"text": "2", "bbox": [222.0, 94.0, 232.0, 106.0]}, {"text": "Table 2", "bbox": [148.0, 113.0, 195.0, 128.0]}, {"text": "Quality evaluation results of included guidelines ( n =11)", "bbox": [198.0, 112.0, 497.0, 128.0]}, {"text": "(%)", "bbox": [335.0, 138.0, 361.0, 153.0]}, {"text": "≥ 60%", "bbox": [434.0, 137.0, 470.0, 152.0]}, {"text": "1 30%", "bbox": [486.0, 137.0, 522.0, 153.0]}, {"text": "( )", "bbox": [440.0, 178.0, 465.0, 194.0]}, {"text": "( )", "bbox": [492.0, 178.0, 516.0, 193.0]}, {"text": "EULAR [17]", "bbox": [88.0, 195.0, 141.0, 212.0]}, {"text": "48.95", "bbox": [257.0, 195.0, 287.0, 211.0]}, {"text": "50.00", "bbox": [337.0, 195.0, 369.0, 211.0]}, {"text": "100", "bbox": [387.0, 195.0, 408.0, 211.0]}, {"text": "100", "bbox": [179.0, 196.0, 202.0, 211.0]}, {"text": "100", "bbox": [223.0, 196.0, 246.0, 211.0]}, {"text": "100", "bbox": [304.0, 196.0, 326.0, 211.0]}, {"text": "4", "bbox": [447.0, 198.0, 457.0, 211.0]}, {"text": "o", "bbox": [498.0, 198.0, 510.0, 211.0]}, {"text": "B", "bbox": [541.0, 197.0, 555.0, 212.0]}, {"text": "NICE [21]", "bbox": [89.0, 214.0, 132.0, 230.0]}, {"text": "100", "bbox": [179.0, 215.0, 201.0, 230.0]}, {"text": "91.66", "bbox": [217.0, 215.0, 250.0, 230.0]}, {"text": "89.58", "bbox": [256.0, 215.0, 287.0, 230.0]}, {"text": "100", "bbox": [304.0, 215.0, 326.0, 230.0]}, {"text": "72.91", "bbox": [337.0, 215.0, 368.0, 230.0]}, {"text": "100", "bbox": [387.0, 215.0, 408.0, 230.0]}, {"text": "o", "bbox": [498.0, 216.0, 510.0, 229.0]}, {"text": "6", "bbox": [447.0, 217.0, 458.0, 230.0]}, {"text": "A", "bbox": [543.0, 217.0, 554.0, 230.0]}, {"text": "RACGP (201", "bbox": [88.0, 233.0, 141.0, 249.0]}, {"text": "100", "bbox": [179.0, 234.0, 201.0, 249.0]}, {"text": "97.91", "bbox": [256.0, 234.0, 287.0, 249.0]}, {"text": "94.44", "bbox": [299.0, 234.0, 330.0, 249.0]}, {"text": "77.08", "bbox": [337.0, 234.0, 369.0, 249.0]}, {"text": "100", "bbox": [387.0, 234.0, 408.0, 249.0]}, {"text": "86.11", "bbox": [217.0, 235.0, 248.0, 249.0]}, {"text": "6", "bbox": [446.0, 235.0, 457.0, 250.0]}, {"text": "A", "bbox": [542.0, 235.0, 554.0, 250.0]}, {"text": "o", "bbox": [498.0, 236.0, 510.0, 249.0]}, {"text": "EULAR [14]", "bbox": [88.0, 254.0, 142.0, 269.0]}, {"text": "100", "bbox": [179.0, 255.0, 201.0, 269.0]}, {"text": "100", "bbox": [222.0, 255.0, 245.0, 269.0]}, {"text": "65.63", "bbox": [257.0, 255.0, 287.0, 269.0]}, {"text": "100", "bbox": [304.0, 255.0, 325.0, 269.0]}, {"text": "81.25", "bbox": [336.0, 255.0, 369.0, 270.0]}, {"text": "100", "bbox": [387.0, 255.0, 408.0, 269.0]}, {"text": "o", "bbox": [498.0, 255.0, 510.0, 269.0]}, {"text": "A", "bbox": [542.0, 255.0, 554.0, 270.0]}, {"text": "6", "bbox": [447.0, 256.0, 458.0, 269.0]}, {"text": "3.3", "bbox": [574.0, 265.0, 594.0, 282.0]}, {"text": "OARSI [ 71", "bbox": [88.0, 273.0, 135.0, 289.0]}, {"text": "100", "bbox": [179.0, 273.0, 202.0, 289.0]}, {"text": "97.22", "bbox": [217.0, 273.0, 250.0, 289.0]}, {"text": "88.54", "bbox": [256.0, 273.0, 288.0, 289.0]}, {"text": "100", "bbox": [304.0, 273.0, 325.0, 289.0]}, {"text": "62.50", "bbox": [336.0, 273.0, 369.0, 289.0]}, {"text": "100", "bbox": [387.0, 273.0, 408.0, 289.0]}, {"text": "6", "bbox": [447.0, 273.0, 458.0, 289.0]}, {"text": "o", "bbox": [498.0, 274.0, 510.0, 288.0]}, {"text": "A", "bbox": [543.0, 274.0, 554.0, 289.0]}, {"text": "[13] [13]", "bbox": [138.0, 292.0, 152.0, 304.0]}, {"text": "97.22", "bbox": [173.0, 293.0, 205.0, 309.0]}, {"text": "100", "bbox": [222.0, 293.0, 245.0, 308.0]}, {"text": "65.63", "bbox": [257.0, 293.0, 287.0, 308.0]}, {"text": "25.00", "bbox": [337.0, 293.0, 369.0, 308.0]}, {"text": "70.83", "bbox": [385.0, 293.0, 414.0, 308.0]}, {"text": "5", "bbox": [447.0, 293.0, 457.0, 309.0]}, {"text": "100", "bbox": [304.0, 294.0, 324.0, 308.0]}, {"text": "B", "bbox": [542.0, 294.0, 554.0, 308.0]}, {"text": "I", "bbox": [500.0, 295.0, 509.0, 308.0]}, {"text": "[18] [18]", "bbox": [138.0, 312.0, 152.0, 325.0]}, {"text": "97.22", "bbox": [174.0, 312.0, 205.0, 328.0]}, {"text": "66.66", "bbox": [217.0, 313.0, 250.0, 328.0]}, {"text": "54.16", "bbox": [256.0, 312.0, 288.0, 327.0]}, {"text": "100", "bbox": [304.0, 313.0, 325.0, 327.0]}, {"text": "41.66", "bbox": [337.0, 312.0, 369.0, 328.0]}, {"text": "100", "bbox": [387.0, 312.0, 409.0, 327.0]}, {"text": "4", "bbox": [447.0, 312.0, 458.0, 327.0]}, {"text": "B", "bbox": [542.0, 313.0, 554.0, 327.0]}, {"text": "o", "bbox": [498.0, 314.0, 510.0, 327.0]}, {"text": "[16] [16]", "bbox": [138.0, 332.0, 152.0, 344.0]}, {"text": "100", "bbox": [179.0, 333.0, 202.0, 347.0]}, {"text": "61.90", "bbox": [217.0, 333.0, 250.0, 347.0]}, {"text": "95.83", "bbox": [256.0, 332.0, 287.0, 347.0]}, {"text": "100", "bbox": [304.0, 333.0, 325.0, 347.0]}, {"text": "91.66", "bbox": [336.0, 332.0, 369.0, 347.0]}, {"text": "75.00", "bbox": [384.0, 332.0, 416.0, 347.0]}, {"text": "6", "bbox": [447.0, 333.0, 457.0, 347.0]}, {"text": "o", "bbox": [498.0, 333.0, 510.0, 347.0]}, {"text": "A", "bbox": [543.0, 335.0, 554.0, 347.0]}, {"text": "[19] [19]", "bbox": [138.0, 351.0, 155.0, 364.0]}, {"text": "Mitchell", "bbox": [89.0, 352.0, 134.0, 366.0]}, {"text": "100", "bbox": [179.0, 352.0, 201.0, 366.0]}, {"text": "86.11", "bbox": [217.0, 352.0, 249.0, 366.0]}, {"text": "84.37", "bbox": [256.0, 352.0, 287.0, 366.0]}, {"text": "100", "bbox": [304.0, 352.0, 325.0, 366.0]}, {"text": "89.58", "bbox": [336.0, 352.0, 369.0, 366.0]}, {"text": "100", "bbox": [387.0, 352.0, 408.0, 366.0]}, {"text": "6", "bbox": [447.0, 353.0, 458.0, 366.0]}, {"text": "o", "bbox": [498.0, 353.0, 510.0, 366.0]}, {"text": "A", "bbox": [543.0, 353.0, 555.0, 367.0]}, {"text": "141", "bbox": [138.0, 371.0, 150.0, 382.0]}, {"text": "100", "bbox": [179.0, 371.0, 202.0, 387.0]}, {"text": "91.66", "bbox": [217.0, 371.0, 250.0, 386.0]}, {"text": "63.54", "bbox": [256.0, 371.0, 288.0, 387.0]}, {"text": "70.83", "bbox": [337.0, 371.0, 369.0, 387.0]}, {"text": "100", "bbox": [386.0, 371.0, 409.0, 387.0]}, {"text": "6", "bbox": [447.0, 371.0, 457.0, 387.0]}, {"text": "o", "bbox": [498.0, 371.0, 510.0, 387.0]}, {"text": "100", "bbox": [304.0, 372.0, 326.0, 387.0]}, {"text": "A", "bbox": [543.0, 372.0, 554.0, 387.0]}, {"text": "AAOS [15]", "bbox": [89.0, 389.0, 134.0, 405.0]}, {"text": "94.44", "bbox": [174.0, 390.0, 205.0, 405.0]}, {"text": "91.66", "bbox": [217.0, 390.0, 250.0, 406.0]}, {"text": "79.10", "bbox": [256.0, 390.0, 289.0, 405.0]}, {"text": "95.83", "bbox": [299.0, 390.0, 330.0, 405.0]}, {"text": "95.83", "bbox": [336.0, 390.0, 369.0, 405.0]}, {"text": "97.91", "bbox": [384.0, 390.0, 414.0, 406.0]}, {"text": "o", "bbox": [498.0, 391.0, 510.0, 405.0]}, {"text": "6", "bbox": [447.0, 392.0, 457.0, 405.0]}, {"text": "A", "bbox": [543.0, 392.0, 555.0, 406.0]}, {"text": "; EULAR", "bbox": [101.0, 414.0, 147.0, 429.0]}, {"text": "; NICE", "bbox": [252.0, 414.0, 287.0, 429.0]}, {"text": "; RACGP", "bbox": [489.0, 414.0, 534.0, 429.0]}, {"text": "; OARSI", "bbox": [230.0, 432.0, 274.0, 449.0]}, {"text": "; AAOS", "bbox": [401.0, 433.0, 441.0, 449.0]}, {"text": "o", "bbox": [545.0, 439.0, 553.0, 449.0]}, {"text": "[20]", "bbox": [516.0, 479.0, 535.0, 494.0]}, {"text": ",", "bbox": [141.0, 488.0, 149.0, 497.0]}, {"text": ",", "bbox": [177.0, 488.0, 183.0, 497.0]}, {"text": "(40%~60%", "bbox": [126.0, 503.0, 193.0, 519.0]}, {"text": ">60%)", "bbox": [203.0, 503.0, 248.0, 519.0]}, {"text": ",", "bbox": [387.0, 509.0, 396.0, 520.0]}, {"text": ",", "bbox": [435.0, 511.0, 443.0, 520.0]}, {"text": "[43]", "bbox": [582.0, 521.0, 602.0, 537.0]}, {"text": "×(220–", "bbox": [312.0, 523.0, 359.0, 540.0]}, {"text": "=", "bbox": [205.0, 526.0, 217.0, 539.0]}, {"text": "-", "bbox": [385.0, 527.0, 395.0, 538.0]}, {"text": ":", "bbox": [141.0, 529.0, 150.0, 541.0]}], "type": "Table", "position": 4}, {"raw_context": [{"text": "10.", "bbox": [619.0, 166.0, 628.0, 175.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": ",", "bbox": [679.0, 187.0, 687.0, 195.0]}], "type": "Text", "position": 6}, {"raw_context": [{"text": "[42]", "bbox": [706.0, 220.0, 726.0, 235.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "Chapter 3", "bbox": [715.0, 251.0, 723.0, 260.0]}], "type": "Text", "position": 8}, {"raw_context": [{"text": "21~23", "bbox": [616.0, 309.0, 657.0, 325.0]}], "type": "Text", "position": 9}, {"raw_context": [{"text": "KOA", "bbox": [657.0, 330.0, 689.0, 346.0]}], "type": "Text", "position": 10}, {"raw_context": [{"text": ",", "bbox": [633.0, 360.0, 642.0, 370.0]}, {"text": "141", "bbox": [138.0, 371.0, 150.0, 382.0]}, {"text": "100", "bbox": [179.0, 371.0, 202.0, 387.0]}, {"text": "91.66", "bbox": [217.0, 371.0, 250.0, 386.0]}, {"text": "63.54", "bbox": [256.0, 371.0, 288.0, 387.0]}, {"text": "70.83", "bbox": [337.0, 371.0, 369.0, 387.0]}, {"text": "100", "bbox": [386.0, 371.0, 409.0, 387.0]}, {"text": "6", "bbox": [447.0, 371.0, 457.0, 387.0]}, {"text": "o", "bbox": [498.0, 371.0, 510.0, 387.0]}, {"text": "100", "bbox": [304.0, 372.0, 326.0, 387.0]}, {"text": "A", "bbox": [543.0, 372.0, 554.0, 387.0]}, {"text": "AAOS [15]", "bbox": [89.0, 389.0, 134.0, 405.0]}, {"text": "94.44", "bbox": [174.0, 390.0, 205.0, 405.0]}, {"text": "91.66", "bbox": [217.0, 390.0, 250.0, 406.0]}, {"text": "79.10", "bbox": [256.0, 390.0, 289.0, 405.0]}, {"text": "95.83", "bbox": [299.0, 390.0, 330.0, 405.0]}, {"text": "95.83", "bbox": [336.0, 390.0, 369.0, 405.0]}, {"text": "97.91", "bbox": [384.0, 390.0, 414.0, 406.0]}, {"text": "o", "bbox": [498.0, 391.0, 510.0, 405.0]}, {"text": "6", "bbox": [447.0, 392.0, 457.0, 405.0]}, {"text": "A", "bbox": [543.0, 392.0, 555.0, 406.0]}, {"text": "; EULAR", "bbox": [101.0, 414.0, 147.0, 429.0]}, {"text": "; NICE", "bbox": [252.0, 414.0, 287.0, 429.0]}, {"text": "; RACGP", "bbox": [489.0, 414.0, 534.0, 429.0]}, {"text": "[14,16,18,20,25]", "bbox": [664.0, 414.0, 725.0, 428.0]}, {"text": "; OARSI", "bbox": [230.0, 432.0, 274.0, 449.0]}, {"text": "; AAOS", "bbox": [401.0, 433.0, 441.0, 449.0]}, {"text": "o", "bbox": [545.0, 439.0, 553.0, 449.0]}, {"text": "1", "bbox": [662.0, 441.0, 672.0, 454.0]}, {"text": "o", "bbox": [684.0, 444.0, 694.0, 454.0]}, {"text": "KOA", "bbox": [629.0, 459.0, 661.0, 476.0]}, {"text": "[20]", "bbox": [516.0, 479.0, 535.0, 494.0]}, {"text": ",", "bbox": [141.0, 488.0, 149.0, 497.0]}, {"text": ",", "bbox": [177.0, 488.0, 183.0, 497.0]}, {"text": "(40%~60%", "bbox": [126.0, 503.0, 193.0, 519.0]}, {"text": ">60%)", "bbox": [203.0, 503.0, 248.0, 519.0]}, {"text": ",", "bbox": [387.0, 509.0, 396.0, 520.0]}, {"text": ",", "bbox": [435.0, 511.0, 443.0, 520.0]}, {"text": "[43]", "bbox": [582.0, 521.0, 602.0, 537.0]}, {"text": "×(220–", "bbox": [312.0, 523.0, 359.0, 540.0]}, {"text": "=", "bbox": [205.0, 526.0, 217.0, 539.0]}, {"text": "-", "bbox": [385.0, 527.0, 395.0, 538.0]}, {"text": ":", "bbox": [141.0, 529.0, 150.0, 541.0]}, {"text": ",", "bbox": [435.0, 532.0, 443.0, 543.0]}, {"text": "[40] [40]", "bbox": [209.0, 542.0, 230.0, 557.0]}, {"text": "(1)+", "bbox": [140.0, 546.0, 158.0, 561.0]}, {"text": "(", "bbox": [678.0, 548.0, 688.0, 563.0]}, {"text": "KOA", "bbox": [97.0, 566.0, 129.0, 583.0]}, {"text": "5.0%~7.5%),", "bbox": [447.0, 567.0, 529.0, 583.0]}, {"text": ",", "bbox": [226.0, 574.0, 234.0, 584.0]}, {"text": ",", "bbox": [316.0, 574.0, 326.0, 583.0]}, {"text": "Chapter 1", "bbox": [686.0, 574.0, 694.0, 584.0]}, {"text": "[14] [14]", "bbox": [559.0, 586.0, 578.0, 600.0]}, {"text": ",", "bbox": [678.0, 596.0, 688.0, 607.0]}, {"text": ",", "bbox": [273.0, 597.0, 281.0, 606.0]}, {"text": ",", "bbox": [99.0, 617.0, 108.0, 627.0]}, {"text": ",", "bbox": [247.0, 618.0, 255.0, 627.0]}, {"text": "[39]", "bbox": [209.0, 628.0, 229.0, 643.0]}, {"text": ",", "bbox": [301.0, 660.0, 308.0, 670.0]}, {"text": ",", "bbox": [129.0, 661.0, 137.0, 670.0]}, {"text": "", "bbox": [194.0, 662.0, 201.0, 670.0]}, {"text": ",", "bbox": [574.0, 662.0, 582.0, 671.0]}, {"text": "o", "bbox": [694.0, 662.0, 702.0, 670.0]}, {"text": "[26] [26]", "bbox": [649.0, 673.0, 668.0, 688.0]}, {"text": "Borg", "bbox": [168.0, 675.0, 198.0, 691.0]}, {"text": "12~17", "bbox": [294.0, 675.0, 333.0, 691.0]}, {"text": "(", "bbox": [342.0, 677.0, 353.0, 691.0]}, {"text": ",", "bbox": [588.0, 683.0, 598.0, 694.0]}, {"text": ",", "bbox": [694.0, 683.0, 702.0, 693.0]}, {"text": ")", "bbox": [99.0, 697.0, 109.0, 712.0]}, {"text": "KOA", "bbox": [488.0, 698.0, 521.0, 714.0]}, {"text": ";", "bbox": [135.0, 700.0, 144.0, 714.0]}, {"text": "Chapter 3", "bbox": [659.0, 704.0, 667.0, 713.0]}, {"text": "[16] [16]", "bbox": [650.0, 716.0, 668.0, 731.0]}, {"text": ",", "bbox": [99.0, 724.0, 107.0, 735.0]}, {"text": ",", "bbox": [463.0, 726.0, 471.0, 737.0]}, {"text": "1", "bbox": [257.0, 741.0, 266.0, 756.0]}, {"text": ",", "bbox": [172.0, 748.0, 178.0, 756.0]}, {"text": ",", "bbox": [598.0, 748.0, 607.0, 758.0]}, {"text": "o", "bbox": [686.0, 748.0, 694.0, 756.0]}, {"text": "50%~60%", "bbox": [84.0, 761.0, 149.0, 777.0]}, {"text": ">60%~80% .", "bbox": [159.0, 761.0, 238.0, 777.0]}, {"text": "3.4", "bbox": [418.0, 761.0, 441.0, 777.0]}, {"text": ",", "bbox": [358.0, 768.0, 365.0, 777.0]}, {"text": "3", "bbox": [336.0, 783.0, 350.0, 799.0]}, {"text": ".", "bbox": [359.0, 790.0, 368.0, 799.0]}, {"text": "8~15", "bbox": [160.0, 804.0, 193.0, 821.0]}, {"text": "24~30", "bbox": [461.0, 804.0, 502.0, 821.0]}, {"text": "KOA", "bbox": [583.0, 804.0, 615.0, 821.0]}, {"text": "30 min,", "bbox": [84.0, 805.0, 135.0, 821.0]}, {"text": "10.", "bbox": [232.0, 811.0, 241.0, 821.0]}, {"text": ",", "bbox": [268.0, 812.0, 276.0, 821.0]}, {"text": ",", "bbox": [359.0, 812.0, 367.0, 821.0]}, {"text": "[41] [41]", "bbox": [368.0, 823.0, 390.0, 839.0]}, {"text": ",", "bbox": [174.0, 833.0, 181.0, 842.0]}, {"text": ",", "bbox": [477.0, 834.0, 486.0, 845.0]}, {"text": ",", "bbox": [578.0, 835.0, 586.0, 845.0]}, {"text": "9", "bbox": [97.0, 848.0, 110.0, 862.0]}, {"text": "KOA", "bbox": [249.0, 848.0, 281.0, 864.0]}, {"text": ",", "bbox": [596.0, 855.0, 604.0, 866.0]}, {"text": "[4,20]", "bbox": [182.0, 865.0, 207.0, 881.0]}, {"text": "KOA", "bbox": [336.0, 869.0, 367.0, 884.0]}, {"text": "Chapter 1", "bbox": [113.0, 874.0, 123.0, 886.0]}, {"text": ",", "bbox": [233.0, 876.0, 240.0, 885.0]}, {"text": ",", "bbox": [344.0, 898.0, 354.0, 910.0]}, {"text": ",", "bbox": [588.0, 898.0, 598.0, 910.0]}, {"text": ",", "bbox": [156.0, 899.0, 162.0, 908.0]}, {"text": "[7]", "bbox": [113.0, 910.0, 129.0, 924.0]}, {"text": "[30]", "bbox": [195.0, 910.0, 213.0, 924.0]}, {"text": "[44]", "bbox": [629.0, 910.0, 648.0, 924.0]}, {"text": "Meta", "bbox": [138.0, 912.0, 170.0, 928.0]}, {"text": "10. See also  ,", "bbox": [255.0, 919.0, 264.0, 928.0]}, {"text": ",", "bbox": [463.0, 920.0, 470.0, 930.0]}, {"text": "Chapter 1", "bbox": [553.0, 920.0, 561.0, 929.0]}, {"text": ",", "bbox": [357.0, 941.0, 367.0, 950.0]}, {"text": ",", "bbox": [115.0, 942.0, 122.0, 951.0]}, {"text": ",", "bbox": [236.0, 942.0, 244.0, 951.0]}, {"text": ",", "bbox": [462.0, 942.0, 471.0, 954.0]}, {"text": ",", "bbox": [554.0, 943.0, 561.0, 952.0]}], "type": "Text", "position": 11}, {"raw_context": [{"text": ".", "bbox": [199.0, 963.0, 207.0, 973.0]}], "type": "Text", "position": 12}, {"raw_context": [{"text": ",", "bbox": [304.0, 964.0, 311.0, 973.0]}], "type": "Text", "position": 13}, {"raw_context": [{"text": "Chapter 3", "bbox": [271.0, 984.0, 279.0, 993.0]}], "type": "Text", "position": 14}, {"raw_context": [{"text": ",", "bbox": [314.0, 984.0, 322.0, 994.0]}], "type": "Text", "position": 15}, {"raw_context": [{"text": ",", "bbox": [435.0, 963.0, 443.0, 972.0]}], "type": "Text", "position": 16}, {"raw_context": [{"text": ",", "bbox": [490.0, 986.0, 498.0, 995.0]}], "type": "Text", "position": 17}, {"raw_context": [{"text": "o KOA", "bbox": [525.0, 956.0, 562.0, 971.0]}], "type": "Text", "position": 18}, {"raw_context": [{"text": "739", "bbox": [733.0, 1021.0, 754.0, 1029.0]}], "type": "Text", "position": 19}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/骨科/解读/膝骨关节炎患者自我管理的最佳证据总结.pdf", "page_num": 5}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": null, "type3": null, "type4": null, "type5": null, "type6": "信息有用性#0#22#无用内容"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:41", "update_time": "2024-05-07 19:23:55"}
{"id": 1082603, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 738, "source_info": {"seq_id": "99d383d3-79d9-453e-ae3a-57995c5195b3", "title": null, "text": "【0】页码:3\n one of the following: (1) ≥ 2 long bone fractures by the age of 10 years and (2) ≥ 3 long bone fractures at any age up to 19 years. 99\n\n【1】## Conditions Associated With Low Bmd 2\n\n【2】\n There are primary and secondary causes of reduced bone mass and increased fracture risk (Table 1). Primary osteoporosis occurs due to intrinsic skeletal defects originating from genetic or idiopathic causes, while secondary osteoporosis results from chronic systemic illnesses in children due to either the effects of the disease process on the skeleton or from treatment. 8\n\n【3】## // 1. Primary Osteoporosis\n\n【4】\n 1) Osteogenesis imperfecta Osteogenesis imperfecta is a rare genetic disorder with an incidence of approximately 1/25,000. Clinical manifestations include low bone mass, frequent fractures, bone deformity, short stature, wormian bones, blue sclerae, hypermobility of joints, dentinogenesis imperfecta, and deafness. There are 5 types of osteogenesis imperfecta according to clinical severity.\n\n【5】Type 1 is the least severe and nondeforming; type 2 is lethal in the perinatal period because of respiratory insufficiency due to multiple rib fractures; type 3 is associated with limb deformities and is progressively deforming; type 4 has an intermediate phenotype between types 1 and 3; and type 5 has a phenotype similar to that of type 4 but is associated with calcification of interosseous membranes and hypertrophic callus formation at healing fracture sites. The most common mutations in all types are found in COL1A1 and COL1A2 , but novel mutations in other genes have been found (Table 2). 107 f 2) Idiopathic juvenile osteoporosis Idiopathic juvenile osteoporosis is a disease of unknown etiology that is considered genetically heterogeneous in origin.\n\n【6】The clinical manifestations include bone pain and fractures with minimal trauma in girls or boys aged 8–12 years. Symptom severity tends to abate spontaneously with variable residual manifestations. 10,12 ) Differential diagnosis of osteogenesis imperfecta and idiopathic juvenile osteoporosis is shown in Table 3.\n\n【7】 infantile-onset disease. Its clinical manifestations include severe visual impairment, bone fragility, ligamentous laxity, hypotonia, and cognitive impairment. It is transmitted as an autosomal recessive trait and is associated with several types of mutations in LRP5\n\n【8】## 2. Secondary Osteoporosis\n\n【9】\n## 1) Endocrine Disorders\n\n【10】\n Hypogonadism, growth hormone (GH) deficiency, hyperthyroidism or hypothyroidism, hyperparathyroidism, diabetes mellitus (DM), and Cushing syndrome are associated with low bone mass. 8.10.11) Hypogonadism is associated with decreases in cortical width, trabecular number, and osteoid and mineralization activity because of the decreased lifespan of osteoblasts and osteocytes but increased lifespan of osteoclasts, histomorphometrically. 133 GH deficiency is associated with decreases in osteoblast differentiation and proliferation, osteoblast synthesis of insulin-like growth factor-I (IGF-I), insulin like growth factor binding protein-3, osteocalcin, bone-specific alkaline-phosphatase, procollagen type I, and osteoprotegerin. 14 , 15 ), Thyroid disorders also lead to secondary osteoporosis in children. In hyperthyroidism, rates of cartilage maturation, bone turnover, and osteoclastogenic effects increase. 16) In hypothyroidism, cartilage maturation and endochondral bone formation decrease. Additionally, thyroid hormone deficiency in early life delays the development of epiphyseal centers of ossification. 16) In hyperparathyroidism, excess parathyroid\n\n【11】 other genes have been found (Table 2). 107 f Table 3. Differential diagnosis between osteogenesis imperfecta and idiopathic juvenile osteoporosis 2) Idiopathic juvenile osteoporosis Osteogenesis Idiopathic juvenile Characteristic imperfecta osteoporosis Idiopathic juvenile osteoporosis is a disease of unknown Family history ( ) (-) etiology that is considered genetically heterogeneous in origin.\n\n【12】Genetic (+) (-) The clinical manifestations include bone pain and fractures mutation with minimal trauma in girls or boys aged 8–12 years. Symptom Clinical Short stature, deafness, Denti, Scoliosis severity tends to abate spontaneously with variable residual manifestation nogenesis imperfecta Abnormal gait pattern manifestations. 10,12 ) Differential diagnosis of osteogenesis Blue sclerae Bone pain imperfecta and idiopathic juvenile osteoporosis is shown in Hypermobility of joint Table 3.\n\n【13】Radiographic Thin bone and rib Lumbar fracture findings Pathologic fracture Metaphyseal fracture 3) Osteoporosis-pseudoglioma syndrome Disease duration Life long For 2–3 years Osteoporosis-pseudoglioma syndrome is a congenital or (usually prepubertal) Table 2. Types of osteogenesis imperfecta Genetic defect Severity Inheritance Type AD 4 Nondeforming form COLIA1 , COLIA2 Perinatal lethal form COL FA1, COL 1A2, CRTAP, LEPREL 1, PPIB AD, AR 2 Progressively deforming form COL 1A1 , COL 1A2 , CRTAP , LEPREL 1, PPIB , SERPINH1 , BMP1 , FKBP10 , PLOD2 , 3 AD, AR SERPINF1, SP7, WNT1, TMEM38B, CREB3L1, SEC24D COL1A1, COL1A2, CRTAP, PPIB, FKBP10, SERPINF1, WNT1, SP7 Moderate form 4 AD, AR With calcification of the interosseous membranes IFITM5 5 AD and/or hypertrophic callus AD, autosomal dominant; AR, autosomal recessive.\n", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "one of the following: (1) ≥ 2 long bone fractures by the age of 10", "bbox": [65.0, 93.0, 384.0, 108.0]}, {"text": "years and (2) ≥ 3 long bone fractures at any age up to 19 years. 99", "bbox": [66.0, 109.0, 373.0, 124.0]}], "type": "Text", "position": 2}, {"raw_context": [{"text": "Conditions associated with low BMD 2", "bbox": [66.0, 142.0, 322.0, 157.0]}], "type": "Section-header", "position": 3}, {"raw_context": [{"text": "There are primary and secondary causes of reduced bone", "bbox": [78.0, 175.0, 383.0, 190.0]}, {"text": "mass and increased fracture risk (Table 1). Primary osteoporosis", "bbox": [66.0, 191.0, 383.0, 206.0]}, {"text": "occurs due to intrinsic skeletal defects originating from genetic", "bbox": [66.0, 208.0, 383.0, 221.0]}, {"text": "or idiopathic causes, while secondary osteoporosis results from", "bbox": [65.0, 223.0, 383.0, 238.0]}, {"text": "chronic systemic illnesses in children due to either the effects of", "bbox": [66.0, 239.0, 383.0, 253.0]}, {"text": "the disease process on the skeleton or from treatment. 8", "bbox": [66.0, 255.0, 334.0, 269.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": "//", "bbox": [72.0, 272.0, 89.0, 284.0]}, {"text": "1. Primary osteoporosis", "bbox": [66.0, 285.0, 195.0, 301.0]}], "type": "Section-header", "position": 5}, {"raw_context": [{"text": "1) Osteogenesis imperfecta", "bbox": [77.0, 322.0, 215.0, 336.0]}, {"text": "Osteogenesis imperfecta is a rare genetic disorder with an", "bbox": [77.0, 337.0, 383.0, 352.0]}, {"text": "incidence of approximately 1/25,000. Clinical manifestations", "bbox": [66.0, 353.0, 383.0, 368.0]}, {"text": "include low bone mass, frequent fractures, bone deformity,", "bbox": [66.0, 368.0, 383.0, 383.0]}, {"text": "short stature, wormian bones, blue sclerae, hypermobility of", "bbox": [66.0, 384.0, 383.0, 398.0]}, {"text": "joints, dentinogenesis imperfecta, and deafness. There are 5", "bbox": [66.0, 400.0, 383.0, 414.0]}, {"text": "types of osteogenesis imperfecta according to clinical severity.", "bbox": [65.0, 416.0, 382.0, 429.0]}, {"text": "Type 1 is the least severe and nondeforming; type 2 is lethal in", "bbox": [66.0, 431.0, 383.0, 446.0]}, {"text": "the perinatal period because of respiratory insufficiency due to", "bbox": [66.0, 447.0, 383.0, 461.0]}, {"text": "multiple rib fractures; type 3 is associated with limb deformities", "bbox": [66.0, 463.0, 383.0, 478.0]}, {"text": "and is progressively deforming; type 4 has an intermediate", "bbox": [64.0, 479.0, 383.0, 493.0]}, {"text": "phenotype between types 1 and 3; and type 5 has a phenotype", "bbox": [64.0, 495.0, 383.0, 509.0]}, {"text": "similar to that of type 4 but is associated with calcification of", "bbox": [66.0, 510.0, 383.0, 525.0]}, {"text": "interosseous membranes and hypertrophic callus formation at", "bbox": [66.0, 525.0, 383.0, 540.0]}, {"text": "healing fracture sites. The most common mutations in all types", "bbox": [66.0, 541.0, 383.0, 556.0]}, {"text": "are found in COL1A1 and COL1A2 , but novel mutations in", "bbox": [66.0, 557.0, 383.0, 571.0]}, {"text": "other genes have been found (Table 2). 107 f", "bbox": [66.0, 572.0, 272.0, 587.0]}, {"text": "2) Idiopathic juvenile osteoporosis", "bbox": [77.0, 604.0, 250.0, 619.0]}, {"text": "Idiopathic juvenile osteoporosis is a disease of unknown", "bbox": [77.0, 620.0, 383.0, 634.0]}, {"text": "etiology that is considered genetically heterogeneous in origin.", "bbox": [66.0, 636.0, 382.0, 651.0]}, {"text": "The clinical manifestations include bone pain and fractures", "bbox": [66.0, 652.0, 383.0, 666.0]}, {"text": "with minimal trauma in girls or boys aged 8–12 years. Symptom", "bbox": [66.0, 668.0, 383.0, 683.0]}, {"text": "severity tends to abate spontaneously with variable residual", "bbox": [66.0, 683.0, 383.0, 698.0]}, {"text": "manifestations. 10,12 ) Differential diagnosis of osteogenesis", "bbox": [66.0, 697.0, 383.0, 715.0]}, {"text": "imperfecta and idiopathic juvenile osteoporosis is shown in", "bbox": [66.0, 714.0, 383.0, 729.0]}, {"text": "Table 3.", "bbox": [66.0, 730.0, 105.0, 744.0]}], "type": "Text", "position": 6}, {"raw_context": [{"text": "infantile-onset disease. Its clinical manifestations include severe", "bbox": [410.0, 94.0, 726.0, 108.0]}, {"text": "visual impairment, bone fragility, ligamentous laxity, hypotonia,", "bbox": [410.0, 109.0, 726.0, 124.0]}, {"text": "and cognitive impairment. It is transmitted as an autosomal", "bbox": [410.0, 126.0, 727.0, 140.0]}, {"text": "recessive trait and is associated with several types of mutations", "bbox": [410.0, 141.0, 727.0, 155.0]}, {"text": "in LRP5", "bbox": [408.0, 156.0, 455.0, 171.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "2. Secondary osteoporosis", "bbox": [410.0, 187.0, 557.0, 203.0]}], "type": "Section-header", "position": 8}, {"raw_context": [{"text": "1) Endocrine disorders", "bbox": [421.0, 223.0, 538.0, 238.0]}], "type": "Section-header", "position": 9}, {"raw_context": [{"text": "Hypogonadism, growth hormone (GH) deficiency, hyperthy-", "bbox": [421.0, 239.0, 725.0, 253.0]}, {"text": "roidism or hypothyroidism, hyperparathyroidism, diabetes", "bbox": [410.0, 255.0, 729.0, 270.0]}, {"text": "mellitus (DM), and Cushing syndrome are associated with", "bbox": [410.0, 270.0, 731.0, 285.0]}, {"text": "low bone mass. 8.10.11) Hypogonadism is associated with", "bbox": [410.0, 283.0, 727.0, 303.0]}, {"text": "decreases in cortical width, trabecular number, and osteoid", "bbox": [410.0, 301.0, 727.0, 316.0]}, {"text": "and mineralization activity because of the decreased lifespan of", "bbox": [410.0, 317.0, 727.0, 332.0]}, {"text": "osteoblasts and osteocytes but increased lifespan of osteoclasts,", "bbox": [410.0, 333.0, 727.0, 348.0]}, {"text": "histomorphometrically. 133 GH deficiency is associated with", "bbox": [410.0, 348.0, 727.0, 364.0]}, {"text": "decreases in osteoblast differentiation and proliferation,", "bbox": [410.0, 364.0, 727.0, 380.0]}, {"text": "osteoblast synthesis of insulin-like growth factor-I (IGF-I),", "bbox": [410.0, 381.0, 728.0, 396.0]}, {"text": "insulin like growth factor binding protein-3, osteocalcin,", "bbox": [410.0, 396.0, 727.0, 411.0]}, {"text": "bone-specific alkaline-phosphatase, procollagen type I, and", "bbox": [410.0, 412.0, 727.0, 427.0]}, {"text": "osteoprotegerin. 14 , 15 ),", "bbox": [410.0, 428.0, 514.0, 442.0]}, {"text": "Thyroid disorders also lead to secondary osteoporosis in", "bbox": [422.0, 443.0, 728.0, 458.0]}, {"text": "children. In hyperthyroidism, rates of cartilage maturation,", "bbox": [410.0, 459.0, 728.0, 474.0]}, {"text": "bone turnover, and osteoclastogenic effects increase. 16) In", "bbox": [410.0, 475.0, 727.0, 489.0]}, {"text": "hypothyroidism, cartilage maturation and endochondral bone", "bbox": [410.0, 491.0, 727.0, 506.0]}, {"text": "formation decrease. Additionally, thyroid hormone deficiency", "bbox": [410.0, 507.0, 726.0, 521.0]}, {"text": "in early life delays the development of epiphyseal centers of", "bbox": [410.0, 522.0, 727.0, 537.0]}, {"text": "ossification. 16) In hyperparathyroidism, excess parathyroid", "bbox": [410.0, 537.0, 727.0, 554.0]}], "type": "Text", "position": 10}, {"raw_context": [{"text": "other genes have been found (Table 2). 107 f", "bbox": [66.0, 572.0, 272.0, 587.0]}, {"text": "Table 3. Differential diagnosis between osteogenesis imperfecta", "bbox": [411.0, 572.0, 726.0, 587.0]}, {"text": "and idiopathic juvenile osteoporosis", "bbox": [412.0, 588.0, 589.0, 602.0]}, {"text": "2) Idiopathic juvenile osteoporosis", "bbox": [77.0, 604.0, 250.0, 619.0]}, {"text": "Osteogenesis", "bbox": [528.0, 605.0, 588.0, 616.0]}, {"text": "Idiopathic juvenile", "bbox": [634.0, 605.0, 717.0, 616.0]}, {"text": "Characteristic", "bbox": [411.0, 610.0, 472.0, 623.0]}, {"text": "imperfecta", "bbox": [532.0, 617.0, 583.0, 630.0]}, {"text": "osteoporosis", "bbox": [645.0, 617.0, 705.0, 630.0]}, {"text": "Idiopathic juvenile osteoporosis is a disease of unknown", "bbox": [77.0, 620.0, 383.0, 634.0]}, {"text": "Family history", "bbox": [412.0, 633.0, 474.0, 646.0]}, {"text": "( )", "bbox": [549.0, 635.0, 567.0, 646.0]}, {"text": "(-)", "bbox": [668.0, 635.0, 681.0, 645.0]}, {"text": "etiology that is considered genetically heterogeneous in origin.", "bbox": [66.0, 636.0, 382.0, 651.0]}, {"text": "Genetic", "bbox": [412.0, 650.0, 447.0, 661.0]}, {"text": "(+)", "bbox": [549.0, 651.0, 565.0, 662.0]}, {"text": "(-)", "bbox": [668.0, 651.0, 681.0, 662.0]}, {"text": "The clinical manifestations include bone pain and fractures", "bbox": [66.0, 652.0, 383.0, 666.0]}, {"text": "mutation", "bbox": [414.0, 664.0, 460.0, 675.0]}, {"text": "with minimal trauma in girls or boys aged 8–12 years. Symptom", "bbox": [66.0, 668.0, 383.0, 683.0]}, {"text": "Clinical", "bbox": [412.0, 678.0, 446.0, 690.0]}, {"text": "Short stature, deafness, Denti, Scoliosis", "bbox": [492.0, 679.0, 664.0, 690.0]}, {"text": "severity tends to abate spontaneously with variable residual", "bbox": [66.0, 683.0, 383.0, 698.0]}, {"text": "manifestation", "bbox": [416.0, 692.0, 478.0, 704.0]}, {"text": "nogenesis imperfecta", "bbox": [498.0, 692.0, 596.0, 705.0]}, {"text": "Abnormal gait pattern", "bbox": [625.0, 692.0, 724.0, 704.0]}, {"text": "manifestations. 10,12 ) Differential diagnosis of osteogenesis", "bbox": [66.0, 697.0, 383.0, 715.0]}, {"text": "Blue sclerae", "bbox": [492.0, 706.0, 545.0, 718.0]}, {"text": "Bone pain", "bbox": [625.0, 706.0, 674.0, 719.0]}, {"text": "imperfecta and idiopathic juvenile osteoporosis is shown in", "bbox": [66.0, 714.0, 383.0, 729.0]}, {"text": "Hypermobility of joint", "bbox": [490.0, 719.0, 590.0, 732.0]}, {"text": "Table 3.", "bbox": [66.0, 730.0, 105.0, 744.0]}, {"text": "Radiographic", "bbox": [412.0, 735.0, 471.0, 747.0]}, {"text": "Thin bone and rib", "bbox": [492.0, 735.0, 573.0, 747.0]}, {"text": "Lumbar fracture", "bbox": [625.0, 735.0, 697.0, 747.0]}, {"text": "findings", "bbox": [415.0, 749.0, 456.0, 761.0]}, {"text": "Pathologic fracture", "bbox": [491.0, 749.0, 575.0, 760.0]}, {"text": "Metaphyseal fracture", "bbox": [625.0, 749.0, 720.0, 761.0]}, {"text": "3) Osteoporosis-pseudoglioma syndrome", "bbox": [77.0, 762.0, 285.0, 777.0]}, {"text": "Disease duration Life long", "bbox": [412.0, 764.0, 532.0, 776.0]}, {"text": "For 2–3 years", "bbox": [625.0, 764.0, 686.0, 775.0]}, {"text": "Osteoporosis-pseudoglioma syndrome is a congenital or", "bbox": [77.0, 778.0, 383.0, 792.0]}, {"text": "(usually prepubertal)", "bbox": [631.0, 778.0, 723.0, 791.0]}, {"text": "Table 2. Types of osteogenesis imperfecta", "bbox": [67.0, 823.0, 269.0, 838.0]}, {"text": "Genetic defect", "bbox": [529.0, 840.0, 596.0, 854.0]}, {"text": "Severity", "bbox": [68.0, 841.0, 105.0, 854.0]}, {"text": "Inheritance", "bbox": [344.0, 841.0, 393.0, 855.0]}, {"text": "Type", "bbox": [308.0, 842.0, 330.0, 855.0]}, {"text": "AD 4", "bbox": [360.0, 854.0, 388.0, 869.0]}, {"text": "Nondeforming form", "bbox": [67.0, 855.0, 158.0, 870.0]}, {"text": "COLIA1 , COLIA2", "bbox": [413.0, 855.0, 487.0, 869.0]}, {"text": "Perinatal lethal form", "bbox": [66.0, 870.0, 158.0, 884.0]}, {"text": "COL FA1, COL 1A2, CRTAP, LEPREL 1, PPIB", "bbox": [413.0, 870.0, 578.0, 884.0]}, {"text": "AD, AR", "bbox": [353.0, 871.0, 386.0, 884.0]}, {"text": "2", "bbox": [313.0, 872.0, 321.0, 883.0]}, {"text": "Progressively deforming form", "bbox": [66.0, 886.0, 199.0, 900.0]}, {"text": "COL 1A1 , COL 1A2 , CRTAP , LEPREL 1, PPIB , SERPINH1 , BMP1 , FKBP10 , PLOD2 ,", "bbox": [413.0, 886.0, 720.0, 900.0]}, {"text": "3", "bbox": [313.0, 888.0, 322.0, 900.0]}, {"text": "AD, AR", "bbox": [353.0, 887.0, 386.0, 900.0]}, {"text": "SERPINF1, SP7, WNT1, TMEM38B, CREB3L1, SEC24D", "bbox": [420.0, 900.0, 637.0, 913.0]}, {"text": "COL1A1, COL1A2, CRTAP, PPIB, FKBP10, SERPINF1, WNT1, SP7", "bbox": [413.0, 915.0, 666.0, 930.0]}, {"text": "Moderate form", "bbox": [66.0, 916.0, 136.0, 930.0]}, {"text": "4", "bbox": [313.0, 916.0, 321.0, 927.0]}, {"text": "AD, AR", "bbox": [353.0, 916.0, 385.0, 930.0]}, {"text": "With calcification of the interosseous membranes", "bbox": [66.0, 931.0, 297.0, 945.0]}, {"text": "IFITM5", "bbox": [413.0, 931.0, 445.0, 945.0]}, {"text": "5", "bbox": [313.0, 933.0, 320.0, 943.0]}, {"text": "AD", "bbox": [361.0, 933.0, 377.0, 945.0]}, {"text": "and/or hypertrophic callus", "bbox": [75.0, 946.0, 194.0, 959.0]}, {"text": "AD, autosomal dominant; AR, autosomal recessive.", "bbox": [67.0, 962.0, 309.0, 974.0]}], "type": "Table", "position": 11}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2022】全科室最全临床指南+专家共识（最全版）/2022全科室临床指南/内分泌科/KSPE：优化儿童和青少年骨健康的临床实践指南（2022）.pdf", "page_num": 3}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type2": "缺少换行#4#4#Osteogenesis imperfecta is a另起一行\n缺少换行#5#5#2) Idiopathic juvenile osteoporosis另起一行\nIdiopathic juvenile osteoporosis另起一行\n缺少换行#10#10#Thyroid disorders also lead to另起一行", "type3": "无关文本#0#13# to 19 years. 99部分段落末尾，以及句末的数字问题无关噪声应用全文\n无关文本#1#1# 2\n无关文本#2#2#  (Table 1)\n无关文本#5#5#  (Table 2). 107 f", "type4": "语义不完整#7#7#前面缺少3) Osteoporosis-pseudoglioma syndrome\nOsteoporosis-pseudoglioma syndrome is a congenital or\n栏目混乱#6#11#内容顺序上下颠倒，穿插出现", "type6": "准确性#11#13#表格内容内容杂乱"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:41", "update_time": "2024-05-08 00:20:00"}
{"id": 1082602, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 738, "source_info": {"seq_id": "b3931e26-f936-49aa-8a41-12153d06e7e3", "title": null, "text": "【0】页码:95\n e fo\n\n【1】 小狗科 s\n# 附件7\n\n【2】\n 小狗科研究所\n\n【3】 n the formation of the second that the sec 小狗科研究 差: 病侧乳腺有严重畸形。\n\n【4】\n e f\n\n【5】 s. S\n l 19 Dis\n 小狗科研公开课\n 47 is\n\n【6】 41 3\n\n【7】 s fo\n 小狗科研公共 is\n\n【8】 l 19 big\n\n【9】 小狗科研公开课\n 4 H 2 H 2\n\n【10】 \n\n【11】 l to the same time to the same time the same time time the same time time the same time time the same time time time the same time time time the same time time time time time\n\n【12】 e f\n\n【13】 小狗科研究所 is", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "e fo", "bbox": [526.0, 15.0, 589.0, 65.0]}], "type": "Text", "position": 0}, {"raw_context": [{"text": "小狗科 s", "bbox": [22.0, 36.0, 126.0, 95.0]}], "type": "Text", "position": 1}, {"raw_context": [{"text": "附件7", "bbox": [115.0, 95.0, 178.0, 131.0]}], "type": "Title", "position": 2}, {"raw_context": [{"text": "小狗科研究所", "bbox": [600.0, 32.0, 776.0, 118.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "n the formation of the second that the sec", "bbox": [159.0, 111.0, 794.0, 319.0]}, {"text": "小狗科研究 差: 病侧乳腺有严重畸形。\n", "bbox": [57.0, 288.0, 434.0, 377.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": "e f", "bbox": [3.0, 271.0, 50.0, 313.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "s. S", "bbox": [103.0, 422.0, 160.0, 488.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "l 19 Dis", "bbox": [167.0, 455.0, 342.0, 559.0]}], "type": "Formula", "position": 8}, {"raw_context": [{"text": "小狗科研公开课", "bbox": [396.0, 395.0, 576.0, 484.0]}], "type": "Formula", "position": 9}, {"raw_context": [{"text": "47 is", "bbox": [0.0, 500.0, 76.0, 547.0]}], "type": "Formula", "position": 10}, {"raw_context": [{"text": "41 3", "bbox": [750.0, 516.0, 794.0, 553.0]}], "type": "Text", "position": 11}, {"raw_context": [{"text": "s fo", "bbox": [479.0, 556.0, 535.0, 610.0]}], "type": "Text", "position": 13}, {"raw_context": [{"text": "小狗科研公共 is", "bbox": [232.0, 576.0, 410.0, 662.0]}], "type": "Formula", "position": 15}, {"raw_context": [{"text": "l 19 big", "bbox": [544.0, 583.0, 719.0, 687.0]}], "type": "Text", "position": 17}, {"raw_context": [{"text": "小狗科研公开课", "bbox": [586.0, 694.0, 767.0, 782.0]}], "type": "Text", "position": 18}, {"raw_context": [{"text": "4 H 2 H 2", "bbox": [0.0, 755.0, 119.0, 817.0]}], "type": "Formula", "position": 19}, {"raw_context": [{"text": "", "bbox": [137.0, 784.0, 504.0, 955.0]}], "type": "Text", "position": 20}, {"raw_context": [{"text": "l to the same time to the same time the same time time the same time time the same time time the same time time time the same time time time the same time time time time time", "bbox": [514.0, 913.0, 794.0, 1052.0]}], "type": "Text", "position": 22}, {"raw_context": [{"text": "e f", "bbox": [29.0, 1008.0, 88.0, 1062.0]}], "type": "Text", "position": 23}, {"raw_context": [{"text": "小狗科研究所 is", "bbox": [100.0, 1027.0, 279.0, 1112.0]}], "type": "Text", "position": 25}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2022】全科室最全临床指南+专家共识（最全版）/2022全科室临床指南/肿瘤科/乳腺癌诊疗指南（2022年版）.pdf", "page_num": 95}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": null, "type3": null, "type4": null, "type5": null, "type6": "有用性#0#13#全篇为水印和其他无关内容"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:41", "update_time": "2024-05-08 00:47:59"}
{"id": 1082601, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 738, "source_info": {"seq_id": "d6c1ff98-5e98-45b2-8480-065f86d9a2c0", "title": null, "text": "【0】页码:5\n However, a lack of real-life data, including cost-effectiveness, has limited the widespread implementation of these approaches in HCT recipients. T2Candida appears promising in children based on a recent clinical trial [47] .\n\n【1】## Faq15: Should Candida Primary Prophylaxis Be Continued Postengraftment In Patients Without Gvhd?\n\n【2】\n In the pivotal clinical trials, fluconazole prophylaxis in HCT was continued until posttransplantation day 75 or 100 [ 34 , 35 ].\n\n【3】A post hoc analysis of one of these trials demonstrated lower incidence of gastrointestinal GVHD and a sustained 8-year survival benefit in the fluconazole arm over placebo [48] . However, HCT recipients without severe mucositis or gastrointestinal GVHD are less likely to translocate gut flora, including Candida species, after engraftment. More data are needed to evaluate the effect of fluconazole prophylaxis beyond engraftment on clinical outcomes. Pending more data, prolonging fluconazole prophylaxis until post-transplantation day 75 should be considered, if feasible and well-tolerated (A-I).\n\n【4】## Faq16: What Is The Utility Of Adjunctive Treatments, Such As Granulocyte Transfusions, In Managing Severe Ic In Hct Recipients?\n\n【5】\n Based on the available data and their short half-life, granulocyte transfusions do not appear to provide a significant benefit (D-II) [ 49 , 50 ]. However, they may be considered in patients with sustained candidemia and prolonged profound neutropenia when count recovery is anticipated [ 23 ].\n\n【6】## Acknowledgments\n\n【7】\n Financial disclosure: G.A.P. was supported in part by the National Cancer Institute (Grant P30 CA008748).\n\n【8】Conflict of interest statement : D.N. has received research support from MSD and Pfizer and consulting fees from MSD, Pfizer, Basilea, and Gilead. W.J.S. has received consulting fees from Sfunga. P.A.C has received research support and/or consulting fees from AbbVie and consulting fees from Intellisphere, and Janssen Biotech. G.A.P. has received research support (funds paid to institution) from Merck and Shire Pharmaceutical (now known as Takeda) and consulting/other fees from AlloVir, Amplyx, Cidara, Merck & Co, Octapharma, SLC Behring, Takeda, SymBio, and Vera. M.A.S. reports receiving research support from Gilead and Merck and honoraria from lectures for Pfizer, Gilead, and Merck, and serving as a consultant for Pfizer, Merck, Roche, and F2G. The other authors have no conflicts of interest to report.\n\n【9】## Supplementary Materials\n\n【10】\n Supplementary material associated with this article can be found in the online version at doi: 10.1016/j.jtct.2023.01.011 .\n\n【11】## References\n\n【12】\n 1. Cesaro S, Tridello G, Blijlevens N, et al. Incidence, risk factors, and longterm outcome of acute leukemia patients with early candidemia after allogeneic stem cell transplantation: a study by the Acute Leukemia and Infectious Diseases Working Parties of European Society for Blood and Marrow Transplantation. Clin Infect Dis . 2018;67:564–572.\n\n【13】2. Carpenter PA, Papanicolaou G, Chemaly RF, Boeckh M, Savani BN. American Society for Transplantation and Cellular Therapy infectious disease guidelines: preface to the series. Transplant Cell Ther . 2021;27:103–104.\n 3. Marr KA. Invasive Candida infections: the changing epidemiology. Oncology (Williston Park).. 2004;18(14 suppl 13):9–14.\n\n【14】4. Horn DL, Neofytos D, Anaissie EJ, et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the Prospective Antifungal Therapy Alliance registry. Clin Infect Dis . 2009;48:1695–1703.\n\n【15】5. Safdar A, van Rhee F, Henslee-Downey JP, Singhal S, Mehta J. Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow\n\n【16】 transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome. Bone Marrow Transplant .. 2001;28:873–878.\n\n【17】6. Dufresne SF, Marr KA, Sydnor E, et al. Epidemiology of Candida kefyr in patients with hematologic malignancies. J Clin Microbiol. 2014;52:1830– 1837.\n\n【18】7. Lamoth F, Kontoyiannis DP. The Candida auris alert: facts and perspectives.\n\n【19】J Infect Dis ., 2018;217:516–520.\n\n【20】8. Guarana M, Nucci M. Acute disseminated candidiasis with skin lesions: a systematic review. Clin Microbiol Infect .. 2018;24:246–250.\n\n【21】9. Rammaert B, Desjardins A, Lortholary O. New insights into hepatosplenic candidosis, a manifestation of chronic disseminated candidosis. Mycoses ..\n\n【22】2012;55:e74–e84.\n\n【23】10. Berenguer J, Buck M, Witebsky F, Stock F, Pizzo PA, Walsh TJ. Lysis-centrifugation blood cultures in the detection of tissue-proven invasive candidiasis. Disseminated versus single-organ infection. Diagn Microbiol Infect Dis .. 1993;17:103–109.\n\n【24】11. Horvath LL, George BJ, Murray CK, Harrison LS, Hospenthal DR. Direct comparison of the BACTEC 9240 and BacT/ALERT 3D automated blood culture systems for Candida growth detection. J Clin Microbiol ., 2004;42: 115–118.\n\n【25】12. Spanu T, Posteraro B, Fiori B, et al. Direct MALDI-TOF mass spectrometry assay of blood culture broths for rapid identification of Candida species causing bloodstream infections: an observational study in two large microbiology laboratories. J Clin Microbiol . 2012;50:176–179.\n\n【26】13. Datcu R, Boel J, Jensen IM, Arpi M. Comparison of BACTEC™ blood culture media for the detection of fungemia. Eur J Clin Microbiol Infect Dis .\n\n【27】2017;36:131–137.\n\n【28】14. Arendrup MC, Bergmann OJ, Larsson L, Nielsen HV, Jarløv JO, Christensson B. Detection of candidaemia in patients with and without underlying haematological disease. Clin Microbiol Infect. . 2010;16:855–862.\n\n【29】15. Kontoyiannis DP, Luna MA, Samuels BI, Bodey GP. Hepatosplenic candidiasis. A manifestation of chronic disseminated candidiasis. Infect Dis Clin North Am . , 2000;14:721–739.\n\n【30】16. Odabasi Z, Mattiuzzi G, Estey E, et al. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis . . 2004;39:199–205.\n\n【31】17. Ostrosky-Zeichner L, BD Alexander, Kett DH, et al. Multicenter clinical evaluation of the (1 → 3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis . 2005;41:654–659.\n\n【32】18. Obayashi T, Negishi K, Suzuki T, Funata N. Reappraisal of the serum (1 → 3)-beta-D-glucan assay for the diagnosis of invasive fungal infections—a study based on autopsy cases from 6 years. Clin Infect Dis. , 2008;46:1864–1870.\n\n【33】19. Lamoth F, Cruciani M, Mengoli C, et al. ß-Glucan antigenemia assay for the diagnosis of invasive fungal infections in patients with hematological malignancies: a systematic review and meta-analysis of cohort studies from the Third European Conference on Infections in Leukemia (ECIL-3).\n\n【34】Clin Infect Dis. . 2012;54:633–643.\n\n【35】20. Otto WR, Dvorak CC, Boge CLK, et al. Prospective evaluation of the Fungitell® (1 → 3) beta-D-glucan assay as a diagnostic tool for invasive fungal disease in pediatric allogeneic hematopoietic cell transplantation: a report from the Children's Oncology Group. Pediatr Transplant . 2023;27:e14399.\n\n【36】21. Marty FM, Koo S. Role of (1 → 3)-beta-D-glucan in the diagnosis of invasive aspergillosis. Med Mycol. , 2009;47(suppl 1)):$233–$240.\n\n【37】22. Tschopp J, Brunel AS, Spartina O, Croxatto A, Lamothe F, Bochud PY. High false-positive rate of (1,3)- B -D-glucan in onco-hematological patients receiving immunoglobulins and therapeutic antibodies. Clin Infect Dis ., 2022;75:330–333.\n\n【38】23. Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. . 2016;62:e1–e50.\n\n【39】24. Mora-Duarte J, Betts R, Rothstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med. . 2002;347:2020– 2029.\n\n【40】25. Riboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med . 2007;356:2472–2482.\n\n【41】26. Pappas PG, Rothstein CM, Betts RF, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis . 2007;45:883–893 .\n\n【42】27. Fisher BT, Agoutis TE, Xiao R, et al. Comparative effectiveness of echinocandins vs triazoles or amphotericin B formulations as initial directed therapy for invasive candidiasis in children and adolescents. J Pediatric Infect Dis Soc . 2021;10(11):994–1000.\n\n【43】28. Alexander BD, Johnson MD, Pfeiffer CD, et  al. Increasing echinocandin resistance in Candida glabrata : clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis.. 2013;56:1724–1732.\n\n【44】29. Lewis 2nd JS, Wieder hold NP, Wickes BL, Patterson TF, Jorgensen JH.\n\n【45】Rapid emergence of echinocandin resistance in Candida glabrata resulting in clinical and microbiologic failure. Antimicrob Agents Che mother ..\n\n【46】2013;57:4559–4561.\n Children's Oncology Group. Pediatr Transplant . 2023;27:e14399.\n\n【47】21. Marty FM, Koo S. Role of (1 → 3)-beta-D-glucan in the diagnosis of invasive aspergillosis. Med Mycol. , 2009;47(suppl 1)):$233–$240.\n\n【48】22. Tschopp J, Brunel AS, Spartina O, Croxatto A, Lamothe F, Bochud PY. High false-positive rate of (1,3)- B -D-glucan in onco-hematological patients receiving immunoglobulins and therapeutic antibodies. Clin Infect Dis ., 2022;75:330–333.\n\n【49】23. Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. . 2016;62:e1–e50.\n\n【50】24. Mora-Duarte J, Betts R, Rothstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med. . 2002;347:2020– 2029.\n\n【51】25. Riboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med . 2007;356:2472–2482.\n\n【52】26. Pappas PG, Rothstein CM, Betts RF, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis . 2007;45:883–893 .\n\n【53】27. Fisher BT, Agoutis TE, Xiao R, et al. Comparative effectiveness of echinocandins vs triazoles or amphotericin B formulations as initial directed therapy for invasive candidiasis in children and adolescents. J Pediatric Infect Dis Soc . 2021;10(11):994–1000.\n\n【54】28. Alexander BD, Johnson MD, Pfeiffer CD, et  al. Increasing echinocandin resistance in Candida glabrata : clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis.. 2013;56:1724–1732.\n\n【55】29. Lewis 2nd JS, Wieder hold NP, Wickes BL, Patterson TF, Jorgensen JH.\n\n【56】Rapid emergence of echinocandin resistance in Candida glabrata resulting in clinical and microbiologic failure. Antimicrob Agents Che mother ..\n\n【57】2013;57:4559–4561.\n\n【58】30. Spec A, Pullman J, Thompson GR, et al. MSG-10: a phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-\n\n【59】 226", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "However, a lack of real-life data, including cost-effectiveness,", "bbox": [83.0, 73.0, 390.0, 88.0]}, {"text": "has limited the widespread implementation of these", "bbox": [83.0, 89.0, 390.0, 102.0]}, {"text": "approaches in HCT recipients. T2Candida appears promising in", "bbox": [83.0, 102.0, 391.0, 116.0]}, {"text": "children based on a recent clinical trial [47] .", "bbox": [82.0, 117.0, 297.0, 130.0]}], "type": "Text", "position": 1}, {"raw_context": [{"text": "FAQ15: Should Candida primary prophylaxis be continued", "bbox": [83.0, 146.0, 374.0, 160.0]}, {"text": "postengraftment in patients without GVHD?", "bbox": [83.0, 161.0, 307.0, 174.0]}], "type": "Section-header", "position": 2}, {"raw_context": [{"text": "In the pivotal clinical trials, fluconazole prophylaxis in HCT", "bbox": [99.0, 174.0, 390.0, 188.0]}, {"text": "was continued until posttransplantation day 75 or 100 [ 34 , 35 ].", "bbox": [83.0, 188.0, 390.0, 202.0]}, {"text": "A post hoc analysis of one of these trials demonstrated lower", "bbox": [83.0, 203.0, 390.0, 216.0]}, {"text": "incidence of gastrointestinal GVHD and a sustained 8-year sur-", "bbox": [83.0, 216.0, 389.0, 230.0]}, {"text": "vival benefit in the fluconazole arm over placebo [48] . However,", "bbox": [83.0, 230.0, 389.0, 244.0]}, {"text": "HCT recipients without severe mucositis or gastrointestinal", "bbox": [83.0, 244.0, 390.0, 258.0]}, {"text": "GVHD are less likely to translocate gut flora, including Candida", "bbox": [82.0, 258.0, 391.0, 272.0]}, {"text": "species, after engraftment. More data are needed to evaluate", "bbox": [83.0, 272.0, 390.0, 286.0]}, {"text": "the effect of fluconazole prophylaxis beyond engraftment on", "bbox": [83.0, 285.0, 391.0, 300.0]}, {"text": "clinical outcomes. Pending more data, prolonging fluconazole", "bbox": [82.0, 300.0, 390.0, 314.0]}, {"text": "prophylaxis until post-transplantation day 75 should be consid-", "bbox": [83.0, 315.0, 389.0, 327.0]}, {"text": "ered, if feasible and well-tolerated (A-I).", "bbox": [83.0, 328.0, 275.0, 340.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "FAQ16: What is the utility of adjunctive treatments, such as", "bbox": [83.0, 357.0, 382.0, 371.0]}, {"text": "granulocyte transfusions, in managing severe IC in HCT", "bbox": [83.0, 372.0, 359.0, 385.0]}, {"text": "recipients?", "bbox": [83.0, 387.0, 141.0, 399.0]}], "type": "Section-header", "position": 4}, {"raw_context": [{"text": "Based on the available data and their short half-life, granu-", "bbox": [99.0, 398.0, 390.0, 413.0]}, {"text": "locyte transfusions do not appear to provide a significant bene-", "bbox": [83.0, 413.0, 389.0, 427.0]}, {"text": "fit (D-II) [ 49 , 50 ]. However, they may be considered in patients", "bbox": [83.0, 427.0, 390.0, 441.0]}, {"text": "with sustained candidemia and prolonged profound neutrope-", "bbox": [83.0, 441.0, 388.0, 455.0]}, {"text": "nia when count recovery is anticipated [ 23 ].", "bbox": [83.0, 455.0, 298.0, 469.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "ACKNOWLEDGMENTS", "bbox": [83.0, 484.0, 196.0, 498.0]}], "type": "Section-header", "position": 6}, {"raw_context": [{"text": "Financial disclosure: G.A.P. was supported in part by the", "bbox": [99.0, 499.0, 391.0, 513.0]}, {"text": "National Cancer Institute (Grant P30 CA008748).", "bbox": [83.0, 513.0, 319.0, 527.0]}, {"text": "Conflict of interest statement : D.N. has received research", "bbox": [99.0, 528.0, 391.0, 541.0]}, {"text": "support from MSD and Pfizer and consulting fees from MSD,", "bbox": [83.0, 542.0, 390.0, 555.0]}, {"text": "Pfizer, Basilea, and Gilead. W.J.S. has received consulting fees", "bbox": [83.0, 556.0, 391.0, 569.0]}, {"text": "from Sfunga. P.A.C has received research support and/or con-", "bbox": [83.0, 570.0, 389.0, 583.0]}, {"text": "sulting fees from AbbVie and consulting fees from Intelli-", "bbox": [83.0, 584.0, 389.0, 597.0]}, {"text": "sphere, and Janssen Biotech. G.A.P. has received research", "bbox": [83.0, 598.0, 390.0, 610.0]}, {"text": "support (funds paid to institution) from Merck and Shire Phar-", "bbox": [83.0, 610.0, 389.0, 624.0]}, {"text": "maceutical (now known as Takeda) and consulting/other fees", "bbox": [83.0, 624.0, 390.0, 638.0]}, {"text": "from AlloVir, Amplyx, Cidara, Merck & Co, Octapharma, SLC", "bbox": [83.0, 638.0, 390.0, 652.0]}, {"text": "Behring, Takeda, SymBio, and Vera. M.A.S. reports receiving", "bbox": [83.0, 652.0, 390.0, 667.0]}, {"text": "research support from Gilead and Merck and honoraria from", "bbox": [83.0, 666.0, 391.0, 681.0]}, {"text": "lectures for Pfizer, Gilead, and Merck, and serving as a consul-", "bbox": [83.0, 680.0, 389.0, 695.0]}, {"text": "tant for Pfizer, Merck, Roche, and F2G. The other authors have", "bbox": [83.0, 694.0, 390.0, 709.0]}, {"text": "no conflicts of interest to report.", "bbox": [83.0, 708.0, 242.0, 722.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "SUPPLEMENTARY MATERIALS", "bbox": [83.0, 737.0, 237.0, 752.0]}], "type": "Section-header", "position": 8}, {"raw_context": [{"text": "Supplementary material associated with this article can be", "bbox": [99.0, 752.0, 390.0, 766.0]}, {"text": "found in the online version at doi: 10.1016/j.jtct.2023.01.011 .", "bbox": [83.0, 767.0, 380.0, 780.0]}], "type": "Text", "position": 9}, {"raw_context": [{"text": "REFERENCES", "bbox": [84.0, 797.0, 152.0, 809.0]}], "type": "Section-header", "position": 10}, {"raw_context": [{"text": "1. Cesaro S, Tridello G, Blijlevens N, et al. Incidence, risk factors, and long-", "bbox": [90.0, 809.0, 388.0, 821.0]}, {"text": "term outcome of acute leukemia patients with early candidemia after allo-", "bbox": [101.0, 821.0, 389.0, 833.0]}, {"text": "geneic stem cell transplantation: a study by the Acute Leukemia and Infec-", "bbox": [101.0, 831.0, 389.0, 843.0]}, {"text": "tious Diseases Working Parties of European Society for Blood and Marrow", "bbox": [102.0, 842.0, 390.0, 854.0]}, {"text": "Transplantation. Clin Infect Dis . 2018;67:564–572.", "bbox": [101.0, 852.0, 298.0, 865.0]}, {"text": "2. Carpenter PA, Papanicolaou G, Chemaly RF, Boeckh M, Savani BN. Ameri-", "bbox": [89.0, 863.0, 389.0, 874.0]}, {"text": "can Society for Transplantation and Cellular Therapy infectious disease", "bbox": [101.0, 873.0, 390.0, 886.0]}, {"text": "guidelines: preface to the series. Transplant Cell Ther . 2021;27:103–104.", "bbox": [101.0, 884.0, 383.0, 896.0]}], "type": "Text", "position": 11}, {"raw_context": [{"text": "3. Marr KA. Invasive Candida infections: the changing epidemiology. Oncol-", "bbox": [89.0, 894.0, 388.0, 907.0]}, {"text": "ogy (Williston Park).. 2004;18(14 suppl 13):9–14.", "bbox": [100.0, 905.0, 293.0, 917.0]}, {"text": "4. Horn DL, Neofytos D, Anaissie EJ, et al. Epidemiology and outcomes of can-", "bbox": [89.0, 916.0, 389.0, 928.0]}, {"text": "didemia in 2019 patients: data from the Prospective Antifungal Therapy", "bbox": [102.0, 926.0, 390.0, 938.0]}, {"text": "Alliance registry. Clin Infect Dis . 2009;48:1695–1703.", "bbox": [101.0, 937.0, 309.0, 949.0]}, {"text": "5. Safdar A, van Rhee F, Henslee-Downey JP, Singhal S, Mehta J. Candida glab-", "bbox": [89.0, 948.0, 388.0, 960.0]}, {"text": "rata and Candida krusei fungemia after high-risk allogeneic marrow", "bbox": [100.0, 959.0, 390.0, 970.0]}], "type": "List-item", "position": 12}, {"raw_context": [{"text": "transplantation: no adverse effect of low-dose fluconazole prophylaxis on", "bbox": [436.0, 76.0, 726.0, 88.0]}, {"text": "incidence and outcome. Bone Marrow Transplant .. 2001;28:873–878.", "bbox": [436.0, 88.0, 702.0, 100.0]}, {"text": "6. Dufresne SF, Marr KA, Sydnor E, et al. Epidemiology of Candida kefyr in", "bbox": [423.0, 98.0, 726.0, 111.0]}, {"text": "patients with hematologic malignancies. J Clin Microbiol. 2014;52:1830–", "bbox": [436.0, 110.0, 724.0, 120.0]}, {"text": "1837.", "bbox": [436.0, 120.0, 460.0, 131.0]}, {"text": "7. Lamoth F, Kontoyiannis DP. The Candida auris alert: facts and perspectives.", "bbox": [424.0, 128.0, 724.0, 142.0]}, {"text": "J Infect Dis ., 2018;217:516–520.", "bbox": [435.0, 141.0, 559.0, 153.0]}, {"text": "8. Guarana M, Nucci M. Acute disseminated candidiasis with skin lesions: a", "bbox": [423.0, 152.0, 726.0, 163.0]}, {"text": "systematic review. Clin Microbiol Infect .. 2018;24:246–250.", "bbox": [436.0, 162.0, 665.0, 174.0]}, {"text": "9. Rammaert B, Desjardins A, Lortholary O. New insights into hepatosplenic", "bbox": [423.0, 173.0, 724.0, 184.0]}, {"text": "candidosis, a manifestation of chronic disseminated candidosis. Mycoses ..", "bbox": [436.0, 183.0, 724.0, 195.0]}, {"text": "2012;55:e74–e84.", "bbox": [436.0, 194.0, 508.0, 205.0]}, {"text": "10. Berenguer J, Buck M, Witebsky F, Stock F, Pizzo PA, Walsh TJ. Lysis-centri-", "bbox": [421.0, 205.0, 724.0, 217.0]}, {"text": "fugation blood cultures in the detection of tissue-proven invasive candidi-", "bbox": [436.0, 215.0, 724.0, 227.0]}, {"text": "asis. Disseminated versus single-organ infection. Diagn Microbiol Infect", "bbox": [436.0, 226.0, 725.0, 237.0]}, {"text": "Dis .. 1993;17:103–109.", "bbox": [436.0, 236.0, 527.0, 248.0]}, {"text": "11. Horvath LL, George BJ, Murray CK, Harrison LS, Hospenthal DR. Direct com-", "bbox": [420.0, 247.0, 724.0, 258.0]}, {"text": "parison of the BACTEC 9240 and BacT/ALERT 3D automated blood cul-", "bbox": [436.0, 257.0, 724.0, 270.0]}, {"text": "ture systems for Candida growth detection. J Clin Microbiol ., 2004;42:", "bbox": [437.0, 268.0, 725.0, 280.0]}, {"text": "115–118.", "bbox": [436.0, 279.0, 476.0, 290.0]}, {"text": "12. Spanu T, Posteraro B, Fiori B, et al. Direct MALDI-TOF mass spectrometry", "bbox": [420.0, 289.0, 724.0, 301.0]}, {"text": "assay of blood culture broths for rapid identification of Candida species", "bbox": [436.0, 300.0, 724.0, 312.0]}, {"text": "causing bloodstream infections: an observational study in two large", "bbox": [436.0, 310.0, 724.0, 322.0]}, {"text": "microbiology laboratories. J Clin Microbiol . 2012;50:176–179.", "bbox": [436.0, 321.0, 675.0, 333.0]}, {"text": "13. Datcu R, Boel J, Jensen IM, Arpi M. Comparison of BACTEC™ blood culture", "bbox": [420.0, 331.0, 724.0, 344.0]}, {"text": "media for the detection of fungemia. Eur J Clin Microbiol Infect Dis .", "bbox": [436.0, 343.0, 723.0, 354.0]}, {"text": "2017;36:131–137.", "bbox": [436.0, 352.0, 510.0, 364.0]}, {"text": "14. Arendrup MC, Bergmann OJ, Larsson L, Nielsen HV, Jarløv JO, Christensson", "bbox": [420.0, 363.0, 725.0, 375.0]}, {"text": "B. Detection of candidaemia in patients with and without underlying hae-", "bbox": [436.0, 374.0, 724.0, 386.0]}, {"text": "matological disease. Clin Microbiol Infect. . 2010;16:855–862.", "bbox": [436.0, 385.0, 669.0, 396.0]}, {"text": "15. Kontoyiannis DP, Luna MA, Samuels BI, Bodey GP. Hepatosplenic candidia-", "bbox": [420.0, 395.0, 724.0, 407.0]}, {"text": "sis. A manifestation of chronic disseminated candidiasis. Infect Dis Clin", "bbox": [436.0, 406.0, 726.0, 418.0]}, {"text": "North Am . , 2000;14:721–739.", "bbox": [436.0, 417.0, 553.0, 428.0]}, {"text": "16. Odabasi Z, Mattiuzzi G, Estey E, et al. Beta-D-glucan as a diagnostic adjunct", "bbox": [420.0, 427.0, 725.0, 439.0]}, {"text": "for invasive fungal infections: validation, cutoff development, and perfor-", "bbox": [436.0, 438.0, 724.0, 449.0]}, {"text": "mance in patients with acute myelogenous leukemia and myelodysplastic", "bbox": [436.0, 448.0, 725.0, 460.0]}, {"text": "syndrome. Clin Infect Dis . . 2004;39:199–205.", "bbox": [436.0, 459.0, 609.0, 471.0]}, {"text": "17. Ostrosky-Zeichner L, BD Alexander, Kett DH, et al. Multicenter clinical", "bbox": [420.0, 469.0, 725.0, 481.0]}, {"text": "evaluation of the (1 → 3) beta-D-glucan assay as an aid to diagnosis of fun-", "bbox": [436.0, 480.0, 724.0, 491.0]}, {"text": "gal infections in humans. Clin Infect Dis . 2005;41:654–659.", "bbox": [436.0, 491.0, 665.0, 503.0]}, {"text": "18. Obayashi T, Negishi K, Suzuki T, Funata N. Reappraisal of the serum", "bbox": [420.0, 501.0, 726.0, 513.0]}, {"text": "(1 → 3)-beta-D-glucan assay for the diagnosis of invasive fungal infec-", "bbox": [435.0, 513.0, 724.0, 524.0]}, {"text": "tions—a study based on autopsy cases from 6 years. Clin Infect Dis. ,", "bbox": [436.0, 525.0, 724.0, 536.0]}, {"text": "2008;46:1864–1870.", "bbox": [436.0, 534.0, 520.0, 544.0]}, {"text": "19. Lamoth F, Cruciani M, Mengoli C, et al. ß-Glucan antigenemia assay for the", "bbox": [421.0, 543.0, 725.0, 556.0]}, {"text": "diagnosis of invasive fungal infections in patients with hematological", "bbox": [436.0, 556.0, 725.0, 565.0]}, {"text": "malignancies: a systematic review and meta-analysis of cohort studies", "bbox": [436.0, 566.0, 725.0, 576.0]}, {"text": "from the Third European Conference on Infections in Leukemia (ECIL-3).", "bbox": [436.0, 578.0, 725.0, 589.0]}, {"text": "Clin Infect Dis. . 2012;54:633–643.", "bbox": [436.0, 588.0, 566.0, 596.0]}, {"text": "20. Otto WR, Dvorak CC, Boge CLK, et al. Prospective evaluation of the Fungitell®", "bbox": [420.0, 597.0, 724.0, 610.0]}, {"text": "(1 → 3) beta-D-glucan assay as a diagnostic tool for invasive fungal disease in", "bbox": [436.0, 609.0, 726.0, 619.0]}, {"text": "pediatric allogeneic hematopoietic cell transplantation: a report from the", "bbox": [436.0, 620.0, 725.0, 629.0]}, {"text": "Children's Oncology Group. Pediatr Transplant . 2023;27:e14399.", "bbox": [436.0, 630.0, 678.0, 643.0]}, {"text": "21. Marty FM, Koo S. Role of (1 → 3)-beta-D-glucan in the diagnosis of invasive", "bbox": [419.0, 639.0, 725.0, 652.0]}, {"text": "aspergillosis. Med Mycol. , 2009;47(suppl 1)):$233–$240.", "bbox": [436.0, 649.0, 655.0, 664.0]}, {"text": "22. Tschopp J, Brunel AS, Spartina O, Croxatto A, Lamothe F, Bochud PY. High", "bbox": [419.0, 662.0, 726.0, 674.0]}, {"text": "false-positive rate of (1,3)- B -D-glucan in onco-hematological patients", "bbox": [436.0, 673.0, 726.0, 684.0]}, {"text": "receiving immunoglobulins and therapeutic antibodies. Clin Infect Dis .,", "bbox": [436.0, 683.0, 724.0, 695.0]}, {"text": "2022;75:330–333.", "bbox": [436.0, 694.0, 508.0, 705.0]}, {"text": "23. Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the", "bbox": [419.0, 704.0, 725.0, 716.0]}, {"text": "management of candidiasis: 2016 update by the Infectious Diseases Soci-", "bbox": [436.0, 715.0, 724.0, 726.0]}, {"text": "ety of America. Clin Infect Dis. . 2016;62:e1–e50.", "bbox": [436.0, 726.0, 623.0, 737.0]}, {"text": "24. Mora-Duarte J, Betts R, Rothstein C, et al. Comparison of caspofungin and", "bbox": [419.0, 736.0, 726.0, 748.0]}, {"text": "amphotericin B for invasive candidiasis. N Engl J Med. . 2002;347:2020–", "bbox": [436.0, 747.0, 724.0, 759.0]}, {"text": "2029.", "bbox": [436.0, 758.0, 460.0, 766.0]}, {"text": "25. Riboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole", "bbox": [419.0, 768.0, 725.0, 779.0]}, {"text": "for invasive candidiasis. N Engl J Med . 2007;356:2472–2482.", "bbox": [436.0, 778.0, 671.0, 791.0]}, {"text": "26. Pappas PG, Rothstein CM, Betts RF, et al. Micafungin versus caspofungin", "bbox": [419.0, 789.0, 726.0, 800.0]}, {"text": "for treatment of candidemia and other forms of invasive candidiasis. Clin", "bbox": [436.0, 799.0, 725.0, 812.0]}, {"text": "Infect Dis . 2007;45:883–893 .", "bbox": [436.0, 810.0, 551.0, 821.0]}, {"text": "27. Fisher BT, Agoutis TE, Xiao R, et al. Comparative effectiveness of echino-", "bbox": [419.0, 821.0, 724.0, 832.0]}, {"text": "candins vs triazoles or amphotericin B formulations as initial directed", "bbox": [436.0, 831.0, 725.0, 843.0]}, {"text": "therapy for invasive candidiasis in children and adolescents. J Pediatric", "bbox": [436.0, 842.0, 724.0, 853.0]}, {"text": "Infect Dis Soc . 2021;10(11):994–1000.", "bbox": [436.0, 852.0, 586.0, 865.0]}, {"text": "28. Alexander BD, Johnson MD, Pfeiffer CD, et  al. Increasing echinocandin", "bbox": [419.0, 863.0, 724.0, 875.0]}, {"text": "resistance in Candida glabrata : clinical failure correlates with presence of", "bbox": [436.0, 873.0, 725.0, 886.0]}, {"text": "FKS mutations and elevated minimum inhibitory concentrations. Clin", "bbox": [436.0, 885.0, 725.0, 896.0]}, {"text": "Infect Dis.. 2013;56:1724–1732.", "bbox": [436.0, 894.0, 559.0, 906.0]}, {"text": "29. Lewis 2nd JS, Wieder hold NP, Wickes BL, Patterson TF, Jorgensen JH.", "bbox": [419.0, 906.0, 724.0, 916.0]}, {"text": "Rapid emergence of echinocandin resistance in Candida glabrata resulting", "bbox": [436.0, 916.0, 726.0, 928.0]}, {"text": "in clinical and microbiologic failure. Antimicrob Agents Che mother ..", "bbox": [437.0, 927.0, 724.0, 938.0]}, {"text": "2013;57:4559–4561.", "bbox": [436.0, 937.0, 521.0, 949.0]}], "type": "Text", "position": 13}, {"raw_context": [{"text": "Children's Oncology Group. Pediatr Transplant . 2023;27:e14399.", "bbox": [436.0, 630.0, 678.0, 643.0]}, {"text": "21. Marty FM, Koo S. Role of (1 → 3)-beta-D-glucan in the diagnosis of invasive", "bbox": [419.0, 639.0, 725.0, 652.0]}, {"text": "aspergillosis. Med Mycol. , 2009;47(suppl 1)):$233–$240.", "bbox": [436.0, 649.0, 655.0, 664.0]}, {"text": "22. Tschopp J, Brunel AS, Spartina O, Croxatto A, Lamothe F, Bochud PY. High", "bbox": [419.0, 662.0, 726.0, 674.0]}, {"text": "false-positive rate of (1,3)- B -D-glucan in onco-hematological patients", "bbox": [436.0, 673.0, 726.0, 684.0]}, {"text": "receiving immunoglobulins and therapeutic antibodies. Clin Infect Dis .,", "bbox": [436.0, 683.0, 724.0, 695.0]}, {"text": "2022;75:330–333.", "bbox": [436.0, 694.0, 508.0, 705.0]}, {"text": "23. Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the", "bbox": [419.0, 704.0, 725.0, 716.0]}, {"text": "management of candidiasis: 2016 update by the Infectious Diseases Soci-", "bbox": [436.0, 715.0, 724.0, 726.0]}, {"text": "ety of America. Clin Infect Dis. . 2016;62:e1–e50.", "bbox": [436.0, 726.0, 623.0, 737.0]}, {"text": "24. Mora-Duarte J, Betts R, Rothstein C, et al. Comparison of caspofungin and", "bbox": [419.0, 736.0, 726.0, 748.0]}, {"text": "amphotericin B for invasive candidiasis. N Engl J Med. . 2002;347:2020–", "bbox": [436.0, 747.0, 724.0, 759.0]}, {"text": "2029.", "bbox": [436.0, 758.0, 460.0, 766.0]}, {"text": "25. Riboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole", "bbox": [419.0, 768.0, 725.0, 779.0]}, {"text": "for invasive candidiasis. N Engl J Med . 2007;356:2472–2482.", "bbox": [436.0, 778.0, 671.0, 791.0]}, {"text": "26. Pappas PG, Rothstein CM, Betts RF, et al. Micafungin versus caspofungin", "bbox": [419.0, 789.0, 726.0, 800.0]}, {"text": "for treatment of candidemia and other forms of invasive candidiasis. Clin", "bbox": [436.0, 799.0, 725.0, 812.0]}, {"text": "Infect Dis . 2007;45:883–893 .", "bbox": [436.0, 810.0, 551.0, 821.0]}, {"text": "27. Fisher BT, Agoutis TE, Xiao R, et al. Comparative effectiveness of echino-", "bbox": [419.0, 821.0, 724.0, 832.0]}, {"text": "candins vs triazoles or amphotericin B formulations as initial directed", "bbox": [436.0, 831.0, 725.0, 843.0]}, {"text": "therapy for invasive candidiasis in children and adolescents. J Pediatric", "bbox": [436.0, 842.0, 724.0, 853.0]}, {"text": "Infect Dis Soc . 2021;10(11):994–1000.", "bbox": [436.0, 852.0, 586.0, 865.0]}, {"text": "28. Alexander BD, Johnson MD, Pfeiffer CD, et  al. Increasing echinocandin", "bbox": [419.0, 863.0, 724.0, 875.0]}, {"text": "resistance in Candida glabrata : clinical failure correlates with presence of", "bbox": [436.0, 873.0, 725.0, 886.0]}, {"text": "FKS mutations and elevated minimum inhibitory concentrations. Clin", "bbox": [436.0, 885.0, 725.0, 896.0]}, {"text": "Infect Dis.. 2013;56:1724–1732.", "bbox": [436.0, 894.0, 559.0, 906.0]}, {"text": "29. Lewis 2nd JS, Wieder hold NP, Wickes BL, Patterson TF, Jorgensen JH.", "bbox": [419.0, 906.0, 724.0, 916.0]}, {"text": "Rapid emergence of echinocandin resistance in Candida glabrata resulting", "bbox": [436.0, 916.0, 726.0, 928.0]}, {"text": "in clinical and microbiologic failure. Antimicrob Agents Che mother ..", "bbox": [437.0, 927.0, 724.0, 938.0]}, {"text": "2013;57:4559–4561.", "bbox": [436.0, 937.0, 521.0, 949.0]}, {"text": "30. Spec A, Pullman J, Thompson GR, et al. MSG-10: a phase 2 study of oral", "bbox": [420.0, 948.0, 725.0, 960.0]}, {"text": "ibrexafungerp (SCY-078) following initial echinocandin therapy in non-", "bbox": [436.0, 959.0, 724.0, 970.0]}], "type": "List-item", "position": 14}, {"raw_context": [{"text": "226", "bbox": [83.0, 30.0, 102.0, 42.0]}], "type": "Text", "position": 15}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/血液科/2023 ASTCT指南：造血细胞移植受者侵袭性念珠菌病的管理.pdf", "page_num": 5}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": null, "type3": "无关文本#0#11#[47] 类似的[   ]无关引用过多", "type4": null, "type5": null, "type6": "有用性#6#10#文章的补充材料和资金\n有用性#11#59#参考文献内容"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:41", "update_time": "2024-05-07 23:18:55"}
{"id": 1082600, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 738, "source_info": {"seq_id": "9e50d32a-448e-431c-b173-444bfa249088", "title": null, "text": "【0】页码:89\n 小狗科研究 小狗科碑&Fig pN3b:     pN1a或pN2a伴有cN2bん影像学证实的内乳 淋巴结转移 );  或pN2a伴有pN1b。 net to the prophet of the prophet to the prophet of the prophet to the prophet of th l ha 小狗科研分期: T1包括T1mi, 而N1mi对分期有意义; 如果淋巴 结只有前哨 则标记Nx (sn) \n\n【1】 c / cM0 ( i+ ):       无临床或影像学证据证实远处转移; 但在没有转移症状 种体征的患者中，分子生物学或显微镜下 41 – 1 检测到循环血中、骨髓中或其他非区域淋巴结组织中有≤0.2 mm的肿瘤细胞熟忍 甲瘤细胞勇科班  学证实转移灶 >0.2 mm\n 11 /\n M0\n M0\n M0\n\n【2】 468 2 F\n\n【3】## 分期\n\n【4】 Tis NO 200 LAU (2) T N0 forder in th I B期 N1mi T0N1miM0    T1N1miM0\n\n【5】 II A期\n T0, T1\n N1\n\n【6】 4/ 1648 1649", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "小狗科研究", "bbox": [597.0, 30.0, 714.0, 97.0]}, {"text": "小狗科碑&Fig", "bbox": [20.0, 39.0, 681.0, 182.0]}, {"text": "pN3b:     pN1a或pN2a伴有cN2bん影像学证实的内乳", "bbox": [180.0, 176.0, 677.0, 213.0]}, {"text": "淋巴结转移 );  或pN2a伴有pN1b。", "bbox": [116.0, 226.0, 494.0, 252.0]}, {"text": "net to the prophet of the prophet to the prophet of the prophet to the prophet of th", "bbox": [177.0, 233.0, 680.0, 295.0]}, {"text": "l ha", "bbox": [728.0, 272.0, 794.0, 316.0]}, {"text": "小狗科研分期: T1包括T1mi, 而N1mi对分期有意义; 如果淋巴", "bbox": [57.0, 287.0, 673.0, 353.0]}, {"text": "结只有前哨 则标记Nx (sn)", "bbox": [117.0, 338.0, 394.0, 374.0]}, {"text": "", "bbox": [162.0, 361.0, 538.0, 461.0]}], "type": "Text", "position": 0}, {"raw_context": [{"text": "c / cM0 ( i+ ):       无临床或影像学证据证实远处转移;", "bbox": [160.0, 456.0, 665.0, 491.0]}, {"text": "但在没有转移症状 种体征的患者中，分子生物学或显微镜下", "bbox": [116.0, 498.0, 688.0, 534.0]}, {"text": "41 – 1", "bbox": [745.0, 513.0, 794.0, 552.0]}, {"text": "检测到循环血中、骨髓中或其他非区域淋巴结组织中有≤0.2", "bbox": [117.0, 542.0, 678.0, 573.0]}, {"text": "mm的肿瘤细胞熟忍", "bbox": [116.0, 576.0, 317.0, 622.0]}, {"text": "甲瘤细胞勇科班 ", "bbox": [182.0, 591.0, 716.0, 667.0]}, {"text": "学证实转移灶 >0.2 mm", "bbox": [117.0, 665.0, 337.0, 692.0]}], "type": "Text", "position": 1}, {"raw_context": [{"text": "11 /", "bbox": [565.0, 691.0, 729.0, 764.0]}], "type": "Formula", "position": 2}, {"raw_context": [{"text": "M0", "bbox": [563.0, 787.0, 598.0, 811.0]}], "type": "Formula", "position": 3}, {"raw_context": [{"text": "M0", "bbox": [576.0, 829.0, 611.0, 851.0]}], "type": "Formula", "position": 5}, {"raw_context": [{"text": "M0", "bbox": [641.0, 869.0, 677.0, 891.0]}], "type": "Formula", "position": 6}, {"raw_context": [{"text": "468 2 F", "bbox": [2.0, 747.0, 87.0, 812.0]}], "type": "Text", "position": 9}, {"raw_context": [{"text": "分期", "bbox": [158.0, 746.0, 206.0, 772.0]}], "type": "Section-header", "position": 10}, {"raw_context": [{"text": "Tis", "bbox": [265.0, 789.0, 299.0, 811.0]}, {"text": "NO", "bbox": [399.0, 789.0, 431.0, 811.0]}, {"text": "200", "bbox": [135.0, 792.0, 196.0, 824.0]}, {"text": "LAU (2) T", "bbox": [171.0, 805.0, 300.0, 874.0]}, {"text": "N0", "bbox": [410.0, 828.0, 443.0, 850.0]}, {"text": "forder in th", "bbox": [288.0, 849.0, 455.0, 934.0]}, {"text": "I B期", "bbox": [166.0, 866.0, 224.0, 891.0]}, {"text": "N1mi", "bbox": [455.0, 869.0, 510.0, 890.0]}, {"text": "T0N1miM0    T1N1miM0", "bbox": [116.0, 906.0, 366.0, 931.0]}], "type": "Formula", "position": 11}, {"raw_context": [{"text": "II A期", "bbox": [162.0, 988.0, 269.0, 1011.0]}], "type": "Text", "position": 12}, {"raw_context": [{"text": "T0, T1", "bbox": [267.0, 988.0, 344.0, 1011.0]}], "type": "Formula", "position": 14}, {"raw_context": [{"text": "N1", "bbox": [424.0, 989.0, 454.0, 1011.0]}], "type": "Formula", "position": 15}, {"raw_context": [{"text": "4/ 1648 1649", "bbox": [100.0, 1027.0, 278.0, 1110.0]}], "type": "Text", "position": 16}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2022】全科室最全临床指南+专家共识（最全版）/2022全科室临床指南/肿瘤科/乳腺癌诊疗指南（2022年版）.pdf", "page_num": 89}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "格式杂乱#0#6#格式杂乱，无法理解", "type3": null, "type4": null, "type5": null, "type6": null}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:41", "update_time": "2024-05-08 00:22:05"}
{"id": 1082599, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 738, "source_info": {"seq_id": "27a1ebba-c3ec-46ad-bc78-845160713b86", "title": null, "text": "【0】页码:1\n\n【1】## Interpretation Of Chinese Expert Consensus On The Application Of Optical Coherence Tomography In The Interventional Diagnosis And Treatment Of Coronary Artery Disease Jia Haibo 1 · 2 He Luping 1 · 2 Xu Yishuo 1 • 2 Yu Bo 1 • 2\n\n【2】\n ( ' Department of Cardiology, The 2nd Affiliated Hospital of Harbin Medical University, Harbin, 150086, China; 2 The Key Laboratory of Myocardial Ischemia, Chinese Ministry of Education) Corresponding author: YU Bo, E-mail: yubodr@163.com Abstract Optical coherence tomography(OCT) plays an important role in guiding percutaneous coronary in¬ terventions. In spite of this, the adoption of OCT remains limited in routine clinical practice and lack of standards in China. In Feb 2023, Chinese Society of Cardiology issued the\" Chinese expert consensus on the application of optical coherence tomography in the interventional diagnosis and treatment of coronary artery disease\" , which mainly focus on clinical indication, the impact of OCT on planning procedural strategy, optimization stent implantation and percutaneous coronary intervention result and the value of OCT in different patients or lesions. In order [1].\n\n【3】1.\n\n【4】s :\n\n【5】 [1].\n\n【6】1.\n\n【7】s .2023.39(3):167-171.DOI:10. 13201/j.issn.1001 -1439 2023 03 002.\n\n【8】\n ,150086)\n\n【9】 ,E-mail:yubodr@163.com\n\n【10】 [13] Crotti L, Odening KE, Sanguinetti MC. Heritable arrhythmias associated with abnormal function of cardiac potassium channels[J]. Cardiovasc Res, 2020, 116 (9):1542-1556.\n\n【11】 [14] Walsh R, Adler A, Amin AS, et al. Evaluation of gene validity for CPVT and short QT syndrome in sudden arrhythmic death[J].Eur Heart J, 2022,43(15),1500- 1510.\n\n【12】 [15] Charron P, Arad M, Arbustini E, et al. Genetic counselling and testing in cardiomyopathies: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases[J].Eur Heart J,2010,31(22),2715-2726.\n\n【13】[16] Ahmad F, Menally EM, Ackerman MJ, et al. Establishment of Specialized Clinical Cardiovascular Genetics Programs: Recognizing the Need and Meeting Standards: A Scientific Statement From the American\n\n【14】 Heart Association[J].Circ Genom Precis Med, 2019, 12(6):e54.\n\n【15】[17] Elliott P, Andersson B, Arbustini E, et al. Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases[J]. Eur Heart J,2008,29(2),270-276.\n\n【16】[18] van Lint F, Murray B, Tichnell C, et al. Arrhythmogenic Right Ventricular Cardiomyopathy-Associated Desmosomal Variants Are Rarely De Novo[J]. Circ Genom Precis Med,2019,12(8):e2467.\n\n【17】[19] Fressart V, Duthoit G, Donal E, et al. Desmosomal gene analysis in arrhythmogenic right ventricular dysplasia/cardiomyopathy, spectrum of mutations and clinical impact in practice[J]. Europace, 2010, 12(6): 861-868.\n\n【18】.2023-02-13)", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "Interpretation of Chinese expert consensus on the application of optical", "bbox": [113.0, 386.0, 681.0, 405.0]}, {"text": "coherence tomography in the interventional diagnosis", "bbox": [185.0, 409.0, 608.0, 430.0]}, {"text": "and treatment of coronary artery disease", "bbox": [234.0, 435.0, 559.0, 452.0]}, {"text": "JIA Haibo 1 · 2 HE Luping 1 · 2", "bbox": [216.0, 456.0, 420.0, 473.0]}, {"text": "XU Yishuo 1 • 2", "bbox": [417.0, 456.0, 509.0, 473.0]}, {"text": "YU Bo 1 • 2", "bbox": [516.0, 456.0, 575.0, 472.0]}], "type": "Section-header", "position": 4}, {"raw_context": [{"text": "( ' Department of Cardiology, The 2nd Affiliated Hospital of Harbin Medical University, Harbin,", "bbox": [106.0, 476.0, 686.0, 493.0]}, {"text": "150086, China; 2 The Key Laboratory of Myocardial Ischemia, Chinese Ministry of Education)", "bbox": [106.0, 496.0, 674.0, 511.0]}, {"text": "Corresponding author: YU Bo, E-mail: yubodr@163.com", "bbox": [104.0, 516.0, 463.0, 532.0]}, {"text": "Abstract Optical coherence tomography(OCT) plays an important role in guiding percutaneous coronary in¬", "bbox": [131.0, 534.0, 686.0, 550.0]}, {"text": "terventions. In spite of this, the adoption of OCT remains limited in routine clinical practice and lack of standards", "bbox": [106.0, 553.0, 687.0, 568.0]}, {"text": "in China. In Feb 2023, Chinese Society of Cardiology issued the\" Chinese expert consensus on the application of", "bbox": [105.0, 570.0, 688.0, 585.0]}, {"text": "optical coherence tomography in the interventional diagnosis and treatment of coronary artery disease\" , which", "bbox": [105.0, 588.0, 688.0, 603.0]}, {"text": "mainly focus on clinical indication, the impact of OCT on planning procedural strategy, optimization stent implan-", "bbox": [106.0, 606.0, 685.0, 620.0]}, {"text": "tation and percutaneous coronary intervention result and the value of OCT in different patients or lesions. In order", "bbox": [106.0, 624.0, 686.0, 639.0]}, {"text": "[1].", "bbox": [664.0, 651.0, 689.0, 665.0]}, {"text": "1.", "bbox": [283.0, 653.0, 295.0, 664.0]}, {"text": "s", "bbox": [635.0, 653.0, 643.0, 662.0]}, {"text": ":", "bbox": [140.0, 654.0, 148.0, 664.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "[1].", "bbox": [664.0, 651.0, 689.0, 665.0]}, {"text": "1.", "bbox": [283.0, 653.0, 295.0, 664.0]}, {"text": "s", "bbox": [635.0, 653.0, 643.0, 662.0]}, {"text": ".2023.39(3):167-171.DOI:10. 13201/j.issn.1001 -1439 2023 03 002.", "bbox": [230.0, 667.0, 591.0, 683.0]}], "type": "Table", "position": 6}, {"raw_context": [{"text": ",150086)", "bbox": [318.0, 700.0, 367.0, 714.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": ",E-mail:yubodr@163.com", "bbox": [162.0, 727.0, 299.0, 743.0]}], "type": "Text", "position": 8}, {"raw_context": [{"text": "[13] Crotti L, Odening KE, Sanguinetti MC. Heritable ar-", "bbox": [76.0, 758.0, 381.0, 773.0]}, {"text": "rhythmias associated with abnormal function of cardi-", "bbox": [108.0, 776.0, 381.0, 791.0]}, {"text": "ac potassium channels[J]. Cardiovasc Res, 2020, 116", "bbox": [108.0, 794.0, 383.0, 810.0]}, {"text": "(9):1542-1556.", "bbox": [108.0, 814.0, 189.0, 826.0]}], "type": "Text", "position": 9}, {"raw_context": [{"text": "[14] Walsh R, Adler A, Amin AS, et al. Evaluation of gene", "bbox": [77.0, 831.0, 383.0, 845.0]}, {"text": "validity for CPVT and short QT syndrome in sudden", "bbox": [107.0, 849.0, 383.0, 862.0]}, {"text": "arrhythmic death[J].Eur Heart J, 2022,43(15),1500-", "bbox": [107.0, 865.0, 381.0, 880.0]}, {"text": "1510.", "bbox": [109.0, 885.0, 138.0, 897.0]}], "type": "Text", "position": 10}, {"raw_context": [{"text": "[15] Charron P, Arad M, Arbustini E, et al. Genetic coun-", "bbox": [76.0, 902.0, 381.0, 916.0]}, {"text": "selling and testing in cardiomyopathies: a position", "bbox": [108.0, 921.0, 383.0, 934.0]}, {"text": "statement of the European Society of Cardiology", "bbox": [107.0, 937.0, 383.0, 952.0]}, {"text": "Working Group on Myocardial and Pericardial Disea-", "bbox": [107.0, 955.0, 381.0, 970.0]}, {"text": "ses[J].Eur Heart J,2010,31(22),2715-2726.", "bbox": [108.0, 973.0, 340.0, 987.0]}, {"text": "[16] Ahmad F, Menally EM, Ackerman MJ, et al. Estab-", "bbox": [77.0, 991.0, 382.0, 1006.0]}, {"text": "lishment of Specialized Clinical Cardiovascular Genet-", "bbox": [107.0, 1008.0, 381.0, 1023.0]}, {"text": "ics Programs: Recognizing the Need and Meeting", "bbox": [107.0, 1027.0, 383.0, 1042.0]}, {"text": "Standards: A Scientific Statement From the American", "bbox": [107.0, 1045.0, 383.0, 1059.0]}], "type": "Text", "position": 11}, {"raw_context": [{"text": "Heart Association[J].Circ Genom Precis Med, 2019,", "bbox": [440.0, 758.0, 715.0, 773.0]}, {"text": "12(6):e54.", "bbox": [441.0, 777.0, 498.0, 791.0]}, {"text": "[17] Elliott P, Andersson B, Arbustini E, et al. Classifica-", "bbox": [409.0, 794.0, 714.0, 809.0]}, {"text": "tion of the cardiomyopathies: a position statement", "bbox": [440.0, 814.0, 715.0, 827.0]}, {"text": "from the European Society Of Cardiology Working", "bbox": [440.0, 831.0, 715.0, 845.0]}, {"text": "Group on Myocardial and Pericardial Diseases[J]. Eur", "bbox": [440.0, 848.0, 715.0, 862.0]}, {"text": "Heart J,2008,29(2),270-276.", "bbox": [440.0, 865.0, 594.0, 880.0]}, {"text": "[18] van Lint F, Murray B, Tichnell C, et al. Arrhythmo-", "bbox": [409.0, 884.0, 714.0, 898.0]}, {"text": "genic Right Ventricular Cardiomyopathy-Associated", "bbox": [440.0, 902.0, 716.0, 916.0]}, {"text": "Desmosomal Variants Are Rarely De Novo[J]. Circ", "bbox": [440.0, 920.0, 715.0, 933.0]}, {"text": "Genom Precis Med,2019,12(8):e2467.", "bbox": [440.0, 937.0, 643.0, 952.0]}, {"text": "[19] Fressart V, Duthoit G, Donal E, et al. Desmosomal", "bbox": [409.0, 955.0, 716.0, 970.0]}, {"text": "gene analysis in arrhythmogenic right ventricular dys-", "bbox": [440.0, 975.0, 714.0, 987.0]}, {"text": "plasia/cardiomyopathy, spectrum of mutations and", "bbox": [440.0, 991.0, 716.0, 1006.0]}, {"text": "clinical impact in practice[J]. Europace, 2010, 12(6):", "bbox": [440.0, 1008.0, 714.0, 1023.0]}, {"text": "861-868.", "bbox": [440.0, 1028.0, 486.0, 1041.0]}, {"text": ".2023-02-13)", "bbox": [622.0, 1046.0, 691.0, 1058.0]}], "type": "Text", "position": 12}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/心血管/解读/《光学相干断层成像技术在冠心病介入诊疗中应用的中国专家共识》解读.pdf", "page_num": 1}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "多余标点#2#2#( ’ Department of Cardiology,   里面的 ’  \n缺少换行#2#2#Abstract Optical coherence 另起一行\n标点错误#2#2#  in¬  去掉 ¬\n格式杂乱#3#9#文本无显示内容", "type3": "无关文本#2#2#2 The Key  里面的数字2   [1]", "type4": null, "type5": null, "type6": "有用性#10#18#参考文献的内容"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:41", "update_time": "2024-05-07 22:11:46"}
{"id": 1082598, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 738, "source_info": {"seq_id": "b56aea0d-e88f-4912-a531-ee4a464854c5", "title": null, "text": "【0】页码:8\n\n【1】 Table 6 – Recommendations for systemic and palliative therapies for advanced disease Recommendation Strength rating Systemic therapies Offer patients with distant metastatic disease platinum- Weak based chemotherapy as the preferred approach for firstline palliative systemic therapy Do not offer bleomycin because of the pulmonary toxicity Strong risk.\n\n【2】Offer patients with progressive disease under platinum Strong chemotherapy the opportunity to receive experimental therapies within clinical trials.\n\n【3】Radiotherapy Offer radiotherapy for symptom control (palliation) in Strong dvanced diseas\n\n【4】\n Radiotherapy 3.6.3.\n\n【5】Radiotherapy is frequently necessary for palliation of penile cancer and should be customised as necessary. While standard palliative regimens can be readily used, providers should be aware that retreatment may be necessary for durable disease control [107] .\n\n【6】Table 6 lists recommendations for systemic and palliative therapies for advanced disease.\n\n【7】 3.7.\n\n【8】## Follow-Up\n\n【9】\n From an oncological perspective, surveillance is important, as early detection of recurrence may increase the likelihood of curative treatment. Disease that has spread to the inguinal LNs greatly reduces the rate of long-term CSS. Followup is also important for survivorship, allowing for detection and management of the physical and psychological impacts of treatments.\n\n【10】Local or regional nodal recurrences usually occur within 2–3 yr of primary treatment [ 108–111 ]. A recent study of 509 patients reported that 52.3% of local recurrences occurred within 2 yr and 79.5% within 3 yr [110] . Fewer than 5% of regional or distant recurrences occur after 2 yr, with the majority occurring within the first year after treatment [109,110] . This supports an intensive follow-up regimen during the first 2 yr, with less intensive follow-up later for a total of at least 5 yr (Table 7) [108] .\n\n【11】 Access to psychological support, counselling, psychosexual therapy, lymphoedema services, and palliative care are critical components of a holistic and multidisciplinary survivorship service.\n\n【12】## 3.8.\n\n【13】Quality Of Life\n\n【14】\n There are very few data on QoL after treatment for penile cancer. In particular, there is heterogeneity of the psychometric tools used to assess QoL outcomes and further research is needed to develop disease-specific patientreported outcome measures for penile cancer.\n\n【15】A recent systematic review reported on post-treatment QoL from ten studies involving 346 men [112–121] . Two studies evaluated QoL as the primary endpoint and compared the outcomes for various treatment modalities [116,120] . One of these studies used the European Organization for Research and Treatment of Cancer quality of life (EORTC QLQ) C-30 questionnaire. The authors observed that the treatment itself was not related to overall wellbeing or to social contact and activity. However, half of the individuals had psychological symptoms at follow up [ 120 ]. By contrast, a retrospective study of men who underwent penile-preserving surgery reported a significant impact of surgery for every domain of the EORTC QLQ-C30 questionnaire [ 114 ].\n\n【16】Urinary function is an important topic to discuss with men before penile cancer treatment. Some will already be experiencing difficulty in voiding because their tumour is causing urethral obstruction, and many men report a need to sit down to pass urine because of the spraying caused by the tumour. As a result, some patients report an improvement in function following surgery, often in terms of flow, but spraying and needing to sit down to void or use a funnel or bottle can be debilitating for many men.\n\n【17】Sexual and erectile functions after penile cancer vary between studies and between treatments. In general, penile-preserving surgery preserves erectile function, although glans sensation and orgasm can be affected. Overall, partial penectomy is associated with poorer sexual outcomes.\n\n【18】Lymphoedema may significantly impact QoL in patients with penile cancer. Men should be assessed for genital and lower-limb lymphoedema at each outpatient clinic\n\n【19】 Table 7 – Follow-up regime for penile cancer Recommendation Surveillance period Examinations and investigations MinimumFU duration Years Years 3–5 1–2 Primary tumour FU Penile-preserving Regular PEx or self-examination. Repeat biopsy after topical or laser treatment for 5 ут 3- monthly monthly PeIN (optional).\n\n【20】treatment Amputation.\n\n【21】Annually Regular physician or self-examination.\n\n【22】5 yr 3- monthly Inguinal node FU Regular PEx or self-examination. US ± FNAC optional.\n\n【23】Surveillance 3- 6- 5 yr monthly monthly Regular PEx or self-examination. US ± FNAC optional.\n\n【24】pN0 3- Annually 5 yr monthly Regular PEx or self-examination. US ± FNAC, CT chest/abdomen/pelvis or 18 FDG-PET/ pN+ 3-3-3-3 5 yr monthly monthly CT optional.\n\n【25】CT = computed tomography; ¹ªFDG = ¹ªF-fluoro-2-deoxy-D-glucose; FNAC = fine-needle aspiration cytology; FU = follow-up; PeIN = penile intraepithelial neoplasia; PEx = physician examination; PET = positron emission tomography; US = ultrasound.\n\n【26】\n Please cite this article as: O.R. Brouwer, M. Albersen, A. Parnham et al., European Association of Urology-American Society of Clinical Oncology Collaborative Guideline on Penile Cancer: 2023 Update, Eur Urol (2023), https://doi.org/10.1016/j.eururo.2023.02.027\n\n【27】 8", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "Table 6 – Recommendations for systemic and palliative therapies for", "bbox": [69.0, 89.0, 382.0, 100.0]}, {"text": "advanced disease", "bbox": [69.0, 100.0, 146.0, 112.0]}, {"text": "Recommendation", "bbox": [72.0, 121.0, 151.0, 132.0]}, {"text": "Strength", "bbox": [320.0, 121.0, 359.0, 133.0]}, {"text": "rating", "bbox": [321.0, 134.0, 346.0, 143.0]}, {"text": "Systemic therapies", "bbox": [73.0, 149.0, 150.0, 160.0]}, {"text": "Offer patients with distant metastatic disease platinum-", "bbox": [72.0, 160.0, 303.0, 172.0]}, {"text": "Weak", "bbox": [320.0, 160.0, 345.0, 172.0]}, {"text": "based chemotherapy as the preferred approach for first-", "bbox": [84.0, 172.0, 308.0, 184.0]}, {"text": "line palliative systemic therapy", "bbox": [84.0, 184.0, 213.0, 195.0]}, {"text": "Do not offer bleomycin because of the pulmonary toxicity", "bbox": [72.0, 195.0, 310.0, 206.0]}, {"text": "Strong", "bbox": [319.0, 195.0, 348.0, 206.0]}, {"text": "risk.", "bbox": [84.0, 208.0, 102.0, 216.0]}, {"text": "Offer patients with progressive disease under platinum", "bbox": [72.0, 217.0, 300.0, 230.0]}, {"text": "Strong", "bbox": [320.0, 219.0, 346.0, 228.0]}, {"text": "chemotherapy the opportunity to receive experimental", "bbox": [84.0, 230.0, 310.0, 241.0]}, {"text": "therapies within clinical trials.", "bbox": [84.0, 241.0, 209.0, 253.0]}, {"text": "Radiotherapy", "bbox": [72.0, 252.0, 133.0, 263.0]}, {"text": "Offer radiotherapy for symptom control (palliation) in", "bbox": [72.0, 263.0, 297.0, 276.0]}, {"text": "Strong", "bbox": [319.0, 265.0, 348.0, 276.0]}, {"text": "dvanced diseas", "bbox": [89.0, 277.0, 148.0, 285.0]}], "type": "Table", "position": 2}, {"raw_context": [{"text": "Radiotherapy", "bbox": [109.0, 318.0, 176.0, 332.0]}, {"text": "3.6.3.", "bbox": [62.0, 320.0, 89.0, 331.0]}, {"text": "Radiotherapy is frequently necessary for palliation of penile", "bbox": [61.0, 333.0, 383.0, 347.0]}, {"text": "cancer and should be customised as necessary. While stan-", "bbox": [61.0, 349.0, 382.0, 362.0]}, {"text": "dard palliative regimens can be readily used, providers", "bbox": [61.0, 364.0, 383.0, 378.0]}, {"text": "should be aware that retreatment may be necessary for dur-", "bbox": [61.0, 380.0, 381.0, 393.0]}, {"text": "able disease control [107] .", "bbox": [61.0, 395.0, 204.0, 408.0]}, {"text": "Table 6 lists recommendations for systemic and pallia-", "bbox": [78.0, 410.0, 382.0, 425.0]}, {"text": "tive therapies for advanced disease.", "bbox": [61.0, 426.0, 255.0, 439.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "3.7.", "bbox": [61.0, 483.0, 81.0, 496.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": "Follow-up", "bbox": [101.0, 483.0, 152.0, 496.0]}], "type": "Section-header", "position": 5}, {"raw_context": [{"text": "From an oncological perspective, surveillance is important,", "bbox": [61.0, 506.0, 382.0, 521.0]}, {"text": "as early detection of recurrence may increase the likelihood", "bbox": [61.0, 522.0, 383.0, 535.0]}, {"text": "of curative treatment. Disease that has spread to the ingu-", "bbox": [60.0, 537.0, 382.0, 551.0]}, {"text": "inal LNs greatly reduces the rate of long-term CSS. Follow-", "bbox": [61.0, 553.0, 381.0, 567.0]}, {"text": "up is also important for survivorship, allowing for detection", "bbox": [61.0, 568.0, 383.0, 581.0]}, {"text": "and management of the physical and psychological impacts", "bbox": [61.0, 583.0, 383.0, 598.0]}, {"text": "of treatments.", "bbox": [60.0, 599.0, 138.0, 612.0]}, {"text": "Local or regional nodal recurrences usually occur within", "bbox": [76.0, 614.0, 383.0, 627.0]}, {"text": "2–3 yr of primary treatment [ 108–111 ]. A recent study of", "bbox": [61.0, 629.0, 383.0, 644.0]}, {"text": "509 patients reported that 52.3% of local recurrences", "bbox": [61.0, 645.0, 383.0, 659.0]}, {"text": "occurred within 2 yr and 79.5% within 3 yr [110] . Fewer", "bbox": [61.0, 660.0, 383.0, 674.0]}, {"text": "than 5% of regional or distant recurrences occur after 2 yr,", "bbox": [61.0, 675.0, 382.0, 690.0]}, {"text": "with the majority occurring within the first year after treat-", "bbox": [61.0, 690.0, 382.0, 705.0]}, {"text": "ment [109,110] . This supports an intensive follow-up regi-", "bbox": [61.0, 706.0, 382.0, 719.0]}, {"text": "men during the first 2 yr, with less intensive follow-up", "bbox": [61.0, 721.0, 383.0, 736.0]}, {"text": "later for a total of at least 5 yr (Table 7) [108] .", "bbox": [61.0, 736.0, 314.0, 751.0]}], "type": "Text", "position": 6}, {"raw_context": [{"text": "Access to psychological support, counselling, psychosex-", "bbox": [419.0, 87.0, 725.0, 101.0]}, {"text": "ual therapy, lymphoedema services, and palliative care are", "bbox": [403.0, 102.0, 726.0, 115.0]}, {"text": "critical components of a holistic and multidisciplinary sur-", "bbox": [402.0, 117.0, 725.0, 131.0]}, {"text": "vivorship service.", "bbox": [403.0, 134.0, 500.0, 147.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "3.8.", "bbox": [404.0, 163.0, 424.0, 175.0]}, {"text": "Quality of life", "bbox": [443.0, 162.0, 513.0, 175.0]}], "type": "Section-header", "position": 8}, {"raw_context": [{"text": "There are very few data on QoL after treatment for penile", "bbox": [403.0, 186.0, 726.0, 200.0]}, {"text": "cancer. In particular, there is heterogeneity of the psycho-", "bbox": [402.0, 201.0, 725.0, 215.0]}, {"text": "metric tools used to assess QoL outcomes and further", "bbox": [402.0, 216.0, 726.0, 231.0]}, {"text": "research is needed to develop disease-specific patient-", "bbox": [402.0, 232.0, 725.0, 246.0]}, {"text": "reported outcome measures for penile cancer.", "bbox": [402.0, 247.0, 655.0, 261.0]}, {"text": "A recent systematic review reported on post-treatment", "bbox": [419.0, 262.0, 726.0, 277.0]}, {"text": "QoL from ten studies involving 346 men [112–121] . Two", "bbox": [402.0, 277.0, 726.0, 292.0]}, {"text": "studies evaluated QoL as the primary endpoint and com-", "bbox": [402.0, 292.0, 725.0, 307.0]}, {"text": "pared the outcomes for various treatment modalities", "bbox": [402.0, 307.0, 726.0, 322.0]}, {"text": "[116,120] . One of these studies used the European Organi-", "bbox": [403.0, 323.0, 725.0, 337.0]}, {"text": "zation for Research and Treatment of Cancer quality of life", "bbox": [403.0, 338.0, 726.0, 352.0]}, {"text": "(EORTC QLQ) C-30 questionnaire. The authors observed that", "bbox": [402.0, 353.0, 726.0, 368.0]}, {"text": "the treatment itself was not related to overall wellbeing or", "bbox": [402.0, 369.0, 726.0, 383.0]}, {"text": "to social contact and activity. However, half of the individ-", "bbox": [402.0, 384.0, 725.0, 398.0]}, {"text": "uals had psychological symptoms at follow up [ 120 ]. By", "bbox": [402.0, 399.0, 726.0, 414.0]}, {"text": "contrast, a retrospective study of men who underwent", "bbox": [402.0, 415.0, 726.0, 429.0]}, {"text": "penile-preserving surgery reported a significant impact of", "bbox": [403.0, 430.0, 726.0, 444.0]}, {"text": "surgery for every domain of the EORTC QLQ-C30 question-", "bbox": [402.0, 445.0, 725.0, 460.0]}, {"text": "naire [ 114 ].", "bbox": [403.0, 461.0, 468.0, 475.0]}, {"text": "Urinary function is an important topic to discuss with", "bbox": [419.0, 476.0, 727.0, 489.0]}, {"text": "men before penile cancer treatment. Some will already be", "bbox": [402.0, 491.0, 726.0, 505.0]}, {"text": "experiencing difficulty in voiding because their tumour is", "bbox": [402.0, 507.0, 726.0, 520.0]}, {"text": "causing urethral obstruction, and many men report a need", "bbox": [402.0, 522.0, 726.0, 536.0]}, {"text": "to sit down to pass urine because of the spraying caused", "bbox": [402.0, 537.0, 726.0, 552.0]}, {"text": "by the tumour. As a result, some patients report an", "bbox": [402.0, 553.0, 727.0, 567.0]}, {"text": "improvement in function following surgery, often in terms", "bbox": [402.0, 567.0, 726.0, 582.0]}, {"text": "of flow, but spraying and needing to sit down to void or", "bbox": [402.0, 583.0, 726.0, 597.0]}, {"text": "use a funnel or bottle can be debilitating for many men.", "bbox": [403.0, 599.0, 711.0, 612.0]}, {"text": "Sexual and erectile functions after penile cancer vary", "bbox": [419.0, 614.0, 725.0, 627.0]}, {"text": "between studies and between treatments. In general,", "bbox": [402.0, 629.0, 726.0, 644.0]}, {"text": "penile-preserving surgery preserves erectile function,", "bbox": [403.0, 645.0, 726.0, 659.0]}, {"text": "although glans sensation and orgasm can be affected. Over-", "bbox": [403.0, 660.0, 725.0, 674.0]}, {"text": "all, partial penectomy is associated with poorer sexual", "bbox": [403.0, 675.0, 726.0, 690.0]}, {"text": "outcomes.", "bbox": [403.0, 692.0, 461.0, 704.0]}, {"text": "Lymphoedema may significantly impact QoL in patients", "bbox": [419.0, 706.0, 726.0, 719.0]}, {"text": "with penile cancer. Men should be assessed for genital", "bbox": [403.0, 721.0, 727.0, 735.0]}, {"text": "and lower-limb lymphoedema at each outpatient clinic", "bbox": [403.0, 736.0, 726.0, 751.0]}], "type": "Text", "position": 9}, {"raw_context": [{"text": "Table 7 – Follow-up regime for penile cancer", "bbox": [68.0, 763.0, 268.0, 778.0]}, {"text": "Recommendation", "bbox": [72.0, 785.0, 154.0, 796.0]}, {"text": "Surveillance period", "bbox": [180.0, 785.0, 270.0, 796.0]}, {"text": "Examinations and investigations", "bbox": [278.0, 785.0, 424.0, 796.0]}, {"text": "MinimumFU", "bbox": [631.0, 785.0, 688.0, 796.0]}, {"text": "duration", "bbox": [630.0, 797.0, 672.0, 807.0]}, {"text": "Years", "bbox": [181.0, 809.0, 207.0, 820.0]}, {"text": "Years", "bbox": [229.0, 809.0, 255.0, 820.0]}, {"text": "3–5", "bbox": [230.0, 821.0, 249.0, 831.0]}, {"text": "1–2", "bbox": [181.0, 822.0, 200.0, 831.0]}, {"text": "Primary tumour FU", "bbox": [73.0, 837.0, 158.0, 848.0]}, {"text": "Penile-preserving", "bbox": [72.0, 848.0, 146.0, 860.0]}, {"text": "Regular PEx or self-examination. Repeat biopsy after topical or laser treatment for", "bbox": [279.0, 848.0, 615.0, 860.0]}, {"text": "5 ут", "bbox": [630.0, 849.0, 648.0, 861.0]}, {"text": "3-", "bbox": [181.0, 850.0, 191.0, 858.0]}, {"text": "monthly", "bbox": [228.0, 859.0, 266.0, 871.0]}, {"text": "monthly", "bbox": [181.0, 860.0, 218.0, 871.0]}, {"text": "PeIN (optional).", "bbox": [278.0, 861.0, 344.0, 870.0]}, {"text": "treatment", "bbox": [83.0, 862.0, 127.0, 870.0]}, {"text": "Amputation.", "bbox": [72.0, 872.0, 122.0, 882.0]}, {"text": "Annually", "bbox": [230.0, 872.0, 267.0, 881.0]}, {"text": "Regular physician or self-examination.", "bbox": [278.0, 872.0, 435.0, 882.0]}, {"text": "5 yr", "bbox": [630.0, 872.0, 649.0, 884.0]}, {"text": "3-", "bbox": [182.0, 874.0, 189.0, 879.0]}, {"text": "monthly", "bbox": [181.0, 883.0, 216.0, 894.0]}, {"text": "Inguinal node FU", "bbox": [72.0, 893.0, 149.0, 905.0]}, {"text": "Regular PEx or self-examination. US ± FNAC optional.", "bbox": [278.0, 905.0, 496.0, 916.0]}, {"text": "Surveillance", "bbox": [72.0, 906.0, 124.0, 916.0]}, {"text": "3-", "bbox": [181.0, 908.0, 190.0, 915.0]}, {"text": "6-", "bbox": [230.0, 908.0, 238.0, 915.0]}, {"text": "5 yr", "bbox": [630.0, 907.0, 649.0, 919.0]}, {"text": "monthly", "bbox": [181.0, 916.0, 218.0, 928.0]}, {"text": "monthly", "bbox": [228.0, 916.0, 265.0, 927.0]}, {"text": "Regular PEx or self-examination. US ± FNAC optional.", "bbox": [277.0, 929.0, 496.0, 940.0]}, {"text": "pN0", "bbox": [72.0, 930.0, 92.0, 940.0]}, {"text": "3-", "bbox": [181.0, 930.0, 190.0, 938.0]}, {"text": "Annually", "bbox": [230.0, 930.0, 267.0, 940.0]}, {"text": "5 yr", "bbox": [630.0, 930.0, 649.0, 941.0]}, {"text": "monthly", "bbox": [181.0, 940.0, 217.0, 951.0]}, {"text": "Regular PEx or self-examination. US ± FNAC, CT chest/abdomen/pelvis or 18 FDG-PET/", "bbox": [278.0, 951.0, 622.0, 964.0]}, {"text": "pN+", "bbox": [72.0, 953.0, 90.0, 964.0]}, {"text": "3-3-3-3", "bbox": [181.0, 953.0, 191.0, 961.0]}, {"text": "5 yr", "bbox": [629.0, 953.0, 649.0, 964.0]}, {"text": "monthly", "bbox": [181.0, 963.0, 218.0, 974.0]}, {"text": "monthly", "bbox": [228.0, 964.0, 267.0, 972.0]}, {"text": "CT optional.", "bbox": [276.0, 964.0, 328.0, 976.0]}, {"text": "CT = computed tomography; ¹ªFDG = ¹ªF-fluoro-2-deoxy-D-glucose; FNAC = fine-needle aspiration cytology; FU = follow-up; PeIN = penile intraepithelial", "bbox": [72.0, 978.0, 715.0, 991.0]}, {"text": "neoplasia; PEx = physician examination; PET = positron emission tomography; US = ultrasound.", "bbox": [72.0, 990.0, 465.0, 1001.0]}], "type": "Table", "position": 10}, {"raw_context": [{"text": "Please cite this article as: O.R. Brouwer, M. Albersen, A. Parnham et al., European Association of Urology-American Society of Clinical Oncology Col-", "bbox": [63.0, 1028.0, 721.0, 1040.0]}, {"text": "laborative Guideline on Penile Cancer: 2023 Update, Eur Urol (2023), https://doi.org/10.1016/j.eururo.2023.02.027", "bbox": [63.0, 1040.0, 582.0, 1053.0]}], "type": "Text", "position": 11}, {"raw_context": [{"text": "8", "bbox": [61.0, 43.0, 70.0, 54.0]}], "type": "Text", "position": 12}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/泌尿外科/2023 EAU／ASCO指南：阴茎癌（更新版）.pdf", "page_num": 8}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "缺少换行#1#1#Recommendation Strength另起一行\n序号格式不一致#4#4#Radiotherapy 3.6.3.  序号应该在前\n多余换行#8#8#Follow-Up联接7段序号\n多余换行#13#13#Quality Of Life联接12段序号", "type3": "无关文本#5#26# [107]  类似的 [   ]引用过多\n无关文本#27#27# 8", "type4": null, "type5": null, "type6": "准确性#1#3#表格的内容，但是表格标题下的内容互相穿插\n准确性#19#25#表格的内容，但是表格标题下的内容互相穿插\n有用性#26#26#参考引用的内容"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:41", "update_time": "2024-05-07 22:38:08"}
{"id": 1082597, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 738, "source_info": {"seq_id": "156e7fec-a494-4723-b266-a44f4c5f0a36", "title": null, "text": "【0】页码:8\n\n【1】## S Bjhaem\n\n【2】\n If unsuccessful fibrinolysis by these criteria, consider repeating thrombolysis if haemodynamically stable.\n\n【3】Escalation of anticoagulant management should be considered in pregnant individuals with MVT, for example switch from LMWH to IV UFH and then to a VKA with aspirin 75 mg daily when no further immediate interventions required.\n\n【4】If the MDT opinion is that cardiac surgery is required either as the primary treatment modality or because of ongoing haemodynamic instability despite medical treatment, then an experienced MDT team should consider the optimal foetal management. If gestation supports emergent delivery at the start of the cardiac surgical procedure, then this should be performed with exquisite attention to haemostasis at the obstetric site. A meta-analysis in 2018 of cardiac surgery during pregnancy for all indications, that is not only MVT, suggested a maternal mortality rate of 11.2%, maternal complication rate of 8.1%, pregnancy loss rate of 33.1% and neonatal complications in 10.8%. 40 There are considerations in the cardiac surgical bypass procedure that may reduce the risks to the foetus including minimising hypothermia, maintaining mean arterial pressure > 70 mmHg, avoiding maternal hypoglycaemia, maintaining maternal haematocrit and maintaining a left lateral tilted position to minimise compression of the great vessels.\n\n【5】## Peripartum Care\n\n【6】\n Birth represents a particularly high-risk time to pregnant individuals with MHV, due to the need to balance the risk of haemorrhage with the risk of MVT because of a prolonged period of reduced anticoagulation. The MDT should document a delivery plan that should include the anticoagulation regimen, analgesic options during labour, anaesthetic options for an operative intervention (e.g. caesarean birth), haemodynamic monitoring, the uterotonic agents to be utilised and the recommended postpartum anticoagulation regimen following childbirth.\n\n【7】A high proportion of pregnant individuals will deliver by caesarean section (CS), but vaginal birth has advantages for selected individuals as it avoids the risk of surgical bleeding, in particular wound haematoma and is recommended by ESC guidelines. 7 The UKOSS surveillance data 5 reported a 53% rate of CS, only one of which was an emergency procedure and a 45% rate of vaginal birth. In one retrospective case series comparison between two large centres in the UK and the Netherlands, 41 the relative increased incidence of primary/secondary PPH and wound haematoma in one centre appeared to correlate with a higher rate of CS ( Table 3 ).\n\n【8】Scheduled delivery has been recommended for individuals on therapeutic LMWH in the context of venous thromboembolic (VTE) disease 42 ; citations include a single-centre retrospective observational study of pregnant individuals receiving therapeutic-dose LMWH for the management of VTE; individuals with spontaneous onset of labour had\n\n【9】 a 1.9-fold (95% CI: 0.6–5.8) increase in the risk of PPH (≥500mL) compared with planned induction of labour. 43\n\n【10】## Optimal Anticoagulation Prior To Delivery\n\n【11】\n There is an absence of data to inform the best options for anticoagulation around the time of birth. Any data available are derived from registries/observational retrospective data.\n\n【12】For individuals receiving VKAs, a transition to therapeutic LMWH or UFH is recommended by 36 weeks (or 2 weeks before the planned birth). If presenting in labour on VKA, the INR should be measured and corrected to decrease maternal haemorrhage risk with a four-factor prothrombin complex concentrate (PCC) at a dose of 25–50 u/kg in addition to vitamin K 10 mg IV. This is preferable to administering 15 mL/kg of fresh frozen plasma, which is only partially effective at improving the INR, time-consuming and requires higher fluid volume. 44 A CS should be considered in view of the foetal bleeding risks.\n\n【13】For individuals with MHV, the risk of prolonged interruption of LMWH during the labour induction process is a potential risk for MVT. It is possible that this risk is reduced by bridging with UFH. It should be recognised that there are no studies examining the competing risks of bleeding versus valve thrombosis to inform recommendations on the mode of delivery in individuals with MHV.\n\n【14】It is recommended that, in individuals receiving therapeutic LMWH, the last dose should be ≥ 24 h prior to the planned induction. Consideration can be given to further doses, including prophylactic and intermediate doses, and this should be discussed by the MDT as it may impact choices for labour analgesia. However, there are no data on which to make clear recommendations. Alternatively, a switch to therapeutic IV UFH at least 36h prior to scheduled induction can be considered, especially in individuals where induction may be prolonged. The UFH infusion needs to be discontinued 4–6h prior to delivery, which may be difficult to predict.\n\n【15】Practically, the infusion is stopped when the patient is in early labour. A meta-analysis in non-pregnant patients did not show superiority of UFH over LMWH for bridging patients with MHV and familiarity of doctors with UFH is poor and the risks of over and under anticoagulation are significant so LMWH may in practice offer less overall risk. 3 Many guidelines recommend a specific activated partial thromboplastin time ratio (APTTR) target range for pregnant individuals with MHV; however, the therapeutic APTTR range for UFH should be determined by the local laboratory as the appropriate therapeutic target depends on the reagents used. In addition, monitoring UFH by APTTR is problematic as the heparin dose to achieve the equivalent APTTR in pregnancy may differ from outside of pregnancy, usually requiring higher doses to achieve the same target APTTR with a risk of overdose and bleeding. UFH can be monitored using an appropriately calibrated anti-Xa assay 45 and we recommended this in preference to sole reliance on the APTTR; however, we acknowledge that this may not be available in a timely fashion in all laboratories.\n\n【16】 milno roliw , yandid yiers viru M & V sesat , - 13 ns Aq 1828 1 : 49/1 111.0 1/19/1103 : xaliw , yan\n\n【17】 15 but smot, org and 1 (20240/81) no candidate", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "s BJHaem", "bbox": [57.0, 23.0, 160.0, 63.0]}], "type": "Section-header", "position": 1}, {"raw_context": [{"text": "If unsuccessful fibrinolysis by these criteria, consider re-", "bbox": [74.0, 65.0, 385.0, 79.0]}, {"text": "peating thrombolysis if haemodynamically stable.", "bbox": [58.0, 80.0, 329.0, 95.0]}, {"text": "Escalation of anticoagulant management should be con-", "bbox": [74.0, 97.0, 385.0, 112.0]}, {"text": "sidered in pregnant individuals with MVT, for example", "bbox": [58.0, 113.0, 387.0, 127.0]}, {"text": "switch from LMWH to IV UFH and then to a VKA with as-", "bbox": [58.0, 129.0, 385.0, 144.0]}, {"text": "pirin 75 mg daily when no further immediate interventions", "bbox": [58.0, 145.0, 387.0, 160.0]}, {"text": "required.", "bbox": [58.0, 161.0, 111.0, 176.0]}, {"text": "If the MDT opinion is that cardiac surgery is required", "bbox": [74.0, 177.0, 387.0, 192.0]}, {"text": "either as the primary treatment modality or because of", "bbox": [58.0, 194.0, 387.0, 207.0]}, {"text": "ongoing haemodynamic instability despite medical treat-", "bbox": [58.0, 210.0, 385.0, 225.0]}, {"text": "ment, then an experienced MDT team should consider the", "bbox": [58.0, 226.0, 387.0, 240.0]}, {"text": "optimal foetal management. If gestation supports emer-", "bbox": [58.0, 241.0, 385.0, 256.0]}, {"text": "gent delivery at the start of the cardiac surgical procedure,", "bbox": [58.0, 258.0, 387.0, 273.0]}, {"text": "then this should be performed with exquisite attention to", "bbox": [58.0, 274.0, 387.0, 288.0]}, {"text": "haemostasis at the obstetric site. A meta-analysis in 2018", "bbox": [58.0, 290.0, 387.0, 305.0]}, {"text": "of cardiac surgery during pregnancy for all indications,", "bbox": [58.0, 306.0, 387.0, 321.0]}, {"text": "that is not only MVT, suggested a maternal mortality rate", "bbox": [58.0, 322.0, 387.0, 336.0]}, {"text": "of 11.2%, maternal complication rate of 8.1%, pregnancy", "bbox": [58.0, 338.0, 385.0, 353.0]}, {"text": "loss rate of 33.1% and neonatal complications in 10.8%. 40", "bbox": [58.0, 354.0, 383.0, 368.0]}, {"text": "There are considerations in the cardiac surgical bypass", "bbox": [58.0, 370.0, 387.0, 385.0]}, {"text": "procedure that may reduce the risks to the foetus includ-", "bbox": [58.0, 386.0, 385.0, 401.0]}, {"text": "ing minimising hypothermia, maintaining mean arterial", "bbox": [58.0, 402.0, 387.0, 416.0]}, {"text": "pressure > 70 mmHg, avoiding maternal hypoglycaemia,", "bbox": [58.0, 418.0, 386.0, 433.0]}, {"text": "maintaining maternal haematocrit and maintaining a left", "bbox": [58.0, 435.0, 387.0, 448.0]}, {"text": "lateral tilted position to minimise compression of the great", "bbox": [58.0, 450.0, 386.0, 465.0]}, {"text": "vessels.", "bbox": [58.0, 467.0, 103.0, 481.0]}], "type": "Text", "position": 2}, {"raw_context": [{"text": "Peripartum care", "bbox": [58.0, 513.0, 171.0, 528.0]}], "type": "Section-header", "position": 3}, {"raw_context": [{"text": "Birth represents a particularly high-risk time to pregnant in-", "bbox": [58.0, 546.0, 385.0, 561.0]}, {"text": "dividuals with MHV, due to the need to balance the risk of", "bbox": [58.0, 562.0, 387.0, 576.0]}, {"text": "haemorrhage with the risk of MVT because of a prolonged", "bbox": [58.0, 578.0, 387.0, 593.0]}, {"text": "period of reduced anticoagulation. The MDT should docu-", "bbox": [58.0, 595.0, 385.0, 609.0]}, {"text": "ment a delivery plan that should include the anticoagula-", "bbox": [58.0, 609.0, 385.0, 624.0]}, {"text": "tion regimen, analgesic options during labour, anaesthetic", "bbox": [58.0, 626.0, 387.0, 641.0]}, {"text": "options for an operative intervention (e.g. caesarean birth),", "bbox": [58.0, 642.0, 387.0, 656.0]}, {"text": "haemodynamic monitoring, the uterotonic agents to be uti-", "bbox": [58.0, 658.0, 385.0, 673.0]}, {"text": "lised and the recommended postpartum anticoagulation", "bbox": [58.0, 675.0, 387.0, 689.0]}, {"text": "regimen following childbirth.", "bbox": [58.0, 690.0, 222.0, 704.0]}, {"text": "A high proportion of pregnant individuals will deliver by", "bbox": [75.0, 706.0, 386.0, 721.0]}, {"text": "caesarean section (CS), but vaginal birth has advantages for", "bbox": [58.0, 722.0, 387.0, 736.0]}, {"text": "selected individuals as it avoids the risk of surgical bleed-", "bbox": [58.0, 738.0, 385.0, 753.0]}, {"text": "ing, in particular wound haematoma and is recommended", "bbox": [58.0, 755.0, 387.0, 769.0]}, {"text": "by ESC guidelines. 7 The UKOSS surveillance data 5 reported", "bbox": [58.0, 769.0, 387.0, 784.0]}, {"text": "a 53% rate of CS, only one of which was an emergency pro-", "bbox": [58.0, 786.0, 385.0, 801.0]}, {"text": "cedure and a 45% rate of vaginal birth. In one retrospective", "bbox": [58.0, 802.0, 387.0, 816.0]}, {"text": "case series comparison between two large centres in the UK", "bbox": [58.0, 818.0, 387.0, 833.0]}, {"text": "and the Netherlands, 41 the relative increased incidence of", "bbox": [58.0, 832.0, 387.0, 849.0]}, {"text": "primary/secondary PPH and wound haematoma in one cen-", "bbox": [58.0, 849.0, 385.0, 864.0]}, {"text": "tre appeared to correlate with a higher rate of CS ( Table 3 ).", "bbox": [58.0, 866.0, 387.0, 881.0]}, {"text": "Scheduled delivery has been recommended for individuals", "bbox": [58.0, 882.0, 387.0, 896.0]}, {"text": "on therapeutic LMWH in the context of venous thrombo-", "bbox": [58.0, 898.0, 385.0, 913.0]}, {"text": "embolic (VTE) disease 42 ; citations include a single-centre", "bbox": [58.0, 913.0, 387.0, 930.0]}, {"text": "retrospective observational study of pregnant individuals", "bbox": [58.0, 930.0, 387.0, 944.0]}, {"text": "receiving therapeutic-dose LMWH for the management", "bbox": [58.0, 946.0, 387.0, 961.0]}, {"text": "of VTE; individuals with spontaneous onset of labour had", "bbox": [58.0, 963.0, 386.0, 977.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": "a 1.9-fold (95% CI: 0.6–5.8) increase in the risk of PPH", "bbox": [406.0, 65.0, 734.0, 79.0]}, {"text": "(≥500mL) compared with planned induction of labour. 43", "bbox": [406.0, 80.0, 715.0, 95.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "Optimal anticoagulation prior to delivery", "bbox": [406.0, 128.0, 688.0, 144.0]}], "type": "Section-header", "position": 6}, {"raw_context": [{"text": "There is an absence of data to inform the best options for an-", "bbox": [407.0, 160.0, 733.0, 175.0]}, {"text": "ticoagulation around the time of birth. Any data available", "bbox": [406.0, 177.0, 735.0, 192.0]}, {"text": "are derived from registries/observational retrospective data.", "bbox": [406.0, 194.0, 734.0, 208.0]}, {"text": "For individuals receiving VKAs, a transition to therapeutic", "bbox": [406.0, 209.0, 735.0, 225.0]}, {"text": "LMWH or UFH is recommended by 36 weeks (or 2 weeks be-", "bbox": [406.0, 226.0, 733.0, 240.0]}, {"text": "fore the planned birth). If presenting in labour on VKA, the", "bbox": [406.0, 242.0, 735.0, 256.0]}, {"text": "INR should be measured and corrected to decrease maternal", "bbox": [407.0, 258.0, 735.0, 273.0]}, {"text": "haemorrhage risk with a four-factor prothrombin complex con-", "bbox": [406.0, 274.0, 733.0, 288.0]}, {"text": "centrate (PCC) at a dose of 25–50 u/kg in addition to vitamin K", "bbox": [406.0, 289.0, 735.0, 305.0]}, {"text": "10 mg IV. This is preferable to administering 15 mL/kg of fresh", "bbox": [408.0, 306.0, 735.0, 321.0]}, {"text": "frozen plasma, which is only partially effective at improving", "bbox": [406.0, 322.0, 734.0, 336.0]}, {"text": "the INR, time-consuming and requires higher fluid volume. 44", "bbox": [406.0, 338.0, 731.0, 353.0]}, {"text": "A CS should be considered in view of the foetal bleeding risks.", "bbox": [407.0, 354.0, 731.0, 368.0]}, {"text": "For individuals with MHV, the risk of prolonged inter-", "bbox": [422.0, 370.0, 733.0, 385.0]}, {"text": "ruption of LMWH during the labour induction process is a", "bbox": [406.0, 386.0, 735.0, 401.0]}, {"text": "potential risk for MVT. It is possible that this risk is reduced", "bbox": [406.0, 402.0, 735.0, 416.0]}, {"text": "by bridging with UFH. It should be recognised that there are", "bbox": [406.0, 418.0, 735.0, 433.0]}, {"text": "no studies examining the competing risks of bleeding versus", "bbox": [406.0, 435.0, 735.0, 448.0]}, {"text": "valve thrombosis to inform recommendations on the mode", "bbox": [406.0, 450.0, 735.0, 464.0]}, {"text": "of delivery in individuals with MHV.", "bbox": [406.0, 466.0, 610.0, 481.0]}, {"text": "It is recommended that, in individuals receiving ther-", "bbox": [422.0, 482.0, 733.0, 496.0]}, {"text": "apeutic LMWH, the last dose should be ≥ 24 h prior to the", "bbox": [406.0, 498.0, 735.0, 513.0]}, {"text": "planned induction. Consideration can be given to further", "bbox": [406.0, 515.0, 734.0, 528.0]}, {"text": "doses, including prophylactic and intermediate doses, and", "bbox": [406.0, 530.0, 735.0, 545.0]}, {"text": "this should be discussed by the MDT as it may impact choices", "bbox": [406.0, 546.0, 735.0, 561.0]}, {"text": "for labour analgesia. However, there are no data on which to", "bbox": [406.0, 562.0, 735.0, 576.0]}, {"text": "make clear recommendations. Alternatively, a switch to ther-", "bbox": [406.0, 578.0, 733.0, 593.0]}, {"text": "apeutic IV UFH at least 36h prior to scheduled induction can", "bbox": [406.0, 595.0, 735.0, 608.0]}, {"text": "be considered, especially in individuals where induction may", "bbox": [406.0, 609.0, 734.0, 624.0]}, {"text": "be prolonged. The UFH infusion needs to be discontinued", "bbox": [406.0, 626.0, 735.0, 641.0]}, {"text": "4–6h prior to delivery, which may be difficult to predict.", "bbox": [406.0, 642.0, 734.0, 656.0]}, {"text": "Practically, the infusion is stopped when the patient is in early", "bbox": [406.0, 658.0, 735.0, 673.0]}, {"text": "labour. A meta-analysis in non-pregnant patients did not", "bbox": [406.0, 675.0, 735.0, 689.0]}, {"text": "show superiority of UFH over LMWH for bridging patients", "bbox": [406.0, 689.0, 735.0, 705.0]}, {"text": "with MHV and familiarity of doctors with UFH is poor and", "bbox": [406.0, 706.0, 735.0, 721.0]}, {"text": "the risks of over and under anticoagulation are significant so", "bbox": [406.0, 722.0, 735.0, 736.0]}, {"text": "LMWH may in practice offer less overall risk. 3 Many guide-", "bbox": [406.0, 738.0, 733.0, 753.0]}, {"text": "lines recommend a specific activated partial thromboplastin", "bbox": [406.0, 755.0, 735.0, 769.0]}, {"text": "time ratio (APTTR) target range for pregnant individuals", "bbox": [406.0, 770.0, 735.0, 784.0]}, {"text": "with MHV; however, the therapeutic APTTR range for UFH", "bbox": [406.0, 786.0, 735.0, 801.0]}, {"text": "should be determined by the local laboratory as the appro-", "bbox": [406.0, 803.0, 733.0, 816.0]}, {"text": "priate therapeutic target depends on the reagents used. In", "bbox": [406.0, 818.0, 735.0, 833.0]}, {"text": "addition, monitoring UFH by APTTR is problematic as the", "bbox": [406.0, 833.0, 735.0, 850.0]}, {"text": "heparin dose to achieve the equivalent APTTR in pregnancy", "bbox": [406.0, 849.0, 734.0, 866.0]}, {"text": "may differ from outside of pregnancy, usually requiring", "bbox": [406.0, 866.0, 735.0, 881.0]}, {"text": "higher doses to achieve the same target APTTR with a risk of", "bbox": [406.0, 883.0, 735.0, 896.0]}, {"text": "overdose and bleeding. UFH can be monitored using an ap-", "bbox": [406.0, 898.0, 734.0, 913.0]}, {"text": "propriately calibrated anti-Xa assay 45 and we recommended", "bbox": [406.0, 914.0, 735.0, 929.0]}, {"text": "this in preference to sole reliance on the APTTR; however, we", "bbox": [406.0, 930.0, 735.0, 944.0]}, {"text": "acknowledge that this may not be available in a timely fashion", "bbox": [406.0, 946.0, 735.0, 961.0]}, {"text": "in all laboratories.", "bbox": [406.0, 963.0, 506.0, 977.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "milno roliw , yandid yiers viru M & V sesat , - 13 ns Aq 1828 1 : 49/1 111.0 1/19/1103 : xaliw , yan", "bbox": [768.0, 156.0, 781.0, 412.0]}], "type": "Text", "position": 8}, {"raw_context": [{"text": "15 but smot, org and 1 (20240/81) no candidate", "bbox": [768.0, 419.0, 780.0, 542.0]}], "type": "Text", "position": 9}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/心血管/指南/2023 BSH 指南：机械心脏瓣膜妊娠个体抗凝管理(1).pdf", "page_num": 8}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "多余换行#8#9#为同段", "type3": "页眉#1#1#非正文\n无关文本#0#17#全文存在多处无关数字", "type4": null, "type5": null, "type6": "信息有用性#16#17#无用内容"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:41", "update_time": "2024-05-07 19:19:31"}
{"id": 1082596, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 738, "source_info": {"seq_id": "5b043cec-042c-4792-a3f6-46fae18cffa3", "title": null, "text": "【0】页码:7\n and other medications. The elderly and young children may have an increased elimination half-life and therefore caution should be used in these groups 6–8 JAG recommend that in patients over the age of 70 years, a total dose > 2.5 mg should be used with extreme caution, especially if combined with an opiate. 9 Midazolam is metabolised by glucuronide conjugation by the cytochrome P450-3A4 enzyme in the liver and by glucuronide conjugation. Other medications that interact with midazolam generally do so via interaction with this enzyme system.\n\n【1】Prolonged action of midazolam can be seen with drugs that inhibit metabolism and include nefazodone, sertraline, fluoxetine, protease inhibitors, macrolide antimicrobials and diltiazem.\n\n【2】Enhanced effect of midazolam also occurs with sedating antidepressants, some anticonvulsants such as carbamazepine, sedating antihistamines, opiates and alcohol. 1 Most of the side effects of midazolam are those that are desirable for producing a sedative effect. However, the effects may last several hours, and return to normal function and cognition is variable.\n\n【3】## Remimazolam\n\n【4】\n Remimazolam is an ultra-short-acting intravenous benzodiazepine undergoing organ-independent metabolism with no significant accumulation of active components. 11 Approval for clinical use was provided in the USA and Europe in 2020. Clinical reports provide evidence of clinical application in endoscopy.\n\n【5】Remimazolam can be differentiated from other intravenous sedatives by its low liability for cardiovascular depression, respiratory depression and injection pain.\n\n【6】A single dose, repeat bolus or infusion of remimazolam can be used safely and effectively for procedural sedation.\n\n【7】Remimazolam reversal with flumazenil can be achieved. The short duration of action may not expose the patient to re-sedation with flumazenil breakdown. 1 Several published clinical trials have used remimazolam as a sedative for upper gastrointestinal endoscopy and colonoscopy. 13 14 There is some evidence of performance improvements in comparison with midazolam and propofol.\n\n【8】## Fentanyl\n\n【9】\n Fentanyl is a strong synthetic opioid commonly used as an adjunct to benzodiazepines during endoscopic procedures and should be given first. It has a rapid onset and its effects generally last for under 2 hours. 15 Common side effects of fentanyl include nausea, vomiting, constipation, sedation and confusion. 15 Serious side effects may include respiratory depression, hallucinations, serotonin syndrome, low blood pressure or development of an opioid use disorder. 1 Use of concomitant opiates potentiates the effects of the benzodiazepine, meaning that doses should be reduced, particularly in patients with renal disease, liver disease, cardiorespiratory disease and increasing age. 9\n\n【10】## Pethidine\n\n【11】\n Pethidine (also known as meperidine) is a synthetic opioid initially used for the treatment of moderate to severe pain. The side effect profile is similar to that of other opiates but due to interactions with serotonergic drugs, additional problems can occur if used in combination with monoamineoxidase inhibitors or selective serotonin reuptake inhibitors. 10 Pethidine has a rapid onset but can last in the serum for 120–150 min. Doses should also be reduced in high-risk groups and the elderly. 3\n\n【12】 Sidhu R, et al. Gut 2023;0:1–27. doi:10.1136/gutjnl-2023-330396\n\n【13】 Entonox Entonox is a gaseous mixture of 50% nitrous oxide and 50% oxygen that is a potent analgesia that is used widely in healthcare, including obstetrics, emergency units and endoscopy. It has a rapid, predictable onset and is eliminated from the body within a very short time. It can be used alone or in addition to other analgesics and sedatives, and in endoscopy is a very useful adjunct for lower intestinal endoscopy. 1 Entonox has been shown to be as effective for colonoscopy in comparison with intravenous sedation with midazolam, fentanyl or propofol. 19 Entonox is easy to administer using a mouthpieceheld delivery device, and the onset of action is within 1–2 min.\n\n【14】The rapid elimination means that patients can return to normal functioning more quickly than with intravenous agents. 2 The recovery profile allows discharge within 30 min of procedure completion. There are no requirements regarding driving or supervision overnight. Both diagnostic and therapeutic colonoscopy procedures show high completion rates without complications. 21 There are several important patient groups for whom Entonox should not be used, which include those with recent eye surgery involving gas bubble insertion, head injury, pneumothorax, suspected intestinal obstruction, bullous emphysema, middle ear procedures and following a recent dive. There are environmental concerns regarding staff exposure and the broader impact of nitrous oxide as a greenhouse gas. Scavenging systems are, however, available to reduce staff exposure but are currently limited. 19 Installation of catalytic destruction systems to reduce environmental escape could have considerable impact on reducing greenhouse gas emissions. These factors need to be considered in the overall gases strategy of every hospital.\n\n【15】## Patient Information, Choice And Expectation 3. We Recommend That Patients Receive Comprehensive Information About What To Expect From The Sedation And Sensory Experience Of The Procedure\n\n【16】\n Grade of evidence: High. Strength of recommendation: Strong.\n\n【17】Level of agreement: 100% Providing patients with adequate information is a basic principle of consent and this should occur prior to attendance for the procedure. 22 Information may be written, but, where possible, it should be tailored to individual patients' needs or preferences and may include verbal, web-based or video formats. Online supplemental appendix 1 includes a patient leaflet on sedation, adapted from the RCoA.\n\n【18】Patient experience may be negatively affected when there is a mismatch between their expectations and the reality of sedation effects or the sensory experience of endoscopic procedures— that is, what the procedure feels like to the patient. 23 24 A significant proportion of patients choosing sedation are not aware that they will not be 'put to sleep' during the procedure, which may not only affect patient experience and increase anxiety, but raises the question as to whether these patients have received adequate information to allow informed consent. 252 Providing information about the expected effects of sedation can reduce patient anxiety. 26 27 Anxiety may also be reduced when information is provided about the sensory experience and comfort of the procedure. 28 29 It is therefore crucial that preprocedural information is easily understandable, tailored to the individual and encompasses the effects of sedation and the sensory experience of the procedure.\n\n【19】4. We recommend that patients are involved in shared decisionmaking, where possible, when choosing which sedative medication (if any) to proceed with during an endoscopic procedure", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "and other medications. The elderly and young children may have", "bbox": [54.0, 60.0, 386.0, 75.0]}, {"text": "an increased elimination half-life and therefore caution should", "bbox": [53.0, 76.0, 386.0, 90.0]}, {"text": "be used in these groups 6–8 JAG recommend that in patients over", "bbox": [53.0, 90.0, 385.0, 107.0]}, {"text": "the age of 70 years, a total dose > 2.5 mg should be used with", "bbox": [53.0, 105.0, 386.0, 120.0]}, {"text": "extreme caution, especially if combined with an opiate. 9", "bbox": [53.0, 120.0, 344.0, 135.0]}, {"text": "Midazolam is metabolised by glucuronide conjugation by", "bbox": [65.0, 135.0, 386.0, 150.0]}, {"text": "the cytochrome P450-3A4 enzyme in the liver and by glucuro-", "bbox": [53.0, 150.0, 385.0, 164.0]}, {"text": "nide conjugation. Other medications that interact with midaz-", "bbox": [53.0, 165.0, 385.0, 179.0]}, {"text": "olam generally do so via interaction with this enzyme system.", "bbox": [53.0, 180.0, 385.0, 193.0]}, {"text": "Prolonged action of midazolam can be seen with drugs that", "bbox": [53.0, 194.0, 386.0, 208.0]}, {"text": "inhibit metabolism and include nefazodone, sertraline, fluoxe-", "bbox": [53.0, 209.0, 385.0, 222.0]}, {"text": "tine, protease inhibitors, macrolide antimicrobials and diltiazem.", "bbox": [53.0, 223.0, 385.0, 237.0]}, {"text": "Enhanced effect of midazolam also occurs with sedating antide-", "bbox": [53.0, 238.0, 385.0, 252.0]}, {"text": "pressants, some anticonvulsants such as carbamazepine, sedating", "bbox": [53.0, 252.0, 387.0, 266.0]}, {"text": "antihistamines, opiates and alcohol. 1", "bbox": [53.0, 268.0, 242.0, 281.0]}, {"text": "Most of the side effects of midazolam are those that are desir-", "bbox": [64.0, 281.0, 385.0, 295.0]}, {"text": "able for producing a sedative effect. However, the effects may", "bbox": [53.0, 297.0, 385.0, 310.0]}, {"text": "last several hours, and return to normal function and cognition", "bbox": [53.0, 311.0, 387.0, 325.0]}, {"text": "is variable.", "bbox": [53.0, 325.0, 112.0, 339.0]}], "type": "Text", "position": 0}, {"raw_context": [{"text": "Remimazolam", "bbox": [53.0, 360.0, 125.0, 374.0]}], "type": "Section-header", "position": 1}, {"raw_context": [{"text": "Remimazolam is an ultra-short-acting intravenous benzodiaze-", "bbox": [53.0, 374.0, 385.0, 390.0]}, {"text": "pine undergoing organ-independent metabolism with no signifi-", "bbox": [53.0, 389.0, 385.0, 404.0]}, {"text": "cant accumulation of active components. 11 Approval for clinical", "bbox": [53.0, 404.0, 386.0, 419.0]}, {"text": "use was provided in the USA and Europe in 2020. Clinical", "bbox": [53.0, 419.0, 386.0, 433.0]}, {"text": "reports provide evidence of clinical application in endoscopy.", "bbox": [53.0, 434.0, 373.0, 447.0]}, {"text": "Remimazolam can be differentiated from other intravenous", "bbox": [66.0, 449.0, 387.0, 462.0]}, {"text": "sedatives by its low liability for cardiovascular depression, respi-", "bbox": [53.0, 463.0, 385.0, 477.0]}, {"text": "ratory depression and injection pain.", "bbox": [53.0, 477.0, 244.0, 492.0]}, {"text": "A single dose, repeat bolus or infusion of remimazolam can be", "bbox": [66.0, 492.0, 387.0, 506.0]}, {"text": "used safely and effectively for procedural sedation.", "bbox": [53.0, 507.0, 317.0, 521.0]}, {"text": "Remimazolam reversal with flumazenil can be achieved. The", "bbox": [66.0, 522.0, 387.0, 535.0]}, {"text": "short duration of action may not expose the patient to re-seda-", "bbox": [53.0, 536.0, 385.0, 550.0]}, {"text": "tion with flumazenil breakdown. 1", "bbox": [53.0, 551.0, 226.0, 564.0]}, {"text": "Several published clinical trials have used remimazolam as", "bbox": [65.0, 565.0, 387.0, 580.0]}, {"text": "a sedative for upper gastrointestinal endoscopy and colonos-", "bbox": [53.0, 580.0, 385.0, 594.0]}, {"text": "copy. 13 14 There is some evidence of performance improvements", "bbox": [53.0, 594.0, 387.0, 608.0]}, {"text": "in comparison with midazolam and propofol.", "bbox": [53.0, 610.0, 290.0, 623.0]}], "type": "Text", "position": 2}, {"raw_context": [{"text": "Fentanyl", "bbox": [53.0, 643.0, 98.0, 658.0]}], "type": "Section-header", "position": 3}, {"raw_context": [{"text": "Fentanyl is a strong synthetic opioid commonly used as an", "bbox": [53.0, 658.0, 387.0, 673.0]}, {"text": "adjunct to benzodiazepines during endoscopic procedures and", "bbox": [53.0, 674.0, 386.0, 687.0]}, {"text": "should be given first. It has a rapid onset and its effects generally", "bbox": [53.0, 688.0, 386.0, 701.0]}, {"text": "last for under 2 hours. 15 Common side effects of fentanyl include", "bbox": [53.0, 702.0, 387.0, 716.0]}, {"text": "nausea, vomiting, constipation, sedation and confusion. 15 Serious", "bbox": [53.0, 717.0, 387.0, 731.0]}, {"text": "side effects may include respiratory depression, hallucinations,", "bbox": [53.0, 731.0, 385.0, 746.0]}, {"text": "serotonin syndrome, low blood pressure or development of an", "bbox": [53.0, 745.0, 387.0, 760.0]}, {"text": "opioid use disorder. 1", "bbox": [53.0, 762.0, 159.0, 775.0]}, {"text": "Use of concomitant opiates potentiates the effects of the", "bbox": [65.0, 775.0, 387.0, 789.0]}, {"text": "benzodiazepine, meaning that doses should be reduced, partic-", "bbox": [53.0, 790.0, 385.0, 804.0]}, {"text": "ularly in patients with renal disease, liver disease, cardiorespira-", "bbox": [53.0, 805.0, 385.0, 820.0]}, {"text": "tory disease and increasing age. 9", "bbox": [53.0, 819.0, 220.0, 833.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": "Pethidine", "bbox": [53.0, 853.0, 101.0, 867.0]}], "type": "Section-header", "position": 5}, {"raw_context": [{"text": "Pethidine (also known as meperidine) is a synthetic opioid", "bbox": [53.0, 868.0, 387.0, 883.0]}, {"text": "initially used for the treatment of moderate to severe pain. The", "bbox": [53.0, 883.0, 387.0, 898.0]}, {"text": "side effect profile is similar to that of other opiates but due to", "bbox": [53.0, 898.0, 387.0, 912.0]}, {"text": "interactions with serotonergic drugs, additional problems can", "bbox": [53.0, 913.0, 387.0, 927.0]}, {"text": "occur if used in combination with monoamineoxidase inhibitors", "bbox": [53.0, 928.0, 387.0, 941.0]}, {"text": "or selective serotonin reuptake inhibitors. 10", "bbox": [54.0, 943.0, 275.0, 955.0]}, {"text": "Pethidine has a rapid onset but can last in the serum for", "bbox": [64.0, 956.0, 386.0, 970.0]}, {"text": "120–150 min. Doses should also be reduced in high-risk groups", "bbox": [54.0, 971.0, 386.0, 986.0]}, {"text": "and the elderly. 3", "bbox": [53.0, 986.0, 137.0, 1000.0]}], "type": "Text", "position": 6}, {"raw_context": [{"text": "Sidhu R, et al. Gut 2023;0:1–27. doi:10.1136/gutjnl-2023-330396", "bbox": [54.0, 1009.0, 317.0, 1022.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "Entonox", "bbox": [406.0, 61.0, 449.0, 75.0]}, {"text": "Entonox is a gaseous mixture of 50% nitrous oxide and 50%", "bbox": [406.0, 75.0, 740.0, 90.0]}, {"text": "oxygen that is a potent analgesia that is used widely in health-", "bbox": [406.0, 91.0, 739.0, 105.0]}, {"text": "care, including obstetrics, emergency units and endoscopy. It", "bbox": [406.0, 106.0, 741.0, 120.0]}, {"text": "has a rapid, predictable onset and is eliminated from the body", "bbox": [406.0, 120.0, 740.0, 135.0]}, {"text": "within a very short time. It can be used alone or in addition to", "bbox": [406.0, 135.0, 741.0, 150.0]}, {"text": "other analgesics and sedatives, and in endoscopy is a very useful", "bbox": [406.0, 150.0, 740.0, 165.0]}, {"text": "adjunct for lower intestinal endoscopy. 1", "bbox": [406.0, 165.0, 612.0, 179.0]}, {"text": "Entonox has been shown to be as effective for colonoscopy in", "bbox": [418.0, 180.0, 741.0, 194.0]}, {"text": "comparison with intravenous sedation with midazolam, fentanyl", "bbox": [406.0, 195.0, 740.0, 209.0]}, {"text": "or propofol. 19 Entonox is easy to administer using a mouthpiece-", "bbox": [406.0, 209.0, 738.0, 224.0]}, {"text": "held delivery device, and the onset of action is within 1–2 min.", "bbox": [406.0, 224.0, 739.0, 238.0]}, {"text": "The rapid elimination means that patients can return to normal", "bbox": [407.0, 239.0, 740.0, 253.0]}, {"text": "functioning more quickly than with intravenous agents. 2", "bbox": [406.0, 254.0, 696.0, 267.0]}, {"text": "The recovery profile allows discharge within 30 min of proce-", "bbox": [420.0, 268.0, 739.0, 282.0]}, {"text": "dure completion. There are no requirements regarding driving", "bbox": [406.0, 283.0, 740.0, 297.0]}, {"text": "or supervision overnight. Both diagnostic and therapeutic", "bbox": [406.0, 298.0, 740.0, 312.0]}, {"text": "colonoscopy procedures show high completion rates without", "bbox": [406.0, 313.0, 740.0, 326.0]}, {"text": "complications. 21 There are several important patient groups for", "bbox": [406.0, 325.0, 739.0, 343.0]}, {"text": "whom Entonox should not be used, which include those with", "bbox": [406.0, 342.0, 740.0, 355.0]}, {"text": "recent eye surgery involving gas bubble insertion, head injury,", "bbox": [406.0, 356.0, 739.0, 370.0]}, {"text": "pneumothorax, suspected intestinal obstruction, bullous emphy-", "bbox": [406.0, 371.0, 739.0, 385.0]}, {"text": "sema, middle ear procedures and following a recent dive. There", "bbox": [406.0, 385.0, 740.0, 400.0]}, {"text": "are environmental concerns regarding staff exposure and the", "bbox": [407.0, 401.0, 740.0, 414.0]}, {"text": "broader impact of nitrous oxide as a greenhouse gas. Scavenging", "bbox": [406.0, 416.0, 740.0, 429.0]}, {"text": "systems are, however, available to reduce staff exposure but are", "bbox": [406.0, 430.0, 740.0, 443.0]}, {"text": "currently limited. 19 Installation of catalytic destruction systems", "bbox": [406.0, 444.0, 740.0, 460.0]}, {"text": "to reduce environmental escape could have considerable impact", "bbox": [406.0, 459.0, 741.0, 473.0]}, {"text": "on reducing greenhouse gas emissions. These factors need to be", "bbox": [406.0, 474.0, 740.0, 488.0]}, {"text": "considered in the overall gases strategy of every hospital.", "bbox": [406.0, 488.0, 702.0, 503.0]}], "type": "Text", "position": 9}, {"raw_context": [{"text": "Patient information, choice and expectation", "bbox": [406.0, 529.0, 643.0, 543.0]}, {"text": "3. We recommend that patients receive comprehensive informa-", "bbox": [407.0, 544.0, 739.0, 559.0]}, {"text": "tion about what to expect from the sedation and sensory expe-", "bbox": [406.0, 559.0, 739.0, 573.0]}, {"text": "rience of the procedure", "bbox": [406.0, 574.0, 529.0, 588.0]}], "type": "Section-header", "position": 10}, {"raw_context": [{"text": "Grade of evidence: High. Strength of recommendation: Strong.", "bbox": [418.0, 588.0, 739.0, 602.0]}, {"text": "Level of agreement: 100%", "bbox": [419.0, 605.0, 557.0, 617.0]}, {"text": "Providing patients with adequate information is a basic prin-", "bbox": [418.0, 618.0, 739.0, 632.0]}, {"text": "ciple of consent and this should occur prior to attendance for the", "bbox": [405.0, 632.0, 740.0, 647.0]}, {"text": "procedure. 22 Information may be written, but, where possible, it", "bbox": [406.0, 646.0, 741.0, 661.0]}, {"text": "should be tailored to individual patients' needs or preferences", "bbox": [406.0, 662.0, 740.0, 676.0]}, {"text": "and may include verbal, web-based or video formats. Online", "bbox": [406.0, 677.0, 739.0, 690.0]}, {"text": "supplemental appendix 1 includes a patient leaflet on sedation,", "bbox": [406.0, 691.0, 740.0, 706.0]}, {"text": "adapted from the RCoA.", "bbox": [406.0, 706.0, 536.0, 721.0]}, {"text": "Patient experience may be negatively affected when there is a", "bbox": [418.0, 721.0, 741.0, 736.0]}, {"text": "mismatch between their expectations and the reality of sedation", "bbox": [406.0, 736.0, 741.0, 751.0]}, {"text": "effects or the sensory experience of endoscopic procedures—", "bbox": [406.0, 751.0, 737.0, 765.0]}, {"text": "that is, what the procedure feels like to the patient. 23 24 A signifi-", "bbox": [406.0, 765.0, 739.0, 779.0]}, {"text": "cant proportion of patients choosing sedation are not aware that", "bbox": [406.0, 780.0, 741.0, 794.0]}, {"text": "they will not be 'put to sleep' during the procedure, which may", "bbox": [406.0, 795.0, 739.0, 809.0]}, {"text": "not only affect patient experience and increase anxiety, but raises", "bbox": [406.0, 809.0, 740.0, 824.0]}, {"text": "the question as to whether these patients have received adequate", "bbox": [406.0, 824.0, 739.0, 838.0]}, {"text": "information to allow informed consent. 252", "bbox": [406.0, 841.0, 627.0, 852.0]}, {"text": "Providing information about the expected effects of sedation", "bbox": [418.0, 854.0, 740.0, 867.0]}, {"text": "can reduce patient anxiety. 26 27 Anxiety may also be reduced", "bbox": [406.0, 867.0, 740.0, 881.0]}, {"text": "when information is provided about the sensory experience and", "bbox": [406.0, 881.0, 740.0, 896.0]}, {"text": "comfort of the procedure. 28 29 It is therefore crucial that prepro-", "bbox": [406.0, 896.0, 739.0, 912.0]}, {"text": "cedural information is easily understandable, tailored to the indi-", "bbox": [406.0, 912.0, 739.0, 926.0]}, {"text": "vidual and encompasses the effects of sedation and the sensory", "bbox": [406.0, 928.0, 739.0, 941.0]}, {"text": "experience of the procedure.", "bbox": [406.0, 942.0, 557.0, 955.0]}, {"text": "4. We recommend that patients are involved in shared decision-", "bbox": [418.0, 956.0, 739.0, 970.0]}, {"text": "making, where possible, when choosing which sedative medica-", "bbox": [406.0, 971.0, 739.0, 986.0]}, {"text": "tion (if any) to proceed with during an endoscopic procedure", "bbox": [406.0, 986.0, 725.0, 1000.0]}], "type": "Text", "position": 11}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/消化科/_2023 BSG指南：胃肠内窥镜检查中的镇静.pdf", "page_num": 7}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "缺少换行#0#0#Midazolam is metabolised by这里开始应换行\n缺少换行#2#2#Most of the side effects of这里开始应换行\n缺少换行#7#7# Several published clinical trials这里开始应换行\n缺少换行#13#13# Entonox is a gaseous 这里开始应换行\n缺少换行#14#14#The recovery profile allow这里开始应换行\n缺少换行#15#15#3. We Recommend That Patients这里开始应换行\n缺少换行#17#17# Providing patients with adequate这里开始应换行\n缺少换行#18#18#Providing information about the 这里开始应换行", "type3": "无关文本#0#19#存在多处无关数字\n页脚#12#12#非正文", "type4": null, "type5": null, "type6": null}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:41", "update_time": "2024-05-07 18:28:56"}
{"id": 1082595, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 738, "source_info": {"seq_id": "93ce230b-e49a-4c9c-8d99-424db69c2984", "title": null, "text": "【0】页码:18\n 小街യ\n\n【1】## Authors And Affiliations\n\n【2】\n M. Weber 1 · M. Lam 2 · C. Chiesa 3 · M. Konijnenberg 4 · M. Cremonesi 5 · P. Flamen 6 · S. Gnesin 7 · L. Bodei 8 · T. Kracmerova 9 · M. Luster¹ ⁰ · E. Garin¹¹ · K. Herrmann¹\n\n【3】 1 M. Weber manuel.weber@uk-essen.de\n\n【4】 1\n\n【5】 Department of Nuclear medicine, University clinic Essen, Essen, Germany\n\n【6】 2.\n\n【7】Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, Heidelberglaan 100, 3584, CX, Utrecht, The Netherlands 2000 Nuclear Medicine, Foundation IRCCS National Tumour Institute, Milan, Italy 4 Nuclear Medicine Department, Erasmus MC, Rotterdam, The Netherlands\n\n【8】 5\n\n【9】 Radiation Research Unit, IEO European Institute of Oncology IRCCS, Via Giuseppe Ripamonti, 435, 20141 Milan, MI, Italy\n\n【10】 Figu\n\n【11】 Department of Nuclear Medicine, Institut Jules Bordet-Universite Libre de Bruxelles (ULB), 1000 Brussels, Belgium 27\n\n【12】 7\n\n【13】 Institute of Radiation physics, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland J\n\n【14】 8.\n\n【15】 Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, USA\n\n【16】 9\n\n【17】 Department of Medical Physics, Motol University Hospital, Prague, Czech Republic\n\n【18】 1010\n\n【19】 小狗科 :\n\n【20】 Department of Nuclear medicine, University hospital Marburg, Marburg, Germany\n\n【21】 10.11 Department of Nuclear Medicine, Cancer, Institute Eugène 小狗科研究所 is\n\n【22】 47 fro\n\n【23】 // H\n\n【24】 e\n\n【25】 小狗科研公开课\n\n【26】 ed\n\n【27】 小狗科研公开课\n\n【28】 平研公开课\n\n【29】 e f\n\n【30】 小狗科研公开课", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "小街യ", "bbox": [34.0, 24.0, 111.0, 62.0]}], "type": "Text", "position": 0}, {"raw_context": [{"text": "Authors and Affiliations", "bbox": [66.0, 65.0, 238.0, 93.0]}], "type": "Section-header", "position": 2}, {"raw_context": [{"text": "M. Weber 1 · M. Lam 2 · C. Chiesa 3 · M. Konijnenberg 4 · M. Cremonesi 5 · P. Flamen 6 · S. Gnesin 7 · L. Bodei 8 ·", "bbox": [66.0, 108.0, 648.0, 124.0]}, {"text": "T. Kracmerova 9 · M. Luster¹ ⁰ · E. Garin¹¹ · K. Herrmann¹", "bbox": [66.0, 125.0, 374.0, 141.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "1 M. Weber", "bbox": [64.0, 161.0, 134.0, 174.0]}, {"text": "manuel.weber@uk-essen.de", "bbox": [84.0, 175.0, 214.0, 189.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": "1", "bbox": [66.0, 200.0, 74.0, 210.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "Department of Nuclear medicine, University clinic Essen,", "bbox": [84.0, 202.0, 352.0, 216.0]}, {"text": "Essen, Germany", "bbox": [85.0, 216.0, 162.0, 228.0]}], "type": "Text", "position": 6}, {"raw_context": [{"text": "2.", "bbox": [66.0, 233.0, 74.0, 243.0]}, {"text": "Department of Radiology and Nuclear Medicine, University", "bbox": [84.0, 234.0, 359.0, 248.0]}, {"text": "Medical Center Utrecht, Heidelberglaan 100, 3584, CX,", "bbox": [85.0, 249.0, 342.0, 261.0]}, {"text": "Utrecht, The Netherlands", "bbox": [85.0, 261.0, 203.0, 276.0]}, {"text": "2000", "bbox": [66.0, 279.0, 76.0, 291.0]}, {"text": "Nuclear Medicine, Foundation IRCCS National Tumour", "bbox": [82.0, 281.0, 342.0, 295.0]}, {"text": "Institute, Milan, Italy", "bbox": [85.0, 293.0, 186.0, 310.0]}, {"text": "4", "bbox": [66.0, 313.0, 74.0, 325.0]}, {"text": "Nuclear Medicine Department, Erasmus MC, Rotterdam,", "bbox": [84.0, 314.0, 346.0, 329.0]}, {"text": "The Netherlands", "bbox": [85.0, 327.0, 163.0, 341.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "5", "bbox": [66.0, 347.0, 74.0, 356.0]}], "type": "Text", "position": 8}, {"raw_context": [{"text": "Radiation Research Unit, IEO European Institute", "bbox": [84.0, 348.0, 310.0, 363.0]}, {"text": "of Oncology IRCCS, Via Giuseppe Ripamonti, 435,", "bbox": [84.0, 363.0, 324.0, 375.0]}, {"text": "20141 Milan, MI, Italy", "bbox": [86.0, 377.0, 191.0, 389.0]}], "type": "Text", "position": 9}, {"raw_context": [{"text": "Figu", "bbox": [378.0, 144.0, 425.0, 174.0]}], "type": "Text", "position": 10}, {"raw_context": [{"text": "Department of Nuclear Medicine, Institut Jules", "bbox": [424.0, 161.0, 641.0, 174.0]}, {"text": "Bordet-Universite Libre de Bruxelles (ULB), 1000 Brussels,", "bbox": [424.0, 175.0, 702.0, 188.0]}, {"text": "Belgium 27", "bbox": [425.0, 189.0, 499.0, 202.0]}], "type": "Text", "position": 11}, {"raw_context": [{"text": "7", "bbox": [406.0, 206.0, 414.0, 218.0]}], "type": "Text", "position": 12}, {"raw_context": [{"text": "Institute of Radiation physics, Lausanne University Hospital,", "bbox": [424.0, 207.0, 703.0, 222.0]}, {"text": "University of Lausanne, Lausanne, Switzerland J", "bbox": [425.0, 223.0, 644.0, 234.0]}], "type": "Text", "position": 13}, {"raw_context": [{"text": "8.", "bbox": [406.0, 240.0, 414.0, 251.0]}], "type": "Text", "position": 14}, {"raw_context": [{"text": "Molecular Imaging and Therapy Service, Department", "bbox": [424.0, 242.0, 672.0, 255.0]}, {"text": "of Radiology, Memorial Sloan Kettering Cancer Center,", "bbox": [425.0, 256.0, 684.0, 269.0]}, {"text": "New York, USA", "bbox": [424.0, 268.0, 502.0, 282.0]}], "type": "Text", "position": 15}, {"raw_context": [{"text": "9", "bbox": [406.0, 286.0, 414.0, 298.0]}], "type": "Text", "position": 16}, {"raw_context": [{"text": "Department of Medical Physics, Motol University Hospital,", "bbox": [424.0, 288.0, 699.0, 301.0]}, {"text": "Prague, Czech Republic", "bbox": [424.0, 302.0, 537.0, 315.0]}], "type": "Text", "position": 17}, {"raw_context": [{"text": "1010", "bbox": [406.0, 320.0, 418.0, 329.0]}], "type": "Text", "position": 18}, {"raw_context": [{"text": "小狗科 :", "bbox": [701.0, 247.0, 783.0, 299.0]}], "type": "Text", "position": 19}, {"raw_context": [{"text": "Department of Nuclear medicine, University hospital", "bbox": [424.0, 321.0, 669.0, 335.0]}, {"text": "Marburg, Marburg, Germany", "bbox": [425.0, 336.0, 559.0, 349.0]}], "type": "Text", "position": 20}, {"raw_context": [{"text": "10.11", "bbox": [406.0, 354.0, 418.0, 364.0]}, {"text": "Department of Nuclear Medicine, Cancer, Institute Eugène", "bbox": [424.0, 355.0, 695.0, 368.0]}, {"text": "小狗科研究所 is", "bbox": [397.0, 369.0, 567.0, 451.0]}], "type": "Text", "position": 21}, {"raw_context": [{"text": "47 fro", "bbox": [11.0, 463.0, 89.0, 518.0]}], "type": "Text", "position": 22}, {"raw_context": [{"text": "// H", "bbox": [734.0, 487.0, 782.0, 522.0]}], "type": "Text", "position": 23}, {"raw_context": [{"text": "e", "bbox": [185.0, 532.0, 238.0, 571.0]}], "type": "Text", "position": 24}, {"raw_context": [{"text": "小狗科研公开课", "bbox": [236.0, 534.0, 413.0, 631.0]}], "type": "Text", "position": 25}, {"raw_context": [{"text": "ed", "bbox": [510.0, 643.0, 576.0, 683.0]}], "type": "Text", "position": 26}, {"raw_context": [{"text": "小狗科研公开课", "bbox": [575.0, 649.0, 755.0, 742.0]}], "type": "Text", "position": 27}, {"raw_context": [{"text": "平研公开课", "bbox": [11.0, 705.0, 133.0, 782.0]}], "type": "Text", "position": 28}, {"raw_context": [{"text": "e f", "bbox": [224.0, 793.0, 281.0, 831.0]}], "type": "Text", "position": 29}, {"raw_context": [{"text": "小狗科研公开课", "bbox": [278.0, 797.0, 456.0, 890.0]}], "type": "Text", "position": 30}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2022】全科室最全临床指南+专家共识（最全版）/2022全科室临床指南/肿瘤科/EANM：动脉内放射性化合物治疗肝癌和转移性肝癌指南（2022）(1).pdf", "page_num": 18}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "多余换行#4#5#1.Department of Nuclear medicine....是一句话\n多余换行#6#7#2.Department of Radiology and Nuclear....是一句话\n缺少换行#7#7#Nuclear Medicine, Foundation另起一行\n4 Nuclear Medicine Department,另起一行\n序号格式不一致#7#7#Nuclear Medicine, Foundation前面缺少3.序号\n多余换行#8#9#5.Radiation Research Unit, ....是一句话\n序号格式不一致#11#11#Department of Nuclear Medicine前面缺少6.序号\n多余换行#12#13#7.Institute of Radiation physics ....是一句话\n多余换行#14#15#8. Molecular Imaging and ....是一句话\n多余换行#16#17#9.Department of Medical Physics,....是一句话\n多余换行#18#20#10.Department of Nuclear....是一句话\n", "type3": "无关文本#0#0#小街യ\n无关文本#3#3#1 \n无关文本#7#7#2000 \n无关文本#10#10# Figu\n无关文本#19#19#小狗科 :\n无关文本#21#21# 10.\n小狗科研究所 is\n无关文本#22#30#无关文本本和上文无连接", "type4": "语意重复#18#18#10", "type5": null, "type6": null}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:41", "update_time": "2024-05-07 22:11:23"}
{"id": 1082594, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 738, "source_info": {"seq_id": "ab2b9369-f952-4e0d-83f1-b1e9fdaf0b0d", "title": null, "text": "【0】页码:7\n 3\n\n【1】 6\n\n【2】 ,\n\n【3】 [26]\n\n【4】 KOA\n\n【5】 (2018) 10[1] .\n\n【6】,2018,38(12):705-715.\n\n【7】The Joint Surgery Branch of the Chinese Orthopaedic Association.Guidelines for the diagnosis and treatment of osteoarthritis(2018 edition)[J] . Chin J Orthop,2018,38(12):705-715.\n\n【8】Prieto-Alhambra D,Judge A,Javaid MK,et  al. Incidence and risk factors for clinically diagnosed knee hip and hand osteoarthritis ; influences of age , gender and osteoarthritis affecting other joints[J]. Ann Rheum Dis , 2014 , 73(9) : 1659-1664.\n\n【9】 Meta [J] .\n\n【10】,2018 ,22(4) :650-656.\n\n【11】Tie XJ,Zheng RG,Zhao M,et al.Prevalence of knee osteoarthritis in the middle-aged and elderly in China a Metaanalysis[J]. Chin J Tissue Eng Res, 2018, 22(4):650-656.\n\n【12】 [4]\n\n【13】## 1291-1314.\n\n【14】\n## (2021) 100.\n\n【15】\n## ,2021,41(18):\n\n【16】\n The Joint Surgery Branch of the Chinese Orthopaedic Association;The Subspecialty Group of Osteoarthritis , Chinese Association of Orthopaedic Surgeons ; The National Clinical Research Center for Geriatric Disorders,et  al.Chinese guideline for diagnosis and treatment of osteoarthritis(2021 edition)[J]. Chin J\n\n【17】 [28]\n\n【18】## [5]\n\n【19】\n## Orthop , 2021 , 41 ( 18 ) ; 1291-1341.\n\n【20】\n 57 (12) ; 1413-1420.\n\n【21】 [1].\n\n【22】 100, 2022,\n\n【23】 Chen HB,Hu YH,Wang YL,et al. Effect of exercise intervention based on transtheoretical model on elderly patients with knee osteoarthritis in communities [J] . Chin J Nurs , 2022 , 57 (12) : 1413-1420.\n\n【24】 [6]\n\n【25】 [7]\n\n【26】 [8]\n\n【27】 ,\n\n【28】 López-Gómez JJ,Izaola-Jóuregui O,Torres-Torres B,et al. Influence of a meal-replacement diet on quality of life in women with obesity and knee osteoarthritis before orthopedic surgery [J] . Nutr Hosp , 2018 , 35 (1) , 71-77.\n\n【29】Bannuru RR,Osani MC,Vaysbrot EE,et al. OARSI guidelines for the non-surgical management of knee,hip,and polyarticular osteoarthritis[J]. Osteoarthritis Cartilage , 2019 , 27 ( 11 ) , 1578-1589.\n\n【30】[1].\n\n【31】.\n\n【32】,2017,32(21):1991-1994.\n\n【33】 Zhu Z, Hu Y, Xing WJ, et  al. Composition of different types of evidence-based problems[J]. J Nurses Train,2017,32(21):1991- 1994.\n\n【34】 [9]\n\n【35】 [10]\n\n【36】 Brouwers MC,Kho ME,Browman GP,et al. AGREE 111 ,  111 vancing guideline development,reporting and evaluation in health care[J]. CMAJ, 2010, 182(18) : E839-E842.\n\n【37】 [11]\n\n【38】 Murad MH , Asi N , Alsawas M , et  al. New evidence pyramid[J].\n\n【39】Evid Based Med ,  2016 ,  21 ( 4 )  :  125-127 .\n\n【40】## [1]\n\n【41】\n [2]\n\n【42】 [3]\n\n【43】 ,2016 ,31(11):44-48.\n\n【44】Qiao J. Theoretical basis and modeling application of intraclass correlation coefficient[J]. Stat Inf Forum,2016,31(11): 44 -48.\n\n【45】[M]. 2 .\n\n【46】, .\n\n【47】:\n\n【48】 [12]\n\n【49】 2018.\n\n【50】 [13]\n\n【51】## 1129.\n\n【52】\n## [1].\n\n【53】\n ,2020 , 100 ( 15 ) : 1123-\n\n【54】 Writing group of clinical practice guidelines for exercise treatment for knee osteoarthritis. Clinical practice guidelines for exercise therapy for knee osteoarthritis [ J ]. Natl Med J Chin , 2020 , 100 ( 15 ) , 1123-1129.\n\n【55】 [14]\n\n【56】 [15]\n\n【57】 Geenen R,Overman CL,Christensen R,et al.EULAR recommendations for the health professional's approach to pain management in inflammatory arthritis and osteoarthritis[J]. Ann Rheum Dis ,  2018 ,  77 ( 6 )  :  797 -807 .\n\n【58】Fillingham Y, Brophy RH.American academy of orthopaedic surgeons management of osteoarthritis of the knee(non-arthroplasty ) evidence-based clinical practice guideline [EB/OL].\n\n【59】( 2021 - 08 - 31 ) [ 2022 - 05 - 30 ]. https://www.aaos.org/oak3cpgPub-\n\n【60】 Hu Y , Hao YF. Evidence-based nursing[M]. 2nd ed.Beijing : People's Medical Publishing House,2018.\n\n【61】 [1].\n\n【62】 14.4", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "3", "bbox": [198.0, 48.0, 211.0, 60.0]}], "type": "Text", "position": 1}, {"raw_context": [{"text": "6", "bbox": [276.0, 49.0, 287.0, 60.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": ",", "bbox": [184.0, 100.0, 192.0, 109.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": "[26]", "bbox": [260.0, 91.0, 277.0, 104.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "KOA", "bbox": [83.0, 521.0, 115.0, 536.0]}], "type": "Text", "position": 9}, {"raw_context": [{"text": "(2018)", "bbox": [112.0, 597.0, 142.0, 609.0]}, {"text": "10[1] .", "bbox": [160.0, 598.0, 186.0, 610.0]}, {"text": ",2018,38(12):705-715.", "bbox": [248.0, 597.0, 357.0, 609.0]}, {"text": "The Joint Surgery Branch of the Chinese Orthopaedic Associ-", "bbox": [112.0, 615.0, 393.0, 627.0]}, {"text": "ation.Guidelines for the diagnosis and treatment of osteoarthri-", "bbox": [112.0, 634.0, 393.0, 646.0]}, {"text": "tis(2018 edition)[J] . Chin J Orthop,2018,38(12):705-715.", "bbox": [111.0, 650.0, 381.0, 664.0]}, {"text": "Prieto-Alhambra D,Judge A,Javaid MK,et  al. Incidence and", "bbox": [111.0, 669.0, 396.0, 682.0]}, {"text": "risk factors for clinically diagnosed knee hip and hand os-", "bbox": [112.0, 688.0, 395.0, 700.0]}, {"text": "teoarthritis ; influences of age , gender and osteoarthritis affecting", "bbox": [111.0, 705.0, 395.0, 719.0]}, {"text": "other joints[J]. Ann Rheum Dis , 2014 , 73(9) : 1659-1664.", "bbox": [111.0, 723.0, 367.0, 736.0]}], "type": "Text", "position": 11}, {"raw_context": [{"text": "Meta", "bbox": [133.0, 759.0, 160.0, 772.0]}, {"text": "[J] .", "bbox": [174.0, 759.0, 195.0, 773.0]}, {"text": ",2018 ,22(4) :650-656.", "bbox": [280.0, 759.0, 383.0, 772.0]}, {"text": "Tie XJ,Zheng RG,Zhao M,et al.Prevalence of knee oste-", "bbox": [112.0, 777.0, 394.0, 790.0]}, {"text": "oarthritis in the middle-aged and elderly in China a Meta-", "bbox": [111.0, 795.0, 395.0, 809.0]}, {"text": "analysis[J]. Chin J Tissue Eng Res, 2018, 22(4):650-656.", "bbox": [111.0, 812.0, 372.0, 827.0]}], "type": "Text", "position": 12}, {"raw_context": [{"text": "[4]", "bbox": [83.0, 830.0, 104.0, 846.0]}], "type": "Text", "position": 13}, {"raw_context": [{"text": "1291-1314.", "bbox": [111.0, 884.0, 163.0, 900.0]}], "type": "Section-header", "position": 14}, {"raw_context": [{"text": "(2021)", "bbox": [193.0, 867.0, 223.0, 882.0]}, {"text": "100.", "bbox": [240.0, 868.0, 264.0, 882.0]}], "type": "Section-header", "position": 15}, {"raw_context": [{"text": ",2021,41(18):", "bbox": [326.0, 867.0, 395.0, 882.0]}], "type": "Section-header", "position": 16}, {"raw_context": [{"text": "The Joint Surgery Branch of the Chinese Orthopaedic Associ-", "bbox": [111.0, 903.0, 393.0, 918.0]}, {"text": "ation;The Subspecialty Group of Osteoarthritis , Chinese Associ-", "bbox": [112.0, 923.0, 395.0, 936.0]}, {"text": "ation of Orthopaedic Surgeons ; The National Clinical Research", "bbox": [111.0, 939.0, 395.0, 954.0]}, {"text": "Center for Geriatric Disorders,et  al.Chinese guideline for di-", "bbox": [111.0, 959.0, 395.0, 971.0]}, {"text": "agnosis and treatment of osteoarthritis(2021 edition)[J]. Chin J", "bbox": [111.0, 976.0, 396.0, 990.0]}], "type": "Text", "position": 17}, {"raw_context": [{"text": "[28]", "bbox": [329.0, 156.0, 348.0, 167.0]}], "type": "Text", "position": 18}, {"raw_context": [{"text": "[5]", "bbox": [418.0, 110.0, 438.0, 123.0]}], "type": "Section-header", "position": 19}, {"raw_context": [{"text": "Orthop , 2021 , 41 ( 18 ) ; 1291-1341.", "bbox": [445.0, 91.0, 594.0, 106.0]}], "type": "Section-header", "position": 20}, {"raw_context": [{"text": "57 (12) ; 1413-1420.", "bbox": [445.0, 147.0, 533.0, 160.0]}], "type": "Text", "position": 21}, {"raw_context": [{"text": "[1].", "bbox": [602.0, 131.0, 625.0, 143.0]}], "type": "Text", "position": 22}, {"raw_context": [{"text": "100, 2022,", "bbox": [692.0, 130.0, 726.0, 142.0]}], "type": "Text", "position": 23}, {"raw_context": [{"text": "Chen HB,Hu YH,Wang YL,et al. Effect of exercise interven-", "bbox": [445.0, 165.0, 729.0, 179.0]}, {"text": "tion based on transtheoretical model on elderly patients with", "bbox": [445.0, 184.0, 731.0, 197.0]}, {"text": "knee osteoarthritis in communities [J] . Chin J Nurs , 2022 , 57", "bbox": [445.0, 202.0, 731.0, 217.0]}, {"text": "(12) : 1413-1420.", "bbox": [445.0, 220.0, 524.0, 235.0]}], "type": "Text", "position": 24}, {"raw_context": [{"text": "[6]", "bbox": [419.0, 241.0, 441.0, 253.0]}], "type": "Text", "position": 25}, {"raw_context": [{"text": "[7]", "bbox": [419.0, 314.0, 440.0, 326.0]}], "type": "Text", "position": 26}, {"raw_context": [{"text": "[8]", "bbox": [419.0, 370.0, 439.0, 382.0]}], "type": "Text", "position": 27}, {"raw_context": [{"text": ",", "bbox": [387.0, 464.0, 395.0, 473.0]}], "type": "Text", "position": 28}, {"raw_context": [{"text": "López-Gómez JJ,Izaola-Jóuregui O,Torres-Torres B,et al. Influ-", "bbox": [443.0, 239.0, 729.0, 254.0]}, {"text": "ence of a meal-replacement diet on quality of life in women", "bbox": [445.0, 258.0, 731.0, 272.0]}, {"text": "with obesity and knee osteoarthritis before orthopedic surgery", "bbox": [445.0, 276.0, 730.0, 290.0]}, {"text": "[J] . Nutr Hosp , 2018 , 35 (1) , 71-77.", "bbox": [445.0, 294.0, 605.0, 308.0]}, {"text": "Bannuru RR,Osani MC,Vaysbrot EE,et al. OARSI guidelines", "bbox": [444.0, 312.0, 731.0, 326.0]}, {"text": "for the non-surgical management of knee,hip,and polyarticular", "bbox": [445.0, 332.0, 731.0, 345.0]}, {"text": "osteoarthritis[J]. Osteoarthritis Cartilage , 2019 , 27 ( 11 ) , 1578-1589.", "bbox": [445.0, 349.0, 726.0, 363.0]}, {"text": "[1].", "bbox": [676.0, 371.0, 694.0, 382.0]}, {"text": ".", "bbox": [469.0, 372.0, 477.0, 381.0]}, {"text": ",2017,32(21):1991-1994.", "bbox": [480.0, 387.0, 597.0, 401.0]}], "type": "Text", "position": 29}, {"raw_context": [{"text": "Zhu Z, Hu Y, Xing WJ, et  al. Composition of different types of", "bbox": [445.0, 406.0, 731.0, 419.0]}, {"text": "evidence-based problems[J]. J Nurses Train,2017,32(21):1991-", "bbox": [445.0, 424.0, 731.0, 438.0]}, {"text": "1994.", "bbox": [447.0, 443.0, 473.0, 455.0]}], "type": "Text", "position": 30}, {"raw_context": [{"text": "[9]", "bbox": [419.0, 462.0, 441.0, 475.0]}], "type": "Text", "position": 31}, {"raw_context": [{"text": "[10]", "bbox": [419.0, 500.0, 445.0, 512.0]}], "type": "Text", "position": 32}, {"raw_context": [{"text": "Brouwers MC,Kho ME,Browman GP,et al. AGREE", "bbox": [449.0, 497.0, 693.0, 512.0]}, {"text": "111 ,  111", "bbox": [708.0, 500.0, 729.0, 511.0]}, {"text": "vancing guideline development,reporting and evaluation in", "bbox": [450.0, 516.0, 731.0, 530.0]}, {"text": "health care[J]. CMAJ, 2010, 182(18) : E839-E842.", "bbox": [450.0, 534.0, 672.0, 548.0]}], "type": "Text", "position": 33}, {"raw_context": [{"text": "[11]", "bbox": [418.0, 553.0, 443.0, 566.0]}], "type": "Text", "position": 34}, {"raw_context": [{"text": "Murad MH , Asi N , Alsawas M , et  al. New evidence pyramid[J].", "bbox": [443.0, 460.0, 731.0, 475.0]}, {"text": "Evid Based Med ,  2016 ,  21 ( 4 )  :  125-127 .", "bbox": [445.0, 478.0, 624.0, 493.0]}], "type": "Text", "position": 35}, {"raw_context": [{"text": "[1]", "bbox": [83.0, 579.0, 104.0, 593.0]}], "type": "Section-header", "position": 36}, {"raw_context": [{"text": "[2]", "bbox": [85.0, 671.0, 105.0, 682.0]}], "type": "Text", "position": 37}, {"raw_context": [{"text": "[3]", "bbox": [84.0, 741.0, 104.0, 755.0]}], "type": "Text", "position": 38}, {"raw_context": [{"text": ",2016 ,31(11):44-48.", "bbox": [474.0, 571.0, 570.0, 584.0]}, {"text": "Qiao J. Theoretical basis and modeling application of intra-", "bbox": [450.0, 590.0, 729.0, 604.0]}, {"text": "class correlation coefficient[J]. Stat Inf Forum,2016,31(11):", "bbox": [450.0, 608.0, 731.0, 623.0]}, {"text": "44 -48.", "bbox": [451.0, 628.0, 482.0, 640.0]}, {"text": "[M]. 2 .", "bbox": [572.0, 646.0, 621.0, 659.0]}, {"text": ",", "bbox": [473.0, 649.0, 481.0, 658.0]}, {"text": ".", "bbox": [511.0, 649.0, 518.0, 658.0]}, {"text": ":", "bbox": [639.0, 649.0, 647.0, 659.0]}], "type": "Text", "position": 39}, {"raw_context": [{"text": "[12]", "bbox": [418.0, 645.0, 443.0, 659.0]}], "type": "Text", "position": 40}, {"raw_context": [{"text": "2018.", "bbox": [451.0, 665.0, 478.0, 677.0]}], "type": "Text", "position": 41}, {"raw_context": [{"text": "[13]", "bbox": [418.0, 718.0, 443.0, 733.0]}], "type": "Text", "position": 42}, {"raw_context": [{"text": "1129.", "bbox": [451.0, 757.0, 478.0, 769.0]}], "type": "Section-header", "position": 43}, {"raw_context": [{"text": "[1].", "bbox": [538.0, 738.0, 560.0, 752.0]}], "type": "Section-header", "position": 44}, {"raw_context": [{"text": ",2020 , 100 ( 15 ) : 1123-", "bbox": [627.0, 737.0, 731.0, 751.0]}], "type": "Text", "position": 45}, {"raw_context": [{"text": "Writing group of clinical practice guidelines for exercise", "bbox": [451.0, 775.0, 731.0, 788.0]}, {"text": "treatment for knee osteoarthritis. Clinical practice guidelines", "bbox": [451.0, 795.0, 731.0, 807.0]}, {"text": "for exercise therapy for knee osteoarthritis [ J ]. Natl Med J", "bbox": [450.0, 812.0, 731.0, 825.0]}, {"text": "Chin , 2020 , 100 ( 15 ) , 1123-1129.", "bbox": [450.0, 830.0, 596.0, 843.0]}], "type": "Text", "position": 46}, {"raw_context": [{"text": "[14]", "bbox": [419.0, 849.0, 445.0, 861.0]}], "type": "Text", "position": 47}, {"raw_context": [{"text": "[15]", "bbox": [419.0, 924.0, 445.0, 936.0]}], "type": "Text", "position": 48}, {"raw_context": [{"text": "Geenen R,Overman CL,Christensen R,et al.EULAR recom-", "bbox": [449.0, 848.0, 731.0, 861.0]}, {"text": "mendations for the health professional's approach to pain", "bbox": [450.0, 866.0, 731.0, 881.0]}, {"text": "management in inflammatory arthritis and osteoarthritis[J]. Ann", "bbox": [450.0, 884.0, 731.0, 899.0]}, {"text": "Rheum Dis ,  2018 ,  77 ( 6 )  :  797 -807 .", "bbox": [450.0, 903.0, 604.0, 918.0]}, {"text": "Fillingham Y, Brophy RH.American academy of orthopaedic", "bbox": [449.0, 922.0, 731.0, 936.0]}, {"text": "surgeons management of osteoarthritis of the knee(non-arthro-", "bbox": [451.0, 940.0, 730.0, 954.0]}, {"text": "plasty ) evidence-based clinical practice guideline [EB/OL].", "bbox": [450.0, 959.0, 731.0, 972.0]}, {"text": "( 2021 - 08 - 31 ) [ 2022 - 05 - 30 ]. https://www.aaos.org/oak3cpgPub-", "bbox": [450.0, 977.0, 729.0, 991.0]}], "type": "Text", "position": 49}, {"raw_context": [{"text": "Hu Y , Hao YF. Evidence-based nursing[M]. 2nd ed.Beijing :", "bbox": [450.0, 681.0, 730.0, 696.0]}, {"text": "People's Medical Publishing House,2018.", "bbox": [450.0, 700.0, 636.0, 714.0]}], "type": "Text", "position": 51}, {"raw_context": [{"text": "[1].", "bbox": [652.0, 555.0, 673.0, 566.0]}], "type": "Text", "position": 52}, {"raw_context": [{"text": "14.4", "bbox": [83.0, 332.0, 95.0, 344.0]}], "type": "Text", "position": 53}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/骨科/解读/膝骨关节炎患者自我管理的最佳证据总结.pdf", "page_num": 7}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "格式杂乱#0#62#全篇格式杂乱", "type3": null, "type4": null, "type5": null, "type6": null}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:41", "update_time": "2024-05-07 22:53:54"}
{"id": 1082593, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 738, "source_info": {"seq_id": "802af3fc-7423-4b0c-b4e9-237fa34bbed7", "title": null, "text": "【0】页码:2\n 4 1 1\n\n【1】 小狗科碑名字词\n\n【2】\n (1) 每月1次乳腺自我检查。    / (2) 每1~3年1次临床检查。\n\n【3】 \n\n【4】 t el\n\n【5】 小狗科$$2.40 ~ 69 $\n\n【6】 ( T i \n\n【7】 /\n\n【8】 (2) 每1 ~ 2年1次乳腺X 线检查 ڊ/或乳腺超声 。 (3) 对条件不具备的地区或致密型乳腺（腺体为C型或 . \n\n【9】(4) 每月 1 次 乳腺自我检查 .\n\n【10】(5) 每年1次临床检查.\n\n【11】Ag 3.70岁以日的科研究者症状或可疑体征时进行影像常势 jy\n\n【12】 查 ).\n\n【13】 (2) 每月1次乳腺自我检查。\n\n【14】 (3) 每年1次临床检查.\n \n\n【15】 /( ニ ) 高危人群乳腺癌筛查策略。\n建议对乳腺癌高危人群提前进行筛查 ( 小于40岁 ), 筛 查间期推荐每年1次, 1 筛查手段整体原则应联合乳腺X线检查 和乳腺超声，必要时还可以应用MRI等影像学手段。 乳腺癌高危人群符合以下3个条件，即： 1.5有阴显的乳 Many common to the common of the common to the common the common to the common the common to the common to the common to the common to the common the common to the common to \n\n【16】 4H 2019\n\n【17】 小狗科研公开课", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "4 1 1", "bbox": [600.0, 31.0, 741.0, 104.0]}], "type": "Text", "position": 0}, {"raw_context": [{"text": "小狗科碑名字词\n", "bbox": [21.0, 36.0, 558.0, 249.0]}], "type": "Text", "position": 1}, {"raw_context": [{"text": "(1) 每月1次乳腺自我检查。    /", "bbox": [166.0, 224.0, 471.0, 253.0]}, {"text": "(2) 每1~3年1次临床检查。", "bbox": [166.0, 263.0, 432.0, 291.0]}], "type": "Text", "position": 2}, {"raw_context": [{"text": "", "bbox": [541.0, 224.0, 794.0, 333.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": "t el", "bbox": [0.0, 271.0, 50.0, 312.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "小狗科$$2.40 ~ 69 $", "bbox": [53.0, 283.0, 264.0, 350.0]}], "type": "Text", "position": 6}, {"raw_context": [{"text": "( T i ", "bbox": [165.0, 334.0, 502.0, 379.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "/", "bbox": [76.0, 457.0, 95.0, 486.0]}], "type": "Text", "position": 8}, {"raw_context": [{"text": "(2) 每1 ~ 2年1次乳腺X 线检查 ڊ/或乳腺超声 。", "bbox": [167.0, 382.0, 600.0, 412.0]}, {"text": "(3) 对条件不具备的地区或致密型乳腺（腺体为C型或", "bbox": [166.0, 414.0, 673.0, 458.0]}, {"text": ". ", "bbox": [90.0, 431.0, 393.0, 517.0]}, {"text": "(4) 每月 1 次 乳腺自我检查 .", "bbox": [166.0, 497.0, 429.0, 536.0]}, {"text": "(5) 每年1次临床检查.", "bbox": [166.0, 543.0, 387.0, 572.0]}, {"text": "Ag", "bbox": [479.0, 551.0, 535.0, 613.0]}, {"text": "3.70岁以日的科研究者症状或可疑体征时进行影像常势 jy", "bbox": [158.0, 579.0, 716.0, 669.0]}], "type": "Text", "position": 9}, {"raw_context": [{"text": "查 ).", "bbox": [117.0, 666.0, 161.0, 692.0]}], "type": "Text", "position": 11}, {"raw_context": [{"text": "(2) 每月1次乳腺自我检查。", "bbox": [168.0, 701.0, 430.0, 735.0]}], "type": "Text", "position": 12}, {"raw_context": [{"text": "(3) 每年1次临床检查.", "bbox": [166.0, 743.0, 388.0, 772.0]}], "type": "Text", "position": 13}, {"raw_context": [{"text": "", "bbox": [526.0, 677.0, 765.0, 775.0]}], "type": "Formula", "position": 15}, {"raw_context": [{"text": "/( ニ ) 高危人群乳腺癌筛查策略。\n建议对乳腺癌高危人群提前进行筛查 ( 小于40岁 ), 筛", "bbox": [132.0, 783.0, 675.0, 854.0]}, {"text": "查间期推荐每年1次, 1 筛查手段整体原则应联合乳腺X线检查", "bbox": [118.0, 855.0, 675.0, 899.0]}, {"text": "和乳腺超声，必要时还可以应用MRI等影像学手段。", "bbox": [117.0, 899.0, 595.0, 933.0]}, {"text": "乳腺癌高危人群符合以下3个条件，即： 1.5有阴显的乳", "bbox": [161.0, 941.0, 676.0, 973.0]}, {"text": "Many common to the common of the common to the common the common to the common the common to the common to the common to the common to the common the common to the common to ", "bbox": [118.0, 953.0, 794.0, 1044.0]}], "type": "Text", "position": 16}, {"raw_context": [{"text": "4H 2019", "bbox": [0.0, 755.0, 127.0, 814.0]}], "type": "Text", "position": 18}, {"raw_context": [{"text": "小狗科研公开课", "bbox": [100.0, 1024.0, 278.0, 1114.0]}], "type": "Text", "position": 19}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2022】全科室最全临床指南+专家共识（最全版）/2022全科室临床指南/肿瘤科/乳腺癌诊疗指南（2022年版）.pdf", "page_num": 2}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": null, "type3": "无关文本#0#0#4 1 1\n无关文本#1#1#小狗科碑名字词\n无关文本#4#4# t el\n无关文本#5#5# 小狗科$$和 $\n无关文本#6#6#  ( T i\n无关文本#7#7#  /\n无关文本#8#8# ڊ\n无关文本#11#11#Ag 和日的科研究者症状或可疑体征时进行影像常势 jy\n无关文本#15#15#5和 Many common to the common of the common to the common the common to the common the common to the common to the common to the common to the common the common to the common to\n无关文本#16#16#4H 2019\n无关文本#17#17#小狗科研公开课", "type4": "语义不完整#2#2#(1) 每月1次乳腺自我检查。前面缺少（一）一般风险人群妇女乳腺癌筛查策略。\n1.20～39岁\n语义不完整#8#8#（腺体为C型或 .后面缺少：D型），可首选乳腺超声检查。\n语义不完整#12#12#缺少（1）机会性筛查（有症状或可疑体征时进行影像学检\n语义不完整#15#15#1.有明显的乳，后面缺少：腺癌遗传倾向者（见下段基因检测标准）；2.既往有乳腺导", "type5": null, "type6": null}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:41", "update_time": "2024-05-07 22:29:45"}
{"id": 1082592, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 738, "source_info": {"seq_id": "f085ca63-f7e2-434c-928e-2e0f062f392e", "title": null, "text": "【0】页码:36\n\n【1】## Appendix 3: Learning Outcomes From Esge/Esgena Curriculum\n\n【2】\n The content of this appendix contains the learning outcomes from the European curriculum for sedation training in GI endoscopy²³ ⁴ (copied verbatim from the European curriculum for sedation training in gastrointestinal endoscopy: position statement of the European Society of Gastrointestinal Endoscopy (ESGE) and European Society of Gastroenterology and Endoscopy Nurses and Associates (ESGENA)).\n\n【3】 Learning outcomes–competencies to be achieved 234 Pre-procedure assessment\n\n【4】 After completing the course the participant should be able to: Demonstrate an understanding of the principles of informed consent according to national law .\n\n【5】 Be able to inform patients appropriately about the sedation, possible side effects and alternatives as well as post interventional behaviour, and give the patients the opportunity to ask questions\n\n【6】 .\n\n【7】 .\n\n【8】 Assess the patient's health status and risks; clearly document the patient's pre-procedure assessment by using standardized health care questionnaires, scores and nurse-based or physician-based documentation, including:\n\n【9】 o current health status (e.g., ASA classification, pregnancy)\n\n【10】 risk factors for sleep apnoea o\n\n【11】 abnormal head and neck features o\n\n【12】 chronic obstructive pulmonary disease of stages 3–4\n\n【13】 cardiac failure of stages 3–4 o\n\n【14】 history of bronchial aspiration\n\n【15】 trouble with previous anaesthesia or sedation\n\n【16】 Gut\n\n【17】 o\n\n【18】 o\n\n【19】 o", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "Appendix 3: Learning outcomes from ESGE/ESGENA curriculum", "bbox": [119.0, 244.0, 467.0, 259.0]}], "type": "Section-header", "position": 2}, {"raw_context": [{"text": "The content of this appendix contains the learning outcomes from the European curriculum for sedation", "bbox": [119.0, 277.0, 684.0, 292.0]}, {"text": "training in GI endoscopy²³ ⁴ (copied verbatim from the European curriculum for sedation training in", "bbox": [119.0, 300.0, 653.0, 315.0]}, {"text": "gastrointestinal endoscopy: position statement of the European Society of Gastrointestinal Endoscopy", "bbox": [119.0, 324.0, 671.0, 340.0]}, {"text": "(ESGE) and European Society of Gastroenterology and Endoscopy Nurses and Associates (ESGENA)).", "bbox": [119.0, 349.0, 657.0, 364.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "Learning outcomes–competencies to be achieved 234", "bbox": [119.0, 398.0, 402.0, 412.0]}, {"text": "Pre-procedure assessment", "bbox": [119.0, 422.0, 265.0, 437.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": "After completing the course the participant should be able to:", "bbox": [119.0, 446.0, 455.0, 461.0]}, {"text": "Demonstrate an understanding of the principles of informed consent according to national law", "bbox": [161.0, 469.0, 675.0, 484.0]}, {"text": ".", "bbox": [141.0, 472.0, 155.0, 484.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "Be able to inform patients appropriately about the sedation, possible side effects and", "bbox": [161.0, 506.0, 625.0, 520.0]}, {"text": "alternatives as well as post interventional behaviour, and give the patients the opportunity to", "bbox": [161.0, 531.0, 669.0, 546.0]}, {"text": "ask questions", "bbox": [161.0, 555.0, 240.0, 570.0]}], "type": "Text", "position": 6}, {"raw_context": [{"text": ".", "bbox": [140.0, 508.0, 153.0, 520.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": ".", "bbox": [141.0, 593.0, 153.0, 605.0]}], "type": "Text", "position": 8}, {"raw_context": [{"text": "Assess the patient's health status and risks; clearly document the patient's pre-procedure", "bbox": [161.0, 591.0, 646.0, 606.0]}, {"text": "assessment by using standardized health care questionnaires, scores and nurse-based or", "bbox": [162.0, 614.0, 641.0, 631.0]}, {"text": "physician-based documentation, including:", "bbox": [161.0, 639.0, 397.0, 653.0]}], "type": "Text", "position": 9}, {"raw_context": [{"text": "o current health status (e.g., ASA classification, pregnancy)", "bbox": [182.0, 676.0, 516.0, 689.0]}], "type": "Text", "position": 10}, {"raw_context": [{"text": "risk factors for sleep apnoea", "bbox": [203.0, 711.0, 363.0, 726.0]}, {"text": "o", "bbox": [183.0, 715.0, 204.0, 726.0]}], "type": "Text", "position": 11}, {"raw_context": [{"text": "abnormal head and neck features", "bbox": [204.0, 748.0, 391.0, 762.0]}, {"text": "o", "bbox": [184.0, 751.0, 201.0, 762.0]}], "type": "Text", "position": 12}, {"raw_context": [{"text": "chronic obstructive pulmonary disease of stages 3–4", "bbox": [204.0, 784.0, 495.0, 799.0]}], "type": "Text", "position": 13}, {"raw_context": [{"text": "cardiac failure of stages 3–4", "bbox": [203.0, 820.0, 363.0, 835.0]}, {"text": "o", "bbox": [183.0, 823.0, 206.0, 835.0]}], "type": "Text", "position": 14}, {"raw_context": [{"text": "history of bronchial aspiration", "bbox": [204.0, 856.0, 371.0, 871.0]}], "type": "Text", "position": 15}, {"raw_context": [{"text": "trouble with previous anaesthesia or sedation", "bbox": [204.0, 894.0, 457.0, 907.0]}], "type": "Text", "position": 16}, {"raw_context": [{"text": "Gut", "bbox": [775.0, 14.0, 796.0, 27.0]}], "type": "Text", "position": 17}, {"raw_context": [{"text": "o", "bbox": [183.0, 787.0, 198.0, 799.0]}], "type": "Text", "position": 19}, {"raw_context": [{"text": "o", "bbox": [183.0, 858.0, 199.0, 871.0]}], "type": "Text", "position": 20}, {"raw_context": [{"text": "o", "bbox": [184.0, 896.0, 197.0, 907.0]}], "type": "Text", "position": 21}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/消化科/_2023 BSG指南：胃肠内窥镜检查中的镇静.pdf", "page_num": 36}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "缺少换行#3#3#Pre-procedure assessment另起一行\n缺少换行#4#4#Demonstrate an understanding 另起一行\n序号格式不一致#9#19#o应该在句首", "type3": "无关文本#0#19#GI endoscopy²³ ⁴ 部分段落末尾，以及句末的数字问题无关噪声应用全文\n无关文本#16#16#Gut", "type4": null, "type5": null, "type6": null}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:41", "update_time": "2024-05-08 00:07:57"}
{"id": 1082591, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 738, "source_info": {"seq_id": "98f24361-cd80-41b9-b9f3-4b4a8f69ab44", "title": null, "text": "【0】页码:2\n\n【1】## Purpose\n\n【2】\n The purpose of this guideline is to assist nuclear medicine physicians in:\n\n【3】 1. 1.\n\n【4】 2.\n\n【5】 1.1.13.\n Patient selection: evaluating patients who might betcandidates for treatment using intra-arterial radioactive microspheres for primary or secondary liver cancer.\n\n【6】Treatment procedures: providing information on treatment methods.\n Clinical follow-up: understanding and evaluating efficacy and toxicity.\n\n【7】 These guidelines represent an update of the 2011 EANM guidelines on the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. Information still considered to be up to date was retained. Due to the limited use of 131 I-lipiodol in Europe, no further update will be provided on this specific treatment modality. In the light of recent trials, the main focus of this update will instead be placed on dosimetric concepts in different treatment scenarios and the use of the newly introduced 166 Ho-microspheres.\n\n【8】 90 Y also emits positrons in 32 decays over a million. Despite this scarcity. 90Y PET imaging is routinely performed posttreatment. The maximum and mean beta particle energies are 2.28 and 0.94 MeV, respectively. The maximum and mean ranges in soft tissue are 11 and 4 mm, respectively [ 1 ].\n\n【9】.166Ho is a beta-emitting radionuclide with a physical halflife of 1.1 days (26.8 h). The beta particle energies include 1.85 MeV (50.0%) and 1.77 MeV (48.7%). The maximum and mean ranges in soft tissues are 8.7 and 2.2 mm, respectively. 166 Ho emits gamma photons at 80 keV (yield 6.7%) and 1.4 MeV (yield 0.9%).\n\n【10】99m Tc is a metastable nuclear isomer of 99 Tc with a halflife of 6.0 h. It emits gamma photons with a photon energy of 140 keV.\n\n【11】## Radioactive Microspheres (Table 1 )\n\n【12】\n limited use of 131 I-lipiodol in Europe, no further update will Resin microspheres are made of an acrylic polymer with a median size of 30 µ m in diameter, in which 90 Y is bound be provided on this specific treatment modality. In the light of recent trials, the main focus of this update will instead be to the carboxylic group on the surface of the polymer after production of microspheres.\n\n【13】placed on dosimetric concepts in different treatment scenar- Glass microspheres are made of glass with a median size ios and the use of the newly introduced 166 Ho-microspheres.\n\n【14】of 25 µm, in which 89 Y, embedded in the glass matrix, is activated to 90 Y in a nuclear reactor.\n\n【15】Background information and definitions 166 Ho-microspheres are made of poly-L-lactic acid with a median size of 30 µ m, in which 165 Ho, embedded in the matrix, is activated to 166 Ho by neutron activation in a Definitions nuclear reactor.\n\n【16】99m Tc-macroaggregated albumin (MAA) particles mostly Radionuclides have a size between 10 and 100 µ m; 99 m Tc-human serum 90 Y is a beta-emitting radionuclide with a physical half-life albumin (HSA) particles mostly have a size between 15 and ,50 µ m. Both are synthesized by labeling of MAA and HSA- of 2.67 days (64.2 h), without emission of gamma photons kits with 99n1 Tc, respectively.\n\n【17】but with the emission of secondary \"bremsstrahlung\" photons.\n\n【18】 Table 1 Radioembolization microspheres characteristics\n\n【19】\n Characteristics SIR-Spheres® TheraSphere® Material Resin Glass 30 (20–60) 25 (20–30) Particle size and range ( μ m) Embolic effect Moderate Mild Activity per sphere (Bq) 40–70 4534 * Specific gravity (g/dL) 1.6 3.7 Activity available (GBq) 3–20^ \" 3* Handling for dispensing Required Not required Multiple dosing from one vial Possible Not possible Modified from Salem and Thurston [ 2 ], Smits [ 3 ] and Westcott [ 4 ]\n\n【20】\n QuiremSpheres® Poly-L-lactic acid.\n\n【21】30 (15–60).\n\n【22】Moderate 200–400 1.4 Not required Not possible\n\n【23】\n *Direct measure by Pasciak et al. [3] at calibration, the IFU provide a value of 2500 Bq. The value is variable according to physical decay depending on the day and time of treatment #Prescribed activity should be withdrawn on site. The FLEXdose option allows injection 3 days before calibration, when the vial activity is 10 GBq ^Vials of 3–20 GBq in steps of 0.5 GBq, calibrated at noon on the Sunday before treatment with a shelf-life of 12 days \"Patient-specific activity is calibrated at the day and time of treatment", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "Purpose", "bbox": [66.0, 77.0, 127.0, 91.0]}], "type": "Section-header", "position": 0}, {"raw_context": [{"text": "The purpose of this guideline is to assist nuclear medicine", "bbox": [66.0, 109.0, 387.0, 124.0]}, {"text": "physicians in:", "bbox": [66.0, 127.0, 143.0, 142.0]}], "type": "Text", "position": 1}, {"raw_context": [{"text": "1. 1.", "bbox": [67.0, 161.0, 80.0, 174.0]}], "type": "Text", "position": 2}, {"raw_context": [{"text": "2.", "bbox": [66.0, 209.0, 78.0, 224.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "1.1.13.", "bbox": [67.0, 245.0, 79.0, 257.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": "Patient selection: evaluating patients who might bet-", "bbox": [86.0, 160.0, 386.0, 174.0]}, {"text": "candidates for treatment using intra-arterial radioactive", "bbox": [87.0, 176.0, 387.0, 191.0]}, {"text": "microspheres for primary or secondary liver cancer.", "bbox": [88.0, 193.0, 369.0, 208.0]}, {"text": "Treatment procedures: providing information on treat-", "bbox": [86.0, 211.0, 385.0, 225.0]}, {"text": "ment methods.", "bbox": [88.0, 226.0, 168.0, 241.0]}], "type": "List-item", "position": 5}, {"raw_context": [{"text": "Clinical follow-up: understanding and evaluating effi-", "bbox": [85.0, 243.0, 385.0, 258.0]}, {"text": "cacy and toxicity.", "bbox": [86.0, 260.0, 183.0, 274.0]}], "type": "List-item", "position": 6}, {"raw_context": [{"text": "These guidelines represent an update of the 2011 EANM", "bbox": [80.0, 293.0, 387.0, 308.0]}, {"text": "guidelines on the treatment of liver cancer and liver metas-", "bbox": [66.0, 310.0, 384.0, 325.0]}, {"text": "tases with intra-arterial radioactive compounds. Information", "bbox": [66.0, 327.0, 387.0, 341.0]}, {"text": "still considered to be up to date was retained. Due to the", "bbox": [66.0, 344.0, 387.0, 357.0]}, {"text": "limited use of 131 I-lipiodol in Europe, no further update will", "bbox": [66.0, 358.0, 386.0, 377.0]}, {"text": "be provided on this specific treatment modality. In the light", "bbox": [65.0, 377.0, 387.0, 392.0]}, {"text": "of recent trials, the main focus of this update will instead be", "bbox": [65.0, 393.0, 387.0, 408.0]}, {"text": "placed on dosimetric concepts in different treatment scenar-", "bbox": [66.0, 410.0, 385.0, 424.0]}, {"text": "ios and the use of the newly introduced 166 Ho-microspheres.", "bbox": [66.0, 426.0, 385.0, 441.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "90 Y also emits positrons in 32 decays over a million. Despite", "bbox": [405.0, 72.0, 727.0, 91.0]}, {"text": "this scarcity. 90Y PET imaging is routinely performed post-", "bbox": [405.0, 89.0, 725.0, 108.0]}, {"text": "treatment. The maximum and mean beta particle energies are", "bbox": [405.0, 109.0, 727.0, 123.0]}, {"text": "2.28 and 0.94 MeV, respectively. The maximum and mean", "bbox": [406.0, 124.0, 727.0, 139.0]}, {"text": "ranges in soft tissue are 11 and 4 mm, respectively [ 1 ].", "bbox": [405.0, 141.0, 690.0, 156.0]}, {"text": ".166Ho is a beta-emitting radionuclide with a physical half-", "bbox": [420.0, 158.0, 726.0, 173.0]}, {"text": "life of 1.1 days (26.8 h). The beta particle energies include", "bbox": [405.0, 174.0, 727.0, 189.0]}, {"text": "1.85 MeV (50.0%) and 1.77 MeV (48.7%). The maximum", "bbox": [406.0, 191.0, 727.0, 206.0]}, {"text": "and mean ranges in soft tissues are 8.7 and 2.2 mm, respec-", "bbox": [405.0, 208.0, 725.0, 223.0]}, {"text": "tively. 166 Ho emits gamma photons at 80 keV (yield 6.7%)", "bbox": [405.0, 225.0, 728.0, 240.0]}, {"text": "and 1.4 MeV (yield 0.9%).", "bbox": [405.0, 241.0, 551.0, 255.0]}, {"text": "99m Tc is a metastable nuclear isomer of 99 Tc with a half-", "bbox": [422.0, 256.0, 729.0, 272.0]}, {"text": "life of 6.0 h. It emits gamma photons with a photon energy", "bbox": [405.0, 275.0, 726.0, 290.0]}, {"text": "of 140 keV.", "bbox": [405.0, 291.0, 471.0, 306.0]}], "type": "Text", "position": 9}, {"raw_context": [{"text": "Radioactive microspheres (Table 1 )", "bbox": [405.0, 324.0, 596.0, 340.0]}], "type": "Section-header", "position": 10}, {"raw_context": [{"text": "limited use of 131 I-lipiodol in Europe, no further update will", "bbox": [66.0, 358.0, 386.0, 377.0]}, {"text": "Resin microspheres are made of an acrylic polymer with a", "bbox": [405.0, 358.0, 728.0, 373.0]}, {"text": "median size of 30 µ m in diameter, in which 90 Y is bound", "bbox": [405.0, 374.0, 727.0, 389.0]}, {"text": "be provided on this specific treatment modality. In the light", "bbox": [65.0, 377.0, 387.0, 392.0]}, {"text": "of recent trials, the main focus of this update will instead be", "bbox": [65.0, 393.0, 387.0, 408.0]}, {"text": "to the carboxylic group on the surface of the polymer after", "bbox": [404.0, 392.0, 727.0, 407.0]}, {"text": "production of microspheres.", "bbox": [405.0, 408.0, 559.0, 423.0]}, {"text": "placed on dosimetric concepts in different treatment scenar-", "bbox": [66.0, 410.0, 385.0, 424.0]}, {"text": "Glass microspheres are made of glass with a median size", "bbox": [420.0, 425.0, 727.0, 439.0]}, {"text": "ios and the use of the newly introduced 166 Ho-microspheres.", "bbox": [66.0, 426.0, 385.0, 441.0]}, {"text": "of 25 µm, in which 89 Y, embedded in the glass matrix, is", "bbox": [405.0, 441.0, 727.0, 457.0]}, {"text": "activated to 90 Y in a nuclear reactor.", "bbox": [405.0, 457.0, 602.0, 474.0]}, {"text": "Background information and definitions", "bbox": [64.0, 474.0, 355.0, 492.0]}, {"text": "166 Ho-microspheres are made of poly-L-lactic acid with", "bbox": [422.0, 475.0, 727.0, 489.0]}, {"text": "a median size of 30 µ m, in which 165 Ho, embedded in the", "bbox": [405.0, 490.0, 727.0, 506.0]}, {"text": "matrix, is activated to 166 Ho by neutron activation in a", "bbox": [405.0, 507.0, 727.0, 523.0]}, {"text": "Definitions", "bbox": [65.0, 509.0, 136.0, 526.0]}, {"text": "nuclear reactor.", "bbox": [405.0, 524.0, 491.0, 539.0]}, {"text": "99m Tc-macroaggregated albumin (MAA) particles mostly", "bbox": [422.0, 541.0, 727.0, 557.0]}, {"text": "Radionuclides", "bbox": [65.0, 544.0, 144.0, 558.0]}, {"text": "have a size between 10 and 100 µ m; 99 m Tc-human serum", "bbox": [405.0, 558.0, 727.0, 573.0]}, {"text": "90 Y is a beta-emitting radionuclide with a physical half-life", "bbox": [66.0, 574.0, 387.0, 593.0]}, {"text": "albumin (HSA) particles mostly have a size between 15 and", "bbox": [405.0, 574.0, 727.0, 589.0]}, {"text": ",50 µ m. Both are synthesized by labeling of MAA and HSA-", "bbox": [406.0, 591.0, 726.0, 606.0]}, {"text": "of 2.67 days (64.2 h), without emission of gamma photons", "bbox": [64.0, 594.0, 387.0, 608.0]}, {"text": "kits with 99n1 Tc, respectively.", "bbox": [404.0, 607.0, 562.0, 625.0]}, {"text": "but with the emission of secondary \"bremsstrahlung\" photons.", "bbox": [65.0, 611.0, 387.0, 625.0]}], "type": "Text", "position": 11}, {"raw_context": [{"text": "Table 1 Radioembolization", "bbox": [66.0, 662.0, 195.0, 676.0]}, {"text": "microspheres characteristics", "bbox": [67.0, 677.0, 197.0, 690.0]}], "type": "Table", "position": 12}, {"raw_context": [{"text": "Characteristics", "bbox": [236.0, 668.0, 306.0, 681.0]}, {"text": "SIR-Spheres®", "bbox": [418.0, 668.0, 485.0, 681.0]}, {"text": "TheraSphere®", "bbox": [530.0, 669.0, 604.0, 681.0]}, {"text": "Material", "bbox": [236.0, 693.0, 278.0, 705.0]}, {"text": "Resin", "bbox": [418.0, 694.0, 447.0, 705.0]}, {"text": "Glass", "bbox": [529.0, 694.0, 557.0, 705.0]}, {"text": "30 (20–60)", "bbox": [418.0, 709.0, 471.0, 722.0]}, {"text": "25 (20–30)", "bbox": [529.0, 709.0, 583.0, 723.0]}, {"text": "Particle size and range ( μ m)", "bbox": [236.0, 710.0, 366.0, 723.0]}, {"text": "Embolic effect", "bbox": [236.0, 726.0, 306.0, 740.0]}, {"text": "Moderate", "bbox": [418.0, 726.0, 464.0, 740.0]}, {"text": "Mild", "bbox": [529.0, 727.0, 556.0, 739.0]}, {"text": "Activity per sphere (Bq)", "bbox": [236.0, 742.0, 350.0, 756.0]}, {"text": "40–70", "bbox": [418.0, 742.0, 450.0, 756.0]}, {"text": "4534 *", "bbox": [529.0, 742.0, 563.0, 756.0]}, {"text": "Specific gravity (g/dL)", "bbox": [236.0, 759.0, 343.0, 773.0]}, {"text": "1.6", "bbox": [419.0, 761.0, 436.0, 772.0]}, {"text": "3.7", "bbox": [529.0, 761.0, 546.0, 772.0]}, {"text": "Activity available (GBq)", "bbox": [236.0, 776.0, 350.0, 790.0]}, {"text": "3–20^ \"", "bbox": [530.0, 776.0, 567.0, 789.0]}, {"text": "3*", "bbox": [419.0, 777.0, 430.0, 788.0]}, {"text": "Handling for dispensing", "bbox": [235.0, 792.0, 348.0, 807.0]}, {"text": "Required", "bbox": [418.0, 793.0, 462.0, 807.0]}, {"text": "Not required", "bbox": [529.0, 793.0, 590.0, 807.0]}, {"text": "Multiple dosing from one vial", "bbox": [235.0, 809.0, 375.0, 824.0]}, {"text": "Possible", "bbox": [418.0, 809.0, 458.0, 823.0]}, {"text": "Not possible", "bbox": [529.0, 810.0, 588.0, 823.0]}, {"text": "Modified from Salem and Thurston [ 2 ], Smits [ 3 ] and Westcott [ 4 ]", "bbox": [236.0, 833.0, 541.0, 849.0]}], "type": "Table", "position": 14}, {"raw_context": [{"text": "QuiremSpheres®", "bbox": [641.0, 668.0, 723.0, 681.0]}, {"text": "Poly-L-lactic acid.", "bbox": [641.0, 693.0, 725.0, 705.0]}, {"text": "30 (15–60).", "bbox": [642.0, 709.0, 698.0, 723.0]}, {"text": "Moderate", "bbox": [641.0, 726.0, 689.0, 739.0]}, {"text": "200–400", "bbox": [642.0, 742.0, 685.0, 756.0]}, {"text": "1.4", "bbox": [643.0, 761.0, 659.0, 772.0]}, {"text": "Not required", "bbox": [641.0, 793.0, 702.0, 807.0]}, {"text": "Not possible", "bbox": [641.0, 810.0, 701.0, 823.0]}], "type": "Table", "position": 15}, {"raw_context": [{"text": "*Direct measure by Pasciak et al. [3] at calibration, the IFU provide a value of 2500 Bq. The value is vari-", "bbox": [236.0, 851.0, 726.0, 865.0]}, {"text": "able according to physical decay depending on the day and time of treatment", "bbox": [236.0, 865.0, 586.0, 880.0]}, {"text": "#Prescribed activity should be withdrawn on site. The FLEXdose option allows injection 3 days before cali-", "bbox": [236.0, 880.0, 725.0, 896.0]}, {"text": "bration, when the vial activity is 10 GBq", "bbox": [236.0, 896.0, 424.0, 909.0]}, {"text": "^Vials of 3–20 GBq in steps of 0.5 GBq, calibrated at noon on the Sunday before treatment with a shelf-life", "bbox": [236.0, 911.0, 726.0, 928.0]}, {"text": "of 12 days", "bbox": [236.0, 926.0, 286.0, 940.0]}, {"text": "\"Patient-specific activity is calibrated at the day and time of treatment", "bbox": [236.0, 943.0, 556.0, 956.0]}], "type": "Text", "position": 16}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2022】全科室最全临床指南+专家共识（最全版）/2022全科室临床指南/肿瘤科/EANM：动脉内放射性化合物治疗肝癌和转移性肝癌指南（2022）(1).pdf", "page_num": 2}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "多余换行#3#6#3段序号联接5段Patient selection: evaluating ... 4段序号联接6段reatment procedures:... treatment methods.5段序号联接6段Clinical follow-up: ...efficacy and toxicity.", "type3": "无关文本#3#3#1. 1. 多了一个1. \n无关文本#5#5# 1.1.1\n无关文本#7#23#... limited use of 131 I-lipiodol ...像这样在.号或，号的开头或结尾和句子中间出现的数字都是无关引用[ 1 ]类引用过多\n", "type4": "栏目混乱#8#23#文章内容和表格穿插，没有顺序", "type5": null, "type6": null}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:41", "update_time": "2024-05-07 23:10:18"}
{"id": 1082590, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 738, "source_info": {"seq_id": "aa1d1a72-f262-4d8f-80e7-6ff73cf0f3e6", "title": null, "text": "【0】页码:2\n\n【1】## ² Bj Haem\n\n【2】\n • As low adherence with the chosen anticoagulant strategy is a common cause of morbidity and mortality in individuals with MHV in pregnancy, this should be a key component of pre-pregnancy counselling along with measures to facilitate adherence during pregnancy and postpartum (Grade 1D).\n\n【3】• Vitamin K antagonists (VKAs) are superior to low molecular weight heparin (LMWH) for preventing MVT in pregnancy and are recommended as optimal therapy for improving maternal outcomes (Grade 1C).\n\n【4】There is insufficient evidence to recommend that lower doses of warfarin (e.g. less than 5 mg) are safe in terms of adverse foetal outcome (Grade 2C).\n\n【5】• When using VKAs in pregnancy, non-pregnancy international normalised ratio (INR) targets can be used. The INR should be checked at least weekly if unstable and if stable, at least fortnightly with the option of self-testing when appropriate (Grade 2C).\n\n【6】When switching from VKA to LMWH in pregnancy, we recommend that the starting dose of LMWH should be higher than the standard therapeutic dose as there appears to be a high rate of MVT in the first trimester during transition (e.g. total 2.5 mg/kg/day for enoxaparin, 250 IU/ kg/day for dalteparin and 250 IU/kg/day for tinzaparin in divided doses) (Grade 2C).\n\n【7】• Regular monitoring of LMWH using an anti-Xa assay is recommended; there is currently insufficient evidence to recommend the routine use of specific trough levels or the use of LMWH injections more frequently than twice daily. A peak anti-Xa target of 1.0–1.4IU/mL taken 3–4h following a BD (twice daily) LMWH dose is suggested as a reasonable compromise (Grade 2C).\n\n【8】• We recommend the addition of low-dose aspirin (LDA) 75 mg to anticoagulation with LMWH in individuals with MHV during pregnancy in the absence of a contraindication (Grade 2C).\n\n【9】• An increase in the dose of aspirin to 150 mg at 12-week gestation can be considered if indicated for prevention of pre-eclampsia (Grade 2D).\n\n【10】• Surgical management is recommended for miscarriage and termination of pregnancy in the first trimester (Grade 2C).\n\n【11】• MVT requires MDT management in a specialist centre with the use of thrombolysis where appropriate (Grade 2C).\n\n【12】• There is insufficient evidence to recommend a specific mode of delivery in pregnant individuals with MHV.\n\n【13】An individualised plan for timing and mode of delivery should be agreed in advance, with input from the MDT, and involvement and agreement of the pregnant individual (Grade 2C).\n\n【14】• Documented delivery and emergency plans should be easily available, and a copy carried by the pregnant individual, in case of unplanned attendances at any maternity unit (Grade 2C).\n\n【15】• VKAs should be switched to heparin at least 2 weeks prior to anticipated delivery and by 36 weeks at the latest (Grade 1C).\n\n【16】 esquid more bobe oliviocl ,0 , 111 , 125 96\n\n【17】 Visagat) and to S last army ' adv of ($50540/81) no candid online colier ' , vandid yies strill M &A assot ' - is us yd 18581.46/1111 01/84/1850.colier candianities/:s\n\n【18】 • If presenting in labour and on VKA within 2weeks of scheduled delivery, a caesarean birth should be considered to decrease foetal bleeding complications from labour (Grade 2C).\n\n【19】Therapeutic LMWH should be paused for at least 24 h prior to surgical delivery to facilitate neuraxial analgesia/ anaesthesia (Grade 1B).\n\n【20】Prolonged pre-delivery interruption of anticoagulation should be avoided, for example, during induction of labour. Consideration should be given to the use of a prophylactic or an intermediate dose LMWH or intravenous (IV) unfractionated heparin (UFH) during induction of labour after MDT discussion with haematology and anaesthetic teams (Grade 2C).\n\n【21】• In view of the high risk of PPH, consider stopping aspirin for at least 3 days prior to scheduled delivery (Grade (2C).\n\n【22】• Prophylactic or intermediate doses of LMWH for the first 24–48h postpartum are recommended. Restarting a VKA around days 5–7 should be considered to balance the risk of thrombosis against major bleeding (Grade 2C).\n\n【23】• If using UFH postpartum, a gradual increase in anticoagulant intensity is recommended for the first few days (Grade 2C).\n\n【24】• Postpartum, individuals should not leave hospital without a plan for contraception. Insertion of an intrauterine contraceptive device or implant may be suitable for some individuals at the time of delivery or on the postnatal ward (Grade 2C).\n\n【25】• Postnatal follow-up is recommended where the pregnancy can be reviewed and plans made for any future pregnancies (Grade 2C).\n\n【26】## Pre-Pregnancy\n\n【27】\n Prior to cardiac surgery, all individuals of childbearing age should be counselled about the impact of valve replacement choice on future pregnancy risk by an appropriately trained Cardiologist, recognising individual clinical situations.\n\n【28】Discussion should include the risks of re-do surgery and involve a cardiac surgeon. Guidelines recommend consideration of bio-prosthetic valves or, where appropriate, a Ross operation in individuals of childbearing age in view of the high risk of complications during pregnancy in individuals with MHV. 1,2 Pre-pregnancy counselling is recommended for every individual of reproductive age with a MHV and should be performed by a MDT, including an obstetrician/obstetric physician, cardiologist and a haematologist as appropriate, referred to in this guideline as the specialist team. Suggested roles and responsibilities of the specialist team are given in Appendix S2 . Counselling should include the following:\n\n【29】 • Evaluation of current condition: assessment of symptoms, echocardiographic evaluation of ventricular function and prosthetic valve function.\n\n【30】 search abdesibility oth ed bomarieg an earths: AO could be soluted caradici stillsO coli/W  no (strotibuto-bus-amon meo coli/w candi", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "² BJ Haem", "bbox": [57.0, 22.0, 161.0, 63.0]}], "type": "Section-header", "position": 0}, {"raw_context": [{"text": "• As low adherence with the chosen anticoagulant strategy", "bbox": [58.0, 65.0, 387.0, 79.0]}, {"text": "is a common cause of morbidity and mortality in individ-", "bbox": [70.0, 80.0, 385.0, 95.0]}, {"text": "uals with MHV in pregnancy, this should be a key com-", "bbox": [71.0, 97.0, 385.0, 112.0]}, {"text": "ponent of pre-pregnancy counselling along with measures", "bbox": [71.0, 113.0, 387.0, 127.0]}, {"text": "to facilitate adherence during pregnancy and postpartum", "bbox": [70.0, 129.0, 387.0, 144.0]}, {"text": "(Grade 1D).", "bbox": [71.0, 145.0, 138.0, 160.0]}, {"text": "• Vitamin K antagonists (VKAs) are superior to low mo-", "bbox": [59.0, 160.0, 385.0, 176.0]}, {"text": "lecular weight heparin (LMWH) for preventing MVT in", "bbox": [70.0, 177.0, 387.0, 192.0]}, {"text": "pregnancy and are recommended as optimal therapy for", "bbox": [71.0, 194.0, 387.0, 208.0]}, {"text": "improving maternal outcomes (Grade 1C).", "bbox": [70.0, 210.0, 302.0, 225.0]}, {"text": "There is insufficient evidence to recommend that lower", "bbox": [68.0, 226.0, 387.0, 240.0]}, {"text": "doses of warfarin (e.g. less than 5 mg) are safe in terms of", "bbox": [71.0, 242.0, 387.0, 256.0]}, {"text": "adverse foetal outcome (Grade 2C).", "bbox": [71.0, 258.0, 265.0, 273.0]}, {"text": "• When using VKAs in pregnancy, non-pregnancy inter-", "bbox": [59.0, 274.0, 385.0, 288.0]}, {"text": "national normalised ratio (INR) targets can be used. The", "bbox": [71.0, 289.0, 387.0, 305.0]}, {"text": "INR should be checked at least weekly if unstable and if", "bbox": [71.0, 306.0, 387.0, 321.0]}, {"text": "stable, at least fortnightly with the option of self-testing", "bbox": [70.0, 322.0, 387.0, 336.0]}, {"text": "when appropriate (Grade 2C).", "bbox": [71.0, 338.0, 235.0, 353.0]}, {"text": "When switching from VKA to LMWH in pregnancy, we", "bbox": [69.0, 354.0, 387.0, 368.0]}, {"text": "recommend that the starting dose of LMWH should be", "bbox": [71.0, 370.0, 387.0, 385.0]}, {"text": "higher than the standard therapeutic dose as there ap-", "bbox": [70.0, 386.0, 385.0, 401.0]}, {"text": "pears to be a high rate of MVT in the first trimester during", "bbox": [70.0, 402.0, 387.0, 416.0]}, {"text": "transition (e.g. total 2.5 mg/kg/day for enoxaparin, 250 IU/", "bbox": [70.0, 418.0, 386.0, 433.0]}, {"text": "kg/day for dalteparin and 250 IU/kg/day for tinzaparin in", "bbox": [70.0, 434.0, 387.0, 448.0]}, {"text": "divided doses) (Grade 2C).", "bbox": [70.0, 450.0, 218.0, 465.0]}, {"text": "• Regular monitoring of LMWH using an anti-Xa assay is", "bbox": [59.0, 466.0, 387.0, 481.0]}, {"text": "recommended; there is currently insufficient evidence to", "bbox": [71.0, 481.0, 387.0, 496.0]}, {"text": "recommend the routine use of specific trough levels or", "bbox": [71.0, 498.0, 387.0, 513.0]}, {"text": "the use of LMWH injections more frequently than twice", "bbox": [70.0, 515.0, 387.0, 528.0]}, {"text": "daily. A peak anti-Xa target of 1.0–1.4IU/mL taken 3–4h", "bbox": [70.0, 530.0, 387.0, 545.0]}, {"text": "following a BD (twice daily) LMWH dose is suggested as a", "bbox": [70.0, 546.0, 387.0, 561.0]}, {"text": "reasonable compromise (Grade 2C).", "bbox": [71.0, 562.0, 267.0, 576.0]}, {"text": "• We recommend the addition of low-dose aspirin (LDA)", "bbox": [59.0, 577.0, 387.0, 593.0]}, {"text": "75 mg to anticoagulation with LMWH in individuals with", "bbox": [71.0, 594.0, 387.0, 608.0]}, {"text": "MHV during pregnancy in the absence of a contraindica-", "bbox": [71.0, 609.0, 385.0, 625.0]}, {"text": "tion (Grade 2C).", "bbox": [71.0, 626.0, 160.0, 641.0]}, {"text": "• An increase in the dose of aspirin to 150 mg at 12-week", "bbox": [58.0, 642.0, 387.0, 656.0]}, {"text": "gestation can be considered if indicated for prevention of", "bbox": [71.0, 658.0, 387.0, 673.0]}, {"text": "pre-eclampsia (Grade 2D).", "bbox": [71.0, 675.0, 217.0, 689.0]}, {"text": "• Surgical management is recommended for miscarriage", "bbox": [58.0, 689.0, 387.0, 705.0]}, {"text": "and termination of pregnancy in the first trimester (Grade", "bbox": [71.0, 706.0, 387.0, 721.0]}, {"text": "2C).", "bbox": [72.0, 722.0, 97.0, 736.0]}, {"text": "• MVT requires MDT management in a specialist centre", "bbox": [58.0, 737.0, 387.0, 753.0]}, {"text": "with the use of thrombolysis where appropriate (Grade 2C).", "bbox": [70.0, 754.0, 387.0, 769.0]}, {"text": "• There is insufficient evidence to recommend a specific", "bbox": [58.0, 769.0, 387.0, 785.0]}, {"text": "mode of delivery in pregnant individuals with MHV.", "bbox": [71.0, 786.0, 387.0, 801.0]}, {"text": "An individualised plan for timing and mode of delivery", "bbox": [72.0, 802.0, 387.0, 816.0]}, {"text": "should be agreed in advance, with input from the MDT,", "bbox": [71.0, 818.0, 387.0, 833.0]}, {"text": "and involvement and agreement of the pregnant individ-", "bbox": [71.0, 835.0, 385.0, 849.0]}, {"text": "ual (Grade 2C).", "bbox": [71.0, 849.0, 156.0, 864.0]}, {"text": "• Documented delivery and emergency plans should be", "bbox": [59.0, 866.0, 387.0, 881.0]}, {"text": "easily available, and a copy carried by the pregnant indi-", "bbox": [70.0, 882.0, 385.0, 896.0]}, {"text": "vidual, in case of unplanned attendances at any maternity", "bbox": [70.0, 898.0, 387.0, 913.0]}, {"text": "unit (Grade 2C).", "bbox": [71.0, 915.0, 162.0, 928.0]}, {"text": "• VKAs should be switched to heparin at least 2 weeks prior", "bbox": [58.0, 930.0, 387.0, 944.0]}, {"text": "to anticipated delivery and by 36 weeks at the latest (Grade", "bbox": [71.0, 946.0, 387.0, 961.0]}, {"text": "1C).", "bbox": [72.0, 963.0, 96.0, 977.0]}], "type": "Text", "position": 1}, {"raw_context": [{"text": "esquid more bobe oliviocl ,0 , 111 , 125 96", "bbox": [770.0, 26.0, 780.0, 125.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "Visagat) and to S last army ' adv of ($50540/81) no candid online colier ' , vandid yies strill M &A assot ' - is us yd 18581.46/1111 01/84/1850.colier candianities/:s", "bbox": [768.0, 122.0, 782.0, 588.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": "• If presenting in labour and on VKA within 2weeks of", "bbox": [407.0, 65.0, 735.0, 79.0]}, {"text": "scheduled delivery, a caesarean birth should be considered", "bbox": [419.0, 80.0, 735.0, 95.0]}, {"text": "to decrease foetal bleeding complications from labour", "bbox": [419.0, 97.0, 735.0, 112.0]}, {"text": "(Grade 2C).", "bbox": [418.0, 113.0, 485.0, 127.0]}, {"text": "Therapeutic LMWH should be paused for at least 24 h", "bbox": [418.0, 128.0, 735.0, 144.0]}, {"text": "prior to surgical delivery to facilitate neuraxial analgesia/", "bbox": [419.0, 145.0, 734.0, 160.0]}, {"text": "anaesthesia (Grade 1B).", "bbox": [419.0, 161.0, 549.0, 176.0]}, {"text": "Prolonged pre-delivery interruption of anticoagulation", "bbox": [415.0, 177.0, 735.0, 192.0]}, {"text": "should be avoided, for example, during induction of la-", "bbox": [419.0, 194.0, 734.0, 208.0]}, {"text": "bour. Consideration should be given to the use of a pro-", "bbox": [418.0, 209.0, 734.0, 225.0]}, {"text": "phylactic or an intermediate dose LMWH or intravenous", "bbox": [419.0, 226.0, 735.0, 240.0]}, {"text": "(IV) unfractionated heparin (UFH) during induction of", "bbox": [418.0, 242.0, 735.0, 256.0]}, {"text": "labour after MDT discussion with haematology and an-", "bbox": [418.0, 258.0, 734.0, 273.0]}, {"text": "aesthetic teams (Grade 2C).", "bbox": [419.0, 274.0, 571.0, 288.0]}, {"text": "• In view of the high risk of PPH, consider stopping aspi-", "bbox": [407.0, 289.0, 734.0, 305.0]}, {"text": "rin for at least 3 days prior to scheduled delivery (Grade", "bbox": [419.0, 306.0, 735.0, 321.0]}, {"text": "(2C).", "bbox": [420.0, 324.0, 445.0, 336.0]}, {"text": "• Prophylactic or intermediate doses of LMWH for the first", "bbox": [407.0, 337.0, 735.0, 353.0]}, {"text": "24–48h postpartum are recommended. Restarting a VKA", "bbox": [419.0, 354.0, 735.0, 368.0]}, {"text": "around days 5–7 should be considered to balance the risk", "bbox": [419.0, 370.0, 735.0, 385.0]}, {"text": "of thrombosis against major bleeding (Grade 2C).", "bbox": [419.0, 386.0, 690.0, 401.0]}, {"text": "• If using UFH postpartum, a gradual increase in antico-", "bbox": [406.0, 401.0, 735.0, 416.0]}, {"text": "agulant intensity is recommended for the first few days", "bbox": [419.0, 418.0, 735.0, 433.0]}, {"text": "(Grade 2C).", "bbox": [418.0, 435.0, 486.0, 448.0]}, {"text": "• Postpartum, individuals should not leave hospital without", "bbox": [407.0, 449.0, 735.0, 465.0]}, {"text": "a plan for contraception. Insertion of an intrauterine con-", "bbox": [418.0, 466.0, 734.0, 481.0]}, {"text": "traceptive device or implant may be suitable for some in-", "bbox": [418.0, 482.0, 734.0, 496.0]}, {"text": "dividuals at the time of delivery or on the postnatal ward", "bbox": [418.0, 498.0, 736.0, 513.0]}, {"text": "(Grade 2C).", "bbox": [419.0, 515.0, 485.0, 528.0]}, {"text": "• Postnatal follow-up is recommended where the pregnancy", "bbox": [407.0, 529.0, 734.0, 545.0]}, {"text": "can be reviewed and plans made for any future pregnan-", "bbox": [418.0, 546.0, 733.0, 561.0]}, {"text": "cies (Grade 2C).", "bbox": [419.0, 562.0, 509.0, 576.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "PRE-PREGNANCY", "bbox": [406.0, 608.0, 562.0, 625.0]}], "type": "Section-header", "position": 6}, {"raw_context": [{"text": "Prior to cardiac surgery, all individuals of childbearing age", "bbox": [406.0, 642.0, 735.0, 656.0]}, {"text": "should be counselled about the impact of valve replacement", "bbox": [406.0, 657.0, 735.0, 673.0]}, {"text": "choice on future pregnancy risk by an appropriately trained", "bbox": [406.0, 675.0, 735.0, 688.0]}, {"text": "Cardiologist, recognising individual clinical situations.", "bbox": [406.0, 689.0, 735.0, 705.0]}, {"text": "Discussion should include the risks of re-do surgery and", "bbox": [406.0, 706.0, 735.0, 721.0]}, {"text": "involve a cardiac surgeon. Guidelines recommend consid-", "bbox": [406.0, 722.0, 734.0, 736.0]}, {"text": "eration of bio-prosthetic valves or, where appropriate, a Ross", "bbox": [406.0, 738.0, 735.0, 753.0]}, {"text": "operation in individuals of childbearing age in view of the", "bbox": [406.0, 755.0, 735.0, 769.0]}, {"text": "high risk of complications during pregnancy in individuals", "bbox": [406.0, 769.0, 735.0, 785.0]}, {"text": "with MHV. 1,2", "bbox": [406.0, 786.0, 482.0, 800.0]}, {"text": "Pre-pregnancy counselling is recommended for every", "bbox": [422.0, 802.0, 735.0, 816.0]}, {"text": "individual of reproductive age with a MHV and should be", "bbox": [406.0, 817.0, 735.0, 833.0]}, {"text": "performed by a MDT, including an obstetrician/obstetric", "bbox": [406.0, 834.0, 735.0, 849.0]}, {"text": "physician, cardiologist and a haematologist as appropriate,", "bbox": [406.0, 849.0, 735.0, 866.0]}, {"text": "referred to in this guideline as the specialist team. Suggested", "bbox": [406.0, 866.0, 735.0, 881.0]}, {"text": "roles and responsibilities of the specialist team are given in", "bbox": [406.0, 882.0, 735.0, 896.0]}, {"text": "Appendix S2 . Counselling should include the following:", "bbox": [407.0, 897.0, 713.0, 913.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "• Evaluation of current condition: assessment of symptoms,", "bbox": [406.0, 930.0, 735.0, 944.0]}, {"text": "echocardiographic evaluation of ventricular function and", "bbox": [418.0, 946.0, 735.0, 961.0]}, {"text": "prosthetic valve function.", "bbox": [419.0, 962.0, 561.0, 977.0]}], "type": "Text", "position": 8}, {"raw_context": [{"text": "search abdesibility oth ed bomarieg an earths: AO could be soluted caradici stillsO coli/W  no (strotibuto-bus-amon meo coli/w candi", "bbox": [768.0, 609.0, 781.0, 962.0]}], "type": "Text", "position": 9}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/心血管/指南/2023 BSH 指南：机械心脏瓣膜妊娠个体抗凝管理(1).pdf", "page_num": 2}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "序号格式不一致#0#25#序号时有时无\n缺少换行#28#28#Pre-pregnancy counselling is recommended这里开始应换行", "type3": "页眉#1#1#非正文\n无关文本#28#28# 1,2", "type4": null, "type5": null, "type6": "信息有用性#16#17#无用内容\n信息有用性#30#30#无用内容"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:41", "update_time": "2024-05-07 18:51:06"}
{"id": 1082589, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 738, "source_info": {"seq_id": "5d01fa42-c6b3-41dd-a8a6-1eb638421a9d", "title": null, "text": "【0】页码:42\n\n【1】## Appendix 4: Learning Outcomes From The Aomrc Safe Sedation Practice For Healthcare Recommendations\n\n【2】\n This section includes a copy of the learning outcomes from the AoMRC safe sedation practice for healthcare guidelines. Further information about key competences and expected methods of assessments is available here: https://www.aomrc.org.uk/wpcontent/uploads/2016/05/Safe_Sedation_Practice_1213.pdf\n\n【3】 Learning outcomes':\n\n【4】 ■ To gain a fundamental understanding of what is meant by conscious sedation and the risks associated with deeper levels of sedation.\n\n【5】 ■ To be able to describe the differences between conscious sedation and deeper levels of sedation, with its attendant potential risks to patient safety.\n\n【6】 ■ To gain a fundamental understanding that loss of verbal responsiveness/deep sedation requires the same level of skills and care as for general anaesthesia.\n\n【7】 ■ To recognise the important principle of minimum intervention, where the simplest and safest technique which is likely to be effective is used to achieve the clinical goal.\n\n【8】 ■ To gain a fundamental understanding of the particular dangers associated with the use of multiple sedative drugs, especially in the elderly and young children.\n\n【9】 ■ To be able to safely deliver pharmacological sedation to appropriate patients and recognise the limits of their competency and experience.\n\n【10】 ■ To be able to discuss where and when deeper levels of sedation or anaesthesia may be indicated.\n\n【11】 ■ To be able to manage sedation-related side effects in a timely manner, ensuring patient safety is of paramount consideration at all times.\n\n【12】 To gain a fundamental understanding that for all but brief and simple procedures, undertaken on fit patients, serious consideration must be given to the use of a trained dedicated sedationist,", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "Appendix 4: Learning outcomes from the AoMRC Safe Sedation practice for healthcare", "bbox": [119.0, 190.0, 597.0, 205.0]}, {"text": "recommendations", "bbox": [119.0, 214.0, 224.0, 229.0]}], "type": "Section-header", "position": 3}, {"raw_context": [{"text": "This section includes a copy of the learning outcomes from the AoMRC safe sedation practice for", "bbox": [120.0, 239.0, 641.0, 254.0]}, {"text": "healthcare guidelines. Further information about key competences and expected methods of", "bbox": [119.0, 263.0, 623.0, 278.0]}, {"text": "assessments is available here: https://www.aomrc.org.uk/wp-", "bbox": [120.0, 287.0, 456.0, 302.0]}, {"text": "content/uploads/2016/05/Safe_Sedation_Practice_1213.pdf", "bbox": [119.0, 310.0, 449.0, 325.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": "Learning outcomes':", "bbox": [119.0, 359.0, 233.0, 374.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "■ To gain a fundamental understanding of what is meant by conscious sedation and the risks", "bbox": [137.0, 383.0, 648.0, 399.0]}, {"text": "associated with deeper levels of sedation.", "bbox": [157.0, 408.0, 385.0, 423.0]}], "type": "Text", "position": 6}, {"raw_context": [{"text": "■ To be able to describe the differences between conscious sedation and deeper levels of sedation,", "bbox": [137.0, 443.0, 684.0, 459.0]}, {"text": "with its attendant potential risks to patient safety.", "bbox": [157.0, 468.0, 430.0, 483.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "■ To gain a fundamental understanding that loss of verbal responsiveness/deep sedation requires", "bbox": [137.0, 504.0, 675.0, 520.0]}, {"text": "the same level of skills and care as for general anaesthesia.", "bbox": [157.0, 528.0, 477.0, 543.0]}], "type": "Text", "position": 8}, {"raw_context": [{"text": "■ To recognise the important principle of minimum intervention, where the simplest and safest", "bbox": [137.0, 564.0, 662.0, 579.0]}, {"text": "technique which is likely to be effective is used to achieve the clinical goal.", "bbox": [157.0, 588.0, 559.0, 604.0]}], "type": "Text", "position": 9}, {"raw_context": [{"text": "■ To gain a fundamental understanding of the particular dangers associated with the use of", "bbox": [137.0, 624.0, 641.0, 639.0]}, {"text": "multiple sedative drugs, especially in the elderly and young children.", "bbox": [157.0, 648.0, 527.0, 664.0]}], "type": "Text", "position": 10}, {"raw_context": [{"text": "■ To be able to safely deliver pharmacological sedation to appropriate patients and recognise the", "bbox": [137.0, 685.0, 673.0, 701.0]}, {"text": "limits of their competency and experience.", "bbox": [157.0, 711.0, 390.0, 725.0]}], "type": "Text", "position": 11}, {"raw_context": [{"text": "■ To be able to discuss where and when deeper levels of sedation or anaesthesia may be indicated.", "bbox": [137.0, 746.0, 683.0, 761.0]}], "type": "Text", "position": 12}, {"raw_context": [{"text": "■ To be able to manage sedation-related side effects in a timely manner, ensuring patient safety is", "bbox": [137.0, 781.0, 679.0, 797.0]}, {"text": "of paramount consideration at all times.", "bbox": [156.0, 806.0, 376.0, 821.0]}], "type": "Text", "position": 13}, {"raw_context": [{"text": "To gain a fundamental understanding that for all but brief and simple procedures, undertaken on", "bbox": [148.0, 879.0, 672.0, 894.0]}, {"text": "fit patients, serious consideration must be given to the use of a trained dedicated sedationist,", "bbox": [147.0, 903.0, 652.0, 917.0]}], "type": "Text", "position": 14}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/消化科/_2023 BSG指南：胃肠内窥镜检查中的镇静.pdf", "page_num": 42}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": null, "type3": "无关文本#3#3# Learning outcomes’里面的 ’", "type4": null, "type5": null, "type6": null}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:41", "update_time": "2024-05-07 18:36:59"}
{"id": 1082588, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 738, "source_info": {"seq_id": "bd091b68-a489-4ba2-a9da-99c78b75f66c", "title": null, "text": "【0】页码:6\n 2022     8        35          8            China J Orthop Trauma , Aug.2022, Vol.35 , No.8 795  • 4 ,4~8 , o , 10,818 , __ , 5. 2 __ [38] , .\n\n【1】Chapter 1 5. 3. 3 , 100 .\n\n【2】.\n\n【3】. \n\n【4】.\n\n【5】, [39–40] Chapter 1 , [34] , Chapter 1 __ ,  6 , __ 6. 1 , 5. 2. 1 (       1~2     ), .\n\n【6】Construction , __ ,  __ Chapter 1 , .\n\n【7】__ o , ., 3~6    ),  5. 2. 2 ( , 100 __ , , , , o o , (       6      ~6         ), 6. 2 5. 2. 3  . \n\n【8】, .\n\n【9】, Construction , , and the content of the .\n\n【10】.\n\n【11】Long Congress .\n\n【12】.\n\n【13】.\n\n【14】Chapter 2 5.3 the content of the conte .\n\n【15】Chapter 1 __ , the complete of the complete complete and the complete of the complete complete and the complete of the complete complete Chapter 1 ..\n\n【16】__ __  Construction o Chapter 1 .\n\n【17】6. 3 . \n\n【18】. \n\n【19】.\n\n【20】Copyright 2017 Cengage Learning. All Rights Reserved. May not be copied, scanned, or  , , [36] Construction o , 5. 3. 1 2  Chapter Portage ..\n\n【21】\n\n【22】, . \n\n【23】, , 100 __ __ __ Chapter 1 .\n\n【24】o [37] .\n\n【25】7   Chapter 2 Chapter 1 .\n\n【26】__ , __ , ,  , 5. 3. 2 , .\n\n【27】, .\n\n【28】C 5 Chapter 3 Line 1996 , , )  __ ,  ., __ , 10.1.1.1 __ .\n\n【29】, o , Chapter 3 __ ,", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "2022     8        35          8            China J Orthop Trauma , Aug.2022, Vol.35 , No.8", "bbox": [124.0, 66.0, 473.0, 84.0]}, {"text": "795  •", "bbox": [665.0, 66.0, 721.0, 82.0]}, {"text": "4 ,4~8", "bbox": [121.0, 106.0, 186.0, 123.0]}, {"text": ",", "bbox": [311.0, 110.0, 340.0, 123.0]}, {"text": "o", "bbox": [555.0, 110.0, 610.0, 123.0]}, {"text": ",", "bbox": [673.0, 110.0, 720.0, 125.0]}, {"text": "10,818", "bbox": [121.0, 127.0, 142.0, 143.0]}, {"text": ",", "bbox": [684.0, 127.0, 729.0, 149.0]}, {"text": "__", "bbox": [149.0, 130.0, 225.0, 147.0]}, {"text": ",", "bbox": [524.0, 130.0, 570.0, 144.0]}, {"text": "5. 2", "bbox": [78.0, 146.0, 109.0, 164.0]}, {"text": "__", "bbox": [631.0, 151.0, 729.0, 165.0]}, {"text": "[38]", "bbox": [655.0, 161.0, 725.0, 182.0]}, {"text": ",", "bbox": [504.0, 170.0, 561.0, 184.0]}, {"text": ".", "bbox": [339.0, 171.0, 374.0, 185.0]}, {"text": "Chapter 1", "bbox": [152.0, 172.0, 233.0, 184.0]}, {"text": "5. 3. 3", "bbox": [411.0, 183.0, 456.0, 203.0]}, {"text": ", 100", "bbox": [164.0, 187.0, 259.0, 204.0]}, {"text": ".", "bbox": [92.0, 190.0, 123.0, 204.0]}, {"text": ".", "bbox": [659.0, 190.0, 674.0, 205.0]}, {"text": ". ", "bbox": [85.0, 205.0, 205.0, 224.0]}, {"text": ".", "bbox": [598.0, 211.0, 623.0, 224.0]}, {"text": ",", "bbox": [494.0, 212.0, 518.0, 225.0]}, {"text": "[39–40]", "bbox": [410.0, 222.0, 465.0, 238.0]}, {"text": "Chapter 1", "bbox": [179.0, 229.0, 311.0, 246.0]}, {"text": ",", "bbox": [614.0, 231.0, 674.0, 244.0]}, {"text": "[34]", "bbox": [92.0, 241.0, 310.0, 265.0]}, {"text": ",", "bbox": [603.0, 250.0, 668.0, 265.0]}, {"text": "Chapter 1", "bbox": [415.0, 260.0, 469.0, 286.0]}, {"text": "__", "bbox": [103.0, 268.0, 151.0, 285.0]}, {"text": ", ", "bbox": [196.0, 288.0, 383.0, 323.0]}, {"text": "6", "bbox": [410.0, 287.0, 449.0, 301.0]}, {"text": ",", "bbox": [88.0, 289.0, 146.0, 305.0]}, {"text": "__", "bbox": [354.0, 289.0, 384.0, 304.0]}, {"text": "6. 1", "bbox": [410.0, 305.0, 441.0, 322.0]}, {"text": ",", "bbox": [234.0, 311.0, 253.0, 324.0]}, {"text": "5. 2. 1", "bbox": [78.0, 325.0, 123.0, 343.0]}, {"text": "(       1~2     ),", "bbox": [232.0, 325.0, 361.0, 343.0]}, {"text": ".", "bbox": [629.0, 330.0, 686.0, 344.0]}, {"text": "Construction ,", "bbox": [414.0, 344.0, 520.0, 366.0]}, {"text": "__", "bbox": [85.0, 348.0, 209.0, 366.0]}, {"text": ", ", "bbox": [588.0, 348.0, 708.0, 366.0]}, {"text": "__", "bbox": [222.0, 349.0, 370.0, 365.0]}, {"text": "Chapter 1", "bbox": [91.0, 365.0, 213.0, 386.0]}, {"text": ",", "bbox": [616.0, 370.0, 649.0, 385.0]}, {"text": ".", "bbox": [416.0, 371.0, 449.0, 385.0]}, {"text": "__", "bbox": [683.0, 387.0, 733.0, 405.0]}, {"text": "o", "bbox": [93.0, 389.0, 123.0, 404.0]}, {"text": ",", "bbox": [524.0, 389.0, 587.0, 404.0]}, {"text": ".,", "bbox": [606.0, 389.0, 682.0, 404.0]}, {"text": "3~6    ), ", "bbox": [277.0, 403.0, 671.0, 447.0]}, {"text": "5. 2. 2", "bbox": [78.0, 404.0, 123.0, 423.0]}, {"text": "(", "bbox": [238.0, 405.0, 277.0, 423.0]}, {"text": ", 100", "bbox": [680.0, 410.0, 719.0, 424.0]}, {"text": "__", "bbox": [83.0, 426.0, 123.0, 446.0]}, {"text": ",", "bbox": [236.0, 426.0, 320.0, 447.0]}, {"text": ",", "bbox": [659.0, 430.0, 700.0, 445.0]}, {"text": ",", "bbox": [173.0, 431.0, 205.0, 445.0]}, {"text": ",", "bbox": [84.0, 448.0, 121.0, 463.0]}, {"text": "o", "bbox": [270.0, 447.0, 334.0, 462.0]}, {"text": "o", "bbox": [599.0, 448.0, 674.0, 463.0]}, {"text": ",", "bbox": [451.0, 449.0, 524.0, 464.0]}, {"text": "(       6      ~6         ),", "bbox": [248.0, 464.0, 389.0, 484.0]}, {"text": "6. 2", "bbox": [410.0, 464.0, 441.0, 483.0]}, {"text": "5. 2. 3", "bbox": [78.0, 465.0, 124.0, 483.0]}, {"text": "", "bbox": [662.0, 481.0, 717.0, 506.0]}, {"text": ". ", "bbox": [336.0, 487.0, 380.0, 506.0]}, {"text": ",", "bbox": [123.0, 489.0, 170.0, 503.0]}, {"text": ".", "bbox": [613.0, 489.0, 657.0, 504.0]}, {"text": ",", "bbox": [207.0, 490.0, 231.0, 504.0]}, {"text": "", "bbox": [231.0, 490.0, 333.0, 504.0]}, {"text": "Construction", "bbox": [596.0, 506.0, 718.0, 524.0]}, {"text": ",", "bbox": [148.0, 509.0, 183.0, 524.0]}, {"text": ", and the content of the", "bbox": [94.0, 523.0, 537.0, 544.0]}, {"text": ".", "bbox": [610.0, 527.0, 703.0, 543.0]}, {"text": ".", "bbox": [702.0, 531.0, 717.0, 543.0]}, {"text": "Long Congress", "bbox": [204.0, 549.0, 287.0, 566.0]}, {"text": ".", "bbox": [637.0, 549.0, 702.0, 564.0]}, {"text": ".", "bbox": [136.0, 550.0, 190.0, 564.0]}, {"text": ".", "bbox": [702.0, 550.0, 717.0, 564.0]}, {"text": "Chapter 2", "bbox": [419.0, 552.0, 491.0, 564.0]}, {"text": "5.3", "bbox": [78.0, 563.0, 110.0, 582.0]}, {"text": "the content of the conte", "bbox": [500.0, 563.0, 702.0, 587.0]}, {"text": ".", "bbox": [702.0, 569.0, 717.0, 584.0]}, {"text": "Chapter 1", "bbox": [240.0, 586.0, 335.0, 605.0]}, {"text": "__", "bbox": [410.0, 587.0, 698.0, 603.0]}, {"text": ",", "bbox": [236.0, 608.0, 292.0, 624.0]}, {"text": "the complete of the complete complete and the complete of the complete complete and the complete of the complete complete ", "bbox": [418.0, 607.0, 705.0, 624.0]}, {"text": "Chapter 1", "bbox": [575.0, 625.0, 674.0, 646.0]}, {"text": "..", "bbox": [425.0, 629.0, 501.0, 643.0]}, {"text": "__", "bbox": [246.0, 630.0, 297.0, 643.0]}, {"text": "__", "bbox": [674.0, 631.0, 716.0, 643.0]}, {"text": "", "bbox": [253.0, 642.0, 343.0, 668.0]}, {"text": "Construction o", "bbox": [443.0, 645.0, 649.0, 664.0]}, {"text": "Chapter 1", "bbox": [114.0, 646.0, 178.0, 665.0]}, {"text": ".", "bbox": [84.0, 649.0, 116.0, 663.0]}, {"text": "6. 3", "bbox": [410.0, 662.0, 449.0, 681.0]}, {"text": ". ", "bbox": [246.0, 668.0, 361.0, 685.0]}, {"text": ". ", "bbox": [82.0, 669.0, 171.0, 685.0]}, {"text": ".", "bbox": [172.0, 670.0, 233.0, 685.0]}, {"text": "Copyright 2017 Cengage Learning. All Rights Reserved. May not be copied, scanned, or", "bbox": [524.0, 683.0, 729.0, 704.0]}, {"text": "", "bbox": [86.0, 686.0, 136.0, 710.0]}, {"text": ",", "bbox": [283.0, 689.0, 322.0, 704.0]}, {"text": ",", "bbox": [135.0, 690.0, 167.0, 703.0]}, {"text": "[36]", "bbox": [153.0, 698.0, 216.0, 721.0]}, {"text": "Construction o", "bbox": [412.0, 706.0, 633.0, 727.0]}, {"text": ",", "bbox": [641.0, 709.0, 668.0, 724.0]}, {"text": "5. 3. 1", "bbox": [78.0, 724.0, 123.0, 742.0]}, {"text": "2 ", "bbox": [255.0, 725.0, 308.0, 741.0]}, {"text": "Chapter Portage", "bbox": [512.0, 728.0, 678.0, 745.0]}, {"text": "..", "bbox": [409.0, 745.0, 491.0, 759.0]}, {"text": "", "bbox": [490.0, 745.0, 723.0, 766.0]}, {"text": ",", "bbox": [83.0, 749.0, 126.0, 765.0]}, {"text": ". ", "bbox": [253.0, 749.0, 321.0, 761.0]}, {"text": ",", "bbox": [177.0, 769.0, 223.0, 784.0]}, {"text": ", 100", "bbox": [676.0, 769.0, 721.0, 784.0]}, {"text": "__", "bbox": [284.0, 770.0, 332.0, 782.0]}, {"text": "__", "bbox": [412.0, 771.0, 514.0, 793.0]}, {"text": "__", "bbox": [543.0, 771.0, 658.0, 784.0]}, {"text": "Chapter 1", "bbox": [266.0, 788.0, 330.0, 802.0]}, {"text": ".", "bbox": [515.0, 787.0, 547.0, 803.0]}, {"text": "o", "bbox": [619.0, 787.0, 700.0, 802.0]}, {"text": "[37] .", "bbox": [276.0, 798.0, 381.0, 826.0]}, {"text": "7", "bbox": [410.0, 802.0, 429.0, 820.0]}, {"text": "", "bbox": [110.0, 804.0, 222.0, 815.0]}, {"text": "", "bbox": [98.0, 828.0, 236.0, 864.0]}, {"text": "Chapter 2", "bbox": [285.0, 828.0, 355.0, 843.0]}, {"text": "Chapter 1", "bbox": [298.0, 847.0, 374.0, 865.0]}, {"text": ".", "bbox": [93.0, 849.0, 136.0, 863.0]}, {"text": "__", "bbox": [408.0, 849.0, 449.0, 862.0]}, {"text": ",", "bbox": [633.0, 849.0, 666.0, 862.0]}, {"text": "__", "bbox": [427.0, 863.0, 476.0, 884.0]}, {"text": ",", "bbox": [178.0, 865.0, 248.0, 883.0]}, {"text": ", ", "bbox": [280.0, 866.0, 388.0, 883.0]}, {"text": ",", "bbox": [715.0, 871.0, 729.0, 881.0]}, {"text": "5. 3. 2", "bbox": [78.0, 882.0, 123.0, 901.0]}, {"text": ",", "bbox": [341.0, 889.0, 375.0, 904.0]}, {"text": ".", "bbox": [543.0, 889.0, 603.0, 904.0]}, {"text": ",", "bbox": [628.0, 889.0, 697.0, 904.0]}, {"text": ".", "bbox": [715.0, 890.0, 732.0, 904.0]}, {"text": "C 5", "bbox": [152.0, 904.0, 191.0, 920.0]}, {"text": "Chapter 3", "bbox": [196.0, 906.0, 253.0, 919.0]}, {"text": "Line 1996", "bbox": [533.0, 906.0, 604.0, 921.0]}, {"text": ",", "bbox": [283.0, 908.0, 316.0, 923.0]}, {"text": ",", "bbox": [450.0, 907.0, 485.0, 922.0]}, {"text": ") ", "bbox": [425.0, 923.0, 493.0, 942.0]}, {"text": "__", "bbox": [153.0, 925.0, 238.0, 940.0]}, {"text": ", ", "bbox": [150.0, 947.0, 237.0, 964.0]}, {"text": ".,", "bbox": [352.0, 947.0, 408.0, 962.0]}, {"text": "__", "bbox": [417.0, 949.0, 469.0, 968.0]}, {"text": ",", "bbox": [469.0, 949.0, 484.0, 963.0]}, {"text": "10.1.1.1", "bbox": [94.0, 962.0, 113.0, 979.0]}, {"text": "__", "bbox": [351.0, 966.0, 398.0, 984.0]}, {"text": ".", "bbox": [268.0, 969.0, 323.0, 984.0]}, {"text": ",", "bbox": [526.0, 969.0, 580.0, 983.0]}, {"text": "o", "bbox": [222.0, 989.0, 281.0, 1003.0]}, {"text": ",", "bbox": [553.0, 990.0, 602.0, 1003.0]}, {"text": "Chapter 3", "bbox": [543.0, 1005.0, 596.0, 1025.0]}, {"text": "__", "bbox": [96.0, 1007.0, 135.0, 1023.0]}, {"text": ",", "bbox": [342.0, 1009.0, 375.0, 1022.0]}], "type": "Text", "position": 0}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/骨科/共识/脊髓型颈椎病中西医结合诊疗专家共识.pdf", "page_num": 6}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type2": "格式杂乱#0#29#内容无法理解", "type3": null, "type6": null}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:41", "update_time": "2024-05-07 18:29:32"}
{"id": 1082587, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 738, "source_info": {"seq_id": "870bebb9-9fd3-4019-be7d-17893575366c", "title": null, "text": "【0】页码:6\n Recommendation 5.2: MRI surveillance may be conducted by the medical oncologist or the radiation oncologist. ( Level of Agreement: Unanimous).\n\n【1】Recommendation 5.3: Computed tomography should only be used when MRI is not an option. ( Level of Agreement: Unanimous ).\n\n【2】Clinical Rationale: In agreement with ASTRO, the expert working group recommended that if PCI is determined to be inappropriate based on discussions between the patient and radiation oncologist, routine MRI surveillance should be initiated to monitor for brain metastases.\n\n【3】Neither the ASTRO guidelines nor the ASCO endorsement provide guidance on the timing of MRI surveillance after completion of initial therapy [24,25] . In alignment with the design of the Phase III trial by Takahashi and colleagues [22] and other published recommendations (e.g., the ASCO guidelines for lung cancer surveillance after curativeintent therapy) [60,70] , the expert working group recommended that MRI surveillance occur every three months in Year 1 and every six months in Year 2. Surveillance may be conducted by either the medical or radiation oncologist; good communication is required across the MDT to confirm who is responsible and to ensure that assessments are completed as planned. As per the ASTRO guidelines, MRI with contrast is the preferred imaging modality given high diagnostic sensitivity for small brain lesions; however, when MRI is unavailable or contraindicated (e.g., for patients with pacemakers), contrast-enhanced CT maintains a role in surveillance of patients with ES-SCLC [24,71–73] .\n\n【4】CLINICAL QUESTION 6: What is the appropriate dose-fractionation sedule for PCI?\n\n【5】Recommendation 6.1: PCI to a dose of 25 Gy in 10 fractions is recommended; 20 Gy in 5 fractions is an alternative. ( Level of Agreement: Unanimous).\n\n【6】Clinical Rationale: The expert working group agreed that the PCI dose-fractionation schedules recommended by ASTRO (25 Gy in 10 fractions and 20 Gy in 5) are appropriate. Use of 25 Gy in 10 fractions has been extensively studied among patients with ES-SCLC, showing acceptable disease control and neurotoxicity [6,22,58,65,74–76] ; higher doses have been associated with increased rates of toxicity and mortality [74,75] . Evidence for the efficacy of 20 Gy in 5 fractions is also available from a randomized-controlled trial, in which 62% of patients received this dosing schedule, although the neurocognitive effects of this schedule have not been evaluated [6] . The 20 Gy in 5 fraction schedule may be more appropriate depending on patient location and/or their willingness to travel.\n\n【7】As highlighted above, concerns remain regarding the late neurocognitive impact of PCI among patients with ES-SCLC [63,77,78] . In a pooled analysis of data from the randomized RTOG 0212 [75] and 0214 [79] trials, PCI was associated with a significantly higher risk of decline in self-reported cognitive functioning at 6 and 12 months compared with observation [63] . Although other studies have not observed significant cognitive effects, risk mitigation options that can be applied during PCI may be considered, such as hippocampal avoidance and use of memantine, a partial antagonist of the N–methyl-D-aspartate (NMDA) receptor [32,80–84] .\n\n【8】CLINICAL QUESTON 7: What is the optimal timing of PCI during immunotherapy?\n\n【9】Recommendation 7.1: Concurrent treatment with PCI and immunotherapy is appropriate. ( Level of Agreement: Unanimous ).\n\n【10】Recommendation 7.2: PCI should be provided after completion of concurrent chemo-immunotherapy. (Level of Agreement: Unanimous) .\n\n【11】Clinical Rationale: Similar to TRT, limited evidence is available for use of PCI among patients receiving immunotherapy, although the Phase III IMpower133 and KEYNOTE-604 trials did permit such use [28,30] . In CASPIAN, PCI was only permitted in the control arm [29,85] . In IMpower133, PCI could be administered during the maintenance phase after completion of concurrent chemo-immunotherapy as per local standard of care and was received by 11% of patients in each study arm [28,86] . In KEYNOTE-604, patients who achieved a complete or partial response after cycle 4 could receive up to 25 Gy of PCI in 10 fractions at\n\n【12】 the investigator's discretion [30] . Twenty-seven patients (11.8%) in the pembrolizumab + EP group and 32 (14.2%) patients in the placebo + EP group received PCI. Neither IMpower133 nor KEYNOTE-604 noted safety concerns among patients who received PCI and immunotherapy.\n\n【13】Four additional studies conducted in ES-SCLC have also permitted use of PCI during immunotherapy, although both therapies were generally received in a small proportion of patients; accordingly, conclusions regarding safety, efficacy, and appropriate timing cannot be discerned [37,42,43,58] . In contrast, a Phase I/II trial of pembrolizumab and concurrent PCI in LS-SCLC found that mOS was significantly longer among patients who received PCI than those who did not (NR vs. 39.5 months; p < 0.05) [44] . Notably, at the discretion of the treating physician, the study permitted pembrolizumab to be withheld for up to 21 days for administration of PCI.\n\n【14】Overall, the safety, efficacy, and optimal timing of combining immunotherapy and PCI in ES-SCLC remain unclear. It is possible that given the improvements in systemic disease control and OS observed with new immunotherapies, the benefits of controlling CNS disease are now of even greater importance; however, penetration of the bloodbrain barrier by these agents may be sufficient to control microscopic brain metastases [80] . Moreover, avoidance of early brain RT may be favorable in terms of cognitive functioning and HRQoL, leading to greater use of MRI surveillance and salvage RT where appropriate [80] .\n\n【15】Additional evidence on the experience of patients receiving PCI and immunotherapy is expected from the MAVERICK and LUMINANCE trials. As discussed above, MAVERICK is a randomized Phase III study of MRI surveillance with or without PCI in SCLC [32] ; immunotherapy (concurrent with and/or adjuvant to first-line therapy) and TRT are allowed at the discretion of the treating physician. The primary endpoint of MAVERICK is OS, while secondary endpoints include cognitive failure-free survival, brain metastasis-free survival, HRQoL, and toxicity, among others. The primary study completion date is estimated for November 2025. LUMINANCE is a Phase IIIb, single-arm, multicenter study of the safety and tolerability of durvalumab + EP in firstline treatment of patients with ES-SCLC; response rates, PFS, and OS will also be assessed [36] . The primary study completion date is estimated for June 2023.\n\n【16】While awaiting additional clinical data and considering known risks, the expert working group recommended that among suitable patients (see Question 4), PCI can be initiated after completion of concurrent chemo-immunotherapy, once toxicity from chemotherapy has subsided and re-staging brain MRI excludes CNS involvement. PCI and immunotherapy can be received concurrently as long as toxicity is not a concern. As noted above, patients with an elevated risk of toxicity may include those of advanced age and pre-existing conditions and appropriate treatment should be determined on a case-by-case basis [23,24,60] .\n\n【17】CLINICAL QUESTION 8: What is the optimal timing of TRT + PCI among patients receiving immunotherapy?\n\n【18】Recommendation 8.1: Concurrent treatment with TRT, PCI, and immunotherapy is appropriate. Level of Agreement: Unanimous ).\n\n【19】Recommendation 8.2: Consolidation TRT and PCI should be provided after completion of concurrent chemo-immunotherapy.\n\n【20】As expected, evidence supporting concurrent use of TRT, PCI, and immunotherapy is even more limited than individual combinations of RT and immunotherapy. Although concurrent use of TRT and PCI is well established as part of the standard of care for ES-SCLC [17,18] , the Phase III immunotherapy trials IMpower133, CASPIAN, and KEYNOTE-604 did not permit use of TRT [28–30] . Few other studies have permitted combination of TRT, PCI, and immunotherapy in ES-SCLC, and their publications do not report the number of patients who received all three therapies or their clinical outcomes [39,40] . In the Phase I study of pembrolizumab and RT in ES-SCLC, PCI was allowed but only received by 15% of patients; when administered, TRT and pembrolizumab were delayed by one cycle (21 days) [39] . Although no notable safety concerns were reported in this study or in the other analysis that has been", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "Recommendation 5.2: MRI surveillance may be conducted by the", "bbox": [64.0, 69.0, 387.0, 83.0]}, {"text": "medical oncologist or the radiation oncologist. ( Level of Agreement:", "bbox": [48.0, 85.0, 386.0, 97.0]}, {"text": "Unanimous).", "bbox": [48.0, 99.0, 107.0, 111.0]}, {"text": "Recommendation 5.3: Computed tomography should only be used", "bbox": [63.0, 112.0, 387.0, 126.0]}, {"text": "when MRI is not an option. ( Level of Agreement: Unanimous ).", "bbox": [48.0, 127.0, 336.0, 139.0]}, {"text": "Clinical Rationale: In agreement with ASTRO, the expert working", "bbox": [63.0, 140.0, 387.0, 153.0]}, {"text": "group recommended that if PCI is determined to be inappropriate based", "bbox": [47.0, 154.0, 387.0, 167.0]}, {"text": "on discussions between the patient and radiation oncologist, routine", "bbox": [47.0, 167.0, 387.0, 181.0]}, {"text": "MRI surveillance should be initiated to monitor for brain metastases.", "bbox": [47.0, 181.0, 385.0, 195.0]}, {"text": "Neither the ASTRO guidelines nor the ASCO endorsement provide", "bbox": [47.0, 195.0, 387.0, 210.0]}, {"text": "guidance on the timing of MRI surveillance after completion of initial", "bbox": [48.0, 210.0, 387.0, 224.0]}, {"text": "therapy [24,25] . In alignment with the design of the Phase III trial by", "bbox": [47.0, 223.0, 387.0, 238.0]}, {"text": "Takahashi and colleagues [22] and other published recommendations", "bbox": [48.0, 236.0, 387.0, 253.0]}, {"text": "(e.g., the ASCO guidelines for lung cancer surveillance after curative-", "bbox": [47.0, 250.0, 385.0, 267.0]}, {"text": "intent therapy) [60,70] , the expert working group recommended that", "bbox": [47.0, 265.0, 387.0, 279.0]}, {"text": "MRI surveillance occur every three months in Year 1 and every six", "bbox": [48.0, 280.0, 387.0, 292.0]}, {"text": "months in Year 2. Surveillance may be conducted by either the medical", "bbox": [48.0, 294.0, 387.0, 306.0]}, {"text": "or radiation oncologist; good communication is required across the MDT", "bbox": [47.0, 307.0, 387.0, 320.0]}, {"text": "to confirm who is responsible and to ensure that assessments are", "bbox": [47.0, 321.0, 387.0, 334.0]}, {"text": "completed as planned. As per the ASTRO guidelines, MRI with contrast", "bbox": [47.0, 335.0, 387.0, 348.0]}, {"text": "is the preferred imaging modality given high diagnostic sensitivity for", "bbox": [47.0, 349.0, 387.0, 362.0]}, {"text": "small brain lesions; however, when MRI is unavailable or contra-", "bbox": [47.0, 363.0, 386.0, 376.0]}, {"text": "indicated (e.g., for patients with pacemakers), contrast-enhanced CT", "bbox": [47.0, 377.0, 387.0, 390.0]}, {"text": "maintains a role in surveillance of patients with ES-SCLC [24,71–73] .", "bbox": [47.0, 391.0, 381.0, 405.0]}, {"text": "CLINICAL QUESTION 6: What is the appropriate dose-fractionation", "bbox": [62.0, 405.0, 387.0, 419.0]}, {"text": "sedule for PCI?", "bbox": [48.0, 420.0, 134.0, 432.0]}, {"text": "Recommendation 6.1: PCI to a dose of 25 Gy in 10 fractions is", "bbox": [62.0, 433.0, 387.0, 447.0]}, {"text": "recommended; 20 Gy in 5 fractions is an alternative. ( Level of Agreement:", "bbox": [48.0, 447.0, 387.0, 460.0]}, {"text": "Unanimous).", "bbox": [48.0, 463.0, 109.0, 474.0]}, {"text": "Clinical Rationale: The expert working group agreed that the PCI", "bbox": [62.0, 474.0, 387.0, 490.0]}, {"text": "dose-fractionation schedules recommended by ASTRO (25 Gy in 10", "bbox": [47.0, 488.0, 387.0, 503.0]}, {"text": "fractions and 20 Gy in 5) are appropriate. Use of 25 Gy in 10 fractions", "bbox": [47.0, 503.0, 387.0, 517.0]}, {"text": "has been extensively studied among patients with ES-SCLC, showing", "bbox": [47.0, 517.0, 387.0, 531.0]}, {"text": "acceptable disease control and neurotoxicity [6,22,58,65,74–76] ;", "bbox": [47.0, 531.0, 387.0, 545.0]}, {"text": "higher doses have been associated with increased rates of toxicity and", "bbox": [47.0, 545.0, 387.0, 559.0]}, {"text": "mortality [74,75] . Evidence for the efficacy of 20 Gy in 5 fractions is also", "bbox": [47.0, 558.0, 387.0, 572.0]}, {"text": "available from a randomized-controlled trial, in which 62% of patients", "bbox": [47.0, 572.0, 387.0, 586.0]}, {"text": "received this dosing schedule, although the neurocognitive effects of this", "bbox": [48.0, 587.0, 387.0, 600.0]}, {"text": "schedule have not been evaluated [6] . The 20 Gy in 5 fraction schedule", "bbox": [48.0, 601.0, 387.0, 614.0]}, {"text": "may be more appropriate depending on patient location and/or their", "bbox": [48.0, 615.0, 386.0, 628.0]}, {"text": "willingness to travel.", "bbox": [48.0, 629.0, 149.0, 641.0]}, {"text": "As highlighted above, concerns remain regarding the late neuro-", "bbox": [63.0, 642.0, 385.0, 655.0]}, {"text": "cognitive impact of PCI among patients with ES-SCLC [63,77,78] . In a", "bbox": [47.0, 656.0, 387.0, 669.0]}, {"text": "pooled analysis of data from the randomized RTOG 0212 [75] and 0214", "bbox": [48.0, 670.0, 387.0, 683.0]}, {"text": "[79] trials, PCI was associated with a significantly higher risk of decline", "bbox": [48.0, 685.0, 386.0, 698.0]}, {"text": "in self-reported cognitive functioning at 6 and 12 months compared with", "bbox": [48.0, 699.0, 387.0, 712.0]}, {"text": "observation [63] . Although other studies have not observed significant", "bbox": [48.0, 713.0, 386.0, 725.0]}, {"text": "cognitive effects, risk mitigation options that can be applied during PCI", "bbox": [48.0, 727.0, 386.0, 739.0]}, {"text": "may be considered, such as hippocampal avoidance and use of mem-", "bbox": [48.0, 741.0, 385.0, 753.0]}, {"text": "antine, a partial antagonist of the N–methyl-D-aspartate (NMDA) re-", "bbox": [48.0, 754.0, 385.0, 767.0]}, {"text": "ceptor [32,80–84] .", "bbox": [48.0, 768.0, 140.0, 781.0]}, {"text": "CLINICAL QUESTON 7: What is the optimal timing of PCI during", "bbox": [62.0, 781.0, 386.0, 796.0]}, {"text": "immunotherapy?", "bbox": [48.0, 797.0, 132.0, 810.0]}, {"text": "Recommendation 7.1: Concurrent treatment with PCI and immu-", "bbox": [62.0, 810.0, 385.0, 824.0]}, {"text": "notherapy is appropriate. ( Level of Agreement: Unanimous ).", "bbox": [48.0, 824.0, 328.0, 838.0]}, {"text": "Recommendation 7.2: PCI should be provided after completion of", "bbox": [62.0, 838.0, 387.0, 852.0]}, {"text": "concurrent chemo-immunotherapy. (Level of Agreement: Unanimous) .", "bbox": [48.0, 852.0, 377.0, 866.0]}, {"text": "Clinical Rationale: Similar to TRT, limited evidence is available for", "bbox": [62.0, 865.0, 387.0, 879.0]}, {"text": "use of PCI among patients receiving immunotherapy, although the Phase", "bbox": [47.0, 879.0, 387.0, 893.0]}, {"text": "III IMpower133 and KEYNOTE-604 trials did permit such use [28,30] . In", "bbox": [47.0, 893.0, 387.0, 908.0]}, {"text": "CASPIAN, PCI was only permitted in the control arm [29,85] . In", "bbox": [46.0, 908.0, 387.0, 922.0]}, {"text": "IMpower133, PCI could be administered during the maintenance phase", "bbox": [47.0, 922.0, 387.0, 935.0]}, {"text": "after completion of concurrent chemo-immunotherapy as per local", "bbox": [48.0, 937.0, 387.0, 949.0]}, {"text": "standard of care and was received by 11% of patients in each study arm", "bbox": [48.0, 950.0, 387.0, 962.0]}, {"text": "[28,86] . In KEYNOTE-604, patients who achieved a complete or partial", "bbox": [48.0, 963.0, 387.0, 976.0]}, {"text": "response after cycle 4 could receive up to 25 Gy of PCI in 10 fractions at", "bbox": [48.0, 977.0, 387.0, 991.0]}], "type": "Text", "position": 1}, {"raw_context": [{"text": "the investigator's discretion [30] . Twenty-seven patients (11.8%) in the", "bbox": [406.0, 69.0, 745.0, 83.0]}, {"text": "pembrolizumab + EP group and 32 (14.2%) patients in the placebo + EP", "bbox": [406.0, 83.0, 745.0, 98.0]}, {"text": "group received PCI. Neither IMpower133 nor KEYNOTE-604 noted", "bbox": [406.0, 99.0, 746.0, 112.0]}, {"text": "safety concerns among patients who received PCI and immunotherapy.", "bbox": [406.0, 112.0, 744.0, 125.0]}, {"text": "Four additional studies conducted in ES-SCLC have also permitted use of", "bbox": [406.0, 126.0, 746.0, 139.0]}, {"text": "PCI during immunotherapy, although both therapies were generally", "bbox": [405.0, 140.0, 745.0, 153.0]}, {"text": "received in a small proportion of patients; accordingly, conclusions", "bbox": [406.0, 154.0, 745.0, 168.0]}, {"text": "regarding safety, efficacy, and appropriate timing cannot be discerned", "bbox": [406.0, 168.0, 746.0, 181.0]}, {"text": "[37,42,43,58] . In contrast, a Phase I/II trial of pembrolizumab and", "bbox": [406.0, 181.0, 746.0, 195.0]}, {"text": "concurrent PCI in LS-SCLC found that mOS was significantly longer", "bbox": [406.0, 195.0, 745.0, 210.0]}, {"text": "among patients who received PCI than those who did not (NR vs. 39.5", "bbox": [406.0, 210.0, 746.0, 224.0]}, {"text": "months; p < 0.05) [44] . Notably, at the discretion of the treating", "bbox": [406.0, 223.0, 745.0, 238.0]}, {"text": "physician, the study permitted pembrolizumab to be withheld for up to", "bbox": [406.0, 238.0, 747.0, 251.0]}, {"text": "21 days for administration of PCI.", "bbox": [406.0, 253.0, 570.0, 265.0]}, {"text": "Overall, the safety, efficacy, and optimal timing of combining", "bbox": [421.0, 265.0, 745.0, 279.0]}, {"text": "immunotherapy and PCI in ES-SCLC remain unclear. It is possible that", "bbox": [406.0, 280.0, 746.0, 292.0]}, {"text": "given the improvements in systemic disease control and OS observed", "bbox": [406.0, 294.0, 746.0, 306.0]}, {"text": "with new immunotherapies, the benefits of controlling CNS disease are", "bbox": [406.0, 307.0, 745.0, 320.0]}, {"text": "now of even greater importance; however, penetration of the blood-", "bbox": [406.0, 321.0, 745.0, 334.0]}, {"text": "brain barrier by these agents may be sufficient to control microscopic", "bbox": [405.0, 335.0, 745.0, 348.0]}, {"text": "brain metastases [80] . Moreover, avoidance of early brain RT may be", "bbox": [405.0, 349.0, 746.0, 362.0]}, {"text": "favorable in terms of cognitive functioning and HRQoL, leading to", "bbox": [406.0, 363.0, 747.0, 376.0]}, {"text": "greater use of MRI surveillance and salvage RT where appropriate [80] .", "bbox": [406.0, 377.0, 745.0, 390.0]}, {"text": "Additional evidence on the experience of patients receiving PCI and", "bbox": [406.0, 391.0, 746.0, 405.0]}, {"text": "immunotherapy is expected from the MAVERICK and LUMINANCE tri-", "bbox": [406.0, 406.0, 745.0, 419.0]}, {"text": "als. As discussed above, MAVERICK is a randomized Phase III study of", "bbox": [406.0, 420.0, 747.0, 433.0]}, {"text": "MRI surveillance with or without PCI in SCLC [32] ; immunotherapy", "bbox": [405.0, 433.0, 745.0, 446.0]}, {"text": "(concurrent with and/or adjuvant to first-line therapy) and TRT are", "bbox": [405.0, 447.0, 745.0, 460.0]}, {"text": "allowed at the discretion of the treating physician. The primary endpoint", "bbox": [406.0, 461.0, 746.0, 475.0]}, {"text": "of MAVERICK is OS, while secondary endpoints include cognitive", "bbox": [405.0, 475.0, 745.0, 488.0]}, {"text": "failure-free survival, brain metastasis-free survival, HRQoL, and", "bbox": [405.0, 488.0, 746.0, 503.0]}, {"text": "toxicity, among others. The primary study completion date is estimated", "bbox": [405.0, 503.0, 747.0, 517.0]}, {"text": "for November 2025. LUMINANCE is a Phase IIIb, single-arm, multi-", "bbox": [405.0, 517.0, 745.0, 531.0]}, {"text": "center study of the safety and tolerability of durvalumab + EP in first-", "bbox": [405.0, 531.0, 745.0, 545.0]}, {"text": "line treatment of patients with ES-SCLC; response rates, PFS, and OS", "bbox": [406.0, 544.0, 746.0, 559.0]}, {"text": "will also be assessed [36] . The primary study completion date is esti-", "bbox": [406.0, 558.0, 745.0, 573.0]}, {"text": "mated for June 2023.", "bbox": [406.0, 573.0, 511.0, 585.0]}, {"text": "While awaiting additional clinical data and considering known risks,", "bbox": [422.0, 586.0, 745.0, 600.0]}, {"text": "the expert working group recommended that among suitable patients", "bbox": [406.0, 601.0, 746.0, 615.0]}, {"text": "(see Question 4), PCI can be initiated after completion of concurrent", "bbox": [406.0, 615.0, 745.0, 627.0]}, {"text": "chemo-immunotherapy, once toxicity from chemotherapy has subsided", "bbox": [405.0, 628.0, 746.0, 641.0]}, {"text": "and re-staging brain MRI excludes CNS involvement. PCI and immu-", "bbox": [406.0, 642.0, 745.0, 655.0]}, {"text": "notherapy can be received concurrently as long as toxicity is not a", "bbox": [406.0, 656.0, 746.0, 669.0]}, {"text": "concern. As noted above, patients with an elevated risk of toxicity may", "bbox": [406.0, 670.0, 745.0, 683.0]}, {"text": "include those of advanced age and pre-existing conditions and appro-", "bbox": [406.0, 685.0, 745.0, 698.0]}, {"text": "priate treatment should be determined on a case-by-case basis", "bbox": [406.0, 698.0, 745.0, 712.0]}, {"text": "[23,24,60] .", "bbox": [408.0, 713.0, 463.0, 725.0]}, {"text": "CLINICAL QUESTION 8: What is the optimal timing of TRT + PCI", "bbox": [421.0, 725.0, 746.0, 739.0]}, {"text": "among patients receiving immunotherapy?", "bbox": [407.0, 741.0, 614.0, 753.0]}, {"text": "Recommendation 8.1: Concurrent treatment with TRT, PCI, and", "bbox": [422.0, 753.0, 746.0, 767.0]}, {"text": "immunotherapy is appropriate. Level of Agreement: Unanimous ).", "bbox": [406.0, 768.0, 709.0, 781.0]}, {"text": "Recommendation 8.2: Consolidation TRT and PCI should be pro-", "bbox": [421.0, 781.0, 745.0, 796.0]}, {"text": "vided after completion of concurrent chemo-immunotherapy.", "bbox": [406.0, 796.0, 699.0, 810.0]}, {"text": "As expected, evidence supporting concurrent use of TRT, PCI, and", "bbox": [422.0, 810.0, 747.0, 824.0]}, {"text": "immunotherapy is even more limited than individual combinations of", "bbox": [406.0, 824.0, 746.0, 838.0]}, {"text": "RT and immunotherapy. Although concurrent use of TRT and PCI is well", "bbox": [405.0, 838.0, 746.0, 852.0]}, {"text": "established as part of the standard of care for ES-SCLC [17,18] , the Phase", "bbox": [406.0, 851.0, 745.0, 865.0]}, {"text": "III immunotherapy trials IMpower133, CASPIAN, and KEYNOTE-604", "bbox": [405.0, 865.0, 746.0, 879.0]}, {"text": "did not permit use of TRT [28–30] . Few other studies have permitted", "bbox": [405.0, 879.0, 747.0, 893.0]}, {"text": "combination of TRT, PCI, and immunotherapy in ES-SCLC, and their", "bbox": [405.0, 893.0, 745.0, 908.0]}, {"text": "publications do not report the number of patients who received all three", "bbox": [406.0, 908.0, 745.0, 922.0]}, {"text": "therapies or their clinical outcomes [39,40] . In the Phase I study of", "bbox": [405.0, 922.0, 747.0, 935.0]}, {"text": "pembrolizumab and RT in ES-SCLC, PCI was allowed but only received", "bbox": [406.0, 937.0, 746.0, 949.0]}, {"text": "by 15% of patients; when administered, TRT and pembrolizumab were", "bbox": [406.0, 951.0, 745.0, 962.0]}, {"text": "delayed by one cycle (21 days) [39] . Although no notable safety con-", "bbox": [405.0, 963.0, 745.0, 976.0]}, {"text": "cerns were reported in this study or in the other analysis that has been", "bbox": [405.0, 977.0, 745.0, 991.0]}], "type": "Text", "position": 3}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/肿瘤科/共识/加拿大共识建议：在接受免疫治疗的广泛期小细胞肺癌患者中使用放射治疗.pdf", "page_num": 6}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "多余换行#11#12#为同段内容", "type3": "无关文本#0#20#存在多处无关数字", "type4": null, "type5": null, "type6": null}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:41", "update_time": "2024-05-07 21:32:31"}
{"id": 1082586, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 738, "source_info": {"seq_id": "6aac24ba-9e63-484b-9df1-2b52adf53499", "title": null, "text": "【0】页码:90\n  M0\n\n【1】 e f\n\n【2】 小狗科\t$79, 151 [ 4 ]\n  N0 M0 小狗科研究\nNotes M0 M0 l Mo N2 IIIA期 T0, T1, T2 T3 N1, N2 小狗科 gramma T4 NO, N1, N2 M0 mc期* 任何T\n任何Top / 小狗科研公开::: 任何T IV 期 Ap d 19 [ 1 ] [ 1 ] e d by\n\n【3】 47 s\n\n【4】 e f\n 小狗科研公开课\n  d 19 (1) is\n\n【5】  小狗科研公开课\n 4 H 2 H 2 \n\n【6】 \n e\n\n【7】 90", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "", "bbox": [527.0, 6.0, 780.0, 118.0]}, {"text": "M0", "bbox": [571.0, 107.0, 608.0, 132.0]}], "type": "Text", "position": 0}, {"raw_context": [{"text": "e f", "bbox": [0.0, 270.0, 54.0, 314.0]}], "type": "Text", "position": 1}, {"raw_context": [{"text": "小狗科\t$79, 151 [ 4 ]\n ", "bbox": [23.0, 30.0, 353.0, 234.0]}, {"text": "N0", "bbox": [406.0, 107.0, 440.0, 131.0]}, {"text": "M0", "bbox": [571.0, 107.0, 608.0, 132.0]}, {"text": "小狗科研究\nNotes", "bbox": [355.0, 133.0, 539.0, 239.0]}, {"text": "M0", "bbox": [574.0, 147.0, 610.0, 173.0]}, {"text": "M0", "bbox": [549.0, 188.0, 586.0, 212.0]}, {"text": "l Mo", "bbox": [544.0, 214.0, 794.0, 325.0]}, {"text": "N2", "bbox": [436.0, 224.0, 472.0, 252.0]}, {"text": "IIIA期", "bbox": [158.0, 226.0, 222.0, 253.0]}, {"text": "T0, T1, T2", "bbox": [269.0, 228.0, 435.0, 252.0]}, {"text": "T3", "bbox": [265.0, 268.0, 295.0, 292.0]}, {"text": "N1, N2", "bbox": [406.0, 267.0, 486.0, 292.0]}, {"text": "小狗科 gramma", "bbox": [55.0, 283.0, 222.0, 351.0]}, {"text": "T4", "bbox": [268.0, 306.0, 300.0, 332.0]}, {"text": "NO, N1, N2", "bbox": [410.0, 306.0, 537.0, 333.0]}, {"text": "M0", "bbox": [595.0, 307.0, 631.0, 333.0]}, {"text": "mc期*", "bbox": [159.0, 335.0, 238.0, 373.0]}, {"text": "任何T\n任何Top / 小狗科研公开:::", "bbox": [272.0, 340.0, 581.0, 484.0]}, {"text": "任何T", "bbox": [269.0, 346.0, 335.0, 373.0]}, {"text": "IV 期", "bbox": [160.0, 385.0, 207.0, 413.0]}, {"text": "Ap", "bbox": [99.0, 419.0, 161.0, 490.0]}, {"text": "d 19 [ 1 ] [ 1 ]", "bbox": [166.0, 453.0, 344.0, 559.0]}, {"text": "e", "bbox": [676.0, 498.0, 741.0, 540.0]}, {"text": "d by", "bbox": [746.0, 512.0, 794.0, 555.0]}], "type": "Text", "position": 2}, {"raw_context": [{"text": "47 s", "bbox": [0.0, 496.0, 78.0, 554.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "e f", "bbox": [160.0, 557.0, 224.0, 611.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": "小狗科研公开课", "bbox": [232.0, 573.0, 412.0, 668.0]}], "type": "Formula", "position": 5}, {"raw_context": [{"text": "", "bbox": [452.0, 565.0, 533.0, 606.0]}, {"text": "d 19 (1) is", "bbox": [542.0, 581.0, 720.0, 687.0]}], "type": "Formula", "position": 6}, {"raw_context": [{"text": "", "bbox": [514.0, 677.0, 581.0, 723.0]}, {"text": "小狗科研公开课", "bbox": [578.0, 689.0, 768.0, 786.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "4 H 2 H 2", "bbox": [0.0, 755.0, 124.0, 818.0]}, {"text": "", "bbox": [136.0, 782.0, 508.0, 958.0]}], "type": "Formula", "position": 8}, {"raw_context": [{"text": "", "bbox": [514.0, 911.0, 794.0, 1061.0]}], "type": "Text", "position": 9}, {"raw_context": [{"text": "e", "bbox": [27.0, 1010.0, 90.0, 1054.0]}], "type": "Formula", "position": 10}, {"raw_context": [{"text": "90", "bbox": [400.0, 1093.0, 416.0, 1108.0]}], "type": "Text", "position": 12}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2022】全科室最全临床指南+专家共识（最全版）/2022全科室临床指南/肿瘤科/乳腺癌诊疗指南（2022年版）.pdf", "page_num": 90}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": null, "type3": null, "type4": null, "type5": null, "type6": "信息有用性#0#7#无用内容"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:41", "update_time": "2024-05-07 19:09:14"}
{"id": 1082585, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 738, "source_info": {"seq_id": "c7628c03-316a-42fc-897e-d22c153f4f9d", "title": null, "text": "【0】页码:2\n Grade of evidence: Low. Strength of recommendation: Strong.\n\n【1】Level of agreement: 100%\n\n【2】## Procedure Room Requirements\n\n【3】\n 10. We recommend that all patients undergoing gastrointestinal endoscopy (sedated or unsedated) have monitoring of pulse, blood pressure, oxygen saturations and respiration rates as a minimum before and after the procedure. We recommend supplemental oxygen where any level of sedation is used Grade of evidence: Very Low. Strength of recommendation: Strong.\n\n【4】Level of agreement: 100% 11. Electrocardiography (ECG) monitoring is not recommended routinely for patients requiring gastrointestinal endoscopy with minimal sedation.\n\n【5】Grade of evidence: Very Low. Strength of recommendation: Strong.\n\n【6】Level of agreement: 100% 12. We recommend that where the endoscopist–sedationist administers sedation and also performs the procedure, there must be at least an appropriately trained second member of the team monitoring the patient's status.\n\n【7】Grade of evidence: Low. Strength of recommendation: Strong.\n\n【8】Level of agreement: 100% 13. We recommend that an accurate, contemporaneous record of all drugs is completed and becomes part of the patient record and endoscopy report. This should include additional drugs (eg, hyoscine) used to assist endoscopy.\n\n【9】Grade of evidence: Very Low. Strength of recommendation: Strong.\n\n【10】Level of agreement: 100% 14. We recommend that for patients undergoing endoscopy under deep sedation (propofol) or general anaesthetic, ECG, automated non-invasive blood pressure, capnography and core body temperature should be monitored and recorded.\n\n【11】Grade of evidence: Low. Strength of recommendation: Strong.\n\n【12】Level of agreement: 100%\n\n【13】## Sedation Protocol\n\n【14】\n 15. We recommend governance oversight of the process of sedation for endoscopy.\n\n【15】Grade of evidence: Very Low. Strength of recommendation: Strong.\n\n【16】Level of agreement: 92.3%\n\n【17】## Recovery And Discharge\n\n【18】\n 16. We recommend that monitoring of sedation should extend into the recovery period until the patient's conscious state has consistently returned to baseline. This requires sufficient staff trained in sedation, monitoring and the recognition of complications.\n\n【19】Grade of evidence: Very Low. Strength of recommendation: Strong.\n\n【20】Level of agreement: 100% 17. We recommend that the endoscopist–sedationist should be responsible for ensuring the safe and complete recovery of the patient after endoscopy.\n\n【21】Grade of evidence: Very Low. Strength of recommendation: Strong.\n\n【22】Level of agreement: 100% 18. We recommend that patients should be formally assessed for suitability for discharge. This should be documented\n\n【23】 to demonstrate recovery from sedation and the absence of complications.\n\n【24】Grade of evidence: Very Low. Strength of recommendation: Strong.\n\n【25】Level of agreement: 100% 19. We recommend that patients receiving sedation and/ or analgesia for endoscopy should not drive a vehicle or ride a bicycle, operate machinery, sign legal documents or make important decisions, or drink alcohol for 24 hours after the procedure.\n\n【26】Grade of evidence: Very Low. Strength of recommendation: Strong.\n\n【27】Level of agreement: 92.3% 20. We recommend that all patients and any carers providing support after the procedure should receive clear instructions and advice for late recovery, in verbal and written form that includes contact information.\n\n【28】Grade of evidence: Very Low. Strength of recommendation: Strong.\n\n【29】Level of agreement: 100%\n\n【30】## Complications Related To Sedation And Reversal Agents\n\n【31】\n 21. In patients with opiate or benzodiazepine-induced respiratory depression during or following endoscopy, we recommend the use of a relevant reversal agent.\n\n【32】Grade of evidence: Low. Strength of recommendation: Strong.\n\n【33】Level of agreement: 92.3% 22. We recommend that only low-strength midazolam (1 mg/ mL) is stocked and used instead of high-strength midazolam to reduce the risk of adverse events related to oversedation.\n\n【34】Grade of evidence: Very Low. Strength of recommendation: Strong.\n\n【35】Level of agreement: 92.3% 23. We recommend that all endoscopy rooms (or units) stock flumazenil and naloxone; and all endoscopy clinical staff should be aware of where they are stored and how to access them in case of sedation-related emergencies.\n\n【36】Grade of evidence: Very Low. Strength of recommendation: Strong .\n\n【37】Level of agreement: 100%\n\n【38】 24. We recommend that all cases of benzodiazepine or opiate toxicity, requiring the use of reversal should be reported through local incident reporting systems, and any lessons learnt disseminated.\n\n【39】Grade of evidence: Very Low. Strength of recommendation: Strong.\n\n【40】Level of agreement: 100% 25. We do not recommend routine benzodiazepine reversal after gastrointestinal endoscopy in patients receiving conscious sedation with a benzodiazepine.\n\n【41】Grade of evidence: Moderate. Strength of recommendation: Strong.\n\n【42】Level of agreement: 100%\n\n【43】## Special Considerations: Emergency Endoscopy In The Sick Patient\n\n【44】\n 26. In the critically ill patient requiring emergency endoscopy, we recommend discussion with the anaesthetic team about the choice of sedation technique and the appropriateness of escalation to critical care.\n\n【45】Grade of evidence: Low. Strength of recommendation: Strong.\n\n【46】Level of agreement: 100% Sidhu R, et al. Gut 2023;0:1–27. doi:10.1136/gutjnl-2023-330396", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "Grade of evidence: Low. Strength of recommendation: Strong.", "bbox": [65.0, 60.0, 383.0, 75.0]}, {"text": "Level of agreement: 100%", "bbox": [65.0, 76.0, 205.0, 90.0]}], "type": "Text", "position": 1}, {"raw_context": [{"text": "Procedure room requirements", "bbox": [53.0, 115.0, 215.0, 129.0]}], "type": "Section-header", "position": 2}, {"raw_context": [{"text": "10. We recommend that all patients undergoing gastrointes-", "bbox": [54.0, 130.0, 385.0, 144.0]}, {"text": "tinal endoscopy (sedated or unsedated) have monitoring of", "bbox": [54.0, 145.0, 386.0, 158.0]}, {"text": "pulse, blood pressure, oxygen saturations and respiration rates", "bbox": [53.0, 159.0, 386.0, 173.0]}, {"text": "as a minimum before and after the procedure. We recommend", "bbox": [53.0, 173.0, 386.0, 188.0]}, {"text": "supplemental oxygen where any level of sedation is used", "bbox": [53.0, 188.0, 349.0, 202.0]}, {"text": "Grade of evidence: Very Low. Strength of recommendation:", "bbox": [64.0, 203.0, 385.0, 217.0]}, {"text": "Strong.", "bbox": [54.0, 220.0, 91.0, 232.0]}, {"text": "Level of agreement: 100%", "bbox": [64.0, 232.0, 203.0, 246.0]}, {"text": "11. Electrocardiography (ECG) monitoring is not recom-", "bbox": [66.0, 247.0, 385.0, 262.0]}, {"text": "mended routinely for patients requiring gastrointestinal endos-", "bbox": [53.0, 262.0, 385.0, 277.0]}, {"text": "copy with minimal sedation.", "bbox": [53.0, 277.0, 203.0, 291.0]}, {"text": "Grade of evidence: Very Low. Strength of recommendation:", "bbox": [64.0, 292.0, 386.0, 306.0]}, {"text": "Strong.", "bbox": [53.0, 307.0, 91.0, 320.0]}, {"text": "Level of agreement: 100%", "bbox": [65.0, 321.0, 203.0, 334.0]}, {"text": "12. We recommend that where the endoscopist–sedationist", "bbox": [66.0, 335.0, 387.0, 349.0]}, {"text": "administers sedation and also performs the procedure, there", "bbox": [53.0, 350.0, 386.0, 364.0]}, {"text": "must be at least an appropriately trained second member of the", "bbox": [53.0, 364.0, 386.0, 379.0]}, {"text": "team monitoring the patient's status.", "bbox": [53.0, 380.0, 243.0, 393.0]}, {"text": "Grade of evidence: Low. Strength of recommendation: Strong.", "bbox": [65.0, 394.0, 383.0, 408.0]}, {"text": "Level of agreement: 100%", "bbox": [65.0, 409.0, 203.0, 422.0]}, {"text": "13. We recommend that an accurate, contemporaneous record", "bbox": [66.0, 423.0, 387.0, 437.0]}, {"text": "of all drugs is completed and becomes part of the patient record", "bbox": [53.0, 438.0, 386.0, 451.0]}, {"text": "and endoscopy report. This should include additional drugs (eg,", "bbox": [53.0, 452.0, 386.0, 467.0]}, {"text": "hyoscine) used to assist endoscopy.", "bbox": [53.0, 467.0, 234.0, 481.0]}, {"text": "Grade of evidence: Very Low. Strength of recommendation:", "bbox": [64.0, 482.0, 385.0, 496.0]}, {"text": "Strong.", "bbox": [54.0, 498.0, 91.0, 510.0]}, {"text": "Level of agreement: 100%", "bbox": [65.0, 511.0, 203.0, 525.0]}, {"text": "14. We recommend that for patients undergoing endoscopy", "bbox": [66.0, 526.0, 385.0, 540.0]}, {"text": "under deep sedation (propofol) or general anaesthetic, ECG,", "bbox": [53.0, 540.0, 385.0, 555.0]}, {"text": "automated non-invasive blood pressure, capnography and core", "bbox": [53.0, 555.0, 386.0, 570.0]}, {"text": "body temperature should be monitored and recorded.", "bbox": [53.0, 570.0, 334.0, 585.0]}, {"text": "Grade of evidence: Low. Strength of recommendation: Strong.", "bbox": [64.0, 585.0, 384.0, 599.0]}, {"text": "Level of agreement: 100%", "bbox": [65.0, 600.0, 203.0, 614.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "Sedation protocol", "bbox": [53.0, 638.0, 152.0, 652.0]}], "type": "Section-header", "position": 4}, {"raw_context": [{"text": "15. We recommend governance oversight of the process of seda-", "bbox": [54.0, 653.0, 385.0, 668.0]}, {"text": "tion for endoscopy.", "bbox": [53.0, 668.0, 156.0, 682.0]}, {"text": "Grade of evidence: Very Low. Strength of recommendation:", "bbox": [64.0, 682.0, 386.0, 697.0]}, {"text": "Strong.", "bbox": [54.0, 698.0, 91.0, 711.0]}, {"text": "Level of agreement: 92.3%", "bbox": [64.0, 713.0, 207.0, 727.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "Recovery and discharge", "bbox": [53.0, 751.0, 183.0, 765.0]}], "type": "Section-header", "position": 6}, {"raw_context": [{"text": "16. We recommend that monitoring of sedation should extend", "bbox": [54.0, 766.0, 386.0, 781.0]}, {"text": "into the recovery period until the patient's conscious state", "bbox": [53.0, 781.0, 386.0, 795.0]}, {"text": "has consistently returned to baseline. This requires sufficient", "bbox": [53.0, 796.0, 386.0, 810.0]}, {"text": "staff trained in sedation, monitoring and the recognition of", "bbox": [53.0, 811.0, 386.0, 825.0]}, {"text": "complications.", "bbox": [54.0, 826.0, 131.0, 839.0]}, {"text": "Grade of evidence: Very Low. Strength of recommendation:", "bbox": [64.0, 839.0, 385.0, 854.0]}, {"text": "Strong.", "bbox": [54.0, 856.0, 92.0, 867.0]}, {"text": "Level of agreement: 100%", "bbox": [64.0, 868.0, 203.0, 882.0]}, {"text": "17. We recommend that the endoscopist–sedationist should be", "bbox": [66.0, 883.0, 387.0, 898.0]}, {"text": "responsible for ensuring the safe and complete recovery of the", "bbox": [53.0, 898.0, 387.0, 913.0]}, {"text": "patient after endoscopy.", "bbox": [54.0, 914.0, 178.0, 926.0]}, {"text": "Grade of evidence: Very Low. Strength of recommendation:", "bbox": [64.0, 928.0, 386.0, 941.0]}, {"text": "Strong.", "bbox": [54.0, 944.0, 91.0, 956.0]}, {"text": "Level of agreement: 100%", "bbox": [65.0, 957.0, 203.0, 970.0]}, {"text": "18. We recommend that patients should be formally assessed", "bbox": [66.0, 971.0, 387.0, 985.0]}, {"text": "for suitability for discharge. This should be documented", "bbox": [53.0, 987.0, 387.0, 1000.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "to demonstrate recovery from sedation and the absence of", "bbox": [406.0, 60.0, 740.0, 75.0]}, {"text": "complications.", "bbox": [406.0, 77.0, 484.0, 90.0]}, {"text": "Grade of evidence: Very Low. Strength of recommendation:", "bbox": [417.0, 91.0, 739.0, 105.0]}, {"text": "Strong.", "bbox": [406.0, 107.0, 445.0, 119.0]}, {"text": "Level of agreement: 100%", "bbox": [418.0, 120.0, 557.0, 135.0]}, {"text": "19. We recommend that patients receiving sedation and/", "bbox": [419.0, 135.0, 740.0, 150.0]}, {"text": "or analgesia for endoscopy should not drive a vehicle or ride", "bbox": [406.0, 150.0, 740.0, 165.0]}, {"text": "a bicycle, operate machinery, sign legal documents or make", "bbox": [406.0, 165.0, 740.0, 179.0]}, {"text": "important decisions, or drink alcohol for 24 hours after the", "bbox": [406.0, 180.0, 740.0, 194.0]}, {"text": "procedure.", "bbox": [406.0, 195.0, 465.0, 209.0]}, {"text": "Grade of evidence: Very Low. Strength of recommendation:", "bbox": [418.0, 209.0, 740.0, 224.0]}, {"text": "Strong.", "bbox": [406.0, 225.0, 443.0, 238.0]}, {"text": "Level of agreement: 92.3%", "bbox": [418.0, 239.0, 559.0, 253.0]}, {"text": "20. We recommend that all patients and any carers providing", "bbox": [418.0, 254.0, 740.0, 267.0]}, {"text": "support after the procedure should receive clear instructions and", "bbox": [406.0, 269.0, 741.0, 282.0]}, {"text": "advice for late recovery, in verbal and written form that includes", "bbox": [406.0, 283.0, 741.0, 298.0]}, {"text": "contact information.", "bbox": [406.0, 298.0, 515.0, 311.0]}, {"text": "Grade of evidence: Very Low. Strength of recommendation:", "bbox": [418.0, 313.0, 739.0, 326.0]}, {"text": "Strong.", "bbox": [406.0, 329.0, 445.0, 341.0]}, {"text": "Level of agreement: 100%", "bbox": [418.0, 343.0, 557.0, 355.0]}], "type": "Text", "position": 8}, {"raw_context": [{"text": "Complications related to sedation and reversal agents", "bbox": [406.0, 383.0, 698.0, 398.0]}], "type": "Section-header", "position": 9}, {"raw_context": [{"text": "21. In patients with opiate or benzodiazepine-induced respira-", "bbox": [406.0, 398.0, 739.0, 412.0]}, {"text": "tory depression during or following endoscopy, we recommend", "bbox": [406.0, 413.0, 740.0, 427.0]}, {"text": "the use of a relevant reversal agent.", "bbox": [406.0, 428.0, 590.0, 442.0]}, {"text": "Grade of evidence: Low. Strength of recommendation: Strong.", "bbox": [418.0, 442.0, 737.0, 457.0]}, {"text": "Level of agreement: 92.3%", "bbox": [418.0, 458.0, 561.0, 471.0]}, {"text": "22. We recommend that only low-strength midazolam (1 mg/", "bbox": [419.0, 471.0, 739.0, 486.0]}, {"text": "mL) is stocked and used instead of high-strength midazolam to", "bbox": [406.0, 487.0, 740.0, 500.0]}, {"text": "reduce the risk of adverse events related to oversedation.", "bbox": [406.0, 502.0, 703.0, 515.0]}, {"text": "Grade of evidence: Very Low. Strength of recommendation:", "bbox": [418.0, 516.0, 740.0, 531.0]}, {"text": "Strong.", "bbox": [407.0, 531.0, 446.0, 546.0]}, {"text": "Level of agreement: 92.3%", "bbox": [418.0, 546.0, 560.0, 560.0]}, {"text": "23. We recommend that all endoscopy rooms (or units) stock", "bbox": [418.0, 561.0, 740.0, 574.0]}, {"text": "flumazenil and naloxone; and all endoscopy clinical staff should", "bbox": [406.0, 575.0, 741.0, 589.0]}, {"text": "be aware of where they are stored and how to access them in", "bbox": [405.0, 590.0, 741.0, 604.0]}, {"text": "case of sedation-related emergencies.", "bbox": [405.0, 603.0, 598.0, 620.0]}, {"text": "Grade of evidence: Very Low. Strength of recommendation:", "bbox": [418.0, 619.0, 740.0, 633.0]}, {"text": "Strong .", "bbox": [406.0, 636.0, 444.0, 648.0]}, {"text": "Level of agreement: 100%", "bbox": [418.0, 649.0, 556.0, 663.0]}], "type": "Text", "position": 10}, {"raw_context": [{"text": "24. We recommend that all cases of benzodiazepine or", "bbox": [418.0, 663.0, 739.0, 677.0]}, {"text": "opiate toxicity, requiring the use of reversal should be reported", "bbox": [405.0, 678.0, 741.0, 693.0]}, {"text": "through local incident reporting systems, and any lessons learnt", "bbox": [406.0, 693.0, 741.0, 707.0]}, {"text": "disseminated.", "bbox": [406.0, 709.0, 478.0, 721.0]}, {"text": "Grade of evidence: Very Low. Strength of recommendation:", "bbox": [418.0, 722.0, 740.0, 736.0]}, {"text": "Strong.", "bbox": [406.0, 739.0, 445.0, 751.0]}, {"text": "Level of agreement: 100%", "bbox": [418.0, 752.0, 557.0, 766.0]}, {"text": "25. We do not recommend routine benzodiazepine reversal", "bbox": [418.0, 766.0, 741.0, 781.0]}, {"text": "after gastrointestinal endoscopy in patients receiving conscious", "bbox": [406.0, 782.0, 740.0, 796.0]}, {"text": "sedation with a benzodiazepine.", "bbox": [406.0, 797.0, 574.0, 811.0]}, {"text": "Grade of evidence: Moderate. Strength of recommendation:", "bbox": [418.0, 811.0, 739.0, 826.0]}, {"text": "Strong.", "bbox": [407.0, 827.0, 445.0, 841.0]}, {"text": "Level of agreement: 100%", "bbox": [418.0, 841.0, 557.0, 856.0]}], "type": "Text", "position": 11}, {"raw_context": [{"text": "Special considerations: emergency endoscopy in the sick", "bbox": [406.0, 882.0, 710.0, 896.0]}, {"text": "patient", "bbox": [406.0, 897.0, 449.0, 911.0]}], "type": "Section-header", "position": 12}, {"raw_context": [{"text": "26. In the critically ill patient requiring emergency endoscopy,", "bbox": [407.0, 912.0, 740.0, 926.0]}, {"text": "we recommend discussion with the anaesthetic team about the", "bbox": [406.0, 927.0, 740.0, 941.0]}, {"text": "choice of sedation technique and the appropriateness of escala-", "bbox": [406.0, 942.0, 739.0, 955.0]}, {"text": "tion to critical care.", "bbox": [406.0, 957.0, 509.0, 970.0]}, {"text": "Grade of evidence: Low. Strength of recommendation: Strong.", "bbox": [418.0, 971.0, 737.0, 986.0]}, {"text": "Level of agreement: 100%", "bbox": [418.0, 986.0, 557.0, 1000.0]}, {"text": "Sidhu R, et al. Gut 2023;0:1–27. doi:10.1136/gutjnl-2023-330396", "bbox": [477.0, 1008.0, 739.0, 1022.0]}], "type": "Text", "position": 13}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/消化科/_2023 BSG指南：胃肠内窥镜检查中的镇静.pdf", "page_num": 2}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "缺少换行#4#4# 11. Electrocardiography 这里开始换行\n缺少换行#6#6#12. We recommend that where这里开始换行\n缺少换行#8#8#13. We recommend that an accurate这里开始换行\n缺少换行#10#10#14. We recommend that for patients 这里开始换行\n缺少换行#20#20#17. We recommend that the 这里开始应换行\n缺少换行#22#22#18. We recommend that patients这里开始应换行\n多余换行#22#23#为同段\n缺少换行#25#25#19. We recommend that patients这里开始应换行\n缺少换行#27#27#20. We recommend that all这里开始应换行\n缺少换行#33#33# 22. We recommend that 这里开始应换行\n缺少换行#35#35# 23. We recommend that 这里开始应换行\n缺少换行#40#40#25. We do not recommend 这里开始应换行", "type3": "页脚#46#46#Sidhu R, et al. Gut 2023;0:1–27. doi:10.1136/gutjnl-2023-330396", "type4": null, "type5": null, "type6": null}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:41", "update_time": "2024-05-07 19:49:05"}
{"id": 1082584, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 738, "source_info": {"seq_id": "f515ca3d-e629-4696-b8bf-0ab1dcbf43bf", "title": null, "text": "【0】页码:37\n o\n\n【1】 allergies\n\n【2】 o\n\n【3】 current medication\n\n【4】 o\n\n【5】 tobacco, alcohol, and drug consumption\n\n【6】 assessment of correct preparation (e.g., adequate duration of fasting before a o procedure or adequate preparation for colonoscopy)\n\n【7】 .\n\n【8】 Identify high risk situations that require the presence of an anesthesiologist. This includes:\n\n【9】 o\n\n【10】 high ASA grade (III–IV) and a difficult endoscopic intervention\n\n【11】 presence of pathological or anatomical features associated with a higher risk of airway o obstruction during the intervention (for example:\n\n【12】 .\n\n【13】 a history of stridor, snoring or sleep apnoea\n\n【14】 .\n\n【15】 patients with dysmorphic facial features [e.g., trisomy 21] or oral abnormalities such as small opening [i.e., <3 cm in an adult], high arched palate, macroglossia, tonsillar hypertrophy, or a nonvisible uvula\n\n【16】 .\n\n【17】 patients with neck abnormalities, such as obesity, trauma, tracheal deviation, or advanced rheumatoid arthritis\n\n【18】 .\n\n【19】 patients with jaw abnormalities such as micrognathia, retrognathia, trismus or significant malocclusion)\n\n【20】 patients receiving significant amounts of chronic pain medication or who for other o reasons may have a high tolerance to agents used during sedation and analgesia.\n\n【21】 .\n\n【22】 Critically judge their own limitations concerning knowledge and skills in sedation in gastrointestinal endoscopy\n\n【23】 .\n\n【24】 Prepare the patient according to the planned procedure (e.g., correct positioning)\n\n【25】 .\n\n【26】 Prepare the appropriate standard monitoring equipment (pulse oximetry and non-invasive blood pressure measurement for all patients undergoing sedation, electrocardiography [ECG] for patients with a history of cardiac and/or pulmonary disease)", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "o", "bbox": [184.0, 145.0, 199.0, 156.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "allergies", "bbox": [204.0, 142.0, 255.0, 157.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": "o", "bbox": [184.0, 181.0, 197.0, 192.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "current medication", "bbox": [204.0, 178.0, 314.0, 192.0]}], "type": "Text", "position": 6}, {"raw_context": [{"text": "o", "bbox": [184.0, 217.0, 197.0, 228.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "tobacco, alcohol, and drug consumption", "bbox": [204.0, 214.0, 426.0, 228.0]}], "type": "Text", "position": 8}, {"raw_context": [{"text": "assessment of correct preparation (e.g., adequate duration of fasting before a", "bbox": [204.0, 250.0, 631.0, 266.0]}, {"text": "o", "bbox": [184.0, 254.0, 197.0, 265.0]}, {"text": "procedure or adequate preparation for colonoscopy)", "bbox": [205.0, 275.0, 495.0, 290.0]}], "type": "Text", "position": 9}, {"raw_context": [{"text": ".", "bbox": [142.0, 313.0, 152.0, 325.0]}], "type": "Text", "position": 10}, {"raw_context": [{"text": "Identify high risk situations that require the presence of an anesthesiologist. This includes:", "bbox": [161.0, 311.0, 650.0, 326.0]}], "type": "Text", "position": 11}, {"raw_context": [{"text": "o", "bbox": [184.0, 350.0, 198.0, 361.0]}], "type": "Text", "position": 12}, {"raw_context": [{"text": "high ASA grade (III–IV) and a difficult endoscopic intervention", "bbox": [203.0, 347.0, 543.0, 361.0]}], "type": "Text", "position": 13}, {"raw_context": [{"text": "presence of pathological or anatomical features associated with a higher risk of airway", "bbox": [204.0, 382.0, 673.0, 397.0]}, {"text": "o", "bbox": [184.0, 386.0, 197.0, 398.0]}, {"text": "obstruction during the intervention (for example:", "bbox": [205.0, 408.0, 474.0, 422.0]}], "type": "Text", "position": 14}, {"raw_context": [{"text": ".", "bbox": [227.0, 445.0, 240.0, 457.0]}], "type": "Text", "position": 15}, {"raw_context": [{"text": "a history of stridor, snoring or sleep apnoea", "bbox": [248.0, 444.0, 488.0, 459.0]}], "type": "Text", "position": 16}, {"raw_context": [{"text": ".", "bbox": [227.0, 481.0, 239.0, 493.0]}], "type": "Text", "position": 17}, {"raw_context": [{"text": "patients with dysmorphic facial features [e.g., trisomy 21] or oral abnormalities", "bbox": [248.0, 479.0, 680.0, 495.0]}, {"text": "such as small opening [i.e., <3 cm in an adult], high arched palate, macroglossia,", "bbox": [248.0, 504.0, 684.0, 520.0]}, {"text": "tonsillar hypertrophy, or a nonvisible uvula", "bbox": [248.0, 528.0, 484.0, 543.0]}], "type": "Text", "position": 18}, {"raw_context": [{"text": ".", "bbox": [227.0, 564.0, 238.0, 578.0]}], "type": "Text", "position": 19}, {"raw_context": [{"text": "patients with neck abnormalities, such as obesity, trauma, tracheal deviation, or", "bbox": [248.0, 563.0, 683.0, 579.0]}, {"text": "advanced rheumatoid arthritis", "bbox": [248.0, 587.0, 418.0, 603.0]}], "type": "Text", "position": 20}, {"raw_context": [{"text": ".", "bbox": [227.0, 626.0, 239.0, 638.0]}], "type": "Text", "position": 21}, {"raw_context": [{"text": "patients with jaw abnormalities such as micrognathia, retrognathia, trismus or", "bbox": [248.0, 625.0, 673.0, 639.0]}, {"text": "significant malocclusion)", "bbox": [248.0, 649.0, 385.0, 664.0]}], "type": "Text", "position": 22}, {"raw_context": [{"text": "patients receiving significant amounts of chronic pain medication or who for other", "bbox": [204.0, 685.0, 651.0, 699.0]}, {"text": "o", "bbox": [183.0, 688.0, 197.0, 700.0]}, {"text": "reasons may have a high tolerance to agents used during sedation and analgesia.", "bbox": [205.0, 709.0, 643.0, 724.0]}], "type": "Text", "position": 23}, {"raw_context": [{"text": ".", "bbox": [141.0, 747.0, 153.0, 759.0]}], "type": "Text", "position": 24}, {"raw_context": [{"text": "Critically judge their own limitations concerning knowledge and skills in sedation in", "bbox": [161.0, 745.0, 612.0, 759.0]}, {"text": "gastrointestinal endoscopy", "bbox": [161.0, 770.0, 311.0, 784.0]}], "type": "Text", "position": 25}, {"raw_context": [{"text": ".", "bbox": [141.0, 808.0, 153.0, 820.0]}], "type": "Text", "position": 26}, {"raw_context": [{"text": "Prepare the patient according to the planned procedure (e.g., correct positioning)", "bbox": [161.0, 806.0, 607.0, 821.0]}], "type": "Text", "position": 27}, {"raw_context": [{"text": ".", "bbox": [141.0, 843.0, 153.0, 857.0]}], "type": "Text", "position": 28}, {"raw_context": [{"text": "Prepare the appropriate standard monitoring equipment (pulse oximetry and non-invasive", "bbox": [161.0, 841.0, 652.0, 857.0]}, {"text": "blood pressure measurement for all patients undergoing sedation, electrocardiography [ECG]", "bbox": [161.0, 865.0, 668.0, 881.0]}, {"text": "for patients with a history of cardiac and/or pulmonary disease)", "bbox": [162.0, 890.0, 509.0, 905.0]}], "type": "Text", "position": 29}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/消化科/_2023 BSG指南：胃肠内窥镜检查中的镇静.pdf", "page_num": 37}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "多余换行#0#5#0段序号o对于1段allergies内容，依次往下\n序号格式不一致#6#6#前面缺少序号o\n多余换行#10#10# high ASA grade...与上面9段序号联接\n序号格式不一致#11#11#前面缺少序号o\n多余换行#12#19#12段序号 .对于13段a history of stridor,内容，依次往下。但是序号都提取错误，应该是▪\n序号格式不一致#20#20#前面缺少序号o\n多余换行#21#26#21段序号 .对于22段Critically judge their own ...内容，依次往下。但是序号都提取错误，应该是▪", "type3": "无关文本#7#7#  .", "type4": null, "type5": null, "type6": null}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:41", "update_time": "2024-05-07 18:23:02"}
{"id": 1082583, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 738, "source_info": {"seq_id": "4575980c-6da1-4e16-aaad-ab0386327825", "title": null, "text": "【0】页码:12\n [76] Fankhauser CD, Lee EWC, Issa A, et al. Saphenous-sparing ascending video endoscopic inguinal lymph node dissection using a leg approach: surgical technique and perioperative and pathological outcomes. Eur Urol Open Sci 2022;35:9–13 .\n\n【1】[77] Wang S, Du P, Tang X, An C, Zhang N, Yang Y. Comparison of efficiency of video endoscopy and open inguinal lymph node dissection. Anticancer Res 2017;37:4623–8 .\n\n【2】[78] Shao Y, Hu X, Ren S, et al. Comparison of different surgical methods and strategies for inguinal lymph node dissection in patients with penile cancer. Sci Rep 2022;12:2560 .\n\n【3】[79] Chipollini J, Tang DH, Gilbert SM, et al. Delay to inguinal lymph node dissection greater than 3 months predicts poorer recurrencefree survival for patients with penile cancer. J Urol 2017; 198:1346–52 .\n\n【4】[80] Lont AP, Kroon BK, Gallee MP, van Tinteren H, Moonen LM, Horenblas S. Pelvic lymph node dissection for penile carcinoma: extent of inguinal lymph node involvement as an indicator for pelvic lymph node involvement and survival. J Urol 2007;177:947–52 .\n\n【5】[81] Liu JY, Li YH, Zhang ZL, et al. The risk factors for the presence of pelvic lymph node metastasis in penile squamous cell carcinoma patients with inguinal lymph node dissection. World J Urol 2013;31:1519–24 .\n\n【6】[82] Djajadiningrat RS, van Werkhoven E, Horenblas S. Prophylactic pelvic lymph node dissection in patients with penile cancer. J Urol 2015; 193:1976–80 .\n\n【7】[83] Lughezzani G, Catanzaro M, Torelli T, et al. The relationship between characteristics of inguinal lymph nodes and pelvic lymph node involvement in penile squamous cell carcinoma: a single institution experience. J Urol 2014;191:977–82 .\n\n【8】[84] Li ZS, Deng CZ, Yao K, et al. Bilateral pelvic lymph node dissection for Chinese patients with penile cancer: a multicenter collaboration study. J Cancer Res Clin Oncol 2017;143:329–35 .\n\n【9】[85] Jaipuria J, Kohli T, Venkatasubramaniyan M, et al. Adjuvant radiation compares favorably to chemotherapy in patients with carcinoma penis and nodal positivity restricted to groin. Urol Oncol 2020;38:641.e9–e18 .\n\n【10】[86] Ager M, Njoku K, Serra M, et al. Long-term multicentre experience of adjuvant radiotherapy for pN3 squamous cell carcinoma of the penis. BJU Int 2021;128:451–9 .\n\n【11】[87] Maibom SL, Jakobsen JK, Aagaard M, Als AB, Petersen PM. DaPeCa- 4: outcome in penile cancer patients with N3 disease due to extra nodal extension treated with surgery and chemo-irradiation.\n\n【12】Scand J Urol 2020;54:334–8 .\n\n【13】[88] Paz Rojas JF, Ballestas Almario CA, García-Perdomo HA.\n\n【14】Effectiveness and safety of adjuvant chemotherapy compared to neoadjuvant chemotherapy in patients with penile cancer and positive lymph nodes regarding overall survival and free disease survival: a systematic review and meta-analysis. Urol Oncol 2022;40:200.e11–e18 .\n\n【15】[89] Alnajjar HM, MacAskill F, Christodoulidou M, et al. Long-term outcomes for penile cancer patients presenting with advanced N3 disease requiring a myocutaneous flap reconstruction or primary closure-a retrospective single centre study. Transl Androl Urol 2019;8:S13–21 .\n\n【16】[90] Koifman L, Hampl D, Ginsberg M, et al. The role of primary inguinal surgical debulking for locally advanced penile cancer followed by reconstruction with myocutaneous flap. Int Braz J Urol 2021;47:1162–75 .\n\n【17】[91] Azizi M, Aydin AM, Hajiran A, et al. Systematic review and metaanalysis—is there a benefit in using neoadjuvant systemic chemotherapy for locally advanced penile squamous cell carcinoma? J Urol 2020;203:1147-55 .\n\n【18】[92] Djajadiningrat RS, Bergman AM, van Werkhoven E, Vegt E, Horenblas       S.        Neoadjuvant      taxane-based      combination chemotherapy in patients with advanced penile cancer. Clin Genitourin Cancer 2015;13:44–9 .\n\n【19】[93] Pagliaro LC, Williams DL, Daliani D, et al. Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. J Clin Oncol 2010;28:3851–7 .\n\n【20】[94] Nicholson S, Hall E, Harland SJ, et al. Phase II trial of docetaxel, cisplatin and 5FU chemotherapy in locally advanced and metastatic penis cancer (CRUK/09/001).\n\n【21】Br 1990.\n\n【22】Cancer 2013;109:2554–9 .\n\n【23】 [95] Zhang S, Zhu Y, Ye D. Phase II study of docetaxel, cisplatin, and fluorouracil in patients with distantly metastatic penile cancer as first-line chemotherapy. Oncotarget 2015;6:32212–9 .\n\n【24】[96] Di Lorenzo G, Buonerba C, Federico P, et al. Cisplatin and 5– fluorouracil in inoperable, stage IV squamous cell carcinoma of the penis. BJU Int 2012;110:E661–6 .\n\n【25】[97] Di Lorenzo G, Federico P, Buonerba C, et al. paclitaxel in pretreated metastatic penile cancer: final results of a phase 2 study. Eur Urol 2011;60:1280–4 .\n\n【26】[98] Noronha V, Patil V, Ostwal V, Tongaonkar H, Bakshi G, Prabhash K.\n\n【27】Role of paclitaxel and platinum-based adjuvant chemotherapy in high-risk penile cancer. Urol Ann 2012;4:150–3 .\n\n【28】[99] Bermejo C, Busby JE, Spiess PE, Heller L, Pagliaro LC, Pettaway CA.\n\n【29】Neoadjuvant chemotherapy followed by aggressive surgical consolidation for metastatic penile squamous cell carcinoma. J Urol 2007;177:1335–8 .\n\n【30】[100] Joshi VB, Spiess PE, Necchi A, Pettaway CA, Chahoud J. Immunebased therapies in penile cancer. Nat Rev Urol 2022;19:457–74 .\n\n【31】[101] Pouessel D, Beylot-Barry M, Esma SB, et al. 715P Nivolumab in pretreated metastatic penile squamous cell carcinoma: results of the penile cohort from the French AcSé prospective program. Ann Oncol 2021;32:S720 .\n\n【32】[102] de Vries HM, Feijter JD, Bekers E, et al. Clinical results of PERICLES: a phase II trial investigating atezolizumab ± radiotherapy for advanced squamous cell carcinoma of the penis. J Clin Oncol 2022;40(6 Suppl):3 .\n\n【33】[103] Brown A, Ma Y, Danenberg K, et al. Epidermal growth factor receptor-targeted therapy in squamous cell carcinoma of the penis: a report of 3 cases. Urology 2014;83:159–65 .\n\n【34】[104] Carthon BC, Ng CS, Pettaway CA, Pagliaro LC. Epidermal growth factor receptor- targeted therapy in locally advanced or metastatic squamous cell carcinoma of the penis. BJU Int 2014;113:871–7 .\n\n【35】[105] Necchi A, Nicolai N, Colecchia M, et al. Proof of activity of antiepidermal growth factor receptor-targeted therapy for relapsed squamous cell carcinoma of the penis. J Clin Oncol 2011;29: e650–2 .\n\n【36】[106] Necchi A, Lo Vullo S, Perrone F, et al. First-line therapy with dacomitinib, an orally available pan-HER tyrosine kinase inhibitor, for locally advanced or metastatic penile squamous cell carcinoma: results of an open-label, single-arm, single-centre, phase 2 study. BJU Int 2018;121:348–56 .\n\n【37】[107] Lutz ST, Jones J, Chow E. Role of radiation therapy in palliative care of the patient with cancer. J Clin Oncol 2014;32:2913–9 .\n\n【38】[108] Leijte JA, Kirrander P, Antonini N, Windahl T, Horenblas S.\n\n【39】Recurrence patterns of squamous cell carcinoma of the penis: recommendations for follow-up based on a two-centre analysis of 700 patients. Eur Urol 2008;54:161–8 .\n\n【40】[109] Ager M, Manjunath A, Yan S, et al. MP49-15 Surveillance CT algorithm for node positive squamous cell carcinoma of the penis.\n\n【41】J Urol 2019;201:e711 .\n\n【42】[110] Arora A, Prakash G, Pal M, et al. A0694 - Patterns of recurrence in penile cancer: implications for surveillance strategies. Eur Urol 2022;81:S1033 .\n\n【43】[111] Chakiryan NH, Dahmen A, Bandini M, et al. Patterns of recurrence following inguinal lymph node dissection for penile cancer: optimizing surveillance strategies. J Urol 2021;206:960–9 .\n\n【44】[112] Pérez J, Chavarriaga J, Ortiz A, et al. Oncological and functional outcomes after organ-sparing plastic reconstructive surgery for penile cancer. Urology 2020;142:161–165.e1 .\n\n【45】[113] Gambachidze D, Lebacle C, Maroun P, et al. Long-term evaluation of urinary, sexual, and quality of life outcomes after brachytherapy for penile carcinoma.\n\n【46】Brachytherapy 2018; 17:221–6 .\n\n【47】[114] Draeger DL, Sievert KD, Hakenberg OW. Cross-sectional patientreported outcome measuring of health-related quality of life with establishment of cancer- and treatment-specific functional and symptom scales in patients with penile cancer. Clin Genitourin Cancer 2018;16:e1215–20 .\n\n【48】[115] Kieffer JM, Djajadiningrat RS, van Muilekom EA, Graafland NM, Horenblas S, Aaronson NK. Quality of life for patients treated for penile cancer. J Urol 2014;192:1105–10 .\n\n【49】[116] Sosnowski R, Wolski JK, Kulpa M, et al. Assessment of quality of life in patients surgically treated for penile cancer: Impact of aggressiveness in surgery. Eur J Oncol Nurs 2017;31:1–5 .", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "[76] Fankhauser CD, Lee EWC, Issa A, et al. Saphenous-sparing", "bbox": [64.0, 88.0, 382.0, 100.0]}, {"text": "ascending video endoscopic inguinal lymph node dissection", "bbox": [89.0, 99.0, 382.0, 112.0]}, {"text": "using a leg approach: surgical technique and perioperative and", "bbox": [88.0, 111.0, 383.0, 123.0]}, {"text": "pathological outcomes. Eur Urol Open Sci 2022;35:9–13 .", "bbox": [88.0, 124.0, 344.0, 135.0]}, {"text": "[77] Wang S, Du P, Tang X, An C, Zhang N, Yang Y. Comparison of", "bbox": [64.0, 135.0, 383.0, 148.0]}, {"text": "efficiency of video endoscopy and open inguinal lymph node", "bbox": [88.0, 147.0, 382.0, 161.0]}, {"text": "dissection. Anticancer Res 2017;37:4623–8 .", "bbox": [88.0, 159.0, 286.0, 172.0]}, {"text": "[78] Shao Y, Hu X, Ren S, et al. Comparison of different surgical", "bbox": [64.0, 171.0, 383.0, 182.0]}, {"text": "methods and strategies for inguinal lymph node dissection in", "bbox": [89.0, 184.0, 383.0, 195.0]}, {"text": "patients with penile cancer. Sci Rep 2022;12:2560 .", "bbox": [88.0, 195.0, 318.0, 207.0]}, {"text": "[79] Chipollini J, Tang DH, Gilbert SM, et al. Delay to inguinal lymph", "bbox": [64.0, 208.0, 383.0, 220.0]}, {"text": "node dissection greater than 3 months predicts poorer recurrence-", "bbox": [88.0, 219.0, 381.0, 232.0]}, {"text": "free survival for patients with penile cancer. J Urol", "bbox": [88.0, 232.0, 383.0, 243.0]}, {"text": "2017; 198:1346–52 .", "bbox": [88.0, 243.0, 177.0, 256.0]}, {"text": "[80] Lont AP, Kroon BK, Gallee MP, van Tinteren H, Moonen LM,", "bbox": [64.0, 255.0, 383.0, 267.0]}, {"text": "Horenblas S. Pelvic lymph node dissection for penile carcinoma:", "bbox": [88.0, 267.0, 382.0, 281.0]}, {"text": "extent of inguinal lymph node involvement as an indicator for", "bbox": [88.0, 279.0, 382.0, 292.0]}, {"text": "pelvic lymph node involvement and survival. J Urol", "bbox": [88.0, 292.0, 383.0, 303.0]}, {"text": "2007;177:947–52 .", "bbox": [88.0, 301.0, 174.0, 316.0]}, {"text": "[81] Liu JY, Li YH, Zhang ZL, et al. The risk factors for the presence of", "bbox": [64.0, 315.0, 383.0, 327.0]}, {"text": "pelvic lymph node metastasis in penile squamous cell carcinoma", "bbox": [88.0, 328.0, 383.0, 340.0]}, {"text": "patients with inguinal lymph node dissection. World J Urol", "bbox": [88.0, 339.0, 382.0, 352.0]}, {"text": "2013;31:1519–24 .", "bbox": [89.0, 351.0, 173.0, 362.0]}, {"text": "[82] Djajadiningrat RS, van Werkhoven E, Horenblas S. Prophylactic", "bbox": [64.0, 363.0, 382.0, 375.0]}, {"text": "pelvic lymph node dissection in patients with penile cancer. J Urol", "bbox": [88.0, 375.0, 383.0, 387.0]}, {"text": "2015; 193:1976–80 .", "bbox": [89.0, 387.0, 180.0, 398.0]}, {"text": "[83] Lughezzani G, Catanzaro M, Torelli T, et al. The relationship", "bbox": [64.0, 399.0, 382.0, 411.0]}, {"text": "between characteristics of inguinal lymph nodes and pelvic lymph", "bbox": [88.0, 411.0, 383.0, 422.0]}, {"text": "node involvement in penile squamous cell carcinoma: a single", "bbox": [88.0, 422.0, 382.0, 435.0]}, {"text": "institution experience. J Urol 2014;191:977–82 .", "bbox": [88.0, 435.0, 303.0, 447.0]}, {"text": "[84] Li ZS, Deng CZ, Yao K, et al. Bilateral pelvic lymph node dissection", "bbox": [64.0, 446.0, 383.0, 458.0]}, {"text": "for Chinese patients with penile cancer: a multicenter", "bbox": [88.0, 459.0, 382.0, 471.0]}, {"text": "collaboration study. J Cancer Res Clin Oncol 2017;143:329–35 .", "bbox": [88.0, 470.0, 372.0, 482.0]}, {"text": "[85] Jaipuria J, Kohli T, Venkatasubramaniyan M, et al. Adjuvant", "bbox": [64.0, 482.0, 382.0, 495.0]}, {"text": "radiation compares favorably to chemotherapy in patients with", "bbox": [88.0, 495.0, 383.0, 506.0]}, {"text": "carcinoma penis and nodal positivity restricted to groin. Urol", "bbox": [88.0, 506.0, 383.0, 518.0]}, {"text": "Oncol 2020;38:641.e9–e18 .", "bbox": [88.0, 518.0, 214.0, 531.0]}, {"text": "[86] Ager M, Njoku K, Serra M, et al. Long-term multicentre experience", "bbox": [64.0, 530.0, 382.0, 542.0]}, {"text": "of adjuvant radiotherapy for pN3 squamous cell carcinoma of the", "bbox": [88.0, 540.0, 382.0, 557.0]}, {"text": "penis. BJU Int 2021;128:451–9 .", "bbox": [89.0, 555.0, 230.0, 566.0]}, {"text": "[87] Maibom SL, Jakobsen JK, Aagaard M, Als AB, Petersen PM. DaPeCa-", "bbox": [64.0, 566.0, 382.0, 578.0]}, {"text": "4: outcome in penile cancer patients with N3 disease due to extra", "bbox": [88.0, 579.0, 383.0, 591.0]}, {"text": "nodal extension treated with surgery and chemo-irradiation.", "bbox": [88.0, 590.0, 381.0, 602.0]}, {"text": "Scand J Urol 2020;54:334–8 .", "bbox": [88.0, 602.0, 220.0, 614.0]}, {"text": "[88] Paz Rojas JF, Ballestas Almario CA, García-Perdomo HA.", "bbox": [65.0, 614.0, 381.0, 626.0]}, {"text": "Effectiveness and safety of adjuvant chemotherapy compared to", "bbox": [88.0, 626.0, 383.0, 638.0]}, {"text": "neoadjuvant chemotherapy in patients with penile cancer and", "bbox": [88.0, 639.0, 383.0, 651.0]}, {"text": "positive lymph nodes regarding overall survival and free disease", "bbox": [88.0, 650.0, 382.0, 662.0]}, {"text": "survival: a systematic review and meta-analysis. Urol Oncol", "bbox": [88.0, 662.0, 383.0, 675.0]}, {"text": "2022;40:200.e11–e18 .", "bbox": [88.0, 675.0, 189.0, 686.0]}, {"text": "[89] Alnajjar HM, MacAskill F, Christodoulidou M, et al. Long-term", "bbox": [64.0, 686.0, 383.0, 698.0]}, {"text": "outcomes for penile cancer patients presenting with advanced N3", "bbox": [88.0, 699.0, 383.0, 711.0]}, {"text": "disease requiring a myocutaneous flap reconstruction or primary", "bbox": [88.0, 710.0, 382.0, 722.0]}, {"text": "closure-a retrospective single centre study. Transl Androl Urol", "bbox": [88.0, 723.0, 383.0, 734.0]}, {"text": "2019;8:S13–21 .", "bbox": [89.0, 734.0, 160.0, 745.0]}, {"text": "[90] Koifman L, Hampl D, Ginsberg M, et al. The role of primary inguinal", "bbox": [64.0, 745.0, 383.0, 758.0]}, {"text": "surgical debulking for locally advanced penile cancer followed by", "bbox": [88.0, 757.0, 383.0, 770.0]}, {"text": "reconstruction with myocutaneous flap. Int Braz J Urol", "bbox": [88.0, 770.0, 382.0, 781.0]}, {"text": "2021;47:1162–75 .", "bbox": [88.0, 781.0, 174.0, 793.0]}, {"text": "[91] Azizi M, Aydin AM, Hajiran A, et al. Systematic review and meta-", "bbox": [64.0, 793.0, 382.0, 806.0]}, {"text": "analysis—is there a benefit in using neoadjuvant systemic", "bbox": [88.0, 805.0, 381.0, 818.0]}, {"text": "chemotherapy for locally advanced penile squamous cell", "bbox": [88.0, 816.0, 383.0, 831.0]}, {"text": "carcinoma? J Urol 2020;203:1147-55 .", "bbox": [88.0, 828.0, 260.0, 841.0]}, {"text": "[92] Djajadiningrat RS, Bergman AM, van Werkhoven E, Vegt E,", "bbox": [64.0, 841.0, 383.0, 853.0]}, {"text": "Horenblas       S.        Neoadjuvant      taxane-based      combination", "bbox": [88.0, 854.0, 383.0, 865.0]}, {"text": "chemotherapy in patients with advanced penile cancer. Clin", "bbox": [88.0, 865.0, 383.0, 878.0]}, {"text": "Genitourin Cancer 2015;13:44–9 .", "bbox": [88.0, 877.0, 239.0, 888.0]}, {"text": "[93] Pagliaro LC, Williams DL, Daliani D, et al. Neoadjuvant paclitaxel,", "bbox": [64.0, 889.0, 381.0, 901.0]}, {"text": "ifosfamide, and cisplatin chemotherapy for metastatic penile", "bbox": [88.0, 901.0, 382.0, 913.0]}, {"text": "cancer: a phase II study. J Clin Oncol 2010;28:3851–7 .", "bbox": [88.0, 915.0, 334.0, 924.0]}, {"text": "[94] Nicholson S, Hall E, Harland SJ, et al. Phase II trial of docetaxel,", "bbox": [64.0, 925.0, 381.0, 938.0]}, {"text": "cisplatin and 5FU chemotherapy in locally advanced and", "bbox": [88.0, 937.0, 383.0, 949.0]}, {"text": "metastatic penis", "bbox": [88.0, 950.0, 177.0, 961.0]}, {"text": "cancer (CRUK/09/001).", "bbox": [184.0, 950.0, 302.0, 961.0]}, {"text": "Br", "bbox": [308.0, 950.0, 329.0, 961.0]}, {"text": "1990.", "bbox": [328.0, 951.0, 341.0, 961.0]}, {"text": "Cancer", "bbox": [346.0, 951.0, 382.0, 961.0]}, {"text": "2013;109:2554–9 .", "bbox": [88.0, 961.0, 173.0, 973.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "[95] Zhang S, Zhu Y, Ye D. Phase II study of docetaxel, cisplatin, and", "bbox": [408.0, 88.0, 727.0, 100.0]}, {"text": "fluorouracil in patients with distantly metastatic penile cancer as", "bbox": [432.0, 99.0, 726.0, 112.0]}, {"text": "first-line chemotherapy. Oncotarget 2015;6:32212–9 .", "bbox": [431.0, 111.0, 673.0, 123.0]}, {"text": "[96] Di Lorenzo G, Buonerba C, Federico P, et al. Cisplatin and 5–", "bbox": [408.0, 124.0, 727.0, 135.0]}, {"text": "fluorouracil in inoperable, stage IV squamous cell carcinoma of the", "bbox": [430.0, 135.0, 727.0, 147.0]}, {"text": "penis. BJU Int 2012;110:E661–6 .", "bbox": [432.0, 148.0, 580.0, 159.0]}, {"text": "[97] Di Lorenzo G, Federico P, Buonerba C, et al. paclitaxel in pretreated", "bbox": [408.0, 159.0, 726.0, 172.0]}, {"text": "metastatic penile cancer: final results of a phase 2 study. Eur Urol", "bbox": [431.0, 169.0, 727.0, 185.0]}, {"text": "2011;60:1280–4 .", "bbox": [432.0, 184.0, 508.0, 195.0]}, {"text": "[98] Noronha V, Patil V, Ostwal V, Tongaonkar H, Bakshi G, Prabhash K.", "bbox": [408.0, 195.0, 726.0, 207.0]}, {"text": "Role of paclitaxel and platinum-based adjuvant chemotherapy in", "bbox": [431.0, 208.0, 727.0, 220.0]}, {"text": "high-risk penile cancer. Urol Ann 2012;4:150–3 .", "bbox": [430.0, 219.0, 649.0, 232.0]}, {"text": "[99] Bermejo C, Busby JE, Spiess PE, Heller L, Pagliaro LC, Pettaway CA.", "bbox": [408.0, 231.0, 725.0, 243.0]}, {"text": "Neoadjuvant chemotherapy followed by aggressive surgical", "bbox": [431.0, 244.0, 727.0, 255.0]}, {"text": "consolidation for metastatic penile squamous cell carcinoma. J", "bbox": [431.0, 255.0, 727.0, 268.0]}, {"text": "Urol 2007;177:1335–8 .", "bbox": [430.0, 267.0, 538.0, 279.0]}, {"text": "[100] Joshi VB, Spiess PE, Necchi A, Pettaway CA, Chahoud J. Immune-", "bbox": [403.0, 279.0, 725.0, 292.0]}, {"text": "based therapies in penile cancer. Nat Rev Urol 2022;19:457–74 .", "bbox": [432.0, 291.0, 722.0, 303.0]}, {"text": "[101] Pouessel D, Beylot-Barry M, Esma SB, et al. 715P Nivolumab in", "bbox": [403.0, 303.0, 726.0, 315.0]}, {"text": "pretreated metastatic penile squamous cell carcinoma: results of", "bbox": [432.0, 315.0, 727.0, 327.0]}, {"text": "the penile cohort from the French AcSé prospective program. Ann", "bbox": [432.0, 328.0, 727.0, 340.0]}, {"text": "Oncol 2021;32:S720 .", "bbox": [432.0, 339.0, 526.0, 351.0]}, {"text": "[102] de Vries HM, Feijter JD, Bekers E, et al. Clinical results of PERICLES:", "bbox": [403.0, 351.0, 726.0, 362.0]}, {"text": "a phase II trial investigating atezolizumab ± radiotherapy for", "bbox": [432.0, 364.0, 726.0, 375.0]}, {"text": "advanced squamous cell carcinoma of the penis. J Clin Oncol", "bbox": [432.0, 375.0, 727.0, 387.0]}, {"text": "2022;40(6 Suppl):3 .", "bbox": [432.0, 386.0, 525.0, 400.0]}, {"text": "[103] Brown A, Ma Y, Danenberg K, et al. Epidermal growth factor", "bbox": [403.0, 399.0, 726.0, 412.0]}, {"text": "receptor-targeted therapy in squamous cell carcinoma of the", "bbox": [432.0, 411.0, 726.0, 422.0]}, {"text": "penis: a report of 3 cases. Urology 2014;83:159–65 .", "bbox": [432.0, 421.0, 666.0, 435.0]}, {"text": "[104] Carthon BC, Ng CS, Pettaway CA, Pagliaro LC. Epidermal growth", "bbox": [403.0, 435.0, 727.0, 447.0]}, {"text": "factor receptor- targeted therapy in locally advanced or metastatic", "bbox": [432.0, 446.0, 726.0, 458.0]}, {"text": "squamous cell carcinoma of the penis. BJU Int 2014;113:871–7 .", "bbox": [432.0, 459.0, 720.0, 471.0]}, {"text": "[105] Necchi A, Nicolai N, Colecchia M, et al. Proof of activity of anti-", "bbox": [403.0, 470.0, 725.0, 482.0]}, {"text": "epidermal growth factor receptor-targeted therapy for relapsed", "bbox": [432.0, 482.0, 727.0, 495.0]}, {"text": "squamous cell carcinoma of the penis. J Clin Oncol 2011;29:", "bbox": [432.0, 495.0, 726.0, 507.0]}, {"text": "e650–2 .", "bbox": [432.0, 506.0, 471.0, 518.0]}, {"text": "[106] Necchi A, Lo Vullo S, Perrone F, et al. First-line therapy with", "bbox": [403.0, 518.0, 727.0, 531.0]}, {"text": "dacomitinib, an orally available pan-HER tyrosine kinase inhibitor,", "bbox": [432.0, 530.0, 725.0, 542.0]}, {"text": "for locally advanced or metastatic penile squamous cell", "bbox": [432.0, 541.0, 726.0, 555.0]}, {"text": "carcinoma: results of an open-label, single-arm, single-centre,", "bbox": [432.0, 555.0, 725.0, 567.0]}, {"text": "phase 2 study. BJU Int 2018;121:348–56 .", "bbox": [432.0, 566.0, 617.0, 578.0]}, {"text": "[107] Lutz ST, Jones J, Chow E. Role of radiation therapy in palliative care", "bbox": [403.0, 578.0, 727.0, 591.0]}, {"text": "of the patient with cancer. J Clin Oncol 2014;32:2913–9 .", "bbox": [432.0, 590.0, 688.0, 602.0]}, {"text": "[108] Leijte JA, Kirrander P, Antonini N, Windahl T, Horenblas S.", "bbox": [403.0, 602.0, 725.0, 615.0]}, {"text": "Recurrence patterns of squamous cell carcinoma of the penis:", "bbox": [432.0, 615.0, 726.0, 627.0]}, {"text": "recommendations for follow-up based on a two-centre analysis of", "bbox": [432.0, 625.0, 726.0, 638.0]}, {"text": "700 patients. Eur Urol 2008;54:161–8 .", "bbox": [432.0, 638.0, 605.0, 651.0]}, {"text": "[109] Ager M, Manjunath A, Yan S, et al. MP49-15 Surveillance CT", "bbox": [403.0, 650.0, 726.0, 662.0]}, {"text": "algorithm for node positive squamous cell carcinoma of the penis.", "bbox": [432.0, 662.0, 725.0, 675.0]}, {"text": "J Urol 2019;201:e711 .", "bbox": [432.0, 675.0, 533.0, 686.0]}, {"text": "[110] Arora A, Prakash G, Pal M, et al. A0694 - Patterns of recurrence in", "bbox": [403.0, 686.0, 727.0, 697.0]}, {"text": "penile cancer: implications for surveillance strategies. Eur Urol", "bbox": [433.0, 698.0, 727.0, 711.0]}, {"text": "2022;81:S1033 .", "bbox": [432.0, 710.0, 506.0, 721.0]}, {"text": "[111] Chakiryan NH, Dahmen A, Bandini M, et al. Patterns of recurrence", "bbox": [403.0, 722.0, 726.0, 733.0]}, {"text": "following inguinal lymph node dissection for penile cancer:", "bbox": [433.0, 735.0, 726.0, 746.0]}, {"text": "optimizing surveillance strategies. J Urol 2021;206:960–9 .", "bbox": [432.0, 745.0, 696.0, 758.0]}, {"text": "[112] Pérez J, Chavarriaga J, Ortiz A, et al. Oncological and functional", "bbox": [403.0, 757.0, 727.0, 770.0]}, {"text": "outcomes after organ-sparing plastic reconstructive surgery for", "bbox": [433.0, 770.0, 726.0, 781.0]}, {"text": "penile cancer. Urology 2020;142:161–165.e1 .", "bbox": [432.0, 781.0, 640.0, 793.0]}, {"text": "[113] Gambachidze D, Lebacle C, Maroun P, et al. Long-term evaluation", "bbox": [403.0, 793.0, 727.0, 807.0]}, {"text": "of urinary, sexual, and quality of life outcomes after", "bbox": [432.0, 805.0, 726.0, 818.0]}, {"text": "brachytherapy", "bbox": [432.0, 818.0, 502.0, 829.0]}, {"text": "for", "bbox": [514.0, 818.0, 531.0, 827.0]}, {"text": "penile", "bbox": [544.0, 818.0, 578.0, 828.0]}, {"text": "carcinoma.", "bbox": [589.0, 817.0, 643.0, 828.0]}, {"text": "Brachytherapy", "bbox": [657.0, 818.0, 726.0, 829.0]}, {"text": "2018; 17:221–6 .", "bbox": [432.0, 830.0, 504.0, 841.0]}, {"text": "[114] Draeger DL, Sievert KD, Hakenberg OW. Cross-sectional patient-", "bbox": [403.0, 841.0, 725.0, 853.0]}, {"text": "reported outcome measuring of health-related quality of life with", "bbox": [432.0, 854.0, 727.0, 866.0]}, {"text": "establishment of cancer- and treatment-specific functional and", "bbox": [432.0, 865.0, 726.0, 878.0]}, {"text": "symptom scales in patients with penile cancer. Clin Genitourin", "bbox": [432.0, 876.0, 727.0, 891.0]}, {"text": "Cancer 2018;16:e1215–20 .", "bbox": [432.0, 890.0, 554.0, 901.0]}, {"text": "[115] Kieffer JM, Djajadiningrat RS, van Muilekom EA, Graafland NM,", "bbox": [403.0, 901.0, 726.0, 913.0]}, {"text": "Horenblas S, Aaronson NK. Quality of life for patients treated for", "bbox": [432.0, 913.0, 726.0, 925.0]}, {"text": "penile cancer. J Urol 2014;192:1105–10 .", "bbox": [432.0, 925.0, 614.0, 938.0]}, {"text": "[116] Sosnowski R, Wolski JK, Kulpa M, et al. Assessment of quality of", "bbox": [403.0, 937.0, 726.0, 950.0]}, {"text": "life in patients surgically treated for penile cancer: Impact of", "bbox": [432.0, 950.0, 727.0, 962.0]}, {"text": "aggressiveness in surgery. Eur J Oncol Nurs 2017;31:1–5 .", "bbox": [432.0, 961.0, 690.0, 974.0]}], "type": "Text", "position": 4}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/泌尿外科/2023 EAU／ASCO指南：阴茎癌（更新版）.pdf", "page_num": 12}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": null, "type3": null, "type4": null, "type5": null, "type6": "信息有用性#0#49#参考文献"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:41", "update_time": "2024-05-07 19:42:05"}
{"id": 1082582, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 738, "source_info": {"seq_id": "49198759-cb3e-436e-8924-69874a79b11f", "title": null, "text": "【0】页码:9\n // apem\n\n【1】 secondary osteoporosis. Curr Med Res Opin 2012;28:737-\n\n【2】 47.\n\n【3】25. Rodd C, Lang B, Ramsay T, Alos N, Huber AM, Cabral DA, et al. Incident vertebral fractures among children with rheumatic disorders 12 months after glucocorticoid 5 initiation: a national observational study. Arthritis Care Res (Hoboken) 2012;64:122-31.\n\n【4】Vierucci F, Saggese G, Cimaz R. Osteoporosis in childhood.\n\n【5】26.\n\n【6】Curr Opin Rheumatol 2017;29:535-46.\n\n【7】Schmidt S, Mellstrom D, Norjavaara E, Sundh SV, Saalman 27.\n\n【8】R. Low bone mineral density in children and adolescents /with inflammatory bowel disease: a population-based study from Western Sweden. Inflamm Bowel Dis 2009;15:1844- 50.\n\n【9】T 11 H 28. El-Matary W, Sikora S, Spady D. Bone mineral density, vitamin D, and disease activity in children newly diagnosed with inflammatory bowel disease. Dig Dis Sci 2011;56:825- 19.\n\n【10】29. Pappa H, Thayu M, Sylvester F, Leonard M, Zemel B, Gordon C. Skeletal health of children and adolescents with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2011;53:11-25.\n\n【11】30. Hogler W, Wehl G, van Staa T, Meister B, Klein-Franke A, Kropshofer G. Incidence of skeletal complications during treatment of childhood acute lymphoblastic leukemia: comparison of fracture risk with the General Practice Research Database. Pediatr Blood Cancer 2007;48:21-7.\n\n【12】31. Alos N, Grant RM, Ramsay T, Halton J, Cummings EA, Miettunen PM, et al. High incidence of vertebral fractures in children with acute lymphoblastic leukemia 12 months after the initiation of therapy. J Clin Oncol 2012;30:2760-7.\n\n【13】32.\n\n【14】Lalayiannis AD, Crabtree NJ, Fewtrell M, Biassoni L, Milford DV, Ferro CJ, et al. Assessing bone mineralisation in children with chronic kidney disease: what clinical and t research tools are available? Pediatr Nephrol 2020;35:937- 57.\n\n【15】33. Helenius I, Remes V, Salminen S, Valta H, Makitie O,\n\n【16】 Holmberg C, et al. Incidence and predictors of fractures in children after solid organ transplantation: a 5-year prospective, population-based study. J Bone Miner Res 2006;21:380-7.\n\n【17】34 Johnston CC Jr, Miller JZ, Slemenda CW, Reister TK, Hui S, Christian JC, et al. Calcium supplementation and increases in bone mineral density in children. N Engl J Med 1992;327:82-7.\n\n【18】35. Lloyd T, Andon MB, Rollings N, Martel JK, Landis JR, Demers LM, et al. Calcium supplementation and bone mineral density in adolescent girls. JAMA 1993;270:841-4.\n\n【19】Winzenberg TM, Powell S, Shaw KA, Jones G. Vitamin 36.\n\n【20】D supplementation for improving bone mineral density in children. Cochrane Database Syst Rev 2010;(10):CD006944.\n\n【21】37.\n\n【22】Greene DA, Naughton GA. Calcium and vitamin-D supplementation on bone structural properties in peripubertal female identical twins: a randomised controlled trial. Osteoporos Int 2011;22:489-98.\n\n【23】 38. The Korean Nutrition Society. 2020 Dietary reference intakes for Koreans: application [Internet]. Seoul (Korea): The Korean Nutrition Society [cited 2022 Feb 1]. Available from: http://www.kns.or.kr.\n\n【24】39 / Rosen CJ, Abrams SA, Aloia JF, Brannon PM, Clinton SK, Durazo-Arvizu RA, et al. IOM committee members respond to Endocrine Society vitamin D guideline. J Clin Endocrinol Metab 2012;97:1146-52.\n\n【25】40. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al. Evaluation, treatment, and prevention of vitamin D deficiency: Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011;96:1911-30.\n\n【26】41. Committee on Nutrition and the Council on Sports Medicine and Fitness. Sports drinks and energy drinks for children and adolescents: are they appropriate? Pediatrics 2011;127:1182-9.\n\n【27】42. Hind K, Burrows M. Weight-bearing exercise and bone mineral accrual in children and adolescents: a review of controlled trials. Bone 2007;40:14-27.\n\n【28】43. McKay HA, Petit MA, Schutz RW, Prior JC, Barr SI, Khan KM. Augmented trochanteric bone mineral density after modified physical education classes: a randomized schoolbased exercise intervention study in prepubescent and early pubescent children. J Pediatr 2000;136:156-62.\n\n【29】44. MacKelvie KJ, Khan KM, Petit MA, Janssen PA, McKay HA. A school-based exercise intervention elicits substantial bone health benefits: a 2-year randomized controlled trial in girls. Pediatrics 2003;112:e447.\n\n【30】45. Petit MA, McKay HA, MacKelvie KJ, Heinonen A, Khan KM, Beck TJ. A randomized school-based jumping intervention confers site and maturity-specific benefits on bone structural properties in girls: a hip structural analysis study. J Bone Miner Res 2002;17:363-72.\n\n【31】46. Specker B, Thiex NW, Sudhagoni RG. Does exercise influence pediatric bone? A systematic review. Clin Orthop Relat Res 2015;473:3658-72.\n\n【32】Field AE, Gordon CM, Pierce LM, Ramappa A, Kocher MS.\n\n【33】47.\n\n【34】Prospective study of physical activity and risk of developing a stress fracture among preadolescent and adolescent girls.\n\n【35】Arch Pediatr Adolesc Med 2011;165:723-8.\n\n【36】Hohman EE, Balantekin KN, Birch LL, Savage JS.\n\n【37】10.148.\n\n【38】Dieting is associated with reduced bone mineral accrual in a longitudinal cohort of girls. BMC Public Health 2018;18:1285.\n\n【39】49.\n\n【40】Baroncelli GI, Bertelloni S. The use of bisphosphonates in pediatrics. Horm Res Paediatr 2014;82:290-302.\n\n【41】50. Dwan K, Phillipi CA, Steiner RD, Basel D. Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev 2016;10:CD005088.\n\n【42】51. Alcausin MB, Briody J, Pacey V, Ault J, McQuade M, Bridge C, et al. Intravenous pamidronate treatment in children with moderate-to-severe osteogenesis imperfecta started under three years of age. Horm Res Paediatr.2013;79:333- 1491559 40.\n\n【43】52. Baroncelli GI, Vierucci F, Bertelloni S, Erba P, Zampollo", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "// apem", "bbox": [35.0, 31.0, 133.0, 64.0]}], "type": "Text", "position": 0}, {"raw_context": [{"text": "secondary osteoporosis. Curr Med Res Opin 2012;28:737-", "bbox": [88.0, 94.0, 381.0, 108.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "47.", "bbox": [88.0, 111.0, 106.0, 123.0]}, {"text": "25. Rodd C, Lang B, Ramsay T, Alos N, Huber AM, Cabral", "bbox": [66.0, 125.0, 383.0, 140.0]}, {"text": "DA, et al. Incident vertebral fractures among children", "bbox": [88.0, 141.0, 384.0, 155.0]}, {"text": "with rheumatic disorders 12 months after glucocorticoid 5", "bbox": [88.0, 157.0, 385.0, 172.0]}, {"text": "initiation: a national observational study. Arthritis Care Res", "bbox": [88.0, 172.0, 383.0, 187.0]}, {"text": "(Hoboken) 2012;64:122-31.", "bbox": [88.0, 188.0, 228.0, 202.0]}, {"text": "Vierucci F, Saggese G, Cimaz R. Osteoporosis in childhood.", "bbox": [87.0, 204.0, 383.0, 218.0]}, {"text": "26.", "bbox": [66.0, 205.0, 86.0, 217.0]}, {"text": "Curr Opin Rheumatol 2017;29:535-46.", "bbox": [88.0, 219.0, 283.0, 234.0]}, {"text": "Schmidt S, Mellstrom D, Norjavaara E, Sundh SV, Saalman", "bbox": [86.0, 235.0, 383.0, 249.0]}, {"text": "27.", "bbox": [67.0, 236.0, 86.0, 249.0]}, {"text": "R. Low bone mineral density in children and adolescents", "bbox": [88.0, 251.0, 383.0, 266.0]}, {"text": "/with inflammatory bowel disease: a population-based study", "bbox": [83.0, 267.0, 382.0, 281.0]}, {"text": "from Western Sweden. Inflamm Bowel Dis 2009;15:1844-", "bbox": [88.0, 282.0, 381.0, 297.0]}, {"text": "50.", "bbox": [89.0, 300.0, 107.0, 312.0]}, {"text": "T 11 H", "bbox": [135.0, 300.0, 169.0, 312.0]}, {"text": "28. El-Matary W, Sikora S, Spady D. Bone mineral density,", "bbox": [66.0, 314.0, 383.0, 330.0]}, {"text": "vitamin D, and disease activity in children newly diagnosed", "bbox": [88.0, 330.0, 383.0, 345.0]}, {"text": "with inflammatory bowel disease. Dig Dis Sci 2011;56:825-", "bbox": [88.0, 345.0, 381.0, 360.0]}, {"text": "19.", "bbox": [88.0, 363.0, 99.0, 374.0]}, {"text": "29. Pappa H, Thayu M, Sylvester F, Leonard M, Zemel B,", "bbox": [66.0, 377.0, 383.0, 391.0]}, {"text": "Gordon C. Skeletal health of children and adolescents with", "bbox": [88.0, 392.0, 383.0, 407.0]}, {"text": "inflammatory bowel disease. J Pediatr Gastroenterol Nutr", "bbox": [88.0, 409.0, 382.0, 423.0]}, {"text": "2011;53:11-25.", "bbox": [88.0, 424.0, 164.0, 439.0]}, {"text": "30. Hogler W, Wehl G, van Staa T, Meister B, Klein-Franke A,", "bbox": [66.0, 440.0, 383.0, 454.0]}, {"text": "Kropshofer G. Incidence of skeletal complications during", "bbox": [88.0, 456.0, 383.0, 471.0]}, {"text": "treatment of childhood acute lymphoblastic leukemia:", "bbox": [88.0, 472.0, 383.0, 486.0]}, {"text": "comparison of fracture risk with the General Practice", "bbox": [88.0, 488.0, 383.0, 502.0]}, {"text": "Research Database. Pediatr Blood Cancer 2007;48:21-7.", "bbox": [88.0, 503.0, 364.0, 518.0]}, {"text": "31. Alos N, Grant RM, Ramsay T, Halton J, Cummings EA,", "bbox": [66.0, 518.0, 383.0, 533.0]}, {"text": "Miettunen PM, et al. High incidence of vertebral fractures", "bbox": [88.0, 534.0, 383.0, 549.0]}, {"text": "in children with acute lymphoblastic leukemia 12 months", "bbox": [88.0, 550.0, 383.0, 565.0]}, {"text": "after the initiation of therapy. J Clin Oncol 2012;30:2760-7.", "bbox": [88.0, 566.0, 379.0, 581.0]}, {"text": "32.", "bbox": [67.0, 583.0, 86.0, 595.0]}, {"text": "Lalayiannis AD, Crabtree NJ, Fewtrell M, Biassoni L,", "bbox": [84.0, 582.0, 383.0, 596.0]}, {"text": "Milford DV, Ferro CJ, et al. Assessing bone mineralisation", "bbox": [88.0, 597.0, 386.0, 612.0]}, {"text": "in children with chronic kidney disease: what clinical and t", "bbox": [88.0, 614.0, 384.0, 627.0]}, {"text": "research tools are available? Pediatr Nephrol 2020;35:937-", "bbox": [88.0, 629.0, 381.0, 644.0]}, {"text": "57.", "bbox": [88.0, 646.0, 106.0, 659.0]}, {"text": "33. Helenius I, Remes V, Salminen S, Valta H, Makitie O,", "bbox": [66.0, 660.0, 383.0, 675.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": "Holmberg C, et al. Incidence and predictors of fractures", "bbox": [88.0, 676.0, 383.0, 690.0]}, {"text": "in children after solid organ transplantation: a 5-year", "bbox": [88.0, 692.0, 383.0, 707.0]}, {"text": "prospective, population-based study. J Bone Miner Res", "bbox": [88.0, 708.0, 383.0, 722.0]}, {"text": "2006;21:380-7.", "bbox": [89.0, 723.0, 164.0, 737.0]}, {"text": "34 Johnston CC Jr, Miller JZ, Slemenda CW, Reister TK,", "bbox": [66.0, 738.0, 382.0, 754.0]}, {"text": "Hui S, Christian JC, et al. Calcium supplementation and", "bbox": [88.0, 755.0, 383.0, 770.0]}, {"text": "increases in bone mineral density in children. N Engl J Med", "bbox": [88.0, 771.0, 383.0, 786.0]}, {"text": "1992;327:82-7.", "bbox": [89.0, 787.0, 164.0, 801.0]}, {"text": "35. Lloyd T, Andon MB, Rollings N, Martel JK, Landis JR,", "bbox": [66.0, 802.0, 383.0, 818.0]}, {"text": "Demers LM, et al. Calcium supplementation and bone", "bbox": [88.0, 818.0, 383.0, 833.0]}, {"text": "mineral density in adolescent girls. JAMA 1993;270:841-4.", "bbox": [88.0, 833.0, 379.0, 848.0]}, {"text": "Winzenberg TM, Powell S, Shaw KA, Jones G. Vitamin", "bbox": [87.0, 849.0, 389.0, 864.0]}, {"text": "36.", "bbox": [67.0, 850.0, 87.0, 863.0]}, {"text": "D supplementation for improving bone mineral", "bbox": [88.0, 865.0, 384.0, 880.0]}, {"text": "density in children. Cochrane Database Syst Rev", "bbox": [88.0, 881.0, 383.0, 895.0]}, {"text": "2010;(10):CD006944.", "bbox": [88.0, 897.0, 199.0, 911.0]}, {"text": "37.", "bbox": [66.0, 912.0, 86.0, 926.0]}, {"text": "Greene DA, Naughton GA. Calcium and vitamin-D", "bbox": [84.0, 912.0, 384.0, 927.0]}, {"text": "supplementation on bone structural properties in", "bbox": [88.0, 928.0, 384.0, 943.0]}, {"text": "peripubertal female identical twins: a randomised", "bbox": [88.0, 944.0, 383.0, 959.0]}, {"text": "controlled trial. Osteoporos Int 2011;22:489-98.", "bbox": [88.0, 960.0, 324.0, 974.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "38. The Korean Nutrition Society. 2020 Dietary reference", "bbox": [410.0, 93.0, 725.0, 108.0]}, {"text": "intakes for Koreans: application [Internet]. Seoul (Korea):", "bbox": [432.0, 109.0, 727.0, 124.0]}, {"text": "The Korean Nutrition Society [cited 2022 Feb 1]. Available", "bbox": [432.0, 125.0, 727.0, 140.0]}, {"text": "from: http://www.kns.or.kr.", "bbox": [432.0, 141.0, 569.0, 155.0]}, {"text": "39 / Rosen CJ, Abrams SA, Aloia JF, Brannon PM, Clinton", "bbox": [408.0, 157.0, 728.0, 172.0]}, {"text": "SK, Durazo-Arvizu RA, et al. IOM committee members", "bbox": [430.0, 172.0, 727.0, 187.0]}, {"text": "respond to Endocrine Society vitamin D guideline. J Clin", "bbox": [432.0, 187.0, 728.0, 202.0]}, {"text": "Endocrinol Metab 2012;97:1146-52.", "bbox": [432.0, 204.0, 615.0, 218.0]}, {"text": "40. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM,", "bbox": [410.0, 219.0, 728.0, 234.0]}, {"text": "Hanley DA, Heaney RP, et al. Evaluation, treatment, and", "bbox": [432.0, 236.0, 727.0, 249.0]}, {"text": "prevention of vitamin D deficiency: Endocrine Society", "bbox": [432.0, 251.0, 727.0, 266.0]}, {"text": "clinical practice guideline. J Clin Endocrinol Metab", "bbox": [432.0, 267.0, 733.0, 282.0]}, {"text": "2011;96:1911-30.", "bbox": [432.0, 283.0, 520.0, 297.0]}, {"text": "41. Committee on Nutrition and the Council on Sports", "bbox": [410.0, 299.0, 727.0, 313.0]}, {"text": "Medicine and Fitness. Sports drinks and energy drinks for", "bbox": [432.0, 314.0, 727.0, 329.0]}, {"text": "children and adolescents: are they appropriate? Pediatrics", "bbox": [432.0, 330.0, 727.0, 345.0]}, {"text": "2011;127:1182-9.", "bbox": [432.0, 345.0, 521.0, 360.0]}, {"text": "42. Hind K, Burrows M. Weight-bearing exercise and bone", "bbox": [410.0, 360.0, 727.0, 376.0]}, {"text": "mineral accrual in children and adolescents: a review of", "bbox": [432.0, 377.0, 727.0, 391.0]}, {"text": "controlled trials. Bone 2007;40:14-27.", "bbox": [430.0, 392.0, 618.0, 407.0]}, {"text": "43. McKay HA, Petit MA, Schutz RW, Prior JC, Barr SI, Khan", "bbox": [410.0, 408.0, 727.0, 423.0]}, {"text": "KM. Augmented trochanteric bone mineral density after", "bbox": [432.0, 424.0, 727.0, 439.0]}, {"text": "modified physical education classes: a randomized school-", "bbox": [432.0, 441.0, 725.0, 454.0]}, {"text": "based exercise intervention study in prepubescent and early", "bbox": [432.0, 456.0, 727.0, 471.0]}, {"text": "pubescent children. J Pediatr 2000;136:156-62.", "bbox": [432.0, 472.0, 666.0, 486.0]}, {"text": "44. MacKelvie KJ, Khan KM, Petit MA, Janssen PA, McKay", "bbox": [410.0, 488.0, 727.0, 503.0]}, {"text": "HA. A school-based exercise intervention elicits substantial", "bbox": [432.0, 503.0, 727.0, 518.0]}, {"text": "bone health benefits: a 2-year randomized controlled trial", "bbox": [432.0, 519.0, 727.0, 533.0]}, {"text": "in girls. Pediatrics 2003;112:e447.", "bbox": [432.0, 534.0, 598.0, 549.0]}, {"text": "45. Petit MA, McKay HA, MacKelvie KJ, Heinonen A, Khan", "bbox": [410.0, 550.0, 728.0, 565.0]}, {"text": "KM, Beck TJ. A randomized school-based jumping", "bbox": [432.0, 566.0, 727.0, 581.0]}, {"text": "intervention confers site and maturity-specific benefits on", "bbox": [432.0, 582.0, 727.0, 596.0]}, {"text": "bone structural properties in girls: a hip structural analysis", "bbox": [432.0, 597.0, 728.0, 612.0]}, {"text": "study. J Bone Miner Res 2002;17:363-72.", "bbox": [432.0, 614.0, 634.0, 628.0]}, {"text": "46. Specker B, Thiex NW, Sudhagoni RG. Does exercise", "bbox": [410.0, 629.0, 728.0, 644.0]}, {"text": "influence pediatric bone? A systematic review. Clin Orthop", "bbox": [432.0, 645.0, 727.0, 660.0]}, {"text": "Relat Res 2015;473:3658-72.", "bbox": [432.0, 660.0, 574.0, 675.0]}, {"text": "Field AE, Gordon CM, Pierce LM, Ramappa A, Kocher MS.", "bbox": [429.0, 675.0, 727.0, 690.0]}, {"text": "47.", "bbox": [411.0, 677.0, 430.0, 690.0]}, {"text": "Prospective study of physical activity and risk of developing", "bbox": [432.0, 692.0, 727.0, 707.0]}, {"text": "a stress fracture among preadolescent and adolescent girls.", "bbox": [432.0, 708.0, 728.0, 722.0]}, {"text": "Arch Pediatr Adolesc Med 2011;165:723-8.", "bbox": [432.0, 723.0, 647.0, 738.0]}, {"text": "Hohman EE, Balantekin KN, Birch LL, Savage JS.", "bbox": [430.0, 739.0, 726.0, 754.0]}, {"text": "10.148.", "bbox": [411.0, 740.0, 430.0, 752.0]}, {"text": "Dieting is associated with reduced bone mineral accrual", "bbox": [432.0, 755.0, 727.0, 770.0]}, {"text": "in a longitudinal cohort of girls. BMC Public Health", "bbox": [432.0, 771.0, 728.0, 786.0]}, {"text": "2018;18:1285.", "bbox": [432.0, 787.0, 504.0, 801.0]}, {"text": "49.", "bbox": [411.0, 803.0, 430.0, 816.0]}, {"text": "Baroncelli GI, Bertelloni S. The use of bisphosphonates in", "bbox": [430.0, 802.0, 728.0, 817.0]}, {"text": "pediatrics. Horm Res Paediatr 2014;82:290-302.", "bbox": [432.0, 818.0, 670.0, 833.0]}, {"text": "50. Dwan K, Phillipi CA, Steiner RD, Basel D. Bisphosphonate", "bbox": [410.0, 833.0, 727.0, 848.0]}, {"text": "therapy for osteogenesis imperfecta. Cochrane Database", "bbox": [432.0, 850.0, 727.0, 863.0]}, {"text": "Syst Rev 2016;10:CD005088.", "bbox": [431.0, 865.0, 578.0, 880.0]}, {"text": "51. Alcausin MB, Briody J, Pacey V, Ault J, McQuade M, Bridge", "bbox": [410.0, 880.0, 727.0, 895.0]}, {"text": "C, et al. Intravenous pamidronate treatment in children", "bbox": [432.0, 897.0, 728.0, 911.0]}, {"text": "with moderate-to-severe osteogenesis imperfecta started", "bbox": [432.0, 913.0, 728.0, 927.0]}, {"text": "under three years of age. Horm Res Paediatr.2013;79:333-", "bbox": [432.0, 928.0, 725.0, 943.0]}, {"text": "1491559", "bbox": [641.0, 943.0, 695.0, 958.0]}, {"text": "40.", "bbox": [433.0, 946.0, 450.0, 958.0]}, {"text": "52. Baroncelli GI, Vierucci F, Bertelloni S, Erba P, Zampollo", "bbox": [410.0, 960.0, 731.0, 974.0]}], "type": "Text", "position": 6}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2022】全科室最全临床指南+专家共识（最全版）/2022全科室临床指南/内分泌科/KSPE：优化儿童和青少年骨健康的临床实践指南（2022）.pdf", "page_num": 9}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": null, "type3": null, "type4": null, "type5": null, "type6": "有用性#0#43#参考文献的内容"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:41", "update_time": "2024-05-07 23:43:48"}
{"id": 1082581, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 738, "source_info": {"seq_id": "7371925c-0183-40c2-a521-af81c1f0cb6a", "title": null, "text": "【0】页码:9\n literacy), clinician (unconscious bias, lack of underrepresented clinicians), system (access to and quality of care), or policy (health insurance, resource allocation) sources. 50 Factors that influence disparities may include a focus on individual risk factors without addressing social determinants of health such as access to transportation, fewer primary care physicians in both rural and high-risk areas, and high costs of care. Culturally tailored behavioral interventions should address both the individual's risk factors and their social determinants of health. 61 Development of Telestroke networks provide rural and\n\n【1】 under-resourced communities greater access to vascular neurologists, which is especially relevant for time-sensitive treatments such as thrombolytic therapy for acute ischemic stroke in patients with ongoing symptoms. Telemedicine, similarly, might also be a useful way for physicians to facilitate rapid TIA diagnosis, identify underlying causes, implement individualized risk reduction plans, and provide access to stroke prevention clinics attended by vascular neurologists.\n\n【2】## Education Required: Signs And Symptoms Of Stroke\n\n【3】\n A patient's knowledge retention of stroke signs and symptoms or stroke risk factors is often poor after discharge, with TIA or stroke. 7273 Furthermore, patients with TIA or mild symptoms are less likely to activate emergency services on a subsequent visit. 74 It is therefore critical to develop consistent, innovative approaches to provide education for patients with TIA and their families in the ED. Multilingual education materials on stroke signs and symptoms, when to return for emergency care, time sensitivity of treatment options, and understanding the importance of secondary prevention treatments should be provided. Further studies are needed to develop effective approaches to stroke and TIA education in the ED setting.\n\n【4】## Considerations For Clinical Practice\n\n【5】\n Maximal medical therapy includes antithrombotic therapy paired with blood pressure, glucose and lipid control with targets adherent to established guidelines. 17\n The ABCD 2 score can be used to guide antithrombotic regimens.\n\n【6】Counseling paired with medical management may be helpful to patients with substance use disorders.\n\n【7】Attention to social determinants of health can aid in addressing health disparities.\n\n【8】## Follow-Up Appointments\n\n【9】\n Primary care providers are essential in the long-term man¬ agement of cardiovascular risk factors and should be notified when a patient presents to the ED with TIA. Given the\n\n【10】 subsequent risk for recurrent stroke after TIA 75 rapid followup with both a neurologist and primary care physician is warranted. One study found a significant reduction in 90-day stroke risk when time from TIA to stroke specialist review changed from 3 days to 1 day (10.3% to 2.1%, respectively). 74 Telehealth or other electronic modalities of commu¬ nication are potential options for clinicians to address risk factor management if resources are limited. Nurseled, telephone-based interventions and other integrated mobile health technology programs have led to improved blood-pressure control and lipid management in rural populations by increasing the proportion of patients reached through these interventions. 76 , 77\n\n【11】## Conclusions\n\n【12】\n TIA is a strong predictor of future stroke and requires careful evaluation to properly identify high-risk patients. Several tools are available to aid in the evaluation of patients with suspected TIA, including risk stratification scales, acute phase imaging, and neurological consultation. Incorporating these steps into a clinical pathway can facilitate appropriate disposition of patients with TIA, such as hospital admission for those at highest risk while reducing unnecessary hospitalizations for lower-risk patients. Implementation of patient-specific secondary prevention strategies is critical to prevent future events. It is up to each center to use the resources available and create a pathway to ensure successful management and disposition of patients with TIA, with the ultimate goal of reducing the risk of future stroke.\n\n【13】## Article Information\n\n【14】\n The American Heart Association makes every effort to avoid any actual or potential conflicts of interest that may arise as a result of an outside relationship or a personal, professional, or business interest of a member of the writing panel. Specifically, all members of the writing group are required to complete and submit a Disclosure Questionnaire showing all such relationships that might be perceived as real or potential conflicts of interest.\n\n【15】This statement was approved by the American Heart Association Science Advisory and Coordinating Committee on September 12, 2022, and the American Heart Association Executive Committee on October 26, 2022. A copy of the document is available at https://professional.heart.org/statements by using either \"Search for Guidelines & Statements' or the \"Browse by Topic\" area. To purchase additional reprints, call 215-356-2721 or email Meredith.Edelman@wolterskluwer.com.\n\n【16】The American Heart Association requests that this document be cited as follows: Amin HP, Madsen TE, Bravata DM, Wira CR, Johnston SC, Ashcraft S, Burrus TM, Panagos PD, Wintermark M, Esenwa C; on behalf of the American Heart Association Emergency Neurovascular Care Committee of the Stroke Council and Council on Peripheral Vascular Disease. Diagnosis, workup, risk reduction of translent ischemic attack in the emergency department setting: a scientific statement from the American Heart Association. Stroke. 2023;54:e***- e***. doi: 10.1161/STR00000000000418 The expert peer review of AHA-commissioned documents (eg, scientific statements, clinical practice guidelines, systematic reviews) is conducted by the AHA Office of Science Operations. For more on AHA statements and guidelines development, visit https://professional.heart.org/statements. Select the \"Guidelines & Statements\" drop-down menu, then click \"Publication Development\" Permissions: Permissions: Multiple copies, modification, alteration, enhancement, and distribution of this document are not permitted without the express permission of the American Heart Association. Instructions for obtaining permission are located at https://www.heart.org/permissions. A link to the \"Copyright Permissions Request Form\" appears in the second paragraph ( https://www.heart.\n\n【17】org/en/about-us/statements-and-policies/copyright-request-form).\n\n【18】 STN3M3TATS TVOINING\n\n【19】 '9 Arenided up aq aro stemnolede//dnd mort bebeomwoO", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "literacy), clinician (unconscious bias, lack of underrep-", "bbox": [63.0, 77.0, 378.0, 93.0]}, {"text": "resented clinicians), system (access to and quality of", "bbox": [63.0, 93.0, 380.0, 108.0]}, {"text": "care), or policy (health insurance, resource allocation)", "bbox": [63.0, 109.0, 380.0, 124.0]}, {"text": "sources. 50 Factors that influence disparities may include", "bbox": [63.0, 126.0, 380.0, 140.0]}, {"text": "a focus on individual risk factors without addressing", "bbox": [63.0, 142.0, 380.0, 156.0]}, {"text": "social determinants of health such as access to trans-", "bbox": [63.0, 158.0, 377.0, 173.0]}, {"text": "portation, fewer primary care physicians in both rural and", "bbox": [63.0, 174.0, 380.0, 188.0]}, {"text": "high-risk areas, and high costs of care. Culturally tai-", "bbox": [63.0, 190.0, 378.0, 204.0]}, {"text": "lored behavioral interventions should address both the", "bbox": [63.0, 206.0, 380.0, 220.0]}, {"text": "individual's risk factors and their social determinants of", "bbox": [63.0, 222.0, 380.0, 236.0]}, {"text": "health. 61", "bbox": [63.0, 237.0, 112.0, 252.0]}, {"text": "Development of Telestroke networks provide rural and", "bbox": [79.0, 254.0, 380.0, 268.0]}], "type": "Text", "position": 2}, {"raw_context": [{"text": "under-resourced communities greater access to vascular", "bbox": [63.0, 270.0, 379.0, 284.0]}, {"text": "neurologists, which is especially relevant for time-sensi-", "bbox": [63.0, 286.0, 378.0, 301.0]}, {"text": "tive treatments such as thrombolytic therapy for acute", "bbox": [63.0, 302.0, 380.0, 316.0]}, {"text": "ischemic stroke in patients with ongoing symptoms. Tele-", "bbox": [63.0, 318.0, 378.0, 333.0]}, {"text": "medicine, similarly, might also be a useful way for physi-", "bbox": [63.0, 334.0, 378.0, 348.0]}, {"text": "cians to facilitate rapid TIA diagnosis, identify underlying", "bbox": [63.0, 350.0, 380.0, 364.0]}, {"text": "causes, implement individualized risk reduction plans,", "bbox": [63.0, 366.0, 378.0, 381.0]}, {"text": "and provide access to stroke prevention clinics attended", "bbox": [63.0, 382.0, 379.0, 396.0]}, {"text": "by vascular neurologists.", "bbox": [63.0, 398.0, 203.0, 413.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "Education Required: Signs and Symptoms of", "bbox": [63.0, 435.0, 361.0, 453.0]}, {"text": "Stroke", "bbox": [63.0, 454.0, 111.0, 468.0]}], "type": "Section-header", "position": 4}, {"raw_context": [{"text": "A patient's knowledge retention of stroke signs and symp-", "bbox": [63.0, 476.0, 378.0, 491.0]}, {"text": "toms or stroke risk factors is often poor after discharge,", "bbox": [63.0, 493.0, 379.0, 507.0]}, {"text": "with TIA or stroke. 7273 Furthermore, patients with TIA", "bbox": [63.0, 508.0, 380.0, 523.0]}, {"text": "or mild symptoms are less likely to activate emergency", "bbox": [63.0, 525.0, 378.0, 539.0]}, {"text": "services on a subsequent visit. 74 It is therefore critical", "bbox": [63.0, 539.0, 379.0, 555.0]}, {"text": "to develop consistent, innovative approaches to provide", "bbox": [63.0, 556.0, 379.0, 572.0]}, {"text": "education for patients with TIA and their families in the", "bbox": [63.0, 573.0, 380.0, 587.0]}, {"text": "ED. Multilingual education materials on stroke signs and", "bbox": [63.0, 588.0, 380.0, 603.0]}, {"text": "symptoms, when to return for emergency care, time sen-", "bbox": [63.0, 605.0, 378.0, 619.0]}, {"text": "sitivity of treatment options, and understanding the impor-", "bbox": [63.0, 621.0, 378.0, 635.0]}, {"text": "tance of secondary prevention treatments should be", "bbox": [63.0, 636.0, 380.0, 651.0]}, {"text": "provided. Further studies are needed to develop effective", "bbox": [63.0, 653.0, 379.0, 667.0]}, {"text": "approaches to stroke and TIA education in the ED setting.", "bbox": [63.0, 669.0, 379.0, 683.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "Considerations for Clinical Practice", "bbox": [63.0, 707.0, 295.0, 724.0]}], "type": "Section-header", "position": 6}, {"raw_context": [{"text": "Maximal medical therapy includes antithrombotic ther-", "bbox": [91.0, 730.0, 378.0, 746.0]}, {"text": "apy paired with blood pressure, glucose and lipid con-", "bbox": [92.0, 747.0, 378.0, 761.0]}, {"text": "trol with targets adherent to established guidelines. 17", "bbox": [91.0, 762.0, 373.0, 777.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "The ABCD 2 score can be used to guide antithrom-", "bbox": [91.0, 779.0, 378.0, 793.0]}, {"text": "botic regimens.", "bbox": [91.0, 795.0, 180.0, 809.0]}, {"text": "Counseling paired with medical management may", "bbox": [90.0, 810.0, 379.0, 825.0]}, {"text": "be helpful to patients with substance use disorders.", "bbox": [91.0, 827.0, 379.0, 841.0]}, {"text": "Attention to social determinants of health can aid in", "bbox": [91.0, 843.0, 380.0, 857.0]}, {"text": "addressing health disparities.", "bbox": [92.0, 859.0, 256.0, 874.0]}], "type": "List-item", "position": 8}, {"raw_context": [{"text": "FOLLOW-UP APPOINTMENTS", "bbox": [63.0, 902.0, 281.0, 921.0]}], "type": "Section-header", "position": 9}, {"raw_context": [{"text": "Primary care providers are essential in the long-term man¬", "bbox": [63.0, 927.0, 378.0, 941.0]}, {"text": "agement of cardiovascular risk factors and should be noti-", "bbox": [63.0, 943.0, 378.0, 957.0]}, {"text": "fied when a patient presents to the ED with TIA. Given the", "bbox": [63.0, 958.0, 380.0, 973.0]}], "type": "Text", "position": 10}, {"raw_context": [{"text": "subsequent risk for recurrent stroke after TIA 75 rapid follow-", "bbox": [399.0, 77.0, 714.0, 92.0]}, {"text": "up with both a neurologist and primary care physician is war-", "bbox": [399.0, 93.0, 714.0, 108.0]}, {"text": "ranted. One study found a significant reduction in 90-day", "bbox": [399.0, 110.0, 715.0, 124.0]}, {"text": "stroke risk when time from TIA to stroke specialist review", "bbox": [399.0, 126.0, 715.0, 140.0]}, {"text": "changed from 3 days to 1 day (10.3% to 2.1%, respectively). 74", "bbox": [399.0, 142.0, 714.0, 156.0]}, {"text": "Telehealth or other electronic modalities of commu¬", "bbox": [416.0, 158.0, 715.0, 173.0]}, {"text": "nication are potential options for clinicians to address", "bbox": [399.0, 174.0, 716.0, 188.0]}, {"text": "risk factor management if resources are limited. Nurse-", "bbox": [399.0, 190.0, 715.0, 204.0]}, {"text": "led, telephone-based interventions and other integrated", "bbox": [399.0, 206.0, 716.0, 220.0]}, {"text": "mobile health technology programs have led to improved", "bbox": [399.0, 222.0, 716.0, 237.0]}, {"text": "blood-pressure control and lipid management in rural", "bbox": [399.0, 238.0, 716.0, 253.0]}, {"text": "populations by increasing the proportion of patients", "bbox": [399.0, 254.0, 716.0, 268.0]}, {"text": "reached through these interventions. 76 , 77", "bbox": [399.0, 270.0, 621.0, 284.0]}], "type": "Text", "position": 12}, {"raw_context": [{"text": "CONCLUSIONS", "bbox": [400.0, 313.0, 517.0, 332.0]}], "type": "Section-header", "position": 13}, {"raw_context": [{"text": "TIA is a strong predictor of future stroke and requires care-", "bbox": [401.0, 338.0, 714.0, 352.0]}, {"text": "ful evaluation to properly identify high-risk patients. Several", "bbox": [399.0, 354.0, 716.0, 368.0]}, {"text": "tools are available to aid in the evaluation of patients with", "bbox": [399.0, 369.0, 716.0, 384.0]}, {"text": "suspected TIA, including risk stratification scales, acute", "bbox": [400.0, 386.0, 716.0, 400.0]}, {"text": "phase imaging, and neurological consultation. Incorporating", "bbox": [399.0, 401.0, 715.0, 416.0]}, {"text": "these steps into a clinical pathway can facilitate appropri-", "bbox": [399.0, 418.0, 714.0, 433.0]}, {"text": "ate disposition of patients with TIA, such as hospital admis-", "bbox": [399.0, 434.0, 714.0, 448.0]}, {"text": "sion for those at highest risk while reducing unnecessary", "bbox": [400.0, 449.0, 715.0, 465.0]}, {"text": "hospitalizations for lower-risk patients. Implementation of", "bbox": [399.0, 466.0, 715.0, 481.0]}, {"text": "patient-specific secondary prevention strategies is critical", "bbox": [400.0, 482.0, 716.0, 496.0]}, {"text": "to prevent future events. It is up to each center to use the", "bbox": [399.0, 496.0, 716.0, 514.0]}, {"text": "resources available and create a pathway to ensure suc-", "bbox": [399.0, 514.0, 713.0, 528.0]}, {"text": "cessful management and disposition of patients with TIA,", "bbox": [398.0, 529.0, 716.0, 544.0]}, {"text": "with the ultimate goal of reducing the risk of future stroke.", "bbox": [398.0, 546.0, 714.0, 561.0]}], "type": "Text", "position": 14}, {"raw_context": [{"text": "ARTICLE INFORMATION", "bbox": [399.0, 581.0, 538.0, 596.0]}], "type": "Section-header", "position": 15}, {"raw_context": [{"text": "The American Heart Association makes every effort to avoid any actual or poten-", "bbox": [400.0, 601.0, 715.0, 614.0]}, {"text": "tial conflicts of interest that may arise as a result of an outside relationship or a", "bbox": [399.0, 614.0, 716.0, 625.0]}, {"text": "personal, professional, or business interest of a member of the writing panel. Spe-", "bbox": [399.0, 626.0, 715.0, 637.0]}, {"text": "cifically, all members of the writing group are required to complete and submit a", "bbox": [399.0, 637.0, 716.0, 649.0]}, {"text": "Disclosure Questionnaire showing all such relationships that might be perceived", "bbox": [399.0, 650.0, 716.0, 662.0]}, {"text": "as real or potential conflicts of interest.", "bbox": [400.0, 662.0, 553.0, 673.0]}, {"text": "This statement was approved by the American Heart Association Science Advi-", "bbox": [415.0, 674.0, 715.0, 684.0]}, {"text": "sory and Coordinating Committee on September 12, 2022, and the American Heart", "bbox": [399.0, 686.0, 716.0, 697.0]}, {"text": "Association Executive Committee on October 26, 2022. A copy of the document", "bbox": [399.0, 697.0, 716.0, 709.0]}, {"text": "is available at https://professional.heart.org/statements by using either \"Search for", "bbox": [399.0, 710.0, 716.0, 722.0]}, {"text": "Guidelines & Statements' or the \"Browse by Topic\" area. To purchase additional re-", "bbox": [399.0, 721.0, 714.0, 733.0]}, {"text": "prints, call 215-356-2721 or email Meredith.Edelman@wolterskluwer.com.", "bbox": [399.0, 732.0, 683.0, 747.0]}, {"text": "The American Heart Association requests that this document be cited as fol-", "bbox": [417.0, 746.0, 715.0, 757.0]}, {"text": "lows: Amin HP, Madsen TE, Bravata DM, Wira CR, Johnston SC, Ashcraft S, Bur-", "bbox": [399.0, 757.0, 715.0, 769.0]}, {"text": "rus TM, Panagos PD, Wintermark M, Esenwa C; on behalf of the American Heart", "bbox": [399.0, 769.0, 715.0, 782.0]}, {"text": "Association Emergency Neurovascular Care Committee of the Stroke Council", "bbox": [399.0, 782.0, 716.0, 793.0]}, {"text": "and Council on Peripheral Vascular Disease. Diagnosis, workup, risk reduction", "bbox": [400.0, 794.0, 715.0, 805.0]}, {"text": "of translent ischemic attack in the emergency department setting: a scientific", "bbox": [399.0, 805.0, 716.0, 816.0]}, {"text": "statement from the American Heart Association. Stroke. 2023;54:e***- e***. doi:", "bbox": [399.0, 818.0, 715.0, 829.0]}, {"text": "10.1161/STR00000000000418", "bbox": [401.0, 829.0, 547.0, 841.0]}, {"text": "The expert peer review of AHA-commissioned documents (eg, scientific", "bbox": [415.0, 842.0, 715.0, 854.0]}, {"text": "statements, clinical practice guidelines, systematic reviews) is conducted by the", "bbox": [400.0, 853.0, 716.0, 865.0]}, {"text": "AHA Office of Science Operations. For more on AHA statements and guidelines", "bbox": [399.0, 866.0, 716.0, 877.0]}, {"text": "development, visit https://professional.heart.org/statements. Select the \"Guide-", "bbox": [399.0, 877.0, 714.0, 890.0]}, {"text": "lines & Statements\" drop-down menu, then click \"Publication Development\"", "bbox": [399.0, 890.0, 695.0, 901.0]}, {"text": "Permissions: Permissions: Multiple copies, modification, alteration, enhance-", "bbox": [415.0, 902.0, 715.0, 914.0]}, {"text": "ment, and distribution of this document are not permitted without the express", "bbox": [399.0, 912.0, 716.0, 926.0]}, {"text": "permission of the American Heart Association. Instructions for obtaining permis-", "bbox": [399.0, 926.0, 715.0, 937.0]}, {"text": "sion are located at https://www.heart.org/permissions. A link to the \"Copyright", "bbox": [399.0, 937.0, 716.0, 949.0]}, {"text": "Permissions Request Form\" appears in the second paragraph ( https://www.heart.", "bbox": [399.0, 950.0, 715.0, 962.0]}, {"text": "org/en/about-us/statements-and-policies/copyright-request-form).", "bbox": [399.0, 962.0, 665.0, 974.0]}], "type": "Text", "position": 16}, {"raw_context": [{"text": "STN3M3TATS TVOINING", "bbox": [737.0, 94.0, 771.0, 204.0]}], "type": "Text", "position": 17}, {"raw_context": [{"text": "'9 Arenided up aq aro stemnolede//dnd mort bebeomwoO", "bbox": [17.0, 526.0, 37.0, 779.0]}], "type": "Text", "position": 18}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/神经科/共识/2023 AHA科学声明：急诊科短暂性脑缺血发作的诊断、检查和风险降低(1).pdf", "page_num": 9}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "缺少换行#0#0#Development of Telestroke ...另起一行\n多余换行#1#1#under-resourced communities ...与上面0段后面联接\n多余换行#10#10#subsequent risk for recurrent stroke...与9段联接\n缺少换行#10#10#Telehealth or other electronic  另起一行\n标点错误#10#10# commu¬  去掉 ¬", "type3": "无关文本#0#17#61 Development of Telestroke ...\n...resource allocation) sources. 50 像这样在.号或，号的开头或结尾出现的数字都是无关引用\n无关文本#18#19#侧面栏目信息", "type4": null, "type5": null, "type6": "有用性#13#17#文章补充信息的内容"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:41", "update_time": "2024-05-07 19:01:05"}
{"id": 1082580, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 738, "source_info": {"seq_id": "479efd66-8c2b-4fc3-8478-64c7cb4b34b7", "title": null, "text": "【0】页码:18\n  Guideline\n\n【1】 Suggested dose adjustments in high-risk groups Table 3 High-risk groups Benzodiazepine Opioid Elderly/frail Reduce dose and increments Reduce dose and increments Reduce dose and increments Reduce dose and increments Decompensated chronic liver disease 50% adult dose 50% adult dose Chronic renal failure (eGFR<30) Reduce dose and increments Reduce dose and increments 50% adult dose 50% adult dose Respiratory failure (FVC<50% predicted) Minimise dose and consider adjunctive NIV Minimise dose and consider adjunctive NIV Chronic progressive neuromyopathic disorders (FVC<50% predicted) Minimise dose and consider adjunctive NIV Minimise dose and consider adjunctive NIV NB: Benzodiazepines and opioids act synergistically and if co-administered further dose reduction (by, for example, 30%) should be considered. Short-acting opioids should be preferred. 51 eGFR, estimated glomerular filtration rate; FVC, forced vital capacity; NIV, non-invasive ventilation.\n\n【2】\n much for many patients. Following the publication of guidelines for standards of colonoscopy training and practice, the safety of sedation for colonoscopy in the UK has improved significantly, with a national audit reporting the use of reversal agents during colonoscopy in only 0.1% in 2011, compared with 14% in 2004. 210 21 36. We recommend that frail, elderly or comorbid patients (ASA grade 3 or greater) are given half or less of the dose required for younger healthy patients and need smaller incremental doses, if required Grade of evidence: Low. Strength of recommendation: Strong.\n\n【3】Level of agreement: 92.3% Elderly patients (over 70 years of age) are more sensitive to sedative and analgesic drugs than younger patients due to a combination of factors, including age-related pharmacokinetic changes (eg, reduced hepatic and renal drug clearance), increased central sensitivity and blunted cardiorespiratory stimulation by hypoxia or hypercapnia. 212 The dose of any sedation given to the elderly needs to be carefully considered. Subsequent incremental and cumulative doses should also be reduced. 213 Finally, needing to use reversal agents for sedation has also been reported to be more common with increasing ASA grade, when age is adjusted for. 214 Table 3 recommends dose adjustments in high-risk groups.\n\n【4】Capnography has been shown to reduce the incidences of hypoxaemic events during procedural sedation in emergency and elective dental setting. 69 71 Although there is limited evidence of the role of capnography in GI endoscopy, we would recommend its use in this patient group to reduce the risk of adverse events.\n\n【5】37. We suggest that patients with established cardiovascular disease at high risk of cardiac dysrhythmias undergo ECG monitoring and have supplemental oxygen during endoscopy with sedation Grade of evidence: Low. Strength of recommendation: Weak.\n\n【6】Level of agreement: 84.6% Cardiopulmonary adverse events are the the most common type of endoscopy-related events, accounting for over 60% of unplanned events during sedated upper GI endoscopy. 215 These include significant cardiovascular events, such as dysrhythmias, angina, myocardial infarction or stroke. Patient-related risk factors for these events include pre-existing cardiopulmonary disease, advancing age, an ASA grade of 3 or above and inpatient status. 109 216 217 An analysis of nearly 2 million endoscopies revealed that age was the key predictor for cardiocerebrovascular events following upper GI endoscopy, which typically occurred within 3 days of endoscopy, but age and sedation were independently associated with such events following colonoscopy. 38 Sinus bradycardia can be induced by vagal stimulation, which usually occurs during stretching of the sigmoid mesentery during colonoscopy or flexible sigmoidoscopy. More serious 18\n\n【7】 dysrhythmias are rare during endoscopy, but assessing heart rate prior to endoscopy on baseline observations and using ECG monitoring in patients with cardiovascular disease at increased risk of dysrhythmias (eg, pacemaker or known dysrhythmia) is suggested as good practice. In addition, the endoscopist performing the procedure should have sufficient training to interpret ECG and recognition of arrythmia and when to seek assistance of the cardiology team.\n\n【8】38. We recommend that patients at risk of myocardial ischaemia during endoscopy with sedation should continue their normal anti-anginal therapy and receive supplemental oxygen before, during and after endoscopy Grade of evidence: Low. Strength of recommendation: Strong.\n\n【9】Level of agreement: 100% Myocardial infarction can occur either during, or in the few days after, endoscopy with or without sedation. Haemodynamic changes with increased myocardial oxygen demand and reduced myocardial perfusion during endoscopy may contribute. 218 The following measures have been suggested to prevent or minimise the risk of myocardial ischemia/infarction during endoscopy: (1) pre-oxygenation in at risk patients and continuous oxygen during the procedure; (2) continuing normal anti-hypertensive or anti-anginal therapy right up to the endoscopy in all patients with a history of ischaemic heart disease; managing angina during an endoscopy by giving sublingual glyceryl trinitrate, oxygen and discontinuing the examination; and (4) if angina or myocardial infarction is suspected during or following endoscopy, arrange an urgent ECG to exclude myocardial infarction. 2 39. We recommend that patients with decompensated chronic liver disease undergoing endoscopy with sedation should be assessed for hepatic encephalopathy prior to endoscopy Grade of evidence: Low. Strength of recommendation: Strong.\n\n【10】Level of agreement: 92.3% Chronic liver disease can impair the metabolism of drugs usually administered for sedation for endoscopy. Liver dysfunction can reduce both the clearance of drugs eliminated by hepatic metabolism or biliary excretion and affect plasma protein binding. 219 Chronic liver disease is also associated with a reduction in drug-metabolising activities, such as the activity of the CYP450 enzymes.\n\n【11】In a case series from Pakistan of patients undergoing endos-\n\n【12】 copy with sedation with midazolam, 4.2% developed clinically overt encephalopathy following endoscopy, although all recovered by 6 hours. 220 This was related to higher Child-Pugh class and midazolam dose. The pre-endoscopy evaluation of patients with Child-Pugh B or C cirrhosis should therefore include an assessment of neuropsychiatric findings suggestive of hepatic encephalopathy.\n\n【13】 Sidhu R, et al. Gut 2023;0:1–27. doi:10.1136/gutjnl-2023-330396", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": " Guideline", "bbox": [54.0, 30.0, 127.0, 46.0]}], "type": "Text", "position": 0}, {"raw_context": [{"text": "Suggested dose adjustments in high-risk groups", "bbox": [105.0, 68.0, 326.0, 82.0]}, {"text": "Table 3", "bbox": [58.0, 69.0, 100.0, 83.0]}, {"text": "High-risk groups", "bbox": [58.0, 89.0, 129.0, 101.0]}, {"text": "Benzodiazepine", "bbox": [345.0, 89.0, 412.0, 100.0]}, {"text": "Opioid", "bbox": [539.0, 90.0, 570.0, 100.0]}, {"text": "Elderly/frail", "bbox": [59.0, 107.0, 105.0, 119.0]}, {"text": "Reduce dose and increments", "bbox": [345.0, 107.0, 456.0, 119.0]}, {"text": "Reduce dose and increments", "bbox": [538.0, 107.0, 651.0, 119.0]}, {"text": "Reduce dose and increments", "bbox": [345.0, 122.0, 456.0, 136.0]}, {"text": "Reduce dose and increments", "bbox": [539.0, 123.0, 651.0, 135.0]}, {"text": "Decompensated chronic liver disease", "bbox": [59.0, 124.0, 202.0, 135.0]}, {"text": "50% adult dose", "bbox": [345.0, 135.0, 407.0, 147.0]}, {"text": "50% adult dose", "bbox": [539.0, 135.0, 602.0, 147.0]}, {"text": "Chronic renal failure (eGFR<30)", "bbox": [59.0, 150.0, 182.0, 164.0]}, {"text": "Reduce dose and increments", "bbox": [345.0, 150.0, 456.0, 165.0]}, {"text": "Reduce dose and increments", "bbox": [539.0, 150.0, 650.0, 164.0]}, {"text": "50% adult dose", "bbox": [345.0, 165.0, 408.0, 176.0]}, {"text": "50% adult dose", "bbox": [539.0, 165.0, 602.0, 176.0]}, {"text": "Respiratory failure (FVC<50% predicted)", "bbox": [59.0, 179.0, 216.0, 192.0]}, {"text": "Minimise dose and consider adjunctive NIV", "bbox": [345.0, 179.0, 512.0, 192.0]}, {"text": "Minimise dose and consider adjunctive NIV", "bbox": [538.0, 180.0, 706.0, 192.0]}, {"text": "Chronic progressive neuromyopathic disorders (FVC<50% predicted)", "bbox": [59.0, 195.0, 322.0, 207.0]}, {"text": "Minimise dose and consider adjunctive NIV", "bbox": [345.0, 195.0, 511.0, 206.0]}, {"text": "Minimise dose and consider adjunctive NIV", "bbox": [539.0, 195.0, 706.0, 206.0]}, {"text": "NB: Benzodiazepines and opioids act synergistically and if co-administered further dose reduction (by, for example, 30%) should be considered. Short-acting opioids should be", "bbox": [58.0, 211.0, 721.0, 225.0]}, {"text": "preferred. 51", "bbox": [59.0, 226.0, 103.0, 238.0]}, {"text": "eGFR, estimated glomerular filtration rate; FVC, forced vital capacity; NIV, non-invasive ventilation.", "bbox": [58.0, 235.0, 433.0, 251.0]}], "type": "Table", "position": 1}, {"raw_context": [{"text": "much for many patients. Following the publication of guidelines", "bbox": [53.0, 281.0, 386.0, 295.0]}, {"text": "for standards of colonoscopy training and practice, the safety", "bbox": [53.0, 296.0, 385.0, 310.0]}, {"text": "of sedation for colonoscopy in the UK has improved signifi-", "bbox": [53.0, 311.0, 385.0, 326.0]}, {"text": "cantly, with a national audit reporting the use of reversal agents", "bbox": [53.0, 325.0, 387.0, 340.0]}, {"text": "during colonoscopy in only 0.1% in 2011, compared with 14%", "bbox": [53.0, 340.0, 387.0, 354.0]}, {"text": "in 2004. 210 21", "bbox": [53.0, 357.0, 122.0, 367.0]}, {"text": "36. We recommend that frail, elderly or comorbid patients", "bbox": [66.0, 369.0, 385.0, 383.0]}, {"text": "(ASA grade 3 or greater) are given half or less of the dose", "bbox": [53.0, 384.0, 385.0, 398.0]}, {"text": "required for younger healthy patients and need smaller incre-", "bbox": [53.0, 399.0, 384.0, 413.0]}, {"text": "mental doses, if required", "bbox": [53.0, 414.0, 185.0, 428.0]}, {"text": "Grade of evidence: Low. Strength of recommendation: Strong.", "bbox": [65.0, 428.0, 383.0, 443.0]}, {"text": "Level of agreement: 92.3%", "bbox": [66.0, 444.0, 208.0, 457.0]}, {"text": "Elderly patients (over 70 years of age) are more sensitive to", "bbox": [65.0, 458.0, 386.0, 472.0]}, {"text": "sedative and analgesic drugs than younger patients due to a", "bbox": [53.0, 473.0, 386.0, 487.0]}, {"text": "combination of factors, including age-related pharmacokinetic", "bbox": [53.0, 488.0, 386.0, 502.0]}, {"text": "changes (eg, reduced hepatic and renal drug clearance), increased", "bbox": [53.0, 502.0, 386.0, 517.0]}, {"text": "central sensitivity and blunted cardiorespiratory stimulation by", "bbox": [53.0, 517.0, 385.0, 531.0]}, {"text": "hypoxia or hypercapnia. 212 The dose of any sedation given to the", "bbox": [53.0, 530.0, 386.0, 547.0]}, {"text": "elderly needs to be carefully considered. Subsequent incremental", "bbox": [53.0, 546.0, 385.0, 560.0]}, {"text": "and cumulative doses should also be reduced. 213 Finally, needing", "bbox": [53.0, 561.0, 386.0, 574.0]}, {"text": "to use reversal agents for sedation has also been reported to be", "bbox": [53.0, 576.0, 386.0, 589.0]}, {"text": "more common with increasing ASA grade, when age is adjusted", "bbox": [53.0, 590.0, 386.0, 604.0]}, {"text": "for. 214 Table 3 recommends dose adjustments in high-risk groups.", "bbox": [53.0, 604.0, 385.0, 619.0]}, {"text": "Capnography has been shown to reduce the incidences of", "bbox": [65.0, 620.0, 386.0, 633.0]}, {"text": "hypoxaemic events during procedural sedation in emergency and", "bbox": [53.0, 635.0, 385.0, 649.0]}, {"text": "elective dental setting. 69 71 Although there is limited evidence of", "bbox": [53.0, 645.0, 385.0, 662.0]}, {"text": "the role of capnography in GI endoscopy, we would recommend", "bbox": [53.0, 663.0, 385.0, 677.0]}, {"text": "its use in this patient group to reduce the risk of adverse events.", "bbox": [53.0, 678.0, 384.0, 692.0]}, {"text": "37. We suggest that patients with established cardiovascular", "bbox": [66.0, 693.0, 385.0, 706.0]}, {"text": "disease at high risk of cardiac dysrhythmias undergo ECG moni-", "bbox": [53.0, 707.0, 385.0, 721.0]}, {"text": "toring and have supplemental oxygen during endoscopy with", "bbox": [53.0, 722.0, 385.0, 736.0]}, {"text": "sedation", "bbox": [54.0, 738.0, 100.0, 751.0]}, {"text": "Grade of evidence: Low. Strength of recommendation: Weak.", "bbox": [65.0, 751.0, 377.0, 766.0]}, {"text": "Level of agreement: 84.6%", "bbox": [66.0, 766.0, 207.0, 780.0]}, {"text": "Cardiopulmonary adverse events are the the most common", "bbox": [64.0, 781.0, 386.0, 795.0]}, {"text": "type of endoscopy-related events, accounting for over 60% of", "bbox": [53.0, 796.0, 385.0, 810.0]}, {"text": "unplanned events during sedated upper GI endoscopy. 215 These", "bbox": [53.0, 811.0, 385.0, 823.0]}, {"text": "include significant cardiovascular events, such as dysrhythmias,", "bbox": [53.0, 826.0, 385.0, 839.0]}, {"text": "angina, myocardial infarction or stroke. Patient-related risk", "bbox": [53.0, 840.0, 385.0, 853.0]}, {"text": "factors for these events include pre-existing cardiopulmonary", "bbox": [53.0, 854.0, 385.0, 868.0]}, {"text": "disease, advancing age, an ASA grade of 3 or above and inpa-", "bbox": [53.0, 869.0, 385.0, 884.0]}, {"text": "tient status. 109 216 217 An analysis of nearly 2 million endoscopies", "bbox": [53.0, 881.0, 387.0, 900.0]}, {"text": "revealed that age was the key predictor for cardiocerebrovascular", "bbox": [53.0, 899.0, 385.0, 913.0]}, {"text": "events following upper GI endoscopy, which typically occurred", "bbox": [53.0, 914.0, 385.0, 927.0]}, {"text": "within 3 days of endoscopy, but age and sedation were inde-", "bbox": [53.0, 928.0, 384.0, 941.0]}, {"text": "pendently associated with such events following colonoscopy. 38", "bbox": [53.0, 943.0, 381.0, 957.0]}, {"text": "Sinus bradycardia can be induced by vagal stimulation, which", "bbox": [65.0, 957.0, 386.0, 971.0]}, {"text": "usually occurs during stretching of the sigmoid mesentery", "bbox": [53.0, 971.0, 385.0, 986.0]}, {"text": "during colonoscopy or flexible sigmoidoscopy. More serious", "bbox": [53.0, 985.0, 386.0, 1002.0]}, {"text": "18", "bbox": [55.0, 1010.0, 68.0, 1021.0]}], "type": "Text", "position": 2}, {"raw_context": [{"text": "dysrhythmias are rare during endoscopy, but assessing heart rate", "bbox": [406.0, 281.0, 739.0, 295.0]}, {"text": "prior to endoscopy on baseline observations and using ECG", "bbox": [406.0, 296.0, 739.0, 310.0]}, {"text": "monitoring in patients with cardiovascular disease at increased", "bbox": [406.0, 311.0, 740.0, 325.0]}, {"text": "risk of dysrhythmias (eg, pacemaker or known dysrhythmia)", "bbox": [406.0, 326.0, 740.0, 339.0]}, {"text": "is suggested as good practice. In addition, the endoscopist", "bbox": [406.0, 340.0, 740.0, 354.0]}, {"text": "performing the procedure should have sufficient training to", "bbox": [407.0, 355.0, 740.0, 369.0]}, {"text": "interpret ECG and recognition of arrythmia and when to seek", "bbox": [406.0, 370.0, 739.0, 383.0]}, {"text": "assistance of the cardiology team.", "bbox": [408.0, 385.0, 582.0, 399.0]}, {"text": "38. We recommend that patients at risk of myocardial isch-", "bbox": [418.0, 399.0, 739.0, 413.0]}, {"text": "aemia during endoscopy with sedation should continue their", "bbox": [407.0, 413.0, 739.0, 428.0]}, {"text": "normal anti-anginal therapy and receive supplemental oxygen", "bbox": [406.0, 428.0, 739.0, 443.0]}, {"text": "before, during and after endoscopy", "bbox": [407.0, 444.0, 590.0, 458.0]}, {"text": "Grade of evidence: Low. Strength of recommendation: Strong.", "bbox": [418.0, 458.0, 737.0, 472.0]}, {"text": "Level of agreement: 100%", "bbox": [418.0, 473.0, 557.0, 486.0]}, {"text": "Myocardial infarction can occur either during, or in the", "bbox": [418.0, 488.0, 740.0, 502.0]}, {"text": "few days after, endoscopy with or without sedation. Haemo-", "bbox": [407.0, 502.0, 739.0, 516.0]}, {"text": "dynamic changes with increased myocardial oxygen demand", "bbox": [406.0, 517.0, 740.0, 531.0]}, {"text": "and reduced myocardial perfusion during endoscopy may", "bbox": [407.0, 532.0, 739.0, 546.0]}, {"text": "contribute. 218 The following measures have been suggested to", "bbox": [406.0, 544.0, 740.0, 562.0]}, {"text": "prevent or minimise the risk of myocardial ischemia/infarc-", "bbox": [406.0, 561.0, 738.0, 574.0]}, {"text": "tion during endoscopy: (1) pre-oxygenation in at risk patients", "bbox": [406.0, 576.0, 740.0, 589.0]}, {"text": "and continuous oxygen during the procedure; (2) continuing", "bbox": [407.0, 590.0, 739.0, 605.0]}, {"text": "normal anti-hypertensive or anti-anginal therapy right up", "bbox": [406.0, 605.0, 739.0, 619.0]}, {"text": "to the endoscopy in all patients with a history of ischaemic", "bbox": [406.0, 619.0, 739.0, 633.0]}, {"text": "heart disease; managing angina during an endoscopy by giving", "bbox": [406.0, 634.0, 740.0, 648.0]}, {"text": "sublingual glyceryl trinitrate, oxygen and discontinuing the", "bbox": [406.0, 649.0, 739.0, 662.0]}, {"text": "examination; and (4) if angina or myocardial infarction is", "bbox": [406.0, 663.0, 740.0, 677.0]}, {"text": "suspected during or following endoscopy, arrange an urgent", "bbox": [406.0, 678.0, 740.0, 692.0]}, {"text": "ECG to exclude myocardial infarction. 2", "bbox": [406.0, 693.0, 615.0, 707.0]}, {"text": "39. We recommend that patients with decompensated chronic", "bbox": [419.0, 707.0, 739.0, 721.0]}, {"text": "liver disease undergoing endoscopy with sedation should be", "bbox": [406.0, 722.0, 739.0, 736.0]}, {"text": "assessed for hepatic encephalopathy prior to endoscopy", "bbox": [407.0, 737.0, 696.0, 751.0]}, {"text": "Grade of evidence: Low. Strength of recommendation: Strong.", "bbox": [418.0, 751.0, 737.0, 766.0]}, {"text": "Level of agreement: 92.3%", "bbox": [418.0, 766.0, 560.0, 780.0]}, {"text": "Chronic liver disease can impair the metabolism of drugs", "bbox": [418.0, 781.0, 739.0, 795.0]}, {"text": "usually administered for sedation for endoscopy. Liver dysfunc-", "bbox": [406.0, 795.0, 737.0, 810.0]}, {"text": "tion can reduce both the clearance of drugs eliminated by hepatic", "bbox": [406.0, 811.0, 739.0, 825.0]}, {"text": "metabolism or biliary excretion and affect plasma protein", "bbox": [406.0, 826.0, 739.0, 839.0]}, {"text": "binding. 219 Chronic liver disease is also associated with a reduc-", "bbox": [406.0, 837.0, 738.0, 855.0]}, {"text": "tion in drug-metabolising activities, such as the activity of the", "bbox": [406.0, 855.0, 739.0, 869.0]}, {"text": "CYP450 enzymes.", "bbox": [406.0, 869.0, 502.0, 883.0]}, {"text": "In a case series from Pakistan of patients undergoing endos-", "bbox": [418.0, 883.0, 739.0, 898.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "copy with sedation with midazolam, 4.2% developed clinically", "bbox": [406.0, 898.0, 739.0, 912.0]}, {"text": "overt encephalopathy following endoscopy, although all recov-", "bbox": [406.0, 913.0, 738.0, 927.0]}, {"text": "ered by 6 hours. 220 This was related to higher Child-Pugh class", "bbox": [406.0, 927.0, 739.0, 941.0]}, {"text": "and midazolam dose. The pre-endoscopy evaluation of patients", "bbox": [407.0, 943.0, 740.0, 956.0]}, {"text": "with Child-Pugh B or C cirrhosis should therefore include an", "bbox": [406.0, 957.0, 740.0, 970.0]}, {"text": "assessment of neuropsychiatric findings suggestive of hepatic", "bbox": [407.0, 971.0, 739.0, 986.0]}, {"text": "encephalopathy.", "bbox": [406.0, 987.0, 492.0, 1000.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": "Sidhu R, et al. Gut 2023;0:1–27. doi:10.1136/gutjnl-2023-330396", "bbox": [477.0, 1008.0, 739.0, 1022.0]}], "type": "Text", "position": 5}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/消化科/_2023 BSG指南：胃肠内窥镜检查中的镇静.pdf", "page_num": 18}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "缺少换行#2#2#36. We recommend that frail, \nGrade of evidence: Low. 都另起一行\n缺少换行#3#3# Elderly patients (over 70 years of age) 另起一行\n缺少换行#5#5# Grade of evidence: Low. 另起一行\n缺少换行#6#6# Cardiopulmonary adverse events...\nSinus bradycardia can be induced...都另起一行\n多余换行#7#7#dysrhythmias are rare during endoscopy,与上面6段联接\n缺少换行#8#8# Grade of evidence: Low. 另起一行\n缺少换行#9#9# Myocardial infarction can occur ...\n39. We recommend that patients...\nGrade of evidence: Low. 都另起一行\n缺少换行#10#10#Chronic liver disease can impair...另起一行\n多余换行#12#12#copy with sedation with midazolam, 与上面11段联接", "type3": "无关文本#2#12#,compared with 14% in 2004. 210 21 \nor hypercapnia. 212类似出现在句子末尾的文字引用过多", "type4": null, "type5": null, "type6": "准确性#1#1#表格的内容，但里面的顺序杂乱\n有用性#13#13#页脚内容"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:41", "update_time": "2024-05-08 00:12:56"}
{"id": 1082579, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 738, "source_info": {"seq_id": "578e7fb2-1156-49e5-bab5-74adeaa9c9e4", "title": null, "text": "【0】页码:15\n Therapy. Molecules. 2020 , 25(20):4764.\n [5]\n Chau CH, Steeg PS, Figg WD. Antibody-drug conjugates for cancer. Lancet. 2019 , 394(10200):793-804.\n [6] FDA: Clinical Pharmacology Considerations for Antibody-Drug Conjugates Guidance for Industry.\n\n【1】 https://www.fda.gov/regulatory-information/search-fda-guidance-\n\n【2】 documents/clinical-pharmacology-considerations-antibody-drug-conjugatesguidance-industry\n [7] Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat Rev Clin Oncol. 2021 ,18(6):327-344.\n [8]     中 国 抗 癌 协 会 册 瘤 药 物 临 床 研 究 专 业 委 员 会 等 ，抗 体 药 物 偶 联 物 治 疗 恶 性 肿 瘤 临 床 应 用 专 家 共 识 （ 2020 版 ） . 中 华 肿 瘤 杂 芯 ,2021,43(1):1-14.\n [9]  国家药监局药审中心关于发布《抗肿瘤药联合治疗临床试验技术指 导 原 则 》 的 通 告 ( 2020 年 第 55 号 ) .\n\n【3】https://www.cde.org.cn/zdyz/opinioninfopage?zdyzIdCODE=70c43f6aac23f2e81 9c219775bd81850&rddt=1", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "Therapy. Molecules. 2020 , 25(20):4764.", "bbox": [149.0, 102.0, 415.0, 120.0]}], "type": "Text", "position": 0}, {"raw_context": [{"text": "[5]", "bbox": [117.0, 134.0, 150.0, 152.0]}], "type": "List-item", "position": 1}, {"raw_context": [{"text": "Chau CH, Steeg PS, Figg WD. Antibody-drug conjugates for cancer. Lancet. 2019 ,", "bbox": [148.0, 133.0, 681.0, 152.0]}, {"text": "394(10200):793-804.", "bbox": [149.0, 164.0, 291.0, 182.0]}], "type": "List-item", "position": 2}, {"raw_context": [{"text": "[6] FDA: Clinical Pharmacology Considerations for Antibody-Drug Conjugates", "bbox": [117.0, 196.0, 677.0, 216.0]}, {"text": "Guidance for Industry.", "bbox": [148.0, 228.0, 297.0, 245.0]}], "type": "List-item", "position": 3}, {"raw_context": [{"text": "https://www.fda.gov/regulatory-information/search-fda-guidance-", "bbox": [145.0, 259.0, 573.0, 278.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": "documents/clinical-pharmacology-considerations-antibody-drug-conjugates-", "bbox": [144.0, 291.0, 647.0, 310.0]}, {"text": "guidance-industry", "bbox": [145.0, 322.0, 269.0, 341.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "[7] Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of antibody-drug", "bbox": [117.0, 352.0, 677.0, 370.0]}, {"text": "conjugates for cancer therapy. Nat Rev Clin Oncol. 2021 ,18(6):327-344.", "bbox": [148.0, 383.0, 623.0, 402.0]}], "type": "List-item", "position": 6}, {"raw_context": [{"text": "[8]     中 国 抗 癌 协 会 册 瘤 药 物 临 床 研 究 专 业 委 员 会 等 ，抗 体 药 物 偶 联 物 治", "bbox": [117.0, 415.0, 672.0, 435.0]}, {"text": "疗 恶 性 肿 瘤 临 床 应 用 专 家 共 识 （ 2020 版 ） . 中 华 肿 瘤 杂", "bbox": [149.0, 445.0, 672.0, 466.0]}, {"text": "芯 ,2021,43(1):1-14.", "bbox": [150.0, 478.0, 303.0, 496.0]}], "type": "List-item", "position": 7}, {"raw_context": [{"text": "[9]  国家药监局药审中心关于发布《抗肿瘤药联合治疗临床试验技术指", "bbox": [117.0, 507.0, 674.0, 527.0]}, {"text": "导 原 则 》 的 通 告 ( 2020 年 第 55 号 ) .", "bbox": [151.0, 539.0, 443.0, 559.0]}, {"text": "https://www.cde.org.cn/zdyz/opinioninfopage?zdyzIdCODE=70c43f6aac23f2e81", "bbox": [146.0, 571.0, 669.0, 589.0]}, {"text": "9c219775bd81850&rddt=1", "bbox": [146.0, 602.0, 328.0, 621.0]}], "type": "List-item", "position": 8}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/肿瘤科/共识/抗肿瘤抗体偶联药物临床研发技术指导原则(1).pdf", "page_num": 15}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": null, "type3": null, "type4": null, "type5": null, "type6": "信息有用性#0#3#参考文献"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:41", "update_time": "2024-05-08 23:25:03"}
{"id": 1082578, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 738, "source_info": {"seq_id": "d3cf881c-224d-4f6d-b880-39cce32d48e4", "title": null, "text": "【0】页码:14\n\n【1】## \" Bjhaem\n\n【2】\n 47. Effect of early tranexamic acid administration on mortality, Hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, doubleblind, placebo-controlled trial. Lancet. 2017;389:2105–16.\n\n【3】48. Li C, Hirsh J, Xie C, Johnston MA, Eikelboom JW. Reversal of the anti-platelet effects of aspirin and clopidogrel. J Thromb Haemost.\n\n【4】2012;10:521–8.\n\n【5】49. Devereaux PJ, Mrkobrada M, Sessler DI, Leslie K, Alonso- Coello P, Kurz A, et al. Aspirin in patients undergoing noncardiac surgery. N Engl J Med. 2014;370:1494–503.\n\n【6】50. Siegal D, Yudin J, Kaatz S, Douketis JD, Lim W, Spyropoulos AC.\n\n【7】Periprocedural heparin bridging in patients receiving vitamin K antagonists: systematic review and meta-analysis of bleeding and thromboembolic rates. Circulation. 2012;126:1630–9.\n\n【8】51. Passaglia LG, de Barros GM, de Sousa MR. Early postoperative bridging anticoagulation after mechanical heart valve replacement: a systematic review and meta-analysis. J Thromb Haemost.\n\n【9】2015;13:1557–67.\n\n【10】Kovacs MJ, Wells PS, Anderson DR, Lazo-Langner A, Kearon C, 52.\n\n【11】Bates SM, et al. Postoperative low molecular weight heparin bridging treatment for patients at high risk of arterial thromboembolism (PERIOP2): double blind randomised controlled trial. BMJ (Clinical Research Ed). 2021;373:n1205.\n\n【12】53. Intrapartum care for women with existing medical conditions or obstetric complications and their babies. NICE guideline 121. Published 6 March 2019. www.nice.org.uk/guidance/ng121- complications- andtheir-babies-pdf-66141653845957 [Accessed 30 December 22].\n\n【13】54. Regional anaesthesia and patients with abnormalities of coagulation: The Association of Anaesthetists of Great Britain & Ireland the Obstetric Anaesthetists' Association regional Anaesthesia UK.\n\n【14】Anaesthesia. 2013;68:966–72.\n\n【15】55. Khader KA, Saad AS, Abdelshafy M. Pregnancy outcome in women with mechanical prosthetic heart valves treated with unfractionated heparin (UFH) or enoxaparin. J Obstet Gynaecol India.\n\n【16】2016;66:321–6.\n\n【17】56. Abildgaard U, Sandset PM, Hammerstrøm J, Gjestvang FT, Tveit A. Management of pregnant women with mechanical heart valve prosthesis: thromboprophylaxis with low molecular weight heparin.\n\n【18】Thromb Res. 2009;124:262–7.\n\n【19】57. Irani RA, Santa-Ines A, Elder RW, Lipkind HS, Paidas MJ, Campbell KH. Postpartum anticoagulation in women with mechanical heart valves. Int J Womens Health. 2018;10:663–70.\n\n【20】Kariv S, Azibani F, Baard J, Osman A, Soma-Pillay P, Anthony J, et al.\n\n【21】Haemorrhage and other complications in pregnant women on anticoagulation for mechanical heart valves: a prospective observational cohort study. Cardiovasc J Afr. 2018;29:289–95.\n\n【22】 59. Cousin B, Guglielminotti J, Iung B, Montravers P. Retrospective study of anaesthetic management of pregnancy patients with mechanical heart valve prosthesis and anticoagulants. Anaesth Crit Care Pain Med. 2018;37:225–31.\n\n【23】60. Bhatia K, Shehata N, D'Souza R. Anaesthetic considerations and anticoagulation in pregnant patients with mechanical heart valves. BJA Educ. 2022;22:273–81.\n\n【24】61. Horlocker TT, Vandermeuelen E, Kopp SL, Gogarten W, Leffert LR, Benzon HT. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine evidence-based guidelines (fourth edition). Reg Anesth Pain Med. 2018;43:263–309.\n\n【25】62. Davidson BL, Verheijen S, Lensing AW, Gebel M, Brighton TA, Lyons RM, et al. Bleeding risk of patients with acute venous thromboembolism taking nonsteroidal anti-inflammatory drugs or aspirin. JAMA Intern Med. 2014;174:947–53.\n\n【26】63. Caesarean Birth NICE Guideline NG 192. Published: 31 March 2021.\n\n【27】www.nice.org.uk/guidance/ng192 [Accessed 30 December 22].\n\n【28】Noga T, Bruce AA, Blain H, Nahirniak S. Four-factor prothrombin complex concentrates in paediatric patients—a retrospective case series. Vox Sang. 2016;110:253–7.\n\n【29】65. Mitsiakos G, Karametou M, Gkampeta A, Karali C, Papathanasiou AE, Papacharalambous E, et al. Effectiveness and safety of 4-factor prothrombin complex concentrate (4PCC) in neonates with intractable bleeding or severe coagulation disturbances: a retrospective study of 37 cases. J Pediatr Hematol Oncol. 2019;41:e135–40.\n\n【30】66. FSRH. Clinical guideline: contraceptive choices for women with cardiac disease. 2014 https://www.fsrh.org/documents/ceu-guidance-contr aceptive-choices-for-women-with-cardiac/ [Accessed 20 March 22].\n\n【31】## Supporting Information\n\n【32】\n Additional supporting information can be found online in the Supporting Information section at the end of this article.\n\n【33】 How to cite this article: Lester W, Walker N, Bhatia K, Ciantar E, Banerjee A, Trinder J, et al. British Society for Haematology guideline for anticoagulant management of pregnant individuals with mechanical heart valves. Br J Haematol.\n\n【34】2023;00:1–14. https://doi.org/10.1111/bjh.18781\n\n【35】 upering and in the content and version from the bring of the content of an any more because the sense of the content on the bring one of the content domain one only one one o", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "\" BJHaem", "bbox": [59.0, 24.0, 161.0, 59.0]}], "type": "Section-header", "position": 0}, {"raw_context": [{"text": "47. Effect of early tranexamic acid administration on mortality,", "bbox": [60.0, 58.0, 385.0, 72.0]}, {"text": "Hysterectomy, and other morbidities in women with post-partum", "bbox": [80.0, 73.0, 386.0, 85.0]}, {"text": "haemorrhage (WOMAN): an international, randomised, double-", "bbox": [80.0, 85.0, 385.0, 99.0]}, {"text": "blind, placebo-controlled trial. Lancet. 2017;389:2105–16.", "bbox": [80.0, 100.0, 334.0, 111.0]}, {"text": "48. Li C, Hirsh J, Xie C, Johnston MA, Eikelboom JW. Reversal of the", "bbox": [60.0, 113.0, 387.0, 125.0]}, {"text": "anti-platelet effects of aspirin and clopidogrel. J Thromb Haemost.", "bbox": [80.0, 127.0, 386.0, 139.0]}, {"text": "2012;10:521–8.", "bbox": [81.0, 140.0, 147.0, 152.0]}, {"text": "49. Devereaux PJ, Mrkobrada M, Sessler DI, Leslie K, Alonso- Coello P,", "bbox": [60.0, 152.0, 385.0, 166.0]}, {"text": "Kurz A, et al. Aspirin in patients undergoing noncardiac surgery. N", "bbox": [80.0, 167.0, 387.0, 179.0]}, {"text": "Engl J Med. 2014;370:1494–503.", "bbox": [80.0, 179.0, 221.0, 191.0]}, {"text": "50. Siegal D, Yudin J, Kaatz S, Douketis JD, Lim W, Spyropoulos AC.", "bbox": [60.0, 192.0, 385.0, 205.0]}, {"text": "Periprocedural heparin bridging in patients receiving vitamin K", "bbox": [80.0, 206.0, 386.0, 218.0]}, {"text": "antagonists: systematic review and meta-analysis of bleeding and", "bbox": [80.0, 219.0, 386.0, 232.0]}, {"text": "thromboembolic rates. Circulation. 2012;126:1630–9.", "bbox": [80.0, 234.0, 316.0, 245.0]}, {"text": "51. Passaglia LG, de Barros GM, de Sousa MR. Early postoperative", "bbox": [60.0, 247.0, 387.0, 259.0]}, {"text": "bridging anticoagulation after mechanical heart valve replace-", "bbox": [80.0, 260.0, 385.0, 272.0]}, {"text": "ment: a systematic review and meta-analysis. J Thromb Haemost.", "bbox": [80.0, 272.0, 387.0, 286.0]}, {"text": "2015;13:1557–67.", "bbox": [81.0, 287.0, 156.0, 298.0]}, {"text": "Kovacs MJ, Wells PS, Anderson DR, Lazo-Langner A, Kearon C,", "bbox": [78.0, 298.0, 385.0, 312.0]}, {"text": "52.", "bbox": [60.0, 299.0, 78.0, 311.0]}, {"text": "Bates SM, et al. Postoperative low molecular weight heparin bridg-", "bbox": [80.0, 314.0, 385.0, 325.0]}, {"text": "ing treatment for patients at high risk of arterial thromboembolism", "bbox": [80.0, 327.0, 386.0, 339.0]}, {"text": "(PERIOP2): double blind randomised controlled trial. BMJ (Clinical", "bbox": [80.0, 339.0, 387.0, 352.0]}, {"text": "Research Ed). 2021;373:n1205.", "bbox": [80.0, 353.0, 217.0, 365.0]}, {"text": "53. Intrapartum care for women with existing medical conditions or ob-", "bbox": [60.0, 365.0, 385.0, 378.0]}, {"text": "stetric complications and their babies. NICE guideline 121. Published", "bbox": [80.0, 379.0, 386.0, 392.0]}, {"text": "6 March 2019. www.nice.org.uk/guidance/ng121- complications- and-", "bbox": [80.0, 394.0, 385.0, 406.0]}, {"text": "their-babies-pdf-66141653845957 [Accessed 30 December 22].", "bbox": [80.0, 406.0, 355.0, 419.0]}, {"text": "54. Regional anaesthesia and patients with abnormalities of coagula-", "bbox": [59.0, 419.0, 385.0, 432.0]}, {"text": "tion: The Association of Anaesthetists of Great Britain & Ireland", "bbox": [80.0, 433.0, 386.0, 445.0]}, {"text": "the Obstetric Anaesthetists' Association regional Anaesthesia UK.", "bbox": [80.0, 447.0, 386.0, 458.0]}, {"text": "Anaesthesia. 2013;68:966–72.", "bbox": [81.0, 460.0, 211.0, 472.0]}, {"text": "55. Khader KA, Saad AS, Abdelshafy M. Pregnancy outcome in women", "bbox": [60.0, 471.0, 387.0, 486.0]}, {"text": "with mechanical prosthetic heart valves treated with unfrac-", "bbox": [80.0, 487.0, 385.0, 499.0]}, {"text": "tionated heparin (UFH) or enoxaparin. J Obstet Gynaecol India.", "bbox": [80.0, 499.0, 386.0, 513.0]}, {"text": "2016;66:321–6.", "bbox": [81.0, 513.0, 148.0, 524.0]}, {"text": "56. Abildgaard U, Sandset PM, Hammerstrøm J, Gjestvang FT, Tveit", "bbox": [59.0, 525.0, 387.0, 538.0]}, {"text": "A. Management of pregnant women with mechanical heart valve", "bbox": [80.0, 539.0, 387.0, 552.0]}, {"text": "prosthesis: thromboprophylaxis with low molecular weight heparin.", "bbox": [81.0, 554.0, 385.0, 566.0]}, {"text": "Thromb Res. 2009;124:262–7.", "bbox": [81.0, 567.0, 213.0, 579.0]}, {"text": "57. Irani RA, Santa-Ines A, Elder RW, Lipkind HS, Paidas MJ, Campbell", "bbox": [60.0, 578.0, 387.0, 593.0]}, {"text": "KH. Postpartum anticoagulation in women with mechanical heart", "bbox": [80.0, 592.0, 387.0, 606.0]}, {"text": "valves. Int J Womens Health. 2018;10:663–70.", "bbox": [80.0, 607.0, 282.0, 618.0]}, {"text": "Kariv S, Azibani F, Baard J, Osman A, Soma-Pillay P, Anthony J, et al.", "bbox": [76.0, 619.0, 386.0, 632.0]}, {"text": "Haemorrhage and other complications in pregnant women on anti-", "bbox": [80.0, 634.0, 385.0, 646.0]}, {"text": "coagulation for mechanical heart valves: a prospective observational", "bbox": [80.0, 647.0, 387.0, 659.0]}, {"text": "cohort study. Cardiovasc J Afr. 2018;29:289–95.", "bbox": [80.0, 660.0, 291.0, 673.0]}], "type": "Text", "position": 1}, {"raw_context": [{"text": "59. Cousin B, Guglielminotti J, Iung B, Montravers P. Retrospective study", "bbox": [408.0, 58.0, 733.0, 72.0]}, {"text": "of anaesthetic management of pregnancy patients with mechanical", "bbox": [428.0, 73.0, 735.0, 85.0]}, {"text": "heart valve prosthesis and anticoagulants. Anaesth Crit Care Pain", "bbox": [429.0, 87.0, 735.0, 99.0]}, {"text": "Med. 2018;37:225–31.", "bbox": [430.0, 99.0, 525.0, 111.0]}, {"text": "60. Bhatia K, Shehata N, D'Souza R. Anaesthetic considerations and an-", "bbox": [408.0, 112.0, 733.0, 126.0]}, {"text": "ticoagulation in pregnant patients with mechanical heart valves. BJA", "bbox": [429.0, 127.0, 735.0, 138.0]}, {"text": "Educ. 2022;22:273–81.", "bbox": [429.0, 140.0, 528.0, 152.0]}, {"text": "61. Horlocker TT, Vandermeuelen E, Kopp SL, Gogarten W, Leffert", "bbox": [408.0, 152.0, 735.0, 166.0]}, {"text": "LR, Benzon HT. Regional anesthesia in the patient receiving anti-", "bbox": [429.0, 167.0, 734.0, 179.0]}, {"text": "thrombotic or thrombolytic therapy: American Society of Regional", "bbox": [429.0, 178.0, 735.0, 193.0]}, {"text": "Anesthesia and Pain Medicine evidence-based guidelines (fourth edi-", "bbox": [430.0, 193.0, 733.0, 206.0]}, {"text": "tion). Reg Anesth Pain Med. 2018;43:263–309.", "bbox": [429.0, 206.0, 633.0, 218.0]}, {"text": "62. Davidson BL, Verheijen S, Lensing AW, Gebel M, Brighton TA, Lyons", "bbox": [407.0, 218.0, 735.0, 232.0]}, {"text": "RM, et al. Bleeding risk of patients with acute venous thromboembo-", "bbox": [429.0, 234.0, 734.0, 246.0]}, {"text": "lism taking nonsteroidal anti-inflammatory drugs or aspirin. JAMA", "bbox": [429.0, 247.0, 735.0, 259.0]}, {"text": "Intern Med. 2014;174:947–53.", "bbox": [429.0, 260.0, 561.0, 272.0]}, {"text": "63. Caesarean Birth NICE Guideline NG 192. Published: 31 March 2021.", "bbox": [408.0, 272.0, 734.0, 285.0]}, {"text": "www.nice.org.uk/guidance/ng192 [Accessed 30 December 22].", "bbox": [430.0, 286.0, 705.0, 298.0]}, {"text": "Noga T, Bruce AA, Blain H, Nahirniak S. Four-factor prothrombin", "bbox": [426.0, 299.0, 735.0, 312.0]}, {"text": "complex concentrates in paediatric patients—a retrospective case se-", "bbox": [428.0, 314.0, 733.0, 326.0]}, {"text": "ries. Vox Sang. 2016;110:253–7.", "bbox": [429.0, 327.0, 567.0, 339.0]}, {"text": "65. Mitsiakos G, Karametou M, Gkampeta A, Karali C, Papathanasiou", "bbox": [408.0, 339.0, 735.0, 352.0]}, {"text": "AE, Papacharalambous E, et al. Effectiveness and safety of 4-factor", "bbox": [429.0, 353.0, 735.0, 365.0]}, {"text": "prothrombin complex concentrate (4PCC) in neonates with intracta-", "bbox": [430.0, 366.0, 733.0, 378.0]}, {"text": "ble bleeding or severe coagulation disturbances: a retrospective study", "bbox": [428.0, 380.0, 734.0, 392.0]}, {"text": "of 37 cases. J Pediatr Hematol Oncol. 2019;41:e135–40.", "bbox": [428.0, 392.0, 668.0, 407.0]}, {"text": "66. FSRH. Clinical guideline: contraceptive choices for women with car-", "bbox": [408.0, 407.0, 734.0, 419.0]}, {"text": "diac disease. 2014 https://www.fsrh.org/documents/ceu-guidance-contr", "bbox": [428.0, 420.0, 734.0, 432.0]}, {"text": "aceptive-choices-for-women-with-cardiac/ [Accessed 20 March 22].", "bbox": [428.0, 432.0, 719.0, 446.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "SUPPORTING INFORMATION", "bbox": [406.0, 465.0, 626.0, 481.0]}], "type": "Section-header", "position": 4}, {"raw_context": [{"text": "Additional supporting information can be found online in", "bbox": [407.0, 481.0, 735.0, 496.0]}, {"text": "the Supporting Information section at the end of this article.", "bbox": [406.0, 498.0, 733.0, 512.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "How to cite this article: Lester W, Walker N, Bhatia", "bbox": [424.0, 556.0, 706.0, 572.0]}, {"text": "K, Ciantar E, Banerjee A, Trinder J, et al. British", "bbox": [424.0, 574.0, 686.0, 589.0]}, {"text": "Society for Haematology guideline for", "bbox": [424.0, 590.0, 631.0, 605.0]}, {"text": "anticoagulant management of pregnant individuals", "bbox": [424.0, 606.0, 704.0, 621.0]}, {"text": "with mechanical heart valves. Br J Haematol.", "bbox": [424.0, 622.0, 668.0, 636.0]}, {"text": "2023;00:1–14. https://doi.org/10.1111/bjh.18781", "bbox": [424.0, 638.0, 675.0, 652.0]}], "type": "Text", "position": 6}, {"raw_context": [{"text": "upering and in the content and version from the bring of the content of an any more because the sense of the content on the bring one of the content domain one only one one o", "bbox": [768.0, 26.0, 782.0, 966.0]}], "type": "Text", "position": 7}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/心血管/指南/2023 BSH 指南：机械心脏瓣膜妊娠个体抗凝管理(1).pdf", "page_num": 14}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": null, "type3": "无关文本#1#1#页眉内容，与正文无关", "type4": null, "type5": null, "type6": "有用性#2#35#参考文献的内容"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:41", "update_time": "2024-05-07 18:31:51"}
{"id": 1082577, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 738, "source_info": {"seq_id": "0f6b9dcd-8f41-41d6-bb6a-6c1be1b4d947", "title": null, "text": "【0】页码:1\n 3\n\n【1】 6\n\n【2】 l\n\n【3】 l\n\n【4】 Evidence summary of self-management for patients with knee osteoarthritis/SHAN Xueqi,YU Jiangxuan, WANG Junjie,XU Yawen,SHEN Rui,WANG Xixi\n\n【5】 [Abstract] Objective To extract,summarize and evaluate the best evidence of self-management for patients with knee osteoarthritis(KOA),and to provide evidence-based evidence for improving self-management of patients with KOA. Methods  We searched the guidelines websites,association official websites and integrated databases,for all literature on self-management of patients with KOA;the types of literature included clinical decision-making, guidelines,evidence summaries,expert-consensuses,systematic reviews and randomized controlled trials. The retrieval time was from January 2012 to October 2022. Results A total of 25 articles were included,including 11 guidelines,4 expert consensuses,1 clinical decision,4 systematic reviews and 5 randomized controlled trials. A total of 30 pieces of evidence were extracted. After sorting and discussion,the evidence was integrated into 4 areas, namely learning KOA related knowledge,exercise management,weight management and joint protection. Conclusion The evidence of self-management of patients with KOA is abundant,high quality and authoritative,which can provide evidence-based bases for clinical medical staff,so as to help patients with KOA carry out self-management more scientifically and effectively.\n\n【6】[Key words] Osteoarthritis,Knee; Self-Management; Evidence-Based Nursing\n\n【7】 2022-07-29\n\n【8】 1", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "3", "bbox": [199.0, 48.0, 211.0, 60.0]}], "type": "Text", "position": 1}, {"raw_context": [{"text": "6", "bbox": [276.0, 48.0, 287.0, 61.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "l", "bbox": [113.0, 343.0, 121.0, 357.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "l", "bbox": [155.0, 344.0, 163.0, 357.0]}], "type": "Text", "position": 6}, {"raw_context": [{"text": "Evidence summary of self-management for patients with knee osteoarthritis/SHAN Xueqi,YU Jiangxuan,", "bbox": [111.0, 362.0, 702.0, 377.0]}, {"text": "WANG Junjie,XU Yawen,SHEN Rui,WANG Xixi", "bbox": [111.0, 380.0, 390.0, 396.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "[Abstract] Objective To extract,summarize and evaluate the best evidence of self-management for patients with", "bbox": [112.0, 401.0, 702.0, 415.0]}, {"text": "knee osteoarthritis(KOA),and to provide evidence-based evidence for improving self-management of patients with", "bbox": [111.0, 420.0, 702.0, 434.0]}, {"text": "KOA. Methods  We searched the guidelines websites,association official websites and integrated databases,for all", "bbox": [111.0, 440.0, 703.0, 454.0]}, {"text": "literature on self-management of patients with KOA;the types of literature included clinical decision-making,", "bbox": [111.0, 459.0, 702.0, 474.0]}, {"text": "guidelines,evidence summaries,expert-consensuses,systematic reviews and randomized controlled trials. The retrieval", "bbox": [111.0, 478.0, 702.0, 494.0]}, {"text": "time was from January 2012 to October 2022. Results A total of 25 articles were included,including 11", "bbox": [111.0, 498.0, 702.0, 512.0]}, {"text": "guidelines,4 expert consensuses,1 clinical decision,4 systematic reviews and 5 randomized controlled trials. A total", "bbox": [111.0, 518.0, 703.0, 532.0]}, {"text": "of 30 pieces of evidence were extracted. After sorting and discussion,the evidence was integrated into 4 areas,", "bbox": [111.0, 537.0, 702.0, 552.0]}, {"text": "namely learning KOA related knowledge,exercise management,weight management and joint protection. Conclusion", "bbox": [111.0, 556.0, 703.0, 572.0]}, {"text": "The evidence of self-management of patients with KOA is abundant,high quality and authoritative,which can", "bbox": [111.0, 575.0, 703.0, 591.0]}, {"text": "provide evidence-based bases for clinical medical staff,so as to help patients with KOA carry out self-management", "bbox": [111.0, 595.0, 702.0, 609.0]}, {"text": "more scientifically and effectively.", "bbox": [111.0, 615.0, 285.0, 629.0]}, {"text": "[Key words] Osteoarthritis,Knee; Self-Management; Evidence-Based Nursing", "bbox": [111.0, 634.0, 525.0, 649.0]}], "type": "Text", "position": 8}, {"raw_context": [{"text": "2022-07-29", "bbox": [85.0, 980.0, 138.0, 994.0]}], "type": "Text", "position": 10}, {"raw_context": [{"text": "1", "bbox": [420.0, 977.0, 430.0, 989.0]}], "type": "Text", "position": 11}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/骨科/解读/膝骨关节炎患者自我管理的最佳证据总结.pdf", "page_num": 1}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "格式杂乱#0#8#全篇格式杂乱", "type3": null, "type4": null, "type5": null, "type6": null}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:41", "update_time": "2024-05-07 23:22:27"}
{"id": 1082576, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 738, "source_info": {"seq_id": "42bb85ea-460a-474c-89ec-e24eab575a78", "title": null, "text": "【0】页码:7\n\n【1】## 〈 † ¶ M G E S S 》 2020年第30 S 第10期\n\n【2】\n predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas [ J ] . Clin Cancer Res, 2014, 20(3): 764–775.\n\n【3】MOORE K, COLOMBO N , SCAMBIA G, et al. Maintenance [ 5 ] olaparib in patients with newly diagnosed advanced ovarian cancer [ J ] . N Engl J Med, 379, 26(2018): 2495–2505.\n\n【4】[ 6 ] ANTONIOU A, PHAROAH P D, NAROD S, et al. Average risks of breast and ovarian cancer associated with BRCA 1 or BRCA 2 mutations detected in case series unselected for family history: a combined analysis of 22 studies [ J ] . Am J Hum Genet , 2003, 72(5): 1117-1130.\n\n【5】[ 7 ] CHEN S, PARMIGIANI G. Meta-analysis of BRCA 1 and BRCA2 penetrance [J] . J Clin Oncol, 2007, 25(11): 1329- 1333.\n\n【6】[ 8 ] HOWLADER N , NOONE A M , KRAPCHO M , et al. SEER cancer statistics review, 1975-2011. Bethesda, MD: National Cancer Institute, 2014, 19 [ EB/OL ] . https://seer.cancer.gov/ archive/csr/1975_2011/.\n\n【7】LEONGAMORNLERT D, MAHMUD N, TYMRAKIEWICZ M, [ 9 ] et al. Germline BRCA 1 mutations increase prostate cancer risk [ J ] . Br J Cancer, 2012, 106(10): 1697-1701.\n\n【8】IQBAL J, RAGONE A, LUBINSKI J, et al. The incidence of [ 10 ] pancreatic cancer in BRCA 1 and BRCA 2 mutation carriers [ J ] . Br J Cancer, 2012, 107(12): 2005-2009.\n\n【9】TAI Y C, DOMCHEK S, PARMIGIANI G, et al. Breast cancer [ 11 ] ) risk among male BRCA 1 and BRCA 2 mutation carriers [ J ] . J Natl Cancer Inst, 2007, 99(23): 1811-1814.\n\n【10】[ 12 ].\n\n【11】MORAN A, O'HARA C, KHAN S, et al. Risk of cancer other than breast or ovarian in individuals with BRCA 1 and BRCA 2 mutations [ J ] . Fam Cancer, 2012, 11(2): 235-242.\n\n【12】[ 13 ] > MEUERS-HEUBOER H, VAN GEEL B, VAN PUTTEN W L, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA 1 or BRCA 2 mutation [ J ] . N Engl J Med, 2001, 345(3): 159-164.\n\n【13】[ 14 ] DOMCHEK S M, FRIEBEL T M, SINGER C F, et al.\n\n【14】Association of risk-reducing surgery in BRCA 1 or BRCA 2 mutation carriers with cancer risk and mortality [ J ] . JAMA, 2010, 304(9): 967-975.\n\n【15】LORD C J, ASHWORTH A. BRCAness revisited [ J ] . Nat Rev [ 15 ] Cancer, 2016, 16(2): 110.\n\n【16】SUN Y, MCCORVIE T J, YATES L A, et al. Structural basis of [ 16 ] homologous recombination [ J ] . Cell Mol Life Sci, 2020, 77(1): 3–18.\n\n【17】[ 17 ] MCCABE N , TURNER N C , LORD C J, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly (ADP–ribose) polymerase inhibition [ J ] .\n\n【18】Cancer Res ,  2006 ,  66 ( 16 ):  8109 – 8115 .\n\n【19】HOPPE M M, SUNDAR R, TAN D S P, et al. Biomarkers for [ 18 ] homologous recombination deficiency in cancer [ J ] . J Natl Cancer Inst, 2018, 110(7): 704–713. ( [ 19 ] HODGSON D R, DOUGHERTY B A, LAI Z, et al. Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes [ N ] & Brit J Cancer, 2018, 119(11):\n\n【20】 [ 20 ]\n\n【21】 [ 21 ]\n\n【22】 [ 22 ] [ 23 ] [ 24 ]\n\n【23】 [ 25 ]\n\n【24】 [ 26 ]\n\n【25】 [ 27 ]\n\n【26】 [28] .\n\n【27】 [ 29 ]\n\n【28】 [ 30 ]\n\n【29】 [ 31 ]\n\n【30】 1401–1409.\n\n【31】MIRZA M R, FENG B, SHAN M, et al. Elucidation of PARP inhibitor activity in BRCAwt recurrent ovarian cancer by HRR mutational gene profile analysis [ J ] [ - J Clin Oncol, 2019, 37(15): 5568.\n\n【32】O'MALLEY, DAVID M. Post progression outcomes in patients with ovarian carcinoma associated with a mutation in a non– BRCA homologous recombination repair gene receiving rucaparib maintenance tre atment: results from the phase 3 study ARIEL3 [ C ] . SGO 2020 Annual Meeting on Women's Cancer. SGO, 2020.\n\n【33】MOSCHETTA M, GEORGE A, KAYE S B, et al. BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer [ J ] . Ann Oncol, 2016, 27(8): 1449–1455.\n\n【34】SWISHER E M, HARRELL M I, LIN K, et al. BRCA 1 and RAD 51C promoter hypermethylation confer sensitivity to the PARP inhibitor rucaparib in patients with relapsed, platinum– sensitive ovarian carcinoma in ARIEL2 Part 1 [ J ] . Gynecol Oncol, 2017, 145: 5.\n\n【35】KONDRASHOVA O, TOPP M, NESIC K, et al. Methylation of all BRCA 1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma [ J ] . Nat Commun, 2018, 9(1): 1–16.\n\n【36】FRANZESE E, CENTONZE S, DIANA A, et al. Genomic profile and BRCA 1 promoter methylation status in BRCA mutated ovarian cancer: new insights in predictive biomarkers of olaparib response [ J ] . Front Oncol, 2019, 9: 1289.\n\n【37】中华医学会妇科肿瘤学分会. 卵巢癌PARP抑制剂临床应用 指南 [ J ] . 中国医学前沿杂志 ( 电子版 ) , 2020, 12(5): 29– 37.\n\n【38】Chinese Society of Gynecological Oncology, Chinese Medical Association. Guidelines for clinical application of PARP inhibitors in ovarian cancer [J] . Chin J Frontier Med (Electronic Edition), 2020, 12(5): 29–37 中国抗癌协会妇科肿瘤专业委员会. 中国卵巢上皮性癌维 持治疗专家共识(2020) [ J ] . 中国实用妇科与产科杂志 , 2020, 36(3): 234–238.\n\n【39】Gynecological Oncology Committee of China Anti Cancer Association. Expert consensus on maintenance treatment of epithelial ovarian cancer in China (2020) [ J ] . Chin J Pract Gynecol Obstetr, 020, 36(3): 234–238.\n\n【40】National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology. Ovarian Cancer, Version 1.\n\n【41】2020.\n\n【42】RAY–COQUARD I, PAUTIER P, PIGNATA S, et al. Olaparib plus bevacizumab as first–line maintenance in ovarian cancer [ J ] . N Engl J Med, 2019, 381(25): 2416–2428.\n\n【43】GONZALEZ-MARTIN A, POTHURI B, VERGOTE I, et al.\n\n【44】Niraparib in patients with newly diagnosed advanced ovarian cancer [ J ] . N Engl J Med, 2019, 381(25): 2391–2402.\n\n【45】ALEXANDROV L B, NIK–ZAINAL S, WEDGE D C, et al.\n\n【46】Signatures of mutational processes in human cancer [ J ] .\n\n【47】Nature, 2013, 500(7463): 415.", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "〈 † ¶ m g e s s 》 2020年第30 s 第10期", "bbox": [56.0, 60.0, 277.0, 78.0]}], "type": "Section-header", "position": 0}, {"raw_context": [{"text": "predict platinum response and survival in ovarian, fallopian", "bbox": [91.0, 88.0, 364.0, 101.0]}, {"text": "tube, and peritoneal carcinomas [ J ] . Clin Cancer Res, 2014,", "bbox": [91.0, 106.0, 364.0, 119.0]}, {"text": "20(3): 764–775.", "bbox": [91.0, 124.0, 162.0, 137.0]}, {"text": "MOORE K, COLOMBO N , SCAMBIA G, et al. Maintenance", "bbox": [91.0, 139.0, 364.0, 155.0]}, {"text": "[ 5 ]", "bbox": [58.0, 140.0, 81.0, 155.0]}, {"text": "olaparib in patients with newly diagnosed advanced ovarian", "bbox": [91.0, 158.0, 364.0, 171.0]}, {"text": "cancer [ J ] . N Engl J Med, 379, 26(2018): 2495–2505.", "bbox": [91.0, 175.0, 331.0, 189.0]}, {"text": "[ 6 ]", "bbox": [58.0, 193.0, 81.0, 207.0]}, {"text": "ANTONIOU A, PHAROAH P D, NAROD S, et al. Average risks", "bbox": [91.0, 192.0, 364.0, 207.0]}, {"text": "of breast and ovarian cancer associated with BRCA 1 or BRCA 2", "bbox": [91.0, 209.0, 364.0, 224.0]}, {"text": "mutations detected in case series unselected for family history: a", "bbox": [91.0, 227.0, 365.0, 241.0]}, {"text": "combined analysis of 22 studies [ J ] . Am J Hum Genet , 2003,", "bbox": [91.0, 244.0, 364.0, 258.0]}, {"text": "72(5): 1117-1130.", "bbox": [92.0, 262.0, 170.0, 275.0]}, {"text": "[ 7 ]", "bbox": [57.0, 279.0, 81.0, 294.0]}, {"text": "CHEN S, PARMIGIANI G. Meta-analysis of BRCA 1 and", "bbox": [91.0, 279.0, 364.0, 293.0]}, {"text": "BRCA2 penetrance [J] . J Clin Oncol, 2007, 25(11): 1329-", "bbox": [91.0, 296.0, 363.0, 310.0]}, {"text": "1333.", "bbox": [93.0, 316.0, 119.0, 327.0]}, {"text": "[ 8 ]", "bbox": [58.0, 331.0, 81.0, 345.0]}, {"text": "HOWLADER N , NOONE A M , KRAPCHO M , et al. SEER", "bbox": [91.0, 331.0, 364.0, 345.0]}, {"text": "cancer statistics review, 1975-2011. Bethesda, MD: National", "bbox": [91.0, 348.0, 364.0, 363.0]}, {"text": "Cancer Institute, 2014, 19 [ EB/OL ] . https://seer.cancer.gov/", "bbox": [91.0, 365.0, 364.0, 380.0]}, {"text": "archive/csr/1975_2011/.", "bbox": [92.0, 384.0, 197.0, 397.0]}, {"text": "LEONGAMORNLERT D, MAHMUD N, TYMRAKIEWICZ M,", "bbox": [91.0, 400.0, 364.0, 414.0]}, {"text": "[ 9 ]", "bbox": [58.0, 402.0, 81.0, 414.0]}, {"text": "et al. Germline BRCA 1 mutations increase prostate cancer risk", "bbox": [91.0, 418.0, 364.0, 432.0]}, {"text": "[ J ] . Br J Cancer, 2012, 106(10): 1697-1701.", "bbox": [95.0, 435.0, 291.0, 449.0]}, {"text": "IQBAL J, RAGONE A, LUBINSKI J, et al. The incidence of", "bbox": [89.0, 453.0, 364.0, 466.0]}, {"text": "[ 10 ]", "bbox": [59.0, 454.0, 89.0, 466.0]}, {"text": "pancreatic cancer in BRCA 1 and BRCA 2 mutation carriers", "bbox": [91.0, 470.0, 364.0, 484.0]}, {"text": "[ J ] . Br J Cancer, 2012, 107(12): 2005-2009.", "bbox": [95.0, 487.0, 291.0, 501.0]}, {"text": "TAI Y C, DOMCHEK S, PARMIGIANI G, et al. Breast cancer", "bbox": [90.0, 504.0, 364.0, 519.0]}, {"text": "[ 11 ] )", "bbox": [59.0, 506.0, 86.0, 519.0]}, {"text": "risk among male BRCA 1 and BRCA 2 mutation carriers [ J ] . J", "bbox": [91.0, 522.0, 364.0, 536.0]}, {"text": "Natl Cancer Inst, 2007, 99(23): 1811-1814.", "bbox": [91.0, 539.0, 275.0, 553.0]}, {"text": "[ 12 ].", "bbox": [59.0, 558.0, 86.0, 570.0]}, {"text": "MORAN A, O'HARA C, KHAN S, et al. Risk of cancer other", "bbox": [90.0, 557.0, 364.0, 571.0]}, {"text": "than breast or ovarian in individuals with BRCA 1 and BRCA 2", "bbox": [91.0, 574.0, 364.0, 588.0]}, {"text": "mutations [ J ] . Fam Cancer, 2012, 11(2): 235-242.", "bbox": [91.0, 591.0, 313.0, 605.0]}, {"text": "[ 13 ] > MEUERS-HEUBOER H, VAN GEEL B, VAN PUTTEN W L,", "bbox": [58.0, 609.0, 364.0, 622.0]}, {"text": "et al. Breast cancer after prophylactic bilateral mastectomy in", "bbox": [91.0, 627.0, 365.0, 640.0]}, {"text": "women with a BRCA 1 or BRCA 2 mutation [ J ] . N Engl J Med,", "bbox": [92.0, 644.0, 364.0, 658.0]}, {"text": "2001, 345(3): 159-164.", "bbox": [92.0, 661.0, 192.0, 675.0]}, {"text": "[ 14 ]", "bbox": [58.0, 678.0, 88.0, 692.0]}, {"text": "DOMCHEK S M, FRIEBEL T M, SINGER C F, et al.", "bbox": [89.0, 678.0, 363.0, 692.0]}, {"text": "Association of risk-reducing surgery in BRCA 1 or BRCA 2", "bbox": [93.0, 696.0, 364.0, 710.0]}, {"text": "mutation carriers with cancer risk and mortality [ J ] . JAMA,", "bbox": [91.0, 713.0, 364.0, 728.0]}, {"text": "2010, 304(9): 967-975.", "bbox": [92.0, 730.0, 192.0, 744.0]}, {"text": "LORD C J, ASHWORTH A. BRCAness revisited [ J ] . Nat Rev", "bbox": [90.0, 747.0, 364.0, 761.0]}, {"text": "[ 15 ]", "bbox": [59.0, 749.0, 87.0, 761.0]}, {"text": "Cancer, 2016, 16(2): 110.", "bbox": [92.0, 766.0, 201.0, 778.0]}, {"text": "SUN Y, MCCORVIE T J, YATES L A, et al. Structural basis of", "bbox": [90.0, 783.0, 366.0, 796.0]}, {"text": "[ 16 ]", "bbox": [59.0, 784.0, 87.0, 796.0]}, {"text": "homologous recombination [ J ] . Cell Mol Life Sci, 2020, 77(1):", "bbox": [91.0, 800.0, 364.0, 814.0]}, {"text": "3–18.", "bbox": [93.0, 819.0, 120.0, 830.0]}, {"text": "[ 17 ]", "bbox": [58.0, 834.0, 87.0, 848.0]}, {"text": "MCCABE N , TURNER N C , LORD C J, et al. Deficiency in", "bbox": [90.0, 834.0, 364.0, 848.0]}, {"text": "the repair of DNA damage by homologous recombination and", "bbox": [91.0, 852.0, 364.0, 866.0]}, {"text": "sensitivity to poly (ADP–ribose) polymerase inhibition [ J ] .", "bbox": [91.0, 869.0, 365.0, 884.0]}, {"text": "Cancer Res ,  2006 ,  66 ( 16 ):  8109 – 8115 .", "bbox": [91.0, 886.0, 258.0, 900.0]}, {"text": "HOPPE M M, SUNDAR R, TAN D S P, et al. Biomarkers for", "bbox": [89.0, 903.0, 364.0, 917.0]}, {"text": "[ 18 ]", "bbox": [59.0, 905.0, 87.0, 917.0]}, {"text": "homologous recombination deficiency in cancer [ J ] . J Natl", "bbox": [91.0, 921.0, 364.0, 935.0]}, {"text": "Cancer Inst, 2018, 110(7): 704–713. (", "bbox": [91.0, 938.0, 247.0, 952.0]}, {"text": "[ 19 ]", "bbox": [59.0, 956.0, 86.0, 969.0]}, {"text": "HODGSON D R, DOUGHERTY B A, LAI Z, et al. Candidate", "bbox": [90.0, 956.0, 364.0, 969.0]}, {"text": "biomarkers of PARP inhibitor sensitivity in ovarian cancer", "bbox": [91.0, 973.0, 364.0, 987.0]}, {"text": "beyond the BRCA genes [ N ] & Brit J Cancer, 2018, 119(11):", "bbox": [91.0, 991.0, 364.0, 1005.0]}], "type": "Text", "position": 1}, {"raw_context": [{"text": "[ 20 ]", "bbox": [395.0, 107.0, 423.0, 119.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "[ 21 ]", "bbox": [394.0, 177.0, 423.0, 190.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": "[ 22 ]", "bbox": [395.0, 280.0, 424.0, 294.0]}, {"text": "[ 23 ]", "bbox": [394.0, 332.0, 422.0, 345.0]}, {"text": "[ 24 ]", "bbox": [395.0, 419.0, 425.0, 433.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "[ 25 ]", "bbox": [394.0, 488.0, 424.0, 501.0]}], "type": "Text", "position": 6}, {"raw_context": [{"text": "[ 26 ]", "bbox": [395.0, 558.0, 423.0, 570.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "[ 27 ]", "bbox": [395.0, 680.0, 424.0, 692.0]}], "type": "Text", "position": 8}, {"raw_context": [{"text": "[28] .", "bbox": [395.0, 800.0, 423.0, 814.0]}], "type": "Text", "position": 9}, {"raw_context": [{"text": "[ 29 ]", "bbox": [396.0, 853.0, 424.0, 865.0]}], "type": "Text", "position": 10}, {"raw_context": [{"text": "[ 30 ]", "bbox": [395.0, 905.0, 425.0, 916.0]}], "type": "Text", "position": 11}, {"raw_context": [{"text": "[ 31 ]", "bbox": [395.0, 957.0, 423.0, 969.0]}], "type": "Text", "position": 12}, {"raw_context": [{"text": "1401–1409.", "bbox": [429.0, 89.0, 481.0, 101.0]}, {"text": "MIRZA M R, FENG B, SHAN M, et al. Elucidation of PARP", "bbox": [427.0, 104.0, 701.0, 119.0]}, {"text": "inhibitor activity in BRCAwt recurrent ovarian cancer by HRR", "bbox": [429.0, 123.0, 700.0, 137.0]}, {"text": "mutational gene profile analysis [ J ] [ - J Clin Oncol, 2019,", "bbox": [429.0, 140.0, 700.0, 155.0]}, {"text": "37(15): 5568.", "bbox": [429.0, 158.0, 487.0, 171.0]}, {"text": "O'MALLEY, DAVID M. Post progression outcomes in patients", "bbox": [426.0, 175.0, 701.0, 189.0]}, {"text": "with ovarian carcinoma associated with a mutation in a non–", "bbox": [429.0, 193.0, 700.0, 207.0]}, {"text": "BRCA homologous recombination repair gene receiving", "bbox": [428.0, 209.0, 701.0, 224.0]}, {"text": "rucaparib maintenance tre atment: results from the phase 3", "bbox": [429.0, 227.0, 701.0, 241.0]}, {"text": "study ARIEL3 [ C ] . SGO 2020 Annual Meeting on Women's", "bbox": [429.0, 244.0, 701.0, 258.0]}, {"text": "Cancer. SGO, 2020.", "bbox": [428.0, 262.0, 514.0, 275.0]}, {"text": "MOSCHETTA M, GEORGE A, KAYE S B, et al. BRCA somatic", "bbox": [427.0, 279.0, 700.0, 293.0]}, {"text": "mutations and epigenetic BRCA modifications in serous ovarian", "bbox": [429.0, 297.0, 701.0, 310.0]}, {"text": "cancer [ J ] . Ann Oncol, 2016, 27(8): 1449–1455.", "bbox": [429.0, 314.0, 643.0, 328.0]}, {"text": "SWISHER E M, HARRELL M I, LIN K, et al. BRCA 1 and", "bbox": [426.0, 332.0, 701.0, 345.0]}, {"text": "RAD 51C promoter hypermethylation confer sensitivity to the", "bbox": [429.0, 349.0, 701.0, 363.0]}, {"text": "PARP inhibitor rucaparib in patients with relapsed, platinum–", "bbox": [428.0, 366.0, 700.0, 380.0]}, {"text": "sensitive ovarian carcinoma in ARIEL2 Part 1 [ J ] . Gynecol", "bbox": [428.0, 384.0, 701.0, 397.0]}, {"text": "Oncol, 2017, 145: 5.", "bbox": [428.0, 401.0, 517.0, 414.0]}, {"text": "KONDRASHOVA O, TOPP M, NESIC K, et al. Methylation", "bbox": [425.0, 418.0, 702.0, 432.0]}, {"text": "of all BRCA 1 copies predicts response to the PARP inhibitor", "bbox": [429.0, 435.0, 701.0, 449.0]}, {"text": "rucaparib in ovarian carcinoma [ J ] . Nat Commun, 2018, 9(1):", "bbox": [429.0, 453.0, 701.0, 466.0]}, {"text": "1–16.", "bbox": [429.0, 472.0, 456.0, 483.0]}, {"text": "FRANZESE E, CENTONZE S, DIANA A, et al. Genomic profile", "bbox": [425.0, 486.0, 701.0, 502.0]}, {"text": "and BRCA 1 promoter methylation status in BRCA mutated", "bbox": [429.0, 504.0, 701.0, 519.0]}, {"text": "ovarian cancer: new insights in predictive biomarkers of olaparib", "bbox": [429.0, 522.0, 701.0, 536.0]}, {"text": "response [ J ] . Front Oncol, 2019, 9: 1289.", "bbox": [429.0, 539.0, 614.0, 554.0]}, {"text": "中华医学会妇科肿瘤学分会. 卵巢癌PARP抑制剂临床应用", "bbox": [427.0, 557.0, 701.0, 571.0]}, {"text": "指南 [ J ] . 中国医学前沿杂志 ( 电子版 ) , 2020, 12(5): 29–", "bbox": [429.0, 574.0, 699.0, 589.0]}, {"text": "37.", "bbox": [429.0, 593.0, 446.0, 605.0]}, {"text": "Chinese Society of Gynecological Oncology, Chinese Medical", "bbox": [429.0, 609.0, 701.0, 622.0]}, {"text": "Association. Guidelines for clinical application of PARP", "bbox": [429.0, 627.0, 701.0, 640.0]}, {"text": "inhibitors in ovarian cancer [J] . Chin J Frontier Med", "bbox": [429.0, 644.0, 701.0, 658.0]}, {"text": "(Electronic Edition), 2020, 12(5): 29–37", "bbox": [428.0, 660.0, 600.0, 675.0]}, {"text": "中国抗癌协会妇科肿瘤专业委员会. 中国卵巢上皮性癌维", "bbox": [426.0, 678.0, 699.0, 692.0]}, {"text": "持治疗专家共识(2020) [ J ] . 中国实用妇科与产科杂志 ,", "bbox": [429.0, 695.0, 699.0, 710.0]}, {"text": "2020, 36(3): 234–238.", "bbox": [429.0, 713.0, 527.0, 727.0]}, {"text": "Gynecological Oncology Committee of China Anti Cancer", "bbox": [428.0, 730.0, 701.0, 744.0]}, {"text": "Association. Expert consensus on maintenance treatment of", "bbox": [429.0, 748.0, 701.0, 761.0]}, {"text": "epithelial ovarian cancer in China (2020) [ J ] . Chin J Pract", "bbox": [428.0, 765.0, 701.0, 779.0]}, {"text": "Gynecol Obstetr, 020, 36(3): 234–238.", "bbox": [428.0, 783.0, 591.0, 796.0]}, {"text": "National Comprehensive Cancer Network (NCCN). Clinical", "bbox": [427.0, 799.0, 701.0, 814.0]}, {"text": "Practice Guidelines in Oncology. Ovarian Cancer, Version 1.", "bbox": [429.0, 817.0, 700.0, 831.0]}, {"text": "2020.", "bbox": [429.0, 835.0, 455.0, 848.0]}, {"text": "RAY–COQUARD I, PAUTIER P, PIGNATA S, et al. Olaparib", "bbox": [425.0, 851.0, 701.0, 866.0]}, {"text": "plus bevacizumab as first–line maintenance in ovarian cancer", "bbox": [429.0, 869.0, 701.0, 884.0]}, {"text": "[ J ] . N Engl J Med, 2019, 381(25): 2416–2428.", "bbox": [431.0, 886.0, 639.0, 900.0]}, {"text": "GONZALEZ-MARTIN A, POTHURI B, VERGOTE I, et al.", "bbox": [425.0, 904.0, 701.0, 917.0]}, {"text": "Niraparib in patients with newly diagnosed advanced ovarian", "bbox": [429.0, 921.0, 701.0, 935.0]}, {"text": "cancer [ J ] . N Engl J Med, 2019, 381(25): 2391–2402.", "bbox": [429.0, 938.0, 666.0, 952.0]}, {"text": "ALEXANDROV L B, NIK–ZAINAL S, WEDGE D C, et al.", "bbox": [427.0, 956.0, 701.0, 969.0]}, {"text": "Signatures of mutational processes in human cancer [ J ] .", "bbox": [429.0, 974.0, 701.0, 987.0]}, {"text": "Nature, 2013, 500(7463): 415.", "bbox": [429.0, 991.0, 557.0, 1004.0]}], "type": "Text", "position": 13}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2021】全科室临床指南中&英文版/15大科室分类/妇产领域/【妇产领域】上皮性卵巢癌PARP抑制剂相关生物标志物检测的中国专家共识.pdf", "page_num": 7}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": null, "type3": null, "type4": null, "type5": null, "type6": "信息有用性#0#47#参考文献"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:41", "update_time": "2024-05-07 17:51:03"}
{"id": 1082575, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 738, "source_info": {"seq_id": "647c4308-74eb-4e6d-9767-0e4f48e53e51", "title": null, "text": "【0】页码:1\n 2023\n\n【1】 DOI 10. 3969 /j. issn. 1005-6483. 2023. 01. 007\n\n【2】 .\n\n【3】 .\n\n【4】 http: //www. lcwkzz. com/CN/10. 3969/j. issn. 1005-6483. 2023. 01. 007 Journal of Clinical Surgery 2023 31 (1):021-023\n\n【5】 .\n\n【6】## ( 2022 , V2)\n\n【7】\n :\n\n【8】 ;\n\n【9】 2022 ( NCCN ) 1 2022. V2 MSI ) .\n\n【10】( NCCN 2021. V4, V5\n\n【11】 NGS PCR\n\n【12】 2022. V1\n\n【13】 IHC/ISH\n\n【14】 :\n\n【15】 1. 1.\n\n【16】 ( MSI ) (MMR) : 1 ( programmed death 1 PD-1 ) 1 ( programmed death ligand-I PD-L1)\n\n【17】 NGS 3.\n\n【18】: DNA\n\n【19】 PFS)\n\n【20】 ( progression-free survival ( overall survival OS)\n\n【21】 ( clinical\n\n【22】 laboratory improvement amendments CLIA) NGS\n\n【23】 MSI/MMR\n\n【24】 100–110\n\n【25】 MSI/dMMR\n\n【26】 4.\n\n【27】 :\n\n【28】 540–540\n\n【29】 4\n\n【30】 MSI/MMR\n\n【31】 2.\n\n【32】 ( next generation sequencing NGS) : MSI/MMR NGS 97%\n\n【33】 :\n\n【34】 PCR\n\n【35】 96%\n\n【36】 MMR C ERBB2 N NTRK TMB\n\n【37】 2B 2A\n\n【38】 ;\n\n【39】 NGS\n\n【40】 a\n\n【41】 NGS\"\n\n【42】 ” \"IHC/ISH\n\n【43】 1.\n\n【44】 :\n\n【45】 cT2\n\n【46】 .\n\n【47】 N\n\n【48】 1\n\n【49】 (81702386 82072730) :  \" : ( BCF-NH-ZL-20201119-002 ) \"\n\n【50】 : 430022\n\n【51】 Email: zhangpengwh@ hust. edu. cn\n\n【52】 3\n\n【53】 4\n\n【54】 Chapter 1\n\n【55】 FDG-PET/CT\n\n【56】 .\n\n【57】 :\n\n【58】 100–117.9", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "2023", "bbox": [125.0, 58.0, 172.0, 72.0]}], "type": "Text", "position": 0}, {"raw_context": [{"text": "DOI 10. 3969 /j. issn. 1005-6483. 2023. 01. 007", "bbox": [139.0, 92.0, 345.0, 108.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": ".", "bbox": [573.0, 117.0, 584.0, 131.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": ".", "bbox": [713.0, 118.0, 723.0, 131.0]}], "type": "Text", "position": 6}, {"raw_context": [{"text": "http: //www. lcwkzz. com/CN/10. 3969/j. issn. 1005-6483. 2023. 01. 007", "bbox": [134.0, 115.0, 445.0, 132.0]}, {"text": "Journal of Clinical Surgery 2023 31 (1):021-023", "bbox": [134.0, 139.0, 348.0, 156.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": ".", "bbox": [508.0, 206.0, 515.0, 215.0]}], "type": "Text", "position": 8}, {"raw_context": [{"text": "( 2022 , V2)", "bbox": [119.0, 221.0, 240.0, 247.0]}], "type": "Section-header", "position": 9}, {"raw_context": [{"text": ":", "bbox": [144.0, 321.0, 152.0, 335.0]}], "type": "Text", "position": 10}, {"raw_context": [{"text": ";", "bbox": [283.0, 321.0, 291.0, 334.0]}], "type": "Text", "position": 11}, {"raw_context": [{"text": "2022", "bbox": [86.0, 359.0, 118.0, 376.0]}, {"text": "( NCCN )", "bbox": [312.0, 359.0, 367.0, 378.0]}, {"text": "1", "bbox": [135.0, 361.0, 144.0, 376.0]}, {"text": "2022. V2", "bbox": [88.0, 380.0, 144.0, 397.0]}, {"text": "MSI", "bbox": [426.0, 380.0, 451.0, 397.0]}, {"text": ") .", "bbox": [365.0, 381.0, 383.0, 398.0]}, {"text": "(", "bbox": [273.0, 383.0, 283.0, 397.0]}, {"text": "NCCN", "bbox": [140.0, 401.0, 179.0, 418.0]}, {"text": "2021. V4, V5", "bbox": [279.0, 401.0, 363.0, 418.0]}], "type": "Text", "position": 12}, {"raw_context": [{"text": "NGS", "bbox": [611.0, 359.0, 641.0, 376.0]}, {"text": "PCR", "bbox": [657.0, 359.0, 687.0, 376.0]}], "type": "Text", "position": 13}, {"raw_context": [{"text": "2022. V1", "bbox": [58.0, 421.0, 111.0, 437.0]}], "type": "Text", "position": 14}, {"raw_context": [{"text": "IHC/ISH", "bbox": [637.0, 422.0, 693.0, 439.0]}], "type": "Text", "position": 15}, {"raw_context": [{"text": ":", "bbox": [723.0, 425.0, 731.0, 437.0]}], "type": "Text", "position": 16}, {"raw_context": [{"text": "1. 1.", "bbox": [86.0, 485.0, 103.0, 502.0]}], "type": "Text", "position": 17}, {"raw_context": [{"text": "( MSI )", "bbox": [184.0, 483.0, 225.0, 502.0]}, {"text": "(MMR)", "bbox": [295.0, 484.0, 346.0, 501.0]}, {"text": ":", "bbox": [373.0, 487.0, 382.0, 501.0]}, {"text": "1 ( programmed death 1 PD-1 )", "bbox": [189.0, 505.0, 367.0, 523.0]}, {"text": "1 ( programmed death ligand-I PD-L1)", "bbox": [159.0, 526.0, 380.0, 543.0]}], "type": "Text", "position": 18}, {"raw_context": [{"text": "NGS", "bbox": [407.0, 464.0, 439.0, 481.0]}, {"text": "3.", "bbox": [434.0, 486.0, 449.0, 503.0]}, {"text": ":", "bbox": [506.0, 488.0, 514.0, 502.0]}, {"text": "DNA", "bbox": [498.0, 506.0, 528.0, 523.0]}], "type": "Text", "position": 19}, {"raw_context": [{"text": "PFS)", "bbox": [58.0, 589.0, 89.0, 606.0]}], "type": "Text", "position": 20}, {"raw_context": [{"text": "( progression-free survival", "bbox": [227.0, 569.0, 377.0, 585.0]}, {"text": "( overall survival OS)", "bbox": [160.0, 590.0, 287.0, 606.0]}], "type": "Text", "position": 21}, {"raw_context": [{"text": "( clinical", "bbox": [680.0, 570.0, 733.0, 587.0]}], "type": "Text", "position": 22}, {"raw_context": [{"text": "laboratory improvement amendments CLIA)", "bbox": [407.0, 592.0, 657.0, 609.0]}, {"text": "NGS", "bbox": [573.0, 612.0, 603.0, 628.0]}], "type": "Text", "position": 23}, {"raw_context": [{"text": "MSI/MMR", "bbox": [124.0, 630.0, 188.0, 649.0]}], "type": "Text", "position": 24}, {"raw_context": [{"text": "100–110", "bbox": [191.0, 609.0, 207.0, 623.0]}], "type": "Text", "position": 25}, {"raw_context": [{"text": "MSI/dMMR", "bbox": [294.0, 672.0, 365.0, 691.0]}], "type": "Text", "position": 26}, {"raw_context": [{"text": "4.", "bbox": [434.0, 677.0, 449.0, 693.0]}], "type": "Text", "position": 27}, {"raw_context": [{"text": ":", "bbox": [607.0, 680.0, 615.0, 691.0]}], "type": "Text", "position": 28}, {"raw_context": [{"text": "540–540", "bbox": [76.0, 733.0, 95.0, 748.0]}], "type": "Text", "position": 29}, {"raw_context": [{"text": "4", "bbox": [189.0, 693.0, 197.0, 703.0]}], "type": "Text", "position": 30}, {"raw_context": [{"text": "MSI/MMR", "bbox": [58.0, 756.0, 123.0, 774.0]}], "type": "Text", "position": 31}, {"raw_context": [{"text": "2.", "bbox": [85.0, 779.0, 99.0, 795.0]}], "type": "Text", "position": 32}, {"raw_context": [{"text": "( next generation sequencing NGS) :", "bbox": [156.0, 778.0, 367.0, 796.0]}, {"text": "MSI/MMR", "bbox": [272.0, 799.0, 335.0, 816.0]}, {"text": "NGS", "bbox": [209.0, 800.0, 240.0, 816.0]}, {"text": "97%", "bbox": [235.0, 820.0, 265.0, 837.0]}], "type": "Text", "position": 33}, {"raw_context": [{"text": ":", "bbox": [464.0, 828.0, 472.0, 841.0]}], "type": "Text", "position": 34}, {"raw_context": [{"text": "PCR", "bbox": [58.0, 841.0, 88.0, 859.0]}], "type": "Text", "position": 35}, {"raw_context": [{"text": "96%", "bbox": [119.0, 820.0, 149.0, 837.0]}], "type": "Text", "position": 36}, {"raw_context": [{"text": "MMR", "bbox": [288.0, 842.0, 322.0, 859.0]}, {"text": "C ERBB2", "bbox": [134.0, 863.0, 188.0, 878.0]}, {"text": "N NTRK", "bbox": [220.0, 862.0, 267.0, 879.0]}, {"text": "TMB", "bbox": [352.0, 862.0, 383.0, 879.0]}], "type": "Text", "position": 37}, {"raw_context": [{"text": "2B", "bbox": [407.0, 866.0, 427.0, 883.0]}, {"text": "2A", "bbox": [484.0, 866.0, 507.0, 884.0]}], "type": "Text", "position": 38}, {"raw_context": [{"text": ";", "bbox": [519.0, 870.0, 529.0, 884.0]}], "type": "Text", "position": 39}, {"raw_context": [{"text": "NGS", "bbox": [181.0, 883.0, 211.0, 900.0]}], "type": "Text", "position": 40}, {"raw_context": [{"text": "a", "bbox": [213.0, 904.0, 222.0, 915.0]}], "type": "Text", "position": 41}, {"raw_context": [{"text": "NGS\"", "bbox": [118.0, 924.0, 196.0, 942.0]}], "type": "Text", "position": 42}, {"raw_context": [{"text": "”", "bbox": [298.0, 924.0, 310.0, 937.0]}, {"text": "\"IHC/ISH", "bbox": [320.0, 924.0, 383.0, 943.0]}], "type": "Text", "position": 43}, {"raw_context": [{"text": "1.", "bbox": [436.0, 952.0, 451.0, 968.0]}], "type": "Text", "position": 44}, {"raw_context": [{"text": ":", "bbox": [522.0, 953.0, 530.0, 967.0]}], "type": "Text", "position": 45}, {"raw_context": [{"text": "cT2", "bbox": [561.0, 950.0, 586.0, 967.0]}], "type": "Text", "position": 46}, {"raw_context": [{"text": ".", "bbox": [633.0, 955.0, 641.0, 968.0]}], "type": "Text", "position": 47}, {"raw_context": [{"text": "N", "bbox": [672.0, 950.0, 686.0, 967.0]}], "type": "Text", "position": 48}, {"raw_context": [{"text": "1", "bbox": [690.0, 974.0, 699.0, 988.0]}], "type": "Text", "position": 49}, {"raw_context": [{"text": "(81702386 82072730) :  \"", "bbox": [212.0, 963.0, 332.0, 977.0]}, {"text": ":", "bbox": [122.0, 966.0, 132.0, 979.0]}, {"text": "( BCF-NH-ZL-20201119-002 )", "bbox": [161.0, 973.0, 290.0, 992.0]}, {"text": "\"", "bbox": [134.0, 974.0, 143.0, 984.0]}], "type": "Text", "position": 50}, {"raw_context": [{"text": ": 430022", "bbox": [121.0, 988.0, 163.0, 1003.0]}], "type": "Text", "position": 51}, {"raw_context": [{"text": "Email: zhangpengwh@ hust. edu. cn", "bbox": [153.0, 1013.0, 305.0, 1029.0]}], "type": "Text", "position": 52}, {"raw_context": [{"text": "3", "bbox": [494.0, 1014.0, 506.0, 1031.0]}], "type": "Text", "position": 53}, {"raw_context": [{"text": "4", "bbox": [648.0, 1015.0, 660.0, 1031.0]}], "type": "Text", "position": 54}, {"raw_context": [{"text": "Chapter 1", "bbox": [689.0, 1020.0, 697.0, 1030.0]}], "type": "Text", "position": 55}, {"raw_context": [{"text": "FDG-PET/CT", "bbox": [426.0, 739.0, 507.0, 757.0]}], "type": "Text", "position": 58}, {"raw_context": [{"text": ".", "bbox": [361.0, 964.0, 371.0, 976.0]}], "type": "Text", "position": 59}, {"raw_context": [{"text": ":", "bbox": [122.0, 1016.0, 131.0, 1028.0]}], "type": "Text", "position": 60}, {"raw_context": [{"text": "100–117.9", "bbox": [77.0, 879.0, 93.0, 893.0]}], "type": "Text", "position": 61}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/肿瘤科/解读/美国国立综合癌症网络临床实践指南：胃癌(2022.V2)更新解读(1).pdf", "page_num": 1}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "格式杂乱#0#58#内容无法理解", "type3": null, "type4": null, "type5": null, "type6": null}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:41", "update_time": "2024-05-08 00:51:14"}
{"id": 1082574, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 738, "source_info": {"seq_id": "5327f5a8-1eb5-4f1f-9c50-9888b83f2628", "title": null, "text": "【0】页码:1\n apent.2244060.030\n\n【1】 Ann Pediatr Endocrinol Metab 2022;27:5-14\n# Clinical Practice Guidelines For Optimizing Bone\nHealth In Korean Children And Adolescents\n\n【2】\n Young Ah Lee 1 , Ahreum Kwon 2 Jae Hyun Kim 3 , Hyo-Kyoung Nam 4 , Jae-Ho Yoo 5 , Jung Sub Lim 6 , Sung Yoon Cho', Won Kyoung Cho', Kye Shik Shim'; and the Committee on Pediatric Bone Health of Korean Children and Adolescents on behalf of Korean Society of Pediatric Endocrinology (KSPE)\n\n【3】 'Department of Pediatrics, Seoul National University Children's Hospital, Seoul National University College of Medicine, Seoul, Korea 2 Department of Pediatrics, Severance Children's Hospital, Endocrine Research Institute, Yonsei University College of Medicine, Seoul, Korea 'Department of Pediatrics, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea 'Department of Pediatrics, Korea University College of Medicine, Seoul, Korea 5 Department of Pediatrics, Dong-A University Hospital, Busan, Korea \"Department of Pediatrics, Korea Cancer\" Center Hospital, Seoul, Korea 7 Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea 8 Department of Pediatrics, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea 'Department of Pediatrics, Kyung Hee University Hospital at Gangdong, Kyung Hee University College of Medicine, Seoul, Korea\n\n【4】 Received /5 February, 2022 Accepted: 10 February, 2022.\n\n【5】 Address for correspondence: Kye Shik Shim Department of Pediatrics, Kyung Hee University Hospital at Gangdong, Kyung Hee University College of Medicine, 892 Dongnam-ro, Gangdong-gu, Seoul 05278, Korea Email: 64sks@khu.ac.kr https://orcid.org/0000-0002-8004- 151X\n\n【6】 The Committee on Pediatric Bone Health of the Korean Society of Pediatric Endocrinology has newly developed evidence-based clinical practice guidelines for optimizing bone health in Korean children and adolescents. These guidelines a present recommendations based on the Grading of Recommendations, which includes the quality of evidence. In the absence of sufficient evidence, conclusions were based on expert opinion. These guidelines include processes of bone acquisition, definition, and evaluation of low bone mineral density (BMD), causes of osteoporosis, methods for optimizing bone health, and pharmacological treatments for enhancing BMD in children and adolescents. While these guidelines provide current evidencé-based recommendations, further research is required to strengthen these guidelines. 511 J\n\n【7】 Keywords: Practice guidelines, Bone, Child, Adolescent, Korea\n\n【8】## Highlights\n\n【9】\n The Committee on Pediatric Bone Health of the Korean Society of Pediatric Endocrinology has newly developed evidence-based clinical practice guidelines for optimizing bone health in Korean children and adolescents. These guidelines include /processes of bone acquisition, definition, and evaluation of low bone mineral density (BMD), causes of osteoporosis, methods for optimizing bone health, and pharmacological treatments for enhancing BMD in children and adolescents.\n\n【10】## Introduction\n\n【11】\n Osteoporosis was previously thought to be a disease exclusiye/to older adults. However, it is now increasingly recognized in younger adults due, in part, to the longer survival of chronically ill children. Children with osteoporosis are at a high risk of skeletal morbidity not only during youth, but also in adult life. 17 Bone mass attained in early life is thought to 7 be the most important modifiable determinant of lifelong skeletal health. 27 In this context, the Committee on Pediatric Bone Health of the Korean Society of Pediatric Endocrinology recently developed evidence-based clinical practice guidelines for optimizing bone health in Korean children and adolescents. Recommendations were determined according to the quality of evidence graded by the steering committee on quality improvement and management in the American Academy of Pediatrics. 3 This guideline, comprises the physiological processes of bone acquisition, definition, and evaluation of low bone mineral density (BMD), causes of osteoporosis, conservative management for optimizing bone health, and pharmacological treatments for enhancing BMD in children and adolescents.\n This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http:// creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any\n medium, provided the original work is properly cited.", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "apent.2244060.030", "bbox": [169.0, 78.0, 251.0, 88.0]}], "type": "Text", "position": 2}, {"raw_context": [{"text": "Ann Pediatr Endocrinol Metab 2022;27:5-14", "bbox": [67.0, 92.0, 252.0, 103.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "Clinical practice guidelines for optimizing bone\nhealth in Korean children and adolescents", "bbox": [63.0, 133.0, 730.0, 202.0]}], "type": "Title", "position": 6}, {"raw_context": [{"text": "Young Ah Lee 1 , Ahreum Kwon 2", "bbox": [66.0, 237.0, 235.0, 252.0]}, {"text": "Jae Hyun Kim 3 , Hyo-Kyoung Nam 4 ,", "bbox": [66.0, 251.0, 238.0, 266.0]}, {"text": "Jae-Ho Yoo 5 , Jung Sub Lim 6 , Sung", "bbox": [66.0, 265.0, 239.0, 279.0]}, {"text": "Yoon Cho', Won Kyoung Cho', Kye", "bbox": [67.0, 279.0, 239.0, 292.0]}, {"text": "Shik Shim'; and the Committee", "bbox": [67.0, 292.0, 239.0, 306.0]}, {"text": "on Pediatric Bone Health of", "bbox": [66.0, 305.0, 239.0, 319.0]}, {"text": "Korean Children and Adolescents", "bbox": [66.0, 319.0, 240.0, 332.0]}, {"text": "on behalf of Korean Society of", "bbox": [66.0, 332.0, 238.0, 345.0]}, {"text": "Pediatric Endocrinology (KSPE)", "bbox": [66.0, 345.0, 222.0, 360.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "'Department of Pediatrics, Seoul National", "bbox": [67.0, 371.0, 239.0, 383.0]}, {"text": "University Children's Hospital, Seoul", "bbox": [66.0, 383.0, 240.0, 395.0]}, {"text": "National University College of Medicine,", "bbox": [66.0, 396.0, 238.0, 407.0]}, {"text": "Seoul, Korea", "bbox": [67.0, 407.0, 118.0, 419.0]}, {"text": "2 Department of Pediatrics, Severance", "bbox": [67.0, 419.0, 239.0, 431.0]}, {"text": "Children's Hospital, Endocrine Research", "bbox": [66.0, 431.0, 239.0, 443.0]}, {"text": "Institute, Yonsei University College of", "bbox": [66.0, 442.0, 239.0, 456.0]}, {"text": "Medicine, Seoul, Korea", "bbox": [66.0, 456.0, 156.0, 467.0]}, {"text": "'Department of Pediatrics, Seoul National", "bbox": [68.0, 467.0, 239.0, 479.0]}, {"text": "University Bundang Hospital, Seoul National", "bbox": [66.0, 480.0, 239.0, 491.0]}, {"text": "University College of Medicine, Seongnam,", "bbox": [66.0, 492.0, 238.0, 503.0]}, {"text": "Korea", "bbox": [66.0, 503.0, 92.0, 513.0]}, {"text": "'Department of Pediatrics, Korea University", "bbox": [68.0, 516.0, 238.0, 527.0]}, {"text": "College of Medicine, Seoul, Korea", "bbox": [67.0, 527.0, 200.0, 539.0]}, {"text": "5 Department of Pediatrics, Dong-A", "bbox": [67.0, 538.0, 239.0, 552.0]}, {"text": "University Hospital, Busan, Korea", "bbox": [66.0, 552.0, 197.0, 563.0]}, {"text": "\"Department of Pediatrics, Korea Cancer\"", "bbox": [67.0, 562.0, 241.0, 576.0]}, {"text": "Center Hospital, Seoul, Korea", "bbox": [66.0, 576.0, 179.0, 587.0]}, {"text": "7 Department of Pediatrics, Samsung", "bbox": [68.0, 587.0, 239.0, 600.0]}, {"text": "Medical Center, Sungkyunkwan University", "bbox": [66.0, 601.0, 239.0, 614.0]}, {"text": "School of Medicine, Seoul, Korea", "bbox": [67.0, 615.0, 191.0, 626.0]}, {"text": "8 Department of Pediatrics, St. Vincent's", "bbox": [67.0, 626.0, 240.0, 638.0]}, {"text": "Hospital, College of Medicine, The Catholic", "bbox": [66.0, 639.0, 238.0, 652.0]}, {"text": "University of Korea, Seoul, Korea", "bbox": [66.0, 653.0, 193.0, 664.0]}, {"text": "'Department of Pediatrics, Kyung Hee", "bbox": [68.0, 664.0, 239.0, 676.0]}, {"text": "University Hospital at Gangdong, Kyung", "bbox": [66.0, 676.0, 239.0, 688.0]}, {"text": "Hee University College of Medicine, Seoul,", "bbox": [65.0, 689.0, 238.0, 700.0]}, {"text": "Korea", "bbox": [66.0, 701.0, 92.0, 712.0]}], "type": "Text", "position": 8}, {"raw_context": [{"text": "Received /5 February, 2022", "bbox": [66.0, 751.0, 195.0, 764.0]}, {"text": "Accepted: 10 February, 2022.", "bbox": [66.0, 766.0, 203.0, 779.0]}], "type": "Text", "position": 9}, {"raw_context": [{"text": "Address for correspondence:", "bbox": [67.0, 795.0, 213.0, 807.0]}, {"text": "Kye Shik Shim", "bbox": [66.0, 809.0, 136.0, 820.0]}, {"text": "Department of Pediatrics, Kyung", "bbox": [66.0, 821.0, 241.0, 834.0]}, {"text": "Hee University Hospital at Gang-", "bbox": [66.0, 837.0, 238.0, 849.0]}, {"text": "dong, Kyung Hee University College", "bbox": [66.0, 851.0, 239.0, 863.0]}, {"text": "of Medicine, 892 Dongnam-ro,", "bbox": [66.0, 865.0, 238.0, 878.0]}, {"text": "Gangdong-gu, Seoul 05278, Korea", "bbox": [66.0, 879.0, 230.0, 892.0]}, {"text": "Email: 64sks@khu.ac.kr", "bbox": [66.0, 893.0, 167.0, 906.0]}, {"text": "https://orcid.org/0000-0002-8004-", "bbox": [66.0, 906.0, 238.0, 919.0]}, {"text": "151X", "bbox": [67.0, 920.0, 93.0, 932.0]}], "type": "Text", "position": 10}, {"raw_context": [{"text": "The Committee on Pediatric Bone Health of the Korean Society of Pediatric", "bbox": [261.0, 237.0, 726.0, 253.0]}, {"text": "Endocrinology has newly developed evidence-based clinical practice guidelines", "bbox": [260.0, 254.0, 727.0, 269.0]}, {"text": "for optimizing bone health in Korean children and adolescents. These guidelines a", "bbox": [260.0, 270.0, 728.0, 285.0]}, {"text": "present recommendations based on the Grading of Recommendations, which", "bbox": [260.0, 285.0, 727.0, 300.0]}, {"text": "includes the quality of evidence. In the absence of sufficient evidence, conclusions", "bbox": [260.0, 301.0, 726.0, 316.0]}, {"text": "were based on expert opinion. These guidelines include processes of bone", "bbox": [260.0, 317.0, 726.0, 333.0]}, {"text": "acquisition, definition, and evaluation of low bone mineral density (BMD), causes", "bbox": [261.0, 334.0, 727.0, 348.0]}, {"text": "of osteoporosis, methods for optimizing bone health, and pharmacological", "bbox": [260.0, 349.0, 726.0, 365.0]}, {"text": "treatments for enhancing BMD in children and adolescents. While these guidelines", "bbox": [260.0, 366.0, 726.0, 380.0]}, {"text": "provide current evidencé-based recommendations, further research is required to", "bbox": [260.0, 382.0, 726.0, 397.0]}, {"text": "strengthen these guidelines. 511 J", "bbox": [261.0, 398.0, 440.0, 413.0]}], "type": "Text", "position": 11}, {"raw_context": [{"text": "Keywords: Practice guidelines, Bone, Child, Adolescent, Korea", "bbox": [260.0, 428.0, 602.0, 444.0]}], "type": "Text", "position": 12}, {"raw_context": [{"text": "Highlights", "bbox": [260.0, 481.0, 336.0, 500.0]}], "type": "Section-header", "position": 13}, {"raw_context": [{"text": "The Committee on Pediatric Bone Health of the Korean Society of Pediatric", "bbox": [280.0, 517.0, 725.0, 533.0]}, {"text": "Endocrinology has newly developed evidence-based clinical practice guidelines for", "bbox": [283.0, 533.0, 727.0, 548.0]}, {"text": "optimizing bone health in Korean children and adolescents. These guidelines include", "bbox": [283.0, 550.0, 727.0, 564.0]}, {"text": "/processes of bone acquisition, definition, and evaluation of low bone mineral density", "bbox": [280.0, 566.0, 727.0, 580.0]}, {"text": "(BMD), causes of osteoporosis, methods for optimizing bone health, and pharmacological", "bbox": [283.0, 582.0, 727.0, 596.0]}, {"text": "treatments for enhancing BMD in children and adolescents.", "bbox": [283.0, 596.0, 579.0, 614.0]}], "type": "Text", "position": 14}, {"raw_context": [{"text": "Introduction", "bbox": [261.0, 630.0, 350.0, 646.0]}], "type": "Section-header", "position": 15}, {"raw_context": [{"text": "Osteoporosis was previously thought to be a disease exclusiye/to older adults. However,", "bbox": [271.0, 664.0, 727.0, 680.0]}, {"text": "it is now increasingly recognized in younger adults due, in part, to the longer survival of", "bbox": [260.0, 681.0, 727.0, 696.0]}, {"text": "chronically ill children. Children with osteoporosis are at a high risk of skeletal morbidity", "bbox": [260.0, 697.0, 726.0, 712.0]}, {"text": "not only during youth, but also in adult life. 17 Bone mass attained in early life is thought to 7", "bbox": [260.0, 713.0, 733.0, 728.0]}, {"text": "be the most important modifiable determinant of lifelong skeletal health. 27 In this context,", "bbox": [260.0, 728.0, 728.0, 743.0]}, {"text": "the Committee on Pediatric Bone Health of the Korean Society of Pediatric Endocrinology", "bbox": [260.0, 744.0, 726.0, 759.0]}, {"text": "recently developed evidence-based clinical practice guidelines for optimizing bone health in", "bbox": [260.0, 761.0, 727.0, 775.0]}, {"text": "Korean children and adolescents. Recommendations were determined according to the quality", "bbox": [261.0, 777.0, 727.0, 792.0]}, {"text": "of evidence graded by the steering committee on quality improvement and management in the", "bbox": [260.0, 793.0, 727.0, 807.0]}, {"text": "American Academy of Pediatrics. 3", "bbox": [262.0, 809.0, 428.0, 824.0]}, {"text": "This guideline, comprises the physiological processes of bone acquisition, definition,", "bbox": [273.0, 825.0, 728.0, 840.0]}, {"text": "and evaluation of low bone mineral density (BMD), causes of osteoporosis, conservative", "bbox": [261.0, 841.0, 727.0, 856.0]}, {"text": "management for optimizing bone health, and pharmacological treatments for enhancing BMD", "bbox": [261.0, 857.0, 727.0, 871.0]}, {"text": "in children and adolescents.", "bbox": [260.0, 872.0, 400.0, 887.0]}], "type": "Text", "position": 16}, {"raw_context": [{"text": "This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://", "bbox": [67.0, 950.0, 589.0, 961.0]}, {"text": "creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any", "bbox": [65.0, 960.0, 588.0, 974.0]}], "type": "Footnote", "position": 17}, {"raw_context": [{"text": "medium, provided the original work is properly cited.", "bbox": [66.0, 972.0, 273.0, 983.0]}], "type": "Footnote", "position": 19}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2022】全科室最全临床指南+专家共识（最全版）/2022全科室临床指南/内分泌科/KSPE：优化儿童和青少年骨健康的临床实践指南（2022）.pdf", "page_num": 1}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "缺少换行#11#11# This guideline, comprises the physiological...另起一行", "type3": "无关文本#0#0#apent.2244060.030\n无关文本#1#1#Ann Pediatr Endocrinol Metab 2022;27:5-14\n无关文本#1#11# to 7 be the most important...\n...Academy of Pediatrics. 3类似的数字无关引用过多\n无关文本#6#6#511 J", "type4": null, "type5": null, "type6": "有用性#1#5#撰写人和方针指南的内容\n有用性#11#11#This is an Open Access article distributed...work is properly cited.文章的获取链接等"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:41", "update_time": "2024-05-08 23:20:55"}
{"id": 1082573, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 738, "source_info": {"seq_id": "cc480239-a292-4846-92d9-81c394fbcef6", "title": null, "text": "【0】页码:4\n\n【1】 MHV IN PREGNANCY -BJHaem Maternal and foetal benefits and risks of different anticoagulant regimens in pregnant individuals with MHV. 56.8–13 T A B L E  2 Anticoagulation regimen Maternal benefits/risks Foetal benefits/risks Lowest composite maternal risk (death, mechanical valve Highest overall foetal loss (32.54%). 10 Warfarin from a positive pregnancy test until 36 weeks: failure or thromboembolism) at 5% 8 Strongly consider when high Lowest maternal mortality rate 0.9% (0.4–1.4) 9 Highest overall composite foetal risk risk of maternal MVT (miscarriage, termination, foetal • Continue warfarin till 36 weeks abnormality) 39%. 1 • Introduce LMWH from Lowest thromboembolic complications rate 2.7% (1.4%–4%) 9 Live births 83.6% (75.8–91.4) with warfarin 36 weeks to delivery to <5mg/day and 43.9% (32.8–55) with minimise the risk of foetal and warfarin > 5 mg/day. 9 maternal haemorrhage However, there is an increased risk of bleeding in some studies Foetal embryopathy/fetopathy 2.3% (0.7–4) (both antepartum and postpartum) 5.11.1 with warfarin <5 mg/day and 12.4% (3.3– 21.6) with warfarin >5mg/day. 9 Foetal intracranial haemorrhage thought to be a risk with vaginal delivery if recent (<1 week) warfarin dosing LMWH throughout pregnancy Use of LMWH throughout has a higher composite maternal Lowest composite foetal risk at 13% 8 risk of 15.5% 8 Higher mortality rate 2.9% (0.2–5.7) 9 Overall foetal loss rate (mostly miscarriage) 12.2% 10 to 13.9% 8 Higher thromboembolic complications 8.7% (3.9–13.4), 9 but Highest livebirth rate 92% (86.1–98) 9 reported up to 53% 13 Optimal dosing with the use of anti-Xa levels is not yet fully No placental transfer to foetus during established so close monitoring is required pregnancy Combination (sequential LMWH/ Combination/sequential LMWH/warfarin has a similar Composite foetal risk 23% 8 warfarin/LMWH) composite maternal risk to LMWH alone, of 15.9% 8 Overall foetal loss rate 22.65% 10 • LMWH from positive Mortality rate 2% (0.8–3.1) 9 which is lower than LMWH Fetopathy (foetal haemorrhage) 1.4% pregnancy test to week 13 throughout, but higher than with warfarin alone (0.3– 2.5) 5 • Warfarin weeks 13–36 Live birth 79.9% (74.3–85.6) 9 • LMWH week 36 until MVT risk higher than warfarin delivery (as above) 50% of MVT in pregnancy occur during first trimester LMWH 6 Better livebirth rate than with >5mg/day warfarin Thromboembolic complications, 5.8% (3.8–7.7) 9 No placental transfer to foetus during first trimester Requires very close monitoring during transitions to limit subtherapeutic anticoagulation Requires high maternal compliance with treatment/monitoring regimes Unfractionated heparin only Very rarely recommended due to MVT > 10% (11.2% [2.8–19.6]) 9 Low rate of live births however number of and risk of maternal osteoporosis and thrombocytopaenia pregnancies analysed small Combination (UFH/warfarin) Composite maternal risk of 33.6% 8 Slightly higher than Composite foetal risk of 34% 8 LMWH/warfarin regimen More complex drug delivery/monitoring Osteoporosis/thrombocytopenia Other anticoagulants Have not been shown to be as effective as warfarin in patients Limited evidence, currently contraindicated with MHVs, and cross the placenta so are not recommended Not recommended in individuals that are breast feeding For example, dabigatran, rivaroxaban, apixaban, fondaparinux Abbreviations: LMWH, low molecular weight heparin; MHV, mechanical heart valve; MVT, mechanical valve thrombosis.\n\n【2】\n outcome compared to the Registry of Pregnancy and Cardiac (ROPAC) disease European registry, 6 where individuals with a MHV had a 58% chance of experiencing an uncomplicated pregnancy with a live birth.\n\n【3】Caring for pregnant individuals with MHV is logis¬ tically challenging involving multiple specialist teams\n\n【4】 including maternal/foetal medicine, cardiology, haematology and anaesthesia. The UKOSS study estimated the incidence of MHV in pregnancy to be 3.7 (95% CI: 2.7–4.7) per 100 000 maternities, so familiarity in management of pregnant patients outside of specialist centres will be limited. In view of the high risks involved and requirement\n\n【5】 (sque) and her 5 las arroT odi vo 8 (50540/81) no candidaninO coli/r , candid plen vin 0 M &A assoT - is no 6418281.00/111101/sel/use-galler.colonias//\n\n【6】 loves are solving VC) cash to solving variable online volities no (anotibility)\n\n【7】 to obtrainings out out of both", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "MHV IN PREGNANCY", "bbox": [636.0, 27.0, 733.0, 40.0]}, {"text": "-BJHaem", "bbox": [79.0, 30.0, 155.0, 53.0]}, {"text": "Maternal and foetal benefits and risks of different anticoagulant regimens in pregnant individuals with MHV. 56.8–13", "bbox": [122.0, 58.0, 634.0, 71.0]}, {"text": "T A B L E  2", "bbox": [59.0, 59.0, 112.0, 71.0]}, {"text": "Anticoagulation regimen", "bbox": [64.0, 83.0, 183.0, 96.0]}, {"text": "Maternal benefits/risks", "bbox": [230.0, 83.0, 339.0, 96.0]}, {"text": "Foetal benefits/risks", "bbox": [523.0, 83.0, 619.0, 96.0]}, {"text": "Lowest composite maternal risk (death, mechanical valve", "bbox": [230.0, 103.0, 483.0, 117.0]}, {"text": "Highest overall foetal loss (32.54%). 10", "bbox": [522.0, 104.0, 689.0, 116.0]}, {"text": "Warfarin from a positive", "bbox": [65.0, 105.0, 177.0, 117.0]}, {"text": "pregnancy test until 36 weeks:", "bbox": [81.0, 119.0, 215.0, 130.0]}, {"text": "failure or thromboembolism) at 5% 8", "bbox": [246.0, 119.0, 404.0, 130.0]}, {"text": "Strongly consider when high", "bbox": [74.0, 132.0, 207.0, 144.0]}, {"text": "Lowest maternal mortality rate 0.9% (0.4–1.4) 9", "bbox": [230.0, 135.0, 435.0, 149.0]}, {"text": "Highest overall composite foetal risk", "bbox": [523.0, 136.0, 687.0, 148.0]}, {"text": "risk of maternal MVT", "bbox": [78.0, 145.0, 177.0, 157.0]}, {"text": "(miscarriage, termination, foetal", "bbox": [539.0, 150.0, 686.0, 162.0]}, {"text": "• Continue warfarin till 36 weeks", "bbox": [65.0, 158.0, 219.0, 169.0]}, {"text": "abnormality) 39%. 1", "bbox": [541.0, 164.0, 623.0, 175.0]}, {"text": "• Introduce LMWH from", "bbox": [66.0, 171.0, 185.0, 183.0]}, {"text": "Lowest thromboembolic complications rate 2.7% (1.4%–4%) 9", "bbox": [229.0, 180.0, 498.0, 194.0]}, {"text": "Live births 83.6% (75.8–91.4) with warfarin", "bbox": [522.0, 180.0, 717.0, 194.0]}, {"text": "36 weeks to delivery to", "bbox": [78.0, 185.0, 179.0, 197.0]}, {"text": "<5mg/day and 43.9% (32.8–55) with", "bbox": [540.0, 195.0, 701.0, 207.0]}, {"text": "minimise the risk of foetal and", "bbox": [78.0, 199.0, 216.0, 211.0]}, {"text": "warfarin > 5 mg/day. 9", "bbox": [540.0, 209.0, 630.0, 220.0]}, {"text": "maternal haemorrhage", "bbox": [78.0, 213.0, 180.0, 224.0]}, {"text": "However, there is an increased risk of bleeding in some studies", "bbox": [230.0, 226.0, 507.0, 240.0]}, {"text": "Foetal embryopathy/fetopathy 2.3% (0.7–4)", "bbox": [522.0, 226.0, 717.0, 239.0]}, {"text": "(both antepartum and postpartum) 5.11.1", "bbox": [246.0, 240.0, 419.0, 253.0]}, {"text": "with warfarin <5 mg/day and 12.4% (3.3–", "bbox": [539.0, 240.0, 722.0, 253.0]}, {"text": "21.6) with warfarin >5mg/day. 9", "bbox": [540.0, 254.0, 678.0, 266.0]}, {"text": "Foetal intracranial haemorrhage thought to", "bbox": [523.0, 272.0, 718.0, 284.0]}, {"text": "be a risk with vaginal delivery if recent", "bbox": [539.0, 286.0, 712.0, 298.0]}, {"text": "(<1 week) warfarin dosing", "bbox": [538.0, 300.0, 656.0, 312.0]}, {"text": "LMWH throughout pregnancy", "bbox": [64.0, 315.0, 205.0, 329.0]}, {"text": "Use of LMWH throughout has a higher composite maternal", "bbox": [228.0, 315.0, 496.0, 329.0]}, {"text": "Lowest composite foetal risk at 13% 8", "bbox": [522.0, 316.0, 685.0, 329.0]}, {"text": "risk of 15.5% 8", "bbox": [246.0, 330.0, 307.0, 342.0]}, {"text": "Higher mortality rate 2.9% (0.2–5.7) 9", "bbox": [228.0, 348.0, 394.0, 361.0]}, {"text": "Overall foetal loss rate (mostly miscarriage)", "bbox": [522.0, 347.0, 719.0, 362.0]}, {"text": "12.2% 10 to 13.9% 8", "bbox": [540.0, 361.0, 615.0, 374.0]}, {"text": "Higher thromboembolic complications 8.7% (3.9–13.4), 9 but", "bbox": [228.0, 380.0, 496.0, 393.0]}, {"text": "Highest livebirth rate 92% (86.1–98) 9", "bbox": [522.0, 380.0, 687.0, 394.0]}, {"text": "reported up to 53% 13", "bbox": [246.0, 394.0, 336.0, 406.0]}, {"text": "Optimal dosing with the use of anti-Xa levels is not yet fully", "bbox": [228.0, 411.0, 494.0, 424.0]}, {"text": "No placental transfer to foetus during", "bbox": [522.0, 411.0, 692.0, 424.0]}, {"text": "established so close monitoring is required", "bbox": [246.0, 425.0, 436.0, 438.0]}, {"text": "pregnancy", "bbox": [539.0, 427.0, 588.0, 440.0]}, {"text": "Combination (sequential LMWH/", "bbox": [64.0, 443.0, 220.0, 456.0]}, {"text": "Combination/sequential LMWH/warfarin has a similar", "bbox": [227.0, 442.0, 477.0, 456.0]}, {"text": "Composite foetal risk 23% 8", "bbox": [522.0, 442.0, 644.0, 456.0]}, {"text": "warfarin/LMWH)", "bbox": [82.0, 457.0, 166.0, 469.0]}, {"text": "composite maternal risk to LMWH alone, of 15.9% 8", "bbox": [248.0, 457.0, 474.0, 470.0]}, {"text": "Overall foetal loss rate 22.65% 10", "bbox": [522.0, 462.0, 665.0, 475.0]}, {"text": "• LMWH from positive", "bbox": [65.0, 471.0, 176.0, 482.0]}, {"text": "Mortality rate 2% (0.8–3.1) 9 which is lower than LMWH", "bbox": [230.0, 479.0, 479.0, 493.0]}, {"text": "Fetopathy (foetal haemorrhage) 1.4%", "bbox": [522.0, 480.0, 688.0, 493.0]}, {"text": "pregnancy test to week 13", "bbox": [78.0, 484.0, 193.0, 496.0]}, {"text": "throughout, but higher than with warfarin alone", "bbox": [246.0, 494.0, 461.0, 507.0]}, {"text": "(0.3– 2.5) 5", "bbox": [539.0, 495.0, 582.0, 507.0]}, {"text": "• Warfarin weeks 13–36", "bbox": [65.0, 498.0, 179.0, 510.0]}, {"text": "Live birth 79.9% (74.3–85.6) 9", "bbox": [522.0, 511.0, 651.0, 525.0]}, {"text": "• LMWH week 36 until", "bbox": [77.0, 512.0, 188.0, 523.0]}, {"text": "MVT risk higher than warfarin", "bbox": [229.0, 512.0, 371.0, 526.0]}, {"text": "delivery (as above)", "bbox": [88.0, 524.0, 174.0, 537.0]}, {"text": "50% of MVT in pregnancy occur during first trimester LMWH 6", "bbox": [230.0, 529.0, 514.0, 544.0]}, {"text": "Better livebirth rate than with >5mg/day", "bbox": [522.0, 529.0, 705.0, 543.0]}, {"text": "warfarin", "bbox": [540.0, 545.0, 581.0, 558.0]}, {"text": "Thromboembolic complications, 5.8% (3.8–7.7) 9", "bbox": [230.0, 562.0, 443.0, 575.0]}, {"text": "No placental transfer to foetus during first", "bbox": [523.0, 562.0, 713.0, 575.0]}, {"text": "trimester", "bbox": [539.0, 576.0, 583.0, 588.0]}, {"text": "Requires very close monitoring during transitions to limit sub-", "bbox": [230.0, 581.0, 507.0, 593.0]}, {"text": "therapeutic anticoagulation", "bbox": [247.0, 595.0, 370.0, 608.0]}, {"text": "Requires high maternal compliance with treatment/monitoring", "bbox": [229.0, 612.0, 512.0, 625.0]}, {"text": "regimes", "bbox": [246.0, 628.0, 283.0, 640.0]}, {"text": "Unfractionated heparin only", "bbox": [64.0, 643.0, 195.0, 657.0]}, {"text": "Very rarely recommended due to MVT > 10% (11.2% [2.8–19.6]) 9", "bbox": [230.0, 643.0, 514.0, 656.0]}, {"text": "Low rate of live births however number of", "bbox": [522.0, 643.0, 710.0, 656.0]}, {"text": "and risk of maternal osteoporosis and thrombocytopaenia", "bbox": [246.0, 657.0, 504.0, 670.0]}, {"text": "pregnancies analysed small", "bbox": [538.0, 657.0, 662.0, 670.0]}, {"text": "Combination (UFH/warfarin)", "bbox": [64.0, 675.0, 202.0, 689.0]}, {"text": "Composite maternal risk of 33.6% 8 Slightly higher than", "bbox": [228.0, 675.0, 476.0, 689.0]}, {"text": "Composite foetal risk of 34% 8", "bbox": [522.0, 675.0, 655.0, 689.0]}, {"text": "LMWH/warfarin regimen", "bbox": [245.0, 689.0, 364.0, 702.0]}, {"text": "More complex drug delivery/monitoring", "bbox": [230.0, 707.0, 411.0, 722.0]}, {"text": "Osteoporosis/thrombocytopenia", "bbox": [228.0, 726.0, 377.0, 739.0]}, {"text": "Other anticoagulants", "bbox": [64.0, 745.0, 162.0, 758.0]}, {"text": "Have not been shown to be as effective as warfarin in patients", "bbox": [229.0, 745.0, 504.0, 758.0]}, {"text": "Limited evidence, currently contraindicated", "bbox": [522.0, 745.0, 722.0, 758.0]}, {"text": "with MHVs, and cross the placenta so are not recommended", "bbox": [246.0, 759.0, 513.0, 773.0]}, {"text": "Not recommended in individuals that are breast feeding", "bbox": [229.0, 776.0, 478.0, 790.0]}, {"text": "For example, dabigatran,", "bbox": [64.0, 777.0, 178.0, 790.0]}, {"text": "rivaroxaban, apixaban,", "bbox": [82.0, 791.0, 184.0, 803.0]}, {"text": "fondaparinux", "bbox": [81.0, 804.0, 144.0, 817.0]}, {"text": "Abbreviations: LMWH, low molecular weight heparin; MHV, mechanical heart valve; MVT, mechanical valve thrombosis.", "bbox": [59.0, 825.0, 533.0, 840.0]}], "type": "Table", "position": 1}, {"raw_context": [{"text": "outcome compared to the Registry of Pregnancy and Cardiac", "bbox": [58.0, 881.0, 387.0, 896.0]}, {"text": "(ROPAC) disease European registry, 6 where individuals with", "bbox": [58.0, 897.0, 386.0, 913.0]}, {"text": "a MHV had a 58% chance of experiencing an uncomplicated", "bbox": [58.0, 914.0, 386.0, 929.0]}, {"text": "pregnancy with a live birth.", "bbox": [58.0, 930.0, 209.0, 944.0]}, {"text": "Caring for pregnant individuals with MHV is logis¬", "bbox": [74.0, 946.0, 385.0, 960.0]}, {"text": "tically challenging involving multiple specialist teams", "bbox": [58.0, 962.0, 386.0, 977.0]}], "type": "Text", "position": 2}, {"raw_context": [{"text": "including maternal/foetal medicine, cardiology, haema-", "bbox": [406.0, 881.0, 733.0, 896.0]}, {"text": "tology and anaesthesia. The UKOSS study estimated the", "bbox": [406.0, 897.0, 735.0, 913.0]}, {"text": "incidence of MHV in pregnancy to be 3.7 (95% CI: 2.7–4.7)", "bbox": [406.0, 914.0, 734.0, 929.0]}, {"text": "per 100 000 maternities, so familiarity in management of", "bbox": [406.0, 930.0, 735.0, 944.0]}, {"text": "pregnant patients outside of specialist centres will be lim-", "bbox": [407.0, 946.0, 733.0, 961.0]}, {"text": "ited. In view of the high risks involved and requirement", "bbox": [406.0, 962.0, 734.0, 977.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "(sque) and her 5 las arroT odi vo 8 (50540/81) no candidaninO coli/r , candid plen vin 0 M &A assoT - is no 6418281.00/111101/sel/use-galler.colonias//", "bbox": [769.0, 125.0, 781.0, 587.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": "loves are solving VC) cash to solving variable online volities no (anotibility)", "bbox": [770.0, 686.0, 780.0, 886.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "to obtrainings out out of both", "bbox": [770.0, 892.0, 780.0, 950.0]}], "type": "Text", "position": 6}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/心血管/指南/2023 BSH 指南：机械心脏瓣膜妊娠个体抗凝管理(1).pdf", "page_num": 4}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "多余换行#4#4# including maternal/foetal medicine, 与3段联接", "type3": "无关文本#1#1#MHV IN PREGNANCY -BJHaem页眉的内容\n无关文本#1#6#...individuals with MHV. 56.8–13\n...foetal loss (32.54%). 10 类似的数字引用过多\n无关文本#5#7#侧边栏目的信息", "type4": null, "type5": null, "type6": "有用性#1#1#表格的内容，但是内容杂乱"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:41", "update_time": "2024-05-08 01:25:08"}
{"id": 1082572, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 738, "source_info": {"seq_id": "81954d14-2585-4fa4-8b08-55e4368889fa", "title": null, "text": "【0】页码:8\n [1] Russell BW, Douglas N, Marcia W, et al. The neurological manifestations of cervical spondylosis[J]. Brain, 1952,75(2):187–225.\n\n【1】 [2]\n\n【2】 [3]\n\n【3】 [4]\n\n【4】## [5]\n\n【5】\n [6]\n\n【6】 [7]\n\n【7】 [8]\n\n【8】 [9]\n\n【9】 [ 10 ]\n\n【10】 [ 11 ]\n\n【11】 ,2018,56(6):401–402.\n\n【12】(2018)[ J ].\n\n【13】Editorial Department of Chinese Journal of Surgery. Expert consensus on classification , diagnosis and non-surgical treatment of cervical spondylosis(2018)[J]. Zhonghua Wai Ke Za Zhi , 2018, 56(6) : 401–402. Chinese.\n\n【14】 Zileli M, Borkar SA, Sinha S, et  al. Cervical spondylotic myelopathy ; natural course and the value of diagnostic techniques – WFNS Spine Committee Recommendations [J]. Korean J Spine,2019,16 (3):386–447.\n\n【15】 Baptiste DC , Fehlings MG. Pathophysiology of cervical myelopathy [J]. Spine J, 2006, 6(6): 190–197.\n\n【16】Toledano M , Bartleson JD.  Cervical spondylotic myelopathy [J].\n\n【17】Neurologic Clinics, 2013, 75 (1):287–305.\n\n【18】 [1]\n\n【19】## 1998, 11 (6):17–18.\n\n【20】\n WU T. Treatment of cervical spondylotic myelopathy based on spasm and flaccidity syndrome[J]. Shang Hai Zhong Yi Yao Za Zhi , 1998, 11(6): 17–18. Chinese.\n\n【21】Lees F, Turner JWA. Natural history and prognosis of cervical spondylosis[J]. BMJ,1963,2(5373):1607–1610.\n\n【22】 [1].\n\n【23】 , 2002 , 10( 13 ) : 1301–1304.\n\n【24】CHEN XS , JIA LS , YUAN W , et al. Study on the natural history of cervical spondylotic myelopathy [ J ]. Zhongguo Jiao Xing Wai Ke Za Zhi ,2002,10(13):1301–1304. Chinese.\n\n【25】 Emery SE. Cervical spondylotic myelopathy diagnosis and treat- [ 12 ] ment[J]. Am Acad Orthop Surg , 2001 , 9(6):376–388.\n\n【26】McCormick JR,Sama AJ,Schiller NC,et al. Cervical spondylotic [ 13 ] myelopathy : a guide to diagnosis and management [J]. J Am Board Fam Med , 2020 , 33(2) : 303–313.\n\n【27】[ 14 ] Sumi M, Miyamoto H, Suzuki T, et al. Prospective cohort study of mild cervical spondylotic myelopathy without surgical treatment [J] . J Neurosurg Spine , 2012 , 16(1) : 8–14.\n\n【28】[15] .\n\n【29】.\n .\n\n【30】[1].\n\n【31】 ,2021,55(4):\n\n【32】 ZHANG CB,TONG ZY,XU JH,et al. Study on syndrome and treatment rules of traditional Chinese medicine in the treatment of cervical spondylotic myelopathy based on data mining[J]. Shang Hai Zhong Yi Yao Za Zhi , 2021 , 55(4) : 15–20. Chinese.\n\n【33】 [16]\n\n【34】 .\n [1].\n\n【35】 , 2005 , 46\n\n【36】 (9) : 102–104.\n\n【37】MO W ,SHI Q , HOU BX , et al. To evaluate the effect of oral and external application of traditional Chinese medicine in the treatment of mild cervical spondylotic myelopathy by single disease quality management[J]. Zhongguo Lin Chuang Kang Fu,2005,46(9): 102–104. Chinese.\n\n【38】 [17]\n\n【39】 .\n\n【40】 544.\n .\n\n【41】[1].\n ,2017,41(6):538–\n\n【42】 TIAN M,LOU TW,JIA HL,et al. Study on acupoint selection rules of acupuncture and moxibustion in the treatment of cervical spondylotic myelopathy based on literature [ J ]. Zhe Jiang Zhong Yi Yao Da Xue Xue Bao , 2017 , 41(6) : 538–544. Chinese.\n\n【43】Meta [D].\n\n【44】 [18]\n\n【45】## 11. S. 2017.\n\n【46】\n [19]\n\n【47】 .\n\n【48】 ,\n\n【49】## Dti\n\n【50】 [1].\n\n【51】## , 2019 , 41 (11) : 833–837.\n\n【52】\n ZHAO DD. Meta analysis of acupuncture and moxibustion in the treatment of cervical spondylotic myelopathy[D]. Shandong University of Traditional Chinese Medicine , 2017. Chinese.\n\n【53】 SHEN CH,FENG YJ,SONG YC,et al. DTI study on the effect of perioperative hyperbaric oxygen therapy on postoperative spinal cord function of cervical spondylotic myelopathy [J]. Zhonghua Wu Li Yi Xue Yu Kang Fu Za Zhi ,2019 ,41(11) ,833–837. Chinese.\n\n【54】 [20]\n\n【55】## , 2011 , 18(12) : 106–108.\n\n【56】\n , 2011 , 18(12) : 106–108.\n\n【57】[1].\n\n【58】YAN MR,ZHOU J,DING QM. Research progress of Tuina in the treatment of cervical spondylotic myelopathy [J]. Zhongguo Zhong Yi Yao Xin Xi Za Zhi , 2011 , 18(12) ; 106–108. Chinese.\n\n【59】 [21]\n\n【60】 .\n\n【61】 .\n\n【62】 . \n\n【63】 ,2016,39(2):71–74.\n\n【64】[1].\n\n【65】ZHU CL,XU B,LI Y,et al. Systematic evaluation of Tuina in the treatment of cervical spondylotic myelopath [ J ]. Shan Xi Zhong Yi Yao Da Xue Xue Bao , 2016 , 39 (2) , 71–74. Chinese.\n\n【66】## ,2010 , 31 ( 4 )  :  249–251 .\n\n【67】\n ,2010 , 31 ( 4 )  :  249–251 .\n\n【68】[1] .\n\n【69】WU YW , GAO XP. Review and prospect of Tuina in the treatment of cervical spondylotic myelopathy[J]. Jing Yao Tong Za Zhi , 2010 , 31(4):249–251. Chinese.\n\n【70】## [23]\n\n【71】\n ,2014,33(4):285–287.\n\n【72】[1] .\n\n【73】WANG DZ, DING QM. Clinical observation of positioning, rotating, lifting, shaking and pulling in the treatment of cervical spondylotic myelopathy[J]. Bei Jing Zhong Yi Yao,2014,33(4): 285–287. Chinese.\n\n【74】 [1] .\n\n【75】, 2006 , 19(11) , 691.\n\n【76】LUO J , YU J , ZHU LG , et al. Clinical observation of cervical spondylotic myelopathy with manipulation [J]. Zhongguo Gu Shang/Chi-\n\n【77】 [M].\n\n【78】: , 2012 ; 57–59.\n\n【79】Chinese Society of Traditional Chinese Medicine. Guide to Diagnosis and Treatment of Common Diseases in Orthopedics and Traumatology of Traditional Chinese Medicine[M]. Beijing,China Traditional Chinese Medicine Press , 2012 :57–59. Chinese.\n\n【80】Fehlings MG,Tetreault LA,Riew KD,et al. A clinical practice guideline for the management of patients with degenerative cervical myelopathy ; recommendations for patients with mild , moderate , and severe disease and monmyelopathic patients with evidence of cord compression[J] . Global Spine J , 2017 , 7(3):70–83.\n [M].\n\n【81】 ,2008,46(23):1796–1799.\n\n【82】[1] .\n\n【83】LI ZC , CHEN DY , WU DS , et al. Summary of the third national symposium on cervical spondylosis [J]. Zhonghua Wai Ke Za Zhi , 2008 , 46(23) : 1796–1799. Chinese.\n\n【84】 15–20.\n\n【85】 [24]\n\n【86】 [22]", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "[1] Russell BW, Douglas N, Marcia W, et al. The neurological manifes-", "bbox": [80.0, 123.0, 391.0, 138.0]}, {"text": "tations of cervical spondylosis[J]. Brain, 1952,75(2):187–225.", "bbox": [106.0, 139.0, 381.0, 154.0]}], "type": "Text", "position": 2}, {"raw_context": [{"text": "[2]", "bbox": [80.0, 159.0, 101.0, 171.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "[3]", "bbox": [80.0, 239.0, 101.0, 254.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": "[4]", "bbox": [80.0, 340.0, 101.0, 352.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "[5]", "bbox": [80.0, 422.0, 100.0, 436.0]}], "type": "Section-header", "position": 6}, {"raw_context": [{"text": "[6]", "bbox": [80.0, 523.0, 105.0, 535.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "[7]", "bbox": [80.0, 589.0, 102.0, 602.0]}], "type": "Text", "position": 8}, {"raw_context": [{"text": "[8]", "bbox": [80.0, 623.0, 101.0, 634.0]}], "type": "Text", "position": 9}, {"raw_context": [{"text": "[9]", "bbox": [80.0, 655.0, 99.0, 668.0]}], "type": "Text", "position": 10}, {"raw_context": [{"text": "[ 10 ]", "bbox": [80.0, 739.0, 107.0, 751.0]}], "type": "Text", "position": 11}, {"raw_context": [{"text": "[ 11 ]", "bbox": [80.0, 770.0, 106.0, 784.0]}], "type": "Text", "position": 12}, {"raw_context": [{"text": ",2018,56(6):401–402.", "bbox": [244.0, 438.0, 350.0, 452.0]}, {"text": "(2018)[ J ].", "bbox": [128.0, 439.0, 181.0, 452.0]}, {"text": "Editorial Department of Chinese Journal of Surgery. Expert consen-", "bbox": [107.0, 456.0, 390.0, 469.0]}, {"text": "sus on classification , diagnosis and non-surgical treatment of cervi-", "bbox": [107.0, 472.0, 391.0, 485.0]}, {"text": "cal spondylosis(2018)[J]. Zhonghua Wai Ke Za Zhi , 2018, 56(6) :", "bbox": [106.0, 488.0, 393.0, 501.0]}, {"text": "401–402. Chinese.", "bbox": [107.0, 506.0, 187.0, 518.0]}], "type": "Text", "position": 13}, {"raw_context": [{"text": "Zileli M, Borkar SA, Sinha S, et  al. Cervical spondylotic myelopa-", "bbox": [103.0, 522.0, 391.0, 535.0]}, {"text": "thy ; natural course and the value of diagnostic techniques – WFNS", "bbox": [107.0, 539.0, 393.0, 551.0]}, {"text": "Spine Committee Recommendations [J]. Korean J Spine,2019,16", "bbox": [107.0, 555.0, 393.0, 568.0]}, {"text": "(3):386–447.", "bbox": [107.0, 572.0, 171.0, 584.0]}], "type": "Text", "position": 14}, {"raw_context": [{"text": "Baptiste DC , Fehlings MG. Pathophysiology of cervical myelopathy", "bbox": [105.0, 587.0, 392.0, 603.0]}, {"text": "[J]. Spine J, 2006, 6(6): 190–197.", "bbox": [107.0, 605.0, 259.0, 617.0]}, {"text": "Toledano M , Bartleson JD.  Cervical spondylotic myelopathy [J].", "bbox": [106.0, 622.0, 393.0, 635.0]}, {"text": "Neurologic Clinics, 2013, 75 (1):287–305.", "bbox": [107.0, 639.0, 292.0, 651.0]}], "type": "Text", "position": 15}, {"raw_context": [{"text": "[1]", "bbox": [282.0, 657.0, 302.0, 668.0]}], "type": "Text", "position": 16}, {"raw_context": [{"text": "1998, 11 (6):17–18.", "bbox": [107.0, 670.0, 197.0, 684.0]}], "type": "Section-header", "position": 17}, {"raw_context": [{"text": "WU T. Treatment of cervical spondylotic myelopathy based on spasm", "bbox": [106.0, 687.0, 393.0, 701.0]}, {"text": "and flaccidity syndrome[J]. Shang Hai Zhong Yi Yao Za Zhi , 1998,", "bbox": [107.0, 705.0, 392.0, 718.0]}, {"text": "11(6): 17–18. Chinese.", "bbox": [107.0, 721.0, 207.0, 734.0]}, {"text": "Lees F, Turner JWA. Natural history and prognosis of cervical", "bbox": [108.0, 736.0, 393.0, 751.0]}, {"text": "spondylosis[J]. BMJ,1963,2(5373):1607–1610.", "bbox": [112.0, 754.0, 327.0, 766.0]}], "type": "Text", "position": 18}, {"raw_context": [{"text": "[1].", "bbox": [373.0, 772.0, 393.0, 784.0]}], "type": "Text", "position": 19}, {"raw_context": [{"text": ", 2002 , 10( 13 ) : 1301–1304.", "bbox": [198.0, 788.0, 318.0, 799.0]}, {"text": "CHEN XS , JIA LS , YUAN W , et al. Study on the natural history of", "bbox": [111.0, 802.0, 393.0, 817.0]}, {"text": "cervical spondylotic myelopathy [ J ]. Zhongguo Jiao Xing Wai Ke Za", "bbox": [112.0, 820.0, 393.0, 833.0]}, {"text": "Zhi ,2002,10(13):1301–1304. Chinese.", "bbox": [112.0, 837.0, 286.0, 850.0]}], "type": "Text", "position": 20}, {"raw_context": [{"text": "Emery SE. Cervical spondylotic myelopathy diagnosis and treat-", "bbox": [109.0, 853.0, 390.0, 866.0]}, {"text": "[ 12 ]", "bbox": [80.0, 854.0, 107.0, 867.0]}, {"text": "ment[J]. Am Acad Orthop Surg , 2001 , 9(6):376–388.", "bbox": [113.0, 871.0, 346.0, 883.0]}, {"text": "McCormick JR,Sama AJ,Schiller NC,et al. Cervical spondylotic", "bbox": [111.0, 886.0, 393.0, 900.0]}, {"text": "[ 13 ]", "bbox": [80.0, 887.0, 107.0, 899.0]}, {"text": "myelopathy : a guide to diagnosis and management [J]. J Am Board", "bbox": [112.0, 904.0, 393.0, 916.0]}, {"text": "Fam Med , 2020 , 33(2) : 303–313.", "bbox": [112.0, 919.0, 256.0, 933.0]}, {"text": "[ 14 ] Sumi M, Miyamoto H, Suzuki T, et al. Prospective cohort study of", "bbox": [80.0, 936.0, 393.0, 949.0]}, {"text": "mild cervical spondylotic myelopathy without surgical treatment", "bbox": [112.0, 953.0, 393.0, 967.0]}, {"text": "[J] . J Neurosurg Spine , 2012 , 16(1) : 8–14.", "bbox": [112.0, 969.0, 297.0, 982.0]}, {"text": "[15]", "bbox": [80.0, 985.0, 106.0, 1000.0]}, {"text": ".", "bbox": [144.0, 989.0, 152.0, 1000.0]}, {"text": ".", "bbox": [219.0, 990.0, 228.0, 999.0]}], "type": "Text", "position": 21}, {"raw_context": [{"text": ".", "bbox": [219.0, 990.0, 228.0, 999.0]}, {"text": "[1].", "bbox": [230.0, 1003.0, 252.0, 1017.0]}], "type": "Formula", "position": 22}, {"raw_context": [{"text": ",2021,55(4):", "bbox": [327.0, 1003.0, 393.0, 1015.0]}], "type": "Text", "position": 23}, {"raw_context": [{"text": "ZHANG CB,TONG ZY,XU JH,et al. Study on syndrome and", "bbox": [445.0, 106.0, 727.0, 119.0]}, {"text": "treatment rules of traditional Chinese medicine in the treatment of", "bbox": [445.0, 122.0, 726.0, 136.0]}, {"text": "cervical spondylotic myelopathy based on data mining[J]. Shang", "bbox": [445.0, 139.0, 726.0, 152.0]}, {"text": "Hai Zhong Yi Yao Za Zhi , 2021 , 55(4) : 15–20. Chinese.", "bbox": [445.0, 157.0, 684.0, 170.0]}], "type": "Text", "position": 25}, {"raw_context": [{"text": "[16]", "bbox": [414.0, 173.0, 438.0, 185.0]}], "type": "Text", "position": 26}, {"raw_context": [{"text": ".", "bbox": [467.0, 176.0, 476.0, 186.0]}], "type": "Text", "position": 27}, {"raw_context": [{"text": "[1].", "bbox": [591.0, 190.0, 612.0, 202.0]}], "type": "Formula", "position": 28}, {"raw_context": [{"text": ", 2005 , 46", "bbox": [682.0, 191.0, 726.0, 202.0]}], "type": "Text", "position": 30}, {"raw_context": [{"text": "(9) : 102–104.", "bbox": [445.0, 205.0, 509.0, 218.0]}, {"text": "MO W ,SHI Q , HOU BX , et al. To evaluate the effect of oral and ex-", "bbox": [445.0, 222.0, 723.0, 235.0]}, {"text": "ternal application of traditional Chinese medicine in the treatment", "bbox": [445.0, 239.0, 726.0, 251.0]}, {"text": "of mild cervical spondylotic myelopathy by single disease quality", "bbox": [445.0, 255.0, 725.0, 268.0]}, {"text": "management[J]. Zhongguo Lin Chuang Kang Fu,2005,46(9):", "bbox": [445.0, 272.0, 726.0, 286.0]}, {"text": "102–104. Chinese.", "bbox": [445.0, 289.0, 526.0, 301.0]}], "type": "Text", "position": 31}, {"raw_context": [{"text": "[17]", "bbox": [414.0, 306.0, 438.0, 319.0]}], "type": "Text", "position": 32}, {"raw_context": [{"text": ".", "bbox": [467.0, 308.0, 476.0, 318.0]}], "type": "Text", "position": 33}, {"raw_context": [{"text": "544.", "bbox": [445.0, 338.0, 467.0, 351.0]}], "type": "Text", "position": 34}, {"raw_context": [{"text": ".", "bbox": [504.0, 308.0, 514.0, 318.0]}, {"text": "[1].", "bbox": [512.0, 321.0, 535.0, 336.0]}], "type": "Formula", "position": 35}, {"raw_context": [{"text": ",2017,41(6):538–", "bbox": [639.0, 322.0, 727.0, 334.0]}], "type": "Formula", "position": 36}, {"raw_context": [{"text": "TIAN M,LOU TW,JIA HL,et al. Study on acupoint selection", "bbox": [445.0, 354.0, 726.0, 368.0]}, {"text": "rules of acupuncture and moxibustion in the treatment of cervical", "bbox": [445.0, 372.0, 726.0, 384.0]}, {"text": "spondylotic myelopathy based on literature [ J ]. Zhe Jiang Zhong", "bbox": [445.0, 388.0, 727.0, 401.0]}, {"text": "Yi Yao Da Xue Xue Bao , 2017 , 41(6) : 538–544. Chinese.", "bbox": [445.0, 404.0, 690.0, 418.0]}, {"text": "Meta", "bbox": [602.0, 423.0, 627.0, 434.0]}, {"text": "[D].", "bbox": [647.0, 423.0, 670.0, 434.0]}], "type": "Text", "position": 37}, {"raw_context": [{"text": "[18]", "bbox": [413.0, 421.0, 439.0, 435.0]}], "type": "Text", "position": 38}, {"raw_context": [{"text": "11. S. 2017.", "bbox": [469.0, 437.0, 499.0, 450.0]}], "type": "Section-header", "position": 39}, {"raw_context": [{"text": "[19]", "bbox": [414.0, 505.0, 439.0, 517.0]}], "type": "Text", "position": 40}, {"raw_context": [{"text": ".", "bbox": [477.0, 508.0, 486.0, 517.0]}], "type": "Text", "position": 41}, {"raw_context": [{"text": ",", "bbox": [514.0, 508.0, 522.0, 517.0]}], "type": "Text", "position": 42}, {"raw_context": [{"text": "DTI", "bbox": [565.0, 521.0, 587.0, 532.0]}], "type": "Section-header", "position": 44}, {"raw_context": [{"text": "[1].", "bbox": [606.0, 521.0, 627.0, 534.0]}], "type": "Formula", "position": 45}, {"raw_context": [{"text": ", 2019 , 41 (11) : 833–837.", "bbox": [469.0, 537.0, 578.0, 550.0]}], "type": "Section-header", "position": 46}, {"raw_context": [{"text": "ZHAO DD. Meta analysis of acupuncture and moxibustion in the", "bbox": [445.0, 453.0, 726.0, 469.0]}, {"text": "treatment of cervical spondylotic myelopathy[D]. Shandong Uni-", "bbox": [445.0, 472.0, 723.0, 484.0]}, {"text": "versity of Traditional Chinese Medicine , 2017. Chinese.", "bbox": [445.0, 488.0, 678.0, 500.0]}], "type": "Text", "position": 47}, {"raw_context": [{"text": "SHEN CH,FENG YJ,SONG YC,et al. DTI study on the effect of", "bbox": [445.0, 553.0, 727.0, 566.0]}, {"text": "perioperative hyperbaric oxygen therapy on postoperative spinal", "bbox": [445.0, 571.0, 726.0, 584.0]}, {"text": "cord function of cervical spondylotic myelopathy [J]. Zhonghua Wu", "bbox": [445.0, 587.0, 727.0, 601.0]}, {"text": "Li Yi Xue Yu Kang Fu Za Zhi ,2019 ,41(11) ,833–837. Chinese.", "bbox": [445.0, 603.0, 715.0, 617.0]}], "type": "Text", "position": 48}, {"raw_context": [{"text": "[20]", "bbox": [414.0, 620.0, 438.0, 634.0]}], "type": "Text", "position": 49}, {"raw_context": [{"text": ", 2011 , 18(12) : 106–108.", "bbox": [562.0, 636.0, 672.0, 649.0]}], "type": "Section-header", "position": 50}, {"raw_context": [{"text": ", 2011 , 18(12) : 106–108.", "bbox": [562.0, 636.0, 672.0, 649.0]}, {"text": "[1].", "bbox": [445.0, 638.0, 467.0, 649.0]}, {"text": "YAN MR,ZHOU J,DING QM. Research progress of Tuina in the", "bbox": [445.0, 650.0, 727.0, 668.0]}, {"text": "treatment of cervical spondylotic myelopathy [J]. Zhongguo Zhong", "bbox": [445.0, 670.0, 727.0, 682.0]}, {"text": "Yi Yao Xin Xi Za Zhi , 2011 , 18(12) ; 106–108. Chinese.", "bbox": [445.0, 685.0, 684.0, 700.0]}], "type": "Text", "position": 51}, {"raw_context": [{"text": "[21]", "bbox": [414.0, 703.0, 439.0, 716.0]}], "type": "Text", "position": 52}, {"raw_context": [{"text": ".", "bbox": [480.0, 706.0, 488.0, 715.0]}], "type": "Text", "position": 53}, {"raw_context": [{"text": ".", "bbox": [506.0, 707.0, 516.0, 716.0]}], "type": "Text", "position": 54}, {"raw_context": [{"text": ". ", "bbox": [535.0, 707.0, 544.0, 715.0]}], "type": "Text", "position": 55}, {"raw_context": [{"text": ",2016,39(2):71–74.", "bbox": [562.0, 720.0, 656.0, 733.0]}, {"text": "[1].", "bbox": [445.0, 721.0, 467.0, 733.0]}, {"text": "ZHU CL,XU B,LI Y,et al. Systematic evaluation of Tuina in the", "bbox": [445.0, 736.0, 726.0, 749.0]}, {"text": "treatment of cervical spondylotic myelopath [ J ]. Shan Xi Zhong Yi", "bbox": [445.0, 754.0, 726.0, 766.0]}, {"text": "Yao Da Xue Xue Bao , 2016 , 39 (2) , 71–74. Chinese.", "bbox": [446.0, 769.0, 668.0, 782.0]}], "type": "Text", "position": 56}, {"raw_context": [{"text": ",2010 , 31 ( 4 )  :  249–251 .", "bbox": [519.0, 801.0, 625.0, 816.0]}], "type": "Section-header", "position": 57}, {"raw_context": [{"text": ",2010 , 31 ( 4 )  :  249–251 .", "bbox": [519.0, 801.0, 625.0, 816.0]}, {"text": "[1] .", "bbox": [445.0, 803.0, 467.0, 816.0]}, {"text": "WU YW , GAO XP. Review and prospect of Tuina in the treatment of", "bbox": [445.0, 819.0, 726.0, 832.0]}, {"text": "cervical spondylotic myelopathy[J]. Jing Yao Tong Za Zhi , 2010 ,", "bbox": [445.0, 836.0, 725.0, 850.0]}, {"text": "31(4):249–251. Chinese.", "bbox": [445.0, 852.0, 558.0, 865.0]}], "type": "Text", "position": 58}, {"raw_context": [{"text": "[23]", "bbox": [414.0, 868.0, 439.0, 882.0]}], "type": "Section-header", "position": 59}, {"raw_context": [{"text": ",2014,33(4):285–287.", "bbox": [551.0, 884.0, 657.0, 898.0]}, {"text": "[1] .", "bbox": [477.0, 886.0, 498.0, 898.0]}, {"text": "WANG DZ, DING QM. Clinical observation of positioning, rotat-", "bbox": [445.0, 899.0, 724.0, 917.0]}, {"text": "ing, lifting, shaking and pulling in the treatment of cervical", "bbox": [445.0, 918.0, 726.0, 931.0]}, {"text": "spondylotic myelopathy[J]. Bei Jing Zhong Yi Yao,2014,33(4):", "bbox": [445.0, 936.0, 725.0, 948.0]}, {"text": "285–287. Chinese.", "bbox": [445.0, 952.0, 527.0, 964.0]}], "type": "Text", "position": 60}, {"raw_context": [{"text": "[1] .", "bbox": [445.0, 985.0, 467.0, 997.0]}, {"text": ", 2006 , 19(11) , 691.", "bbox": [509.0, 985.0, 598.0, 997.0]}, {"text": "LUO J , YU J , ZHU LG , et al. Clinical observation of cervical spond-", "bbox": [445.0, 1002.0, 725.0, 1014.0]}, {"text": "ylotic myelopathy with manipulation [J]. Zhongguo Gu Shang/Chi-", "bbox": [445.0, 1018.0, 724.0, 1031.0]}], "type": "Text", "position": 61}, {"raw_context": [{"text": "[M].", "bbox": [315.0, 240.0, 342.0, 254.0]}, {"text": ":", "bbox": [363.0, 243.0, 371.0, 254.0]}, {"text": ", 2012 ; 57–59.", "bbox": [173.0, 256.0, 234.0, 269.0]}, {"text": "Chinese Society of Traditional Chinese Medicine. Guide to Diagno-", "bbox": [106.0, 272.0, 390.0, 287.0]}, {"text": "sis and Treatment of Common Diseases in Orthopedics and Trauma-", "bbox": [107.0, 290.0, 389.0, 302.0]}, {"text": "tology of Traditional Chinese Medicine[M]. Beijing,China Tradi-", "bbox": [107.0, 307.0, 391.0, 319.0]}, {"text": "tional Chinese Medicine Press , 2012 :57–59. Chinese.", "bbox": [107.0, 323.0, 334.0, 336.0]}, {"text": "Fehlings MG,Tetreault LA,Riew KD,et al. A clinical practice", "bbox": [106.0, 340.0, 393.0, 352.0]}, {"text": "guideline for the management of patients with degenerative cervical", "bbox": [107.0, 356.0, 393.0, 369.0]}, {"text": "myelopathy ; recommendations for patients with mild , moderate , and", "bbox": [107.0, 373.0, 393.0, 385.0]}, {"text": "severe disease and monmyelopathic patients with evidence of cord", "bbox": [107.0, 390.0, 393.0, 403.0]}, {"text": "compression[J] . Global Spine J , 2017 , 7(3):70–83.", "bbox": [106.0, 405.0, 329.0, 419.0]}], "type": "Text", "position": 62}, {"raw_context": [{"text": "[M].", "bbox": [315.0, 240.0, 342.0, 254.0]}], "type": "Formula", "position": 63}, {"raw_context": [{"text": ",2008,46(23):1796–1799.", "bbox": [203.0, 172.0, 323.0, 187.0]}, {"text": "[1] .", "bbox": [117.0, 174.0, 140.0, 187.0]}, {"text": "LI ZC , CHEN DY , WU DS , et al. Summary of the third national sym-", "bbox": [106.0, 190.0, 390.0, 203.0]}, {"text": "posium on cervical spondylosis [J]. Zhonghua Wai Ke Za Zhi , 2008 ,", "bbox": [107.0, 207.0, 392.0, 221.0]}, {"text": "46(23) : 1796–1799. Chinese.", "bbox": [107.0, 223.0, 235.0, 236.0]}], "type": "Text", "position": 64}, {"raw_context": [{"text": "15–20.", "bbox": [112.0, 1020.0, 144.0, 1033.0]}], "type": "Text", "position": 65}, {"raw_context": [{"text": "[24]", "bbox": [414.0, 969.0, 439.0, 981.0]}], "type": "Text", "position": 66}, {"raw_context": [{"text": "[22]", "bbox": [413.0, 785.0, 438.0, 798.0]}], "type": "Text", "position": 67}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/骨科/共识/脊髓型颈椎病中西医结合诊疗专家共识.pdf", "page_num": 8}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": null, "type3": null, "type4": null, "type5": null, "type6": "信息有用性#0#86#参考文献"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:41", "update_time": "2024-05-07 21:32:55"}
{"id": 1082571, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 738, "source_info": {"seq_id": "2bd0643a-66e4-4285-9369-b8d0acad93a4", "title": null, "text": "【0】页码:8\n Legislation and Ethics, The Korean Society for Bone and Mineral Research), Hye Ran Yang (Director of the External Cooperation Committee, The Korean Society of Pediatric Gastroenterology, Hepatology, and Nutrition), Ara Ko ( The Korean Child Neurology Society), Joo Hoon Lee (Directore of the Education and Training Committee, Korean Society of Pediatric Nephrology), Jun Ah Lee (Director of the Committee of Insurance, The Korean Society of Pediatric Hematology- Oncology) provided significant counsel for these guidelines.\n\n【1】Also, we would like to thank Eworldediting (www.\n\n【2】eworldediting.com) & Editage ( www.editage.co.kr)for English language editing.\n\n【3】ORCID/ 天 / Young Ah Lee: 0000-0001-9179-1247 Ahreum Kwon: 0000-0002-9692-2135 Jae Hyun Kim: 0000-0002-0203-7443 Hyo-Kyoung Nam: 0000-0003-1512-2062 Jae-Ho Yoo: 0000-0003-3065-944X Jung Sub Lim: 0000-0001-9560-8921 Sung Yoon Cho: 0000-0003-2913-059X Won Kyoung Cho: 0000-0003-0918-0565 Kye Shik Shim: 0000-0002-8004-151X\n\n【4】## References\n\n【5】\n 14.\n\n【6】Ma NS, Gordon CM. Pediatric osteoporosis: where are we now? J Pediatr 2012;161:983-90.\n\n【7】2.\n\n【8】Heaney RP, Abrams S, Dawson-Hughes B, Looker A, Marcus R, Matkovic V, et al. Peak bone mass. Osteoporos Int 2000;11:985-1009.\n\n【9】American Academy of Pediatrics Steering Committee 3.\n\n【10】on Quality Improvement and Management. Classifying recommendations for clinical practice guidelines. Pediatrics 2004;114:874-7.\n\n【11】Boot AM, de Ridder MA, van der Sluis IM, van Slobbe 4.\n\n【12】I, Krenning EP, Keizer-Schrama SM. Peak bone mineral density, lean body mass and fractures. Bone 2010;46:336- 41.\n\n【13】Berger C, Goltzman D, Langsetmo L, Joseph L, Jackson S, 5.\n\n【14】Kreiger N, et al. Peak bone mass from longitudinal data: implications for the prevalence, pathophysiology, and diagnosis of osteoporosis. J Bone Miner Res 2010;25:1948- 57. 71 Lim JS, Hwang JS, Lee JA, Kim DH, Park KD, Cheon GJ, et 1.6.6.\n\n【15】al. Bone mineral density according to age, bone age, and pubertal stages in Korean children and adolescents. J Clin Densitom 2010;13:68-76.\n\n【16】7.\n\n【17】Yi KH, Hwang JS, Kim EY, Lee JA, Kim DH, Lim JS / Reference values for bone mineral density according to 4 age with body size adjustment in Korean children and adolescents. J Bone Miner Metab 2014;32:281-9.\n\n【18】1.18.\n\n【19】Golden NH, Abrams SA; Committee on Nutrition.\n\n【20】Optimizing bone health in children and adolescents.\n\n【21】Pediatrics 2014;134:e1229-43.\n\n【22】Bishop N, Arundel P, Clark E, Dimitri P, Farr J, Jones G, et\n\n【23】 al. Fracture prediction and the definition of osteoporosis in children and adolescents: the ISCD 2013 Pediatric Official Positions. J Clin Densitom 2014;17:275-80.\n\n【24】10. Root AW, Levine MA. Disorders of mineral metabolism ' H. Abnormalities of mineral homeostasis in the newborn, infant, child and adolescent. In: Sperling MA, editor.\n\n【25】Pediatric endocrinology. 5th ed. Philadelphia (PA): Elsevier 2021:705-813.\n\n【26】11. De Paula F, Black DM, Rosen CJ. Osteoporosis: basic and clinical aspects. In: Melmed S, Auchus RJ, Goldfine AB, Koennig RJ, Rosen CJ, editors. William's textbook of endocrinology. 14th ed. Philadelphia (PA): Elsevier f 2020:1256-97.\n\n【27】12.\n\n【28】Imerci A, Canbek U, Haghari S, Surer L, Kocak M.\n\n【29】Idiopathic juvenile osteoporosis: a case report and review of the literature. Int J Surg Case Rep 2015;9:127-9.\n\n【30】13. Drake MT, Khosla S. Role of sex steroids in the pathogenesis of osteoporosis. In: Rosen CJ, editor. Primer on the metabolic bone diseases and disorders of mineral metabolism. 7th ed. Washington DC: The American Society of Bone and Mineral Metabolism 2008;208-13.\n\n【31】14. Tritos NA, Klibanski A. Effects of growth hormome on bone. Prog Mol Biol Transl Sci 2016;138:193-211.\n\n【32】Giustina A, Mazziotti G, Ganalis E. Growth hormone, 15.\n\n【33】insulin-like growth factors, and the skeleton. Endocr Rev 2008;29:535-59.\n\n【34】Bassett JH. Williams GR. Role of thyroid hormones in 16.\n\n【35】skeletal development and bone maintenance. Endocr Rev 2016;37:135-87.\n\n【36】17. Sundaraghavan V, Mazur MM, Evans B, Liu J, Ebraheim NA. Diabetes and bone health: latest evidence and clinical implications. Ther Adv Musculoskelet Dis 2017;9:67-74.\n\n【37】Castrogiovanni P, Trovato FM, Szychlinska MA, Nsir H, 18.\n\n【38】Imbesi R, Musumeci G. The importance of physical activity in osteoporosis. From the molecular pathways to the clinical evidence. Histol Histopathol 2016;31:1183-94.\n\n【39】19. Grover M, Bachrach LK. Osteoporosis in children with chronic illness. Diagnosis, monitoring, and treatment. Curr Osteoporos Rep 2017;15:271-82.\n\n【40】20. Compston J. Glucocorticoid-induced osteoporosis, an update. Endocrine 2018;61:7-16.\n\n【41】Henderson RC, Berglund LM, May R, Zemel BS, Grossberg 21.\n\n【42】RI, Johnson J, et al. The relationship between fractures and DXA measures of BMD in the distal femur of children and adolescents with cerebral palsy or muscular dystrophy. J Bone Miner Res 2010;25:520-6.\n\n【43】22. Fehlings D, Switzer L, Agarwal P, Wong C, Sochett E, Stevenson R, et al. Informing evidence-based clinical practice guidelines for children with cerebral palsy at risk of osteoporosis: a systematic review. Dev Med Child Neurol 2012;54:106-16.\n\n【44】23. Hough JP, Boyd RN, Keating JL. Systematic review of interventions for low bone mineral density in children with cerebral palsy. Pediatrics 2010;125:e670-8!\n\n【45】24. Iwasaki T, Nonoda Y, Ishii M. Long-term outcomes of children and adolescents who had cerebral palsy with", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "Legislation and Ethics, The Korean Society for Bone and", "bbox": [65.0, 94.0, 383.0, 109.0]}, {"text": "Mineral Research), Hye Ran Yang (Director of the External", "bbox": [66.0, 110.0, 383.0, 125.0]}, {"text": "Cooperation Committee, The Korean Society of Pediatric", "bbox": [64.0, 127.0, 382.0, 141.0]}, {"text": "Gastroenterology, Hepatology, and Nutrition), Ara Ko ( The", "bbox": [64.0, 142.0, 385.0, 157.0]}, {"text": "Korean Child Neurology Society), Joo Hoon Lee (Directore", "bbox": [66.0, 158.0, 383.0, 173.0]}, {"text": "of the Education and Training Committee, Korean Society of", "bbox": [65.0, 174.0, 383.0, 189.0]}, {"text": "Pediatric Nephrology), Jun Ah Lee (Director of the Committee", "bbox": [66.0, 190.0, 383.0, 205.0]}, {"text": "of Insurance, The Korean Society of Pediatric Hematology-", "bbox": [65.0, 206.0, 381.0, 221.0]}, {"text": "Oncology) provided significant counsel for these guidelines.", "bbox": [64.0, 222.0, 363.0, 237.0]}, {"text": "Also, we would like to thank Eworldediting (www.", "bbox": [78.0, 238.0, 382.0, 253.0]}, {"text": "eworldediting.com) & Editage ( www.editage.co.kr)for English", "bbox": [66.0, 254.0, 383.0, 269.0]}, {"text": "language editing.", "bbox": [66.0, 270.0, 151.0, 285.0]}, {"text": "ORCID/ 天 /", "bbox": [76.0, 285.0, 144.0, 301.0]}, {"text": "Young Ah Lee: 0000-0001-9179-1247", "bbox": [77.0, 300.0, 265.0, 316.0]}, {"text": "Ahreum Kwon: 0000-0002-9692-2135", "bbox": [77.0, 318.0, 269.0, 332.0]}, {"text": "Jae Hyun Kim: 0000-0002-0203-7443", "bbox": [77.0, 333.0, 266.0, 348.0]}, {"text": "Hyo-Kyoung Nam: 0000-0003-1512-2062", "bbox": [77.0, 350.0, 287.0, 364.0]}, {"text": "Jae-Ho Yoo: 0000-0003-3065-944X", "bbox": [77.0, 366.0, 253.0, 380.0]}, {"text": "Jung Sub Lim: 0000-0001-9560-8921", "bbox": [77.0, 382.0, 262.0, 397.0]}, {"text": "Sung Yoon Cho: 0000-0003-2913-059X", "bbox": [77.0, 398.0, 275.0, 412.0]}, {"text": "Won Kyoung Cho: 0000-0003-0918-0565", "bbox": [77.0, 413.0, 285.0, 428.0]}, {"text": "Kye Shik Shim: 0000-0002-8004-151X", "bbox": [77.0, 429.0, 269.0, 444.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "References", "bbox": [66.0, 463.0, 143.0, 479.0]}], "type": "Section-header", "position": 4}, {"raw_context": [{"text": "14.", "bbox": [60.0, 495.0, 86.0, 512.0]}, {"text": "Ma NS, Gordon CM. Pediatric osteoporosis: where are we", "bbox": [87.0, 496.0, 383.0, 512.0]}, {"text": "now? J Pediatr 2012;161:983-90.", "bbox": [88.0, 512.0, 249.0, 527.0]}, {"text": "2.", "bbox": [65.0, 527.0, 78.0, 542.0]}, {"text": "Heaney RP, Abrams S, Dawson-Hughes B, Looker A,", "bbox": [88.0, 528.0, 384.0, 542.0]}, {"text": "Marcus R, Matkovic V, et al. Peak bone mass. Osteoporos", "bbox": [88.0, 543.0, 383.0, 559.0]}, {"text": "Int 2000;11:985-1009.", "bbox": [88.0, 560.0, 201.0, 574.0]}, {"text": "American Academy of Pediatrics Steering Committee", "bbox": [88.0, 575.0, 383.0, 591.0]}, {"text": "3.", "bbox": [66.0, 576.0, 78.0, 589.0]}, {"text": "on Quality Improvement and Management. Classifying", "bbox": [88.0, 592.0, 384.0, 606.0]}, {"text": "recommendations for clinical practice guidelines. Pediatrics", "bbox": [88.0, 607.0, 387.0, 623.0]}, {"text": "2004;114:874-7.", "bbox": [88.0, 623.0, 170.0, 638.0]}, {"text": "Boot AM, de Ridder MA, van der Sluis IM, van Slobbe", "bbox": [88.0, 638.0, 383.0, 653.0]}, {"text": "4.", "bbox": [66.0, 639.0, 78.0, 652.0]}, {"text": "I, Krenning EP, Keizer-Schrama SM. Peak bone mineral", "bbox": [88.0, 654.0, 383.0, 669.0]}, {"text": "density, lean body mass and fractures. Bone 2010;46:336-", "bbox": [88.0, 670.0, 381.0, 684.0]}, {"text": "41.", "bbox": [89.0, 687.0, 106.0, 700.0]}, {"text": "Berger C, Goltzman D, Langsetmo L, Joseph L, Jackson S,", "bbox": [88.0, 701.0, 382.0, 715.0]}, {"text": "5.", "bbox": [66.0, 702.0, 78.0, 715.0]}, {"text": "Kreiger N, et al. Peak bone mass from longitudinal data:", "bbox": [88.0, 717.0, 383.0, 732.0]}, {"text": "implications for the prevalence, pathophysiology, and", "bbox": [88.0, 734.0, 383.0, 747.0]}, {"text": "diagnosis of osteoporosis. J Bone Miner Res 2010;25:1948-", "bbox": [88.0, 749.0, 381.0, 764.0]}, {"text": "57. 71", "bbox": [89.0, 766.0, 119.0, 778.0]}, {"text": "Lim JS, Hwang JS, Lee JA, Kim DH, Park KD, Cheon GJ, et", "bbox": [88.0, 780.0, 383.0, 796.0]}, {"text": "1.6.6.", "bbox": [64.0, 781.0, 78.0, 794.0]}, {"text": "al. Bone mineral density according to age, bone age, and", "bbox": [88.0, 796.0, 383.0, 811.0]}, {"text": "pubertal stages in Korean children and adolescents. J Clin", "bbox": [88.0, 812.0, 383.0, 827.0]}, {"text": "Densitom 2010;13:68-76.", "bbox": [88.0, 828.0, 216.0, 842.0]}, {"text": "7.", "bbox": [64.0, 841.0, 78.0, 857.0]}, {"text": "Yi KH, Hwang JS, Kim EY, Lee JA, Kim DH, Lim JS /", "bbox": [88.0, 843.0, 391.0, 858.0]}, {"text": "Reference values for bone mineral density according to 4", "bbox": [88.0, 859.0, 386.0, 874.0]}, {"text": "age with body size adjustment in Korean children and", "bbox": [88.0, 875.0, 383.0, 889.0]}, {"text": "adolescents. J Bone Miner Metab 2014;32:281-9.", "bbox": [88.0, 891.0, 328.0, 905.0]}, {"text": "1.18.", "bbox": [64.0, 907.0, 78.0, 920.0]}, {"text": "Golden NH, Abrams SA; Committee on Nutrition.", "bbox": [88.0, 907.0, 382.0, 921.0]}, {"text": "Optimizing bone health in children and adolescents.", "bbox": [88.0, 922.0, 382.0, 937.0]}, {"text": "Pediatrics 2014;134:e1229-43.", "bbox": [88.0, 938.0, 238.0, 952.0]}, {"text": "Bishop N, Arundel P, Clark E, Dimitri P, Farr J, Jones G, et", "bbox": [87.0, 953.0, 383.0, 968.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "al. Fracture prediction and the definition of osteoporosis in", "bbox": [432.0, 94.0, 726.0, 108.0]}, {"text": "children and adolescents: the ISCD 2013 Pediatric Official", "bbox": [432.0, 109.0, 727.0, 124.0]}, {"text": "Positions. J Clin Densitom 2014;17:275-80.", "bbox": [432.0, 126.0, 645.0, 140.0]}, {"text": "10. Root AW, Levine MA. Disorders of mineral metabolism", "bbox": [410.0, 140.0, 727.0, 156.0]}, {"text": "' H. Abnormalities of mineral homeostasis in the newborn,", "bbox": [430.0, 157.0, 727.0, 172.0]}, {"text": "infant, child and adolescent. In: Sperling MA, editor.", "bbox": [431.0, 172.0, 727.0, 187.0]}, {"text": "Pediatric endocrinology. 5th ed. Philadelphia (PA): Elsevier", "bbox": [432.0, 187.0, 727.0, 203.0]}, {"text": "2021:705-813.", "bbox": [432.0, 204.0, 507.0, 217.0]}, {"text": "11. De Paula F, Black DM, Rosen CJ. Osteoporosis: basic", "bbox": [410.0, 218.0, 727.0, 234.0]}, {"text": "and clinical aspects. In: Melmed S, Auchus RJ, Goldfine", "bbox": [432.0, 235.0, 727.0, 249.0]}, {"text": "AB, Koennig RJ, Rosen CJ, editors. William's textbook", "bbox": [432.0, 251.0, 727.0, 266.0]}, {"text": "of endocrinology. 14th ed. Philadelphia (PA): Elsevier f", "bbox": [432.0, 267.0, 733.0, 282.0]}, {"text": "2020:1256-97.", "bbox": [432.0, 283.0, 505.0, 297.0]}, {"text": "12.", "bbox": [410.0, 298.0, 430.0, 312.0]}, {"text": "Imerci A, Canbek U, Haghari S, Surer L, Kocak M.", "bbox": [428.0, 298.0, 725.0, 313.0]}, {"text": "Idiopathic juvenile osteoporosis: a case report and review", "bbox": [432.0, 314.0, 727.0, 329.0]}, {"text": "of the literature. Int J Surg Case Rep 2015;9:127-9.", "bbox": [432.0, 330.0, 678.0, 345.0]}, {"text": "13. Drake MT, Khosla S. Role of sex steroids in the", "bbox": [410.0, 345.0, 727.0, 360.0]}, {"text": "pathogenesis of osteoporosis. In: Rosen CJ, editor. Primer", "bbox": [432.0, 361.0, 727.0, 376.0]}, {"text": "on the metabolic bone diseases and disorders of mineral", "bbox": [432.0, 377.0, 727.0, 391.0]}, {"text": "metabolism. 7th ed. Washington DC: The American Society", "bbox": [430.0, 392.0, 726.0, 407.0]}, {"text": "of Bone and Mineral Metabolism 2008;208-13.", "bbox": [432.0, 409.0, 666.0, 422.0]}, {"text": "14. Tritos NA, Klibanski A. Effects of growth hormome on", "bbox": [410.0, 424.0, 727.0, 439.0]}, {"text": "bone. Prog Mol Biol Transl Sci 2016;138:193-211.", "bbox": [432.0, 441.0, 677.0, 454.0]}, {"text": "Giustina A, Mazziotti G, Ganalis E. Growth hormone,", "bbox": [429.0, 456.0, 727.0, 471.0]}, {"text": "15.", "bbox": [411.0, 458.0, 430.0, 470.0]}, {"text": "insulin-like growth factors, and the skeleton. Endocr Rev", "bbox": [432.0, 472.0, 726.0, 486.0]}, {"text": "2008;29:535-59.", "bbox": [432.0, 487.0, 514.0, 502.0]}, {"text": "Bassett JH. Williams GR. Role of thyroid hormones in", "bbox": [430.0, 503.0, 727.0, 518.0]}, {"text": "16.", "bbox": [411.0, 505.0, 430.0, 517.0]}, {"text": "skeletal development and bone maintenance. Endocr Rev", "bbox": [432.0, 518.0, 727.0, 533.0]}, {"text": "2016;37:135-87.", "bbox": [432.0, 534.0, 514.0, 548.0]}, {"text": "17. Sundaraghavan V, Mazur MM, Evans B, Liu J, Ebraheim", "bbox": [410.0, 550.0, 727.0, 564.0]}, {"text": "NA. Diabetes and bone health: latest evidence and clinical", "bbox": [432.0, 566.0, 727.0, 580.0]}, {"text": "implications. Ther Adv Musculoskelet Dis 2017;9:67-74.", "bbox": [432.0, 582.0, 711.0, 596.0]}, {"text": "Castrogiovanni P, Trovato FM, Szychlinska MA, Nsir H,", "bbox": [430.0, 597.0, 727.0, 612.0]}, {"text": "18.", "bbox": [411.0, 599.0, 429.0, 611.0]}, {"text": "Imbesi R, Musumeci G. The importance of physical activity", "bbox": [432.0, 614.0, 726.0, 628.0]}, {"text": "in osteoporosis. From the molecular pathways to the", "bbox": [432.0, 629.0, 727.0, 644.0]}, {"text": "clinical evidence. Histol Histopathol 2016;31:1183-94.", "bbox": [432.0, 645.0, 700.0, 659.0]}, {"text": "19. Grover M, Bachrach LK. Osteoporosis in children with", "bbox": [410.0, 660.0, 728.0, 675.0]}, {"text": "chronic illness. Diagnosis, monitoring, and treatment. Curr", "bbox": [432.0, 675.0, 726.0, 690.0]}, {"text": "Osteoporos Rep 2017;15:271-82.", "bbox": [432.0, 692.0, 597.0, 706.0]}, {"text": "20. Compston J. Glucocorticoid-induced osteoporosis, an", "bbox": [410.0, 707.0, 733.0, 722.0]}, {"text": "update. Endocrine 2018;61:7-16.", "bbox": [432.0, 723.0, 594.0, 738.0]}, {"text": "Henderson RC, Berglund LM, May R, Zemel BS, Grossberg", "bbox": [428.0, 739.0, 727.0, 754.0]}, {"text": "21.", "bbox": [411.0, 740.0, 430.0, 753.0]}, {"text": "RI, Johnson J, et al. The relationship between fractures and", "bbox": [432.0, 755.0, 727.0, 769.0]}, {"text": "DXA measures of BMD in the distal femur of children and", "bbox": [432.0, 771.0, 727.0, 786.0]}, {"text": "adolescents with cerebral palsy or muscular dystrophy. J", "bbox": [432.0, 787.0, 727.0, 801.0]}, {"text": "Bone Miner Res 2010;25:520-6.", "bbox": [432.0, 802.0, 589.0, 817.0]}, {"text": "22. Fehlings D, Switzer L, Agarwal P, Wong C, Sochett E,", "bbox": [410.0, 818.0, 727.0, 833.0]}, {"text": "Stevenson R, et al. Informing evidence-based clinical", "bbox": [432.0, 833.0, 727.0, 848.0]}, {"text": "practice guidelines for children with cerebral palsy at risk", "bbox": [432.0, 850.0, 727.0, 863.0]}, {"text": "of osteoporosis: a systematic review. Dev Med Child Neurol", "bbox": [431.0, 865.0, 728.0, 880.0]}, {"text": "2012;54:106-16.", "bbox": [432.0, 881.0, 514.0, 895.0]}, {"text": "23. Hough JP, Boyd RN, Keating JL. Systematic review of", "bbox": [410.0, 896.0, 727.0, 912.0]}, {"text": "interventions for low bone mineral density in children with", "bbox": [432.0, 913.0, 727.0, 927.0]}, {"text": "cerebral palsy. Pediatrics 2010;125:e670-8!", "bbox": [432.0, 928.0, 641.0, 943.0]}, {"text": "24. Iwasaki T, Nonoda Y, Ishii M. Long-term outcomes of", "bbox": [410.0, 944.0, 728.0, 959.0]}, {"text": "children and adolescents who had cerebral palsy with", "bbox": [432.0, 960.0, 733.0, 975.0]}], "type": "Text", "position": 7}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2022】全科室最全临床指南+专家共识（最全版）/2022全科室临床指南/内分泌科/KSPE：优化儿童和青少年骨健康的临床实践指南（2022）.pdf", "page_num": 8}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": null, "type3": null, "type4": null, "type5": null, "type6": "信息有用性#0#45#参考文献"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:41", "update_time": "2024-05-07 19:41:43"}
{"id": 1082570, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 738, "source_info": {"seq_id": "c2c408b0-85cd-40f3-9bb8-679b01279983", "title": null, "text": "【0】页码:4\n 2023\n\n【1】 3\n\n【2】 58\n\n【3】 6\n\n【4】 1\n\n【5】 (n=25)\n\n【6】 Table 1 Characteristics of included literature( n =25)\n\n【7】 ) Chapter 1 2021 AAOS AAOS [15] 141 2021 [19] [19] Mitchell 2020 PubMed [16] [16] 2020 [18] [18] 2020 [13] [13] 2020 OARSI [ 71 2019 OARSI EULAR [14] 2019 RACGP ( 201 2018 GIN NICE [21] 2014 NICE : EULAR [17] PubMed 2013 [21] 2020 ( ) [25] 2020 2016 Web of Science PANLAR [24] [23] 2012 [26] 2022 UpToDate Leticia [30] 2020 Meta [29] 2019 Goh Web of Science , , [28] Lu 2018 Web of Science Kinesio Umehara [27] 2017 Web of Science [31] [31] 2022 PubMed Ince [32] Rewald 2020 PubMed [33] 2019 PubMed Azizi [34] 2018 PubMed Kabiri 3 [35] 2013 PubMed Messier 1. AAOS ; OARSI ;EULAR ;RACGP ; NICE ; PANLAR ; GIN .\n\n【8】[13-14,16,18,21] KOA o , , 3.2 KOA , , KOA 2~ o Chapter 1 , , 20 KOA .\n\n【9】, [39] [39] , , [13] , 10.\n\n\n 738 |\n\n【11】 Chin J Nurs, March 2023, Vol. 58, No. 6\n\n【12】 (C) 1994-2023 China Academic Journal Electronic Publishing House. All rights reserved. http://www.cnki.net", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "2023", "bbox": [566.0, 46.0, 594.0, 61.0]}], "type": "Text", "position": 0}, {"raw_context": [{"text": "3", "bbox": [606.0, 48.0, 618.0, 60.0]}], "type": "Text", "position": 1}, {"raw_context": [{"text": "58", "bbox": [643.0, 46.0, 659.0, 61.0]}], "type": "Text", "position": 2}, {"raw_context": [{"text": "6", "bbox": [684.0, 47.0, 696.0, 61.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "1", "bbox": [309.0, 97.0, 320.0, 111.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": "(n=25)", "bbox": [434.0, 97.0, 475.0, 112.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "Table 1 Characteristics of included literature( n =25)", "bbox": [241.0, 115.0, 530.0, 132.0]}], "type": "Text", "position": 6}, {"raw_context": [{"text": ")", "bbox": [174.0, 161.0, 185.0, 175.0]}, {"text": "Chapter 1", "bbox": [156.0, 162.0, 171.0, 175.0]}, {"text": "2021", "bbox": [150.0, 179.0, 179.0, 195.0]}, {"text": "AAOS", "bbox": [191.0, 179.0, 226.0, 195.0]}, {"text": "AAOS [15]", "bbox": [63.0, 180.0, 110.0, 194.0]}, {"text": "141", "bbox": [113.0, 198.0, 127.0, 211.0]}, {"text": "2021", "bbox": [150.0, 198.0, 177.0, 214.0]}, {"text": "[19] [19]", "bbox": [117.0, 218.0, 134.0, 231.0]}, {"text": "Mitchell", "bbox": [64.0, 219.0, 109.0, 234.0]}, {"text": "2020", "bbox": [150.0, 219.0, 179.0, 233.0]}, {"text": "PubMed", "bbox": [191.0, 219.0, 235.0, 234.0]}, {"text": "[16] [16]", "bbox": [113.0, 238.0, 129.0, 250.0]}, {"text": "2020", "bbox": [150.0, 237.0, 179.0, 253.0]}, {"text": "[18] [18]", "bbox": [112.0, 276.0, 129.0, 289.0]}, {"text": "2020", "bbox": [150.0, 276.0, 179.0, 292.0]}, {"text": "[13] [13]", "bbox": [112.0, 295.0, 129.0, 308.0]}, {"text": "2020", "bbox": [150.0, 296.0, 179.0, 311.0]}, {"text": "OARSI [ 71", "bbox": [63.0, 315.0, 112.0, 330.0]}, {"text": "2019", "bbox": [150.0, 316.0, 179.0, 330.0]}, {"text": "OARSI", "bbox": [190.0, 316.0, 229.0, 331.0]}, {"text": "EULAR [14]", "bbox": [63.0, 335.0, 117.0, 350.0]}, {"text": "2019", "bbox": [150.0, 335.0, 179.0, 351.0]}, {"text": "RACGP ( 201", "bbox": [63.0, 354.0, 117.0, 370.0]}, {"text": "2018", "bbox": [150.0, 354.0, 179.0, 370.0]}, {"text": "GIN", "bbox": [190.0, 354.0, 216.0, 370.0]}, {"text": "NICE [21]", "bbox": [63.0, 373.0, 107.0, 389.0]}, {"text": "2014", "bbox": [150.0, 374.0, 179.0, 389.0]}, {"text": "NICE", "bbox": [191.0, 374.0, 223.0, 390.0]}, {"text": ":", "bbox": [338.0, 380.0, 347.0, 390.0]}, {"text": "EULAR [17]", "bbox": [63.0, 392.0, 119.0, 408.0]}, {"text": "PubMed", "bbox": [191.0, 393.0, 234.0, 408.0]}, {"text": "2013", "bbox": [150.0, 394.0, 179.0, 408.0]}, {"text": "[21]", "bbox": [112.0, 412.0, 129.0, 425.0]}, {"text": "2020", "bbox": [150.0, 414.0, 179.0, 429.0]}, {"text": "(", "bbox": [408.0, 415.0, 419.0, 429.0]}, {"text": ")", "bbox": [475.0, 415.0, 486.0, 429.0]}, {"text": "[25]", "bbox": [99.0, 431.0, 118.0, 445.0]}, {"text": "2020", "bbox": [150.0, 432.0, 179.0, 448.0]}, {"text": "2016", "bbox": [150.0, 471.0, 180.0, 487.0]}, {"text": "Web of Science", "bbox": [191.0, 471.0, 275.0, 487.0]}, {"text": "PANLAR [24]", "bbox": [63.0, 472.0, 124.0, 486.0]}, {"text": "[23]", "bbox": [112.0, 490.0, 129.0, 503.0]}, {"text": "2012", "bbox": [150.0, 492.0, 179.0, 507.0]}, {"text": "[26]", "bbox": [111.0, 529.0, 128.0, 541.0]}, {"text": "2022", "bbox": [150.0, 530.0, 179.0, 546.0]}, {"text": "UpToDate", "bbox": [191.0, 530.0, 244.0, 547.0]}, {"text": "Leticia", "bbox": [63.0, 531.0, 101.0, 546.0]}, {"text": "[30]", "bbox": [113.0, 548.0, 129.0, 562.0]}, {"text": "2020", "bbox": [150.0, 549.0, 179.0, 565.0]}, {"text": "Meta", "bbox": [539.0, 549.0, 567.0, 565.0]}, {"text": "[29]", "bbox": [97.0, 568.0, 115.0, 582.0]}, {"text": "2019", "bbox": [150.0, 569.0, 179.0, 584.0]}, {"text": "Goh", "bbox": [63.0, 570.0, 89.0, 584.0]}, {"text": "Web of Science", "bbox": [191.0, 570.0, 274.0, 584.0]}, {"text": ",", "bbox": [512.0, 575.0, 522.0, 587.0]}, {"text": ",", "bbox": [543.0, 575.0, 553.0, 587.0]}, {"text": "[28]", "bbox": [91.0, 608.0, 107.0, 620.0]}, {"text": "Lu", "bbox": [63.0, 609.0, 83.0, 624.0]}, {"text": "2018", "bbox": [150.0, 609.0, 179.0, 624.0]}, {"text": "Web of Science", "bbox": [191.0, 609.0, 275.0, 624.0]}, {"text": "Kinesio", "bbox": [289.0, 609.0, 329.0, 624.0]}, {"text": "Umehara", "bbox": [64.0, 628.0, 112.0, 643.0]}, {"text": "[27]", "bbox": [121.0, 627.0, 139.0, 640.0]}, {"text": "2017", "bbox": [150.0, 627.0, 178.0, 642.0]}, {"text": "Web of Science", "bbox": [191.0, 627.0, 274.0, 644.0]}, {"text": "[31] [31]", "bbox": [98.0, 646.0, 117.0, 660.0]}, {"text": "2022", "bbox": [150.0, 646.0, 179.0, 662.0]}, {"text": "PubMed", "bbox": [191.0, 646.0, 235.0, 662.0]}, {"text": "Ince", "bbox": [64.0, 647.0, 91.0, 662.0]}, {"text": "[32]", "bbox": [112.0, 665.0, 131.0, 679.0]}, {"text": "Rewald", "bbox": [64.0, 666.0, 107.0, 681.0]}, {"text": "2020", "bbox": [150.0, 666.0, 180.0, 681.0]}, {"text": "PubMed", "bbox": [191.0, 666.0, 234.0, 681.0]}, {"text": "[33]", "bbox": [102.0, 705.0, 119.0, 717.0]}, {"text": "2019", "bbox": [150.0, 705.0, 179.0, 721.0]}, {"text": "PubMed", "bbox": [191.0, 705.0, 235.0, 721.0]}, {"text": "Azizi", "bbox": [64.0, 706.0, 94.0, 721.0]}, {"text": "[34]", "bbox": [107.0, 723.0, 125.0, 738.0]}, {"text": "2018", "bbox": [150.0, 724.0, 179.0, 740.0]}, {"text": "PubMed", "bbox": [191.0, 724.0, 234.0, 740.0]}, {"text": "Kabiri", "bbox": [64.0, 725.0, 99.0, 740.0]}, {"text": "3", "bbox": [289.0, 725.0, 301.0, 740.0]}, {"text": "[35]", "bbox": [114.0, 763.0, 132.0, 776.0]}, {"text": "2013", "bbox": [150.0, 763.0, 180.0, 778.0]}, {"text": "PubMed", "bbox": [190.0, 763.0, 235.0, 778.0]}, {"text": "Messier", "bbox": [64.0, 764.0, 106.0, 778.0]}, {"text": "1. AAOS", "bbox": [79.0, 806.0, 118.0, 822.0]}, {"text": "; OARSI", "bbox": [224.0, 806.0, 266.0, 821.0]}, {"text": ";EULAR", "bbox": [397.0, 806.0, 443.0, 821.0]}, {"text": ";RACGP", "bbox": [550.0, 806.0, 597.0, 821.0]}, {"text": "; NICE", "bbox": [126.0, 826.0, 162.0, 842.0]}, {"text": "; PANLAR", "bbox": [336.0, 826.0, 391.0, 842.0]}, {"text": "; GIN", "bbox": [483.0, 826.0, 512.0, 842.0]}, {"text": ".", "bbox": [604.0, 832.0, 612.0, 842.0]}, {"text": "[13-14,16,18,21]", "bbox": [410.0, 865.0, 469.0, 879.0]}, {"text": "KOA", "bbox": [74.0, 867.0, 107.0, 883.0]}, {"text": "o", "bbox": [357.0, 874.0, 367.0, 886.0]}, {"text": ",", "bbox": [496.0, 874.0, 505.0, 886.0]}, {"text": ",", "bbox": [187.0, 875.0, 194.0, 885.0]}, {"text": "3.2", "bbox": [60.0, 889.0, 84.0, 904.0]}, {"text": "KOA", "bbox": [633.0, 889.0, 666.0, 904.0]}, {"text": ",", "bbox": [496.0, 896.0, 504.0, 907.0]}, {"text": ",", "bbox": [587.0, 896.0, 595.0, 906.0]}, {"text": "KOA", "bbox": [162.0, 910.0, 195.0, 927.0]}, {"text": "2~", "bbox": [353.0, 910.0, 373.0, 927.0]}, {"text": "o", "bbox": [326.0, 917.0, 335.0, 929.0]}, {"text": "Chapter 1", "bbox": [453.0, 918.0, 462.0, 929.0]}, {"text": ",", "bbox": [532.0, 919.0, 540.0, 928.0]}, {"text": ",", "bbox": [567.0, 919.0, 575.0, 928.0]}, {"text": "20", "bbox": [60.0, 932.0, 80.0, 949.0]}, {"text": "KOA", "bbox": [158.0, 933.0, 191.0, 948.0]}, {"text": ".", "bbox": [352.0, 939.0, 359.0, 949.0]}, {"text": ",", "bbox": [441.0, 939.0, 451.0, 950.0]}, {"text": "[39] [39]", "bbox": [661.0, 952.0, 682.0, 966.0]}, {"text": ",", "bbox": [177.0, 961.0, 186.0, 972.0]}, {"text": ",", "bbox": [483.0, 961.0, 492.0, 972.0]}, {"text": "[13]", "bbox": [410.0, 973.0, 429.0, 987.0]}, {"text": ",", "bbox": [178.0, 981.0, 187.0, 993.0]}, {"text": "10.", "bbox": [273.0, 981.0, 282.0, 993.0]}], "type": "Table", "position": 7}, {"raw_context": [{"text": "738 |", "bbox": [38.0, 1019.0, 72.0, 1033.0]}], "type": "Text", "position": 8}, {"raw_context": [{"text": "Chin J Nurs, March 2023, Vol. 58, No. 6", "bbox": [76.0, 1016.0, 290.0, 1033.0]}], "type": "Text", "position": 9}, {"raw_context": [{"text": "(C) 1994-2023 China Academic Journal Electronic Publishing House. All rights reserved. http://www.cnki.net", "bbox": [23.0, 1038.0, 664.0, 1056.0]}], "type": "Text", "position": 10}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/骨科/解读/膝骨关节炎患者自我管理的最佳证据总结.pdf", "page_num": 4}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "格式杂乱#4#9#内容无法理解", "type3": "无关文本#0#3#页码内容", "type4": null, "type5": null, "type6": "有用性#11#12#页脚内容"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:41", "update_time": "2024-05-07 22:29:55"}
{"id": 1082569, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 738, "source_info": {"seq_id": "ef6fed0d-f171-4563-bc02-c8bdfe4a8da6", "title": null, "text": "【0】页码:11\n\n【1】## References\n\n【2】\n 1. Albers GW, Caplan LR, Easton JD, Fayad PB, Mohr JP, Saver JL, Sherman DG; TIA Working Group. Transient ischemic attack: proposal for a new definition. N Engl J Med. 2002;347:1713–1716. doi: 10.1056/NEJMsb020987 2. Toole JF. The Willis lecture: transient ischemic attacks, scientific method, and new realities. Stroke. 1991;22:99–104. doi: 10.1161/01.str.22.1.99 Easton JD, Saver JL, Albers GW, Alberts MJ, Chaturvedi S, Feldmann E, Hatsukami TS, Higashida RT, Johnston SC, Kidwell CS, et al. Definition and evaluation of transient ischemic attack: a scientific statement for healthcare professionals from the American Heart Association/ American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary Council on Peripheral Vascular Disease. Stroke . 2009;40:2276–2293. doi: 10.1161/STROKEAHA.108.192218 4.\n\n【3】Johnston SC, Gress DR, Browner WS, Sidney S. Short-term prognosis after emergency department diagnosis of TIA. JAMA . 2000;284:2901-2906.\n\n【4】doi: 10.1001/jama.284.22.2901 5.\n\n【5】Johnston SC, Rothwell PM, Nguyen-Huynh MN, Giles MF, Elkins JS, Bernstein AL, Sidney S. Validation and refinement of scores to predict very early stroke risk after transient ischaemic attack. Lancet. 2007;369:283– 292. doi: 10.1016/S0140-6736(07)60150-0 1. 6.\n\n【6】Kleindorfer D, Panagos P, Pancioli A, Khoury J, Kissela B, Woo D, Schneider A, Alwell K, Jauch E, Miller R, et al. Incidence and short-term prognosis of transient ischemic attack in a population-based study. Stroke .\n\n【7】2005;36:720-723. doi: 10.1 161/01.STR.0000158917.59233.b7 7. Madsen TE, Khoury JC, Alwell K, Moomaw CJ, Rademacher E, Flaherty ML, Woo D, La Rosa FLR, Mackey J, Martini S, et al. Temporal trends of sex differences in transient ischemic attack incidence within a population. J Stroke Cerebrovasc Dis . 2019;28:2468–2474. doi: 10.1016/j.\n\n【8】jstrokecerebrovasdis.2019.06.020 8. Yu AYX, Lindsay MP, Kamal N, Fang J, Coutts SB, Hill MD. Shifting trend of transient ischemic attack admission and prognosis in Canada. Can J Neurol Sci. 2017;44:391–396. doi: 10.1017/cjn.2016.305 9. Chang BP, Rostanski S, Willey J, Kummer B, Miller E, Elkind M. Can I, send this patient with stroke home? Strategies managing transient ischemic attack and minor stroke in the emergency department. J Emerg Med.\n\n【9】2018;54:636–644. doi: 10.1016/jjemermed.2017.12.015 10. Garg A, Maran I, Amin H, Mieks K, Neuschatz K, Coppola A, Poskus K Johnson J, Davis M, Minja F, et al. Expedited and comprehensive management of low-risk TIA patients in the emergency department is safe and less costly. J Stroke Cerebrovasc Dis. 2021;30:106016. doi: 10.1016/j.jstrokecerebrovasdis.2021.106016 Wintermark M, Sanelli PC, Albers GW, Bello JA, Derdeyn CP, Hetts SW, 11.\n\n【10】Johnson MH, Kidwell CS, Lev MH, Liebeskind DS, et al; American Society of Neuroradiology; American College of Radiology; Society of NeuroInterventional Surgery. Imaging recommendations for acute stroke and transient ischemic attack patients: a joint statement by the American Society of Neuroradiology, the American College of Radiology and the Society of NeuroInterventional Surgery. J Am Coll Radiol. 2013;10:828-832. doi: 10.1016/j.jacr.2013.06.019 Inatomi Y, Kimura K, Yonehara T, Fujioka S, Uchino M. DWI abnormalities 12.\n\n【11】and clinical characteristics in TIA patients. Neurology. 2004;62:376-380.\n\n【12】doi: 10.1212/01.wnl.0000110303.57683.3a 13. Cucchiara BL, Messe SR, Taylor RA, Pacelli J, Maus D, Shah O, Kasner SE. Is the ABCD score useful for risk stratification of patients with acute transient ischemic attack? Stroke . 2006;37:1710–1714. doi: 10.1161/ 01.STR0000227195.46336.93 Douglas VC, Johnston CM, Elkins J, Sidney S, Gress DR, Johnston SC.\n\n【13】14.\n\n【14】Head computed tomography findings predict short-term stroke risk after transient ischemic attack. Stroke. 2003;34:2894-2898. doi: 10.1161/ 01.STR0000102900.74360.D9 15. Moreau F, Modi J, Almekhlafi M, Bal S, Goyal M, Hill MD, Coutts SB.\n\n【15】Early magnetic resonance imaging in transient ischemic attack and minor stroke: do it or lose it. Stroke. 2013;44:671-674. doi: 10.1161/ STROKEAHA.111.680033 16. Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, Biller J, Brown M, Demaerschalk BM, Hoh B, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2019;50:e344-e418.\n\n【16】doi: 10.1 161./STR.0000000000021 1\n\n【17】 Ammqad uo Ad aro slemmolede// dud modi babeomwork\n\n【18】 6,\n\n【19】 17.\n\n【20】Kleindorfer DO, Towfighi A, Chaturvedi S, Cockroft KM, Gutierrez J, Lombardi-Hill D, Kamel H, Kernan WN, Kittner SJ, Leira EC, et al.\n\n【21】2021 Guideline for the prevention of stroke in patients with stroke and transientischemic attack: a guideline from the American Heart Association/American Stroke Association. Stroke. 2021;52:e364-e467. doi: 10.1161/STR.00000000000375 18. Coutts SB, Modi J, Patel SK, Demchuk AM, Goyal M, Hill MD; Calgary Stroke Program. CT/CT angiography and MRI findings predict recurrent stroke after transient ischemic attack and minor stroke: results of the prospective CATCH study. Stroke. 2012;43:1013–1017. doi: 10.1161/ STROKEAHA.111.637421 19.\n\n【22】Prabhakaran S, Chong JY, Sacco RL. Impact of abnormal diffusion-weighted imaging results on short-term outcome following transient ischemic attack.\n\n【23】Arch Neurol. 2007;64:1105–1109. doi: 10.1001/archneur.64.8.1105 Sangha RS, Naidech AM, Corado C, Ansari SA, Prabhakaran S. Chal- 20.\n\n【24】lenges in the medical management of symptomatic intracranial stenosis in an urban setting. Stroke. 2017;48:2158-2163. doi: 10.1161/ STROKEAHA.116.016254 21. Kasner SE, Lynn MJ, Chimowitz MI, Frankel MR, Howlett-Smith H, Hertzberg VS, Chaturvedi S, Levine SR, Stern BJ, Benesch CG, et al; Warfarin Aspirin Symptomatic Intracranial Disease (WASID) Trial Investigators. Warfarin vs aspirin for symptomatic intracranial stenosis: subgroup analyses from WASID. Neurology . 2006;67:1275-1278. doi: 10.1212/01.wnl.0000238506.76873.2f 22. Adla T, Adlova R. Multimodality imaging of carotid stenosis. Int J Angiol.\n\n【25】2015;24:179–184. doi: 10.1055/s-0035-1556056 23.\n\n【26】Wardlaw JM, Chappell FM, Best JJ, Wartolowska K, Berry E; NHS Research and Development Health Technology Assessment Carotid Stenosis Imaging Group. Non-invasive imaging compared with intra-arterial angiography in the diagnosis of symptomatic carotid stenosis: a meta-analysis. Lancet.\n\n【27】2006;367:1503-1512. doi: 10.1016/S0140-6736(06)68650-9 24. Bash S, Villablanca JP, Jahan R, Duckwiler G, Tillis M, Kidwell C, Saver J, Sayre J. Intracranial vascular stenosis and occlusive disease: evaluation with CT angiography, MR angiography, and digital subtraction angiography.\n\n【28】AJNR Am J Neuroradiol. 2005;26:1012-1021.\n\n【29】25. Nguyen-Huynh MN, Wintermark M, English J, Lam J, Vittinghoff E, Smith WS, Johnston SC. How accurate is CT angiography in evaluating intracranial atherosclerotic disease? Stroke. 2008;39:1184-1188. doi: 10.1161/STROKEAHA.107.502906 Brinjikji W, Demchuk AM, Murad MH, Rabinstein AA, McDonald 2012.\n\n【30】RJ, McDonald JS, Kallmes DF. Neurons over nephrons: systematic review and meta-analysis of contrast-induced nephropathy in patients with acute stroke. Stroke. 2017;48:1862-1868. doi: 10.1161/ STROKEAHA.117.016771 Platzek I, Sieron D, Wiggermann P, Laniado M. Carotid artery stenosis : 27.\n\n【31】comparison of 3D time-of-flight MR angiography and contrast-enhanced MR angiography at 3T. Radial Res Pract . 2014;2014:508715. doi: 10.1155/2014/508715 28. Sidhu D, Naugler C. Fasting time and lipid levels in a community-based population: a cross-sectional study. Arch Intern Med. 2012;172:1707–1710.\n\n【32】doi: 10.1001/archinternmed.2012.3708 19. 29.\n\n【33】Sposato LA, Cipriano LE, Saposnik G, Ruíz Vargas E, Riccio PM, Hachinski V. Diagnosis of atrial fibrillation after stroke and transient ischaemic attack: a systematic review and meta-analysis. Lancet Neurol. 2015;14:377–387.\n\n【34】doi: 10.1016/S1474-4422(15)70027-X 30.\n\n【35】Saxena R, Koudstaal P. Anticoagulants versus antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a his¬ tory of stroke or transient ischemic attack. Cochrane Database Syst Rev.\n\n【36】2004;4:CD000187. doi: 10.1002/14651858.CD000187.pub2 31.\n\n【37】Bravata DM, Myers LJ, Reeves M, Cheng EM, Baye F, Ofner S, Miech EJ, Damush T, Sico JJ, Zillich A, et al. Processes of care associated with risk of mortality and recurrent stroke among patients with transient ischemic attack and nonsevere ischemic stroke. JAMA Netw Open . 2019;2:e196716. doi: 10.1001/jamanetworkopen.2019.6716 32. Hatcher-Martin JM, Adams JL, Anderson ER, Bove R, Burrus TM, Chehrenama M, Dolan O'Brien M, Eliashiv DS, Erten-Lyons D, Giesser BS, et al. Telemedicine in neurology: Telemedicine Work Group of the American Academy of Neurology update. Neurology . 2020;94:30–38. doi: 10.1212/WNL00000000008708 33.\n\n【38】Rothwell PM, Warlow CP. Timing of TIAs preceding stroke: time window for prevention is very short. Neurology. 2005;64:817–820. doi: 10.1212/01.WNL.0000152985.32732.EE 34. Amarenco P. Transient ischemic attack. N Engl J Med. 2020;382:1933– 1941. doi: 10.1056/NEJMcp1908837", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "REFERENCES", "bbox": [63.0, 79.0, 147.0, 93.0]}], "type": "Section-header", "position": 1}, {"raw_context": [{"text": "1. Albers GW, Caplan LR, Easton JD, Fayad PB, Mohr JP, Saver JL, Sherman", "bbox": [72.0, 101.0, 378.0, 113.0]}, {"text": "DG; TIA Working Group. Transient ischemic attack: proposal for a new defi-", "bbox": [85.0, 113.0, 378.0, 125.0]}, {"text": "nition. N Engl J Med. 2002;347:1713–1716. doi: 10.1056/NEJMsb020987", "bbox": [87.0, 126.0, 378.0, 137.0]}, {"text": "2. Toole JF. The Willis lecture: transient ischemic attacks, scientific method,", "bbox": [71.0, 137.0, 378.0, 148.0]}, {"text": "and new realities. Stroke. 1991;22:99–104. doi: 10.1161/01.str.22.1.99", "bbox": [85.0, 150.0, 368.0, 161.0]}, {"text": "Easton JD, Saver JL, Albers GW, Alberts MJ, Chaturvedi S, Feldmann", "bbox": [83.0, 161.0, 379.0, 173.0]}, {"text": "E, Hatsukami TS, Higashida RT, Johnston SC, Kidwell CS, et al. Defini-", "bbox": [85.0, 174.0, 379.0, 186.0]}, {"text": "tion and evaluation of transient ischemic attack: a scientific statement", "bbox": [85.0, 186.0, 378.0, 197.0]}, {"text": "for healthcare professionals from the American Heart Association/", "bbox": [85.0, 198.0, 378.0, 209.0]}, {"text": "American Stroke Association Stroke Council; Council on Cardiovascu-", "bbox": [86.0, 209.0, 378.0, 221.0]}, {"text": "lar Surgery and Anesthesia; Council on Cardiovascular Radiology and", "bbox": [85.0, 221.0, 380.0, 233.0]}, {"text": "Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary", "bbox": [85.0, 234.0, 378.0, 245.0]}, {"text": "Council on Peripheral Vascular Disease. Stroke . 2009;40:2276–2293. doi:", "bbox": [85.0, 245.0, 379.0, 257.0]}, {"text": "10.1161/STROKEAHA.108.192218", "bbox": [87.0, 258.0, 235.0, 269.0]}, {"text": "4.", "bbox": [72.0, 269.0, 84.0, 279.0]}, {"text": "Johnston SC, Gress DR, Browner WS, Sidney S. Short-term prognosis after", "bbox": [83.0, 269.0, 378.0, 281.0]}, {"text": "emergency department diagnosis of TIA. JAMA . 2000;284:2901-2906.", "bbox": [85.0, 281.0, 378.0, 294.0]}, {"text": "doi: 10.1001/jama.284.22.2901", "bbox": [85.0, 294.0, 214.0, 305.0]}, {"text": "5.", "bbox": [71.0, 305.0, 84.0, 315.0]}, {"text": "Johnston SC, Rothwell PM, Nguyen-Huynh MN, Giles MF, Elkins JS,", "bbox": [83.0, 305.0, 378.0, 318.0]}, {"text": "Bernstein AL, Sidney S. Validation and refinement of scores to predict very", "bbox": [85.0, 317.0, 378.0, 329.0]}, {"text": "early stroke risk after transient ischaemic attack. Lancet. 2007;369:283–", "bbox": [85.0, 330.0, 378.0, 341.0]}, {"text": "292. doi: 10.1016/S0140-6736(07)60150-0", "bbox": [87.0, 341.0, 269.0, 353.0]}, {"text": "1. 6.", "bbox": [71.0, 353.0, 83.0, 364.0]}, {"text": "Kleindorfer D, Panagos P, Pancioli A, Khoury J, Kissela B, Woo D,", "bbox": [83.0, 354.0, 380.0, 364.0]}, {"text": "Schneider A, Alwell K, Jauch E, Miller R, et al. Incidence and short-term", "bbox": [86.0, 366.0, 380.0, 377.0]}, {"text": "prognosis of transient ischemic attack in a population-based study. Stroke .", "bbox": [86.0, 377.0, 378.0, 388.0]}, {"text": "2005;36:720-723. doi: 10.1 161/01.STR.0000158917.59233.b7", "bbox": [86.0, 390.0, 345.0, 401.0]}, {"text": "7. Madsen TE, Khoury JC, Alwell K, Moomaw CJ, Rademacher E, Flaherty", "bbox": [74.0, 401.0, 379.0, 413.0]}, {"text": "ML, Woo D, La Rosa FLR, Mackey J, Martini S, et al. Temporal trends of", "bbox": [85.0, 414.0, 380.0, 426.0]}, {"text": "sex differences in transient ischemic attack incidence within a popula-", "bbox": [86.0, 425.0, 377.0, 437.0]}, {"text": "tion. J Stroke Cerebrovasc Dis . 2019;28:2468–2474. doi: 10.1016/j.", "bbox": [86.0, 436.0, 378.0, 448.0]}, {"text": "jstrokecerebrovasdis.2019.06.020", "bbox": [85.0, 449.0, 223.0, 461.0]}, {"text": "8. Yu AYX, Lindsay MP, Kamal N, Fang J, Coutts SB, Hill MD. Shifting trend of", "bbox": [71.0, 461.0, 380.0, 475.0]}, {"text": "transient ischemic attack admission and prognosis in Canada. Can J Neurol", "bbox": [86.0, 474.0, 380.0, 485.0]}, {"text": "Sci. 2017;44:391–396. doi: 10.1017/cjn.2016.305", "bbox": [87.0, 485.0, 291.0, 497.0]}, {"text": "9. Chang BP, Rostanski S, Willey J, Kummer B, Miller E, Elkind M. Can I,", "bbox": [71.0, 498.0, 379.0, 510.0]}, {"text": "send this patient with stroke home? Strategies managing transient isch-", "bbox": [85.0, 509.0, 377.0, 521.0]}, {"text": "emic attack and minor stroke in the emergency department. J Emerg Med.", "bbox": [87.0, 522.0, 377.0, 534.0]}, {"text": "2018;54:636–644. doi: 10.1016/jjemermed.2017.12.015", "bbox": [85.0, 533.0, 323.0, 545.0]}, {"text": "10. Garg A, Maran I, Amin H, Mieks K, Neuschatz K, Coppola A, Poskus K", "bbox": [67.0, 545.0, 375.0, 559.0]}, {"text": "Johnson J, Davis M, Minja F, et al. Expedited and comprehensive man-", "bbox": [86.0, 557.0, 376.0, 569.0]}, {"text": "agement of low-risk TIA patients in the emergency department is", "bbox": [86.0, 569.0, 379.0, 580.0]}, {"text": "safe and less costly. J Stroke Cerebrovasc Dis. 2021;30:106016. doi:", "bbox": [87.0, 582.0, 378.0, 594.0]}, {"text": "10.1016/j.jstrokecerebrovasdis.2021.106016", "bbox": [87.0, 593.0, 270.0, 604.0]}, {"text": "Wintermark M, Sanelli PC, Albers GW, Bello JA, Derdeyn CP, Hetts SW,", "bbox": [83.0, 605.0, 378.0, 617.0]}, {"text": "11.", "bbox": [67.0, 606.0, 82.0, 615.0]}, {"text": "Johnson MH, Kidwell CS, Lev MH, Liebeskind DS, et al; American Society", "bbox": [86.0, 617.0, 378.0, 629.0]}, {"text": "of Neuroradiology; American College of Radiology; Society of NeuroInter-", "bbox": [85.0, 630.0, 378.0, 642.0]}, {"text": "ventional Surgery. Imaging recommendations for acute stroke and tran-", "bbox": [85.0, 642.0, 378.0, 653.0]}, {"text": "sient ischemic attack patients: a joint statement by the American Society", "bbox": [85.0, 655.0, 378.0, 665.0]}, {"text": "of Neuroradiology, the American College of Radiology and the Society of", "bbox": [85.0, 665.0, 379.0, 677.0]}, {"text": "NeuroInterventional Surgery. J Am Coll Radiol. 2013;10:828-832. doi:", "bbox": [85.0, 677.0, 380.0, 689.0]}, {"text": "10.1016/j.jacr.2013.06.019", "bbox": [87.0, 689.0, 199.0, 701.0]}, {"text": "Inatomi Y, Kimura K, Yonehara T, Fujioka S, Uchino M. DWI abnormalities", "bbox": [83.0, 701.0, 378.0, 713.0]}, {"text": "12.", "bbox": [67.0, 702.0, 83.0, 712.0]}, {"text": "and clinical characteristics in TIA patients. Neurology. 2004;62:376-380.", "bbox": [86.0, 714.0, 378.0, 725.0]}, {"text": "doi: 10.1212/01.wnl.0000110303.57683.3a", "bbox": [85.0, 725.0, 265.0, 736.0]}, {"text": "13. Cucchiara BL, Messe SR, Taylor RA, Pacelli J, Maus D, Shah O, Kasner", "bbox": [67.0, 737.0, 379.0, 749.0]}, {"text": "SE. Is the ABCD score useful for risk stratification of patients with acute", "bbox": [86.0, 749.0, 378.0, 761.0]}, {"text": "transient ischemic attack? Stroke . 2006;37:1710–1714. doi: 10.1161/", "bbox": [85.0, 762.0, 379.0, 774.0]}, {"text": "01.STR0000227195.46336.93", "bbox": [84.0, 773.0, 215.0, 785.0]}, {"text": "Douglas VC, Johnston CM, Elkins J, Sidney S, Gress DR, Johnston SC.", "bbox": [83.0, 784.0, 378.0, 797.0]}, {"text": "14.", "bbox": [67.0, 785.0, 82.0, 795.0]}, {"text": "Head computed tomography findings predict short-term stroke risk after", "bbox": [85.0, 797.0, 378.0, 809.0]}, {"text": "transient ischemic attack. Stroke. 2003;34:2894-2898. doi: 10.1161/", "bbox": [85.0, 809.0, 378.0, 822.0]}, {"text": "01.STR0000102900.74360.D9", "bbox": [85.0, 822.0, 215.0, 833.0]}, {"text": "15. Moreau F, Modi J, Almekhlafi M, Bal S, Goyal M, Hill MD, Coutts SB.", "bbox": [66.0, 833.0, 379.0, 845.0]}, {"text": "Early magnetic resonance imaging in transient ischemic attack and", "bbox": [84.0, 846.0, 380.0, 857.0]}, {"text": "minor stroke: do it or lose it. Stroke. 2013;44:671-674. doi: 10.1161/", "bbox": [85.0, 857.0, 378.0, 869.0]}, {"text": "STROKEAHA.111.680033", "bbox": [85.0, 870.0, 198.0, 880.0]}, {"text": "16. Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC,", "bbox": [67.0, 882.0, 378.0, 893.0]}, {"text": "Becker K, Biller J, Brown M, Demaerschalk BM, Hoh B, et al. Guidelines", "bbox": [84.0, 893.0, 379.0, 905.0]}, {"text": "for the early management of patients with acute ischemic stroke: 2019", "bbox": [85.0, 905.0, 379.0, 917.0]}, {"text": "update to the 2018 guidelines for the early management of acute ischemic", "bbox": [85.0, 917.0, 378.0, 929.0]}, {"text": "stroke: a guideline for healthcare professionals from the American Heart", "bbox": [85.0, 930.0, 379.0, 942.0]}, {"text": "Association/American Stroke Association. Stroke. 2019;50:e344-e418.", "bbox": [84.0, 942.0, 379.0, 953.0]}, {"text": "doi: 10.1 161./STR.0000000000021 1", "bbox": [85.0, 954.0, 248.0, 965.0]}], "type": "Text", "position": 2}, {"raw_context": [{"text": "Ammqad uo Ad aro slemmolede// dud modi babeomwork", "bbox": [18.0, 535.0, 36.0, 769.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": "6,", "bbox": [23.0, 766.0, 35.0, 778.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "17.", "bbox": [404.0, 77.0, 419.0, 88.0]}, {"text": "Kleindorfer DO, Towfighi A, Chaturvedi S, Cockroft KM, Gutierrez J,", "bbox": [419.0, 77.0, 715.0, 89.0]}, {"text": "Lombardi-Hill D, Kamel H, Kernan WN, Kittner SJ, Leira EC, et al.", "bbox": [421.0, 89.0, 716.0, 101.0]}, {"text": "2021 Guideline for the prevention of stroke in patients with stroke and", "bbox": [421.0, 101.0, 716.0, 113.0]}, {"text": "transientischemic attack: a guideline from the American Heart Asso-", "bbox": [421.0, 114.0, 714.0, 124.0]}, {"text": "ciation/American Stroke Association. Stroke. 2021;52:e364-e467. doi:", "bbox": [422.0, 126.0, 715.0, 137.0]}, {"text": "10.1161/STR.00000000000375", "bbox": [422.0, 137.0, 569.0, 148.0]}, {"text": "18. Coutts SB, Modi J, Patel SK, Demchuk AM, Goyal M, Hill MD; Calgary", "bbox": [404.0, 149.0, 715.0, 161.0]}, {"text": "Stroke Program. CT/CT angiography and MRI findings predict recurrent", "bbox": [421.0, 161.0, 716.0, 173.0]}, {"text": "stroke after transient ischemic attack and minor stroke: results of the", "bbox": [422.0, 174.0, 715.0, 186.0]}, {"text": "prospective CATCH study. Stroke. 2012;43:1013–1017. doi: 10.1161/", "bbox": [421.0, 185.0, 715.0, 197.0]}, {"text": "STROKEAHA.111.637421", "bbox": [421.0, 198.0, 529.0, 208.0]}, {"text": "19.", "bbox": [404.0, 209.0, 419.0, 220.0]}, {"text": "Prabhakaran S, Chong JY, Sacco RL. Impact of abnormal diffusion-weighted", "bbox": [419.0, 209.0, 716.0, 221.0]}, {"text": "imaging results on short-term outcome following transient ischemic attack.", "bbox": [422.0, 221.0, 714.0, 232.0]}, {"text": "Arch Neurol. 2007;64:1105–1109. doi: 10.1001/archneur.64.8.1105", "bbox": [421.0, 234.0, 696.0, 245.0]}, {"text": "Sangha RS, Naidech AM, Corado C, Ansari SA, Prabhakaran S. Chal-", "bbox": [418.0, 244.0, 715.0, 258.0]}, {"text": "20.", "bbox": [403.0, 246.0, 419.0, 255.0]}, {"text": "lenges in the medical management of symptomatic intracranial steno-", "bbox": [420.0, 258.0, 714.0, 269.0]}, {"text": "sis in an urban setting. Stroke. 2017;48:2158-2163. doi: 10.1161/", "bbox": [421.0, 269.0, 716.0, 281.0]}, {"text": "STROKEAHA.116.016254", "bbox": [421.0, 281.0, 532.0, 293.0]}, {"text": "21. Kasner SE, Lynn MJ, Chimowitz MI, Frankel MR, Howlett-Smith H,", "bbox": [402.0, 293.0, 716.0, 305.0]}, {"text": "Hertzberg VS, Chaturvedi S, Levine SR, Stern BJ, Benesch CG, et al;", "bbox": [420.0, 305.0, 716.0, 317.0]}, {"text": "Warfarin Aspirin Symptomatic Intracranial Disease (WASID) Trial Inves-", "bbox": [420.0, 317.0, 715.0, 329.0]}, {"text": "tigators. Warfarin vs aspirin for symptomatic intracranial stenosis: sub-", "bbox": [421.0, 328.0, 715.0, 343.0]}, {"text": "group analyses from WASID. Neurology . 2006;67:1275-1278. doi:", "bbox": [421.0, 341.0, 716.0, 354.0]}, {"text": "10.1212/01.wnl.0000238506.76873.2f", "bbox": [422.0, 353.0, 585.0, 364.0]}, {"text": "22. Adla T, Adlova R. Multimodality imaging of carotid stenosis. Int J Angiol.", "bbox": [403.0, 366.0, 715.0, 377.0]}, {"text": "2015;24:179–184. doi: 10.1055/s-0035-1556056", "bbox": [421.0, 377.0, 628.0, 388.0]}, {"text": "23.", "bbox": [403.0, 389.0, 420.0, 401.0]}, {"text": "Wardlaw JM, Chappell FM, Best JJ, Wartolowska K, Berry E; NHS Research", "bbox": [418.0, 389.0, 716.0, 401.0]}, {"text": "and Development Health Technology Assessment Carotid Stenosis Imag-", "bbox": [421.0, 401.0, 715.0, 413.0]}, {"text": "ing Group. Non-invasive imaging compared with intra-arterial angiography", "bbox": [420.0, 414.0, 716.0, 426.0]}, {"text": "in the diagnosis of symptomatic carotid stenosis: a meta-analysis. Lancet.", "bbox": [421.0, 426.0, 715.0, 437.0]}, {"text": "2006;367:1503-1512. doi: 10.1016/S0140-6736(06)68650-9", "bbox": [421.0, 438.0, 677.0, 448.0]}, {"text": "24. Bash S, Villablanca JP, Jahan R, Duckwiler G, Tillis M, Kidwell C, Saver J,", "bbox": [403.0, 449.0, 716.0, 461.0]}, {"text": "Sayre J. Intracranial vascular stenosis and occlusive disease: evaluation", "bbox": [421.0, 461.0, 716.0, 475.0]}, {"text": "with CT angiography, MR angiography, and digital subtraction angiography.", "bbox": [421.0, 474.0, 716.0, 486.0]}, {"text": "AJNR Am J Neuroradiol. 2005;26:1012-1021.", "bbox": [421.0, 485.0, 608.0, 496.0]}, {"text": "25. Nguyen-Huynh MN, Wintermark M, English J, Lam J, Vittinghoff E,", "bbox": [403.0, 498.0, 715.0, 509.0]}, {"text": "Smith WS, Johnston SC. How accurate is CT angiography in evaluating", "bbox": [421.0, 509.0, 716.0, 521.0]}, {"text": "intracranial atherosclerotic disease? Stroke. 2008;39:1184-1188. doi:", "bbox": [422.0, 522.0, 715.0, 534.0]}, {"text": "10.1161/STROKEAHA.107.502906", "bbox": [423.0, 533.0, 569.0, 545.0]}, {"text": "Brinjikji W, Demchuk AM, Murad MH, Rabinstein AA, McDonald", "bbox": [419.0, 545.0, 716.0, 558.0]}, {"text": "2012.", "bbox": [401.0, 546.0, 418.0, 556.0]}, {"text": "RJ, McDonald JS, Kallmes DF. Neurons over nephrons: systematic", "bbox": [421.0, 557.0, 715.0, 569.0]}, {"text": "review and meta-analysis of contrast-induced nephropathy in patients", "bbox": [421.0, 569.0, 716.0, 581.0]}, {"text": "with acute stroke. Stroke. 2017;48:1862-1868. doi: 10.1161/", "bbox": [421.0, 582.0, 715.0, 593.0]}, {"text": "STROKEAHA.117.016771", "bbox": [421.0, 593.0, 534.0, 604.0]}, {"text": "Platzek I, Sieron D, Wiggermann P, Laniado M. Carotid artery stenosis :", "bbox": [419.0, 604.0, 716.0, 617.0]}, {"text": "27.", "bbox": [404.0, 605.0, 417.0, 616.0]}, {"text": "comparison of 3D time-of-flight MR angiography and contrast-enhanced", "bbox": [421.0, 617.0, 716.0, 629.0]}, {"text": "MR angiography at 3T. Radial Res Pract . 2014;2014:508715. doi:", "bbox": [421.0, 630.0, 716.0, 642.0]}, {"text": "10.1155/2014/508715", "bbox": [422.0, 642.0, 521.0, 653.0]}, {"text": "28. Sidhu D, Naugler C. Fasting time and lipid levels in a community-based", "bbox": [403.0, 653.0, 716.0, 666.0]}, {"text": "population: a cross-sectional study. Arch Intern Med. 2012;172:1707–1710.", "bbox": [421.0, 665.0, 715.0, 677.0]}, {"text": "doi: 10.1001/archinternmed.2012.3708", "bbox": [420.0, 678.0, 582.0, 689.0]}, {"text": "19. 29.", "bbox": [404.0, 689.0, 417.0, 700.0]}, {"text": "Sposato LA, Cipriano LE, Saposnik G, Ruíz Vargas E, Riccio PM, Hachinski", "bbox": [420.0, 689.0, 716.0, 702.0]}, {"text": "V. Diagnosis of atrial fibrillation after stroke and transient ischaemic attack:", "bbox": [420.0, 701.0, 716.0, 712.0]}, {"text": "a systematic review and meta-analysis. Lancet Neurol. 2015;14:377–387.", "bbox": [421.0, 714.0, 715.0, 725.0]}, {"text": "doi: 10.1016/S1474-4422(15)70027-X", "bbox": [421.0, 725.0, 583.0, 736.0]}, {"text": "30.", "bbox": [403.0, 737.0, 420.0, 749.0]}, {"text": "Saxena R, Koudstaal P. Anticoagulants versus antiplatelet therapy for pre-", "bbox": [418.0, 737.0, 716.0, 749.0]}, {"text": "venting stroke in patients with nonrheumatic atrial fibrillation and a his¬", "bbox": [421.0, 749.0, 715.0, 761.0]}, {"text": "tory of stroke or transient ischemic attack. Cochrane Database Syst Rev.", "bbox": [421.0, 761.0, 716.0, 775.0]}, {"text": "2004;4:CD000187. doi: 10.1002/14651858.CD000187.pub2", "bbox": [422.0, 773.0, 668.0, 785.0]}, {"text": "31.", "bbox": [403.0, 785.0, 419.0, 796.0]}, {"text": "Bravata DM, Myers LJ, Reeves M, Cheng EM, Baye F, Ofner S, Miech EJ,", "bbox": [419.0, 785.0, 715.0, 797.0]}, {"text": "Damush T, Sico JJ, Zillich A, et al. Processes of care associated with risk of", "bbox": [420.0, 797.0, 716.0, 809.0]}, {"text": "mortality and recurrent stroke among patients with transient ischemic attack", "bbox": [421.0, 809.0, 716.0, 821.0]}, {"text": "and nonsevere ischemic stroke. JAMA Netw Open . 2019;2:e196716. doi:", "bbox": [422.0, 822.0, 715.0, 833.0]}, {"text": "10.1001/jamanetworkopen.2019.6716", "bbox": [422.0, 833.0, 580.0, 844.0]}, {"text": "32. Hatcher-Martin JM, Adams JL, Anderson ER, Bove R, Burrus TM,", "bbox": [403.0, 845.0, 716.0, 857.0]}, {"text": "Chehrenama M, Dolan O'Brien M, Eliashiv DS, Erten-Lyons D, Giesser", "bbox": [420.0, 857.0, 715.0, 869.0]}, {"text": "BS, et al. Telemedicine in neurology: Telemedicine Work Group of the", "bbox": [421.0, 870.0, 716.0, 881.0]}, {"text": "American Academy of Neurology update. Neurology . 2020;94:30–38. doi:", "bbox": [421.0, 881.0, 716.0, 893.0]}, {"text": "10.1212/WNL00000000008708", "bbox": [422.0, 893.0, 572.0, 904.0]}, {"text": "33.", "bbox": [403.0, 905.0, 419.0, 916.0]}, {"text": "Rothwell PM, Warlow CP. Timing of TIAs preceding stroke: time win-", "bbox": [418.0, 905.0, 715.0, 917.0]}, {"text": "dow for prevention is very short. Neurology. 2005;64:817–820. doi:", "bbox": [422.0, 917.0, 716.0, 930.0]}, {"text": "10.1212/01.WNL.0000152985.32732.EE", "bbox": [422.0, 930.0, 594.0, 941.0]}, {"text": "34. Amarenco P. Transient ischemic attack. N Engl J Med. 2020;382:1933–", "bbox": [403.0, 941.0, 715.0, 954.0]}, {"text": "1941. doi: 10.1056/NEJMcp1908837", "bbox": [422.0, 954.0, 579.0, 965.0]}], "type": "Text", "position": 7}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/神经科/共识/2023 AHA科学声明：急诊科短暂性脑缺血发作的诊断、检查和风险降低(1).pdf", "page_num": 11}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": null, "type3": null, "type4": null, "type5": null, "type6": "有用性#0#38#参考文献的内容"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:41", "update_time": "2024-05-07 21:39:45"}
{"id": 1082568, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 738, "source_info": {"seq_id": "aeb98db6-d6b1-4151-925d-9bd2d59f2a2b", "title": null, "text": "【0】页码:22\n complications, involving both endoscopists and assisting staff.\n\n【1】The training must include recognition of airway compromise, with inadvertent entry into a deeper plane of sedation than intended, in addition to basic life support for all staff within endoscopy. In addition, at least one member of the endoscopy team within every room should have training in immediate life support according to RCoA guidance. All endoscopy units should ensure this recommendation on immediate life support training is implemented in the next 2 years.\n\n【2】Formal evaluation of such training programmes to demonstrate improved objective patient safety outcomes is, however, lacking. 4 245 In the UK, JAG have endorsed multiple national endoscopy courses for trainees, focusing on the knowledge and technical and non-technical skills required to perform safe endoscopies. The basic upper GI and lower GI courses are mandatory for trainees wishing to attain full certification in respective endoscopic modalities. 246 Some objectives relating to sedation competencies are covered in most of these courses, but the content does not cover the breadth and depth offered by the ESGE/ESGENA 244 (online supplemental appendix 3) and expected by the AoMRC (online supplemental appendix 4). 1 Unsurprisingly, a previous survey of UK gastroenterology trainees has highlighted gaps in trainees' knowledge on sedation agents. 243 To increase the validity of training courses on safe sedation by non-anaesthetists, the RCoA also recommends the involvement of anaesthetists in the training of non-anaesthetists in the provision of safe seda- 3 A commercial 'National Safe Sedation' course, endorsed tion. 1 by the Academy of Medical Royal Colleges, and supported by the RCoA is available to UK trainees but not mandated. 13 24\n\n【3】## Guideline Implications For Service Providers\n\n【4】\n The recommendations in this guideline might have implications for endoscopy services, including significant costs. Although most units have existing robust processes to ensure the quality and safety of endoscopic procedures, the clinical landscape is continually evolving, with the ability to perform increasingly complex, and/or prolonged procedures in ageing and often frail patients. The importance of individualised patient consent that emphasises proportionality of risk has been highlighted in GMC 91 and BSG guidance, 22 and this extends to choice of sedation method(s) for endoscopy. Units may need to review information provided to patients regarding sedation, including alternatives— for example, general anaesthesia, use of no sedation, etc, in their consent and pre-assessment processes. Use of non-pharmacological interventions as adjuncts to sedation and regular auditing of patient experience of sedation might also have implications for services, as might the recommendation that patients with OSA or with a BMI ≥ 35 kg/m 2 should undergo formal pre-assessment.\n\n【5】The recommendation for ECG monitoring and consideration of capnography for specific groups and patients having procedures under deep sedation or GA might have implications for equipment costs and training, but many of these procedures will be performed in operating theatres where such facilities already exist. The expanded use of deep sedation or GA support for patients undergoing interventional procedures such as complex ERCP, interventional EUS or DAE might also impact units where these are currently performed under mild–moderate sedation.\n\n【6】The recommendations for enhanced monitoring, including monitoring of patients with established cardiac disease, the need for anaesthetic support for patients with advanced chronic liver disease (eg, ASA grade 4, hepatic encephalopathy) and the 10, 122\n\n【7】 availability of non-invasive ventilation (NIV) high-flow oxygen and capnography for those with severe neuromyopathic disease or respiratory failure might also have implications for service providers.\n\n【8】Lastly, there is a need to ensure that all endoscopy staff involved in the care of patients undergoing sedation have formal training in safe sedation practices, including the recognition and management of sedation-related complications and this should be a career-long continuing process. This might require additional funding for training courses.\n\n【9】The use of inhalational agents (Entonox) as an alternative to sedation has implications for the environment and sustainability.\n\n【10】Hospitals should review the overall gas strategy in every department, and scavenging and catalytic destruction systems should be considered.\n\n【11】## Areas For Development, Audit And Research\n\n【12】\n Many of the recommendations in this guideline are based on low-quality evidence, which is a limitation, and there is need for further audit and research in many areas of sedation practice for GI endoscopy.\n\n【13】The impact of PREMs as quality metrics to measure patient experience of comfort and sedation during endoscopic procedures merits further research.\n\n【14】The impact of pre-assessment, especially in reducing adverse events in patients at higher risk of sedation-related complications, requires further evaluation. This includes patients with OSA, BMI ≥ 35 kg/m 2 , those with significant cardiorespiratory disease or other major comorbidities. Similarly, the role of ECG monitoring in these patients merits further study. Within this guideline, we have recommended the use of capnography as per RCoA, for specific high-risk groups and prolonged procedures under moderate sedation. This warrants further study including a NICE technology appraisal to clarify the value of these interventions in these patient groups to support additional funding of infrastructure and personnel training. The GDG would modify these recommendations if future studies showed clear benefit in other patient populations or procedures.\n\n【15】There is low-quality evidence that many adverse events occur late after endoscopy—for example, infections, thromboembolic or circulatory events, and large scale, prospective studies of the true rate of late postendoscopy, sedation-related complications are required.\n\n【16】We have not suggested any change to the recommendation that patients should not drive, operate machinery, etc for 24 hours following sedation to remain in line with recommendations of other authorities (RCoA, BNF) but this merits further study, recognising that such research may be logistically difficult to design and undertake. Various factors can affect patient comfort levels, including previous abuse. The evidence in this area is lacking and merits further study in the future.\n\n【17】## Author Affiliations\n\n【18】\n 1 Academic Department of Gastroenterology, Royal Hallamshire Hospital, Sheffield, 2 Department of Infection, Immunity & Cardiovascular Disease, The University of Sheffield, Sheffield, UK Department of Anaesthetics, Royal Hallamshire Hospital, Sheffield, UK \"Department of Gastroenterology, University Hospital Llandough, Llandough, UK 2 Institute of Life Sciences, Swansea University, Swansea, UK Hepato-Pancreato-Biliary Unit, Freeman Hospital, Newcastle upon Tyne, UK Newcastle University Population Health Sciences Institute, Newcastle upon Tyne, UK 8 Airedale NHS Foundation Trust, Keighley, UK 3 Department of Gastroenterology, University Hospital of North Midlands, Stoke-on- Trent, UK.", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "complications, involving both endoscopists and assisting staff.", "bbox": [53.0, 60.0, 385.0, 75.0]}, {"text": "The training must include recognition of airway compromise,", "bbox": [54.0, 76.0, 386.0, 90.0]}, {"text": "with inadvertent entry into a deeper plane of sedation than", "bbox": [53.0, 91.0, 387.0, 105.0]}, {"text": "intended, in addition to basic life support for all staff within", "bbox": [53.0, 105.0, 387.0, 120.0]}, {"text": "endoscopy. In addition, at least one member of the endoscopy", "bbox": [53.0, 120.0, 386.0, 135.0]}, {"text": "team within every room should have training in immediate", "bbox": [53.0, 135.0, 387.0, 150.0]}, {"text": "life support according to RCoA guidance. All endoscopy units", "bbox": [53.0, 150.0, 387.0, 164.0]}, {"text": "should ensure this recommendation on immediate life support", "bbox": [53.0, 165.0, 387.0, 179.0]}, {"text": "training is implemented in the next 2 years.", "bbox": [53.0, 180.0, 279.0, 193.0]}, {"text": "Formal evaluation of such training programmes to demon-", "bbox": [65.0, 195.0, 385.0, 208.0]}, {"text": "strate improved objective patient safety outcomes is, however,", "bbox": [53.0, 209.0, 385.0, 223.0]}, {"text": "lacking. 4 245", "bbox": [54.0, 225.0, 115.0, 237.0]}, {"text": "In the UK, JAG have endorsed multiple national endoscopy", "bbox": [65.0, 238.0, 385.0, 252.0]}, {"text": "courses for trainees, focusing on the knowledge and technical and", "bbox": [53.0, 254.0, 386.0, 267.0]}, {"text": "non-technical skills required to perform safe endoscopies. The", "bbox": [53.0, 268.0, 387.0, 281.0]}, {"text": "basic upper GI and lower GI courses are mandatory for trainees", "bbox": [53.0, 283.0, 387.0, 296.0]}, {"text": "wishing to attain full certification in respective endoscopic", "bbox": [53.0, 297.0, 387.0, 311.0]}, {"text": "modalities. 246 Some objectives relating to sedation competencies", "bbox": [53.0, 311.0, 387.0, 327.0]}, {"text": "are covered in most of these courses, but the content does not", "bbox": [53.0, 327.0, 387.0, 341.0]}, {"text": "cover the breadth and depth offered by the ESGE/ESGENA 244", "bbox": [53.0, 341.0, 383.0, 355.0]}, {"text": "(online supplemental appendix 3) and expected by the AoMRC", "bbox": [53.0, 356.0, 386.0, 369.0]}, {"text": "(online supplemental appendix 4). 1 Unsurprisingly, a previous", "bbox": [53.0, 370.0, 387.0, 384.0]}, {"text": "survey of UK gastroenterology trainees has highlighted gaps", "bbox": [53.0, 385.0, 387.0, 399.0]}, {"text": "in trainees' knowledge on sedation agents. 243 To increase the", "bbox": [53.0, 398.0, 387.0, 414.0]}, {"text": "validity of training courses on safe sedation by non-anaesthetists,", "bbox": [53.0, 414.0, 385.0, 428.0]}, {"text": "the RCoA also recommends the involvement of anaesthetists in", "bbox": [53.0, 430.0, 387.0, 443.0]}, {"text": "the training of non-anaesthetists in the provision of safe seda-", "bbox": [53.0, 444.0, 385.0, 458.0]}, {"text": "3 A commercial 'National Safe Sedation' course, endorsed", "bbox": [90.0, 458.0, 386.0, 473.0]}, {"text": "tion. 1", "bbox": [54.0, 460.0, 84.0, 472.0]}, {"text": "by the Academy of Medical Royal Colleges, and supported by", "bbox": [53.0, 473.0, 385.0, 488.0]}, {"text": "the RCoA is available to UK trainees but not mandated. 13 24", "bbox": [53.0, 488.0, 359.0, 503.0]}], "type": "Text", "position": 1}, {"raw_context": [{"text": "Guideline implications for service providers", "bbox": [53.0, 529.0, 289.0, 542.0]}], "type": "Section-header", "position": 2}, {"raw_context": [{"text": "The recommendations in this guideline might have implications", "bbox": [54.0, 544.0, 387.0, 558.0]}, {"text": "for endoscopy services, including significant costs. Although", "bbox": [53.0, 558.0, 387.0, 573.0]}, {"text": "most units have existing robust processes to ensure the quality", "bbox": [53.0, 573.0, 387.0, 587.0]}, {"text": "and safety of endoscopic procedures, the clinical landscape is", "bbox": [53.0, 589.0, 387.0, 602.0]}, {"text": "continually evolving, with the ability to perform increasingly", "bbox": [53.0, 603.0, 387.0, 616.0]}, {"text": "complex, and/or prolonged procedures in ageing and often", "bbox": [53.0, 617.0, 387.0, 631.0]}, {"text": "frail patients. The importance of individualised patient consent", "bbox": [53.0, 632.0, 386.0, 646.0]}, {"text": "that emphasises proportionality of risk has been highlighted", "bbox": [53.0, 646.0, 386.0, 661.0]}, {"text": "in GMC 91 and BSG guidance, 22 and this extends to choice of", "bbox": [53.0, 660.0, 387.0, 676.0]}, {"text": "sedation method(s) for endoscopy. Units may need to review", "bbox": [53.0, 676.0, 386.0, 690.0]}, {"text": "information provided to patients regarding sedation, including", "bbox": [53.0, 691.0, 387.0, 705.0]}, {"text": "alternatives— for example, general anaesthesia, use of no seda-", "bbox": [54.0, 707.0, 385.0, 720.0]}, {"text": "tion, etc, in their consent and pre-assessment processes. Use", "bbox": [53.0, 721.0, 387.0, 736.0]}, {"text": "of non-pharmacological interventions as adjuncts to sedation", "bbox": [53.0, 736.0, 387.0, 750.0]}, {"text": "and regular auditing of patient experience of sedation might", "bbox": [53.0, 751.0, 387.0, 765.0]}, {"text": "also have implications for services, as might the recommenda-", "bbox": [53.0, 766.0, 385.0, 779.0]}, {"text": "tion that patients with OSA or with a BMI ≥ 35 kg/m 2 should", "bbox": [53.0, 780.0, 386.0, 793.0]}, {"text": "undergo formal pre-assessment.", "bbox": [54.0, 796.0, 218.0, 808.0]}, {"text": "The recommendation for ECG monitoring and consideration", "bbox": [66.0, 808.0, 387.0, 823.0]}, {"text": "of capnography for specific groups and patients having proce-", "bbox": [53.0, 823.0, 385.0, 838.0]}, {"text": "dures under deep sedation or GA might have implications for", "bbox": [53.0, 839.0, 386.0, 852.0]}, {"text": "equipment costs and training, but many of these procedures will", "bbox": [53.0, 854.0, 386.0, 867.0]}, {"text": "be performed in operating theatres where such facilities already", "bbox": [53.0, 868.0, 386.0, 881.0]}, {"text": "exist. The expanded use of deep sedation or GA support for", "bbox": [53.0, 882.0, 386.0, 896.0]}, {"text": "patients undergoing interventional procedures such as complex", "bbox": [53.0, 897.0, 387.0, 912.0]}, {"text": "ERCP, interventional EUS or DAE might also impact units where", "bbox": [53.0, 912.0, 387.0, 926.0]}, {"text": "these are currently performed under mild–moderate sedation.", "bbox": [53.0, 927.0, 385.0, 941.0]}, {"text": "The recommendations for enhanced monitoring, including", "bbox": [53.0, 942.0, 387.0, 955.0]}, {"text": "monitoring of patients with established cardiac disease, the", "bbox": [53.0, 956.0, 387.0, 969.0]}, {"text": "need for anaesthetic support for patients with advanced chronic", "bbox": [53.0, 971.0, 387.0, 984.0]}, {"text": "liver disease (eg, ASA grade 4, hepatic encephalopathy) and the", "bbox": [53.0, 985.0, 387.0, 1000.0]}, {"text": "10, 122", "bbox": [54.0, 1011.0, 68.0, 1022.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "availability of non-invasive ventilation (NIV) high-flow oxygen", "bbox": [407.0, 60.0, 740.0, 75.0]}, {"text": "and capnography for those with severe neuromyopathic disease", "bbox": [406.0, 76.0, 739.0, 90.0]}, {"text": "or respiratory failure might also have implications for service", "bbox": [406.0, 91.0, 740.0, 105.0]}, {"text": "providers.", "bbox": [407.0, 107.0, 463.0, 119.0]}, {"text": "Lastly, there is a need to ensure that all endoscopy staff", "bbox": [418.0, 120.0, 740.0, 135.0]}, {"text": "involved in the care of patients undergoing sedation have formal", "bbox": [406.0, 135.0, 740.0, 150.0]}, {"text": "training in safe sedation practices, including the recognition and", "bbox": [406.0, 150.0, 741.0, 164.0]}, {"text": "management of sedation-related complications and this should", "bbox": [406.0, 165.0, 741.0, 179.0]}, {"text": "be a career-long continuing process. This might require addi-", "bbox": [406.0, 180.0, 739.0, 193.0]}, {"text": "tional funding for training courses.", "bbox": [406.0, 195.0, 588.0, 208.0]}, {"text": "The use of inhalational agents (Entonox) as an alternative to", "bbox": [420.0, 209.0, 741.0, 223.0]}, {"text": "sedation has implications for the environment and sustainability.", "bbox": [406.0, 224.0, 739.0, 238.0]}, {"text": "Hospitals should review the overall gas strategy in every depart-", "bbox": [406.0, 239.0, 739.0, 253.0]}, {"text": "ment, and scavenging and catalytic destruction systems should", "bbox": [406.0, 254.0, 740.0, 267.0]}, {"text": "be considered.", "bbox": [406.0, 268.0, 484.0, 281.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": "Areas for development, audit and research", "bbox": [406.0, 307.0, 637.0, 322.0]}], "type": "Section-header", "position": 5}, {"raw_context": [{"text": "Many of the recommendations in this guideline are based on", "bbox": [407.0, 324.0, 740.0, 337.0]}, {"text": "low-quality evidence, which is a limitation, and there is need for", "bbox": [406.0, 338.0, 739.0, 352.0]}, {"text": "further audit and research in many areas of sedation practice for", "bbox": [406.0, 353.0, 739.0, 366.0]}, {"text": "GI endoscopy.", "bbox": [406.0, 368.0, 483.0, 381.0]}, {"text": "The impact of PREMs as quality metrics to measure patient", "bbox": [420.0, 381.0, 741.0, 397.0]}, {"text": "experience of comfort and sedation during endoscopic proce-", "bbox": [406.0, 396.0, 739.0, 411.0]}, {"text": "dures merits further research.", "bbox": [406.0, 412.0, 561.0, 425.0]}, {"text": "The impact of pre-assessment, especially in reducing adverse", "bbox": [420.0, 426.0, 740.0, 440.0]}, {"text": "events in patients at higher risk of sedation-related complica-", "bbox": [406.0, 441.0, 739.0, 454.0]}, {"text": "tions, requires further evaluation. This includes patients with", "bbox": [406.0, 455.0, 741.0, 469.0]}, {"text": "OSA, BMI ≥ 35 kg/m 2 , those with significant cardiorespiratory", "bbox": [406.0, 469.0, 739.0, 484.0]}, {"text": "disease or other major comorbidities. Similarly, the role of ECG", "bbox": [406.0, 484.0, 739.0, 499.0]}, {"text": "monitoring in these patients merits further study. Within this", "bbox": [406.0, 500.0, 741.0, 513.0]}, {"text": "guideline, we have recommended the use of capnography as per", "bbox": [407.0, 515.0, 739.0, 528.0]}, {"text": "RCoA, for specific high-risk groups and prolonged procedures", "bbox": [407.0, 529.0, 740.0, 542.0]}, {"text": "under moderate sedation. This warrants further study including", "bbox": [406.0, 543.0, 741.0, 557.0]}, {"text": "a NICE technology appraisal to clarify the value of these inter-", "bbox": [406.0, 558.0, 739.0, 573.0]}, {"text": "ventions in these patient groups to support additional funding of", "bbox": [406.0, 572.0, 740.0, 587.0]}, {"text": "infrastructure and personnel training. The GDG would modify", "bbox": [406.0, 587.0, 740.0, 602.0]}, {"text": "these recommendations if future studies showed clear benefit in", "bbox": [406.0, 602.0, 741.0, 616.0]}, {"text": "other patient populations or procedures.", "bbox": [406.0, 617.0, 618.0, 630.0]}, {"text": "There is low-quality evidence that many adverse events occur", "bbox": [419.0, 631.0, 740.0, 645.0]}, {"text": "late after endoscopy—for example, infections, thromboembolic", "bbox": [406.0, 646.0, 740.0, 660.0]}, {"text": "or circulatory events, and large scale, prospective studies of the", "bbox": [406.0, 660.0, 740.0, 675.0]}, {"text": "true rate of late postendoscopy, sedation-related complications", "bbox": [406.0, 675.0, 740.0, 690.0]}, {"text": "are required.", "bbox": [407.0, 691.0, 475.0, 704.0]}, {"text": "We have not suggested any change to the recommendation", "bbox": [419.0, 704.0, 741.0, 719.0]}, {"text": "that patients should not drive, operate machinery, etc for 24", "bbox": [406.0, 720.0, 740.0, 733.0]}, {"text": "hours following sedation to remain in line with recommenda-", "bbox": [406.0, 735.0, 739.0, 748.0]}, {"text": "tions of other authorities (RCoA, BNF) but this merits further", "bbox": [406.0, 749.0, 739.0, 763.0]}, {"text": "study, recognising that such research may be logistically diffi-", "bbox": [406.0, 763.0, 739.0, 778.0]}, {"text": "cult to design and undertake. Various factors can affect patient", "bbox": [406.0, 778.0, 740.0, 792.0]}, {"text": "comfort levels, including previous abuse. The evidence in this", "bbox": [406.0, 793.0, 740.0, 807.0]}, {"text": "area is lacking and merits further study in the future.", "bbox": [407.0, 808.0, 680.0, 821.0]}], "type": "Text", "position": 6}, {"raw_context": [{"text": "Author affiliations", "bbox": [408.0, 843.0, 492.0, 856.0]}], "type": "Section-header", "position": 7}, {"raw_context": [{"text": "1 Academic Department of Gastroenterology, Royal Hallamshire Hospital, Sheffield,", "bbox": [408.0, 855.0, 726.0, 869.0]}, {"text": "2 Department of Infection, Immunity & Cardiovascular Disease, The University of", "bbox": [408.0, 878.0, 716.0, 893.0]}, {"text": "Sheffield, Sheffield, UK", "bbox": [408.0, 893.0, 498.0, 904.0]}, {"text": "Department of Anaesthetics, Royal Hallamshire Hospital, Sheffield, UK", "bbox": [410.0, 904.0, 682.0, 915.0]}, {"text": "\"Department of Gastroenterology, University Hospital Llandough, Llandough, UK", "bbox": [409.0, 916.0, 722.0, 929.0]}, {"text": "2 Institute of Life Sciences, Swansea University, Swansea, UK", "bbox": [409.0, 929.0, 643.0, 940.0]}, {"text": "Hepato-Pancreato-Biliary Unit, Freeman Hospital, Newcastle upon Tyne, UK", "bbox": [410.0, 940.0, 702.0, 952.0]}, {"text": "Newcastle University Population Health Sciences Institute, Newcastle upon Tyne, UK", "bbox": [411.0, 953.0, 737.0, 965.0]}, {"text": "8 Airedale NHS Foundation Trust, Keighley, UK", "bbox": [408.0, 964.0, 585.0, 976.0]}, {"text": "3 Department of Gastroenterology, University Hospital of North Midlands, Stoke-on-", "bbox": [409.0, 976.0, 731.0, 990.0]}, {"text": "Trent, UK.", "bbox": [408.0, 989.0, 445.0, 1000.0]}], "type": "Text", "position": 8}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/消化科/_2023 BSG指南：胃肠内窥镜检查中的镇静.pdf", "page_num": 22}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "多余换行#6#7#为同段", "type3": "无关文本#0#4#存在多处无关数字", "type4": null, "type5": null, "type6": "信息有用性#18#18#无用内容"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:41", "update_time": "2024-05-07 19:30:30"}
{"id": 1082567, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 738, "source_info": {"seq_id": "ca1fb0ed-3577-4e06-8cdb-ef231b8a7ad1", "title": null, "text": "【0】页码:3\n\n【1】## A. Sun Et Al.\n\n【2】\n recent meta-analyses that included patients with NSCLC. All records underwent screening by two reviewers to determine relevance and studies of interest were identified.\n\n【3】## 2.3. Expert Working Group Meeting 2\n\n【4】\n Based on discussions during Meeting 1 and the results of the targeted literature review, the eight key clinical questions were refined, preliminary consensus recommendations were drafted, underlying considerations and caveats were compiled, and newly identified study data were abstracted. This information was provided to the expert working group for review in advance of Meeting 2. During Meeting 2, which occurred in late March 2022, the phrasing of the eight key clinical questions was agreed upon; considering these questions, the preliminary consensus recommendations were discussed and refined. The expert working group then voted on each recommendation; strong consensus was defined as agreement by at least seven of nine experts. Additional considerations and caveats underlying the recommendations were recorded.\n\n【5】## 3. Results And Discussion\n\n【6】\n## 3.1. Targeted Literature Search Results\n\n【7】\n A total of 527 records were identified in the primary PubMed search for ES-SCLC; of these, 253 records were selected for further review based on a title screen conducted by one reviewer. After de-duplication and removal of records published before 2019 (the year of approval of atezolizumab), a total of 120 records underwent screening by two reviewers. Of these records, seven were found to provide information related to the key clinical questions. In the searches of the ASCO, ESMO, and WCLC conference libraries, 18 records were selected by two reviewers for full abstract, poster, or publication review. Of these records, four were found to provide information related to the clinical questions.\n\n【8】After reviewing studies identified via hand searching and other supplementary online searches, a total of 19 records were found to provide relevant evidence for the safety, efficacy, and/or timing of combination RT and immunotherapy in ES-SCLC.\n\n【9】## 3.2. Summary Of Recommendations\n\n【10】\n A summary of the key clinical questions developed by the expert working group, their recommendations, and related considerations and caveats is presented in Table 1 . For all recommendations, the level of agreement was unanimous. Details on the rationale underlying these recommendations are provided below.\n\n【11】## 3.3. Detailed Recommendations\n\n【12】\n CLINICAL QUESTION 1: Which patients with ES-SCLC should be referred to a radiation oncologist for consideration of consolidation TRT?\n\n【13】Recommendation 1.1: All patients with a response to concurrent chemo-immunotherapy, good PS, and limited metastases should be considered for consolidation TRT. (Level of Agreement: Unanimous) .\n\n【14】Recommendation 1.2: Patients with expected or existing lung cancer symptoms should also be considered for palliative TRT, regardless of response to concurrent chemo-immunotherapy. (Level of Agreement: Unanimous) .\n\n【15】Clinical Rationale: As highlighted above, planned TRT was not permitted in the pivotal IMpower133 and CASPIAN trials that resulted in regulatory approval of first-line atezolizumab and durvalumab, respectively, in ES-SCLC [28,29] . The expert working group agreed, however, that in almost all cases, patients with ES-SCLC who have a response to concurrent chemotherapy and immunotherapy (chemoimmunotherapy; including a complete response), good performance\n\n【16】 status (PS), and limited metastases should be referred to a radiation oncologist for consideration of TRT. In a secondary analysis of data from the CREST trial, patients with 0–2 metastases (or with no liver or bone metastases) had better PFS after TRT than those with more than 2 metastases [50] . Referral and practice patterns vary across geographic regions and healthcare institutions; as such, in some centers, referral may be initiated before the end of concurrent chemo-immunotherapy to facilitate timely case review and planning. In others, evidence of adequate response may need to be demonstrated before consultation.\n\n【17】For symptomatic patients or those expected to be symptomatic given a large burden of central disease close to the airways, esophagus, and/or vasculature, referral should still occur for consideration of palliative TRT regardless of response to concurrent chemo-immunotherapy.\n\n【18】It should be noted that despite these recommendations, some patients may be unsuitable for consolidation TRT. Such patients include those without a response to initial concurrent chemo-immunotherapy, with poor PS at the time of consideration of TRT, or with major contraindications (e.g., interstitial lung disease, end-stage pulmonary fibrosis), in addition to patients who are unwilling to receive TRT.\n\n【19】CLINICAL QUESTION 2: What is the appropriate dose-fractionation schedule for consolidation TRT?\n\n【20】Recommendation 2.1: TRT to a dose of 30 Gy in 10 fractions is recommended; a modified schedule may be appropriate based on patient characteristics and preferences. (Level of Agreement: Unanimous) .\n\n【21】Clinical Rationale: In alignment with the ASTRO guidelines [24] , the expert working group recommended that TRT be administered to a dose of 30 Gy in 10 fractions. This dose-fractionation schedule was used in the CREST trial and a Phase I/II study of ipilimumab and nivolumab in ES-SCLC, with no significant toxicity observed [13,38] . As per ASTRO, higher doses and fractions (e.g., 45 Gy in 15 fractions, as used in the Radiation Therapy Oncology Group [RTOG] 0937 study [15] and a Phase I trial of pembrolizumab [39] ) may be considered for patients with good PS who have an excellent response to concurrent chemoimmunotherapy and who are expected to have prolonged survival [24] . Additionally, the expert working group suggested that a pragmatic approach with lower doses and fractions (e.g., 20 Gy in 5 fractions) may be appropriate for patients receiving palliative TRT for symptom control or for those unable or unwilling to travel for ongoing TRT.\n\n【22】CLINICAL QUESTION 3: What is the optimal timing of consolidation TRT during immunotherapy?\n\n【23】Recommendation 3.1: Although current randomized Phase III trials did not include TRT, concurrent treatment with TRT and maintenance immunotherapy can be initiated if considered appropriate based on discussions between the medical oncologist and radiation oncologist.\n\n【24】(Level of Agreement: Unanimous).\n\n【25】Recommendation 3.2: Consolidation TRT should be provided after completion of concurrent chemo-immunotherapy. ( Level of Agreement: Unanimous) .\n\n【26】Clinical Rationale: Historically, TRT has been used in ES-SCLC to reduce the risk of local progression in the lung. In the IMpower133 and CASPIAN trials, the lung remained a common site of relapse regardless of whether chemotherapy or chemotherapy + immunotherapy was received [51,52] . Given that consolidation TRT was not permitted in IMpower133 and CASPIAN, as well as in KEYNOTE-604, robust evidence is not yet available for the safety, efficacy, or optimal timing of combining TRT and immunotherapy among patients with ES-SCLC. The results of several early-phase and retrospective analyses conducted in this population, however, as well as studies conducted in other lung cancer settings suggest that toxicity is not increased and that efficacy may in fact be improved with addition of TRT.\n\n【27】The targeted literature review identified nine publications in which some patients with ES-SCLC had received both maintenance immunotherapy and TRT. These studies included an exploratory analysis of CASPIAN [31] , two prospective Phase I and I/I trials [38,39] , and six retrospective analyses conducted in various regions worldwide [37,40,41,53–55] . None of these studies indicated safety concerns", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "A. Sun et al.", "bbox": [48.0, 45.0, 96.0, 58.0]}], "type": "Section-header", "position": 0}, {"raw_context": [{"text": "recent meta-analyses that included patients with NSCLC. All records", "bbox": [47.0, 69.0, 387.0, 83.0]}, {"text": "underwent screening by two reviewers to determine relevance and", "bbox": [48.0, 85.0, 387.0, 97.0]}, {"text": "studies of interest were identified.", "bbox": [48.0, 99.0, 212.0, 112.0]}], "type": "Text", "position": 1}, {"raw_context": [{"text": "2.3. Expert working group Meeting 2", "bbox": [47.0, 126.0, 220.0, 140.0]}], "type": "Section-header", "position": 2}, {"raw_context": [{"text": "Based on discussions during Meeting 1 and the results of the targeted", "bbox": [63.0, 152.0, 387.0, 167.0]}, {"text": "literature review, the eight key clinical questions were refined, pre-", "bbox": [47.0, 167.0, 386.0, 181.0]}, {"text": "liminary consensus recommendations were drafted, underlying consid-", "bbox": [47.0, 181.0, 386.0, 195.0]}, {"text": "erations and caveats were compiled, and newly identified study data", "bbox": [47.0, 195.0, 387.0, 210.0]}, {"text": "were abstracted. This information was provided to the expert working", "bbox": [48.0, 210.0, 387.0, 224.0]}, {"text": "group for review in advance of Meeting 2. During Meeting 2, which", "bbox": [47.0, 223.0, 387.0, 238.0]}, {"text": "occurred in late March 2022, the phrasing of the eight key clinical", "bbox": [47.0, 236.0, 387.0, 252.0]}, {"text": "questions was agreed upon; considering these questions, the preliminary", "bbox": [47.0, 251.0, 387.0, 265.0]}, {"text": "consensus recommendations were discussed and refined. The expert", "bbox": [48.0, 266.0, 387.0, 279.0]}, {"text": "working group then voted on each recommendation; strong consensus", "bbox": [47.0, 279.0, 387.0, 293.0]}, {"text": "was defined as agreement by at least seven of nine experts. Additional", "bbox": [47.0, 293.0, 387.0, 307.0]}, {"text": "considerations and caveats underlying the recommendations were", "bbox": [47.0, 307.0, 387.0, 321.0]}, {"text": "recorded.", "bbox": [47.0, 322.0, 96.0, 335.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "3. Results and discussion", "bbox": [47.0, 349.0, 183.0, 363.0]}], "type": "Section-header", "position": 4}, {"raw_context": [{"text": "3.1. Targeted literature search results", "bbox": [47.0, 377.0, 222.0, 391.0]}], "type": "Section-header", "position": 5}, {"raw_context": [{"text": "A total of 527 records were identified in the primary PubMed search", "bbox": [63.0, 405.0, 387.0, 419.0]}, {"text": "for ES-SCLC; of these, 253 records were selected for further review based", "bbox": [47.0, 419.0, 387.0, 432.0]}, {"text": "on a title screen conducted by one reviewer. After de-duplication and", "bbox": [47.0, 433.0, 387.0, 446.0]}, {"text": "removal of records published before 2019 (the year of approval of ate-", "bbox": [47.0, 447.0, 386.0, 460.0]}, {"text": "zolizumab), a total of 120 records underwent screening by two re-", "bbox": [47.0, 461.0, 387.0, 474.0]}, {"text": "viewers. Of these records, seven were found to provide information", "bbox": [47.0, 474.0, 387.0, 488.0]}, {"text": "related to the key clinical questions. In the searches of the ASCO, ESMO,", "bbox": [47.0, 488.0, 387.0, 503.0]}, {"text": "and WCLC conference libraries, 18 records were selected by two re-", "bbox": [47.0, 503.0, 386.0, 517.0]}, {"text": "viewers for full abstract, poster, or publication review. Of these records,", "bbox": [47.0, 517.0, 387.0, 531.0]}, {"text": "four were found to provide information related to the clinical questions.", "bbox": [48.0, 531.0, 387.0, 544.0]}, {"text": "After reviewing studies identified via hand searching and other sup-", "bbox": [48.0, 544.0, 387.0, 558.0]}, {"text": "plementary online searches, a total of 19 records were found to provide", "bbox": [47.0, 558.0, 387.0, 572.0]}, {"text": "relevant evidence for the safety, efficacy, and/or timing of combination", "bbox": [47.0, 572.0, 387.0, 586.0]}, {"text": "RT and immunotherapy in ES-SCLC.", "bbox": [47.0, 586.0, 221.0, 600.0]}], "type": "Text", "position": 6}, {"raw_context": [{"text": "3.2. Summary of recommendations", "bbox": [47.0, 615.0, 212.0, 629.0]}], "type": "Section-header", "position": 7}, {"raw_context": [{"text": "A summary of the key clinical questions developed by the expert", "bbox": [64.0, 643.0, 387.0, 656.0]}, {"text": "working group, their recommendations, and related considerations and", "bbox": [48.0, 657.0, 387.0, 669.0]}, {"text": "caveats is presented in Table 1 . For all recommendations, the level of", "bbox": [48.0, 671.0, 387.0, 683.0]}, {"text": "agreement was unanimous. Details on the rationale underlying these", "bbox": [47.0, 684.0, 387.0, 698.0]}, {"text": "recommendations are provided below.", "bbox": [47.0, 698.0, 232.0, 712.0]}], "type": "Text", "position": 8}, {"raw_context": [{"text": "3.3. Detailed recommendations", "bbox": [47.0, 727.0, 192.0, 740.0]}], "type": "Section-header", "position": 9}, {"raw_context": [{"text": "CLINICAL QUESTION 1: Which patients with ES-SCLC should be", "bbox": [62.0, 754.0, 387.0, 768.0]}, {"text": "referred to a radiation oncologist for consideration of consolidation", "bbox": [47.0, 769.0, 387.0, 782.0]}, {"text": "TRT?", "bbox": [48.0, 784.0, 76.0, 796.0]}, {"text": "Recommendation 1.1: All patients with a response to concurrent", "bbox": [63.0, 796.0, 387.0, 811.0]}, {"text": "chemo-immunotherapy, good PS, and limited metastases should be", "bbox": [48.0, 811.0, 387.0, 825.0]}, {"text": "considered for consolidation TRT. (Level of Agreement: Unanimous) .", "bbox": [48.0, 825.0, 368.0, 840.0]}, {"text": "Recommendation 1.2: Patients with expected or existing lung", "bbox": [63.0, 839.0, 386.0, 852.0]}, {"text": "cancer symptoms should also be considered for palliative TRT, regard-", "bbox": [48.0, 853.0, 387.0, 866.0]}, {"text": "less of response to concurrent chemo-immunotherapy. (Level of Agree-", "bbox": [47.0, 867.0, 385.0, 880.0]}, {"text": "ment: Unanimous) .", "bbox": [48.0, 882.0, 137.0, 894.0]}, {"text": "Clinical Rationale: As highlighted above, planned TRT was not", "bbox": [62.0, 893.0, 387.0, 908.0]}, {"text": "permitted in the pivotal IMpower133 and CASPIAN trials that resulted", "bbox": [48.0, 908.0, 387.0, 922.0]}, {"text": "in regulatory approval of first-line atezolizumab and durvalumab,", "bbox": [47.0, 922.0, 386.0, 935.0]}, {"text": "respectively, in ES-SCLC [28,29] . The expert working group agreed,", "bbox": [47.0, 936.0, 387.0, 949.0]}, {"text": "however, that in almost all cases, patients with ES-SCLC who have a", "bbox": [48.0, 951.0, 387.0, 963.0]}, {"text": "response to concurrent chemotherapy and immunotherapy (chemo-", "bbox": [48.0, 965.0, 386.0, 976.0]}, {"text": "immunotherapy; including a complete response), good performance", "bbox": [48.0, 979.0, 387.0, 991.0]}], "type": "Text", "position": 10}, {"raw_context": [{"text": "status (PS), and limited metastases should be referred to a radiation", "bbox": [406.0, 69.0, 746.0, 83.0]}, {"text": "oncologist for consideration of TRT. In a secondary analysis of data from", "bbox": [406.0, 84.0, 746.0, 97.0]}, {"text": "the CREST trial, patients with 0–2 metastases (or with no liver or bone", "bbox": [406.0, 98.0, 746.0, 111.0]}, {"text": "metastases) had better PFS after TRT than those with more than 2 me-", "bbox": [406.0, 112.0, 745.0, 125.0]}, {"text": "tastases [50] . Referral and practice patterns vary across geographic re-", "bbox": [406.0, 127.0, 745.0, 139.0]}, {"text": "gions and healthcare institutions; as such, in some centers, referral may", "bbox": [406.0, 140.0, 745.0, 153.0]}, {"text": "be initiated before the end of concurrent chemo-immunotherapy to", "bbox": [405.0, 154.0, 747.0, 167.0]}, {"text": "facilitate timely case review and planning. In others, evidence of", "bbox": [406.0, 167.0, 747.0, 181.0]}, {"text": "adequate response may need to be demonstrated before consultation.", "bbox": [406.0, 181.0, 745.0, 195.0]}, {"text": "For symptomatic patients or those expected to be symptomatic given a", "bbox": [406.0, 195.0, 747.0, 210.0]}, {"text": "large burden of central disease close to the airways, esophagus, and/or", "bbox": [406.0, 210.0, 746.0, 224.0]}, {"text": "vasculature, referral should still occur for consideration of palliative", "bbox": [406.0, 222.0, 747.0, 239.0]}, {"text": "TRT regardless of response to concurrent chemo-immunotherapy.", "bbox": [406.0, 238.0, 719.0, 251.0]}, {"text": "It should be noted that despite these recommendations, some pa-", "bbox": [421.0, 251.0, 746.0, 265.0]}, {"text": "tients may be unsuitable for consolidation TRT. Such patients include", "bbox": [405.0, 265.0, 746.0, 278.0]}, {"text": "those without a response to initial concurrent chemo-immunotherapy,", "bbox": [406.0, 280.0, 745.0, 292.0]}, {"text": "with poor PS at the time of consideration of TRT, or with major con-", "bbox": [406.0, 293.0, 745.0, 306.0]}, {"text": "traindications (e.g., interstitial lung disease, end-stage pulmonary", "bbox": [406.0, 307.0, 745.0, 320.0]}, {"text": "fibrosis), in addition to patients who are unwilling to receive TRT.", "bbox": [406.0, 321.0, 724.0, 334.0]}, {"text": "CLINICAL QUESTION 2: What is the appropriate dose-fractionation", "bbox": [421.0, 335.0, 747.0, 348.0]}, {"text": "schedule for consolidation TRT?", "bbox": [406.0, 350.0, 563.0, 362.0]}, {"text": "Recommendation 2.1: TRT to a dose of 30 Gy in 10 fractions is", "bbox": [421.0, 362.0, 747.0, 376.0]}, {"text": "recommended; a modified schedule may be appropriate based on pa-", "bbox": [406.0, 377.0, 745.0, 390.0]}, {"text": "tient characteristics and preferences. (Level of Agreement: Unanimous) .", "bbox": [405.0, 391.0, 740.0, 405.0]}, {"text": "Clinical Rationale: In alignment with the ASTRO guidelines [24] ,", "bbox": [421.0, 405.0, 747.0, 419.0]}, {"text": "the expert working group recommended that TRT be administered to a", "bbox": [406.0, 420.0, 747.0, 433.0]}, {"text": "dose of 30 Gy in 10 fractions. This dose-fractionation schedule was used", "bbox": [406.0, 434.0, 747.0, 446.0]}, {"text": "in the CREST trial and a Phase I/II study of ipilimumab and nivolumab in", "bbox": [405.0, 447.0, 747.0, 460.0]}, {"text": "ES-SCLC, with no significant toxicity observed [13,38] . As per ASTRO,", "bbox": [406.0, 461.0, 745.0, 474.0]}, {"text": "higher doses and fractions (e.g., 45 Gy in 15 fractions, as used in the", "bbox": [405.0, 474.0, 746.0, 488.0]}, {"text": "Radiation Therapy Oncology Group [RTOG] 0937 study [15] and a", "bbox": [406.0, 488.0, 747.0, 503.0]}, {"text": "Phase I trial of pembrolizumab [39] ) may be considered for patients", "bbox": [406.0, 503.0, 747.0, 517.0]}, {"text": "with good PS who have an excellent response to concurrent chemo-", "bbox": [406.0, 517.0, 745.0, 531.0]}, {"text": "immunotherapy and who are expected to have prolonged survival", "bbox": [406.0, 531.0, 747.0, 545.0]}, {"text": "[24] . Additionally, the expert working group suggested that a pragmatic", "bbox": [406.0, 544.0, 746.0, 559.0]}, {"text": "approach with lower doses and fractions (e.g., 20 Gy in 5 fractions) may", "bbox": [405.0, 556.0, 746.0, 574.0]}, {"text": "be appropriate for patients receiving palliative TRT for symptom control", "bbox": [406.0, 572.0, 747.0, 587.0]}, {"text": "or for those unable or unwilling to travel for ongoing TRT.", "bbox": [406.0, 587.0, 688.0, 600.0]}, {"text": "CLINICAL QUESTION 3: What is the optimal timing of consolidation", "bbox": [421.0, 600.0, 747.0, 615.0]}, {"text": "TRT during immunotherapy?", "bbox": [407.0, 615.0, 547.0, 627.0]}, {"text": "Recommendation 3.1: Although current randomized Phase III trials", "bbox": [422.0, 627.0, 746.0, 641.0]}, {"text": "did not include TRT, concurrent treatment with TRT and maintenance", "bbox": [406.0, 642.0, 745.0, 655.0]}, {"text": "immunotherapy can be initiated if considered appropriate based on", "bbox": [406.0, 656.0, 747.0, 669.0]}, {"text": "discussions between the medical oncologist and radiation oncologist.", "bbox": [406.0, 671.0, 745.0, 683.0]}, {"text": "(Level of Agreement: Unanimous).", "bbox": [406.0, 685.0, 563.0, 697.0]}, {"text": "Recommendation 3.2: Consolidation TRT should be provided after", "bbox": [422.0, 697.0, 746.0, 711.0]}, {"text": "completion of concurrent chemo-immunotherapy. ( Level of Agreement:", "bbox": [406.0, 713.0, 745.0, 725.0]}, {"text": "Unanimous) .", "bbox": [406.0, 727.0, 467.0, 739.0]}, {"text": "Clinical Rationale: Historically, TRT has been used in ES-SCLC to", "bbox": [421.0, 739.0, 747.0, 753.0]}, {"text": "reduce the risk of local progression in the lung. In the IMpower133 and", "bbox": [405.0, 754.0, 747.0, 767.0]}, {"text": "CASPIAN trials, the lung remained a common site of relapse regardless", "bbox": [405.0, 768.0, 746.0, 781.0]}, {"text": "of whether chemotherapy or chemotherapy + immunotherapy was", "bbox": [405.0, 781.0, 746.0, 796.0]}, {"text": "received [51,52] . Given that consolidation TRT was not permitted in", "bbox": [406.0, 796.0, 747.0, 810.0]}, {"text": "IMpower133 and CASPIAN, as well as in KEYNOTE-604, robust evi-", "bbox": [406.0, 810.0, 745.0, 823.0]}, {"text": "dence is not yet available for the safety, efficacy, or optimal timing of", "bbox": [406.0, 822.0, 747.0, 839.0]}, {"text": "combining TRT and immunotherapy among patients with ES-SCLC. The", "bbox": [405.0, 836.0, 746.0, 853.0]}, {"text": "results of several early-phase and retrospective analyses conducted in", "bbox": [406.0, 851.0, 747.0, 865.0]}, {"text": "this population, however, as well as studies conducted in other lung", "bbox": [406.0, 866.0, 746.0, 879.0]}, {"text": "cancer settings suggest that toxicity is not increased and that efficacy", "bbox": [405.0, 879.0, 745.0, 893.0]}, {"text": "may in fact be improved with addition of TRT.", "bbox": [406.0, 895.0, 631.0, 906.0]}, {"text": "The targeted literature review identified nine publications in which", "bbox": [422.0, 908.0, 747.0, 922.0]}, {"text": "some patients with ES-SCLC had received both maintenance immuno-", "bbox": [406.0, 922.0, 745.0, 935.0]}, {"text": "therapy and TRT. These studies included an exploratory analysis of", "bbox": [406.0, 937.0, 747.0, 948.0]}, {"text": "CASPIAN [31] , two prospective Phase I and I/I trials [38,39] , and six", "bbox": [406.0, 951.0, 747.0, 962.0]}, {"text": "retrospective analyses conducted in various regions worldwide", "bbox": [406.0, 964.0, 745.0, 976.0]}, {"text": "[37,40,41,53–55] . None of these studies indicated safety concerns", "bbox": [406.0, 977.0, 745.0, 991.0]}], "type": "Text", "position": 12}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/肿瘤科/共识/加拿大共识建议：在接受免疫治疗的广泛期小细胞肺癌患者中使用放射治疗.pdf", "page_num": 3}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "多余换行#15#16#good performance和status (PS), and limited metastases是一句话\n多余换行#23#24#radiation oncologist.和(Level of Agreement: Unanimous).是一句话", "type3": "无关文本#0#27# in ES-SCLC [28,29].部分段落末尾，以及句末的数字问题无关噪声应用全文", "type4": null, "type5": null, "type6": null}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:41", "update_time": "2024-05-08 00:43:13"}
{"id": 1082566, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 738, "source_info": {"seq_id": "219443b3-96fc-48d6-b07f-c96195ad374d", "title": null, "text": "【0】页码:7\n MHV if needed for other indications, for example, prevention of pre-eclampsia toxaemia (PET) rather than for thromboprophylaxis per se.\n\n【1】Although there is an absence of high-quality data on the role of aspirin in pregnant individuals with MHV, in view of the increased risk of valve thrombosis in pregnancy, it is reasonable to add LDA (75mg daily) from early pregnancy onwards if there are no contraindications or bleeding concerns, especially in pregnant individuals with a higher risk MHV ( Table 1 ) and this should be continued for the duration of pregnancy. In pregnant individuals with risk factors for placental failure/PET who are eligible for LDA at 12 weeks of gestation, there is indirect evidence that aspirin at a dose greater than 75 mg may be associated with the highest reduction in preterm pre-eclampsia. 37 In the absence of clear evidence of increased bleeding when increasing the aspirin dose from 75 to 150 mg daily in combination with therapeutic anticoagulation, we consider that an increase in the dose of aspirin from 75 to 150mg at 12-week gestation can be considered if indicated for prevention of pre-eclampsia in individuals with MHV.\n\n【2】## Management Of Miscarriage And Termination Of Pregnancy\n\n【3】\n Non-surgical management of first trimester miscarriage, that is expectant management (waiting for spontaneous miscarriage) or medical management with prostaglandin has become increasingly popular in comparison to surgical management. For anticoagulated pregnant individuals, the reduced success rates in achieving complete miscarriage, higher need for unplanned surgical evacuation and increased bleeding with these management options make them less suitable in this context. 38 Likewise, for termination of pregnancy, the benefits of surgical management in minimising blood loss and unplanned surgical intervention make it the recommended option. The gestation up to which this can be carried out will depend on the expertise within a unit. For later gestations, medical management will be required.\n\n【4】For both miscarriage treatment and termination of pregnancy, the duration of interrupted anticoagulation should be minimised whilst avoiding an excessive risk of bleeding which could prolong that interruption. A risk assessment by the specialist team is required and discussion regarding management of anticoagulation should be carried out. Contraception should be discussed and administered if appropriate (in the case of an intrauterine contraceptive device or progesterone implant).\n\n【5】## Diagnosis And Management Of M V T\n\n【6】\n## Diagnosis\n\n【7】\n This requires a low index of suspicion in view of the heightened risk in pregnancy. Signs and symptoms of potential valve thrombosis include no longer hearing the clicks from\n\n【8】 the valve closure, obstructive symptoms such as increased breathlessness, heart failure, syncope or pre-syncope, cardiogenic shock ± non-obstructive symptoms such as an embolic event, for example, stroke, renal or splenic infarct (manifesting as new onset abdominal pain). Right-sided mechanical valve replacement thrombosis obstructive symptoms may be more insidious with loss of appetite, lower limb oedema and/or ascites ± non-obstructive symptoms such as pulmonary emboli as embolic events.\n\n【9】Examination may reveal increased heart rate, low blood pressure, quiet or absent mechanical valve sounds, a new murmur, increased respiratory rate and inspiratory crepitations. A high index of suspicion for the potential of MVT with embolism is required with urgent senior cardiology review, urgent echo and further imaging (e.g.\n\n【10】fluoroscopy, transoesophageal echo, +/or CT) as deemed appropriate.\n\n【11】## Management Of Mvt Presenting With Stroke\n\n【12】\n In cases where MVT presents with a stroke, emergency stroke team review and assessment is essential. Senior MDT discussions including obstetrics, cardiology, anaesthetics, cardiac surgery and neurology/stroke medicine are recommended and location of care needs to balance the competing needs of the pregnant individual, considering MVT management, stroke and ongoing pregnancy needs and should be individualised.\n\n【13】## Management Of Mvt With Obstruction\n\n【14】\n Initial assessment is based on clinical stability of patient.\n\n【15】If haemodynamically unstable, then this is a clinical emergency requiring MDT input from senior clinicians including obstetrician, cardiologist with interest in obstetrics, anaesthetist and cardiothoracic surgeon to consider management options. Ensure correct location for care and clear escalation plan, usually critical care unit/cardiac intensive care unit with obstetric input. 4 Opinion generally supports a trial of thrombolysis, especially for right-sided lesions but there are no comparative data of strategies. 7 Obstetric management will be based on the foetal condition and gestation in conjunction with the maternal condition. A molecular weight > 1000 Da prevents most thrombolytic agents from easily crossing the placenta. Alteplase (a recombinant tissue plasminogen activator) has the highest molecular weight and does not cross the placenta. Successful thrombolysis is defined as achieving at least two out of three of the following 39 .\n\n【16】 1. Resolution of elevated Doppler gradient 2. Reduction in thrombus size (area or length) of >50% 3. Improvement in symptoms\n\n【17】 (sque) and in 9 las armor on 105 [150540/81] no rendle online colier, ventili pierving MAA assoT - is us gd 1858 l.4641 111 0 1/86/mes colier contains/\n\n【18】 weg on solatine VO com to solut and varadel onlin0 voliW no (anotabuco-", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "MHV if needed for other indications, for example, preven-", "bbox": [58.0, 65.0, 385.0, 79.0]}, {"text": "tion of pre-eclampsia toxaemia (PET) rather than for throm-", "bbox": [58.0, 80.0, 385.0, 95.0]}, {"text": "boprophylaxis per se.", "bbox": [58.0, 97.0, 176.0, 111.0]}, {"text": "Although there is an absence of high-quality data on the", "bbox": [75.0, 113.0, 387.0, 127.0]}, {"text": "role of aspirin in pregnant individuals with MHV, in view of", "bbox": [58.0, 128.0, 387.0, 144.0]}, {"text": "the increased risk of valve thrombosis in pregnancy, it is rea-", "bbox": [58.0, 145.0, 385.0, 160.0]}, {"text": "sonable to add LDA (75mg daily) from early pregnancy on-", "bbox": [58.0, 160.0, 385.0, 176.0]}, {"text": "wards if there are no contraindications or bleeding concerns,", "bbox": [58.0, 177.0, 386.0, 192.0]}, {"text": "especially in pregnant individuals with a higher risk MHV", "bbox": [58.0, 194.0, 385.0, 208.0]}, {"text": "( Table 1 ) and this should be continued for the duration of preg-", "bbox": [58.0, 209.0, 385.0, 224.0]}, {"text": "nancy. In pregnant individuals with risk factors for placental", "bbox": [58.0, 226.0, 387.0, 240.0]}, {"text": "failure/PET who are eligible for LDA at 12 weeks of gestation,", "bbox": [58.0, 242.0, 386.0, 256.0]}, {"text": "there is indirect evidence that aspirin at a dose greater than", "bbox": [58.0, 258.0, 387.0, 273.0]}, {"text": "75 mg may be associated with the highest reduction in preterm", "bbox": [58.0, 274.0, 387.0, 288.0]}, {"text": "pre-eclampsia. 37 In the absence of clear evidence of increased", "bbox": [58.0, 289.0, 387.0, 306.0]}, {"text": "bleeding when increasing the aspirin dose from 75 to 150 mg", "bbox": [58.0, 306.0, 387.0, 321.0]}, {"text": "daily in combination with therapeutic anticoagulation, we", "bbox": [58.0, 322.0, 387.0, 336.0]}, {"text": "consider that an increase in the dose of aspirin from 75 to", "bbox": [58.0, 338.0, 387.0, 353.0]}, {"text": "150mg at 12-week gestation can be considered if indicated for", "bbox": [58.0, 354.0, 386.0, 368.0]}, {"text": "prevention of pre-eclampsia in individuals with MHV.", "bbox": [58.0, 370.0, 348.0, 385.0]}], "type": "Text", "position": 2}, {"raw_context": [{"text": "MANAGEMENT OF MISCARRIAGE", "bbox": [58.0, 414.0, 354.0, 434.0]}, {"text": "AND TERMINATION OF PREGNANCY", "bbox": [58.0, 432.0, 383.0, 449.0]}], "type": "Section-header", "position": 3}, {"raw_context": [{"text": "Non-surgical management of first trimester miscarriage,", "bbox": [58.0, 466.0, 387.0, 481.0]}, {"text": "that is expectant management (waiting for spontaneous", "bbox": [58.0, 482.0, 387.0, 496.0]}, {"text": "miscarriage) or medical management with prostaglandin", "bbox": [58.0, 498.0, 387.0, 513.0]}, {"text": "has become increasingly popular in comparison to surgical", "bbox": [58.0, 515.0, 387.0, 529.0]}, {"text": "management. For anticoagulated pregnant individuals, the", "bbox": [58.0, 530.0, 387.0, 545.0]}, {"text": "reduced success rates in achieving complete miscarriage,", "bbox": [58.0, 546.0, 385.0, 561.0]}, {"text": "higher need for unplanned surgical evacuation and increased", "bbox": [58.0, 562.0, 387.0, 576.0]}, {"text": "bleeding with these management options make them less", "bbox": [58.0, 578.0, 387.0, 593.0]}, {"text": "suitable in this context. 38 Likewise, for termination of preg-", "bbox": [58.0, 595.0, 385.0, 608.0]}, {"text": "nancy, the benefits of surgical management in minimising", "bbox": [58.0, 609.0, 387.0, 625.0]}, {"text": "blood loss and unplanned surgical intervention make it the", "bbox": [58.0, 626.0, 387.0, 641.0]}, {"text": "recommended option. The gestation up to which this can be", "bbox": [58.0, 642.0, 387.0, 656.0]}, {"text": "carried out will depend on the expertise within a unit. For", "bbox": [58.0, 658.0, 387.0, 673.0]}, {"text": "later gestations, medical management will be required.", "bbox": [58.0, 675.0, 355.0, 689.0]}, {"text": "For both miscarriage treatment and termination of preg-", "bbox": [74.0, 690.0, 385.0, 705.0]}, {"text": "nancy, the duration of interrupted anticoagulation should be", "bbox": [58.0, 706.0, 387.0, 721.0]}, {"text": "minimised whilst avoiding an excessive risk of bleeding which", "bbox": [58.0, 722.0, 387.0, 736.0]}, {"text": "could prolong that interruption. A risk assessment by the spe-", "bbox": [58.0, 738.0, 385.0, 753.0]}, {"text": "cialist team is required and discussion regarding management", "bbox": [58.0, 755.0, 387.0, 769.0]}, {"text": "of anticoagulation should be carried out. Contraception should", "bbox": [58.0, 769.0, 387.0, 784.0]}, {"text": "be discussed and administered if appropriate (in the case of an", "bbox": [58.0, 786.0, 387.0, 801.0]}, {"text": "intrauterine contraceptive device or progesterone implant).", "bbox": [58.0, 803.0, 367.0, 816.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": "DIAGNOSIS AND MANAGEMENT", "bbox": [58.0, 848.0, 343.0, 865.0]}, {"text": "OF M V T", "bbox": [58.0, 864.0, 130.0, 880.0]}], "type": "Section-header", "position": 5}, {"raw_context": [{"text": "Diagnosis", "bbox": [58.0, 896.0, 129.0, 913.0]}], "type": "Section-header", "position": 6}, {"raw_context": [{"text": "This requires a low index of suspicion in view of the height-", "bbox": [58.0, 930.0, 385.0, 944.0]}, {"text": "ened risk in pregnancy. Signs and symptoms of potential", "bbox": [58.0, 946.0, 387.0, 961.0]}, {"text": "valve thrombosis include no longer hearing the clicks from", "bbox": [58.0, 962.0, 386.0, 977.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "the valve closure, obstructive symptoms such as increased", "bbox": [406.0, 65.0, 734.0, 79.0]}, {"text": "breathlessness, heart failure, syncope or pre-syncope, car-", "bbox": [405.0, 80.0, 733.0, 95.0]}, {"text": "diogenic shock ± non-obstructive symptoms such as an", "bbox": [406.0, 97.0, 735.0, 112.0]}, {"text": "embolic event, for example, stroke, renal or splenic infarct", "bbox": [406.0, 113.0, 735.0, 127.0]}, {"text": "(manifesting as new onset abdominal pain). Right-sided me-", "bbox": [406.0, 129.0, 733.0, 144.0]}, {"text": "chanical valve replacement thrombosis obstructive symp-", "bbox": [406.0, 146.0, 733.0, 159.0]}, {"text": "toms may be more insidious with loss of appetite, lower limb", "bbox": [406.0, 161.0, 735.0, 176.0]}, {"text": "oedema and/or ascites ± non-obstructive symptoms such as", "bbox": [406.0, 177.0, 735.0, 192.0]}, {"text": "pulmonary emboli as embolic events.", "bbox": [406.0, 194.0, 610.0, 208.0]}, {"text": "Examination may reveal increased heart rate, low", "bbox": [423.0, 210.0, 735.0, 225.0]}, {"text": "blood pressure, quiet or absent mechanical valve sounds,", "bbox": [406.0, 226.0, 735.0, 240.0]}, {"text": "a new murmur, increased respiratory rate and inspiratory", "bbox": [406.0, 242.0, 734.0, 256.0]}, {"text": "crepitations. A high index of suspicion for the potential", "bbox": [406.0, 258.0, 735.0, 273.0]}, {"text": "of MVT with embolism is required with urgent senior", "bbox": [406.0, 274.0, 735.0, 288.0]}, {"text": "cardiology review, urgent echo and further imaging (e.g.", "bbox": [406.0, 290.0, 733.0, 305.0]}, {"text": "fluoroscopy, transoesophageal echo, +/or CT) as deemed", "bbox": [406.0, 306.0, 735.0, 321.0]}, {"text": "appropriate.", "bbox": [406.0, 322.0, 477.0, 337.0]}], "type": "Text", "position": 8}, {"raw_context": [{"text": "Management of MVT presenting with stroke", "bbox": [406.0, 368.0, 709.0, 386.0]}], "type": "Section-header", "position": 9}, {"raw_context": [{"text": "In cases where MVT presents with a stroke, emergency stroke", "bbox": [406.0, 401.0, 735.0, 416.0]}, {"text": "team review and assessment is essential. Senior MDT discus-", "bbox": [406.0, 418.0, 733.0, 433.0]}, {"text": "sions including obstetrics, cardiology, anaesthetics, cardiac", "bbox": [406.0, 435.0, 735.0, 448.0]}, {"text": "surgery and neurology/stroke medicine are recommended", "bbox": [406.0, 449.0, 735.0, 464.0]}, {"text": "and location of care needs to balance the competing needs", "bbox": [406.0, 466.0, 735.0, 481.0]}, {"text": "of the pregnant individual, considering MVT manage-", "bbox": [406.0, 482.0, 733.0, 496.0]}, {"text": "ment, stroke and ongoing pregnancy needs and should be", "bbox": [406.0, 498.0, 735.0, 513.0]}, {"text": "individualised.", "bbox": [406.0, 514.0, 490.0, 528.0]}], "type": "Text", "position": 10}, {"raw_context": [{"text": "Management of MVT with obstruction", "bbox": [406.0, 560.0, 671.0, 577.0]}], "type": "Section-header", "position": 11}, {"raw_context": [{"text": "Initial assessment is based on clinical stability of patient.", "bbox": [406.0, 594.0, 734.0, 608.0]}, {"text": "If haemodynamically unstable, then this is a clinical emer-", "bbox": [406.0, 609.0, 733.0, 624.0]}, {"text": "gency requiring MDT input from senior clinicians including", "bbox": [406.0, 626.0, 735.0, 641.0]}, {"text": "obstetrician, cardiologist with interest in obstetrics, anaes-", "bbox": [406.0, 642.0, 733.0, 656.0]}, {"text": "thetist and cardiothoracic surgeon to consider management", "bbox": [406.0, 658.0, 735.0, 673.0]}, {"text": "options. Ensure correct location for care and clear escalation", "bbox": [406.0, 675.0, 735.0, 689.0]}, {"text": "plan, usually critical care unit/cardiac intensive care unit", "bbox": [406.0, 690.0, 735.0, 705.0]}, {"text": "with obstetric input. 4", "bbox": [406.0, 706.0, 520.0, 721.0]}, {"text": "Opinion generally supports a trial of thromboly-", "bbox": [422.0, 722.0, 734.0, 736.0]}, {"text": "sis, especially for right-sided lesions but there are no", "bbox": [406.0, 737.0, 735.0, 753.0]}, {"text": "comparative data of strategies. 7 Obstetric management", "bbox": [406.0, 755.0, 735.0, 769.0]}, {"text": "will be based on the foetal condition and gestation in", "bbox": [406.0, 769.0, 735.0, 784.0]}, {"text": "conjunction with the maternal condition. A molecular", "bbox": [406.0, 786.0, 735.0, 801.0]}, {"text": "weight > 1000 Da prevents most thrombolytic agents", "bbox": [406.0, 803.0, 735.0, 816.0]}, {"text": "from easily crossing the placenta. Alteplase (a recombi-", "bbox": [406.0, 818.0, 734.0, 833.0]}, {"text": "nant tissue plasminogen activator) has the highest mo-", "bbox": [406.0, 834.0, 734.0, 849.0]}, {"text": "lecular weight and does not cross the placenta. Successful", "bbox": [405.0, 849.0, 735.0, 864.0]}, {"text": "thrombolysis is defined as achieving at least two out of", "bbox": [406.0, 866.0, 735.0, 881.0]}, {"text": "three of the following 39 .", "bbox": [406.0, 882.0, 547.0, 896.0]}], "type": "Text", "position": 12}, {"raw_context": [{"text": "1. Resolution of elevated Doppler gradient", "bbox": [423.0, 914.0, 653.0, 928.0]}, {"text": "2. Reduction in thrombus size (area or length) of", "bbox": [422.0, 929.0, 735.0, 946.0]}, {"text": ">50%", "bbox": [406.0, 946.0, 441.0, 960.0]}, {"text": "3. Improvement in symptoms", "bbox": [422.0, 963.0, 586.0, 977.0]}], "type": "Text", "position": 13}, {"raw_context": [{"text": "(sque) and in 9 las armor on 105 [150540/81] no rendle online colier, ventili pierving MAA assoT - is us gd 1858 l.4641 111 0 1/86/mes colier contains/", "bbox": [768.0, 127.0, 782.0, 587.0]}], "type": "Text", "position": 14}, {"raw_context": [{"text": "weg on solatine VO com to solut and varadel onlin0 voliW no (anotabuco-", "bbox": [768.0, 685.0, 780.0, 883.0]}], "type": "Text", "position": 15}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/心血管/指南/2023 BSH 指南：机械心脏瓣膜妊娠个体抗凝管理(1).pdf", "page_num": 7}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type2": "多余换行#7#8#hearing the clicks from和 the valve closure, obstructive是一句话\n多余换行#9#10#further imaging (e.g.和 fluoroscopy, transoesophageal是一句话\n缺少换行#15#15#Opinion generally supports另起一行\n缺少换行#16#16# 2. Reduction in thrombus另起一行\n3. Improvement in symptoms另起一行", "type3": "无关文本#1#1#( Table 1 )\n无关文本#0#18#pre-eclampsia. 37部分段落末尾，以及句末的数字问题无关噪声应用全文\n无关文本#17#18#( Table 1 )(sque) and in 9 las armor on ....与正文无关"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:41", "update_time": "2024-05-08 00:46:49"}
{"id": 1082565, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 738, "source_info": {"seq_id": "4424538a-0c73-4dfa-bed2-1a2a049f375a", "title": null, "text": "【0】页码:5\n Sometimes complications associated with sedation occur. This guideline informs clinicians on when a reversal agent should be used to counter the effects of sedative drugs and highlights the importance of all endoscopy staff being aware of where these drugs are kept in case of emergencies. Sedation should only be administered if there is immediate access to the resources (staff and facilities) to manage any complications that might arise. In addition, only lower strengths of the sedative drug midazolam should be stocked to prevent inadvertent oversedation. Any occurrence of oversedation that requires a reversal agent needs to be reported through local safety incident reporting systems, and lessons learnt should be shared within the organisation.\n\n【1】## Patient Discharge\n\n【2】\n Patients should be formally assessed for suitability for discharge.\n\n【3】This should be documented to demonstrate recovery from sedation and the absence of complications. With the majority of sedative drugs, a responsible adult is required to accompany the patient home as these drugs can last for up to 24 hours in the body after the procedure. Patients are also advised not to drive or operate machinery for the first 24 hours after having sedation. Clear instructions should be provided at discharge for late recovery with appropriate contact information.\n\n【4】## Specific Patient Groups\n\n【5】\n This guideline also covers sedation for specific groups. There are certain procedures where a deeper level of sedation is recommended. Examples include patients with reduced conscious level due to advanced liver disease, when the camera goes deep into the small bowel, when a pancreatic cyst requires drainage or when a metal/plastic tube is inserted into the bile duct (therapeutic ERCP). Smaller doses of sedation should be used in the elderly or in patients with kidney or liver failure. Additional heart trace monitoring (ECG) is recommended in patients who have heart disease with a history of significant abnormal heart rhythms. Breathing machines can be used as an adjunct when using sedation in patients with significant chest and neurological disorders.\n\n【6】A thin camera via the nose (TNE) which can be carried out without sedation, is a reasonable alternative to oral endoscopy in specific groups of patients. For camera tests of the large bowel (colonoscopy), alternatives to sedation such as inhaled gases (eg, nitrous oxide/Entonox) can also be considered as an adjunct, but deeper sedation may be required for planned prolonged or complex procedures. Special consideration is given to younger people (16–18 year olds), who should be invited to a structured transition programme where education around the choice of sedative agents used for endoscopic procedures are covered. The key to a good patient experience is balancing communication, understanding and expectations.\n\n【7】Some patients who require endoscopy might have a learning disability. Information about the endoscopic procedure, including a description of the use and risks of sedation, should be provided in a format that is tailored to the patient's needs and preferred method of communication. Sufficient time should be employed to allow the patient to ask questions.\n\n【8】If during a sedated endoscopy, a patient appears to be tolerating the procedure poorly, the clinician should stop the procedure in order to assess the patient's capacity and wishes. Further sedation may be appropriate. If the patient has capacity but indicates withdrawal of consent, the procedure should be stopped (unless this would result in immediate patient harm).\n\n【9】Sidhu R, et al. Gut 2023;0:1–27. doi:10.1136/gutjnl-2023-330396\n\n【10】 This guideline also provides recommendations on which sedative drugs can safely be used in the pregnant patient and highlights the increased risk of aspiration in pregnancy. Mothers are safe to breast feed after endoscopy with the vast majority of drugs used.\n\n【11】## Training\n\n【12】\n This guideline recommends that all endoscopy staff involved in providing sedation have formal training in sedation practices and that this is a continuing process. Every hospital should have a sedation committee to ensure safe practice is carried out and monitored.\n\n【13】## Introduction\n\n【14】\n In the United Kingdom, over 2.5 million gastrointestinal endoscopic procedures are carried out annually. The majority are performed with local anaesthetic or conscious sedation, with deep sedation and general anaesthetic support being used for a minority of procedures. In the last decade, both the complexity and volume of endoscopic procedures undertaken have increased.\n\n【15】There is a need for better patient experience and tolerance in line with patient expectation and acceptability. The increased use of sedation brings safety concerns. The main objectives of these guidelines are to provide evidence-based recommendations on the evaluation of adult patients undergoing gastrointestinal endoscopy with or without sedation, the roles and competencies required for clinicians to safely deliver sedation, the minimum monitoring requirements and the prevention and management of adverse events from sedation. This guideline encompasses the commonly used drugs for sedation, interactions and postprocedure discharge criteria. The indications and criteria for deep sedation or general anaesthetic for endoscopic procedures by anaesthesiologists are also detailed. These guidelines update the previous 2013 guidelines. 1\n\n【16】## Development Of Guidelines\n\n【17】\n This guideline was commissioned by the BSG Endoscopy Committee and developed in collaboration with representatives from key stakeholders, including the Joint Advisory Group on GI Endoscopy (JAG), the Royal College of Anaesthetists (RCoA) and the British Society of Gastroenterology Nurses Association (BSGNA). The aim of the guideline is to review and update the previous 2013 guideline, encompassing advances and the complexity of endoscopic procedures carried out currently. The guideline development group (GDG) members were selected from the BSG Endoscopy Committee as well as representatives from affiliated committees and stakeholder organisations. The BSG also advertised for two other members of the BSG (not members of the Endoscopy Committee) to apply for positions within the GDG, via submission of a curriculum vitae and supporting statement. Two patient representatives were also invited to form part of the GDG, one through the Royal College of Physicians Patient Involvement Unit.\n\n【18】The GDG met via multiple teleconferences using both Microsoft Teams and face-to-face meetings. The domains for the guideline were discussed in detail. As these guidelines have an impact on several groups of health professionals, stakeholders were invited to comment on the agreed domains to be covered by the guideline. These stakeholders included RCoA, JAG, Association of Upper Gastrointestinal Surgery of Great Britain and Ireland (AUGIS), Association of Coloproctology of Great Britain and Ireland (ACPGBI), British Geriatric Society (BGS) and British Society of Gynaecology and Pancreatic Society of Great Britain", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "Sometimes complications associated with sedation occur. This", "bbox": [66.0, 60.0, 387.0, 75.0]}, {"text": "guideline informs clinicians on when a reversal agent should be", "bbox": [53.0, 76.0, 386.0, 90.0]}, {"text": "used to counter the effects of sedative drugs and highlights the", "bbox": [53.0, 91.0, 387.0, 105.0]}, {"text": "importance of all endoscopy staff being aware of where these", "bbox": [53.0, 105.0, 387.0, 120.0]}, {"text": "drugs are kept in case of emergencies. Sedation should only be", "bbox": [53.0, 120.0, 387.0, 135.0]}, {"text": "administered if there is immediate access to the resources (staff", "bbox": [53.0, 135.0, 387.0, 150.0]}, {"text": "and facilities) to manage any complications that might arise. In", "bbox": [53.0, 150.0, 387.0, 165.0]}, {"text": "addition, only lower strengths of the sedative drug midazolam", "bbox": [53.0, 165.0, 387.0, 179.0]}, {"text": "should be stocked to prevent inadvertent oversedation. Any", "bbox": [53.0, 180.0, 385.0, 194.0]}, {"text": "occurrence of oversedation that requires a reversal agent needs", "bbox": [53.0, 195.0, 387.0, 209.0]}, {"text": "to be reported through local safety incident reporting systems,", "bbox": [53.0, 209.0, 385.0, 224.0]}, {"text": "and lessons learnt should be shared within the organisation.", "bbox": [53.0, 223.0, 365.0, 240.0]}], "type": "Text", "position": 0}, {"raw_context": [{"text": "Patient discharge", "bbox": [53.0, 264.0, 149.0, 278.0]}], "type": "Section-header", "position": 1}, {"raw_context": [{"text": "Patients should be formally assessed for suitability for discharge.", "bbox": [53.0, 278.0, 385.0, 293.0]}, {"text": "This should be documented to demonstrate recovery from seda-", "bbox": [54.0, 294.0, 385.0, 308.0]}, {"text": "tion and the absence of complications. With the majority of", "bbox": [53.0, 309.0, 387.0, 323.0]}, {"text": "sedative drugs, a responsible adult is required to accompany the", "bbox": [53.0, 324.0, 387.0, 337.0]}, {"text": "patient home as these drugs can last for up to 24 hours in the", "bbox": [53.0, 339.0, 387.0, 353.0]}, {"text": "body after the procedure. Patients are also advised not to drive", "bbox": [53.0, 353.0, 387.0, 368.0]}, {"text": "or operate machinery for the first 24 hours after having seda-", "bbox": [53.0, 368.0, 385.0, 383.0]}, {"text": "tion. Clear instructions should be provided at discharge for late", "bbox": [53.0, 383.0, 386.0, 398.0]}, {"text": "recovery with appropriate contact information.", "bbox": [53.0, 398.0, 300.0, 412.0]}], "type": "Text", "position": 2}, {"raw_context": [{"text": "Specific patient groups", "bbox": [53.0, 438.0, 179.0, 453.0]}], "type": "Section-header", "position": 3}, {"raw_context": [{"text": "This guideline also covers sedation for specific groups. There are", "bbox": [53.0, 454.0, 386.0, 468.0]}, {"text": "certain procedures where a deeper level of sedation is recom-", "bbox": [53.0, 469.0, 385.0, 482.0]}, {"text": "mended. Examples include patients with reduced conscious level", "bbox": [53.0, 483.0, 387.0, 496.0]}, {"text": "due to advanced liver disease, when the camera goes deep into", "bbox": [53.0, 498.0, 387.0, 511.0]}, {"text": "the small bowel, when a pancreatic cyst requires drainage or", "bbox": [53.0, 512.0, 386.0, 526.0]}, {"text": "when a metal/plastic tube is inserted into the bile duct (thera-", "bbox": [53.0, 527.0, 385.0, 541.0]}, {"text": "peutic ERCP). Smaller doses of sedation should be used in the", "bbox": [53.0, 543.0, 386.0, 556.0]}, {"text": "elderly or in patients with kidney or liver failure. Additional", "bbox": [53.0, 557.0, 387.0, 570.0]}, {"text": "heart trace monitoring (ECG) is recommended in patients who", "bbox": [53.0, 571.0, 387.0, 585.0]}, {"text": "have heart disease with a history of significant abnormal heart", "bbox": [53.0, 586.0, 387.0, 601.0]}, {"text": "rhythms. Breathing machines can be used as an adjunct when", "bbox": [53.0, 601.0, 387.0, 615.0]}, {"text": "using sedation in patients with significant chest and neurological", "bbox": [53.0, 616.0, 386.0, 630.0]}, {"text": "disorders.", "bbox": [53.0, 631.0, 107.0, 645.0]}, {"text": "A thin camera via the nose (TNE) which can be carried out", "bbox": [65.0, 645.0, 386.0, 659.0]}, {"text": "without sedation, is a reasonable alternative to oral endoscopy", "bbox": [53.0, 660.0, 385.0, 674.0]}, {"text": "in specific groups of patients. For camera tests of the large bowel", "bbox": [53.0, 675.0, 386.0, 690.0]}, {"text": "(colonoscopy), alternatives to sedation such as inhaled gases (eg,", "bbox": [53.0, 690.0, 386.0, 704.0]}, {"text": "nitrous oxide/Entonox) can also be considered as an adjunct,", "bbox": [53.0, 706.0, 386.0, 719.0]}, {"text": "but deeper sedation may be required for planned prolonged or", "bbox": [53.0, 720.0, 385.0, 733.0]}, {"text": "complex procedures. Special consideration is given to younger", "bbox": [53.0, 735.0, 386.0, 748.0]}, {"text": "people (16–18 year olds), who should be invited to a structured", "bbox": [53.0, 749.0, 387.0, 764.0]}, {"text": "transition programme where education around the choice of", "bbox": [53.0, 764.0, 387.0, 778.0]}, {"text": "sedative agents used for endoscopic procedures are covered. The", "bbox": [53.0, 779.0, 387.0, 793.0]}, {"text": "key to a good patient experience is balancing communication,", "bbox": [53.0, 794.0, 385.0, 807.0]}, {"text": "understanding and expectations.", "bbox": [54.0, 810.0, 223.0, 821.0]}, {"text": "Some patients who require endoscopy might have a learning", "bbox": [64.0, 822.0, 387.0, 837.0]}, {"text": "disability. Information about the endoscopic procedure,", "bbox": [53.0, 837.0, 385.0, 852.0]}, {"text": "including a description of the use and risks of sedation, should", "bbox": [53.0, 852.0, 386.0, 866.0]}, {"text": "be provided in a format that is tailored to the patient's needs and", "bbox": [53.0, 868.0, 386.0, 881.0]}, {"text": "preferred method of communication. Sufficient time should be", "bbox": [53.0, 882.0, 387.0, 895.0]}, {"text": "employed to allow the patient to ask questions.", "bbox": [53.0, 897.0, 300.0, 911.0]}, {"text": "If during a sedated endoscopy, a patient appears to be toler-", "bbox": [64.0, 911.0, 385.0, 926.0]}, {"text": "ating the procedure poorly, the clinician should stop the proce-", "bbox": [53.0, 926.0, 385.0, 940.0]}, {"text": "dure in order to assess the patient's capacity and wishes. Further", "bbox": [53.0, 942.0, 386.0, 955.0]}, {"text": "sedation may be appropriate. If the patient has capacity but indi-", "bbox": [53.0, 956.0, 385.0, 969.0]}, {"text": "cates withdrawal of consent, the procedure should be stopped", "bbox": [53.0, 970.0, 387.0, 984.0]}, {"text": "(unless this would result in immediate patient harm).", "bbox": [53.0, 985.0, 328.0, 999.0]}, {"text": "Sidhu R, et al. Gut 2023;0:1–27. doi:10.1136/gutjnl-2023-330396", "bbox": [54.0, 1009.0, 317.0, 1022.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": "This guideline also provides recommendations on which", "bbox": [419.0, 60.0, 740.0, 75.0]}, {"text": "sedative drugs can safely be used in the pregnant patient and", "bbox": [406.0, 76.0, 740.0, 90.0]}, {"text": "highlights the increased risk of aspiration in pregnancy. Mothers", "bbox": [406.0, 91.0, 740.0, 105.0]}, {"text": "are safe to breast feed after endoscopy with the vast majority of", "bbox": [406.0, 105.0, 739.0, 120.0]}, {"text": "drugs used.", "bbox": [406.0, 120.0, 469.0, 135.0]}], "type": "Text", "position": 6}, {"raw_context": [{"text": "Training", "bbox": [407.0, 154.0, 453.0, 168.0]}], "type": "Section-header", "position": 7}, {"raw_context": [{"text": "This guideline recommends that all endoscopy staff involved in", "bbox": [408.0, 169.0, 741.0, 183.0]}, {"text": "providing sedation have formal training in sedation practices", "bbox": [406.0, 184.0, 740.0, 198.0]}, {"text": "and that this is a continuing process. Every hospital should have", "bbox": [406.0, 198.0, 740.0, 213.0]}, {"text": "a sedation committee to ensure safe practice is carried out and", "bbox": [406.0, 213.0, 740.0, 227.0]}, {"text": "monitored.", "bbox": [406.0, 228.0, 467.0, 241.0]}], "type": "Text", "position": 8}, {"raw_context": [{"text": "INTRODUCTION", "bbox": [406.0, 261.0, 496.0, 276.0]}], "type": "Section-header", "position": 9}, {"raw_context": [{"text": "In the United Kingdom, over 2.5 million gastrointestinal endo-", "bbox": [406.0, 276.0, 739.0, 291.0]}, {"text": "scopic procedures are carried out annually. The majority are", "bbox": [406.0, 292.0, 740.0, 306.0]}, {"text": "performed with local anaesthetic or conscious sedation, with", "bbox": [406.0, 307.0, 741.0, 320.0]}, {"text": "deep sedation and general anaesthetic support being used for a", "bbox": [406.0, 321.0, 741.0, 334.0]}, {"text": "minority of procedures. In the last decade, both the complexity", "bbox": [406.0, 335.0, 739.0, 349.0]}, {"text": "and volume of endoscopic procedures undertaken have increased.", "bbox": [407.0, 350.0, 739.0, 364.0]}, {"text": "There is a need for better patient experience and tolerance in", "bbox": [408.0, 365.0, 741.0, 379.0]}, {"text": "line with patient expectation and acceptability. The increased", "bbox": [406.0, 380.0, 740.0, 393.0]}, {"text": "use of sedation brings safety concerns. The main objectives of", "bbox": [406.0, 395.0, 739.0, 408.0]}, {"text": "these guidelines are to provide evidence-based recommendations", "bbox": [406.0, 409.0, 740.0, 422.0]}, {"text": "on the evaluation of adult patients undergoing gastrointestinal", "bbox": [406.0, 423.0, 740.0, 437.0]}, {"text": "endoscopy with or without sedation, the roles and competencies", "bbox": [406.0, 438.0, 741.0, 452.0]}, {"text": "required for clinicians to safely deliver sedation, the minimum", "bbox": [406.0, 452.0, 741.0, 467.0]}, {"text": "monitoring requirements and the prevention and management", "bbox": [406.0, 468.0, 740.0, 481.0]}, {"text": "of adverse events from sedation. This guideline encompasses the", "bbox": [406.0, 483.0, 740.0, 496.0]}, {"text": "commonly used drugs for sedation, interactions and postpro-", "bbox": [406.0, 497.0, 739.0, 510.0]}, {"text": "cedure discharge criteria. The indications and criteria for deep", "bbox": [406.0, 511.0, 740.0, 525.0]}, {"text": "sedation or general anaesthetic for endoscopic procedures by", "bbox": [406.0, 526.0, 739.0, 540.0]}, {"text": "anaesthesiologists are also detailed. These guidelines update the", "bbox": [407.0, 540.0, 740.0, 555.0]}, {"text": "previous 2013 guidelines. 1", "bbox": [406.0, 555.0, 542.0, 570.0]}], "type": "Text", "position": 10}, {"raw_context": [{"text": "DEVELOPMENT OF GUIDELINES", "bbox": [406.0, 589.0, 581.0, 602.0]}], "type": "Section-header", "position": 11}, {"raw_context": [{"text": "This guideline was commissioned by the BSG Endoscopy", "bbox": [407.0, 604.0, 739.0, 618.0]}, {"text": "Committee and developed in collaboration with representatives", "bbox": [406.0, 619.0, 740.0, 633.0]}, {"text": "from key stakeholders, including the Joint Advisory Group on", "bbox": [406.0, 634.0, 740.0, 648.0]}, {"text": "GI Endoscopy (JAG), the Royal College of Anaesthetists (RCoA)", "bbox": [406.0, 649.0, 740.0, 662.0]}, {"text": "and the British Society of Gastroenterology Nurses Association", "bbox": [407.0, 663.0, 741.0, 677.0]}, {"text": "(BSGNA). The aim of the guideline is to review and update", "bbox": [406.0, 678.0, 740.0, 692.0]}, {"text": "the previous 2013 guideline, encompassing advances and the", "bbox": [406.0, 693.0, 740.0, 707.0]}, {"text": "complexity of endoscopic procedures carried out currently. The", "bbox": [406.0, 707.0, 740.0, 721.0]}, {"text": "guideline development group (GDG) members were selected", "bbox": [406.0, 722.0, 740.0, 736.0]}, {"text": "from the BSG Endoscopy Committee as well as representatives", "bbox": [406.0, 737.0, 740.0, 751.0]}, {"text": "from affiliated committees and stakeholder organisations. The", "bbox": [406.0, 751.0, 740.0, 765.0]}, {"text": "BSG also advertised for two other members of the BSG (not", "bbox": [406.0, 766.0, 740.0, 780.0]}, {"text": "members of the Endoscopy Committee) to apply for positions", "bbox": [406.0, 781.0, 740.0, 795.0]}, {"text": "within the GDG, via submission of a curriculum vitae and", "bbox": [406.0, 796.0, 740.0, 810.0]}, {"text": "supporting statement. Two patient representatives were also", "bbox": [406.0, 810.0, 740.0, 824.0]}, {"text": "invited to form part of the GDG, one through the Royal College", "bbox": [406.0, 824.0, 739.0, 839.0]}, {"text": "of Physicians Patient Involvement Unit.", "bbox": [406.0, 840.0, 612.0, 853.0]}, {"text": "The GDG met via multiple teleconferences using both Micro-", "bbox": [418.0, 854.0, 739.0, 868.0]}, {"text": "soft Teams and face-to-face meetings. The domains for the guide-", "bbox": [406.0, 869.0, 739.0, 883.0]}, {"text": "line were discussed in detail. As these guidelines have an impact", "bbox": [406.0, 883.0, 740.0, 898.0]}, {"text": "on several groups of health professionals, stakeholders were", "bbox": [406.0, 899.0, 740.0, 912.0]}, {"text": "invited to comment on the agreed domains to be covered by the", "bbox": [406.0, 913.0, 740.0, 927.0]}, {"text": "guideline. These stakeholders included RCoA, JAG, Association", "bbox": [406.0, 928.0, 740.0, 941.0]}, {"text": "of Upper Gastrointestinal Surgery of Great Britain and Ireland", "bbox": [406.0, 942.0, 740.0, 955.0]}, {"text": "(AUGIS), Association of Coloproctology of Great Britain and", "bbox": [406.0, 957.0, 740.0, 971.0]}, {"text": "Ireland (ACPGBI), British Geriatric Society (BGS) and British", "bbox": [406.0, 971.0, 741.0, 986.0]}, {"text": "Society of Gynaecology and Pancreatic Society of Great Britain", "bbox": [406.0, 986.0, 740.0, 1000.0]}], "type": "Text", "position": 12}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/消化科/_2023 BSG指南：胃肠内窥镜检查中的镇静.pdf", "page_num": 5}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": null, "type3": null, "type4": null, "type5": null, "type6": "有用性#9#9#Sidhu R, et al. Gut 2023;0:1–27. doi:10.1136/gutjnl-2023-330396为页脚内容"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:41", "update_time": "2024-05-07 23:47:03"}
{"id": 1082564, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 738, "source_info": {"seq_id": "eca29fe3-356e-4590-b809-369ff33c74ce", "title": null, "text": "【0】页码:4\n 4\n\n【1】 Table 2 – TNM clinical and pathological classification of penile cancer according to the Union for International Cancer Control/American Joint Committee on Cancer 8th edition\n\n【2】 Clinical classification\n\n【3】 T: primary tumour\n\n【4】 cNO: No palpable or visibly enlarged inguinal lymph nodes\n\n【5】 cN1: Palpable mobile solitary inguinal lymph node\n\n【6】 cN2: Palpable mobile multiple or bilateral inguinal lymph nodes\n\n【7】 cN3: Fixed inguinal nodal mass or pelvic lymphadenopathy, unilateral or bilateral\n\n【8】 M: distant metastasis\n\n【9】 cMO: No distant metastasis\n\n【10】 cM1: Distant metastasis\n\n【11】 Pathological classification\n\n【12】 The pT categories correspond to the clinical T categories The pN categories are based on biopsy or surgical excision.\n\n【13】pN: regional lymph nodes\n\n【14】 pNX: Regional lymph nodes cannot be assessed pNO: No regional lymph node metastasis pN1: Metastasis in one or two inguinal lymph nodes (unilateral) pN2: Metastasis in more than two unilateral inguinal nodes or bilateral inguinal lymph nodes pN3: Metastasis in pelvic lymph node(s), unilateral or bilateral or extranodal extension of regional lymph node metastasis\n\n【15】 pM : distant metastasis\n\n【16】 pM1: Distant metastasis microscopically confirmed\n\n【17】 G: histopathological grading\n\n【18】 GX: Grade of differentiation cannot be assessed\n\n【19】 G1: Well differentiated\n\n【20】 G2:\n\n【21】 Moderately differentiated\n\n【22】 G3: Poorly differentiated\n\n【23】 G4: Undifferentiated\n\n【24】 * Including verrucous carcinoma.\n\n【25】 Lymph node staging 3.3.3.\n\n【26】On the basis of careful palpation of both groins, patients can be divided into those without suspicious lymph nodes (LNs) on physical examination (clinically node-negative, cNO) and those with palpable LNs (clinically node-positive, cN+).\n\n【27】Among patients with cN0 groins, 20–25% may still harbour occult metastasis. A nonrandomised controlled trial observed that early LN surgery led to a 3-yr survival rate of 84% in comparison to 35% for patients who underwent delayed LN surgery [ 25 ]. Therefore, detection of lymphatic spread as early as possible is crucial. Unfortunately, current noninvasive staging options such as computed tomography (CT) and positron emission tomography (PET)/CT are not reliable enough to detect micrometastatic disease, and should not be routinely performed in patients with cN0 status [ 26 – 28 ]. As a result, surgical staging remains indispensable, but is associated with considerable morbidity and represents overtreatment in the majority of patients.\n\n【28】To select patients who are at risk of nodal metastases, risk categories have been established. In patients with low-risk tumours (pTa, pTis, and pT1a G1), the risk of metastases is too low to justify surgical staging. pT1a G2 tumours are considered to be of intermediate risk and are\n\n【29】 associated with a 6–8% probability of micrometastatic LN disease, whereas the risk for pT1b G2 tumours is 22-30% [29,30] . Therefore, surgical staging is recommended for all high-risk tumours ( > pT1b). For intermediate-risk tumours, the risk of LN metastasis should be balanced against the morbidity of surgical staging on a case-by-case basis.\n\n【30】Inguinal LN dissection (ILND) is the most reliable surgical staging procedure but is associated with high morbidity, which can be reduced if modified templates or minimally invasive techniques are applied [ 31 , 32 ]. Of all surgical staging modalities, dynamic sentinel node biopsy (DSNB) has the lowest morbidity while retaining high diagnostic accuracy, especially in high-volume centres (sensitivity 92– 96%, false-negative rate 4–8%, complication rate 6–14%) [33–36] . In the case of a positive sentinel node, ipsilateral completion ILND is indicated [ 37 ]. In centres that offer DSNB, inguinal US + fine-needle aspiration cytology (FNAC) of sonographically abnormal nodes can reduce the need for DSNB when tumour-positive, allowing for earlier therapeutic LN dissection [33] .\n\n【31】Among patients with cN+ status, nodal metastases are present in 45–80% of cases [38] . Pathological confirmation (via biopsy) and additional imaging for staging of pelvic", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "4", "bbox": [61.0, 43.0, 70.0, 54.0]}], "type": "Text", "position": 0}, {"raw_context": [{"text": "Table 2 – TNM clinical and pathological classification of penile cancer according to the Union for International Cancer Control/American Joint Committee", "bbox": [68.0, 87.0, 725.0, 100.0]}, {"text": "on Cancer 8th edition", "bbox": [68.0, 100.0, 166.0, 112.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "Clinical classification", "bbox": [71.0, 120.0, 172.0, 133.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": "T: primary tumour", "bbox": [72.0, 138.0, 146.0, 150.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "cNO: No palpable or visibly enlarged inguinal lymph nodes", "bbox": [83.0, 294.0, 331.0, 306.0]}], "type": "Text", "position": 8}, {"raw_context": [{"text": "cN1: Palpable mobile solitary inguinal lymph node", "bbox": [84.0, 307.0, 299.0, 319.0]}], "type": "Text", "position": 9}, {"raw_context": [{"text": "cN2: Palpable mobile multiple or bilateral inguinal lymph nodes", "bbox": [84.0, 318.0, 355.0, 330.0]}], "type": "Text", "position": 10}, {"raw_context": [{"text": "cN3: Fixed inguinal nodal mass or pelvic lymphadenopathy, unilateral or bilateral", "bbox": [84.0, 330.0, 427.0, 341.0]}], "type": "Text", "position": 11}, {"raw_context": [{"text": "M: distant metastasis", "bbox": [73.0, 341.0, 156.0, 353.0]}], "type": "Text", "position": 12}, {"raw_context": [{"text": "cMO: No distant metastasis", "bbox": [72.0, 357.0, 190.0, 368.0]}], "type": "Text", "position": 13}, {"raw_context": [{"text": "cM1: Distant metastasis", "bbox": [84.0, 368.0, 191.0, 380.0]}], "type": "Text", "position": 14}, {"raw_context": [{"text": "Pathological classification", "bbox": [72.0, 379.0, 185.0, 390.0]}], "type": "Text", "position": 15}, {"raw_context": [{"text": "The pT categories correspond to the clinical T categories", "bbox": [73.0, 396.0, 302.0, 407.0]}, {"text": "The pN categories are based on biopsy or surgical excision.", "bbox": [84.0, 407.0, 325.0, 418.0]}, {"text": "pN: regional lymph nodes", "bbox": [72.0, 420.0, 174.0, 430.0]}], "type": "Text", "position": 16}, {"raw_context": [{"text": "pNX: Regional lymph nodes cannot be assessed", "bbox": [72.0, 435.0, 272.0, 446.0]}, {"text": "pNO: No regional lymph node metastasis", "bbox": [84.0, 447.0, 260.0, 458.0]}, {"text": "pN1: Metastasis in one or two inguinal lymph nodes (unilateral)", "bbox": [83.0, 459.0, 355.0, 468.0]}, {"text": "pN2: Metastasis in more than two unilateral inguinal nodes or bilateral inguinal lymph nodes", "bbox": [85.0, 470.0, 475.0, 479.0]}, {"text": "pN3: Metastasis in pelvic lymph node(s), unilateral or bilateral or extranodal extension of regional lymph node metastasis", "bbox": [86.0, 480.0, 591.0, 493.0]}], "type": "Text", "position": 17}, {"raw_context": [{"text": "pM : distant metastasis", "bbox": [72.0, 492.0, 162.0, 503.0]}], "type": "Text", "position": 18}, {"raw_context": [{"text": "pM1: Distant metastasis microscopically confirmed", "bbox": [72.0, 509.0, 289.0, 520.0]}], "type": "Text", "position": 19}, {"raw_context": [{"text": "G: histopathological grading", "bbox": [72.0, 519.0, 182.0, 532.0]}], "type": "Text", "position": 20}, {"raw_context": [{"text": "GX: Grade of differentiation cannot be assessed", "bbox": [72.0, 535.0, 274.0, 548.0]}], "type": "Text", "position": 21}, {"raw_context": [{"text": "G1: Well differentiated", "bbox": [83.0, 548.0, 187.0, 558.0]}], "type": "Text", "position": 22}, {"raw_context": [{"text": "G2:", "bbox": [84.0, 559.0, 104.0, 570.0]}], "type": "Text", "position": 23}, {"raw_context": [{"text": "Moderately differentiated", "bbox": [105.0, 559.0, 213.0, 570.0]}], "type": "Text", "position": 24}, {"raw_context": [{"text": "G3: Poorly differentiated", "bbox": [84.0, 570.0, 194.0, 581.0]}], "type": "Text", "position": 25}, {"raw_context": [{"text": "G4: Undifferentiated", "bbox": [84.0, 583.0, 177.0, 594.0]}], "type": "Text", "position": 26}, {"raw_context": [{"text": "* Including verrucous carcinoma.", "bbox": [62.0, 597.0, 197.0, 610.0]}], "type": "Text", "position": 27}, {"raw_context": [{"text": "Lymph node staging", "bbox": [109.0, 645.0, 210.0, 659.0]}, {"text": "3.3.3.", "bbox": [62.0, 646.0, 89.0, 658.0]}, {"text": "On the basis of careful palpation of both groins, patients can", "bbox": [60.0, 660.0, 383.0, 674.0]}, {"text": "be divided into those without suspicious lymph nodes (LNs)", "bbox": [61.0, 675.0, 383.0, 690.0]}, {"text": "on physical examination (clinically node-negative, cNO) and", "bbox": [61.0, 691.0, 383.0, 705.0]}, {"text": "those with palpable LNs (clinically node-positive, cN+).", "bbox": [61.0, 706.0, 361.0, 720.0]}, {"text": "Among patients with cN0 groins, 20–25% may still har-", "bbox": [77.0, 721.0, 381.0, 736.0]}, {"text": "bour occult metastasis. A nonrandomised controlled trial", "bbox": [61.0, 737.0, 383.0, 751.0]}, {"text": "observed that early LN surgery led to a 3-yr survival rate", "bbox": [60.0, 752.0, 383.0, 766.0]}, {"text": "of 84% in comparison to 35% for patients who underwent", "bbox": [60.0, 767.0, 383.0, 781.0]}, {"text": "delayed LN surgery [ 25 ]. Therefore, detection of lymphatic", "bbox": [61.0, 783.0, 382.0, 796.0]}, {"text": "spread as early as possible is crucial. Unfortunately, current", "bbox": [61.0, 798.0, 383.0, 811.0]}, {"text": "noninvasive staging options such as computed tomography", "bbox": [61.0, 813.0, 383.0, 827.0]}, {"text": "(CT) and positron emission tomography (PET)/CT are not", "bbox": [60.0, 829.0, 382.0, 842.0]}, {"text": "reliable enough to detect micrometastatic disease, and", "bbox": [61.0, 844.0, 383.0, 858.0]}, {"text": "should not be routinely performed in patients with cN0 sta-", "bbox": [61.0, 859.0, 382.0, 873.0]}, {"text": "tus [ 26 – 28 ]. As a result, surgical staging remains indispens-", "bbox": [61.0, 875.0, 381.0, 888.0]}, {"text": "able, but is associated with considerable morbidity and", "bbox": [62.0, 891.0, 383.0, 903.0]}, {"text": "represents overtreatment in the majority of patients.", "bbox": [61.0, 905.0, 349.0, 919.0]}, {"text": "To select patients who are at risk of nodal metastases,", "bbox": [78.0, 921.0, 382.0, 934.0]}, {"text": "risk categories have been established. In patients with", "bbox": [61.0, 936.0, 383.0, 949.0]}, {"text": "low-risk tumours (pTa, pTis, and pT1a G1), the risk of", "bbox": [61.0, 951.0, 383.0, 965.0]}, {"text": "metastases is too low to justify surgical staging. pT1a G2", "bbox": [61.0, 967.0, 382.0, 980.0]}, {"text": "tumours are considered to be of intermediate risk and are", "bbox": [61.0, 982.0, 383.0, 995.0]}], "type": "Text", "position": 28}, {"raw_context": [{"text": "associated with a 6–8% probability of micrometastatic LN", "bbox": [403.0, 645.0, 726.0, 660.0]}, {"text": "disease, whereas the risk for pT1b G2 tumours is 22-30%", "bbox": [402.0, 660.0, 726.0, 675.0]}, {"text": "[29,30] . Therefore, surgical staging is recommended for all", "bbox": [402.0, 677.0, 726.0, 690.0]}, {"text": "high-risk tumours ( > pT1b). For intermediate-risk tumours,", "bbox": [402.0, 692.0, 726.0, 706.0]}, {"text": "the risk of LN metastasis should be balanced against the", "bbox": [402.0, 706.0, 727.0, 722.0]}, {"text": "morbidity of surgical staging on a case-by-case basis.", "bbox": [403.0, 722.0, 694.0, 736.0]}, {"text": "Inguinal LN dissection (ILND) is the most reliable surgical", "bbox": [418.0, 737.0, 727.0, 751.0]}, {"text": "staging procedure but is associated with high morbidity,", "bbox": [403.0, 753.0, 725.0, 767.0]}, {"text": "which can be reduced if modified templates or minimally", "bbox": [403.0, 769.0, 726.0, 782.0]}, {"text": "invasive techniques are applied [ 31 , 32 ]. Of all surgical stag-", "bbox": [403.0, 784.0, 725.0, 797.0]}, {"text": "ing modalities, dynamic sentinel node biopsy (DSNB) has", "bbox": [402.0, 798.0, 727.0, 813.0]}, {"text": "the lowest morbidity while retaining high diagnostic accu-", "bbox": [402.0, 814.0, 725.0, 828.0]}, {"text": "racy, especially in high-volume centres (sensitivity 92–", "bbox": [402.0, 829.0, 725.0, 843.0]}, {"text": "96%, false-negative rate 4–8%, complication rate 6–14%)", "bbox": [402.0, 844.0, 726.0, 859.0]}, {"text": "[33–36] . In the case of a positive sentinel node, ipsilateral", "bbox": [402.0, 860.0, 726.0, 874.0]}, {"text": "completion ILND is indicated [ 37 ]. In centres that offer", "bbox": [402.0, 875.0, 725.0, 889.0]}, {"text": "DSNB, inguinal US + fine-needle aspiration cytology (FNAC)", "bbox": [403.0, 889.0, 726.0, 906.0]}, {"text": "of sonographically abnormal nodes can reduce the need for", "bbox": [403.0, 906.0, 726.0, 920.0]}, {"text": "DSNB when tumour-positive, allowing for earlier therapeu-", "bbox": [402.0, 921.0, 725.0, 935.0]}, {"text": "tic LN dissection [33] .", "bbox": [402.0, 935.0, 522.0, 951.0]}, {"text": "Among patients with cN+ status, nodal metastases are", "bbox": [419.0, 951.0, 726.0, 965.0]}, {"text": "present in 45–80% of cases [38] . Pathological confirmation", "bbox": [403.0, 967.0, 727.0, 981.0]}, {"text": "(via biopsy) and additional imaging for staging of pelvic", "bbox": [403.0, 982.0, 726.0, 997.0]}], "type": "Text", "position": 29}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/泌尿外科/2023 EAU／ASCO指南：阴茎癌（更新版）.pdf", "page_num": 4}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "缺少换行#12#12#The pN categories are ...另起一行\n缺少换行#14#14#分别以pNO:    pN1:   pN2:   pN3: 另起一行\n多余换行#21#21#Moderately differentiated与20段联接\n序号格式不一致#25#25#Lymph node staging 3.3.3.  序号应该在前\n多余换行#29#29#associated with a 6–8% ...与28段联接", "type3": "无关文本#0#0#4 页码\n无关文本#27#31# [ 25 ]类似的 [    ].类引用过多", "type4": "语义不完整#4#4# cNO: No palpable or visibly enlarged...前面缺少内容", "type5": null, "type6": null}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:41", "update_time": "2024-05-08 01:04:44"}
{"id": 1082563, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 738, "source_info": {"seq_id": "c39f7f4a-817d-42a9-b490-35253d9b1c71", "title": null, "text": "【0】页码:2\n\n【1】## Bone Acquisition And Peak Bone Mass\n\n【2】\n Bone is a living structure comprising a matrix of collagen, hydroxyapatite crystals, and noncollagenous proteins. The matrix becomes mineralized with deposits of calcium and phosphate, which confer strength to the structure. 17 Bone mineral deposition begins in utero, and bone mineral content increases 40-fold from birth to adulthood. BMD of the lumbar spine (BMDLS) showed the greatest increase from the age of 11 to 13 years in girls and from 12 to 14 years in boys. BMD of the total body less head (BMDTBLH) shows a relatively modest increase from the age of 10 to 15 years in girls and from 10 to 18 years in boys. 451 In Korea, peak bone mass is achieved at approximately 19 and 21 years of age in girls and boys, respectively. 6.7 ) There are numerous factors that affect bone mineral deposition and bone mass formation. These are largely divided into 2 groups: nonmodifiable factors including genetics, sex, and ethnicity and modifiable factors including nutrition, exercise, lifestyle,body weight and composition,and hormonal status. 8 1\n\n【3】## Bmd Measurement\n\n【4】\n BMD in children and adolescents is most commonly assessed , with dual-energy x-ray absorptiometry (DXA) because it is /less time-consuming and more precise and widely available, safer, and less costly than other options. 97 The posteroanterior lumbar spine and total body less head are the preferred skeletal sites for BMD measurement in most pediatric patients, while other sites are recommended only for specific cases. 91 BMDLS measurement is a feasible and reproducible method, especially for infants and young children aged 0–5 years. BMDTBLH measurement can be used for children aged 3 years and older. 97 The standard methods of BMD evaluation in children and adolescents are performed using BMD z -score calculations according to comparisons with reference data in children of each age, sex, pubertal stage, and ethnicity. 679 ) In children with short stature or growth delay, BMDLS should be adjusted with bone mineral apparent density or height z -score and BMDTBLH with the height z -score. 9 Two types of bone densitometers (GE Lunar Prodigy Advance bone densitometer, Absolute Medical Inc, Stony Point, NY, USA and Hologic QDR densitometer, Hologic Inc, Bedford, MA, USA) were used. Normal BMD reference values for Koreans were compared to each densitometry measurement. 67 )\n\n【5】## Definition Of Low Bmd And Osteoporosis\n\n【6】\n Low BMD is the preferred term for DXA reports in children when the BMD z -score is less than or equal to -2.0 standard deviation (SD). 97 Osteoporosis in children is defined as the presence of ≥ 1 vertebral compression fracture in the absence of local disease or high-energy trauma or the presence of both a clinically significant fracture history and a BMD z -score of -2.0 or lower. A clinically significant fracture history includes at least\n\n【7】 Table 1. Causes of osteoporosis in children and adolescents\n\n【8】 Primary Osteogenesis imperfecta ldiopathic juvenile osteoporosis Fibrous dysplasia Cleido-crainial dysplasia Hajdu-Cheney syndrome Osteoporosis-pseudoglioma syndrome Ehlers-Danlos syndrome Marfan syndrome Calvarial doughnut lesions Secondary Endocrine disorders Anorexia nervosa Hypogonadism Growth hormone deficiency\n\n【9】\n Anorexia nervosa Hypogonadism Growth hormone deficiency Hyperthyroidism Hypothyroidism Hyperparathyroidism Cushing disease Type I diabetes Neuromuscular disorder.\n\n【10】Cerebral palsy Duchenne muscular dystrophy Spinal muscular atrophy Connective tissue disorders Systemic lupus erythematosus Juvenile idiopathic arthritis Juvenile dermatomyositis Gastrointestinal disorders Inflammatory bowel disease Celiac disease Malabsorption Milk intolerance Chronic obstructive jaundice Chronic hepatitis Hemato-oncologic disorders Hemoglobinopathy Leukemia Lymphoma Renal disorders Chronic renal failure Kidney transplatation Others Immobilization Poor calcium intake Inborn error of metabolism Excessive exercise Medication Glucocorticoids Anticonvulsants Chemotherapeutic agents Immune suppressants Anticoagulant Proton pump inhibitor Selective serotonin reuptake inhibitor\n\n【11】 Chronic hepatitis Primary biliary cirrhosis and other cirrhosis Hemoglobinopathy Leukemia Lymphoma Chronic renal failure Kidney transplatation Immobilization\n", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "Bone acquisition and peak bone mass", "bbox": [66.0, 94.0, 316.0, 111.0]}], "type": "Section-header", "position": 2}, {"raw_context": [{"text": "Bone is a living structure comprising a matrix of collagen,", "bbox": [77.0, 127.0, 382.0, 142.0]}, {"text": "hydroxyapatite crystals, and noncollagenous proteins. The", "bbox": [65.0, 144.0, 383.0, 158.0]}, {"text": "matrix becomes mineralized with deposits of calcium and", "bbox": [66.0, 159.0, 383.0, 174.0]}, {"text": "phosphate, which confer strength to the structure. 17", "bbox": [66.0, 176.0, 315.0, 190.0]}, {"text": "Bone mineral deposition begins in utero, and bone mineral", "bbox": [77.0, 191.0, 383.0, 206.0]}, {"text": "content increases 40-fold from birth to adulthood. BMD of", "bbox": [65.0, 207.0, 383.0, 221.0]}, {"text": "the lumbar spine (BMDLS) showed the greatest increase from", "bbox": [65.0, 223.0, 383.0, 238.0]}, {"text": "the age of 11 to 13 years in girls and from 12 to 14 years in", "bbox": [66.0, 239.0, 383.0, 253.0]}, {"text": "boys. BMD of the total body less head (BMDTBLH) shows a", "bbox": [66.0, 254.0, 383.0, 269.0]}, {"text": "relatively modest increase from the age of 10 to 15 years in girls", "bbox": [65.0, 270.0, 383.0, 285.0]}, {"text": "and from 10 to 18 years in boys. 451 In Korea, peak bone mass is", "bbox": [66.0, 285.0, 383.0, 300.0]}, {"text": "achieved at approximately 19 and 21 years of age in girls and", "bbox": [66.0, 300.0, 383.0, 316.0]}, {"text": "boys, respectively. 6.7 )", "bbox": [66.0, 317.0, 165.0, 332.0]}, {"text": "There are numerous factors that affect bone mineral", "bbox": [78.0, 332.0, 383.0, 348.0]}, {"text": "deposition and bone mass formation. These are largely divided", "bbox": [64.0, 349.0, 383.0, 363.0]}, {"text": "into 2 groups: nonmodifiable factors including genetics, sex, and", "bbox": [65.0, 364.0, 383.0, 379.0]}, {"text": "ethnicity and modifiable factors including nutrition, exercise,", "bbox": [65.0, 381.0, 383.0, 394.0]}, {"text": "lifestyle,body weight and composition,and hormonal status. 8 1", "bbox": [65.0, 396.0, 371.0, 411.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "BMD measurement", "bbox": [66.0, 427.0, 199.0, 446.0]}], "type": "Section-header", "position": 4}, {"raw_context": [{"text": "BMD in children and adolescents is most commonly assessed", "bbox": [77.0, 462.0, 383.0, 478.0]}, {"text": ", with dual-energy x-ray absorptiometry (DXA) because it is", "bbox": [64.0, 479.0, 383.0, 493.0]}, {"text": "/less time-consuming and more precise and widely available,", "bbox": [62.0, 494.0, 383.0, 509.0]}, {"text": "safer, and less costly than other options. 97 The posteroanterior", "bbox": [66.0, 510.0, 383.0, 525.0]}, {"text": "lumbar spine and total body less head are the preferred skeletal", "bbox": [66.0, 525.0, 383.0, 540.0]}, {"text": "sites for BMD measurement in most pediatric patients, while", "bbox": [66.0, 540.0, 383.0, 556.0]}, {"text": "other sites are recommended only for specific cases. 91 BMDLS", "bbox": [65.0, 557.0, 383.0, 572.0]}, {"text": "measurement is a feasible and reproducible method, especially", "bbox": [66.0, 572.0, 382.0, 587.0]}, {"text": "for infants and young children aged 0–5 years. BMDTBLH", "bbox": [66.0, 589.0, 384.0, 603.0]}, {"text": "measurement can be used for children aged 3 years and older. 97", "bbox": [66.0, 604.0, 381.0, 619.0]}, {"text": "The standard methods of BMD evaluation in children and", "bbox": [66.0, 621.0, 382.0, 634.0]}, {"text": "adolescents are performed using BMD z -score calculations", "bbox": [66.0, 636.0, 383.0, 651.0]}, {"text": "according to comparisons with reference data in children of", "bbox": [66.0, 652.0, 383.0, 666.0]}, {"text": "each age, sex, pubertal stage, and ethnicity. 679 ) In children with", "bbox": [65.0, 668.0, 383.0, 682.0]}, {"text": "short stature or growth delay, BMDLS should be adjusted", "bbox": [66.0, 683.0, 383.0, 698.0]}, {"text": "with bone mineral apparent density or height z -score and", "bbox": [66.0, 698.0, 383.0, 713.0]}, {"text": "BMDTBLH with the height z -score. 9", "bbox": [66.0, 714.0, 245.0, 729.0]}, {"text": "Two types of bone densitometers (GE Lunar Prodigy Advance", "bbox": [78.0, 730.0, 383.0, 744.0]}, {"text": "bone densitometer, Absolute Medical Inc, Stony Point, NY, USA", "bbox": [63.0, 745.0, 383.0, 760.0]}, {"text": "and Hologic QDR densitometer, Hologic Inc, Bedford, MA,", "bbox": [66.0, 762.0, 384.0, 776.0]}, {"text": "USA) were used. Normal BMD reference values for Koreans", "bbox": [66.0, 777.0, 383.0, 792.0]}, {"text": "were compared to each densitometry measurement. 67 )", "bbox": [66.0, 793.0, 334.0, 807.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "Definition of low BMD and osteoporosis", "bbox": [66.0, 826.0, 341.0, 841.0]}], "type": "Section-header", "position": 6}, {"raw_context": [{"text": "Low BMD is the preferred term for DXA reports in children", "bbox": [77.0, 860.0, 383.0, 874.0]}, {"text": "when the BMD z -score is less than or equal to -2.0 standard", "bbox": [66.0, 875.0, 383.0, 890.0]}, {"text": "deviation (SD). 97 Osteoporosis in children is defined as the", "bbox": [65.0, 891.0, 383.0, 906.0]}, {"text": "presence of ≥ 1 vertebral compression fracture in the absence of", "bbox": [66.0, 907.0, 383.0, 922.0]}, {"text": "local disease or high-energy trauma or the presence of both a", "bbox": [66.0, 923.0, 383.0, 938.0]}, {"text": "clinically significant fracture history and a BMD z -score of -2.0", "bbox": [64.0, 938.0, 383.0, 953.0]}, {"text": "or lower. A clinically significant fracture history includes at least", "bbox": [64.0, 953.0, 383.0, 968.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "Table 1. Causes of osteoporosis in children and adolescents", "bbox": [412.0, 93.0, 696.0, 108.0]}], "type": "Text", "position": 8}, {"raw_context": [{"text": "Primary", "bbox": [411.0, 110.0, 453.0, 125.0]}, {"text": "Osteogenesis imperfecta", "bbox": [412.0, 127.0, 519.0, 140.0]}, {"text": "ldiopathic juvenile osteoporosis", "bbox": [410.0, 142.0, 548.0, 155.0]}, {"text": "Fibrous dysplasia", "bbox": [410.0, 156.0, 485.0, 171.0]}, {"text": "Cleido-crainial dysplasia", "bbox": [410.0, 172.0, 516.0, 186.0]}, {"text": "Hajdu-Cheney syndrome", "bbox": [410.0, 187.0, 522.0, 202.0]}, {"text": "Osteoporosis-pseudoglioma syndrome", "bbox": [410.0, 202.0, 577.0, 217.0]}, {"text": "Ehlers-Danlos syndrome", "bbox": [410.0, 218.0, 516.0, 232.0]}, {"text": "Marfan syndrome", "bbox": [410.0, 233.0, 489.0, 247.0]}, {"text": "Calvarial doughnut lesions", "bbox": [410.0, 247.0, 525.0, 262.0]}, {"text": "Secondary", "bbox": [411.0, 264.0, 469.0, 278.0]}, {"text": "Endocrine disorders", "bbox": [412.0, 280.0, 498.0, 294.0]}, {"text": "Anorexia nervosa", "bbox": [419.0, 296.0, 495.0, 309.0]}, {"text": "Hypogonadism", "bbox": [418.0, 310.0, 488.0, 323.0]}, {"text": "Growth hormone deficiency", "bbox": [418.0, 325.0, 541.0, 339.0]}], "type": "Table", "position": 9}, {"raw_context": [{"text": "Anorexia nervosa", "bbox": [419.0, 296.0, 495.0, 309.0]}, {"text": "Hypogonadism", "bbox": [418.0, 310.0, 488.0, 323.0]}, {"text": "Growth hormone deficiency", "bbox": [418.0, 325.0, 541.0, 339.0]}, {"text": "Hyperthyroidism", "bbox": [418.0, 341.0, 492.0, 355.0]}, {"text": "Hypothyroidism", "bbox": [418.0, 356.0, 490.0, 370.0]}, {"text": "Hyperparathyroidism", "bbox": [418.0, 373.0, 511.0, 386.0]}, {"text": "Cushing disease", "bbox": [414.0, 388.0, 490.0, 401.0]}, {"text": "Type I diabetes", "bbox": [418.0, 402.0, 490.0, 417.0]}, {"text": "Neuromuscular disorder.", "bbox": [412.0, 420.0, 515.0, 432.0]}, {"text": "Cerebral palsy", "bbox": [418.0, 434.0, 481.0, 447.0]}, {"text": "Duchenne muscular dystrophy", "bbox": [418.0, 450.0, 551.0, 464.0]}, {"text": "Spinal muscular atrophy", "bbox": [419.0, 466.0, 524.0, 478.0]}, {"text": "Connective tissue disorders", "bbox": [413.0, 480.0, 530.0, 493.0]}, {"text": "Systemic lupus erythematosus", "bbox": [418.0, 495.0, 551.0, 510.0]}, {"text": "Juvenile idiopathic arthritis", "bbox": [419.0, 510.0, 535.0, 525.0]}, {"text": "Juvenile dermatomyositis", "bbox": [419.0, 525.0, 529.0, 539.0]}, {"text": "Gastrointestinal disorders", "bbox": [412.0, 540.0, 522.0, 555.0]}, {"text": "Inflammatory bowel disease", "bbox": [418.0, 557.0, 541.0, 570.0]}, {"text": "Celiac disease", "bbox": [418.0, 572.0, 481.0, 585.0]}, {"text": "Malabsorption", "bbox": [418.0, 587.0, 483.0, 601.0]}, {"text": "Milk intolerance", "bbox": [418.0, 603.0, 488.0, 616.0]}, {"text": "Chronic obstructive jaundice", "bbox": [418.0, 618.0, 543.0, 632.0]}, {"text": "Chronic hepatitis", "bbox": [418.0, 634.0, 493.0, 647.0]}, {"text": "Hemato-oncologic disorders", "bbox": [413.0, 664.0, 541.0, 678.0]}, {"text": "Hemoglobinopathy", "bbox": [418.0, 680.0, 505.0, 693.0]}, {"text": "Leukemia", "bbox": [418.0, 695.0, 464.0, 709.0]}, {"text": "Lymphoma", "bbox": [418.0, 710.0, 471.0, 725.0]}, {"text": "Renal disorders", "bbox": [412.0, 726.0, 479.0, 740.0]}, {"text": "Chronic renal failure", "bbox": [418.0, 743.0, 506.0, 754.0]}, {"text": "Kidney transplatation", "bbox": [418.0, 756.0, 512.0, 771.0]}, {"text": "Others", "bbox": [414.0, 773.0, 443.0, 786.0]}, {"text": "Immobilization", "bbox": [418.0, 788.0, 486.0, 801.0]}, {"text": "Poor calcium intake", "bbox": [418.0, 803.0, 504.0, 817.0]}, {"text": "Inborn error of metabolism", "bbox": [418.0, 818.0, 536.0, 832.0]}, {"text": "Excessive exercise", "bbox": [418.0, 833.0, 496.0, 847.0]}, {"text": "Medication", "bbox": [411.0, 848.0, 462.0, 863.0]}, {"text": "Glucocorticoids", "bbox": [418.0, 864.0, 487.0, 878.0]}, {"text": "Anticonvulsants", "bbox": [419.0, 879.0, 490.0, 893.0]}, {"text": "Chemotherapeutic agents", "bbox": [419.0, 897.0, 532.0, 909.0]}, {"text": "Immune suppressants", "bbox": [420.0, 911.0, 516.0, 923.0]}, {"text": "Anticoagulant", "bbox": [419.0, 926.0, 483.0, 940.0]}, {"text": "Proton pump inhibitor", "bbox": [418.0, 942.0, 516.0, 955.0]}, {"text": "Selective serotonin reuptake inhibitor", "bbox": [419.0, 957.0, 578.0, 970.0]}], "type": "Text", "position": 10}, {"raw_context": [{"text": "Chronic hepatitis", "bbox": [418.0, 634.0, 493.0, 647.0]}, {"text": "Primary biliary cirrhosis and other cirrhosis", "bbox": [419.0, 650.0, 598.0, 662.0]}, {"text": "Hemoglobinopathy", "bbox": [418.0, 680.0, 505.0, 693.0]}, {"text": "Leukemia", "bbox": [418.0, 695.0, 464.0, 709.0]}, {"text": "Lymphoma", "bbox": [418.0, 710.0, 471.0, 725.0]}, {"text": "Chronic renal failure", "bbox": [418.0, 743.0, 506.0, 754.0]}, {"text": "Kidney transplatation", "bbox": [418.0, 756.0, 512.0, 771.0]}, {"text": "Immobilization", "bbox": [418.0, 788.0, 486.0, 801.0]}], "type": "Table", "position": 14}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2022】全科室最全临床指南+专家共识（最全版）/2022全科室临床指南/内分泌科/KSPE：优化儿童和青少年骨健康的临床实践指南（2022）.pdf", "page_num": 2}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "缺少换行#2#2#Bone mineral deposition begins...\nThere are numerous factors...都另起一行\n缺少换行#4#4#Two types of bone densitometers ...另起一行", "type3": "无关文本#2#10# ...and boys, respectively. 6.7 )\n...strength to the structure. 17 像这样在.号或，号的开头或结尾出现的数字都是无关引用\n无关文本#11#11#原文内容找不到出处", "type4": "语义重复#9#9#Anorexia nervosa Hypogonadism Growth hormone deficiency 与上面8段后面重复", "type5": null, "type6": null}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:41", "update_time": "2024-05-07 19:33:00"}
{"id": 1082562, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 738, "source_info": {"seq_id": "ca68adf4-cee9-4aaf-8ebe-c7b46d2105d9", "title": null, "text": "【0】页码:5\n [8] [8]\n\n【1】 [9]\n\n【2】 [10]\n\n【3】 intracoronary imaging. Part 1, guidance and optimization of coronary interventions. An expert consensus document of the European Association of Percutaneous Cardiovascular Interventions [J]. Eur Heart J, 2018,39(35):3281-3300.\n\n【4】 Wijns W, Shite J, Jones MR, et al. Optical coherence tomography imaging during percutaneous coronary intervention impacts physician decision-making, ILUM- IEN I study[J].Eur Heart J,2015,36(47):3346-3355.\n\n【5】Ali ZA, Machara A, Genereux P, et al. Optical coherence tomography compared with intravascular ultra¬ sound and with angiography to guide coronary stent implantation(ILUMIEN III; OPTIMIZE PCI); a randomised controlled trial [J]. Lancet, 2016, 388 (10060):2618-2628.\n\n【6】Jones DA, Rathod KS, Koganti S, et al. Angiography\n\n【7】 Alone Versus Angiography Plus Optical Coherence Tomography to Guide Percutaneous Coronary Intervention: Outcomes From the Pan-London PCI Cohort [J]. JACC Cardiovasc Interv, 2018, 11 (14), 1313- 1321.\n\n【8】 [11] Meneveau N, Souteyrand G, Motreff P, et al. Optical Coherence Tomography to Optimize Results of Percutaneous Coronary Intervention in Patients with Non- ST-Elevation Acute Coronary Syndrome: Results of the Multicenter, Randomized DOCTORS Study (Does Optical Coherence Tomography Optimize Results of Stenting)[J].Circulation, 2016 , 134 (13), 906-917.\n\n【9】[12] Lee SY,Kim JS,Yoon HJ,et al.Early Strut Coverage in Patients Receiving Drug-Eluting Stents and its Implications for Dual Antiplatelet Therapy: A Randomized Trial [J]. JACC Cardiovasc Imaging, 2018, 11 (12):1810–1819.\n\n【10】[13] Chamié D,Costa JR Jr,Damiani LP,et al.Optical Co-\n\n【11】 herence Tomography Versus Intravascular Ultrasound and Angiography to Guide Percutaneous Coronary Interventions. The iSIGHT Randomized Trial[J]. Circ Cardiovasc Interv, 2021, 14(3): e009452.\n\n【12】[14] Croce K,Wollmuth J,Mathew R,et al.LightLab study [R] . EuroPCR , 2020 .\n\n【13】[15] Leistner DM, Riedel M, Steinbeck L, et al. Real-time\n\n【14】 optical coherence tomography coregistration with angiography in percutaneous coronary intervention-impact on physician decision-making. The OPTICO-in-\n\n【15】 tegration study[J]. Catheter Cardiovasc Interv, 2018, 92(1):30-37.\n\n【16】[16] Jia H, Dai J, Hou J, et al. Effective anti thrombotic therapy without stenting: intravascular optical coherence tomography-based management in plaque erosion.\n\n【17】(the EROSION study) [J]. Eur Heart J, 2017, 38 (11) , 792–800.\n\n【18】 [17] Jia H,Dai J,He L,et al.EROSION III,A Multicenter RCT of OCT-Guided Reperfusion in STEMI With Early Infarct Artery Patency[J].JACC Cardiovasc Interv,2022,15(8):846-856.\n\n【19】[18] Haddad K, Tanguay JF, Potter BJ, et al. Longer Inflation Duration and Predilation Sizing-Postdilation Improve Bioresorbable Scaffold Outcomes in a Longterm All-Comers Canadian Registry[J]. Can J Cardiol,2018,34(6):752-758 .\n\n【20】[19] Ortega-Paz L,Capodanno D,Gori T,et al.Predilation, sizing and post-dilation scoring in patients undergoing everolimus-eluting bioresorbable scaffold implantation for prediction of cardiac adverse events: development and internal validation of the PSP score[J].EuroIntervention, 2017, 12(17), 2110-2117.\n\n【21】[20] Jeger RV, Eccleshall S, Wan Ahmad WA, et al. Drug- Coated Balloons for Coronary Artery Disease: Third Report of the International DCB Consensus Group[J].\n\n【22】JACC Cardiovasc Interv,2020,13(12):1391-1402.\n\n【23】[21] Li L, Zhao L, Wang J, et al. Optical coherence tomography-guided drug coated balloon in non-small de novo coronary artery lesions, a prospective clinical research[J]. Am J Transl Res, 2021, 13 (10): 11617- 11624.\n\n【24】[22] Adriaenssens T,Joner M,Godschalk TC,et al.Optical\n\n【25】 Coherence Tomography Findings in Patients With Coronary Stent Thrombosis: A Report of the PRES- TIGE Consortium (Prevention of Late Stent Thrombosis by an Interdisciplinary Global European Effort) [J].Circulation, 2017, 136(11), 1007-1021.\n\n【26】[23] Souteyrand G, Amabile N, Mangin L, et al. Mechanisms of stent thrombosis analysed by optical coherence tomography: insights from the national PESTO French registry[J]. Eur Heart J, 2016,37(15):1208- 1216.\n\n【27】.2022-11-01)", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "[8] [8]", "bbox": [76.0, 189.0, 99.0, 204.0]}], "type": "Text", "position": 1}, {"raw_context": [{"text": "[9]", "bbox": [77.0, 261.0, 99.0, 275.0]}], "type": "Text", "position": 2}, {"raw_context": [{"text": "[10]", "bbox": [77.0, 368.0, 107.0, 380.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "intracoronary imaging. Part 1, guidance and optimiza-", "bbox": [106.0, 99.0, 381.0, 114.0]}, {"text": "tion of coronary interventions. An expert consensus", "bbox": [106.0, 116.0, 383.0, 131.0]}, {"text": "document of the European Association of Percutane-", "bbox": [107.0, 136.0, 381.0, 149.0]}, {"text": "ous Cardiovascular Interventions [J]. Eur Heart J,", "bbox": [106.0, 153.0, 382.0, 167.0]}, {"text": "2018,39(35):3281-3300.", "bbox": [107.0, 171.0, 235.0, 185.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": "Wijns W, Shite J, Jones MR, et al. Optical coherence", "bbox": [106.0, 189.0, 383.0, 204.0]}, {"text": "tomography imaging during percutaneous coronary in-", "bbox": [107.0, 206.0, 381.0, 220.0]}, {"text": "tervention impacts physician decision-making, ILUM-", "bbox": [107.0, 224.0, 381.0, 238.0]}, {"text": "IEN I study[J].Eur Heart J,2015,36(47):3346-3355.", "bbox": [107.0, 242.0, 381.0, 257.0]}, {"text": "Ali ZA, Machara A, Genereux P, et al. Optical coher-", "bbox": [106.0, 260.0, 380.0, 275.0]}, {"text": "ence tomography compared with intravascular ultra¬", "bbox": [107.0, 277.0, 381.0, 292.0]}, {"text": "sound and with angiography to guide coronary stent", "bbox": [107.0, 297.0, 383.0, 309.0]}, {"text": "implantation(ILUMIEN III; OPTIMIZE PCI); a ran-", "bbox": [106.0, 314.0, 381.0, 328.0]}, {"text": "domised controlled trial [J]. Lancet, 2016, 388", "bbox": [106.0, 332.0, 383.0, 347.0]}, {"text": "(10060):2618-2628.", "bbox": [106.0, 349.0, 212.0, 364.0]}, {"text": "Jones DA, Rathod KS, Koganti S, et al. Angiography", "bbox": [106.0, 366.0, 383.0, 381.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "Alone Versus Angiography Plus Optical Coherence", "bbox": [108.0, 385.0, 383.0, 399.0]}, {"text": "Tomography to Guide Percutaneous Coronary Inter-", "bbox": [108.0, 403.0, 380.0, 419.0]}, {"text": "vention: Outcomes From the Pan-London PCI Cohort", "bbox": [106.0, 421.0, 383.0, 436.0]}, {"text": "[J]. JACC Cardiovasc Interv, 2018, 11 (14), 1313-", "bbox": [106.0, 438.0, 381.0, 453.0]}, {"text": "1321.", "bbox": [107.0, 457.0, 138.0, 470.0]}], "type": "Text", "position": 6}, {"raw_context": [{"text": "[11] Meneveau N, Souteyrand G, Motreff P, et al. Optical", "bbox": [76.0, 474.0, 383.0, 488.0]}, {"text": "Coherence Tomography to Optimize Results of Percu-", "bbox": [106.0, 492.0, 381.0, 507.0]}, {"text": "taneous Coronary Intervention in Patients with Non-", "bbox": [107.0, 510.0, 381.0, 525.0]}, {"text": "ST-Elevation Acute Coronary Syndrome: Results of", "bbox": [107.0, 528.0, 383.0, 541.0]}, {"text": "the Multicenter, Randomized DOCTORS Study (Does", "bbox": [106.0, 546.0, 382.0, 560.0]}, {"text": "Optical Coherence Tomography Optimize Results of", "bbox": [106.0, 564.0, 383.0, 578.0]}, {"text": "Stenting)[J].Circulation, 2016 , 134 (13), 906-917.", "bbox": [106.0, 581.0, 359.0, 596.0]}, {"text": "[12] Lee SY,Kim JS,Yoon HJ,et al.Early Strut Coverage", "bbox": [77.0, 599.0, 383.0, 613.0]}, {"text": "in Patients Receiving Drug-Eluting Stents and its Im-", "bbox": [107.0, 617.0, 381.0, 631.0]}, {"text": "plications for Dual Antiplatelet Therapy: A Random-", "bbox": [107.0, 635.0, 381.0, 649.0]}, {"text": "ized Trial [J]. JACC Cardiovasc Imaging, 2018, 11", "bbox": [106.0, 653.0, 383.0, 668.0]}, {"text": "(12):1810–1819.", "bbox": [106.0, 670.0, 193.0, 685.0]}, {"text": "[13] Chamié D,Costa JR Jr,Damiani LP,et al.Optical Co-", "bbox": [76.0, 688.0, 381.0, 702.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "herence Tomography Versus Intravascular Ultrasound", "bbox": [107.0, 708.0, 383.0, 721.0]}, {"text": "and Angiography to Guide Percutaneous Coronary In-", "bbox": [106.0, 724.0, 381.0, 739.0]}, {"text": "terventions. The iSIGHT Randomized Trial[J]. Circ", "bbox": [106.0, 742.0, 383.0, 757.0]}, {"text": "Cardiovasc Interv, 2021, 14(3): e009452.", "bbox": [106.0, 759.0, 312.0, 773.0]}, {"text": "[14] Croce K,Wollmuth J,Mathew R,et al.LightLab study", "bbox": [76.0, 778.0, 382.0, 792.0]}, {"text": "[R] . EuroPCR , 2020 .", "bbox": [106.0, 796.0, 213.0, 810.0]}, {"text": "[15] Leistner DM, Riedel M, Steinbeck L, et al. Real-time", "bbox": [76.0, 813.0, 383.0, 829.0]}], "type": "Text", "position": 8}, {"raw_context": [{"text": "optical coherence tomography coregistration with an-", "bbox": [107.0, 832.0, 381.0, 845.0]}, {"text": "giography in percutaneous coronary intervention-im-", "bbox": [107.0, 850.0, 381.0, 863.0]}, {"text": "pact on physician decision-making. The OPTICO-in-", "bbox": [107.0, 867.0, 381.0, 883.0]}], "type": "Text", "position": 9}, {"raw_context": [{"text": "tegration study[J]. Catheter Cardiovasc Interv, 2018,", "bbox": [440.0, 99.0, 715.0, 114.0]}, {"text": "92(1):30-37.", "bbox": [440.0, 117.0, 508.0, 131.0]}, {"text": "[16] Jia H, Dai J, Hou J, et al. Effective anti thrombotic", "bbox": [409.0, 134.0, 716.0, 149.0]}, {"text": "therapy without stenting: intravascular optical coher-", "bbox": [440.0, 153.0, 713.0, 167.0]}, {"text": "ence tomography-based management in plaque erosion.", "bbox": [440.0, 172.0, 715.0, 186.0]}, {"text": "(the EROSION study) [J]. Eur Heart J, 2017, 38", "bbox": [440.0, 189.0, 716.0, 204.0]}, {"text": "(11) , 792–800.", "bbox": [440.0, 207.0, 514.0, 219.0]}], "type": "Text", "position": 10}, {"raw_context": [{"text": "[17] Jia H,Dai J,He L,et al.EROSION III,A Multicenter", "bbox": [409.0, 223.0, 715.0, 238.0]}, {"text": "RCT of OCT-Guided Reperfusion in STEMI With", "bbox": [440.0, 242.0, 716.0, 257.0]}, {"text": "Early Infarct Artery Patency[J].JACC Cardiovasc In-", "bbox": [440.0, 260.0, 714.0, 275.0]}, {"text": "terv,2022,15(8):846-856.", "bbox": [440.0, 277.0, 578.0, 292.0]}, {"text": "[18] Haddad K, Tanguay JF, Potter BJ, et al. Longer Infla-", "bbox": [409.0, 295.0, 714.0, 309.0]}, {"text": "tion Duration and Predilation Sizing-Postdilation Im-", "bbox": [440.0, 314.0, 713.0, 328.0]}, {"text": "prove Bioresorbable Scaffold Outcomes in a Long-", "bbox": [440.0, 331.0, 714.0, 346.0]}, {"text": "term All-Comers Canadian Registry[J]. Can J Cardi-", "bbox": [440.0, 347.0, 713.0, 365.0]}, {"text": "ol,2018,34(6):752-758 .", "bbox": [440.0, 366.0, 567.0, 380.0]}, {"text": "[19] Ortega-Paz L,Capodanno D,Gori T,et al.Predilation,", "bbox": [409.0, 385.0, 715.0, 399.0]}, {"text": "sizing and post-dilation scoring in patients undergoing", "bbox": [440.0, 403.0, 715.0, 417.0]}, {"text": "everolimus-eluting bioresorbable scaffold implantation", "bbox": [440.0, 421.0, 717.0, 436.0]}, {"text": "for prediction of cardiac adverse events: development", "bbox": [440.0, 438.0, 716.0, 452.0]}, {"text": "and internal validation of the PSP score[J].EuroInter-", "bbox": [440.0, 456.0, 713.0, 470.0]}, {"text": "vention, 2017, 12(17), 2110-2117.", "bbox": [440.0, 475.0, 610.0, 488.0]}, {"text": "[20] Jeger RV, Eccleshall S, Wan Ahmad WA, et al. Drug-", "bbox": [409.0, 492.0, 715.0, 507.0]}, {"text": "Coated Balloons for Coronary Artery Disease: Third", "bbox": [440.0, 510.0, 717.0, 525.0]}, {"text": "Report of the International DCB Consensus Group[J].", "bbox": [440.0, 527.0, 715.0, 541.0]}, {"text": "JACC Cardiovasc Interv,2020,13(12):1391-1402.", "bbox": [440.0, 546.0, 697.0, 560.0]}, {"text": "[21] Li L, Zhao L, Wang J, et al. Optical coherence tomo-", "bbox": [409.0, 564.0, 714.0, 578.0]}, {"text": "graphy-guided drug coated balloon in non-small de no-", "bbox": [440.0, 581.0, 714.0, 596.0]}, {"text": "vo coronary artery lesions, a prospective clinical re-", "bbox": [440.0, 600.0, 714.0, 613.0]}, {"text": "search[J]. Am J Transl Res, 2021, 13 (10): 11617-", "bbox": [440.0, 617.0, 714.0, 631.0]}, {"text": "11624.", "bbox": [440.0, 637.0, 477.0, 649.0]}, {"text": "[22] Adriaenssens T,Joner M,Godschalk TC,et al.Optical", "bbox": [409.0, 653.0, 716.0, 668.0]}], "type": "Text", "position": 11}, {"raw_context": [{"text": "Coherence Tomography Findings in Patients With", "bbox": [440.0, 670.0, 716.0, 685.0]}, {"text": "Coronary Stent Thrombosis: A Report of the PRES-", "bbox": [440.0, 688.0, 713.0, 702.0]}, {"text": "TIGE Consortium (Prevention of Late Stent Throm-", "bbox": [440.0, 707.0, 713.0, 720.0]}, {"text": "bosis by an Interdisciplinary Global European Effort)", "bbox": [440.0, 724.0, 715.0, 739.0]}, {"text": "[J].Circulation, 2017, 136(11), 1007-1021.", "bbox": [440.0, 742.0, 657.0, 757.0]}, {"text": "[23] Souteyrand G, Amabile N, Mangin L, et al. Mecha-", "bbox": [410.0, 760.0, 714.0, 774.0]}, {"text": "nisms of stent thrombosis analysed by optical coher-", "bbox": [440.0, 778.0, 713.0, 792.0]}, {"text": "ence tomography: insights from the national PESTO", "bbox": [440.0, 797.0, 716.0, 810.0]}, {"text": "French registry[J]. Eur Heart J, 2016,37(15):1208-", "bbox": [440.0, 814.0, 713.0, 829.0]}, {"text": "1216.", "bbox": [440.0, 832.0, 470.0, 845.0]}, {"text": ".2022-11-01)", "bbox": [623.0, 850.0, 691.0, 863.0]}], "type": "Text", "position": 12}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/心血管/解读/《光学相干断层成像技术在冠心病介入诊疗中应用的中国专家共识》解读.pdf", "page_num": 5}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": null, "type3": null, "type4": null, "type5": null, "type6": "有用性#0#27#参考文献的内容"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:41", "update_time": "2024-05-07 22:52:28"}
{"id": 1082561, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 738, "source_info": {"seq_id": "b93a61ae-bf63-469a-943f-833d3d047046", "title": null, "text": "【0】页码:34\n\n【1】 Minimal sedation Moderate sedation Deep sedation (anxiolysis) (conscious sedation) You will have a small You will have a little more You will have a higher dose of one or amount of a sedative sedative more sedative drugs drug You will feel relaxed and You will feel very relaxed You will sleep during most of your less worried by what is and sleepy treatment happening around you You will be sleepy but can You will be awake and You will sleep and be unlikely to talk talk normally and follow able to talk normally during most of your treatment simple instructions if asked likely You are to You are unlikely to remember much of remember having your You may remember some your treatment – the level of sedation treatment, but not all the parts of your treatment will be adjusted as needed detail Your breathing may slow down . Your sedationist will monitor and help if needed.\n\n【2】Minimal sedation should Moderate sedation should In the UK, deep sedation must be not affect your breathing not affect your breathing administered by staff who have the level of training and skill of an anaesthetic doctor.\n", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "Minimal sedation", "bbox": [147.0, 174.0, 248.0, 189.0]}, {"text": "Moderate sedation", "bbox": [299.0, 174.0, 409.0, 189.0]}, {"text": "Deep sedation", "bbox": [501.0, 182.0, 585.0, 197.0]}, {"text": "(anxiolysis)", "bbox": [165.0, 190.0, 230.0, 205.0]}, {"text": "(conscious sedation)", "bbox": [297.0, 190.0, 412.0, 205.0]}, {"text": "You will have a small", "bbox": [127.0, 224.0, 269.0, 237.0]}, {"text": "You will have a little more", "bbox": [278.0, 231.0, 429.0, 245.0]}, {"text": "You will have a higher dose of one or", "bbox": [438.0, 231.0, 648.0, 245.0]}, {"text": "amount of a sedative", "bbox": [127.0, 240.0, 268.0, 254.0]}, {"text": "sedative", "bbox": [278.0, 247.0, 328.0, 262.0]}, {"text": "more sedative drugs", "bbox": [438.0, 247.0, 554.0, 262.0]}, {"text": "drug", "bbox": [125.0, 256.0, 156.0, 270.0]}, {"text": "You will feel relaxed and", "bbox": [126.0, 286.0, 268.0, 301.0]}, {"text": "You will feel very relaxed", "bbox": [278.0, 294.0, 429.0, 309.0]}, {"text": "You will sleep during most of your", "bbox": [438.0, 294.0, 646.0, 311.0]}, {"text": "less worried by what is", "bbox": [125.0, 303.0, 268.0, 318.0]}, {"text": "and sleepy", "bbox": [278.0, 312.0, 340.0, 327.0]}, {"text": "treatment", "bbox": [438.0, 312.0, 497.0, 326.0]}, {"text": "happening around you", "bbox": [125.0, 320.0, 252.0, 335.0]}, {"text": "You will be sleepy but can", "bbox": [278.0, 352.0, 429.0, 367.0]}, {"text": "You will be awake and", "bbox": [127.0, 359.0, 268.0, 374.0]}, {"text": "You will sleep and be unlikely to talk", "bbox": [439.0, 359.0, 648.0, 374.0]}, {"text": "talk normally and follow", "bbox": [278.0, 368.0, 428.0, 382.0]}, {"text": "able to talk normally", "bbox": [126.0, 376.0, 242.0, 391.0]}, {"text": "during most of your treatment", "bbox": [438.0, 376.0, 606.0, 391.0]}, {"text": "simple instructions if asked", "bbox": [278.0, 384.0, 426.0, 399.0]}, {"text": "likely", "bbox": [202.0, 416.0, 238.0, 431.0]}, {"text": "You", "bbox": [126.0, 417.0, 153.0, 431.0]}, {"text": "are", "bbox": [167.0, 418.0, 189.0, 431.0]}, {"text": "to", "bbox": [252.0, 417.0, 269.0, 431.0]}, {"text": "You are unlikely to remember much of", "bbox": [439.0, 425.0, 648.0, 439.0]}, {"text": "remember having your", "bbox": [125.0, 433.0, 269.0, 448.0]}, {"text": "You may remember some", "bbox": [278.0, 433.0, 427.0, 448.0]}, {"text": "your treatment – the level of sedation", "bbox": [439.0, 440.0, 648.0, 455.0]}, {"text": "treatment, but not all the", "bbox": [126.0, 449.0, 269.0, 463.0]}, {"text": "parts of your treatment", "bbox": [277.0, 450.0, 409.0, 463.0]}, {"text": "will be adjusted as needed ", "bbox": [439.0, 457.0, 586.0, 471.0]}, {"text": "detail", "bbox": [125.0, 465.0, 162.0, 480.0]}, {"text": "Your breathing may slow down . Your", "bbox": [439.0, 497.0, 648.0, 512.0]}, {"text": "sedationist will monitor and help if", "bbox": [438.0, 513.0, 648.0, 528.0]}, {"text": "needed.", "bbox": [438.0, 528.0, 486.0, 543.0]}, {"text": "Minimal sedation should", "bbox": [126.0, 537.0, 264.0, 551.0]}, {"text": "Moderate sedation should", "bbox": [277.0, 537.0, 424.0, 551.0]}, {"text": "In the UK, deep sedation must be", "bbox": [438.0, 559.0, 648.0, 575.0]}, {"text": "not affect your breathing", "bbox": [126.0, 568.0, 269.0, 583.0]}, {"text": "not affect your breathing", "bbox": [276.0, 568.0, 420.0, 583.0]}, {"text": "administered by staff who have the", "bbox": [438.0, 577.0, 648.0, 590.0]}, {"text": "level of training and skill of an", "bbox": [438.0, 592.0, 648.0, 607.0]}, {"text": "anaesthetic doctor.", "bbox": [438.0, 608.0, 545.0, 623.0]}], "type": "Table", "position": 2}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/消化科/_2023 BSG指南：胃肠内窥镜检查中的镇静.pdf", "page_num": 34}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": null, "type3": null, "type4": null, "type5": null, "type6": "准确性#1#2#表格的内容，但是内容杂乱，没有顺序"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:41", "update_time": "2024-05-08 01:28:42"}
{"id": 1082560, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 738, "source_info": {"seq_id": "1cc08a22-d4b6-466c-b2d1-d326301d9c9b", "title": null, "text": "【0】页码:15\n 25. Lam MG, et al. Safety of 90Y radioembolization in patients who have undergone previous external beam radiation therapy. Int J Radiat Oncol Biol Phys. 2013;87(2):323–9.\n\n【1】26.\n\n【2】Young JY, et al. Radiation dose limits and liver toxicities resulting from multiple yttrium-90 radioembolization treatments for hepatocellular carcinoma. J Vase Interv Radiol.\n\n【3】2007;18(11):1375–82.\n\n【4】27.\n\n【5】Ezziddin S, et al. 90Y radioembolization after radiation exposure from peptide receptor radionuclide therapy. J Nucl Med.\n\n【6】2012;53(11):1663–9.\n\n【7】28.\n\n【8】Braat A, et al. Radioembolization with (90)Y resin microspheres of neuroendocrine liver metastases after initial peptide receptor radionuclide therapy. Cardiovasc Intervent Radiol.\n\n【9】2020;43(2):246–53.\n\n【10】29.\n\n【11】Sangro B, et al. Liver disease induced by radioembolization of liver tumors: description and possible risk factors. Cancer.\n\n【12】2008;112(7):1538–46.\n\n【13】30.\n\n【14】van Hazel GA, et al. SIRFLOX: randomized phase III trial comparing first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer. J Clin Oncol. 2016;34(15):1723–31.\n\n【15】31. Mulcahy, M.F., et al., Radioembolization with chemotherapy for colorectal liver metastases: a randomized, open-label, international, multicenter, phase III trial. J Clin Oncol, 2021: p. JCO2101839.\n\n【16】32.\n\n【17】Wasan HS, et al. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-global): a combined analysis of three multicentre, randomised, phase 3 trials. Lancet Oncol. 2017;18(9):1159–71.\n\n【18】Ricke J, et al. Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. J Hepatol. 2019;71(6):1164–74.\n\n【19】34.\n\n【20】Edeline, J., et al., Radioembolization plus chemotherapy for first-line treatment of locally advanced intrahepatic cholangiocarcinoma: a phase 2 clinical trial, JAMA Oncol, 2019.\n\n【21】35.\n\n【22】Shady W, et al. Metabolic tumor volume and total lesion glycolysis on FDG-PET/CT can predict overall survival after (90) Y radioembolization of colorectal liver metastases: a comparison with SUVmax, SUVpeak, and RECIST 1.0. Eur J Radiol A 2016;85(6):1224–31.\n\n【23】36. Shady W, et al. Surrogate imaging biomarkers of response of colorectal liver metastases after salvage radioembolization using 90Y-loaded resin microspheres. AJR Am J Roentgenol.\n\n【24】2016;207(3):661–70.\n\n【25】37.\n\n【26】Fendler WP, et al. Validation of several SUV-based parameters derived from 18F-FDG PET for prediction of survival after SIRT of hepatic metastases from colorectal cancer. J Nucl Med. 2013;54(8):1202–8.\n\n【27】38. Gulec SA, et al. The prognostic value of functional tumor volunic and total lesion glycolysis in patients with colorectal cancer liver metastases undergoing 90Y selective internal radiation therapy plus chemotherapy. Eur J Nucl Med Mol Imaging.\n\n【28】2011;38(7):1289–95.\n\n【29】39.\n\n【30】Soydal C, et al. The prognostic value of quantitative parameters of 18F-FDG PET/CT in the evaluation of response to internal radiation therapy with yttrium-90 in patients with liver metastases of colorectal cancer. Nucl Med Commun.\n\n【31】2013;34(5):501–6.\n\n【32】Zerizer I, et al. The role of early (1)(8)F-FDG PET/CT in predic- 40.\n\n【33】tion of progression-free survival after (9)(0)Y radioembolization: comparison with RECIST and tumour density criteria. Eur J Nucl Med Mol Imaging. 2012;39(9):1391–9.\n\n【34】 42.\n\n【35】 51.\n\n【36】 52.\n\n【37】 53.\n\n【38】 55.\n\n【39】 1956.\n\n【40】57.\n\n【41】 41.\n\n【42】Braat M, et al. Hepatobiliary scintigraphy may improve radioembolization treatment planning in HCC patients. EJNMMI Res.\n\n【43】2017;7(1):2.\n\n【44】42.\n\n【45】Vilgrain V, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2017;18(12):1624–36.\n\n【46】43.\n\n【47】Dutton SJ, et al. FOXFIRE protocol: an open-label, randomised, phase III trial of 5-fluorouracil, oxaliplatin and folinic acid (OxMdG) with or without interventional selective internal radiation therapy (SIRT) as first-line treatment for patients with unresectable liver-only or liver-dominant metastatic colorectal cancer.\n\n【48】BMC Cancer. 2014;14:497.\n\n【49】44.\n\n【50】Gray B, et al. Randomised trial of SIR-spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol.\n\n【51】2001;12(12):1711–20.\n\n【52】Chow PKH, et al. SIRveNIB: selective internal radiation therapy 45.\n\n【53】versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma. J Clin Oncol. 2018;36(19):1913–21.\n\n【54】46.\n\n【55】Helmberger T, et al. Clinical application of trans-arterial radioembolization in hepatic malignancies in europe: first results from the prospective multicentre observational study CIRSE registry for SIR-spheres therapy (CIRT). Cardiovasc Intervent Radiol. 2021;44(1):21–35.\n\n【56】47.\n\n【57】Schutte K, et al. Impact of extrahepatic metastases on overall survival in patients with advanced liver dominant hepatocellular carcinoma: a subanalysis of the SORAMIC trial. Liver Cancer.\n\n【58】2020;9(6):771–86.\n\n【59】48.\n\n【60】Kohler M, et al. Prognostic factors for overall survival in advanced intrahepatic cholangiocarcinoma treated with yttrium-90 radioembolization. J Clin Med. 2019;9:1.\n\n【61】49.\n\n【62】Hunt AP, et al. Preparation of Tc-99m-macroaggregated albumin from recombinant human albumin for lung perfusion imaging.\n\n【63】Eur J Pharm Biopharm. 2006;62(1):26–31.\n\n【64】50.\n\n【65】Chiesa C, Maccauro M. (166)Ho microsphere scout dose for more accurate radioembolization treatment planning. Eur J Nucl Med Mol Imaging. 2020;47(4):744 – 7.\n\n【66】51.\n\n【67】Grosser OS, et al. Pharmacokinetics of 99mTc-MAA- and 99mTc-HSA-microspheres used in preradioembolization dosimetry: influence on the liver-lung shunt. J Nucl Med.\n\n【68】2016;57(6):925–7.\n\n【69】52.\n\n【70】Lopez B, et al. Calculation of lung mean dose and quantification of error for (90) Y-microsphere radioembolization using (99m) Tc-MAA SPECT/CT and diagnostic chest CT. Med Phys.\n\n【71】2019;46(9):3929–40.\n\n【72】Das A, et al. Safety and efficacy of radioembolization with glass 53.\n\n【73】microspheres in hepatocellular carcinoma patients with elevated 7 lung shunt fraction: analysis of a 103-patient cohort. Eur J Nucl ' Med Mol Imaging. 2020;47(4):807–15.\n\n【74】54.\n\n【75】Ho S, et al. Clinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancer. Eur J Nucl Med. 1997;24(3):293–8.\n\n【76】55.\n\n【77】Salem R, et  al. Incidence of radiation pneumonitis after hepatic intra-arterial radiotherapy with yttrium-90 microspheres assuming uniform lung distribution. Am J Clin Oncol.\n\n【78】2008;31(5):431–8.\n\n【79】1956.\n\n【80】Jadoul A, et al. Comparative dosimetry between (99m)Tc-MAA 'SPECT/CT and (90)Y PET/CT in primary and metastatic liver tumors. Eur J Nucl Med Mol Imaging. 2020;47(4):828–37.\n\n【81】57.\n\n【82】Gnesin S, et al. Partition model based Tc-99m-MAA SPECT/ CT predictive dosimetry compared with Y-90 TOF PET/CT posttreatment dosimetry in radioembolization of hepatocellular carcinoma: a quantitative agreement comparison, J Nucl Med.\n\n【83】2016;57(11):1672–8.", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "25. Lam MG, et al. Safety of 90Y radioembolization in patients who", "bbox": [72.0, 73.0, 387.0, 87.0]}, {"text": "have undergone previous external beam radiation therapy. Int J", "bbox": [93.0, 88.0, 387.0, 101.0]}, {"text": "Radiat Oncol Biol Phys. 2013;87(2):323–9.", "bbox": [93.0, 101.0, 293.0, 114.0]}, {"text": "26.", "bbox": [72.0, 115.0, 91.0, 127.0]}, {"text": "Young JY, et al. Radiation dose limits and liver toxicities", "bbox": [91.0, 115.0, 387.0, 127.0]}, {"text": "resulting from multiple yttrium-90 radioembolization treat-", "bbox": [93.0, 128.0, 385.0, 140.0]}, {"text": "ments for hepatocellular carcinoma. J Vase Interv Radiol.", "bbox": [93.0, 141.0, 385.0, 153.0]}, {"text": "2007;18(11):1375–82.", "bbox": [94.0, 155.0, 196.0, 167.0]}, {"text": "27.", "bbox": [72.0, 166.0, 91.0, 180.0]}, {"text": "Ezziddin S, et al. 90Y radioembolization after radiation expo-", "bbox": [89.0, 167.0, 385.0, 181.0]}, {"text": "sure from peptide receptor radionuclide therapy. J Nucl Med.", "bbox": [93.0, 181.0, 385.0, 193.0]}, {"text": "2012;53(11):1663–9.", "bbox": [93.0, 195.0, 191.0, 207.0]}, {"text": "28.", "bbox": [72.0, 208.0, 91.0, 219.0]}, {"text": "Braat A, et al. Radioembolization with (90)Y resin micro-", "bbox": [89.0, 207.0, 386.0, 220.0]}, {"text": "spheres of neuroendocrine liver metastases after initial peptide", "bbox": [93.0, 222.0, 387.0, 233.0]}, {"text": "receptor radionuclide therapy. Cardiovasc Intervent Radiol.", "bbox": [93.0, 235.0, 386.0, 247.0]}, {"text": "2020;43(2):246–53.", "bbox": [93.0, 248.0, 187.0, 261.0]}, {"text": "29.", "bbox": [72.0, 261.0, 86.0, 273.0]}, {"text": "Sangro B, et al. Liver disease induced by radioembolization", "bbox": [93.0, 261.0, 387.0, 273.0]}, {"text": "of liver tumors: description and possible risk factors. Cancer.", "bbox": [91.0, 275.0, 386.0, 287.0]}, {"text": "2008;112(7):1538–46.", "bbox": [93.0, 289.0, 200.0, 300.0]}, {"text": "30.", "bbox": [72.0, 300.0, 89.0, 312.0]}, {"text": "van Hazel GA, et al. SIRFLOX: randomized phase III trial", "bbox": [91.0, 301.0, 387.0, 313.0]}, {"text": "comparing first-line mFOLFOX6 (plus or minus bevacizumab)", "bbox": [93.0, 314.0, 387.0, 327.0]}, {"text": "versus mFOLFOX6 (plus or minus bevacizumab) plus selective", "bbox": [93.0, 328.0, 387.0, 340.0]}, {"text": "internal radiation therapy in patients with metastatic colorectal", "bbox": [93.0, 341.0, 387.0, 354.0]}, {"text": "cancer. J Clin Oncol. 2016;34(15):1723–31.", "bbox": [93.0, 356.0, 301.0, 367.0]}, {"text": "31. Mulcahy, M.F., et al., Radioembolization with chemotherapy", "bbox": [72.0, 368.0, 386.0, 381.0]}, {"text": "for colorectal liver metastases: a randomized, open-label,", "bbox": [93.0, 381.0, 385.0, 393.0]}, {"text": "international, multicenter, phase III trial. J Clin Oncol, 2021:", "bbox": [93.0, 395.0, 387.0, 407.0]}, {"text": "p. JCO2101839.", "bbox": [93.0, 408.0, 171.0, 420.0]}, {"text": "32.", "bbox": [72.0, 420.0, 90.0, 433.0]}, {"text": "Wasan HS, et al. First-line selective internal radiotherapy plus", "bbox": [91.0, 420.0, 387.0, 434.0]}, {"text": "chemotherapy versus chemotherapy alone in patients with liver", "bbox": [93.0, 435.0, 386.0, 447.0]}, {"text": "metastases from colorectal cancer (FOXFIRE, SIRFLOX, and", "bbox": [93.0, 448.0, 387.0, 459.0]}, {"text": "FOXFIRE-global): a combined analysis of three multicentre,", "bbox": [93.0, 461.0, 386.0, 473.0]}, {"text": "randomised, phase 3 trials. Lancet Oncol. 2017;18(9):1159–71.", "bbox": [93.0, 475.0, 387.0, 487.0]}, {"text": "Ricke J, et al. Impact of combined selective internal radiation", "bbox": [91.0, 488.0, 387.0, 501.0]}, {"text": "therapy and sorafenib on survival in advanced hepatocellular", "bbox": [93.0, 502.0, 387.0, 513.0]}, {"text": "carcinoma. J Hepatol. 2019;71(6):1164–74.", "bbox": [93.0, 515.0, 302.0, 527.0]}, {"text": "34.", "bbox": [72.0, 528.0, 89.0, 539.0]}, {"text": "Edeline, J., et al., Radioembolization plus chemotherapy for", "bbox": [92.0, 528.0, 387.0, 540.0]}, {"text": "first-line treatment of locally advanced intrahepatic cholan-", "bbox": [93.0, 542.0, 385.0, 553.0]}, {"text": "giocarcinoma: a phase 2 clinical trial, JAMA Oncol, 2019.", "bbox": [93.0, 555.0, 373.0, 567.0]}, {"text": "35.", "bbox": [72.0, 567.0, 90.0, 579.0]}, {"text": "Shady W, et al. Metabolic tumor volume and total lesion gly-", "bbox": [91.0, 567.0, 385.0, 580.0]}, {"text": "colysis on FDG-PET/CT can predict overall survival after (90)", "bbox": [93.0, 581.0, 387.0, 593.0]}, {"text": "Y radioembolization of colorectal liver metastases: a compari-", "bbox": [93.0, 594.0, 387.0, 607.0]}, {"text": "son with SUVmax, SUVpeak, and RECIST 1.0. Eur J Radiol A", "bbox": [93.0, 609.0, 389.0, 621.0]}, {"text": "2016;85(6):1224–31.", "bbox": [93.0, 621.0, 196.0, 634.0]}, {"text": "36. Shady W, et al. Surrogate imaging biomarkers of response of", "bbox": [72.0, 634.0, 387.0, 648.0]}, {"text": "colorectal liver metastases after salvage radioembolization", "bbox": [93.0, 648.0, 387.0, 660.0]}, {"text": "using 90Y-loaded resin microspheres. AJR Am J Roentgenol.", "bbox": [93.0, 661.0, 385.0, 674.0]}, {"text": "2016;207(3):661–70.", "bbox": [93.0, 675.0, 195.0, 687.0]}, {"text": "37.", "bbox": [72.0, 687.0, 91.0, 700.0]}, {"text": "Fendler WP, et al. Validation of several SUV-based param-", "bbox": [90.0, 687.0, 386.0, 701.0]}, {"text": "eters derived from 18F-FDG PET for prediction of survival", "bbox": [93.0, 701.0, 387.0, 713.0]}, {"text": "after SIRT of hepatic metastases from colorectal cancer. J Nucl", "bbox": [93.0, 715.0, 387.0, 727.0]}, {"text": "Med. 2013;54(8):1202–8.", "bbox": [93.0, 728.0, 217.0, 741.0]}, {"text": "38. Gulec SA, et al. The prognostic value of functional tumor vol-", "bbox": [73.0, 741.0, 387.0, 755.0]}, {"text": "unic and total lesion glycolysis in patients with colorectal can-", "bbox": [91.0, 755.0, 386.0, 768.0]}, {"text": "cer liver metastases undergoing 90Y selective internal radia-", "bbox": [93.0, 768.0, 385.0, 780.0]}, {"text": "tion therapy plus chemotherapy. Eur J Nucl Med Mol Imaging.", "bbox": [93.0, 781.0, 386.0, 793.0]}, {"text": "2011;38(7):1289–95.", "bbox": [93.0, 795.0, 195.0, 807.0]}, {"text": "39.", "bbox": [72.0, 807.0, 89.0, 819.0]}, {"text": "Soydal C, et al. The prognostic value of quantitative param-", "bbox": [91.0, 807.0, 385.0, 821.0]}, {"text": "eters of 18F-FDG PET/CT in the evaluation of response to", "bbox": [93.0, 821.0, 387.0, 834.0]}, {"text": "internal radiation therapy with yttrium-90 in patients with", "bbox": [93.0, 835.0, 388.0, 847.0]}, {"text": "liver metastases of colorectal cancer. Nucl Med Commun.", "bbox": [93.0, 848.0, 388.0, 860.0]}, {"text": "2013;34(5):501–6.", "bbox": [93.0, 862.0, 183.0, 873.0]}, {"text": "Zerizer I, et al. The role of early (1)(8)F-FDG PET/CT in predic-", "bbox": [89.0, 873.0, 385.0, 887.0]}, {"text": "40.", "bbox": [72.0, 875.0, 91.0, 887.0]}, {"text": "tion of progression-free survival after (9)(0)Y radioembolization:", "bbox": [93.0, 888.0, 386.0, 900.0]}, {"text": "comparison with RECIST and tumour density criteria. Eur J Nucl", "bbox": [93.0, 902.0, 386.0, 913.0]}, {"text": "Med Mol Imaging. 2012;39(9):1391–9.", "bbox": [93.0, 914.0, 275.0, 927.0]}], "type": "Text", "position": 1}, {"raw_context": [{"text": "42.", "bbox": [411.0, 114.0, 430.0, 125.0]}], "type": "Text", "position": 2}, {"raw_context": [{"text": "51.", "bbox": [411.0, 595.0, 429.0, 606.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "52.", "bbox": [411.0, 647.0, 430.0, 660.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": "53.", "bbox": [411.0, 701.0, 430.0, 713.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "55.", "bbox": [411.0, 793.0, 428.0, 806.0]}], "type": "Text", "position": 6}, {"raw_context": [{"text": "1956.", "bbox": [410.0, 848.0, 428.0, 859.0]}, {"text": "57.", "bbox": [411.0, 888.0, 430.0, 900.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "41.", "bbox": [412.0, 74.0, 431.0, 86.0]}, {"text": "Braat M, et al. Hepatobiliary scintigraphy may improve radioem-", "bbox": [431.0, 74.0, 723.0, 87.0]}, {"text": "bolization treatment planning in HCC patients. EJNMMI Res.", "bbox": [433.0, 88.0, 724.0, 101.0]}, {"text": "2017;7(1):2.", "bbox": [435.0, 101.0, 492.0, 114.0]}, {"text": "42.", "bbox": [411.0, 114.0, 430.0, 125.0]}, {"text": "Vilgrain V, et al. Efficacy and safety of selective internal radio-", "bbox": [432.0, 114.0, 726.0, 126.0]}, {"text": "therapy with yttrium-90 resin microspheres compared with", "bbox": [433.0, 128.0, 728.0, 139.0]}, {"text": "sorafenib in locally advanced and inoperable hepatocellular car-", "bbox": [434.0, 141.0, 726.0, 153.0]}, {"text": "cinoma (SARAH): an open-label randomised controlled phase 3", "bbox": [432.0, 155.0, 727.0, 167.0]}, {"text": "trial. Lancet Oncol. 2017;18(12):1624–36.", "bbox": [432.0, 167.0, 630.0, 180.0]}, {"text": "43.", "bbox": [412.0, 181.0, 428.0, 192.0]}, {"text": "Dutton SJ, et al. FOXFIRE protocol: an open-label, randomised,", "bbox": [432.0, 181.0, 727.0, 193.0]}, {"text": "phase III trial of 5-fluorouracil, oxaliplatin and folinic acid", "bbox": [433.0, 194.0, 728.0, 206.0]}, {"text": "(OxMdG) with or without interventional selective internal radia-", "bbox": [433.0, 208.0, 726.0, 220.0]}, {"text": "tion therapy (SIRT) as first-line treatment for patients with unre-", "bbox": [433.0, 222.0, 725.0, 233.0]}, {"text": "sectable liver-only or liver-dominant metastatic colorectal cancer.", "bbox": [433.0, 234.0, 727.0, 247.0]}, {"text": "BMC Cancer. 2014;14:497.", "bbox": [434.0, 247.0, 563.0, 260.0]}, {"text": "44.", "bbox": [412.0, 261.0, 429.0, 272.0]}, {"text": "Gray B, et al. Randomised trial of SIR-spheres plus chemo-", "bbox": [432.0, 261.0, 727.0, 273.0]}, {"text": "therapy vs. chemotherapy alone for treating patients with", "bbox": [433.0, 275.0, 728.0, 287.0]}, {"text": "liver metastases from primary large bowel cancer. Ann Oncol.", "bbox": [434.0, 289.0, 725.0, 300.0]}, {"text": "2001;12(12):1711–20.", "bbox": [434.0, 301.0, 539.0, 313.0]}, {"text": "Chow PKH, et al. SIRveNIB: selective internal radiation therapy", "bbox": [432.0, 313.0, 727.0, 326.0]}, {"text": "45.", "bbox": [412.0, 314.0, 429.0, 325.0]}, {"text": "versus sorafenib in Asia-Pacific patients with hepatocellular car-", "bbox": [434.0, 327.0, 725.0, 340.0]}, {"text": "cinoma. J Clin Oncol. 2018;36(19):1913–21.", "bbox": [434.0, 341.0, 639.0, 354.0]}, {"text": "46.", "bbox": [412.0, 355.0, 430.0, 365.0]}, {"text": "Helmberger T, et al. Clinical application of trans-arterial radi-", "bbox": [432.0, 355.0, 726.0, 367.0]}, {"text": "oembolization in hepatic malignancies in europe: first results", "bbox": [433.0, 366.0, 727.0, 382.0]}, {"text": "from the prospective multicentre observational study CIRSE", "bbox": [432.0, 381.0, 727.0, 392.0]}, {"text": "registry for SIR-spheres therapy (CIRT). Cardiovasc Intervent", "bbox": [432.0, 393.0, 726.0, 407.0]}, {"text": "Radiol. 2021;44(1):21–35.", "bbox": [434.0, 408.0, 556.0, 420.0]}, {"text": "47.", "bbox": [412.0, 421.0, 430.0, 433.0]}, {"text": "Schutte K, et al. Impact of extrahepatic metastases on overall", "bbox": [432.0, 421.0, 728.0, 434.0]}, {"text": "survival in patients with advanced liver dominant hepatocellular", "bbox": [434.0, 434.0, 727.0, 446.0]}, {"text": "carcinoma: a subanalysis of the SORAMIC trial. Liver Cancer.", "bbox": [433.0, 448.0, 726.0, 459.0]}, {"text": "2020;9(6):771–86.", "bbox": [434.0, 461.0, 520.0, 473.0]}, {"text": "48.", "bbox": [412.0, 474.0, 428.0, 486.0]}, {"text": "Kohler M, et al. Prognostic factors for overall survival in", "bbox": [432.0, 474.0, 728.0, 487.0]}, {"text": "advanced intrahepatic cholangiocarcinoma treated with", "bbox": [434.0, 487.0, 727.0, 501.0]}, {"text": "yttrium-90 radioembolization. J Clin Med. 2019;9:1.", "bbox": [434.0, 501.0, 678.0, 513.0]}, {"text": "49.", "bbox": [412.0, 514.0, 428.0, 525.0]}, {"text": "Hunt AP, et al. Preparation of Tc-99m-macroaggregated albumin", "bbox": [433.0, 514.0, 727.0, 526.0]}, {"text": "from recombinant human albumin for lung perfusion imaging.", "bbox": [434.0, 528.0, 726.0, 540.0]}, {"text": "Eur J Pharm Biopharm. 2006;62(1):26–31.", "bbox": [434.0, 541.0, 632.0, 553.0]}, {"text": "50.", "bbox": [412.0, 553.0, 430.0, 565.0]}, {"text": "Chiesa C, Maccauro M. (166)Ho microsphere scout dose for", "bbox": [432.0, 554.0, 727.0, 567.0]}, {"text": "more accurate radioembolization treatment planning. Eur J Nucl", "bbox": [434.0, 567.0, 727.0, 580.0]}, {"text": "Med Mol Imaging. 2020;47(4):744 – 7.", "bbox": [434.0, 581.0, 610.0, 593.0]}, {"text": "51.", "bbox": [411.0, 595.0, 429.0, 606.0]}, {"text": "Grosser OS, et al. Pharmacokinetics of 99mTc-MAA- and", "bbox": [432.0, 595.0, 728.0, 606.0]}, {"text": "99mTc-HSA-microspheres used in preradioembolization", "bbox": [433.0, 608.0, 727.0, 620.0]}, {"text": "dosimetry: influence on the liver-lung shunt. J Nucl Med.", "bbox": [433.0, 621.0, 727.0, 634.0]}, {"text": "2016;57(6):925–7.", "bbox": [434.0, 634.0, 520.0, 646.0]}, {"text": "52.", "bbox": [411.0, 647.0, 430.0, 660.0]}, {"text": "Lopez B, et al. Calculation of lung mean dose and quantifica-", "bbox": [432.0, 647.0, 726.0, 660.0]}, {"text": "tion of error for (90) Y-microsphere radioembolization using", "bbox": [433.0, 662.0, 727.0, 673.0]}, {"text": "(99m) Tc-MAA SPECT/CT and diagnostic chest CT. Med Phys.", "bbox": [433.0, 674.0, 726.0, 687.0]}, {"text": "2019;46(9):3929–40.", "bbox": [434.0, 687.0, 533.0, 698.0]}, {"text": "Das A, et al. Safety and efficacy of radioembolization with glass", "bbox": [432.0, 700.0, 728.0, 713.0]}, {"text": "53.", "bbox": [411.0, 701.0, 430.0, 713.0]}, {"text": "microspheres in hepatocellular carcinoma patients with elevated 7", "bbox": [433.0, 713.0, 731.0, 727.0]}, {"text": "lung shunt fraction: analysis of a 103-patient cohort. Eur J Nucl '", "bbox": [434.0, 728.0, 729.0, 741.0]}, {"text": "Med Mol Imaging. 2020;47(4):807–15.", "bbox": [434.0, 742.0, 616.0, 754.0]}, {"text": "54.", "bbox": [412.0, 754.0, 429.0, 765.0]}, {"text": "Ho S, et al. Clinical evaluation of the partition model for estimat-", "bbox": [432.0, 755.0, 726.0, 765.0]}, {"text": "ing radiation doses from yttrium-90 microspheres in the treat-", "bbox": [433.0, 768.0, 726.0, 779.0]}, {"text": "ment of hepatic cancer. Eur J Nucl Med. 1997;24(3):293–8.", "bbox": [434.0, 781.0, 709.0, 793.0]}, {"text": "55.", "bbox": [411.0, 793.0, 428.0, 806.0]}, {"text": "Salem R, et  al. Incidence of radiation pneumonitis after", "bbox": [432.0, 795.0, 727.0, 807.0]}, {"text": "hepatic intra-arterial radiotherapy with yttrium-90 micro-", "bbox": [433.0, 807.0, 726.0, 821.0]}, {"text": "spheres assuming uniform lung distribution. Am J Clin Oncol.", "bbox": [434.0, 821.0, 726.0, 833.0]}, {"text": "2008;31(5):431–8.", "bbox": [434.0, 834.0, 521.0, 846.0]}, {"text": "1956.", "bbox": [410.0, 848.0, 428.0, 859.0]}, {"text": "Jadoul A, et al. Comparative dosimetry between (99m)Tc-MAA", "bbox": [432.0, 847.0, 727.0, 860.0]}, {"text": "'SPECT/CT and (90)Y PET/CT in primary and metastatic liver", "bbox": [434.0, 861.0, 727.0, 873.0]}, {"text": "tumors. Eur J Nucl Med Mol Imaging. 2020;47(4):828–37.", "bbox": [433.0, 874.0, 705.0, 887.0]}, {"text": "57.", "bbox": [411.0, 888.0, 430.0, 900.0]}, {"text": "Gnesin S, et al. Partition model based Tc-99m-MAA SPECT/", "bbox": [431.0, 887.0, 726.0, 900.0]}, {"text": "CT predictive dosimetry compared with Y-90 TOF PET/CT", "bbox": [432.0, 901.0, 725.0, 913.0]}, {"text": "posttreatment dosimetry in radioembolization of hepatocellular", "bbox": [433.0, 915.0, 726.0, 927.0]}, {"text": "carcinoma: a quantitative agreement comparison, J Nucl Med.", "bbox": [433.0, 928.0, 725.0, 940.0]}, {"text": "2016;57(11):1672–8.", "bbox": [434.0, 940.0, 533.0, 954.0]}], "type": "Text", "position": 8}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2022】全科室最全临床指南+专家共识（最全版）/2022全科室临床指南/肿瘤科/EANM：动脉内放射性化合物治疗肝癌和转移性肝癌指南（2022）(1).pdf", "page_num": 15}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": null, "type3": null, "type4": null, "type5": null, "type6": "信息有用性#0#83#参考文献"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:41", "update_time": "2024-05-07 22:04:38"}
{"id": 1082559, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 738, "source_info": {"seq_id": "7be52bb9-5b95-44b2-8464-72bf048de3b1", "title": null, "text": "【0】页码:3\n • 792 •\n\n【1】 3.3.2 CT\n\n【2】 ,\n\n【3】 o\n\n【4】 3.3.3 MRI\n\n【5】 .\n\n【6】 MRI o\n\n【7】 o\n\n【8】 ,\n\n【9】 .\n\n【10】 , 100\n\n【11】 ,\n\n【12】 Chapter 1\n\n【13】 4 4. 1\n\n【14】 ,\n\n【15】 .\n\n【16】 (mJOA 15~17 ) o , .\n\n【17】 ,\n\n【18】 .\n\n【19】 ..\n\n【20】 ,\n\n【21】 (diffusion tensor imaging , DTI)\n\n【22】 (magnetic resonance spectro- , scopy , MRS) , (magnetization transfer , MT) , (functional MRI,fMRI) o , 3.3.4 CSM , Chapter 1 ,\n\n【23】\n 3 o , , , [7–8] , the state of the s .\n\n【24】Chapter 1  .\n\n【25】, , (mJOA 12~14 (1985) .\n\n【26】, (mJOA <11 (1995) 1. See also  1990   \n\n【27】 , , ,\n\n【28】 o\n\n【29】 3. 4\n\n【30】 3. 4. 1\n\n【31】 . \n\n【32】 , o , 100  ,\n\n【33】 [2-6]\n\n【34】 (Japanese Orthopaedic Association , JOA ) (modified Japanese Orthopaedic Association , mJOA ) , Nuricks (40) 24 4. 2 ), , (myelopathy disability index , MDI) , 30 m ,Quick–DASH , [13] , - 3. 4. 2 JOA , 24 JOA T16751.2 1 3 : ,15~17 ;   ,12~14   ; JOA 1 1 13 ,<11 , Chapter 1 2 [6,14] , .\n\n【35】, 24 5 10,0~5 4. 2. 1 ,6~10 , 11~15 , 16~20 , , , [2] .\n\n【36】,21~24 o , 100 3. 5 o 4. 2. 2 , 100 10. See also   1990.\n\n【37】, o : , , , Chapter 1 Chapter 1 Chapter 1 , [2,5] 4. 2. 3 Chapter 1 .\n\n【38】3. 6 , .\n\n【39】, 4. 2. 4 Chapter 1 Chapter 1\n\n【40】\n , , , , .\n\n【41】[15] GB/ , 100 s , Chapter 1 5 o .\n\n【42】, , Line 1990.\n\n【43】, , , , : o .\n\n【44】o , 100 o .\n\n【45】, 10. See also   1990.\n\n【46】. \n\n【47】, : , .\n\n【48】Chapter 1 . \n\n【49】, o ,      ,             : , o o , , , 100 , o o : , 100 o o , ,\n\n【50】 ,\n\n【51】 ,\n\n【52】 o\n\n【53】 MRI ,\n\n【54】 100, 1188\n\n【55】 2022\n\n【56】 4. 2. 5\n", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "• 792 •", "bbox": [76.0, 65.0, 113.0, 83.0]}], "type": "Text", "position": 0}, {"raw_context": [{"text": "3.3.2 CT", "bbox": [64.0, 106.0, 135.0, 123.0]}], "type": "Text", "position": 1}, {"raw_context": [{"text": ",", "bbox": [205.0, 131.0, 219.0, 144.0]}], "type": "Text", "position": 2}, {"raw_context": [{"text": "o", "bbox": [164.0, 151.0, 174.0, 163.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "3.3.3 MRI", "bbox": [64.0, 165.0, 144.0, 183.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": ".", "bbox": [207.0, 191.0, 219.0, 203.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "MRI", "bbox": [205.0, 205.0, 236.0, 222.0]}, {"text": "o", "bbox": [164.0, 211.0, 174.0, 224.0]}], "type": "Text", "position": 6}, {"raw_context": [{"text": "o", "bbox": [234.0, 231.0, 244.0, 244.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": ",", "bbox": [277.0, 232.0, 287.0, 245.0]}], "type": "Text", "position": 8}, {"raw_context": [{"text": ".", "bbox": [291.0, 113.0, 302.0, 124.0]}], "type": "Text", "position": 9}, {"raw_context": [{"text": ", 100", "bbox": [332.0, 171.0, 345.0, 183.0]}], "type": "Text", "position": 10}, {"raw_context": [{"text": ",", "bbox": [312.0, 191.0, 323.0, 203.0]}], "type": "Text", "position": 11}, {"raw_context": [{"text": "Chapter 1", "bbox": [369.0, 112.0, 381.0, 125.0]}], "type": "Text", "position": 12}, {"raw_context": [{"text": "4", "bbox": [397.0, 106.0, 410.0, 123.0]}, {"text": "4. 1", "bbox": [397.0, 127.0, 424.0, 143.0]}], "type": "Text", "position": 13}, {"raw_context": [{"text": ",", "bbox": [428.0, 232.0, 440.0, 244.0]}], "type": "Text", "position": 14}, {"raw_context": [{"text": ".", "bbox": [483.0, 232.0, 504.0, 244.0]}], "type": "Text", "position": 15}, {"raw_context": [{"text": "(mJOA 15~17 )", "bbox": [519.0, 185.0, 629.0, 202.0]}, {"text": "o", "bbox": [454.0, 191.0, 467.0, 203.0]}, {"text": ",", "bbox": [483.0, 213.0, 493.0, 224.0]}, {"text": ".", "bbox": [604.0, 213.0, 616.0, 224.0]}], "type": "Text", "position": 16}, {"raw_context": [{"text": ",", "bbox": [672.0, 171.0, 684.0, 184.0]}], "type": "Text", "position": 17}, {"raw_context": [{"text": ".", "bbox": [666.0, 212.0, 703.0, 222.0]}], "type": "Text", "position": 18}, {"raw_context": [{"text": "..", "bbox": [686.0, 231.0, 699.0, 244.0]}], "type": "Text", "position": 19}, {"raw_context": [{"text": ",", "bbox": [688.0, 253.0, 696.0, 262.0]}], "type": "Text", "position": 20}, {"raw_context": [{"text": "(diffusion tensor imaging , DTI)", "bbox": [66.0, 245.0, 244.0, 264.0]}], "type": "Text", "position": 21}, {"raw_context": [{"text": "(magnetic resonance spectro-", "bbox": [213.0, 266.0, 379.0, 282.0]}, {"text": ",", "bbox": [123.0, 272.0, 131.0, 282.0]}, {"text": "scopy , MRS) ,", "bbox": [64.0, 285.0, 149.0, 302.0]}, {"text": "(magnetization transfer , MT) ,", "bbox": [205.0, 286.0, 379.0, 302.0]}, {"text": "(functional MRI,fMRI)", "bbox": [197.0, 305.0, 334.0, 322.0]}, {"text": "o", "bbox": [350.0, 330.0, 365.0, 344.0]}, {"text": ",", "bbox": [205.0, 332.0, 217.0, 344.0]}, {"text": "3.3.4", "bbox": [64.0, 345.0, 107.0, 363.0]}, {"text": "CSM", "bbox": [329.0, 365.0, 361.0, 382.0]}, {"text": ",", "bbox": [236.0, 371.0, 285.0, 383.0]}, {"text": "Chapter 1", "bbox": [95.0, 372.0, 106.0, 385.0]}, {"text": ",", "bbox": [186.0, 372.0, 198.0, 385.0]}], "type": "Table", "position": 22}, {"raw_context": [{"text": "3", "bbox": [555.0, 266.0, 569.0, 281.0]}, {"text": "o", "bbox": [453.0, 271.0, 468.0, 284.0]}, {"text": ",", "bbox": [554.0, 291.0, 565.0, 305.0]}, {"text": ",", "bbox": [659.0, 291.0, 670.0, 304.0]}, {"text": ",", "bbox": [483.0, 312.0, 494.0, 325.0]}, {"text": "[7–8] ,", "bbox": [439.0, 322.0, 469.0, 341.0]}, {"text": "the state of the s", "bbox": [553.0, 331.0, 614.0, 344.0]}, {"text": ".", "bbox": [651.0, 331.0, 671.0, 345.0]}, {"text": "Chapter 1", "bbox": [617.0, 332.0, 629.0, 345.0]}, {"text": "", "bbox": [630.0, 333.0, 653.0, 345.0]}, {"text": ".", "bbox": [671.0, 332.0, 700.0, 343.0]}, {"text": ",", "bbox": [483.0, 351.0, 494.0, 364.0]}, {"text": ",", "bbox": [659.0, 351.0, 670.0, 363.0]}, {"text": "(mJOA 12~14", "bbox": [533.0, 365.0, 622.0, 382.0]}, {"text": "(1985)", "bbox": [622.0, 367.0, 644.0, 382.0]}, {"text": ".", "bbox": [467.0, 371.0, 499.0, 383.0]}, {"text": ",", "bbox": [441.0, 392.0, 471.0, 404.0]}, {"text": "(mJOA <11", "bbox": [561.0, 405.0, 631.0, 422.0]}, {"text": "(1995)", "bbox": [639.0, 407.0, 657.0, 422.0]}, {"text": "1. See also  1990   ", "bbox": [496.0, 411.0, 507.0, 424.0]}], "type": "Text", "position": 23}, {"raw_context": [{"text": ",", "bbox": [121.0, 392.0, 135.0, 404.0]}, {"text": ",", "bbox": [255.0, 392.0, 267.0, 404.0]}, {"text": ",", "bbox": [136.0, 413.0, 144.0, 422.0]}], "type": "Text", "position": 24}, {"raw_context": [{"text": "o", "bbox": [337.0, 410.0, 350.0, 424.0]}], "type": "Text", "position": 25}, {"raw_context": [{"text": "3. 4", "bbox": [64.0, 425.0, 91.0, 442.0]}], "type": "Text", "position": 26}, {"raw_context": [{"text": "3. 4. 1", "bbox": [64.0, 446.0, 105.0, 462.0]}], "type": "Text", "position": 27}, {"raw_context": [{"text": ". ", "bbox": [469.0, 432.0, 481.0, 444.0]}], "type": "Text", "position": 28}, {"raw_context": [{"text": ",", "bbox": [469.0, 470.0, 480.0, 483.0]}, {"text": "o", "bbox": [495.0, 490.0, 510.0, 503.0]}, {"text": ", 100", "bbox": [524.0, 511.0, 537.0, 523.0]}, {"text": "", "bbox": [566.0, 516.0, 621.0, 544.0]}, {"text": ",", "bbox": [553.0, 530.0, 568.0, 543.0]}], "type": "Text", "position": 29}, {"raw_context": [{"text": "[2-6]", "bbox": [656.0, 521.0, 681.0, 537.0]}], "type": "Text", "position": 30}, {"raw_context": [{"text": "(Japanese Orthopaedic Association , JOA )", "bbox": [66.0, 485.0, 302.0, 503.0]}, {"text": "(modified Japanese Orthopaedic As-", "bbox": [170.0, 505.0, 377.0, 523.0]}, {"text": "sociation , mJOA )", "bbox": [64.0, 524.0, 168.0, 542.0]}, {"text": ", Nuricks", "bbox": [219.0, 524.0, 275.0, 542.0]}, {"text": "(40)", "bbox": [214.0, 544.0, 242.0, 561.0]}, {"text": "24", "bbox": [283.0, 544.0, 305.0, 561.0]}, {"text": "4. 2", "bbox": [397.0, 544.0, 424.0, 561.0]}, {"text": "),", "bbox": [332.0, 545.0, 350.0, 562.0]}, {"text": ",", "bbox": [93.0, 550.0, 107.0, 564.0]}, {"text": "(myelopathy disability index , MDI) ,", "bbox": [170.0, 564.0, 379.0, 582.0]}, {"text": "30 m", "bbox": [64.0, 585.0, 98.0, 601.0]}, {"text": ",Quick–DASH", "bbox": [153.0, 585.0, 241.0, 601.0]}, {"text": ",", "bbox": [355.0, 591.0, 364.0, 604.0]}, {"text": "[13]", "bbox": [218.0, 603.0, 243.0, 620.0]}, {"text": ",", "bbox": [108.0, 608.0, 118.0, 622.0]}, {"text": "-", "bbox": [155.0, 607.0, 169.0, 619.0]}, {"text": "3. 4. 2", "bbox": [64.0, 624.0, 107.0, 642.0]}, {"text": "JOA", "bbox": [302.0, 625.0, 332.0, 641.0]}, {"text": ",", "bbox": [441.0, 632.0, 450.0, 642.0]}, {"text": "24", "bbox": [151.0, 644.0, 172.0, 660.0]}, {"text": "JOA", "bbox": [64.0, 664.0, 94.0, 681.0]}, {"text": "T16751.2 1", "bbox": [396.0, 664.0, 463.0, 681.0]}, {"text": "3 : ,15~17", "bbox": [187.0, 665.0, 279.0, 682.0]}, {"text": ";   ,12~14   ;", "bbox": [289.0, 665.0, 381.0, 681.0]}, {"text": "JOA", "bbox": [251.0, 684.0, 280.0, 701.0]}, {"text": "1 1 13", "bbox": [308.0, 684.0, 341.0, 701.0]}, {"text": ",<11", "bbox": [79.0, 685.0, 112.0, 702.0]}, {"text": ",", "bbox": [354.0, 689.0, 364.0, 702.0]}, {"text": "Chapter 1", "bbox": [125.0, 691.0, 135.0, 702.0]}, {"text": "2", "bbox": [164.0, 703.0, 179.0, 722.0]}, {"text": "[6,14]", "bbox": [296.0, 702.0, 328.0, 721.0]}, {"text": ",", "bbox": [190.0, 711.0, 203.0, 723.0]}, {"text": ".", "bbox": [413.0, 711.0, 425.0, 723.0]}, {"text": ",", "bbox": [477.0, 712.0, 486.0, 723.0]}, {"text": "24", "bbox": [156.0, 724.0, 177.0, 741.0]}, {"text": "5", "bbox": [268.0, 724.0, 282.0, 740.0]}, {"text": "10,0~5", "bbox": [297.0, 724.0, 331.0, 741.0]}, {"text": "4. 2. 1", "bbox": [397.0, 724.0, 438.0, 741.0]}, {"text": ",6~10", "bbox": [80.0, 744.0, 121.0, 761.0]}, {"text": ", 11~15", "bbox": [179.0, 745.0, 225.0, 762.0]}, {"text": ", 16~20", "bbox": [285.0, 745.0, 332.0, 762.0]}, {"text": ",", "bbox": [412.0, 749.0, 425.0, 764.0]}, {"text": ",", "bbox": [447.0, 749.0, 460.0, 764.0]}, {"text": ",", "bbox": [482.0, 751.0, 493.0, 763.0]}, {"text": "[2] .", "bbox": [249.0, 761.0, 269.0, 779.0]}, {"text": ",21~24", "bbox": [79.0, 764.0, 126.0, 780.0]}, {"text": "o", "bbox": [475.0, 770.0, 488.0, 783.0]}, {"text": ", 100", "bbox": [412.0, 771.0, 425.0, 784.0]}, {"text": "3. 5", "bbox": [63.0, 785.0, 91.0, 801.0]}, {"text": "o", "bbox": [453.0, 789.0, 466.0, 801.0]}, {"text": "4. 2. 2", "bbox": [397.0, 804.0, 440.0, 821.0]}, {"text": ", 100", "bbox": [319.0, 810.0, 330.0, 821.0]}, {"text": "10. See also   1990.", "bbox": [432.0, 828.0, 488.0, 841.0]}, {"text": ",", "bbox": [122.0, 830.0, 134.0, 842.0]}, {"text": "o", "bbox": [254.0, 830.0, 286.0, 841.0]}, {"text": ":", "bbox": [412.0, 848.0, 425.0, 862.0]}, {"text": ",", "bbox": [283.0, 850.0, 295.0, 862.0]}, {"text": ",", "bbox": [475.0, 850.0, 486.0, 862.0]}, {"text": ",", "bbox": [164.0, 851.0, 174.0, 862.0]}, {"text": "Chapter 1", "bbox": [285.0, 868.0, 311.0, 884.0]}, {"text": "Chapter 1", "bbox": [203.0, 870.0, 215.0, 883.0]}, {"text": "Chapter 1", "bbox": [454.0, 870.0, 465.0, 880.0]}, {"text": ",", "bbox": [124.0, 871.0, 134.0, 883.0]}, {"text": "[2,5]", "bbox": [342.0, 881.0, 369.0, 897.0]}, {"text": "4. 2. 3", "bbox": [397.0, 883.0, 440.0, 901.0]}, {"text": "Chapter 1", "bbox": [120.0, 890.0, 131.0, 903.0]}, {"text": ".", "bbox": [193.0, 891.0, 205.0, 903.0]}, {"text": "3. 6", "bbox": [63.0, 903.0, 91.0, 921.0]}, {"text": ",", "bbox": [455.0, 909.0, 467.0, 922.0]}, {"text": ".", "bbox": [291.0, 930.0, 304.0, 942.0]}, {"text": ",", "bbox": [453.0, 930.0, 461.0, 941.0]}, {"text": "4. 2. 4", "bbox": [397.0, 943.0, 440.0, 961.0]}, {"text": "Chapter 1", "bbox": [310.0, 949.0, 322.0, 962.0]}, {"text": "Chapter 1", "bbox": [232.0, 950.0, 243.0, 962.0]}], "type": "Table", "position": 31}, {"raw_context": [{"text": ",", "bbox": [554.0, 591.0, 565.0, 603.0]}, {"text": ",", "bbox": [554.0, 611.0, 565.0, 623.0]}, {"text": ",", "bbox": [596.0, 631.0, 608.0, 643.0]}, {"text": ",", "bbox": [441.0, 632.0, 450.0, 642.0]}, {"text": ".", "bbox": [675.0, 632.0, 684.0, 641.0]}, {"text": "[15]", "bbox": [525.0, 641.0, 551.0, 660.0]}, {"text": "GB/", "bbox": [680.0, 644.0, 711.0, 660.0]}, {"text": ", 100", "bbox": [644.0, 651.0, 655.0, 662.0]}, {"text": "s", "bbox": [574.0, 664.0, 589.0, 681.0]}, {"text": ",", "bbox": [702.0, 670.0, 711.0, 683.0]}, {"text": "Chapter 1", "bbox": [596.0, 690.0, 608.0, 703.0]}, {"text": "5", "bbox": [540.0, 704.0, 553.0, 720.0]}, {"text": "o", "bbox": [594.0, 710.0, 606.0, 723.0]}, {"text": ".", "bbox": [413.0, 711.0, 425.0, 723.0]}, {"text": ",", "bbox": [477.0, 712.0, 486.0, 723.0]}, {"text": ",", "bbox": [588.0, 731.0, 600.0, 744.0]}, {"text": "Line 1990.", "bbox": [559.0, 747.0, 621.0, 764.0]}, {"text": ",", "bbox": [412.0, 749.0, 425.0, 764.0]}, {"text": ",", "bbox": [447.0, 749.0, 460.0, 764.0]}, {"text": ",", "bbox": [482.0, 751.0, 493.0, 763.0]}, {"text": ",", "bbox": [532.0, 751.0, 557.0, 763.0]}, {"text": ":", "bbox": [514.0, 769.0, 527.0, 783.0]}, {"text": "o", "bbox": [475.0, 770.0, 488.0, 783.0]}, {"text": ".", "bbox": [577.0, 770.0, 640.0, 786.0]}, {"text": "o", "bbox": [638.0, 770.0, 653.0, 783.0]}, {"text": ", 100", "bbox": [412.0, 771.0, 425.0, 784.0]}, {"text": "o", "bbox": [453.0, 789.0, 466.0, 801.0]}, {"text": ".", "bbox": [568.0, 809.0, 657.0, 823.0]}, {"text": ",", "bbox": [659.0, 809.0, 670.0, 822.0]}, {"text": "10. See also   1990.", "bbox": [432.0, 828.0, 488.0, 841.0]}, {"text": ". ", "bbox": [552.0, 828.0, 702.0, 843.0]}, {"text": ",", "bbox": [490.0, 829.0, 551.0, 842.0]}, {"text": ":", "bbox": [412.0, 848.0, 425.0, 862.0]}, {"text": ",", "bbox": [475.0, 850.0, 486.0, 862.0]}, {"text": ".", "bbox": [538.0, 850.0, 550.0, 862.0]}, {"text": "Chapter 1", "bbox": [454.0, 870.0, 465.0, 880.0]}, {"text": ". ", "bbox": [591.0, 890.0, 630.0, 901.0]}, {"text": ",", "bbox": [659.0, 890.0, 670.0, 902.0]}, {"text": "o", "bbox": [517.0, 908.0, 530.0, 922.0]}, {"text": ",      ,             :", "bbox": [532.0, 908.0, 712.0, 923.0]}, {"text": ",", "bbox": [455.0, 909.0, 467.0, 922.0]}, {"text": "o", "bbox": [510.0, 929.0, 522.0, 942.0]}, {"text": "o", "bbox": [694.0, 929.0, 707.0, 942.0]}, {"text": ",", "bbox": [453.0, 930.0, 461.0, 941.0]}, {"text": ",", "bbox": [651.0, 948.0, 664.0, 962.0]}, {"text": ", 100", "bbox": [651.0, 968.0, 700.0, 982.0]}, {"text": ",", "bbox": [413.0, 969.0, 424.0, 982.0]}, {"text": "o ", "bbox": [564.0, 969.0, 653.0, 982.0]}, {"text": "o", "bbox": [700.0, 969.0, 712.0, 982.0]}, {"text": ":", "bbox": [426.0, 987.0, 438.0, 1001.0]}, {"text": ", 100", "bbox": [489.0, 989.0, 502.0, 1002.0]}, {"text": "o", "bbox": [653.0, 989.0, 676.0, 1002.0]}, {"text": "o", "bbox": [552.0, 990.0, 565.0, 1002.0]}, {"text": ",", "bbox": [659.0, 1010.0, 669.0, 1022.0]}, {"text": ",", "bbox": [593.0, 1011.0, 605.0, 1022.0]}], "type": "Text", "position": 32}, {"raw_context": [{"text": ",", "bbox": [80.0, 970.0, 92.0, 983.0]}], "type": "Text", "position": 33}, {"raw_context": [{"text": ",", "bbox": [80.0, 990.0, 91.0, 1002.0]}], "type": "Text", "position": 34}, {"raw_context": [{"text": "o", "bbox": [121.0, 1010.0, 131.0, 1022.0]}], "type": "Text", "position": 35}, {"raw_context": [{"text": "MRI", "bbox": [199.0, 983.0, 229.0, 1000.0]}, {"text": ",", "bbox": [161.0, 990.0, 171.0, 1001.0]}], "type": "Text", "position": 36}, {"raw_context": [{"text": "100, 1188", "bbox": [394.0, 68.0, 413.0, 83.0]}], "type": "Text", "position": 37}, {"raw_context": [{"text": "2022", "bbox": [365.0, 67.0, 394.0, 83.0]}], "type": "Text", "position": 38}, {"raw_context": [{"text": "4. 2. 5", "bbox": [397.0, 1003.0, 438.0, 1021.0]}], "type": "Table", "position": 40}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/骨科/共识/脊髓型颈椎病中西医结合诊疗专家共识.pdf", "page_num": 3}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "格式杂乱#0#56#内容难以理解", "type3": null, "type4": null, "type5": null, "type6": null}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:41", "update_time": "2024-05-07 21:36:53"}
{"id": 1082558, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 738, "source_info": {"seq_id": "fa991d90-ccdd-47e8-9351-6c2205cfe0a5", "title": null, "text": "【0】页码:8\n\n【1】## 本刊地址和通讯方式\n\n【2】\n with negative findings by visual evaluation[J]. Clin Respir J, 2019, 13(12):741-750. DOI: 10.1111/crj.13084.\n\n【3】金晨望, 梁志冉, 段海峰, 等 . 基于体素的空气潘留定量测量 [27] 方法的建立及初步临床应用[]]. 中华放射学杂志 , 2019, 53(1): 21-25. DOI: 10.3760/cma.j.issn.1005-1201.2019.01.006.\n\n【4】[28] 周秀秀, 蕾瑜, 张迪, 等. 基于参数响应图参数的随机森林 模型预测胸部疾病患者的肺功能[J].中华放射学杂志, 56(9): 1001-1008.\n\n【5】DOI:     10.3760/cma.    j.\n\n【6】2022, cn112149-20210907-00829.\n\n【7】黄晓旗, 牛媛, 雷禹, 等. 基于 CT 双气相定量研究吸烟合并 [29] 侵性阻塞性肺疾病患者的肺叶小气道病变及肺气肿损伤 程度 [J]. 中华放射学杂志 , 2022, 56(5): 536-541. DOI: 10.3760/cma.j.cn112149-20210428-00418.\n\n【8】[30] Koo HK, Vasilescu DM, Booth S, et al. Small airways disease in mild and moderate chronic obstructive pulmonary disease: a cross-sectional study[J]. Lancet Respir Med, 2018, 6(8): 591-602. DOI: 10.1016/ $2213-2600(18)30196-6.\n\n【9】[31] Cao X, Gao X, Yu N, et al. Potential value of expiratory CT in quantitative assessment of pulmonary vessels in COPD [J]. Front Med (Lausanne), 2021, 8:761804. DOI: 10.3389/ fmed.2021.761804.\n\n【10】[32] Xia Y, Guan Y, Fan L, et al. Dynamic contrast enhanced\n\n【11】 10.3109/15412555.2014.948990.\n\n【12】[33] Guan Y, Xia Y, Fan L, et al. Quantitative assessment of pulmonary perfusion using dynamic contrast-enhanced CT in patients with chronic obstructive pulmonary disease: correlations with pulmonary function test and CT volumetric parameters[J]. Acta Radiol, 2015, 56(5): 573-580. DOI: 10.1177/0284185114535208.\n\n【13】Kim M, Doganay O, Hwang HJ, et al. Lobar ventilation in [34] patients with COPD assessed with the full-scale airway network flow model and xenon-enhanced dual-energy CT [J]. Radiology, 2021, 298(1): 201-209. DOI: 10.1148/ radiol.2020202485.\n\n【14】中华医学会放射学分会, 中国医师协会放射医师分会, 安 [35] 徽省影像临床医学研究中心.能量CT临床应用中国专家 共识[J]. 中华放射学杂志 , 2022, 56(5):12. DOI: 10.3760/ cma.j.cn112149-20220118-00051.\n\n【15】刘文燕,武志峰.CT评估慢性阻塞性肺炎病患者胸部骨骼 [36] [36] 肌功能障碍的研究进展 [J]. 中华放射学杂志 , 2022, 56(3): 321-324. DOI: 10.3760/cma.j.cn112149-20210421-00394.\n\n【16】Mouronte-Roibás C, Leiro-Fernández V, Fernández-Villar [37] A, et al. COPD, emphysema and the onset of lung cancer. A systematic review[J]. Cancer Lett, 2016, 382(2):240-244.\n\n【17】DOI: 10.1016/j.canlet.2016.09.002.\n\n【18】 《中华放射学杂志》编辑部 邮政编码 : 100052\n\n【19】 张琳琳,编辑部主任 联系电话 :010-51322326\n\n【20】 联系电话 :010-51322329\n\n【21】 Email:zhanglinlin@cmaph.org 分管专业: 心血管放射学 、介人放射学 、影像技术学\n\n【22】 Email:shixiaojuan@cmaph.org 分管专业 : 中枢神经系统放射学 、胸部放射学 、 乳腺故射学\n\n【23】 胡凌,编辑\n\n【24】 联系电话:010-51322325\n\n【25】 李毅, 编务\n\n【26】 联系电话:010-51322321.\n\n【27】Email:liyi@cmaph.org\n\n【28】 Email:huling@cmaph.org 分管专业:头颈部放射学、腹部放射学、骨骼肌肉 系统放射学、儿童放射学\n\n【29】 编辑部工作人员及联系方式\n\n【30】 ( 本刊 ) { $ { $ } }", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "本刊地址和通讯方式", "bbox": [84.0, 671.0, 279.0, 700.0]}], "type": "Section-header", "position": 3}, {"raw_context": [{"text": "with negative findings by visual evaluation[J]. Clin Respir", "bbox": [122.0, 102.0, 390.0, 116.0]}, {"text": "J, 2019, 13(12):741-750. DOI: 10.1111/crj.13084.", "bbox": [123.0, 118.0, 350.0, 131.0]}, {"text": "金晨望, 梁志冉, 段海峰, 等 . 基于体素的空气潘留定量测量", "bbox": [122.0, 131.0, 390.0, 145.0]}, {"text": "[27]", "bbox": [87.0, 132.0, 113.0, 146.0]}, {"text": "方法的建立及初步临床应用[]]. 中华放射学杂志 , 2019, 53(1):", "bbox": [123.0, 146.0, 391.0, 160.0]}, {"text": "21-25. DOI: 10.3760/cma.j.issn.1005-1201.2019.01.006.", "bbox": [123.0, 162.0, 355.0, 175.0]}, {"text": "[28]", "bbox": [87.0, 176.0, 113.0, 191.0]}, {"text": "周秀秀, 蕾瑜, 张迪, 等. 基于参数响应图参数的随机森林", "bbox": [122.0, 177.0, 390.0, 190.0]}, {"text": "模型预测胸部疾病患者的肺功能[J].中华放射学杂志,", "bbox": [122.0, 191.0, 391.0, 206.0]}, {"text": "56(9): 1001-1008.", "bbox": [161.0, 208.0, 266.0, 220.0]}, {"text": "DOI:     10.3760/cma.    j.", "bbox": [268.0, 208.0, 391.0, 220.0]}, {"text": "2022,", "bbox": [123.0, 209.0, 156.0, 220.0]}, {"text": "cn112149-20210907-00829.", "bbox": [123.0, 222.0, 257.0, 235.0]}, {"text": "黄晓旗, 牛媛, 雷禹, 等. 基于 CT 双气相定量研究吸烟合并", "bbox": [122.0, 236.0, 390.0, 251.0]}, {"text": "[29]", "bbox": [88.0, 238.0, 113.0, 251.0]}, {"text": "侵性阻塞性肺疾病患者的肺叶小气道病变及肺气肿损伤", "bbox": [122.0, 251.0, 390.0, 265.0]}, {"text": "程度 [J]. 中华放射学杂志 , 2022, 56(5): 536-541. DOI:", "bbox": [123.0, 265.0, 390.0, 280.0]}, {"text": "10.3760/cma.j.cn112149-20210428-00418.", "bbox": [123.0, 282.0, 326.0, 295.0]}, {"text": "[30]", "bbox": [88.0, 297.0, 112.0, 309.0]}, {"text": "Koo HK, Vasilescu DM, Booth S, et al. Small airways", "bbox": [122.0, 297.0, 390.0, 310.0]}, {"text": "disease in mild and moderate chronic obstructive", "bbox": [123.0, 312.0, 390.0, 325.0]}, {"text": "pulmonary disease: a cross-sectional study[J]. Lancet", "bbox": [123.0, 327.0, 390.0, 340.0]}, {"text": "Respir Med, 2018, 6(8): 591-602. DOI: 10.1016/", "bbox": [123.0, 341.0, 390.0, 354.0]}, {"text": "$2213-2600(18)30196-6.", "bbox": [123.0, 356.0, 241.0, 369.0]}, {"text": "[31]", "bbox": [87.0, 370.0, 113.0, 384.0]}, {"text": "Cao X, Gao X, Yu N, et al. Potential value of expiratory CT", "bbox": [121.0, 370.0, 390.0, 384.0]}, {"text": "in quantitative assessment of pulmonary vessels in COPD", "bbox": [123.0, 385.0, 391.0, 398.0]}, {"text": "[J]. Front Med (Lausanne), 2021, 8:761804. DOI: 10.3389/", "bbox": [122.0, 399.0, 390.0, 413.0]}, {"text": "fmed.2021.761804.", "bbox": [123.0, 416.0, 213.0, 428.0]}, {"text": "[32]", "bbox": [87.0, 429.0, 112.0, 444.0]}, {"text": "Xia Y, Guan Y, Fan L, et al. Dynamic contrast enhanced", "bbox": [121.0, 429.0, 392.0, 444.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": "10.3109/15412555.2014.948990.", "bbox": [463.0, 102.0, 620.0, 116.0]}, {"text": "[33]", "bbox": [428.0, 119.0, 453.0, 132.0]}, {"text": "Guan Y, Xia Y, Fan L, et al. Quantitative assessment of", "bbox": [461.0, 119.0, 731.0, 131.0]}, {"text": "pulmonary perfusion using dynamic contrast-enhanced", "bbox": [463.0, 133.0, 731.0, 145.0]}, {"text": "CT in patients with chronic obstructive pulmonary", "bbox": [462.0, 148.0, 731.0, 160.0]}, {"text": "disease: correlations with pulmonary function test and", "bbox": [462.0, 163.0, 731.0, 175.0]}, {"text": "CT volumetric parameters[J]. Acta Radiol, 2015, 56(5):", "bbox": [462.0, 177.0, 731.0, 190.0]}, {"text": "573-580. DOI: 10.1177/0284185114535208.", "bbox": [463.0, 192.0, 671.0, 206.0]}, {"text": "Kim M, Doganay O, Hwang HJ, et al. Lobar ventilation in", "bbox": [461.0, 207.0, 731.0, 221.0]}, {"text": "[34]", "bbox": [428.0, 209.0, 453.0, 220.0]}, {"text": "patients with COPD assessed with the full-scale airway", "bbox": [462.0, 221.0, 731.0, 236.0]}, {"text": "network flow model and xenon-enhanced dual-energy CT", "bbox": [463.0, 237.0, 731.0, 250.0]}, {"text": "[J]. Radiology, 2021, 298(1): 201-209. DOI: 10.1148/", "bbox": [462.0, 251.0, 731.0, 265.0]}, {"text": "radiol.2020202485.", "bbox": [463.0, 266.0, 556.0, 279.0]}, {"text": "中华医学会放射学分会, 中国医师协会放射医师分会, 安", "bbox": [461.0, 280.0, 731.0, 295.0]}, {"text": "[35]", "bbox": [428.0, 281.0, 453.0, 295.0]}, {"text": "徽省影像临床医学研究中心.能量CT临床应用中国专家", "bbox": [462.0, 296.0, 731.0, 310.0]}, {"text": "共识[J]. 中华放射学杂志 , 2022, 56(5):12. DOI: 10.3760/", "bbox": [463.0, 311.0, 731.0, 325.0]}, {"text": "cma.j.cn112149-20220118-00051.", "bbox": [462.0, 326.0, 622.0, 340.0]}, {"text": "刘文燕,武志峰.CT评估慢性阻塞性肺炎病患者胸部骨骼", "bbox": [462.0, 341.0, 731.0, 354.0]}, {"text": "[36] [36]", "bbox": [428.0, 342.0, 452.0, 354.0]}, {"text": "肌功能障碍的研究进展 [J]. 中华放射学杂志 , 2022, 56(3):", "bbox": [462.0, 355.0, 730.0, 369.0]}, {"text": "321-324. DOI: 10.3760/cma.j.cn112149-20210421-00394.", "bbox": [462.0, 370.0, 722.0, 384.0]}, {"text": "Mouronte-Roibás C, Leiro-Fernández V, Fernández-Villar", "bbox": [461.0, 385.0, 731.0, 398.0]}, {"text": "[37]", "bbox": [428.0, 386.0, 454.0, 399.0]}, {"text": "A, et al. COPD, emphysema and the onset of lung cancer. A", "bbox": [462.0, 401.0, 731.0, 413.0]}, {"text": "systematic review[J]. Cancer Lett, 2016, 382(2):240-244.", "bbox": [463.0, 416.0, 731.0, 429.0]}, {"text": "DOI: 10.1016/j.canlet.2016.09.002.", "bbox": [463.0, 430.0, 626.0, 443.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "《中华放射学杂志》编辑部", "bbox": [108.0, 716.0, 245.0, 733.0]}, {"text": "邮政编码 : 100052", "bbox": [125.0, 755.0, 219.0, 770.0]}], "type": "Text", "position": 6}, {"raw_context": [{"text": "张琳琳,编辑部主任", "bbox": [120.0, 801.0, 224.0, 815.0]}, {"text": "联系电话 :010-51322326", "bbox": [119.0, 819.0, 247.0, 835.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "联系电话 :010-51322329", "bbox": [452.0, 820.0, 581.0, 833.0]}], "type": "Text", "position": 8}, {"raw_context": [{"text": "Email:zhanglinlin@cmaph.org", "bbox": [119.0, 839.0, 264.0, 853.0]}, {"text": "分管专业: 心血管放射学 、介人放射学 、影像技术学", "bbox": [120.0, 858.0, 381.0, 873.0]}], "type": "Text", "position": 9}, {"raw_context": [{"text": "Email:shixiaojuan@cmaph.org", "bbox": [452.0, 839.0, 599.0, 853.0]}, {"text": "分管专业 : 中枢神经系统放射学 、胸部放射学 、", "bbox": [453.0, 858.0, 689.0, 873.0]}, {"text": "乳腺故射学", "bbox": [507.0, 877.0, 570.0, 892.0]}], "type": "Text", "position": 10}, {"raw_context": [{"text": "胡凌,编辑", "bbox": [120.0, 891.0, 177.0, 906.0]}], "type": "Text", "position": 11}, {"raw_context": [{"text": "联系电话:010-51322325", "bbox": [119.0, 910.0, 246.0, 925.0]}], "type": "Text", "position": 12}, {"raw_context": [{"text": "李毅, 编务", "bbox": [454.0, 910.0, 509.0, 925.0]}], "type": "Text", "position": 13}, {"raw_context": [{"text": "联系电话:010-51322321.", "bbox": [452.0, 929.0, 579.0, 944.0]}, {"text": "Email:liyi@cmaph.org", "bbox": [453.0, 949.0, 561.0, 962.0]}], "type": "Text", "position": 14}, {"raw_context": [{"text": "Email:huling@cmaph.org", "bbox": [119.0, 929.0, 241.0, 944.0]}, {"text": "分管专业:头颈部放射学、腹部放射学、骨骼肌肉", "bbox": [120.0, 947.0, 381.0, 963.0]}, {"text": "系统放射学、儿童放射学", "bbox": [177.0, 967.0, 305.0, 981.0]}], "type": "Text", "position": 15}, {"raw_context": [{"text": "编辑部工作人员及联系方式", "bbox": [108.0, 781.0, 255.0, 797.0]}], "type": "Text", "position": 16}, {"raw_context": [{"text": "( 本刊 ) { $ { $ } }", "bbox": [655.0, 967.0, 731.0, 981.0]}], "type": "Text", "position": 17}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/呼吸科/_慢性阻塞性肺疾病胸部CT检查及评价中国专家共识.pdf", "page_num": 8}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": null, "type3": null, "type4": null, "type5": null, "type6": "信息有用性#0#30#参考文献"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:41", "update_time": "2024-05-07 19:37:20"}
{"id": 1082557, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 738, "source_info": {"seq_id": "5045004c-da2f-43c9-a916-7ee4bd827c8b", "title": null, "text": "【0】页码:8\n 848\n\n【1】## 上皮性卵巢癌Parp抑制剂相关生物标志物检测的中国专家共识\n\n【2】\n NAIPAL K A, VERKAIK N S, AMEZIANE N, et al. Functional [ 32 ] ex vivo assay to select homologous recombination–deficient breast tumors for PARP inhibitor treatment [ J ] . Clin Cancer Res, 2014, 20(18): 4816–4826.\n\n【3】DAVIES H, GLODZIK D, MORGANELLA S, et al. HRDetect [ 33 ] is a predictor of BRCA 1 and BRCA 2 deficiency based on mutational signatures [ J ] . Nat Med, 2017, 23(4): 517.\n\n【4】[ 34 ] 《 基于下一代测序技术的BRCA 1/2基因检测指南 ( 2019 ) 版 ) 》编写组. 基于下一代测序技术的BRCA1/2基因检测 指南（2019版 ） [ J ] . 中华病理学杂志 , 2019, 48(9): 670– 677.\n\n【5】Working Group of Guideline on Next–Generation Sequencing– Based BRCA 1/2 Testing (2019). Guideline on next–generation sequencing–based BRCA 1/2 testing (2019) [ J ] . Chin J Pathol, 2019, 48(9): 670–677.\n\n【6】BRCA数据解读中国专家共识编写组. BRCA数据解读中国 [ 35 ] 专家共识 [ J ] . 中华病理学杂志 , 2017, 46(5): 293–297.\n\n【7】Working Group of Chinese experts consensus on the Interpretation of BRCA data. Chinese experts consensus on the Interpretation of BRCA data [J] . Chin J Pathol, 2017, 46(5): 293–297.\n\n【8】[ 36 ] RICHARDS S, AZIZ N, BALE S, et al. Standards and guidelines forthe interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology [1] . Genet Med, 2015, 17(5): 405-424.\n\n【9】ENIGMA Consortium. ENIGMA BRCA 1/2 gene variant [ 37 ] classification criteria [ EB-OL] . Version 2.5.1 29 June 2017.\n\n【10】https://enigmaconsortium.org/wp–content/uploads/2018/10/ ENIGMA_Rules_2017–06–29–v2.5.1.pdf.\n\n【11】[ 38 ] > CHAKRAVARTY D, GAO J, PHILLIPS S M, et al. OncoKB: a precision oncology knowledge base [J] . JCO Precis Oncol, 201717.00011.\n\n【12】LI M M, DATTO M, DUNCAVAGE E J, et al. Standards and [ 39 ] guidelines for the interpretation and reporting of sequence variants in cancer [ J ] . J Mol Diagn, 2017, 19(1): 4–23.\n\n【13】W ATKINS J A, IRSHAD S, GRIGORIADIS A, et al. Genomic [ 40 ] scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers [J] . Breast Cancer Res, 2014, 16(3): 211.\n\n【14】[ 41 ] ABKEVICH V, TIMMS K M, HENNESSY B T, et al. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer [ J ] . Br J Cancer, 2012, 107(10): 1776–1782.\n\n【15】POPOVA T, MANIÉ E, RIEUNIER G, et al. Ploidy and large– [ 42 ] scale genomic instability consistently identify basal–like breast carcinomas with BRCA 1/2 inactivation [ J ] . Cancer Res, 2012, 72(21): 5454–5462.\n\n【16】BIRKBAK N J, WANG Z C, KIM J Y, et al. Telomeric allelic [ 43 ] imbalance indicates defective DNA repair and sensitivity to DNA–damaging agents [ J ] .  Cancer Discov, 2012, 2(4): 366– 375.\n\n【17】[ 44 ] STRONACH E A, PAULNJ, TIMMS K M, et al. Biomarker\n\n【18】 [ 45 ] [ 46 ].\n\n【19】[ 47 , ] ,\n\n【20】 [ 48 ]\n\n【21】 [ 49 ] [ 50 ]\n\n【22】 [ 51 ]\n\n【23】 [ 52 ]\n\n【24】 [ 53 ] [54]\n\n【25】 [ 55 ]\n\n【26】 [ 56 ]\n\n【27】 assessment of HR deficiency, tumor BRCA 1/2 mutations, and CCNE1 copy number in ovarian cancer: associations with clinical outcome following platinum monotherapy [ J ] . Mol Cancer Res, 2018, 16(7): 1103–1111.\n\n【28】FDA. Myriad myChoice CDx – P190014. [ EB/OL ] .https:// www.fda.gov/medical–devices/recently–approved–devices/ myriad–mychoice–cdx–p190014.\n\n【29】FDA. FoundationFocus CDxBRCA LOH – P160018/S001 [ EB/ OL ]    https://www.fda.gov/medical–devices/recently–approved– devices/foundationfocus–cdx brca –loh–p160018s001.\n\n【30】' 国家药品监督管理局. 体外诊断试剂注册管理办法 ( 国家 食品药品监督管理总局令第5号 ) [ EB/OL ] . https://www.\n\n【31】nmpa gov .cn /xxgk /fgwj /bmgzh /20140730170001489 .html .\n\n【32】国家药品监督管理局医疗器械技术审评中心. 肿瘤相关突 变基因检测试剂 ( 高通量测序法 ) 性能评价通用注册技术 审查指导原则(2019年第83号) [ EB/OL ] . https://www.nmpa.\n\n【33】gov.cn/ .\n\n【34】国家药品监督管理局医疗器械技术审评中心. 体\n\n【35】 外 诊 断 试 剂 临 床 试 验 技 术 指 导 原 则 ( 2014年第16 号 ) [ EB/OL ] . https://www.nmpa.gov.cn/xxgk/ggtg/ qtggtg/20140911120001840.html.\n\n【36】FDA. In Vitro Companion Diagnostic Devices, document issued on August 6, 2014. [ EB/OL ] . https://www.fda.gov/ regulatory–information/search–fda–guidance–documents/vitro– companion–diagnostic–devices .\n\n【37】FDA. Considerations for Design, Development, and Analytical Validation of Next Generation Sequencing (NGS) – Based In Vitro Diagnostics (IVDs) Intended to Aid in the Diagnosis of Suspected Germline Diseases, document issued on April 13, 2018 [ EB/OL ] . https://www.fda.gov/regulatory–information/ search– fda– guidance– documents/ considerations– design– development–and–analytical–validation–next–generation– sequencing–ngs–based.\n\n【38】JENNINGS L, VAN DEERLIN V M, GULLEY M L, et al.\n\n【39】Recommended principles and practices for validating clinical molecular pathology tests [ J ] . Arch Pathol Lab Med, 2009, 133(5): 743–755.\n\n【40】KHAN M U, BOWSHER R R, CAMERON M, et al.\n\n【41】Recommendations for adaptation and validation of commercial kits for biomarker quantification in drug development [ J ] .\n\n【42】Bioanalysis ,  2015 ,  7( 2 ):  229–242 .\n\n【43】KONSTANTINOPOULOS P A, NORQUIST B, LACCHETTI C, et al. Germline and somatic tumor testing in epithelial ovarian cancer: ASCO guideline [ J ] . J Clin Oncol, 2020, 38 (11): 1222–1245.\n\n【44】TEW W P, LACCHETTI C, ELLIS A, et al. PARP inhibitors in the management of ovarian cancer: ASCO guideline [ J ] . J Clin Oncol, 2020: JCO2001924.\n\n【45】DALY M B, PILARSKI R, YURGELUN M B, et al.NCCN guidelines insights: genetic/familial high–risk assessment: breast, ovarian, and pancreatic, version 1.2020 [ J ] . J Natl Compr Canc Netw ,  2020 ,  18 ( 4 ):  380 – 391 .\n\n【46】( 收稿日期: 2020-09-29  修回日期: 2020-09-30)", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "848", "bbox": [53.0, 61.0, 77.0, 75.0]}], "type": "Text", "position": 0}, {"raw_context": [{"text": "上皮性卵巢癌PARP抑制剂相关生物标志物检测的中国专家共识", "bbox": [411.0, 62.0, 701.0, 78.0]}], "type": "Section-header", "position": 1}, {"raw_context": [{"text": "NAIPAL K A, VERKAIK N S, AMEZIANE N, et al. Functional", "bbox": [90.0, 88.0, 365.0, 101.0]}, {"text": "[ 32 ]", "bbox": [58.0, 90.0, 87.0, 101.0]}, {"text": "ex vivo assay to select homologous recombination–deficient", "bbox": [91.0, 106.0, 364.0, 119.0]}, {"text": "breast tumors for PARP inhibitor treatment [ J ] . Clin Cancer", "bbox": [91.0, 123.0, 365.0, 137.0]}, {"text": "Res, 2014, 20(18): 4816–4826.", "bbox": [91.0, 140.0, 224.0, 154.0]}, {"text": "DAVIES H, GLODZIK D, MORGANELLA S, et al. HRDetect", "bbox": [90.0, 156.0, 365.0, 171.0]}, {"text": "[ 33 ]", "bbox": [59.0, 158.0, 87.0, 171.0]}, {"text": "is a predictor of BRCA 1 and BRCA 2 deficiency based on", "bbox": [91.0, 174.0, 365.0, 189.0]}, {"text": "mutational signatures [ J ] . Nat Med, 2017, 23(4): 517.", "bbox": [91.0, 192.0, 328.0, 206.0]}, {"text": "[ 34 ]", "bbox": [58.0, 209.0, 86.0, 224.0]}, {"text": "《 基于下一代测序技术的BRCA 1/2基因检测指南 ( 2019 )", "bbox": [93.0, 209.0, 366.0, 224.0]}, {"text": "版 ) 》编写组. 基于下一代测序技术的BRCA1/2基因检测", "bbox": [91.0, 226.0, 364.0, 241.0]}, {"text": "指南（2019版 ） [ J ] . 中华病理学杂志 , 2019, 48(9): 670–", "bbox": [91.0, 244.0, 362.0, 258.0]}, {"text": "677.", "bbox": [91.0, 263.0, 114.0, 275.0]}, {"text": "Working Group of Guideline on Next–Generation Sequencing–", "bbox": [91.0, 279.0, 363.0, 293.0]}, {"text": "Based BRCA 1/2 Testing (2019). Guideline on next–generation", "bbox": [91.0, 297.0, 364.0, 310.0]}, {"text": "sequencing–based BRCA 1/2 testing (2019) [ J ] . Chin J", "bbox": [91.0, 314.0, 364.0, 328.0]}, {"text": "Pathol, 2019, 48(9): 670–677.", "bbox": [91.0, 331.0, 221.0, 345.0]}, {"text": "BRCA数据解读中国专家共识编写组. BRCA数据解读中国", "bbox": [90.0, 348.0, 364.0, 363.0]}, {"text": "[ 35 ]", "bbox": [58.0, 349.0, 86.0, 363.0]}, {"text": "专家共识 [ J ] . 中华病理学杂志 , 2017, 46(5): 293–297.", "bbox": [93.0, 365.0, 343.0, 380.0]}, {"text": "Working Group of Chinese experts consensus on the", "bbox": [91.0, 383.0, 364.0, 398.0]}, {"text": "Interpretation of BRCA data. Chinese experts consensus on the", "bbox": [91.0, 401.0, 364.0, 414.0]}, {"text": "Interpretation of BRCA data [J] . Chin J Pathol, 2017, 46(5):", "bbox": [91.0, 418.0, 364.0, 433.0]}, {"text": "293–297.", "bbox": [92.0, 436.0, 136.0, 449.0]}, {"text": "[ 36 ]", "bbox": [58.0, 452.0, 87.0, 466.0]}, {"text": "RICHARDS S, AZIZ N, BALE S, et al. Standards and guidelines", "bbox": [90.0, 452.0, 364.0, 466.0]}, {"text": "forthe interpretation of sequence variants: a joint consensus", "bbox": [91.0, 471.0, 364.0, 484.0]}, {"text": "recommendation of the American College of Medical Genetics", "bbox": [91.0, 488.0, 364.0, 501.0]}, {"text": "and Genomics and the Association for Molecular Pathology", "bbox": [91.0, 504.0, 364.0, 519.0]}, {"text": "[1] . Genet Med, 2015, 17(5): 405-424.", "bbox": [95.0, 522.0, 267.0, 536.0]}, {"text": "ENIGMA Consortium. ENIGMA BRCA 1/2 gene variant", "bbox": [90.0, 539.0, 364.0, 553.0]}, {"text": "[ 37 ]", "bbox": [59.0, 541.0, 86.0, 552.0]}, {"text": "classification criteria [ EB-OL] . Version 2.5.1 29 June 2017.", "bbox": [91.0, 556.0, 364.0, 570.0]}, {"text": "https://enigmaconsortium.org/wp–content/uploads/2018/10/", "bbox": [91.0, 574.0, 364.0, 588.0]}, {"text": "ENIGMA_Rules_2017–06–29–v2.5.1.pdf.", "bbox": [91.0, 591.0, 272.0, 605.0]}, {"text": "[ 38 ] > CHAKRAVARTY D, GAO J, PHILLIPS S M, et al. OncoKB: a", "bbox": [58.0, 609.0, 365.0, 622.0]}, {"text": "precision oncology knowledge base [J] . JCO Precis Oncol,", "bbox": [91.0, 627.0, 364.0, 640.0]}, {"text": "201717.00011.", "bbox": [93.0, 643.0, 159.0, 657.0]}, {"text": "LI M M, DATTO M, DUNCAVAGE E J, et al. Standards and", "bbox": [88.0, 659.0, 365.0, 675.0]}, {"text": "[ 39 ]", "bbox": [59.0, 661.0, 88.0, 675.0]}, {"text": "guidelines for the interpretation and reporting of sequence", "bbox": [92.0, 678.0, 364.0, 692.0]}, {"text": "variants in cancer [ J ] . J Mol Diagn, 2017, 19(1): 4–23.", "bbox": [91.0, 695.0, 336.0, 710.0]}, {"text": "W ATKINS J A, IRSHAD S, GRIGORIADIS A, et al. Genomic", "bbox": [91.0, 713.0, 364.0, 727.0]}, {"text": "[ 40 ]", "bbox": [59.0, 714.0, 86.0, 728.0]}, {"text": "scars as biomarkers of homologous recombination deficiency", "bbox": [91.0, 730.0, 364.0, 744.0]}, {"text": "and drug response in breast and ovarian cancers [J] . Breast", "bbox": [92.0, 749.0, 365.0, 760.0]}, {"text": "Cancer Res, 2014, 16(3): 211.", "bbox": [91.0, 765.0, 220.0, 778.0]}, {"text": "[ 41 ]", "bbox": [59.0, 783.0, 86.0, 796.0]}, {"text": "ABKEVICH V, TIMMS K M, HENNESSY B T, et al. Patterns of", "bbox": [91.0, 782.0, 366.0, 796.0]}, {"text": "genomic loss of heterozygosity predict homologous recombination", "bbox": [91.0, 800.0, 364.0, 814.0]}, {"text": "repair defects in epithelial ovarian cancer [ J ] . Br J Cancer,", "bbox": [91.0, 817.0, 366.0, 831.0]}, {"text": "2012, 107(10): 1776–1782.", "bbox": [92.0, 834.0, 209.0, 848.0]}, {"text": "POPOVA T, MANIÉ E, RIEUNIER G, et al. Ploidy and large–", "bbox": [90.0, 851.0, 363.0, 866.0]}, {"text": "[ 42 ]", "bbox": [58.0, 852.0, 87.0, 866.0]}, {"text": "scale genomic instability consistently identify basal–like breast", "bbox": [91.0, 869.0, 365.0, 884.0]}, {"text": "carcinomas with BRCA 1/2 inactivation [ J ] . Cancer Res, 2012,", "bbox": [91.0, 886.0, 364.0, 900.0]}, {"text": "72(21): 5454–5462.", "bbox": [91.0, 903.0, 178.0, 916.0]}, {"text": "BIRKBAK N J, WANG Z C, KIM J Y, et al. Telomeric allelic", "bbox": [90.0, 921.0, 364.0, 935.0]}, {"text": "[ 43 ]", "bbox": [59.0, 923.0, 88.0, 935.0]}, {"text": "imbalance indicates defective DNA repair and sensitivity to", "bbox": [91.0, 938.0, 365.0, 952.0]}, {"text": "DNA–damaging agents [ J ] .  Cancer Discov, 2012, 2(4): 366–", "bbox": [91.0, 955.0, 363.0, 969.0]}, {"text": "375.", "bbox": [93.0, 975.0, 114.0, 986.0]}, {"text": "[ 44 ] STRONACH E A, PAULNJ, TIMMS K M, et al. Biomarker", "bbox": [58.0, 990.0, 364.0, 1005.0]}], "type": "Text", "position": 2}, {"raw_context": [{"text": "[ 45 ]", "bbox": [395.0, 159.0, 424.0, 171.0]}, {"text": "[ 46 ].", "bbox": [396.0, 210.0, 427.0, 223.0]}, {"text": "[ 47 , ] ,", "bbox": [395.0, 263.0, 425.0, 274.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "[ 48 ]", "bbox": [395.0, 316.0, 422.0, 327.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": "[ 49 ]", "bbox": [395.0, 385.0, 425.0, 397.0]}, {"text": "[ 50 ]", "bbox": [395.0, 454.0, 425.0, 465.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "[ 51 ]", "bbox": [395.0, 524.0, 424.0, 536.0]}], "type": "Text", "position": 6}, {"raw_context": [{"text": "[ 52 ]", "bbox": [395.0, 662.0, 423.0, 675.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "[ 53 ]", "bbox": [395.0, 731.0, 425.0, 744.0]}, {"text": "[54]", "bbox": [394.0, 800.0, 424.0, 813.0]}], "type": "Text", "position": 8}, {"raw_context": [{"text": "[ 55 ]", "bbox": [395.0, 870.0, 423.0, 884.0]}], "type": "Text", "position": 9}, {"raw_context": [{"text": "[ 56 ]", "bbox": [395.0, 923.0, 425.0, 935.0]}], "type": "Text", "position": 10}, {"raw_context": [{"text": "assessment of HR deficiency, tumor BRCA 1/2 mutations, and", "bbox": [429.0, 88.0, 701.0, 102.0]}, {"text": "CCNE1 copy number in ovarian cancer: associations with", "bbox": [428.0, 106.0, 701.0, 119.0]}, {"text": "clinical outcome following platinum monotherapy [ J ] . Mol", "bbox": [428.0, 124.0, 701.0, 137.0]}, {"text": "Cancer Res, 2018, 16(7): 1103–1111.", "bbox": [428.0, 140.0, 590.0, 154.0]}, {"text": "FDA. Myriad myChoice CDx – P190014. [ EB/OL ] .https://", "bbox": [425.0, 157.0, 701.0, 171.0]}, {"text": "www.fda.gov/medical–devices/recently–approved–devices/", "bbox": [429.0, 175.0, 701.0, 189.0]}, {"text": "myriad–mychoice–cdx–p190014.", "bbox": [429.0, 193.0, 572.0, 206.0]}, {"text": "FDA. FoundationFocus CDxBRCA LOH – P160018/S001 [ EB/", "bbox": [425.0, 210.0, 701.0, 223.0]}, {"text": "OL ]    https://www.fda.gov/medical–devices/recently–approved–", "bbox": [428.0, 227.0, 701.0, 241.0]}, {"text": "devices/foundationfocus–cdx brca –loh–p160018s001.", "bbox": [429.0, 244.0, 655.0, 257.0]}, {"text": "' 国家药品监督管理局. 体外诊断试剂注册管理办法 ( 国家", "bbox": [425.0, 262.0, 700.0, 275.0]}, {"text": "食品药品监督管理总局令第5号 ) [ EB/OL ] . https://www.", "bbox": [428.0, 279.0, 701.0, 293.0]}, {"text": "nmpa gov .cn /xxgk /fgwj /bmgzh /20140730170001489 .html .", "bbox": [429.0, 296.0, 673.0, 310.0]}, {"text": "国家药品监督管理局医疗器械技术审评中心. 肿瘤相关突", "bbox": [427.0, 314.0, 700.0, 328.0]}, {"text": "变基因检测试剂 ( 高通量测序法 ) 性能评价通用注册技术", "bbox": [429.0, 331.0, 701.0, 345.0]}, {"text": "审查指导原则(2019年第83号) [ EB/OL ] . https://www.nmpa.", "bbox": [429.0, 348.0, 700.0, 363.0]}, {"text": "gov.cn/ .", "bbox": [430.0, 368.0, 464.0, 380.0]}, {"text": "国家药品监督管理局医疗器械技术审评中心. 体", "bbox": [425.0, 382.0, 701.0, 397.0]}], "type": "Text", "position": 11}, {"raw_context": [{"text": "外 诊 断 试 剂 临 床 试 验 技 术 指 导 原 则 ( 2014年第16", "bbox": [429.0, 400.0, 702.0, 415.0]}, {"text": "号 ) [ EB/OL ] . https://www.nmpa.gov.cn/xxgk/ggtg/", "bbox": [429.0, 418.0, 701.0, 433.0]}, {"text": "qtggtg/20140911120001840.html.", "bbox": [429.0, 435.0, 573.0, 449.0]}, {"text": "FDA. In Vitro Companion Diagnostic Devices, document", "bbox": [425.0, 453.0, 701.0, 466.0]}, {"text": "issued on August 6, 2014. [ EB/OL ] . https://www.fda.gov/", "bbox": [429.0, 471.0, 701.0, 484.0]}, {"text": "regulatory–information/search–fda–guidance–documents/vitro–", "bbox": [429.0, 488.0, 700.0, 502.0]}, {"text": "companion–diagnostic–devices .", "bbox": [429.0, 506.0, 565.0, 519.0]}, {"text": "FDA. Considerations for Design, Development, and Analytical", "bbox": [425.0, 522.0, 701.0, 536.0]}, {"text": "Validation of Next Generation Sequencing (NGS) – Based In", "bbox": [429.0, 538.0, 701.0, 555.0]}, {"text": "Vitro Diagnostics (IVDs) Intended to Aid in the Diagnosis of", "bbox": [429.0, 557.0, 701.0, 570.0]}, {"text": "Suspected Germline Diseases, document issued on April 13,", "bbox": [429.0, 574.0, 701.0, 588.0]}, {"text": "2018 [ EB/OL ] . https://www.fda.gov/regulatory–information/", "bbox": [429.0, 591.0, 701.0, 605.0]}, {"text": "search– fda– guidance– documents/ considerations– design–", "bbox": [429.0, 609.0, 700.0, 622.0]}, {"text": "development–and–analytical–validation–next–generation–", "bbox": [429.0, 626.0, 699.0, 640.0]}, {"text": "sequencing–ngs–based.", "bbox": [430.0, 644.0, 533.0, 657.0]}, {"text": "JENNINGS L, VAN DEERLIN V M, GULLEY M L, et al.", "bbox": [426.0, 659.0, 701.0, 675.0]}, {"text": "Recommended principles and practices for validating clinical", "bbox": [429.0, 678.0, 701.0, 692.0]}, {"text": "molecular pathology tests [ J ] . Arch Pathol Lab Med, 2009,", "bbox": [429.0, 695.0, 700.0, 710.0]}, {"text": "133(5): 743–755.", "bbox": [429.0, 713.0, 505.0, 727.0]}, {"text": "KHAN M U, BOWSHER R R, CAMERON M, et al.", "bbox": [425.0, 729.0, 701.0, 744.0]}, {"text": "Recommendations for adaptation and validation of commercial", "bbox": [429.0, 748.0, 701.0, 761.0]}, {"text": "kits for biomarker quantification in drug development [ J ] .", "bbox": [428.0, 765.0, 701.0, 779.0]}, {"text": "Bioanalysis ,  2015 ,  7( 2 ):  229–242 .", "bbox": [429.0, 783.0, 572.0, 796.0]}, {"text": "KONSTANTINOPOULOS P A, NORQUIST B, LACCHETTI C,", "bbox": [425.0, 799.0, 701.0, 814.0]}, {"text": "et al. Germline and somatic tumor testing in epithelial ovarian", "bbox": [428.0, 817.0, 701.0, 832.0]}, {"text": "cancer: ASCO guideline [ J ] . J Clin Oncol, 2020, 38 (11):", "bbox": [427.0, 834.0, 701.0, 848.0]}, {"text": "1222–1245.", "bbox": [429.0, 852.0, 483.0, 866.0]}, {"text": "TEW W P, LACCHETTI C, ELLIS A, et al. PARP inhibitors", "bbox": [427.0, 869.0, 701.0, 884.0]}, {"text": "in the management of ovarian cancer: ASCO guideline [ J ] . J", "bbox": [429.0, 886.0, 701.0, 900.0]}, {"text": "Clin Oncol, 2020: JCO2001924.", "bbox": [428.0, 903.0, 565.0, 917.0]}, {"text": "DALY M B, PILARSKI R, YURGELUN M B, et al.NCCN", "bbox": [425.0, 921.0, 701.0, 935.0]}, {"text": "guidelines insights: genetic/familial high–risk assessment:", "bbox": [429.0, 938.0, 701.0, 952.0]}, {"text": "breast, ovarian, and pancreatic, version 1.2020 [ J ] . J Natl", "bbox": [428.0, 956.0, 701.0, 969.0]}, {"text": "Compr Canc Netw ,  2020 ,  18 ( 4 ):  380 – 391 .", "bbox": [428.0, 974.0, 605.0, 987.0]}, {"text": "( 收稿日期: 2020-09-29  修回日期: 2020-09-30)", "bbox": [484.0, 993.0, 698.0, 1008.0]}], "type": "Text", "position": 12}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2021】全科室临床指南中&英文版/15大科室分类/妇产领域/【妇产领域】上皮性卵巢癌PARP抑制剂相关生物标志物检测的中国专家共识.pdf", "page_num": 8}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": null, "type3": null, "type4": null, "type5": null, "type6": "有用性#0#46#参考文献的内容"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:41", "update_time": "2024-05-07 23:00:12"}
{"id": 1082556, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 738, "source_info": {"seq_id": "39df22a7-eff8-4b5e-841d-f08bfa9a6157", "title": null, "text": "【0】页码:9\n Voser, B. Ruepp, P. Mitchell, R.A. Stahel, C. Le Pechoux, D. De Ruysscher, Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy - results from the randomised phase II ETOP/IFCT 4–12 STIMULI trial, Ann Oncol. 33 (1) (2022) 67–79, https:// doi.org/10.1016/j.annone.2021.09.011 .\n\n【1】[46] J.E. Bauman, S.D. Karam, M. Nishio, M.J. Ahn, D.W. Kim, S.W. Kim, H. Murakami, L. Wang, J. Shetty, K.Y. Wu, P.A. Dennis, B.C. Cho, 1056P Durvalumab (D) in combination with chemoradiotherapy (CRT) in solid tumours: Phase I CLOVER study, Ann Oncol. 31 (2020) S721-S722. 10.1016/j.annonc.2020.08.1176.\n\n【2】[47] B. Li, C. Jiang, L. Pang, B. Zou, M. Ding, X. Sun, J. Yu, L. Wang, Toxicity profile of combining PD-1/PD-L1 inhibitors and thoracic radiotherapy in non small cell lung cancer: a systematic review, Front Immunol. 12 (2021), 627197, https://doi.org/ 10.3389/fimmu.2021.627197.\n\n【3】[48] Y. Geng, Q. Zhang, S. Feng, C. Li, L. Wang, X. Zhao, Z. Yang, Z. Li, H. Luo, R. Liu, B. Lu, X. Wang, Safety and Efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis, Cancer Med. 10 (4) (2021) 1222–1239, https://doi.org/10.1002/ cam4.3718 .\n\n【4】[49] B. Kea, B.-C.-A. Sun, Consensus development for healthcare professionals, Intern.\n\n【5】Emerg. Med. 10 (3) (2015) 373–383, https://doi.org/10.1007/s11739-014-1156- [50] B.J. Slotman, C. Faivre-Finn, H. van Tinteren, A. Keijser, J. Praag, J. Knegjens, M. Hatton, I. van Dam, A. van der Leest, B. Reymen, J. Stigt, K. Haslett, D. Tripathi, E.F. Smit, S. Senan, Which patients with ES-SCLC are most likely to benefit from more aggressive radiotherapy: A secondary analysis of the Phase III CREST trial, Lung Cancer 108 (2017) 150–153, https://doi.org/10.1016/j.\n\n【6】lungcan, 2017.03.007 .\n\n【7】[51] L. Paz-Ares, J.W. Goldman, M.C. Garassino, M. Dvorkin, D. Trukhin, G. Statsenko, K. Hotta, J.H. Ji, M.J. Hochmair, O. Voitko, L. Havel, A. Poltoratskiy, G. Losonczy, N. Reinmuth, Y. Shrestha, N. Patel, H. Mann, H. Jiang, M. Özgüroğlu, Y. Chen, PD- L1 expression, patterns of progression and patient-reported outcomes (PROs) with durvalumab plus platinum-etoposide in ES-SCLC: Results from CASPIAN. Abstract #3837. European Society for Medical Oncology 2019 Congress. Barcelona, Spain.\n\n【8】(2019).\n\n【9】[52] S.V. Liu, M. Reck, A.S. Mansfield, T. Mok, A. Scherpereel, N. Reinmuth, M.\n\n【10】C. Garassino, J. De Castro Carpeno, R. Califano, M. Nishio, F. Orlandi, J. Alatorre- Alexander, T. Leal, Y. Cheng, J.S. Lee, S. Lam, M. McCleland, Y. Deng, S. Phan, L. Horn, Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133), Supplement J Clin Oncol. 39 (6) (2021) 619–630, https://doi.org/10.1200/jco.20.01055 .\n\n【11】[53] A. Bruni, F. Bertonlini, E. D'Angelo, F. Barbieri, J. Imbrescia, L. Trudu, A. Cappelli, F. Lohr, M. Dominici, G. Guaitoli, Chemo-immunotherapy with or without consolidative radiotherapy in ES-SCLC: an initial report of clinical outcome and safety. Abstract #5239 (poster). European Lung Cancer Congress. Mar 30 - Apr 2, 2022. Prague, Czechia (2022).\n\n【12】[54] M. Zhuo, H. Chen, X. Ma, J. Liu, Y. Yang, Y. Fang, L. Wang, J. Zhao, Clinical outcomes of atezolizumab in combination with etoposide/platinum for treatment of extensive-stage small cell lung cancer: a real-world, multicentre, retrospective, controlled study in China. Abstract #482; Poster #145P. European Lung Cancer Congress. Mar 30 - Apr 2, 2022. Prague, Czechia (2022).\n\n【13】[55] S. Daher, A. Allen, Y. Rottenberg, H. Nasrallah, L. Yosef, P. Blumenfeld, M. Wolner, S. Appel, H. Nechushtan, M. Moskovits, J. Bar, A. Zer, Real-world data of consoldiateve radiotherapy for extensive strage (ES)-SCLC treated by chemoimmunotherapy (chemo-IO). Abstract #432 (poster). European Lung Cancer Congress. Mar 30 - Apr 2, 2022. Prague, Czechia (2022).\n\n【14】[56] Hoffmann-La Roche Ltd., Product monograph including patient medication information. TECENTRIQ(R) (atezolizumab for injection. Date of revision: 31 Mar 2022. Available at: https://www.rochecanada.com/PMs/Tecentriq/Tecentriq_PM_ E.pdf. Accessed: 14 April 2022. (2022).\n\n【15】[57] AstraZeneca Canada Inc., Product monograph including patient medication information. IMFINIZI(R) (durvalumab for injection). Date of revision: 4 Apr 2022.\n\n【16】Available at: https://www.astrazeneca.ca/content/dam/az-ca/downloads/ productinformation/imfinzi-product-monograph-en.pdf. Accessed: 14 April 2022.\n\n【17】(2022).\n\n【18】[58] A. Keller, S. Ghanta, J.L. Rodríguez-López, A. Patel, S. Beriwal, Utility of prophylactic cranial irradiation for extensive-stage small-cell lung cancer in the MRI screening era, Clin Lung Cancer. 22(6) (2021) e808-e816. 10.1016/j.\n\n【19】cllc.2021.03.009.\n\n【20】[59] H. Gao, Y. Dang, T. Qi, S. Huang, X. Zhang, Mining prognostic factors of extensivestage small-cell lung cancer patients using nomogram model, Medicine 99 (33) (2020).\n\n【21】[60] N.J. Myall, H. Yu, S.G. Soltys, H.A. Wakelee, E. Pollom, Management of brain metastases in lung cancer: evolving roles for radiation and systemic treatment in the era of targeted and immune therapies, Neurooncol Adv. 3 (Suppl 5) (2021) v52–v62, https://doi.org/10.1093/noajnl/vdab106 .\n\n【22】[61] A. Auperin, R. Arriagada, J.P. Pignon, C. Le Pechoux, A. Gregor, R.J. Stephens, P.\n\n【23】E. Kristjansen, B.E. Johnson, H. Ueoka, H. Wagner, J. Aisner, Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission Prophylactic Cranial Irradiation Overview Collaborative Group, N Engl J Med. 341 (7) (1999) 476–484, https://doi.org/10.1056/NEJM199908123410703 .\n\n【24】[62] A.P. Meert, M. Paesmans, T. Berghmans, B. Martin, C. Mascaux, F. Vallot, J.\n\n【25】M. Verdebout, J.J. Lafitte, J.P. Sculier, Prophylactic cranial irradiation in small cell lung cancer: a systematic review of the literature with meta-analysis, BMC Cancer 1 (2001) 5, https://doi.org/10.1186/1471-2407-1-5 .\n\n【26】 [63] V. Gondi, R. Paulus, D.W. Bruner, C.A. Meyers, E.M. Gore, A. Wolfson, M. Werner- Wasik, A.Y. Sun, H. Choy, B. Movsas, Decline in tested and self-reported cognitive functioning after prophylactic cranial irradiation for lung cancer: pooled secondary analysis of Radiation Therapy Oncology Group randomized trials 0212 and 0214, Int J Rad Oncol Biol Phys. 86 (4) (2013) 656–664, https://doi.org/10.1016/j.\n\n【27】ijrobp.2013.02.033 .\n\n【28】[64] W. Ge, H. Xu, Y. Yan, D. Cao, The effects of prophylactic cranial irradiation versus control on survival of patients with extensive-stage small-cell lung cancer: a metaanalysis of 14 trials, Radiat Oncol. 13 (1) (2018) 155, https://doi.org/10.1186/ s13014-018-1101-3 .\n\n【29】[65] A. Bang, W.S. Kendal, S.A. Laurie, G. Cook, R.M. MacRae, Prophylactic cranial irradiation in extensive stage small cell lung cancer: outcomes at a comprehensive cancer centre, Int J Radiat Oncol Biol Phys. 101 (5) (2018) 1133–1140, https:// doi.org/10.1016/j.ijrobp.2018.04.058 .\n\n【30】[66] O. Gjyshi, E.B. Ludmir, T.A. Pezzi, D. Boyce-Fappiano, A.E. Dursteler, T. Mitin, S.\n\n【31】H. Lin, Evolving practice patterns in the use of prophylactic cranial irradiation for extensive-stage small cell lung cancer, JAMA Netw. Open 2 (8) (2019) e199135–e, https://doi.org/10.1001/jamanetworkopen.2019.9135 .\n\n【32】[67] A. Shinde, D. Akhavan, M. Sedrak, S. Glaser, A. Amini, Shifting paradigms: whole brain radiation therapy versus stereotactic radiosurgery for brain metastases, CNS oncology. 8 (1) (2019) CNS27-CNS27. 10.2217/cns-2018-0016.\n\n【33】[68] K. Gaebe, A.Y. Li, A. Park, A. Parmar, B.H. Lok, A. Sahgal, K.K. Chan, A.W.\n\n【34】Erickson, S. Das, Stereotactic radiosurgery (SRS) versus whole brain radiation therapy (WBRT) in patients with small cell lung cancer (SCLC) and intracranial metastatic disease (IMD): A systematic review and meta-analysis, J Clin Oncol. 40 (16 suppl) (2022) 8570-8570. 10.1200/JCO.2022.40.16 suppl.8570.\n\n【35】[69] C.G. Rusthoven, M. Yamamoto, D. Bernhardt, D.E. Smith, D. Gao, T. Serizawa, S. Yomo, H. Aiyama, Y. Higuchi, T. Shuto, A. Akabane, Y. Sato, A. Niranjan, A.\n\n【36】M. Faramand, L.D. Lunsford, J. McInerney, L.C. Tuanquin, B.E. Zacharia, V. Chiang, C. Singh, J.B. Yu, S. Braunstein, D. Mathieu, C.J. Touchette, C.-C. Lee, H.-C. Yang, A.A. Aizer, D.N. Cagney, M.D. Chan, D. Kondziolka, K. Bernstein, J.\n\n【37】S. Silverman, I.S. Grills, Z.A. Siddiqui, J.C. Yuan, J.P. Sheehan, D. Cordeiro, K. Nosaki, T. Seto, C.P. Deibert, V. Verma, S. Day, L.M. Halasz, R.E. Warnick, D.\n\n【38】M. Trifiletti, J.D. Palmer, A. Attia, B. Li, C.P. Cifarelli, P.D. Brown, J.A. Vargo, S.\n\n【39】E. Combs, K.A. Kessel, S. Rieken, S. Patel, M. Guckenberger, N. Andratschke, B.\n\n【40】D. Kavanagh, T.P. Robin, Evaluation of first-line radiosurgery vs whole-brain radiotherapy for small cell lung cancer brain metastases: The FIRE-SCLC Cohort Study, JAMA Oncol. 6 (7) (2020) 1028–1037, https://doi.org/10.1001/ jamaoncol, 2020, 1271 .\n\n【41】[70] B.J. Schneider, N. Ismaila, J. Aerts, C. Chiles, M.E. Daly, F.C. Detterbeck, J.W.\n\n【42】D. Hearn, S.I. Katz, N.B. Leighl, B. Levy, B. Meyers, S. Murgu, L. Nekhlyudov, E.\n\n【43】S. Santos, N. Singh, J. Tashbar, D. Yankelevitz, N. Altorki, Lung cancer surveillance after definitive curative-intent therapy: ASCO guideline, J Clin Oncol. 38 (7) (2020) 753–766, https://doi.org/10.1200/JCO.19.02748 .\n\n【44】[71] W.B. Pope, Brain metastases: neuroimaging, Handb Clin Neurol. 149 (2018) 89–112, https://doi.org/10.1016/b978-0-12-811161-1.00007-4 .\n\n【45】[72] P.D. Schellinger, H.M. Meinck, A. Thron, Diagnostic accuracy of MRI compared to CCT in patients with brain metastases, J Neurooncol. 44 (3) (1999) 275–281, https://doi.org/10.1023/a:1006308808769 .\n\n【46】[73] P.C. Davis, P.A. Hudgins, S.B. Peterman, J.C. Hoffman Jr., Diagnosis of cerebral metastases: double-dose delayed CT vs contrast-enhanced MR imaging, AJNR Am J Neuroradiol. 12 (2) (1991) 293–300 .\n\n【47】[74] C. Le Péchoux, A. Dunant, S. Senan, A. Wolfson, E. Quoix, C. Faivre-Finn, T. Ciuleanu, R. Arriagada, R. Jones, R. Wanders, D. Lerouge, A. Laplanche, Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99–01, EORTC 22003–08004, RTOG 0212, and IFCT 99–01): a randomised clinical trial, Lancet Oncol. 10 (5) (2009) 467–474, https://doi.org/10.1016/S1470-2045(09)70101-9 .\n\n【48】[75] A.H. Wolfson, K. Bae, R. Komaki, C. Meyers, B. Movsas, C. Le Pechoux, M. Werner- Wasik, G.M.M. Videtic, Y.I. Garces, H. Choy, Primary analysis of a Phase II randomized trial Radiation Therapy Oncology Group (RTOG) 0212: Impact of different total doses and schedules of prophylactic cranial irradiation on chronic neurotoxicity and quality of life for patients with limited-disease small-cell lung cancer, Int J Radiation Oncol Biol Phys. 81 (1) (2011) 77–84, https://doi.org/ 10.1016/j.ijrobp.2010.05.013 .\n\n【49】[76] Y. Chen, J. Li, Y. Hu, Y. Zhang, Z. Lin, Z. Zhao, S. Jiao, Prophylactic cranial irradiation could improve overall survival in patients with extensive small cell lung cancer, Strahlenther. Onkol. 192 (12) (2016) 905–912, https://doi.org/10.1007/ s00066-016-1038-0 .\n\n【50】[77] C. Le Péchoux, A. Sun, B.J. Slotman, D. De Ruysscher, J. Belderbos, E.M. Gore, Prophylactic cranial irradiation for patients with lung cancer, Lancet Oncol. 17(7) (2016) e277-e293. 10.1016/s1470-2045(16)30065-1.\n\n【51】[78] Y. Nakahara, Y. Takagi, Y. Okuma, Y. Hosomi, T. Okamura, M. Shibuya, N. Masuda, Neurotoxicity due to prophylactic cranial irradiation for small-cell lung cancer: A retrospective analysis, Mol Clin Oncol. 3 (5) (2015) 1048–1052, https:// doi.org/10.3892/mco.2015.581 .\n\n【52】[79] A. Sun, K. Bae, E.M. Gore, B. Movsas, S.J. Wong, C.A. Meyers, J.A. Bonner, S.\n\n【53】E. Schild, L.E. Gaspar, J.A. Bogart, M. Werner-Wasik, H. Choy, Phase III trial of prophylactic cranial irradiation compared with observation in patients with locally advanced non-small-cell lung cancer: neurocognitive and quality-of-life analysis, J Clin Oncol. 29 (3) (2011) 279–286, https://doi.org/10.1200/JCO.2010.29.6053 .\n\n【54】[80] J.M. Taylor, C.G. Rusthoven, D. Moghanaki, Prophylactic cranial irradiation or MRI surveillance for extensive stage small cell lung cancer, J Thorac Dis. 12(10) (2020) 6225-6233. 10.21037/jtd.2020.03.80.", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "Voser, B. Ruepp, P. Mitchell, R.A. Stahel, C. Le Pechoux, D. De Ruysscher,", "bbox": [70.0, 70.0, 355.0, 82.0]}, {"text": "Consolidation nivolumab and ipilimumab versus observation in limited-disease", "bbox": [70.0, 82.0, 374.0, 93.0]}, {"text": "small-cell lung cancer after chemo-radiotherapy - results from the randomised", "bbox": [70.0, 92.0, 373.0, 104.0]}, {"text": "phase II ETOP/IFCT 4–12 STIMULI trial, Ann Oncol. 33 (1) (2022) 67–79, https://", "bbox": [70.0, 103.0, 382.0, 114.0]}, {"text": "doi.org/10.1016/j.annone.2021.09.011 .", "bbox": [71.0, 113.0, 221.0, 125.0]}, {"text": "[46] J.E. Bauman, S.D. Karam, M. Nishio, M.J. Ahn, D.W. Kim, S.W. Kim, H. Murakami,", "bbox": [48.0, 124.0, 382.0, 135.0]}, {"text": "L. Wang, J. Shetty, K.Y. Wu, P.A. Dennis, B.C. Cho, 1056P Durvalumab (D) in", "bbox": [70.0, 135.0, 371.0, 147.0]}, {"text": "combination with chemoradiotherapy (CRT) in solid tumours: Phase I CLOVER", "bbox": [70.0, 145.0, 374.0, 157.0]}, {"text": "study, Ann Oncol. 31 (2020) S721-S722. 10.1016/j.annonc.2020.08.1176.", "bbox": [70.0, 156.0, 355.0, 167.0]}, {"text": "[47] B. Li, C. Jiang, L. Pang, B. Zou, M. Ding, X. Sun, J. Yu, L. Wang, Toxicity profile of", "bbox": [48.0, 166.0, 384.0, 178.0]}, {"text": "combining PD-1/PD-L1 inhibitors and thoracic radiotherapy in non small cell lung", "bbox": [70.0, 177.0, 383.0, 188.0]}, {"text": "cancer: a systematic review, Front Immunol. 12 (2021), 627197, https://doi.org/", "bbox": [70.0, 187.0, 380.0, 199.0]}, {"text": "10.3389/fimmu.2021.627197.", "bbox": [70.0, 198.0, 184.0, 210.0]}, {"text": "[48] Y. Geng, Q. Zhang, S. Feng, C. Li, L. Wang, X. Zhao, Z. Yang, Z. Li, H. Luo, R. Liu,", "bbox": [48.0, 209.0, 382.0, 221.0]}, {"text": "B. Lu, X. Wang, Safety and Efficacy of PD-1/PD-L1 inhibitors combined with", "bbox": [70.0, 219.0, 367.0, 232.0]}, {"text": "radiotherapy in patients with non-small-cell lung cancer: a systematic review and", "bbox": [70.0, 230.0, 383.0, 241.0]}, {"text": "meta-analysis, Cancer Med. 10 (4) (2021) 1222–1239, https://doi.org/10.1002/", "bbox": [70.0, 240.0, 375.0, 252.0]}, {"text": "cam4.3718 .", "bbox": [70.0, 252.0, 117.0, 262.0]}, {"text": "[49] B. Kea, B.-C.-A. Sun, Consensus development for healthcare professionals, Intern.", "bbox": [48.0, 262.0, 379.0, 273.0]}, {"text": "Emerg. Med. 10 (3) (2015) 373–383, https://doi.org/10.1007/s11739-014-1156-", "bbox": [70.0, 272.0, 379.0, 285.0]}, {"text": "[50] B.J. Slotman, C. Faivre-Finn, H. van Tinteren, A. Keijser, J. Praag, J. Knegjens,", "bbox": [48.0, 293.0, 373.0, 306.0]}, {"text": "M. Hatton, I. van Dam, A. van der Leest, B. Reymen, J. Stigt, K. Haslett, D. Tripathi,", "bbox": [70.0, 304.0, 382.0, 316.0]}, {"text": "E.F. Smit, S. Senan, Which patients with ES-SCLC are most likely to benefit from", "bbox": [70.0, 315.0, 380.0, 327.0]}, {"text": "more aggressive radiotherapy: A secondary analysis of the Phase III CREST trial,", "bbox": [70.0, 325.0, 380.0, 337.0]}, {"text": "Lung Cancer 108 (2017) 150–153, https://doi.org/10.1016/j.", "bbox": [70.0, 337.0, 305.0, 348.0]}, {"text": "lungcan, 2017.03.007 .", "bbox": [70.0, 348.0, 154.0, 358.0]}, {"text": "[51] L. Paz-Ares, J.W. Goldman, M.C. Garassino, M. Dvorkin, D. Trukhin, G. Statsenko,", "bbox": [48.0, 358.0, 382.0, 369.0]}, {"text": "K. Hotta, J.H. Ji, M.J. Hochmair, O. Voitko, L. Havel, A. Poltoratskiy, G. Losonczy,", "bbox": [70.0, 368.0, 382.0, 380.0]}, {"text": "N. Reinmuth, Y. Shrestha, N. Patel, H. Mann, H. Jiang, M. Özgüroğlu, Y. Chen, PD-", "bbox": [70.0, 378.0, 382.0, 390.0]}, {"text": "L1 expression, patterns of progression and patient-reported outcomes (PROs) with", "bbox": [70.0, 390.0, 383.0, 401.0]}, {"text": "durvalumab plus platinum-etoposide in ES-SCLC: Results from CASPIAN. Abstract", "bbox": [70.0, 399.0, 383.0, 412.0]}, {"text": "#3837. European Society for Medical Oncology 2019 Congress. Barcelona, Spain.", "bbox": [70.0, 410.0, 382.0, 422.0]}, {"text": "(2019).", "bbox": [69.0, 422.0, 101.0, 432.0]}, {"text": "[52] S.V. Liu, M. Reck, A.S. Mansfield, T. Mok, A. Scherpereel, N. Reinmuth, M.", "bbox": [48.0, 431.0, 357.0, 443.0]}, {"text": "C. Garassino, J. De Castro Carpeno, R. Califano, M. Nishio, F. Orlandi, J. Alatorre-", "bbox": [70.0, 442.0, 381.0, 454.0]}, {"text": "Alexander, T. Leal, Y. Cheng, J.S. Lee, S. Lam, M. McCleland, Y. Deng, S. Phan,", "bbox": [70.0, 453.0, 376.0, 465.0]}, {"text": "L. Horn, Updated overall survival and PD-L1 subgroup analysis of patients with", "bbox": [70.0, 464.0, 377.0, 475.0]}, {"text": "extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and", "bbox": [70.0, 474.0, 383.0, 486.0]}, {"text": "etoposide (IMpower133), Supplement J Clin Oncol. 39 (6) (2021) 619–630,", "bbox": [70.0, 485.0, 361.0, 496.0]}, {"text": "https://doi.org/10.1200/jco.20.01055 .", "bbox": [70.0, 495.0, 217.0, 507.0]}, {"text": "[53] A. Bruni, F. Bertonlini, E. D'Angelo, F. Barbieri, J. Imbrescia, L. Trudu, A. Cappelli,", "bbox": [48.0, 505.0, 383.0, 518.0]}, {"text": "F. Lohr, M. Dominici, G. Guaitoli, Chemo-immunotherapy with or without", "bbox": [70.0, 517.0, 357.0, 528.0]}, {"text": "consolidative radiotherapy in ES-SCLC: an initial report of clinical outcome and", "bbox": [70.0, 527.0, 377.0, 539.0]}, {"text": "safety. Abstract #5239 (poster). European Lung Cancer Congress. Mar 30 - Apr 2,", "bbox": [70.0, 537.0, 383.0, 551.0]}, {"text": "2022. Prague, Czechia (2022).", "bbox": [70.0, 548.0, 189.0, 560.0]}, {"text": "[54] M. Zhuo, H. Chen, X. Ma, J. Liu, Y. Yang, Y. Fang, L. Wang, J. Zhao, Clinical", "bbox": [48.0, 558.0, 368.0, 572.0]}, {"text": "outcomes of atezolizumab in combination with etoposide/platinum for treatment", "bbox": [70.0, 570.0, 381.0, 582.0]}, {"text": "of extensive-stage small cell lung cancer: a real-world, multicentre, retrospective,", "bbox": [70.0, 581.0, 381.0, 591.0]}, {"text": "controlled study in China. Abstract #482; Poster #145P. European Lung Cancer", "bbox": [70.0, 592.0, 378.0, 602.0]}, {"text": "Congress. Mar 30 - Apr 2, 2022. Prague, Czechia (2022).", "bbox": [70.0, 601.0, 289.0, 613.0]}, {"text": "[55] S. Daher, A. Allen, Y. Rottenberg, H. Nasrallah, L. Yosef, P. Blumenfeld, M. Wolner,", "bbox": [48.0, 612.0, 382.0, 624.0]}, {"text": "S. Appel, H. Nechushtan, M. Moskovits, J. Bar, A. Zer, Real-world data of", "bbox": [69.0, 623.0, 356.0, 636.0]}, {"text": "consoldiateve radiotherapy for extensive strage (ES)-SCLC treated by chemo-", "bbox": [70.0, 633.0, 363.0, 644.0]}, {"text": "immunotherapy (chemo-IO). Abstract #432 (poster). European Lung Cancer", "bbox": [70.0, 645.0, 363.0, 656.0]}, {"text": "Congress. Mar 30 - Apr 2, 2022. Prague, Czechia (2022).", "bbox": [70.0, 655.0, 291.0, 668.0]}, {"text": "[56] Hoffmann-La Roche Ltd., Product monograph including patient medication", "bbox": [48.0, 666.0, 358.0, 677.0]}, {"text": "information. TECENTRIQ(R) (atezolizumab for injection. Date of revision: 31 Mar", "bbox": [70.0, 676.0, 383.0, 688.0]}, {"text": "2022. Available at: https://www.rochecanada.com/PMs/Tecentriq/Tecentriq_PM_", "bbox": [70.0, 689.0, 382.0, 699.0]}, {"text": "E.pdf. Accessed: 14 April 2022. (2022).", "bbox": [70.0, 699.0, 224.0, 708.0]}, {"text": "[57] AstraZeneca Canada Inc., Product monograph including patient medication", "bbox": [48.0, 708.0, 360.0, 722.0]}, {"text": "information. IMFINIZI(R) (durvalumab for injection). Date of revision: 4 Apr 2022.", "bbox": [70.0, 719.0, 381.0, 728.0]}, {"text": "Available at: https://www.astrazeneca.ca/content/dam/az-ca/downloads/", "bbox": [70.0, 730.0, 355.0, 739.0]}, {"text": "productinformation/imfinzi-product-monograph-en.pdf. Accessed: 14 April 2022.", "bbox": [70.0, 742.0, 380.0, 753.0]}, {"text": "(2022).", "bbox": [70.0, 752.0, 99.0, 760.0]}, {"text": "[58] A. Keller, S. Ghanta, J.L. Rodríguez-López, A. Patel, S. Beriwal, Utility of", "bbox": [48.0, 761.0, 352.0, 775.0]}, {"text": "prophylactic cranial irradiation for extensive-stage small-cell lung cancer in the", "bbox": [70.0, 773.0, 377.0, 785.0]}, {"text": "MRI screening era, Clin Lung Cancer. 22(6) (2021) e808-e816. 10.1016/j.", "bbox": [70.0, 784.0, 355.0, 796.0]}, {"text": "cllc.2021.03.009.", "bbox": [70.0, 795.0, 138.0, 803.0]}, {"text": "[59] H. Gao, Y. Dang, T. Qi, S. Huang, X. Zhang, Mining prognostic factors of extensive-", "bbox": [48.0, 803.0, 381.0, 816.0]}, {"text": "stage small-cell lung cancer patients using nomogram model, Medicine 99 (33)", "bbox": [70.0, 816.0, 374.0, 826.0]}, {"text": "(2020).", "bbox": [70.0, 826.0, 99.0, 834.0]}, {"text": "[60] N.J. Myall, H. Yu, S.G. Soltys, H.A. Wakelee, E. Pollom, Management of brain", "bbox": [48.0, 836.0, 371.0, 848.0]}, {"text": "metastases in lung cancer: evolving roles for radiation and systemic treatment in", "bbox": [70.0, 848.0, 381.0, 859.0]}, {"text": "the era of targeted and immune therapies, Neurooncol Adv. 3 (Suppl 5) (2021)", "bbox": [70.0, 858.0, 376.0, 870.0]}, {"text": "v52–v62, https://doi.org/10.1093/noajnl/vdab106 .", "bbox": [70.0, 869.0, 268.0, 879.0]}, {"text": "[61] A. Auperin, R. Arriagada, J.P. Pignon, C. Le Pechoux, A. Gregor, R.J. Stephens, P.", "bbox": [48.0, 878.0, 383.0, 891.0]}, {"text": "E. Kristjansen, B.E. Johnson, H. Ueoka, H. Wagner, J. Aisner, Prophylactic cranial", "bbox": [70.0, 890.0, 384.0, 901.0]}, {"text": "irradiation for patients with small-cell lung cancer in complete remission", "bbox": [70.0, 901.0, 352.0, 912.0]}, {"text": "Prophylactic Cranial Irradiation Overview Collaborative Group, N Engl J Med. 341", "bbox": [70.0, 911.0, 383.0, 923.0]}, {"text": "(7) (1999) 476–484, https://doi.org/10.1056/NEJM199908123410703 .", "bbox": [70.0, 922.0, 344.0, 932.0]}, {"text": "[62] A.P. Meert, M. Paesmans, T. Berghmans, B. Martin, C. Mascaux, F. Vallot, J.", "bbox": [48.0, 931.0, 363.0, 944.0]}, {"text": "M. Verdebout, J.J. Lafitte, J.P. Sculier, Prophylactic cranial irradiation in small cell", "bbox": [70.0, 943.0, 384.0, 954.0]}, {"text": "lung cancer: a systematic review of the literature with meta-analysis, BMC Cancer 1", "bbox": [70.0, 953.0, 383.0, 965.0]}, {"text": "(2001) 5, https://doi.org/10.1186/1471-2407-1-5 .", "bbox": [70.0, 964.0, 264.0, 976.0]}], "type": "Text", "position": 1}, {"raw_context": [{"text": "[63] V. Gondi, R. Paulus, D.W. Bruner, C.A. Meyers, E.M. Gore, A. Wolfson, M. Werner-", "bbox": [406.0, 70.0, 741.0, 82.0]}, {"text": "Wasik, A.Y. Sun, H. Choy, B. Movsas, Decline in tested and self-reported cognitive", "bbox": [430.0, 82.0, 743.0, 93.0]}, {"text": "functioning after prophylactic cranial irradiation for lung cancer: pooled secondary", "bbox": [429.0, 92.0, 742.0, 104.0]}, {"text": "analysis of Radiation Therapy Oncology Group randomized trials 0212 and 0214,", "bbox": [430.0, 103.0, 742.0, 115.0]}, {"text": "Int J Rad Oncol Biol Phys. 86 (4) (2013) 656–664, https://doi.org/10.1016/j.", "bbox": [429.0, 113.0, 726.0, 125.0]}, {"text": "ijrobp.2013.02.033 .", "bbox": [430.0, 124.0, 506.0, 135.0]}, {"text": "[64] W. Ge, H. Xu, Y. Yan, D. Cao, The effects of prophylactic cranial irradiation versus", "bbox": [406.0, 135.0, 742.0, 147.0]}, {"text": "control on survival of patients with extensive-stage small-cell lung cancer: a meta-", "bbox": [430.0, 145.0, 741.0, 157.0]}, {"text": "analysis of 14 trials, Radiat Oncol. 13 (1) (2018) 155, https://doi.org/10.1186/", "bbox": [430.0, 156.0, 734.0, 167.0]}, {"text": "s13014-018-1101-3 .", "bbox": [430.0, 167.0, 505.0, 175.0]}, {"text": "[65] A. Bang, W.S. Kendal, S.A. Laurie, G. Cook, R.M. MacRae, Prophylactic cranial", "bbox": [406.0, 177.0, 733.0, 188.0]}, {"text": "irradiation in extensive stage small cell lung cancer: outcomes at a comprehensive", "bbox": [429.0, 187.0, 742.0, 200.0]}, {"text": "cancer centre, Int J Radiat Oncol Biol Phys. 101 (5) (2018) 1133–1140, https://", "bbox": [429.0, 198.0, 733.0, 210.0]}, {"text": "doi.org/10.1016/j.ijrobp.2018.04.058 .", "bbox": [430.0, 209.0, 576.0, 220.0]}, {"text": "[66] O. Gjyshi, E.B. Ludmir, T.A. Pezzi, D. Boyce-Fappiano, A.E. Dursteler, T. Mitin, S.", "bbox": [406.0, 219.0, 741.0, 232.0]}, {"text": "H. Lin, Evolving practice patterns in the use of prophylactic cranial irradiation for", "bbox": [429.0, 230.0, 742.0, 242.0]}, {"text": "extensive-stage small cell lung cancer, JAMA Netw. Open 2 (8) (2019) e199135–e,", "bbox": [429.0, 240.0, 742.0, 253.0]}, {"text": "https://doi.org/10.1001/jamanetworkopen.2019.9135 .", "bbox": [429.0, 252.0, 639.0, 263.0]}, {"text": "[67] A. Shinde, D. Akhavan, M. Sedrak, S. Glaser, A. Amini, Shifting paradigms: whole", "bbox": [406.0, 262.0, 741.0, 274.0]}, {"text": "brain radiation therapy versus stereotactic radiosurgery for brain metastases, CNS", "bbox": [429.0, 272.0, 743.0, 285.0]}, {"text": "oncology. 8 (1) (2019) CNS27-CNS27. 10.2217/cns-2018-0016.", "bbox": [430.0, 283.0, 668.0, 294.0]}, {"text": "[68] K. Gaebe, A.Y. Li, A. Park, A. Parmar, B.H. Lok, A. Sahgal, K.K. Chan, A.W.", "bbox": [406.0, 293.0, 718.0, 306.0]}, {"text": "Erickson, S. Das, Stereotactic radiosurgery (SRS) versus whole brain radiation", "bbox": [429.0, 304.0, 728.0, 316.0]}, {"text": "therapy (WBRT) in patients with small cell lung cancer (SCLC) and intracranial", "bbox": [430.0, 315.0, 736.0, 327.0]}, {"text": "metastatic disease (IMD): A systematic review and meta-analysis, J Clin Oncol. 40", "bbox": [429.0, 325.0, 743.0, 337.0]}, {"text": "(16 suppl) (2022) 8570-8570. 10.1200/JCO.2022.40.16 suppl.8570.", "bbox": [428.0, 336.0, 691.0, 348.0]}, {"text": "[69] C.G. Rusthoven, M. Yamamoto, D. Bernhardt, D.E. Smith, D. Gao, T. Serizawa,", "bbox": [406.0, 346.0, 731.0, 359.0]}, {"text": "S. Yomo, H. Aiyama, Y. Higuchi, T. Shuto, A. Akabane, Y. Sato, A. Niranjan, A.", "bbox": [429.0, 357.0, 734.0, 369.0]}, {"text": "M. Faramand, L.D. Lunsford, J. McInerney, L.C. Tuanquin, B.E. Zacharia,", "bbox": [429.0, 368.0, 709.0, 380.0]}, {"text": "V. Chiang, C. Singh, J.B. Yu, S. Braunstein, D. Mathieu, C.J. Touchette, C.-C. Lee,", "bbox": [429.0, 378.0, 741.0, 390.0]}, {"text": "H.-C. Yang, A.A. Aizer, D.N. Cagney, M.D. Chan, D. Kondziolka, K. Bernstein, J.", "bbox": [428.0, 390.0, 737.0, 401.0]}, {"text": "S. Silverman, I.S. Grills, Z.A. Siddiqui, J.C. Yuan, J.P. Sheehan, D. Cordeiro,", "bbox": [429.0, 399.0, 722.0, 412.0]}, {"text": "K. Nosaki, T. Seto, C.P. Deibert, V. Verma, S. Day, L.M. Halasz, R.E. Warnick, D.", "bbox": [428.0, 410.0, 738.0, 422.0]}, {"text": "M. Trifiletti, J.D. Palmer, A. Attia, B. Li, C.P. Cifarelli, P.D. Brown, J.A. Vargo, S.", "bbox": [429.0, 421.0, 741.0, 433.0]}, {"text": "E. Combs, K.A. Kessel, S. Rieken, S. Patel, M. Guckenberger, N. Andratschke, B.", "bbox": [429.0, 431.0, 735.0, 443.0]}, {"text": "D. Kavanagh, T.P. Robin, Evaluation of first-line radiosurgery vs whole-brain", "bbox": [429.0, 443.0, 727.0, 454.0]}, {"text": "radiotherapy for small cell lung cancer brain metastases: The FIRE-SCLC Cohort", "bbox": [429.0, 453.0, 737.0, 465.0]}, {"text": "Study, JAMA Oncol. 6 (7) (2020) 1028–1037, https://doi.org/10.1001/", "bbox": [430.0, 464.0, 700.0, 475.0]}, {"text": "jamaoncol, 2020, 1271 .", "bbox": [430.0, 474.0, 515.0, 485.0]}, {"text": "[70] B.J. Schneider, N. Ismaila, J. Aerts, C. Chiles, M.E. Daly, F.C. Detterbeck, J.W.", "bbox": [406.0, 485.0, 731.0, 496.0]}, {"text": "D. Hearn, S.I. Katz, N.B. Leighl, B. Levy, B. Meyers, S. Murgu, L. Nekhlyudov, E.", "bbox": [428.0, 495.0, 738.0, 507.0]}, {"text": "S. Santos, N. Singh, J. Tashbar, D. Yankelevitz, N. Altorki, Lung cancer surveillance", "bbox": [429.0, 506.0, 742.0, 518.0]}, {"text": "after definitive curative-intent therapy: ASCO guideline, J Clin Oncol. 38 (7)", "bbox": [429.0, 517.0, 725.0, 528.0]}, {"text": "(2020) 753–766, https://doi.org/10.1200/JCO.19.02748 .", "bbox": [428.0, 527.0, 651.0, 539.0]}, {"text": "[71] W.B. Pope, Brain metastases: neuroimaging, Handb Clin Neurol. 149 (2018)", "bbox": [406.0, 538.0, 722.0, 551.0]}, {"text": "89–112, https://doi.org/10.1016/b978-0-12-811161-1.00007-4 .", "bbox": [430.0, 549.0, 673.0, 560.0]}, {"text": "[72] P.D. Schellinger, H.M. Meinck, A. Thron, Diagnostic accuracy of MRI compared to", "bbox": [406.0, 559.0, 743.0, 570.0]}, {"text": "CCT in patients with brain metastases, J Neurooncol. 44 (3) (1999) 275–281,", "bbox": [428.0, 571.0, 727.0, 581.0]}, {"text": "https://doi.org/10.1023/a:1006308808769 .", "bbox": [430.0, 582.0, 596.0, 591.0]}, {"text": "[73] P.C. Davis, P.A. Hudgins, S.B. Peterman, J.C. Hoffman Jr., Diagnosis of cerebral", "bbox": [406.0, 591.0, 737.0, 602.0]}, {"text": "metastases: double-dose delayed CT vs contrast-enhanced MR imaging, AJNR Am J", "bbox": [430.0, 601.0, 742.0, 613.0]}, {"text": "Neuroradiol. 12 (2) (1991) 293–300 .", "bbox": [430.0, 612.0, 574.0, 623.0]}, {"text": "[74] C. Le Péchoux, A. Dunant, S. Senan, A. Wolfson, E. Quoix, C. Faivre-Finn,", "bbox": [406.0, 623.0, 713.0, 635.0]}, {"text": "T. Ciuleanu, R. Arriagada, R. Jones, R. Wanders, D. Lerouge, A. Laplanche,", "bbox": [430.0, 634.0, 717.0, 644.0]}, {"text": "Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients", "bbox": [429.0, 645.0, 743.0, 655.0]}, {"text": "with limited-stage small-cell lung cancer in complete remission after chemotherapy", "bbox": [429.0, 656.0, 741.0, 668.0]}, {"text": "and thoracic radiotherapy (PCI 99–01, EORTC 22003–08004, RTOG 0212, and", "bbox": [429.0, 666.0, 733.0, 676.0]}, {"text": "IFCT 99–01): a randomised clinical trial, Lancet Oncol. 10 (5) (2009) 467–474,", "bbox": [429.0, 676.0, 735.0, 689.0]}, {"text": "https://doi.org/10.1016/S1470-2045(09)70101-9 .", "bbox": [429.0, 689.0, 621.0, 698.0]}, {"text": "[75] A.H. Wolfson, K. Bae, R. Komaki, C. Meyers, B. Movsas, C. Le Pechoux, M. Werner-", "bbox": [406.0, 696.0, 741.0, 710.0]}, {"text": "Wasik, G.M.M. Videtic, Y.I. Garces, H. Choy, Primary analysis of a Phase II", "bbox": [429.0, 706.0, 720.0, 723.0]}, {"text": "randomized trial Radiation Therapy Oncology Group (RTOG) 0212: Impact of", "bbox": [429.0, 720.0, 729.0, 730.0]}, {"text": "different total doses and schedules of prophylactic cranial irradiation on chronic", "bbox": [429.0, 730.0, 738.0, 740.0]}, {"text": "neurotoxicity and quality of life for patients with limited-disease small-cell lung", "bbox": [429.0, 742.0, 737.0, 751.0]}, {"text": "cancer, Int J Radiation Oncol Biol Phys. 81 (1) (2011) 77–84, https://doi.org/", "bbox": [428.0, 752.0, 728.0, 761.0]}, {"text": "10.1016/j.ijrobp.2010.05.013 .", "bbox": [430.0, 763.0, 547.0, 772.0]}, {"text": "[76] Y. Chen, J. Li, Y. Hu, Y. Zhang, Z. Lin, Z. Zhao, S. Jiao, Prophylactic cranial", "bbox": [406.0, 773.0, 723.0, 785.0]}, {"text": "irradiation could improve overall survival in patients with extensive small cell lung", "bbox": [429.0, 784.0, 741.0, 793.0]}, {"text": "cancer, Strahlenther. Onkol. 192 (12) (2016) 905–912, https://doi.org/10.1007/", "bbox": [429.0, 795.0, 737.0, 805.0]}, {"text": "s00066-016-1038-0 .", "bbox": [430.0, 805.0, 506.0, 813.0]}, {"text": "[77] C. Le Péchoux, A. Sun, B.J. Slotman, D. De Ruysscher, J. Belderbos, E.M. Gore,", "bbox": [406.0, 814.0, 732.0, 828.0]}, {"text": "Prophylactic cranial irradiation for patients with lung cancer, Lancet Oncol. 17(7)", "bbox": [430.0, 826.0, 743.0, 838.0]}, {"text": "(2016) e277-e293. 10.1016/s1470-2045(16)30065-1.", "bbox": [429.0, 837.0, 633.0, 845.0]}, {"text": "[78] Y. Nakahara, Y. Takagi, Y. Okuma, Y. Hosomi, T. Okamura, M. Shibuya,", "bbox": [406.0, 847.0, 707.0, 860.0]}, {"text": "N. Masuda, Neurotoxicity due to prophylactic cranial irradiation for small-cell lung", "bbox": [429.0, 858.0, 742.0, 869.0]}, {"text": "cancer: A retrospective analysis, Mol Clin Oncol. 3 (5) (2015) 1048–1052, https://", "bbox": [429.0, 869.0, 734.0, 879.0]}, {"text": "doi.org/10.3892/mco.2015.581 .", "bbox": [429.0, 879.0, 553.0, 891.0]}, {"text": "[79] A. Sun, K. Bae, E.M. Gore, B. Movsas, S.J. Wong, C.A. Meyers, J.A. Bonner, S.", "bbox": [406.0, 890.0, 728.0, 902.0]}, {"text": "E. Schild, L.E. Gaspar, J.A. Bogart, M. Werner-Wasik, H. Choy, Phase III trial of", "bbox": [429.0, 901.0, 737.0, 912.0]}, {"text": "prophylactic cranial irradiation compared with observation in patients with locally", "bbox": [429.0, 911.0, 742.0, 923.0]}, {"text": "advanced non-small-cell lung cancer: neurocognitive and quality-of-life analysis,", "bbox": [430.0, 922.0, 738.0, 933.0]}, {"text": "J Clin Oncol. 29 (3) (2011) 279–286, https://doi.org/10.1200/JCO.2010.29.6053 .", "bbox": [429.0, 932.0, 741.0, 944.0]}, {"text": "[80] J.M. Taylor, C.G. Rusthoven, D. Moghanaki, Prophylactic cranial irradiation or", "bbox": [407.0, 943.0, 733.0, 955.0]}, {"text": "MRI surveillance for extensive stage small cell lung cancer, J Thorac Dis. 12(10)", "bbox": [429.0, 953.0, 739.0, 965.0]}, {"text": "(2020) 6225-6233. 10.21037/jtd.2020.03.80.", "bbox": [429.0, 964.0, 604.0, 976.0]}], "type": "Text", "position": 3}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/肿瘤科/共识/加拿大共识建议：在接受免疫治疗的广泛期小细胞肺癌患者中使用放射治疗.pdf", "page_num": 9}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": null, "type3": null, "type4": null, "type5": null, "type6": "有用性#0#54#全篇为其他参考文献内容"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:41", "update_time": "2024-05-07 23:46:00"}
{"id": 1082555, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 738, "source_info": {"seq_id": "ee66dbfb-de32-4a91-b103-20019a5d4124", "title": null, "text": "【0】页码:35\n Appendix 2 : American Society of Anaesthesiologist Classification ( ASA)\n\n【1】 ASA Status ASA 1: Healthy person.\n\n【2】ASA 2: Mild systemic disease.\n\n【3】ASA 3: Severe systemic disease.\n\n【4】ASA 4: Severe systemic disease that is a constant threat to life.\n\n【5】ASA 5: A moribund person who is not expected to survive without the procedure.\n", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "Appendix 2 : American Society of Anaesthesiologist Classification ( ASA)", "bbox": [119.0, 211.0, 508.0, 228.0]}], "type": "Text", "position": 2}, {"raw_context": [{"text": "ASA Status", "bbox": [246.0, 278.0, 313.0, 297.0]}, {"text": "ASA 1: Healthy person.", "bbox": [124.0, 295.0, 253.0, 314.0]}, {"text": "ASA 2: Mild systemic disease.", "bbox": [124.0, 313.0, 289.0, 330.0]}, {"text": "ASA 3: Severe systemic disease.", "bbox": [125.0, 330.0, 301.0, 348.0]}, {"text": "ASA 4: Severe systemic disease that is a constant threat", "bbox": [124.0, 346.0, 434.0, 362.0]}, {"text": "to life.", "bbox": [125.0, 362.0, 165.0, 380.0]}, {"text": "ASA 5: A moribund person who is not expected to survive ", "bbox": [125.0, 379.0, 435.0, 396.0]}, {"text": "without the procedure.", "bbox": [125.0, 396.0, 255.0, 411.0]}], "type": "Table", "position": 3}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/消化科/_2023 BSG指南：胃肠内窥镜检查中的镇静.pdf", "page_num": 35}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "缺少换行#1#1#ASA 1: Healthy person.另起一行", "type3": null, "type4": null, "type5": null, "type6": null}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:41", "update_time": "2024-05-07 22:54:28"}
{"id": 1082554, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 738, "source_info": {"seq_id": "1c223bc8-6579-4a33-af0e-ed582acceabc", "title": null, "text": "【0】页码:26\n 140 Turnbull D, Krovvidi H, Gannon J. Chapter 7 guidelines for the provision of anaesthesia services (GPAS) in the non-theatre environment. 2020. Available: https://www.rcoa.ac.uk/sites/default/files/documents/2020-02/GPAS-2020-07- ANTE.pdf 141   Flood C, Matthew L, Marsh R, et al. Reducing risk of overdose with midazolam injection in adults: an evaluation of change in clinical practice to improve patient safety in England. J Eval Clin Pract 2015;21:57–66.\n\n【1】142 Ravindran S, Bassett P, Shaw T, et al . Improving safety and reducing error in endoscopy (ISREE): a survey of UK services. Frontline Gastroenterol 2021;12:593–600.\n\n【2】143 Gralnek IM, Stanley AJ, Morris AJ, et al. Endoscopic diagnosis and management of nonvariceal upper gastrointestinal hemorrhage (NVUGIH): European Society of Gastrointestinal Endoscopy (ESGE) guideline - update 2021. Endoscopy 2021;53:300–32.\n\n【3】144 Kim JS, Kim B-W, Kim DH, et al. Guidelines for nonvariceal upper gastrointestinal bleeding. Gut Liver 2020;14:560–70.\n\n【4】145 Lekharaju VPK, Iqbal J, Noorullah O, et al. Emergency endoscopic retrograde cholangiopancreatography in critically ill patients is a safe and effective procedure.\n\n【5】Frontline Gastroenterol 2013;4:138–42.\n\n【6】Lipper B, Simon D, Cerrone F. Pulmonary aspiration during emergency endoscopy in 146 patients with upper gastrointestinal hemorrhage. Crit Care Med 1991;19:330–3.\n\n【7】147 Goudra B, Nuzat A, Singh P, et al. Cardiac arrests in patients undergoing gastrointestinal endoscopy: a retrospective analysis of 73,029 procedures. Saudi J Gastroenterol 2015;21:400.\n\n【8】148 Rehman A, Iscimen R, Yilmaz M, et al. Prophylactic endotracheal intubation in critically ill patients undergoing endoscopy for upper GI hemorrhage. Gastrointest Endosc 2009;69:e55–9.\n\n【9】149   Waye JD. Intubation and sedation in patients who have emergency upper GI endoscopy for GI bleeding. Gastrointestinal Endosc 2000;51:768–71.\n\n【10】150 Griesdale DEG, Bosma TL, Kurth T, et al. Complications of endotracheal intubation in the critically ill Intensive Care Med 2008;34:1835–42.\n\n【11】151 Hayat U, Lee PJ, Ullah H, et al. Association of prophylactic endotracheal intubation in critically ill patients with upper GI bleeding and cardiopulmonary unplanned events.\n\n【12】Gastrointest Endosc 2017;86:500–9.\n\n【13】152 Beg S, Ragunath K, Wyman A, et al. Quality standards in upper gastrointestinal endoscopy: a position statement of the British Society of Gastroenterology (BSG) and Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland (AUGIS).\n\n【14】Gut 2017;66:1886–99.\n\n【15】153 Basturk A, Artan R, Yilmaz A. Investigation of efficacy of lidocaine spray for sedated esophagogastroduodenoscopy in children. Pediatr Gastroenterol Hepatol Nutr 2017;20:87–93.\n\n【16】154 Campo R, Brullet E, Montserrat A, et al. Topical pharyngeal anesthesia improves tolerance of upper gastrointestinal endoscopy: a randomized double-blind study.\n\n【17】Endoscopy 1995;27:659–64.\n\n【18】155 Evans LT, Saberi S, Kim HM, et al. Pharyngeal anesthesia during sedated EGDs: is 'the spray' beneficial? A meta-analysis and systematic review. Gastrointest Endosc 2006;63:761–6.\n\n【19】156 Heuss LT, Hanhart A, Dell-Kuster S, et al. Propofol sedation alone or in combination with pharyngeal lidocaine anesthesia for routine upper GI endoscopy: a randomized, double-blind, placebo-controlled, non-inferiority trial. Gastrointest Endosc 2011;74:1207-14.\n\n【20】157 Quine MA, Bell GD, McCloy RF, et al. Prospective audit of upper gastrointestinal endoscopy in two regions of England: safety, staffing, and sedation methods. Gut 1995;36:462-7.\n\n【21】158 Prout BJ, Metreweli C. Pulmonary aspiration after fibre-endoscopy of the upper gastrointestinal tract. BMJ 1972;4:269–71.\n\n【22】159 Green SM, Mason KP, Krauss BS. Pulmonary aspiration during procedural sedation: a comprehensive systematic review. Br J Anaesth 2017;118:344–54.\n\n【23】160 Khan KJ, Fergani H, Ganguli SC, et al. The benefit of fentanyl in effective sedation and quality of upper endoscopy: a double-blinded randomized trial of fentanyl added to midazolam versus midazolam alone for sedation. J Can Assoc Gastroenterol 2019;2:86–90.\n\n【24】161 Rong Q-H, Zhao G-L, Xie J-P, et al. Feasibility and safety of endoscopic submucosal dissection of esophageal or gastric carcinomas under general anesthesia. Med Princ Pract 2013;22:280–4.\n\n【25】162 Nonaka S, Kawaguchi Y, Oda I, et al. Safety and effectiveness of propofol-based monitored anesthesia care without intubation during endoscopic submucosal dissection for early gastric and esophageal cancers. Dig Endosc 2015;27:665–73.\n\n【26】163 Yoo YC, Park CH, Shin S, et al. A comparison of sedation protocols for gastric endoscopic submucosal dissection: moderate sedation with analgesic supplementation vs analgesia targeted light sedation. Br J Anaesth 2015;115:84–8.\n\n【27】164 Park CH, Shin S, Lee SK, et al. Assessing the stability and safety of procedure during endoscopic submucosal dissection according to sedation methods: a randomized trial. PLoS One 2015;10:e0120529.\n\n【28】165 Kim SH, Choi YS, Lee SK, et al. Comparison of general anesthesia and conscious sedation in procedure-related complications during esophageal endoscopic submucosal dissection. Surg Endosc 2020;34:3560–6.\n\n【29】 166 Cha M-H, Sandooja R, Khalid S, et al. Complication rates in emergent endoscopy for foreign bodies under different sedation modalities: a large single-center retrospective review. World J Gastrointest Endosc 2021;13:45–55.\n\n【30】167 Jirapinyo P, Abu Dayyeh BK, Thompson CC. Conscious sedation for upper endoscopy in the gastric bypass patient: prevalence of cardiopulmonary adverse events and predictors of sedation requirement. Dig Dis Sci 2014;59:2173–7.\n\n【31】168 Triantafillidis JK, Merikas E, Nikolakis D, et al. Sedation in gastrointestinal endoscopy: current issues. World J Gastroenterol 2013;19:463–81.\n\n【32】169 Akhter A, Patel R, Nelsen E, et al. Prospective comparison of moderate conscious sedation and anesthesia assistance for the performance of endoscopic retrograde cholangiopancreatography (ERCP). Can J Gastroenterol Hepatol 2021;2021:8892085.\n\n【33】170 Dhaliwal A, Dhindsa BS, Saghir SM. Choice of sedation in endoscopic retrograde cholangiopancreatography: is monitored anesthesia care as safe as general anesthesia? A systematic review and meta-analysis. Ann Gastroenterol 2021;34:879–87.\n\n【34】171 Kongkam P, Rerknimitr R, Punyathavorn S, et al. Propofol infusion versus intermittent meperidine and midazolam injection for conscious sedation in ERCP. J Gastrointestin Liver Dis 2008;17:291–7.\n\n【35】172 Vargo JI, Zuccaro G Jr, Dumot JA, et al. Gastroenterologist-administered propofol versus meperidine and midazolam for advanced upper endoscopy: a prospective, randomized trial. Gastroenterology 2002;123:8–16.\n\n【36】173 Garewal D, Powell S, Milan SJ, et al. Sedative techniques for endoscopic retrograde cholangiopancreatography. Cochrane Database Syst Rev 2012;CD007274.\n\n【37】174 Redondo-Cerezo E, Sánchez-Robaina A, Martinez Cara JG, et al. Gastroenterologistguided sedation with propofol for endoscopic ultrasonography in averagerisk and high-risk patients: a prospective series. Eur J Gastroenterol Hepatol 2012;24:506-12.\n\n【38】175 Campbell JA, Irvine AJ, Hopper AD. Endoscopic ultrasound sedation in the United Kingdom: is life without propofol tolerable World J Gastroenterol 2017;23:560.\n\n【39】176 Möschler O, May A, Müller M, et al. Complications in and performance of doubleballoon enteroscopy (DBE): results from a large prospective DBE database in Germany. Endoscopy 2011;43:484–9.\n\n【40】177 Byeon J-S, Jung KW, Song H-S, et al. A pilot study about tolerability to double balloon endoscopy: comparison to esophagogastroduodenoscopy and colonoscopy.\n\n【41】Dig Dis Sci 2009;54:2434–40.\n\n【42】178 Sidhu R, Sanders DS. Double-balloon enteroscopy in the elderly with obscure gastrointestinal bleeding: safety and feasibility. Eur J Gastroenterol Hepatol 2013;25:1230–4.\n\n【43】179 Chetcuti Zammit S, Sanders DS, Sidhu R. Device assisted enteroscopy in the elderly - a systematic review and meta-analysis. Dig Liver Dis 2019;51:1249–56.\n\n【44】180 Tanaka S, Mitsui K, Tatsuguchi A, et al. Current status of double balloon endoscopy- -indications, insertion route, sedation, complications, technical matters. Gastrointest Endosc 2007;66:S30–3.\n\n【45】181 Nishizawa T, Suzuki H, Fujimoto A, et a/. Effects of carbon dioxide insufflation in balloon-assisted enteroscopy: a systematic review and meta-analysis. United European Gastroenterol J 2016;4:11–7.\n\n【46】182 Lin Y, Zhang X, Li L, et al. High-flow nasal cannula oxygen therapy and hypoxia during gastroscopy with propofol sedation: a randomized multicenter clinical trial.\n\n【47】Gastrointest Endosc 2019;90:591–601.\n\n【48】183 Arantes V, Albuquerque W, Salles JMP, et al. Effectiveness of unsedated transnasal endoscopy with white-light, flexible spectral imaging color enhancement, and lugol staining for esophageal cancer screening in high-risk patients. J Clin Gastroenterol 2013;47:314-21.\n\n【49】184 Kawai T, Takagi Y, Yamamoto K, et al. Narrow-band imaging on screening of esophageal lesions using an ultrathin transnasal endoscopy. J Gastroenterol Hepatol 2012;27 Suppl 3:34–9.\n\n【50】185 Shariff MK, Varghese S, O'Donovan M, et a /. Pilot randomized crossover study comparing the efficacy of transnasal disposable endosheath with standard endoscopy to detect Barrett's esophagus. Endoscopy 2016;48:110–6.\n\n【51】186 Ai Z-L, Lan C-H, Fan L-L, et al. Unsedated transnasal upper gastrointestinal endoscopy has favorable diagnostic effectiveness, cardiopulmonary safety, and patient satisfaction compared with conventional or sedated endoscopy. Surg Endosc 2012;26:3565–72.\n\n【52】187 Alexandridis E, Inglis S, McAvoy NC, et al. Randomised clinical study: comparison of acceptability, patient tolerance, cardiac stress and endoscopic views in transnasal and transoral endoscopy under local anaesthetic. Aliment Pharmacol Ther 2014;40:467–76.\n\n【53】188 Kadayifci A, Atar M, Parlar S, et al. Transnasal endoscopy is preferred by transoral endoscopy experienced patients. J Gastrointestin Liver Dis 2014;23:27–31.\n\n【54】189 Knuth J, Kunze DE, Benz C, et al. Is the transnasal access for esophagogastroduodenoscopy in routine use equal to the transoral route? A prospective, randomized trial. Z Gastroenterol 2013;51:1369–76.\n\n【55】190 Miyake K, Kusunoki M, Ueki N, et al. Classification of patients who experience a higher distress level to transoral esophagogastroduodenoscopy than to transnasal esophagogastroduodenoscopy. Dig Endosc 2013;25:397–405.", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "140 Turnbull D, Krovvidi H, Gannon J. Chapter 7 guidelines for the provision of", "bbox": [54.0, 61.0, 347.0, 75.0]}, {"text": "anaesthesia services (GPAS) in the non-theatre environment. 2020. Available:", "bbox": [76.0, 75.0, 358.0, 86.0]}, {"text": "https://www.rcoa.ac.uk/sites/default/files/documents/2020-02/GPAS-2020-07-", "bbox": [76.0, 86.0, 363.0, 97.0]}, {"text": "ANTE.pdf", "bbox": [76.0, 99.0, 114.0, 110.0]}, {"text": "141   Flood C, Matthew L, Marsh R, et al. Reducing risk of overdose with midazolam", "bbox": [54.0, 110.0, 364.0, 122.0]}, {"text": "injection in adults: an evaluation of change in clinical practice to improve patient", "bbox": [75.0, 121.0, 372.0, 135.0]}, {"text": "safety in England. J Eval Clin Pract 2015;21:57–66.", "bbox": [76.0, 135.0, 264.0, 146.0]}, {"text": "142", "bbox": [54.0, 146.0, 73.0, 157.0]}, {"text": "Ravindran S, Bassett P, Shaw T, et al . Improving safety and reducing error", "bbox": [72.0, 146.0, 342.0, 157.0]}, {"text": "in endoscopy (ISREE): a survey of UK services. Frontline Gastroenterol", "bbox": [75.0, 158.0, 329.0, 171.0]}, {"text": "2021;12:593–600.", "bbox": [76.0, 169.0, 147.0, 183.0]}, {"text": "143 Gralnek IM, Stanley AJ, Morris AJ, et al. Endoscopic diagnosis and management", "bbox": [54.0, 181.0, 366.0, 195.0]}, {"text": "of nonvariceal upper gastrointestinal hemorrhage (NVUGIH): European Society", "bbox": [75.0, 195.0, 363.0, 207.0]}, {"text": "of Gastrointestinal Endoscopy (ESGE) guideline - update 2021. Endoscopy", "bbox": [75.0, 206.0, 347.0, 218.0]}, {"text": "2021;53:300–32.", "bbox": [75.0, 219.0, 144.0, 229.0]}, {"text": "144 Kim JS, Kim B-W, Kim DH, et al. Guidelines for nonvariceal upper gastrointestinal", "bbox": [54.0, 230.0, 371.0, 242.0]}, {"text": "bleeding. Gut Liver 2020;14:560–70.", "bbox": [76.0, 241.0, 213.0, 254.0]}, {"text": "145 Lekharaju VPK, Iqbal J, Noorullah O, et al. Emergency endoscopic retrograde", "bbox": [54.0, 254.0, 353.0, 266.0]}, {"text": "cholangiopancreatography in critically ill patients is a safe and effective procedure.", "bbox": [76.0, 266.0, 377.0, 277.0]}, {"text": "Frontline Gastroenterol 2013;4:138–42.", "bbox": [75.0, 279.0, 224.0, 291.0]}, {"text": "Lipper B, Simon D, Cerrone F. Pulmonary aspiration during emergency endoscopy in", "bbox": [72.0, 290.0, 379.0, 302.0]}, {"text": "146", "bbox": [54.0, 291.0, 73.0, 301.0]}, {"text": "patients with upper gastrointestinal hemorrhage. Crit Care Med 1991;19:330–3.", "bbox": [75.0, 302.0, 372.0, 314.0]}, {"text": "147 Goudra B, Nuzat A, Singh P, et al. Cardiac arrests in patients undergoing", "bbox": [54.0, 315.0, 340.0, 326.0]}, {"text": "gastrointestinal endoscopy: a retrospective analysis of 73,029 procedures. Saudi J", "bbox": [76.0, 326.0, 375.0, 337.0]}, {"text": "Gastroenterol 2015;21:400.", "bbox": [76.0, 338.0, 180.0, 350.0]}, {"text": "148 Rehman A, Iscimen R, Yilmaz M, et al. Prophylactic endotracheal intubation in", "bbox": [54.0, 350.0, 360.0, 362.0]}, {"text": "critically ill patients undergoing endoscopy for upper GI hemorrhage. Gastrointest", "bbox": [75.0, 362.0, 374.0, 375.0]}, {"text": "Endosc 2009;69:e55–9.", "bbox": [76.0, 375.0, 166.0, 386.0]}, {"text": "149   Waye JD. Intubation and sedation in patients who have emergency upper GI", "bbox": [54.0, 385.0, 355.0, 398.0]}, {"text": "endoscopy for GI bleeding. Gastrointestinal Endosc 2000;51:768–71.", "bbox": [76.0, 398.0, 329.0, 411.0]}, {"text": "150 Griesdale DEG, Bosma TL, Kurth T, et al. Complications of endotracheal intubation in", "bbox": [54.0, 410.0, 383.0, 422.0]}, {"text": "the critically ill Intensive Care Med 2008;34:1835–42.", "bbox": [75.0, 421.0, 276.0, 434.0]}, {"text": "151 Hayat U, Lee PJ, Ullah H, et al. Association of prophylactic endotracheal intubation in", "bbox": [54.0, 435.0, 385.0, 446.0]}, {"text": "critically ill patients with upper GI bleeding and cardiopulmonary unplanned events.", "bbox": [75.0, 446.0, 381.0, 458.0]}, {"text": "Gastrointest Endosc 2017;86:500–9.", "bbox": [75.0, 458.0, 214.0, 470.0]}, {"text": "152 Beg S, Ragunath K, Wyman A, et al. Quality standards in upper gastrointestinal", "bbox": [54.0, 470.0, 363.0, 482.0]}, {"text": "endoscopy: a position statement of the British Society of Gastroenterology (BSG) and", "bbox": [75.0, 482.0, 387.0, 494.0]}, {"text": "Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland (AUGIS).", "bbox": [76.0, 495.0, 384.0, 506.0]}, {"text": "Gut 2017;66:1886–99.", "bbox": [75.0, 506.0, 164.0, 518.0]}, {"text": "153 Basturk A, Artan R, Yilmaz A. Investigation of efficacy of lidocaine spray for sedated", "bbox": [54.0, 518.0, 380.0, 531.0]}, {"text": "esophagogastroduodenoscopy in children. Pediatr Gastroenterol Hepatol Nutr", "bbox": [76.0, 530.0, 360.0, 542.0]}, {"text": "2017;20:87–93.", "bbox": [76.0, 542.0, 139.0, 553.0]}, {"text": "154 Campo R, Brullet E, Montserrat A, et al. Topical pharyngeal anesthesia improves", "bbox": [54.0, 555.0, 367.0, 566.0]}, {"text": "tolerance of upper gastrointestinal endoscopy: a randomized double-blind study.", "bbox": [76.0, 566.0, 370.0, 578.0]}, {"text": "Endoscopy 1995;27:659–64.", "bbox": [76.0, 578.0, 184.0, 590.0]}, {"text": "155 Evans LT, Saberi S, Kim HM, et al. Pharyngeal anesthesia during sedated EGDs: is", "bbox": [54.0, 590.0, 370.0, 602.0]}, {"text": "'the spray' beneficial? A meta-analysis and systematic review. Gastrointest Endosc", "bbox": [77.0, 602.0, 376.0, 615.0]}, {"text": "2006;63:761–6.", "bbox": [76.0, 615.0, 138.0, 626.0]}, {"text": "156 Heuss LT, Hanhart A, Dell-Kuster S, et al. Propofol sedation alone or in combination", "bbox": [54.0, 626.0, 378.0, 638.0]}, {"text": "with pharyngeal lidocaine anesthesia for routine upper GI endoscopy: a randomized,", "bbox": [75.0, 638.0, 383.0, 651.0]}, {"text": "double-blind, placebo-controlled, non-inferiority trial. Gastrointest Endosc", "bbox": [76.0, 650.0, 343.0, 662.0]}, {"text": "2011;74:1207-14.", "bbox": [76.0, 661.0, 148.0, 673.0]}, {"text": "157 Quine MA, Bell GD, McCloy RF, et al. Prospective audit of upper gastrointestinal", "bbox": [54.0, 674.0, 368.0, 686.0]}, {"text": "endoscopy in two regions of England: safety, staffing, and sedation methods. Gut", "bbox": [76.0, 686.0, 373.0, 698.0]}, {"text": "1995;36:462-7.", "bbox": [76.0, 699.0, 138.0, 711.0]}, {"text": "158 Prout BJ, Metreweli C. Pulmonary aspiration after fibre-endoscopy of the upper", "bbox": [54.0, 710.0, 364.0, 723.0]}, {"text": "gastrointestinal tract. BMJ 1972;4:269–71.", "bbox": [76.0, 723.0, 234.0, 736.0]}, {"text": "159 Green SM, Mason KP, Krauss BS. Pulmonary aspiration during procedural sedation: a", "bbox": [54.0, 735.0, 385.0, 747.0]}, {"text": "comprehensive systematic review. Br J Anaesth 2017;118:344–54.", "bbox": [77.0, 747.0, 320.0, 758.0]}, {"text": "160 Khan KJ, Fergani H, Ganguli SC, et al. The benefit of fentanyl in effective sedation", "bbox": [54.0, 759.0, 373.0, 772.0]}, {"text": "and quality of upper endoscopy: a double-blinded randomized trial of fentanyl added", "bbox": [75.0, 771.0, 386.0, 783.0]}, {"text": "to midazolam versus midazolam alone for sedation. J Can Assoc Gastroenterol", "bbox": [76.0, 784.0, 363.0, 796.0]}, {"text": "2019;2:86–90.", "bbox": [76.0, 795.0, 134.0, 807.0]}, {"text": "161 Rong Q-H, Zhao G-L, Xie J-P, et al. Feasibility and safety of endoscopic submucosal", "bbox": [54.0, 807.0, 379.0, 819.0]}, {"text": "dissection of esophageal or gastric carcinomas under general anesthesia. Med Princ", "bbox": [76.0, 819.0, 381.0, 832.0]}, {"text": "Pract 2013;22:280–4.", "bbox": [76.0, 831.0, 158.0, 842.0]}, {"text": "162 Nonaka S, Kawaguchi Y, Oda I, et al. Safety and effectiveness of propofol-based", "bbox": [54.0, 843.0, 367.0, 856.0]}, {"text": "monitored anesthesia care without intubation during endoscopic submucosal", "bbox": [76.0, 855.0, 358.0, 867.0]}, {"text": "dissection for early gastric and esophageal cancers. Dig Endosc 2015;27:665–73.", "bbox": [76.0, 867.0, 373.0, 879.0]}, {"text": "163 Yoo YC, Park CH, Shin S, et al. A comparison of sedation protocols for", "bbox": [54.0, 879.0, 329.0, 892.0]}, {"text": "gastric endoscopic submucosal dissection: moderate sedation with analgesic", "bbox": [76.0, 891.0, 354.0, 902.0]}, {"text": "supplementation vs analgesia targeted light sedation. Br J Anaesth 2015;115:84–8.", "bbox": [76.0, 904.0, 382.0, 915.0]}, {"text": "164 Park CH, Shin S, Lee SK, et al. Assessing the stability and safety of procedure during", "bbox": [54.0, 915.0, 381.0, 927.0]}, {"text": "endoscopic submucosal dissection according to sedation methods: a randomized", "bbox": [75.0, 927.0, 371.0, 939.0]}, {"text": "trial. PLoS One 2015;10:e0120529.", "bbox": [75.0, 939.0, 207.0, 951.0]}, {"text": "165 Kim SH, Choi YS, Lee SK, et al. Comparison of general anesthesia and conscious", "bbox": [54.0, 951.0, 367.0, 962.0]}, {"text": "sedation in procedure-related complications during esophageal endoscopic", "bbox": [75.0, 964.0, 350.0, 976.0]}, {"text": "submucosal dissection. Surg Endosc 2020;34:3560–6.", "bbox": [76.0, 976.0, 275.0, 987.0]}], "type": "Text", "position": 1}, {"raw_context": [{"text": "166 Cha M-H, Sandooja R, Khalid S, et al. Complication rates in emergent endoscopy", "bbox": [408.0, 60.0, 723.0, 73.0]}, {"text": "for foreign bodies under different sedation modalities: a large single-center", "bbox": [428.0, 73.0, 704.0, 85.0]}, {"text": "retrospective review. World J Gastrointest Endosc 2021;13:45–55.", "bbox": [430.0, 85.0, 671.0, 97.0]}, {"text": "167", "bbox": [408.0, 97.0, 427.0, 108.0]}, {"text": "Jirapinyo P, Abu Dayyeh BK, Thompson CC. Conscious sedation for upper endoscopy", "bbox": [426.0, 97.0, 735.0, 109.0]}, {"text": "in the gastric bypass patient: prevalence of cardiopulmonary adverse events and", "bbox": [428.0, 110.0, 723.0, 121.0]}, {"text": "predictors of sedation requirement. Dig Dis Sci 2014;59:2173–7.", "bbox": [429.0, 121.0, 667.0, 133.0]}, {"text": "168", "bbox": [408.0, 133.0, 427.0, 144.0]}, {"text": "Triantafillidis JK, Merikas E, Nikolakis D, et al. Sedation in gastrointestinal endoscopy:", "bbox": [427.0, 133.0, 739.0, 145.0]}, {"text": "current issues. World J Gastroenterol 2013;19:463–81.", "bbox": [429.0, 145.0, 631.0, 157.0]}, {"text": "169 Akhter A, Patel R, Nelsen E, et al. Prospective comparison of moderate conscious", "bbox": [408.0, 157.0, 724.0, 169.0]}, {"text": "sedation and anesthesia assistance for the performance of endoscopic", "bbox": [429.0, 170.0, 686.0, 182.0]}, {"text": "retrograde cholangiopancreatography (ERCP). Can J Gastroenterol Hepatol", "bbox": [429.0, 182.0, 702.0, 195.0]}, {"text": "2021;2021:8892085.", "bbox": [430.0, 195.0, 510.0, 206.0]}, {"text": "170", "bbox": [408.0, 206.0, 428.0, 217.0]}, {"text": "Dhaliwal A, Dhindsa BS, Saghir SM. Choice of sedation in endoscopic retrograde", "bbox": [426.0, 206.0, 721.0, 217.0]}, {"text": "cholangiopancreatography: is monitored anesthesia care as safe as general", "bbox": [428.0, 218.0, 704.0, 231.0]}, {"text": "anesthesia? A systematic review and meta-analysis. Ann Gastroenterol", "bbox": [430.0, 231.0, 686.0, 242.0]}, {"text": "2021;34:879–87.", "bbox": [430.0, 243.0, 496.0, 255.0]}, {"text": "171", "bbox": [408.0, 255.0, 426.0, 266.0]}, {"text": "Kongkam P, Rerknimitr R, Punyathavorn S, et al. Propofol infusion versus intermittent", "bbox": [426.0, 255.0, 739.0, 267.0]}, {"text": "meperidine and midazolam injection for conscious sedation in ERCP. J Gastrointestin", "bbox": [430.0, 268.0, 737.0, 279.0]}, {"text": "Liver Dis 2008;17:291–7.", "bbox": [429.0, 279.0, 524.0, 291.0]}, {"text": "172", "bbox": [408.0, 291.0, 428.0, 302.0]}, {"text": "Vargo JI, Zuccaro G Jr, Dumot JA, et al. Gastroenterologist-administered propofol", "bbox": [426.0, 291.0, 725.0, 302.0]}, {"text": "versus meperidine and midazolam for advanced upper endoscopy: a prospective,", "bbox": [429.0, 304.0, 724.0, 316.0]}, {"text": "randomized trial. Gastroenterology 2002;123:8–16.", "bbox": [429.0, 317.0, 619.0, 327.0]}, {"text": "173 Garewal D, Powell S, Milan SJ, et al. Sedative techniques for endoscopic retrograde", "bbox": [408.0, 329.0, 731.0, 340.0]}, {"text": "cholangiopancreatography. Cochrane Database Syst Rev 2012;CD007274.", "bbox": [429.0, 340.0, 702.0, 352.0]}, {"text": "174 Redondo-Cerezo E, Sánchez-Robaina A, Martinez Cara JG, et al. Gastroenterologist-", "bbox": [408.0, 352.0, 734.0, 365.0]}, {"text": "guided sedation with propofol for endoscopic ultrasonography in average-", "bbox": [429.0, 364.0, 700.0, 376.0]}, {"text": "risk and high-risk patients: a prospective series. Eur J Gastroenterol Hepatol", "bbox": [429.0, 377.0, 705.0, 390.0]}, {"text": "2012;24:506-12.", "bbox": [430.0, 390.0, 496.0, 401.0]}, {"text": "175", "bbox": [408.0, 401.0, 428.0, 412.0]}, {"text": "Campbell JA, Irvine AJ, Hopper AD. Endoscopic ultrasound sedation in the United", "bbox": [426.0, 401.0, 725.0, 412.0]}, {"text": "Kingdom: is life without propofol tolerable World J Gastroenterol 2017;23:560.", "bbox": [429.0, 413.0, 719.0, 426.0]}, {"text": "176 Möschler O, May A, Müller M, et al. Complications in and performance of double-", "bbox": [408.0, 425.0, 725.0, 436.0]}, {"text": "balloon enteroscopy (DBE): results from a large prospective DBE database in", "bbox": [429.0, 438.0, 708.0, 450.0]}, {"text": "Germany. Endoscopy 2011;43:484–9.", "bbox": [429.0, 451.0, 570.0, 461.0]}, {"text": "177", "bbox": [408.0, 463.0, 427.0, 473.0]}, {"text": "Byeon J-S, Jung KW, Song H-S, et al. A pilot study about tolerability to double", "bbox": [426.0, 463.0, 712.0, 474.0]}, {"text": "balloon endoscopy: comparison to esophagogastroduodenoscopy and colonoscopy.", "bbox": [429.0, 474.0, 734.0, 486.0]}, {"text": "Dig Dis Sci 2009;54:2434–40.", "bbox": [429.0, 487.0, 543.0, 497.0]}, {"text": "178 Sidhu R, Sanders DS. Double-balloon enteroscopy in the elderly with obscure", "bbox": [408.0, 498.0, 709.0, 510.0]}, {"text": "gastrointestinal bleeding: safety and feasibility. Eur J Gastroenterol Hepatol", "bbox": [430.0, 510.0, 704.0, 524.0]}, {"text": "2013;25:1230–4.", "bbox": [430.0, 524.0, 494.0, 534.0]}, {"text": "179 Chetcuti Zammit S, Sanders DS, Sidhu R. Device assisted enteroscopy in the elderly -", "bbox": [408.0, 534.0, 734.0, 548.0]}, {"text": "a systematic review and meta-analysis. Dig Liver Dis 2019;51:1249–56.", "bbox": [430.0, 548.0, 691.0, 559.0]}, {"text": "180", "bbox": [408.0, 559.0, 427.0, 570.0]}, {"text": "Tanaka S, Mitsui K, Tatsuguchi A, et al. Current status of double balloon endoscopy-", "bbox": [427.0, 559.0, 733.0, 570.0]}, {"text": "-indications, insertion route, sedation, complications, technical matters. Gastrointest", "bbox": [430.0, 572.0, 734.0, 585.0]}, {"text": "Endosc 2007;66:S30–3.", "bbox": [429.0, 584.0, 519.0, 595.0]}, {"text": "181 Nishizawa T, Suzuki H, Fujimoto A, et a/. Effects of carbon dioxide insufflation", "bbox": [408.0, 596.0, 711.0, 608.0]}, {"text": "in balloon-assisted enteroscopy: a systematic review and meta-analysis. United", "bbox": [429.0, 608.0, 718.0, 620.0]}, {"text": "European Gastroenterol J 2016;4:11–7.", "bbox": [429.0, 621.0, 575.0, 630.0]}, {"text": "182 Lin Y, Zhang X, Li L, et al. High-flow nasal cannula oxygen therapy and hypoxia", "bbox": [408.0, 632.0, 717.0, 645.0]}, {"text": "during gastroscopy with propofol sedation: a randomized multicenter clinical trial.", "bbox": [428.0, 645.0, 727.0, 656.0]}, {"text": "Gastrointest Endosc 2019;90:591–601.", "bbox": [430.0, 657.0, 575.0, 669.0]}, {"text": "183 Arantes V, Albuquerque W, Salles JMP, et al. Effectiveness of unsedated transnasal", "bbox": [408.0, 668.0, 728.0, 681.0]}, {"text": "endoscopy with white-light, flexible spectral imaging color enhancement, and lugol", "bbox": [429.0, 682.0, 733.0, 693.0]}, {"text": "staining for esophageal cancer screening in high-risk patients. J Clin Gastroenterol", "bbox": [429.0, 693.0, 729.0, 705.0]}, {"text": "2013;47:314-21.", "bbox": [430.0, 706.0, 496.0, 717.0]}, {"text": "184 Kawai T, Takagi Y, Yamamoto K, et al. Narrow-band imaging on screening of", "bbox": [408.0, 717.0, 706.0, 730.0]}, {"text": "esophageal lesions using an ultrathin transnasal endoscopy. J Gastroenterol Hepatol", "bbox": [429.0, 731.0, 737.0, 743.0]}, {"text": "2012;27 Suppl 3:34–9.", "bbox": [430.0, 743.0, 516.0, 754.0]}, {"text": "185", "bbox": [408.0, 753.0, 427.0, 765.0]}, {"text": "Shariff MK, Varghese S, O'Donovan M, et a /. Pilot randomized crossover study", "bbox": [426.0, 753.0, 711.0, 766.0]}, {"text": "comparing the efficacy of transnasal disposable endosheath with standard", "bbox": [428.0, 766.0, 702.0, 779.0]}, {"text": "endoscopy to detect Barrett's esophagus. Endoscopy 2016;48:110–6.", "bbox": [428.0, 779.0, 683.0, 791.0]}, {"text": "186", "bbox": [408.0, 791.0, 427.0, 803.0]}, {"text": "Ai Z-L, Lan C-H, Fan L-L, et al. Unsedated transnasal upper gastrointestinal", "bbox": [426.0, 791.0, 702.0, 803.0]}, {"text": "endoscopy has favorable diagnostic effectiveness, cardiopulmonary safety, and", "bbox": [429.0, 803.0, 717.0, 814.0]}, {"text": "patient satisfaction compared with conventional or sedated endoscopy. Surg Endosc", "bbox": [429.0, 816.0, 737.0, 827.0]}, {"text": "2012;26:3565–72.", "bbox": [430.0, 827.0, 501.0, 839.0]}, {"text": "187", "bbox": [408.0, 839.0, 426.0, 850.0]}, {"text": "Alexandridis E, Inglis S, McAvoy NC, et al. Randomised clinical study: comparison of", "bbox": [427.0, 839.0, 735.0, 852.0]}, {"text": "acceptability, patient tolerance, cardiac stress and endoscopic views in transnasal", "bbox": [429.0, 852.0, 726.0, 863.0]}, {"text": "and transoral endoscopy under local anaesthetic. Aliment Pharmacol Ther", "bbox": [429.0, 865.0, 697.0, 877.0]}, {"text": "2014;40:467–76.", "bbox": [430.0, 877.0, 494.0, 887.0]}, {"text": "188 Kadayifci A, Atar M, Parlar S, et al. Transnasal endoscopy is preferred by transoral", "bbox": [408.0, 886.0, 725.0, 901.0]}, {"text": "endoscopy experienced patients. J Gastrointestin Liver Dis 2014;23:27–31.", "bbox": [429.0, 901.0, 702.0, 912.0]}, {"text": "189", "bbox": [408.0, 913.0, 426.0, 922.0]}, {"text": "Knuth J, Kunze DE, Benz C, et al. Is the transnasal access for", "bbox": [426.0, 912.0, 649.0, 924.0]}, {"text": "esophagogastroduodenoscopy in routine use equal to the transoral route? A", "bbox": [429.0, 925.0, 709.0, 937.0]}, {"text": "prospective, randomized trial. Z Gastroenterol 2013;51:1369–76.", "bbox": [428.0, 937.0, 668.0, 948.0]}, {"text": "190 Miyake K, Kusunoki M, Ueki N, et al. Classification of patients who experience a", "bbox": [408.0, 949.0, 721.0, 962.0]}, {"text": "higher distress level to transoral esophagogastroduodenoscopy than to transnasal", "bbox": [428.0, 961.0, 729.0, 973.0]}, {"text": "esophagogastroduodenoscopy. Dig Endosc 2013;25:397–405.", "bbox": [429.0, 974.0, 658.0, 986.0]}], "type": "Text", "position": 2}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/消化科/_2023 BSG指南：胃肠内窥镜检查中的镇静.pdf", "page_num": 26}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": null, "type3": null, "type4": null, "type5": null, "type6": "有用性#0#55#全篇为其他参考文献内容"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:41", "update_time": "2024-05-08 22:52:59"}
{"id": 1082553, "user_id": "6597f314962a88e852fcd01f", "user_name": "李鹏飞", "task_id": 738, "source_info": {"seq_id": "f8f8538f-4a8a-4abc-8423-5d7bef533c56", "title": null, "text": "【0】页码:6\n\n【1】## ’ Bj Haem\n\n【2】\n in the first half of pregnancy. 5 Transition from VKA to heparin in the first trimester therefore requires particular attention as this represents a period of very high risk for MVT. As soon as a positive pregnancy test is confirmed, the individual should stop VKA and commence twice-daily LMWH injections.\n\n【3】The INR need not be in the normal range when commencing LMWH. Many guidelines focus on the peripartum management of anticoagulation; however, evidence suggests that the risk of MVT is predominantly antenatal and poor adherence with anticoagulation is a key theme.\n\n【4】Although there is no firm evidence that monitoring LMWH with anti-Xa levels in pregnancy improves maternal outcomes, 22 there is evidence that standard fixed doses of LMWH are associated with a higher risk of MVT in pregnancy. 23,24 Fatal thrombotic events in two pregnant individuals in the HiP-CAT study occurred with low peak anti-Xa levels. 15 In a small study of 11 pregnant patients 25 with a starting dose of 1 mg/kg BD enoxaparin and subsequent monitoring of LMWH to achieve a peak enoxaparin anti-Xa level of 1.0– 1.2 IU/mL, a mean increase in LMWH dose of 54% was required. In another retrospective study, 26 an enoxaparin dose of 1.3 mg/kg BD was required to achieve a peak enoxaparin anti-Xa level of 1.0–1.2 IU/mL.\n\n【5】Based on data from the UKOSS study, the authors suggest starting doses of LMWH of 2.5 mg/kg/day for enoxaparin, 250 IU/kg/day for dalteparin and 250 IU/kg/day for tinzaparin to ensure minimal delay in reaching a reasonable level of anticoagulation. 5 It was also noted that most pregnant individuals required dose escalation between 10 and 20 weeks of gestation. Although LMWH products differ in terms of ratio of anti-Xa to antithrombin activity due to variation in processing and average molecular weight, 27 there is currently insufficient data to recommend a specific product for use in pregnant individuals with MHV.\n\n【6】Trough LMWH testing has been recommended by some groups. 28,29 A meta-analysis of six studies of mainly prophylactic LMWH dosing suggested a benefit to trough monitoring versus no monitoring but not for peak monitoring 30 ; however, this was dominated by a study checking anti-Xa levels 12h post a standard prophylactic dose of dalteparin in high-risk trauma patients. 31 Goland et al. defined subtherapeutic anticoagulation with LMWH in individuals with MHV in pregnancy as a trough level of <0.6 IU/mL; however, this definition was accepted as arbitrary. 32 They found that even with peak anti-Xa levels >1.2 IU/mL on a BD dosing regimen, 31% trough levels were <0.6 IU/mL. Peak and trough levels showed some correlation but with variability.\n\n【7】In the UKOSS study, 5 the incidence of maternal complications was similar in individuals with post-dose only LMWH monitoring versus pre- and post-dose.\n\n【8】The American College of Cardiology and American Heart Association (ACC/AHA) guidelines recommend target LMWH levels by anti-Xa assay of 0.8–1.2IU/mL at 4–6h after dose. 1 They also state that measurement of trough levels to maintain a trough level>0.6IU/mL may help pregnant individuals to maintain therapeutic anticoagulation while on LMWH. The ESC and European Association for Cardio-Thoracic Surgery\n\n【9】 dar0 coli/W , condi/l viscovin/UM&V secol, - 13 ns 64 1 828 1 4R/1 111 0 1/10/10/11/10/1101/10\n\n【10】 thes amor, our 208 [EZDEA0/81] no candi\n\n【11】 guidelines recommend switching to LMWH during the first trimester with strict monitoring (peak therapeutic range: 0.8– 1.2 IU/mL for aortic valve prosthesis; and 1.0–1.2 IU/mL for mitral and right-sided valve prosthesis). 2 In summary, there are sufficient data to suggest that standard therapeutic doses of LMWH are inadequate and that monitoring is prudent. However, there are insufficient data on trough versus peak monitoring to make firm recommendations. We consider that a trough target of 0.6 IU/mL is arbitrary. An additional consideration is that it is more timeconsuming and inconvenient for pregnant individuals to have both trough and peak levels monitored and the use of more frequent LMWH dosing than BD is highly invasive and not adequately studied in terms of risk/benefit. Moreover, one of the most important causes of MVT is poor adherence with anticoagulation and the physical burden and injection site toxicity of such a regimen could easily be counterproductive.\n\n【12】In the absence of further supportive data, we consider a peak target of 1.0–1.4IU/mL at 3–4h post-BD dosing to be a reasonable target in the absence of bleeding complications and gives a better opportunity for a reasonable trough with a BD dosing regimen. Peak testing was preferred by the majority of haematology/thrombosis specialists in an ISTH SSC survey, although this survey did not have many cardiology respondents due to questionnaire distribution. 33 Routine use of trough LMWH levels cannot be recommended currently.\n\n【13】Trough levels should not currently replace peak level monitoring. We consider that trough monitoring to achieve >0.6IU/ mL LMWH levels along with more than twice-daily LMWH dosing regimens should be evaluated as a matter of urgency to assess whether they offer superior protection against MVT to pregnant individuals without excessive bleeding.\n\n【14】Monitoring requires regular access to outpatient setting with timed blood sampling and excellent communication of results and impact on dose with plans for next levels. There is no clear evidence to guide the frequency of LMWH monitoring. However, in view of the risks of valve thrombosis in the initial transition to LMWH, we recommend at least weekly monitoring until the target level is achieved or when there is a below target at any stage and then regular monitoring thereafter (e.g. every 2–4 weeks depending on stability).\n\n【15】## A S P I R I N\n\n【16】\n Historical studies outside of pregnancy show that the addition of LDA to VKAs in patients with MHV reduces the risk of MVT but at a cost of a higher risk of major bleeding. 34 Aspirin 75–100mg in addition to anticoagulation has been recommended routinely in individuals with MHV in pregnancy. 14 , 35 , 36 In the ROPAC registry, no pregnant patients on aspirin developed MVT but more haemorrhagic events were described; however, only 6.1% of patients were given aspirin so no conclusions can be drawn. 6 The ACC/AHA guidelines 1 state that LDA is regarded as safe during pregnancy and can be used in individuals with", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "’ BJ Haem", "bbox": [57.0, 23.0, 161.0, 63.0]}], "type": "Section-header", "position": 0}, {"raw_context": [{"text": "in the first half of pregnancy. 5 Transition from VKA to heparin", "bbox": [58.0, 64.0, 387.0, 79.0]}, {"text": "in the first trimester therefore requires particular attention as", "bbox": [58.0, 80.0, 387.0, 95.0]}, {"text": "this represents a period of very high risk for MVT. As soon as", "bbox": [58.0, 97.0, 387.0, 112.0]}, {"text": "a positive pregnancy test is confirmed, the individual should", "bbox": [58.0, 113.0, 387.0, 127.0]}, {"text": "stop VKA and commence twice-daily LMWH injections.", "bbox": [58.0, 129.0, 386.0, 144.0]}, {"text": "The INR need not be in the normal range when commencing", "bbox": [58.0, 145.0, 387.0, 160.0]}, {"text": "LMWH. Many guidelines focus on the peripartum manage-", "bbox": [58.0, 161.0, 384.0, 176.0]}, {"text": "ment of anticoagulation; however, evidence suggests that the", "bbox": [58.0, 177.0, 387.0, 193.0]}, {"text": "risk of MVT is predominantly antenatal and poor adherence", "bbox": [58.0, 194.0, 387.0, 208.0]}, {"text": "with anticoagulation is a key theme.", "bbox": [58.0, 209.0, 248.0, 224.0]}, {"text": "Although there is no firm evidence that monitoring LMWH", "bbox": [74.0, 226.0, 386.0, 240.0]}, {"text": "with anti-Xa levels in pregnancy improves maternal out-", "bbox": [58.0, 242.0, 385.0, 256.0]}, {"text": "comes, 22 there is evidence that standard fixed doses of LMWH", "bbox": [58.0, 258.0, 387.0, 273.0]}, {"text": "are associated with a higher risk of MVT in pregnancy. 23,24", "bbox": [58.0, 274.0, 384.0, 288.0]}, {"text": "Fatal thrombotic events in two pregnant individuals in the", "bbox": [58.0, 289.0, 387.0, 305.0]}, {"text": "HiP-CAT study occurred with low peak anti-Xa levels. 15", "bbox": [58.0, 306.0, 350.0, 321.0]}, {"text": "In a small study of 11 pregnant patients 25 with a starting", "bbox": [74.0, 322.0, 387.0, 336.0]}, {"text": "dose of 1 mg/kg BD enoxaparin and subsequent monitoring", "bbox": [58.0, 338.0, 387.0, 353.0]}, {"text": "of LMWH to achieve a peak enoxaparin anti-Xa level of 1.0–", "bbox": [58.0, 354.0, 385.0, 368.0]}, {"text": "1.2 IU/mL, a mean increase in LMWH dose of 54% was re-", "bbox": [58.0, 369.0, 385.0, 385.0]}, {"text": "quired. In another retrospective study, 26 an enoxaparin dose", "bbox": [58.0, 386.0, 387.0, 401.0]}, {"text": "of 1.3 mg/kg BD was required to achieve a peak enoxaparin", "bbox": [58.0, 401.0, 387.0, 416.0]}, {"text": "anti-Xa level of 1.0–1.2 IU/mL.", "bbox": [58.0, 418.0, 224.0, 433.0]}, {"text": "Based on data from the UKOSS study, the authors suggest", "bbox": [74.0, 434.0, 387.0, 448.0]}, {"text": "starting doses of LMWH of 2.5 mg/kg/day for enoxaparin,", "bbox": [58.0, 449.0, 387.0, 465.0]}, {"text": "250 IU/kg/day for dalteparin and 250 IU/kg/day for tinzapa-", "bbox": [58.0, 466.0, 385.0, 481.0]}, {"text": "rin to ensure minimal delay in reaching a reasonable level of", "bbox": [58.0, 482.0, 387.0, 496.0]}, {"text": "anticoagulation. 5 It was also noted that most pregnant indi-", "bbox": [58.0, 498.0, 385.0, 513.0]}, {"text": "viduals required dose escalation between 10 and 20 weeks of", "bbox": [58.0, 513.0, 387.0, 529.0]}, {"text": "gestation. Although LMWH products differ in terms of ratio", "bbox": [58.0, 529.0, 387.0, 545.0]}, {"text": "of anti-Xa to antithrombin activity due to variation in pro-", "bbox": [58.0, 546.0, 385.0, 561.0]}, {"text": "cessing and average molecular weight, 27 there is currently", "bbox": [58.0, 561.0, 386.0, 578.0]}, {"text": "insufficient data to recommend a specific product for use in", "bbox": [58.0, 578.0, 387.0, 593.0]}, {"text": "pregnant individuals with MHV.", "bbox": [58.0, 595.0, 238.0, 608.0]}, {"text": "Trough LMWH testing has been recommended by some", "bbox": [75.0, 609.0, 387.0, 624.0]}, {"text": "groups. 28,29 A meta-analysis of six studies of mainly prophy-", "bbox": [58.0, 624.0, 385.0, 641.0]}, {"text": "lactic LMWH dosing suggested a benefit to trough moni-", "bbox": [58.0, 642.0, 385.0, 656.0]}, {"text": "toring versus no monitoring but not for peak monitoring 30 ;", "bbox": [58.0, 658.0, 386.0, 673.0]}, {"text": "however, this was dominated by a study checking anti-Xa", "bbox": [58.0, 674.0, 387.0, 689.0]}, {"text": "levels 12h post a standard prophylactic dose of dalteparin in", "bbox": [58.0, 689.0, 387.0, 705.0]}, {"text": "high-risk trauma patients. 31 Goland et al. defined subther-", "bbox": [58.0, 706.0, 385.0, 721.0]}, {"text": "apeutic anticoagulation with LMWH in individuals with", "bbox": [58.0, 721.0, 387.0, 736.0]}, {"text": "MHV in pregnancy as a trough level of <0.6 IU/mL; how-", "bbox": [58.0, 737.0, 384.0, 753.0]}, {"text": "ever, this definition was accepted as arbitrary. 32 They found", "bbox": [58.0, 755.0, 387.0, 768.0]}, {"text": "that even with peak anti-Xa levels >1.2 IU/mL on a BD dos-", "bbox": [58.0, 769.0, 385.0, 784.0]}, {"text": "ing regimen, 31% trough levels were <0.6 IU/mL. Peak and", "bbox": [58.0, 786.0, 387.0, 801.0]}, {"text": "trough levels showed some correlation but with variability.", "bbox": [58.0, 802.0, 387.0, 816.0]}, {"text": "In the UKOSS study, 5 the incidence of maternal complica-", "bbox": [58.0, 817.0, 385.0, 833.0]}, {"text": "tions was similar in individuals with post-dose only LMWH", "bbox": [58.0, 834.0, 387.0, 849.0]}, {"text": "monitoring versus pre- and post-dose.", "bbox": [58.0, 849.0, 265.0, 865.0]}, {"text": "The American College of Cardiology and American Heart", "bbox": [74.0, 866.0, 387.0, 880.0]}, {"text": "Association (ACC/AHA) guidelines recommend target LMWH", "bbox": [58.0, 882.0, 386.0, 896.0]}, {"text": "levels by anti-Xa assay of 0.8–1.2IU/mL at 4–6h after dose. 1", "bbox": [58.0, 897.0, 384.0, 913.0]}, {"text": "They also state that measurement of trough levels to maintain", "bbox": [58.0, 915.0, 387.0, 929.0]}, {"text": "a trough level>0.6IU/mL may help pregnant individuals to", "bbox": [58.0, 930.0, 387.0, 944.0]}, {"text": "maintain therapeutic anticoagulation while on LMWH. The", "bbox": [58.0, 946.0, 387.0, 961.0]}, {"text": "ESC and European Association for Cardio-Thoracic Surgery", "bbox": [58.0, 963.0, 386.0, 977.0]}], "type": "Text", "position": 1}, {"raw_context": [{"text": "dar0 coli/W , condi/l viscovin/UM&V secol, - 13 ns 64 1 828 1 4R/1 111 0 1/10/10/11/10/1101/10", "bbox": [768.0, 155.0, 781.0, 408.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "thes amor, our 208 [EZDEA0/81] no candi", "bbox": [768.0, 421.0, 780.0, 537.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": "guidelines recommend switching to LMWH during the first", "bbox": [406.0, 65.0, 735.0, 79.0]}, {"text": "trimester with strict monitoring (peak therapeutic range: 0.8–", "bbox": [406.0, 80.0, 733.0, 95.0]}, {"text": "1.2 IU/mL for aortic valve prosthesis; and 1.0–1.2 IU/mL for", "bbox": [408.0, 97.0, 734.0, 112.0]}, {"text": "mitral and right-sided valve prosthesis). 2", "bbox": [406.0, 113.0, 617.0, 127.0]}, {"text": "In summary, there are sufficient data to suggest that stan-", "bbox": [422.0, 128.0, 734.0, 144.0]}, {"text": "dard therapeutic doses of LMWH are inadequate and that", "bbox": [406.0, 145.0, 735.0, 160.0]}, {"text": "monitoring is prudent. However, there are insufficient data", "bbox": [406.0, 160.0, 735.0, 176.0]}, {"text": "on trough versus peak monitoring to make firm recommen-", "bbox": [406.0, 177.0, 734.0, 192.0]}, {"text": "dations. We consider that a trough target of 0.6 IU/mL is", "bbox": [406.0, 194.0, 735.0, 207.0]}, {"text": "arbitrary. An additional consideration is that it is more time-", "bbox": [406.0, 209.0, 734.0, 225.0]}, {"text": "consuming and inconvenient for pregnant individuals to have", "bbox": [406.0, 226.0, 735.0, 240.0]}, {"text": "both trough and peak levels monitored and the use of more", "bbox": [406.0, 242.0, 735.0, 256.0]}, {"text": "frequent LMWH dosing than BD is highly invasive and not", "bbox": [406.0, 258.0, 735.0, 273.0]}, {"text": "adequately studied in terms of risk/benefit. Moreover, one of", "bbox": [406.0, 274.0, 735.0, 288.0]}, {"text": "the most important causes of MVT is poor adherence with", "bbox": [406.0, 290.0, 735.0, 304.0]}, {"text": "anticoagulation and the physical burden and injection site", "bbox": [406.0, 306.0, 735.0, 321.0]}, {"text": "toxicity of such a regimen could easily be counterproductive.", "bbox": [406.0, 322.0, 733.0, 336.0]}, {"text": "In the absence of further supportive data, we consider a peak", "bbox": [406.0, 338.0, 735.0, 353.0]}, {"text": "target of 1.0–1.4IU/mL at 3–4h post-BD dosing to be a rea-", "bbox": [406.0, 354.0, 734.0, 368.0]}, {"text": "sonable target in the absence of bleeding complications and", "bbox": [406.0, 370.0, 735.0, 385.0]}, {"text": "gives a better opportunity for a reasonable trough with a BD", "bbox": [406.0, 386.0, 735.0, 401.0]}, {"text": "dosing regimen. Peak testing was preferred by the majority", "bbox": [406.0, 401.0, 734.0, 416.0]}, {"text": "of haematology/thrombosis specialists in an ISTH SSC sur-", "bbox": [406.0, 418.0, 733.0, 433.0]}, {"text": "vey, although this survey did not have many cardiology re-", "bbox": [406.0, 435.0, 733.0, 448.0]}, {"text": "spondents due to questionnaire distribution. 33 Routine use", "bbox": [406.0, 450.0, 735.0, 464.0]}, {"text": "of trough LMWH levels cannot be recommended currently.", "bbox": [406.0, 466.0, 735.0, 481.0]}, {"text": "Trough levels should not currently replace peak level monitor-", "bbox": [407.0, 482.0, 733.0, 496.0]}, {"text": "ing. We consider that trough monitoring to achieve >0.6IU/", "bbox": [406.0, 498.0, 735.0, 513.0]}, {"text": "mL LMWH levels along with more than twice-daily LMWH", "bbox": [406.0, 514.0, 735.0, 528.0]}, {"text": "dosing regimens should be evaluated as a matter of urgency to", "bbox": [406.0, 530.0, 735.0, 545.0]}, {"text": "assess whether they offer superior protection against MVT to", "bbox": [406.0, 546.0, 735.0, 561.0]}, {"text": "pregnant individuals without excessive bleeding.", "bbox": [406.0, 562.0, 666.0, 576.0]}, {"text": "Monitoring requires regular access to outpatient setting", "bbox": [422.0, 578.0, 735.0, 593.0]}, {"text": "with timed blood sampling and excellent communication of", "bbox": [406.0, 595.0, 735.0, 609.0]}, {"text": "results and impact on dose with plans for next levels. There", "bbox": [406.0, 610.0, 735.0, 624.0]}, {"text": "is no clear evidence to guide the frequency of LMWH mon-", "bbox": [406.0, 626.0, 734.0, 641.0]}, {"text": "itoring. However, in view of the risks of valve thrombosis", "bbox": [406.0, 642.0, 735.0, 656.0]}, {"text": "in the initial transition to LMWH, we recommend at least", "bbox": [406.0, 657.0, 735.0, 673.0]}, {"text": "weekly monitoring until the target level is achieved or when", "bbox": [406.0, 675.0, 735.0, 689.0]}, {"text": "there is a below target at any stage and then regular monitor-", "bbox": [406.0, 689.0, 733.0, 705.0]}, {"text": "ing thereafter (e.g. every 2–4 weeks depending on stability).", "bbox": [406.0, 706.0, 731.0, 721.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "A S P I R I N", "bbox": [408.0, 751.0, 484.0, 769.0]}], "type": "Section-header", "position": 6}, {"raw_context": [{"text": "Historical studies outside of pregnancy show that the ad-", "bbox": [406.0, 785.0, 733.0, 802.0]}, {"text": "dition of LDA to VKAs in patients with MHV reduces the", "bbox": [406.0, 802.0, 735.0, 816.0]}, {"text": "risk of MVT but at a cost of a higher risk of major bleed-", "bbox": [406.0, 817.0, 734.0, 834.0]}, {"text": "ing. 34 Aspirin 75–100mg in addition to anticoagulation has", "bbox": [406.0, 833.0, 735.0, 849.0]}, {"text": "been recommended routinely in individuals with MHV in", "bbox": [406.0, 849.0, 735.0, 865.0]}, {"text": "pregnancy. 14 , 35 , 36", "bbox": [406.0, 867.0, 495.0, 881.0]}, {"text": "In the ROPAC registry, no pregnant patients on aspirin", "bbox": [422.0, 882.0, 735.0, 896.0]}, {"text": "developed MVT but more haemorrhagic events were de-", "bbox": [406.0, 897.0, 733.0, 913.0]}, {"text": "scribed; however, only 6.1% of patients were given aspirin so", "bbox": [406.0, 914.0, 735.0, 929.0]}, {"text": "no conclusions can be drawn. 6", "bbox": [406.0, 930.0, 571.0, 944.0]}, {"text": "The ACC/AHA guidelines 1 state that LDA is regarded as", "bbox": [423.0, 945.0, 735.0, 961.0]}, {"text": "safe during pregnancy and can be used in individuals with", "bbox": [407.0, 963.0, 735.0, 977.0]}], "type": "Text", "position": 7}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/心血管/指南/2023 BSH 指南：机械心脏瓣膜妊娠个体抗凝管理(1).pdf", "page_num": 6}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": null, "finished": false, "dropped": false, "create_time": "2024-05-07 05:06:41", "update_time": "2024-05-07 05:23:31"}
{"id": 1082552, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 738, "source_info": {"seq_id": "d94d7a96-28bb-4285-b60d-6f657b7f5c8b", "title": null, "text": "【0】页码:4\n • 793 •\n\n【1】 MRI) CC Chapter 1 o , 100 , , 100 [20-31]  __ __ , 100 1. I o , l .\n\n【2】[22-24]  4.3 , ≥ 50% .\n\n【3】__ , .\n\n【4】.\n\n【5】__ , JOA . \n\n【6】. \n\n【7】, .\n\n【8】11. I 14 , Hoffmann ; ,           , , .\n\n【9】, Chapter 1 Chapter 1 Chapter 3 , .\n\n【10】, . \n\n【11】 , [2-6]  , 4.4 _.\n\n【12】.\n\n【13】.\n\n【14】, , , , , 100 , , , , , __ , 100 , o __ 4. 8 . \n\n【15】, [16] , , 4.5 , , .\n\n【16】, 10. See , , o , Hoffmann .\n\n【17】Chapter 1 , .\n\n【18】, [17–18] , . CSM , .\n\n【19】Design path o       , 10.\n\n【20】.\n\n【21】..       , Chapter 1 .\n\n【22】Chapter 3 .\n\n【23】, , o Chapter 1 CONSULTATION .\n\n【24】o 4. 9 ., ..\n\n【25】Appendix D - Guidelines 4. 9. 1 Construction , 100 , Chapter 9 , __ , .\n\n【26】. \n\n【27】, __  , .\n\n【28】, o __ , Chapter Portage Chapter 1 , [2] .\n\n【29】o .\n\n【30】4. 6  .\n\n【31】[25] .\n\n【32】, .\n\n【33】.\n\n【34】.\n\n【35】[19] .\n\n【36】4. 9. 2 JOA 1 ,  13 ,  2 , , , 100 __  CSM  .\n\n【37】, 100 >50% .\n\n【38】Chapter 1 Chapter 1 . \n\n【39】3 o , , [26] .\n\n【40】. \n\n【41】.\n\n【42】o 4. 9. 3 , o , 4. 7 , CSM , , 100 .\n\n【43】x ( Chapter 1 o Chapter 3", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "• 793 •", "bbox": [676.0, 65.0, 716.0, 83.0]}], "type": "Text", "position": 2}, {"raw_context": [{"text": "MRI)", "bbox": [462.0, 105.0, 510.0, 124.0]}, {"text": "CC", "bbox": [428.0, 106.0, 461.0, 123.0]}, {"text": "Chapter 1", "bbox": [687.0, 108.0, 715.0, 126.0]}, {"text": "o", "bbox": [305.0, 110.0, 327.0, 124.0]}, {"text": ", 100", "bbox": [135.0, 111.0, 150.0, 124.0]}, {"text": ",", "bbox": [262.0, 111.0, 276.0, 124.0]}, {"text": ", 100", "bbox": [199.0, 112.0, 212.0, 124.0]}, {"text": "[20-31] ", "bbox": [648.0, 118.0, 708.0, 144.0]}, {"text": "__", "bbox": [290.0, 127.0, 335.0, 146.0]}, {"text": "__", "bbox": [89.0, 130.0, 211.0, 144.0]}, {"text": ", 100", "bbox": [259.0, 132.0, 272.0, 145.0]}, {"text": "1. I", "bbox": [475.0, 149.0, 499.0, 165.0]}, {"text": "o", "bbox": [177.0, 151.0, 206.0, 165.0]}, {"text": ",", "bbox": [551.0, 151.0, 595.0, 166.0]}, {"text": "l .", "bbox": [644.0, 152.0, 697.0, 161.0]}, {"text": "[22-24] ", "bbox": [468.0, 160.0, 505.0, 181.0]}, {"text": "4.3", "bbox": [78.0, 165.0, 109.0, 184.0]}, {"text": ",", "bbox": [659.0, 170.0, 706.0, 185.0]}, {"text": "≥ 50% .", "bbox": [537.0, 184.0, 594.0, 203.0]}, {"text": "__", "bbox": [675.0, 190.0, 704.0, 201.0]}, {"text": ",", "bbox": [220.0, 191.0, 234.0, 203.0]}, {"text": ".", "bbox": [473.0, 191.0, 506.0, 205.0]}, {"text": ".", "bbox": [657.0, 191.0, 674.0, 205.0]}, {"text": "__", "bbox": [301.0, 192.0, 350.0, 202.0]}, {"text": ", JOA", "bbox": [651.0, 204.0, 711.0, 223.0]}, {"text": ". ", "bbox": [224.0, 208.0, 240.0, 224.0]}, {"text": ". ", "bbox": [291.0, 207.0, 360.0, 226.0]}, {"text": ",", "bbox": [93.0, 211.0, 115.0, 225.0]}, {"text": ".", "bbox": [441.0, 213.0, 456.0, 223.0]}, {"text": "11. I 14 , Hoffmann", "bbox": [427.0, 223.0, 565.0, 243.0]}, {"text": ";", "bbox": [226.0, 229.0, 240.0, 244.0]}, {"text": ",           ,", "bbox": [291.0, 229.0, 383.0, 247.0]}, {"text": ",", "bbox": [701.0, 230.0, 715.0, 245.0]}, {"text": ".", "bbox": [112.0, 231.0, 181.0, 244.0]}, {"text": ",", "bbox": [573.0, 231.0, 608.0, 244.0]}, {"text": "", "bbox": [678.0, 232.0, 703.0, 244.0]}, {"text": "Chapter 1", "bbox": [428.0, 248.0, 517.0, 266.0]}, {"text": "Chapter 1", "bbox": [121.0, 249.0, 185.0, 266.0]}, {"text": "Chapter 3", "bbox": [320.0, 250.0, 391.0, 266.0]}, {"text": ",", "bbox": [645.0, 251.0, 661.0, 265.0]}, {"text": ".", "bbox": [478.0, 269.0, 541.0, 287.0]}, {"text": ",", "bbox": [295.0, 272.0, 319.0, 285.0]}, {"text": ". ", "bbox": [643.0, 284.0, 730.0, 306.0]}, {"text": "", "bbox": [435.0, 287.0, 627.0, 327.0]}, {"text": ",", "bbox": [352.0, 290.0, 397.0, 305.0]}, {"text": "[2-6] ", "bbox": [148.0, 302.0, 179.0, 321.0]}, {"text": ",", "bbox": [715.0, 313.0, 728.0, 325.0]}, {"text": "4.4", "bbox": [78.0, 325.0, 108.0, 343.0]}, {"text": "_.", "bbox": [611.0, 350.0, 639.0, 365.0]}, {"text": ".", "bbox": [193.0, 351.0, 208.0, 364.0]}, {"text": ".", "bbox": [260.0, 351.0, 273.0, 364.0]}, {"text": ",", "bbox": [367.0, 351.0, 397.0, 364.0]}, {"text": ",", "bbox": [236.0, 371.0, 285.0, 385.0]}, {"text": ",", "bbox": [355.0, 371.0, 396.0, 385.0]}, {"text": ",", "bbox": [552.0, 371.0, 586.0, 384.0]}, {"text": ", 100", "bbox": [664.0, 371.0, 702.0, 383.0]}, {"text": ",", "bbox": [475.0, 391.0, 526.0, 404.0]}, {"text": ",", "bbox": [553.0, 391.0, 589.0, 404.0]}, {"text": ",", "bbox": [594.0, 391.0, 657.0, 404.0]}, {"text": ",", "bbox": [234.0, 392.0, 251.0, 404.0]}, {"text": ",", "bbox": [419.0, 392.0, 462.0, 404.0]}, {"text": "__", "bbox": [413.0, 407.0, 443.0, 425.0]}, {"text": ", 100", "bbox": [136.0, 411.0, 149.0, 424.0]}, {"text": ",", "bbox": [354.0, 411.0, 393.0, 426.0]}, {"text": "o", "bbox": [489.0, 411.0, 504.0, 426.0]}, {"text": "__", "bbox": [356.0, 424.0, 399.0, 445.0]}, {"text": "4. 8", "bbox": [409.0, 425.0, 440.0, 442.0]}, {"text": ". ", "bbox": [240.0, 429.0, 293.0, 446.0]}, {"text": ",", "bbox": [136.0, 432.0, 150.0, 445.0]}, {"text": "[16]", "bbox": [162.0, 442.0, 189.0, 459.0]}, {"text": ",", "bbox": [553.0, 449.0, 606.0, 465.0]}, {"text": ",", "bbox": [674.0, 450.0, 704.0, 463.0]}, {"text": "4.5", "bbox": [78.0, 464.0, 108.0, 483.0]}, {"text": ",", "bbox": [545.0, 468.0, 610.0, 484.0]}, {"text": ",", "bbox": [666.0, 469.0, 703.0, 484.0]}, {"text": ".", "bbox": [524.0, 489.0, 560.0, 506.0]}, {"text": ",", "bbox": [253.0, 490.0, 281.0, 503.0]}, {"text": "10. See ,", "bbox": [342.0, 490.0, 373.0, 502.0]}, {"text": ",", "bbox": [177.0, 510.0, 193.0, 523.0]}, {"text": "o", "bbox": [333.0, 510.0, 381.0, 524.0]}, {"text": ",", "bbox": [639.0, 510.0, 651.0, 523.0]}, {"text": "Hoffmann", "bbox": [539.0, 523.0, 606.0, 543.0]}, {"text": ".", "bbox": [335.0, 527.0, 385.0, 555.0]}, {"text": "Chapter 1", "bbox": [605.0, 529.0, 656.0, 545.0]}, {"text": ",", "bbox": [181.0, 530.0, 195.0, 543.0]}, {"text": ".", "bbox": [501.0, 530.0, 520.0, 543.0]}, {"text": ",", "bbox": [245.0, 531.0, 260.0, 543.0]}, {"text": "[17–18] ,", "bbox": [178.0, 538.0, 216.0, 561.0]}, {"text": ". CSM", "bbox": [668.0, 543.0, 711.0, 561.0]}, {"text": ",", "bbox": [587.0, 549.0, 629.0, 564.0]}, {"text": ".", "bbox": [369.0, 550.0, 383.0, 564.0]}, {"text": "Design path", "bbox": [331.0, 563.0, 396.0, 587.0]}, {"text": "o       ,", "bbox": [240.0, 567.0, 301.0, 584.0]}, {"text": "10.", "bbox": [612.0, 569.0, 638.0, 584.0]}, {"text": ".", "bbox": [93.0, 570.0, 114.0, 584.0]}, {"text": "..       ,", "bbox": [159.0, 587.0, 213.0, 604.0]}, {"text": "Chapter 1", "bbox": [242.0, 588.0, 314.0, 606.0]}, {"text": ".", "bbox": [340.0, 588.0, 394.0, 605.0]}, {"text": "Chapter 3", "bbox": [417.0, 589.0, 458.0, 605.0]}, {"text": ".", "bbox": [109.0, 590.0, 131.0, 604.0]}, {"text": ",", "bbox": [673.0, 590.0, 708.0, 605.0]}, {"text": ",", "bbox": [242.0, 608.0, 303.0, 624.0]}, {"text": "o ", "bbox": [138.0, 609.0, 209.0, 624.0]}, {"text": "Chapter 1", "bbox": [334.0, 609.0, 390.0, 624.0]}, {"text": "CONSULTATION", "bbox": [494.0, 609.0, 562.0, 625.0]}, {"text": ".", "bbox": [93.0, 610.0, 119.0, 624.0]}, {"text": "o", "bbox": [601.0, 610.0, 638.0, 624.0]}, {"text": "4. 9", "bbox": [411.0, 623.0, 442.0, 642.0]}, {"text": ".,", "bbox": [93.0, 628.0, 123.0, 644.0]}, {"text": "..", "bbox": [334.0, 627.0, 385.0, 645.0]}, {"text": "Appendix D - Guidelines", "bbox": [161.0, 629.0, 306.0, 645.0]}, {"text": "4. 9. 1", "bbox": [411.0, 644.0, 454.0, 661.0]}, {"text": "Construction , 100", "bbox": [185.0, 645.0, 324.0, 666.0]}, {"text": ",", "bbox": [339.0, 646.0, 393.0, 664.0]}, {"text": "Chapter 9", "bbox": [700.0, 648.0, 729.0, 664.0]}, {"text": ",", "bbox": [96.0, 649.0, 145.0, 664.0]}, {"text": "__", "bbox": [111.0, 669.0, 239.0, 684.0]}, {"text": ",", "bbox": [240.0, 670.0, 345.0, 684.0]}, {"text": ".", "bbox": [355.0, 670.0, 396.0, 683.0]}, {"text": ". ", "bbox": [484.0, 670.0, 570.0, 684.0]}, {"text": ",", "bbox": [700.0, 670.0, 716.0, 684.0]}, {"text": "__", "bbox": [108.0, 687.0, 396.0, 704.0]}, {"text": "", "bbox": [514.0, 689.0, 555.0, 703.0]}, {"text": ",", "bbox": [553.0, 690.0, 567.0, 703.0]}, {"text": ".", "bbox": [519.0, 705.0, 577.0, 730.0]}, {"text": ",", "bbox": [124.0, 710.0, 150.0, 724.0]}, {"text": "o", "bbox": [332.0, 710.0, 347.0, 724.0]}, {"text": "__", "bbox": [248.0, 711.0, 289.0, 724.0]}, {"text": ",", "bbox": [646.0, 711.0, 660.0, 724.0]}, {"text": "Chapter Portage", "bbox": [156.0, 728.0, 283.0, 745.0]}, {"text": "Chapter 1", "bbox": [426.0, 728.0, 491.0, 745.0]}, {"text": ",", "bbox": [118.0, 729.0, 156.0, 745.0]}, {"text": "[2] .", "bbox": [564.0, 742.0, 589.0, 761.0]}, {"text": "o", "bbox": [121.0, 750.0, 152.0, 764.0]}, {"text": ".", "bbox": [715.0, 751.0, 732.0, 765.0]}, {"text": "4. 6", "bbox": [78.0, 764.0, 107.0, 781.0]}, {"text": "", "bbox": [442.0, 769.0, 554.0, 785.0]}, {"text": ".", "bbox": [584.0, 771.0, 598.0, 784.0]}, {"text": "[25] .", "bbox": [579.0, 782.0, 610.0, 798.0]}, {"text": ",", "bbox": [164.0, 788.0, 183.0, 803.0]}, {"text": ".", "bbox": [292.0, 788.0, 336.0, 803.0]}, {"text": ".", "bbox": [223.0, 789.0, 242.0, 803.0]}, {"text": ".", "bbox": [368.0, 790.0, 383.0, 803.0]}, {"text": "[19] .", "bbox": [166.0, 800.0, 202.0, 820.0]}, {"text": "4. 9. 2", "bbox": [411.0, 803.0, 457.0, 822.0]}, {"text": "JOA", "bbox": [532.0, 804.0, 565.0, 821.0]}, {"text": "1 ,  13 ,", "bbox": [572.0, 804.0, 651.0, 821.0]}, {"text": "", "bbox": [458.0, 806.0, 486.0, 820.0]}, {"text": "2", "bbox": [457.0, 823.0, 474.0, 842.0]}, {"text": ",", "bbox": [524.0, 828.0, 559.0, 842.0]}, {"text": ",", "bbox": [293.0, 829.0, 332.0, 842.0]}, {"text": ", 100", "bbox": [135.0, 830.0, 150.0, 842.0]}, {"text": "__", "bbox": [604.0, 830.0, 662.0, 842.0]}, {"text": "", "bbox": [590.0, 836.0, 673.0, 869.0]}, {"text": "CSM", "bbox": [457.0, 843.0, 492.0, 862.0]}, {"text": "", "bbox": [426.0, 845.0, 455.0, 858.0]}, {"text": ".", "bbox": [292.0, 847.0, 328.0, 864.0]}, {"text": ", 100", "bbox": [521.0, 850.0, 538.0, 862.0]}, {"text": ">50% .", "bbox": [426.0, 862.0, 477.0, 881.0]}, {"text": "Chapter 1", "bbox": [523.0, 863.0, 568.0, 884.0]}, {"text": "Chapter 1", "bbox": [626.0, 867.0, 665.0, 884.0]}, {"text": ". ", "bbox": [278.0, 869.0, 328.0, 882.0]}, {"text": "3", "bbox": [526.0, 882.0, 545.0, 900.0]}, {"text": "o", "bbox": [139.0, 889.0, 179.0, 903.0]}, {"text": ",", "bbox": [291.0, 889.0, 327.0, 904.0]}, {"text": ",", "bbox": [455.0, 889.0, 469.0, 902.0]}, {"text": "[26]", "bbox": [416.0, 899.0, 467.0, 919.0]}, {"text": ".", "bbox": [275.0, 906.0, 333.0, 926.0]}, {"text": ". ", "bbox": [121.0, 909.0, 183.0, 922.0]}, {"text": ".", "bbox": [188.0, 909.0, 232.0, 923.0]}, {"text": "o", "bbox": [365.0, 909.0, 381.0, 923.0]}, {"text": "4. 9. 3", "bbox": [412.0, 922.0, 457.0, 941.0]}, {"text": ",", "bbox": [220.0, 929.0, 234.0, 943.0]}, {"text": "o", "bbox": [162.0, 948.0, 176.0, 963.0]}, {"text": ",", "bbox": [432.0, 948.0, 469.0, 963.0]}, {"text": "4. 7", "bbox": [78.0, 961.0, 107.0, 980.0]}, {"text": ",", "bbox": [609.0, 969.0, 642.0, 983.0]}, {"text": "CSM", "bbox": [138.0, 982.0, 172.0, 1000.0]}, {"text": ",", "bbox": [316.0, 990.0, 333.0, 1003.0]}, {"text": ", 100", "bbox": [580.0, 990.0, 597.0, 1002.0]}, {"text": ".", "bbox": [717.0, 990.0, 732.0, 1003.0]}, {"text": "x", "bbox": [378.0, 1002.0, 396.0, 1022.0]}, {"text": "(", "bbox": [340.0, 1004.0, 354.0, 1022.0]}, {"text": "Chapter 1", "bbox": [440.0, 1007.0, 568.0, 1024.0]}, {"text": "o", "bbox": [93.0, 1009.0, 107.0, 1022.0]}, {"text": "Chapter 3", "bbox": [568.0, 1009.0, 631.0, 1024.0]}], "type": "Text", "position": 3}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/骨科/共识/脊髓型颈椎病中西医结合诊疗专家共识.pdf", "page_num": 4}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "格式杂乱#0#43#全篇格式杂乱", "type3": null, "type4": null, "type5": null, "type6": null}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:41", "update_time": "2024-05-07 22:59:46"}
{"id": 1082551, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 738, "source_info": {"seq_id": "203def98-c285-4238-81f1-76d5522c783c", "title": null, "text": "【0】页码:4\n Table 3\n\n【1】 Prevention of Candida Infection in HCT Recipients Agent Dose Route Start Day Stop Day 200–400 mg once daily Fluconazole (A-I) [34–36] Conditioning–stem cell infusion Day 75-100 i.v./oral Micafungin (A-I) [38] 50 mg once daily\" Conditioning Day 100 i.v./oral Voriconazole (A-I) [ 37 ] 200 mg twice daily 1 i.v./oral Conditioning Day 100 Posaconazole (A-I) [40] 300 mg once daily 1 GVHD ≥ grade 2 Steroid dose taper < 20 mg/day i.v./oral Micafungin has been studied as primary antifungal prophylaxis at a dose of 50 mg/day, which remains the recommended prophylactic dose (A-I). Notably, micafungin may be administered at a dose of 100 mg/day in clinical practice despite a lack of relevant data to support this prophylactic dose.\n\n【2】\n fungin may be administered at a dose of 100 mg/day in clinical practice despite a lack of relevant data to support this prophylactic dose.\n\n【3】A loading dose of voriconazole 6 mg/kg twice daily for the first day should be administered. For maintenance dose, weight-based dosing at 4 mg/kg twice daily is preferred to a universal dose of 200 mg twice daily (B-III). Therapeutic drug monitoring of trough voriconazole blood concentrations may be used to decrease potential voriconazole-associated toxicities [ 52 , 53 ] (A-I).\n\n【4】 This dose refers to the oral pill or i.v. formulation of posaconazole. A loading dose of posaconazole at 300 mg twice daily for the first day should be administered.\n\n【5】Trough posaconazole blood concentrations may be monitored to ascertain adequate blood concentrations [ 52 , 54 , 55 ] (B-II). If posaconazole suspension is used, 200 mg thrice daily administered with (fatty) meals is recommended.\n\n【6】 Candida endophthalmitis (A-II) [23] . In cases of endophthalmitis, an ophthalmology consultation to assess the extent of infection and need for surgical intervention and longer treatment courses (4 to 6 weeks) with agents with optimal eye penetration, including fluconazole and voriconazole, are strongly recommended (A-II) [23] .\n\n【7】## Faq7: Is Combination Therapy Recommended For The Treatment Of Ic In Hct Recipients?\n\n【8】\n Echinocandins are highly efficacious and safe agents for most cases of IC, and thus combination therapy is not routinely recommended (D-III). However, for C. auris candidemia, before the antifungal susceptibility profile is available, combination therapy with more than 1 agent based on local epidemiology could be considered in critically ill neutropenic patients [33] (B-III).\n\n【9】## Faq8: Should A Central Line Be Removed In Hct Recipients With Candidemia?\n\n【10】\n We strongly favor CVC removal in neutropenic patients with candidemia when feasible (A-II) [23] . In non-neutropenic nonthrombocytopenic patients, CVC removal is strongly recommended (A-II) [23] . Daily blood cultures should be obtained to confirm sterility, particularly if the CVC is not removed.\n\n【11】## Antifungal Prophylaxis Faq9: Who Should Receive Anti-Candida Primary Prophylaxis, When, And For How Long?\n\n【12】\n Administration of primary anti-Candida prophylaxis is recommended for all allogeneic HCT recipients, starting with either conditioning or stem cell infusion and continuing until 75 to 100 days post-transplantation (A-I) (Table 3) [34–38] .\n\n【13】Although the timing of prophylaxis initiation has varied in clinical trials, we recommend that antifungal prophylaxis be started on initiation or immediately after completion of the conditioning regimen, in the event of concerns for drug interactions between azoles and conditioning agents, particularly cyclophosphamide (A-I) [39] . In patients with GVHD treated with corticosteroids at doses ≥ 1 mg/kg daily, we recommend antifungal prophylaxis with posaconazole for effective Candida and mold coverage, until symptom resolution and corticosteroid dose taper to < 20 mg/day (A-I) [40] . In autologous HCT recipients, primary antifungal prophylaxis may be discontinued after resolution of neutropenia (B-III).\n\n【14】## Faq10: Which Antifungal Agents Can Be Used For Candida Prophylaxis In Hct Recipients?\n\n【15】\n Fluconazole, voriconazole, posaconazole, and micafungin all provide effective prophylaxis (A-I) [ 34 , 35 , 37 , 38 , 40 ]. We\n\n【16】 favor the administration of fluconazole prophylaxis based on the accumulated body of evidence and clinical experience, as well as its excellent bioavailability and efficacy and safety profile (A-I). Prophylaxis with mold-active agents, such as voriconazole (A-I) or posaconazole (A-I), may be used in patients at high risk for invasive aspergillosis or other mold infections to provide mold coverage [ 37 , 40 ]. An echinocandin may be considered in cases of colonization or prior infections with azoleresistant Candida species or in cases of azole-intolerance or other contraindications (eg, drug interactions, abnormal liver function, QTc prolongation) (B-III). Posaconazole is recommended postengraftment if acute GVHD is being treated with corticosteroids at doses ≥ 1 mg/kg/day (A-I) [40] . The suggested time frame and doses of antifungal prophylaxis are summarized in Table 3 .\n\n【17】## Faq11: Are There Special Considerations For Candida Prophylaxis In Pediatric Hct Recipients?\n\n【18】\n This has not been well studied in children, but similar approaches as in adults have been adopted and appear feasible (A-III).\n\n【19】## Special Considerations Faq12: Should Further Adjustments In Candida Prophylaxis Be Made In Cord Blood, Haploidentical Or T Cell-Depleted Hct Recipients?\n\n【20】\n There are no current data to suggest that prophylaxis approaches should differ in recipients of cord blood, haploidentical or T cell-depleted grafts (C-III).\n\n【21】## Faq13: Should Car-T Cell Recipients Receive Candida Primary Prophylaxis?\n\n【22】\n Because CAR-T cell recipients frequently develop mucositis and prolonged neutropenia after administration of cytotoxic chemotherapy, they are at risk for Candida infections. Despite a paucity of relevant data, administration of anti- Candida prophylaxis from the start of chemotherapy until resolution of neutropenia and mucositis should be strongly considered (A- III) [ 41 , 42 ]. A mold-active agent (eg, posaconazole) is recommended in CAR-T cell recipients who are at elevated risk for mold infections because of prior allogeneic HCT, corticosteroid therapy at doses ≥ 1 mg/kg/day, or IL-6 inhibitors (A-III) [ 41 , 42 ].\n\n【23】## Unmet Needs And Future Directions Faq14: What Is The Utility Of Pcr Or T2Candida-Mr Panel For Diagnosing Ic In Hct Recipients?\n\n【24】\n These assays have showed excellent performance in diagnosing candidemia in clinical studies [43–46] ( Table 1 ).", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "Table 3", "bbox": [67.0, 75.0, 99.0, 87.0]}], "type": "Text", "position": 2}, {"raw_context": [{"text": "Prevention of Candida Infection in HCT Recipients", "bbox": [66.0, 88.0, 260.0, 99.0]}, {"text": "Agent", "bbox": [73.0, 108.0, 101.0, 119.0]}, {"text": "Dose", "bbox": [213.0, 108.0, 235.0, 118.0]}, {"text": "Route", "bbox": [341.0, 107.0, 368.0, 118.0]}, {"text": "Start Day", "bbox": [410.0, 107.0, 450.0, 118.0]}, {"text": "Stop Day", "bbox": [574.0, 107.0, 613.0, 119.0]}, {"text": "200–400 mg once daily", "bbox": [215.0, 121.0, 305.0, 136.0]}, {"text": "Fluconazole (A-I) [34–36]", "bbox": [73.0, 123.0, 177.0, 135.0]}, {"text": "Conditioning–stem cell infusion", "bbox": [410.0, 123.0, 539.0, 135.0]}, {"text": "Day 75-100", "bbox": [574.0, 122.0, 623.0, 135.0]}, {"text": "i.v./oral", "bbox": [341.0, 124.0, 374.0, 135.0]}, {"text": "Micafungin (A-I) [38]", "bbox": [73.0, 138.0, 161.0, 150.0]}, {"text": "50 mg once daily\"", "bbox": [214.0, 138.0, 285.0, 150.0]}, {"text": "Conditioning", "bbox": [410.0, 138.0, 465.0, 149.0]}, {"text": "Day 100", "bbox": [574.0, 138.0, 611.0, 150.0]}, {"text": "i.v./oral", "bbox": [341.0, 139.0, 375.0, 150.0]}, {"text": "Voriconazole (A-I) [ 37 ]", "bbox": [74.0, 152.0, 165.0, 163.0]}, {"text": "200 mg twice daily 1", "bbox": [215.0, 152.0, 290.0, 163.0]}, {"text": "i.v./oral", "bbox": [341.0, 152.0, 374.0, 163.0]}, {"text": "Conditioning", "bbox": [410.0, 152.0, 463.0, 162.0]}, {"text": "Day 100", "bbox": [574.0, 152.0, 611.0, 163.0]}, {"text": "Posaconazole (A-I) [40]", "bbox": [73.0, 166.0, 165.0, 177.0]}, {"text": "300 mg once daily 1", "bbox": [215.0, 166.0, 287.0, 177.0]}, {"text": "GVHD ≥ grade 2", "bbox": [410.0, 166.0, 473.0, 177.0]}, {"text": "Steroid dose taper < 20 mg/day", "bbox": [575.0, 166.0, 700.0, 178.0]}, {"text": "i.v./oral", "bbox": [341.0, 167.0, 374.0, 177.0]}, {"text": "Micafungin has been studied as primary antifungal prophylaxis at a dose of 50 mg/day, which remains the recommended prophylactic dose (A-I). Notably, mica-", "bbox": [81.0, 181.0, 704.0, 193.0]}, {"text": "fungin may be administered at a dose of 100 mg/day in clinical practice despite a lack of relevant data to support this prophylactic dose.", "bbox": [66.0, 193.0, 590.0, 205.0]}], "type": "Table", "position": 3}, {"raw_context": [{"text": "fungin may be administered at a dose of 100 mg/day in clinical practice despite a lack of relevant data to support this prophylactic dose.", "bbox": [66.0, 193.0, 590.0, 205.0]}, {"text": "A loading dose of voriconazole 6 mg/kg twice daily for the first day should be administered. For maintenance dose, weight-based dosing at 4 mg/kg twice daily is", "bbox": [80.0, 205.0, 708.0, 215.0]}, {"text": "preferred to a universal dose of 200 mg twice daily (B-III). Therapeutic drug monitoring of trough voriconazole blood concentrations may be used to decrease poten-", "bbox": [67.0, 215.0, 705.0, 227.0]}, {"text": "tial voriconazole-associated toxicities [ 52 , 53 ] (A-I).", "bbox": [67.0, 227.0, 264.0, 238.0]}, {"text": " This dose refers to the oral pill or i.v. formulation of posaconazole. A loading dose of posaconazole at 300 mg twice daily for the first day should be administered.", "bbox": [79.0, 239.0, 706.0, 250.0]}, {"text": "Trough posaconazole blood concentrations may be monitored to ascertain adequate blood concentrations [ 52 , 54 , 55 ] (B-II). If posaconazole suspension is used,", "bbox": [67.0, 250.0, 706.0, 262.0]}, {"text": "200 mg thrice daily administered with (fatty) meals is recommended.", "bbox": [67.0, 262.0, 337.0, 273.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": "Candida endophthalmitis (A-II) [23] . In cases of endophthalmi-", "bbox": [66.0, 297.0, 371.0, 312.0]}, {"text": "tis, an ophthalmology consultation to assess the extent of", "bbox": [66.0, 312.0, 372.0, 325.0]}, {"text": "infection and need for surgical intervention and longer treat-", "bbox": [66.0, 325.0, 371.0, 339.0]}, {"text": "ment courses (4 to 6 weeks) with agents with optimal eye pen-", "bbox": [66.0, 339.0, 371.0, 353.0]}, {"text": "etration, including fluconazole and voriconazole, are strongly", "bbox": [66.0, 353.0, 372.0, 367.0]}, {"text": "recommended (A-II) [23] .", "bbox": [66.0, 367.0, 191.0, 381.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "FAQ7: Is combination therapy recommended for the", "bbox": [66.0, 395.0, 325.0, 410.0]}, {"text": "treatment of IC in HCT recipients?", "bbox": [66.0, 410.0, 235.0, 423.0]}], "type": "Section-header", "position": 6}, {"raw_context": [{"text": "Echinocandins are highly efficacious and safe agents for", "bbox": [81.0, 423.0, 372.0, 438.0]}, {"text": "most cases of IC, and thus combination therapy is not routinely", "bbox": [66.0, 437.0, 372.0, 451.0]}, {"text": "recommended (D-III). However, for C. auris candidemia, before", "bbox": [66.0, 451.0, 372.0, 465.0]}, {"text": "the antifungal susceptibility profile is available, combination", "bbox": [66.0, 465.0, 372.0, 480.0]}, {"text": "therapy with more than 1 agent based on local epidemiology", "bbox": [66.0, 479.0, 371.0, 493.0]}, {"text": "could be considered in critically ill neutropenic patients [33]", "bbox": [66.0, 493.0, 372.0, 507.0]}, {"text": "(B-III).", "bbox": [65.0, 507.0, 99.0, 521.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "FAQ8: Should a central line be removed in HCT recipients", "bbox": [65.0, 534.0, 348.0, 548.0]}, {"text": "with candidemia?", "bbox": [66.0, 550.0, 159.0, 562.0]}], "type": "Section-header", "position": 8}, {"raw_context": [{"text": "We strongly favor CVC removal in neutropenic patients", "bbox": [82.0, 562.0, 372.0, 576.0]}, {"text": "with candidemia when feasible (A-II) [23] . In non-neutropenic", "bbox": [66.0, 577.0, 370.0, 590.0]}, {"text": "nonthrombocytopenic patients, CVC removal is strongly rec-", "bbox": [67.0, 592.0, 370.0, 604.0]}, {"text": "ommended (A-II) [23] . Daily blood cultures should be obtained", "bbox": [66.0, 606.0, 372.0, 618.0]}, {"text": "to confirm sterility, particularly if the CVC is not removed.", "bbox": [66.0, 619.0, 347.0, 632.0]}], "type": "Text", "position": 9}, {"raw_context": [{"text": "ANTIFUNGAL PROPHYLAXIS", "bbox": [66.0, 645.0, 209.0, 660.0]}, {"text": "FAQ9: Who should receive anti-Candida primary prophylaxis,", "bbox": [66.0, 659.0, 371.0, 674.0]}, {"text": "when, and for how long?", "bbox": [66.0, 675.0, 191.0, 688.0]}], "type": "Section-header", "position": 10}, {"raw_context": [{"text": "Administration of primary anti-Candida prophylaxis is rec-", "bbox": [82.0, 688.0, 370.0, 702.0]}, {"text": "ommended for all allogeneic HCT recipients, starting with", "bbox": [66.0, 703.0, 372.0, 716.0]}, {"text": "either conditioning or stem cell infusion and continuing until", "bbox": [66.0, 718.0, 372.0, 730.0]}, {"text": "75 to 100 days post-transplantation (A-I) (Table 3) [34–38] .", "bbox": [67.0, 732.0, 370.0, 744.0]}, {"text": "Although the timing of prophylaxis initiation has varied in", "bbox": [67.0, 746.0, 372.0, 758.0]}, {"text": "clinical trials, we recommend that antifungal prophylaxis be", "bbox": [66.0, 759.0, 372.0, 772.0]}, {"text": "started on initiation or immediately after completion of the", "bbox": [66.0, 773.0, 372.0, 786.0]}, {"text": "conditioning regimen, in the event of concerns for drug inter-", "bbox": [66.0, 787.0, 370.0, 798.0]}, {"text": "actions between azoles and conditioning agents, particularly", "bbox": [66.0, 800.0, 372.0, 813.0]}, {"text": "cyclophosphamide (A-I) [39] . In patients with GVHD treated", "bbox": [66.0, 814.0, 372.0, 827.0]}, {"text": "with corticosteroids at doses ≥ 1 mg/kg daily, we recommend", "bbox": [66.0, 828.0, 372.0, 841.0]}, {"text": "antifungal prophylaxis with posaconazole for effective Candida", "bbox": [67.0, 843.0, 372.0, 855.0]}, {"text": "and mold coverage, until symptom resolution and corticoste-", "bbox": [67.0, 857.0, 370.0, 869.0]}, {"text": "roid dose taper to < 20 mg/day (A-I) [40] . In autologous HCT", "bbox": [66.0, 871.0, 372.0, 883.0]}, {"text": "recipients, primary antifungal prophylaxis may be discontin-", "bbox": [66.0, 885.0, 370.0, 897.0]}, {"text": "ued after resolution of neutropenia (B-III).", "bbox": [66.0, 899.0, 270.0, 910.0]}], "type": "Text", "position": 11}, {"raw_context": [{"text": "FAQ10: Which antifungal agents can be used for Candida", "bbox": [65.0, 925.0, 349.0, 938.0]}, {"text": "prophylaxis in HCT recipients?", "bbox": [66.0, 941.0, 221.0, 953.0]}], "type": "Section-header", "position": 12}, {"raw_context": [{"text": "Fluconazole, voriconazole, posaconazole, and micafungin", "bbox": [81.0, 954.0, 372.0, 967.0]}, {"text": "all provide effective prophylaxis (A-I) [ 34 , 35 , 37 , 38 , 40 ]. We", "bbox": [66.0, 967.0, 372.0, 982.0]}], "type": "Text", "position": 13}, {"raw_context": [{"text": "favor the administration of fluconazole prophylaxis based on", "bbox": [399.0, 297.0, 708.0, 311.0]}, {"text": "the accumulated body of evidence and clinical experience, as", "bbox": [399.0, 311.0, 708.0, 325.0]}, {"text": "well as its excellent bioavailability and efficacy and safety pro-", "bbox": [399.0, 325.0, 706.0, 339.0]}, {"text": "file (A-I). Prophylaxis with mold-active agents, such as vorico-", "bbox": [399.0, 339.0, 706.0, 353.0]}, {"text": "nazole (A-I) or posaconazole (A-I), may be used in patients at", "bbox": [399.0, 353.0, 708.0, 367.0]}, {"text": "high risk for invasive aspergillosis or other mold infections to", "bbox": [399.0, 367.0, 708.0, 381.0]}, {"text": "provide mold coverage [ 37 , 40 ]. An echinocandin may be con-", "bbox": [400.0, 382.0, 706.0, 396.0]}, {"text": "sidered in cases of colonization or prior infections with azole-", "bbox": [399.0, 396.0, 706.0, 410.0]}, {"text": "resistant Candida species or in cases of azole-intolerance or", "bbox": [400.0, 410.0, 707.0, 424.0]}, {"text": "other contraindications (eg, drug interactions, abnormal liver", "bbox": [399.0, 424.0, 707.0, 438.0]}, {"text": "function, QTc prolongation) (B-III). Posaconazole is recom-", "bbox": [400.0, 439.0, 706.0, 452.0]}, {"text": "mended postengraftment if acute GVHD is being treated with", "bbox": [399.0, 451.0, 708.0, 466.0]}, {"text": "corticosteroids at doses ≥ 1 mg/kg/day (A-I) [40] . The sug-", "bbox": [399.0, 465.0, 706.0, 479.0]}, {"text": "gested time frame and doses of antifungal prophylaxis are", "bbox": [399.0, 479.0, 707.0, 493.0]}, {"text": "summarized in Table 3 .", "bbox": [400.0, 494.0, 516.0, 507.0]}], "type": "Text", "position": 14}, {"raw_context": [{"text": "FAQ11: Are there special considerations for Candida", "bbox": [399.0, 520.0, 661.0, 534.0]}, {"text": "prophylaxis in pediatric HCT recipients?", "bbox": [400.0, 535.0, 602.0, 548.0]}], "type": "Section-header", "position": 15}, {"raw_context": [{"text": "This has not been well studied in children, but similar", "bbox": [417.0, 549.0, 708.0, 562.0]}, {"text": "approaches as in adults have been adopted and appear feasible", "bbox": [400.0, 563.0, 707.0, 576.0]}, {"text": "(A-III).", "bbox": [400.0, 578.0, 434.0, 590.0]}], "type": "Text", "position": 16}, {"raw_context": [{"text": "SPECIAL CONSIDERATIONS", "bbox": [399.0, 603.0, 537.0, 617.0]}, {"text": "FAQ12: Should further adjustments in Candida prophylaxis", "bbox": [399.0, 618.0, 697.0, 631.0]}, {"text": "be made in cord blood, haploidentical or T cell-depleted HCT", "bbox": [400.0, 634.0, 699.0, 645.0]}, {"text": "recipients?", "bbox": [400.0, 648.0, 458.0, 660.0]}], "type": "Section-header", "position": 17}, {"raw_context": [{"text": "There are no current data to suggest that prophylaxis", "bbox": [417.0, 660.0, 708.0, 674.0]}, {"text": "approaches should differ in recipients of cord blood, haploi-", "bbox": [401.0, 675.0, 706.0, 688.0]}, {"text": "dentical or T cell-depleted grafts (C-III).", "bbox": [400.0, 689.0, 592.0, 702.0]}], "type": "Text", "position": 18}, {"raw_context": [{"text": "FAQ13: Should CAR-T cell recipients receive Candida primary", "bbox": [399.0, 716.0, 704.0, 730.0]}, {"text": "prophylaxis?", "bbox": [400.0, 732.0, 468.0, 744.0]}], "type": "Section-header", "position": 19}, {"raw_context": [{"text": "Because CAR-T cell recipients frequently develop mucositis", "bbox": [416.0, 744.0, 708.0, 758.0]}, {"text": "and prolonged neutropenia after administration of cytotoxic", "bbox": [401.0, 760.0, 706.0, 772.0]}, {"text": "chemotherapy, they are at risk for Candida infections. Despite", "bbox": [400.0, 773.0, 707.0, 786.0]}, {"text": "a paucity of relevant data, administration of anti- Candida pro-", "bbox": [400.0, 786.0, 706.0, 799.0]}, {"text": "phylaxis from the start of chemotherapy until resolution of", "bbox": [399.0, 799.0, 708.0, 813.0]}, {"text": "neutropenia and mucositis should be strongly considered (A-", "bbox": [399.0, 814.0, 706.0, 827.0]}, {"text": "III) [ 41 , 42 ]. A mold-active agent (eg, posaconazole) is recom-", "bbox": [400.0, 828.0, 706.0, 841.0]}, {"text": "mended in CAR-T cell recipients who are at elevated risk for", "bbox": [400.0, 843.0, 707.0, 855.0]}, {"text": "mold infections because of prior allogeneic HCT, corticosteroid", "bbox": [400.0, 857.0, 708.0, 869.0]}, {"text": "therapy at doses ≥ 1 mg/kg/day, or IL-6 inhibitors (A-III)", "bbox": [400.0, 871.0, 708.0, 883.0]}, {"text": "[ 41 , 42 ].", "bbox": [399.0, 884.0, 440.0, 898.0]}], "type": "Text", "position": 20}, {"raw_context": [{"text": "UNMET NEEDS AND FUTURE DIRECTIONS", "bbox": [399.0, 911.0, 610.0, 924.0]}, {"text": "FAQ14: What is the utility of PCR or T2Candida-MR panel for", "bbox": [399.0, 925.0, 704.0, 938.0]}, {"text": "diagnosing IC in HCT recipients?", "bbox": [400.0, 940.0, 563.0, 953.0]}], "type": "Section-header", "position": 21}, {"raw_context": [{"text": "These assays have showed excellent performance in diag-", "bbox": [417.0, 953.0, 706.0, 967.0]}, {"text": "nosing candidemia in clinical studies [43–46] ( Table 1 ).", "bbox": [401.0, 968.0, 707.0, 981.0]}], "type": "Text", "position": 22}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/血液科/2023 ASTCT指南：造血细胞移植受者侵袭性念珠菌病的管理.pdf", "page_num": 4}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "缺少换行#11#11# Faq9: Who Should Receive Anti-Candida...另起一行\n多余换行#16#16#favor the administration of...与上面15段联接\n缺少换行#19#19# Faq12: Should Further Adjustments...另起一行\n缺少换行#23#23# Faq14: What Is The Utility Of ...另起一行", "type3": "无关文本#1#24#[ 37 ]   类似的[    ] 类引用过多", "type4": "语义重复#2#2#fungin may be administered at...与上面1段最后重复", "type5": null, "type6": "准确性#1#1#表格的信息，但是里面顺序杂乱"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:41", "update_time": "2024-05-08 00:50:25"}
{"id": 1082550, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 738, "source_info": {"seq_id": "277a8d09-5979-4c62-9121-01bc89b2b4e0", "title": null, "text": "【0】页码:1\n\n【1】## 性高胰岛素血症性低血糖诊治 家共识(2022)\n\n【2】\n 中华医学会儿科学分会内分这连传代谢学组 中华儿科条志编辑委员会 通信作者: 傅君芬, 浙江大学医学院附属儿童医院内分沈科 国家儿童健康与疾病临床 医学研究中心 , 杭州 310052, Email:fjf68@zju.edu.cn; 罗飞宏 , 国家儿童医学中心 复旦 大 学 附 爲 儿 科 医 院 内 分 注 连 待 代 串 科 , 上 海 201102, Email: luofh@fudan.edu.cn\n\n【3】 【摘要】 先天性高胰岛素血症是导致儿童(尤其是新生儿)持续性高胰岛素血症性低血糖的一组 遗传异质性疾病。病因复杂,临床表现谱广,神经发育障碍发生的风险性高使其早期诊治至关重要。 在综合国内外学科进展的基础上,经广泛征求专家意见,特制定先天性高胰岛素血症性低血糖诊治专 家共识(2022),旨在指导临床实践,提高我国儿科医师对该病的诊治水平,改善患儿预后。 基金项目: 国家重点研发计划 (2021YFC2701904) \n\n Expert consensus on the diagnosis and treatment of congenital hyperinsulinemic hypoglycemia(2022) The Subspecialty Group of Endocrinologic, Hereditary and Metabolic Diseases, the Society of Pediatrics, Chinese Medical Association; the Editorial Board, Chinese Journal of Pediatrics Corresponding author: Fu Junfen, Department of Endocrinology, the Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou 310052 , China, Email: fff68@zju.edu.cn; Luo Feihong, Department of Pediatric Endocrinology and Inherited Metabolic Diseases, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai 201102, China, Email: luofh@fudan.edu.cn 11 - D | C A 11\n\n【5】 先 天 性 高 胰 岛 素 血 症 (congenital    科和小儿外科医生的临床实践。 hyperinsulinemia, CHI) 是由于胰腺 β 细胞功能失调、 一、致病机制与分类 胰岛素持续释放导致血胰岛素水平不适当增高而致 低血糖的内分泌疾病。CHI是儿童顽固性低血糖的 主要病因。国外发病率为 1/50 000~1/30 000 11 , 我 国发病情况不详。低血糖可导致不可逆的严重脑损 伤,后遗症发生率高达25%~50%,救治不及时甚至 死亡 [2] 。早期诊断和治疗至关重要。为进一步提高 我国 CHI 诊疗水平 , 在综合国内外诊治进展并凝聚 国内专家经验的基础上,中华医学会儿科学分会内 分泌遗传代谢病学组联合中华儿科杂志编辑委员会 历时近2年制定先天性高胰岛素血症性低血糖诊治 泌从而发生低血糖。 专家共识(2022),指导新生儿科、儿童内分泌、普儿\n\n【6】 一、致病机制与分类 1. 发生机制 : 正常情况下 , 葡萄糖通过胰岛 β 细 胞膜上的葡萄糖转运蛋白2转运进人细胞,在葡萄糖 激酶(glucokinase, GCK)作用下转化为葡萄糖-6-磷 酸,产生三磷酸腺苷(adenosine triphosphate, ATP), 细胞内 ATP/腺苷二磷酸増加,导致 ATP敏感的钾离 子通 道 (adenosine triphosphate-sensitive K + channel, K x n ) 关闭 ; 膜去极化和钙离子内流 , 胞内钙离子浓度 升高戀发胰岛素释放。先天胰岛β细胞合成和分泌 胰岛素的关键调控通路缺陷,胰岛素不适当持续分 泌从而发生低血糖。 2. 分类 : (1) 按病程 : CHI 导致的高胰岛素血症\n\n【7】 DOI : 10.3760/cma.j.cn112140–20221031–00924 Services  111 , 本文编辑   苗时雨 引用本文:中华医学会儿科学分会内分泌遗传代谢学组,中华儿科杂志编辑委员会.先天性高胰岛素血 症 性 低 血 糖 诊 治 专 家 共 识 (2022) [J]. 中 华 儿 科 杂 志 , 2023, 61(5): 412–417. DOI: 10.3760/cma.j.\n\n【8】cn112140–20221031–00924.\n\n【9】14. A 2012", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "性高胰岛素血症性低血糖诊治", "bbox": [140.0, 146.0, 499.0, 180.0]}, {"text": "家共识(2022)", "bbox": [124.0, 185.0, 283.0, 211.0]}], "type": "Section-header", "position": 3}, {"raw_context": [{"text": "中华医学会儿科学分会内分这连传代谢学组", "bbox": [86.0, 232.0, 352.0, 250.0]}, {"text": "中华儿科条志编辑委员会", "bbox": [85.0, 253.0, 241.0, 270.0]}, {"text": "通信作者: 傅君芬, 浙江大学医学院附属儿童医院内分沈科 国家儿童健康与疾病临床", "bbox": [85.0, 274.0, 604.0, 291.0]}, {"text": "医学研究中心 , 杭州 310052, Email:fjf68@zju.edu.cn; 罗飞宏 , 国家儿童医学中心 复旦", "bbox": [85.0, 296.0, 604.0, 313.0]}, {"text": "大 学 附 爲 儿 科 医 院 内 分 注 连 待 代 串 科 , 上 海 201102, Email: luofh@fudan.edu.cn", "bbox": [86.0, 318.0, 561.0, 335.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": "【摘要】 先天性高胰岛素血症是导致儿童(尤其是新生儿)持续性高胰岛素血症性低血糖的一组", "bbox": [108.0, 351.0, 605.0, 368.0]}, {"text": "遗传异质性疾病。病因复杂,临床表现谱广,神经发育障碍发生的风险性高使其早期诊治至关重要。", "bbox": [85.0, 371.0, 603.0, 387.0]}, {"text": "在综合国内外学科进展的基础上,经广泛征求专家意见,特制定先天性高胰岛素血症性低血糖诊治专", "bbox": [85.0, 391.0, 603.0, 407.0]}, {"text": "家共识(2022),旨在指导临床实践,提高我国儿科医师对该病的诊治水平,改善患儿预后。", "bbox": [85.0, 410.0, 543.0, 426.0]}, {"text": "基金项目: 国家重点研发计划 (2021YFC2701904) ", "bbox": [108.0, 429.0, 404.0, 444.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "Expert consensus on the diagnosis and treatment of congenital hyperinsulinemic", "bbox": [85.0, 463.0, 605.0, 479.0]}, {"text": "hypoglycemia(2022)", "bbox": [85.0, 482.0, 203.0, 495.0]}, {"text": "The Subspecialty Group of Endocrinologic, Hereditary and Metabolic Diseases, the Society of Pediatrics,", "bbox": [85.0, 495.0, 605.0, 511.0]}, {"text": "Chinese Medical Association; the Editorial Board, Chinese Journal of Pediatrics", "bbox": [85.0, 513.0, 482.0, 527.0]}, {"text": "Corresponding author: Fu Junfen, Department of Endocrinology, the Children's Hospital, Zhejiang", "bbox": [85.0, 530.0, 605.0, 544.0]}, {"text": "University School of Medicine, National Clinical Research Center for Child Health, Hangzhou 310052 ,", "bbox": [85.0, 546.0, 605.0, 561.0]}, {"text": "China, Email: fff68@zju.edu.cn; Luo Feihong, Department of Pediatric Endocrinology and Inherited", "bbox": [85.0, 562.0, 605.0, 577.0]}, {"text": "Metabolic Diseases, Children's Hospital of Fudan University, National Children's Medical Center,", "bbox": [85.0, 579.0, 605.0, 594.0]}, {"text": "Shanghai 201102, China, Email: luofh@fudan.edu.cn 11 - D | C A 11", "bbox": [85.0, 591.0, 429.0, 614.0]}], "type": "Text", "position": 6}, {"raw_context": [{"text": "先 天 性 高 胰 岛 素 血 症 (congenital    科和小儿外科医生的临床实践。", "bbox": [113.0, 625.0, 612.0, 642.0]}, {"text": "hyperinsulinemia, CHI) 是由于胰腺 β 细胞功能失调、", "bbox": [85.0, 647.0, 392.0, 664.0]}, {"text": "一、致病机制与分类", "bbox": [453.0, 647.0, 575.0, 663.0]}, {"text": "胰岛素持续释放导致血胰岛素水平不适当增高而致", "bbox": [85.0, 669.0, 391.0, 684.0]}, {"text": "低血糖的内分泌疾病。CHI是儿童顽固性低血糖的", "bbox": [85.0, 689.0, 394.0, 705.0]}, {"text": "主要病因。国外发病率为 1/50 000~1/30 000 11 , 我", "bbox": [85.0, 711.0, 392.0, 727.0]}, {"text": "国发病情况不详。低血糖可导致不可逆的严重脑损", "bbox": [85.0, 732.0, 391.0, 748.0]}, {"text": "伤,后遗症发生率高达25%~50%,救治不及时甚至", "bbox": [85.0, 753.0, 390.0, 770.0]}, {"text": "死亡 [2] 。早期诊断和治疗至关重要。为进一步提高", "bbox": [85.0, 774.0, 390.0, 791.0]}, {"text": "我国 CHI 诊疗水平 , 在综合国内外诊治进展并凝聚", "bbox": [85.0, 796.0, 390.0, 813.0]}, {"text": "国内专家经验的基础上,中华医学会儿科学分会内", "bbox": [85.0, 817.0, 391.0, 834.0]}, {"text": "分泌遗传代谢病学组联合中华儿科杂志编辑委员会", "bbox": [85.0, 838.0, 390.0, 855.0]}, {"text": "历时近2年制定先天性高胰岛素血症性低血糖诊治", "bbox": [85.0, 859.0, 390.0, 876.0]}, {"text": "泌从而发生低血糖。", "bbox": [425.0, 859.0, 542.0, 875.0]}, {"text": "专家共识(2022),指导新生儿科、儿童内分泌、普儿", "bbox": [85.0, 880.0, 390.0, 898.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "一、致病机制与分类", "bbox": [453.0, 647.0, 575.0, 663.0]}, {"text": "1. 发生机制 : 正常情况下 , 葡萄糖通过胰岛 β 细", "bbox": [452.0, 668.0, 731.0, 684.0]}, {"text": "胞膜上的葡萄糖转运蛋白2转运进人细胞,在葡萄糖", "bbox": [424.0, 690.0, 731.0, 706.0]}, {"text": "激酶(glucokinase, GCK)作用下转化为葡萄糖-6-磷", "bbox": [424.0, 711.0, 731.0, 727.0]}, {"text": "酸,产生三磷酸腺苷(adenosine triphosphate, ATP),", "bbox": [424.0, 732.0, 730.0, 748.0]}, {"text": "细胞内 ATP/腺苷二磷酸増加,导致 ATP敏感的钾离", "bbox": [425.0, 753.0, 731.0, 770.0]}, {"text": "子通 道 (adenosine triphosphate-sensitive K + channel,", "bbox": [426.0, 774.0, 730.0, 791.0]}, {"text": "K x n ) 关闭 ; 膜去极化和钙离子内流 , 胞内钙离子浓度", "bbox": [425.0, 796.0, 731.0, 813.0]}, {"text": "升高戀发胰岛素释放。先天胰岛β细胞合成和分泌", "bbox": [425.0, 817.0, 731.0, 834.0]}, {"text": "胰岛素的关键调控通路缺陷,胰岛素不适当持续分", "bbox": [425.0, 838.0, 731.0, 855.0]}, {"text": "泌从而发生低血糖。", "bbox": [425.0, 859.0, 542.0, 875.0]}, {"text": "2. 分类 : (1) 按病程 : CHI 导致的高胰岛素血症", "bbox": [452.0, 881.0, 731.0, 898.0]}], "type": "Text", "position": 8}, {"raw_context": [{"text": "DOI : 10.3760/cma.j.cn112140–20221031–00924", "bbox": [85.0, 932.0, 327.0, 947.0]}, {"text": "Services  111 ,", "bbox": [85.0, 950.0, 238.0, 965.0]}, {"text": "本文编辑   苗时雨", "bbox": [236.0, 950.0, 335.0, 966.0]}, {"text": "引用本文:中华医学会儿科学分会内分泌遗传代谢学组,中华儿科杂志编辑委员会.先天性高胰岛素血", "bbox": [85.0, 968.0, 619.0, 985.0]}, {"text": "症 性 低 血 糖 诊 治 专 家 共 识 (2022) [J]. 中 华 儿 科 杂 志 , 2023, 61(5): 412–417. DOI: 10.3760/cma.j.", "bbox": [85.0, 988.0, 619.0, 1003.0]}, {"text": "cn112140–20221031–00924.", "bbox": [84.0, 1008.0, 232.0, 1022.0]}, {"text": "14. A 2012", "bbox": [138.0, 1025.0, 221.0, 1035.0]}], "type": "Text", "position": 9}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/内分泌科/先天性高胰岛素血症性低血糖诊治专家共识（2022）.pdf", "page_num": 1}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": null, "type3": null, "type4": null, "type5": null, "type6": "有用性#0#8#前面指南页的内容"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:41", "update_time": "2024-05-07 19:47:42"}
{"id": 1082549, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 738, "source_info": {"seq_id": "6fdf51bb-deea-4b9a-a977-ac2730808ce7", "title": null, "text": "【0】页码:9\n 9\n\n【1】 Author contributions: Oscar R. Brouwer had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.\n\n【2】Study concept and design : Brouwer, Albersen, Parnham, Protzel, Pettaway, Ayres, Crook, van der Heijden, Johnstone, Manzie, Marcus, Necchi, Oliveira, Osborne, Pagliaro, Rumble, Sánchez Martínez, Spiess, Tagawa.\n\n【3】Acquisition of data : Brouwer, Albersen, Parnham, Ayres, Antunes-Lopes, Barreto, Campi, Fernández-Pello, Greco, Garcia-Perdomo, Kailavasan, Sachdeva, Sakalis, Zapala, Sánchez Martínez, Analysis and interpretation of data : Brouwer, Albersen, Parnham, Protzel, Pettaway, Ayres, Crook, van der Heijden, Johnstone, Manzie, Marcus, Necchi, Oliveira, Osborne, Pagliaro, Rumble, Sánchez Martínez, Spiess, Tagawa.\n\n【4】Drafting of the manuscript : Brouwer, Albersen, Parnham.\n\n【5】Critical revision of the manuscript for important intellectual content : Brouwer, Albersen, Parnham, Protzel, Pettaway, Ayres, Antunes-Lopes, Barreto, Campi, Crook, Fernández-Pello, Greco, van der Heijden, Johnstone, Manzie, Marcus, Necchi, Oliveira, Osborne, Pagliaro, Garcia- Perdomo, Kailavasan, Rumble, Sachdeva, Sakalis, Zapala, Sánchez Martínez, Spiess, Tagawa.\n\n【6】Statistical analysis : None.\n\n【7】Obtaining funding : None.\n\n【8】Administrative, technical, or material support : None.\n\n【9】Supervision : Brouwer, Tagawa.\n\n【10】Other : None.\n\n【11】 Financial disclosures: Oscar R. Brouwer certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Maarten Albersen has received research funding from Pfizer and Ipsen and honoraria from MSD Oncology, Pfizer, Venmeda, and Boston Scientific. Benjamin Ayres has received a speaker honorarium from Olympus KeyMed, is a company consultant for Cepheid UK, and participates is a trial run by MSD. Juanita Crook has received consultancy fees from Concure Oncology (Breast Microseed), Tersera, Astellas Pharma, and Tolmar. Peter A.S. Johnstone has received a travel grant from ViewRay. Arie Parnham has received a speaker honorarium from Boston Scientific and participated in a trial run by VELRAD. Curtis A. Pettaway has received consultancy fees from Wolters Kluwer for contributing to their Up to Date series on penile cancer. Philippe E. Spiess is president of the Global Society of Genitourinary Tumours, Vice-chair of the NCCN Bladder and Penile Cancer Guidelines, and Chair of the AUA Core-Curriculum Committee. Ashwin Sachdeva has received a travel grant from AIRAmatrix. The remaining authors have nothing to disclose.\n\n【12】## Funding/Support And Role Of The Sponsor: None.\n\n【13】\n Guideline disclaimer: The clinical practice guidelines and other guidance published herein are provided by the American Society of Clinical Oncology, Inc. (ASCO) to assist providers in clinical decision-making. The information herein should not be relied upon as being complete or accurate, nor should it be considered as inclusive of all proper treatments or methods of care or as a statement of the standard of care. With the rapid development of scientific knowledge, new evidence may emerge between the time information is developed and when it is published or read. The information is not continually updated and may not reflect the most recent evidence. The information addresses only the topics specifically identified herein and is not applicable to other interventions, diseases, or stages of diseases. This information does not mandate any particular course of\n\n【14】 Please cite this article as: O.R. Brouwer, M. Albersen, A. Parnham et al., European Association of Urology-American Society of Clinical Oncology Collaborative Guideline on Penile Cancer: 2023 Update, Eur Urol (2023), https://doi.org/10.1016/j.eururo.2023.02.027\n\n【15】 Table 8 – Recommendation for centralisation Recommendation Strength rating Deliver penile cancer care as part of an extended Strong multidisciplinary team comprising urologists specialising in penile cancer, specialist nurses, pathologists, uroradiologists, nuclear medicine specialists, medical and radiation oncologists, lymphoedema therapists, psychologists, counsellors, palliative care teams for early symptom control, reconstructive surgeons, vascular surgeons, and sex therapists.\n\n【16】Follow men after penile cancer treatment, initially three- Strong monthly for 2 yr and then less frequently to assess for\n\n【17】\n appointment, and advised about good skin care, compression, exercise, massage, and elevation when resting as the mainstays of treatment. Following nodal surgery, patients would ideally be referred to a specialist lymphoedema service for assessment and management before any significant lymphoedema occurs.\n\n【18】## Centralisation 3.9.\n\n【19】\n Current large-volume centres offer specialist nursing, psychological support, and specialised lymphoedema services to their patients. Centralisation of penile cancer services has additional advantages of reducing system delays [122] and allowing specialist pathological review, multidisciplinary expert review of cases, better adherence to guidelines, recruitment to clinical trials, and innovation [ 123 ]. An improvement in survival has also been reported [ 124 ].\n\n【20】Table 10.8 lists the recommendations regarding centralisation.\n\n【21】## 4. Conclusions\n\n【22】\n Penile cancer is a rare disease but the incidence is increasing and there are many unmet needs to address. This collaborative penile cancer guideline is a complete revision of prior versions and provides updated information on the diagnosis and treatment of penile cancer for use in clinical practice. Owing to a lack of controlled trials and large series, the levels of evidence and grades of recommendation are low in comparison to those for more common diseases.\n\n【23】Referral to centres of expertise is recommended. The panel hopes that future collaborations between the EAU and ASCO will serve to establish other internationally approved guidelines, offering physician and patient guidance worldwide.", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "9", "bbox": [722.0, 43.0, 732.0, 54.0]}], "type": "Text", "position": 2}, {"raw_context": [{"text": "Author contributions: Oscar R. Brouwer had full access to all the data in", "bbox": [411.0, 88.0, 733.0, 100.0]}, {"text": "the study and takes responsibility for the integrity of the data and the", "bbox": [410.0, 103.0, 732.0, 114.0]}, {"text": "accuracy of the data analysis.", "bbox": [411.0, 117.0, 542.0, 129.0]}, {"text": "Study concept and design : Brouwer, Albersen, Parnham, Protzel, Pettaway,", "bbox": [411.0, 135.0, 733.0, 148.0]}, {"text": "Ayres, Crook, van der Heijden, Johnstone, Manzie, Marcus, Necchi, Oli-", "bbox": [410.0, 150.0, 731.0, 164.0]}, {"text": "veira, Osborne, Pagliaro, Rumble, Sánchez Martínez, Spiess, Tagawa.", "bbox": [410.0, 165.0, 715.0, 178.0]}, {"text": "Acquisition of data : Brouwer, Albersen, Parnham, Ayres, Antunes-Lopes,", "bbox": [410.0, 180.0, 732.0, 193.0]}, {"text": "Barreto, Campi, Fernández-Pello, Greco, Garcia-Perdomo, Kailavasan,", "bbox": [410.0, 195.0, 732.0, 207.0]}, {"text": "Sachdeva, Sakalis, Zapala, Sánchez Martínez,", "bbox": [410.0, 210.0, 608.0, 221.0]}, {"text": "Analysis and interpretation of data : Brouwer, Albersen, Parnham, Protzel,", "bbox": [410.0, 224.0, 732.0, 236.0]}, {"text": "Pettaway, Ayres, Crook, van der Heijden, Johnstone, Manzie, Marcus,", "bbox": [410.0, 239.0, 732.0, 251.0]}, {"text": "Necchi, Oliveira, Osborne, Pagliaro, Rumble, Sánchez Martínez, Spiess,", "bbox": [410.0, 254.0, 732.0, 266.0]}, {"text": "Tagawa.", "bbox": [410.0, 269.0, 447.0, 280.0]}, {"text": "Drafting of the manuscript : Brouwer, Albersen, Parnham.", "bbox": [410.0, 283.0, 661.0, 295.0]}, {"text": "Critical revision of the manuscript for important intellectual content :", "bbox": [410.0, 297.0, 731.0, 309.0]}, {"text": "Brouwer, Albersen, Parnham, Protzel, Pettaway, Ayres, Antunes-Lopes,", "bbox": [410.0, 312.0, 733.0, 324.0]}, {"text": "Barreto, Campi, Crook, Fernández-Pello, Greco, van der Heijden, John-", "bbox": [410.0, 326.0, 731.0, 337.0]}, {"text": "stone, Manzie, Marcus, Necchi, Oliveira, Osborne, Pagliaro, Garcia-", "bbox": [410.0, 341.0, 731.0, 353.0]}, {"text": "Perdomo, Kailavasan, Rumble, Sachdeva, Sakalis, Zapala, Sánchez Martí-", "bbox": [410.0, 356.0, 732.0, 368.0]}, {"text": "nez, Spiess, Tagawa.", "bbox": [410.0, 371.0, 501.0, 383.0]}, {"text": "Statistical analysis : None.", "bbox": [411.0, 385.0, 520.0, 397.0]}, {"text": "Obtaining funding : None.", "bbox": [410.0, 399.0, 520.0, 412.0]}, {"text": "Administrative, technical, or material support : None.", "bbox": [410.0, 414.0, 637.0, 426.0]}, {"text": "Supervision : Brouwer, Tagawa.", "bbox": [410.0, 429.0, 546.0, 441.0]}, {"text": "Other : None.", "bbox": [410.0, 443.0, 467.0, 455.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "Financial disclosures: Oscar R. Brouwer certifies that all conflicts of inter-", "bbox": [410.0, 480.0, 731.0, 493.0]}, {"text": "est, including specific financial interests and relationships and affiliations", "bbox": [410.0, 495.0, 732.0, 507.0]}, {"text": "relevant to the subject matter or materials discussed in the manuscript", "bbox": [410.0, 510.0, 733.0, 521.0]}, {"text": "(eg, employment/affiliation, grants or funding, consultancies, honoraria,", "bbox": [409.0, 524.0, 733.0, 537.0]}, {"text": "stock ownership or options, expert testimony, royalties, or patents filed,", "bbox": [411.0, 539.0, 732.0, 552.0]}, {"text": "received, or pending), are the following: Maarten Albersen has received", "bbox": [411.0, 555.0, 733.0, 566.0]}, {"text": "research funding from Pfizer and Ipsen and honoraria from MSD Oncol-", "bbox": [411.0, 569.0, 731.0, 580.0]}, {"text": "ogy, Pfizer, Venmeda, and Boston Scientific. Benjamin Ayres has received", "bbox": [410.0, 583.0, 733.0, 595.0]}, {"text": "a speaker honorarium from Olympus KeyMed, is a company consultant", "bbox": [410.0, 598.0, 732.0, 609.0]}, {"text": "for Cepheid UK, and participates is a trial run by MSD. Juanita Crook", "bbox": [410.0, 612.0, 732.0, 623.0]}, {"text": "has received consultancy fees from Concure Oncology (Breast Microseed),", "bbox": [410.0, 627.0, 732.0, 639.0]}, {"text": "Tersera, Astellas Pharma, and Tolmar. Peter A.S. Johnstone has received a", "bbox": [411.0, 641.0, 733.0, 653.0]}, {"text": "travel grant from ViewRay. Arie Parnham has received a speaker honorar-", "bbox": [410.0, 657.0, 731.0, 668.0]}, {"text": "ium from Boston Scientific and participated in a trial run by VELRAD. Cur-", "bbox": [411.0, 671.0, 731.0, 683.0]}, {"text": "tis A. Pettaway has received consultancy fees from Wolters Kluwer for", "bbox": [410.0, 685.0, 731.0, 698.0]}, {"text": "contributing to their Up to Date series on penile cancer. Philippe E. Spiess", "bbox": [410.0, 700.0, 733.0, 712.0]}, {"text": "is president of the Global Society of Genitourinary Tumours, Vice-chair of", "bbox": [410.0, 714.0, 733.0, 727.0]}, {"text": "the NCCN Bladder and Penile Cancer Guidelines, and Chair of the AUA", "bbox": [410.0, 729.0, 733.0, 741.0]}, {"text": "Core-Curriculum Committee. Ashwin Sachdeva has received a travel grant", "bbox": [410.0, 744.0, 732.0, 756.0]}, {"text": "from AIRAmatrix. The remaining authors have nothing to disclose.", "bbox": [411.0, 758.0, 704.0, 771.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": "Funding/Support and role of the sponsor: None.", "bbox": [410.0, 796.0, 625.0, 809.0]}], "type": "Section-header", "position": 5}, {"raw_context": [{"text": "Guideline disclaimer: The clinical practice guidelines and other guidance", "bbox": [410.0, 833.0, 732.0, 845.0]}, {"text": "published herein are provided by the American Society of Clinical Oncol-", "bbox": [411.0, 848.0, 731.0, 859.0]}, {"text": "ogy, Inc. (ASCO) to assist providers in clinical decision-making. The infor-", "bbox": [410.0, 862.0, 731.0, 874.0]}, {"text": "mation herein should not be relied upon as being complete or accurate,", "bbox": [411.0, 877.0, 733.0, 888.0]}, {"text": "nor should it be considered as inclusive of all proper treatments or meth-", "bbox": [411.0, 891.0, 731.0, 903.0]}, {"text": "ods of care or as a statement of the standard of care. With the rapid devel-", "bbox": [410.0, 906.0, 731.0, 918.0]}, {"text": "opment of scientific knowledge, new evidence may emerge between the", "bbox": [410.0, 922.0, 733.0, 933.0]}, {"text": "time information is developed and when it is published or read. The infor-", "bbox": [410.0, 936.0, 731.0, 947.0]}, {"text": "mation is not continually updated and may not reflect the most recent", "bbox": [410.0, 950.0, 732.0, 962.0]}, {"text": "evidence. The information addresses only the topics specifically identified", "bbox": [410.0, 964.0, 733.0, 976.0]}, {"text": "herein and is not applicable to other interventions, diseases, or stages of", "bbox": [410.0, 979.0, 733.0, 991.0]}, {"text": "diseases. This information does not mandate any particular course of", "bbox": [410.0, 994.0, 733.0, 1006.0]}], "type": "Text", "position": 6}, {"raw_context": [{"text": "Please cite this article as: O.R. Brouwer, M. Albersen, A. Parnham et al., European Association of Urology-American Society of Clinical Oncology Col-", "bbox": [70.0, 1028.0, 729.0, 1040.0]}, {"text": "laborative Guideline on Penile Cancer: 2023 Update, Eur Urol (2023), https://doi.org/10.1016/j.eururo.2023.02.027", "bbox": [70.0, 1041.0, 590.0, 1053.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "Table 8 – Recommendation for centralisation", "bbox": [75.0, 89.0, 275.0, 100.0]}, {"text": "Recommendation", "bbox": [78.0, 109.0, 160.0, 120.0]}, {"text": "Strength", "bbox": [324.0, 110.0, 366.0, 121.0]}, {"text": "rating", "bbox": [326.0, 121.0, 353.0, 133.0]}, {"text": "Deliver penile cancer care as part of an extended", "bbox": [80.0, 138.0, 281.0, 150.0]}, {"text": "Strong", "bbox": [326.0, 138.0, 353.0, 149.0]}, {"text": "multidisciplinary team comprising urologists", "bbox": [91.0, 150.0, 277.0, 160.0]}, {"text": "specialising in penile cancer, specialist nurses,", "bbox": [91.0, 160.0, 281.0, 172.0]}, {"text": "pathologists, uroradiologists, nuclear medicine", "bbox": [91.0, 171.0, 282.0, 183.0]}, {"text": "specialists, medical and radiation oncologists,", "bbox": [91.0, 184.0, 278.0, 193.0]}, {"text": "lymphoedema therapists, psychologists, counsellors,", "bbox": [91.0, 195.0, 306.0, 206.0]}, {"text": "palliative care teams for early symptom control,", "bbox": [91.0, 206.0, 287.0, 217.0]}, {"text": "reconstructive surgeons, vascular surgeons, and sex", "bbox": [91.0, 217.0, 303.0, 228.0]}, {"text": "therapists.", "bbox": [91.0, 230.0, 134.0, 239.0]}, {"text": "Follow men after penile cancer treatment, initially three-", "bbox": [78.0, 240.0, 315.0, 251.0]}, {"text": "Strong", "bbox": [325.0, 240.0, 355.0, 251.0]}, {"text": "monthly for 2 yr and then less frequently to assess for", "bbox": [91.0, 252.0, 314.0, 263.0]}], "type": "Table", "position": 8}, {"raw_context": [{"text": "appointment, and advised about good skin care, compres-", "bbox": [66.0, 487.0, 388.0, 500.0]}, {"text": "sion, exercise, massage, and elevation when resting as the", "bbox": [66.0, 502.0, 390.0, 517.0]}, {"text": "mainstays of treatment. Following nodal surgery, patients", "bbox": [67.0, 518.0, 389.0, 532.0]}, {"text": "would ideally be referred to a specialist lymphoedema ser-", "bbox": [66.0, 533.0, 389.0, 546.0]}, {"text": "vice for assessment and management before any significant", "bbox": [66.0, 548.0, 389.0, 563.0]}, {"text": "lymphoedema occurs.", "bbox": [66.0, 564.0, 185.0, 578.0]}], "type": "Text", "position": 12}, {"raw_context": [{"text": "Centralisation", "bbox": [107.0, 595.0, 179.0, 608.0]}, {"text": "3.9.", "bbox": [67.0, 596.0, 87.0, 608.0]}], "type": "Section-header", "position": 13}, {"raw_context": [{"text": "Current large-volume centres offer specialist nursing, psy-", "bbox": [66.0, 619.0, 389.0, 633.0]}, {"text": "chological support, and specialised lymphoedema services", "bbox": [66.0, 635.0, 389.0, 648.0]}, {"text": "to their patients. Centralisation of penile cancer services", "bbox": [66.0, 650.0, 389.0, 665.0]}, {"text": "has additional advantages of reducing system delays [122]", "bbox": [66.0, 666.0, 388.0, 679.0]}, {"text": "and allowing specialist pathological review, multidisci-", "bbox": [66.0, 681.0, 388.0, 694.0]}, {"text": "plinary expert review of cases, better adherence to guideli-", "bbox": [66.0, 696.0, 389.0, 709.0]}, {"text": "nes, recruitment to clinical trials, and innovation [ 123 ]. An", "bbox": [66.0, 712.0, 389.0, 725.0]}, {"text": "improvement in survival has also been reported [ 124 ].", "bbox": [66.0, 727.0, 365.0, 740.0]}, {"text": "Table", "bbox": [84.0, 743.0, 117.0, 755.0]}, {"text": "10.8", "bbox": [126.0, 743.0, 139.0, 754.0]}, {"text": "lists", "bbox": [150.0, 743.0, 179.0, 755.0]}, {"text": "the", "bbox": [186.0, 743.0, 212.0, 755.0]}, {"text": "recommendations", "bbox": [219.0, 742.0, 324.0, 755.0]}, {"text": "regarding", "bbox": [333.0, 743.0, 390.0, 755.0]}, {"text": "centralisation.", "bbox": [66.0, 758.0, 144.0, 772.0]}], "type": "Text", "position": 14}, {"raw_context": [{"text": "4. Conclusions", "bbox": [66.0, 793.0, 154.0, 806.0]}], "type": "Section-header", "position": 15}, {"raw_context": [{"text": "Penile cancer is a rare disease but the incidence is increas-", "bbox": [66.0, 826.0, 388.0, 841.0]}, {"text": "ing and there are many unmet needs to address. This collab-", "bbox": [66.0, 842.0, 389.0, 856.0]}, {"text": "orative penile cancer guideline is a complete revision of", "bbox": [67.0, 858.0, 389.0, 871.0]}, {"text": "prior versions and provides updated information on the", "bbox": [66.0, 872.0, 390.0, 886.0]}, {"text": "diagnosis and treatment of penile cancer for use in clinical", "bbox": [67.0, 889.0, 389.0, 902.0]}, {"text": "practice. Owing to a lack of controlled trials and large series,", "bbox": [67.0, 904.0, 390.0, 916.0]}, {"text": "the levels of evidence and grades of recommendation are", "bbox": [66.0, 918.0, 390.0, 933.0]}, {"text": "low in comparison to those for more common diseases.", "bbox": [66.0, 934.0, 389.0, 947.0]}, {"text": "Referral to centres of expertise is recommended. The panel", "bbox": [66.0, 949.0, 389.0, 962.0]}, {"text": "hopes that future collaborations between the EAU and ASCO", "bbox": [66.0, 964.0, 390.0, 978.0]}, {"text": "will serve to establish other internationally approved guide-", "bbox": [66.0, 980.0, 387.0, 993.0]}, {"text": "lines, offering physician and patient guidance worldwide.", "bbox": [66.0, 995.0, 380.0, 1008.0]}], "type": "Text", "position": 16}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/泌尿外科/2023 EAU／ASCO指南：阴茎癌（更新版）.pdf", "page_num": 9}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type2": "序号格式不一致#18#18#Centralisation 3.9.  序号要在前面", "type3": "无关文本#19#19#[122]  [ 123 ] [ 124 ]", "type4": "栏目混乱#1#23#左右侧内容颠倒", "type6": "有用性#1#14#作者信息，文章披露等内容\n准确性#15#16#表格内容，但缺少大量内容"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:41", "update_time": "2024-05-08 01:10:38"}
{"id": 1082548, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 738, "source_info": {"seq_id": "9425ffb9-35b1-4aa2-b2ee-d585aff83de5", "title": null, "text": "【0】页码:3\n Table 2.\n Advantages and Limitations of Noninvasive Techniques Available to Assess Patients With TIA 22,22\n\n【1】 Advantages and Limitations of Noninvasive Techniques Available to Assess Patients With TIA 22,22 Table 2.\n\n【2】Sensitiv- Specific- Sensitiv- Specificity for ity for ity for ity for 50%–69% 50%–69% 70%–99% 70%–99% Noninvacarotid carotid carotid carotid sive techstenosis, stenosis, stenosis, stenosis, niques Limitations 96 56 % 96 Advantages Considerations Doppler Operator variability 36 91 89 84 Low cost ultrasonog- No intravenous contrast Results might be affected raphy by patient body habitus or vessel anatomy Only assesses cervical vessels Insensitive for dissection Not available in the emergency department, but potentially available in observation units Computed 67 87 19595 Widely available as a STAT sca Requires intravenous Should be ordered as 79 computed tomography angitomography in emergency departments contrast angiography ography head and neck Can be performed simultane Radiation exposure ously with noncontrast head Limitations in interpretacomputed tomography tion in the setting of Can assess cervical and significant calcification intracranial vessels Sensitive for cervical and intracranial atherosclerosis, dissection, other vasculopathies Magnetic 777777 97 88 84 Can be performed simultane- Contraindicated in some Should be ordered as head ously with magnetic resopatients with implants resonance and neck.\n\n【3】angiography nance imaging of brain and devices.\n\n【4】Contrast-enhanced magnetic Can assess cervical and Costly compared with resonance angiography allows intracranial vessels computed tomography for higher-quality images and and Doppler ultrasonogless motion artifact Sensitive for dissection raphy Food and Drug Administra- No radiation Longer time to schedule, tion warning on gadolinium Can be performed without perform, can rarely because of retention in the contrast perform acutelybody and brain, especially in the case of repeated injec- May overestimate tions stenosis Adapted from The Lancet, 27 Copyright 2006, with permission from Elsevier.\n\n【5】 Adapted from The Lancet, 27 Copyright 2006, with permission from Elsevier.\n\n【6】 that might occur with delayed imaging capture. 15 A TIA evaluation without MRI might miss higher-risk patients who require closer monitoring.\n\n【7】## Vascular Imaging\n\n【8】\n Evaluation of TIA requires adequate vascular imaging.\n\n【9】Noninvasive imaging to screen for carotid stenosis (or vertebral artery stenosis for patients with posterior circu¬ lation symptoms) should be a routine component of the acute phase imaging for patients with TIAs. 11 , 16 A primary goal of vascular imaging is to identify patients with highgrade cervical carotid stenosis who might be candidates for revascularization. 11 , 16 -18 Nearly half of patients with transient neurological symptoms and DWI lesions have stenosis or occlusion of either extracranial or intracranial large arteries. 19 Symptomatic intracranial stenosis is associated with higher risk of recurrent stroke, therefore many centers include intracranial in addition to cervical vascular imaging in the workup of patients with TIA. 20,21\n\n【10】 Identification of symptomatic intracranial stenosis might sway toward admission for centers with low risk tolerance, and potentially caution clinicians against overly aggressive blood pressure reduction that might lead to the recurrence of symptoms.\n\n【11】Multiple noninvasive techniques are available to assess cervical carotid and intracranial vasculature from the ED (Table 2). 22,23 Computed tomography angiography (CTA) is the most widely accessible modality in EDs and can be obtained rapidly in conjunction with NCCT. CTA has a higher sensitivity and positive pre¬ dictive value than magnetic resonance angiography (MRA) for detection of intracranial stenosis and occlu¬ sion, and is recommended over time-of-flight (without contrast) MRA. 24,25 Further, CTA is considered safe in patients with known chronic kidney disease and is not associated with significant risk of acute kidney injury. 26 Centers may still obtain a serum creatinine before obtaining CTA, however, to establish baseline renal function. For patients in whom the administration\n\n【12】 TN 3M 3TATS  1V01\n\n【13】 '9 funds I uo fd aro slemnoleds// qud mort bebeom", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "Table 2.", "bbox": [64.0, 78.0, 111.0, 89.0]}], "type": "Caption", "position": 2}, {"raw_context": [{"text": "Advantages and Limitations of Noninvasive Techniques Available to Assess Patients With TIA 22,22", "bbox": [111.0, 76.0, 607.0, 90.0]}], "type": "Caption", "position": 3}, {"raw_context": [{"text": "Advantages and Limitations of Noninvasive Techniques Available to Assess Patients With TIA 22,22", "bbox": [111.0, 76.0, 607.0, 90.0]}, {"text": "Table 2.", "bbox": [64.0, 78.0, 111.0, 89.0]}, {"text": "Sensitiv-", "bbox": [128.0, 99.0, 170.0, 110.0]}, {"text": "Specific-", "bbox": [183.0, 99.0, 224.0, 110.0]}, {"text": "Sensitiv-", "bbox": [239.0, 99.0, 282.0, 110.0]}, {"text": "Specific-", "bbox": [293.0, 100.0, 334.0, 110.0]}, {"text": "ity for", "bbox": [128.0, 112.0, 158.0, 123.0]}, {"text": "ity for", "bbox": [183.0, 113.0, 213.0, 123.0]}, {"text": "ity for", "bbox": [240.0, 112.0, 269.0, 123.0]}, {"text": "ity for", "bbox": [294.0, 112.0, 323.0, 123.0]}, {"text": "50%–69%", "bbox": [128.0, 123.0, 172.0, 134.0]}, {"text": "50%–69%", "bbox": [183.0, 123.0, 229.0, 134.0]}, {"text": "70%–99%", "bbox": [239.0, 123.0, 284.0, 134.0]}, {"text": "70%–99%", "bbox": [294.0, 125.0, 336.0, 135.0]}, {"text": "Noninva-", "bbox": [69.0, 136.0, 113.0, 147.0]}, {"text": "carotid", "bbox": [128.0, 136.0, 165.0, 147.0]}, {"text": "carotid", "bbox": [183.0, 136.0, 219.0, 147.0]}, {"text": "carotid", "bbox": [240.0, 136.0, 275.0, 147.0]}, {"text": "carotid", "bbox": [294.0, 137.0, 328.0, 148.0]}, {"text": "sive tech-", "bbox": [69.0, 147.0, 113.0, 159.0]}, {"text": "stenosis,", "bbox": [183.0, 148.0, 225.0, 159.0]}, {"text": "stenosis,", "bbox": [128.0, 149.0, 170.0, 159.0]}, {"text": "stenosis,", "bbox": [239.0, 149.0, 282.0, 159.0]}, {"text": "stenosis,", "bbox": [293.0, 150.0, 334.0, 160.0]}, {"text": "niques", "bbox": [69.0, 160.0, 104.0, 172.0]}, {"text": "Limitations", "bbox": [475.0, 160.0, 528.0, 172.0]}, {"text": "96", "bbox": [129.0, 161.0, 140.0, 170.0]}, {"text": "56", "bbox": [183.0, 161.0, 195.0, 170.0]}, {"text": "%", "bbox": [240.0, 161.0, 251.0, 172.0]}, {"text": "96", "bbox": [294.0, 161.0, 304.0, 171.0]}, {"text": "Advantages", "bbox": [347.0, 161.0, 399.0, 172.0]}, {"text": "Considerations", "bbox": [588.0, 161.0, 656.0, 172.0]}, {"text": "Doppler", "bbox": [68.0, 178.0, 105.0, 189.0]}, {"text": "Operator variability", "bbox": [475.0, 178.0, 553.0, 189.0]}, {"text": "36", "bbox": [129.0, 179.0, 143.0, 189.0]}, {"text": "91", "bbox": [183.0, 179.0, 196.0, 189.0]}, {"text": "89", "bbox": [239.0, 179.0, 254.0, 189.0]}, {"text": "84", "bbox": [293.0, 179.0, 308.0, 189.0]}, {"text": "Low cost", "bbox": [345.0, 179.0, 385.0, 189.0]}, {"text": "ultrasonog-", "bbox": [69.0, 191.0, 115.0, 201.0]}, {"text": "No intravenous contrast", "bbox": [346.0, 193.0, 443.0, 203.0]}, {"text": "Results might be affected", "bbox": [476.0, 193.0, 580.0, 204.0]}, {"text": "raphy", "bbox": [70.0, 203.0, 94.0, 214.0]}, {"text": "by patient body habitus", "bbox": [475.0, 206.0, 572.0, 217.0]}, {"text": "or vessel anatomy", "bbox": [476.0, 218.0, 549.0, 227.0]}, {"text": "Only assesses cervical", "bbox": [475.0, 232.0, 570.0, 242.0]}, {"text": "vessels", "bbox": [477.0, 245.0, 507.0, 255.0]}, {"text": "Insensitive for dissection", "bbox": [476.0, 259.0, 575.0, 269.0]}, {"text": "Not available in the", "bbox": [475.0, 273.0, 555.0, 284.0]}, {"text": "emergency department,", "bbox": [477.0, 287.0, 572.0, 297.0]}, {"text": "but potentially available in", "bbox": [476.0, 299.0, 577.0, 307.0]}, {"text": "observation units", "bbox": [476.0, 310.0, 547.0, 321.0]}, {"text": "Computed", "bbox": [70.0, 328.0, 115.0, 339.0]}, {"text": "67", "bbox": [129.0, 328.0, 141.0, 339.0]}, {"text": "87", "bbox": [239.0, 328.0, 252.0, 339.0]}, {"text": "19595", "bbox": [295.0, 328.0, 306.0, 339.0]}, {"text": "Widely available as a STAT sca", "bbox": [347.0, 327.0, 462.0, 339.0]}, {"text": "Requires intravenous", "bbox": [475.0, 328.0, 562.0, 339.0]}, {"text": "Should be ordered as", "bbox": [588.0, 327.0, 677.0, 339.0]}, {"text": "79", "bbox": [185.0, 329.0, 196.0, 338.0]}, {"text": "computed tomography angi-", "bbox": [588.0, 340.0, 700.0, 350.0]}, {"text": "tomography", "bbox": [70.0, 341.0, 118.0, 350.0]}, {"text": "in emergency departments", "bbox": [347.0, 341.0, 448.0, 351.0]}, {"text": "contrast", "bbox": [477.0, 341.0, 512.0, 349.0]}, {"text": "angiography", "bbox": [71.0, 353.0, 120.0, 364.0]}, {"text": "ography head and neck", "bbox": [588.0, 352.0, 684.0, 363.0]}, {"text": "Can be performed simultane", "bbox": [346.0, 355.0, 460.0, 366.0]}, {"text": "Radiation exposure", "bbox": [475.0, 355.0, 555.0, 366.0]}, {"text": "ously with noncontrast head", "bbox": [347.0, 367.0, 459.0, 378.0]}, {"text": "Limitations in interpreta-", "bbox": [476.0, 369.0, 572.0, 381.0]}, {"text": "computed tomography", "bbox": [346.0, 380.0, 438.0, 391.0]}, {"text": "tion in the setting of", "bbox": [477.0, 383.0, 558.0, 391.0]}, {"text": "Can assess cervical and", "bbox": [346.0, 394.0, 445.0, 405.0]}, {"text": "significant calcification", "bbox": [477.0, 394.0, 568.0, 405.0]}, {"text": "intracranial vessels", "bbox": [346.0, 407.0, 423.0, 415.0]}, {"text": "Sensitive for cervical and", "bbox": [347.0, 421.0, 443.0, 432.0]}, {"text": "intracranial atherosclerosis, dis-", "bbox": [346.0, 433.0, 464.0, 444.0]}, {"text": "section, other vasculopathies", "bbox": [347.0, 446.0, 458.0, 456.0]}, {"text": "Magnetic", "bbox": [68.0, 463.0, 110.0, 475.0]}, {"text": "777777", "bbox": [130.0, 463.0, 141.0, 473.0]}, {"text": "97", "bbox": [183.0, 463.0, 196.0, 474.0]}, {"text": "88", "bbox": [239.0, 463.0, 254.0, 475.0]}, {"text": "84", "bbox": [294.0, 463.0, 308.0, 474.0]}, {"text": "Can be performed simultane-", "bbox": [346.0, 463.0, 462.0, 474.0]}, {"text": "Contraindicated in some", "bbox": [476.0, 463.0, 575.0, 475.0]}, {"text": "Should be ordered as head", "bbox": [588.0, 463.0, 700.0, 475.0]}, {"text": "ously with magnetic reso-", "bbox": [346.0, 475.0, 448.0, 486.0]}, {"text": "patients with implants", "bbox": [477.0, 475.0, 564.0, 486.0]}, {"text": "resonance", "bbox": [70.0, 476.0, 113.0, 485.0]}, {"text": "and neck.", "bbox": [588.0, 476.0, 625.0, 485.0]}, {"text": "angiography", "bbox": [70.0, 488.0, 120.0, 499.0]}, {"text": "nance imaging of brain", "bbox": [347.0, 488.0, 440.0, 499.0]}, {"text": "and devices.", "bbox": [477.0, 488.0, 525.0, 498.0]}, {"text": "Contrast-enhanced magnetic", "bbox": [588.0, 490.0, 707.0, 501.0]}, {"text": "Can assess cervical and", "bbox": [347.0, 502.0, 445.0, 513.0]}, {"text": "Costly compared with", "bbox": [477.0, 502.0, 566.0, 513.0]}, {"text": "resonance angiography allows", "bbox": [588.0, 502.0, 708.0, 514.0]}, {"text": "intracranial vessels", "bbox": [347.0, 515.0, 421.0, 523.0]}, {"text": "computed tomography", "bbox": [477.0, 515.0, 568.0, 523.0]}, {"text": "for higher-quality images and", "bbox": [588.0, 515.0, 705.0, 524.0]}, {"text": "and Doppler ultrasonog-", "bbox": [477.0, 527.0, 573.0, 537.0]}, {"text": "less motion artifact", "bbox": [588.0, 527.0, 666.0, 537.0]}, {"text": "Sensitive for dissection", "bbox": [347.0, 529.0, 440.0, 540.0]}, {"text": "raphy", "bbox": [476.0, 540.0, 500.0, 548.0]}, {"text": "Food and Drug Administra-", "bbox": [588.0, 541.0, 697.0, 552.0]}, {"text": "No radiation", "bbox": [347.0, 544.0, 397.0, 555.0]}, {"text": "Longer time to schedule,", "bbox": [476.0, 554.0, 575.0, 564.0]}, {"text": "tion warning on gadolinium", "bbox": [587.0, 554.0, 698.0, 565.0]}, {"text": "Can be performed without", "bbox": [347.0, 559.0, 453.0, 568.0]}, {"text": "perform, can rarely", "bbox": [476.0, 565.0, 552.0, 576.0]}, {"text": "because of retention in the", "bbox": [588.0, 565.0, 697.0, 576.0]}, {"text": "contrast", "bbox": [349.0, 572.0, 382.0, 581.0]}, {"text": "perform acutely-", "bbox": [477.0, 578.0, 541.0, 588.0]}, {"text": "body and brain, especially in", "bbox": [588.0, 578.0, 702.0, 587.0]}, {"text": "the case of repeated injec-", "bbox": [588.0, 589.0, 694.0, 601.0]}, {"text": "May overestimate", "bbox": [476.0, 592.0, 547.0, 603.0]}, {"text": "tions", "bbox": [588.0, 602.0, 610.0, 610.0]}, {"text": "stenosis", "bbox": [476.0, 605.0, 510.0, 614.0]}, {"text": "Adapted from The Lancet, 27 Copyright 2006, with permission from Elsevier.", "bbox": [76.0, 623.0, 367.0, 635.0]}], "type": "Table", "position": 4}, {"raw_context": [{"text": "Adapted from The Lancet, 27 Copyright 2006, with permission from Elsevier.", "bbox": [76.0, 623.0, 367.0, 635.0]}], "type": "Caption", "position": 5}, {"raw_context": [{"text": "that might occur with delayed imaging capture. 15 A TIA", "bbox": [63.0, 655.0, 380.0, 669.0]}, {"text": "evaluation without MRI might miss higher-risk patients", "bbox": [63.0, 671.0, 379.0, 685.0]}, {"text": "who require closer monitoring.", "bbox": [63.0, 687.0, 234.0, 701.0]}], "type": "Text", "position": 6}, {"raw_context": [{"text": "Vascular Imaging", "bbox": [63.0, 728.0, 180.0, 744.0]}], "type": "Section-header", "position": 7}, {"raw_context": [{"text": "Evaluation of TIA requires adequate vascular imaging.", "bbox": [63.0, 750.0, 379.0, 764.0]}, {"text": "Noninvasive imaging to screen for carotid stenosis (or", "bbox": [63.0, 767.0, 379.0, 781.0]}, {"text": "vertebral artery stenosis for patients with posterior circu¬", "bbox": [63.0, 783.0, 378.0, 797.0]}, {"text": "lation symptoms) should be a routine component of the", "bbox": [63.0, 799.0, 380.0, 813.0]}, {"text": "acute phase imaging for patients with TIAs. 11 , 16 A primary", "bbox": [63.0, 815.0, 380.0, 829.0]}, {"text": "goal of vascular imaging is to identify patients with high-", "bbox": [63.0, 830.0, 378.0, 844.0]}, {"text": "grade cervical carotid stenosis who might be candidates", "bbox": [63.0, 846.0, 380.0, 861.0]}, {"text": "for revascularization. 11 , 16 -18 Nearly half of patients with", "bbox": [63.0, 860.0, 380.0, 878.0]}, {"text": "transient neurological symptoms and DWI lesions have", "bbox": [63.0, 877.0, 380.0, 893.0]}, {"text": "stenosis or occlusion of either extracranial or intracra-", "bbox": [63.0, 895.0, 378.0, 910.0]}, {"text": "nial large arteries. 19 Symptomatic intracranial stenosis is", "bbox": [63.0, 911.0, 380.0, 925.0]}, {"text": "associated with higher risk of recurrent stroke, therefore", "bbox": [63.0, 926.0, 380.0, 941.0]}, {"text": "many centers include intracranial in addition to cervical", "bbox": [63.0, 943.0, 380.0, 957.0]}, {"text": "vascular imaging in the workup of patients with TIA. 20,21", "bbox": [63.0, 959.0, 378.0, 973.0]}], "type": "Text", "position": 8}, {"raw_context": [{"text": "Identification of symptomatic intracranial stenosis might", "bbox": [399.0, 654.0, 717.0, 669.0]}, {"text": "sway toward admission for centers with low risk toler-", "bbox": [399.0, 671.0, 715.0, 684.0]}, {"text": "ance, and potentially caution clinicians against overly", "bbox": [400.0, 687.0, 716.0, 701.0]}, {"text": "aggressive blood pressure reduction that might lead to", "bbox": [399.0, 702.0, 717.0, 716.0]}, {"text": "the recurrence of symptoms.", "bbox": [399.0, 719.0, 562.0, 733.0]}, {"text": "Multiple noninvasive techniques are available to", "bbox": [415.0, 735.0, 717.0, 749.0]}, {"text": "assess cervical carotid and intracranial vasculature", "bbox": [399.0, 750.0, 716.0, 764.0]}, {"text": "from the ED (Table 2). 22,23 Computed tomography angi-", "bbox": [399.0, 766.0, 715.0, 781.0]}, {"text": "ography (CTA) is the most widely accessible modality", "bbox": [399.0, 783.0, 716.0, 797.0]}, {"text": "in EDs and can be obtained rapidly in conjunction with", "bbox": [399.0, 799.0, 716.0, 813.0]}, {"text": "NCCT. CTA has a higher sensitivity and positive pre¬", "bbox": [399.0, 815.0, 715.0, 829.0]}, {"text": "dictive value than magnetic resonance angiography", "bbox": [399.0, 831.0, 716.0, 844.0]}, {"text": "(MRA) for detection of intracranial stenosis and occlu¬", "bbox": [399.0, 847.0, 715.0, 861.0]}, {"text": "sion, and is recommended over time-of-flight (without", "bbox": [399.0, 863.0, 717.0, 877.0]}, {"text": "contrast) MRA. 24,25 Further, CTA is considered safe", "bbox": [399.0, 877.0, 716.0, 894.0]}, {"text": "in patients with known chronic kidney disease and is", "bbox": [399.0, 894.0, 716.0, 910.0]}, {"text": "not associated with significant risk of acute kidney", "bbox": [399.0, 911.0, 716.0, 924.0]}, {"text": "injury. 26 Centers may still obtain a serum creatinine", "bbox": [399.0, 926.0, 716.0, 941.0]}, {"text": "before obtaining CTA, however, to establish baseline", "bbox": [399.0, 943.0, 716.0, 957.0]}, {"text": "renal function. For patients in whom the administration", "bbox": [399.0, 959.0, 716.0, 973.0]}], "type": "Text", "position": 10}, {"raw_context": [{"text": "TN 3M 3TATS  1V01", "bbox": [754.0, 117.0, 770.0, 194.0]}], "type": "Text", "position": 11}, {"raw_context": [{"text": "'9 funds I uo fd aro slemnoleds// qud mort bebeom", "bbox": [19.0, 547.0, 36.0, 779.0]}], "type": "Text", "position": 12}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/神经科/共识/2023 AHA科学声明：急诊科短暂性脑缺血发作的诊断、检查和风险降低(1).pdf", "page_num": 3}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": null, "type3": "无关文本#0#13# imaging capture. 15部分段落末尾，以及句末的数字问题无关噪声应用全文", "type4": "语意重复#1#1#Advantages and Limitations of Noninvasive Techniques Available to Assess Patients With TIA 22,22 Table 2.", "type5": null, "type6": "准确性#1#4#为表格内容杂乱\n有用性#12#13#TN 3M 3TATS  1V01和 '9 funds I uo fd aro slemnoleds// qud mort bebeom为页脚内容"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:41", "update_time": "2024-05-08 01:04:47"}
{"id": 1082547, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 738, "source_info": {"seq_id": "8c3b36eb-17e0-430f-861a-c53c84844b47", "title": null, "text": "【0】页码:6\n [1] . The panel's systematic review identified 21 studies evaluating the efficacy of radiotherapy for a total of 1222 men, with a cumulative mean 5-yr RFR of 78.6% after brachytherapy (for tumours >4 cm in size) and 55.2% after external beam radiation therapy [ 1 ]. Clinicians should be aware of the risk of understaging as a result of incisional biopsy followed by ablation versus complete resection [15,58].\n\n【1】 Treatment of locally advanced disease (T3–T4) 3.4.3.\n\n【2】For patients with cT3 disease with obvious involvement of the corpora cavernosa, partial amputation is the standard of care, with radical amputation and diversion of urination via a perineal urethrostomy reserved for patients in whom resection with a safe margin would result in an inability to void standing upright or without wetting the scrotum.\n\n【3】In cases of locally advanced and ulcerated cases that are resectable, flaps may be needed to cover the surgical defect [59] . For nonresectable tumours, induction chemotherapy offers the ability to downstage the disease and thereby facilitate surgical resection in responders. Two recent systematic reviews revealed pooled objective response rates of 57% (95% confidence interval [CI] 46–67%) for taxaneplatinum combinations and 54% (95% CI 31–76%) for nontaxane platinum combinations [60] at the cost of considerable toxicity. When a sufficient response for adequate resection is not achieved, or in patients not willing to undergo extensive surgery, (chemo-)radiotherapy is an option.\n\n【4】Table 4 lists recommendations for treatment of the primary tumour.\n\n【5】## Regional Ln Management 3.5.\n\n【6】\n 3.5.1.\n\n【7】cN1–N2 disease ILND remains the standard of care. A systematic review of the literature identified two templates used in clinical N1– 2 disease: Dasseler's original description of a radical ILND (rILND), and a single study describing fascial-sparing ILND.\n\n【8】The latter has comparable oncological outcomes to rILND, with 3- yr disease- free survival of 92.1% and a complication rate of 29.3% [61] .\n\n【9】rILND carries significant morbidity of 21-55% [62-65].\n\n【10】The complications most frequently reported in recent series were wound infections (2–43%), skin necrosis (3–50%), lymphoedema (3.1–30%), lymphocele formation (1.8–26%), and seroma (2.4–60%) [62,64–73] .\n\n【11】Minimally invasive approaches (videoendoscopic inguinal LND and robotassisted videoendoscopic inguinal LND) using rILND or fascial-sparing ILND templates may reduce morbidity. Narrative review suggests similar LN yields to those with open ILND, shorter hospital stays, and lower rates of wound complications, although lymphocele and readmission rates were equivalent [32,74-78] . Follow-up was short and predominantly used for staging as opposed to the approach for clinically node-positive disease.\n\n【12】The evidence in pN1–2 disease regarding the optimal timing of LN management is limited. Chipollini et al [79] examined early versus late (>3 mo after primary surgery) ILND in 84 patients with cN0 or cN+ disease. Subanalysis in the cN+ cohort for early versus late dissection failed to identify a statistically significant benefit (5-yr disease-\n\n【13】 Table 4 – Recommendations for treatment of the primary tumour\n\n【14】 Strength rating\n\n【15】\n amputation surgery.\n\n【16】 Topical therapy\n\n【17】 neoplasia (PeIN).\n\n【18】 Laser ablation\n\n【19】 with strict follow-up.\n\n【20】 of resection.\n\n【21】 and brachytherapy)\n\n【22】 partial amputation,\n\n【23】 Multimodal therapy\n responders, or chemoradiotherapy to patients with nonresectable advanced primary lesions and patients.\n\n【24】 with locally advanced disease who refuse surgical\n\n【25】 management\n\n【26】 specific survival [DSS] 31.8% vs 35.3%). In a study of 28 patients undergoing rILND stratified by time after treatment of the primary tumour (<6 mo vs >6 mo), Gulia et al. [67] observed 5-yr CSS of 91% versus 13% ( p = 0.007).\n\n【27】Prophylactic pelvic LND (pPLND) is a staging procedure that may identify candidates for adjuvant therapy, although it may provide a therapeutic benefit in selected patients. To help in identifying patients with pelvic LN metastasis in the absence of radiological evidence of LN involvement, several studies have evaluated potential predictive factors. The number of positive inguinal LNs (one to two vs three or more, with no extracapsular extension) was associated with positive pelvic LNs in 0–6.5% versus 33–67% of patients [80,81] . The presence of extracapsular spread was also consistently significantly associated with positive ipsilateral pelvic LN metastasis [80–83] . There is limited evidence of a therapeutic role of pPLND over surveillance or adjuvant radiotherapy. Djajadiningrat et al. [82] estimated 5-year DSS of 51% among patients treated with pPLND. Patients with positive pelvic nodes had significantly worse 5-yr", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "[1] . The panel's systematic review identified 21 studies", "bbox": [60.0, 87.0, 382.0, 101.0]}, {"text": "evaluating the efficacy of radiotherapy for a total of 1222", "bbox": [60.0, 102.0, 382.0, 116.0]}, {"text": "men, with a cumulative mean 5-yr RFR of 78.6% after", "bbox": [61.0, 117.0, 383.0, 132.0]}, {"text": "brachytherapy (for tumours >4 cm in size) and 55.2% after", "bbox": [61.0, 134.0, 382.0, 147.0]}, {"text": "external beam radiation therapy [ 1 ]. Clinicians should be", "bbox": [61.0, 149.0, 383.0, 163.0]}, {"text": "aware of the risk of understaging as a result of incisional", "bbox": [61.0, 164.0, 383.0, 178.0]}, {"text": "biopsy followed by ablation versus complete resection", "bbox": [61.0, 180.0, 383.0, 193.0]}, {"text": "[15,58].", "bbox": [60.0, 195.0, 105.0, 210.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "Treatment of locally advanced disease (T3–T4)", "bbox": [109.0, 224.0, 339.0, 238.0]}, {"text": "3.4.3.", "bbox": [62.0, 226.0, 89.0, 238.0]}, {"text": "For patients with cT3 disease with obvious involvement of", "bbox": [61.0, 240.0, 383.0, 253.0]}, {"text": "the corpora cavernosa, partial amputation is the standard", "bbox": [61.0, 255.0, 383.0, 269.0]}, {"text": "of care, with radical amputation and diversion of urination", "bbox": [60.0, 270.0, 383.0, 284.0]}, {"text": "via a perineal urethrostomy reserved for patients in whom", "bbox": [60.0, 285.0, 383.0, 299.0]}, {"text": "resection with a safe margin would result in an inability", "bbox": [61.0, 300.0, 383.0, 314.0]}, {"text": "to void standing upright or without wetting the scrotum.", "bbox": [61.0, 315.0, 382.0, 330.0]}, {"text": "In cases of locally advanced and ulcerated cases that are", "bbox": [61.0, 331.0, 382.0, 345.0]}, {"text": "resectable, flaps may be needed to cover the surgical defect", "bbox": [61.0, 346.0, 383.0, 360.0]}, {"text": "[59] . For nonresectable tumours, induction chemotherapy", "bbox": [61.0, 361.0, 383.0, 375.0]}, {"text": "offers the ability to downstage the disease and thereby", "bbox": [60.0, 377.0, 382.0, 390.0]}, {"text": "facilitate surgical resection in responders. Two recent sys-", "bbox": [61.0, 391.0, 382.0, 405.0]}, {"text": "tematic reviews revealed pooled objective response rates", "bbox": [61.0, 406.0, 383.0, 421.0]}, {"text": "of 57% (95% confidence interval [CI] 46–67%) for taxane-", "bbox": [60.0, 423.0, 381.0, 436.0]}, {"text": "platinum combinations and 54% (95% CI 31–76%) for non-", "bbox": [61.0, 437.0, 382.0, 451.0]}, {"text": "taxane platinum combinations [60] at the cost of consider-", "bbox": [61.0, 453.0, 382.0, 467.0]}, {"text": "able toxicity. When a sufficient response for adequate resec-", "bbox": [61.0, 468.0, 382.0, 482.0]}, {"text": "tion is not achieved, or in patients not willing to undergo", "bbox": [61.0, 483.0, 383.0, 497.0]}, {"text": "extensive surgery, (chemo-)radiotherapy is an option.", "bbox": [61.0, 498.0, 353.0, 513.0]}, {"text": "Table 4 lists recommendations for treatment of the pri-", "bbox": [78.0, 515.0, 381.0, 528.0]}, {"text": "mary tumour.", "bbox": [61.0, 530.0, 138.0, 543.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": "Regional LN management", "bbox": [101.0, 558.0, 229.0, 573.0]}, {"text": "3.5.", "bbox": [62.0, 560.0, 80.0, 572.0]}], "type": "Section-header", "position": 5}, {"raw_context": [{"text": "3.5.1.", "bbox": [62.0, 583.0, 89.0, 594.0]}, {"text": "cN1–N2 disease", "bbox": [109.0, 583.0, 188.0, 594.0]}, {"text": "ILND remains the standard of care. A systematic review of", "bbox": [60.0, 596.0, 383.0, 610.0]}, {"text": "the literature identified two templates used in clinical N1–", "bbox": [60.0, 612.0, 382.0, 626.0]}, {"text": "2 disease: Dasseler's original description of a radical ILND", "bbox": [61.0, 628.0, 383.0, 641.0]}, {"text": "(rILND), and a single study describing fascial-sparing ILND.", "bbox": [60.0, 643.0, 382.0, 656.0]}, {"text": "The latter has comparable oncological outcomes to rILND,", "bbox": [61.0, 657.0, 383.0, 672.0]}, {"text": "with 3- yr disease- free survival of 92.1% and a complication", "bbox": [61.0, 674.0, 383.0, 687.0]}, {"text": "rate of 29.3% [61] .", "bbox": [62.0, 690.0, 160.0, 702.0]}, {"text": "rILND carries significant morbidity of 21-55% [62-65].", "bbox": [77.0, 703.0, 382.0, 718.0]}, {"text": "The complications most frequently reported in recent series", "bbox": [61.0, 720.0, 383.0, 733.0]}, {"text": "were wound infections (2–43%), skin necrosis (3–50%), lym-", "bbox": [62.0, 736.0, 382.0, 748.0]}, {"text": "phoedema (3.1–30%), lymphocele formation (1.8–26%), and", "bbox": [61.0, 750.0, 383.0, 764.0]}, {"text": "seroma", "bbox": [62.0, 766.0, 105.0, 778.0]}, {"text": "(2.4–60%)", "bbox": [115.0, 766.0, 177.0, 778.0]}, {"text": "[62,64–73] .", "bbox": [185.0, 766.0, 253.0, 779.0]}, {"text": "Minimally", "bbox": [262.0, 766.0, 324.0, 778.0]}, {"text": "invasive", "bbox": [334.0, 766.0, 383.0, 778.0]}, {"text": "approaches (videoendoscopic inguinal LND and robot-", "bbox": [61.0, 780.0, 382.0, 794.0]}, {"text": "assisted videoendoscopic inguinal LND) using rILND or", "bbox": [61.0, 795.0, 383.0, 810.0]}, {"text": "fascial-sparing ILND templates may reduce morbidity. Nar-", "bbox": [61.0, 811.0, 382.0, 825.0]}, {"text": "rative review suggests similar LN yields to those with open", "bbox": [61.0, 826.0, 383.0, 840.0]}, {"text": "ILND, shorter hospital stays, and lower rates of wound com-", "bbox": [61.0, 841.0, 382.0, 856.0]}, {"text": "plications, although lymphocele and readmission rates were", "bbox": [61.0, 856.0, 383.0, 871.0]}, {"text": "equivalent [32,74-78] . Follow-up was short and predomi-", "bbox": [60.0, 871.0, 382.0, 886.0]}, {"text": "nantly used for staging as opposed to the approach for clin-", "bbox": [61.0, 886.0, 382.0, 901.0]}, {"text": "ically node-positive disease.", "bbox": [62.0, 904.0, 213.0, 916.0]}, {"text": "The evidence in pN1–2 disease regarding the optimal", "bbox": [77.0, 917.0, 383.0, 931.0]}, {"text": "timing of LN management is limited. Chipollini et al [79]", "bbox": [61.0, 932.0, 383.0, 947.0]}, {"text": "examined early versus late (>3 mo after primary surgery)", "bbox": [61.0, 948.0, 384.0, 962.0]}, {"text": "ILND in 84 patients with cN0 or cN+ disease. Subanalysis", "bbox": [61.0, 963.0, 383.0, 977.0]}, {"text": "in the cN+ cohort for early versus late dissection failed to", "bbox": [61.0, 978.0, 383.0, 993.0]}, {"text": "identify a statistically significant benefit (5-yr disease-", "bbox": [61.0, 994.0, 381.0, 1008.0]}], "type": "Text", "position": 6}, {"raw_context": [{"text": "Table 4 – Recommendations for treatment of the primary tumour", "bbox": [411.0, 89.0, 701.0, 100.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "Strength", "bbox": [662.0, 110.0, 702.0, 120.0]}, {"text": "rating", "bbox": [663.0, 121.0, 691.0, 133.0]}], "type": "Table", "position": 10}, {"raw_context": [{"text": "amputation surgery.", "bbox": [427.0, 195.0, 511.0, 206.0]}], "type": "Text", "position": 12}, {"raw_context": [{"text": "Topical therapy", "bbox": [416.0, 206.0, 484.0, 217.0]}], "type": "Text", "position": 13}, {"raw_context": [{"text": "neoplasia (PeIN).", "bbox": [428.0, 240.0, 497.0, 252.0]}], "type": "Text", "position": 14}, {"raw_context": [{"text": "Laser ablation", "bbox": [414.0, 286.0, 477.0, 297.0]}], "type": "Text", "position": 15}, {"raw_context": [{"text": "with strict follow-up.", "bbox": [427.0, 378.0, 516.0, 387.0]}], "type": "Text", "position": 16}, {"raw_context": [{"text": "of resection.", "bbox": [427.0, 413.0, 479.0, 421.0]}], "type": "Text", "position": 18}, {"raw_context": [{"text": "and brachytherapy)", "bbox": [427.0, 457.0, 515.0, 468.0]}], "type": "Text", "position": 19}, {"raw_context": [{"text": "partial amputation,", "bbox": [428.0, 572.0, 508.0, 583.0]}], "type": "Text", "position": 22}, {"raw_context": [{"text": "Multimodal therapy", "bbox": [415.0, 605.0, 504.0, 617.0]}], "type": "Text", "position": 23}, {"raw_context": [{"text": "responders, or chemoradiotherapy to patients with", "bbox": [428.0, 629.0, 638.0, 640.0]}, {"text": "nonresectable advanced primary lesions and patients.", "bbox": [427.0, 639.0, 645.0, 652.0]}], "type": "List-item", "position": 24}, {"raw_context": [{"text": "with locally advanced disease who refuse surgical", "bbox": [427.0, 652.0, 633.0, 662.0]}], "type": "Text", "position": 25}, {"raw_context": [{"text": "management", "bbox": [429.0, 665.0, 479.0, 674.0]}], "type": "Text", "position": 26}, {"raw_context": [{"text": "specific survival [DSS] 31.8% vs 35.3%). In a study of 28", "bbox": [403.0, 701.0, 726.0, 715.0]}, {"text": "patients undergoing rILND stratified by time after treatment", "bbox": [402.0, 716.0, 726.0, 729.0]}, {"text": "of the primary tumour (<6 mo vs >6 mo), Gulia et al. [67]", "bbox": [402.0, 731.0, 726.0, 745.0]}, {"text": "observed 5-yr CSS of 91% versus 13% ( p = 0.007).", "bbox": [402.0, 747.0, 668.0, 761.0]}, {"text": "Prophylactic pelvic LND (pPLND) is a staging procedure", "bbox": [419.0, 762.0, 726.0, 776.0]}, {"text": "that may identify candidates for adjuvant therapy, although", "bbox": [402.0, 777.0, 727.0, 792.0]}, {"text": "it may provide a therapeutic benefit in selected patients. To", "bbox": [402.0, 793.0, 727.0, 807.0]}, {"text": "help in identifying patients with pelvic LN metastasis in the", "bbox": [402.0, 809.0, 726.0, 822.0]}, {"text": "absence of radiological evidence of LN involvement, several", "bbox": [403.0, 823.0, 726.0, 838.0]}, {"text": "studies have evaluated potential predictive factors. The", "bbox": [403.0, 840.0, 726.0, 853.0]}, {"text": "number of positive inguinal LNs (one to two vs three or", "bbox": [402.0, 855.0, 726.0, 868.0]}, {"text": "more, with no extracapsular extension) was associated with", "bbox": [402.0, 870.0, 727.0, 884.0]}, {"text": "positive pelvic LNs in 0–6.5% versus 33–67% of patients", "bbox": [403.0, 885.0, 726.0, 899.0]}, {"text": "[80,81] . The presence of extracapsular spread was also con-", "bbox": [402.0, 900.0, 725.0, 914.0]}, {"text": "sistently significantly associated with positive ipsilateral", "bbox": [403.0, 915.0, 726.0, 930.0]}, {"text": "pelvic LN metastasis [80–83] . There is limited evidence of", "bbox": [403.0, 931.0, 726.0, 945.0]}, {"text": "a therapeutic role of pPLND over surveillance or adjuvant", "bbox": [402.0, 946.0, 726.0, 959.0]}, {"text": "radiotherapy. Djajadiningrat et al. [82] estimated 5-year", "bbox": [402.0, 961.0, 726.0, 976.0]}, {"text": "DSS of 51% among patients treated with pPLND. Patients", "bbox": [402.0, 976.0, 726.0, 991.0]}, {"text": "with positive pelvic nodes had significantly worse 5-yr", "bbox": [403.0, 991.0, 726.0, 1006.0]}], "type": "Text", "position": 27}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/泌尿外科/2023 EAU／ASCO指南：阴茎癌（更新版）.pdf", "page_num": 6}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "序号格式不一致#1#1#...advanced disease (T3–T4) 3.4.3.  序号应该在前\n序号格式不一致#5#5#Regional Ln Management 3.5. 序号应该在前\n多余换行#7#7#cN1–N2 disease与上面6的内容联接\n缺少换行#7#7#ILND remains the standard of 应该另起一行\n多余换行#26#26# specific survival [DSS] 31.8% vs 35.3%)...与上面12段内容联接", "type3": "无关文本#0#27#[1]  类似的[  ]类无关引用过多", "type4": null, "type5": null, "type6": "准确性#13#25#表格的内容，但内容杂乱不全"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:41", "update_time": "2024-05-07 22:59:40"}
{"id": 1082546, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 738, "source_info": {"seq_id": "1fac458b-8297-49b6-a848-f5d7cab3be55", "title": null, "text": "【0】页码:17\n metastatic liver diseases with yttrium-90 resin microspheres.\n\n【1】Eur J Nucl Med Mol Imaging, 2021.\n\n【2】94. Levillain H, et al. Personalised radioembolization improves outcomes in refractory intra-hepatic cholangiocarcinoma: a multicenter study. Eur J Nucl Med Mol Imaging. 2019;46(11):2270–9.\n\n【3】195.\n\n【4】van den Hoven AF, et al. Insights into the dose-response relationship of radioembolization with resin 90y-microspheres: a prospective cohort study in patients with colorectal cancer liver metastases. J Nucl Med. 2016;57(7):1014–9.\n\n【5】96.\n\n【6】Bastiaannet R, et al. First evidence for a dose-response relationship in patients treated with (166)Ho radioembolization: a prospective study. J Nucl Med. 2020;61(4):608–12.\n\n【7】97.\n\n【8】van Roekel C, et  al. Dose-effect relationships of (166) Ho radioembolization in colorectal cancer. J Nucl Med.\n\n【9】2021;62(2):272–9.\n\n【10】98.\n\n【11】Vauthey JN, et al. Body surface area and body weight predict total liver volume in Western adults. Liver Transpl. 2002;8(3):233-40.\n\n【12】99.\n\n【13】Ahmadzadehfar H, et al. Evaluation of the delivered activity of yttrium-90 resin microspheres using sterile water and 5% glucose during administration. EJNMMI Res. 2015;5(1):54.\n\n【14】100.\n\n【15】Giammarile F, et al. EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. Eur J Nucl Med Mol Imaging.\n\n【16】2011;38(7):1393–406.\n\n【17】101. Lhommel R, et al. Feasibility of 90Y TOF PET-based dosimetry in liver metastasis therapy using SIR-spheres. Eur J Nucl Med Mol Imaging. 2010;37(9):1654 – 62.\n\n【18】102.\n\n【19】Selwyn RG, et al. A new internal pair production branching ratio of 90Y: the development of a non-destructive assay for 90Y and 90Sr. Appl Radiat Isot. 2007;65(3):318–27.\n\n【20】103.\n\n【21】Kesim S, et al. Unexpected radiation pneumonitis after SIRT with significant decrease in DLCO with internal radiation exposure: a case report. BMC Med Imaging. 2020;20(1):52.\n\n【22】104.\n\n【23】Auditore L, et al. Monte Carlo (90)Y PET/CT dosimetry of unexpected focal radiation-induced lung damage after hepatic radioembolisation. Phys Med Biol. 2020;65(23):235014.\n\n【24】105.\n\n【25】Scott NP, McGowan DR. Optimising quantitative (90)Y PET imaging: an investigation into the effects of sean length and Bayesian penalised likelihood reconstruction, EJNMMI Res.\n\n【26】2019;9(1):40.\n\n【27】106.\n\n【28】Elschot M, et al. Quantitative evaluation of scintillation camera imaging characteristics of isotopes used in liver radioembolization. PLoS One. 2011;6(11):e26174.\n\n【29】107.\n\n【30】van de Maat GH, et al. MRI-based biodistribution assessment of holmium-166 poly(L-lactic acid) microspheres after radioembolisation. Eur Radiol. 2013;23(3):827–35.\n\n【31】108.\n\n【32】John, L., Discharge of patients undergoing treatment with radioactive substances , A.R.P.a.N.S. Agency, Editor. 2002: Australia 109. Prince JF, et al. Radiation emission from patients treated with holmium-166 radioembolization. J Vasc Interv Radiol.\n\n【33】2014;25(12):1956–1963e1.\n\n【34】110.\n\n【35】Laffont S, et al. Occupational radiation exposure of medical staff performing (9)(0)Y-loaded microsphere radioembolization. Eur J Nucl Med Mol Imaging. 2016;43(5):824–31.\n\n【36】111.\n\n【37】Taleb J, et al. Radiation dose measurements for staff members involved in holmium-166 preclinical trial. Radiat Meas.\n\n【38】2013;58:75–8.\n\n【39】Gulec SA, Mesoloras G, Stabin M. Dosimetric techniques in 112.\n\n【40】90Y-microsphere therapy of liver cancer: the MIRD equations for dose calculations. J Nucl Med. 2006;47(7):1209–11.\n\n【41】113. Metyko J, et al. Long-lived impurities of 90Y-labeled microspheres, TheraSphere and SIR-spheres, and the impact on patient\n\n【42】 dose and waste management. Health Phys. 2012;103(5 Suppl 3):S204 – 8.\n\n【43】Elsayed M, et al. Incidence of radioembolization-induced liver 114.\n\n【44】disease and liver toxicity following repeat 90Y-radioembolization: outcomes at a large tertiary care center. Clin Nucl Med.\n\n【45】2020;45(2):100 – 4.\n\n【46】Lam MG, et al. Safety of repeated yttrium-90 radioembolization.\n\n【47】115.\n\n【48】Cardiovasc Intervent Radiol. 2013;36(5):1320–8.\n\n【49】Masthoff M, et al. Repeated radioembolization in advanced liver 116.\n\n【50】cancer. Ann Transl Med. 2020;8(17):1055.\n\n【51】Zarva A, et al. Safety of repeated radioembolizations in patients 117.\n\n【52】with advanced primary and secondary liver tumors and progressive disease after first selective internal radiotherapy. J Nucl Med. 2014;55(3):360–6.\n\n【53】Prajapati HJ, et al. mRECIST and EASL responses at early 118.\n\n【54】time point by contrast-enhanced dynamic MRI predict survivalin patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE). Ann Oncol. 2013;24(4):965–73.\n\n【55】119.\n\n【56】Lencioni R, Llovet JM.  Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis.\n\n【57】2010;30(1):52–60.\n\n【58】Shim JH, et al. Which response criteria best help predict survival 120.\n\n【59】of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models. Radiology.\n\n【60】2012;262(2):708–18.\n\n【61】121.\n\n【62】Gillmore R, et al. EASL, and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. J Hepatol.\n\n【63】2011;55(6):1309–16.\n\n【64】122.\n\n【65】European Association for the Study of the Liver. Electronic address, e.e.e. and L. European Association for the Study of the, EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol, 2018. 69(1): p. 182–236.\n\n【66】123.\n\n【67】Pollock RF, et al. Association between objective response rate and overall survival in metastatic neuroendocrine tumors treated with radioembolization: a systematic literature review and regression analysis. Expert Rev Anticancer Ther. 2020;20(11):997–1009.\n\n【68】124.\n\n【69】Braat A, et al. Radioembolization with (90)Y resin microspheres of neuroendocrine liver metastases: international multicenter study on efficacy and toxicity. Cardiovasc Intervent Radiol.\n\n【70】2019;42(3):413–25.\n\n【71】125.\n\n【72】Memon K, et al. Radioembolization for neuroendocrine liver metastases: safety, imaging, and long-term outcomes. Int J Radiat Oncol Biol Phys. 2012;83(3):887–94.\n\n【73】Beuzit L, et al. Comparison of Choi criteria and response evalu- 126.\n\n【74】ation criteria in solid tumors (RECIST) for intrahepatic cholangiocarcinoma treated with glass-microspheres yurium-90 selective internal radiation therapy (SIRT). Eur J Radiol.\n\n【75】2016;85(8):1445–52.\n\n【76】127.\n\n【77】Camacho JC, et al. Modified response evaluation criteria in solid tumors and European Association for the Study of the liver criteria using delayed-phase imaging at an early time point predict survival in patients with unresectable intrahepatic cholangiocarcinoma following yttrium-90 radioembolization. J Vasc Interv Radiol. 2014;25(2):256–65.\n\n【78】128.\n\n【79】Akinwande O, et al. Comparison of tumor response assessment methods in patients with metastatic colorectal cancer after locoregional therapy. J Surg Oncol. 2016;113(4):443–8.\n\n【80】Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "metastatic liver diseases with yttrium-90 resin microspheres.", "bbox": [93.0, 73.0, 385.0, 87.0]}, {"text": "Eur J Nucl Med Mol Imaging, 2021.", "bbox": [93.0, 88.0, 258.0, 101.0]}, {"text": "94. Levillain H, et al. Personalised radioembolization improves out-", "bbox": [72.0, 100.0, 385.0, 115.0]}, {"text": "comes in refractory intra-hepatic cholangiocarcinoma: a multi-", "bbox": [93.0, 115.0, 386.0, 128.0]}, {"text": "center study. Eur J Nucl Med Mol Imaging. 2019;46(11):2270–9.", "bbox": [93.0, 128.0, 385.0, 140.0]}, {"text": "195.", "bbox": [72.0, 140.0, 89.0, 152.0]}, {"text": "van den Hoven AF, et al. Insights into the dose-response rela-", "bbox": [91.0, 141.0, 386.0, 153.0]}, {"text": "tionship of radioembolization with resin 90y-microspheres: a", "bbox": [93.0, 155.0, 390.0, 167.0]}, {"text": "prospective cohort study in patients with colorectal cancer liver", "bbox": [93.0, 168.0, 387.0, 181.0]}, {"text": "metastases. J Nucl Med. 2016;57(7):1014–9.", "bbox": [93.0, 181.0, 300.0, 194.0]}, {"text": "96.", "bbox": [72.0, 195.0, 91.0, 206.0]}, {"text": "Bastiaannet R, et al. First evidence for a dose-response relation-", "bbox": [90.0, 195.0, 386.0, 206.0]}, {"text": "ship in patients treated with (166)Ho radioembolization: a pro-", "bbox": [93.0, 208.0, 385.0, 220.0]}, {"text": "spective study. J Nucl Med. 2020;61(4):608–12.", "bbox": [93.0, 222.0, 314.0, 233.0]}, {"text": "97.", "bbox": [72.0, 234.0, 89.0, 247.0]}, {"text": "van Roekel C, et  al. Dose-effect relationships of (166)", "bbox": [92.0, 235.0, 387.0, 247.0]}, {"text": "Ho radioembolization in colorectal cancer. J Nucl Med.", "bbox": [93.0, 247.0, 386.0, 262.0]}, {"text": "2021;62(2):272–9.", "bbox": [93.0, 261.0, 181.0, 273.0]}, {"text": "98.", "bbox": [72.0, 274.0, 88.0, 286.0]}, {"text": "Vauthey JN, et al. Body surface area and body weight predict total", "bbox": [90.0, 274.0, 387.0, 287.0]}, {"text": "liver volume in Western adults. Liver Transpl. 2002;8(3):233-40.", "bbox": [93.0, 289.0, 385.0, 300.0]}, {"text": "99.", "bbox": [72.0, 300.0, 89.0, 312.0]}, {"text": "Ahmadzadehfar H, et al. Evaluation of the delivered activity of", "bbox": [92.0, 302.0, 387.0, 314.0]}, {"text": "yttrium-90 resin microspheres using sterile water and 5% glucose", "bbox": [93.0, 314.0, 387.0, 327.0]}, {"text": "during administration. EJNMMI Res. 2015;5(1):54.", "bbox": [93.0, 327.0, 331.0, 340.0]}, {"text": "100.", "bbox": [67.0, 341.0, 91.0, 353.0]}, {"text": "Giammarile F, et al. EANM procedure guideline for the treat-", "bbox": [89.0, 341.0, 386.0, 354.0]}, {"text": "ment of liver cancer and liver metastases with intra-arte-", "bbox": [93.0, 355.0, 385.0, 367.0]}, {"text": "rial radioactive compounds. Eur J Nucl Med Mol Imaging.", "bbox": [93.0, 367.0, 384.0, 382.0]}, {"text": "2011;38(7):1393–406.", "bbox": [93.0, 381.0, 197.0, 392.0]}, {"text": "101. Lhommel R, et al. Feasibility of 90Y TOF PET-based dosimetry", "bbox": [67.0, 394.0, 385.0, 407.0]}, {"text": "in liver metastasis therapy using SIR-spheres. Eur J Nucl Med", "bbox": [93.0, 408.0, 387.0, 421.0]}, {"text": "Mol Imaging. 2010;37(9):1654 – 62.", "bbox": [93.0, 422.0, 256.0, 434.0]}, {"text": "102.", "bbox": [67.0, 435.0, 89.0, 447.0]}, {"text": "Selwyn RG, et al. A new internal pair production branching ratio", "bbox": [91.0, 435.0, 387.0, 448.0]}, {"text": "of 90Y: the development of a non-destructive assay for 90Y and", "bbox": [93.0, 448.0, 387.0, 459.0]}, {"text": "90Sr. Appl Radiat Isot. 2007;65(3):318–27.", "bbox": [93.0, 461.0, 293.0, 473.0]}, {"text": "103.", "bbox": [67.0, 475.0, 89.0, 487.0]}, {"text": "Kesim S, et al. Unexpected radiation pneumonitis after SIRT with", "bbox": [91.0, 475.0, 387.0, 487.0]}, {"text": "significant decrease in DLCO with internal radiation exposure: a", "bbox": [93.0, 488.0, 387.0, 501.0]}, {"text": "case report. BMC Med Imaging. 2020;20(1):52.", "bbox": [93.0, 502.0, 316.0, 513.0]}, {"text": "104.", "bbox": [67.0, 515.0, 88.0, 526.0]}, {"text": "Auditore L, et al. Monte Carlo (90)Y PET/CT dosimetry of", "bbox": [92.0, 515.0, 387.0, 527.0]}, {"text": "unexpected focal radiation-induced lung damage after hepatic", "bbox": [93.0, 528.0, 386.0, 540.0]}, {"text": "radioembolisation. Phys Med Biol. 2020;65(23):235014.", "bbox": [93.0, 541.0, 355.0, 553.0]}, {"text": "105.", "bbox": [67.0, 554.0, 88.0, 567.0]}, {"text": "Scott NP, McGowan DR. Optimising quantitative (90)Y PET", "bbox": [92.0, 555.0, 387.0, 567.0]}, {"text": "imaging: an investigation into the effects of sean length and", "bbox": [93.0, 567.0, 387.0, 580.0]}, {"text": "Bayesian penalised likelihood reconstruction, EJNMMI Res.", "bbox": [93.0, 581.0, 384.0, 593.0]}, {"text": "2019;9(1):40.", "bbox": [93.0, 594.0, 158.0, 607.0]}, {"text": "106.", "bbox": [67.0, 608.0, 91.0, 620.0]}, {"text": "Elschot M, et al. Quantitative evaluation of scintillation camera", "bbox": [90.0, 608.0, 388.0, 620.0]}, {"text": "imaging characteristics of isotopes used in liver radioemboliza-", "bbox": [93.0, 621.0, 385.0, 633.0]}, {"text": "tion. PLoS One. 2011;6(11):e26174.", "bbox": [93.0, 634.0, 262.0, 647.0]}, {"text": "107.", "bbox": [67.0, 647.0, 89.0, 660.0]}, {"text": "van de Maat GH, et al. MRI-based biodistribution assessment of", "bbox": [92.0, 647.0, 387.0, 660.0]}, {"text": "holmium-166 poly(L-lactic acid) microspheres after radioembo-", "bbox": [93.0, 662.0, 385.0, 674.0]}, {"text": "lisation. Eur Radiol. 2013;23(3):827–35.", "bbox": [93.0, 675.0, 280.0, 687.0]}, {"text": "108.", "bbox": [67.0, 688.0, 89.0, 700.0]}, {"text": "John, L., Discharge of patients undergoing treatment with radio-", "bbox": [91.0, 688.0, 386.0, 700.0]}, {"text": "active substances , A.R.P.a.N.S. Agency, Editor. 2002: Australia", "bbox": [93.0, 701.0, 387.0, 713.0]}, {"text": "109. Prince JF, et al. Radiation emission from patients treated", "bbox": [67.0, 714.0, 387.0, 727.0]}, {"text": "with holmium-166 radioembolization. J Vasc Interv Radiol.", "bbox": [93.0, 728.0, 385.0, 741.0]}, {"text": "2014;25(12):1956–1963e1.", "bbox": [93.0, 742.0, 220.0, 754.0]}, {"text": "110.", "bbox": [67.0, 755.0, 91.0, 767.0]}, {"text": "Laffont S, et al. Occupational radiation exposure of medical staff", "bbox": [90.0, 755.0, 387.0, 768.0]}, {"text": "performing (9)(0)Y-loaded microsphere radioembolization. Eur", "bbox": [93.0, 768.0, 387.0, 779.0]}, {"text": "J Nucl Med Mol Imaging. 2016;43(5):824–31.", "bbox": [93.0, 781.0, 308.0, 793.0]}, {"text": "111.", "bbox": [67.0, 795.0, 88.0, 807.0]}, {"text": "Taleb J, et al. Radiation dose measurements for staff mem-", "bbox": [93.0, 795.0, 385.0, 807.0]}, {"text": "bers involved in holmium-166 preclinical trial. Radiat Meas.", "bbox": [93.0, 807.0, 385.0, 821.0]}, {"text": "2013;58:75–8.", "bbox": [93.0, 821.0, 162.0, 833.0]}, {"text": "Gulec SA, Mesoloras G, Stabin M. Dosimetric techniques in", "bbox": [91.0, 834.0, 388.0, 847.0]}, {"text": "112.", "bbox": [67.0, 835.0, 89.0, 847.0]}, {"text": "90Y-microsphere therapy of liver cancer: the MIRD equations", "bbox": [93.0, 848.0, 388.0, 860.0]}, {"text": "for dose calculations. J Nucl Med. 2006;47(7):1209–11.", "bbox": [93.0, 862.0, 351.0, 873.0]}, {"text": "113. Metyko J, et al. Long-lived impurities of 90Y-labeled micro-", "bbox": [67.0, 874.0, 385.0, 887.0]}, {"text": "spheres, TheraSphere and SIR-spheres, and the impact on patient", "bbox": [93.0, 887.0, 387.0, 901.0]}], "type": "Text", "position": 1}, {"raw_context": [{"text": "dose and waste management. Health Phys. 2012;103(5 Suppl", "bbox": [433.0, 74.0, 727.0, 87.0]}, {"text": "3):S204 – 8.", "bbox": [435.0, 87.0, 485.0, 100.0]}, {"text": "Elsayed M, et al. Incidence of radioembolization-induced liver", "bbox": [431.0, 100.0, 726.0, 114.0]}, {"text": "114.", "bbox": [407.0, 101.0, 430.0, 113.0]}, {"text": "disease and liver toxicity following repeat 90Y-radioemboliza-", "bbox": [433.0, 114.0, 725.0, 126.0]}, {"text": "tion: outcomes at a large tertiary care center. Clin Nucl Med.", "bbox": [433.0, 128.0, 726.0, 140.0]}, {"text": "2020;45(2):100 – 4.", "bbox": [435.0, 141.0, 519.0, 153.0]}, {"text": "Lam MG, et al. Safety of repeated yttrium-90 radioembolization.", "bbox": [432.0, 152.0, 726.0, 167.0]}, {"text": "115.", "bbox": [406.0, 154.0, 428.0, 167.0]}, {"text": "Cardiovasc Intervent Radiol. 2013;36(5):1320–8.", "bbox": [432.0, 167.0, 661.0, 181.0]}, {"text": "Masthoff M, et al. Repeated radioembolization in advanced liver", "bbox": [433.0, 180.0, 727.0, 193.0]}, {"text": "116.", "bbox": [408.0, 181.0, 428.0, 193.0]}, {"text": "cancer. Ann Transl Med. 2020;8(17):1055.", "bbox": [433.0, 194.0, 630.0, 206.0]}, {"text": "Zarva A, et al. Safety of repeated radioembolizations in patients", "bbox": [432.0, 207.0, 727.0, 220.0]}, {"text": "117.", "bbox": [408.0, 209.0, 428.0, 220.0]}, {"text": "with advanced primary and secondary liver tumors and progres-", "bbox": [434.0, 221.0, 726.0, 233.0]}, {"text": "sive disease after first selective internal radiotherapy. J Nucl", "bbox": [433.0, 234.0, 727.0, 247.0]}, {"text": "Med. 2014;55(3):360–6.", "bbox": [434.0, 247.0, 547.0, 260.0]}, {"text": "Prajapati HJ, et al. mRECIST and EASL responses at early", "bbox": [432.0, 260.0, 727.0, 273.0]}, {"text": "118.", "bbox": [408.0, 261.0, 428.0, 273.0]}, {"text": "time point by contrast-enhanced dynamic MRI predict survival-", "bbox": [433.0, 275.0, 727.0, 287.0]}, {"text": "in patients with unresectable hepatocellular carcinoma (HCC)", "bbox": [433.0, 289.0, 727.0, 300.0]}, {"text": "treated by doxorubicin drug-eluting beads transarterial chem-", "bbox": [433.0, 301.0, 725.0, 313.0]}, {"text": "oembolization (DEB TACE). Ann Oncol. 2013;24(4):965–73.", "bbox": [433.0, 314.0, 721.0, 326.0]}, {"text": "119.", "bbox": [408.0, 328.0, 429.0, 340.0]}, {"text": "Lencioni R, Llovet JM.  Modified RECIST (mRECIST)", "bbox": [432.0, 327.0, 727.0, 340.0]}, {"text": "assessment for hepatocellular carcinoma. Semin Liver Dis.", "bbox": [434.0, 341.0, 725.0, 354.0]}, {"text": "2010;30(1):52–60.", "bbox": [435.0, 355.0, 520.0, 367.0]}, {"text": "Shim JH, et al. Which response criteria best help predict survival", "bbox": [432.0, 366.0, 728.0, 382.0]}, {"text": "120.", "bbox": [408.0, 367.0, 430.0, 380.0]}, {"text": "of patients with hepatocellular carcinoma following chemoembo-", "bbox": [432.0, 381.0, 725.0, 392.0]}, {"text": "lization? A validation study of old and new models. Radiology.", "bbox": [433.0, 394.0, 726.0, 407.0]}, {"text": "2012;262(2):708–18.", "bbox": [435.0, 408.0, 531.0, 420.0]}, {"text": "121.", "bbox": [407.0, 421.0, 429.0, 434.0]}, {"text": "Gillmore R, et al. EASL, and mRECIST responses are inde-", "bbox": [432.0, 421.0, 726.0, 434.0]}, {"text": "pendent prognostic factors for survival in hepatocellular can-", "bbox": [433.0, 434.0, 725.0, 446.0]}, {"text": "cer patients treated with transarterial embolization. J Hepatol.", "bbox": [433.0, 448.0, 726.0, 459.0]}, {"text": "2011;55(6):1309–16.", "bbox": [434.0, 461.0, 532.0, 473.0]}, {"text": "122.", "bbox": [407.0, 472.0, 428.0, 487.0]}, {"text": "European Association for the Study of the Liver. Electronic", "bbox": [432.0, 473.0, 726.0, 487.0]}, {"text": "address, e.e.e. and L. European Association for the Study of the,", "bbox": [434.0, 487.0, 726.0, 501.0]}, {"text": "EASL clinical practice guidelines: management of hepatocellular", "bbox": [434.0, 501.0, 726.0, 513.0]}, {"text": "carcinoma. J Hepatol, 2018. 69(1): p. 182–236.", "bbox": [433.0, 514.0, 651.0, 526.0]}, {"text": "123.", "bbox": [408.0, 528.0, 428.0, 539.0]}, {"text": "Pollock RF, et al. Association between objective response rate and", "bbox": [432.0, 528.0, 727.0, 540.0]}, {"text": "overall survival in metastatic neuroendocrine tumors treated with", "bbox": [433.0, 542.0, 727.0, 553.0]}, {"text": "radioembolization: a systematic literature review and regression", "bbox": [433.0, 554.0, 727.0, 567.0]}, {"text": "analysis. Expert Rev Anticancer Ther. 2020;20(11):997–1009.", "bbox": [434.0, 567.0, 722.0, 580.0]}, {"text": "124.", "bbox": [408.0, 581.0, 428.0, 592.0]}, {"text": "Braat A, et al. Radioembolization with (90)Y resin microspheres", "bbox": [432.0, 582.0, 727.0, 593.0]}, {"text": "of neuroendocrine liver metastases: international multicenter", "bbox": [433.0, 595.0, 726.0, 606.0]}, {"text": "study on efficacy and toxicity. Cardiovasc Intervent Radiol.", "bbox": [434.0, 608.0, 726.0, 620.0]}, {"text": "2019;42(3):413–25.", "bbox": [435.0, 621.0, 526.0, 633.0]}, {"text": "125.", "bbox": [407.0, 633.0, 429.0, 646.0]}, {"text": "Memon K, et al. Radioembolization for neuroendocrine liver", "bbox": [432.0, 634.0, 727.0, 646.0]}, {"text": "metastases: safety, imaging, and long-term outcomes. Int J Radiat", "bbox": [433.0, 647.0, 727.0, 660.0]}, {"text": "Oncol Biol Phys. 2012;83(3):887–94.", "bbox": [433.0, 662.0, 606.0, 674.0]}, {"text": "Beuzit L, et al. Comparison of Choi criteria and response evalu-", "bbox": [432.0, 673.0, 726.0, 687.0]}, {"text": "126.", "bbox": [407.0, 674.0, 429.0, 686.0]}, {"text": "ation criteria in solid tumors (RECIST) for intrahepatic chol-", "bbox": [433.0, 686.0, 726.0, 701.0]}, {"text": "angiocarcinoma treated with glass-microspheres yurium-90", "bbox": [433.0, 701.0, 727.0, 713.0]}, {"text": "selective internal radiation therapy (SIRT). Eur J Radiol.", "bbox": [433.0, 713.0, 730.0, 727.0]}, {"text": "2016;85(8):1445–52.", "bbox": [434.0, 728.0, 531.0, 740.0]}, {"text": "127.", "bbox": [408.0, 741.0, 428.0, 754.0]}, {"text": "Camacho JC, et al. Modified response evaluation criteria in solid", "bbox": [432.0, 741.0, 727.0, 754.0]}, {"text": "tumors and European Association for the Study of the liver cri-", "bbox": [433.0, 754.0, 726.0, 765.0]}, {"text": "teria using delayed-phase imaging at an early time point predict", "bbox": [433.0, 768.0, 727.0, 779.0]}, {"text": "survival in patients with unresectable intrahepatic cholangiocar-", "bbox": [434.0, 781.0, 726.0, 793.0]}, {"text": "cinoma following yttrium-90 radioembolization. J Vasc Interv", "bbox": [433.0, 794.0, 726.0, 807.0]}, {"text": "Radiol. 2014;25(2):256–65.", "bbox": [434.0, 807.0, 563.0, 821.0]}, {"text": "128.", "bbox": [408.0, 821.0, 428.0, 832.0]}, {"text": "Akinwande O, et al. Comparison of tumor response assess-", "bbox": [433.0, 821.0, 726.0, 833.0]}, {"text": "ment methods in patients with metastatic colorectal cancer after", "bbox": [434.0, 834.0, 726.0, 846.0]}, {"text": "locoregional therapy. J Surg Oncol. 2016;113(4):443–8.", "bbox": [434.0, 847.0, 690.0, 860.0]}, {"text": "Publisher's note Springer Nature remains neutral with regard to", "bbox": [406.0, 874.0, 728.0, 887.0]}, {"text": "jurisdictional claims in published maps and institutional affiliations.", "bbox": [406.0, 889.0, 717.0, 900.0]}], "type": "Text", "position": 2}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2022】全科室最全临床指南+专家共识（最全版）/2022全科室临床指南/肿瘤科/EANM：动脉内放射性化合物治疗肝癌和转移性肝癌指南（2022）(1).pdf", "page_num": 17}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": null, "type3": null, "type4": null, "type5": null, "type6": "有用性#0#80#参考文献的内容"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:41", "update_time": "2024-05-07 19:48:38"}
{"id": 1082545, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 738, "source_info": {"seq_id": "269a6bac-6988-4b44-89b6-0ebbc0789405", "title": null, "text": "【0】页码:28\n\n【1】## Appendix 1: Patient Leaflet\n\n【2】\n This leaflet has been adapted from the Patient Sedation Leaflet produced by the Royal College of Anaesthetists (RCoA) leaflet \"Sedation explained\" 2 nd Edition June 2021\n\n【3】## Sedation Explained\n\n【4】\n This leaflet explains what sedation is, how it works and when you may need it. It also explains the benefits and risks of using sedation for your endoscopy.\n\n【5】 Importantly, it tells you what you will need to plan for your care after sedation.\n\n【6】 Sedation is when drugs are given to help you feel more relaxed during an endoscopy. The drugs (sedatives) are usually given into your vein (intravenous or IV) but can sometimes inhaled (via a face mask or breathing tube).\n\n【7】 Sedationist is the name given to the healthcare professional who administers your sedation. In the endoscopy room, that person is usually the endoscopist who performs your endoscopy. This may be a nurse or doctor. In some circumstances, a dedicated sedationist, usually an anaesthetist or anaesthetic nurse may administer and monitor the sedation.\n\n【8】 Whilst this leaflet is designed to support you in having your endoscopy test, it always should be read together with any other information about the endoscopy test you are having.\n\n【9】 What is intravenous sedation?\n\n【10】 The most usual type of sedation used in endoscopy is intravenous sedation.\n\n【11】 Intravenous sedation is when a sedative to relax you is injected into your bloodstream using a small plastic tube (also called a cannula) usually placed in a vein in your arm or hand.\n\n【12】 Endoscopists are trained to give the right amount of sedative and manage any side effects. Your endoscopist/sedationist will stay with you during your treatment and monitor your breathing and oxygen levels.", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "Appendix 1: Patient Leaflet", "bbox": [119.0, 176.0, 273.0, 190.0]}], "type": "Section-header", "position": 2}, {"raw_context": [{"text": "This leaflet has been adapted from the Patient Sedation Leaflet produced by the Royal College of", "bbox": [120.0, 236.0, 643.0, 251.0]}, {"text": "Anaesthetists (RCoA) leaflet \"Sedation explained\" 2 nd Edition June 2021", "bbox": [120.0, 253.0, 506.0, 268.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "Sedation explained", "bbox": [119.0, 282.0, 229.0, 298.0]}], "type": "Section-header", "position": 4}, {"raw_context": [{"text": "This leaflet explains what sedation is, how it works and when you may need it. It also explains the", "bbox": [120.0, 314.0, 646.0, 329.0]}, {"text": "benefits and risks of using sedation for your endoscopy.", "bbox": [119.0, 330.0, 422.0, 344.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "Importantly, it tells you what you will need to plan for your care after sedation.", "bbox": [119.0, 361.0, 547.0, 375.0]}], "type": "Text", "position": 6}, {"raw_context": [{"text": "Sedation is when drugs are given to help you feel more relaxed during an endoscopy. The drugs", "bbox": [119.0, 390.0, 637.0, 405.0]}, {"text": "(sedatives) are usually given into your vein (intravenous or IV) but can sometimes inhaled (via a face", "bbox": [120.0, 408.0, 660.0, 421.0]}, {"text": "mask or breathing tube).", "bbox": [119.0, 423.0, 256.0, 438.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "Sedationist is the name given to the healthcare professional who administers your sedation. In the", "bbox": [119.0, 454.0, 654.0, 469.0]}, {"text": "endoscopy room, that person is usually the endoscopist who performs your endoscopy. This may be a", "bbox": [119.0, 470.0, 670.0, 484.0]}, {"text": "nurse or doctor. In some circumstances, a dedicated sedationist, usually an anaesthetist or anaesthetic", "bbox": [119.0, 486.0, 675.0, 501.0]}, {"text": "nurse may administer and monitor the sedation.", "bbox": [120.0, 502.0, 382.0, 516.0]}], "type": "Text", "position": 8}, {"raw_context": [{"text": "Whilst this leaflet is designed to support you in having your endoscopy test, it always should be read", "bbox": [119.0, 533.0, 662.0, 548.0]}, {"text": "together with any other information about the endoscopy test you are having.", "bbox": [119.0, 549.0, 543.0, 564.0]}], "type": "Text", "position": 9}, {"raw_context": [{"text": "What is intravenous sedation?", "bbox": [120.0, 581.0, 286.0, 596.0]}], "type": "Text", "position": 10}, {"raw_context": [{"text": "The most usual type of sedation used in endoscopy is intravenous sedation.", "bbox": [120.0, 613.0, 529.0, 628.0]}], "type": "Text", "position": 11}, {"raw_context": [{"text": "Intravenous sedation is when a sedative to relax you is injected into your bloodstream using a small", "bbox": [119.0, 646.0, 657.0, 660.0]}, {"text": "plastic tube (also called a cannula) usually placed in a vein in your arm or hand.", "bbox": [120.0, 662.0, 546.0, 677.0]}], "type": "Text", "position": 12}, {"raw_context": [{"text": "Endoscopists are trained to give the right amount of sedative and manage any side effects. Your", "bbox": [119.0, 692.0, 638.0, 706.0]}, {"text": "endoscopist/sedationist will stay with you during your treatment and monitor your breathing and", "bbox": [119.0, 708.0, 646.0, 723.0]}, {"text": "oxygen levels.", "bbox": [120.0, 725.0, 197.0, 739.0]}], "type": "Text", "position": 13}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/消化科/_2023 BSG指南：胃肠内窥镜检查中的镇静.pdf", "page_num": 28}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": null, "type3": null, "type4": null, "type5": null, "type6": null}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:41", "update_time": "2024-05-08 01:27:51"}
{"id": 1082544, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 738, "source_info": {"seq_id": "d3886335-c2c0-4635-b5a4-14707f844675", "title": null, "text": "【0】页码:30\n What are the differences between sedation and general anaesthesia ?\n\n【1】 The main differences between sedation and general anaesthesia are your level of consciousness, the need for equipment to help support your breathing and possible side effects.  With minimal and moderate sedation, you feel comfortable, sleepy and relaxed. You may drift off to sleep at times but will be easy to wake. With general anaesthesia, you are completely unaware and unconscious during the procedure. Deep sedation provides you with stronger medication that will make you sleep during most of your treatment. In the UK, this can only be given by the anaesthetic team. Facilities for a general anaesthetic and deep sedation are more limited and may take some time to arrange.\n\n【2】## Who Decides Whether I Can Have Sedation?\n\n【3】\n You can discuss whether there is the option of sedation for your procedure with your doctor or nurse at the time of assessment. If it hasn't been offered, you can always ask to see if it is possible to have it. If you are at higher risk from existing medical conditions, your doctors will discuss the options with you.\n\n【4】You can then agree together the best option for you. What can I do to prepare for a procedure with sedation?\n\n【5】 1.\n\n【6】 2.\n\n【7】 3.\n\n【8】 4.\n\n【9】 5.\n\n【10】 1.6.\n 7.\n\n【11】 Bring some loose clothing, such as a dressing gown or a fleece, to keep you comfortable and warm. Wear flat shoes that are easy to put on.\n\n【12】 Can I eat and drink before my treatment?\n\n【13】 The clinic or hospital will give you exact instructions, including when to stop eating and drinking.  If you have diabetes, you should ask for specific instructions about when you should take your diabetic medication and stop eating food.\n\n【14】## What Will Happen On The Day Of My Treatment?\n\n【15】\n Sometimes you will be asked to change into a gown. Many endoscopy tests however do not require you to change out of your normal clothing. When you go to the procedure room, your endoscopy team will attach some monitoring equipment to you. The equipment used will usually include:\n\n【16】 1. a blood pressure cuff on your arm 2. a clip on your finger to measure your oxygen levels\n\n【17】 If you have people that you look after, for example children or older people, you will need to plan for someone else to look after them until the day after the procedure.\n\n【18】A capable adult will need to take you home by car or taxi ideally – using public transport is not advised after sedation. As the effects of sedation can last up to 24 hours, they should stay overnight to look after you.\n\n【19】Take all your medicines to hospital with you, including any inhalers and any over-the-counter medicines you take regularly.\n\n【20】If you have an illness or a cold, or you are pregnant, please contact your hospital or clinic, as it may not be safe to have sedation. Your treatment may have to be rearranged.\n\n【21】Let your doctor know on the day of the procedure if you are breastfeeding.\n\n【22】Remove all makeup – including nail varnish and jewelry – before coming to hospital or clinic. You may wear a wedding ring. You may wish to bring a book or a tablet to use during your wait in the department.", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "What are the differences between sedation and general anaesthesia ?", "bbox": [120.0, 141.0, 495.0, 156.0]}], "type": "Text", "position": 2}, {"raw_context": [{"text": "The main differences between sedation and general anaesthesia are your level of consciousness, the", "bbox": [120.0, 172.0, 663.0, 187.0]}, {"text": "need for equipment to help support your breathing and possible side effects.  With minimal and", "bbox": [119.0, 189.0, 650.0, 203.0]}, {"text": "moderate sedation, you feel comfortable, sleepy and relaxed. You may drift off to sleep at times but will", "bbox": [119.0, 205.0, 682.0, 220.0]}, {"text": "be easy to wake. With general anaesthesia, you are completely unaware and unconscious during the", "bbox": [119.0, 221.0, 663.0, 235.0]}, {"text": "procedure. Deep sedation provides you with stronger medication that will make you sleep during most", "bbox": [120.0, 238.0, 675.0, 252.0]}, {"text": "of your treatment. In the UK, this can only be given by the anaesthetic team. Facilities for a general", "bbox": [119.0, 254.0, 655.0, 269.0]}, {"text": "anaesthetic and deep sedation are more limited and may take some time to arrange.", "bbox": [120.0, 271.0, 577.0, 284.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "Who decides whether I can have sedation?", "bbox": [120.0, 300.0, 352.0, 315.0]}], "type": "Section-header", "position": 4}, {"raw_context": [{"text": "You can discuss whether there is the option of sedation for your procedure with your doctor or nurse at", "bbox": [119.0, 330.0, 680.0, 345.0]}, {"text": "the time of assessment. If it hasn't been offered, you can always ask to see if it is possible to have it. If", "bbox": [119.0, 347.0, 671.0, 361.0]}, {"text": "you are at higher risk from existing medical conditions, your doctors will discuss the options with you.", "bbox": [119.0, 363.0, 668.0, 377.0]}, {"text": "You can then agree together the best option for you. What can I do to prepare for a procedure with", "bbox": [120.0, 380.0, 658.0, 393.0]}, {"text": "sedation?", "bbox": [120.0, 395.0, 176.0, 410.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "1.", "bbox": [142.0, 427.0, 162.0, 440.0]}], "type": "Text", "position": 6}, {"raw_context": [{"text": "2.", "bbox": [140.0, 460.0, 161.0, 472.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "3.", "bbox": [140.0, 507.0, 162.0, 520.0]}], "type": "Text", "position": 8}, {"raw_context": [{"text": "4.", "bbox": [140.0, 541.0, 159.0, 553.0]}], "type": "Text", "position": 9}, {"raw_context": [{"text": "5.", "bbox": [140.0, 572.0, 161.0, 585.0]}], "type": "Text", "position": 10}, {"raw_context": [{"text": "1.6.", "bbox": [140.0, 589.0, 161.0, 601.0]}], "type": "Text", "position": 11}, {"raw_context": [{"text": "7.", "bbox": [142.0, 636.0, 161.0, 649.0]}], "type": "List-item", "position": 12}, {"raw_context": [{"text": "Bring some loose clothing, such as a dressing gown or a fleece, to keep you comfortable and", "bbox": [160.0, 635.0, 661.0, 650.0]}, {"text": "warm. Wear flat shoes that are easy to put on.", "bbox": [162.0, 652.0, 416.0, 666.0]}], "type": "Text", "position": 13}, {"raw_context": [{"text": "Can I eat and drink before my treatment?", "bbox": [119.0, 682.0, 345.0, 696.0]}], "type": "Text", "position": 14}, {"raw_context": [{"text": "The clinic or hospital will give you exact instructions, including when to stop eating and drinking.  If you", "bbox": [119.0, 711.0, 676.0, 726.0]}, {"text": "have diabetes, you should ask for specific instructions about when you should take your diabetic", "bbox": [119.0, 728.0, 640.0, 743.0]}, {"text": "medication and stop eating food.", "bbox": [119.0, 745.0, 299.0, 759.0]}], "type": "Text", "position": 15}, {"raw_context": [{"text": "What will happen on the day of my treatment?", "bbox": [120.0, 775.0, 375.0, 790.0]}], "type": "Section-header", "position": 16}, {"raw_context": [{"text": "Sometimes you will be asked to change into a gown. Many endoscopy tests however do not require you", "bbox": [119.0, 806.0, 681.0, 821.0]}, {"text": "to change out of your normal clothing. When you go to the procedure room, your endoscopy team will", "bbox": [119.0, 821.0, 675.0, 836.0]}, {"text": "attach some monitoring equipment to you. The equipment used will usually include:", "bbox": [120.0, 838.0, 575.0, 853.0]}], "type": "Text", "position": 17}, {"raw_context": [{"text": "1. a blood pressure cuff on your arm", "bbox": [142.0, 869.0, 349.0, 883.0]}, {"text": "2. a clip on your finger to measure your oxygen levels", "bbox": [141.0, 885.0, 439.0, 900.0]}], "type": "Text", "position": 18}, {"raw_context": [{"text": "If you have people that you look after, for example children or older people, you will need to", "bbox": [159.0, 425.0, 665.0, 440.0]}, {"text": "plan for someone else to look after them until the day after the procedure.", "bbox": [161.0, 442.0, 567.0, 456.0]}, {"text": "A capable adult will need to take you home by car or taxi ideally – using public transport is not", "bbox": [160.0, 458.0, 671.0, 472.0]}, {"text": "advised after sedation. As the effects of sedation can last up to 24 hours, they should stay", "bbox": [161.0, 474.0, 648.0, 488.0]}, {"text": "overnight to look after you.", "bbox": [161.0, 490.0, 312.0, 505.0]}, {"text": "Take all your medicines to hospital with you, including any inhalers and any over-the-counter", "bbox": [160.0, 506.0, 665.0, 520.0]}, {"text": "medicines you take regularly.", "bbox": [161.0, 522.0, 323.0, 536.0]}, {"text": "If you have an illness or a cold, or you are pregnant, please contact your hospital or clinic, as it", "bbox": [160.0, 538.0, 671.0, 553.0]}, {"text": "may not be safe to have sedation. Your treatment may have to be rearranged.", "bbox": [161.0, 556.0, 585.0, 569.0]}, {"text": "Let your doctor know on the day of the procedure if you are breastfeeding.", "bbox": [160.0, 571.0, 568.0, 586.0]}, {"text": "Remove all makeup – including nail varnish and jewelry – before coming to hospital or clinic. You", "bbox": [160.0, 587.0, 686.0, 601.0]}, {"text": "may wear a wedding ring. You may wish to bring a book or a tablet to use during your wait in", "bbox": [161.0, 602.0, 665.0, 617.0]}, {"text": "the department.", "bbox": [161.0, 619.0, 255.0, 633.0]}], "type": "Text", "position": 19}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/消化科/_2023 BSG指南：胃肠内窥镜检查中的镇静.pdf", "page_num": 30}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": null, "type3": null, "type4": "栏目混乱#5#22#序号和内容分离，内容之间互相穿插没有顺序", "type5": null, "type6": null}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:41", "update_time": "2024-05-07 18:47:43"}
{"id": 1082543, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 738, "source_info": {"seq_id": "cc98922c-a96b-4f30-99c0-7be7b5870f7d", "title": null, "text": "【0】页码:10\n\n【1】 Patient and procedural factors to be considered in the choice of sedation Table 2 Patient factors Drug history: high intake of pain medications/sedatives Potential drug interactions/previous problems with sedation/anaesthesia Patient preference Oral/jaw or neck abnormalities, dysmorphic features: micrognathia, retrognathia or significant malocclusion, limited neck extension OSA/patients at risk of OSA Pregnancy Comorbidity: severe pulmonary, cardiac, neurological, renal, hepatic disease or high-risk of aspiration, elderly Upper and lower GI: polypectomy/resection of neoplasia/prolonged procedures >60 min Procedural factors Endoscopic bariatric surgery Large variceal bleed/significant gastric contents Foreign body retrieval Hepatobiliary procedures: Therapeutic endoscopic ultrasound or endoscopic retrograde cholangiopancreatography Pancreatic fluid collection drainage Small bowel device-assisted enteroscopy, including double balloon, single balloon or spiral enteroscopy OSA, obstructive sleep apnoea.\n\n【2】\n## Pre-Assessment In Pregnancy\n\n【3】\n The pre-assessment of the pregnant patient should involve the obstetric team especially to determine the degree of fetal monitoring required. There should be a strong indication for endoscopy, and elective procedures should preferably be deferred until the second trimester. The impact of sedation and monitoring requirements in the different patient groups are discussed in more detail in subsequent sections.\n\n【4】## Procedure Room Requirements\n\n【5】\n 10. We recommend that all patients undergoing gastrointestinal endoscopy (sedated or unsedated) have monitoring of pulse, blood pressure, oxygen saturations and respiration rates as a minimum before and after the procedure. We recommend supplemental oxygen where any level of sedation is used.\n\n【6】Grade of evidence: Very Low. Strength of recommendation: Strong.\n\n【7】Level of agreement: 100%\n\n【8】 Sedation practices and therefore room requirements vary across countries supported by heterogeneous society guidelines and position statements. There is often a lack of evidence to support these differences, which most probably reflect local custom and practice development. 73 How this affects patient access, utility, safety and effectiveness remains unclear. It is attractive to place safety first and increase the amount of monitoring and staff, but this can increase costs, complexity and resource consumption. Room requirements for endoscopy using sedation include the staff, their roles and equipment available to monitor sedated patients. 73 Staff are drawn from many different professional groups, including endoscopists (surgical, medical, clinical/non-medical), endoscopy nurses, healthcare support workers and operating department assistants. Leadership of sedation, while remaining usually with the endoscopist, is also shared by appropriately trained endoscopy nurses. All members of the team should be cognisant of the importance of safe sedation in endoscopy delivery.\n\n【9】Staffing requirements for endoscopy in the UK have been reviewed by the BSG. 74 It is difficult to be prescriptive about a minimum standard and this has been the cause of debate even within the UK where there are differences across the devolved nations and challenges to professional boundaries— for example, the development of advanced healthcare support workers. In addition to the endoscopist/seditionist, a minimum of two additional members of staff has been recommended by the BSG and recently endorsed by the Academy of Medical Royal Colleges There should always be an endoscopist/ (AoMRC) update. 75 10\n\n【10】 sedationist as a minimum supported by at least one registered professional trained to monitor the patient's safety, comfort and level of sedation, usually a qualified nurse and an additional assistant to the endoscopist. When the procedure is long or complex or the patient has significant comorbidity, a dedicated sedationist should be considered.\n\n【11】Monitoring the patient's status and physiology during endoscopy allows both the direct effect of the procedure and, if used, sedation, to be assessed, monitored and recorded. 1 This is facilitated during both unsedated and sedated (minimal/moderate) procedures by use of pulse oximetry, which is widely available.\n\n【12】Pulse oximetry supports early recognition of disturbances to circulation and oxygenation, even prior to the start of the test. 76 Practice of sedation within the UK and its use in multiple different clinical settings has been guided by the Academy of Medical Royal Colleges with the detailed publication of standards and guidance 1 in 2013 followed by an update in 2021. 7 Dossa et al 2021 established that the most consistent advice from learnt societies and national bodies is that as a minimum non-invasive blood pressure monitoring and pulse oximetry is required for all sedated patients. 73 11. ECG monitoring is not recommended routinely for patients requiring GI endoscopy with minimal sedation Grade of evidence: Very Low. Strength of recommendation: Strong.\n\n【13】Level of agreement: 100%\n\n【14】 The need for ECG monitoring depends on the level of sedation used and whether the patient is considered to be at increased risk of cardiovascular complications (see statement 1537 later).\n\n【15】Data to support its use are lacking but ECG monitoring is recommended in most international guidelines where moderate sedation is used. For minimal sedation, the advice is varied. The UK AoMRC advice from 2013 1 states that \"where conscious sedation is used and continuous verbal contact is maintained, ECG monitoring is not essential\". This position is supported here as ECG monitoring has disadvantages as well as strengths—for example, additional use of consumables, or inhibition of patient position change. The AoMRC update in 2021 suggests that ECG monitoring is required for patients in deeper plane of sedation other than minimal sedation. 7 12. We recommend that where the endoscopist–sedationist administers sedation and also performs the procedure, there must be at least an appropriately trained second member of the team solely monitoring the patient's status Grade of evidence: Low. Strength of recommendation: Strong.\n\n【16】Level of agreement: 100% Sidhu R, et al. Gut 2023;0:1–27. doi:10.1136/gutjnl-2023-330396", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "Patient and procedural factors to be considered in the choice of sedation", "bbox": [105.0, 68.0, 441.0, 82.0]}, {"text": "Table 2", "bbox": [59.0, 70.0, 99.0, 82.0]}, {"text": "Patient factors", "bbox": [59.0, 89.0, 117.0, 101.0]}, {"text": "Drug history: high intake of pain medications/sedatives", "bbox": [171.0, 89.0, 380.0, 100.0]}, {"text": "Potential drug interactions/previous problems with sedation/anaesthesia", "bbox": [170.0, 102.0, 446.0, 113.0]}, {"text": "Patient preference", "bbox": [170.0, 114.0, 241.0, 126.0]}, {"text": "Oral/jaw or neck abnormalities, dysmorphic features: micrognathia, retrognathia or significant malocclusion, limited neck extension", "bbox": [170.0, 129.0, 669.0, 142.0]}, {"text": "OSA/patients at risk of OSA", "bbox": [170.0, 145.0, 277.0, 157.0]}, {"text": "Pregnancy", "bbox": [170.0, 161.0, 211.0, 175.0]}, {"text": "Comorbidity: severe pulmonary, cardiac, neurological, renal, hepatic disease or high-risk of aspiration, elderly", "bbox": [169.0, 174.0, 584.0, 188.0]}, {"text": "Upper and lower GI: polypectomy/resection of neoplasia/prolonged procedures >60 min", "bbox": [170.0, 190.0, 506.0, 203.0]}, {"text": "Procedural factors", "bbox": [59.0, 192.0, 131.0, 203.0]}, {"text": "Endoscopic bariatric surgery", "bbox": [170.0, 205.0, 278.0, 217.0]}, {"text": "Large variceal bleed/significant gastric contents", "bbox": [170.0, 216.0, 353.0, 230.0]}, {"text": "Foreign body retrieval", "bbox": [170.0, 230.0, 255.0, 242.0]}, {"text": "Hepatobiliary procedures: Therapeutic endoscopic ultrasound or endoscopic retrograde cholangiopancreatography", "bbox": [169.0, 240.0, 604.0, 255.0]}, {"text": "Pancreatic fluid collection drainage", "bbox": [170.0, 255.0, 305.0, 267.0]}, {"text": "Small bowel device-assisted enteroscopy, including double balloon, single balloon or spiral enteroscopy", "bbox": [170.0, 267.0, 563.0, 281.0]}, {"text": "OSA, obstructive sleep apnoea.", "bbox": [58.0, 286.0, 179.0, 298.0]}], "type": "Table", "position": 1}, {"raw_context": [{"text": "Pre-assessment in pregnancy", "bbox": [53.0, 323.0, 210.0, 337.0]}], "type": "Section-header", "position": 2}, {"raw_context": [{"text": "The pre-assessment of the pregnant patient should involve the", "bbox": [54.0, 338.0, 387.0, 353.0]}, {"text": "obstetric team especially to determine the degree of fetal moni-", "bbox": [53.0, 352.0, 385.0, 368.0]}, {"text": "toring required. There should be a strong indication for endos-", "bbox": [53.0, 368.0, 385.0, 383.0]}, {"text": "copy, and elective procedures should preferably be deferred until", "bbox": [53.0, 383.0, 386.0, 397.0]}, {"text": "the second trimester. The impact of sedation and monitoring", "bbox": [53.0, 398.0, 386.0, 411.0]}, {"text": "requirements in the different patient groups are discussed in", "bbox": [53.0, 412.0, 386.0, 426.0]}, {"text": "more detail in subsequent sections.", "bbox": [53.0, 427.0, 234.0, 440.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "Procedure room requirements", "bbox": [53.0, 458.0, 216.0, 472.0]}], "type": "Section-header", "position": 4}, {"raw_context": [{"text": "10. We recommend that all patients undergoing gastrointes-", "bbox": [54.0, 473.0, 385.0, 486.0]}, {"text": "tinal endoscopy (sedated or unsedated) have monitoring of", "bbox": [53.0, 487.0, 387.0, 502.0]}, {"text": "pulse, blood pressure, oxygen saturations and respiration rates", "bbox": [53.0, 502.0, 386.0, 516.0]}, {"text": "as a minimum before and after the procedure. We recommend", "bbox": [53.0, 516.0, 385.0, 531.0]}, {"text": "supplemental oxygen where any level of sedation is used.", "bbox": [53.0, 531.0, 350.0, 545.0]}, {"text": "Grade of evidence: Very Low. Strength of recommendation:", "bbox": [65.0, 546.0, 385.0, 560.0]}, {"text": "Strong.", "bbox": [54.0, 562.0, 91.0, 574.0]}, {"text": "Level of agreement: 100%", "bbox": [66.0, 577.0, 203.0, 589.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "Sedation practices and therefore room requirements vary", "bbox": [65.0, 590.0, 385.0, 603.0]}, {"text": "across countries supported by heterogeneous society guide-", "bbox": [53.0, 604.0, 384.0, 619.0]}, {"text": "lines and position statements. There is often a lack of evidence", "bbox": [53.0, 618.0, 385.0, 633.0]}, {"text": "to support these differences, which most probably reflect local", "bbox": [53.0, 634.0, 385.0, 648.0]}, {"text": "custom and practice development. 73 How this affects patient", "bbox": [53.0, 647.0, 385.0, 662.0]}, {"text": "access, utility, safety and effectiveness remains unclear. It is", "bbox": [53.0, 663.0, 387.0, 677.0]}, {"text": "attractive to place safety first and increase the amount of moni-", "bbox": [53.0, 678.0, 385.0, 692.0]}, {"text": "toring and staff, but this can increase costs, complexity and", "bbox": [53.0, 692.0, 386.0, 706.0]}, {"text": "resource consumption. Room requirements for endoscopy using", "bbox": [53.0, 707.0, 387.0, 721.0]}, {"text": "sedation include the staff, their roles and equipment available to", "bbox": [53.0, 722.0, 387.0, 736.0]}, {"text": "monitor sedated patients. 73 Staff are drawn from many different", "bbox": [53.0, 737.0, 385.0, 751.0]}, {"text": "professional groups, including endoscopists (surgical, medical,", "bbox": [53.0, 751.0, 385.0, 765.0]}, {"text": "clinical/non-medical), endoscopy nurses, healthcare support", "bbox": [53.0, 766.0, 386.0, 780.0]}, {"text": "workers and operating department assistants. Leadership of", "bbox": [53.0, 781.0, 386.0, 795.0]}, {"text": "sedation, while remaining usually with the endoscopist, is also", "bbox": [53.0, 795.0, 387.0, 810.0]}, {"text": "shared by appropriately trained endoscopy nurses. All members", "bbox": [53.0, 810.0, 386.0, 824.0]}, {"text": "of the team should be cognisant of the importance of safe seda-", "bbox": [53.0, 825.0, 385.0, 839.0]}, {"text": "tion in endoscopy delivery.", "bbox": [53.0, 840.0, 195.0, 853.0]}, {"text": "Staffing requirements for endoscopy in the UK have been", "bbox": [65.0, 854.0, 387.0, 869.0]}, {"text": "reviewed by the BSG. 74 It is difficult to be prescriptive about a", "bbox": [53.0, 868.0, 387.0, 883.0]}, {"text": "minimum standard and this has been the cause of debate even", "bbox": [53.0, 883.0, 387.0, 898.0]}, {"text": "within the UK where there are differences across the devolved", "bbox": [53.0, 898.0, 386.0, 912.0]}, {"text": "nations and challenges to professional boundaries— for example,", "bbox": [53.0, 913.0, 385.0, 927.0]}, {"text": "the development of advanced healthcare support workers. In", "bbox": [53.0, 928.0, 386.0, 941.0]}, {"text": "addition to the endoscopist/seditionist, a minimum of two addi-", "bbox": [53.0, 942.0, 385.0, 955.0]}, {"text": "tional members of staff has been recommended by the BSG and", "bbox": [53.0, 957.0, 386.0, 970.0]}, {"text": "recently endorsed by the Academy of Medical Royal Colleges", "bbox": [53.0, 971.0, 386.0, 985.0]}, {"text": "There should always be an endoscopist/", "bbox": [164.0, 986.0, 385.0, 1000.0]}, {"text": "(AoMRC) update. 75", "bbox": [53.0, 987.0, 163.0, 1000.0]}, {"text": "10", "bbox": [55.0, 1011.0, 68.0, 1021.0]}], "type": "Text", "position": 6}, {"raw_context": [{"text": "sedationist as a minimum supported by at least one registered", "bbox": [406.0, 322.0, 740.0, 337.0]}, {"text": "professional trained to monitor the patient's safety, comfort and", "bbox": [407.0, 338.0, 739.0, 352.0]}, {"text": "level of sedation, usually a qualified nurse and an additional", "bbox": [406.0, 353.0, 739.0, 367.0]}, {"text": "assistant to the endoscopist. When the procedure is long or", "bbox": [407.0, 368.0, 739.0, 383.0]}, {"text": "complex or the patient has significant comorbidity, a dedicated", "bbox": [406.0, 382.0, 740.0, 397.0]}, {"text": "sedationist should be considered.", "bbox": [406.0, 397.0, 578.0, 411.0]}, {"text": "Monitoring the patient's status and physiology during endos-", "bbox": [418.0, 412.0, 738.0, 426.0]}, {"text": "copy allows both the direct effect of the procedure and, if used,", "bbox": [406.0, 427.0, 739.0, 440.0]}, {"text": "sedation, to be assessed, monitored and recorded. 1 This is facil-", "bbox": [406.0, 441.0, 739.0, 455.0]}, {"text": "itated during both unsedated and sedated (minimal/moderate)", "bbox": [406.0, 456.0, 739.0, 469.0]}, {"text": "procedures by use of pulse oximetry, which is widely available.", "bbox": [407.0, 470.0, 739.0, 485.0]}, {"text": "Pulse oximetry supports early recognition of disturbances to", "bbox": [407.0, 485.0, 740.0, 499.0]}, {"text": "circulation and oxygenation, even prior to the start of the test. 76", "bbox": [406.0, 500.0, 736.0, 513.0]}, {"text": "Practice of sedation within the UK and its use in multiple", "bbox": [418.0, 515.0, 739.0, 528.0]}, {"text": "different clinical settings has been guided by the Academy of", "bbox": [406.0, 529.0, 739.0, 543.0]}, {"text": "Medical Royal Colleges with the detailed publication of stan-", "bbox": [407.0, 544.0, 739.0, 558.0]}, {"text": "dards and guidance 1 in 2013 followed by an update in 2021. 7", "bbox": [406.0, 558.0, 733.0, 573.0]}, {"text": "Dossa et al 2021 established that the most consistent advice", "bbox": [407.0, 573.0, 740.0, 587.0]}, {"text": "from learnt societies and national bodies is that as a minimum", "bbox": [406.0, 588.0, 740.0, 602.0]}, {"text": "non-invasive blood pressure monitoring and pulse oximetry is", "bbox": [406.0, 603.0, 740.0, 616.0]}, {"text": "required for all sedated patients. 73", "bbox": [406.0, 617.0, 581.0, 630.0]}, {"text": "11. ECG monitoring is not recommended routinely for", "bbox": [420.0, 632.0, 739.0, 646.0]}, {"text": "patients requiring GI endoscopy with minimal sedation", "bbox": [406.0, 646.0, 695.0, 661.0]}, {"text": "Grade of evidence: Very Low. Strength of recommendation:", "bbox": [419.0, 661.0, 739.0, 675.0]}, {"text": "Strong.", "bbox": [407.0, 678.0, 444.0, 690.0]}, {"text": "Level of agreement: 100%", "bbox": [418.0, 691.0, 556.0, 705.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "The need for ECG monitoring depends on the level of seda-", "bbox": [419.0, 706.0, 739.0, 721.0]}, {"text": "tion used and whether the patient is considered to be at increased", "bbox": [406.0, 721.0, 740.0, 735.0]}, {"text": "risk of cardiovascular complications (see statement 1537 later).", "bbox": [406.0, 736.0, 739.0, 750.0]}, {"text": "Data to support its use are lacking but ECG monitoring is recom-", "bbox": [406.0, 750.0, 739.0, 764.0]}, {"text": "mended in most international guidelines where moderate seda-", "bbox": [406.0, 766.0, 738.0, 779.0]}, {"text": "tion is used. For minimal sedation, the advice is varied. The UK", "bbox": [406.0, 780.0, 739.0, 793.0]}, {"text": "AoMRC advice from 2013 1 states that \"where conscious seda-", "bbox": [407.0, 794.0, 739.0, 808.0]}, {"text": "tion is used and continuous verbal contact is maintained, ECG", "bbox": [406.0, 809.0, 739.0, 823.0]}, {"text": "monitoring is not essential\". This position is supported here as", "bbox": [406.0, 822.0, 740.0, 838.0]}, {"text": "ECG monitoring has disadvantages as well as strengths—for", "bbox": [406.0, 838.0, 739.0, 852.0]}, {"text": "example, additional use of consumables, or inhibition of patient", "bbox": [406.0, 853.0, 739.0, 867.0]}, {"text": "position change. The AoMRC update in 2021 suggests that ECG", "bbox": [407.0, 868.0, 739.0, 881.0]}, {"text": "monitoring is required for patients in deeper plane of sedation", "bbox": [406.0, 882.0, 740.0, 896.0]}, {"text": "other than minimal sedation. 7", "bbox": [406.0, 897.0, 560.0, 911.0]}, {"text": "12. We recommend that where the endoscopist–sedationist", "bbox": [419.0, 912.0, 740.0, 926.0]}, {"text": "administers sedation and also performs the procedure, there", "bbox": [407.0, 927.0, 739.0, 941.0]}, {"text": "must be at least an appropriately trained second member of the", "bbox": [407.0, 942.0, 739.0, 955.0]}, {"text": "team solely monitoring the patient's status", "bbox": [408.0, 956.0, 629.0, 969.0]}, {"text": "Grade of evidence: Low. Strength of recommendation: Strong.", "bbox": [418.0, 971.0, 737.0, 985.0]}, {"text": "Level of agreement: 100%", "bbox": [418.0, 985.0, 557.0, 1000.0]}, {"text": "Sidhu R, et al. Gut 2023;0:1–27. doi:10.1136/gutjnl-2023-330396", "bbox": [477.0, 1009.0, 739.0, 1022.0]}], "type": "Text", "position": 8}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/消化科/_2023 BSG指南：胃肠内窥镜检查中的镇静.pdf", "page_num": 10}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": "语句不通顺#9#9#There should always be an endoscopist/ (AoMRC) update. 后面的(AoMRC) update应该在There should always...前面", "type2": "多余换行#10#10# sedationist as a minimum supported...与上面9段联接\n缺少换行#12#12#Practice of sedation within...\n11. ECG monitoring is not recommended...\nGrade of evidence: Very ...都另起一行\n缺少换行#15#15#12. We recommend that where...\nGrade of evidence: Low. ...都另起一行", "type3": "无关文本#8#15#...and practice development. 73 类似的数字引用本文存在多处", "type6": "准确性#1#1#表格内容， Table 2应该在开头。Procedural factors应该在Upper and lower GI: polypectomy/resection......的前面\n有用性#16#16#Sidhu R, et al. Gut 2023;0:1–27. doi:10.1136/gutjnl-2023-330396页脚内容"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:41", "update_time": "2024-05-07 23:29:47"}
{"id": 1082542, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 738, "source_info": {"seq_id": "6ffcf6f2-0626-4b09-9b43-7528be0a0c78", "title": null, "text": "【0】页码:1\n# 慢性阻塞性肺疾病胸部 Ct检查及评价 中国专家共识\n\n【1】\n 中华医学会教射学分会む胸学组 通 信 作 者 : ‡ 敏 文 , 空 军 军 医 大 学 商 京 医 院 放 射 诊 断 科 , 西 安 710032, Email: zhengmw2007@163.com; 新佑長 , 西安交通大学 第一附属医院医学影像科 , 西安 710061, Email:cjr.guoyoumin@vip.163.com; 刘士达,海军军医大学第二附属医院就射诊 断科 , 上海 200003, Email:cjr.liushiyuan@vip.163.com\n\n【2】 【摘要】 的研究发展迅速,但缺乏一致性认识。为此,中华医学会放射学分会牵头组织心胸学组专家,参考国 际 COPD 的诊疗現状, 结合我国胸部CT 临床实践, 经反复讨论形成以下共识, 包括 COPD 临床诊断, 胸 部 CT 检查前准备及扫描方案,胸部 CT定性、定量、功能评价, COPD 急性加重及合并症的胸部 CT评价 以及胸部 CT 结构化报告 。 【关键词】 肺疾病, 授性阻塞性 ;  体层摄影术, X 线计算机 ;  专家共识 基 金 项 目 : 国 家 自 然 科 学 基 金 (81930049, 82171926, 81871321) ; 科 技 部 重 点 研 发 计 划 (2022YFC2010000,2022YFC2010002); 国家卫健委数据库建设项目(YXFSC2022JJSJ002)\n\n【3】 Chinese expert consensus on chest CT scanning and evaluation of chronic obstruction pulmonary disease Cardio-thoracic Group of Chinese Society of Radiology Chinese Medical Association Corresponding author: Zheng Minwen, Department of Radiology, Xijing Hospital, Air Force Military Medical University, Xi'an 710032, China, Email: zhengmw2007@163.com; Guo Youmin, Department of Radiology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China, Email: cjr.\n\n【4】guoyoumin@vip. 163. com; Liu Shiyuan, Department of Radiology, the Second Affiliated Hospital of Naval Medical University, Shanghai 200003, China, Email: cjr.liushiyuan@vip.163.com\n\n【5】 慢 性 阻 塞 性 肺 疾 病 (chronic obstruction V ) pulmonary disease, COPD)是全球关注的重大公共 卫生问题, 2019 年世界卫生组织统计 COPD 是全球 第 3 大致死疾病。2018 年中国国家慢病和非传染 性疾病预防控制中心报道,我国 COPD 患者高达 1 亿人,每分钟有 1.9 人死于 COPD, 2004 至 2015 年 发病率增幅为 65.9%, 40 岁以上人群发病率为 13.6% [1-2] 。 与 COPD 严峻的诊疗现状相对应的却是 我国民众对该病的低知晓率(仅0.9%),这直接导\n\n【6】 致了早诊早治的延误,疾病确诊时往往已是进展 期,此时治疗效果明显下降。同时,不佳的疗效和 迁延不愈的病程,会大大増加患者的医疗费用,造 成了严重的医疗资源浪费和社会经济负担 ¶ 。 肺功能检测(pulmonary function test, PFT)是 目前临床诊断 COPD 的金标准,但早期诊断的灵敏 度不高,通常肺结构破坏 30%以上,才会出现指标 的异常 , 且不能反映 COPD 的异质性 [3] 。此外 PFT 的单一國值诊断标准[使用支气管扩张剂后,第\n\n【7】 DOI : 10.3760/cma.j.cn112149–20220929–00785\n\n【8】 Services 本文编辑 史晓娟 引用本文 : 中华医学会放射学分会心胸学组 . 慢性阻塞性肺疾病胸部 CT检查及评价中国专家共识[J] : 中 华放射学杂志 , 2023, 57(6): 600–607. DOI: 10.3760/cma.j.cn112149–20220929–00785.", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "慢性阻塞性肺疾病胸部 CT检查及评价", "bbox": [85.0, 146.0, 547.0, 180.0]}, {"text": "中国专家共识", "bbox": [84.0, 185.0, 255.0, 211.0]}], "type": "Title", "position": 3}, {"raw_context": [{"text": "中华医学会教射学分会む胸学组", "bbox": [85.0, 247.0, 283.0, 263.0]}, {"text": "通 信 作 者 : ‡ 敏 文 , 空 军 军 医 大 学 商 京 医 院 放 射 诊 断 科 , 西 安 710032, Email:", "bbox": [85.0, 267.0, 604.0, 286.0]}, {"text": "zhengmw2007@163.com; 新佑長 , 西安交通大学 第一附属医院医学影像科 , 西安", "bbox": [85.0, 289.0, 604.0, 307.0]}, {"text": "710061, Email:cjr.guoyoumin@vip.163.com; 刘士达,海军军医大学第二附属医院就射诊", "bbox": [85.0, 312.0, 604.0, 327.0]}, {"text": "断科 , 上海 200003, Email:cjr.liushiyuan@vip.163.com", "bbox": [85.0, 333.0, 398.0, 350.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": "【摘要】", "bbox": [108.0, 381.0, 606.0, 397.0]}, {"text": "的研究发展迅速,但缺乏一致性认识。为此,中华医学会放射学分会牵头组织心胸学组专家,参考国", "bbox": [85.0, 400.0, 605.0, 417.0]}, {"text": "际 COPD 的诊疗現状, 结合我国胸部CT 临床实践, 经反复讨论形成以下共识, 包括 COPD 临床诊断, 胸", "bbox": [85.0, 420.0, 605.0, 437.0]}, {"text": "部 CT 检查前准备及扫描方案,胸部 CT定性、定量、功能评价, COPD 急性加重及合并症的胸部 CT评价", "bbox": [85.0, 440.0, 604.0, 456.0]}, {"text": "以及胸部 CT 结构化报告 。", "bbox": [85.0, 461.0, 219.0, 475.0]}, {"text": "【关键词】 肺疾病, 授性阻塞性 ;  体层摄影术, X 线计算机 ;  专家共识", "bbox": [108.0, 479.0, 486.0, 495.0]}, {"text": "基 金 项 目 : 国 家 自 然 科 学 基 金 (81930049, 82171926, 81871321) ; 科 技 部 重 点 研 发 计 划", "bbox": [108.0, 498.0, 605.0, 515.0]}, {"text": "(2022YFC2010000,2022YFC2010002); 国家卫健委数据库建设项目(YXFSC2022JJSJ002)", "bbox": [85.0, 517.0, 543.0, 534.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "Chinese expert consensus on chest CT scanning and evaluation of chronic obstruction", "bbox": [85.0, 566.0, 605.0, 582.0]}, {"text": "pulmonary disease", "bbox": [85.0, 583.0, 193.0, 597.0]}, {"text": "Cardio-thoracic Group of Chinese Society of Radiology Chinese Medical Association", "bbox": [85.0, 599.0, 497.0, 615.0]}, {"text": "Corresponding author: Zheng Minwen, Department of Radiology, Xijing Hospital, Air Force Military", "bbox": [85.0, 616.0, 605.0, 632.0]}, {"text": "Medical University, Xi'an 710032, China, Email: zhengmw2007@163.com; Guo Youmin, Department of", "bbox": [85.0, 634.0, 606.0, 648.0]}, {"text": "Radiology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China, Email: cjr.", "bbox": [85.0, 650.0, 605.0, 665.0]}, {"text": "guoyoumin@vip. 163. com; Liu Shiyuan, Department of Radiology, the Second Affiliated Hospital of", "bbox": [85.0, 667.0, 605.0, 681.0]}, {"text": "Naval Medical University, Shanghai 200003, China, Email: cjr.liushiyuan@vip.163.com", "bbox": [85.0, 682.0, 518.0, 698.0]}], "type": "Text", "position": 6}, {"raw_context": [{"text": "慢 性 阻 塞 性 肺 疾 病 (chronic obstruction V )", "bbox": [113.0, 728.0, 420.0, 745.0]}, {"text": "pulmonary disease, COPD)是全球关注的重大公共", "bbox": [85.0, 749.0, 391.0, 766.0]}, {"text": "卫生问题, 2019 年世界卫生组织统计 COPD 是全球", "bbox": [85.0, 770.0, 391.0, 787.0]}, {"text": "第 3 大致死疾病。2018 年中国国家慢病和非传染", "bbox": [85.0, 792.0, 390.0, 808.0]}, {"text": "性疾病预防控制中心报道,我国 COPD 患者高达", "bbox": [85.0, 814.0, 391.0, 830.0]}, {"text": "1 亿人,每分钟有 1.9 人死于 COPD, 2004 至 2015 年", "bbox": [85.0, 836.0, 390.0, 852.0]}, {"text": "发病率增幅为 65.9%, 40 岁以上人群发病率为", "bbox": [85.0, 857.0, 391.0, 873.0]}, {"text": "13.6% [1-2] 。 与 COPD 严峻的诊疗现状相对应的却是", "bbox": [85.0, 876.0, 390.0, 895.0]}, {"text": "我国民众对该病的低知晓率(仅0.9%),这直接导", "bbox": [85.0, 900.0, 391.0, 916.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "致了早诊早治的延误,疾病确诊时往往已是进展", "bbox": [424.0, 728.0, 731.0, 745.0]}, {"text": "期,此时治疗效果明显下降。同时,不佳的疗效和", "bbox": [425.0, 749.0, 732.0, 766.0]}, {"text": "迁延不愈的病程,会大大増加患者的医疗费用,造", "bbox": [425.0, 770.0, 731.0, 787.0]}, {"text": "成了严重的医疗资源浪费和社会经济负担 ¶ 。", "bbox": [425.0, 792.0, 696.0, 809.0]}, {"text": "肺功能检测(pulmonary function test, PFT)是", "bbox": [452.0, 814.0, 731.0, 831.0]}, {"text": "目前临床诊断 COPD 的金标准,但早期诊断的灵敏", "bbox": [425.0, 836.0, 731.0, 852.0]}, {"text": "度不高,通常肺结构破坏 30%以上,才会出现指标", "bbox": [425.0, 857.0, 731.0, 873.0]}, {"text": "的异常 , 且不能反映 COPD 的异质性 [3] 。此外 PFT", "bbox": [425.0, 879.0, 731.0, 895.0]}, {"text": "的单一國值诊断标准[使用支气管扩张剂后,第", "bbox": [425.0, 900.0, 731.0, 916.0]}], "type": "Text", "position": 8}, {"raw_context": [{"text": "DOI : 10.3760/cma.j.cn112149–20220929–00785", "bbox": [85.0, 950.0, 327.0, 966.0]}], "type": "Text", "position": 9}, {"raw_context": [{"text": "Services", "bbox": [85.0, 969.0, 235.0, 984.0]}, {"text": "本文编辑 史晓娟", "bbox": [237.0, 969.0, 335.0, 984.0]}, {"text": "引用本文 : 中华医学会放射学分会心胸学组 . 慢性阻塞性肺疾病胸部 CT检查及评价中国专家共识[J] : 中", "bbox": [85.0, 989.0, 620.0, 1003.0]}, {"text": "华放射学杂志 , 2023, 57(6): 600–607. DOI: 10.3760/cma.j.cn112149–20220929–00785.", "bbox": [85.0, 1007.0, 512.0, 1023.0]}], "type": "Text", "position": 10}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/呼吸科/_慢性阻塞性肺疾病胸部CT检查及评价中国专家共识.pdf", "page_num": 1}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": "错别字#1#1#む胸应是心胸\n ‡ 敏 文 应是郑 敏 文\n\n", "type2": "缺少换行#2#2#【关键词】 肺疾病, 另起一行\n基 金 项 目 : 国 家 自 然 科 学 基 金另起一行\n多余换行#5#6#这直接导   致了早诊早治的延误,是一句话", "type3": "无关文本#0#8#[1-2] 部分段落末尾，以及句末的数字问题无关噪声应用全文\n无关文本#6#6#¶ ", "type4": null, "type5": null, "type6": "有用性#7#8#DOI : 10.3760/cma.j.cn112149–20220929–00785......为页脚内容"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:41", "update_time": "2024-05-08 01:38:43"}
{"id": 1082541, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 738, "source_info": {"seq_id": "ecb18fbe-aca4-44da-864f-f87703da2397", "title": null, "text": "【0】页码:2\n 2\n\n【1】 Diagnosis Management Primary tumour Lymph node management Surgery Chemotherapy Radiotherapy Follow-up Quality of life\n\n【2】\n## 1. Introduction\n\n【3】\n Penile cancer is a rare disease, but it has a significant impact on quality of life (QoL) in many ways. Patients suffer not only the psychological and emotional stress of a cancer diagnosis and what that means for the rest of their lives, but also the psychological impact and stigma of cancer in an intimate part of the body. The guideline panel (Supplementary Table 1 ) strongly recommends that these emotional, social, and physical needs are discussed and addressed early in the patient pathway via a holistic and multidisciplinary approach.\n\n【4】This guideline is the result of a collaboration between the European Association of Urology (EAU) and the American Society of Clinical Oncology (ASCO) to produce a complete revision of prior versions, with the aim of offering worldwide physician and patient guidance regarding the management of this rare disease. For more detailed information and a full list of references, please refer to the full-text version available at https://uroweb.org/guidelines/penile-cancer_and_www.asco.\n\n【5】org/genitourinary-cancer-guidelines .\n\n【6】## 2. Evidence Acquisition\n\n【7】\n New and relevant evidence was identified, collated, and appraised via a structured assessment of the literature.\n\n【8】Comprehensive literature searches were performed for each section topic. Databases searched included Medline, EMBASE, and the Cochrane Libraries. In addition, three systematic reviews were conducted [1–3] . Levels of evidence were assessed and a strength rating for each recommendation was assigned according to the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) methodology.\n\n【9】 and a strength rating for each recommendation was assigned according to the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) methodology.\n\n【10】Evidence synthesis: Penile cancer is a rare disease but its global incidence is increasing.\n\n【11】Human papillomavirus (HPV) is the main risk factor for penile cancer and pathology should include an assessment of HPV status. The main aim of primary tumour treatment is complete tumour eradication, which has to be balanced against optimal organ preservation without compromising oncological control. Early detection and treatment of lymph node (LN) metastasis is the main determinant of survival. Surgical LN staging with sentinel node biopsy is recommended for patients with a high-risk ( ≥ pT1b) tumour with cN0 status. While (inguinal) LN dissection remains the standard for node-positive disease, multimodal treatment is needed in patients with advanced disease. Owing to a lack of controlled trials and large series, the levels of evidence and grades of recommendation are low in comparison to those for more common diseases.\n\n【12】Conclusions:  This collaborative penile cancer guideline provides updated information on the diagnosis and treatment of penile cancer for use in clinical practice. Organpreserving surgery should be offered for treatment of the primary tumour when feasible.\n\n【13】Adequate and timely LN management remains a challenge, especially in advanced disease stages. Referral to centres of expertise is recommended.\n\n【14】 Patient summary: Penile cancer is a rare disease that significantly impacts quality of life.\n\n【15】While the disease can be cured in most cases without lymph node involvement, management of advanced disease remains challenging. Many unmet needs and unanswered questions remain, underlining the importance of research collaborations and centralisation of penile cancer services.\n\n【16】© 2023 European Association of Urology. Published by Elsevier B.V. All rights reserved.\n\n【17】\n## 3. Evidence Synthesis\n\n【18】\n## Epidemiology, Aetiology, And Pathology 3.1.\n\n【19】\n 3.1.1.\n\n【20】Epidemiology The incidence of penile cancer varies according to geographical location, race, and ethnicity. In industrialised countries, penile cancer is uncommon, with an overall incidence of approximately 0.94 per 100 000 males in Europe and 0.5 per 100 000 males in the USA [4] . By contrast, the incidence is much higher in South America, Southeast Asia, and parts of Africa and can account for 1–2% of malignant disease cases among men. The annual age-adjusted incidence per 100 000 is 0.7–3.0 in India and 8.3 in Brazil, and is even higher in parts of Africa such as Uganda [4] . In recent years, a slight increase in incidence has been observed in Western and developed countries, most likely caused by higher rates of infection with human papillomavirus (HPV), which is a trend also observed for other cancers [5,6] .\n\n【21】The incidence of penile cancer increases with age, with a peak in the sixth decade, but it does occur in younger patients [ 7 ].\n\n【22】 3.1.2.\n\n【23】Aetiology More than 95% of penile cancers are squamous cell carcinoma (SCC). Different histological subtypes of penile SCC exist ( Table 1 ). Other malignant lesions of the penis include sarcomatoid lesions, melanocytic and mesenchymal tumours, lymphomas, and metastases, all of which are extremely rare in comparison to SCC. Penile SCC usually arises from the epithelium of the inner prepuce or the glans.\n\n【24】Penile intraepithelial neoplasia (PeIN) is considered the precursor lesion of penile SCC (clinical terms such as erythroplasia of Queyrat, carcinoma in situ, and Bowen's", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "2", "bbox": [61.0, 42.0, 72.0, 55.0]}], "type": "Text", "position": 0}, {"raw_context": [{"text": "Diagnosis", "bbox": [61.0, 89.0, 115.0, 104.0]}, {"text": "Management", "bbox": [61.0, 104.0, 134.0, 118.0]}, {"text": "Primary tumour", "bbox": [61.0, 119.0, 150.0, 131.0]}, {"text": "Lymph node management", "bbox": [60.0, 132.0, 205.0, 145.0]}, {"text": "Surgery", "bbox": [62.0, 147.0, 106.0, 159.0]}, {"text": "Chemotherapy", "bbox": [60.0, 159.0, 142.0, 173.0]}, {"text": "Radiotherapy", "bbox": [61.0, 173.0, 135.0, 187.0]}, {"text": "Follow-up", "bbox": [61.0, 188.0, 119.0, 201.0]}, {"text": "Quality of life", "bbox": [60.0, 202.0, 138.0, 216.0]}], "type": "Table", "position": 3}, {"raw_context": [{"text": "1. Introduction", "bbox": [61.0, 476.0, 152.0, 490.0]}], "type": "Section-header", "position": 4}, {"raw_context": [{"text": "Penile cancer is a rare disease, but it has a significant impact", "bbox": [61.0, 510.0, 382.0, 525.0]}, {"text": "on quality of life (QoL) in many ways. Patients suffer not", "bbox": [61.0, 525.0, 383.0, 540.0]}, {"text": "only the psychological and emotional stress of a cancer", "bbox": [61.0, 541.0, 382.0, 555.0]}, {"text": "diagnosis and what that means for the rest of their lives,", "bbox": [61.0, 557.0, 382.0, 570.0]}, {"text": "but also the psychological impact and stigma of cancer in", "bbox": [61.0, 572.0, 383.0, 585.0]}, {"text": "an intimate part of the body. The guideline panel (Supple-", "bbox": [61.0, 587.0, 381.0, 601.0]}, {"text": "mentary Table 1 ) strongly recommends that these emo-", "bbox": [61.0, 603.0, 382.0, 616.0]}, {"text": "tional, social, and physical needs are discussed and", "bbox": [61.0, 617.0, 383.0, 631.0]}, {"text": "addressed early in the patient pathway via a holistic and", "bbox": [61.0, 632.0, 383.0, 647.0]}, {"text": "multidisciplinary approach.", "bbox": [61.0, 649.0, 210.0, 662.0]}, {"text": "This guideline is the result of a collaboration between the", "bbox": [77.0, 663.0, 383.0, 677.0]}, {"text": "European Association of Urology (EAU) and the American", "bbox": [61.0, 678.0, 383.0, 693.0]}, {"text": "Society of Clinical Oncology (ASCO) to produce a complete", "bbox": [61.0, 694.0, 383.0, 708.0]}, {"text": "revision of prior versions, with the aim of offering worldwide", "bbox": [61.0, 709.0, 383.0, 723.0]}, {"text": "physician and patient guidance regarding the management of", "bbox": [61.0, 724.0, 383.0, 739.0]}, {"text": "this rare disease. For more detailed information and a full list", "bbox": [61.0, 740.0, 383.0, 754.0]}, {"text": "of references, please refer to the full-text version available at", "bbox": [61.0, 755.0, 383.0, 769.0]}, {"text": "https://uroweb.org/guidelines/penile-cancer_and_www.asco.", "bbox": [61.0, 770.0, 382.0, 784.0]}, {"text": "org/genitourinary-cancer-guidelines .", "bbox": [61.0, 785.0, 252.0, 799.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "2. Evidence acquisition", "bbox": [60.0, 822.0, 197.0, 836.0]}], "type": "Section-header", "position": 6}, {"raw_context": [{"text": "New and relevant evidence was identified, collated, and", "bbox": [61.0, 856.0, 383.0, 871.0]}, {"text": "appraised via a structured assessment of the literature.", "bbox": [61.0, 871.0, 382.0, 886.0]}, {"text": "Comprehensive literature searches were performed for each", "bbox": [61.0, 886.0, 383.0, 901.0]}, {"text": "section topic. Databases searched included Medline,", "bbox": [61.0, 903.0, 383.0, 916.0]}, {"text": "EMBASE, and the Cochrane Libraries. In addition, three sys-", "bbox": [61.0, 917.0, 382.0, 931.0]}, {"text": "tematic reviews were conducted [1–3] . Levels of evidence", "bbox": [61.0, 932.0, 383.0, 947.0]}, {"text": "were assessed and a strength rating for each recommenda-", "bbox": [61.0, 948.0, 382.0, 962.0]}, {"text": "tion was assigned according to the GRADE (Grading of Rec-", "bbox": [61.0, 963.0, 382.0, 977.0]}, {"text": "ommendations, Assessment, Development, and Evaluation)", "bbox": [61.0, 978.0, 384.0, 992.0]}, {"text": "methodology.", "bbox": [61.0, 994.0, 136.0, 1008.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "and a strength rating for each recommendation was assigned according to the GRADE", "bbox": [281.0, 89.0, 725.0, 104.0]}, {"text": "(Grading of Recommendations, Assessment, Development, and Evaluation) methodology.", "bbox": [279.0, 104.0, 713.0, 118.0]}, {"text": "Evidence synthesis: Penile cancer is a rare disease but its global incidence is increasing.", "bbox": [280.0, 118.0, 725.0, 131.0]}, {"text": "Human papillomavirus (HPV) is the main risk factor for penile cancer and pathology", "bbox": [279.0, 131.0, 726.0, 145.0]}, {"text": "should include an assessment of HPV status. The main aim of primary tumour treatment", "bbox": [280.0, 145.0, 726.0, 159.0]}, {"text": "is complete tumour eradication, which has to be balanced against optimal organ preser-", "bbox": [279.0, 159.0, 725.0, 173.0]}, {"text": "vation without compromising oncological control. Early detection and treatment of", "bbox": [279.0, 173.0, 726.0, 187.0]}, {"text": "lymph node (LN) metastasis is the main determinant of survival. Surgical LN staging", "bbox": [279.0, 187.0, 726.0, 201.0]}, {"text": "with sentinel node biopsy is recommended for patients with a high-risk ( ≥ pT1b) tumour", "bbox": [279.0, 202.0, 726.0, 215.0]}, {"text": "with cN0 status. While (inguinal) LN dissection remains the standard for node-positive", "bbox": [279.0, 216.0, 726.0, 229.0]}, {"text": "disease, multimodal treatment is needed in patients with advanced disease. Owing to a", "bbox": [279.0, 230.0, 727.0, 243.0]}, {"text": "lack of controlled trials and large series, the levels of evidence and grades of recommen-", "bbox": [280.0, 245.0, 725.0, 257.0]}, {"text": "dation are low in comparison to those for more common diseases.", "bbox": [280.0, 259.0, 619.0, 270.0]}, {"text": "Conclusions:  This collaborative penile cancer guideline provides updated information on", "bbox": [280.0, 272.0, 727.0, 285.0]}, {"text": "the diagnosis and treatment of penile cancer for use in clinical practice. Organ-", "bbox": [279.0, 285.0, 725.0, 299.0]}, {"text": "preserving surgery should be offered for treatment of the primary tumour when feasible.", "bbox": [280.0, 300.0, 725.0, 313.0]}, {"text": "Adequate and timely LN management remains a challenge, especially in advanced dis-", "bbox": [280.0, 314.0, 725.0, 327.0]}, {"text": "ease stages. Referral to centres of expertise is recommended.", "bbox": [280.0, 329.0, 591.0, 340.0]}], "type": "Text", "position": 8}, {"raw_context": [{"text": "Patient summary: Penile cancer is a rare disease that significantly impacts quality of life.", "bbox": [280.0, 341.0, 725.0, 354.0]}, {"text": "While the disease can be cured in most cases without lymph node involvement, manage-", "bbox": [279.0, 355.0, 725.0, 368.0]}, {"text": "ment of advanced disease remains challenging. Many unmet needs and unanswered", "bbox": [279.0, 369.0, 727.0, 383.0]}, {"text": "questions remain, underlining the importance of research collaborations and centralisa-", "bbox": [279.0, 383.0, 725.0, 397.0]}, {"text": "tion of penile cancer services.", "bbox": [280.0, 398.0, 432.0, 411.0]}, {"text": "© 2023 European Association of Urology. Published by Elsevier B.V. All rights reserved.", "bbox": [281.0, 410.0, 725.0, 425.0]}], "type": "Table", "position": 9}, {"raw_context": [{"text": "3. Evidence synthesis", "bbox": [403.0, 476.0, 529.0, 490.0]}], "type": "Section-header", "position": 10}, {"raw_context": [{"text": "Epidemiology, aetiology, and pathology", "bbox": [443.0, 508.0, 638.0, 523.0]}, {"text": "3.1.", "bbox": [403.0, 510.0, 424.0, 523.0]}], "type": "Section-header", "position": 11}, {"raw_context": [{"text": "3.1.1.", "bbox": [404.0, 533.0, 432.0, 546.0]}, {"text": "Epidemiology", "bbox": [452.0, 533.0, 520.0, 546.0]}, {"text": "The incidence of penile cancer varies according to geo-", "bbox": [403.0, 547.0, 725.0, 561.0]}, {"text": "graphical location, race, and ethnicity. In industrialised", "bbox": [403.0, 562.0, 726.0, 577.0]}, {"text": "countries, penile cancer is uncommon, with an overall inci-", "bbox": [403.0, 578.0, 725.0, 592.0]}, {"text": "dence of approximately 0.94 per 100 000 males in Europe", "bbox": [403.0, 593.0, 726.0, 607.0]}, {"text": "and 0.5 per 100 000 males in the USA [4] . By contrast, the", "bbox": [403.0, 608.0, 727.0, 623.0]}, {"text": "incidence is much higher in South America, Southeast Asia,", "bbox": [402.0, 623.0, 726.0, 638.0]}, {"text": "and parts of Africa and can account for 1–2% of malignant", "bbox": [403.0, 639.0, 726.0, 653.0]}, {"text": "disease cases among men. The annual age-adjusted inci-", "bbox": [402.0, 654.0, 725.0, 668.0]}, {"text": "dence per 100 000 is 0.7–3.0 in India and 8.3 in Brazil,", "bbox": [403.0, 669.0, 726.0, 683.0]}, {"text": "and is even higher in parts of Africa such as Uganda [4] . In", "bbox": [403.0, 684.0, 727.0, 698.0]}, {"text": "recent years, a slight increase in incidence has been", "bbox": [402.0, 699.0, 727.0, 714.0]}, {"text": "observed in Western and developed countries, most likely", "bbox": [402.0, 715.0, 726.0, 729.0]}, {"text": "caused by higher rates of infection with human papillo-", "bbox": [402.0, 730.0, 725.0, 744.0]}, {"text": "mavirus (HPV), which is a trend also observed for other can-", "bbox": [402.0, 745.0, 725.0, 760.0]}, {"text": "cers [5,6] .", "bbox": [403.0, 763.0, 458.0, 775.0]}, {"text": "The incidence of penile cancer increases with age, with a", "bbox": [420.0, 776.0, 727.0, 790.0]}, {"text": "peak in the sixth decade, but it does occur in younger", "bbox": [402.0, 791.0, 726.0, 805.0]}, {"text": "patients [ 7 ].", "bbox": [403.0, 807.0, 471.0, 821.0]}], "type": "Text", "position": 12}, {"raw_context": [{"text": "3.1.2.", "bbox": [404.0, 843.0, 432.0, 855.0]}, {"text": "Aetiology", "bbox": [453.0, 843.0, 500.0, 855.0]}, {"text": "More than 95% of penile cancers are squamous cell carci-", "bbox": [402.0, 856.0, 726.0, 871.0]}, {"text": "noma (SCC). Different histological subtypes of penile SCC", "bbox": [402.0, 871.0, 726.0, 886.0]}, {"text": "exist ( Table 1 ). Other malignant lesions of the penis include", "bbox": [402.0, 886.0, 726.0, 901.0]}, {"text": "sarcomatoid lesions,", "bbox": [513.0, 903.0, 642.0, 916.0]}, {"text": "melanocytic", "bbox": [404.0, 904.0, 477.0, 916.0]}, {"text": "and", "bbox": [480.0, 904.0, 512.0, 916.0]}, {"text": "mesenchymal", "bbox": [647.0, 904.0, 726.0, 916.0]}, {"text": "tumours, lymphomas, and metastases, all of which are", "bbox": [402.0, 917.0, 726.0, 931.0]}, {"text": "extremely rare in comparison to SCC. Penile SCC usually", "bbox": [402.0, 932.0, 726.0, 947.0]}, {"text": "arises from the epithelium of the inner prepuce or the glans.", "bbox": [403.0, 948.0, 725.0, 962.0]}, {"text": "Penile intraepithelial neoplasia (PeIN) is considered the", "bbox": [419.0, 963.0, 726.0, 977.0]}, {"text": "precursor lesion of penile SCC (clinical terms such as", "bbox": [403.0, 978.0, 726.0, 993.0]}, {"text": "erythroplasia of Queyrat, carcinoma in situ, and Bowen's", "bbox": [403.0, 994.0, 726.0, 1008.0]}], "type": "Text", "position": 13}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/泌尿外科/2023 EAU／ASCO指南：阴茎癌（更新版）.pdf", "page_num": 2}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "多余换行#4#5#and_www.asco.和org/genitourinary-cancer-guidelines .是一句话\n多余换行#8#9#and Evaluation) methodology.和and a strength rating for each是一句话\n序号格式不一致#18#18#3.1.应该在句首\n缺少换行#20#20#The incidence of penile cancer varies另起一行\n序号格式不一致#23#23#More than 95% of penile cancers 另起一行\n", "type3": null, "type4": null, "type5": null, "type6": null}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:41", "update_time": "2024-05-07 23:27:52"}
{"id": 1082540, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 738, "source_info": {"seq_id": "0e39b14a-4695-4a80-a2b3-7008d7388983", "title": null, "text": "【0】页码:12\n\n【1】## Facility And Personnel\n\n【2】\n The facilities required will depend on national legislation for the emission of beta- ( 90 Y-microspheres) and beta- and gamma-emitting ( 166 Ho) therapeutics. If required by law, the patient should be admitted to an approved isolation facility comprising an appropriately shielded room and en suite bathroom facilities. The radiation field at 1 m from the patient's abdomen immediately after administration is 1.14 µSv/h/GBq for 90 Y microspheres [ 108 ]. This gives 3 µ Sv/h for typical 2.6 GBq glass microsphere administration, and 1.8 µSv/h for 1.6 GBq resin microspheres. For 166Ho, external exposure at 1-m spans from 8 to 60 pSv/h at 1 m [109] . / The facility in which treatment is administered must have appropriate personnel, radiation safety equipment, procedures available for waste handling and disposal, handling of contamination, monitoring personnel for accidental contamination and controlling contamination spread.\n\n【3】The administration of 90 Y- and 166 Ho-microspheres should be undertaken by trained medical staff with supporting physics and nursing staff. Clinicians involved in unsealed source therapy must be knowledgeable about and compliant with all applicable national and local legislation and regulations.\n\n【4】To summarize, the development and establishment of an interdisciplinary team (interventional radiology; medical, radiation and surgical oncology; transplant surgery; nuclear medicine; hepatology; medical physics; and radiation safety) is crucial to the success of the treatment.\n\n【5】## Staff Exposure\n\n【6】\n The most critical steps of exposure are the microsphere injections and, eventually, the microsphere preparation in the radiopharmacy (activity measuring and aliquoting when required).\n\n【7】A comparative study has evaluated occupational exposure for glass and resin 90 Y-microspheres [ 110 ]. Reported equivalent doses H p (10) are less than 2 µ Sv/GBq for both microspheres for preparation and injection. Reported finger exposure with 90 Y glass microspheres is 14.0 ± 7.9 µ Sv/GBq for the operator injecting microspheres and 13.5 ± 5.2 µ Sv/ GBq for the radiopharmacist measuring the vial activity.\n\n【8】With 90 Y resin microspheres reported finger exposure are 235.5 ± 156 µ Sv/GBq for the operator injecting microspheres and 295.2 ± 271.9 µ Sv/GBq for the radiopharmacist measuring the vial activity and aliquoting the vial.\n\n【9】Another group evaluated equivalent doses H p (10) and finger doses from 166 Ho exposure [ 111 ]. Reported wholebody doses were less than 3 µ Sv/GBq. Maximum finger\n\n【10】 doses of 2.9 ± 0.2 × 10 3 µ Sv/GBq and 2.5 ± 0.3 × 10 3 µ Sv/ GBq (2.9±0.2 µSv/MBq and 2.5±0.3 µSv/MBq) have been reported for the for preparation and injection of 166 Ho microspheres, respectively.\n\n【11】It should be taken into consideration that the limited ring sensitivity to beta emissions from 166Ho and 90Y may lead to a severe underestimation of actual absorbed doses. To account for this, measured dose rates can be complemented by an assessment of theoretical dose rates using dedicated software.\n\n【12】## Patient Information And Instruction\n\n【13】\n Patients should receive both written and verbal information on the procedure prior to therapy. Depending on the respective country's legislation, informed written consent from the patient should be obtained. Unless performed in a preoperative setting, patients should be told that this therapy is not likely to cure their disease and is a palliative treatment directed to their liver lesion(s). Patients must be informed of the potential side effects of therapy and alternative treatment options. Patients must be advised to reduce unnecessary radiation exposure and contamination to family members and the public. Written instructions should be provided where required.\n\n【14】## Radiation Protection\n\n【15】\n Any significant medical conditions should be noted, and contingency plans made in case radiation precautions must be breached for a medical emergency. Concern about radiation exposure should not interfere with the prompt appropriate medical treatment of the patient. Dose rate to the workers should be monitored during the treatment. Written instructions should be provided where required. The required radiation protection attention is different depending on the used radionuclide. It is minimal with 90 Y since the external dose/ rate is low for all products used. With 166 Ho, a significantly higher exposure rate after treatment should be considered.\n\n【16】For all three products, substantial skin doses may occur in case of contamination during preparation or administration.\n\n【17】After the treatment, patients should avoid pregnancy for at least 4 months. In reality, it is unlikely that women of childbearing age will be eligible for this therapy. Anyway, Gulec et al. [ 112 ] calculated that pregnancy shortly after a simulated treatment with 90 Y-microspheres does not induce a relevant irradiation to the embryo. Long-lived radioisotope impurities have been observed and may be taken into consideration in the context of waste management [ 113 ]. They do", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "Facility and personnel", "bbox": [65.0, 69.0, 227.0, 92.0]}], "type": "Section-header", "position": 0}, {"raw_context": [{"text": "The facilities required will depend on national legislation", "bbox": [66.0, 108.0, 387.0, 123.0]}, {"text": "for the emission of beta- ( 90 Y-microspheres) and beta- and", "bbox": [66.0, 124.0, 387.0, 141.0]}, {"text": "gamma-emitting ( 166 Ho) therapeutics. If required by law,", "bbox": [66.0, 141.0, 387.0, 157.0]}, {"text": "the patient should be admitted to an approved isolation", "bbox": [65.0, 159.0, 389.0, 174.0]}, {"text": "facility comprising an appropriately shielded room and en", "bbox": [66.0, 175.0, 387.0, 190.0]}, {"text": "suite bathroom facilities. The radiation field at 1 m from", "bbox": [66.0, 193.0, 388.0, 207.0]}, {"text": "the patient's abdomen immediately after administration is", "bbox": [65.0, 209.0, 387.0, 224.0]}, {"text": "1.14 µSv/h/GBq for 90 Y microspheres [ 108 ]. This gives", "bbox": [66.0, 225.0, 387.0, 240.0]}, {"text": "3 µ Sv/h for typical 2.6 GBq glass microsphere administra-", "bbox": [66.0, 242.0, 386.0, 257.0]}, {"text": "tion, and 1.8 µSv/h for 1.6 GBq resin microspheres. For", "bbox": [65.0, 258.0, 387.0, 275.0]}, {"text": "166Ho, external exposure at 1-m spans from 8 to 60 pSv/h", "bbox": [66.0, 275.0, 387.0, 291.0]}, {"text": "at 1 m [109] . /", "bbox": [65.0, 292.0, 143.0, 307.0]}, {"text": "The facility in which treatment is administered must have", "bbox": [82.0, 309.0, 387.0, 324.0]}, {"text": "appropriate personnel, radiation safety equipment, proce-", "bbox": [65.0, 326.0, 386.0, 340.0]}, {"text": "dures available for waste handling and disposal, handling of", "bbox": [64.0, 342.0, 387.0, 357.0]}, {"text": "contamination, monitoring personnel for accidental contami-", "bbox": [65.0, 359.0, 385.0, 374.0]}, {"text": "nation and controlling contamination spread.", "bbox": [65.0, 376.0, 309.0, 390.0]}, {"text": "The administration of 90 Y- and 166 Ho-microspheres", "bbox": [82.0, 391.0, 387.0, 407.0]}, {"text": "should be undertaken by trained medical staff with sup-", "bbox": [65.0, 408.0, 385.0, 423.0]}, {"text": "porting physics and nursing staff. Clinicians involved in", "bbox": [66.0, 426.0, 388.0, 440.0]}, {"text": "unsealed source therapy must be knowledgeable about and", "bbox": [65.0, 443.0, 387.0, 457.0]}, {"text": "compliant with all applicable national and local legislation", "bbox": [65.0, 459.0, 387.0, 473.0]}, {"text": "and regulations.", "bbox": [65.0, 475.0, 154.0, 490.0]}, {"text": "To summarize, the development and establishment of an", "bbox": [78.0, 492.0, 387.0, 508.0]}, {"text": "interdisciplinary team (interventional radiology; medical,", "bbox": [66.0, 509.0, 387.0, 523.0]}, {"text": "radiation and surgical oncology; transplant surgery; nuclear", "bbox": [66.0, 526.0, 387.0, 540.0]}, {"text": "medicine; hepatology; medical physics; and radiation safety)", "bbox": [66.0, 542.0, 387.0, 557.0]}, {"text": "is crucial to the success of the treatment.", "bbox": [66.0, 559.0, 288.0, 574.0]}], "type": "Text", "position": 1}, {"raw_context": [{"text": "Staff exposure", "bbox": [65.0, 607.0, 172.0, 625.0]}], "type": "Section-header", "position": 2}, {"raw_context": [{"text": "The most critical steps of exposure are the microsphere", "bbox": [66.0, 642.0, 387.0, 656.0]}, {"text": "injections and, eventually, the microsphere preparation in", "bbox": [65.0, 659.0, 387.0, 674.0]}, {"text": "the radiopharmacy (activity measuring and aliquoting when", "bbox": [65.0, 676.0, 387.0, 691.0]}, {"text": "required).", "bbox": [65.0, 693.0, 121.0, 707.0]}, {"text": "A comparative study has evaluated occupational expo-", "bbox": [80.0, 708.0, 385.0, 723.0]}, {"text": "sure for glass and resin 90 Y-microspheres [ 110 ]. Reported", "bbox": [65.0, 724.0, 387.0, 741.0]}, {"text": "equivalent doses H p (10) are less than 2 µ Sv/GBq for both", "bbox": [64.0, 742.0, 388.0, 757.0]}, {"text": "microspheres for preparation and injection. Reported finger", "bbox": [65.0, 759.0, 387.0, 773.0]}, {"text": "exposure with 90 Y glass microspheres is 14.0 ± 7.9 µ Sv/GBq", "bbox": [65.0, 775.0, 387.0, 790.0]}, {"text": "for the operator injecting microspheres and 13.5 ± 5.2 µ Sv/", "bbox": [65.0, 793.0, 387.0, 807.0]}, {"text": "GBq for the radiopharmacist measuring the vial activity.", "bbox": [64.0, 809.0, 387.0, 824.0]}, {"text": "With 90 Y resin microspheres reported finger exposure are", "bbox": [66.0, 826.0, 387.0, 841.0]}, {"text": "235.5 ± 156 µ Sv/GBq for the operator injecting micro-", "bbox": [66.0, 842.0, 389.0, 857.0]}, {"text": "spheres and 295.2 ± 271.9 µ Sv/GBq for the radiopharmacist", "bbox": [66.0, 859.0, 388.0, 874.0]}, {"text": "measuring the vial activity and aliquoting the vial.", "bbox": [65.0, 876.0, 339.0, 891.0]}, {"text": "Another group evaluated equivalent doses H p (10) and", "bbox": [81.0, 893.0, 387.0, 908.0]}, {"text": "finger doses from 166 Ho exposure [ 111 ]. Reported whole-", "bbox": [65.0, 909.0, 385.0, 924.0]}, {"text": "body doses were less than 3 µ Sv/GBq. Maximum finger", "bbox": [64.0, 925.0, 387.0, 940.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "doses of 2.9 ± 0.2 × 10 3 µ Sv/GBq and 2.5 ± 0.3 × 10 3 µ Sv/", "bbox": [405.0, 72.0, 728.0, 88.0]}, {"text": "GBq (2.9±0.2 µSv/MBq and 2.5±0.3 µSv/MBq) have been", "bbox": [405.0, 90.0, 727.0, 105.0]}, {"text": "reported for the for preparation and injection of 166 Ho micro-", "bbox": [405.0, 107.0, 726.0, 121.0]}, {"text": "spheres, respectively.", "bbox": [405.0, 123.0, 522.0, 138.0]}, {"text": "It should be taken into consideration that the limited ring", "bbox": [421.0, 140.0, 727.0, 155.0]}, {"text": "sensitivity to beta emissions from 166Ho and 90Y may lead", "bbox": [406.0, 157.0, 727.0, 171.0]}, {"text": "to a severe underestimation of actual absorbed doses. To", "bbox": [405.0, 174.0, 727.0, 189.0]}, {"text": "account for this, measured dose rates can be complemented", "bbox": [406.0, 190.0, 728.0, 205.0]}, {"text": "by an assessment of theoretical dose rates using dedicated", "bbox": [405.0, 207.0, 727.0, 221.0]}, {"text": "software.", "bbox": [406.0, 224.0, 458.0, 239.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "Patient information and instruction", "bbox": [406.0, 271.0, 662.0, 289.0]}], "type": "Section-header", "position": 6}, {"raw_context": [{"text": "Patients should receive both written and verbal informa-", "bbox": [405.0, 306.0, 726.0, 321.0]}, {"text": "tion on the procedure prior to therapy. Depending on the", "bbox": [405.0, 323.0, 727.0, 339.0]}, {"text": "respective country's legislation, informed written consent", "bbox": [405.0, 341.0, 727.0, 355.0]}, {"text": "from the patient should be obtained. Unless performed in a", "bbox": [405.0, 357.0, 727.0, 371.0]}, {"text": "preoperative setting, patients should be told that this therapy", "bbox": [405.0, 373.0, 727.0, 388.0]}, {"text": "is not likely to cure their disease and is a palliative treatment", "bbox": [405.0, 390.0, 727.0, 405.0]}, {"text": "directed to their liver lesion(s). Patients must be informed", "bbox": [405.0, 407.0, 727.0, 422.0]}, {"text": "of the potential side effects of therapy and alternative treat-", "bbox": [405.0, 423.0, 726.0, 438.0]}, {"text": "ment options. Patients must be advised to reduce unneces-", "bbox": [405.0, 440.0, 726.0, 455.0]}, {"text": "sary radiation exposure and contamination to family mem-", "bbox": [406.0, 457.0, 726.0, 472.0]}, {"text": "bers and the public. Written instructions should be provided", "bbox": [405.0, 474.0, 727.0, 488.0]}, {"text": "where required.", "bbox": [405.0, 491.0, 492.0, 505.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "Radiation protection", "bbox": [406.0, 547.0, 557.0, 564.0]}], "type": "Section-header", "position": 8}, {"raw_context": [{"text": "Any significant medical conditions should be noted, and", "bbox": [406.0, 582.0, 727.0, 596.0]}, {"text": "contingency plans made in case radiation precautions must", "bbox": [404.0, 599.0, 727.0, 614.0]}, {"text": "be breached for a medical emergency. Concern about radia-", "bbox": [405.0, 616.0, 726.0, 631.0]}, {"text": "tion exposure should not interfere with the prompt appropri-", "bbox": [405.0, 633.0, 726.0, 647.0]}, {"text": "ate medical treatment of the patient. Dose rate to the workers", "bbox": [405.0, 649.0, 727.0, 663.0]}, {"text": "should be monitored during the treatment. Written instruc-", "bbox": [405.0, 665.0, 726.0, 680.0]}, {"text": "tions should be provided where required. The required radia-", "bbox": [405.0, 683.0, 726.0, 698.0]}, {"text": "tion protection attention is different depending on the used", "bbox": [405.0, 699.0, 727.0, 713.0]}, {"text": "radionuclide. It is minimal with 90 Y since the external dose/", "bbox": [405.0, 714.0, 731.0, 730.0]}, {"text": "rate is low for all products used. With 166 Ho, a significantly", "bbox": [405.0, 731.0, 726.0, 747.0]}, {"text": "higher exposure rate after treatment should be considered.", "bbox": [405.0, 749.0, 726.0, 763.0]}, {"text": "For all three products, substantial skin doses may occur in", "bbox": [405.0, 766.0, 728.0, 780.0]}, {"text": "case of contamination during preparation or administration.", "bbox": [405.0, 783.0, 726.0, 797.0]}, {"text": "After the treatment, patients should avoid pregnancy for", "bbox": [406.0, 799.0, 727.0, 814.0]}, {"text": "at least 4 months. In reality, it is unlikely that women of", "bbox": [405.0, 815.0, 727.0, 830.0]}, {"text": "childbearing age will be eligible for this therapy. Anyway,", "bbox": [405.0, 833.0, 727.0, 847.0]}, {"text": "Gulec et al. [ 112 ] calculated that pregnancy shortly after a", "bbox": [405.0, 850.0, 728.0, 864.0]}, {"text": "simulated treatment with 90 Y-microspheres does not induce", "bbox": [405.0, 865.0, 727.0, 881.0]}, {"text": "a relevant irradiation to the embryo. Long-lived radioisotope", "bbox": [405.0, 882.0, 727.0, 897.0]}, {"text": "impurities have been observed and may be taken into consid-", "bbox": [405.0, 900.0, 726.0, 914.0]}, {"text": "eration in the context of waste management [ 113 ]. They do", "bbox": [405.0, 916.0, 728.0, 931.0]}], "type": "Text", "position": 9}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2022】全科室最全临床指南+专家共识（最全版）/2022全科室临床指南/肿瘤科/EANM：动脉内放射性化合物治疗肝癌和转移性肝癌指南（2022）(1).pdf", "page_num": 12}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type2": "缺少换行#2#2#The facility in which treatment另起一行\n多余换行#9#10#Maximum finger和doses of 2.9 ± 0.2 × 10 3 是一句话", "type3": "无关文本#0#17#microspheres [ 108 ]部分段落末尾，以及句末的数字问题无关噪声应用全文"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:41", "update_time": "2024-05-07 23:21:55"}
{"id": 1082539, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 738, "source_info": {"seq_id": "8f759e75-f028-4ad8-80f4-eebdc02fbd64", "title": null, "text": "【0】页码:3\n 2023\n\n【1】 3\n\n【2】 10.\n\n【3】, [14] \" \"  [15] \",\" \",\" \",\" \" \" .\n\n【4】(2014 ) [12] 1~5 o\n\n【5】 (n=13 648);UpToDate(n=1); (n =1); (n =1); (n= (n =1); 1); (n=1); (n=1); (n= 1 637); ( n =1 692);PubMed( n =1 585);\n\n【6】\n ,\n\n【7】 Embase ( n =490); Cochrane Library ( n =3 172); Web of Science\n\n【8】 ( n =4 564 ) (n =3 302) ( n =10 346) (n =10 124) : (n =8 436); ( n =1 688 ) n =222) (n=197): (n=25) (n=124); 111111111111111111 15:44.\n\n【9】(n=73) 151, 151 14.4.4.4 111;5\n\n【10】\n 2 2.1 (n=197): (n=25) (n=124); 13 648 111111111111111111 15:44.\n\n【11】(n=73) 10 346 151, 151 14.4.4.4 111;5 25   , 11 10,4 11.1 4 10.5 1 1, 1.\n\n【12】Figure 1 Flow chart of literature search and 2.2 screening [4,7,13-21] , ICC 111 0.979 .\n\n【13】0.809 ,0.792 ,0.827 ,0.92 ,0.779 ,0.535 ,0.672 ,0.693 , 30 , .\n\n【14】0.500 , 0.651 , 2.\n\n【15】4.4 .\n\n【16】, .\n\n【17】[2225] 4 3.\n\n【18】, 100 6 \"_ \" \"     \" \" \" 3 [26] UpToDate , 3.1 1 o , [27-30] 10.4 Goh [29] . \n\n【19】\"  KOA 5\" l , 10.\n\n【20】\" \" \", [13-14,16,18,25] 6\" 11\" \"      \"      \" [36] ,KOA \" \"; [30] \", , 6 \"  , 1990, \" \" : [27-28] 2 , 10.\n\n【21】\" \" \" .\n\n【22】10. See also , o , [31-38] 5 Rewald o         , 2\" KOA Messier [35] , , 100 [37] \" \" \", 4\" .\n\n【23】.\n\n【24】, \"  5\" 1. \" \" \"; Azizi [38] .\n\n【25】, \"  \" 9\" 4.\n\n【26】5 ; Chapter 1 \" \"; \" \" \" \" o KOA , \"       \" 5 Ince [31] Construction .\n\n【27】\" \".\n\n【28】Chapter 1 , .\n\n【29】2.3\n\n【30】 58\n\n【31】  6", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "2023", "bbox": [159.0, 46.0, 187.0, 61.0]}], "type": "Text", "position": 0}, {"raw_context": [{"text": "3", "bbox": [199.0, 48.0, 211.0, 60.0]}], "type": "Text", "position": 1}, {"raw_context": [{"text": "10.", "bbox": [357.0, 100.0, 366.0, 109.0]}, {"text": ",", "bbox": [146.0, 101.0, 154.0, 110.0]}, {"text": "[14]", "bbox": [97.0, 111.0, 122.0, 126.0]}, {"text": "\"", "bbox": [157.0, 114.0, 170.0, 126.0]}, {"text": "\" ", "bbox": [113.0, 133.0, 127.0, 146.0]}, {"text": "[15]", "bbox": [211.0, 132.0, 234.0, 147.0]}, {"text": "\",\" \",\" \",\" \"", "bbox": [315.0, 166.0, 324.0, 175.0]}, {"text": "\" .", "bbox": [262.0, 176.0, 279.0, 197.0]}, {"text": "(2014 ) [12]", "bbox": [200.0, 223.0, 279.0, 236.0]}, {"text": "1~5", "bbox": [253.0, 244.0, 282.0, 260.0]}, {"text": "o", "bbox": [167.0, 272.0, 178.0, 283.0]}], "type": "Text", "position": 2}, {"raw_context": [{"text": "(n=13 648);UpToDate(n=1);", "bbox": [516.0, 79.0, 653.0, 95.0]}, {"text": "(n =1);", "bbox": [528.0, 97.0, 596.0, 110.0]}, {"text": "(n =1);", "bbox": [595.0, 97.0, 635.0, 110.0]}, {"text": "(n=", "bbox": [707.0, 98.0, 725.0, 111.0]}, {"text": "(n =1);", "bbox": [531.0, 111.0, 597.0, 128.0]}, {"text": "1);", "bbox": [428.0, 112.0, 454.0, 128.0]}, {"text": "(n=1);", "bbox": [428.0, 129.0, 468.0, 143.0]}, {"text": "(n=1);", "bbox": [533.0, 129.0, 663.0, 143.0]}, {"text": "(n=", "bbox": [707.0, 131.0, 726.0, 142.0]}, {"text": "1 637);", "bbox": [428.0, 144.0, 470.0, 159.0]}, {"text": "( n =1 692);PubMed( n =1 585);", "bbox": [525.0, 145.0, 727.0, 158.0]}], "type": "Table", "position": 3}, {"raw_context": [{"text": ",", "bbox": [387.0, 142.0, 397.0, 154.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": "Embase ( n =490); Cochrane Library ( n =3 172); Web of Science", "bbox": [427.0, 160.0, 726.0, 176.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "( n =4 564 )", "bbox": [429.0, 176.0, 479.0, 191.0]}, {"text": "(n =3 302)", "bbox": [653.0, 202.0, 703.0, 217.0]}, {"text": "( n =10 346)", "bbox": [442.0, 241.0, 491.0, 257.0]}, {"text": "(n =10 124) :", "bbox": [600.0, 251.0, 661.0, 265.0]}, {"text": "(n =8 436);", "bbox": [600.0, 266.0, 657.0, 282.0]}, {"text": "( n =1 688 )", "bbox": [600.0, 283.0, 650.0, 299.0]}, {"text": "n =222)", "bbox": [494.0, 291.0, 530.0, 306.0]}, {"text": "(n=197):", "bbox": [599.0, 332.0, 648.0, 347.0]}, {"text": "(n=25)", "bbox": [505.0, 341.0, 542.0, 354.0]}, {"text": "(n=124);", "bbox": [590.0, 348.0, 643.0, 363.0]}, {"text": "111111111111111111", "bbox": [441.0, 356.0, 457.0, 371.0]}, {"text": "15:44.", "bbox": [486.0, 357.0, 502.0, 371.0]}, {"text": "(n=73)", "bbox": [590.0, 364.0, 627.0, 379.0]}, {"text": "151, 151", "bbox": [452.0, 373.0, 468.0, 388.0]}, {"text": "14.4.4.4", "bbox": [521.0, 374.0, 537.0, 388.0]}, {"text": "111;5", "bbox": [487.0, 390.0, 503.0, 404.0]}], "type": "Table", "position": 6}, {"raw_context": [{"text": "2", "bbox": [83.0, 309.0, 97.0, 325.0]}, {"text": "2.1", "bbox": [84.0, 330.0, 107.0, 346.0]}, {"text": "(n=197):", "bbox": [599.0, 332.0, 648.0, 347.0]}, {"text": "(n=25)", "bbox": [505.0, 341.0, 542.0, 354.0]}, {"text": "(n=124);", "bbox": [590.0, 348.0, 643.0, 363.0]}, {"text": "13 648", "bbox": [268.0, 352.0, 312.0, 367.0]}, {"text": "111111111111111111", "bbox": [441.0, 356.0, 457.0, 371.0]}, {"text": "15:44.", "bbox": [486.0, 357.0, 502.0, 371.0]}, {"text": "(n=73)", "bbox": [590.0, 364.0, 627.0, 379.0]}, {"text": "10 346", "bbox": [187.0, 373.0, 234.0, 389.0]}, {"text": "151, 151", "bbox": [452.0, 373.0, 468.0, 388.0]}, {"text": "14.4.4.4", "bbox": [521.0, 374.0, 537.0, 388.0]}, {"text": "111;5", "bbox": [487.0, 390.0, 503.0, 404.0]}, {"text": "25   ,", "bbox": [84.0, 395.0, 125.0, 411.0]}, {"text": "11", "bbox": [150.0, 395.0, 170.0, 411.0]}, {"text": "10,4", "bbox": [198.0, 397.0, 228.0, 412.0]}, {"text": "11.1", "bbox": [277.0, 398.0, 316.0, 412.0]}, {"text": "4", "bbox": [82.0, 417.0, 100.0, 432.0]}, {"text": "10.5", "bbox": [167.0, 417.0, 185.0, 432.0]}, {"text": "1", "bbox": [520.0, 432.0, 529.0, 446.0]}, {"text": "1,", "bbox": [89.0, 438.0, 117.0, 455.0]}, {"text": "1.", "bbox": [267.0, 439.0, 288.0, 455.0]}, {"text": "Figure 1 Flow chart of literature search and", "bbox": [447.0, 450.0, 702.0, 466.0]}, {"text": "2.2", "bbox": [83.0, 459.0, 107.0, 476.0]}, {"text": "screening", "bbox": [549.0, 471.0, 605.0, 486.0]}, {"text": "[4,7,13-21] , ICC", "bbox": [248.0, 476.0, 322.0, 500.0]}, {"text": "111", "bbox": [193.0, 481.0, 215.0, 497.0]}, {"text": "0.979 .", "bbox": [352.0, 481.0, 396.0, 497.0]}, {"text": "0.809 ,0.792 ,0.827 ,0.92 ,0.779 ,0.535 ,0.672 ,0.693 ,", "bbox": [82.0, 502.0, 389.0, 520.0]}, {"text": "30", "bbox": [607.0, 503.0, 629.0, 519.0]}, {"text": ",", "bbox": [664.0, 509.0, 681.0, 521.0]}, {"text": ".", "bbox": [504.0, 510.0, 518.0, 521.0]}, {"text": "0.500 , 0.651 ,", "bbox": [83.0, 523.0, 171.0, 541.0]}, {"text": "2.", "bbox": [378.0, 525.0, 395.0, 541.0]}, {"text": "4.4", "bbox": [667.0, 526.0, 684.0, 540.0]}, {"text": ".", "bbox": [606.0, 530.0, 621.0, 543.0]}, {"text": ",", "bbox": [262.0, 531.0, 274.0, 543.0]}, {"text": ".", "bbox": [542.0, 531.0, 555.0, 543.0]}, {"text": "[2225]", "bbox": [335.0, 542.0, 365.0, 557.0]}, {"text": "4", "bbox": [239.0, 547.0, 279.0, 562.0]}, {"text": "3.", "bbox": [447.0, 547.0, 465.0, 563.0]}, {"text": ", 100", "bbox": [165.0, 552.0, 180.0, 563.0]}, {"text": "6 \"_", "bbox": [97.0, 569.0, 134.0, 580.0]}, {"text": "\"", "bbox": [98.0, 586.0, 113.0, 600.0]}, {"text": "\"     \"", "bbox": [132.0, 587.0, 173.0, 600.0]}, {"text": "\"", "bbox": [285.0, 588.0, 299.0, 600.0]}, {"text": "\"", "bbox": [306.0, 587.0, 320.0, 599.0]}, {"text": "3", "bbox": [418.0, 589.0, 432.0, 605.0]}, {"text": "[26]", "bbox": [279.0, 609.0, 300.0, 623.0]}, {"text": "UpToDate ,", "bbox": [328.0, 610.0, 397.0, 627.0]}, {"text": "3.1", "bbox": [418.0, 611.0, 440.0, 627.0]}, {"text": "1", "bbox": [203.0, 612.0, 215.0, 626.0]}, {"text": "o", "bbox": [160.0, 616.0, 187.0, 629.0]}, {"text": ",", "bbox": [99.0, 617.0, 113.0, 630.0]}, {"text": "[27-30]", "bbox": [254.0, 629.0, 286.0, 645.0]}, {"text": "10.4", "bbox": [176.0, 633.0, 191.0, 648.0]}, {"text": "Goh [29]", "bbox": [311.0, 633.0, 372.0, 645.0]}, {"text": ". ", "bbox": [132.0, 638.0, 175.0, 648.0]}, {"text": "\" ", "bbox": [362.0, 652.0, 383.0, 673.0]}, {"text": "KOA", "bbox": [537.0, 653.0, 572.0, 670.0]}, {"text": "5\"", "bbox": [134.0, 654.0, 153.0, 667.0]}, {"text": "l", "bbox": [460.0, 654.0, 473.0, 670.0]}, {"text": ",", "bbox": [99.0, 660.0, 113.0, 672.0]}, {"text": "10.", "bbox": [707.0, 662.0, 718.0, 670.0]}, {"text": "\" \"", "bbox": [249.0, 673.0, 310.0, 687.0]}, {"text": "\",", "bbox": [315.0, 673.0, 333.0, 693.0]}, {"text": "[13-14,16,18,25]", "bbox": [664.0, 672.0, 727.0, 687.0]}, {"text": "6\"", "bbox": [97.0, 675.0, 117.0, 690.0]}, {"text": "11\"", "bbox": [356.0, 675.0, 384.0, 690.0]}, {"text": "\"      \"      \"", "bbox": [252.0, 693.0, 309.0, 707.0]}, {"text": "[36]", "bbox": [523.0, 694.0, 547.0, 709.0]}, {"text": ",KOA", "bbox": [547.0, 697.0, 606.0, 713.0]}, {"text": "\" \";", "bbox": [84.0, 716.0, 123.0, 735.0]}, {"text": "[30]", "bbox": [175.0, 717.0, 195.0, 731.0]}, {"text": "\",", "bbox": [335.0, 717.0, 354.0, 738.0]}, {"text": ", 6 \" ", "bbox": [232.0, 723.0, 335.0, 728.0]}, {"text": ",", "bbox": [448.0, 726.0, 459.0, 737.0]}, {"text": "1990,", "bbox": [664.0, 726.0, 679.0, 736.0]}, {"text": "\" \" :", "bbox": [128.0, 736.0, 168.0, 754.0]}, {"text": "[27-28]", "bbox": [265.0, 737.0, 310.0, 751.0]}, {"text": "2", "bbox": [197.0, 742.0, 208.0, 754.0]}, {"text": ",", "bbox": [504.0, 747.0, 514.0, 759.0]}, {"text": "10.", "bbox": [644.0, 748.0, 655.0, 757.0]}, {"text": "\" \" \" .", "bbox": [84.0, 759.0, 123.0, 779.0]}, {"text": "10. See also ,", "bbox": [238.0, 768.0, 256.0, 778.0]}, {"text": "o", "bbox": [302.0, 768.0, 313.0, 779.0]}, {"text": ",", "bbox": [664.0, 768.0, 694.0, 779.0]}, {"text": "[31-38]", "bbox": [238.0, 781.0, 282.0, 795.0]}, {"text": "5", "bbox": [139.0, 784.0, 155.0, 799.0]}, {"text": "Rewald", "bbox": [289.0, 785.0, 384.0, 798.0]}, {"text": "o         ,", "bbox": [531.0, 788.0, 579.0, 802.0]}, {"text": "2\"", "bbox": [233.0, 803.0, 254.0, 819.0]}, {"text": "KOA", "bbox": [670.0, 804.0, 704.0, 821.0]}, {"text": "Messier [35]", "bbox": [84.0, 805.0, 161.0, 819.0]}, {"text": ",", "bbox": [198.0, 811.0, 213.0, 823.0]}, {"text": ", 100", "bbox": [545.0, 812.0, 565.0, 822.0]}, {"text": "[37]", "bbox": [445.0, 823.0, 468.0, 839.0]}, {"text": "\" \"", "bbox": [110.0, 824.0, 163.0, 839.0]}, {"text": "\",", "bbox": [196.0, 825.0, 213.0, 846.0]}, {"text": "4\"", "bbox": [236.0, 827.0, 258.0, 840.0]}, {"text": ".", "bbox": [511.0, 833.0, 551.0, 845.0]}, {"text": ".", "bbox": [573.0, 833.0, 586.0, 846.0]}, {"text": ",", "bbox": [637.0, 834.0, 649.0, 846.0]}, {"text": "\" ", "bbox": [112.0, 846.0, 132.0, 859.0]}, {"text": "5\"", "bbox": [153.0, 847.0, 172.0, 862.0]}, {"text": "1. \"", "bbox": [517.0, 851.0, 553.0, 865.0]}, {"text": "\"", "bbox": [156.0, 868.0, 171.0, 882.0]}, {"text": "\"; Azizi", "bbox": [177.0, 868.0, 334.0, 885.0]}, {"text": "[38] .", "bbox": [662.0, 867.0, 688.0, 884.0]}, {"text": ",", "bbox": [533.0, 875.0, 557.0, 887.0]}, {"text": "\" ", "bbox": [182.0, 889.0, 200.0, 901.0]}, {"text": "\"", "bbox": [155.0, 891.0, 176.0, 903.0]}, {"text": "9\"", "bbox": [211.0, 891.0, 245.0, 904.0]}, {"text": "4.", "bbox": [97.0, 893.0, 138.0, 908.0]}, {"text": "5", "bbox": [140.0, 892.0, 154.0, 906.0]}, {"text": ";", "bbox": [623.0, 895.0, 635.0, 908.0]}, {"text": "Chapter 1", "bbox": [517.0, 898.0, 547.0, 908.0]}, {"text": "\" \";", "bbox": [357.0, 905.0, 397.0, 931.0]}, {"text": "\" \" \" \"", "bbox": [211.0, 910.0, 271.0, 925.0]}, {"text": "o KOA", "bbox": [664.0, 913.0, 703.0, 929.0]}, {"text": ",", "bbox": [531.0, 918.0, 546.0, 932.0]}, {"text": "\"       \"", "bbox": [256.0, 934.0, 301.0, 945.0]}, {"text": "5", "bbox": [238.0, 935.0, 254.0, 950.0]}, {"text": "Ince [31]", "bbox": [83.0, 936.0, 147.0, 947.0]}, {"text": "Construction", "bbox": [185.0, 941.0, 204.0, 952.0]}, {"text": ".", "bbox": [629.0, 941.0, 641.0, 952.0]}, {"text": "\" \".", "bbox": [83.0, 953.0, 125.0, 972.0]}, {"text": "Chapter 1", "bbox": [289.0, 961.0, 313.0, 973.0]}, {"text": ",", "bbox": [239.0, 963.0, 250.0, 975.0]}, {"text": ".", "bbox": [477.0, 963.0, 489.0, 974.0]}, {"text": "2.3", "bbox": [84.0, 978.0, 107.0, 993.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "58", "bbox": [236.0, 48.0, 252.0, 60.0]}], "type": "Text", "position": 9}, {"raw_context": [{"text": " 6", "bbox": [276.0, 49.0, 286.0, 59.0]}], "type": "Text", "position": 10}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/骨科/解读/膝骨关节炎患者自我管理的最佳证据总结.pdf", "page_num": 3}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "格式杂乱#0#31#内容无法理解", "type3": null, "type4": null, "type5": null, "type6": null}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:40", "update_time": "2024-05-07 22:26:57"}
{"id": 1082538, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 738, "source_info": {"seq_id": "b8a0d398-caad-4343-afe1-64504c717cc0", "title": null, "text": "【0】页码:23\n 10 Department of Gastroenterology, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK Specialist Pharmacist Breastfeeding and Medication, Portsmouth, UK 12 Digestive Diseases Unit, Kettering General Hospital; Kettering, Kettering, UK 13 Department of Population Health Sciences, College of Life Science, University of Leicester, Leicester, UK.\n\n【1】14 Department of Gastroenterology, University College London, UK, London, UK 15 Department of Gastroenterology, South Tyneside District Hospital, South Shields, UK 16 Patient Representative on Guideline Development Group and member of Independent Cancer Patients' Voice, Sheffield, UK 17 Patient Representative on Guideline Development Group, Manchester, UK 18 Department of Gastroenterology, Sandwell General Hospital, West Bromwich, UK 13 Centre for Liver and Digestive Disorders, Royal Infirmary Edinburgh, Edinburgh, UK Twitter Reena Sidhu @drreenasidhu1, John S Leeds @Nendoscopy, Mohammad Farhad Peerally @FarhadPeerally2, Manu Nayar @drmanuknayar and Ian Penman @ Gastronaulan\n\n【2】 Acknowledgements The authors gratefully acknowledge the contributions and support of Dr Stuart Gittens, ECD Solutions in assisting with the online voting platform.\n\n【3】 Contributors HH undertook the literature search and initial sorting of manuscripts.\n\n【4】Subsequent review of manuscripts was undertaken by Core Writing Group leads: JSL (type of sedation, LN (patient information, choice and expectations), RS (preassessment), CH (procedure room requirements), DT (deep sedation and sedation protocols), CH and SB (recovery and discharge), MFP (complications relating to sedation agents and reversal agents and training), SH (upper GI endoscopy, endoscopic ultrasound and endoscopic retrograde cholagio-pancreatography), MN (endoscopic ultrasound/endoscopic retrograde cholangio-pancreatography), RS (device-assisted endoscopy), IP (transnasal endocopy), NJT (lower GI endoscopy and high-risk groups), JSL (pregnancy and breast feeding), PC (transition groups, learning disability and lone working). PICO Statements and guideline statements were developed within these working groups by all members. All members contributed to discussion and voting (organised by HNH through ECD Solutions). All core writing group leads contributed to manuscript writing within their group. RS completed all other sections including all revisions and provided responses to all comments from the stakeholders. Lay members contributed comments to all parts of the manuscript preparation, including structure of the domains, the lay summary and with particular input on the section on patient information, choice and expectation.\n\n【5】All other authors fulfil the ICMJE recommendations for authorship with appropriate involvement at all stages of the guideline development process, and drafting of the manuscript.\n\n【6】Funding The authors have not declared a specific grant for this research from any\n\n【7】 funding agency in the public, commercial or not-for-profit sectors.\n\n【8】Disclaimer These Guidelines have been endorsed by the Joint Advisory Group, British Society of Gastroenterology Nurses Association (BSGNA), Association of Coloproctology Great Britain & Northern Ireland (ACPGBI), United Kingdom & Ireland EUS Society (UKIEUS) and the Royal College of Anaesthetics (RCoA).\n\n【9】Competing interests None declared.\n\n【10】## Patient Consent For Publication Not Applicable.\n\n【11】\n## Ethics Approval Not Applicable.\n\n【12】\n Provenance and peer review Not commissioned; externally peer reviewed.\n\n【13】Supplemental material This content has been supplied by the author(s).\n\n【14】It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content.\n\n【15】Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.\n\n【16】 Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.\n\n【17】 ORCID iDs Reena Sidhu http://orcid.org/0000-0003-0820-2400\n\n【18】 John S Leeds http://orcid.org/0000-0002-5140-6225 Manu Nayar http://orcid.org/0000-0002-1196-3406 Nigel J Trudgill http://orcid.org/0000-0002-8040-8158\n\n【19】## References\n\n【20】\n AoMRC. Practice for healthcare. 2013. Available: https://www.aomrc.org.uk/wpcontent/uploads/2016/05/Safe_Sedation_Practice_1213.pdf Rajasekhar PT, Clifford GM, Lee TJW, et al. Bowel cancer screening is safe, detects earlier stage cancer and adenomas in 50% of cases: experience of the prevalent round of screening from two first wave centres in the north east of England.\n\n【21】Frontline Gastroenterol 2012;3:10–5.\n\n【22】3 Sidhu R, Turnbull D, Newton M, et al. Deep sedation and anaesthesia in complex gastrointestinal endoscopy: a joint position statement endorsed by the British Society of Gastroenterology (BSG), Joint Advisory Group (JAG) and Royal College of Anaesthetists (RCoA). Frontline Gastroenterol 2019;10:141–7.\n\n【23】4 Manno M, Deiana S, Gabbani T, et al. Implementation of the European Society of Gastrointestinal Endoscopy (ESGE) and European Society of Gastroenterology and Endoscopy Nurses and Associates (ESGENA) sedation training course in a regular endoscopy unit. Endoscopy 2021;53:65–71.\n\n【24】5 McQuaid KR, Laine L. A systematic review and meta-analysis of randomized, controlled trials of moderate sedation for routine endoscopic procedures.\n\n【25】Gastrointest Endosc 2008;67:910–23.\n\n【26】10.6 Medicines.org. Midazolam 1 mg/ml solution for injection or infusion. n.d. Available: https://www.medicines.org.uk/emc/product/6419/smpc#gref Gemma M, Pennoni F, Tritto R, et al. Risk of adverse events in gastrointestinal endoscopy: zero-inflated Poisson regression mixture model for count data and multinomial logit model for the type of event. PLoS One 2021;16:e0253515.\n\n【27】8.\n\n【28】Kitagawa E, lida A, Kimura Y, et al. Responses to intravenous sedation by elderly patients at the Hokkaido University dental hospital Anesth Prog 1992;39:73–8.\n\n【29】1999 Rees CJ, Thomas Gibson S, Rutter MD, et a/. UK key performance indicators and quality assurance standards for colonoscopy. Gut 2016;65:1923–9.\n\n【30】10 Nordt SP, Clark RF. Midazolam: a review of therapeutic uses and toxicity. J Emerg Med 1997;15:357–65.\n\n【31】11 Kilpatrick GJ. Remimazolam: non-clinical and clinical profile of a new sedative/ anesthetic agent. Front Pharmacol 2021;12:690875.\n\n【32】Yamamoto T, Kurabe M, Kamiya Y. Re-sleeping after reversal of remimazolam by 1212 flumazenil. J Anesth 2021;35:322.\n\n【33】13 Chen S-H, Yuan T-M, Zhang J, et al. Remimazolam tosilate in upper gastrointestinal endoscopy: a multicenter, randomized, non-inferiority, phase Ill trial. J Gastroenterol Hepatol 2021;36:474–81.\n\n【34】14 Zhu X, Wang H, Yuan S, et al. Efficacy and safety of remimazolam in endoscopic sedation-a systematic review and meta-analysis. Front Med 2021;8:655042.\n\n【35】15 Drugs.com. Fentanyl side effects_ common, severe, long term - drugs. 2023.\n\n【36】Available: https://www.drugs.com/sfx/fentanyl-side-effects.html 16 Mather LE, Meffin PJ. Clinical pharmacokinetics of pethidine. Clin Pharmacokinet 1978;3:352-68.\n\n【37】Robertson AR, Kennedy NA, Robertson JA, et al. Colonoscopy quality with Entonox( ® ) vs intravenous conscious sedation: 18608 colonoscopy retrospective study . World J Gastrointest Endosc 2017;9:471.\n\n【38】18 Ball AJ, Din S, Donnelly M, et al. A randomized controlled trial comparing continuous and as-required nitrous oxide use during screening colonoscopy. Eur J Gastroenterol Hepatol 2015;27:271–8.\n\n【39】19 Forbes GM, Collins BJ. Nitrous oxide for colonoscopy: a randomized controlled study.\n\n【40】Gastrointest Endosc 2000;51:271–7.\n\n【41】2012 Maslekar S, Gardiner A, Hughes M, et al. Randomized clinical trial of Entonox versus midazolam-fentanyl sedation for colonoscopy. Br J Surg 2009;96:361–8.\n\n【42】21 Maslekar S, Balaji P, Gardiner A, et al. Randomized controlled trial of patientcontrolled sedation for colonoscopy: Entonox vs modified patient-maintained targetcontrolled propofol. Colorectal Dis 2011;13:48–57.\n\n【43】22 Everett SM, Griffiths H, Nandasoma U, et al. Guideline for obtaining valid consent for gastrointestinal endoscopy procedures. Gut 2016;65:1585–601.\n\n【44】Rollbusch N, Mikocka-Walus AA, Andrews JM. The experience of anxiety 10.1223 in colonoscopy outpatients: a mixed-method study. Gastroenterol Nurs 2014;37:166–75.\n\n【45】24 Neilson LJ, Patterson J, von Wagner C, et al. Patient experience of gastrointestinal endoscopy: informing the development of the Newcastle ENDOPREM™. Frontline Gastroenterol 2020;11:209–17.\n\n【46】25 Quinn L, Kelly ME, Khan A, et al. Sedation for gastroscopy: is it an adequately understood and informed choice Ir J Med Sci 2016;185:785–9.\n\n【47】Yang C, Sriranjan V, Abou-Setta AM, et al. Anxiety associated with colonoscopy 261226 and flexible sigmoidoscopy: a systematic review. Am J Gastroenterol 2018;113:1810-8.\n\n【48】27 Parker S, Zipursky J, Ma H, et al . A web-based multimedia program before colonoscopy increased knowledge and decreased anxiety, sedation requirement, and procedure time. J Clin Gastroenterol 2018;52:519–23.", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "10 Department of Gastroenterology, Liverpool University Hospitals NHS Foundation", "bbox": [54.0, 60.0, 373.0, 75.0]}, {"text": "Trust, Liverpool, UK", "bbox": [54.0, 75.0, 130.0, 86.0]}, {"text": "Specialist Pharmacist Breastfeeding and Medication, Portsmouth, UK", "bbox": [62.0, 85.0, 328.0, 97.0]}, {"text": "12 Digestive Diseases Unit, Kettering General Hospital; Kettering, Kettering, UK", "bbox": [54.0, 93.0, 357.0, 114.0]}, {"text": "13 Department of Population Health Sciences, College of Life Science, University of", "bbox": [54.0, 108.0, 371.0, 125.0]}, {"text": "Leicester, Leicester, UK.", "bbox": [54.0, 124.0, 144.0, 135.0]}, {"text": "14 Department of Gastroenterology, University College London, UK, London, UK", "bbox": [56.0, 135.0, 361.0, 147.0]}, {"text": "15 Department of Gastroenterology, South Tyneside District Hospital, South Shields,", "bbox": [54.0, 145.0, 371.0, 163.0]}, {"text": "UK", "bbox": [54.0, 160.0, 69.0, 171.0]}, {"text": "16 Patient Representative on Guideline Development Group and member of", "bbox": [54.0, 172.0, 345.0, 187.0]}, {"text": "Independent Cancer Patients' Voice, Sheffield, UK", "bbox": [54.0, 185.0, 247.0, 196.0]}, {"text": "17 Patient Representative on Guideline Development Group, Manchester, UK", "bbox": [54.0, 195.0, 347.0, 212.0]}, {"text": "18 Department of Gastroenterology, Sandwell General Hospital, West Bromwich, UK", "bbox": [54.0, 206.0, 377.0, 225.0]}, {"text": "13 Centre for Liver and Digestive Disorders, Royal Infirmary Edinburgh, Edinburgh, UK", "bbox": [54.0, 220.0, 381.0, 238.0]}, {"text": "Twitter Reena Sidhu @drreenasidhu1, John S Leeds @Nendoscopy, Mohammad", "bbox": [54.0, 240.0, 371.0, 253.0]}, {"text": "Farhad Peerally @FarhadPeerally2, Manu Nayar @drmanuknayar and Ian Penman @", "bbox": [54.0, 254.0, 383.0, 266.0]}, {"text": "Gastronaulan", "bbox": [54.0, 268.0, 109.0, 280.0]}], "type": "Text", "position": 0}, {"raw_context": [{"text": "Acknowledgements The authors gratefully acknowledge the contributions", "bbox": [54.0, 291.0, 356.0, 302.0]}, {"text": "and support of Dr Stuart Gittens, ECD Solutions in assisting with the online voting", "bbox": [54.0, 303.0, 373.0, 315.0]}, {"text": "platform.", "bbox": [54.0, 316.0, 91.0, 327.0]}], "type": "Text", "position": 1}, {"raw_context": [{"text": "Contributors HH undertook the literature search and initial sorting of manuscripts.", "bbox": [54.0, 333.0, 383.0, 345.0]}, {"text": "Subsequent review of manuscripts was undertaken by Core Writing Group leads:", "bbox": [54.0, 346.0, 367.0, 359.0]}, {"text": "JSL (type of sedation, LN (patient information, choice and expectations), RS (pre-", "bbox": [54.0, 359.0, 367.0, 371.0]}, {"text": "assessment), CH (procedure room requirements), DT (deep sedation and sedation", "bbox": [54.0, 371.0, 371.0, 383.0]}, {"text": "protocols), CH and SB (recovery and discharge), MFP (complications relating", "bbox": [54.0, 383.0, 351.0, 395.0]}, {"text": "to sedation agents and reversal agents and training), SH (upper GI endoscopy,", "bbox": [54.0, 396.0, 357.0, 408.0]}, {"text": "endoscopic ultrasound and endoscopic retrograde cholagio-pancreatography), MN", "bbox": [54.0, 408.0, 376.0, 420.0]}, {"text": "(endoscopic ultrasound/endoscopic retrograde cholangio-pancreatography), RS", "bbox": [54.0, 420.0, 361.0, 433.0]}, {"text": "(device-assisted endoscopy), IP (transnasal endocopy), NJT (lower GI endoscopy and", "bbox": [54.0, 434.0, 382.0, 446.0]}, {"text": "high-risk groups), JSL (pregnancy and breast feeding), PC (transition groups, learning", "bbox": [54.0, 445.0, 385.0, 458.0]}, {"text": "disability and lone working). PICO Statements and guideline statements were", "bbox": [54.0, 458.0, 356.0, 471.0]}, {"text": "developed within these working groups by all members. All members contributed to", "bbox": [54.0, 471.0, 381.0, 482.0]}, {"text": "discussion and voting (organised by HNH through ECD Solutions). All core writing", "bbox": [54.0, 483.0, 372.0, 495.0]}, {"text": "group leads contributed to manuscript writing within their group. RS completed", "bbox": [54.0, 495.0, 365.0, 507.0]}, {"text": "all other sections including all revisions and provided responses to all comments", "bbox": [54.0, 509.0, 367.0, 520.0]}, {"text": "from the stakeholders. Lay members contributed comments to all parts of the", "bbox": [54.0, 520.0, 355.0, 532.0]}, {"text": "manuscript preparation, including structure of the domains, the lay summary and", "bbox": [54.0, 533.0, 369.0, 545.0]}, {"text": "with particular input on the section on patient information, choice and expectation.", "bbox": [54.0, 545.0, 378.0, 556.0]}, {"text": "All other authors fulfil the ICMJE recommendations for authorship with appropriate", "bbox": [54.0, 558.0, 379.0, 570.0]}, {"text": "involvement at all stages of the guideline development process, and drafting of the", "bbox": [54.0, 570.0, 377.0, 582.0]}, {"text": "manuscript.", "bbox": [54.0, 584.0, 101.0, 594.0]}, {"text": "Funding The authors have not declared a specific grant for this research from any", "bbox": [54.0, 600.0, 378.0, 612.0]}], "type": "Text", "position": 2}, {"raw_context": [{"text": "funding agency in the public, commercial or not-for-profit sectors.", "bbox": [54.0, 613.0, 308.0, 625.0]}, {"text": "Disclaimer These Guidelines have been endorsed by the Joint Advisory Group,", "bbox": [54.0, 631.0, 364.0, 643.0]}, {"text": "British Society of Gastroenterology Nurses Association (BSGNA), Association of", "bbox": [54.0, 643.0, 361.0, 655.0]}, {"text": "Coloproctology Great Britain & Northern Ireland (ACPGBI), United Kingdom &", "bbox": [54.0, 655.0, 358.0, 668.0]}, {"text": "Ireland EUS Society (UKIEUS) and the Royal College of Anaesthetics (RCoA).", "bbox": [54.0, 668.0, 350.0, 680.0]}, {"text": "Competing interests None declared.", "bbox": [54.0, 686.0, 211.0, 698.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "Patient consent for publication Not applicable.", "bbox": [54.0, 704.0, 257.0, 715.0]}], "type": "Section-header", "position": 4}, {"raw_context": [{"text": "Ethics approval Not applicable.", "bbox": [54.0, 721.0, 187.0, 733.0]}], "type": "Section-header", "position": 5}, {"raw_context": [{"text": "Provenance and peer review Not commissioned; externally peer reviewed.", "bbox": [54.0, 738.0, 361.0, 751.0]}, {"text": "Supplemental material This content has been supplied by the author(s).", "bbox": [54.0, 757.0, 359.0, 768.0]}, {"text": "It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not", "bbox": [54.0, 769.0, 359.0, 781.0]}, {"text": "have been peer-reviewed. Any opinions or recommendations discussed are", "bbox": [54.0, 781.0, 357.0, 794.0]}, {"text": "solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all", "bbox": [54.0, 795.0, 363.0, 806.0]}, {"text": "liability and responsibility arising from any reliance placed on the content.", "bbox": [54.0, 806.0, 354.0, 818.0]}, {"text": "Where the content includes any translated material, BMJ does not warrant the", "bbox": [54.0, 819.0, 371.0, 832.0]}, {"text": "accuracy and reliability of the translations (including but not limited to local", "bbox": [54.0, 831.0, 363.0, 844.0]}, {"text": "regulations, clinical guidelines, terminology, drug names and drug dosages), and", "bbox": [54.0, 844.0, 379.0, 856.0]}, {"text": "is not responsible for any error and/or omissions arising from translation and", "bbox": [54.0, 856.0, 366.0, 868.0]}, {"text": "adaptation or otherwise.", "bbox": [54.0, 869.0, 154.0, 881.0]}], "type": "Text", "position": 6}, {"raw_context": [{"text": "Open access This is an open access article distributed in accordance with the", "bbox": [53.0, 886.0, 363.0, 899.0]}, {"text": "Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which", "bbox": [54.0, 899.0, 361.0, 911.0]}, {"text": "permits others to distribute, remix, adapt, build upon this work non-commercially,", "bbox": [54.0, 912.0, 371.0, 923.0]}, {"text": "and license their derivative works on different terms, provided the original work is", "bbox": [54.0, 924.0, 373.0, 937.0]}, {"text": "properly cited, appropriate credit is given, any changes made indicated, and the use", "bbox": [54.0, 936.0, 379.0, 948.0]}, {"text": "is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.", "bbox": [54.0, 949.0, 332.0, 961.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "ORCID iDs", "bbox": [54.0, 974.0, 102.0, 987.0]}, {"text": "Reena Sidhu http://orcid.org/0000-0003-0820-2400", "bbox": [53.0, 985.0, 260.0, 999.0]}], "type": "Text", "position": 8}, {"raw_context": [{"text": "John S Leeds http://orcid.org/0000-0002-5140-6225", "bbox": [408.0, 61.0, 615.0, 74.0]}, {"text": "Manu Nayar http://orcid.org/0000-0002-1196-3406", "bbox": [406.0, 75.0, 613.0, 87.0]}, {"text": "Nigel J Trudgill http://orcid.org/0000-0002-8040-8158", "bbox": [406.0, 86.0, 621.0, 99.0]}], "type": "Text", "position": 11}, {"raw_context": [{"text": "REFERENCES", "bbox": [406.0, 123.0, 477.0, 137.0]}], "type": "Section-header", "position": 12}, {"raw_context": [{"text": "AoMRC. Practice for healthcare. 2013. Available: https://www.aomrc.org.uk/wp-", "bbox": [427.0, 138.0, 721.0, 150.0]}, {"text": "content/uploads/2016/05/Safe_Sedation_Practice_1213.pdf", "bbox": [428.0, 150.0, 651.0, 163.0]}, {"text": "Rajasekhar PT, Clifford GM, Lee TJW, et al. Bowel cancer screening is safe, detects", "bbox": [427.0, 163.0, 727.0, 175.0]}, {"text": "earlier stage cancer and adenomas in 50% of cases: experience of the prevalent", "bbox": [428.0, 175.0, 722.0, 187.0]}, {"text": "round of screening from two first wave centres in the north east of England.", "bbox": [428.0, 187.0, 706.0, 199.0]}, {"text": "Frontline Gastroenterol 2012;3:10–5.", "bbox": [428.0, 200.0, 566.0, 211.0]}, {"text": "3", "bbox": [416.0, 212.0, 426.0, 224.0]}, {"text": "Sidhu R, Turnbull D, Newton M, et al. Deep sedation and anaesthesia in complex", "bbox": [427.0, 212.0, 723.0, 225.0]}, {"text": "gastrointestinal endoscopy: a joint position statement endorsed by the British", "bbox": [429.0, 225.0, 714.0, 235.0]}, {"text": "Society of Gastroenterology (BSG), Joint Advisory Group (JAG) and Royal College of", "bbox": [430.0, 237.0, 733.0, 249.0]}, {"text": "Anaesthetists (RCoA). Frontline Gastroenterol 2019;10:141–7.", "bbox": [429.0, 249.0, 658.0, 261.0]}, {"text": "4", "bbox": [417.0, 261.0, 425.0, 271.0]}, {"text": "Manno M, Deiana S, Gabbani T, et al. Implementation of the European Society of", "bbox": [427.0, 262.0, 725.0, 273.0]}, {"text": "Gastrointestinal Endoscopy (ESGE) and European Society of Gastroenterology and", "bbox": [428.0, 273.0, 729.0, 285.0]}, {"text": "Endoscopy Nurses and Associates (ESGENA) sedation training course in a regular", "bbox": [428.0, 286.0, 725.0, 299.0]}, {"text": "endoscopy unit. Endoscopy 2021;53:65–71.", "bbox": [428.0, 298.0, 591.0, 309.0]}, {"text": "5", "bbox": [416.0, 309.0, 426.0, 322.0]}, {"text": "McQuaid KR, Laine L. A systematic review and meta-analysis of randomized,", "bbox": [426.0, 310.0, 707.0, 322.0]}, {"text": "controlled trials of moderate sedation for routine endoscopic procedures.", "bbox": [429.0, 322.0, 694.0, 334.0]}, {"text": "Gastrointest Endosc 2008;67:910–23.", "bbox": [429.0, 336.0, 569.0, 347.0]}, {"text": "10.6", "bbox": [416.0, 348.0, 426.0, 357.0]}, {"text": "Medicines.org. Midazolam 1 mg/ml solution for injection or infusion. n.d. Available:", "bbox": [426.0, 347.0, 733.0, 359.0]}, {"text": "https://www.medicines.org.uk/emc/product/6419/smpc#gref", "bbox": [428.0, 360.0, 652.0, 372.0]}, {"text": "Gemma M, Pennoni F, Tritto R, et al. Risk of adverse events in gastrointestinal", "bbox": [427.0, 372.0, 711.0, 383.0]}, {"text": "endoscopy: zero-inflated Poisson regression mixture model for count data and", "bbox": [428.0, 385.0, 714.0, 397.0]}, {"text": "multinomial logit model for the type of event. PLoS One 2021;16:e0253515.", "bbox": [428.0, 397.0, 709.0, 409.0]}, {"text": "8.", "bbox": [416.0, 409.0, 426.0, 420.0]}, {"text": "Kitagawa E, lida A, Kimura Y, et al. Responses to intravenous sedation by elderly", "bbox": [426.0, 410.0, 720.0, 421.0]}, {"text": "patients at the Hokkaido University dental hospital Anesth Prog 1992;39:73–8.", "bbox": [428.0, 421.0, 721.0, 433.0]}, {"text": "1999", "bbox": [416.0, 435.0, 427.0, 444.0]}, {"text": "Rees CJ, Thomas Gibson S, Rutter MD, et a/. UK key performance indicators and", "bbox": [426.0, 435.0, 719.0, 446.0]}, {"text": "quality assurance standards for colonoscopy. Gut 2016;65:1923–9.", "bbox": [429.0, 446.0, 676.0, 458.0]}, {"text": "10", "bbox": [413.0, 458.0, 426.0, 468.0]}, {"text": "Nordt SP, Clark RF. Midazolam: a review of therapeutic uses and toxicity. J Emerg", "bbox": [426.0, 459.0, 723.0, 471.0]}, {"text": "Med 1997;15:357–65.", "bbox": [429.0, 471.0, 514.0, 482.0]}, {"text": "11 Kilpatrick GJ. Remimazolam: non-clinical and clinical profile of a new sedative/", "bbox": [412.0, 483.0, 716.0, 495.0]}, {"text": "anesthetic agent. Front Pharmacol 2021;12:690875.", "bbox": [430.0, 495.0, 621.0, 507.0]}, {"text": "Yamamoto T, Kurabe M, Kamiya Y. Re-sleeping after reversal of remimazolam by", "bbox": [426.0, 508.0, 720.0, 520.0]}, {"text": "1212", "bbox": [412.0, 509.0, 427.0, 519.0]}, {"text": "flumazenil. J Anesth 2021;35:322.", "bbox": [429.0, 520.0, 555.0, 532.0]}, {"text": "13 Chen S-H, Yuan T-M, Zhang J, et al. Remimazolam tosilate in upper gastrointestinal", "bbox": [413.0, 533.0, 732.0, 544.0]}, {"text": "endoscopy: a multicenter, randomized, non-inferiority, phase Ill trial. J Gastroenterol", "bbox": [429.0, 544.0, 733.0, 556.0]}, {"text": "Hepatol 2021;36:474–81.", "bbox": [428.0, 557.0, 527.0, 569.0]}, {"text": "14 Zhu X, Wang H, Yuan S, et al. Efficacy and safety of remimazolam in endoscopic", "bbox": [413.0, 569.0, 719.0, 581.0]}, {"text": "sedation-a systematic review and meta-analysis. Front Med 2021;8:655042.", "bbox": [428.0, 581.0, 708.0, 593.0]}, {"text": "15 Drugs.com. Fentanyl side effects_ common, severe, long term - drugs. 2023.", "bbox": [413.0, 593.0, 706.0, 606.0]}, {"text": "Available: https://www.drugs.com/sfx/fentanyl-side-effects.html", "bbox": [430.0, 607.0, 662.0, 618.0]}, {"text": "16 Mather LE, Meffin PJ. Clinical pharmacokinetics of pethidine. Clin Pharmacokinet", "bbox": [412.0, 618.0, 724.0, 630.0]}, {"text": "1978;3:352-68.", "bbox": [430.0, 631.0, 491.0, 643.0]}, {"text": "Robertson AR, Kennedy NA, Robertson JA, et al. Colonoscopy quality with", "bbox": [427.0, 643.0, 698.0, 655.0]}, {"text": "Entonox( ® ) vs intravenous conscious sedation: 18608 colonoscopy retrospective", "bbox": [428.0, 653.0, 725.0, 668.0]}, {"text": "study . World J Gastrointest Endosc 2017;9:471.", "bbox": [429.0, 668.0, 606.0, 680.0]}, {"text": "18 Ball AJ, Din S, Donnelly M, et al. A randomized controlled trial comparing continuous", "bbox": [412.0, 680.0, 737.0, 692.0]}, {"text": "and as-required nitrous oxide use during screening colonoscopy. Eur J Gastroenterol", "bbox": [430.0, 692.0, 736.0, 705.0]}, {"text": "Hepatol 2015;27:271–8.", "bbox": [428.0, 705.0, 522.0, 717.0]}, {"text": "19 Forbes GM, Collins BJ. Nitrous oxide for colonoscopy: a randomized controlled study.", "bbox": [412.0, 717.0, 737.0, 729.0]}, {"text": "Gastrointest Endosc 2000;51:271–7.", "bbox": [428.0, 731.0, 566.0, 740.0]}, {"text": "2012", "bbox": [412.0, 743.0, 426.0, 753.0]}, {"text": "Maslekar S, Gardiner A, Hughes M, et al. Randomized clinical trial of Entonox versus", "bbox": [426.0, 742.0, 737.0, 754.0]}, {"text": "midazolam-fentanyl sedation for colonoscopy. Br J Surg 2009;96:361–8.", "bbox": [428.0, 754.0, 696.0, 766.0]}, {"text": "21 Maslekar S, Balaji P, Gardiner A, et al. Randomized controlled trial of patient-", "bbox": [412.0, 766.0, 708.0, 779.0]}, {"text": "controlled sedation for colonoscopy: Entonox vs modified patient-maintained target-", "bbox": [428.0, 779.0, 737.0, 792.0]}, {"text": "controlled propofol. Colorectal Dis 2011;13:48–57.", "bbox": [430.0, 791.0, 615.0, 803.0]}, {"text": "22 Everett SM, Griffiths H, Nandasoma U, et al. Guideline for obtaining valid consent for", "bbox": [412.0, 803.0, 739.0, 815.0]}, {"text": "gastrointestinal endoscopy procedures. Gut 2016;65:1585–601.", "bbox": [429.0, 816.0, 664.0, 827.0]}, {"text": "Rollbusch N, Mikocka-Walus AA, Andrews JM. The experience of anxiety", "bbox": [426.0, 828.0, 692.0, 839.0]}, {"text": "10.1223", "bbox": [412.0, 829.0, 426.0, 838.0]}, {"text": "in colonoscopy outpatients: a mixed-method study. Gastroenterol Nurs", "bbox": [429.0, 841.0, 686.0, 852.0]}, {"text": "2014;37:166–75.", "bbox": [429.0, 852.0, 496.0, 863.0]}, {"text": "24 Neilson LJ, Patterson J, von Wagner C, et al. Patient experience of gastrointestinal", "bbox": [412.0, 865.0, 726.0, 878.0]}, {"text": "endoscopy: informing the development of the Newcastle ENDOPREM™. Frontline", "bbox": [428.0, 877.0, 726.0, 889.0]}, {"text": "Gastroenterol 2020;11:209–17.", "bbox": [429.0, 890.0, 547.0, 901.0]}, {"text": "25 Quinn L, Kelly ME, Khan A, et al. Sedation for gastroscopy: is it an adequately", "bbox": [412.0, 901.0, 711.0, 914.0]}, {"text": "understood and informed choice Ir J Med Sci 2016;185:785–9.", "bbox": [428.0, 915.0, 659.0, 926.0]}, {"text": "Yang C, Sriranjan V, Abou-Setta AM, et al. Anxiety associated with colonoscopy", "bbox": [426.0, 926.0, 724.0, 938.0]}, {"text": "261226", "bbox": [412.0, 927.0, 425.0, 937.0]}, {"text": "and flexible sigmoidoscopy: a systematic review. Am J Gastroenterol", "bbox": [430.0, 939.0, 684.0, 951.0]}, {"text": "2018;113:1810-8.", "bbox": [429.0, 951.0, 502.0, 962.0]}, {"text": "27 Parker S, Zipursky J, Ma H, et al . A web-based multimedia program before", "bbox": [412.0, 963.0, 698.0, 976.0]}, {"text": "colonoscopy increased knowledge and decreased anxiety, sedation requirement, and", "bbox": [428.0, 975.0, 739.0, 987.0]}, {"text": "procedure time. J Clin Gastroenterol 2018;52:519–23.", "bbox": [428.0, 989.0, 628.0, 1000.0]}], "type": "Text", "position": 13}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/消化科/_2023 BSG指南：胃肠内窥镜检查中的镇静.pdf", "page_num": 23}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "缺少换行#0#0# Centre for Liver and Digestive另起一行\n12 Digestive Diseases Unit, 另起一行\n13 Department of Population另起一行\n序号格式不一致#0#0# Centre for Liver and Digestive前面缺少序号11\n缺少换行#1#1#15 Department of Gastroenterology另起一行\n16 Patient Representative on另起一行\n17 Patient Representative on 另起一行\n18 Department of Gastroenterology另起一行\n13 Centre for Liver and Digestive另起一行\nTwitter Reena Sidhu @drreenasidhu1另起一行\n序号错误#1#1#13 Centre for Liver and Digestive应该是19 Centre for Liver and Digestive\n多余换行#6#7#research from any和funding agency in 是一句话", "type3": "无关文本#17#18#ORCID iDs Reena Sidhu http://orcid.org/0000-0003-0820-2400与上文无衔接", "type4": null, "type5": null, "type6": "有用性#19#48#参考文献"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:40", "update_time": "2024-05-07 22:53:30"}
{"id": 1082537, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 738, "source_info": {"seq_id": "835e80a1-23ad-4615-9eb6-eee9927a09e7", "title": null, "text": "【0】页码:5\n related to combining TRT with various types of immunotherapy (atezolizumab, durvalumab, pembrolizumab, nivolumab). Furthermore, when evaluated, efficacy outcomes were improved with combination immunotherapy and TRT compared with immunotherapy alone [37,41,53,55] . The largest study to report such findings was a retrospective, hospital-based analysis of the United States (US)-based National Cancer Database, which evaluated the impact of TRT among patients with ES-SCLC receiving immunotherapy between 2012 and 2017 (N = 244; 63 [26%] received TRT) [41] . After propensity score matching, a trend was observed towards improved median survival (11 vs. 9 months) and two-year OS (18.1% vs. 12.0%) with the addition of TRT versus chemotherapy + immunotherapy alone. An Israeli realworld retrospective study similarly evaluated outcomes among consecutive patients with ES-SCLC treated with platinum-based chemotherapy and atezolizumab or durvalumab, some of whom went on to receive consolidation TRT (n = 25 TRT; n = 101 no TRT) [55] . Both mOS (8.5 vs. 5.6 months, p = 0.003) and mPFS (27.7 vs. 13.2 months, p = 0.007) were significantly longer among patients who received TRT. Comparable findings were also reported in an Italian retrospective analysis of 31 patients who received chemo-immunotherapy (2020–2021), of whom 7 (23%) also received consolidation TRT: OS was significantly improved among those receiving TRT ( p < 0.007) [53] . Finally, a Canadian, realworld, retrospective analysis evaluated outcomes among patients with ES-SCLC receiving first-line atezolizumab who were captured in a provincial institutional database (2017–2019) [37] . Although only four patients (12%) received TRT, these individuals had prolonged mPFS (12.5 vs. 5.8 months; p = 0.095) and mOS (not reached [NR] vs. 11.5 months; p = 0.095) compared with those not receiving TRT. In multivariate analyses, TRT was a favorable prognostic factor for OS (hazard ratio [HR] = 0.33, 95% CI: 0.13–0.88, p = 0.03). It should be noted, however, that at presentation, a smaller proportion of patients who received TRT also had distant metastases than those who did not receive TRT (64% vs. 89%, p = 0.04). Additional studies conducted in LS–SCLC and NSCLC provide further support for use of concurrent TRT and immunotherapy in lung cancer, showing acceptable tolerability and survival benefits [44,46–48] .\n\n【1】Three new ES-SCLC clinical trials with robust study designs— TRIPLEX, TREASURE, and RAPTOR— are currently ongoing, with primary read-outs expected in 2026 and 2027 [33–35] . TRIPLEX is a Phase III randomized trial evaluating the OS benefit of adding TRT to durvalumab + EP chemotherapy; safety, PFS, response rates, HRQoL, and cognitive function will also be assessed [33] . The Phase II randomized TREASURE trial is an open-label study of the efficacy and safety of RT + atezolizumab [34] . Endpoints include survival, response rates, intrathoracic tumor control, adverse events (AEs), and HRQoL, among others. The third study, RAPTOR (NRG–LU007) is a randomized Phase II/III trial of the addition of TRT to atezolizumab maintenance therapy that will evaluate PFS, OS, and safety [35] .\n\n【2】While awaiting emerging clinical trial information and considering studies conducted to date, as well as the relatively long half-lives of both atezolizumab (27 days) [56] and durvalumab (18 days) [57] , the expert working group suggested that holding immunotherapy during TRT may not be beneficial to patients with ES-SCLC. If considered appropriate based on discussions between the medical and radiation oncologists and the rest of the multidisciplinary team, consolidation TRT can be provided during maintenance immunotherapy on a case-by-case basis, after completion of concurrent chemo-immunotherapy.\n\n【3】CLINICAL QUESTION 4: Which patients with ES-SCLC should be referred to a radiation oncologist for consideration of PCI or MRI surveillance?\n\n【4】Recommendation 4.1: All patients who respond to concurrent chemo-immunotherapy should undergo restaging with brain MRI to guide decision-making regarding PCI or MRI surveillance alone. ( Level of Agreement: Unanimous).\n\n【5】Recommendation 4.2: Consultation with a radiation oncologist is recommended to enhance shared decision-making on PCI versus MRI\n\n【6】 surveillance alone. (Level of Agreement: Unanimous) .\n\n【7】Recommendation 4.3: Patients with a response to concurrent chemo-immunotherapy, without brain metastases and with good PS, should be considered for PCI. ( Level of Agreement: Unanimous ).\n\n【8】Clinical Rationale: Rates of brain metastasis are reported to exceed 60% among patients with ES-SCLC [6,22] , with approximately 16% of metastases being asymptomatic after chemotherapy [58] . In the IMPower133 and CASPIAN trials, the brain was one of the most common sites of disease relapse, with comparable rates of progression observed between immunotherapy + chemotherapy and chemotherapy alone in both studies [51,52] . As brain lesions are generally resistant to therapy and associated with a poor prognosis, ongoing surveillance and/or treatment with RT are critical components of the treatment strategy for this population [59,60] . However, the optimal roles of MRI surveillance and PCI have yet to be fully established in ES-SCLC.\n\n【9】To date, no randomized trials have evaluated the benefits of MRI surveillance compared with observation alone in the detection of brain metastases in ES-SCLC, although the Phase III MAVERICK trial (SWOG S1827) aims to study MRI surveillance with and without PCI in SCLC (see Question 7) [32] . In contrast, considerable evidence is available for use of PCI in ES-SCLC; however, the intervention remains controversial given conflicting findings for survival, neurocognitive function, and HRQoL across several clinical trials and meta-analyses [6,22,58,61–65] .\n\n【10】Although studies consistently show reductions in the incidence of brain metastases with PCI, its impact on OS continues to be questioned and concerns regarding cognition and HRQoL have prompted research into risk mitigation techniques (see Question 6). Overall use of PCI appears to have decreased over time in some regions, including among patients receiving immunotherapy, since the 2017 publication of a Phase III trial by Takahashi and colleagues that showed no survival benefit of PCI compared with observation in ES-SCLC [22,43,66] . In a 2019 US-based survey of radiation oncologists, most respondents (82%) indicated willingness to enroll patients with LS-SCLC and/or ES-SCLC in a trial comparing PCI with MRI surveillance, indicating support of new investigations such as MAVERICK [32,66] .\n\n【11】Given that uncontrolled disease within the central nervous system (CNS) is a predominant cause of death in ES-SCLC, the expert working group agreed with ASTRO that all patients who respond to concurrent chemo-immunotherapy should undergo restaging using brain MRI to guide decision-making on selection of PCI versus ongoing MRI surveillance alone. All patients should have a consultation with a radiation oncologist to discuss the goals (i.e., prevention of large, symptomatic CNS disease), benefits, and risks of these options. For patients who can adhere to the schedule (see Question 5), routine MRI surveillance may be preferable over PCI. Brain MRI is likely to pick up small, asymptomatic lesions that may be amenable to stereotactic radiosurgery, or allow for whole brain radiation therapy (WBRT) prior to lesions becoming symptomatic [67–69] . If access to routine MRI is challenging, PCI is encouraged for suitable patients, as computed tomography (CT) surveillance is less sensitive and not considered to have clinical equipoise with MRI. Patients with a response to concurrent chemoimmunotherapy, without brain metastases and with good PS, should be considered for PCI on an individual basis (see Question 6 ). Patient age, pre-existing neurocognitive conditions, and other significant comorbidities may impact the tolerability of PCI and should be factored into treatment decisions [23,24,60] . Clear and frequent communication should occur across the MDT to confirm responsibilities for the scheduling and follow-up of MRI surveillance and/or PCI. If both MRI surveillance and PCI are not options, CT surveillance can be offered to patients (see Question 5).\n\n【12】CLINICAL QUESTION 5: What is the recommended timing of MRI surveillance?\n\n【13】Recommendation 5.1: MRI surveillance should be conducted for 2 years after response to concurrent chemo-immunotherapy: every 3 months in Year 1 and every 6 months in Year 2. (Level of Agreement: Unanimous) .", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "related to combining TRT with various types of immunotherapy (ate-", "bbox": [47.0, 69.0, 386.0, 83.0]}, {"text": "zolizumab, durvalumab, pembrolizumab, nivolumab). Furthermore,", "bbox": [47.0, 84.0, 385.0, 97.0]}, {"text": "when evaluated, efficacy outcomes were improved with combination", "bbox": [48.0, 99.0, 387.0, 112.0]}, {"text": "immunotherapy and TRT compared with immunotherapy alone", "bbox": [48.0, 113.0, 387.0, 126.0]}, {"text": "[37,41,53,55] . The largest study to report such findings was a retro-", "bbox": [48.0, 127.0, 385.0, 139.0]}, {"text": "spective, hospital-based analysis of the United States (US)-based Na-", "bbox": [48.0, 141.0, 385.0, 153.0]}, {"text": "tional Cancer Database, which evaluated the impact of TRT among", "bbox": [48.0, 155.0, 385.0, 167.0]}, {"text": "patients with ES-SCLC receiving immunotherapy between 2012 and", "bbox": [48.0, 168.0, 387.0, 181.0]}, {"text": "2017 (N = 244; 63 [26%] received TRT) [41] . After propensity score", "bbox": [48.0, 181.0, 387.0, 195.0]}, {"text": "matching, a trend was observed towards improved median survival (11", "bbox": [47.0, 195.0, 387.0, 210.0]}, {"text": "vs. 9 months) and two-year OS (18.1% vs. 12.0%) with the addition of", "bbox": [48.0, 210.0, 387.0, 224.0]}, {"text": "TRT versus chemotherapy + immunotherapy alone. An Israeli real-", "bbox": [48.0, 224.0, 385.0, 238.0]}, {"text": "world retrospective study similarly evaluated outcomes among consec-", "bbox": [48.0, 237.0, 385.0, 251.0]}, {"text": "utive patients with ES-SCLC treated with platinum-based chemotherapy", "bbox": [48.0, 251.0, 386.0, 265.0]}, {"text": "and atezolizumab or durvalumab, some of whom went on to receive", "bbox": [48.0, 266.0, 387.0, 279.0]}, {"text": "consolidation TRT (n = 25 TRT; n = 101 no TRT) [55] . Both mOS (8.5", "bbox": [48.0, 280.0, 387.0, 292.0]}, {"text": "vs. 5.6 months, p = 0.003) and mPFS (27.7 vs. 13.2 months, p = 0.007)", "bbox": [48.0, 293.0, 387.0, 306.0]}, {"text": "were significantly longer among patients who received TRT. Compara-", "bbox": [48.0, 307.0, 385.0, 320.0]}, {"text": "ble findings were also reported in an Italian retrospective analysis of 31", "bbox": [47.0, 321.0, 386.0, 334.0]}, {"text": "patients who received chemo-immunotherapy (2020–2021), of whom 7", "bbox": [48.0, 335.0, 386.0, 348.0]}, {"text": "(23%) also received consolidation TRT: OS was significantly improved", "bbox": [47.0, 349.0, 387.0, 362.0]}, {"text": "among those receiving TRT ( p < 0.007) [53] . Finally, a Canadian, real-", "bbox": [48.0, 363.0, 385.0, 376.0]}, {"text": "world, retrospective analysis evaluated outcomes among patients with", "bbox": [48.0, 377.0, 387.0, 390.0]}, {"text": "ES-SCLC receiving first-line atezolizumab who were captured in a pro-", "bbox": [48.0, 392.0, 385.0, 405.0]}, {"text": "vincial institutional database (2017–2019) [37] . Although only four", "bbox": [48.0, 405.0, 387.0, 419.0]}, {"text": "patients (12%) received TRT, these individuals had prolonged mPFS", "bbox": [48.0, 420.0, 387.0, 432.0]}, {"text": "(12.5 vs. 5.8 months; p = 0.095) and mOS (not reached [NR] vs. 11.5", "bbox": [48.0, 434.0, 387.0, 446.0]}, {"text": "months; p = 0.095) compared with those not receiving TRT. In multi-", "bbox": [47.0, 447.0, 386.0, 460.0]}, {"text": "variate analyses, TRT was a favorable prognostic factor for OS (hazard", "bbox": [47.0, 461.0, 387.0, 475.0]}, {"text": "ratio [HR] = 0.33, 95% CI: 0.13–0.88, p = 0.03). It should be noted,", "bbox": [47.0, 474.0, 387.0, 488.0]}, {"text": "however, that at presentation, a smaller proportion of patients who", "bbox": [47.0, 488.0, 387.0, 503.0]}, {"text": "received TRT also had distant metastases than those who did not receive", "bbox": [47.0, 503.0, 387.0, 517.0]}, {"text": "TRT (64% vs. 89%, p = 0.04). Additional studies conducted in LS–SCLC", "bbox": [48.0, 517.0, 387.0, 531.0]}, {"text": "and NSCLC provide further support for use of concurrent TRT and", "bbox": [47.0, 531.0, 387.0, 545.0]}, {"text": "immunotherapy in lung cancer, showing acceptable tolerability and", "bbox": [47.0, 545.0, 387.0, 559.0]}, {"text": "survival benefits [44,46–48] .", "bbox": [48.0, 559.0, 189.0, 572.0]}, {"text": "Three new ES-SCLC clinical trials with robust study design-", "bbox": [64.0, 572.0, 386.0, 586.0]}, {"text": "s— TRIPLEX, TREASURE, and RAPTOR— are currently ongoing, with", "bbox": [48.0, 587.0, 387.0, 600.0]}, {"text": "primary read-outs expected in 2026 and 2027 [33–35] . TRIPLEX is a", "bbox": [48.0, 601.0, 387.0, 613.0]}, {"text": "Phase III randomized trial evaluating the OS benefit of adding TRT to", "bbox": [48.0, 615.0, 387.0, 627.0]}, {"text": "durvalumab + EP chemotherapy; safety, PFS, response rates, HRQoL,", "bbox": [47.0, 628.0, 387.0, 641.0]}, {"text": "and cognitive function will also be assessed [33] . The Phase II ran-", "bbox": [48.0, 642.0, 385.0, 655.0]}, {"text": "domized TREASURE trial is an open-label study of the efficacy and", "bbox": [48.0, 656.0, 387.0, 669.0]}, {"text": "safety of RT + atezolizumab [34] . Endpoints include survival, response", "bbox": [48.0, 670.0, 386.0, 683.0]}, {"text": "rates, intrathoracic tumor control, adverse events (AEs), and HRQoL,", "bbox": [48.0, 685.0, 385.0, 698.0]}, {"text": "among others. The third study, RAPTOR (NRG–LU007) is a randomized", "bbox": [48.0, 698.0, 387.0, 711.0]}, {"text": "Phase II/III trial of the addition of TRT to atezolizumab maintenance", "bbox": [48.0, 713.0, 386.0, 725.0]}, {"text": "therapy that will evaluate PFS, OS, and safety [35] .", "bbox": [48.0, 727.0, 294.0, 739.0]}, {"text": "While awaiting emerging clinical trial information and considering", "bbox": [64.0, 739.0, 386.0, 753.0]}, {"text": "studies conducted to date, as well as the relatively long half-lives of both", "bbox": [48.0, 754.0, 387.0, 767.0]}, {"text": "atezolizumab (27 days) [56] and durvalumab (18 days) [57] , the expert", "bbox": [48.0, 768.0, 386.0, 781.0]}, {"text": "working group suggested that holding immunotherapy during TRT may", "bbox": [48.0, 782.0, 386.0, 796.0]}, {"text": "not be beneficial to patients with ES-SCLC. If considered appropriate", "bbox": [48.0, 796.0, 387.0, 810.0]}, {"text": "based on discussions between the medical and radiation oncologists and", "bbox": [47.0, 810.0, 387.0, 824.0]}, {"text": "the rest of the multidisciplinary team, consolidation TRT can be pro-", "bbox": [47.0, 824.0, 385.0, 838.0]}, {"text": "vided during maintenance immunotherapy on a case-by-case basis, after", "bbox": [48.0, 838.0, 386.0, 852.0]}, {"text": "completion of concurrent chemo-immunotherapy.", "bbox": [48.0, 853.0, 287.0, 865.0]}, {"text": "CLINICAL QUESTION 4: Which patients with ES-SCLC should be", "bbox": [62.0, 865.0, 387.0, 879.0]}, {"text": "referred to a radiation oncologist for consideration of PCI or MRI", "bbox": [47.0, 879.0, 387.0, 893.0]}, {"text": "surveillance?", "bbox": [48.0, 894.0, 114.0, 907.0]}, {"text": "Recommendation 4.1: All patients who respond to concurrent", "bbox": [62.0, 908.0, 387.0, 922.0]}, {"text": "chemo-immunotherapy should undergo restaging with brain MRI to", "bbox": [47.0, 922.0, 387.0, 936.0]}, {"text": "guide decision-making regarding PCI or MRI surveillance alone. ( Level of", "bbox": [48.0, 936.0, 387.0, 949.0]}, {"text": "Agreement: Unanimous).", "bbox": [48.0, 951.0, 162.0, 962.0]}, {"text": "Recommendation 4.2: Consultation with a radiation oncologist is", "bbox": [63.0, 963.0, 387.0, 976.0]}, {"text": "recommended to enhance shared decision-making on PCI versus MRI", "bbox": [48.0, 977.0, 387.0, 991.0]}], "type": "Text", "position": 1}, {"raw_context": [{"text": "surveillance alone. (Level of Agreement: Unanimous) .", "bbox": [406.0, 69.0, 653.0, 83.0]}, {"text": "Recommendation 4.3: Patients with a response to concurrent", "bbox": [422.0, 85.0, 745.0, 97.0]}, {"text": "chemo-immunotherapy, without brain metastases and with good PS,", "bbox": [406.0, 98.0, 745.0, 112.0]}, {"text": "should be considered for PCI. ( Level of Agreement: Unanimous ).", "bbox": [406.0, 113.0, 703.0, 126.0]}, {"text": "Clinical Rationale: Rates of brain metastasis are reported to exceed", "bbox": [422.0, 127.0, 746.0, 139.0]}, {"text": "60% among patients with ES-SCLC [6,22] , with approximately 16% of", "bbox": [406.0, 141.0, 747.0, 153.0]}, {"text": "metastases being asymptomatic after chemotherapy [58] . In the", "bbox": [406.0, 155.0, 745.0, 167.0]}, {"text": "IMPower133 and CASPIAN trials, the brain was one of the most common", "bbox": [406.0, 167.0, 745.0, 181.0]}, {"text": "sites of disease relapse, with comparable rates of progression observed", "bbox": [406.0, 182.0, 746.0, 195.0]}, {"text": "between immunotherapy + chemotherapy and chemotherapy alone in", "bbox": [406.0, 195.0, 747.0, 210.0]}, {"text": "both studies [51,52] . As brain lesions are generally resistant to therapy", "bbox": [406.0, 210.0, 745.0, 224.0]}, {"text": "and associated with a poor prognosis, ongoing surveillance and/or", "bbox": [406.0, 224.0, 746.0, 238.0]}, {"text": "treatment with RT are critical components of the treatment strategy for", "bbox": [405.0, 238.0, 745.0, 252.0]}, {"text": "this population [59,60] . However, the optimal roles of MRI surveillance", "bbox": [405.0, 251.0, 746.0, 265.0]}, {"text": "and PCI have yet to be fully established in ES-SCLC.", "bbox": [406.0, 266.0, 655.0, 279.0]}, {"text": "To date, no randomized trials have evaluated the benefits of MRI", "bbox": [422.0, 280.0, 747.0, 292.0]}, {"text": "surveillance compared with observation alone in the detection of brain", "bbox": [406.0, 294.0, 747.0, 306.0]}, {"text": "metastases in ES-SCLC, although the Phase III MAVERICK trial (SWOG", "bbox": [405.0, 307.0, 746.0, 320.0]}, {"text": "S1827) aims to study MRI surveillance with and without PCI in SCLC", "bbox": [405.0, 321.0, 746.0, 334.0]}, {"text": "(see Question 7) [32] . In contrast, considerable evidence is available for", "bbox": [405.0, 335.0, 745.0, 348.0]}, {"text": "use of PCI in ES-SCLC; however, the intervention remains controversial", "bbox": [406.0, 349.0, 746.0, 362.0]}, {"text": "given conflicting findings for survival, neurocognitive function, and", "bbox": [406.0, 363.0, 746.0, 376.0]}, {"text": "HRQoL across several clinical trials and meta-analyses [6,22,58,61–65] .", "bbox": [405.0, 377.0, 745.0, 390.0]}, {"text": "Although studies consistently show reductions in the incidence of brain", "bbox": [406.0, 391.0, 746.0, 405.0]}, {"text": "metastases with PCI, its impact on OS continues to be questioned and", "bbox": [406.0, 406.0, 746.0, 419.0]}, {"text": "concerns regarding cognition and HRQoL have prompted research into", "bbox": [406.0, 420.0, 746.0, 433.0]}, {"text": "risk mitigation techniques (see Question 6). Overall use of PCI appears", "bbox": [406.0, 434.0, 746.0, 447.0]}, {"text": "to have decreased over time in some regions, including among patients", "bbox": [406.0, 448.0, 746.0, 460.0]}, {"text": "receiving immunotherapy, since the 2017 publication of a Phase III trial", "bbox": [405.0, 461.0, 747.0, 474.0]}, {"text": "by Takahashi and colleagues that showed no survival benefit of PCI", "bbox": [405.0, 475.0, 746.0, 489.0]}, {"text": "compared with observation in ES-SCLC [22,43,66] . In a 2019 US-based", "bbox": [405.0, 488.0, 746.0, 503.0]}, {"text": "survey of radiation oncologists, most respondents (82%) indicated", "bbox": [405.0, 503.0, 746.0, 517.0]}, {"text": "willingness to enroll patients with LS-SCLC and/or ES-SCLC in a trial", "bbox": [406.0, 517.0, 747.0, 531.0]}, {"text": "comparing PCI with MRI surveillance, indicating support of new in-", "bbox": [405.0, 531.0, 745.0, 545.0]}, {"text": "vestigations such as MAVERICK [32,66] .", "bbox": [406.0, 544.0, 602.0, 558.0]}, {"text": "Given that uncontrolled disease within the central nervous system", "bbox": [421.0, 558.0, 747.0, 572.0]}, {"text": "(CNS) is a predominant cause of death in ES-SCLC, the expert working", "bbox": [405.0, 572.0, 746.0, 586.0]}, {"text": "group agreed with ASTRO that all patients who respond to concurrent", "bbox": [406.0, 587.0, 746.0, 599.0]}, {"text": "chemo-immunotherapy should undergo restaging using brain MRI to", "bbox": [406.0, 601.0, 747.0, 614.0]}, {"text": "guide decision-making on selection of PCI versus ongoing MRI surveil-", "bbox": [406.0, 615.0, 745.0, 627.0]}, {"text": "lance alone. All patients should have a consultation with a radiation", "bbox": [406.0, 628.0, 745.0, 641.0]}, {"text": "oncologist to discuss the goals (i.e., prevention of large, symptomatic", "bbox": [406.0, 642.0, 745.0, 655.0]}, {"text": "CNS disease), benefits, and risks of these options. For patients who can", "bbox": [406.0, 656.0, 745.0, 669.0]}, {"text": "adhere to the schedule (see Question 5), routine MRI surveillance may", "bbox": [406.0, 670.0, 745.0, 683.0]}, {"text": "be preferable over PCI. Brain MRI is likely to pick up small, asymp-", "bbox": [406.0, 684.0, 745.0, 698.0]}, {"text": "tomatic lesions that may be amenable to stereotactic radiosurgery, or", "bbox": [406.0, 699.0, 745.0, 712.0]}, {"text": "allow for whole brain radiation therapy (WBRT) prior to lesions", "bbox": [406.0, 713.0, 745.0, 725.0]}, {"text": "becoming symptomatic [67–69] . If access to routine MRI is challenging,", "bbox": [406.0, 727.0, 745.0, 739.0]}, {"text": "PCI is encouraged for suitable patients, as computed tomography (CT)", "bbox": [406.0, 740.0, 746.0, 753.0]}, {"text": "surveillance is less sensitive and not considered to have clinical equi-", "bbox": [406.0, 755.0, 745.0, 767.0]}, {"text": "poise with MRI. Patients with a response to concurrent chemo-", "bbox": [406.0, 768.0, 745.0, 781.0]}, {"text": "immunotherapy, without brain metastases and with good PS, should", "bbox": [406.0, 781.0, 746.0, 796.0]}, {"text": "be considered for PCI on an individual basis (see Question 6 ). Patient", "bbox": [406.0, 796.0, 745.0, 810.0]}, {"text": "age, pre-existing neurocognitive conditions, and other significant", "bbox": [406.0, 810.0, 745.0, 824.0]}, {"text": "comorbidities may impact the tolerability of PCI and should be factored", "bbox": [406.0, 825.0, 746.0, 837.0]}, {"text": "into treatment decisions [23,24,60] . Clear and frequent communication", "bbox": [406.0, 838.0, 746.0, 852.0]}, {"text": "should occur across the MDT to confirm responsibilities for the sched-", "bbox": [406.0, 852.0, 745.0, 865.0]}, {"text": "uling and follow-up of MRI surveillance and/or PCI. If both MRI sur-", "bbox": [406.0, 865.0, 745.0, 879.0]}, {"text": "veillance and PCI are not options, CT surveillance can be offered to", "bbox": [406.0, 879.0, 746.0, 893.0]}, {"text": "patients (see Question 5).", "bbox": [406.0, 894.0, 533.0, 907.0]}, {"text": "CLINICAL QUESTION 5: What is the recommended timing of MRI", "bbox": [421.0, 908.0, 746.0, 922.0]}, {"text": "surveillance?", "bbox": [406.0, 923.0, 472.0, 935.0]}, {"text": "Recommendation 5.1: MRI surveillance should be conducted for 2", "bbox": [421.0, 935.0, 747.0, 949.0]}, {"text": "years after response to concurrent chemo-immunotherapy: every 3", "bbox": [406.0, 951.0, 747.0, 962.0]}, {"text": "months in Year 1 and every 6 months in Year 2. (Level of Agreement:", "bbox": [406.0, 963.0, 745.0, 976.0]}, {"text": "Unanimous) .", "bbox": [406.0, 978.0, 467.0, 990.0]}], "type": "Text", "position": 3}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/肿瘤科/共识/加拿大共识建议：在接受免疫治疗的广泛期小细胞肺癌患者中使用放射治疗.pdf", "page_num": 5}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "多余换行#5#6#为同段内容", "type3": "无关文本#0#13#存在多处无关数字", "type4": null, "type5": null, "type6": null}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:40", "update_time": "2024-05-07 17:53:38"}
{"id": 1082536, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 738, "source_info": {"seq_id": "585f2063-93ba-4d3d-922e-028295d49396", "title": null, "text": "【0】页码:8\n A. Sun et al.\n\n【1】 with previously untreated extensive-stage disease small-cell lung cancer, J Clin Oncol. 24 (13) (2006) 2038–2043, https://doi.org/10.1200/JCO.2005.04.8595 .\n\n【2】[13] B.J. Slotman, H. van Tinteren, J.O. Praag, J.L. Knegjens, S.Y. El Sharouni, M. Hatton, A. Keijser, C. Faivre-Finn, S. Senan, Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial, Lancet 385 (9962) (2015) 36–42, https://doi.org/10.1016/S0140-6736(14)61085-\n\n【3】 [14] B. Jeremic, Y. Shibamoto, N. Nīkolic, B. Mīlicic, S. Milisavljevic, A. Dagovic, J. Aleksandrovic, G. Radosavljevic- Asic, Role of radiation therapy in the combinedmodality treatment of patients with extensive disease small-cell lung cancer: A randomized study, J Clin Oncol. 17 (7) (1999) 2092–2099, https://doi.org/ 10.1200/jco.1999.17.7.2092 .\n\n【4】[15] E.M. Gore, C. Hu, A.Y. Sun, D.F. Grimm, S.S. Ramalingam, N.E. Dunlap, K.\n\n【5】A. Higgins, M. Werner- Wasik, A.M. Allen, P. Iyengar, G.M.M. Videtic, R.K. Hales, R.C. McGarry, J.J. Urbanic, A.T. Pu, C.A. Johnstone, V.W. Stieber, R. Paulus, J.\n\n【6】D. Bradley, Randomized Phase II study comparing prophylactic cranial irradiation alone to prophylactic cranial irradiation and consolidative extracranial irradiation for extensive-disease small cell lung cancer (ED SCLC): NRG Oncology RTOG 0937, J Thorac Oncol. 12 (10) (2017) 1561–1570, https://doi.org/10.1016/j.\n\n【7】jtho.2017.06.015 .\n\n【8】[16] D.A. Palma, A. Warner, A.V. Louie, S. Senan, B. Slotman, G.B. Rodrigues, Thoracic radiotherapy for extensive stage small-cell lung cancer: a meta-analysis, Clin Lung Cancer. 17 (4) (2016) 239–244, https://doi.org/10.1016/j.cllc.2015.09.007 .\n\n【9】[17] A.C. Dingemans, M. Früh, A. Ardizzoni, B. Besse, C. Faivre-Finn, L.E. Hendriks, S. Lantuejoul, S. Peters, N. Reguart, C.M. Rudin, D. De Ruysscher, P.E. Van Schil, J. Vansteenkiste, M. Reck, Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol. 32 (7) (2021) 839–853, https://doi.org/10.1016/j.annonc.2021.03.207 .\n\n【10】[18] NCCN, NCCN Clinical Practice Guidelines in Oncology. Small cell lung cancer.\n\n【11】Version 2.2022, November 24, 2021, 2022. https://www.nccn.org/professionals/ physician_gls/pdf/sclc.pdf. (Accessed 6 April 2022 2022).\n\n【12】[19] C.M. Post, V. Verma, T. Mitin, C.B. Simone 2nd, Practice patterns of thoracic radiotherapy for extensive-stage small-cell lung cancer: survey of US academic thoracic radiation oncologists, Clin Lung Cancer. 18 (3) (2017) 310–315.e1, https://doi.org/10.1016/j.cllc.2016.12.004 .\n\n【13】[20] S. Johal, R. Hettle, J. Carroll, P. Maguire, T. Wynne, Real-world treatment patterns and outcomes in small-cell lung cancer: a systematic literature review, J Thorac Dis. 13(6) (2021) 3692-3707. 10.21037/jtd-20-3034.\n\n【14】[21] A. Sun, L.D. Durocher-Allen, P.M. Ellis, Y.C. Ung, J.R. Goffin, K. Ramchandar, G. Darling, Guideline for the initial management of small cell lung cancer (limited and extensive stage) and the role of thoracic radiotherapy and first-line chemotherapy, Clin Oncol (R Coll Radiol). 30 (10) (2018) 658–666, https://doi.\n\n【15】org/10.1016/j.clon.2018.06.008 .\n\n【16】[22] T. Takahashi, T. Yamanaka, T. Seto, H. Harada, H. Nokihara, H. Saka, M. Nishio, H. Kaneda, K. Takayama, O. Ishimoto, K. Takeda, H. Yoshioka, M. Tachihara, H. Sakai, K. Goto, N. Yamamoto, Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial, Lancet Oncol. 18 (5) (2017) 663–671, https://doi.org/10.1016/S1470-2045(17)30230-9 [23] H. Zeng, L.E.L. Hendriks, W.H. van Geffen, W.J.A. Witlox, D.B.P. Eekers, D.K.M. De Ruysscher, Risk factors for neurocognitive decline in lung cancer patients treated with prophylactic cranial irradiation: A systematic review, Cancer Treat Rev. 88 (2020), 102025. https://doi.org/10.1016/j.ctrv.2020.102025 [24] C.B. Simone II, J.A. Bogan, A.R. Cabrera, M.E. Daly, N.J. DeNunzio, F. Detterbeck, C. Faivre-Finn, N. Gatschet, E. Gore, S.K. Jabbour, T.J. Kruser, B.J. Schneider, B. Slotman, A. Turrisi, A.J. Wu, J. Zeng, K.E. Rosenzweig, Radiation therapy for small cell lung cancer: An ASTRO Clinical Practice Guideline, Pract. Radiat. Oncol.\n\n【17】10 (3) (2020) 158–173, https://doi.org/10.1016/j.prro.2020.02.009 .\n\n【18】[25] M.E. Daly, N. Ismaila, R.H. Decker, K. Higgins, D. Owen, A. Saxena, G.E. Franklin, D. Donaldson, B.J. Schneider, Radiation therapy for small-cell lung cancer: ASCO guideline endorsement of an ASTRO guideline, J Clin Oncol. 39 (8) (2021) 931–939. https://doi.org/10.1200/jco.20.03364 .\n\n【19】[26] M. Peifer, L. Fernandez-Cuesta, M.L. Sos, J. George, D. Seidel, L.H. Kasper, D. Plenker, F. Leenders, R. Sun, T. Zander, R. Menon, M. Koker, I. Dahmen, C. Muller, V. Di Cerbo, H.U. Schildhaus, J. Altmuller, I. Baessmann, C. Becker, B. de Wilde, J. Vandesompele, D. Bohm, S. Ansen, F. Gabler, I. Wilkening, S. Heynck, J.\n\n【20】M. Heuckmann, X. Lu, S.L. Carter, K. Cibulskis, S. Banerji, G. Getz, K.S. Park, D. Rauh, C. Grutter, M. Fischer, L. Pasqualucci, G. Wright, Z. Wainer, P. Russell, I. Petersen, Y. Chen, E. Stoelben, C. Ludwig, P. Schnabel, H. Hoffmann, T. Muley, M. Brockmann, W. Engel-Riedel, L.A. Muscarella, V.M. Fazio, H. Groen, W. Timens, H. Sietsma, E. Thunnissen, E. Smit, D.A. Heideman, P.J. Snijders, F. Cappuzzo, C. Ligorio, S. Damiani, J. Field, S. Solberg, O.T. Brustugun, M. Lund-Iversen, J. Sanger, J.H. Clement, A. Soltermann, H. Moch, W. Weder, B. Solomon, J.\n\n【21】C. Soria, P. Validire, B. Besse, E. Brambilla, C. Brambilla, S. Lantuejoul, P. Lorimier, P.M. Schneider, M. Hallek, W. Pao, M. Meyerson, J. Sage, J. Shendure, R. Schneider, R. Buttner, J. Wolf, P. Nurnberg, S. Perner, L.C. Heukamp, P.\n\n【22】K. Brindle, S. Haas, R.K. Thomas, Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer, Nat Genet. 44 (10) (2012) 1104–1110, https://doi.org/10.1038/ng.2396 [27] M. Sebastian, S. Koschade, J.A. Stratmann, SCLC, paraneoplastic syndromes, and the immune system, J Thorac Oncol. 14 (11) (2019) 1878–1880, https://doi.org/ 10.1016/j.jtho.2019.07.033 .\n\n【23】[28] L. Horn, A.S. Mansfield, A. Szczesna, L. Havel, M. Krzakowski, M.J. Hochmair, F.\n\n【24】Huemer, G. Losonczy, M.L. Johnson, M. Nishio, M. Reck, T. Mok, S. Lam, D.S.\n\n【25】Shames, J. Liu, B. Ding, A. Lopez-Chavez, F. Kabbinavar, W. Lin, A. Sandler, S.V.\n\n【26】Liu, LM.S. Group, First-line atezolizumab plus chemotherapy in extensive-stage\n\n【27】 small-cell lung cancer, N Engl J Med. 379(23) (2018) 2220-2229. 10.1056/ NEJMoa1809064.\n\n【28】[29] L. Paz-Ares, M. Dvorkin, Y. Chen, N. Reinmuth, K. Hotta, D. Trukhin, G. Statsenko, M.J. Hochmair, M. Ozguroglu, J.H. Ji, O. Voitko, A. Poltoratskiy, S. Ponce, F.\n\n【29】Verderame, L. Havel, I. Bondarenko, A. Kazarnowicz, G. Losonczy, N.V. Conev, J.\n\n【30】Armstrong, N. Byrne, N. Shire, H. Jiang, J.W. Goldman, C. investigators, Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial, Lancet. 394(10212) (2019) 1929-1939.\n\n【31】10.1016/S0140-6736(19)32222-6.\n\n【32】[30] C.M. Rudin, M.M. Awad, A. Navarro, M. Gottfried, S. Peters, T. Cs ō szi, P.K.\n\n【33】Cheema, D. Rodriguez- Abreu, M. Wollner, J. C.- H. Yang, J. Mazieres, F.J. Orlandi, A. Luft, M. Gümüş, T. Kato, G.P. Kalemkerian, Y. Luo, V. Ebiana, M.C. Pietanza, H.\n\n【34】R. Kim, o.b.o.t.K.-. Investigators, Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, Phase III KEYNOTE-604 study, J Clin Oncol. 38(21) (2020) 2369-2379. 10.1200/jco.20.00793.\n\n【35】[31] Reinmuth, P48.03 - First-line durvalumab plus platinum-etoposide in extensivestage (ES)-SCLC: exploratory analyses based on extent of disease in CASPIAN.\n\n【36】WCLC 2021. (2021).\n\n【37】[32] NIH, SWOG S1827 (MAVERICK) Testing whether the use of brain scans alone instead of brain scans plus preventive brain radiation affects lifespan in patients with small cell lung cancer. Available at: https://clinicaltrials.gov/ct2/show/ NCT04155034?term=maverick&draw=2&rank=5. Accessed: 6 April 2022.\n\n【38】(2022).\n\n【39】[33] NIH, Chemo-immunotherapy plus thoracic radiotherapy in extensive stage smallcell lung cancer (TRIPLEX). Available at: https://clinicaltrials.gov/ct2/show/ NCT05223647?term=TRIPLEX&cond=SCLC&draw=2&rank=1. Accessed: 6 April 2022, 2022.\n\n【40】[34] NIH, Thoracic RadiothErapy with Atezolizumab in Small cell lUng canceR Extensive disease (TREASURE). Available at: https://clinicaltrials.gov/ct2/show/ NCT04462276?term=TREASURE&cond=SCLC&draw=2&rank=1. Accessed: 6 April 2022, 2022.\n\n【41】[35] NIH, Testing the addition of radiation therapy to the usual immune therapy treatment (atezolizumab) for extensive stage small cell lung cancer - The RAPTOR Trial. Available at: Accessed: https://clinicaltrials.gov/ct2/show/NCT04402788?\n\n【42】term=RAPTOR&cond=sclc&draw=2&rank=1. 6 April 2022, 2022.\n\n【43】[36] NIH, Study of durvalumab in combination with platinum and etoposide for the first line treatment of patients with extensive-stage small cell lung cancer (LUMINANCE). Available at: https://clinicaltrials.gov/ct2/show/NCT04774380?\n\n【44】term–luminance&cond–sclc&draw–2&rank–1. Accessed: 14 April 2022, 2022.\n\n【45】[37] A.A. Elegbede, A.J. Gibson, A.S. Fung, W.Y. Cheung, M.I. Dean, D.G. Bebb, A. Pabani, A real-world evaluation of atezolizumab plus platinum-etoposide chemotherapy in patients with extensive-stage SCLC in Canada, JTO Clin Res Rep.\n\n【46】2 (12) (2021), 100249, https://doi.org/10.1016/j.jtocrr.2021.100249 .\n\n【47】[38] B.A. Perez, S. Kim, M. Wang, A.M. Karimi, C. Powell, J. Li, T.J. Dilling, A. Chiappori, K. Latifi, T. Rose, A. Lannon, G. MacMillan, J. Saller, G.D. Grass, S. Rosenberg, J. Gray, E. Haura, B. Creelan, T. Tanvetyanon, A. Saltos, M. Shafique, T.A. Boyle, M.J. Schell, J.R. Conejo-Garcia, S.J. Antonia, Prospective single-arm phase 1 and 2 study: ipilimumab and nivolumab with thoracic radiation therapy after platinum chemotherapy in extensive-stage small cell lung cancer, Int J Radiat Oncol Biol Phys. 109 (2) (2021) 425–435, https://doi.org/10.1016/j.\n\n【48】ijrobp, 2020 . 09 . 031 .\n\n【49】[39] J.W. Welsh, J.V. Heymach, D. Chen, V. Verma, T.R. Cushman, K.R. Hess, G. Shroff, C. Tang, F. Skoulidis, M. Jeter, H. Menon, Q.N. Nguyen, J.Y. Chang, M. Altan, V.\n\n【50】A. Papadimitrakopoulou, G.R. Simon, U. Raju, L. Byers, B. Glisson, Phase I trial of pembrolizumab and radiation therapy after induction chemotherapy for extensivestage small cell lung cancer, J Thorac Oncol. 15 (2) (2020) 266–273, https://doi.\n\n【51】org/10.1016/j.jtho.2019.10.001 .\n\n【52】[40] J.M. Galuba, I. Stöver, A. Koziorowski, S. Bölükbas, G. Nīlius, D.C. Christoph, 1652P Safety of simultaneously performed radiotherapy in patients with small cell lung cancer undergoing atezolizumab treatment, Ann Oncol. 32 (2021) S1165, https://doi.org/10.1016/j.annonc.2021.08.236 .\n\n【53】[41] A.J. Gross, M.Z. Kharouta, T.K. Podder, S. Choi, T. Biswas, Role of thoracic radiotherapy in extensive stage small cell lung cancer (ES-SCLC) in the immunotherapy era: a national hospital-based registry analysis, Int J Rad Oncol Biol Phys. 111 (3) (2021) e466.\n\n【54】[42] S. Lee, H.S. Shim, B.C. Ahn, S.M. Lim, H.R. Kim, B.C. Cho, M.H. Hong, Efficacy and safety of atezolizumab, in combination with etoposide and carboplatin regimen, in the first-line treatment of extensive-stage small-cell lung cancer: a single-center experience, Cancer Immunol Immunother. (2021), https://doi.org/10.1007/ s00262-021-03052-w .\n\n【55】[43] D.X. Yang, V. Jairam, H.S. Park, R.H. Decker, A.C. Chiang, C.P. Gross, J.B. Yu, Use of prophylactic cranial irradiation in patients with extensive-stage small cell lung cancer receiving immunotherapy, J Clin Oncol. 38 (15 suppl) (2020) e19309–e, https://doi.org/10.1200/JCO.2020.38.15_suppl.e19309 .\n\n【56】[44] J.W. Welsh, J.V. Heymach, C. Guo, H. Menon, K. Klein, T.R. Cushman, V. Verma, K.\n\n【57】R. Hess, G. Shroff, C. Tang, F. Skoulidis, M. Jeter, N. Comeaux, R.R. Patel, D. Chen, T. Ozgen, Q.N. Nguyen, J.Y. Chang, M. Altan, J. Zhang, V.A. Papadimitrakopoulou, G.R. Simon, L.A. Byers, B. Glisson, Phase 1/2 trial of pembrolizumab and concurrent chemoradiation therapy for limited-stage SCLC, J Thorac Oncol. 15 (12) (2020) 1919–1927, https://doi.org/10.1016/j.jtho.2020.08.022 , [45] S. Peters, J.L. Pujol, U. Dafni, M. Dómine, S. Popat, M. Reck, J. Andrade, A. Becker, D. Moro-Sibilot, A. Curioni-Fontecedro, O. Molinier, K. Nackaerts, A. Insa Mollá, R. Gervais, G. López Vīvanco, J. Madelaine, J. Mazieres, M. Faehling, F. Griesinger, M. Majem, J.L. González Larriba, M. Provencio Pulla, K. Vervita, H. Roschitzki-", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "A. Sun et al.", "bbox": [48.0, 46.0, 95.0, 58.0]}], "type": "Text", "position": 0}, {"raw_context": [{"text": "with previously untreated extensive-stage disease small-cell lung cancer, J Clin", "bbox": [70.0, 70.0, 375.0, 82.0]}, {"text": "Oncol. 24 (13) (2006) 2038–2043, https://doi.org/10.1200/JCO.2005.04.8595 .", "bbox": [70.0, 82.0, 376.0, 93.0]}, {"text": "[13] B.J. Slotman, H. van Tinteren, J.O. Praag, J.L. Knegjens, S.Y. El Sharouni,", "bbox": [48.0, 92.0, 356.0, 104.0]}, {"text": "M. Hatton, A. Keijser, C. Faivre-Finn, S. Senan, Use of thoracic radiotherapy for", "bbox": [70.0, 103.0, 377.0, 114.0]}, {"text": "extensive stage small-cell lung cancer: a phase 3 randomised controlled trial,", "bbox": [70.0, 113.0, 367.0, 125.0]}, {"text": "Lancet 385 (9962) (2015) 36–42, https://doi.org/10.1016/S0140-6736(14)61085-", "bbox": [70.0, 124.0, 381.0, 135.0]}], "type": "Text", "position": 1}, {"raw_context": [{"text": "[14] B. Jeremic, Y. Shibamoto, N. Nīkolic, B. Mīlicic, S. Milisavljevic, A. Dagovic,", "bbox": [48.0, 145.0, 364.0, 157.0]}, {"text": "J. Aleksandrovic, G. Radosavljevic- Asic, Role of radiation therapy in the combined-", "bbox": [70.0, 156.0, 383.0, 167.0]}, {"text": "modality treatment of patients with extensive disease small-cell lung cancer: A", "bbox": [70.0, 166.0, 373.0, 178.0]}, {"text": "randomized study, J Clin Oncol. 17 (7) (1999) 2092–2099, https://doi.org/", "bbox": [70.0, 177.0, 359.0, 188.0]}, {"text": "10.1200/jco.1999.17.7.2092 .", "bbox": [72.0, 187.0, 182.0, 199.0]}, {"text": "[15] E.M. Gore, C. Hu, A.Y. Sun, D.F. Grimm, S.S. Ramalingam, N.E. Dunlap, K.", "bbox": [48.0, 197.0, 357.0, 210.0]}, {"text": "A. Higgins, M. Werner- Wasik, A.M. Allen, P. Iyengar, G.M.M. Videtic, R.K. Hales,", "bbox": [70.0, 209.0, 382.0, 221.0]}, {"text": "R.C. McGarry, J.J. Urbanic, A.T. Pu, C.A. Johnstone, V.W. Stieber, R. Paulus, J.", "bbox": [70.0, 219.0, 377.0, 232.0]}, {"text": "D. Bradley, Randomized Phase II study comparing prophylactic cranial irradiation", "bbox": [70.0, 230.0, 383.0, 242.0]}, {"text": "alone to prophylactic cranial irradiation and consolidative extracranial irradiation", "bbox": [70.0, 240.0, 383.0, 253.0]}, {"text": "for extensive-disease small cell lung cancer (ED SCLC): NRG Oncology RTOG 0937,", "bbox": [70.0, 251.0, 383.0, 263.0]}, {"text": "J Thorac Oncol. 12 (10) (2017) 1561–1570, https://doi.org/10.1016/j.", "bbox": [70.0, 262.0, 342.0, 273.0]}, {"text": "jtho.2017.06.015 .", "bbox": [70.0, 273.0, 140.0, 284.0]}, {"text": "[16] D.A. Palma, A. Warner, A.V. Louie, S. Senan, B. Slotman, G.B. Rodrigues, Thoracic", "bbox": [48.0, 283.0, 383.0, 294.0]}, {"text": "radiotherapy for extensive stage small-cell lung cancer: a meta-analysis, Clin Lung", "bbox": [70.0, 293.0, 383.0, 306.0]}, {"text": "Cancer. 17 (4) (2016) 239–244, https://doi.org/10.1016/j.cllc.2015.09.007 .", "bbox": [70.0, 304.0, 361.0, 316.0]}, {"text": "[17] A.C. Dingemans, M. Früh, A. Ardizzoni, B. Besse, C. Faivre-Finn, L.E. Hendriks,", "bbox": [48.0, 315.0, 373.0, 327.0]}, {"text": "S. Lantuejoul, S. Peters, N. Reguart, C.M. Rudin, D. De Ruysscher, P.E. Van Schil,", "bbox": [70.0, 325.0, 383.0, 337.0]}, {"text": "J. Vansteenkiste, M. Reck, Small-cell lung cancer: ESMO Clinical Practice", "bbox": [70.0, 337.0, 353.0, 348.0]}, {"text": "Guidelines for diagnosis, treatment and follow-up, Ann Oncol. 32 (7) (2021)", "bbox": [70.0, 347.0, 365.0, 359.0]}, {"text": "839–853, https://doi.org/10.1016/j.annonc.2021.03.207 .", "bbox": [70.0, 358.0, 292.0, 369.0]}, {"text": "[18] NCCN, NCCN Clinical Practice Guidelines in Oncology. Small cell lung cancer.", "bbox": [48.0, 368.0, 370.0, 380.0]}, {"text": "Version 2.2022, November 24, 2021, 2022. https://www.nccn.org/professionals/", "bbox": [70.0, 378.0, 382.0, 390.0]}, {"text": "physician_gls/pdf/sclc.pdf. (Accessed 6 April 2022 2022).", "bbox": [70.0, 390.0, 292.0, 401.0]}, {"text": "[19] C.M. Post, V. Verma, T. Mitin, C.B. Simone 2nd, Practice patterns of thoracic", "bbox": [48.0, 399.0, 366.0, 412.0]}, {"text": "radiotherapy for extensive-stage small-cell lung cancer: survey of US academic", "bbox": [70.0, 410.0, 371.0, 422.0]}, {"text": "thoracic radiation oncologists, Clin Lung Cancer. 18 (3) (2017) 310–315.e1,", "bbox": [70.0, 421.0, 363.0, 433.0]}, {"text": "https://doi.org/10.1016/j.cllc.2016.12.004 .", "bbox": [70.0, 432.0, 237.0, 443.0]}, {"text": "[20] S. Johal, R. Hettle, J. Carroll, P. Maguire, T. Wynne, Real-world treatment patterns", "bbox": [48.0, 443.0, 384.0, 454.0]}, {"text": "and outcomes in small-cell lung cancer: a systematic literature review, J Thorac", "bbox": [70.0, 453.0, 377.0, 465.0]}, {"text": "Dis. 13(6) (2021) 3692-3707. 10.21037/jtd-20-3034.", "bbox": [70.0, 463.0, 274.0, 475.0]}, {"text": "[21] A. Sun, L.D. Durocher-Allen, P.M. Ellis, Y.C. Ung, J.R. Goffin, K. Ramchandar,", "bbox": [48.0, 474.0, 370.0, 486.0]}, {"text": "G. Darling, Guideline for the initial management of small cell lung cancer (limited", "bbox": [70.0, 485.0, 384.0, 496.0]}, {"text": "and extensive stage) and the role of thoracic radiotherapy and first-line", "bbox": [70.0, 495.0, 346.0, 507.0]}, {"text": "chemotherapy, Clin Oncol (R Coll Radiol). 30 (10) (2018) 658–666, https://doi.", "bbox": [70.0, 506.0, 377.0, 518.0]}, {"text": "org/10.1016/j.clon.2018.06.008 .", "bbox": [70.0, 517.0, 196.0, 528.0]}, {"text": "[22] T. Takahashi, T. Yamanaka, T. Seto, H. Harada, H. Nokihara, H. Saka, M. Nishio,", "bbox": [48.0, 527.0, 382.0, 539.0]}, {"text": "H. Kaneda, K. Takayama, O. Ishimoto, K. Takeda, H. Yoshioka, M. Tachihara,", "bbox": [70.0, 538.0, 369.0, 549.0]}, {"text": "H. Sakai, K. Goto, N. Yamamoto, Prophylactic cranial irradiation versus", "bbox": [70.0, 548.0, 346.0, 560.0]}, {"text": "observation in patients with extensive-disease small-cell lung cancer: a", "bbox": [70.0, 559.0, 343.0, 570.0]}, {"text": "multicentre, randomised, open-label, phase 3 trial, Lancet Oncol. 18 (5) (2017)", "bbox": [70.0, 570.0, 376.0, 583.0]}, {"text": "663–671, https://doi.org/10.1016/S1470-2045(17)30230-9", "bbox": [70.0, 581.0, 298.0, 591.0]}, {"text": "[23] H. Zeng, L.E.L. Hendriks, W.H. van Geffen, W.J.A. Witlox, D.B.P. Eekers, D.K.M. De", "bbox": [48.0, 591.0, 383.0, 602.0]}, {"text": "Ruysscher, Risk factors for neurocognitive decline in lung cancer patients treated", "bbox": [70.0, 601.0, 382.0, 613.0]}, {"text": "with prophylactic cranial irradiation: A systematic review, Cancer Treat Rev. 88", "bbox": [70.0, 612.0, 380.0, 623.0]}, {"text": "(2020), 102025. https://doi.org/10.1016/j.ctrv.2020.102025", "bbox": [70.0, 623.0, 304.0, 633.0]}, {"text": "[24] C.B. Simone II, J.A. Bogan, A.R. Cabrera, M.E. Daly, N.J. DeNunzio, F. Detterbeck,", "bbox": [48.0, 633.0, 382.0, 645.0]}, {"text": "C. Faivre-Finn, N. Gatschet, E. Gore, S.K. Jabbour, T.J. Kruser, B.J. Schneider,", "bbox": [70.0, 644.0, 371.0, 656.0]}, {"text": "B. Slotman, A. Turrisi, A.J. Wu, J. Zeng, K.E. Rosenzweig, Radiation therapy for", "bbox": [70.0, 656.0, 378.0, 668.0]}, {"text": "small cell lung cancer: An ASTRO Clinical Practice Guideline, Pract. Radiat. Oncol.", "bbox": [70.0, 666.0, 381.0, 675.0]}, {"text": "10 (3) (2020) 158–173, https://doi.org/10.1016/j.prro.2020.02.009 .", "bbox": [70.0, 676.0, 334.0, 688.0]}, {"text": "[25] M.E. Daly, N. Ismaila, R.H. Decker, K. Higgins, D. Owen, A. Saxena, G.E. Franklin,", "bbox": [48.0, 688.0, 382.0, 700.0]}, {"text": "D. Donaldson, B.J. Schneider, Radiation therapy for small-cell lung cancer: ASCO", "bbox": [70.0, 699.0, 382.0, 709.0]}, {"text": "guideline endorsement of an ASTRO guideline, J Clin Oncol. 39 (8) (2021)", "bbox": [70.0, 707.0, 360.0, 722.0]}, {"text": "931–939. https://doi.org/10.1200/jco.20.03364 .", "bbox": [70.0, 721.0, 256.0, 728.0]}, {"text": "[26] M. Peifer, L. Fernandez-Cuesta, M.L. Sos, J. George, D. Seidel, L.H. Kasper,", "bbox": [48.0, 727.0, 358.0, 743.0]}, {"text": "D. Plenker, F. Leenders, R. Sun, T. Zander, R. Menon, M. Koker, I. Dahmen,", "bbox": [70.0, 742.0, 361.0, 753.0]}, {"text": "C. Muller, V. Di Cerbo, H.U. Schildhaus, J. Altmuller, I. Baessmann, C. Becker, B. de", "bbox": [70.0, 751.0, 383.0, 761.0]}, {"text": "Wilde, J. Vandesompele, D. Bohm, S. Ansen, F. Gabler, I. Wilkening, S. Heynck, J.", "bbox": [70.0, 762.0, 383.0, 773.0]}, {"text": "M. Heuckmann, X. Lu, S.L. Carter, K. Cibulskis, S. Banerji, G. Getz, K.S. Park,", "bbox": [70.0, 773.0, 367.0, 785.0]}, {"text": "D. Rauh, C. Grutter, M. Fischer, L. Pasqualucci, G. Wright, Z. Wainer, P. Russell,", "bbox": [70.0, 784.0, 379.0, 796.0]}, {"text": "I. Petersen, Y. Chen, E. Stoelben, C. Ludwig, P. Schnabel, H. Hoffmann, T. Muley,", "bbox": [70.0, 795.0, 383.0, 806.0]}, {"text": "M. Brockmann, W. Engel-Riedel, L.A. Muscarella, V.M. Fazio, H. Groen, W. Timens,", "bbox": [70.0, 804.0, 382.0, 814.0]}, {"text": "H. Sietsma, E. Thunnissen, E. Smit, D.A. Heideman, P.J. Snijders, F. Cappuzzo,", "bbox": [70.0, 815.0, 373.0, 826.0]}, {"text": "C. Ligorio, S. Damiani, J. Field, S. Solberg, O.T. Brustugun, M. Lund-Iversen,", "bbox": [70.0, 826.0, 364.0, 838.0]}, {"text": "J. Sanger, J.H. Clement, A. Soltermann, H. Moch, W. Weder, B. Solomon, J.", "bbox": [70.0, 837.0, 361.0, 847.0]}, {"text": "C. Soria, P. Validire, B. Besse, E. Brambilla, C. Brambilla, S. Lantuejoul, P. Lorimier,", "bbox": [70.0, 848.0, 382.0, 858.0]}, {"text": "P.M. Schneider, M. Hallek, W. Pao, M. Meyerson, J. Sage, J. Shendure,", "bbox": [70.0, 858.0, 342.0, 870.0]}, {"text": "R. Schneider, R. Buttner, J. Wolf, P. Nurnberg, S. Perner, L.C. Heukamp, P.", "bbox": [70.0, 869.0, 359.0, 880.0]}, {"text": "K. Brindle, S. Haas, R.K. Thomas, Integrative genome analyses identify key somatic", "bbox": [70.0, 879.0, 383.0, 891.0]}, {"text": "driver mutations of small-cell lung cancer, Nat Genet. 44 (10) (2012) 1104–1110,", "bbox": [70.0, 890.0, 383.0, 901.0]}, {"text": "https://doi.org/10.1038/ng.2396", "bbox": [70.0, 901.0, 198.0, 911.0]}, {"text": "[27] M. Sebastian, S. Koschade, J.A. Stratmann, SCLC, paraneoplastic syndromes, and", "bbox": [48.0, 911.0, 381.0, 923.0]}, {"text": "the immune system, J Thorac Oncol. 14 (11) (2019) 1878–1880, https://doi.org/", "bbox": [70.0, 922.0, 381.0, 933.0]}, {"text": "10.1016/j.jtho.2019.07.033 .", "bbox": [70.0, 932.0, 179.0, 943.0]}, {"text": "[28] L. Horn, A.S. Mansfield, A. Szczesna, L. Havel, M. Krzakowski, M.J. Hochmair, F.", "bbox": [48.0, 943.0, 382.0, 954.0]}, {"text": "Huemer, G. Losonczy, M.L. Johnson, M. Nishio, M. Reck, T. Mok, S. Lam, D.S.", "bbox": [70.0, 953.0, 371.0, 965.0]}, {"text": "Shames, J. Liu, B. Ding, A. Lopez-Chavez, F. Kabbinavar, W. Lin, A. Sandler, S.V.", "bbox": [70.0, 964.0, 381.0, 976.0]}, {"text": "Liu, LM.S. Group, First-line atezolizumab plus chemotherapy in extensive-stage", "bbox": [70.0, 975.0, 375.0, 987.0]}], "type": "Text", "position": 2}, {"raw_context": [{"text": "small-cell lung cancer, N Engl J Med. 379(23) (2018) 2220-2229. 10.1056/", "bbox": [430.0, 69.0, 720.0, 82.0]}, {"text": "NEJMoa1809064.", "bbox": [429.0, 82.0, 499.0, 90.0]}, {"text": "[29] L. Paz-Ares, M. Dvorkin, Y. Chen, N. Reinmuth, K. Hotta, D. Trukhin, G. Statsenko,", "bbox": [406.0, 91.0, 742.0, 104.0]}, {"text": "M.J. Hochmair, M. Ozguroglu, J.H. Ji, O. Voitko, A. Poltoratskiy, S. Ponce, F.", "bbox": [429.0, 103.0, 727.0, 115.0]}, {"text": "Verderame, L. Havel, I. Bondarenko, A. Kazarnowicz, G. Losonczy, N.V. Conev, J.", "bbox": [429.0, 113.0, 742.0, 125.0]}, {"text": "Armstrong, N. Byrne, N. Shire, H. Jiang, J.W. Goldman, C. investigators,", "bbox": [430.0, 124.0, 707.0, 136.0]}, {"text": "Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line", "bbox": [429.0, 135.0, 718.0, 147.0]}, {"text": "treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised,", "bbox": [429.0, 145.0, 727.0, 157.0]}, {"text": "controlled, open-label, phase 3 trial, Lancet. 394(10212) (2019) 1929-1939.", "bbox": [430.0, 156.0, 721.0, 167.0]}, {"text": "10.1016/S0140-6736(19)32222-6.", "bbox": [430.0, 166.0, 563.0, 177.0]}, {"text": "[30] C.M. Rudin, M.M. Awad, A. Navarro, M. Gottfried, S. Peters, T. Cs ō szi, P.K.", "bbox": [406.0, 177.0, 719.0, 188.0]}, {"text": "Cheema, D. Rodriguez- Abreu, M. Wollner, J. C.- H. Yang, J. Mazieres, F.J. Orlandi,", "bbox": [429.0, 187.0, 741.0, 200.0]}, {"text": "A. Luft, M. Gümüş, T. Kato, G.P. Kalemkerian, Y. Luo, V. Ebiana, M.C. Pietanza, H.", "bbox": [429.0, 198.0, 742.0, 210.0]}, {"text": "R. Kim, o.b.o.t.K.-. Investigators, Pembrolizumab or placebo plus etoposide and", "bbox": [429.0, 209.0, 735.0, 220.0]}, {"text": "platinum as first-line therapy for extensive-stage small-cell lung cancer:", "bbox": [429.0, 219.0, 703.0, 232.0]}, {"text": "randomized, double-blind, Phase III KEYNOTE-604 study, J Clin Oncol. 38(21)", "bbox": [430.0, 230.0, 733.0, 241.0]}, {"text": "(2020) 2369-2379. 10.1200/jco.20.00793.", "bbox": [429.0, 240.0, 592.0, 253.0]}, {"text": "[31] Reinmuth, P48.03 - First-line durvalumab plus platinum-etoposide in extensive-", "bbox": [406.0, 251.0, 733.0, 264.0]}, {"text": "stage (ES)-SCLC: exploratory analyses based on extent of disease in CASPIAN.", "bbox": [430.0, 262.0, 727.0, 273.0]}, {"text": "WCLC 2021. (2021).", "bbox": [430.0, 272.0, 510.0, 284.0]}, {"text": "[32] NIH, SWOG S1827 (MAVERICK) Testing whether the use of brain scans alone", "bbox": [406.0, 281.0, 729.0, 296.0]}, {"text": "instead of brain scans plus preventive brain radiation affects lifespan in patients", "bbox": [430.0, 293.0, 737.0, 306.0]}, {"text": "with small cell lung cancer. Available at: https://clinicaltrials.gov/ct2/show/", "bbox": [430.0, 305.0, 725.0, 316.0]}, {"text": "NCT04155034?term=maverick&draw=2&rank=5. Accessed: 6 April 2022.", "bbox": [430.0, 315.0, 715.0, 326.0]}, {"text": "(2022).", "bbox": [430.0, 326.0, 459.0, 337.0]}, {"text": "[33] NIH, Chemo-immunotherapy plus thoracic radiotherapy in extensive stage small-", "bbox": [406.0, 337.0, 740.0, 348.0]}, {"text": "cell lung cancer (TRIPLEX). Available at: https://clinicaltrials.gov/ct2/show/", "bbox": [429.0, 346.0, 724.0, 359.0]}, {"text": "NCT05223647?term=TRIPLEX&cond=SCLC&draw=2&rank=1. Accessed: 6 April", "bbox": [430.0, 357.0, 743.0, 369.0]}, {"text": "2022, 2022.", "bbox": [430.0, 368.0, 477.0, 379.0]}, {"text": "[34] NIH, Thoracic RadiothErapy with Atezolizumab in Small cell lUng canceR", "bbox": [406.0, 378.0, 714.0, 390.0]}, {"text": "Extensive disease (TREASURE). Available at: https://clinicaltrials.gov/ct2/show/", "bbox": [430.0, 389.0, 739.0, 401.0]}, {"text": "NCT04462276?term=TREASURE&cond=SCLC&draw=2&rank=1. Accessed: 6", "bbox": [430.0, 399.0, 730.0, 411.0]}, {"text": "April 2022, 2022.", "bbox": [430.0, 411.0, 498.0, 421.0]}, {"text": "[35] NIH, Testing the addition of radiation therapy to the usual immune therapy", "bbox": [406.0, 421.0, 721.0, 433.0]}, {"text": "treatment (atezolizumab) for extensive stage small cell lung cancer - The RAPTOR", "bbox": [430.0, 432.0, 742.0, 443.0]}, {"text": "Trial. Available at: Accessed: https://clinicaltrials.gov/ct2/show/NCT04402788?", "bbox": [430.0, 443.0, 739.0, 454.0]}, {"text": "term=RAPTOR&cond=sclc&draw=2&rank=1. 6 April 2022, 2022.", "bbox": [430.0, 453.0, 686.0, 465.0]}, {"text": "[36] NIH, Study of durvalumab in combination with platinum and etoposide for the first", "bbox": [406.0, 464.0, 742.0, 475.0]}, {"text": "line treatment of patients with extensive-stage small cell lung cancer", "bbox": [429.0, 474.0, 694.0, 486.0]}, {"text": "(LUMINANCE). Available at: https://clinicaltrials.gov/ct2/show/NCT04774380?", "bbox": [429.0, 485.0, 737.0, 496.0]}, {"text": "term–luminance&cond–sclc&draw–2&rank–1. Accessed: 14 April 2022, 2022.", "bbox": [429.0, 495.0, 737.0, 507.0]}, {"text": "[37] A.A. Elegbede, A.J. Gibson, A.S. Fung, W.Y. Cheung, M.I. Dean, D.G. Bebb,", "bbox": [406.0, 506.0, 720.0, 518.0]}, {"text": "A. Pabani, A real-world evaluation of atezolizumab plus platinum-etoposide", "bbox": [429.0, 517.0, 721.0, 528.0]}, {"text": "chemotherapy in patients with extensive-stage SCLC in Canada, JTO Clin Res Rep.", "bbox": [429.0, 527.0, 741.0, 539.0]}, {"text": "2 (12) (2021), 100249, https://doi.org/10.1016/j.jtocrr.2021.100249 .", "bbox": [429.0, 539.0, 698.0, 549.0]}, {"text": "[38] B.A. Perez, S. Kim, M. Wang, A.M. Karimi, C. Powell, J. Li, T.J. Dilling,", "bbox": [406.0, 548.0, 704.0, 560.0]}, {"text": "A. Chiappori, K. Latifi, T. Rose, A. Lannon, G. MacMillan, J. Saller, G.D. Grass,", "bbox": [429.0, 559.0, 733.0, 570.0]}, {"text": "S. Rosenberg, J. Gray, E. Haura, B. Creelan, T. Tanvetyanon, A. Saltos, M. Shafique,", "bbox": [429.0, 571.0, 741.0, 581.0]}, {"text": "T.A. Boyle, M.J. Schell, J.R. Conejo-Garcia, S.J. Antonia, Prospective single-arm", "bbox": [429.0, 581.0, 737.0, 592.0]}, {"text": "phase 1 and 2 study: ipilimumab and nivolumab with thoracic radiation therapy", "bbox": [429.0, 592.0, 740.0, 602.0]}, {"text": "after platinum chemotherapy in extensive-stage small cell lung cancer, Int J Radiat", "bbox": [429.0, 602.0, 742.0, 613.0]}, {"text": "Oncol Biol Phys. 109 (2) (2021) 425–435, https://doi.org/10.1016/j.", "bbox": [429.0, 612.0, 694.0, 623.0]}, {"text": "ijrobp, 2020 . 09 . 031 .", "bbox": [431.0, 625.0, 504.0, 633.0]}, {"text": "[39] J.W. Welsh, J.V. Heymach, D. Chen, V. Verma, T.R. Cushman, K.R. Hess, G. Shroff,", "bbox": [406.0, 633.0, 742.0, 645.0]}, {"text": "C. Tang, F. Skoulidis, M. Jeter, H. Menon, Q.N. Nguyen, J.Y. Chang, M. Altan, V.", "bbox": [428.0, 644.0, 742.0, 656.0]}, {"text": "A. Papadimitrakopoulou, G.R. Simon, U. Raju, L. Byers, B. Glisson, Phase I trial of", "bbox": [429.0, 656.0, 743.0, 668.0]}, {"text": "pembrolizumab and radiation therapy after induction chemotherapy for extensive-", "bbox": [428.0, 667.0, 741.0, 676.0]}, {"text": "stage small cell lung cancer, J Thorac Oncol. 15 (2) (2020) 266–273, https://doi.", "bbox": [429.0, 677.0, 741.0, 687.0]}, {"text": "org/10.1016/j.jtho.2019.10.001 .", "bbox": [430.0, 689.0, 556.0, 698.0]}, {"text": "[40] J.M. Galuba, I. Stöver, A. Koziorowski, S. Bölükbas, G. Nīlius, D.C. Christoph,", "bbox": [406.0, 697.0, 728.0, 709.0]}, {"text": "1652P Safety of simultaneously performed radiotherapy in patients with small cell", "bbox": [430.0, 709.0, 743.0, 721.0]}, {"text": "lung cancer undergoing atezolizumab treatment, Ann Oncol. 32 (2021) S1165,", "bbox": [429.0, 721.0, 731.0, 729.0]}, {"text": "https://doi.org/10.1016/j.annonc.2021.08.236 .", "bbox": [428.0, 731.0, 611.0, 740.0]}, {"text": "[41] A.J. Gross, M.Z. Kharouta, T.K. Podder, S. Choi, T. Biswas, Role of thoracic", "bbox": [406.0, 741.0, 718.0, 754.0]}, {"text": "radiotherapy in extensive stage small cell lung cancer (ES-SCLC) in the", "bbox": [429.0, 752.0, 702.0, 760.0]}, {"text": "immunotherapy era: a national hospital-based registry analysis, Int J Rad Oncol", "bbox": [430.0, 762.0, 736.0, 773.0]}, {"text": "Biol Phys. 111 (3) (2021) e466.", "bbox": [429.0, 773.0, 550.0, 782.0]}, {"text": "[42] S. Lee, H.S. Shim, B.C. Ahn, S.M. Lim, H.R. Kim, B.C. Cho, M.H. Hong, Efficacy and", "bbox": [406.0, 782.0, 743.0, 795.0]}, {"text": "safety of atezolizumab, in combination with etoposide and carboplatin regimen, in", "bbox": [429.0, 795.0, 743.0, 806.0]}, {"text": "the first-line treatment of extensive-stage small-cell lung cancer: a single-center", "bbox": [429.0, 805.0, 734.0, 815.0]}, {"text": "experience, Cancer Immunol Immunother. (2021), https://doi.org/10.1007/", "bbox": [429.0, 815.0, 720.0, 826.0]}, {"text": "s00262-021-03052-w .", "bbox": [430.0, 826.0, 512.0, 835.0]}, {"text": "[43] D.X. Yang, V. Jairam, H.S. Park, R.H. Decker, A.C. Chiang, C.P. Gross, J.B. Yu, Use", "bbox": [406.0, 834.0, 743.0, 848.0]}, {"text": "of prophylactic cranial irradiation in patients with extensive-stage small cell lung", "bbox": [429.0, 848.0, 742.0, 858.0]}, {"text": "cancer receiving immunotherapy, J Clin Oncol. 38 (15 suppl) (2020) e19309–e,", "bbox": [429.0, 858.0, 736.0, 871.0]}, {"text": "https://doi.org/10.1200/JCO.2020.38.15_suppl.e19309 .", "bbox": [430.0, 869.0, 642.0, 879.0]}, {"text": "[44] J.W. Welsh, J.V. Heymach, C. Guo, H. Menon, K. Klein, T.R. Cushman, V. Verma, K.", "bbox": [406.0, 878.0, 742.0, 891.0]}, {"text": "R. Hess, G. Shroff, C. Tang, F. Skoulidis, M. Jeter, N. Comeaux, R.R. Patel, D. Chen,", "bbox": [429.0, 890.0, 741.0, 901.0]}, {"text": "T. Ozgen, Q.N. Nguyen, J.Y. Chang, M. Altan, J. Zhang, V.A. Papadimitrakopoulou,", "bbox": [429.0, 901.0, 742.0, 912.0]}, {"text": "G.R. Simon, L.A. Byers, B. Glisson, Phase 1/2 trial of pembrolizumab and", "bbox": [428.0, 911.0, 713.0, 923.0]}, {"text": "concurrent chemoradiation therapy for limited-stage SCLC, J Thorac Oncol. 15", "bbox": [428.0, 922.0, 733.0, 933.0]}, {"text": "(12) (2020) 1919–1927, https://doi.org/10.1016/j.jtho.2020.08.022 ,", "bbox": [428.0, 932.0, 693.0, 944.0]}, {"text": "[45] S. Peters, J.L. Pujol, U. Dafni, M. Dómine, S. Popat, M. Reck, J. Andrade, A. Becker,", "bbox": [406.0, 943.0, 741.0, 954.0]}, {"text": "D. Moro-Sibilot, A. Curioni-Fontecedro, O. Molinier, K. Nackaerts, A. Insa Mollá,", "bbox": [429.0, 953.0, 739.0, 965.0]}, {"text": "R. Gervais, G. López Vīvanco, J. Madelaine, J. Mazieres, M. Faehling, F. Griesinger,", "bbox": [429.0, 964.0, 741.0, 976.0]}, {"text": "M. Majem, J.L. González Larriba, M. Provencio Pulla, K. Vervita, H. Roschitzki-", "bbox": [429.0, 975.0, 734.0, 986.0]}], "type": "Text", "position": 4}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/肿瘤科/共识/加拿大共识建议：在接受免疫治疗的广泛期小细胞肺癌患者中使用放射治疗.pdf", "page_num": 8}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": null, "type3": null, "type4": null, "type5": null, "type6": "有用性#0#57#全篇为其他参考文献内容"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:40", "update_time": "2024-05-07 22:59:21"}
{"id": 1082535, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 738, "source_info": {"seq_id": "dc8c7ffe-0a63-454c-b2fb-ad1f5ec795d7", "title": null, "text": "【0】页码:7\n\n【1】## 参\n\n【2】\n 中医院医学影像科)  放射科 )  学附属中山医院医学影像科) . 曾庆思 ( 广州医科大学附属第一医 院放射科) , 张洪(天津市胸科医院影像科) , 张景峰(中国科学院大 学宁波华美医院医学影像科)、张琳琳（中华放射学杂志编辑部）、 张龙江(南京大学医学院附属金陵医院医学影像科)、赵绍宏(解放 军总医院第一医学中心放射科) 科 ) , 第 缴文 ( 空军军医大学第一附属医院放射診断科 ) , 周 缴 ( 上海 交通大学医学院附属瑞金医院呼吸内科) 第二用属医院放射诊断科) 利益冲突    所有作者声明无利益冲突\n\n【3】 of chronic obstructive pulmonary disease: a statement of the Fleischner Society[J]. Radiology, 2015, 277(1): 192-205. DOI: 10.1148/radiol.2015141579.\n\n【4】Schiska A. The role of computed tomography in the diagnosis and treatment of emphysema[J]. Radiol Technol, 2016, 87(3):340-343.\n\n【5】Fan L, Xia Y, Guan Y, et al. Characteristic features of pulmonary function test, CT volume analysis and MR perfusion imaging in COPD patients with different HRCT phenotypes[J]. Clin Respir J, 2014, 8(1): 45-54. DOI: 10.1111/crj.12033.\n\n【6】Hasenstab KA, Yuan N, Retson T, et al. Automated CT staging of chronic obstructive pulmonary disease severity for predicting disease progression and mortality with a deep learning convolutional neural network[J]. Radiol Cardiothorac Imaging, 2021, 3(2): e200477. DOI: 10.1148/ryct.2021200477.\n\n【7】Humphries SM, Notary AM, Centeno JP, et al. Deep learning enables automatic classification of emphysema pattern at CT[J]. Radiology, 2020, 294(2):434-444. DOI: 10.1148/radiol.2019191022.\n\n【8】Lor KL, Liu CP, Chang YC, et al. Predictive modelling of\n\n【9】 Fang L, Gao P, Bao H, et al. Chronic obstructive pulmonary disease in China: a nationwide prevalence study[J].\n\n【10】Lancet Respir Med, 2018, 6(6): 421-430. DOI: 10.1016/ $2213-2600(18)30103-6.\n\n【11】Wang C, Xu J, Yang L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study[J]. Lancet, 2018, 391(10131): 1706-1717. DOI: 10.1016/S0140-6736(18)30841-9.\n\n【12】Agusti A, Calverley PM, Celli B, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort[J]. Respir Res, 2010, 11(1):122. DOI: 10.1186/1465-9921-11-122.\n\n【13】Miller MR, Levy ML.  Chronic obstructive pulmonary disease: missed diagnosis versus misdiagnosis[J]. BMJ, 2015, 351:h3021. DOI: 10.1136/bmj.h3021.\n\n【14】Tanday S. Rethinking COPD diagnosis: imaging and GOLD criteria[J]. Lancet Respir Med, 2015, 3(8): 605. DOI: 10.1016/S2213-2600(15)00293-3.\n\n【15】Keener A. Redefining the diagnostic criteria for COPD[J].\n\n【16】Nature, 2020, 581(7807): S4-S4. DOI: 10.1038/ d41586-020-01373-x.\n\n【17】Fan L, Xia Y, Guan Y, et al. Capability of differentiating smokers with normal pulmonary function from COPD patients: a comparison of CT pulmonary volume analysis and MR perfusion imaging[J]. Eur Radiol, 2013, 23(5): 1234-1241. DOI: 10.1007/s00330-012-2729-2.\n\n【18】Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD Executive Summary[J]. Am J Respir Crit Care Med, 2017, 195(5): 557-582. DOI: 10.1164/rccm.201701-0218PP.\n\n【19】中华医学会放射学分会对比剂安全使用工作组. 碘对比剂 使用指南 (第 2 版) [J]. 中华放射学杂志, 2013, 47(10): 869-872. DOI: 10.3760/cma.j.issn.1005-1201.2013.10.001.\n\n【20】中华医学会放射学分会心胸学组 . 低剂量螺旋 CT肺癌筛 查专家共识[J]. 中华放射学杂志 , 2015, 49(5):328-335.\n\n【21】DOI: 10.3760/cma.j.issn.1005-1201.2015.05.003.\n\n【22】张丽 , 于红 , 刘士远 , 等 . 迭代重建技术对低剂量肺部平扫 CT 图 像 质 量 的 影 响 [J]. 中 华 放 射 学 杂 志 , 2013, 47(4): 316-320.DOI: 10.3760/cma.j.issn.1005-1201.2013.04.006.\n\n【23】Cao X, Jin C, Tan T, et al. Optimal threshold in low-dose CT quantification of emphysema[J]. Eur J Radiol, 2020, 129: 109094. DOI: 10.1016/j.ejrad.2020.109094.\n\n【24】Lynch DA, Austin JH, Hogg JC, et al. CT-definable subtypes\n\n【25】 [1] [1] [2] [3] [4] [5] [6]\n\n【26】 [7] [7] [8] [9] [9]\n\n【27】 morphological phenotypes of COPD and clinical characteristics in surgically resected patients with COPD and concomitant lung cancer[J]. Int J Chron Obstruct Pulmon Dis, 2022, 17: 1443-1452. DOI: 10.2147/COPD.\n\n【28】S366265.\n\n【29】Nikolaou V, Massaro S, Garn W, et al. The cardiovascular phenotype of chronic obstructive pulmonary disease (COPD): applying machine learning to the prediction of cardiovascular comorbidities[J]. Respir Med, 2021, 186: 106528. DOI: 10.1016/j.rmed.2021.106528.\n\n【30】Shimizu K, Tanabe N, Tho NV, et al. Per cent low attenuation volume and fractal dimension of low attenuation clusters on CT predict different long-term outcomes in COPD[J]. Thorax, 2020, 75(2):116-122. DOI: 10.1136/thoraxjnl-2019-213525.\n\n【31】Makino Y, Shimada Y, Hagiwara M, et al. Assessment of emphysema severity as measured on three-dimensional computed tomography images for predicting respiratory complications after lung surgery[J]. Eur J Cardiothorac Surg, 2018, 54(4):671-676. DOI: 10.1093/ejcts/ezy112.\n\n【32】Li Z, Xia Y, Fang Y, et al. The importance of CT quantitative evaluation of emphysema in lung cancer screening cohort\n\n【33】 [10]\n\n【34】 [11]\n\n【35】 [12]\n\n【36】 [14] [14]\n\n【37】 [15]\n\n【38】 [16]\n\n【39】 [17] .\n\n【40】 [18]\n\n【41】 [19]\n\n【42】 [20] .\n\n【43】 [21]\n\n【44】 [22]\n\n【45】 [23]\n\n【46】 [24]\n\n【47】 [25]\n\n【48】 [26]\n\n【49】 [13]\n\n【50】 lung function using emphysematous density distribution [J]. Sci Rep, 2019, 9(1): 19763. DOI: 10.1038/ s41598-019-56351-9.\n\n【51】Ying J, Dutta J, Guo N, et al. Classification of exacerbation frequency in the COPDGene cohort using deep learning with deep belief networks[J]. IEEE J Biomed Health Inform, 2020, 24(6): 1805-1813. DOI: 10.1109/ JBHI.2016.2642944.\n\n【52】Cho YH, Seo JB, Lee SM, et al. Radiomics approach for survival prediction in chronic obstructive pulmonary disease[J]. Eur Radiol, 2021, 31(10): 7316-7324. DOI: 10.1007/s00330-021-07747-7.\n\n【53】Yun J, Cho YH, Lee SM, et al. Deep radiomics-based survival prediction in patients with chronic obstructive pulmonary disease[J]. Sci Rep, 2021, 11(1): 15144. DOI: 10.1038/s41598-021-94535-4.\n\n【54】Suzuki Y, Kitaguchi Y, Ueno F, et al. Associations between", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "参 ", "bbox": [194.0, 320.0, 281.0, 336.0]}], "type": "Section-header", "position": 2}, {"raw_context": [{"text": "中医院医学影像科) ", "bbox": [85.0, 102.0, 391.0, 117.0]}, {"text": "放射科 ) ", "bbox": [85.0, 120.0, 391.0, 134.0]}, {"text": "学附属中山医院医学影像科) . 曾庆思 ( 广州医科大学附属第一医", "bbox": [85.0, 137.0, 390.0, 152.0]}, {"text": "院放射科) , 张洪(天津市胸科医院影像科) , 张景峰(中国科学院大", "bbox": [84.0, 154.0, 390.0, 170.0]}, {"text": "学宁波华美医院医学影像科)、张琳琳（中华放射学杂志编辑部）、", "bbox": [85.0, 173.0, 390.0, 187.0]}, {"text": "张龙江(南京大学医学院附属金陵医院医学影像科)、赵绍宏(解放", "bbox": [85.0, 190.0, 391.0, 206.0]}, {"text": "军总医院第一医学中心放射科)", "bbox": [85.0, 209.0, 391.0, 224.0]}, {"text": "科 ) , 第 缴文 ( 空军军医大学第一附属医院放射診断科 ) , 周 缴 ( 上海", "bbox": [85.0, 227.0, 390.0, 242.0]}, {"text": "交通大学医学院附属瑞金医院呼吸内科)", "bbox": [85.0, 245.0, 390.0, 260.0]}, {"text": "第二用属医院放射诊断科)", "bbox": [85.0, 263.0, 377.0, 277.0]}, {"text": "利益冲突    所有作者声明无利益冲突", "bbox": [85.0, 281.0, 258.0, 296.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "of chronic obstructive pulmonary disease: a statement of", "bbox": [462.0, 102.0, 732.0, 116.0]}, {"text": "the Fleischner Society[J]. Radiology, 2015, 277(1):", "bbox": [463.0, 119.0, 731.0, 131.0]}, {"text": "192-205. DOI: 10.1148/radiol.2015141579.", "bbox": [464.0, 133.0, 665.0, 146.0]}, {"text": "Schiska A. The role of computed tomography in the", "bbox": [462.0, 149.0, 731.0, 162.0]}, {"text": "diagnosis and treatment of emphysema[J]. Radiol", "bbox": [463.0, 164.0, 733.0, 176.0]}, {"text": "Technol, 2016, 87(3):340-343.", "bbox": [464.0, 179.0, 605.0, 192.0]}, {"text": "Fan L, Xia Y, Guan Y, et al. Characteristic features of", "bbox": [462.0, 194.0, 732.0, 207.0]}, {"text": "pulmonary function test, CT volume analysis and MR", "bbox": [464.0, 209.0, 731.0, 221.0]}, {"text": "perfusion imaging in COPD patients with different HRCT", "bbox": [463.0, 224.0, 731.0, 237.0]}, {"text": "phenotypes[J]. Clin Respir J, 2014, 8(1): 45-54. DOI:", "bbox": [463.0, 240.0, 731.0, 252.0]}, {"text": "10.1111/crj.12033.", "bbox": [464.0, 254.0, 556.0, 267.0]}, {"text": "Hasenstab KA, Yuan N, Retson T, et al. Automated CT", "bbox": [462.0, 269.0, 732.0, 283.0]}, {"text": "staging of chronic obstructive pulmonary disease severity", "bbox": [463.0, 286.0, 731.0, 297.0]}, {"text": "for predicting disease progression and mortality with a", "bbox": [463.0, 300.0, 732.0, 313.0]}, {"text": "deep learning convolutional neural network[J]. Radiol", "bbox": [462.0, 316.0, 731.0, 328.0]}, {"text": "Cardiothorac Imaging, 2021, 3(2): e200477. DOI:", "bbox": [462.0, 330.0, 731.0, 343.0]}, {"text": "10.1148/ryct.2021200477.", "bbox": [464.0, 345.0, 590.0, 357.0]}, {"text": "Humphries SM, Notary AM, Centeno JP, et al. Deep", "bbox": [462.0, 360.0, 732.0, 373.0]}, {"text": "learning enables automatic classification of emphysema", "bbox": [463.0, 374.0, 731.0, 387.0]}, {"text": "pattern at CT[J]. Radiology, 2020, 294(2):434-444. DOI:", "bbox": [463.0, 390.0, 731.0, 402.0]}, {"text": "10.1148/radiol.2019191022.", "bbox": [463.0, 405.0, 600.0, 418.0]}, {"text": "Lor KL, Liu CP, Chang YC, et al. Predictive modelling of", "bbox": [461.0, 419.0, 733.0, 434.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": "Fang L, Gao P, Bao H, et al. Chronic obstructive pulmonary", "bbox": [120.0, 361.0, 391.0, 374.0]}, {"text": "disease in China: a nationwide prevalence study[J].", "bbox": [123.0, 377.0, 391.0, 390.0]}, {"text": "Lancet Respir Med, 2018, 6(6): 421-430. DOI: 10.1016/", "bbox": [123.0, 392.0, 390.0, 405.0]}, {"text": "$2213-2600(18)30103-6.", "bbox": [123.0, 407.0, 243.0, 419.0]}, {"text": "Wang C, Xu J, Yang L, et al. Prevalence and risk factors of", "bbox": [121.0, 421.0, 394.0, 435.0]}, {"text": "chronic obstructive pulmonary disease in China (the", "bbox": [123.0, 437.0, 392.0, 450.0]}, {"text": "China Pulmonary Health [CPH] study): a national", "bbox": [122.0, 452.0, 392.0, 465.0]}, {"text": "cross-sectional study[J]. Lancet, 2018, 391(10131):", "bbox": [123.0, 467.0, 392.0, 481.0]}, {"text": "1706-1717. DOI: 10.1016/S0140-6736(18)30841-9.", "bbox": [123.0, 482.0, 365.0, 495.0]}, {"text": "Agusti A, Calverley PM, Celli B, et al. Characterisation of", "bbox": [122.0, 498.0, 392.0, 511.0]}, {"text": "COPD heterogeneity in the ECLIPSE cohort[J]. Respir Res,", "bbox": [123.0, 513.0, 391.0, 526.0]}, {"text": "2010, 11(1):122. DOI: 10.1186/1465-9921-11-122.", "bbox": [123.0, 528.0, 360.0, 540.0]}, {"text": "Miller MR, Levy ML.  Chronic obstructive pulmonary", "bbox": [121.0, 543.0, 391.0, 556.0]}, {"text": "disease: missed diagnosis versus misdiagnosis[J]. BMJ,", "bbox": [123.0, 558.0, 394.0, 571.0]}, {"text": "2015, 351:h3021. DOI: 10.1136/bmj.h3021.", "bbox": [123.0, 572.0, 329.0, 585.0]}, {"text": "Tanday S. Rethinking COPD diagnosis: imaging and GOLD", "bbox": [122.0, 588.0, 390.0, 600.0]}, {"text": "criteria[J]. Lancet Respir Med, 2015, 3(8): 605. DOI:", "bbox": [123.0, 603.0, 393.0, 616.0]}, {"text": "10.1016/S2213-2600(15)00293-3.", "bbox": [123.0, 617.0, 286.0, 630.0]}, {"text": "Keener A. Redefining the diagnostic criteria for COPD[J].", "bbox": [121.0, 633.0, 390.0, 647.0]}, {"text": "Nature, 2020, 581(7807): S4-S4. DOI: 10.1038/", "bbox": [123.0, 648.0, 390.0, 661.0]}, {"text": "d41586-020-01373-x.", "bbox": [123.0, 664.0, 226.0, 676.0]}, {"text": "Fan L, Xia Y, Guan Y, et al. Capability of differentiating", "bbox": [121.0, 678.0, 391.0, 692.0]}, {"text": "smokers with normal pulmonary function from COPD", "bbox": [123.0, 693.0, 391.0, 706.0]}, {"text": "patients: a comparison of CT pulmonary volume analysis", "bbox": [123.0, 709.0, 390.0, 721.0]}, {"text": "and MR perfusion imaging[J]. Eur Radiol, 2013, 23(5):", "bbox": [123.0, 724.0, 391.0, 737.0]}, {"text": "1234-1241. DOI: 10.1007/s00330-012-2729-2.", "bbox": [123.0, 738.0, 341.0, 751.0]}, {"text": "Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy", "bbox": [121.0, 754.0, 391.0, 767.0]}, {"text": "for the diagnosis, management, and prevention of chronic", "bbox": [123.0, 770.0, 391.0, 782.0]}, {"text": "obstructive lung disease 2017 report. GOLD Executive", "bbox": [123.0, 784.0, 391.0, 797.0]}, {"text": "Summary[J]. Am J Respir Crit Care Med, 2017, 195(5):", "bbox": [123.0, 799.0, 391.0, 812.0]}, {"text": "557-582. DOI: 10.1164/rccm.201701-0218PP.", "bbox": [123.0, 814.0, 326.0, 826.0]}, {"text": "中华医学会放射学分会对比剂安全使用工作组. 碘对比剂", "bbox": [121.0, 828.0, 391.0, 842.0]}, {"text": "使用指南 (第 2 版) [J]. 中华放射学杂志, 2013, 47(10):", "bbox": [123.0, 844.0, 390.0, 857.0]}, {"text": "869-872. DOI: 10.3760/cma.j.issn.1005-1201.2013.10.001.", "bbox": [123.0, 859.0, 382.0, 872.0]}, {"text": "中华医学会放射学分会心胸学组 . 低剂量螺旋 CT肺癌筛", "bbox": [122.0, 874.0, 390.0, 888.0]}, {"text": "查专家共识[J]. 中华放射学杂志 , 2015, 49(5):328-335.", "bbox": [123.0, 890.0, 391.0, 903.0]}, {"text": "DOI: 10.3760/cma.j.issn.1005-1201.2015.05.003.", "bbox": [123.0, 905.0, 351.0, 918.0]}, {"text": "张丽 , 于红 , 刘士远 , 等 . 迭代重建技术对低剂量肺部平扫", "bbox": [123.0, 920.0, 392.0, 933.0]}, {"text": "CT 图 像 质 量 的 影 响 [J]. 中 华 放 射 学 杂 志 , 2013, 47(4):", "bbox": [123.0, 935.0, 391.0, 947.0]}, {"text": "316-320.DOI: 10.3760/cma.j.issn.1005-1201.2013.04.006.", "bbox": [123.0, 950.0, 379.0, 963.0]}, {"text": "Cao X, Jin C, Tan T, et al. Optimal threshold in low-dose CT", "bbox": [121.0, 965.0, 390.0, 978.0]}, {"text": "quantification of emphysema[J]. Eur J Radiol, 2020, 129:", "bbox": [123.0, 980.0, 390.0, 992.0]}, {"text": "109094. DOI: 10.1016/j.ejrad.2020.109094.", "bbox": [123.0, 995.0, 326.0, 1007.0]}, {"text": "Lynch DA, Austin JH, Hogg JC, et al. CT-definable subtypes", "bbox": [123.0, 1010.0, 391.0, 1023.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "[1] [1]", "bbox": [93.0, 363.0, 113.0, 375.0]}, {"text": "[2]", "bbox": [93.0, 422.0, 112.0, 435.0]}, {"text": "[3]", "bbox": [93.0, 498.0, 112.0, 511.0]}, {"text": "[4]", "bbox": [93.0, 542.0, 111.0, 556.0]}, {"text": "[5]", "bbox": [93.0, 587.0, 111.0, 602.0]}, {"text": "[6]", "bbox": [93.0, 634.0, 111.0, 647.0]}], "type": "Text", "position": 6}, {"raw_context": [{"text": "[7] [7]", "bbox": [93.0, 680.0, 110.0, 692.0]}, {"text": "[8]", "bbox": [93.0, 753.0, 111.0, 768.0]}, {"text": "[9] [9]", "bbox": [93.0, 829.0, 112.0, 842.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "morphological phenotypes of COPD and clinical", "bbox": [462.0, 693.0, 731.0, 705.0]}, {"text": "characteristics in surgically resected patients with COPD", "bbox": [462.0, 707.0, 731.0, 721.0]}, {"text": "and concomitant lung cancer[J]. Int J Chron Obstruct", "bbox": [463.0, 723.0, 731.0, 736.0]}, {"text": "Pulmon Dis, 2022, 17: 1443-1452. DOI: 10.2147/COPD.", "bbox": [464.0, 737.0, 731.0, 750.0]}, {"text": "S366265.", "bbox": [463.0, 753.0, 509.0, 765.0]}, {"text": "Nikolaou V, Massaro S, Garn W, et al. The cardiovascular", "bbox": [462.0, 768.0, 731.0, 781.0]}, {"text": "phenotype of chronic obstructive pulmonary disease", "bbox": [463.0, 782.0, 731.0, 795.0]}, {"text": "(COPD): applying machine learning to the prediction of", "bbox": [463.0, 799.0, 731.0, 812.0]}, {"text": "cardiovascular comorbidities[J]. Respir Med, 2021, 186:", "bbox": [463.0, 814.0, 731.0, 826.0]}, {"text": "106528. DOI: 10.1016/j.rmed.2021.106528.", "bbox": [464.0, 829.0, 667.0, 842.0]}, {"text": "Shimizu K, Tanabe N, Tho NV, et al. Per cent low", "bbox": [462.0, 844.0, 731.0, 857.0]}, {"text": "attenuation volume and fractal dimension of low", "bbox": [464.0, 859.0, 731.0, 871.0]}, {"text": "attenuation clusters on CT predict different long-term", "bbox": [463.0, 874.0, 731.0, 887.0]}, {"text": "outcomes in COPD[J]. Thorax, 2020, 75(2):116-122. DOI:", "bbox": [463.0, 889.0, 731.0, 902.0]}, {"text": "10.1136/thoraxjnl-2019-213525.", "bbox": [464.0, 903.0, 619.0, 916.0]}, {"text": "Makino Y, Shimada Y, Hagiwara M, et al. Assessment of", "bbox": [462.0, 919.0, 732.0, 933.0]}, {"text": "emphysema severity as measured on three-dimensional", "bbox": [463.0, 935.0, 731.0, 947.0]}, {"text": "computed tomography images for predicting respiratory", "bbox": [463.0, 950.0, 731.0, 963.0]}, {"text": "complications after lung surgery[J]. Eur J Cardiothorac", "bbox": [463.0, 965.0, 731.0, 978.0]}, {"text": "Surg, 2018, 54(4):671-676. DOI: 10.1093/ejcts/ezy112.", "bbox": [463.0, 979.0, 720.0, 992.0]}, {"text": "Li Z, Xia Y, Fang Y, et al. The importance of CT quantitative", "bbox": [462.0, 995.0, 731.0, 1007.0]}, {"text": "evaluation of emphysema in lung cancer screening cohort", "bbox": [463.0, 1010.0, 732.0, 1023.0]}], "type": "Text", "position": 8}, {"raw_context": [{"text": "[10]", "bbox": [88.0, 875.0, 112.0, 889.0]}], "type": "Text", "position": 9}, {"raw_context": [{"text": "[11]", "bbox": [88.0, 920.0, 112.0, 933.0]}], "type": "Text", "position": 10}, {"raw_context": [{"text": "[12]", "bbox": [87.0, 966.0, 112.0, 978.0]}], "type": "Text", "position": 11}, {"raw_context": [{"text": "[14] [14]", "bbox": [428.0, 150.0, 453.0, 162.0]}], "type": "Text", "position": 12}, {"raw_context": [{"text": "[15]", "bbox": [428.0, 195.0, 452.0, 207.0]}], "type": "Text", "position": 13}, {"raw_context": [{"text": "[16]", "bbox": [428.0, 269.0, 452.0, 283.0]}], "type": "Text", "position": 14}, {"raw_context": [{"text": "[17] .", "bbox": [428.0, 360.0, 452.0, 373.0]}], "type": "Text", "position": 15}, {"raw_context": [{"text": "[18]", "bbox": [428.0, 422.0, 452.0, 434.0]}], "type": "Text", "position": 16}, {"raw_context": [{"text": "[19]", "bbox": [428.0, 481.0, 452.0, 494.0]}], "type": "Text", "position": 17}, {"raw_context": [{"text": "[20] .", "bbox": [428.0, 558.0, 453.0, 571.0]}], "type": "Text", "position": 18}, {"raw_context": [{"text": "[21]", "bbox": [428.0, 617.0, 452.0, 630.0]}], "type": "Text", "position": 19}, {"raw_context": [{"text": "[22]", "bbox": [428.0, 679.0, 452.0, 692.0]}], "type": "Text", "position": 20}, {"raw_context": [{"text": "[23]", "bbox": [428.0, 767.0, 452.0, 781.0]}], "type": "Text", "position": 21}, {"raw_context": [{"text": "[24]", "bbox": [428.0, 845.0, 452.0, 857.0]}], "type": "Text", "position": 22}, {"raw_context": [{"text": "[25]", "bbox": [428.0, 919.0, 452.0, 933.0]}], "type": "Text", "position": 23}, {"raw_context": [{"text": "[26]", "bbox": [428.0, 995.0, 452.0, 1008.0]}], "type": "Text", "position": 24}, {"raw_context": [{"text": "[13]", "bbox": [88.0, 1011.0, 112.0, 1022.0]}], "type": "Text", "position": 25}, {"raw_context": [{"text": "lung function using emphysematous density distribution", "bbox": [462.0, 437.0, 731.0, 449.0]}, {"text": "[J]. Sci Rep, 2019, 9(1): 19763. DOI: 10.1038/", "bbox": [463.0, 451.0, 731.0, 463.0]}, {"text": "s41598-019-56351-9.", "bbox": [462.0, 466.0, 566.0, 479.0]}, {"text": "Ying J, Dutta J, Guo N, et al. Classification of exacerbation", "bbox": [461.0, 480.0, 731.0, 494.0]}, {"text": "frequency in the COPDGene cohort using deep learning", "bbox": [463.0, 495.0, 731.0, 508.0]}, {"text": "with deep belief networks[J]. IEEE J Biomed Health", "bbox": [463.0, 511.0, 731.0, 523.0]}, {"text": "Inform, 2020, 24(6): 1805-1813. DOI: 10.1109/", "bbox": [462.0, 526.0, 731.0, 539.0]}, {"text": "JBHI.2016.2642944.", "bbox": [462.0, 541.0, 557.0, 555.0]}, {"text": "Cho YH, Seo JB, Lee SM, et al. Radiomics approach for", "bbox": [461.0, 556.0, 731.0, 570.0]}, {"text": "survival prediction in chronic obstructive pulmonary", "bbox": [464.0, 572.0, 731.0, 584.0]}, {"text": "disease[J]. Eur Radiol, 2021, 31(10): 7316-7324. DOI:", "bbox": [462.0, 587.0, 731.0, 600.0]}, {"text": "10.1007/s00330-021-07747-7.", "bbox": [462.0, 602.0, 608.0, 615.0]}, {"text": "Yun J, Cho YH, Lee SM, et al. Deep radiomics-based", "bbox": [462.0, 616.0, 731.0, 629.0]}, {"text": "survival prediction in patients with chronic obstructive", "bbox": [463.0, 632.0, 731.0, 644.0]}, {"text": "pulmonary disease[J]. Sci Rep, 2021, 11(1): 15144. DOI:", "bbox": [464.0, 647.0, 731.0, 660.0]}, {"text": "10.1038/s41598-021-94535-4.", "bbox": [464.0, 661.0, 610.0, 674.0]}, {"text": "Suzuki Y, Kitaguchi Y, Ueno F, et al. Associations between", "bbox": [462.0, 678.0, 731.0, 691.0]}], "type": "Text", "position": 26}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/呼吸科/_慢性阻塞性肺疾病胸部CT检查及评价中国专家共识.pdf", "page_num": 7}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": null, "type3": null, "type4": null, "type5": null, "type6": "信息有用性#0#54#参考文献"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:40", "update_time": "2024-05-07 18:30:54"}
{"id": 1082534, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 738, "source_info": {"seq_id": "5cb2a86c-0e12-4424-ae57-3b8dd5a683f7", "title": null, "text": "【0】页码:14\n ADC 药物与其他药物联合治疗的探索研究，关注药物间相 互作用、联合是否协同增效以及是否増加安全性风险等; 者联合治疗导致某一不良事件发生率显著增加，则需进行 相关发生机制的进一步研究。\n\n【1】## 因、总结\n\n【2】\n 随着科学技术的进步,后续将不断有新的 ADC 产品进 入到临床试验中，比如双表位或双靶点 ADC、使用两种不 同的有效载荷组合等。可预期的是，与目前已有的 ADC 药 物 一 样 ， 其 每 一 个 组 成 部 分 都 可 能 会 影 响 到 产 品 的 安 全 性 和有效性。 因此，除了必须遵循抗肿瘤药物的一般研发规 律，还应该注重以临床需求为出发点，结合 ADC 药物的分 子 结构 种机 制 特征， 关 注 临 床 研 发 要 点， 深 入 探 索 分 析 其 临床优势，合理地制定开发策略。\n\n【3】## 参考文献\n\n【4】 [1] Thomas A, Teicher BA, Hassan R. Antibody-drug conjugates for cancer therapy.\n\n【5】Lancet Oncol. 2016,17(6) : e254-e262.\n [2] 国家药监局药审中心关于发布《以临床价值为导向的抗肿瘤药物临 床 研 发 指 导 原 则 》 的 通 告 ( 2021 年 第 46 号 ) https://www.cde.org.cn/main/news/viewInfoCommon/ef7bfde96c769308ad080bb7 ab2f538e.\n [3] Fu Z, Li S, Han S, et al. Antibody drug conjugate: the \"biological missile\" for targeted cancer therapy. Signal Transduct Target Ther. 2022 , 7(1):93.\n [4]   Hafeez U, Parakh S, Gan HK, et al. Antibody-Drug Conjugates for Cancer", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "ADC 药物与其他药物联合治疗的探索研究，关注药物间相", "bbox": [118.0, 106.0, 674.0, 127.0]}, {"text": "互作用、联合是否协同增效以及是否増加安全性风险等;", "bbox": [119.0, 148.0, 663.0, 169.0]}, {"text": "者联合治疗导致某一不良事件发生率显著增加，则需进行", "bbox": [118.0, 189.0, 672.0, 210.0]}, {"text": "相关发生机制的进一步研究。", "bbox": [118.0, 231.0, 395.0, 251.0]}], "type": "Text", "position": 0}, {"raw_context": [{"text": "因、总结", "bbox": [119.0, 282.0, 202.0, 304.0]}], "type": "Section-header", "position": 1}, {"raw_context": [{"text": "随着科学技术的进步,后续将不断有新的 ADC 产品进", "bbox": [162.0, 335.0, 673.0, 357.0]}, {"text": "入到临床试验中，比如双表位或双靶点 ADC、使用两种不", "bbox": [119.0, 378.0, 673.0, 398.0]}, {"text": "同的有效载荷组合等。可预期的是，与目前已有的 ADC 药", "bbox": [119.0, 417.0, 672.0, 439.0]}, {"text": "物 一 样 ， 其 每 一 个 组 成 部 分 都 可 能 会 影 响 到 产 品 的 安 全 性", "bbox": [119.0, 461.0, 672.0, 481.0]}, {"text": "和有效性。 因此，除了必须遵循抗肿瘤药物的一般研发规", "bbox": [119.0, 502.0, 674.0, 523.0]}, {"text": "律，还应该注重以临床需求为出发点，结合 ADC 药物的分", "bbox": [118.0, 543.0, 673.0, 565.0]}, {"text": "子 结构 种机 制 特征， 关 注 临 床 研 发 要 点， 深 入 探 索 分 析 其", "bbox": [119.0, 584.0, 673.0, 606.0]}, {"text": "临床优势，合理地制定开发策略。", "bbox": [117.0, 627.0, 439.0, 647.0]}], "type": "Text", "position": 2}, {"raw_context": [{"text": "参考文献", "bbox": [118.0, 710.0, 203.0, 730.0]}], "type": "Section-header", "position": 3}, {"raw_context": [{"text": "[1] Thomas A, Teicher BA, Hassan R. Antibody-drug conjugates for cancer therapy.", "bbox": [117.0, 747.0, 673.0, 766.0]}, {"text": "Lancet Oncol. 2016,17(6) : e254-e262.", "bbox": [149.0, 779.0, 402.0, 795.0]}], "type": "List-item", "position": 4}, {"raw_context": [{"text": "[2] 国家药监局药审中心关于发布《以临床价值为导向的抗肿瘤药物临", "bbox": [117.0, 809.0, 671.0, 827.0]}, {"text": "床 研 发 指 导 原 则 》 的 通 告 ( 2021 年 第 46 号 )", "bbox": [154.0, 842.0, 508.0, 859.0]}, {"text": "https://www.cde.org.cn/main/news/viewInfoCommon/ef7bfde96c769308ad080bb7", "bbox": [146.0, 875.0, 674.0, 889.0]}, {"text": "ab2f538e.", "bbox": [145.0, 904.0, 213.0, 921.0]}], "type": "List-item", "position": 5}, {"raw_context": [{"text": "[3] Fu Z, Li S, Han S, et al. Antibody drug conjugate: the \"biological missile\" for", "bbox": [117.0, 936.0, 674.0, 952.0]}, {"text": "targeted cancer therapy. Signal Transduct Target Ther. 2022 , 7(1):93.", "bbox": [153.0, 967.0, 602.0, 984.0]}], "type": "List-item", "position": 6}, {"raw_context": [{"text": "[4]   Hafeez U, Parakh S, Gan HK, et al. Antibody-Drug Conjugates for Cancer", "bbox": [117.0, 998.0, 674.0, 1016.0]}], "type": "List-item", "position": 7}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/肿瘤科/共识/抗肿瘤抗体偶联药物临床研发技术指导原则(1).pdf", "page_num": 14}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": "错别字#1#1#因应是四", "type2": null, "type3": null, "type4": null, "type5": null, "type6": "有用性#3#5#参考文献内容"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:40", "update_time": "2024-05-07 23:10:51"}
{"id": 1082533, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 738, "source_info": {"seq_id": "e106585f-7cae-4652-bad8-39f8048ce3b9", "title": null, "text": "【0】页码:12\n 35.\n\n【1】Wang Y, Wang Y, Zhao X, Liu L, Wang D, Wang C, Wang C, Li H, Meng X, Cui L, et al; CHANCE Investigators. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med . 2013;369:11–19. doi: 10.1056/NEJMoa1215340 Johnston SC, Easton JD, Farrant M, Barsan W, Conwit RA, Elm JJ, Kim AS, 36.\n\n【2】Lindblad AS, Palesch YY; Clinical Research Collaboration, Neurological Emergencies Treatment Trials Network, and the POINT Investigators. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA. N Engl J Med.\n\n【3】2018;379:215–225. doi: 10.1056/NEJMoa1800410 Josephson SA, Sidney S, Pham TN, Bernstein AL, Johnston SC. Higher ABCD2 score predicts patients most likely to have true transient ischemic attack. Stroke. 2008;39:3096-3098. doi: 10.1161/STROKEAHA.\n\n【4】108.514562 38.\n\n【5】Sanders LM, Srikanth VK, Blacker DJ, Jolley DJ, Cooper KA, Phan TG. Performance of the ABCD 2 score for stroke risk post TIA: metaanalysis and probability modeling. Neurology. 2012;79:971-980. doi: 10.1212/WNL0b013e31825f9d02 39. Chaturvedi S, Rothwell PM. Stroke risk with symptomatic carotid stenosis: the future is not what it used to be. Neurology. 2016;86:494-495. doi: 10.1212/WNL00000000002363 40. Jarhult SJ, Howell ML, Barnaure-Nachbar I, Chang Y, White BA, Amatangelo M, Brown DF, Singhal AB, Schwamm LH, Silverman SB, et al. Implementation of a rapid, protocol-based TIA management pathway. West J Emerg Med.\n\n【6】2018;19:216-223. doi: 10.5811/westjem.2017.9.35341 41. Merwick A, Albers GW, Amarenco P, Arsava EM, Ay H, Calvet D, Coutts SB, Cucchiara BL, Demchuk AM, Furie KL, et al. Addition of brain and carotid imaging to the ABCD 2 score to identify patients at early risk of stroke after transient ischaemic attack: a multicentre observational study. Lancet Neurol.\n\n【7】2010;9:1060–1069. doi: 10.1016/S1474-4422(10)70240-4 Giles MF, Albers GW, Amarenco P, Arsava MM, Asimos A, Ay H, Calvet 42.\n\n【8】D, Coutts S, Cucchiara BL, Demchuk AM, et al. Addition of brain infarction to the ABCD 2 score (ABCD 2 ): a collaborative analysis of unpublished data on 4574 patients. Stroke. 2010;41:1907-1913. doi: 10.1161/ STROKEAHA 110 .578971 43. Kiyohara T, Kamouchi M, Kumai Y, Ninomiya T, Hata J, Yoshimura S, Ago T, Okada Y, Kitazono T; Fukuoka Stroke Registry Investigators. ABCD3 and ABCD3-I scores are superior to ABCD2 score in the prediction of short- and long-term risks of stroke after transient ischemic attack. Stroke.\n\n【9】2014;45:418-425. doi: 10.1161/STROKEAHA113.003077/ 44. Wilson SE, Mayberg MR, Yatsu F, Weiss DG. Crescendo transient ischemic attacks: a surgical imperative. Veterans Affairs trialists. J Vasc Surg.\n\n【10】1993;17:249-255; discussion 255. doi: 10.1067/mva.1993.42734 45. Lo BM, Carpenter CR, Hatten BW, Wright BJ, Brown MD. Clinical policy: critical issues in the evaluation of adult patients with suspected transient ischemic attack in the emergency department. Ann Emerg Med.\n\n【11】2016;68:354-370. doi: 10.1016/j.annemergmed.2016.06.048 46. Qureshi Al, Adil MM, Zacharatos H, Suri MF. Factors associated with length of hospitalization in patients admitted with transient ischemic attack in United States. Stroke. 2013;44:1601-1605. doi: 10.1161/STROKEAHA.111.000590 47. Ross MA, Compton S, Medado P, Fitzgerald M, Kilanowski P, O'Neil BJ. An emergency department diagnostic protocol for patients with transient ischemic attack: a randomized controlled trial. Ann Emerg Med. 2007;50:109– 119. doi: 10.1016/j.annemergmed.2007.03.008 48. Joshi JK, Ouyang B, Prabhakaran S. Should TIA patients be hospitalized or referred to a same-day clinic?: a decision analysis. Neurology .\n\n【12】2011;77:2082–2088. doi: 10.1212/WNL0b013e31823d763f 49. Olivot JM, Wolford C, Castle J, Mlynash M, Schwartz NE, Lansberg MG, Kemp S, Albers GW. Two aces: transient ischemic attack work-up as outpatient assessment of clinical evaluation and safety. Stroke. 2011;42:1839– 1843. doi: 10.1161/STROKEAHA.110.608380 50. Levine DA, Duncan PW, Nguyen-Huynh MN, Ogedegbe OG. Interventions targeting racial/ethnic disparities in stroke prevention and treatment.\n\n【13】Stroke. 2020;51:3425-3432. doi: 10.1161/STROKEAHA.120.030427 51. Ranta A, Barber PA.  Transient ischemic attack service provision: A review of available service models. Neurology. 2016;86:947-953. doi: 10.1212/WNL00000000002339 Johnston SC, Amarenco P, Denison H, Evans SR, Himmelmann A, James 52.\n\n【14】S, Knutsson M, Ladenvall P, Molina CA, Wang Y; THALES Investigators.\n\n【15】Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA. N Engl J Med . 2020;383:207–217. doi: 10.1056/NEJMoa1916870 53. Bhatia K, Jain V, Aggarwal D, Vaduganathan M, Arora S, Hussain Z, Uberoi G, Tafur A, Zhang C, Ricciardi M, et al. Dual antiplatelet therapy versus aspirin in patients with stroke or transient ischemic attack:\n\n【16】 meta-analysis of randomized controlled trials. Stroke . 2021;52:e217-e223.\n\n【17】doi: 10.1161/STROKEAHA.120.033033 54. Coll-Vinent B, Martín A, Sánchez J, Tamargo J, Suero C, Malagón F, Varona M, Cancio M, Sánchez S, Carbajosa J, et al. Benefits of emergency departments' contribution to stroke prophylaxis in atrial fibrillation: the EMERG-AF Study (Emergency Department Stroke Prophylaxis and Guidelines Implementation in Atrial Fibrillation). Stroke. 2017;48:1344-1352.\n\n【18】doi: 10.1161/STROKEAHA.116.014855 55.\n\n【19】Man-Son-Hing M, Nichol G, Lau A, Laupacis A. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med. 1999;159:677-685. doi: 10.1001/archinte.159.7.677 56.\n\n【20】Goldstein LB, Amarenco P, Zivin J, Messig M, Altafullah I, Callahan A, Hennerici M, MacLeod MJ, Sillesen H, Zweifler R, et al; Stroke Prevention by Aggressive Reduction in Cholesterol Levels Investigators. Statin treatment and stroke outcome in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke. 2009;40:3526-3531.\n\n【21】doi: 10.1 161/STROKEAHA.109.557330 57. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation . 2004;109(23 suppl 1):III39–III43. doi: 10.1161/01.CIR.\n\n【22】0000131517.20177.5a 58.  Chen W, Pan Y, Jing J, Zhao X, Liu L, Meng X, Wang Y, Wang Y, CHANCE Investigators. Recurrent stroke in minor ischemic stroke or transient ischemic attack with metabolic syndrome and/or diabetes mellitus. J Am Heart Assoc . 2017;6:e005446. doi: 10.1161/JAHA.116.005446 59. Pan Y, Wang Y, Li H, Gaisano HY, Wang Y, He Y. Association of diabetes and prognosis of minor stroke and its subtypes: a prospective observational study. PLoS One. 2016;11:e0153178. doi: 10.1371/journal.pone.0153178 60. Bloomgarden Z, Handelsman Y. Management and prevention of cardiovascular disease for type 2 diabetes: integrating the diabetes management recommendations of AACE, ADA, EASD, AHA, ACC, and ESC. Am J Prev Cardiol. 2020;1:100007. doi: 10.1016/j.ajpc.2020.100007 61. Boden-Albala B, GoldmanniE, Parikh NS, Carman H, Roberts ET, Lord AS, Torrico V, Appleton N, Birkemeier J, Parides M, et  al. Efficacy of a discharge educational strategy vs standard discharge care on reduction of vascular risk in patients with stroke and transient ischemic attack: the DESERVE randomized clinical trial. JAMA Neurol. 2019;76:20-27. doi: 10.1001/jamaneurol.2018.2926 Towfight A, Cheng EM, Ayala-Rivera M, Barry F, McCreath H, Ganz DA, 62.\n\n【23】Lee ML, Sanossian N, Mehta B, Dutta T, et al; Secondary Stroke Prevention by Uniting Community and Chronic Care Model Teams Early to End Disparities (SUCCEED) Investigators. Effect of a coordinated community and chronic care model team intervention vs usual care on systolic blood pressure in patients with stroke or transient ischemic attack: the SUC- CEED randomized clinical trial. JAMA Netw Open. 2021;4:e2036227. doi: 10.1001/jamanetworkopen.2020.36227 63. Heron N, Kee F, Cardwell C, Tully MA, Donnelly M, Cupples ME. Secondary prevention lifestyle interventions initiated within 90 days after TIA or 'minor' stroke: a systematic review and meta-analysis of rehabilitation programmes.\n\n【24】Br J Gen Pract. 2017;67:e57-e66. doi: 10.3399/bjgp16X688369 64. Ranta A, Dovey S, Weatherall M, O'Dea D, Gommans J, Tilyard M. Cluster randomized controlled trial of TIA electronic decision support in primary care.\n\n【25】Neurology. 2015;84:1545–1551. doi: 10.1212/WNL00000000001472 10.65.\n\n【26】Turan TN, Nizam A, Lynn MJ, Egan BM, Le NA, Lopes-Virella MF, Hermayer KL, Harrell J, Derdeyn CP, Fiorella D, et  al. Relationship between risk factor control and vascular events in the SAMMPRIS trial. Neurology .\n\n【27】2017;88:379-385. doi: 10.1212/WNL00000000003534 66. Vahlberg B, Lundström E, Eriksson S, Holmbäck U, Cederholm T. Effects on walking performance and lower body strength by short message service guided training after stroke or transient ischemic attack (The STROKE- WALK Study): a randomized controlled trial. Clin Rehabil. 2021;35:276–287.\n\n【28】doi: 10.1177/0269215520954346 67. Prior PL, Hachinski V, Unsworth K, Chan R, Mytka S, O'Callaghan C, Suskin N. Comprehensive cardiac rehabilitation for secondary prevention after transient ischemic attack or mild stroke: I: feasibility and risk factors. Stroke .\n\n【29】2011;42:3207-3213. doi: 10.1161/STROKEAHA.111.620187 68.\n\n【30】Wang C, Redgrave J, Shafizadeh M, Majid A, Kilner K, Ali AN. Aerobic exercise interventions reduce blood pressure in patients after stroke or transient ischaemic attack: a systematic review and meta-analysis. Br J Sports Med .\n\n【31】2019;53:1515-1525. doi: 10.1136/bjsports-2017-098903 69.\n\n【32】Chiavaroli L, Viguiliouk E, Nishi SK, Blanco Mejia S, Rahelić D, Kahleová H, Salas-Salvadó J, Kendall CW, Sievenpiper JL. DASH dietary pattern and cardiometabolic outcomes: an umbrella review of systematic reviews and meta-analyses. Nutrients . 2019;11:338. doi: 10.3390/ nu11020338\n\n【33】 '9 KenidsH uo Aq ano stemnolede//dud mort bebeomworth", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "35.", "bbox": [66.0, 78.0, 83.0, 88.0]}, {"text": "Wang Y, Wang Y, Zhao X, Liu L, Wang D, Wang C, Wang C, Li H, Meng X,", "bbox": [83.0, 77.0, 378.0, 89.0]}, {"text": "Cui L, et al; CHANCE Investigators. Clopidogrel with aspirin in acute minor", "bbox": [85.0, 89.0, 378.0, 101.0]}, {"text": "stroke or transient ischemic attack. N Engl J Med . 2013;369:11–19. doi:", "bbox": [87.0, 101.0, 378.0, 113.0]}, {"text": "10.1056/NEJMoa1215340", "bbox": [87.0, 113.0, 202.0, 124.0]}, {"text": "Johnston SC, Easton JD, Farrant M, Barsan W, Conwit RA, Elm JJ, Kim AS,", "bbox": [84.0, 125.0, 378.0, 137.0]}, {"text": "36.", "bbox": [66.0, 126.0, 83.0, 136.0]}, {"text": "Lindblad AS, Palesch YY; Clinical Research Collaboration, Neurological", "bbox": [85.0, 137.0, 380.0, 148.0]}, {"text": "Emergencies Treatment Trials Network, and the POINT Investigators. Clopi-", "bbox": [85.0, 150.0, 378.0, 161.0]}, {"text": "dogrel and aspirin in acute ischemic stroke and high-risk TIA. N Engl J Med.", "bbox": [85.0, 161.0, 378.0, 173.0]}, {"text": "2018;379:215–225. doi: 10.1056/NEJMoa1800410", "bbox": [85.0, 174.0, 298.0, 185.0]}, {"text": "Josephson SA, Sidney S, Pham TN, Bernstein AL, Johnston SC. Higher", "bbox": [83.0, 185.0, 378.0, 197.0]}, {"text": "ABCD2 score predicts patients most likely to have true transient isch-", "bbox": [85.0, 198.0, 379.0, 209.0]}, {"text": "emic attack. Stroke. 2008;39:3096-3098. doi: 10.1161/STROKEAHA.", "bbox": [87.0, 209.0, 378.0, 221.0]}, {"text": "108.514562", "bbox": [87.0, 221.0, 140.0, 233.0]}, {"text": "38.", "bbox": [66.0, 234.0, 85.0, 245.0]}, {"text": "Sanders LM, Srikanth VK, Blacker DJ, Jolley DJ, Cooper KA, Phan", "bbox": [83.0, 234.0, 379.0, 246.0]}, {"text": "TG. Performance of the ABCD 2 score for stroke risk post TIA: meta-", "bbox": [86.0, 245.0, 379.0, 258.0]}, {"text": "analysis and probability modeling. Neurology. 2012;79:971-980. doi:", "bbox": [87.0, 258.0, 379.0, 269.0]}, {"text": "10.1212/WNL0b013e31825f9d02", "bbox": [87.0, 269.0, 235.0, 281.0]}, {"text": "39. Chaturvedi S, Rothwell PM. Stroke risk with symptomatic carotid stenosis:", "bbox": [66.0, 281.0, 379.0, 294.0]}, {"text": "the future is not what it used to be. Neurology. 2016;86:494-495. doi:", "bbox": [86.0, 294.0, 380.0, 305.0]}, {"text": "10.1212/WNL00000000002363", "bbox": [87.0, 306.0, 238.0, 316.0]}, {"text": "40. Jarhult SJ, Howell ML, Barnaure-Nachbar I, Chang Y, White BA, Amatangelo", "bbox": [66.0, 317.0, 379.0, 329.0]}, {"text": "M, Brown DF, Singhal AB, Schwamm LH, Silverman SB, et al. Implementation", "bbox": [84.0, 328.0, 380.0, 343.0]}, {"text": "of a rapid, protocol-based TIA management pathway. West J Emerg Med.", "bbox": [85.0, 341.0, 378.0, 354.0]}, {"text": "2018;19:216-223. doi: 10.5811/westjem.2017.9.35341", "bbox": [85.0, 353.0, 308.0, 364.0]}, {"text": "41. Merwick A, Albers GW, Amarenco P, Arsava EM, Ay H, Calvet D, Coutts", "bbox": [66.0, 366.0, 378.0, 377.0]}, {"text": "SB, Cucchiara BL, Demchuk AM, Furie KL, et al. Addition of brain and carotid", "bbox": [86.0, 377.0, 380.0, 388.0]}, {"text": "imaging to the ABCD 2 score to identify patients at early risk of stroke after", "bbox": [85.0, 390.0, 378.0, 401.0]}, {"text": "transient ischaemic attack: a multicentre observational study. Lancet Neurol.", "bbox": [85.0, 401.0, 378.0, 413.0]}, {"text": "2010;9:1060–1069. doi: 10.1016/S1474-4422(10)70240-4", "bbox": [85.0, 414.0, 333.0, 425.0]}, {"text": "Giles MF, Albers GW, Amarenco P, Arsava MM, Asimos A, Ay H, Calvet", "bbox": [84.0, 425.0, 379.0, 437.0]}, {"text": "42.", "bbox": [66.0, 426.0, 81.0, 436.0]}, {"text": "D, Coutts S, Cucchiara BL, Demchuk AM, et al. Addition of brain infarc-", "bbox": [84.0, 438.0, 378.0, 449.0]}, {"text": "tion to the ABCD 2 score (ABCD 2 ): a collaborative analysis of unpublished", "bbox": [85.0, 449.0, 379.0, 461.0]}, {"text": "data on 4574 patients. Stroke. 2010;41:1907-1913. doi: 10.1161/", "bbox": [85.0, 462.0, 379.0, 472.0]}, {"text": "STROKEAHA 110 .578971", "bbox": [86.0, 474.0, 193.0, 485.0]}, {"text": "43. Kiyohara T, Kamouchi M, Kumai Y, Ninomiya T, Hata J, Yoshimura S, Ago", "bbox": [66.0, 485.0, 380.0, 496.0]}, {"text": "T, Okada Y, Kitazono T; Fukuoka Stroke Registry Investigators. ABCD3", "bbox": [85.0, 498.0, 380.0, 510.0]}, {"text": "and ABCD3-I scores are superior to ABCD2 score in the prediction of", "bbox": [85.0, 509.0, 380.0, 521.0]}, {"text": "short- and long-term risks of stroke after transient ischemic attack. Stroke.", "bbox": [86.0, 522.0, 377.0, 533.0]}, {"text": "2014;45:418-425. doi: 10.1161/STROKEAHA113.003077/", "bbox": [85.0, 533.0, 330.0, 545.0]}, {"text": "44. Wilson SE, Mayberg MR, Yatsu F, Weiss DG. Crescendo transient isch-", "bbox": [66.0, 545.0, 375.0, 558.0]}, {"text": "emic attacks: a surgical imperative. Veterans Affairs trialists. J Vasc Surg.", "bbox": [87.0, 557.0, 376.0, 569.0]}, {"text": "1993;17:249-255; discussion 255. doi: 10.1067/mva.1993.42734", "bbox": [87.0, 569.0, 356.0, 580.0]}, {"text": "45. Lo BM, Carpenter CR, Hatten BW, Wright BJ, Brown MD. Clinical policy:", "bbox": [66.0, 582.0, 379.0, 594.0]}, {"text": "critical issues in the evaluation of adult patients with suspected tran-", "bbox": [85.0, 594.0, 378.0, 606.0]}, {"text": "sient ischemic attack in the emergency department. Ann Emerg Med.", "bbox": [87.0, 606.0, 378.0, 618.0]}, {"text": "2016;68:354-370. doi: 10.1016/j.annemergmed.2016.06.048", "bbox": [85.0, 617.0, 338.0, 629.0]}, {"text": "46. Qureshi Al, Adil MM, Zacharatos H, Suri MF. Factors associated with", "bbox": [66.0, 630.0, 380.0, 642.0]}, {"text": "length of hospitalization in patients admitted with transient isch-", "bbox": [85.0, 642.0, 378.0, 653.0]}, {"text": "emic attack in United States. Stroke. 2013;44:1601-1605. doi:", "bbox": [86.0, 652.0, 379.0, 667.0]}, {"text": "10.1161/STROKEAHA.111.000590", "bbox": [87.0, 665.0, 235.0, 676.0]}, {"text": "47. Ross MA, Compton S, Medado P, Fitzgerald M, Kilanowski P, O'Neil BJ. An", "bbox": [68.0, 677.0, 380.0, 689.0]}, {"text": "emergency department diagnostic protocol for patients with transient isch-", "bbox": [85.0, 689.0, 378.0, 702.0]}, {"text": "emic attack: a randomized controlled trial. Ann Emerg Med. 2007;50:109–", "bbox": [86.0, 700.0, 377.0, 713.0]}, {"text": "119. doi: 10.1016/j.annemergmed.2007.03.008", "bbox": [87.0, 714.0, 276.0, 725.0]}, {"text": "48. Joshi JK, Ouyang B, Prabhakaran S. Should TIA patients be hospital-", "bbox": [66.0, 725.0, 378.0, 737.0]}, {"text": "ized or referred to a same-day clinic?: a decision analysis. Neurology .", "bbox": [85.0, 738.0, 378.0, 749.0]}, {"text": "2011;77:2082–2088. doi: 10.1212/WNL0b013e31823d763f", "bbox": [85.0, 749.0, 339.0, 761.0]}, {"text": "49. Olivot JM, Wolford C, Castle J, Mlynash M, Schwartz NE, Lansberg MG,", "bbox": [66.0, 762.0, 378.0, 774.0]}, {"text": "Kemp S, Albers GW. Two aces: transient ischemic attack work-up as outpa-", "bbox": [85.0, 774.0, 378.0, 785.0]}, {"text": "tient assessment of clinical evaluation and safety. Stroke. 2011;42:1839–", "bbox": [86.0, 786.0, 378.0, 796.0]}, {"text": "1843. doi: 10.1161/STROKEAHA.110.608380", "bbox": [87.0, 797.0, 277.0, 809.0]}, {"text": "50. Levine DA, Duncan PW, Nguyen-Huynh MN, Ogedegbe OG. Interventions", "bbox": [66.0, 809.0, 380.0, 822.0]}, {"text": "targeting racial/ethnic disparities in stroke prevention and treatment.", "bbox": [86.0, 822.0, 378.0, 833.0]}, {"text": "Stroke. 2020;51:3425-3432. doi: 10.1161/STROKEAHA.120.030427", "bbox": [87.0, 833.0, 367.0, 844.0]}, {"text": "51. Ranta A, Barber PA.  Transient ischemic attack service provision: A", "bbox": [66.0, 845.0, 380.0, 858.0]}, {"text": "review of available service models. Neurology. 2016;86:947-953. doi:", "bbox": [85.0, 857.0, 380.0, 870.0]}, {"text": "10.1212/WNL00000000002339", "bbox": [87.0, 870.0, 239.0, 880.0]}, {"text": "Johnston SC, Amarenco P, Denison H, Evans SR, Himmelmann A, James", "bbox": [83.0, 881.0, 379.0, 893.0]}, {"text": "52.", "bbox": [66.0, 882.0, 83.0, 892.0]}, {"text": "S, Knutsson M, Ladenvall P, Molina CA, Wang Y; THALES Investigators.", "bbox": [85.0, 894.0, 378.0, 905.0]}, {"text": "Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA. N", "bbox": [87.0, 905.0, 380.0, 917.0]}, {"text": "Engl J Med . 2020;383:207–217. doi: 10.1056/NEJMoa1916870", "bbox": [85.0, 916.0, 349.0, 929.0]}, {"text": "53. Bhatia K, Jain V, Aggarwal D, Vaduganathan M, Arora S, Hussain Z,", "bbox": [66.0, 930.0, 378.0, 942.0]}, {"text": "Uberoi G, Tafur A, Zhang C, Ricciardi M, et al. Dual antiplatelet ther-", "bbox": [84.0, 942.0, 378.0, 954.0]}, {"text": "apy versus aspirin in patients with stroke or transient ischemic attack:", "bbox": [86.0, 954.0, 379.0, 965.0]}], "type": "Text", "position": 2}, {"raw_context": [{"text": "meta-analysis of randomized controlled trials. Stroke . 2021;52:e217-e223.", "bbox": [422.0, 77.0, 715.0, 89.0]}, {"text": "doi: 10.1161/STROKEAHA.120.033033", "bbox": [421.0, 89.0, 588.0, 100.0]}, {"text": "54. Coll-Vinent B, Martín A, Sánchez J, Tamargo J, Suero C, Malagón F,", "bbox": [401.0, 101.0, 716.0, 113.0]}, {"text": "Varona M, Cancio M, Sánchez S, Carbajosa J, et al. Benefits of emergency", "bbox": [421.0, 113.0, 716.0, 126.0]}, {"text": "departments' contribution to stroke prophylaxis in atrial fibrillation: the", "bbox": [422.0, 126.0, 715.0, 138.0]}, {"text": "EMERG-AF Study (Emergency Department Stroke Prophylaxis and Guide-", "bbox": [421.0, 137.0, 715.0, 148.0]}, {"text": "lines Implementation in Atrial Fibrillation). Stroke. 2017;48:1344-1352.", "bbox": [421.0, 150.0, 715.0, 161.0]}, {"text": "doi: 10.1161/STROKEAHA.116.014855", "bbox": [421.0, 161.0, 592.0, 173.0]}, {"text": "55.", "bbox": [403.0, 173.0, 417.0, 184.0]}, {"text": "Man-Son-Hing M, Nichol G, Lau A, Laupacis A. Choosing antithrombotic", "bbox": [419.0, 173.0, 715.0, 186.0]}, {"text": "therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch", "bbox": [421.0, 185.0, 716.0, 197.0]}, {"text": "Intern Med. 1999;159:677-685. doi: 10.1001/archinte.159.7.677", "bbox": [422.0, 197.0, 680.0, 209.0]}, {"text": "56.", "bbox": [403.0, 209.0, 418.0, 220.0]}, {"text": "Goldstein LB, Amarenco P, Zivin J, Messig M, Altafullah I, Callahan A,", "bbox": [419.0, 209.0, 716.0, 221.0]}, {"text": "Hennerici M, MacLeod MJ, Sillesen H, Zweifler R, et al; Stroke Prevention", "bbox": [421.0, 221.0, 716.0, 234.0]}, {"text": "by Aggressive Reduction in Cholesterol Levels Investigators. Statin treat-", "bbox": [421.0, 234.0, 715.0, 246.0]}, {"text": "ment and stroke outcome in the Stroke Prevention by Aggressive Reduc-", "bbox": [421.0, 244.0, 715.0, 257.0]}, {"text": "tion in Cholesterol Levels (SPARCL) trial. Stroke. 2009;40:3526-3531.", "bbox": [421.0, 258.0, 715.0, 269.0]}, {"text": "doi: 10.1 161/STROKEAHA.109.557330", "bbox": [421.0, 269.0, 588.0, 281.0]}, {"text": "57. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Cir-", "bbox": [404.0, 281.0, 716.0, 294.0]}, {"text": "culation . 2004;109(23 suppl 1):III39–III43. doi: 10.1161/01.CIR.", "bbox": [422.0, 294.0, 716.0, 305.0]}, {"text": "0000131517.20177.5a", "bbox": [421.0, 306.0, 521.0, 316.0]}, {"text": "58.  Chen W, Pan Y, Jing J, Zhao X, Liu L, Meng X, Wang Y, Wang Y, CHANCE", "bbox": [403.0, 317.0, 716.0, 329.0]}, {"text": "Investigators. Recurrent stroke in minor ischemic stroke or transient isch-", "bbox": [421.0, 329.0, 716.0, 341.0]}, {"text": "emic attack with metabolic syndrome and/or diabetes mellitus. J Am Heart", "bbox": [422.0, 341.0, 716.0, 354.0]}, {"text": "Assoc . 2017;6:e005446. doi: 10.1161/JAHA.116.005446", "bbox": [421.0, 353.0, 657.0, 364.0]}, {"text": "59. Pan Y, Wang Y, Li H, Gaisano HY, Wang Y, He Y. Association of diabetes", "bbox": [402.0, 366.0, 716.0, 377.0]}, {"text": "and prognosis of minor stroke and its subtypes: a prospective observational", "bbox": [421.0, 377.0, 716.0, 388.0]}, {"text": "study. PLoS One. 2016;11:e0153178. doi: 10.1371/journal.pone.0153178", "bbox": [422.0, 390.0, 713.0, 401.0]}, {"text": "60. Bloomgarden Z, Handelsman Y. Management and prevention of cardiovas-", "bbox": [402.0, 401.0, 715.0, 413.0]}, {"text": "cular disease for type 2 diabetes: integrating the diabetes management", "bbox": [421.0, 414.0, 716.0, 426.0]}, {"text": "recommendations of AACE, ADA, EASD, AHA, ACC, and ESC. Am J Prev", "bbox": [421.0, 425.0, 716.0, 437.0]}, {"text": "Cardiol. 2020;1:100007. doi: 10.1016/j.ajpc.2020.100007", "bbox": [422.0, 437.0, 654.0, 449.0]}, {"text": "61. Boden-Albala B, GoldmanniE, Parikh NS, Carman H, Roberts ET, Lord", "bbox": [402.0, 449.0, 716.0, 461.0]}, {"text": "AS, Torrico V, Appleton N, Birkemeier J, Parides M, et  al. Efficacy of a", "bbox": [421.0, 461.0, 716.0, 475.0]}, {"text": "discharge educational strategy vs standard discharge care on reduction", "bbox": [421.0, 474.0, 716.0, 486.0]}, {"text": "of vascular risk in patients with stroke and transient ischemic attack: the", "bbox": [421.0, 485.0, 716.0, 496.0]}, {"text": "DESERVE randomized clinical trial. JAMA Neurol. 2019;76:20-27. doi:", "bbox": [421.0, 498.0, 715.0, 509.0]}, {"text": "10.1001/jamaneurol.2018.2926", "bbox": [422.0, 509.0, 553.0, 521.0]}, {"text": "Towfight A, Cheng EM, Ayala-Rivera M, Barry F, McCreath H, Ganz DA,", "bbox": [421.0, 521.0, 715.0, 534.0]}, {"text": "62.", "bbox": [403.0, 522.0, 419.0, 533.0]}, {"text": "Lee ML, Sanossian N, Mehta B, Dutta T, et al; Secondary Stroke Preven-", "bbox": [421.0, 534.0, 715.0, 545.0]}, {"text": "tion by Uniting Community and Chronic Care Model Teams Early to End", "bbox": [422.0, 546.0, 716.0, 557.0]}, {"text": "Disparities (SUCCEED) Investigators. Effect of a coordinated community", "bbox": [422.0, 557.0, 715.0, 569.0]}, {"text": "and chronic care model team intervention vs usual care on systolic blood", "bbox": [421.0, 568.0, 716.0, 581.0]}, {"text": "pressure in patients with stroke or transient ischemic attack: the SUC-", "bbox": [421.0, 582.0, 715.0, 593.0]}, {"text": "CEED randomized clinical trial. JAMA Netw Open. 2021;4:e2036227. doi:", "bbox": [421.0, 594.0, 716.0, 604.0]}, {"text": "10.1001/jamanetworkopen.2020.36227", "bbox": [422.0, 606.0, 585.0, 617.0]}, {"text": "63. Heron N, Kee F, Cardwell C, Tully MA, Donnelly M, Cupples ME. Secondary", "bbox": [402.0, 617.0, 715.0, 629.0]}, {"text": "prevention lifestyle interventions initiated within 90 days after TIA or 'minor'", "bbox": [421.0, 629.0, 715.0, 642.0]}, {"text": "stroke: a systematic review and meta-analysis of rehabilitation programmes.", "bbox": [422.0, 642.0, 716.0, 653.0]}, {"text": "Br J Gen Pract. 2017;67:e57-e66. doi: 10.3399/bjgp16X688369", "bbox": [422.0, 654.0, 687.0, 665.0]}, {"text": "64. Ranta A, Dovey S, Weatherall M, O'Dea D, Gommans J, Tilyard M. Cluster", "bbox": [402.0, 665.0, 715.0, 677.0]}, {"text": "randomized controlled trial of TIA electronic decision support in primary care.", "bbox": [421.0, 676.0, 715.0, 690.0]}, {"text": "Neurology. 2015;84:1545–1551. doi: 10.1212/WNL00000000001472", "bbox": [422.0, 689.0, 716.0, 701.0]}, {"text": "10.65.", "bbox": [402.0, 701.0, 418.0, 712.0]}, {"text": "Turan TN, Nizam A, Lynn MJ, Egan BM, Le NA, Lopes-Virella MF, Hermayer", "bbox": [419.0, 701.0, 715.0, 713.0]}, {"text": "KL, Harrell J, Derdeyn CP, Fiorella D, et  al. Relationship between risk", "bbox": [421.0, 714.0, 716.0, 726.0]}, {"text": "factor control and vascular events in the SAMMPRIS trial. Neurology .", "bbox": [421.0, 724.0, 715.0, 737.0]}, {"text": "2017;88:379-385. doi: 10.1212/WNL00000000003534", "bbox": [422.0, 738.0, 668.0, 749.0]}, {"text": "66. Vahlberg B, Lundström E, Eriksson S, Holmbäck U, Cederholm T. Effects", "bbox": [402.0, 749.0, 716.0, 761.0]}, {"text": "on walking performance and lower body strength by short message service", "bbox": [421.0, 762.0, 716.0, 774.0]}, {"text": "guided training after stroke or transient ischemic attack (The STROKE-", "bbox": [421.0, 774.0, 715.0, 785.0]}, {"text": "WALK Study): a randomized controlled trial. Clin Rehabil. 2021;35:276–287.", "bbox": [422.0, 785.0, 716.0, 796.0]}, {"text": "doi: 10.1177/0269215520954346", "bbox": [421.0, 797.0, 566.0, 809.0]}, {"text": "67. Prior PL, Hachinski V, Unsworth K, Chan R, Mytka S, O'Callaghan C, Suskin", "bbox": [404.0, 809.0, 716.0, 821.0]}, {"text": "N. Comprehensive cardiac rehabilitation for secondary prevention after tran-", "bbox": [421.0, 822.0, 716.0, 833.0]}, {"text": "sient ischemic attack or mild stroke: I: feasibility and risk factors. Stroke .", "bbox": [422.0, 833.0, 715.0, 844.0]}, {"text": "2011;42:3207-3213. doi: 10.1161/STROKEAHA.111.620187", "bbox": [421.0, 846.0, 675.0, 857.0]}, {"text": "68.", "bbox": [402.0, 857.0, 419.0, 867.0]}, {"text": "Wang C, Redgrave J, Shafizadeh M, Majid A, Kilner K, Ali AN. Aerobic exer-", "bbox": [419.0, 857.0, 715.0, 869.0]}, {"text": "cise interventions reduce blood pressure in patients after stroke or transient", "bbox": [421.0, 870.0, 716.0, 882.0]}, {"text": "ischaemic attack: a systematic review and meta-analysis. Br J Sports Med .", "bbox": [421.0, 882.0, 715.0, 893.0]}, {"text": "2019;53:1515-1525. doi: 10.1136/bjsports-2017-098903", "bbox": [421.0, 893.0, 666.0, 905.0]}, {"text": "69.", "bbox": [401.0, 905.0, 419.0, 916.0]}, {"text": "Chiavaroli L, Viguiliouk E, Nishi SK, Blanco Mejia S, Rahelić D, Kahleová", "bbox": [419.0, 905.0, 716.0, 917.0]}, {"text": "H, Salas-Salvadó J, Kendall CW, Sievenpiper JL. DASH dietary pat-", "bbox": [421.0, 917.0, 715.0, 930.0]}, {"text": "tern and cardiometabolic outcomes: an umbrella review of systematic", "bbox": [421.0, 930.0, 715.0, 942.0]}, {"text": "reviews and meta-analyses. Nutrients . 2019;11:338. doi: 10.3390/", "bbox": [421.0, 942.0, 715.0, 953.0]}, {"text": "nu11020338", "bbox": [421.0, 954.0, 481.0, 965.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "'9 KenidsH uo Aq ano stemnolede//dud mort bebeomworth", "bbox": [18.0, 535.0, 36.0, 779.0]}], "type": "Text", "position": 4}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/神经科/共识/2023 AHA科学声明：急诊科短暂性脑缺血发作的诊断、检查和风险降低(1).pdf", "page_num": 12}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": null, "type3": null, "type4": null, "type5": null, "type6": "信息有用性#0#33#参考文献"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:40", "update_time": "2024-05-07 19:12:11"}
{"id": 1082532, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 738, "source_info": {"seq_id": "22059457-4fb3-485c-8efa-84df68202124", "title": null, "text": "【0】页码:6\n Figure. A potential TIA pathway that incorporates clinical evaluation, imaging, and risk stratification to guide disposition\n\n【1】 decisions.\n\n【2】 Modifications are expected when rapid neurology consultation or MRI are not available. CT indicates component as tomography; CTA, computed tomography angiography; MRA, magnetic resonance angiography; MRI, magnetic resonance imaging; and TIA, transient ischemic attack.\n Given their limitations, TIA risk stratification scales should be part of a more comprehensive evaluation.\n\n【3】Vessel imaging in the ED is warranted regardless of ABCD 2 score or likelihood of admission.\n\n【4】## Patient Disposition\n\n【5】\n Factors affecting the capability of EDs or medical centers to care for patients with suspected TIA include clinician experience, risk tolerance for neurovascular conditions, availability of CT and MRI, and access to neurovascular expertise. Acute stroke–ready hospitals, primary stroke centers, and comprehensive stroke centers have staff education, neuro-imaging resources, and acute neurovascular consultation availability. Where designated stroke centers are not present, protocols for the care of neurovascular patients may need to be modified to reflect available resources.\n\n【6】Expedited TIA management pathways and diagnostic protocols have been evaluated in nonrandomized trials in a variety of clinical environments and are supported by earlier clinical policy statements. 45 Implementation of these pathways has been associated with increased use of evidence-based strategies, reductions in treatment delays (ie, time to MRI), reduction in ED length of stay, reduction in admission rates, and cost savings without evidence of an increase in short-term stroke risk or mortality. 10,17,40 Several studies have reported that the cost of an inpatient TIA workup ranges from $1547\n\n【7】 to as high as $10876 for a 24-hour admission, com¬ pared with a range of $890 to $1600 for expedited outpatient workup. 10,46,47 Prolonged ED and hospital stays may therefore be more costly, add to the current national ED boarding crisis, and may not be justified for patients with TIA at low risk of subsequent stroke if reasonable alternatives are available. 48 Many of these investigations, however, were performed at certified stroke centers, so such protocols may be difficult to deploy in more resource-limited settings.\n\n【8】Successful ED TIA protocols include several components that may account for their effect: a clinical protocol enabling rapid identification and diagnosis, rapid access to diagnostic testing and advanced imaging, risk strati¬ fication criteria (eg, ABCD 2 score), access to neurovascular expertise, implementation of appropriate secondary prevention interventions, and access to a short-term follow-up clinic (Figure 1). To successfully facilitate an expedited TIA pathway, partnership across departments and service lines is necessary (ie, having an agreement with radiology to provide reserved MRI time slots for patients with TIA in the ED or in short-term observation areas, time-sensitive outpatient access to echocardiograms for suitable patients, and rapid access to neurol¬ ogy/TIA clinics). Different thresholds for ABCD 2 score have been reported in the TIA pathway literature to guide the decision to admit to hospital (eg, ABCD 2 >6, ABCD 2 >4) versus a 24-hour observation unit, or discharge to a TIA clinic for lower ABCD 2 scores. 10 , 40 , 41 , 49 The presence\n\n【9】 '9 Among the state of the state of the state of the state of the state.", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "Figure. A potential TIA pathway that incorporates clinical evaluation, imaging, and risk stratification to guide disposition", "bbox": [64.0, 435.0, 713.0, 450.0]}], "type": "Caption", "position": 4}, {"raw_context": [{"text": "decisions.", "bbox": [65.0, 450.0, 121.0, 461.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "Modifications are expected when rapid neurology consultation or MRI are not available. CT indicates component as tomography; CTA, computed", "bbox": [64.0, 461.0, 687.0, 475.0]}, {"text": "tomography angiography; MRA, magnetic resonance angiography; MRI, magnetic resonance imaging; and TIA, transient ischemic attack.", "bbox": [65.0, 476.0, 671.0, 489.0]}], "type": "Text", "position": 6}, {"raw_context": [{"text": "Given their limitations, TIA risk stratification scales", "bbox": [89.0, 510.0, 378.0, 525.0]}, {"text": "should be part of a more comprehensive evaluation.", "bbox": [91.0, 527.0, 377.0, 542.0]}, {"text": "Vessel imaging in the ED is warranted regardless of", "bbox": [91.0, 542.0, 376.0, 557.0]}, {"text": "ABCD 2 score or likelihood of admission.", "bbox": [92.0, 558.0, 323.0, 573.0]}], "type": "List-item", "position": 7}, {"raw_context": [{"text": "PATIENT DISPOSITION", "bbox": [63.0, 597.0, 235.0, 617.0]}], "type": "Section-header", "position": 8}, {"raw_context": [{"text": "Factors affecting the capability of EDs or medical centers", "bbox": [63.0, 622.0, 379.0, 637.0]}, {"text": "to care for patients with suspected TIA include clinician", "bbox": [63.0, 639.0, 380.0, 653.0]}, {"text": "experience, risk tolerance for neurovascular conditions,", "bbox": [63.0, 655.0, 379.0, 669.0]}, {"text": "availability of CT and MRI, and access to neurovascular", "bbox": [63.0, 671.0, 378.0, 685.0]}, {"text": "expertise. Acute stroke–ready hospitals, primary stroke", "bbox": [63.0, 687.0, 379.0, 701.0]}, {"text": "centers, and comprehensive stroke centers have staff", "bbox": [63.0, 702.0, 379.0, 717.0]}, {"text": "education, neuro-imaging resources, and acute neu-", "bbox": [63.0, 719.0, 378.0, 733.0]}, {"text": "rovascular consultation availability. Where designated", "bbox": [63.0, 735.0, 380.0, 749.0]}, {"text": "stroke centers are not present, protocols for the care", "bbox": [63.0, 751.0, 379.0, 765.0]}, {"text": "of neurovascular patients may need to be modified to", "bbox": [63.0, 766.0, 380.0, 781.0]}, {"text": "reflect available resources.", "bbox": [63.0, 783.0, 215.0, 796.0]}, {"text": "Expedited TIA management pathways and diagnostic", "bbox": [79.0, 798.0, 379.0, 813.0]}, {"text": "protocols have been evaluated in nonrandomized trials", "bbox": [63.0, 815.0, 378.0, 829.0]}, {"text": "in a variety of clinical environments and are supported", "bbox": [63.0, 831.0, 379.0, 844.0]}, {"text": "by earlier clinical policy statements. 45 Implementation", "bbox": [63.0, 846.0, 380.0, 861.0]}, {"text": "of these pathways has been associated with increased", "bbox": [63.0, 863.0, 379.0, 876.0]}, {"text": "use of evidence-based strategies, reductions in treat-", "bbox": [63.0, 879.0, 378.0, 893.0]}, {"text": "ment delays (ie, time to MRI), reduction in ED length", "bbox": [63.0, 895.0, 380.0, 910.0]}, {"text": "of stay, reduction in admission rates, and cost savings", "bbox": [63.0, 911.0, 379.0, 924.0]}, {"text": "without evidence of an increase in short-term stroke", "bbox": [63.0, 926.0, 379.0, 941.0]}, {"text": "risk or mortality. 10,17,40 Several studies have reported that", "bbox": [63.0, 941.0, 380.0, 958.0]}, {"text": "the cost of an inpatient TIA workup ranges from $1547", "bbox": [63.0, 958.0, 378.0, 973.0]}], "type": "Text", "position": 9}, {"raw_context": [{"text": "to as high as $10876 for a 24-hour admission, com¬", "bbox": [399.0, 510.0, 715.0, 525.0]}, {"text": "pared with a range of $890 to $1600 for expedited", "bbox": [398.0, 526.0, 716.0, 541.0]}, {"text": "outpatient workup. 10,46,47 Prolonged ED and hospital", "bbox": [397.0, 542.0, 716.0, 557.0]}, {"text": "stays may therefore be more costly, add to the current", "bbox": [399.0, 558.0, 716.0, 573.0]}, {"text": "national ED boarding crisis, and may not be justified", "bbox": [399.0, 575.0, 716.0, 589.0]}, {"text": "for patients with TIA at low risk of subsequent stroke if", "bbox": [399.0, 591.0, 716.0, 605.0]}, {"text": "reasonable alternatives are available. 48 Many of these", "bbox": [399.0, 607.0, 716.0, 621.0]}, {"text": "investigations, however, were performed at certified", "bbox": [398.0, 622.0, 716.0, 637.0]}, {"text": "stroke centers, so such protocols may be difficult to", "bbox": [399.0, 639.0, 716.0, 653.0]}, {"text": "deploy in more resource-limited settings.", "bbox": [399.0, 655.0, 633.0, 669.0]}, {"text": "Successful ED TIA protocols include several compo-", "bbox": [415.0, 671.0, 715.0, 685.0]}, {"text": "nents that may account for their effect: a clinical protocol", "bbox": [399.0, 687.0, 716.0, 701.0]}, {"text": "enabling rapid identification and diagnosis, rapid access", "bbox": [399.0, 702.0, 716.0, 717.0]}, {"text": "to diagnostic testing and advanced imaging, risk strati¬", "bbox": [399.0, 719.0, 715.0, 733.0]}, {"text": "fication criteria (eg, ABCD 2 score), access to neurovas-", "bbox": [399.0, 735.0, 715.0, 749.0]}, {"text": "cular expertise, implementation of appropriate secondary", "bbox": [399.0, 751.0, 715.0, 765.0]}, {"text": "prevention interventions, and access to a short-term", "bbox": [399.0, 766.0, 716.0, 782.0]}, {"text": "follow-up clinic (Figure 1). To successfully facilitate an", "bbox": [400.0, 783.0, 716.0, 797.0]}, {"text": "expedited TIA pathway, partnership across departments", "bbox": [399.0, 799.0, 715.0, 813.0]}, {"text": "and service lines is necessary (ie, having an agreement", "bbox": [399.0, 815.0, 716.0, 829.0]}, {"text": "with radiology to provide reserved MRI time slots for", "bbox": [399.0, 831.0, 716.0, 845.0]}, {"text": "patients with TIA in the ED or in short-term observation", "bbox": [399.0, 846.0, 716.0, 862.0]}, {"text": "areas, time-sensitive outpatient access to echocardio-", "bbox": [399.0, 863.0, 714.0, 876.0]}, {"text": "grams for suitable patients, and rapid access to neurol¬", "bbox": [399.0, 879.0, 715.0, 893.0]}, {"text": "ogy/TIA clinics). Different thresholds for ABCD 2 score", "bbox": [399.0, 895.0, 716.0, 910.0]}, {"text": "have been reported in the TIA pathway literature to guide", "bbox": [399.0, 911.0, 716.0, 924.0]}, {"text": "the decision to admit to hospital (eg, ABCD 2 >6, ABCD 2", "bbox": [399.0, 926.0, 715.0, 941.0]}, {"text": ">4) versus a 24-hour observation unit, or discharge to a", "bbox": [399.0, 943.0, 716.0, 957.0]}, {"text": "TIA clinic for lower ABCD 2 scores. 10 , 40 , 41 , 49 The presence", "bbox": [400.0, 959.0, 716.0, 972.0]}], "type": "Text", "position": 10}, {"raw_context": [{"text": "'9 Among the state of the state of the state of the state of the state.", "bbox": [16.0, 537.0, 36.0, 780.0]}], "type": "Text", "position": 11}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/神经科/共识/2023 AHA科学声明：急诊科短暂性脑缺血发作的诊断、检查和风险降低(1).pdf", "page_num": 6}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "多余换行#1#1#decisions.与上面0段联接\n多余换行#7#7#to as high as $10876 for a ...与上面6段联接", "type3": "无关文本#6#6#45   10,17,40\n无关文本#7#7#10,46,47   48\n无关文本#8#8#10 , 40 , 41 , 49 \n无关文本#9#9# '9 Among the state of the state of the state of the state of the state. 原文内容不存在", "type4": null, "type5": null, "type6": null}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:40", "update_time": "2024-05-07 21:39:12"}
{"id": 1082531, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 738, "source_info": {"seq_id": "53690176-d966-4eda-a2cc-b4b8e41b7d0e", "title": null, "text": "【0】页码:11\n The catheter must be placed well distal (> 3-4 cm) to the gastroduodenal artery and any other artery that is supplying blood to the gastrointestinal system. The microspheres are delivered slowly at a rate of no more than 5 ml/min, as rapid delivery may cause reflux. The use of 5% glucose solution should be preferred over sterile water as it reduces stasis and thereby procedural patient discomfort [ 99 ]. During the procedure, the radiologist must repeatedly check the position of the catheter to ensure its position and continued forward flow. This is performed by injecting contrast medium through the left-hand port of the delivery set [ 100 ].\n\n【1】For glass 90 Y-microspheres, a typical treatment consists of injecting 1,2–8 millions of glass 90 Y-microspheres. The volume of saline solution required to infuse a vial is low (typically 20–60 ml). Furthermore, given the low number of microspheres infused, the entire vascular bed is never completely saturated and continuous fl uoroscopic guidance during the infusion is not necessary. A complete infusion usually requires 20–60 ml and 5 min and should be performed with slow hand injection under free breathing.\n\n【2】For 166 Ho-microspheres, the same administration system is used for both the scout dose and the treatment dose. A typical treatment consists of 20–30 million microspheres.\n\n【3】Given the embolic load (albeit less compared with resin 90 Y-microspheres), no blind infusions should be performed.\n\n【4】The catheter must be placed well distal (> 3–4 cm) to the gastroduodenal artery, and any other artery that is supplying blood to the gastrointestinal system. The microspheres are delivered slowly at a rate of no more than 5 ml/min, as rapid delivery may cause reflux. Instead of 5% glucose, ordinary saline is used. During the procedure, administration of microspheres and contrast agent can be alternated by rotation of the dial between the administration and the 1 contrast position, to check the catheter position and continued forward flow.\n\n【5】## Post-Treatment Imaging\n\n【6】\n For 90 Y-microspheres, routine 90 Y PET, planar scintigra- 'phy and bremsstrahlung single-photon emission computed tomography with integrated computed tomography (SPECT/ CT) can be considered for post-treatment imaging. Treating physicians should confirm sufficient tumour uptake, acceptable pulmonary absorbed dose and the absence of visceral 90 Y concentration, in line with the pre-therapeutic. 99 m Tc- MAA SPECT/CT.\n\n【7】Despite the low amount of positron emission (31.86 ± 0.37 × 10 − 6 ), due to its high sensitivity and available time-of-flight (TOF) information, PET/CT quantitative imaging and dosimetry of 90 Y-microspheres are feasible [ 101 , 102 ]. In addition, PET/CT allows for a superior quantification and spatial resolution compared with bremsstrahlung\n\n【8】 SPECT/CT [ 5 ]. In patients with a considerable lung shunt fraction on pre-treatment 99 m Tc-MAA scintigraphy, image acquisition should comprise the whole liver and lungs. Posttreatment planar imaging covering the lung region is advisable to identify unexpected lung shunt and complications that can be investigated more in detail with 3D modality [103, 104] . In the absence of a clinically relevant lung shunt fraction, coverage of the lungs is not necessary. With present PET/CT technology (3D acquisition and < 600 ps TOF resolution), to account for the low true-coincidence rate, emission times of at least 15 min (preferably more) are recommended [ 5 , 105 ].\n\n【9】Due to the gamma-emitting properties of 166 Ho-microspheres, post-treatment imaging can be performed by virtue of SPECT [ 106 ], ideally in conjunction with additional lowdose CT.\n\n【10】Upon decay, the isotope 166 Ho emits several gamma photons, most of which are 81 keV (abundance 6.7%), 1379 keV (0.9%) or 1581 keV (0.2%). To quantify 166 Ho accurately, the SPECT detector has to be set to register photons with an energy window of 7.5% around the photon peak of 81 keV. However, bremsstrahlung photons and other high-energy photons cause image-degrading effects because of scattering. Although this may limit accurate activity quantification, using a down-scatter window and a medium-energy collimator can reduce these effects.\n\n【11】Immediately after administration, when the activity in the scanner is above approximately 1420 MBq (i.e. dependent on the SPECT/CT system), there is an excess of gamma photons that significantly increases detector dead time [ 106 ]. Dependent on the amount of administered activity, it is advised to perform post-treatment 166 Ho SPECT/CT between 2 and 5 days after treatment.\n\n【12】Because of its paramagnetic properties, 166 Ho can also be visualized and quantified using MRI techniques. MRI is independent of administered activity; however, because of artefacts, it is limited to tissue without air and metal. MRI has a higher resolution than SPECT/CT and takes less time.\n\n【13】The presence of 166 Ho accelerates the decay of the T2 vector, of tissue. A linear relationship exists between T2* times and 166 Ho concentration. This relationship, called the relaxivity (R2*), depends on the strength of the main magnetic field of the scanner and the 166 Ho content.\n\n【14】The feasibility of MRI quantification of 166 Ho-microspheres was validated in patients using SPECT/CT as a reference standard [ 107 ]. The recovery of 166Ho-microspheres in the liver using MRI proved to be sufficient (i.e. > 95%) for dosimetry purposes in patients without local surgical clips. A downside of the paramagnetic effects of 166 Ho-microspheres is that its susceptibility artefacts obscure gadolinium enhancement on follow-up scans, which can potentially mask enhancing viable residual lesions.", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "The catheter must be placed well distal (> 3-4 cm) to the", "bbox": [66.0, 73.0, 387.0, 88.0]}, {"text": "gastroduodenal artery and any other artery that is supplying", "bbox": [66.0, 91.0, 387.0, 105.0]}, {"text": "blood to the gastrointestinal system. The microspheres are", "bbox": [64.0, 107.0, 387.0, 122.0]}, {"text": "delivered slowly at a rate of no more than 5 ml/min, as rapid", "bbox": [64.0, 123.0, 387.0, 138.0]}, {"text": "delivery may cause reflux. The use of 5% glucose solution", "bbox": [64.0, 140.0, 391.0, 155.0]}, {"text": "should be preferred over sterile water as it reduces stasis", "bbox": [65.0, 158.0, 389.0, 171.0]}, {"text": "and thereby procedural patient discomfort [ 99 ]. During the", "bbox": [66.0, 174.0, 387.0, 189.0]}, {"text": "procedure, the radiologist must repeatedly check the posi-", "bbox": [66.0, 190.0, 387.0, 205.0]}, {"text": "tion of the catheter to ensure its position and continued for-", "bbox": [64.0, 207.0, 386.0, 222.0]}, {"text": "ward flow. This is performed by injecting contrast medium", "bbox": [66.0, 224.0, 387.0, 238.0]}, {"text": "through the left-hand port of the delivery set [ 100 ].", "bbox": [64.0, 240.0, 343.0, 255.0]}, {"text": "For glass 90 Y-microspheres, a typical treatment consists", "bbox": [80.0, 256.0, 387.0, 273.0]}, {"text": "of injecting 1,2–8 millions of glass 90 Y-microspheres. The", "bbox": [64.0, 274.0, 387.0, 289.0]}, {"text": "volume of saline solution required to infuse a vial is low", "bbox": [66.0, 291.0, 387.0, 305.0]}, {"text": "(typically 20–60 ml). Furthermore, given the low number", "bbox": [64.0, 307.0, 387.0, 322.0]}, {"text": "of microspheres infused, the entire vascular bed is never", "bbox": [64.0, 324.0, 387.0, 339.0]}, {"text": "completely saturated and continuous fl uoroscopic guidance", "bbox": [64.0, 341.0, 387.0, 355.0]}, {"text": "during the infusion is not necessary. A complete infusion", "bbox": [64.0, 357.0, 387.0, 371.0]}, {"text": "usually requires 20–60 ml and 5 min and should be per-", "bbox": [65.0, 374.0, 385.0, 388.0]}, {"text": "formed with slow hand injection under free breathing.", "bbox": [64.0, 391.0, 359.0, 406.0]}, {"text": "For 166 Ho-microspheres, the same administration system", "bbox": [80.0, 406.0, 387.0, 422.0]}, {"text": "is used for both the scout dose and the treatment dose. A", "bbox": [64.0, 424.0, 387.0, 438.0]}, {"text": "typical treatment consists of 20–30 million microspheres.", "bbox": [64.0, 440.0, 386.0, 455.0]}, {"text": "Given the embolic load (albeit less compared with resin", "bbox": [64.0, 457.0, 387.0, 472.0]}, {"text": "90 Y-microspheres), no blind infusions should be performed.", "bbox": [65.0, 473.0, 387.0, 489.0]}, {"text": "The catheter must be placed well distal (> 3–4 cm) to the", "bbox": [64.0, 490.0, 387.0, 505.0]}, {"text": "gastroduodenal artery, and any other artery that is supply-", "bbox": [65.0, 507.0, 385.0, 522.0]}, {"text": "ing blood to the gastrointestinal system. The microspheres", "bbox": [64.0, 523.0, 387.0, 538.0]}, {"text": "are delivered slowly at a rate of no more than 5 ml/min,", "bbox": [65.0, 541.0, 387.0, 554.0]}, {"text": "as rapid delivery may cause reflux. Instead of 5% glucose,", "bbox": [65.0, 557.0, 387.0, 572.0]}, {"text": "ordinary saline is used. During the procedure, administra-", "bbox": [64.0, 574.0, 386.0, 589.0]}, {"text": "tion of microspheres and contrast agent can be alternated", "bbox": [65.0, 590.0, 388.0, 605.0]}, {"text": "by rotation of the dial between the administration and the 1", "bbox": [64.0, 608.0, 389.0, 621.0]}, {"text": "contrast position, to check the catheter position and contin-", "bbox": [64.0, 624.0, 385.0, 639.0]}, {"text": "ued forward flow.", "bbox": [66.0, 640.0, 163.0, 655.0]}], "type": "Text", "position": 1}, {"raw_context": [{"text": "Post-treatment imaging", "bbox": [65.0, 689.0, 239.0, 705.0]}], "type": "Section-header", "position": 2}, {"raw_context": [{"text": "For 90 Y-microspheres, routine 90 Y PET, planar scintigra-", "bbox": [64.0, 721.0, 385.0, 739.0]}, {"text": "'phy and bremsstrahlung single-photon emission computed", "bbox": [63.0, 741.0, 387.0, 755.0]}, {"text": "tomography with integrated computed tomography (SPECT/", "bbox": [64.0, 757.0, 387.0, 772.0]}, {"text": "CT) can be considered for post-treatment imaging. Treating", "bbox": [64.0, 774.0, 387.0, 789.0]}, {"text": "physicians should confirm sufficient tumour uptake, accept-", "bbox": [64.0, 791.0, 386.0, 805.0]}, {"text": "able pulmonary absorbed dose and the absence of visceral", "bbox": [65.0, 807.0, 387.0, 822.0]}, {"text": "90 Y concentration, in line with the pre-therapeutic. 99 m Tc-", "bbox": [66.0, 823.0, 385.0, 840.0]}, {"text": "MAA SPECT/CT.", "bbox": [65.0, 841.0, 168.0, 856.0]}, {"text": "Despite the low amount of positron emission", "bbox": [80.0, 855.0, 388.0, 875.0]}, {"text": "(31.86 ± 0.37 × 10 − 6 ), due to its high sensitivity and avail-", "bbox": [64.0, 873.0, 386.0, 888.0]}, {"text": "able time-of-flight (TOF) information, PET/CT quantitative", "bbox": [65.0, 890.0, 387.0, 905.0]}, {"text": "imaging and dosimetry of 90 Y-microspheres are feasible", "bbox": [65.0, 907.0, 387.0, 923.0]}, {"text": "[ 101 , 102 ]. In addition, PET/CT allows for a superior quanti-", "bbox": [64.0, 924.0, 385.0, 938.0]}, {"text": "fication and spatial resolution compared with bremsstrahlung", "bbox": [65.0, 941.0, 387.0, 955.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "SPECT/CT [ 5 ]. In patients with a considerable lung shunt", "bbox": [406.0, 72.0, 727.0, 88.0]}, {"text": "fraction on pre-treatment 99 m Tc-MAA scintigraphy, image", "bbox": [405.0, 88.0, 727.0, 106.0]}, {"text": "acquisition should comprise the whole liver and lungs. Post-", "bbox": [406.0, 107.0, 726.0, 122.0]}, {"text": "treatment planar imaging covering the lung region is advis-", "bbox": [405.0, 123.0, 726.0, 138.0]}, {"text": "able to identify unexpected lung shunt and complications", "bbox": [405.0, 140.0, 727.0, 155.0]}, {"text": "that can be investigated more in detail with 3D modality", "bbox": [404.0, 158.0, 727.0, 171.0]}, {"text": "[103, 104] . In the absence of a clinically relevant lung shunt", "bbox": [405.0, 174.0, 727.0, 189.0]}, {"text": "fraction, coverage of the lungs is not necessary. With pre-", "bbox": [405.0, 190.0, 727.0, 205.0]}, {"text": "sent PET/CT technology (3D acquisition and < 600 ps TOF", "bbox": [406.0, 207.0, 727.0, 222.0]}, {"text": "resolution), to account for the low true-coincidence rate,", "bbox": [405.0, 224.0, 727.0, 238.0]}, {"text": "emission times of at least 15 min (preferably more) are rec-", "bbox": [405.0, 240.0, 726.0, 255.0]}, {"text": "ommended [ 5 , 105 ].", "bbox": [405.0, 257.0, 518.0, 272.0]}, {"text": "Due to the gamma-emitting properties of 166 Ho-micro-", "bbox": [420.0, 274.0, 727.0, 288.0]}, {"text": "spheres, post-treatment imaging can be performed by virtue", "bbox": [406.0, 291.0, 727.0, 305.0]}, {"text": "of SPECT [ 106 ], ideally in conjunction with additional low-", "bbox": [405.0, 306.0, 726.0, 323.0]}, {"text": "dose CT.", "bbox": [405.0, 324.0, 457.0, 338.0]}, {"text": "Upon decay, the isotope 166 Ho emits several gamma", "bbox": [421.0, 338.0, 727.0, 355.0]}, {"text": "photons, most of which are 81 keV (abundance 6.7%),", "bbox": [405.0, 356.0, 728.0, 371.0]}, {"text": "1379 keV (0.9%) or 1581 keV (0.2%). To quantify 166 Ho", "bbox": [405.0, 373.0, 728.0, 388.0]}, {"text": "accurately, the SPECT detector has to be set to register", "bbox": [405.0, 390.0, 727.0, 405.0]}, {"text": "photons with an energy window of 7.5% around the photon", "bbox": [405.0, 407.0, 727.0, 422.0]}, {"text": "peak of 81 keV. However, bremsstrahlung photons and", "bbox": [405.0, 424.0, 728.0, 438.0]}, {"text": "other high-energy photons cause image-degrading effects", "bbox": [405.0, 440.0, 727.0, 455.0]}, {"text": "because of scattering. Although this may limit accurate", "bbox": [405.0, 458.0, 727.0, 472.0]}, {"text": "activity quantification, using a down-scatter window and", "bbox": [405.0, 474.0, 727.0, 488.0]}, {"text": "a medium-energy collimator can reduce these effects.", "bbox": [405.0, 491.0, 727.0, 505.0]}, {"text": "Immediately after administration, when the activity in the", "bbox": [406.0, 507.0, 727.0, 522.0]}, {"text": "scanner is above approximately 1420 MBq (i.e. dependent", "bbox": [405.0, 523.0, 727.0, 538.0]}, {"text": "on the SPECT/CT system), there is an excess of gamma", "bbox": [405.0, 540.0, 728.0, 555.0]}, {"text": "photons that significantly increases detector dead time", "bbox": [405.0, 557.0, 727.0, 572.0]}, {"text": "[ 106 ]. Dependent on the amount of administered activity,", "bbox": [405.0, 574.0, 727.0, 589.0]}, {"text": "it is advised to perform post-treatment 166 Ho SPECT/CT", "bbox": [405.0, 591.0, 727.0, 605.0]}, {"text": "between 2 and 5 days after treatment.", "bbox": [404.0, 607.0, 614.0, 621.0]}, {"text": "Because of its paramagnetic properties, 166 Ho can also", "bbox": [421.0, 624.0, 728.0, 638.0]}, {"text": "be visualized and quantified using MRI techniques. MRI is", "bbox": [405.0, 640.0, 728.0, 655.0]}, {"text": "independent of administered activity; however, because of", "bbox": [405.0, 657.0, 728.0, 671.0]}, {"text": "artefacts, it is limited to tissue without air and metal. MRI", "bbox": [405.0, 674.0, 727.0, 688.0]}, {"text": "has a higher resolution than SPECT/CT and takes less time.", "bbox": [405.0, 691.0, 725.0, 705.0]}, {"text": "The presence of 166 Ho accelerates the decay of the T2 vector,", "bbox": [406.0, 706.0, 731.0, 722.0]}, {"text": "of tissue. A linear relationship exists between T2* times and", "bbox": [405.0, 724.0, 731.0, 739.0]}, {"text": "166 Ho concentration. This relationship, called the relaxivity", "bbox": [406.0, 740.0, 727.0, 756.0]}, {"text": "(R2*), depends on the strength of the main magnetic field", "bbox": [405.0, 757.0, 728.0, 772.0]}, {"text": "of the scanner and the 166 Ho content.", "bbox": [405.0, 774.0, 606.0, 788.0]}, {"text": "The feasibility of MRI quantification of", "bbox": [422.0, 791.0, 728.0, 806.0]}, {"text": "166 Ho-microspheres was validated in patients using", "bbox": [406.0, 805.0, 727.0, 825.0]}, {"text": "SPECT/CT as a reference standard [ 107 ]. The recovery", "bbox": [406.0, 823.0, 727.0, 840.0]}, {"text": "of 166Ho-microspheres in the liver using MRI proved", "bbox": [405.0, 840.0, 728.0, 857.0]}, {"text": "to be sufficient (i.e. > 95%) for dosimetry purposes in", "bbox": [404.0, 858.0, 729.0, 872.0]}, {"text": "patients without local surgical clips. A downside of the", "bbox": [405.0, 874.0, 728.0, 888.0]}, {"text": "paramagnetic effects of 166 Ho-microspheres is that its", "bbox": [405.0, 889.0, 728.0, 905.0]}, {"text": "susceptibility artefacts obscure gadolinium enhancement", "bbox": [405.0, 908.0, 727.0, 923.0]}, {"text": "on follow-up scans, which can potentially mask enhancing", "bbox": [405.0, 924.0, 727.0, 938.0]}, {"text": "viable residual lesions.", "bbox": [405.0, 941.0, 535.0, 955.0]}], "type": "Text", "position": 4}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2022】全科室最全临床指南+专家共识（最全版）/2022全科室临床指南/肿瘤科/EANM：动脉内放射性化合物治疗肝癌和转移性肝癌指南（2022）(1).pdf", "page_num": 11}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "多余换行#7#8# with bremsstrahlung和 SPECT/CT [ 5 ]. In patients 是一句话\n", "type3": "无关文本#0#14#delivery set [ 100 ].部分段落末尾，以及句末的数字问题无关噪声应用全文", "type4": null, "type5": null, "type6": null}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:40", "update_time": "2024-05-07 23:01:24"}
{"id": 1082530, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 738, "source_info": {"seq_id": "d4966170-3080-43e1-98e9-d5fc60d4eae6", "title": null, "text": "【0】页码:3\n . .\n\n【1】 ,\n\n【2】 .\n\n【3】 JIA Haibo, et al. Interpretation of Chinese expert consensus on the application of optical coherence ... • 169 • OCT OCT BRS BRS 2015; , .\n\n【4】OCT ; 3 .\n\n【5】.\n\n【6】: O ACR BRS .\n\n【7】.\n\n【8】BRS OCT BRS : © OCT .\n\n【9】; © .\n\n【10】.\n\n【11】BRS 199 , , OCT\n\n【12】\n • BRS , , o 2018     ESC/EACTS .\n\n【13】o.\n\n【14】OCT DCB ISR  , DCB 9 __  > 4. 5 mm 2 ; 2 ) , , ,    < 3 mm, (ACS 1  __ OCT DCB . \n\n【15】.\n\n【16】, < 1 mm; Q ..\n\n【17】.\n\n【18】.\n\n【19】100 – 3 < 10%, 2 10%  A > 2 5 mm 90%; © , OCT DCB \" .\n\n【20】17.\n\n【21】[21] .\n\n【22】OCT \" 1. 4 OCT , .\n\n【23】 DCB ISR\n\n【24】 /\n\n【25】 1. 3\n\n【26】 .\n\n【27】ST.\n\n【28】ISR , \"  .\n\n【29】ACS .\n\n【30】 \",\" \"  .\n\n【31】.\n\n【32】.\n\n【33】ACS ( , .\n\n【34】, ) , 10.1.1.3 .\n\n【35】ACS       1/3, , , ACS . OCT OCT, , , .\n\n【36】, , EROSION  OCT o [2-3.7] , OCT ACS OCT [16] 。 EROSION OCT , ISR ST .\n\n【37】[17] .\n\n【38】ISR OCT .\n\n【39】ACS ISR .\n\n【40】.\n\n【41】, , ISR , OCT 5 : I .\n\n【42】; II , < 70% .\n\n【43】; III 1999; IV , .\n\n【44】\".\n\n【45】” ISR; V .\n\n【46】BRS OCT 5 ISR , .\n\n【47】PSP BRS .\n\n【48】.\n\n【49】.\n\n【50】[18-19] , OCT , OCT ST ST Chapter 1 PSP ST .\n\n【51】 III\n\n【52】 ,\n\n【53】 (C) 1994-2023 China Academic Journal Electronic Publishing House. All rights reserved. http://www.cnki.net\n\n【54】 1.", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": ". .", "bbox": [217.0, 53.0, 246.0, 64.0]}], "type": "Text", "position": 0}, {"raw_context": [{"text": ",", "bbox": [93.0, 104.0, 101.0, 116.0]}], "type": "Text", "position": 1}, {"raw_context": [{"text": ".", "bbox": [119.0, 165.0, 132.0, 177.0]}], "type": "Text", "position": 2}, {"raw_context": [{"text": "JIA Haibo, et al. Interpretation of Chinese expert consensus on the application of optical coherence ... • 169 •", "bbox": [138.0, 63.0, 713.0, 82.0]}, {"text": "OCT", "bbox": [293.0, 98.0, 329.0, 115.0]}, {"text": "OCT", "bbox": [454.0, 98.0, 492.0, 115.0]}, {"text": "BRS", "bbox": [685.0, 98.0, 717.0, 115.0]}, {"text": "BRS", "bbox": [561.0, 99.0, 594.0, 115.0]}, {"text": "2015;", "bbox": [240.0, 100.0, 269.0, 116.0]}, {"text": ",", "bbox": [634.0, 103.0, 647.0, 116.0]}, {"text": ".", "bbox": [359.0, 105.0, 369.0, 116.0]}, {"text": "OCT", "bbox": [481.0, 118.0, 518.0, 135.0]}, {"text": "; 3", "bbox": [277.0, 119.0, 304.0, 136.0]}, {"text": ".", "bbox": [358.0, 124.0, 369.0, 136.0]}, {"text": ".", "bbox": [676.0, 124.0, 688.0, 137.0]}, {"text": ": O", "bbox": [187.0, 139.0, 216.0, 156.0]}, {"text": "ACR", "bbox": [242.0, 139.0, 279.0, 155.0]}, {"text": "BRS", "bbox": [408.0, 139.0, 441.0, 155.0]}, {"text": ".", "bbox": [663.0, 144.0, 675.0, 155.0]}, {"text": ".", "bbox": [146.0, 145.0, 169.0, 158.0]}, {"text": "BRS", "bbox": [408.0, 158.0, 441.0, 175.0]}, {"text": "OCT", "bbox": [496.0, 158.0, 533.0, 174.0]}, {"text": "BRS", "bbox": [653.0, 158.0, 687.0, 174.0]}, {"text": ": © OCT", "bbox": [140.0, 160.0, 217.0, 173.0]}, {"text": ".", "bbox": [615.0, 162.0, 636.0, 177.0]}, {"text": "; ©", "bbox": [257.0, 179.0, 284.0, 195.0]}, {"text": ".", "bbox": [617.0, 182.0, 631.0, 196.0]}, {"text": ".", "bbox": [553.0, 184.0, 565.0, 196.0]}, {"text": "BRS", "bbox": [609.0, 198.0, 641.0, 215.0]}, {"text": "199", "bbox": [201.0, 199.0, 228.0, 216.0]}, {"text": ",", "bbox": [555.0, 200.0, 569.0, 216.0]}, {"text": ",", "bbox": [521.0, 202.0, 533.0, 215.0]}, {"text": "OCT", "bbox": [494.0, 218.0, 531.0, 233.0]}], "type": "Table", "position": 3}, {"raw_context": [{"text": "•", "bbox": [246.0, 225.0, 256.0, 236.0]}, {"text": "BRS", "bbox": [490.0, 238.0, 523.0, 254.0]}, {"text": ",", "bbox": [451.0, 242.0, 467.0, 256.0]}, {"text": ",", "bbox": [164.0, 264.0, 176.0, 277.0]}, {"text": "o", "bbox": [452.0, 264.0, 462.0, 274.0]}, {"text": "2018     ESC/EACTS", "bbox": [436.0, 277.0, 575.0, 293.0]}, {"text": ".", "bbox": [92.0, 282.0, 102.0, 294.0]}, {"text": "o.", "bbox": [374.0, 283.0, 385.0, 295.0]}, {"text": "OCT", "bbox": [191.0, 296.0, 228.0, 313.0]}, {"text": "DCB", "bbox": [635.0, 296.0, 669.0, 313.0]}, {"text": "ISR ", "bbox": [468.0, 297.0, 608.0, 313.0]}, {"text": ", DCB", "bbox": [552.0, 318.0, 596.0, 333.0]}, {"text": "9", "bbox": [94.0, 319.0, 132.0, 335.0]}, {"text": "__", "bbox": [132.0, 319.0, 287.0, 334.0]}, {"text": "", "bbox": [533.0, 320.0, 555.0, 332.0]}, {"text": "> 4. 5 mm 2 ; 2 )", "bbox": [229.0, 336.0, 355.0, 354.0]}, {"text": ",", "bbox": [91.0, 341.0, 121.0, 355.0]}, {"text": ",", "bbox": [492.0, 341.0, 529.0, 354.0]}, {"text": ",", "bbox": [604.0, 343.0, 614.0, 355.0]}, {"text": "  ", "bbox": [487.0, 354.0, 566.0, 371.0]}, {"text": "< 3 mm,", "bbox": [215.0, 356.0, 281.0, 373.0]}, {"text": "(ACS", "bbox": [409.0, 356.0, 449.0, 372.0]}, {"text": "1 ", "bbox": [92.0, 360.0, 198.0, 370.0]}, {"text": "__", "bbox": [110.0, 374.0, 190.0, 394.0]}, {"text": "OCT", "bbox": [408.0, 376.0, 445.0, 392.0]}, {"text": "DCB", "bbox": [500.0, 376.0, 537.0, 392.0]}, {"text": ". ", "bbox": [224.0, 377.0, 383.0, 395.0]}, {"text": ".", "bbox": [537.0, 379.0, 569.0, 391.0]}, {"text": ",", "bbox": [619.0, 381.0, 629.0, 393.0]}, {"text": "< 1 mm; Q", "bbox": [95.0, 396.0, 181.0, 413.0]}, {"text": "..", "bbox": [220.0, 399.0, 273.0, 414.0]}, {"text": ".", "bbox": [312.0, 400.0, 330.0, 413.0]}, {"text": ".", "bbox": [551.0, 401.0, 576.0, 415.0]}, {"text": "100 – 3", "bbox": [477.0, 415.0, 535.0, 432.0]}, {"text": "< 10%,", "bbox": [152.0, 416.0, 211.0, 432.0]}, {"text": "2 10%", "bbox": [233.0, 416.0, 280.0, 433.0]}, {"text": "", "bbox": [558.0, 434.0, 604.0, 450.0]}, {"text": "A", "bbox": [132.0, 435.0, 152.0, 452.0]}, {"text": "> 2 5 mm", "bbox": [465.0, 435.0, 539.0, 454.0]}, {"text": "90%; ©", "bbox": [299.0, 436.0, 355.0, 452.0]}, {"text": ", OCT", "bbox": [607.0, 437.0, 668.0, 451.0]}, {"text": "DCB", "bbox": [560.0, 454.0, 595.0, 470.0]}, {"text": "\"", "bbox": [105.0, 461.0, 118.0, 474.0]}, {"text": ".", "bbox": [225.0, 463.0, 253.0, 473.0]}, {"text": "17.", "bbox": [269.0, 473.0, 282.0, 485.0]}, {"text": "[21] .", "bbox": [434.0, 472.0, 468.0, 490.0]}, {"text": "OCT \"", "bbox": [140.0, 475.0, 203.0, 490.0]}, {"text": "1. 4 OCT", "bbox": [409.0, 495.0, 479.0, 511.0]}, {"text": ",", "bbox": [479.0, 517.0, 492.0, 533.0]}, {"text": ".", "bbox": [662.0, 521.0, 672.0, 531.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": "DCB", "bbox": [683.0, 277.0, 718.0, 293.0]}, {"text": "ISR", "bbox": [688.0, 317.0, 716.0, 334.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "/", "bbox": [87.0, 417.0, 151.0, 431.0]}], "type": "Text", "position": 6}, {"raw_context": [{"text": "1. 3", "bbox": [76.0, 475.0, 107.0, 492.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": ".", "bbox": [273.0, 539.0, 287.0, 553.0]}, {"text": "ST.", "bbox": [512.0, 553.0, 544.0, 572.0]}, {"text": "ISR", "bbox": [469.0, 554.0, 499.0, 570.0]}, {"text": ",", "bbox": [285.0, 560.0, 313.0, 574.0]}, {"text": "\" ", "bbox": [258.0, 572.0, 272.0, 584.0]}, {"text": ".", "bbox": [293.0, 600.0, 305.0, 612.0]}, {"text": "ACS", "bbox": [318.0, 613.0, 352.0, 630.0]}, {"text": ".", "bbox": [424.0, 620.0, 436.0, 632.0]}], "type": "Text", "position": 8}, {"raw_context": [{"text": "\",\"", "bbox": [175.0, 572.0, 193.0, 589.0]}, {"text": "\" ", "bbox": [258.0, 572.0, 272.0, 584.0]}, {"text": ".", "bbox": [535.0, 578.0, 547.0, 592.0]}, {"text": ".", "bbox": [556.0, 599.0, 566.0, 611.0]}, {"text": ".", "bbox": [293.0, 600.0, 305.0, 612.0]}, {"text": "ACS", "bbox": [318.0, 613.0, 352.0, 630.0]}, {"text": "(", "bbox": [610.0, 615.0, 623.0, 630.0]}, {"text": ",", "bbox": [135.0, 619.0, 145.0, 631.0]}, {"text": ".", "bbox": [424.0, 620.0, 436.0, 632.0]}, {"text": ",", "bbox": [691.0, 620.0, 702.0, 632.0]}, {"text": ")", "bbox": [690.0, 634.0, 703.0, 650.0]}, {"text": ",", "bbox": [133.0, 640.0, 144.0, 653.0]}, {"text": "10.1.1.3", "bbox": [121.0, 655.0, 148.0, 669.0]}, {"text": ".", "bbox": [649.0, 661.0, 658.0, 672.0]}, {"text": "ACS       1/3,", "bbox": [219.0, 671.0, 328.0, 690.0]}, {"text": ",", "bbox": [568.0, 678.0, 577.0, 689.0]}, {"text": ",", "bbox": [677.0, 679.0, 686.0, 689.0]}, {"text": "ACS", "bbox": [151.0, 693.0, 185.0, 709.0]}, {"text": ". OCT", "bbox": [249.0, 693.0, 307.0, 710.0]}, {"text": "OCT,", "bbox": [426.0, 692.0, 467.0, 709.0]}, {"text": ",", "bbox": [606.0, 700.0, 617.0, 712.0]}, {"text": ",", "bbox": [606.0, 717.0, 617.0, 730.0]}, {"text": ".", "bbox": [322.0, 719.0, 334.0, 731.0]}, {"text": ",", "bbox": [132.0, 738.0, 144.0, 751.0]}, {"text": ", EROSION", "bbox": [231.0, 751.0, 309.0, 769.0]}, {"text": "", "bbox": [316.0, 753.0, 342.0, 765.0]}, {"text": "OCT", "bbox": [495.0, 752.0, 531.0, 768.0]}, {"text": "o", "bbox": [132.0, 758.0, 143.0, 769.0]}, {"text": "[2-3.7] ,", "bbox": [434.0, 766.0, 477.0, 788.0]}, {"text": "OCT", "bbox": [107.0, 772.0, 143.0, 787.0]}, {"text": "ACS", "bbox": [332.0, 772.0, 368.0, 788.0]}, {"text": "OCT", "bbox": [590.0, 772.0, 629.0, 787.0]}, {"text": "[16] 。 EROSION", "bbox": [280.0, 788.0, 384.0, 811.0]}, {"text": "OCT", "bbox": [630.0, 792.0, 665.0, 808.0]}, {"text": ",", "bbox": [545.0, 797.0, 553.0, 807.0]}, {"text": "ISR ST", "bbox": [408.0, 812.0, 478.0, 829.0]}, {"text": ".", "bbox": [586.0, 818.0, 601.0, 831.0]}, {"text": "[17] .", "bbox": [277.0, 830.0, 341.0, 847.0]}, {"text": "ISR", "bbox": [468.0, 831.0, 497.0, 848.0]}, {"text": "OCT", "bbox": [618.0, 831.0, 655.0, 847.0]}, {"text": ".", "bbox": [524.0, 836.0, 543.0, 850.0]}, {"text": "ACS", "bbox": [159.0, 851.0, 193.0, 867.0]}, {"text": "ISR", "bbox": [408.0, 851.0, 437.0, 867.0]}, {"text": ".", "bbox": [119.0, 856.0, 133.0, 869.0]}, {"text": ".", "bbox": [220.0, 857.0, 231.0, 869.0]}, {"text": ",", "bbox": [373.0, 858.0, 384.0, 870.0]}, {"text": ",", "bbox": [585.0, 858.0, 596.0, 870.0]}, {"text": "ISR", "bbox": [408.0, 871.0, 438.0, 887.0]}, {"text": ", OCT", "bbox": [276.0, 872.0, 338.0, 886.0]}, {"text": "5 : I", "bbox": [493.0, 872.0, 543.0, 889.0]}, {"text": ".", "bbox": [631.0, 875.0, 645.0, 889.0]}, {"text": "; II", "bbox": [522.0, 892.0, 545.0, 909.0]}, {"text": ",", "bbox": [633.0, 895.0, 644.0, 908.0]}, {"text": "< 70% .", "bbox": [167.0, 910.0, 223.0, 928.0]}, {"text": "; III", "bbox": [571.0, 913.0, 605.0, 929.0]}, {"text": "1999; IV", "bbox": [563.0, 932.0, 586.0, 948.0]}, {"text": ",", "bbox": [147.0, 936.0, 158.0, 947.0]}, {"text": ".", "bbox": [350.0, 939.0, 361.0, 948.0]}, {"text": "\".", "bbox": [130.0, 947.0, 146.0, 963.0]}, {"text": "”", "bbox": [209.0, 948.0, 221.0, 962.0]}, {"text": "ISR; V", "bbox": [408.0, 950.0, 454.0, 967.0]}, {"text": ".", "bbox": [373.0, 956.0, 385.0, 968.0]}, {"text": "BRS", "bbox": [108.0, 970.0, 140.0, 986.0]}, {"text": "OCT", "bbox": [408.0, 970.0, 444.0, 986.0]}, {"text": "5", "bbox": [469.0, 970.0, 516.0, 987.0]}, {"text": "ISR", "bbox": [516.0, 970.0, 545.0, 986.0]}, {"text": ",", "bbox": [573.0, 974.0, 584.0, 987.0]}, {"text": ".", "bbox": [328.0, 975.0, 340.0, 988.0]}, {"text": "PSP", "bbox": [266.0, 989.0, 298.0, 1006.0]}, {"text": "BRS", "bbox": [108.0, 990.0, 140.0, 1006.0]}, {"text": ".", "bbox": [479.0, 996.0, 494.0, 1010.0]}, {"text": ".", "bbox": [176.0, 1015.0, 187.0, 1027.0]}, {"text": ".", "bbox": [357.0, 1015.0, 370.0, 1027.0]}, {"text": "[18-19] , OCT", "bbox": [262.0, 1025.0, 335.0, 1048.0]}, {"text": ", OCT", "bbox": [466.0, 1030.0, 509.0, 1047.0]}, {"text": "ST", "bbox": [693.0, 1030.0, 716.0, 1047.0]}, {"text": "ST", "bbox": [534.0, 1031.0, 579.0, 1047.0]}, {"text": "Chapter 1", "bbox": [654.0, 1035.0, 666.0, 1049.0]}, {"text": "PSP", "bbox": [135.0, 1049.0, 170.0, 1065.0]}, {"text": "ST", "bbox": [542.0, 1050.0, 567.0, 1066.0]}, {"text": ".", "bbox": [308.0, 1056.0, 320.0, 1069.0]}], "type": "Text", "position": 9}, {"raw_context": [{"text": "III", "bbox": [77.0, 813.0, 93.0, 829.0]}], "type": "Text", "position": 10}, {"raw_context": [{"text": ",", "bbox": [92.0, 916.0, 101.0, 927.0]}], "type": "Text", "position": 11}, {"raw_context": [{"text": "(C) 1994-2023 China Academic Journal Electronic Publishing House. All rights reserved. http://www.cnki.net", "bbox": [23.0, 1082.0, 663.0, 1099.0]}], "type": "Text", "position": 12}, {"raw_context": [{"text": "1.", "bbox": [580.0, 52.0, 590.0, 61.0]}], "type": "Text", "position": 13}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/心血管/解读/《光学相干断层成像技术在冠心病介入诊疗中应用的中国专家共识》解读.pdf", "page_num": 3}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "格式杂乱#0#54#全篇格式杂乱", "type3": null, "type4": null, "type5": null, "type6": null}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:40", "update_time": "2024-05-08 01:09:27"}
{"id": 1082529, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 738, "source_info": {"seq_id": "adb02bc4-4990-4849-a20d-69d6f56ab406", "title": null, "text": "【0】页码:16\n Ilhan H, et al. Predictive value of 99mTc-MAA SPECT for 58.\n\n【1】90Y-labeled resin microsphere distribution in radioembolization of primary and secondary hepatic tumors. J Nucl Med.\n\n【2】2015;56(11):1654 – 60.\n\n【3】59.\n\n【4】Wondergem M, et al. 99mTc-macroaggregated albumin poorly predicts the intrahepatic distribution of 90Y resin microspheres in hepatic radioembolization. J Nucl Med. 2013;54(8):1294–301. J 60.\n\n【5】Haste P, et al. Correlation of technetium-99m macroaggregated albumin and yttrium-90 glass microsphere biodistribution in hepatocellular carcinoma: a retrospective review of pretreatment single photon emission ct and posttreatment positron emission tomography/CT. J Vasc Interv Radiol. 2017;28(5):722–30.\n\n【6】61.\n\n【7】Garin E, et al. Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept. Eur J , Nucl Med Mol Imaging. 2013;40(7):1057–68.\n\n【8】62.\n\n【9】Garin E, et al. Dosimetry based on 99mTc-macroaggregated albumin SPECT/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres; preliminary results. J Nucl Med.\n\n【10】2012;53(2):255–63.\n\n【11】63. Chiesa C, et al. Need, feasibility and convenience of dosimetric treatment planning in liver selective internal radiation therapy with (90)Y microspheres: the experience of the National Tumor Institute of Milan. Q J Nucl Med Mol Imaging.\n\n【12】2011;55(2):168–97.\n\n【13】64. Ho CL, et al. Radioembolization with (90)Y glass microspheres for hepatocellular carcinoma: significance of pretreatment (11) C-acetate and (18)F-FDG PET/CT and posttreatment (90)Y PET/ CT in individualized dose prescription. Eur J Nucl Med Mol Imaging. 2018;45(12):2110–21.\n\n【14】10.65.\n\n【15】Hermann AL, et al. Relationship of tumor radiation-absorbed dose to survival and response in hepatocellular carcinoma treated with transarterial radioembolization with (90)Y in the SARAH study. Radiology. 2020;296(3):673–84.\n\n【16】66.\n\n【17】Lau WY, et al. Treatment of inoperable hepatocellular carcinoma with intrahepatic arterial yttrium-90 microspheres: a phase I and II study. Br J Cancer. 1994;70(5):994–9 .\n\n【18】67.\n\n【19】Garin, E., et al., Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally.\n\n【20】advanced hepatocellular carcinoma (DOSISPHERE-01): a rándomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol  ,  2020 68.\n\n【21】Smits MLJ, et al. The superior predictive value of (166)Ho-scout compared with (99m)Tc-macroaggregated albumin prior to (166) Ho-microspheres radioembolization in patients with liver metastases. Eur J Nucl Med Mol Imaging. 2020;47(4):798–806.\n\n【22】69.\n\n【23】Salem R, et al. Clinical and dosimetric considerations for Y90: recommendations from an international multidisciplinary working group. Eur J Nucl Med Mol Imaging. 2019;46(8):1695–704.\n\n【24】70. Lewandowski RJ, et al. Radiation segmentectomy: potential curative therapy for early hepatocellular carcinoma. Radiology.\n\n【25】2018;287(3):1050–8.\n\n【26】71.\n\n【27】Meiers C, et al. Safety and initial efficacy of radiation segmentectomy for the treatment of hepatic metastases. J Gastrointest Oncol. 2018;9(2):311–5.\n\n【28】72.\n\n【29】Padia SA, et al. Superselective yttrium-90 radioembolization for hepatocellular carcinoma yields high response rates with minimal toxicity. J Vasc Interv Radiol. 2014;25(7):1067–73. [ 1 ], 73. Biederman DM, et al. Radiation segmentectomy versus selective chemoembolization in the treatment of early-stage hepatocellular carcinoma. J Vasc Interv Radiol. 2018;29(1):30–7 e2 .\n\n【30】74.\n\n【31】Garin E, et al. Personalized dosimetry with intensification using 90Y-loaded glass microsphere radioembolization induces prolonged overall survival in hepatocellular carcinoma patients with portal vein thrombosis. J Nucl Med. 2015;56(3):339–46.\n\n【32】 75.\n\n【33】Konijnenberg M., et al. EANM position paper on article 56 of the Council Directive 2013/59/Euratom (basic safety standards) for nuclear medicine therapy. Eur J Nucl Med Mol Imaging.\n\n【34】2021:48(1);67–72 76.\n\n【35】Ho S, et al. Partition model for estimating radiation doses from yttrium-90 microspheres in treating hepatic tumours. Eur J Nucl Med. 1996;23(8):947–52.\n\n【36】Chiesa C, et al. Radioembolization of hepatocarcinoma with (90) 77.\n\n【37】Y glass microspheres: development of an individualized treatment planning strategy based on dosimetry and radiobiology. Eur J Nucl Med Mol Imaging. 2015;42(11):1718–38.\n\n【38】78.\n\n【39】Chiesa C, Bardies M, Zaidi H. Voxel-based dosimetry is superior to mean absorbed dose approach for establishing doseeffect relationship in targeted radionuclide therapy. Med Phys.\n\n【40】2019;46(12):5403–6.\n\n【41】79.\n\n【42】Dewaraja YK, et al. Prediction of tumor control in (90)Y radioembolization by logit models with PET/CT-based dose metrics.\n\n【43】J Nucl Med. 2020;61(1):104–11.\n\n【44】Kappadath SC, et al. Hepatocellular carcinoma tumor dose 80.\n\n【45】response after (90)Y-radioembolization with glass microspheres using (90)Y-SPECT/CT-based voxel dosimetry. Int J Radiat Oncol Biol Phys. 2018;102(2):451–61.\n\n【46】381. Chiesa, C., et al. EANM dosimetry committee series on standard operational procedures: a unified methodology for 99m Tc-MAA pre- and 90 Y peri-therapy dosimetry in liver radioembolization with 90 Y microspheres. EJNMMI Phys. 2021:8(1);77 82.\n\n【47】Roosen, J., et al., To 1000 Gy and back again: a systematic review on dose-response evaluation in selective internal radiation therapy for primary and secondary liver cancer. Eur J Nucl Med Mol Imaging, 2021.\n\n【48】83.\n\n【49】Salem R, et al. Yttrium-90 radioembolization for the treatment of solitary, unresectable hepatocellular carcinoma: the LEGACY study. Hepatology. 2021.\n\n【50】84.\n\n【51】Lewandowski RJ, et  al. (90) Y radiation lobectomy: outcomes following surgical resection in patients with hepatic tumors and small future liver remnant volumes. J Surg Oncol.\n\n【52】2016;114(1):99–105.\n\n【53】85.\n\n【54】Palard X, et al. Dosimetric parameters predicting contralateral liver hypertrophy after unilobar radioembolization of hepatocellular carcinoma. Eur J Nucl Med Mol Imaging.\n\n【55】2018;45(3):392–401.\n\n【56】Chiesa C, et al. Radioembolization of hepatocarcinoma with 86.\n\n【57】(90)Y glass microspheres: treatment optimization using the dose-toxicity relationship. Eur J Nucl Med Mol Imaging.\n\n【58】2020;47(13):3018–32.\n\n【59】Shepherd FA, et al. A phase I dose escalation trial of yttrium-90 87.\n\n【60】microspheres in the treatment of primary hepatocellular carcinoma. Cancer. 1992;70(9):2250–4.\n\n【61】Bourien H, et al. Yttrium-90 glass microspheres radioemboliza- 7 88.\n\n【62】tion (RE) for biliary tract cancer: a large single-center experience. Eur J Nucl Med Mol Imaging. 2019;46(3):669–76.\n\n【63】89.\n\n【64】Mouli S, et al. Yttrium-90 radioembolization for intrahepatic cholangiocarcinoma: safety, response, and survival analysis. J Vasc Interv Radiol. 2013;24(8):1227–34.\n\n【65】90.\n\n【66】Padia SA, et al. Yttrium-90 radiation segmentectomy for hepatic metastases: a multi-institutional study of safety and efficacy. J Surg Oncol. 2021;123(1):172–8.\n\n【67】91.\n\n【68】Alsultan, A.A., et al., Dose-response and dose-toxicity relationships for yttrium-90 glass radioembolization in patients with colorectal cancer liver metastases. J Nucl Med, 2021.\n\n【69】92.\n\n【70】Lewandowski RJ, et al. Twelve-year experience of radioembolization for colorectal hepatic metastases in 214 patients: survival by era and chemotherapy. Eur J Nucl Med Mol Imaging.\n\n【71】2014;41(10):1861–9.\n\n【72】193.\n\n【73】Levillain, H., et al., International recommendations for personalised selective internal radiation therapy of primary and", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "Ilhan H, et al. Predictive value of 99mTc-MAA SPECT for", "bbox": [91.0, 73.0, 387.0, 87.0]}, {"text": "58.", "bbox": [72.0, 75.0, 89.0, 86.0]}, {"text": "90Y-labeled resin microsphere distribution in radioemboliza-", "bbox": [93.0, 88.0, 385.0, 101.0]}, {"text": "tion of primary and secondary hepatic tumors. J Nucl Med.", "bbox": [93.0, 101.0, 385.0, 114.0]}, {"text": "2015;56(11):1654 – 60.", "bbox": [93.0, 115.0, 197.0, 127.0]}, {"text": "59.", "bbox": [72.0, 128.0, 91.0, 139.0]}, {"text": "Wondergem M, et al. 99mTc-macroaggregated albumin poorly", "bbox": [91.0, 128.0, 386.0, 141.0]}, {"text": "predicts the intrahepatic distribution of 90Y resin microspheres", "bbox": [93.0, 141.0, 387.0, 153.0]}, {"text": "in hepatic radioembolization. J Nucl Med. 2013;54(8):1294–301. J", "bbox": [93.0, 155.0, 387.0, 167.0]}, {"text": "60.", "bbox": [72.0, 167.0, 91.0, 180.0]}, {"text": "Haste P, et al. Correlation of technetium-99m macroaggregated", "bbox": [89.0, 168.0, 387.0, 181.0]}, {"text": "albumin and yttrium-90 glass microsphere biodistribution in", "bbox": [93.0, 181.0, 387.0, 193.0]}, {"text": "hepatocellular carcinoma: a retrospective review of pretreatment", "bbox": [93.0, 195.0, 387.0, 206.0]}, {"text": "single photon emission ct and posttreatment positron emission", "bbox": [93.0, 208.0, 387.0, 220.0]}, {"text": "tomography/CT. J Vasc Interv Radiol. 2017;28(5):722–30.", "bbox": [93.0, 222.0, 365.0, 233.0]}, {"text": "61.", "bbox": [72.0, 235.0, 91.0, 247.0]}, {"text": "Garin E, et al. Boosted selective internal radiation therapy with", "bbox": [90.0, 235.0, 387.0, 247.0]}, {"text": "90Y-loaded glass microspheres (B-SIRT) for hepatocellular car-", "bbox": [93.0, 248.0, 385.0, 260.0]}, {"text": "cinoma patients: a new personalized promising concept. Eur J", "bbox": [93.0, 261.0, 387.0, 273.0]}, {"text": ",", "bbox": [73.0, 271.0, 82.0, 281.0]}, {"text": "Nucl Med Mol Imaging. 2013;40(7):1057–68.", "bbox": [91.0, 275.0, 306.0, 287.0]}, {"text": "62.", "bbox": [72.0, 287.0, 86.0, 299.0]}, {"text": "Garin E, et al. Dosimetry based on 99mTc-macroaggregated", "bbox": [91.0, 289.0, 387.0, 301.0]}, {"text": "albumin SPECT/CT accurately predicts tumor response and", "bbox": [93.0, 301.0, 387.0, 314.0]}, {"text": "survival in hepatocellular carcinoma patients treated with", "bbox": [93.0, 314.0, 387.0, 327.0]}, {"text": "90Y-loaded glass microspheres; preliminary results. J Nucl Med.", "bbox": [93.0, 328.0, 385.0, 340.0]}, {"text": "2012;53(2):255–63.", "bbox": [93.0, 341.0, 185.0, 354.0]}, {"text": "63. Chiesa C, et al. Need, feasibility and convenience of dosi-", "bbox": [72.0, 355.0, 385.0, 368.0]}, {"text": "metric treatment planning in liver selective internal radia-", "bbox": [93.0, 368.0, 385.0, 381.0]}, {"text": "tion therapy with (90)Y microspheres: the experience of the", "bbox": [93.0, 381.0, 387.0, 393.0]}, {"text": "National Tumor Institute of Milan. Q J Nucl Med Mol Imaging.", "bbox": [93.0, 394.0, 385.0, 407.0]}, {"text": "2011;55(2):168–97.", "bbox": [94.0, 408.0, 185.0, 420.0]}, {"text": "64. Ho CL, et al. Radioembolization with (90)Y glass microspheres", "bbox": [71.0, 419.0, 387.0, 434.0]}, {"text": "for hepatocellular carcinoma: significance of pretreatment (11)", "bbox": [93.0, 434.0, 387.0, 447.0]}, {"text": "C-acetate and (18)F-FDG PET/CT and posttreatment (90)Y PET/", "bbox": [93.0, 448.0, 387.0, 459.0]}, {"text": "CT in individualized dose prescription. Eur J Nucl Med Mol", "bbox": [93.0, 461.0, 387.0, 473.0]}, {"text": "Imaging. 2018;45(12):2110–21.", "bbox": [93.0, 475.0, 241.0, 487.0]}, {"text": "10.65.", "bbox": [70.0, 488.0, 89.0, 500.0]}, {"text": "Hermann AL, et al. Relationship of tumor radiation-absorbed", "bbox": [91.0, 488.0, 387.0, 501.0]}, {"text": "dose to survival and response in hepatocellular carcinoma treated", "bbox": [93.0, 502.0, 387.0, 513.0]}, {"text": "with transarterial radioembolization with (90)Y in the SARAH", "bbox": [93.0, 515.0, 387.0, 526.0]}, {"text": "study. Radiology. 2020;296(3):673–84.", "bbox": [93.0, 528.0, 273.0, 540.0]}, {"text": "66.", "bbox": [72.0, 541.0, 89.0, 552.0]}, {"text": "Lau WY, et al. Treatment of inoperable hepatocellular carcinoma", "bbox": [91.0, 541.0, 387.0, 553.0]}, {"text": "with intrahepatic arterial yttrium-90 microspheres: a phase I and", "bbox": [93.0, 554.0, 387.0, 567.0]}, {"text": "II study. Br J Cancer. 1994;70(5):994–9 .", "bbox": [93.0, 567.0, 287.0, 580.0]}, {"text": "67.", "bbox": [72.0, 581.0, 91.0, 592.0]}, {"text": "Garin, E., et al., Personalised versus standard dosimetry approach", "bbox": [89.0, 581.0, 387.0, 593.0]}, {"text": "of selective internal radiation therapy in patients with locally.", "bbox": [93.0, 594.0, 387.0, 607.0]}, {"text": "advanced hepatocellular carcinoma (DOSISPHERE-01): a rán-", "bbox": [93.0, 609.0, 387.0, 620.0]}, {"text": "domised, multicentre, open-label phase 2 trial. Lancet Gastroen-", "bbox": [93.0, 621.0, 385.0, 634.0]}, {"text": "terol Hepatol  ,  2020", "bbox": [93.0, 634.0, 185.0, 647.0]}, {"text": "68.", "bbox": [72.0, 647.0, 90.0, 660.0]}, {"text": "Smits MLJ, et al. The superior predictive value of (166)Ho-scout", "bbox": [91.0, 647.0, 387.0, 660.0]}, {"text": "compared with (99m)Tc-macroaggregated albumin prior to (166)", "bbox": [93.0, 662.0, 387.0, 674.0]}, {"text": "Ho-microspheres radioembolization in patients with liver metas-", "bbox": [93.0, 676.0, 385.0, 687.0]}, {"text": "tases. Eur J Nucl Med Mol Imaging. 2020;47(4):798–806.", "bbox": [93.0, 688.0, 361.0, 700.0]}, {"text": "69.", "bbox": [72.0, 701.0, 91.0, 713.0]}, {"text": "Salem R, et al. Clinical and dosimetric considerations for Y90:", "bbox": [90.0, 701.0, 387.0, 713.0]}, {"text": "recommendations from an international multidisciplinary work-", "bbox": [93.0, 714.0, 385.0, 727.0]}, {"text": "ing group. Eur J Nucl Med Mol Imaging. 2019;46(8):1695–704.", "bbox": [93.0, 728.0, 385.0, 741.0]}, {"text": "70. Lewandowski RJ, et al. Radiation segmentectomy: potential", "bbox": [73.0, 741.0, 387.0, 755.0]}, {"text": "curative therapy for early hepatocellular carcinoma. Radiology.", "bbox": [91.0, 755.0, 386.0, 768.0]}, {"text": "2018;287(3):1050–8.", "bbox": [94.0, 768.0, 192.0, 779.0]}, {"text": "71.", "bbox": [72.0, 780.0, 90.0, 793.0]}, {"text": "Meiers C, et al. Safety and initial efficacy of radiation segmen-", "bbox": [91.0, 780.0, 385.0, 793.0]}, {"text": "tectomy for the treatment of hepatic metastases. J Gastrointest", "bbox": [93.0, 795.0, 387.0, 807.0]}, {"text": "Oncol. 2018;9(2):311–5.", "bbox": [93.0, 808.0, 209.0, 821.0]}, {"text": "72.", "bbox": [72.0, 821.0, 91.0, 832.0]}, {"text": "Padia SA, et al. Superselective yttrium-90 radioembolization for", "bbox": [90.0, 821.0, 387.0, 834.0]}, {"text": "hepatocellular carcinoma yields high response rates with mini-", "bbox": [93.0, 835.0, 386.0, 847.0]}, {"text": "mal toxicity. J Vasc Interv Radiol. 2014;25(7):1067–73. [ 1 ],", "bbox": [93.0, 848.0, 363.0, 860.0]}, {"text": "73. Biederman DM, et al. Radiation segmentectomy versus selective", "bbox": [72.0, 860.0, 387.0, 875.0]}, {"text": "chemoembolization in the treatment of early-stage hepatocellular", "bbox": [93.0, 874.0, 387.0, 887.0]}, {"text": "carcinoma. J Vasc Interv Radiol. 2018;29(1):30–7 e2 .", "bbox": [93.0, 887.0, 340.0, 901.0]}, {"text": "74.", "bbox": [72.0, 900.0, 91.0, 912.0]}, {"text": "Garin E, et al. Personalized dosimetry with intensification using", "bbox": [91.0, 902.0, 387.0, 913.0]}, {"text": "90Y-loaded glass microsphere radioembolization induces pro-", "bbox": [93.0, 915.0, 385.0, 927.0]}, {"text": "longed overall survival in hepatocellular carcinoma patients with", "bbox": [93.0, 929.0, 387.0, 940.0]}, {"text": "portal vein thrombosis. J Nucl Med. 2015;56(3):339–46.", "bbox": [93.0, 941.0, 354.0, 953.0]}], "type": "Text", "position": 0}, {"raw_context": [{"text": "75.", "bbox": [412.0, 73.0, 431.0, 86.0]}, {"text": "Konijnenberg M., et al. EANM position paper on article 56 of", "bbox": [430.0, 72.0, 729.0, 87.0]}, {"text": "the Council Directive 2013/59/Euratom (basic safety standards)", "bbox": [433.0, 87.0, 727.0, 100.0]}, {"text": "for nuclear medicine therapy. Eur J Nucl Med Mol Imaging.", "bbox": [434.0, 101.0, 725.0, 114.0]}, {"text": "2021:48(1);67–72", "bbox": [435.0, 114.0, 520.0, 126.0]}, {"text": "76.", "bbox": [412.0, 128.0, 430.0, 139.0]}, {"text": "Ho S, et al. Partition model for estimating radiation doses from", "bbox": [432.0, 128.0, 727.0, 140.0]}, {"text": "yttrium-90 microspheres in treating hepatic tumours. Eur J Nucl", "bbox": [436.0, 141.0, 727.0, 153.0]}, {"text": "Med. 1996;23(8):947–52.", "bbox": [434.0, 154.0, 551.0, 167.0]}, {"text": "Chiesa C, et al. Radioembolization of hepatocarcinoma with (90)", "bbox": [431.0, 165.0, 728.0, 182.0]}, {"text": "77.", "bbox": [411.0, 167.0, 429.0, 179.0]}, {"text": "Y glass microspheres: development of an individualized treat-", "bbox": [435.0, 181.0, 726.0, 193.0]}, {"text": "ment planning strategy based on dosimetry and radiobiology. Eur", "bbox": [434.0, 194.0, 727.0, 206.0]}, {"text": "J Nucl Med Mol Imaging. 2015;42(11):1718–38.", "bbox": [434.0, 208.0, 659.0, 220.0]}, {"text": "78.", "bbox": [412.0, 221.0, 430.0, 232.0]}, {"text": "Chiesa C, Bardies M, Zaidi H. Voxel-based dosimetry is supe-", "bbox": [432.0, 221.0, 726.0, 233.0]}, {"text": "rior to mean absorbed dose approach for establishing dose-", "bbox": [433.0, 234.0, 726.0, 247.0]}, {"text": "effect relationship in targeted radionuclide therapy. Med Phys.", "bbox": [433.0, 247.0, 726.0, 261.0]}, {"text": "2019;46(12):5403–6.", "bbox": [435.0, 261.0, 531.0, 273.0]}, {"text": "79.", "bbox": [412.0, 273.0, 428.0, 285.0]}, {"text": "Dewaraja YK, et al. Prediction of tumor control in (90)Y radi-", "bbox": [432.0, 273.0, 725.0, 286.0]}, {"text": "oembolization by logit models with PET/CT-based dose metrics.", "bbox": [434.0, 288.0, 726.0, 300.0]}, {"text": "J Nucl Med. 2020;61(1):104–11.", "bbox": [434.0, 301.0, 586.0, 313.0]}, {"text": "Kappadath SC, et al. Hepatocellular carcinoma tumor dose", "bbox": [432.0, 313.0, 727.0, 326.0]}, {"text": "80.", "bbox": [411.0, 314.0, 430.0, 325.0]}, {"text": "response after (90)Y-radioembolization with glass microspheres", "bbox": [432.0, 327.0, 727.0, 340.0]}, {"text": "using (90)Y-SPECT/CT-based voxel dosimetry. Int J Radiat", "bbox": [433.0, 341.0, 727.0, 353.0]}, {"text": "Oncol Biol Phys. 2018;102(2):451–61.", "bbox": [433.0, 354.0, 614.0, 367.0]}, {"text": "381. Chiesa, C., et al. EANM dosimetry committee series on standard", "bbox": [411.0, 367.0, 728.0, 380.0]}, {"text": "operational procedures: a unified methodology for 99m Tc-MAA", "bbox": [432.0, 381.0, 727.0, 392.0]}, {"text": "pre- and 90 Y peri-therapy dosimetry in liver radioembolization", "bbox": [432.0, 393.0, 727.0, 407.0]}, {"text": "with 90 Y microspheres. EJNMMI Phys. 2021:8(1);77", "bbox": [434.0, 408.0, 685.0, 420.0]}, {"text": "82.", "bbox": [411.0, 421.0, 429.0, 433.0]}, {"text": "Roosen, J., et al., To 1000 Gy and back again: a systematic review", "bbox": [432.0, 421.0, 727.0, 434.0]}, {"text": "on dose-response evaluation in selective internal radiation ther-", "bbox": [433.0, 434.0, 726.0, 446.0]}, {"text": "apy for primary and secondary liver cancer. Eur J Nucl Med Mol", "bbox": [434.0, 448.0, 727.0, 459.0]}, {"text": "Imaging, 2021.", "bbox": [434.0, 461.0, 503.0, 473.0]}, {"text": "83.", "bbox": [411.0, 473.0, 429.0, 486.0]}, {"text": "Salem R, et al. Yttrium-90 radioembolization for the treatment", "bbox": [432.0, 472.0, 727.0, 487.0]}, {"text": "of solitary, unresectable hepatocellular carcinoma: the LEGACY", "bbox": [433.0, 487.0, 725.0, 501.0]}, {"text": "study. Hepatology. 2021.", "bbox": [433.0, 502.0, 549.0, 514.0]}, {"text": "84.", "bbox": [411.0, 514.0, 428.0, 525.0]}, {"text": "Lewandowski RJ, et  al. (90) Y radiation lobectomy: out-", "bbox": [432.0, 514.0, 726.0, 526.0]}, {"text": "comes following surgical resection in patients with hepatic", "bbox": [432.0, 527.0, 726.0, 540.0]}, {"text": "tumors and small future liver remnant volumes. J Surg Oncol.", "bbox": [433.0, 542.0, 726.0, 553.0]}, {"text": "2016;114(1):99–105.", "bbox": [434.0, 553.0, 533.0, 566.0]}, {"text": "85.", "bbox": [411.0, 567.0, 429.0, 579.0]}, {"text": "Palard X, et al. Dosimetric parameters predicting contralat-", "bbox": [432.0, 567.0, 726.0, 581.0]}, {"text": "eral liver hypertrophy after unilobar radioembolization of", "bbox": [433.0, 581.0, 727.0, 593.0]}, {"text": "hepatocellular carcinoma. Eur J Nucl Med Mol Imaging.", "bbox": [433.0, 595.0, 725.0, 607.0]}, {"text": "2018;45(3):392–401.", "bbox": [434.0, 608.0, 531.0, 620.0]}, {"text": "Chiesa C, et al. Radioembolization of hepatocarcinoma with", "bbox": [432.0, 619.0, 728.0, 635.0]}, {"text": "86.", "bbox": [411.0, 621.0, 430.0, 633.0]}, {"text": "(90)Y glass microspheres: treatment optimization using the", "bbox": [433.0, 634.0, 727.0, 646.0]}, {"text": "dose-toxicity relationship. Eur J Nucl Med Mol Imaging.", "bbox": [432.0, 647.0, 726.0, 661.0]}, {"text": "2020;47(13):3018–32.", "bbox": [435.0, 662.0, 538.0, 673.0]}, {"text": "Shepherd FA, et al. A phase I dose escalation trial of yttrium-90", "bbox": [432.0, 672.0, 728.0, 687.0]}, {"text": "87.", "bbox": [411.0, 674.0, 429.0, 686.0]}, {"text": "microspheres in the treatment of primary hepatocellular carci-", "bbox": [433.0, 687.0, 726.0, 700.0]}, {"text": "noma. Cancer. 1992;70(9):2250–4.", "bbox": [433.0, 701.0, 594.0, 713.0]}, {"text": "Bourien H, et al. Yttrium-90 glass microspheres radioemboliza- 7", "bbox": [432.0, 713.0, 730.0, 727.0]}, {"text": "88.", "bbox": [411.0, 714.0, 428.0, 726.0]}, {"text": "tion (RE) for biliary tract cancer: a large single-center experi-", "bbox": [433.0, 728.0, 727.0, 741.0]}, {"text": "ence. Eur J Nucl Med Mol Imaging. 2019;46(3):669–76.", "bbox": [433.0, 742.0, 695.0, 754.0]}, {"text": "89.", "bbox": [411.0, 754.0, 429.0, 765.0]}, {"text": "Mouli S, et al. Yttrium-90 radioembolization for intrahepatic", "bbox": [432.0, 754.0, 727.0, 766.0]}, {"text": "cholangiocarcinoma: safety, response, and survival analysis. J", "bbox": [433.0, 768.0, 727.0, 779.0]}, {"text": "Vasc Interv Radiol. 2013;24(8):1227–34.", "bbox": [435.0, 781.0, 623.0, 793.0]}, {"text": "90.", "bbox": [411.0, 793.0, 429.0, 805.0]}, {"text": "Padia SA, et al. Yttrium-90 radiation segmentectomy for hepatic", "bbox": [432.0, 794.0, 727.0, 807.0]}, {"text": "metastases: a multi-institutional study of safety and efficacy. J", "bbox": [434.0, 807.0, 727.0, 821.0]}, {"text": "Surg Oncol. 2021;123(1):172–8.", "bbox": [434.0, 821.0, 585.0, 833.0]}, {"text": "91.", "bbox": [411.0, 834.0, 428.0, 845.0]}, {"text": "Alsultan, A.A., et al., Dose-response and dose-toxicity relation-", "bbox": [433.0, 834.0, 726.0, 846.0]}, {"text": "ships for yttrium-90 glass radioembolization in patients with", "bbox": [434.0, 848.0, 727.0, 860.0]}, {"text": "colorectal cancer liver metastases. J Nucl Med, 2021.", "bbox": [433.0, 862.0, 678.0, 873.0]}, {"text": "92.", "bbox": [411.0, 873.0, 428.0, 886.0]}, {"text": "Lewandowski RJ, et al. Twelve-year experience of radioembo-", "bbox": [432.0, 874.0, 726.0, 887.0]}, {"text": "lization for colorectal hepatic metastases in 214 patients: sur-", "bbox": [434.0, 887.0, 726.0, 900.0]}, {"text": "vival by era and chemotherapy. Eur J Nucl Med Mol Imaging.", "bbox": [434.0, 901.0, 726.0, 913.0]}, {"text": "2014;41(10):1861–9.", "bbox": [435.0, 915.0, 532.0, 926.0]}, {"text": "193.", "bbox": [411.0, 928.0, 430.0, 940.0]}, {"text": "Levillain, H., et al., International recommendations for per-", "bbox": [432.0, 928.0, 727.0, 940.0]}, {"text": "sonalised selective internal radiation therapy of primary and", "bbox": [435.0, 940.0, 727.0, 955.0]}], "type": "Text", "position": 3}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2022】全科室最全临床指南+专家共识（最全版）/2022全科室临床指南/肿瘤科/EANM：动脉内放射性化合物治疗肝癌和转移性肝癌指南（2022）(1).pdf", "page_num": 16}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": null, "type3": null, "type4": null, "type5": null, "type6": "有用性#0#73#全篇为其他参考文献内容"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:40", "update_time": "2024-05-08 00:35:36"}
{"id": 1082528, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 738, "source_info": {"seq_id": "7affa557-fad0-446b-af88-f215c789cc43", "title": null, "text": "【0】页码:1\n available at www.sciencedirect.com journal homepage: www.europeanurology.com\n\n【1】 Review – Penile Cancer\n\n【2】## European Association Of Urology-American Society Of Clinical Oncology Collaborative Guideline On Penile Cancer: 2023 Update\n\n【3】\n Oscar R. Brouwer α , * , Maarten Albersen b , Arie Parnham c , Chris Protzel α , Curtis A. Pettaway c , Benjamin Ayres f , Tiago Antunes-Lopes ® , Lenka Barreto h , Riccardo Campi f , Juanita Crook f , Sergio Fernández-Pello k , Isabella Greco 1 , Michiel S. van der Heijden ™ , Peter A.S. Johnstone ™ , Mithun Kailavasan ® , Kenneth Manzie ® , Jack David Marcus ® , Andrea Necchi ® , Pedro Oliveira ® , . . . , John Osborne P , Lance C. Pagliaro v , Herney A. Garcia-Perdomo w , R. Bryan Rumble x , Ashwin Sachdeva 9 , Vasileios I. Sakalis 2 , Łukasz Zapala aa , Diego F. Sánchez Martínez bb , Philippe E. Spiess cc , Scott T. Tagawa dd\n\n【4】 ² The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands; b Department of Urology, University Hospitals Leuven, Leuven, Belgium: '' Department of Urology, The Christie NHS Foundation Trust, Manchester, UK: a Helios Clinics Schwerin, Schwerin, Germany: '' The University of Texas MD Anderson Cancer Center, Houston, TX, USA; ⸢ Department of Urology, St George's University Hospitals NHS Foundation Trust, London, UK ; 8 Department of Urology, Hospital de S. João, Porto, Portugal; h Department of Urology, University Hospital Nitra, Nitra, Slovakia; † Unit of Oncologic Minimally- Invasive Urology and Andrology, Careggi University Hospital, San Luca Nuovo, Florence, Italy: † British Columbia Cancer Agency, University of British Columbia, Kelowna, Canada ; k Department of Urology, Cabueñes University Hospital, Gijón, Spain ; ' Department of Urological Minimally Invasive and Robotic Surgery and Kidney Transplantation, Careggi Hospital, University of Florence, Florence, Italy; m Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands; \" Departments of Radiation Oncology and Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, USA : \" Nottingham City Hospital, Nottingham, UK; P Orchid, London, UK; a Multicancer Fighter Patient Advocate, Us TOO, New York, NY, USA; ' Department of Urology and Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; c Department of Pathology, The Christie NHS Foundation Trust, Manchester, UK: c Centre for the Research and Technology of Agro-Environmental and Biological Sciences, University of Trásos-Montes and Alto Douro, Vila Real, Portugal: \" Veterinary Sciences Department, University of Trásos-Montes and Alto Douro, Vila Real, Portugal; º Department of Oncology, Mayo Clinic, Rochester, MN, USA; '\" Division of Urology/Uro-oncology, Department of Surgery, School of Medicine, Universidad Del Valle, Cali, Colombia; * American Society of Clinical Oncology, Alexandria, VA, USA; ª Division of Cancer Sciences, University of Manchester, Manchester, UK; ² Department of Urology, Agios Pavlos General Hospital, Thessaloniki, Greece; ³² Department of Urology, Medical University of Warsaw, Warsaw, Poland; ¹ ⁰ Facultad de Ciencias Medicas, Universidad Nacional de Asuncion, Asuncion, Paraguay; \" Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FI, USA;  dd Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York, NY, USA\n\n【5】 Article info\n\n【6】 Article history: Accepted February 25, 2023 Associate Editor: James Catto Keywords : Penile cancer\n\n【7】\n## Abstract\n\n【8】\n Context: Penile cancer is a rare disease but has a significant impact on quality of life. Its incidence is increasing, so it is important to include new and relevant evidence in clinical practice guidelines.\n\n【9】Objective: To provide a collaborative guideline that offers worldwide physician and patient guidance for the management of penile cancer.\n\n【10】Evidence acquisition: Comprehensive literature searches were performed for each section topic. In addition, three systematic reviews were conducted. Levels of evidence were assessed,\n\n【11】 * Corresponding author. The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands. Tel. +31 6 2598 7321.\n\n【12】E-mail address: o.brouwer@nki.nl (O.R. Brouwer).\n\n【13】 https://doi.org/10.1016/j.eururo.2023.02.027 0302-2838/© 2023 European Association of Urology. Published by Elsevier B.V. All rights reserved.", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "available at www.sciencedirect.com", "bbox": [67.0, 84.0, 287.0, 97.0]}, {"text": "journal homepage: www.europeanurology.com", "bbox": [66.0, 99.0, 352.0, 113.0]}], "type": "Text", "position": 2}, {"raw_context": [{"text": "Review – Penile Cancer", "bbox": [67.0, 225.0, 228.0, 240.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": "European Association of Urology-American Society of Clinical", "bbox": [66.0, 261.0, 672.0, 285.0]}, {"text": "Oncology Collaborative Guideline on Penile Cancer: 2023 Update", "bbox": [66.0, 289.0, 703.0, 315.0]}], "type": "Section-header", "position": 6}, {"raw_context": [{"text": "Oscar R. Brouwer α , * , Maarten Albersen b , Arie Parnham c , Chris Protzel α , Curtis A. Pettaway c ,", "bbox": [66.0, 338.0, 701.0, 360.0]}, {"text": "Benjamin Ayres f , Tiago Antunes-Lopes ® , Lenka Barreto h , Riccardo Campi f , Juanita Crook f ,", "bbox": [66.0, 360.0, 683.0, 378.0]}, {"text": "Sergio Fernández-Pello k , Isabella Greco 1 , Michiel S. van der Heijden ™ , Peter A.S. Johnstone ™ ,", "bbox": [66.0, 379.0, 694.0, 398.0]}, {"text": "Mithun Kailavasan ® , Kenneth Manzie ® , Jack David Marcus ® , Andrea Necchi ® , Pedro Oliveira ® , . . . ,", "bbox": [66.0, 400.0, 721.0, 418.0]}, {"text": "John Osborne P , Lance C. Pagliaro v , Herney A. Garcia-Perdomo w , R. Bryan Rumble x ,", "bbox": [66.0, 418.0, 634.0, 436.0]}, {"text": "Ashwin Sachdeva 9 , Vasileios I. Sakalis 2 , Łukasz Zapala aa , Diego F. Sánchez Martínez bb ,", "bbox": [66.0, 439.0, 657.0, 455.0]}, {"text": "Philippe E. Spiess cc , Scott T. Tagawa dd", "bbox": [66.0, 456.0, 330.0, 476.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "² The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands; b Department of Urology, University Hospitals Leuven,", "bbox": [66.0, 485.0, 731.0, 499.0]}, {"text": "Leuven, Belgium: '' Department of Urology, The Christie NHS Foundation Trust, Manchester, UK: a Helios Clinics Schwerin, Schwerin, Germany: '' The University", "bbox": [67.0, 500.0, 732.0, 512.0]}, {"text": "of Texas MD Anderson Cancer Center, Houston, TX, USA; ⸢ Department of Urology, St George's University Hospitals NHS Foundation Trust, London, UK ;", "bbox": [67.0, 513.0, 731.0, 525.0]}, {"text": "8 Department of Urology, Hospital de S. João, Porto, Portugal; h Department of Urology, University Hospital Nitra, Nitra, Slovakia; † Unit of Oncologic Minimally-", "bbox": [67.0, 526.0, 731.0, 539.0]}, {"text": "Invasive Urology and Andrology, Careggi University Hospital, San Luca Nuovo, Florence, Italy: † British Columbia Cancer Agency, University of British Columbia,", "bbox": [67.0, 540.0, 731.0, 553.0]}, {"text": "Kelowna, Canada ; k Department of Urology, Cabueñes University Hospital, Gijón, Spain ; ' Department of Urological Minimally Invasive and Robotic Surgery and", "bbox": [67.0, 554.0, 732.0, 566.0]}, {"text": "Kidney Transplantation, Careggi Hospital, University of Florence, Florence, Italy; m Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam,", "bbox": [67.0, 566.0, 732.0, 579.0]}, {"text": "The Netherlands; \" Departments of Radiation Oncology and Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, USA : \" Nottingham City Hospital,", "bbox": [67.0, 579.0, 732.0, 592.0]}, {"text": "Nottingham, UK; P Orchid, London, UK; a Multicancer Fighter Patient Advocate, Us TOO, New York, NY, USA; ' Department of Urology and Medical Oncology,", "bbox": [67.0, 593.0, 732.0, 606.0]}, {"text": "Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; c Department of Pathology, The Christie NHS Foundation Trust, Manchester, UK: c Centre for the", "bbox": [67.0, 607.0, 733.0, 619.0]}, {"text": "Research and Technology of Agro-Environmental and Biological Sciences, University of Trásos-Montes and Alto Douro, Vila Real, Portugal: \" Veterinary Sciences", "bbox": [67.0, 620.0, 733.0, 632.0]}, {"text": "Department, University of Trásos-Montes and Alto Douro, Vila Real, Portugal; º Department of Oncology, Mayo Clinic, Rochester, MN, USA; '\" Division of", "bbox": [67.0, 633.0, 733.0, 645.0]}, {"text": "Urology/Uro-oncology, Department of Surgery, School of Medicine, Universidad Del Valle, Cali, Colombia; * American Society of Clinical Oncology, Alexandria,", "bbox": [67.0, 646.0, 732.0, 659.0]}, {"text": "VA, USA; ª Division of Cancer Sciences, University of Manchester, Manchester, UK; ² Department of Urology, Agios Pavlos General Hospital, Thessaloniki, Greece;", "bbox": [67.0, 660.0, 731.0, 673.0]}, {"text": "³² Department of Urology, Medical University of Warsaw, Warsaw, Poland; ¹ ⁰ Facultad de Ciencias Medicas, Universidad Nacional de Asuncion, Asuncion,", "bbox": [68.0, 672.0, 732.0, 686.0]}, {"text": "Paraguay; \" Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FI, USA;  dd Division of Hematology and", "bbox": [67.0, 686.0, 732.0, 698.0]}, {"text": "Medical Oncology, Weill Cornell Medical College, New York, NY, USA", "bbox": [67.0, 700.0, 361.0, 712.0]}], "type": "Text", "position": 8}, {"raw_context": [{"text": "Article info", "bbox": [66.0, 741.0, 132.0, 756.0]}], "type": "Text", "position": 9}, {"raw_context": [{"text": "Article history:", "bbox": [66.0, 767.0, 148.0, 781.0]}, {"text": "Accepted February 25, 2023", "bbox": [66.0, 783.0, 221.0, 796.0]}, {"text": "Associate Editor:", "bbox": [66.0, 811.0, 160.0, 824.0]}, {"text": "James Catto", "bbox": [67.0, 826.0, 134.0, 838.0]}, {"text": "Keywords :", "bbox": [67.0, 856.0, 127.0, 868.0]}, {"text": "Penile cancer", "bbox": [67.0, 869.0, 140.0, 881.0]}], "type": "Table", "position": 10}, {"raw_context": [{"text": "Abstract", "bbox": [286.0, 740.0, 335.0, 754.0]}], "type": "Section-header", "position": 12}, {"raw_context": [{"text": "Context: Penile cancer is a rare disease but has a significant impact on quality of life. Its", "bbox": [286.0, 767.0, 733.0, 781.0]}, {"text": "incidence is increasing, so it is important to include new and relevant evidence in clinical", "bbox": [286.0, 781.0, 733.0, 796.0]}, {"text": "practice guidelines.", "bbox": [287.0, 796.0, 387.0, 809.0]}, {"text": "Objective: To provide a collaborative guideline that offers worldwide physician and", "bbox": [286.0, 809.0, 733.0, 823.0]}, {"text": "patient guidance for the management of penile cancer.", "bbox": [287.0, 824.0, 569.0, 836.0]}, {"text": "Evidence acquisition: Comprehensive literature searches were performed for each section", "bbox": [287.0, 838.0, 733.0, 849.0]}, {"text": "topic. In addition, three systematic reviews were conducted. Levels of evidence were assessed,", "bbox": [287.0, 851.0, 732.0, 863.0]}], "type": "Text", "position": 13}, {"raw_context": [{"text": "* Corresponding author. The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital,", "bbox": [287.0, 922.0, 732.0, 934.0]}, {"text": "Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands. Tel. +31 6 2598 7321.", "bbox": [287.0, 934.0, 644.0, 946.0]}, {"text": "E-mail address: o.brouwer@nki.nl (O.R. Brouwer).", "bbox": [287.0, 946.0, 508.0, 958.0]}], "type": "Text", "position": 14}, {"raw_context": [{"text": "https://doi.org/10.1016/j.eururo.2023.02.027", "bbox": [67.0, 982.0, 267.0, 993.0]}, {"text": "0302-2838/© 2023 European Association of Urology. Published by Elsevier B.V. All rights reserved.", "bbox": [67.0, 992.0, 509.0, 1005.0]}], "type": "Text", "position": 15}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/泌尿外科/2023 EAU／ASCO指南：阴茎癌（更新版）.pdf", "page_num": 1}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": null, "type3": null, "type4": null, "type5": null, "type6": "有用性#0#13#属于首页文章信息摘要等内容"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:40", "update_time": "2024-05-07 22:51:58"}
{"id": 1082527, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 738, "source_info": {"seq_id": "8e7d9451-1165-4335-a166-07cb5f6ac9b7", "title": null, "text": "【0】页码:20\n  Guideline\n\n【1】 Table 4 Drugs in pregnancy and breast feeding Breast feeding Agent Pregnancy Local anaesthetic throat spray Compatible for use Compatible for use Nitrous oxide Compatible for use Compatible for use Hyoscine Single dose probably safe if needed Compatible for use Benzodiazepines Diazepam to be avoided Breast feeding can continue when mother alert and awake Midazolam can be used for procedural sedation Opioids Compatible for use Breast feeding can continue when mother awake and alert Compatible for use Breast feeding can continue when mother alert and awake Propofol\n\n【2】\n risk of aspiration as pregnancy progresses and the possibility of medication-related effects on the fetus, particularly early in pregnancy. 230 231 Additionally, positioning for endoscopy can become more challenging later in pregnancy, particularly for procedures such as ERCP, which again may increase the aspiration risk. Early anaesthetic involvement is important to assess whether deep sedation or general anaesthesia with airway protection should be considered. If conscious sedation is deemed appropriate then the lowest effective doses should be administered. Opiates and propofol appear to have the best safety profile Prolonged use of diazepam has been associated with neurological birth defects, but no study has examined single doses of midazolam used for an endoscopic procedure in this setting. 232 If a benzodiazepine is needed then midazolam is recommended.\n\n【3】Table 4 delineates recommendations for drugs used in endoscopy in the pregnant patient or those who are breast feeding.\n\n【4】## Breast Feeding\n\n【5】\n In general, most sedative and anaesthetic agents have poor oral bioavailability and although some are excreted into breast milk, the concentrations are low. 233 Midazolam is excreted into breast milk, but the levels are virtually undetectable around 7 hours after administration, with studies finding a level of 0.004% of the maternal dose within 24 hours. 234 235 The latest national guidance suggests that breast feeding can recommence once the patient has recovered enough cognitive function. 233 236 Fentanyl is excreted into breast milk, but the levels are 0.024% within 24 hours of administration, meaning that breast feeding does not need to be suspended. 235 236 Pethidine is metabolised to normeperidine, which can cause neurotoxic effects. Normeperidine is concentrated in breast milk and has been associated with neurological effects in breastfeeding children, but one study showed that this was seen only in infants under 6 weeks old. 237 However, there is no evidence that a single intravenous dose of pethidine leads to significant toxicity in breastfeeding infants. Propofol is excreted into breast milk but at very low levels and the oral bioavailability is low. Breast feeding after propofol does not need to be suspended and can be resumed as soon as the patient has recovered from anaesthesia. 125 253\n\n【6】## Adjunctive Medications\n\n【7】\n Several other medications are regularly used in patients undergoing gastrointestinal endoscopy, including local anaesthetic agents, nitrous oxide and hyoscine. Local anaesthetic agents have been shown to cause fetal bradycardia when used intravenously, but the amounts used in topical throat spray are unlikely to cause problems for either the unborn child or the breastfeeding infant. Nitrous oxide is commonly used during labour and is safe. Nitrous oxide is eliminated extremely quickly and therefore has no consequences for the breastfeeding infant.\n\n【8】 Regular use of hyoscine is not recommended in pregnancy, but this can be a useful adjunct in both colonoscopy and ERCP.\n\n【9】Fortunately, these procedures are rarely required in pregnancy but should a single dose of hyoscine be required then this could be considered. There appear to be no consequences of using hyoscine during breast feeding. Table 4 details safety of drugs in pregnancy.\n\n【10】## Special Considerations: Transition Group\n\n【11】\n 48. We recommend that young patients undergoing endoscopy should participate in a structured transition programme, including education around the choice of sedative agents Grade of evidence: Very Low. Strength of recommendation: Strong.\n\n【12】Level of agreement: 92.3% 49. We recommend that information about the risks and benefits of endoscopy with sedation should be tailored to the individual young person Grade of evidence: Very Low. Strength of recommendation: Strong.\n\n【13】Level of agreement: 100%\n\n【14】 Young patients (aged 16–18 years) undergoing endoscopy may be having investigation or endoscopic therapy for a chronic condition for which they have been under the care of paediatric services. Young people transitioning from paediatric to adult services (with previous experience of endoscopy under a general anaesthetic) will probably benefit from participating in a structured transition programme. 238 Such patients might have undergone previous procedures under general anaesthetic. This might influence their expectations and preconceptions when they move into adult services, where general anaesthetic is not routinely used for most endoscopic procedures.\n\n【15】For all young patients, a discussion about the choice of sedation and alternatives (such as the use of a general anaesthetic) will be framed on a case-by-case basis. Factors such as patient anxiety, complexity and length of the procedures should be taken into account.\n\n【16】Young people (16–18 years) are presumed to have capacity to consent for endoscopic procedures. 22 Parents and other primary caregivers may assist in the discussions with the young person about the procedure. Information should be provided in a format that is suitable for the individual patient. The intended effect of sedation in a young person is the same as in an adult population— that is, to facilitate a successful endoscopic procedure by minimising anxiety or discomfort. 2\n\n【17】## Special Considerations: Including Learning Disability\n\n【18】\n 50. We recommend that in patients with cognitive impairment and/or learning disability, an assessment of capacity is carried out to inform the discussion around choice of sedation Grade of evidence: Very Low. Strength of recommendation: Strong.\n\n【19】 2020", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": " Guideline", "bbox": [54.0, 30.0, 127.0, 46.0]}], "type": "Text", "position": 0}, {"raw_context": [{"text": "Table 4 Drugs in pregnancy and breast feeding", "bbox": [58.0, 68.0, 287.0, 82.0]}, {"text": "Breast feeding", "bbox": [483.0, 89.0, 548.0, 101.0]}, {"text": "Agent", "bbox": [58.0, 90.0, 88.0, 101.0]}, {"text": "Pregnancy", "bbox": [252.0, 90.0, 299.0, 101.0]}, {"text": "Local anaesthetic throat spray", "bbox": [59.0, 107.0, 176.0, 120.0]}, {"text": "Compatible for use", "bbox": [252.0, 107.0, 327.0, 119.0]}, {"text": "Compatible for use", "bbox": [483.0, 107.0, 557.0, 119.0]}, {"text": "Nitrous oxide", "bbox": [59.0, 123.0, 114.0, 135.0]}, {"text": "Compatible for use", "bbox": [252.0, 123.0, 328.0, 135.0]}, {"text": "Compatible for use", "bbox": [483.0, 123.0, 558.0, 135.0]}, {"text": "Hyoscine", "bbox": [59.0, 138.0, 96.0, 150.0]}, {"text": "Single dose probably safe if needed", "bbox": [252.0, 137.0, 390.0, 150.0]}, {"text": "Compatible for use", "bbox": [483.0, 138.0, 557.0, 150.0]}, {"text": "Benzodiazepines", "bbox": [59.0, 151.0, 125.0, 169.0]}, {"text": "Diazepam to be avoided", "bbox": [252.0, 153.0, 348.0, 165.0]}, {"text": "Breast feeding can continue when mother alert and awake", "bbox": [483.0, 153.0, 708.0, 167.0]}, {"text": "Midazolam can be used for procedural sedation", "bbox": [252.0, 165.0, 436.0, 179.0]}, {"text": "Opioids", "bbox": [59.0, 181.0, 91.0, 195.0]}, {"text": "Compatible for use", "bbox": [252.0, 181.0, 327.0, 194.0]}, {"text": "Breast feeding can continue when mother awake and alert", "bbox": [482.0, 182.0, 709.0, 193.0]}, {"text": "Compatible for use", "bbox": [252.0, 195.0, 328.0, 210.0]}, {"text": "Breast feeding can continue when mother alert and awake", "bbox": [483.0, 195.0, 708.0, 210.0]}, {"text": "Propofol", "bbox": [58.0, 196.0, 94.0, 210.0]}], "type": "Table", "position": 1}, {"raw_context": [{"text": "risk of aspiration as pregnancy progresses and the possibility of", "bbox": [53.0, 249.0, 386.0, 263.0]}, {"text": "medication-related effects on the fetus, particularly early in preg-", "bbox": [53.0, 264.0, 384.0, 277.0]}, {"text": "nancy. 230 231 Additionally, positioning for endoscopy can become", "bbox": [53.0, 276.0, 386.0, 293.0]}, {"text": "more challenging later in pregnancy, particularly for procedures", "bbox": [53.0, 293.0, 386.0, 307.0]}, {"text": "such as ERCP, which again may increase the aspiration risk. Early", "bbox": [53.0, 307.0, 385.0, 322.0]}, {"text": "anaesthetic involvement is important to assess whether deep", "bbox": [53.0, 322.0, 385.0, 337.0]}, {"text": "sedation or general anaesthesia with airway protection should", "bbox": [53.0, 337.0, 385.0, 351.0]}, {"text": "be considered. If conscious sedation is deemed appropriate then", "bbox": [53.0, 352.0, 385.0, 367.0]}, {"text": "the lowest effective doses should be administered. Opiates and", "bbox": [53.0, 367.0, 385.0, 380.0]}, {"text": "propofol appear to have the best safety profile", "bbox": [53.0, 381.0, 295.0, 395.0]}, {"text": "Prolonged use of diazepam has been associated with neuro-", "bbox": [65.0, 396.0, 385.0, 410.0]}, {"text": "logical birth defects, but no study has examined single doses of", "bbox": [53.0, 410.0, 385.0, 425.0]}, {"text": "midazolam used for an endoscopic procedure in this setting. 232", "bbox": [53.0, 425.0, 381.0, 439.0]}, {"text": "If a benzodiazepine is needed then midazolam is recommended.", "bbox": [53.0, 440.0, 385.0, 454.0]}, {"text": "Table 4 delineates recommendations for drugs used in endos-", "bbox": [54.0, 455.0, 384.0, 468.0]}, {"text": "copy in the pregnant patient or those who are breast feeding.", "bbox": [53.0, 469.0, 371.0, 483.0]}], "type": "Text", "position": 2}, {"raw_context": [{"text": "Breast feeding", "bbox": [53.0, 500.0, 127.0, 514.0]}], "type": "Section-header", "position": 3}, {"raw_context": [{"text": "In general, most sedative and anaesthetic agents have poor oral", "bbox": [53.0, 515.0, 386.0, 529.0]}, {"text": "bioavailability and although some are excreted into breast milk,", "bbox": [53.0, 530.0, 385.0, 544.0]}, {"text": "the concentrations are low. 233 Midazolam is excreted into breast", "bbox": [53.0, 544.0, 386.0, 559.0]}, {"text": "milk, but the levels are virtually undetectable around 7 hours", "bbox": [53.0, 558.0, 387.0, 573.0]}, {"text": "after administration, with studies finding a level of 0.004% of", "bbox": [53.0, 574.0, 386.0, 588.0]}, {"text": "the maternal dose within 24 hours. 234 235 The latest national", "bbox": [53.0, 586.0, 385.0, 602.0]}, {"text": "guidance suggests that breast feeding can recommence once the", "bbox": [53.0, 603.0, 386.0, 616.0]}, {"text": "patient has recovered enough cognitive function. 233 236 Fentanyl", "bbox": [53.0, 618.0, 386.0, 631.0]}, {"text": "is excreted into breast milk, but the levels are 0.024% within 24", "bbox": [53.0, 633.0, 385.0, 646.0]}, {"text": "hours of administration, meaning that breast feeding does not", "bbox": [53.0, 646.0, 385.0, 661.0]}, {"text": "need to be suspended. 235 236 Pethidine is metabolised to norme-", "bbox": [53.0, 660.0, 384.0, 675.0]}, {"text": "peridine, which can cause neurotoxic effects. Normeperidine is", "bbox": [53.0, 675.0, 386.0, 690.0]}, {"text": "concentrated in breast milk and has been associated with neuro-", "bbox": [53.0, 691.0, 385.0, 705.0]}, {"text": "logical effects in breastfeeding children, but one study showed", "bbox": [53.0, 706.0, 385.0, 720.0]}, {"text": "that this was seen only in infants under 6 weeks old. 237 However,", "bbox": [53.0, 721.0, 386.0, 735.0]}, {"text": "there is no evidence that a single intravenous dose of pethidine", "bbox": [53.0, 736.0, 385.0, 750.0]}, {"text": "leads to significant toxicity in breastfeeding infants. Propofol", "bbox": [53.0, 751.0, 385.0, 765.0]}, {"text": "is excreted into breast milk but at very low levels and the oral", "bbox": [53.0, 766.0, 385.0, 779.0]}, {"text": "bioavailability is low. Breast feeding after propofol does not need", "bbox": [53.0, 780.0, 385.0, 793.0]}, {"text": "to be suspended and can be resumed as soon as the patient has", "bbox": [53.0, 794.0, 386.0, 808.0]}, {"text": "recovered from anaesthesia. 125 253", "bbox": [54.0, 810.0, 231.0, 822.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": "Adjunctive medications", "bbox": [53.0, 840.0, 181.0, 854.0]}], "type": "Section-header", "position": 5}, {"raw_context": [{"text": "Several other medications are regularly used in patients under-", "bbox": [53.0, 854.0, 385.0, 870.0]}, {"text": "going gastrointestinal endoscopy, including local anaesthetic", "bbox": [53.0, 869.0, 386.0, 884.0]}, {"text": "agents, nitrous oxide and hyoscine. Local anaesthetic agents", "bbox": [53.0, 885.0, 387.0, 898.0]}, {"text": "have been shown to cause fetal bradycardia when used intra-", "bbox": [53.0, 900.0, 385.0, 913.0]}, {"text": "venously, but the amounts used in topical throat spray are", "bbox": [53.0, 914.0, 386.0, 927.0]}, {"text": "unlikely to cause problems for either the unborn child or the", "bbox": [53.0, 928.0, 386.0, 942.0]}, {"text": "breastfeeding infant. Nitrous oxide is commonly used during", "bbox": [53.0, 943.0, 385.0, 957.0]}, {"text": "labour and is safe. Nitrous oxide is eliminated extremely", "bbox": [53.0, 957.0, 385.0, 972.0]}, {"text": "quickly and therefore has no consequences for the breast-", "bbox": [53.0, 973.0, 384.0, 986.0]}, {"text": "feeding infant.", "bbox": [53.0, 987.0, 133.0, 1001.0]}], "type": "Text", "position": 6}, {"raw_context": [{"text": "Regular use of hyoscine is not recommended in pregnancy,", "bbox": [418.0, 248.0, 739.0, 262.0]}, {"text": "but this can be a useful adjunct in both colonoscopy and ERCP.", "bbox": [406.0, 263.0, 739.0, 277.0]}, {"text": "Fortunately, these procedures are rarely required in pregnancy but", "bbox": [407.0, 278.0, 740.0, 292.0]}, {"text": "should a single dose of hyoscine be required then this could be", "bbox": [406.0, 293.0, 739.0, 307.0]}, {"text": "considered. There appear to be no consequences of using hyoscine", "bbox": [406.0, 307.0, 739.0, 322.0]}, {"text": "during breast feeding. Table 4 details safety of drugs in pregnancy.", "bbox": [406.0, 322.0, 739.0, 337.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "Special considerations: transition group", "bbox": [406.0, 353.0, 620.0, 368.0]}], "type": "Section-header", "position": 8}, {"raw_context": [{"text": "48. We recommend that young patients undergoing endos-", "bbox": [407.0, 368.0, 739.0, 383.0]}, {"text": "copy should participate in a structured transition programme,", "bbox": [407.0, 383.0, 739.0, 398.0]}, {"text": "including education around the choice of sedative agents", "bbox": [406.0, 398.0, 702.0, 412.0]}, {"text": "Grade of evidence: Very Low. Strength of recommendation:", "bbox": [418.0, 413.0, 739.0, 427.0]}, {"text": "Strong.", "bbox": [408.0, 428.0, 444.0, 441.0]}, {"text": "Level of agreement: 92.3%", "bbox": [418.0, 442.0, 560.0, 456.0]}, {"text": "49. We recommend that information about the risks and bene-", "bbox": [418.0, 456.0, 739.0, 471.0]}, {"text": "fits of endoscopy with sedation should be tailored to the indi-", "bbox": [406.0, 471.0, 739.0, 485.0]}, {"text": "vidual young person", "bbox": [407.0, 488.0, 516.0, 499.0]}, {"text": "Grade of evidence: Very Low. Strength of recommendation:", "bbox": [418.0, 500.0, 739.0, 515.0]}, {"text": "Strong.", "bbox": [407.0, 517.0, 445.0, 528.0]}, {"text": "Level of agreement: 100%", "bbox": [418.0, 530.0, 556.0, 543.0]}], "type": "Text", "position": 9}, {"raw_context": [{"text": "Young patients (aged 16–18 years) undergoing endoscopy", "bbox": [418.0, 543.0, 739.0, 559.0]}, {"text": "may be having investigation or endoscopic therapy for a chronic", "bbox": [407.0, 559.0, 739.0, 573.0]}, {"text": "condition for which they have been under the care of paedi-", "bbox": [406.0, 574.0, 739.0, 588.0]}, {"text": "atric services. Young people transitioning from paediatric to", "bbox": [407.0, 589.0, 740.0, 602.0]}, {"text": "adult services (with previous experience of endoscopy under a", "bbox": [406.0, 603.0, 741.0, 616.0]}, {"text": "general anaesthetic) will probably benefit from participating in", "bbox": [406.0, 617.0, 740.0, 632.0]}, {"text": "a structured transition programme. 238 Such patients might have", "bbox": [406.0, 631.0, 739.0, 646.0]}, {"text": "undergone previous procedures under general anaesthetic. This", "bbox": [406.0, 646.0, 740.0, 661.0]}, {"text": "might influence their expectations and preconceptions when", "bbox": [406.0, 662.0, 740.0, 676.0]}, {"text": "they move into adult services, where general anaesthetic is not", "bbox": [406.0, 677.0, 739.0, 690.0]}, {"text": "routinely used for most endoscopic procedures.", "bbox": [406.0, 691.0, 653.0, 705.0]}, {"text": "For all young patients, a discussion about the choice of seda-", "bbox": [418.0, 706.0, 739.0, 719.0]}, {"text": "tion and alternatives (such as the use of a general anaesthetic)", "bbox": [406.0, 721.0, 740.0, 735.0]}, {"text": "will be framed on a case-by-case basis. Factors such as patient", "bbox": [406.0, 736.0, 740.0, 750.0]}, {"text": "anxiety, complexity and length of the procedures should be", "bbox": [407.0, 750.0, 739.0, 765.0]}, {"text": "taken into account.", "bbox": [406.0, 766.0, 508.0, 779.0]}, {"text": "Young people (16–18 years) are presumed to have capacity", "bbox": [419.0, 780.0, 739.0, 793.0]}, {"text": "to consent for endoscopic procedures. 22 Parents and other", "bbox": [406.0, 794.0, 739.0, 808.0]}, {"text": "primary caregivers may assist in the discussions with the young", "bbox": [406.0, 809.0, 740.0, 822.0]}, {"text": "person about the procedure. Information should be provided in", "bbox": [406.0, 823.0, 740.0, 838.0]}, {"text": "a format that is suitable for the individual patient. The intended", "bbox": [406.0, 838.0, 740.0, 852.0]}, {"text": "effect of sedation in a young person is the same as in an adult", "bbox": [406.0, 853.0, 739.0, 867.0]}, {"text": "population— that is, to facilitate a successful endoscopic proce-", "bbox": [407.0, 867.0, 738.0, 881.0]}, {"text": "dure by minimising anxiety or discomfort. 2", "bbox": [406.0, 882.0, 629.0, 897.0]}], "type": "Text", "position": 10}, {"raw_context": [{"text": "Special considerations: including learning disability", "bbox": [406.0, 913.0, 682.0, 927.0]}], "type": "Section-header", "position": 11}, {"raw_context": [{"text": "50. We recommend that in patients with cognitive impairment", "bbox": [407.0, 928.0, 740.0, 942.0]}, {"text": "and/or learning disability, an assessment of capacity is carried", "bbox": [406.0, 943.0, 740.0, 957.0]}, {"text": "out to inform the discussion around choice of sedation", "bbox": [406.0, 957.0, 692.0, 972.0]}, {"text": "Grade of evidence: Very Low. Strength of recommendation:", "bbox": [418.0, 972.0, 739.0, 986.0]}, {"text": "Strong.", "bbox": [407.0, 988.0, 445.0, 1001.0]}], "type": "Text", "position": 12}, {"raw_context": [{"text": "2020", "bbox": [54.0, 1011.0, 68.0, 1021.0]}], "type": "Text", "position": 14}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/消化科/_2023 BSG指南：胃肠内窥镜检查中的镇静.pdf", "page_num": 20}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "表格格式错误#1#1#非表格格式\n缺少换行#12#12# 49. We recommend that information这里开始应换行", "type3": "无关文本#2#16#存在多处无关数字", "type4": "", "type5": null, "type6": null}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:40", "update_time": "2024-05-07 21:58:31"}
{"id": 1082526, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 738, "source_info": {"seq_id": "caf71065-2d8a-4562-8cbb-3fc57a209991", "title": null, "text": "【0】页码:41\n .\n\n【1】 National law, guidelines and local standards\n\n【2】 .\n\n【3】 His/her responsibilities and limitations according to the job description and national and local\n\n【4】 regulations concerning delegation.", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": ".", "bbox": [139.0, 141.0, 154.0, 157.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "National law, guidelines and local standards", "bbox": [160.0, 140.0, 404.0, 159.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": ".", "bbox": [139.0, 177.0, 154.0, 193.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "His/her responsibilities and limitations according to the job description and national and local", "bbox": [160.0, 176.0, 670.0, 195.0]}], "type": "Text", "position": 6}, {"raw_context": [{"text": "regulations concerning delegation.", "bbox": [161.0, 200.0, 354.0, 219.0]}], "type": "Text", "position": 7}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/消化科/_2023 BSG指南：胃肠内窥镜检查中的镇静.pdf", "page_num": 41}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": null, "type3": null, "type4": null, "type5": null, "type6": "信息有用性#0#4#无用内容"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:40", "update_time": "2024-05-07 19:31:27"}
{"id": 1082525, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 738, "source_info": {"seq_id": "fd9f6dc8-485f-459b-86cf-f131b530cf26", "title": null, "text": "【0】页码:7\n\n【1】## A. Sun Et Al.\n\n【2】\n conducted to date, questions remain regarding the safety and efficacy of combined therapy and more rigorous evaluation is needed.\n\n【3】Considering the aforementioned evidence for administration of TRT or PCI alone during maintenance immunotherapy in ES-SCLC, reports on the use of these treatments in LS-SCLC and NSCLC [44,46–48] , and the fact that the toxicities associated with TRT and PCI do not overlap [6,13,22] , the expert working group stated that it is appropriate to consider concurrent treatment with TRT, PCI, and immunotherapy for patients with ES-SCLC. Treatment with RT should occur after completion of chemo-immunotherapy, restaging of the chest (CT) and brain (MRI), and resolution of any chemotherapy toxicities. TRT and PCI can be provided concurrently during immunotherapy or separately. The results of the MAVERICK trial will hopefully provide clarity on the optimal roles of TRT, PCI, and MRI surveillance among patients receiving immunotherapy [32] .\n\n【4】## 4. Conclusions\n\n【5】\n The inclusion of consolidation TRT and PCI (in some settings) into standard treatment protocols has significantly improved clinical outcomes in ES-SCLC, as has the more recent introduction of immunotherapy with atezolizumab and durvalumab. Robust evidence for the safety and efficacy of concurrent immunotherapy and RT, as well as the optimal timing of their administration, will not be available from randomized clinical trials for several years. After reviewing guidelines for RT from ASTRO and ASCO, recently available data in ES-SCLC, LS-SCLC, and NSCLC, and their own clinical experiences, the expert working group was fully aligned on the importance of considering TRT, PCI, and MRI surveillance in the management of ES-SCLC during immunotherapy. Patient suitability for these treatment options should be discussed on a case-by-case basis by the MDT until additional clinical data can inform treatment decisions.\n\n【6】## Funding Source\n\n【7】\n## The Work Was Supported By Astrazeneca Canada.\n\n【8】\n## Credit Authorship Contribution Statement\n\n【9】\n Alexander Sun: Conceptualization, Methodology, Writing – original draft, Writing – review & editing. Bassam Abdulkarim: Validation, Writing – review & editing. Normand Blais: Validation, Writing – review & editing. Jonathan Greenland: Validation, Writing – review & editing. Alexander V. Louie: Validation, Writing – review & editing.\n\n【10】Barbara Melosky: Validation, Writing – review & editing. Devin Schellenberg: Validation, Writing – review & editing. Stephanie Snow: Validation, Writing – review & editing. Geoffrey Liu: Conceptualization, Validation, Writing – review & editing.\n\n【11】## Declaration Of Competing Interest\n\n【12】\n The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: A.\n\n【13】Sun has received honoraria from and participated in advisory boards with AstraZeneca. B. Abdulkarim has no conflicts to disclose. N. Blais reports receiving consulting fees from AstraZeneca. J. Greenland has received honoraria from AstraZeneca for attendance at advisory boards.\n\n【14】A.V. Louie reports receiving honoraria from AstraZeneca for a speakers bureau and an advisory board. B. Melosky has received honoraria from AstraZeneca, BMS, Merck, and Roche. D. Schellenberg reports receiving institutional grants from Varian Medical Systems and payments from AstraZeneca, Merck, and Pfizer for presentations/educational events and advisory board participation. He also reports participation in Linear Accelerator selection for BC Cancer and receipt of a class action lawsuit payment from Medtronic. S. Snow reports research/trial funding paid to her institution by AstraZeneca, BMS, Merck, Novartis, Sanofi, and\n\n【15】 Takeda and receiving consulting fees from Novartis and Roche. She has also received honoraria for lectures and presentations at educational events from Amgen, AstraZeneca, Bayer, BMS, Elvium Life Sciences, Jazz Pharmaceuticals, Pfizer, and Taiho. S. Snow has also participated in advisory boards for Amgen, Astellas, AstraZeneca, Bayer, BeiGene, BMS, EMD Serono, Janssen, Jazz Pharmaceuticals, Merck, MSD, Novartis, Pfizer, Roche, Sanofi, Takeda, and Taiho, and was the President of Lung Cancer Canada and on its Board of Directors at the time of publication.\n\n【16】G. Liu has received institutional research grants from NCI (US), CIHR (Canada), CCSRI (Canada), Amgen, AstraZeneca, Boehringer Ingelheim, and Takeda. He has received payment or honoraria from AstraZeneca, EMD Serono, Jazz Pharmaceuticals, Novartis, Pfizer, and Takeda, and has participated in data safety monitoring boards or advisory boards with AbbVie, AstraZeneca, BMS, EMD Serono, Jazz Pharmaceuticals, Eli Lilly, Merck, Novartis, Pfizer, Roche, and Takeda.\n\n【17】## Acknowledgements\n\n【18】\n The authors wish to thank AstraZeneca Canada for supporting the expert working group meeting and Dana L. Anger of WRITRIX Medical Communications Inc. for assistance with medical writing. Medical writing support was funded by AstraZeneca Canada in accordance with Version 3 of the Good Publication Practice guidelines (https:// www.\n\n【19】ismpp.org/gpp3).\n\n【20】## References\n\n【21】\n [1] H. Sung, J. Ferlay, R.L. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal, F. Bray, Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J Clin. 71 (3) (2021) 209–249, https://doi.org/10.3322/caac.21660 .\n\n【22】[2] Canadian Cancer Society, Canadian Cancer Statistics. A 2020 special report on lung cancer. Available at: https://edn.cancer.ca/-/media/files/cancer-information/ resources/publications/2020-canadian-cancer-statistics-special-report/2020- canadian-cancer-statistics-special-report-en.pdf. Accessed: 14 Apr 2022. (2020).\n\n【23】[3] C.M. Rudin, E. Brambilla, C. Faivre-Finn, J. Sage, Small-cell lung cancer, Nature reviews. Disease primers. 7 (1) (2021) 3-3. 10.1038/s41572-020-00235-0.\n\n【24】[4] P. Micke, A. Faldum, T. Metz, K.M. Beeh, F. Bittinger, J.G. Hengstler, R. Buhl, Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer–what limits limited disease?\n\n【25】Lung Cancer 37 (3) (2002) 271–276, https://doi.org/10.1016/s0169-5002(02) [5] P. Goldstraw, K. Chansky, J. Crowley, R. Rami-Porta, H. Asamura, W.E. Eberhardt, A.G. Nicholson, P. Groome, A. Mitchell, V. Bolejack, The IASLC Lung Cancer Staging Project: Proposals for revision of the TNM stage groupings in the forthcoming (Eighth) edition of the TNM classification for lung cancer, J Thorac Oncol. 11 (1) (2016) 39–51, https://doi.org/10.1016/j.jtho.2015.09.009 .\n\n【26】[6] B. Slotman, C. Faivre-Finn, G. Kramer, E. Rankin, M. Snee, M. Hatton, P. Postmus, L. Collette, E. Musat, S. Senan, Prophylactic cranial irradiation in extensive smallcell lung cancer, N Engl J Med. 357 (7) (2007) 664–672, https://doi.org/10.1056/ NEJMoa071780 [7] R.A. Green, E. Humphrey, H. Close, M.E. Patno, Alkylating agents in bronchogenic carcinoma, Am J Med. 46 (4) (1969) 516–525, https://doi.org/10.1016/0002 9343(69)90071-0 .\n\n【27】[8] M.C. Pietanza, L.A. Byers, J.D. Minna, C.M. Rudin, Small cell lung cancer: will recent progress lead to improved outcomes? Clin Cancer Res. 21 (10) (2015) 2244–2255, https://doi.org/10.1158/1078-0432.Ccr-14-2958 .\n\n【28】[9] M. Reck, L. Horn, S. Novello, F. Barlesi, L Albert, E. Juhasz, D. Kowalski, G. Robinet, J. Cadranel, P. Bidoli, J. Chung, A. Fritsch, U. Drews, A. Wagner, R. Govindan, Phase II study of roniciclib in combination with cisplatin/etoposide or carboplatin/etoposide as first-Line therapy in patients with extensive-disease small cell lung cancer, J Thorac Oncol. 14 (4) (2019) 701–711, https://doi.org/ 10.1016/j.jtho.2019.01.010 .\n\n【29】[10] M.A. Socinski, E.F. Smit, P. Lorigan, K. Konduri, M. Reck, A. Szczesna, J. Blakely, P. Serwatowski, N.A. Karaseva, T. Ciuleanu, J. Jassem, M. Dediu, S. Hong, C. Visseren-Grul, A.R. Hanauske, C.K. Obasaju, S.C. Guba, N. Thatcher, Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer, J Clin Oncol. 27 (28) (2009) 4787–4792, https://doi.org/10.1200/JCO.2009.23.1548 .\n\n【30】[11] P.N. Lara Jr., R. Natale, J. Crowley, H.J. Lenz, M.W. Redman, J.E. Carleton, J. Jett, C.J. Langer, J.P. Kuebler, S.R. Dakhil, K. Chansky, D.R. Gandara, Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage smallcell lung cancer: clinical and pharmacogenomic results from SWOG S0124, J Clin Oncol. 27 (15) (2009) 2530–2535, https://doi.org/10.1200/JCO.2008.20.1061 .\n\n【31】[12] N. Hanna, P.A. Bunn Jr., C. Langer, L. Einhorn, T. Guthrie Jr., T. Beck, R. Ansari, P. Ellis, M. Byrne, M. Morrison, S. Hariharan, B. Wang, A. Sandler, Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "A. Sun et al.", "bbox": [48.0, 46.0, 95.0, 58.0]}], "type": "Section-header", "position": 0}, {"raw_context": [{"text": "conducted to date, questions remain regarding the safety and efficacy of", "bbox": [47.0, 69.0, 387.0, 83.0]}, {"text": "combined therapy and more rigorous evaluation is needed.", "bbox": [48.0, 85.0, 328.0, 97.0]}, {"text": "Considering the aforementioned evidence for administration of TRT", "bbox": [64.0, 99.0, 385.0, 111.0]}, {"text": "or PCI alone during maintenance immunotherapy in ES-SCLC, reports on", "bbox": [48.0, 113.0, 386.0, 125.0]}, {"text": "the use of these treatments in LS-SCLC and NSCLC [44,46–48] , and the", "bbox": [48.0, 127.0, 386.0, 139.0]}, {"text": "fact that the toxicities associated with TRT and PCI do not overlap", "bbox": [48.0, 141.0, 386.0, 153.0]}, {"text": "[6,13,22] , the expert working group stated that it is appropriate to", "bbox": [48.0, 155.0, 387.0, 167.0]}, {"text": "consider concurrent treatment with TRT, PCI, and immunotherapy for", "bbox": [48.0, 169.0, 385.0, 181.0]}, {"text": "patients with ES-SCLC. Treatment with RT should occur after comple-", "bbox": [48.0, 183.0, 385.0, 195.0]}, {"text": "tion of chemo-immunotherapy, restaging of the chest (CT) and brain", "bbox": [48.0, 197.0, 387.0, 210.0]}, {"text": "(MRI), and resolution of any chemotherapy toxicities. TRT and PCI can", "bbox": [48.0, 211.0, 387.0, 224.0]}, {"text": "be provided concurrently during immunotherapy or separately. The", "bbox": [48.0, 225.0, 386.0, 238.0]}, {"text": "results of the MAVERICK trial will hopefully provide clarity on the", "bbox": [48.0, 237.0, 386.0, 252.0]}, {"text": "optimal roles of TRT, PCI, and MRI surveillance among patients", "bbox": [48.0, 253.0, 387.0, 266.0]}, {"text": "receiving immunotherapy [32] .", "bbox": [48.0, 267.0, 199.0, 280.0]}], "type": "Text", "position": 1}, {"raw_context": [{"text": "4. Conclusions", "bbox": [48.0, 293.0, 129.0, 307.0]}], "type": "Section-header", "position": 2}, {"raw_context": [{"text": "The inclusion of consolidation TRT and PCI (in some settings) into", "bbox": [64.0, 322.0, 387.0, 334.0]}, {"text": "standard treatment protocols has significantly improved clinical out-", "bbox": [48.0, 336.0, 385.0, 348.0]}, {"text": "comes in ES-SCLC, as has the more recent introduction of immuno-", "bbox": [48.0, 350.0, 385.0, 362.0]}, {"text": "therapy with atezolizumab and durvalumab. Robust evidence for the", "bbox": [48.0, 364.0, 386.0, 376.0]}, {"text": "safety and efficacy of concurrent immunotherapy and RT, as well as the", "bbox": [48.0, 378.0, 387.0, 390.0]}, {"text": "optimal timing of their administration, will not be available from ran-", "bbox": [48.0, 392.0, 385.0, 405.0]}, {"text": "domized clinical trials for several years. After reviewing guidelines for", "bbox": [48.0, 406.0, 386.0, 419.0]}, {"text": "RT from ASTRO and ASCO, recently available data in ES-SCLC, LS-SCLC,", "bbox": [48.0, 420.0, 385.0, 433.0]}, {"text": "and NSCLC, and their own clinical experiences, the expert working", "bbox": [48.0, 435.0, 386.0, 446.0]}, {"text": "group was fully aligned on the importance of considering TRT, PCI, and", "bbox": [48.0, 449.0, 386.0, 460.0]}, {"text": "MRI surveillance in the management of ES-SCLC during immuno-", "bbox": [48.0, 462.0, 385.0, 474.0]}, {"text": "therapy. Patient suitability for these treatment options should be dis-", "bbox": [48.0, 476.0, 385.0, 488.0]}, {"text": "cussed on a case-by-case basis by the MDT until additional clinical data", "bbox": [48.0, 489.0, 386.0, 503.0]}, {"text": "can inform treatment decisions.", "bbox": [48.0, 504.0, 199.0, 517.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "Funding source", "bbox": [47.0, 530.0, 129.0, 545.0]}], "type": "Section-header", "position": 4}, {"raw_context": [{"text": "The work was supported by AstraZeneca Canada.", "bbox": [64.0, 560.0, 299.0, 573.0]}], "type": "Section-header", "position": 5}, {"raw_context": [{"text": "CRediT authorship contribution statement", "bbox": [47.0, 586.0, 267.0, 600.0]}], "type": "Section-header", "position": 6}, {"raw_context": [{"text": "Alexander Sun: Conceptualization, Methodology, Writing – original", "bbox": [64.0, 615.0, 386.0, 629.0]}, {"text": "draft, Writing – review & editing. Bassam Abdulkarim: Validation,", "bbox": [48.0, 630.0, 385.0, 642.0]}, {"text": "Writing – review & editing. Normand Blais: Validation, Writing – re-", "bbox": [48.0, 644.0, 385.0, 655.0]}, {"text": "view & editing. Jonathan Greenland: Validation, Writing – review &", "bbox": [48.0, 658.0, 385.0, 669.0]}, {"text": "editing. Alexander V. Louie: Validation, Writing – review & editing.", "bbox": [48.0, 672.0, 385.0, 683.0]}, {"text": "Barbara Melosky: Validation, Writing – review & editing. Devin", "bbox": [48.0, 685.0, 386.0, 698.0]}, {"text": "Schellenberg: Validation, Writing – review & editing. Stephanie", "bbox": [48.0, 699.0, 386.0, 712.0]}, {"text": "Snow: Validation, Writing – review & editing. Geoffrey Liu: Concep-", "bbox": [48.0, 713.0, 385.0, 726.0]}, {"text": "tualization, Validation, Writing – review & editing.", "bbox": [48.0, 728.0, 291.0, 740.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "Declaration of Competing Interest", "bbox": [47.0, 754.0, 223.0, 768.0]}], "type": "Section-header", "position": 8}, {"raw_context": [{"text": "The authors declare the following financial interests/personal re-", "bbox": [64.0, 783.0, 385.0, 796.0]}, {"text": "lationships which may be considered as potential competing interests: A.", "bbox": [48.0, 798.0, 385.0, 811.0]}, {"text": "Sun has received honoraria from and participated in advisory boards", "bbox": [48.0, 812.0, 385.0, 825.0]}, {"text": "with AstraZeneca. B. Abdulkarim has no conflicts to disclose. N. Blais", "bbox": [48.0, 826.0, 385.0, 838.0]}, {"text": "reports receiving consulting fees from AstraZeneca. J. Greenland has", "bbox": [48.0, 841.0, 385.0, 852.0]}, {"text": "received honoraria from AstraZeneca for attendance at advisory boards.", "bbox": [48.0, 855.0, 384.0, 866.0]}, {"text": "A.V. Louie reports receiving honoraria from AstraZeneca for a speakers", "bbox": [48.0, 869.0, 386.0, 880.0]}, {"text": "bureau and an advisory board. B. Melosky has received honoraria from", "bbox": [48.0, 882.0, 385.0, 894.0]}, {"text": "AstraZeneca, BMS, Merck, and Roche. D. Schellenberg reports receiving", "bbox": [48.0, 896.0, 385.0, 908.0]}, {"text": "institutional grants from Varian Medical Systems and payments from", "bbox": [48.0, 908.0, 386.0, 922.0]}, {"text": "AstraZeneca, Merck, and Pfizer for presentations/educational events", "bbox": [48.0, 923.0, 386.0, 935.0]}, {"text": "and advisory board participation. He also reports participation in Linear", "bbox": [48.0, 937.0, 385.0, 949.0]}, {"text": "Accelerator selection for BC Cancer and receipt of a class action lawsuit", "bbox": [48.0, 951.0, 385.0, 963.0]}, {"text": "payment from Medtronic. S. Snow reports research/trial funding paid to", "bbox": [48.0, 965.0, 387.0, 976.0]}, {"text": "her institution by AstraZeneca, BMS, Merck, Novartis, Sanofi, and", "bbox": [48.0, 979.0, 386.0, 991.0]}], "type": "Text", "position": 9}, {"raw_context": [{"text": "Takeda and receiving consulting fees from Novartis and Roche. She has", "bbox": [406.0, 69.0, 745.0, 83.0]}, {"text": "also received honoraria for lectures and presentations at educational", "bbox": [406.0, 85.0, 745.0, 97.0]}, {"text": "events from Amgen, AstraZeneca, Bayer, BMS, Elvium Life Sciences,", "bbox": [406.0, 99.0, 744.0, 112.0]}, {"text": "Jazz Pharmaceuticals, Pfizer, and Taiho. S. Snow has also participated in", "bbox": [407.0, 113.0, 745.0, 125.0]}, {"text": "advisory boards for Amgen, Astellas, AstraZeneca, Bayer, BeiGene, BMS,", "bbox": [406.0, 127.0, 744.0, 139.0]}, {"text": "EMD Serono, Janssen, Jazz Pharmaceuticals, Merck, MSD, Novartis,", "bbox": [406.0, 141.0, 745.0, 153.0]}, {"text": "Pfizer, Roche, Sanofi, Takeda, and Taiho, and was the President of Lung", "bbox": [406.0, 155.0, 745.0, 167.0]}, {"text": "Cancer Canada and on its Board of Directors at the time of publication.", "bbox": [406.0, 169.0, 744.0, 181.0]}, {"text": "G. Liu has received institutional research grants from NCI (US), CIHR", "bbox": [406.0, 183.0, 745.0, 195.0]}, {"text": "(Canada), CCSRI (Canada), Amgen, AstraZeneca, Boehringer Ingelheim,", "bbox": [406.0, 197.0, 744.0, 210.0]}, {"text": "and Takeda. He has received payment or honoraria from AstraZeneca,", "bbox": [406.0, 211.0, 744.0, 224.0]}, {"text": "EMD Serono, Jazz Pharmaceuticals, Novartis, Pfizer, and Takeda, and", "bbox": [406.0, 225.0, 745.0, 238.0]}, {"text": "has participated in data safety monitoring boards or advisory boards", "bbox": [406.0, 239.0, 745.0, 251.0]}, {"text": "with AbbVie, AstraZeneca, BMS, EMD Serono, Jazz Pharmaceuticals, Eli", "bbox": [406.0, 253.0, 745.0, 265.0]}, {"text": "Lilly, Merck, Novartis, Pfizer, Roche, and Takeda.", "bbox": [405.0, 266.0, 642.0, 279.0]}], "type": "Text", "position": 11}, {"raw_context": [{"text": "Acknowledgements", "bbox": [406.0, 293.0, 509.0, 306.0]}], "type": "Section-header", "position": 12}, {"raw_context": [{"text": "The authors wish to thank AstraZeneca Canada for supporting the", "bbox": [422.0, 321.0, 745.0, 334.0]}, {"text": "expert working group meeting and Dana L. Anger of WRITRIX Medical", "bbox": [406.0, 336.0, 745.0, 348.0]}, {"text": "Communications Inc. for assistance with medical writing. Medical", "bbox": [406.0, 350.0, 745.0, 362.0]}, {"text": "writing support was funded by AstraZeneca Canada in accordance with", "bbox": [406.0, 364.0, 745.0, 376.0]}, {"text": "Version 3 of the Good Publication Practice guidelines (https:// www.", "bbox": [406.0, 378.0, 744.0, 390.0]}, {"text": "ismpp.org/gpp3).", "bbox": [406.0, 392.0, 490.0, 405.0]}], "type": "Text", "position": 13}, {"raw_context": [{"text": "References", "bbox": [406.0, 420.0, 465.0, 432.0]}], "type": "Section-header", "position": 14}, {"raw_context": [{"text": "[1] H. Sung, J. Ferlay, R.L. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal, F. Bray,", "bbox": [411.0, 445.0, 742.0, 458.0]}, {"text": "Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality", "bbox": [430.0, 456.0, 733.0, 467.0]}, {"text": "worldwide for 36 cancers in 185 countries, CA Cancer J Clin. 71 (3) (2021)", "bbox": [430.0, 466.0, 721.0, 479.0]}, {"text": "209–249, https://doi.org/10.3322/caac.21660 .", "bbox": [430.0, 478.0, 608.0, 489.0]}, {"text": "[2] Canadian Cancer Society, Canadian Cancer Statistics. A 2020 special report on lung", "bbox": [411.0, 488.0, 742.0, 500.0]}, {"text": "cancer. Available at: https://edn.cancer.ca/-/media/files/cancer-information/", "bbox": [428.0, 499.0, 725.0, 510.0]}, {"text": "resources/publications/2020-canadian-cancer-statistics-special-report/2020-", "bbox": [429.0, 508.0, 717.0, 522.0]}, {"text": "canadian-cancer-statistics-special-report-en.pdf. Accessed: 14 Apr 2022. (2020).", "bbox": [428.0, 519.0, 733.0, 532.0]}, {"text": "[3] C.M. Rudin, E. Brambilla, C. Faivre-Finn, J. Sage, Small-cell lung cancer, Nature", "bbox": [411.0, 531.0, 737.0, 542.0]}, {"text": "reviews. Disease primers. 7 (1) (2021) 3-3. 10.1038/s41572-020-00235-0.", "bbox": [428.0, 541.0, 709.0, 552.0]}, {"text": "[4] P. Micke, A. Faldum, T. Metz, K.M. Beeh, F. Bittinger, J.G. Hengstler, R. Buhl,", "bbox": [411.0, 552.0, 729.0, 563.0]}, {"text": "Staging small cell lung cancer: Veterans Administration Lung Study Group versus", "bbox": [430.0, 563.0, 741.0, 574.0]}, {"text": "International Association for the Study of Lung Cancer–what limits limited disease?", "bbox": [429.0, 573.0, 741.0, 585.0]}, {"text": "Lung Cancer 37 (3) (2002) 271–276, https://doi.org/10.1016/s0169-5002(02)", "bbox": [429.0, 584.0, 731.0, 595.0]}, {"text": "[5] P. Goldstraw, K. Chansky, J. Crowley, R. Rami-Porta, H. Asamura, W.E. Eberhardt,", "bbox": [411.0, 605.0, 741.0, 616.0]}, {"text": "A.G. Nicholson, P. Groome, A. Mitchell, V. Bolejack, The IASLC Lung Cancer", "bbox": [429.0, 615.0, 724.0, 627.0]}, {"text": "Staging Project: Proposals for revision of the TNM stage groupings in the", "bbox": [430.0, 626.0, 710.0, 638.0]}, {"text": "forthcoming (Eighth) edition of the TNM classification for lung cancer, J Thorac", "bbox": [428.0, 637.0, 738.0, 648.0]}, {"text": "Oncol. 11 (1) (2016) 39–51, https://doi.org/10.1016/j.jtho.2015.09.009 .", "bbox": [428.0, 647.0, 707.0, 659.0]}, {"text": "[6] B. Slotman, C. Faivre-Finn, G. Kramer, E. Rankin, M. Snee, M. Hatton, P. Postmus,", "bbox": [411.0, 658.0, 741.0, 669.0]}, {"text": "L. Collette, E. Musat, S. Senan, Prophylactic cranial irradiation in extensive small-", "bbox": [428.0, 668.0, 741.0, 680.0]}, {"text": "cell lung cancer, N Engl J Med. 357 (7) (2007) 664–672, https://doi.org/10.1056/", "bbox": [428.0, 680.0, 739.0, 690.0]}, {"text": "NEJMoa071780", "bbox": [430.0, 692.0, 488.0, 699.0]}, {"text": "[7] R.A. Green, E. Humphrey, H. Close, M.E. Patno, Alkylating agents in bronchogenic", "bbox": [411.0, 700.0, 741.0, 713.0]}, {"text": "carcinoma, Am J Med. 46 (4) (1969) 516–525, https://doi.org/10.1016/0002", "bbox": [428.0, 710.0, 727.0, 722.0]}, {"text": "9343(69)90071-0 .", "bbox": [430.0, 722.0, 498.0, 733.0]}, {"text": "[8] M.C. Pietanza, L.A. Byers, J.D. Minna, C.M. Rudin, Small cell lung cancer: will", "bbox": [411.0, 732.0, 731.0, 743.0]}, {"text": "recent progress lead to improved outcomes? Clin Cancer Res. 21 (10) (2015)", "bbox": [428.0, 743.0, 725.0, 754.0]}, {"text": "2244–2255, https://doi.org/10.1158/1078-0432.Ccr-14-2958 .", "bbox": [429.0, 753.0, 667.0, 765.0]}, {"text": "[9] M. Reck, L. Horn, S. Novello, F. Barlesi, L Albert, E. Juhasz, D. Kowalski,", "bbox": [411.0, 764.0, 710.0, 775.0]}, {"text": "G. Robinet, J. Cadranel, P. Bidoli, J. Chung, A. Fritsch, U. Drews, A. Wagner,", "bbox": [429.0, 775.0, 727.0, 785.0]}, {"text": "R. Govindan, Phase II study of roniciclib in combination with cisplatin/etoposide", "bbox": [428.0, 786.0, 741.0, 796.0]}, {"text": "or carboplatin/etoposide as first-Line therapy in patients with extensive-disease", "bbox": [428.0, 798.0, 735.0, 807.0]}, {"text": "small cell lung cancer, J Thorac Oncol. 14 (4) (2019) 701–711, https://doi.org/", "bbox": [428.0, 808.0, 734.0, 818.0]}, {"text": "10.1016/j.jtho.2019.01.010 .", "bbox": [430.0, 818.0, 536.0, 827.0]}, {"text": "[10] M.A. Socinski, E.F. Smit, P. Lorigan, K. Konduri, M. Reck, A. Szczesna, J. Blakely,", "bbox": [406.0, 827.0, 742.0, 839.0]}, {"text": "P. Serwatowski, N.A. Karaseva, T. Ciuleanu, J. Jassem, M. Dediu, S. Hong,", "bbox": [428.0, 840.0, 715.0, 850.0]}, {"text": "C. Visseren-Grul, A.R. Hanauske, C.K. Obasaju, S.C. Guba, N. Thatcher, Phase III", "bbox": [428.0, 850.0, 739.0, 860.0]}, {"text": "study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in", "bbox": [429.0, 861.0, 741.0, 870.0]}, {"text": "chemotherapy-naive patients with extensive-stage small-cell lung cancer, J Clin", "bbox": [428.0, 871.0, 735.0, 882.0]}, {"text": "Oncol. 27 (28) (2009) 4787–4792, https://doi.org/10.1200/JCO.2009.23.1548 .", "bbox": [429.0, 883.0, 735.0, 893.0]}, {"text": "[11] P.N. Lara Jr., R. Natale, J. Crowley, H.J. Lenz, M.W. Redman, J.E. Carleton, J. Jett,", "bbox": [406.0, 892.0, 741.0, 904.0]}, {"text": "C.J. Langer, J.P. Kuebler, S.R. Dakhil, K. Chansky, D.R. Gandara, Phase III trial of", "bbox": [429.0, 903.0, 743.0, 915.0]}, {"text": "irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-", "bbox": [429.0, 915.0, 737.0, 926.0]}, {"text": "cell lung cancer: clinical and pharmacogenomic results from SWOG S0124, J Clin", "bbox": [429.0, 925.0, 741.0, 936.0]}, {"text": "Oncol. 27 (15) (2009) 2530–2535, https://doi.org/10.1200/JCO.2008.20.1061 .", "bbox": [429.0, 936.0, 734.0, 946.0]}, {"text": "[12] N. Hanna, P.A. Bunn Jr., C. Langer, L. Einhorn, T. Guthrie Jr., T. Beck, R. Ansari,", "bbox": [406.0, 945.0, 741.0, 955.0]}, {"text": "P. Ellis, M. Byrne, M. Morrison, S. Hariharan, B. Wang, A. Sandler, Randomized", "bbox": [428.0, 957.0, 738.0, 968.0]}, {"text": "phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients", "bbox": [430.0, 968.0, 741.0, 979.0]}], "type": "Text", "position": 15}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/肿瘤科/共识/加拿大共识建议：在接受免疫治疗的广泛期小细胞肺癌患者中使用放射治疗.pdf", "page_num": 7}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": null, "type3": "页眉#1#1#非正文\n无关文本#3#3# [44,46–48]     [6,13,22]    [32]", "type4": null, "type5": null, "type6": "信息有用性#6#29#参考文献等内容"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:40", "update_time": "2024-05-07 18:42:46"}
{"id": 1082524, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 738, "source_info": {"seq_id": "76d9179f-23e2-46ed-83aa-1f07280af355", "title": null, "text": "【0】页码:9\n 小狗科研究\n\n【1】 小街村駅\n\n【2】 ® 2 ⁄ 4 1 ⁄ 3  乳腺癌术后 臺乳治疗后療病与肿瘤复发。 ⑥评估肿块切除术 后切缘阳性患者的残留病灶。⑦乳腺假体植入术后评价。⑧ 高危人群的乳腺癌筛查。 ⑨引导乳腺病灶的定位及活检。 (2) 禁忌证: ①体内有起搏器、外科金属关等執機性(途小狗科) 小狗物质及其他不得接近强磁场者。②具有对任何 乱整合物过敏 史者。③幽闭恐惧症者。④妊娠期妇女。③一般情况很差, 不能耐受磁共振检查者。。 . 耐 受磁共 W E H  4- 正电子发射计算机体层成像 根据美国国立综合癌症网络 ( National Comprehensive 41 h Cancer Network, NCCN ) 指南、欧洲册瘤内科学会 ( European Society for Medical Oncology,  ESMO )  指南、日本孔腺癌学 l Construction of the United States of the United States from the United States of the 协会指南 .\n\n【3】 ( 1 ) 正 电 子 发 射 计 算 机 体 层 成 像 （ positron emission tomography-computed tomography，PET-CT）检查适应证: ~~ 移的患者狩前分期以尤其是常规影像检查对是否存在远处转 移难以判断或存在争议时 ) .  ② 术后患者随访过程中可疑出 现局部复发或转移，包括查体或常规影像检查出现异常、肿 瘤标志物升高等（对于鉴别复发种放射性纤维化) PET-CT 瘤林慈薇介護 ( 2018 ).\n\n【4】 468 2 E", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "小狗科研究", "bbox": [22.0, 36.0, 165.0, 104.0]}], "type": "Text", "position": 0}, {"raw_context": [{"text": "小街村駅", "bbox": [598.0, 32.0, 696.0, 88.0]}], "type": "Text", "position": 1}, {"raw_context": [{"text": "® 2 ⁄ 4 1 ⁄ 3 ", "bbox": [114.0, 85.0, 682.0, 146.0]}, {"text": "乳腺癌术后 臺乳治疗后療病与肿瘤复发。 ⑥评估肿块切除术", "bbox": [117.0, 139.0, 675.0, 179.0]}, {"text": "后切缘阳性患者的残留病灶。⑦乳腺假体植入术后评价。⑧", "bbox": [117.0, 182.0, 674.0, 212.0]}, {"text": "高危人群的乳腺癌筛查。 ⑨引导乳腺病灶的定位及活检。", "bbox": [117.0, 225.0, 643.0, 251.0]}, {"text": "(2) 禁忌证: ①体内有起搏器、外科金属关等執機性(途小狗科)", "bbox": [167.0, 245.0, 794.0, 314.0]}, {"text": "小狗物质及其他不得接近强磁场者。②具有对任何 乱整合物过敏", "bbox": [59.0, 289.0, 681.0, 346.0]}, {"text": "史者。③幽闭恐惧症者。④妊娠期妇女。③一般情况很差,", "bbox": [119.0, 340.0, 665.0, 375.0]}, {"text": "不能耐受磁共振检查者。。", "bbox": [117.0, 384.0, 383.0, 414.0]}, {"text": ". 耐 受磁共 W E H ", "bbox": [156.0, 392.0, 575.0, 477.0]}, {"text": "4- 正电子发射计算机体层成像", "bbox": [157.0, 465.0, 455.0, 493.0]}, {"text": "根据美国国立综合癌症网络 ( National Comprehensive", "bbox": [158.0, 501.0, 686.0, 536.0]}, {"text": "41 h", "bbox": [747.0, 512.0, 794.0, 551.0]}, {"text": "Cancer Network, NCCN ) 指南、欧洲册瘤内科学会 ( European", "bbox": [115.0, 544.0, 679.0, 574.0]}, {"text": "Society for Medical Oncology,  ESMO )  指南、日本孔腺癌学", "bbox": [116.0, 583.0, 674.0, 612.0]}, {"text": "l Construction of the United States of the United States from the United States of the", "bbox": [118.0, 612.0, 714.0, 665.0]}, {"text": "协会指南 .", "bbox": [118.0, 666.0, 218.0, 692.0]}], "type": "Text", "position": 2}, {"raw_context": [{"text": "( 1 ) 正 电 子 发 射 计 算 机 体 层 成 像 （ positron emission", "bbox": [166.0, 705.0, 677.0, 732.0]}, {"text": "tomography-computed tomography，PET-CT）检查适应证:", "bbox": [115.0, 751.0, 692.0, 769.0]}, {"text": "~~", "bbox": [85.0, 786.0, 674.0, 813.0]}, {"text": "移的患者狩前分期以尤其是常规影像检查对是否存在远处转", "bbox": [119.0, 820.0, 674.0, 860.0]}, {"text": "移难以判断或存在争议时 ) .  ② 术后患者随访过程中可疑出", "bbox": [118.0, 858.0, 675.0, 907.0]}, {"text": "现局部复发或转移，包括查体或常规影像检查出现异常、肿", "bbox": [118.0, 903.0, 675.0, 931.0]}, {"text": "瘤标志物升高等（对于鉴别复发种放射性纤维化) PET-CT", "bbox": [117.0, 943.0, 677.0, 971.0]}, {"text": "瘤林慈薇介護 ( 2018 ).", "bbox": [118.0, 956.0, 794.0, 1043.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "468 2 E", "bbox": [1.0, 750.0, 89.0, 809.0]}], "type": "Text", "position": 5}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2022】全科室最全临床指南+专家共识（最全版）/2022全科室临床指南/肿瘤科/乳腺癌诊疗指南（2022年版）.pdf", "page_num": 9}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": "错别字#2#2#乳腺癌术后 臺乳治疗后療病与肿瘤复发  应该是乳腺癌术后鉴别治疗后瘢痕与肿瘤复发\n外科金属关等執機性(途小狗科) 小狗物质及其他不得接近强磁场者  应该是外科金属夹等铁磁性\n物质及其他不得接近强磁场者\n乱整合物  应该是钆螯合物\n日本孔腺癌学 l Co... States of the 协会指南 . 整句话提取错误\n错别字#3#3#复发种  应该是复发和\n PET-CT 瘤林慈薇介護 ( 2018 ).  应该是关于PET-CT在乳腺癌骨转", "type2": "缺少换行#2#2#(2) 禁忌证: ①体内有起搏器、另起一行\n4- 正电子发射计算机体层成像 ...另起一行", "type3": "无关文本#0#1#与原文无关内容\n无关文本#2#2# ® 2 ⁄ 4 1 ⁄ 3 \n无关文本#3#3#~~ \n无关文本#4#4# 468 2 E", "type4": "语义不完整#2#2# 乳腺癌术后 臺乳治疗后療病与肿瘤复发。前面缺少内容\n语义不完整#3#3#移的患者狩前分期...前面缺少内容", "type5": null, "type6": null}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:40", "update_time": "2024-05-08 23:13:23"}
{"id": 1082523, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 738, "source_info": {"seq_id": "7ffd673a-3dc1-47cf-83ff-39aab433c400", "title": null, "text": "【0】页码:7\n • 796 • 2022 8 100, 135 8 China J Orthop Trauma , Aug.2022, Vol.35 , No.8 ), ( , ), ( , , C ,     ), .\n\n【1】Chapter 1 , ), ( , , 100 ), , o ), ( ), , ( , 1. See also   1990   ), ( ), , .\n\n【2】Chapter 1 ( ), , 100 , ( ), , , ), ( L , , [41] , ), ( , ), ( , 100 , , ),  ), ( , , , 100 s ( ( , , , 100 ), o , ), ( ( , , ), o Chapter 1 , , >> ( , >> ( . \n\n【3】, ), (1999).\n\n【4】( ), , , ), ( ) : Chapter 3 ).\n\n【5】), ( ), Chapter 1 , ( ): ( ( ), ,      ),  __ ), Chapter 1 Chapter 1 ), , ), ( ( ), , si ), ( ( ( ), Chapter 3 , ), ( ), ( Chapter 1 , ),  ), Chapter 1 Chapter 1 , ,  , ), ), ), ( Chapter 1 ), ), ( ( ( ,      ), ), ( ), Chapter 1 ( , ), ), ( ( , ), ), ), Chapter 1 ( , ), ), ( 1 ) ( ( ,  ), Chapter 1 ),  , ), ), ), ), , 100 ,  ),  : ( ( –   ).\n\n【6】), ), Chapter 1 Chapter 1 ), ( ): ( Chapter 1 , ), ( ), Chapter 1 ( ,  , ), ), ( , ,  __ ( ), ( ), ,      ), __ ), ( ), ( , , (1), ( 1996 ), pp. 100.\n\n【7】), ( , , ), ( (1999).\n\n【8】( , ,", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "• 796 •", "bbox": [76.0, 65.0, 117.0, 83.0]}, {"text": "2022 8", "bbox": [365.0, 66.0, 414.0, 83.0]}, {"text": "100, 135", "bbox": [432.0, 66.0, 449.0, 82.0]}, {"text": "8", "bbox": [467.0, 66.0, 482.0, 82.0]}, {"text": "China J Orthop Trauma , Aug.2022, Vol.35 , No.8", "bbox": [500.0, 66.0, 711.0, 84.0]}, {"text": "),", "bbox": [557.0, 106.0, 583.0, 126.0]}, {"text": "(", "bbox": [609.0, 106.0, 631.0, 125.0]}, {"text": ",", "bbox": [495.0, 109.0, 510.0, 127.0]}, {"text": "),", "bbox": [531.0, 124.0, 555.0, 146.0]}, {"text": "(", "bbox": [565.0, 125.0, 588.0, 144.0]}, {"text": ",", "bbox": [467.0, 127.0, 486.0, 145.0]}, {"text": ",", "bbox": [234.0, 131.0, 246.0, 145.0]}, {"text": "C", "bbox": [536.0, 141.0, 588.0, 170.0]}, {"text": ",     ),", "bbox": [455.0, 146.0, 515.0, 165.0]}, {"text": ".", "bbox": [273.0, 149.0, 294.0, 166.0]}, {"text": "Chapter 1", "bbox": [309.0, 149.0, 324.0, 166.0]}, {"text": ",", "bbox": [166.0, 150.0, 180.0, 165.0]}, {"text": "),", "bbox": [463.0, 165.0, 508.0, 185.0]}, {"text": "(", "bbox": [533.0, 165.0, 553.0, 184.0]}, {"text": ",", "bbox": [412.0, 169.0, 427.0, 185.0]}, {"text": ", 100", "bbox": [686.0, 170.0, 700.0, 184.0]}, {"text": "),", "bbox": [440.0, 185.0, 510.0, 204.0]}, {"text": ",", "bbox": [685.0, 188.0, 702.0, 205.0]}, {"text": "o", "bbox": [93.0, 190.0, 106.0, 205.0]}, {"text": "), (", "bbox": [440.0, 206.0, 514.0, 225.0]}, {"text": "),", "bbox": [664.0, 206.0, 702.0, 224.0]}, {"text": ",", "bbox": [601.0, 208.0, 619.0, 225.0]}, {"text": "(", "bbox": [416.0, 226.0, 466.0, 244.0]}, {"text": ",", "bbox": [604.0, 227.0, 625.0, 246.0]}, {"text": "1. See also   1990  ", "bbox": [289.0, 230.0, 305.0, 244.0]}, {"text": "), (", "bbox": [412.0, 244.0, 469.0, 265.0]}, {"text": "),", "bbox": [664.0, 244.0, 708.0, 265.0]}, {"text": ",", "bbox": [601.0, 248.0, 644.0, 267.0]}, {"text": ".", "bbox": [193.0, 250.0, 208.0, 265.0]}, {"text": "Chapter 1", "bbox": [227.0, 251.0, 241.0, 266.0]}, {"text": "(", "bbox": [411.0, 266.0, 440.0, 284.0]}, {"text": "),", "bbox": [670.0, 266.0, 716.0, 284.0]}, {"text": ", 100", "bbox": [625.0, 267.0, 649.0, 287.0]}, {"text": ",", "bbox": [136.0, 271.0, 148.0, 285.0]}, {"text": "(", "bbox": [413.0, 285.0, 444.0, 304.0]}, {"text": "),", "bbox": [628.0, 286.0, 686.0, 304.0]}, {"text": ",", "bbox": [93.0, 288.0, 107.0, 304.0]}, {"text": ",", "bbox": [586.0, 288.0, 602.0, 306.0]}, {"text": "), (", "bbox": [629.0, 304.0, 692.0, 325.0]}, {"text": "L", "bbox": [397.0, 305.0, 449.0, 328.0]}, {"text": ",", "bbox": [563.0, 307.0, 583.0, 326.0]}, {"text": ",", "bbox": [93.0, 309.0, 107.0, 326.0]}, {"text": "[41] ,", "bbox": [251.0, 322.0, 280.0, 343.0]}, {"text": "),", "bbox": [516.0, 325.0, 542.0, 344.0]}, {"text": "(", "bbox": [566.0, 325.0, 590.0, 344.0]}, {"text": ",", "bbox": [452.0, 329.0, 469.0, 345.0]}, {"text": "),", "bbox": [495.0, 345.0, 520.0, 364.0]}, {"text": "(", "bbox": [555.0, 346.0, 595.0, 365.0]}, {"text": ", 100", "bbox": [425.0, 347.0, 444.0, 364.0]}, {"text": ", ,", "bbox": [652.0, 348.0, 695.0, 361.0]}, {"text": "),", "bbox": [410.0, 365.0, 448.0, 384.0]}, {"text": "", "bbox": [555.0, 365.0, 579.0, 391.0]}, {"text": "),", "bbox": [653.0, 365.0, 701.0, 384.0]}, {"text": "(", "bbox": [452.0, 366.0, 470.0, 385.0]}, {"text": ",", "bbox": [616.0, 368.0, 651.0, 385.0]}, {"text": ",", "bbox": [78.0, 370.0, 95.0, 385.0]}, {"text": ", 100", "bbox": [325.0, 370.0, 339.0, 384.0]}, {"text": "s", "bbox": [623.0, 378.0, 656.0, 412.0]}, {"text": "(", "bbox": [655.0, 385.0, 702.0, 404.0]}, {"text": "(", "bbox": [411.0, 387.0, 432.0, 404.0]}, {"text": ",", "bbox": [563.0, 387.0, 602.0, 407.0]}, {"text": ",", "bbox": [242.0, 390.0, 259.0, 405.0]}, {"text": ", 100", "bbox": [148.0, 391.0, 163.0, 405.0]}, {"text": "),", "bbox": [663.0, 405.0, 702.0, 426.0]}, {"text": "o", "bbox": [246.0, 407.0, 262.0, 426.0]}, {"text": ",", "bbox": [569.0, 407.0, 655.0, 426.0]}, {"text": "),", "bbox": [627.0, 425.0, 653.0, 446.0]}, {"text": "(", "bbox": [397.0, 426.0, 417.0, 444.0]}, {"text": "(", "bbox": [666.0, 426.0, 704.0, 444.0]}, {"text": ",", "bbox": [588.0, 428.0, 611.0, 447.0]}, {"text": ",", "bbox": [220.0, 429.0, 240.0, 445.0]}, {"text": "),", "bbox": [629.0, 446.0, 655.0, 465.0]}, {"text": "o", "bbox": [224.0, 448.0, 260.0, 465.0]}, {"text": "Chapter 1", "bbox": [657.0, 447.0, 702.0, 465.0]}, {"text": ",", "bbox": [79.0, 449.0, 94.0, 464.0]}, {"text": ",", "bbox": [525.0, 449.0, 551.0, 465.0]}, {"text": ">>", "bbox": [530.0, 463.0, 558.0, 488.0]}, {"text": "(", "bbox": [561.0, 465.0, 604.0, 484.0]}, {"text": ",", "bbox": [468.0, 468.0, 481.0, 485.0]}, {"text": ">>", "bbox": [567.0, 482.0, 612.0, 508.0]}, {"text": "(", "bbox": [629.0, 484.0, 658.0, 502.0]}, {"text": ". ", "bbox": [190.0, 485.0, 252.0, 503.0]}, {"text": ",", "bbox": [468.0, 488.0, 481.0, 504.0]}, {"text": "),", "bbox": [105.0, 504.0, 173.0, 523.0]}, {"text": "(1999).", "bbox": [322.0, 504.0, 346.0, 523.0]}, {"text": "(", "bbox": [684.0, 504.0, 705.0, 522.0]}, {"text": "),", "bbox": [629.0, 505.0, 657.0, 523.0]}, {"text": ",", "bbox": [566.0, 508.0, 613.0, 523.0]}, {"text": ",", "bbox": [567.0, 523.0, 594.0, 544.0]}, {"text": "), (", "bbox": [600.0, 523.0, 664.0, 543.0]}, {"text": ")", "bbox": [209.0, 524.0, 230.0, 543.0]}, {"text": ":", "bbox": [160.0, 525.0, 178.0, 544.0]}, {"text": "Chapter 3", "bbox": [105.0, 526.0, 163.0, 542.0]}, {"text": ").", "bbox": [301.0, 540.0, 337.0, 566.0]}, {"text": "), (", "bbox": [92.0, 544.0, 158.0, 564.0]}, {"text": "),", "bbox": [568.0, 544.0, 592.0, 565.0]}, {"text": "Chapter 1", "bbox": [607.0, 544.0, 667.0, 564.0]}, {"text": ",", "bbox": [531.0, 548.0, 545.0, 564.0]}, {"text": "(", "bbox": [188.0, 564.0, 210.0, 584.0]}, {"text": "):", "bbox": [296.0, 564.0, 336.0, 583.0]}, {"text": "(", "bbox": [352.0, 564.0, 370.0, 584.0]}, {"text": "(", "bbox": [505.0, 564.0, 520.0, 583.0]}, {"text": "),", "bbox": [688.0, 564.0, 715.0, 584.0]}, {"text": ",      ),", "bbox": [410.0, 565.0, 470.0, 583.0]}, {"text": "", "bbox": [209.0, 566.0, 229.0, 580.0]}, {"text": "__", "bbox": [625.0, 567.0, 673.0, 584.0]}, {"text": "),", "bbox": [236.0, 584.0, 261.0, 604.0]}, {"text": "", "bbox": [188.0, 585.0, 223.0, 600.0]}, {"text": "Chapter 1", "bbox": [294.0, 585.0, 329.0, 605.0]}, {"text": "Chapter 1", "bbox": [440.0, 585.0, 471.0, 604.0]}, {"text": "),", "bbox": [628.0, 585.0, 671.0, 603.0]}, {"text": ",", "bbox": [537.0, 587.0, 554.0, 606.0]}, {"text": "),", "bbox": [165.0, 603.0, 208.0, 623.0]}, {"text": "(", "bbox": [205.0, 604.0, 228.0, 624.0]}, {"text": "(", "bbox": [397.0, 604.0, 413.0, 623.0]}, {"text": "),", "bbox": [643.0, 605.0, 669.0, 623.0]}, {"text": ",", "bbox": [559.0, 608.0, 589.0, 624.0]}, {"text": "si", "bbox": [93.0, 622.0, 134.0, 648.0]}, {"text": "),", "bbox": [309.0, 623.0, 337.0, 645.0]}, {"text": "(", "bbox": [132.0, 625.0, 149.0, 643.0]}, {"text": "(", "bbox": [352.0, 625.0, 368.0, 643.0]}, {"text": "(", "bbox": [397.0, 625.0, 412.0, 643.0]}, {"text": "),", "bbox": [642.0, 625.0, 670.0, 644.0]}, {"text": "Chapter 3", "bbox": [210.0, 627.0, 246.0, 643.0]}, {"text": ",", "bbox": [559.0, 627.0, 590.0, 645.0]}, {"text": "),", "bbox": [218.0, 643.0, 248.0, 663.0]}, {"text": "(", "bbox": [279.0, 644.0, 296.0, 663.0]}, {"text": "),", "bbox": [628.0, 644.0, 671.0, 666.0]}, {"text": "(", "bbox": [685.0, 645.0, 713.0, 663.0]}, {"text": "Chapter 1", "bbox": [397.0, 646.0, 415.0, 664.0]}, {"text": ",", "bbox": [563.0, 647.0, 578.0, 663.0]}, {"text": "),", "bbox": [164.0, 663.0, 188.0, 683.0]}, {"text": "", "bbox": [134.0, 665.0, 164.0, 681.0]}, {"text": "),", "bbox": [504.0, 665.0, 528.0, 682.0]}, {"text": "Chapter 1", "bbox": [563.0, 665.0, 582.0, 684.0]}, {"text": "Chapter 1", "bbox": [222.0, 666.0, 241.0, 684.0]}, {"text": ",", "bbox": [687.0, 666.0, 716.0, 684.0]}, {"text": ", ", "bbox": [627.0, 667.0, 669.0, 704.0]}, {"text": ",", "bbox": [469.0, 669.0, 486.0, 683.0]}, {"text": "),", "bbox": [107.0, 682.0, 136.0, 703.0]}, {"text": "),", "bbox": [346.0, 683.0, 368.0, 704.0]}, {"text": "),", "bbox": [453.0, 683.0, 481.0, 704.0]}, {"text": "(", "bbox": [136.0, 685.0, 187.0, 704.0]}, {"text": "Chapter 1", "bbox": [508.0, 685.0, 528.0, 704.0]}, {"text": "),", "bbox": [689.0, 685.0, 716.0, 705.0]}, {"text": "),", "bbox": [267.0, 703.0, 293.0, 723.0]}, {"text": "(", "bbox": [425.0, 704.0, 440.0, 723.0]}, {"text": "(", "bbox": [91.0, 705.0, 109.0, 723.0]}, {"text": "(", "bbox": [324.0, 705.0, 341.0, 723.0]}, {"text": ",      ),", "bbox": [615.0, 706.0, 674.0, 723.0]}, {"text": "),", "bbox": [207.0, 724.0, 231.0, 744.0]}, {"text": "(", "bbox": [397.0, 724.0, 412.0, 744.0]}, {"text": "),", "bbox": [626.0, 724.0, 650.0, 744.0]}, {"text": "Chapter 1", "bbox": [265.0, 725.0, 284.0, 744.0]}, {"text": "(", "bbox": [684.0, 725.0, 712.0, 743.0]}, {"text": ",", "bbox": [563.0, 726.0, 585.0, 744.0]}, {"text": "),", "bbox": [559.0, 740.0, 596.0, 765.0]}, {"text": "),", "bbox": [135.0, 744.0, 162.0, 763.0]}, {"text": "(", "bbox": [193.0, 745.0, 232.0, 764.0]}, {"text": "(", "bbox": [615.0, 745.0, 655.0, 763.0]}, {"text": ",", "bbox": [537.0, 748.0, 557.0, 765.0]}, {"text": "),", "bbox": [79.0, 764.0, 104.0, 783.0]}, {"text": "),", "bbox": [330.0, 764.0, 354.0, 783.0]}, {"text": "),", "bbox": [557.0, 764.0, 585.0, 784.0]}, {"text": "Chapter 1", "bbox": [135.0, 766.0, 156.0, 784.0]}, {"text": "(", "bbox": [616.0, 766.0, 641.0, 783.0]}, {"text": ",", "bbox": [495.0, 767.0, 514.0, 785.0]}, {"text": "),", "bbox": [254.0, 784.0, 279.0, 804.0]}, {"text": "),", "bbox": [516.0, 784.0, 543.0, 804.0]}, {"text": "( 1 )", "bbox": [565.0, 784.0, 589.0, 803.0]}, {"text": "(", "bbox": [64.0, 785.0, 80.0, 803.0]}, {"text": "(", "bbox": [310.0, 785.0, 324.0, 803.0]}, {"text": ",", "bbox": [453.0, 788.0, 467.0, 806.0]}, {"text": "", "bbox": [136.0, 794.0, 165.0, 822.0]}, {"text": "),", "bbox": [194.0, 804.0, 232.0, 822.0]}, {"text": "Chapter 1", "bbox": [235.0, 804.0, 254.0, 823.0]}, {"text": "),", "bbox": [492.0, 804.0, 592.0, 824.0]}, {"text": "", "bbox": [256.0, 808.0, 285.0, 824.0]}, {"text": ",", "bbox": [426.0, 808.0, 441.0, 825.0]}, {"text": "),", "bbox": [320.0, 819.0, 357.0, 845.0]}, {"text": "),", "bbox": [107.0, 822.0, 166.0, 842.0]}, {"text": "),", "bbox": [477.0, 824.0, 543.0, 844.0]}, {"text": "),", "bbox": [674.0, 824.0, 703.0, 843.0]}, {"text": ", 100", "bbox": [598.0, 826.0, 644.0, 846.0]}, {"text": ",", "bbox": [412.0, 827.0, 439.0, 846.0]}, {"text": "", "bbox": [197.0, 839.0, 224.0, 862.0]}, {"text": "),", "bbox": [267.0, 841.0, 295.0, 863.0]}, {"text": " :", "bbox": [616.0, 841.0, 647.0, 867.0]}, {"text": "(", "bbox": [77.0, 843.0, 94.0, 862.0]}, {"text": "(", "bbox": [416.0, 843.0, 442.0, 862.0]}, {"text": "–", "bbox": [324.0, 844.0, 351.0, 864.0]}, {"text": "", "bbox": [480.0, 848.0, 511.0, 860.0]}, {"text": "", "bbox": [665.0, 848.0, 702.0, 862.0]}, {"text": ").", "bbox": [204.0, 861.0, 229.0, 885.0]}, {"text": "),", "bbox": [425.0, 863.0, 451.0, 883.0]}, {"text": "),", "bbox": [664.0, 863.0, 709.0, 883.0]}, {"text": "", "bbox": [273.0, 864.0, 296.0, 879.0]}, {"text": "Chapter 1", "bbox": [480.0, 864.0, 530.0, 881.0]}, {"text": "Chapter 1", "bbox": [600.0, 866.0, 646.0, 882.0]}, {"text": "),", "bbox": [676.0, 881.0, 717.0, 904.0]}, {"text": "(", "bbox": [176.0, 883.0, 222.0, 902.0]}, {"text": "):", "bbox": [279.0, 882.0, 307.0, 903.0]}, {"text": "(", "bbox": [410.0, 883.0, 442.0, 903.0]}, {"text": "Chapter 1", "bbox": [314.0, 884.0, 359.0, 903.0]}, {"text": ",", "bbox": [601.0, 886.0, 645.0, 904.0]}, {"text": "),", "bbox": [174.0, 903.0, 223.0, 923.0]}, {"text": "(", "bbox": [253.0, 903.0, 270.0, 923.0]}, {"text": "),", "bbox": [584.0, 903.0, 629.0, 924.0]}, {"text": "Chapter 1", "bbox": [418.0, 904.0, 443.0, 923.0]}, {"text": "(", "bbox": [627.0, 904.0, 644.0, 923.0]}, {"text": ",", "bbox": [502.0, 905.0, 539.0, 924.0]}, {"text": "", "bbox": [339.0, 906.0, 361.0, 924.0]}, {"text": ",", "bbox": [93.0, 907.0, 118.0, 924.0]}, {"text": "),", "bbox": [590.0, 918.0, 644.0, 945.0]}, {"text": "),", "bbox": [144.0, 923.0, 205.0, 942.0]}, {"text": "(", "bbox": [670.0, 925.0, 688.0, 942.0]}, {"text": ",", "bbox": [508.0, 926.0, 541.0, 945.0]}, {"text": ", ", "bbox": [77.0, 927.0, 120.0, 942.0]}, {"text": "__", "bbox": [342.0, 927.0, 366.0, 943.0]}, {"text": "(", "bbox": [148.0, 943.0, 179.0, 962.0]}, {"text": "),", "bbox": [571.0, 943.0, 594.0, 962.0]}, {"text": "(", "bbox": [622.0, 943.0, 645.0, 962.0]}, {"text": "),", "bbox": [81.0, 944.0, 128.0, 962.0]}, {"text": ",      ),", "bbox": [310.0, 944.0, 369.0, 963.0]}, {"text": "__", "bbox": [514.0, 944.0, 552.0, 963.0]}, {"text": "),", "bbox": [315.0, 960.0, 369.0, 987.0]}, {"text": "(", "bbox": [77.0, 963.0, 95.0, 981.0]}, {"text": "),", "bbox": [516.0, 962.0, 549.0, 982.0]}, {"text": "(", "bbox": [572.0, 964.0, 592.0, 982.0]}, {"text": ",", "bbox": [268.0, 966.0, 285.0, 986.0]}, {"text": ",", "bbox": [412.0, 969.0, 429.0, 985.0]}, {"text": "(1),", "bbox": [314.0, 983.0, 344.0, 1003.0]}, {"text": "( 1996 ), pp. 100.", "bbox": [78.0, 984.0, 95.0, 1001.0]}, {"text": "),", "bbox": [517.0, 984.0, 542.0, 1002.0]}, {"text": "(", "bbox": [573.0, 984.0, 590.0, 1002.0]}, {"text": ",", "bbox": [248.0, 986.0, 263.0, 1003.0]}, {"text": ",", "bbox": [453.0, 988.0, 467.0, 1003.0]}, {"text": "),", "bbox": [237.0, 1003.0, 262.0, 1023.0]}, {"text": "(", "bbox": [262.0, 1003.0, 294.0, 1022.0]}, {"text": "(1999).", "bbox": [489.0, 1003.0, 508.0, 1022.0]}, {"text": "(", "bbox": [64.0, 1005.0, 78.0, 1022.0]}, {"text": ",", "bbox": [426.0, 1005.0, 440.0, 1023.0]}, {"text": ",", "bbox": [172.0, 1006.0, 186.0, 1023.0]}], "type": "Text", "position": 1}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/骨科/共识/脊髓型颈椎病中西医结合诊疗专家共识.pdf", "page_num": 7}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type2": "格式杂乱#0#8#无有效内容", "type3": null, "type6": ""}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:40", "update_time": "2024-05-07 17:58:31"}
{"id": 1082522, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 738, "source_info": {"seq_id": "1c0ab80a-96d6-4b66-a689-09b9f20aba5f", "title": null, "text": "【0】页码:10\n\n【1】## Disclosures\n\n【2】\n CAL STATE\n\n【3】 Writing Group Disclosures Speakers' Consultant/ Writing group Research Other research bureau/ Expert Ownership advisory member honoraria witness interest Other Employment grant support board Yale University School Hardik P. Amin None None None None None None None of Medicine Tracy E. Madsen Alpert Medical School NHLBI None None None None None None of Brown University (research grant related to stroke) t Susan Ashcraft Novant Health None None None None None None None Dawn M. Bravata Richard L. Roudebush None None None None None None None VA Medical Center Tamika M. Burrus SOC Telemed None None None None None None None Charles Esenwall Montefiore Medical None None None None None None None Center/Albert Einstein College of Medicine S. Claiborne Dell Medical School, AstraZeneca (Institutional None None None None None None Johnston University of Texas support for his time in supporting a European Medicines Authority submission Compensation was not dependent on a positive outcome so doesn't really nerican meet third criterion.) t Peter D. Panagos Washington Univer- None None None None None None None sity, St. Louis Max Wintermark Stanford University None None None None None None None Charles R. Wira Yale University School None None None None None None None of Medicine This table represents the relationships of withing group membass that may be perceived as actual gr reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the willing group are required to complete and submit. A relationship is considered to be \"significant\" if (a) the person\n\n【4】\n receives $5000 or more during ariy 12-month period, or 5% or more of the person's gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns $5000 or more of the fair market value of the entity. A relationship is considered to be \"modest\" if it is less than \"significant\" under the preceding definit tSignificant.\n\n【5】## Reviewer Disclosures\n\n【6】\n Other Speakers' Consultant/ Ownership research bureau/ Expert advisory Reviewer Employment Research grant support honoraria witness interest board Other Seemant Chaturvedi School of Medicine, Univer- NINDS (CREST Astra Zeneca* None None None None None sity of Maryland 2 Executive Con mittee)* VA Puget Sound Health Andrew Huffer None None None None None None None Care System; University of Washington Deborah Kerrigan Vanderbilt University Medi- None None None None None None None cal Center Digvijaya Navalkele Emory University, School of None None None None None None None Medicine Jose G. Romano University of Miami Miller None None None None None None None School of Medicine This table represents the relationships of reviewers that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Ques-\n\n【7】\n tionnaire, which all reviewers are required to complete and submit. A relationship is considered to be \"significant\" if (a) the person receives $5000 or more during any 12-month period, or 5% or more of the person's gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns $5000 or more of the fair market value of the entity. A relationship is considered to be \"modest\" if it is less than \"significant\" under the preceding definition.\n\n【8】\"Modest.\n\n【9】 mod babeoluv\n\n【10】 gro stemmoteds // qui i", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "Disclosures", "bbox": [64.0, 80.0, 124.0, 92.0]}], "type": "Section-header", "position": 2}, {"raw_context": [{"text": "CAL STATE", "bbox": [9.0, 124.0, 40.0, 176.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "Writing Group Disclosures", "bbox": [64.0, 107.0, 202.0, 120.0]}, {"text": "Speakers'", "bbox": [438.0, 130.0, 485.0, 141.0]}, {"text": "Consultant/", "bbox": [610.0, 130.0, 667.0, 141.0]}, {"text": "Writing group", "bbox": [69.0, 143.0, 133.0, 155.0]}, {"text": "Research", "bbox": [250.0, 143.0, 295.0, 154.0]}, {"text": "Other research", "bbox": [326.0, 143.0, 396.0, 154.0]}, {"text": "bureau/", "bbox": [438.0, 143.0, 477.0, 154.0]}, {"text": "Expert", "bbox": [500.0, 143.0, 533.0, 154.0]}, {"text": "Ownership", "bbox": [549.0, 143.0, 600.0, 154.0]}, {"text": "advisory", "bbox": [611.0, 143.0, 650.0, 154.0]}, {"text": "member", "bbox": [69.0, 154.0, 111.0, 166.0]}, {"text": "honoraria", "bbox": [438.0, 154.0, 484.0, 166.0]}, {"text": "witness", "bbox": [500.0, 154.0, 537.0, 166.0]}, {"text": "interest", "bbox": [549.0, 154.0, 587.0, 166.0]}, {"text": "Other", "bbox": [675.0, 154.0, 703.0, 166.0]}, {"text": "Employment", "bbox": [152.0, 155.0, 211.0, 166.0]}, {"text": "grant", "bbox": [250.0, 155.0, 277.0, 166.0]}, {"text": "support", "bbox": [326.0, 155.0, 365.0, 166.0]}, {"text": "board", "bbox": [611.0, 155.0, 640.0, 166.0]}, {"text": "Yale University School", "bbox": [152.0, 171.0, 241.0, 184.0]}, {"text": "Hardik P. Amin", "bbox": [68.0, 172.0, 131.0, 183.0]}, {"text": "None", "bbox": [250.0, 173.0, 273.0, 182.0]}, {"text": "None", "bbox": [326.0, 173.0, 351.0, 183.0]}, {"text": "None", "bbox": [438.0, 173.0, 463.0, 183.0]}, {"text": "None", "bbox": [500.0, 173.0, 523.0, 182.0]}, {"text": "None", "bbox": [549.0, 173.0, 574.0, 183.0]}, {"text": "None", "bbox": [674.0, 173.0, 699.0, 182.0]}, {"text": "None", "bbox": [610.0, 174.0, 635.0, 182.0]}, {"text": "of Medicine", "bbox": [152.0, 185.0, 200.0, 196.0]}, {"text": "Tracy E. Madsen", "bbox": [70.0, 214.0, 136.0, 225.0]}, {"text": "Alpert Medical School", "bbox": [152.0, 214.0, 241.0, 225.0]}, {"text": "NHLBI", "bbox": [250.0, 214.0, 282.0, 225.0]}, {"text": "None", "bbox": [327.0, 214.0, 351.0, 225.0]}, {"text": "None", "bbox": [438.0, 214.0, 464.0, 225.0]}, {"text": "None", "bbox": [500.0, 214.0, 524.0, 225.0]}, {"text": "None", "bbox": [549.0, 214.0, 573.0, 225.0]}, {"text": "None", "bbox": [610.0, 214.0, 635.0, 225.0]}, {"text": "None", "bbox": [674.0, 214.0, 699.0, 225.0]}, {"text": "of Brown University", "bbox": [152.0, 227.0, 232.0, 237.0]}, {"text": "(research grant", "bbox": [250.0, 227.0, 313.0, 238.0]}, {"text": "related to", "bbox": [250.0, 238.0, 291.0, 249.0]}, {"text": "stroke) t", "bbox": [250.0, 250.0, 285.0, 261.0]}, {"text": "Susan Ashcraft", "bbox": [69.0, 267.0, 134.0, 280.0]}, {"text": "Novant Health", "bbox": [152.0, 267.0, 211.0, 280.0]}, {"text": "None", "bbox": [250.0, 268.0, 274.0, 280.0]}, {"text": "None", "bbox": [326.0, 268.0, 351.0, 280.0]}, {"text": "None", "bbox": [438.0, 268.0, 463.0, 280.0]}, {"text": "None", "bbox": [500.0, 268.0, 525.0, 280.0]}, {"text": "None", "bbox": [549.0, 268.0, 573.0, 280.0]}, {"text": "None", "bbox": [610.0, 268.0, 635.0, 280.0]}, {"text": "None", "bbox": [674.0, 268.0, 700.0, 280.0]}, {"text": "Dawn M. Bravata", "bbox": [69.0, 285.0, 139.0, 297.0]}, {"text": "Richard L. Roudebush", "bbox": [152.0, 286.0, 240.0, 297.0]}, {"text": "None", "bbox": [250.0, 286.0, 274.0, 297.0]}, {"text": "None", "bbox": [327.0, 286.0, 350.0, 297.0]}, {"text": "None", "bbox": [438.0, 286.0, 461.0, 297.0]}, {"text": "None", "bbox": [500.0, 286.0, 523.0, 297.0]}, {"text": "None", "bbox": [549.0, 286.0, 573.0, 297.0]}, {"text": "None", "bbox": [611.0, 286.0, 635.0, 297.0]}, {"text": "None", "bbox": [675.0, 286.0, 698.0, 297.0]}, {"text": "VA Medical Center", "bbox": [152.0, 297.0, 229.0, 308.0]}, {"text": "Tamika M. Burrus", "bbox": [70.0, 314.0, 141.0, 326.0]}, {"text": "SOC Telemed", "bbox": [152.0, 314.0, 212.0, 326.0]}, {"text": "None", "bbox": [250.0, 314.0, 274.0, 326.0]}, {"text": "None", "bbox": [326.0, 314.0, 352.0, 326.0]}, {"text": "None", "bbox": [438.0, 314.0, 463.0, 326.0]}, {"text": "None", "bbox": [499.0, 314.0, 525.0, 326.0]}, {"text": "None", "bbox": [549.0, 314.0, 574.0, 326.0]}, {"text": "None", "bbox": [611.0, 314.0, 635.0, 326.0]}, {"text": "None", "bbox": [674.0, 314.0, 700.0, 326.0]}, {"text": "Charles Esenwall", "bbox": [69.0, 333.0, 136.0, 343.0]}, {"text": "Montefiore Medical", "bbox": [152.0, 332.0, 231.0, 343.0]}, {"text": "None", "bbox": [250.0, 334.0, 273.0, 342.0]}, {"text": "None", "bbox": [326.0, 334.0, 351.0, 342.0]}, {"text": "None", "bbox": [438.0, 334.0, 462.0, 342.0]}, {"text": "None", "bbox": [499.0, 334.0, 524.0, 342.0]}, {"text": "None", "bbox": [549.0, 334.0, 573.0, 342.0]}, {"text": "None", "bbox": [611.0, 334.0, 635.0, 342.0]}, {"text": "None", "bbox": [674.0, 334.0, 699.0, 342.0]}, {"text": "Center/Albert Einstein", "bbox": [152.0, 345.0, 239.0, 356.0]}, {"text": "College of Medicine", "bbox": [152.0, 356.0, 235.0, 368.0]}, {"text": "S. Claiborne", "bbox": [69.0, 374.0, 122.0, 386.0]}, {"text": "Dell Medical School,", "bbox": [152.0, 374.0, 235.0, 385.0]}, {"text": "AstraZeneca (Institutional", "bbox": [327.0, 374.0, 426.0, 385.0]}, {"text": "None", "bbox": [250.0, 375.0, 274.0, 385.0]}, {"text": "None", "bbox": [438.0, 375.0, 462.0, 385.0]}, {"text": "None", "bbox": [499.0, 375.0, 525.0, 386.0]}, {"text": "None", "bbox": [549.0, 375.0, 574.0, 386.0]}, {"text": "None", "bbox": [611.0, 375.0, 635.0, 386.0]}, {"text": "None", "bbox": [674.0, 375.0, 700.0, 386.0]}, {"text": "Johnston", "bbox": [71.0, 387.0, 107.0, 398.0]}, {"text": "University of Texas", "bbox": [152.0, 387.0, 226.0, 398.0]}, {"text": "support for his time in sup-", "bbox": [327.0, 387.0, 427.0, 398.0]}, {"text": "porting a European Medi-", "bbox": [326.0, 398.0, 425.0, 409.0]}, {"text": "cines Authority submission", "bbox": [328.0, 411.0, 425.0, 422.0]}, {"text": "Compensation was not", "bbox": [326.0, 422.0, 418.0, 434.0]}, {"text": "dependent on a positive", "bbox": [327.0, 435.0, 419.0, 447.0]}, {"text": "outcome so doesn't really", "bbox": [326.0, 447.0, 425.0, 458.0]}, {"text": "nerican", "bbox": [551.0, 457.0, 566.0, 465.0]}, {"text": "meet third criterion.) t", "bbox": [327.0, 459.0, 409.0, 470.0]}, {"text": "Peter D. Panagos", "bbox": [68.0, 474.0, 141.0, 488.0]}, {"text": "Washington Univer-", "bbox": [152.0, 475.0, 231.0, 487.0]}, {"text": "None", "bbox": [250.0, 476.0, 274.0, 487.0]}, {"text": "None", "bbox": [326.0, 476.0, 351.0, 487.0]}, {"text": "None", "bbox": [438.0, 476.0, 463.0, 487.0]}, {"text": "None", "bbox": [500.0, 476.0, 523.0, 487.0]}, {"text": "None", "bbox": [549.0, 476.0, 573.0, 485.0]}, {"text": "None", "bbox": [611.0, 476.0, 635.0, 486.0]}, {"text": "None", "bbox": [674.0, 476.0, 698.0, 486.0]}, {"text": "sity, St. Louis", "bbox": [152.0, 488.0, 207.0, 500.0]}, {"text": "Max Wintermark", "bbox": [68.0, 505.0, 136.0, 517.0]}, {"text": "Stanford University", "bbox": [152.0, 505.0, 230.0, 517.0]}, {"text": "None", "bbox": [250.0, 506.0, 274.0, 517.0]}, {"text": "None", "bbox": [326.0, 506.0, 351.0, 517.0]}, {"text": "None", "bbox": [438.0, 506.0, 462.0, 517.0]}, {"text": "None", "bbox": [500.0, 506.0, 524.0, 516.0]}, {"text": "None", "bbox": [549.0, 506.0, 573.0, 516.0]}, {"text": "None", "bbox": [611.0, 506.0, 635.0, 517.0]}, {"text": "None", "bbox": [674.0, 506.0, 700.0, 517.0]}, {"text": "Charles R. Wira", "bbox": [69.0, 523.0, 136.0, 535.0]}, {"text": "Yale University School", "bbox": [152.0, 523.0, 242.0, 535.0]}, {"text": "None", "bbox": [250.0, 523.0, 273.0, 535.0]}, {"text": "None", "bbox": [326.0, 523.0, 352.0, 535.0]}, {"text": "None", "bbox": [438.0, 523.0, 464.0, 535.0]}, {"text": "None", "bbox": [500.0, 524.0, 525.0, 534.0]}, {"text": "None", "bbox": [549.0, 524.0, 575.0, 535.0]}, {"text": "None", "bbox": [611.0, 524.0, 635.0, 535.0]}, {"text": "None", "bbox": [674.0, 524.0, 700.0, 534.0]}, {"text": "of Medicine", "bbox": [152.0, 536.0, 201.0, 547.0]}, {"text": "This table represents the relationships of withing group membass that may be perceived as actual gr reasonably perceived conflicts of interest as reported on the", "bbox": [75.0, 555.0, 715.0, 568.0]}, {"text": "Disclosure Questionnaire, which all members of the willing group are required to complete and submit. A relationship is considered to be \"significant\" if (a) the person", "bbox": [63.0, 568.0, 715.0, 580.0]}], "type": "Table", "position": 4}, {"raw_context": [{"text": "receives $5000 or more during ariy 12-month period, or 5% or more of the person's gross income; or (b) the person owns 5% or more of the voting stock or share of the", "bbox": [63.0, 579.0, 716.0, 591.0]}, {"text": "entity, or owns $5000 or more of the fair market value of the entity. A relationship is considered to be \"modest\" if it is less than \"significant\" under the preceding definit", "bbox": [65.0, 592.0, 714.0, 603.0]}, {"text": "tSignificant.", "bbox": [76.0, 603.0, 126.0, 615.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "Reviewer Disclosures", "bbox": [63.0, 675.0, 176.0, 688.0]}], "type": "Section-header", "position": 6}, {"raw_context": [{"text": "Other", "bbox": [383.0, 697.0, 412.0, 709.0]}, {"text": "Speakers'", "bbox": [436.0, 697.0, 482.0, 709.0]}, {"text": "Consultant/", "bbox": [604.0, 697.0, 661.0, 709.0]}, {"text": "Ownership", "bbox": [546.0, 709.0, 594.0, 721.0]}, {"text": "research", "bbox": [383.0, 710.0, 423.0, 722.0]}, {"text": "bureau/", "bbox": [436.0, 710.0, 476.0, 721.0]}, {"text": "Expert", "bbox": [495.0, 710.0, 528.0, 722.0]}, {"text": "advisory", "bbox": [605.0, 710.0, 644.0, 722.0]}, {"text": "Reviewer", "bbox": [69.0, 722.0, 114.0, 733.0]}, {"text": "Employment", "bbox": [185.0, 722.0, 244.0, 733.0]}, {"text": "Research grant", "bbox": [302.0, 722.0, 374.0, 733.0]}, {"text": "support", "bbox": [383.0, 722.0, 421.0, 733.0]}, {"text": "honoraria", "bbox": [436.0, 722.0, 482.0, 733.0]}, {"text": "witness", "bbox": [495.0, 722.0, 532.0, 733.0]}, {"text": "interest", "bbox": [546.0, 722.0, 583.0, 733.0]}, {"text": "board", "bbox": [604.0, 722.0, 635.0, 733.0]}, {"text": "Other", "bbox": [675.0, 722.0, 703.0, 733.0]}, {"text": "Seemant Chaturvedi", "bbox": [70.0, 739.0, 154.0, 750.0]}, {"text": "School of Medicine, Univer-", "bbox": [185.0, 739.0, 293.0, 750.0]}, {"text": "NINDS (CREST", "bbox": [302.0, 739.0, 372.0, 750.0]}, {"text": "Astra Zeneca*", "bbox": [604.0, 739.0, 664.0, 750.0]}, {"text": "None", "bbox": [383.0, 740.0, 408.0, 749.0]}, {"text": "None", "bbox": [435.0, 740.0, 460.0, 749.0]}, {"text": "None", "bbox": [495.0, 740.0, 520.0, 749.0]}, {"text": "None", "bbox": [545.0, 740.0, 570.0, 749.0]}, {"text": "None", "bbox": [674.0, 740.0, 700.0, 749.0]}, {"text": "sity of Maryland", "bbox": [185.0, 752.0, 250.0, 763.0]}, {"text": "2 Executive Con", "bbox": [304.0, 752.0, 369.0, 763.0]}, {"text": "mittee)*", "bbox": [304.0, 763.0, 336.0, 775.0]}, {"text": "VA Puget Sound Health", "bbox": [185.0, 781.0, 283.0, 792.0]}, {"text": "Andrew Huffer", "bbox": [69.0, 782.0, 131.0, 792.0]}, {"text": "None", "bbox": [302.0, 783.0, 328.0, 791.0]}, {"text": "None", "bbox": [383.0, 782.0, 408.0, 793.0]}, {"text": "None", "bbox": [435.0, 783.0, 461.0, 793.0]}, {"text": "None", "bbox": [495.0, 783.0, 520.0, 792.0]}, {"text": "None", "bbox": [545.0, 783.0, 570.0, 793.0]}, {"text": "None", "bbox": [604.0, 782.0, 630.0, 793.0]}, {"text": "None", "bbox": [674.0, 782.0, 700.0, 793.0]}, {"text": "Care System; University of", "bbox": [185.0, 794.0, 290.0, 805.0]}, {"text": "Washington", "bbox": [185.0, 805.0, 234.0, 816.0]}, {"text": "Deborah Kerrigan", "bbox": [69.0, 823.0, 143.0, 834.0]}, {"text": "Vanderbilt University Medi-", "bbox": [185.0, 823.0, 291.0, 834.0]}, {"text": "None", "bbox": [302.0, 823.0, 328.0, 834.0]}, {"text": "None", "bbox": [383.0, 823.0, 408.0, 834.0]}, {"text": "None", "bbox": [436.0, 823.0, 460.0, 834.0]}, {"text": "None", "bbox": [495.0, 823.0, 520.0, 834.0]}, {"text": "None", "bbox": [546.0, 823.0, 570.0, 834.0]}, {"text": "None", "bbox": [604.0, 823.0, 630.0, 834.0]}, {"text": "None", "bbox": [674.0, 823.0, 700.0, 834.0]}, {"text": "cal Center", "bbox": [185.0, 836.0, 229.0, 846.0]}, {"text": "Digvijaya Navalkele", "bbox": [68.0, 853.0, 148.0, 865.0]}, {"text": "Emory University, School of", "bbox": [185.0, 853.0, 295.0, 864.0]}, {"text": "None", "bbox": [302.0, 853.0, 328.0, 864.0]}, {"text": "None", "bbox": [383.0, 853.0, 407.0, 864.0]}, {"text": "None", "bbox": [436.0, 853.0, 460.0, 864.0]}, {"text": "None", "bbox": [495.0, 853.0, 519.0, 864.0]}, {"text": "None", "bbox": [545.0, 853.0, 570.0, 864.0]}, {"text": "None", "bbox": [604.0, 853.0, 629.0, 864.0]}, {"text": "None", "bbox": [674.0, 853.0, 699.0, 864.0]}, {"text": "Medicine", "bbox": [185.0, 864.0, 224.0, 876.0]}, {"text": "Jose G. Romano", "bbox": [70.0, 883.0, 139.0, 894.0]}, {"text": "University of Miami Miller", "bbox": [185.0, 883.0, 285.0, 893.0]}, {"text": "None", "bbox": [302.0, 883.0, 328.0, 893.0]}, {"text": "None", "bbox": [383.0, 883.0, 407.0, 893.0]}, {"text": "None", "bbox": [436.0, 883.0, 460.0, 893.0]}, {"text": "None", "bbox": [495.0, 883.0, 520.0, 893.0]}, {"text": "None", "bbox": [545.0, 883.0, 570.0, 893.0]}, {"text": "None", "bbox": [604.0, 883.0, 629.0, 893.0]}, {"text": "None", "bbox": [674.0, 883.0, 699.0, 892.0]}, {"text": "School of Medicine", "bbox": [185.0, 895.0, 264.0, 906.0]}, {"text": "This table represents the relationships of reviewers that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Ques-", "bbox": [75.0, 915.0, 713.0, 926.0]}], "type": "Table", "position": 7}, {"raw_context": [{"text": "tionnaire, which all reviewers are required to complete and submit. A relationship is considered to be \"significant\" if (a) the person receives $5000 or more during any", "bbox": [65.0, 926.0, 715.0, 938.0]}, {"text": "12-month period, or 5% or more of the person's gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns $5000 or more of", "bbox": [66.0, 938.0, 715.0, 950.0]}, {"text": "the fair market value of the entity. A relationship is considered to be \"modest\" if it is less than \"significant\" under the preceding definition.", "bbox": [64.0, 950.0, 594.0, 963.0]}, {"text": "\"Modest.", "bbox": [76.0, 963.0, 111.0, 974.0]}], "type": "Text", "position": 8}, {"raw_context": [{"text": "mod babeoluv", "bbox": [22.0, 545.0, 35.0, 608.0]}], "type": "Text", "position": 9}, {"raw_context": [{"text": "gro stemmoteds // qui i", "bbox": [22.0, 604.0, 35.0, 701.0]}], "type": "Text", "position": 10}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/神经科/共识/2023 AHA科学声明：急诊科短暂性脑缺血发作的诊断、检查和风险降低(1).pdf", "page_num": 10}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": null, "type3": null, "type4": null, "type5": null, "type6": "信息有用性#0#10#类似参考文献内容"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:40", "update_time": "2024-05-07 18:30:24"}
{"id": 1082521, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 738, "source_info": {"seq_id": "273cf276-31a9-4afe-b513-e7e336cf7e45", "title": null, "text": "【0】页码:38\n .\n\n【1】 Prepare equipment for airway management (different tubes such as Guedel and laryngeal tubes, mask) and resuscitation equipment\n\n【2】 .\n\n【3】 Prepare drugs according to the relevant guidelines, for health and safety as well as for hygiene.\n\n【4】 Intraprocedural sedation management and patient care\n\n【5】 After completing the course the participant should be able to:\n\n【6】 .\n\n【7】 Demonstrate understanding of the relevant anatomy and physiology of the heart and\n\n【8】 respiratory tract\n\n【9】 .\n\n【10】 Demonstrate understanding of the basics of pharmacology and pharmacokinetics of the\n\n【11】 following drugs, including different sedation concepts, their possibilities and limitations, possible side effects, and prevention and treatment of complications:\n\n【12】 Benzodiazepines and their antagonists o\n\n【13】 o\n\n【14】 Opioids and their antagonists\n\n【15】 Propofol Chapter 1\n\n【16】 o\n\n【17】 Oxygen\n\n【18】 .\n\n【19】 Plan, perform and state reasons for individually adapted nursing and medical actions performed during the individual procedure\n\n【20】 .\n\n【21】 Use the appropriate equipment for patient monitoring, including:\n\n【22】 continuous pulse oximetry and automated non-invasive blood pressure measurement at o baseline and then at 3–5-minute intervals\n\n【23】 ECG for patients with a history of cardiac and/or pulmonary disease o\n\n【24】 .\n\n【25】 Assess patient status by using standardized methods and scores, including:\n\n【26】 cardiorespiratory activity o\n\n【27】 o\n\n【28】 sedation level", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": ".", "bbox": [141.0, 143.0, 153.0, 156.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "Prepare equipment for airway management (different tubes such as Guedel and laryngeal tubes,", "bbox": [161.0, 141.0, 685.0, 157.0]}, {"text": "mask) and resuscitation equipment", "bbox": [161.0, 166.0, 357.0, 181.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": ".", "bbox": [140.0, 205.0, 154.0, 216.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "Prepare drugs according to the relevant guidelines, for health and safety as well as for hygiene.", "bbox": [161.0, 201.0, 675.0, 217.0]}], "type": "Text", "position": 6}, {"raw_context": [{"text": "Intraprocedural sedation management and patient care", "bbox": [119.0, 287.0, 422.0, 301.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "After completing the course the participant should be able to:", "bbox": [119.0, 311.0, 456.0, 326.0]}], "type": "Text", "position": 8}, {"raw_context": [{"text": ".", "bbox": [140.0, 337.0, 155.0, 349.0]}], "type": "Text", "position": 9}, {"raw_context": [{"text": "Demonstrate understanding of the relevant anatomy and physiology of the heart and", "bbox": [161.0, 335.0, 625.0, 350.0]}], "type": "Text", "position": 10}, {"raw_context": [{"text": "respiratory tract", "bbox": [161.0, 359.0, 255.0, 374.0]}], "type": "Text", "position": 11}, {"raw_context": [{"text": ".", "bbox": [141.0, 398.0, 153.0, 410.0]}], "type": "Text", "position": 12}, {"raw_context": [{"text": "Demonstrate understanding of the basics of pharmacology and pharmacokinetics of the", "bbox": [161.0, 396.0, 638.0, 410.0]}], "type": "Text", "position": 13}, {"raw_context": [{"text": "following drugs, including different sedation concepts, their possibilities and limitations, possible", "bbox": [161.0, 419.0, 686.0, 435.0]}, {"text": "side effects, and prevention and treatment of complications:", "bbox": [161.0, 444.0, 493.0, 459.0]}], "type": "Text", "position": 14}, {"raw_context": [{"text": "Benzodiazepines and their antagonists", "bbox": [204.0, 480.0, 417.0, 495.0]}, {"text": "o", "bbox": [183.0, 483.0, 203.0, 494.0]}], "type": "Text", "position": 15}, {"raw_context": [{"text": "o", "bbox": [183.0, 519.0, 198.0, 530.0]}], "type": "Text", "position": 16}, {"raw_context": [{"text": "Opioids and their antagonists", "bbox": [203.0, 516.0, 368.0, 530.0]}], "type": "Text", "position": 17}, {"raw_context": [{"text": "Propofol", "bbox": [204.0, 552.0, 257.0, 567.0]}, {"text": "Chapter 1", "bbox": [183.0, 555.0, 201.0, 565.0]}], "type": "Text", "position": 18}, {"raw_context": [{"text": "o", "bbox": [184.0, 592.0, 204.0, 603.0]}], "type": "Text", "position": 19}, {"raw_context": [{"text": "Oxygen", "bbox": [204.0, 589.0, 250.0, 604.0]}], "type": "Text", "position": 20}, {"raw_context": [{"text": ".", "bbox": [141.0, 627.0, 153.0, 638.0]}], "type": "Text", "position": 21}, {"raw_context": [{"text": "Plan, perform and state reasons for individually adapted nursing and medical actions performed", "bbox": [161.0, 624.0, 682.0, 639.0]}, {"text": "during the individual procedure", "bbox": [161.0, 649.0, 336.0, 664.0]}], "type": "Text", "position": 22}, {"raw_context": [{"text": ".", "bbox": [141.0, 687.0, 153.0, 698.0]}], "type": "Text", "position": 23}, {"raw_context": [{"text": "Use the appropriate equipment for patient monitoring, including:", "bbox": [161.0, 685.0, 518.0, 699.0]}], "type": "Text", "position": 24}, {"raw_context": [{"text": "continuous pulse oximetry and automated non-invasive blood pressure measurement at", "bbox": [204.0, 721.0, 685.0, 736.0]}, {"text": "o", "bbox": [183.0, 724.0, 201.0, 735.0]}, {"text": "baseline and then at 3–5-minute intervals", "bbox": [205.0, 745.0, 437.0, 760.0]}], "type": "Text", "position": 25}, {"raw_context": [{"text": "ECG for patients with a history of cardiac and/or pulmonary disease", "bbox": [203.0, 782.0, 573.0, 797.0]}, {"text": "o", "bbox": [184.0, 784.0, 203.0, 796.0]}], "type": "Text", "position": 26}, {"raw_context": [{"text": ".", "bbox": [141.0, 821.0, 153.0, 832.0]}], "type": "Text", "position": 27}, {"raw_context": [{"text": "Assess patient status by using standardized methods and scores, including:", "bbox": [161.0, 818.0, 567.0, 833.0]}], "type": "Text", "position": 28}, {"raw_context": [{"text": "cardiorespiratory activity", "bbox": [204.0, 854.0, 344.0, 869.0]}, {"text": "o", "bbox": [183.0, 857.0, 204.0, 868.0]}], "type": "Text", "position": 29}, {"raw_context": [{"text": "o", "bbox": [184.0, 893.0, 199.0, 905.0]}], "type": "Text", "position": 30}, {"raw_context": [{"text": "sedation level", "bbox": [204.0, 890.0, 284.0, 904.0]}], "type": "Text", "position": 31}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/消化科/_2023 BSG指南：胃肠内窥镜检查中的镇静.pdf", "page_num": 38}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "多余换行#0#28#全篇序号和正文分离\n多余换行#7#8#为同段\n多余换行#10#11#为同段", "type3": "无关文本#15#15#1", "type4": "栏目混乱#12#17#序号正文穿插\n栏目混乱#26#28#序号正文穿插", "type5": null, "type6": null}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:40", "update_time": "2024-05-07 18:35:18"}
{"id": 1082520, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 738, "source_info": {"seq_id": "60cf7dfb-d74d-4079-9114-b8c0fcef41a4", "title": null, "text": "【0】页码:10\n 10\n\n【1】 medical care. Further, the information is not intended to substitute for the independent professional judgment of the treating provider, as the information does not account for individual variation among patients. Recommendations specify the level of confidence that the recommendation reflects the net effect of a given course of action. The use of words such as \"must\", \"must not\", \"should\", and \"should not\" indicates that a course of action is recommended or not recommended for either most or many patients, but there is latitude for the treating physician to select other courses of action in individual cases. In all cases, the selected course of action should be considered by the treating provider in the context of treating the individual patient. Use of the information is voluntary. ASCO does not endorse third-party drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions. Any use of a brand or trade name is for identification purposes only. ASCO provides this information on an \"as is\" basis and makes no warranty, express or implied, regarding the information. ASCO specifically disclaims any warranties of merchantability or fitness for a particular use or purpose.\n\n【2】ASCO assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of this information, or for any errors or omissions.\n\n【3】## Supplementary Data\n\n【4】\n Supplementary data to this article can be found online at https://doi.org/10.1016/j.eururo.2023.02.027 .\n\n【5】## References\n\n【6】\n [1] Sakalis VI, Campi R, Barreto L, et al. What is the most effective management of the primary tumor in men with invasive penile cancer: a systematic review of the available treatment options and their outcomes. Eur Urol Open Sci 2022;40:58–94 .\n\n【7】[2] Sakalis V, Tagawa S, Brouwer O, et al. Management of lymph nodepositive penile cancer: a systematic review. PROSPERO. https:// www.crd.york.ac.uk/prospero/display_record.php?RecordID= 290784 .\n\n【8】[3] Fernandez-Pello S, Sakalis V, Greco I, et al. Nodal staging in penile cancer: a systematic review and meta-analysis. PROSPERO. https:// www.crd.york.ac.uk/prospero/display_record.php?RecordID= 395174.\n\n【9】[4] Fu L, Tian T, Yao K, et al. Global pattern and trends in penile cancer incidence: population-based study. JMIR Public Health Surveill 2022;8:e34874 .\n\n【10】[5] Hansen BT, Orumaa M, Lie AK, Brennhovd B, Nygård M. Trends in incidence, mortality and survival of penile squamous cell carcinoma in Norway 1956–2015. Int J Cancer 2018;142:1586–93 .\n\n【11】[6] Qi F, Wei X, Zheng Y, Ren X, Li X, Zhao E. Incidence trends and survival outcomes of penile squamous cell carcinoma: evidence from the Surveillance, Epidemiology and End Results populationbased data. Ann Transl Med 2020;8:1428 .\n\n【12】[7] Cancer Research UK. Penile cancer incidence trends over time.\n\n【13】https://www.cancerresearchuk.org/health-professional/cancerstatistics/statistics-by-cancer-type/penile-cancer/ incidence#heading-Two .\n\n【14】[8] Moch H, Amin MB, Berney DM, et al. The 2022 World Health Organization classification of tumours of the urinary system and male genital organs—part A: renal, penile, and testicular tumours.\n\n【15】Eur Urol 2022;82:458–68 .\n\n【16】[9] Olesen TB, Sand FL, Rasmussen CL, et al. Prevalence of human papillomavirus DNA and p16(INK4a) in penile cancer and penile intraepithelial neoplasia: a systematic review and meta-analysis.\n\n【17】Lancet Oncol 2019;20:145–58 .\n\n【18】[10] Lont AP, Kroon BK, Horenblas S, et al. Presence of high-risk human papillomavirus DNA in penile carcinoma predicts favorable outcome in survival. Int J Cancer 2006;119:1078–81 .\n\n【19】[11] Bezerra AL, Lopes A, Santiago GH, Ribeiro KC, Latorre MR, Villa LL.\n\n【20】Human papillomavirus as a prognostic factor in carcinoma of the penis: analysis of 82 patients treated with amputation and bilateral lymphadenectomy. Cancer 2001;91:2315–21 .\n\n【21】 [12] Douglawi A, Masterson TA. Updates on the epidemiology and risk actors for penile cancer. Transl Androl Urol 2017;6:785–90.\n\n【22】[13] WHO Classification of Tumours Editorial Board. Urinary and male genital tumours. WHO classification of tumours, volume 8. ed. 5.\n\n【23】Lyon, France: IARC; 2022.\n\n【24】[14] Sanchez DF, Soares F, Alvarado-Cabrero I, et al. Pathological factors, behavior, and histological prognostic risk groups in subtypes of penile squamous cell carcinomas (SCC). Semin Diagn Pathol 2015;32:222–31 .\n\n【25】[15] Thomas A, Necchi A, Muneer A, et al. Penile cancer. Nat Rev Dis Primers 2021;7:11 .\n\n【26】[16] Horenblas S, van Tinteren H. Squamous cell carcinoma of the penis. IV. Prognostic factors of survival: analysis of tumor, nodes and metastasis classification system. J Urol 1994;151:1239–43 .\n\n【27】[17] Deng X, Liu Y, Zhan X, et al. Trends in incidence, mortality, and survival of penile cancer in the United States: a population-based study. Front Oncol 2022;12:891623 .\n\n【28】[18] Corbishley C, Chaux A, Colecchia M, et al. Carcinoma of the penis and distal urethra histopathology reporting guide.\n\n【29】1st edition. Sydney, Australia: International Collaboration on Cancer Reporting; 2017 .\n\n【30】[19] Brierley J, Gospodarowicz M, Wittekind C. TNM classification of malignant tumours. ed. 8. Chichester, UK: Wiley-Blackwell; 2016 .\n\n【31】[20] Amin MB, Greene FL, Edge SB, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a populationbased to a more \"personalized\" approach to cancer staging. CA Cancer J Clin 2017;67:93–9 .\n\n【32】[21] Chipollini J, De la Rosa AH, Azizi M, Shayegan B, Zorn KC, Spiess PE.\n\n【33】Patient presentation, differential diagnosis, and management of penile lesions. Can Urol Assoc J 2019;13:S2–8 .\n\n【34】[22] Bertolotto M, Serafini G, Dogliotti L, et al. Primary and secondary malignancies of the penis: ultrasound features. Abdom Imaging 2005; 30: 108–12 .\n\n【35】[23] Kayes O, Minhas S, Allen C, Hare C, Freeman A, Ralph D. The role of magnetic resonance imaging in the local staging of penile cancer.\n\n【36】Eur Urol 2007;51:1313–8 .\n\n【37】[24] Bozzini G, Provenzano M, Romero Otero J, et al. Role of penile Doppler US in the preoperative assessment of penile squamous cell carcinoma patients: results from a large prospective multicenter European study. Urology 2016;90:131–5 .\n\n【38】[25] Kroon BK, Horenblas S, Lont AP, Tanis PJ, Gallee MP, Nieweg OE.\n\n【39】Patients with penile carcinoma benefit from immediate resection of clinically occult lymph node metastases.\n\n【40】Urol 2005; 173:816–9 .\n\n【41】[26] Mueller-Lisse UG, Scher B, Scherr MK, Seitz M. Functional imaging in penile cancer: PET/computed tomography, MRI, and sentinel lymph node biopsy. Curr Opin Urol 2008;18:105–10 .\n\n【42】[27] Leijte JA, Graafland NM, Valdes Olmos RA, van Boven HH, Hoefnagel CA, Horenblas S. Prospective evaluation of hybrid 18F- fluorodeoxyglucose positron emission tomography/computed tomography in staging clinically node-negative patients with penile carcinoma. BJU Int 2009; 104:640–4 .\n\n【43】[28] Schlenker B, Scher B, Tiling R, et al. Detection of inguinal lymph node involvement in penile squamous cell carcinoma by ' fluorodeoxyglucose PET/CT: a prospective single- center study.\n\n【44】Urol Oncol 2012;30:55–9 .\n\n【45】[29] Fankhauser CD, de Vries HM, Roussel E, et al. Lymphovascular and perineural invasion are risk factors for inguinal lymph node metastases in men with T1G2 penile cancer. J Cancer Res Clin Oncol 2022;148:2231–4 .\n\n【46】[30] Graafland NM, Lam W, Leijte JA, et al. Prognostic factors for occult inguinal lymph node involvement in penile carcinoma and assessment of the high-risk EAU subgroup: a two-institution analysis of 342 clinically node-negative patients. Eur Urol 2010;58:742–7 .\n\n【47】[31] d'Ancona CA, de Lucena RG, Querne FA, Martins MH, Denardi F, Netto Jr NR. Long-term followup of penile carcinoma treated with penectomy and bilateral modified inguinal lymphadenectomy. J Urol 2004;172:498–501 .\n\n【48】[32] Thyavihally YB, Dev P, Waigankar SS, et al. Comparative study of perioperative and survival outcomes after video endoscopic inguinal lymphadenectomy (VEIL) and open inguinal lymph node dissection (O-ILND) in the management of inguinal lymph nodes in carcinoma of the penis. J Robot Surg 2021;15:905–14 .\n\n【49】[33] Lee EWC, Issa A, Oliveira P, et al. High diagnostic accuracy of inguinal ultrasonography and fine-needle aspiration followed by\n\n【50】 Please cite this article as: O.R. Brouwer, M. Albersen, A. Parnham et al., European Association of Urology–American Society of Clinical Oncology Collaborative Guideline on Penile Cancer: 2023 Update, Eur Urol (2023), https://doi.org/10.1016/j.eururo.2023.02.027", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "10", "bbox": [62.0, 42.0, 78.0, 54.0]}], "type": "Text", "position": 0}, {"raw_context": [{"text": "medical care. Further, the information is not intended to substitute for the", "bbox": [62.0, 87.0, 383.0, 99.0]}, {"text": "independent professional judgment of the treating provider, as the infor-", "bbox": [62.0, 103.0, 382.0, 115.0]}, {"text": "mation does not account for individual variation among patients. Recom-", "bbox": [62.0, 117.0, 382.0, 128.0]}, {"text": "mendations specify the level of confidence that the recommendation", "bbox": [62.0, 131.0, 383.0, 143.0]}, {"text": "reflects the net effect of a given course of action. The use of words such", "bbox": [62.0, 146.0, 383.0, 158.0]}, {"text": "as \"must\", \"must not\", \"should\", and \"should not\" indicates that a course", "bbox": [62.0, 160.0, 383.0, 172.0]}, {"text": "of action is recommended or not recommended for either most or many", "bbox": [61.0, 175.0, 382.0, 187.0]}, {"text": "patients, but there is latitude for the treating physician to select other", "bbox": [62.0, 191.0, 382.0, 202.0]}, {"text": "courses of action in individual cases. In all cases, the selected course of", "bbox": [62.0, 205.0, 383.0, 217.0]}, {"text": "action should be considered by the treating provider in the context of", "bbox": [62.0, 219.0, 383.0, 232.0]}, {"text": "treating the individual patient. Use of the information is voluntary. ASCO", "bbox": [62.0, 233.0, 383.0, 246.0]}, {"text": "does not endorse third-party drugs, devices, services, or therapies used to", "bbox": [62.0, 248.0, 383.0, 260.0]}, {"text": "diagnose, treat, monitor, manage, or alleviate health conditions. Any use", "bbox": [61.0, 263.0, 383.0, 275.0]}, {"text": "of a brand or trade name is for identification purposes only. ASCO pro-", "bbox": [61.0, 277.0, 382.0, 289.0]}, {"text": "vides this information on an \"as is\" basis and makes no warranty, express", "bbox": [62.0, 292.0, 383.0, 305.0]}, {"text": "or implied, regarding the information. ASCO specifically disclaims any", "bbox": [61.0, 307.0, 383.0, 319.0]}, {"text": "warranties of merchantability or fitness for a particular use or purpose.", "bbox": [62.0, 322.0, 382.0, 334.0]}, {"text": "ASCO assumes no responsibility for any injury or damage to persons or", "bbox": [62.0, 336.0, 383.0, 348.0]}, {"text": "property arising out of or related to any use of this information, or for", "bbox": [62.0, 350.0, 382.0, 362.0]}, {"text": "any errors or omissions.", "bbox": [62.0, 365.0, 168.0, 376.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "Supplementary data", "bbox": [60.0, 405.0, 178.0, 419.0]}], "type": "Section-header", "position": 4}, {"raw_context": [{"text": "Supplementary data to this article can be found online at", "bbox": [61.0, 437.0, 383.0, 451.0]}, {"text": "https://doi.org/10.1016/j.eururo.2023.02.027 .", "bbox": [60.0, 453.0, 305.0, 467.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "References", "bbox": [61.0, 490.0, 122.0, 504.0]}], "type": "Section-header", "position": 6}, {"raw_context": [{"text": "[1] Sakalis VI, Campi R, Barreto L, et al. What is the most effective", "bbox": [70.0, 517.0, 383.0, 528.0]}, {"text": "management of the primary tumor in men with invasive penile", "bbox": [88.0, 530.0, 382.0, 541.0]}, {"text": "cancer: a systematic review of the available treatment options and", "bbox": [88.0, 541.0, 382.0, 553.0]}, {"text": "their outcomes. Eur Urol Open Sci 2022;40:58–94 .", "bbox": [87.0, 555.0, 314.0, 565.0]}, {"text": "[2] Sakalis V, Tagawa S, Brouwer O, et al. Management of lymph node-", "bbox": [70.0, 565.0, 380.0, 578.0]}, {"text": "positive penile cancer: a systematic review. PROSPERO. https://", "bbox": [88.0, 578.0, 382.0, 589.0]}, {"text": "www.crd.york.ac.uk/prospero/display_record.php?RecordID=", "bbox": [88.0, 590.0, 358.0, 601.0]}, {"text": "290784 .", "bbox": [88.0, 601.0, 125.0, 613.0]}, {"text": "[3] Fernandez-Pello S, Sakalis V, Greco I, et al. Nodal staging in penile", "bbox": [70.0, 613.0, 382.0, 626.0]}, {"text": "cancer: a systematic review and meta-analysis. PROSPERO. https://", "bbox": [88.0, 625.0, 382.0, 638.0]}, {"text": "www.crd.york.ac.uk/prospero/display_record.php?RecordID=", "bbox": [88.0, 638.0, 358.0, 650.0]}, {"text": "395174.", "bbox": [88.0, 650.0, 125.0, 661.0]}, {"text": "[4] Fu L, Tian T, Yao K, et al. Global pattern and trends in penile cancer", "bbox": [70.0, 661.0, 382.0, 674.0]}, {"text": "incidence: population-based study. JMIR Public Health Surveill", "bbox": [88.0, 674.0, 383.0, 686.0]}, {"text": "2022;8:e34874 .", "bbox": [88.0, 686.0, 160.0, 697.0]}, {"text": "[5] Hansen BT, Orumaa M, Lie AK, Brennhovd B, Nygård M. Trends in", "bbox": [70.0, 696.0, 383.0, 710.0]}, {"text": "incidence, mortality and survival of penile squamous cell", "bbox": [88.0, 710.0, 383.0, 721.0]}, {"text": "carcinoma in Norway 1956–2015. Int J Cancer 2018;142:1586–93 .", "bbox": [88.0, 721.0, 382.0, 733.0]}, {"text": "[6] Qi F, Wei X, Zheng Y, Ren X, Li X, Zhao E. Incidence trends and", "bbox": [70.0, 734.0, 383.0, 746.0]}, {"text": "survival outcomes of penile squamous cell carcinoma: evidence", "bbox": [89.0, 745.0, 382.0, 757.0]}, {"text": "from the Surveillance, Epidemiology and End Results population-", "bbox": [88.0, 757.0, 381.0, 768.0]}, {"text": "based data. Ann Transl Med 2020;8:1428 .", "bbox": [88.0, 768.0, 276.0, 780.0]}, {"text": "[7] Cancer Research UK. Penile cancer incidence trends over time.", "bbox": [70.0, 781.0, 381.0, 792.0]}, {"text": "https://www.cancerresearchuk.org/health-professional/cancer-", "bbox": [88.0, 793.0, 369.0, 803.0]}, {"text": "statistics/statistics-by-cancer-type/penile-cancer/", "bbox": [88.0, 805.0, 308.0, 817.0]}, {"text": "incidence#heading-Two .", "bbox": [88.0, 817.0, 199.0, 828.0]}, {"text": "[8] Moch H, Amin MB, Berney DM, et al. The 2022 World Health", "bbox": [70.0, 828.0, 383.0, 841.0]}, {"text": "Organization classification of tumours of the urinary system and", "bbox": [88.0, 841.0, 382.0, 852.0]}, {"text": "male genital organs—part A: renal, penile, and testicular tumours.", "bbox": [88.0, 853.0, 381.0, 864.0]}, {"text": "Eur Urol 2022;82:458–68 .", "bbox": [88.0, 865.0, 205.0, 877.0]}, {"text": "[9] Olesen TB, Sand FL, Rasmussen CL, et al. Prevalence of human", "bbox": [70.0, 877.0, 382.0, 888.0]}, {"text": "papillomavirus DNA and p16(INK4a) in penile cancer and penile", "bbox": [88.0, 888.0, 382.0, 901.0]}, {"text": "intraepithelial neoplasia: a systematic review and meta-analysis.", "bbox": [88.0, 901.0, 381.0, 913.0]}, {"text": "Lancet Oncol 2019;20:145–58 .", "bbox": [88.0, 912.0, 226.0, 923.0]}, {"text": "[10] Lont AP, Kroon BK, Horenblas S, et al. Presence of high-risk human", "bbox": [64.0, 924.0, 382.0, 937.0]}, {"text": "papillomavirus DNA in penile carcinoma predicts favorable", "bbox": [88.0, 937.0, 382.0, 948.0]}, {"text": "outcome in survival. Int J Cancer 2006;119:1078–81 .", "bbox": [88.0, 950.0, 326.0, 959.0]}, {"text": "[11] Bezerra AL, Lopes A, Santiago GH, Ribeiro KC, Latorre MR, Villa LL.", "bbox": [64.0, 961.0, 381.0, 973.0]}, {"text": "Human papillomavirus as a prognostic factor in carcinoma of the", "bbox": [88.0, 972.0, 383.0, 983.0]}, {"text": "penis: analysis of 82 patients treated with amputation and", "bbox": [89.0, 985.0, 383.0, 997.0]}, {"text": "bilateral lymphadenectomy. Cancer 2001;91:2315–21 .", "bbox": [89.0, 997.0, 334.0, 1008.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "[12] Douglawi A, Masterson TA. Updates on the epidemiology and risk", "bbox": [408.0, 89.0, 726.0, 100.0]}, {"text": "actors for penile cancer. Transl Androl Urol 2017;6:785–90.", "bbox": [437.0, 100.0, 700.0, 111.0]}, {"text": "[13] WHO Classification of Tumours Editorial Board. Urinary and male", "bbox": [408.0, 111.0, 726.0, 122.0]}, {"text": "genital tumours. WHO classification of tumours, volume 8. ed. 5.", "bbox": [432.0, 124.0, 725.0, 135.0]}, {"text": "Lyon, France: IARC; 2022.", "bbox": [431.0, 135.0, 547.0, 147.0]}, {"text": "[14] Sanchez DF, Soares F, Alvarado-Cabrero I, et al. Pathological", "bbox": [408.0, 147.0, 726.0, 159.0]}, {"text": "factors, behavior, and histological prognostic risk groups in", "bbox": [432.0, 159.0, 726.0, 172.0]}, {"text": "subtypes of penile squamous cell carcinomas (SCC). Semin Diagn", "bbox": [432.0, 172.0, 726.0, 183.0]}, {"text": "Pathol 2015;32:222–31 .", "bbox": [432.0, 184.0, 539.0, 195.0]}, {"text": "[15] Thomas A, Necchi A, Muneer A, et al. Penile cancer. Nat Rev Dis", "bbox": [408.0, 195.0, 726.0, 208.0]}, {"text": "Primers 2021;7:11 .", "bbox": [431.0, 209.0, 519.0, 219.0]}, {"text": "[16] Horenblas S, van Tinteren H. Squamous cell carcinoma of the", "bbox": [408.0, 220.0, 725.0, 231.0]}, {"text": "penis. IV. Prognostic factors of survival: analysis of tumor, nodes", "bbox": [432.0, 231.0, 726.0, 242.0]}, {"text": "and metastasis classification system. J Urol 1994;151:1239–43 .", "bbox": [432.0, 244.0, 716.0, 255.0]}, {"text": "[17] Deng X, Liu Y, Zhan X, et al. Trends in incidence, mortality, and", "bbox": [408.0, 255.0, 726.0, 267.0]}, {"text": "survival of penile cancer in the United States: a population-based", "bbox": [432.0, 268.0, 727.0, 279.0]}, {"text": "study. Front Oncol 2022;12:891623 .", "bbox": [432.0, 279.0, 594.0, 292.0]}, {"text": "[18] Corbishley C, Chaux A, Colecchia M, et al. Carcinoma of the penis", "bbox": [408.0, 292.0, 726.0, 304.0]}, {"text": "and distal urethra histopathology reporting guide.", "bbox": [432.0, 304.0, 703.0, 315.0]}, {"text": "1st", "bbox": [708.0, 305.0, 725.0, 314.0]}, {"text": "edition. Sydney, Australia: International Collaboration on Cancer", "bbox": [431.0, 315.0, 726.0, 327.0]}, {"text": "Reporting; 2017 .", "bbox": [431.0, 329.0, 507.0, 340.0]}, {"text": "[19] Brierley J, Gospodarowicz M, Wittekind C. TNM classification of", "bbox": [408.0, 339.0, 726.0, 352.0]}, {"text": "malignant tumours. ed. 8. Chichester, UK: Wiley-Blackwell; 2016 .", "bbox": [432.0, 351.0, 726.0, 362.0]}, {"text": "[20] Amin MB, Greene FL, Edge SB, et al. The eighth edition AJCC cancer", "bbox": [408.0, 364.0, 726.0, 375.0]}, {"text": "staging manual: continuing to build a bridge from a population-", "bbox": [432.0, 375.0, 725.0, 387.0]}, {"text": "based to a more \"personalized\" approach to cancer staging. CA", "bbox": [430.0, 388.0, 726.0, 400.0]}, {"text": "Cancer J Clin 2017;67:93–9 .", "bbox": [431.0, 399.0, 557.0, 411.0]}, {"text": "[21] Chipollini J, De la Rosa AH, Azizi M, Shayegan B, Zorn KC, Spiess PE.", "bbox": [408.0, 410.0, 724.0, 422.0]}, {"text": "Patient presentation, differential diagnosis, and management of", "bbox": [431.0, 421.0, 727.0, 435.0]}, {"text": "penile lesions. Can Urol Assoc J 2019;13:S2–8 .", "bbox": [431.0, 435.0, 639.0, 446.0]}, {"text": "[22] Bertolotto M, Serafini G, Dogliotti L, et al. Primary and secondary", "bbox": [408.0, 446.0, 726.0, 458.0]}, {"text": "malignancies of the penis: ultrasound features. Abdom Imaging", "bbox": [432.0, 459.0, 726.0, 471.0]}, {"text": "2005; 30: 108–12 .", "bbox": [432.0, 471.0, 510.0, 481.0]}, {"text": "[23] Kayes O, Minhas S, Allen C, Hare C, Freeman A, Ralph D. The role of", "bbox": [408.0, 482.0, 726.0, 495.0]}, {"text": "magnetic resonance imaging in the local staging of penile cancer.", "bbox": [432.0, 495.0, 725.0, 507.0]}, {"text": "Eur Urol 2007;51:1313–8 .", "bbox": [431.0, 506.0, 549.0, 518.0]}, {"text": "[24] Bozzini G, Provenzano M, Romero Otero J, et al. Role of penile", "bbox": [408.0, 518.0, 726.0, 531.0]}, {"text": "Doppler US in the preoperative assessment of penile squamous", "bbox": [430.0, 531.0, 726.0, 542.0]}, {"text": "cell carcinoma patients: results from a large prospective", "bbox": [430.0, 543.0, 726.0, 555.0]}, {"text": "multicenter European study. Urology 2016;90:131–5 .", "bbox": [432.0, 555.0, 670.0, 566.0]}, {"text": "[25] Kroon BK, Horenblas S, Lont AP, Tanis PJ, Gallee MP, Nieweg OE.", "bbox": [408.0, 566.0, 725.0, 577.0]}, {"text": "Patients with penile carcinoma benefit from immediate resection", "bbox": [431.0, 579.0, 726.0, 591.0]}, {"text": "of", "bbox": [431.0, 591.0, 443.0, 601.0]}, {"text": "clinically", "bbox": [451.0, 591.0, 498.0, 602.0]}, {"text": "occult", "bbox": [504.0, 591.0, 537.0, 601.0]}, {"text": "lymph", "bbox": [544.0, 591.0, 580.0, 602.0]}, {"text": "node", "bbox": [586.0, 591.0, 614.0, 601.0]}, {"text": "metastases.", "bbox": [622.0, 591.0, 676.0, 601.0]}, {"text": "Urol", "bbox": [702.0, 592.0, 726.0, 601.0]}, {"text": "2005; 173:816–9 .", "bbox": [432.0, 602.0, 509.0, 613.0]}, {"text": "[26] Mueller-Lisse UG, Scher B, Scherr MK, Seitz M. Functional imaging", "bbox": [408.0, 615.0, 725.0, 626.0]}, {"text": "in penile cancer: PET/computed tomography, MRI, and sentinel", "bbox": [431.0, 626.0, 726.0, 638.0]}, {"text": "lymph node biopsy. Curr Opin Urol 2008;18:105–10 .", "bbox": [431.0, 639.0, 668.0, 651.0]}, {"text": "[27] Leijte JA, Graafland NM, Valdes Olmos RA, van Boven HH,", "bbox": [408.0, 650.0, 725.0, 662.0]}, {"text": "Hoefnagel CA, Horenblas S. Prospective evaluation of hybrid 18F-", "bbox": [431.0, 663.0, 725.0, 674.0]}, {"text": "fluorodeoxyglucose positron emission tomography/computed", "bbox": [431.0, 675.0, 727.0, 687.0]}, {"text": "tomography in staging clinically node-negative patients with", "bbox": [431.0, 685.0, 727.0, 699.0]}, {"text": "penile carcinoma. BJU Int 2009; 104:640–4 .", "bbox": [432.0, 699.0, 625.0, 711.0]}, {"text": "[28] Schlenker B, Scher B, Tiling R, et al. Detection of inguinal lymph", "bbox": [408.0, 710.0, 726.0, 722.0]}, {"text": "node involvement in penile squamous cell carcinoma by '", "bbox": [432.0, 723.0, 709.0, 734.0]}, {"text": "fluorodeoxyglucose PET/CT: a prospective single- center study.", "bbox": [432.0, 735.0, 725.0, 746.0]}, {"text": "Urol Oncol 2012;30:55–9 .", "bbox": [430.0, 745.0, 549.0, 758.0]}, {"text": "[29] Fankhauser CD, de Vries HM, Roussel E, et al. Lymphovascular and", "bbox": [408.0, 758.0, 726.0, 770.0]}, {"text": "perineural invasion are risk factors for inguinal lymph node", "bbox": [432.0, 770.0, 725.0, 781.0]}, {"text": "metastases in men with T1G2 penile cancer. J Cancer Res Clin", "bbox": [431.0, 781.0, 726.0, 793.0]}, {"text": "Oncol 2022;148:2231–4 .", "bbox": [430.0, 793.0, 543.0, 806.0]}, {"text": "[30] Graafland NM, Lam W, Leijte JA, et al. Prognostic factors for occult", "bbox": [408.0, 805.0, 725.0, 818.0]}, {"text": "inguinal lymph node involvement in penile carcinoma and", "bbox": [431.0, 818.0, 727.0, 829.0]}, {"text": "assessment of the high-risk EAU subgroup: a two-institution", "bbox": [432.0, 830.0, 727.0, 841.0]}, {"text": "analysis of 342 clinically node-negative patients. Eur Urol", "bbox": [432.0, 841.0, 726.0, 853.0]}, {"text": "2010;58:742–7 .", "bbox": [432.0, 854.0, 504.0, 864.0]}, {"text": "[31] d'Ancona CA, de Lucena RG, Querne FA, Martins MH, Denardi F,", "bbox": [408.0, 865.0, 725.0, 878.0]}, {"text": "Netto Jr NR. Long-term followup of penile carcinoma treated with", "bbox": [430.0, 877.0, 727.0, 889.0]}, {"text": "penectomy and bilateral modified inguinal lymphadenectomy. J", "bbox": [432.0, 890.0, 726.0, 901.0]}, {"text": "Urol 2004;172:498–501 .", "bbox": [430.0, 901.0, 541.0, 913.0]}, {"text": "[32] Thyavihally YB, Dev P, Waigankar SS, et al. Comparative study of", "bbox": [408.0, 914.0, 726.0, 926.0]}, {"text": "perioperative and survival outcomes after video endoscopic", "bbox": [431.0, 925.0, 725.0, 938.0]}, {"text": "inguinal lymphadenectomy (VEIL) and open inguinal lymph", "bbox": [431.0, 937.0, 726.0, 949.0]}, {"text": "node dissection (O-ILND) in the management of inguinal lymph", "bbox": [431.0, 950.0, 726.0, 961.0]}, {"text": "nodes in carcinoma of the penis. J Robot Surg 2021;15:905–14 .", "bbox": [431.0, 961.0, 718.0, 973.0]}, {"text": "[33] Lee EWC, Issa A, Oliveira P, et al. High diagnostic accuracy of", "bbox": [408.0, 973.0, 727.0, 985.0]}, {"text": "inguinal ultrasonography and fine-needle aspiration followed by", "bbox": [432.0, 985.0, 726.0, 998.0]}], "type": "Text", "position": 8}, {"raw_context": [{"text": "Please cite this article as: O.R. Brouwer, M. Albersen, A. Parnham et al., European Association of Urology–American Society of Clinical Oncology Col-", "bbox": [62.0, 1028.0, 722.0, 1040.0]}, {"text": "laborative Guideline on Penile Cancer: 2023 Update, Eur Urol (2023), https://doi.org/10.1016/j.eururo.2023.02.027", "bbox": [63.0, 1040.0, 583.0, 1053.0]}], "type": "Text", "position": 9}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/泌尿外科/2023 EAU／ASCO指南：阴茎癌（更新版）.pdf", "page_num": 10}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": null, "type3": "无关文本#0#0# 10", "type4": null, "type5": null, "type6": "有用性#3#50#属于参考文献的内容"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:40", "update_time": "2024-05-07 18:12:16"}
{"id": 1082519, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 738, "source_info": {"seq_id": "f127fc0d-00d0-46a6-a61b-6bcd3abd9f49", "title": null, "text": "【0】页码:3\n\n【1】## Background 2\n\n【2】\n The treatment of hepatic malignancies via the hepatic arterial route is based on the existence of arterial tumoural hypervascularization. Tumours bigger than 2 cm in diameter draw more than 80% of their blood supply from the hepatic artery. Normal liver parenchyma draws more than 80% of blood from the portal vein. Highly selective tumour targeting can thus be achieved by delivery of radioactive microspheres into the hepatic artery [ 6 – 8 ].\n\n【3】Unlike hepatocellular carcinoma (HCC), liver metastases\n\n【4】 may have variable vascularity, from avascular hepatic cysts to normal hepatic parenchyma, less vascularised metastatic lesions (e.g. colon, pancreas, breast) and finally hypervascular metastases (e.g. renal, neuroendocrine, thyroid).\n\n【5】In 90 Y-microspheres radioembolization, pre-treatment intra-arterial 99 m Tc-labelled albumin macroaggregated albumin 1 ( 99 nv Tc-MAA) scintigraphy 2 (see below) is mandatory to quantify potential liver-lung shunting and to exclude reflux to bowel, stomach or pancreas [ 9 , 10 ]. Note that the use of 99m Tc-MAA (although accepted worldwide) is in principle off-label, since its use is indicated only for lung .\n\n【6】perfusion scintigraphy. In 166 Ho-microspheres radioembo- .\n\n【7】lization, the administration of a scout dose of 166 Ho-micro- .\n\n【8】spheres (i.e. 250 MBq) has been shown to be safe and more Laccurate for the calculation of the lung shunt fraction when compared to 99 m Tc-MAA [ 11 , 12 ]. The therapeutic effect of .\n\n【9】radioembolization is essentially driven by a radiation effect, as opposed to the ischaemia associated with chemoembolization or bland embolization. The radiobiological effect results from beta particle irradiation, which causes delayed death of tumour cells surrounding microvessels containing a , high radioactive microspheres concentration [ 13 – 19 ].\n\n【10】One of the main differences between the different microspheres is the specific activity of each microsphere at the calibration time, being much higher for glass microspheres .\n\n【11】(i.e. approximately 4500 Bq/microsphere at calibration), in contrast to approximately 340 Bq/microsphere for 166 Homicrospheres and 50 Bq/microsphere for resin microspheres.\n\n【12】Commercially available vials of glass microspheres contain up to 20 GBq, 166 Ho-microspheres up to approximately .\n\n【13】15 GBq and resin microspheres 10 GBq fixed. Consequently, at the same prescribed activity, glass microspheres have the least embolic effect, being injected in much lower numbers.\n\n【14】Potentially, at the same prescribed activity, the higher number of resin microspheres may provide a more uniform dose .\n\n【15】distribution, with a higher biological effect (i.e. toxicity and efficacy), with 166 Ho-microspheres falling in between. This\n 1 99m Tc-labelled human serum albumin (HSA) particles are not widely available but can also be used.\n\n【16】2 Planar and, possibly, single-photon emission computed tomography with integrated computed tomography (SPECT/CT)\n\n【17】 argument holds if the clustering effect is neglected. Being present in both kinds of 90 Y-microspheres [ 16 ], the optimal number of microspheres to obtain uniform coverage is still unclear [ 20 ]. A theoretical disadvantage of glass microspheres is the often quoted, but never demonstrated influence of gravity on their biodistribution [ 21 – 24 ]. Resin microspheres are also available at higher specific activity, the so-called 1-, 2- or 3-day calibration, with 3 GBq activity calibrated at day 0, but supplied days before to increase specific activity.\n\n【18】## Indication\n\n【19】\n Primary or secondary liver tumours. With mounting evidence, the indication with regard to tumour type and specific clinical settings will rapidly change over the years. This falls outside the scope of this procedural guideline.\n\n【20】## Contraindications\n\n【21】\n## Absolute\n\n【22】\n## Pregnancy, Breastfeeding\n\n【23】\n Life expectancy of less than 3 months Clinical liver failure (i.e. ascites, icterus, encephalopathy) Disseminated extrahepatic malignant disease (see section Diagnostic work-up for reference) In case the pre-treatment intra-arterial scout dose scintigraphy (or peri-procedural C-arm CT) shows any extrahepatic activity (or contrast enhancement) in the gastrointestinal tract that cannot be corrected by angiographic techniques (exceptions include the gallbladder, lymph nodes, falciform ligament)\n\n【24】## Relative\n\n【25】\n Child-Pugh score higher than B7. A liver decompensation rate as high as 89% after glass administration with standard dosage (i.e. single compartment modelling) has been reported in patients with B7 liver cirrhosis [ 68 ]. Caution is warranted in any treatment that is not (bi-)segmental.\n\n【26】High intrahepatic tumour burden. Depending on tumour type, more (e.g. neuroendocrine, more indolent, hypervascular, symptomatic disease in need of palliation) or less (hepatocellular carcinoma, underlying liver disease, more aggressive) tumour burden is acceptable. A cut-off of 50–70% is often reported.\n\n【27】High extrahepatic tumour burden. Depending on tumour type, more (e.g. neuroendocrine, prognosis depends on liver disease, more indolent) or less (e.g. intrahepatic cholangiocarcinoma (ICC), more aggressive) extrahepatic disease is acceptable. Hilar lymph nodes (up to 2 cm short axis) and lung nodules (up to 1 cm; up to 5) are often accepted.", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "Background 2", "bbox": [65.0, 74.0, 162.0, 91.0]}], "type": "Section-header", "position": 1}, {"raw_context": [{"text": "The treatment of hepatic malignancies via the hepatic arte-", "bbox": [66.0, 109.0, 385.0, 123.0]}, {"text": "rial route is based on the existence of arterial tumoural", "bbox": [65.0, 126.0, 387.0, 140.0]}, {"text": "hypervascularization. Tumours bigger than 2 cm in diameter", "bbox": [65.0, 143.0, 387.0, 157.0]}, {"text": "draw more than 80% of their blood supply from the hepatic", "bbox": [64.0, 159.0, 387.0, 174.0]}, {"text": "artery. Normal liver parenchyma draws more than 80% of", "bbox": [66.0, 176.0, 387.0, 190.0]}, {"text": "blood from the portal vein. Highly selective tumour targeting", "bbox": [65.0, 193.0, 387.0, 207.0]}, {"text": "can thus be achieved by delivery of radioactive microspheres", "bbox": [65.0, 209.0, 387.0, 224.0]}, {"text": "into the hepatic artery [ 6 – 8 ].", "bbox": [65.0, 226.0, 221.0, 240.0]}, {"text": "Unlike hepatocellular carcinoma (HCC), liver metastases", "bbox": [80.0, 242.0, 387.0, 258.0]}], "type": "Text", "position": 2}, {"raw_context": [{"text": "may have variable vascularity, from avascular hepatic cysts", "bbox": [65.0, 260.0, 387.0, 274.0]}, {"text": "to normal hepatic parenchyma, less vascularised metastatic", "bbox": [66.0, 276.0, 387.0, 291.0]}, {"text": "lesions (e.g. colon, pancreas, breast) and finally hypervascu-", "bbox": [66.0, 292.0, 385.0, 307.0]}, {"text": "lar metastases (e.g. renal, neuroendocrine, thyroid).", "bbox": [66.0, 309.0, 345.0, 324.0]}, {"text": "In 90 Y-microspheres radioembolization, pre-treatment", "bbox": [80.0, 326.0, 387.0, 341.0]}, {"text": "intra-arterial 99 m Tc-labelled albumin macroaggregated albu-", "bbox": [65.0, 341.0, 385.0, 359.0]}, {"text": "min 1 ( 99 nv Tc-MAA) scintigraphy 2 (see below) is mandatory", "bbox": [66.0, 359.0, 385.0, 374.0]}, {"text": "to quantify potential liver-lung shunting and to exclude", "bbox": [66.0, 376.0, 387.0, 391.0]}, {"text": "reflux to bowel, stomach or pancreas [ 9 , 10 ]. Note that the", "bbox": [66.0, 392.0, 387.0, 407.0]}, {"text": "use of 99m Tc-MAA (although accepted worldwide) is in", "bbox": [66.0, 408.0, 387.0, 425.0]}, {"text": "principle off-label, since its use is indicated only for lung", "bbox": [66.0, 426.0, 387.0, 441.0]}, {"text": ".", "bbox": [406.0, 426.0, 418.0, 436.0]}, {"text": "perfusion scintigraphy. In 166 Ho-microspheres radioembo-", "bbox": [66.0, 441.0, 385.0, 458.0]}, {"text": ".", "bbox": [406.0, 442.0, 417.0, 454.0]}, {"text": "lization, the administration of a scout dose of 166 Ho-micro-", "bbox": [66.0, 458.0, 385.0, 473.0]}, {"text": ".", "bbox": [406.0, 459.0, 417.0, 470.0]}, {"text": "spheres (i.e. 250 MBq) has been shown to be safe and more", "bbox": [64.0, 476.0, 387.0, 491.0]}, {"text": "Laccurate for the calculation of the lung shunt fraction when", "bbox": [63.0, 493.0, 387.0, 508.0]}, {"text": "compared to 99 m Tc-MAA [ 11 , 12 ]. The therapeutic effect of", "bbox": [65.0, 508.0, 387.0, 524.0]}, {"text": ".", "bbox": [406.0, 509.0, 416.0, 521.0]}, {"text": "radioembolization is essentially driven by a radiation effect,", "bbox": [66.0, 526.0, 387.0, 540.0]}, {"text": "as opposed to the ischaemia associated with chemoembo-", "bbox": [66.0, 543.0, 386.0, 558.0]}, {"text": "lization or bland embolization. The radiobiological effect", "bbox": [66.0, 560.0, 387.0, 574.0]}, {"text": "results from beta particle irradiation, which causes delayed", "bbox": [66.0, 576.0, 387.0, 590.0]}, {"text": "death of tumour cells surrounding microvessels containing a ,", "bbox": [65.0, 593.0, 392.0, 607.0]}, {"text": "high radioactive microspheres concentration [ 13 – 19 ].", "bbox": [64.0, 609.0, 356.0, 624.0]}, {"text": "One of the main differences between the different micro-", "bbox": [80.0, 626.0, 386.0, 640.0]}, {"text": "spheres is the specific activity of each microsphere at the", "bbox": [65.0, 643.0, 387.0, 657.0]}, {"text": "calibration time, being much higher for glass microspheres", "bbox": [64.0, 659.0, 387.0, 674.0]}, {"text": ".", "bbox": [406.0, 659.0, 416.0, 670.0]}, {"text": "(i.e. approximately 4500 Bq/microsphere at calibration), in", "bbox": [64.0, 676.0, 387.0, 691.0]}, {"text": "contrast to approximately 340 Bq/microsphere for 166 Ho-", "bbox": [65.0, 692.0, 385.0, 707.0]}, {"text": "microspheres and 50 Bq/microsphere for resin microspheres.", "bbox": [66.0, 708.0, 385.0, 725.0]}, {"text": "Commercially available vials of glass microspheres contain", "bbox": [80.0, 726.0, 387.0, 741.0]}, {"text": "up to 20 GBq, 166 Ho-microspheres up to approximately", "bbox": [63.0, 742.0, 387.0, 757.0]}, {"text": ".", "bbox": [406.0, 743.0, 416.0, 754.0]}, {"text": "15 GBq and resin microspheres 10 GBq fixed. Consequently,", "bbox": [66.0, 759.0, 387.0, 774.0]}, {"text": "at the same prescribed activity, glass microspheres have the", "bbox": [66.0, 777.0, 387.0, 790.0]}, {"text": "least embolic effect, being injected in much lower numbers.", "bbox": [66.0, 793.0, 386.0, 807.0]}, {"text": "Potentially, at the same prescribed activity, the higher number", "bbox": [66.0, 809.0, 387.0, 824.0]}, {"text": "of resin microspheres may provide a more uniform dose", "bbox": [65.0, 826.0, 387.0, 841.0]}, {"text": ".", "bbox": [406.0, 843.0, 416.0, 854.0]}, {"text": "distribution, with a higher biological effect (i.e. toxicity and", "bbox": [65.0, 844.0, 391.0, 858.0]}, {"text": "efficacy), with 166 Ho-microspheres falling in between. This", "bbox": [65.0, 858.0, 389.0, 874.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "1 99m Tc-labelled human serum albumin (HSA) particles are not", "bbox": [66.0, 896.0, 387.0, 916.0]}, {"text": "widely available but can also be used.", "bbox": [66.0, 915.0, 238.0, 927.0]}, {"text": "2 Planar and, possibly, single-photon emission computed tomography", "bbox": [66.0, 929.0, 386.0, 945.0]}, {"text": "with integrated computed tomography (SPECT/CT)", "bbox": [67.0, 945.0, 305.0, 958.0]}], "type": "Footnote", "position": 4}, {"raw_context": [{"text": "argument holds if the clustering effect is neglected. Being", "bbox": [405.0, 73.0, 726.0, 88.0]}, {"text": "present in both kinds of 90 Y-microspheres [ 16 ], the optimal", "bbox": [405.0, 88.0, 727.0, 107.0]}, {"text": "number of microspheres to obtain uniform coverage is still", "bbox": [405.0, 107.0, 727.0, 122.0]}, {"text": "unclear [ 20 ]. A theoretical disadvantage of glass microspheres", "bbox": [405.0, 123.0, 727.0, 138.0]}, {"text": "is the often quoted, but never demonstrated influence of gravity", "bbox": [405.0, 141.0, 727.0, 155.0]}, {"text": "on their biodistribution [ 21 – 24 ]. Resin microspheres are also", "bbox": [405.0, 158.0, 727.0, 171.0]}, {"text": "available at higher specific activity, the so-called 1-, 2- or", "bbox": [405.0, 174.0, 727.0, 189.0]}, {"text": "3-day calibration, with 3 GBq activity calibrated at day 0, but", "bbox": [406.0, 190.0, 727.0, 205.0]}, {"text": "supplied days before to increase specific activity.", "bbox": [406.0, 207.0, 661.0, 222.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "Indication", "bbox": [405.0, 240.0, 471.0, 255.0]}], "type": "Section-header", "position": 6}, {"raw_context": [{"text": "Primary or secondary liver tumours. With mounting evi-", "bbox": [405.0, 274.0, 725.0, 288.0]}, {"text": "dence, the indication with regard to tumour type and specific", "bbox": [405.0, 291.0, 727.0, 305.0]}, {"text": "clinical settings will rapidly change over the years. This falls", "bbox": [405.0, 307.0, 727.0, 322.0]}, {"text": "outside the scope of this procedural guideline.", "bbox": [405.0, 324.0, 656.0, 339.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "Contraindications", "bbox": [405.0, 356.0, 518.0, 371.0]}], "type": "Section-header", "position": 8}, {"raw_context": [{"text": "Absolute", "bbox": [405.0, 389.0, 460.0, 406.0]}], "type": "Section-header", "position": 9}, {"raw_context": [{"text": "Pregnancy, breastfeeding", "bbox": [421.0, 424.0, 563.0, 438.0]}], "type": "Section-header", "position": 10}, {"raw_context": [{"text": "Life expectancy of less than 3 months", "bbox": [421.0, 441.0, 631.0, 455.0]}, {"text": "Clinical liver failure (i.e. ascites, icterus, encephalopathy)", "bbox": [421.0, 458.0, 728.0, 472.0]}, {"text": "Disseminated extrahepatic malignant disease (see section", "bbox": [422.0, 474.0, 727.0, 488.0]}, {"text": "Diagnostic work-up for reference)", "bbox": [424.0, 491.0, 609.0, 505.0]}, {"text": "In case the pre-treatment intra-arterial scout dose scin-", "bbox": [422.0, 507.0, 726.0, 522.0]}, {"text": "tigraphy (or peri-procedural C-arm CT) shows any extra-", "bbox": [422.0, 523.0, 726.0, 538.0]}, {"text": "hepatic activity (or contrast enhancement) in the gastro-", "bbox": [423.0, 541.0, 726.0, 555.0]}, {"text": "intestinal tract that cannot be corrected by angiographic", "bbox": [423.0, 558.0, 727.0, 572.0]}, {"text": "techniques (exceptions include the gallbladder, lymph", "bbox": [423.0, 574.0, 728.0, 589.0]}, {"text": "nodes, falciform ligament)", "bbox": [423.0, 590.0, 570.0, 605.0]}], "type": "Text", "position": 11}, {"raw_context": [{"text": "Relative", "bbox": [421.0, 623.0, 467.0, 639.0]}], "type": "Section-header", "position": 12}, {"raw_context": [{"text": "Child-Pugh score higher than B7. A liver decompensation", "bbox": [421.0, 657.0, 727.0, 671.0]}, {"text": "rate as high as 89% after glass administration with standard", "bbox": [423.0, 674.0, 727.0, 688.0]}, {"text": "dosage (i.e. single compartment modelling) has been", "bbox": [423.0, 691.0, 727.0, 705.0]}, {"text": "reported in patients with B7 liver cirrhosis [ 68 ]. Caution is", "bbox": [423.0, 707.0, 731.0, 722.0]}, {"text": "warranted in any treatment that is not (bi-)segmental.", "bbox": [424.0, 724.0, 702.0, 739.0]}, {"text": "High intrahepatic tumour burden. Depending on tumour", "bbox": [422.0, 742.0, 727.0, 755.0]}, {"text": "type, more (e.g. neuroendocrine, more indolent, hyper-", "bbox": [423.0, 758.0, 726.0, 772.0]}, {"text": "vascular, symptomatic disease in need of palliation) or", "bbox": [424.0, 774.0, 727.0, 789.0]}, {"text": "less (hepatocellular carcinoma, underlying liver disease,", "bbox": [424.0, 791.0, 727.0, 806.0]}, {"text": "more aggressive) tumour burden is acceptable. A cut-off", "bbox": [424.0, 808.0, 728.0, 822.0]}, {"text": "of 50–70% is often reported.", "bbox": [423.0, 824.0, 579.0, 840.0]}, {"text": "High extrahepatic tumour burden. Depending on tumour", "bbox": [422.0, 841.0, 728.0, 856.0]}, {"text": "type, more (e.g. neuroendocrine, prognosis depends on", "bbox": [423.0, 858.0, 728.0, 873.0]}, {"text": "liver disease, more indolent) or less (e.g. intrahepatic", "bbox": [423.0, 875.0, 727.0, 888.0]}, {"text": "cholangiocarcinoma (ICC), more aggressive) extrahe-", "bbox": [422.0, 891.0, 726.0, 906.0]}, {"text": "patic disease is acceptable. Hilar lymph nodes (up to", "bbox": [423.0, 908.0, 727.0, 923.0]}, {"text": "2 cm short axis) and lung nodules (up to 1 cm; up to 5)", "bbox": [424.0, 924.0, 727.0, 939.0]}, {"text": "are often accepted.", "bbox": [424.0, 941.0, 527.0, 955.0]}], "type": "Text", "position": 13}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2022】全科室最全临床指南+专家共识（最全版）/2022全科室临床指南/肿瘤科/EANM：动脉内放射性化合物治疗肝癌和转移性肝癌指南（2022）(1).pdf", "page_num": 3}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "多余换行#3#4#liver metastases和may have variable vascularity是一句话\n多余换行#5#9#In 90 Y-microspheres和microspheres concentration是一句话\n多余换行#10#11#One of the main differences和(i.e. approximately 4500 是一句话\n多余换行#12#17#Commercially available vials和 increase specific activity.是一句话\n缺少换行#23#23#Clinical liver failure另起一行\nDisseminated extrahepatic另起一行\n In case the pre-treatment 另起一行\n", "type3": "无关文本#1#1#2\n无关文本#0#58#hepatic artery [ 6 – 8 ]部分段落末尾，以及句末的数字问题无关噪声应用全文", "type4": null, "type5": null, "type6": null}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:40", "update_time": "2024-05-07 22:36:37"}
{"id": 1082518, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 738, "source_info": {"seq_id": "d05b370c-abc4-45a9-bfe1-427b0550d9ab", "title": null, "text": "【0】页码:8\n\n【1】## Activity Calculation And Treatment Planning\n\n【2】\n Methodological details on the various technical aspects of dosimetry are reported in the recent EANM 90Y microspheres dosimetry guideline [ 81 ]. These guidelines do not apply to 166Ho microspheres, yet in the absence of dedicated guidelines, some of the underlying concepts may be applicable to treatment with 166Ho microspheres.\n\n【3】Whenever possible, multi-compartment dosimetry should be used. Whenever possible means that tumour segmentation is feasible and the clinical data support tumouricidal doses and maximum tolerated dose for the product used, the tumour histology and the indication (curative/palliative).\n\n【4】When multi-compartment dosimetry is not possible (e.g.\n\n【5】infiltrative lesion, no/insufficient clinical dosimetry data available), simple single compartment dosimetry applied to the whole liver is conservative and should be used.\n\n【6】Approaches described in the instruction for users of each product (e.g. single compartment dosimetry) can be used from a legal point of view, but they do not optimize treatment.\n\n【7】Although the current data on multi-compartment dosimetry indicate a dose–response relationship, reported dose thresholds vary and are mostly derived from retrospective studies [ 82 ]. The following sections and Tables 2 , 3 and 4 provide an overview of\n\n【8】 dose thresholds that can be used for orientation, including the level of evidence supporting them. The reported data will be subject to change. Since most of the data was derived from noncomparative, retrospective analyses of dose–effect relationships, these preliminary data are very heterogeneous. Differences exist in terms of segmentation methods/software used, pre- versus post-treatment analysis, response criteria and reported dose metric (e.g. median/mean of response category, ROC analysis, most sensitive/specific for response). The reported numbers are based on current recommendations and reported literature; it is advised to read this literature before implementing dosimetrybased treatment planning in clinical practice.\n\n【9】Dosimetric planning driven mainly by tumour dose has two major weak points: first, for 90 Y microspheres, the MAA lesion dose prediction may have an unacceptably large discrepancy with the actual therapeutic dose. Second, even a post-therapy 90 Y PET dose above the proposed thresholds cannot guarantee response due to the overlap in dose distribution of responding and non-responding lesions. Therefore, in patients in whom level 1 evidence is not available [ 67 ], the administration of the maximum tolerable whole normal liver dose with a predicted tumour dose above the efficacy threshold constitutes an alternative driving criterion. Tumour dose is anyhow of outstanding importance in planning, since we\n\n【10】 Table 2 Absorbed dose recommendations for 90 Y glass microspheres and the respective level of evidence (LOE) Single compartment Multi-compartment Clinical scenario Perfused volume dose.\n\n【11】LOE Normal liver dose Tumour dose LOE HCC > 400 [ 83 ] Segmentectomy Not applicable Lobectomy > 150 if whole liver dose < 150 [ 67 2 88** [85] ≥ 205 [67] 140–150 [84] < 75 (range: 50/90***) ≥ 250–300*** [86] Unilobar > 150 if whole liver dose <150 [ 67 ] < 120** if HR < 30% [67] : ≥ 205 [67] 1* 80–150 [61, 74] < 75 (range: 50/90***) [86].\n\n【12】≥ 250–300**** 80–150**** [ 13 , 69 , 87 ] < 50/90*** [86] Bilobar 1, 4 ≥ 205 [62] 13.\n\n【13】ICC Segmentectomy > 400 [60] Not applicable 4 Lobectomy 140–150 4 < 75 (range: 50/90***) ≥ 260 [88] Unilobar 80–150 [89] 3 < 75 (range: 50/90***) [88] 260 Bilobar 80–150 [89] 3 < 75 (range: 50/90***) ≥ 260 [88] mCRC > 400 [90] Segmentectomy 19.3 Not applicable 140–150 < 75 (range: 50/90***) 2 189 [ 91 ] Lobectomy 4.4 3 80–150 [92] Unilobar < 75 (range: 50/90***) ≥ 189 [91] 3 3 80–150 [92] < 75 (range: 50/90***) Bilobar 2 189 [ 91 ] 13 HR , hepatic reserve, i.e. untreated liver fraction\n\n【14】\n *In patients comparable to the DOSISPHERE-01 [ 67 ] study population (Child-Pugh A, large lesions, at least 30% of hepatic reserve) **Dose to the normal perfused liver, based on the first treatment ***Dose to the whole normal liver. In HCC patients with total bilirubin levels >1.1 mg/dl, an upper threshold of 50 Gy should be used; in patients with total bilirubin levels <1.1 mg/dl, the whole normal liver dose should be kept below 90 Gy. Data are derived from unilobar treatments without prior RE only. Since these thresholds have been established in mostly cirrhotic HCC patients, they can be considered safe for non- HCC patients; however, caution is warranted particularly in ICC patients with underlying cirrhosis and after chemotherapy / ****For large lesions [ 67 ]", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "Activity calculation and treatment planning", "bbox": [65.0, 70.0, 380.0, 92.0]}], "type": "Section-header", "position": 1}, {"raw_context": [{"text": "Methodological details on the various technical aspects", "bbox": [66.0, 109.0, 387.0, 123.0]}, {"text": "of dosimetry are reported in the recent EANM 90Y", "bbox": [65.0, 126.0, 385.0, 140.0]}, {"text": "microspheres dosimetry guideline [ 81 ]. These guidelines", "bbox": [66.0, 143.0, 387.0, 157.0]}, {"text": "do not apply to 166Ho microspheres, yet in the absence of", "bbox": [65.0, 159.0, 387.0, 174.0]}, {"text": "dedicated guidelines, some of the underlying concepts may be", "bbox": [65.0, 175.0, 387.0, 190.0]}, {"text": "applicable to treatment with 166Ho microspheres.", "bbox": [66.0, 193.0, 329.0, 206.0]}, {"text": "Whenever possible, multi-compartment dosimetry should", "bbox": [82.0, 210.0, 387.0, 224.0]}, {"text": "be used. Whenever possible means that tumour segmenta-", "bbox": [65.0, 225.0, 385.0, 240.0]}, {"text": "tion is feasible and the clinical data support tumouricidal", "bbox": [66.0, 242.0, 387.0, 257.0]}, {"text": "doses and maximum tolerated dose for the product used,", "bbox": [66.0, 260.0, 387.0, 273.0]}, {"text": "the tumour histology and the indication (curative/palliative).", "bbox": [65.0, 276.0, 385.0, 291.0]}, {"text": "When multi-compartment dosimetry is not possible (e.g.", "bbox": [81.0, 292.0, 385.0, 307.0]}, {"text": "infiltrative lesion, no/insufficient clinical dosimetry data", "bbox": [66.0, 309.0, 387.0, 324.0]}, {"text": "available), simple single compartment dosimetry applied", "bbox": [66.0, 327.0, 387.0, 340.0]}, {"text": "to the whole liver is conservative and should be used.", "bbox": [66.0, 343.0, 385.0, 357.0]}, {"text": "Approaches described in the instruction for users of each", "bbox": [66.0, 359.0, 387.0, 374.0]}, {"text": "product (e.g. single compartment dosimetry) can be used", "bbox": [66.0, 376.0, 387.0, 390.0]}, {"text": "from a legal point of view, but they do not optimize treatment.", "bbox": [66.0, 393.0, 386.0, 407.0]}, {"text": "Although the current data on multi-compartment dosimetry", "bbox": [82.0, 409.0, 387.0, 423.0]}, {"text": "indicate a dose–response relationship, reported dose thresholds", "bbox": [66.0, 426.0, 387.0, 441.0]}, {"text": "vary and are mostly derived from retrospective studies [ 82 ]. The", "bbox": [66.0, 443.0, 387.0, 457.0]}, {"text": "following sections and Tables 2 , 3 and 4 provide an overview of", "bbox": [66.0, 459.0, 387.0, 473.0]}], "type": "Text", "position": 2}, {"raw_context": [{"text": "dose thresholds that can be used for orientation, including the", "bbox": [405.0, 73.0, 727.0, 88.0]}, {"text": "level of evidence supporting them. The reported data will be", "bbox": [405.0, 91.0, 726.0, 105.0]}, {"text": "subject to change. Since most of the data was derived from non-", "bbox": [405.0, 107.0, 725.0, 122.0]}, {"text": "comparative, retrospective analyses of dose–effect relationships,", "bbox": [405.0, 123.0, 725.0, 138.0]}, {"text": "these preliminary data are very heterogeneous. Differences exist", "bbox": [405.0, 140.0, 727.0, 155.0]}, {"text": "in terms of segmentation methods/software used, pre- versus", "bbox": [405.0, 158.0, 727.0, 171.0]}, {"text": "post-treatment analysis, response criteria and reported dose", "bbox": [405.0, 173.0, 726.0, 189.0]}, {"text": "metric (e.g. median/mean of response category, ROC analysis,", "bbox": [405.0, 190.0, 726.0, 205.0]}, {"text": "most sensitive/specific for response). The reported numbers are", "bbox": [405.0, 207.0, 727.0, 221.0]}, {"text": "based on current recommendations and reported literature; it is", "bbox": [405.0, 225.0, 727.0, 238.0]}, {"text": "advised to read this literature before implementing dosimetry-", "bbox": [405.0, 240.0, 725.0, 255.0]}, {"text": "based treatment planning in clinical practice.", "bbox": [405.0, 257.0, 635.0, 272.0]}, {"text": "Dosimetric planning driven mainly by tumour dose has", "bbox": [421.0, 274.0, 727.0, 288.0]}, {"text": "two major weak points: first, for 90 Y microspheres, the MAA", "bbox": [405.0, 290.0, 726.0, 305.0]}, {"text": "lesion dose prediction may have an unacceptably large dis-", "bbox": [405.0, 307.0, 725.0, 321.0]}, {"text": "crepancy with the actual therapeutic dose. Second, even a", "bbox": [405.0, 324.0, 727.0, 339.0]}, {"text": "post-therapy 90 Y PET dose above the proposed thresholds", "bbox": [405.0, 339.0, 727.0, 355.0]}, {"text": "cannot guarantee response due to the overlap in dose distri-", "bbox": [405.0, 357.0, 726.0, 371.0]}, {"text": "bution of responding and non-responding lesions. Therefore,", "bbox": [406.0, 374.0, 726.0, 388.0]}, {"text": "in patients in whom level 1 evidence is not available [ 67 ], the", "bbox": [405.0, 391.0, 727.0, 406.0]}, {"text": "administration of the maximum tolerable whole normal liver", "bbox": [406.0, 407.0, 727.0, 421.0]}, {"text": "dose with a predicted tumour dose above the efficacy thresh-", "bbox": [406.0, 424.0, 726.0, 438.0]}, {"text": "old constitutes an alternative driving criterion. Tumour dose", "bbox": [405.0, 441.0, 727.0, 455.0]}, {"text": "is anyhow of outstanding importance in planning, since we", "bbox": [406.0, 458.0, 727.0, 472.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "Table 2 Absorbed dose recommendations for 90 Y glass microspheres and the respective level of evidence (LOE)", "bbox": [66.0, 497.0, 580.0, 512.0]}, {"text": "Single compartment", "bbox": [177.0, 522.0, 255.0, 533.0]}, {"text": "Multi-compartment", "bbox": [433.0, 522.0, 509.0, 533.0]}, {"text": "Clinical scenario", "bbox": [65.0, 542.0, 131.0, 553.0]}, {"text": "Perfused volume dose.", "bbox": [176.0, 542.0, 260.0, 553.0]}, {"text": "LOE", "bbox": [377.0, 542.0, 398.0, 553.0]}, {"text": "Normal liver dose", "bbox": [432.0, 542.0, 502.0, 553.0]}, {"text": "Tumour dose", "bbox": [596.0, 543.0, 645.0, 553.0]}, {"text": "LOE", "bbox": [700.0, 542.0, 722.0, 553.0]}, {"text": "HCC", "bbox": [66.0, 565.0, 88.0, 575.0]}, {"text": "> 400 [ 83 ]", "bbox": [176.0, 580.0, 220.0, 591.0]}, {"text": "Segmentectomy", "bbox": [66.0, 581.0, 127.0, 592.0]}, {"text": "Not applicable", "bbox": [432.0, 581.0, 490.0, 592.0]}, {"text": "Lobectomy", "bbox": [66.0, 595.0, 110.0, 606.0]}, {"text": "> 150 if whole liver dose < 150 [ 67", "bbox": [177.0, 595.0, 308.0, 606.0]}, {"text": "2 88** [85]", "bbox": [433.0, 595.0, 481.0, 606.0]}, {"text": "≥ 205 [67]", "bbox": [595.0, 595.0, 637.0, 606.0]}, {"text": "140–150 [84]", "bbox": [177.0, 607.0, 229.0, 618.0]}, {"text": "< 75 (range: 50/90***)", "bbox": [432.0, 607.0, 522.0, 617.0]}, {"text": "≥ 250–300***", "bbox": [594.0, 607.0, 653.0, 617.0]}, {"text": "[86]", "bbox": [432.0, 620.0, 451.0, 631.0]}, {"text": "Unilobar", "bbox": [66.0, 633.0, 101.0, 645.0]}, {"text": "> 150 if whole liver dose <150 [ 67 ]", "bbox": [177.0, 633.0, 314.0, 645.0]}, {"text": "< 120** if HR < 30% [67] :", "bbox": [433.0, 633.0, 535.0, 645.0]}, {"text": "≥ 205 [67]", "bbox": [595.0, 633.0, 637.0, 645.0]}, {"text": "1*", "bbox": [378.0, 634.0, 387.0, 643.0]}, {"text": "80–150 [61, 74]", "bbox": [176.0, 646.0, 239.0, 657.0]}, {"text": "< 75 (range: 50/90***) [86].", "bbox": [433.0, 646.0, 540.0, 656.0]}, {"text": "≥ 250–300****", "bbox": [594.0, 647.0, 655.0, 655.0]}, {"text": "80–150**** [ 13 , 69 , 87 ]", "bbox": [176.0, 658.0, 272.0, 673.0]}, {"text": "< 50/90*** [86]", "bbox": [433.0, 659.0, 498.0, 671.0]}, {"text": "Bilobar", "bbox": [66.0, 661.0, 95.0, 672.0]}, {"text": "1, 4", "bbox": [377.0, 662.0, 393.0, 673.0]}, {"text": "≥ 205 [62]", "bbox": [595.0, 662.0, 636.0, 670.0]}, {"text": "13.", "bbox": [702.0, 662.0, 709.0, 671.0]}, {"text": "ICC", "bbox": [66.0, 676.0, 84.0, 687.0]}, {"text": "Segmentectomy", "bbox": [66.0, 693.0, 127.0, 705.0]}, {"text": "> 400 [60]", "bbox": [177.0, 692.0, 220.0, 705.0]}, {"text": "Not applicable", "bbox": [432.0, 693.0, 490.0, 705.0]}, {"text": "4", "bbox": [377.0, 694.0, 385.0, 703.0]}, {"text": "Lobectomy", "bbox": [67.0, 708.0, 109.0, 719.0]}, {"text": "140–150", "bbox": [177.0, 707.0, 213.0, 719.0]}, {"text": "4", "bbox": [377.0, 708.0, 385.0, 719.0]}, {"text": "< 75 (range: 50/90***)", "bbox": [433.0, 707.0, 522.0, 720.0]}, {"text": "≥ 260 [88]", "bbox": [595.0, 708.0, 636.0, 719.0]}, {"text": "Unilobar", "bbox": [67.0, 722.0, 100.0, 734.0]}, {"text": "80–150 [89]", "bbox": [176.0, 722.0, 224.0, 734.0]}, {"text": "3", "bbox": [377.0, 723.0, 385.0, 733.0]}, {"text": "< 75 (range: 50/90***)", "bbox": [433.0, 722.0, 522.0, 734.0]}, {"text": "[88] 260", "bbox": [594.0, 722.0, 638.0, 734.0]}, {"text": "Bilobar", "bbox": [66.0, 738.0, 94.0, 750.0]}, {"text": "80–150 [89]", "bbox": [176.0, 738.0, 224.0, 750.0]}, {"text": "3", "bbox": [377.0, 739.0, 385.0, 749.0]}, {"text": "< 75 (range: 50/90***)", "bbox": [433.0, 739.0, 522.0, 750.0]}, {"text": "≥ 260 [88]", "bbox": [595.0, 739.0, 638.0, 750.0]}, {"text": "mCRC", "bbox": [66.0, 753.0, 95.0, 764.0]}, {"text": "> 400 [90]", "bbox": [177.0, 768.0, 219.0, 779.0]}, {"text": "Segmentectomy", "bbox": [66.0, 770.0, 126.0, 779.0]}, {"text": "19.3", "bbox": [377.0, 770.0, 385.0, 778.0]}, {"text": "Not applicable", "bbox": [432.0, 770.0, 490.0, 780.0]}, {"text": "140–150", "bbox": [177.0, 783.0, 213.0, 794.0]}, {"text": "< 75 (range: 50/90***)", "bbox": [433.0, 784.0, 523.0, 795.0]}, {"text": "2 189 [ 91 ]", "bbox": [594.0, 784.0, 639.0, 795.0]}, {"text": "Lobectomy", "bbox": [66.0, 785.0, 109.0, 795.0]}, {"text": "4.4", "bbox": [377.0, 785.0, 385.0, 793.0]}, {"text": "3", "bbox": [702.0, 785.0, 709.0, 793.0]}, {"text": "80–150 [92]", "bbox": [176.0, 798.0, 226.0, 810.0]}, {"text": "Unilobar", "bbox": [66.0, 799.0, 100.0, 810.0]}, {"text": "< 75 (range: 50/90***)", "bbox": [433.0, 799.0, 522.0, 811.0]}, {"text": "≥ 189 [91]", "bbox": [594.0, 799.0, 638.0, 810.0]}, {"text": "3", "bbox": [377.0, 800.0, 384.0, 809.0]}, {"text": "3", "bbox": [702.0, 800.0, 709.0, 808.0]}, {"text": "80–150 [92]", "bbox": [177.0, 813.0, 226.0, 825.0]}, {"text": "< 75 (range: 50/90***)", "bbox": [433.0, 813.0, 522.0, 825.0]}, {"text": "Bilobar", "bbox": [66.0, 814.0, 96.0, 825.0]}, {"text": "2 189 [ 91 ]", "bbox": [594.0, 814.0, 639.0, 825.0]}, {"text": "13", "bbox": [702.0, 814.0, 709.0, 823.0]}, {"text": "HR , hepatic reserve, i.e. untreated liver fraction", "bbox": [66.0, 835.0, 285.0, 849.0]}], "type": "Table", "position": 4}, {"raw_context": [{"text": "*In patients comparable to the DOSISPHERE-01 [ 67 ] study population (Child-Pugh A, large lesions, at least 30% of hepatic reserve)", "bbox": [66.0, 851.0, 672.0, 866.0]}, {"text": "**Dose to the normal perfused liver, based on the first treatment", "bbox": [66.0, 868.0, 361.0, 882.0]}, {"text": "***Dose to the whole normal liver. In HCC patients with total bilirubin levels >1.1 mg/dl, an upper threshold of 50 Gy should be used; in", "bbox": [66.0, 885.0, 727.0, 899.0]}, {"text": "patients with total bilirubin levels <1.1 mg/dl, the whole normal liver dose should be kept below 90 Gy. Data are derived from unilobar treat-", "bbox": [66.0, 900.0, 726.0, 913.0]}, {"text": "ments without prior RE only. Since these thresholds have been established in mostly cirrhotic HCC patients, they can be considered safe for non-", "bbox": [67.0, 914.0, 725.0, 926.0]}, {"text": "HCC patients; however, caution is warranted particularly in ICC patients with underlying cirrhosis and after chemotherapy /", "bbox": [66.0, 926.0, 632.0, 940.0]}, {"text": "****For large lesions [ 67 ]", "bbox": [67.0, 943.0, 189.0, 957.0]}], "type": "Text", "position": 5}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2022】全科室最全临床指南+专家共识（最全版）/2022全科室临床指南/肿瘤科/EANM：动脉内放射性化合物治疗肝癌和转移性肝癌指南（2022）(1).pdf", "page_num": 8}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "多余换行#5#5#infiltrative lesion, 与上面4段联接\n多余换行#8#8# dose thresholds that can...与上面7段联接\n缺少换行#14#14#**Dose to the normal perfused...\n ***Dose to the whole normal liver....\n****For large lesions [ 67 ]都另起一行", "type3": "无关文本#2#2# [ 81 ]  类似的 [    ]引用过多", "type4": null, "type5": null, "type6": "准确性#10#13#表格的内容，但是内容顺序杂乱"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:40", "update_time": "2024-05-07 18:01:23"}
{"id": 1082517, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 738, "source_info": {"seq_id": "bf5ee790-e472-4d6e-8d7c-484471be028f", "title": null, "text": "【0】页码:3\n I\n\n【1】 2\n\n【2】 3\n\n【3】 4\n\n【4】 5\n\n【5】 6\n\n【6】 7\n\n【7】 instability in prostate cancer by PCR or next – generation sequencing J . J Immunother Cancer 2018 6(1):29-36.\n\n【8】8 Lee Y Lee JA Park HE et al. Targeted next-generation sequencing– based detection of microsatellite instability in colorectal carcinomas J . PLoS One 2021 16(2):e0246356.\n\n【9】9 Salipante SJ Scroggins SM Hampel HL et al. Microsatellite instability detection by next generation sequencing J . Clin Chem 2014 60 (9) : 1192–1199.\n\n【10】1010 Smalley SR Benedetti JK Haller DG et  al. Updated analysis of SWOG–directed intergroup study 0116: a phase III trial of adjuvant ra– diochemotherapy versus observation after curative gastric cancer resec– tion J . J Clin Oncol 2012 30(19):2327-2333.\n\n【11】11 Janjigian YY Shitara K Moehler M et  al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric gastro– oesophageal junction and oesophageal adenocarcinoma ( CheckMate 649) : a randomised open-label phase 3 trial J . The Lancet 2021 398 (10294) : 27-40.\n\n【12】10112 Berton D  Banerjee SN  Curigliano G  et  al.  Antitumor activity of dostarlimab in patients with mismatch repair – deficient/microsatellite instability – high tumors: A combined analysis of two cohorts in the GARNET study J . Journal of Clinical Oncology 2021 39 (15 _ suppl) : 2564–2564.\n\n【13】13113 Moningi S  Ajani JA  Badgwell BD  et al. IMRT Reduces Acute Toxici– ty in Patients Treated With Preoperative Chemoradiation for Gastric Cancer J . Adv Radiat Oncol 2020 5(3):369-376.\n\n【14】14114 Ren F   Li S   Zhang Y   et al.  Efficacy and safety of intensity – modu– lated radiation therapy versus three – dimensional conformal radiation treatment for patients with gastric cancer: a systematic review and me– ta – analysis J . Radiat Oncol 2019 14(1):84-93.\n\n【15】151, 15 Ringash J Perkins G Brierley J et al. IMRT for adjuvant radiation in gastric cancer: a preferred plan  J  ? Int J Radiat Oncol Biol Phys 2005  63(3):732-738.\n\n【16】Trip AK Nijkamp J van Tinteren H et al. IMRT limits nephrotoxicity 1616 after chemoradiotherapy for gastric cancer J . Radiother Oncol 2014 112(2):289-294.\n\n【17】1717 Gagliardi G Constine LS Moiseenko V et al. Radiation Dose–Volume Effects in the Heart J . International Journal of Radiation Oncology* Biology* Physics 2010 76(3):S77-885.\n\n【18】Kavanagh BD Pan CC Dawson LA et  al. Radiation Dose–Volume 18.18 Effects in the Stomach and Small Bowel J . Int J Radiat Oncol Biol Phys  2010  76(3):S101-S107.\n\n【19】 : 2022–11–20)\n\n【20】 e a se\n\n【21】 Boku N Ryu MH Oh DY et al. LBA7_PR Nivolumab plus chemo– therapy versus chemotherapy alone in patients with previously untreat– ed advanced or recurrent gastric/gastroesophageal junction ( G/GEJ) cancer: ATTRACTION – 4 ( ONO – 4538 – 37) study J . Annals of Oncology  2020   31 : S1192-S1192.\n\n【22】Chao J Fuchs CS Shitara K et  al. Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability–High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE– 059 KEYNOTE-061 and KEYNOTE-062 Clinical Trials J . JAMA Oncol 2021 7(6):895-902.\n\n【23】Moehler M Shitara K Garrido M et al. LBA6_PR Nivolumab (ni– vo) plus chemotherapy ( chemo) versus chemo as first – line ( 1L) treatment for advanced gastric cancer/gastroesophageal junction cancer ( GC/GEJC) /esophageal adenocarcinoma ( EAC) :  First results of the CheckMate 649 study J . Annals of Oncology 2020 31: S1191–S1191.\n\n【24】Haag GM Czink E Ahadova A et al. Prognostic significance of micro– satellite–instability in gastric and gastroesophageal junction cancer pa– tients undergoing neoadjuvant chemotherapy J . Int J Cancer 2019 144(7):1697–1703.\n\n【25】Guo H  Ding P  Sun C  et al. Efficacy and safety of sintilimab plus XE– LOX as a neoadjuvant regimen in patients with locally advanced gastric cancer: A single-arm open-label phase II trial J . Front Oncol 2022 12: 927781.\n\n【26】Jiang H Yu X Li N et al. Efficacy and safety of neoadjuvant sintil– imab oxaliplatin and capecitabine in patients with locally advanced resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study J . J Immunother Cancer 2022 10 (3) : e003635.\n\n【27】Hempelmann JA Lockwood CM Konnick EQ et al. Microsatellite\n\n【28】 .\n\n【29】 .", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "I", "bbox": [64.0, 297.0, 75.0, 309.0]}], "type": "Text", "position": 0}, {"raw_context": [{"text": "2", "bbox": [64.0, 364.0, 74.0, 376.0]}], "type": "Text", "position": 1}, {"raw_context": [{"text": "3", "bbox": [64.0, 429.0, 75.0, 442.0]}], "type": "Text", "position": 2}, {"raw_context": [{"text": "4", "bbox": [64.0, 509.0, 75.0, 522.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "5", "bbox": [64.0, 561.0, 75.0, 574.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": "6", "bbox": [64.0, 614.0, 75.0, 627.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "7", "bbox": [64.0, 679.0, 74.0, 690.0]}], "type": "Text", "position": 6}, {"raw_context": [{"text": "instability in prostate cancer by PCR or next – generation sequencing", "bbox": [438.0, 91.0, 734.0, 104.0]}, {"text": "J . J Immunother Cancer 2018 6(1):29-36.", "bbox": [443.0, 105.0, 645.0, 117.0]}, {"text": "8", "bbox": [414.0, 118.0, 425.0, 131.0]}, {"text": "Lee Y Lee JA Park HE et al. Targeted next-generation sequencing–", "bbox": [438.0, 117.0, 735.0, 134.0]}, {"text": "based detection of microsatellite instability in colorectal carcinomas", "bbox": [438.0, 131.0, 733.0, 145.0]}, {"text": "J . PLoS One 2021 16(2):e0246356.", "bbox": [443.0, 145.0, 613.0, 157.0]}, {"text": "9", "bbox": [414.0, 158.0, 425.0, 170.0]}, {"text": "Salipante SJ Scroggins SM Hampel HL et al. Microsatellite instability", "bbox": [438.0, 158.0, 733.0, 171.0]}, {"text": "detection by next generation sequencing J . Clin Chem 2014 60", "bbox": [438.0, 172.0, 734.0, 185.0]}, {"text": "(9) : 1192–1199.", "bbox": [438.0, 185.0, 512.0, 197.0]}, {"text": "1010", "bbox": [416.0, 198.0, 430.0, 209.0]}, {"text": "Smalley SR Benedetti JK Haller DG et  al. Updated analysis of", "bbox": [436.0, 197.0, 735.0, 211.0]}, {"text": "SWOG–directed intergroup study 0116: a phase III trial of adjuvant ra–", "bbox": [438.0, 211.0, 734.0, 223.0]}, {"text": "diochemotherapy versus observation after curative gastric cancer resec–", "bbox": [438.0, 225.0, 733.0, 237.0]}, {"text": "tion J . J Clin Oncol 2012 30(19):2327-2333.", "bbox": [438.0, 237.0, 647.0, 250.0]}, {"text": "11", "bbox": [415.0, 251.0, 428.0, 263.0]}, {"text": "Janjigian YY Shitara K Moehler M et  al. First-line nivolumab plus", "bbox": [437.0, 251.0, 735.0, 264.0]}, {"text": "chemotherapy versus chemotherapy alone for advanced gastric gastro–", "bbox": [437.0, 263.0, 735.0, 277.0]}, {"text": "oesophageal junction and oesophageal adenocarcinoma ( CheckMate", "bbox": [438.0, 277.0, 733.0, 290.0]}, {"text": "649) : a randomised open-label phase 3 trial J . The Lancet 2021", "bbox": [436.0, 290.0, 729.0, 302.0]}, {"text": "398 (10294) : 27-40.", "bbox": [438.0, 304.0, 526.0, 316.0]}, {"text": "10112", "bbox": [416.0, 318.0, 429.0, 329.0]}, {"text": "Berton D  Banerjee SN  Curigliano G  et  al.  Antitumor activity of", "bbox": [438.0, 317.0, 735.0, 330.0]}, {"text": "dostarlimab in patients with mismatch repair – deficient/microsatellite", "bbox": [438.0, 330.0, 733.0, 343.0]}, {"text": "instability – high tumors: A combined analysis of two cohorts in the", "bbox": [438.0, 343.0, 734.0, 354.0]}, {"text": "GARNET study J . Journal of Clinical Oncology 2021 39 (15 _", "bbox": [438.0, 356.0, 731.0, 368.0]}, {"text": "suppl) : 2564–2564.", "bbox": [437.0, 370.0, 521.0, 381.0]}, {"text": "13113", "bbox": [415.0, 383.0, 429.0, 394.0]}, {"text": "Moningi S  Ajani JA  Badgwell BD  et al. IMRT Reduces Acute Toxici–", "bbox": [438.0, 382.0, 735.0, 395.0]}, {"text": "ty in Patients Treated With Preoperative Chemoradiation for Gastric", "bbox": [438.0, 396.0, 733.0, 408.0]}, {"text": "Cancer J . Adv Radiat Oncol 2020 5(3):369-376.", "bbox": [438.0, 408.0, 662.0, 422.0]}, {"text": "14114", "bbox": [415.0, 422.0, 429.0, 433.0]}, {"text": "Ren F   Li S   Zhang Y   et al.  Efficacy and safety of intensity – modu–", "bbox": [436.0, 422.0, 735.0, 436.0]}, {"text": "lated radiation therapy versus three – dimensional conformal radiation", "bbox": [438.0, 436.0, 734.0, 448.0]}, {"text": "treatment for patients with gastric cancer: a systematic review and me–", "bbox": [438.0, 450.0, 734.0, 462.0]}, {"text": "ta – analysis J . Radiat Oncol 2019 14(1):84-93.", "bbox": [438.0, 462.0, 666.0, 474.0]}, {"text": "151, 15", "bbox": [416.0, 475.0, 429.0, 487.0]}, {"text": "Ringash J Perkins G Brierley J et al. IMRT for adjuvant radiation in", "bbox": [437.0, 475.0, 734.0, 488.0]}, {"text": "gastric cancer: a preferred plan  J  ? Int J Radiat Oncol Biol Phys", "bbox": [438.0, 488.0, 729.0, 500.0]}, {"text": "2005  63(3):732-738.", "bbox": [438.0, 502.0, 537.0, 514.0]}, {"text": "Trip AK Nijkamp J van Tinteren H et al. IMRT limits nephrotoxicity", "bbox": [437.0, 514.0, 733.0, 527.0]}, {"text": "1616", "bbox": [416.0, 515.0, 430.0, 526.0]}, {"text": "after chemoradiotherapy for gastric cancer J . Radiother Oncol 2014", "bbox": [438.0, 528.0, 729.0, 541.0]}, {"text": "112(2):289-294.", "bbox": [438.0, 540.0, 516.0, 553.0]}, {"text": "1717", "bbox": [416.0, 554.0, 428.0, 566.0]}, {"text": "Gagliardi G Constine LS Moiseenko V et al. Radiation Dose–Volume", "bbox": [437.0, 554.0, 733.0, 567.0]}, {"text": "Effects in the Heart J . International Journal of Radiation Oncology*", "bbox": [438.0, 568.0, 728.0, 581.0]}, {"text": "Biology* Physics 2010 76(3):S77-885.", "bbox": [438.0, 581.0, 614.0, 594.0]}, {"text": "Kavanagh BD Pan CC Dawson LA et  al. Radiation Dose–Volume", "bbox": [438.0, 594.0, 733.0, 607.0]}, {"text": "18.18", "bbox": [415.0, 595.0, 428.0, 604.0]}, {"text": "Effects in the Stomach and Small Bowel J . Int J Radiat Oncol Biol", "bbox": [438.0, 607.0, 733.0, 620.0]}, {"text": "Phys  2010  76(3):S101-S107.", "bbox": [438.0, 620.0, 573.0, 633.0]}], "type": "Text", "position": 13}, {"raw_context": [{"text": ": 2022–11–20)", "bbox": [649.0, 656.0, 710.0, 669.0]}], "type": "Text", "position": 14}, {"raw_context": [{"text": "e a se", "bbox": [61.0, 720.0, 731.0, 732.0]}], "type": "Text", "position": 15}, {"raw_context": [{"text": "Boku N Ryu MH Oh DY et al. LBA7_PR Nivolumab plus chemo–", "bbox": [88.0, 297.0, 384.0, 310.0]}, {"text": "therapy versus chemotherapy alone in patients with previously untreat–", "bbox": [88.0, 311.0, 384.0, 324.0]}, {"text": "ed advanced or recurrent gastric/gastroesophageal junction ( G/GEJ)", "bbox": [87.0, 325.0, 382.0, 336.0]}, {"text": "cancer: ATTRACTION – 4 ( ONO – 4538 – 37) study J . Annals of", "bbox": [89.0, 337.0, 384.0, 350.0]}, {"text": "Oncology  2020   31 : S1192-S1192.", "bbox": [88.0, 350.0, 238.0, 362.0]}, {"text": "Chao J Fuchs CS Shitara K et  al. Assessment of Pembrolizumab", "bbox": [88.0, 364.0, 384.0, 377.0]}, {"text": "Therapy for the Treatment of Microsatellite Instability–High Gastric or", "bbox": [88.0, 377.0, 385.0, 390.0]}, {"text": "Gastroesophageal Junction Cancer Among Patients in the KEYNOTE–", "bbox": [88.0, 390.0, 384.0, 403.0]}, {"text": "059 KEYNOTE-061 and KEYNOTE-062 Clinical Trials J . JAMA", "bbox": [87.0, 402.0, 384.0, 415.0]}, {"text": "Oncol 2021 7(6):895-902.", "bbox": [88.0, 416.0, 209.0, 429.0]}, {"text": "Moehler M Shitara K Garrido M et al. LBA6_PR Nivolumab (ni–", "bbox": [88.0, 429.0, 385.0, 443.0]}, {"text": "vo) plus chemotherapy ( chemo) versus chemo as first – line ( 1L)", "bbox": [88.0, 443.0, 383.0, 455.0]}, {"text": "treatment for advanced gastric cancer/gastroesophageal junction cancer", "bbox": [88.0, 457.0, 383.0, 469.0]}, {"text": "( GC/GEJC) /esophageal adenocarcinoma ( EAC) :  First results of the", "bbox": [88.0, 468.0, 383.0, 481.0]}, {"text": "CheckMate 649 study", "bbox": [88.0, 481.0, 194.0, 495.0]}, {"text": "J . Annals of Oncology 2020", "bbox": [199.0, 482.0, 358.0, 495.0]}, {"text": "31:", "bbox": [361.0, 483.0, 381.0, 493.0]}, {"text": "S1191–S1191.", "bbox": [88.0, 495.0, 148.0, 508.0]}, {"text": "Haag GM Czink E Ahadova A et al. Prognostic significance of micro–", "bbox": [88.0, 509.0, 385.0, 522.0]}, {"text": "satellite–instability in gastric and gastroesophageal junction cancer pa–", "bbox": [88.0, 522.0, 384.0, 534.0]}, {"text": "tients undergoing neoadjuvant chemotherapy J . Int J Cancer 2019", "bbox": [88.0, 536.0, 379.0, 548.0]}, {"text": "144(7):1697–1703.", "bbox": [88.0, 548.0, 178.0, 560.0]}, {"text": "Guo H  Ding P  Sun C  et al. Efficacy and safety of sintilimab plus XE–", "bbox": [88.0, 562.0, 384.0, 575.0]}, {"text": "LOX as a neoadjuvant regimen in patients with locally advanced gas-", "bbox": [88.0, 575.0, 382.0, 587.0]}, {"text": "tric cancer: A single-arm open-label phase II trial J . Front Oncol", "bbox": [88.0, 588.0, 379.0, 601.0]}, {"text": "2022 12: 927781.", "bbox": [88.0, 600.0, 164.0, 612.0]}, {"text": "Jiang H Yu X Li N et al. Efficacy and safety of neoadjuvant sintil–", "bbox": [88.0, 613.0, 384.0, 628.0]}, {"text": "imab oxaliplatin and capecitabine in patients with locally advanced", "bbox": [88.0, 627.0, 380.0, 641.0]}, {"text": "resectable gastric or gastroesophageal junction adenocarcinoma: early", "bbox": [88.0, 641.0, 383.0, 654.0]}, {"text": "results of a phase 2 study J . J Immunother Cancer 2022", "bbox": [88.0, 655.0, 368.0, 668.0]}, {"text": "10", "bbox": [369.0, 656.0, 383.0, 664.0]}, {"text": "(3) : e003635.", "bbox": [88.0, 667.0, 151.0, 679.0]}, {"text": "Hempelmann JA Lockwood CM Konnick EQ et al. Microsatellite", "bbox": [88.0, 679.0, 383.0, 693.0]}], "type": "Text", "position": 16}, {"raw_context": [{"text": ".", "bbox": [488.0, 747.0, 498.0, 757.0]}], "type": "Text", "position": 17}, {"raw_context": [{"text": ".", "bbox": [573.0, 747.0, 582.0, 757.0]}], "type": "Text", "position": 18}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/肿瘤科/解读/美国国立综合癌症网络临床实践指南：胃癌(2022.V2)更新解读(1).pdf", "page_num": 3}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": null, "type3": null, "type4": null, "type5": null, "type6": "有用性#0#29#参考文献的内容，但是内容混乱"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:40", "update_time": "2024-05-08 22:54:56"}
{"id": 1082516, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 738, "source_info": {"seq_id": "95caf651-c76e-496e-a939-1cd2912fa0ff", "title": null, "text": "【0】页码:32\n Endoscopist and the endoscopy team take a lot of care to avoid all the risks outlined. They will be able to give you more information about any of these risks and what they do to avoid them. People vary in how they interpret words and numbers. The scale below is provided to help: -\n\n【1】 Very common - 1 in 10 - One person in your family\n\n【2】 Common - 1 in 100 - One person in a street\n\n【3】 Uncommon - 1 in 1,000 - One person in a village\n\n【4】 Rare - 1 in 10,000 - One person in a small town\n\n【5】 Very rare - 1 in 100,000 - One person in a large town\n\n【6】## Risks During Your Sedation\n\n【7】\n 1. Your breathing rate may become slow and shallow. This is particularly common in deep sedation, but is a risk whenever sedation is used. Your endoscopy team is skilled in monitoring you and can support your breathing if required.\n\n【8】2. It is very common for your blood pressure to drop by a small amount, but your endoscopist is trained in treating this too.\n\n【9】3. It is very common to be left with a small bruise where your cannula was placed.\n\n【10】4. Feeling sick or vomiting is uncommon.\n\n【11】There is a rare risk of stomach contents going into your lungs. It is important to follow the 5.\n\n【12】instructions for eating and drinking to keep this risk very low.\n\n【13】Any allergic reaction to the sedation drugs is very rare. Risks after your sedation 1.6.\n\n【14】7. It is very common to feel drowsy and less steady on your feet. You may be at higher risk of falling, especially if you are elderly.\n\n【15】8. It is common for sedation to affect your judgement and memory for up to 24 hours.\n\n【16】 Questions you may like to ask about your sedation\n\n【17】 Who will give my sedation?\n\n【18】1.\n\n【19】What type of sedation is best for me and the procedure I am having?\n\n【20】2.\n\n【21】Do I have any specific risks?\n\n【22】3.\n\n【23】When should I stop eating and drinking before my procedure?\n\n【24】4.\n\n【25】5.\n\n【26】What time should I arrange to be collected?\n\n【27】## Additional Resources\n\n【28】\n Caring for someone who has had sedation (rcoa.ac.uk/patientinfo/sedation).\n\n【29】1.\n\n【30】Academy of Medical Royal Colleges. Safe Sedation Practice for Healthcare Procedures: An 2.\n\n【31】update. AoMRC , 2021 (https:/bit.ly/3wEoHGy).\n\n【32】3. Academy of Medical Royal Colleges. Safe Sedation Practice for Healthcare Procedures: Standards and Guidance. AoMRC, 2013 (http:/bit.ly/301ndq8).\n\n【33】 Disclaimer and Acknowledgement.", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "Endoscopist and the endoscopy team take a lot of care to avoid all the risks outlined. They will be", "bbox": [140.0, 141.0, 667.0, 156.0]}, {"text": " able to give you more information about any of these risks and what they do to avoid them. People", "bbox": [140.0, 158.0, 675.0, 172.0]}, {"text": "vary in how they interpret words and numbers. The scale below is provided to help: -", "bbox": [140.0, 174.0, 599.0, 189.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "Very common - 1 in 10 - One person in your family", "bbox": [119.0, 205.0, 393.0, 220.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": "Common - 1 in 100 - One person in a street", "bbox": [119.0, 235.0, 354.0, 249.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "Uncommon - 1 in 1,000 - One person in a village", "bbox": [119.0, 266.0, 381.0, 280.0]}], "type": "Text", "position": 6}, {"raw_context": [{"text": "Rare - 1 in 10,000 - One person in a small town", "bbox": [119.0, 296.0, 375.0, 310.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "Very rare - 1 in 100,000 - One person in a large town", "bbox": [119.0, 327.0, 405.0, 341.0]}], "type": "Text", "position": 8}, {"raw_context": [{"text": "Risks during your sedation", "bbox": [119.0, 357.0, 267.0, 372.0]}], "type": "Section-header", "position": 9}, {"raw_context": [{"text": "1. Your breathing rate may become slow and shallow. This is particularly common in deep", "bbox": [141.0, 388.0, 635.0, 403.0]}, {"text": "sedation, but is a risk whenever sedation is used. Your endoscopy team is skilled in monitoring", "bbox": [161.0, 404.0, 673.0, 418.0]}, {"text": "you and can support your breathing if required.", "bbox": [161.0, 420.0, 420.0, 434.0]}, {"text": "2. It is very common for your blood pressure to drop by a small amount, but your endoscopist is", "bbox": [140.0, 436.0, 667.0, 450.0]}, {"text": "trained in treating this too.", "bbox": [161.0, 452.0, 310.0, 466.0]}, {"text": "3. It is very common to be left with a small bruise where your cannula was placed.", "bbox": [140.0, 468.0, 592.0, 483.0]}, {"text": "4. Feeling sick or vomiting is uncommon.", "bbox": [140.0, 485.0, 371.0, 498.0]}, {"text": "There is a rare risk of stomach contents going into your lungs. It is important to follow the", "bbox": [159.0, 501.0, 648.0, 515.0]}, {"text": "5.", "bbox": [140.0, 502.0, 162.0, 514.0]}, {"text": "instructions for eating and drinking to keep this risk very low.", "bbox": [161.0, 517.0, 492.0, 531.0]}, {"text": "Any allergic reaction to the sedation drugs is very rare. Risks after your sedation", "bbox": [160.0, 534.0, 594.0, 547.0]}, {"text": "1.6.", "bbox": [140.0, 535.0, 161.0, 547.0]}, {"text": "7. It is very common to feel drowsy and less steady on your feet. You may be at higher risk of", "bbox": [141.0, 549.0, 651.0, 564.0]}, {"text": "falling, especially if you are elderly.", "bbox": [161.0, 565.0, 354.0, 579.0]}, {"text": "8. It is common for sedation to affect your judgement and memory for up to 24 hours.", "bbox": [140.0, 581.0, 614.0, 596.0]}], "type": "Text", "position": 10}, {"raw_context": [{"text": "Questions you may like to ask about your sedation", "bbox": [141.0, 642.0, 414.0, 656.0]}], "type": "Text", "position": 11}, {"raw_context": [{"text": "Who will give my sedation?", "bbox": [204.0, 673.0, 357.0, 688.0]}, {"text": "1.", "bbox": [184.0, 674.0, 204.0, 687.0]}, {"text": "What type of sedation is best for me and the procedure I am having?", "bbox": [204.0, 689.0, 578.0, 703.0]}, {"text": "2.", "bbox": [184.0, 690.0, 202.0, 703.0]}, {"text": "Do I have any specific risks?", "bbox": [203.0, 705.0, 358.0, 719.0]}, {"text": "3.", "bbox": [183.0, 707.0, 206.0, 718.0]}, {"text": "When should I stop eating and drinking before my procedure?", "bbox": [203.0, 721.0, 542.0, 735.0]}, {"text": "4.", "bbox": [183.0, 723.0, 204.0, 734.0]}, {"text": "5.", "bbox": [184.0, 738.0, 204.0, 751.0]}, {"text": "What time should I arrange to be collected?", "bbox": [203.0, 737.0, 444.0, 751.0]}], "type": "Text", "position": 12}, {"raw_context": [{"text": "Additional resources", "bbox": [119.0, 768.0, 236.0, 783.0]}], "type": "Section-header", "position": 13}, {"raw_context": [{"text": "Caring for someone who has had sedation (rcoa.ac.uk/patientinfo/sedation).", "bbox": [160.0, 798.0, 577.0, 812.0]}, {"text": "1.", "bbox": [142.0, 800.0, 161.0, 812.0]}, {"text": "Academy of Medical Royal Colleges. Safe Sedation Practice for Healthcare Procedures: An", "bbox": [160.0, 814.0, 645.0, 828.0]}, {"text": "2.", "bbox": [141.0, 816.0, 161.0, 828.0]}, {"text": "update. AoMRC , 2021 (https:/bit.ly/3wEoHGy).", "bbox": [161.0, 831.0, 418.0, 845.0]}, {"text": "3. Academy of Medical Royal Colleges. Safe Sedation Practice for Healthcare Procedures: Standards", "bbox": [140.0, 847.0, 684.0, 861.0]}, {"text": "and Guidance. AoMRC, 2013 (http:/bit.ly/301ndq8).", "bbox": [161.0, 863.0, 444.0, 878.0]}], "type": "Text", "position": 14}, {"raw_context": [{"text": "Disclaimer and Acknowledgement.", "bbox": [119.0, 894.0, 308.0, 908.0]}], "type": "Text", "position": 15}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/消化科/_2023 BSG指南：胃肠内窥镜检查中的镇静.pdf", "page_num": 32}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "多余换行#11#12#important to follow the和instructions for eating是一句话\n序号格式不一致#11#11#5.应该在句首\n序号格式不一致#13#13#6.应该在句首\n多余换行#17#26#序号和正文分离1.和Who will give my sedation?相连，以此类推\n多余换行#28#32#序号和正文分离1.和Caring for someone who has had sedation (rcoa.ac.uk/patientinfo/sedation).相连，以此类推\n序号格式不一致#30#30#2.应该在句首\n多余换行#30#31#Healthcare Procedures: An和update. AoMRC , 2021 (https:/bit.ly/3wEoHGy).是一句话", "type3": "无关文本#13#13#1.\n", "type4": null, "type5": null, "type6": null}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:40", "update_time": "2024-05-08 00:40:46"}
{"id": 1082515, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 738, "source_info": {"seq_id": "350286b9-342c-4032-91c1-88f56ca6d1d6", "title": null, "text": "【0】页码:31\n 3.\n\n【1】 Sometime stickers on your upper chest to record your heart rhythm or less commonly with moderate or deep sedation, a thin plastic tube attached to a face mask that measures the amount of carbon dioxide that you breathe out.\n\n【2】 How is intravenous sedation given?\n\n【3】 1.\n\n【4】 2.\n\n【5】 The sedation is given through a drip (cannula) which is put into a vein in your arm or the back of your hand. More sedative can be given if you need it during the procedure. In deep sedation, you will usually have a drug given continuously into your vein.\n\n【6】You will have extra oxygen to breathe from a plastic tube sitting just inside your nose, or occasionally a face mask.\n\n【7】## What Does Sedation Feel Like?\n\n【8】\n This will vary between people, depending on how much of the drug they are given. In deep sedation you will be asleep, but in minimal and moderate sedation you usually feel pleasantly relaxed. When we asked some patients what it felt like, some answers were: I felt very spaced out and dreamy.' 'I thought I had been awake during it all, but I must have drifted off at times as suddenly it was an hour later.' I felt really relaxed and happy.' 'It was weird – I felt very detached from what was happening around me.'\n\n【9】## Going Home After The Procedure?\n\n【10】\n 1.\n\n【11】 If you have light or moderate sedation, you can usually go home within an hour or two of your treatment.\n\n【12】 2.\n\n【13】3.\n\n【14】4.\n\n【15】5.\n\n【16】6.\n\n【17】7.\n\n【18】8.\n\n【19】9.\n\n【20】  If you have deep sedation, your recovery will usually take two hours or longer. When you can go home may also depend on how long it will take you to recover from the procedure itself.\n\n【21】As previously mentioned, a capable adult will need to take you home by car or taxi – ideally not public transport – and remain with you overnight. If you have not organised for someone to be with you after treatment, you may need to stay in hospital overnight, or your treatment may need to be postponed.\n\n【22】Sedation may make you unsteady on your feet. Please be careful on stairs and have somebody with you if you feel unsteady.\n\n【23】Your ability to make decisions and judgements may be affected for up to 24 hours after your treatment, so you should not make any important decisions during that time. You should avoid posting on social media/public forums too.\n\n【24】You should not return to work, look after dependents, drive, cook or operate any machinery for 24 hours as it may take this length of time for the drugs to leave your body.\n\n【25】You should not take any alcohol or sleeping tablets for 24 hours after the procedure.\n\n【26】Your doctor will give written instructions about further treatment to follow at home.\n\n【27】The hospital will give you a contact telephone number to call if you feel unwell at all. If after the procedure you are concerned, feel unwell, or cannot find the hospital contact number, you can call your GP, ring 111 or go to your local accident and emergency department with a capable adult if necessary.\n\n【28】## Side Effects, Complications, And Risks\n\n【29】\n In modern sedation, serious problems are uncommon. Risk cannot be removed completely, but modern drugs, equipment and training have made sedation much safer in recent years. The", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "3.", "bbox": [140.0, 143.0, 160.0, 155.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "Sometime stickers on your upper chest to record your heart rhythm or less commonly with", "bbox": [160.0, 141.0, 654.0, 156.0]}, {"text": "moderate or deep sedation, a thin plastic tube attached to a face mask that measures the", "bbox": [162.0, 158.0, 648.0, 172.0]}, {"text": "amount of carbon dioxide that you breathe out.", "bbox": [162.0, 175.0, 422.0, 188.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": "How is intravenous sedation given?", "bbox": [119.0, 205.0, 312.0, 220.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "1.", "bbox": [142.0, 237.0, 159.0, 249.0]}], "type": "Text", "position": 6}, {"raw_context": [{"text": "2.", "bbox": [141.0, 285.0, 159.0, 298.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "The sedation is given through a drip (cannula) which is put into a vein in your arm or the back of", "bbox": [161.0, 234.0, 680.0, 249.0]}, {"text": "your hand. More sedative can be given if you need it during the procedure. In deep sedation,", "bbox": [161.0, 251.0, 665.0, 265.0]}, {"text": "you will usually have a drug given continuously into your vein.", "bbox": [162.0, 267.0, 497.0, 281.0]}, {"text": "You will have extra oxygen to breathe from a plastic tube sitting just inside your nose, or", "bbox": [160.0, 284.0, 640.0, 298.0]}, {"text": "occasionally a face mask.", "bbox": [162.0, 300.0, 299.0, 315.0]}], "type": "Text", "position": 8}, {"raw_context": [{"text": "What does sedation feel like?", "bbox": [142.0, 330.0, 302.0, 344.0]}], "type": "Section-header", "position": 9}, {"raw_context": [{"text": "This will vary between people, depending on how much of the drug they are given. In deep sedation", "bbox": [141.0, 361.0, 682.0, 375.0]}, {"text": "you will be asleep, but in minimal and moderate sedation you usually feel pleasantly relaxed. When", "bbox": [141.0, 377.0, 678.0, 391.0]}, {"text": "we asked some patients what it felt like, some answers were: I felt very spaced out and dreamy.' 'I", "bbox": [140.0, 394.0, 673.0, 407.0]}, {"text": "thought I had been awake during it all, but I must have drifted off at times as suddenly it was an", "bbox": [140.0, 409.0, 660.0, 424.0]}, {"text": "hour later.' I felt really relaxed and happy.' 'It was weird – I felt very detached from what was", "bbox": [140.0, 425.0, 645.0, 440.0]}, {"text": "happening around me.'", "bbox": [141.0, 440.0, 269.0, 455.0]}], "type": "Text", "position": 10}, {"raw_context": [{"text": "Going home after the procedure?", "bbox": [119.0, 472.0, 301.0, 487.0]}], "type": "Section-header", "position": 11}, {"raw_context": [{"text": "1.", "bbox": [142.0, 504.0, 159.0, 516.0]}], "type": "Text", "position": 12}, {"raw_context": [{"text": "If you have light or moderate sedation, you can usually go home within an hour or two of your", "bbox": [160.0, 502.0, 671.0, 516.0]}, {"text": "treatment.", "bbox": [161.0, 519.0, 223.0, 533.0]}], "type": "Text", "position": 13}, {"raw_context": [{"text": "2.", "bbox": [140.0, 536.0, 161.0, 549.0]}, {"text": "3.", "bbox": [140.0, 568.0, 159.0, 580.0]}, {"text": "4.", "bbox": [140.0, 632.0, 159.0, 645.0]}, {"text": "5.", "bbox": [140.0, 665.0, 157.0, 677.0]}, {"text": "6.", "bbox": [140.0, 713.0, 157.0, 726.0]}, {"text": "7.", "bbox": [142.0, 744.0, 157.0, 757.0]}, {"text": "8.", "bbox": [140.0, 762.0, 159.0, 773.0]}, {"text": "9.", "bbox": [140.0, 778.0, 159.0, 790.0]}], "type": "Text", "position": 14}, {"raw_context": [{"text": " If you have deep sedation, your recovery will usually take two hours or longer. When you can go", "bbox": [160.0, 535.0, 682.0, 550.0]}, {"text": "home may also depend on how long it will take you to recover from the procedure itself.", "bbox": [161.0, 551.0, 641.0, 565.0]}, {"text": "As previously mentioned, a capable adult will need to take you home by car or taxi – ideally not", "bbox": [160.0, 567.0, 678.0, 581.0]}, {"text": "public transport – and remain with you overnight. If you have not organised for someone to be", "bbox": [162.0, 584.0, 675.0, 597.0]}, {"text": "with you after treatment, you may need to stay in hospital overnight, or your treatment may", "bbox": [161.0, 599.0, 665.0, 614.0]}, {"text": "need to be postponed.", "bbox": [161.0, 615.0, 287.0, 629.0]}, {"text": "Sedation may make you unsteady on your feet. Please be careful on stairs and have somebody", "bbox": [161.0, 630.0, 673.0, 645.0]}, {"text": "with you if you feel unsteady.", "bbox": [162.0, 648.0, 324.0, 661.0]}, {"text": "Your ability to make decisions and judgements may be affected for up to 24 hours after your", "bbox": [161.0, 664.0, 663.0, 678.0]}, {"text": "treatment, so you should not make any important decisions during that time. You should avoid", "bbox": [161.0, 680.0, 675.0, 695.0]}, {"text": "posting on social media/public forums too.", "bbox": [162.0, 696.0, 395.0, 710.0]}, {"text": "You should not return to work, look after dependents, drive, cook or operate any machinery for", "bbox": [161.0, 711.0, 679.0, 726.0]}, {"text": "24 hours as it may take this length of time for the drugs to leave your body.", "bbox": [162.0, 728.0, 569.0, 741.0]}, {"text": "You should not take any alcohol or sleeping tablets for 24 hours after the procedure.", "bbox": [161.0, 744.0, 618.0, 758.0]}, {"text": "Your doctor will give written instructions about further treatment to follow at home.", "bbox": [161.0, 760.0, 619.0, 774.0]}, {"text": "The hospital will give you a contact telephone number to call if you feel unwell at all. If after the", "bbox": [161.0, 777.0, 681.0, 791.0]}, {"text": "procedure you are concerned, feel unwell, or cannot find the hospital contact number, you can", "bbox": [161.0, 792.0, 676.0, 806.0]}, {"text": "call your GP, ring 111 or go to your local accident and emergency department with a capable", "bbox": [161.0, 809.0, 663.0, 823.0]}, {"text": "adult if necessary.", "bbox": [163.0, 825.0, 263.0, 839.0]}], "type": "Text", "position": 15}, {"raw_context": [{"text": "Side effects, complications, and risks", "bbox": [119.0, 855.0, 325.0, 869.0]}], "type": "Section-header", "position": 16}, {"raw_context": [{"text": "In modern sedation, serious problems are uncommon. Risk cannot be removed completely, but", "bbox": [141.0, 886.0, 656.0, 900.0]}, {"text": "modern drugs, equipment and training have made sedation much safer in recent years. The", "bbox": [141.0, 902.0, 636.0, 916.0]}], "type": "Text", "position": 17}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/消化科/_2023 BSG指南：胃肠内窥镜检查中的镇静.pdf", "page_num": 31}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "多余换行#3#6#序号和正文分离1.和The sedation is given through相连，以此类推\n多余换行#10#27#序号和正文分离1.和If you have light or moderate相连，以此类推", "type3": null, "type4": null, "type5": null, "type6": null}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:40", "update_time": "2024-05-07 23:09:54"}
{"id": 1082514, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 738, "source_info": {"seq_id": "aaf41cab-282f-4923-a870-b93e7e3f4dbe", "title": null, "text": "【0】页码:7\n Fig. 2. (A) Bisphosphonate treatment in patients with osteogenesis imperfecta (OI),(B) βisphosphonate treatment in patients with secondary osteoporosis. DXA, dualenergy x-ray absorptiometry; BMD, bone mineral density; Tx, treatment.  Pamidronate 9 mg/kg/y/x-6,divided doses or zoledronate 0.1 mg/kg/yr, 2 divided doses. \"Initial Tx of bisphosphonate, pamidronate 9 mg/kg/year, 4-6 divided doses or zoledronate 0.1 mg/kg/year, 2 divided doses. \"Maintenance Tx, pamidronate 3 mg/kg/yr in 2 divided doses or zoledronate 0.025 mg/kg annually. Modified from Simm et al. J Paediatr Child Health 2018-54213; 33 with permission of Paediatrics and Child Health Division (The Royal Australasian College of Physicians). 50\n\n【1】 pregnancy, severe renal disease, and active rickets. Reduced renal function is a relative contraindication because approximately 40%–60% of the dose is distributed to the bone; the remainder is excreted unaltered in the urine, with no substantial metabolism. 65,66 ) The acute adverse effects of bisphosphonate treatment in pediatric patients are flu-like symptoms and hypocalcemia, with possible long-term effects of delayed bone healing, osteopetrosis, and gastroesophageal reflux. The potential side effects are atypical femoral fractures, osteonecrosis.\n\n【2】of the jaw, orbital inflammation, growth impairment, and teratogenicity. 65,66 ) Therefore, clinical, biochemical, and imaging assessments must be performed. 49,54 General clinical examination with growth and nutritional evaluation, dental and eye examination, complete blood cell count, electrolytes, alkaline phosphatase, bone turnover markers, liver function test, renal function test, serum vitamin D and parathyroid hormone levels, urine analysis, urinary calcium excretion, radiography of the wrist and knee, and BMD should be included in the assessments.\n\n【3】## 2. New Therapeutic Agents\n\n【4】\n Several new drugs, such as teriparatide (recombinant human parathyroid hormone), strontium ranelate, and denosumab (monoclonal anti-RANKL antibody), increase bone formation and decrease bone resorption. However, reports on the effect and safety of these medications in children are insufficient. 10.11.87 )\n\n【5】## Conclusions\n\n【6】\n Bone mineral deposition shows the highest increase during the pubertal period in girls and boys and can be a major\n\n【7】 determinant of BMD in later life. Therefore, modifiable determinants of bone mass, including nutrition, exercise, lifestyle, body weight, lean body mass, and hormonal status should be adequately maintained to optimize bone health in children and adolescents.\n\n【8】The definition of osteoporosis in children is different from that in adults. In pediatric patients with primary or secondary osteoporosis, underlying conditions should be treated first, and then conservative and pharmacologic therapies should be considered.\n\n【9】## Notes\n\n【10】\n Conflicts of interest: No potential conflict of interest relevant to this article was reported.\n\n【11】Funding: This study received no specific grant from any funding agency in the public, commercial, or not-for-profit / sectors.\n\n【12】 Author contribution Conceptualization: KSS; Data curation: AK, JHY, WKC; Formal analysis: JHK, JSL; Methodology: HN; Visualization: SYC; Writing - original draft: YA; Writing - review & editing: KSS\n\n【13】 Acknowledgments: The Authors greatly appreciate the help from Pf. Choong Ho Shin (Past President of The Korean Society of Pediatric Endocrinology) and Pf. Ho Yeon Chung (Past Chairman of The Korean Society for Bone and Mineral Research) in organizing the committee for these guidelines.\n\n【14】Further, Pf. Deog Yoon Kim (Past Chairman of The Korean Society for Bone and Mineral Research), Pf. Yumie Rhee (Secretary General, The Korean Society for Bone and Mineral Research), Pf. Seong Bin Hong (Director, Committee of", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "Fig. 2. (A) Bisphosphonate treatment in patients with osteogenesis imperfecta (OI),(B) βisphosphonate treatment in patients with secondary osteoporosis. DXA, dual-", "bbox": [66.0, 379.0, 726.0, 393.0]}, {"text": "energy x-ray absorptiometry; BMD, bone mineral density; Tx, treatment.  Pamidronate 9 mg/kg/y/x-6,divided doses or zoledronate 0.1 mg/kg/yr, 2 divided doses. \"Initial", "bbox": [66.0, 392.0, 727.0, 405.0]}, {"text": "Tx of bisphosphonate, pamidronate 9 mg/kg/year, 4-6 divided doses or zoledronate 0.1 mg/kg/year, 2 divided doses. \"Maintenance Tx, pamidronate 3 mg/kg/yr in 2", "bbox": [66.0, 405.0, 727.0, 419.0]}, {"text": "divided doses or zoledronate 0.025 mg/kg annually. Modified from Simm et al. J Paediatr Child Health 2018-54213; 33 with permission of Paediatrics and Child Health", "bbox": [66.0, 418.0, 728.0, 431.0]}, {"text": "Division (The Royal Australasian College of Physicians). 50", "bbox": [66.0, 431.0, 281.0, 443.0]}], "type": "Caption", "position": 2}, {"raw_context": [{"text": "pregnancy, severe renal disease, and active rickets. Reduced renal", "bbox": [66.0, 460.0, 383.0, 475.0]}, {"text": "function is a relative contraindication because approximately", "bbox": [66.0, 476.0, 383.0, 491.0]}, {"text": "40%–60% of the dose is distributed to the bone; the remainder", "bbox": [66.0, 492.0, 383.0, 507.0]}, {"text": "is excreted unaltered in the urine, with no substantial", "bbox": [66.0, 508.0, 383.0, 523.0]}, {"text": "metabolism. 65,66 ) The acute adverse effects of bisphosphonate", "bbox": [66.0, 522.0, 383.0, 540.0]}, {"text": "treatment in pediatric patients are flu-like symptoms and", "bbox": [65.0, 540.0, 383.0, 555.0]}, {"text": "hypocalcemia, with possible long-term effects of delayed", "bbox": [65.0, 555.0, 383.0, 570.0]}, {"text": "bone healing, osteopetrosis, and gastroesophageal reflux. The", "bbox": [64.0, 571.0, 383.0, 585.0]}, {"text": "potential side effects are atypical femoral fractures, osteonecrosis.", "bbox": [66.0, 586.0, 384.0, 601.0]}, {"text": "of the jaw, orbital inflammation, growth impairment, and", "bbox": [65.0, 603.0, 384.0, 617.0]}, {"text": "teratogenicity. 65,66 ) Therefore, clinical, biochemical, and", "bbox": [65.0, 617.0, 383.0, 633.0]}, {"text": "imaging assessments must be performed. 49,54 General clinical", "bbox": [66.0, 631.0, 383.0, 648.0]}, {"text": "examination with growth and nutritional evaluation, dental", "bbox": [65.0, 650.0, 383.0, 665.0]}, {"text": "and eye examination, complete blood cell count, electrolytes,", "bbox": [66.0, 666.0, 383.0, 680.0]}, {"text": "alkaline phosphatase, bone turnover markers, liver function test,", "bbox": [66.0, 681.0, 383.0, 696.0]}, {"text": "renal function test, serum vitamin D and parathyroid hormone", "bbox": [66.0, 698.0, 383.0, 712.0]}, {"text": "levels, urine analysis, urinary calcium excretion, radiography", "bbox": [66.0, 713.0, 383.0, 728.0]}, {"text": "of the wrist and knee, and BMD should be included in the", "bbox": [66.0, 728.0, 383.0, 743.0]}, {"text": "assessments.", "bbox": [64.0, 744.0, 129.0, 759.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "2. New therapeutic agents", "bbox": [66.0, 775.0, 209.0, 791.0]}], "type": "Section-header", "position": 4}, {"raw_context": [{"text": "Several new drugs, such as teriparatide (recombinant human", "bbox": [77.0, 811.0, 383.0, 826.0]}, {"text": "parathyroid hormone), strontium ranelate, and denosumab", "bbox": [66.0, 826.0, 383.0, 841.0]}, {"text": "(monoclonal anti-RANKL antibody), increase bone formation", "bbox": [66.0, 842.0, 390.0, 856.0]}, {"text": "and decrease bone resorption. However, reports on the effect", "bbox": [66.0, 857.0, 387.0, 873.0]}, {"text": "and safety of these medications in children are insufficient. 10.11.87 )", "bbox": [66.0, 874.0, 383.0, 888.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "Conclusions", "bbox": [66.0, 907.0, 151.0, 923.0]}], "type": "Section-header", "position": 6}, {"raw_context": [{"text": "Bone mineral deposition shows the highest increase during", "bbox": [77.0, 939.0, 383.0, 954.0]}, {"text": "the pubertal period in girls and boys and can be a major", "bbox": [64.0, 956.0, 383.0, 970.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "determinant of BMD in later life. Therefore, modifiable", "bbox": [409.0, 460.0, 727.0, 475.0]}, {"text": "determinants of bone mass, including nutrition, exercise,", "bbox": [409.0, 476.0, 726.0, 491.0]}, {"text": "lifestyle, body weight, lean body mass, and hormonal status", "bbox": [409.0, 492.0, 728.0, 507.0]}, {"text": "should be adequately maintained to optimize bone health in", "bbox": [410.0, 508.0, 727.0, 523.0]}, {"text": "children and adolescents.", "bbox": [409.0, 524.0, 536.0, 538.0]}, {"text": "The definition of osteoporosis in children is different from", "bbox": [421.0, 540.0, 727.0, 554.0]}, {"text": "that in adults. In pediatric patients with primary or secondary", "bbox": [410.0, 555.0, 726.0, 570.0]}, {"text": "osteoporosis, underlying conditions should be treated first,", "bbox": [410.0, 571.0, 728.0, 585.0]}, {"text": "and then conservative and pharmacologic therapies should be", "bbox": [410.0, 586.0, 727.0, 602.0]}, {"text": "considered.", "bbox": [410.0, 603.0, 469.0, 617.0]}], "type": "Text", "position": 8}, {"raw_context": [{"text": "Notes", "bbox": [410.0, 635.0, 453.0, 650.0]}], "type": "Section-header", "position": 9}, {"raw_context": [{"text": "Conflicts of interest: No potential conflict of interest relevant", "bbox": [420.0, 668.0, 727.0, 683.0]}, {"text": "to this article was reported.", "bbox": [410.0, 685.0, 546.0, 699.0]}, {"text": "Funding: This study received no specific grant from any", "bbox": [421.0, 700.0, 727.0, 715.0]}, {"text": "funding agency in the public, commercial, or not-for-profit /", "bbox": [410.0, 716.0, 732.0, 732.0]}, {"text": "sectors.", "bbox": [410.0, 734.0, 449.0, 747.0]}], "type": "Text", "position": 10}, {"raw_context": [{"text": "Author contribution", "bbox": [421.0, 749.0, 525.0, 764.0]}, {"text": "Conceptualization: KSS; Data curation: AK, JHY, WKC;", "bbox": [420.0, 765.0, 727.0, 780.0]}, {"text": "Formal analysis: JHK, JSL; Methodology: HN; Visualization:", "bbox": [410.0, 781.0, 727.0, 796.0]}, {"text": "SYC; Writing - original draft: YA; Writing - review & editing:", "bbox": [410.0, 797.0, 727.0, 812.0]}, {"text": "KSS", "bbox": [410.0, 813.0, 435.0, 827.0]}], "type": "Text", "position": 11}, {"raw_context": [{"text": "Acknowledgments: The Authors greatly appreciate the", "bbox": [421.0, 829.0, 728.0, 844.0]}, {"text": "help from Pf. Choong Ho Shin (Past President of The Korean", "bbox": [408.0, 843.0, 727.0, 861.0]}, {"text": "Society of Pediatric Endocrinology) and Pf. Ho Yeon Chung", "bbox": [408.0, 861.0, 727.0, 876.0]}, {"text": "(Past Chairman of The Korean Society for Bone and Mineral", "bbox": [410.0, 877.0, 727.0, 892.0]}, {"text": "Research) in organizing the committee for these guidelines.", "bbox": [410.0, 893.0, 727.0, 908.0]}, {"text": "Further, Pf. Deog Yoon Kim (Past Chairman of The Korean", "bbox": [410.0, 909.0, 727.0, 923.0]}, {"text": "Society for Bone and Mineral Research), Pf. Yumie Rhee", "bbox": [410.0, 924.0, 727.0, 940.0]}, {"text": "(Secretary General, The Korean Society for Bone and Mineral", "bbox": [410.0, 941.0, 727.0, 955.0]}, {"text": "Research), Pf. Seong Bin Hong (Director, Committee of", "bbox": [410.0, 956.0, 731.0, 972.0]}], "type": "Text", "position": 12}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2022】全科室最全临床指南+专家共识（最全版）/2022全科室临床指南/内分泌科/KSPE：优化儿童和青少年骨健康的临床实践指南（2022）.pdf", "page_num": 7}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "多余换行#1#2#为同段内容\n多余换行#6#7#为同段内容", "type3": "无关文本#0#0#非正文内容\n无关文本#1#4#存在多处无关数字", "type4": null, "type5": null, "type6": null}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:40", "update_time": "2024-05-07 21:36:09"}
{"id": 1082513, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 738, "source_info": {"seq_id": "5dd3ff96-98bd-40ff-9f0e-56343e105746", "title": null, "text": "【0】页码:39\n o\n\n【1】 pain (e.g., visual analogue scale from 0 to 10 with 0 equivalent to no pain)\n\n【2】 .\n\n【3】 Use standardized medical and nursing protocols for documenting:\n\n【4】 o\n\n【5】 vital signs\n\n【6】 o\n\n【7】 sedation level\n\n【8】 o\n\n【9】 pain level\n\n【10】 o\n\n【11】 changes in the patient's health status\n\n【12】 o\n\n【13】 adverse events and complications\n\n【14】 o\n\n【15】 related adequate patient care and medical action\n\n【16】 .\n\n【17】 Administer sedation and rescue drugs taking into the account the pharmacokinetics, the\n\n【18】 patient's individual risk assessment, and the endoscopic procedure\n\n【19】 .\n\n【20】Apply health and safety guidelines (e.g., safe positioning, safe injection practices)\n\n【21】 Apply hygiene-relevant guidelines for drug application and storage.\n\n【22】.\n\n【23】## Complication Management\n\n【24】\n After completing the course the participant should be able to:\n\n【25】 .\n\n【26】 Demonstrate understanding of definitions of adverse events and complication (e.g., hypoxia, apnoea, shock) and should be able to link this to the risk profile of the individual patient\n\n【27】 .\n\n【28】 Identify conditions associated with increased risks of bronchial aspiration (e.g., acute upper gastrointestinal bleeding, delayed gastric emptying) and to initiate relevant precautionary maneuvers and treatment\n\n【29】 .\n\n【30】 Identify clinical and technical signs of cardiorespiratory insufficiency and allergic reactions (e.g., airway obstruction, hypoxemia, hypotonia, apnoea, laryngospasm) and to initiate relevant precaution manoeuvres and treatment", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "o", "bbox": [184.0, 145.0, 198.0, 157.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "pain (e.g., visual analogue scale from 0 to 10 with 0 equivalent to no pain)", "bbox": [203.0, 141.0, 608.0, 157.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": ".", "bbox": [141.0, 180.0, 153.0, 191.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "Use standardized medical and nursing protocols for documenting:", "bbox": [161.0, 178.0, 520.0, 192.0]}], "type": "Text", "position": 6}, {"raw_context": [{"text": "o", "bbox": [184.0, 216.0, 200.0, 228.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "vital signs", "bbox": [204.0, 214.0, 263.0, 229.0]}], "type": "Text", "position": 8}, {"raw_context": [{"text": "o", "bbox": [183.0, 254.0, 197.0, 265.0]}], "type": "Text", "position": 9}, {"raw_context": [{"text": "sedation level", "bbox": [204.0, 250.0, 284.0, 266.0]}], "type": "Text", "position": 10}, {"raw_context": [{"text": "o", "bbox": [183.0, 290.0, 198.0, 301.0]}], "type": "Text", "position": 11}, {"raw_context": [{"text": "pain level", "bbox": [204.0, 287.0, 262.0, 301.0]}], "type": "Text", "position": 12}, {"raw_context": [{"text": "o", "bbox": [184.0, 325.0, 197.0, 337.0]}], "type": "Text", "position": 13}, {"raw_context": [{"text": "changes in the patient's health status", "bbox": [204.0, 322.0, 411.0, 337.0]}], "type": "Text", "position": 14}, {"raw_context": [{"text": "o", "bbox": [183.0, 361.0, 198.0, 374.0]}], "type": "Text", "position": 15}, {"raw_context": [{"text": "adverse events and complications", "bbox": [203.0, 359.0, 392.0, 374.0]}], "type": "Text", "position": 16}, {"raw_context": [{"text": "o", "bbox": [184.0, 397.0, 200.0, 410.0]}], "type": "Text", "position": 17}, {"raw_context": [{"text": "related adequate patient care and medical action", "bbox": [204.0, 395.0, 475.0, 410.0]}], "type": "Text", "position": 18}, {"raw_context": [{"text": ".", "bbox": [141.0, 432.0, 153.0, 445.0]}], "type": "Text", "position": 19}, {"raw_context": [{"text": "Administer sedation and rescue drugs taking into the account the pharmacokinetics, the", "bbox": [161.0, 431.0, 640.0, 446.0]}], "type": "Text", "position": 20}, {"raw_context": [{"text": "patient's individual risk assessment, and the endoscopic procedure", "bbox": [161.0, 456.0, 526.0, 470.0]}], "type": "Text", "position": 21}, {"raw_context": [{"text": ".", "bbox": [140.0, 493.0, 153.0, 506.0]}, {"text": "Apply health and safety guidelines (e.g., safe positioning, safe injection practices)", "bbox": [161.0, 492.0, 603.0, 507.0]}], "type": "Text", "position": 22}, {"raw_context": [{"text": "Apply hygiene-relevant guidelines for drug application and storage.", "bbox": [161.0, 528.0, 527.0, 543.0]}, {"text": ".", "bbox": [141.0, 529.0, 153.0, 542.0]}], "type": "Text", "position": 23}, {"raw_context": [{"text": "Complication management", "bbox": [120.0, 613.0, 269.0, 628.0]}], "type": "Section-header", "position": 24}, {"raw_context": [{"text": "After completing the course the participant should be able to:", "bbox": [119.0, 637.0, 456.0, 652.0]}], "type": "Text", "position": 25}, {"raw_context": [{"text": ".", "bbox": [141.0, 663.0, 153.0, 674.0]}], "type": "Text", "position": 26}, {"raw_context": [{"text": "Demonstrate understanding of definitions of adverse events and complication (e.g., hypoxia,", "bbox": [161.0, 660.0, 665.0, 676.0]}, {"text": "apnoea, shock) and should be able to link this to the risk profile of the individual patient", "bbox": [162.0, 685.0, 638.0, 700.0]}], "type": "Text", "position": 27}, {"raw_context": [{"text": ".", "bbox": [141.0, 722.0, 153.0, 735.0]}], "type": "Text", "position": 28}, {"raw_context": [{"text": "Identify conditions associated with increased risks of bronchial aspiration (e.g., acute upper", "bbox": [161.0, 719.0, 658.0, 736.0]}, {"text": "gastrointestinal bleeding, delayed gastric emptying) and to initiate relevant precautionary", "bbox": [161.0, 745.0, 648.0, 761.0]}, {"text": "maneuvers and treatment", "bbox": [161.0, 770.0, 308.0, 785.0]}], "type": "Text", "position": 29}, {"raw_context": [{"text": ".", "bbox": [141.0, 807.0, 153.0, 821.0]}], "type": "Text", "position": 30}, {"raw_context": [{"text": "Identify clinical and technical signs of cardiorespiratory insufficiency and allergic reactions (e.g.,", "bbox": [161.0, 805.0, 680.0, 821.0]}, {"text": "airway obstruction, hypoxemia, hypotonia, apnoea, laryngospasm) and to initiate relevant", "bbox": [162.0, 830.0, 650.0, 845.0]}, {"text": "precaution manoeuvres and treatment", "bbox": [162.0, 854.0, 376.0, 869.0]}], "type": "Text", "position": 31}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/消化科/_2023 BSG指南：胃肠内窥镜检查中的镇静.pdf", "page_num": 39}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "多余换行#1#1#pain (e.g., visual analogue...与上面0段序号标点链接\n序号格式不一致#2#2# .应该是•\n多余换行#3#3#Use standardized medical ...与上面2段序号标点链接\n多余换行#4#15#4段序号o联接5段 vital signs内容，依次往下\n多余换行#17#18# Administer sedation and...都与上面16段 .联接，但标点应该是•\n多余换行#20#20# Apply health and safety guidelines...都与上面19段 .联接，但标点应该是•\n多余换行#21#21#Apply hygiene-relevant...都与下面22段 .联接，但标点应该是•\n多余换行#25#30#25段 .与下面26段 Demonstrate understanding联接，依次往下。但标点应该是•", "type3": null, "type4": null, "type5": null, "type6": null}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:40", "update_time": "2024-05-08 00:35:33"}
{"id": 1082512, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 738, "source_info": {"seq_id": "326ce7c1-5572-47b7-85de-5016625977b3", "title": null, "text": "【0】页码:24\n 28 Liu YY, Liu YQ, Petrini MA. Effect of information of patients' coping style on pregastroscopy anxiety. Gastroenterol Nurs 2018;41:47–58.\n\n【1】29 Shafer LA, Walker JR, Waldman C, et al. Factors associated with anxiety about colonoscopy: the preparation, the procedure, and the anticipated findings. Dig Dis Sci 2018;63:610–8.\n\n【2】30 NHS England. The NHS constitution for England - GOV.UK . 2017: 1–60. Available: https://www.gov.uk/government/publications/the-nhs-constitution-for-england/thenhs-constitution-for-england 31 Denters MJ, Schreuder M, Depla ACTM, et al. Patients' perception of colonoscopy: patients with inflammatory bowel disease and irritable bowel syndrome experience the largest burden. Eur J Gastroenterol Hepatol 2013;25:964–72.\n\n【3】32 Mikocka-Walus AA, Moulds LG, Rollbusch N, et al. It's a tube up your bottom; it makes people nervous': the experience of anxiety in initial colonoscopy patients.\n\n【4】Gastroenterol Nurs 2012;35:392–401.\n\n【5】33 McGoran J, Bennett A, Cooper J, et al. Acceptability to patients of screening disposable transnasal endoscopy: qualitative interview analysis. BMJ Open 2019;9:e030467.\n\n【6】34 Paggi S, Radaelli F, Amato A, et al . Unsedated colonoscopy: an option for some but not for all. Gastrointest Endosc 2012;75:392–8.\n\n【7】35 Blokzijl SJ, Lamberts KF, van der Waaij LA, et al. Short article: willingness to undergo colonoscopy with virtual reality instead of procedural sedation and analgesia. Eur J Gastroenterol Hepatol 2019;31:334–9.\n\n【8】36 McEntire J, Sahota J, Hydes T, et al. An evaluation of patient attitudes to colonoscopy and the importance of endoscopist interaction and the endoscopy environment to satisfaction and value. Scand J Gastroenterol 2013;48:366–73.\n\n【9】Ekkelenkamp VE, Dowler K, Valori RM, et al. Patient comfort and quality in 37.\n\n【10】colonoscopy. World J Gastroenterol 2013;19:2355–61.\n\n【11】38 Rostom A, Ross ED, Dubé C, et al. Development and validation of a nurse-assessed patient comfort score for colonoscopy. Gastrointest Endosc 2013;77:255–61.\n\n【12】39 Telford J, Tavakoli I, Takach O, et al. Validation of the St. Paul's Endoscopy Comfort Scale (SPECS) for colonoscopy. J Can Assoc Gastroenterol 2020;3:91–5.\n\n【13】40 Brown S, Bevan R, Rubin G, et al. Patient-derived measures of GI endoscopy: a metanarrative review of the literature. Gastrointest Endosc 2015;81:1130–40.\n\n【14】Heuss LT, Sughanda SP, Degen LP. Endoscopy teams' judgment of discomfort among patients undergoing colonoscopy: 'how bad was it really Swiss Med Wkly 2012;142:w13726.\n\n【15】42.42 Black N, Jenkinson C. Measuring patients' experiences and outcomes. BMJ 2009;339:b2495.\n\n【16】43 Rees CJ, Trebble TM, Von Wagner C, et al. British Society of Gastroenterology position statement on patient experience of GI endoscopy. Gut 2020;69:1.\n\n【17】Kaminski MF, Thomas-Gibson S, Bugajski M, et al. Performance measures for lower gastrointestinal endoscopy: a European Society of Gastrointestinal Endoscopy (ESGE) quality improvement initiative. United European Gastroenterol J 2017;5:309–34.\n\n【18】100, 145 Neilson LJ, Sharp L, Patterson JM, et al. The Newcastle ENDOPREM™: a validated patient reported experience measure for gastrointestinal endoscopy. BMJ Open Gastroenterol 2021;8:e000653.\n\n【19】46  46 Forbes N, Chau M, Koury HF, et al . Development and validation of a patient-reported scale for tolerability of endoscopic procedures using conscious sedation. Gastrointest Endosc 2021;94:103–10.\n\n【20】47.47 Bal BS, Crowell MD, Kohli DR, et al. What factors are associated with the difficult-tosedate endoscopy patient Dig Dis Sci 2012;57:2527–34.\n\n【21】48 Chung K-C, Juang S-E, Lee K-C, et al . The effect of pre-procedure anxiety on sedative requirements for sedation during colonoscopy. Anaesthesia 2013;68:253–9.\n\n【22】49.49 Yang M, Lu L-L, Zhao M, et al. Associations of anxiety with discomfort and tolerance in Chinese patients undergoing esophagogastroduodenoscopy. PLoS One 2019;14:e0212180.\n\n【23】50 Wang MC, Zhang LY, Zhang YL, et al. Effect of music in endoscopy procedures: systematic review and meta-analysis of randomized controlled trials. Pain Med 2014;15:1786–94.\n\n【24】Spagnuolo R, Corea A, Blumetti M, et al . Effects of listening to music in 51 digestive endoscopy: a prospective intervention study led by nursing. J Adv Nurs 2020;76:2993–3002.\n\n【25】1052 Umezawa S, Higurashi T, Uchiyama S, et al. Visual distraction alone for the improvement of colonoscopy-related pain and satisfaction. World J Gastroenterol 2015;21:4707-14.\n\n【26】1055 Sjölander A, Jakobsson Ung E, Theorell T, et al. Hospital design with nature films reduces stress-related variables in patients undergoing colonoscopy. HERD 2019;12:186–96.\n\n【27】54 Liu Q, Zang Y, Zang W, et al. Implementation of virtual reality technology to decrease patients' pain and nervousness during colonoscopies: a prospective randomised controlled single-blinded trial. Clin Med 2022;22:clinmed.\n\n【28】55 Enestvedt BK, Eisen GM, Holub J, et al. Is the American Society of Anesthesiologists classification useful in risk stratification for endoscopic procedures? Gastrointest Endosc 2013;77:464–71.\n\n【29】56 Finkelmeier F, Tal A, Ajouaou M, et al. ERCP in elderly patients: increased risk of sedation adverse events but low frequency of post-ERCP pancreatitis. Gastrointest Endosc 2015;82:1051–9.\n\n【30】24.24\n\n【31】 57 Kitano R, Inoue T, Ibusuki M, et al. Safety and efficacy of endoscopic retrograde cholangiopancreatography in patients with performance status 4. Dig Dis Sci 2021;66:1291–6.\n\n【32】58 Kim SY, Moon CM, Kim MH, et al. Impacts of age and sedation on cardiocerebrovascular adverse events after diagnostic GI endoscopy: a nationwide population-based study. Gastrointest Endosc 2020;92:591–602.\n\n【33】59 Kollmann CM, Schmiegel W, Brechmann T. Gastrointestinal endoscopy under sedation is associated with pneumonia in older Inpatients-results of a retrospective case-control study. United European Gastroenterol J 2018;6:382–90.\n\n【34】60 Andrade CM, Patel B, Vellanki M, et al. Safety of gastrointestinal endoscopy with conscious sedation in obstructive sleep apnea. World J Gastrointest Endosc 2017;9:552–7.\n\n【35】Leslie K, Allen ML, Hessian EC, et al. Safety of sedation for gastrointestinal 61 endoscopy in a group of university-affiliated hospitals: a prospective cohort study. Br J Anaesth 2017;118:90–9.\n\n【36】62 Mehta PP, Kochhar G, Kalra S, et al. Can a validated sleep apnea scoring system predict cardiopulmonary events using propofol sedation for routine EGD or colonoscopy? A prospective cohort study. Gastrointest Endosc 2014;79:436–44.\n\n【37】63 Boese ML, Ransom RK, Roadfuss RJ, et al. Utility of the Berlin questionnaire to screen for obstructive sleep apnea among patients receiving intravenous sedation for colonoscopy. AANA J 2014;82:38–45.\n\n【38】64 Chung F, Abdullah HR, Liao P. STOP-bang questionnaire: a practical approach to screen for obstructive sleep apnea. Chest 2016;149:631–8.\n\n【39】65 Liou S-C, Hsu C-M, Chen C, et al. Assessment of the Berlin questionnaire for evaluation of hypoxemia risk in subjects undergoing deep sedation for screening gastrointestinal endoscopy. Ther Clin Risk Manag 2018;14:1331–6.\n\n【40】1000 1000 Nay M-A, Fromont L, Eugene A, et al. High-flow nasal oxygenation or standard oxygenation for gastrointestinal endoscopy with sedation in patients at risk of hypoxaemia: a multicentre randomised controlled trial (ODEPHI trial). Br J Anaesth 2021;127:133–42.\n\n【41】100, 1167 Mador MJ, Nadler J, Mreyoud A, et al. Do patients at risk of sleep apnea have an increased risk of cardio-respiratory complications during endoscopy procedures Sleep Breath 2012;16:609–15.\n\n【42】100, 1168 Suzuki M, Fujimoto S, Sakamoto K, et al. Clinical usefulness of end-tidal CO(2) measured using a portable capnometer in patients with respiratory disease. Clin Respir J 2023;17:96–104.\n\n【43】69 Cook T, Woodall N, Frerk C. Major complications of airway management in the United Kingdom. In: Report and findings. Fourth Natl Audit Proj R Coll Anaesth Difficult Airw Soc . 2011: 1–219. Available: https://www.nationalauditprojects.org.\n\n【44】uk/downloads/NAP4 Full Report.pdf 70 Corbett G, Pugh P, Herre J, et al. Service evaluation of the impact of capnography on the safety of procedural sedation. Front Med 2022;9:867536.\n\n【45】71 Parker W, Estrich CG, Abt E, et al. Benefits and harms of capnography during procedures involving moderate sedation: a rapid review and meta-analysis. J Am Dent Assoc 2018;149:38–50.\n\n【46】Mallampati SR, Gatt SP, Gugino LD, et al. A clinical sign to predict difficult tracheal 10772 intubation: a prospective study. Can Anaesth Soc J 1985;32:429–34.\n\n【47】10773 Dossa F, Megetto O, Yakubu M, et al . Sedation practices for routine gastrointestinal endoscopy: a systematic review of recommendations. BMC Gastroenterol 2021;21:22.\n\n【48】74 Dunkley I, Griffiths H, Follows R, et al. UK consensus on non-medical staffing required to deliver safe, quality-assured care for adult patients undergoing gastrointestinal endoscopy. Frontline Gastroenterol 2019;10:24–34.\n\n【49】10775 AoMRC. Safe sedation practice for healthcare procedures an update. 2021.\n\n【50】Available: https://www.aomrc.org.uk/wp-content/uploads/2021/0 .https://www.\n\n【51】aomrc.org.uk/wp-content/uploads/2021/02/Safe_sedation_practice_for_healthcare_ procedures_update_0521.pdf 76 Hinkelbein J, Lamperti M, Akeson J, et al. European Society of Anaesthesiology and European Board of Anaesthesiology guidelines for procedural sedation and analgesia in adults. Eur J Anaesthesiol 2018;35:6–24.\n\n【52】1077777 AoMRC. Safe sedation practice for healthcare procedures an update. 2021.\n\n【53】Available: https://www.aomrc.org.uk/wp-content/uploads/2021/0 78 Cohen LB, Delegge MH, Aisenberg J, et al. AGA Institute review of endoscopic sedation. Gastroenterology 2007;133:675–701.\n\n【54】79 Youn AM, Ko Y-K, Kim Y-H. Anesthesia and sedation outside of the operating room.\n\n【55】Korean J Anesthesiol 2015;68:323–31.\n\n【56】Antonelli MT, Seaver D, Urman RD. Procedural sedation and implications for quality 80 and risk management. J Healthc Risk Manag 2013;33:3–10.\n\n【57】81 Carayon P, Schoofs Hundt A, Karsh B-T, et al. Work system design for patient safety: the SEIPS model. Qual Saf Health Care 2006;15 Suppl 1:i50–8.\n\n【58】1082 Holden RJ, Carayon P, Gurses AP, et al. SEIPS 2.0: a human factors framework for studying and improving the work of healthcare professionals and patients.\n\n【59】Ergonomics 2013;56:1669–86.\n\n【60】Cullinane M, Gray AJG, Hargraves CMK, et al. The 2004 report of the National 1083 confidential enquiry into patient outcome and death. In: 2004 Rep Natl Confid Enq into Patient Outcome Death . 2004: 191. Available: https://www.ncepod.org.uk/ 2004report/Full_Report_2004.pdf%0Ahttp://www.ncepod.org.uk/pdf/2004/Full_ Report_2004.pdf Sidhu R, et al. Gut 2023;0:1–27. doi:10.1136/gutjnl-2023-330396", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "28 Liu YY, Liu YQ, Petrini MA. Effect of information of patients' coping style on", "bbox": [59.0, 60.0, 350.0, 75.0]}, {"text": "pregastroscopy anxiety. Gastroenterol Nurs 2018;41:47–58.", "bbox": [76.0, 75.0, 297.0, 86.0]}, {"text": "29 Shafer LA, Walker JR, Waldman C, et al. Factors associated with anxiety about", "bbox": [59.0, 86.0, 360.0, 97.0]}, {"text": "colonoscopy: the preparation, the procedure, and the anticipated findings. Dig Dis", "bbox": [77.0, 99.0, 374.0, 112.0]}, {"text": "Sci 2018;63:610–8.", "bbox": [76.0, 111.0, 150.0, 122.0]}, {"text": "30 NHS England. The NHS constitution for England - GOV.UK . 2017: 1–60. Available:", "bbox": [59.0, 123.0, 375.0, 135.0]}, {"text": "https://www.gov.uk/government/publications/the-nhs-constitution-for-england/the-", "bbox": [74.0, 134.0, 379.0, 147.0]}, {"text": "nhs-constitution-for-england", "bbox": [75.0, 148.0, 183.0, 158.0]}, {"text": "31 Denters MJ, Schreuder M, Depla ACTM, et al. Patients' perception of colonoscopy:", "bbox": [59.0, 159.0, 375.0, 172.0]}, {"text": "patients with inflammatory bowel disease and irritable bowel syndrome experience", "bbox": [75.0, 171.0, 380.0, 183.0]}, {"text": "the largest burden. Eur J Gastroenterol Hepatol 2013;25:964–72.", "bbox": [75.0, 183.0, 316.0, 195.0]}, {"text": "32 Mikocka-Walus AA, Moulds LG, Rollbusch N, et al. It's a tube up your bottom; it", "bbox": [59.0, 195.0, 367.0, 207.0]}, {"text": "makes people nervous': the experience of anxiety in initial colonoscopy patients.", "bbox": [75.0, 208.0, 369.0, 219.0]}, {"text": "Gastroenterol Nurs 2012;35:392–401.", "bbox": [76.0, 219.0, 218.0, 231.0]}, {"text": "33 McGoran J, Bennett A, Cooper J, et al. Acceptability to patients of screening", "bbox": [59.0, 231.0, 351.0, 243.0]}, {"text": "disposable transnasal endoscopy: qualitative interview analysis. BMJ Open", "bbox": [76.0, 243.0, 348.0, 255.0]}, {"text": "2019;9:e030467.", "bbox": [76.0, 255.0, 140.0, 267.0]}, {"text": "34 Paggi S, Radaelli F, Amato A, et al . Unsedated colonoscopy: an option for some but", "bbox": [59.0, 265.0, 379.0, 281.0]}, {"text": "not for all. Gastrointest Endosc 2012;75:392–8.", "bbox": [75.0, 279.0, 252.0, 292.0]}, {"text": "35 Blokzijl SJ, Lamberts KF, van der Waaij LA, et al. Short article: willingness to undergo", "bbox": [59.0, 291.0, 382.0, 303.0]}, {"text": "colonoscopy with virtual reality instead of procedural sedation and analgesia. Eur J", "bbox": [76.0, 304.0, 379.0, 315.0]}, {"text": "Gastroenterol Hepatol 2019;31:334–9.", "bbox": [75.0, 315.0, 222.0, 327.0]}, {"text": "36 McEntire J, Sahota J, Hydes T, et al. An evaluation of patient attitudes to colonoscopy", "bbox": [59.0, 327.0, 385.0, 339.0]}, {"text": "and the importance of endoscopist interaction and the endoscopy environment to", "bbox": [76.0, 339.0, 375.0, 352.0]}, {"text": "satisfaction and value. Scand J Gastroenterol 2013;48:366–73.", "bbox": [76.0, 351.0, 307.0, 362.0]}, {"text": "Ekkelenkamp VE, Dowler K, Valori RM, et al. Patient comfort and quality in", "bbox": [72.0, 363.0, 349.0, 375.0]}, {"text": "37.", "bbox": [58.0, 364.0, 73.0, 372.0]}, {"text": "colonoscopy. World J Gastroenterol 2013;19:2355–61.", "bbox": [76.0, 375.0, 278.0, 387.0]}, {"text": "38", "bbox": [59.0, 387.0, 73.0, 398.0]}, {"text": "Rostom A, Ross ED, Dubé C, et al. Development and validation of a nurse-assessed", "bbox": [73.0, 387.0, 379.0, 399.0]}, {"text": "patient comfort score for colonoscopy. Gastrointest Endosc 2013;77:255–61.", "bbox": [76.0, 399.0, 359.0, 412.0]}, {"text": "39 Telford J, Tavakoli I, Takach O, et al. Validation of the St. Paul's Endoscopy Comfort", "bbox": [59.0, 410.0, 375.0, 423.0]}, {"text": "Scale (SPECS) for colonoscopy. J Can Assoc Gastroenterol 2020;3:91–5.", "bbox": [76.0, 424.0, 338.0, 435.0]}, {"text": "40 Brown S, Bevan R, Rubin G, et al. Patient-derived measures of GI endoscopy: a meta-", "bbox": [59.0, 435.0, 385.0, 447.0]}, {"text": "narrative review of the literature. Gastrointest Endosc 2015;81:1130–40.", "bbox": [75.0, 447.0, 344.0, 458.0]}, {"text": "Heuss LT, Sughanda SP, Degen LP. Endoscopy teams' judgment of discomfort", "bbox": [74.0, 459.0, 353.0, 472.0]}, {"text": "among patients undergoing colonoscopy: 'how bad was it really Swiss Med Wkly", "bbox": [76.0, 471.0, 371.0, 483.0]}, {"text": "2012;142:w13726.", "bbox": [76.0, 483.0, 150.0, 495.0]}, {"text": "42.42", "bbox": [59.0, 495.0, 73.0, 506.0]}, {"text": "Black N, Jenkinson C. Measuring patients' experiences and outcomes. BMJ", "bbox": [74.0, 495.0, 348.0, 507.0]}, {"text": "2009;339:b2495.", "bbox": [76.0, 507.0, 142.0, 518.0]}, {"text": "43 Rees CJ, Trebble TM, Von Wagner C, et al. British Society of Gastroenterology position", "bbox": [59.0, 519.0, 387.0, 532.0]}, {"text": "statement on patient experience of GI endoscopy. Gut 2020;69:1.", "bbox": [75.0, 531.0, 318.0, 542.0]}, {"text": "Kaminski MF, Thomas-Gibson S, Bugajski M, et al. Performance measures", "bbox": [74.0, 543.0, 346.0, 555.0]}, {"text": "for lower gastrointestinal endoscopy: a European Society of Gastrointestinal", "bbox": [75.0, 555.0, 357.0, 567.0]}, {"text": "Endoscopy (ESGE) quality improvement initiative. United European Gastroenterol J", "bbox": [75.0, 567.0, 381.0, 579.0]}, {"text": "2017;5:309–34.", "bbox": [76.0, 580.0, 138.0, 592.0]}, {"text": "100, 145", "bbox": [59.0, 592.0, 73.0, 602.0]}, {"text": "Neilson LJ, Sharp L, Patterson JM, et al. The Newcastle ENDOPREM™: a validated", "bbox": [72.0, 592.0, 373.0, 604.0]}, {"text": "patient reported experience measure for gastrointestinal endoscopy. BMJ Open", "bbox": [76.0, 604.0, 365.0, 616.0]}, {"text": "Gastroenterol 2021;8:e000653.", "bbox": [75.0, 615.0, 195.0, 627.0]}, {"text": "46  46", "bbox": [59.0, 628.0, 73.0, 639.0]}, {"text": "Forbes N, Chau M, Koury HF, et al . Development and validation of a patient-reported", "bbox": [74.0, 628.0, 385.0, 640.0]}, {"text": "scale for tolerability of endoscopic procedures using conscious sedation. Gastrointest", "bbox": [75.0, 639.0, 385.0, 652.0]}, {"text": "Endosc 2021;94:103–10.", "bbox": [75.0, 652.0, 171.0, 663.0]}, {"text": "47.47", "bbox": [59.0, 664.0, 73.0, 675.0]}, {"text": "Bal BS, Crowell MD, Kohli DR, et al. What factors are associated with the difficult-to-", "bbox": [72.0, 664.0, 383.0, 676.0]}, {"text": "sedate endoscopy patient Dig Dis Sci 2012;57:2527–34.", "bbox": [76.0, 675.0, 285.0, 688.0]}, {"text": "48 Chung K-C, Juang S-E, Lee K-C, et al . The effect of pre-procedure anxiety on sedative", "bbox": [59.0, 689.0, 385.0, 700.0]}, {"text": "requirements for sedation during colonoscopy. Anaesthesia 2013;68:253–9.", "bbox": [75.0, 700.0, 356.0, 712.0]}, {"text": "49.49", "bbox": [60.0, 712.0, 73.0, 722.0]}, {"text": "Yang M, Lu L-L, Zhao M, et al. Associations of anxiety with discomfort and", "bbox": [74.0, 713.0, 349.0, 724.0]}, {"text": "tolerance in Chinese patients undergoing esophagogastroduodenoscopy. PLoS One", "bbox": [76.0, 724.0, 379.0, 736.0]}, {"text": "2019;14:e0212180.", "bbox": [76.0, 736.0, 151.0, 747.0]}, {"text": "50", "bbox": [59.0, 748.0, 74.0, 759.0]}, {"text": "Wang MC, Zhang LY, Zhang YL, et al. Effect of music in endoscopy procedures:", "bbox": [72.0, 747.0, 361.0, 760.0]}, {"text": "systematic review and meta-analysis of randomized controlled trials. Pain Med", "bbox": [76.0, 760.0, 363.0, 772.0]}, {"text": "2014;15:1786–94.", "bbox": [76.0, 773.0, 148.0, 783.0]}, {"text": "Spagnuolo R, Corea A, Blumetti M, et al . Effects of listening to music in", "bbox": [74.0, 784.0, 335.0, 796.0]}, {"text": "51", "bbox": [59.0, 785.0, 72.0, 796.0]}, {"text": "digestive endoscopy: a prospective intervention study led by nursing. J Adv Nurs", "bbox": [76.0, 796.0, 368.0, 808.0]}, {"text": "2020;76:2993–3002.", "bbox": [76.0, 808.0, 156.0, 820.0]}, {"text": "1052", "bbox": [59.0, 820.0, 73.0, 831.0]}, {"text": "Umezawa S, Higurashi T, Uchiyama S, et al. Visual distraction alone for the", "bbox": [72.0, 820.0, 346.0, 832.0]}, {"text": "improvement of colonoscopy-related pain and satisfaction. World J Gastroenterol", "bbox": [76.0, 834.0, 372.0, 843.0]}, {"text": "2015;21:4707-14.", "bbox": [76.0, 844.0, 148.0, 856.0]}, {"text": "1055", "bbox": [59.0, 856.0, 73.0, 866.0]}, {"text": "Sjölander A, Jakobsson Ung E, Theorell T, et al. Hospital design with nature films", "bbox": [74.0, 856.0, 368.0, 868.0]}, {"text": "reduces stress-related variables in patients undergoing colonoscopy. HERD", "bbox": [76.0, 869.0, 349.0, 880.0]}, {"text": "2019;12:186–96.", "bbox": [76.0, 880.0, 143.0, 892.0]}, {"text": "54 Liu Q, Zang Y, Zang W, et al. Implementation of virtual reality technology to decrease", "bbox": [59.0, 892.0, 384.0, 905.0]}, {"text": "patients' pain and nervousness during colonoscopies: a prospective randomised", "bbox": [75.0, 904.0, 368.0, 916.0]}, {"text": "controlled single-blinded trial. Clin Med 2022;22:clinmed.", "bbox": [76.0, 916.0, 287.0, 927.0]}, {"text": "55 Enestvedt BK, Eisen GM, Holub J, et al. Is the American Society of Anesthesiologists", "bbox": [59.0, 928.0, 380.0, 940.0]}, {"text": "classification useful in risk stratification for endoscopic procedures? Gastrointest", "bbox": [75.0, 940.0, 369.0, 952.0]}, {"text": "Endosc 2013;77:464–71.", "bbox": [75.0, 952.0, 172.0, 963.0]}, {"text": "56 Finkelmeier F, Tal A, Ajouaou M, et al. ERCP in elderly patients: increased risk of", "bbox": [59.0, 964.0, 366.0, 976.0]}, {"text": "sedation adverse events but low frequency of post-ERCP pancreatitis. Gastrointest", "bbox": [75.0, 976.0, 377.0, 989.0]}, {"text": "Endosc 2015;82:1051–9.", "bbox": [76.0, 989.0, 171.0, 1000.0]}, {"text": "24.24", "bbox": [54.0, 1010.0, 68.0, 1021.0]}], "type": "Text", "position": 1}, {"raw_context": [{"text": "57 Kitano R, Inoue T, Ibusuki M, et al. Safety and efficacy of endoscopic retrograde", "bbox": [411.0, 60.0, 717.0, 73.0]}, {"text": "cholangiopancreatography in patients with performance status 4. Dig Dis Sci", "bbox": [428.0, 74.0, 710.0, 85.0]}, {"text": "2021;66:1291–6.", "bbox": [430.0, 85.0, 494.0, 97.0]}, {"text": "58 Kim SY, Moon CM, Kim MH, et al. Impacts of age and sedation on", "bbox": [412.0, 95.0, 671.0, 110.0]}, {"text": "cardiocerebrovascular adverse events after diagnostic GI endoscopy: a nationwide", "bbox": [429.0, 110.0, 729.0, 122.0]}, {"text": "population-based study. Gastrointest Endosc 2020;92:591–602.", "bbox": [428.0, 122.0, 666.0, 133.0]}, {"text": "59", "bbox": [412.0, 134.0, 426.0, 145.0]}, {"text": "Kollmann CM, Schmiegel W, Brechmann T. Gastrointestinal endoscopy under", "bbox": [427.0, 135.0, 707.0, 146.0]}, {"text": "sedation is associated with pneumonia in older Inpatients-results of a retrospective", "bbox": [429.0, 146.0, 733.0, 157.0]}, {"text": "case-control study. United European Gastroenterol J 2018;6:382–90.", "bbox": [428.0, 158.0, 682.0, 170.0]}, {"text": "60 Andrade CM, Patel B, Vellanki M, et al. Safety of gastrointestinal endoscopy", "bbox": [411.0, 170.0, 704.0, 182.0]}, {"text": "with conscious sedation in obstructive sleep apnea. World J Gastrointest Endosc", "bbox": [430.0, 181.0, 721.0, 194.0]}, {"text": "2017;9:552–7.", "bbox": [430.0, 195.0, 486.0, 206.0]}, {"text": "Leslie K, Allen ML, Hessian EC, et al. Safety of sedation for gastrointestinal", "bbox": [426.0, 205.0, 701.0, 217.0]}, {"text": "61", "bbox": [411.0, 206.0, 428.0, 217.0]}, {"text": "endoscopy in a group of university-affiliated hospitals: a prospective cohort study. Br", "bbox": [429.0, 217.0, 737.0, 231.0]}, {"text": "J Anaesth 2017;118:90–9.", "bbox": [429.0, 230.0, 528.0, 242.0]}, {"text": "62 Mehta PP, Kochhar G, Kalra S, et al. Can a validated sleep apnea scoring system", "bbox": [411.0, 241.0, 721.0, 255.0]}, {"text": "predict cardiopulmonary events using propofol sedation for routine EGD or", "bbox": [429.0, 255.0, 701.0, 266.0]}, {"text": "colonoscopy? A prospective cohort study. Gastrointest Endosc 2014;79:436–44.", "bbox": [429.0, 266.0, 723.0, 277.0]}, {"text": "63 Boese ML, Ransom RK, Roadfuss RJ, et al. Utility of the Berlin questionnaire to", "bbox": [411.0, 277.0, 717.0, 291.0]}, {"text": "screen for obstructive sleep apnea among patients receiving intravenous sedation", "bbox": [430.0, 290.0, 727.0, 302.0]}, {"text": "for colonoscopy. AANA J 2014;82:38–45.", "bbox": [429.0, 301.0, 584.0, 314.0]}, {"text": "64 Chung F, Abdullah HR, Liao P. STOP-bang questionnaire: a practical approach to", "bbox": [411.0, 313.0, 721.0, 328.0]}, {"text": "screen for obstructive sleep apnea. Chest 2016;149:631–8.", "bbox": [429.0, 326.0, 647.0, 337.0]}, {"text": "65 Liou S-C, Hsu C-M, Chen C, et al. Assessment of the Berlin questionnaire for", "bbox": [411.0, 338.0, 707.0, 351.0]}, {"text": "evaluation of hypoxemia risk in subjects undergoing deep sedation for screening", "bbox": [429.0, 350.0, 725.0, 362.0]}, {"text": "gastrointestinal endoscopy. Ther Clin Risk Manag 2018;14:1331–6.", "bbox": [428.0, 361.0, 678.0, 375.0]}, {"text": "1000 1000", "bbox": [411.0, 374.0, 426.0, 386.0]}, {"text": "Nay M-A, Fromont L, Eugene A, et al. High-flow nasal oxygenation or standard", "bbox": [427.0, 375.0, 717.0, 386.0]}, {"text": "oxygenation for gastrointestinal endoscopy with sedation in patients at risk of", "bbox": [428.0, 386.0, 716.0, 398.0]}, {"text": "hypoxaemia: a multicentre randomised controlled trial (ODEPHI trial). Br J Anaesth", "bbox": [428.0, 398.0, 729.0, 411.0]}, {"text": "2021;127:133–42.", "bbox": [430.0, 410.0, 500.0, 421.0]}, {"text": "100, 1167", "bbox": [411.0, 421.0, 428.0, 433.0]}, {"text": "Mador MJ, Nadler J, Mreyoud A, et al. Do patients at risk of sleep apnea have an", "bbox": [426.0, 421.0, 725.0, 435.0]}, {"text": "increased risk of cardio-respiratory complications during endoscopy procedures Sleep", "bbox": [428.0, 435.0, 739.0, 446.0]}, {"text": "Breath 2012;16:609–15.", "bbox": [429.0, 446.0, 522.0, 458.0]}, {"text": "100, 1168", "bbox": [411.0, 458.0, 428.0, 469.0]}, {"text": "Suzuki M, Fujimoto S, Sakamoto K, et al. Clinical usefulness of end-tidal CO(2)", "bbox": [426.0, 458.0, 716.0, 471.0]}, {"text": "measured using a portable capnometer in patients with respiratory disease. Clin", "bbox": [429.0, 470.0, 721.0, 482.0]}, {"text": "Respir J 2023;17:96–104.", "bbox": [428.0, 481.0, 525.0, 493.0]}, {"text": "69 Cook T, Woodall N, Frerk C. Major complications of airway management in the", "bbox": [411.0, 494.0, 715.0, 506.0]}, {"text": "United Kingdom. In: Report and findings. Fourth Natl Audit Proj R Coll Anaesth", "bbox": [429.0, 505.0, 717.0, 518.0]}, {"text": "Difficult Airw Soc . 2011: 1–219. Available: https://www.nationalauditprojects.org.", "bbox": [428.0, 518.0, 728.0, 531.0]}, {"text": "uk/downloads/NAP4 Full Report.pdf", "bbox": [428.0, 530.0, 562.0, 542.0]}, {"text": "70 Corbett G, Pugh P, Herre J, et al. Service evaluation of the impact of capnography on", "bbox": [412.0, 540.0, 737.0, 555.0]}, {"text": "the safety of procedural sedation. Front Med 2022;9:867536.", "bbox": [428.0, 555.0, 655.0, 566.0]}, {"text": "71 Parker W, Estrich CG, Abt E, et al. Benefits and harms of capnography during", "bbox": [412.0, 566.0, 707.0, 578.0]}, {"text": "procedures involving moderate sedation: a rapid review and meta-analysis. J Am", "bbox": [430.0, 578.0, 723.0, 591.0]}, {"text": "Dent Assoc 2018;149:38–50.", "bbox": [429.0, 590.0, 539.0, 602.0]}, {"text": "Mallampati SR, Gatt SP, Gugino LD, et al. A clinical sign to predict difficult tracheal", "bbox": [426.0, 601.0, 731.0, 615.0]}, {"text": "10772", "bbox": [412.0, 602.0, 426.0, 613.0]}, {"text": "intubation: a prospective study. Can Anaesth Soc J 1985;32:429–34.", "bbox": [429.0, 615.0, 682.0, 626.0]}, {"text": "10773", "bbox": [412.0, 626.0, 428.0, 637.0]}, {"text": "Dossa F, Megetto O, Yakubu M, et al . Sedation practices for routine gastrointestinal", "bbox": [426.0, 626.0, 733.0, 638.0]}, {"text": "endoscopy: a systematic review of recommendations. BMC Gastroenterol", "bbox": [429.0, 638.0, 696.0, 651.0]}, {"text": "2021;21:22.", "bbox": [430.0, 651.0, 475.0, 662.0]}, {"text": "74 Dunkley I, Griffiths H, Follows R, et al. UK consensus on non-medical staffing", "bbox": [412.0, 661.0, 710.0, 674.0]}, {"text": "required to deliver safe, quality-assured care for adult patients undergoing", "bbox": [428.0, 675.0, 702.0, 686.0]}, {"text": "gastrointestinal endoscopy. Frontline Gastroenterol 2019;10:24–34.", "bbox": [428.0, 686.0, 678.0, 698.0]}, {"text": "10775", "bbox": [412.0, 698.0, 426.0, 709.0]}, {"text": "AoMRC. Safe sedation practice for healthcare procedures an update. 2021.", "bbox": [427.0, 698.0, 704.0, 710.0]}, {"text": "Available: https://www.aomrc.org.uk/wp-content/uploads/2021/0 .https://www.", "bbox": [429.0, 710.0, 719.0, 722.0]}, {"text": "aomrc.org.uk/wp-content/uploads/2021/02/Safe_sedation_practice_for_healthcare_", "bbox": [429.0, 720.0, 737.0, 735.0]}, {"text": "procedures_update_0521.pdf", "bbox": [429.0, 735.0, 541.0, 746.0]}, {"text": "76 Hinkelbein J, Lamperti M, Akeson J, et al. European Society of Anaesthesiology", "bbox": [412.0, 746.0, 715.0, 758.0]}, {"text": "and European Board of Anaesthesiology guidelines for procedural sedation and", "bbox": [429.0, 758.0, 720.0, 771.0]}, {"text": "analgesia in adults. Eur J Anaesthesiol 2018;35:6–24.", "bbox": [429.0, 771.0, 626.0, 782.0]}, {"text": "1077777", "bbox": [412.0, 782.0, 426.0, 794.0]}, {"text": "AoMRC. Safe sedation practice for healthcare procedures an update. 2021.", "bbox": [426.0, 783.0, 704.0, 796.0]}, {"text": "Available: https://www.aomrc.org.uk/wp-content/uploads/2021/0", "bbox": [429.0, 795.0, 670.0, 807.0]}, {"text": "78 Cohen LB, Delegge MH, Aisenberg J, et al. AGA Institute review of endoscopic", "bbox": [412.0, 807.0, 713.0, 819.0]}, {"text": "sedation. Gastroenterology 2007;133:675–701.", "bbox": [430.0, 819.0, 605.0, 831.0]}, {"text": "79 Youn AM, Ko Y-K, Kim Y-H. Anesthesia and sedation outside of the operating room.", "bbox": [412.0, 831.0, 731.0, 842.0]}, {"text": "Korean J Anesthesiol 2015;68:323–31.", "bbox": [428.0, 843.0, 574.0, 856.0]}, {"text": "Antonelli MT, Seaver D, Urman RD. Procedural sedation and implications for quality", "bbox": [426.0, 855.0, 733.0, 867.0]}, {"text": "80", "bbox": [412.0, 856.0, 426.0, 866.0]}, {"text": "and risk management. J Healthc Risk Manag 2013;33:3–10.", "bbox": [429.0, 866.0, 652.0, 878.0]}, {"text": "81 Carayon P, Schoofs Hundt A, Karsh B-T, et al. Work system design for patient safety:", "bbox": [411.0, 879.0, 733.0, 891.0]}, {"text": "the SEIPS model. Qual Saf Health Care 2006;15 Suppl 1:i50–8.", "bbox": [429.0, 891.0, 659.0, 902.0]}, {"text": "1082", "bbox": [411.0, 903.0, 427.0, 915.0]}, {"text": "Holden RJ, Carayon P, Gurses AP, et al. SEIPS 2.0: a human factors framework", "bbox": [426.0, 902.0, 711.0, 916.0]}, {"text": "for studying and improving the work of healthcare professionals and patients.", "bbox": [429.0, 915.0, 713.0, 927.0]}, {"text": "Ergonomics 2013;56:1669–86.", "bbox": [428.0, 927.0, 545.0, 939.0]}, {"text": "Cullinane M, Gray AJG, Hargraves CMK, et al. The 2004 report of the National", "bbox": [426.0, 938.0, 714.0, 952.0]}, {"text": "1083", "bbox": [411.0, 939.0, 427.0, 950.0]}, {"text": "confidential enquiry into patient outcome and death. In: 2004 Rep Natl Confid Enq", "bbox": [428.0, 951.0, 732.0, 962.0]}, {"text": "into Patient Outcome Death . 2004: 191. Available: https://www.ncepod.org.uk/", "bbox": [428.0, 963.0, 721.0, 976.0]}, {"text": "2004report/Full_Report_2004.pdf%0Ahttp://www.ncepod.org.uk/pdf/2004/Full_", "bbox": [430.0, 975.0, 725.0, 987.0]}, {"text": "Report_2004.pdf", "bbox": [429.0, 988.0, 494.0, 999.0]}, {"text": "Sidhu R, et al. Gut 2023;0:1–27. doi:10.1136/gutjnl-2023-330396", "bbox": [477.0, 1009.0, 739.0, 1022.0]}], "type": "Text", "position": 2}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/消化科/_2023 BSG指南：胃肠内窥镜检查中的镇静.pdf", "page_num": 24}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": null, "type3": null, "type4": null, "type5": null, "type6": "有用性#0#60#全篇为其他参考文献内容"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:40", "update_time": "2024-05-08 00:08:22"}
{"id": 1082511, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 738, "source_info": {"seq_id": "1c161929-6b3b-4521-8afd-ffd7fd49f55e", "title": null, "text": "【0】页码:4\n\n【1】## Ya, Et Al. • Clinical Guidelines For Optimizing Bone Health In Korean Children\n\n【2】\n hormone induces the production of receptor activator for nuclear factor κB ligand (RANKL) and inhibits the production of osteoprotegerin, increasing osteoclastogenesis and bone resorption. 11 In DM, hyperglycemia is related to accumulation of glycated proteins, which impairs differentiation of mesenchymal stem cells into chondrocytes and osteoblasts with decreased synthesis of osteocalcin. 17) Finally, in Cushing syndrome, glucocorticoid excess is directly associated with inhibition of osteoblastogenesis and promotion of osteoblast and osteocyte apoptosis. Further, the excess glucocorticoid indirectly impairs bone accretion by inhibiting secretion of IGF-I and intestinal calcium absorption. 11\n\n【3】 2) Neuromuscular disorders 7 Children with cerebral palsy, Duchenne muscular dystrophy, and spinal muscular atrophy cannot bear weight in the same way as children without these neuromuscular disorders, resulting in decreased bone formation with continued bone resorption and development of lower bone mass. 2\n\n【4】## 3) Connective Tissue Disorders\n\n【5】\n In children with systemic lupus erythematosus, juvenile idiopathic arthritis, and juvenile dermatomyositis, bone mass is decreased due to chronic inflammation, production of pro- (osteoclastic cytokines, and glucocorticoid therapy. 25,26 )\n\n【6】 4) Gastrointestinal disorders Nutritional deficiency, secondary hyperparathyroidism,\n\n【7】 chronic inflammatory state, and glucocorticoid therapy can decrease bone formation and increase bone resorption in children with chronic inflammatory bowel or celiac disease. 27- 29 )\n\n【8】 3   5  Hemato-oncologic disorders Cytokine, induced osteoclastogenesis, radiation- or chemotherapeutic agent-induced bone injury, decreased physical activity, and nutritional deficiency result in diminished bone mass in children with leukemia or cancer. 3\n\n【9】## 6) Renal Disorders\n\n【10】\n Nutritional deficiency or immunosuppressive therapy can result in bone loss in children with chronic renal failure and kidney transplantation. 37\n\n【11】 7) Nutritional deprivation Anorexia nervosa and female athlete triad are examples of both nutrition- and hormone-induced bone loss that can lead /to early-onset osteoporosis. 8)\n\n【12】## 8) Medications ,\n\n【13】\n Numerous medications such as glucocorticoids, anticonvulsants, chemotherapeutic agents, immunosuppressive agents, heparin, proton pump inhibitors, and selective serotonin reuptake inhibitors can increase the risk of low bone mass. 87 In children, studies have reported that use of oral glucocorticoids for more than 3 months reduced bone density and increased the risk of spinal compression fractures. Therefore, it is recommended that glucocorticoids be used in low doses every\n\n【14】 nitrogen; Cr, creatinine; PTH, parathyroid hormone; DXA, dual-energy x-ray absorptiometry; BMD, bone mineral density; Tx, treatment.", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "YA, et al. • Clinical guidelines for optimizing bone health in Korean children", "bbox": [88.0, 38.0, 468.0, 54.0]}], "type": "Section-header", "position": 0}, {"raw_context": [{"text": "hormone induces the production of receptor activator for", "bbox": [65.0, 93.0, 383.0, 108.0]}, {"text": "nuclear factor κB ligand (RANKL) and inhibits the production", "bbox": [66.0, 109.0, 383.0, 124.0]}, {"text": "of osteoprotegerin, increasing osteoclastogenesis and bone", "bbox": [65.0, 124.0, 383.0, 140.0]}, {"text": "resorption. 11", "bbox": [66.0, 141.0, 129.0, 156.0]}, {"text": "In DM, hyperglycemia is related to accumulation of glycated", "bbox": [77.0, 157.0, 384.0, 171.0]}, {"text": "proteins, which impairs differentiation of mesenchymal", "bbox": [65.0, 172.0, 383.0, 187.0]}, {"text": "stem cells into chondrocytes and osteoblasts with decreased", "bbox": [66.0, 187.0, 383.0, 202.0]}, {"text": "synthesis of osteocalcin. 17) Finally, in Cushing syndrome,", "bbox": [66.0, 202.0, 383.0, 220.0]}, {"text": "glucocorticoid excess is directly associated with inhibition of", "bbox": [66.0, 218.0, 383.0, 234.0]}, {"text": "osteoblastogenesis and promotion of osteoblast and osteocyte", "bbox": [66.0, 235.0, 383.0, 249.0]}, {"text": "apoptosis. Further, the excess glucocorticoid indirectly impairs", "bbox": [66.0, 250.0, 383.0, 265.0]}, {"text": "bone accretion by inhibiting secretion of IGF-I and intestinal", "bbox": [65.0, 266.0, 383.0, 281.0]}, {"text": "calcium absorption. 11", "bbox": [66.0, 282.0, 170.0, 297.0]}], "type": "Text", "position": 1}, {"raw_context": [{"text": "2) Neuromuscular disorders 7", "bbox": [77.0, 314.0, 226.0, 329.0]}, {"text": "Children with cerebral palsy, Duchenne muscular dystrophy,", "bbox": [76.0, 330.0, 383.0, 345.0]}, {"text": "and spinal muscular atrophy cannot bear weight in the same", "bbox": [66.0, 345.0, 383.0, 360.0]}, {"text": "way as children without these neuromuscular disorders,", "bbox": [66.0, 360.0, 383.0, 375.0]}, {"text": "resulting in decreased bone formation with continued bone", "bbox": [66.0, 377.0, 384.0, 391.0]}, {"text": "resorption and development of lower bone mass. 2", "bbox": [66.0, 392.0, 310.0, 407.0]}], "type": "Text", "position": 2}, {"raw_context": [{"text": "3) Connective tissue disorders", "bbox": [77.0, 424.0, 228.0, 439.0]}], "type": "Section-header", "position": 3}, {"raw_context": [{"text": "In children with systemic lupus erythematosus, juvenile", "bbox": [77.0, 440.0, 383.0, 454.0]}, {"text": "idiopathic arthritis, and juvenile dermatomyositis, bone mass", "bbox": [66.0, 455.0, 383.0, 471.0]}, {"text": "is decreased due to chronic inflammation, production of pro-", "bbox": [66.0, 472.0, 382.0, 485.0]}, {"text": "(osteoclastic cytokines, and glucocorticoid therapy. 25,26 )", "bbox": [66.0, 487.0, 330.0, 502.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": "4) Gastrointestinal disorders", "bbox": [77.0, 518.0, 220.0, 533.0]}, {"text": "Nutritional deficiency, secondary hyperparathyroidism,", "bbox": [77.0, 534.0, 383.0, 548.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "chronic inflammatory state, and glucocorticoid therapy can", "bbox": [409.0, 93.0, 725.0, 108.0]}, {"text": "decrease bone formation and increase bone resorption in", "bbox": [408.0, 109.0, 727.0, 123.0]}, {"text": "children with chronic inflammatory bowel or celiac disease. 27- 29 )", "bbox": [409.0, 124.0, 725.0, 139.0]}], "type": "Text", "position": 6}, {"raw_context": [{"text": "3   5  Hemato-oncologic disorders", "bbox": [410.0, 156.0, 579.0, 172.0]}, {"text": "Cytokine, induced osteoclastogenesis, radiation- or", "bbox": [420.0, 172.0, 727.0, 187.0]}, {"text": "chemotherapeutic agent-induced bone injury, decreased", "bbox": [409.0, 187.0, 727.0, 202.0]}, {"text": "physical activity, and nutritional deficiency result in diminished", "bbox": [410.0, 203.0, 727.0, 217.0]}, {"text": "bone mass in children with leukemia or cancer. 3", "bbox": [410.0, 219.0, 645.0, 233.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "6) Renal disorders", "bbox": [420.0, 250.0, 514.0, 265.0]}], "type": "Section-header", "position": 8}, {"raw_context": [{"text": "Nutritional deficiency or immunosuppressive therapy can", "bbox": [421.0, 266.0, 726.0, 281.0]}, {"text": "result in bone loss in children with chronic renal failure and", "bbox": [410.0, 282.0, 724.0, 296.0]}, {"text": "kidney transplantation. 37", "bbox": [409.0, 298.0, 531.0, 312.0]}], "type": "Text", "position": 9}, {"raw_context": [{"text": "7) Nutritional deprivation", "bbox": [421.0, 330.0, 552.0, 345.0]}, {"text": "Anorexia nervosa and female athlete triad are examples of", "bbox": [421.0, 345.0, 727.0, 359.0]}, {"text": "both nutrition- and hormone-induced bone loss that can lead", "bbox": [409.0, 360.0, 727.0, 375.0]}, {"text": "/to early-onset osteoporosis. 8)", "bbox": [406.0, 377.0, 551.0, 390.0]}], "type": "Text", "position": 10}, {"raw_context": [{"text": "8) Medications ,", "bbox": [420.0, 407.0, 508.0, 422.0]}], "type": "Section-header", "position": 11}, {"raw_context": [{"text": "Numerous medications such as glucocorticoids, anticonvul-", "bbox": [421.0, 423.0, 726.0, 439.0]}, {"text": "sants, chemotherapeutic agents, immunosuppressive agents,", "bbox": [410.0, 440.0, 727.0, 454.0]}, {"text": "heparin, proton pump inhibitors, and selective serotonin", "bbox": [409.0, 456.0, 727.0, 471.0]}, {"text": "reuptake inhibitors can increase the risk of low bone mass. 87 In", "bbox": [410.0, 472.0, 727.0, 485.0]}, {"text": "children, studies have reported that use of oral glucocorticoids", "bbox": [409.0, 487.0, 727.0, 502.0]}, {"text": "for more than 3 months reduced bone density and increased", "bbox": [410.0, 503.0, 727.0, 518.0]}, {"text": "the risk of spinal compression fractures. Therefore, it is", "bbox": [409.0, 518.0, 728.0, 533.0]}, {"text": "recommended that glucocorticoids be used in low doses every", "bbox": [410.0, 533.0, 726.0, 548.0]}], "type": "Text", "position": 12}, {"raw_context": [{"text": "nitrogen; Cr, creatinine; PTH, parathyroid hormone; DXA, dual-energy x-ray absorptiometry; BMD,", "bbox": [205.0, 950.0, 586.0, 964.0]}, {"text": "bone mineral density; Tx, treatment.", "bbox": [205.0, 963.0, 346.0, 977.0]}], "type": "Text", "position": 14}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2022】全科室最全临床指南+专家共识（最全版）/2022全科室临床指南/内分泌科/KSPE：优化儿童和青少年骨健康的临床实践指南（2022）.pdf", "page_num": 4}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "缺少换行#3#3#Children with cerebral palsy这里开始应分行\n多余换行#6#7#为同段\n缺少换行#6#6# Nutritional deficiency,这里开始应换行\n缺少换行#8#8#Cytokine, induced osteo这里开始应换行\n缺少换行#11#11#Anorexia nervosa and female这里开始应换行", "type3": "页眉#1#1#非正文\n无关文本#2#14#存在多处无关数字", "type4": null, "type5": null, "type6": "信息有用性#14#14#无用内容"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:40", "update_time": "2024-05-07 18:21:28"}
{"id": 1082510, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 738, "source_info": {"seq_id": "58868f18-5366-4e6d-a8dc-e93ac3fa5da4", "title": null, "text": "【0】页码:21\n Level of agreement: 100% 51. We recommend that if during a sedated endoscopy, the patient appears to be tolerating the procedure poorly, the endos¬ copist should stop the procedure (if safe to do so) in order to assess the patient's wishes and decide if the procedure should be abandoned and alternatives arranged Grade of evidence: Very Low. Strength of recommendation: Strong.\n\n【1】Level of agreement: 92.3%\n\n【2】 There is primary legislation covering capacity in England, Wales and Scotland. 240 241 In Northern Ireland, common law governs decision-making around medical interventions in those who lack capacity. 242 In all parts of the UK, the laws governing the medical care of patients who lack capacity presume that an adult has capacity unless it has been clearly established that they do not.\n\n【3】For patients with cognitive impairment or learning disability, an assessment of capacity should therefore be undertaken to determine if the patient is able to give consent for the procedure.\n\n【4】The mental capacity legal framework allows for the use of proxy decision-makers (lasting power of attorney relevant to health and welfare or a court-appointed deputy), an advanced directive/statement and the use of an independent mental capacity advocate. The process of consent takes into account the patient's best interests.\n\n【5】The consent process will include a consideration of the use and risk of sedation and potential alternatives, such as general anaesthetic or investigations that do not use sedative drugs. In order to share information about the procedure with the patient, information may need to be provided in a number of different formats. Pictures and/or verbal descriptions may be more appropriate than written information for some patients, and the patient's preferred method of communication should be ascertained to facilitate consent.\n\n【6】Preparation for a procedure undertaken under sedation requires a period of psychological preparation. 1 This may be particularly pertinent for patients with learning disabilities.\n\n【7】Carers play an important role in preparing the patient for the procedure and in facilitating the consent process. Learning disability teams exist in most hospitals and should be used to support the consent process for this patient group.\n\n【8】A full set of recommendations relating to consent for patients undergoing gastrointestinal endoscopy with and without capacity is provided in separate BSG guidance. 4 During an endoscopic procedure, if a patient appears to be tolerating the procedure poorly or gives any other indication that they wish the procedure to stop, the endoscopist should, if possible, stop the procedure and attempt to establish the patient's concerns. It may be appropriate to recommence the endoscopy following reassurance or the administration of further sedation.\n\n【9】The administration of sedation in patients with prior capacity may lead to a degree of cognitive impairment such that it can be difficult to assess capacity during the test. If the endoscopist establishes that the patient has capacity and wishes the procedure to be discontinued (withdrawal of consent), the procedure should be stopped, unless this would result in the patient coming to immediate harm. If a patient, regardless of capacity, has persistent distress, termination of the procedure should be considered and alternatives discussed and arranged.\n\n【10】## Special Considerations: Ione Working\n\n【11】\n 52. We recommend that a minimum of two appropriately trained endoscopy assistants are required for endoscopic procedures in which sedation has been administered\n\n【12】 Sidhu R, et al. Gut 2023;0:1–27. doi:10.1136/gutjnl-2023-330396\n\n【13】 Grade of evidence: Very Low. Strength of recommendation: Strong.\n\n【14】Level of agreement: 100% 53. We recommend that sedation should be administered only if there is immediate access to the resources (staff and facilities) required to manage complications of sedation Grade of evidence: Very Low. Strength of recommendation: Strong.\n\n【15】Level of agreement: 100%\n\n【16】 For patients undergoing deep sedation, a dedicated sedationist will be present. For most endoscopic procedures undertaken under conscious sedation, the endoscopist will be the person responsible for administering sedative drugs. While performing the endoscopic procedure, the operator may have insufficient situational awareness to monitor the patient's condition safely.\n\n【17】A minimum of two endoscopy assistants is required. 1 While one assistant may be assisting with the endoscopic procedure, the other assistant should be entirely focused on monitoring the patient and is responsible for alerting the endoscopist to any important changes.\n\n【18】In the event of a complication of sedation arising, such as respiratory depression or a cardiorespiratory arrest, the endoscopy assistant should have the skills to assist in managing the medical emergency. Endoscopy assistants should have appropriate training (and timely retraining) to undertake this role.\n\n【19】Some endoscopy is undertaken in units outside an acute hospital. Sedation should only be administered in the nonhospital setting if adverse events related to sedation can be immediately managed. The range of facilities (including immediate access to a resuscitation trolley) and the skills of available staff that can be immediately mobilised in the event of a complication of sedation should be commensurate to that available in an acute hospital. 1\n\n【20】## Training\n\n【21】\n 54. We recommend that all endoscopy staff responsible for risk assessing, administering sedation and monitoring of patients, undergo formal training in the recognition and management of related complications, and this should be a continuing process Grade of evidence: Low. Strength of recommendation: Strong.\n\n【22】Level of agreement: 100%\n\n【23】## Current Gap In Training\n\n【24】\n Appropriate training in sedation practices and in the recognition and management of potential complications are vital aspects of training for endoscopists. In the UK, the 2004 National Confidential Enquiry into Patient Outcome and Death (NCEPOD) 209 highlighted an existing gap in sedation training for endoscopists, with only 35% of surveyed endoscopists having attended a sedation course. A subsequent survey of UK gastroenterology higher specialty trainees a few years later showed that only 49% had received sedation training. 243 The need for formal training for all practitioners providing sedation has been recognised as a matter of priority by the RCoA 140 and the AoMRC. 1\n\n【25】## Available Curricula\n\n【26】\n The Multisociety Sedation Curriculum for Gastrointestinal Endoscopy, 125 the Society of Gastroenterology and Endoscopy Nurses and Associates (ESGE/ESGENA) 244 and the UK AoMRC 77 have provided curricula and competency assessment guidance for sedation training. A common denominator across all guidelines is the need for training in both theoretical and practical skills related to sedation and potential associated\n\n【27】 21.21", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "Level of agreement: 100%", "bbox": [66.0, 61.0, 204.0, 75.0]}, {"text": "51. We recommend that if during a sedated endoscopy, the", "bbox": [66.0, 75.0, 387.0, 90.0]}, {"text": "patient appears to be tolerating the procedure poorly, the endos¬", "bbox": [53.0, 91.0, 385.0, 104.0]}, {"text": "copist should stop the procedure (if safe to do so) in order to", "bbox": [53.0, 105.0, 387.0, 120.0]}, {"text": "assess the patient's wishes and decide if the procedure should be", "bbox": [53.0, 120.0, 387.0, 135.0]}, {"text": "abandoned and alternatives arranged", "bbox": [53.0, 135.0, 250.0, 150.0]}, {"text": "Grade of evidence: Very Low. Strength of recommendation:", "bbox": [64.0, 149.0, 386.0, 164.0]}, {"text": "Strong.", "bbox": [54.0, 166.0, 91.0, 179.0]}, {"text": "Level of agreement: 92.3%", "bbox": [65.0, 180.0, 207.0, 193.0]}], "type": "Text", "position": 0}, {"raw_context": [{"text": "There is primary legislation covering capacity in England, Wales", "bbox": [66.0, 194.0, 387.0, 208.0]}, {"text": "and Scotland. 240 241 In Northern Ireland, common law governs", "bbox": [53.0, 206.0, 387.0, 224.0]}, {"text": "decision-making around medical interventions in those who lack", "bbox": [53.0, 223.0, 386.0, 238.0]}, {"text": "capacity. 242 In all parts of the UK, the laws governing the medical", "bbox": [53.0, 237.0, 387.0, 252.0]}, {"text": "care of patients who lack capacity presume that an adult has", "bbox": [53.0, 253.0, 387.0, 267.0]}, {"text": "capacity unless it has been clearly established that they do not.", "bbox": [53.0, 268.0, 385.0, 281.0]}, {"text": "For patients with cognitive impairment or learning disability, an", "bbox": [53.0, 283.0, 387.0, 296.0]}, {"text": "assessment of capacity should therefore be undertaken to deter-", "bbox": [53.0, 297.0, 385.0, 311.0]}, {"text": "mine if the patient is able to give consent for the procedure.", "bbox": [53.0, 312.0, 358.0, 326.0]}, {"text": "The mental capacity legal framework allows for the use of", "bbox": [66.0, 327.0, 387.0, 340.0]}, {"text": "proxy decision-makers (lasting power of attorney relevant to", "bbox": [53.0, 342.0, 387.0, 355.0]}, {"text": "health and welfare or a court-appointed deputy), an advanced", "bbox": [53.0, 356.0, 386.0, 369.0]}, {"text": "directive/statement and the use of an independent mental", "bbox": [53.0, 370.0, 387.0, 384.0]}, {"text": "capacity advocate. The process of consent takes into account the", "bbox": [53.0, 385.0, 387.0, 399.0]}, {"text": "patient's best interests.", "bbox": [53.0, 400.0, 174.0, 414.0]}, {"text": "The consent process will include a consideration of the use", "bbox": [66.0, 413.0, 386.0, 428.0]}, {"text": "and risk of sedation and potential alternatives, such as general", "bbox": [53.0, 430.0, 386.0, 443.0]}, {"text": "anaesthetic or investigations that do not use sedative drugs. In", "bbox": [53.0, 444.0, 387.0, 458.0]}, {"text": "order to share information about the procedure with the patient,", "bbox": [53.0, 459.0, 387.0, 473.0]}, {"text": "information may need to be provided in a number of different", "bbox": [53.0, 473.0, 387.0, 488.0]}, {"text": "formats. Pictures and/or verbal descriptions may be more appro-", "bbox": [53.0, 488.0, 385.0, 503.0]}, {"text": "priate than written information for some patients, and the", "bbox": [53.0, 503.0, 387.0, 518.0]}, {"text": "patient's preferred method of communication should be ascer-", "bbox": [53.0, 518.0, 385.0, 532.0]}, {"text": "tained to facilitate consent.", "bbox": [54.0, 533.0, 195.0, 546.0]}, {"text": "Preparation for a procedure undertaken under sedation", "bbox": [65.0, 548.0, 387.0, 562.0]}, {"text": "requires a period of psychological preparation. 1 This may be", "bbox": [53.0, 562.0, 387.0, 577.0]}, {"text": "particularly pertinent for patients with learning disabilities.", "bbox": [53.0, 577.0, 385.0, 591.0]}, {"text": "Carers play an important role in preparing the patient for the", "bbox": [53.0, 592.0, 387.0, 606.0]}, {"text": "procedure and in facilitating the consent process. Learning", "bbox": [53.0, 607.0, 387.0, 620.0]}, {"text": "disability teams exist in most hospitals and should be used to", "bbox": [53.0, 621.0, 387.0, 634.0]}, {"text": "support the consent process for this patient group.", "bbox": [53.0, 636.0, 316.0, 650.0]}, {"text": "A full set of recommendations relating to consent for patients", "bbox": [66.0, 650.0, 387.0, 665.0]}, {"text": "undergoing gastrointestinal endoscopy with and without capacity", "bbox": [53.0, 665.0, 387.0, 679.0]}, {"text": "is provided in separate BSG guidance. 4", "bbox": [54.0, 682.0, 252.0, 694.0]}, {"text": "During an endoscopic procedure, if a patient appears to be", "bbox": [64.0, 695.0, 386.0, 708.0]}, {"text": "tolerating the procedure poorly or gives any other indication", "bbox": [53.0, 709.0, 387.0, 723.0]}, {"text": "that they wish the procedure to stop, the endoscopist should, if", "bbox": [53.0, 724.0, 387.0, 738.0]}, {"text": "possible, stop the procedure and attempt to establish the patient's", "bbox": [53.0, 738.0, 387.0, 753.0]}, {"text": "concerns. It may be appropriate to recommence the endoscopy", "bbox": [53.0, 753.0, 386.0, 767.0]}, {"text": "following reassurance or the administration of further sedation.", "bbox": [53.0, 769.0, 385.0, 782.0]}, {"text": "The administration of sedation in patients with prior capacity", "bbox": [54.0, 783.0, 386.0, 796.0]}, {"text": "may lead to a degree of cognitive impairment such that it can", "bbox": [54.0, 798.0, 387.0, 811.0]}, {"text": "be difficult to assess capacity during the test. If the endoscopist", "bbox": [53.0, 812.0, 387.0, 826.0]}, {"text": "establishes that the patient has capacity and wishes the proce-", "bbox": [53.0, 826.0, 385.0, 841.0]}, {"text": "dure to be discontinued (withdrawal of consent), the proce-", "bbox": [53.0, 842.0, 385.0, 856.0]}, {"text": "dure should be stopped, unless this would result in the patient", "bbox": [53.0, 857.0, 386.0, 871.0]}, {"text": "coming to immediate harm. If a patient, regardless of capacity,", "bbox": [53.0, 871.0, 387.0, 885.0]}, {"text": "has persistent distress, termination of the procedure should be", "bbox": [53.0, 886.0, 387.0, 900.0]}, {"text": "considered and alternatives discussed and arranged.", "bbox": [53.0, 901.0, 322.0, 915.0]}], "type": "Text", "position": 1}, {"raw_context": [{"text": "Special considerations: Ione working", "bbox": [53.0, 941.0, 252.0, 955.0]}], "type": "Section-header", "position": 2}, {"raw_context": [{"text": "52. We recommend that a minimum of two appropriately trained", "bbox": [53.0, 956.0, 386.0, 970.0]}, {"text": "endoscopy assistants are required for endoscopic procedures in", "bbox": [53.0, 971.0, 387.0, 985.0]}, {"text": "which sedation has been administered", "bbox": [53.0, 985.0, 253.0, 999.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "Sidhu R, et al. Gut 2023;0:1–27. doi:10.1136/gutjnl-2023-330396", "bbox": [54.0, 1009.0, 317.0, 1022.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": "Grade of evidence: Very Low. Strength of recommendation:", "bbox": [418.0, 60.0, 739.0, 75.0]}, {"text": "Strong.", "bbox": [408.0, 78.0, 445.0, 90.0]}, {"text": "Level of agreement: 100%", "bbox": [418.0, 91.0, 556.0, 105.0]}, {"text": "53. We recommend that sedation should be administered only", "bbox": [418.0, 105.0, 739.0, 119.0]}, {"text": "if there is immediate access to the resources (staff and facilities)", "bbox": [406.0, 120.0, 740.0, 134.0]}, {"text": "required to manage complications of sedation", "bbox": [406.0, 135.0, 647.0, 150.0]}, {"text": "Grade of evidence: Very Low. Strength of recommendation:", "bbox": [418.0, 150.0, 740.0, 164.0]}, {"text": "Strong.", "bbox": [406.0, 166.0, 445.0, 178.0]}, {"text": "Level of agreement: 100%", "bbox": [418.0, 180.0, 557.0, 193.0]}], "type": "Text", "position": 6}, {"raw_context": [{"text": "For patients undergoing deep sedation, a dedicated sedationist", "bbox": [418.0, 194.0, 741.0, 207.0]}, {"text": "will be present. For most endoscopic procedures undertaken", "bbox": [406.0, 209.0, 741.0, 222.0]}, {"text": "under conscious sedation, the endoscopist will be the person", "bbox": [406.0, 223.0, 741.0, 237.0]}, {"text": "responsible for administering sedative drugs. While performing", "bbox": [406.0, 238.0, 741.0, 252.0]}, {"text": "the endoscopic procedure, the operator may have insufficient", "bbox": [406.0, 253.0, 740.0, 267.0]}, {"text": "situational awareness to monitor the patient's condition safely.", "bbox": [406.0, 268.0, 739.0, 281.0]}, {"text": "A minimum of two endoscopy assistants is required. 1 While one", "bbox": [406.0, 282.0, 739.0, 295.0]}, {"text": "assistant may be assisting with the endoscopic procedure, the", "bbox": [407.0, 297.0, 740.0, 310.0]}, {"text": "other assistant should be entirely focused on monitoring the", "bbox": [406.0, 311.0, 740.0, 325.0]}, {"text": "patient and is responsible for alerting the endoscopist to any", "bbox": [406.0, 325.0, 739.0, 340.0]}, {"text": "important changes.", "bbox": [406.0, 341.0, 506.0, 354.0]}, {"text": "In the event of a complication of sedation arising, such as", "bbox": [418.0, 355.0, 740.0, 369.0]}, {"text": "respiratory depression or a cardiorespiratory arrest, the endos-", "bbox": [406.0, 370.0, 739.0, 383.0]}, {"text": "copy assistant should have the skills to assist in managing the", "bbox": [405.0, 384.0, 740.0, 398.0]}, {"text": "medical emergency. Endoscopy assistants should have appro-", "bbox": [406.0, 399.0, 739.0, 413.0]}, {"text": "priate training (and timely retraining) to undertake this role.", "bbox": [406.0, 413.0, 721.0, 428.0]}, {"text": "Some endoscopy is undertaken in units outside an acute", "bbox": [418.0, 428.0, 740.0, 443.0]}, {"text": "hospital. Sedation should only be administered in the non-", "bbox": [406.0, 443.0, 739.0, 458.0]}, {"text": "hospital setting if adverse events related to sedation can be", "bbox": [406.0, 458.0, 739.0, 472.0]}, {"text": "immediately managed. The range of facilities (including imme-", "bbox": [406.0, 473.0, 739.0, 486.0]}, {"text": "diate access to a resuscitation trolley) and the skills of available", "bbox": [406.0, 487.0, 740.0, 501.0]}, {"text": "staff that can be immediately mobilised in the event of a compli-", "bbox": [406.0, 502.0, 739.0, 516.0]}, {"text": "cation of sedation should be commensurate to that available in", "bbox": [406.0, 517.0, 741.0, 531.0]}, {"text": "an acute hospital. 1", "bbox": [407.0, 532.0, 502.0, 546.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "Training", "bbox": [406.0, 565.0, 453.0, 579.0]}], "type": "Section-header", "position": 8}, {"raw_context": [{"text": "54. We recommend that all endoscopy staff responsible for risk", "bbox": [407.0, 580.0, 740.0, 594.0]}, {"text": "assessing, administering sedation and monitoring of patients,", "bbox": [406.0, 595.0, 739.0, 608.0]}, {"text": "undergo formal training in the recognition and management of", "bbox": [406.0, 610.0, 740.0, 623.0]}, {"text": "related complications, and this should be a continuing process", "bbox": [406.0, 624.0, 733.0, 638.0]}, {"text": "Grade of evidence: Low. Strength of recommendation: Strong.", "bbox": [418.0, 638.0, 737.0, 653.0]}, {"text": "Level of agreement: 100%", "bbox": [418.0, 653.0, 557.0, 668.0]}], "type": "Text", "position": 9}, {"raw_context": [{"text": "Current gap in training", "bbox": [406.0, 687.0, 532.0, 701.0]}], "type": "Section-header", "position": 10}, {"raw_context": [{"text": "Appropriate training in sedation practices and in the recognition", "bbox": [406.0, 702.0, 741.0, 716.0]}, {"text": "and management of potential complications are vital aspects of", "bbox": [406.0, 717.0, 740.0, 731.0]}, {"text": "training for endoscopists. In the UK, the 2004 National Confi-", "bbox": [406.0, 731.0, 739.0, 746.0]}, {"text": "dential Enquiry into Patient Outcome and Death (NCEPOD) 209", "bbox": [406.0, 747.0, 739.0, 760.0]}, {"text": "highlighted an existing gap in sedation training for endoscopists,", "bbox": [406.0, 762.0, 739.0, 775.0]}, {"text": "with only 35% of surveyed endoscopists having attended a seda-", "bbox": [406.0, 776.0, 739.0, 789.0]}, {"text": "tion course. A subsequent survey of UK gastroenterology higher", "bbox": [406.0, 790.0, 739.0, 804.0]}, {"text": "specialty trainees a few years later showed that only 49% had", "bbox": [406.0, 805.0, 740.0, 819.0]}, {"text": "received sedation training. 243 The need for formal training for all", "bbox": [406.0, 818.0, 740.0, 834.0]}, {"text": "practitioners providing sedation has been recognised as a matter", "bbox": [406.0, 834.0, 739.0, 848.0]}, {"text": "of priority by the RCoA 140 and the AoMRC. 1", "bbox": [406.0, 848.0, 641.0, 863.0]}], "type": "Text", "position": 11}, {"raw_context": [{"text": "Available curricula", "bbox": [406.0, 883.0, 509.0, 897.0]}], "type": "Section-header", "position": 12}, {"raw_context": [{"text": "The Multisociety Sedation Curriculum for Gastrointestinal", "bbox": [407.0, 898.0, 741.0, 912.0]}, {"text": "Endoscopy, 125 the Society of Gastroenterology and Endos-", "bbox": [406.0, 914.0, 739.0, 927.0]}, {"text": "copy Nurses and Associates (ESGE/ESGENA) 244 and the UK", "bbox": [406.0, 927.0, 740.0, 941.0]}, {"text": "AoMRC 77 have provided curricula and competency assess-", "bbox": [407.0, 943.0, 739.0, 955.0]}, {"text": "ment guidance for sedation training. A common denominator", "bbox": [406.0, 957.0, 739.0, 970.0]}, {"text": "across all guidelines is the need for training in both theoretical", "bbox": [406.0, 971.0, 740.0, 986.0]}, {"text": "and practical skills related to sedation and potential associated", "bbox": [407.0, 987.0, 740.0, 1000.0]}], "type": "Text", "position": 13}, {"raw_context": [{"text": "21.21", "bbox": [726.0, 1011.0, 738.0, 1021.0]}], "type": "Text", "position": 14}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/消化科/_2023 BSG指南：胃肠内窥镜检查中的镇静.pdf", "page_num": 21}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "多余标点#0#0#endos¬ copist为换行连接字符，可以不需要\n缺少换行#1#1#We recommend that if during另起一行\nGrade of evidence: Very Low另起一行\n缺少换行#8#8#During an endoscopic procedure另起一行\n缺少换行#14#14#53. We recommend that sedat另起一行\n缺少换行#21#21#Grade of evidence: Low.另起一行\n", "type3": "无关文本#0#27#and Scotland. 240 241部分段落末尾，以及句末的数字问题无关噪声应用全文\n无关文本#27#27#21.21", "type4": null, "type5": null, "type6": "有用性#12#12#Sidhu R, et al. Gut 2023;0:1–27. doi:10.1136/gutjnl-2023-330396为页脚内容"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:40", "update_time": "2024-05-08 01:22:29"}
{"id": 1082509, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 738, "source_info": {"seq_id": "9aded614-5f61-4ba5-839d-2ad2b4aa6cd0", "title": null, "text": "【0】页码:7\n tomography–guided navigation of thoracic pedicle screws for adolescent idiopathic scoliosis results in more accurate placement and less screw removal [J]. Spine (Phila Pa 1976),2012,37(8): E473–E478.\n\n【1】[16] KOÇ T, LAM K S, WEBB J K. Are intraspinal anomalies in early onset idiopathic scoliosis as common as once thought? A two centre United Kingdom study [J]. Eur Spine J, 2013, 22(6): 1250– 1254.\n\n【2】[17] 钱乙 . 小儿药证宜诀[M] . 北京 : 人民卫生出版社 , 2006 ; 26 .\n\n【3】QIAN Y. Xiao'er Yao Zheng Zhi Jue [M]. Beijing: People's Medical Publishing House, 2006: 26.\n\n【4】[18] 周奇,王玲,杨楠,等.基于GRADE康复临床实践指南证据质 量与推荐强度研究[J]. 中国康复理论与实践,2020,26(2): 156–160.\n\n【5】ZHOU Q, WANG L, YANG N, et al. Quality of evidence and strength of recommendations of clinical practice guidelines of rehabilitation based on GRADE [J]. Chin J Rehabil Theory Pract, 2020, 26( 2 ): 156–160.\n\n【6】[19] 吳勉华 , 石岩 . 中医内科学[M]. 5 版. 北京 : 中国中医药出版 社 , 2021 : 127.\n\n【7】WU M H, SHI Y. Chinese internal medicine[M]. 5th Ed. Beijing: China Press of Traditional Chinese Medicine ,  2021 ;  127 .\n\n【8】[20] 王绍辉 . 王国才整脊手法治疗特发性脊柱侧夸的临床研究[J].\n\n【9】中国医学创新,2011,8(34):121–122.\n\n【10】WANG S H. Clinical study of Wang Guocai chiropractic manipulation in the treatment of idiopathic scoliosis [J]. Med Innov China, 2011, 8(34): 121–122.\n\n【11】[21] 刘鼎,吕立江,王玮娃,等.吕立江运用杠杆定位手法结合脉冲 电场治疗青少年特发性脊柱侧弯经验[J]. 浙江中医杂志 , 2019, 54( 1 ): 36–37.\n\n【12】LIU D, LYU L J, WANG W W, et al. LYU Lijiang's experience in treating adolescent idiopathic scoliosis by lever positioning combined with pulsed electric field [J]. Zhejiang J Tradit Chin Med, 2019 , 54(1):36–37.\n\n【13】[22] 谢云兴,吕立江,陈插峰.吕立江教授治疗青少年特发性脊柱 側夸经验[J]. 新江中医药大学学报 , 2017 , 41(3):243–245.\n\n【14】XIE Y X,LYU L J,CHEN Y F. Professor LYU Lijiang's experience on treatment adolescent idiopathic scoliosis [J]. J Zhejiang Chin Med Univ, 2017, 41(3): 243–245.\n\n【15】[23] 王书勤 , 朱其广 , 林远方 . \" 卧位辛顿 \" 手法治疗青少年特发性 脊柱侧弯症临床研究[J]. 湖北中医杂志 , 2014 , 36(2): 15–16.\n\n【16】WANG S Q , ZHU Q G , LIN Y F. Clinical research of sudden–traction manipulation in supine position in treatment of adolescent idiopathic scoliosis [J]. Hubei J Tradit Chin Med, 2014, 36 (2) : 15–16.\n\n【17】[24] 应佳丽,沈嘉平. 龙氏俯卧李抖冲压法治疗青少年特发性脊柱 llt[J]. 中医正肯,2018,30(3):64-65,69.\n\n【18】YING J L, SHEN J P. Treatment of adolescent idiopathic scoliosis with Long's prone traction and shaking punching method [J]. J Tradit Chin Orthop Traumatol , 2018, 30( 3 ) : 64–65, 69.\n\n【19】[25] 吉登军 , 顾非 , 刘棍鹏 , 等 . \" 以衡制夸 \" 观指导推拿治疗青少 年特发性脊柱侧夸浅析[J]. 江苏中医药,2017,49(3):65–66.\n\n【20】JI D J , GU F , LIU K P , et al. Analysis on the treatment of adolescent idiopathic scoliosis by massage guided by the concept of \"balancing bending\" [J]. Jiangsu J Tradit Chin Med, 2017, 49 (3): 65–66.\n\n【21】 [26] 孙珂,闫显栋,李守栋.平衡正脊法治疗青少年特发性脊柱侧 $ 1 [ 1 ].  江苏中医药 , 2020 , 52( 3 ):43–45.\n\n【22】SUN K, YAN X D, LI S D. Treatment of adolescent idiopathic scoliosis with balanced chiropractic method [J]. Jiangsu J Tradit Chin Med , 2020 , 52(3):43–45.\n\n【23】[27] 王怀隐 . 太平圣惠方[ m ] . 北京 : 人民卫生出版社 , 2016 ; 281 .\n\n【24】WANG H Y. Taiping Shenghui Fang [M]. Beijing: The people's medical publishing house, 2016; 281.\n\n【25】[28] 荷甜, 육卫平, 马德睿, 等 . 青少年特发性脊柱側凸的中医治疗 进展[1] . 中医临床研究, 2022, 14(4): 126–129.\n\n【26】GOU T, YAN W P, MA D R, et al. A review on treating adolescent idiopathic scoliosis in TCM [J]. Clin J Chin Med, 2022, 14(4): 1126–129.\n\n【27】[29] 第秋菊 . 电针结合整脊法治疗青少年特发性脊柱侧弯临床观 察[J]. 实用中医药杂志, 2021, 37(3):470–472.\n\n【28】ZHENG Q J. Clinical observation on treatment of adolescent idiopathic scoliosis with electroacupuncture combined with chiropractic therapy [J]. J Pract Tradit Chin Med,2021,37(3):470–472.\n\n【29】[30] 魏晖,杜红根,叶树良,等.脊柱平衡法治疗青少年特发性脊柱 側凸症的随机对照研究[J]. 中华中医药学刊,2014,32(5): 1070–1073.\n\n【30】WEI H , DU H G , YE S L , et al. Randomized controlled study on treatment of adolescent idiopathic scoliosis with spinal balance method [J]. Chin Arch Tradit Chin Med, 2014, 32(5): 1070–1073.\n\n【31】[31] 孙武东,蔡倩,郭建业,等. 基吊训练治疗青少年特发性非双夸 型脊柱側弯疗效观察[J]. 康复学报,2021,31(4):317–322.\n\n【32】SUN W D , CAI Q , GUO J Y , et al. Effect of sling exercise therapy on adolescent patients with idiopathic non–double–curved scoliosis [J]. Rehabil Med,2021,31(4):317–322.\n\n【33】[32] 何丽苹,付燕,但男 . 八段锦对大学生脊柱活动度干预效果评 价[J]. 中国学校卫生, 2019, 40(4):590–592.\n\n【34】HE L P, FU Y, DAN Y. Evaluation on the intervention effect of Baduanjin on college students' spinal mobility [J]. Chin J Sch Health, 2019, 40(4):590–592.\n\n【35】[33] 李丽 , 章文春 . 中国传统康复技能 第2 版[M] . 北京 : 人民卫生 出版社 , 2018. 03.\n\n【36】Li L, Zhang WC. Chinese traditional rehabilitation skills 2nd edition [M]. Beijing : People's Health Publishing House , 2018. 03.\n\n【37】[34] KARIMI M T, RABCZUK T. Scoliosis conservative treatment: a review of literature [ J ] . J Craniovertebr Junction Spine , 2018 , 9(1):3–8.\n\n【38】[35] 谢锐填 , 魏伟明 , 黄济嘉 , 等 . 中药町剂联合施罗特疗法治疗青 少年特发性脊柱侧弯效果[J]. 中外医学研究,2020,18(9): 35–37.\n\n【39】XIE R T, WEI W M, HUANG J J, et al. Effect of Chinese medicine tincture combined with schrott therapy on adolescent idiopathic scoliosis [J]. Chin Foreign Med Res, 2020, 18(9):35–37.\n\n【40】[36] 韩娜娜,余蕾,黄晖明.功能性训练对青少年特发性脊柱侧夸 疗效的 Meta分析[J]. 中国学校卫生,2021,42(8):1169–1174.\n\n【41】HAN N N , YU L , HUANG H M. A Meta–analysis of the effect of functional training on idiopathic scoliosis in adolescents [ J ].\n\n【42】Chin J Sch Health ,  2021 ,  42 ( 8 )  :  1169–1174 .\n\n【43】[37] DUNN J, HENRIKSON N B, MORRISON C C, et al. Screening for adolescent idiopathic scoliosis : evidence report and systematic review for the US preventive services task force [J]. JAMA, 2018, 319(2):173–187.", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "tomography–guided navigation of thoracic pedicle screws for ado-", "bbox": [92.0, 106.0, 377.0, 119.0]}, {"text": "lescent idiopathic scoliosis results in more accurate placement", "bbox": [92.0, 122.0, 377.0, 134.0]}, {"text": "and less screw removal [J]. Spine (Phila Pa 1976),2012,37(8):", "bbox": [93.0, 138.0, 376.0, 150.0]}, {"text": "E473–E478.", "bbox": [92.0, 153.0, 149.0, 165.0]}, {"text": "[16] KOÇ T, LAM K S, WEBB J K. Are intraspinal anomalies in early", "bbox": [65.0, 166.0, 377.0, 183.0]}, {"text": "onset idiopathic scoliosis as common as once thought? A two cen-", "bbox": [93.0, 185.0, 376.0, 197.0]}, {"text": "tre United Kingdom study [J]. Eur Spine J, 2013, 22(6): 1250–", "bbox": [92.0, 199.0, 375.0, 213.0]}, {"text": "1254.", "bbox": [94.0, 216.0, 120.0, 227.0]}, {"text": "[17] 钱乙 . 小儿药证宜诀[M] . 北京 : 人民卫生出版社 , 2006 ; 26 .", "bbox": [65.0, 230.0, 359.0, 243.0]}, {"text": "QIAN Y. Xiao'er Yao Zheng Zhi Jue [M]. Beijing: People's Medi-", "bbox": [92.0, 245.0, 375.0, 258.0]}, {"text": "cal Publishing House, 2006: 26.", "bbox": [92.0, 261.0, 231.0, 274.0]}, {"text": "[18] 周奇,王玲,杨楠,等.基于GRADE康复临床实践指南证据质", "bbox": [65.0, 276.0, 375.0, 289.0]}, {"text": "量与推荐强度研究[J]. 中国康复理论与实践,2020,26(2):", "bbox": [93.0, 291.0, 376.0, 305.0]}, {"text": "156–160.", "bbox": [94.0, 309.0, 136.0, 320.0]}, {"text": "ZHOU Q, WANG L, YANG N, et al. Quality of evidence and", "bbox": [92.0, 322.0, 377.0, 335.0]}, {"text": "strength of recommendations of clinical practice guidelines of re-", "bbox": [92.0, 338.0, 376.0, 351.0]}, {"text": "habilitation based on GRADE [J]. Chin J Rehabil Theory Pract,", "bbox": [92.0, 353.0, 375.0, 366.0]}, {"text": "2020, 26( 2 ): 156–160.", "bbox": [94.0, 370.0, 194.0, 381.0]}, {"text": "[19] 吳勉华 , 石岩 . 中医内科学[M]. 5 版. 北京 : 中国中医药出版", "bbox": [65.0, 383.0, 375.0, 398.0]}, {"text": "社 , 2021 : 127.", "bbox": [94.0, 401.0, 157.0, 413.0]}, {"text": "WU M H, SHI Y. Chinese internal medicine[M]. 5th Ed. Beijing:", "bbox": [93.0, 413.0, 375.0, 428.0]}, {"text": "China Press of Traditional Chinese Medicine ,  2021 ;  127 .", "bbox": [92.0, 429.0, 334.0, 443.0]}, {"text": "[20] 王绍辉 . 王国才整脊手法治疗特发性脊柱侧夸的临床研究[J].", "bbox": [65.0, 446.0, 377.0, 459.0]}, {"text": "中国医学创新,2011,8(34):121–122.", "bbox": [93.0, 462.0, 265.0, 474.0]}, {"text": "WANG S H. Clinical study of Wang Guocai chiropractic manipu-", "bbox": [93.0, 477.0, 377.0, 490.0]}, {"text": "lation in the treatment of idiopathic scoliosis [J]. Med Innov", "bbox": [92.0, 492.0, 376.0, 505.0]}, {"text": "China, 2011, 8(34): 121–122.", "bbox": [92.0, 508.0, 224.0, 520.0]}, {"text": "[21] 刘鼎,吕立江,王玮娃,等.吕立江运用杠杆定位手法结合脉冲", "bbox": [65.0, 523.0, 377.0, 537.0]}, {"text": "电场治疗青少年特发性脊柱侧弯经验[J]. 浙江中医杂志 ,", "bbox": [92.0, 538.0, 376.0, 552.0]}, {"text": "2019, 54( 1 ): 36–37.", "bbox": [94.0, 555.0, 185.0, 567.0]}, {"text": "LIU D, LYU L J, WANG W W, et al. LYU Lijiang's experience in", "bbox": [92.0, 569.0, 388.0, 583.0]}, {"text": "treating adolescent idiopathic scoliosis by lever positioning com-", "bbox": [92.0, 586.0, 375.0, 597.0]}, {"text": "bined with pulsed electric field [J]. Zhejiang J Tradit Chin Med,", "bbox": [92.0, 599.0, 375.0, 613.0]}, {"text": "2019 , 54(1):36–37.", "bbox": [93.0, 616.0, 184.0, 629.0]}, {"text": "[22] 谢云兴,吕立江,陈插峰.吕立江教授治疗青少年特发性脊柱", "bbox": [65.0, 630.0, 376.0, 644.0]}, {"text": "側夸经验[J]. 新江中医药大学学报 , 2017 , 41(3):243–245.", "bbox": [92.0, 646.0, 360.0, 660.0]}, {"text": "XIE Y X,LYU L J,CHEN Y F. Professor LYU Lijiang's experience", "bbox": [92.0, 662.0, 383.0, 675.0]}, {"text": "on treatment adolescent idiopathic scoliosis [J]. J Zhejiang Chin", "bbox": [92.0, 678.0, 377.0, 691.0]}, {"text": "Med Univ, 2017, 41(3): 243–245.", "bbox": [93.0, 693.0, 240.0, 706.0]}, {"text": "[23] 王书勤 , 朱其广 , 林远方 . \" 卧位辛顿 \" 手法治疗青少年特发性", "bbox": [65.0, 708.0, 375.0, 721.0]}, {"text": "脊柱侧弯症临床研究[J]. 湖北中医杂志 , 2014 , 36(2): 15–16.", "bbox": [94.0, 723.0, 372.0, 737.0]}, {"text": "WANG S Q , ZHU Q G , LIN Y F. Clinical research of sudden–trac-", "bbox": [94.0, 740.0, 376.0, 752.0]}, {"text": "tion manipulation in supine position in treatment of adolescent id-", "bbox": [92.0, 755.0, 376.0, 768.0]}, {"text": "iopathic scoliosis [J]. Hubei J Tradit Chin Med, 2014, 36 (2) :", "bbox": [92.0, 769.0, 375.0, 783.0]}, {"text": "15–16.", "bbox": [94.0, 787.0, 125.0, 799.0]}, {"text": "[24] 应佳丽,沈嘉平. 龙氏俯卧李抖冲压法治疗青少年特发性脊柱", "bbox": [65.0, 800.0, 376.0, 814.0]}, {"text": "llt[J]. 中医正肯,2018,30(3):64-65,69.", "bbox": [92.0, 816.0, 290.0, 830.0]}, {"text": "YING J L, SHEN J P. Treatment of adolescent idiopathic scoliosis", "bbox": [94.0, 833.0, 377.0, 845.0]}, {"text": "with Long's prone traction and shaking punching method [J]. J", "bbox": [92.0, 848.0, 377.0, 861.0]}, {"text": "Tradit Chin Orthop Traumatol , 2018, 30( 3 ) : 64–65, 69.", "bbox": [92.0, 863.0, 330.0, 876.0]}, {"text": "[25] 吉登军 , 顾非 , 刘棍鹏 , 等 . \" 以衡制夸 \" 观指导推拿治疗青少", "bbox": [65.0, 878.0, 375.0, 892.0]}, {"text": "年特发性脊柱侧夸浅析[J]. 江苏中医药,2017,49(3):65–66.", "bbox": [93.0, 893.0, 371.0, 908.0]}, {"text": "JI D J , GU F , LIU K P , et al. Analysis on the treatment of adoles-", "bbox": [93.0, 911.0, 376.0, 923.0]}, {"text": "cent idiopathic scoliosis by massage guided by the concept of \"bal-", "bbox": [92.0, 925.0, 376.0, 938.0]}, {"text": "ancing bending\" [J]. Jiangsu J Tradit Chin Med, 2017, 49 (3):", "bbox": [92.0, 939.0, 375.0, 954.0]}, {"text": "65–66.", "bbox": [92.0, 957.0, 125.0, 969.0]}], "type": "Text", "position": 0}, {"raw_context": [{"text": "[26] 孙珂,闫显栋,李守栋.平衡正脊法治疗青少年特发性脊柱侧", "bbox": [401.0, 105.0, 712.0, 119.0]}, {"text": "$ 1 [ 1 ].  江苏中医药 , 2020 , 52( 3 ):43–45.", "bbox": [429.0, 121.0, 630.0, 134.0]}, {"text": "SUN K, YAN X D, LI S D. Treatment of adolescent idiopathic sco-", "bbox": [428.0, 136.0, 712.0, 150.0]}, {"text": "liosis with balanced chiropractic method [J]. Jiangsu J Tradit", "bbox": [428.0, 152.0, 712.0, 165.0]}, {"text": "Chin Med , 2020 , 52(3):43–45.", "bbox": [429.0, 169.0, 565.0, 181.0]}, {"text": "[27] 王怀隐 . 太平圣惠方[ m ] . 北京 : 人民卫生出版社 , 2016 ; 281 .", "bbox": [401.0, 183.0, 701.0, 197.0]}, {"text": "WANG H Y. Taiping Shenghui Fang [M]. Beijing: The people's", "bbox": [429.0, 200.0, 713.0, 212.0]}, {"text": "medical publishing house, 2016; 281.", "bbox": [429.0, 216.0, 589.0, 228.0]}, {"text": "[28] 荷甜, 육卫平, 马德睿, 等 . 青少年特发性脊柱側凸的中医治疗", "bbox": [400.0, 230.0, 712.0, 243.0]}, {"text": "进展[1] . 中医临床研究, 2022, 14(4): 126–129.", "bbox": [429.0, 246.0, 642.0, 258.0]}, {"text": "GOU T, YAN W P, MA D R, et al. A review on treating adolescent", "bbox": [428.0, 260.0, 712.0, 274.0]}, {"text": "idiopathic scoliosis in TCM [J]. Clin J Chin Med, 2022, 14(4):", "bbox": [429.0, 276.0, 712.0, 289.0]}, {"text": "1126–129.", "bbox": [429.0, 292.0, 473.0, 304.0]}, {"text": "[29] 第秋菊 . 电针结合整脊法治疗青少年特发性脊柱侧弯临床观", "bbox": [400.0, 306.0, 712.0, 320.0]}, {"text": "察[J]. 实用中医药杂志, 2021, 37(3):470–472.", "bbox": [429.0, 322.0, 640.0, 335.0]}, {"text": "ZHENG Q J. Clinical observation on treatment of adolescent idio-", "bbox": [429.0, 338.0, 712.0, 351.0]}, {"text": "pathic scoliosis with electroacupuncture combined with chiroprac-", "bbox": [429.0, 355.0, 711.0, 366.0]}, {"text": "tic therapy [J]. J Pract Tradit Chin Med,2021,37(3):470–472.", "bbox": [429.0, 370.0, 705.0, 382.0]}, {"text": "[30] 魏晖,杜红根,叶树良,等.脊柱平衡法治疗青少年特发性脊柱", "bbox": [401.0, 384.0, 711.0, 398.0]}, {"text": "側凸症的随机对照研究[J]. 中华中医药学刊,2014,32(5):", "bbox": [429.0, 400.0, 712.0, 413.0]}, {"text": "1070–1073.", "bbox": [429.0, 416.0, 482.0, 427.0]}, {"text": "WEI H , DU H G , YE S L , et al. Randomized controlled study on", "bbox": [429.0, 429.0, 712.0, 443.0]}, {"text": "treatment of adolescent idiopathic scoliosis with spinal balance", "bbox": [428.0, 446.0, 712.0, 459.0]}, {"text": "method [J]. Chin Arch Tradit Chin Med, 2014, 32(5): 1070–1073.", "bbox": [429.0, 462.0, 711.0, 474.0]}, {"text": "[31] 孙武东,蔡倩,郭建业,等. 基吊训练治疗青少年特发性非双夸", "bbox": [401.0, 477.0, 712.0, 490.0]}, {"text": "型脊柱側弯疗效观察[J]. 康复学报,2021,31(4):317–322.", "bbox": [429.0, 492.0, 695.0, 505.0]}, {"text": "SUN W D , CAI Q , GUO J Y , et al. Effect of sling exercise therapy", "bbox": [429.0, 508.0, 712.0, 521.0]}, {"text": "on adolescent patients with idiopathic non–double–curved scolio-", "bbox": [429.0, 524.0, 712.0, 536.0]}, {"text": "sis [J]. Rehabil Med,2021,31(4):317–322.", "bbox": [429.0, 539.0, 624.0, 551.0]}, {"text": "[32] 何丽苹,付燕,但男 . 八段锦对大学生脊柱活动度干预效果评", "bbox": [401.0, 553.0, 712.0, 567.0]}, {"text": "价[J]. 中国学校卫生, 2019, 40(4):590–592.", "bbox": [429.0, 571.0, 629.0, 583.0]}, {"text": "HE L P, FU Y, DAN Y. Evaluation on the intervention effect of", "bbox": [429.0, 586.0, 713.0, 597.0]}, {"text": "Baduanjin on college students' spinal mobility [J]. Chin J Sch", "bbox": [429.0, 599.0, 713.0, 613.0]}, {"text": "Health, 2019, 40(4):590–592.", "bbox": [429.0, 617.0, 564.0, 629.0]}, {"text": "[33] 李丽 , 章文春 . 中国传统康复技能 第2 版[M] . 北京 : 人民卫生", "bbox": [401.0, 630.0, 712.0, 644.0]}, {"text": "出版社 , 2018. 03.", "bbox": [429.0, 648.0, 508.0, 660.0]}, {"text": "Li L, Zhang WC. Chinese traditional rehabilitation skills 2nd edi-", "bbox": [429.0, 662.0, 712.0, 675.0]}, {"text": "tion [M]. Beijing : People's Health Publishing House , 2018. 03.", "bbox": [429.0, 678.0, 701.0, 690.0]}, {"text": "[34] KARIMI M T, RABCZUK T. Scoliosis conservative treatment: a", "bbox": [401.0, 693.0, 712.0, 706.0]}, {"text": "review of literature [ J ] . J Craniovertebr Junction Spine , 2018 ,", "bbox": [429.0, 708.0, 712.0, 722.0]}, {"text": "9(1):3–8.", "bbox": [429.0, 725.0, 477.0, 737.0]}, {"text": "[35] 谢锐填 , 魏伟明 , 黄济嘉 , 等 . 中药町剂联合施罗特疗法治疗青", "bbox": [400.0, 738.0, 711.0, 752.0]}, {"text": "少年特发性脊柱侧弯效果[J]. 中外医学研究,2020,18(9):", "bbox": [429.0, 754.0, 712.0, 768.0]}, {"text": "35–37.", "bbox": [429.0, 770.0, 462.0, 783.0]}, {"text": "XIE R T, WEI W M, HUANG J J, et al. Effect of Chinese medi-", "bbox": [429.0, 786.0, 712.0, 799.0]}, {"text": "cine tincture combined with schrott therapy on adolescent idio-", "bbox": [429.0, 802.0, 712.0, 814.0]}, {"text": "pathic scoliosis [J]. Chin Foreign Med Res, 2020, 18(9):35–37.", "bbox": [429.0, 817.0, 708.0, 830.0]}, {"text": "[36] 韩娜娜,余蕾,黄晖明.功能性训练对青少年特发性脊柱侧夸", "bbox": [401.0, 832.0, 712.0, 845.0]}, {"text": "疗效的 Meta分析[J]. 中国学校卫生,2021,42(8):1169–1174.", "bbox": [429.0, 847.0, 709.0, 861.0]}, {"text": "HAN N N , YU L , HUANG H M. A Meta–analysis of the effect of", "bbox": [428.0, 863.0, 712.0, 876.0]}, {"text": "functional training on idiopathic scoliosis in adolescents [ J ].", "bbox": [429.0, 879.0, 713.0, 892.0]}, {"text": "Chin J Sch Health ,  2021 ,  42 ( 8 )  :  1169–1174 .", "bbox": [429.0, 894.0, 623.0, 907.0]}, {"text": "[37] DUNN J, HENRIKSON N B, MORRISON C C, et al. Screening", "bbox": [401.0, 910.0, 712.0, 923.0]}, {"text": "for adolescent idiopathic scoliosis : evidence report and systematic", "bbox": [429.0, 925.0, 712.0, 938.0]}, {"text": "review for the US preventive services task force [J]. JAMA, 2018,", "bbox": [429.0, 939.0, 710.0, 954.0]}, {"text": "319(2):173–187.", "bbox": [429.0, 957.0, 510.0, 969.0]}], "type": "Text", "position": 2}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/骨科/指南/中医康复临床实践指南·儿童青少年特发性脊柱侧弯.pdf", "page_num": 7}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": null, "type3": null, "type4": null, "type5": null, "type6": "信息有用性#0#43#参考文献"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:40", "update_time": "2024-05-07 19:24:23"}
{"id": 1082508, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 738, "source_info": {"seq_id": "1bdb8fbc-3311-4b4f-b0f0-222fa76dd414", "title": null, "text": "【0】页码:9\n 3 3\n# Icu\n\n【1】\n ICU l l ICU PubMed , Embase , Web of Science , Cochrane Library , CINAHL , 2022 6 , 1992 (Newcastle-Ottawa Quality Scale , NOS) Stata  SE.12 51.84% [95% CI 28 . ICU .     3  170 (45.17%~58.51%)] .\n\n【2】Chapter 1 l 11–3 3 > 3 -6 >6 50.51% [95%CI(40.97%~60.05%)] ,53.34% [95%CI(44.86%~61.82%)] ,49.44% [95%CI(32.71%~66.16%)] ,29.55% [ 95%CI ( 13.28%~45.82% ) ] .\n\n【3】Meta ( P <0.05) .\n\n【4】ICU\n\n【5】## L L : Icu ; Prevalence Of Sleep Disorders In Post-Icu Patients: A Systematic Review/Song Xiuxiu,Wu Juan,Wang Yinan\n\n【6】\n [Abstract] Objective To systematically evaluate the prevalence of sleep disorders and provide evidence for early prevention of sleep disorders in post-ICU patients. Methods  PubMed,Embase,Web of Science,the Cochrane Library, CINAHL, CBM, CNKI, WanFang Data and VIP were searched from inception to June 2022. There were 2 researchers who independently screened the literature and assessed the quality of included studies using Critical Appraisal Tools published by Newcastle-Ottawa Quality Scale(NOS). The meta-analysis was performed by StataSE.12 software. Results  A total of 28 studies were included in this study with a total of 3 170 patients. The prevalence\n\n【7】 DOI : 10.3761/j.issn.0254-1769.2023.06.015\n\n【8】 226001\n\n【9】 ( ,E-mail ; texu1910@163.com .\n\n【10】) , E-mail : 1970798195@qq.com.\n\n【11】. .\n\n【12】Chapter 1\n\n【13】 2022-08-31\n\n【14】 the complete o\n\n【15】 (Tfh2101)\n\n【16】 );\n\n【17】 Huo SJ, Zhao L, Wei YT, et  al. A Meta-analysis of the efficacy and safety of outpatient rehabilitation and home rehabilitation after knee replacement[J] . Chin J Nurs,2022,57(10): 1190-1198.\n\n【18】[39] Zeng CY,Zhang ZR,Tang ZM,et al.Benefits and mechanisms of exercise training for knee osteoarthritis[J]. Front Physiol, 2021 , 12 , 794062.\n\n【19】 [40]\n\n【20】 [M].2 .\n\n【21】 :\n\n【22】 2018.\n\n【23】Wang YJ,Pan HS.Sports medicine[M].2nd ed.Beijing,People's Medical Publishing House , 2018.\n\n【24】 [41]\n\n【25】 1760.\n\n【26】 [42]\n\n【27】 ,2019,54(3):458-462.\n\n【28】[1].\n\n【29】Wang JM, Wang AP. Research progress of exercise therapy and nursing for patients with knee osteoarthritis [ J ]. Chin J Nurs, 2019, 54( 3 ), 458-462.\n\n【30】[43] Wang T,He C. Pro-inflammatory cytokines,the link between obesity and osteoarthritis[J]. Cytokine Growth Factor Rev, 2018, 44 :38-50.\n\n【31】 [44]\n\n【32】 .\n\n【33】.\n\n【34】[1].\n\n【35】,2017,32(6):526-528.\n\n【36】Zhang M, Pang J, Chen B, et  al. Research progress of orthopedic AIDS in the treatment of knee osteoarthritis[J]. Chin J Rehabil, 2017, 32(6):526-528.\n\n【37】 [1].\n\n【38】.\n\n【39】,2021 ,41(8):1756-1760.\n\n【40】Deng CY,Zhou GJ,Wang TT,et al.Progress in physical therapy of knee arthritis[J]. Chin J Gerontol,2021,41(8):1756-", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "3 3", "bbox": [191.0, 48.0, 210.0, 58.0]}], "type": "Text", "position": 1}, {"raw_context": [{"text": "ICU", "bbox": [194.0, 117.0, 242.0, 140.0]}], "type": "Title", "position": 3}, {"raw_context": [{"text": "ICU", "bbox": [244.0, 205.0, 269.0, 220.0]}, {"text": "l", "bbox": [111.0, 206.0, 123.0, 220.0]}, {"text": "l", "bbox": [142.0, 206.0, 154.0, 221.0]}, {"text": "ICU", "bbox": [476.0, 206.0, 500.0, 220.0]}, {"text": "PubMed , Embase , Web of Science , Cochrane Library , CINAHL ,", "bbox": [209.0, 226.0, 524.0, 240.0]}, {"text": "2022 6 ,", "bbox": [363.0, 247.0, 428.0, 259.0]}, {"text": "1992", "bbox": [434.0, 248.0, 444.0, 258.0]}, {"text": "(Newcastle-Ottawa Quality Scale , NOS)", "bbox": [225.0, 263.0, 424.0, 280.0]}, {"text": "Stata  SE.12", "bbox": [580.0, 264.0, 643.0, 278.0]}, {"text": "51.84% [95% CI", "bbox": [621.0, 283.0, 704.0, 297.0]}, {"text": "28", "bbox": [243.0, 284.0, 260.0, 297.0]}, {"text": ". ICU", "bbox": [388.0, 284.0, 423.0, 297.0]}, {"text": ".     3  170", "bbox": [294.0, 286.0, 354.0, 297.0]}, {"text": "(45.17%~58.51%)] .", "bbox": [112.0, 301.0, 219.0, 317.0]}, {"text": "Chapter 1", "bbox": [318.0, 303.0, 347.0, 317.0]}, {"text": "l", "bbox": [365.0, 303.0, 377.0, 316.0]}, {"text": "11–3", "bbox": [408.0, 303.0, 441.0, 317.0]}, {"text": "3 > 3 -6", "bbox": [455.0, 303.0, 495.0, 317.0]}, {"text": ">6", "bbox": [524.0, 303.0, 542.0, 316.0]}, {"text": "50.51% [95%CI(40.97%~60.05%)] ,53.34% [95%CI(44.86%~61.82%)] ,49.44% [95%CI(32.71%~66.16%)] ,29.55%", "bbox": [123.0, 320.0, 702.0, 335.0]}, {"text": "[ 95%CI ( 13.28%~45.82% ) ] .", "bbox": [111.0, 340.0, 263.0, 354.0]}, {"text": "Meta", "bbox": [326.0, 342.0, 353.0, 354.0]}, {"text": "( P <0.05) .", "bbox": [645.0, 342.0, 702.0, 353.0]}, {"text": "ICU", "bbox": [147.0, 360.0, 171.0, 372.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": "l", "bbox": [113.0, 398.0, 122.0, 412.0]}, {"text": "l", "bbox": [152.0, 397.0, 164.0, 413.0]}, {"text": ": ICU", "bbox": [220.0, 399.0, 260.0, 412.0]}, {"text": ";", "bbox": [305.0, 401.0, 312.0, 411.0]}, {"text": "Prevalence of sleep disorders in post-ICU patients: a systematic review/SONG Xiuxiu,WU Juan,WANG", "bbox": [111.0, 417.0, 703.0, 432.0]}, {"text": "Yinan", "bbox": [112.0, 436.0, 148.0, 450.0]}], "type": "Section-header", "position": 5}, {"raw_context": [{"text": "[Abstract] Objective To systematically evaluate the prevalence of sleep disorders and provide evidence for early", "bbox": [112.0, 455.0, 702.0, 469.0]}, {"text": "prevention of sleep disorders in post-ICU patients. Methods  PubMed,Embase,Web of Science,the Cochrane", "bbox": [111.0, 474.0, 702.0, 488.0]}, {"text": "Library, CINAHL, CBM, CNKI, WanFang Data and VIP were searched from inception to June 2022. There were 2", "bbox": [111.0, 493.0, 702.0, 508.0]}, {"text": "researchers who independently screened the literature and assessed the quality of included studies using Critical", "bbox": [111.0, 512.0, 702.0, 527.0]}, {"text": "Appraisal Tools published by Newcastle-Ottawa Quality Scale(NOS). The meta-analysis was performed by StataSE.12", "bbox": [112.0, 531.0, 703.0, 546.0]}, {"text": "software. Results  A total of 28 studies were included in this study with a total of 3 170 patients. The prevalence", "bbox": [111.0, 549.0, 702.0, 565.0]}], "type": "Text", "position": 6}, {"raw_context": [{"text": "DOI : 10.3761/j.issn.0254-1769.2023.06.015", "bbox": [84.0, 585.0, 274.0, 600.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "226001", "bbox": [127.0, 622.0, 169.0, 636.0]}], "type": "Text", "position": 8}, {"raw_context": [{"text": "(", "bbox": [336.0, 626.0, 346.0, 637.0]}, {"text": ",E-mail ; texu1910@163.com", "bbox": [154.0, 640.0, 284.0, 654.0]}, {"text": ".", "bbox": [127.0, 645.0, 140.0, 655.0]}, {"text": ") , E-mail : 1970798195@qq.com.", "bbox": [206.0, 659.0, 344.0, 673.0]}, {"text": ". .", "bbox": [117.0, 662.0, 144.0, 673.0]}, {"text": "Chapter 1", "bbox": [156.0, 662.0, 168.0, 673.0]}], "type": "Text", "position": 9}, {"raw_context": [{"text": "2022-08-31", "bbox": [84.0, 677.0, 138.0, 691.0]}], "type": "Text", "position": 10}, {"raw_context": [{"text": "the complete o", "bbox": [89.0, 698.0, 359.0, 710.0]}], "type": "Text", "position": 11}, {"raw_context": [{"text": "(Tfh2101)", "bbox": [323.0, 604.0, 373.0, 618.0]}], "type": "Text", "position": 12}, {"raw_context": [{"text": ");", "bbox": [413.0, 626.0, 426.0, 637.0]}], "type": "Text", "position": 13}, {"raw_context": [{"text": "Huo SJ, Zhao L, Wei YT, et  al. A Meta-analysis of the effica-", "bbox": [115.0, 719.0, 395.0, 733.0]}, {"text": "cy and safety of outpatient rehabilitation and home rehabili-", "bbox": [115.0, 737.0, 395.0, 752.0]}, {"text": "tation after knee replacement[J] . Chin J Nurs,2022,57(10):", "bbox": [115.0, 757.0, 395.0, 770.0]}, {"text": "1190-1198.", "bbox": [117.0, 774.0, 168.0, 788.0]}, {"text": "[39] Zeng CY,Zhang ZR,Tang ZM,et al.Benefits and mechanisms", "bbox": [84.0, 793.0, 395.0, 807.0]}, {"text": "of exercise training for knee osteoarthritis[J]. Front Physiol,", "bbox": [115.0, 812.0, 395.0, 825.0]}, {"text": "2021 , 12 , 794062.", "bbox": [117.0, 830.0, 195.0, 843.0]}], "type": "Text", "position": 14}, {"raw_context": [{"text": "[40]", "bbox": [84.0, 848.0, 110.0, 863.0]}], "type": "Text", "position": 15}, {"raw_context": [{"text": "[M].2 .", "bbox": [236.0, 850.0, 287.0, 863.0]}], "type": "Text", "position": 16}, {"raw_context": [{"text": ":", "bbox": [303.0, 852.0, 312.0, 862.0]}], "type": "Text", "position": 17}, {"raw_context": [{"text": "2018.", "bbox": [117.0, 867.0, 144.0, 881.0]}, {"text": "Wang YJ,Pan HS.Sports medicine[M].2nd ed.Beijing,People's", "bbox": [117.0, 885.0, 397.0, 900.0]}, {"text": "Medical Publishing House , 2018.", "bbox": [116.0, 905.0, 263.0, 918.0]}], "type": "Text", "position": 18}, {"raw_context": [{"text": "[41]", "bbox": [84.0, 923.0, 111.0, 936.0]}], "type": "Text", "position": 19}, {"raw_context": [{"text": "1760.", "bbox": [451.0, 720.0, 478.0, 733.0]}], "type": "Text", "position": 20}, {"raw_context": [{"text": "[42]", "bbox": [418.0, 738.0, 445.0, 752.0]}], "type": "Text", "position": 21}, {"raw_context": [{"text": ",2019,54(3):458-462.", "bbox": [576.0, 756.0, 680.0, 770.0]}, {"text": "[1].", "bbox": [487.0, 757.0, 516.0, 770.0]}, {"text": "Wang JM, Wang AP. Research progress of exercise therapy", "bbox": [450.0, 774.0, 731.0, 788.0]}, {"text": "and nursing for patients with knee osteoarthritis [ J ]. Chin J", "bbox": [451.0, 794.0, 731.0, 806.0]}, {"text": "Nurs, 2019, 54( 3 ), 458-462.", "bbox": [450.0, 811.0, 576.0, 824.0]}, {"text": "[43] Wang T,He C. Pro-inflammatory cytokines,the link between", "bbox": [419.0, 830.0, 731.0, 843.0]}, {"text": "obesity and osteoarthritis[J]. Cytokine Growth Factor Rev, 2018,", "bbox": [450.0, 848.0, 730.0, 861.0]}, {"text": "44 :38-50.", "bbox": [451.0, 866.0, 498.0, 879.0]}], "type": "Text", "position": 22}, {"raw_context": [{"text": "[44]", "bbox": [419.0, 885.0, 445.0, 898.0]}], "type": "Text", "position": 23}, {"raw_context": [{"text": ".", "bbox": [473.0, 888.0, 485.0, 898.0]}, {"text": ".", "bbox": [500.0, 888.0, 514.0, 898.0]}, {"text": "[1].", "bbox": [451.0, 903.0, 473.0, 916.0]}, {"text": ",2017,32(6):526-528.", "bbox": [477.0, 902.0, 616.0, 915.0]}, {"text": "Zhang M, Pang J, Chen B, et  al. Research progress of ortho-", "bbox": [450.0, 920.0, 727.0, 934.0]}, {"text": "pedic AIDS in the treatment of knee osteoarthritis[J]. Chin J", "bbox": [450.0, 938.0, 731.0, 953.0]}, {"text": "Rehabil, 2017, 32(6):526-528.", "bbox": [450.0, 956.0, 588.0, 971.0]}], "type": "Text", "position": 24}, {"raw_context": [{"text": "[1].", "bbox": [374.0, 925.0, 395.0, 936.0]}, {"text": ".", "bbox": [148.0, 927.0, 160.0, 938.0]}, {"text": ",2021 ,41(8):1756-1760.", "bbox": [190.0, 941.0, 307.0, 954.0]}, {"text": "Deng CY,Zhou GJ,Wang TT,et al.Progress in physical ther-", "bbox": [115.0, 960.0, 395.0, 974.0]}, {"text": "apy of knee arthritis[J]. Chin J Gerontol,2021,41(8):1756-", "bbox": [116.0, 979.0, 395.0, 993.0]}], "type": "Text", "position": 25}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/骨科/解读/膝骨关节炎患者自我管理的最佳证据总结.pdf", "page_num": 9}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": null, "type3": null, "type4": null, "type5": null, "type6": "信息有用性#0#40#参考文献"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:40", "update_time": "2024-05-07 19:34:59"}
{"id": 1082507, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 738, "source_info": {"seq_id": "66475aac-9649-4893-b389-88176d48fe33", "title": null, "text": "【0】页码:10\n\n【1】## 10 Bjhaem\n\n【2】\n## Postpartum Anticoagulation\n\n【3】\n There are no high-quality studies assessing the bleeding risk versus the benefits of early therapeutic anticoagulation post-delivery in individuals with MHV; however, there are extensive data on these risks in the postoperative setting.\n\n【4】Therapeutic anticoagulation with heparins has been associated with a fivefold increase bleeding without reducing the thrombosis risk. 51 Specifically, in patients with MHV, Passaglia et al. 51 concluded that 'Early bridging therapy with LMWH appears to be associated with consistently high bleeding rates across multiple analyses'.\n\n【5】In the PERIOP2 study 52 including patients with mechanical valve replacement ± AF, all received preprocedure therapeutic LMWH bridging but were randomised to post-procedure escalation to therapeutic LMWH after 48 h versus no post-op therapeutic LMWH.\n\n【6】There was no difference in bleeding; however, patients considered at higher risk of bleeding only received prophylactic LMWH post-procedure. No significant benefit was found for postoperative dalteparin bridging to prevent thromboembolism. Although pregnancy is associated with a pro-thrombotic state and significant risk of valve thrombosis, the risk of thrombosis after pausing anticoagulation over a brief period is likely to be low; however, the risk of bleeding is high in the peripartum period and is likely to be exacerbated using very early postpartum therapeutic anticoagulation.\n\n【7】The ESC guidance 7 recommends restarting UFH 4–6 h after delivery if there are no bleeding complications and NICE guidance NG121 53 recommends restarting therapeutic LMWH or UFH 4–6h after birth. The Association of Anaesthetists (AOA) guidelines 54 provide recommendations on time intervals for commencing anticoagulation postpartum but also recommend delaying introducing therapeutic anticoagulation with LMWH for 24 h if a neuraxial block was utilised during birth and was traumatic. There is no supporting evidence for these recommendations in terms of risk/benefit. The UKOSS study 5 confirmed the high risk of haemorrhage for pregnant individuals with MHV who are anticoagulated. Postpartum bleeding complications necessitating return to theatre or transfusion occurred in 29%, and in 40% of pregnant individuals delivered by CS. Most bleeding complications occurred after 24 h in this observational study. The reasons for this cannot be established from observational data alone but the use of aggressive peripartum anticoagulation due to concerns over valve thrombosis may be a factor.\n\n【8】We recommend timely recognition and management of wound and intra-abdominal haematoma in this cohort as their occurrence can lead to interruptions in therapeutic anticoagulation. An MDT approach with low threshold for imaging (e.g. CT scan) and intervention (re-exploration) to rule out surgical bleeding is recommended and any unexpected fall in haemoglobin should be investigated quickly in view of the intensity of anticoagulation postpartum.\n\n【9】 Table 3 summarises observational cohort data on the risk of peripartum and PPH in pregnant individuals with MHVs.\n\n【10】Although there is no standardised definition of bleeding, making any comparisons difficult, the risk of bleeding appears to be high.\n\n【11】Haemorrhagic complications associated with delivery in pregnant individuals with MHV may result in a paradoxical increase in thrombosis risk as anticoagulants have to be reversed/paused after major bleeding, including returns to theatre for haematoma along with the attendant risk of wound infection and prolonged hospital stay. We therefore recommend a more cautious re-introduction of anticoagulation including a step-wise increase in the level of anticoagulation to try and reduce these risks. We recommend prophylactic or intermediate doses of LMWH for the first 24–48 h following delivery. The risk of MVT exists across the whole of pregnancy and postpartum period rather than being confined to peripartum period. However, the risk of major haemorrhage is concentrated in the relatively short period of time around delivery. We also recommend that individuals with MHV should start VKAs from 5 to 7 days following delivery, overlapping with LMWH until therapeutic INR achieved.\n\n【12】Anecdotal experience suggests a higher bleeding risk with earlier reintroduction of VKAs. Registries collecting data on pregnancy outcomes of individuals with MHV should ideally have a standardised definition of bleeding.\n\n【13】## Anaesthetic Considerations\n\n【14】\n## Labour Analgesia\n\n【15】\n Patients with MHVs should be reviewed by an obstetric anaesthetist before 28 weeks (as preterm delivery rates are high) in a dedicated anaesthetic clinic. 60 This allows a detailed discussion on the options of the analgesic and the anaesthetic components of peripartum care.\n\n【16】For labour, non-neuraxial pharmacological analgesics that can be considered include simple oral analgesia (e.g.\n\n【17】paracetamol, dihydrocodeine), a 50:50 mixture of nitrous oxide and oxygen, and parenteral opioids such as diamorphine or IV patient-controlled analgesia (PCA) using fentanyl or remifentanil. The advantage of non-neuraxial analgesic regimens in this cohort is that they are not dependent on cessation of anticoagulation. These are commonly utilised when a patient with MHV on therapeutic anticoagulation with LMWH presents in spontaneous labour.\n\n【18】The neuraxial labour analgesia regimens include the following: epidural, spinal, combined spinal–epidural or a dural puncture epidural. These provide superior analgesia compared to non-neuraxial techniques. Interventions using an epidural catheter have the advantage of extending the analgesia to anaesthesia in case of an emergent caesarean birth.\n\n【19】Their disadvantage includes the need to cease anticoagulation at specific time intervals before they can be utilised.\n\n【20】Also, specific time intervals need to elapse before anticoagulation can be recommenced.\n\n【21】 program of the program area will be seen to be seen to be a complex for any and the best programmed with any research on the content programme programme with the complex for ", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "10 BJHaem", "bbox": [58.0, 23.0, 164.0, 63.0]}], "type": "Section-header", "position": 1}, {"raw_context": [{"text": "Postpartum anticoagulation", "bbox": [58.0, 64.0, 252.0, 80.0]}], "type": "Section-header", "position": 2}, {"raw_context": [{"text": "There are no high-quality studies assessing the bleeding", "bbox": [58.0, 96.0, 387.0, 112.0]}, {"text": "risk versus the benefits of early therapeutic anticoagulation", "bbox": [58.0, 113.0, 387.0, 127.0]}, {"text": "post-delivery in individuals with MHV; however, there are", "bbox": [58.0, 128.0, 387.0, 143.0]}, {"text": "extensive data on these risks in the postoperative setting.", "bbox": [58.0, 145.0, 386.0, 159.0]}, {"text": "Therapeutic anticoagulation with heparins has been associ-", "bbox": [58.0, 160.0, 385.0, 175.0]}, {"text": "ated with a fivefold increase bleeding without reducing the", "bbox": [58.0, 177.0, 387.0, 192.0]}, {"text": "thrombosis risk. 51", "bbox": [58.0, 193.0, 154.0, 209.0]}, {"text": "Specifically, in patients with MHV, Passaglia et al. 51 con-", "bbox": [74.0, 209.0, 385.0, 225.0]}, {"text": "cluded that 'Early bridging therapy with LMWH appears to", "bbox": [58.0, 226.0, 387.0, 240.0]}, {"text": "be associated with consistently high bleeding rates across", "bbox": [58.0, 242.0, 387.0, 256.0]}, {"text": "multiple analyses'.", "bbox": [58.0, 258.0, 160.0, 273.0]}, {"text": "In the PERIOP2 study 52 including patients with", "bbox": [74.0, 272.0, 387.0, 288.0]}, {"text": "mechanical valve replacement ± AF, all received pre-", "bbox": [58.0, 289.0, 385.0, 305.0]}, {"text": "procedure therapeutic LMWH bridging but were ran-", "bbox": [58.0, 306.0, 385.0, 321.0]}, {"text": "domised to post-procedure escalation to therapeutic", "bbox": [58.0, 322.0, 387.0, 336.0]}, {"text": "LMWH after 48 h versus no post-op therapeutic LMWH.", "bbox": [58.0, 338.0, 386.0, 353.0]}, {"text": "There was no difference in bleeding; however, patients", "bbox": [58.0, 354.0, 387.0, 368.0]}, {"text": "considered at higher risk of bleeding only received pro-", "bbox": [58.0, 370.0, 385.0, 385.0]}, {"text": "phylactic LMWH post-procedure. No significant benefit", "bbox": [58.0, 386.0, 387.0, 401.0]}, {"text": "was found for postoperative dalteparin bridging to pre-", "bbox": [58.0, 402.0, 385.0, 416.0]}, {"text": "vent thromboembolism. Although pregnancy is associ-", "bbox": [58.0, 418.0, 385.0, 433.0]}, {"text": "ated with a pro-thrombotic state and significant risk of", "bbox": [58.0, 435.0, 387.0, 448.0]}, {"text": "valve thrombosis, the risk of thrombosis after pausing an-", "bbox": [58.0, 450.0, 385.0, 465.0]}, {"text": "ticoagulation over a brief period is likely to be low; how-", "bbox": [58.0, 466.0, 385.0, 481.0]}, {"text": "ever, the risk of bleeding is high in the peripartum period", "bbox": [58.0, 482.0, 387.0, 496.0]}, {"text": "and is likely to be exacerbated using very early postpar-", "bbox": [58.0, 498.0, 384.0, 513.0]}, {"text": "tum therapeutic anticoagulation.", "bbox": [58.0, 515.0, 246.0, 528.0]}, {"text": "The ESC guidance 7 recommends restarting UFH 4–6 h", "bbox": [74.0, 529.0, 386.0, 544.0]}, {"text": "after delivery if there are no bleeding complications and", "bbox": [58.0, 546.0, 386.0, 561.0]}, {"text": "NICE guidance NG121 53 recommends restarting therapeu-", "bbox": [58.0, 561.0, 385.0, 578.0]}, {"text": "tic LMWH or UFH 4–6h after birth. The Association of", "bbox": [58.0, 578.0, 387.0, 593.0]}, {"text": "Anaesthetists (AOA) guidelines 54 provide recommendations", "bbox": [58.0, 594.0, 387.0, 609.0]}, {"text": "on time intervals for commencing anticoagulation postpar-", "bbox": [58.0, 609.0, 385.0, 625.0]}, {"text": "tum but also recommend delaying introducing therapeutic", "bbox": [58.0, 626.0, 387.0, 642.0]}, {"text": "anticoagulation with LMWH for 24 h if a neuraxial block", "bbox": [58.0, 642.0, 387.0, 656.0]}, {"text": "was utilised during birth and was traumatic. There is no", "bbox": [58.0, 658.0, 387.0, 673.0]}, {"text": "supporting evidence for these recommendations in terms of", "bbox": [58.0, 675.0, 387.0, 689.0]}, {"text": "risk/benefit. The UKOSS study 5 confirmed the high risk of", "bbox": [58.0, 690.0, 387.0, 705.0]}, {"text": "haemorrhage for pregnant individuals with MHV who are", "bbox": [58.0, 706.0, 387.0, 721.0]}, {"text": "anticoagulated. Postpartum bleeding complications necessi-", "bbox": [58.0, 722.0, 385.0, 736.0]}, {"text": "tating return to theatre or transfusion occurred in 29%, and", "bbox": [58.0, 738.0, 387.0, 753.0]}, {"text": "in 40% of pregnant individuals delivered by CS. Most bleed-", "bbox": [58.0, 755.0, 385.0, 768.0]}, {"text": "ing complications occurred after 24 h in this observational", "bbox": [58.0, 770.0, 387.0, 784.0]}, {"text": "study. The reasons for this cannot be established from ob-", "bbox": [58.0, 786.0, 385.0, 801.0]}, {"text": "servational data alone but the use of aggressive peripartum", "bbox": [58.0, 803.0, 387.0, 816.0]}, {"text": "anticoagulation due to concerns over valve thrombosis may", "bbox": [58.0, 818.0, 386.0, 833.0]}, {"text": "be a factor.", "bbox": [58.0, 835.0, 120.0, 849.0]}, {"text": "We recommend timely recognition and management of", "bbox": [74.0, 849.0, 387.0, 865.0]}, {"text": "wound and intra-abdominal haematoma in this cohort as", "bbox": [58.0, 866.0, 387.0, 881.0]}, {"text": "their occurrence can lead to interruptions in therapeutic an-", "bbox": [58.0, 883.0, 385.0, 896.0]}, {"text": "ticoagulation. An MDT approach with low threshold for im-", "bbox": [58.0, 898.0, 385.0, 913.0]}, {"text": "aging (e.g. CT scan) and intervention (re-exploration) to rule", "bbox": [58.0, 915.0, 387.0, 929.0]}, {"text": "out surgical bleeding is recommended and any unexpected", "bbox": [58.0, 930.0, 387.0, 944.0]}, {"text": "fall in haemoglobin should be investigated quickly in view of", "bbox": [58.0, 946.0, 387.0, 961.0]}, {"text": "the intensity of anticoagulation postpartum.", "bbox": [58.0, 963.0, 301.0, 977.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "Table 3 summarises observational cohort data on the risk", "bbox": [423.0, 65.0, 734.0, 79.0]}, {"text": "of peripartum and PPH in pregnant individuals with MHVs.", "bbox": [406.0, 80.0, 733.0, 95.0]}, {"text": "Although there is no standardised definition of bleeding,", "bbox": [407.0, 97.0, 735.0, 112.0]}, {"text": "making any comparisons difficult, the risk of bleeding ap-", "bbox": [406.0, 113.0, 733.0, 127.0]}, {"text": "pears to be high.", "bbox": [406.0, 129.0, 499.0, 143.0]}, {"text": "Haemorrhagic complications associated with delivery in", "bbox": [422.0, 145.0, 735.0, 159.0]}, {"text": "pregnant individuals with MHV may result in a paradoxical", "bbox": [406.0, 160.0, 735.0, 175.0]}, {"text": "increase in thrombosis risk as anticoagulants have to be re-", "bbox": [406.0, 177.0, 733.0, 192.0]}, {"text": "versed/paused after major bleeding, including returns to the-", "bbox": [406.0, 194.0, 733.0, 207.0]}, {"text": "atre for haematoma along with the attendant risk of wound", "bbox": [406.0, 210.0, 735.0, 224.0]}, {"text": "infection and prolonged hospital stay. We therefore recom-", "bbox": [406.0, 226.0, 733.0, 240.0]}, {"text": "mend a more cautious re-introduction of anticoagulation in-", "bbox": [406.0, 242.0, 733.0, 256.0]}, {"text": "cluding a step-wise increase in the level of anticoagulation to", "bbox": [406.0, 258.0, 735.0, 273.0]}, {"text": "try and reduce these risks. We recommend prophylactic or", "bbox": [406.0, 274.0, 735.0, 288.0]}, {"text": "intermediate doses of LMWH for the first 24–48 h following", "bbox": [406.0, 288.0, 735.0, 306.0]}, {"text": "delivery. The risk of MVT exists across the whole of preg-", "bbox": [406.0, 306.0, 733.0, 321.0]}, {"text": "nancy and postpartum period rather than being confined", "bbox": [406.0, 322.0, 735.0, 336.0]}, {"text": "to peripartum period. However, the risk of major haemor-", "bbox": [406.0, 338.0, 733.0, 353.0]}, {"text": "rhage is concentrated in the relatively short period of time", "bbox": [406.0, 354.0, 735.0, 368.0]}, {"text": "around delivery. We also recommend that individuals with", "bbox": [406.0, 370.0, 735.0, 385.0]}, {"text": "MHV should start VKAs from 5 to 7 days following delivery,", "bbox": [406.0, 386.0, 735.0, 401.0]}, {"text": "overlapping with LMWH until therapeutic INR achieved.", "bbox": [406.0, 402.0, 734.0, 416.0]}, {"text": "Anecdotal experience suggests a higher bleeding risk with", "bbox": [407.0, 418.0, 735.0, 433.0]}, {"text": "earlier reintroduction of VKAs. Registries collecting data on", "bbox": [406.0, 435.0, 735.0, 448.0]}, {"text": "pregnancy outcomes of individuals with MHV should ide-", "bbox": [406.0, 449.0, 733.0, 465.0]}, {"text": "ally have a standardised definition of bleeding.", "bbox": [406.0, 466.0, 662.0, 481.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": "ANAESTHETIC CONSIDERATIONS", "bbox": [408.0, 511.0, 705.0, 530.0]}], "type": "Section-header", "position": 5}, {"raw_context": [{"text": "Labour analgesia", "bbox": [406.0, 545.0, 524.0, 561.0]}], "type": "Section-header", "position": 6}, {"raw_context": [{"text": "Patients with MHVs should be reviewed by an obstetric", "bbox": [406.0, 577.0, 735.0, 593.0]}, {"text": "anaesthetist before 28 weeks (as preterm delivery rates are", "bbox": [406.0, 594.0, 735.0, 608.0]}, {"text": "high) in a dedicated anaesthetic clinic. 60 This allows a de-", "bbox": [406.0, 609.0, 733.0, 624.0]}, {"text": "tailed discussion on the options of the analgesic and the an-", "bbox": [406.0, 626.0, 733.0, 641.0]}, {"text": "aesthetic components of peripartum care.", "bbox": [406.0, 642.0, 633.0, 656.0]}, {"text": "For labour, non-neuraxial pharmacological analgesics", "bbox": [422.0, 658.0, 735.0, 673.0]}, {"text": "that can be considered include simple oral analgesia (e.g.", "bbox": [406.0, 674.0, 734.0, 689.0]}, {"text": "paracetamol, dihydrocodeine), a 50:50 mixture of nitrous", "bbox": [406.0, 690.0, 735.0, 704.0]}, {"text": "oxide and oxygen, and parenteral opioids such as diamor-", "bbox": [406.0, 706.0, 733.0, 721.0]}, {"text": "phine or IV patient-controlled analgesia (PCA) using fen-", "bbox": [406.0, 722.0, 734.0, 736.0]}, {"text": "tanyl or remifentanil. The advantage of non-neuraxial", "bbox": [406.0, 738.0, 735.0, 753.0]}, {"text": "analgesic regimens in this cohort is that they are not depen-", "bbox": [406.0, 755.0, 733.0, 768.0]}, {"text": "dent on cessation of anticoagulation. These are commonly", "bbox": [406.0, 769.0, 734.0, 784.0]}, {"text": "utilised when a patient with MHV on therapeutic anticoag-", "bbox": [406.0, 786.0, 733.0, 801.0]}, {"text": "ulation with LMWH presents in spontaneous labour.", "bbox": [406.0, 803.0, 696.0, 816.0]}, {"text": "The neuraxial labour analgesia regimens include the", "bbox": [423.0, 818.0, 735.0, 833.0]}, {"text": "following: epidural, spinal, combined spinal–epidural or a", "bbox": [406.0, 835.0, 735.0, 849.0]}, {"text": "dural puncture epidural. These provide superior analgesia", "bbox": [406.0, 850.0, 735.0, 864.0]}, {"text": "compared to non-neuraxial techniques. Interventions using", "bbox": [406.0, 866.0, 735.0, 881.0]}, {"text": "an epidural catheter have the advantage of extending the an-", "bbox": [406.0, 883.0, 733.0, 896.0]}, {"text": "algesia to anaesthesia in case of an emergent caesarean birth.", "bbox": [406.0, 898.0, 735.0, 913.0]}, {"text": "Their disadvantage includes the need to cease anticoagu-", "bbox": [406.0, 915.0, 733.0, 928.0]}, {"text": "lation at specific time intervals before they can be utilised.", "bbox": [406.0, 930.0, 734.0, 944.0]}, {"text": "Also, specific time intervals need to elapse before anticoagu-", "bbox": [407.0, 946.0, 733.0, 961.0]}, {"text": "lation can be recommenced.", "bbox": [406.0, 963.0, 561.0, 977.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "program of the program area will be seen to be seen to be a complex for any and the best programmed with any research on the content programme programme with the complex for ", "bbox": [768.0, 26.0, 782.0, 962.0]}], "type": "Text", "position": 8}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/心血管/指南/2023 BSH 指南：机械心脏瓣膜妊娠个体抗凝管理(1).pdf", "page_num": 10}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "缺少换行#4#4#Specifically, in patients with MHV另起一行\n多余换行#16#17#simple oral analgesia (e.g.和paracetamol, dihydrocodeine), 是一句话", "type3": "无关文本#1#1#10 Bjhaem页眉内容\n无关文本#0#58#thrombosis risk. 51 部分段落末尾，以及句末的数字问题无关噪声应用全文\n无关文本#21#21#program of the program area....与正文无关", "type4": null, "type5": null, "type6": null}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:40", "update_time": "2024-05-07 23:18:53"}
{"id": 1082506, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 738, "source_info": {"seq_id": "1c1fdb14-5554-4084-b676-bc911d304924", "title": null, "text": "【0】页码:5\n 18 F-fluorodeoxyglucose (FDG) PET is performed for staging purposes, to identify metabolically active liver disease and to rule out prognostically relevant extrahepatic disease. Moreover, metabolic response can be seen 4–6 weeks after radioembolization, whereas response at cross-sectional anatomic.\n\n【1】imaging may take longer (e.g. 2–3 months) [ 35 , 36 ]. Both preand early post-therapeutic FDG-PET have shown potential to stratify patients with regard to OS and PFS [ 37 – 40 ]. Pre-therapeutic hepatobiliary scintigraphy (e.g. using 99m Tc-mebrofenin) may be considered, particularly in patients scheduled for partial liver treatment, to measure segmental distribution of liver function and quantify functional liver remnants [ 41 ].\n\n【2】There is consensus that radioembolization is generally only indicated in scenarios with no or very limited extrahepatic spread; however, different definitions of limited extrahepatic spread have been employed [ 30 , 42 – 46 ]. In an analysis of over 1000 patients with primary and metastatic liver neoplasms prospectively included in the observational study 'CIRSE Registry for SIR-Spheres® Therapy (CIRT)', low overall survival (OS) was mainly associated with extrahepatic disease extent [ 46 ]. In HCC, a sub-analysis of the SORAMIC trial study cohort did not show a negative impact of limited extrahepatic spread, which was defined as involvement of lymph nodes, bones and/or adrenal glands [ 47 ]. In mCRC, up to five pulmonary nodules and either lymph nodes belonging to one region [ 30 ] or one additional metastatic site amenable to future definitive trèatment [ 43 ] have been employed as thresholds for limited extrahepatic spread and may be used for reference.\n\n【3】In patients with ICC, lymph node metastases have not shown any negative impact on OS and may therefore not be viewed as exclusion criteria [ 48 ]. In the presence of solid organ metastases, caution is warranted, and treatment should be decided on a case-by-case basis depending on whether the intra- or extrahepatic tumour spread is considered life-limiting.\n\n【4】## Peri-Procedural Imaging\n\n【5】\n Peri-procedural angiography, performed by high-speed multislice CT (angio-CT), cone-beam CT, or digital subtraction angiography, is valuable for procedure planning, in order (1) to assess the hepatic vascular anatomy, (2) to verify the presence or absence of portal venous thrombosis in the portal venous phase, and the possible presence of major arteriovenous malformations or aberrant vasculature, (3) to assess perfused volumes and tumour targeting, (4) to assess intrahepatic interval progression and potential new lesions, and (5) to assess extrahepatic contrast enhancement, precluding safe administration of radioactive microspheres.\n\n【6】99mTc-MAA scintigraphy / 166Ho-microspheres scout dose9 9mTc-MAA is a surrogate for the estimated activity distribution of 90Y- and 166Ho-microspheres. Intrinsic differences in size and rheological properties between MAA [ 49 ] and microspheres, together with the operator\n\n【7】 dependent positioning of the catheter tip in the therapeutic session, are responsible for documented major variations in a minority of patients between MAA predicted and actual therapeutic distribution [ 50 ]. Scintigraphy should be performed as soon as possible (preferably within one hour) after administration because of the degradation of 99mTc- MAA (timing of preparation is of less importance); 99mTchuman serum albumin is more resistant to degradation, but also less available [ 51 ]. A total of approximately 150 MBq of 99mTc-MAA is administered into the respective branch (or branches) of the hepatic artery.\n\n【8】Planar imaging is used for the first liver-lung shunt calculation. The estimate without attenuation correction gives' a large overestimation in comparison with attenuation-corrected evaluations [ 12 , 52 ]. Scatter correction could also be important, especially for the right lung, strongly influenced by liver photon emission. However, since tolerance doses for the lungs were empirically established using planar imaging, lung doses must be primarily calculated with this approach [53 – 55] . For more accurate calculation, an attenuation and scatter corrected tomographic SPECT/CT covering lung is suggested in cases of substantial lung shunt fraction (> 10%), both pre- and post-treatment.\n\n【9】In the case of multifocal HCC, liver-lung shunting may be assessed before each treatment at the lobar level, because tumours located in different lobes may shunt to varying degrees. The lung shunt fraction is determined by the following equation:\n\n【10】## Lung Counts Lung Shunt Fraction = 7 Lung + Liver Counts\n\n【11】\n SPECT (or SPECT/CT) centred on the upper abdomen is advised for the assessment of gastrointestinal shunting, 3 appreciation of tumour targeting and better visualization.\n\n【12】Moreover, obtained images allow for dosimetric evaluation.\n\n【13】Pre-treatment 99 m Tc-MAA targeting predicts the 90 Y absorbed dose to the non-tumour and (less accurately) to the tumour tissue [ 56 , 57 ]. It can be used for personalized dosimetry and treatment planning, even if some reports have 7 shown poor prediction of post-treatment 90 Y-microsphere distribution by 99 m Tc-MAA [ 58 – 60 ].\n\n【14】Indeed, many studies have demonstrated a clear dose–response relationship based on 99 m Tc-MAA dosimetry a least for HCC using both glass [ 61 – 64 ] or resin microspheres [ 65 , 66 ].\n\n【15】Most importantly, level 1 evidence of the clinical impact of 99 m Tc-MAA planning based on personalized dosimetry\n Oral administration of sodium perchlorate before the MAA injection can be considered to prevent physiological uptake of free 99m pertechnetate in the stomach that can be mistaken for visceral shunt-\n\n【16】 ing.", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "18 F-fluorodeoxyglucose (FDG) PET is performed for staging", "bbox": [66.0, 72.0, 387.0, 90.0]}, {"text": "purposes, to identify metabolically active liver disease and to", "bbox": [65.0, 91.0, 387.0, 105.0]}, {"text": "rule out prognostically relevant extrahepatic disease. Moreo-", "bbox": [65.0, 107.0, 385.0, 122.0]}, {"text": "ver, metabolic response can be seen 4–6 weeks after radi-", "bbox": [66.0, 123.0, 385.0, 138.0]}, {"text": "oembolization, whereas response at cross-sectional anatomic.", "bbox": [66.0, 140.0, 387.0, 155.0]}, {"text": "imaging may take longer (e.g. 2–3 months) [ 35 , 36 ]. Both pre-", "bbox": [66.0, 158.0, 386.0, 171.0]}, {"text": "and early post-therapeutic FDG-PET have shown potential to", "bbox": [66.0, 174.0, 387.0, 189.0]}, {"text": "stratify patients with regard to OS and PFS [ 37 – 40 ]. Pre-ther-", "bbox": [66.0, 190.0, 385.0, 205.0]}, {"text": "apeutic hepatobiliary scintigraphy (e.g. using 99m Tc-mebro-", "bbox": [66.0, 207.0, 385.0, 221.0]}, {"text": "fenin) may be considered, particularly in patients scheduled", "bbox": [66.0, 225.0, 387.0, 238.0]}, {"text": "for partial liver treatment, to measure segmental distribution", "bbox": [66.0, 240.0, 387.0, 255.0]}, {"text": "of liver function and quantify functional liver remnants [ 41 ].", "bbox": [65.0, 257.0, 385.0, 272.0]}, {"text": "There is consensus that radioembolization is generally only", "bbox": [79.0, 274.0, 387.0, 288.0]}, {"text": "indicated in scenarios with no or very limited extrahepatic", "bbox": [66.0, 291.0, 387.0, 305.0]}, {"text": "spread; however, different definitions of limited extrahepatic", "bbox": [66.0, 307.0, 387.0, 322.0]}, {"text": "spread have been employed [ 30 , 42 – 46 ]. In an analysis of over", "bbox": [66.0, 324.0, 387.0, 339.0]}, {"text": "1000 patients with primary and metastatic liver neoplasms", "bbox": [66.0, 341.0, 387.0, 355.0]}, {"text": "prospectively included in the observational study 'CIRSE", "bbox": [66.0, 357.0, 387.0, 371.0]}, {"text": "Registry for SIR-Spheres® Therapy (CIRT)', low overall", "bbox": [66.0, 374.0, 387.0, 388.0]}, {"text": "survival (OS) was mainly associated with extrahepatic disease", "bbox": [66.0, 391.0, 387.0, 406.0]}, {"text": "extent [ 46 ]. In HCC, a sub-analysis of the SORAMIC trial study", "bbox": [66.0, 407.0, 386.0, 422.0]}, {"text": "cohort did not show a negative impact of limited extrahepatic", "bbox": [65.0, 424.0, 387.0, 438.0]}, {"text": "spread, which was defined as involvement of lymph nodes, bones", "bbox": [66.0, 441.0, 387.0, 455.0]}, {"text": "and/or adrenal glands [ 47 ]. In mCRC, up to five pulmonary", "bbox": [66.0, 455.0, 385.0, 473.0]}, {"text": "nodules and either lymph nodes belonging to one region [ 30 ]", "bbox": [66.0, 474.0, 387.0, 488.0]}, {"text": "or one additional metastatic site amenable to future definitive", "bbox": [64.0, 491.0, 387.0, 505.0]}, {"text": "trèatment [ 43 ] have been employed as thresholds for limited", "bbox": [65.0, 508.0, 387.0, 522.0]}, {"text": "extrahepatic spread and may be used for reference.", "bbox": [65.0, 523.0, 323.0, 538.0]}, {"text": "In patients with ICC, lymph node metastases have not", "bbox": [80.0, 540.0, 387.0, 556.0]}, {"text": "shown any negative impact on OS and may therefore not be", "bbox": [66.0, 558.0, 387.0, 572.0]}, {"text": "viewed as exclusion criteria [ 48 ]. In the presence of solid", "bbox": [66.0, 574.0, 387.0, 589.0]}, {"text": "organ metastases, caution is warranted, and treatment should", "bbox": [66.0, 590.0, 388.0, 605.0]}, {"text": "be decided on a case-by-case basis depending on whether the", "bbox": [66.0, 608.0, 388.0, 621.0]}, {"text": "intra- or extrahepatic tumour spread is considered life-limiting.", "bbox": [66.0, 624.0, 385.0, 639.0]}], "type": "Text", "position": 1}, {"raw_context": [{"text": "Peri-procedural imaging", "bbox": [65.0, 656.0, 217.0, 671.0]}], "type": "Section-header", "position": 2}, {"raw_context": [{"text": "Peri-procedural angiography, performed by high-speed mul-", "bbox": [65.0, 691.0, 385.0, 705.0]}, {"text": "tislice CT (angio-CT), cone-beam CT, or digital subtraction", "bbox": [65.0, 707.0, 387.0, 722.0]}, {"text": "angiography, is valuable for procedure planning, in order (1)", "bbox": [66.0, 724.0, 387.0, 739.0]}, {"text": "to assess the hepatic vascular anatomy, (2) to verify the pres-", "bbox": [64.0, 742.0, 385.0, 755.0]}, {"text": "ence or absence of portal venous thrombosis in the portal", "bbox": [66.0, 758.0, 387.0, 772.0]}, {"text": "venous phase, and the possible presence of major arterio-", "bbox": [66.0, 774.0, 385.0, 789.0]}, {"text": "venous malformations or aberrant vasculature, (3) to assess", "bbox": [66.0, 791.0, 387.0, 805.0]}, {"text": "perfused volumes and tumour targeting, (4) to assess intra-", "bbox": [66.0, 808.0, 385.0, 822.0]}, {"text": "hepatic interval progression and potential new lesions, and", "bbox": [65.0, 824.0, 387.0, 839.0]}, {"text": "(5) to assess extrahepatic contrast enhancement, precluding", "bbox": [64.0, 841.0, 387.0, 856.0]}, {"text": "safe administration of radioactive microspheres.", "bbox": [66.0, 858.0, 326.0, 873.0]}, {"text": "99mTc-MAA scintigraphy / 166Ho-microspheres scout dose9", "bbox": [80.0, 874.0, 387.0, 888.0]}, {"text": "9mTc-MAA is a surrogate for the estimated activity", "bbox": [80.0, 891.0, 387.0, 905.0]}, {"text": "distribution of 90Y- and 166Ho-microspheres. Intrinsic", "bbox": [64.0, 908.0, 387.0, 923.0]}, {"text": "differences in size and rheological properties between", "bbox": [64.0, 924.0, 387.0, 938.0]}, {"text": "MAA [ 49 ] and microspheres, together with the operator", "bbox": [65.0, 941.0, 387.0, 955.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "dependent positioning of the catheter tip in the therapeutic", "bbox": [405.0, 73.0, 726.0, 88.0]}, {"text": "session, are responsible for documented major variations", "bbox": [406.0, 91.0, 727.0, 105.0]}, {"text": "in a minority of patients between MAA predicted and", "bbox": [406.0, 108.0, 727.0, 122.0]}, {"text": "actual therapeutic distribution [ 50 ]. Scintigraphy should be", "bbox": [406.0, 123.0, 727.0, 138.0]}, {"text": "performed as soon as possible (preferably within one hour)", "bbox": [406.0, 140.0, 727.0, 155.0]}, {"text": "after administration because of the degradation of 99mTc-", "bbox": [406.0, 158.0, 726.0, 171.0]}, {"text": "MAA (timing of preparation is of less importance); 99mTc-", "bbox": [406.0, 174.0, 726.0, 189.0]}, {"text": "human serum albumin is more resistant to degradation, but", "bbox": [405.0, 190.0, 727.0, 205.0]}, {"text": "also less available [ 51 ]. A total of approximately 150 MBq", "bbox": [406.0, 207.0, 727.0, 222.0]}, {"text": "of 99mTc-MAA is administered into the respective branch", "bbox": [406.0, 225.0, 727.0, 238.0]}, {"text": "(or branches) of the hepatic artery.", "bbox": [405.0, 241.0, 596.0, 255.0]}, {"text": "Planar imaging is used for the first liver-lung shunt cal-", "bbox": [421.0, 257.0, 728.0, 272.0]}, {"text": "culation. The estimate without attenuation correction gives'", "bbox": [405.0, 274.0, 728.0, 288.0]}, {"text": "a large overestimation in comparison with attenuation-cor-", "bbox": [405.0, 291.0, 726.0, 305.0]}, {"text": "rected evaluations [ 12 , 52 ]. Scatter correction could also be", "bbox": [405.0, 307.0, 727.0, 322.0]}, {"text": "important, especially for the right lung, strongly influenced", "bbox": [405.0, 324.0, 727.0, 339.0]}, {"text": "by liver photon emission. However, since tolerance doses for", "bbox": [405.0, 341.0, 727.0, 355.0]}, {"text": "the lungs were empirically established using planar imaging,", "bbox": [405.0, 357.0, 727.0, 371.0]}, {"text": "lung doses must be primarily calculated with this approach", "bbox": [405.0, 374.0, 727.0, 388.0]}, {"text": "[53 – 55] . For more accurate calculation, an attenuation and", "bbox": [405.0, 391.0, 728.0, 406.0]}, {"text": "scatter corrected tomographic SPECT/CT covering lung", "bbox": [406.0, 407.0, 727.0, 422.0]}, {"text": "is suggested in cases of substantial lung shunt fraction (>", "bbox": [405.0, 424.0, 726.0, 438.0]}, {"text": "10%), both pre- and post-treatment.", "bbox": [407.0, 441.0, 598.0, 455.0]}, {"text": "In the case of multifocal HCC, liver-lung shunting may", "bbox": [421.0, 458.0, 726.0, 472.0]}, {"text": "be assessed before each treatment at the lobar level, because", "bbox": [405.0, 474.0, 726.0, 488.0]}, {"text": "tumours located in different lobes may shunt to varying", "bbox": [405.0, 491.0, 726.0, 505.0]}, {"text": "degrees. The lung shunt fraction is determined by the fol-", "bbox": [405.0, 507.0, 725.0, 522.0]}, {"text": "lowing equation:", "bbox": [406.0, 523.0, 499.0, 538.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": "lung counts", "bbox": [549.0, 552.0, 614.0, 565.0]}, {"text": "Lung shunt fraction = 7", "bbox": [405.0, 559.0, 535.0, 574.0]}, {"text": "lung + liver counts", "bbox": [529.0, 567.0, 633.0, 582.0]}], "type": "Section-header", "position": 5}, {"raw_context": [{"text": "SPECT (or SPECT/CT) centred on the upper abdomen", "bbox": [420.0, 595.0, 727.0, 611.0]}, {"text": "is advised for the assessment of gastrointestinal shunting, 3", "bbox": [405.0, 613.0, 725.0, 627.0]}, {"text": "appreciation of tumour targeting and better visualization.", "bbox": [405.0, 630.0, 726.0, 644.0]}, {"text": "Moreover, obtained images allow for dosimetric evaluation.", "bbox": [405.0, 647.0, 726.0, 661.0]}, {"text": "Pre-treatment 99 m Tc-MAA targeting predicts the 90 Y", "bbox": [421.0, 662.0, 725.0, 677.0]}, {"text": "absorbed dose to the non-tumour and (less accurately) to", "bbox": [405.0, 679.0, 728.0, 694.0]}, {"text": "the tumour tissue [ 56 , 57 ]. It can be used for personalized", "bbox": [405.0, 696.0, 727.0, 711.0]}, {"text": "dosimetry and treatment planning, even if some reports have 7", "bbox": [406.0, 713.0, 731.0, 727.0]}, {"text": "shown poor prediction of post-treatment 90 Y-microsphere", "bbox": [405.0, 728.0, 727.0, 744.0]}, {"text": "distribution by 99 m Tc-MAA [ 58 – 60 ].", "bbox": [405.0, 745.0, 605.0, 761.0]}, {"text": "Indeed, many studies have demonstrated a clear", "bbox": [421.0, 763.0, 727.0, 778.0]}, {"text": "dose–response relationship based on 99 m Tc-MAA dosimetry", "bbox": [405.0, 778.0, 726.0, 793.0]}, {"text": "a least for HCC using both glass [ 61 – 64 ] or resin micro-", "bbox": [405.0, 796.0, 726.0, 811.0]}, {"text": "spheres [ 65 , 66 ].", "bbox": [406.0, 813.0, 498.0, 828.0]}, {"text": "Most importantly, level 1 evidence of the clinical impact", "bbox": [421.0, 829.0, 727.0, 844.0]}, {"text": "of 99 m Tc-MAA planning based on personalized dosimetry", "bbox": [405.0, 845.0, 726.0, 862.0]}], "type": "Text", "position": 6}, {"raw_context": [{"text": "Oral administration of sodium perchlorate before the MAA injec-", "bbox": [413.0, 904.0, 724.0, 916.0]}, {"text": "tion can be considered to prevent physiological uptake of free 99m", "bbox": [406.0, 918.0, 710.0, 931.0]}, {"text": "pertechnetate in the stomach that can be mistaken for visceral shunt-", "bbox": [406.0, 932.0, 724.0, 944.0]}], "type": "Footnote", "position": 7}, {"raw_context": [{"text": "ing.", "bbox": [406.0, 946.0, 424.0, 958.0]}], "type": "Text", "position": 8}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2022】全科室最全临床指南+专家共识（最全版）/2022全科室临床指南/肿瘤科/EANM：动脉内放射性化合物治疗肝癌和转移性肝癌指南（2022）(1).pdf", "page_num": 5}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "多余换行#0#1#为同段内容\n多余换行#6#7#为同段内容\n公式格式错误#10#10#识别错误", "type3": null, "type4": null, "type5": null, "type6": "信息有用性#15#15#无用内容"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:40", "update_time": "2024-05-07 18:15:06"}
{"id": 1082505, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 738, "source_info": {"seq_id": "91daaf59-5e36-47ae-a308-781a8296729b", "title": null, "text": "【0】页码:5\n\n【1】 Comparison of ABCD 2 , ABCD 3 , and ABCD 3 -I Scores Table 3.\n\n【2】ABCD 2 ABCD 2 ABCD 2 -1 ABCD 2 -1 (d, Components score score score c/i) score Risk factor Age ≥60 y 1 1 1 1 Blood pressure ≥140/90 mmHg 1 1 i Diabetes 1 1 1 Clinical features Unilateral weakness 2.2 2 2 2 Language disturbance without weakness 1 1 1 Symptom duration, min 260 2 2 2 2 10–59 1 1 1 1 <10 o o o o N/A N/A >10 o 10.0 Dual transient ischemic attack N/A 2 2 2 Imaging Ipsilateral ≥50% stenosis of internal carotid artery N/A N/A 2 N/A lpsilateral ≥50% stenosis of internal carotid artery and N/A N/A N/A 2.2 major cerebral artery Acute diffusion-weighted imaging hyperintensity N/A N/A 2.2 2.2 Total points 10–7 0–9 0–13 0–13 ABCD 2 score 90-d risk (96) 2-d risk (%) 7-d risk (%) Low (0–3) 1.0 1.2 3.1 Moderate (4–5) 5.9 9.8 4.1 High (6–7) 8.1 11.7 17.8 ABCD 5 indicates age/ blood pressure/ clinical features of transient ischemic attack/ duration/ diabetes score; ABCD 5 , ABCD 5 plus Dual TIA; c, carotid stenosis; d, diffusion-weighted image; l, imaging; i, intracranial stenosis; and N/A, not applicable.\n\n【3】\n S TN 3M 3TATS  TVO IN IT D\n\n【4】 INITIOIN9\n\n【5】 '9 AmnidaH no Aq ano stemnolede// diid mort babaolawork\n\n【6】 clinical features and medical history (Table 3). 5,32 ABCD 2 has also been used for clinical trial enrollment 35,36 and may be helpful in identifying patients with true TIA versus mimics. 37 A meta-analysis of 33 studies and just over 16000 patients found that the ABCD 2 had high sensitivity but low specificity when stratifying high risk (score of 6–7) versus low risk (score of 0–3) patients; at 7 days after TIA, the high-risk group had a recurrent stroke risk of 7% versus 2.1% in the low-risk group. 38 It is important, however, to note the limitations of the ABCD 2 score. First, it does not include symptoms that might suggest a \"posterior circulation\" process, such as dysmetria, ataxia, or homonymous hemianopia. It also does not account for TIA mechanism or the presence of ipsilateral large artery stenosis on imaging, and therefore should be part of a more comprehensive assessment. 38 Large artery disease (eg, unstable or severe carotid atherosclerosis, intracranial atherosclerosis, cervical artery dissection, or carotid web) or AF may further increase the risk of recurrent stroke or neurological worsening beyond that of a traditional risk-scoring score. 39 Performing acute phase vessel imaging in the ED is important regardless of ABCD 2 score because it can guide immediate management. 10,40,41 For example, in\n\n【7】 patients with presumed symptomatic cervical or intracra¬ nial stenosis, more frequent neurological checks, stricter blood pressure parameters to avoid hypotension, dual antiplatelet therapy, and early consultation of surgical specialties could all be considered, potentially preventing early recurrence of symptoms.\n\n【8】TIA scores have evolved to incorporate radiographic data and a history of dual (≥2 episodes of TIA symptoms within the past 7 days) TIA to better identify high-risk patients. In the ABCD 3 system, new or old infarction on MRI or CT imaging was independently associated with recurrent stroke risk and increased predictive value. 42 ABCD 3 -I incorporates dual TIA, MRI findings, and carotid stenosis, and ABCD 3 -I (d, c/i) incorporates intracranial stenosis. 41 -43 Dual TIA and crescendo TIA 44 (recurrent, transient, events characterized by increasing duration, frequency, or severity) are high-risk clinical features that may warrant admission. Crescendo TIAs specifically may suggest the presence of ipsilateral carotid stenosis.\n\n【9】## Considerations For Clinical Practice\n\n【10】\n TIA risk stratification scales aid in the identification of high-risk patients and help guide disposition.", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "Comparison of ABCD 2 , ABCD 3 , and ABCD 3 -I Scores", "bbox": [161.0, 76.0, 424.0, 90.0]}, {"text": "Table 3.", "bbox": [115.0, 78.0, 156.0, 89.0]}, {"text": "ABCD 2", "bbox": [412.0, 100.0, 443.0, 112.0]}, {"text": "ABCD 2", "bbox": [477.0, 100.0, 509.0, 112.0]}, {"text": "ABCD 2 -1", "bbox": [543.0, 100.0, 581.0, 112.0]}, {"text": "ABCD 2 -1 (d,", "bbox": [609.0, 100.0, 660.0, 112.0]}, {"text": "Components", "bbox": [118.0, 113.0, 178.0, 124.0]}, {"text": "score", "bbox": [412.0, 113.0, 440.0, 124.0]}, {"text": "score", "bbox": [477.0, 113.0, 505.0, 124.0]}, {"text": "score", "bbox": [542.0, 113.0, 570.0, 123.0]}, {"text": "c/i) score", "bbox": [607.0, 113.0, 654.0, 125.0]}, {"text": "Risk factor", "bbox": [118.0, 130.0, 162.0, 141.0]}, {"text": "Age ≥60 y", "bbox": [128.0, 147.0, 172.0, 159.0]}, {"text": "1", "bbox": [477.0, 148.0, 485.0, 159.0]}, {"text": "1", "bbox": [542.0, 148.0, 551.0, 159.0]}, {"text": "1", "bbox": [412.0, 149.0, 419.0, 158.0]}, {"text": "1", "bbox": [608.0, 149.0, 614.0, 158.0]}, {"text": "Blood pressure ≥140/90 mmHg", "bbox": [128.0, 165.0, 260.0, 177.0]}, {"text": "1", "bbox": [477.0, 167.0, 484.0, 176.0]}, {"text": "1", "bbox": [542.0, 167.0, 550.0, 176.0]}, {"text": "i", "bbox": [609.0, 167.0, 614.0, 175.0]}, {"text": "Diabetes", "bbox": [118.0, 183.0, 156.0, 194.0]}, {"text": "1", "bbox": [477.0, 185.0, 484.0, 194.0]}, {"text": "1", "bbox": [542.0, 185.0, 550.0, 194.0]}, {"text": "1", "bbox": [608.0, 186.0, 614.0, 194.0]}, {"text": "Clinical features", "bbox": [128.0, 200.0, 193.0, 212.0]}, {"text": "Unilateral weakness", "bbox": [128.0, 220.0, 208.0, 231.0]}, {"text": "2.2", "bbox": [412.0, 220.0, 419.0, 229.0]}, {"text": "2", "bbox": [477.0, 220.0, 485.0, 230.0]}, {"text": "2", "bbox": [542.0, 220.0, 551.0, 230.0]}, {"text": "2", "bbox": [608.0, 220.0, 616.0, 229.0]}, {"text": "Language disturbance without weakness", "bbox": [128.0, 237.0, 291.0, 248.0]}, {"text": "1", "bbox": [477.0, 238.0, 485.0, 247.0]}, {"text": "1", "bbox": [542.0, 238.0, 550.0, 247.0]}, {"text": "1", "bbox": [609.0, 238.0, 615.0, 247.0]}, {"text": "Symptom duration, min", "bbox": [118.0, 254.0, 213.0, 266.0]}, {"text": "260", "bbox": [128.0, 272.0, 148.0, 283.0]}, {"text": "2", "bbox": [412.0, 273.0, 420.0, 283.0]}, {"text": "2", "bbox": [477.0, 273.0, 486.0, 283.0]}, {"text": "2", "bbox": [542.0, 272.0, 552.0, 283.0]}, {"text": "2", "bbox": [608.0, 272.0, 617.0, 283.0]}, {"text": "10–59", "bbox": [128.0, 289.0, 159.0, 301.0]}, {"text": "1", "bbox": [412.0, 290.0, 419.0, 300.0]}, {"text": "1", "bbox": [477.0, 290.0, 486.0, 301.0]}, {"text": "1", "bbox": [543.0, 290.0, 551.0, 301.0]}, {"text": "1", "bbox": [609.0, 290.0, 615.0, 300.0]}, {"text": "<10", "bbox": [128.0, 307.0, 147.0, 318.0]}, {"text": "o", "bbox": [412.0, 308.0, 420.0, 317.0]}, {"text": "o", "bbox": [477.0, 307.0, 486.0, 318.0]}, {"text": "o", "bbox": [542.0, 307.0, 552.0, 318.0]}, {"text": "o", "bbox": [607.0, 307.0, 617.0, 318.0]}, {"text": "N/A", "bbox": [412.0, 324.0, 430.0, 336.0]}, {"text": "N/A", "bbox": [477.0, 324.0, 495.0, 336.0]}, {"text": ">10", "bbox": [128.0, 325.0, 147.0, 336.0]}, {"text": "o", "bbox": [542.0, 325.0, 552.0, 336.0]}, {"text": "10.0", "bbox": [607.0, 325.0, 617.0, 335.0]}, {"text": "Dual transient ischemic attack", "bbox": [118.0, 342.0, 240.0, 354.0]}, {"text": "N/A", "bbox": [412.0, 342.0, 430.0, 354.0]}, {"text": "2", "bbox": [542.0, 343.0, 552.0, 355.0]}, {"text": "2", "bbox": [607.0, 343.0, 617.0, 354.0]}, {"text": "2", "bbox": [477.0, 345.0, 486.0, 355.0]}, {"text": "Imaging", "bbox": [119.0, 360.0, 152.0, 371.0]}, {"text": "Ipsilateral ≥50% stenosis of internal carotid artery", "bbox": [128.0, 376.0, 326.0, 390.0]}, {"text": "N/A", "bbox": [412.0, 377.0, 430.0, 389.0]}, {"text": "N/A", "bbox": [477.0, 377.0, 495.0, 389.0]}, {"text": "2", "bbox": [542.0, 378.0, 551.0, 388.0]}, {"text": "N/A", "bbox": [607.0, 377.0, 626.0, 388.0]}, {"text": "lpsilateral ≥50% stenosis of internal carotid artery and", "bbox": [128.0, 394.0, 343.0, 407.0]}, {"text": "N/A", "bbox": [412.0, 395.0, 430.0, 407.0]}, {"text": "N/A", "bbox": [477.0, 395.0, 495.0, 407.0]}, {"text": "N/A", "bbox": [542.0, 395.0, 561.0, 407.0]}, {"text": "2.2", "bbox": [609.0, 397.0, 616.0, 405.0]}, {"text": "major cerebral artery", "bbox": [129.0, 408.0, 211.0, 419.0]}, {"text": "Acute diffusion-weighted imaging hyperintensity", "bbox": [128.0, 425.0, 321.0, 436.0]}, {"text": "N/A", "bbox": [412.0, 425.0, 430.0, 436.0]}, {"text": "N/A", "bbox": [477.0, 425.0, 495.0, 436.0]}, {"text": "2.2", "bbox": [544.0, 426.0, 551.0, 436.0]}, {"text": "2.2", "bbox": [609.0, 426.0, 616.0, 435.0]}, {"text": "Total points", "bbox": [120.0, 442.0, 167.0, 455.0]}, {"text": "10–7", "bbox": [412.0, 442.0, 430.0, 454.0]}, {"text": "0–9", "bbox": [477.0, 442.0, 497.0, 454.0]}, {"text": "0–13", "bbox": [542.0, 442.0, 568.0, 455.0]}, {"text": "0–13", "bbox": [608.0, 442.0, 633.0, 455.0]}, {"text": "ABCD 2 score", "bbox": [120.0, 460.0, 176.0, 472.0]}, {"text": "90-d risk (96)", "bbox": [544.0, 460.0, 598.0, 472.0]}, {"text": "2-d risk (%)", "bbox": [412.0, 461.0, 461.0, 472.0]}, {"text": "7-d risk (%)", "bbox": [477.0, 461.0, 526.0, 472.0]}, {"text": "Low (0–3)", "bbox": [128.0, 477.0, 172.0, 489.0]}, {"text": "1.0", "bbox": [413.0, 478.0, 428.0, 489.0]}, {"text": "1.2", "bbox": [478.0, 478.0, 492.0, 489.0]}, {"text": "3.1", "bbox": [544.0, 478.0, 557.0, 488.0]}, {"text": "Moderate (4–5)", "bbox": [128.0, 495.0, 193.0, 507.0]}, {"text": "5.9", "bbox": [477.0, 495.0, 494.0, 507.0]}, {"text": "9.8", "bbox": [542.0, 495.0, 559.0, 507.0]}, {"text": "4.1", "bbox": [412.0, 496.0, 427.0, 507.0]}, {"text": "High (6–7)", "bbox": [128.0, 513.0, 174.0, 526.0]}, {"text": "8.1", "bbox": [412.0, 514.0, 427.0, 525.0]}, {"text": "11.7", "bbox": [477.0, 514.0, 498.0, 525.0]}, {"text": "17.8", "bbox": [544.0, 514.0, 562.0, 525.0]}, {"text": "ABCD 5 indicates age/ blood pressure/ clinical features of transient ischemic attack/ duration/ diabetes score; ABCD 5 , ABCD 5 plus Dual TIA;", "bbox": [124.0, 533.0, 664.0, 545.0]}, {"text": "c, carotid stenosis; d, diffusion-weighted image; l, imaging; i, intracranial stenosis; and N/A, not applicable.", "bbox": [113.0, 546.0, 523.0, 558.0]}], "type": "Table", "position": 2}, {"raw_context": [{"text": "S TN 3M 3TATS  TVO IN IT D", "bbox": [753.0, 88.0, 770.0, 205.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "INITIOIN9", "bbox": [737.0, 127.0, 756.0, 180.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": "'9 AmnidaH no Aq ano stemnolede// diid mort babaolawork", "bbox": [18.0, 535.0, 36.0, 780.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "clinical features and medical history (Table 3). 5,32 ABCD 2", "bbox": [63.0, 577.0, 376.0, 590.0]}, {"text": "has also been used for clinical trial enrollment 35,36 and", "bbox": [63.0, 593.0, 378.0, 607.0]}, {"text": "may be helpful in identifying patients with true TIA ver-", "bbox": [63.0, 608.0, 377.0, 623.0]}, {"text": "sus mimics. 37 A meta-analysis of 33 studies and just over", "bbox": [63.0, 625.0, 378.0, 639.0]}, {"text": "16000 patients found that the ABCD 2 had high sensitiv-", "bbox": [65.0, 641.0, 378.0, 655.0]}, {"text": "ity but low specificity when stratifying high risk (score of", "bbox": [63.0, 657.0, 379.0, 671.0]}, {"text": "6–7) versus low risk (score of 0–3) patients; at 7 days", "bbox": [63.0, 673.0, 378.0, 688.0]}, {"text": "after TIA, the high-risk group had a recurrent stroke risk", "bbox": [63.0, 689.0, 379.0, 703.0]}, {"text": "of 7% versus 2.1% in the low-risk group. 38", "bbox": [63.0, 705.0, 302.0, 719.0]}, {"text": "It is important, however, to note the limitations of the", "bbox": [78.0, 721.0, 379.0, 736.0]}, {"text": "ABCD 2 score. First, it does not include symptoms that", "bbox": [63.0, 737.0, 380.0, 751.0]}, {"text": "might suggest a \"posterior circulation\" process, such as", "bbox": [63.0, 753.0, 379.0, 768.0]}, {"text": "dysmetria, ataxia, or homonymous hemianopia. It also", "bbox": [63.0, 769.0, 380.0, 783.0]}, {"text": "does not account for TIA mechanism or the presence of", "bbox": [63.0, 785.0, 379.0, 799.0]}, {"text": "ipsilateral large artery stenosis on imaging, and therefore", "bbox": [63.0, 801.0, 379.0, 816.0]}, {"text": "should be part of a more comprehensive assessment. 38", "bbox": [63.0, 817.0, 378.0, 831.0]}, {"text": "Large artery disease (eg, unstable or severe carotid ath-", "bbox": [63.0, 833.0, 378.0, 847.0]}, {"text": "erosclerosis, intracranial atherosclerosis, cervical artery", "bbox": [63.0, 850.0, 378.0, 863.0]}, {"text": "dissection, or carotid web) or AF may further increase", "bbox": [63.0, 865.0, 379.0, 879.0]}, {"text": "the risk of recurrent stroke or neurological worsening", "bbox": [63.0, 881.0, 379.0, 896.0]}, {"text": "beyond that of a traditional risk-scoring score. 39", "bbox": [63.0, 897.0, 329.0, 910.0]}, {"text": "Performing acute phase vessel imaging in the ED is", "bbox": [79.0, 913.0, 379.0, 928.0]}, {"text": "important regardless of ABCD 2 score because it can", "bbox": [63.0, 929.0, 379.0, 943.0]}, {"text": "guide immediate management. 10,40,41 For example, in", "bbox": [63.0, 943.0, 380.0, 959.0]}], "type": "Text", "position": 6}, {"raw_context": [{"text": "patients with presumed symptomatic cervical or intracra¬", "bbox": [400.0, 577.0, 715.0, 591.0]}, {"text": "nial stenosis, more frequent neurological checks, stricter", "bbox": [399.0, 593.0, 715.0, 608.0]}, {"text": "blood pressure parameters to avoid hypotension, dual", "bbox": [399.0, 609.0, 716.0, 623.0]}, {"text": "antiplatelet therapy, and early consultation of surgical", "bbox": [400.0, 625.0, 715.0, 639.0]}, {"text": "specialties could all be considered, potentially preventing", "bbox": [400.0, 641.0, 716.0, 655.0]}, {"text": "early recurrence of symptoms.", "bbox": [399.0, 657.0, 570.0, 671.0]}, {"text": "TIA scores have evolved to incorporate radiographic", "bbox": [416.0, 673.0, 715.0, 688.0]}, {"text": "data and a history of dual (≥2 episodes of TIA symptoms", "bbox": [399.0, 689.0, 715.0, 703.0]}, {"text": "within the past 7 days) TIA to better identify high-risk", "bbox": [399.0, 705.0, 715.0, 719.0]}, {"text": "patients. In the ABCD 3 system, new or old infarction on", "bbox": [400.0, 721.0, 716.0, 736.0]}, {"text": "MRI or CT imaging was independently associated with", "bbox": [400.0, 737.0, 716.0, 751.0]}, {"text": "recurrent stroke risk and increased predictive value. 42", "bbox": [400.0, 753.0, 715.0, 767.0]}, {"text": "ABCD 3 -I incorporates dual TIA, MRI findings, and carotid", "bbox": [400.0, 769.0, 716.0, 783.0]}, {"text": "stenosis, and ABCD 3 -I (d, c/i) incorporates intracranial", "bbox": [399.0, 785.0, 715.0, 799.0]}, {"text": "stenosis. 41 -43 Dual TIA and crescendo TIA 44 (recurrent,", "bbox": [400.0, 800.0, 715.0, 816.0]}, {"text": "transient, events characterized by increasing duration,", "bbox": [399.0, 817.0, 715.0, 831.0]}, {"text": "frequency, or severity) are high-risk clinical features that", "bbox": [399.0, 833.0, 716.0, 848.0]}, {"text": "may warrant admission. Crescendo TIAs specifically may", "bbox": [399.0, 849.0, 715.0, 863.0]}, {"text": "suggest the presence of ipsilateral carotid stenosis.", "bbox": [399.0, 865.0, 687.0, 879.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "Considerations for Clinical Practice", "bbox": [400.0, 904.0, 632.0, 921.0]}], "type": "Section-header", "position": 8}, {"raw_context": [{"text": "TIA risk stratification scales aid in the identification", "bbox": [426.0, 929.0, 716.0, 943.0]}, {"text": "of high-risk patients and help guide disposition.", "bbox": [428.0, 945.0, 694.0, 959.0]}], "type": "Text", "position": 9}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/神经科/共识/2023 AHA科学声明：急诊科短暂性脑缺血发作的诊断、检查和风险降低(1).pdf", "page_num": 5}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type2": "缺少换行#6#6#It is important, however, to note ...\n Performing acute phase vessel...都应另起一行\n多余换行#7#7#patients with presumed symptomatic ...与上面6段最后联接", "type3": "无关文本#1#8#...enrollment 35,36 and may be ...\n...medical history (Table 3). 5,32像这样在.号或，号的开头或结尾出现的数字都是无关引用\n无关文本#3#5#侧面信息等无关内容", "type6": "准确性#2#2#表格的内容，但是内容顺序杂乱"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:40", "update_time": "2024-05-07 18:45:24"}
{"id": 1082504, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 738, "source_info": {"seq_id": "031e52b4-93d6-4d2c-bb35-49c37f4e54a6", "title": null, "text": "【0】页码:8\n\n【1】## Antithrombotics\n\n【2】\n Antithrombotic therapy is warranted in all patients with suspected TIA who have no known contraindications.\n\n【3】Antiplatelet therapy is recommended for stroke preven¬ tion in patients who do not have an indication for anticoagulation. 17 Short-term dual antiplatelet therapy with aspirin plus either clopidogrel or ticagrelor has been shown to reduce risk of recurrent events in selected high-risk patients with TIA who present within 24 hours of symptom onset. 35 , 36 , 52 , 53 Consider consulting vascular neurology to determine the appropriateness and dura¬ tion of dual antiplatelet therapy, to arrange follow-up, and to ensure transition back to monotherapy to reduce risk of future bleeding complications. For patients with TIA already on single-agent therapy, it is not well established whether increasing antiplatelet doses or switching to another agent confers any benefit. 17 Therapeutic anticoagulation is effective at lowering the risk of stroke in patients with AF, and evidence has shown it can safely be prescribed from the ED. 30,54 For patients who have TIA with known AF not previously receiving anticoagulation, contacting the primary care physician or cardiologist to discuss risks versus benefits of anticoagulation, or other options where anticoagula¬ tion may be contraindicated, can be helpful to ensure appropriate secondary prevention. Even for patients with history of falls, evidence suggests that therapeutic anticoagulation remains the optimal therapy and outweighs bleeding risks in most cases. 56 MRI can also detect DWI hyperintensities and cortical microhemorrhages that might sway decision-making, therefore, waiting to start anticoagulation until MRLis complete is reasonable.\n\n【4】## Statins\n\n【5】\n High-intensity statin therapy has been shown to reduce stroke recurrence in patients with ischemic stroke by 16% and has been well-established as a key aspect of secondary prevention after TIA or stroke. 1756 Beyond reduction in low-density lipoprotein levels, statins are also beneficial for plaque stabilization, improvement in endothelial dysfunction, and inflammatory responses. 57\n\n【6】## Hypertension\n\n【7】\n Initiation of antihypertensive agents, preferably in partnership with outpatient clinicians, is critical for lowering risk of future events. Reducing blood pressure with an ultimate outpatient target of <130/80 mm Hg has dem¬ onstrated a reduction in recurrent stroke risk by 22%. 1756\n\n【8】## Diabetes\n\n【9】\n Among patients with TIA or ischemic stroke, diabetes and hyperglycemia are associated with early neurological worsening and stroke recurrence. 5859 A screening\n\n【10】 hemoglobin A1c is suggested in patients with suspected TIA. Severe hyperglycemia at the time of presentation may warrant hospital admission for glycemic management. First-line treatments for those with type 2 diabetes include metformin and lifestyle optimization. 17 Additional agents to consider include sodium-glucose linked transporter inhibitors and the glucagon-like peptide-1 receptor agonists, although these agents would typically be pre¬ scribed by primary care physicians or endocrinologists. 60\n\n【11】## Behavioral And Lifestyle Counseling\n\n【12】\n The American Heart Association/American Stroke Association recommends implementing behavior change interventions to improve stroke literacy, lifestyle, and medication adherence to reduce the risk of recurrent stroke. 17 Although lifestyle and behavioral interventions that improve vascular risk factor control can be difficult to implement after stroke/TIA, 81 - 83 several evidence-based interventions (eg, electronic decision support for primary care physicians) have successfully improved counseling or risk factor control. 17, 64 Whereas extensive counseling may be considered out of the scope of acute care in the ED, incorporating behavioral health counseling as part of an ED observation pathway should be considered.\n\n【13】Increased physical activity is another cornerstone of stroke prevention. 17 Among patients with TIA or nondisabling stroke caused by intracranial stenosis in the medical therapy group of the SAMMPRIS trial (Stenting vs. Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis), greater physical activity was associated with a decreased likelihood of a recurrent stroke. 65 Various interventions have improved physical activity after stroke/TIA (eg, text-messaging, 66 cardiac rehabilitation) 67 ; however, the effect is strongest among studies that imple¬ ment interventions early after the event. 17,68 Likewise, discussions about a healthy diet, specifically Mediterranean-type or DASH (Dietary Approaches to Stop Hypertension) diets that have demonstrated reductions in stroke risk, can be implemented successfully. 69 The American Heart Association/American Stroke Association recommends that patients with TIA receive counseling to limit excessive alcohol intake and referral for specialized services for patients with substance use disorders. 17 A systematic review of smoking-cessation interventions for patients with stroke and TIA found that the combined use of smoking-cessation medications with behavioral interventions may increase smoking ces¬ sation, but the quality of the evidence was low. 70\n\n【14】## Underserved And Rural Communities\n\n【15】\n Despite improved emphasis on stroke systems of care in recent years, disparities in treatment rates, mortal¬ ity, and 30-day readmissions have remained constant or widened in rural populations. 71 Disparities in underresourced communities may stem from patient (mistrust,\n\n【16】 Stroke. 2023;54:00-00. DOI: 10.1 161/STR.000000000000418\n\n【17】 '9 Ammqs4 no Ad aro slemmojeds// qud mort bebeomwood", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "Antithrombotics", "bbox": [63.0, 79.0, 171.0, 96.0]}], "type": "Section-header", "position": 2}, {"raw_context": [{"text": "Antithrombotic therapy is warranted in all patients with", "bbox": [63.0, 101.0, 380.0, 116.0]}, {"text": "suspected TIA who have no known contraindications.", "bbox": [63.0, 118.0, 380.0, 132.0]}, {"text": "Antiplatelet therapy is recommended for stroke preven¬", "bbox": [63.0, 133.0, 378.0, 148.0]}, {"text": "tion in patients who do not have an indication for anti-", "bbox": [63.0, 150.0, 378.0, 165.0]}, {"text": "coagulation. 17 Short-term dual antiplatelet therapy with", "bbox": [63.0, 166.0, 380.0, 180.0]}, {"text": "aspirin plus either clopidogrel or ticagrelor has been", "bbox": [63.0, 181.0, 380.0, 196.0]}, {"text": "shown to reduce risk of recurrent events in selected", "bbox": [63.0, 198.0, 380.0, 212.0]}, {"text": "high-risk patients with TIA who present within 24 hours", "bbox": [63.0, 213.0, 380.0, 228.0]}, {"text": "of symptom onset. 35 , 36 , 52 , 53 Consider consulting vascular", "bbox": [63.0, 228.0, 380.0, 246.0]}, {"text": "neurology to determine the appropriateness and dura¬", "bbox": [63.0, 246.0, 378.0, 260.0]}, {"text": "tion of dual antiplatelet therapy, to arrange follow-up,", "bbox": [63.0, 261.0, 380.0, 276.0]}, {"text": "and to ensure transition back to monotherapy to reduce", "bbox": [63.0, 278.0, 380.0, 292.0]}, {"text": "risk of future bleeding complications. For patients with", "bbox": [63.0, 294.0, 380.0, 308.0]}, {"text": "TIA already on single-agent therapy, it is not well estab-", "bbox": [63.0, 310.0, 378.0, 325.0]}, {"text": "lished whether increasing antiplatelet doses or switch-", "bbox": [63.0, 326.0, 378.0, 341.0]}, {"text": "ing to another agent confers any benefit. 17", "bbox": [63.0, 341.0, 309.0, 356.0]}, {"text": "Therapeutic anticoagulation is effective at lowering", "bbox": [81.0, 358.0, 380.0, 372.0]}, {"text": "the risk of stroke in patients with AF, and evidence has", "bbox": [63.0, 374.0, 379.0, 388.0]}, {"text": "shown it can safely be prescribed from the ED. 30,54 For", "bbox": [63.0, 390.0, 379.0, 404.0]}, {"text": "patients who have TIA with known AF not previously", "bbox": [63.0, 406.0, 380.0, 420.0]}, {"text": "receiving anticoagulation, contacting the primary care", "bbox": [63.0, 421.0, 380.0, 436.0]}, {"text": "physician or cardiologist to discuss risks versus benefits", "bbox": [63.0, 438.0, 380.0, 452.0]}, {"text": "of anticoagulation, or other options where anticoagula¬", "bbox": [63.0, 454.0, 378.0, 468.0]}, {"text": "tion may be contraindicated, can be helpful to ensure", "bbox": [63.0, 470.0, 380.0, 485.0]}, {"text": "appropriate secondary prevention. Even for patients with", "bbox": [63.0, 486.0, 380.0, 500.0]}, {"text": "history of falls, evidence suggests that therapeutic anti-", "bbox": [63.0, 501.0, 380.0, 516.0]}, {"text": "coagulation remains the optimal therapy and outweighs", "bbox": [63.0, 518.0, 379.0, 532.0]}, {"text": "bleeding risks in most cases. 56 MRI can also detect DWI", "bbox": [63.0, 533.0, 379.0, 548.0]}, {"text": "hyperintensities and cortical microhemorrhages that", "bbox": [63.0, 549.0, 380.0, 565.0]}, {"text": "might sway decision-making, therefore, waiting to start", "bbox": [63.0, 566.0, 383.0, 580.0]}, {"text": "anticoagulation until MRLis complete is reasonable.", "bbox": [63.0, 582.0, 353.0, 596.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "Statins", "bbox": [63.0, 623.0, 113.0, 640.0]}], "type": "Section-header", "position": 4}, {"raw_context": [{"text": "High-intensity statin therapy has been shown to reduce", "bbox": [63.0, 647.0, 380.0, 662.0]}, {"text": "stroke recurrence in patients with ischemic stroke by", "bbox": [63.0, 663.0, 380.0, 677.0]}, {"text": "16% and has been well-established as a key aspect", "bbox": [65.0, 679.0, 380.0, 694.0]}, {"text": "of secondary prevention after TIA or stroke. 1756 Beyond", "bbox": [63.0, 694.0, 380.0, 709.0]}, {"text": "reduction in low-density lipoprotein levels, statins are", "bbox": [63.0, 710.0, 380.0, 725.0]}, {"text": "also beneficial for plaque stabilization, improvement in", "bbox": [63.0, 727.0, 380.0, 742.0]}, {"text": "endothelial dysfunction, and inflammatory responses. 57", "bbox": [63.0, 743.0, 367.0, 757.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "Hypertension", "bbox": [63.0, 788.0, 154.0, 803.0]}], "type": "Section-header", "position": 6}, {"raw_context": [{"text": "Initiation of antihypertensive agents, preferably in part-", "bbox": [63.0, 809.0, 378.0, 824.0]}, {"text": "nership with outpatient clinicians, is critical for lowering", "bbox": [63.0, 824.0, 380.0, 841.0]}, {"text": "risk of future events. Reducing blood pressure with an", "bbox": [63.0, 842.0, 380.0, 856.0]}, {"text": "ultimate outpatient target of <130/80 mm Hg has dem¬", "bbox": [63.0, 858.0, 378.0, 872.0]}, {"text": "onstrated a reduction in recurrent stroke risk by 22%. 1756", "bbox": [63.0, 874.0, 379.0, 888.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "Diabetes", "bbox": [63.0, 913.0, 126.0, 929.0]}], "type": "Section-header", "position": 8}, {"raw_context": [{"text": "Among patients with TIA or ischemic stroke, diabetes", "bbox": [63.0, 936.0, 379.0, 951.0]}, {"text": "and hyperglycemia are associated with early neurologi-", "bbox": [63.0, 953.0, 378.0, 968.0]}, {"text": "cal worsening and stroke recurrence. 5859 A screening", "bbox": [63.0, 968.0, 380.0, 983.0]}], "type": "Text", "position": 9}, {"raw_context": [{"text": "hemoglobin A1c is suggested in patients with suspected", "bbox": [398.0, 77.0, 716.0, 93.0]}, {"text": "TIA. Severe hyperglycemia at the time of presentation", "bbox": [399.0, 93.0, 716.0, 108.0]}, {"text": "may warrant hospital admission for glycemic manage-", "bbox": [398.0, 110.0, 714.0, 124.0]}, {"text": "ment. First-line treatments for those with type 2 diabetes", "bbox": [398.0, 126.0, 716.0, 140.0]}, {"text": "include metformin and lifestyle optimization. 17 Additional", "bbox": [399.0, 142.0, 716.0, 156.0]}, {"text": "agents to consider include sodium-glucose linked trans-", "bbox": [399.0, 158.0, 714.0, 173.0]}, {"text": "porter inhibitors and the glucagon-like peptide-1 receptor", "bbox": [399.0, 174.0, 716.0, 188.0]}, {"text": "agonists, although these agents would typically be pre¬", "bbox": [399.0, 190.0, 715.0, 204.0]}, {"text": "scribed by primary care physicians or endocrinologists. 60", "bbox": [399.0, 206.0, 714.0, 220.0]}], "type": "Text", "position": 11}, {"raw_context": [{"text": "Behavioral and Lifestyle Counseling", "bbox": [399.0, 245.0, 637.0, 261.0]}], "type": "Section-header", "position": 12}, {"raw_context": [{"text": "The American Heart Association/American Stroke", "bbox": [401.0, 268.0, 716.0, 283.0]}, {"text": "Association recommends implementing behavior change", "bbox": [399.0, 285.0, 716.0, 299.0]}, {"text": "interventions to improve stroke literacy, lifestyle, and", "bbox": [398.0, 301.0, 716.0, 315.0]}, {"text": "medication adherence to reduce the risk of recurrent", "bbox": [399.0, 317.0, 716.0, 332.0]}, {"text": "stroke. 17 Although lifestyle and behavioral interventions", "bbox": [399.0, 333.0, 716.0, 347.0]}, {"text": "that improve vascular risk factor control can be difficult to", "bbox": [399.0, 348.0, 716.0, 363.0]}, {"text": "implement after stroke/TIA, 81 - 83 several evidence-based", "bbox": [398.0, 364.0, 716.0, 379.0]}, {"text": "interventions (eg, electronic decision support for primary", "bbox": [399.0, 380.0, 716.0, 395.0]}, {"text": "care physicians) have successfully improved counseling", "bbox": [399.0, 396.0, 716.0, 412.0]}, {"text": "or risk factor control. 17, 64 Whereas extensive counseling", "bbox": [399.0, 412.0, 716.0, 427.0]}, {"text": "may be considered out of the scope of acute care in the", "bbox": [399.0, 428.0, 716.0, 443.0]}, {"text": "ED, incorporating behavioral health counseling as part of", "bbox": [399.0, 445.0, 716.0, 459.0]}, {"text": "an ED observation pathway should be considered.", "bbox": [399.0, 461.0, 680.0, 475.0]}, {"text": "Increased physical activity is another cornerstone of", "bbox": [414.0, 476.0, 716.0, 493.0]}, {"text": "stroke prevention. 17 Among patients with TIA or nondis-", "bbox": [400.0, 493.0, 715.0, 508.0]}, {"text": "abling stroke caused by intracranial stenosis in the medical", "bbox": [399.0, 508.0, 716.0, 523.0]}, {"text": "therapy group of the SAMMPRIS trial (Stenting vs. Aggres-", "bbox": [399.0, 525.0, 715.0, 539.0]}, {"text": "sive Medical Management for Preventing Recurrent Stroke", "bbox": [399.0, 541.0, 716.0, 555.0]}, {"text": "in Intracranial Stenosis), greater physical activity was asso-", "bbox": [399.0, 556.0, 714.0, 572.0]}, {"text": "ciated with a decreased likelihood of a recurrent stroke. 65", "bbox": [399.0, 573.0, 715.0, 587.0]}, {"text": "Various interventions have improved physical activity after", "bbox": [399.0, 588.0, 716.0, 603.0]}, {"text": "stroke/TIA (eg, text-messaging, 66 cardiac rehabilitation) 67 ;", "bbox": [399.0, 604.0, 715.0, 621.0]}, {"text": "however, the effect is strongest among studies that imple¬", "bbox": [399.0, 621.0, 715.0, 635.0]}, {"text": "ment interventions early after the event. 17,68 Likewise,", "bbox": [399.0, 636.0, 716.0, 651.0]}, {"text": "discussions about a healthy diet, specifically Mediterra-", "bbox": [399.0, 653.0, 715.0, 667.0]}, {"text": "nean-type or DASH (Dietary Approaches to Stop Hyper-", "bbox": [398.0, 669.0, 715.0, 683.0]}, {"text": "tension) diets that have demonstrated reductions in stroke", "bbox": [399.0, 685.0, 716.0, 699.0]}, {"text": "risk, can be implemented successfully. 69", "bbox": [399.0, 701.0, 614.0, 716.0]}, {"text": "The American Heart Association/American Stroke", "bbox": [416.0, 716.0, 716.0, 731.0]}, {"text": "Association recommends that patients with TIA receive", "bbox": [399.0, 733.0, 716.0, 747.0]}, {"text": "counseling to limit excessive alcohol intake and referral", "bbox": [399.0, 749.0, 716.0, 763.0]}, {"text": "for specialized services for patients with substance use", "bbox": [399.0, 765.0, 716.0, 779.0]}, {"text": "disorders. 17 A systematic review of smoking-cessation", "bbox": [399.0, 781.0, 716.0, 796.0]}, {"text": "interventions for patients with stroke and TIA found that", "bbox": [398.0, 796.0, 716.0, 811.0]}, {"text": "the combined use of smoking-cessation medications", "bbox": [399.0, 813.0, 716.0, 827.0]}, {"text": "with behavioral interventions may increase smoking ces¬", "bbox": [399.0, 829.0, 715.0, 843.0]}, {"text": "sation, but the quality of the evidence was low. 70", "bbox": [399.0, 845.0, 668.0, 859.0]}], "type": "Text", "position": 13}, {"raw_context": [{"text": "Underserved and Rural Communities", "bbox": [399.0, 880.0, 646.0, 896.0]}], "type": "Section-header", "position": 14}, {"raw_context": [{"text": "Despite improved emphasis on stroke systems of care", "bbox": [399.0, 903.0, 716.0, 917.0]}, {"text": "in recent years, disparities in treatment rates, mortal¬", "bbox": [399.0, 919.0, 715.0, 933.0]}, {"text": "ity, and 30-day readmissions have remained constant", "bbox": [399.0, 935.0, 716.0, 949.0]}, {"text": "or widened in rural populations. 71 Disparities in under-", "bbox": [399.0, 950.0, 714.0, 965.0]}, {"text": "resourced communities may stem from patient (mistrust,", "bbox": [399.0, 967.0, 716.0, 982.0]}], "type": "Text", "position": 15}, {"raw_context": [{"text": "Stroke. 2023;54:00-00. DOI: 10.1 161/STR.000000000000418", "bbox": [413.0, 997.0, 716.0, 1011.0]}], "type": "Text", "position": 16}, {"raw_context": [{"text": "'9 Ammqs4 no Ad aro slemmojeds// qud mort bebeomwood", "bbox": [17.0, 530.0, 39.0, 780.0]}], "type": "Text", "position": 17}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/神经科/共识/2023 AHA科学声明：急诊科短暂性脑缺血发作的诊断、检查和风险降低(1).pdf", "page_num": 8}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type2": "多余标点#3#3#preven¬ tion为换行连接字符，可以不需要\ndura¬ tion为换行连接字符，可以不需要\nanticoagula¬ tion为换行连接字符，可以不需要\n缺少换行#3#3#Therapeutic anticoagulation is另起一行\n多余换行#9#10#A screening和 hemoglobin A1c is suggested 是一句话\n缺少换行#13#13#The American Heart Association/American另起一行", "type3": "无关文本#0#17#symptom onset. 35 , 36 , 52 , 53部分段落末尾，以及句末的数字问题无关噪声应用全文", "type6": "有用性#16#16#Stroke. 2023;54:00-00. DOI: 10.1 161/STR.000000000000418为页脚内容"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:40", "update_time": "2024-05-07 20:02:35"}
{"id": 1082503, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 738, "source_info": {"seq_id": "ceca5d46-dd57-4c0f-b8cf-e52c43f88e75", "title": null, "text": "【0】页码:11\n All members of the endoscopy team responsible for monitoring the patient must be suitably trained to use the equipment, able to assess the level of sedation and recognise the patient's condition/sedation level. 77 If the second member of the team is required to assist the endoscopist–sedationist with technical aspects of therapeutic intervention—for example, ERCP or advanced polypectomy, they can no longer be relied on to be fully cognisant of the patient status. The endoscopist must consider if there are enough trained individuals within the room to support any planned intervention before starting.\n\n【1】13. We recommend that an accurate, contemporaneous record of all drugs is completed and becomes part of the patient record and endoscopy report. This should include additional drugs (eg, hyoscine) used to assist endoscopy Grade of evidence: Very Low. Strength of recommendation: Strong.\n\n【2】Level of agreement: 100%\n\n【3】 Accurate and complete recording of any endoscopy procedure should include the dose of drugs given, whether single bolus or aliquots and the time administered. This facilitates management of recovery, any arising complications, audit and governance.\n\n【4】## Deep Sedation\n\n【5】\n 14. We recommend that for patients undergoing endoscopy under deep sedation (propofol) or general anaesthetic, ECG, automated non-invasive blood pressure, capnography and core body temperature should be monitored and recorded Grade of evidence: Low. Strength of recommendation: Strong.\n\n【6】Level of agreement: 100% Deep sedation (propofol) or general anaesthesia services are often procedure-specific and involve a multidisciplinary team of experts. In the UK, this can only be delivered by trained anaesthetists. The facilities are often set apart from the main theatre environment. The non-theatre environment is known to be high-risk for anaesthesia and sedation services. 79 When considering safety and monitoring requirements, the focus should not be centred on equipment and facilities, rather the starting point should be a positive safety culture, an educational programme and an institutional network of sedation providers developing local protocols, collecting critical incidents data and sharing best practice. 80 It is important to highlight that even with the delivery of deep sedation, it is imperative that the sedation team, which should include an anaesthetic nurse or operating department practitioner, have the skills to identify and deal with patients who are inadvertently in a deeper plane of sedation than expected.\n\n【7】This organisational approach to delivering patient safety should work alongside considerations of monitoring and room requirements. 81 82 Patient monitoring platforms applied to procedural monitoring should be comparable with monitoring provided in the preoperative and postoperative periods, and familiar to staff. Physiological changes of deep sedation are comparable to the changes observed during general anaesthesia.\n\n【8】Non-invasive blood pressure, ECG and pulse oximetry are minimal requirements and are shown to reduce the number of sedation-related adverse effects. 87 Hypoxia and apnoea dominate the critical events associated with procedural sedation. 84 Traditional low-flow nasal or facial oxygen therapy techniques are often insufficient to maintain acceptable oxygen levels and prevent periprocedural hypoxia.\n\n【9】High-flow nasal oxygen delivers warm humidified oxygen up to 70 L/min, at oxygen concentrations between 21% and 100% and reduces the incidence of hypoxic events. Many studies observe that pairing procedural sedation with high-flow nasal oxygen Sidhu R, et al. Gut 2023;0:1–27. doi:10.1136/gutjnl-2023-330396\n\n【10】 reduces the number of hypoxaemic events. 66 85 High-flow nasal oxygen should be made available for procedural sedation where patients are at risk of periprocedural hypoxia. 8 Procedural capnography is complementary to qualitative, clinical observations of respiratory pattern by a skilled operator able to recognise and manage respiratory deterioration. 71 The National Audit Project (NAP4): Major complications of airway management in the UK, examined patients who had anaesthesia and rapid sequence induction in the emergency department and in the intensive care unit and highlighted the importance of capnography to reduce deaths in such settings. 69 Capnography has also been studied for procedural sedation with dental procedures. A meta-analysis of 16 studies showed that capnography had a higher sensitivity to detect adverse respiratory events than standard monitoring alone with pulse oximetry (0.92; 95% CI 0.65 to 0.99). 71 While further studies are awaited within endoscopy, the benefit noted in other settings suggests that this should also be used in high-risk patient groups or patients undergoing prolonged procedures under moderate sedation to reduce the risk of inadvertent entry into a deeper plane of sedation than intended. The high-risk groups include the elderly and comorbid patients, those with significant respiratory and chronic progressive neuromyopathic disorders. This is particularly important if top-up doses of sedation are used.\n\n【11】Monitoring of the conscious level may limit the opportunity for the depth of sedation to exceed deep sedation. However, there is no evidence that depth of sedation monitoring, through EEG analysis, confers any safety benefits over clinical observation. 81 The thermal redistribution of core body temperature with subsequent temperature drop is likely to be a feature of deep sedation, as it is with general anaesthesia. Core temperature may fall up to 1.5°C in the first 30 min of general anaesthesia. Few clinical studies of temperature monitoring during deep sedation are available for review. Therefore, a pragmatic solution is that if perioperative hypothermia is expected, measurements of core temperature should be done routinely. Similarly, methods to provide surface warming in the perioperative period should be considered. 5 Prospective record keeping should be a requirement for deep sedation procedures. While the National Confidential Enquiry into Patient Outcome and Death (NCEPOD) has highlighted deficits in the recording of monitoring during sedation cases, the frequency of recording of vital signs is not defined. In the absence of clinical trial data, it would be precautionary to provide a monitoring chart recording data prior to induction, at 5- or 10-minute intervals during the procedure, and thereafter the frequency and duration of monitoring to be prescribed by the clinical team depending on the procedural and patient risk factors. 91 91\n\n【12】## Sedation Protocol 15. We Recommend Governance Oversight Of The Process Of Sedation For Endoscopy\n\n【13】\n Grade of evidence: Very Low. Strength of recommendation: Strong.\n\n【14】Level of agreement: 92.3% Good governance and leadership should be at the heart of procedural sedation services to ensure patient safety. 93 Clinical governance of a procedural sedation service should have an objective of continuous quality improvement. The procedural sedation service will involve many stakeholders, including sedation practitioners, anaesthetists, medical staff, operators, nurses,\n\n【15】 111", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "All members of the endoscopy team responsible for moni-", "bbox": [66.0, 60.0, 385.0, 75.0]}, {"text": "toring the patient must be suitably trained to use the equipment,", "bbox": [53.0, 76.0, 386.0, 90.0]}, {"text": "able to assess the level of sedation and recognise the patient's", "bbox": [53.0, 91.0, 387.0, 105.0]}, {"text": "condition/sedation level. 77 If the second member of the team", "bbox": [53.0, 105.0, 387.0, 121.0]}, {"text": "is required to assist the endoscopist–sedationist with tech-", "bbox": [53.0, 120.0, 386.0, 135.0]}, {"text": "nical aspects of therapeutic intervention—for example, ERCP", "bbox": [53.0, 135.0, 387.0, 150.0]}, {"text": "or advanced polypectomy, they can no longer be relied on to", "bbox": [53.0, 150.0, 387.0, 164.0]}, {"text": "be fully cognisant of the patient status. The endoscopist must", "bbox": [53.0, 165.0, 387.0, 179.0]}, {"text": "consider if there are enough trained individuals within the room", "bbox": [53.0, 180.0, 387.0, 193.0]}, {"text": "to support any planned intervention before starting.", "bbox": [53.0, 195.0, 324.0, 208.0]}, {"text": "13. We recommend that an accurate, contemporaneous record", "bbox": [66.0, 209.0, 387.0, 223.0]}, {"text": "of all drugs is completed and becomes part of the patient record", "bbox": [53.0, 223.0, 387.0, 238.0]}, {"text": "and endoscopy report. This should include additional drugs (eg,", "bbox": [53.0, 238.0, 387.0, 252.0]}, {"text": "hyoscine) used to assist endoscopy", "bbox": [53.0, 254.0, 234.0, 267.0]}, {"text": "Grade of evidence: Very Low. Strength of recommendation:", "bbox": [64.0, 268.0, 386.0, 281.0]}, {"text": "Strong.", "bbox": [53.0, 282.0, 92.0, 296.0]}, {"text": "Level of agreement: 100%", "bbox": [65.0, 297.0, 204.0, 312.0]}], "type": "Text", "position": 0}, {"raw_context": [{"text": "Accurate and complete recording of any endoscopy procedure", "bbox": [66.0, 311.0, 387.0, 326.0]}, {"text": "should include the dose of drugs given, whether single bolus or", "bbox": [53.0, 327.0, 386.0, 341.0]}, {"text": "aliquots and the time administered. This facilitates management", "bbox": [53.0, 342.0, 386.0, 355.0]}, {"text": "of recovery, any arising complications, audit and governance.", "bbox": [53.0, 356.0, 371.0, 370.0]}], "type": "Text", "position": 1}, {"raw_context": [{"text": "Deep sedation", "bbox": [53.0, 396.0, 134.0, 411.0]}], "type": "Section-header", "position": 2}, {"raw_context": [{"text": "14. We recommend that for patients undergoing endoscopy", "bbox": [53.0, 412.0, 385.0, 426.0]}, {"text": "under deep sedation (propofol) or general anaesthetic, ECG,", "bbox": [53.0, 427.0, 386.0, 440.0]}, {"text": "automated non-invasive blood pressure, capnography and core", "bbox": [53.0, 441.0, 386.0, 455.0]}, {"text": "body temperature should be monitored and recorded", "bbox": [53.0, 455.0, 331.0, 469.0]}, {"text": "Grade of evidence: Low. Strength of recommendation: Strong.", "bbox": [65.0, 470.0, 384.0, 485.0]}, {"text": "Level of agreement: 100%", "bbox": [66.0, 485.0, 205.0, 499.0]}, {"text": "Deep sedation (propofol) or general anaesthesia services are", "bbox": [66.0, 500.0, 386.0, 514.0]}, {"text": "often procedure-specific and involve a multidisciplinary team of", "bbox": [53.0, 515.0, 386.0, 528.0]}, {"text": "experts. In the UK, this can only be delivered by trained anaes-", "bbox": [53.0, 529.0, 385.0, 543.0]}, {"text": "thetists. The facilities are often set apart from the main theatre", "bbox": [53.0, 544.0, 387.0, 558.0]}, {"text": "environment. The non-theatre environment is known to be", "bbox": [53.0, 558.0, 387.0, 573.0]}, {"text": "high-risk for anaesthesia and sedation services. 79 When consid-", "bbox": [53.0, 573.0, 386.0, 587.0]}, {"text": "ering safety and monitoring requirements, the focus should not", "bbox": [53.0, 589.0, 387.0, 602.0]}, {"text": "be centred on equipment and facilities, rather the starting point", "bbox": [53.0, 603.0, 386.0, 616.0]}, {"text": "should be a positive safety culture, an educational programme", "bbox": [53.0, 617.0, 387.0, 631.0]}, {"text": "and an institutional network of sedation providers developing", "bbox": [53.0, 632.0, 387.0, 646.0]}, {"text": "local protocols, collecting critical incidents data and sharing best", "bbox": [53.0, 646.0, 387.0, 661.0]}, {"text": "practice. 80 It is important to highlight that even with the delivery", "bbox": [53.0, 661.0, 385.0, 675.0]}, {"text": "of deep sedation, it is imperative that the sedation team, which", "bbox": [53.0, 677.0, 387.0, 690.0]}, {"text": "should include an anaesthetic nurse or operating department", "bbox": [53.0, 691.0, 387.0, 705.0]}, {"text": "practitioner, have the skills to identify and deal with patients who", "bbox": [53.0, 706.0, 387.0, 719.0]}, {"text": "are inadvertently in a deeper plane of sedation than expected.", "bbox": [53.0, 721.0, 376.0, 736.0]}, {"text": "This organisational approach to delivering patient safety", "bbox": [66.0, 736.0, 386.0, 750.0]}, {"text": "should work alongside considerations of monitoring and room", "bbox": [53.0, 751.0, 387.0, 765.0]}, {"text": "requirements. 81 82 Patient monitoring platforms applied to", "bbox": [53.0, 763.0, 387.0, 780.0]}, {"text": "procedural monitoring should be comparable with monitoring", "bbox": [53.0, 780.0, 387.0, 793.0]}, {"text": "provided in the preoperative and postoperative periods, and", "bbox": [53.0, 794.0, 387.0, 808.0]}, {"text": "familiar to staff. Physiological changes of deep sedation are", "bbox": [53.0, 809.0, 387.0, 823.0]}, {"text": "comparable to the changes observed during general anaesthesia.", "bbox": [53.0, 823.0, 385.0, 838.0]}, {"text": "Non-invasive blood pressure, ECG and pulse oximetry are", "bbox": [53.0, 837.0, 387.0, 854.0]}, {"text": "minimal requirements and are shown to reduce the number of", "bbox": [53.0, 853.0, 386.0, 867.0]}, {"text": "sedation-related adverse effects. 87", "bbox": [53.0, 868.0, 224.0, 881.0]}, {"text": "Hypoxia and apnoea dominate the critical events associated", "bbox": [64.0, 882.0, 387.0, 896.0]}, {"text": "with procedural sedation. 84 Traditional low-flow nasal or facial", "bbox": [53.0, 897.0, 387.0, 913.0]}, {"text": "oxygen therapy techniques are often insufficient to maintain", "bbox": [53.0, 912.0, 387.0, 926.0]}, {"text": "acceptable oxygen levels and prevent periprocedural hypoxia.", "bbox": [53.0, 927.0, 386.0, 941.0]}, {"text": "High-flow nasal oxygen delivers warm humidified oxygen up to", "bbox": [53.0, 942.0, 387.0, 955.0]}, {"text": "70 L/min, at oxygen concentrations between 21% and 100% and", "bbox": [54.0, 956.0, 387.0, 969.0]}, {"text": "reduces the incidence of hypoxic events. Many studies observe", "bbox": [53.0, 970.0, 387.0, 984.0]}, {"text": "that pairing procedural sedation with high-flow nasal oxygen", "bbox": [53.0, 985.0, 387.0, 1000.0]}, {"text": "Sidhu R, et al. Gut 2023;0:1–27. doi:10.1136/gutjnl-2023-330396", "bbox": [54.0, 1009.0, 316.0, 1022.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "reduces the number of hypoxaemic events. 66 85 High-flow nasal", "bbox": [406.0, 59.0, 740.0, 75.0]}, {"text": "oxygen should be made available for procedural sedation where", "bbox": [406.0, 77.0, 740.0, 89.0]}, {"text": "patients are at risk of periprocedural hypoxia. 8", "bbox": [406.0, 91.0, 648.0, 105.0]}, {"text": "Procedural capnography is complementary to qualitative,", "bbox": [418.0, 105.0, 741.0, 120.0]}, {"text": "clinical observations of respiratory pattern by a skilled operator", "bbox": [406.0, 120.0, 740.0, 135.0]}, {"text": "able to recognise and manage respiratory deterioration. 71", "bbox": [407.0, 135.0, 700.0, 150.0]}, {"text": "The", "bbox": [714.0, 136.0, 741.0, 148.0]}, {"text": "National Audit Project (NAP4): Major complications of airway", "bbox": [406.0, 150.0, 740.0, 165.0]}, {"text": "management in the UK, examined patients who had anaesthesia", "bbox": [406.0, 165.0, 741.0, 179.0]}, {"text": "and rapid sequence induction in the emergency department and", "bbox": [406.0, 180.0, 741.0, 193.0]}, {"text": "in the intensive care unit and highlighted the importance of", "bbox": [406.0, 194.0, 741.0, 208.0]}, {"text": "capnography to reduce deaths in such settings. 69 Capnography", "bbox": [406.0, 208.0, 739.0, 223.0]}, {"text": "has also been studied for procedural sedation with dental proce-", "bbox": [406.0, 223.0, 738.0, 238.0]}, {"text": "dures. A meta-analysis of 16 studies showed that capnography", "bbox": [406.0, 239.0, 739.0, 253.0]}, {"text": "had a higher sensitivity to detect adverse respiratory events than", "bbox": [406.0, 254.0, 740.0, 267.0]}, {"text": "standard monitoring alone with pulse oximetry (0.92; 95% CI", "bbox": [406.0, 268.0, 740.0, 281.0]}, {"text": "0.65 to 0.99). 71 While further studies are awaited within endos-", "bbox": [406.0, 282.0, 739.0, 296.0]}, {"text": "copy, the benefit noted in other settings suggests that this should", "bbox": [406.0, 297.0, 741.0, 312.0]}, {"text": "also be used in high-risk patient groups or patients undergoing", "bbox": [406.0, 312.0, 741.0, 326.0]}, {"text": "prolonged procedures under moderate sedation to reduce the", "bbox": [406.0, 327.0, 740.0, 341.0]}, {"text": "risk of inadvertent entry into a deeper plane of sedation than", "bbox": [406.0, 342.0, 741.0, 355.0]}, {"text": "intended. The high-risk groups include the elderly and comorbid", "bbox": [406.0, 356.0, 741.0, 369.0]}, {"text": "patients, those with significant respiratory and chronic progres-", "bbox": [406.0, 370.0, 739.0, 384.0]}, {"text": "sive neuromyopathic disorders. This is particularly important if", "bbox": [406.0, 385.0, 741.0, 399.0]}, {"text": "top-up doses of sedation are used.", "bbox": [406.0, 400.0, 585.0, 414.0]}, {"text": "Monitoring of the conscious level may limit the opportunity", "bbox": [417.0, 413.0, 740.0, 428.0]}, {"text": "for the depth of sedation to exceed deep sedation. However,", "bbox": [406.0, 430.0, 740.0, 443.0]}, {"text": "there is no evidence that depth of sedation monitoring, through", "bbox": [406.0, 444.0, 741.0, 458.0]}, {"text": "EEG analysis, confers any safety benefits over clinical observa-", "bbox": [406.0, 459.0, 739.0, 473.0]}, {"text": "tion. 81", "bbox": [406.0, 474.0, 438.0, 488.0]}, {"text": "The thermal redistribution of core body temperature with", "bbox": [418.0, 488.0, 741.0, 503.0]}, {"text": "subsequent temperature drop is likely to be a feature of deep", "bbox": [406.0, 503.0, 741.0, 518.0]}, {"text": "sedation, as it is with general anaesthesia. Core temperature may", "bbox": [406.0, 518.0, 740.0, 532.0]}, {"text": "fall up to 1.5°C in the first 30 min of general anaesthesia. Few", "bbox": [406.0, 533.0, 740.0, 546.0]}, {"text": "clinical studies of temperature monitoring during deep sedation", "bbox": [406.0, 548.0, 741.0, 561.0]}, {"text": "are available for review. Therefore, a pragmatic solution is that", "bbox": [407.0, 562.0, 741.0, 577.0]}, {"text": "if perioperative hypothermia is expected, measurements of core", "bbox": [405.0, 577.0, 740.0, 591.0]}, {"text": "temperature should be done routinely. Similarly, methods to", "bbox": [406.0, 592.0, 741.0, 606.0]}, {"text": "provide surface warming in the perioperative period should be", "bbox": [406.0, 607.0, 740.0, 620.0]}, {"text": "considered. 5", "bbox": [406.0, 621.0, 470.0, 634.0]}, {"text": "Prospective record keeping should be a requirement for deep", "bbox": [418.0, 635.0, 741.0, 650.0]}, {"text": "sedation procedures. While the National Confidential Enquiry", "bbox": [406.0, 650.0, 740.0, 665.0]}, {"text": "into Patient Outcome and Death (NCEPOD) has highlighted", "bbox": [406.0, 664.0, 741.0, 679.0]}, {"text": "deficits in the recording of monitoring during sedation cases,", "bbox": [406.0, 680.0, 740.0, 694.0]}, {"text": "the frequency of recording of vital signs is not defined. In the", "bbox": [406.0, 695.0, 740.0, 708.0]}, {"text": "absence of clinical trial data, it would be precautionary to", "bbox": [406.0, 709.0, 741.0, 722.0]}, {"text": "provide a monitoring chart recording data prior to induction, at", "bbox": [406.0, 723.0, 741.0, 737.0]}, {"text": "5- or 10-minute intervals during the procedure, and thereafter", "bbox": [407.0, 738.0, 740.0, 753.0]}, {"text": "the frequency and duration of monitoring to be prescribed by", "bbox": [406.0, 753.0, 739.0, 767.0]}, {"text": "the clinical team depending on the procedural and patient risk", "bbox": [406.0, 768.0, 739.0, 782.0]}, {"text": "factors. 91 91", "bbox": [407.0, 784.0, 463.0, 795.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "Sedation protocol", "bbox": [406.0, 823.0, 506.0, 838.0]}, {"text": "15. We recommend governance oversight of the process of seda-", "bbox": [408.0, 838.0, 740.0, 853.0]}, {"text": "tion for endoscopy", "bbox": [406.0, 854.0, 508.0, 867.0]}], "type": "Section-header", "position": 6}, {"raw_context": [{"text": "Grade of evidence: Very Low. Strength of recommendation:", "bbox": [417.0, 866.0, 740.0, 881.0]}, {"text": "Strong.", "bbox": [407.0, 884.0, 445.0, 896.0]}, {"text": "Level of agreement: 92.3%", "bbox": [418.0, 897.0, 561.0, 912.0]}, {"text": "Good governance and leadership should be at the heart of", "bbox": [418.0, 911.0, 741.0, 926.0]}, {"text": "procedural sedation services to ensure patient safety. 93 Clinical", "bbox": [406.0, 928.0, 741.0, 941.0]}, {"text": "governance of a procedural sedation service should have an", "bbox": [406.0, 942.0, 741.0, 955.0]}, {"text": "objective of continuous quality improvement. The procedural", "bbox": [406.0, 956.0, 741.0, 969.0]}, {"text": "sedation service will involve many stakeholders, including seda-", "bbox": [406.0, 970.0, 739.0, 984.0]}, {"text": "tion practitioners, anaesthetists, medical staff, operators, nurses,", "bbox": [406.0, 985.0, 739.0, 1000.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "111", "bbox": [727.0, 1011.0, 738.0, 1021.0]}], "type": "Text", "position": 8}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/消化科/_2023 BSG指南：胃肠内窥镜检查中的镇静.pdf", "page_num": 11}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "缺少换行#1#1#Grade of evidence: Very 另起一行\n缺少换行#5#5#Grade of evidence: Low.另起一行\n缺少换行#6#6#Deep sedation (propofol) or 另起一行\n缺少换行#8#8#Hypoxia and apnoea dominate另起一行\n多余换行#9#10#nasal oxygen和reduces the number是一句话\n缺少换行#10#10#Procedural capnography is 另起一行\n缺少换行#11#11#The thermal redistribution of 另起一行\nProspective record keeping另起一行\n缺少换行#12#12#15. We Recommend Governance另起一行\n缺少换行#14#14#Good governance and leadership另起一行", "type3": "无关文本#0#15#sedation level. 77 部分段落末尾，以及句末的数字问题无关噪声应用全文\n无关文本#15#15# 111", "type4": null, "type5": null, "type6": "有用性#9#9#Sidhu R, et al. Gut 2023;0:1–27. doi:10.1136/gutjnl-2023-330396为页脚内容"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:40", "update_time": "2024-05-07 23:45:27"}
{"id": 1082502, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 738, "source_info": {"seq_id": "4b1541b8-e04a-46a3-ba40-56b3775f1895", "title": null, "text": "【0】页码:9\n\n【1】 European Journal of Nuclear Medicine and Molecular Imaging Table 3 Absorbed dose Single compartment Multi-compartment recommendations for 90 Y resin microspheres and the respective Clinical scenario Perfused volume dose LOE Normal perfused liver dose Tumour dose LOE level of evidence (LOE) HCC > 150 [ 93 ] Segmentectomy Not applicable ≥ 100–120 [ 93 ] > 70 [93]* Lobectomy Not recomm 4 ≥ 100–120 [65] Unilobar [ 40 , [93] 3 4 ≥ 100–120 [65] Bilobar < 30**/40 [ 93 ] 3 4 ICC > 150 [ 93 ] Segmentectomy Not applicable 4 > 70 [ 93 ] ≥ 100–120 [94] Lobectomy Not recommended Unilobar < 40 [ 93 ] 2 100–120 *** [94] Bilobar < 30**/40 [ 93 ] ≥ 100–120 *** [94] 3 mCRC > 150 [93] Segmentectomy Not applicable > 100 **** [ 93 ] Lobectomy Not recommender [ 93 ] 4 > 100 **** [95] Unilobar 3 4 Bilobar < 30**/40 [93] > 100 **** [95] 3 4 Modified from Levillain et al. [ 93 ] *Dose to the normal perfused liver with a hepatic reserve of > 30% **In pretreated patients or those with compromised liver function ***Longer OS for patients treated with a partition model-derived mean tumour dose of 86 Gy vs. BSA-\n\n【2】\n derived tumour dose of 38 Gy ***Tumour absorbed doses > 100 Gy have been associated with higher rates of metabolic complete response, whereas a lower threshold of >40–60 Gy predicted metabolic partial response\n\n【3】 do have level 1 evidence [ 60 ] that it prolongs median OS. ' In ' s patients, in whom sufficient tumour doses cannot be reached without exceeding the proposed whole normal liver dose, alternative treatments may be considered.\n\n【4】Despite being outside of the recommendations provided in the IFU, doses >150 Gy to the whole liver have been shown to be safe [ 86 ], if the whole normal liver dose was . <50/90 Gy. Due to lacking data (especially on OS), a general recommendation cannot be given.\n\n【5】## Resin 90 Y-Microspheres\n\n【6】\n The body surface area (BSA)-based method, initially advocated for resin 90 Y-microspheres, was based on the observation that BSA correlates with liver volume in the healthy population [ 98 ]. The lack of personalization of activity prescription according to the true liver and tumour volumes of the patient, together with concerns about efficacy of this prescription method after several negative multicentre trials implementing this method (e.g. SIRFLOX, FOXFIRE,\n\n【7】 ( SARAH), induced further research on the absorbed dose–response relationship. The results lead to the recently published recommendation of a multidisciplinary expert panel to use the 3-compartimental partition model (or a voxel-based dosimetry method) and no longer the BSA- method or one-compartment approaches for activity prescription [ 93 ].\n\n【8】## Glass 90 Y-Microspheres\n\n【9】\n For glass 90 Y-microspheres, the absorbed dose of a compartment (e.g. lung, tumour, normal perfused liver) is calculated using the simplified MIRD formula:\n\n【10】## A [Gbq] X 50 Gbq [Gy]\n\n【11】\n## M [ Kg ]\n\n【12】\n where D = absorbed dose in the selected compartment, A = activity contained in the selected compartment and M the mass of this compartment. 1", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "European Journal of Nuclear Medicine and Molecular Imaging", "bbox": [66.0, 41.0, 336.0, 54.0]}, {"text": "Table 3 Absorbed dose", "bbox": [66.0, 74.0, 179.0, 89.0]}, {"text": "Single compartment", "bbox": [324.0, 81.0, 417.0, 94.0]}, {"text": "Multi-compartment", "bbox": [465.0, 81.0, 557.0, 94.0]}, {"text": "recommendations for 90 Y resin", "bbox": [66.0, 88.0, 209.0, 101.0]}, {"text": "microspheres and the respective", "bbox": [66.0, 102.0, 213.0, 115.0]}, {"text": "Clinical scenario Perfused volume dose", "bbox": [236.0, 106.0, 428.0, 117.0]}, {"text": "LOE", "bbox": [432.0, 106.0, 459.0, 117.0]}, {"text": "Normal perfused liver dose", "bbox": [464.0, 106.0, 595.0, 118.0]}, {"text": "Tumour dose", "bbox": [596.0, 106.0, 661.0, 117.0]}, {"text": "LOE", "bbox": [702.0, 106.0, 725.0, 117.0]}, {"text": "level of evidence (LOE)", "bbox": [67.0, 116.0, 177.0, 128.0]}, {"text": "HCC", "bbox": [236.0, 122.0, 262.0, 134.0]}, {"text": "> 150 [ 93 ]", "bbox": [321.0, 138.0, 373.0, 152.0]}, {"text": "Segmentectomy", "bbox": [236.0, 139.0, 314.0, 152.0]}, {"text": "Not applicable", "bbox": [465.0, 139.0, 533.0, 152.0]}, {"text": "≥ 100–120 [ 93 ]", "bbox": [598.0, 154.0, 674.0, 167.0]}, {"text": "> 70 [93]*", "bbox": [466.0, 155.0, 515.0, 167.0]}, {"text": "Lobectomy", "bbox": [236.0, 156.0, 289.0, 167.0]}, {"text": "Not recomm", "bbox": [323.0, 156.0, 379.0, 167.0]}, {"text": "4", "bbox": [702.0, 157.0, 710.0, 167.0]}, {"text": "≥ 100–120 [65]", "bbox": [598.0, 170.0, 674.0, 184.0]}, {"text": "Unilobar", "bbox": [236.0, 171.0, 278.0, 184.0]}, {"text": "[ 40 , [93]", "bbox": [465.0, 172.0, 508.0, 182.0]}, {"text": "3", "bbox": [702.0, 172.0, 710.0, 183.0]}, {"text": "4", "bbox": [702.0, 187.0, 710.0, 197.0]}, {"text": "≥ 100–120 [65]", "bbox": [598.0, 200.0, 674.0, 214.0]}, {"text": "Bilobar", "bbox": [236.0, 202.0, 273.0, 214.0]}, {"text": "< 30**/40 [ 93 ]", "bbox": [467.0, 202.0, 537.0, 214.0]}, {"text": "3", "bbox": [702.0, 202.0, 710.0, 213.0]}, {"text": "4", "bbox": [702.0, 217.0, 710.0, 227.0]}, {"text": "ICC", "bbox": [236.0, 232.0, 258.0, 244.0]}, {"text": "> 150 [ 93 ]", "bbox": [322.0, 247.0, 375.0, 261.0]}, {"text": "Segmentectomy", "bbox": [236.0, 249.0, 313.0, 262.0]}, {"text": "Not applicable", "bbox": [465.0, 249.0, 535.0, 261.0]}, {"text": "4", "bbox": [433.0, 250.0, 441.0, 260.0]}, {"text": "> 70 [ 93 ]", "bbox": [465.0, 264.0, 512.0, 278.0]}, {"text": "≥ 100–120 [94]", "bbox": [598.0, 264.0, 673.0, 278.0]}, {"text": "Lobectomy", "bbox": [236.0, 266.0, 289.0, 278.0]}, {"text": "Not recommended", "bbox": [324.0, 266.0, 408.0, 278.0]}, {"text": "Unilobar", "bbox": [236.0, 295.0, 278.0, 308.0]}, {"text": "< 40 [ 93 ]", "bbox": [466.0, 295.0, 512.0, 308.0]}, {"text": "2 100–120 *** [94]", "bbox": [599.0, 295.0, 695.0, 307.0]}, {"text": "Bilobar", "bbox": [234.0, 324.0, 272.0, 338.0]}, {"text": "< 30**/40 [ 93 ]", "bbox": [466.0, 324.0, 538.0, 338.0]}, {"text": "≥ 100–120 *** [94]", "bbox": [598.0, 324.0, 696.0, 338.0]}, {"text": "3", "bbox": [701.0, 326.0, 710.0, 337.0]}, {"text": "mCRC", "bbox": [236.0, 355.0, 270.0, 367.0]}, {"text": "> 150 [93]", "bbox": [323.0, 371.0, 373.0, 385.0]}, {"text": "Segmentectomy", "bbox": [236.0, 372.0, 313.0, 385.0]}, {"text": "Not applicable", "bbox": [465.0, 372.0, 535.0, 385.0]}, {"text": "> 100 **** [ 93 ]", "bbox": [599.0, 387.0, 677.0, 400.0]}, {"text": "Lobectomy", "bbox": [236.0, 389.0, 290.0, 401.0]}, {"text": "Not recommender", "bbox": [324.0, 389.0, 398.0, 400.0]}, {"text": "[ 93 ]", "bbox": [466.0, 389.0, 511.0, 400.0]}, {"text": "4", "bbox": [702.0, 389.0, 710.0, 400.0]}, {"text": "> 100 **** [95]", "bbox": [600.0, 403.0, 677.0, 416.0]}, {"text": "Unilobar", "bbox": [236.0, 404.0, 278.0, 417.0]}, {"text": "3", "bbox": [702.0, 405.0, 710.0, 416.0]}, {"text": "4", "bbox": [702.0, 420.0, 710.0, 430.0]}, {"text": "Bilobar", "bbox": [236.0, 433.0, 273.0, 448.0]}, {"text": "< 30**/40 [93]", "bbox": [467.0, 434.0, 539.0, 447.0]}, {"text": "> 100 **** [95]", "bbox": [599.0, 434.0, 677.0, 446.0]}, {"text": "3", "bbox": [702.0, 435.0, 710.0, 447.0]}, {"text": "4", "bbox": [702.0, 450.0, 709.0, 458.0]}, {"text": "Modified from Levillain et al. [ 93 ]", "bbox": [236.0, 472.0, 395.0, 487.0]}, {"text": "*Dose to the normal perfused liver with a hepatic reserve of > 30%", "bbox": [236.0, 489.0, 541.0, 503.0]}, {"text": "**In pretreated patients or those with compromised liver function", "bbox": [236.0, 506.0, 536.0, 520.0]}, {"text": "***Longer OS for patients treated with a partition model-derived mean tumour dose of 86 Gy vs. BSA-", "bbox": [236.0, 523.0, 725.0, 539.0]}], "type": "Table", "position": 0}, {"raw_context": [{"text": "derived tumour dose of 38 Gy", "bbox": [236.0, 539.0, 375.0, 551.0]}, {"text": "***Tumour absorbed doses > 100 Gy have been associated with higher rates of metabolic complete", "bbox": [236.0, 553.0, 726.0, 569.0]}, {"text": "response, whereas a lower threshold of >40–60 Gy predicted metabolic partial response", "bbox": [236.0, 569.0, 637.0, 582.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "do have level 1 evidence [ 60 ] that it prolongs median OS. ' In ' s", "bbox": [65.0, 607.0, 389.0, 621.0]}, {"text": "patients, in whom sufficient tumour doses cannot be reached", "bbox": [66.0, 624.0, 387.0, 638.0]}, {"text": "without exceeding the proposed whole normal liver dose,", "bbox": [66.0, 640.0, 385.0, 655.0]}, {"text": "alternative treatments may be considered.", "bbox": [65.0, 657.0, 291.0, 671.0]}, {"text": "Despite being outside of the recommendations provided", "bbox": [80.0, 674.0, 387.0, 688.0]}, {"text": "in the IFU, doses >150 Gy to the whole liver have been", "bbox": [65.0, 690.0, 387.0, 705.0]}, {"text": "shown to be safe [ 86 ], if the whole normal liver dose was", "bbox": [66.0, 706.0, 387.0, 721.0]}, {"text": ". <50/90 Gy. Due to lacking data (especially on OS), a general", "bbox": [66.0, 724.0, 387.0, 738.0]}, {"text": "recommendation cannot be given.", "bbox": [63.0, 741.0, 249.0, 755.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": "Resin 90 Y-microspheres", "bbox": [66.0, 770.0, 209.0, 789.0]}], "type": "Section-header", "position": 5}, {"raw_context": [{"text": "The body surface area (BSA)-based method, initially advo-", "bbox": [66.0, 806.0, 385.0, 822.0]}, {"text": "cated for resin 90 Y-microspheres, was based on the observa-", "bbox": [65.0, 823.0, 385.0, 838.0]}, {"text": "tion that BSA correlates with liver volume in the healthy", "bbox": [65.0, 841.0, 389.0, 855.0]}, {"text": "population [ 98 ]. The lack of personalization of activity pre-", "bbox": [66.0, 858.0, 386.0, 871.0]}, {"text": "scription according to the true liver and tumour volumes", "bbox": [66.0, 873.0, 387.0, 888.0]}, {"text": "of the patient, together with concerns about efficacy of this", "bbox": [64.0, 890.0, 387.0, 905.0]}, {"text": "prescription method after several negative multicentre tri-", "bbox": [66.0, 907.0, 385.0, 922.0]}, {"text": "als implementing this method (e.g. SIRFLOX, FOXFIRE,", "bbox": [66.0, 924.0, 385.0, 938.0]}], "type": "Text", "position": 6}, {"raw_context": [{"text": "( SARAH), induced further research on the absorbed", "bbox": [404.0, 607.0, 727.0, 621.0]}, {"text": "dose–response relationship. The results lead to the recently", "bbox": [405.0, 624.0, 726.0, 639.0]}, {"text": "published recommendation of a multidisciplinary expert", "bbox": [405.0, 640.0, 727.0, 655.0]}, {"text": "panel to use the 3-compartimental partition model (or a", "bbox": [405.0, 657.0, 727.0, 671.0]}, {"text": "voxel-based dosimetry method) and no longer the BSA-", "bbox": [406.0, 674.0, 725.0, 688.0]}, {"text": "method or one-compartment approaches for activity pre-", "bbox": [405.0, 691.0, 725.0, 705.0]}, {"text": "scription [ 93 ].", "bbox": [406.0, 707.0, 485.0, 721.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "Glass 90 Y-microspheres", "bbox": [405.0, 737.0, 547.0, 756.0]}], "type": "Section-header", "position": 8}, {"raw_context": [{"text": "For glass 90 Y-microspheres, the absorbed dose of a compart-", "bbox": [405.0, 773.0, 726.0, 788.0]}, {"text": "ment (e.g. lung, tumour, normal perfused liver) is calculated", "bbox": [405.0, 791.0, 727.0, 805.0]}, {"text": "using the simplified MIRD formula:", "bbox": [405.0, 807.0, 603.0, 822.0]}], "type": "Text", "position": 9}, {"raw_context": [{"text": "A [GBq] x 50 GBq", "bbox": [459.0, 835.0, 555.0, 861.0]}, {"text": "[Gy]", "bbox": [407.0, 855.0, 445.0, 870.0]}], "type": "Section-header", "position": 10}, {"raw_context": [{"text": "M [ kg ]", "bbox": [491.0, 866.0, 526.0, 883.0]}], "type": "Section-header", "position": 11}, {"raw_context": [{"text": "where D = absorbed dose in the selected compartment,", "bbox": [406.0, 896.0, 726.0, 910.0]}, {"text": "A = activity contained in the selected compartment and M", "bbox": [406.0, 913.0, 727.0, 927.0]}, {"text": "the mass of this compartment. 1", "bbox": [405.0, 930.0, 575.0, 944.0]}], "type": "Text", "position": 12}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2022】全科室最全临床指南+专家共识（最全版）/2022全科室临床指南/肿瘤科/EANM：动脉内放射性化合物治疗肝癌和转移性肝癌指南（2022）(1).pdf", "page_num": 9}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "缺少换行#1#1#Table 3 Absorbed dose Single另起一行\n缺少换行#1#1#Modified from Levillain et al. [ 93 ] 另起一行\n*Dose to the normal perfused另起一行\n**In pretreated patients or另起一行\n***Longer OS for patients另起一行\n缺少换行#2#2#***Tumour absorbed doses > 100 另起一行\n多余换行#6#7#SIRFLOX, FOXFIRE,和 ( SARAH), induced 是一句话\n多余标点#7#7# ( SARAH)句首的（多余\n公式格式错误#10#11#A [Gbq] X 50 Gbq [Gy]", "type3": "无关文本#0#58#Modified from Levillain et al. [93]部分段落末尾，以及句末的数字问题无关噪声应用全文\n无关文本#12#12#1", "type4": null, "type5": null, "type6": "准确性#1#1#为表格内容，内容杂乱"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:40", "update_time": "2024-05-08 23:23:24"}
{"id": 1082501, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 738, "source_info": {"seq_id": "5d1c74ed-d68f-4161-aabe-c018827a4f08", "title": null, "text": "【0】页码:8\n 3\n\n【1】 58\n\n【2】 6\n\n【3】## [16]\n\n【4】\n [17]\n\n【5】## [18] [18]\n\n【6】\n [19]\n\n【7】 [20]\n\n【8】 [ 21 ]\n\n【9】 [22]\n\n【10】## Lished08/31/2021.\n\n【11】\n (2020) .\n\n【12】0.00 ,2020,40(8):469-476.\n\n【13】Wang K Z, Lei GH. Chinese clinical practice guideline for pain management in osteoarthritis ( 2020 edition ) [ J ]. Chin J Orthop, 2020, 40(8): 469-476.\n\n【14】Fernandes L,Hagen KB,Bijlsma JW,et al.EULAR recommendations for the non-pharmacological core management of hip and knee osteoarthritis[J]. Ann Rheum Dis , 2013 , 72 (7) , 1125- 1135.\n\n【15】 (2020 100[1].\n\n【16】2020, 32( 10) : 1-14.\n\n【17】Chen WH. Guide to TCM diagnosis and treatment of knee arthritis ( 2020 edition ) [ J ]. J Tradit Chin Orthop Traumatol , 2020 , 32(10) , 1-14.\n\n【18】Van Doormaal MCM,Meerhoff GA,Vliet Vlieland TPM,et  al.\n\n【19】A clinical practice guideline for physical therapy in patients with hip or knee osteoarthritis[J].Musculoskeletal Care,2020, 18(4):575-595.\n\n【20】The Royal Australian College of Genaral Practitioners. Guideline for the management of knee and hip osteoarthritis [EB/ OL].(2018-07-09)[2022-08-08] . https://www.racgp.org.au/download/Documents/Guidelines/Musculoskeletal/guideline-for-the_management-of-knee-and-hip-oa-2nd-edition.pdf.\n\n【21】National Institute for Health and Clinical Excellence. Osteoarthritis: care and management[EB/OL]. (2014-02-12)[2022- 11-08]. https//www.nice.org.uk/guidance/cg177.\n\n【22】(\n\n【23】 , 2020 , 11 ( 19 ) : 1-4.\n\n【24】[1].\n\n【25】(1985) Xu XM, Liu WG,Zhan HS,et  al. Expert consensus on muscle training and rehabilitation for knee arthralgia[J] . Chin Massage Rehabil,2020,11(19):1-4.\n\n【26】 [23]\n\n【27】 1.4\n\n【28】 \n\n【29】 [1].\n\n【30】,2012,34(12):951-953.\n\n【31】Zhou MW,Li T,Yue SW,et al.Expert consensus on rehabilitation treatment of osteoarthritis[J]. Chin J Phys Med Rehabil , 2012 , 34(12) : 951-953.\n\n【32】 [24]\n\n【33】 Rillo O,Riera H,Acosta C,et al.Panlar consensus recommendations for the management in osteoarthritis of hand , hip , and knee[J].J Clin Rheumatol,2016,22(7):345-354.\n\n【34】 [25]\n\n【35】## 2020,24(4):221-225.\n\n【36】\n [26]\n\n【37】 [27]\n\n【38】 Liu Y. Experts consensus on the management of osteoarthritis [J] Chin J Rheumatol, 2020, 24(4): 221-225.\n\n【39】Leticia AD, Kim B. Management of knee osteoarthritis [EB/OL].\n\n【40】( 2022 -04 -05) [ 2022 -05 -05]. http ://www-uptodate-cn-s.webvpn.\n\n【41】zju.edu.cn/ .\n\n【42】 [1] .\n\n【43】 [35]\n\n【44】 [36]\n\n【45】 [37]\n\n【46】## 2022 , 57 ( 10 ) ; 1172-1177.\n\n【47】\n Wang LM, Chen HB, Wang Q, et  al. Construction of disease recognition map of knee osteoarthritis based on public health education and non-drug intervention[J] . Chin J Nurs,2022, 57(10):1172-1177.\n\n【48】 Umehara T, Tanaka R. Effective exercise intervention period for improving body function or activity in patients with knee osteoarthritis undergoing total knee arthroplasty : a systematic\n\n【49】 Lu ZJ,Li XM,Chen RC,et al.Kinesio taping improves pain and function in patients with knee osteoarthritis :a Meta-analysis of randomized controlled trials[J]. Int J Surg , 2018 , 59 : 27 -35.\n\n【50】Goh SL,Persson MSM,Stocks J,et al.Relative efficacy of different exercises for pain,function,performance and quality of life in knee and hip ostecarthritis systematic review and network Meta-analysis[J].Sports Med,2019,49(5):743-761.\n\n【51】 [29]\n\n【52】 [30]\n\n【53】 Meta ,2020 ,41(6):88-100.\n\n【54】[1].\n\n【55】Zhao RT, Sheng L, Wang YC. The effect of aquatic exercise rehabilitation on the functional recovery of patients with knee joint injury ; a Meta-analysis[J].Sports and Science , 2020 , 41(6) ; 88-100.\n\n【56】 [ 31 ]\n\n【57】 [32]\n\n【58】 [33]\n\n【59】 [34]\n\n【60】 Azizi S,Dadarkhah A,Rezasoltani Z,et  al.Randomized controlled trial of aquatic exercise for treatment of knee osteoarthritis in elderly people[J]. Interv Med Appl Sci,2019, 11(3):161-167.\n\n【61】Kabiri S, Halabchi F, Angoorani H, et  al. Comparison of three modes of aerobic exercise combined with resistance training on the pain and function of patients with knee osteoarthritis : a randomized controlled trial [ J ]. Phys Ther Sport , 2018 , 32 : 22 -28.\n\n【62】Messier SP, Mihalko SL, Legault C, et  al. Effects of intensive\n\n【63】 diet and exercise on knee joint loads, inflammation, and clinical outcomes among overweight and obese adults with knee osteoarthritis : the IDEA randomized clinical trial[J]. JAMA,2013, 310(12) ; 1263-1273.\n\n【64】Cai L, Liu Y, Xu H, et  al. Incidence and risk factors of kinesiophobia after total knee arthroplasty in Zhengzhou , China , a cross-sectional study[J].J Arthroplasty,2018,33(9):2858-2862.\n\n【65】## [1].\n\n【66】\n [38]\n\n【67】 1190-1198.\n\n【68】 Meta\n\n【69】 [1].\n\n【70】 ,2022 ,57(10) :\n\n【71】 review and Meta-analysis[J]. Braz J Phys Ther,2017,22(4): 265-275.\n\n【72】 [28]\n\n【73】 Ince B,Goksel Karatepe A,Akcay S,et al.The efficacy of balance and proprioception exercises in female patients with knee osteoarthritis ; a randomized controlled study[J]. Clin Rehabil,2022;2692155221111929.\n\n【74】Rewald S, Lenssen AFT, Emans PJ, et  al. Aquatic cycling improves knee pain and physical functioning in patients with knee osteoarthritis ; a randomized controlled trial[J] . Arch Phys Med Rehabil,2020,101(8):1288-1295.", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "3", "bbox": [604.0, 48.0, 618.0, 59.0]}], "type": "Text", "position": 1}, {"raw_context": [{"text": "58", "bbox": [643.0, 48.0, 658.0, 60.0]}], "type": "Text", "position": 2}, {"raw_context": [{"text": "6", "bbox": [684.0, 49.0, 695.0, 60.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "[16]", "bbox": [61.0, 111.0, 87.0, 124.0]}], "type": "Section-header", "position": 4}, {"raw_context": [{"text": "[17]", "bbox": [62.0, 203.0, 91.0, 215.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "[18] [18]", "bbox": [61.0, 273.0, 87.0, 289.0]}], "type": "Section-header", "position": 6}, {"raw_context": [{"text": "[19]", "bbox": [61.0, 363.0, 88.0, 378.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "[20]", "bbox": [62.0, 438.0, 89.0, 450.0]}], "type": "Text", "position": 8}, {"raw_context": [{"text": "[ 21 ]", "bbox": [62.0, 529.0, 88.0, 540.0]}], "type": "Text", "position": 9}, {"raw_context": [{"text": "[22]", "bbox": [61.0, 582.0, 88.0, 596.0]}], "type": "Text", "position": 10}, {"raw_context": [{"text": "lished08/31/2021.", "bbox": [93.0, 90.0, 172.0, 106.0]}], "type": "Section-header", "position": 11}, {"raw_context": [{"text": "(2020)", "bbox": [334.0, 112.0, 364.0, 124.0]}, {"text": ".", "bbox": [125.0, 115.0, 132.0, 123.0]}, {"text": "0.00", "bbox": [104.0, 130.0, 131.0, 142.0]}, {"text": ",2020,40(8):469-476.", "bbox": [195.0, 130.0, 296.0, 141.0]}, {"text": "Wang K Z, Lei GH. Chinese clinical practice guideline for", "bbox": [93.0, 148.0, 373.0, 160.0]}, {"text": "pain management in osteoarthritis ( 2020 edition ) [ J ]. Chin J", "bbox": [93.0, 165.0, 373.0, 178.0]}, {"text": "Orthop, 2020, 40(8): 469-476.", "bbox": [93.0, 183.0, 226.0, 196.0]}, {"text": "Fernandes L,Hagen KB,Bijlsma JW,et al.EULAR recommen-", "bbox": [90.0, 202.0, 374.0, 216.0]}, {"text": "dations for the non-pharmacological core management of hip", "bbox": [93.0, 220.0, 374.0, 233.0]}, {"text": "and knee osteoarthritis[J]. Ann Rheum Dis , 2013 , 72 (7) , 1125-", "bbox": [93.0, 238.0, 373.0, 252.0]}, {"text": "1135.", "bbox": [93.0, 256.0, 121.0, 269.0]}], "type": "Text", "position": 12}, {"raw_context": [{"text": "(2020", "bbox": [248.0, 275.0, 281.0, 288.0]}, {"text": "100[1].", "bbox": [297.0, 276.0, 324.0, 289.0]}, {"text": "2020, 32( 10) : 1-14.", "bbox": [93.0, 291.0, 182.0, 305.0]}, {"text": "Chen WH. Guide to TCM diagnosis and treatment of knee", "bbox": [93.0, 310.0, 373.0, 324.0]}, {"text": "arthritis ( 2020 edition ) [ J ]. J Tradit Chin Orthop Traumatol ,", "bbox": [93.0, 327.0, 372.0, 342.0]}, {"text": "2020 , 32(10) , 1-14.", "bbox": [93.0, 345.0, 182.0, 360.0]}, {"text": "Van Doormaal MCM,Meerhoff GA,Vliet Vlieland TPM,et  al.", "bbox": [92.0, 363.0, 373.0, 378.0]}, {"text": "A clinical practice guideline for physical therapy in patients", "bbox": [93.0, 382.0, 373.0, 397.0]}, {"text": "with hip or knee osteoarthritis[J].Musculoskeletal Care,2020,", "bbox": [93.0, 400.0, 367.0, 415.0]}, {"text": "18(4):575-595.", "bbox": [94.0, 420.0, 166.0, 432.0]}, {"text": "The Royal Australian College of Genaral Practitioners. Guide-", "bbox": [91.0, 436.0, 373.0, 450.0]}, {"text": "line for the management of knee and hip osteoarthritis [EB/", "bbox": [93.0, 456.0, 374.0, 468.0]}, {"text": "OL].(2018-07-09)[2022-08-08] . https://www.racgp.org.au/down-", "bbox": [93.0, 473.0, 373.0, 486.0]}, {"text": "load/Documents/Guidelines/Musculoskeletal/guideline-for-the_ma-", "bbox": [93.0, 492.0, 372.0, 504.0]}, {"text": "nagement-of-knee-and-hip-oa-2nd-edition.pdf.", "bbox": [93.0, 509.0, 290.0, 522.0]}, {"text": "National Institute for Health and Clinical Excellence. Oste-", "bbox": [93.0, 528.0, 373.0, 540.0]}, {"text": "oarthritis: care and management[EB/OL]. (2014-02-12)[2022-", "bbox": [93.0, 546.0, 373.0, 559.0]}, {"text": "11-08]. https//www.nice.org.uk/guidance/cg177.", "bbox": [93.0, 564.0, 297.0, 577.0]}, {"text": "(", "bbox": [332.0, 585.0, 340.0, 594.0]}], "type": "Text", "position": 13}, {"raw_context": [{"text": ", 2020 , 11 ( 19 ) : 1-4.", "bbox": [259.0, 600.0, 344.0, 613.0]}, {"text": "[1].", "bbox": [163.0, 601.0, 183.0, 613.0]}, {"text": "(1985)", "bbox": [115.0, 602.0, 124.0, 611.0]}, {"text": "Xu XM, Liu WG,Zhan HS,et  al. Expert consensus on muscle", "bbox": [93.0, 618.0, 373.0, 631.0]}, {"text": "training and rehabilitation for knee arthralgia[J] . Chin Mas-", "bbox": [93.0, 636.0, 369.0, 649.0]}, {"text": "sage Rehabil,2020,11(19):1-4.", "bbox": [93.0, 653.0, 238.0, 667.0]}], "type": "Text", "position": 14}, {"raw_context": [{"text": "[23]", "bbox": [61.0, 671.0, 88.0, 686.0]}], "type": "Text", "position": 15}, {"raw_context": [{"text": "1.4", "bbox": [207.0, 675.0, 223.0, 685.0]}], "type": "Text", "position": 16}, {"raw_context": [{"text": "", "bbox": [321.0, 674.0, 329.0, 684.0]}], "type": "Text", "position": 17}, {"raw_context": [{"text": "[1].", "bbox": [93.0, 690.0, 115.0, 705.0]}, {"text": ",2012,34(12):951-953.", "bbox": [230.0, 691.0, 339.0, 705.0]}, {"text": "Zhou MW,Li T,Yue SW,et al.Expert consensus on rehabili-", "bbox": [93.0, 708.0, 373.0, 723.0]}, {"text": "tation treatment of osteoarthritis[J]. Chin J Phys Med Rehabil ,", "bbox": [93.0, 726.0, 373.0, 741.0]}, {"text": "2012 , 34(12) : 951-953.", "bbox": [93.0, 744.0, 197.0, 759.0]}], "type": "Text", "position": 18}, {"raw_context": [{"text": "[24]", "bbox": [62.0, 764.0, 91.0, 777.0]}], "type": "Text", "position": 19}, {"raw_context": [{"text": "Rillo O,Riera H,Acosta C,et al.Panlar consensus recommen-", "bbox": [89.0, 763.0, 374.0, 777.0]}, {"text": "dations for the management in osteoarthritis of hand , hip , and", "bbox": [93.0, 780.0, 374.0, 795.0]}, {"text": "knee[J].J Clin Rheumatol,2016,22(7):345-354.", "bbox": [93.0, 798.0, 314.0, 813.0]}], "type": "Text", "position": 20}, {"raw_context": [{"text": "[25]", "bbox": [61.0, 816.0, 87.0, 831.0]}], "type": "Text", "position": 21}, {"raw_context": [{"text": "2020,24(4):221-225.", "bbox": [93.0, 835.0, 193.0, 849.0]}], "type": "Section-header", "position": 22}, {"raw_context": [{"text": "[26]", "bbox": [62.0, 891.0, 91.0, 903.0]}], "type": "Text", "position": 23}, {"raw_context": [{"text": "[27]", "bbox": [62.0, 945.0, 88.0, 957.0]}], "type": "Text", "position": 24}, {"raw_context": [{"text": "Liu Y. Experts consensus on the management of osteoarthritis", "bbox": [93.0, 853.0, 373.0, 867.0]}, {"text": "[J] Chin J Rheumatol, 2020, 24(4): 221-225.", "bbox": [93.0, 872.0, 296.0, 885.0]}, {"text": "Leticia AD, Kim B. Management of knee osteoarthritis [EB/OL].", "bbox": [90.0, 891.0, 373.0, 903.0]}, {"text": "( 2022 -04 -05) [ 2022 -05 -05]. http ://www-uptodate-cn-s.webvpn.", "bbox": [93.0, 908.0, 372.0, 921.0]}, {"text": "zju.edu.cn/ .", "bbox": [93.0, 926.0, 145.0, 939.0]}], "type": "Text", "position": 25}, {"raw_context": [{"text": "[1] .", "bbox": [260.0, 820.0, 279.0, 831.0]}], "type": "Text", "position": 26}, {"raw_context": [{"text": "[35]", "bbox": [397.0, 680.0, 422.0, 692.0]}], "type": "Text", "position": 27}, {"raw_context": [{"text": "[36]", "bbox": [398.0, 769.0, 423.0, 781.0]}], "type": "Text", "position": 28}, {"raw_context": [{"text": "[37]", "bbox": [396.0, 821.0, 422.0, 835.0]}], "type": "Text", "position": 29}, {"raw_context": [{"text": "2022 , 57 ( 10 ) ; 1172-1177.", "bbox": [428.0, 856.0, 543.0, 869.0]}], "type": "Section-header", "position": 30}, {"raw_context": [{"text": "Wang LM, Chen HB, Wang Q, et  al. Construction of disease", "bbox": [428.0, 874.0, 708.0, 888.0]}, {"text": "recognition map of knee osteoarthritis based on public health", "bbox": [428.0, 892.0, 709.0, 906.0]}, {"text": "education and non-drug intervention[J] . Chin J Nurs,2022,", "bbox": [428.0, 910.0, 707.0, 924.0]}, {"text": "57(10):1172-1177.", "bbox": [428.0, 927.0, 518.0, 940.0]}], "type": "Text", "position": 31}, {"raw_context": [{"text": "Umehara T, Tanaka R. Effective exercise intervention period", "bbox": [93.0, 945.0, 374.0, 957.0]}, {"text": "for improving body function or activity in patients with knee", "bbox": [93.0, 963.0, 373.0, 976.0]}, {"text": "osteoarthritis undergoing total knee arthroplasty : a systematic", "bbox": [93.0, 981.0, 373.0, 994.0]}], "type": "Text", "position": 32}, {"raw_context": [{"text": "Lu ZJ,Li XM,Chen RC,et al.Kinesio taping improves pain", "bbox": [426.0, 128.0, 709.0, 141.0]}, {"text": "and function in patients with knee osteoarthritis :a Meta-anal-", "bbox": [429.0, 147.0, 707.0, 159.0]}, {"text": "ysis of randomized controlled trials[J]. Int J Surg , 2018 , 59 :", "bbox": [428.0, 162.0, 708.0, 176.0]}, {"text": "27 -35.", "bbox": [429.0, 182.0, 459.0, 194.0]}, {"text": "Goh SL,Persson MSM,Stocks J,et al.Relative efficacy of dif-", "bbox": [426.0, 198.0, 707.0, 213.0]}, {"text": "ferent exercises for pain,function,performance and quality of", "bbox": [428.0, 218.0, 709.0, 231.0]}, {"text": "life in knee and hip ostecarthritis systematic review and", "bbox": [428.0, 235.0, 709.0, 248.0]}, {"text": "network Meta-analysis[J].Sports Med,2019,49(5):743-761.", "bbox": [427.0, 252.0, 698.0, 266.0]}], "type": "Text", "position": 33}, {"raw_context": [{"text": "[29]", "bbox": [397.0, 201.0, 424.0, 212.0]}], "type": "Text", "position": 34}, {"raw_context": [{"text": "[30]", "bbox": [397.0, 271.0, 422.0, 283.0]}], "type": "Text", "position": 35}, {"raw_context": [{"text": "Meta", "bbox": [482.0, 289.0, 510.0, 300.0]}, {"text": ",2020 ,41(6):88-100.", "bbox": [598.0, 289.0, 695.0, 301.0]}, {"text": "[1].", "bbox": [523.0, 290.0, 544.0, 302.0]}, {"text": "Zhao RT, Sheng L, Wang YC. The effect of aquatic exercise", "bbox": [428.0, 307.0, 708.0, 319.0]}, {"text": "rehabilitation on the functional recovery of patients with knee", "bbox": [428.0, 325.0, 707.0, 336.0]}, {"text": "joint injury ; a Meta-analysis[J].Sports and Science , 2020 , 41(6) ;", "bbox": [428.0, 341.0, 708.0, 354.0]}, {"text": "88-100.", "bbox": [429.0, 360.0, 464.0, 371.0]}], "type": "Text", "position": 36}, {"raw_context": [{"text": "[ 31 ]", "bbox": [397.0, 378.0, 422.0, 390.0]}], "type": "Text", "position": 37}, {"raw_context": [{"text": "[32]", "bbox": [397.0, 450.0, 423.0, 461.0]}], "type": "Text", "position": 38}, {"raw_context": [{"text": "[33]", "bbox": [397.0, 521.0, 424.0, 533.0]}], "type": "Text", "position": 39}, {"raw_context": [{"text": "[34]", "bbox": [397.0, 592.0, 427.0, 603.0]}], "type": "Text", "position": 40}, {"raw_context": [{"text": "Azizi S,Dadarkhah A,Rezasoltani Z,et  al.Randomized con-", "bbox": [428.0, 519.0, 709.0, 533.0]}, {"text": "trolled trial of aquatic exercise for treatment of knee os-", "bbox": [428.0, 538.0, 707.0, 550.0]}, {"text": "teoarthritis in elderly people[J]. Interv Med Appl Sci,2019,", "bbox": [428.0, 554.0, 705.0, 569.0]}, {"text": "11(3):161-167.", "bbox": [430.0, 573.0, 501.0, 585.0]}, {"text": "Kabiri S, Halabchi F, Angoorani H, et  al. Comparison of three", "bbox": [426.0, 590.0, 709.0, 604.0]}, {"text": "modes of aerobic exercise combined with resistance training", "bbox": [428.0, 609.0, 709.0, 621.0]}, {"text": "on the pain and function of patients with knee osteoarthritis :", "bbox": [428.0, 627.0, 709.0, 639.0]}, {"text": "a randomized controlled trial [ J ]. Phys Ther Sport , 2018 , 32 :", "bbox": [428.0, 644.0, 708.0, 657.0]}, {"text": "22 -28.", "bbox": [428.0, 661.0, 459.0, 674.0]}, {"text": "Messier SP, Mihalko SL, Legault C, et  al. Effects of intensive", "bbox": [427.0, 679.0, 708.0, 692.0]}], "type": "Text", "position": 41}, {"raw_context": [{"text": "diet and exercise on knee joint loads, inflammation, and clin-", "bbox": [428.0, 697.0, 707.0, 710.0]}, {"text": "ical outcomes among overweight and obese adults with knee", "bbox": [428.0, 715.0, 707.0, 728.0]}, {"text": "osteoarthritis : the IDEA randomized clinical trial[J]. JAMA,2013,", "bbox": [428.0, 733.0, 707.0, 745.0]}, {"text": "310(12) ; 1263-1273.", "bbox": [429.0, 751.0, 522.0, 763.0]}, {"text": "Cai L, Liu Y, Xu H, et  al. Incidence and risk factors of kine-", "bbox": [426.0, 768.0, 707.0, 781.0]}, {"text": "siophobia after total knee arthroplasty in Zhengzhou , China , a", "bbox": [428.0, 786.0, 709.0, 799.0]}, {"text": "cross-sectional study[J].J Arthroplasty,2018,33(9):2858-2862.", "bbox": [427.0, 803.0, 704.0, 817.0]}], "type": "Text", "position": 42}, {"raw_context": [{"text": "[1].", "bbox": [609.0, 839.0, 631.0, 853.0]}], "type": "Section-header", "position": 43}, {"raw_context": [{"text": "[38]", "bbox": [397.0, 946.0, 422.0, 958.0]}], "type": "Text", "position": 44}, {"raw_context": [{"text": "1190-1198.", "bbox": [430.0, 981.0, 479.0, 994.0]}], "type": "Text", "position": 45}, {"raw_context": [{"text": "Meta", "bbox": [520.0, 964.0, 546.0, 976.0]}], "type": "Text", "position": 46}, {"raw_context": [{"text": "[1].", "bbox": [559.0, 964.0, 579.0, 977.0]}], "type": "Text", "position": 47}, {"raw_context": [{"text": ",2022 ,57(10) :", "bbox": [640.0, 964.0, 707.0, 976.0]}], "type": "Text", "position": 48}, {"raw_context": [{"text": "review and Meta-analysis[J]. Braz J Phys Ther,2017,22(4):", "bbox": [428.0, 91.0, 708.0, 106.0]}, {"text": "265-275.", "bbox": [429.0, 111.0, 470.0, 123.0]}], "type": "Text", "position": 50}, {"raw_context": [{"text": "[28]", "bbox": [397.0, 129.0, 424.0, 141.0]}], "type": "Text", "position": 51}, {"raw_context": [{"text": "Ince B,Goksel Karatepe A,Akcay S,et al.The efficacy of", "bbox": [428.0, 377.0, 709.0, 390.0]}, {"text": "balance and proprioception exercises in female patients with", "bbox": [428.0, 396.0, 708.0, 407.0]}, {"text": "knee osteoarthritis ; a randomized controlled study[J]. Clin Re-", "bbox": [428.0, 414.0, 707.0, 425.0]}, {"text": "habil,2022;2692155221111929.", "bbox": [427.0, 430.0, 571.0, 443.0]}, {"text": "Rewald S, Lenssen AFT, Emans PJ, et  al. Aquatic cycling im-", "bbox": [427.0, 449.0, 707.0, 461.0]}, {"text": "proves knee pain and physical functioning in patients with", "bbox": [428.0, 467.0, 708.0, 479.0]}, {"text": "knee osteoarthritis ; a randomized controlled trial[J] . Arch Phys", "bbox": [428.0, 484.0, 709.0, 497.0]}, {"text": "Med Rehabil,2020,101(8):1288-1295.", "bbox": [428.0, 501.0, 604.0, 515.0]}], "type": "Text", "position": 52}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/骨科/解读/膝骨关节炎患者自我管理的最佳证据总结.pdf", "page_num": 8}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "格式杂乱#0#74#全篇格式杂乱", "type3": null, "type4": null, "type5": null, "type6": null}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:40", "update_time": "2024-05-08 00:36:21"}
{"id": 1082500, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 738, "source_info": {"seq_id": "59a5a907-d87e-4539-b4d5-6cde7446b4de", "title": null, "text": "【0】页码:5\n\n【1】## Choice Of Anticoagulant Regimen\n\n【2】\n## Vka Monitoring In Pregnancy\n\n【3】\n## Foetal Complications Of Vkas\n\n【4】\n## Monitoring Of Lmwh Dose\n\n【5】\n for input by an experienced multidisciplinary specialist team, we support guidance by other specialist societies and recommend that all pregnant individuals with MHV are managed in a tertiary specialist centre with the relevant expertise. 1,2,7\n\n【6】 low-dose VKA (≤ 5mg/day warfarin or ≤ 2mg/day acenocoumarol or ≤ 3 mg/day phenprocoumon).\n\n【7】It is currently considered likely that the neurodevelopmental effects of VKA are secondary to bleeding complications such as intracerebral haemorrhage. In a study of 274 school-age children with in utero exposure to coumarins, 19 the vast majority showed no clinically significant difference in growth and development compared with controls; however, 18 children (7%) of the coumarin-exposed cohort and 2 children (<1%) in the control cohort had two or more adverse outcome-measures, although the authors acknowledge potential confounding by indication, because the mothers of the exposed children had a medical indication for anticoagulation.\n\n【8】 All anticoagulation regimens are associated with risks for the mother and foetus and management will be planned on an individual basis through discussion between the pregnant individual and the MDT ideally in a pre-pregnancy setting. Table 2 summarises the maternal and foetal benefits and risks of different anticoagulant regimens in pregnant individuals with MHV.\n\n【9】Warfarin is the superior anticoagulant in terms of prevention of MVT but is associated with a higher risk to the foetus. The use of LMWH anticoagulation regimens avert the foetal risks observed with VKAs as they do not traverse the placenta, but their use is associated with poorer maternal outcomes.\n\n【10】 Cohort studies indicate that the use of a VKA throughout pregnancy is the best option for preventing MVT in pregnancy, although some international guidelines nuance the advice for the first trimester based on the individual's usual daily warfarin dose. 7 The choice of regimen ultimately requires careful counselling and an individual's preference and likely compliance will be a key factor. However, it is reasonable to weight recommendations from the specialist team towards warfarin for pregnant individuals at higher risk of MVT ( Table 1 ) and any decision can be reviewed if circumstances change during the pregnancy.\n\n【11】The European Society of Cardiology (ESC) guidance 7 recommends using the same INR range as outside of pregnancy with INR monitoring weekly or every 2 weeks with self-monitoring of INR in suitable patients. It is particularly important to try and avoid high INRs in view of the enhanced anticoagulation in the foetus.\n\n【12】 The most commonly used VKA in the UK is warfarin and most of the published data are for this coumarin; however, the same principles apply to other VKAs.\n\n【13】Warfarin is an established teratogen. Foetal warfarin syndrome (FWS) comprises of nasal bone hypoplasia and skeletal abnormalities and occurs following warfarin exposure between 6 and 12 weeks of gestation. The risk of FWS varies, but recent studies would suggest that it affects between 6% and 12% of foetuses exposed. Some studies suggest a dose–response relationship with lower levels of FWS at warfarin dosages ≤ 5 mg/ day 9.10.14 ; however, the data are far from conclusive. 15 Running the INR target below the recommended range to keep the warfarin dose <5 mg is not recommended due to the increased risk of MVT with this approach and the limitations of the studies on which the evidence regarding <5mg warfarin is based.\n\n【14】Warfarin readily crosses the placenta and the foetus is more anticoagulated than the mother, attributed to the immature foetal liver enzymes with low levels of vitamin K-dependent clotting factors and relative absence of foetal vitamin K.\n\n【15】Beyond the first trimester of pregnancy, VKA use is associated with foetal, placental and neonatal haemorrhage. 16–18 Data on risk are summarised in Table 2 . It should be noted that published rates of adverse events are susceptible to reporting bias.\n\n【16】When restricted to prospective studies only, Xu et al. 10 found similar foetal loss rates for VKA, LMWH/VKA and LMWH regimens (18.44% vs. 18.36% and 16.98%). However, the prospective, observational ROPAC registry 6 showed that the use of VKA during pregnancy resulted in fewer live births, with a higher rate of miscarriage (28.6% vs. 9.2% in individuals receiving heparin; p < 0.001) and late foetal death (7.1% vs. 0.7%; p =0.016). In this study, the reported rate of miscarriage and foetal loss were not significantly different in high- versus\n\n【17】 In the prospective multicentre study by van Hagen et al., 6 half of the MVT occurred in pregnant individuals who were undergoing transition from a VKA to a LMWH in the first trimester with three events in second trimester and two in the third trimester and none described with onset postpartum. In a review of maternal and foetal complications in 92 individuals from 5 prospective cohort studies treated with dose-adjusted LMWH throughout pregnancy, 20 nine episodes of valve thrombosis were reported and were attributed to poor compliance or suboptimal LMWH doses in the majority of the cases. The majority of events occurred antenatally rather than postpartum.\n\n【18】In a prior case series by the same author, 21 five cases of MVT were associated with enoxaparin therapy; three occurred in the first or second trimester and were all associated with inadequate anticoagulation and compliance issues and both cases of postpartum thrombosis were associated with subtherapeutic anticoagulation in late pregnancy (both received UFH peridelivery). The UKOSS survey did not give detail on the timing of onset of MVT in all cases but two of the five deaths occurred\n\n【19】 milar/capab) and ins S las arroff attrock [CDCA0 81] no candid online collect and plants drills A assot - is us (1 878 1 , dept 1 1 ) is the most online collect online (capab\n\n【20】 O obtestings oth in bomarog ane solation AO coun to earn and varieties onlinO voliW no (amilions", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "CHOICE OF", "bbox": [58.0, 174.0, 160.0, 191.0]}, {"text": "ANTICOAGULANT REGIMEN", "bbox": [58.0, 191.0, 311.0, 209.0]}], "type": "Section-header", "position": 3}, {"raw_context": [{"text": "VKA MONITORING IN PREGNANCY", "bbox": [408.0, 302.0, 720.0, 321.0]}], "type": "Section-header", "position": 4}, {"raw_context": [{"text": "FOETAL COMPLICATIONS OF VKAS", "bbox": [58.0, 431.0, 371.0, 449.0]}], "type": "Section-header", "position": 5}, {"raw_context": [{"text": "MONITORING OF LMWH DOSE", "bbox": [406.0, 638.0, 678.0, 657.0]}], "type": "Section-header", "position": 6}, {"raw_context": [{"text": "for input by an experienced multidisciplinary specialist", "bbox": [58.0, 65.0, 387.0, 79.0]}, {"text": "team, we support guidance by other specialist societies and", "bbox": [58.0, 80.0, 387.0, 95.0]}, {"text": "recommend that all pregnant individuals with MHV are", "bbox": [58.0, 97.0, 387.0, 112.0]}, {"text": "managed in a tertiary specialist centre with the relevant", "bbox": [58.0, 113.0, 387.0, 127.0]}, {"text": "expertise. 1,2,7", "bbox": [58.0, 129.0, 132.0, 143.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "low-dose VKA (≤ 5mg/day warfarin or ≤ 2mg/day acenocou-", "bbox": [406.0, 64.0, 732.0, 80.0]}, {"text": "marol or ≤ 3 mg/day phenprocoumon).", "bbox": [406.0, 80.0, 608.0, 95.0]}, {"text": "It is currently considered likely that the neurodevelopmental", "bbox": [422.0, 97.0, 735.0, 112.0]}, {"text": "effects of VKA are secondary to bleeding complications such", "bbox": [406.0, 113.0, 735.0, 127.0]}, {"text": "as intracerebral haemorrhage. In a study of 274 school-age chil-", "bbox": [406.0, 128.0, 733.0, 144.0]}, {"text": "dren with in utero exposure to coumarins, 19 the vast majority", "bbox": [406.0, 144.0, 734.0, 160.0]}, {"text": "showed no clinically significant difference in growth and de-", "bbox": [406.0, 161.0, 734.0, 175.0]}, {"text": "velopment compared with controls; however, 18 children (7%)", "bbox": [406.0, 177.0, 735.0, 192.0]}, {"text": "of the coumarin-exposed cohort and 2 children (<1%) in the", "bbox": [406.0, 194.0, 735.0, 208.0]}, {"text": "control cohort had two or more adverse outcome-measures,", "bbox": [406.0, 209.0, 735.0, 224.0]}, {"text": "although the authors acknowledge potential confounding by", "bbox": [406.0, 226.0, 734.0, 240.0]}, {"text": "indication, because the mothers of the exposed children had a", "bbox": [406.0, 242.0, 735.0, 256.0]}, {"text": "medical indication for anticoagulation.", "bbox": [406.0, 258.0, 614.0, 273.0]}], "type": "Text", "position": 8}, {"raw_context": [{"text": "All anticoagulation regimens are associated with risks for the", "bbox": [58.0, 226.0, 387.0, 240.0]}, {"text": "mother and foetus and management will be planned on an in-", "bbox": [58.0, 242.0, 385.0, 256.0]}, {"text": "dividual basis through discussion between the pregnant indi-", "bbox": [58.0, 258.0, 385.0, 273.0]}, {"text": "vidual and the MDT ideally in a pre-pregnancy setting. Table 2", "bbox": [58.0, 274.0, 386.0, 288.0]}, {"text": "summarises the maternal and foetal benefits and risks of differ-", "bbox": [58.0, 289.0, 385.0, 305.0]}, {"text": "ent anticoagulant regimens in pregnant individuals with MHV.", "bbox": [58.0, 306.0, 386.0, 321.0]}, {"text": "Warfarin is the superior anticoagulant in terms of prevention", "bbox": [58.0, 322.0, 387.0, 336.0]}, {"text": "of MVT but is associated with a higher risk to the foetus. The", "bbox": [58.0, 338.0, 387.0, 353.0]}, {"text": "use of LMWH anticoagulation regimens avert the foetal risks", "bbox": [58.0, 354.0, 387.0, 368.0]}, {"text": "observed with VKAs as they do not traverse the placenta, but", "bbox": [58.0, 370.0, 386.0, 385.0]}, {"text": "their use is associated with poorer maternal outcomes.", "bbox": [58.0, 386.0, 340.0, 401.0]}], "type": "Text", "position": 9}, {"raw_context": [{"text": "Cohort studies indicate that the use of a VKA throughout", "bbox": [406.0, 337.0, 735.0, 353.0]}, {"text": "pregnancy is the best option for preventing MVT in preg-", "bbox": [406.0, 354.0, 733.0, 368.0]}, {"text": "nancy, although some international guidelines nuance the", "bbox": [406.0, 369.0, 735.0, 385.0]}, {"text": "advice for the first trimester based on the individual's usual", "bbox": [406.0, 386.0, 735.0, 401.0]}, {"text": "daily warfarin dose. 7 The choice of regimen ultimately re-", "bbox": [406.0, 402.0, 733.0, 416.0]}, {"text": "quires careful counselling and an individual's preference", "bbox": [406.0, 418.0, 735.0, 433.0]}, {"text": "and likely compliance will be a key factor. However, it is rea-", "bbox": [406.0, 435.0, 733.0, 448.0]}, {"text": "sonable to weight recommendations from the specialist team", "bbox": [406.0, 450.0, 735.0, 465.0]}, {"text": "towards warfarin for pregnant individuals at higher risk of", "bbox": [406.0, 466.0, 735.0, 481.0]}, {"text": "MVT ( Table 1 ) and any decision can be reviewed if circum-", "bbox": [406.0, 482.0, 733.0, 496.0]}, {"text": "stances change during the pregnancy.", "bbox": [406.0, 498.0, 612.0, 513.0]}, {"text": "The European Society of Cardiology (ESC) guidance 7", "bbox": [424.0, 514.0, 732.0, 528.0]}, {"text": "recommends using the same INR range as outside of preg-", "bbox": [406.0, 530.0, 733.0, 545.0]}, {"text": "nancy with INR monitoring weekly or every 2 weeks with", "bbox": [406.0, 546.0, 735.0, 561.0]}, {"text": "self-monitoring of INR in suitable patients. It is particularly", "bbox": [406.0, 562.0, 734.0, 576.0]}, {"text": "important to try and avoid high INRs in view of the en-", "bbox": [406.0, 578.0, 733.0, 593.0]}, {"text": "hanced anticoagulation in the foetus.", "bbox": [406.0, 595.0, 610.0, 609.0]}], "type": "Text", "position": 10}, {"raw_context": [{"text": "The most commonly used VKA in the UK is warfarin and", "bbox": [58.0, 465.0, 387.0, 481.0]}, {"text": "most of the published data are for this coumarin; however,", "bbox": [58.0, 482.0, 386.0, 496.0]}, {"text": "the same principles apply to other VKAs.", "bbox": [58.0, 498.0, 282.0, 513.0]}, {"text": "Warfarin is an established teratogen. Foetal warfarin syn-", "bbox": [75.0, 515.0, 385.0, 528.0]}, {"text": "drome (FWS) comprises of nasal bone hypoplasia and skeletal", "bbox": [58.0, 530.0, 387.0, 544.0]}, {"text": "abnormalities and occurs following warfarin exposure between", "bbox": [58.0, 546.0, 387.0, 560.0]}, {"text": "6 and 12 weeks of gestation. The risk of FWS varies, but recent", "bbox": [58.0, 562.0, 387.0, 576.0]}, {"text": "studies would suggest that it affects between 6% and 12% of", "bbox": [58.0, 578.0, 387.0, 593.0]}, {"text": "foetuses exposed. Some studies suggest a dose–response rela-", "bbox": [58.0, 595.0, 385.0, 608.0]}, {"text": "tionship with lower levels of FWS at warfarin dosages ≤ 5 mg/", "bbox": [58.0, 609.0, 385.0, 624.0]}, {"text": "day 9.10.14 ; however, the data are far from conclusive. 15 Running", "bbox": [58.0, 624.0, 387.0, 641.0]}, {"text": "the INR target below the recommended range to keep the war-", "bbox": [58.0, 642.0, 385.0, 656.0]}, {"text": "farin dose <5 mg is not recommended due to the increased risk", "bbox": [58.0, 658.0, 387.0, 673.0]}, {"text": "of MVT with this approach and the limitations of the studies", "bbox": [58.0, 675.0, 387.0, 689.0]}, {"text": "on which the evidence regarding <5mg warfarin is based.", "bbox": [58.0, 690.0, 359.0, 704.0]}, {"text": "Warfarin readily crosses the placenta and the foetus is more", "bbox": [74.0, 706.0, 387.0, 721.0]}, {"text": "anticoagulated than the mother, attributed to the immature", "bbox": [58.0, 722.0, 387.0, 736.0]}, {"text": "foetal liver enzymes with low levels of vitamin K-dependent", "bbox": [58.0, 738.0, 386.0, 753.0]}, {"text": "clotting factors and relative absence of foetal vitamin K.", "bbox": [58.0, 755.0, 385.0, 768.0]}, {"text": "Beyond the first trimester of pregnancy, VKA use is associated", "bbox": [58.0, 769.0, 387.0, 784.0]}, {"text": "with foetal, placental and neonatal haemorrhage. 16–18 Data on", "bbox": [58.0, 786.0, 387.0, 800.0]}, {"text": "risk are summarised in Table 2 . It should be noted that pub-", "bbox": [58.0, 802.0, 385.0, 816.0]}, {"text": "lished rates of adverse events are susceptible to reporting bias.", "bbox": [58.0, 818.0, 386.0, 833.0]}, {"text": "When restricted to prospective studies only, Xu et al. 10 found", "bbox": [58.0, 833.0, 387.0, 849.0]}, {"text": "similar foetal loss rates for VKA, LMWH/VKA and LMWH", "bbox": [58.0, 849.0, 387.0, 864.0]}, {"text": "regimens (18.44% vs. 18.36% and 16.98%). However, the pro-", "bbox": [58.0, 866.0, 385.0, 880.0]}, {"text": "spective, observational ROPAC registry 6 showed that the use", "bbox": [58.0, 881.0, 387.0, 896.0]}, {"text": "of VKA during pregnancy resulted in fewer live births, with", "bbox": [58.0, 897.0, 387.0, 913.0]}, {"text": "a higher rate of miscarriage (28.6% vs. 9.2% in individuals re-", "bbox": [58.0, 914.0, 385.0, 928.0]}, {"text": "ceiving heparin; p < 0.001) and late foetal death (7.1% vs. 0.7%;", "bbox": [58.0, 930.0, 386.0, 944.0]}, {"text": "p =0.016). In this study, the reported rate of miscarriage and", "bbox": [58.0, 946.0, 387.0, 961.0]}, {"text": "foetal loss were not significantly different in high- versus", "bbox": [58.0, 963.0, 386.0, 977.0]}], "type": "Text", "position": 11}, {"raw_context": [{"text": "In the prospective multicentre study by van Hagen et al., 6 half", "bbox": [406.0, 673.0, 736.0, 689.0]}, {"text": "of the MVT occurred in pregnant individuals who were under-", "bbox": [406.0, 689.0, 733.0, 704.0]}, {"text": "going transition from a VKA to a LMWH in the first trimester", "bbox": [406.0, 706.0, 735.0, 720.0]}, {"text": "with three events in second trimester and two in the third tri-", "bbox": [406.0, 722.0, 734.0, 736.0]}, {"text": "mester and none described with onset postpartum. In a review", "bbox": [406.0, 738.0, 735.0, 753.0]}, {"text": "of maternal and foetal complications in 92 individuals from 5", "bbox": [406.0, 754.0, 735.0, 768.0]}, {"text": "prospective cohort studies treated with dose-adjusted LMWH", "bbox": [406.0, 769.0, 735.0, 784.0]}, {"text": "throughout pregnancy, 20 nine episodes of valve thrombosis", "bbox": [406.0, 784.0, 735.0, 802.0]}, {"text": "were reported and were attributed to poor compliance or sub-", "bbox": [406.0, 802.0, 734.0, 816.0]}, {"text": "optimal LMWH doses in the majority of the cases. The ma-", "bbox": [406.0, 817.0, 734.0, 833.0]}, {"text": "jority of events occurred antenatally rather than postpartum.", "bbox": [406.0, 835.0, 734.0, 848.0]}, {"text": "In a prior case series by the same author, 21 five cases of MVT", "bbox": [406.0, 849.0, 734.0, 864.0]}, {"text": "were associated with enoxaparin therapy; three occurred in", "bbox": [406.0, 866.0, 735.0, 880.0]}, {"text": "the first or second trimester and were all associated with inad-", "bbox": [406.0, 882.0, 734.0, 896.0]}, {"text": "equate anticoagulation and compliance issues and both cases", "bbox": [406.0, 898.0, 735.0, 913.0]}, {"text": "of postpartum thrombosis were associated with subtherapeu-", "bbox": [406.0, 915.0, 733.0, 928.0]}, {"text": "tic anticoagulation in late pregnancy (both received UFH peri-", "bbox": [406.0, 930.0, 734.0, 944.0]}, {"text": "delivery). The UKOSS survey did not give detail on the timing", "bbox": [406.0, 946.0, 734.0, 961.0]}, {"text": "of onset of MVT in all cases but two of the five deaths occurred", "bbox": [406.0, 963.0, 734.0, 977.0]}], "type": "Text", "position": 12}, {"raw_context": [{"text": "milar/capab) and ins S las arroff attrock [CDCA0 81] no candid online collect and plants drills A assot - is us (1 878 1 , dept 1 1 ) is the most online collect online (capab", "bbox": [768.0, 25.0, 782.0, 602.0]}], "type": "Text", "position": 13}, {"raw_context": [{"text": "O obtestings oth in bomarog ane solation AO coun to earn and varieties onlinO voliW no (amilions", "bbox": [768.0, 684.0, 781.0, 952.0]}], "type": "Text", "position": 14}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/心血管/指南/2023 BSH 指南：机械心脏瓣膜妊娠个体抗凝管理(1).pdf", "page_num": 5}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": null, "type3": "无关文本#19#20#与上下文不衔接\n无关文本#0#18#relevant expertise. 1,2,7部分段落末尾，以及句末的数字问题无关噪声应用全文\n", "type4": "栏目混乱#1#18#小标题与内容分离，并且内容顺序上下颠倒，穿插出现", "type5": null, "type6": null}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:40", "update_time": "2024-05-07 22:58:25"}
{"id": 1082499, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 738, "source_info": {"seq_id": "59ca6051-a1c6-4e0a-a40a-bb948bec768c", "title": null, "text": "【0】页码:19\n 40. We recommend patients with hepatic encephalopathy or chronic liver disease with American Society of Anesthesiologists (ASA) grade 4 or more who are undergoing endoscopy should have this undertaken with anaesthetic support Grade of evidence: Low. Strength of recommendation: Strong.\n\n【1】Level of agreement: 100% General anaesthesia with endotracheal intubation should be considered in patients with decompensated chronic liver disease undergoing endoscopy, if airway protection may be an important clinical issue. This mostly commonly arises in patients with chronic liver disease with gastrointestinal haemorrhage or other complicating factors, such as encephalopathy, that place the patient at high risk of aspiration. 221 41. We recommend adjunctive non-invasive ventilation and high-flow oxygen in patients with chronic progressive neuromyopathic disorders and severely impaired respiratory function (forced vital capacity <50% predicted) undergoing endoscopy with conscious sedation.\n\n【2】Grade of evidence: Moderate. Strength of recommendation: Strong.\n\n【3】Level of agreement: 100% Patients with chronic progressive neuromyopathic disorders (eg, motor neurone disease) often require endoscopy for the insertion of a percutaneous endoscopic gastrostomy (PEG) when they cannot safely meet their nutritional needs by the oral route. Traditionally this is done with conscious sedation but PEG insertion without sedation can be acceptable to patients and should be discussed with them prior to endoscopy. 222 Unsedated PEG insertion has been facilitated in patients with chronic progressive neuromyopathic disorders by the availability of ultrathin endoscopes. 2 We recommend multidisciplinary pre-assessment and management of such patients undergoing endoscopy. This may include gastroenterologists, nutrition teams, neurologists, anaesthetists and respiratory physicians, depending on the indication for endoscopy. Pulmonary function tests and arterial blood gas assessment may be helpful in risk stratification of patients prior to endoscopy. While there is inadequate evidence to mandate this in all patients, it should be considered on a case to case basis. 224 Periprocedural NIV has been used during endoscopy to improve oxygenation and avoid general anaesthesia and its attendant risks. 225 The development of dedicated NIV equipment to permit endoscopy at the same time, allows preendoscopy, during endoscopy and postendoscopy NIV to permit safe and effective respiratory support for insertion of PEG tubes with minimal sedation in patients with chronic progressive neuromyopathic disorders. 226 227 There is some evidence that high-flow oxygen reduces the incidence of hypoxia during endoscopy and it may therefore have a role in high-risk groups, such as those with respiratory and neuromyopathic disorders. 8 Extrapolating evidence from other settings, we would recommend capnography in this patient group, to reduce the risk of episodes of hypoxaemia. 69 7 42. We recommend that patients with renal impairment (estimated glomerular filtration rate < 30 ml/min/1.73 m 2 ) undergoing endoscopy with sedation should have their doses of opioids or benzodiazepines reduced Grade of evidence: Low. Strength of recommendation: Strong.\n\n【4】Level of agreement: 100% In a case series of 500 patients with upper GI bleeding, aspiration pneumonia developed in 4.8% after endoscopic haemostasis. 228 Endotracheal intubation was required for three of them, and one died of the complication. Multivariate analysis revealed that haemodialysis (OR=3.6 (95% CI 1.2 to 11), p=0.024) was independently associated with developing aspiration pneumonia.\n\n【5】Sidhu R, et al. Gut 2023;0:1–27. doi:10.1136/gutjnl-2023-330396\n\n【6】 Midazolam has delayed metabolism and elimination in significant renal impairment, and the dose should be reduced if used for sedation. Opiates also accumulate in significant renal failure, and thus the doses used for sedation at endoscopy should be reduced and shorter-acting opiates are preferable.\n\n【7】43. We recommend the use of adjunctive non-invasive ventilation (NIV) and high-flow oxygen in patients with respiratory failure undergoing endoscopy Grade of evidence: Low. Strength of recommendation: Strong.\n\n【8】Level of agreement: 100% A small study of patients with chronic respiratory failure undergoing endoscopy, who were receiving long-term home oxygen therapy, found that the degree of respiratory failure influenced the decrease in oxygen saturation during endoscopy. 229 Cardiopulmonary adverse events account for over 60% of unplanned events during sedated upper GI endoscopy. 215 These include significant respiratory events, such as oxygen desaturation, aspiration pneumonia and respiratory arrest.\n\n【9】We recommend multidisciplinary pre-assessment and management of such patients undergoing endoscopy. This should include gastroenterologists, anaesthetists and respiratory physicians. Pulmonary function tests and arterial blood gas assessment may be helpful in risk stratification of patients prior to endoscopy. Dedicated NIV equipment for endoscopy permits safe and effective respiratory support for patients with chronic progressive neuromyopathic disorders, 226 227 and this approach would be equally applicable to patients with respiratory failure (forced vital capacity < 50% predicted) requiring endoscopy with sedation. Similarly, high-flow oxygen and capnography would also be beneficial and recommended in this group. 8\n\n【10】## Special Considerations: Pregnancy And Breast Feeding\n\n【11】\n 44. We recommend that sedation providers should be aware of the actions and interactions of sedative agents in pregnant women, including the increased risk of aspiration Grade of evidence: Low. Strength of recommendation: Strong.\n\n【12】Level of agreement: 100% 45. The use of diazepam in the first trimester has been associated with congenital malformations, whereas no associations have been reported for midazolam. We recommend single doses of midazolam for endoscopic procedures during pregnancy if clinically necessary Grade of evidence: Low. Strength of recommendation: Strong.\n\n【13】Level of agreement: 92.3% 46. We recommend that fentanyl, propofol and nitrous oxide (Entonox) can safely be used in pregnancy Grade of evidence: Low. Strength of recommendation: Strong.\n\n【14】Level of agreement: 100% 47. We recommend that breast feeding does not need to be suspended after a single intravenous dose of midazolam, fentanyl or pethidine (or when used in combination), or after administration of propofol Grade of evidence: Low. Strength of recommendation: Strong.\n\n【15】Level of agreement: 100%\n\n【16】## Pregnancy\n\n【17】\n Endoscopic procedures can be required in pregnant and breast feeding women and some conditions are more prevalent in these patients—for example, gallstones. First and foremost, the risks to the patient need to be considered, both from performing an endoscopy and from opting for alternative, non-endoscopic management. From a sedation perspective there are some additional risks that need to be considered—namely, an increased\n\n【18】 19", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "40. We recommend patients with hepatic encephalopathy or", "bbox": [66.0, 60.0, 386.0, 75.0]}, {"text": "chronic liver disease with American Society of Anesthesiologists", "bbox": [53.0, 76.0, 386.0, 90.0]}, {"text": "(ASA) grade 4 or more who are undergoing endoscopy should", "bbox": [53.0, 91.0, 387.0, 105.0]}, {"text": "have this undertaken with anaesthetic support", "bbox": [53.0, 105.0, 297.0, 119.0]}, {"text": "Grade of evidence: Low. Strength of recommendation: Strong.", "bbox": [64.0, 120.0, 384.0, 135.0]}, {"text": "Level of agreement: 100%", "bbox": [65.0, 136.0, 204.0, 149.0]}, {"text": "General anaesthesia with endotracheal intubation should", "bbox": [64.0, 149.0, 387.0, 164.0]}, {"text": "be considered in patients with decompensated chronic liver", "bbox": [53.0, 165.0, 386.0, 179.0]}, {"text": "disease undergoing endoscopy, if airway protection may be an", "bbox": [53.0, 180.0, 387.0, 193.0]}, {"text": "important clinical issue. This mostly commonly arises in patients", "bbox": [53.0, 194.0, 387.0, 207.0]}, {"text": "with chronic liver disease with gastrointestinal haemorrhage or", "bbox": [53.0, 208.0, 387.0, 222.0]}, {"text": "other complicating factors, such as encephalopathy, that place", "bbox": [53.0, 223.0, 386.0, 237.0]}, {"text": "the patient at high risk of aspiration. 221", "bbox": [53.0, 238.0, 254.0, 252.0]}, {"text": "41. We recommend adjunctive non-invasive ventilation and", "bbox": [65.0, 253.0, 387.0, 266.0]}, {"text": "high-flow oxygen in patients with chronic progressive neuro-", "bbox": [53.0, 268.0, 385.0, 281.0]}, {"text": "myopathic disorders and severely impaired respiratory function", "bbox": [53.0, 282.0, 387.0, 295.0]}, {"text": "(forced vital capacity <50% predicted) undergoing endoscopy", "bbox": [53.0, 296.0, 386.0, 310.0]}, {"text": "with conscious sedation.", "bbox": [53.0, 311.0, 183.0, 324.0]}, {"text": "Grade of evidence: Moderate. Strength of recommendation:", "bbox": [64.0, 325.0, 385.0, 340.0]}, {"text": "Strong.", "bbox": [53.0, 340.0, 91.0, 354.0]}, {"text": "Level of agreement: 100%", "bbox": [66.0, 356.0, 203.0, 369.0]}, {"text": "Patients with chronic progressive neuromyopathic disorders (eg,", "bbox": [65.0, 370.0, 386.0, 383.0]}, {"text": "motor neurone disease) often require endoscopy for the insertion", "bbox": [53.0, 384.0, 387.0, 398.0]}, {"text": "of a percutaneous endoscopic gastrostomy (PEG) when they cannot", "bbox": [53.0, 399.0, 387.0, 413.0]}, {"text": "safely meet their nutritional needs by the oral route. Traditionally", "bbox": [53.0, 413.0, 386.0, 428.0]}, {"text": "this is done with conscious sedation but PEG insertion without", "bbox": [53.0, 428.0, 387.0, 443.0]}, {"text": "sedation can be acceptable to patients and should be discussed with", "bbox": [53.0, 444.0, 387.0, 457.0]}, {"text": "them prior to endoscopy. 222 Unsedated PEG insertion has been", "bbox": [53.0, 455.0, 387.0, 472.0]}, {"text": "facilitated in patients with chronic progressive neuromyopathic", "bbox": [53.0, 473.0, 387.0, 486.0]}, {"text": "disorders by the availability of ultrathin endoscopes. 2", "bbox": [53.0, 487.0, 318.0, 501.0]}, {"text": "We recommend multidisciplinary pre-assessment and manage-", "bbox": [66.0, 502.0, 385.0, 517.0]}, {"text": "ment of such patients undergoing endoscopy. This may include", "bbox": [53.0, 516.0, 387.0, 531.0]}, {"text": "gastroenterologists, nutrition teams, neurologists, anaesthe-", "bbox": [53.0, 532.0, 385.0, 546.0]}, {"text": "tists and respiratory physicians, depending on the indication", "bbox": [53.0, 546.0, 387.0, 560.0]}, {"text": "for endoscopy. Pulmonary function tests and arterial blood", "bbox": [53.0, 561.0, 386.0, 574.0]}, {"text": "gas assessment may be helpful in risk stratification of patients", "bbox": [53.0, 575.0, 387.0, 589.0]}, {"text": "prior to endoscopy. While there is inadequate evidence to", "bbox": [53.0, 590.0, 387.0, 604.0]}, {"text": "mandate this in all patients, it should be considered on a case to", "bbox": [53.0, 604.0, 387.0, 619.0]}, {"text": "case basis. 224 Periprocedural NIV has been used during endos-", "bbox": [53.0, 618.0, 385.0, 633.0]}, {"text": "copy to improve oxygenation and avoid general anaesthesia", "bbox": [53.0, 634.0, 386.0, 648.0]}, {"text": "and its attendant risks. 225 The development of dedicated NIV", "bbox": [53.0, 646.0, 385.0, 662.0]}, {"text": "equipment to permit endoscopy at the same time, allows pre-", "bbox": [53.0, 663.0, 385.0, 677.0]}, {"text": "endoscopy, during endoscopy and postendoscopy NIV to permit", "bbox": [53.0, 678.0, 387.0, 693.0]}, {"text": "safe and effective respiratory support for insertion of PEG", "bbox": [53.0, 692.0, 387.0, 707.0]}, {"text": "tubes with minimal sedation in patients with chronic progres-", "bbox": [53.0, 707.0, 385.0, 722.0]}, {"text": "sive neuromyopathic disorders. 226 227 There is some evidence", "bbox": [54.0, 721.0, 387.0, 736.0]}, {"text": "that high-flow oxygen reduces the incidence of hypoxia during", "bbox": [53.0, 736.0, 387.0, 751.0]}, {"text": "endoscopy and it may therefore have a role in high-risk groups,", "bbox": [53.0, 752.0, 385.0, 765.0]}, {"text": "such as those with respiratory and neuromyopathic disorders. 8", "bbox": [53.0, 766.0, 380.0, 781.0]}, {"text": "Extrapolating evidence from other settings, we would recom-", "bbox": [53.0, 781.0, 385.0, 795.0]}, {"text": "mend capnography in this patient group, to reduce the risk of", "bbox": [53.0, 795.0, 387.0, 810.0]}, {"text": "episodes of hypoxaemia. 69 7", "bbox": [54.0, 812.0, 195.0, 823.0]}, {"text": "42. We recommend that patients with renal impairment (esti-", "bbox": [65.0, 824.0, 386.0, 839.0]}, {"text": "mated glomerular filtration rate < 30 ml/min/1.73 m 2 ) under-", "bbox": [53.0, 840.0, 385.0, 853.0]}, {"text": "going endoscopy with sedation should have their doses of", "bbox": [53.0, 854.0, 387.0, 868.0]}, {"text": "opioids or benzodiazepines reduced", "bbox": [53.0, 869.0, 242.0, 883.0]}, {"text": "Grade of evidence: Low. Strength of recommendation: Strong.", "bbox": [64.0, 883.0, 385.0, 898.0]}, {"text": "Level of agreement: 100%", "bbox": [66.0, 898.0, 205.0, 912.0]}, {"text": "In a case series of 500 patients with upper GI bleeding, aspi-", "bbox": [65.0, 913.0, 385.0, 927.0]}, {"text": "ration pneumonia developed in 4.8% after endoscopic haemo-", "bbox": [53.0, 928.0, 385.0, 941.0]}, {"text": "stasis. 228 Endotracheal intubation was required for three of them,", "bbox": [53.0, 942.0, 385.0, 955.0]}, {"text": "and one died of the complication. Multivariate analysis revealed", "bbox": [53.0, 957.0, 387.0, 970.0]}, {"text": "that haemodialysis (OR=3.6 (95% CI 1.2 to 11), p=0.024) was", "bbox": [53.0, 971.0, 387.0, 986.0]}, {"text": "independently associated with developing aspiration pneumonia.", "bbox": [53.0, 985.0, 385.0, 1002.0]}, {"text": "Sidhu R, et al. Gut 2023;0:1–27. doi:10.1136/gutjnl-2023-330396", "bbox": [54.0, 1009.0, 316.0, 1022.0]}], "type": "Text", "position": 0}, {"raw_context": [{"text": "Midazolam has delayed metabolism and elimination in signif-", "bbox": [418.0, 60.0, 739.0, 75.0]}, {"text": "icant renal impairment, and the dose should be reduced if used", "bbox": [406.0, 76.0, 740.0, 90.0]}, {"text": "for sedation. Opiates also accumulate in significant renal failure,", "bbox": [406.0, 91.0, 741.0, 105.0]}, {"text": "and thus the doses used for sedation at endoscopy should be", "bbox": [407.0, 106.0, 740.0, 120.0]}, {"text": "reduced and shorter-acting opiates are preferable.", "bbox": [406.0, 120.0, 665.0, 135.0]}, {"text": "43. We recommend the use of adjunctive non-invasive venti-", "bbox": [418.0, 135.0, 740.0, 150.0]}, {"text": "lation (NIV) and high-flow oxygen in patients with respiratory", "bbox": [406.0, 150.0, 740.0, 164.0]}, {"text": "failure undergoing endoscopy", "bbox": [407.0, 165.0, 563.0, 179.0]}, {"text": "Grade of evidence: Low. Strength of recommendation: Strong.", "bbox": [418.0, 180.0, 737.0, 194.0]}, {"text": "Level of agreement: 100%", "bbox": [418.0, 194.0, 557.0, 207.0]}, {"text": "A small study of patients with chronic respiratory failure under-", "bbox": [418.0, 207.0, 739.0, 223.0]}, {"text": "going endoscopy, who were receiving long-term home oxygen", "bbox": [406.0, 223.0, 741.0, 237.0]}, {"text": "therapy, found that the degree of respiratory failure influenced", "bbox": [406.0, 238.0, 740.0, 252.0]}, {"text": "the decrease in oxygen saturation during endoscopy. 229 Cardio-", "bbox": [406.0, 253.0, 739.0, 266.0]}, {"text": "pulmonary adverse events account for over 60% of unplanned", "bbox": [406.0, 268.0, 740.0, 281.0]}, {"text": "events during sedated upper GI endoscopy. 215 These include", "bbox": [406.0, 279.0, 740.0, 295.0]}, {"text": "significant respiratory events, such as oxygen desaturation, aspi-", "bbox": [406.0, 296.0, 739.0, 310.0]}, {"text": "ration pneumonia and respiratory arrest.", "bbox": [406.0, 311.0, 618.0, 325.0]}, {"text": "We recommend multidisciplinary pre-assessment and manage-", "bbox": [419.0, 326.0, 739.0, 340.0]}, {"text": "ment of such patients undergoing endoscopy. This should", "bbox": [406.0, 340.0, 741.0, 354.0]}, {"text": "include gastroenterologists, anaesthetists and respiratory physi-", "bbox": [406.0, 355.0, 739.0, 369.0]}, {"text": "cians. Pulmonary function tests and arterial blood gas assessment", "bbox": [406.0, 370.0, 740.0, 383.0]}, {"text": "may be helpful in risk stratification of patients prior to endos-", "bbox": [406.0, 384.0, 739.0, 398.0]}, {"text": "copy. Dedicated NIV equipment for endoscopy permits safe and", "bbox": [406.0, 399.0, 740.0, 413.0]}, {"text": "effective respiratory support for patients with chronic progres-", "bbox": [406.0, 413.0, 739.0, 428.0]}, {"text": "sive neuromyopathic disorders, 226 227 and this approach would", "bbox": [406.0, 427.0, 741.0, 443.0]}, {"text": "be equally applicable to patients with respiratory failure (forced", "bbox": [406.0, 442.0, 740.0, 458.0]}, {"text": "vital capacity < 50% predicted) requiring endoscopy with seda-", "bbox": [406.0, 458.0, 739.0, 472.0]}, {"text": "tion. Similarly, high-flow oxygen and capnography would also", "bbox": [406.0, 473.0, 741.0, 486.0]}, {"text": "be beneficial and recommended in this group. 8", "bbox": [406.0, 488.0, 647.0, 502.0]}], "type": "Text", "position": 2}, {"raw_context": [{"text": "Special considerations: pregnancy and breast feeding", "bbox": [406.0, 523.0, 693.0, 538.0]}], "type": "Section-header", "position": 3}, {"raw_context": [{"text": "44. We recommend that sedation providers should be aware", "bbox": [406.0, 539.0, 740.0, 553.0]}, {"text": "of the actions and interactions of sedative agents in pregnant", "bbox": [406.0, 554.0, 740.0, 567.0]}, {"text": "women, including the increased risk of aspiration", "bbox": [407.0, 568.0, 665.0, 581.0]}, {"text": "Grade of evidence: Low. Strength of recommendation: Strong.", "bbox": [418.0, 582.0, 737.0, 596.0]}, {"text": "Level of agreement: 100%", "bbox": [418.0, 597.0, 557.0, 611.0]}, {"text": "45. The use of diazepam in the first trimester has been asso-", "bbox": [418.0, 612.0, 739.0, 626.0]}, {"text": "ciated with congenital malformations, whereas no associations", "bbox": [406.0, 626.0, 740.0, 641.0]}, {"text": "have been reported for midazolam. We recommend single doses", "bbox": [406.0, 642.0, 740.0, 655.0]}, {"text": "of midazolam for endoscopic procedures during pregnancy if", "bbox": [406.0, 656.0, 741.0, 670.0]}, {"text": "clinically necessary", "bbox": [406.0, 672.0, 508.0, 684.0]}, {"text": "Grade of evidence: Low. Strength of recommendation: Strong.", "bbox": [418.0, 685.0, 737.0, 700.0]}, {"text": "Level of agreement: 92.3%", "bbox": [418.0, 700.0, 561.0, 714.0]}, {"text": "46. We recommend that fentanyl, propofol and nitrous oxide", "bbox": [419.0, 714.0, 740.0, 729.0]}, {"text": "(Entonox) can safely be used in pregnancy", "bbox": [408.0, 729.0, 628.0, 743.0]}, {"text": "Grade of evidence: Low. Strength of recommendation: Strong.", "bbox": [418.0, 744.0, 737.0, 758.0]}, {"text": "Level of agreement: 100%", "bbox": [418.0, 759.0, 557.0, 773.0]}, {"text": "47. We recommend that breast feeding does not need to", "bbox": [418.0, 773.0, 741.0, 788.0]}, {"text": "be suspended after a single intravenous dose of midazolam,", "bbox": [406.0, 788.0, 739.0, 803.0]}, {"text": "fentanyl or pethidine (or when used in combination), or after", "bbox": [406.0, 803.0, 739.0, 817.0]}, {"text": "administration of propofol", "bbox": [408.0, 819.0, 549.0, 832.0]}, {"text": "Grade of evidence: Low. Strength of recommendation: Strong.", "bbox": [418.0, 833.0, 737.0, 847.0]}, {"text": "Level of agreement: 100%", "bbox": [418.0, 847.0, 557.0, 861.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": "Pregnancy", "bbox": [406.0, 883.0, 460.0, 897.0]}], "type": "Section-header", "position": 5}, {"raw_context": [{"text": "Endoscopic procedures can be required in pregnant and breast", "bbox": [406.0, 898.0, 741.0, 913.0]}, {"text": "feeding women and some conditions are more prevalent in these", "bbox": [406.0, 913.0, 740.0, 927.0]}, {"text": "patients—for example, gallstones. First and foremost, the risks", "bbox": [406.0, 928.0, 741.0, 941.0]}, {"text": "to the patient need to be considered, both from performing an", "bbox": [406.0, 942.0, 741.0, 955.0]}, {"text": "endoscopy and from opting for alternative, non-endoscopic", "bbox": [406.0, 957.0, 740.0, 970.0]}, {"text": "management. From a sedation perspective there are some addi-", "bbox": [406.0, 970.0, 739.0, 987.0]}, {"text": "tional risks that need to be considered—namely, an increased", "bbox": [406.0, 986.0, 740.0, 1000.0]}], "type": "Text", "position": 6}, {"raw_context": [{"text": "19", "bbox": [727.0, 1011.0, 739.0, 1021.0]}], "type": "Text", "position": 7}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/消化科/_2023 BSG指南：胃肠内窥镜检查中的镇静.pdf", "page_num": 19}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type2": "缺少换行#0#0#Grade of evidence: Low. Strength of recommendation: Strong.另起一行\n缺少换行#1#1#General anaesthesia with endotracheal...\n41. We recommend adjunctive...另起一行\n缺少换行#3#3#Patients with chronic progressive...\nWe recommend multidisciplinary...\n42. We recommend that patients...\nGrade of evidence: ...都另起一行\n缺少换行#4#4# In a case series of 500 patients...都另起一行\n缺少换行#7#7#Grade of evidence:...都另起一行\n缺少换行#8#8# A small study of patients with...都另起一行\n缺少换行#12#12#45. The use of diazepam in ...\n Grade of evidence: Low...都另起一行\n缺少换行#13#13#46. We recommend that...\nGrade of evidence: Low....都另起一行\n缺少换行#14#14#47. We recommend that breast...\nGrade of evidence: Low....都另起一行", "type3": "无关文本#1#17#66 immediate referral to ...\n...risk of aspiration. 221像这样在.号或，号的开头或结尾出现的数字都是无关引用\n无关文本#18#18#19  页码内容", "type6": "有用性#5#5#页脚的内容"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:40", "update_time": "2024-05-07 19:16:05"}
{"id": 1082498, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 738, "source_info": {"seq_id": "9405ab16-fb0e-4763-970f-2b832f975f31", "title": null, "text": "【0】页码:2\n to better understand the expert consensus and standardize the clinical practice of OCT, this paper interprets its core contents.\n\n【1】Key words coronary artery disease; optical coherence tomography; coronary interventions; expert consensus; interpretation\n\n【2】 2023 2\n\n【3】 (stent thrombosis,ST)\n\n【4】 f\n 2 [1] .\n\n【5】 2017\n\n【6】 f\n\n【7】 s\n\n【8】 ,OCT\n\n【9】 (bioresorbable scaffold, BRS) (drug-coated balloon,DCB)\n\n【10】\n DCB\n\n【11】 (optical coherence tomography, OCT)\n\n【12】 1. 2 OCT\n\n【13】 PCI\n\n【14】 1\n\n【15】 1. 1\n\n【16】 OCT\n\n【17】 ,\n\n【18】 . ILUMI-\n\n【19】 , DOCTORS EN , Pan-Landon ,DETECT OCT .iSIGHT\n\n【20】 (10)\n\n【21】 ~15 mm),\n\n【22】 (\n\n【23】 )\n\n【24】 ,\n\n【25】 , OCT\n\n【26】 PCI\n\n【27】 [8-13]\n\n【28】 OCT\n\n【29】 PCI OCT > 80 % ; > 4. 5 mm 2 ; ESC/EACTS < 50 % ; 2021 < 60° .\n\n【30】OCT 2 mm < 1 mm [ 7 ] (percutaneous coronary in¬ < 0. 4 mm OCT II a PCI ST ST 2020 EuroPCR LightLab , OCT PCI , (MLD MAX), OCT OCT [4-6] e 2018 (morphology), EAPCI , (length) (diameter), OCT (medial dissec- PCI tion) , (apposition) (xpan- [2] [2] MLD sion) MAX , OCT 88% 80 % [14] [14] , OCT (Angio Co-Registration, ACR) PCI , OPTICO-integration ; ,ACR 40. 7% PCI (acute coro- [15] OCT (in-stent restenosis, ISR) PCI 1. D\n\n【31】\n , OCT\n\n【32】 ,2018 ACC/AHA/SCAI\n\n【33】 tervention, PCI) [2-3]\n\n【34】 (C) 1994-2023 China Academic Journal Electronic Publishing House. All rights reserved.\n\n【35】http://www.cnki.net\n\n【36】 OCT\n\n【37】 nary syndrome, ACS)", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "to better understand the expert consensus and standardize the clinical practice of OCT, this paper interprets its", "bbox": [105.0, 97.0, 688.0, 114.0]}, {"text": "core contents.", "bbox": [105.0, 116.0, 178.0, 131.0]}, {"text": "Key words coronary artery disease; optical coherence tomography; coronary interventions; expert consen-", "bbox": [130.0, 134.0, 684.0, 150.0]}, {"text": "sus; interpretation", "bbox": [105.0, 153.0, 205.0, 168.0]}], "type": "Text", "position": 1}, {"raw_context": [{"text": "2023", "bbox": [104.0, 188.0, 138.0, 204.0]}, {"text": "2", "bbox": [156.0, 189.0, 168.0, 204.0]}], "type": "Text", "position": 2}, {"raw_context": [{"text": "(stent thrombosis,ST)", "bbox": [410.0, 188.0, 553.0, 204.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "f", "bbox": [104.0, 210.0, 115.0, 223.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": "2 [1] .", "bbox": [204.0, 226.0, 232.0, 244.0]}], "type": "Formula", "position": 5}, {"raw_context": [{"text": "2017", "bbox": [254.0, 228.0, 286.0, 244.0]}], "type": "Text", "position": 6}, {"raw_context": [{"text": "f", "bbox": [343.0, 229.0, 354.0, 246.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "s", "bbox": [162.0, 271.0, 172.0, 284.0]}], "type": "Text", "position": 8}, {"raw_context": [{"text": ",OCT", "bbox": [543.0, 247.0, 583.0, 263.0]}], "type": "Text", "position": 9}, {"raw_context": [{"text": "(bioresorbable scaffold, BRS)", "bbox": [410.0, 288.0, 598.0, 305.0]}, {"text": "(drug-coated balloon,DCB)", "bbox": [410.0, 307.0, 580.0, 324.0]}], "type": "Table", "position": 10}, {"raw_context": [{"text": "DCB", "bbox": [666.0, 307.0, 700.0, 323.0]}], "type": "Text", "position": 11}, {"raw_context": [{"text": "(optical coherence tomography, OCT)", "bbox": [132.0, 329.0, 368.0, 346.0]}], "type": "Text", "position": 12}, {"raw_context": [{"text": "1. 2 OCT", "bbox": [410.0, 367.0, 478.0, 384.0]}], "type": "Text", "position": 13}, {"raw_context": [{"text": "PCI", "bbox": [537.0, 368.0, 564.0, 384.0]}], "type": "Text", "position": 14}, {"raw_context": [{"text": "1", "bbox": [78.0, 391.0, 88.0, 405.0]}], "type": "Text", "position": 15}, {"raw_context": [{"text": "1. 1", "bbox": [77.0, 409.0, 104.0, 425.0]}], "type": "Text", "position": 16}, {"raw_context": [{"text": "OCT", "bbox": [104.0, 408.0, 144.0, 424.0]}], "type": "Text", "position": 17}, {"raw_context": [{"text": ",", "bbox": [425.0, 414.0, 432.0, 423.0]}], "type": "Text", "position": 18}, {"raw_context": [{"text": ". ILUMI-", "bbox": [650.0, 427.0, 713.0, 444.0]}], "type": "Text", "position": 19}, {"raw_context": [{"text": ", DOCTORS", "bbox": [498.0, 448.0, 580.0, 464.0]}, {"text": "EN", "bbox": [409.0, 449.0, 434.0, 464.0]}, {"text": ", Pan-Landon", "bbox": [612.0, 449.0, 696.0, 465.0]}, {"text": ",DETECT OCT", "bbox": [425.0, 467.0, 526.0, 484.0]}, {"text": ".iSIGHT", "bbox": [555.0, 468.0, 614.0, 484.0]}], "type": "Text", "position": 20}, {"raw_context": [{"text": "(10)", "bbox": [356.0, 450.0, 383.0, 465.0]}], "type": "Text", "position": 21}, {"raw_context": [{"text": "~15 mm),", "bbox": [78.0, 469.0, 150.0, 485.0]}], "type": "Text", "position": 22}, {"raw_context": [{"text": "(", "bbox": [252.0, 471.0, 262.0, 484.0]}], "type": "Text", "position": 23}, {"raw_context": [{"text": ")", "bbox": [291.0, 471.0, 301.0, 484.0]}], "type": "Text", "position": 24}, {"raw_context": [{"text": ",", "bbox": [374.0, 475.0, 383.0, 487.0]}], "type": "Text", "position": 25}, {"raw_context": [{"text": ", OCT", "bbox": [614.0, 488.0, 653.0, 504.0]}], "type": "Text", "position": 26}, {"raw_context": [{"text": "PCI", "bbox": [576.0, 508.0, 604.0, 523.0]}], "type": "Text", "position": 27}, {"raw_context": [{"text": "[8-13]", "bbox": [569.0, 525.0, 598.0, 540.0]}], "type": "Text", "position": 28}, {"raw_context": [{"text": "OCT", "bbox": [77.0, 548.0, 110.0, 565.0]}], "type": "Text", "position": 29}, {"raw_context": [{"text": "PCI", "bbox": [426.0, 568.0, 455.0, 583.0]}, {"text": "OCT", "bbox": [206.0, 588.0, 239.0, 605.0]}, {"text": "> 80 % ;", "bbox": [575.0, 588.0, 627.0, 606.0]}, {"text": "> 4. 5 mm 2 ;", "bbox": [424.0, 589.0, 502.0, 605.0]}, {"text": "ESC/EACTS", "bbox": [145.0, 608.0, 231.0, 625.0]}, {"text": "< 50 % ;", "bbox": [451.0, 609.0, 503.0, 625.0]}, {"text": "2021", "bbox": [352.0, 610.0, 382.0, 625.0]}, {"text": "< 60° .", "bbox": [629.0, 610.0, 670.0, 625.0]}, {"text": "OCT", "bbox": [270.0, 628.0, 303.0, 644.0]}, {"text": "2 mm", "bbox": [409.0, 629.0, 449.0, 645.0]}, {"text": "< 1 mm [ 7 ]", "bbox": [641.0, 649.0, 707.0, 665.0]}, {"text": "(percutaneous coronary in¬", "bbox": [217.0, 650.0, 381.0, 665.0]}, {"text": "< 0. 4 mm", "bbox": [512.0, 650.0, 580.0, 665.0]}, {"text": "OCT", "bbox": [543.0, 669.0, 576.0, 685.0]}, {"text": "II a", "bbox": [361.0, 670.0, 383.0, 685.0]}, {"text": "PCI", "bbox": [641.0, 670.0, 667.0, 685.0]}, {"text": "ST", "bbox": [312.0, 688.0, 334.0, 705.0]}, {"text": "ST", "bbox": [228.0, 709.0, 251.0, 725.0]}, {"text": "2020", "bbox": [437.0, 709.0, 471.0, 725.0]}, {"text": "EuroPCR", "bbox": [486.0, 709.0, 547.0, 725.0]}, {"text": "LightLab", "bbox": [623.0, 710.0, 682.0, 726.0]}, {"text": ",", "bbox": [207.0, 714.0, 216.0, 725.0]}, {"text": "OCT", "bbox": [561.0, 729.0, 595.0, 744.0]}, {"text": "PCI", "bbox": [627.0, 729.0, 655.0, 745.0]}, {"text": ",", "bbox": [495.0, 733.0, 503.0, 745.0]}, {"text": "(MLD MAX),", "bbox": [410.0, 748.0, 504.0, 765.0]}, {"text": "OCT", "bbox": [584.0, 748.0, 617.0, 764.0]}, {"text": "OCT", "bbox": [243.0, 749.0, 277.0, 765.0]}, {"text": "[4-6] e 2018", "bbox": [210.0, 766.0, 279.0, 786.0]}, {"text": "(morphology),", "bbox": [410.0, 769.0, 504.0, 785.0]}, {"text": "EAPCI", "bbox": [336.0, 770.0, 383.0, 785.0]}, {"text": ",", "bbox": [295.0, 772.0, 303.0, 785.0]}, {"text": "(length)", "bbox": [437.0, 789.0, 492.0, 805.0]}, {"text": "(diameter),", "bbox": [532.0, 789.0, 608.0, 805.0]}, {"text": "OCT", "bbox": [681.0, 789.0, 715.0, 804.0]}, {"text": "(medial dissec-", "bbox": [619.0, 809.0, 713.0, 825.0]}, {"text": "PCI", "bbox": [268.0, 830.0, 295.0, 845.0]}, {"text": "tion) ,", "bbox": [410.0, 831.0, 450.0, 845.0]}, {"text": "(apposition)", "bbox": [505.0, 831.0, 584.0, 845.0]}, {"text": "(xpan-", "bbox": [670.0, 831.0, 713.0, 845.0]}, {"text": "[2] [2]", "bbox": [145.0, 847.0, 164.0, 862.0]}, {"text": "MLD", "bbox": [680.0, 849.0, 716.0, 865.0]}, {"text": "sion)", "bbox": [410.0, 850.0, 444.0, 866.0]}, {"text": "MAX", "bbox": [409.0, 869.0, 446.0, 885.0]}, {"text": ", OCT", "bbox": [505.0, 869.0, 546.0, 885.0]}, {"text": "88%", "bbox": [623.0, 869.0, 656.0, 885.0]}, {"text": "80 %", "bbox": [534.0, 889.0, 567.0, 904.0]}, {"text": "[14] [14]", "bbox": [650.0, 889.0, 671.0, 902.0]}, {"text": ",", "bbox": [425.0, 893.0, 435.0, 905.0]}, {"text": "OCT", "bbox": [426.0, 910.0, 461.0, 926.0]}, {"text": "(Angio Co-Registration,", "bbox": [559.0, 910.0, 713.0, 926.0]}, {"text": "ACR)", "bbox": [410.0, 930.0, 449.0, 946.0]}, {"text": "PCI", "bbox": [316.0, 950.0, 344.0, 965.0]}, {"text": ", OPTICO-integration", "bbox": [424.0, 950.0, 560.0, 966.0]}, {"text": ";", "bbox": [236.0, 955.0, 244.0, 966.0]}, {"text": ",ACR", "bbox": [424.0, 970.0, 465.0, 986.0]}, {"text": "40. 7%", "bbox": [612.0, 970.0, 656.0, 986.0]}, {"text": "PCI", "bbox": [440.0, 990.0, 467.0, 1006.0]}, {"text": "(acute coro-", "bbox": [303.0, 991.0, 381.0, 1006.0]}, {"text": "[15]", "bbox": [479.0, 1008.0, 503.0, 1022.0]}, {"text": "OCT", "bbox": [633.0, 1030.0, 667.0, 1046.0]}, {"text": "(in-stent restenosis, ISR)", "bbox": [124.0, 1050.0, 287.0, 1066.0]}, {"text": "PCI", "bbox": [426.0, 1050.0, 454.0, 1065.0]}, {"text": "1. D", "bbox": [621.0, 1051.0, 646.0, 1068.0]}], "type": "Table", "position": 30}, {"raw_context": [{"text": ", OCT", "bbox": [196.0, 449.0, 235.0, 465.0]}], "type": "Text", "position": 31}, {"raw_context": [{"text": ",2018", "bbox": [92.0, 610.0, 132.0, 625.0]}, {"text": "ACC/AHA/SCAI", "bbox": [94.0, 628.0, 207.0, 645.0]}], "type": "Text", "position": 32}, {"raw_context": [{"text": "tervention, PCI)", "bbox": [77.0, 670.0, 177.0, 685.0]}, {"text": "[2-3]", "bbox": [119.0, 687.0, 146.0, 702.0]}], "type": "Text", "position": 33}, {"raw_context": [{"text": "(C) 1994-2023 China Academic Journal Electronic Publishing House. All rights reserved.", "bbox": [24.0, 1082.0, 537.0, 1099.0]}, {"text": "http://www.cnki.net", "bbox": [542.0, 1084.0, 662.0, 1099.0]}], "type": "Text", "position": 34}, {"raw_context": [{"text": "OCT", "bbox": [108.0, 909.0, 141.0, 926.0]}], "type": "Text", "position": 35}, {"raw_context": [{"text": "nary syndrome, ACS)", "bbox": [77.0, 1010.0, 211.0, 1027.0]}], "type": "Text", "position": 36}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/心血管/解读/《光学相干断层成像技术在冠心病介入诊疗中应用的中国专家共识》解读.pdf", "page_num": 2}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "格式杂乱#0#37#全篇格式杂乱", "type3": null, "type4": null, "type5": null, "type6": null}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:40", "update_time": "2024-05-08 00:04:35"}
{"id": 1082497, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 738, "source_info": {"seq_id": "afe421bb-5678-490c-b695-a6a7c855cfab", "title": null, "text": "【0】页码:9\n [25]\n\n【1】 [26]\n\n【2】 .\n\n【3】 ,\n\n【4】 .\n\n【5】 [27]\n\n【6】 .\n\n【7】 ,\n\n【8】 [1].\n\n【9】 .\n\n【10】 ,2019,12(7):486–\n\n【11】 DING C , HONG Y , WANG BY , et al. Expert consensus on the implementation of enhanced recovery after surgery in anterior cervical spine surgery [J]. Zhonghua Gu Yu Guan Jie Wai Ke Za Zhi ,2019,\n\n【12】 12(7):486–497. Chinese.\n\n【13】 Hukuda S, Mochizuki T, Ogata M, et  al. Operations for cervical spondylotic myelopathy[J]. J Bone Joint Surg Am , 1985 , 67 (4) : 609–615.\n\n【14】 [1].\n\n【15】,2016,29(3):197–199.\n\n【16】HE XJ,CAI X,HE GL. Selection of surgical method for cervical spondylotic myelopathy[J]. Zhongguo Gu Shang/China J Orthop Trauma , 2016 , 29(3): 197–199. Chinese.\n\n【17】## ,2016,29(6):561–565.\n\n【18】\n ZHOU YJ , CHAI XB.  Opinions about diagnosis and treatment of multilevel cervical spondylotic myelopathy[J]. Zhongguo Gu Shang/China J Orthop Trauma , 2016 , 29(6):561–565. Chinese with abstract in English.\n\n【19】 , 2018 , 31 (1) : 1–4.\n\n【20】[1] .\n\n【21】TAN MS,QI YN,WU XJ. Thinking of the surgical treatment for cervical spondylotic myelopathy and the dredging Du meridian [ J ].\n\n【22】Zhongguo Gu Shang/China J Orthop Trauma,2018,31(1):1–4.\n\n【23】Chinese.\n\n【24】 [1].\n\n【25】 ,2021 ,34(4) :327–332.\n\n【26】XU YX,LUO QS,LI YH,et al. Microscope assisted anterior cervical discectomy and fusion for the treatment of single segment cervical spondylotic myelopathy[J]. Zhongguo Gu Shang/China J Orthop Trauma , 2021 , 34(4) ; 327–332. Chinese with abstract in English.\n\n【27】 [33]\n\n【28】 [J].\n\n【29】,2019 , 12 ( 7 ) :498–508.\n\n【30】ZHOU FF , HAN B , LIU N , et al. Expert consensus on the implementation of enhanced recovery after surgery in posterior cervical spine surgery [J]. Zhonghua Gu Yu Guan Jie Wai Ke Za Zhi , 2019, 12(7):498–508. Chinese.\n\n【31】 [28]\n\n【32】 [29]\n\n【33】 [30]\n\n【34】 [1].\n\n【35】 [31]\n\n【36】 [32]\n\n【37】 ,2016,29(3):216–219.\n\n【38】[1].\n\n【39】TANG Y , JIA ZW , WU JH , et al. Factors of prognosis in cervical spondylotic myelopathy : a review[J]. Zhongguo Gu Shang/China J Orthop Trauma,2016,29(3):216–219. Chinese with abstract in English.\n\n【40】 [35]\n\n【41】 [36]\n\n【42】 ,\n\n【43】 .\n\n【44】 .\n [1].\n\n【45】 2021, 28\n\n【46】 (7):1–4.\n\n【47】LONG SW , LI JY , ZHENG CY , et al. Research progress in traditional Chinese medicine treatment of postoperative spinal nerve function rehabilitation of cervical spondylotic myelopathy [ J ].\n\n【48】Zhongguo Zhong Yi Yao Xin Xi Za Zhi , 2021 , 28(7) ; 1–4. Chinese.\n\n【49】.\n\n【50】## [1].\n\n【51】\n## , 2015 , 47 ( 7 ) , 222–224.\n\n【52】\n LIU X,CAO Y,XU JH. Clinical observation on acupuncture at Jiaji acupoints in the treatment of postoperative axial symptoms of cervical spondylotic myelopathy[J]. Xin Zhong Yi,2015,47(7): 222–224. Chinese.\n\n【53】 [1].\n , 2014 , 34\n\n【54】 (16):4620–4622.\n\n【55】LU YZ. Effects of electroacupuncture stimulation on motor function and nerve growth factor expression in rats with acute spinal cord injury[J]. Zhongguo Lao Nian Xue Za Zhi,2014,34(16): 4620–4622. Chinese.\n\n【56】 [39]\n\n【57】 2020,41(6):661–665.\n\n【58】TAN B,SHAO CL,ZHAO WW,et al. Effect of modified Taiji \"Unsu\" on postoperative balance function and diffusion tensor imaging in patients with cervical spondylotic myelopathy [J]. Jing Yao Tong Za Zhi , 2020 , 41 ( 6 ) ; 661–665. Chinese.\n\n【59】 [40]\n\n【60】## ,2019 ,19(28) ,17–19.\n\n【61】\n WANG YZ,LIU XH,WU ZJ,et al. Effect of pestle needle combined with Baduanjin on rehabilitation of patients with postoperative axial symptoms of cervical spondylotic myelopathy [J]. Shi Jie Zui Xin Yi Xue Xin Xi Wen Zhai , 2019 , 19(28) ; 17–19. Chinese.\n\n【62】 [41]\n\n【63】## [1].\n\n【64】\n## , 2015 , 10( 11 ) ; 1796–1801.\n\n【65】\n YANG L,YAO M,SUN YL,et al. Research status of evidencebased treatment of cervical spondylotic myelopathy [ J ]. Shi Jie Zhong Yi Yao,2015,10(11):1796–1801. Chinese.\n\n【66】: 2021–12–22.\n\n【67】(\n\n【68】 [34]\n\n【69】 [J].\n\n【70】,2017 ,30(9) :77–80.\n\n【71】LIANG XQ , LAN XF , WANG SK , et al. Research progress of traditional Chinese medicine treatment of postoperative residual neurological symptoms of cervical spondylotic myelopathy [J]. Zhong Yi Yan Jiu,2017,30(9):77–80. Chinese.\n\n【72】 [J].\n\n【73】, 2018 , 31(1):30–36.\n\n【74】YANG F,TAN MS,YI P,et al. Clinical study on spinal cord decompression combined with traditional Chinese medicine for the treatment of cervical spondylotic myelopathy [ J ]. Zhongguo Gu Shang/China J Orthop Trauma , 2018 , 31(1) , 30–36. Chinese with abstract in English.\n\n【75】 [37]\n\n【76】 [38]\n\n【77】 .\n [J].\n\n【78】## [1].\n\n【79】\n , , .\n\n【80】,2018,31(8):740–745.\n\n【81】[1] .\n\n【82】DAIB , GAO P , DONG QR , et al. Clinical study of the application of enhanced recovery after surgery in cervical spondylotic myelopathy [J] . Zhongguo Gu Shang/China J Orthop Trauma,2018,31 (8): 740–745. Chinese with abstract in English.\n\n【83】 na J Orthop Trauma , 2006 , 19(11) , 691. Chinese.\n\n【84】 497.", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "[25]", "bbox": [64.0, 121.0, 91.0, 136.0]}], "type": "Text", "position": 1}, {"raw_context": [{"text": "[26]", "bbox": [65.0, 223.0, 90.0, 235.0]}], "type": "Text", "position": 2}, {"raw_context": [{"text": ".", "bbox": [130.0, 226.0, 138.0, 235.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": ",", "bbox": [154.0, 226.0, 164.0, 235.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": ".", "bbox": [182.0, 227.0, 192.0, 236.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "[27]", "bbox": [64.0, 320.0, 91.0, 335.0]}], "type": "Text", "position": 6}, {"raw_context": [{"text": ".", "bbox": [120.0, 326.0, 128.0, 335.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": ",", "bbox": [146.0, 325.0, 155.0, 335.0]}], "type": "Text", "position": 8}, {"raw_context": [{"text": "[1].", "bbox": [161.0, 340.0, 182.0, 352.0]}], "type": "Text", "position": 9}, {"raw_context": [{"text": ".", "bbox": [184.0, 325.0, 215.0, 336.0]}], "type": "Text", "position": 10}, {"raw_context": [{"text": ",2019,12(7):486–", "bbox": [290.0, 339.0, 378.0, 352.0]}], "type": "Text", "position": 12}, {"raw_context": [{"text": "DING C , HONG Y , WANG BY , et al. Expert consensus on the im-", "bbox": [96.0, 369.0, 376.0, 387.0]}, {"text": "plementation of enhanced recovery after surgery in anterior cervical", "bbox": [96.0, 388.0, 377.0, 401.0]}, {"text": "spine surgery [J]. Zhonghua Gu Yu Guan Jie Wai Ke Za Zhi ,2019,", "bbox": [96.0, 404.0, 377.0, 418.0]}], "type": "Text", "position": 13}, {"raw_context": [{"text": "12(7):486–497. Chinese.", "bbox": [98.0, 422.0, 208.0, 434.0]}], "type": "Text", "position": 14}, {"raw_context": [{"text": "Hukuda S, Mochizuki T, Ogata M, et  al. Operations for cervical", "bbox": [96.0, 436.0, 379.0, 451.0]}, {"text": "spondylotic myelopathy[J]. J Bone Joint Surg Am , 1985 , 67 (4) :", "bbox": [96.0, 453.0, 377.0, 468.0]}, {"text": "609–615.", "bbox": [97.0, 471.0, 140.0, 484.0]}], "type": "Text", "position": 15}, {"raw_context": [{"text": "[1].", "bbox": [344.0, 489.0, 365.0, 501.0]}, {"text": ",2016,29(3):197–199.", "bbox": [130.0, 502.0, 235.0, 517.0]}, {"text": "HE XJ,CAI X,HE GL. Selection of surgical method for cervical", "bbox": [96.0, 520.0, 379.0, 533.0]}, {"text": "spondylotic myelopathy[J]. Zhongguo Gu Shang/China J Orthop", "bbox": [97.0, 538.0, 378.0, 551.0]}, {"text": "Trauma , 2016 , 29(3): 197–199. Chinese.", "bbox": [96.0, 553.0, 272.0, 567.0]}], "type": "Text", "position": 16}, {"raw_context": [{"text": ",2016,29(6):561–565.", "bbox": [161.0, 586.0, 265.0, 600.0]}], "type": "Section-header", "position": 17}, {"raw_context": [{"text": "ZHOU YJ , CHAI XB.  Opinions about diagnosis and treatment", "bbox": [96.0, 603.0, 377.0, 617.0]}, {"text": "of multilevel cervical spondylotic myelopathy[J]. Zhongguo Gu", "bbox": [95.0, 619.0, 379.0, 634.0]}, {"text": "Shang/China J Orthop Trauma , 2016 , 29(6):561–565. Chinese", "bbox": [96.0, 636.0, 377.0, 649.0]}, {"text": "with abstract in English.", "bbox": [97.0, 654.0, 204.0, 667.0]}], "type": "Text", "position": 18}, {"raw_context": [{"text": ", 2018 , 31 (1) : 1–4.", "bbox": [201.0, 686.0, 287.0, 700.0]}, {"text": "[1] .", "bbox": [139.0, 687.0, 160.0, 700.0]}, {"text": "TAN MS,QI YN,WU XJ. Thinking of the surgical treatment for", "bbox": [96.0, 702.0, 378.0, 716.0]}, {"text": "cervical spondylotic myelopathy and the dredging Du meridian [ J ].", "bbox": [96.0, 720.0, 377.0, 733.0]}, {"text": "Zhongguo Gu Shang/China J Orthop Trauma,2018,31(1):1–4.", "bbox": [96.0, 735.0, 377.0, 749.0]}, {"text": "Chinese.", "bbox": [96.0, 753.0, 136.0, 766.0]}], "type": "Text", "position": 19}, {"raw_context": [{"text": "[1].", "bbox": [322.0, 787.0, 342.0, 799.0]}], "type": "Text", "position": 20}, {"raw_context": [{"text": ",2021 ,34(4) :327–332.", "bbox": [109.0, 801.0, 213.0, 816.0]}, {"text": "XU YX,LUO QS,LI YH,et al. Microscope assisted anterior cer-", "bbox": [96.0, 819.0, 377.0, 832.0]}, {"text": "vical discectomy and fusion for the treatment of single segment", "bbox": [96.0, 836.0, 377.0, 849.0]}, {"text": "cervical spondylotic myelopathy[J]. Zhongguo Gu Shang/China J", "bbox": [96.0, 852.0, 378.0, 865.0]}, {"text": "Orthop Trauma , 2021 , 34(4) ; 327–332. Chinese with abstract in", "bbox": [95.0, 867.0, 378.0, 882.0]}, {"text": "English.", "bbox": [97.0, 885.0, 134.0, 898.0]}], "type": "Text", "position": 21}, {"raw_context": [{"text": "[33]", "bbox": [64.0, 901.0, 90.0, 915.0]}], "type": "Text", "position": 22}, {"raw_context": [{"text": "[J].", "bbox": [138.0, 238.0, 161.0, 251.0]}, {"text": ",2019 , 12 ( 7 ) :498–508.", "bbox": [266.0, 239.0, 371.0, 251.0]}, {"text": "ZHOU FF , HAN B , LIU N , et al. Expert consensus on the imple-", "bbox": [96.0, 253.0, 375.0, 270.0]}, {"text": "mentation of enhanced recovery after surgery in posterior cervical", "bbox": [96.0, 272.0, 377.0, 286.0]}, {"text": "spine surgery [J]. Zhonghua Gu Yu Guan Jie Wai Ke Za Zhi , 2019,", "bbox": [97.0, 289.0, 376.0, 302.0]}, {"text": "12(7):498–508. Chinese.", "bbox": [97.0, 305.0, 210.0, 319.0]}], "type": "Text", "position": 23}, {"raw_context": [{"text": "[28]", "bbox": [65.0, 437.0, 91.0, 451.0]}], "type": "Text", "position": 24}, {"raw_context": [{"text": "[29]", "bbox": [65.0, 488.0, 91.0, 500.0]}], "type": "Text", "position": 25}, {"raw_context": [{"text": "[30]", "bbox": [64.0, 570.0, 90.0, 584.0]}], "type": "Text", "position": 26}, {"raw_context": [{"text": "[1].", "bbox": [97.0, 588.0, 119.0, 600.0]}], "type": "Text", "position": 27}, {"raw_context": [{"text": "[31]", "bbox": [64.0, 670.0, 90.0, 682.0]}], "type": "Text", "position": 28}, {"raw_context": [{"text": "[32]", "bbox": [64.0, 768.0, 91.0, 783.0]}], "type": "Text", "position": 29}, {"raw_context": [{"text": ",2016,29(3):216–219.", "bbox": [181.0, 139.0, 287.0, 152.0]}, {"text": "[1].", "bbox": [119.0, 140.0, 139.0, 152.0]}, {"text": "TANG Y , JIA ZW , WU JH , et al. Factors of prognosis in cervical", "bbox": [96.0, 155.0, 379.0, 170.0]}, {"text": "spondylotic myelopathy : a review[J]. Zhongguo Gu Shang/China J", "bbox": [97.0, 172.0, 379.0, 185.0]}, {"text": "Orthop Trauma,2016,29(3):216–219. Chinese with abstract in", "bbox": [95.0, 188.0, 378.0, 202.0]}, {"text": "English.", "bbox": [97.0, 206.0, 135.0, 218.0]}], "type": "Text", "position": 30}, {"raw_context": [{"text": "[35]", "bbox": [398.0, 205.0, 424.0, 218.0]}], "type": "Text", "position": 31}, {"raw_context": [{"text": "[36]", "bbox": [398.0, 320.0, 424.0, 335.0]}], "type": "Text", "position": 32}, {"raw_context": [{"text": ",", "bbox": [463.0, 326.0, 470.0, 335.0]}], "type": "Text", "position": 33}, {"raw_context": [{"text": ".", "bbox": [500.0, 327.0, 508.0, 335.0]}], "type": "Text", "position": 34}, {"raw_context": [{"text": ".", "bbox": [538.0, 328.0, 559.0, 335.0]}], "type": "Text", "position": 35}, {"raw_context": [{"text": "[1].", "bbox": [541.0, 340.0, 563.0, 353.0]}], "type": "Formula", "position": 36}, {"raw_context": [{"text": "2021, 28", "bbox": [666.0, 339.0, 711.0, 352.0]}], "type": "Text", "position": 37}, {"raw_context": [{"text": "(7):1–4.", "bbox": [430.0, 355.0, 473.0, 367.0]}, {"text": "LONG SW , LI JY , ZHENG CY , et al. Research progress in tradi-", "bbox": [429.0, 370.0, 709.0, 385.0]}, {"text": "tional Chinese medicine treatment of postoperative spinal nerve", "bbox": [430.0, 388.0, 711.0, 401.0]}, {"text": "function rehabilitation of cervical spondylotic myelopathy [ J ].", "bbox": [429.0, 404.0, 711.0, 418.0]}, {"text": "Zhongguo Zhong Yi Yao Xin Xi Za Zhi , 2021 , 28(7) ; 1–4. Chinese.", "bbox": [429.0, 420.0, 710.0, 435.0]}, {"text": ".", "bbox": [453.0, 442.0, 461.0, 451.0]}], "type": "Text", "position": 38}, {"raw_context": [{"text": "[1].", "bbox": [494.0, 456.0, 517.0, 468.0]}], "type": "Section-header", "position": 39}, {"raw_context": [{"text": ", 2015 , 47 ( 7 ) , 222–224.", "bbox": [546.0, 455.0, 652.0, 468.0]}], "type": "Section-header", "position": 40}, {"raw_context": [{"text": "LIU X,CAO Y,XU JH. Clinical observation on acupuncture at Ji-", "bbox": [430.0, 471.0, 709.0, 484.0]}, {"text": "aji acupoints in the treatment of postoperative axial symptoms of", "bbox": [430.0, 488.0, 711.0, 500.0]}, {"text": "cervical spondylotic myelopathy[J]. Xin Zhong Yi,2015,47(7):", "bbox": [430.0, 503.0, 710.0, 518.0]}, {"text": "222–224. Chinese.", "bbox": [430.0, 521.0, 512.0, 533.0]}], "type": "Text", "position": 41}, {"raw_context": [{"text": "[1].", "bbox": [559.0, 553.0, 580.0, 568.0]}], "type": "Text", "position": 42}, {"raw_context": [{"text": ", 2014 , 34", "bbox": [666.0, 553.0, 711.0, 565.0]}], "type": "Formula", "position": 43}, {"raw_context": [{"text": "(16):4620–4622.", "bbox": [430.0, 571.0, 510.0, 583.0]}, {"text": "LU YZ. Effects of electroacupuncture stimulation on motor func-", "bbox": [429.0, 586.0, 709.0, 601.0]}, {"text": "tion and nerve growth factor expression in rats with acute spinal", "bbox": [430.0, 604.0, 711.0, 617.0]}, {"text": "cord injury[J]. Zhongguo Lao Nian Xue Za Zhi,2014,34(16):", "bbox": [429.0, 619.0, 711.0, 634.0]}, {"text": "4620–4622. Chinese.", "bbox": [430.0, 637.0, 524.0, 649.0]}], "type": "Text", "position": 44}, {"raw_context": [{"text": "[39]", "bbox": [398.0, 654.0, 424.0, 667.0]}], "type": "Text", "position": 45}, {"raw_context": [{"text": "2020,41(6):661–665.", "bbox": [430.0, 685.0, 531.0, 700.0]}, {"text": "TAN B,SHAO CL,ZHAO WW,et al. Effect of modified Taiji", "bbox": [430.0, 702.0, 711.0, 717.0]}, {"text": "\"Unsu\" on postoperative balance function and diffusion tensor", "bbox": [430.0, 720.0, 711.0, 733.0]}, {"text": "imaging in patients with cervical spondylotic myelopathy [J]. Jing", "bbox": [430.0, 736.0, 712.0, 749.0]}, {"text": "Yao Tong Za Zhi , 2020 , 41 ( 6 ) ; 661–665. Chinese.", "bbox": [430.0, 752.0, 647.0, 766.0]}], "type": "Text", "position": 46}, {"raw_context": [{"text": "[40]", "bbox": [398.0, 768.0, 424.0, 783.0]}], "type": "Text", "position": 47}, {"raw_context": [{"text": ",2019 ,19(28) ,17–19.", "bbox": [443.0, 801.0, 541.0, 816.0]}], "type": "Section-header", "position": 48}, {"raw_context": [{"text": "WANG YZ,LIU XH,WU ZJ,et al. Effect of pestle needle com-", "bbox": [430.0, 819.0, 709.0, 832.0]}, {"text": "bined with Baduanjin on rehabilitation of patients with postopera-", "bbox": [430.0, 835.0, 709.0, 849.0]}, {"text": "tive axial symptoms of cervical spondylotic myelopathy [J]. Shi Jie", "bbox": [429.0, 852.0, 711.0, 865.0]}, {"text": "Zui Xin Yi Xue Xin Xi Wen Zhai , 2019 , 19(28) ; 17–19. Chinese.", "bbox": [429.0, 867.0, 707.0, 882.0]}], "type": "Text", "position": 49}, {"raw_context": [{"text": "[41]", "bbox": [398.0, 886.0, 424.0, 899.0]}], "type": "Text", "position": 50}, {"raw_context": [{"text": "[1].", "bbox": [430.0, 903.0, 453.0, 915.0]}], "type": "Section-header", "position": 51}, {"raw_context": [{"text": ", 2015 , 10( 11 ) ; 1796–1801.", "bbox": [504.0, 901.0, 625.0, 915.0]}], "type": "Section-header", "position": 52}, {"raw_context": [{"text": "YANG L,YAO M,SUN YL,et al. Research status of evidence-", "bbox": [430.0, 917.0, 710.0, 932.0]}, {"text": "based treatment of cervical spondylotic myelopathy [ J ]. Shi Jie", "bbox": [430.0, 937.0, 711.0, 949.0]}, {"text": "Zhong Yi Yao,2015,10(11):1796–1801. Chinese.", "bbox": [430.0, 952.0, 651.0, 966.0]}, {"text": ": 2021–12–22.", "bbox": [554.0, 969.0, 616.0, 982.0]}, {"text": "(", "bbox": [506.0, 971.0, 514.0, 980.0]}], "type": "Text", "position": 53}, {"raw_context": [{"text": "[34]", "bbox": [398.0, 106.0, 424.0, 119.0]}], "type": "Text", "position": 58}, {"raw_context": [{"text": "[J].", "bbox": [535.0, 122.0, 557.0, 137.0]}, {"text": ",2017 ,30(9) :77–80.", "bbox": [601.0, 122.0, 696.0, 136.0]}, {"text": "LIANG XQ , LAN XF , WANG SK , et al. Research progress of tra-", "bbox": [430.0, 138.0, 709.0, 152.0]}, {"text": "ditional Chinese medicine treatment of postoperative residual neu-", "bbox": [430.0, 155.0, 709.0, 170.0]}, {"text": "rological symptoms of cervical spondylotic myelopathy [J]. Zhong", "bbox": [430.0, 172.0, 712.0, 185.0]}, {"text": "Yi Yan Jiu,2017,30(9):77–80. Chinese.", "bbox": [430.0, 188.0, 608.0, 202.0]}], "type": "Text", "position": 59}, {"raw_context": [{"text": "[J].", "bbox": [483.0, 223.0, 504.0, 235.0]}, {"text": ", 2018 , 31(1):30–36.", "bbox": [546.0, 223.0, 641.0, 235.0]}, {"text": "YANG F,TAN MS,YI P,et al. Clinical study on spinal cord de-", "bbox": [430.0, 238.0, 709.0, 252.0]}, {"text": "compression combined with traditional Chinese medicine for the", "bbox": [429.0, 255.0, 711.0, 268.0]}, {"text": "treatment of cervical spondylotic myelopathy [ J ]. Zhongguo Gu", "bbox": [430.0, 272.0, 712.0, 286.0]}, {"text": "Shang/China J Orthop Trauma , 2018 , 31(1) , 30–36. Chinese with", "bbox": [430.0, 288.0, 711.0, 302.0]}, {"text": "abstract in English.", "bbox": [430.0, 306.0, 512.0, 319.0]}], "type": "Text", "position": 60}, {"raw_context": [{"text": "[37]", "bbox": [398.0, 436.0, 424.0, 451.0]}], "type": "Text", "position": 61}, {"raw_context": [{"text": "[38]", "bbox": [398.0, 538.0, 424.0, 551.0]}], "type": "Text", "position": 62}, {"raw_context": [{"text": ".", "bbox": [526.0, 657.0, 550.0, 667.0]}], "type": "Text", "position": 64}, {"raw_context": [{"text": "[J].", "bbox": [627.0, 670.0, 649.0, 683.0]}], "type": "Formula", "position": 65}, {"raw_context": [{"text": "[1].", "bbox": [591.0, 787.0, 612.0, 799.0]}], "type": "Section-header", "position": 66}, {"raw_context": [{"text": ",", "bbox": [119.0, 905.0, 127.0, 915.0]}, {"text": ",", "bbox": [144.0, 905.0, 154.0, 916.0]}, {"text": ".", "bbox": [183.0, 905.0, 204.0, 915.0]}, {"text": ",2018,31(8):740–745.", "bbox": [255.0, 918.0, 361.0, 931.0]}, {"text": "[1] .", "bbox": [193.0, 919.0, 213.0, 932.0]}, {"text": "DAIB , GAO P , DONG QR , et al. Clinical study of the application of", "bbox": [96.0, 934.0, 379.0, 948.0]}, {"text": "enhanced recovery after surgery in cervical spondylotic myelopathy", "bbox": [97.0, 952.0, 377.0, 965.0]}, {"text": "[J] . Zhongguo Gu Shang/China J Orthop Trauma,2018,31 (8):", "bbox": [97.0, 969.0, 377.0, 981.0]}, {"text": "740–745. Chinese with abstract in English.", "bbox": [97.0, 985.0, 275.0, 997.0]}], "type": "Text", "position": 67}, {"raw_context": [{"text": "na J Orthop Trauma , 2006 , 19(11) , 691. Chinese.", "bbox": [96.0, 106.0, 306.0, 119.0]}], "type": "Text", "position": 68}, {"raw_context": [{"text": "497.", "bbox": [97.0, 355.0, 119.0, 367.0]}], "type": "Text", "position": 69}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/骨科/共识/脊髓型颈椎病中西医结合诊疗专家共识.pdf", "page_num": 9}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "格式杂乱#0#84#全篇格式杂乱", "type3": null, "type4": null, "type5": null, "type6": null}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:40", "update_time": "2024-05-07 22:00:00"}
{"id": 1082496, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 738, "source_info": {"seq_id": "d801f879-e749-456b-b91b-6ed9548ffbe7", "title": null, "text": "【0】页码:1\n# Open Access\n\n【1】\n . Additional supplemental material is published online only. To view, please visit the journal online (http://dx.doi.org/ 10.1136/gutjnl-2023-330396).\n\n【2】 For numbered affiliations see end of article.\n\n【3】 Correspondence to Professor Reena Sidhu, Royal Hallamshire Hospital, Sheffield S10 2JF, UK; reenasidhu@nhs.net Received 31 May 2023 Accepted 6 September 2023\n\n【4】 ( R ) Check for updates\n\n【5】 ✪ Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.\n\n【6】 To cite: Sidhu R, Turnbull D, Haboubi H, et al. Gut Epub ahead of print: [ please include Day Month Year].\n\n【7】doi:10.1136/ gutjnl-2023-330396\n# British Society Of Gastroenterology Guidelines On Sedation In Gastrointestinal Endoscopy\n\n【8】\n Reena Sidhu  © , 1,2 David Turnbull, 3 Hasan Haboubi, 4,5 John S Leeds  © , 6,7 Chris Healey, 8 Srisha Hebbar, 9 Paul Collins, 10 Wendy Jones, 1 Chris Healey, \"Sha Hebball,\" Paul Collins,\" Wendy Sones,\nMohammad Farhad Peerally, 12, 13 Sara Brogden, 14 Laura J Neilson, 15 Manu Nayar  © , 6, 7 Jacqui Gath, 16 Graham Foulkes, 17 Nigel J Trudgill  © , 18 Ian Penman 19\n\n【9】## Abstract\n\n【10】\n Over 2.5 million gastrointestinal endoscopic procedures are carried out in the United Kingdom (UK) every year.\n\n【11】Procedures are carried out with local anaesthetic r with sedation. Sedation is commonly used for gastrointestinal endoscopy, but the type and amount of sedation administered is influenced by the complexity and nature of the procedure and patient factors. The elective and emergency nature of endoscopy procedures and local resources also have a significant impact on the delivery of sedation. In the UK, the vast majority of sedated procedures are carried out using benzodiazepines, with or without opiates, whereas deeper sedation using propofol or general anaesthetic requires the involvement of an anaesthetic team. Patients undergoing gastrointestinal endoscopy need to have good understanding of the options for sedation, including the option for no sedation and alternatives, balancing the intended aims of the procedure and reducing the risk of complications. These guidelines were commissioned by the British Society of Gastroenterology (BSG) Endoscopy Committee with input from major stakeholders, to provide a detailed update, incorporating recent advances in sedation for gastrointestinal endoscopy.\n\n【12】This guideline covers aspects from pre-assessment of the elective 'well' patient to patients with significant comorbidity requiring emergency procedures. Types of sedation are discussed, procedure and room requirements and the recovery period, providing guidance to enhance safety and minimise complications.\n\n【13】These guidelines are intended to inform practising clinicians and all staff involved in the delivery of gastrointestinal endoscopy with an expectation that this guideline will be revised in 5-years' time.\n\n【14】## Executive Summary Of Recommendations Type Of Sedation\n\n【15】\n 1. We recommend that sedation providers should tailor the doses dependent on patient factors, procedure type and duration, and complexity Grade of evidence: Moderate. Strength of recom¬ mendation: Strong .\n\n【16】Level of agreement: 92.3% 2. We recommend the provision of inhalational agents to provide the patient with an alternative to sedation Grade of evidence: Moderate. Strength of recom¬ mendation: Strong.\n\n【17】Sidhu R, et al. Gut 2023;0:1–27. doi:10.1136/gutjnl-2023-330396\n\n【18】 Level of agreement: 100%\n\n【19】 Patient information, choice and expectations 3. We recommend that patients receive comprehensive information about what to expect from the sedation and sensory experience of the procedure.\n\n【20】Grade of evidence: High. Strength of recommen¬ dation: Strong .\n\n【21】Level of agreement: 100% 4. We recommend that patients are involved in shared decision-making, where possible, when choosing which sedative medication (if any) to proceed with during an endoscopic procedure.\n\n【22】Grade of evidence: Low. Strength of recommen¬ dation: Strong .\n\n【23】Level of agreement: 100% 5. We recommend that patient comfort should be continually assessed during the procedure and sedation/analgesia titrated appropriately.\n\n【24】Grade of evidence: Low. Strength of recommen¬ dation: Strong .\n\n【25】Level of agreement: 100% 6. We recommend that patient experience of comfort and sedation should be measured and recorded.\n\n【26】Grade of evidence: Low. Strength of recommen¬ dation: Strong .\n\n【27】Level of agreement: 100% 7. We recommend the use of non-pharmacological interventions, such as auditory or visual distraction, to reduce patient anxiety.\n\n【28】Grade of evidence: Moderate. Strength of recom¬ mendation: Moderate.\n\n【29】Level of agreement: 100%\n\n【30】## Pre-Assessment\n\n【31】\n 8. To reduce the risk of sedation-related complications, we recommend pre-assessment to balance the indication and intended aim of the procedure against the physical status of the patient.\n\n【32】Grade of evidence: Moderate. Strength of recom¬ mendation: Strong .\n\n【33】Level of agreement: 84.6% 9. In patients with obstructive sleep apnoea (OSA) and/or a high body mass index (BMI) (≥ 35 kg/ m 2 ) we recommend pre-assessment and enhanced periprocedural monitoring as these patients may be at an increased risk of periprocedural apnoea.\n\n【34】 BMJ", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "OPEN ACCESS", "bbox": [72.0, 112.0, 162.0, 127.0]}], "type": "Title", "position": 1}, {"raw_context": [{"text": ". Additional supplemental", "bbox": [54.0, 273.0, 168.0, 286.0]}, {"text": "material is published online ", "bbox": [54.0, 286.0, 164.0, 299.0]}, {"text": "only. To view, please visit the ", "bbox": [54.0, 298.0, 170.0, 310.0]}, {"text": "journal online (http://dx.doi.org/", "bbox": [54.0, 311.0, 178.0, 322.0]}, {"text": "10.1136/gutjnl-2023-330396).", "bbox": [54.0, 322.0, 176.0, 334.0]}], "type": "Text", "position": 2}, {"raw_context": [{"text": "For numbered affiliations see", "bbox": [54.0, 342.0, 168.0, 354.0]}, {"text": "end of article.", "bbox": [54.0, 354.0, 109.0, 366.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "Correspondence to", "bbox": [54.0, 382.0, 142.0, 394.0]}, {"text": "Professor Reena Sidhu, Royal", "bbox": [54.0, 396.0, 169.0, 404.0]}, {"text": "Hallamshire Hospital, Sheffield", "bbox": [54.0, 406.0, 174.0, 419.0]}, {"text": "S10 2JF, UK;", "bbox": [54.0, 418.0, 104.0, 429.0]}, {"text": "reenasidhu@nhs.net", "bbox": [54.0, 431.0, 136.0, 443.0]}, {"text": "Received 31 May 2023", "bbox": [54.0, 452.0, 146.0, 466.0]}, {"text": "Accepted 6 September 2023", "bbox": [54.0, 466.0, 168.0, 478.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": "( R ) Check for updates", "bbox": [59.0, 815.0, 175.0, 826.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "✪ Author(s) (or their", "bbox": [54.0, 841.0, 135.0, 853.0]}, {"text": "employer(s)) 2023. Re-use", "bbox": [54.0, 853.0, 158.0, 866.0]}, {"text": "permitted under CC BY-NC. No", "bbox": [54.0, 865.0, 175.0, 877.0]}, {"text": "commercial re-use. See rights", "bbox": [54.0, 877.0, 171.0, 888.0]}, {"text": "and permissions. Published", "bbox": [54.0, 890.0, 162.0, 901.0]}, {"text": "by BMJ.", "bbox": [54.0, 901.0, 86.0, 913.0]}], "type": "Text", "position": 8}, {"raw_context": [{"text": "To cite: Sidhu R, Turnbull D,", "bbox": [58.0, 923.0, 170.0, 934.0]}, {"text": "Haboubi H, et al. Gut Epub", "bbox": [58.0, 936.0, 165.0, 947.0]}, {"text": "ahead of print: [ please", "bbox": [59.0, 947.0, 149.0, 959.0]}, {"text": "include Day Month Year].", "bbox": [59.0, 960.0, 156.0, 972.0]}, {"text": "doi:10.1136/", "bbox": [59.0, 971.0, 113.0, 983.0]}, {"text": "gutjnl-2023-330396", "bbox": [58.0, 983.0, 139.0, 996.0]}], "type": "Text", "position": 9}, {"raw_context": [{"text": "British Society of Gastroenterology guidelines on", "bbox": [190.0, 60.0, 688.0, 91.0]}, {"text": "sedation in gastrointestinal endoscopy", "bbox": [190.0, 93.0, 585.0, 121.0]}], "type": "Title", "position": 10}, {"raw_context": [{"text": "Reena Sidhu  © , 1,2 David Turnbull, 3 Hasan Haboubi, 4,5 John S Leeds  © , 6,7", "bbox": [191.0, 132.0, 664.0, 156.0]}, {"text": "Chris Healey, 8 Srisha Hebbar, 9 Paul Collins, 10 Wendy Jones, 1", "bbox": [191.0, 154.0, 566.0, 175.0]}, {"text": "Chris Healey, \"Sha Hebball,\" Paul Collins,\" Wendy Sones,\nMohammad Farhad Peerally, 12, 13 Sara Brogden, 14 Laura J Neilson, 15", "bbox": [191.0, 170.0, 619.0, 195.0]}, {"text": "Manu Nayar  © , 6, 7 Jacqui Gath, 16 Graham Foulkes, 17 Nigel J Trudgill  © , 18", "bbox": [191.0, 192.0, 664.0, 215.0]}, {"text": "Ian Penman 19", "bbox": [190.0, 219.0, 281.0, 233.0]}], "type": "Text", "position": 11}, {"raw_context": [{"text": "ABSTRACT", "bbox": [191.0, 272.0, 252.0, 287.0]}], "type": "Section-header", "position": 12}, {"raw_context": [{"text": "Over 2.5 million gastrointestinal endoscopic procedures", "bbox": [191.0, 287.0, 451.0, 302.0]}, {"text": "are carried out in the United Kingdom (UK) every year.", "bbox": [191.0, 303.0, 444.0, 316.0]}, {"text": "Procedures are carried out with local anaesthetic r with", "bbox": [191.0, 317.0, 449.0, 330.0]}, {"text": "sedation. Sedation is commonly used for gastrointestinal", "bbox": [191.0, 332.0, 455.0, 345.0]}, {"text": "endoscopy, but the type and amount of sedation", "bbox": [191.0, 346.0, 420.0, 361.0]}, {"text": "administered is influenced by the complexity and nature", "bbox": [191.0, 361.0, 451.0, 375.0]}, {"text": "of the procedure and patient factors. The elective and", "bbox": [191.0, 376.0, 441.0, 390.0]}, {"text": "emergency nature of endoscopy procedures and local", "bbox": [191.0, 391.0, 441.0, 405.0]}, {"text": "resources also have a significant impact on the delivery", "bbox": [191.0, 405.0, 448.0, 419.0]}, {"text": "of sedation. In the UK, the vast majority of sedated", "bbox": [191.0, 420.0, 430.0, 435.0]}, {"text": "procedures are carried out using benzodiazepines,", "bbox": [191.0, 435.0, 424.0, 450.0]}, {"text": "with or without opiates, whereas deeper sedation", "bbox": [191.0, 450.0, 424.0, 464.0]}, {"text": "using propofol or general anaesthetic requires the", "bbox": [191.0, 465.0, 424.0, 479.0]}, {"text": "involvement of an anaesthetic team. Patients undergoing", "bbox": [191.0, 480.0, 457.0, 493.0]}, {"text": "gastrointestinal endoscopy need to have good", "bbox": [191.0, 494.0, 408.0, 507.0]}, {"text": "understanding of the options for sedation, including the", "bbox": [191.0, 508.0, 453.0, 522.0]}, {"text": "option for no sedation and alternatives, balancing the", "bbox": [191.0, 523.0, 443.0, 537.0]}, {"text": "intended aims of the procedure and reducing the risk of", "bbox": [191.0, 537.0, 451.0, 552.0]}, {"text": "complications. These guidelines were commissioned by", "bbox": [191.0, 552.0, 447.0, 566.0]}, {"text": "the British Society of Gastroenterology (BSG) Endoscopy", "bbox": [191.0, 567.0, 452.0, 581.0]}, {"text": "Committee with input from major stakeholders, to", "bbox": [191.0, 582.0, 426.0, 595.0]}, {"text": "provide a detailed update, incorporating recent advances", "bbox": [191.0, 596.0, 456.0, 609.0]}, {"text": "in sedation for gastrointestinal endoscopy.", "bbox": [191.0, 611.0, 389.0, 624.0]}, {"text": "This guideline covers aspects from pre-assessment of", "bbox": [191.0, 625.0, 438.0, 639.0]}, {"text": "the elective 'well' patient to patients with significant", "bbox": [191.0, 639.0, 436.0, 654.0]}, {"text": "comorbidity requiring emergency procedures. Types", "bbox": [191.0, 655.0, 430.0, 669.0]}, {"text": "of sedation are discussed, procedure and room", "bbox": [191.0, 670.0, 411.0, 683.0]}, {"text": "requirements and the recovery period, providing", "bbox": [191.0, 684.0, 416.0, 698.0]}, {"text": "guidance to enhance safety and minimise complications.", "bbox": [191.0, 699.0, 453.0, 713.0]}, {"text": "These guidelines are intended to inform practising", "bbox": [192.0, 713.0, 426.0, 728.0]}, {"text": "clinicians and all staff involved in the delivery of", "bbox": [191.0, 728.0, 416.0, 743.0]}, {"text": "gastrointestinal endoscopy with an expectation that this", "bbox": [191.0, 743.0, 453.0, 758.0]}, {"text": "guideline will be revised in 5-years' time.", "bbox": [191.0, 758.0, 382.0, 772.0]}], "type": "Text", "position": 13}, {"raw_context": [{"text": "EXECUTIVE SUMMARY OF RECOMMENDATIONS", "bbox": [191.0, 808.0, 455.0, 824.0]}, {"text": "Type of sedation", "bbox": [191.0, 825.0, 283.0, 838.0]}], "type": "Section-header", "position": 14}, {"raw_context": [{"text": "1. We recommend that sedation providers should", "bbox": [193.0, 840.0, 459.0, 853.0]}, {"text": "tailor the doses dependent on patient factors,", "bbox": [191.0, 852.0, 459.0, 870.0]}, {"text": "procedure type and duration, and complexity", "bbox": [191.0, 869.0, 429.0, 883.0]}, {"text": "Grade of evidence: Moderate. Strength of recom¬", "bbox": [203.0, 883.0, 458.0, 898.0]}, {"text": "mendation: Strong .", "bbox": [191.0, 898.0, 292.0, 912.0]}, {"text": "Level of agreement: 92.3%", "bbox": [204.0, 914.0, 346.0, 926.0]}, {"text": "2. We recommend the provision of inhalational", "bbox": [204.0, 927.0, 459.0, 941.0]}, {"text": "agents to provide the patient with an alternative to", "bbox": [191.0, 942.0, 459.0, 956.0]}, {"text": "sedation", "bbox": [192.0, 958.0, 239.0, 970.0]}, {"text": "Grade of evidence: Moderate. Strength of recom¬", "bbox": [203.0, 971.0, 459.0, 986.0]}, {"text": "mendation: Strong.", "bbox": [191.0, 987.0, 291.0, 1000.0]}, {"text": "Sidhu R, et al. Gut 2023;0:1–27. doi:10.1136/gutjnl-2023-330396", "bbox": [265.0, 1008.0, 528.0, 1022.0]}], "type": "Text", "position": 15}, {"raw_context": [{"text": "Level of agreement: 100%", "bbox": [483.0, 273.0, 623.0, 288.0]}], "type": "Text", "position": 16}, {"raw_context": [{"text": "Patient information, choice and expectations", "bbox": [471.0, 314.0, 714.0, 328.0]}, {"text": "3. We recommend that patients receive compre-", "bbox": [472.0, 329.0, 739.0, 343.0]}, {"text": "hensive information about what to expect from the", "bbox": [471.0, 343.0, 739.0, 358.0]}, {"text": "sedation and sensory experience of the procedure.", "bbox": [471.0, 359.0, 734.0, 372.0]}, {"text": "Grade of evidence: High. Strength of recommen¬", "bbox": [483.0, 373.0, 739.0, 387.0]}, {"text": "dation: Strong .", "bbox": [471.0, 388.0, 551.0, 401.0]}, {"text": "Level of agreement: 100%", "bbox": [483.0, 402.0, 622.0, 416.0]}, {"text": "4. We recommend that patients are involved in", "bbox": [482.0, 417.0, 741.0, 430.0]}, {"text": "shared decision-making, where possible, when", "bbox": [471.0, 431.0, 741.0, 446.0]}, {"text": "choosing which sedative medication (if any) to", "bbox": [471.0, 446.0, 741.0, 460.0]}, {"text": "proceed with during an endoscopic procedure.", "bbox": [471.0, 461.0, 715.0, 475.0]}, {"text": "Grade of evidence: Low. Strength of recommen¬", "bbox": [483.0, 476.0, 739.0, 489.0]}, {"text": "dation: Strong .", "bbox": [472.0, 491.0, 551.0, 503.0]}, {"text": "Level of agreement: 100%", "bbox": [483.0, 505.0, 622.0, 517.0]}, {"text": "5. We recommend that patient comfort should be", "bbox": [484.0, 519.0, 740.0, 533.0]}, {"text": "continually assessed during the procedure and seda-", "bbox": [471.0, 534.0, 739.0, 548.0]}, {"text": "tion/analgesia titrated appropriately.", "bbox": [471.0, 549.0, 660.0, 563.0]}, {"text": "Grade of evidence: Low. Strength of recommen¬", "bbox": [483.0, 563.0, 739.0, 578.0]}, {"text": "dation: Strong .", "bbox": [472.0, 579.0, 550.0, 592.0]}, {"text": "Level of agreement: 100%", "bbox": [483.0, 593.0, 622.0, 608.0]}, {"text": "6. We recommend that patient experience of", "bbox": [483.0, 608.0, 740.0, 622.0]}, {"text": "comfort and sedation should be measured and", "bbox": [471.0, 622.0, 740.0, 637.0]}, {"text": "recorded.", "bbox": [472.0, 639.0, 524.0, 651.0]}, {"text": "Grade of evidence: Low. Strength of recommen¬", "bbox": [483.0, 652.0, 739.0, 666.0]}, {"text": "dation: Strong .", "bbox": [471.0, 667.0, 551.0, 680.0]}, {"text": "Level of agreement: 100%", "bbox": [484.0, 682.0, 622.0, 695.0]}, {"text": "7. We recommend the use of non-pharmacological", "bbox": [484.0, 695.0, 740.0, 709.0]}, {"text": "interventions, such as auditory or visual distraction,", "bbox": [472.0, 710.0, 739.0, 725.0]}, {"text": "to reduce patient anxiety.", "bbox": [471.0, 726.0, 605.0, 739.0]}, {"text": "Grade of evidence: Moderate. Strength of recom¬", "bbox": [482.0, 740.0, 739.0, 753.0]}, {"text": "mendation: Moderate.", "bbox": [472.0, 755.0, 588.0, 768.0]}, {"text": "Level of agreement: 100%", "bbox": [483.0, 769.0, 622.0, 783.0]}], "type": "Text", "position": 17}, {"raw_context": [{"text": "Pre-assessment", "bbox": [471.0, 811.0, 557.0, 824.0]}], "type": "Section-header", "position": 18}, {"raw_context": [{"text": "8. To reduce the risk of sedation-related compli-", "bbox": [471.0, 824.0, 739.0, 839.0]}, {"text": "cations, we recommend pre-assessment to balance", "bbox": [471.0, 840.0, 739.0, 853.0]}, {"text": "the indication and intended aim of the procedure", "bbox": [471.0, 854.0, 740.0, 868.0]}, {"text": "against the physical status of the patient.", "bbox": [472.0, 869.0, 683.0, 883.0]}, {"text": "Grade of evidence: Moderate. Strength of recom¬", "bbox": [483.0, 883.0, 739.0, 898.0]}, {"text": "mendation: Strong .", "bbox": [473.0, 898.0, 572.0, 912.0]}, {"text": "Level of agreement: 84.6%", "bbox": [484.0, 913.0, 625.0, 927.0]}, {"text": "9. In patients with obstructive sleep apnoea (OSA)", "bbox": [483.0, 927.0, 741.0, 941.0]}, {"text": "and/or a high body mass index (BMI) (≥ 35 kg/", "bbox": [472.0, 942.0, 739.0, 955.0]}, {"text": "m 2 ) we recommend pre-assessment and enhanced", "bbox": [471.0, 956.0, 740.0, 970.0]}, {"text": "periprocedural monitoring as these patients may be", "bbox": [471.0, 971.0, 739.0, 986.0]}, {"text": "at an increased risk of periprocedural apnoea.", "bbox": [472.0, 985.0, 709.0, 1002.0]}], "type": "Text", "position": 19}, {"raw_context": [{"text": "BMJ", "bbox": [53.0, 1013.0, 86.0, 1029.0]}], "type": "Text", "position": 20}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/消化科/_2023 BSG指南：胃肠内窥镜检查中的镇静.pdf", "page_num": 1}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "多余标点#15#15#recom¬ mendation为换行连接字符，可以不需要\n多余标点#16#16#recom¬ mendation为换行连接字符，可以不需要\n缺少换行#16#16#2. We recommend the另起一行\nGrade of evidence: 另起一行\n多余换行#16#18#recom¬ mendation: Strong.和Level of agreement: 100%是一句话\n缺少换行#19#19#3. We recommend that patients另起一行\n缺少换行#21#21#4. We recommend that另起一行\n缺少换行#23#23#5. We recommend that patient另起一行\n多余标点#0#34#recommen¬ dation为换行连接字符，可以不需要，应用全文\n缺少换行#25#25#6. We recommend that patient另起一行\n缺少换行#27#27#7. We recommend the use 另起一行\n多余标点#28#28#recom¬ mendation为换行连接字符，可以不需要\n多余标点#32#32#recom¬ mendation为换行连接字符，可以不需要\n缺少换行#33#33#9. In patients with obstructive另起一行\n", "type3": "无关文本#0#0#Open Access\n无关文本#8#8#©源文本为链接标志，并且识别错误\n无关文本#8#8#Reena Sidhu  © , 1,2部分段落末尾的数字问题无关噪声\n无关文本#34#34#BMJ", "type4": null, "type5": null, "type6": "有用性#1#7#为侧边栏目内容，非正文内容\n有用性#17#17#Sidhu R, et al. Gut 2023;0:1–27. doi:10.1136/gutjnl-2023-330396为页脚内容，非正文内容"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:40", "update_time": "2024-05-08 23:16:03"}
{"id": 1082495, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 738, "source_info": {"seq_id": "87e42a0f-26b7-4f5c-a295-4cfdc8c8fd1f", "title": null, "text": "【0】页码:7\n\n【1】 Table 4. Secondary Prevention Checklist for Patients With Suspected Transient Ischemic Attack 17 ABCD 2 ≥ 6 and symptomatic ipsilateral Care component ABCD 2 <4 (low risk) ABCD 2 >4* (high risk) intracranial stenosis' Antiplatelet (should be started within 12–24 h of Aspirin 50–325 mg daily Aspirin 81 mg plus Aspirin 81 mg plus clopidogrel 75 mg daily clopidogrel 75 mg daily for 21–90 d symptom onset) OR for 21–90 dt OR Clopidogrel 75 mg daily THEN transition to single Ticagrelor 180 mg load followed by 90 mg OR therapy twice daily plus aspirin 75–100 mg daily Aspirin 25 mg/extended release for 30 d‡ dipyridamole 200 mg twice daily THEN transition to single therapy Angiotensin-converting enzyme inhibitor, angiotensin II receptor blockers, thiazide diuretic. Calcium channel Antihypertensives (long-term goal blood pressur blockers can be considered for patients who need additional options.\n\n【2】< 130/80 mm Hg) Anticoagulation (for patients with atrial fibrillation Apixaban, dabigatran, edoxaban, rivaroxaban, warfarin or other indications 5 ) 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (first line), and ezetimibe then PCSK9 (propro- Lipid lowering (goal low-density lipoprotein cholesterol <70 mg/dL) tein convertase subtilisin/kexin type 9) inhibitor (if needed for very-high-risk patients) Nutritionist consult Encourage a low sodium or Mediterranean diet. For patients with diabetes, start conversation and consider referral to a nutrition specialist.\n\n【3】Counsel regarding modification of lifestyle factors Smoking cessation in an individualized, culturally sensitive manner Physical activity Alcohol moderation Follow-up appointment Expedited transient ischemic attack/neurology and primary care clinics.\n\n【4】\"When possible, strongly consider hospital admission.\n\n【5】\n †Based on CHANCE trial (Clopidogrei in High-Risk Patients With Acute Non-Disabling Cerebrovascular Events) and POINT trial (Platelet-Oriented Inhibition in New TLA and Minor Ischemic Stroke) protocols. 3334 #Based on THALES trial (Acute Stroke or Transient Ischaemic Attack Treated With Ticagrelor and ASA for Preventions f Stroke and Death) protocol 20 § In patients with moderate to severe mitral stenosis or mechanical heart valve, warfarin is preferred.\n\n【6】ABCD and indicates age/blood pressure/clinical features of transient ischemic attack/duration/diabetes score; and TIA, transiënt ischemic attack.\n\n【7】 '9 fremdsH uo fd gro slemnolede// qud moril bebeomwoO\n\n【8】 of a high ABCD 2 score, infarction on MRI, or presumed symptomatic (>50%) extracranial or intracranial stenosis resulted in hospital admission in these studies. In the absence of a high-risk ABCD 2 score or presumed symptomatic stenosis, other high-risk features such as MRI evidence of infarction, severe hypertension, dual TIA, severe metabolic derangements, or abnormal electrocardiography findings, including a new diagnosis of AF, may also warrant hospital admission. Patients in underserved areas or who face barriers such as lack of transportation to follow-up appointments or timely completion of outpatient studies may also benefit from admission. 50 Admission to the hospital for high-risk patients may also allow for faster administration of acute stroke treatments in the case of a recurrent event.\n\n【9】Although completion of the evaluation may be faster in the ED and hospital in some institutions, other institutions have shown that dedicated outpatient clinics performing an expedited workup after the initial ED visit can also complete the evaluation safely and rapidly. 51 Discharging a patient with a TIA from the ED can be safe if proper protocols are in place before discharge, followed by outpatient completion of the workup and rapid follow-up in a dedicated TIA clinic, preferably within 48 hours. Lack of such a clinic might warrant either ED observation or admission, even for the low-risk patient.\n\n【10】Ultimately, the appropriate disposition for patients with TIA is based on both clinical/patient characteristics, and on available resources locally, as well. The individual patient and institutional factors are critical in making Stroke. 2023;54:00-00. DOI: 10.1161/STR.000000000000418\n\n【11】 the appropriate decision about where patients with TIA should be managed.\n\n【12】## Considerations For Clinical Practice\n\n【13】 Presumed symptomatic (>50%) extracranial or intracranial stenosis warrant hospital admission.\n\n【14】Acceptable disposition options include rapid ED TIA protocols with expedited referral to specialized cerebrovascular or TIA-specific clinics, admission to a 24-hour ED observation unit, or standard hospital admission.\n\n【15】To determine disposition of patients with TIA, consider short-term stroke risk on the basis of presentation and vessel imaging, timeliness of a reliable workup, availability of rapid outpatient follow-up, and the patient's ability to return for rapid workup in a clinic setting.\n\n【16】Institutional and regional factors should guide pro¬ tocols for the decision-making about disposition for patients with TIA.\n\n【17】## Risk Reduction After Tia\n\n【18】\n Patients with TIA require prompt initiation of evidence¬ based interventions. The ABCD 2 score can help to guide appropriate treatment, with patients with higher scores likely benefiting from dual antiplatelet therapy. 35,36 We pro¬ vide a brief overview of evidence-based medical therapy that might be considered (Table 4) 1735,36,52 ; however, this topic is covered more extensively in recent guidelines. 17\n\n【19】 TBD 2023", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "Table 4. Secondary Prevention Checklist for Patients With Suspected Transient Ischemic Attack 17", "bbox": [64.0, 76.0, 563.0, 90.0]}, {"text": "ABCD 2 ≥ 6 and symptomatic ipsilateral", "bbox": [531.0, 100.0, 702.0, 113.0]}, {"text": "Care component", "bbox": [69.0, 113.0, 146.0, 124.0]}, {"text": "ABCD 2 <4 (low risk)", "bbox": [277.0, 112.0, 367.0, 124.0]}, {"text": "ABCD 2 >4* (high risk)", "bbox": [419.0, 112.0, 516.0, 124.0]}, {"text": "intracranial stenosis'", "bbox": [530.0, 113.0, 625.0, 124.0]}, {"text": "Antiplatelet (should be started within 12–24 h of", "bbox": [69.0, 130.0, 265.0, 141.0]}, {"text": "Aspirin 50–325 mg daily", "bbox": [277.0, 130.0, 378.0, 141.0]}, {"text": "Aspirin 81 mg plus", "bbox": [419.0, 130.0, 496.0, 141.0]}, {"text": "Aspirin 81 mg plus clopidogrel 75 mg daily", "bbox": [531.0, 130.0, 703.0, 141.0]}, {"text": "clopidogrel 75 mg daily", "bbox": [419.0, 143.0, 515.0, 154.0]}, {"text": "for 21–90 d", "bbox": [531.0, 143.0, 583.0, 154.0]}, {"text": "symptom onset)", "bbox": [70.0, 144.0, 135.0, 154.0]}, {"text": "OR", "bbox": [277.0, 146.0, 295.0, 157.0]}, {"text": "for 21–90 dt", "bbox": [419.0, 155.0, 475.0, 166.0]}, {"text": "OR", "bbox": [531.0, 158.0, 547.0, 168.0]}, {"text": "Clopidogrel 75 mg daily", "bbox": [278.0, 160.0, 375.0, 172.0]}, {"text": "THEN transition to single", "bbox": [419.0, 167.0, 521.0, 183.0]}, {"text": "Ticagrelor 180 mg load followed by 90 mg", "bbox": [531.0, 172.0, 702.0, 183.0]}, {"text": "OR", "bbox": [278.0, 175.0, 296.0, 187.0]}, {"text": "therapy", "bbox": [420.0, 183.0, 451.0, 194.0]}, {"text": "twice daily plus aspirin 75–100 mg daily", "bbox": [531.0, 185.0, 694.0, 196.0]}, {"text": "Aspirin 25 mg/extended release", "bbox": [278.0, 190.0, 405.0, 203.0]}, {"text": "for 30 d‡", "bbox": [531.0, 197.0, 570.0, 207.0]}, {"text": "dipyridamole 200 mg twice daily", "bbox": [278.0, 203.0, 408.0, 214.0]}, {"text": "THEN transition to single therapy", "bbox": [531.0, 210.0, 666.0, 225.0]}, {"text": "Angiotensin-converting enzyme inhibitor, angiotensin II receptor blockers, thiazide diuretic. Calcium channel", "bbox": [278.0, 228.0, 703.0, 240.0]}, {"text": "Antihypertensives (long-term goal blood pressur", "bbox": [70.0, 229.0, 258.0, 240.0]}, {"text": "blockers can be considered for patients who need additional options.", "bbox": [278.0, 240.0, 551.0, 253.0]}, {"text": "< 130/80 mm Hg)", "bbox": [70.0, 241.0, 141.0, 252.0]}, {"text": "Anticoagulation (for patients with atrial fibrillation", "bbox": [69.0, 259.0, 263.0, 270.0]}, {"text": "Apixaban, dabigatran, edoxaban, rivaroxaban, warfarin", "bbox": [278.0, 259.0, 492.0, 270.0]}, {"text": "or other indications 5 )", "bbox": [70.0, 272.0, 157.0, 281.0]}, {"text": "3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (first line), and ezetimibe then PCSK9 (propro-", "bbox": [278.0, 288.0, 702.0, 301.0]}, {"text": "Lipid lowering (goal low-density lipoprotein cho-", "bbox": [68.0, 289.0, 260.0, 301.0]}, {"text": "lesterol <70 mg/dL)", "bbox": [69.0, 301.0, 152.0, 312.0]}, {"text": "tein convertase subtilisin/kexin type 9) inhibitor (if needed for very-high-risk patients)", "bbox": [278.0, 301.0, 612.0, 312.0]}, {"text": "Nutritionist consult", "bbox": [69.0, 318.0, 146.0, 328.0]}, {"text": "Encourage a low sodium or Mediterranean diet. For patients with diabetes, start conversation and consider", "bbox": [277.0, 317.0, 702.0, 329.0]}, {"text": "referral to a nutrition specialist.", "bbox": [277.0, 331.0, 401.0, 341.0]}, {"text": "Counsel regarding modification of lifestyle factors", "bbox": [69.0, 348.0, 267.0, 359.0]}, {"text": "Smoking cessation", "bbox": [277.0, 348.0, 355.0, 360.0]}, {"text": "in an individualized, culturally sensitive manner", "bbox": [70.0, 360.0, 251.0, 371.0]}, {"text": "Physical activity", "bbox": [278.0, 363.0, 342.0, 374.0]}, {"text": "Alcohol moderation", "bbox": [277.0, 377.0, 357.0, 388.0]}, {"text": "Follow-up appointment", "bbox": [68.0, 396.0, 163.0, 408.0]}, {"text": "Expedited transient ischemic attack/neurology and primary care clinics.", "bbox": [276.0, 396.0, 557.0, 408.0]}, {"text": "\"When possible, strongly consider hospital admission.", "bbox": [76.0, 415.0, 282.0, 427.0]}], "type": "Table", "position": 2}, {"raw_context": [{"text": "†Based on CHANCE trial (Clopidogrei in High-Risk Patients With Acute Non-Disabling Cerebrovascular Events) and POINT trial (Platelet-Oriented Inhibition in New", "bbox": [76.0, 427.0, 714.0, 440.0]}, {"text": "TLA and Minor Ischemic Stroke) protocols. 3334", "bbox": [66.0, 440.0, 240.0, 451.0]}, {"text": "#Based on THALES trial (Acute Stroke or Transient Ischaemic Attack Treated With Ticagrelor and ASA for Preventions f Stroke and Death) protocol 20", "bbox": [75.0, 450.0, 659.0, 463.0]}, {"text": "§ In patients with moderate to severe mitral stenosis or mechanical heart valve, warfarin is preferred.", "bbox": [76.0, 463.0, 463.0, 475.0]}, {"text": "ABCD and indicates age/blood pressure/clinical features of transient ischemic attack/duration/diabetes score; and TIA, transiënt ischemic attack.", "bbox": [75.0, 476.0, 631.0, 487.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "'9 fremdsH uo fd gro slemnolede// qud moril bebeomwoO", "bbox": [19.0, 527.0, 36.0, 779.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": "of a high ABCD 2 score, infarction on MRI, or presumed", "bbox": [63.0, 506.0, 380.0, 521.0]}, {"text": "symptomatic (>50%) extracranial or intracranial steno-", "bbox": [63.0, 522.0, 377.0, 537.0]}, {"text": "sis resulted in hospital admission in these studies. In the", "bbox": [63.0, 539.0, 378.0, 553.0]}, {"text": "absence of a high-risk ABCD 2 score or presumed symp-", "bbox": [63.0, 554.0, 377.0, 569.0]}, {"text": "tomatic stenosis, other high-risk features such as MRI", "bbox": [63.0, 571.0, 378.0, 585.0]}, {"text": "evidence of infarction, severe hypertension, dual TIA,", "bbox": [63.0, 587.0, 378.0, 601.0]}, {"text": "severe metabolic derangements, or abnormal electrocar-", "bbox": [63.0, 602.0, 378.0, 617.0]}, {"text": "diography findings, including a new diagnosis of AF, may", "bbox": [63.0, 619.0, 378.0, 633.0]}, {"text": "also warrant hospital admission. Patients in underserved", "bbox": [63.0, 635.0, 379.0, 649.0]}, {"text": "areas or who face barriers such as lack of transporta-", "bbox": [63.0, 651.0, 378.0, 665.0]}, {"text": "tion to follow-up appointments or timely completion of", "bbox": [63.0, 668.0, 379.0, 681.0]}, {"text": "outpatient studies may also benefit from admission. 50", "bbox": [63.0, 682.0, 379.0, 697.0]}, {"text": "Admission to the hospital for high-risk patients may also", "bbox": [63.0, 699.0, 380.0, 713.0]}, {"text": "allow for faster administration of acute stroke treatments", "bbox": [63.0, 715.0, 379.0, 729.0]}, {"text": "in the case of a recurrent event.", "bbox": [63.0, 731.0, 244.0, 745.0]}, {"text": "Although completion of the evaluation may be faster", "bbox": [79.0, 747.0, 379.0, 761.0]}, {"text": "in the ED and hospital in some institutions, other institu-", "bbox": [63.0, 762.0, 378.0, 777.0]}, {"text": "tions have shown that dedicated outpatient clinics per-", "bbox": [63.0, 779.0, 378.0, 793.0]}, {"text": "forming an expedited workup after the initial ED visit", "bbox": [63.0, 795.0, 380.0, 809.0]}, {"text": "can also complete the evaluation safely and rapidly. 51", "bbox": [63.0, 811.0, 378.0, 825.0]}, {"text": "Discharging a patient with a TIA from the ED can be", "bbox": [63.0, 827.0, 380.0, 841.0]}, {"text": "safe if proper protocols are in place before discharge,", "bbox": [63.0, 843.0, 379.0, 857.0]}, {"text": "followed by outpatient completion of the workup and", "bbox": [63.0, 859.0, 380.0, 873.0]}, {"text": "rapid follow-up in a dedicated TIA clinic, preferably within", "bbox": [63.0, 875.0, 380.0, 890.0]}, {"text": "48 hours. Lack of such a clinic might warrant either ED", "bbox": [63.0, 890.0, 379.0, 905.0]}, {"text": "observation or admission, even for the low-risk patient.", "bbox": [63.0, 907.0, 379.0, 921.0]}, {"text": "Ultimately, the appropriate disposition for patients with", "bbox": [63.0, 923.0, 379.0, 937.0]}, {"text": "TIA is based on both clinical/patient characteristics,", "bbox": [64.0, 939.0, 379.0, 953.0]}, {"text": "and on available resources locally, as well. The individual", "bbox": [63.0, 955.0, 379.0, 970.0]}, {"text": "patient and institutional factors are critical in making", "bbox": [63.0, 970.0, 379.0, 985.0]}, {"text": "Stroke. 2023;54:00-00. DOI: 10.1161/STR.000000000000418", "bbox": [65.0, 997.0, 367.0, 1011.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "the appropriate decision about where patients with TIA", "bbox": [399.0, 507.0, 716.0, 521.0]}, {"text": "should be managed.", "bbox": [401.0, 522.0, 515.0, 537.0]}], "type": "Text", "position": 6}, {"raw_context": [{"text": "Considerations for Clinical Practice", "bbox": [401.0, 561.0, 633.0, 579.0]}], "type": "Section-header", "position": 7}, {"raw_context": [{"text": "Presumed symptomatic (>50%) extracranial or", "bbox": [427.0, 585.0, 716.0, 600.0]}, {"text": "intracranial stenosis warrant hospital admission.", "bbox": [427.0, 602.0, 696.0, 615.0]}, {"text": "Acceptable disposition options include rapid ED", "bbox": [427.0, 618.0, 716.0, 632.0]}, {"text": "TIA protocols with expedited referral to specialized", "bbox": [429.0, 634.0, 716.0, 649.0]}, {"text": "cerebrovascular or TIA-specific clinics, admission to", "bbox": [427.0, 650.0, 716.0, 663.0]}, {"text": "a 24-hour ED observation unit, or standard hospital", "bbox": [427.0, 665.0, 716.0, 680.0]}, {"text": "admission.", "bbox": [428.0, 682.0, 490.0, 696.0]}, {"text": "To determine disposition of patients with TIA, consider", "bbox": [427.0, 697.0, 716.0, 712.0]}, {"text": "short-term stroke risk on the basis of presentation and", "bbox": [428.0, 714.0, 716.0, 729.0]}, {"text": "vessel imaging, timeliness of a reliable workup, avail-", "bbox": [428.0, 730.0, 713.0, 743.0]}, {"text": "ability of rapid outpatient follow-up, and the patient's", "bbox": [428.0, 746.0, 716.0, 760.0]}, {"text": "ability to return for rapid workup in a clinic setting.", "bbox": [428.0, 762.0, 694.0, 776.0]}, {"text": "Institutional and regional factors should guide pro¬", "bbox": [426.0, 778.0, 715.0, 792.0]}, {"text": "tocols for the decision-making about disposition for", "bbox": [428.0, 794.0, 715.0, 809.0]}, {"text": "patients with TIA.", "bbox": [427.0, 809.0, 527.0, 824.0]}], "type": "List-item", "position": 8}, {"raw_context": [{"text": "RISK REDUCTION AFTER TIA", "bbox": [401.0, 849.0, 615.0, 870.0]}], "type": "Section-header", "position": 9}, {"raw_context": [{"text": "Patients with TIA require prompt initiation of evidence¬", "bbox": [399.0, 874.0, 715.0, 890.0]}, {"text": "based interventions. The ABCD 2 score can help to guide", "bbox": [399.0, 890.0, 716.0, 905.0]}, {"text": "appropriate treatment, with patients with higher scores", "bbox": [400.0, 907.0, 716.0, 921.0]}, {"text": "likely benefiting from dual antiplatelet therapy. 35,36 We pro¬", "bbox": [399.0, 923.0, 715.0, 937.0]}, {"text": "vide a brief overview of evidence-based medical therapy", "bbox": [399.0, 939.0, 715.0, 953.0]}, {"text": "that might be considered (Table 4) 1735,36,52 ; however, this", "bbox": [399.0, 955.0, 715.0, 969.0]}, {"text": "topic is covered more extensively in recent guidelines. 17", "bbox": [399.0, 970.0, 705.0, 985.0]}], "type": "Text", "position": 10}, {"raw_context": [{"text": "TBD 2023", "bbox": [637.0, 999.0, 690.0, 1011.0]}], "type": "Text", "position": 11}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/神经科/共识/2023 AHA科学声明：急诊科短暂性脑缺血发作的诊断、检查和风险降低(1).pdf", "page_num": 7}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "缺少换行#5#5# #Based on THALES trial (Acute Stroke...\n§ In patients with moderate to...另起一行\n多余换行#11#11#the appropriate decision ...与10段联接", "type3": "无关文本#0#18#...in recent guidelines. 17像这样在.号或，号的开头或结尾出现的数字都是无关引用 应用全文\n无关文本#7#7# '9 fremdsH uo fd gro slemnolede// qud moril bebeomwoO原文并未出现\n无关文本#10#10#Stroke. 2023;54:00-00. DOI: 10.1161/STR.000000000000418\n无关文本#19#19#TBD 2023  页码内容", "type4": null, "type5": null, "type6": "准确性#1#3#表格里的内容，但内容互相穿插"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:40", "update_time": "2024-05-07 22:26:06"}
{"id": 1082494, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 738, "source_info": {"seq_id": "2e3f55d3-4ffb-43ee-bbf9-47454730e2ce", "title": null, "text": "【0】页码:1\n# Aha Scientific Statement\n\n【1】# Diagnosis, Workup, Risk Reduction Of Transient Ischemic Attack In The Emergency Department Setting: A Scientific Statement From The American Heart Association\n\n【2】\n Hardik P. Amin, MD, Chair; Tracy E. Madsen, MD, PhD, Vice Chair; Dawn M. Bravata, MD; Charles R. Wira, MD; S. Claiborne Johnston, MD, PhD; Susan Ashcraft, DNP; Tamika M. Burrus, MD; Peter D. Panagos, MD; Max Wintermark, MD, MAS; Charles Esenwa, MD, MS; on behalf of the American Heart Association Emergency Neurovascular Care Committee of the Stroke Council and Council on Peripheral Vascular Disease\n\n【3】 ABSTRACT: At least 240000 individuals experience a transient ischemic attack each year in the United States. Transient ischemic attack is a strong predictor of subsequent stroke. The 90-day stroke risk after transient ischemic attack can be as high as 17.8%, with almost half occurring within 2 days of the index event. Diagnosing transient ischemic attack can also be challenging given the transitory nature of symptoms, often reassuring neurological examination at the time of evaluation, and lack of confirmatory testing. Limited resources, such as imaging availability and access to specialists, can further exacerbate this challenge. This scientific statement focuses on the correct clinical diagnosis, risk assessment, and management decisions of patients with suspected transient ischemic attack. Identification of high-risk patients can be achieved through use of comprehensive protocols incorporating acute phase imaging of both the brain and cerebral vasculature, thoughtful use of risk stratification scales, and ancillary testing with the ultimate goal of determining who can be safely discharged home from the emergency department versus admitted to the hospital. We discuss various methods for rapid yet comprehensive avaluations, keeping resource-limited sites in mind In addition, we discuss strategies for secondary prevention of future cerebrovascular events using maximal medical therapy and patient education.\n\n【4】 EZOZ '9 Ammgon no Ad aro sleumoleds// qud moril bebeolarwork\n\n【5】 Key Words:  AHA Scientific Statements ■ atrial fibrillation ■ cerebral angiography ■ diffusion magnetic resonance imaging ◾ emergency service, hospital ◾ ischemic attack, transient ◾ stroke\n\n【6】 ■ ransient ischemic attack (TIA) is clinically described as an acute onset of focal neurological symptoms followed by complete resolution. TIA has been recognized as a risk factor for future stroke since the 1950s.\n\n【7】Use of a time-based versus tissue-based definition for TIA has been debated since the 1980s and intensified with the widespread availability of magnetic resonance imaging (MRI). 12 In 2009, the American Heart Association redefined TIA using a tissue-based approach (ie, symptom resolution plus absence of infarction on brain imaging) rather than the time-based approach (ie, symptom resolution within 24 hours alone). 3 TIA is now widely understood to be an acute neurovascular syndrome attributable to a vascular territory that rapidly resolves, leaving no evidence of tissue infarction on diffusion-weighted\n\n【8】 imaging (DWI) MRI. A patient with resolved symptoms and MRI demonstrating infarct should be diagnosed with an ischemic stroke.\n\n【9】## Epidemiology\n\n【10】\n The true incidence of TIA in the United States is difficult to determine given its transitory nature and the lack of standardized national surveillance systems. In addition, lack of symptom recognition by the public suggests that many TIAs go undetected. Estimates of 90-day stroke risk after TIA range from 10% to 18% and highlight the importance of rapid evaluation and initiation of secondary prevention strategies in the emergency depart¬ ment (ED). 4 -6 In a large and nationally representative", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "AHA SCIENTIFIC STATEMENT", "bbox": [62.0, 120.0, 317.0, 150.0]}], "type": "Title", "position": 1}, {"raw_context": [{"text": "Diagnosis, Workup, Risk Reduction of Transient", "bbox": [63.0, 169.0, 683.0, 201.0]}, {"text": "Ischemic Attack in the Emergency Department", "bbox": [65.0, 201.0, 673.0, 242.0]}, {"text": "Setting: A Scientific Statement From the", "bbox": [63.0, 236.0, 593.0, 271.0]}, {"text": "American Heart Association", "bbox": [62.0, 273.0, 432.0, 307.0]}], "type": "Title", "position": 2}, {"raw_context": [{"text": "Hardik P. Amin, MD, Chair; Tracy E. Madsen, MD, PhD, Vice Chair; Dawn M. Bravata, MD; Charles R. Wira, MD;", "bbox": [63.0, 320.0, 614.0, 335.0]}, {"text": "S. Claiborne Johnston, MD, PhD; Susan Ashcraft, DNP; Tamika M. Burrus, MD; Peter D. Panagos, MD;", "bbox": [63.0, 336.0, 576.0, 351.0]}, {"text": "Max Wintermark, MD, MAS; Charles Esenwa, MD, MS; on behalf of the American Heart Association Emergency Neurovascular", "bbox": [63.0, 353.0, 698.0, 368.0]}, {"text": "Care Committee of the Stroke Council and Council on Peripheral Vascular Disease", "bbox": [63.0, 368.0, 480.0, 383.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "ABSTRACT: At least 240000 individuals experience a transient ischemic attack each year in the United States. Transient", "bbox": [63.0, 409.0, 716.0, 424.0]}, {"text": "ischemic attack is a strong predictor of subsequent stroke. The 90-day stroke risk after transient ischemic attack can", "bbox": [63.0, 425.0, 716.0, 440.0]}, {"text": "be as high as 17.8%, with almost half occurring within 2 days of the index event. Diagnosing transient ischemic attack", "bbox": [63.0, 439.0, 716.0, 454.0]}, {"text": "can also be challenging given the transitory nature of symptoms, often reassuring neurological examination at the time", "bbox": [63.0, 455.0, 716.0, 468.0]}, {"text": "of evaluation, and lack of confirmatory testing. Limited resources, such as imaging availability and access to specialists,", "bbox": [63.0, 469.0, 715.0, 482.0]}, {"text": "can further exacerbate this challenge. This scientific statement focuses on the correct clinical diagnosis, risk assessment,", "bbox": [63.0, 483.0, 716.0, 497.0]}, {"text": "and management decisions of patients with suspected transient ischemic attack. Identification of high-risk patients can", "bbox": [63.0, 498.0, 716.0, 513.0]}, {"text": "be achieved through use of comprehensive protocols incorporating acute phase imaging of both the brain and cerebral", "bbox": [63.0, 513.0, 716.0, 527.0]}, {"text": "vasculature, thoughtful use of risk stratification scales, and ancillary testing with the ultimate goal of determining who can", "bbox": [63.0, 528.0, 715.0, 542.0]}, {"text": "be safely discharged home from the emergency department versus admitted to the hospital. We discuss various methods for", "bbox": [63.0, 542.0, 715.0, 556.0]}, {"text": "rapid yet comprehensive avaluations, keeping resource-limited sites in mind In addition, we discuss strategies for secondary", "bbox": [63.0, 557.0, 716.0, 572.0]}, {"text": "prevention of future cerebrovascular events using maximal medical therapy and patient education.", "bbox": [63.0, 571.0, 582.0, 586.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": "EZOZ '9 Ammgon no Ad aro sleumoleds// qud moril bebeolarwork", "bbox": [16.0, 533.0, 36.0, 800.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "Key Words:  AHA Scientific Statements ■ atrial fibrillation ■ cerebral angiography ■ diffusion magnetic resonance imaging", "bbox": [117.0, 603.0, 661.0, 617.0]}, {"text": "◾ emergency service, hospital ◾ ischemic attack, transient ◾ stroke", "bbox": [237.0, 618.0, 541.0, 631.0]}], "type": "Text", "position": 6}, {"raw_context": [{"text": "■ ransient ischemic attack (TIA) is clinically described", "bbox": [84.0, 681.0, 380.0, 696.0]}, {"text": "as an acute onset of focal neurological symptoms", "bbox": [86.0, 698.0, 379.0, 712.0]}, {"text": "followed by complete resolution. TIA has been rec-", "bbox": [84.0, 714.0, 377.0, 729.0]}, {"text": "ognized as a risk factor for future stroke since the 1950s.", "bbox": [63.0, 730.0, 380.0, 743.0]}, {"text": "Use of a time-based versus tissue-based definition for", "bbox": [63.0, 745.0, 379.0, 760.0]}, {"text": "TIA has been debated since the 1980s and intensified", "bbox": [63.0, 762.0, 380.0, 776.0]}, {"text": "with the widespread availability of magnetic resonance", "bbox": [63.0, 777.0, 380.0, 792.0]}, {"text": "imaging (MRI). 12 In 2009, the American Heart Associa-", "bbox": [63.0, 792.0, 378.0, 809.0]}, {"text": "tion redefined TIA using a tissue-based approach (ie,", "bbox": [63.0, 809.0, 379.0, 825.0]}, {"text": "symptom resolution plus absence of infarction on brain", "bbox": [63.0, 826.0, 380.0, 840.0]}, {"text": "imaging) rather than the time-based approach (ie, symp-", "bbox": [63.0, 842.0, 377.0, 856.0]}, {"text": "tom resolution within 24 hours alone). 3 TIA is now widely", "bbox": [63.0, 858.0, 379.0, 872.0]}, {"text": "understood to be an acute neurovascular syndrome attrib-", "bbox": [63.0, 874.0, 377.0, 889.0]}, {"text": "utable to a vascular territory that rapidly resolves, leaving", "bbox": [63.0, 890.0, 379.0, 903.0]}, {"text": "no evidence of tissue infarction on diffusion-weighted", "bbox": [63.0, 905.0, 379.0, 920.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "imaging (DWI) MRI. A patient with resolved symptoms", "bbox": [399.0, 681.0, 716.0, 696.0]}, {"text": "and MRI demonstrating infarct should be diagnosed with", "bbox": [400.0, 697.0, 716.0, 712.0]}, {"text": "an ischemic stroke.", "bbox": [400.0, 714.0, 508.0, 729.0]}], "type": "Text", "position": 8}, {"raw_context": [{"text": "EPIDEMIOLOGY", "bbox": [401.0, 752.0, 520.0, 772.0]}], "type": "Section-header", "position": 9}, {"raw_context": [{"text": "The true incidence of TIA in the United States is difficult", "bbox": [401.0, 776.0, 716.0, 792.0]}, {"text": "to determine given its transitory nature and the lack of", "bbox": [399.0, 794.0, 716.0, 809.0]}, {"text": "standardized national surveillance systems. In addition,", "bbox": [400.0, 810.0, 715.0, 823.0]}, {"text": "lack of symptom recognition by the public suggests that", "bbox": [399.0, 825.0, 716.0, 840.0]}, {"text": "many TIAs go undetected. Estimates of 90-day stroke", "bbox": [399.0, 842.0, 716.0, 856.0]}, {"text": "risk after TIA range from 10% to 18% and highlight", "bbox": [399.0, 857.0, 716.0, 872.0]}, {"text": "the importance of rapid evaluation and initiation of sec-", "bbox": [399.0, 874.0, 713.0, 889.0]}, {"text": "ondary prevention strategies in the emergency depart¬", "bbox": [399.0, 890.0, 714.0, 903.0]}, {"text": "ment (ED). 4 -6 In a large and nationally representative", "bbox": [399.0, 905.0, 716.0, 921.0]}], "type": "Text", "position": 10}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/神经科/共识/2023 AHA科学声明：急诊科短暂性脑缺血发作的诊断、检查和风险降低(1).pdf", "page_num": 1}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": "错别字#6#6# ■ ransient应是Transient", "type2": "多余换行#7#8#diffusion-weighted和 imaging (DWI) MRI是一句话", "type3": "无关文本#0#10# imaging (MRI). 12部分段落末尾，以及句末的数字问题无关噪声应用全文", "type4": null, "type6": null}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:40", "update_time": "2024-05-08 00:25:14"}
{"id": 1082493, "user_id": "65dea7050c9e908864e3bcde", "user_name": "焦瀚远", "task_id": 738, "source_info": {"seq_id": "c2df6994-b5e3-4ded-96fc-26a26ae0fb26", "title": null, "text": "【0】页码:27\n 191 Kadayifci A, Parlar S, Aydinli M, et al. Unsedated transnasal versus conventional oral endoscopy in endoscopy naïve patients. Acta Gastroenterol Belg 2014;77:224–8.\n\n【1】192 Sami SS, Dunagan KT, Johnson ML, et al. A randomized comparative effectiveness trial of novel endoscopic techniques and approaches for Barrett's esophagus screening in the community. Am J Gastroenterol 2015;110:148–58.\n\n【2】193 Castro Filho EC, Perazzo H, Guimaraes RAP, et al. Reliability and safety of transnasal compared to conventional endoscopy for detecting oesophageal varices in cirrhotic patients. Liver Int 2018;38:1418–26.\n\n【3】194   Uchiyama K, Ishikawa T, Sakamoto N, et al. Analysis of cardiopulmonary stress during endoscopy: is unsedated transnasal esophagogastroduodenoscopy appropriate for elderly patients? Can J Gastroenterol Hepatol 2014;28:31–4.\n\n【4】195 Mori A, Ohashi N, Tatebe H, et al . Autonomic nervous function in upper gastrointestinal endoscopy: a prospective randomized comparison between transnasal and oral procedures. J Gastroenterol 2008;43:38–44.\n\n【5】196 Parker C, Alexandridis E, Plevris J, et al. Transnasal endoscopy: no gagging no panic!\n\n【6】Frontline Gastroenterol 2016;7:246–56.\n\n【7】197 Bugajski M, Wieszczy P, Hoff G, et al. Modifiable factors associated with patientreported pain during and after screening colonoscopy. Gut 2018;67:1958–64.\n\n【8】Aljebreen AM, Almadi MA, Leung FW. Sedated vs unsedated colonoscopy: a 198 prospective study. World J Gastroenterol 2014;20:5113–8.\n\n【9】199 Aboumarzouk OM, Agarwal T, Syed Nong Chek SAH, et al. Nitrous oxide for colonoscopy. Cochrane Database Syst Rev 2011;CD008506.\n\n【10】200 Cadoni S, Falt P, Gallittu P, et al. Impact of carbon dioxide insufflation and water exchange on postcolonoscopy outcomes in patients receiving on-demand sedation: a randomized controlled trial. Gastrointest Endosc 2017;85:210–8.\n\n【11】201 Nicolai MPJ, Keller JJ, de Vries L, et al. The impact of sexual abuse in patients undergoing colonoscopy. PLoS One 2014;9:e85034.\n\n【12】202 Holme O, Bretthauer M, de Lange T, et al. Risk stratification to predict pain during unsedated colonoscopy: results of a multicenter cohort study. Endoscopy 2013;45:691–6.\n\n【13】203 Singh H, Poluha W, Cheung M, et al. Propofol for sedation during colonoscopy.\n\n【14】Cochrane Database Syst Rev 2008; :CD006268.\n\n【15】Adeyemo A, Bannazadeh M, Riggs T, et al. Does sedation type affect colonoscopy 204 perforation rates Dis Colon Rectum 2014;57:110–4.\n\n【16】205 Cooper GS, Kou TD, Rex DK. Complications following colonoscopy with anesthesia assistance: a population-based analysis. JAMA Intern Med 2013;173:551–6.\n\n【17】206 Bielawska B, Day AG, Lieberman DA, et al. Risk factors for early colonoscopic perforation include non-gastroenterologist endoscopists: a multivariable analysis.\n\n【18】Clin Gastroenterol Hepatol 2014;12:85–92.\n\n【19】207 Bielawska B, Hookey LC, Sutradhar R, et al. Anesthesia assistance in outpatient colonoscopy and risk of aspiration pneumonia, bowel perforation, and splenic injury.\n\n【20】Gastroenterology 2018;154:77–85.\n\n【21】208 Wernli KJ, Brenner AT, Rutter CM, et al. Risks associated with anesthesia services during colonoscopy. Gastroenterology 2016;150:888–94.\n\n【22】209 Cullinane M, Gray AJG, Hargraves CMK, et al. The 2004 report of the National confidential enquiry into patient outcome and death. In: 2004 Rep Natl Confid Enq into Patient Outcome Death . 2004: 191.\n\n【23】210 Bowles CJA, Leicester R, Romaya C, et al. A prospective study of colonoscopy practice in the UK today: are we adequately prepared for national colorectal cancer screening tomorrow Gut 2004;53:277–83.\n\n【24】211 Gavin DR, Valori RM, Anderson JT, et al. The National Colonoscopy Audit: a nationwide assessment of the quality and safety of colonoscopy in the UK. Gut 2013;62:242–9.\n\n【25】212 ASGE Standards of Practice Committee, Chandrasekhara V, Early DS, et al.\n\n【26】Modifications in endoscopic practice for the elderly. Gastrointest Endosc 2013;78:1–7.\n\n【27】213 Lord D, Bell G, Gray A, et al. Sedation for gastrointestinal endoscopic procedures in the elderly: getting safer but still not nearly safe enough. BSG 2006:1–14.\n\n【28】214 Hung A, Marshall J, Barnett S, et al. Risk factors and outcomes of reversal agent use in moderate sedation during endoscopy and colonoscopy. J Clin Gastroenterol 2016;50:e25–9.\n\n【29】215 ASGE Standards of Practice Committee, Ben-Menachem T, Decker GA, et al. Adverse events of upper GI endoscopy. Gastrointest Endosc 2012;76:707-18.\n\n【30】216 Clarke GA, Jacobson BC, Hammett RJ, et al . The indications, utilization and safety of gastrointestinal endoscopy in an extremely elderly patient cohort. Endoscopy 2001;33:580–4.\n\n【31】217 Gangi S, Saidi F, Patel K, et al. Cardiovascular complications after GI endoscopy: occurrence and risks in a large hospital system. Gastrointest Endosc 2004;60:679–85.\n\n【32】218 Amornyotin S. Sedation-related complications in gastrointestinal endoscopy. World J Gastrointest Endosc 2013;5:527–33.\n\n【33】219 Bamji N, Cohen LB. Endoscopic sedation of patients with chronic liver disease. Clin Liver Dis 2010;14:185–94.\n\n【34】 220 Haq MM, Faisal N, Khalil A, et al. Midazolam for sedation during diagnostic or therapeutic upper gastrointestinal endoscopy in cirrhotic patients. Eur J Gastroenterol Hepatol 2012;24:1214–8.\n\n【35】221 Edelson J, Suarez AL, Zhang J, et al. Sedation during endoscopy in patients with cirrhosis: safety and predictors of adverse events. Dig Dis Sci 2020;65:1258–65.\n\n【36】22 Steed H, Barrett D, Emm C, et al. Unsedated percutaneous endoscopic gastrostomy insertion: a safe, effective, and well-tolerated method. JPEN J Parenter Enteral Nutr 2012;36:231–4.\n\n【37】223 Sato Y, Goshi S, Kawauchi Y, et al. Safety of unsedated PEG placement using transoral ultrathin endoscopy in patients with amyotrophic lateral sclerosis.\n\n【38】Nutritional Neuroscience 2017;20:71–5.\n\n【39】224 Thompson AG, Blackwell V, Marsden R, et al. A risk stratifying tool to facilitate safe late-stage percutaneous endoscopic gastrostomy in ALS. Amyotroph Lateral Scler Frontotemporal Degener 2017;18:243–8.\n\n【40】225 Pieri M, Landoni G, Cabrini L. Noninvasive ventilation during endoscopic procedures: rationale, clinical use, and devices. J Cardiothorac Vasc Anesth 2018;32:928–34.\n\n【41】226 Wikman-Jorgensen P, Llenas-García J, Hobbins M, et al . Microscopic observation drug susceptibility assay for the diagnosis of TB and MDR-TB in HIV-infected patients: a systematic review and meta-analysis. Eur Respir J 2014;44:973–84.\n\n【42】Gaspar R, Ramalho R, Coelho R, et al. Percutaneous endoscopic gastrostomy 22 placement under NIV in amyotrophic lateral sclerosis with severe ventilatory dysfunction: a safe and effective procedure. GE Port J Gastroenterol 2023;30:61–7.\n\n【43】228 Kawanishi K, Kato J, Toda N, et al. Risk factors for aspiration pneumonia after endoscopic hemostasis. Dig Dis Sci 2016;61:835–40.\n\n【44】229   Fujimura M, Ishiura Y, Myou S, et al . Cardiopulmonary complications during gastroscopy in patients with chronic respiratory failure undergoing long-term home oxygen therapy. Endoscopy 2000;32:33–6.\n\n【45】230 Baron TH, Ramirez B, Richter JE. Gastrointestinal motility disorders during pregnancy.\n\n【46】Ann Intern Med 1993;118:366.\n\n【47】Bruno JM, Kroser J. Efficacy and safety of upper endoscopy procedures during 231 pregnancy. Gastrointest Endosc Clin N Am 2006;16:33–40.\n\n【48】232 Dolovich LR, Addis A, Vaillancourt JMR, et al. Benzodiazepine use in pregnancy and major malformations or oral cleft: meta-analysis of cohort and case-control studies.\n\n【49】BM/ 1998;317:839–43.\n\n【50】233 Mitchell J, Jones W, Winkley E, et al. Guideline on anaesthesia and sedation in breastfeeding women 2020: guideline from the Association of Anaesthetists.\n\n【51】Anaesthesia 2020;75:1482–93.\n\n【52】234 Matheson I, Lunde PK, Bredesen JE. Midazolam and nitrazepam in the maternity ward: milk concentrations and clinical effects. Br J Clin Pharmacol 1990;30:787–93.\n\n【53】Nitsun M, Szokol JW, Saleh HJ, et al. Pharmacokinetics of midazolam, propofol, and 235 fentanyl transfer to human breast milk. Clin Pharmacol Ther 2006;79:549–57.\n\n【54】236 ASGE Standard of Practice Committee, Shergill AK, Ben-Menachem T, et al.\n\n【55】Guidelines for endoscopy in pregnant and lactating women. Gastrointest Endosc 2012;76:18–24.\n\n【56】237 Borgatta L, Jenny RW, Gruss L, et a/. Clinical significance of methohexital, meperidine, and diazepam in breast milk. J Clin Pharmacol 1997;37:186–92.\n\n【57】238 Brooks AJ, Smith PJ, Cohen R, et al. UK guideline on transition of adolescent and young persons with chronic digestive diseases from paediatric to adult care. Gut 2017;66:988–1000.\n\n【58】239 NICE. Sedation in under 19s: using sedation for diagnostic and therapeutic procedures. 2019. Available: www.nice.org.uk/guidance/cq112 240 Mental capacity act 2005. n.d. Available: https://www.legislation.gov.uk/ukpga/ 2005/9/contents Legislation.co.uk. Adults with incapacity (Scotland) act 2000. n.d. Available: https:// 241 www.legislation.gov.uk/asp/2000/4/section/1 Department Of Health. Consent for examination, treatment or care. 2016. Available: 242 https://www.health-ni.gov.uk/articles/consent-examination-treatment-or-care 243 Mohanaruban A, Bryce K, Radhakrishnan A, et al. Safe sedation practices among gastroenterology registrars: do we need more training Frontline Gastroenterol 2015;6:223–8.\n\n【59】244 Dumonceau J-M, Riphaus A, Beilenhoff U, et al. European curriculum for sedation training in gastrointestinal endoscopy: position statement of the European Society of Gastrointestinal Endoscopy (ESGE) and European Society of Gastroenterology and Endoscopy Nurses and Associates (ESGENA). Endoscopy 2013;45:496–504.\n\n【60】Schilling D, Leicht K, Beilenhoff U, et a/. Impact of S3 training courses 'sedation 245 and emergency management in endoscopy for endoscopy nurses and assisting personnel' on the process and structure quality in gastroenterological endoscopy in practices and clinics - results of a nationwide survey. Z Gastroenterol 2013;51:619–27.\n\n【61】246 Joint Advisory Group on Gastrointestinal Endoscopy. JETS course overview. 2014.\n\n【62】Available: https://www.thejag.org.uk/downloads/JAG approved training courses/ JETS course overview v3.0.pdf 247 National safe sedation - home. n.d. Available: https://nationalsafesedation.com/", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "191 Kadayifci A, Parlar S, Aydinli M, et al. Unsedated transnasal versus conventional", "bbox": [54.0, 61.0, 374.0, 74.0]}, {"text": "oral endoscopy in endoscopy naïve patients. Acta Gastroenterol Belg", "bbox": [76.0, 75.0, 334.0, 87.0]}, {"text": "2014;77:224–8.", "bbox": [76.0, 86.0, 139.0, 97.0]}, {"text": "192", "bbox": [54.0, 97.0, 74.0, 109.0]}, {"text": "Sami SS, Dunagan KT, Johnson ML, et al. A randomized comparative effectiveness", "bbox": [72.0, 97.0, 374.0, 111.0]}, {"text": "trial of novel endoscopic techniques and approaches for Barrett's esophagus", "bbox": [75.0, 110.0, 355.0, 122.0]}, {"text": "screening in the community. Am J Gastroenterol 2015;110:148–58.", "bbox": [75.0, 122.0, 324.0, 134.0]}, {"text": "193", "bbox": [54.0, 135.0, 73.0, 146.0]}, {"text": "Castro Filho EC, Perazzo H, Guimaraes RAP, et al. Reliability and safety of transnasal", "bbox": [72.0, 135.0, 382.0, 147.0]}, {"text": "compared to conventional endoscopy for detecting oesophageal varices in cirrhotic", "bbox": [76.0, 146.0, 379.0, 161.0]}, {"text": "patients. Liver Int 2018;38:1418–26.", "bbox": [75.0, 159.0, 212.0, 171.0]}, {"text": "194   Uchiyama K, Ishikawa T, Sakamoto N, et al. Analysis of cardiopulmonary stress during", "bbox": [54.0, 171.0, 386.0, 182.0]}, {"text": "endoscopy: is unsedated transnasal esophagogastroduodenoscopy appropriate for", "bbox": [76.0, 184.0, 377.0, 195.0]}, {"text": "elderly patients? Can J Gastroenterol Hepatol 2014;28:31–4.", "bbox": [75.0, 195.0, 301.0, 207.0]}, {"text": "195 Mori A, Ohashi N, Tatebe H, et al . Autonomic nervous function in upper", "bbox": [54.0, 207.0, 336.0, 220.0]}, {"text": "gastrointestinal endoscopy: a prospective randomized comparison between", "bbox": [76.0, 219.0, 351.0, 232.0]}, {"text": "transnasal and oral procedures. J Gastroenterol 2008;43:38–44.", "bbox": [75.0, 231.0, 312.0, 242.0]}, {"text": "196 Parker C, Alexandridis E, Plevris J, et al. Transnasal endoscopy: no gagging no panic!", "bbox": [54.0, 243.0, 382.0, 255.0]}, {"text": "Frontline Gastroenterol 2016;7:246–56.", "bbox": [76.0, 255.0, 222.0, 267.0]}, {"text": "197 Bugajski M, Wieszczy P, Hoff G, et al. Modifiable factors associated with patient-", "bbox": [54.0, 266.0, 369.0, 279.0]}, {"text": "reported pain during and after screening colonoscopy. Gut 2018;67:1958–64.", "bbox": [76.0, 279.0, 361.0, 292.0]}, {"text": "Aljebreen AM, Almadi MA, Leung FW. Sedated vs unsedated colonoscopy: a", "bbox": [72.0, 291.0, 355.0, 303.0]}, {"text": "198", "bbox": [54.0, 292.0, 72.0, 300.0]}, {"text": "prospective study. World J Gastroenterol 2014;20:5113–8.", "bbox": [76.0, 304.0, 293.0, 315.0]}, {"text": "199 Aboumarzouk OM, Agarwal T, Syed Nong Chek SAH, et al. Nitrous oxide for", "bbox": [54.0, 315.0, 353.0, 327.0]}, {"text": "colonoscopy. Cochrane Database Syst Rev 2011;CD008506.", "bbox": [76.0, 328.0, 296.0, 339.0]}, {"text": "200 Cadoni S, Falt P, Gallittu P, et al. Impact of carbon dioxide insufflation and water", "bbox": [54.0, 339.0, 368.0, 352.0]}, {"text": "exchange on postcolonoscopy outcomes in patients receiving on-demand sedation:", "bbox": [76.0, 351.0, 380.0, 363.0]}, {"text": "a randomized controlled trial. Gastrointest Endosc 2017;85:210–8.", "bbox": [75.0, 364.0, 321.0, 375.0]}, {"text": "201", "bbox": [54.0, 375.0, 72.0, 386.0]}, {"text": "Nicolai MPJ, Keller JJ, de Vries L, et al. The impact of sexual abuse in patients", "bbox": [73.0, 375.0, 356.0, 387.0]}, {"text": "undergoing colonoscopy. PLoS One 2014;9:e85034.", "bbox": [76.0, 388.0, 268.0, 398.0]}, {"text": "202 Holme O, Bretthauer M, de Lange T, et al. Risk stratification to predict pain", "bbox": [54.0, 399.0, 348.0, 412.0]}, {"text": "during unsedated colonoscopy: results of a multicenter cohort study. Endoscopy", "bbox": [76.0, 411.0, 367.0, 424.0]}, {"text": "2013;45:691–6.", "bbox": [76.0, 424.0, 138.0, 435.0]}, {"text": "203 Singh H, Poluha W, Cheung M, et al. Propofol for sedation during colonoscopy.", "bbox": [54.0, 435.0, 363.0, 447.0]}, {"text": "Cochrane Database Syst Rev 2008; :CD006268.", "bbox": [75.0, 447.0, 253.0, 458.0]}, {"text": "Adeyemo A, Bannazadeh M, Riggs T, et al. Does sedation type affect colonoscopy", "bbox": [74.0, 459.0, 372.0, 472.0]}, {"text": "204", "bbox": [54.0, 460.0, 72.0, 471.0]}, {"text": "perforation rates Dis Colon Rectum 2014;57:110–4.", "bbox": [76.0, 471.0, 269.0, 482.0]}, {"text": "205 Cooper GS, Kou TD, Rex DK. Complications following colonoscopy with anesthesia", "bbox": [54.0, 483.0, 377.0, 496.0]}, {"text": "assistance: a population-based analysis. JAMA Intern Med 2013;173:551–6.", "bbox": [76.0, 495.0, 357.0, 507.0]}, {"text": "206 Bielawska B, Day AG, Lieberman DA, et al. Risk factors for early colonoscopic", "bbox": [54.0, 507.0, 357.0, 519.0]}, {"text": "perforation include non-gastroenterologist endoscopists: a multivariable analysis.", "bbox": [76.0, 519.0, 371.0, 532.0]}, {"text": "Clin Gastroenterol Hepatol 2014;12:85–92.", "bbox": [75.0, 531.0, 237.0, 542.0]}, {"text": "207", "bbox": [54.0, 543.0, 73.0, 555.0]}, {"text": "Bielawska B, Hookey LC, Sutradhar R, et al. Anesthesia assistance in outpatient", "bbox": [73.0, 543.0, 365.0, 555.0]}, {"text": "colonoscopy and risk of aspiration pneumonia, bowel perforation, and splenic injury.", "bbox": [75.0, 555.0, 384.0, 567.0]}, {"text": "Gastroenterology 2018;154:77–85.", "bbox": [75.0, 569.0, 207.0, 578.0]}, {"text": "208 Wernli KJ, Brenner AT, Rutter CM, et al. Risks associated with anesthesia services", "bbox": [54.0, 578.0, 371.0, 591.0]}, {"text": "during colonoscopy. Gastroenterology 2016;150:888–94.", "bbox": [75.0, 591.0, 287.0, 602.0]}, {"text": "209 Cullinane M, Gray AJG, Hargraves CMK, et al. The 2004 report of the National", "bbox": [54.0, 603.0, 361.0, 615.0]}, {"text": "confidential enquiry into patient outcome and death. In: 2004 Rep Natl Confid Enq", "bbox": [75.0, 615.0, 379.0, 627.0]}, {"text": "into Patient Outcome Death . 2004: 191.", "bbox": [75.0, 627.0, 225.0, 638.0]}, {"text": "210 Bowles CJA, Leicester R, Romaya C, et al. A prospective study of colonoscopy", "bbox": [54.0, 639.0, 357.0, 652.0]}, {"text": "practice in the UK today: are we adequately prepared for national colorectal cancer", "bbox": [75.0, 651.0, 380.0, 664.0]}, {"text": "screening tomorrow Gut 2004;53:277–83.", "bbox": [76.0, 664.0, 232.0, 675.0]}, {"text": "211 Gavin DR, Valori RM, Anderson JT, et al. The National Colonoscopy Audit: a", "bbox": [54.0, 675.0, 350.0, 687.0]}, {"text": "nationwide assessment of the quality and safety of colonoscopy in the UK. Gut", "bbox": [75.0, 687.0, 364.0, 699.0]}, {"text": "2013;62:242–9.", "bbox": [76.0, 699.0, 138.0, 711.0]}, {"text": "212 ASGE Standards of Practice Committee, Chandrasekhara V, Early DS, et al.", "bbox": [54.0, 711.0, 344.0, 722.0]}, {"text": "Modifications in endoscopic practice for the elderly. Gastrointest Endosc", "bbox": [75.0, 724.0, 339.0, 736.0]}, {"text": "2013;78:1–7.", "bbox": [76.0, 736.0, 127.0, 746.0]}, {"text": "213 Lord D, Bell G, Gray A, et al. Sedation for gastrointestinal endoscopic procedures in", "bbox": [54.0, 746.0, 379.0, 759.0]}, {"text": "the elderly: getting safer but still not nearly safe enough. BSG 2006:1–14.", "bbox": [76.0, 759.0, 347.0, 772.0]}, {"text": "214 Hung A, Marshall J, Barnett S, et al. Risk factors and outcomes of reversal agent", "bbox": [54.0, 771.0, 369.0, 782.0]}, {"text": "use in moderate sedation during endoscopy and colonoscopy. J Clin Gastroenterol", "bbox": [76.0, 784.0, 376.0, 796.0]}, {"text": "2016;50:e25–9.", "bbox": [76.0, 794.0, 139.0, 808.0]}, {"text": "215 ASGE Standards of Practice Committee, Ben-Menachem T, Decker GA, et al. Adverse", "bbox": [54.0, 807.0, 382.0, 819.0]}, {"text": "events of upper GI endoscopy. Gastrointest Endosc 2012;76:707-18.", "bbox": [78.0, 819.0, 329.0, 831.0]}, {"text": "216 Clarke GA, Jacobson BC, Hammett RJ, et al . The indications, utilization and safety", "bbox": [54.0, 831.0, 372.0, 842.0]}, {"text": "of gastrointestinal endoscopy in an extremely elderly patient cohort. Endoscopy", "bbox": [75.0, 844.0, 366.0, 856.0]}, {"text": "2001;33:580–4.", "bbox": [76.0, 856.0, 138.0, 867.0]}, {"text": "217 Gangi S, Saidi F, Patel K, et al. Cardiovascular complications after GI endoscopy:", "bbox": [54.0, 866.0, 366.0, 880.0]}, {"text": "occurrence and risks in a large hospital system. Gastrointest Endosc", "bbox": [76.0, 879.0, 323.0, 892.0]}, {"text": "2004;60:679–85.", "bbox": [76.0, 891.0, 142.0, 902.0]}, {"text": "218 Amornyotin S. Sedation-related complications in gastrointestinal endoscopy. World J", "bbox": [54.0, 902.0, 385.0, 917.0]}, {"text": "Gastrointest Endosc 2013;5:527–33.", "bbox": [76.0, 916.0, 214.0, 927.0]}, {"text": "219 Bamji N, Cohen LB. Endoscopic sedation of patients with chronic liver disease. Clin", "bbox": [54.0, 929.0, 377.0, 940.0]}, {"text": "Liver Dis 2010;14:185–94.", "bbox": [75.0, 940.0, 177.0, 952.0]}], "type": "Text", "position": 0}, {"raw_context": [{"text": "220 Haq MM, Faisal N, Khalil A, et al. Midazolam for sedation during diagnostic", "bbox": [407.0, 61.0, 704.0, 74.0]}, {"text": "or therapeutic upper gastrointestinal endoscopy in cirrhotic patients. Eur J", "bbox": [428.0, 75.0, 698.0, 87.0]}, {"text": "Gastroenterol Hepatol 2012;24:1214–8.", "bbox": [429.0, 86.0, 578.0, 97.0]}, {"text": "221 Edelson J, Suarez AL, Zhang J, et al. Sedation during endoscopy in patients with", "bbox": [408.0, 98.0, 720.0, 111.0]}, {"text": "cirrhosis: safety and predictors of adverse events. Dig Dis Sci 2020;65:1258–65.", "bbox": [429.0, 110.0, 721.0, 122.0]}, {"text": "22", "bbox": [408.0, 123.0, 426.0, 134.0]}, {"text": "Steed H, Barrett D, Emm C, et al. Unsedated percutaneous endoscopic gastrostomy", "bbox": [427.0, 122.0, 731.0, 135.0]}, {"text": "insertion: a safe, effective, and well-tolerated method. JPEN J Parenter Enteral Nutr", "bbox": [430.0, 135.0, 730.0, 146.0]}, {"text": "2012;36:231–4.", "bbox": [430.0, 146.0, 492.0, 157.0]}, {"text": "223 Sato Y, Goshi S, Kawauchi Y, et al. Safety of unsedated PEG placement using", "bbox": [408.0, 157.0, 707.0, 171.0]}, {"text": "transoral ultrathin endoscopy in patients with amyotrophic lateral sclerosis.", "bbox": [430.0, 170.0, 703.0, 182.0]}, {"text": "Nutritional Neuroscience 2017;20:71–5.", "bbox": [430.0, 182.0, 578.0, 194.0]}, {"text": "224 Thompson AG, Blackwell V, Marsden R, et al. A risk stratifying tool to facilitate safe", "bbox": [407.0, 195.0, 731.0, 207.0]}, {"text": "late-stage percutaneous endoscopic gastrostomy in ALS. Amyotroph Lateral Scler", "bbox": [428.0, 206.0, 724.0, 217.0]}, {"text": "Frontotemporal Degener 2017;18:243–8.", "bbox": [429.0, 218.0, 583.0, 230.0]}, {"text": "225 Pieri M, Landoni G, Cabrini L. Noninvasive ventilation during endoscopic procedures:", "bbox": [407.0, 230.0, 737.0, 242.0]}, {"text": "rationale, clinical use, and devices. J Cardiothorac Vasc Anesth 2018;32:928–34.", "bbox": [429.0, 241.0, 723.0, 254.0]}, {"text": "226", "bbox": [408.0, 255.0, 428.0, 266.0]}, {"text": "Wikman-Jorgensen P, Llenas-García J, Hobbins M, et al . Microscopic observation", "bbox": [426.0, 255.0, 721.0, 266.0]}, {"text": "drug susceptibility assay for the diagnosis of TB and MDR-TB in HIV-infected", "bbox": [429.0, 266.0, 709.0, 277.0]}, {"text": "patients: a systematic review and meta-analysis. Eur Respir J 2014;44:973–84.", "bbox": [428.0, 279.0, 716.0, 291.0]}, {"text": "Gaspar R, Ramalho R, Coelho R, et al. Percutaneous endoscopic gastrostomy", "bbox": [427.0, 290.0, 709.0, 302.0]}, {"text": "22", "bbox": [407.0, 291.0, 426.0, 301.0]}, {"text": "placement under NIV in amyotrophic lateral sclerosis with severe ventilatory", "bbox": [428.0, 302.0, 707.0, 314.0]}, {"text": "dysfunction: a safe and effective procedure. GE Port J Gastroenterol 2023;30:61–7.", "bbox": [429.0, 315.0, 733.0, 327.0]}, {"text": "228 Kawanishi K, Kato J, Toda N, et al. Risk factors for aspiration pneumonia after", "bbox": [407.0, 326.0, 712.0, 337.0]}, {"text": "endoscopic hemostasis. Dig Dis Sci 2016;61:835–40.", "bbox": [430.0, 339.0, 624.0, 350.0]}, {"text": "229   Fujimura M, Ishiura Y, Myou S, et al . Cardiopulmonary complications during", "bbox": [407.0, 350.0, 705.0, 362.0]}, {"text": "gastroscopy in patients with chronic respiratory failure undergoing long-term home", "bbox": [428.0, 362.0, 734.0, 375.0]}, {"text": "oxygen therapy. Endoscopy 2000;32:33–6.", "bbox": [430.0, 375.0, 588.0, 386.0]}, {"text": "230 Baron TH, Ramirez B, Richter JE. Gastrointestinal motility disorders during pregnancy.", "bbox": [407.0, 386.0, 739.0, 398.0]}, {"text": "Ann Intern Med 1993;118:366.", "bbox": [429.0, 398.0, 545.0, 410.0]}, {"text": "Bruno JM, Kroser J. Efficacy and safety of upper endoscopy procedures during", "bbox": [426.0, 410.0, 712.0, 422.0]}, {"text": "231", "bbox": [408.0, 411.0, 426.0, 421.0]}, {"text": "pregnancy. Gastrointest Endosc Clin N Am 2006;16:33–40.", "bbox": [430.0, 422.0, 647.0, 433.0]}, {"text": "232 Dolovich LR, Addis A, Vaillancourt JMR, et al. Benzodiazepine use in pregnancy and", "bbox": [407.0, 435.0, 733.0, 446.0]}, {"text": "major malformations or oral cleft: meta-analysis of cohort and case-control studies.", "bbox": [428.0, 446.0, 733.0, 458.0]}, {"text": "BM/ 1998;317:839–43.", "bbox": [429.0, 458.0, 520.0, 470.0]}, {"text": "233 Mitchell J, Jones W, Winkley E, et al. Guideline on anaesthesia and sedation in", "bbox": [407.0, 470.0, 713.0, 482.0]}, {"text": "breastfeeding women 2020: guideline from the Association of Anaesthetists.", "bbox": [428.0, 481.0, 709.0, 495.0]}, {"text": "Anaesthesia 2020;75:1482–93.", "bbox": [430.0, 495.0, 547.0, 506.0]}, {"text": "234 Matheson I, Lunde PK, Bredesen JE. Midazolam and nitrazepam in the maternity", "bbox": [407.0, 506.0, 724.0, 518.0]}, {"text": "ward: milk concentrations and clinical effects. Br J Clin Pharmacol 1990;30:787–93.", "bbox": [428.0, 519.0, 735.0, 529.0]}, {"text": "Nitsun M, Szokol JW, Saleh HJ, et al. Pharmacokinetics of midazolam, propofol, and", "bbox": [427.0, 530.0, 733.0, 542.0]}, {"text": "235", "bbox": [408.0, 531.0, 425.0, 541.0]}, {"text": "fentanyl transfer to human breast milk. Clin Pharmacol Ther 2006;79:549–57.", "bbox": [429.0, 542.0, 715.0, 553.0]}, {"text": "236 ASGE Standard of Practice Committee, Shergill AK, Ben-Menachem T, et al.", "bbox": [408.0, 555.0, 700.0, 566.0]}, {"text": "Guidelines for endoscopy in pregnant and lactating women. Gastrointest Endosc", "bbox": [430.0, 566.0, 723.0, 578.0]}, {"text": "2012;76:18–24.", "bbox": [430.0, 578.0, 492.0, 590.0]}, {"text": "237 Borgatta L, Jenny RW, Gruss L, et a/. Clinical significance of methohexital,", "bbox": [407.0, 590.0, 695.0, 602.0]}, {"text": "meperidine, and diazepam in breast milk. J Clin Pharmacol 1997;37:186–92.", "bbox": [428.0, 601.0, 711.0, 614.0]}, {"text": "238", "bbox": [408.0, 615.0, 426.0, 625.0]}, {"text": "Brooks AJ, Smith PJ, Cohen R, et al. UK guideline on transition of adolescent and", "bbox": [427.0, 615.0, 723.0, 626.0]}, {"text": "young persons with chronic digestive diseases from paediatric to adult care. Gut", "bbox": [430.0, 626.0, 721.0, 638.0]}, {"text": "2017;66:988–1000.", "bbox": [429.0, 639.0, 505.0, 649.0]}, {"text": "239 NICE. Sedation in under 19s: using sedation for diagnostic and therapeutic", "bbox": [408.0, 650.0, 702.0, 662.0]}, {"text": "procedures. 2019. Available: www.nice.org.uk/guidance/cq112", "bbox": [430.0, 661.0, 661.0, 674.0]}, {"text": "240", "bbox": [408.0, 675.0, 427.0, 685.0]}, {"text": "Mental capacity act 2005. n.d. Available: https://www.legislation.gov.uk/ukpga/", "bbox": [426.0, 675.0, 721.0, 686.0]}, {"text": "2005/9/contents", "bbox": [430.0, 686.0, 492.0, 698.0]}, {"text": "Legislation.co.uk. Adults with incapacity (Scotland) act 2000. n.d. Available: https://", "bbox": [427.0, 696.0, 735.0, 712.0]}, {"text": "241", "bbox": [408.0, 698.0, 426.0, 709.0]}, {"text": "www.legislation.gov.uk/asp/2000/4/section/1", "bbox": [430.0, 710.0, 597.0, 722.0]}, {"text": "Department Of Health. Consent for examination, treatment or care. 2016. Available:", "bbox": [426.0, 721.0, 736.0, 734.0]}, {"text": "242", "bbox": [407.0, 722.0, 428.0, 733.0]}, {"text": "https://www.health-ni.gov.uk/articles/consent-examination-treatment-or-care", "bbox": [430.0, 735.0, 711.0, 746.0]}, {"text": "243 Mohanaruban A, Bryce K, Radhakrishnan A, et al. Safe sedation practices among", "bbox": [407.0, 746.0, 725.0, 758.0]}, {"text": "gastroenterology registrars: do we need more training Frontline Gastroenterol", "bbox": [430.0, 759.0, 713.0, 769.0]}, {"text": "2015;6:223–8.", "bbox": [430.0, 771.0, 485.0, 781.0]}, {"text": "244 Dumonceau J-M, Riphaus A, Beilenhoff U, et al. European curriculum for", "bbox": [407.0, 781.0, 704.0, 794.0]}, {"text": "sedation training in gastrointestinal endoscopy: position statement of the", "bbox": [429.0, 795.0, 708.0, 807.0]}, {"text": "European Society of Gastrointestinal Endoscopy (ESGE) and European Society of", "bbox": [429.0, 806.0, 734.0, 818.0]}, {"text": "Gastroenterology and Endoscopy Nurses and Associates (ESGENA). Endoscopy", "bbox": [429.0, 818.0, 726.0, 831.0]}, {"text": "2013;45:496–504.", "bbox": [430.0, 830.0, 503.0, 841.0]}, {"text": "Schilling D, Leicht K, Beilenhoff U, et a/. Impact of S3 training courses 'sedation", "bbox": [426.0, 841.0, 718.0, 854.0]}, {"text": "245", "bbox": [407.0, 842.0, 428.0, 853.0]}, {"text": "and emergency management in endoscopy for endoscopy nurses and assisting", "bbox": [430.0, 855.0, 717.0, 866.0]}, {"text": "personnel' on the process and structure quality in gastroenterological endoscopy", "bbox": [428.0, 866.0, 724.0, 878.0]}, {"text": "in practices and clinics - results of a nationwide survey. Z Gastroenterol", "bbox": [428.0, 878.0, 689.0, 891.0]}, {"text": "2013;51:619–27.", "bbox": [430.0, 891.0, 496.0, 901.0]}, {"text": "246 Joint Advisory Group on Gastrointestinal Endoscopy. JETS course overview. 2014.", "bbox": [407.0, 901.0, 726.0, 914.0]}, {"text": "Available: https://www.thejag.org.uk/downloads/JAG approved training courses/", "bbox": [429.0, 915.0, 723.0, 926.0]}, {"text": "JETS course overview v3.0.pdf", "bbox": [429.0, 926.0, 542.0, 938.0]}, {"text": "247 National safe sedation - home. n.d. Available: https://nationalsafesedation.com/", "bbox": [408.0, 938.0, 721.0, 951.0]}], "type": "Text", "position": 2}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/消化科/_2023 BSG指南：胃肠内窥镜检查中的镇静.pdf", "page_num": 27}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": null, "type3": null, "type4": null, "type5": null, "type6": "信息有用性#0#62#参考文献"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:40", "update_time": "2024-05-07 21:39:47"}
{"id": 1082492, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 738, "source_info": {"seq_id": "f381edaa-3006-457f-a9bc-a739e22baf79", "title": null, "text": "【0】页码:3\n\n【1】 Risk factors for thrombosis with MHV – adapted from T A B L E  1 Vahanian et al. 2 Prosthesis Other factors that increase thrombosis thrombogenicity risk Lower Mitral, tricuspid or pulmonary replacement Previous thromboembolism Carbomedics, Valve dysfunction/mismatch Medtronic Hall, St Left ventricular dysfunction Jude Medical, On-X Atrial fibrillation Medium Poor adherence with medication Other bi-leaflet valves Higher Lillehei-Kaster, Omniscience, Starr-Edwards, Bjork-Shiley, other tilting-disc valves\n\n【2】\n • Clarifying the valve type, number of MHVs, indication\n and age of the valve.\n • Adherence with prior anticoagulant therapy.\n\n【3】• Risk stratification for thrombotic events (including MVT) based on prosthesis and patient factors to aid choice of anticoagulant regimen ( Table 1 ).\n\n【4】 • Detailed discussion regarding risks associated with pregnancy and advantages and disadvantages associated with different anticoagulation options ( Table 2 ).\n\n【5】Ensuring that the individual considering pregnancy is aware of the early effects of VKAs/warfarin on foetal development (from 6 weeks of gestation). It is important that they perform a pregnancy test early if they think they may be pregnant. Contact details for the specialist team should be provided for the individual to be reviewed at an early stage.\n\n【6】The anticoagulation regimen that is chosen should be planned in detail. The individual should be made aware of the importance of adherence during pregnancy and the need for frequent hospital appointments, and that travel to the tertiary specialist centre with the relevant expertise will be required and that this may have financial and employment implications.\n\n【7】Discussing the risks of unplanned pregnancy and the need for effective contraception when not planning pregnancy should be emphasised. Individuals should be signposted to family planning clinics/general practitioner (GP) practices to facilitate contraception provision.\n\n【8】General aspects of preconception counselling should be addressed, including the need for folic acid, vitamin D, healthy lifestyle and the need to maintain a healthy weight. Other risks in pregnancy due to other specific patient-related factors should also be discussed.\n\n【9】Patients with congenital heart disease should be informed of the increased risk of congenital heart disease in their newborn.\n\n【10】• All medication should be reviewed and optimised for pregnancy. The UK Teratology Information Service ( www.\n\n【11】uktis.org) is a helpful resource for information regarding medication use in pregnancy.\n • Patients and their GP should be provided with a written summary of the discussion, including risks, benefits and plans for pregnancy. The method of making early contact as soon as pregnancy is confirmed with the specialist team must be included.\n\n【12】## Assisted Conception\n\n【13】\n Assisted conception should not proceed without prior involvement of the specialist team who can recommend on the suitability, preparatory investigations and management of assisted conception. Assisted reproductive techniques (ART) involving ovarian stimulation are an additional risk factor for thrombosis. For invasive procedures associated with bleeding, for example, egg collection in an individual anticoagulated with a VKA should be bridged with twice-daily therapeutic LMWH for the minimum period of time before restarting the VKA. There is insufficient evidence to support admission for UFH. 3 The last dose of therapeutic LMWH should be ≥ 24h before the scheduled procedure and immediate therapeutic anticoagulation should be avoided postprocedure as per bridging practices used in international studies. 4 The bleeding and thrombotic risks of egg collection in individuals anticoagulated for MHV are unknown and likely to be significant. Any individual with an MHV considering ART should have a consultation with the specialist team and their anticoagulation titrated accordingly.\n\n【14】## Antenatal Referral And Risk Assessment\n\n【15】\n All individuals with MHV and confirmed pregnancy should be referred to the specialist team as a matter of urgency (as soon as a pregnancy test is positive) and ideally reviewed by the MDT before 6 weeks of gestation. Individuals should have been informed how to self-refer but any healthcare professional made aware of the pregnancy can refer as a matter of urgency. The first encounter may be with the anticoagulant clinic whose staff should escalate to the specialist team immediately. In very early pregnancy, complex decisions are required regarding optimal anticoagulation regimens and balancing competing risks. If not already completed pre-pregnancy, a written care plan should be agreed and widely circulated with a copy to the individual. Risks associated with pregnancy in this population overall are outlined in Table 2 . Pregnancy in individuals with MHV is considered very high risk. Data from the United Kingdom Obstetric Surveillance System (UKOSS) 5 showed that maternal mortality was 9% and the risk of severe morbidity was 41%, with 16% of individuals suffering valve thrombosis and 9% having a cerebrovascular accident. Foetal risks are also high, with an increased risk of miscarriage, stillbirth, foetal haemorrhage, and warfarin-induced teratogenicity. Only 16 (28%) pregnant individuals had a good maternal and foetal\n\n【16】 Assqua) antibility of tas annot wh sale [ [ 2024 / 6 ] no vardilanial ( valify , vandil gies with M &V assot - is no 4 ] 828 [ 46\n\n【17】 O obtestings oth ed bomarcog an solatho AO to an to soluted caradel onlin0 col/W no (anotability-", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "Risk factors for thrombosis with MHV – adapted from", "bbox": [121.0, 58.0, 365.0, 71.0]}, {"text": "T A B L E  1", "bbox": [59.0, 59.0, 115.0, 71.0]}, {"text": "Vahanian et al. 2", "bbox": [59.0, 72.0, 130.0, 86.0]}, {"text": "Prosthesis", "bbox": [66.0, 97.0, 117.0, 109.0]}, {"text": "Other factors that increase thrombosis", "bbox": [184.0, 97.0, 365.0, 109.0]}, {"text": "thrombogenicity", "bbox": [66.0, 110.0, 146.0, 123.0]}, {"text": "risk", "bbox": [184.0, 112.0, 205.0, 123.0]}, {"text": "Lower", "bbox": [67.0, 133.0, 97.0, 144.0]}, {"text": "Mitral, tricuspid or pulmonary replacement", "bbox": [185.0, 132.0, 371.0, 144.0]}, {"text": "Previous thromboembolism", "bbox": [185.0, 146.0, 310.0, 157.0]}, {"text": "Carbomedics,", "bbox": [72.0, 150.0, 135.0, 162.0]}, {"text": "Valve dysfunction/mismatch", "bbox": [185.0, 158.0, 313.0, 170.0]}, {"text": "Medtronic Hall, St", "bbox": [77.0, 163.0, 163.0, 176.0]}, {"text": "Left ventricular dysfunction", "bbox": [185.0, 172.0, 311.0, 184.0]}, {"text": "Jude Medical, On-X", "bbox": [77.0, 177.0, 168.0, 190.0]}, {"text": "Atrial fibrillation", "bbox": [185.0, 185.0, 264.0, 197.0]}, {"text": "Medium", "bbox": [66.0, 194.0, 107.0, 207.0]}, {"text": "Poor adherence with medication", "bbox": [185.0, 199.0, 331.0, 211.0]}, {"text": "Other bi-leaflet", "bbox": [76.0, 213.0, 148.0, 227.0]}, {"text": "valves", "bbox": [82.0, 227.0, 111.0, 240.0]}, {"text": "Higher", "bbox": [66.0, 245.0, 101.0, 259.0]}, {"text": "Lillehei-Kaster,", "bbox": [77.0, 262.0, 146.0, 276.0]}, {"text": "Omniscience,", "bbox": [82.0, 277.0, 145.0, 291.0]}, {"text": "Starr-Edwards,", "bbox": [82.0, 290.0, 150.0, 304.0]}, {"text": "Bjork-Shiley, other", "bbox": [82.0, 304.0, 166.0, 316.0]}, {"text": "tilting-disc valves", "bbox": [82.0, 317.0, 162.0, 330.0]}], "type": "Table", "position": 1}, {"raw_context": [{"text": "• Clarifying the valve type, number of MHVs, indication", "bbox": [58.0, 369.0, 387.0, 385.0]}], "type": "Text", "position": 2}, {"raw_context": [{"text": "and age of the valve.", "bbox": [72.0, 386.0, 181.0, 400.0]}], "type": "List-item", "position": 3}, {"raw_context": [{"text": "• Adherence with prior anticoagulant therapy.", "bbox": [58.0, 401.0, 313.0, 416.0]}, {"text": "• Risk stratification for thrombotic events (including MVT)", "bbox": [58.0, 418.0, 387.0, 433.0]}, {"text": "based on prosthesis and patient factors to aid choice of an-", "bbox": [70.0, 435.0, 385.0, 448.0]}, {"text": "ticoagulant regimen ( Table 1 ).", "bbox": [71.0, 450.0, 236.0, 464.0]}], "type": "List-item", "position": 4}, {"raw_context": [{"text": "• Detailed discussion regarding risks associated with preg-", "bbox": [58.0, 466.0, 384.0, 481.0]}, {"text": "nancy and advantages and disadvantages associated with", "bbox": [71.0, 482.0, 386.0, 496.0]}, {"text": "different anticoagulation options ( Table 2 ).", "bbox": [71.0, 498.0, 305.0, 513.0]}, {"text": "Ensuring that the individual considering pregnancy is", "bbox": [68.0, 515.0, 387.0, 529.0]}, {"text": "aware of the early effects of VKAs/warfarin on foetal devel-", "bbox": [71.0, 530.0, 385.0, 545.0]}, {"text": "opment (from 6 weeks of gestation). It is important that they", "bbox": [71.0, 546.0, 386.0, 561.0]}, {"text": "perform a pregnancy test early if they think they may be", "bbox": [71.0, 562.0, 387.0, 576.0]}, {"text": "pregnant. Contact details for the specialist team should be", "bbox": [71.0, 578.0, 387.0, 593.0]}, {"text": "provided for the individual to be reviewed at an early stage.", "bbox": [71.0, 595.0, 385.0, 609.0]}, {"text": "The anticoagulation regimen that is chosen should be", "bbox": [69.0, 609.0, 387.0, 624.0]}, {"text": "planned in detail. The individual should be made aware", "bbox": [71.0, 626.0, 387.0, 641.0]}, {"text": "of the importance of adherence during pregnancy and the", "bbox": [70.0, 642.0, 387.0, 656.0]}, {"text": "need for frequent hospital appointments, and that travel", "bbox": [71.0, 658.0, 387.0, 673.0]}, {"text": "to the tertiary specialist centre with the relevant expertise", "bbox": [71.0, 675.0, 387.0, 689.0]}, {"text": "will be required and that this may have financial and em-", "bbox": [71.0, 689.0, 385.0, 705.0]}, {"text": "ployment implications.", "bbox": [72.0, 706.0, 197.0, 720.0]}, {"text": "Discussing the risks of unplanned pregnancy and the need", "bbox": [68.0, 722.0, 387.0, 736.0]}, {"text": "for effective contraception when not planning pregnancy", "bbox": [71.0, 738.0, 385.0, 753.0]}, {"text": "should be emphasised. Individuals should be signposted", "bbox": [71.0, 755.0, 387.0, 769.0]}, {"text": "to family planning clinics/general practitioner (GP) prac-", "bbox": [71.0, 769.0, 384.0, 784.0]}, {"text": "tices to facilitate contraception provision.", "bbox": [71.0, 786.0, 297.0, 801.0]}, {"text": "General aspects of preconception counselling should", "bbox": [68.0, 802.0, 387.0, 816.0]}, {"text": "be addressed, including the need for folic acid, vitamin", "bbox": [70.0, 818.0, 387.0, 833.0]}, {"text": "D, healthy lifestyle and the need to maintain a healthy", "bbox": [71.0, 835.0, 386.0, 849.0]}, {"text": "weight. Other risks in pregnancy due to other specific", "bbox": [71.0, 850.0, 387.0, 864.0]}, {"text": "patient-related factors should also be discussed.", "bbox": [71.0, 866.0, 330.0, 880.0]}, {"text": "Patients with congenital heart disease should be informed of", "bbox": [68.0, 883.0, 387.0, 896.0]}, {"text": "the increased risk of congenital heart disease in their newborn.", "bbox": [71.0, 898.0, 387.0, 913.0]}, {"text": "• All medication should be reviewed and optimised for", "bbox": [58.0, 915.0, 387.0, 929.0]}, {"text": "pregnancy. The UK Teratology Information Service ( www.", "bbox": [71.0, 930.0, 385.0, 944.0]}, {"text": "uktis.org) is a helpful resource for information regarding", "bbox": [71.0, 946.0, 387.0, 961.0]}, {"text": "medication use in pregnancy.", "bbox": [72.0, 963.0, 232.0, 977.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "• Patients and their GP should be provided with a written", "bbox": [407.0, 64.0, 734.0, 79.0]}, {"text": "summary of the discussion, including risks, benefits and", "bbox": [419.0, 80.0, 735.0, 95.0]}, {"text": "plans for pregnancy. The method of making early contact", "bbox": [419.0, 97.0, 735.0, 112.0]}, {"text": "as soon as pregnancy is confirmed with the specialist team", "bbox": [418.0, 113.0, 735.0, 127.0]}, {"text": "must be included.", "bbox": [419.0, 129.0, 518.0, 144.0]}], "type": "List-item", "position": 7}, {"raw_context": [{"text": "ASSISTED CONCEPTION", "bbox": [407.0, 191.0, 621.0, 209.0]}], "type": "Section-header", "position": 8}, {"raw_context": [{"text": "Assisted conception should not proceed without prior in-", "bbox": [407.0, 226.0, 733.0, 240.0]}, {"text": "volvement of the specialist team who can recommend on the", "bbox": [406.0, 242.0, 734.0, 256.0]}, {"text": "suitability, preparatory investigations and management of", "bbox": [406.0, 258.0, 735.0, 273.0]}, {"text": "assisted conception. Assisted reproductive techniques (ART)", "bbox": [406.0, 274.0, 735.0, 288.0]}, {"text": "involving ovarian stimulation are an additional risk factor", "bbox": [406.0, 290.0, 734.0, 305.0]}, {"text": "for thrombosis. For invasive procedures associated with", "bbox": [406.0, 306.0, 735.0, 321.0]}, {"text": "bleeding, for example, egg collection in an individual anti-", "bbox": [406.0, 322.0, 733.0, 336.0]}, {"text": "coagulated with a VKA should be bridged with twice-daily", "bbox": [406.0, 338.0, 734.0, 353.0]}, {"text": "therapeutic LMWH for the minimum period of time before", "bbox": [406.0, 354.0, 735.0, 368.0]}, {"text": "restarting the VKA. There is insufficient evidence to support", "bbox": [406.0, 370.0, 735.0, 385.0]}, {"text": "admission for UFH. 3 The last dose of therapeutic LMWH", "bbox": [406.0, 386.0, 735.0, 401.0]}, {"text": "should be ≥ 24h before the scheduled procedure and imme-", "bbox": [406.0, 401.0, 733.0, 416.0]}, {"text": "diate therapeutic anticoagulation should be avoided post-", "bbox": [406.0, 418.0, 733.0, 433.0]}, {"text": "procedure as per bridging practices used in international", "bbox": [406.0, 435.0, 735.0, 448.0]}, {"text": "studies. 4 The bleeding and thrombotic risks of egg collection", "bbox": [406.0, 449.0, 735.0, 465.0]}, {"text": "in individuals anticoagulated for MHV are unknown and", "bbox": [406.0, 466.0, 735.0, 481.0]}, {"text": "likely to be significant. Any individual with an MHV con-", "bbox": [406.0, 482.0, 733.0, 496.0]}, {"text": "sidering ART should have a consultation with the specialist", "bbox": [406.0, 498.0, 735.0, 513.0]}, {"text": "team and their anticoagulation titrated accordingly.", "bbox": [406.0, 515.0, 690.0, 528.0]}], "type": "Text", "position": 9}, {"raw_context": [{"text": "ANTENATAL REFERRAL AND", "bbox": [408.0, 559.0, 664.0, 577.0]}, {"text": "RISK ASSESSMENT", "bbox": [407.0, 577.0, 569.0, 593.0]}], "type": "Section-header", "position": 10}, {"raw_context": [{"text": "All individuals with MHV and confirmed pregnancy should", "bbox": [407.0, 609.0, 735.0, 624.0]}, {"text": "be referred to the specialist team as a matter of urgency (as", "bbox": [406.0, 626.0, 735.0, 641.0]}, {"text": "soon as a pregnancy test is positive) and ideally reviewed", "bbox": [406.0, 642.0, 735.0, 656.0]}, {"text": "by the MDT before 6 weeks of gestation. Individuals should", "bbox": [406.0, 658.0, 735.0, 673.0]}, {"text": "have been informed how to self-refer but any healthcare pro-", "bbox": [406.0, 674.0, 733.0, 689.0]}, {"text": "fessional made aware of the pregnancy can refer as a matter", "bbox": [406.0, 689.0, 735.0, 706.0]}, {"text": "of urgency. The first encounter may be with the anticoagu-", "bbox": [406.0, 706.0, 733.0, 721.0]}, {"text": "lant clinic whose staff should escalate to the specialist team", "bbox": [406.0, 722.0, 735.0, 736.0]}, {"text": "immediately. In very early pregnancy, complex decisions", "bbox": [406.0, 738.0, 735.0, 753.0]}, {"text": "are required regarding optimal anticoagulation regimens", "bbox": [406.0, 755.0, 735.0, 769.0]}, {"text": "and balancing competing risks. If not already completed", "bbox": [406.0, 769.0, 735.0, 785.0]}, {"text": "pre-pregnancy, a written care plan should be agreed and", "bbox": [406.0, 786.0, 735.0, 801.0]}, {"text": "widely circulated with a copy to the individual. Risks as-", "bbox": [406.0, 802.0, 733.0, 816.0]}, {"text": "sociated with pregnancy in this population overall are out-", "bbox": [406.0, 817.0, 733.0, 833.0]}, {"text": "lined in Table 2 . Pregnancy in individuals with MHV is", "bbox": [406.0, 835.0, 735.0, 849.0]}, {"text": "considered very high risk. Data from the United Kingdom", "bbox": [406.0, 849.0, 735.0, 864.0]}, {"text": "Obstetric Surveillance System (UKOSS) 5 showed that mater-", "bbox": [406.0, 866.0, 733.0, 881.0]}, {"text": "nal mortality was 9% and the risk of severe morbidity was", "bbox": [406.0, 882.0, 735.0, 896.0]}, {"text": "41%, with 16% of individuals suffering valve thrombosis and", "bbox": [407.0, 898.0, 735.0, 913.0]}, {"text": "9% having a cerebrovascular accident. Foetal risks are also", "bbox": [406.0, 915.0, 735.0, 928.0]}, {"text": "high, with an increased risk of miscarriage, stillbirth, foetal", "bbox": [405.0, 930.0, 735.0, 944.0]}, {"text": "haemorrhage, and warfarin-induced teratogenicity. Only 16", "bbox": [406.0, 946.0, 735.0, 961.0]}, {"text": "(28%) pregnant individuals had a good maternal and foetal", "bbox": [406.0, 963.0, 735.0, 977.0]}], "type": "Text", "position": 11}, {"raw_context": [{"text": "Assqua) antibility of tas annot wh sale [ [ 2024 / 6 ] no vardilanial ( valify , vandil gies with M &V assot - is no 4 ] 828 [ 46", "bbox": [768.0, 145.0, 782.0, 588.0]}], "type": "Text", "position": 12}, {"raw_context": [{"text": "O obtestings oth ed bomarcog an solatho AO to an to soluted caradel onlin0 col/W no (anotability-", "bbox": [768.0, 683.0, 781.0, 951.0]}], "type": "Text", "position": 13}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/心血管/指南/2023 BSH 指南：机械心脏瓣膜妊娠个体抗凝管理(1).pdf", "page_num": 3}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": "多余换行#2#2# Clarifying the valve...age of the valve.是一句话\n多余换行#11#11# uktis.org) is a helpful resource...与上面10段联接\n序号格式不一致#5#9#前面缺少标点序号• ", "type3": "无关文本#1#1#et al. 2  里面的数字2 \n无关文本#13#13#for UFH. 3\n   international studies. 4里面的数字3 4\n无关文本#15#15#(UKOSS) 5  里面的数字5\n无关文本#16#17#可能是侧目栏信息", "type4": null, "type5": null, "type6": "准确性#1#1#表格内容，但内容互相穿插"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:40", "update_time": "2024-05-07 21:53:16"}
{"id": 1082491, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 738, "source_info": {"seq_id": "79473ac3-a836-4691-a5e4-e33fcf8e9304", "title": null, "text": "【0】页码:5\n 5\n\n【1】 LNs and distant sites are recommended. CT is broadly available, but has sensitivity of only 20–38% for detection of pelvic LN metastasis. A meta-analysis comparing CT and MRI showed comparable results, with pooled sensitivity of 42% for CT and 39% for MRI and pooled specificity of 82% for 18 F-Fluoro-2-deoxy-D-glucose (FDG)-PET/CT both [39].\n\n【2】showed sensitivity of 91% and specificity of 100% for detection of pelvic LN metastases in patients with US + FNAC–con firmed positive inguinal LNs [40] .\n\n【3】Table 3 lists recommendations for diagnostic evaluation and staging.\n\n【4】## Treatment Of The Primary Tumour 3.4.\n\n【5】\n Besides its role in sexual functioning and urination, a fully functional penis is central to a patient's sense of wholeness, desirability, and masculinity. Hence, the aim for treatment of the primary tumour is complete tumour removal or ablation with as much organ preservation as possible without compromising oncological control. A systematic review by the guidelines panel revealed a complete absence of both randomised controlled trials and prospective trials assess-\n\n【6】 Table 3 – Recommendations for diagnostic evaluation and staging Recommendation Strength rating Primary tumour Perform a detailed physical examination of the penis and Strong external genitalia, recording the morphology, size, and location of the penile lesion, including the extent and invasion of penile (adjacent) structures.\n\n【7】Perform magnetic resonance imaging (MRI) of the penis/ Weak primary tumour (artificial erection not mandatory)\n\n【8】\n primary tumour (artificial erection not mandatory)\n\n【9】 option.\n\n【10】 malignancy is not clinically obvious, or when nonsurgical treatment of the primary lesion is planned (eg, topical agents, laser, radiotherapy).\n\n【11】Inguinal lymph nodes (LNs) number, laterality, and characteristics of any palpable/suspicious inguinal nodes.\n\n【12】Clinically node-negative (cN0) examination, offer surgical LN staging to all patients at high risk of having micrometastatic disease (T1b or higher).\n\n【13】alternative to surgical staging with patients willing to comply with strict follow-up.\n\n【14】node biopsy (DSNB).If DSNB is not available and referral is not feasible, or if preferred by the patient after being well informed, offer inguinal LN dissection (open or video-endoscopic surgery).\n\n【15】If DSNB is planned, perform inguinal US first, with fineneedle aspiration cytology of sonographically abnormal LNs.\n\n【16】Clinically node-positive (cN+) If there is a palpable/suspicious node on physical examination (cN+), obtain (image-guided) biopsy to confirm nodal metastasis before initiating treatment.\n\n【17】In cN+ patients, stage the pelvis and exclude distant metastases with 18F-fluoro-2-deoxy-D-glucose positron emission tomography ( 18 FDG-PET) computed tomography (CT) or CT of the chest and abdomen before initiating treatment\n\n【18】 Strong\n Weak\n\n【19】 Strong\n\n【20】\n Strong\n\n【21】\n Strong\n\n【22】 ing and comparing the effectiveness of interventions for managing the primary tumour in penile cancer [ 1 ].\n\n【23】 3.4.1.\n\n【24】Treatment of superficial noninvasive disease (PeIN, Ta) PeIN can progress to invasive lesions in 2.6–13% of patients despite treatment [41–43] . Most PeIN lesions are located on the mucosal surfaces of the glans or prepuce, while lichen sclerosus also affects the prepuce [ 42 ]. Circumcision, wide local excision, and (partial) glans resurfacing are surgical options [43–45] . Recurrences are reported to be low (0– 20%) [44,46,47] . Resection, as opposed to ablative or topical treatments, provides the advantage of complete histopathological local staging and detection of areas of invasion, as up to 20% of patients harbour invasive disease [44] . Topical therapy with imiquimod or 5-fluorouracil (5-FU) is an effective noninvasive alternative [ 48 ]. There is no consensus or comparative data on the optimal treatment schedule for these therapies and tolerance can be problematic [49,50] .\n\n【25】A systematic review of low-quality data showed response and recurrence rates of 40–100% and 20% for imiquimod, versus 48–74% and 11% for 5-FU, respectively [ 51 ]. It is advised that treatment effects must be clinically assessed and in cases of doubt evaluated via biopsy, as insufficient responses and recurrences may signify underlying invasive disease. Tumour ablation using Nd:YAG or CO 2 laser results in response rates of 52–100%, with recurrence rates of 7– 48% reported for patients with noninvasive disease [ 51 , 52 ].\n\n【26】 3.4.2.\n\n【27】Treatment of invasive disease confined to the glans (cT1/ (2012) Recent decades have seen a shift towards organ-sparing surgery on the basis of the assumption derived from heterogeneous cohorts that local recurrence has little influence on long-term survival [ 15 ]. However, a large series looking at higher-risk tumours treated with glansectomy [ 53 ] revealed that patients experiencing local recurrence have poorer survival, which challenges this dogma. A systematic review by the guidelines panel found a cumulative 5-yr recurrencefree rate (RFR) of 82% in case series and 76.7% in nonrandomised controlled studies for organ-sparing surgery. The limits of organ-sparing surgery are not completely clear and the higher risk of local recurrence in comparison to partial amputation should be discussed with the patient when making a treatment plan. The concept of organ-preserving surgery is based on observations of how the distance between the tumour and the resection margin affects local recurrence. A 2018 study from a supraregional referral centre found that local recurrence rates only increased considerably when the distance from the tumour to the margin was <1 mm [54] . To ensure complete removal with histologically negative margins, standard excision must therefore include a margin of clinically normal-appearing skin around the tumour and surrounding erythema. As the aim is for negative surgical margins, it is the panel's opinion that frozen section analysis is a helpful tool in cases of doubt, whereas routine use is not recommended [ 54 – 57 ]. According to our systematic review, laser therapy for invasive penile cancer resulted in a cumulative mean 5-yr RFR of 69.4% [1] . Radiotherapy is an organ-preserving approach with good results in selected patients with T1–2 lesions\n\n【28】 Please cite this article as: O.R. Brouwer, M. Albersen, A. Parnham et al., European Association of Urology-American Society of Clinical Oncology Collaborative Guideline on Penile Cancer: 2023 Update, Eur Urol (2023), https://doi.org/10.1016/j.eururo.2023.02.027", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "5", "bbox": [722.0, 42.0, 732.0, 55.0]}], "type": "Text", "position": 2}, {"raw_context": [{"text": "LNs and distant sites are recommended. CT is broadly avail-", "bbox": [66.0, 88.0, 389.0, 101.0]}, {"text": "able, but has sensitivity of only 20–38% for detection of pel-", "bbox": [66.0, 102.0, 389.0, 116.0]}, {"text": "vic LN metastasis. A meta-analysis comparing CT and MRI", "bbox": [66.0, 117.0, 389.0, 132.0]}, {"text": "showed comparable results, with pooled sensitivity of 42%", "bbox": [66.0, 134.0, 389.0, 147.0]}, {"text": "for CT and 39% for MRI and pooled specificity of 82% for", "bbox": [66.0, 149.0, 390.0, 163.0]}, {"text": "18 F-Fluoro-2-deoxy-D-glucose (FDG)-PET/CT", "bbox": [140.0, 163.0, 389.0, 179.0]}, {"text": "both [39].", "bbox": [67.0, 164.0, 136.0, 178.0]}, {"text": "showed sensitivity of 91% and specificity of 100% for detec-", "bbox": [66.0, 180.0, 388.0, 193.0]}, {"text": "tion of pelvic LN metastases in patients with US + FNAC–con", "bbox": [66.0, 195.0, 390.0, 209.0]}, {"text": "firmed positive inguinal LNs [40] .", "bbox": [66.0, 210.0, 250.0, 224.0]}, {"text": "Table 3 lists recommendations for diagnostic evaluation", "bbox": [84.0, 225.0, 390.0, 239.0]}, {"text": "and staging.", "bbox": [66.0, 240.0, 135.0, 255.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "Treatment of the primary tumour", "bbox": [107.0, 271.0, 276.0, 285.0]}, {"text": "3.4.", "bbox": [67.0, 272.0, 87.0, 285.0]}], "type": "Section-header", "position": 4}, {"raw_context": [{"text": "Besides its role in sexual functioning and urination, a fully", "bbox": [66.0, 294.0, 389.0, 308.0]}, {"text": "functional penis is central to a patient's sense of wholeness,", "bbox": [66.0, 310.0, 389.0, 323.0]}, {"text": "desirability, and masculinity. Hence, the aim for treatment", "bbox": [66.0, 325.0, 390.0, 339.0]}, {"text": "of the primary tumour is complete tumour removal or abla-", "bbox": [66.0, 340.0, 388.0, 354.0]}, {"text": "tion with as much organ preservation as possible without", "bbox": [66.0, 356.0, 389.0, 369.0]}, {"text": "compromising oncological control. A systematic review by", "bbox": [66.0, 371.0, 389.0, 385.0]}, {"text": "the guidelines panel revealed a complete absence of both", "bbox": [66.0, 387.0, 390.0, 400.0]}, {"text": "randomised controlled trials and prospective trials assess-", "bbox": [66.0, 402.0, 387.0, 415.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "Table 3 – Recommendations for diagnostic evaluation and staging", "bbox": [75.0, 441.0, 365.0, 453.0]}, {"text": "Recommendation", "bbox": [78.0, 463.0, 159.0, 473.0]}, {"text": "Strength", "bbox": [325.0, 463.0, 366.0, 474.0]}, {"text": "rating", "bbox": [327.0, 473.0, 354.0, 487.0]}, {"text": "Primary tumour", "bbox": [78.0, 491.0, 148.0, 501.0]}, {"text": "Perform a detailed physical examination of the penis and", "bbox": [78.0, 501.0, 316.0, 513.0]}, {"text": "Strong", "bbox": [324.0, 502.0, 354.0, 512.0]}, {"text": "external genitalia, recording the morphology, size, and", "bbox": [91.0, 512.0, 314.0, 525.0]}, {"text": "location of the penile lesion, including the extent and", "bbox": [91.0, 524.0, 311.0, 535.0]}, {"text": "invasion of penile (adjacent) structures.", "bbox": [91.0, 536.0, 253.0, 548.0]}, {"text": "Perform magnetic resonance imaging (MRI) of the penis/", "bbox": [78.0, 548.0, 313.0, 559.0]}, {"text": "Weak", "bbox": [324.0, 548.0, 352.0, 558.0]}, {"text": "primary tumour (artificial erection not mandatory)", "bbox": [91.0, 559.0, 303.0, 570.0]}], "type": "Table", "position": 6}, {"raw_context": [{"text": "primary tumour (artificial erection not mandatory)", "bbox": [91.0, 559.0, 303.0, 570.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "option.", "bbox": [91.0, 605.0, 119.0, 615.0]}], "type": "Text", "position": 8}, {"raw_context": [{"text": "malignancy is not clinically obvious, or when", "bbox": [91.0, 627.0, 279.0, 638.0]}, {"text": "nonsurgical treatment of the primary lesion is planned", "bbox": [91.0, 639.0, 316.0, 651.0]}, {"text": "(eg, topical agents, laser, radiotherapy).", "bbox": [90.0, 651.0, 252.0, 661.0]}, {"text": "Inguinal lymph nodes (LNs)", "bbox": [78.0, 660.0, 200.0, 672.0]}, {"text": "number, laterality, and characteristics of any", "bbox": [91.0, 685.0, 275.0, 695.0]}, {"text": "palpable/suspicious inguinal nodes.", "bbox": [91.0, 696.0, 234.0, 707.0]}, {"text": "Clinically node-negative (cN0)", "bbox": [78.0, 707.0, 209.0, 719.0]}, {"text": "examination, offer surgical LN staging to all patients at", "bbox": [91.0, 731.0, 316.0, 742.0]}, {"text": "high risk of having micrometastatic disease (T1b or", "bbox": [91.0, 742.0, 302.0, 753.0]}, {"text": "higher).", "bbox": [91.0, 754.0, 124.0, 764.0]}, {"text": "alternative to surgical staging with patients willing to", "bbox": [91.0, 775.0, 313.0, 789.0]}, {"text": "comply with strict follow-up.", "bbox": [91.0, 788.0, 211.0, 798.0]}, {"text": "node biopsy (DSNB).If DSNB is not available and referral", "bbox": [91.0, 810.0, 316.0, 821.0]}, {"text": "is not feasible, or if preferred by the patient after being", "bbox": [90.0, 822.0, 316.0, 833.0]}, {"text": "well informed, offer inguinal LN dissection (open or", "bbox": [91.0, 833.0, 303.0, 845.0]}, {"text": "video-endoscopic surgery).", "bbox": [91.0, 844.0, 202.0, 856.0]}, {"text": "If DSNB is planned, perform inguinal US first, with fine-", "bbox": [78.0, 856.0, 308.0, 867.0]}, {"text": "needle aspiration cytology of sonographically abnormal", "bbox": [91.0, 868.0, 316.0, 878.0]}, {"text": "LNs.", "bbox": [91.0, 879.0, 107.0, 888.0]}, {"text": "Clinically node-positive (cN+)", "bbox": [78.0, 890.0, 207.0, 901.0]}, {"text": "If there is a palpable/suspicious node on physical", "bbox": [78.0, 901.0, 283.0, 913.0]}, {"text": "examination (cN+), obtain (image-guided) biopsy to", "bbox": [91.0, 914.0, 305.0, 923.0]}, {"text": "confirm nodal metastasis before initiating treatment.", "bbox": [91.0, 925.0, 307.0, 933.0]}, {"text": "In cN+ patients, stage the pelvis and exclude distant", "bbox": [78.0, 936.0, 295.0, 947.0]}, {"text": "metastases with 18F-fluoro-2-deoxy-D-glucose positron", "bbox": [91.0, 946.0, 316.0, 960.0]}, {"text": "emission tomography ( 18 FDG-PET) computed", "bbox": [91.0, 957.0, 279.0, 969.0]}, {"text": "tomography (CT) or CT of the chest and abdomen before", "bbox": [91.0, 969.0, 316.0, 982.0]}, {"text": "initiating treatment", "bbox": [92.0, 983.0, 169.0, 992.0]}], "type": "Table", "position": 10}, {"raw_context": [{"text": "Strong", "bbox": [324.0, 719.0, 355.0, 730.0]}], "type": "List-item", "position": 11}, {"raw_context": [{"text": "Weak", "bbox": [325.0, 764.0, 351.0, 775.0]}], "type": "List-item", "position": 12}, {"raw_context": [{"text": "Strong", "bbox": [326.0, 856.0, 355.0, 867.0]}], "type": "Table", "position": 13}, {"raw_context": [{"text": "Strong", "bbox": [326.0, 902.0, 355.0, 913.0]}], "type": "Table", "position": 14}, {"raw_context": [{"text": "Strong", "bbox": [326.0, 937.0, 355.0, 947.0]}], "type": "Text", "position": 15}, {"raw_context": [{"text": "ing and comparing the effectiveness of interventions for", "bbox": [410.0, 88.0, 731.0, 101.0]}, {"text": "managing the primary tumour in penile cancer [ 1 ].", "bbox": [410.0, 103.0, 689.0, 117.0]}], "type": "Text", "position": 16}, {"raw_context": [{"text": "3.4.1.", "bbox": [411.0, 138.0, 438.0, 150.0]}, {"text": "Treatment of superficial noninvasive disease (PeIN, Ta)", "bbox": [458.0, 137.0, 729.0, 150.0]}, {"text": "PeIN can progress to invasive lesions in 2.6–13% of patients", "bbox": [410.0, 151.0, 733.0, 165.0]}, {"text": "despite treatment [41–43] . Most PeIN lesions are located on", "bbox": [410.0, 166.0, 733.0, 181.0]}, {"text": "the mucosal surfaces of the glans or prepuce, while lichen", "bbox": [410.0, 182.0, 732.0, 196.0]}, {"text": "sclerosus also affects the prepuce [ 42 ]. Circumcision, wide", "bbox": [410.0, 197.0, 732.0, 211.0]}, {"text": "local excision, and (partial) glans resurfacing are surgical", "bbox": [410.0, 213.0, 733.0, 227.0]}, {"text": "options [43–45] . Recurrences are reported to be low (0–", "bbox": [410.0, 228.0, 731.0, 242.0]}, {"text": "20%) [44,46,47] . Resection, as opposed to ablative or topical", "bbox": [411.0, 244.0, 733.0, 256.0]}, {"text": "treatments, provides the advantage of complete histopatho-", "bbox": [410.0, 258.0, 731.0, 272.0]}, {"text": "logical local staging and detection of areas of invasion, as up", "bbox": [410.0, 274.0, 733.0, 287.0]}, {"text": "to 20% of patients harbour invasive disease [44] . Topical", "bbox": [410.0, 290.0, 733.0, 302.0]}, {"text": "therapy with imiquimod or 5-fluorouracil (5-FU) is an effec-", "bbox": [410.0, 304.0, 731.0, 318.0]}, {"text": "tive noninvasive alternative [ 48 ]. There is no consensus or", "bbox": [410.0, 320.0, 732.0, 333.0]}, {"text": "comparative data on the optimal treatment schedule for", "bbox": [410.0, 335.0, 732.0, 348.0]}, {"text": "these therapies and tolerance can be problematic [49,50] .", "bbox": [410.0, 350.0, 731.0, 365.0]}, {"text": "A systematic review of low-quality data showed response", "bbox": [410.0, 366.0, 732.0, 380.0]}, {"text": "and recurrence rates of 40–100% and 20% for imiquimod,", "bbox": [411.0, 382.0, 732.0, 395.0]}, {"text": "versus 48–74% and 11% for 5-FU, respectively [ 51 ]. It is", "bbox": [410.0, 396.0, 733.0, 411.0]}, {"text": "advised that treatment effects must be clinically assessed", "bbox": [410.0, 412.0, 733.0, 425.0]}, {"text": "and in cases of doubt evaluated via biopsy, as insufficient", "bbox": [410.0, 427.0, 732.0, 440.0]}, {"text": "responses and recurrences may signify underlying invasive", "bbox": [410.0, 442.0, 732.0, 457.0]}, {"text": "disease. Tumour ablation using Nd:YAG or CO 2 laser results", "bbox": [410.0, 458.0, 732.0, 472.0]}, {"text": "in response rates of 52–100%, with recurrence rates of 7–", "bbox": [410.0, 473.0, 731.0, 486.0]}, {"text": "48% reported for patients with noninvasive disease [ 51 , 52 ].", "bbox": [410.0, 488.0, 732.0, 502.0]}], "type": "Text", "position": 17}, {"raw_context": [{"text": "3.4.2.", "bbox": [411.0, 523.0, 438.0, 534.0]}, {"text": "Treatment of invasive disease confined to the glans (cT1/", "bbox": [459.0, 522.0, 732.0, 535.0]}, {"text": "(2012)", "bbox": [411.0, 537.0, 430.0, 549.0]}, {"text": "Recent decades have seen a shift towards organ-sparing", "bbox": [410.0, 551.0, 732.0, 564.0]}, {"text": "surgery on the basis of the assumption derived from hetero-", "bbox": [410.0, 566.0, 731.0, 580.0]}, {"text": "geneous cohorts that local recurrence has little influence on", "bbox": [410.0, 582.0, 732.0, 595.0]}, {"text": "long-term survival [ 15 ]. However, a large series looking at", "bbox": [410.0, 597.0, 733.0, 610.0]}, {"text": "higher-risk tumours treated with glansectomy [ 53 ] revealed", "bbox": [410.0, 612.0, 733.0, 626.0]}, {"text": "that patients experiencing local recurrence have poorer sur-", "bbox": [410.0, 628.0, 731.0, 641.0]}, {"text": "vival, which challenges this dogma. A systematic review by", "bbox": [410.0, 643.0, 731.0, 656.0]}, {"text": "the guidelines panel found a cumulative 5-yr recurrence-", "bbox": [410.0, 658.0, 731.0, 672.0]}, {"text": "free rate (RFR) of 82% in case series and 76.7% in nonran-", "bbox": [410.0, 674.0, 731.0, 687.0]}, {"text": "domised controlled studies for organ-sparing surgery. The", "bbox": [410.0, 689.0, 732.0, 702.0]}, {"text": "limits of organ-sparing surgery are not completely clear", "bbox": [410.0, 704.0, 732.0, 718.0]}, {"text": "and the higher risk of local recurrence in comparison to par-", "bbox": [410.0, 720.0, 731.0, 733.0]}, {"text": "tial amputation should be discussed with the patient when", "bbox": [410.0, 735.0, 733.0, 748.0]}, {"text": "making a treatment plan. The concept of organ-preserving", "bbox": [410.0, 750.0, 732.0, 764.0]}, {"text": "surgery is based on observations of how the distance", "bbox": [410.0, 766.0, 732.0, 779.0]}, {"text": "between the tumour and the resection margin affects local", "bbox": [410.0, 781.0, 733.0, 794.0]}, {"text": "recurrence. A 2018 study from a supraregional referral cen-", "bbox": [410.0, 795.0, 731.0, 810.0]}, {"text": "tre found that local recurrence rates only increased consid-", "bbox": [410.0, 811.0, 731.0, 825.0]}, {"text": "erably when the distance from the tumour to the margin", "bbox": [409.0, 826.0, 733.0, 840.0]}, {"text": "was <1 mm [54] . To ensure complete removal with histo-", "bbox": [410.0, 841.0, 731.0, 856.0]}, {"text": "logically negative margins, standard excision must there-", "bbox": [410.0, 857.0, 731.0, 871.0]}, {"text": "fore include a margin of clinically normal-appearing skin", "bbox": [410.0, 871.0, 733.0, 886.0]}, {"text": "around the tumour and surrounding erythema. As the aim", "bbox": [410.0, 887.0, 733.0, 901.0]}, {"text": "is for negative surgical margins, it is the panel's opinion that", "bbox": [410.0, 903.0, 732.0, 916.0]}, {"text": "frozen section analysis is a helpful tool in cases of doubt,", "bbox": [410.0, 918.0, 733.0, 931.0]}, {"text": "whereas routine use is not recommended [ 54 – 57 ]. Accord-", "bbox": [410.0, 933.0, 732.0, 947.0]}, {"text": "ing to our systematic review, laser therapy for invasive", "bbox": [410.0, 949.0, 732.0, 962.0]}, {"text": "penile cancer resulted in a cumulative mean 5-yr RFR of", "bbox": [410.0, 964.0, 733.0, 977.0]}, {"text": "69.4% [1] . Radiotherapy is an organ-preserving approach", "bbox": [410.0, 979.0, 733.0, 993.0]}, {"text": "with good results in selected patients with T1–2 lesions", "bbox": [410.0, 995.0, 732.0, 1008.0]}], "type": "Text", "position": 18}, {"raw_context": [{"text": "Please cite this article as: O.R. Brouwer, M. Albersen, A. Parnham et al., European Association of Urology-American Society of Clinical Oncology Col-", "bbox": [70.0, 1028.0, 729.0, 1040.0]}, {"text": "laborative Guideline on Penile Cancer: 2023 Update, Eur Urol (2023), https://doi.org/10.1016/j.eururo.2023.02.027", "bbox": [70.0, 1040.0, 589.0, 1053.0]}], "type": "Text", "position": 19}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/泌尿外科/2023 EAU／ASCO指南：阴茎癌（更新版）.pdf", "page_num": 5}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": "语句不通顺#1#1#specificity of 82% for 18 F-Fluoro-2-deoxy-D-glucose (FDG)-PET/CT both   里面的both   应该在 18  F-Fluoro-2-deoxy-D-glucose的前面\n错别字#27#27#(cT1/ (2012)应该是 (cT1/T2)", "type2": "多余换行#2#2#showed sensitivity of 91% and与上面1段联接\n序号格式不一致#4#4#Treatment Of The Primary Tumour 3.4.序号应该在前面\n多余换行#22#22# ing and comparing the effectiveness ...与上面5段联接\n多余换行#24#24#Treatment of superficial noninvasive disease (PeIN, Ta)与上面序号联接\n缺少换行#24#24#PeIN can progress to invasive lesions...另起一行\n多余换行#27#27#Treatment of invasive disease confined to the glans (cT1/ (2012)与上面序号联接\n缺少换行#27#27#Recent decades have seen a shift ...另起一行\n", "type3": "无关文本#1#28#[39]  类似的[   ]无关引用过多", "type4": null, "type5": null, "type6": "准确性#6#21#表格的内容，但是内容顺序有问题。并缺少内容\n有用性#28#28#页脚内容"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:40", "update_time": "2024-05-08 22:54:07"}
{"id": 1082490, "user_id": "65e7dd234a08e7753ad36f9f", "user_name": "黄艳玲", "task_id": 738, "source_info": {"seq_id": "f89e4814-26ef-4e2d-83d5-776285cc9c42", "title": null, "text": "【0】页码:6\n 二医院(吴章); 苏州大学附属儿童医院(陈临琪); 天津市儿童医院 (孟英韬);天津医科大学息医院(刘戈力、郑荣秀);武汉市儿童医 院(姚辉);新疆医科大学第一附属医院(米热古丽•买买提);云南 省第一人民医院(李利) ; 新江大学医学院附属第一医院(王春林) ; 浙江大学医学院附属儿童医院( 傅若芬、王金玲、吳蔚 ); 郑州大学 第三閣属医院(王伟);中国医科大学附属盛京医院(辛類、 赵云静 ) ; 中国医学科学院 北京协和医学院 北京协和医院 ( 马明圣 , 邱正庆 ) ; 中南大学湘雅二医院( 张星星 ) ; 中山大学附属 第一医院(李燕虹);中山大学孙逸仙纪念医院(梁立阳) 利益冲突 所有作者声明无利益冲突 志謝    复旦大学附属儿科医院(倪锦文、程若倩、徐真然、李晓静、 吳静 ( 秋 成 君 )\n\n【1】## 参\n\n【2】\n Hawton K, Senniappan S.\n\n【3】Congenital [1] Giri D, hyperinsulinism:  recent  updates on 1 molecular mechanisms, diagnosis and management[J]. J Pediatr Endocrinol Metab, 2022, 35(3): 279-296. DOI: 10.1515/ jpem-2021-0369.\n\n【4】[2] Galcheva S, Al-Khawaga S, Hussain K. Diagnosis and management of hyperinsulinaemic hypoglycaemia[J].\n\n【5】Best Pract Res Clin Endocrinol Metab, 2018, 32(4): 551-573. DOI: 10.1016/j.beem.2018.05.014.\n\n【6】[3] Yorifuji T, Horikawa R, Hasegawa T, et al. Clinical practice guidelines for congenital hyperinsulinism[J]. Clin Pediatr Endocrinol, 2017, 26(3): 127-152. DOI: 10.1297/ cpe.26.127.\n\n【7】[4] Wang WY, Sun Y, Zhao WT, et al. Congenital hyperinsulinism in China: a review of Chinese literature over the past 15 years[J]. J Clin Res Pediatr Endocrinol, 2017, 9(3):194-201. DOI: 10.4274/jcrpe.3934.\n\n【8】[5] Palladino AA, Stanley CA.\n\n【9】The hyperinsulinism/hyperammonemia syndrome[J].\n\n【10】Rev Endocr Metab Disord, 2010, 11(3): 171-178. DOI: 10.1007/s11154-010-9146-0.\n\n【11】Otonkoski T, Kaminen N, Ustinov J, et al. Physical [6] exercise-induced hyperinsulinemic hypoglycemia is an autosomal-dominant trait characterized by abnormal pyruvate-induced insulin release[J]. Diabetes, 2003, 52(1):199-204. DOI: 10.2337/diabetes.52.1.199.\n\n【12】[7] [7] Yamada Y, Kitayama K, Oyachi M, et al. Nationwide survey of endogenous hyperinsulinemic hypoglycemia in Japan (2017-2018): congenital hyperinsulinism, insulinoma, non-insulinoma pancreatogenous hypoglycemia syndrome and insulin autoimmune syndrome (Hirata's disease)[J]. J Diabetes Investig, 2020, 11(3):554-563. DOI: 10.1111/jdi.13180.\n\n【13】Muukkonen L, Männistö J, Jääskeläinen J, et al. The effect [8] of hypoglycaemia on neurocognitive outcome in children and adolescents with transient or persistent congenital hyperinsulinism[J]. Dev Med Child Neurol, 2019, 61(4): 451-457. DOI: 10.1111/dmcn.14039.\n\n【14】[9] Thornton PS, Stanley CA, De Leon DD, et al.\n\n【15】Recommendations from the pediatric endocrine society and management of persistent for evaluation hypoglycemia in neonates, infants, and children[J]. J Pediatr, 2015, 167(2): 238-245. DOI: 10.1016/j.\n\n【16】 jpeds.2015.03.057.\n\n【17】Xu ZR, Zhu XY, Lu W, et al. Altered serum amino acid and [10] acylcarnitine profiles in hyperinsulinemic hypoglycemia ketotic  hypoglycemia[J].  Front Endocrinol and (Lausanne), 2020, 11  577373.     DOI: 10.3389/ fendo.2020.577373.\n\n【18】Fourtner SH, Stanley CA, Kelly A. Protein-sensitive [11] hypoglycemia without leucine sensitivity in the international and products of the second the second theme to the second them.\n\n【19】hyperinsulinism caused by K(ATP) channel mutations[J]. J Pediatr, 2006, 149(1): 47-52.\n\n【20】DOI: 10.1016/j.\n\n【21】jpeds.2006.02.033.\n\n【22】[12] Shah P, PP, Rahman SA,       Demirbilek H, et al.\n\n【23】Hyperinsulinaemic hypoglycaemia in children and adults [J]. Lancet Diabetes Endocrinol, 2017, 5(9):729-742. DOI: 10.1016/S2213-8587(16)30323-0.\n\n【24】[13] Arya VB, Guemes M, Nessa A, et al. Clinical and histological heterogeneity of congenital hyperinsulinism due to paternally inherited heterozygous ABCC8/KCNJ11 mutations[J]. Eur J Endocrinol, 2014, 171(6): 685-695.\n\n【25】DOI: 10.1530/EJE-14-0353.\n\n【26】Hussain K, Flanagan SE, Smith VV, et al. An ABCC8 gene [14] 1 mutation and mosaic uniparental isodisomy resulting in atypical diffuse congenital hyperinsulinism[J]. Diabetes, 2008, 57(1):259-263. DOI: 10.2337/db07-0998.\n\n【27】[15] Imperiale A, Boursier C, Sahakian N, et al. Value of (68) Ga- DOTATOC and Carbidopa- assisted (18)F- DOPA PET/CT for insulinoma localization[J]. J Nucl Med, 2022, 63(3):384-388. DOI: 10.2967/jnumed.121.262401.\n\n【28】[16] Boardman JP, Wusthoff CJ, Cowan FM.  Hypoglycaemia and neonatal brain injury[J]. Arch Dis Child Educ Pract Ed, 2013, 98(1):2-6. DOI: 10.1136/archdischild-2012-302569.\n\n【29】[17] Banerjee I, Salomon-Estebanez M, Shah P, et al. Therapies and outcomes of congenital hyperinsulinism-induced hypoglycaemia[J]. Diabet Med, 2019, 36(1): 9-21. DOI: 10.1111/dme.13823.\n\n【30】De Cosio AP, Thornton P. Current and emerging agents for [18] .\n\n【31】the treatment of hypoglycemia in patients with congenital hyperinsulinism[J]. Paediatr Drugs, 2019, 21(3):123-136.\n\n【32】DOI: 10.1007/s40272-019-00334-w.\n\n【33】Panigrahy N, Chirla DK, Bagga N, et al. Sirolimus in infants [19] with congenital hyperinsulinism (CHI)-a single-centre experience[J]. Eur J Pediatr, 2022, 181(1): 407-412. DOI: 10.1007/s00431-021-04209-6.\n\n【34】Adzick NS, De Leon DD, States LJ, et al. Surgical treatment [20] of congenital hyperinsulinism: results from 500 pancreatectomies in neonates and children[J]. J Pediatr Surg, 2019,     54(1):     27-32.\n\n【35】DOI: 10.1016/j.\n\n【36】jpedsurg.2018.10.030.\n\n【37】章秦浩, 周怡瑶, 陈婕好, 等 . 蛋白敏感性低血糖５例病例报 [21] 道及文献复习 [J]. 中华内分泌代谢杂志 , 2019, 35(1):7-14.\n\n【38】DOI: 10.3760/cma.j.issn.1000-6699.2019.01.002.\n\n【39】[22] Arya VB, Senniappan S, Demirbilek H, et al. Pancreatic endocrine and exocrine function in children following near-total pancreatectomy for diffuse congenital hyperinsulinism[J]. PLoS One, 2014, 9(5): e98054. DOI: 10.1371/journal.pone.0098054.\n\n【40】Welters A, Lerch C, Kummer S, et al. Long-term medical [23] treatment in congenital hyperinsulinism: a descriptive analysis in a large cohort of patients from different clinical centers[J]. Orphanet J Rare Dis, 2015, 10:150. DOI: 10.1186/s13023-015-0367-x.", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "二医院(吴章); 苏州大学附属儿童医院(陈临琪); 天津市儿童医院", "bbox": [85.0, 102.0, 391.0, 117.0]}, {"text": "(孟英韬);天津医科大学息医院(刘戈力、郑荣秀);武汉市儿童医", "bbox": [85.0, 120.0, 390.0, 134.0]}, {"text": "院(姚辉);新疆医科大学第一附属医院(米热古丽•买买提);云南", "bbox": [85.0, 137.0, 390.0, 152.0]}, {"text": "省第一人民医院(李利) ; 新江大学医学院附属第一医院(王春林) ;", "bbox": [85.0, 154.0, 391.0, 170.0]}, {"text": "浙江大学医学院附属儿童医院( 傅若芬、王金玲、吳蔚 ); 郑州大学", "bbox": [85.0, 173.0, 390.0, 188.0]}, {"text": "第三閣属医院(王伟);中国医科大学附属盛京医院(辛類、", "bbox": [85.0, 190.0, 390.0, 206.0]}, {"text": "赵云静 ) ; 中国医学科学院 北京协和医学院 北京协和医院", "bbox": [85.0, 209.0, 390.0, 224.0]}, {"text": "( 马明圣 , 邱正庆 ) ; 中南大学湘雅二医院( 张星星 ) ; 中山大学附属", "bbox": [85.0, 227.0, 390.0, 242.0]}, {"text": "第一医院(李燕虹);中山大学孙逸仙纪念医院(梁立阳)", "bbox": [85.0, 244.0, 339.0, 259.0]}, {"text": "利益冲突 所有作者声明无利益冲突", "bbox": [85.0, 262.0, 258.0, 276.0]}, {"text": "志謝    复旦大学附属儿科医院(倪锦文、程若倩、徐真然、李晓静、", "bbox": [85.0, 279.0, 389.0, 295.0]}, {"text": "吳静 ( 秋 成 君 )", "bbox": [85.0, 298.0, 153.0, 313.0]}], "type": "Text", "position": 2}, {"raw_context": [{"text": "参 ", "bbox": [194.0, 332.0, 281.0, 346.0]}], "type": "Section-header", "position": 3}, {"raw_context": [{"text": "Hawton K, Senniappan S.", "bbox": [174.0, 364.0, 330.0, 377.0]}, {"text": "Congenital", "bbox": [337.0, 364.0, 392.0, 377.0]}, {"text": "[1]", "bbox": [93.0, 365.0, 113.0, 378.0]}, {"text": "Giri D,", "bbox": [121.0, 365.0, 176.0, 376.0]}, {"text": "hyperinsulinism:  recent  updates", "bbox": [123.0, 380.0, 307.0, 393.0]}, {"text": "on 1", "bbox": [311.0, 381.0, 336.0, 393.0]}, {"text": "molecular", "bbox": [340.0, 381.0, 391.0, 392.0]}, {"text": "mechanisms, diagnosis and management[J]. J Pediatr", "bbox": [123.0, 395.0, 390.0, 408.0]}, {"text": "Endocrinol Metab, 2022, 35(3): 279-296. DOI: 10.1515/", "bbox": [123.0, 411.0, 392.0, 422.0]}, {"text": "jpem-2021-0369.", "bbox": [123.0, 425.0, 205.0, 438.0]}, {"text": "[2]", "bbox": [93.0, 440.0, 112.0, 453.0]}, {"text": "Galcheva S, Al-Khawaga S, Hussain K. Diagnosis and", "bbox": [121.0, 440.0, 392.0, 452.0]}, {"text": "management of hyperinsulinaemic hypoglycaemia[J].", "bbox": [123.0, 455.0, 391.0, 468.0]}, {"text": "Best Pract Res Clin Endocrinol Metab, 2018, 32(4):", "bbox": [123.0, 470.0, 391.0, 483.0]}, {"text": "551-573. DOI: 10.1016/j.beem.2018.05.014.", "bbox": [123.0, 485.0, 327.0, 497.0]}, {"text": "[3]", "bbox": [93.0, 500.0, 111.0, 513.0]}, {"text": "Yorifuji T, Horikawa R, Hasegawa T, et al. Clinical practice", "bbox": [122.0, 500.0, 391.0, 512.0]}, {"text": "guidelines for congenital hyperinsulinism[J]. Clin Pediatr", "bbox": [123.0, 515.0, 391.0, 527.0]}, {"text": "Endocrinol, 2017, 26(3): 127-152. DOI: 10.1297/", "bbox": [123.0, 530.0, 391.0, 542.0]}, {"text": "cpe.26.127.", "bbox": [122.0, 545.0, 178.0, 557.0]}, {"text": "[4]", "bbox": [93.0, 560.0, 111.0, 573.0]}, {"text": "Wang WY, Sun Y, Zhao WT, et al. Congenital", "bbox": [121.0, 560.0, 394.0, 573.0]}, {"text": "hyperinsulinism in China: a review of Chinese literature", "bbox": [122.0, 575.0, 390.0, 588.0]}, {"text": "over the past 15 years[J]. J Clin Res Pediatr Endocrinol,", "bbox": [123.0, 590.0, 390.0, 603.0]}, {"text": "2017, 9(3):194-201. DOI: 10.4274/jcrpe.3934.", "bbox": [123.0, 605.0, 337.0, 617.0]}, {"text": "[5]", "bbox": [93.0, 620.0, 111.0, 633.0]}, {"text": "Palladino", "bbox": [121.0, 620.0, 170.0, 632.0]}, {"text": "AA,", "bbox": [200.0, 621.0, 219.0, 632.0]}, {"text": "Stanley", "bbox": [249.0, 621.0, 288.0, 632.0]}, {"text": "CA.", "bbox": [319.0, 621.0, 338.0, 632.0]}, {"text": "The", "bbox": [370.0, 621.0, 390.0, 632.0]}, {"text": "hyperinsulinism/hyperammonemia syndrome[J].", "bbox": [123.0, 635.0, 369.0, 648.0]}, {"text": "Rev", "bbox": [367.0, 636.0, 390.0, 647.0]}, {"text": "Endocr Metab Disord, 2010, 11(3): 171-178. DOI:", "bbox": [123.0, 649.0, 390.0, 662.0]}, {"text": "10.1007/s11154-010-9146-0.", "bbox": [123.0, 665.0, 263.0, 677.0]}, {"text": "Otonkoski T, Kaminen N, Ustinov J, et al. Physical", "bbox": [121.0, 680.0, 391.0, 693.0]}, {"text": "[6]", "bbox": [93.0, 681.0, 111.0, 693.0]}, {"text": "exercise-induced hyperinsulinemic hypoglycemia is an", "bbox": [123.0, 693.0, 390.0, 709.0]}, {"text": "autosomal-dominant trait characterized by abnormal", "bbox": [123.0, 709.0, 390.0, 723.0]}, {"text": "pyruvate-induced insulin release[J]. Diabetes, 2003,", "bbox": [123.0, 725.0, 390.0, 737.0]}, {"text": "52(1):199-204. DOI: 10.2337/diabetes.52.1.199.", "bbox": [123.0, 739.0, 347.0, 753.0]}, {"text": "[7] [7]", "bbox": [93.0, 755.0, 110.0, 769.0]}, {"text": "Yamada Y, Kitayama K, Oyachi M, et al. Nationwide survey", "bbox": [123.0, 756.0, 390.0, 768.0]}, {"text": "of endogenous hyperinsulinemic hypoglycemia in Japan", "bbox": [123.0, 770.0, 390.0, 782.0]}, {"text": "(2017-2018): congenital hyperinsulinism, insulinoma,", "bbox": [123.0, 785.0, 390.0, 798.0]}, {"text": "non-insulinoma", "bbox": [123.0, 801.0, 202.0, 813.0]}, {"text": "pancreatogenous", "bbox": [218.0, 801.0, 307.0, 813.0]}, {"text": "hypoglycemia", "bbox": [322.0, 801.0, 391.0, 813.0]}, {"text": "syndrome and insulin autoimmune syndrome (Hirata's", "bbox": [123.0, 815.0, 391.0, 828.0]}, {"text": "disease)[J]. J Diabetes Investig, 2020, 11(3):554-563. DOI:", "bbox": [123.0, 830.0, 391.0, 844.0]}, {"text": "10.1111/jdi.13180.", "bbox": [123.0, 847.0, 215.0, 859.0]}, {"text": "Muukkonen L, Männistö J, Jääskeläinen J, et al. The effect", "bbox": [121.0, 859.0, 391.0, 874.0]}, {"text": "[8]", "bbox": [93.0, 862.0, 112.0, 874.0]}, {"text": "of hypoglycaemia on neurocognitive outcome in children", "bbox": [123.0, 877.0, 391.0, 889.0]}, {"text": "and adolescents with transient or persistent congenital", "bbox": [123.0, 891.0, 391.0, 903.0]}, {"text": "hyperinsulinism[J]. Dev Med Child Neurol, 2019, 61(4):", "bbox": [123.0, 906.0, 390.0, 919.0]}, {"text": "451-457. DOI: 10.1111/dmcn.14039.", "bbox": [123.0, 921.0, 293.0, 934.0]}, {"text": "[9]", "bbox": [93.0, 936.0, 112.0, 949.0]}, {"text": "Thornton PS, Stanley CA, De Leon DD, et al.", "bbox": [122.0, 936.0, 390.0, 948.0]}, {"text": "Recommendations from the pediatric endocrine society", "bbox": [123.0, 951.0, 390.0, 963.0]}, {"text": "and management of persistent", "bbox": [209.0, 966.0, 391.0, 978.0]}, {"text": "for", "bbox": [123.0, 967.0, 141.0, 978.0]}, {"text": "evaluation", "bbox": [149.0, 967.0, 211.0, 978.0]}, {"text": "hypoglycemia in neonates, infants, and children[J]. J", "bbox": [122.0, 981.0, 391.0, 993.0]}, {"text": "Pediatr,", "bbox": [123.0, 998.0, 164.0, 1007.0]}, {"text": "2015,", "bbox": [168.0, 998.0, 206.0, 1007.0]}, {"text": "167(2): 238-245. DOI: 10.1016/j.", "bbox": [206.0, 997.0, 391.0, 1009.0]}], "type": "Text", "position": 4}, {"raw_context": [{"text": "jpeds.2015.03.057.", "bbox": [463.0, 103.0, 552.0, 116.0]}, {"text": "Xu ZR, Zhu XY, Lu W, et al. Altered serum amino acid and", "bbox": [462.0, 118.0, 731.0, 131.0]}, {"text": "[10]", "bbox": [428.0, 120.0, 453.0, 132.0]}, {"text": "acylcarnitine profiles in hyperinsulinemic hypoglycemia", "bbox": [463.0, 133.0, 731.0, 145.0]}, {"text": "ketotic  hypoglycemia[J].  Front", "bbox": [494.0, 148.0, 668.0, 160.0]}, {"text": "Endocrinol", "bbox": [677.0, 148.0, 731.0, 160.0]}, {"text": "and", "bbox": [463.0, 149.0, 487.0, 160.0]}, {"text": "(Lausanne), 2020,", "bbox": [463.0, 163.0, 563.0, 175.0]}, {"text": "11  577373.     DOI:", "bbox": [570.0, 163.0, 676.0, 175.0]}, {"text": "10.3389/", "bbox": [684.0, 163.0, 731.0, 175.0]}, {"text": "fendo.2020.577373.", "bbox": [463.0, 177.0, 558.0, 190.0]}, {"text": "Fourtner SH, Stanley CA, Kelly A. Protein-sensitive", "bbox": [462.0, 193.0, 731.0, 206.0]}, {"text": "[11]", "bbox": [428.0, 194.0, 452.0, 207.0]}, {"text": "hypoglycemia", "bbox": [462.0, 209.0, 533.0, 220.0]}, {"text": "without", "bbox": [543.0, 209.0, 589.0, 220.0]}, {"text": "leucine", "bbox": [599.0, 209.0, 639.0, 220.0]}, {"text": "sensitivity", "bbox": [651.0, 209.0, 704.0, 220.0]}, {"text": "in the international and products of the second the second theme to the second them.", "bbox": [717.0, 209.0, 731.0, 219.0]}, {"text": "hyperinsulinism caused by K(ATP) channel mutations[J]. J", "bbox": [462.0, 223.0, 731.0, 236.0]}, {"text": "Pediatr,", "bbox": [463.0, 239.0, 504.0, 250.0]}, {"text": "2006,", "bbox": [509.0, 239.0, 546.0, 251.0]}, {"text": "149(1): 47-52.", "bbox": [551.0, 239.0, 635.0, 251.0]}, {"text": "DOI:", "bbox": [642.0, 239.0, 670.0, 251.0]}, {"text": "10.1016/j.", "bbox": [679.0, 239.0, 731.0, 251.0]}, {"text": "jpeds.2006.02.033.", "bbox": [463.0, 252.0, 552.0, 264.0]}, {"text": "[12]", "bbox": [428.0, 267.0, 452.0, 280.0]}, {"text": "Shah", "bbox": [462.0, 268.0, 492.0, 280.0]}, {"text": "P, PP,", "bbox": [499.0, 268.0, 518.0, 279.0]}, {"text": "Rahman", "bbox": [518.0, 268.0, 578.0, 280.0]}, {"text": "SA,       Demirbilek", "bbox": [578.0, 267.0, 670.0, 280.0]}, {"text": "H,", "bbox": [678.0, 267.0, 695.0, 279.0]}, {"text": "et al.", "bbox": [703.0, 268.0, 731.0, 279.0]}, {"text": "Hyperinsulinaemic hypoglycaemia in children and adults", "bbox": [463.0, 283.0, 731.0, 295.0]}, {"text": "[J]. Lancet Diabetes Endocrinol, 2017, 5(9):729-742. DOI:", "bbox": [463.0, 297.0, 731.0, 309.0]}, {"text": "10.1016/S2213-8587(16)30323-0.", "bbox": [464.0, 312.0, 626.0, 325.0]}, {"text": "[13]", "bbox": [428.0, 328.0, 452.0, 340.0]}, {"text": "Arya VB, Guemes M, Nessa A, et al. Clinical and", "bbox": [462.0, 327.0, 731.0, 340.0]}, {"text": "histological heterogeneity of congenital hyperinsulinism", "bbox": [463.0, 341.0, 731.0, 354.0]}, {"text": "due to paternally inherited heterozygous ABCC8/KCNJ11", "bbox": [463.0, 356.0, 731.0, 369.0]}, {"text": "mutations[J]. Eur J Endocrinol, 2014, 171(6): 685-695.", "bbox": [463.0, 371.0, 730.0, 384.0]}, {"text": "DOI: 10.1530/EJE-14-0353.", "bbox": [463.0, 386.0, 591.0, 398.0]}, {"text": "Hussain K, Flanagan SE, Smith VV, et al. An ABCC8 gene", "bbox": [462.0, 400.0, 731.0, 413.0]}, {"text": "[14] 1", "bbox": [428.0, 401.0, 452.0, 415.0]}, {"text": "mutation and mosaic uniparental isodisomy resulting in", "bbox": [463.0, 416.0, 731.0, 428.0]}, {"text": "atypical diffuse congenital hyperinsulinism[J]. Diabetes,", "bbox": [463.0, 430.0, 731.0, 443.0]}, {"text": "2008, 57(1):259-263. DOI: 10.2337/db07-0998.", "bbox": [464.0, 445.0, 685.0, 458.0]}, {"text": "[15]", "bbox": [427.0, 460.0, 452.0, 474.0]}, {"text": "Imperiale A, Boursier C, Sahakian N, et al. Value of (68)", "bbox": [462.0, 461.0, 731.0, 473.0]}, {"text": "Ga- DOTATOC and Carbidopa- assisted (18)F- DOPA", "bbox": [462.0, 475.0, 731.0, 487.0]}, {"text": "PET/CT for insulinoma localization[J]. J Nucl Med, 2022,", "bbox": [462.0, 490.0, 731.0, 503.0]}, {"text": "63(3):384-388. DOI: 10.2967/jnumed.121.262401.", "bbox": [463.0, 505.0, 699.0, 517.0]}, {"text": "[16]", "bbox": [428.0, 519.0, 452.0, 533.0]}, {"text": "Boardman JP, Wusthoff CJ, Cowan FM.  Hypoglycaemia and", "bbox": [462.0, 520.0, 731.0, 533.0]}, {"text": "neonatal brain injury[J]. Arch Dis Child Educ Pract Ed, 2013,", "bbox": [463.0, 535.0, 731.0, 548.0]}, {"text": "98(1):2-6. DOI: 10.1136/archdischild-2012-302569.", "bbox": [464.0, 550.0, 694.0, 562.0]}, {"text": "[17]", "bbox": [427.0, 565.0, 452.0, 578.0]}, {"text": "Banerjee I, Salomon-Estebanez M, Shah P, et al. Therapies", "bbox": [463.0, 565.0, 731.0, 577.0]}, {"text": "and outcomes of congenital hyperinsulinism-induced", "bbox": [464.0, 580.0, 731.0, 593.0]}, {"text": "hypoglycaemia[J]. Diabet Med, 2019, 36(1): 9-21. DOI:", "bbox": [464.0, 594.0, 731.0, 606.0]}, {"text": "10.1111/dme.13823.", "bbox": [464.0, 609.0, 563.0, 621.0]}, {"text": "De Cosio AP, Thornton P. Current and emerging agents for", "bbox": [462.0, 624.0, 731.0, 637.0]}, {"text": "[18] .", "bbox": [427.0, 625.0, 454.0, 637.0]}, {"text": "the treatment of hypoglycemia in patients with congenital", "bbox": [462.0, 639.0, 731.0, 651.0]}, {"text": "hyperinsulinism[J]. Paediatr Drugs, 2019, 21(3):123-136.", "bbox": [462.0, 654.0, 731.0, 666.0]}, {"text": "DOI: 10.1007/s40272-019-00334-w.", "bbox": [463.0, 669.0, 634.0, 681.0]}, {"text": "Panigrahy N, Chirla DK, Bagga N, et al. Sirolimus in infants", "bbox": [462.0, 683.0, 732.0, 696.0]}, {"text": "[19]", "bbox": [428.0, 684.0, 452.0, 697.0]}, {"text": "with congenital hyperinsulinism (CHI)-a single-centre", "bbox": [462.0, 698.0, 731.0, 710.0]}, {"text": "experience[J]. Eur J Pediatr, 2022, 181(1): 407-412. DOI:", "bbox": [462.0, 713.0, 731.0, 726.0]}, {"text": "10.1007/s00431-021-04209-6.", "bbox": [464.0, 727.0, 610.0, 740.0]}, {"text": "Adzick NS, De Leon DD, States LJ, et al. Surgical treatment", "bbox": [462.0, 743.0, 732.0, 756.0]}, {"text": "[20]", "bbox": [428.0, 744.0, 452.0, 757.0]}, {"text": "of congenital hyperinsulinism: results from 500", "bbox": [462.0, 758.0, 731.0, 770.0]}, {"text": "pancreatectomies in neonates and children[J]. J Pediatr", "bbox": [463.0, 773.0, 731.0, 786.0]}, {"text": "Surg,", "bbox": [463.0, 789.0, 492.0, 801.0]}, {"text": "2019,     54(1):     27-32.", "bbox": [503.0, 789.0, 629.0, 801.0]}, {"text": "DOI:", "bbox": [637.0, 789.0, 667.0, 801.0]}, {"text": "10.1016/j.", "bbox": [679.0, 789.0, 731.0, 801.0]}, {"text": "jpedsurg.2018.10.030.", "bbox": [464.0, 803.0, 568.0, 815.0]}, {"text": "章秦浩, 周怡瑶, 陈婕好, 等 . 蛋白敏感性低血糖５例病例报", "bbox": [462.0, 814.0, 731.0, 830.0]}, {"text": "[21]", "bbox": [428.0, 818.0, 452.0, 830.0]}, {"text": "道及文献复习 [J]. 中华内分泌代谢杂志 , 2019, 35(1):7-14.", "bbox": [464.0, 832.0, 731.0, 845.0]}, {"text": "DOI: 10.3760/cma.j.issn.1000-6699.2019.01.002.", "bbox": [463.0, 847.0, 691.0, 859.0]}, {"text": "[22]", "bbox": [428.0, 862.0, 452.0, 875.0]}, {"text": "Arya VB, Senniappan S, Demirbilek H, et al. Pancreatic", "bbox": [462.0, 862.0, 731.0, 875.0]}, {"text": "endocrine and exocrine function in children following", "bbox": [463.0, 877.0, 731.0, 890.0]}, {"text": "near-total pancreatectomy for diffuse congenital", "bbox": [463.0, 892.0, 731.0, 904.0]}, {"text": "hyperinsulinism[J]. PLoS One, 2014, 9(5): e98054. DOI:", "bbox": [463.0, 907.0, 731.0, 919.0]}, {"text": "10.1371/journal.pone.0098054.", "bbox": [464.0, 921.0, 612.0, 934.0]}, {"text": "Welters A, Lerch C, Kummer S, et al. Long-term medical", "bbox": [462.0, 935.0, 731.0, 948.0]}, {"text": "[23]", "bbox": [428.0, 936.0, 452.0, 948.0]}, {"text": "treatment in congenital hyperinsulinism: a descriptive", "bbox": [462.0, 951.0, 731.0, 963.0]}, {"text": "analysis in a large cohort of patients from different", "bbox": [463.0, 966.0, 731.0, 978.0]}, {"text": "clinical centers[J]. Orphanet J Rare Dis, 2015, 10:150. DOI:", "bbox": [462.0, 980.0, 731.0, 993.0]}, {"text": "10.1186/s13023-015-0367-x.", "bbox": [464.0, 996.0, 602.0, 1009.0]}], "type": "Text", "position": 5}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/内分泌科/先天性高胰岛素血症性低血糖诊治专家共识（2022）.pdf", "page_num": 6}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": null, "type2": null, "type3": null, "type4": null, "type5": null, "type6": "有用性#0#40#全篇为其他声明和参考文献内容"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:40", "update_time": "2024-05-08 01:32:12"}
{"id": 1082489, "user_id": "65e7dd68e6dc6a3a8618a668", "user_name": "王磊", "task_id": 738, "source_info": {"seq_id": "197504d6-83b9-4d9d-b57f-e1c0b4569245", "title": null, "text": "【0】页码:2\n Table 1.\n\n【1】 Table 1.\n\n【2】Factors Suggestive of TIA Versus TIA Mimic Factors TIA TIA mimic Older age Demo- Younger patient without ascular risk factors graphics Medical Presence of vascular risk factors History of epilepsy, history (hypertension, diabetes, coronary migraines, brain tumo artery disease, peripheral artery disease, smoking, obesity, hyperlipidemia, atrial fibrillation, previous stroke, obstructive sleep apnea) Symptom Abrupt onset Symptoms that spread/ atology march from site of onset.\n\n【3】Maximal symptoms at onset might suggest seizure Duration typically <60 min Altered mentation Preserved mentation Migraine headache Localizing/focal neurological Presence of signs or symptoms corresponding to a.\n\n【4】symptoms suggesting an vascular territory: dysarthria/ alternative diagnosis (ie, aphasia, facial droop, hemipares, positive visual phenomhemibody numbness ena, seizure-like activity, Dizziness paired with cranial positional vertigo without neuropathies, vision loss/diplopia, ocalizing/focal symptom difficulty with coordination or gait/ truncal ataxia, severe nausea/ vomiting may suggest posterior circulation process Hypertensive on presentation Headache with ptosis and miosis might indicate dissection This table is meant as a guide to approaching a patient with neurological\n\n【5】\n symptoms and should not be the sole determinant of ultimate diagnosis. Patientspecific factors must also be considered.\n\n【6】TIA indicates transient ischemic attack.\n\n【7】 '9 Ammqs4 no vq ano stemmolede// dmd moril bebeolarwork\n\n【8】 population-based study, Kleindorfer et al 8 estimated an incidence of 240000 TIAs in the United States in 2002. 6 Similar to cardiovascular disease and stroke, TIA incidence increases with age. Significant race-based disparities have been reported with Black Americans having a 1.4 times greater risk of TIA compared with White Americans, 6 although recent data on these disparities are lacking.\n\n【9】Population data have demonstrated an overall reduction in both TIA incidence and TIA admission rates over time. 78 These findings have been attributed to improved vascular risk reduction and stroke care, 8 changing trends in hospital admissions, and implementation of ED TIA protocols emphasizing short-term follow-up in dedicated TIA clinics. 9 Some evidence suggests that TIA incidence is decreasing more substantially in men than in women. 7\n\n【10】## Clinical Evaluation\n\n【11】\n Acute onset of focal neurological symptoms followed by complete resolution is suggestive of a TIA. Therefore, patients for whom TIA is being considered must have a neurological examination consistent with their baseline status. Specific details of the history and presentation can help differentiate TIA from alternate diagnoses. Nonspecific symptoms or examination findings (eg, isolated confusion/lethargy/encephalopathy), dizziness, focal\n\n【12】 e2e2\n\n【13】 symptoms with other features (eg, headache, seizure), or new radiological findings (eg, mass lesion) may suggest an alternate diagnosis or \"mimic\" (Table 1). In cases of diagnostic uncertainty, conventional wisdom suggests performing a neurovascular workup for suspected TIA to reduce the risk of a recurrent event, ideally with expedited neurological consultation.\n\n【14】## Diagnostic Evaluation\n\n【15】\n## Brain Imaging\n\n【16】\n In the ED, the role of acute phase imaging is to rule out alternative diagnoses, aid in risk stratification, and iden¬ tify potentially symptomatic lesions. An initial noncontrast head computed tomography (NCCT) is part of many stroke/TIA protocols given its accessibility in the ED setting, 10 and is a useful initial test to evaluate for subacute ischemia, hemorrhage, or mass lesion. NCCT alone, however, has limited utility in patients whose symptoms have resolved. 3 Although its sensitivity to detect an acute infarct is low, it does have utility in ruling out TIA mimics.\n\n【17】Multimodal brain MRI is the preferred method to evaluate for acute ischemic infarct and ideally should be obtained within 24 hours of symptom onset, and in most centers will follow a NCCT. 11 Some centers might have rapid access to MRI in the ED. In cases where MRI with DWI can be obtained without delay, NCCT can be safely avoided in a stable patient with completely resolved symptoms.\n\n【18】TIAs typically last minutes with a linear increase in the likelihood of infarction with increasing symptom dura¬ tion. 12 MRI with DWI demonstrates lesions in ~40% of patients presenting with TIA symptoms, and DWI positivity is associated with a >6-fold increased risk of recurrent stroke at 1 year. 13 If a DWI-positive lesion is identified, a diagnosis of ischemic stroke is typically made, followed by hospital admission. The distribution of DWI lesions can help with identification of stroke pathogenesis (eg, a single lacune in a deep structure suggests small vessel disease; scattered emboli in multiple territories might point to cardioembolic mechanism such as atrial fibrillation [AF]; watershed distribution of lesions suggests large vessel disease) and guides further workup and secondary prevention strategies.\n\n【19】In the clinical scenario in which MRI cannot be obtained acutely to definitively distinguish TIA from stroke, it remains reasonable to make a clinical diagnosis of TIA in the ED on the basis of a negative NCCT and symptom resolution within 24 hours. 14 A potential next step would be hospital admission for MRI, comprehensive workup, and neurology consultation. Other options might include transferring patients to a facility with advanced imaging and vascular neurology expertise or arranging a timely (ideally <24 hours) outpatient MRI. Early MRI can identify higher-risk patients and avoids MRI degradation", "tags": {}, "lang": "en", "attr": {"raw_info": [{"raw_context": [{"text": "Table 1.", "bbox": [65.0, 78.0, 109.0, 89.0]}], "type": "Text", "position": 3}, {"raw_context": [{"text": "Table 1.", "bbox": [65.0, 78.0, 109.0, 89.0]}, {"text": "Factors Suggestive of TIA Versus TIA Mimic", "bbox": [111.0, 77.0, 339.0, 90.0]}, {"text": " Factors", "bbox": [68.0, 100.0, 105.0, 113.0]}, {"text": "TIA", "bbox": [123.0, 100.0, 141.0, 112.0]}, {"text": "TIA mimic", "bbox": [271.0, 100.0, 317.0, 112.0]}, {"text": "Older age", "bbox": [125.0, 118.0, 167.0, 131.0]}, {"text": "Demo-", "bbox": [69.0, 119.0, 97.0, 130.0]}, {"text": "Younger patient without", "bbox": [273.0, 120.0, 365.0, 130.0]}, {"text": "ascular risk factors", "bbox": [277.0, 131.0, 351.0, 140.0]}, {"text": "graphics", "bbox": [70.0, 132.0, 105.0, 141.0]}, {"text": "Medical", "bbox": [69.0, 147.0, 103.0, 159.0]}, {"text": "Presence of vascular risk factors", "bbox": [124.0, 148.0, 256.0, 159.0]}, {"text": "History of epilepsy,", "bbox": [271.0, 147.0, 349.0, 159.0]}, {"text": "history", "bbox": [70.0, 160.0, 98.0, 172.0]}, {"text": "(hypertension, diabetes, coronary", "bbox": [125.0, 160.0, 258.0, 172.0]}, {"text": "migraines, brain tumo", "bbox": [275.0, 160.0, 357.0, 172.0]}, {"text": "artery disease, peripheral artery", "bbox": [126.0, 172.0, 252.0, 183.0]}, {"text": "disease, smoking, obesity, hyper-", "bbox": [125.0, 185.0, 256.0, 196.0]}, {"text": "lipidemia, atrial fibrillation, previous", "bbox": [125.0, 196.0, 260.0, 207.0]}, {"text": "stroke, obstructive sleep apnea)", "bbox": [125.0, 208.0, 252.0, 218.0]}, {"text": "Symptom", "bbox": [69.0, 227.0, 107.0, 238.0]}, {"text": "Abrupt onset", "bbox": [124.0, 227.0, 178.0, 238.0]}, {"text": "Symptoms that spread/", "bbox": [271.0, 227.0, 367.0, 237.0]}, {"text": "atology", "bbox": [71.0, 237.0, 102.0, 251.0]}, {"text": "march from site of onset.", "bbox": [272.0, 238.0, 369.0, 249.0]}, {"text": "Maximal symptoms at onset", "bbox": [124.0, 240.0, 236.0, 252.0]}, {"text": "might suggest seizure", "bbox": [272.0, 251.0, 361.0, 262.0]}, {"text": "Duration typically <60 min", "bbox": [124.0, 255.0, 230.0, 267.0]}, {"text": "Altered mentation", "bbox": [272.0, 265.0, 344.0, 276.0]}, {"text": "Preserved mentation", "bbox": [124.0, 271.0, 208.0, 282.0]}, {"text": "Migraine headache", "bbox": [271.0, 280.0, 349.0, 291.0]}, {"text": "Localizing/focal neurological", "bbox": [124.0, 286.0, 240.0, 297.0]}, {"text": "Presence of signs or", "bbox": [271.0, 294.0, 353.0, 306.0]}, {"text": "symptoms corresponding to a.", "bbox": [125.0, 299.0, 244.0, 307.0]}, {"text": "symptoms suggesting an", "bbox": [272.0, 307.0, 368.0, 319.0]}, {"text": "vascular territory: dysarthria/", "bbox": [125.0, 310.0, 239.0, 321.0]}, {"text": "alternative diagnosis (ie,", "bbox": [273.0, 319.0, 364.0, 330.0]}, {"text": "aphasia, facial droop, hemipares,", "bbox": [124.0, 321.0, 253.0, 333.0]}, {"text": "positive visual phenom-", "bbox": [273.0, 331.0, 361.0, 342.0]}, {"text": "hemibody numbness", "bbox": [124.0, 334.0, 207.0, 346.0]}, {"text": "ena, seizure-like activity,", "bbox": [272.0, 342.0, 364.0, 354.0]}, {"text": "Dizziness paired with cranial", "bbox": [124.0, 348.0, 239.0, 360.0]}, {"text": "positional vertigo without", "bbox": [273.0, 355.0, 367.0, 367.0]}, {"text": "neuropathies, vision loss/diplopia,", "bbox": [125.0, 362.0, 258.0, 371.0]}, {"text": "ocalizing/focal symptom", "bbox": [276.0, 367.0, 366.0, 378.0]}, {"text": "difficulty with coordination or gait/", "bbox": [124.0, 373.0, 260.0, 384.0]}, {"text": "truncal ataxia, severe nausea/", "bbox": [124.0, 386.0, 242.0, 394.0]}, {"text": "vomiting may suggest posterior", "bbox": [126.0, 397.0, 248.0, 408.0]}, {"text": "circulation process", "bbox": [125.0, 409.0, 202.0, 420.0]}, {"text": "Hypertensive on presentation", "bbox": [124.0, 425.0, 243.0, 435.0]}, {"text": "Headache with ptosis and miosis", "bbox": [124.0, 439.0, 255.0, 450.0]}, {"text": "might indicate dissection", "bbox": [124.0, 451.0, 222.0, 461.0]}, {"text": "This table is meant as a guide to approaching a patient with neurological", "bbox": [76.0, 472.0, 378.0, 482.0]}], "type": "Table", "position": 4}, {"raw_context": [{"text": "symptoms and should not be the sole determinant of ultimate diagnosis. Patient-", "bbox": [65.0, 484.0, 377.0, 495.0]}, {"text": "specific factors must also be considered.", "bbox": [64.0, 496.0, 224.0, 507.0]}, {"text": "TIA indicates transient ischemic attack.", "bbox": [76.0, 508.0, 227.0, 519.0]}], "type": "Text", "position": 5}, {"raw_context": [{"text": "'9 Ammqs4 no vq ano stemmolede// dmd moril bebeolarwork", "bbox": [17.0, 536.0, 37.0, 779.0]}], "type": "Text", "position": 6}, {"raw_context": [{"text": "population-based study, Kleindorfer et al 8 estimated", "bbox": [63.0, 533.0, 378.0, 549.0]}, {"text": "an incidence of 240000 TIAs in the United States in", "bbox": [63.0, 550.0, 379.0, 565.0]}, {"text": "2002. 6 Similar to cardiovascular disease and stroke, TIA", "bbox": [63.0, 567.0, 380.0, 581.0]}, {"text": "incidence increases with age. Significant race-based", "bbox": [63.0, 582.0, 380.0, 597.0]}, {"text": "disparities have been reported with Black Americans", "bbox": [63.0, 599.0, 379.0, 614.0]}, {"text": "having a 1.4 times greater risk of TIA compared with", "bbox": [63.0, 615.0, 380.0, 629.0]}, {"text": "White Americans, 6 although recent data on these dis-", "bbox": [63.0, 630.0, 378.0, 645.0]}, {"text": "parities are lacking.", "bbox": [63.0, 647.0, 177.0, 661.0]}, {"text": "Population data have demonstrated an overall reduc-", "bbox": [78.0, 662.0, 378.0, 677.0]}, {"text": "tion in both TIA incidence and TIA admission rates over", "bbox": [63.0, 679.0, 379.0, 694.0]}, {"text": "time. 78 These findings have been attributed to improved", "bbox": [63.0, 695.0, 379.0, 709.0]}, {"text": "vascular risk reduction and stroke care, 8 changing trends", "bbox": [63.0, 711.0, 379.0, 725.0]}, {"text": "in hospital admissions, and implementation of ED TIA", "bbox": [63.0, 727.0, 380.0, 742.0]}, {"text": "protocols emphasizing short-term follow-up in dedicated", "bbox": [63.0, 743.0, 380.0, 757.0]}, {"text": "TIA clinics. 9 Some evidence suggests that TIA incidence", "bbox": [65.0, 759.0, 379.0, 774.0]}, {"text": "is decreasing more substantially in men than in women. 7", "bbox": [63.0, 776.0, 375.0, 789.0]}], "type": "Text", "position": 7}, {"raw_context": [{"text": "CLINICAL EVALUATION", "bbox": [63.0, 816.0, 233.0, 836.0]}], "type": "Section-header", "position": 8}, {"raw_context": [{"text": "Acute onset of focal neurological symptoms followed by", "bbox": [63.0, 843.0, 379.0, 857.0]}, {"text": "complete resolution is suggestive of a TIA. Therefore,", "bbox": [63.0, 859.0, 379.0, 873.0]}, {"text": "patients for whom TIA is being considered must have a", "bbox": [63.0, 875.0, 380.0, 890.0]}, {"text": "neurological examination consistent with their baseline", "bbox": [63.0, 891.0, 380.0, 905.0]}, {"text": "status. Specific details of the history and presentation", "bbox": [63.0, 907.0, 380.0, 921.0]}, {"text": "can help differentiate TIA from alternate diagnoses. Non-", "bbox": [63.0, 923.0, 378.0, 937.0]}, {"text": "specific symptoms or examination findings (eg, isolated", "bbox": [63.0, 939.0, 379.0, 953.0]}, {"text": "confusion/lethargy/encephalopathy),", "bbox": [127.0, 955.0, 343.0, 970.0]}, {"text": "dizziness,", "bbox": [63.0, 956.0, 122.0, 970.0]}, {"text": "focal", "bbox": [347.0, 957.0, 379.0, 969.0]}], "type": "Text", "position": 9}, {"raw_context": [{"text": "e2e2", "bbox": [63.0, 999.0, 79.0, 1011.0]}], "type": "Text", "position": 10}, {"raw_context": [{"text": "symptoms with other features (eg, headache, seizure), or", "bbox": [399.0, 77.0, 715.0, 93.0]}, {"text": "new radiological findings (eg, mass lesion) may suggest", "bbox": [399.0, 93.0, 716.0, 108.0]}, {"text": "an alternate diagnosis or \"mimic\" (Table 1). In cases of", "bbox": [399.0, 110.0, 718.0, 124.0]}, {"text": "diagnostic uncertainty, conventional wisdom suggests", "bbox": [399.0, 126.0, 716.0, 140.0]}, {"text": "performing a neurovascular workup for suspected TIA to", "bbox": [399.0, 142.0, 716.0, 156.0]}, {"text": "reduce the risk of a recurrent event, ideally with expe-", "bbox": [399.0, 158.0, 713.0, 173.0]}, {"text": "dited neurological consultation.", "bbox": [399.0, 174.0, 575.0, 188.0]}], "type": "Text", "position": 12}, {"raw_context": [{"text": "DIAGNOSTIC EVALUATION", "bbox": [399.0, 216.0, 596.0, 237.0]}], "type": "Section-header", "position": 13}, {"raw_context": [{"text": "Brain Imaging", "bbox": [399.0, 243.0, 495.0, 261.0]}], "type": "Section-header", "position": 14}, {"raw_context": [{"text": "In the ED, the role of acute phase imaging is to rule out", "bbox": [399.0, 265.0, 716.0, 281.0]}, {"text": "alternative diagnoses, aid in risk stratification, and iden¬", "bbox": [399.0, 281.0, 715.0, 296.0]}, {"text": "tify potentially symptomatic lesions. An initial noncontrast", "bbox": [399.0, 298.0, 716.0, 312.0]}, {"text": "head computed tomography (NCCT) is part of many", "bbox": [399.0, 314.0, 716.0, 328.0]}, {"text": "stroke/TIA protocols given its accessibility in the ED set-", "bbox": [399.0, 330.0, 715.0, 344.0]}, {"text": "ting, 10 and is a useful initial test to evaluate for subacute", "bbox": [399.0, 346.0, 716.0, 361.0]}, {"text": "ischemia, hemorrhage, or mass lesion. NCCT alone,", "bbox": [399.0, 362.0, 716.0, 376.0]}, {"text": "however, has limited utility in patients whose symptoms", "bbox": [399.0, 378.0, 715.0, 392.0]}, {"text": "have resolved. 3 Although its sensitivity to detect an acute", "bbox": [399.0, 394.0, 716.0, 408.0]}, {"text": "infarct is low, it does have utility in ruling out TIA mimics.", "bbox": [399.0, 410.0, 715.0, 424.0]}, {"text": "Multimodal brain MRI is the preferred method to", "bbox": [415.0, 426.0, 716.0, 441.0]}, {"text": "evaluate for acute ischemic infarct and ideally should", "bbox": [399.0, 441.0, 716.0, 456.0]}, {"text": "be obtained within 24 hours of symptom onset, and", "bbox": [399.0, 457.0, 716.0, 472.0]}, {"text": "in most centers will follow a NCCT. 11 Some centers", "bbox": [399.0, 474.0, 716.0, 488.0]}, {"text": "might have rapid access to MRI in the ED. In cases", "bbox": [399.0, 490.0, 716.0, 504.0]}, {"text": "where MRI with DWI can be obtained without delay,", "bbox": [399.0, 506.0, 716.0, 521.0]}, {"text": "NCCT can be safely avoided in a stable patient with", "bbox": [399.0, 522.0, 716.0, 536.0]}, {"text": "completely resolved symptoms.", "bbox": [399.0, 538.0, 580.0, 552.0]}, {"text": "TIAs typically last minutes with a linear increase in the", "bbox": [416.0, 554.0, 716.0, 568.0]}, {"text": "likelihood of infarction with increasing symptom dura¬", "bbox": [399.0, 570.0, 715.0, 584.0]}, {"text": "tion. 12 MRI with DWI demonstrates lesions in ~40% of", "bbox": [399.0, 585.0, 716.0, 600.0]}, {"text": "patients presenting with TIA symptoms, and DWI positiv-", "bbox": [399.0, 602.0, 714.0, 616.0]}, {"text": "ity is associated with a >6-fold increased risk of recurrent", "bbox": [399.0, 618.0, 716.0, 632.0]}, {"text": "stroke at 1 year. 13 If a DWI-positive lesion is identified, a", "bbox": [399.0, 634.0, 716.0, 649.0]}, {"text": "diagnosis of ischemic stroke is typically made, followed", "bbox": [399.0, 650.0, 716.0, 663.0]}, {"text": "by hospital admission. The distribution of DWI lesions", "bbox": [399.0, 666.0, 715.0, 681.0]}, {"text": "can help with identification of stroke pathogenesis (eg,", "bbox": [399.0, 682.0, 717.0, 696.0]}, {"text": "a single lacune in a deep structure suggests small ves-", "bbox": [399.0, 698.0, 714.0, 712.0]}, {"text": "sel disease; scattered emboli in multiple territories might", "bbox": [400.0, 714.0, 716.0, 729.0]}, {"text": "point to cardioembolic mechanism such as atrial fibril-", "bbox": [401.0, 730.0, 714.0, 743.0]}, {"text": "lation [AF]; watershed distribution of lesions suggests", "bbox": [400.0, 746.0, 716.0, 760.0]}, {"text": "large vessel disease) and guides further workup and", "bbox": [399.0, 762.0, 716.0, 776.0]}, {"text": "secondary prevention strategies.", "bbox": [400.0, 778.0, 581.0, 792.0]}, {"text": "In the clinical scenario in which MRI cannot be", "bbox": [415.0, 794.0, 716.0, 808.0]}, {"text": "obtained acutely to definitively distinguish TIA from", "bbox": [399.0, 810.0, 716.0, 823.0]}, {"text": "stroke, it remains reasonable to make a clinical diagnosis", "bbox": [399.0, 825.0, 715.0, 840.0]}, {"text": "of TIA in the ED on the basis of a negative NCCT and", "bbox": [399.0, 842.0, 716.0, 856.0]}, {"text": "symptom resolution within 24 hours. 14 A potential next", "bbox": [399.0, 857.0, 716.0, 872.0]}, {"text": "step would be hospital admission for MRI, comprehensive", "bbox": [399.0, 874.0, 716.0, 888.0]}, {"text": "workup, and neurology consultation. Other options might", "bbox": [399.0, 890.0, 716.0, 903.0]}, {"text": "include transferring patients to a facility with advanced", "bbox": [399.0, 906.0, 716.0, 920.0]}, {"text": "imaging and vascular neurology expertise or arranging a", "bbox": [399.0, 922.0, 716.0, 936.0]}, {"text": "timely (ideally <24 hours) outpatient MRI. Early MRI can", "bbox": [399.0, 938.0, 716.0, 952.0]}, {"text": "identify higher-risk patients and avoids MRI degradation", "bbox": [399.0, 954.0, 716.0, 969.0]}], "type": "Text", "position": 15}], "obj_key": "oss://inf-beta/datasets/medical_guidelines/指南数据/【2023】全科室指南+解读+共识（最新版）/神经科/共识/2023 AHA科学声明：急诊科短暂性脑缺血发作的诊断、检查和风险降低(1).pdf", "page_num": 2}, "ext": null, "dataset": "guidelines_liangyong_surya", "batch_name": "20240507", "version": "version0"}, "result_info": {"type1": "语句不通顺#11#11# (eg, isolated confusion/lethargy/encephalopathy), dizziness, focal里面的dizziness, 应该在confusion/前面", "type2": "多余换行#13#13# symptoms with other features..与上面11段联接", "type3": "无关文本#7#7# '9 Ammqs4 no vq ano stemmolede// dmd moril bebeolarwork原文没有找到出处\n无关文本#8#19#Kleindorfer et al 8 estimated an ...\n... in men than in women. 7文章开头中间结尾都有出现，应用全文\n无关文本#12#12#e2e2", "type4": null, "type5": null, "type6": "准确性#0#6#表格内容，内容杂乱"}, "finished": true, "dropped": false, "create_time": "2024-05-07 05:06:40", "update_time": "2024-05-07 23:41:49"}